PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	SC	GA	UT	PM	OA	HC	HP	DA
J	Cnossen, MC; Huijben, JA; van der Jagt, M; Volovici, V; van Essen, T; Polinder, S; Nelson, D; Ercole, A; Stocchetti, N; Citerio, G; Peul, WC; Maas, AIR; Menon, D; Steyerberg, EW; Lingsma, HF				Cnossen, Maryse C.; Huijben, Jilske A.; van der Jagt, Mathieu; Volovici, Victor; van Essen, Thomas; Polinder, Suzanne; Nelson, David; Ercole, Ari; Stocchetti, Nino; Citerio, Giuseppe; Peul, Wilco C.; Maas, Andrew I. R.; Menon, David; Steyerberg, Ewout W.; Lingsma, Hester F.		CENTER-TBI Investigators	Variation in monitoring and treatment policies for intracranial hypertension in traumatic brain injury: a survey in 66 neurotrauma centers participating in the CENTER-TBI study	CRITICAL CARE			English	Article						Traumatic brain injury; Intracranial hypertension; ICP; ICU; Comparative effectiveness research; Survey	EUROPEAN-BRAIN; MANAGEMENT; CARE; PRESSURE; MODERATE; IMPACT	Background: No definitive evidence exists on how intracranial hypertension should be treated in patients with traumatic brain injury (TBI). It is therefore likely that centers and practitioners individually balance potential benefits and risks of different intracranial pressure (ICP) management strategies, resulting in practice variation. The aim of this study was to examine variation in monitoring and treatment policies for intracranial hypertension in patients with TBI. Methods: A 29-item survey on ICP monitoring and treatment was developed on the basis of literature and expert opinion, and it was pilot-tested in 16 centers. The questionnaire was sent to 68 neurotrauma centers participating in the Collaborative European Neurotrauma Effectiveness Research in Traumatic Brain Injury (CENTER-TBI) study. Results: The survey was completed by 66 centers (97% response rate). Centers were mainly academic hospitals (n = 60, 91%) and designated level I trauma centers (n = 44, 67%). The Brain Trauma Foundation guidelines were used in 49 (74%) centers. Approximately 90% of the participants (n = 58) indicated placing an ICP monitor in patients with severe TBI and computed tomographic abnormalities. There was no consensus on other indications or on peri-insertion precautions. We found wide variation in the use of first-and second-tier treatments for elevated ICP. Approximately half of the centers were classified as using a relatively aggressive approach to ICP monitoring and treatment (n = 32, 48%), whereas the others were considered more conservative (n = 34, 52%). Conclusions: Substantial variation was found regarding monitoring and treatment policies in patients with TBI and intracranial hypertension. The results of this survey indicate a lack of consensus between European neurotrauma centers and provide an opportunity and necessity for comparative effectiveness research.	[Cnossen, Maryse C.; Huijben, Jilske A.; Volovici, Victor; Polinder, Suzanne; Steyerberg, Ewout W.; Lingsma, Hester F.] Erasmus MC, Ctr Med Decis Making, Dept Publ Hlth, Rotterdam, Netherlands; [van der Jagt, Mathieu] Erasmus MC, Dept Intens Care, Rotterdam, Netherlands; [Volovici, Victor] Erasmus MC, Dept Neurosurg, Rotterdam, Netherlands; [van Essen, Thomas; Peul, Wilco C.] Leiden Univ, Med Ctr, Dept Neurosurg, Leiden, Netherlands; [Nelson, David] Karolinska Inst, Sect Perioperat Med & Intens Care, Dept Physiol & Pharmacol, Stockholm, Sweden; [Ercole, Ari; Menon, David] Univ Cambridge, Addenbrookes Hosp, Div Anesthesia, Cambridge, England; [Stocchetti, Nino] Univ Milan, Dept Pathophysiol & Transplants, Milan, Italy; [Stocchetti, Nino] Fdn IRCCS Ca Granda, Osped Maggiore Policlin, Dept Anesthesia & Crit Care, Neurosci Intens Care Unit, Milan, Italy; [Citerio, Giuseppe] Univ Milano Bicocca, Sch Med & Surg, Milan, Italy; [Citerio, Giuseppe] ASST Monza, San Gerardo Hosp, Neurointens Care Unit, Monza, Italy; [Peul, Wilco C.] Haaglanden Med Ctr, Dept Neurosurg, The Hague, Netherlands; [Maas, Andrew I. R.] Antwerp Univ Hosp, Dept Neurosurg, Edegem, Belgium; [Maas, Andrew I. R.] Univ Antwerp, Edegem, Belgium; [Steyerberg, Ewout W.] Leiden Univ, Med Ctr, Dept Med Stat & Bioinformat, Leiden, Netherlands	Cnossen, MC (corresponding author), Erasmus MC, Ctr Med Decis Making, Dept Publ Hlth, Rotterdam, Netherlands.	m.c.cnossen@erasmusmc.nl	Raj, Rahul/K-7693-2012; Ercole, Ari/B-6288-2009; Lanyon, Linda/L-9238-2019; Lagares, Alfonso/B-2969-2011; Maas, Andrew IR/C-5584-2013; Gomez, Pedro/N-5051-2019; Sahuquillo, Juan/B-3577-2008; Sahakian, Barbara/AAW-1198-2020; Badenes, Rafael/K-6628-2019; Citerio, Giuseppe/B-1839-2015; Volovici, Victor/AAZ-8901-2020; Cooper, D. James/G-7961-2013; Gomez, Pedro A/E-2411-2014; Bartels, Ronald HMA/L-4184-2015; Castano-Leon, Ana M/ABF-6322-2020; Laureys, Steven/AAN-2097-2021; Freo, Ulderico/V-8249-2017; Oresic, Matej/K-7673-2016; Hoedemaekers, C.W.E./L-4375-2015; Boogert, Hugo F den/B-2782-2016; Belli, Antonio/I-3799-2015	Raj, Rahul/0000-0003-4243-9591; Ercole, Ari/0000-0001-8350-8093; Lanyon, Linda/0000-0002-0885-1825; Lagares, Alfonso/0000-0003-3996-0554; Maas, Andrew IR/0000-0003-1612-1264; Gomez, Pedro/0000-0002-4185-5238; Sahuquillo, Juan/0000-0003-0713-5875; Sahakian, Barbara/0000-0001-7352-1745; Badenes, Rafael/0000-0001-7017-0150; Citerio, Giuseppe/0000-0002-5374-3161; Volovici, Victor/0000-0002-5798-5360; Cooper, D. James/0000-0002-5872-9051; Gomez, Pedro A/0000-0002-4185-5238; Bartels, Ronald HMA/0000-0002-8638-4660; Castano-Leon, Ana M/0000-0002-7918-5049; Laureys, Steven/0000-0002-3096-3807; Freo, Ulderico/0000-0001-6183-2909; Oresic, Matej/0000-0002-2856-9165; Parizel, Paul M./0000-0002-0221-2854; Pirinen, Matti/0000-0002-1664-1350; Bullinger, Monika/0000-0001-8876-0159; Pullens, Pim/0000-0003-2014-7248; Stamatakis, Emmanuel Andreas/0000-0001-6955-9601; Newcombe, Virginia/0000-0001-6044-9035; Andelic, Nada/0000-0002-3719-4406; Wang, Kevin/0000-0002-9343-6473; Pomposo Gaztelu, Inigo/0000-0002-3095-2649; Morganti-Kossmann, Cristina/0000-0002-0807-2063; Kolias, Angelos/0000-0003-3992-0587; MARTIN, Didier/0000-0001-7325-4958; Santos, Edgar/0000-0002-8976-5549; Hartings, Jed/0000-0001-8583-3471; Belli, Antonio/0000-0002-3211-9933; Lozano Roig, Angels/0000-0001-9761-4938; Della Corte, Francesco/0000-0003-1736-2318; Te Ao, Braden/0000-0002-1050-200X; Feigin, Valery L./0000-0002-6372-1740; Ledig, Christian/0000-0003-4862-3138; Blaabjerg, Morten/0000-0001-6007-1861; Wade, Derick/0000-0002-1188-8442; Rossi, Sandra/0000-0002-9963-8121; Bragge, Peter/0000-0003-0745-5131; Sanchez-Porras, Renan/0000-0002-9084-8114; Cameron, Peter/0000-0002-1443-557X; Dawes, Helen/0000-0002-2933-5213; Huijben, Jilske (Antonia)/0000-0002-2892-5406; Dippel, Diederik/0000-0002-9234-3515; Kondziella, Daniel/0000-0001-5562-9808	European CommissionEuropean CommissionEuropean Commission Joint Research Centre [602150]; Dutch Brain Foundation (Hersenstichting Nederland); Academy of Medical Sciences (AMS)Academy of Medical Sciences (AMS) [AMS-CSF4-Newcombe] Funding Source: researchfish; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600986] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [ACF-2009-14-007, NIHR-RP-R3-12-013] Funding Source: researchfish	Data used in the preparation of this article were obtained in the context of CENTER-TBI, a large collaborative project with the support of the European Commission Seventh Framework program (602150). In addition, TvE and WCP were supported by a grant from the Dutch Brain Foundation (Hersenstichting Nederland) for the Neurotraumatology Quality Registry (Net-QuRe) study.	Balestreri M, 2006, NEUROCRIT CARE, V4, P8, DOI 10.1385/NCC:4:1:008; Bosco JLF, 2010, J CLIN EPIDEMIOL, V63, P64, DOI 10.1016/j.jclinepi.2009.03.001; Bragge P, 2016, J NEUROTRAUM, V33, P1461, DOI 10.1089/neu.2015.4233; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Cnossen MC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161367; Cnossen MC, 2017, CRIT CARE MED, V45, P660, DOI 10.1097/CCM.0000000000002263; Enblad P, 2004, INTENS CARE MED, V30, P1058, DOI 10.1007/s00134-004-2206-8; European Commission, 2007, SOC SIT EUR UN 2007, P1; Hesdorffer DC, 2007, J TRAUMA, V63, P841, DOI 10.1097/TA.0b013e318123fc21; IBM Corporation, 2012, IBM SPSS STAT WIND V; Maas AIR, 2015, NEUROSURGERY, V76, P67, DOI 10.1227/NEU.0000000000000575; Maas AIR, 2012, J NEUROTRAUM, V29, P32, DOI 10.1089/neu.2010.1599; Nathens AB, 2006, ANN SURG, V244, P545, DOI 10.1097/01.sla.0000239005.26353.49; Sharma S, 2014, J AM COLL SURGEONS, V218, P51, DOI 10.1016/j.jamcollsurg.2013.10.005; Signorello Lisa B, 2002, Am J Ther, V9, P199, DOI 10.1097/00045391-200205000-00005; Skoglund K, 2013, J NEUROSCI NURS, V45, P360, DOI 10.1097/JNN.0b013e3182a3cf4f; Stocchetti N, 2001, INTENS CARE MED, V27, P400, DOI 10.1007/s001340000825; Thomas L, 2000, COCHRANE DB SYST REV; Timmons SD, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.6.FOCUS1296; van Essen TA, 2017, J NEUROTRAUM, V34, P881, DOI 10.1089/neu.2016.4495; Zuercher P, 2016, J NEUROTRAUM, V33, P1768, DOI 10.1089/neu.2015.4266	21	42	42	0	15	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care	SEP 6	2017	21								233	10.1186/s13054-017-1816-9			12	Critical Care Medicine	General & Internal Medicine	FF8KB	WOS:000409265900001	28874206	DOAJ Gold, Green Published, Green Accepted			2021-06-18	
J	Brunden, KR; Lee, VMY; Smith, AB; Trojanowski, BQ; Ballatore, C				Brunden, Kurt R.; Lee, Virginia M-Y.; Smith, Amos B., III; Trojanowski, Bjohn Q.; Ballatore, Carlo			Altered microtubule dynamics in neurodegenerative disease: Therapeutic potential of microtubule-stabilizing drugs	NEUROBIOLOGY OF DISEASE			English	Article						Alzheimer; Amyotrophic lateral sclerosis; Axons; Frontotemporal lobar degeneration; Microtubules; Neurodegeneration; Parkinson; Transport; Traumatic brain injury	TRANSGENIC MOUSE MODEL; PAIRED HELICAL FILAMENTS; AXONAL-TRANSPORT DEFECTS; ALZHEIMERS-DISEASE; ALPHA-SYNUCLEIN; EPOTHILONE D; BRAIN-PENETRANT; TAU-HYPERPHOSPHORYLATION; NEUROFIBRILLARY TANGLES; DOPAMINERGIC-NEURONS	Many neurodegenerative diseases are characterized by deficiencies in neuronal axonal transport, a process in which cellular cargo is shuttled with the aid of molecular motors from the cell body to axonal termini and back along microtubules (MTs). Proper axonal transport is critical to the normal functioning of neurons, and impairments in this process could contribute to the neuronal damage and death that is characteristic of neurodegenerative disease. Although the causes of axonal transport abnormalities may vary among the various neurodegenerative conditions, in many cases it appears that the transport deficiencies result from a diminution of axonal MT stability. Here we review the evidence of MT abnormalities in a number of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and traumatic brain injury, and highlight the potential benefit of MT-stabilizing agents in improving axonal transport and nerve function in these diseases. Moreover, we discuss the challenges associated with the utilization of MT-stabilizing drugs as therapeutic candidates for neurodegenerative conditions. (C) 2016 Elsevier Inc. All rights reserved.	[Brunden, Kurt R.; Lee, Virginia M-Y.; Trojanowski, Bjohn Q.] Univ Penn, Perelman Sch Med, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA; [Smith, Amos B., III] Univ Penn, Dept Chem, Sch Arts & Sci, Philadelphia, PA 19104 USA; [Ballatore, Carlo] Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, La Jolla, CA 92093 USA	Brunden, KR (corresponding author), Ctr Neurodegenerat Dis Res, 3600 Spruce St,Maloney 3, Philadelphia, PA 19104 USA.	kbrunden@upenn.edu	Ballatore, Carlo/L-1034-2017	Ballatore, Carlo/0000-0002-2718-3850	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AG044332, NS087059]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS087059] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG044332, P01AG017586, P30AG010124] Funding Source: NIH RePORTER	This work was supported in part by National Institutes of Health grants AG044332 and NS087059. The authors also gratefully acknowledge the charitable contributions to the Center for Neurodegenerative Disease Research from the "The Woods" Charitable Foundation, the Karen Cohen Segal and Christopher S. Segal Alzheimer Drug Discovery Initiative Fund, the Paula C. Schmerler Fund for Alzheimer's Research, the Barrist Neurodegenerative Disease Research Fund, the Eleanor Margaret Kurtz Endowed Fund, the Mary Rasmus Endowed Fund for Alzheimer's Research, Mrs. Gloria J. Miller and Arthur Peck, M.D.	Alonso AD, 1997, P NATL ACAD SCI USA, V94, P298, DOI 10.1073/pnas.94.1.298; ALONSO AD, 1994, NEUROBIOL AGING, V15, pS37; Amos LA, 2004, ORG BIOMOL CHEM, V2, P2153, DOI 10.1039/b403634d; ARRIAGADA PV, 1992, NEUROLOGY, V42, P631, DOI 10.1212/WNL.42.3.631; Baldwin KR, 2016, HUM MOL GENET, V25, P2378, DOI 10.1093/hmg/ddw105; Ball M, 1997, NEUROBIOL AGING, V18, pS1, DOI 10.1016/s0197-4580(97)00057-2; Ballatore C, 2007, NAT REV NEUROSCI, V8, P663, DOI 10.1038/nrn2194; Ballatore C, 2012, J MED CHEM, V55, P8979, DOI 10.1021/jm301079z; Barghorn S, 2000, BIOCHEMISTRY-US, V39, P11714, DOI 10.1021/bi000850r; Barten DM, 2012, J NEUROSCI, V32, P7137, DOI 10.1523/JNEUROSCI.0188-12.2012; Bedard PL, 2010, NAT REV CLIN ONCOL, V7, P22, DOI 10.1038/nrclinonc.2009.186; Bellouze S, 2016, MOL NEURODEGENER, V11, DOI 10.1186/s13024-016-0111-6; Black MM, 1996, J NEUROSCI, V16, P3601; Boxer AL, 2014, LANCET NEUROL, V13, P676, DOI 10.1016/S1474-4422(14)70088-2; Braak H, 2003, NEUROBIOL AGING, V24, P197, DOI 10.1016/S0197-4580(02)00065-9; BRINKLEY BR, 1974, EXP CELL RES, V85, P41, DOI 10.1016/0014-4827(74)90210-9; Brizuela M, 2015, MOL CELL NEUROSCI, V66, P129, DOI 10.1016/j.mcn.2015.02.006; Brunden KR, 2014, BIOORGAN MED CHEM, V22, P5040, DOI 10.1016/j.bmc.2013.12.046; Brunden KR, 2013, ACS MED CHEM LETT, V4, P886, DOI 10.1021/ml400233e; Brunden KR, 2011, PHARMACOL RES, V63, P341, DOI 10.1016/j.phrs.2010.12.002; Brunden KR, 2010, J NEUROSCI, V30, P13861, DOI 10.1523/JNEUROSCI.3059-10.2010; Burre J, 2015, J PARKINSON DIS, V5, P699, DOI 10.3233/JPD-150642; Cappelletti G, 2005, FEBS LETT, V579, P4781, DOI 10.1016/j.febslet.2005.07.058; Cappelletti G, 1999, J NEUROSCI RES, V56, P28, DOI 10.1002/(SICI)1097-4547(19990401)56:1<28::AID-JNR4>3.0.CO;2-2; Cartelli D, 2013, SCI REP-UK, V3, DOI 10.1038/srep01837; Cartelli D, 2010, J NEUROCHEM, V115, P247, DOI 10.1111/j.1471-4159.2010.06924.x; Cohen TJ, 2011, TRENDS MOL MED, V17, P659, DOI 10.1016/j.molmed.2011.06.004; Cortes J, 2007, ONCOLOGIST, V12, P271, DOI 10.1634/theoncologist.12-3-271; Cross DJ, 2015, BRAIN RES, V1618, P299, DOI 10.1016/j.brainres.2015.06.006; Daniels JA, 2008, AM J SURG PATHOL, V32, P473, DOI 10.1097/PAS.0b013e3181582331; Dawson HN, 2001, J CELL SCI, V114, P1179; Dayanandan R, 1999, FEBS LETT, V446, P228, DOI 10.1016/S0014-5793(99)00222-7; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; Dixit R, 2008, SCIENCE, V319, P1086, DOI 10.1126/science.1152993; DRECHSEL DN, 1992, MOL BIOL CELL, V3, P1141; Falzone TL, 2010, HUM MOL GENET, V19, P4399, DOI 10.1093/hmg/ddq363; Falzone TL, 2009, J NEUROSCI, V29, P5758, DOI 10.1523/JNEUROSCI.0780-09.2009; Fanara P, 2007, J BIOL CHEM, V282, P23465, DOI 10.1074/jbc.M703434200; Fanara P, 2012, J CLIN INVEST, V122, P3159, DOI 10.1172/JCI64575; Fitzgerald DP, 2012, MOL CANCER THER, V11, P1959, DOI 10.1158/1535-7163.MCT-12-0061; Fukushima N, 2009, J NEUROCHEM, V109, P683, DOI 10.1111/j.1471-4159.2009.06013.x; Gardner A, 2014, BRIT J SPORT MED, V48, P84, DOI 10.1136/bjsports-2013-092646; GomezIsla T, 1997, ANN NEUROL, V41, P17, DOI 10.1002/ana.410410106; Gozes I, 2015, FRONT AGING NEUROSCI, V7, DOI 10.3389/fnagi.2015.00205; GUSTKE N, 1994, BIOCHEMISTRY-US, V33, P9511, DOI 10.1021/bi00198a017; Haggerty T, 2011, EUR J NEUROSCI, V33, P1598, DOI 10.1111/j.1460-9568.2011.07660.x; HARADA A, 1994, NATURE, V369, P488, DOI 10.1038/369488a0; Hasegawa M, 1998, FEBS LETT, V437, P207, DOI 10.1016/S0014-5793(98)01217-4; Hempen B, 1996, J NEUROPATH EXP NEUR, V55, P964, DOI 10.1097/00005072-199609000-00003; Hirokawa N, 2008, PHYSIOL REV, V88, P1089, DOI 10.1152/physrev.00023.2007; Holy J, 1998, J TOXICOL ENV HEAL A, V54, P319, DOI 10.1080/009841098158872; Hong M, 1998, SCIENCE, V282, P1914, DOI 10.1126/science.282.5395.1914; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; Irwin DJ, 2013, NAT REV NEUROSCI, V14, P626, DOI 10.1038/nrn3549; Ishikawa T, 2012, J STRUCT BIOL, V179, P229, DOI 10.1016/j.jsb.2012.05.016; Janning D, 2014, MOL BIOL CELL, V25, P3541, DOI 10.1091/mbc.E14-06-1099; Jiang Q, 2008, J NEUROSCI, V28, P12993, DOI 10.1523/JNEUROSCI.2860-08.2008; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kaul T, 2011, BMC NEUROSCI, V12, DOI 10.1186/1471-2202-12-79; Kawakami F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030834; Ke Yazi D, 2012, Int J Alzheimers Dis, V2012, P873270, DOI 10.1155/2012/873270; Kempf M, 1996, J NEUROSCI, V16, P5583; Kett LR, 2012, HUM MOL GENET, V21, P890, DOI 10.1093/hmg/ddr526; Khanna MR, 2016, ALZHEIMERS DEMENT, V12, P1051, DOI 10.1016/j.jalz.2016.06.006; KIDD M, 1963, NATURE, V197, P192, DOI 10.1038/197192b0; Killinger BA, 2016, J NEUROCHEM, V136, P510, DOI 10.1111/jnc.13391; Kitada T, 1998, NATURE, V392, P605; Kleele T, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5827; Konzack S, 2007, J NEUROSCI, V27, P9916, DOI 10.1523/JNEUROSCI.0927-07.2007; Kovalevich J, 2016, J PHARMACOL EXP THER, V357, P432, DOI 10.1124/jpet.115.231175; Lee HJ, 2006, EUR J NEUROSCI, V24, P3153, DOI 10.1111/j.1460-9568.2006.05210.x; Lee VMY, 2006, NEURON, V52, P33, DOI 10.1016/j.neuron.2006.09.026; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Leo L, 2015, CELL REP, V12, P1723, DOI 10.1016/j.celrep.2015.08.017; Lin X, 2009, NEURON, V64, P807, DOI 10.1016/j.neuron.2009.11.006; Lou K, 2014, J MED CHEM, V57, P6116, DOI 10.1021/jm5005623; Magrane J, 2014, HUM MOL GENET, V23, P1413, DOI 10.1093/hmg/ddt528; Makani V, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0378-4; Malamut R, 2013, ALZHEIMERS DEMENT, V9, DOI [10.1016/j.jalz.2013.05.1378, DOI 10.1016/j.jalz.2013.05.1378]; MARSHALL LE, 1978, BIOCHIM BIOPHYS ACTA, V543, P590, DOI 10.1016/0304-4165(78)90315-X; Matsuda W, 2009, J NEUROSCI, V29, P444, DOI 10.1523/JNEUROSCI.4029-08.2009; Matsuoka Y, 2008, J PHARMACOL EXP THER, V325, P146, DOI 10.1124/jpet.107.130526; Matsuoka Y, 2007, J MOL NEUROSCI, V31, P165, DOI 10.1385/JMN/31:02:165; McKee AC, 2016, NEUROSURG CLIN N AM, V27, P529, DOI 10.1016/j.nec.2016.05.009; Munch C, 2005, ANN NEUROL, V58, P777, DOI 10.1002/ana.20631; Nacharaju P, 1999, J NEUROPATH EXP NEUR, V58, P545, DOI 10.1097/00005072-199905000-00157; Nelson PT, 2016, J NEUROPATH EXP NEUR, V75, P482, DOI 10.1093/jnen/nlw033; Neumann M, 2006, SCIENCE, V314, P130, DOI 10.1126/science.1134108; Oliveira SA, 2003, ANN NEUROL, V53, P624, DOI 10.1002/ana.10524; Ori-McKenney KM, 2012, NEURON, V76, P921, DOI 10.1016/j.neuron.2012.10.008; Paisan-Ruiz C, 2004, NEURON, V44, P595, DOI 10.1016/j.neuron.2004.10.023; Penazzi L, 2016, INT REV CEL MOL BIO, V321, P89, DOI 10.1016/bs.ircmb.2015.09.004; Peters OM, 2015, J CLIN INVEST, V125, P2548, DOI 10.1172/JCI82693; Puls I, 2003, NAT GENET, V33, P455, DOI 10.1038/ng1123; Qiang L, 2006, J NEUROSCI, V26, P3120, DOI 10.1523/JNEUROSCI.5392-05.2006; Ren Y, 2005, J BIOL CHEM, V280, P34105, DOI 10.1074/jbc.M503483200; Ren Y, 2015, STEM CELLS, V33, P68, DOI 10.1002/stem.1854; Robberecht W, 2013, NAT REV NEUROSCI, V14, P248, DOI 10.1038/nrn3430; Rosso SB, 2000, TOXICOL SCI, V56, P133, DOI 10.1093/toxsci/56.1.133; Roy S, 2005, ACTA NEUROPATHOL, V109, P5, DOI 10.1007/s00401-004-0952-x; Saulle M, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/816069; Shaw CA, 2008, NEUROMOL MED, V10, P1, DOI 10.1007/s12017-007-8016-8; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; St George-Hyslop PH, 2005, CR BIOL, V328, P119, DOI 10.1016/j.crvi.2004.10.013; Stiess M, 2010, SCIENCE, V327, P704, DOI 10.1126/science.1182179; Sudo H, 2011, HUM MOL GENET, V20, P763, DOI 10.1093/hmg/ddq521; Tang-Schomer MD, 2012, EXP NEUROL, V233, P364, DOI 10.1016/j.expneurol.2011.10.030; Tang-Schomer MD, 2010, FASEB J, V24, P1401, DOI 10.1096/fj.09-142844; Toledo JB, 2013, BRAIN, V136, P2697, DOI 10.1093/brain/awt188; Vershinin M, 2007, P NATL ACAD SCI USA, V104, P87, DOI 10.1073/pnas.0607919104; Wade Richard H, 2007, Methods Mol Med, V137, P1, DOI 10.1007/978-1-59745-442-1_1; WILCOCK GK, 1982, J NEUROL SCI, V56, P343, DOI 10.1016/0022-510X(82)90155-1; Williamson TL, 1999, NAT NEUROSCI, V2, P50; Wills J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017953; Young JS, 2016, CURR PSYCHIAT REP, V18, DOI 10.1007/s11920-016-0719-9; Yu WQ, 2008, MOL BIOL CELL, V19, P1485, DOI 10.1091/mbc.E07-09-0878; Yuan A, 2008, J NEUROSCI, V28, P1682, DOI 10.1523/JNEUROSCI.5242-07.2008; Zhang B, 1997, J CELL BIOL, V139, P1307, DOI 10.1083/jcb.139.5.1307; Zhang B, 2005, P NATL ACAD SCI USA, V102, P227, DOI 10.1073/pnas.0406361102; Zhang B, 2012, J NEUROSCI, V32, P3601, DOI 10.1523/JNEUROSCI.4922-11.2012; Zhao Y, 2016, PHARMACOL THERAPEUT, V162, P134, DOI 10.1016/j.pharmthera.2015.12.006; Zimprich A, 2004, NEURON, V44, P601, DOI 10.1016/j.neuron.2004.11.005	123	42	42	1	15	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	SEP	2017	105						328	335		10.1016/j.nbd.2016.12.021			8	Neurosciences	Neurosciences & Neurology	FC3JG	WOS:000406734300027	28012891	Green Accepted			2021-06-18	
J	Donnelly, J; Czosnyka, M; Adams, H; Robba, C; Steiner, LA; Cardim, D; Cabella, B; Liu, XY; Ercole, A; Hutchinson, PJ; Menon, DK; Aries, MJH; Smielewski, P				Donnelly, Joseph; Czosnyka, Marek; Adams, Hadie; Robba, Chiara; Steiner, Luzius A.; Cardim, Danilo; Cabella, Brenno; Liu, Xiuyun; Ercole, Ari; Hutchinson, Peter John; Menon, David Krishna; Aries, Marcel J. H.; Smielewski, Peter			Individualizing Thresholds of Cerebral Perfusion Pressure Using Estimated Limits of Autoregulation	CRITICAL CARE MEDICINE			English	Article						autoregulation; cerebral hemodynamics; cerebral perfusion pressure; intracranial pressure; traumatic brain injury	TRAUMATIC BRAIN-INJURY; CEREBROVASCULAR REACTIVITY; MANAGEMENT; BEDSIDE; TIME	Objectives: In severe traumatic brain injury, cerebral perfusion pressure management based on cerebrovascular pressure reactivity index has the potential to provide a personalized treatment target to improve patient outcomes. So far, the methods have focused on identifying "one" autoregulation-guided cerebral perfusion pressure target-called "cerebral perfusion pressure optimal". We investigated whether a cerebral perfusion pressure autoregulation range-which uses a continuous estimation of the "lower" and "upper" cerebral perfusion pressure limits of cerebrovascular pressure autoregulation (assessed with pressure reactivity index)-has prognostic value. Design: Single-center retrospective analysis of prospectively collected data. Setting: The neurocritical care unit at a tertiary academic medical center. Patients: Data from 729 severe traumatic brain injury patients admitted between 1996 and 2016 were used. Treatment was guided by controlling intracranial pressure and cerebral perfusion pressure according to a local protocol. Interventions: None. Methods and Main Results: Cerebral perfusion pressure-pressure reactivity index curves were fitted automatically using a previously published curve-fitting heuristic from the relationship between pressure reactivity index and cerebral perfusion pressure. The cerebral perfusion pressure values at which this "U-shaped curve" crossed the fixed threshold from intact to impaired pressure reactivity (pressure reactivity index = 0.3) were denoted automatically the "lower" and "upper" cerebral perfusion pressure limits of reactivity, respectively. The percentage of time with cerebral perfusion pressure below (% cerebral perfusion pressure < lower limit of reactivity), above (% cerebral perfusion pressure > upper limit of reactivity), or within these reactivity limits (% cerebral perfusion pressure within limits of reactivity) was calculated for each patient and compared across dichotomized Glasgow Outcome Scores. After adjusting for age, initial Glasgow Coma Scale, and mean intracranial pressure, percentage of time with cerebral perfusion pressure less than lower limit of reactivity was associated with unfavorable outcome (odds ratio % cerebral perfusion pressure < lower limit of reactivity, 1.04; 95% CI, 1.02- 1.06; p < 0.001) and mortality (odds ratio, 1.06; 95% CI, 1.04-1.08; p < 0.001). Conclusions: Individualized autoregulation-guided cerebral perfusion pressure management may be a plausible alternative to fixed cerebral perfusion pressure threshold management in severe traumatic brain injury patients. Prospective randomized research will help define which autoregulation-guided method is beneficial, safe, and most practical.	[Donnelly, Joseph; Czosnyka, Marek; Adams, Hadie; Cardim, Danilo; Cabella, Brenno; Liu, Xiuyun; Aries, Marcel J. H.; Smielewski, Peter] Univ Cambridge, Dept Clin Neurosci, Div Neurosurg, Brain Phys Lab, Cambridge Biomed Campus, Cambridge, England; [Czosnyka, Marek] Warsaw Univ Technol, Inst Elect Syst, Warsaw, Poland; [Robba, Chiara; Ercole, Ari; Menon, David Krishna] Univ Cambridge, Addenbrookes Hosp, Dept Med, Div Anaesthesia, Cambridge, England; [Robba, Chiara] Univ Genoa, Dept Neurosci, Genoa, Italy; [Steiner, Luzius A.] Univ Basel, Univ Basel Hosp, Dept Anesthesia Surg Intens Care Prehosp Emergenc, Basel, Switzerland; [Hutchinson, Peter John] Univ Cambridge, Addenbrookes Hosp, Dept Clin Neurosci, Div Neurosurg, Cambridge, England; [Aries, Marcel J. H.] Maastricht Univ, Med Ctr, Univ Maastricht, Dept Intens Care, Maastricht, Netherlands	Donnelly, J (corresponding author), Univ Cambridge, Dept Clin Neurosci, Div Neurosurg, Brain Phys Lab, Cambridge Biomed Campus, Cambridge, England.	jd634@cam.ac.uk	Ercole, Ari/B-6288-2009; Donnelly, Joseph/N-6803-2019; Cardim, Danilo Augusto/B-8447-2012; Robba, Chiara/AAS-7421-2020; Steiner, Luzius/J-1987-2019; Liu, Xiuyun/V-4427-2017; Donnelly, Joseph/E-9235-2018; Cabella, Brenno C.T./G-6169-2012	Ercole, Ari/0000-0001-8350-8093; Donnelly, Joseph/0000-0002-6502-8069; Cardim, Danilo Augusto/0000-0002-9261-1321; Liu, Xiuyun/0000-0001-9540-4865; Donnelly, Joseph/0000-0002-6502-8069; Cabella, Brenno C.T./0000-0003-2214-645X	Woolf Fisher scholarship; Cambridge Enterprise, Cambridge, United Kingdom; Bill & Melinda Gates FoundationBill & Melinda Gates Foundation; National Institute of Health Research (NIHR) Research Professorship; Academy of Medical Sciences/Health Foundation Senior Surgical Scientist Fellowship; Ornim Medical; Shire Medical; Neurovive; Calico; NIHRNational Institute for Health Research (NIHR); GlaxoSmithKlineGlaxoSmithKline; Brainscope; Solvay; NIHR Cambridge Biomedical Centre [RCZB/004]; NIHR Senior Investigator Award [RCZB/014]; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0601025, G0600986] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0512-10090, NIHR-RP-R3-12-013] Funding Source: researchfish	Dr. Donnelly received support from a Woolf Fisher scholarship. Dr. Czosnyka has financial interest in a fraction of the licensing fee, and his institution received funding from Cambridge Enterprise, Cambridge, United Kingdom. Dr. Cardim disclosed other support from use of software developed in-house for data analysis. Dr. Liu received support for article research from the Bill & Melinda Gates Foundation. Dr. Hutchinson disclosed that he is a Director of Technicam manufacturer of the Cranial Access Device and he received support from a National Institute of Health Research (NIHR) Research Professorship, Academy of Medical Sciences/Health Foundation Senior Surgical Scientist Fellowship. Dr. Menon received other support from Ornim Medical, Shire Medical, Neurovive, and Calico; he received support for article research from the NIHR; his institution received funding from GlaxoSmithKline and Brainscope; and he received funding from Solvay and the NIHR Cambridge Biomedical Centre (RCZB/004) and an NIHR Senior Investigator Award (RCZB/014). Dr. Smielewski disclosed receiving a fraction of the licensing fees of the software, ICM+ (licensed by Cambridge Enterprise, United Kingdom), used for data collection and analysis in this study. The remaining authors have disclosed that they do not have any potential conflicts of interest.	Al-Rawi PG, 2000, ZBL NEUROCHIR, V61, P74, DOI 10.1055/s-2000-8263; Aries MJH, 2016, CRIT CARE MED, V44, pE996, DOI 10.1097/CCM.0000000000001816; Aries MJH, 2012, CRIT CARE MED, V40, P2456, DOI 10.1097/CCM.0b013e3182514eb6; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Carney N, 2016, NEUROSURGERY, P1, DOI DOI 10.1227/NEU.0000000000001432; Depreitere B, 2014, J NEUROSURG, V120, P1451, DOI 10.3171/2014.3.JNS131500; Dias C, 2015, NEUROCRIT CARE, V23, P92, DOI 10.1007/s12028-014-0103-8; Dias C, 2015, NEUROCRIT CARE, V22, P192, DOI 10.1007/s12028-014-0045-1; Donnelly J, 2017, J CEREBR BLOOD F MET, V37, P694, DOI 10.1177/0271678X16639060; Donnelly J, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1293-6; Donnelly J, 2015, NEUROCRIT CARE, V22, P20, DOI 10.1007/s12028-014-0042-4; Donnelly J, 2015, EXPERT REV NEUROTHER, V15, P169, DOI 10.1586/14737175.2015.996552; Eker C, 1998, CRIT CARE MED, V26, P1881, DOI 10.1097/00003246-199811000-00033; Griesdale DEG, 2015, J CRIT CARE, V30, P111, DOI 10.1016/j.jcrc.2014.07.026; Guiza F, 2015, INTENS CARE MED, V41, P1067, DOI 10.1007/s00134-015-3806-1; JENNETT B, 1975, LANCET, V1, P480; Lavinio A, 2007, BRIT J ANAESTH, V99, P237, DOI 10.1093/bja/aem118; Le Roux P, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-012-0331-2; Lewis PM, 2015, PEDIATR CRIT CARE ME, V16, P739, DOI 10.1097/PCC.0000000000000471; Maas AIR, 2015, NEUROSURGERY, V76, P67, DOI 10.1227/NEU.0000000000000575; Maas AIR, 2012, LANCET NEUROL, V11, P12, DOI 10.1016/S1474-4422(11)70267-8; McLeod A. I., 2017, bestglm: Best subset GLM; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; Needham E, 2017, J NEUROTRAUM, V34, P963, DOI 10.1089/neu.2016.4450; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Robertson CS, 2001, ANESTHESIOLOGY, V95, P1513, DOI 10.1097/00000542-200112000-00034; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Sekhon MS, 2015, NEUROCRIT CARE, V23, P210, DOI 10.1007/s12028-015-0141-x; Smirl JD, 2014, J APPL PHYSIOL, V116, P1614, DOI 10.1152/japplphysiol.01266.2013; Sorrentino E, 2012, NEUROCRIT CARE, V16, P258, DOI 10.1007/s12028-011-9630-8; Spiotta AM, 2010, J NEUROSURG, V113, P571, DOI 10.3171/2010.1.JNS09506; Stein SC, 2010, J NEUROTRAUM, V27, P1343, DOI 10.1089/neu.2009.1206; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Wickham H., 2016, DPLYR GRAMMAR DATA M; Wickham H, 2009, ELEGANT GRAPHICS DAT; Young AMH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148817	40	42	43	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	SEP	2017	45	9					1464	1471		10.1097/CCM.0000000000002575			8	Critical Care Medicine	General & Internal Medicine	FD9LJ	WOS:000407843600025	28816837	Green Accepted			2021-06-18	
J	Semple, BD; O'Brien, TJ; Gimlin, K; Wright, DK; Kim, SE; Casillas-Espinosa, PM; Webster, KM; Petrou, S; Noble-Haeusslein, LJ				Semple, Bridgette D.; O'Brien, Terence J.; Gimlin, Kayleen; Wright, David K.; Kim, Shi Eun; Casillas-Espinosa, Pablo M.; Webster, Kyria M.; Petrou, Steven; Noble-Haeusslein, Linda J.			Interleukin-1 Receptor in Seizure Susceptibility after Traumatic Injury to the Pediatric Brain	JOURNAL OF NEUROSCIENCE			English	Article						cytokine; interleukin; neurotrauma; pediatric; seizure; traumatic brain injury	CONTROLLED CORTICAL IMPACT; POSTTRAUMATIC EPILEPSY; IMMATURE BRAIN; DENTATE GYRUS; TEMPORAL-LOBE; ANIMAL-MODELS; MICE; ANTAGONIST; RATS; NEUTRALIZATION	Epilepsy after pediatric traumatic brain injury (TBI) is associated with poor quality of life. This study aimed to characterize post-traumatic epilepsy in a mouse model of pediatric brain injury, and to evaluate the role of interleukin-1 (IL-1) signaling as a target for pharmacological intervention. Male mice received a controlled cortical impact or sham surgery at postnatal day 21, approximating a toddler-aged child. Mice were treated acutely with an IL-1 receptor antagonist (IL-1Ra; 100 mg/kg, s.c.) or vehicle. Spontaneous and evoked seizures were evaluated from video-EEG recordings. Behavioral assays tested for functional outcomes, postmortem analyses assessed neuropathology, and brain atrophy was detected by ex vivo magnetic resonance imaging. At 2 weeks and 3 months post-injury, TBI mice showed an elevated seizure response to the convulsant pentylenetetrazol compared with sham mice, associated with abnormal hippocampal mossy fiber sprouting. A robust increase in IL-1 beta and IL-1 receptor were detected after TBI. IL-1Ra treatment reduced seizure susceptibility 2 weeks after TBI compared with vehicle, and a reduction in hippocampal astrogliosis. In a chronic study, IL-1Ra-TBI mice showed improved spatial memory at 4 months post-injury. At 5 months, most TBI mice exhibited spontaneous seizures during a 7 d video-EEG recording period. At 6 months, IL-1Ra-TBI mice had fewer evoked seizures compared with vehicle controls, coinciding with greater preservation of cortical tissue. Findings demonstrate this model's utility to delineate mechanisms underlying epileptogenesis after pediatric brain injury, and provide evidence of IL-1 signaling as a mediator of post-traumatic astrogliosis and seizure susceptibility.	[Semple, Bridgette D.; O'Brien, Terence J.; Kim, Shi Eun; Casillas-Espinosa, Pablo M.; Webster, Kyria M.] Univ Melbourne, Dept Med, Melbourne Brain Ctr, Royal Melbourne Hosp, Kenneth Myer Bldg, Parkville, Vic 3050, Australia; [Gimlin, Kayleen; Noble-Haeusslein, Linda J.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; [Wright, David K.] Florey Inst Neurosci & Mental Hlth, Parkville, Vic 3050, Australia; [Noble-Haeusslein, Linda J.] Univ Texas Austin, Dell Med Sch, Dept Psychol, Austin, TX 78701 USA; [Noble-Haeusslein, Linda J.] Univ Texas Austin, Dell Med Sch, Dept Neurol, Austin, TX 78701 USA	Semple, BD (corresponding author), Univ Melbourne, Dept Med, Melbourne Brain Ctr, Royal Melbourne Hosp, Kenneth Myer Bldg, Parkville, Vic 3050, Australia.	Bridgette.Semple@unimelb.edu.au	Tercovich, Kayleen/I-8941-2018	Tercovich, Kayleen/0000-0003-0450-8912; Petrou, Steven/0000-0002-4960-6375; O'Brien, Terence/0000-0002-7198-8621; Wright, David/0000-0002-7535-8651	NHMRC Early Career FellowshipNational Health and Medical Research Council of Australia; UoM Early Career Grant; NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS077767]; Rebecca L. Cooper Medical Research Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS077767, R01NS050159] Funding Source: NIH RePORTER	This work was supported by an NHMRC Early Career Fellowship, a UoM Early Career Grant, NIH/NINDS R01 NS077767, and funding from the Rebecca L. Cooper Medical Research Foundation. We thank Ann Turnley (UoM) for providing access to the controlled cortical impactor device, Leigh Johnson (UoM) for guidance and oversight of neuroimaging, and the scientific and technical assistance of the animal MRI facility at the Florey Institute of Neuroscience and Mental Health, a node of the National Imaging Facility.	ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; Annegers JF, 2000, SEIZURE-EUR J EPILEP, V9, P453, DOI 10.1053/seiz.2000.0458; Arndt DH, 2013, EPILEPSIA, V54, P1780, DOI 10.1111/epi.12369; Ates O, 2006, CHILD NERV SYST, V22, P279, DOI 10.1007/s00381-005-1177-6; Babb T L, 1997, Adv Neurol, V72, P45; Bao YH, 2011, J NEUROTRAUM, V28, P35, DOI 10.1089/neu.2010.1383; Barlow KM, 2000, DEV MED CHILD NEUROL, V42, P591, DOI 10.1017/S0012162200001110; Blanco MM, 2009, EPILEPSIA, V50, P824, DOI 10.1111/j.1528-1167.2008.01797.x; Bolkvadze T, 2012, J NEUROTRAUM, V29, P789, DOI 10.1089/neu.2011.1954; Brough D, 2011, TRENDS PHARMACOL SCI, V32, P617, DOI 10.1016/j.tips.2011.06.002; Clausen F, 2011, EUR J NEUROSCI, V34, P110, DOI 10.1111/j.1460-9568.2011.07723.x; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; Cole TB, 2000, EPILEPSY RES, V39, P153, DOI 10.1016/S0920-1211(99)00121-7; Dube C, 2005, ANN NEUROL, V57, P152, DOI 10.1002/ana.20358; Ekmark-Lewen S, 2016, EUR J NEUROSCI, V43, P1016, DOI 10.1111/ejn.13190; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; Galic MA, 2008, J NEUROSCI, V28, P6904, DOI 10.1523/JNEUROSCI.1901-08.2008; Greenhalgh AD, 2010, BRIT J PHARMACOL, V160, P153, DOI 10.1111/j.1476-5381.2010.00684.x; HAHN YS, 1988, NEUROSURGERY, V22, P864, DOI 10.1227/00006123-198805000-00008; Helmy A, 2014, J CEREBR BLOOD F MET, V34, P845, DOI 10.1038/jcbfm.2014.23; Hunt RF, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00089; Hunt RF, 2010, J NEUROPHYSIOL, V103, P1490, DOI 10.1152/jn.00957.2009; Hunt RF, 2009, EXP NEUROL, V215, P243, DOI 10.1016/j.expneurol.2008.10.005; Huusko N, 2015, BRAIN STRUCT FUNCT, V220, P153, DOI 10.1007/s00429-013-0644-1; Jeub M, 1999, NEUROSCIENCE, V94, P465, DOI 10.1016/S0306-4522(99)00249-3; John GR, 2004, J NEUROSCI, V24, P2837, DOI 10.1523/JNEUROSCI.4789-03.2004; Liu SJ, 2016, BRAIN, V139, P1919, DOI 10.1093/brain/aww116; LOSCHER W, 1991, EPILEPSY RES, V9, P1, DOI 10.1016/0920-1211(91)90041-D; Luttjohann A, 2009, PHYSIOL BEHAV, V98, P579, DOI 10.1016/j.physbeh.2009.09.005; Maroso M, 2011, NEUROTHERAPEUTICS, V8, P304, DOI 10.1007/s13311-011-0039-z; McCann SK, 2016, TRANSL STROKE RES, V7, P395, DOI 10.1007/s12975-016-0489-z; Nardou R, 2013, SEMIN FETAL NEONAT M, V18, P175, DOI 10.1016/j.siny.2013.02.003; Nehlig A, 1996, EPILEPSY RES, V26, P93, DOI 10.1016/S0920-1211(96)00045-9; Ortinski PI, 2010, NAT NEUROSCI, V13, P584, DOI 10.1038/nn.2535; Pinteaux E, 2009, CYTOKINE, V45, P1, DOI 10.1016/j.cyto.2008.10.008; Pitkanen A, 2009, EPILEPSIA, V50, P21, DOI 10.1111/j.1528-1167.2008.02007.x; Potts Mathew B, 2006, NeuroRx, V3, P143; Pullela R, 2006, DEV NEUROSCI-BASEL, V28, P396, DOI 10.1159/000094166; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Rattka M, 2011, NEUROPHARMACOLOGY, V60, P505, DOI 10.1016/j.neuropharm.2010.11.005; Robel S, 2015, J NEUROSCI, V35, P3330, DOI 10.1523/JNEUROSCI.1574-14.2015; Santhakumar V, 2005, J NEUROPHYSIOL, V93, P437, DOI 10.1152/jn.00777.2004; Semple BD, 2017, BEHAV BRAIN RES, V319, P48, DOI 10.1016/j.bbr.2016.10.045; Semple BD, 2015, NEUROBIOL DIS, V74, P263, DOI 10.1016/j.nbd.2014.12.003; Shultz SR, 2013, EPILEPSIA, V54, P1240, DOI 10.1111/epi.12223; Statler KD, 2009, EPILEPSY RES, V86, P221, DOI 10.1016/j.eplepsyres.2009.05.006; SUTULA T, 1989, ANN NEUROL, V26, P321, DOI 10.1002/ana.410260303; TAUCK DL, 1985, J NEUROSCI, V5, P1016; Van Nieuwenhuyse B, 2015, BRAIN RES, V1627, P1, DOI 10.1016/j.brainres.2015.08.016; Vezzani A, 1999, J NEUROSCI, V19, P5054; Vezzani A, 2000, P NATL ACAD SCI USA, V97, P11534, DOI 10.1073/pnas.190206797; Viviani B, 2003, J NEUROSCI, V23, P8692; Webster KM, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-016-0786-1; Ziyatdinova S, 2011, EPILEPSY RES, V94, P75, DOI 10.1016/j.eplepsyres.2011.01.003	54	42	46	0	6	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	AUG 16	2017	37	33					7864	7877		10.1523/JNEUROSCI.0982-17.2017			14	Neurosciences	Neurosciences & Neurology	FD7KR	WOS:000407705500009	28724747	Green Published, Bronze			2021-06-18	
J	Wallisch, JS; Simon, DW; Bayir, H; Bell, MJ; Kochanek, PM; Clark, RSB				Wallisch, Jessica S.; Simon, Dennis W.; Bayir, Huelya; Bell, Michael J.; Kochanek, Patrick M.; Clark, Robert S. B.			Cerebrospinal Fluid NLRP3 is Increased After Severe Traumatic Brain Injury in Infants and Children	NEUROCRITICAL CARE			English	Article						NLRP3; NLRP1; Inflammasome; Traumatic brain injury; Biomarker; Neuroinflammation; Secondary brain injury; Pediatric	INFLAMMATORY RESPONSE; HEAD TRAUMA; CELL-DEATH; ACTIVATION; INTERLEUKIN-1-BETA; NEUTRALIZATION; INHIBITION; PYROPTOSIS; MEDIATORS; TISSUE	Background Inflammasome-mediated neuroinflammation may cause secondary injury following traumatic brain injury (TBI) in children. The pattern recognition receptors NACHT domain-, Leucine-rich repeat-, and PYD-containing Protein 1 (NLRP1) and NLRP3 are essential components of their respective inflammasome complexes. We sought to investigate whether NLRP1 and/or NLRP3 abundance is altered in children with severe TBI. Methods Cerebrospinal fluid (CSF) from children (n = 34) with severe TBI (Glasgow coma scale score [GCS] <= 8) who had externalized ventricular drains (EVD) placed for routine care was evaluated for NLRP1 and NLRP3 at 0-24, 25-48, 49-72, and >72 h post-TBI and was compared to infection-free controls that underwent lumbar puncture to rule out CNS infection (n = 8). Patient age, sex, initial GCS, mechanism of injury, treatment with therapeutic hypothermia, and 6-month Glasgow outcome score were collected. Results CSF NLRP1 was undetectable in controls and detected in 2 TBI patients at only <24 h post-TBI. CSF NLRP3 levels were increased in TBI patients compared with controls at all time points, p < 0.001. TBI patients <= 4 years of age had higher peak NLRP3 levels versus patients >4 (15.50 [3.65-25.71] vs. 3.04 [1.52-8.87] ng/mL, respectively; p = 0.048). Controlling for initial GCS in multivariate analysis, peak NLRP3 >6.63 ng/mL was independently associated with poor outcome at 6 months. Conclusions In the first report of NLRP1 and NLRP3 in childhood neurotrauma, we found that CSF NLRP3 is elevated in children with severe TBI and independently associated with younger age and poor outcome. Future studies correlating NLRP3 with other markers of inflammation and response to therapy are warranted.	[Wallisch, Jessica S.; Simon, Dennis W.; Bayir, Huelya; Bell, Michael J.; Kochanek, Patrick M.; Clark, Robert S. B.] Univ Pittsburgh, Childrens Hosp Pittsburgh, Dept Crit Care Med, UPMC,Sch Med, 4401 Penn Ave, Pittsburgh, PA 15224 USA; [Wallisch, Jessica S.; Simon, Dennis W.; Bayir, Huelya; Bell, Michael J.; Kochanek, Patrick M.; Clark, Robert S. B.] Univ Pittsburgh, Sch Med, Dept Pediat, Childrens Hosp Pittsburgh,UPMC, Pittsburgh, PA 15261 USA; [Wallisch, Jessica S.; Simon, Dennis W.; Bayir, Huelya; Bell, Michael J.; Kochanek, Patrick M.; Clark, Robert S. B.] Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; [Bayir, Huelya] Univ Pittsburgh, Sch Med, Dept Environm & Occupat Hlth, Ctr Free Rad & Antioxidant Hlth, Pittsburgh, PA USA; [Bell, Michael J.] Univ Pittsburgh, Sch Med, Dept Neurol Surg, Childrens Hosp Pittsburgh,UPMC, Pittsburgh, PA 15261 USA	Simon, DW (corresponding author), Univ Pittsburgh, Childrens Hosp Pittsburgh, Dept Crit Care Med, UPMC,Sch Med, 4401 Penn Ave, Pittsburgh, PA 15224 USA.; Simon, DW (corresponding author), Univ Pittsburgh, Sch Med, Dept Pediat, Childrens Hosp Pittsburgh,UPMC, Pittsburgh, PA 15261 USA.; Simon, DW (corresponding author), Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA.	dennis.simon2@chp.edu		Wallisch, Jessica/0000-0002-7908-9479; Simon, Dennis/0000-0002-3824-2326	NINDS Grants [R01 NS38620, U01 NS081041]; NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32 HD40686]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS081041, R01NS038620] Funding Source: NIH RePORTER	NINDS Grants R01 NS38620 (RC) and U01 NS081041 (MB); NICHD T32 HD40686 (DS, JW).	Adamczak S, 2012, J NEUROSURG, V117, P1119, DOI 10.3171/2012.9.JNS12815; Adelson PD, 2013, LANCET NEUROL, V12, P546, DOI 10.1016/S1474-4422(13)70077-2; Bergsbaken T, 2009, NAT REV MICROBIOL, V7, P99, DOI 10.1038/nrmicro2070; Chiaretti A, 2005, CHILD NERV SYST, V21, P185, DOI 10.1007/s00381-004-1032-1; Christian CW, 2009, PEDIATRICS, V123, P1409, DOI 10.1542/peds.2009-0408; Clausen F, 2011, EUR J NEUROSCI, V34, P110, DOI 10.1111/j.1460-9568.2011.07723.x; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; Coll RC, 2015, NAT MED, V21, P248, DOI 10.1038/nm.3806; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Fink KB, 1999, NEUROSCIENCE, V94, P1213, DOI 10.1016/S0306-4522(99)00345-0; Fink SL, 2008, P NATL ACAD SCI USA, V105, P4312, DOI 10.1073/pnas.0707370105; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; Helmy A, 2014, J CEREBR BLOOD F MET, V34, P845, DOI 10.1038/jcbfm.2014.23; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Hutchinson PJ, 2007, J NEUROTRAUM, V24, P1545, DOI 10.1089/neu.2007.0295; Kemp AM, 2010, ARCH DIS CHILD, V95, P355, DOI 10.1136/adc.2009.169110; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Lamkanfi M, 2009, J CELL BIOL, V187, P61, DOI 10.1083/jcb.200903124; Latz E, 2013, NAT REV IMMUNOL, V13, P397, DOI 10.1038/nri3452; Liu HD, 2013, NEUROCHEM RES, V38, P2072, DOI 10.1007/s11064-013-1115-z; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Moreau JF, 2013, PEDIATR CRIT CARE ME, V14, P801, DOI 10.1097/PCC.0b013e31828aa71f; Newell E, 2015, PEDIATR CRIT CARE ME, V16, P549, DOI 10.1097/PCC.0000000000000400; Perez-Barcena J, 2011, CRIT CARE MED, V39, P533, DOI 10.1097/CCM.0b013e318205c7a4; Satchell MA, 2005, J CEREBR BLOOD F MET, V25, P919, DOI 10.1038/sj.jcbfm.9600088; Savage CD, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00288; Schmidt OI, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-13; Shein SL, 2012, J PEDIATR-US, V161, P716, DOI 10.1016/j.jpeds.2012.03.046; Shiozaki T, 2005, SHOCK, V23, P406, DOI 10.1097/01.shk.0000161385.62758.24; Sifringer M, 2007, NEUROBIOL DIS, V25, P614, DOI 10.1016/j.nbd.2006.11.003; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; Vaccari JPD, 2016, J NEUROCHEM, V136, P39, DOI 10.1111/jnc.13036; Vaccari JPD, 2014, J CEREBR BLOOD F MET, V34, P369, DOI 10.1038/jcbfm.2013.227; Vaccari JPD, 2009, J CEREBR BLOOD F MET, V29, P1251, DOI 10.1038/jcbfm.2009.46; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008; Youm YH, 2015, NAT MED, V21, P263, DOI 10.1038/nm.3804; Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663	38	42	46	2	9	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	AUG	2017	27	1					44	50		10.1007/s12028-017-0378-7			7	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	FB7GX	WOS:000406310200007	28181102	Green Accepted			2021-06-18	
J	Irrera, N; Pizzino, G; Calo, M; Pallio, G; Mannino, F; Fama, F; Arcoraci, V; Fodale, V; David, A; Francesca, C; Minutoli, L; Mazzon, E; Bramanti, P; Squadrito, F; Altavilla, D; Bitto, A				Irrera, Natasha; Pizzino, Gabriele; Calo, Margherita; Pallio, Giovanni; Mannino, Federica; Fama, Fausto; Arcoraci, Vincenzo; Fodale, Vincenzo; David, Antonio; Francesca, Cosentino; Minutoli, Letteria; Mazzon, Emanuela; Bramanti, Placido; Squadrito, Francesco; Altavilla, Domenica; Bitto, Alessandra			Lack of the Nlrp3 Inflammasome Improves Mice Recovery Following Traumatic Brain Injury	FRONTIERS IN PHARMACOLOGY			English	Article						NLRP3 inflammasome; traumatic brain injury; inflammation; cytokines; apoptosis	CEREBRAL-CORTEX; KAPPA-B; ACTIVATION; APOPTOSIS; NEURONS; EXPRESSION; RATS; DEGENERATION; HEMORRHAGE; CASPASE-1	Treatment for traumatic brain injury (TBI) remains elusive despite compelling evidence from animal models for a variety of therapeutic targets. The activation of the NLRP3 (Nucleotide-binding oligomerization domain-like receptor family pyrin domain-containing 3) inflammasome has been proposed as key point in the brain damage associated with TBI. NLRP3 was tested as potential target for reducing neuronal loss and promoting functional recovery in a mouse model of TBI. Male NLRP3(-/-) (n = 20) and wild type (n = 27) mice were used. A closed TBI model was performed and inflammatory and apoptotic markers were evaluated. A group of WT mice also received BAY 11-7082, a NLRP3 inhibitor, to further evaluate the role of this pathway. At 24 h following TBI NLRP3 = animals demonstrated a preserved cognitive function as compared to WT mice, additionally brain damage was less severe and the inflammatory mediators were reduced in brain lysates. The administration of BAY 11-7082 in WT animals subjected to TBI produced overlapping results. At day 7 histology revealed a more conserved brain structure with reduced damage in TBI NLRP3 = animals compared to WT. Our data indicate that the NLRP3 pathway might be exploited as molecular target for the short-term sequelae of TBI.	[Irrera, Natasha; Pizzino, Gabriele; Pallio, Giovanni; Mannino, Federica; Arcoraci, Vincenzo; Minutoli, Letteria; Squadrito, Francesco; Bitto, Alessandra] Univ Messina, AOU Policlin G Martino, Dept Clin & Expt Med, Messina, Italy; [Calo, Margherita] Univ Messina, Dept Vet Sci, Messina, Italy; [Fama, Fausto; Fodale, Vincenzo; David, Antonio; Francesca, Cosentino] Univ Messina, AOU Policlin G Martino, Dept Human Pathol, Messina, Italy; [Mazzon, Emanuela; Bramanti, Placido] IRCCS Ctr Neurolesi Bonino Pulejo, Messina, Italy; [Altavilla, Domenica] Univ Messina, AOU Policlin G Martino, Dept Biomed & Dent Sci & Morphol & Funct Sci, Messina, Italy	Squadrito, F (corresponding author), Univ Messina, AOU Policlin G Martino, Dept Clin & Expt Med, Messina, Italy.	fsquadrito@unime.it	Fodale, Vincenzo/G-5554-2010; Irrera, Natasha/K-5411-2018; Fama', Fausto/L-3071-2015; Pallio, Giovanni/AAM-1136-2021; Mazzon, Emanuela/AAL-4334-2020; Pallio, Giovanni/AAC-2420-2019; Bramanti, Placido/K-5117-2016	Fodale, Vincenzo/0000-0001-9540-5665; Fama', Fausto/0000-0002-9017-1991; Pallio, Giovanni/0000-0002-4187-2265; mazzon, emanuela/0000-0002-5073-717X			Antunes M, 2012, COGN PROCESS, V13, P93, DOI 10.1007/s10339-011-0430-z; Bar-Peled O, 1999, J NEUROSCI RES, V55, P542, DOI 10.1002/(SICI)1097-4547(19990301)55:5<542::AID-JNR2>3.0.CO;2-7; Bell KFS, 2013, BIOCHEM SOC T, V41, P1541, DOI 10.1042/BST20130245; Brouns R, 2009, CLIN NEUROL NEUROSUR, V111, P483, DOI 10.1016/j.clineuro.2009.04.001; Cao GD, 2002, J NEUROSCI, V22, P5423; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; Craven RR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007446; d'Avila JC, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-31; Dix SL, 1999, BEHAV BRAIN RES, V99, P191, DOI 10.1016/S0166-4328(98)00079-5; Dong YS, 2016, J PINEAL RES, V60, P253, DOI 10.1111/jpi.12300; Ferrari D, 2006, J IMMUNOL, V176, P3877, DOI 10.4049/jimmunol.176.7.3877; Grabinger T, 2013, CELL DEATH DIFFER, V20, P1128, DOI 10.1038/cdd.2013.80; Halle A, 2008, NAT IMMUNOL, V9, P857, DOI 10.1038/ni.1636; Hang CH, 2006, BRAIN RES, V1109, P14, DOI 10.1016/j.brainres.2006.06.045; Jha S, 2010, J NEUROSCI, V30, P15811, DOI 10.1523/JNEUROSCI.4088-10.2010; Kaushal V, 2015, CELL DEATH DIFFER, V22, P1676, DOI 10.1038/cdd.2015.16; Kawai T, 2007, TRENDS MOL MED, V13, P460, DOI 10.1016/j.molmed.2007.09.002; Kilkenny C, 2010, BRIT J PHARMACOL, V160, P1577, DOI 10.1111/j.1476-5381.2010.00872.x; Kimbler DE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041229; KURTH SM, 1994, BRAIN INJURY, V8, P489, DOI 10.3109/02699059409151001; Lin C, 2017, EXP NEUROL, V290, P115, DOI 10.1016/j.expneurol.2017.01.005; Liu HD, 2013, NEUROCHEM RES, V38, P2072, DOI 10.1007/s11064-013-1115-z; Ma J, 2016, INFLAMMATION, V39, P2094, DOI 10.1007/s10753-016-0446-8; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Martinon F, 2010, EUR J IMMUNOL, V40, P616, DOI 10.1002/eji.200940168; Michael DB, 2005, J CLIN NEUROSCI, V12, P284, DOI 10.1016/j.jocn.2004.11.003; Povlishock J T, 1992, Hum Cell, V5, P345; Ralevic V, 1998, PHARMACOL REV, V50, P413; Reale M, 2009, MINI-REV MED CHEM, V9, P1229, DOI 10.2174/138955709789055199; Russo MV, 2015, TRENDS IMMUNOL, V36, P637, DOI 10.1016/j.it.2015.08.002; Schroder K, 2010, CELL, V140, P821, DOI 10.1016/j.cell.2010.01.040; Shen JX, 2016, SCI REP-UK, V6, DOI 10.1038/srep34682; Silverman WR, 2009, J BIOL CHEM, V284, P18143, DOI 10.1074/jbc.M109.004804; Szabo C, 1998, TRENDS PHARMACOL SCI, V19, P287, DOI 10.1016/S0165-6147(98)01193-6; Vaccari JPDR, 2008, J NEUROSCI, V28, P3404, DOI 10.1523/JNEUROSCI.0157-08.2008; Wallach D, 2016, SCIENCE, V352, DOI 10.1126/science.aaf2154; Wang Q, 2007, J NEUROIMMUNOL, V184, P53, DOI 10.1016/j.jneuroim.2006.11.014; Wei X, 2016, J HUAZHONG U SCI-MED, V36, P576, DOI 10.1007/s11596-016-1628-1; Yan YP, 2009, BRAIN RES, V1288, P116, DOI 10.1016/j.brainres.2009.06.073; Zhao JB, 2011, NEUROSCI LETT, V498, P147, DOI 10.1016/j.neulet.2011.05.001	41	42	44	0	3	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1663-9812			FRONT PHARMACOL	Front. Pharmacol.	JUL 14	2017	8								459	10.3389/fphar.2017.00459			10	Pharmacology & Pharmacy	Pharmacology & Pharmacy	FB5PU	WOS:000406195000001	28769794	DOAJ Gold, Green Published			2021-06-18	
J	Hazeldine, J; Naumann, DN; Toman, E; Davies, D; Bishop, JRB; Su, ZJ; Hampson, P; Dinsdale, RJ; Crombie, N; Duggal, NA; Harrison, P; Belli, A; Lord, JM				Hazeldine, Jon; Naumann, David N.; Toman, Emma; Davies, David; Bishop, Jonathan R. B.; Su, Zhangjie; Hampson, Peter; Dinsdale, Robert J.; Crombie, Nicholas; Duggal, Niharika Arora; Harrison, Paul; Belli, Antonio; Lord, Janet M.			Prehospital immune responses and development of multiple organ dysfunction syndrome following traumatic injury: A prospective cohort study	PLOS MEDICINE			English	Article							MAJOR TRAUMA; BRAIN-INJURY; GENE-EXPRESSION; HEPATOCELLULAR-CARCINOMA; INFLAMMATORY RESPONSE; OXIDASE COMPONENTS; MOLECULAR-PATTERNS; SUPPRESSOR-CELLS; BURN INJURY; LATE-ONSET	Background Almost all studies that have investigated the immune response to trauma have analysed blood samples acquired post-hospital admission. Thus, we know little of the immune status of patients in the immediate postinjury phase and how this might influence patient outcomes. The objective of this study was therefore to comprehensively assess the ultra-early, within 1-hour, immune response to trauma and perform an exploratory analysis of its relationship with the development of multiple organ dysfunction syndrome (MODS). Methods and findings The immune and inflammatory response to trauma was analysed in 89 adult trauma patients (mean age 41 years, range 18-90 years, 75 males) with a mean injury severity score (ISS) of 24 (range 9-66), from whom blood samples were acquired within 1 hour of injury (mean time to sample 42 minutes, range 17-60 minutes). Within minutes of trauma, a comprehensive leukocytosis, elevated serum pro-and anti-inflammatory cytokines, and evidence of innate cell activation that included neutrophil extracellular trap generation and elevated surface expression of toll-like receptor 2 and CD11b on monocytes and neutrophils, respectively, were observed. Features consistent with immune compromise were also detected, notably elevated numbers of immune suppressive CD16(BRIGHT) CD62L(DIM) neutrophils (82.07 x 10(6)/l +/- 18.94 control versus 1,092 x 10(6)/l +/- 165 trauma, p < 0.0005) and CD14(+)HLA-DRlow/- monocytes (34.96 x 10(6)/l +/- 4.48 control versus 95.72 x 10(6)/l +/- 8.0 trauma, p < 0.05) and reduced leukocyte cytokine secretion in response to lipopolysaccharide stimulation. Exploratory analysis via binary logistic regression found a potential association between absolute natural killer T (NKT) cell numbers and the subsequent development of MODS. Study limitations include the relatively small sample size and the absence of data relating to adaptive immune cell function. Conclusions Our study highlighted the dynamic and complex nature of the immune response to trauma, with immune alterations consistent with both activation and suppression evident within 1 hour of injury. The relationship of these changes, especially in NKT cell numbers, to patient outcomes such as MODS warrants further investigation.	[Hazeldine, Jon; Hampson, Peter; Dinsdale, Robert J.; Crombie, Nicholas; Duggal, Niharika Arora; Harrison, Paul; Belli, Antonio; Lord, Janet M.] Univ Birmingham, Inst Inflammat & Ageing, Birmingham, W Midlands, England; [Hazeldine, Jon; Naumann, David N.; Toman, Emma; Davies, David; Bishop, Jonathan R. B.; Su, Zhangjie; Belli, Antonio; Lord, Janet M.] Queen Elizabeth Hosp Birmingham, NIHR Surg Reconstruct & Microbiol Res Ctr, Birmingham, W Midlands, England; [Hampson, Peter; Dinsdale, Robert J.; Harrison, Paul] Scar Free Fdn, Birmingham Ctr Burns Res, Birmingham, W Midlands, England; [Crombie, Nicholas] Midlands Air Ambulance, Unit 16 Enterprise Trading Estate, Brierley Hill, W Midlands, England	Hazeldine, J (corresponding author), Univ Birmingham, Inst Inflammat & Ageing, Birmingham, W Midlands, England.; Hazeldine, J (corresponding author), Queen Elizabeth Hosp Birmingham, NIHR Surg Reconstruct & Microbiol Res Ctr, Birmingham, W Midlands, England.	j.hazeldine@bham.ac.uk	Belli, Antonio/I-3799-2015; Naumann, David/S-9917-2019; Harrison, Paul/AAN-1916-2021; Hazeldine, Jon/T-5725-2019	Belli, Antonio/0000-0002-3211-9933; Naumann, David/0000-0003-2243-2325; Harrison, Paul/0000-0003-4610-8909; Lord, Janet/0000-0003-1030-6786; Bishop, Jonathan/0000-0003-1789-5886; A Duggal, Niharika/0000-0003-4459-4632	National Institute for Health Research Surgical Reconstruction and Microbiology Research Centre; Department of Health and Ministry of Defence; Scar Free Foundation Birmingham Burns Research Centre, which is part of the Burns Collective within the Scar Free Foundation; RoseTrees TrustRosetrees Trust [DTAA.RDBU18237]; Medical Neuroscience Teaching and Research Fund [DTAA.RCLG19305]; Queen Elizabeth Hospital Birmingham Charity; Rosetrees TrustRosetrees Trust [M382] Funding Source: researchfish	For funding this research, the authors acknowledge the National Institute for Health Research Surgical Reconstruction and Microbiology Research Centre, which is joint funded by the Department of Health and Ministry of Defence (http://www.nihr.ac.uk; JH, DNN, ET, DD, JRBB, ZS, NC, AB, and JML), the Scar Free Foundation Birmingham Burns Research Centre, which is part of the Burns Collective within the Scar Free Foundation (www.scarfree.org.uk; PHam, RJD, and PHar), the RoseTrees Trust (www.rosetreestrust.co.uk; JH, AB, and JML; grant number, DTAA.RDBU18237), and the Medical Neuroscience Teaching and Research Fund (https://sites.google.com/site/mntrfund/; JH, AB, and JML; grant number, DTAA.RCLG19305). The authors would also like to acknowledge the Queen Elizabeth Hospital Birmingham Charity for funding the purchase of the Sysmex XN-1000 haematology analyser (https://www.qehb.org; PHar). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aneja R, 2006, J IMMUNOL, V177, P7184, DOI 10.4049/jimmunol.177.10.7184; Arand M, 2001, LANGENBECK ARCH SURG, V386, P241, DOI 10.1007/s004230100204; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Ferreira LCB, 2014, BRAIN INJURY, V28, P1311, DOI 10.3109/02699052.2014.916818; Cheron A, 2010, CRIT CARE, V14, DOI 10.1186/cc9331; Cohen MJ, 2009, CRIT CARE, V13, DOI 10.1186/cc8152; Cuschieri J, 2010, SHOCK, V34, P346, DOI 10.1097/SHK.0b013e3181d8e687; Drifte G, 2013, CRIT CARE MED, V41, P820, DOI 10.1097/CCM.0b013e318274647d; ElBenna J, 1997, J BIOL CHEM, V272, P17204, DOI 10.1074/jbc.272.27.17204; Gebhard F, 2000, ARCH SURG-CHICAGO, V135, P291, DOI 10.1001/archsurg.135.3.291; Gentile LF, 2012, J TRAUMA ACUTE CARE, V72, P1491, DOI 10.1097/TA.0b013e318256e000; Giannoudis PV, 2003, INJURY, V34, P397, DOI 10.1016/S0020-1383(02)00416-3; Gouel-Cheron A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033095; Hampson P, 2016, ANN SURG; Hazeldine J, 2016, BURNS TRAUMA, V4, DOI 10.1186/s41038-016-0059-3; Hietbrink F, 2013, SHOCK, V40, P21, DOI 10.1097/SHK.0b013e318295a40a; Hirose T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111755; Hoechst B, 2008, GASTROENTEROLOGY, V135, P234, DOI 10.1053/j.gastro.2008.03.020; Hoechst B, 2009, HEPATOLOGY, V50, P799, DOI 10.1002/hep.23054; Huang H, 2015, HEPATOLOGY, V62, P600, DOI 10.1002/hep.27841; Jeschke MG, 2014, ANN SURG, V259, P814, DOI 10.1097/SLA.0b013e31828dfbf1; Junger WG, 2013, SHOCK, V40, P366, DOI 10.1097/SHK.0000000000000038; Kasten KR, 2010, BMC IMMUNOL, V11, DOI 10.1186/1471-2172-11-4; Kirchhoff C, 2009, CRIT CARE, V13, DOI 10.1186/cc7914; Kraft R, 2015, SHOCK, V43, P222, DOI 10.1097/SHK.0000000000000294; Laborde RR, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00147; Laudanski K, 2006, P NATL ACAD SCI USA, V103, P15564, DOI 10.1073/pnas.0607028103; Li HP, 2015, J TRAUMA ACUTE CARE, V78, P272, DOI 10.1097/TA.0000000000000509; Liao YL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068963; Lin Y, 2011, BLOOD, V117, P872, DOI 10.1182/blood-2010-05-283820; Liu CL, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3707; Maier B, 2007, SHOCK, V28, P668, DOI 10.1097/shk.0b013e318123e64e; Manson J, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1341-2; Marks W, 2013, CENT EUR J IMMUNOL, V38, P494, DOI 10.5114/ceji.2013.39767; Muszynski JA, 2014, SHOCK, V42, P313, DOI 10.1097/SHK.0000000000000217; Nakagawa M, 1998, CIRCULATION, V98, P2307, DOI 10.1161/01.CIR.98.21.2307; Namas RA, 2016, ANN SURG, V263, P191, DOI 10.1097/SLA.0000000000001001; NAUSEEF WM, 1991, J BIOL CHEM, V266, P5911; Orr SK, 2015, CRIT CARE MED, V43, P2642, DOI 10.1097/CCM.0000000000001312; Perez-Barcena J, 2010, ANN SURG, V251, P521, DOI 10.1097/SLA.0b013e3181cc8f84; Pillay J, 2012, J CLIN INVEST, V122, P327, DOI 10.1172/JCI57990; Pillay J, 2010, J LEUKOCYTE BIOL, V88, P211, DOI 10.1189/jlb.1209793; Raad H, 2009, FASEB J, V23, P1011, DOI 10.1096/fj.08-114553; Rainer TH, 2001, RESUSCITATION, V51, P139, DOI 10.1016/S0300-9572(01)00409-9; Rosenthal J, 1996, BLOOD, V88, P4321; Sauce D, 2017, J GERONTOL A-BIOL, V72, P163, DOI 10.1093/gerona/glw062; Steyerberg EW, 2001, J CLIN EPIDEMIOL, V54, P774, DOI 10.1016/S0895-4356(01)00341-9; Steyerberg EW, 2010, EPIDEMIOLOGY, V21, P128, DOI 10.1097/EDE.0b013e3181c30fb2; Tarlowe MH, 2003, J IMMUNOL, V171, P2066, DOI 10.4049/jimmunol.171.4.2066; Timmermans K, 2016, INTENS CARE MED, V42, P551, DOI 10.1007/s00134-015-4205-3; Torrance HDT, 2015, ANN SURG, V261, P751, DOI 10.1097/SLA.0000000000000653; Torrance HDT, 2015, J TRAUMA ACUTE CARE, V78, P535, DOI 10.1097/TA.0000000000000534; Vanzant EL, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0788-x; Visser T, 2011, EUR J TRAUMA EMERG S, V37, P177, DOI 10.1007/s00068-010-0041-x; Vuk-Pavlovic S, 2010, PROSTATE, V70, P443, DOI 10.1002/pros.21078; West SD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052406; Wolach B, 2001, J NEUROSURG, V94, P706, DOI 10.3171/jns.2001.94.5.0706; Xiao WZ, 2011, J EXP MED, V208, P2581, DOI 10.1084/jem.20111354; Xiu B, 2015, BLOOD CANCER J, V5, DOI 10.1038/bcj.2015.56	59	42	42	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1549-1676			PLOS MED	PLos Med.	JUL	2017	14	7							e1002338	10.1371/journal.pmed.1002338			29	Medicine, General & Internal	General & Internal Medicine	FC1QA	WOS:000406611200008	28719602	DOAJ Gold, Green Published, Green Accepted			2021-06-18	
J	Holleran, L; Kim, JH; Gangolli, M; Stein, T; Alvarez, V; McKee, A; Brody, DL				Holleran, Laurena; Kim, Joong Hee; Gangolli, Mihika; Stein, Thor; Alvarez, Victor; McKee, Ann; Brody, David L.			Axonal disruption in white matter underlying cortical sulcus tau pathology in chronic traumatic encephalopathy	ACTA NEUROPATHOLOGICA			English	Article						Chronic traumatic encephalopathy; Radiological-pathological correlations; White matter; Phosphorylated tau; Diffusion MRI; Fractional anisotropy; Diffusion tensor imaging	EX-VIVO MRI; BRAIN-INJURY; DIFFUSION ANISOTROPY; RELAXATION-TIMES; MEAN DIFFUSIVITY; IN-VIVO; QUANTIFICATION; REGISTRATION; RESOLUTION; DIAGNOSIS	Chronic traumatic encephalopathy (CTE) is a progressive degenerative disorder associated with repetitive traumatic brain injury. One of the primary defining neuropathological lesions in CTE, based on the first consensus conference, is the accumulation of hyperphosphorylated tau in gray matter sulcal depths. Post-mortem CTE studies have also reported myelin loss, axonal injury and white matter degeneration. Currently, the diagnosis of CTE is restricted to post-mortem neuropathological analysis. We hypothesized that high spatial resolution advanced diffusion MRI might be useful for detecting white matter microstructural changes directly adjacent to gray matter tau pathology. To test this hypothesis, formalin-fixed post-mortem tissue blocks from the superior frontal cortex of ten individuals with an established diagnosis of CTE were obtained from the Veterans Affairs-Boston University-Concussion Legacy Foundation brain bank. Advanced diffusion MRI data was acquired using an 11.74 T MRI scanner at Washington University with 250 x 250 x 500 A mu m(3) spatial resolution. Diffusion tensor imaging, diffusion kurtosis imaging and generalized q-sampling imaging analyses were performed in a blinded fashion. Following MRI acquisition, tissue sections were tested for phosphorylated tau immunoreactivity in gray matter sulcal depths. Axonal disruption in underlying white matter was assessed using two-dimensional Fourier transform analysis of myelin black gold staining. A robust image co-registration method was applied to accurately quantify the relationship between diffusion MRI parameters and histopathology. We found that white matter underlying sulci with high levels of tau pathology had substantially impaired myelin black gold Fourier transform power coherence, indicating axonal microstructural disruption (r = -0.55, p = 0.0015). Using diffusion tensor MRI, we found that fractional anisotropy (FA) was modestly (r = 0.53) but significantly (p = 0.0012) correlated with axonal disruption, where lower FA was associated with greater axonal disruption in white matter directly adjacent to hyperphosphorylated tau positive sulci. In summary, our findings indicate that axonal disruption and tau pathology are closely associated, and high spatial resolution ex vivo diffusion MRI has the potential to detect microstructural alterations observed in CTE tissue. Future studies will be required to determine whether this approach can be applied to living people.	[Holleran, Laurena; Kim, Joong Hee; Brody, David L.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; [Gangolli, Mihika] Washington Univ, Sch Med, Dept Biomed Engn, St Louis, MO USA; [Stein, Thor; Alvarez, Victor; McKee, Ann] Boston Univ, Sch Med, Ctr Study Traumat Encephalopathy, Boston, MA 02118 USA; [Brody, David L.] Hope Ctr Neurol Disorders, St Louis, MO 63110 USA	Brody, DL (corresponding author), Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA.; Brody, DL (corresponding author), Hope Ctr Neurol Disorders, St Louis, MO 63110 USA.	brodyd@neuro.wustl.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [UO1 NS086659-02]	NIH UO1 NS086659-02 (Overall PI: A. McKee, Subproject 3 PI: Brody).	ADAMS JH, 1985, MED SCI LAW, V25, P265, DOI 10.1177/002580248502500407; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Calabrese E, 2014, HUM BRAIN MAPP, V35, P5667, DOI 10.1002/hbm.22578; Cherry JD, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0382-8; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Currie S., 2016, MED J, V92, P41, DOI [10.1136/postgradmedj-2014-133211, DOI 10.1136/POSTGRADMEDJ-2014-133211]; D'Arceuil H, 2007, NEUROIMAGE, V36, P64, DOI 10.1016/j.neuroimage.2007.02.039; Dawe RJ, 2009, MAGN RESON MED, V61, P810, DOI 10.1002/mrm.21909; Gajawelli N, 2013, WORLD NEUROSURG, V80, P824, DOI 10.1016/j.wneu.2013.10.020; Gangolli M, 2016, NAT NEUR SOC S LEX K; Ghajari M, 2017, BRAIN, V140, P333, DOI 10.1093/brain/aww317; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Goubran M, 2015, J NEUROSCI METH, V241, P53, DOI 10.1016/j.jneumeth.2014.12.005; Goubran M, 2013, NEUROIMAGE, V83, P770, DOI 10.1016/j.neuroimage.2013.07.053; Hasan KM, 2006, MAGN RESON MED, V56, P130, DOI 10.1002/mrm.20935; Hasan KM, 2003, MAGNET RESON MED, V50, P589, DOI 10.1002/mrm.10552; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Ilvesmaki T, 2014, BRAIN, V137, P1876, DOI 10.1093/brain/awu095; Jensen JH, 2005, MAGNET RESON MED, V53, P1432, DOI 10.1002/mrm.20508; Jones DK, 1999, MAGNET RESON MED, V42, P515, DOI 10.1002/(SICI)1522-2594(199909)42:3<515::AID-MRM14>3.3.CO;2-H; Kamnaksh A, 2014, SCI REP-UK, V4, DOI 10.1038/srep04809; Karperien A, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00003; Koay CG, 2006, J MAGN RESON, V182, P115, DOI 10.1016/j.jmr.2006.06.020; Lawrenz M, 2015, MAGN RESON MED, V73, P773, DOI 10.1002/mrm.25140; Le Bihan D, 2012, NEUROIMAGE, V61, P324, DOI 10.1016/j.neuroimage.2011.11.006; Lee Bruce, 2005, NeuroRx, V2, P372; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Mandelkow EM, 2003, NEUROBIOL AGING, V24, P1079, DOI 10.1016/j.neurobiolaging.2003.04.007; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2015, BRAIN PATHOL, V25, P350, DOI 10.1111/bpa.12248; Mckee Ann C, 2015, Handb Clin Neurol, V127, P45, DOI 10.1016/B978-0-444-52892-6.00004-0; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Millspaugh J., 1937, US NAVAL MED B, V35, P297; Namjoshi DR, 2014, MOL NEURODEGENER, V9, DOI 10.1186/1750-1326-9-55; Robinson S, 2017, J NEUROSCI RES, V95, P1025, DOI 10.1002/jnr.23848; Shahim P, 2016, J NEUROTRAUM, V33, P1995, DOI 10.1089/neu.2014.3741; Shahim P, 2015, BRAIN INJURY, V29, P872, DOI 10.3109/02699052.2015.1018324; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Shively SB, 2017, ACTA NEUROPATHOL, V133, P353, DOI 10.1007/s00401-016-1649-7; Shively SB, 2016, LANCET NEUROL, V15, P944, DOI 10.1016/S1474-4422(16)30057-6; Siman R, 2015, J NEUROTRAUM, V32, P1294, DOI 10.1089/neu.2014.3698; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Smith DH, 2013, J NEUROTRAUM, V30, P307, DOI 10.1089/neu.2012.2825; Stein TD, 2015, CURR PAIN HEADACHE R, V19, DOI 10.1007/s11916-015-0522-z; Stein TD, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt234; Tremblay S, 2014, BRAIN, V137, P2997, DOI 10.1093/brain/awu236; Wang Y, 2015, BRAIN, V138, P1223, DOI 10.1093/brain/awv046; Wansapura JP, 1999, JMRI-J MAGN RESON IM, V9, P531, DOI 10.1002/(SICI)1522-2586(199904)9:4<531::AID-JMRI4>3.0.CO;2-L; Weiss M, 2015, BRAIN STRUCT FUNCT, V220, P1695, DOI 10.1007/s00429-014-0754-4; Yeh FC, 2011, NEUROIMAGE, V55, P1054, DOI 10.1016/j.neuroimage.2010.11.087; Yeh FC, 2010, IEEE T MED IMAGING, V29, P1626, DOI 10.1109/TMI.2010.2045126	54	42	43	1	16	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	MAR	2017	133	3					367	380		10.1007/s00401-017-1686-x			14	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	EL9ST	WOS:000394961100003	28214960				2021-06-18	
J	Liu, XC; Chen, H; Bo, QG; Fan, F; Jia, CX				Liu, Xianchen; Chen, Hua; Bo, Qi-Gui; Fan, Fang; Jia, Cun-Xian			Poor sleep quality and nightmares are associated with non-suicidal self-injury in adolescents	EUROPEAN CHILD & ADOLESCENT PSYCHIATRY			English	Article						Sleep; Nightmares; Self-injury; Adolescents	TRAUMATIC BRAIN-INJURY; SUICIDAL-BEHAVIOR; CHINESE ADOLESCENTS; COMMUNITY SAMPLE; YOUNG-PEOPLE; HARM; PREVALENCE; DEPRESSION; INSOMNIA; HEALTH	Non-suicidal self-injury (NSSI) is prevalent and is associated with increased risk of suicidal behavior in adolescents. This study examined which sleep variables are associated with NSSI, independently from demographics and mental health problems in Chinese adolescents. Participants consisted of 2090 students sampled from three high schools in Shandong, China and had a mean age of 15.49 years. Participants completed a sleep and health questionnaire to report their demographic and family information, sleep duration and sleep problems, impulsiveness, hopelessness, internalizing and externalizing problems, and NSSI. A series of regression analyses were conducted to examine the associations between sleep variables and NSSI. Of the sample, 12.6 % reported having ever engaged in NSSI and 8.8 % engaged during the last year. Univariate logistic analyses demonstrated that multiple sleep variables including short sleep duration, insomnia symptoms, poor sleep quality, sleep insufficiency, unrefreshed sleep, sleep dissatisfaction, daytime sleepiness, fatigue, snoring, and nightmares were associated with increased risk of NSSI. After adjusting for demographic and mental health variables, NSSI was significantly associated with sleeping < 6 h per night, poor sleep quality, sleep dissatisfaction, daytime sleepiness, and frequent nightmares. Stepwise logistic regression model demonstrated that poor sleep quality (OR = 2.18, 95 % CI = 1.37-3.47) and frequent nightmares (OR = 2.88, 95 % CI = 1.45-5.70) were significantly independently associated with NSSI. In conclusion, while multiple sleep variables are associated with NSSI, poor sleep quality and frequent nightmares are independent risk factors of NSSI. These findings may have important implications for further research of sleep self-harm mechanisms and early detection and prevention of NSSI in adolescents.	[Liu, Xianchen; Chen, Hua; Jia, Cun-Xian] Shandong Univ, Sch Publ Hlth, Dept Epidemiol, 44 Wenhuaxi Rd, Jinan 250012, Peoples R China; [Liu, Xianchen; Chen, Hua; Jia, Cun-Xian] Shandong Univ, Ctr Suicide Prevent Res, 44 Wenhuaxi Rd, Jinan 250012, Peoples R China; [Liu, Xianchen] Univ Tennessee, Ctr Hlth Sci, Memphis, TN 38163 USA; [Bo, Qi-Gui] Ctr Dis Control & Prevent Lijin Cty, Lijin 257400, Peoples R China; [Fan, Fang] South China Normal Univ, Sch Psychol, Guangzhou 510631, Guangdong, Peoples R China	Liu, XC; Jia, CX (corresponding author), Shandong Univ, Sch Publ Hlth, Dept Epidemiol, 44 Wenhuaxi Rd, Jinan 250012, Peoples R China.; Liu, XC; Jia, CX (corresponding author), Shandong Univ, Ctr Suicide Prevent Res, 44 Wenhuaxi Rd, Jinan 250012, Peoples R China.	xliu69@uthsc.edu; jiacunxian@sdu.edu.cn			Shandong Scientific Technique Development Plan [2014GSF118163]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81573233]	This work was funded by Shandong Scientific Technique Development Plan (Grant No. 2014GSF118163) and National Natural Science Foundation of China (Grant No. 81573233).	Achenbach T. M., 1991, MANUAL YOUTH SELF RE; Agargun MY, 1998, COMPR PSYCHIAT, V39, P198; Argyropoulos SV, 2003, PSYCHIAT RES, V120, P179, DOI 10.1016/S0165-1781(03)00187-2; BECK AT, 1974, J CONSULT CLIN PSYCH, V42, P861, DOI 10.1037/h0037562; Brent DA, 1999, J AM ACAD CHILD PSY, V38, P1497, DOI 10.1097/00004583-199912000-00010; Brent DA, 2013, J AM ACAD CHILD PSY, V52, P1260, DOI 10.1016/j.jaac.2013.09.009; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Carroll R, 2016, J AFFECT DISORDERS, V192, P8, DOI 10.1016/j.jad.2015.12.007; CHOQUET M, 1990, ACTA PSYCHIAT SCAND, V81, P170, DOI 10.1111/j.1600-0447.1990.tb06474.x; Cooper J, 2005, AM J PSYCHIAT, V162, P297, DOI 10.1176/appi.ajp.162.2.297; Duval M, 2013, J NERV MENT DIS, V201, P767, DOI 10.1097/NMD.0b013e3182a214a1; EYSENCK SBG, 1985, PERS INDIV DIFFER, V6, P613, DOI 10.1016/0191-8869(85)90011-X; Giletta M, 2012, PSYCHIAT RES, V197, P66, DOI 10.1016/j.psychres.2012.02.009; Guan K, 2012, J CONSULT CLIN PSYCH, V80, P842, DOI 10.1037/a0029429; Harvey AG, 2008, SLEEP, V31, P383, DOI 10.1093/sleep/31.3.383; Hawton K, 2002, BMJ-BRIT MED J, V325, P1207, DOI 10.1136/bmj.325.7374.1207; Hawton K, 2005, BRIT MED J, V330, P891, DOI 10.1136/bmj.330.7496.891; Hawton K, 2015, COCHRANE DB SYST REV, V12; Hawton K, 2012, J CHILD PSYCHOL PSYC, V53, P1212, DOI 10.1111/j.1469-7610.2012.02559.x; Hawton K, 2012, LANCET, V379, P2373, DOI 10.1016/S0140-6736(12)60322-5; Hysing M, 2015, BRIT J PSYCHIAT, V207, P306, DOI 10.1192/bjp.bp.114.146514; Levin R, 2002, SLEEP, V25, P205; Liu XC, 2006, CURR OPIN PSYCHIATR, V19, P288, DOI 10.1097/01.yco.0000218600.40593.18; Liu XC, 2005, J AFFECT DISORDERS, V86, P195, DOI 10.1016/j.jad.2005.01.016; Liu XC, 2004, SLEEP, V27, P1351, DOI 10.1093/sleep/27.7.1351; Liu XCGC, 1997, CHIN MENT HLTH J, V11, P200; Liu XC, 2008, PEDIATRICS, V121, P1165, DOI 10.1542/peds.2007-1464; Liu XC, 2015, PSYCHIAT RES, V228, P797, DOI 10.1016/j.psychres.2015.05.023; Lundh LG, 2013, J PSYCHOPATHOL BEHAV, V35, P85, DOI 10.1007/s10862-012-9307-4; Maciejewski DF, 2014, JAMA PSYCHIAT, V71, P699, DOI 10.1001/jamapsychiatry.2014.89; Martin G, 2004, CHILD ABUSE NEGLECT, V28, P491, DOI 10.1016/j.chiabu.2003.08.006; Matamura M, 2014, J SLEEP RES, V23, P290, DOI 10.1111/jsr.12127; McLoughlin AB, 2015, QJM-INT J MED, V108, P765, DOI 10.1093/qjmed/hcv026; Owens C, 2016, BRIT J PSYCHIAT, V208, P286, DOI 10.1192/bjp.bp.113.141242; Owens J, 2014, PEDIATRICS, V134, pE921, DOI 10.1542/peds.2014-1696; Perlis ML, 2016, SLEEP MED REV, V29, P101, DOI 10.1016/j.smrv.2015.10.003; Pigeon Wilfred R, 2012, J Clin Psychiatry, V73, pe1160, DOI 10.4088/JCP.11r07586; Roberts RE, 2001, J YOUTH ADOLESCENCE, V30, P1, DOI 10.1023/A:1005230820074; Roberts RE, 2008, J ADOLESCENT HEALTH, V42, P294, DOI 10.1016/j.jadohealth.2007.09.016; Roberts RE, 2014, SLEEP, V37, P239, DOI 10.5665/sleep.3388; SHEK DTL, 2012, THESCIENTIFICWORLDJO, P1, DOI DOI 10.1100/2012/932540; Sullivan KA, 2015, J NEUROTRAUM, V32, P474, DOI 10.1089/neu.2013.3284; Swannell SV, 2014, SUICIDE LIFE-THREAT, V44, P273, DOI 10.1111/sltb.12070; Tanskanen A, 2001, SLEEP, V24, P844; Tham SW, 2015, J NEUROTRAUM, V32, P847, DOI 10.1089/neu.2014.3559; Wan YH, 2011, EUR CHILD ADOLES PSY, V20, P517, DOI 10.1007/s00787-011-0213-1; Wan YH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131239; Wilkinson P, 2011, AM J PSYCHIAT, V168, P495, DOI 10.1176/appi.ajp.2010.10050718; Wong MM, 2012, J PSYCHIATR RES, V46, P953, DOI 10.1016/j.jpsychires.2012.04.008; Zetterqvist M, 2015, CHILD ADOL PSYCH MEN, V9, DOI 10.1186/s13034-015-0062-7; Zhang J, 2012, J CLIN PSYCHOL, V68, P1313, DOI 10.1002/jclp.21907	51	42	45	3	37	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1018-8827	1435-165X		EUR CHILD ADOLES PSY	Eur. Child Adolesc. Psych.	MAR	2017	26	3					271	279		10.1007/s00787-016-0885-7			9	Psychology, Developmental; Pediatrics; Psychiatry	Psychology; Pediatrics; Psychiatry	EM0HY	WOS:000395000600002	27383464				2021-06-18	
J	Thibaut, A; Wannez, S; Donneau, AF; Chatelle, C; Gosseries, O; Bruno, MA; Laureys, S				Thibaut, Aurore; Wannez, Sarah; Donneau, Anne-Francoise; Chatelle, Camille; Gosseries, Olivia; Bruno, Marie-Aurelie; Laureys, Steven			Controlled clinical trial of repeated prefrontal tDCS in patients with chronic minimally conscious state	BRAIN INJURY			English	Article						Minimally conscious state; tDCS; brain injury; disorders of consciousness; brain stimulation	DIRECT-CURRENT STIMULATION; TRAUMATIC BRAIN-INJURY; UNRESPONSIVE WAKEFULNESS SYNDROME; WORKING-MEMORY; STROKE PATIENTS; EXCITABILITY SHIFTS; PARKINSONS-DISEASE; VEGETATIVE STATE; DC STIMULATION; DISORDERS	Objectives: To assess the effects of repeated transcranial direct current stimulation (tDCS) sessions on the level of consciousness in chronic patients in minimally conscious state (MCS). Methods: In this randomized double-blind sham-controlled crossover study, we enrolled 16 patients in chronic MCS. For 5 consecutive days, each patient received active or sham tDCS over the left prefrontal cortex (2 mA during 20 min). Consciousness was assessed with the Coma Recovery Scale-Revised (CRS-R) before the first stimulation (baseline), after each stimulation (day 1-day 5) and 1 week after the end of each session (day 12). Results: A treatment effect (p = 0.013; effect size = 0.43) was observed at the end of the active tDCS session (day 5) as well as 1 week after the end of the active tDCS session (day 12; p = 0.002; effect size = 0.57). A longitudinal increase of the CRS-R total scores was identified for the active tDCS session (p < 0.001), while no change was found for the sham session (p = 0.64). Nine patients were identified as responders (56%). Conclusion: Our results suggest that repeated (5 days) left prefrontal tDCS improves the recovery of consciousness in some chronic patients in MCS, up to 1 week after the end of the stimulations.	[Thibaut, Aurore; Wannez, Sarah; Chatelle, Camille; Gosseries, Olivia; Bruno, Marie-Aurelie; Laureys, Steven] Univ Liege, Coma Sci Grp, GIGA Res, Liege, Belgium; [Thibaut, Aurore] Harvard Med Sch, Spaulding Neuromodulat Ctr, Spaulding Rehabil Hosp, Boston, MA USA; [Donneau, Anne-Francoise] Univ Liege, Biostat, Dept Publ Hlth, Liege, Belgium; [Chatelle, Camille] Massachusetts Gen Hosp, Lab NeuroImaging Coma & Consciousness, Boston, MA 02114 USA	Thibaut, A (corresponding author), Univ Liege, Coma Sci Grp, Cyclotron Res Ctr, Quartier Hop, GIGA Res B34, B-4000 Liege, Belgium.	athibaut@ulg.ac.be	Laureys, Steven/AAN-2097-2021; Laureys, Steven/A-3349-2011; Gosseries, Olivia/AAB-6469-2020; Thibaut, Aurore/U-8101-2019	Laureys, Steven/0000-0002-3096-3807; Chatelle, Camille/0000-0002-7526-2107; Gosseries, Olivia/0000-0001-9011-7496	European CommissionEuropean CommissionEuropean Commission Joint Research Centre [EU-H2020-fetflagship-hbp-sga1-ga720270, EU-H2020-fetopen-ga686764]	The authors thank Pr. Gustave Moonen, Pr. Pierre Maquet, the Neurology Department staff of the University Hospital of Liege, the ISOSL Rehabilitation Center, Centre d'Accueil de Bouge, the Foyer Saint-Anne, the University of Liege, the Duesberg Foundation, the Belgian American Educational Foundation, the Wallonie-Bruxelles International, the James McDonnell Foundation, Mind Science Foundation, IAP research network P7/06 of the Belgian Government (Belgian Science Policy), the European Commission, Human Brain Project (EU-H2020-fetflagship-hbp-sga1-ga720270), and Luminus project (EU-H2020-fetopen-ga686764). AT and OG are post-doctoral fellows, and SL is research director at FRS-FNRS.	Alonzo A, 2012, BRAIN STIMUL, V5, P208, DOI 10.1016/j.brs.2011.04.006; Altman D. G., 1990, PRACTICAL STAT MED R; Angelakis E, 2014, ARCH PHYS MED REHAB, V95, P283, DOI 10.1016/j.apmr.2013.09.002; Antal A, 2010, J PAIN SYMPTOM MANAG, V39, P890, DOI 10.1016/j.jpainsymman.2009.09.023; Arif-Rahu Mamoona, 2010, Intensive Crit Care Nurs, V26, P343, DOI 10.1016/j.iccn.2010.08.007; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Baker JM, 2010, STROKE, V41, P1229, DOI 10.1161/STROKEAHA.109.576785; Bernat JL, 2006, LANCET, V367, P1181, DOI 10.1016/S0140-6736(06)68508-5; Boggio PS, 2007, RESTOR NEUROL NEUROS, V25, P123; Boggio PS, 2006, J NEUROL SCI, V249, P31, DOI 10.1016/j.jns.2006.05.062; Brunoni AR, 2012, BRAIN STIMUL, V5, P175, DOI 10.1016/j.brs.2011.03.002; Brunoni AR, 2011, INT J NEUROPSYCHOPH, V14, P1133, DOI 10.1017/S1461145710001690; Doruk D, 2014, NEUROSCI LETT, V582, P27, DOI 10.1016/j.neulet.2014.08.043; Fiori V, 2011, J COGNITIVE NEUROSCI, V23, P2309, DOI 10.1162/jocn.2010.21579; Fregni F, 2015, Clin Res Regul Aff, V32, P22; Fregni F, 2005, EXP BRAIN RES, V166, P23, DOI 10.1007/s00221-005-2334-6; Fregni F, 2005, NEUROREPORT, V16, P1551, DOI 10.1097/01.wnr.0000177010.44602.5e; Fritz CO, 2012, J EXP PSYCHOL GEN, V141, P2, DOI 10.1037/a0024338; Giacino JT, 2014, NAT REV NEUROL, V10, P99, DOI 10.1038/nrneurol.2013.279; Giacino JT, 2012, NEW ENGL J MED, V366, P819, DOI 10.1056/NEJMoa1102609; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Gosseries O, 2014, CURR PHARM DESIGN, V20, P4167; GUALTIERI T, 1989, CLIN NEUROPHARMACOL, V12, P258, DOI 10.1097/00002826-198908000-00003; Herwig U, 2003, BRAIN TOPOGR, V16, P95, DOI 10.1023/B:BRAT.0000006333.93597.9d; Javadi AH, 2011, BRAIN STIMUL; Jo JM, 2009, AM J PHYS MED REHAB, V88, P404, DOI 10.1097/PHM.0b013e3181a0e4cb; Kang EK, 2009, RESTOR NEUROL NEUROS, V27, P645, DOI 10.3233/RNN-2009-0514; Kang EK, 2012, J REHABIL MED, V44, P346, DOI 10.2340/16501977-0947; Keeser D, 2011, J NEUROSCI, V31, P15284, DOI 10.1523/JNEUROSCI.0542-11.2011; Laureys S, 2000, LANCET, V355, P1790, DOI 10.1016/S0140-6736(00)02271-6; Laureys S, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-68; Marangolo P, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00539; Mendonca ME, 2016, FRONT HUM NEUROSCI, V10, DOI 10.3389/fnhum.2016.00068; Naro A, 2015, RESTOR NEUROL NEUROS, V33, P159, DOI 10.3233/RNN-140448; NICKELS JL, 1994, BRAIN INJURY, V8, P709, DOI 10.3109/02699059409151025; Nitsche MA, 2003, CLIN NEUROPHYSIOL, V114, P2220, DOI 10.1016/S1388-2457(03)00235-9; Nitsche MA, 2004, EUR J NEUROSCI, V19, P2720, DOI 10.1111/j.0953-816X.2004.03398.x; Nitsche MA, 2003, J PHYSIOL-LONDON, V553, P293, DOI 10.1113/jphysiol.2003.049916; Nitsche MA, 2011, RESTOR NEUROL NEUROS, V29, P463, DOI 10.3233/RNN-2011-0618; Sacco K, 2016, FRONT BEHAV NEUROSCI, V10, DOI 10.3389/fnbeh.2016.00057; Schnakers C, 2012, AAPS J, V14, P437, DOI 10.1208/s12248-012-9346-5; Speth J, 2016, NEUROPSYCHOLOGIA, V86, P57, DOI 10.1016/j.neuropsychologia.2016.04.010; Stagg CJ, 2011, NEUROSCIENTIST, V17, P37, DOI 10.1177/1073858410386614; Straudi S, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/5068127; Thibaut A, 2015, BRAIN STIMUL, V8, P1116, DOI 10.1016/j.brs.2015.07.024; Thibaut A, 2014, NEUROLOGY, V82, P1112, DOI 10.1212/WNL.0000000000000260; Zaehle T, 2011, BMC NEUROSCI, V12, DOI 10.1186/1471-2202-12-2	48	42	47	0	6	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2017	31	4					466	474		10.1080/02699052.2016.1274776			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	ES9TD	WOS:000399902900005	28281845	Green Published			2021-06-18	
J	Stein, MB; Ursano, RJ; Campbell-Sills, L; Colpe, LJ; Fullerton, CS; Heeringa, SG; Nock, MK; Sampson, NA; Schoenbaum, M; Sun, XY; Jain, S; Kessler, RC				Stein, Murray B.; Ursano, Robert J.; Campbell-Sills, Laura; Colpe, Lisa J.; Fullerton, Carol S.; Heeringa, Steven G.; Nock, Matthew K.; Sampson, Nancy A.; Schoenbaum, Michael; Sun, Xiaoying; Jain, Sonia; Kessler, Ronald C.		Army STARRS Collaborators	Prognostic Indicators of Persistent Post-Concussive Symptoms after Deployment-Related Mild Traumatic Brain Injury: A Prospective Longitudinal Study in US Army Soldiers	JOURNAL OF NEUROTRAUMA			English	Article						concussion; deployment; mental health; military; stress; traumatic brain injury	POSTTRAUMATIC-STRESS-DISORDER; MILITARY PERSONNEL; FORCES PERSONNEL; ASSESS RISK; TRACK-TBI; POSTCONCUSSION; PREDICTORS; RESILIENCE; POLYTRAUMA; MANAGEMENT	Mild traumatic brain injury (mTBI), or concussion, is prevalent in the military. The course of recovery can be highly variable. This study investigates whether deployment-acquired mTBI is associated with subsequent presence and severity of post-concussive symptoms (PCS) and identifies predictors of persistent PCS among US Army personnel who sustained mTBI while deployed to Afghanistan. We used data from a prospective longitudinal survey of soldiers assessed 1-2 months before a 10-month deployment to Afghanistan (T0), on redeployment to the United States (T1), approximately 3 months later (T2), and approximately 9 months later (T3). Outcomes of interest were PCS at T2 and T3. Predictors considered were: sociodemographic factors, number of previous deployments, pre-deployment mental health and TBI history, and mTBI and other military-related stress during the index deployment. The study sample comprised 4518 soldiers, 822 (18.2%) of whom experienced mTBI during the index deployment. After adjusting for demographic, clinical, and deployment-related factors, deployment-acquired mTBI was associated with nearly triple the risk of reporting any PCS and with increased severity of PCS when symptoms were present. Among those who sustained mTBI, severity of PCS at follow-up was associated with history of pre-deployment TBI(s), pre-deployment psychological distress, more severe deployment stress, and loss of consciousness or lapse of memory (versus being "dazed'' only) as a result of deployment-acquired mTBI. In summary, we found that sustaining mTBI increases risk for persistent PCS. Previous TBI(s), pre-deployment psychological distress, severe deployment stress, and loss of consciousness or lapse of memory resulting from mTBI(s) are prognostic indicators of persistent PCS after an index mTBI. These observations may have actionable implications for prevention of chronic sequelae of mTBI in the military and other settings.	[Stein, Murray B.; Campbell-Sills, Laura] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA; [Stein, Murray B.; Sun, Xiaoying; Jain, Sonia] Univ Calif San Diego, Dept Family Med & Publ Hlth, La Jolla, CA 92093 USA; [Stein, Murray B.] VA San Diego Healthcare Syst, San Diego, CA USA; [Ursano, Robert J.; Fullerton, Carol S.] Uniformed Serv Univ Hlth Sci, Dept Psychiat, Ctr Study Traumat Stress, Bethesda, MD 20814 USA; [Colpe, Lisa J.; Schoenbaum, Michael] NIMH, Rockville, MD 20857 USA; [Heeringa, Steven G.] Univ Michigan, Inst Social Res, Ann Arbor, MI USA; [Nock, Matthew K.] Harvard Univ, Dept Psychol, 33 Kirkland St, Cambridge, MA 02138 USA; [Sampson, Nancy A.; Kessler, Ronald C.] Harvard Med Sch, Dept Hlth Care Policy, Boston, MA USA	Stein, MB (corresponding author), Univ Calif San Diego, 9500 Gilman Dr,Mailcode 0855, La Jolla, CA 92093 USA.	mstein@ucsd.edu	Ursano, Robert/ABE-6533-2020; Nock, Matthew/AAE-8330-2019	Ursano, Robert/0000-0002-1861-9173	Department of the Army; U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Mental Health (NIH/NIMH) [U01MH087981]	Army STARRS was sponsored by the Department of the Army and funded under cooperative agreement number U01MH087981 with the U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Mental Health (NIH/NIMH). The contents are solely the responsibility of the authors and do not necessarily represent the views of the Department of Health and Human Services, NIMH, the Veterans Administration, Department of the Army, or the Department of Defense.	Bahraini NH, 2014, PSYCHIAT CLIN N AM, V37, P55, DOI 10.1016/j.psc.2013.11.002; Boyle Eleanor, 2014, Arch Phys Med Rehabil, V95, pS230, DOI 10.1016/j.apmr.2013.08.297; Broshek DK, 2015, BRAIN INJURY, V29, P228, DOI 10.3109/02699052.2014.974674; Chase RP, 2015, J HEAD TRAUMA REHAB, V30, pE57, DOI 10.1097/HTR.0000000000000061; Fear NT, 2009, PSYCHOL MED, V39, P1379, DOI 10.1017/S0033291708004595; Garber BG, 2014, BMC PSYCHIATRY, V14, DOI 10.1186/s12888-014-0325-5; Heeringa SG., 2010, APPL SURVEY DATA ANA; Jones N, 2014, BRAIN INJURY, V28, P896, DOI 10.3109/02699052.2014.888479; Kessler RC, 2004, INT J METH PSYCH RES, V13, P93, DOI 10.1002/mpr.168; Lange RT, 2014, ARCH CLIN NEUROPSYCH, V29, P329, DOI 10.1093/arclin/acu013; Lawrence DW, 2015, BRAIN INJURY, V29, P1018, DOI 10.3109/02699052.2015.1005131; Levin HS, 2015, LANCET NEUROL, V14, P506, DOI 10.1016/S1474-4422(15)00002-2; Lingsma HF, 2015, J NEUROTRAUM, V32, P83, DOI 10.1089/neu.2014.3384; Mac Donald CL, 2014, JAMA NEUROL, V71, P994, DOI 10.1001/jamaneurol.2014.1114; MacLeod C, 2012, ANNU REV CLIN PSYCHO, V8, P189, DOI 10.1146/annurev-clinpsy-032511-143052; Marshall S, 2015, BRAIN INJURY, V29, P688, DOI 10.3109/02699052.2015.1004755; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Peskind ER, 2013, J CLIN PSYCHIAT, V74, P180, DOI 10.4088/JCP.12011co1c; Ponsford J, 2016, PSYCHOL MED, V46, P1079, DOI 10.1017/S0033291715002640; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Rabinowitz AR, 2015, J NEUROTRAUM, V32, P1488, DOI 10.1089/neu.2014.3555; Rathbone ATL, 2015, BRAIN BEHAV IMMUN, V46, P1, DOI 10.1016/j.bbi.2015.02.009; Shahim P, 2015, J NEUROTRAUMA; Silverberg ND, 2015, J NEUROTRAUM, V32, P517, DOI 10.1089/neu.2014.3600; Siman R, 2015, J NEUROTRAUM, V32, P1294, DOI 10.1089/neu.2014.3698; Stein MB, 2015, AM J PSYCHIAT, V172, P1101, DOI 10.1176/appi.ajp.2015.14121572; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Theadom A, 2015, SLEEP MED, V16, P926, DOI 10.1016/j.sleep.2015.04.013; Thomas DG, 2015, PEDIATRICS, V135, P213, DOI 10.1542/peds.2014-0966; Ursano RJ, 2014, PSYCHIATRY, V77, P107, DOI 10.1521/psyc.2014.77.2.107; Waldron-Perrine B, 2014, MIL MED, V179, P856, DOI 10.7205/MILMED-D-13-00282; Waljas M, 2015, J NEUROTRAUM, V32, P534, DOI 10.1089/neu.2014.3339	33	42	43	1	18	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC 1	2016	33	23					2125	2132		10.1089/neu.2015.4320			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	ED2JG	WOS:000388669800008	26905672	Green Published			2021-06-18	
J	Ge, XT; Huang, S; Gao, HB; Han, ZL; Chen, FL; Zhang, SS; Wang, ZG; Kang, CS; Jiang, RC; Yue, SY; Lei, P; Zhang, JN				Ge, Xintong; Huang, Shan; Gao, Huabin; Han, Zhaoli; Chen, Fanglian; Zhang, Shishuang; Wang, Zengguang; Kang, Chunsheng; Jiang, Rongcai; Yue, Shuyuan; Lei, Ping; Zhang, Jianning			miR-21-5p alleviates leakage of injured brain microvascular endothelial barrier in vitro through suppressing inflammation and apoptosis	BRAIN RESEARCH			English	Article						MiR-21-5p; Blood-brain barrier; Brain microvascular endothelial barrier; Traumatic brain injury	NF-KAPPA-B; CORTICOSTEROID-INSUFFICIENCY; SIGNALING PATHWAY; GROWTH-FACTOR; EXPRESSION; MICRORNAS; TARGETS; HIPPOCAMPUS; SIMVASTATIN; MIRNA-21	Our recent researches have identified increased expression of miR-21-5p in rats brain following traumatic brain injury (TBI), which protected against blood-brain barrier (BBB) damage. To further study the mechanism underlying the role of miR-21-5p on alleviating BBB damage after TBI, we performed the scratch injury model on cultured brain microvascular endothelial cells (BMVECs), which formed the microvascular endothelial barrier an integral part of the highly specialized BBB. The expression level of miR-21-5p in BMVECs was observed to be increased after scratch injury, and could be further up regulated by transfecting miR-21-5p mimics. We found that up-regulation of miR-21-5p level in BMVECs can alleviate endothelial barrier damage and loss of tight junction proteins. To further investigate the mechanism of this protective effect, we evaluated the impact of miR-21-5p on inflammation and apoptosis in injured BMVECs. On one hand, miR-21-5p suppressed inflammation by regulating the expression of inflammatory cytokines and NF-kB signaling. On the other hand, miR-21-5p inhibited cellular apoptosis by regulating the expression of apoptosis factors and Akt signaling. In addition, we also detected the activity of Ang-1/Tie-2 axis (associated with BBB stabilization) in BMVECs after scratch injury, and found that miR-21-5p can promote its activation. Taken together, miR-21-5p alleviates leakage of injured brain microvascular endothelial barrier through suppressing inflammation and apoptosis, while impacting the activities of NF-kB, Akt and Ang-1/Tie-2 signaling. Thus, miR-21-5p could be a potential therapeutic target for interventions of BBB damage after TBI. (C) 2016 Published by Elsevier B.V.	[Ge, Xintong; Wang, Zengguang; Jiang, Rongcai; Yue, Shuyuan; Zhang, Jianning] Tianjin Med Univ, Gen Hosp, Dept Neurosurg, Tianjin 300052, Peoples R China; [Ge, Xintong; Huang, Shan; Gao, Huabin; Chen, Fanglian; Jiang, Rongcai; Zhang, Jianning] Minist Educ, Key Lab Posttrauma Neurorepair & Regenerat Cent N, Tianjin 300052, Peoples R China; [Ge, Xintong; Huang, Shan; Gao, Huabin; Chen, Fanglian; Jiang, Rongcai; Zhang, Jianning] Tianjin Neurol Inst, Key Lab Injuries Variat & Regenerat Nervous Syst, Tianjin 300052, Peoples R China; [Ge, Xintong; Huang, Shan; Gao, Huabin; Chen, Fanglian; Jiang, Rongcai; Zhang, Jianning] Tianjin Neurol Inst, Lab Neurotrauma, Tianjin 300052, Peoples R China; [Huang, Shan; Gao, Huabin; Han, Zhaoli; Zhang, Shishuang; Lei, Ping; Zhang, Jianning] Tianjin Med Univ, Gen Hosp, Dept Geriatr, Tianjin 300052, Peoples R China; [Han, Zhaoli; Zhang, Shishuang; Lei, Ping] Tianjin Geriatr Inst, Lab Neurotrauma & Neurodegenerat Disorders, Tianjin 300052, Peoples R China; [Kang, Chunsheng] Tianjin Neurol Inst, Lab Neurooncol, Tianjin 300052, Peoples R China	Zhang, JN (corresponding author), Tianjin Med Univ, Gen Hosp, Dept Neurosurg, Tianjin 300052, Peoples R China.; Lei, P (corresponding author), Tianjin Med Univ, Gen Hosp, Dept Geriatr, Tianjin 300052, Peoples R China.	leiping1974@163.com; jianningzhang@hotmail.com	Ge, Xintong/X-4889-2019; Kang, Chunsheng/AAM-5979-2021	Kang, Chunsheng/0000-0002-3255-3369; Ge, Xintong/0000-0001-7153-952X	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81501055, 81330029, 81471252]; Tianjin Municipal Science and Technology Commission Natural Fund Project [15JCZDJC36500, 13JCZDJC30800, 13JCYBJC23700]; Tianjin Science and Technology Foundatoin of Health Bureau [2015KZ118]	This research was supported by Grants from the National Natural Science Foundation of China (Grant no. 81501055 and 81330029, 81471252), Tianjin Municipal Science and Technology Commission Natural Fund Project (Grant no. 15JCZDJC36500, 13JCZDJC30800, 13JCYBJC23700) and Tianjin Science and Technology Foundatoin of Health Bureau (Grant no. 2015KZ118). The authors appreciate Li Liu, Weiyun Cui and Ying Li from Tianjin Neurological Institute for their technical support.	Augustin HG, 2009, NAT REV MOL CELL BIO, V10, P165, DOI 10.1038/nrm2639; Balakathiresan N, 2012, J NEUROTRAUM, V29, P1379, DOI 10.1089/neu.2011.2146; Barnett RE, 2016, J LEUKOCYTE BIOL, V99, P361, DOI 10.1189/jlb.4A1014-489R; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Bucker J, 2015, ACTA PSYCHIAT SCAND, V131, P360, DOI 10.1111/acps.12358; Chaudhuri V, 2006, IN VITRO CELL DEV-AN, V42, P314; Chen JL, 2009, J CELL MOL MED, V13, P1348, DOI 10.1111/j.1582-4934.2008.00380.x; Chen RL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050957; Chen X, 2014, J NEUROL SCI, V342, P93, DOI 10.1016/j.jns.2014.04.032; Chen X, 2013, CRIT CARE, V17, DOI 10.1186/cc13067; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; Corso P, 2015, INJURY PREV, V21, P432, DOI [10.1136/ip.2005.010983rep, 10.1136/injuryprev-2015-041862]; Cui X, 2012, NEUROSCIENCE, V227, P223, DOI 10.1016/j.neuroscience.2012.09.066; Dietrich W.D., 2015, BRAIN RES; Edwards P, 2005, LANCET, V365, P1957; Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074; Fagel DM, 2006, EXP NEUROL, V199, P77, DOI 10.1016/j.expneurol.2005.04.006; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Fukuhara S, 2010, HISTOL HISTOPATHOL, V25, P387, DOI 10.14670/HH-25.387; Ge X., 2015, RNA DIS, V2, pe642; Ge XT, 2014, SCI REP-UK, V4, DOI 10.1038/srep06718; Ge XT, 2015, BRAIN RES, V1603, P150, DOI 10.1016/j.brainres.2015.01.009; Han ZL, 2015, DNA CELL BIOL, V34, P703, DOI 10.1089/dna.2015.2800; Han ZL, 2014, BRAIN RES, V1582, P12, DOI 10.1016/j.brainres.2014.07.045; Haseloff RF, 2015, SEMIN CELL DEV BIOL, V38, P16, DOI 10.1016/j.semcdb.2014.11.004; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; Herbert SP, 2011, NAT REV MOL CELL BIO, V12, P551, DOI 10.1038/nrm3176; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Jeon BH, 2003, CIRC RES, V92, P586, DOI 10.1161/01.RES.0000066881.04116.45; Jowers CT, 2013, J NEUROSCI METH, V218, P1, DOI 10.1016/j.jneumeth.2013.04.020; Kim JY, 2015, J KOREAN MED SCI, V30, P943, DOI 10.3346/jkms.2015.30.7.943; Kulbe JR, 2016, EXP NEUROL, V275, P334, DOI 10.1016/j.expneurol.2015.05.004; Lei P, 2009, BRAIN RES, V1284, P191, DOI 10.1016/j.brainres.2009.05.074; Levin H, 2013, LANCET NEUROL, V12, P15, DOI 10.1016/S1474-4422(12)70300-9; Li M, 2016, CLIN NEUROL NEUROSUR, V144, P7, DOI 10.1016/j.clineuro.2016.02.032; Li SH, 2012, BRAIN RES, V1444, P76, DOI 10.1016/j.brainres.2011.12.055; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Ma XD, 2011, J MOL CELL BIOL, V3, P159, DOI 10.1093/jmcb/mjr007; Marquez RT, 2010, AM J PHYSIOL-GASTR L, V298, pG535, DOI 10.1152/ajpgi.00338.2009; Pasinetti Giulio M, 2012, Am J Neurodegener Dis, V1, P88; Perez-Polo JR, 2013, J NEUROTRAUM, V30, P727, DOI 10.1089/neu.2012.2650; Redell JB, 2011, J NEUROSCI RES, V89, P212, DOI 10.1002/jnr.22539; Redell JB, 2010, J NEUROTRAUM, V27, P2147, DOI 10.1089/neu.2010.1481; Redell JB, 2009, J NEUROSCI RES, V87, P1435, DOI 10.1002/jnr.21945; Robertson CS, 2014, JAMA-J AM MED ASSOC, V312, P36, DOI 10.1001/jama.2014.6490; Rom S, 2015, J CEREBR BLOOD F MET, V35, P1957, DOI 10.1038/jcbfm.2015.154; Rubiano AM, 2015, NATURE, V527, pS193, DOI 10.1038/nature16035; Ruck T, 2014, JOVE-J VIS EXP, DOI 10.3791/52204; Sandhir R, 2014, NEUROCHEM INT, V78, P117, DOI 10.1016/j.neuint.2014.09.009; Sharma A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112019; Sheedy FJ, 2010, NAT IMMUNOL, V11, P141, DOI 10.1038/ni.1828; Si DW, 2014, EXP THER MED, V8, P1010, DOI 10.3892/etm.2014.1840; Skolnick BE, 2014, NEW ENGL J MED, V371, P2467, DOI 10.1056/NEJMoa1411090; Sun TY, 2014, J HUAZHONG U SCI-MED, V34, P548, DOI 10.1007/s11596-014-1313-1; Tado M, 2014, J NEUROTRAUM, V31, P691, DOI 10.1089/neu.2013.2940; Thal SC, 2014, ARCH MED RES, V45, P698, DOI 10.1016/j.arcmed.2014.11.006; Valable S, 2010, J CEREBR BLOOD F MET, V30, P361, DOI 10.1038/jcbfm.2009.222; Valiyaveettil M, 2013, CHEM-BIOL INTERACT, V203, P371, DOI 10.1016/j.cbi.2012.10.022; Xia YF, 2014, CANCER IMMUNOL RES, V2, P823, DOI 10.1158/2326-6066.CIR-14-0112; Xiong BH, 2013, INT J ONCOL, V42, P219, DOI 10.3892/ijo.2012.1707; Yang T., 2016, J NEUROCHEM; Yang Y, 2011, STROKE, V42, P3323, DOI 10.1161/STROKEAHA.110.608257; Zhang W., 2016, DNA CELL BIOL; Zhang W, 2015, CENT EUR J IMMUNOL, V40, P35, DOI 10.5114/ceji.2015.50831; Zink BJ, 2010, PSYCHIAT CLIN N AM, V33, P741, DOI 10.1016/j.psc.2010.08.005; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	66	42	45	0	15	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	NOV 1	2016	1650						31	40		10.1016/j.brainres.2016.07.015			10	Neurosciences	Neurosciences & Neurology	DZ9IF	WOS:000386187800004	27421180				2021-06-18	
J	Bhattacharya, B; Maung, A; Schuster, K; Davis, KA				Bhattacharya, Bishwajit; Maung, Adrian; Schuster, Kevin; Davis, Kimberly A.			The older they are the harder they fall: Injury patterns and outcomes by age after ground level falls	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Ground level fall; Geriatric; Outcome; Mortality	TRAUMATIC BRAIN-INJURY; GERIATRIC TRAUMA; PREINJURY WARFARIN; MORTALITY; CARE; METAANALYSIS; PREVENTION; ADULTS; IMPACT; RISK	Background: Trauma centers are seeing an increasing number of geriatric patients that are more susceptible to injuries even from relatively minor insults such as a ground level fall (GLF). As life expectancy increases, people are living in the geriatric age bracket for decades and often use anticoagulation agents for various comorbidities. We hypothesize that this patient population is not homogenous and we investigated the injury patterns and outcomes after GLF as a function of age and anticoagulation use. We also sought to identify injury patterns and patient characteristics of GLF patients. Methods: A retrospective review of a Level I trauma center's database identified all adult (age >18) trauma patients admitted after GLFs between 1/2003 and 12/2013. Demographics, injury patterns, antiplatelet use, anticoagulation use (including warfarin, enoxaparin, and rivaroxaban) and outcomes were abstracted. Results: The cohort included 5088 patients. 3990 patients were >60 years and 38.2% were male. With each decade, although the mean ISS did not considerably change (range 7.0-8.6), mortality increased (0.9% at <60 years vs. 5.5% at >90 years), and the likelihood of home discharge decreased dramatically (73.7% at <60 years vs. 18.2% at >90 years). Abdominal solid organ injuries were rare (0.8%). Age was associated with an increased incidence of cervical spine (p = 0.002), rib (p = 0.009) and pelvic fractures (p <0.001). Only aspirin use was significantly associated with intracranial bleed (p = 0.001). Aspirin (p = 0.049) or warfarin (p <0.001) use was associated with increased overall mortality. Conclusion: GLF patients are not homogenous as certain injury patterns change with increasing age. Aspirin use was associated with an increased incidence of intracranial bleeds, whereas other antiplatelet or anticoagulation agents were not. GLF is also associated with significant morbidity and mortality that increases dramatically with age. Both aspirin and warfarin are independently associated with increased mortality. These patient differences have implications for their evaluation and management. Level of evidence: Epidemiological/prognostic study level IV. Published by Elsevier Ltd.	[Bhattacharya, Bishwajit; Maung, Adrian; Schuster, Kevin; Davis, Kimberly A.] Yale Sch Med, Sect Gen Surg Trauma & Surg Crit Care, Dept Surg, New Haven, CT 06510 USA	Bhattacharya, B (corresponding author), 330 Cedar St,POB 208062, New Haven, CT 06520 USA.	bishwajit.bhattacharya@yale.edu; adrian.maung@yale.edu; kevin.schuster@yale.edu; kimberly.davis@yale.edu		Bhattacharya, Bishwajit/0000-0002-7118-7621			Ahmed N, 2009, SOUTH MED J, V102, P476, DOI 10.1097/SMJ.0b013e31819f97a3; Bradburn E, 2012, J TRAUMA ACUTE CARE, V73, P435, DOI 10.1097/TA.0b013e31825c7cf4; Collins CE, 2014, AM J SURG, V208, P544, DOI 10.1016/j.amjsurg.2014.05.019; Garwe T, 2012, AM J SURG, V204, P921, DOI 10.1016/j.amjsurg.2012.05.020; GOTTSDANKER R, 1982, J GERONTOL, V37, P342, DOI 10.1093/geronj/37.3.342; Grandhi R, 2015, J TRAUMA ACUTE CARE, V78, P614, DOI 10.1097/TA.0000000000000542; Grove R., 1968, VITAL STAT RATES US; Healy DA, 2014, EMERG MED J, V31, P101, DOI 10.1136/emermed-2012-201892; Hwabejire JO, 2014, JAMA SURG, V149, P1054, DOI 10.1001/jamasurg.2014.473; Ichwan B, 2015, ANN EMERG MED, V65, P92, DOI 10.1016/j.annemergmed.2014.04.019; Mandavia D, 1998, EMERG MED CLIN N AM, V16, P257, DOI 10.1016/S0733-8627(05)70358-8; Mangram AJ, 2012, J TRAUMA ACUTE CARE, V72, P119, DOI 10.1097/TA.0b013e318241f0ba; Murphy Sherry L, 2013, Natl Vital Stat Rep, V61, P1; National Trauma Data Bank, 2012, ANN REP AM COLL SURG; Peden M, 2002, INJURY CHART BOOK GR; Rodriguez RM, 2013, JAMA SURG, V148, P940, DOI 10.1001/jamasurg.2013.2757; Schoene D, 2014, BMC GERIATR, V14, DOI 10.1186/1471-2318-14-107; Shaw JA, 2014, QUAL HEALTH RES, V24, P901, DOI 10.1177/1049732314539194; Sierink Joanne C, 2012, Ned Tijdschr Geneeskd, V156, pA4897; Spaniolas K, 2010, J TRAUMA, V69, P821, DOI 10.1097/TA.0b013e3181efc6c6; Sterling DA, 2001, J TRAUMA, V50, P116, DOI 10.1097/00005373-200101000-00021; Stevens J. A., 2006, Morbidity and Mortality Weekly Report, V55, P1221; Vincent G.K., 2010, NEXT 4 DECADES OLDER, P25; Vlaeyen E, 2015, J AM GERIATR SOC, V63, P211, DOI 10.1111/jgs.13254; Yoshida G, 2014, SPINE, V39, P1121, DOI 10.1097/BRS.0000000000000360; Zafar SN, 2015, J TRAUMA ACUTE CARE, V78, P852, DOI 10.1097/TA.0000000000000557	26	42	42	2	8	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	SEP	2016	47	9					1955	1959		10.1016/j.injury.2016.06.019			5	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	DU5QG	WOS:000382265800016	27346422				2021-06-18	
J	Howell, DR; O'Brien, MJ; Beasley, MA; Mannix, RC; Meehan, WP				Howell, David R.; O'Brien, Michael J.; Beasley, Michael A.; Mannix, Rebekah C.; Meehan, William P.			Initial somatic symptoms are associated with prolonged symptom duration following concussion in adolescents	ACTA PAEDIATRICA			English	Article						Brain injury; Sports; Symptom questionnaire; Symptoms and traumatic brain injury	SPORTS-RELATED CONCUSSION; GAIT BALANCE CONTROL; HIGH-SCHOOL; NEUROCOGNITIVE PERFORMANCE; POSTCONCUSSION SYNDROME; RECOVERY; PREDICTORS; COLLEGIATE; MIGRAINE; CHILDREN	AimTo determine which initial postinjury symptom domains are independently associated with symptoms lasting >28 days in youth athletes who sustained sport-related concussions. MethodsPatients who presented for care at a sport concussion clinic completed the postconcussion symptom scale. They were classified into two groups: those who reported symptom resolution within 28 days of injury and those who did not. Logistic regression models were constructed for children and adolescents to determine the independent association between symptom recovery and potential predictor variables: initial symptom scores in 5 postconcussion symptom scale domains (somatic, vestibular-ocular, cognitive, sleep and emotional), sex, loss of consciousness or amnesia at the time of injury, history of prior concussion, prior treatment for headaches or migraines, or family history of concussion. ResultsSixty-eight child (8-12 years of age) and 250 adolescent (13-18 years of age) athletes were included. For adolescents, initial somatic symptom severity was independently associated with prolonged symptom duration (adjusted odds ratio = 1.162; 95% CI: 1.060, 1.275) and no other predictor variables were. No potential predictor variables were independently associated with prolonged symptom duration for children. ConclusionAmong adolescent athletes, a high initial somatic symptom burden (e.g. headache, nausea, vomiting, etc.) is associated with increased odds of symptoms beyond 28 days postinjury.	[Howell, David R.; O'Brien, Michael J.; Meehan, William P.] Micheli Ctr Sports Injury Prevent, Waltham, MA USA; [Howell, David R.; O'Brien, Michael J.; Beasley, Michael A.; Meehan, William P.] Boston Childrens Hosp, Dept Orthopaed, Div Sports Med, Boston, MA USA; [Howell, David R.; O'Brien, Michael J.; Mannix, Rebekah C.; Meehan, William P.] Boston Childrens Hosp, Brain Injury Ctr, Boston, MA USA; [O'Brien, Michael J.; Beasley, Michael A.; Meehan, William P.] Harvard Med Sch, Dept Orthopaed Surg, Boston, MA USA; [Mannix, Rebekah C.; Meehan, William P.] Boston Childrens Hosp, Div Emergency Med, Boston, MA USA; [Mannix, Rebekah C.; Meehan, William P.] Harvard Med Sch, Dept Pediat, Boston, MA USA	Howell, DR (corresponding author), Boston Childrens Hosp, Micheli Ctr Sports Injury Prevent, Dept Orthopaed, Div Sports Med, 9 Hope Ave, Waltham, MA 02453 USA.	David.Howell2@childrens.harvard.edu	Mannix, Rebekah/AAD-8702-2020	Howell, David/0000-0002-2955-0191	National Football League Players Association; National Hockey League Alumni Association; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040128] Funding Source: NIH RePORTER	Dr. Meehan receives royalties from ABC-Clio publishing for the sale of his book, Kids, Sports, and Concussion: A guide for coaches and parents, and royalties from Wolters Kluwer for working as an author for UpTo Date. He is under contract with ABC-Clio publishing for a future book entitled, Concussions, and with Springer International publishing for a future book entitled, Head and Neck Injuries in Young Athletes. His research is funded, in part, by a grant from the National Football League Players Association and by philanthropic support from the National Hockey League Alumni Association through the Corey C. Griffin Pro-Am Tournament. Dr. O'Brien receives royalties from Wolters Kluwer for working as an author for UpToDate. He is under contract with Springer International publishing for a book entitled, Head and Neck Injuries in Young Athletes. Drs. Howell, Beasley and Mannix have no conflict of interests to report.	Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Ciuffreda Kenneth J, 2008, Optometry, V79, P18, DOI 10.1016/j.optm.2007.10.004; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Corwin DJ, 2015, J PEDIATR-US, V166, P1221, DOI 10.1016/j.jpeds.2015.01.039; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gordon KE, 2006, BRIT J SPORT MED, V40, P184, DOI 10.1136/bjsm.2005.022251; Grubenhoff' JA, 2015, BRAIN INJURY, V29, P1186, DOI 10.3109/02699052.2015.1035325; Guskiewicz KM, 2013, BRIT J SPORT MED, V47, P289, DOI 10.1136/bjsports-2013-092225; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Howell DR, 2015, AM J SPORT MED, V43, P625, DOI 10.1177/0363546514560994; Howell DR, 2013, ARCH PHYS MED REHAB, V94, P1513, DOI 10.1016/j.apmr.2013.04.015; Kontos AP, 2013, AM J SPORT MED, V41, P1497, DOI 10.1177/0363546513488751; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Lau BC, 2011, AM J SPORT MED, V39, P1209, DOI 10.1177/0363546510392016; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; Meehan WP, 2014, NEUROLOGY, V83, P2204, DOI 10.1212/WNL.0000000000001073; Meehan WP, 2013, J PEDIATR-US, V163, P721, DOI 10.1016/j.jpeds.2013.03.012; Meehan WP, 2011, AM J SPORT MED, V39, P2304, DOI 10.1177/0363546511423503; Merritt VC, 2014, J CLIN EXP NEUROPSYC, V36, P1098, DOI 10.1080/13803395.2014.983463; Morgan CD, 2015, J NEUROSURG-PEDIATR, V15, P589, DOI 10.3171/2014.10.PEDS14356; Mucha A, 2014, AM J SPORT MED, V42, P2479, DOI 10.1177/0363546514543775; Pardini D., 2004, BR J SPORTS MED, V38, P661; Sandel NK, 2013, APPL NEUROPSYCH-CHIL, V2, P64, DOI 10.1080/21622965.2012.670580; Simon L, 2015, DETECTING MULTICOLLI; Tator Charles H, 2014, Neurosurgery, V75 Suppl 4, pS106, DOI 10.1227/NEU.0000000000000484	29	42	42	0	18	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0803-5253	1651-2227		ACTA PAEDIATR	Acta Paediatr.	SEP	2016	105	9					E426	E432		10.1111/apa.13486			7	Pediatrics	Pediatrics	DV2IB	WOS:000382742900006	27230721	Green Accepted			2021-06-18	
J	Posti, JP; Takala, RSK; Runtti, H; Newcombe, VF; Outtrim, J; Katila, AJ; Frantzen, J; Ala-Seppala, H; Coles, JP; Hossain, MI; Kyllonen, A; Maanpaa, HR; Tallus, J; Hutchinson, PJ; van Gils, M; Menon, DK; Tenovuo, O				Posti, Jussi P.; Takala, Riikka S. K.; Runtti, Hilkka; Newcombe, Virginia F.; Outtrim, Joanne; Katila, Ari J.; Frantzen, Janek; Ala-Seppala, Henna; Coles, Jonathan P.; Hossain, Md. Iftakher; Kyllonen, Anna; Maanpaa, Henna-Riikka; Tallus, Jussi; Hutchinson, Peter J.; van Gils, Mark; Menon, David K.; Tenovuo, Olli		TBIcare Investigators	The Levels of Glial Fibrillary Acidic Protein and Ubiquitin C-Terminal Hydrolase-L1 During the First Week After a Traumatic Brain Injury: Correlations With Clinical and Imaging Findings	NEUROSURGERY			English	Article						Biomarker; GFAP; Severity; Traumatic brain injury; UCH-L1	GLASGOW COMA SCALE; INTRACRANIAL LESIONS; COMPUTED-TOMOGRAPHY; SERUM-LEVELS; BIOMARKERS; MILD; GFAP	BACKGROUND: Glial fibrillary acidic protein (GFAP) and ubiquitin C-terminal hydrolase-L1 (UCH-L1) are promising biomarkers of traumatic brain injury (TBI). OBJECTIVE: We investigated the relation of the GFAP and UCH-L1 levels to the severity of TBI during the first week after injury. METHODS: Plasma UCH-L1 and GFAP were measured from 324 consecutive patients with acute TBI and 81 control subject enrolled in a 2-center prospective study. The baseline measures included initial Glasgow Coma Scale (GCS), head computed tomographic (CT) scan at admission, and blood samples for protein biomarkers that were collected at admission and on days 1, 2, 3, and 7 after injury. RESULTS: Plasma levels of GFAP and UCH-L1 during the first 2 days after the injury strongly correlated with the initial severity of TBI as assessed with GCS. Additionally, levels of UCH-L1 on the seventh day after the injury were significantly related to the admission GCS scores. At admission, both biomarkers were capable of distinguishing mass lesions from diffuse injuries in CT, and the area under the curve of the receiver-operating characteristic curve for prediction of any pathological finding in CT was 0.739 (95% confidence interval, 0.636-0.815) and 0.621 (95% confidence interval, 0.517-0.713) for GFAP and UCH-L1, respectively. CONCLUSION: These results support the prior findings of the potential role of GFAP and UCH-L1 in acute-phase diagnostics of TBI. The novel finding is that levels of GFAP and UCH-L1 correlated with the initial severity of TBI during the first 2 days after the injury, thus enabling a window for TBI diagnostics with latency.	[Posti, Jussi P.; Frantzen, Janek] Turku Univ Hosp, Dept Neurosurg, Div Clin Neurosci, POB 52, FI-20521 Turku, Finland; [Posti, Jussi P.; Frantzen, Janek; Tenovuo, Olli] Turku Univ Hosp, Dept Rehabil & Brain Trauma, Div Clin Neurosci, Turku, Finland; [Posti, Jussi P.; Ala-Seppala, Henna; Hossain, Md. Iftakher; Kyllonen, Anna; Maanpaa, Henna-Riikka; Tallus, Jussi] Univ Turku, Dept Neurol, Turku, Finland; [Takala, Riikka S. K.; Katila, Ari J.] Turku Univ Hosp, Perioperat Serv, Intens Care Med & Pain Management, Turku, Finland; [Takala, Riikka S. K.; Katila, Ari J.] Univ Turku, Turku, Finland; [Runtti, Hilkka; van Gils, Mark] VTT Tech Res Ctr Finland, Syst Med, Tampere, Finland; [Newcombe, Virginia F.; Outtrim, Joanne; Menon, David K.; Tenovuo, Olli] Univ Cambridge, Addenbrookes Hosp, Div Anaesthesia, Dept Med, Cambridge, England; [Coles, Jonathan P.; Hutchinson, Peter J.] Univ Cambridge, Addenbrookes Hosp, Neurosurg Unit, Dept Clin Neurosci, Cambridge, England	Posti, JP (corresponding author), Turku Univ Hosp, Dept Neurosurg, Div Clin Neurosci, POB 52, FI-20521 Turku, Finland.	jussi.posti@utu.fi	Posti, Jussi P./Y-2908-2019	Posti, Jussi P./0000-0002-5925-5193; Ala-Seppala, Henna/0000-0002-1577-3028; van Gils, Mark/0000-0002-0029-1771; Liedes, Hilkka/0000-0003-4655-7675; Newcombe, Virginia/0000-0001-6044-9035	European CommissionEuropean CommissionEuropean Commission Joint Research Centre [FP7-270259-TBIcare]; EVO; Maire Taponen Foundation; Skulle Implants Ltd.; AbbottAbbott Laboratories; Fresenius-Kabi; UCBUCB Pharma SA; PfizerPfizer; NIHR Research Professorship; NIHR Cambridge BRC; Orion Corp.; Health Foundation/Academy of Medical Sciences Clinician Scientist Fellowship; Academy of Medical Sciences (AMS)Academy of Medical Sciences (AMS) [AMS-CSF4-Newcombe] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0512-10090, ACF-2009-14-007, NIHR-RP-R3-12-013] Funding Source: researchfish	This work was partially funded by the European Commission under the 7th Framework Programme (FP7-270259-TBIcare). Dr Posti has received personal EVO funding and a grant from Maire Taponen Foundation and financial support in form of a congress fee and travel expenses paid by Skulle Implants Ltd. Dr Takala has received speaker fees from Abbott, Fresenius-Kabi, and UCB and conference funding from Pfizer. Dr Takala is a stockholder in Orion. Dr Newcombe has a Health Foundation/Academy of Medical Sciences Clinician Scientist Fellowship. Dr Frantzen is chief medical officer at Skulle Implants Ltd. Dr Hutchinson is a director of Technicam and is supported by an NIHR Research Professorship and the NIHR Cambridge BRC. Dr Tenovuo has received speaker fees from Orion Corp. The other authors have no personal, financial, or institutional interest in any of the drugs, materials, or devices described in this article.	Berger RP, 2006, J HEAD TRAUMA REHAB, V21, P315, DOI 10.1097/00001199-200607000-00004; Brophy GM, 2011, J NEUROTRAUM, V28, P861, DOI 10.1089/neu.2010.1564; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Czeiter E, 2012, J NEUROTRAUM, V29, P1770, DOI 10.1089/neu.2011.2127; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Kou ZF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080296; Majdan M, 2015, J NEUROTRAUM, V32, P101, DOI 10.1089/neu.2014.3438; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; McMahon PJ, 2014, J NEUROTRAUM, V32, P527; Missler U, 1999, CLIN CHEM, V45, P138; Mondello S, 2012, J NEUROTRAUM, V29, P1096, DOI 10.1089/neu.2011.2092; Mondello S, 2012, NEUROSURGERY, V70, P666, DOI 10.1227/NEU.0b013e318236a809; Mondello S, 2011, CRIT CARE, V15, DOI 10.1186/cc10286; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; Okonkwo DO, 2013, J NEUROTRAUM, V30, P1490, DOI 10.1089/neu.2013.2883; Papa L, 2014, J NEUROTRAUM, V31, P1815, DOI 10.1089/neu.2013.3245; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Takala RSK, 2015, WORLD NEUROSURG; Tongaonkar P, 2000, MOL CELL BIOL, V20, P4691, DOI 10.1128/MCB.20.13.4691-4698.2000	22	42	44	1	10	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	SEP	2016	79	3					456	463		10.1227/NEU.0000000000001226			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	DV9PX	WOS:000383274400030	26963330				2021-06-18	
J	McAteer, KM; Corrigan, F; Thornton, E; Turner, RJ; Vink, R				McAteer, Kelly M.; Corrigan, Frances; Thornton, Emma; Turner, Renee Jade; Vink, Robert			Short and Long Term Behavioral and Pathological Changes in a Novel Rodent Model of Repetitive Mild Traumatic Brain Injury	PLOS ONE			English	Article							PROFESSIONAL FOOTBALL PLAYERS; HEAD-INJURY; INTERNATIONAL-CONFERENCE; CLINICAL PRESENTATION; RECURRENT CONCUSSION; CONSENSUS STATEMENT; ALZHEIMERS-DISEASE; HUMAN TAUOPATHIES; CEREBRAL-CORTEX; MOTOR DEFICITS	A history of concussion, particularly repeated injury, has been linked to an increased risk for the development of neurodegenerative diseases, particularly chronic traumatic encephalopathy (CTE). CTE is characterized by abnormal accumulation of hyperphosphorylated tau and deficits in learning and memory. As yet the mechanisms associated with the development of CTE are unknown. Accordingly, the aim of the current study was to develop and characterize a novel model of repetitive mTBI that accurately reproduces the key short and long-term functional and histopathological features seen clinically. Forty male Sprague-Dawley rats were randomly assigned to receive 0, 1 or 3x mTBI spaced five days apart using a modified version of the Marmarou impact-acceleration diffuse-TBI model to deliver 110G of linear force. Functional outcomes were assessed six and twelve weeks post-injury, with histopathology assessed twenty-four hours and twelve weeks post-injury. Repetitive mTBI resulted in mild spatial and recognition memory deficits as reflected by increased escape latency on the Barnes maze and decreased time spent in the novel arm of the Y maze. There was a trend towards increased anxiety-like behavior, with decreased time spent in the inner portion of the open field. At 24 hours and 12 weeks post injury, repetitive mTBI animals showed increased tau phosphorylation and microglial activation within the cortex. Increases in APP immunoreactivity were observed in repetitive mTBI animals at 12 weeks indicating long-term changes in axonal integrity. This novel model of repetitive mTBI with its persistent cognitive deficits, neuroinflammation, axonal injury and tau hyperphosphorylation, thus represents a clinically relevant experimental approach to further explore the underlying pathogenesis of CTE.	[McAteer, Kelly M.; Corrigan, Frances; Thornton, Emma; Turner, Renee Jade] Univ Adelaide, Sch Med, Adelaide Ctr Neurosci Res, Adelaide, SA, Australia; [Vink, Robert] Univ South Australia, Sansom Inst Hlth Res, Adelaide, SA, Australia	Corrigan, F (corresponding author), Univ Adelaide, Sch Med, Adelaide Ctr Neurosci Res, Adelaide, SA, Australia.	frances.corrigan@adelaide.edu.au	AM, Robert Vink/S-5616-2019; Vink, Robert/J-7351-2012	AM, Robert Vink/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667; Corrigan, Frances/0000-0001-6150-8893	National Health and Medical Research CouncilNational Health and Medical Research Council of Australia [APP1068712]; Australian National Health and Medical Research CouncilNational Health and Medical Research Council of Australia	This work was supported by the National Health and Medical Research Council: APP1068712; consultations.nhmrc.gov.au (RV). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.; This work was supported, in part, by a grant from the Australian National Health and Medical Research Council.	Abisambra JF, 2014, J ALZHEIMERS DIS, V40, P495, DOI 10.3233/JAD-131019; Ahmadzadeh H, 2014, BIOPHYS J, V106, P1123, DOI 10.1016/j.bpj.2014.01.024; Angoa-Perez M, 2014, J NEUROCHEM, V129, P916, DOI 10.1111/jnc.12690; Aungst SL, 2014, J CEREBR BLOOD F MET, V34, P1223, DOI 10.1038/jcbfm.2014.75; Ballatore C, 2007, NAT REV NEUROSCI, V8, P663, DOI 10.1038/nrn2194; BARNES CA, 1979, J COMP PHYSIOL PSYCH, V93, P74, DOI 10.1037/h0077579; Barth JT, 2001, J ATHL TRAINING, V36, P253; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Bolton AN, 2014, J NEUROPATH EXP NEUR, V73, P933, DOI 10.1097/NEN.0000000000000115; Breunig JJ, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00026; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cheng JS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115765; Cloots RJH, 2008, ANN BIOMED ENG, V36, P1203, DOI 10.1007/s10439-008-9510-3; Conrad CD, 1996, BEHAV NEUROSCI, V110, P1321, DOI 10.1037/0735-7044.110.6.1321; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Feuillette S, 2010, J NEUROCHEM, V113, P895, DOI 10.1111/j.1471-4159.2010.06663.x; Fischer D, 2009, BIOCHEMISTRY-US, V48, P10047, DOI 10.1021/bi901090m; Forbes JA, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.9.FOCUS12288; Gerson J. E., 2016, J NEUROTRAUMA; Giza CC, 2001, J ATHL TRAINING, V36, P228; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Gould TD, 2009, NEUROMETHODS, V42, P1, DOI 10.1007/978-1-60761-303-9_1; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guzel A, 2010, AM J EMERG MED, V28, P399, DOI 10.1016/j.ajem.2008.12.025; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hanes J, 2009, J NEUROCHEM, V108, P1167, DOI 10.1111/j.1471-4159.2009.05869.x; Hawkins BE, 2013, J BIOL CHEM, V288, P17042, DOI 10.1074/jbc.M113.472746; Hovda DA, 1993, INTRACRANIAL PRESSUR, VVIII, P469; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; King T, 2013, J SCI MED SPORT, V16, P302, DOI 10.1016/j.jsams.2012.09.003; Kushner D, 1998, ARCH INTERN MED, V158, P1617, DOI 10.1001/archinte.158.15.1617; Li Y, 2011, J NEUROTRAUM, V28, P1767, DOI 10.1089/neu.2010.1687; LINDWALL G, 1984, J BIOL CHEM, V259, P5301; Luo J, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00012; Magnoni S, 2012, BRAIN, V135, P1268, DOI 10.1093/brain/awr286; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meaney DF, 2011, CLIN SPORT MED, V30, P19, DOI 10.1016/j.csm.2010.08.009; Miyasaka T, 2010, FEBS LETT, V584, P3227, DOI 10.1016/j.febslet.2010.06.014; Neselius S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081249; Neselius S, 2013, BRAIN INJURY, V27, P425, DOI 10.3109/02699052.2012.750752; Noble JM, 2013, NEUROPSYCHOL REV, V23, P273, DOI 10.1007/s11065-013-9239-0; Ojo JO, 2016, J NEUROPATHOLOGY EXP; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Peskind ER, 2013, J CLIN PSYCHIAT, V74, P180, DOI 10.4088/JCP.12011co1c; Planel E, 2008, J NEUROSCI, V28, P12798, DOI 10.1523/JNEUROSCI.4101-08.2008; Prins ML, 2010, DEV NEUROSCI-BASEL, V32, P510, DOI 10.1159/000316800; Romine J, 2014, JOVE-J VIS EXP, DOI 10.3791/51781; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; Seifert T, 2016, CURR PAIN HEADACHE R, V20, DOI 10.1007/s11916-016-0568-6; Shultz SR, 2012, J NEUROTRAUM, V29, P281, DOI 10.1089/neu.2011.2123; Signoretti S, 2011, PM&R, V3, pS359, DOI 10.1016/j.pmrj.2011.07.018; Smith C, 2013, NEUROPATH APPL NEURO, V39, P654, DOI 10.1111/nan.12008; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Sun T, 2014, NAT REV NEUROSCI, V15, P217, DOI 10.1038/nrn3707; Tavazzi B, 2005, NEUROSURGERY, V56, P582, DOI 10.1227/01.NEU.0000156715.04900.E6; Thies E, 2007, J NEUROSCI, V27, P2896, DOI 10.1523/JNEUROSCI.4674-06.2007; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Urban JE, 2013, ANN BIOMED ENG, V41, P2474, DOI 10.1007/s10439-013-0861-z; Yang SH, 2013, J SURG RES, V184, P981, DOI 10.1016/j.jss.2013.03.075; Zhou YX, 2013, RADIOLOGY, V267, P880, DOI 10.1148/radiol.13122542	69	42	42	0	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 9	2016	11	8							e0160220	10.1371/journal.pone.0160220			18	Multidisciplinary Sciences	Science & Technology - Other Topics	DT3IK	WOS:000381374200027	27505027	DOAJ Gold, Green Published, Green Accepted			2021-06-18	
J	Bosarge, PL; Raff, LA; McGwin, G; Carroll, SL; Bellot, SC; Diaz-Guzman, E; Kerby, JD				Bosarge, Patrick L.; Raff, Lauren Allen; McGwin, Gerald, Jr.; Carroll, Shannon L.; Bellot, Scott C.; Diaz-Guzman, Enrique; Kerby, Jeffrey D.			Early initiation of extracorporeal membrane oxygenation improves survival in adult trauma patients with severe adult respiratory distress syndrome	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						ECMO; ARDS; conventional ventilation; trauma	LIFE-SUPPORT; LUNG INJURY; FAILURE; EXPERIENCE; SHOCK; ECMO	BACKGROUND: The use of extracorporeal membrane oxygenation (ECMO) in the trauma population has been reported to have a mortality benefit in patients with severe refractory hypoxic respiratory failure. This study compares the early initiation of ECMO for the management of severe adult respiratory distress syndrome (ARDS) versus a historical control immediately preceding the use of ECMO for trauma patients. METHODS: A retrospective study was conducted at a single verified Level I trauma center. The study population was limited to trauma patients diagnosed with severe ARDS using the Berlin definition (PaO2/FIO2 ratio < 100). Patients managed with ECMO versus conventional ventilation (CONV) were compared. The primary outcome of interest was mortality; secondary outcomes included hospital length of stay, intensive care unit-free days, and ventilator-free days. RESULTS: Fifteen ECMO patients managed from March 2013 to November 2014 were identified, as were 14 CONV patients managed from March 2012 to February 2013 who met the Berlin definition of severe ARDS. Data related to age, Injury Severity Scores (ISSs), admission lactic acid levels, base deficit, the number of transfused red blood cell units within the first 24 hours, and presence of severe traumatic brain injury were collected and were not statistically different between the groups. Likewise, Murray Lung Injury (MLI), Sequential Organ Failure Assessment (SOFA), and Acute Physiology and Chronic Health Evaluation II (APACHE II) scores determined at the onset of severe ARDS were not statistically different between the groups. Median hospital stay (CONV, 28.0 days [14.0-47.0]; ECMO, 43.5 days [30.0-93.0]; p = 0.15), intensive care unit-free days (CONV, 0.0 days [0.0-5.0]; ECMO, 5.0 days [0.0-7.0]; p = 0.26), and ventilator-free days (CONV, 0.0 days [0.0-10.0]; ECMO, 8.0 days [0.0-19.0]; p = 0.13) were not statistically different between the groups. Mortality in the ECMO group was significantly reduced compared with the CONV group (ECMO, 13.3%; CONV, 64%; p = 0.01). Timing from the onset of severe ARDS to ECMO intervention occurred at a mean 1.9 +/- 1.4 days. CONCLUSION: Patients who were treated with ECMO for severe ARDS had an improved mortality compared with historical controls. ECMO should be considered at the early onset of severe ARDS to improve survival. Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved.	[Bosarge, Patrick L.; Raff, Lauren Allen; McGwin, Gerald, Jr.; Carroll, Shannon L.; Bellot, Scott C.; Diaz-Guzman, Enrique; Kerby, Jeffrey D.] Univ Alabama Birmingham, Div Acute Care Surg, Birmingham, AL USA	Bosarge, PL (corresponding author), Univ Alabama Birmingham, Div Trauma Burns & Surg Crit Care, Med Ctr, 112 Lyons Harrison Res Bldg,701 19th St South, Birmingham, AL 35294 USA.	pbosarge@uabmc.edu	Cannon, Jeremy/T-3875-2019	Cannon, Jeremy/0000-0002-2969-9316			Arlt M, 2010, RESUSCITATION, V81, P804, DOI 10.1016/j.resuscitation.2010.02.020; Biderman P, 2013, J TRAUMA ACUTE CARE, V75, P907, DOI 10.1097/TA.0b013e3182a8334f; Burns KEA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014623; Chughtai T, 2001, J TRAUMA, V50, P1137, DOI 10.1097/00005373-200106000-00025; Cordell-Smith JA, 2006, INJURY, V37, P29, DOI 10.1016/j.injury.2005.03.027; Guirand DM, 2014, J TRAUMA ACUTE CARE, V76, P1275, DOI 10.1097/TA.0000000000000213; HILL JD, 1972, NEW ENGL J MED, V286, P629, DOI 10.1056/NEJM197203232861204; Krug EG, 2000, AM J PUBLIC HEALTH, V90, P523, DOI 10.2105/AJPH.90.4.523; Michaels AJ, 1999, J TRAUMA, V46, P638, DOI 10.1097/00005373-199904000-00013; Muellenbach RM, 2012, J TRAUMA ACUTE CARE, V72, P1444, DOI 10.1097/TA.0b013e31824d68e3; MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720; Peek GJ, 2010, HEALTH TECHNOL ASSES, V14, P1, DOI 10.3310/hta14350; Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669; Ried M, 2013, CRIT CARE, V17, DOI 10.1186/cc12782; Rubenfeld GD, 2007, CHEST, V131, P554, DOI 10.1378/chest.06-1976; Slutsky AS, 2013, NEW ENGL J MED, V369, P2126, DOI 10.1056/NEJMra1208707; Wu SC, 2015, AM J EMERG MED, V33, P658, DOI 10.1016/j.ajem.2015.02.007; Yuan KC, 2008, J TRAUMA, V65, P1151, DOI 10.1097/01.ta.0000235492.09223.83; ZAPOL WM, 1979, JAMA-J AM MED ASSOC, V242, P2193, DOI 10.1001/jama.242.20.2193	19	42	46	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	AUG	2016	81	2					236	243		10.1097/TA.0000000000001068			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	DS5CE	WOS:000380797300004	27032012				2021-06-18	
J	Wasserman, EB; Bazarian, JJ; Mapstone, M; Block, R; van Wijngaarden, E				Wasserman, Erin B.; Bazarian, Jeffrey J.; Mapstone, Mark; Block, Robert; van Wijngaarden, Edwin			Academic Dysfunction After a Concussion Among US High School and College Students	AMERICAN JOURNAL OF PUBLIC HEALTH			English	Article							SPORT-RELATED CONCUSSION; TRAUMATIC BRAIN-INJURY; STATES HIGH-SCHOOL; MILD HEAD-INJURY; INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; PERFORMANCE; ADOLESCENTS; CHILDREN; ACCOMMODATIONS	Objectives. To determine whether concussed students experience greater academic dysfunction than students who sustain other injuries. Methods. We conducted a prospective cohort study from September 2013 through January 2015 involving high school and college students who visited 3 emergency departments in the Rochester, New York, area. Using telephone surveys, we compared self-reported academic dysfunction between 70 students with concussions and a comparison group of 108 students with extremity injuries at 1 week and 1 month after injury. Results. At 1 week after injury, academic dysfunction scores were approximately 16 points higher (b = 16.20; 95% confidence interval = 6.39, 26.00) on a 174-point scale in the concussed group than in the extremity injury group. Although there were no differences overall at 1-month after injury, female students in the concussion group and those with a history of 2 or more prior concussions were more likely to report academic dysfunction. Conclusions. Our results showed academic dysfunction among concussed students, especially female students and those with multiple prior concussions, 1 week after their injury. Such effects appeared to largely resolve after 1 month. Our findings support the need for academic adjustments for concussed students.	[Wasserman, Erin B.; Bazarian, Jeffrey J.; Mapstone, Mark; Block, Robert; van Wijngaarden, Edwin] Univ Rochester, Sch Med & Dent, Rochester, NY USA	Wasserman, EB (corresponding author), Univ N Carolina, Matthew Gfeller Sport Related Traumat Brain Injur, 2207 Stallings Evans Sports Med Complex, Chapel Hill, NC 27599 USA.	ebw@email.unc.edu	van Wijngaarden, Edwin/Q-2073-2019	van Wijngaarden, Edwin/0000-0001-7583-4630; Wasserman, Erin/0000-0001-5957-5878			American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; ARCIA E, 1993, BRAIN INJURY, V7, P481, DOI 10.3109/02699059309008175; Baker JG, 2015, CLIN PEDIATR, V54, P961, DOI 10.1177/0009922815588820; Bigal ME, 2001, HEADACHE, V41, P710, DOI 10.1046/j.1526-4610.2001.041007710.x; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Cancelliere Carol, 2014, Arch Phys Med Rehabil, V95, pS210, DOI 10.1016/j.apmr.2013.06.035; Cantu R., 2012, CONCUSSIONS OUR KIDS; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Castile L, 2012, BRIT J SPORT MED, V46, P603, DOI 10.1136/bjsports-2011-090115; Centers for Disease Control and Prevention, HEADS SCH KNOW YOUR; Cobaugh DJ, 1997, ACAD EMERG MED, V4, P231, DOI 10.1111/j.1553-2712.1997.tb03748.x; Corwin DJ, 2014, J PEDIATR-US, V165, P1207, DOI 10.1016/j.jpeds.2014.08.034; Covassin T, 2013, AM J SPORT MED, V41, P2885, DOI 10.1177/0363546513499230; Curcio G, 2006, SLEEP MED REV, V10, P323, DOI 10.1016/j.smrv.2005.11.001; DeMatteo C, 2015, CLIN PEDIATR, V54, P783, DOI 10.1177/0009922814567305; DeRoma V.M., 2009, COLL STUDENT J, V43, P325; Dougan BK, 2014, J INT NEUROPSYCH SOC, V20, P64, DOI 10.1017/S1355617712001464; Eisenberg MA, 2014, PEDIATRICS, V133, P999, DOI 10.1542/peds.2014-0158; Ferguson RJ, 1999, NEUROPSYCHOLOGY, V13, P582, DOI 10.1037/0894-4105.13.4.582; FERGUSSON DM, 1992, J CHILD PSYCHOL PSYC, V33, P375, DOI 10.1111/j.1469-7610.1992.tb00873.x; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gabbe BJ, 2014, J EPIDEMIOL COMMUN H, V68, P466, DOI 10.1136/jech-2013-203427; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Halstead ME, 2013, PEDIATRICS, V132, P948, DOI 10.1542/peds.2013-2867; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Hawley CA, 2004, BRAIN INJURY, V18, P645, DOI 10.1080/02699050310001646189; Hawley CA, 2004, ARCH DIS CHILD, V89, P136, DOI 10.1136/adc.2002.025577; Hutchison M, 2011, AM J SPORT MED, V39, P2331, DOI 10.1177/0363546511413375; Hux K, 2010, BRAIN INJURY, V24, P13, DOI 10.3109/02699050903446823; Iverson GL, 2004, J INT NEUROPSYCH SOC, V10, P904, DOI 10.1017/S1355617704106139; Kennedy MRT, 2008, NEUROREHABILITATION, V23, P511; Kostyun RO, 2015, SPORTS HEALTH, V7, P52, DOI 10.1177/1941738114555075; Kristman Vicki L, 2014, Arch Phys Med Rehabil, V95, pS265, DOI 10.1016/j.apmr.2013.04.026; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Master CL, 2012, PEDIATR ANN, V41, pE180, DOI 10.3928/00904481-20120827-09; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McGrath N, 2010, J ATHL TRAINING, V45, P492, DOI 10.4085/1062-6050-45.5.492; MICKEY RM, 1989, AM J EPIDEMIOL, V129, P125, DOI 10.1093/oxfordjournals.aje.a115101; Ransom DM, 2015, PEDIATRICS, V135, P1043, DOI 10.1542/peds.2014-3434; Sady MD, 2011, PHYS MED REH CLIN N, V22, P701, DOI 10.1016/j.pmr.2011.08.008; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Weber ML, 2015, J SCH NURS, V31, P146, DOI 10.1177/1059840514540939; Williams RM, 2015, J ATHL TRAINING, V50, P262, DOI 10.4085/1062-6050-49.3.81; YLVISAKER M, 1995, J HEAD TRAUMA REHAB, V10, P42, DOI 10.1097/00001199-199512000-00007	45	42	42	0	16	AMER PUBLIC HEALTH ASSOC INC	WASHINGTON	800 I STREET, NW, WASHINGTON, DC 20001-3710 USA	0090-0036	1541-0048		AM J PUBLIC HEALTH	Am. J. Public Health	JUL	2016	106	7					1247	1253		10.2105/AJPH.2016.303154			7	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	DO7CL	WOS:000377939700046	27196651	Green Published			2021-06-18	
J	Witsch, J; Frey, HP; Patel, S; Park, S; Lahiri, S; Schmidt, JM; Agarwal, S; Falo, MC; Velazquez, A; Jaja, B; Macdonald, RL; Connolly, ES; Claassen, J				Witsch, Jens; Frey, Hans-Peter; Patel, Sweta; Park, Soojin; Lahiri, Shouri; Schmidt, J. Michael; Agarwal, Sachin; Falo, Maria Cristina; Velazquez, Angela; Jaja, Blessing; Macdonald, R. Loch; Connolly, E. Sander; Claassen, Jan			Prognostication of Long-Term Outcomes after Subarachnoid Hemorrhage: The FRESH Score	ANNALS OF NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; IN-HOSPITAL MORTALITY; COGNITIVE IMPAIRMENT; RISK STRATIFICATION; PREDICTION; SCALE; CLASSIFICATION; VALIDATION; WITHDRAWAL; INFARCTION	Objective: To create a multidimensional tool to prognosticate long-term functional, cognitive, and quality of life outcomes after spontaneous subarachnoid hemorrhage (SAH) using data up to 48 hours after admission. Methods: Data were prospectively collected for 1,619 consecutive patients enrolled in the SAH outcome project July 1996 to March 2014. Linear models (LMs) were applied to identify factors associated with outcome in 1,526 patients with complete data. Twelve-month functional, cognitive, and quality of life outcomes were measured using the modified Rankin scale (mRS), Telephone Interview for Cognitive Status, and Sickness Impact Profile. Based on the LM residuals, we constructed the FRESH score (Functional Recovery Expected after Subarachnoid Hemorrhage). Score performance, discrimination, and internal validity were tested using the area under the receiver operating characteristic curve (AUC), Nagelkerke and Cox/ Snell R 2, and bootstrapping. For external validation, we used a control population of SAH patients from the CONSCIOUS-1 study (n = 413). Results: The FRESH score was composed of Hunt & Hess and APACHE-II physiologic scores on admission, age, and aneurysmal rebleed within 48 hours. Separate scores to prognosticate 1-year cognition (FRESH-cog) and quality of life (FRESH-quol) were developed controlling for education and premorbid disability. Poor functional outcome (mRS = 4-6) for score levels 1 through 9 respectively was present in 3, 6, 12, 38, 61, 83, 92, 98, and 100% at 1-year follow-up. Performance of FRESH (AUC = 0.90), FRESH-cog (AUC = 0.80), and FRESH-quol (AUC = 0.78) was high. External validation of our cohort using mRS as endpoint showed satisfactory results (AUC = 0.77). To allow for convenient score calculation, we built a smartphone app available for free download. Interpretation: FRESH is the first clinical tool to prognosticate long-term outcome after spontaneous SAH in a multidimensional manner.	[Witsch, Jens; Frey, Hans-Peter; Patel, Sweta; Park, Soojin; Lahiri, Shouri; Schmidt, J. Michael; Agarwal, Sachin; Falo, Maria Cristina; Velazquez, Angela; Claassen, Jan] Columbia Univ, Dept Neurol, Coll Phys & Surg, Div Crit Care Neurol, New York, NY USA; [Jaja, Blessing; Macdonald, R. Loch] St Michaels Hosp, Div Neurosurg, Labatt Family Ctr Excellence Brain Injury & Traum, Keenan Res Ctr Biomed Sci, Toronto, ON, Canada; [Jaja, Blessing; Macdonald, R. Loch] Univ Toronto, Li Ka Shing Knowledge Inst, Dept Surg, St Michaels Hosp,Inst Med Sci, Toronto, ON, Canada; [Connolly, E. Sander] Columbia Univ, Coll Phys & Surg, Dept Neurosurg, New York, NY USA	Claassen, J (corresponding author), Columbia Univ, Div Crit Care Neurol, 177 Ft Washington Ave,MHB 8 Ctr,Room 300, New York, NY 10032 USA.; Claassen, J (corresponding author), Columbia Univ, Comprehens Epilepsy Ctr, Neurol Inst, 177 Ft Washington Ave,MHB 8 Ctr,Room 300, New York, NY 10032 USA.	jc1439@cumc.columbia.edu	Witsch, Jens/AAL-3997-2020; Lahiri, Shouri/AAG-8724-2021; Claassen, Jan/AAA-5451-2020	Witsch, Jens/0000-0001-8924-851X; Schmidt, J. Michael/0000-0001-8141-2944; Frey, Hans-Peter/0000-0002-1026-008X	Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG) [Wi 4300/1-1]; Physicians Services Incorporated Foundation; Brain Aneurysm Foundation; Canadian Institutes for Health ResearchCanadian Institutes of Health Research (CIHR); Heart and Stroke Foundation of CanadaHeart & Stroke Foundation of Canada	Supported by the Deutsche Forschungsgemeinschaft (Research Fellowship Wi 4300/1-1, J.W.), Physicians Services Incorporated Foundation (R.L.M.), Brain Aneurysm Foundation (R.L.M.), Canadian Institutes for Health Research (R.L.M.), and Heart and Stroke Foundation of Canada (R.L.M.).	Al-Khindi T, 2010, STROKE, V41, pE519, DOI 10.1161/STROKEAHA.110.581975; Becker KJ, 2001, NEUROLOGY, V56, P766, DOI 10.1212/WNL.56.6.766; BERGNER M, 1976, INT J HEALTH SERV, V6, P393, DOI 10.2190/RHE0-GGH4-410W-LA17; Claassen J, 2004, CRIT CARE MED, V32, P832, DOI 10.1097/01.CCM.0000114830.48833.8A; Connolly ES, 2012, STROKE, V43, P1711, DOI 10.1161/STR.0b013e3182587839; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Germanson TP, 1998, SURG NEUROL, V49, P155, DOI 10.1016/S0090-3019(97)00337-6; Gonzalez-Perez A, 2013, NEUROLOGY, V81, P559, DOI 10.1212/WNL.0b013e31829e6eff; Gotoh O, 1996, NEUROSURGERY, V39, P19, DOI 10.1097/00006123-199607000-00005; Hirai S, 1996, NEUROSURGERY, V39, P441, DOI 10.1097/00006123-199609000-00002; Jabbarli R, 2015, J CEREBR BLOOD F MET, V35, P1587, DOI 10.1038/jcbfm.2015.81; Jaja BNR, 2013, NEUROCRIT CARE, V18, P143, DOI 10.1007/s12028-012-9792-z; Kasner SE, 2006, LANCET NEUROL, V5, P603, DOI 10.1016/S1474-4422(06)70495-1; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Knopman DS, 2010, NEUROEPIDEMIOLOGY, V34, P34, DOI 10.1159/000255464; Korja M, 2013, NEUROLOGY, V80, P481, DOI 10.1212/WNL.0b013e31827f0fb5; Lantigua H, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-1036-0; Lee VH, 2014, NEUROCRIT CARE, V21, P14, DOI 10.1007/s12028-013-9952-9; Little RJ, 2012, NEW ENGL J MED, V367, P1355, DOI 10.1056/NEJMsr1203730; Lord AS, 2012, NEUROLOGY, V78, P31, DOI 10.1212/WNL.0b013e31823ed0a4; Lovelock CE, 2010, NEUROLOGY, V74, P1494, DOI 10.1212/WNL.0b013e3181dd42b3; Macdonald RL, 2008, STROKE, V39, P3015, DOI 10.1161/STROKEAHA.108.519942; MACKENZIE EJ, 1993, J ORTHOP TRAUMA, V7, P393, DOI 10.1097/00005131-199310000-00001; MORGAN JA, 1972, TECHNOMETRICS, V14, P317, DOI 10.2307/1267424; Naval NS, 2014, J STROKE CEREBROVASC, V23, P902, DOI 10.1016/j.jstrokecerebrovasdis.2013.07.035; NISKANEN MM, 1993, ACTA NEUROCHIR, V123, P25, DOI 10.1007/BF01476281; Ogilvy CS, 1998, NEUROSURGERY, V42, P959, DOI 10.1097/00006123-199805000-00001; Ogilvy CS, 1998, NEUROSURGERY, V42, P968; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Rosen DS, 2004, NEUROSURGERY, V54, P566, DOI 10.1227/01.NEU.0000108862.32404.A5; Saver JL, 2012, STROKE, V43, P967, DOI 10.1161/STROKEAHA.111.634352; Springer MV, 2009, NEUROSURGERY, V65, P1043, DOI 10.1227/01.NEU.0000359317.15269.20; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Stuart EA, 2009, AM J EPIDEMIOL, V169, P1133, DOI 10.1093/aje/kwp026; Takagi K, 1999, J NEUROSURG, V90, P680, DOI 10.3171/jns.1999.90.4.0680; Tominari S, 2015, ANN NEUROL, V77, P1050, DOI 10.1002/ana.24400; Treece PD, 2004, CRIT CARE MED, V32, P1141, DOI 10.1097/01.CCM.0000125509.34805.0C; van Straten A, 2000, STROKE, V31, P2610, DOI 10.1161/01.STR.31.11.2610; Weinstein MC, 2010, NEW ENGL J MED, V362, P460, DOI 10.1056/NEJMsb0911104; WELSH KA, 1993, NEUROPSY NEUROPSY BE, V6, P103; Witsch J, 2015, NEUROCRIT CARE, V23, P142, DOI 10.1007/s12028-014-0090-9; Wong GKC, 2013, J NEUROL SCI, V335, P204, DOI 10.1016/j.jns.2013.09.033	42	42	43	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0364-5134	1531-8249		ANN NEUROL	Ann. Neurol.	JUL	2016	80	1					46	58		10.1002/ana.24675			13	Clinical Neurology; Neurosciences	Neurosciences & Neurology	DR5JM	WOS:000379939300006	27129898				2021-06-18	
J	Mondello, S; Kobeissy, F; Vestri, A; Hayes, RL; Kochanek, PM; Berger, RP				Mondello, Stefania; Kobeissy, Firas; Vestri, Annarita; Hayes, Ronald L.; Kochanek, Patrick M.; Berger, Rachel P.			Serum Concentrations of Ubiquitin C-Terminal Hydrolase-L1 and Glial Fibrillary Acidic Protein after Pediatric Traumatic Brain Injury	SCIENTIFIC REPORTS			English	Article							MINOR HEAD-INJURY; OUTCOME PREDICTION; S100B LEVELS; MILD; AGE; BIOMARKERS; CHILDREN; LESIONS; BLOOD; GFAP	Objective reliable markers to assess traumatic brain injury (TBI) and predict outcome soon after injury are a highly needed tool for optimizing management of pediatric TBI. We assessed serum concentrations of Glial Fibrillary Acidic Protein (GFAP) and Ubiquitin C-Terminal Hydrolase-L1 (UCH-L1) in a cohort of 45 children with clinical diagnosis of TBI (Glasgow Coma Scale [GCS] 3-15) and 40 healthy subjects, evaluated their associations with clinical characteristics and outcomes, and compared their performance to previously published data on two well-studied blood biomarkers, S100B and MBP. We observed higher serum levels of GFAP and UCH-L1 in brain-injured children compared with controls and also demonstrated a step-wise increase of biomarker concentrations over the continuum of severity from mild to severe TBI. Furthermore, while we found that only the neuronal biomarker UCH-L1 holds potential to detect acute intracranial lesions as assessed by computed tomography (CT), both markers were substantially increased in TBI patients even with a normal CT suggesting the presence of undetected microstructural injuries. Serum UCH-L1 and GFAP concentrations also strongly predicted poor outcome and performed better than S100B and MBP. Our results point to a role of GFAP and UCH-L1 as candidate biomarkers for pediatric TBI. Further studies are warranted.	[Mondello, Stefania] Univ Messina, Dept Biomed & Dent Sci & Morphofunct Imaging, Messina, Italy; [Kobeissy, Firas] Univ Florida, Dept Psychiat, Gainesville, FL 32611 USA; [Vestri, Annarita] Univ Roma La Sapienza, Dept Publ Hlth & Infect Dis, Piazzale Aldo Moro 5, I-00185 Rome, Italy; [Hayes, Ronald L.] Banyan Biomarkers Inc, Alachua, FL USA; [Kochanek, Patrick M.] Safar Ctr Resuscitat Res, Dept Crit Care Med, Pittsburgh, PA USA; [Berger, Rachel P.] UPMC, Childrens Hosp Pittsburgh, Pittsburgh, PA USA	Mondello, S (corresponding author), Univ Messina, Dept Biomed & Dent Sci & Morphofunct Imaging, Messina, Italy.	stm_mondello@hotmail.com	Kobeissy, Firas/E-7042-2017; Mondello, Stefania/A-1813-2012	Kobeissy, Firas/0000-0002-5008-6944; Mondello, Stefania/0000-0002-8587-3614	DOD Award [W81XWH-06-1-0517]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS052831, K23HD43843]; PCTRC of the University of Pittsburgh; Italian MoHMinistry of Health, Italy [GR-2013-02354960]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD043843] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS052831] Funding Source: NIH RePORTER	This work is supported in part by DOD Award #W81XWH-06-1-0517 (RLH), NIH R01NS052831 (RLH), K23HD43843 (RPB), the PCTRC of the University of Pittsburgh (RPB) and Italian MoH GR-2013-02354960 (SM).	Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Bechtel K, 2009, PEDIATRICS, V124, pE697, DOI 10.1542/peds.2008-1493; Berger R. P., 2012, J NEUROTRAUMA, V29; Berger RP, 2006, DEV NEUROSCI-BASEL, V28, P327, DOI 10.1159/000094158; Berger RP, 2006, PEDIATRICS, V117, P325, DOI 10.1542/peds.2005-0711; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Berger RP, 2002, J NEUROTRAUM, V19, P1405, DOI 10.1089/089771502320914633; Brophy GM, 2011, J NEUROTRAUM, V28, P861, DOI 10.1089/neu.2010.1564; Brouns R, 2010, NEUROCHEM RES, V35, P1315, DOI 10.1007/s11064-010-0187-2; Brouns R, 2010, STROKE, V41, P863, DOI 10.1161/STROKEAHA.110.579409; Calcagnile O, 2012, BMC EMERG MED, V12, DOI 10.1186/1471-227X-12-13; De Witte L, 2011, CORTEX, V47, P273, DOI 10.1016/j.cortex.2010.09.002; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P135, DOI 10.1089/neu.2013.3019; Ferguson I, 2011, ANN EMERG MED, V58, pS213, DOI 10.1016/j.annemergmed.2011.06.133; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Fraser DD, 2011, PEDIATR CRIT CARE ME, V12, P319, DOI 10.1097/PCC.0b013e3181e8b32d; Gazzolo D, 2003, CLIN CHEM, V49, P967, DOI 10.1373/49.6.967; Geneva World Health Organization, 2008, WORLD REPORT CHILD I; Giza CC, 2005, BEHAV BRAIN RES, V157, P11, DOI 10.1016/j.bbr.2004.06.003; Godoy D. A., 2016, NEUROCRIT CARE; Huang YL, 2015, NEUROLOGY, V84, P580, DOI 10.1212/WNL.0000000000001237; Kou ZF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080296; Lankes U, 2015, J CHROMATOGR B, V988, P121, DOI 10.1016/j.jchromb.2015.02.013; Laribi S, 2014, CLIN CHEM LAB MED, V52, P527, DOI 10.1515/cclm-2013-0621; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mannix R, 2014, J NEUROTRAUM, V31, P1072, DOI 10.1089/neu.2013.3265; Metting Z, 2012, NEUROLOGY, V78, P1428, DOI 10.1212/WNL.0b013e318253d5c7; Mondello S, 2014, SCI REP-UK, V4, DOI 10.1038/srep06446; Mondello S, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-85; Mondello S, 2012, NEUROSURGERY, V70, P666, DOI 10.1227/NEU.0b013e318236a809; Mondello S, 2011, CRIT CARE, V15, DOI 10.1186/cc10286; Mondello S, 2011, EXPERT REV MOL DIAGN, V11, P65, DOI 10.1586/ERM.10.104; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Pelinka LE, 2004, SHOCK, V21, P72, DOI 10.1097/01.shk.0000101672.49265.14; Pich EM, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt276; Portela LVC, 2002, CLIN CHEM, V48, P950; RAIMONDI AJ, 1984, CHILD BRAIN, V11, P12; Ren CH, 2016, SCI REP-UK, V6, DOI 10.1038/srep24588; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Ryan J. B., 2015, ANN CLIN BIOCH; Sakurai M, 2006, J CELL SCI, V119, P162, DOI 10.1242/jcs.02716; Saunders NR, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00046; Savola O, 2004, J TRAUMA, V56, P1229, DOI 10.1097/01.TA.0000096644.08735.72; Thaler HW, 2015, J NEUROSURG, V123, P1202, DOI 10.3171/2014.12.JNS142276; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Yuh EL, 2014, J NEUROTRAUM, V31, P1457, DOI 10.1089/neu.2013.3171; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783; Zetterberg H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028263	48	42	43	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	JUN 20	2016	6								28203	10.1038/srep28203			8	Multidisciplinary Sciences	Science & Technology - Other Topics	DO8KU	WOS:000378033000001	27319802	DOAJ Gold, Green Published			2021-06-18	
J	Fino, PC				Fino, Peter C.			A preliminary study of longitudinal differences in local dynamic stability between recently concussed and healthy athletes during single and dual-task gait	JOURNAL OF BIOMECHANICS			English	Article						Concussion; Brain injury; Gait; Local dynamic stability; Lyapunov exponents; MTBI	TRAUMATIC BRAIN-INJURY; SPORTS-RELATED CONCUSSION; BALANCE CONTROL; LYAPUNOV EXPONENTS; NONLINEAR DYNAMICS; DIVIDED ATTENTION; VARIABILITY; WALKING; LOCOMOTOR; ABNORMALITIES	Concussed individuals commonly exhibit locomotor deficits during dual-task gait that can last substantially longer than clinical signs and symptoms. Previous studies have examined traditional stability measures, but nonlinear stability may offer further information about the health of the motor control system post-concussion. For up to one year post-concussion, this study longitudinally examined the local dynamic stability of five concussed athletes and four matched healthy controls during single- and dual-task gait. Local dynamic stability (LDS) was estimated using short-term, finite-time maximum Lyapunov exponents calculated from tri-axial accelerometers placed on the trunk and head. No main effects of group or task were found for LDS or stride time variability, but significant group*task interactions were apparent for trunk stability and stride time variability. Concussed individuals exhibited decreased trunk LDS and increased stride time variability during dual-task walking compared to matched controls despite similar single-task stability and variability. These preliminary results reinforce previous reports that concussions persistently affect dual-task processes even when single-tasks may be unaffected. Furthermore, the decreased local dynamic stability during dual-task gait indicates the concussed group attenuated local disturbances less than their healthy teammates. The decreased dynamic stability during dual-task activities was present after the athletes were cleared for competition and may be a contributing factor in the higher rates of musculoskeletal injuries in athletes post-concussion. (C) 2016 Elsevier Ltd. All rights reserved.	[Fino, Peter C.] Virginia Polytech Inst & State Univ, Dept Mech Engn, Blacksburg, VA 24061 USA	Fino, PC (corresponding author), Oregon Hlth & Sci Univ, Dept Neurol, 3181 SW Sam Jackson Pk Rd,L226, Portland, OR 97201 USA.	fino@ohsu.edu		Fino, Peter/0000-0002-8621-3706	National Science FoundationNational Science Foundation (NSF) [DGE0822220]	The authors would like to thank Dr. Thurmon Lockhart, Dr. Maury Nussbaum, and Dr. Gunnar Brolinson for general guidance throughout the study, and Lauren Becker and Brett Griesemer for contributing to data collection. This research was funded by a National Science Foundation Graduate Research Fellowship (Grant No. DGE0822220). Opinions, findings, and conclusions do not reflect the views of the NSF.	Barth A.T., 2009, P 6 INT WORKSH WEAR; Brooks MA, 2016, AM J SPORT MED, V44, P742, DOI 10.1177/0363546515622387; Bruijn SM, 2013, J R SOC INTERFACE, V10, DOI 10.1098/rsif.2012.0999; Bruijn SM, 2012, MED ENG PHYS, V34, P428, DOI 10.1016/j.medengphy.2011.07.024; Bruijn SM, 2009, J BIOMECH, V42, P1506, DOI 10.1016/j.jbiomech.2009.03.047; Bruijn SM, 2009, J NEUROSCI METH, V178, P327, DOI 10.1016/j.jneumeth.2008.12.015; Buckley T.A., 2016, J SPORT HLT IN PRESS; Buckley TA, 2013, GAIT POSTURE, V38, P549, DOI 10.1016/j.gaitpost.2013.02.008; Buzzi UH, 2003, CLIN BIOMECH, V18, P435, DOI 10.1016/S0268-0033(03)00029-9; Catena RD, 2007, EXP BRAIN RES, V176, P23, DOI 10.1007/s00221-006-0596-2; Catena RD, 2007, GAIT POSTURE, V25, P406, DOI 10.1016/j.gaitpost.2006.05.006; Catena RD, 2011, J NEUROENG REHABIL, V8, DOI 10.1186/1743-0003-8-8; Catena RD, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-25; Chiu SL, 2013, GAIT POSTURE, V38, P717, DOI 10.1016/j.gaitpost.2013.03.010; Cossette I, 2014, ARCH PHYS MED REHAB, V95, P1594, DOI 10.1016/j.apmr.2014.03.019; Cross M, 2015, BR J SPORTS MED; De Beaumont L, 2011, J ATHL TRAINING, V46, P234; Dingwell JB, 2006, J BIOMECH, V39, P444, DOI 10.1016/j.jbiomech.2004.12.014; Dingwell JB, 2000, CHAOS, V10, P848, DOI 10.1063/1.1324008; Dingwell JB, 2008, J NEUROENG REHABIL, V5, DOI 10.1186/1743-0003-5-12; England SA, 2007, GAIT POSTURE, V25, P172, DOI 10.1016/j.gaitpost.2006.03.003; Fait P, 2009, BRAIN INJURY, V23, P362, DOI 10.1080/02699050902788485; Fait P, 2013, J HEAD TRAUMA REHAB, V28, P293, DOI 10.1097/HTR.0b013e3182407ace; Howell D, 2015, J BIOMECH, V48, P3364, DOI 10.1016/j.jbiomech.2015.06.014; Howell DR, 2014, EXP BRAIN RES, V232, P1773, DOI 10.1007/s00221-014-3869-1; Howell DR, 2013, ARCH PHYS MED REHAB, V94, P1513, DOI 10.1016/j.apmr.2013.04.015; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Lee H, 2013, J SCI MED SPORT, V16, P2, DOI 10.1016/j.jsams.2012.03.013; Lockhart T, 2008, ERGONOMICS, V51, P1860, DOI 10.1080/00140130802567079; Lynall RC, 2015, MED SCI SPORT EXER, V47, P2487, DOI 10.1249/MSS.0000000000000716; Martini DN, 2011, ARCH PHYS MED REHAB, V92, P585, DOI 10.1016/j.apmr.2010.11.029; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Niechwiej-Szwedo E, 2007, GAIT POSTURE, V25, P70, DOI 10.1016/j.gaitpost.2006.01.002; Nordstrom A, 2014, BRIT J SPORT MED, V48, P1447, DOI 10.1136/bjsports-2013-093406; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Powers KC, 2014, GAIT POSTURE, V39, P728, DOI 10.1016/j.gaitpost.2013.10.005; Register-Mihalik JK, 2013, NEUROPSYCHOL REV, V23, P300, DOI 10.1007/s11065-013-9238-1; ROSENSTEIN MT, 1993, PHYSICA D, V65, P117, DOI 10.1016/0167-2789(93)90009-P; Sinopoli KJ, 2014, J NEUROTRAUM, V31, P1843, DOI 10.1089/neu.2014.3326; Slobounov SM, 2010, EXP BRAIN RES, V202, P341, DOI 10.1007/s00221-009-2141-6; Sloot LH, 2011, ANN BIOMED ENG, V39, P1563, DOI 10.1007/s10439-010-0240-y; Soangra R, 2013, ANN BIOMED ENG, V41, P795, DOI 10.1007/s10439-012-0701-6; Stergiou Nicholas, 2006, J Neurol Phys Ther, V30, P120; Stergiou N, 2011, HUM MOVEMENT SCI, V30, P869, DOI 10.1016/j.humov.2011.06.002; Tenenbaum G., 1993, HDB RES SPORT PSYCHO, P171; Toebes MJP, 2012, GAIT POSTURE, V36, P527, DOI 10.1016/j.gaitpost.2012.05.016; van Schooten KS, 2014, GAIT POSTURE, V39, P695, DOI 10.1016/j.gaitpost.2013.09.020; van Schooten KS, 2013, J BIOMECH, V46, P137, DOI 10.1016/j.jbiomech.2012.10.032; Yogev-Seligmann G, 2008, MOVEMENT DISORD, V23, P329, DOI 10.1002/mds.21720	49	42	42	0	31	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290	1873-2380		J BIOMECH	J. Biomech.	JUN 14	2016	49	9					1983	1988		10.1016/j.jbiomech.2016.05.004			6	Biophysics; Engineering, Biomedical	Biophysics; Engineering	DO4DE	WOS:000377731200079	27207386	Bronze			2021-06-18	
J	Zhao, ZL; Wang, M; Tian, Y; Hilton, T; Salsbery, B; Zhou, EZ; Wu, XP; Thiagarajan, P; Boilard, E; Li, M; Zhang, JN; Dong, JF				Zhao, Zilong; Wang, Min; Tian, Ye; Hilton, Tristan; Salsbery, Breia; Zhou, Eric Z.; Wu, Xiaoping; Thiagarajan, Perumal; Boilard, Eric; Li, Min; Zhang, Jianning; Dong, Jing-fei			Cardiolipin-mediated procoagulant activity of mitochondria contributes to traumatic brain injury-associated coagulopathy in mice	BLOOD			English	Article							ANNEXIN-V; HEAD-INJURY; LIPID-COMPOSITION; OUTER-MEMBRANE; RAT-LIVER; PHOSPHATIDYLSERINE; COAGULATION; BINDING; CELLS; PHOSPHATIDYLETHANOLAMINE	Cardiolipin (CL) is an anionic phospholipid located exclusively in the mitochondrial inner membrane. Its presence in blood indicates mitochondrial damage and release from injured cells. Here, we report the detection of CL-exposed brain-derived mitochondrial microparticles (mtMPs) at 17 547 +/- 2677/mu L in the peripheral blood of mice subjected to fluid percussion injury to the brain. These mtMPs accounted for 55.2% +/- 12.6% of all plasma annexin V-binding microparticles found in the acute phase of injury. They were also released from cultured neuronal and glial cells undergoing apoptosis. The mtMPs synergized with platelets to facilitate vascular leakage by disrupting the endothelial barrier. The disrupted endothelial barrier allowed the release of mtMPs into the systemic circulation to promote coagulation in both traumatically injured and mtMP-or CL-injected mice, leading to enhanced fibrinolysis, vascular fibrin deposition, and thrombosis. This mtMP-induced coagulation was mediated by CL transported from the inner to the outer mitochondrial membrane and was blocked by the scavenging molecule lactadherin. The mtMP-bound CL was similar to 1600 times as active as purified CL in promoting coagulation. This study uncovered a novel procoagulant activity of CL and CL-exposed mitochondria that may contribute to traumatic brain injury-associated coagulopathy and identified potential pathways to block this activity.	[Zhao, Zilong; Tian, Ye; Zhang, Jianning] Tianjin Med Univ, Tianjin Inst Neurol, Dept Neurosurg, Gen Hosp, Tianjin 300052, Peoples R China; [Zhao, Zilong; Hilton, Tristan; Salsbery, Breia; Zhou, Eric Z.; Wu, Xiaoping; Dong, Jing-fei] BloodWorks Northwest Res Inst, Seattle, WA USA; [Wang, Min; Li, Min] Lanzhou Univ, Inst Pathol, Sch Basic Med Sci, Lanzhou 730000, Peoples R China; [Thiagarajan, Perumal] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; [Thiagarajan, Perumal] Baylor Coll Med, Dept Med, Houston, TX 77030 USA; [Boilard, Eric] Univ Laval, Dept Infect Dis & Immun, Ctr Hosp Univ Quebec, Ctr Rech, Quebec City, PQ, Canada; [Boilard, Eric] Univ Laval, Fac Med, Quebec City, PQ G1K 7P4, Canada; [Dong, Jing-fei] Univ Washington, Sch Med, Dept Med, Div Hematol, Seattle, WA 98195 USA	Zhang, JN (corresponding author), Tianjin Med Univ, Tianjin Inst Neurol, Dept Neurosurg, Gen Hosp, Tianjin 300052, Peoples R China.; Li, M (corresponding author), Lanzhou Univ, Inst Pathol, Sch Basic Med Sci, Lanzhou 730000, Peoples R China.; Dong, JF (corresponding author), BloodWorks Res Inst, 1551 Eastlake Ave East, Seattle, WA 98102 USA.	limin@lzu.edu.cn; jianningzhang@hotmail.com; jfdong@bloodworksnw.org	Zhao, Zilong/AAZ-2196-2020		National Institutes of Health, National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS087296]; National Heart, Lung, and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL71895]; American Society of Hematology; National Natural Science Foundation of China State Key Program [81330029]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81271361, 81271359, 81372575]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL071895] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS087296] Funding Source: NIH RePORTER	This study is supported by National Institutes of Health, National Institute of Neurological Disorders and Stroke grant NS087296, National Heart, Lung, and Blood Institute grant HL71895, and a bridge fund from American Society of Hematology (J.-f.D.); National Natural Science Foundation of China State Key Program grant 81330029, and National Natural Science Foundation of China research grants 81271361, 81271359 (J.Z.), and 81372575 (M.L.).	Achleitner G, 1999, EUR J BIOCHEM, V264, P545, DOI 10.1046/j.1432-1327.1999.00658.x; ALBERTS B., 1994, MOL BIOL CELL, P551; ANDREE HAM, 1990, J BIOL CHEM, V265, P4923; Bayir H, 2007, ANN NEUROL, V62, P154, DOI 10.1002/ana.21168; Boilard E, 2015, CURR OPIN HEMATOL, V22, P437, DOI 10.1097/MOH.0000000000000166; Bornstein NM, 2001, NEUROLOGY, V56, P529, DOI 10.1212/WNL.56.4.529; Boudreau LH, 2014, BLOOD, V124, P2173, DOI 10.1182/blood-2014-05-573543; Cairns CB, 1997, J TRAUMA, V42, P532, DOI 10.1097/00005373-199703000-00023; Cap AP, 2011, J TRAUMA, V71, pS78, DOI 10.1097/TA.0b013e3182218cd8; Chu CT, 2013, NAT CELL BIOL, V15, P1197, DOI 10.1038/ncb2837; Dasgupta SK, 2009, BLOOD, V113, P1332, DOI 10.1182/blood-2008-07-167148; deKroon AIPM, 1997, BBA-BIOMEMBRANES, V1325, P108, DOI 10.1016/S0005-2736(96)00240-4; Exner T, 2003, BLOOD COAGUL FIBRIN, V14, P773, DOI 10.1097/00001721-200312000-00015; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; Hiebert JB, 2015, AM J MED SCI, V350, P132, DOI 10.1097/MAJ.0000000000000506; Hoots WK, 1997, SEMIN THROMB HEMOST, V23, P3; HOSTETLER KY, 1979, J LIPID RES, V20, P607; HOSTETLER KY, 1979, CANCER RES, V39, P2978; HOVIUS R, 1990, BIOCHIM BIOPHYS ACTA, V1021, P217, DOI 10.1016/0005-2736(90)90036-N; Hulka F, 1996, ARCH SURG-CHICAGO, V131, P923; Itagaki K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120549; Ji J, 2012, NAT NEUROSCI, V15, P1407, DOI 10.1038/nn.3195; JUNKER M, 1994, BIOCHEMISTRY-US, V33, P8930, DOI 10.1021/bi00196a010; KAUFMAN HH, 1980, NEUROSURGERY, V7, P445, DOI 10.1227/00006123-198011000-00003; LECOCQ J, 1964, BIOCHEMISTRY-US, V3, P976, DOI 10.1021/bi00895a023; Li NY, 2003, J BIOL CHEM, V278, P8516, DOI 10.1074/jbc.M210432200; London F, 1996, BIOCHEMISTRY-US, V35, P16886, DOI 10.1021/bi960712v; Lopez-Escribano H, 2002, ARTHRITIS RHEUM, V46, P3290, DOI 10.1002/art.10684; MEERS P, 1993, BIOCHEMISTRY-US, V32, P11711, DOI 10.1021/bi00094a030; Mileykovskaya E, 2001, FEBS LETT, V507, P187, DOI 10.1016/S0014-5793(01)02948-9; Poot M, 1996, J HISTOCHEM CYTOCHEM, V44, P1363, DOI 10.1177/44.12.8985128; RAVANAT C, 1992, BIOCHEM J, V282, P7, DOI 10.1042/bj2820007; ROSSEN RD, 1994, CIRC RES, V75, P546, DOI 10.1161/01.RES.75.3.546; Salehpour F, 2011, J CRIT CARE, V26, P352, DOI 10.1016/j.jcrc.2010.12.005; SHIAO YJ, 1995, J BIOL CHEM, V270, P11190, DOI 10.1074/jbc.270.19.11190; Simmons JD, 2013, ANN SURG, V258, P591, DOI 10.1097/SLA.0b013e3182a4ea46; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; Sun YR, 2011, BRIT J NEUROSURG, V25, P363, DOI 10.3109/02688697.2011.552650; TAIT JF, 1992, ARCH BIOCHEM BIOPHYS, V298, P187, DOI 10.1016/0003-9861(92)90111-9; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; Tchaikovski SN, 2007, J THROMB HAEMOST, V5, P2079, DOI 10.1111/j.1538-7836.2007.02719.x; Tian Y, 2015, BLOOD, V125, P2151, DOI 10.1182/blood-2014-09-598805; Vance JE, 2013, BBA-MOL CELL BIOL L, V1831, P543, DOI 10.1016/j.bbalip.2012.08.016; VANDERSANDE JJ, 1981, J NEUROSURG, V54, P21, DOI 10.3171/jns.1981.54.1.0021; Wafaisade A, 2010, NEUROCRIT CARE, V12, P211, DOI 10.1007/s12028-009-9281-1; Zhang JN, 2012, J NEUROTRAUM, V29, P2597, DOI 10.1089/neu.2012.2348; Zhang Q, 2010, NATURE, V464, P104, DOI 10.1038/nature08780	47	42	44	1	11	AMER SOC HEMATOLOGY	WASHINGTON	2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA	0006-4971	1528-0020		BLOOD	Blood	JUN 2	2016	127	22					2763	2772		10.1182/blood-2015-12688838			10	Hematology	Hematology	DP2QS	WOS:000378335400018	27002118				2021-06-18	
J	Alway, Y; Gould, KR; Johnston, L; McKenzie, D; Ponsford, J				Alway, Y.; Gould, K. R.; Johnston, L.; McKenzie, D.; Ponsford, J.			A prospective examination of Axis I psychiatric disorders in the first 5 years following moderate to severe traumatic brain injury	PSYCHOLOGICAL MEDICINE			English	Article						Anxiety; depression; longitudinal studies; psychiatric disorders; traumatic brain injury	POSTTRAUMATIC-STRESS-DISORDER; QUALITY-OF-LIFE; MOOD DISORDERS; RISK-FACTOR; DEPRESSION; PREVALENCE; ILLNESS; ANXIETY; POPULATION; PREDICTORS	Background Psychiatric disorders commonly emerge during the first year following traumatic brain injury (TBI). However, it is not clear whether these disorders soon remit or persist for long periods post-injury. This study aimed to examine, prospectively: (1) the frequency, (2) patterns of co-morbidity, (3) trajectory, and (4) risk factors for psychiatric disorders during the first 5 years following TBI. Method Participants were 161 individuals (78.3% male) with moderate (31.2%) or severe (68.8%) TBI. Psychiatric disorders were diagnosed using the Structured Clinical Interview for DSM-IV, administered soon after injury and 3, 6 and 12 months, and 2, 3, 4 and 5 years post-injury. Disorder frequencies and generalized estimating equations were used to identify temporal relationships and risk factors. Results In the first 5 years post-injury, 75.2% received a psychiatric diagnosis, commonly emerging within the first year (77.7%). Anxiety, mood and substance-use disorders were the most common diagnostic classes, often presenting co-morbidly. Many (56.5%) experienced a novel diagnostic class not present prior to injury. Disorder frequency ranged between 61.8 and 35.6% over time, decreasing by 27% [odds ratio (OR) 0.73, 95% confidence interval (CI) 0.65-0.83] with each year post-injury. Anxiety disorders declined significantly over time (OR 0.73, 95% CI 0.63-0.84), whilst mood and substance-use disorder rates remained stable. The strongest predictors of post-injury disorder were pre-injury disorder (OR 2.44, 95% CI 1.41-4.25) and accident-related limb injury (OR 1.78, 95% CI 1.03-3.07). Conclusions Findings suggest the first year post-injury is a critical period for the emergence of psychiatric disorders. Disorder frequency declines thereafter, with anxiety disorders showing greater resolution than mood and substance-use disorders.	[Alway, Y.; Gould, K. R.; Ponsford, J.] Monash Univ, Sch Psychol Sci, Melbourne, Vic 3004, Australia; [Alway, Y.; Gould, K. R.; Ponsford, J.] Monash Univ, Monash Inst Cognit & Clin Neurosci, Melbourne, Vic 3004, Australia; [Alway, Y.; Gould, K. R.; Johnston, L.; Ponsford, J.] Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia; [Gould, K. R.; Ponsford, J.] Natl Trauma Res Inst, Melbourne, Vic, Australia; [McKenzie, D.] Epworth Healthcare, Res Dev & Governance, Melbourne, Vic, Australia; [McKenzie, D.] Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Vic 3004, Australia	Alway, Y (corresponding author), Monash Epworth Rehabil Res Ctr, 185-187 Hoddle St, Richmond, Vic 3121, Australia.	yvette.alway@monash.edu	Gould, Kate/AAA-5511-2020	Gould, Kate/0000-0002-3564-7408	Transport Accident Commission (TAC), through the Institute for Safety, Compensation and Recovery Research (ISCRR)	The authors acknowledge the important contributions of Sylvia Nguyen, Kate Cameron, Natalie Gracia, Mary Karamitsios and Celia Pias in data collection. This project was funded by the Transport Accident Commission (TAC), through the Institute for Safety, Compensation and Recovery Research (ISCRR).	American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; Australian Bureau of Statistics, 2009, NAT SURV MENT HLTH W; Baxter AJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065514; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Burcusa SL, 2007, CLIN PSYCHOL REV, V27, P959, DOI 10.1016/j.cpr.2007.02.005; Deb S, 1999, AM J PSYCHIAT, V156, P374; Diaz AP, 2012, J NEUROTRAUM, V29, P1029, DOI 10.1089/neu.2011.2089; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; First MB., 2002, STRUCTURED CLIN INTE; Fleiss Joseph L., 2003, STAT METHODS RATES P; Gibson R, 2015, BRAIN INJURY, V29, P306, DOI 10.3109/02699052.2014.896471; Gil S, 2005, AM J PSYCHIAT, V162, P963, DOI 10.1176/appi.ajp.162.5.963; Gould KR, 2011, PSYCHOL MED, V41, P2099, DOI 10.1017/S003329171100033X; Gould KR, 2011, J NEUROTRAUM, V28, P1155, DOI 10.1089/neu.2010.1528; Gould KR, 2011, J HEAD TRAUMA REHAB, V26, P79, DOI 10.1097/HTR.0b013e3182036799; Ham TE, 2014, BRAIN, V137, P586, DOI 10.1093/brain/awt350; Hanley JA, 2003, AM J EPIDEMIOL, V157, P364, DOI 10.1093/aje/kwf215; Hart T, 2012, ARCH PHYS MED REHAB, V93, P1343, DOI 10.1016/j.apmr.2012.03.036; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Jablensky A, 2000, AUST NZ J PSYCHIAT, V34, P221, DOI 10.1046/j.1440-1614.2000.00728.x; Jorge RE, 2005, ARCH GEN PSYCHIAT, V62, P742, DOI 10.1001/archpsyc.62.7.742; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; Jorge RE, 2014, PSYCHIAT CLIN N AM, V37, P13, DOI 10.1016/j.psc.2013.11.005; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Koponen S, 2011, BRAIN INJURY, V25, P1029, DOI 10.3109/02699052.2011.607783; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; Mallya S, 2015, J NEUROTRAUM, V32, P411, DOI 10.1089/neu.2014.3504; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; Molloy C, 2011, SCHIZOPHRENIA BULL, V37, P1104, DOI 10.1093/schbul/sbr091; Orlovska S, 2014, AM J PSYCHIAT, V171, P463, DOI 10.1176/appi.ajp.2013.13020190; Osborn AJ, 2014, NEUROSCI BIOBEHAV R, V47, P1, DOI 10.1016/j.neubiorev.2014.07.007; Rao V, 2010, J NEUROPSYCH CLIN N, V22, P100, DOI 10.1176/appi.neuropsych.22.1.100; SPITZER RL, 1983, COMPR PSYCHIAT, V24, P399, DOI 10.1016/0010-440X(83)90032-9; Traumatic Brain Injury Taskforce, 2008, REP ARM SURG GEN DEP; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; Wei WH, 2005, ARCH PHYS MED REHAB, V86, P905, DOI 10.1016/j.apmr.2004.09.026; Wells JE, 2006, AUST NZ J PSYCHIAT, V40, P845, DOI 10.1111/j.1440-1614.2006.01903.x; Whelan-Goodinson R, 2010, J HEAD TRAUMA REHAB, V25, P320, DOI 10.1097/HTR.0b013e3181c8f8e7; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa	48	42	42	0	12	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	0033-2917	1469-8978		PSYCHOL MED	Psychol. Med.	APR	2016	46	6					1331	1341		10.1017/S0033291715002986			11	Psychology, Clinical; Psychiatry; Psychology	Psychology; Psychiatry	DH0ZF	WOS:000372513000018	26867715				2021-06-18	
J	Campbell, KR; Warnica, MJ; Levine, IC; Brooks, JS; Laing, AC; Burkhart, TA; Dickey, JP				Campbell, Kody R.; Warnica, Meagan J.; Levine, Iris C.; Brooks, Jeffrey S.; Laing, Andrew C.; Burkhart, Timothy A.; Dickey, James P.			Laboratory Evaluation of the gForce Tracker (TM), a Head Impact Kinematic Measuring Device for Use in Football Helmets	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Concussion; mTBI; Head acceleration; Head impact biomechanics; Impact monitoring; Helmet sensors	TRAUMATIC BRAIN-INJURY; PROFESSIONAL FOOTBALL; RECURRENT CONCUSSION; ACCELERATION; EPIDEMIOLOGY; DIRECTION; SYSTEM; RISK	This study sought to compare a new head impact-monitoring device, which is not limited to specific helmet styles, against reference accelerometer measurements. Laboratory controlled impacts were delivered using a linear pneumatic impactor to a Hybrid III headform (HIII) fitted with a football helmet and the impact monitoring device (gForce Tracker-GFT) affixed to the inside of the helmet. Linear regression analyses and absolute mean percent error (MAPE) were used to compare the head impact kinematics measured by the GFT to a reference accelerometer located at the HIII's center of mass. The coefficients of determination were strong for the peak linear acceleration, peak rotational velocity, and HIC15 across all impact testing locations (r (2) = 0.82, 0.94, and 0.70, respectively), but there were large MAPE for the peak linear acceleration and HIC15 (MAPE = 49 +/- A 21% and 108 +/- A 58%). The raw GFT was accurate at measuring the peak rotational velocity at the center of mass of the HIII (MAPE = 9%). Results from the impact testing were used to develop a correction algorithm. The coefficients of determination for all impact parameters improved using the correction algorithm for the GFT (r (2) > 0.97), and the MAPE were less than 14%. The GFT appears to be a suitable impact-monitoring device that is not limited to specific styles of football helmets, however, correction algorithms will need to be developed for each helmet style.	[Campbell, Kody R.; Brooks, Jeffrey S.; Dickey, James P.] Western Univ, Sch Kinesiol, Joint Biomech Lab, Thames Hall,1151 Richmond St, London, ON N6A 3K7, Canada; [Warnica, Meagan J.; Levine, Iris C.; Laing, Andrew C.] Univ Waterloo, Dept Kinesiol, Injury Biomech & Aging Lab, 200 Univ Ave West, Waterloo, ON N2L 3G1, Canada; [Burkhart, Timothy A.] Western Univ, Mech & Mat Engn, Thompson Engn Bldg,1151 Richmond St, London, ON N6A 5B9, Canada; [Campbell, Kody R.] Univ N Carolina, Dept Allied Hlth Sci, Stallings Evans Sports Med Ctr 2207, Campus Box 8700, Chapel Hill, NC 27599 USA	Campbell, KR (corresponding author), Univ N Carolina, Dept Allied Hlth Sci, Stallings Evans Sports Med Ctr 2207, Campus Box 8700, Chapel Hill, NC 27599 USA.	kcampb@live.unc.edu	Dickey, James P/K-6776-2013; Burkhart, Timothy/N-8261-2015	Dickey, James P/0000-0002-4101-835X; Burkhart, Timothy/0000-0001-6185-2395; Campbell, Kody/0000-0002-4534-5497	NSERC Engage Grant	The authors would like to thank Artaflex Inc. for providing the gForce Tracker equipment used in this study. The authors would also like to thank the efforts of Chris Withnall and Michael Wonnacott at Biokinetics & Associates, Ltd., Ottawa, Ontario, Canada, for their assistance and expertise during data collection. A NSERC Engage Grant supported this study. None of the authors have any financial interest in any of the systems used in this study.	Allison MA, 2014, ANN BIOMED ENG; Beckwith JG, 2012, ANN BIOMED ENG, V40, P237, DOI 10.1007/s10439-011-0422-2; Bland JM, 1999, STAT METHODS MED RES, V8, P135, DOI 10.1191/096228099673819272; Camarillo DB, 2013, ANN BIOMED ENG, V41, P1939, DOI 10.1007/s10439-013-0801-y; Cichos D., 2006, WORKGROUP DATA PROCE; Cobb B. R., 2014, P I MECH ENG P-J SPO; DiMasi F, 1995, TECHNICAL REPORT; GURDJIAN ES, 1961, SURG GYNECOL OBSTET, V113, P185; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hanlon E, 2010, J APPL BIOMECH, V26, P424, DOI 10.1123/jab.26.4.424; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Manoogian S, 2006, BIOMED SCI INSTRUM, V42, P383; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McAllister TW, 2014, NEUROLOGY, V82, P63, DOI 10.1212/01.wnl.0000438220.16190.42; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; Mihalik JP, 2012, ANN BIOMED ENG, V40, P141, DOI 10.1007/s10439-011-0405-3; National Research Council, 2006, 08104M04 NAT COMM ST, P1; Newman JA, 2005, J BIOMECH, V38, P1469, DOI 10.1016/j.jbiomech.2004.06.025; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Rowson S, 2014, J NEUROSURG, V120, P919, DOI 10.3171/2014.1.JNS13916; Rowson S, 2013, ANN BIOMED ENG, V41, P873, DOI 10.1007/s10439-012-0731-0; Rowson S, 2011, J APPL BIOMECH, V27, P8, DOI 10.1123/jab.27.1.8; Signoretti S, 2011, PM&R, V3, pS359, DOI 10.1016/j.pmrj.2011.07.018; Society of Automotive Engineers, 2007, J2111 SAE; Sullivan S, 2013, J NEUROTRAUM, V30, P538, DOI 10.1089/neu.2012.2594; Takhounts EG, 2008, STAPP CAR C, V52, P1; UNTERHARNSCHEIDT F, 1969, TEX REP BIOL MED, V27, P127; Versace J., 1971, REV SEVERITY INDEX, P771; Weaver AA, 2012, ANN BIOMED ENG, V40, P2005, DOI 10.1007/s10439-012-0553-0	30	42	42	0	14	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	APR	2016	44	4					1246	1256		10.1007/s10439-015-1391-7			11	Engineering, Biomedical	Engineering	DI8HJ	WOS:000373741800035	26198174				2021-06-18	
J	Yang, T; Song, JX; Bu, XM; Wang, C; Wu, J; Cai, JL; Wan, SJ; Fan, CL; Zhang, CN; Wang, JJ				Yang, Ting; Song, Jiaxi; Bu, Xiaomin; Wang, Cheng; Wu, Jia; Cai, Jialu; Wan, Shujun; Fan, Chunli; Zhang, Chunni; Wang, Junjun			Elevated serum miR-93, miR-191, and miR-499 are noninvasive biomarkers for the presence and progression of traumatic brain injury	JOURNAL OF NEUROCHEMISTRY			English	Article						biomarkers; diagnosis; microRNA; qRT-PCR; traumatic brain injury	GLASGOW COMA SCALE; MICRORNA EXPRESSION; OUTCOME PREDICTION; BREAKDOWN PRODUCTS; TUMOR-SUPPRESSOR; MILD; IDENTIFICATION; PROLIFERATION; REGULATORS; DIAGNOSIS	The levels of miR-93, miR-191, and miR-499 have been reported to be up-regulated in the tissues of experimental traumatic brain injury (TBI) rat models. However, the clinical diagnostic and prognostic values of the serum signatures of these 3 miRNAs in TBI remain unclear. The purpose of this study was to determine the expression levels of these 3 microRNAs (miRNAs) in the sera of TBI patients and to evaluate their relationships with the severity and clinical outcome of TBI. The serum levels of these miRNAs were assessed in TBI patients (n=76) and healthy controls (n=38) by quantitative reverse-transcription PCR. The severities and clinical outcomes of the TBI patients were evaluated with the Glasgow coma scale and the Glasgow outcome scale. The serum miR-93, miR-191, and miR-499 levels were significantly increased in the TBI patients compared with the controls at all examined time points, and these levels were significantly higher in the patients with severe TBI than in those with moderate or mild TBI (p<0.05). The serum miR-93, miR-191, and miR-499 levels were significantly higher in the patients with a poor outcome than in those with a good outcome (p<0.05). The AUCs of miR-93, miR-191, and miR-499 for distinguishing the TBI patients from the healthy controls were 1.000 (p<0.001), 0.727 (p<0.001) and 0.801 (p<0.001), respectively. Interestingly, the AUCs of miR-93, miR-191, and miR-499 for distinguishing the mild TBI patients from the healthy controls were 1.000 (p<0.001), 0.742 (p<0.001) and 0.819 (p<0.001), respectively. Taken together, these results indicate that miR-93, miR-191, and miR-499 are potentially valuable indicators of the diagnosis, severity, and prognosis of TBI.	[Yang, Ting; Song, Jiaxi; Bu, Xiaomin; Wang, Cheng; Wu, Jia; Cai, Jialu; Wan, Shujun; Fan, Chunli; Zhang, Chunni; Wang, Junjun] Nanjing Univ, Sch Med, Jinling Hosp, Dept Clin Lab, Nanjing 210008, Jiangsu, Peoples R China	Wang, JJ (corresponding author), Jinling Hosp, Dept Clin Lab, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China.	wangjunjun9202@163.com	jiaxi, song/H-1622-2013; Wang, Cheng/O-7206-2016	Wang, Cheng/0000-0002-1834-2119; Zhang, Chunni/0000-0002-7329-7162	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [812711904, 81401742, 81572073, 81572074]; Special-funded Program on National Key Scientific Instruments and Equipment Development of China [2012YQ030261]; Medical Scientific Research Foundation of Nanjing Military Command [12Z28]	This study was generously funded by the National Natural Science Foundation of China (No. 812711904, 81401742, 81572073 and 81572074), the Special-funded Program on National Key Scientific Instruments and Equipment Development of China (2012YQ030261), and the Medical Scientific Research Foundation of Nanjing Military Command (no. 12Z28). The authors declare no conflict of interest.	Balakathiresan N, 2012, J NEUROTRAUM, V29, P1379, DOI 10.1089/neu.2011.2146; Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Bilgin S, 2012, NEURAL REGEN RES, V7, P1978, DOI 10.3969/j.issn.1673-5374.2012.25.009; Brett JO, 2011, AGING-US, V3, P108, DOI 10.18632/aging.100285; Chen X, 2008, CELL RES, V18, P997, DOI 10.1038/cr.2008.282; Chen X, 2012, TRENDS CELL BIOL, V22, P125, DOI 10.1016/j.tcb.2011.12.001; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; Du LQ, 2009, MOL CANCER RES, V7, P1234, DOI 10.1158/1541-7786.MCR-08-0507; Fang L, 2011, ONCOGENE, V30, P806, DOI 10.1038/onc.2010.465; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Fischer H., 2013, CRS REP C, P7; Goyal A, 2013, J NEUROTRAUM, V30, P946, DOI 10.1089/neu.2012.2579; He Y, 2015, INT J CLIN EXP MED, V8, P674; Heather NL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082245; Hu ZH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039357; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Jiang LL, 2015, J CLIN ENDOCR METAB, V100, pE729, DOI 10.1210/jc.2014-3827; Kesler SR, 2000, BRAIN INJURY, V14, P851; Kok MGM, 2015, FASEB J, V29, P3853, DOI 10.1096/fj.15-271312; Lafferty-Whyte K, 2009, BBA-MOL BASIS DIS, V1792, P341, DOI 10.1016/j.bbadis.2009.02.003; Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6; Laterza OF, 2009, CLIN CHEM, V55, P1977, DOI 10.1373/clinchem.2009.131797; Leach Paul, 2009, J Trauma Manag Outcomes, V3, P5, DOI 10.1186/1752-2897-3-5; Lei P, 2009, BRAIN RES, V1284, P191, DOI 10.1016/j.brainres.2009.05.074; Li XL, 2013, ELECTRON J QUAL THEO; Liu L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103948; Luo Y, 2013, CLIN CHEM, V59, P658, DOI 10.1373/clinchem.2012.195297; Mondello S, 2014, SCI REP-UK, V4, DOI 10.1038/srep06446; Mondello S, 2010, J NEUROTRAUM, V27, P1203, DOI 10.1089/neu.2010.1278; Montalban E, 2014, NEUROMOL MED, V16, P415, DOI 10.1007/s12017-014-8292-z; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Ogata K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120526; Ohta K, 2015, ONCOTARGET, V6, P3211, DOI 10.18632/oncotarget.3085; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Pogoda TK, 2012, J REHABIL RES DEV, V49, P971, DOI 10.1682/JRRD.2011.06.0099; Redell JB, 2011, J NEUROSCI RES, V89, P212, DOI 10.1002/jnr.22539; Redell JB, 2010, J NEUROTRAUM, V27, P2147, DOI 10.1089/neu.2010.1481; Redell JB, 2009, J NEUROSCI RES, V87, P1435, DOI 10.1002/jnr.21945; Turchinovich A, 2012, TRENDS BIOCHEM SCI, V37, P460, DOI 10.1016/j.tibs.2012.08.003; Varendi K, 2014, CELL MOL LIFE SCI, V71, P4443, DOI 10.1007/s00018-014-1628-x; Wu CY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092292; Wu J, 2014, INT J CARDIOL, V172, P232, DOI 10.1016/j.ijcard.2013.12.214; Yang CH, 2013, INT J CANCER, V132, P116, DOI 10.1002/ijc.27657; Yeung ML, 2008, CANCER RES, V68, P8976, DOI 10.1158/0008-5472.CAN-08-0769; Yuh EL, 2012, J NEUROTRAUM, V29, P735, DOI 10.1089/neu.2011.2008	46	42	43	0	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	APR	2016	137	1					122	129		10.1111/jnc.13534			8	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	DH7NG	WOS:000372980100011	26756543	Bronze			2021-06-18	
J	Browning, M; Shear, DA; Bramlett, HM; Dixon, CE; Mondello, S; Schmid, KE; Poloyac, SM; Dietrich, WD; Hayes, RL; Wang, KKW; Povlishock, JT; Tortella, FC; Kochanek, PM				Browning, Megan; Shear, Deborah A.; Bramlett, Helen M.; Dixon, C. Edward; Mondello, Stefania; Schmid, Kara E.; Poloyac, Samuel M.; Dietrich, W. Dalton; Hayes, Ronald L.; Wang, Kevin K. W.; Povlishock, John T.; Tortella, Frank C.; Kochanek, Patrick M.			Levetiracetam Treatment in Traumatic Brain Injury: Operation Brain Trauma Therapy	JOURNAL OF NEUROTRAUMA			English	Article						rat; post-traumatic seizures; penetrating ballistic-like brain injury; fluid percussion; excitotoxicity; controlled cortical impact; biomarker; Keppra; neuroprotection; therapy	CONTROLLED CORTICAL IMPACT; SEIZURE PROPHYLAXIS; INTRAVENOUS LEVETIRACETAM; POSTTRAUMATIC EPILEPSY; STATUS EPILEPTICUS; MODEL; RAT; HYPOTHERMIA; DEFICITS; PROTEIN	Levetiracetam (LEV) is an antiepileptic agent targeting novel pathways. Coupled with a favorable safety profile and increasing empirical clinical use, it was the fifth drug tested by Operation Brain Trauma Therapy (OBTT). We assessed the efficacy of a single 15 min post-injury intravenous (IV) dose (54 or 170 mg/kg) on behavioral, histopathological, and biomarker outcomes after parasagittal fluid percussion brain injury (FPI), controlled cortical impact (CCI), and penetrating ballistic-like brain injury (PBBI) in rats. In FPI, there was no benefit on motor function, but on Morris water maze (MWM), both doses improved latencies and path lengths versus vehicle (p < 0.05). On probe trial, the vehicle group was impaired versus sham, but both LEV treated groups did not differ versus sham, and the 54 mg/kg group was improved versus vehicle (p < 0.05). No histological benefit was seen. In CCI, there was a benefit on beam balance at 170 mg/kg (p < 0.05 vs. vehicle). On MWM, the 54 mg/kg dose was improved and not different from sham. Probe trial did not differ between groups for either dose. There was a reduction in hemispheric tissue loss (p < 0.05 vs. vehicle) with 170 mg/kg. In PBBI, there was no motor, cognitive, or histological benefit from either dose. Regarding biomarkers, in CCI, 24 h glial fibrillary acidic protein (GFAP) blood levels were lower in the 170 mg/kg group versus vehicle (p < 0.05). In PBBI, GFAP blood levels were increased in vehicle and 170 mg/kg groups versus sham (p < 0.05) but not in the 54 mg/kg group. No treatment effects were seen for ubiquitin C-terminal hydrolase-L1 across models. Early single IV LEV produced multiple benefits in CCI and FPI and reduced GFAP levels in PBBI. LEV achieved 10 points at each dose, is the most promising drug tested thus far by OBTT, and the only drug to improve cognitive outcome in any model. LEV has been advanced to testing in the micropig model in OBTT.	[Browning, Megan; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Crit Care Med, 3434 Fifth Ave, Pittsburgh, PA 15260 USA; [Shear, Deborah A.; Schmid, Kara E.; Tortella, Frank C.] Walter Reed Army Inst Res, Ctr Mil Psychiat & Neurosci, Brain Trauma Neuroprotect Neurorestorat, Silver Spring, MD USA; [Bramlett, Helen M.; Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami Project Cure Paralysis, Miami, FL 33136 USA; [Bramlett, Helen M.] Vet Affairs Med Ctr, Bruce W Carter Dept, Miami, FL 33125 USA; [Dixon, C. Edward] Univ Pittsburgh, Sch Med, Brain Trauma Res Ctr, Dept Neurol Surg, Pittsburgh, PA 15260 USA; [Mondello, Stefania] Univ Messina, Dept Neurosci, Messina, Italy; [Poloyac, Samuel M.] Univ Pittsburgh, Sch Pharm, Ctr Pharmaceut Sci, Pittsburgh, PA 15260 USA; [Hayes, Ronald L.] Banyan Biomarkers Inc, Ctr Neuroprote & Biomarkers Res, Ctr Innovat Res, Alachua, FL USA; [Wang, Kevin K. W.] Univ Florida, Dept Psychiat & Neurosci, Ctr Neuroprote & Biomarkers Res, Gainesville, FL USA; [Povlishock, John T.] Virginia Commonwealth Univ, Dept Anat & Neurobiol, Richmond, VA USA	Kochanek, PM (corresponding author), Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Crit Care Med, 3434 Fifth Ave, Pittsburgh, PA 15260 USA.	kochanekpm@ccm.upmc.edu	Mondello, Stefania/A-1813-2012	Mondello, Stefania/0000-0002-8587-3614; Wang, Kevin/0000-0002-9343-6473			Atkins CM, 2010, EUR J NEUROSCI, V32, P1912, DOI 10.1111/j.1460-9568.2010.07467.x; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; Blaya MO, 2014, J NEUROTRAUM, V31, P476, DOI [10.1089/NEU.2013.3135, 10.1089/neu.2013.3135]; Bolkvadze T, 2012, J NEUROTRAUM, V29, P789, DOI 10.1089/neu.2011.1954; Caudle KL, 2014, J NEUROTRAUM, V31, pA80; Crowder KM, 1999, P NATL ACAD SCI USA, V96, P15268, DOI 10.1073/pnas.96.26.15268; Cuomo O, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080852; Darrah SH, 2011, J NEUROTRAUM, V28, P43, DOI 10.1089/neu.2010.1521; Deshpande LS, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00011; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Dixon CE, 1998, J NEUROTRAUM, V15, P95, DOI 10.1089/neu.1998.15.95; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Mendoza-Torreblanca JG, 2013, EUR J NEUROSCI, V38, P3529, DOI 10.1111/ejn.12360; Halma E, 2014, SEIZURE-EUR J EPILEP, V23, P685, DOI 10.1016/j.seizure.2014.06.004; Kirmani BF, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00170; Klitgaard H, 1998, EUR J PHARMACOL, V353, P191, DOI 10.1016/S0014-2999(98)00410-5; Kochanek PM, 2016, J NEUROTRAUM, V33, P513, DOI 10.1089/neu.2015.4113; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Komur M, 2014, CHILD NERV SYST, V30, P1001, DOI 10.1007/s00381-014-2375-x; Loscher W, 1998, J PHARMACOL EXP THER, V284, P474; Lu XCM, 2011, J NEUROTRAUM, V28, P71, DOI 10.1089/neu.2010.1471; McMahon PJ, 2015, J NEUROTRAUM, V32, P527, DOI 10.1089/neu.2014.3635; Mondello S, 2016, J NEUROTRAUM, V33, P595, DOI 10.1089/neu.2015.4132; Pitkanen A, 2006, J NEUROTRAUM, V23, P241, DOI 10.1089/neu.2006.23.241; Rowe AS, 2014, PHARMACOTHERAPY, V34, P396, DOI 10.1002/phar.1374; Shear DA, 2016, J NEUROTRAUM, V33, P523, DOI 10.1089/neu.2015.4115; Shear DA, 2010, J NEUROTRAUM, V27, P1911, DOI 10.1089/neu.2010.1399; Shetty AK, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00172; Stienen MN, 2011, BRIT J PHARMACOL, V162, P491, DOI 10.1111/j.1476-5381.2010.01038.x; Szaflarski JP, 2014, NEUROPSYCH DIS TREAT, V10, P1469, DOI 10.2147/NDT.S50421; Szaflarski JP, 2010, NEUROCRIT CARE, V12, P165, DOI 10.1007/s12028-009-9304-y; Tomic MA, 2013, J PAIN, V14, P1371, DOI 10.1016/j.jpain.2013.06.003; Vespa PM, 2010, NEUROLOGY, V75, P792, DOI 10.1212/WNL.0b013e3181f07334; Vogl C, 2012, MOL PHARMACOL, V82, P199, DOI 10.1124/mol.111.076687; Vossel KA, 2013, JAMA NEUROL, V70, P1158, DOI 10.1001/jamaneurol.2013.136; Wakita M, 2014, J PHARMACOL EXP THER, V348, P246, DOI 10.1124/jpet.113.208751; Wang HC, 2006, NEUROCRIT CARE, V5, P71, DOI 10.1385/NCC:5:1:71; Wright C, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00192; Zou HC, 2015, BRAIN INJURY, V29, P78, DOI 10.3109/02699052.2014.955528; Zou HC, 2013, NEUROREHAB NEURAL RE, V27, P878, DOI 10.1177/1545968313491007	40	42	42	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR 15	2016	33	6					581	594		10.1089/neu.2015.4131			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	DG6HN	WOS:000372184800007	26671550				2021-06-18	
J	Han, K; Chapman, SB; Krawczyk, DC				Han, Kihwan; Chapman, Sandra B.; Krawczyk, Daniel C.			Disrupted Intrinsic Connectivity among Default, Dorsal Attention, and Frontoparietal Control Networks in Individuals with Chronic Traumatic Brain Injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						TBI; Functional connectivity; fMRI; Default network; Attention network; Fronto-parietal control network; Graph theory; Goal-directed cognition	INTERHEMISPHERIC FUNCTIONAL CONNECTIVITY; GLOBAL SIGNAL REGRESSION; IMPAIRED SELF-AWARENESS; RESTING STATE FMRI; STRUCTURAL CONNECTIVITY; MILITARY PERSONNEL; DIRECTED COGNITION; AXONAL INJURY; HEAD MOTION; MODE	Objectives: Individuals with chronic traumatic brain injury (TBI) often show detrimental deficits in higher order cognitive functions requiring coordination of multiple brain networks. Although assessing TBI-related deficits in higher order cognition in the context of network dysfunction is promising, few studies have systematically investigated altered interactions among multiple networks in chronic TBI. Method: We characterized disrupted resting-state functional connectivity of the default mode network (DMN), dorsal attention network (DAN), and frontoparietal control network (FPCN) whose interactions are required for internally and externally focused goal-directed cognition in chronic TBI. Specifically, we compared the network interactions of 40 chronic TBI individuals (8 years post-injury on average) with those of 17 healthy individuals matched for gender, age, and years of education. Results: The network-based statistic (NBS) on DMN-DAN-FPCN connectivity of these groups revealed statistically significant (p(NBS)<.05; |Z|>2.58) reductions in within-DMN, within-FPCN, DMN-DAN, and DMN-FPCN connectivity of the TBI group over healthy controls. Importantly, such disruptions occurred prominently in between-network connectivity. Subsequent analyses further exhibited the disrupted connectivity patterns of the chronic TBI group occurring preferentially in long-range and inter-hemispheric connectivity of DMN-DAN-FPCN. Most importantly, graph-theoretic analysis demonstrated relative reductions in global, local and cost efficiency (p<.05) as a consequence of the network disruption patterns in the TBI group. Conclusion: Our findings suggest that assessing multiple networks-of-interest simultaneously will allow us to better understand deficits in goal-directed cognition and other higher order cognitive phenomena in chronic TBI. Future research will be needed to better understand the behavioral consequences related to these network disruptions.	[Han, Kihwan; Chapman, Sandra B.; Krawczyk, Daniel C.] Univ Texas Dallas, Sch Behav & Brain Sci, Ctr BrainHlth, Dallas, TX 75230 USA; [Krawczyk, Daniel C.] Univ Texas SW Med Ctr Dallas, Dept Psychiat, Dallas, TX 75390 USA	Han, K (corresponding author), Sch Behav & Brain Sci, Ctr Brain Hlth, 2200 West Mockingbird Lane, Dallas, TX 75235 USA.	kihwan.han@utdallas.edu	Han, Kihwan/I-1984-2019	Han, Kihwan/0000-0002-4574-7306	Department of Defense CDMRPUnited States Department of Defense [W81XWH-11-2-0194, W81XWH-11-2-0195]; Meadows Foundation	We thank all study participants and their families who supported this study. This work has been supported by Department of Defense CDMRP grants W81XWH-11-2-0194 to DCK and W81XWH-11-2-0195 to S.B.C. and a grant from the Meadows Foundation to D.C.K. and S.B.C. The authors declare no conflicts of interest.	Achard S, 2007, PLOS COMPUT BIOL, V3, P174, DOI 10.1371/journal.pcbi.0030017; Anderson JS, 2011, HUM BRAIN MAPP, V32, P919, DOI 10.1002/hbm.21079; Arciniegas D, 2000, J NEUROPSYCH CLIN N, V12, P77, DOI 10.1176/jnp.12.1.77; Baird B, 2011, CONSCIOUS COGN, V20, P1604, DOI 10.1016/j.concog.2011.08.007; Beck AT, 1996, BDI 2 BECK DEPRESSIO; Bengtsson SL, 2011, SOC COGN AFFECT NEUR, V6, P417, DOI 10.1093/scan/nsq048; Bonnelle V, 2012, P NATL ACAD SCI USA, V109, P4690, DOI 10.1073/pnas.1113455109; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; Caeyenberghs K, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00726; Caeyenberghs K, 2012, BRAIN, V135, P1293, DOI 10.1093/brain/aws048; Castellanos NP, 2010, BRAIN, V133, P2365, DOI 10.1093/brain/awq174; Chai XQJ, 2012, NEUROIMAGE, V59, P1420, DOI 10.1016/j.neuroimage.2011.08.048; Chang C, 2009, NEUROIMAGE, V47, P1448, DOI 10.1016/j.neuroimage.2009.05.012; Chen GY, 2011, BRAIN CONNECT, V1, P195, DOI 10.1089/brain.2011.0025; Corbetta M, 2002, NAT REV NEUROSCI, V3, P201, DOI 10.1038/nrn755; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; CREPEAU F, 1993, NEUROPSYCHOL REHABIL, V3, P5; de la Plata CDM, 2011, ARCH NEUROL-CHICAGO, V68, P74, DOI 10.1001/archneurol.2010.342; Delis DC, 2001, D KEFS EXECUTIVE FUN; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dixon ML, 2014, NEUROPSYCHOLOGIA, V62, P321, DOI 10.1016/j.neuropsychologia.2014.05.024; Dritschel BH, 1998, BRAIN INJURY, V12, P875; Ellamil M, 2012, NEUROIMAGE, V59, P1783, DOI 10.1016/j.neuroimage.2011.08.008; EVANS AC, 1993, NUCLEAR SCIENCE SYMPOSIUM & MEDICAL IMAGING CONFERENCE, VOLS 1-3, P1813, DOI 10.1109/NSSMIC.1993.373602; Fox MD, 2005, P NATL ACAD SCI USA, V102, P9673, DOI 10.1073/pnas.0504136102; Fox MD, 2009, J NEUROPHYSIOL, V101, P3270, DOI 10.1152/jn.90777.2008; Gerlach KD, 2014, SOC COGN AFFECT NEUR, V9, P1942, DOI 10.1093/scan/nsu001; Gerlach KD, 2011, NEUROIMAGE, V55, P1816, DOI 10.1016/j.neuroimage.2011.01.030; Ham TE, 2014, BRAIN, V137, P586, DOI 10.1093/brain/awt350; Han K, 2014, NEUROIMAGE, V84, P76, DOI 10.1016/j.neuroimage.2013.08.017; Hanten G, 2004, ANN NEUROL, V56, P847, DOI 10.1002/ana.20298; Hillary FG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104021; Honey CJ, 2009, P NATL ACAD SCI USA, V106, P2035, DOI 10.1073/pnas.0811168106; Jo HJ, 2010, NEUROIMAGE, V52, P571, DOI 10.1016/j.neuroimage.2010.04.246; Joel SE, 2011, MAGN RESON MED, V66, P644, DOI 10.1002/mrm.22818; Johnstone T, 2006, HUM BRAIN MAPP, V27, P779, DOI 10.1002/hbm.20219; Kelly AMC, 2008, NEUROIMAGE, V39, P527, DOI 10.1016/j.neuroimage.2007.08.008; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Krawczyk DC, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-29; Kumar S, 2009, J NEUROTRAUM, V26, P665, DOI [10.1089/neu.2008.0644, 10.1089/neu.2008-0644]; Latora V, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.198701; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; Levine B, 1998, J INT NEUROPSYCH SOC, V4, P247, DOI 10.1017/S1355617798002471; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Malec JF, 2007, J HEAD TRAUMA REHAB, V22, P156, DOI 10.1097/01.HTR.0000271116.12028.af; Mateer C.A., 1987, J HEAD TRAUMA REHAB, V2, P74, DOI [10.1097/00001199-198709000-00009, DOI 10.1097/00001199-198709000-00009]; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Murphy K, 2009, NEUROIMAGE, V44, P893, DOI 10.1016/j.neuroimage.2008.09.036; Nakamura T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008220; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; O'Reilly JX, 2013, P NATL ACAD SCI USA, V110, P13982, DOI 10.1073/pnas.1305062110; Pandit AS, 2013, NEUROLOGY, V80, P1826, DOI 10.1212/WNL.0b013e3182929f38; Power JD, 2014, NEUROIMAGE, V84, P320, DOI 10.1016/j.neuroimage.2013.08.048; Power JD, 2012, NEUROIMAGE, V59, P2142, DOI 10.1016/j.neuroimage.2011.10.018; Power JD, 2011, NEURON, V72, P665, DOI 10.1016/j.neuron.2011.09.006; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Rigon A., 2015, J NEUROTRAUM, DOI [10.1089/neu.2014.3847, DOI 10.1089/NEU.2014.3847]; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Rubinov M, 2010, NEUROIMAGE, V52, P1059, DOI 10.1016/j.neuroimage.2009.10.003; Saad ZS, 2012, BRAIN CONNECT, V2, P25, DOI 10.1089/brain.2012.0080; Satterthwaite TD, 2012, NEUROIMAGE, V60, P623, DOI 10.1016/j.neuroimage.2011.12.063; Schonberger M, 2011, BRAIN INJURY, V25, P543, DOI 10.3109/02699052.2011.565013; Seeley WW, 2007, J NEUROSCI, V27, P2349, DOI 10.1523/JNEUROSCI.5587-06.2007; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Singh M, 2010, MAGN RESON IMAGING, V28, P22, DOI 10.1016/j.mri.2009.05.049; Slobounov SM, 2011, NEUROIMAGE, V55, P1716, DOI 10.1016/j.neuroimage.2011.01.024; Smallwood J, 2012, BRAIN RES, V1428, P60, DOI 10.1016/j.brainres.2011.03.072; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Smits M, 2011, NEURORADIOLOGY, V53, P553, DOI 10.1007/s00234-010-0774-6; Sours C, 2015, BRAIN IMAGING BEHAV, V9, P190, DOI 10.1007/s11682-014-9295-y; Sours C, 2013, BRAIN RES, V1537, P201, DOI 10.1016/j.brainres.2013.08.034; Spreng RN, 2013, J COGNITIVE NEUROSCI, V25, P74, DOI 10.1162/jocn_a_00281; Spreng RN, 2010, NEUROIMAGE, V53, P303, DOI 10.1016/j.neuroimage.2010.06.016; Tang L, 2011, RADIOLOGY, V260, P831, DOI 10.1148/radiol.11110014; TEASDALE G, 1974, LANCET, V2, P81; Van Dijk KRA, 2012, NEUROIMAGE, V59, P431, DOI 10.1016/j.neuroimage.2011.07.044; Van Dijk KRA, 2010, J NEUROPHYSIOL, V103, P297, DOI 10.1152/jn.00783.2009; Vincent JL, 2008, J NEUROPHYSIOL, V100, P3328, DOI 10.1152/jn.90355.2008; Weathers F. W., 1993, ANN M INT SOC TRAUM; Wechsler D., 2011, WECHLSER ABBREVIATED; Wechsler D., 2001, WECHSLER TEST ADULT; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wechsler D., 2008, WECHSLER MEMORY SCAL, V3; Whyte J, 1996, J Int Neuropsychol Soc, V2, P274; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Xia MR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068910; Zalesky A, 2010, NEUROIMAGE, V53, P1197, DOI 10.1016/j.neuroimage.2010.06.041; Zgaljardic DJ, 2015, J NEUROTRAUM, V32, P1911, DOI 10.1089/neu.2014.3569	93	42	42	0	12	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	FEB	2016	22	2			SI		263	279		10.1017/S1355617715001393			17	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	DF8TE	WOS:000371631200013	26888622	Green Published, Other Gold			2021-06-18	
J	Plesnila, N				Plesnila, Nikolaus			The immune system in traumatic brain injury	CURRENT OPINION IN PHARMACOLOGY			English	Article							BRADYKININ B-2 RECEPTOR; MICROGLIAL ACTIVATION; HEAD-INJURY; INFLAMMATORY RESPONSE; ADHESION MOLECULES; LEUKOCYTE ADHESION; TEMPORAL PROFILE; B1 PROTECTS; EDEMA; DAMAGE	Traumatic brain injury (TBI) is the major cause of death in children and young adults and one of the major reasons for long-term disability worldwide, however, no specific clinical treatment option could be established so far. This is surprising since it is well known that following the initial mechanical damage to the brain a plethora of delayed processes are activated which ultimately result in additional brain damage. Among these secondary mechanisms, acute and chronic activation of the innate and adaptive immune system is increasingly believed to play an important role for the pathogenesis of TBI. Understanding these processes may results in new, clinically applicable therapeutic options for TBI patients.	[Plesnila, Nikolaus] Univ Munich, Med Ctr, Inst Stroke & Dementia Res, Munich, Germany; [Plesnila, Nikolaus] Univ Munich, Med Ctr, Munich Cluster Syst Neurol Synergy, Munich, Germany	Plesnila, N (corresponding author), Univ Munich, Med Ctr, Inst Stroke & Dementia Res, Munich, Germany.; Plesnila, N (corresponding author), Univ Munich, Med Ctr, Munich Cluster Syst Neurol Synergy, Munich, Germany.	nikolaus.plesnila@med.uni-muenchen.de	Plesnila, Nikolaus/T-7522-2019	Plesnila, Nikolaus/0000-0001-8832-228X			Acosta SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053376; Albert-Weissenberger C, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00345; Albert-Weissenberger C, 2012, J CEREBR BLOOD F MET, V32, P1747, DOI 10.1038/jcbfm.2012.62; Anthony DC, 2014, EXP NEUROL, V258, P105, DOI 10.1016/j.expneurol.2014.03.013; Aspelund A, 2015, J EXP MED, V212, P991, DOI 10.1084/jem.20142290; AUER LM, 1979, ACTA NEUROCHIR, V49, P207, DOI 10.1007/BF01808960; BAETHMANN A, 1988, CRIT CARE MED, V16, P972, DOI 10.1097/00003246-198810000-00008; Balk RA, 2014, VIRULENCE, V5, P20, DOI 10.4161/viru.27135; Barker-Collo SL, 2009, NEUROEPIDEMIOLOGY, V32, P1, DOI 10.1159/000170084; Bergold PJ, 2016, EXP NEUROL, V275, P367, DOI 10.1016/j.expneurol.2015.05.024; Burda JE, 2016, EXP NEUROL, V275, P305, DOI 10.1016/j.expneurol.2015.03.020; Caielli S, 2012, CURR OPIN IMMUNOL, V24, P671, DOI 10.1016/j.coi.2012.09.008; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; Corps KN, 2015, JAMA NEUROL, V72, P355, DOI 10.1001/jamaneurol.2014.3558; Dalgard CL, 2012, FRONT MOL NEUROSCI, V5, DOI 10.3389/fnmol.2012.00006; Daneshvar DH, 2015, MOL CELL NEUROSCI, V66, P81, DOI 10.1016/j.mcn.2015.03.007; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; El Khoury J, 2007, NAT MED, V13, P432, DOI 10.1038/nm1555; Estes ML, 2014, BRAIN PATHOL, V24, P623, DOI 10.1111/bpa.12198; Evans TA, 2014, EXP NEUROL, V254, P109, DOI 10.1016/j.expneurol.2014.01.013; Fee D, 2003, J NEUROIMMUNOL, V136, P54, DOI 10.1016/S0165-5728(03)00008-0; Gadani SP, 2015, NEURON, V87, P47, DOI 10.1016/j.neuron.2015.05.019; Gyoneva S, 2015, TRENDS PHARMACOL SCI, V36, P471, DOI 10.1016/j.tips.2015.04.003; Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997; Harris MG, 2014, SCI REP-UK, V4, DOI 10.1038/srep04422; Hartl R, 1997, ACT NEUR S, V70, P240; Hartl R, 1997, J CEREBR BLOOD F MET, V17, P1210; Haynes SE, 2006, NAT NEUROSCI, V9, P1512, DOI 10.1038/nn1805; Hellal F, 2003, J NEUROTRAUM, V20, P841, DOI 10.1089/089771503322385773; Helmy A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039677; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Hinson HE, 2015, J TRAUMA ACUTE CARE, V78, P184, DOI 10.1097/TA.0000000000000468; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Isaksson J, 2001, ACTA NEUROPATHOL, V102, P246; Israelsson C, 2008, J NEUROTRAUM, V25, P959, DOI 10.1089/neu.2008.0562; Izzy S, 2014, CURR TREAT OPTION NE, V16, DOI 10.1007/s11940-013-0278-x; Jin Q, 2014, BRAIN BEHAV IMMUN, V40, P131, DOI 10.1016/j.bbi.2014.03.003; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kabadi SV, 2014, J CEREBR BLOOD F MET, V34, P502, DOI 10.1038/jcbfm.2013.228; Karve I.P., 2015, BR J PHARM; Kenne E, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-17; Kigerl KA, 2014, EXP NEUROL, V258, P5, DOI 10.1016/j.expneurol.2014.01.001; Knoblach SM, 2002, J NEUROTRAUM, V19, P1039, DOI 10.1089/089771502760341956; Kunz M, 2013, J NEUROTRAUM, V30, P1638, DOI 10.1089/neu.2012.2774; Levin HS, 2015, LANCET NEUROL, V14, P506, DOI 10.1016/S1474-4422(15)00002-2; Loane D.J., 2015, EXP NEUROL; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Longhi L, 2009, CRIT CARE MED, V37, P659, DOI 10.1097/CCM.0b013e318195998a; Lourbopoulos A, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00054; Louveau A, 2015, NATURE, V523, P337, DOI 10.1038/nature14432; Lozano D, 2015, NEUROPSYCH DIS TREAT, V11, P97, DOI 10.2147/NDT.S65815; McKeating EG, 1998, ACT NEUR S, V71, P200; MEDAWAR PB, 1948, BRIT J EXP PATHOL, V29, P58; Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201; Morganti JM, 2015, J NEUROSCI, V35, P748, DOI 10.1523/JNEUROSCI.2405-14.2015; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Nourshargh S, 2014, IMMUNITY, V41, P694, DOI 10.1016/j.immuni.2014.10.008; Perdiguero EG, 2013, GLIA, V61, P112, DOI 10.1002/glia.22393; PERRY VH, 1995, CURR OPIN NEUROBIOL, V5, P636, DOI 10.1016/0959-4388(95)80069-7; Plesnila N, 2001, J NEUROTRAUM, V18, P1049, DOI 10.1089/08977150152693746; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Raslan F, 2010, J CEREBR BLOOD F MET, V30, P1477, DOI 10.1038/jcbfm.2010.28; Rathbone ATL, 2015, BRAIN BEHAV IMMUN, V46, P1, DOI 10.1016/j.bbi.2015.02.009; REILLY PL, 1975, LANCET, V2, P375; Schulz J, 2000, ACT NEUR S, V76, P137; Schwarzmaier SM, 2015, J NEUROTRAUM, V32, P731, DOI 10.1089/neu.2014.3650; Schwarzmaier SM, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-32; Schwarzmaier SM, 2010, J NEUROTRAUM, V27, P121, DOI 10.1089/neu.2009.1114; Semple BD, 2010, NEUROBIOL DIS, V40, P394, DOI 10.1016/j.nbd.2010.06.015; Serhan CN, 2005, NAT IMMUNOL, V6, P1191, DOI 10.1038/ni1276; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Tang DL, 2012, IMMUNOL REV, V249, P158, DOI 10.1111/j.1600-065X.2012.01146.x; Trabold R, 2010, J CEREBR BLOOD F MET, V30, P130, DOI 10.1038/jcbfm.2009.196; Villalba N, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.114.001474; Warner DS, 2014, JAMA NEUROL, V71, P1311, DOI 10.1001/jamaneurol.2014.1238; Weaver KD, 2000, J TRAUMA, V48, P1081, DOI 10.1097/00005373-200006000-00014; Whalen MJ, 1998, J NEUROTRAUM, V15, P777, DOI 10.1089/neu.1998.15.777; Whalen MJ, 2000, J LEUKOCYTE BIOL, V67, P160; Wu Y, 2015, THROMB J, V13, DOI 10.1186/s12959-015-0048-y; Young LA, 2015, SEMIN NEUROL, V35, P5, DOI 10.1055/s-0035-1544242; ZHUANG J, 1993, J TRAUMA, V35, P415, DOI 10.1097/00005373-199309000-00014; Zweckberger K, 2009, NEUROSCI LETT, V454, P115, DOI 10.1016/j.neulet.2009.02.014	84	42	42	0	13	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1471-4892	1471-4973		CURR OPIN PHARMACOL	Curr. Opin. Pharmacol.	FEB	2016	26						110	117		10.1016/j.coph.2015.10.008			8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	DC4RP	WOS:000369208300017	26613129				2021-06-18	
J	Cordaro, M; Impellizzeri, D; Paterniti, I; Bruschetta, G; Siracusa, R; De Stefano, D; Cuzzocrea, S; Esposito, E				Cordaro, Marika; Impellizzeri, Daniela; Paterniti, Irene; Bruschetta, Giuseppe; Siracusa, Rosalba; De Stefano, Daniela; Cuzzocrea, Salvatore; Esposito, Emanuela			Neuroprotective Effects of Co-UltraPEALut on Secondary Inflammatory Process and Autophagy Involved in Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						autophagy; inflammation; luteolin; neuroprotection; palmitoylethanolamide	NITRIC-OXIDE SYNTHASE; FOCAL CEREBRAL-ISCHEMIA; KAPPA-B ACTIVATION; OXIDATIVE STRESS; UNANSWERED QUESTIONS; NEURONAL APOPTOSIS; GROWTH-FACTOR; UP-REGULATION; HEAD-INJURY; CELL-DEATH	Traumatic brain injury (TBI) initiates a neuroinflammatory cascade that contributes to neuronal damage and behavioral impairment. In the present study, we performed a widely used model of TBI to determine the neuroprotective propriety of palmitoylethanolamide (PEA) and the antioxidant effect of a flavonoid luteolin (Lut), given as a co-ultramicronized compound Co-ultraPEALut. We demonstrated that the treatment with Co-ultraPEALut resulted in a significant improvement of motor and cognitive recovery after controlled cortical impact, as well as markedly reducing lesion volumes. Moreover, our results revealed the ability of Co-ultraPEALut to reduce brain trauma through modulation of nuclear factor-B activation. In addition, treatment with Co-ultraPEALut significantly enhanced the post-TBI expression of the neuroprotective neurotrophins glial cell line-derived neurotrophic factor compared with vehicle. Co-ultraPEALut at the dose of 1mg/kg also modulated apoptosis, the release of cytokine and reactive oxygen species, the activation of chymase, tryptase, and nitrotyrosine, and inhibited autophagy. Thus, our data demonstrated that Co-ultraPEALut at a lower dose compared with PEA alone can exert neuroprotective effects and the combination of both could improve their ability to counteract the neurodegeneration and neuroinflammation induced by TBI.	[Cordaro, Marika; Impellizzeri, Daniela; Paterniti, Irene; Bruschetta, Giuseppe; Siracusa, Rosalba; Cuzzocrea, Salvatore; Esposito, Emanuela] Univ Messina, Dept Biol & Environm Sci, I-98166 Messina, Italy; [De Stefano, Daniela] Univ Naples Federico II, Dept Expt Pharmacol, Naples, Italy; [Cuzzocrea, Salvatore] Univ Manchester, Manchester Royal Infirm, Sch Med, Manchester Biomed Res Ctr, Manchester M13 9WL, Lancs, England	Cuzzocrea, S (corresponding author), Univ Messina, Dept Biol & Environm Sci, Viale Ferdinando Stagno DAlcontres 31, I-98166 Messina, Italy.	salvator@unime.it	Cordaro, Marika/K-7329-2016	Cordaro, Marika/0000-0002-3980-0043; Siracusa, Rosalba/0000-0001-7868-2505; Cuzzocrea, Salvatore/0000-0001-6131-3690; Impellizzeri, Daniela/0000-0001-9492-3161			Ahmad A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057208; Ahmad A, 2012, BRAIN BEHAV IMMUN, V26, P1310, DOI 10.1016/j.bbi.2012.07.021; Ansari MA, 2004, BIOL TRACE ELEM RES, V101, P73, DOI 10.1385/BTER:101:1:73; Ansari MA, 2006, FREE RADICAL BIO MED, V41, P1694, DOI 10.1016/j.freeradbiomed.2006.09.002; Baehrecke EH, 2002, NAT REV MOL CELL BIO, V3, P779, DOI 10.1038/nrm931; Beer R, 2000, J CEREBR BLOOD F MET, V20, P669, DOI 10.1097/00004647-200004000-00004; Berdyshev E, 1998, LIFE SCI, V63, pPL125, DOI 10.1016/S0024-3205(98)00324-5; Bethea JR, 1998, J NEUROSCI, V18, P3251; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; Calignano A, 1998, NATURE, V394, P277, DOI 10.1038/28393; Clark RSB, 2008, AUTOPHAGY, V4, P88, DOI 10.4161/auto.5173; Conti AC, 1998, J NEUROSCI, V18, P5663; Culmsee C, 2005, BIOCHEM BIOPH RES CO, V331, P761, DOI 10.1016/j.bbrc.2005.03.149; d'Avila JC, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-31; Di Giovanni S, 2005, P NATL ACAD SCI USA, V102, P8333, DOI 10.1073/pnas.0500989102; Genovese T, 2008, J PHARMACOL EXP THER, V326, P12, DOI 10.1124/jpet.108.136903; GIULIAN D, 1995, NEUROCHEM INT, V27, P119, DOI 10.1016/0197-0186(95)00067-I; Hansen HS, 2000, CHEM PHYS LIPIDS, V108, P135, DOI 10.1016/S0009-3084(00)00192-4; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Hernandez-Ontiveros DG, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00030; Iadecola C, 1996, STROKE, V27, P1373, DOI 10.1161/01.STR.27.8.1373; Ichimura Y, 2008, J BIOL CHEM, V283, P22847, DOI 10.1074/jbc.M802182200; Kawai T, 2007, TRENDS MOL MED, V13, P460, DOI 10.1016/j.molmed.2007.09.002; Kline AE, 2007, BEHAV BRAIN RES, V177, P186, DOI 10.1016/j.bbr.2006.11.036; Klionsky DJ, 2005, J CELL SCI, V118, P7, DOI 10.1242/jcs.01620; La Rosa G, 2004, J NEUROSURG-SPINE, V1, P311, DOI 10.3171/spi.2004.1.3.0311; Lai YC, 2008, J CEREBR BLOOD F MET, V28, P540, DOI 10.1038/sj.jcbfm.9600551; Lambert DM, 2002, CURR MED CHEM, V9, P663, DOI 10.2174/0929867023370707; Lenz A, 2007, INJURY, V38, P1336, DOI 10.1016/j.injury.2007.10.003; Liu CL, 2008, J CEREBR BLOOD F MET, V28, P674, DOI 10.1038/sj.jcbfm.9600587; Liu F, 2012, IMMUNOL REV, V246, P239, DOI 10.1111/j.1600-065X.2012.01107.x; Loos B, 2013, AUTOPHAGY, V9, P1270, DOI 10.4161/auto.25560; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Luo YQ, 1998, J BIOL CHEM, V273, P3756, DOI 10.1074/jbc.273.6.3756; Madrigal JLM, 2001, J NEUROCHEM, V76, P532, DOI 10.1046/j.1471-4159.2001.00108.x; McIntosh TK, 1996, LAB INVEST, V74, P315; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Middleton E, 2000, PHARMACOL REV, V52, P673; Muccioli GG, 2008, NEUROPHARMACOLOGY, V54, P16, DOI 10.1016/j.neuropharm.2007.05.015; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Ola MS, 2011, MOL CELL BIOCHEM, V351, P41, DOI 10.1007/s11010-010-0709-x; Orihara Y, 2001, FORENSIC SCI INT, V123, P142, DOI 10.1016/S0379-0738(01)00537-0; Ozdemir D, 2005, PHYSIOL RES, V54, P631; Park JM, 2013, CANCER BIOL THER, V14, P100, DOI 10.4161/cbt.22954; Paterniti I, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-91; Pyronnet S, 2001, CURR OPIN GENET DEV, V11, P13, DOI 10.1016/S0959-437X(00)00150-7; Reed JC, 2006, CELL DEATH DIFFER, V13, P1378, DOI 10.1038/sj.cdd.4401975; Reggiori F, 2005, CURR OPIN CELL BIOL, V17, P415, DOI 10.1016/j.ceb.2005.06.007; Rhodes J, 2011, CURR OPIN CRIT CARE, V17, P122, DOI 10.1097/MCC.0b013e3283447948; Rockwell P, 2004, CELL SIGNAL, V16, P343, DOI 10.1016/j.cellsig.2003.08.006; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Schabitz WR, 1999, STROKE, V30, P427, DOI 10.1161/01.STR.30.2.427; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Schomacher M, 2008, BRAIN RES, V1240, P213, DOI 10.1016/j.brainres.2008.09.019; Seelinger G, 2008, PLANTA MED, V74, P1667, DOI 10.1055/s-0028-1088314; Shao CX, 2006, FREE RADICAL BIO MED, V41, P77, DOI 10.1016/j.freeradbiomed.2006.03.007; Singh IN, 2007, J NEUROSCI RES, V85, P2216, DOI 10.1002/jnr.21360; Solaroglu I, 2005, J CLIN NEUROSCI, V12, P273, DOI 10.1016/j.jocn.2004.12.002; Venkatesan C, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-32; Walter L, 2002, J BIOL CHEM, V277, P20869, DOI 10.1074/jbc.M110813200; Xiong Y, 2010, DISCOV MED, V10, P434; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yu TS, 2008, J NEUROSCI, V28, P12901, DOI 10.1523/JNEUROSCI.4629-08.2008; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	66	42	42	0	12	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 1	2016	33	1					132	146		10.1089/neu.2014.3460			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CZ4EW	WOS:000367057200016	25046306				2021-06-18	
J	Harrison-Felix, C; Pretz, C; Hammond, FM; Cuthbert, JP; Bell, J; Corrigan, J; Miller, AC; Haarbauer-Krupa, J				Harrison-Felix, Cynthia; Pretz, Christopher; Hammond, Flora M.; Cuthbert, Jeffrey P.; Bell, Jeneita; Corrigan, John; Miller, A. Cate; Haarbauer-Krupa, Juliet			Life Expectancy after Inpatient Rehabilitation for Traumatic Brain Injury in the United States	JOURNAL OF NEUROTRAUMA			English	Article						brain injury; chronic; life expectancy; mortality; rehabilitation	SYSTEMS NATIONAL DATABASE; MODEL SYSTEMS; LATE MORTALITY; HEAD-INJURY; POPULATION; REPRESENTATIVENESS; RISK; CARE	This study characterized life expectancy after traumatic brain injury (TBI). The TBI Model Systems (TBIMS) National Database (NDB) was weighted to represent those 16 years of age completing inpatient rehabilitation for TBI in the United States (US) between 2001 and 2010. Analyses included Standardized Mortality Ratios (SMRs), Cox regression, and life expectancy. The US mortality rates by age, sex, race, and cause of death for 2005 and 2010 were used for comparison purposes. Results indicated that a total of 1325 deaths occurred in the weighted cohort of 6913 individuals. Individuals with TBI were 2.23 times more likely to die than individuals of comparable age, sex, and race in the general population, with a reduced average life expectancy of 9 years. Independent risk factors for death were: older age, male gender, less-than-high school education, previously married at injury, not employed at injury, more recent year of injury, fall-related TBI, not discharged home after rehabilitation, less functional independence, and greater disability. Individuals with TBI were at greatest risk of death from seizures; accidental poisonings; sepsis; aspiration pneumonia; respiratory, mental/behavioral, or nervous system conditions; and other external causes of injury and poisoning, compared with individuals in the general population of similar age, gender, and race. This study confirms prior life expectancy study findings, and provides evidence that the TBIMS NDB is representative of the larger population of adults receiving inpatient rehabilitation for TBI in the US. There is an increased risk of death for individuals with TBI requiring inpatient rehabilitation.	[Harrison-Felix, Cynthia; Pretz, Christopher; Cuthbert, Jeffrey P.] Craig Hosp, Res Dept, Englewood, CO 80113 USA; [Hammond, Flora M.] Rehabil Hosp Indiana, Indianapolis, IN USA; [Bell, Jeneita; Haarbauer-Krupa, Juliet] Natl Ctr Injury Prevent & Control, Traumat Brain Injury Team, Hlth Syst & Trauma Syst Branch, Div Unintent Injury Prevent,Ctr Dis Control & Pre, Atlanta, GA USA; [Corrigan, John] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; [Miller, A. Cate] US DOE, Natl Inst Disabil & Rehabil Res, Washington, DC 20585 USA	Harrison-Felix, C (corresponding author), Craig Hosp, Res Dept, 3425 S Clarkson St, Englewood, CO 80113 USA.	CHarrison-Felix@craighospital.org			US Department of Health and Human Services (HHS) Centers for Disease Control and Prevention (CDC)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA; US Department of Education's Office of Special Education and Rehabilitative Services, NIDRR; NIDRR [H133A110006]; Traumatic Brain Injury Model System Center from NIDRR [H133A120086, H133A120035]	This research was supported by an interagency agreement between the US Department of Health and Human Services (HHS) Centers for Disease Control and Prevention (CDC), and the US Department of Education's Office of Special Education and Rehabilitative Services, NIDRR. Supplemental funding was provided to the NIDRR-funded Traumatic Brain Injury Model Systems National Data and Statistical Center (grant no. H133A110006). The research was also supported by Traumatic Brain Injury Model System Center grants from NIDRR to Ohio State University (grant no. H133A120086) and Indiana University (grant no. H133A120035). This article does not reflect the official policy or opinions of the CDC or the US Department of HHS and does not constitute an endorsement of the individuals or their programs - by CDC, HHS, or other components of the federal government - and none should be inferred. No commercial party having a direct financial interest in the results of the research supporting this article has or will confer a benefit upon the authors or upon any organization with which the authors are associated. This article is written in Dr. Miller's official capacity as part of the national conversation on education and does not necessarily represent the official views of the US Department of Education. The TBI Model Systems National Database is supported by NIDRR and created and maintained by the TBI Model Systems Centers Program. However, these contents do not necessarily reflect the opinions or views of the TBI Model Systems Centers, NIDRR or the US Department of Education.	[Anonymous], 1997, GUID UN DAT SET MED; Baguley IJ, 2012, MED J AUSTRALIA, V196, P40, DOI 10.5694/mja11.10090; Cameron CM, 2008, BRAIN INJURY, V22, P437, DOI 10.1080/02699050802060621; Centers for Disease Control and Prevention, 2012, STOPP ELD ACC DEATHS; Chang BS, 2003, NEUROLOGY, V60, P10, DOI 10.1212/01.WNL.0000031432.05543.14; Colantonio A, 2008, J TRAUMA, V64, P876, DOI 10.1097/TA.0b013e31804d493e; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Corrigan JD, 2012, J HEAD TRAUMA REHAB, V27, P391, DOI 10.1097/HTR.0b013e3182238cdd; Cuthbert JP, 2012, J HEAD TRAUMA REHAB, V27, pE15, DOI 10.1097/HTR.0b013e31826da983; DeVivo M. J, 2002, TOP SPINAL CORD INJ, V7, P49; Dijkers MP, 2010, J HEAD TRAUMA REHAB, V25, P81, DOI 10.1097/HTR.0b013e3181cd3528; Egede LE, 2012, AM J PUBLIC HEALTH, V102, pS266, DOI 10.2105/AJPH.2011.300176; Harrison-Felix C, 2006, J HEAD TRAUMA REHAB, V21, P22, DOI 10.1097/00001199-200601000-00003; Harrison-Felix C, 2004, NEUROREHABILITATION, V19, P45; Harrison-Felix C, 2012, J HEAD TRAUMA REHAB, V27, pE69, DOI 10.1097/HTR.0b013e3182738010; Kalton G., 2003, J OFF STAT, V19, P81; Kobeissy FH, 2011, PM&R, V3, pS139, DOI 10.1016/j.pmrj.2011.02.012; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; McMillan TM, 2007, BRAIN, V130, P2520, DOI 10.1093/brain/awm185; McMillan TM, 2011, J NEUROL NEUROSUR PS, V82, P931, DOI 10.1136/jnnp.2010.222232; Pentland B, 2005, J NEUROL NEUROSUR PS, V76, P395, DOI 10.1136/jnnp.2004.037861; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Ratcliff G, 2005, DISABIL REHABIL, V27, P305, DOI 10.1080/09638280400018338; Selassie AW, 2005, J HEAD TRAUMA REHAB, V20, P257, DOI 10.1097/00001199-200505000-00008; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; The Traumatic Brain Injury Model Systems National Data and Statistical Center, 2012, TBI MOD SYST PRES; Traumatic Brain Injury Model Systems National Data and Statistical Center, 2011, GUID COD PRIM CAUS D; Ventura T, 2010, ARCH PHYS MED REHAB, V91, P20, DOI 10.1016/j.apmr.2009.08.151	28	42	43	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC 1	2015	32	23			SI		1893	1901		10.1089/neu.2014.3353			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CX4TW	WOS:000365694200006	25057965	Green Accepted			2021-06-18	
J	Lucke-Wold, BP; Logsdon, AF; Smith, KE; Turner, RC; Alkon, DL; Tan, ZJ; Naser, ZJ; Knotts, CM; Huber, JD; Rosen, CL				Lucke-Wold, Brandon P.; Logsdon, Aric F.; Smith, Kelly E.; Turner, Ryan C.; Alkon, Daniel L.; Tan, Zhenjun; Naser, Zachary J.; Knotts, Chelsea M.; Huber, Jason D.; Rosen, Charles L.			Bryostatin-1 Restores Blood Brain Barrier Integrity following Blast-Induced Traumatic Brain Injury	MOLECULAR NEUROBIOLOGY			English	Article						Blood brain barrier; Bryostatin-1; Protein kinase C; Tight junction proteins	PROTEIN-KINASE-C; PKC-EPSILON; ISCHEMIC-STROKE; OCCLUDIN EXPRESSION; NEURONAL INJURY; ANIMAL-MODEL; IN-VIVO; ACTIVATION; RAT; ALPHA	Recent wars in Iraq and Afghanistan have accounted for an estimated 270,000 blast exposures among military personnel. Blast traumatic brain injury (TBI) is the 'signature injury' of modern warfare. Blood brain barrier (BBB) disruption following blast TBI can lead to long-term and diffuse neuroinflammation. In this study, we investigate for the first time the role of bryostatin-1, a specific protein kinase C (PKC) modulator, in ameliorating BBB breakdown. Thirty seven Sprague-Dawley rats were used for this study. We utilized a clinically relevant and validated blast model to expose animals to moderate blast exposure. Groups included: control, single blast exposure, and single blast exposure + bryostatin-1. Bryostatin-1 was administered i.p. 2.5 mg/kg after blast exposure. Evan's blue, immunohistochemistry, and western blot analysis were performed to assess injury. Evan's blue binds to albumin and is a marker for BBB disruption. The single blast exposure caused an increase in permeability compared to control (t = 4.808, p < 0.05), and a reduction back toward control levels when bryostatin-1 was administered (t = 5.113, p < 0.01). Three important PKC isozymes, PKC alpha, PKC delta, and PKC epsilon, were co-localized primarily with endothelial cells but not astrocytes. Bryostatin-1 administration reduced toxic PKC alpha levels back toward control levels (t = 4.559, p < 0.01) and increased the neuroprotective isozyme PKC epsilon (t = 6.102, p < 0.01). Bryostatin-1 caused a significant increase in the tight junction proteins VE-cadherin, ZO-1, and occludin through modulation of PKC activity. Bryostatin-1 ultimately decreased BBB breakdown potentially due to modulation of PKC isozymes. Future work will examine the role of bryostatin-1 in preventing chronic neurodegeneration following repetitive neurotrauma.	[Lucke-Wold, Brandon P.; Turner, Ryan C.; Tan, Zhenjun; Naser, Zachary J.; Knotts, Chelsea M.; Rosen, Charles L.] W Virginia Univ, Sch Med, Dept Neurosurg, Morgantown, WV 26506 USA; [Lucke-Wold, Brandon P.; Logsdon, Aric F.; Smith, Kelly E.; Turner, Ryan C.; Tan, Zhenjun; Naser, Zachary J.; Huber, Jason D.; Rosen, Charles L.] W Virginia Univ, Sch Med, Ctr Neurosci, Morgantown, WV 26506 USA; [Logsdon, Aric F.; Smith, Kelly E.; Huber, Jason D.] W Virginia Univ, Sch Pharm, Dept Basic Pharmaceut Sci, Morgantown, WV 26506 USA; [Alkon, Daniel L.] Blanchette Rockefeller Neurosci Inst, Morgantown, WV 26506 USA; [Naser, Zachary J.] Drexel Univ, Coll Med, Off Profess Studies Hlth Sci, Philadelphia, PA 19102 USA; [Rosen, Charles L.] W Virginia Univ, Sch Med, Hlth Sci Ctr, Dept Neurosurg, Morgantown, WV 26506 USA	Rosen, CL (corresponding author), W Virginia Univ, Sch Med, Hlth Sci Ctr, Dept Neurosurg, 1 Med Ctr Dr,Suite 4300,POB 9183, Morgantown, WV 26506 USA.	crosen@hsc.wvu.edu		Fraser, Kelly/0000-0003-1563-050X; Turner, Ryan/0000-0001-5523-0645	West Virginia University Health Sciences Center Office of Research and Graduate Education; WVU Department of Neurosurgery; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [GM08174]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [U54GM104942, T32GM081741, S06GM008174] Funding Source: NIH RePORTER	The authors would like to thank Ryan W. Holt for his help with IHC and western blot analysis. We thank Diana Richardson CDC/NIOSH for tissue preparation for IHC. The authors also thank Dr. Rae Matsumoto and Dr. Steven Frisch for use of western blot resources in their respective laboratories. We thank James E. Robson and Peter Bennett for construction of the blast model and Dr. Robert Gettens and Nic St. John for design of the blast model. A Research Funding and Development Grant (RFDG) from the West Virginia University Health Sciences Center Office of Research and Graduate Education supported this work along with WVU Department of Neurosurgery. R.C.T. was supported by a NIH training grant (GM08174).	Abdul-Muneer PM, 2015, MOL NEUROBIOL, V51, P966, DOI 10.1007/s12035-014-8752-3; Abdul-Muneer PM, 2013, FREE RADICAL BIO MED, V60, P282, DOI 10.1016/j.freeradbiomed.2013.02.029; Adelson PD, 2013, CHILD NERV SYST, V29, P43, DOI 10.1007/s00381-012-1932-4; Alves JL, 2014, J NEUROSCI RES, V92, P141, DOI 10.1002/jnr.23300; Amtul Z, 2014, REV NEUROSCIENCE, V25, P481, DOI 10.1515/revneuro-2013-0041; Arun P, 2013, NEUROSCI RES, V76, P98, DOI 10.1016/j.neures.2013.02.009; Barnes DE, 2014, NEUROLOGY, V83, P312, DOI 10.1212/WNL.0000000000000616; Barzilai A, 2013, DNA REPAIR, V12, P543, DOI 10.1016/j.dnarep.2013.04.007; Bass CR, 2012, ANN BIOMED ENG, V40, P185, DOI 10.1007/s10439-011-0424-0; BERKOW RL, 1993, CANCER RES, V53, P2810; Bolte S, 2006, J MICROSC-OXFORD, V224, P213, DOI 10.1111/j.1365-2818.2006.01706.x; Chamorro D, 2009, MOL BIOL CELL, V20, P4120, DOI 10.1091/mbc.E08-11-1129; Chen T, 2012, NEUROCHEM RES, V37, P983, DOI 10.1007/s11064-011-0691-z; Chen X, 2014, NEUROSCIENCE, V266, P235, DOI 10.1016/j.neuroscience.2013.11.036; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; Dai SS, 2010, J NEUROSCI, V30, P5802, DOI 10.1523/JNEUROSCI.0268-10.2010; De Bock M, 2014, BBA-MOL CELL RES, V1843, P2211, DOI 10.1016/j.bbamcr.2014.04.016; DiNapoli VA, 2010, NEUROSCIENCE, V170, P633, DOI 10.1016/j.neuroscience.2010.07.011; Eckert A, 2014, BBA-MOL BASIS DIS, V1842, P1258, DOI 10.1016/j.bbadis.2013.08.013; Effgen GB, 2014, J NEUROTRAUM, V31, P1202, DOI 10.1089/neu.2013.3227; Ekinci FJ, 1997, INT J DEV NEUROSCI, V15, P867, DOI 10.1016/S0736-5748(97)00037-3; Feng SJ, 2013, NEUROCHEM INT, V63, P69, DOI 10.1016/j.neuint.2013.04.011; Geddes-Klein DM, 2006, J NEUROCHEM, V97, P462, DOI 10.1111/j.1471-4159.2006.03761.x; Giordano G, 2005, J NEUROCHEM, V92, P143, DOI 10.1111/j.1471-4159.2004.02852.x; Girolamo F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084883; Glushakova OY, 2014, J NEUROTRAUM, V31, P1180, DOI 10.1089/neu.2013.3080; Goncalves A, 2012, DIABETES OBES METAB, V14, P454, DOI 10.1111/j.1463-1326.2011.01548.x; Guo DR, 2012, MOL CELL NEUROSCI, V50, P82, DOI 10.1016/j.mcn.2012.03.008; Hang Y, 2012, J MOL NEUROSCI, V46, P236, DOI 10.1007/s12031-011-9584-5; Hongpaisan J, 2011, J NEUROSCI, V31, P630, DOI 10.1523/JNEUROSCI.5209-10.2011; Hoozemans JJM, 2012, INT J BIOCHEM CELL B, V44, P1295, DOI 10.1016/j.biocel.2012.04.023; Hue CD, 2014, J NEUROTRAUM, V31, P951, DOI 10.1089/neu.2013.3149; Kamat PK, 2014, MOL NEUROBIOL, V50, P852, DOI 10.1007/s12035-014-8699-4; Kang JH, 2008, PROTEOMICS, V8, P2006, DOI 10.1002/pmic.200701045; Karasu A, 2010, ULUS TRAVMA ACIL CER, V16, P390; Kim H, 2012, NEUROSCIENCE, V226, P348, DOI 10.1016/j.neuroscience.2012.08.055; Kim YA, 2010, NEUROSCI LETT, V468, P254, DOI 10.1016/j.neulet.2009.11.007; Kizub IV, 2014, INT J CARDIOL, V174, P230, DOI 10.1016/j.ijcard.2014.04.117; Kou ZF, 2014, GLIA, V62, P1831, DOI 10.1002/glia.22690; Lallemend F, 2005, J CELL SCI, V118, P4511, DOI 10.1242/jcs.02572; Lanz TV, 2013, P NATL ACAD SCI USA, V110, P14735, DOI 10.1073/pnas.1302569110; Lim CS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097756; Lin HW, 2012, ADV EXP MED BIOL, V737, P63, DOI 10.1007/978-1-4614-1566-4_10; Liu WJ, 2014, BRAIN RES, V1573, P17, DOI 10.1016/j.brainres.2014.05.022; Lucke-Wold BP, 2015, J ALZHEIMERS DIS, V43, P711, DOI 10.3233/JAD-141422; Lucke-Wold BP, 2014, J NEUROTRAUM, V31, P1129, DOI 10.1089/neu.2013.3303; Luo P, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.116; Marcelo A, 2015, METAB BRAIN DIS, V30, P1, DOI 10.1007/s11011-014-9576-6; Mogha A, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2011.58; Morrow CMK, 2010, PHILOS T R SOC B, V365, P1679, DOI 10.1098/rstb.2010.0025; Muoio V, 2014, ACTA PHYSIOL, V210, P790, DOI 10.1111/apha.12250; Muscella A, 2008, J CELL PHYSIOL, V217, P103, DOI 10.1002/jcp.21478; Naviaux RK, 2014, MITOCHONDRION, V16, P7, DOI 10.1016/j.mito.2013.08.006; Nelson TJ, 2009, TRENDS BIOCHEM SCI, V34, P136, DOI 10.1016/j.tibs.2008.11.006; Novokhatska T, 2013, EUR J PHARMACOL, V718, P401, DOI 10.1016/j.ejphar.2013.08.003; Padmaperuma B, 1996, BRAIN RES, V714, P19, DOI 10.1016/0006-8993(95)01579-5; Pandya Jignesh D, 2013, Front Neuroenergetics, V5, P10, DOI 10.3389/fnene.2013.00010; Panzer MB, 2014, EXP NEUROL, V261, P120, DOI 10.1016/j.expneurol.2014.07.002; Perez-Polo JR, 2013, J NEUROTRAUM, V30, P727, DOI 10.1089/neu.2012.2650; Puvenna V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096296; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Roh DH, 2010, NEUROSCI LETT, V477, P95, DOI 10.1016/j.neulet.2010.04.041; Schneider EB, 2014, NEUROLOGY, V82, P1636, DOI 10.1212/WNL.0000000000000379; Shao BL, 2014, REDOX BIOL, V2, P694, DOI 10.1016/j.redox.2014.05.005; Simard JM, 2014, J NEUROTRAUM, V31, P1292, DOI 10.1089/neu.2013.3016; Stamatovic SM, 2006, J BIOL CHEM, V281, P8379, DOI 10.1074/jbc.M513122200; Stein TD, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt234; Sun MK, 2008, P NATL ACAD SCI USA, V105, P13620, DOI 10.1073/pnas.0805952105; Sun MK, 2006, CNS DRUG REV, V12, P1, DOI 10.1111/j.1527-3458.2006.00001.x; Sun MK, 2014, J PHARMACOL EXP THER, V349, P393, DOI 10.1124/jpet.114.214098; Sun MK, 2014, PROG MOL BIOL TRANSL, V122, P31, DOI 10.1016/B978-0-12-420170-5.00002-7; Sun MK, 2013, BEHAV PHARMACOL, V24, P222, DOI 10.1097/FBP.0b013e3283618afe; Sun MK, 2009, P NATL ACAD SCI USA, V106, P14676, DOI 10.1073/pnas.0907842106; Tan ZJ, 2013, STROKE, V44, P3490, DOI 10.1161/STROKEAHA.113.002411; Teng JCW, 2008, N-S ARCH PHARMACOL, V378, P1, DOI 10.1007/s00210-008-0288-5; Thal SC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050752; Turner RC, 2013, EXP NEUROL, V248, P520, DOI 10.1016/j.expneurol.2013.07.008; Turner RC, 2013, FRONT NEUROL, V3, DOI 10.3389/fneur.2012.00186; Turner RC, 2012, J NEUROSURG, V117, P1110, DOI 10.3171/2012.8.JNS12358; Wu JF, 2014, J NEUROSCI, V34, P10989, DOI 10.1523/JNEUROSCI.5110-13.2014; Wu JF, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-169; Xia YP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068891; Xu C, 2014, NEUROSCIENCE, V268, P75, DOI 10.1016/j.neuroscience.2014.03.008; YANG KY, 1994, J NEUROTRAUM, V11, P523, DOI 10.1089/neu.1994.11.523; YANG KY, 1993, J NEUROTRAUM, V10, P287, DOI 10.1089/neu.1993.10.287; Yang L, 2012, METHODS MOL BIOL, V814, P451, DOI 10.1007/978-1-61779-452-0_30; Yen LF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068595; Yeoh S, 2013, ANN BIOMED ENG, V41, P2206, DOI 10.1007/s10439-013-0805-7; Yoo J, 2003, AM J PHYSIOL-CELL PH, V285, pC300, DOI 10.1152/ajpcell.00267.2002; Zohar O, 2011, NEUROBIOL DIS, V41, P329, DOI 10.1016/j.nbd.2010.10.001	90	42	43	1	39	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	DEC	2015	52	3					1119	1134		10.1007/s12035-014-8902-7			16	Neurosciences	Neurosciences & Neurology	CS2LW	WOS:000361903400005	25301233	Green Accepted			2021-06-18	
J	Pietrosimone, B; Golightly, YM; Mihalik, JP; Guskiewicz, KM				Pietrosimone, Brian; Golightly, Yvonne M.; Mihalik, Jason P.; Guskiewicz, Kevin M.			Concussion Frequency Associates with Musculoskeletal Injury in Retired NFL Players	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						BRAIN; ANTERIOR CRUCIATE LIGAMENT; KNEE INJURY; ANKLE INJURY	LOWER-EXTREMITY INJURY; GAIT STABILITY; HIGH-SCHOOL; FOOTBALL; ADOLESCENTS; DEFICITS; PHASE; RISK; TIME	Objective Concussion is commonly associated with immediate and persistent alterations in motor function affecting postural control and gait. Patients with lower extremity joint injury have demonstrated functional alterations in the cerebral cortex, suggesting that musculoskeletal injury may be linked to alterations in brain function. Therefore, we examined the associations between concussion frequency and lower extremity musculoskeletal injury sustained during professional careers of National Football League (NFL) players in a cross-sectional study. Methods An inclusive health history survey was mailed to 3647 NFL players who retired during 1930-2001. Respondents reported total concussion frequency (zero, one, two, or three or more) and presence (yes/no) of specific knee and ankle musculoskeletal injury during their NFL career. Separate logistic regression models were used to estimate associations between concussion frequency and each musculoskeletal injury type, adjusting for number of years played in the NFL, body mass index while playing in the NFL, and playing position. Results Data from 2429 players (66.6% response rate) were available for analysis. Nearly 61% reported experiencing a concussion while competing in the NFL. Meniscal tear was the most commonly reported musculoskeletal injury (32%). Compared with NFL players who did not sustain a concussion, retired NFL players with one, two, or three or more concussions had between 18% and 63%, 15% and 126%, and 73% and 165% higher odds of reporting various musculoskeletal injuries, respectively. Conclusions A history of concussions was associated with a history of musculoskeletal injuries during NFL careers. These data suggest that a higher number of concussions is linked with higher odds of reporting a musculoskeletal injury.	[Pietrosimone, Brian; Mihalik, Jason P.; Guskiewicz, Kevin M.] Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC 27599 USA; [Pietrosimone, Brian] Univ N Carolina, Neuromuscular Res Lab, Chapel Hill, NC 27599 USA; [Pietrosimone, Brian] Univ N Carolina, Sports Med Res Lab, Chapel Hill, NC 27599 USA; [Golightly, Yvonne M.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27599 USA; [Golightly, Yvonne M.] Univ N Carolina, Thurston Arthrit Res Ctr, Chapel Hill, NC 27599 USA; [Golightly, Yvonne M.; Mihalik, Jason P.] Univ N Carolina, Injury Prevent Res Ctr, Chapel Hill, NC 27599 USA; [Mihalik, Jason P.; Guskiewicz, Kevin M.] Univ N Carolina, Matthew Gfeller Sport Related Traumat Brain Injur, Chapel Hill, NC 27599 USA; [Guskiewicz, Kevin M.] Univ N Carolina, Ctr Study Retired Athletes, Chapel Hill, NC 27599 USA	Pietrosimone, B (corresponding author), Univ N Carolina, Dept Exercise & Sport Sci, Sports Med Res Lab RM 032,210 South Rd Fetzer Hal, Chapel Hill, NC 27599 USA.	brian@unc.edu	Meijer, Anna/K-5118-2016	Golightly, Yvonne/0000-0003-1205-2759			Brophy RH, 2007, MED SCI SPORT EXER, V39, P22, DOI 10.1249/01.mss.0000241637.52231.18; Buckley TA, 2013, GAIT POSTURE, V38, P549, DOI 10.1016/j.gaitpost.2013.02.008; Casson IR, 2010, SPORTS HEALTH, V2, P471, DOI 10.1177/1941738110383963; Chiu SL, 2013, GAIT POSTURE, V38, P717, DOI 10.1016/j.gaitpost.2013.03.010; Covassin T, 2013, AM J SPORT MED, V41, P2885, DOI 10.1177/0363546513499230; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; De Beaumont L, 2013, BMC NEUROL, V13, DOI 10.1186/1471-2377-13-109; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Eckner JT, 2011, PM&R, V3, P212, DOI 10.1016/j.pmrj.2010.12.003; Fait P, 2013, J HEAD TRAUMA REHAB, V28, P293, DOI 10.1097/HTR.0b013e3182407ace; Golightly YM, 2009, J PHYS ACT HEALTH, V6, P638, DOI 10.1123/jpah.6.5.638; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Herman D., 2013, CLIN J SPORT MED, V23, P124; Hershman EB, 2012, AM J SPORT MED, V40, P2200, DOI 10.1177/0363546512458888; Hovda DA, 2014, PROG NEUROL SURG, V28, P28, DOI 10.1159/000358749; Howell DR, 2014, EXP BRAIN RES, V232, P1773, DOI 10.1007/s00221-014-3869-1; Howell DR, 2013, ARCH PHYS MED REHAB, V94, P1513, DOI 10.1016/j.apmr.2013.04.015; Hutchison M, 2011, AM J SPORT MED, V39, P2331, DOI 10.1177/0363546511413375; KANDEL ER, 1991, PRINCIPLES NEURAL SC; Kapreli E, 2009, AM J SPORT MED, V37, P2419, DOI 10.1177/0363546509343201; Kerr ZY, 2012, MED SCI SPORT EXER, V44, P377, DOI 10.1249/MSS.0b013e31823240f2; Kiesel KB, 2014, J SPORT REHABIL, V23, P88, DOI [10.1123/JSR.2012-0130, 10.1123/jsr.2012-0130]; Kontos AP, 2014, J INT NEUROPSYCH SOC, V20, P324, DOI 10.1017/S1355617713001471; Livingston SC, 2010, BRAIN INJURY, V24, P904, DOI 10.3109/02699051003789245; Murugavel M, 2014, J NEUROTRAUM, V31, P1860, DOI 10.1089/neu.2014.3368; Nachev P, 2007, NEUROIMAGE, V36, pT155, DOI 10.1016/j.neuroimage.2007.03.034; Nordstrom A, 2014, BRIT J SPORT MED, V48, P1447, DOI 10.1136/bjsports-2013-093406; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Pietrosimone B, J ATHL TRAI IN PRESS; Pietrosimone BG, 2012, J ATHL TRAINING, V47, P621, DOI 10.4085/1062-6050-47.6.11; Plisky PJ, 2006, J ORTHOP SPORT PHYS, V36, P911, DOI 10.2519/jospt.2006.2244; Powers KC, 2014, BRAIN INJURY, V28, P465, DOI 10.3109/02699052.2014.888759; Schmidt JD, 2012, MED SCI SPORT EXER, V44, P1621, DOI 10.1249/MSS.0b013e318258a9fb; Slobounov S, 2008, CLIN NEUROPHYSIOL, V119, P281, DOI 10.1016/j.clinph.2007.10.006; Swanik CB, 2007, AM J SPORT MED, V35, P943, DOI 10.1177/0363546507299532; Torry MR, 2005, J SPORT SCI MED, V4, P1	39	42	42	1	56	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	NOV	2015	47	11					2366	2372		10.1249/MSS.0000000000000684			7	Sport Sciences	Sport Sciences	CT6RU	WOS:000362940900015	25871466				2021-06-18	
J	Han, ZP; Liu, XR; Luo, YM; Ji, XM				Han, Ziping; Liu, Xiangrong; Luo, Yumin; Ji, Xunming			Therapeutic hypothermia for stroke: Where to go?	EXPERIMENTAL NEUROLOGY			English	Article; Proceedings Paper	3rd Pangu Stroke Conference	OCT 10-12, 2014	Beijing, PEOPLES R CHINA			Hypothermia; Ischemic stroke; Neuroprotection	FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; TISSUE-PLASMINOGEN ACTIVATOR; RANDOMIZED CONTROLLED-TRIAL; ADMISSION BODY-TEMPERATURE; COMBINATION-DRUG THERAPY; UPPER RESPIRATORY-TRACT; LOCAL MILD HYPOTHERMIA; COLD SALINE INFUSION; DAMAGE COOL AID	Ischemic stroke is a major cause of death and long-term disability worldwide. Thrombolysis with recombinant tissue plasminogen activator is the only proven and effective treatment for acute ischemic stroke; however, therapeutic hypothermia is increasingly recognized as having a tissue-protective function and positively influencing neurological outcome, especially in cases of ischemia caused by cardiac arrest or hypoxic-ischemic encephalopathy in newborns. Yet, many aspects of hypothermia as a treatment for ischemic stroke remain unknown. Large-scale studies examining the effects of hypothermia on stroke are currently underway. This review discusses the mechanisms underlying the effect of hypothermia, as well as trends in hypothermia induction methods, methods for achieving optimal protection, side effects, and therapeutic strategies combining hypothermia with other neuroprotective treatments. Finally, outstanding issues that must be addressed before hypothermia treatment is implemented at a clinical level are also presented. (C) 2015 Elsevier Inc. All rights reserved.	[Han, Ziping; Liu, Xiangrong; Luo, Yumin; Ji, Xunming] Capital Med Univ, Xuanwu Hosp, Cerebrovasc Dis Res Inst, Beijing 100053, Peoples R China; [Luo, Yumin; Ji, Xunming] Beijing Inst Brain Disorders, Ctr Stroke, Beijing 100053, Peoples R China; [Ji, Xunming] Capital Med Univ, Xuanwu Hosp, Dept Neurosurg, Beijing 100053, Peoples R China	Ji, XM (corresponding author), Capital Med Univ, Xuanwu Hosp, Cerebrovasc Dis Res Inst, 45 Changchun St, Beijing 100053, Peoples R China.	jixm@ccmu.edu.cn	Ji, Xunming/AAN-3370-2021		National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81171241, 81325007, 81471340]; Ministry of Science and Technology [2011CB707804]	This work was supported by the National Natural Science Foundation of China (81171241, 81325007, and 81471340) and the Ministry of Science and Technology (2011CB707804).	Ahmad M, 2010, TRANSL STROKE RES, V1, P74, DOI 10.1007/s12975-010-0023-7; An CR, 2014, PROG NEUROBIOL, V115, P6, DOI 10.1016/j.pneurobio.2013.12.002; Andrews PJD, 2005, BRIT J ANAESTH, V94, P330, DOI 10.1093/bja/aei025; Ao HS, 2001, RESUSCITATION, V51, P83, DOI 10.1016/S0300-9572(01)00380-X; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Badjatia N, 2009, CRIT CARE MED, V37, P1893, DOI 10.1097/CCM.0b013e31819fffd3; Badjatia N, 2008, STROKE, V39, P3242, DOI 10.1161/STROKEAHA.108.523654; Berger C, 2004, EXP NEUROL, V185, P305, DOI 10.1016/j.expneurol.2003.10.008; Bernard SA, 2003, CRIT CARE MED, V31, P2041, DOI 10.1097/01.CCM.0000069731.18472.61; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Bi M, 2011, CLIN NEUROL NEUROSUR, V113, P768, DOI 10.1016/j.clineuro.2011.08.010; BRISTOW GK, 1994, AVIAT SPACE ENVIR MD, V65, P220; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; Ceulemans AG, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-74; CHANDLER LJ, 1993, ALCOHOL CLIN EXP RES, V17, P54, DOI 10.1111/j.1530-0277.1993.tb00726.x; Chen F, 2014, PROG NEUROBIOL, V115, P246, DOI 10.1016/j.pneurobio.2013.12.007; Chen J, 2013, STROKE, V44, P260, DOI 10.1161/STROKEAHA.112.675462; CHENG C, 1995, ANESTHESIOLOGY, V82, P1160, DOI 10.1097/00000542-199505000-00011; Cheng HK, 2009, NEUROL RES, V31, P340, DOI 10.1179/174313209X443982; Choi JH, 2010, AM J NEURORADIOL, V31, P928, DOI 10.3174/ajnr.A1961; Choi KE, 2012, FASEB J, V26, P2799, DOI 10.1096/fj.11-201822; Clark DL, 2009, EXP NEUROL, V220, P391, DOI 10.1016/j.expneurol.2009.10.002; Colbourne F, 2000, J CEREBR BLOOD F MET, V20, P1702, DOI 10.1097/00004647-200012000-00009; Corbett D, 2000, EXP NEUROL, V163, P200, DOI 10.1006/exnr.2000.7369; Covaciu L, 2011, INTENS CARE MED, V37, P1277, DOI 10.1007/s00134-011-2264-7; Dae MW, 2003, STROKE, V34, P734, DOI 10.1161/01.STR.0000057461.56040.FE; Dai Da-wei, 2006, Zhonghua Yi Xue Za Zhi, V86, P906; De Georgia MA, 2004, NEUROLOGY, V63, P312, DOI 10.1212/01.WNL.0000129840.66938.75; De Witte JL, 1998, ANESTH ANALG, V87, P173, DOI 10.1097/00000539-199807000-00036; Den Hertog HM, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001247.pub2; Deng H, 2003, STROKE, V34, P2495, DOI 10.1161/01.STR.0000091269.67384.E7; Deng J, 2014, PROG NEUROBIOL, V115, P210, DOI 10.1016/j.pneurobio.2014.01.001; DIETRICH WD, 1993, J CEREBR BLOOD F MET, V13, P541, DOI 10.1038/jcbfm.1993.71; Ding YC, 2003, NEUROSCI LETT, V353, P173, DOI 10.1016/j.neulet.2003.09.055; Ding YC, 2002, STROKE, V33, P2492, DOI 10.1161/01.STR.0000028237.15541.CC; Ding YC, 2002, J NEUROSURG, V96, P310, DOI 10.3171/jns.2002.96.2.0310; Ding YC, 2004, NEUROSURGERY, V54, P956, DOI 10.1227/01.NEU.0000114513.96704.29; Dirks M, 2011, STROKE, V42, P1325, DOI 10.1161/STROKEAHA.110.596940; Donnan GA, 2008, LANCET, V371, P1612, DOI 10.1016/S0140-6736(08)60694-7; Ehrlich MP, 2002, ANN THORAC SURG, V73, P191, DOI 10.1016/S0003-4975(01)03273-8; Els T, 2006, CEREBROVASC DIS, V21, P79, DOI 10.1159/000090007; Emsley HC, 2008, LANCET NEUROL, V7, P341, DOI 10.1016/S1474-4422(08)70061-9; Esposito E, 2014, J CEREBR BLOOD F MET, V34, P743, DOI 10.1038/jcbfm.2014.29; Feng JF, 2010, NEUROSURGERY, V67, P730, DOI 10.1227/01.NEU.0000378023.81727.6E; Fukuda H, 2001, BRAIN RES, V910, P187, DOI 10.1016/S0006-8993(01)02659-2; Georgiadis D, 2002, STROKE, V33, P1584, DOI 10.1161/01.STR.0000016970.51004.D9; Georgiadis D, 2001, STROKE, V32, P2550, DOI 10.1161/hs1101.097382; Gerdeman G, 2001, J NEUROPHYSIOL, V85, P468; Giraud R, 2013, CRIT CARE, V17, DOI 10.1186/cc12523; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1250; Gong P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067476; Gonzalez-Ibarra Fernando Pavel, 2011, Front Neurol, V2, P4, DOI 10.3389/fneur.2011.00004; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Grigore AM, 2002, ANESTH ANALG, V94, P4, DOI 10.1097/00000539-200201000-00002; Gu LJ, 2014, CNS NEUROSCI THER, V20, P67, DOI 10.1111/cns.12160; Hacke W, 1996, ARCH NEUROL-CHICAGO, V53, P309, DOI 10.1001/archneur.1996.00550040037012; Hacke W, 2008, NEW ENGL J MED, V359, P1317, DOI 10.1056/NEJMoa0804656; Hajat C, 2000, STROKE, V31, P410, DOI 10.1161/01.STR.31.2.410; Hampson AJ, 2001, EUR J NEUROSCI, V13, P1529, DOI 10.1046/j.0953-816x.2001.01536.x; Han F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069340; Han HS, 2002, J NEUROSCI, V22, P3921, DOI 10.1523/JNEUROSCI.22-10-03921.2002; Harris BA, 2007, BRIT J ANAESTH, V98, P93, DOI 10.1093/bja/ael308; Hemmen TM, 2010, STROKE, V41, P2265, DOI 10.1161/STROKEAHA.110.592295; Hong JM, 2014, STROKE, V45, P134, DOI 10.1161/STROKEAHA.113.003143; Horiguchi T, 2003, J NEUROTRAUM, V20, P511, DOI 10.1089/089771503765355577; Horstmann S, 2003, STROKE, V34, P2165, DOI 10.1161/01.STR.0000088062.86084.F2; Huh PW, 2000, J NEUROSURG, V92, P91, DOI 10.3171/jns.2000.92.1.0091; Imada S, 2010, J NEUROSCI RES, V88, P3457, DOI 10.1002/jnr.22520; Ji XM, 2007, FRONT BIOSCI, V12, P1737, DOI 10.2741/2185; Ji YB, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.5.FOCUS1215; Ji YB, 2012, NEUROL RES, V34, P657, DOI 10.1179/1743132812Y.0000000061; Kammersgaard LP, 2002, STROKE, V33, P1759, DOI 10.1161/01.STR.0000019910.90280.F1; Karnatovskaia LV, 2014, NEUROHOSPITALIST, V4, P153, DOI 10.1177/1941874413519802; Khanna A, 2014, TRANSL STROKE RES, V5, P3, DOI 10.1007/s12975-013-0307-9; Kim JY, 2011, TRANSL STROKE RES, V2, P195, DOI 10.1007/s12975-011-0082-4; Kimberger O, 2007, CRIT CARE, V11, DOI 10.1186/cc5709; Kollmar R, 2007, STROKE, V38, P1585, DOI 10.1161/STROKEAHA.106.475897; Kollmar R, 2009, STROKE, V40, P1907, DOI 10.1161/STROKEAHA.108.530410; Krieger DW, 2004, STROKE, V35, P1482, DOI 10.1161/01.STR.0000126118.44249.5c; Krieger DW, 2001, STROKE, V32, P1847, DOI 10.1161/01.STR.32.8.1847; Kurasako T, 2007, J CEREBR BLOOD F MET, V27, P1919, DOI 10.1038/sj.jcbfm.9600492; Lai TW, 2014, PROG NEUROBIOL, V115, P157, DOI 10.1016/j.pneurobio.2013.11.006; Lee JE, 2005, J NEUROSURG, V103, P289, DOI 10.3171/jns.2005.103.2.0289; Lee SL, 2001, J SURG RES, V100, P150, DOI 10.1006/jsre.2001.6230; Leng TD, 2014, PROG NEUROBIOL, V115, P189, DOI 10.1016/j.pneurobio.2013.12.008; Li HY, 2014, TRANSL STROKE RES, V5, P618, DOI 10.1007/s12975-014-0354-x; Li J, 2004, NEUROL RES, V26, P677, DOI 10.1179/016164104225015903; Liu L, 2008, J NEUROCHEM, V106, P541, DOI 10.1111/j.1471-4159.2008.05411.x; Liu XR, 2014, TRANSL STROKE RES, V5, P692, DOI 10.1007/s12975-014-0359-5; Liu XJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053431; Luan XD, 2004, ACTA NEUROPATHOL, V107, P227, DOI 10.1007/s00401-003-0802-2; Luo YM, 2007, FRONT BIOSCI, V12, P1852, DOI 10.2741/2193; Lyden Patrick D, 2005, J Stroke Cerebrovasc Dis, V14, P107, DOI 10.1016/j.jstrokecerebrovasdis.2005.01.001; Lyden PD, 2006, INT J STROKE, V1, P9, DOI 10.1111/j.1747-4949.2005.00011.x; Mack WJ, 2003, STROKE, V34, P1994, DOI 10.1161/01.STR.0000079813.31539.6D; Macleod MR, 2010, INT J STROKE, V5, P489, DOI 10.1111/j.1747-4949.2010.00520.x; Maier CM, 2002, NEUROBIOL DIS, V11, P28, DOI 10.1006/nbdi.2002.0513; Maier CM, 2001, J NEUROSURG, V94, P90, DOI 10.3171/jns.2001.94.1.0090; Maier CM, 1998, STROKE, V29, P2171, DOI 10.1161/01.STR.29.10.2171; Martin-Schild S, 2009, J STROKE CEREBROVASC, V18, P86, DOI 10.1016/j.jstrokecerebrovasdis.2008.09.015; Matsui T, 2008, J NEUROTRAUM, V25, P709, DOI 10.1089/neu.2007.0482; Matsuwaka R, 1998, J CARDIAC SURG, V13, P463, DOI 10.1111/j.1540-8191.1998.tb01083.x; Mayer SA, 2004, CRIT CARE MED, V32, P2508, DOI 10.1097/01.CCM.0000147441.39670.37; Meisel C, 2005, NAT REV NEUROSCI, V6, P775, DOI 10.1038/nrn1765; Meloni BP, 2009, STROKE, V40, P2236, DOI 10.1161/STROKEAHA.108.542381; Mirzoyev SA, 2010, RESUSCITATION, V81, P1632, DOI 10.1016/j.resuscitation.2010.08.007; Mohr J, 2013, J TRAUMA ACUTE CARE, V74, P1014, DOI 10.1097/TA.0b013e3182826edd; Mokhtarani M, 2001, ANESTH ANALG, V93, P1233, DOI 10.1097/00000539-200111000-00038; Mori K, 2004, SURG NEUROL, V62, P420, DOI 10.1016/j.surneu.2003.12.017; MORIKAWA E, 1992, J CEREBR BLOOD F MET, V12, P380, DOI 10.1038/jcbfm.1992.55; Mueller-Burke D, 2008, INT J DEV NEUROSCI, V26, P67, DOI 10.1016/j.ijdevneu.2007.08.015; Nagel S, 2008, BRAIN RES, V1188, P198, DOI 10.1016/j.brainres.2007.10.052; Nagel Simon, 2008, Expert Rev Neurother, V8, P1255, DOI 10.1586/14737175.8.8.1255; Nakashima K, 1996, STROKE, V27, P913, DOI 10.1161/01.STR.27.5.913; Nunnally ME, 2011, CRIT CARE MED, V39, P1113, DOI 10.1097/CCM.0b013e318206bab2; Patel MD, 2006, AGE AGEING, V35, P273, DOI 10.1093/ageing/afj074; Perrone S, 2010, PEDIATR NEUROL, V43, P236, DOI 10.1016/j.pediatrneurol.2010.05.009; Phanithi PB, 2000, NEUROPATHOLOGY, V20, P273, DOI 10.1046/j.1440-1789.2000.00346.x; Piehl S, 2011, ENDOCR REV, V32, P64, DOI 10.1210/er.2009-0040; Piironen K, 2014, STROKE, V45, P486, DOI 10.1161/STROKEAHA.113.003180; Polderman KH, 2009, CRIT CARE MED, V37, pS186, DOI 10.1097/CCM.0b013e3181aa5241; Polderman KH, 2009, CRIT CARE MED, V37, P1101, DOI 10.1097/CCM.0b013e3181962ad5; Polderman KH, 2005, CRIT CARE MED, V33, P2744, DOI 10.1097/01.CCM.0000190427.88735.19; Reed SD, 2001, STROKE, V32, P1832, DOI 10.1161/01.STR.32.8.1832; RIDENOUR TR, 1992, STROKE, V23, P733, DOI 10.1161/01.STR.23.5.733; Roelfsema V, 2004, J CEREBR BLOOD F MET, V24, P877, DOI 10.1097/01.WCB.0000123904.17746.92; Rogalewski A, 2006, STROKE, V37, P1129, DOI 10.1161/01.STR.0000209330.73175.34; ROSOMOFF HL, 1954, AM J PHYSIOL, V179, P85; Russwurm S, 2002, J INTERF CYTOK RES, V22, P215, DOI 10.1089/107999002753536185; Sánchez-Casado M., 2007, Med. Intensiva, V31, P113; Schmid-Elsaesser R, 1999, STROKE, V30, P1891, DOI 10.1161/01.STR.30.9.1891; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Schmitt KRL, 2010, BRAIN PATHOL, V20, P771, DOI 10.1111/j.1750-3639.2009.00358.x; Scholler K, 2004, BRAIN RES, V1023, P272, DOI 10.1016/j.brainres.2004.01.094; Schwab S, 1998, STROKE, V29, P2461, DOI 10.1161/01.STR.29.12.2461; Schwab S, 2001, STROKE, V32, P2033, DOI 10.1161/hs0901.095394; Seifert HA, 2014, TRANSL STROKE RES, V5, P543, DOI 10.1007/s12975-014-0349-7; Sessler DI, 2009, CRIT CARE MED, V37, pS203, DOI 10.1097/CCM.0b013e3181aa5568; Silasi G, 2012, J CEREBR BLOOD F MET, V32, P1525, DOI 10.1038/jcbfm.2012.38; Silasi G, 2011, J CEREBR BLOOD F MET, V31, P1725, DOI 10.1038/jcbfm.2011.25; Song MK, 2014, TRANSL STROKE RES, V5, P17, DOI 10.1007/s12975-013-0314-x; Staikou C, 2011, W INDIAN MED J, V60, P513; Stetler RA, 2014, PROG NEUROBIOL, V114, P58, DOI 10.1016/j.pneurobio.2013.11.005; Taggart R, 2012, J VET EMERG CRIT CAR, V22, P219, DOI 10.1111/j.1476-4431.2012.00729.x; Talke P, 1997, ANESTHESIOLOGY, V87, P835, DOI 10.1097/00000542-199710000-00017; Tang XN, 2011, ANN NEUROL, V70, P606, DOI 10.1002/ana.22476; Tang XN, 2009, J NEUROTRAUM, V26, P325, DOI 10.1089/neu.2008.0594; Tokutomi T, 2004, NEUROCRIT CARE, V1, P171, DOI 10.1385/NCC:1:2:171; Truettner JS, 2005, MOL BRAIN RES, V138, P124, DOI 10.1016/j.molbrainres.2005.04.006; van der Worp HB, 2007, BRAIN, V130, P3063, DOI 10.1093/brain/awm083; van der Worp HB, 2010, J CEREBR BLOOD F MET, V30, P1079, DOI 10.1038/jcbfm.2010.44; Van Hemelrijck A, 2005, J NEUROCHEM, V95, P1287, DOI 10.1111/j.1471-4159.2005.03450.x; Wang D, 2013, NEUROSCIENCE, V237, P130, DOI 10.1016/j.neuroscience.2013.01.056; Wang Qiong, 2007, Chin J Traumatol, V10, P246; Wang Y, 2000, STROKE, V31, P404, DOI 10.1161/01.STR.31.2.404; Wartenberg KE, 2012, CURR OPIN CRIT CARE, V18, P152, DOI 10.1097/MCC.0b013e32835075c5; White BC, 2000, J NEUROL SCI, V179, P1, DOI 10.1016/S0022-510X(00)00386-5; Wolberg AS, 2004, J TRAUMA, V56, P1221, DOI 10.1097/01.TA.0000064328.97941.FC; Wu TC, 2013, LANCET NEUROL, V12, P275, DOI 10.1016/S1474-4422(13)70013-9; Xiao F, 2004, ACAD EMERG MED, V11, P1001, DOI 10.1197/j.aem.2004.05.026; Xie YC, 2007, NEUROSCI LETT, V422, P87, DOI 10.1016/j.neulet.2007.03.072; Xiong M, 2011, NEUROCHEM INT, V58, P625, DOI 10.1016/j.neuint.2011.01.026; Xiong M, 2009, BRAIN RES BULL, V79, P351, DOI 10.1016/j.brainresbull.2009.03.011; Yanamoto H, 1999, STROKE, V30, P2720, DOI 10.1161/01.STR.30.12.2720; Yenari MA, 2013, FRONT NEUROL NEUROSC, V32, P122, DOI 10.1159/000346428; Yenari MA, 2002, J CEREBR BLOOD F MET, V22, P29, DOI 10.1097/00004647-200201000-00004; YENARI MA, 1995, THROMB RES, V77, P475, DOI 10.1016/0049-3848(95)93883-2; Yenari M, 2008, STROKE, V39, P2910, DOI 10.1161/STROKEAHA.108.514471; Yenari MA, 2012, NAT REV NEUROSCI, V13, P267, DOI 10.1038/nrn3174; Yenari MA, 2010, STROKE, V41, pS72, DOI 10.1161/STROKEAHA.110.595371; Zhang F, 2009, J CEREBR BLOOD F MET, V29, P1022, DOI 10.1038/jcbfm.2009.28; Zhang MJ, 2013, CNS NEUROL DISORD-DR, V12, P371, DOI 10.2174/1871527311312030010; Zhang ZJ, 2001, MOL BRAIN RES, V95, P75, DOI 10.1016/S0169-328X(01)00247-9; Zhao H, 2007, J CEREBR BLOOD F MET, V27, P1879, DOI 10.1038/sj.jcbfm.9600540; Zhao QJ, 2011, J CRIT CARE, V26, P311, DOI 10.1016/j.jcrc.2010.08.014; Zhao WH, 2009, NEUROL RES, V31, P43, DOI 10.1179/174313208X327982; Zhou JQ, 2011, EXPERT OPIN DRUG MET, V7, P803, DOI 10.1517/17425255.2011.574127; Zweifler Richard M, 2003, J Stroke Cerebrovasc Dis, V12, P237, DOI 10.1016/j.jstrokecerebrovasdis.2003.09.006	178	42	44	0	11	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	OCT	2015	272				SI		67	77		10.1016/j.expneurol.2015.06.006			11	Neurosciences	Neurosciences & Neurology	CV6AS	WOS:000364353700009	26057949				2021-06-18	
J	Kerr, ZY; Yeargin, SW; McLeod, TCV; Mensch, J; Hayden, R; Dompier, TP				Kerr, Zachary Y.; Yeargin, Susan W.; McLeod, Tamara C. Valovich; Mensch, James; Hayden, Ross; Dompier, Thomas P.			Comprehensive Coach Education Reduces Head Impact Exposure in American Youth Football	ORTHOPAEDIC JOURNAL OF SPORTS MEDICINE			English	Article						epidemiology; injury; concussion; pediatric; youth sports	CERVICAL-SPINE INJURIES; HIGH-SCHOOL; PLAYERS; CONCUSSION; BIOMECHANICS; ASSOCIATION; SPORTS	Background: Despite little evidence that defines a threshold of head impact exposure or that participation in youth sports leads to long-term cognitive impairments, it is prudent to identify methods of reducing the frequency of head impacts. Purpose: To compare the mean number of head impacts between youth football players in practice and games between leagues that implemented the Heads Up Football (HUF) educational program and those that did not (NHUF). Study Design: Cohort study; Level of evidence, 2. Methods: During the 2014 season, head impact exposure was measured using xPatch accelerometers from 70 youth football players aged 8 to 15 years from 5 leagues. Data were collected during both games and practices. The NHUF group comprised 32 players from 8 teams within 3 leagues. The HUF group comprised 38 players from 7 teams within 2 leagues. Independent-sample t tests evaluated differences in head impact exposure across groups (ie, HUF and NHUF). Results: Players (mean +/- SD: age, 11.7 +/- 1.4 years; height, 152.2 +/- 10.5 cm; weight, 51.6 +/- 9.6 kg) experienced a total of 7478 impacts over 10g, of which 4250 (56.8%) and 3228 (43.2%) occurred in practices and games, respectively. The majority of impacts occurred within the NHUF group (62.0%), followed by the HUF group (38.0%). With a 10g impact threshold, the mean number of impacts during practice per individual event was lower in the HUF group (mean +/- SD, 5.6 +/- 2.9) than in the NHUF group (mean +/- SD, 8.9 +/- 3.1; difference, 3.4; 95% CI, 2.9-3.9). This difference was attenuated when the threshold was changed to 20g but remained significant (difference, 1.0; 95% CI, 0.7-1.3). At both the 10g and 20g impact thresholds, no differences were found in games. Conclusion: Players who participated in HUF leagues accumulated fewer head impacts per practice at both the 10g and 20g thresholds. Youth football leagues should consider the HUF educational program, while exploring additional interventions, to help reduce the number of head impacts in players.	[Kerr, Zachary Y.; Yeargin, Susan W.; McLeod, Tamara C. Valovich; Mensch, James; Hayden, Ross; Dompier, Thomas P.] Datalys Ctr Sports Injury Res & Prevent Inc, 401 West Michigan St,Suite 500, Indianapolis, IN 46202 USA	Kerr, ZY (corresponding author), Datalys Ctr Sports Injury Res & Prevent Inc, 401 West Michigan St,Suite 500, Indianapolis, IN 46202 USA.	zkerr@datalyscenter.org	McLeod, Tamara/AAU-9435-2020	Kerr, Zachary/0000-0003-1423-1259			Beckwith JG, 2013, MED SCI SPORT EXER, V45, P737, DOI 10.1249/MSS.0b013e3182792ed7; Boden BP, 2007, AM J SPORT MED, V35, P1075, DOI 10.1177/0363546507299239; Boden BP, 2006, AM J SPORT MED, V34, P1223, DOI 10.1177/0363546506288306; Cantu RC, 2003, NEUROSURGERY, V53, P358, DOI 10.1227/01.NEU.0000073422.01886.88; Cobb BR, 2013, ANN BIOMED ENG, V41, P2463, DOI 10.1007/s10439-013-0867-6; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Daniel RW, 2012, ANN BIOMED ENG, V40, P976, DOI 10.1007/s10439-012-0530-7; Dick R, 2007, J ATHL TRAINING, V42, P221; Dompier TP, 2007, J ATHL TRAINING, V42, P395; Fainaru S, YOUTH FOOTBALL PARTI; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Kerr ZY, 2015, ORTHOP J SPORTS MED, V3, DOI 10.1177/2325967115594578; Kerr ZY, 2015, AM J SPORT MED, V43, P1134, DOI 10.1177/0363546515570622; Kontos AP, 2013, J PEDIATR-US, V163, P717, DOI 10.1016/j.jpeds.2013.04.011; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Mueller FO, 1998, CLIN SPORT MED, V17, P169, DOI 10.1016/S0278-5919(05)70071-5; Mueller FO, 2001, J ATHL TRAINING, V36, P312; Mueller FO, 2011, PREVENTING SUDDEN DE, P1; Munce TA, 2015, MED SCI SPORT EXER, V47, P1567, DOI 10.1249/MSS.0000000000000591; National Council of Youth Sports, REP TRENDS PART ORG; Ocwieja KE, 2012, ANN BIOMED ENG, V40, P90, DOI 10.1007/s10439-011-0401-7; Pop Warner Football, RUL CHANG REG PRACT; Stamm JM, 2015, NEUROLOGY, V84, P1114, DOI 10.1212/WNL.0000000000001358; USA Football, FOOTB SPONS; Wallerson R, YOUTH PARTICIPATION; Young TJ, 2014, CLIN J SPORT MED, V24, P416, DOI 10.1097/JSM.0000000000000055	26	42	42	0	9	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	2325-9671			ORTHOP J SPORTS MED	Orthop. J. Sports Med.	OCT	2015	3	10							2325967115610545	10.1177/2325967115610545			6	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	DE1ZW	WOS:000370426700003	26779546	DOAJ Gold, Green Published			2021-06-18	
J	Mendelow, AD; Gregson, BA; Rowan, EN; Francis, R; McColl, E; McNamee, P; Chambers, IR; Unterberg, A; Boyers, D; Mitchell, PM				Mendelow, A. David; Gregson, Barbara A.; Rowan, Elise N.; Francis, Richard; McColl, Elaine; McNamee, Paul; Chambers, Iain R.; Unterberg, Andreas; Boyers, Dwayne; Mitchell, Patrick M.		STITCH Trauma Investigators	Early Surgery versus Initial Conservative Treatment in Patients with Traumatic Intracerebral Hemorrhage (STITCH[Trauma]): The First Randomized Trial	JOURNAL OF NEUROTRAUMA			English	Article						craniotomy; controlled trial; intracerebral hemorrhage; traumatic brain injury; randomized	SURGICAL TRIAL; HEMATOMAS; STICH	Intraparenchymal hemorrhages occur in a proportion of severe traumatic brain injury TBI patients, but the role of surgery in their treatment is unclear. This international multi-center, patient-randomized, parallel-group trial compared early surgery (hematoma evacuation within 12 h of randomization) with initial conservative treatment (subsequent evacuation allowed if deemed necessary). Patients were randomized using an independent randomization service within 48 h of TBI. Patients were eligible if they had no more than two intraparenchymal hemorrhages of 10 mL or more and did not have an extradural or subdural hematoma that required surgery. The primary outcome measure was the traditional dichotomous split of the Glasgow Outcome Scale obtained by postal questionnaires sent directly to patients at 6 months. The trial was halted early by the UK funding agency (NIHR HTA) for failure to recruit sufficient patients from the UK (trial registration: ISRCTN19321911). A total of 170 patients were randomized from 31 of 59 registered centers worldwide. Of 82 patients randomized to early surgery with complete follow-up, 30 (37%) had an unfavorable outcome. Of 85 patients randomized to initial conservative treatment with complete follow-up, 40 (47%) had an unfavorable outcome (odds ratio, 0.65; 95% confidence interval, CI 0.35, 1.21; p=0.17), with an absolute benefit of 10.5% (CI, -4.4-25.3%). There were significantly more deaths in the first 6 months in the initial conservative treatment group (33% vs. 15%; p=0.006). The 10.5% absolute benefit with early surgery was consistent with the initial power calculation. However, with the low sample size resulting from the premature termination, we cannot exclude the possibility that this could be a chance finding. A further trial is required urgently to assess whether this encouraging signal can be confirmed.	[Mendelow, A. David; Gregson, Barbara A.; Rowan, Elise N.; Francis, Richard] Newcastle Univ, Neurosurg Trials Grp, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [McColl, Elaine] Newcastle Univ, Newcastle Clin Trials Unit, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [McNamee, Paul; Boyers, Dwayne] Univ Aberdeen, Hlth Econ Res Unit, Aberdeen, Scotland; [Chambers, Iain R.] James Cook Univ Hosp, Dept Med Phys, South Tees Hosp Fdn Trust, Middlesbrough, Cleveland, England; [Unterberg, Andreas] Heidelberg Univ, Dept Neurosurg, Heidelberg, Germany; [Mitchell, Patrick M.] Royal Victoria Infirm, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England	Gregson, BA (corresponding author), Wolfson Res Ctr, Neurosurg Trials Grp, Campus Ageing & Vital, Newcastle Upon Tyne NE4 5PL, Tyne & Wear, England.	Barbara.Gregson@ncl.ac.uk	Agrawal, Amit/C-1511-2011; Boyers, Dwayne/AAJ-8774-2021; Abdullah, J/C-2828-2011; McColl, Elaine/V-9906-2019; Smrcka, Martin/AAM-8872-2021	Agrawal, Amit/0000-0002-3287-5448; Abdullah, J/0000-0002-0258-7410; McColl, Elaine/0000-0001-8300-3204; Hutchinson, Peter/0000-0002-2796-1835; Francis, Richard/0000-0002-6568-1295; Smrcka, Martin/0000-0002-9191-8700	National Institute of Health Research (NIHR) Health Technology Assessment programNational Institute for Health Research (NIHR) [07/37/16]; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0601025] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NIHR-RP-R3-12-013] Funding Source: researchfish; Chief Scientist Office [HERU1, HSRU1] Funding Source: researchfish	This project was funded by the National Institute of Health Research (NIHR) Health Technology Assessment program (project no.: 07/37/16). The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the HTA program, NIHR, NHS, or the Department of Health.	BRODERICK JP, 1993, STROKE, V24, P987, DOI 10.1161/01.STR.24.7.987; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Drummond M, 2009, VALUE HEALTH, V12, P409, DOI 10.1111/j.1524-4733.2008.00489.x; Fearnside M., 1997, NASOPHARYNGEAL CARCI, P1; Francis R., 2015, CHARACTERISTICS; Francis R, 2014, BRIT J NEUROSURG, V28, P663, DOI 10.3109/02688697.2014.881463; Gabbe BJ, 2011, ANN SURG, V253, P138, DOI 10.1097/SLA.0b013e3181f6685b; GALBRAITH S, 1981, J NEUROSURG, V55, P75, DOI 10.3171/jns.1981.55.1.0075; Gregson BA, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-193; Manca A, 2010, PHARMACOECONOMICS, V28, P1079, DOI 10.2165/11537760-000000000-00000; Marion DW, 2006, NEUROSURGERY, V58, P655; Mendelow AD, 2013, LANCET, V382, P397, DOI 10.1016/S0140-6736(13)60986-1; MENDELOW AD, 1979, BRIT MED J, V1, P1240, DOI 10.1136/bmj.1.6173.1240; Mendelow AD, 2005, LANCET, V365, P387; Mendelow AD, 2011, STROKE PATHOPHYSIOLO; Murray GD, 2005, J NEUROTRAUM, V22, P511, DOI 10.1089/neu.2005.22.511; National Institute for Health and Care Excellence, 2003, NICE CLIN GUID SETS; National Institute of Health and Care Excellence, 2007, CLIN GUID CG56 HEAD; Prasad K, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002244.pub3; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Siddique MS, 2002, J NEUROSURG, V96, P86, DOI 10.3171/jns.2002.96.1.0086; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; The World Bank, 2014, GNI PER CAP	24	42	45	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP 1	2015	32	17					1312	1323		10.1089/neu.2014.3644			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CP0KP	WOS:000359564500005	25738794	Green Published			2021-06-18	
J	Molina, DK; DiMaio, VJM				Molina, D. Kimberley; DiMaio, Vincent J. M.			Normal Organ Weights in Women Part II-The Brain, Lungs, Liver, Spleen, and Kidneys	AMERICAN JOURNAL OF FORENSIC MEDICINE AND PATHOLOGY			English	Article						brain; female; forensic; kidney; liver; lung; normal; organ; spleen; weight	NORMAL JAPANESE; POPULATION; HEART; SIZE; AGE	Organomegaly can be a sign of disease and pathology, although standard tables defining organomegaly have yet to be established and universally accepted. This study was designed to address the issue and to determine a normal weight for the major organs in adult human females. A prospective study was undertaken of healthy females who had sudden, traumatic deaths at age 18 to 35 years. Cases were excluded if there was a history of medical illness including illicit drug use, prolonged medical treatment was performed, there was a prolonged period between the time of injury and death, body length and weight could not be accurately assessed, or if any illness or intoxication was identified after gross and microscopic analysis including evidence of systemic disease. Individual organs were excluded if there was significant injury to the organ that could have affected the weight. A total of 102 cases met criteria for inclusion in the study during the approximately 10-year period of data collection from 2004 to 2014. The decedents had an average age of 24.4 years and ranged in length from 141 to 182 cm (56.4-72.8 inches) with an average length of 160 cm (64 inches). The weight ranged from 35.9 to 152 kg (79-334 lb) with an average weight of 65.3 kg (143 lb). The majority of the decedents (86%) died of either ballistic or blunt force (including craniocerebral) injuries. The mean brain weight was 1233 g (range, 1000-1618 g); liver mean weight, 1288 g (range, 775-2395 g); spleen mean weight, 115 g (range, 51-275 g); right lung mean weight, 340 g (range, 142-835 g); left lung mean, 299 g (range, 108-736 g); right kidney mean weight, 108 g (range, 67-261 g); and the left kidney mean weight, 116 g (range, 55-274 g). Regression analysis was performed and showed that there were insufficient associations between organ weight and body length, body weight, and body mass index to allow for predictability. The authors therefore propose establishing a reference range for organ weights in women, much like those in use for other laboratory tests. Reference ranges (95% inclusion) are proposed: brain, 1033 to 1404 g; liver, 603 to 1767 g; spleen, less than 230 g; right lung, 101 to 589 g; left lung, 105 to 515 g; right kidney, 38 to 174 g; and left kidney, 35 to 192 g.	[Molina, D. Kimberley; DiMaio, Vincent J. M.] BCMEO, San Antonio, TX 78229 USA	Molina, DK (corresponding author), BCMEO, 7337 Louis Pasteur Dr, San Antonio, TX 78229 USA.	kmolina@bexar.org					[Anonymous], 1997, 11622AIE A D CO LTD; Boyd E, 1933, ARCH PATHOL, V16, P350; de la Grandmaison GL, 2001, FORENSIC SCI INT, V119, P149, DOI 10.1016/S0379-0738(00)00401-1; DELAND FH, 1968, RADIOLOGY, V91, P1195, DOI 10.1148/91.6.1195; DELAND FH, 1970, RADIOLOGY, V97, P589, DOI 10.1148/97.3.589; GARBY L, 1993, AM J HUM BIOL, V5, P291, DOI 10.1002/ajhb.1310050307; KASISKE BL, 1986, ARCH PATHOL LAB MED, V110, P55; Lindboe CF, 2003, CLIN NEUROPATHOL, V22, P263; MOAR JJ, 1988, AM J PHYS ANTHROPOL, V76, P105, DOI 10.1002/ajpa.1330760109; Molina DK, 2012, AM J FOREN MED PATH, V33, P368, DOI 10.1097/PAF.0b013e31823d29ad; MYERS J, 1974, ARCH PATHOL, V98, P33; Ogiu N, 1997, HEALTH PHYS, V72, P368, DOI 10.1097/00004032-199703000-00004; Sanchez R, 1997, Invest Clin, V38, P83; Smith HL, 1928, AM HEART J, V4, P79, DOI 10.1016/S0002-8703(29)90099-5; SprogoeJakobsen S, 1997, FORENSIC SCI INT, V88, P215, DOI 10.1016/S0379-0738(97)00103-5; TANAKA GI, 1979, HEALTH PHYS, V36, P333, DOI 10.1097/00004032-197903000-00011; WHIMSTER WF, 1971, AM REV RESPIR DIS, V103, P85; WHIMSTER WF, 1974, AM REV RESPIR DIS, V110, P478	18	42	43	1	15	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-7910	1533-404X		AM J FOREN MED PATH	Am. J. Forensic Med. Pathol.	SEP	2015	36	3					182	187		10.1097/PAF.0000000000000175			6	Medicine, Legal; Pathology	Legal Medicine; Pathology	CQ3UX	WOS:000360530200013	26108038				2021-06-18	
J	Villasana, LE; Kim, KN; Westbrook, GL; Schnell, E				Villasana, Laura E.; Kim, Kristine N.; Westbrook, Gary L.; Schnell, Eric			Functional Integration of Adult-Born Hippocampal Neurons after Traumatic Brain Injury	ENEURO			English	Article						adult neurogenesis; functional integration; hippocampus; maturation; synaptic integration; traumatic brain injury		Traumatic brain injury (TBI) increases hippocampal neurogenesis, which may contribute to cognitive recovery after injury. However, it is unknown whether TBI-induced adult-born neurons mature normally and functionally integrate into the hippocampal network. We assessed the generation, morphology, and synaptic integration of new hippocampal neurons after a controlled cortical impact (CCI) injury model of TBI. To label TBI-induced newborn neurons, we used 2-month-old POMC-EGFP mice, which transiently and specifically express EGFP in immature hippocampal neurons, and doublecortin-CreERT2 transgenic mice crossed with Rosa26-CAGtdTomato reporter mice, to permanently pulse-label a cohort of adult-born hippocampal neurons. TBI increased the generation, outward migration, and dendritic complexity of neurons born during post-traumatic neurogenesis. Cells born after TBI had profound alterations in their dendritic structure, with increased dendritic branching proximal to the soma and widely splayed dendritic branches. These changes were apparent during early dendritic outgrowth and persisted as these cells matured. Whole-cell recordings from neurons generated during posttraumatic neurogenesis demonstrate that they are excitable and functionally integrate into the hippocampal circuit. However, despite their dramatic morphologic abnormalities, we found no differences in the rate of their electrophysiological maturation, or their overall degree of synaptic integration when compared to age-matched adult-born cells from sham mice. Our results suggest that cells born after TBI participate in information processing, and receive an apparently normal balance of excitatory and inhibitory inputs. However, TBI-induced changes in their anatomiclocalization and dendritic projection patterns could result in maladaptive network properties.	[Villasana, Laura E.; Schnell, Eric] Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97239 USA; [Kim, Kristine N.; Schnell, Eric] VA Portland Hlth Care Syst, 3710 SW US Vet Hosp Rd,P3ANES, Portland, OR 97239 USA; [Westbrook, Gary L.] Oregon Hlth & Sci Univ, Vollum Inst, Portland, OR 97201 USA	Schnell, E (corresponding author), VA Portland Hlth Care Syst, 3710 SW US Vet Hosp Rd,P3ANES, Portland, OR 97239 USA.	schneler@ohsu.edu		Westbrook, Gary/0000-0002-8108-5223; Kim, Kristine/0000-0001-9747-6547; Schnell, Eric/0000-0002-5623-5015	Department of Veterans Affairs Career Development Award (VA BLRD) [CDA-2 005-10S]; PVARF Summer Fellowship; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [F32-NS083109 NRSA]; Ellison Medical FoundationLawrence Ellison Foundation; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-NS080979, P30-NS061800]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS080979] Funding Source: NIH RePORTER	This work was funded by a Department of Veterans Affairs Career Development Award (VA BLR&D CDA-2 005-10S; E.S.), a PVARF Summer Fellowship (K.N.K.), National Institutes of Health (NIH) Grant F32-NS083109 NRSA (L.E.V.), an Ellison Medical Foundation Award (G.L.W.), and NIH Grants R01-NS080979 (GLW) and P30-NS061800 (Oregon Health & Science University Imaging Center). We thank Drs. Zhi-Qi Xiong and Xuewen Cheng for providing Dcx-CreERT2 mice; and Dr. Stefanie Kaech-Petrie of the Oregon Health & Science University Advanced Light Microscopy Core for assistance with imaging.	Aimone JB, 2014, PHYSIOL REV, V94, P991, DOI 10.1152/physrev.00004.2014; Blaiss CA, 2011, J NEUROSCI, V31, P4906, DOI 10.1523/JNEUROSCI.5265-10.2011; CAMERON HA, 1993, NEUROSCIENCE, V56, P337, DOI 10.1016/0306-4522(93)90335-D; Carlson SW, 2014, J NEUROPATH EXP NEUR, V73, P734, DOI 10.1097/NEN.0000000000000092; Chancey JH, 2013, J NEUROSCI, V33, P6614, DOI 10.1523/JNEUROSCI.0781-13.2013; Cheng XW, 2011, CELL RES, V21, P338, DOI 10.1038/cr.2010.141; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Chohan MO, 2015, NEUROSURGERY, V76, P201, DOI 10.1227/NEU.0000000000000577; Clelland CD, 2009, SCIENCE, V325, P210, DOI 10.1126/science.1173215; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Dupret D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001959; El-Hassar L, 2007, J PHYSIOL-LONDON, V578, P193, DOI 10.1113/jphysiol.2006.119297; Esposito MS, 2005, J NEUROSCI, V25, P10074, DOI 10.1523/JNEUROSCI.3114-05.2005; Freund TF, 1996, HIPPOCAMPUS, V6, P347, DOI 10.1002/(SICI)1098-1063(1996)6:4<347::AID-HIPO1>3.0.CO;2-I; Ge SY, 2006, NATURE, V439, P589, DOI 10.1038/nature04404; Gould E, 1999, NAT NEUROSCI, V2, P260, DOI 10.1038/6365; Gupta A, 2012, J NEUROSCI, V32, P2523, DOI 10.1523/JNEUROSCI.4141-11.2012; Hunt RF, 2012, J NEUROSCI, V32, P12862, DOI 10.1523/JNEUROSCI.1286-12.2012; Jackson J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035557; Jessberger S, 2007, J NEUROSCI, V27, P9400, DOI 10.1523/JNEUROSCI.2002-07.2007; Jin KL, 2001, P NATL ACAD SCI USA, V98, P4710, DOI 10.1073/pnas.081011098; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Lisman JE, 2007, PROG BRAIN RES, V163, P615, DOI 10.1016/S0079-6123(07)63033-7; Liu JL, 1998, J NEUROSCI, V18, P7768; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Lu DY, 2003, J NEUROSURG, V99, P351, DOI 10.3171/jns.2003.99.2.0351; Madisen L, 2010, NAT NEUROSCI, V13, P133, DOI 10.1038/nn.2467; Nakashiba T, 2012, CELL, V149, P188, DOI 10.1016/j.cell.2012.01.046; Niv F, 2012, STROKE, V43, P2468, DOI 10.1161/STROKEAHA.112.660977; Overstreet LS, 2004, J NEUROSCI, V24, P3251, DOI 10.1523/JNEUROSCI.5173-03.2004; Overstreet W. L., 2005, J NEUROPHYSIOL, V94, P4528, DOI DOI 10.1152/JN.00633.2005; Overstreet-Wadiche LS, 2006, J NEUROSCI, V26, P4095, DOI 10.1523/JNEUROSCI.5508-05.2006; Parent JM, 2002, PROG BRAIN RES, V135, P121; Parent JM, 1997, J NEUROSCI, V17, P3727; Perederiy JV, 2013, J NEUROSCI, V33, P4754, DOI 10.1523/JNEUROSCI.4785-12.2013; Pugh P, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00045; Quadrato G, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00017; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; Sahay A, 2011, NATURE, V472, P466, DOI 10.1038/nature09817; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Santhakumar V, 2000, J PHYSIOL-LONDON, V524, P117, DOI 10.1111/j.1469-7793.2000.00117.x; Scharfman HE, 2000, J NEUROSCI, V20, P6144, DOI 10.1523/JNEUROSCI.20-16-06144.2000; Scharfman HE, 2007, SCIENCE, V315, P336, DOI 10.1126/science.1138711; Shapiro LA, 2008, EPILEPSIA, V49, P13, DOI 10.1111/j.1528-1167.2008.01633.x; Shors TJ, 2001, NATURE, V410, P372, DOI 10.1038/35066584; Spalding KL, 2013, CELL, V153, P1219, DOI 10.1016/j.cell.2013.05.002; Sun D, 2007, EXP NEUROL, V204, P264, DOI 10.1016/j.expneurol.2006.11.005; Sun D, 2015, J NEUROTRAUM, V32, P495, DOI 10.1089/neu.2014.3545; Sun D, 2009, EXP NEUROL, V216, P56, DOI 10.1016/j.expneurol.2008.11.011; van Praag H, 1999, P NATL ACAD SCI USA, V96, P13427, DOI 10.1073/pnas.96.23.13427; van Praag H, 2005, J NEUROSCI, V25, P8680, DOI 10.1523/JNEUROSCI.1731-05.2005; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Varela-Nallar L, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00017; Villasana LE, 2014, EXP NEUROL, V261, P156, DOI 10.1016/j.expneurol.2014.05.016; Xie CC, 2015, BRAIN RES, V1602, P1, DOI 10.1016/j.brainres.2014.03.021; Yu TS, 2008, J NEUROSCI, V28, P12901, DOI 10.1523/JNEUROSCI.4629-08.2008; Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033; Zhao CM, 2006, J NEUROSCI, V26, P3, DOI 10.1523/JNEUROSCI.3648-05.2006; Zhu LL, 2005, BRAIN RES, V1055, P1, DOI 10.1016/j.brainres.2005.04.075	60	42	42	1	3	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	2373-2822			ENEURO	eNeuro	SEP-OCT	2015	2	5							UNSP e0056-15.2015	10.1523/ENEURO.0056-15.2015			17	Neurosciences	Neurosciences & Neurology	V3T5V	WOS:000218574600005	26478908	DOAJ Gold, Green Published			2021-06-18	
J	Kitchen, P; Day, RE; Taylor, LHJ; Salman, MM; Bill, RM; Conner, MT; Conner, AC				Kitchen, Philip; Day, Rebecca E.; Taylor, Luke H. J.; Salman, Mootaz M.; Bill, Roslyn M.; Conner, Matthew T.; Conner, Alex C.			Identification and Molecular Mechanisms of the Rapid Tonicity-induced Relocalization of the Aquaporin 4 Channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WATER PERMEABILITY; COLLECTING DUCT; MEMBRANE TRAFFICKING; PLASMA-MEMBRANE; PHOSPHORYLATION; CALMODULIN; AQP4; TRANSLOCATION; CELLS; INVOLVEMENT	The aquaporin family of integral membrane proteins is composed of channels that mediate cellular water flow. Aquaporin 4 (AQP4) is highly expressed in the glial cells of the central nervous system and facilitates the osmotically driven pathological brain swelling associated with stroke and traumatic brain injury. Here we show that AQP4 cell surface expression can be rapidly and reversibly regulated in response to changes of tonicity in primary cortical rat astrocytes and in transfected HEK293 cells. The translocation mechanism involves PKA activation, influx of extracellular calcium, and activation of calmodulin. We identify five putative PKA phosphorylation sites and use site-directed mutagenesis to show that only phosphorylation at one of these sites, serine 276, is necessary for the translocation response. We discuss our findings in the context of the identification of new therapeutic approaches to treating brain edema.	[Kitchen, Philip; Taylor, Luke H. J.] Univ Warwick, Mol Org & Assembly Cells Doctoral Training Ctr, Coventry CV4 7AL, W Midlands, England; [Day, Rebecca E.; Salman, Mootaz M.; Conner, Matthew T.] Sheffield Hallam Univ, Biomed Res Ctr, Sheffield S1 1WB, S Yorkshire, England; [Bill, Roslyn M.] Aston Univ, Sch Life & Hlth Sci, Birmingham B4 7ET, W Midlands, England; [Bill, Roslyn M.] Aston Univ, Aston Res Ctr Hlth Ageing, Birmingham B4 7ET, W Midlands, England; [Conner, Alex C.] Univ Birmingham, Sch Clin & Expt Med, Birmingham B15 2TT, W Midlands, England	Bill, RM (corresponding author), Aston Univ, Sch Life & Hlth Sci, Birmingham B4 7ET, W Midlands, England.	r.m.bill@aston.ac.uk; m.conner@shu.ac.uk; a.c.conner@bham.ac.uk	Bill, Roslyn M/D-4554-2012; Kitchen, Philip/J-6936-2019; Salman, Mootaz M./J-3111-2019	Bill, Roslyn M/0000-0003-1331-0852; Kitchen, Philip/0000-0002-1558-4673; Salman, Mootaz M./0000-0002-5683-1706	Engineering and Physical Sciences Research Council through the Molecular Organisation and Assembly in Cells Doctoral Training Centre, University of Warwick [EP/F500378/1]; Engineering and Physical Sciences Research CouncilUK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC) [1091578] Funding Source: researchfish	This work was supported by the Engineering and Physical Sciences Research Council through the Molecular Organisation and Assembly in Cells Doctoral Training Centre, University of Warwick, Grant EP/F500378/1 (to P. K. and L. H. J. T.). The authors declare that they have no conflicts of interest with the contents of this article.	Assentoft M, 2014, AM J PHYSIOL-CELL PH, V307, pC957, DOI 10.1152/ajpcell.00182.2014; Blom N, 2004, PROTEOMICS, V4, P1633, DOI 10.1002/pmic.200300771; Bustamante M, 2008, J AM SOC NEPHROL, V19, P109, DOI 10.1681/ASN.2007010092; Carmosino M, 2007, BIOL CELL, V99, P25, DOI 10.1042/BC200600068; Conner AC, 2013, MOL MEMBR BIOL, V30, P101, DOI 10.3109/09687688.2012.743194; Conner MT, 2012, J BIOL CHEM, V287, P11516, DOI 10.1074/jbc.M111.329219; Conner MT, 2010, BIOCHEMISTRY-US, V49, P821, DOI 10.1021/bi902068b; De Bellis M, 2014, MOL BIOL CELL, V25, P470, DOI 10.1091/mbc.E13-06-0331; Gouraud S, 2002, J CELL SCI, V115, P3667, DOI 10.1242/jcs.00053; Gunnarson E, 2008, GLIA, V56, P587, DOI 10.1002/glia.20627; Hoffert JD, 2007, J PROTEOME RES, V6, P3501, DOI 10.1021/pr0701153; Huber VJ, 2009, BIOORGAN MED CHEM, V17, P411, DOI 10.1016/j.bmc.2007.12.040; Ishikawa Y, 2002, MOL PHARMACOL, V61, P1423, DOI 10.1124/mol.61.6.1423; JUNG JS, 1994, P NATL ACAD SCI USA, V91, P13052, DOI 10.1073/pnas.91.26.13052; Kalman K, 2008, J BIOL CHEM, V283, P21278, DOI 10.1074/jbc.M801740200; Kato J, 2013, BIOCHEM J, V454, P275, DOI 10.1042/BJ20130046; Katsura T, 1997, Am J Physiol, V272, pF817; Madrid R, 2001, EMBO J, V20, P7008, DOI 10.1093/emboj/20.24.7008; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; MARPLES D, 1995, AM J PHYSIOL-CELL PH, V269, pC655; Moeller HB, 2009, NEUROSCIENCE, V164, P1674, DOI 10.1016/j.neuroscience.2009.09.072; Nejsum LN, 2005, AM J PHYSIOL-RENAL, V288, pF930, DOI 10.1152/ajprenal.00291.2004; Nicchia GP, 2008, GLIA, V56, P1755, DOI 10.1002/glia.20724; Papadopoulos MC, 2013, NAT REV NEUROSCI, V14, P265, DOI 10.1038/nrn3468; Rabaud NE, 2009, BIOCHEM BIOPH RES CO, V383, P54, DOI 10.1016/j.bbrc.2009.03.128; Rash JE, 2004, NEUROSCIENCE, V129, P915, DOI 10.1016/j.neuroscience.2004.06.076; Reichow SL, 2008, STRUCTURE, V16, P1389, DOI 10.1016/j.str.2008.06.011; Rossi A, 2010, J BIOL CHEM, V285, P4562, DOI 10.1074/jbc.M109.069245; Song YT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034936; Tanimura Y, 2009, J STRUCT BIOL, V166, P16, DOI 10.1016/j.jsb.2008.11.010; Varadaraj K, 2005, INVEST OPHTH VIS SCI, V46, P1393, DOI 10.1167/iovs.04-1217; Vriens J, 2004, P NATL ACAD SCI USA, V101, P396, DOI 10.1073/pnas.0303329101; Wisniewski JR, 2010, J PROTEOME RES, V9, P3280, DOI 10.1021/pr1002214; Yap Kyoko L., 2000, Journal of Structural and Functional Genomics, V1, P8, DOI 10.1023/A:1011320027914; Zador Zsolt, 2009, Handb Exp Pharmacol, P159, DOI 10.1007/978-3-540-79885-9_7	35	42	44	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 3	2015	290	27					16873	16881		10.1074/jbc.M115.646034			9	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	CM3HN	WOS:000357572800032	26013827	Other Gold, Green Published, Green Accepted			2021-06-18	
J	Scott, C; McKinlay, A; McLellan, T; Britt, E; Grace, R; MacFarlane, M				Scott, Charis; McKinlay, Audrey; McLellan, Tracey; Britt, Eileen; Grace, Randolph; MacFarlane, Martin			A Comparison of Adult Outcomes for Males Compared to Females Following Pediatric Traumatic Brain Injury	NEUROPSYCHOLOGY			English	Article						traumatic brain injury; gender; offending; depression; behaviors	GENDER-DIFFERENCES; BIRTH COHORT; EXTERNALIZING PSYCHOPATHOLOGY; PSYCHIATRIC-DISORDERS; CRIMINAL BEHAVIOR; MENTAL-HEALTH; CHILDREN; PREVALENCE; DEPRESSION; P300	Objective: To identify the association between traumatic brain injury (TBI) and internalizing and externalizing problem behaviors and determine if these apply equally to males and females. Method: The association between adult psychosocial functioning and childhood TBI for males and females was examined using groups with a history of childhood TBI (mild or moderate/severe) or orthopedic injury (injury age, 1-17, assessed 18-31 at >5 years postinjury), including rates of depression and anxiety disorders, substance abuse/dependence and offending behavior. Repeated-measures logistic regression was used to determine if the rates of internalizing and externalizing problem behaviors varied by group and sex. Results: Overall rates of problem behaviors were significantly greater for both moderate/severe TBI (OR = 4.00) and mild TBI (OR = 3.60) groups compared with orthopedic controls. Females were significantly more likely than males to report a history of internalizing problems (OR = 2.22), whereas males were more likely than females to report externalizing problems (OR = 2.10). The sex difference in internalizing/externalizing problems was found consistently across TBI groups and controls. Conclusions: Childhood TBI is associated with psychosocial problems in adulthood, regardless of injury severity. How deficits are expressed differs between the sexes, with important implications for interventions strategies.	[Scott, Charis; McKinlay, Audrey; McLellan, Tracey; Britt, Eileen; Grace, Randolph] Univ Canterbury, Dept Psychol, Christchurch, New Zealand; [McKinlay, Audrey] Univ Melbourne, Melbourne Sch Psychol Sci, Melbourne, Vic 3010, Australia; [Grace, Randolph] Univ Minho, Sch Psychol, P-4719 Braga, Portugal; [MacFarlane, Martin] Canterbury Dist Hlth Board, Christchurch, New Zealand	McKinlay, A (corresponding author), Univ Melbourne, Melbourne Sch Psychol Sci, Melbourne, Vic 3010, Australia.	audrey.mckinlay@unimelb.edu.au		McKinlay, Audrey/0000-0001-9846-8514	Health Research Council/Accident Compensation Corporation of New Zealand	Audrey McKinlay was supported by a postdoctoral fellowship from the Health Research Council/Accident Compensation Corporation of New Zealand.	Alexandrino-Silva C, 2013, J AFFECT DISORDERS, V147, P355, DOI 10.1016/j.jad.2012.11.041; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; Bloom DR, 2001, J AM ACAD CHILD PSY, V40, P572, DOI 10.1097/00004583-200105000-00017; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Brower MC, 2001, J NEUROL NEUROSUR PS, V71, P720, DOI 10.1136/jnnp.71.6.720; Carlson SR, 2007, J ABNORM PSYCHOL, V116, P565, DOI 10.1037/0021-843X.116.3.565; Carr A., 2006, HDB ADULT CLIN PSYCH; Colantonio A, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-102; Cooper-Evans S, 2008, NEUROPSYCHOL REHABIL, V18, P607, DOI 10.1080/09602010801948516; Costa PT, 2001, J PERS SOC PSYCHOL, V81, P322, DOI 10.1037//0022-3514.81.2.322; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Fergusson DM, 2007, ARCH GEN PSYCHIAT, V64, P1089, DOI 10.1001/archpsyc.64.9.1089; Fergusson DM, 2009, ARCH GEN PSYCHIAT, V66, P260, DOI 10.1001/archgenpsychiatry.2008.543; Fergusson DM, 2005, J CHILD PSYCHOL PSYC, V46, P837, DOI 10.1111/j.1469-7610.2004.00387.x; Fergusson DM, 1998, EUR ARCH PSY CLIN N, V248, P4, DOI 10.1007/s004060050012; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Hanley JA, 2003, AM J EPIDEMIOL, V157, P364, DOI 10.1093/aje/kwf215; Hawley CA, 2003, BRAIN INJURY, V17, P105, DOI 10.1080/0269905021000010131; Hirschberg R, 2008, FUTUR NEUROL, V3, P483, DOI 10.2217/14796708.3.4.483; Houston RJ, 2005, CLIN NEUROPHYSIOL, V116, P1424, DOI 10.1016/j.clinph.2005.01.013; Houston RJ, 2003, PSYCHIAT RES-NEUROIM, V124, P49, DOI 10.1016/S0925-4927(03)00074-X; Iacono WG, 2003, INT J PSYCHOPHYSIOL, V48, P147, DOI 10.1016/S0167-8760(03)00052-7; IBM Corp, 2011, IBM SPSS Statistics for Windows, Version 20.0; Kim E, 2002, NEUROREHABILITATION, V17, P297; Kirkwood M, 2000, CHILD NEUROPSYCHOL, V6, P195, DOI 10.1076/chin.6.3.195.3157; Luis CA, 2002, J CLIN EXP NEUROPSYC, V24, P270, DOI 10.1076/jcen.24.3.270.982; Max JE, 1998, J AM ACAD CHILD PSY, V37, P841, DOI 10.1097/00004583-199808000-00014; Max JE, 1999, J INT NEUROPSYCH SOC, V5, P58, DOI 10.1017/S1355617799511089; McKinlay A, 2008, BRAIN INJURY, V22, P175, DOI 10.1080/02699050801888824; McKinlay A, 2010, CHILD CARE HLTH DEV, V36, P22, DOI 10.1111/j.1365-2214.2009.00947.x; McKinlay A, 2009, J HEAD TRAUMA REHAB, V24, P221, DOI 10.1097/HTR.0b013e3181a40590; Niemeier JP, 2007, NEUROPSYCHOL REHABIL, V17, P293, DOI 10.1080/09602010600814729; Paradiso S, 1998, J NEUROPSYCH CLIN N, V10, P41, DOI 10.1176/jnp.10.1.41; Peloso PM, 2004, J REHABIL MED, V36, P22, DOI 10.1080/16501960410023714; Seeman MV, 1997, AM J PSYCHIAT, V154, P1641, DOI 10.1176/ajp.154.12.1641; SHAYWITZ BA, 1995, NATURE, V373, P607, DOI 10.1038/373607a0; Shiroma EJ, 2012, J CORRECT HEALTH CAR, V16, P273, DOI DOI 10.1177/1078345810378253; Shiroma EJ, 2012, J HEAD TRAUMA REHAB, V27, pE1, DOI 10.1097/HTR.0b013e3182571c14; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Stein DG, 2008, ANN EMERG MED, V51, P164, DOI 10.1016/j.annemergmed.2007.05.001; Timonen M, 2002, PSYCHIAT RES, V113, P217, DOI 10.1016/S0165-1781(02)00269-X; Wasserman GA, 2005, AM J PUBLIC HEALTH, V95, P131, DOI 10.2105/AJPH.2003.024737; Williams WH, 2010, BRAIN INJURY, V24, P1184, DOI 10.3109/02699052.2010.495697; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514	45	42	43	1	19	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	JUL	2015	29	4					501	508		10.1037/neu0000074			8	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	CL5CA	WOS:000356976200001	25495834				2021-06-18	
J	Tam, S; Mckay, A; Sloan, S; Ponsford, J				Tam, Sammi; McKay, Adam; Sloan, Sue; Ponsford, Jennie			The experience of challenging behaviours following severe TBI: A family perspective	BRAIN INJURY			English	Article						Community integration; coping; family experience; thematic analysis; traumatic brain injury	TRAUMATIC BRAIN-INJURY; AGGRESSIVE-BEHAVIOR; SCALE; MANAGEMENT; CAREGIVERS; PEOPLE; ADULTS; CARE	Primary objective: Family caregivers play an important role in managing challenging behaviours after TBI. The aims of this study were to understand how family caregivers of individuals with TBI perceive challenging behaviours and their impact on the TBI individual's community integration and family functioning. Research design: A qualitative research design was employed to capture the lived experience of family caregivers of individuals with TBI. Methods and procedures: Face-to-face interviews were conducted on six female family caregivers of individuals with severe TBI (sustained an average of 17 years earlier) and long-standing challenging behaviours. Main outcomes and results: The results revealed that family caregivers adopted a broader definition of challenging behaviour than that used by professionals and these behaviours impacted on the community integration of the individual with TBI, most notably leading to poor social relationships. Challenging behaviours were viewed as a key source of distress and burden for family caregivers and they used many different strategies to manage the behaviours. Conclusion: Greater understanding of challenging behaviours from the perspectives of family caregivers may help provide more effective support and interventions to improve quality-of-life for individuals with challenging behaviours after TBI and their families.	[Tam, Sammi; McKay, Adam; Ponsford, Jennie] Monash Univ, Sch Psychol Sci, Melbourne, Vic 3004, Australia; [McKay, Adam; Ponsford, Jennie] Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia; [Sloan, Sue] Osborn Sloan & Associates, Melbourne, Vic, Australia; [Ponsford, Jennie] Natl Trauma Res Inst, Melbourne, Vic, Australia	Mckay, A (corresponding author), Monash Univ, Sch Psychol Sci, Clayton, Vic 3800, Australia.	adam.mckay@monash.edu	McKay, Adam JD/M-6003-2017	McKay, Adam JD/0000-0002-0479-7681			Albaugh JA, 2003, ONCOLOGY NURSING FOR, V30, P592; Alderman N, 1997, BRAIN INJURY, V11, P503, DOI 10.1080/713802182; Anderson MI, 2002, BRAIN INJURY, V16, P743, DOI 10.1080/02699050210128906; Baguley IJ, 2006, J HEAD TRAUMA REHAB, V21, P45, DOI 10.1097/00001199-200601000-00005; Braine ME, 2011, J NEUROSCI NURS, V43, P156, DOI 10.1097/JNN.0b013e3182135bb2; Braun V, 2013, SUCCESSFUL QUALITATI; Braun V., 2006, QUALITATIVE RES PSYC, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706qp063oa]; Carnevale GJ, 2006, ARCH PHYS MED REHAB, V87, P1289, DOI 10.1016/j.apmr.2006.06.010; Degeneffe CE, 2001, HEALTH SOC WORK, V26, P257, DOI 10.1093/hsw/26.4.257; Douglas JM, 2000, BRAIN INJURY, V14, P71, DOI 10.1080/026990500120943; EMERSON E, 1995, J INTELL DISABIL RES, V39, P388, DOI 10.1111/j.1365-2788.1995.tb00543.x; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; FEENEY TJ, 1995, J HEAD TRAUMA REHAB, V10, P67; Guest G, 2006, FIELD METHOD, V18, P59, DOI 10.1177/1525822X05279903; Johnson R., 1996, CLIN REHABIL, V10, P173, DOI [DOI 10.1177/026921559601000215, 10.1177/026921559601000215]; Jumisko E, 2007, J FAM NURS, V13, P353, DOI 10.1177/1074840707303842; Kelly G, 2006, BRAIN INJURY, V20, P307, DOI 10.1080/02699050500488074; Kelly G, 2008, BRAIN INJURY, V22, P457, DOI 10.1080/02699050802060647; Lefebvre H, 2008, BRAIN INJURY, V22, P535, DOI 10.1080/02699050802158243; Liamputtong P., 2005, QUALITATIVE RES METH; Lippert-Gruner M, 2002, J REHABIL MED, V34, P211, DOI 10.1080/165019702760279198; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; McCubin M. A., 1991, FAMILY ASSESSMENT IN, P3; Ponsford J., 2013, TRAUMATIC BRAIN INJU, P164; Ponsford J, 2010, J INT NEUROPSYCH SOC, V16, P1; Sabaz M, 2014, J HEAD TRAUMA REHAB, V29, pE19, DOI 10.1097/HTR.0b013e31828dc590; Smeets SM, 2012, ARCH PHYS MED REHAB, V93, P834, DOI 10.1016/j.apmr.2011.10.029; Tate RL, 2004, BRAIN INJURY, V18, P445, DOI 10.1080/02699050310001641183; Tateno A, 2003, J NEUROPSYCH CLIN N, V15, P155, DOI 10.1176/appi.neuropsych.15.2.155; Willer B., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI DOI 10.1097/00001199-199308020-00009; Willis TJ, 2003, J HEAD TRAUMA REHAB, V18, P75, DOI 10.1097/00001199-200301000-00008; Winkler D, 2006, J HEAD TRAUMA REHAB, V21, P8, DOI 10.1097/00001199-200601000-00002	33	42	42	0	10	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUL	2015	29	7-8					813	821		10.3109/02699052.2015.1005134			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	CO0BJ	WOS:000358814800004	25914927				2021-06-18	
J	Kabu, S; Jaffer, H; Petro, M; Dudzinski, D; Stewart, D; Courtney, A; Courtney, M; Labhasetwar, V				Kabu, Shushi; Jaffer, Hayder; Petro, Marianne; Dudzinski, Dave; Stewart, Desiree; Courtney, Amy; Courtney, Michael; Labhasetwar, Vinod			Blast-Associated Shock Waves Result in Increased Brain Vascular Leakage and Elevated ROS Levels in a Rat Model of Traumatic Brain Injury	PLOS ONE			English	Article							OXIDATIVE STRESS; SUPEROXIDE-DISMUTASE; BARRIER DISRUPTION; HUMAN NEURONS; MOUSE MODEL; EDEMA; DEFICITS; DIFFUSE; OVERPRESSURE; BREAKDOWN	Blast-associated shock wave-induced traumatic brain injury (bTBI) remains a persistent risk for armed forces worldwide, yet its detailed pathophysiology remains to be fully investigated. In this study, we have designed and characterized a laboratory-scale shock tube to develop a rodent model of bTBI. Our blast tube, driven by a mixture of oxygen and acetylene, effectively generates blast overpressures of 20-130 psi, with pressure-time profiles similar to those of free-field blast waves. We tested our shock tube for brain injury response to various blast wave conditions in rats. The results show that blast waves cause diffuse vascular brain damage, as determined using a sensitive optical imaging method based on the fluorescence signal of Evans Blue dye extravasation developed in our laboratory. Vascular leakage increased with increasing blast overpressures and mapping of the brain slices for optical signal intensity indicated nonhomogeneous damage to the cerebral vasculature. We confirmed vascular leakage due to disruption in the blood-brain barrier (BBB) integrity following blast exposure. Reactive oxygen species (ROS) levels in the brain also increased with increasing blast pressures and with time post-blast wave exposure. Immunohistochemical analysis of the brain sections analyzed at different time points post blast exposure demonstrated astrocytosis and cell apoptosis, confirming sustained neuronal injury response. The main advantages of our shock-tube design are minimal jet effect and no requirement for specialized equipment or facilities, and effectively generate blast-associated shock waves that are relevant to battle-field conditions. Overall data suggest that increased oxidative stress and BBB disruption could be the crucial factors in the propagation and spread of neuronal degeneration following blast injury. Further studies are required to determine the interplay between increased ROS activity and BBB disruption to develop effective therapeutic strategies that can prevent the resulting cascade of neurodegeneration.	[Kabu, Shushi; Jaffer, Hayder; Petro, Marianne; Stewart, Desiree; Labhasetwar, Vinod] Cleveland Clin, Dept Biomed Engn, Lerner Res Inst, Cleveland, OH 44106 USA; [Dudzinski, Dave] Cleveland Clin, Med Device Solut, Lerner Res Inst, Cleveland, OH 44106 USA; [Courtney, Amy; Courtney, Michael] BTG Res, Colorado Springs, CO USA	Labhasetwar, V (corresponding author), Cleveland Clin, Dept Biomed Engn, Lerner Res Inst, Cleveland, OH 44106 USA.	labhasv@ccf.org	Labhasetwar, Vinod/J-9660-2016	Labhasetwar, Vinod/0000-0001-7950-1542; Courtney, Amy/0000-0002-1925-8736			Ahn HY, 2012, J AM CHEM SOC, V134, P4721, DOI 10.1021/ja210315x; Alley M., 2009, THESIS PURDUE U W LA; Azbill RD, 1997, BRAIN RES, V765, P283, DOI 10.1016/S0006-8993(97)00573-8; Baskaya MK, 2000, J NEUROSURG, V92, P448, DOI 10.3171/jns.2000.92.3.0448; Blixt J, 2015, BRAIN RES; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Cernak Ibolja, 2010, Front Neurol, V1, P151, DOI 10.3389/fneur.2010.00151; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Chen Y, 2013, J NEUROPSYCH CLIN N, V25, P103, DOI 10.1176/appi.neuropsych.12030058; Chen Y, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00117; Chen Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039353; Chen Y, 2011, BRAIN INJURY, V25, P641, DOI 10.3109/02699052.2011.580313; Choi BY, 2012, BRAIN RES, V1481, P49, DOI 10.1016/j.brainres.2012.08.032; Courtney AC, 2009, MED HYPOTHESES, V72, P76, DOI 10.1016/j.mehy.2008.08.015; Courtney AC, 2012, REV SCI INSTRUM, V83, DOI 10.1063/1.3702803; Courtney E, 2014, DEF TECHNOL, V10, P245, DOI 10.1016/j.dt.2014.04.003; Davenport ND, 2012, NEUROIMAGE, V59, P2017, DOI 10.1016/j.neuroimage.2011.10.050; DeWitt DS, 2013, J NEUROTRAUM, V30, P688, DOI 10.1089/neu.2012.2349; DeWitt DS, 2009, J NEUROTRAUM, V26, P877, DOI 10.1089/neu.2007.0439; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; Gilgun-Sherki Y, 2001, NEUROPHARMACOLOGY, V40, P959, DOI 10.1016/S0028-3908(01)00019-3; Her H, 2012, QUANTIFYING MOMENTUM; Hicks RR, 2010, J TRAUMA, V68, P1257, DOI 10.1097/TA.0b013e3181d8956d; Higashida T, 2011, J NEUROSURG, V114, P92, DOI 10.3171/2010.6.JNS10207; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Iffland PH, 2013, NEUROBIOL DIS, V59, P206, DOI 10.1016/j.nbd.2013.07.006; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jaffer H, 2013, SCI REP-UK, V3, DOI 10.1038/srep03117; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; Kuehn R, 2011, J NEUROTRAUM, V28, P2155, DOI 10.1089/neu.2010.1532; Lew HL, 2005, AM J PHYS MED REHAB, V84, P393, DOI 10.1097/01.phm.0000163703.91647.a7; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Liu LD, 2012, NATURE, V483, P608, DOI 10.1038/nature10927; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Magnuson J, 2012, CURR NEUROL NEUROSCI, V12, P570, DOI 10.1007/s11910-012-0303-6; Mediavilla Varas Jesus, 2011, Front Neurol, V2, P58, DOI 10.3389/fneur.2011.00058; Newman AJ, 2015, J NEUROSCI METH, V242, P82, DOI 10.1016/j.jneumeth.2015.01.009; Nimmo AJ, 2004, NEUROPEPTIDES, V38, P40, DOI 10.1016/j.npep.2003.12.003; O'Connor WT, 2011, PHARMACOL THERAPEUT, V130, P106, DOI 10.1016/j.pharmthera.2011.01.001; Obermeier B, 2013, NAT MED, V19, P1584, DOI 10.1038/nm.3407; Pasco A, 2007, J NEUROTRAUM, V24, P1321, DOI 10.1089/neu.2006.0136; Petraglia AL, 2014, J NEUROTRAUM, V31, P1211, DOI 10.1089/neu.2013.3255; Pun Pamela B L, 2011, Front Neurol, V2, P19, DOI 10.3389/fneur.2011.00019; Pun PBL, 2009, FREE RADICAL RES, V43, P348, DOI 10.1080/10715760902751902; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Reddy MK, 2008, APPL BIOCHEM BIOTECH, V151, P565, DOI 10.1007/s12010-008-8232-1; Reddy MK, 2009, FASEB J, V23, P1384, DOI 10.1096/fj.08-116947; Risdall JE, 2011, PHILOS T R SOC B, V366, P241, DOI 10.1098/rstb.2010.0230; Risling M, 2011, NEUROIMAGE, V54, pS89, DOI 10.1016/j.neuroimage.2010.05.031; Rosenfeld JV, 2013, LANCET NEUROL, V12, P882, DOI 10.1016/S1474-4422(13)70161-3; Shetty AK, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00232; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Singhal A, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.362; Stuhmiller JH, 2008, MILITARY QUANTITATIV, P267; Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Turner RC, 2013, EXP NEUROL, V248, P520, DOI 10.1016/j.expneurol.2013.07.008; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Wang Y, 2011, J NEUROTRAUM, V28, P2171, DOI 10.1089/neu.2011.1990; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yeoh S, 2013, ANN BIOMED ENG, V41, P2206, DOI 10.1007/s10439-013-0805-7	64	42	44	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 29	2015	10	5							e0127971	10.1371/journal.pone.0127971			19	Multidisciplinary Sciences	Science & Technology - Other Topics	CJ2MQ	WOS:000355319400062	26024446	DOAJ Gold, Green Published			2021-06-18	
J	Lawrence, DW; Hutchison, MG; Comper, P				Lawrence, David W.; Hutchison, Michael G.; Comper, Paul			Descriptive Epidemiology of Musculoskeletal Injuries and Concussions in the National Football League, 2012-2014	ORTHOPAEDIC JOURNAL OF SPORTS MEDICINE			English	Article						National Football League (NFL); concussion; epidemiology; injury	CHRONIC TRAUMATIC ENCEPHALOPATHY; UPPER EXTREMITY INJURIES; PROFESSIONAL FOOTBALL; BRAIN-INJURY; ICE HOCKEY; PART I; PLAYERS; COLLEGIATE; SPORTS	Background: The risk of all-cause injury and concussion associated with football is significant. The National Football League (NFL) has implemented changes to increase player safety warranting investigation into the incidence and patterns of injury. Purpose: To document the incidence and patterns of all-cause injury and concussions in the NFL. Study Design: Descriptive epidemiology study. Methods: Injury data were collected prospectively from official NFL injury reports over 2 regular seasons from 2012 to 2014, with identification of injury incidence rates and patterns. Concussion rate ratios were calculated using previously reported NFL rates. Results: A total of 4284 injuries were identified, including 301 concussions. The all-cause injury rate was 395.8 per 1000 athletes at risk (AAR) and concussion incidence was 27.8 per 1000 AAR. Only 2.3% of team games were injury free. Wide receivers, tight ends, and defensive backs had the highest incidence of injury and concussion. Concussion incidence was 1.61-fold higher in 2012 to 2014 compared with 2002 to 2007. The knee was injured most frequently, followed by the ankle, hamstring, shoulder, and head. Conclusion: The incidence of all-cause injury and concussion in the NFL is significant. Concussion injury rates are higher than previous reports, potentially reflecting an improvement in recognition and awareness. Injury prevention efforts should continue to reduce the prevalence of injury associated with football.	[Lawrence, David W.; Hutchison, Michael G.; Comper, Paul] Univ Toronto, Toronto, ON, Canada	Lawrence, DW (corresponding author), St Michaels Hosp, Dept Family & Community Med, 30 Bond St, Toronto, ON M5B 1W8, Canada.	dw.lawrence@mail.utoronto.ca					[Anonymous], INJ REP; [Anonymous], ASS PRESS; Anzell AR, 2013, J STRENGTH COND RES, V27, P277, DOI 10.1519/JSC.0b013e31827f4c08; Archer T, SOURCES ROMO TORE RI; Barzilai P, KNEE INJURIES WORRY; Boublik M, 2013, AM J SPORT MED, V41, P1841, DOI 10.1177/0363546513490655; Brooks JHM, 2005, BRIT J SPORT MED, V39, P757, DOI 10.1136/bjsm.2005.018135; Carlisle JC, 2008, AM J SPORT MED, V36, P1945, DOI 10.1177/0363546508318198; Casson IR, 2010, SPORTS HEALTH, V2, P471, DOI 10.1177/1941738110383963; CBS Sports, NFL INJ; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Dick R, 2007, J ATHL TRAINING, V42, P221; Ekstrand J, 2011, BRIT J SPORT MED, V45, P553, DOI 10.1136/bjsm.2009.060582; Elliott MCCW, 2011, AM J SPORT MED, V39, P843, DOI 10.1177/0363546510394647; Feeley BT, 2008, AM J SPORT MED, V36, P2187, DOI 10.1177/0363546508319898; Feeley BT, 2008, AM J SPORT MED, V36, P1597, DOI 10.1177/0363546508316021; Fuller CW, 2006, BRIT J SPORT MED, V40, P193, DOI 10.1136/bjsm.2005.025270; Gissane C, 2002, SPORTS MED, V32, P211, DOI 10.2165/00007256-200232030-00004; Goldberg DS, 2013, J LEGAL MED, V34, P157, DOI 10.1080/01947648.2013.800792; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Hutchison MG, 2015, BRIT J SPORT MED, V49, P547, DOI 10.1136/bjsports-2013-092234; King H, 2014, J PHYS ACT IN PRESS; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Lindenfeld T N, 1988, Am J Sports Med, V16 Suppl 1, pS69; Lynch TS, 2013, AM J SPORT MED, V41, P2904, DOI 10.1177/0363546513504284; Mall NA, 2008, AM J SPORT MED, V36, P1938, DOI 10.1177/0363546508318197; McKay CD, 2014, BRIT J SPORT MED, V48, P57, DOI 10.1136/bjsports-2013-092860; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; National Collegiate Athletic Association, NAT FED HIGH SCH NCA; National Football League, 2014, NFL RET PLAY PROT; National Football League Head Neck and Spine Committee, NAT FOOTB LEAG HEAD; Osbahr DC, 2013, ORTHOPEDICS, V36, pE1378, DOI 10.3928/01477447-20131021-18; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Stovitz SD, 2012, BRIT J SPORT MED, V46, P960, DOI 10.1136/bjsports-2011-090693; Tuominen M, 2015, BRIT J SPORT MED, V49, P30, DOI 10.1136/bjsports-2014-093688	37	42	42	0	9	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	2325-9671			ORTHOP J SPORTS MED	Orthop. J. Sports Med.	MAY	2015	3	5							2325967115583653	10.1177/2325967115583653			7	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	DE1IT	WOS:000370381200004	26675321	DOAJ Gold, Green Published			2021-06-18	
J	Montenigro, PH; Bernick, C; Cantu, RC				Montenigro, Philip H.; Bernick, Charles; Cantu, Robert C.			Clinical Features of Repetitive Traumatic Brain Injury and Chronic Traumatic Encephalopathy	BRAIN PATHOLOGY			English	Article						chronic traumatic encephalopathy; concussion; mild traumatic brain injury; football; boxing; neuropathology	PROFESSIONAL FOOTBALL PLAYERS; NATIONAL INSTITUTE; LEAGUE PLAYERS; HEAD-INJURIES; WHITE-MATTER; CONCUSSION; DEMENTIA; SPECTRUM; DISEASE; BOXERS	Chronic traumatic encephalopathy (CTE) is a neurodegenerative disease characterized by a distinct pattern of hyperphosphorylated tau (p-tau). Thought to be caused by repetitive concussive and subconcussive injuries, CTE is considered largely preventable. The majority of neuropathologically confirmed cases have occurred in professional contact sport athletes (eg, boxing, football). A recent post-mortem case series has magnified concerns for the public's health following its identification in six high school level athletes. CTE is diagnosed with certainty only following a post-mortem autopsy. Efforts to define the etiology and clinical progression during life are ongoing. The goal of this article is to characterize the clinical concepts associated with short- and long-term effects of repetitive traumatic brain injury, with a special emphasis on new clinical diagnostic criteria for CTE. Utilizing these new diagnostic criteria, two cases of neuropathologically confirmed CTE, one in a professional football player and one in a professional boxer, are reported. Differences in cerebellar pathology in CTE confirmed cases in boxing and football are discussed.	[Montenigro, Philip H.; Cantu, Robert C.] Boston Univ, Sch Med, Chron Traumat Encephalopathy Ctr, Boston, MA 02118 USA; [Montenigro, Philip H.] Boston Univ, Sch Med, Dept Anat & Neurobiol, Boston, MA 02118 USA; [Cantu, Robert C.] Boston Univ, Sch Med, Dept Neurol & Neurosurg, Boston, MA 02118 USA; [Cantu, Robert C.] Emerson Hosp, Dept Neurosurg, Concord, MA 01742 USA; [Bernick, Charles] Cleveland Clin, Lou Ruvo Ctr Brain Hlth, Las Vegas, NV USA; [Cantu, Robert C.] Sports Legacy Inst, Waltham, MA USA	Cantu, RC (corresponding author), Emerson Hosp, John Cuming Bldg,Suite 820, Concord, MA 01742 USA.	rcantu@emersonhosp.org		Montenigro, Philip/0000-0003-4442-9207	Top Rank Promotions; Golden Boy Promotions; Bellator/Spike TV; Zuffa	P. Montenigro reports no disclosures. C. Bernick receives research support for the Professional Fighters Brain Health study from Top Rank Promotions, Golden Boy Promotions, Bellator/Spike TV, Zuffa. R. Cantu receives compensation from the National Football League as Senior Advisor to the Head Neck and Spine Committee, from the National Operating Committee on Safety of Athletic Equipment as Chairman of the Scientific Advisory Committee and from Sports Legacy Institute as co-founder and Medical Director for some talks given and research conducted. He receives royalties from Houghton Mifflin Harcourt and compensation from expert legal opinion.	Amen DG, 2011, J PSYCHOACTIVE DRUGS, V43, P1, DOI 10.1080/02791072.2011.566489; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Baugh CM, 2015, J NEUROTRAUM, V32, P314, DOI 10.1089/neu.2014.3582; Baugh CM, 2014, CURR TREAT OPTION NE, V16, DOI 10.1007/s11940-014-0306-5; Bernick C, 2013, ALZHEIMERS RES THER, V5, DOI 10.1186/alzrt177; Bernick C, 2013, AM J EPIDEMIOL, V178, P280, DOI 10.1093/aje/kws456; BETTI O O, 1969, Acta Neurologica Latinoamericana, V15, P47; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Boden BP, 2007, AM J SPORT MED, V35, P1075, DOI 10.1177/0363546507299239; BRANDENBURG W, 1954, Virchows Arch Pathol Anat Physiol Klin Med, V325, P680, DOI 10.1007/BF00955101; Brown LM, 2005, INT J GERIATR PSYCH, V20, P911, DOI 10.1002/gps.1375; Cantu R., 2012, CONCUSSIONS OUR KIDS; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; Cantu RC, 2000, NEUROLOGIC ATHLETIC, P2; Cantu RC, 2006, NEUROSURG FOCUS, V21, P1, DOI [DOI 10.3171/FOC.2006.21.4.4, 10.3171/foc.2006.21.4.4]; Cantu RC, 2013, JAMA NEUROL, V70, P1481, DOI 10.1001/jamaneurol.2013.3231; Cantu RC, 2013, WORLD NEUROSURG, V80, P792, DOI 10.1016/j.wneu.2013.10.011; Cantu RC, 2010, PM&R, V2, P1088, DOI 10.1016/j.pmrj.2010.07.483; CASSON IR, 1982, J NEUROL NEUROSUR PS, V45, P170, DOI 10.1136/jnnp.45.2.170; Constantinidis J, 1967, Schweiz Arch Neurol Neurochir Psychiatr, V100, P117; Cordeiro Q, 2001, ARQ NEURO-PSIQUIAT, V59, P283, DOI 10.1590/S0004-282X2001000200029; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P315, DOI 10.1097/01.HTR.0000300226.67748.3e; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; CRITCHLEY M, 1957, BMJ-BRIT MED J, V1, P357, DOI 10.1136/bmj.1.5015.357; Critchley M., 1949, NEUROCHIRURG HOMMAGE, P131; Crook T, 1983, ASSESSMENT GERIATRIC; Galvin JE, 2005, NEUROLOGY, V65, P559, DOI 10.1212/01.wnl.0000172958.95282.2a; Gardner A, 2014, BRIT J SPORT MED, V48, P84, DOI 10.1136/bjsports-2013-092646; Giza CC, 2005, BEHAV BRAIN RES, V157, P11, DOI 10.1016/j.bbr.2004.06.003; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; GRAHMANN H, 1957, Psychiatr Neurol (Basel), V134, P261; Grinnon ST, 2012, CLIN TRIALS, V9, P322, DOI 10.1177/1740774512438980; Handratta V, 2010, NEUROCASE, V16, P125, DOI 10.1080/13554790903329166; HARVEY PKP, 1974, LANCET, V2, P928; Hazrati LN, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00222; Jayarao M, 2010, PHYSICIAN SPORTSMED, V38, P18, DOI 10.3810/psm.2010.10.1804; JEDLINSKI J, 1971, Acta Medica Polona, V12, P443; Jordan BD, 2013, NAT REV NEUROL, V9, P222, DOI 10.1038/nrneurol.2013.33; JORDAN BD, 1987, ARCH NEUROL-CHICAGO, V44, P453, DOI 10.1001/archneur.1987.00520160083020; Jordan BD, 1998, NEUROBIOLOGY OF PRIMARY DEMENTIA, P191; Jordan BD, 2000, SEMIN NEUROL, V20, P179, DOI 10.1055/s-2000-9826; Jordan BD, 1992, MED ASPECTS BOXING, P150; Kerr ZY, 2012, MED SCI SPORT EXER, V44, P377, DOI 10.1249/MSS.0b013e31823240f2; Koerte IK, 2015, BRAIN PATHOL, V25, P318, DOI 10.1111/bpa.12249; Koerte IK, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12303; La Cava G, 1952, DTSCH SPORTEIRZTE K, V79, P817; Lehman EJ, 2013, ALZHEIMERS RES THER, V5, DOI 10.1186/alzrt188; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; Levin B, 2014, NEUROCRIT CARE, V20, P334, DOI 10.1007/s12028-013-9931-1; Marchi N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056805; Margulies SS, 2015, BRAIN PATHOL, V25, P289, DOI 10.1111/bpa.12247; McCrory P, 2013, BRIT J SPORT MED, V47, P327, DOI 10.1136/bjsports-2013-092248; McKee AC, 2015, BRAIN PATHOL, V25, P350, DOI 10.1111/bpa.12248; McKee AC, 2014, ACTA NEUROPATHOL, V127, P29, DOI 10.1007/s00401-013-1230-6; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; MENDEZ MF, 1995, INT J PSYCHIAT MED, V25, P249, DOI 10.2190/CUMK-THT1-X98M-WB4C; MEYERS KR, 1974, ARCH NEUROL-CHICAGO, V30, P84, DOI 10.1001/archneur.1974.00490310086013; Mez J, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-013-0407-7; Mitsis EM, 2014, TRANSL PSYCHIAT, V4, DOI 10.1038/tp.2014.91; Montenigro PH, 2015, ANNU REV CLIN PSYCHO, V11, P309, DOI 10.1146/annurev-clinpsy-032814-112814; Montenigro PH, 2014, NEUROLOGY, V83, P1992; Montenigro PH, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/s13195-014-0068-z; Ng TSC, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt239; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Otero Siliceo E, 2004, ARCH NEUROCIENC, V9, P114; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Petraglia AL, 2012, NEUROSURGERY, V70, P1520, DOI 10.1227/NEU.0b013e31824cebe8; PFEFFER RI, 1982, J GERONTOL, V37, P323, DOI 10.1093/geronj/37.3.323; Robbins CA, 2014, OPEN ACCESS J SPORTS, V5, P99, DOI 10.2147/OAJSM.S58005; Roberts A, 1969, BRIAN DAMAGE BOXERS; ROSS RJ, 1983, JAMA-J AM MED ASSOC, V249, P211, DOI 10.1001/jama.249.2.211; Sayed N, 2013, J NEUROTRAUM, V30, P1117, DOI 10.1089/neu.2012.2638; Seichepine DR, 2013, J NEUROTRAUM, V30, P1299, DOI 10.1089/neu.2012.2690; Shin W, 2014, AM J NEURORADIOL, V35, P285, DOI 10.3174/ajnr.A3676; Sim A, 2008, J NEUROSURG, V108, P511, DOI 10.3171/JNS/2008/108/3/0511; Singh R, 2014, JAMA-J AM MED ASSOC, V311, P1883, DOI 10.1001/jama.2014.3313; Sinnott RA, 2012, J INT SOC SPORTS S1, V9, pP28; Slobounov S, 2014, BRIT J SPORT MED, V48, P75, DOI 10.1136/bjsports-2013-092362; Small GW, 2013, AM J GERIAT PSYCHIAT, V21, P138, DOI 10.1016/j.jagp.2012.11.019; Smith C, 2015, BRAIN PATHOL, V25, P287, DOI 10.1111/bpa.12251; Sperling RA, 2011, ALZHEIMERS DEMENT, V7, P280, DOI 10.1016/j.jalz.2011.03.003; Spitznagel MB, 2005, ARCH CLIN NEUROPSYCH, V20, P505, DOI 10.1016/j.acn.2004.11.003; Stein TD, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt234; Stern RA, 2015, NEUROLOGY, V85, P1008; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; THORNDIKE A, 1952, NEW ENGL J MED, V247, P554, DOI 10.1056/NEJM195210092471504; Tremblay S, 2014, BRAIN, V137, P2997, DOI 10.1093/brain/awu236; UHL GR, 1982, ANN NEUROL, V12, P99; Viano DC, 2005, NEUROSURGERY, V57, P1154, DOI 10.1227/01.NEU.0000187541.87937.D9; Victoroff J, 2013, NEUROREHABILITATION, V32, P211, DOI 10.3233/NRE-130839; Weir Dr, 2009, NATL FOOTBALL LEAGUE; World Health Organization, 1992, ICD 10 CLASS MENT BE	97	42	43	1	28	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1015-6305	1750-3639		BRAIN PATHOL	Brain Pathol.	MAY	2015	25	3					304	317		10.1111/bpa.12250			14	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	CG6CX	WOS:000353384200008	25904046				2021-06-18	
J	King, D; Gissane, C; Hume, PA; Flaws, M				King, D.; Gissane, C.; Hume, P. A.; Flaws, M.			The King-Devick test was useful in management of concussion in amateur rugby union and rugby league in New Zealand	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article						Brain injury; Sport-related concussion; King-Devick; SCAT3; Vision; Saccadic	SPORTS-RELATED CONCUSSION; VISUAL SCREENING TOOL; STATEMENT; SACCADES	Aim: To use the King-Devick (K-D) test in senior amateur rugby union and rugby league players over a domestic competition season to see if it could identify witnessed and unwitnessed episodes of concussion that occurred from participation in competition matches over three years. Methods: A prospective observational cohort study was conducted on a club level senior amateur rugby union team (n = 36 players in 2012 and 35 players in 2013) and a rugby league team (n = 33 players in 2014) during competition seasons in New Zealand. All 104 players completed two trials 10 min apart of the K-D at the beginning of their competition season. Concussions (witnessed or unwitnessed) were only recorded if they were formally diagnosed by a health practitioner. Results: A total of 52 (8 witnessed; 44 unwitnessed) concussive events were identified over the duration of the study resulting in a concussion injury incidence of 44 (95% CI: 32 to 56) per 1000 match participation hours. There was a six-fold difference between witnessed and unwitnessed concussions recorded. There were observable learning effects observed between the first and the second K-D test baseline testing (50 vs. 45 s; z = -8.81; p < 0.001). For every 1 point reduction in each of the post-injury SAC components there was a corresponding increase (worsening) of K-D test times post-match for changes in orientation (2.9 s), immediate memory (1.8 s) concentration (2.8 s), delayed recall (2.0 s) and SAC total score (1.7 s). Discussion: The rate of undetected concussion was higher than detected concussions by using the K-D test routinely following matches. Worsening of the K-D test post-match was associated with reduction in components of the SAC. The appeal of the K-D test is in the rapid, easy manner of its administration and the reliable, objective results it provides to the administrator. The K-D test helped identify cognitive impairment in players without clinically observable symptoms. (C) 2015 Elsevier B.V. All rights reserved.	[King, D.; Hume, P. A.] Auckland Univ Technol, Fac Hlth & Environm Sci, Sports Performance Res Inst New Zealand, Auckland, New Zealand; [Gissane, C.] St Marys Univ, Sch Sport Hlth & Appl Sci, Twickenham, Middx, England; [Flaws, M.] Hutt Valley Dist Hlth Board, Emergency Dept, Lower Hutt, New Zealand	King, D (corresponding author), Hutt Valley Dist Hlth Board, Emergency Dept, Private Bag 31-907, Lower Hutt, New Zealand.	dking@aut.ac.nz	Gissane, Conor/I-3661-2019; Hume, Patria/AAN-5514-2021	Gissane, Conor/0000-0003-4677-3853; Hume, Patria/0000-0003-1847-8128			ALTMAN DG, 1994, BRIT MED J, V308, P1552, DOI 10.1136/bmj.308.6943.1552; Austin D, 2011, J SCI MED SPORT, V14, P259, DOI 10.1016/j.jsams.2011.01.003; Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Brooks JHM, 2008, CLIN SPORT MED, V27, P51, DOI 10.1016/j.csm.2007.09.001; Ciuffreda Kenneth J, 2007, Optometry, V78, P155, DOI 10.1016/j.optm.2006.11.011; Davies EC, 2012, NEUROLOGY, V78, pE103, DOI 10.1212/WNL.0b013e318251833d; DeSouza JFX, 2003, J NEUROPHYSIOL, V89, P1016, DOI 10.1152/jn.00562.2002; Dhawan PSA, 2014, NEUROL CLIN PRACT, V82, pS11; Dziemianowicz MS, 2012, CURR NEUROL NEUROSCI, V12, P547, DOI 10.1007/s11910-012-0299-y; Eckner JT, 2010, CURR SPORT MED REP, V9, P8, DOI 10.1249/JSR.0b013e3181caa778; Galetta KM, 2011, NEUROLOGY, V76, P1456, DOI 10.1212/WNL.0b013e31821184c9; Galetta KM, 2011, J NEUROL SCI, V309, P34, DOI 10.1016/j.jns.2011.07.039; Galetta MS, 2013, J NEUROL SCI, V328, P28, DOI 10.1016/j.jns.2013.02.008; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Goodrich GL, 2013, OPTOMETRY VISION SCI, V90, P105, DOI 10.1097/OPX.0b013e31827f15a1; Guskiewicz KM, 2013, BRIT J SPORT MED, V47, P289, DOI 10.1136/bjsports-2013-092225; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Heitger M., 2008, C P IEEE ENG MED BIO; Heitger MH, 2002, PROG BRAIN RES, V140, P433; Hunt TN, 2009, CLIN J SPORT MED, V19, P471, DOI 10.1097/JSM.0b013e3181c12c7b; King D, 2013, J NEUROL SCI, V326, P59, DOI 10.1016/j.jns.2013.01.012; King D, 2012, J NEUROL SCI, V320, P16, DOI 10.1016/j.jns.2012.05.049; Koh JO, 2003, BRAIN INJURY, V17, P901, DOI 10.1080/0269905031000088869; Krumholtz I, 2000, Optometry, V71, P426; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Leong DF, 2014, J SPORT MED PHYS FIT, V54, P70; Lin TP, 2014, PARKINSONISM RELAT D, V20, P226, DOI 10.1016/j.parkreldis.2013.10.009; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; Marinides Z, 2014, NEUROL CLIN PRACT; Martini D, 2013, MED SCI SPORT EXER, V45, P755, DOI 10.1249/MSS.0b013e3182798758; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2001, CLIN J SPORT MED, V11, P176, DOI 10.1097/00042752-200107000-00008; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McLeod TCV, 2004, CLIN J SPORT MED, V14, P287, DOI 10.1097/00042752-200409000-00007; Spradley B, 2014, SPORT J         0314; Stepanek J, 2014, AVIAT SPACE ENVIR MD, V85, P700, DOI 10.3357/ASEM.3645.2014; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Tjarks BJ, 2013, J NEUROL SCI, V334, P148, DOI 10.1016/j.jns.2013.08.015; Vartiainen MV, 2014, SCAND J MED SCI SPOR	39	42	42	1	31	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0022-510X	1878-5883		J NEUROL SCI	J. Neurol. Sci.	APR 15	2015	351	1-2					58	64		10.1016/j.jns.2015.02.035			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	CH0UP	WOS:000353738200012	25748294				2021-06-18	
J	Turner, CE; Barker-Collo, SL; Connell, CJW; Gant, N				Turner, Clare E.; Barker-Collo, Suzanne L.; Connell, Charlotte J. W.; Gant, Nicholas			Acute hypoxic gas breathing severely impairs cognition and task learning in humans	PHYSIOLOGY & BEHAVIOR			English	Article						Oxygen deprivation; Neurocognition; Learning effects; High-altitude; Hypoxic emergencies; Mild traumatic brain injury	FRONTAL-SUBCORTICAL CIRCUITS; TRAUMATIC BRAIN-INJURY; CEREBRAL-BLOOD-FLOW; ATTENTION SYSTEM; ADULT SURVIVORS; MECHANISMS; VULNERABILITY; PROFILES; SEQUELAE; BATTERY	Impairments in neural function are common when oxygen supply to the brain is reduced. This study examined neurocognitive processes that are vulnerable to oxygen deprivation. We induced moderate-to-severe hypoxia in healthy adults, thereby inducing impairments caused by low brain oxygen availability. 22 healthy adults participated in this matched-pairs study with a single-blind, randomised design. Baseline neurocognitive function was examined during a familiarisation trial and participants were assigned to hypoxia (10% O-2) or sham (21% O-2) groups. Neurocognitive performance was assessed via computerised test battery after 50 min of breathing a gas mixture that reduced arterial oxygen saturation by 20% (p < 0.01). Hypoxia severely reduced performance across all neurocognitive domain scores; with significant drops in neurocognitive index (-20%), composite memory (-30%), verbal memory (-34%), visual memory (-23%), processing speed (-36%), executive function (-20%), psychomotor speed (-24%), reaction time (-10%), complex attention (-19%) and cognitive flexibility (-18%; all p < 0.05). Practice effects were blocked by hypoxia but occurred in sham for information processing speed ( +30%), executive function (+14%), psychomotor speed (+18%), reaction time (+5%), cognitive flexibility (+14%), and overall cognitive functioning (+9%; all p < 0.05). Neuropsychological performance decrements caused by acute experimental hypoxia are comparable to cognitive domains impaired with high altitude exposure and mild traumatic brain injury. (C) 2015 Elsevier Inc. All rights reserved.	[Turner, Clare E.; Connell, Charlotte J. W.; Gant, Nicholas] Univ Auckland, Ctr Brain Res, Exercise Neurometab Lab, Auckland 1142, New Zealand; [Barker-Collo, Suzanne L.] Univ Auckland, Ctr Brain Res, Sch Psychol, Auckland 1142, New Zealand	Gant, N (corresponding author), Univ Auckland, Ctr Brain Res, Exercise Neurometab Lab, Private Bag 92019, Auckland 1142, New Zealand.	n.gant@auckland.ac.nz		Turner, Clare/0000-0002-1245-0741	University of Auckland	We thank Jhordaine Charlton for data collection and Simon Mitchell for assistance with protocol safety. We are grateful for the support of Andrew Simpson in formulating compressed gas mixtures. This study was funded by the University of Auckland. The authors have no conflicts of interest to declare.	AITKEN PG, 1986, NEUROSCI LETT, V67, P92, DOI 10.1016/0304-3940(86)90215-6; Anderson CA, 2010, NEUROREHABILITATION, V26, P47, DOI 10.3233/NRE-2010-0535; Arciniegas David B, 2005, Neuropsychiatr Dis Treat, V1, P311; Armengol CG, 2000, BRAIN INJURY, V14, P237, DOI 10.1080/026990500120718; Arnsten AFT, 2012, J AM ACAD CHILD PSY, V51, P356, DOI 10.1016/j.jaac.2012.01.008; Beglinger LJ, 2005, ARCH CLIN NEUROPSYCH, V20, P517, DOI 10.1016/j.acn.2004.12.003; Bjursten H, 2010, HIGH ALT MED BIOL, V11, P31, DOI 10.1089/ham.2009.1041; Bonelli Raphael M, 2007, Dialogues Clin Neurosci, V9, P141; Bressler SL, 2008, J NEUROSCI, V28, P10056, DOI 10.1523/JNEUROSCI.1776-08.2008; Buckner RL, 2001, NAT REV NEUROSCI, V2, P624, DOI 10.1038/35090048; Collie A, 2003, J INT NEUROPSYCH SOC, V9, P419, DOI 10.1017/S1355617703930074; CUMMINGS JL, 1993, ARCH NEUROL-CHICAGO, V50, P873, DOI 10.1001/archneur.1993.00540080076020; Debette S, 2002, J NEUROL, V249, P1678, DOI 10.1007/s00415-002-0903-1; Elman I, 1999, BRAIN RES, V815, P243, DOI 10.1016/S0006-8993(98)01137-8; Falleti MG, 2006, J CLIN EXP NEUROPSYC, V28, P1095, DOI 10.1080/13803390500205718; Fleminger S, 2005, BRIT MED J, V331, P1419, DOI 10.1136/bmj.331.7530.1419; Gale SD, 1999, BRAIN INJURY, V13, P229, DOI 10.1080/026990599121601; GRAFTON ST, 1992, J NEUROSCI, V12, P2542; Greer DM, 2006, SEMIN NEUROL, V26, P373, DOI 10.1055/s-2006-948317; Gualtieri CT, 2006, ARCH CLIN NEUROPSYCH, V21, P623, DOI 10.1016/j.acn.2006.05.007; HONIGMAN B, 1993, ANN INTERN MED, V118, P587, DOI 10.7326/0003-4819-118-8-199304150-00003; Hopkins R O, 1995, J Int Neuropsychol Soc, V1, P501; Hopkins RO, 2005, NEUROPSYCHOLOGY, V19, P233, DOI 10.1037/0894-4105.19.2.233; Immink RV, 2014, J APPL PHYSIOL, V116, P844, DOI 10.1152/japplphysiol.00637.2013; Kastner S, 2000, ANNU REV NEUROSCI, V23, P315, DOI 10.1146/annurev.neuro.23.1.315; Keys BA, 2000, J INT NEUROPSYCH SOC, V6, P76, DOI 10.1017/S1355617700611098; Lemos VD, 2012, PSYCHOPHYSIOLOGY, V49, P1298, DOI 10.1111/j.1469-8986.2012.01411.x; Lim C, 2004, NEUROLOGY, V63, P1774, DOI 10.1212/01.WNL.0000144189.83077.8E; Masterman DL, 1997, J PSYCHOPHARMACOL, V11, P107, DOI 10.1177/026988119701100203; MCCAFFREY RJ, 1993, ARCH CLIN NEUROPSYCH, V8, P519; MCFARLAND RA, 1963, ERGONOMICS, V6, P295; MCFARLAND RA, 1972, PHYSL ADAPTATIONS DE, P157; Miyashita Y, 2004, SCIENCE, V306, P435, DOI 10.1126/science.1101864; Neumar RW, 2000, ANN EMERG MED, V36, P483, DOI 10.1067/mem.2000.110995; Peskine A, 2004, BRAIN INJURY, V18, P1243, DOI 10.1080/02699050410001719899; Peskine A, 2010, BRAIN INJURY, V24, P755, DOI 10.3109/02699051003709581; Petersen SE, 2012, ANNU REV NEUROSCI, V35, P73, DOI 10.1146/annurev-neuro-062111-150525; PHELPS ME, 1985, SCIENCE, V228, P799, DOI 10.1126/science.2860723; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; Rossi AF, 2009, EXP BRAIN RES, V192, P489, DOI 10.1007/s00221-008-1642-z; SAMPSON JB, 1994, MIL PSYCHOL, V6, P215, DOI DOI 10.1207/S15327876MP0604_2; Sauve MJ, 1996, HEART LUNG, V25, P172, DOI 10.1016/S0147-9563(96)80027-6; SCHMIDTKASTNER R, 1991, NEUROSCIENCE, V40, P599, DOI 10.1016/0306-4522(91)90001-5; Schneider S, 2009, BEHAV BRAIN RES, V197, P476, DOI 10.1016/j.bbr.2008.10.020; Shetty PK, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00043; Squire RF, 2013, ANNU REV NEUROSCI, V36, P451, DOI 10.1146/annurev-neuro-062111-150439; Virues-Ortega Javier, 2004, Neuropsychology Review, V14, P197; Wilson BA, 1996, BRAIN INJURY, V10, P863, DOI 10.1080/026990596123846; Wilson FC, 2003, NEUROREHABILITATION, V18, P291; Zabel TA, 2005, CHILD NEUROPSYCHOL, V11, P373, DOI 10.1080/09297040490916965	50	42	47	2	20	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0031-9384			PHYSIOL BEHAV	Physiol. Behav.	APR 1	2015	142						104	110		10.1016/j.physbeh.2015.02.006			7	Psychology, Biological; Behavioral Sciences	Psychology; Behavioral Sciences	CE7TF	WOS:000352044000016	25660759				2021-06-18	
J	Wang, K; Zhang, L; Rao, W; Su, N; Hui, H; Wang, L; Peng, C; Tu, Y; Zhang, S; Fei, Z				Wang, Kai; Zhang, Lei; Rao, Wei; Su, Ning; Hui, Hao; Wang, Li; Peng, Cheng; Tu, Yue; Zhang, Sai; Fei, Zhou			Neuroprotective effects of crocin against traumatic brain injury in mice: Involvement of notch signaling pathway	NEUROSCIENCE LETTERS			English	Article						Traumatic brain injury; Crocin; Notch	CLOSED-HEAD INJURY; ACTIVATION; MICROGLIA; CYTOKINE; SAFFRON; MODEL	This study investigated the protective effects and mechanisms of crocin, an extract of saffron, on brain damage after traumatic brain injury (TBI) in mice. C57BL/6 mice were subjected to controlled cortical impact (CCI)-induced TBI. Pretreatment with crocin (20 mg/kg) had protective effects against TBI, demonstrated by improved neurological severity score (NSS) and brain edema, decreased microglial activation and release of several pro-inflammatory cytokines, and decreased cell apoptosis. TBI activated Notch signaling, as shown by upregulated levels of Notch intracellular domain (NICD) and Hes1 mRNA, and pretreatment with crocin further increased Notch activation. However, pretreatment with DAPT (100 mg/kg), a gamma-secretase inhibitor, significantly suppressed crocin-induced activation of Notch signaling and attenuated the ability of crocin to protect mice against TBI-induced inflammation and apoptosis. Therefore, these results suggest that crocin has neuroprotective effects against TBI in mice, and these effects are at least partially dependent on activation of Notch signaling. 2015 Elsevier Ireland Ltd. All rights reserved.	[Wang, Kai; Zhang, Lei; Rao, Wei; Su, Ning; Hui, Hao; Wang, Li; Peng, Cheng] Fourth Mil Med Univ, Xijing Hosp, Xijing Inst Clin Neurosci, Dept Neurosurg, Xian 710032, Shaanxi, Peoples R China; [Tu, Yue; Zhang, Sai] Affiliated Hosp Logist Univ Chinese Armed Police, Dept Neurosurg, Tianjin 300162, Peoples R China	Fei, Z (corresponding author), Fourth Mil Med Univ, Xijing Hosp, Xijing Inst Clin Neurosci, Dept Neurosurg, Xian 710032, Shaanxi, Peoples R China.	zhangsai718@vip.126.com; feizhou@fmmu.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81430043]; National Science and Technology Major Project of China [2013ZX 09J13109-02C]; National Science and Technology Pillar Program of China [2012BAI111302]; Science and Technology Project of Shanxi [2013KTCQ03-01]	The work was supported by National Natural Science Foundation of China (Nos. 81430043), National Science and Technology Major Project of China (2013ZX 09J13109-02C), National Science and Technology Pillar Program of China (No. 2012BAI111302), Science and Technology Project of Shanxi (No. 2013KTCQ03-01).	Arumugam TV, 2006, NAT MED, V12, P621, DOI 10.1038/nm1403; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; HATASHITA S, 1988, J CEREBR BLOOD F MET, V8, P552, DOI 10.1038/jcbfm.1988.96; Hosseinzadeh H, 2012, PHYTOTHER RES, V26, P381, DOI 10.1002/ptr.3566; Israelsson C, 2008, J NEUROTRAUM, V25, P959, DOI 10.1089/neu.2008.0562; Jones NC, 2005, EUR J NEUROSCI, V22, P72, DOI 10.1111/j.1460-9568.2005.04221.x; Kawabata K, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/820415; Kopan R, 2009, CELL, V137, P216, DOI 10.1016/j.cell.2009.03.045; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Nam KN, 2010, EUR J PHARMACOL, V648, P110, DOI 10.1016/j.ejphar.2010.09.003; Ochiai T, 2007, BBA-GEN SUBJECTS, V1770, P578, DOI 10.1016/j.bbagen.2006.11.012; Rajaei Z, 2013, J MED FOOD, V16, P206, DOI 10.1089/jmf.2012.2407; Rastgoo M, 2013, PLANTA MED, V79, P447, DOI 10.1055/s-0032-1328363; Rock RB, 2004, CLIN MICROBIOL REV, V17, P942, DOI 10.1128/CMR.17.4.942-964.2004; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Tamaddonfard E, 2013, PHARMACOL REP, V65, P1272, DOI 10.1016/S1734-1140(13)71485-3; Tatsumi K, 2010, J CHEM NEUROANAT, V39, P15, DOI 10.1016/j.jchemneu.2009.09.003; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Wang Y, 2009, CELL BIOL INT, V33, P1173, DOI 10.1016/j.cellbi.2009.08.004; Yang QZ, 2012, ANESTHESIOLOGY, V117, P996, DOI 10.1097/ALN.0b013e31826cb469; Zheng YQ, 2007, BRAIN RES, V1138, P86, DOI 10.1016/j.brainres.2006.12.064	24	42	43	0	23	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	MAR 30	2015	591						53	58		10.1016/j.neulet.2015.02.016			6	Neurosciences	Neurosciences & Neurology	CE4FO	WOS:000351786700011	25681620				2021-06-18	
J	Fagerholm, ED; Lorenz, R; Scott, G; Dinov, M; Hellyer, PJ; Mirzaei, N; Leeson, C; Carmichael, DW; Sharp, DJ; Shew, WL; Leech, R				Fagerholm, Erik D.; Lorenz, Romy; Scott, Gregory; Dinov, Martin; Hellyer, Peter J.; Mirzaei, Nazanin; Leeson, Clare; Carmichael, David W.; Sharp, David J.; Shew, Woodrow L.; Leech, Robert			Cascades and Cognitive State: Focused Attention Incurs Subcritical Dynamics	JOURNAL OF NEUROSCIENCE			English	Article						attention; criticality; EEG; fMRI; power law	POSTERIOR CINGULATE CORTEX; TRAUMATIC BRAIN-INJURY; DEFAULT MODE; NEURONAL AVALANCHES; SUSTAINED ATTENTION; CORTICAL NETWORKS; ELECTRODE SYSTEM; EEG; CRITICALITY; ROBUST	The analysis of neuronal avalanches supports the hypothesis that the human cortex operates with critical neural dynamics. Here, we investigate the relationship between cascades of activity in electroencephalogram data, cognitive state, and reaction time in humans using a multimodal approach. We recruited 18 healthy volunteers for the acquisition of simultaneous electroencephalogram and functional magnetic resonance imaging during both rest and during a visuomotor cognitive task. We compared distributions of electroencephalogram-derived cascades to reference power laws for task and rest conditions. We then explored the large-scale spatial correspondence of these cascades in the simultaneously acquired functional magnetic resonance imaging data. Furthermore, we investigated whether individual variability in reaction times is associated with the amount of deviation from power law form. We found that while resting state cascades are associated with approximate power law form, the task state is associated with subcritical dynamics. Furthermore, we found that electroencephalogram cascades are related to blood oxygen level-dependent activation, predominantly in sensorimotor brain regions. Finally, we found that decreased reaction times during the task condition are associated with increased proximity to power law form of cascade distributions. These findings suggest that the resting state is associated with near-critical dynamics, in which a high dynamic range and a large repertoire of brain states may be advantageous. In contrast, a focused cognitive task induces subcritical dynamics, which is associated with a lower dynamic range, which in turn may reduce elements of interference affecting task performance.	[Fagerholm, Erik D.; Lorenz, Romy; Scott, Gregory; Dinov, Martin; Hellyer, Peter J.; Mirzaei, Nazanin; Leeson, Clare; Sharp, David J.; Leech, Robert] Univ London Imperial Coll Sci Technol & Med, Computat Cognit & Clin Neuroimaging Lab, Ctr Neurosci, Div Brain Sci, London W12 0NN, England; [Carmichael, David W.] UCL Inst Child Hlth, Imaging & Biophys, London WC1N 1EH, England; [Shew, Woodrow L.] Univ Arkansas, Dept Phys, Fayetteville, AR 72701 USA	Fagerholm, ED (corresponding author), Univ London Imperial Coll Sci Technol & Med, Computat Cognit & Clin Neuroimaging Lab, Ctr Neurosci, Div Brain Sci, Hammersmith Hosp Campus,Du Cane Rd, London W12 0NN, England.	e.fagerholm03@imperial.ac.uk	Leech, Robert/AAE-8254-2019; Sharp, David J/A-2119-2013; Carmichael, David W/A-5391-2009; Hellyer, Peter J/F-7112-2013	Leech, Robert/0000-0002-5801-6318; Carmichael, David W/0000-0001-9972-0718; Hellyer, Peter J/0000-0002-5139-3401; Lorenz, Romy/0000-0002-7742-3162; Scott, Gregory/0000-0001-8063-5871	Medical Research Council (MRC)UK Research & Innovation (UKRI)Medical Research Council UK (MRC); Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [1110783] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NIHR-RP-011-048] Funding Source: researchfish	This work was supported by the Medical Research Council (MRC). We thank the subjects who took part in this study.	Aarts E, 2014, NAT NEUROSCI, V17, P491, DOI 10.1038/nn.3648; Allen PJ, 1998, NEUROIMAGE, V8, P229, DOI 10.1006/nimg.1998.0361; Allen PJ, 2000, NEUROIMAGE, V12, P230, DOI 10.1006/nimg.2000.0599; BAK P, 1988, PHYS REV A, V38, P364, DOI 10.1103/PhysRevA.38.364; Beggs JM, 2003, J NEUROSCI, V23, P11167; Beggs JM, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00163; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; CHATRIAN GE, 1988, J CLIN NEUROPHYSIOL, V5, P183, DOI 10.1097/00004691-198804000-00005; Churchland MM, 2010, NAT NEUROSCI, V13, P369, DOI 10.1038/nn.2501; Clauset A, 2009, SIAM REV, V51, P661, DOI 10.1137/070710111; Cocchi L, 2013, TRENDS COGN SCI, V17, P493, DOI 10.1016/j.tics.2013.08.006; Deco G, 2009, P NATL ACAD SCI USA, V106, P10302, DOI 10.1073/pnas.0901831106; Delorme A, 2004, J NEUROSCI METH, V134, P9, DOI 10.1016/j.jneumeth.2003.10.009; Eichele H, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/fnhum.2010.00065; Esterman M, 2014, J NEUROSCI, V34, P1724, DOI 10.1523/JNEUROSCI.2658-13.2014; Esterman M, 2013, CEREB CORTEX, V23, P2712, DOI 10.1093/cercor/bhs261; Friedman N, 2012, PHYS REV LETT, V108, DOI 10.1103/PhysRevLett.108.208102; Greve DN, 2009, NEUROIMAGE, V48, P63, DOI 10.1016/j.neuroimage.2009.06.060; Gutberlet Ingmar, 2009, P23; Haldeman C, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.058101; He BYJ, 2014, TRENDS COGN SCI, V18, P480, DOI 10.1016/j.tics.2014.04.003; He BJ, 2013, J NEUROSCI, V33, P4672, DOI 10.1523/JNEUROSCI.2922-12.2013; Hellyer PJ, 2014, J NEUROSCI, V34, P451, DOI 10.1523/JNEUROSCI.1853-13.2014; Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132; Jenkinson M, 2001, MED IMAGE ANAL, V5, P143, DOI 10.1016/S1361-8415(01)00036-6; Kinouchi O, 2006, NAT PHYS, V2, P348, DOI 10.1038/nphys289; Klem G H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P3; Larremore DB, 2011, PHYS REV LETT, V106, DOI 10.1103/PhysRevLett.106.058101; Leech R, 2014, BRAIN, V137, P12, DOI 10.1093/brain/awt162; Leech R, 2012, J NEUROSCI, V32, P215, DOI 10.1523/JNEUROSCI.3689-11.2012; Meisel C, 2013, J NEUROSCI, V33, P17363, DOI 10.1523/JNEUROSCI.1516-13.2013; Oostenveld R, 2001, CLIN NEUROPHYSIOL, V112, P713, DOI 10.1016/S1388-2457(00)00527-7; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Rorden C, 2000, BEHAV NEUROL, V12, P191, DOI 10.1155/2000/421719; Scott G, 2014, J NEUROSCI, V34, P16611, DOI 10.1523/JNEUROSCI.3474-14.2014; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Shew WL, 2013, NEUROSCIENTIST, V19, P88, DOI 10.1177/1073858412445487; Shew WL, 2009, J NEUROSCI, V29, P15595, DOI 10.1523/JNEUROSCI.3864-09.2009; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Ullsperger M, 2010, SIMULTANEOUS EEG FMR; VON DER MALSBURG CHRISTOPH, 2010, DYNAMIC COORDINATION; Yang HD, 2012, J NEUROSCI, V32, P1061, DOI 10.1523/JNEUROSCI.2771-11.2012	43	42	43	0	12	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	MAR 18	2015	35	11					4626	4634		10.1523/JNEUROSCI.3694-14.2015			9	Neurosciences	Neurosciences & Neurology	CE9ZM	WOS:000352202300013	25788679	Green Published, Bronze			2021-06-18	
J	Carr, W; Polejaeva, E; Grome, A; Crandall, B; LaValle, C; Eonta, SE; Young, LA				Carr, Walter; Polejaeva, Elena; Grome, Anna; Crandall, Beth; LaValle, Christina; Eonta, Stephanie E.; Young, Lee Ann			Relation of Repeated Low-Level Blast Exposure With Symptomology Similar to Concussion	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						blast; concussion; military; survey; symptoms	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; OPERATION-IRAQI-FREEDOM; POSTCONCUSSIVE SYMPTOMS; HEAD-INJURY; HEALTH; ASSOCIATION; MECHANISMS; PERSONNEL; SEQUELAE	Objective: To investigate anecdotal reports suggesting that repeated exposure to low-level explosive blast has myriad health impacts, including an array of neurological effects. Participants: A total of 184 anonymous survey respondents from military and nonmilitary law enforcement populations (135 exposed to occupational blast and 49 controls). Design: Survey of self-reported history of occupational exposure to repeated low-level blast (breaching blast) and symptomology similar to concussion. Results: Findings suggest that number and severity of symptoms increase with history of chronic blast exposure (F = 18.26, P < .001) and that symptoms can interfere with daily activity (t = 2.60, P = .010). Conclusion: Given the prevalence of repeated exposure to blast among some military and civilian law enforcement occupations, the results of this survey study support a role for blast surveillance programs as well as continued research on health impacts of low-level repeated blast exposure.	[Carr, Walter; LaValle, Christina; Eonta, Stephanie E.] Walter Reed Army Inst Res, Dept Behav Biol, Silver Spring, MD 20910 USA; [Polejaeva, Elena] Naval Med Res Ctr, Dept Neurotrauma, Silver Spring, MD USA; [Grome, Anna; Crandall, Beth; Young, Lee Ann] Appl Res Associates, Albuquerque, NM USA	Carr, W (corresponding author), Walter Reed Army Inst Res, Dept Behav Biol, 503 Robert Grant Ave, Silver Spring, MD 20910 USA.	walter.s.carr.mil@mail.mil		LaValle, Christina/0000-0003-1529-4761	Army MOMRP.accelleration.A0908	This work was supported by Army MOMRP.accelleration.A0908.	American Psychiatric Association, 2000, DIAGN STAT MAN MENT; [Anonymous], 2011, JOINT MENT HLTH ADV; [Anonymous], 2012, VETERANS HLTH ADM TR; Bagchi A, 2013, EVALUATION HEADBORNE; Baker AJ, 2011, J TRAUMA, V71, pS472, DOI 10.1097/TA.0b013e318232e7da; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Benge JF, 2009, REHABIL PSYCHOL, V54, P270, DOI 10.1037/a0016736; BOWEN IG, 1968, ANN NY ACAD SCI, V152, P122, DOI 10.1111/j.1749-6632.1968.tb11971.x; Bryant Richard, 2011, Dialogues Clin Neurosci, V13, P251; Caplan LJ, 2010, J HEAD TRAUMA REHAB, V25, P447, DOI 10.1097/HTR.0b013e3181d5bdbd; Casscells SW, 2007, CONSOLIDATION TRAUMA; Casscells SW, 2007, TRAUMATIC BRAIN INJU; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Embrey EP, 2008, SYMPTOM MANAGEMENT M; Fear NT, 2012, J EPIDEMIOL COMMUN H, V66, pA35, DOI 10.1136/jech-2012-201753.091; Fear NT, 2009, PSYCHOL MED, V39, P1379, DOI 10.1017/S0033291708004595; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hayward P, 2008, LANCET NEUROL, V7, P200, DOI 10.1016/S1474-4422(08)70032-2; Heltemes KJ, 2012, INJURY, V43, P1990, DOI 10.1016/j.injury.2011.07.021; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kontos AP, 2013, J NEUROTRAUM, V30, P680, DOI 10.1089/neu.2012.2506; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; Miller KJ, 2013, J HEAD TRAUMA REHAB, V28, P31, DOI 10.1097/HTR.0b013e318255ceae; Murray CK, 2005, MIL MED, V170, P516, DOI 10.7205/MILMED.170.6.516; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Ryan LM, 1999, ARCH CLIN NEUROPSYCH, V14, P42, DOI 10.1093/arclin/14.1.42a; Saljo A, 2008, J NEUROTRAUM, V25, P1397, DOI 10.1089/neu.2008.0602; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Scott SG, 2006, J AM OSTEOPATH ASSOC, V106, P265; St Onge Paul, 2011, US Army Med Dep J, P97; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Tate CM, 2013, J NEUROTRAUM, V30, P1620, DOI 10.1089/neu.2012.2683; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f	37	42	42	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2015	30	1					47	55		10.1097/HTR.0000000000000064			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AY8BW	WOS:000347780400014	24901327				2021-06-18	
J	Koski, L; Kolivakis, T; Yu, C; Chen, JK; Delaney, S; Ptito, A				Koski, Lisa; Kolivakis, Theodore; Yu, Camilla; Chen, Jen-Kai; Delaney, Scott; Ptito, Alain			Noninvasive Brain Stimulation for Persistent Postconcussion Symptoms in Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						rTMS; brain trauma; head injury; concussion; fMRI	TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT-RESISTANT DEPRESSION; CONCUSSION; FMRI; MIGRAINE; CORTEX; RTMS	Mild traumatic brain injury (mTBI) is typically followed by various postconcussive symptoms (PCS), including headache, depression, and cognitive deficits. In 15-25% of cases, PCS persists beyond the usual 3-month recovery period, interfering with activities of daily living and responding poorly to pharmacotherapy. We tested the safety, tolerability, and efficacy of repetitive transcranial magnetic stimulation (rTMS) over the left dorsolateral prefrontal cortex (DLPFC) for alleviating PCS. Fifteen eligible patients with mTBI and PCS>3 months postinjury consented to 20 sessions of rTMS (20x5-sec trains; 10 Hz at 110% threshold), with clinical and functional magnetic resonance imaging (fMRI) assessments before and after intervention and clinical assessment at 3-month follow-up. Primary outcomes were tolerability, safety, and efficacy, as measured with the PCS Scale. Secondary outcomes included the Cognitive Symptoms Questionnaire, neuropsychological test performance, and working memory task-associated activity as assessed with fMRI. Twelve patients completed all sessions. Three withdrew because of worsening symptoms or for an unrelated event. Stimulation intensity was increased gradually across sessions, and all subjects tolerated the protocol by the sixth session. Commonly reported side effects among completers were increased headache (n=3) and greater sleep disturbance (n=3). Participants also reported positive outcomes such as less sleep disturbance (n=3), and better mental focus (n=3). On average, PCS scores declined by 14.6 points (p=0.009) and fMRI task-related activation peaks in the DLPFC increased after rTMS. rTMS is safe, tolerated by most patients with mTBI, and associated with both a reduction in severity of PCS and an increase in task-related activations in DLPFC. Assessment of this intervention in a randomized, control trial is warranted.	[Koski, Lisa] McGill Univ, Dept Psychol, MUHC, Dept Neurol Neurosurg, Montreal, PQ, Canada; [Koski, Lisa] McGill Univ, Dept Psychol, Montreal, PQ, Canada; [Koski, Lisa] McGill Univ, MUHC, Res Inst, Montreal, PQ, Canada; [Kolivakis, Theodore; Ptito, Alain] McGill Univ, Dept Neurol Neurosurg, Montreal, PQ, Canada; [Kolivakis, Theodore] McGill Univ, Dept Psychiat, Montreal, PQ, Canada; [Yu, Camilla] McGill Univ, Dept Physiol, Montreal, PQ, Canada; [Chen, Jen-Kai] McGill Univ, Montreal Neurol Inst, Montreal, PQ, Canada; [Delaney, Scott] McGill Univ, McGill Univ Hlth Ctr, Dept Emergency Med, Montreal, PQ, Canada; [Delaney, Scott] McGill Univ, McGill Sport Med Clin, Montreal, PQ, Canada; [Ptito, Alain] McGill Univ, McGill Univ Hlth Ctr, Dept Psychol, Montreal, PQ, Canada	Koski, L (corresponding author), Allan Mem Inst Psychiat, P2-142,1025 Pine Ave West, Montreal, PQ H3A 1A1, Canada.	lisa.koski@mcgill.ca			Canadian Institutes of Health Research (CIHR)Canadian Institutes of Health Research (CIHR); AstraZenecaAstraZeneca; LundbeckLundbeck Corporation; Sunovion; Eli LillyEli Lilly; Janssen-Ortho; GlaxoSmithKlineGlaxoSmithKline; Bristol-Myers SquibbBristol-Myers Squibb; CIHRCanadian Institutes of Health Research (CIHR)	Dr. Koski reports grants from the Canadian Institutes of Health Research (CIHR) and nonfinancial support from the MS Society of Canada during the conduct of the study. Dr. Kolivakis reports personal fees and sat on the advisory board of AstraZeneca, personal fees and sat on the advisory board of Lundbeck, personal fees and sat on the advisory board of Sunovion, personal fees and sat on the advisory board of Eli Lilly, personal fees and sat on the advisory board of Janssen-Ortho, personal fees and sat on the advisory board of GlaxoSmithKline, and personal fees and sat on the advisory board of Bristol-Myers Squibb, outside the submitted work. Dr. Ptito reports grants from the CIHR.	Angelakis E, 2014, ARCH PHYS MED REHAB, V95, P283, DOI 10.1016/j.apmr.2013.09.002; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Borckardt JJ, 2009, PAIN MED, V10, P840, DOI 10.1111/j.1526-4637.2009.00657.x; Bottari C., 2008, BRAIN INJ S1, V22, P1; Bottari C, 2009, NEUROPSYCHOL REHABIL, V19, P177, DOI 10.1080/09602010802188435; Bottari C, 2009, BRAIN INJURY, V23, P322, DOI 10.1080/02699050902788436; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; COLLINS DL, 1994, J COMPUT ASSIST TOMO, V18, P192, DOI 10.1097/00004728-199403000-00005; Cosentino G, 2010, NEUROCASE, V16, P267, DOI 10.1080/13554790903456191; Daskalakis ZJ, 2008, CAN J PSYCHIAT, V53, P555, DOI 10.1177/070674370805300902; Dean PJA, 2012, BRAIN INJURY, V26, P14, DOI 10.3109/02699052.2011.635354; Deb S, 1998, J NEUROL NEUROSUR PS, V65, P899, DOI 10.1136/jnnp.65.6.899; Demirtas-Tatlidede A, 2012, J HEAD TRAUMA REHAB, V27, P274, DOI 10.1097/HTR.0b013e318217df55; Epstein CM, 2007, CLIN NEUROPHYSIOL, V118, P2189, DOI 10.1016/j.clinph.2007.07.010; Fitzgerald PB, 2011, J ECT, V27, P38, DOI 10.1097/YCT.0b013e3181eb30c6; Friston KJ, 1998, NEUROIMAGE, V7, P30, DOI 10.1006/nimg.1997.0306; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Jorge RE, 2004, BIOL PSYCHIAT, V55, P398, DOI 10.1016/j.biopsych.2003.08.017; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Kreuzer PM, 2013, J HEAD TRAUMA REHAB, V28, P386, DOI 10.1097/HTR.0b013e318254736e; Lam RW, 2008, CAN J PSYCHIAT, V53, P621, DOI 10.1177/070674370805300909; Leung A, 2009, J PAIN, V10, P1205, DOI 10.1016/j.jpain.2009.03.010; Loo CK, 2008, INT J NEUROPSYCHOPH, V11, P131, DOI 10.1017/S1461145707007717; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Misra UK, 2013, J NEUROL, V260, P2793, DOI 10.1007/s00415-013-7072-2; Nahmias F, 2009, PAIN, V147, P224, DOI 10.1016/j.pain.2009.09.016; O'Reardon JP, 2007, CNS SPECTRUMS, V12, P921, DOI 10.1017/S1092852900015716; Passard A, 2007, BRAIN, V130, P2661, DOI 10.1093/brain/awm189; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Rose EJ, 2006, NEUROIMAGE, V29, P203, DOI 10.1016/j.neuroimage.2005.07.002; Schutter DJLG, 2009, PSYCHOL MED, V39, P65, DOI 10.1017/S0033291708003462; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Villamar MF, 2012, NEUROMODULATION, V15, P326, DOI 10.1111/j.1525-1403.2012.00474.x; Worsley KJ, 2005, NEUROIMAGE, V26, P635, DOI 10.1016/j.neuroimage.2005.02.007; Worsley KJ, 2002, NEUROIMAGE, V15, P1, DOI 10.1006/nimg.2001.0933	39	42	43	0	35	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 1	2015	32	1					38	44		10.1089/neu.2014.3449			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AX4JX	WOS:000346900100006	24955920				2021-06-18	
J	Rom, S; Zuluaga-Ramirez, V; Dykstra, H; Reichenbach, NL; Ramirez, SH; Persidsky, Y				Rom, Slava; Zuluaga-Ramirez, Viviana; Dykstra, Holly; Reichenbach, Nancy L.; Ramirez, Servio H.; Persidsky, Yuri			Poly(ADP-ribose) polymerase-1 inhibition in brain endothelium protects the blood-brain barrier under physiologic and neuroinflammatory conditions	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						BBB; PARP; endothelial dysfunction	CANNABINOID RECEPTOR 2; TRANSCRIPTION FACTORS; CEREBRAL-ISCHEMIA; KINASE; ACTIVATION; EXPRESSION; PARP-1; MIGRATION; OCCLUDIN; PATHWAY	Blood-brain barrier (BBB) dysfunction seen in neuroinflammation contributes to mortality and morbidity in multiple sclerosis, encephalitis, traumatic brain injury, and stroke. Identification of molecular targets maintaining barrier function is of clinical relevance. We used a novel in vivo model of localized aseptic meningitis where tumor necrosis factor alpha (TNF alpha) was introduced intracerebrally and surveyed cerebral vascular changes and leukocyte-endothelium interactions by intravital videomicroscopy. Poly (ADP-ribose) polymerase-1 (PARP) inhibition significantly reduced leukocyte adhesion to and migration across brain endothelium in cortical microvessels. PARP inactivation diminished BBB permeability in an in vivo model of systemic inflammation. PARP suppression in primary human brain microvascular endothelial cells (BMVEC), an in vitro model of BBB, enhanced barrier integrity and augmented expression of tight junction proteins. PARP inhibition in BMVEC diminished human monocyte adhesion to TNF alpha-activated BMVEC (up to 65%) and migration (80-100%) across BBB models. PARP suppression decreased expression of adhesion molecules and decreased activity of GTPases (controlling BBB integrity and monocyte migration across the BBB). PARP inhibitors down-regulated expression of inflammatory genes and dampened secretion of pro-inflammatory factors increased by TNF alpha in BMVEC. These results point to PARP suppression as a novel approach to BBB protection in the setting of endothelial dysfunction caused by inflammation.	[Rom, Slava; Zuluaga-Ramirez, Viviana; Dykstra, Holly; Reichenbach, Nancy L.; Ramirez, Servio H.; Persidsky, Yuri] Temple Univ, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19122 USA	Rom, S (corresponding author), MERB, Dept Pathol, 3500 N Broad St,Room 880, Philadelphia, PA 19140 USA.	srom@temple.edu	Rom, Slava/AAF-6872-2020	ramirez, servio/0000-0002-4609-5653; Rom, Slava/0000-0002-1050-1955	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AA015913, MH65151, R21NS087385, NS086570-01]; Shriners Hospitals for Children [85110-PHI-14]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH065151] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS086570, R21NS087385] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R01AA015913, R37AA015913] Funding Source: NIH RePORTER	This work was supported in part by NIH research grants AA015913 (YP) and MH65151 (YP), R21NS087385 (SR), NS086570-01 (SHR), and The Shriners Hospitals for Children 85110-PHI-14 (SHR).	Aslam M, 2012, CYTOKINE, V57, P269, DOI 10.1016/j.cyto.2011.10.016; Aychek T, 2011, MAGN RESON MED, V66, P235, DOI 10.1002/mrm.22798; Birukov KG, 2009, MICROVASC RES, V77, P46, DOI 10.1016/j.mvr.2008.09.006; Booth G, 2001, AM J PHYSIOL-ENDOC M, V280, pE848; Boudaoud A, 2014, NAT PROTOC, V9, P457, DOI 10.1038/nprot.2014.024; Bruewer M, 2004, AM J PHYSIOL-CELL PH, V287, pC327, DOI 10.1152/ajpcell.00087.2004; Cavone L, 2011, MULT SCLER J, V17, P794, DOI 10.1177/1352458511399113; De Craene B, 2005, CELL SIGNAL, V17, P535, DOI 10.1016/j.cellsig.2004.10.011; Doggett T.M., 2011, J VIS EXP, V57, P3187; Erdelyi K, 2005, MOL PHARMACOL, V68, P895, DOI 10.1124/mol.105.012518; Farez MF, 2009, NAT IMMUNOL, V10, P958, DOI 10.1038/ni.1775; Feldman GJ, 2005, ADV DRUG DELIVER REV, V57, P883, DOI 10.1016/j.addr.2005.01.009; Ha HC, 2002, P NATL ACAD SCI USA, V99, P3270, DOI 10.1073/pnas.052712399; Haddad M, 2006, BRIT J PHARMACOL, V149, P23, DOI 10.1038/sj.bjp.0706837; Hay T, 2009, CANCER RES, V69, P3850, DOI 10.1158/0008-5472.CAN-08-2388; Janzen DM, 2013, MOL CANCER THER, V12, P2917, DOI 10.1158/1535-7163.MCT-13-0572; Kajita M, 2004, MOL CELL BIOL, V24, P7559, DOI 10.1128/MCB.24.17.7559-7566.2004; Koedel U, 2002, J CEREBR BLOOD F MET, V22, P39, DOI 10.1097/00004647-200201000-00005; Kraus WL, 2003, CELL, V113, P677, DOI 10.1016/S0092-8674(03)00433-1; Krishnakumar R, 2010, MOL CELL, V39, P8, DOI 10.1016/j.molcel.2010.06.017; Lenzser G, 2007, J CEREBR BLOOD F MET, V27, P1318, DOI 10.1038/sj.jcbfm.9600437; Lescot T, 2010, J NEUROTRAUM, V27, P1069, DOI 10.1089/neu.2009.1188; Liu LL, 2012, HUM IMMUNOL, V73, P439, DOI 10.1016/j.humimm.2012.02.002; McCullough LD, 2005, J CEREBR BLOOD F MET, V25, P502, DOI 10.1038/sj.jcbfm.9600059; Moroni F, 2008, CURR OPIN PHARMACOL, V8, P96, DOI 10.1016/j.coph.2007.10.005; Persidsky Y, 2006, J NEUROIMMUNE PHARM, V1, P223, DOI 10.1007/s11481-006-9025-3; Ramirez SH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055972; Ramirez SH, 2012, J NEUROSCI, V32, P4004, DOI 10.1523/JNEUROSCI.4628-11.2012; Ramirez SH, 2010, J NEUROSCI, V30, P9454, DOI 10.1523/JNEUROSCI.5796-09.2010; Ramirez SH, 2010, AM J PATHOL, V176, P881, DOI 10.2353/ajpath.2010.090671; Rolfe BE, 2005, ATHEROSCLEROSIS, V183, P1, DOI 10.1016/j.atherosclerosis.2005.04.023; Rom S, 2013, AM J PATHOL, V183, P1548, DOI 10.1016/j.ajpath.2013.07.033; Rom S, 2012, AM J PATHOL, V181, P1414, DOI 10.1016/j.ajpath.2012.06.018; Rouleau M, 2010, NAT REV CANCER, V10, P293, DOI 10.1038/nrc2812; Spindler V, 2010, CARDIOVASC RES, V87, P243, DOI 10.1093/cvr/cvq086; Veres B, 2003, BIOCHEM PHARMACOL, V65, P1373, DOI 10.1016/S0006-2952(03)00077-7; Vestweber D, 2008, ERNST SCHERING FOUND, V3, P151, DOI 10.1007/2789_2007_063; Wu XL, 2014, J MOL NEUROSCI, V53, P1, DOI 10.1007/s12031-013-0175-5; Yamamoto M, 2008, AM J PATHOL, V172, P521, DOI 10.2353/ajpath.2008.070076; Zhang CX, 2004, AM J PHYSIOL-HEART C, V287, pH659, DOI 10.1152/ajpheart.00162.2004	40	42	42	0	13	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JAN	2015	35	1					28	36		10.1038/jcbfm.2014.167			9	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	AY2AZ	WOS:000347392200005	25248836	Green Published, Bronze			2021-06-18	
J	Zhang, Y; Simpson-Durand, CD; Standifer, KM				Zhang, Y.; Simpson-Durand, C. D.; Standifer, K. M.			Nociceptin/orphanin FQ peptide receptor antagonist JTC-801 reverses pain and anxiety symptoms in a rat model of post-traumatic stress disorder	BRITISH JOURNAL OF PHARMACOLOGY			English	Article						PTSD; elevated plus maze; pain sensitivity; nociceptin; orphanin FQ; nociceptin; orphanin FQ peptide receptor; single-prolonged stress; hypocortisolism; allodynia; JTC-801; von Frey test	NEUROPATHIC-PAIN; ORPHANIN FQ; PHARMACOLOGICAL EVALUATION; CEREBROSPINAL-FLUID; MESSENGER-RNA; NERVE INJURY; AGONIST; ORL1; PROTEIN; BRAIN	Background and PurposeSingle-prolonged stress (SPS), a rat model of post-traumatic stress disorder (PTSD), also induces long-lasting hyperalgesia associated with hypocortisolism and elevated nociceptin/orphanin FQ (N/OFQ) levels in serum and CSF. Here, we determined the effect of JTC-801 (N-(4-amino-2-methylquinolin-6-yl)-2-(4-ethylphenoxymethyl) benzamide monohydrochloride), a nociceptin/orphanin FQ peptide (NOP) receptor antagonist, on symptoms of pain and anxiety in rats after SPS exposure, and examined N/OFQ-NOP receptor system changes. Experimental ApproachMale Sprague Dawley rats received JTC-801 (6mgkg(-1) i.p., once daily) during days 7-21 of SPS. The ability of JTC-801 to inhibit N/OFQ-stimulated [S-35]-GTPS binding was confirmed in rat brain membranes. Anxiety-like behaviour and pain sensitivity were monitored by changes in elevated plus maze performance and withdrawal responses to thermal and mechanical stimuli. Serum corticosterone and N/OFQ content in CSF, serum and brain tissues were determined by radioimmunoassay; NOP receptor protein and gene expression in amygdala, hippocampus and periaqueductal grey (PAG) were examined by immunoblotting and real-time PCR respectively. Key ResultsJTC-801 treatment reversed SPS-induced mechanical allodynia, thermal hyperalgesia, anxiety-like behaviour and hypocortisolism. Elevated N/OFQ levels in serum, CSF, PAG and hippocampus at day 21 of SPS were blocked by JTC-801; daily JTC-801 treatment also reversed NOP receptor protein and mRNA up-regulation in amygdala and PAG. Conclusion and ImplicationsJTC-801 reversed SPS-induced anxiety- and pain-like behaviours, and NOP receptor system up-regulation. These findings suggest that N/OFQ plays an important role in hyperalgesia and allodynia maintenance after SPS. NOP receptor antagonists may provide effective treatment for co-morbid PTSD and pain. Linked ArticlesThis article is part of a themed section on Opioids: New Pathways to Functional Selectivity. To view the other articles in this section visit	[Zhang, Y.; Simpson-Durand, C. D.; Standifer, K. M.] Univ Oklahoma, Dept Pharmaceut Sci, Coll Pharm, Hlth Sci Ctr, Oklahoma City, OK 73117 USA; [Standifer, K. M.] Univ Oklahoma, Hlth Sci Ctr, Coll Med, Dept Cell Biol,Oklahoma Ctr Neurosci, Oklahoma City, OK 73117 USA	Standifer, KM (corresponding author), Univ Oklahoma, Dept Pharmaceut Sci, Coll Pharm, Hlth Sci Ctr, 1110 N Stonewall Ave,Suite 326, Oklahoma City, OK 73117 USA.	Kelly-Standifer@ouhsc.edu			Department of the Army DMRDP [W81XWH-11-2-0077]	This study was supported by the Department of the Army DMRDP W81XWH-11-2-0077. The US Army Medical Research Acquisition Activity, 820 Chandler Street, Fort Detrick, MD 21702-5014, is the awarding and administering acquisition office.	Alexander SPH, 2013, BRIT J PHARMACOL, V170, P1459, DOI 10.1111/bph.12445; Andero R, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005656; Asmundson GJG, 2009, DEPRESS ANXIETY, V26, P888, DOI 10.1002/da.20600; Briscini L, 2002, EUR J PHARMACOL, V447, P59, DOI 10.1016/S0014-2999(02)01833-2; Cohen H, 2009, J NEUROENDOCRINOL, V21, P898, DOI 10.1111/j.1365-2826.2009.01913.x; Cornefjord M, 2004, SPINE, V29, P1862, DOI 10.1097/01.brs.0000137070.16592.b2; Corradini L, 2001, BRAIN RES, V905, P127, DOI 10.1016/S0006-8993(01)02520-3; Del Giudice MR, 2011, EUR J MED CHEM, V46, P1207, DOI 10.1016/j.ejmech.2011.01.040; Delaney G, 2012, J NEUROENDOCRINOL, V24, P1527, DOI 10.1111/j.1365-2826.2012.02361.x; Devine DP, 2003, J NEUROENDOCRINOL, V15, P69, DOI 10.1046/j.1365-2826.2003.00868.x; Devine DP, 2001, NEUROSCIENCE, V102, P541, DOI 10.1016/S0306-4522(00)00517-0; Duzzioni M, 2011, BEHAV BRAIN RES, V222, P206, DOI 10.1016/j.bbr.2011.03.056; Fernandez F, 2004, NEUROPSYCHOPHARMACOL, V29, P59, DOI 10.1038/sj.npp.1300308; Gavioli EC, 2007, PEPTIDES, V28, P1229, DOI 10.1016/j.peptides.2007.04.012; Goeldner C, 2012, PSYCHOPHARMACOLOGY, V222, P203, DOI 10.1007/s00213-012-2636-x; Green MK, 2007, NEUROPEPTIDES, V41, P399, DOI 10.1016/j.npep.2007.09.002; Green MK, 2009, NEUROPEPTIDES, V43, P507, DOI 10.1016/j.npep.2009.08.003; Gunduz O, 2011, PHARMACOL BIOCHEM BE, V99, P540, DOI 10.1016/j.pbb.2011.05.029; Hammamieh R, 2012, BEHAV BRAIN RES, V235, P55, DOI 10.1016/j.bbr.2012.07.022; Heinricher MM, 1997, J NEUROPHYSIOL, V78, P3351; Jenck F, 2000, P NATL ACAD SCI USA, V97, P4938, DOI 10.1073/pnas.090514397; Jia M, 2012, JOVE-J VIS EXP, DOI 10.3791/3361; Joseph T, 2007, PEPTIDES, V28, P1433, DOI 10.1016/j.peptides.2007.05.009; Khroyan TV, 2011, J PHARMACOL EXP THER, V339, P687, DOI 10.1124/jpet.111.184663; Kilkenny C, 2010, BRIT J PHARMACOL, V160, P1577, DOI 10.1111/j.1476-5381.2010.00872.x; King MA, 1997, NEUROSCI LETT, V223, P113, DOI 10.1016/S0304-3940(97)13414-0; Ko MH, 2002, NEUROREPORT, V13, P1631, DOI 10.1097/00001756-200209160-00012; Lambert DG, 2008, NAT REV DRUG DISCOV, V7, P694, DOI 10.1038/nrd2572; Leggett JD, 2006, NEUROSCIENCE, V141, P2051, DOI 10.1016/j.neuroscience.2006.05.036; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Liberzon I, 1999, J NEUROENDOCRINOL, V11, P11; Liberzon I, 1997, PSYCHONEUROENDOCRINO, V22, P443, DOI 10.1016/S0306-4530(97)00044-9; Liu EH, 2012, NEUROSCI LETT, V506, P104, DOI 10.1016/j.neulet.2011.10.059; Lu SX, 2011, EUR J PHARMACOL, V661, P63, DOI 10.1016/j.ejphar.2011.04.034; Ma F, 2005, BRAIN RES, V1043, P214, DOI 10.1016/j.brainres.2005.01.037; Mabuchi T, 2003, EUR J NEUROSCI, V17, P1384, DOI 10.1046/j.1460-9568.2003.02575.x; Marti M, 2003, BRIT J PHARMACOL, V138, P91, DOI 10.1038/sj.bjp.0705005; McGrath JC, 2010, BRIT J PHARMACOL, V160, P1573, DOI 10.1111/j.1476-5381.2010.00873.x; Meewisse ML, 2007, BRIT J PSYCHIAT, V191, P387, DOI 10.1192/bjp.bp.106.024877; Mogil JS, 1996, NEUROSCIENCE, V75, P333, DOI 10.1016/0306-4522(96)00338-7; Moore RJ, 2000, NEUROPHARMACOLOGY, V39, P282, DOI 10.1016/S0028-3908(99)00112-4; Morris MC, 2012, CLIN PSYCHOL REV, V32, P301, DOI 10.1016/j.cpr.2012.02.002; Nativio P, 2012, STRESS, V15, P378, DOI 10.3109/10253890.2011.627071; Odagaki Y, 2006, PROG NEURO-PSYCHOPH, V30, P1304, DOI 10.1016/j.pnpbp.2006.05.007; Olszewski PK, 2010, AM J PHYSIOL-REG I, V299, pR655, DOI 10.1152/ajpregu.00556.2009; Ozaki S, 2000, EUR J PHARMACOL, V402, P45, DOI 10.1016/S0014-2999(00)00520-3; Pan ZZ, 2000, NEURON, V26, P515, DOI 10.1016/S0896-6273(00)81183-6; Paxinos G., 2005, RAT BRAIN STEREOTAXI; Pulliam JVK, 2010, J PSYCHIATR RES, V44, P106, DOI 10.1016/j.jpsychires.2009.05.005; Raffaeli W, 2006, J PAIN SYMPTOM MANAG, V32, P372, DOI 10.1016/j.jpainsymman.2006.05.013; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Scoto GM, 2009, LIFE SCI, V85, P206, DOI 10.1016/j.lfs.2009.05.021; Sestili I, 2004, EUR J MED CHEM, V39, P1047, DOI 10.1016/j.ejmech.2004.09.009; Shinkai H, 2000, J MED CHEM, V43, P4667, DOI 10.1021/jm0002073; Shipherd JC, 2007, J REHABIL RES DEV, V44, P153, DOI 10.1682/JRRD.2006.06.0065; Suyama H, 2003, NEUROSCI LETT, V351, P133, DOI 10.1016/S0304-3940(03)00502-0; Tamai H, 2005, EUR J PHARMACOL, V510, P223, DOI 10.1016/j.ejphar.2005.01.033; Tian JH, 1997, BRIT J PHARMACOL, V120, P676, DOI 10.1038/sj.bjp.0700942; Uchiyama H, 2008, NEUROSCI LETT, V431, P66, DOI 10.1016/j.neulet.2007.11.023; Vitale G, 2006, PEPTIDES, V27, P2193, DOI 10.1016/j.peptides.2006.04.003; Witkin JM, 2014, PHARMACOL THERAPEUT, V141, P283, DOI 10.1016/j.pharmthera.2013.10.011; Yamada H, 2002, BRIT J PHARMACOL, V135, P323, DOI 10.1038/sj.bjp.0704478; Yamamoto S, 2009, DEPRESS ANXIETY, V26, P1110, DOI 10.1002/da.20629; Yamamoto T, 1997, NEUROSCIENCE, V81, P249, DOI 10.1016/S0306-4522(97)00166-8; Zaratin PF, 2004, J PHARMACOL EXP THER, V308, P454, DOI 10.1124/jpet.103.055848; Zhang Y, 2012, MOL PAIN, V8, DOI 10.1186/1744-8069-8-76	66	42	42	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0007-1188	1476-5381		BRIT J PHARMACOL	Br. J. Pharmacol.	JAN	2015	172	2			SI		571	582		10.1111/bph.12701			12	Pharmacology & Pharmacy	Pharmacology & Pharmacy	AX3FU	WOS:000346826500029	24666365	Green Published, Bronze			2021-06-18	
J	Brown, FL; Whittingham, K; Boyd, RN; McKinlay, L; Sofronoff, K				Brown, Felicity L.; Whittingham, Koa; Boyd, Roslyn N.; McKinlay, Lynne; Sofronoff, Kate			Improving child and parenting outcomes following paediatric acquired brain injury: a randomised controlled trial of Stepping Stones Triple P plus Acceptance and Commitment Therapy	JOURNAL OF CHILD PSYCHOLOGY AND PSYCHIATRY			English	Article						Acquired brain injury; acceptance and commitment therapy; Stepping Stones Triple P: Positive Parenting Program; behavioural and emotional functioning; parenting style; randomised controlled trial	SKILLS PROGRAM; INTERVENTION; FEASIBILITY; DISORDERS; EFFICACY; MOTHERS; STRESS; MOOD	Background: Persistent behavioural difficulties are common following paediatric acquired brain injury (ABI). Parents and families also experience heightened stress, psychological symptoms and burden, and there is evidence of a reciprocal relationship between parent and child functioning, which may be mediated by the adoption of maladaptive parenting practices. Despite this, there is currently a paucity of research in family interventions in this population. The aim of this study was to determine the efficacy of Stepping Stones Triple P: Positive Parenting Program (SSTP), with an Acceptance and Commitment Therapy (ACT) workshop, in improving child outcomes and parenting practices following paediatric ABI. Methods: Fifty-nine parents of children (mean age 7 years, SD 3 years, 1 month; 35 males, 24 females) with ABI (Traumatic injuries 58%, Tumour 17%, Encephalitis or meningitis 15%, Cardiovascular accident 7%, Hypoxia 3%) who were evidencing at least mild behaviour problems were randomly assigned to treatment or care-as-usual conditions over 10 weeks. Mixed-model repeated-measures linear regression analyses were conducted to compare conditions from pre- to postintervention on child behavioural and emotional functioning (Eyberg Child Behavior Inventory, Strengths and Difficulties Questionnaire) and dysfunctional parenting style (Parenting Scale). Assessment of maintenance of change was conducted at a 6-month follow-up. The trial was registered on Australian New Zealand Clinical Trials Registry (ID: ACTRN12610001051033, www.anzctr.org.au). Results: Significant time-by-condition interactions were identified on number and intensity of child behaviour problems, child emotional symptoms and parenting laxness and overreactivity, indicating significant improvements in the treatment condition, with medium-to-large effect sizes. Most improvements were maintained at 6 months. Conclusions: Group parenting interventions incorporating Triple P and ACT may be efficacious in improving child and parenting outcomes following paediatric ABI.	[Brown, Felicity L.; Whittingham, Koa; Sofronoff, Kate] Univ Queensland, Sch Psychol, Fac Hlth & Behav Sci, Brisbane, Qld, Australia; [Brown, Felicity L.; Whittingham, Koa; Boyd, Roslyn N.; McKinlay, Lynne] Univ Queensland, Sch Med, Fac Med & Biomed Sci, Queensland Cerebral Palsy & Rehabil Res Ctr, Brisbane, Qld, Australia; [Brown, Felicity L.; McKinlay, Lynne] Univ Queensland, Fac Med & Biomed Sci, Queensland Childrens Med Res Inst, Brisbane, Qld, Australia; [McKinlay, Lynne] Royal Childrens Hosp, Queensland Paediat Rehabil Serv, Brisbane, Qld, Australia	Brown, FL (corresponding author), Univ Queensland, Sch Psychol, St Lucia, Qld 4072, Australia.	felicity.brown@uqconnect.edu.au	Boyd, Roslyn N/A-4498-2011; Whittingham, Koa L/C-6766-2009	Boyd, Roslyn N/0000-0002-4919-5975; Whittingham, Koa L/0000-0002-5344-9907; Brown, Felicity/0000-0001-6800-1657; McKinlay, Lynne/0000-0002-6677-0628	Queensland Children's Medical Research Institute Science PhD Scholarship [50002]; National Health and Medical Research Council postdoctoral fellowshipUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [631712]; National Health and Medical Research Council Career Development FellowshipNational Health and Medical Research Council of Australia [473840]; Smart State Fellowship	This study was supported by a Queensland Children's Medical Research Institute Science PhD Scholarship (F.B., grant number 50002); a National Health and Medical Research Council postdoctoral fellowship (K.W., grant number 631712); a National Health and Medical Research Council Career Development Fellowship (R.B., grant number 473840) and a Smart State Fellowship (R.B).	Anderson V, 2006, AM J PHYS MED REHAB, V85, P767, DOI 10.1097/01.phm.0000233176.08480.22; Anderson V, 2011, BRAIN, V134, P2197, DOI 10.1093/brain/awr103; Antonini TN, 2012, J TELEMED TELECARE, V18, P333, DOI 10.1258/jtt.2012.120404; Arnold D., 1993, PSYCHOL ASSESSMENT, V5, P137, DOI [DOI 10.1037/1040-3590.5.2.137, 10.1037/1040-3590.5.2.137.]; Biglan A, 2012, AM PSYCHOL, V67, P257, DOI 10.1037/a0026796; Blackledge JT, 2006, CHILD FAM BEHAV THER, V28, P1, DOI 10.1300/J019v28n01_01; Brown FL, 2013, BRAIN IMPAIR, V14, P253, DOI 10.1017/BrImp.2013.18; Brown FL, 2013, J HEAD TRAUMA REHAB, V28, P349, DOI 10.1097/HTR.0b013e318245fed5; Cheron DM, 2009, CHILD PSYCHIAT HUM D, V40, P383, DOI 10.1007/s10578-009-0135-z; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Cole WR, 2009, DEV DISABIL RES REV, V15, P159, DOI 10.1002/ddrr.58; de Graaf I, 2008, BEHAV MODIF, V32, P714, DOI 10.1177/0145445508317134; de Graaf I, 2008, FAM RELAT, V57, P553, DOI 10.1111/j.1741-3729.2008.00522.x; Eyberg S. M., 1999, ECBI SESBI R EYBERG; Goodman R, 1997, J CHILD PSYCHOL PSYC, V38, P581, DOI 10.1111/j.1469-7610.1997.tb01545.x; Hastings RP, 2004, J CHILD PSYCHOL PSYC, V45, P1338, DOI 10.1111/j.1469-7610.2004.00357.x; Hayes SC, 2006, BEHAV RES THER, V44, P1, DOI 10.1016/j.brat.2005.06.006; Hedeker D., 2006, LONGITUDINAL DATA AN; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; Li L, 2013, DEV MED CHILD NEUROL, V55, P37, DOI 10.1111/j.1469-8749.2012.04414.x; Lloyd T, 2008, J INTELL DISABIL RES, V52, P37, DOI 10.1111/j.1365-2788.2007.00974.x; Lovibond S.H., 1995, MANUAL DEPRESSION AN; Luis CA, 2002, J CLIN EXP NEUROPSYC, V24, P270, DOI 10.1076/jcen.24.3.270.982; Max JE, 2012, J NEUROPSYCH CLIN N, V24, P427, DOI 10.1176/appi.neuropsych.12060149; Micklewright JL, 2012, J INT NEUROPSYCH SOC, V18, P343, DOI 10.1017/S1355617711001792; Morris SB, 2008, ORGAN RES METHODS, V11, P364, DOI 10.1177/1094428106291059; Ost LG, 2008, BEHAV RES THER, V46, P296, DOI 10.1016/j.brat.2007.12.005; Powers MB, 2009, PSYCHOTHER PSYCHOSOM, V78, P73, DOI 10.1159/000190790; Rhoades KA, 2007, J CLIN CHILD ADOLESC, V36, P137, DOI 10.1080/15374410701274157; Sanders M. R., 2009, FACILITATORS MANUAL; Sanders MR, 2012, ANNU REV CLIN PSYCHO, V8, P345, DOI 10.1146/annurev-clinpsy-032511-143104; Shea SE, 2011, CHILD FAM BEHAV THER, V33, P231, DOI 10.1080/07317107.2011.596004; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; Tellegen CL, 2013, RES DEV DISABIL, V34, P1556, DOI 10.1016/j.ridd.2013.01.022; Wackerley D. D., 2008, MATH STAT APPL; Wade SL, 2006, J PEDIATR PSYCHOL, V31, P1072, DOI 10.1093/jpepsy/jsj077; Wade SL, 2011, DEV PSYCHOL, V47, P119, DOI 10.1037/a0021028; Wade SL, 2010, J HEAD TRAUMA REHAB, V25, P409, DOI 10.1097/HTR.0b013e3181fb900d; Wade SL, 2009, J HEAD TRAUMA REHAB, V24, P239, DOI 10.1097/HTR.0b013e3181ad6680; Weiss JA, 2012, AUTISM, V16, P261, DOI 10.1177/1362361311422708; Whittingham K, 2013, CHILD CARE HLTH DEV, V39, P366, DOI 10.1111/j.1365-2214.2012.01396.x; Whittingham K., 2010, STRESS MANAGEM UNPUB; Woods DT, 2012, NEUROREHABILITATION, V30, P189, DOI 10.3233/NRE-2012-0744; Yeates KO, 2010, NEUROPSYCHOLOGY, V24, P345, DOI 10.1037/a0018387; Ylvisaker M, 2007, BRAIN INJURY, V21, P769, DOI 10.1080/02699050701482470	45	42	44	3	51	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0021-9630	1469-7610		J CHILD PSYCHOL PSYC	J. Child Psychol. Psychiatry	OCT	2014	55	10					1172	1183		10.1111/jcpp.12227			12	Psychology, Developmental; Psychiatry; Psychology	Psychology; Psychiatry	AR8KS	WOS:000343824600014	24635872				2021-06-18	
J	Daniel, RW; Rowson, S; Duma, SM				Daniel, Ray W.; Rowson, Steven; Duma, Stefan M.			Head Impact Exposure in Youth Football: Middle School Ages 12-14 Years	JOURNAL OF BIOMECHANICAL ENGINEERING-TRANSACTIONS OF THE ASME			English	Article						concussion; brain injury; biomechanics; helmet; linear; rotational; acceleration; pediatric; child	TRAUMATIC BRAIN-INJURY; PROFESSIONAL FOOTBALL; UNITED-STATES; COLLEGIATE; CONCUSSION; ENCEPHALOPATHY; EPIDEMIOLOGY; MAGNITUDE; LOCATION; KINEMATICS	The head impact exposure experienced by football players at the college and high school levels has been well documented; however, there are limited data regarding youth football despite its dramatically larger population. The objective of this study was to investigate head impact exposure in middle school football. Impacts were monitored using a commercially available accelerometer array installed inside the helmets of 17 players aged 12-14 years. A total of 4678 impacts were measured, with an average (+/- standard deviation) of 275 +/- 190 impacts per player. The average of impact distributions for each player had a median impact of 22 +/- 2 g and 954 +/- 122 rad/s(2), and a 95th percentile impact of 54 +/- 9 g and 2525 +/- 450 rad/s(2). Similar to the head impact exposure experienced by high school and collegiate players, these data show that middle school football players experience a greater number of head impacts during games than practices. There were no significant differences between median and 95th percentile head acceleration magnitudes experienced during games and practices; however, a larger number of impacts greater than 80 g occurred during games than during practices. Impacts to the front and back of the helmet were most common. Overall, these data are similar to high school and college data that have been collected using similar methods. These data have applications toward youth football helmet design, the development of strategies designed to limit head impact exposure, and childspecific brain injury criteria.	[Daniel, Ray W.; Rowson, Steven; Duma, Stefan M.] Wake Forest Univ, Virginia Tech, Sch Biomed Engn & Sci, Blacksburg, VA 24061 USA	Daniel, RW (corresponding author), Wake Forest Univ, Virginia Tech, Sch Biomed Engn & Sci, 440 ICTAS Bldg,Stanger St, Blacksburg, VA 24061 USA.	rwdaniel@vt.edu; srowson@vt.edu; duma@vt.edu	Duma, Stefan/A-8368-2012; Rowson, Steven/B-1270-2012	Rowson, Steven/0000-0002-3227-0596; Daniel, Ray/0000-0002-8666-0979	National Highway Traffic Safety Administration	The authors gratefully acknowledge the National Highway Traffic Safety Administration for supporting this work.	Beckwith JG, 2012, ANN BIOMED ENG, V40, P237, DOI 10.1007/s10439-011-0422-2; Broglio SP, 2012, ANN BIOMED ENG, V40, P37, DOI 10.1007/s10439-011-0396-0; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Brolinson P Gunnar, 2006, Curr Sports Med Rep, V5, P23; Cobb BR, 2013, ANN BIOMED ENG, V41, P2463, DOI 10.1007/s10439-013-0867-6; Cormier J, 2011, J BIOMECH ENG-T ASME, V133, DOI 10.1115/1.4003312; Cormier J, 2011, J BIOMECH ENG-T ASME, V133, DOI 10.1115/1.4004248; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; Crisco JJ, 2012, J APPL BIOMECH, V28, P174, DOI 10.1123/jab.28.2.174; Crisco JJ, 2011, J BIOMECH, V44, P2673, DOI 10.1016/j.jbiomech.2011.08.003; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Daniel RW, 2012, ANN BIOMED ENG, V40, P976, DOI 10.1007/s10439-012-0530-7; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Duma SM, 2011, EXERC SPORT SCI REV, V39, P2, DOI 10.1097/JES.0b013e318203dfdb; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Funk JR, 2012, ANN BIOMED ENG, V40, P79, DOI 10.1007/s10439-011-0400-8; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Guskiewicz KM, 2011, EXERC SPORT SCI REV, V39, P4, DOI 10.1097/JES.0b013e318201f53e; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Iuliano-Burns S, 2001, AM J HUM BIOL, V13, P1; Kuczmarski R J, 2000, Adv Data, P1; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Rowson S, 2013, ANN BIOMED ENG, V41, P873, DOI 10.1007/s10439-012-0731-0; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Rowson S, 2011, ANN BIOMED ENG, V39, P2130, DOI 10.1007/s10439-011-0322-5; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Siervogel RM, 2003, HORM RES, V60, P36, DOI 10.1159/000071224; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Viano DC, 2012, ANN BIOMED ENG, V40, P213, DOI 10.1007/s10439-011-0386-2; Viano DC, 2012, ANN BIOMED ENG, V40, P97, DOI 10.1007/s10439-011-0377-3; Viano DC, 2012, ANN BIOMED ENG, V40, P160, DOI 10.1007/s10439-011-0384-4; Viano DC, 2012, ANN BIOMED ENG, V40, P47, DOI 10.1007/s10439-011-0399-x; Virginia High School League Inc., 2011, HDB POL MAN 2011 201; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	47	42	42	0	22	ASME	NEW YORK	TWO PARK AVE, NEW YORK, NY 10016-5990 USA	0148-0731	1528-8951		J BIOMECH ENG-T ASME	J. Biomech. Eng.-Trans. ASME	SEP	2014	136	9							094501	10.1115/1.4027872			6	Biophysics; Engineering, Biomedical	Biophysics; Engineering	AN5GC	WOS:000340617700011	24950298				2021-06-18	
J	Gressot, LV; Chamoun, RB; Patel, AJ; Valadka, AB; Sum, D; Robertson, CS; Gopinath, SP				Gressot, Loyola V.; Chamoun, Roukoz B.; Patel, Akash J.; Valadka, Alex B.; Sum, Dima; Robertson, Claudia S.; Gopinath, Shankar P.			Predictors of outcome in civilians with gunshot wounds to the head upon presentation	JOURNAL OF NEUROSURGERY			English	Article						gunshot wound to the head; Glasgow Coma Scale; outcome; penetrating head injury; traumatic brain injury	INJURIES; BRAIN; MANAGEMENT; PROGNOSIS	Object. Prediction of outcome from initial presentation after a gunshot wound to the head (GSWH) is essential to further clinical decision making. The authors' goals are to report the survival and functional outcomes of these patients, to identify prognostic factors, and to propose a scoring system that can predict their outcome. Methods. The records of 199 patients admitted with a GSWH with dural penetration between 1990 and 2008 were retrospectively reviewed. The inclusion criterion was a CT scan available for review. Patients declared brain dead on presentation were excluded, which yielded a series of 119 patients. Statistical analysis was performed using a logistic regression model. Results. Fifty-eight (49%) of the 119 patients died. Twenty-three patients (19%) had a favorable outcome defined as a 6-month Glasgow Outcome Scale (GOS) score of moderate disability or good recovery, 35 (29%) had a poor outcome (GOS of persistent vegetative state or severe disability), and 3 (3%) were lost to follow-up. Significant prognostic factors for mortality were age older than 35 years, nonreactive pupils, bullet trajectory. of bihemispheric (excluding bifrontal), and posterior fossa involvement compared with unihemispheric and bifrontal. Factors that were moderately associated with higher mortality included intracranial pressure (ICP) above 20 mm Hg and Glasgow Coma Scale (GCS) score at presentation of 3 or 4. Upon multivariate analysis, the significant factors for mortality were bullet trajectory and pupillary response. Variables found to be significant for good functional outcome were admission GCS score greater than or equal to 5, pupillary reactivity, and bullet trajectory of unihemispheric or bifrontal. Factors moderately associated with good outcome included age of 35 years or younger, initial ICP 20 mm Hg or lower, and lack of transventricular trajectory. In the multivariate analysis, significant factors for good functional outcome were bullet trajectory and pupillary response, with age moderately associated with improved functional outcomes. The authors also propose a scoring system to estimate survival and functional outcome. Conclusions. Age, pupils, GCS score, and bullet trajectory on CT scan can be used to determine likelihood of survival and good functional outcome. The authors advocate assessing patients based on these parameters rather than pronouncing a poor prognosis and withholding aggressive resuscitation based upon low GCS score alone.	[Gressot, Loyola V.; Patel, Akash J.; Robertson, Claudia S.; Gopinath, Shankar P.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; [Chamoun, Roukoz B.] Univ Kansas, Dept Neurosurg, Kansas City, KS USA; [Valadka, Alex B.] Seton Brain & Spine Inst Neurosurg, Austin, TX USA; [Sum, Dima] Univ Texas Houston, MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA	Gopinath, SP (corresponding author), Baylor Coll Med, Dept Neurosurg, 6501 Fannin St NC-100, Houston, TX 77030 USA.	shankarg@bcm.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P01-NS38660]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG017604] Funding Source: NIH RePORTER	This Study is supported by NIH Grant P01-NS38660. The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.	[Anonymous], 2001, J TRAUMA S, V51, pS44; BENZEL EC, 1991, NEUROSURGERY, V29, P67, DOI 10.1227/00006123-199107000-00011; CAVALIERE R, 1988, ACTA NEUROCHIR, V94, P133, DOI 10.1007/BF01435866; Chamoun RB, 2009, J NEUROSURG, V111, P683, DOI 10.3171/2009.2.JNS08817; CLARK WC, 1986, J NEUROSURG, V65, P9, DOI 10.3171/jns.1986.65.1.0009; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; GRAHM TW, 1990, NEUROSURGERY, V27, P696, DOI 10.1227/00006123-199011000-00005; JACOBS DG, 1995, AM SURGEON, V61, P647; KAUFMAN HH, 1986, NEUROSURGERY, V18, P689, DOI 10.1227/00006123-198606000-00002; KAUFMAN HH, 1993, NEUROSURGERY, V32, P962, DOI 10.1227/00006123-199306000-00013; Khan MB, 2013, WORLD NEURO IN PRESS; Kim TW, 2007, J TRAUMA, V62, P1446, DOI 10.1097/01.ta.0000222909.31666.db; Levy M L, 2000, Neurosurg Focus, V8, pe2, DOI 10.3171/foc.2000.8.1.153; LEVY ML, 1994, NEUROSURGERY, V35, P77, DOI 10.1227/00006123-199407000-00012; Martins RS, 2003, SURG NEUROL, V60, P98, DOI 10.1016/S0090-3019(03)00302-1; Murano T, 2005, AM SURGEON, V71, P1009; NAGIB MG, 1986, NEUROSURGERY, V18, P533, DOI 10.1227/00006123-198605000-00003; Nathoo N, 2002, SURG NEUROL, V58, P225, DOI 10.1016/S0090-3019(02)00828-5; Ozkan U, 2002, NEUROSURG REV, V25, P231, DOI 10.1007/s101430100173; ROBERTSON CS, 1995, J NEUROTRAUM, V12, P891, DOI 10.1089/neu.1995.12.891; SHOUNG HM, 1985, ACTA NEUROCHIR, V74, P27, DOI 10.1007/BF01413272; SICCARDI D, 1991, SURG NEUROL, V35, P455, DOI 10.1016/0090-3019(91)90179-D; STONE JL, 1995, NEUROSURGERY, V37, P1104, DOI 10.1227/00006123-199512000-00010; Sustic A, 2001, MIL MED, V166, P331	24	42	43	0	6	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	SEP	2014	121	3					645	652		10.3171/2014.5.JNS131872			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	AN6EW	WOS:000340688700020	24995781				2021-06-18	
J	Jacobsen, A; Nielsen, TH; Nilsson, O; Schalen, W; Nordstrom, CH				Jacobsen, A.; Nielsen, T. H.; Nilsson, O.; Schalen, W.; Nordstrom, C. H.			Bedside diagnosis of mitochondrial dysfunction in aneurysmal subarachnoid hemorrhage	ACTA NEUROLOGICA SCANDINAVICA			English	Article						cerebral energy metabolism; microdialysis; mitochondrial dysfunction; ischemia; lactate; pyruvate; subarachnoid hemorrhage	CEREBRAL ENERGY-METABOLISM; TRAUMATIC BRAIN-INJURY; CYCLOSPORINE-A; INTRACEREBRAL MICRODIALYSIS; GLYCOLYTIC METABOLITES; PERFUSION-PRESSURE; AMINO-ACIDS; ISCHEMIA; VASOSPASM; RATS	Objectives - Aneurysmal subarachnoid hemorrhage (SAH) is frequently associated with delayed neurological deterioration (DND). Several studies have shown that DND is not always related to vasospasm and ischemia. Experimental and clinical studies have recently documented that it is possible to diagnose and separate cerebral ischemia and mitochondrial dysfunction bedside. The study explores whether cerebral biochemical variables in SAH patients most frequently exhibit a pattern indicating ischemia or mitochondrial dysfunction. Methods - In 55 patients with severe SAH, intracerebral microdialysis was performed during neurocritical care with bedside analysis and display of glucose, pyruvate, lactate, glutamate, and glycerol. The biochemical patterns observed were compared to those previously described in animal studies of induced mitochondrial dysfunction as well as the pattern obtained in patients with recirculated cerebral infarcts. Results - In 29 patients, the biochemical pattern indicated mitochondrial dysfunction while 10 patients showed a pattern of cerebral ischemia, six of which also exhibited periods of mitochondrial dysfunction. Mitochondrial dysfunction was observed during 5162 h. An ischemic pattern was obtained during 688 h. Four of the patients (40%) with biochemical signs of ischemia died at the neurosurgical department as compared with three patients (10%) in the group of mitochondrial dysfunction. Conclusions - The study documents that mitochondrial dysfunction is a common cause of disturbed cerebral energy metabolism in patients with SAH. Mitochondrial dysfunction may increase tissue sensitivity to secondary adverse events such as vasospasm and decreased cerebral blood flow. The separation of ischemia and mitochondrial dysfunction bedside by utilizing microdialysis offers a possibility to evaluate new therapies.	[Jacobsen, A.; Nielsen, T. H.; Nordstrom, C. H.] Odense Univ Hosp, Dept Neurosurg, DK-5000 Odense, Denmark; [Nilsson, O.; Schalen, W.] Univ Lund Hosp, Dept Neurosurg, S-22185 Lund, Sweden	Nordstrom, CH (corresponding author), Persikevagen 77, SE-22355 Lund, Sweden.	carl-henrik.nordstrom@med.lu.se	Nielsen, Troels Halfeld/G-3456-2015	Nielsen, Troels Halfeld/0000-0002-3943-8128	Lund University Hospital; Odense University Hospital; University of Southern Denmark	We thank Katarina Nielsen, Department of Neurosurgery, Lund University Hospital, for help with the microdialysis equipment and biochemical analyses. The study was supported by grants from Lund University Hospital, Odense University Hospital, and University of Southern Denmark.	Akdemir G, 2005, NEUROL RES, V27, P827, DOI 10.1179/016164105X63610; Amer-Wahlin I, 2010, J MATERN-FETAL NEO M, V23, P158, DOI 10.3109/14767050903067360; Chen HI, 2011, NEUROSURGERY, V69, P53, DOI 10.1227/NEU.0b013e3182191451; Diringer MN, 2011, NEUROCRIT CARE, V15, P211, DOI 10.1007/s12028-011-9605-9; Etminan N, 2011, J CEREBR BLOOD F MET, V31, P1443, DOI 10.1038/jcbfm.2011.7; Gardenfors A, 2002, ACTA NEUROCHIR, V144, P601, DOI 10.1007/s00701-002-0954-1; Hillered L, 1998, J NEUROL NEUROSUR PS, V64, P486, DOI 10.1136/jnnp.64.4.486; Hillman J, 2002, J NEUROSURG, V97, P771, DOI 10.3171/jns.2002.97.4.0771; Hwang JH, 2010, BRAIN RES, V1359, P208, DOI 10.1016/j.brainres.2010.08.047; JENNETT B, 1977, LANCET, V1, P878; Kronvall E, 2009, J NEUROSURG, V110, P58, DOI 10.3171/2008.7.JNS08178; MACMILLAN VH, 1989, J CEREBR BLOOD F MET, V9, P156, DOI 10.1038/jcbfm.1989.23; Nielsen TH, 2013, ACTA ANAESTH SCAND, V57, P793, DOI 10.1111/aas.12092; Nielsen TH, 2013, ACTA ANAESTH SCAND, V57, P229, DOI 10.1111/j.1399-6576.2012.02783.x; NIELSEN TH, 2013, NEUROCRIT CARE, DOI [10.1007/6s12028-013-9875-5, DOI 10.1007/6S12028-013-9875-5]; NORDSTROM CH, 1978, J NEUROCHEM, V30, P479, DOI 10.1111/j.1471-4159.1978.tb06553.x; NORDSTROM CH, 1978, STROKE, V9, P335, DOI 10.1161/01.STR.9.4.335; Pierre K, 2005, J NEUROCHEM, V94, P1, DOI 10.1111/j.1471-4159.2005.03168.x; Pluta RM, 2009, NEUROL RES, V31, P151, DOI 10.1179/174313209X393564; REHNCRONA S, 1979, STROKE, V10, P437, DOI 10.1161/01.STR.10.4.437; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; Sala N, 2013, J CEREBR BLOOD F MET, V33, P1815, DOI 10.1038/jcbfm.2013.142; Schmidt JM, 2011, STROKE, V42, P1351, DOI 10.1161/STROKEAHA.110.596874; Siesj_o B K, 1978, BRAIN ENERGY METABOL; Skjoth-Rasmussen J, 2004, J NEUROSURG, V100, P8, DOI 10.3171/jns.2004.100.1.0008; Stahl N, 2001, ACTA ANAESTH SCAND, V45, P977, DOI 10.1034/j.1399-6576.2001.450810.x; Uchino H, 1998, BRAIN RES, V812, P216, DOI 10.1016/S0006-8993(98)00902-0; Ungerstedt U, 1997, PHYSIOLOGY, STRESS, AND MALNUTRITION, P361; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vespa PM, 2007, CRIT CARE MED, V35, P1153, DOI 10.1097/01.CCM.0000259466.66310.4F; Washington CW, 2011, NEUROCRIT CARE, V15, P312, DOI 10.1007/s12028-011-9594-8	31	42	42	0	3	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-6314	1600-0404		ACTA NEUROL SCAND	Acta Neurol. Scand.	SEP	2014	130	3					156	163		10.1111/ane.12258			8	Clinical Neurology	Neurosciences & Neurology	AN4OX	WOS:000340568500003	24796605				2021-06-18	
J	Juratli, TA; Zang, B; Litz, RJ; Sitoci, KH; Aschenbrenner, U; Gottschlich, B; Daubner, D; Schackert, G; Sobottka, SB				Juratli, Tareq A.; Zang, Benedikt; Litz, Rainer J.; Sitoci, Kerim-Hakan; Aschenbrenner, Ulf; Gottschlich, Birgit; Daubner, Dirk; Schackert, Gabriele; Sobottka, Stephan B.			Early Hemorrhagic Progression of Traumatic Brain Contusions: Frequency, Correlation with Coagulation Disorders, and Patient Outcome: A Prospective Study	JOURNAL OF NEUROTRAUMA			English	Article						hemorrhagic progression of a contusion; long-term outcome; modified Rankin scale; traumatic brain contusions; trauma-induced coagulopathy	SEVERE HEAD-INJURY; INTRAVASCULAR COAGULATION; INTRACRANIAL HEMORRHAGE; COAGULOPATHY; IMPACT	The focus of this paper is to identify and quantify risk factors for early hemorrhagic progression of brain contusions (HPC) in patients with traumatic brain injury (TBI) and to evaluate their impact on patients' outcome. Further, based on abnormal values in routine blood tests, the role of trauma-induced coagulopathy is analyzed in detail. Therefore, a prospective study of 153 TBI patients was completed at one institution between January 2008 and June 2012. The collected data included demographics, initial Glasgow Coma Scale pupillary response, initial and 6 h follow-up computed tomography scan findings, coagulation parameters (international normalized ratio, partial thromboplastin time, platelet count, fibrinogen, D-dimer and factor XIII), as well as outcome data using the modified Rankin score at discharge and after one year. The overall rate of early HPC within the first 6 h was 43.5%. The frequency of coagulopathy was 47.1%. When analyzing for risk factors that independently influenced outcome in the form of mRS >= 4 at both points, the following variables appeared: elevated D-dimer level (>= 10,000 mu g/L), HPC, and initial brain contusions >= 3 cm. Patients sustaining early HPC had a hazard ratio of 5.4 for unfavorable outcome at discharge (p=0.002) and of 3.9 after one year (p=0.006). Overall, patients who developed early HPC were significantly more likely to be gravely disabled or to die. Unfavorable neurological outcome after an isolated TBI is determined largely by early HPC and coagulopathy, which seem to occur very frequently in TBI patients, irrespective of the severity of the trauma.	[Juratli, Tareq A.; Zang, Benedikt; Sitoci, Kerim-Hakan; Schackert, Gabriele; Sobottka, Stephan B.] Univ Hosp Dresden, Dept Neurosurg, Dresden, Germany; [Aschenbrenner, Ulf] Univ Hosp Dresden, Dept Trauma & Reconstruct Surg, Dresden, Germany; [Gottschlich, Birgit] Univ Hosp Dresden, Dept Anesthesiol & Intens Care Med, Dresden, Germany; [Daubner, Dirk] Univ Hosp Dresden, Dept Neuroradiol, Dresden, Germany; [Litz, Rainer J.] Berufsgenossenschaftliches Univ Klinikum Bergmann, Dept Anesthesiol & Intens Care Med, Bochum, Germany	Juratli, TA (corresponding author), Tech Univ Dresden, Univ Hosp Carl Gustav Carus Dresden, Dept Neurosurg, Fetscherstr 74, D-01307 Dresden, Germany.	tareq.juratli@uniklinikum-dresden.de	Juratli, Tareq/J-6832-2014	Juratli, Tareq/0000-0003-2236-6719			Alahmadi H, 2010, J NEUROSURG, V112, P1139, DOI 10.3171/2009.5.JNS081369; Allard CB, 2009, J TRAUMA, V67, P959, DOI 10.1097/TA.0b013e3181ad5d37; ATWOOD WH, 1959, AM J MED SCI, V238, P720, DOI 10.1097/00000441-195912000-00006; Bakhtiari K, 2004, CRIT CARE MED, V32, P2416, DOI 10.1097/01.CCM.0000147769.07699.E3; Becker S, 1999, EUR J PEDIATR, V158, pS197, DOI 10.1007/PL00014355; BREDBACKA S, 1994, J NEUROSURG ANESTH, V6, P75; Carrick MM, 2005, J TRAUMA, V58, P725, DOI 10.1097/01.TA.0000159249.68363.78; Chang EF, 2006, NEUROSURGERY, V58, P647, DOI 10.1227/01.NEU.0000197101.68538.E6; Cortiana M, 1986, J Neurosurg Sci, V30, P133; GOODNIGHT SH, 1974, NEW ENGL J MED, V290, P1043, DOI 10.1056/NEJM197405092901903; Greuters S, 2011, CRIT CARE, V15, DOI 10.1186/cc9399; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; Hoyt DB, 2004, SEMIN HEMATOL, V41, P40, DOI 10.1053/j.seminhematol.2003.11.009; KEARNEY TJ, 1992, J TRAUMA, V32, P608, DOI 10.1097/00005373-199205000-00012; Kurland D, 2012, J NEUROTRAUM, V29, P19, DOI 10.1089/neu.2011.2122; Kushimoto S, 2003, J NEUROTRAUM, V20, P357, DOI 10.1089/089771503765172318; Lustenberger T, 2010, INJURY, V41, P924, DOI 10.1016/j.injury.2010.04.019; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MISHLER JM, 1975, VOX SANG, V28, P218, DOI 10.1111/j.1423-0410.1975.tb02760.x; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Narayan RK, 2008, J NEUROTRAUM, V25, P629, DOI 10.1089/neu.2007.0385; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; OLSON JD, 1989, NEUROSURGERY, V24, P825, DOI 10.1227/00006123-198906000-00007; Schnuriger B, 2010, J TRAUMA, V68, P881, DOI 10.1097/TA.0b013e3181d3cc58; Schochl H., 2013, J NEUROTRAUM, V28, P2033; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; Stein SC, 2002, J NEUROSURG, V97, P1373, DOI 10.3171/jns.2002.97.6.1373; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; Vavilala MS, 2001, J NEUROSURG ANESTH, V13, P13, DOI 10.1097/00008506-200101000-00003; Wafaisade A, 2010, NEUROCRIT CARE, V12, P211, DOI 10.1007/s12028-009-9281-1	30	42	53	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP 1	2014	31	17					1521	1527		10.1089/neu.2013.3241			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AO7GO	WOS:000341520700007	24738836				2021-06-18	
J	Waljas, M; Iverson, GL; Lange, RT; Liimatainen, S; Hartikainen, KM; Dastidar, P; Soimakallio, S; Ohman, J				Waljas, Minna; Iverson, Grant L.; Lange, Rael T.; Liimatainen, Suvi; Hartikainen, Kaisa M.; Dastidar, Prasun; Soimakallio, Seppo; Ohman, Juha			Return to Work Following Mild Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article; Proceedings Paper	3rd Federal Interagency Conference on Traumatic Brain Injury	JUN 13-15, 2011	Washington, DC			mild traumatic brain injury; outcome; return to work	POSTTRAUMATIC-STRESS-DISORDER; MODERATE HEAD-INJURY; ILLNESS PERCEPTIONS; RISK-FACTORS; RELIABILITY; DEPRESSION; SYMPTOMS; CT	Objective: To examine factors relating to return to work (RTW) following mild traumatic brain injury (mTBI). Participants: One hundred and nine patients (Age: M = 37.4 years, SD = 13.2; 52.3% women) who sustained an mTBI. Design: Inception cohort design with questionnaires and neuropsychological testing completed approximately 3 to 4 weeks postinjury. Setting: Emergency Department of Tampere University Hospital, Finland. Main Outcome Measures: Self-report (postconcussion symptoms, depression, fatigue, and general health) and neurocognitive measures (attention and memory). Results: The cumulative RTW rates were as follows: 1 week = 46.8%, 2 weeks = 59.6%, 3 weeks = 67.0%, 4 weeks = 70.6%, 2 months = 91.7%, and 1 year = 97.2%. Four variables were significant predictors of the number of days to RTW: age, multiple bodily injuries, intracranial abnormality at the day of injury, and fatigue ratings (all P <.001). The largest amount of variance accounted for by these variables in the prediction of RTW was at 30 days following injury (P <.001, R-2 = 0.504). Participants who returned to work fewer than 30 days after injury (n = 82, 75.2%) versus more than 30 days (n = 27, 24.8%) did not differ on demographic or neuropsychological variables. Conclusions: The vast majority of this cohort returned to work within 2 months. Predictors of slower RTW included age, multiple bodily injuries, intracranial abnormality at the day of injury, and fatigue.	[Waljas, Minna; Ohman, Juha] Tampere Univ Hosp, Dept Neurosurg, FIN-3521 Tampere, Finland; [Waljas, Minna; Hartikainen, Kaisa M.; Dastidar, Prasun; Soimakallio, Seppo; Ohman, Juha] Univ Tampere, Sch Med, FIN-33101 Tampere, Finland; [Iverson, Grant L.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA; [Iverson, Grant L.] Red Sox Fdn, Boston, MA USA; [Iverson, Grant L.] Massachusetts Gen Hosp, Home Base Program, Boston, MA 02114 USA; [Lange, Rael T.] Def & Vet Brain Injury Ctr, Bethesda, MD USA; [Lange, Rael T.] Walter Reed Natl Mil Med Ctr, Bethesda, MD USA; [Liimatainen, Suvi] Tampere Univ Hosp, Dept Neurosci & Rehabil & Emergency, Dept Acuta, FIN-3521 Tampere, Finland; [Dastidar, Prasun; Soimakallio, Seppo] Pirkanmaa Hosp Dist, Med Imaging Ctr, Tampere, Finland	Waljas, M (corresponding author), Tampere Univ Hosp, Dept Neurosurg, POB 2000, FIN-3521 Tampere, Finland.	minna.waljas@gmail.com		Hartikainen, Kaisa/0000-0001-7278-9635; Iverson, Grant/0000-0001-7348-9570; Ohman, Juha/0000-0002-6592-1367			Andersson EE, 2011, J REHABIL MED, V43, P323, DOI 10.2340/16501977-0666; Army Individual Test Battery, 1944, MAN DIR SCOR; Babor T., 2001, ALCOHOL USE DISORDER, V2nd ed.; Babor TF, 1992, EVALUATION RELIABILI; Beck A., 1996, MANUAL BDI 2; Beck AT., 1996, BECK DEPRESSION INVE, V2; BOHN MJ, 1995, J STUD ALCOHOL, V56, P423, DOI 10.15288/jsa.1995.56.423; Borgaro SR, 2004, BRAIN INJURY, V18, P685, DOI 10.1080/02699050310001646080; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Ferrari R, 2001, CLIN NEUROL NEUROSUR, V103, P184, DOI 10.1016/S0303-8467(01)00143-3; Haboubi NHJ, 2001, DISABIL REHABIL, V23, P635; Hanlon RE, 1999, BRAIN INJURY, V13, P873; HAYS RD, 1995, BEHAV RES METH INSTR, V27, P277, DOI 10.3758/BF03204745; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Holbrook TL, 2001, J TRAUMA, V51, P287, DOI 10.1097/00005373-200108000-00010; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; IVERSON GL, 2012, REHABIL RES PRACT, V2012, DOI DOI 10.1155/2012/415740; Iverson GL, 2012, BRAIN INJURY MED PRI; Iverson GL, 2006, BRAIN INJURY, V20, P1335, DOI 10.1080/02699050601082156; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Lange RT, 2009, BRAIN INJURY, V23, P83, DOI 10.1080/02699050802635281; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; Michaels AJ, 2000, J TRAUMA, V48, P841, DOI 10.1097/00005373-200005000-00007; Mitrushina M., 2005, NORMATIVE DATA NEURO; Nolin P, 2006, J HEAD TRAUMA REHAB, V21, P514, DOI 10.1097/00001199-200611000-00006; Powell TJ, 1996, DISABIL REHABIL, V18, P231, DOI 10.3109/09638289609166306; Ruffolo CF, 1999, ARCH PHYS MED REHAB, V80, P392, DOI 10.1016/S0003-9993(99)90275-7; Shalev AY, 1998, AM J PSYCHIAT, V155, P630, DOI 10.1176/ajp.155.5.630; Shames J, 2007, DISABIL REHABIL, V29, P1387, DOI 10.1080/09638280701315011; Snell DL, 2011, BRAIN INJURY, V25, P1126, DOI 10.3109/02699052.2011.607786; Spinos P, 2010, J TRAUMA, V69, P789, DOI 10.1097/TA.0b013e3181edea67; Spreen O., 1991, COMPENDIUM NEUROPSYC; Stranjalis G, 2004, J NEUROTRAUM, V21, P1070, DOI 10.1089/0897715041651088; Temkin NR, 2003, J NEUROTRAUM, V20, P229, DOI 10.1089/089771503321532815; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Vuadens P, 2006, COLLECT ACAD EUR MED, P143, DOI 10.1007/2-287-29745-6_10; Wechsler D, 1997, WAIS 3 ADM SCORING M; Whittaker R, 2007, J NEUROL NEUROSUR PS, V78, P644, DOI 10.1136/jnnp.2006.101105; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wilson J. T. L, 1996, RECOVERY TRAUMATIC B, P29; World Health Organization, 2011, ICF INT CLASS FUNCT; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3; Zatzick DF, 2002, AM J PSYCHIAT, V159, P941, DOI 10.1176/appi.ajp.159.6.941	50	42	42	1	18	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2014	29	5					443	450		10.1097/HTR.0000000000000002			8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AP2GW	WOS:000341891700013	24263178				2021-06-18	
J	Pietrzak, E; Pullman, S; McGuire, A				Pietrzak, Eva; Pullman, Stephen; McGuire, Annabel			Using Virtual Reality and Videogames for Traumatic Brain Injury Rehabilitation: A Structured Literature Review	GAMES FOR HEALTH JOURNAL			English	Article							GAME-BASED EXERCISES; BALANCE REHABILITATION; STROKE REHABILITATION; PEOPLE; PROGRAMS	Objective: This article reviews the available literature about the use of novel methods of rehabilitation using virtual reality interventions for people living with posttraumatic brain injuries. Materials and Methods: The MEDLINE, EMBASE, SCOPUS, and Cochrane Library databases were searched using the terms "virtual reality'' OR "video games'' AND "traumatic brain injury.'' Included studies investigated therapeutic use of virtual reality in adults with a brain trauma resulting from acquired closed head injury, reported outcomes that included measures of motor or cognitive functionality, and were published in a peer-reviewed journal written in English. Results: Eighteen articles fulfilled inclusion criteria. Eight were case studies, five studies had a quasi-experimental design with a pre-post comparison, and five were pilot randomized control trials or comparative studies. The virtual reality systems used were commercial or custom designed for the study and ranged from expensive, fully immersive systems to cheap online games or videogames. In before-after comparisons, improvements in balance were seen in four case studies and two small randomized control trials. Between-group comparisons in these randomized control trials showed no difference between virtual reality and traditional therapy. Post-training improvements were also seen for upper extremity functions (five small studies) and for various cognitive function measures (four case studies and one pilot randomized control trial). Attitudes of participants toward virtual reality interventions was more positive than for traditional therapy (three studies). Conclusions: The evidence that the use of virtual reality in rehabilitation of traumatic brain injury improves motor and cognitive functionality is currently very limited. However, this approach has the potential to provide alternative, possibly more affordable and available rehabilitation therapy for traumatic brain injury in settings where access to therapy is limited by geographical or financial constraints.	[Pietrzak, Eva; Pullman, Stephen; McGuire, Annabel] Univ Queensland, Ctr Australian Mil & Vet Hlth, Sch Populat Hlth, Herston, Qld 4006, Australia	McGuire, A (corresponding author), Univ Queensland, Ctr Australian Mil & Vet Hlth, Sch Populat Hlth, Ground Floor,Publ Hlth Bldg,Herston Rd, Herston, Qld 4006, Australia.	a.mcguire@uq.edu.au			E-Health Research Unit, UQ Node, Centre for Australian Military and Veterans' Health	This review was undertaken on behalf of and funded by the E-Health Research Unit, UQ Node, Centre for Australian Military and Veterans' Health.	Almeida TLT, 2012, ACTA FISIATR, V19, P130; Betker AL, 2007, PHYS THER, V87, P1389, DOI 10.2522/ptj.20060229; Betker AL, 2006, ARCH PHYS MED REHAB, V87, P1141, DOI 10.1016/j.apmr.2006.04.010; Caglio M, 2012, NEUROCASE, V18, P123, DOI 10.1080/13554794.2011.568499; Caglio M, 2009, COGN PROCESS, V10, pS195, DOI 10.1007/s10339-009-0295-6; Centers for Disease Control and Prevention, INF PREV CONTR TRAUM; Cox DJ, 2010, MIL MED, V175, P411, DOI 10.7205/MILMED-D-09-00081; Eisenzopf L, 2010, BRAIN INJURY, V24, P167; Entertainment Software Association, ESS FACTS COMP VID G; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Flaghouse, GESTURETEK IREX SYST; Flynn SM, 2010, P INT C DIS VIRT REA, P185; Fondren M, 2011, VIRTUAL REHABILITATI; Gamito P., 2011, INT J DISABIL HUM DE, V10, P309, DOI [10.1515/ijdhd.2011.049, DOI 10.1515/IJDHD.2011.049]; Grealy MA, 1999, ARCH PHYS MED REHAB, V80, P661, DOI 10.1016/S0003-9993(99)90169-7; Holden MK, 2001, ST HEAL T, V81, P192; Khan F, 2003, MED J AUSTRALIA, V178, P290, DOI 10.5694/j.1326-5377.2003.tb05199.x; Kleim JA, 2008, J SPEECH LANG HEAR R, V51, pS225, DOI 10.1044/1092-4388(2008/018); Kwakkel G, 2006, DISABIL REHABIL, V28, P823, DOI 10.1080/09638280500534861; Lange BS, 2010, PHYS MED REH CLIN N, V21, P339, DOI 10.1016/j.pmr.2009.12.007; Laver KE, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008349.pub2; Mumford N, 2012, BRAIN INJURY, V26, P166, DOI 10.3109/02699052.2011.648706; Mumford N, 2010, BRAIN INJURY, V24, P780, DOI 10.3109/02699051003652807; National Stroke Foundation, 2010, NAT STROK AUD REH SE; Rabago CA, 2011, J NEUROL PHYS THER, V35, P185, DOI 10.1097/NPT.0b013e318235d7e6; Rose FD, 2005, CYBERPSYCHOL BEHAV, V8, P241, DOI 10.1089/cpb.2005.8.241; Saposnik G, 2011, STROKE, V42, P1380, DOI 10.1161/STROKEAHA.110.605451; Saposnik G, 2010, STROKE, V41, P1477, DOI 10.1161/STROKEAHA.110.584979; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Shopboat, NINT WII FIT; Sveistrup H, 2003, CYBERPSYCHOL BEHAV, V6, P245, DOI 10.1089/109493103322011524; The Stroke Center University Hospital Newark New Jersey, 2013, STROK STAT 2013; Thornton M, 2005, BRAIN INJURY, V19, P989, DOI 10.1080/02699050500109944; Turner-Stokes L, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004170.pub2; Ustinova KI, 2011, 2011 INT C VIRT REH, P1, DOI [10.1109/ICVR.2011.5971864, DOI 10.1109/ICVR.2011.5971864]; Ustinova KI, 2011, J NEUROENG REHABIL, V8, DOI 10.1186/1743-0003-8-61; Yip BCB, 2013, NEUROREHABILITATION, V32, P103, DOI [10.3233/NRE-30827, 10.3233/NRE-130827]; Yip BCB, 2009, BRAIN INJURY, V23, P1017, DOI 10.3109/02699050903379412	39	42	43	0	26	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	2161-783X	2161-7856		GAMES HEALTH J	Games Health J.	AUG	2014	3	4					202	214		10.1089/g4h.2014.0013			13	Health Policy & Services; Public, Environmental & Occupational Health; Rehabilitation	Health Care Sciences & Services; Public, Environmental & Occupational Health; Rehabilitation	CU2WC	WOS:000363383300003	26192369				2021-06-18	
J	Wagner, AK; Scanlon, JM; Becker, CR; Ritter, AC; Niyonkuru, C; Dixon, CE; Conley, YP; Price, JC				Wagner, Amy K.; Scanlon, Joelle M.; Becker, Carl R.; Ritter, Anne C.; Niyonkuru, Christian; Dixon, Clifton E.; Conley, Yvette P.; Price, Julie C.			The influence of genetic variants on striatal dopamine transporter and D2 receptor binding after TBI	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						beta-CFT; dopamine; genetic variation; PET imaging; raclopride; traumatic brain injury	TRAUMATIC BRAIN-INJURY; MONOAMINE TRANSPORTERS; PARKINSONS-DISEASE; PET; AVAILABILITY; ASSOCIATION; C-11; POLYMORPHISMS; IMPAIRMENT; NUCLEUS	Dopamine (DA) neurotransmission influences cognition and recovery after traumatic brain injury (TBI). We explored whether functional genetic variants affecting the DA transporter (DAT) and D2 receptor (DRD2) impacted in vivo dopaminergic binding with positron emission tomography (PET) using [C-11]beta CFT and [C-11]raclopride. We examined subjects with moderate/severe TBI (N=12) similar to 1 year post injury and similarly matched healthy controls (N=13). The variable number of tandem repeat polymorphism within the DAT gene and the Taql restriction fragment length polymorphism near the DRD2 gene were assessed. TBI subjects had age-adjusted DAT-binding reductions in the caudate, putamen, and ventral striatum, and modestly increased D2 binding in ventral striatum versus controls. Despite small sample sizes, multivariate analysis showed lower caudate and putamen DAT binding among DAT 9-allele carriers and DRD2 A2/A2 homozygotes with TBI versus controls with the same genotype. Among TBI subjects, 9-allele carriers had lower caudate and putamen binding than 10/10 homozygotes. This PET study suggests a hypodopaminergic environment and altered DRD2 autoreceptor DAT interactions that may influence DA transmission after TBI. Future work will relate these findings to cognitive performance; future studies are required to determine how DRD2/DAT1 genotype and DA-ligand binding are associated with neurostimulant response and TBI recovery.	[Wagner, Amy K.; Scanlon, Joelle M.; Ritter, Anne C.; Niyonkuru, Christian; Dixon, Clifton E.] Univ Pittsburgh, Dept Phys Med & Rehabil, Sch Med, Pittsburgh, PA 15213 USA; [Wagner, Amy K.; Dixon, Clifton E.; Conley, Yvette P.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; [Becker, Carl R.; Price, Julie C.] Univ Pittsburgh, Sch Med, Dept Radiol, Pittsburgh, PA 15213 USA; [Dixon, Clifton E.] Univ Pittsburgh, Sch Med, Dept Neurosurg, Pittsburgh, PA 15213 USA; [Conley, Yvette P.] Univ Pittsburgh, Sch Nursing, Dept Hlth Promot & Dev, Pittsburgh, PA 15213 USA	Wagner, AK (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, 3471 Fifth Ave,Suite 202, Pittsburgh, PA 15213 USA.	wagnerak@upmc.edu; pricjc@upmc.edu		Conley, Yvette/0000-0002-1784-6067	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 HD048162, K01 MH01976]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048162] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K01MH001976] Funding Source: NIH RePORTER	Support for this work was provided by NIH R01 HD048162; K01 MH01976.	Abdolmaleky Hamid Mostafavi, 2008, V448, P187, DOI 10.1007/978-1-59745-205-2_9; Bales JW, 2009, NEUROSCI BIOBEHAV R, V33, P981, DOI 10.1016/j.neubiorev.2009.03.011; Bertolino A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009348; Bruck A, 2001, NEUROSCI LETT, V311, P81, DOI 10.1016/S0304-3940(01)02124-3; COMINGS DE, 1991, JAMA-J AM MED ASSOC, V266, P1793, DOI 10.1001/jama.266.13.1793; Crosson B, 2003, J INT NEUROPSYCH SOC, V9, P1027, DOI 10.1017/S1355617703970068; Donnemiller E, 2000, EUR J NUCL MED, V27, P1410, DOI 10.1007/s002590000308; Drevets WC, 2001, BIOL PSYCHIAT, V49, P81, DOI 10.1016/S0006-3223(00)01038-6; Duan JB, 2003, HUM MOL GENET, V12, P205, DOI 10.1093/hmg/ddg055; Forsback S, 2012, EJNMMI RES, V2, DOI 10.1186/2191-219X-2-3; Frank MJ, 2009, NEUROSCIENCE, V164, P131, DOI 10.1016/j.neuroscience.2009.04.048; Genro JP, 2008, AM J MED GENET B, V147B, P1568, DOI 10.1002/ajmg.b.30863; Gu ZQ, 2010, NEUROSCI LETT, V482, P31, DOI 10.1016/j.neulet.2010.06.085; Gunn RN, 1997, NEUROIMAGE, V6, P279, DOI 10.1006/nimg.1997.0303; Gurevich EV, 1999, NEUROPSYCHOPHARMACOL, V20, P60, DOI 10.1016/S0893-133X(98)00066-9; HALLDIN C, 1991, NUCL MED BIOL, V18, P871; Heinz A, 2000, NEUROPSYCHOPHARMACOL, V22, P133, DOI 10.1016/S0893-133X(99)00099-8; Hoffman AF, 1998, J PHARMACOL EXP THER, V287, P487; Innis RB, 2007, J CEREBR BLOOD F MET, V27, P1533, DOI 10.1038/sj.jcbfm.9600493; Laruelle M, 2002, METHODS, V27, P287, DOI 10.1016/S1046-2023(02)00085-3; Lin ZC, 2011, PROG MOL BIOL TRANSL, V98, P1, DOI 10.1016/B978-0-12-385506-0.00001-6; Logan J, 2003, NUCL MED BIOL, V30, P833, DOI 10.1016/S0969-8051(03)00114-8; Mcdougall SA, 2011, SYNAPSE, V65, P583, DOI 10.1002/syn.20877; Meltzer CC, 1999, J NUCL MED, V40, P2053; NAGREN K, 1995, NUCL MED BIOL, V22, P235, DOI 10.1016/0969-8051(94)00083-V; Noble EP, 1997, AM J MED GENET, V74, P162; Ouchi Y, 1999, ANN NEUROL, V45, P601, DOI 10.1002/1531-8249(199905)45:5<601::AID-ANA8>3.0.CO;2-0; Rinne JO, 2000, ARCH NEUROL-CHICAGO, V57, P470, DOI 10.1001/archneur.57.4.470; Ritchie T, 2003, NEUROCHEM RES, V28, P73, DOI 10.1023/A:1021648128758; Rohde LA, 2003, SYNAPSE, V48, P87, DOI 10.1002/syn.10186; Rumpel R, 2013, NEUROBIOL DIS, V59, P230, DOI 10.1016/j.nbd.2013.07.016; Seeman P, 2006, SYNAPSE, V60, P205, DOI 10.1002/syn.20298; Troiano AR, 2010, SYNAPSE, V64, P146, DOI 10.1002/syn.20708; van Dyck CH, 2005, J NUCL MED, V46, P745; Volkow ND, 1998, AM J PSYCHIAT, V155, P344; VOLKOW ND, 1993, SYNAPSE, V14, P169, DOI 10.1002/syn.890140210; Wagner AK, 2005, J NEUROCHEM, V95, P457, DOI 10.1111/j.1471-4159.2005.03382.x; Wagner AK, 2007, J NEUROSURG, V106, P538, DOI 10.3171/jns.2007.106.4.538; Wagner AK, 2009, J NEUROCHEM, V108, P986, DOI 10.1111/j.1471-4159.2008.05840.x; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; WONG DF, 1993, SYNAPSE, V15, P130, DOI 10.1002/syn.890150205; Wu YJ, 2002, J CEREBR BLOOD F MET, V22, P1440, DOI 10.1097/01.WCB.0000033967.83623.34; Xu XH, 2009, BMC PSYCHIATRY, V9, DOI 10.1186/1471-244X-9-3; Zhang ZY, 2007, NEUROSCI LETT, V429, P1, DOI 10.1016/j.neulet.2007.09.061; Zhen J, 2012, J NEUROSCI METH, V203, P19, DOI 10.1016/j.jneumeth.2011.08.044	45	42	42	0	6	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	AUG	2014	34	8					1328	1339		10.1038/jcbfm.2014.87			12	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	AM4ZG	WOS:000339864100009	24849661	Green Published, Bronze			2021-06-18	
J	Vincent, AS; Roebuck-Spencer, TM; Cernich, A				Vincent, Andrea S.; Roebuck-Spencer, Tresa M.; Cernich, Alison			Cognitive changes and dementia risk after traumatic brain injury: Implications for aging military personnel	ALZHEIMERS & DEMENTIA			English	Article						Alzheimer's disease; Traumatic brain injury; Risk factors; Military medicine; Dementia	POSTTRAUMATIC-STRESS-DISORDER; AMYLOID PRECURSOR PROTEIN; SEVERE HEAD-INJURY; NEUROPSYCHOLOGICAL ASSESSMENT METRICS; COLLEGIATE FOOTBALL PLAYERS; SPORT-RELATED CONCUSSION; LONG-TERM ACCUMULATION; SYMPTOM VALIDITY TEST; ALZHEIMERS-DISEASE; MILD TBI	Traumatic brain injury (TBI) is recognized as an important risk factor for the long-term cognitive health of military personnel, particularly in light of growing evidence that TBI increases risk for Alzheimer's disease and other dementias. In this article, we review the neurocognitive and neuropathologic changes after TBI with particular focus on the potential risk for cognitive decline across the life span in military service members. Implications for monitoring and surveillance of cognition in the aging military population are discussed. Additional studies are needed to clarify the factors that increase risk for later life cognitive decline, define the mechanistic link between these factors and dementia, and provide empirically supported interventions to mitigate the impact of TBI on cognition across the life span. (C) 2014 The Alzheimer's Association. All rights reserved.	[Vincent, Andrea S.; Roebuck-Spencer, Tresa M.] Univ Oklahoma, Dept Psychol, Cognit Sci Res Ctr, Norman, OK 73019 USA; [Cernich, Alison] Def Ctr Excellence Psychol Hlth & Traumat Brain I, Dept Vet Affairs, Mental Hlth Serv, Washington, DC USA	Vincent, AS (corresponding author), Univ Oklahoma, Dept Psychol, Cognit Sci Res Ctr, Norman, OK 73019 USA.	avincent@ou.edu			United States Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC)	Publication of this article was supported by the United States Army Medical Research and Materiel Command.	Afari N, 2009, HEADACHE, V49, P1267, DOI 10.1111/j.1526-4610.2009.01517.x; AMADUCCI LA, 1986, NEUROLOGY, V36, P922, DOI 10.1212/WNL.36.7.922; [Anonymous], 2013, COMPR POL NEUR ASS M; Armistead-Jehle P, 2010, APPL NEUROPSYCHOL, V17, P52, DOI 10.1080/09084280903526182; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Barnes SM, 2012, REHABIL PSYCHOL, V57, P18, DOI 10.1037/a0027007; Bazarian JJ, 2009, J HEAD TRAUMA REHAB, V24, P439, DOI 10.1097/HTR.0b013e3181c15600; Belanger HG, 2011, CLIN NEUROPSYCHOL, V25, P702, DOI 10.1080/13854046.2011.566892; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Brenner LA, 2011, J HEAD TRAUMA REHAB, V26, P257, DOI 10.1097/HTR.0b013e31821fdb6e; Brenner LA, 2010, NEUROPSYCHOLOGY, V24, P160, DOI 10.1037/a0017966; Brenner LA, 2009, REHABIL PSYCHOL, V54, P239, DOI 10.1037/a0016908; BROE GA, 1990, NEUROLOGY, V40, P1698, DOI 10.1212/WNL.40.11.1698; Bryan C, 2012, J HEAD TRAUMA REHAB, V27, P45, DOI 10.1097/HTR.0b013e318238f146; Bryan CJ, 2013, JAMA PSYCHIAT, V70, P686, DOI 10.1001/jamapsychiatry.2013.1093; Bryan CJ, 2013, SLEEP, V36, P941, DOI 10.5665/sleep.2730; Burke JF, 2013, NEUROLOGY, V81, P33, DOI 10.1212/WNL.0b013e318297eecf; Carlson KF, 2010, J TRAUMA STRESS, V23, P17, DOI 10.1002/jts.20483; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cederberg D, 2010, CHILD NERV SYST, V26, P221, DOI 10.1007/s00381-009-1029-x; Cernich AN, 2012, J HEAD TRAUMA REHAB, V27, P253, DOI 10.1097/HTR.0b013e3182585cd5; CHANDRA V, 1987, NEUROLOGY, V37, P1295, DOI 10.1212/WNL.37.8.1295; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; Chen YH, 2011, STROKE, V42, P2733, DOI 10.1161/STROKEAHA.111.620112; Chien DT, 2014, J ALZHEIMERS DIS, V38, P171, DOI 10.3233/JAD-130098; Chien DT, 2013, J ALZHEIMERS DIS, V34, P457, DOI 10.3233/JAD-122059; Coldren RL, 2012, MIL MED, V177, P179, DOI 10.7205/MILMED-D-11-00278; Collen J, 2012, CHEST, V142, P622, DOI 10.1378/chest.11-1603; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Cooper DB, 2012, MIL MED, V177, P1157, DOI 10.7205/MILMED-D-12-00098; Corrigan JD, 2012, BRAIN INJURY, V26, P139, DOI 10.3109/02699052.2011.648705; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Dagher JH, 2013, BRAIN INJURY, V27, P189, DOI 10.3109/02699052.2012.729288; Das M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-236; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; DIKMEN S, 1983, ARCH NEUROL-CHICAGO, V40, P333, DOI 10.1001/archneur.1983.04050060033004; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Echemendia RJ, 2012, CLIN NEUROPSYCHOL, V26, P1077, DOI 10.1080/13854046.2012.721006; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Faul M.D., 2010, TRAUMATIC BRAIN INJU; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; FERINISTRAMBI L, 1990, NEUROEPIDEMIOLOGY, V9, P39, DOI 10.1159/000110750; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Fortier CB, 2014, J HEAD TRAUMA REHAB, V29, P89, DOI 10.1097/HTR.0b013e3182865859; FRENCH LR, 1985, AM J EPIDEMIOL, V121, P414, DOI 10.1093/oxfordjournals.aje.a114013; GEDYE A, 1989, J AM GERIATR SOC, V37, P970, DOI 10.1111/j.1532-5415.1989.tb07283.x; Gennarelli T. A., 2005, TXB TRAUMATIC BRAIN, P27; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Giza CC, 2001, J ATHL TRAINING, V36, P228; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Harada R, 2013, EUR J NUCL MED MOL I, V40, P125, DOI 10.1007/s00259-012-2261-2; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; Hawkins BE, 2013, J BIOL CHEM, V288, P17042, DOI 10.1074/jbc.M113.472746; Helmick K, 2012, MIL MED, V177, P86, DOI 10.7205/MILMED-D-12-00174; HEYMAN A, 1984, ANN NEUROL, V15, P335, DOI 10.1002/ana.410150406; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Ivins BJ, 2010, NEUROREHABILITATION, V26, P199, DOI 10.3233/NRE-2010-0556; Ivins BJ, 2009, J HEAD TRAUMA REHAB, V24, P24, DOI 10.1097/HTR.0b013e3181957042; Iwata A, 2002, J NEUROPATH EXP NEUR, V61, P1056, DOI 10.1093/jnen/61.12.1056; Jellinger K A, 2001, BMC Neurol, V1, P3, DOI 10.1186/1471-2377-1-3; Kalmar K, 2008, ARCH PHYS MED REHAB, V89, P942, DOI 10.1016/j.apmr.2008.01.008; KATZMAN R, 1989, ANN NEUROL, V25, P317, DOI 10.1002/ana.410250402; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kelly MP, 2012, ARCH CLIN NEUROPSYCH, V27, P375, DOI 10.1093/arclin/acs036; Kontos AP, 2013, J NEUROTRAUM, V30, P680, DOI 10.1089/neu.2012.2506; Lamberty GJ, 2014, J HEAD TRAUMA REHAB, V29, pE1, DOI 10.1097/HTR.0b013e31829a64d1; Lange RT, 2013, PSYCHOL ASSESSMENT, V25, P339, DOI 10.1037/a0030915; Lange RT, 2013, J NEUROTRAUM, V30, P958, DOI 10.1089/neu.2012.2743; Lange RT, 2012, ARCH CLIN NEUROPSYCH, V27, P480, DOI 10.1093/arclin/acs059; Lange RT, 2012, J INT NEUROPSYCH SOC, V18, P595, DOI 10.1017/S1355617712000239; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Laurin D, 2009, NEUROBIOL AGING, V30, P1724, DOI 10.1016/j.neurobiolaging.2008.01.008; Lee YK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062422; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1993, HEAD INJURY, P525; Lew HL, 2008, J REHABIL RES DEV, V45, pXI, DOI 10.1682/JRRD.2008.05.0064; Ling GSF, 2011, CURR OPIN ANESTHESIO, V24, P124, DOI 10.1097/ACO.0b013e32834458da; Lippa SM, 2010, J INT NEUROPSYCH SOC, V16, P856, DOI 10.1017/S1355617710000743; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; Maas AIR, 2011, J NEUROTRAUM, V28, P177, DOI 10.1089/neu.2010.1617; Macera CA, 2013, SLEEP, V36, P83, DOI 10.5665/sleep.2306; Magnuson J, 2012, CURR NEUROL NEUROSCI, V12, P570, DOI 10.1007/s11910-012-0303-6; Malec JF, 2000, REHABIL PSYCHOL, V45, P227, DOI 10.1037/0090-5550.45.3.227; Management of Concussion/mTBI Working Group, 2009, J Rehabil Res Dev, V46, pCP1; Marr AL., 2004, CENTRAL NERVOUS SYST; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; Marx BP, 2009, ARCH GEN PSYCHIAT, V66, P996, DOI 10.1001/archgenpsychiatry.2009.109; Mathis CA, 2013, NEURON, V79, P1035, DOI 10.1016/j.neuron.2013.09.001; Mauri M, 2006, FUNCT NEUROL, V21, P223; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2008, MILD TRAUMATIC BRAIN; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meyer Kimberly, 2008, J Trauma Nurs, V15, P185, DOI 10.1097/01.JTN.0000343324.55087.de; Miller KJ, 2013, J HEAD TRAUMA REHAB, V28, P31, DOI 10.1097/HTR.0b013e318255ceae; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Millspaugh JA, 1937, US NAV MED B, V35, P297; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Mondello S, 2014, MED RES REV, V34, P503, DOI 10.1002/med.21295; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Nagamoto-Combs K, 2007, J NEUROTRAUM, V24, P1719, DOI 10.1089/neu.2007.0377; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; National Research Council, 2008, GULF WAR AND HLTH, V7; Nelson NW, 2010, ARCH CLIN NEUROPSYCH, V25, P713, DOI 10.1093/arclin/acq075; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Okamura N, 2013, J NUCL MED, V54, P1420, DOI 10.2967/jnumed.112.117341; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; OMeara ES, 1997, AM J EPIDEMIOL, V146, P373, DOI 10.1093/oxfordjournals.aje.a009290; Orff HJ, 2009, J HEAD TRAUMA REHAB, V24, P155, DOI 10.1097/HTR.0b013e3181a0b281; Pietrzak RH, 2009, J NERV MENT DIS, V197, P748, DOI 10.1097/NMD.0b013e3181b97a75; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Qureshi SU, 2010, J AM GERIATR SOC, V58, P1627, DOI 10.1111/j.1532-5415.2010.02977.x; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Randolph C, 2013, J INT NEUROPSYCH SOC, V19, P873, DOI 10.1017/S1355617713000805; Randolph C, 2009, J INT NEUROPSYCH SOC, V15, P512, DOI 10.1017/S135561770909064X; RASMUSSON DX, 1995, BRAIN INJURY, V9, P213, DOI 10.3109/02699059509008194; Raymont Vanessa, 2011, Front Neurol, V2, P15, DOI 10.3389/fneur.2011.00015; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; Roebuck-Spencer TM, 2012, FORENSIC NEUROPSYCHO; Roebuck-Spencer TM, 2013, J ATHL TRAINING, V48, P499, DOI 10.4085/1062-6050-48.3.11; Roebuck-Spencer TM, 2012, CLIN NEUROPSYCHOL, V26, P473, DOI 10.1080/13854046.2011.650214; RUFF RM, 1991, J NEUROSURG, V75, pS50, DOI 10.3171/sup.1991.75.1s.0s50; Salib E, 1997, INT J GERIATR PSYCH, V12, P363, DOI 10.1002/(SICI)1099-1166(199703)12:3<363::AID-GPS515>3.0.CO;2-F; Saunders LL, 2009, BRAIN INJURY, V23, P866, DOI 10.1080/02699050903283213; Schmidt JD, 2012, MED SCI SPORT EXER, V44, P1621, DOI 10.1249/MSS.0b013e318258a9fb; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; Scholten JD, 2012, BRAIN INJURY, V26, P1177, DOI 10.3109/02699052.2012.661914; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; SHALAT SL, 1987, NEUROLOGY, V37, P1630, DOI 10.1212/WNL.37.10.1630; Shavelle RM, 2001, AM J PHYS MED REHAB, V80, P510, DOI 10.1097/00002060-200107000-00009; Skopp Nancy A, 2012, MSMR, V19, P7; Smith C, 2003, NEUROPATH APPL NEURO, V29, P496, DOI 10.1046/j.1365-2990.2003.00488.x; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Sosin DM, 1996, BRAIN INJURY, V10, P47; Spencer RJ, 2010, J REHABIL RES DEV, V47, P521, DOI 10.1682/JRRD.2009.11.0181; Starkstein SE, 2005, INT PSYCHOGERIATR, V17, pS93, DOI 10.1017/S1041610205001973; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; Uryu K, 2004, NEUROBIOL AGING, V25, pS303, DOI 10.1016/S0197-4580(04)80996-5; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Vanderploeg RD, 2014, J HEAD TRAUMA REHAB, V29, P1, DOI 10.1097/HTR.0b013e318281966e; Vanderploeg RD, 2012, ARCH PHYS MED REHAB, V93, P1887, DOI 10.1016/j.apmr.2012.05.024; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; VANDUIJN CM, 1992, AM J EPIDEMIOL, V135, P775, DOI 10.1093/oxfordjournals.aje.a116364; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Veitch DP, 2013, CURR ALZHEIMER RES, V10, P907, DOI 10.2174/15672050113109990142; Villemagne VL, 2012, FUTUR NEUROL, V7, P409, DOI 10.2217/FNL.12.34; Wang HK, 2012, J NEUROL NEUROSUR PS, V83, P1080, DOI 10.1136/jnnp-2012-302633; Weiner MW, 2013, ALZHEIMERS DEMENT, V9, P445, DOI [10.1016/j.jalz.2013.05.1769, 10.1016/j.jalz.2013.03.005]; Whitney KA, 2009, ARCH CLIN NEUROPSYCH, V24, P145, DOI 10.1093/arclin/acp020; WILLIAMS DB, 1991, NEUROLOGY, V41, P1554, DOI 10.1212/WNL.41.10.1554; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Xydakis MS, 2012, ANN NEUROL, V72, P673, DOI 10.1002/ana.23757; Yaffe K, 2010, ARCH GEN PSYCHIAT, V67, P608, DOI 10.1001/archgenpsychiatry.2010.61; Zollman FS, 2014, J HEAD TRAUMA REHAB, V29, P99, DOI 10.1097/HTR.0b013e318294dd37	175	42	43	0	19	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1552-5260	1552-5279		ALZHEIMERS DEMENT	Alzheimers. Dement.	JUN	2014	10	3		1			S174	S187		10.1016/j.jalz.2014.04.006			14	Clinical Neurology	Neurosciences & Neurology	CP8GM	WOS:000360130700012	24924669	Other Gold			2021-06-18	
J	Puvenna, V; Brennan, C; Shaw, G; Yang, C; Marchi, N; Bazarian, JJ; Merchant-Borna, K; Janigro, D				Puvenna, Vikram; Brennan, Chanda; Shaw, Gerald; Yang, Cui; Marchi, Nicola; Bazarian, Jeffrey J.; Merchant-Borna, Kian; Janigro, Damir			Significance of Ubiquitin Carboxy-Terminal Hydrolase L1 Elevations in Athletes after Sub-Concussive Head Hits	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; CARBOHYDRATE-DEFICIENT TRANSFERRIN; CEREBROSPINAL-FLUID; BARRIER DISRUPTION; PERIPHERAL MARKERS; BIOMARKER; PROTEIN; S100-BETA; IMPACT; DAMAGE	The impact of sub-concussive head hits (sub-CHIs) has been recently investigated in American football players, a population at risk for varying degrees of post-traumatic sequelae. Results show how sub-CHIs in athletes translate in serum as the appearance of reporters of blood-brain barrier disruption (BBBD), how the number and severity of sub-CHIs correlate with elevations of putative markers of brain injury is unknown. Serum brain injury markers such as UCH-L1 depend on BBBD. We investigated the effects of sub-CHIs in collegiate football players on markers of BBBD, markers of cerebrospinal fluid leakage (serum beta 2-transferrin) and markers of brain damage. Emergency room patients admitted for a clinically-diagnosed mild traumatic brain injury (mTBI) were used as positive controls. Healthy volunteers were used as negative controls. Specifically this study was designed to determine the use of UCH-L1 as an aid in the diagnosis of sub-concussive head injury in athletes. The extent and intensity of head impacts and serum values of S100B, UCH-L1, and beta-2 transferrin were measured pre-and post-game from 15 college football players who did not experience a concussion after a game. S100B was elevated in players experiencing the most sub-CHIs; UCH-L1 levels were also elevated but did not correlate with S100B or sub-CHIs. Beta-2 transferrin levels remained unchanged. No correlation between UCH-L1 levels and mTBI were measured in patients. Low levels of S100B were able to rule out mTBI and high S100B levels correlated with TBI severity. UCH-L1 did not display any interpretable change in football players or in individuals with mild TBI. The significance of UCH-L1 changes in sub-concussions or mTBI needs to be further elucidated.	[Puvenna, Vikram; Brennan, Chanda; Marchi, Nicola; Janigro, Damir] Cleveland Clin, Lerner Coll Med, Cleveland, OH 44106 USA; [Brennan, Chanda; Marchi, Nicola; Janigro, Damir] Cleveland Clin, Lerner Coll Med, Dept Neurosurg, Cleveland, OH 44106 USA; [Puvenna, Vikram; Brennan, Chanda; Marchi, Nicola; Janigro, Damir] Cleveland Clin, Lerner Coll Med, Dept Mol Med, Cleveland, OH 44106 USA; [Brennan, Chanda; Janigro, Damir] Cleveland State Univ, Dept Clin Bioanalyt Chem, Cleveland, OH 44115 USA; [Bazarian, Jeffrey J.; Merchant-Borna, Kian] Univ Rochester, Med Ctr, Dept Emergency Med, Rochester, NY 14642 USA; [Bazarian, Jeffrey J.; Merchant-Borna, Kian] Univ Rochester, Med Ctr, Dept Neurosurg, Rochester, NY 14642 USA; [Shaw, Gerald; Yang, Cui] Univ Florida, Dept Neurosci, Gainesville, FL 32610 USA	Janigro, D (corresponding author), Cleveland Clin, Lerner Coll Med, Cleveland, OH 44106 USA.	janigrd@ccf.org	, Gerry/X-2377-2019; Marchi, Nicola/J-8607-2016	Marchi, Nicola/0000-0001-9124-0226	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS078307, R01NS43284, R41MH093302, R21NS077236, R42MH093302, UH2TR000491, R21HD057256]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R21HD057256] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UH2TR000491, UH3TR000491] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R42MH093302, R41MH093302] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS078307, R21NS077236, R01NS043284] Funding Source: NIH RePORTER	This work was supported by: National Institutes of Health [R01NS078307, R01NS43284, R41MH093302, R21NS077236, R42MH093302, UH2TR000491, and R21HD057256 to Damir Janigro. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arndt T, 2001, CLIN CHEM, V47, P13; Blyth BJ, 2011, J NEUROTRAUM, V28, P2453, DOI 10.1089/neu.2010.1653; Blyth BJ, 2009, J NEUROTRAUM, V26, P1497, DOI [10.1089/neu.2008.0738, 10.1089/neu.2008-0738]; Chan Danny T M, 2004, Asian J Surg, V27, P39, DOI 10.1016/S1015-9584(09)60242-6; Chen FJ, 2010, P NATL ACAD SCI USA, V107, P1636, DOI 10.1073/pnas.0911516107; DORAN JF, 1983, J NEUROCHEM, V40, P1542, DOI 10.1111/j.1471-4159.1983.tb08124.x; Fazio V, 2004, ANN THORAC SURG, V78, P46, DOI 10.1016/j.athoracsur.2003.11.042; Fleming M, 2004, J AM BOARD FAM PRACT, V17, P247, DOI 10.3122/jabfm.17.4.247; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Ichikawa T, 2010, BIOCHEM BIOPH RES CO, V391, P852, DOI 10.1016/j.bbrc.2009.11.151; Kanner AA, 2003, CANCER, V97, P2806, DOI 10.1002/cncr.11409; Kiechle K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084977; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Liu MC, 2010, EUR J NEUROSCI, V31, P722, DOI 10.1111/j.1460-9568.2010.07097.x; Marchi N, 2004, CLIN CHIM ACTA, V342, P1, DOI 10.1016/j.cccn.2003.12.008; Marchi N, 2003, RESTOR NEUROL NEUROS, V21, P109; Marchi N, 2003, J NEUROSCI, V23, P1949; Marchi N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056805; McGrath N, 2013, BRAIN INJURY, V27, P103, DOI 10.3109/02699052.2012.729282; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mihalik JP, 2010, PEDIATRICS, V125, pE1394, DOI 10.1542/peds.2009-2849; Mondello S, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-85; Mondello S, 2012, NEUROSURGERY, V70, P666, DOI 10.1227/NEU.0b013e318236a809; Mondello S, 2011, CRIT CARE, V15, DOI 10.1186/cc10286; MOORE BW, 1965, BIOCHEM BIOPH RES CO, V19, P739, DOI 10.1016/0006-291X(65)90320-7; Neuwelt EA, 2011, NAT REV NEUROSCI, V12, P169, DOI 10.1038/nrn2995; Papa L, 2013, J NEUROTRAUM, V30, P324, DOI 10.1089/neu.2012.2545; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; Sedaghat F, 2008, HIPPOKRATIA, V12, P198; Steiner J, 2007, BMC NEUROSCI, V8, DOI 10.1186/1471-2202-8-2; Szabo Gyorgy, 2012, Orv Hetil, V153, P514, DOI 10.1556/OH.2012.29337; Warnecke A, 2004, ARCH OTOLARYNGOL, V130, P1178, DOI 10.1001/archotol.130.10.1178; Zongo D, 2012, ANN EMERG MED, V59, P209, DOI 10.1016/j.annemergmed.2011.07.027	34	42	43	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2014	9	5							e96296	10.1371/journal.pone.0096296			9	Multidisciplinary Sciences	Science & Technology - Other Topics	AG9HB	WOS:000335728900045	24806476	DOAJ Gold, Green Published			2021-06-18	
J	Chen, W; Qi, J; Feng, F; Wang, MD; Bao, G; Wang, T; Xiang, M; Xie, WF				Chen, Wei; Qi, Jun; Feng, Feng; Wang, Mao-de; Bao, Gang; Wang, Tuo; Xiang, Mu; Xie, Wan-fu			Neuroprotective effect of allicin against traumatic brain injury via Akt/endothelial nitric oxide synthase pathway-mediated anti-inflammatory and anti-oxidative activities	NEUROCHEMISTRY INTERNATIONAL			English	Article						Traumatic brain injury; Endothelial nitric oxide synthase; Akt; Inflammatory cytokines	CLOSED-HEAD INJURY; SIGNALING PATHWAYS; OXIDATIVE STRESS; CLINICAL-TRIALS; PROTEIN-KINASE; IN-VITRO; CELLS; INFLAMMATION; ACTIVATION; ISCHEMIA	Allicin, one of the main biologically active compounds derived from garlic, has been shown to exert various anti-oxidative and anti-inflammatory activities in in vitro and in vivo studies. Here, we sought to investigate the potential neuroprotective effects of allicin against traumatic brain injury (TBI) in rats. We found that allicin treatment (10 and 50 mg/kg, not 1 mg/kg) significantly reduced brain edema and motor functional deficits, as well as apoptotic neuronal cell death in injured cortex. These protective effects could be observed even if the administration was delayed to 4 h after injury. Moreover, allicin treatment decreased the expression levels of MDA and protein carbonyl, preserved the endogenous antioxidant enzyme activities, and suppressed the expression of inflammatory cytokines. The results of Western blot analysis showed that allicin increased the phosphorylation of Akt and endothelial nitric oxide synthase (eNOS). Blocking Akt/eNOS pathway activation by specific inhibitor LY294002 (10 mu L, 10 mmol/L) or L-NIO (0.5 mg/kg) partly reversed the protective effects of allicin and its anti-inflammatory activities. The allicin induced anti-oxidative activity was partly prevented by LY294002, but not L-NIO. In summary, our data strongly suggested that allicin treatment at an appropriate dose can exert protective effect against TBI through Akt/eNOS pathway-mediated anti-inflammatory and anti-oxidative activities. (C) 2014 Elsevier Ltd. All rights reserved.	[Chen, Wei; Wang, Mao-de; Bao, Gang; Wang, Tuo; Xie, Wan-fu] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Neurosurg, Xian 710061, Shaanxi, Peoples R China; [Qi, Jun] Shannxi Blood Ctr, Inst Xian Blood Bank, Xian 710061, Shaanxi, Peoples R China; [Feng, Feng; Xiang, Mu] Fourth Mil Med Univ, Xijing Hosp, Dept Physiotherapy & Rehabil, Xian 710032, Shaanxi, Peoples R China	Xie, WF (corresponding author), Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Neurosurg, Xian 710061, Shaanxi, Peoples R China.	xijiaodaxiewanfu@163.com		Qi, Jun/0000-0002-8795-3140			Awasthi D, 1997, SURG NEUROL, V47, P575, DOI 10.1016/S0090-3019(96)00461-2; Bains M, 2012, BBA-MOL BASIS DIS, V1822, P675, DOI 10.1016/j.bbadis.2011.10.017; Bayston R, 2000, LANCET, V355, P1813, DOI 10.1016/S0140-6736(00)02275-3; BOLTON S, 1982, AM PHARM, V22, P40, DOI 10.1016/S0160-3450(16)31735-4; Chen T, 2013, CELL SIGNAL, V25, P2863, DOI 10.1016/j.cellsig.2013.09.004; Chen T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055601; Chen T, 2012, NEUROCHEM RES, V37, P983, DOI 10.1007/s11064-011-0691-z; Chen T, 2012, INT J MOL MED, V29, P630, DOI 10.3892/ijmm.2011.870; Chen T, 2012, FREE RADICAL BIO MED, V52, P208, DOI 10.1016/j.freeradbiomed.2011.10.451; Chen T, 2011, BRAIN RES BULL, V84, P163, DOI 10.1016/j.brainresbull.2010.11.015; Chung LY, 2006, J MED FOOD, V9, P205, DOI 10.1089/jmf.2006.9.205; Correale J, 2004, J NEUROL, V251, P1304, DOI 10.1007/s00415-004-0649-z; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Fleming I, 2010, PFLUG ARCH EUR J PHY, V459, P793, DOI 10.1007/s00424-009-0767-7; Forstermann U, 2011, BRIT J PHARMACOL, V164, P213, DOI 10.1111/j.1476-5381.2010.01196.x; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Gajkowska B, 1997, FOLIA NEUROPATHOL, V35, P171; Greenwald BA, 2003, ARCH PHYS MED REHAB, V84, pS3, DOI 10.1053/apmr.2003.50052; Gruhlke MCH, 2010, FREE RADICAL BIO MED, V49, P1916, DOI 10.1016/j.freeradbiomed.2010.09.019; He YL, 2012, BRAIN RES, V1433, P127, DOI 10.1016/j.brainres.2011.11.027; Li XH, 2010, NEUROSCIENCES, V15, P237; Liu C, 2010, J NUTR BIOCHEM, V21, P1238, DOI 10.1016/j.jnutbio.2009.11.001; Lu KT, 2005, NEUROSCI LETT, V386, P40, DOI 10.1016/j.neulet.2005.05.057; Lundblad C, 2009, J NEUROTRAUM, V26, P1953, DOI 10.1089/neu.2009.0955; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; McConeghy KW, 2012, CNS DRUGS, V26, P613, DOI 10.2165/11634020-000000000-00000; Menon DK, 2009, CURR OPIN CRIT CARE, V15, P437, DOI 10.1097/MCC.0b013e3283307a26; Menon DK, 2009, CRIT CARE MED, V37, pS129, DOI 10.1097/CCM.0b013e3181921225; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Nishio S, 1997, ACT NEUR S, V70, P84; Ooboshi H, 2005, CIRCULATION, V111, P913, DOI 10.1161/01.CIR.0000155622.68580.DC; Ortiz PA, 2003, ACTA PHYSIOL SCAND, V179, P107, DOI 10.1046/j.1365-201X.2003.01207.x; Park E, 2008, CAN MED ASSOC J, V178, P1163, DOI 10.1503/cmaj.080282; Peng XQ, 2010, ACTA PHARMACOL SIN, V31, P175, DOI 10.1038/aps.2009.190; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Slemmer JE, 2008, CURR MED CHEM, V15, P404, DOI 10.2174/092986708783497337; Srivastava K, 2012, CELL MOL NEUROBIOL, V32, P319, DOI 10.1007/s10571-011-9777-z; Wu QQ, 2013, EUR J PHARMACOL, V707, P87, DOI 10.1016/j.ejphar.2013.03.027; Zhu JW, 2012, NEUROCHEM INT, V61, P640, DOI 10.1016/j.neuint.2012.06.021	44	42	48	0	11	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0197-0186	1872-9754		NEUROCHEM INT	Neurochem. Int.	MAR	2014	68						28	37		10.1016/j.neuint.2014.01.015			10	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	AF8SF	WOS:000334985200004	24530793				2021-06-18	
J	Joseph, B; Pandit, V; Aziz, H; Kulvatunyou, N; Hashmi, A; Tang, A; O'Keeffe, T; Wynne, J; Vercruysse, G; Friese, RS; Rhee, P				Joseph, Bellal; Pandit, Viraj; Aziz, Hassan; Kulvatunyou, Narong; Hashmi, Ammar; Tang, Andrew; O'Keeffe, Terence; Wynne, Julie; Vercruysse, Gary; Friese, Randall S.; Rhee, Peter			Clinical outcomes in traumatic brain injury patients on preinjury clopidogrel: A prospective analysis	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Clopidogrel therapy; progression on repeat head computed tomography; neurosurgical intervention	PLATELET TRANSFUSION; ANTIPLATELET THERAPY; ELDERLY-PATIENTS; HEAD-INJURIES; ASPIRIN	BACKGROUND Patients receiving antiplatelet medications are considered to be at an increased risk for traumatic intracranial hemorrhage after blunt head trauma. However, most studies have categorized all antiplatelet drugs into one category. The aim of our study was to evaluate clinical outcomes and the requirement of a repeat head computed tomography (RHCT) in patients on preinjury clopidogrel therapy. METHODS Patients with traumatic brain injury with intracranial hemorrhage on initial head CT were prospectively enrolled. Patients on preinjury clopidogrel were matched with patients exclusive of antiplatelet and anticoagulation therapy using a propensity score in a 1:1 ratio for age, Glasgow Coma Scale (GCS), head Abbreviated Injury Scale (h-AIS), Injury Severity Score (ISS), neurologic examination, and platelet transfusion. Outcome measures were progression on RHCT scan and need for neurosurgical intervention. RESULTS A total of 142 patients with intracranial hemorrhage on initial head CT scan (clopidogrel, 71; no clopidogrel, 71) were enrolled. The mean (SD) age was 70.5 (15.1) years, 66% were male, median GCS score was 14 (range, 3-15), and median h-AIS (ISS) was 3 (range, 2-5). The mean (SD) platelet count was 210 (101), and 61% (n = 86) of the patients received platelet transfusion. Patients on preinjury clopidogrel were more likely to have progression on RHCT (odds ratio [OR], 5.1; 95% confidence interval [CI], 3.1-7.1) and RHCT as a result of clinical deterioration (OR, 2.1; 95% CI, 1.8-3.5). The overall rate of neurosurgical intervention was 4.2% (n = 6). Patients on clopidogrel therapy were more likely to require a neurosurgical intervention (OR, 1.8; 95% CI, 1.4-3.1). CONCLUSION Preinjury clopidogrel therapy is associated with progression of initial insult on RHCT scan and need for neurosurgical intervention. Preinjury clopidogrel therapy as an independent variable should warrant the need for a routine RHCT scan in patients with traumatic brain injury. LEVEL OF EVIDENCE Prognostic study, level I; therapeutic study, level II.	[Joseph, Bellal; Pandit, Viraj; Aziz, Hassan; Kulvatunyou, Narong; Hashmi, Ammar; Tang, Andrew; O'Keeffe, Terence; Wynne, Julie; Vercruysse, Gary; Friese, Randall S.; Rhee, Peter] Univ Arizona, Div Trauma Crit Care Emergency Surg & Burns, Dept Surg, Tucson, AZ 85724 USA	Joseph, B (corresponding author), Univ Arizona, Div Trauma Crit Care Emergency Surg & Burns, Dept Surg, 1501 N Campbell Ave,Room 5411, Tucson, AZ 85724 USA.	bjoseph@surgery.arizona.edu					Bachelani AM, 2011, SURGERY, V150, P836, DOI 10.1016/j.surg.2011.07.059; Fabbri A, 2013, CRIT CARE, V17, DOI 10.1186/cc12575; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Ferrera PC, 1999, AM J EMERG MED, V17, P154, DOI 10.1016/S0735-6757(99)90050-5; Jones K, 2006, AM J SURG, V192, P743, DOI 10.1016/j.amjsurg.2006.08.037; Joseph B, 2013, J TRAUMA AC IN PRESS; Joseph B, 2014, AM SURG IN PRESS; Lavoie A, 2004, J TRAUMA, V56, P802, DOI 10.1097/01.TA.0000066183.02177.AF; Lobato RD, 1997, ACTA NEUROCHIR, V139, P385, DOI 10.1007/BF01808871; McMillian WD, 2009, J TRAUMA, V66, P942, DOI 10.1097/TA.0b013e3181978e7b; MILLS DCB, 1992, ARTERIOSCLER THROMB, V12, P430, DOI 10.1161/01.ATV.12.4.430; Ohm C, 2005, J TRAUMA, V58, P518, DOI 10.1097/01.TA.0000151671.35280.8B; Serebruany VL, 2003, AM HEART J, V146, P713, DOI 10.1016/S0002-8703(03)00260-6; Washington CW, 2011, J TRAUMA, V71, P358, DOI 10.1097/TA.0b013e318220ad7e; Wong DK, 2008, J TRAUMA, V65, P1303, DOI 10.1097/TA.0b013e318185e234	15	42	42	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	MAR	2014	76	3					817	820		10.1097/TA.0b013e3182aafcf0			4	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	AB8YW	WOS:000332077100050	24553554				2021-06-18	
J	Kabadi, SV; Stoica, BA; Loane, DJ; Luo, T; Faden, AI				Kabadi, Shruti V.; Stoica, Bogdan A.; Loane, David J.; Luo, Tao; Faden, Alan I.			CR8, a novel inhibitor of CDK, limits microglial activation, astrocytosis, neuronal loss, and neurologic dysfunction after experimental traumatic brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						cell cycle; CR8; cyclin-dependent kinases; neurodegeneration; neuroinflammation; traumatic brain injury	CELL-CYCLE ACTIVATION; ADULT NEUROGENESIS; NEUROINFLAMMATION; NEUROPROTECTION; DEATH; RAT; NEURODEGENERATION; PROLIFERATION; CONTRIBUTES; EXPRESSION	Central nervous system injury causes a marked increase in the expression of cell cycle-related proteins. In this study, we show that cell cycle activation (CCA) is detected in mature neurons at 24 hours after rat lateral fluid percussion (LFP)-induced traumatic brain injury (TBI), as reflected by increased expression of cyclin G1, phosphorylated retinoblastoma (phospho-Rb), E2F1 and proliferating cell nuclear antigen (PCNA). These changes were associated with progressive cortical, hippocampal, and thalamic neuronal loss and microglial and astrocyte activation. Notably, we detected 5-bromo-2'-deoxyuridine (BrdU)-positive neurons, microglia, and astrocytes at 7 days, but not at 24 hours, suggesting that cell cycle reaches the S phase in these cell types at the latter time point. A delayed systemic post-LFP administration at 3 hours of CR8 a potent second-generation cyclin-dependent kinase (CDK) inhibitor reduced CCA; cortical, hippocampal, and thalamic neuronal loss; and cortical microglial and astrocyte activation, Furthermore, CR8 treatment attenuated sensorimotor and cognitive deficits, alleviated depressive-like symptoms, and decreased lesion volume. These findings underscore the contribution of CCA to progressive neurodegeneration and chronic rieuroinflamrnation following TBI, and demonstrate the neuroprotective potential of cell cycle inhibition in a clinically relevant experimental TBI model.	[Kabadi, Shruti V.; Stoica, Bogdan A.; Loane, David J.; Luo, Tao; Faden, Alan I.] Univ Maryland, Ctr Shock Trauma & Anesthesiol STAR ORC, Natl Ctr Trauma & EMS, Dept Anesthesiol,Sch Med, Baltimore, MD 21201 USA	Kabadi, SV (corresponding author), Univ Maryland, Ctr Shock Trauma & Anesthesiol STAR ORC, Natl Ctr Trauma & EMS, Dept Anesthesiol,Sch Med, Bressler Res Bldg BRB,655 W Baltimore St, Baltimore, MD 21201 USA.	skabadi@anes.umm.edu	STOICA, BOGDAN/H-9782-2013	STOICA, BOGDAN/0000-0002-2501-6434; Loane, David/0000-0003-0393-3503; Faden, Alan I./0000-0003-0128-2348	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS052568]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS052568] Funding Source: NIH RePORTER	This work was supported by a grant from the National Institutes of Health, R01 NS052568.	Bettayeb K, 2008, ONCOGENE, V27, P5797, DOI 10.1038/onc.2008.191; Bevins RA, 2006, NAT PROTOC, V1, P1306, DOI 10.1038/nprot.2006.205; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Byrnes KR, 2007, BRAIN, V130, P2977, DOI 10.1093/brain/awm179; Byrnes KR, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-43; Cameron HA, 2001, J COMP NEUROL, V435, P406, DOI 10.1002/cne.1040; Cernak I, 2005, CELL CYCLE, V4, P1286, DOI 10.4161/cc.4.9.1996; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Di Giovanni S, 2005, P NATL ACAD SCI USA, V102, P8333, DOI 10.1073/pnas.0500989102; Graham DI, 2000, ACTA NEUROPATHOL, V99, P117, DOI 10.1007/PL00007414; Greene LA, 2004, CELL DEATH DIFFER, V11, P49, DOI 10.1038/sj.cdd.4401341; Hilton GD, 2008, J CEREBR BLOOD F MET, V28, P1845, DOI 10.1038/jcbfm.2008.75; Kabadi SV, 2012, NEUROTHERAPEUTICS, V9, P405, DOI 10.1007/s13311-011-0095-4; Kabadi SV, 2012, J NEUROTRAUM, V29, P813, DOI 10.1089/neu.2011.1980; Kabadi SV, 2012, J CEREBR BLOOD F MET, V32, P137, DOI 10.1038/jcbfm.2011.117; Kabadi SV, 2010, NAT PROTOC, V5, P1552, DOI 10.1038/nprot.2010.112; Kanaan NM, 2010, NEUROBIOL AGING, V31, P937, DOI 10.1016/j.neurobiolaging.2008.07.006; Lee I, 2004, HIPPOCAMPUS, V14, P66, DOI 10.1002/hipo.10167; Liu DX, 2004, J NEUROSCI, V24, P8720, DOI 10.1523/JNEUROSCI.1821-04.2004; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Long JM, 1998, NEUROBIOL AGING, V19, P497, DOI 10.1016/S0197-4580(98)00088-8; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; Nandoe RDS, 2002, J ALZHEIMERS DIS, V4, P303, DOI 10.3233/JAD-2002-4405; Nauta W. J. H., 1986, FUNDAMENTAL NEUROANA; Piao CS, 2013, NEUROBIOL DIS, V54, P252, DOI 10.1016/j.nbd.2012.12.017; Slattery DA, 2012, NAT PROTOC, V7, P1009, DOI 10.1038/nprot.2012.044; Soltys Z, 2001, J NEUROSCI RES, V63, P90, DOI 10.1002/1097-4547(20010101)63:1<90::AID-JNR11>3.0.CO;2-9; Stoica BA, 2009, NEUROTOX RES, V16, P221, DOI 10.1007/s12640-009-9050-0; Sultana R, 2007, NEUROCHEM RES, V32, P655, DOI 10.1007/s11064-006-9123-x; Taupin P, 2007, BRAIN RES REV, V53, P198, DOI 10.1016/j.brainresrev.2006.08.002; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Urrea C, 2007, RESTOR NEUROL NEUROS, V25, P65; Wu JF, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-169; Wu JY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044027; Yamamoto T, 1988, J NEUROTRAUM, V5, P69, DOI 10.1089/neu.1988.5.69; Yang Y, 2003, J NEUROSCI, V23, P2557; Zhao ZR, 2012, J NEUROTRAUM, V29, P2475, DOI 10.1089/neu.2012.2511	37	42	43	0	5	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	MAR	2014	34	3					502	513		10.1038/jcbfm.2013.228			12	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	AC2QD	WOS:000332348100018	24398934	Bronze, Green Published			2021-06-18	
J	Kelley, E; Sullivan, C; Loughlin, JK; Hutson, L; Dandah, MN; Long, MK; Schwab, KA; Poole, JH				Kelley, Elizabeth; Sullivan, Campbell; Loughlin, Jennifer K.; Hutson, Lee; Dandah, Marie N.; Long, Margaret K.; Schwab, Karen A.; Poole, John H.			Self-Awareness and Neurobehavioral Outcomes, 5 Years or More After Moderate to Severe Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						awareness; brain damage; outcome; quality of life; rehabilitation	HEAD-INJURY; IMPAIRED AWARENESS; FOLLOW-UP; REHABILITATION; INTERVENTION; CAREGIVER; RELATIVES; DISTRESS; RECOVERY; ADULTS	Objective: To examine self-awareness 5 years or more after traumatic brain injury (TBI) and its relation to outcomes. Participants: Sixty-two adults with moderate to severe TBI and significant other (SO) informants (family or close friend). Setting: Regional veterans medical center. Main Measures: TBI Follow-up Interview, Community Integration Questionnaire, Satisfaction with Life Scale, and Caregiver Burden Inventory. Design: Five to 16 years after acute inpatient rehabilitation, separate staff contacted and interviewed subjects and SOs. Subject awareness was defined as inverse subject-SO discrepancy scores. Results: Subjects significantly underreported neurologic symptoms and overreported their work and home functioning; their self-ratings of emotional distress and social functioning did not differ from SO ratings. Employment was associated with greater self-awareness of cognitive deficits, even after controlling for injury severity. Subjects' life-satisfaction was associated with better self-reported neurologic functioning, which frequently did not agree with SO ratings. Caregiver burden was worse as SOs perceived subjects as having worse symptoms and poorer work and social integration. Conclusions: Impaired self-awareness remains evident more than 5 years after TBI. People with TBI are more likely to gain employment when they are aware of their cognitive deficits and abilities. However, subjective quality of life, for subjects and SOs, was related to their own perception of the TBI outcomes.	[Kelley, Elizabeth; Sullivan, Campbell; Loughlin, Jennifer K.; Hutson, Lee; Dandah, Marie N.; Long, Margaret K.; Poole, John H.] Vet Affairs Hlth Care Syst, Def & Vet Brain Injury Ctr, Palo Alto, CA 94304 USA; [Sullivan, Campbell; Hutson, Lee; Long, Margaret K.; Poole, John H.] Vet Affairs Hlth Care Syst, Psychol Serv, Palo Alto, CA 94304 USA; [Kelley, Elizabeth; Sullivan, Campbell; Loughlin, Jennifer K.; Hutson, Lee; Dandah, Marie N.; Long, Margaret K.] Palo Alto Univ, Pacific Grad Sch Psychol, Palo Alto, CA USA; [Schwab, Karen A.] Def & Vet Brain Injury Ctr, Silver Spring, MD USA	Poole, JH (corresponding author), Vet Affairs Hlth Care Syst, 3801 Miranda Ave 116B, Palo Alto, CA 94304 USA.	john.poole@va.gov			Defense and Veterans Brain Injury CenterUS Department of Veterans Affairs	This work was supported by a grant from the Defense and Veterans Brain Injury Center. Dr Jean Langlois Orman of the Centers for Disease Control and Prevention collaborated in developing the TBI Follow-Up Interview and adapting it for this study's military and veteran population. The authors thank Dr Elaine Date for helping plan this long-term outcome study; Rose Salerno, RN, for facilitating participants' informed consent, tracking and periodic follow-up evaluations; and Dr Odette Harris and Dr Darryl Thomander for their thoughtful comments on the manuscript.	BROWN DSO, 1992, ARCH PHYS MED REHAB, V73, P758; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Cusick CP, 2000, J HEAD TRAUMA REHAB, V15, P739, DOI 10.1097/00001199-200002000-00012; Dawson DR, 2005, J HEAD TRAUMA REHAB, V20, P426, DOI 10.1097/00001199-200509000-00004; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dirette DK, 2007, BRAIN INJURY, V21, P1131, DOI 10.1080/02699050701687326; Draper K, 2009, NEUROPSYCHOL REHABIL, V19, P645, DOI 10.1080/17405620802613935; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; Flashman LA, 2002, NEUROREHABILITATION, V17, P285; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; Hart T, 2009, NEUROPSYCHOL REHABIL, V19, P161, DOI 10.1080/09602010802188393; Hillier SL, 1997, BRAIN INJURY, V11, P525, DOI 10.1080/713802189; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Leathem JM, 1998, J CLIN EXP NEUROPSYC, V20, P694, DOI 10.1076/jcen.20.5.694.1122; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; NOVAK M, 1989, GERONTOLOGIST, V29, P798, DOI 10.1093/geront/29.6.798; Parker RS, 1996, NEUROPSYCHOL REV, V6, P135, DOI 10.1007/BF01874895; Pickelsimer EE, 2006, J HEAD TRAUMA REHAB, V21, P491, DOI 10.1097/00001199-200611000-00004; Possl O, 2001, BRAIN INJURY, V15, P15; Prigatano GP, 2005, J HEAD TRAUMA REHAB, V20, P359, DOI 10.1097/00001199-200507000-00007; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; Riggio S, 2009, MT SINAI J MED, V76, P163, DOI 10.1002/msj.20097; Rodgers ML, 2007, AM J PHYS MED REHAB, V86, P482, DOI 10.1097/PHM.0b013e31805c00a1; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Sohlberg MM, 1998, J HEAD TRAUMA REHAB, V13, P62, DOI 10.1097/00001199-199810000-00008; Tepper S, 1996, BRAIN INJURY, V10, P575, DOI 10.1080/026990596124142; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Trudel TM, 1998, REHABIL PSYCHOL, V43, P267, DOI 10.1037/0090-5550.43.4.267; Vanderploeg RD, 2007, J REHABIL RES DEV, V44, P937, DOI 10.1682/JRRD.2006.12.0163; Vanderploeg RD, 2008, ARCH PHYS MED REHAB, V89, P2227, DOI 10.1016/j.apmr.2008.06.015; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009	33	42	43	0	16	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2014	29	2					147	152		10.1097/HTR.0b013e31826db6b9			6	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AH9ZH	WOS:000336504600008	23249770				2021-06-18	
J	Tate, DF; York, GE; Reid, MW; Cooper, DB; Jones, L; Robin, DA; Kennedy, JE; Lewis, J				Tate, D. F.; York, G. E.; Reid, M. W.; Cooper, D. B.; Jones, L.; Robin, D. A.; Kennedy, J. E.; Lewis, J.			Preliminary findings of cortical thickness abnormalities in blast injured service members and their relationship to clinical findings	BRAIN IMAGING AND BEHAVIOR			English	Article						TBI; Blast Injury; Mild TBI; Cortical thickness; Cognition; Behavior; FreeSurfer; MANGO	TRAUMATIC BRAIN-INJURY; LONG-TERM; TINNITUS; DYSFUNCTION; ASSOCIATION; CONCUSSION; CAVITATION; MECHANISM; TRANSIENT; SYMPTOMS	Though cortical abnormalities have been demonstrated in moderate and severe traumatic brain injured (TBI) patients, there have been no studies examining cortical changes following blast related mild TBI (mTBI). The purpose of this study was to determine the effects and functional relevance of blast mTBI on cortical thickness in a small cohort of carefully screened blast injured US Service Members (SM). Twelve SM with mTBI acquired through blast injury were compared to 11 demographically matched control SM without TBI. Both mTBI and control participants were active duty and had completed a combat deployment. Subjects underwent MRI examination and the T1 weighted anatomic images were processed using the FreeSurfer suite of tools. Cortical thickness maps were compared between groups and examined for relationships with time since injury (TSI). Utilizing a large database of functional imaging results (BrainMap), significant regions of interest (ROI) were used to determine the behavioral profiles most consistently associated with the specific ROI. In addition, clinical variables were examined as part of post-hoc analysis of functional relevance. Group comparisons controlling for age demonstrated several significant clusters of cortical thinning for the blast injured SM. After multiple comparisons correction (False Discovery Rate (FDR)), two left hemisphere clusters remained significant (left superior temporal (STG) and frontal (SFG) gyri). No clusters were significantly correlated with TSI after FDR correction. Behavioral analysis for the STG and SFG clusters demonstrated three significant behavioral/cognitive sub-domains, each associated with audition and language. Blast injured SMs demonstrated distinct areas of cortical thinning in the STG and SFG. These areas have been previously shown to be associated with audition and language. Post-hoc analyses of clinical records demonstrated significant abnormal audiology reports for the blast injured SM suggesting that the thinning in these ROIs might be related to injury to the external auditory system rather than direct injury to the brain from the blast. It is clear that additional replication is needed in much larger cohorts. Importantly, the combination of imaging tools and methods in this study successfully demonstrated the potential to define unique ROIs and functional correlates that can be used to design future studies.	[Tate, D. F.; Reid, M. W.; Cooper, D. B.; Kennedy, J. E.] Inc San Antonio Mil Med Ctr SAMMC, Contractor Henry M Jackson Fdn Adv Mil Med, Def & Vet Brain Injury Ctr, San Antonio, TX 78234 USA; [York, G. E.] San Antonio Mil Med Ctr, LTC, MC, San Antonio, TX USA; [Jones, L.] Mayo Clin, Dept Neurol, Rochester, MN USA; [Robin, D. A.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA; [Lewis, J.] Air Force Med Support Agcy, LtCol, MC, Falls Church, VA USA	Tate, DF (corresponding author), Inc San Antonio Mil Med Ctr SAMMC, Contractor Henry M Jackson Fdn Adv Mil Med, Def & Vet Brain Injury Ctr, San Antonio, TX 78234 USA.	dftatephd@mac.com	Tate, David F/I-3963-2013	Tate, David F/0000-0003-0213-1920; Jones, Lyell/0000-0002-5851-8705	 [W91YTZ-12-C-0132]	The views, opinions and/or findings contained in this manuscript are those of the authors and should not be construed as an official Department of Defense or Veterans Affairs position, policy or decision unless so designated by other documentation. Research on this article was done under Contract #W91YTZ-12-C-0132. In the conduct of this research, the investigators adhered to the policies regarding the protection of human subjects as prescribe by Code of Federal Regulations (CFR) Title 45, Volume 1, Part 46; Title 32, Chapter1, Part 219; and Title 21, Chapter 1, Part 50 (Protection of Human Subjects).	Akin FW, 2011, OTOLARYNG CLIN N AM, V44, P323, DOI 10.1016/j.otc.2011.01.005; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; Brenner Lisa A, 2012, Front Neurol, V3, P31, DOI 10.3389/fneur.2012.00031; Cooper DB, 2012, MIL MED, V177, P1157, DOI 10.7205/MILMED-D-12-00098; Cooper DB, 2011, BRAIN INJURY, V25, P1, DOI 10.3109/02699052.2010.531692; Engvig A, 2010, NEUROIMAGE, V52, P1667, DOI 10.1016/j.neuroimage.2010.05.041; Eskridge SL, 2013, J NEUROTRAUM, V30, P1391, DOI 10.1089/neu.2012.2537; Fausti SA, 2009, J REHABIL RES DEV, V46, P797, DOI 10.1682/JRRD.2008.09.0118; Fischl B, 2000, P NATL ACAD SCI USA, V97, P11050, DOI 10.1073/pnas.200033797; Goeller J, 2012, J NEUROTRAUM, V29, P1970, DOI 10.1089/neu.2011.2224; Haier Richard J, 2009, BMC Res Notes, V2, P174, DOI 10.1186/1756-0500-2-174; Lancaster JL, 2012, FRONT NEUROINFORM, V6, DOI 10.3389/fninf.2012.00023; Lange RT, 2012, J INT NEUROPSYCH SOC, V18, P595, DOI 10.1017/S1355617712000239; Lanting CP, 2009, HEARING RES, V255, P1, DOI 10.1016/j.heares.2009.06.009; Lew HL, 2007, J REHABIL RES DEV, V44, P921, DOI 10.1682/JRRD.2007.09.0140; Lin AP, 2012, BRAIN IMAGING BEHAV, V6, P208, DOI 10.1007/s11682-012-9181-4; Martensson J, 2012, NEUROIMAGE, V63, P240, DOI 10.1016/j.neuroimage.2012.06.043; McCauley SR, 2010, DEV NEUROPSYCHOL, V35, P318, DOI 10.1080/87565641003696866; McDonald BC, 2012, BRAIN IMAGING BEHAV, V6, P193, DOI 10.1007/s11682-012-9173-4; Merkley TL, 2008, J NEUROTRAUM, V25, P1343, DOI 10.1089/neu.2008.0615; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Palacios EM, 2013, CORTEX, V49, P646, DOI 10.1016/j.cortex.2012.02.011; Panzer MB, 2012, ANN BIOMED ENG, V40, P1530, DOI 10.1007/s10439-012-0519-2; Ramasamy A, 2011, J TRAUMA, V71, P1694, DOI 10.1097/TA.0b013e318227a999; Ruff RL, 2009, J REHABIL RES DEV, V46, P1071, DOI 10.1682/JRRD.2009.05.0062; Saunders JC, 2007, J COMMUN DISORD, V40, P313, DOI 10.1016/j.jcomdis.2007.03.006; Schecklmann M, 2013, BRAIN STRUCT FUNCT, V218, P1061, DOI 10.1007/s00429-013-0520-z; Schneider P, 2009, NEUROIMAGE, V45, P927, DOI 10.1016/j.neuroimage.2008.12.045; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Slobounov S, 2012, BRAIN IMAGING BEHAV, V6, P224, DOI 10.1007/s11682-012-9167-2; Sylvia FR, 2001, MIL MED, V166, P918; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Wilde EA, 2012, INT J DEV NEUROSCI, V30, P267, DOI 10.1016/j.ijdevneu.2012.01.003; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f; Yang S, 2012, J NEUROPHYSIOL, V108, P1567, DOI 10.1152/jn.00371.2012; Yue Q, 2013, NEUROSCIENCE, V237, P87, DOI 10.1016/j.neuroscience.2012.12.067	37	42	42	0	8	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1931-7557	1931-7565		BRAIN IMAGING BEHAV	Brain Imaging Behav.	MAR	2014	8	1					102	109		10.1007/s11682-013-9257-9			8	Neuroimaging	Neurosciences & Neurology	AB2QD	WOS:000331636300010	24100952	Green Accepted			2021-06-18	
J	Sharma, J; Johnston, MV; Hossain, MA				Sharma, Jaswinder; Johnston, Michael V.; Hossain, Mir Ahamed			Sex differences in mitochondrial biogenesis determine neuronal death and survival in response to oxygen glucose deprivation and reoxygenation	BMC NEUROSCIENCE			English	Article						Hypoxia-ischemia; Mitochondrial DNA; Mitochondrial fusion and fission; Donut mitochondria; Sexual dimorphism	CEREBELLAR GRANULE NEURONS; TRAUMATIC BRAIN-INJURY; CELL-DEATH; HYPOXIA-ISCHEMIA; GROWTH-FACTOR; TRANSCRIPTION; EXPRESSION; APOPTOSIS; DYNAMICS; PATHWAY	Background: Mitochondrial dysfunction has been linked to neuronal death and a wide array of neurodegenerative diseases. Previously, we have shown sex differences in mitochondria-mediated cell death pathways following hypoxia-ischemia. However, the role of mitochondrial biogenesis in hypoxic-ischemic brain injury between male vs. female has not been studied yet. Results: Primary cerebellar granule neurons (CGNs), isolated from P7 male and female mice (CD-1) segregated based on visual inspection of sex, were exposed to 2 h of oxygen glucose deprivation (OGD) followed by 6-24 h of reoxygenation (Reox). Mitochondrial membrane potential (Delta psi(m)) and cellular ATP levels were reduced significantly in XX CGNs as compared to XY CGNs. Mitochondrial DNA (mtDNA) content was increased (>2-fold) at 2 h OGD in XY CGNs and remained increased up to 24 h of Reox compared to XX neurons and normoxia controls. The expression of mitochondrial transcription factor A (Tfam), the nuclear respiratory factor-1 (NRF-1) and the peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1 alpha), a master regulator of mitochondrial biogenesis, were up-regulated (2-fold, ***p < 0.001) in XY CGNs but slightly reduced or remained unchanged in XX neurons. Similarly, the TFAM and PGC-1 alpha protein levels and the mitochondrial proteins HSP60 and COXIV were increased in XY neurons only. Supportively, a balanced stimulation of fusion (Mfn 1 and Mfn 2) and fission (Fis 1 and Drp 1) genes and enhanced formation of donut-shaped mitochondria were observed in XY CGNs vs. XX neurons (**p < 0.01). Conclusions: Our results demonstrate that OGD/Reox alters mitochondrial biogenesis and morphological changes in a sex-specific way, influencing neuronal injury/survival differently in both sexes.	[Sharma, Jaswinder; Johnston, Michael V.; Hossain, Mir Ahamed] Hugo W Moser Res Inst Kennedy Krieger, Dept Neurol, Baltimore, MD 21205 USA; [Sharma, Jaswinder; Johnston, Michael V.; Hossain, Mir Ahamed] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; [Johnston, Michael V.] Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA	Hossain, MA (corresponding author), Hugo W Moser Res Inst Kennedy Krieger, Dept Neurol, Baltimore, MD 21205 USA.	hossain@kennedykrieger.org			National Institutes of Health from National Institute of Neurological Disorders and Stroke [RO1 NS028208, RO1NS046030]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS028208, R01NS046030] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health grants RO1 NS028208 (MVJ) and RO1NS046030 (MAH) from the National Institute of Neurological Disorders and Stroke. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Neurological Disorders and Stroke or the National Institutes of Health.	Arnold S, 2008, J MOL ENDOCRINOL, V41, P289, DOI 10.1677/JME-08-0085; Bertoni-Freddari C, 2006, ANN NY ACAD SCI, V1090, P26, DOI 10.1196/annals.1378.003; Blomgren K, 2006, FREE RADICAL BIO MED, V40, P388, DOI 10.1016/j.freeradbiomed.2005.08.040; Carruth LL, 2002, NAT NEUROSCI, V5, P933, DOI 10.1038/nn922; Chan DC, 2006, CELL, V125, P1241, DOI 10.1016/j.cell.2006.06.010; Chen H, 2001, STROKE, V32, P2382, DOI 10.1161/hs1001.097099; Chen HC, 2003, J CELL BIOL, V160, P189, DOI 10.1083/jcb.200211046; CLAYTON DA, 1984, ANNU REV BIOCHEM, V53, P573; COSSARIZZA A, 1993, BIOCHEM BIOPH RES CO, V197, P40, DOI 10.1006/bbrc.1993.2438; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; Du LN, 2004, J BIOL CHEM, V279, P38563, DOI 10.1074/jbc.M405461200; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Golomb MR, 2008, J CHILD NEUROL, V23, P279, DOI 10.1177/0883073807309246; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Greenbaum D, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-117; Griparic L, 2001, TRAFFIC, V2, P235, DOI 10.1034/j.1600-0854.2001.1r008.x; Guo YF, 2008, ACTA BIOCH BIOPH SIN, V40, P426, DOI 10.1111/j.1745-7270.2008.00418.x; Gutsaeva DR, 2008, J NEUROSCI, V28, P2015, DOI 10.1523/JNEUROSCI.5654-07.2008; Hood DA, 2003, MED SCI SPORT EXER, V35, P86, DOI 10.1097/00005768-200301000-00015; Hossain MA, 2004, J NEUROSCI, V24, P4187, DOI 10.1523/JNEUROSCI.0347-04.2004; Hossain MA, 2002, J NEUROCHEM, V81, P365, DOI 10.1046/j.1471-4159.2002.00837.x; Jeong SY, 2008, BMB REP, V41, P11, DOI 10.5483/BMBRep.2008.41.1.011; Kain KH, 2000, BBA-GENE STRUCT EXPR, V1494, P91, DOI 10.1016/S0167-4781(00)00223-2; Kaufman BA, 2003, J CELL BIOL, V163, P457, DOI 10.1083/jcb.200306132; Lagranha CJ, 2010, CIRC RES, V106, P1681, DOI 10.1161/CIRCRESAHA.109.213645; Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231; Liu FD, 2011, STROKE, V42, P1090, DOI 10.1161/STROKEAHA.110.594861; Liu X, 2011, CELL DEATH DIFFER, V18, P1561, DOI 10.1038/cdd.2011.13; Mandemakers W, 2007, J CELL SCI, V120, P1707, DOI 10.1242/jcs.03443; Mecleiros DM, 2008, METHODS, V46, P288, DOI 10.1016/j.ymeth.2008.09.026; Osellame LD, 2012, BEST PRACT RES CL EN, V26, P711, DOI 10.1016/j.beem.2012.05.003; Penaloza C, 2009, FASEB J, V23, P1869, DOI 10.1096/fj.08-119388; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Puka-Sundvall M, 2000, DEV BRAIN RES, V125, P31, DOI 10.1016/S0165-3806(00)00110-3; Renolleau S, 2008, NEUROSCIENTIST, V14, P46, DOI 10.1177/1073858407308889; Robertson CL, 2004, J BIOENERG BIOMEMBR, V36, P363, DOI 10.1023/B:JOBB.0000041769.06954.e4; Robertson CL, 2009, EXP NEUROL, V218, P371, DOI 10.1016/j.expneurol.2009.04.030; Scarpulla RC, 2008, PHYSIOL REV, V88, P611, DOI 10.1152/physrev.00025.2007; Sharma J, 2011, ASN NEURO, V3, DOI 10.1042/AN20100032; SMILEY ST, 1991, P NATL ACAD SCI USA, V88, P3671, DOI 10.1073/pnas.88.9.3671; Soltys BJ, 1996, EXP CELL RES, V222, P16, DOI 10.1006/excr.1996.0003; Su B, 2010, BBA-MOL BASIS DIS, V1802, P135, DOI 10.1016/j.bbadis.2009.09.013; Suen DF, 2008, GENE DEV, V22, P1577, DOI 10.1101/gad.1658508; Vosler PS, 2009, STROKE, V40, P3149, DOI 10.1161/STROKEAHA.108.543769; Xu SC, 2010, BRAIN RES, V1311, P189, DOI 10.1016/j.brainres.2009.10.062; Yin W, 2008, STROKE, V39, P3057, DOI 10.1161/STROKEAHA.108.520114	46	42	42	1	10	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1471-2202			BMC NEUROSCI	BMC Neurosci.	JAN 10	2014	15								9	10.1186/1471-2202-15-9			14	Neurosciences	Neurosciences & Neurology	294NW	WOS:000330054500001	24410996	DOAJ Gold, Green Published			2021-06-18	
J	Abner, EL; Nelson, PT; Schmitt, FA; Browning, SR; Fardo, DW; Wan, LJ; Jicha, GA; Cooper, GE; Smith, CD; Caban-Holt, AM; Van Eldik, LJ; Kryscio, RJ				Abner, Erin L.; Nelson, Peter T.; Schmitt, Frederick A.; Browning, Steven R.; Fardo, David W.; Wan, Lijie; Jicha, Gregory A.; Cooper, Gregory E.; Smith, Charles D.; Caban-Holt, Allison M.; Van Eldik, Linda J.; Kryscio, Richard J.			Self-Reported Head Injury and Risk of Late-Life Impairment and AD Pathology in an AD Center Cohort	DEMENTIA AND GERIATRIC COGNITIVE DISORDERS			English	Article						Head injury; Alzheimer's disease; Neuropathology; Dementia; Cognition	TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; COGNITIVE IMPAIRMENT; AMYLOID-BETA; DEMENTIA; DEATH; TRANSITIONS; CONCUSSION; SEQUELAE; PLAQUES	Aims: To evaluate the relationship between self-reported head injury and cognitive impairment, dementia, mortality, and Alzheimer's disease (AD)-type pathological changes. Methods: Clinical and neuropathological data from participants enrolled in a longitudinal study of aging and cognition (n = 649) were analyzed to assess the chronic effects of self-reported head injury. Results: The effect of self-reported head injury on the clinical state depended on the age at assessment: for a 1-year increase in age, the OR for the transition to clinical mild cognitive impairment (MCI) at the next visit for participants with a history of head injury was 1.21 and 1.34 for the transition from MCI to dementia. Without respect to age, head injury increased the odds of mortality (OR = 1.54). Moreover, it increased the odds of a pathological diagnosis of AD for men (OR = 1.47) but not women (OR = 1.18). Men with a head injury had higher mean amyloid plaque counts in the neocortex and entorhinal cortex than men without. Conclusions: Self-reported head injury is associated with earlier onset, increased risk of cognitive impairment and dementia, increased risk of mortality, and AD-type pathological changes. (C) 2013 S. Karger AG,	[Abner, Erin L.; Nelson, Peter T.; Schmitt, Frederick A.; Fardo, David W.; Jicha, Gregory A.; Smith, Charles D.; Caban-Holt, Allison M.; Van Eldik, Linda J.; Kryscio, Richard J.] Univ Kentucky, Alzheimers Dis Ctr, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; [Nelson, Peter T.] Univ Kentucky, Dept Pathol, Lexington, KY 40536 USA; [Schmitt, Frederick A.; Jicha, Gregory A.; Smith, Charles D.] Univ Kentucky, Dept Neurol, Lexington, KY 40536 USA; [Abner, Erin L.; Browning, Steven R.] Univ Kentucky, Dept Epidemiol, Lexington, KY 40536 USA; [Fardo, David W.; Kryscio, Richard J.] Univ Kentucky, Dept Biostat, Lexington, KY 40536 USA; [Wan, Lijie; Kryscio, Richard J.] Univ Kentucky, Dept Stat, Lexington, KY 40536 USA; [Caban-Holt, Allison M.] Univ Kentucky, Dept Behav Sci, Lexington, KY 40536 USA; [Van Eldik, Linda J.] Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA; [Cooper, Gregory E.] Baptist Neurol Ctr, Lexington, KY USA	Abner, EL (corresponding author), Univ Kentucky, Sanders Brown Ctr Aging, 800 S Limestone St, Lexington, KY 40536 USA.	erin.abner@uky.edu	Wan, Lijie/AAS-8090-2020	Abner, Erin/0000-0002-9566-4111; Fardo, David/0000-0002-7207-4696	University of Kentucky's Sanders-Brown Center on Aging from the National Institute on Aging [R01 AG038651, R01 AG019241, P30 AG028383]; National Center for Advancing Translational Sciences to the University of Kentucky's Center for Clinical and Translational Science [UL1TR000117]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000117] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG028383, R01AG019241, R01AG038651, K25AG043546] Funding Source: NIH RePORTER	We thank the participants and their families, as well as the University of Kentucky Alzheimer's Disease Center staff members. This work was supported by grants to the University of Kentucky's Sanders-Brown Center on Aging from the National Institute on Aging (grant No. R01 AG038651, R01 AG019241, and P30 AG028383), as well as a grant from the National Center for Advancing Translational Sciences to the University of Kentucky's Center for Clinical and Translational Science (grant No. UL1TR000117). The NIA did not play any role in the study design, in the collection, analysis, and interpretation of data, in the writing of the paper, or in the decision to submit the article for publication. The authors submitted the manuscript independent of funding sources.	Abner EL, 2012, INT J ALZHEIMERS DIS, V2012; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Beach TG, 2012, J NEUROPATH EXP NEUR, V71, P266, DOI 10.1097/NEN.0b013e31824b211b; Brayne C, 1998, DEMENT GERIATR COGN, V9, P175, DOI 10.1159/000017043; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Dams-O'Connor K, 2013, J NEUROL NEUROSUR PS, V84, P177, DOI 10.1136/jnnp-2012-303938; Dashnaw ML, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12284; Davis DG, 1999, J NEUROPATH EXP NEUR, V58, P376, DOI 10.1097/00005072-199904000-00008; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Forstl H, 2010, DTSCH ARZTEBL INT, V107, P835, DOI 10.3238/arztebl.2010.0835; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; GENTLEMAN SM, 1993, PROG BRAIN RES, V96, P237; Iverson G, 2006, INT BRAIN INJURY ASS, V4; Jellinger KA, 2004, CURR OPIN NEUROL, V17, P719, DOI 10.1097/00019052-200412000-00012; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; KONDO K, 1994, DEMENTIA, V5, P314, DOI 10.1159/000106741; Kryscio RJ, 2006, NEUROLOGY, V66, P828, DOI 10.1212/01.wnl.0000203264.71880.45; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; MCKENZIE JE, 1994, NEUROREPORT, V6, P161, DOI 10.1097/00001756-199412300-00041; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; Moretti L, 2012, LANCET NEUROL, V11, P1103, DOI 10.1016/S1474-4422(12)70226-0; Morris JC, 2006, ALZ DIS ASSOC DIS, V20, P210, DOI 10.1097/01.wad.0000213865.09806.92; Murphy TE, 2011, J GERONTOL A-BIOL, V66, P109, DOI 10.1093/gerona/glq188; Nelson PT, 2007, J NEUROPATH EXP NEUR, V66, P1136, DOI 10.1097/nen.0b013e31815c5efb; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Saing T, 2012, J NEUROTRAUM, V29, P1054, DOI 10.1089/neu.2011.1957; Salazar JC, 2007, STAT MED, V26, P568, DOI 10.1002/sim.2437; SAS Institute Inc, 2011, SAS STAT 9 3 PROC GU; Schmitt FA, 2012, CURR ALZHEIMER RES, V9, P724; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; Sundstrom A, 2007, INT PSYCHOGERIATR, V19, P159, DOI 10.1017/S1041610206003498; U.S. Census Bureau, 2011, 2011 AM COMM SURV; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; WILLIAMS DB, 1991, NEUROLOGY, V41, P1554, DOI 10.1212/WNL.41.10.1554; Yu L, 2010, STAT MED, V29, P639, DOI 10.1002/sim.3828	43	42	42	0	9	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1420-8008	1421-9824		DEMENT GERIATR COGN	Dement. Geriatr. Cogn. Disord.		2014	37	5-6					294	306		10.1159/000355478			13	Geriatrics & Gerontology; Clinical Neurology; Psychiatry	Geriatrics & Gerontology; Neurosciences & Neurology; Psychiatry	AJ6IL	WOS:000337795500005	24401791	Green Published, Green Accepted, Bronze			2021-06-18	
J	Allen, BB; Chiu, YL; Gerber, LM; Ghajar, J; Greenfield, JP				Allen, Baxter B.; Chiu, Ya-lin; Gerber, Linda M.; Ghajar, Jamshid; Greenfield, Jeffrey P.			Age-Specific Cerebral Perfusion Pressure Thresholds and Survival in Children and Adolescents With Severe Traumatic Brain Injury	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						cerebral perfusion pressure; head trauma; severe traumatic brain injury; traumatic brain injury management	SEVERE HEAD-INJURY; GLASGOW COMA SCALE; INTRACRANIAL-PRESSURE; RISK-FACTORS; PREDICTORS; AUTOREGULATION; HYPERTENSION; MANAGEMENT; OUTCOMES; SCORE	Objectives: Evidence-based traumatic brain injury guidelines support cerebral perfusion pressure thresholds for adults at a class 2 level, but evidence is lacking in younger patients. The purpose of this study is to identify the impact of age-specific cerebral perfusion pressure thresholds on short-term survival among patients with severe traumatic brain injury. Design: Institutional review board-approved, prospective, observational cohort study. Setting: Level I or II trauma centers in New York State. Patients: Data on all patients with a postresuscitation Glasgow Coma Score less than 9 were added in the Brain Trauma Foundation prospective New York State TBI-trac database. Measurements and Main Results: We calculated the survival rates and relative risks of mortality for patients with severe traumatic brain injury based on predefined age-specific cerebral perfusion pressure thresholds. A higher threshold and a lower threshold were defined for each age group: 60 and 50mm Hg for 12 years old or older, 50 and 35mm Hg for 6-11 years, and 40 and 30mm Hg for 0-5 years. Patients were stratified into age groups of 0-11, 12-17, and 18 years old or older. Three exclusive groups of CPP-L (events below low cerebral perfusion pressure threshold), CPP-B (events between high and low cerebral perfusion pressure thresholds), and CPP-H (events above high cerebral perfusion pressure threshold) were defined. As an internal control, we evaluated the associations between cerebral perfusion pressure events and events of hypotension and elevated intracranial pressure. Survival was significantly higher in 0-11 and 18 years old or older age groups for patients with CPP-H events compared with those with CPP-L events. There was a significant decrease in survival with prolonged exposure to CPP-B events for the 0-11 and 18 years old and older age groups when compared with the patients with CPP-H events (p = 0.0001 and p = 0.042, respectively). There was also a significant decrease in survival with prolonged exposure to CPP-L events in all age groups compared with the patients with CPP-H events (p< 0.0001 for 0- to 11-yr olds, p = 0.0240 for 12- to 17-yr olds, and p < 0.0001 for 18-yr old and older age groups). The 12- to 17-year olds had a significantly higher likelihood of survival compared with adults with prolonged exposure to CPP-L events (< 50mm Hg). CPP-L events were significantly related to systemic hypotension for the 12- to 17-year-old group (p = 0.004) and the 18-year-old and older group (p < 0.0001). CPP-B events were significantly related to systemic hypotension in the 0- to 11-year-old group (p = 0.014). CPP-B and CPP-L events were significantly related to elevated intracranial pressure in all age groups. Conclusions: Our data provide new evidence that cerebral perfusion pressure targets should be age specific. Furthermore, cerebral perfusion pressure goals above 50 or 60mm Hg in adults, above 50mm Hg in 6- to 17-year olds, and above 40mm Hg in 0- to 5-year olds seem to be appropriate targets for treatment-based studies. Systemic hypotension had an inconsistent relationship to events of low cerebral perfusion pressure, whereas elevated intracranial pressure was significantly related to all low cerebral perfusion pressure events across all age groups. This may impart a clinically important difference in care, highlighting the necessity of controlling intracranial pressure at all times, while targeting systolic blood pressure in specific instances.	[Allen, Baxter B.] Weill Cornell Med Coll, Dept Neurol, New York, NY USA; [Chiu, Ya-lin] Weill Cornell Med Coll, Dept Publ Hlth, New York, NY USA; [Gerber, Linda M.; Ghajar, Jamshid] Jamaica Hosp Med Ctr, Dept Surg, New York, NY USA; [Ghajar, Jamshid] Brain Trauma Fdn, New York, NY USA; [Greenfield, Jeffrey P.] Weill Cornell Med Coll, Dept Neurol Surg, New York, NY USA	Allen, BB (corresponding author), Weill Cornell Med Coll, Dept Neurol, New York, NY USA.	bba2003@nyp.org	Allen, Baxter/X-3841-2019	Greenfield, Jeffrey/0000-0003-1904-1040	New York State Department of Health; New York Presbyterian Hospital TBI fund; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000457] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR024996] Funding Source: NIH RePORTER	The authors thank the New York State Department of Health and the New York Presbyterian Hospital TBI fund for their financial support.	Adamo MA, 2009, J NEUROSURG-PEDIATR, V4, P414, DOI 10.3171/2009.6.PEDS0939; Andrews PJD, 2002, J NEUROSURG, V97, P326, DOI 10.3171/jns.2002.97.2.0326; Brady KM, 2009, PEDIATRICS, V124, pE1205, DOI 10.1542/peds.2009-0550; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Bratton SL, 2007, J NEUROTRAUMA S1, V24, P555, DOI DOI 10.1089/NEU.2007.9988; Catala-Temprano A, 2007, J NEUROSURG, V106, P463, DOI 10.3171/ped.2007.106.6.463; Chaiwat O, 2009, J NEUROTRAUM, V26, P657, DOI 10.1089/neu.2008.0770; Chambers IR, 2006, J NEUROL NEUROSUR PS, V77, P234, DOI 10.1136/jnnp.2005.072215; Chambers IR, 2005, CHILD NERV SYST, V21, P195, DOI 10.1007/s00381-004-1060-x; Chamoun RB, 2009, J NEUROSURG, V111, P683, DOI 10.3171/2009.2.JNS08817; CHANGARIS DG, 1987, J TRAUMA, V27, P1007, DOI 10.1097/00005373-198709000-00009; Clifton GL, 2002, CRIT CARE MED, V30, P739, DOI 10.1097/00003246-200204000-00003; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; Cruz J, 1998, CRIT CARE MED, V26, P344, DOI 10.1097/00003246-199802000-00039; Di Gennaro JL, 2010, DEV NEUROSCI-BASEL, V32, P420, DOI 10.1159/000322083; Division of Vital Statistics National Center for Health Statistics Deaths, 2009, PERC TOT DEATHS DEAT; Downard C, 2000, J TRAUMA, V49, P654, DOI 10.1097/00005373-200010000-00012; ELIASJONES AC, 1992, ARCH DIS CHILD, V67, P1430, DOI 10.1136/adc.67.12.1430; Figaji AA, 2009, J NEUROSURG-PEDIATR, V4, P420, DOI 10.3171/2009.6.PEDS096; Grinkeviciute DE, 2008, MEDICINA-LITHUANIA, V44, P119, DOI 10.3390/medicina44020015; Heron M, 2010, PEDIATRICS, V125, P4, DOI 10.1542/peds.2009-2416; Hutchison JS, 2010, DEV NEUROSCI-BASEL, V32, P406, DOI 10.1159/000323260; Jaeger M, 2010, CRIT CARE MED, V38, P1343, DOI 10.1097/CCM.0b013e3181d45530; Johnson U, 2011, NEUROSURGERY, V68, P714, DOI 10.1227/NEU.0b013e3182077313; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; KAISER G, 1984, NEUROPEDIATRICS, V15, P68, DOI 10.1055/s-2008-1052344; Keenan HT, 2006, DEV NEUROSCI-BASEL, V28, P256, DOI 10.1159/000094152; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS24, DOI 10.1097/PCC.0b013e31823f4450; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS18, DOI 10.1097/PCC.0b013e31823f4424; Kokoska ER, 1998, J PEDIATR SURG, V33, P333, DOI 10.1016/S0022-3468(98)90457-2; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lannoo E, 2000, J NEUROTRAUM, V17, P403, DOI 10.1089/neu.2000.17.403; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; McGraw CP, 1989, INTRACRANIAL PRESSUR, P839; Mehta A, 2010, DEV NEUROSCI-BASEL, V32, P413, DOI 10.1159/000316804; Nijboer JMM, 2010, INJURY, V41, P52, DOI 10.1016/j.injury.2009.05.030; Ono J, 2001, J CLIN NEUROSCI, V8, P120, DOI 10.1054/jocn.2000.0732; Pearl GS, 1998, CLIN LAB MED, V18, P39; Prabhakaran P, 2004, J NEUROSURG, V100, P454, DOI 10.3171/ped.2004.100.5.0454; Rhine T, 2012, J TRAUMA ACUTE CARE, V73, pS248, DOI 10.1097/TA.0b013e31826b0062; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; Scaife ER, 2010, CURR OPIN PEDIATR, V22, P339, DOI 10.1097/MOP.0b013e3283395f2b; Schramm P, 2011, J NEUROSURG ANESTH, V23, P41, DOI 10.1097/ANA.0b013e3181f35854; SHARPLES PM, 1995, J NEUROL NEUROSUR PS, V58, P153, DOI 10.1136/jnnp.58.2.153; Shein SL, 2012, J PEDIATR-US, V161, P716, DOI 10.1016/j.jpeds.2012.03.046; Sorrentino E, 2011, NEUROCRIT CARE, V14, P188, DOI 10.1007/s12028-010-9492-5; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tien HC, 2006, J TRAUMA, V60, P274, DOI 10.1097/01.ta.0000197177.13379.f4; White JRM, 2001, CRIT CARE MED, V29, P534, DOI 10.1097/00003246-200103000-00011; Xiong Y, 2009, EXPERT OPIN EMERG DR, V14, P67, DOI [10.1517/14728210902769601, 10.1517/14728210902769601 ]	52	42	45	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	JAN	2014	15	1					62	70		10.1097/PCC.0b013e3182a556ea			9	Critical Care Medicine; Pediatrics	General & Internal Medicine; Pediatrics	285BS	WOS:000329368400014	24196011	Green Accepted			2021-06-18	
J	Cifu, DX; Hart, BB; West, SL; Walker, W; Carne, W				Cifu, David X.; Hart, Brett B.; West, Steven L.; Walker, William; Carne, William			The Effect of Hyperbaric Oxygen on Persistent Postconcussion Symptoms	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						traumatic brain injury; hyperbaric oxygen therapy; postconcussion syndrome	POST-CONCUSSION SYNDROME; TRAUMATIC BRAIN-INJURY; MAJOR DEPRESSION; PLACEBO-RESPONSE; THERAPY; CHECKLIST; MILITARY; DISORDER; PAIN	Background: The high incidence of persistent postconcussion symptoms in service members with combat-related mild traumatic brain injury has prompted research in the use of hyperbaric oxygen (HBO2) for management. Objective: The effects of HBO2 on persistent postconcussion symptoms in 60 military service members with at least 1 combat-related mild traumatic brain injury were examined in a single-center, double-blind, randomized, sham-controlled, prospective trial at the Naval Medicine Operational Training Center at Naval Air Station Pensacola. Methods: Over a 10-week period, subjects received a series of 40, once-daily, hyperbaric chamber compressions at 2.0 atmospheres absolute (ATA). During each session, subjects breathed 1 of 3 preassigned oxygen fractions (10.5%, 75%, or 100%) for 60 minutes, resulting in an oxygen exposure equivalent to breathing surface air, 100% oxygen at 1.5 ATA, or 100% oxygen at 2.0 ATA, respectively. Individual, subscale and total item responses on the Rivermead Postconcussion Symptom Questionnaire and individual and total Posttraumatic Disorder Checklist-Military Version were measured just prior to intervention and immediately postintervention. Results: Between-group testing of pre- and postintervention means revealed no significant differences on individual or total scores on the Posttraumatic Disorder Checklist-Military Version or Rivermead Postconcussion Symptom Questionnaire, demonstrating a successful randomization and no significant main effect for HBO2 at 1.5 or 2.0 ATA equivalent compared with the sham compression. Within-group testing of pre- and postintervention means revealed significant differences on several individual items for each group and difference in the Posttraumatic Disorder Checklist-Military Version total score for the 2.0 ATA HBO2 group. Discussion: The primary analyses of between group differences found no evidence of efficacy for HBO2. The scattered within group differences are threatened by Type 2 errors and could be explained by nonspecific effects. Conclusion: This study demonstrated that HBO2 at either 1.5 or 2.0 ATA equivalent had no effect on postconcussion symptoms after mild traumatic brain injury when compared with sham compression.	[Cifu, David X.] Dept Vet Affairs, Phys Med & Rehabil Program Off, Washington, DC USA; [Cifu, David X.; West, Steven L.; Walker, William; Carne, William] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA 23298 USA; [Cifu, David X.; Walker, William; Carne, William] Hunter Holmes McGuire Vet Affairs Med Ctr, Richmond, VA USA; [Hart, Brett B.] Naval Med Operat Training Ctr, Pensacola, FL USA; [Walker, William; Carne, William] Richmond Def & Vet Brain Injury Ctr, Richmond, VA USA	Cifu, DX (corresponding author), Virginia Commonwealth Univ, Dept Phys Med & Rehabil, 1223 E Marshall St, Richmond, VA 23298 USA.	dcifu@vcu.edu		Cifu, David/0000-0003-1600-9387	Defense Advanced Research Projects Agency grant [N66001-09-2-206]; US Navy Bureau of Medicine and Surgery; US Army Medical Materiel Development Activity; Defense and Veterans Brain Injury CenterUS Department of Veterans Affairs	Funding was provided for the primary study by a Defense Advanced Research Projects Agency grant (N66001-09-2-206), US Navy Bureau of Medicine and Surgery for contract funding temporary duty requirements, and the US Army Medical Materiel Development Activity for end-of-study contract funding. Dr Carne's and Dr Walker's efforts were additionally supported through a contract from the Defense and Veterans Brain Injury Center. The funding sources had no role in the study design, analysis, interpretation of the data, the writing of the paper, or the decision to submit the paper for publication.	Bennett MH, 2012, COCHRANE DB SYST REV, V12, DOI DOI 10.1002/14651858.CD004609.PUB3; Bennett MH, 2012, EXTREME PHYSIOL MED, V1, DOI 10.1186/2046-7648-1-14; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Bliese PD, 2008, J CONSULT CLIN PSYCH, V76, P272, DOI 10.1037/0022-006X.76.2.272; Brunoni AR, 2008, INT J NEUROPSYCHOPH, V11, P1169, DOI 10.1017/S1461145708009309; Cifu D, 2011, OVERCOMING POSTDEPLO; Cifu DX, J REHABIL R IN PRESS; Clarke D, 2009, UNDERSEA HYPERBAR M, V36, P13; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; Gesell L.B., 2008, HYPERBARIC OXYGEN TH, V12th; Harch PG, 2012, J NEUROTRAUM, V29, P168, DOI 10.1089/neu.2011.1895; Harch PG, 2012, P 2 INT S HYP OXYG C, P31; Lange RT, 2013, J NEUROTRAUM, V30, P958, DOI 10.1089/neu.2012.2743; Lew HL, 2007, J REHABIL RES DEV, V44, P1027, DOI 10.1682/JRRD.2007.05.0073; McDonagh M, 2004, ARCH PHYS MED REHAB, V85, P1198, DOI 10.1016/j.apmr.2003.12.026; Peng Y, 2010, PROG NEURO-PSYCHOPH, V34, P1018, DOI 10.1016/j.pnpbp.2010.05.016; Potter S, 2006, J NEUROL, V253, P1603, DOI 10.1007/s00415-006-0275-z; Rockswold SB, 2007, NEUROL RES, V29, P162, DOI 10.1179/016164107X181798; Rockswold SB, 2010, J NEUROSURG, V112, P1080, DOI 10.3171/2009.7.JNS09363; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Stein DJ, 2006, J CLIN PSYCHIAT, V67, P1741, DOI 10.4088/JCP.v67n1111; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558; Walker RL, 2010, PSYCHOL SERV, V7, P136, DOI 10.1037/a0019684; Walsh BT, 2002, JAMA-J AM MED ASSOC, V287, P1840, DOI 10.1001/jama.287.14.1840; Weaver LK, 2012, UNDERSEA HYPERBAR M, V39, P807; Wolf G, 2012, J NEUROTRAUM, V29, P2606, DOI 10.1089/neu.2012.2549	26	42	43	1	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2014	29	1					11	20		10.1097/HTR.0b013e3182a6aaf0			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AH1OC	WOS:000335889400004	24052094				2021-06-18	
J	Clark, AL; Amick, MM; Fortier, C; Milberg, WP; McGlinchey, RE				Clark, Alexandra L.; Amick, Melissa M.; Fortier, Catherine; Milberg, William P.; McGlinchey, Regina E.			Poor Performance Validity Predicts Clinical Characteristics and Cognitive Test Performance of OEF/OIF/OND Veterans in a Research Setting	CLINICAL NEUROPSYCHOLOGIST			English	Article						Symptom validity; Effort testing; Symptom exaggeration; Deployment	TRAUMATIC BRAIN-INJURY; MALINGERED NEUROCOGNITIVE DYSFUNCTION; NEUROPSYCHOLOGICAL TEST-PERFORMANCE; POSTTRAUMATIC-STRESS-DISORDER; WORD MEMORY TEST; SYMPTOM VALIDITY; HEAD-INJURY; DIGIT SPAN; POSTCONCUSSION SYNDROME; COMBAT VETERANS	This study examined the performance of 198 Veteran research participants deployed during Operation Enduring Freedom, Operation Iraqi Freedom, and/or Operation New Dawn (OEF/OIF/OND) on four measures of performance validity: the Medical Symptom Validity Test (MSVT), California Verbal Learning Test: Forced Choice Recognition (FCR), Reliable Digit Span (RDS), and TOVA Symptom Exaggeration Index (SEI). Failure on these performance validity tests (PVTs) ranged from 4% to 9%. The overall base rate of poor performance validity, as measured by failure of the MSVT in conjunction with an embedded PVT (FCR, RDS, SEI), was 5.6%. Regression analyses revealed that poor performance validity predicted cognitive test performance and self-reported psychological symptom severity. Furthermore, a greater prevalence of traumatic brain injury (TBI), Post-Traumatic Stress Disorder (PTSD), co-morbid TBI/PTSD, and other Axis I diagnoses, was observed among participants with poor effort. Although poor performance validity is relatively uncommon in a research setting, these findings demonstrate that clinicians should be cautious when interpreting psychological symptoms and neuropsychological test performance of Veteran participants who fail effort measures.	[Clark, Alexandra L.; Amick, Melissa M.; Fortier, Catherine; Milberg, William P.; McGlinchey, Regina E.] VA Boston Healthcare Syst, Translat Res Ctr TBI & Stress Disorders TRACTS, Boston, MA 02130 USA; [Clark, Alexandra L.; Amick, Melissa M.; Fortier, Catherine; Milberg, William P.; McGlinchey, Regina E.] VA Boston Healthcare Syst, GRECC, Boston, MA 02130 USA; [Fortier, Catherine; Milberg, William P.; McGlinchey, Regina E.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA; [Amick, Melissa M.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA	Amick, MM (corresponding author), VA Boston Healthcare Syst, 150 South Huntington Ave, Boston, MA 02130 USA.	Melissa.Amick@va.gov	McGlinchey, Regina E/R-1971-2016		Translational Research Center for TBI and Stress Disorders (TRACTS) VA Rehabilitation Research and Development Center Grant [B6796-C]	This work was supported by the Translational Research Center for TBI and Stress Disorders (TRACTS) VA Rehabilitation Research and Development Center Grant [B6796-C] awarded to Dr. Regina McGlinchey.	Anil AE, 2003, CLIN NEUROPSYCHOL, V17, P159, DOI 10.1076/clin.17.2.159.16510; Armistead-Jehle P, 2011, ARCH CLIN NEUROPSYCH, V26, P592, DOI 10.1093/arclin/acr049; Armistead-Jehle P, 2010, APPL NEUROPSYCHOL, V17, P52, DOI 10.1080/09084280903526182; Axelrod BN, 2011, APPL NEUROPSYCHOL, V18, P27, DOI 10.1080/09084282.2010.523369; Axelrod BN, 2010, CLIN NEUROPSYCHOL, V24, P873, DOI 10.1080/13854040903527295; Bauer L, 2005, APPL NEUROPSYCHOL, V12, P202, DOI 10.1207/s15324826an1204_3; Berthelson L, 2013, BRAIN INJURY, V27, P909, DOI 10.3109/02699052.2013.793400; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Boone KB, 2009, CLIN NEUROPSYCHOL, V23, P729, DOI 10.1080/13854040802427803; Bowden SC, 2006, CLIN NEUROPSYCHOL, V20, P858, DOI 10.1080/13854040500246935; BURKETT BG, 1998, STOLEN VALOR VIETNAM; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Calhoun PS, 2000, J PERS ASSESS, V75, P338, DOI 10.1207/S15327752JPA7502_11; Carone Dominic A, 2009, Appl Neuropsychol, V16, P309, DOI 10.1080/09084280903297883; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Constantinou M, 2005, ARCH CLIN NEUROPSYCH, V20, P191, DOI 10.1016/j.acn.2004.06.002; Crowson JJ, 1998, J ANXIETY DISORD, V12, P605, DOI 10.1016/S0887-6185(98)00037-1; Delis D., 2001, D KEFS EXAMINERS TEC; Delis DC, 2000, CALIFORNIA VERBAL LE; Demakis GJ, 2008, CLIN NEUROPSYCHOL, V22, P879, DOI 10.1080/13854040701564482; Drane DL, 2006, EPILEPSIA, V47, P1879, DOI 10.1111/j.1528-1167.2006.00611.x; Elhai JD, 2012, PTSD MILD TRAUMATIC, P174; Fortier C. B., J HEAD TRAU IN PRESS, V22; Fortier CB, 2014, J HEAD TRAUMA REHAB, V29, P89, DOI 10.1097/HTR.0b013e3182865859; Fox DD, 2011, CLIN NEUROPSYCHOL, V25, P488, DOI 10.1080/13854046.2011.554443; Freeman T, 2008, PSYCHIAT RES, V158, P374, DOI 10.1016/j.psychres.2007.04.002; Frueh BC, 2005, BRIT J PSYCHIAT, V186, P467, DOI 10.1192/bjp.186.6.467; Gervais RO, 2004, ARCH CLIN NEUROPSYCH, V19, P475, DOI 10.1016/j.acn.2003.05.001; Gervais RO, 2001, J RHEUMATOL, V28, P1892; Gervais RO, 2008, CLIN NEUROPSYCHOL, V22, P1061, DOI 10.1080/13854040701756930; Gfeller JD, 2013, BEHAV SCI LAW, V31, P833, DOI 10.1002/bsl.2084; Grafton KV, 2005, CLIN J PAIN, V21, P73, DOI 10.1097/00002508-200501000-00009; Green P, 2009, BRAIN INJURY, V23, P741, DOI 10.1080/02699050903133962; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Green P, 2003, GREENS MED SYMPTOM V; Green Paul, 2007, Phys Med Rehabil Clin N Am, V18, P43, DOI 10.1016/j.pmr.2006.11.002; GREENBERG LM, 1993, J CHILD PSYCHOL PSYC, V34, P1019, DOI 10.1111/j.1469-7610.1993.tb01105.x; Greiffenstein M F, 1996, J Int Neuropsychol Soc, V2, P477; Greiffenstein MF, 2008, CLIN NEUROPSYCHOL, V22, P565, DOI 10.1080/13854040701377810; Greiffenstein MF, 2006, LEGAL CRIMINOL PSYCH, V11, P131, DOI 10.1348/135532505X49828; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; Haggerty KA, 2007, CLIN NEUROPSYCHOL, V21, P917, DOI 10.1080/13854040600899724; Henry GK, 2009, CLIN NEUROPSYCHOL, V23, P153, DOI 10.1080/13854040801969524; Henry GK, 2005, CLIN NEUROPSYCHOL, V19, P121, DOI 10.1080/13854040490516604; Henry JD, 2005, BRIT J CLIN PSYCHOL, V44, P227, DOI 10.1348/014466505X29657; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Howe LLS, 2007, ARCH CLIN NEUROPSYCH, V22, P753, DOI 10.1016/j.acn.2007.06.003; IBM Corp, 2010, IBM SPSS STAT WIND V; Jacobs ML, 2007, ARCH CLIN NEUROPSYCH, V22, P143, DOI 10.1016/j.acn.2006.12.002; Keane, 1991, PCL C DSM 4; Keen SM, 2008, J REHABIL RES DEV, V45, P465, DOI 10.1682/JRRD.2007.09.0138; Lange RT, 2010, PSYCHIAT RES, V176, P229, DOI 10.1016/j.psychres.2009.03.004; Lange RT, 2012, J CLIN EXP NEUROPSYC, V34, P453, DOI 10.1080/13803395.2011.648175; Lanyon RI, 2001, J PERS ASSESS, V76, P169, DOI 10.1207/S15327752JPA7601_10; Larrabee GJ, 2003, ARCH CLIN NEUROPSYCH, V18, P673, DOI 10.1016/S0887-6177(02)00157-9; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P395, DOI 10.1076/clin.17.3.395.18087; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P54, DOI 10.1076/clin.17.1.54.15627; Larrabee GJ, 2012, J INT NEUROPSYCH SOC, V18, P625, DOI 10.1017/S1355617712000240; Larson EB, 2013, J INT NEUROPSYCH SOC, V19, P88, DOI 10.1017/S1355617712000999; Leark RA, 2002, ARCH CLIN NEUROPSYCH, V17, P335, DOI 10.1016/S0887-6177(01)00118-4; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Mathias CW, 2002, ASSESSMENT, V9, P301, DOI 10.1177/1073191102009003009; McCormick CL, 2013, ARCH CLIN NEUROPSYCH, V28, P808, DOI 10.1093/arclin/act050; Merten T, 2005, ARCH CLIN NEUROPSYCH, V20, P719, DOI 10.1016/j.acn.2005.04.004; Meyers JE, 2011, ARCH CLIN NEUROPSYCH, V26, P8, DOI 10.1093/arclin/acq083; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Moore BA, 2004, BRAIN INJURY, V18, P975, DOI 10.1080/02699050410001672350; Nelson NW, 2007, J INT NEUROPSYCH SOC, V13, P440, DOI 10.1017/S1355617707070373; Nelson NW, 2010, ARCH CLIN NEUROPSYCH, V25, P713, DOI 10.1093/arclin/acq075; Reese CS, 2012, ARCH CLIN NEUROPSYCH, V27, P176, DOI 10.1093/arclin/acr117; Root JC, 2006, J INT NEUROPSYCH SOC, V12, P688, DOI 10.1017/S1355617706060838; Roth R. S., 2013, J PALLIATIVE CARE ME, V1, P2; Ruocco AC, 2008, CLIN NEUROPSYCHOL, V22, P547, DOI 10.1080/13854040701336444; Russo AC, 2012, ARCH CLIN NEUROPSYCH, V27, P840, DOI 10.1093/arclin/acs090; Silver JM, 2012, J NEUROL NEUROSUR PS, V83, P836, DOI 10.1136/jnnp-2011-302078; Slick DJ, 1996, J CLIN EXP NEUROPSYC, V18, P911, DOI 10.1080/01688639608408313; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Stevens A, 2008, PSYCHIAT RES, V157, P191, DOI 10.1016/j.psychres.2007.01.003; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Tiffen J., 1968, PURDUE PEGBOARD EXAM; Tolin DF, 2010, PSYCHOL ASSESSMENT, V22, P729, DOI 10.1037/a0020973; Van Dyke S. A., 2013, CLIN NEUROPSYCHOL, P1; Vanderploeg RD, 2014, J HEAD TRAUMA REHAB, V29, P1, DOI 10.1097/HTR.0b013e318281966e; Victor T, 2009, CLIN NEUROPSYCHOL, V23, P297, DOI 10.1080/13854040802232682; Vogt DS, 2008, ASSESSMENT, V15, P381, DOI 10.1177/1073191108316030; Weschler D., 2008, WESCHLER ADULT INTEL; West LK, 2011, J NEUROPSYCHOL, V5, P114, DOI 10.1348/174866410X521434; Whiteside DM, 2009, CLIN NEUROPSYCHOL, V23, P523, DOI 10.1080/13854040802389169; Whitney KA, 2010, APPL NEUROPSYCHOL, V17, P196, DOI 10.1080/09084282.2010.499787; Whitney KA, 2009, ARCH CLIN NEUROPSYCH, V24, P145, DOI 10.1093/arclin/acp020; WILLIAMS JBW, 1992, ARCH GEN PSYCHIAT, V49, P630; Wisdom N. M., 2013, CLIN NEUROPSYCHOL, V27, P1; Wygant DB, 2007, ARCH CLIN NEUROPSYCH, V22, P489, DOI 10.1016/j.acn.2007.01.027; Young J. C., 2011, AM AC CLIN NEUR M WA; Young JC, 2012, CLIN NEUROPSYCHOL, V26, P147, DOI 10.1080/13854046.2011.647083; Zakzanis KK, 2012, APPL NEUROPSYCH-ADUL, V19, P98, DOI 10.1080/09084282.2011.644099	99	42	42	0	16	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2014	28	5					802	825		10.1080/13854046.2014.904928			24	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	AP4MM	WOS:000342051100008	24766521				2021-06-18	
J	Shohami, E; Biegon, A				Shohami, Esther; Biegon, Anat			Novel Approach to the Role of NMDA Receptors in Traumatic Brain Injury	CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS			English	Article						Cognitive enhancer; D-cycloserine; glutamate receptors; stroke	LONG-TERM POTENTIATION; AGONIST D-CYCLOSERINE; CLOSED-HEAD INJURY; COUPLED GLYCINE RECEPTOR; FLUID PERCUSSION INJURY; EXCITATORY AMINO-ACIDS; D-ASPARTATE RECEPTORS; ACUTE ISCHEMIC-STROKE; CLINICAL-TRIALS; NEUROTROPHIC FACTOR	For more than two decades the intensive research effort on the role of NMDA receptors (NMDAR) in traumatic brain injury (TBI) and cerebral ischemia (stroke) was led by the observations that extracellular concentrations of glutamate and aspartate are elevated after the insult and play a major role in brain pathologies. Indeed, NMDAR antagonists were shown to improve post-injury recovery in animal models and subsequently, large scale placebo-controlled clinical trials in TBI and stroke were performed with NMDAR antagonists. However, all these trials have demonstrated either no benefit or even deleterious effects. The discrepancy between the animal and human studies prompted us to investigate the temporal changes of the NMDAR after brain insult in TBI and stroke mouse models. We found that the early hyperactivation of the NMDAR is followed by loss of functional NMDAR which persists for weeks. Such dynamic changes could well explain the discrepancies between the preclinical and clinical experience as well as suggest alternative modes of treatment, namely, activation, rather than blockade of the NMDAR in the sub-acute period after TBI and stroke. Stimulation of the glycine modulatory site of the glycine/NMDAR by the partial agonist D-cycloserine (DCS) when given at least 24 hrs after TBI or stroke was shown to improve recovery of neurobehavioral and cognitive functions. It was also shown to restore impaired hippocampal Long-Term potentiation (LTP) and induce expression of Brain Derived-Neurotrophic Factor (BDNF) in a TBI model and to improve somatosensory and cognitive function in a stroke model. Experiments to optimize the DCS treatment paradigm showed that similar benefits were demonstrated in TBI mice whether the drug was given as a single injection at 24 or 72 hrs post injury, or as double (24 and 48 hrs) or triple (24, 48 and 72 hrs) doses. Interestingly, beneficial effects of DCS were reported in a range of animal models of human diseases as well as in several clinical indications thought to involve disruptions in NMDAR function, such as drug addiction, post-traumatic stress disorder, Parkinson's disease, aging and psychiatric disorders. As DCS has a good safety profile, and is already in use in humans in several different indications, and based on studies with DCS in the mouse TBI model, a multi-center prospective randomized controlled clinical trial, aiming to assess the effect of a single dose of DCS on cognitive outcome in patients with moderate TBI has recently begun.	[Shohami, Esther] Hebrew Univ Jerusalem, Inst Drug Res, Dept Pharmacol, IL-91120 Jerusalem, Israel; [Biegon, Anat] Brookhaven Natl Lab, Dept Med, Upton, NY 11973 USA; [Biegon, Anat] SUNY Stony Brook, Sch Med, Dept Neurol, Stony Brook, NY USA	Shohami, E (corresponding author), Hebrew Univ Jerusalem, Inst Drug Res, IL-91120 Jerusalem, Israel.	esty@cc.huji.ac.il			BSFUS-Israel Binational Science Foundation [2005-021-01]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R01NS050285]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS050285] Funding Source: NIH RePORTER	Supported by grants from the BSF# 2005-021-01 and from the NIH 1R01NS050285.	Adeleye A, 2010, EUR J PHARMACOL, V629, P25, DOI 10.1016/j.ejphar.2009.11.066; Albensi BC, 2007, CURR PHARM DESIGN, V13, P3185, DOI 10.2174/138161207782341321; Alessandri B, 1996, ACT NEUR S, V67, P6; BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; BARAN H, 1994, BRAIN RES, V652, P195, DOI 10.1016/0006-8993(94)90227-5; BARON H, 1955, Antibiot Annu, V3, P136; Beauchamp K, 2008, MOL MED, V14, P731, DOI 10.2119/2008-00050.Beauchamp; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; Bibel M, 2000, GENE DEV, V14, P2919, DOI 10.1101/gad.841400; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Billard JM, 2007, EUR J NEUROSCI, V25, P2260, DOI 10.1111/j.1460-9568.2007.05488.x; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOWERY NG, 1987, NATURE, V326, P338, DOI 10.1038/326338a0; Brown JIM, 1998, J NEUROTRAUM, V15, P253, DOI 10.1089/neu.1998.15.253; Chasson GS, 2010, BEHAV RES THER, V48, P675, DOI 10.1016/j.brat.2010.03.007; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.neuro.13.1.171; Christensen D, 1999, PAIN, V83, P433, DOI 10.1016/S0304-3959(99)00126-8; D'Ambrosio R, 1998, BRAIN RES, V786, P64, DOI 10.1016/S0006-8993(97)01412-1; Danysz W, 1998, PHARMACOL REV, V50, P597; Davalos A, 1997, STROKE, V28, P708, DOI 10.1161/01.STR.28.4.708; Davis SM, 2000, STROKE, V31, P347, DOI 10.1161/01.STR.31.2.347; Dhawan J, 2011, FUTUR NEUROL, V6, P823, DOI 10.2217/FNL.11.55; Dhawan J, 2010, NEUROIMAGE, V51, P599, DOI 10.1016/j.neuroimage.2010.02.073; Dhonnchadha BAN, 2010, NEUROPSYCHOPHARMACOL, V35, P357, DOI 10.1038/npp.2009.139; Dravid SM, 2010, J NEUROSCI, V30, P2741, DOI 10.1523/JNEUROSCI.5390-09.2010; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fujihira T, 2007, NEUROCHEM INT, V51, P233, DOI 10.1016/j.neuint.2007.06.003; Ginsberg MD, 2008, NEUROPHARMACOLOGY, V55, P363, DOI 10.1016/j.neuropharm.2007.12.007; Gottlieb JD, 2011, SCHIZOPHR RES, V131, P69, DOI 10.1016/j.schres.2011.05.029; Grossman R, 2003, NEUROIMAGE, V20, P1971, DOI 10.1016/j.neuroimage.2003.06.003; Hewitt DJ, 2000, CLIN J PAIN, V16, pS73, DOI 10.1097/00002508-200006001-00013; Hofmann SG, 2006, ARCH GEN PSYCHIAT, V63, P298, DOI 10.1001/archpsyc.63.3.298; HOOD WF, 1989, NEUROSCI LETT, V98, P91, DOI 10.1016/0304-3940(89)90379-0; Hoyte L, 2004, CURR MOL MED, V4, P131, DOI 10.2174/1566524043479248; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; JOHNSON JW, 1987, NATURE, V325, P529, DOI 10.1038/325529a0; Kalia LV, 2008, LANCET NEUROL, V7, P742, DOI 10.1016/S1474-4422(08)70165-0; KLECKNER NW, 1988, SCIENCE, V241, P835, DOI 10.1126/science.2841759; KORTE M, 1995, P NATL ACAD SCI USA, V92, P8856, DOI 10.1073/pnas.92.19.8856; LANTHORN TH, 1994, AMINO ACIDS, V6, P247, DOI 10.1007/BF00813745; Ledgerwood L, 2004, BEHAV NEUROSCI, V118, P505, DOI 10.1037/0735-7044.118.3.505; Ledgerwood L, 2003, BEHAV NEUROSCI, V117, P341, DOI 10.1037/0735-7044.117.2.341; Lees KR, 1997, NEUROLOGY, V49, pS66, DOI 10.1212/WNL.49.5_Suppl_4.S66; Levin ED, 2011, PHARMACOL BIOCHEM BE, V98, P210, DOI 10.1016/j.pbb.2010.12.023; Liraz-Zaltsman S, 2011, J MOL NEUROSCI, V45, pS75; Liraz-Zaltsman S, 2011, SYNAPSE, V65, P634, DOI 10.1002/syn.20889; LYNCH DR, 1994, CURR OPIN NEUROL, V7, P510, DOI 10.1097/00019052-199412000-00007; Maas AIR, 1999, NEUROSURGERY, V44, P1286, DOI 10.1097/00006123-199906000-00076; Madden DR, 2002, NAT REV NEUROSCI, V3, P91, DOI 10.1038/nrn725; Malenka RC, 1999, SCIENCE, V285, P1870, DOI 10.1126/science.285.5435.1870; Matsumoto Y, 2001, EUR J PHARMACOL, V430, P283, DOI 10.1016/S0014-2999(01)01374-7; Millecamps M, 2007, PAIN, V132, P108, DOI 10.1016/j.pain.2007.03.003; Morris GF, 1998, NEUROSURGERY, V43, P1369, DOI 10.1097/00006123-199812000-00063; Morton RF, 1956, ANTIBIOT ANNU, V31, P169; Muir KW, 2006, CURR OPIN PHARMACOL, V6, P53, DOI 10.1016/j.coph.2005.12.002; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Norberg MM, 2008, BIOL PSYCHIAT, V63, P1118, DOI 10.1016/j.biopsych.2008.01.012; Obviagle B, 2003, CURR NEUROL NEUROSCI, V3, P9; OGAWA N, 1991, NEUROCHEM RES, V16, P519, DOI 10.1007/BF00974869; PITKANEN M, 1994, EUR J PHARMACOL, V253, P125, DOI 10.1016/0014-2999(94)90766-8; QUARTERMAIN D, 1994, EUR J PHARMACOL, V257, P7, DOI 10.1016/0014-2999(94)90687-4; Ressler KJ, 2004, ARCH GEN PSYCHIAT, V61, P1136, DOI 10.1001/archpsyc.61.11.1136; Richardson R, 2004, LEARN MEMORY, V11, P510, DOI 10.1101/lm.78204; Rivas Salalzar JL, 1970, SCAND J RESP DIS S, V71, P314; Rothbaum BO, 2008, AM J PSYCHIAT, V165, P293, DOI 10.1176/appi.ajp.2007.07121871; Sanders MJ, 2000, BRAIN RES, V861, P69, DOI 10.1016/S0006-8993(00)01986-7; Schneider JS, 2000, BRAIN RES, V860, P190, DOI 10.1016/S0006-8993(00)02036-9; Schwarzbach E, 2006, HIPPOCAMPUS, V16, P541, DOI 10.1002/hipo.20183; Sharma HS, 2006, ACTA NEUROCHIR SUPPL, V96, P329; Shohami E., 2011, TRAUMATIC BRAIN SPIN; Sick TJ, 1998, BRAIN RES, V785, P287, DOI 10.1016/S0006-8993(97)01418-2; Sucher NJ, 1996, TRENDS PHARMACOL SCI, V17, P348, DOI 10.1016/S0165-6147(96)10046-8; Tan-No K, 2007, J PHARMACOL SCI, V104, P39, DOI 10.1254/jphs.FP0070203; Temple MD, 1996, BRAIN RES, V741, P246, DOI 10.1016/S0006-8993(96)00940-7; Thanos PK, 2011, SYNAPSE, V65, P938, DOI 10.1002/syn.20922; Tolias Christos M, 2004, NeuroRx, V1, P71, DOI 10.1602/neurorx.1.1.71; vanBerckel BNM, 1997, NEUROPSYCHOPHARMACOL, V16, P317, DOI 10.1016/S0893-133X(96)00196-0; WALKER W C, 1957, Tubercle, V38, P297, DOI 10.1016/S0041-3879(57)80097-X; Wang AL, 2010, BEHAV BRAIN RES, V208, P38, DOI 10.1016/j.bbr.2009.11.006; WATSON GB, 1990, BRAIN RES, V510, P158, DOI 10.1016/0006-8993(90)90745-W; Yaka R, 2003, J BIOL CHEM, V278, P9630, DOI 10.1074/jbc.M209141200; Yaka R, 2007, FASEB J, V21, P2033, DOI 10.1096/fj.06-7856com; Zhu M, 2001, PHARMACOTHERAPY, V21, P891, DOI 10.1592/phco.21.11.891.34524	83	42	42	0	13	BENTHAM SCIENCE PUBL LTD	SHARJAH	EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES	1871-5273	1996-3181		CNS NEUROL DISORD-DR	CNS Neurol. Disord.-Drug Targets		2014	13	4					567	573		10.2174/18715273113126660196			7	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	AN8EO	WOS:000340836200005	24168367				2021-06-18	
J	Hellewell, SC; Yan, EB; Alwis, DS; Bye, N; Morganti-Kossmann, MC				Hellewell, Sarah C.; Yan, Edwin B.; Alwis, Dasuni S.; Bye, Nicole; Morganti-Kossmann, M. Cristina			Erythropoietin improves motor and cognitive deficit, axonal pathology, and neuroinflammation in a combined model of diffuse traumatic brain injury and hypoxia, in association with upregulation of the erythropoietin receptor	JOURNAL OF NEUROINFLAMMATION			English	Article						Traumatic brain injury (TBI); Traumatic axonal injury; Hypoxia; Erythropoietin; EPO; Neuroprotection	RECOMBINANT-HUMAN-ERYTHROPOIETIN; LATERAL FLUID PERCUSSION; CLOSED-HEAD INJURY; WHITE-MATTER; INTERLEUKIN-1 RECEPTOR; FUNCTIONAL OUTCOMES; SECONDARY INSULTS; SPATIAL MEMORY; MESSENGER-RNA; RATS	Background: Diffuse axonal injury is a common consequence of traumatic brain injury (TBI) and often co-occurs with hypoxia, resulting in poor neurological outcome for which there is no current therapy. Here, we investigate the ability of the multifunctional compound erythropoietin (EPO) to provide neuroprotection when administered to rats after diffuse TBI alone or with post-traumatic hypoxia. Methods: Sprague-Dawley rats were subjected to diffuse traumatic axonal injury (TAI) followed by 30 minutes of hypoxic (Hx, 12% O-2) or normoxic ventilation, and were administered recombinant human EPO-alpha (5000 IU/kg) or saline at 1 and 24 hours post-injury. The parameters examined included: 1) behavioural and cognitive deficit using the Rotarod, open field and novel object recognition tests; 2) axonal pathology (NF-200); 3) callosal degradation (hematoxylin and eosin stain); 3) dendritic loss (MAP2); 4) expression and localisation of the EPO receptor (EpoR); 5) activation/infiltration of microglia/macrophages (CD68) and production of IL-1 beta. Results: EPO significantly improved sensorimotor and cognitive recovery when administered to TAI rats with hypoxia (TAI + Hx). A single dose of EPO at 1 hour reduced axonal damage in the white matter of TAI + Hx rats at 1 day by 60% compared to vehicle. MAP2 was decreased in the lateral septal nucleus of TAI + Hx rats; however, EPO prevented this loss, and maintained MAP2 density over time. EPO administration elicited an early enhanced expression of EpoR 1 day after TAI + Hx compared with a 7-day peak in vehicle controls. Furthermore, EPO reduced IL-1 beta to sham levels 2 hours after TAI + Hx, concomitant to a decrease in CD68 positive cells at 7 and 14 days. Conclusions: When administered EPO, TAI + Hx rats had improved behavioural and cognitive performance, attenuated white matter damage, resolution of neuronal damage spanning from the axon to the dendrite, and suppressed neuroinflammation, alongside enhanced expression of EpoR. These data provide compelling evidence of EPO's neuroprotective capability. Few benefits were observed when EPO was administered to TAI rats without hypoxia, indicating that EPO's neuroprotective capacity is bolstered under hypoxic conditions, which may be an important consideration when EPO is employed for neuroprotection in the clinic.	[Hellewell, Sarah C.; Alwis, Dasuni S.; Bye, Nicole] Alfred Hosp, Natl Trauma Res Inst, Melbourne, Vic 3000, Australia; [Hellewell, Sarah C.; Bye, Nicole] Monash Univ, Dept Surg, Melbourne, Vic 3000, Australia; [Yan, Edwin B.; Alwis, Dasuni S.] Monash Univ, Dept Physiol, Clayton, Vic 3800, Australia; [Morganti-Kossmann, M. Cristina] Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3000, Australia; [Morganti-Kossmann, M. Cristina] Australian New Zealand Intens Care Res Ctr, Melbourne, Vic 3000, Australia; [Morganti-Kossmann, M. Cristina] Univ Arizona, Dept Child Hlth, Barrow Neurol Inst, Melbourne, Vic 3000, Australia	Hellewell, SC (corresponding author), Alfred Hosp, Natl Trauma Res Inst, Level 4,Burnet Tower,89 Commercial Rd, Melbourne, Vic 3000, Australia.	sarah.hellewell@monash.edu		Morganti-Kossmann, Cristina/0000-0002-0807-2063	National Health and Medical Research Council AustraliaNational Health and Medical Research Council of Australia; Victorian Neurotrauma Initiative	The authors would like to thank Dr. Alan Zhang for design of the novel object recognition software, and Alison Conquest and Doreen Agyapomaa for assistance with animal experiments. The authors would also like to acknowledge the generous financial support from the National Health and Medical Research Council Australia and the Victorian Neurotrauma Initiative, with fellowship support for MCMK, EBY & NB.	Abdel-Dayem HM, 1998, CLIN NUCL MED, V23, P309, DOI 10.1097/00003072-199805000-00009; Albasser MM, 2010, LEARN MEMORY, V17, P407, DOI 10.1101/lm.1879610; Assaf Y, 1999, J NEUROTRAUM, V16, P1165, DOI 10.1089/neu.1999.16.1165; BALLOUGH GPH, 1995, J NEUROSCI METH, V61, P23, DOI 10.1016/0165-0270(95)00019-Q; Basu A, 2002, J NEUROSCI, V22, P6071; Bernaudin M, 2000, GLIA, V30, P271, DOI 10.1002/(SICI)1098-1136(200005)30:3<271::AID-GLIA6>3.3.CO;2-8; Bernaudin M, 1999, J CEREBR BLOOD F MET, V19, P643, DOI 10.1097/00004647-199906000-00007; Bian XX, 2010, NEUROL MED-CHIR, V50, P361, DOI 10.2176/nmc.50.361; Bouzat P, 2011, CRIT CARE MED, V39, P2099, DOI 10.1097/CCM.0b013e31821cb7b2; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Brines M, 2008, J INTERN MED, V264, P405, DOI 10.1111/j.1365-2796.2008.02024.x; Chen G, 2007, NEUROSCI LETT, V425, P177, DOI 10.1016/j.neulet.2007.08.022; Chen ZY, 2006, NEURODEGENER DIS, V3, P68, DOI 10.1159/000092096; Chesnut R M, 1995, New Horiz, V3, P366; Chi JH, 2006, J TRAUMA, V61, P1134, DOI 10.1097/01.ta.0000196644.64653.d8; Colin E, 2008, EMBO J, V27, P2124, DOI 10.1038/emboj.2008.133; DeWitt DS, 1997, J NEUROTRAUM, V14, P223, DOI 10.1089/neu.1997.14.223; DIGICAYLIOGLU M, 1995, P NATL ACAD SCI USA, V92, P3717, DOI 10.1073/pnas.92.9.3717; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; Fan XY, 2011, PEDIATR RES, V69, P56, DOI 10.1203/PDR.0b013e3181fcbef3; Fandrey J, 2004, AM J PHYSIOL-REG I, V286, pR977, DOI 10.1152/ajpregu.00577.2003; Farkas E, 2004, ACTA NEUROPATHOL, V108, P57, DOI 10.1007/s00401-004-0864-9; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Gabrielian L, 2011, J NEUROTRAUM, V28, P2103, DOI 10.1089/neu.2011.1785; Gao GY, 2010, J CEREBR BLOOD F MET, V30, P628, DOI 10.1038/jcbfm.2009.235; Gennarelli TA, 1998, NEUROSCIENTIST, V4, P202, DOI 10.1177/107385849800400316; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Ghabriel M, 2004, PROCEEDINGS OF THE 7TH INTERNATIONAL NEUROTRAUMA SYMPOSIUM, P89; GIULIAN D, 1993, J NEUROSCI RES, V36, P681, DOI 10.1002/jnr.490360609; Grasso G, 2007, BRAIN RES, V1182, P99, DOI 10.1016/j.brainres.2007.08.078; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hellewell SC, 2010, J NEUROTRAUM, V27, P1997, DOI 10.1089/neu.2009.1245; HINO A, 1989, STROKE, V20, P1504, DOI 10.1161/01.STR.20.11.1504; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; Juul SE, 1998, PEDIATR RES, V43, P40, DOI 10.1203/00006450-199801000-00007; Keller M, 2006, NEUROBIOL DIS, V24, P357, DOI 10.1016/j.nbd.2006.07.007; KOCHER M, 1990, J CEREBR BLOOD F MET, V10, P564, DOI 10.1038/jcbfm.1990.99; Kumral A, 2004, BEHAV BRAIN RES, V153, P77, DOI 10.1016/j.bbr.2003.11.002; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Lewczuk P, 2000, NEUROREPORT, V11, P3485, DOI 10.1097/00001756-200011090-00017; Li Y, 2007, J CEREBR BLOOD F MET, V27, P1043, DOI 10.1038/sj.jcbfm.9600417; Liao ZB, 2008, EUR J NEUROL, V15, P140, DOI 10.1111/j.1468-1331.2007.02013.x; Lieutaud T, 2008, J NEUROTRAUM, V25, P1179, DOI 10.1089/neu.2008.0591; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Madan A, 1997, BLOOD CELL MOL DIS, V23, P169, DOI 10.1006/bcmd.1997.0134; Maloyan A, 2005, PHYSIOL GENOMICS, V23, P79, DOI 10.1152/physiolgenomics.00279.2004; Marti HH, 1996, EUR J NEUROSCI, V8, P666, DOI 10.1111/j.1460-9568.1996.tb01252.x; Martinez-Estrada OM, 2003, EUR J NEUROSCI, V18, P2538, DOI 10.1046/j.1460-9568.2003.02987.x; MASUDA S, 1994, J BIOL CHEM, V269, P19488; MASUDA S, 1993, J BIOL CHEM, V268, P11208; Mazur M, 2010, J NEUROSURG-PEDIATR, V6, P206, DOI 10.3171/2010.5.PEDS1032; McHugh GS, 2007, J NEUROTRAUM, V24, P287, DOI 10.1089/neu.2006.0031; Meng YL, 2011, J NEUROSURG, V115, P550, DOI 10.3171/2011.3.JNS101721; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; Minnerup J, 2009, STROKE, V40, P3113, DOI 10.1161/STROKEAHA.109.555789; Montero M, 2007, EXP NEUROL, V204, P106, DOI 10.1016/j.expneurol.2006.09.026; Nagai A, 2001, J NEUROPATH EXP NEUR, V60, P386, DOI 10.1093/jnen/60.4.386; Neumann D, 1996, BIOCHEM J, V313, P391, DOI 10.1042/bj3130391; Posmantur RM, 1996, J NEUROTRAUM, V13, P125, DOI 10.1089/neu.1996.13.125; Rabie T, 2008, PHYSIOLOGY, V23, P263, DOI 10.1152/physiol.00016.2008; Rex TS, 2009, EXP EYE RES, V89, P735, DOI 10.1016/j.exer.2009.06.017; Rockswold GL, 2006, J NEUROSURG, V104, P170, DOI 10.3171/jns.2006.104.1.170; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Sanchez PE, 2009, P NATL ACAD SCI USA, V106, P9848, DOI 10.1073/pnas.0901840106; Sargin D, 2010, BEST PRACT RES-CLIN, V24, P573, DOI 10.1016/j.bpa.2010.10.005; Satoh JI, 2002, NEUROPATH APPL NEURO, V28, P95, DOI 10.1046/j.1365-2990.2002.00375.x; Schober ME, 2010, J NEUROTRAUM, V27, P2011, DOI 10.1089/neu.2009.1226; Siren AL, 2001, ACTA NEUROPATHOL, V101, P271, DOI 10.1007/s004010000297; Smith DH, 2013, J NEUROTRAUM, V30, P307, DOI 10.1089/neu.2012.2825; Spandou E, 2005, BRAIN RES, V1045, P22, DOI 10.1016/j.brainres.2005.03.013; Spandou E, 2004, BRAIN RES, V1021, P167, DOI 10.1016/j.brainres.2004.06.057; Springborg JB, 2002, BRIT J PHARMACOL, V135, P823, DOI 10.1038/sj.bjp.0704521; Stoll G, 2002, DETRIMENTAL BENEFICI, V513; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; TERAYAMA Y, 1993, SURG NEUROL, V39, P177, DOI 10.1016/0090-3019(93)90179-5; Utagawa A, 2008, BRAIN RES, V1207, P155, DOI 10.1016/j.brainres.2008.02.057; Valable S, 2010, J CEREBR BLOOD F MET, V30, P361, DOI 10.1038/jcbfm.2009.222; Verdonck O, 2007, J CEREBR BLOOD F MET, V27, P1369, DOI 10.1038/sj.jcbfm.9600443; Weber A, 2005, NEUROBIOL DIS, V20, P594, DOI 10.1016/j.nbd.2005.04.016; Winters BD, 2008, NEUROSCI BIOBEHAV R, V32, P1055, DOI 10.1016/j.neubiorev.2008.04.004; Xiong Y, 2008, BRAIN RES, V1230, P247, DOI 10.1016/j.brainres.2008.06.127; Xiong Y, 2008, J NEUROSURG, V109, P510, DOI 10.3171/JNS/2008/109/9/0510; Xiong Y, 2010, J NEUROSURG, V113, P598, DOI 10.3171/2009.9.JNS09844; Xiong Y, 2010, J NEUROTRAUM, V27, P205, DOI 10.1089/neu.2009.1001; Yan EB, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-147; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje	91	42	47	0	16	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1742-2094		J NEUROINFLAMM	J. Neuroinflamm.	DEC 18	2013	10								156	10.1186/1742-2094-10-156			21	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	298LR	WOS:000330325900001	24344874	DOAJ Gold, Green Published			2021-06-18	
J	Heinemann, AW; Magasi, S; Bode, RK; Hammel, J; Whiteneck, GG; Bogner, J; Corrigan, JD				Heinemann, Allen W.; Magasi, Susan; Bode, Rita K.; Hammel, Joy; Whiteneck, Gale G.; Bogner, Jennifer; Corrigan, John D.			Measuring Enfranchisement: Importance of and Control Over Participation by People With Disabilities	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Psychometrics; Quality of life; Rehabilitation; Social participation	INTERNATIONAL-CLASSIFICATION; COMMUNITY; HEALTH; PERSPECTIVES; INTEGRATION; COMPONENTS; ISSUES; LIFE	Objective: To evaluate the psychometric properties and validity of an expanded set of community enfranchisement items that are suitable for computer adaptive testing. Design: Survey. Setting: Community setting. Participants: Individuals with disabilities (N=1163) were recruited from an online panel generation company (51%), former rehabilitation inpatients (18%), disability community organizations (13%), a registry of rehabilitation patients (10%), and Traumatic Brain Injury and Spinal Cord Injury Model System facilities (8%). Inclusion criteria were a self-identified disability, aged >= 18 years, and the ability to read and speak English. Interventions: None. Main Outcome Measure: Community enfranchisement. Results: Exploratory and confirmatory factor analyses of the 48 enfranchisement items suggested 2 distinct subsets of items: (1) importance of participation and (2) control over participation. Principal components analysis of the residuals suggested that the 2 item sets are unidimensional. Rating scale analysis provided evidence that the 2 item sets fit the Rasch model. Importance and control were moderately correlated with each other and with disability severity. Conclusions: Importance of participation and control over participation define 2 distinct sets of participation enfranchisement. Preliminary evidence supports their validity. (C) 2013 by the American Congress of Rehabilitation Medicine	[Heinemann, Allen W.] Northwestern Univ, Feinberg Sch Med, Dept Phys Med & Rehabil, Chicago, IL 60611 USA; [Heinemann, Allen W.] Rehabil Inst Chicago, Chicago, IL 60611 USA; [Hammel, Joy] Univ Illinois, Coll Appl Hlth Sci, Chicago, IL USA; [Magasi, Susan; Whiteneck, Gale G.] Craig Hosp, Englewood, CO USA; [Bogner, Jennifer; Corrigan, John D.] Ohio State Univ, Columbus, OH 43210 USA	Heinemann, AW (corresponding author), Northwestern Univ, Feinberg Sch Med, 345 E Super St, Chicago, IL 60611 USA.	a-heinemann@northwestern.edu	Bogner, Jennifer/E-2773-2011; Heinemann, Allen W./AAI-2790-2021	Heinemann, Allen W./0000-0003-2782-7326	National Institute on Disability and Rehabilitation Research through a Rehabilitation Research and Training Center on Measuring Rehabilitation Outcomes and Effectiveness [H133B040032]	Supported by the National Institute on Disability and Rehabilitation Research through a Rehabilitation Research and Training Center on Measuring Rehabilitation Outcomes and Effectiveness grant (no. H133B040032).	Badley EM, 2008, SOC SCI MED, V66, P2335, DOI 10.1016/j.socscimed.2008.01.026; Baum CM, 2011, ARCH PHYS MED REHAB, V92, P169, DOI 10.1016/j.apmr.2010.12.010; Bezruczko N., 2005, RASCH MEASUREMENT HL; Bond T.G., 2007, APPL RASCH MODEL FUN; Brown M, 2004, J HEAD TRAUMA REHAB, V19, P459, DOI 10.1097/00001199-200411000-00004; Choi SW, 2011, J STAT SOFTW, V39, P1; GIBBONS RD, 1992, PSYCHOMETRIKA, V57, P423, DOI 10.1007/BF02295430; Hammel J, 2008, DISABIL REHABIL, V30, P1445, DOI 10.1080/09638280701625534; Heinemann AW, 2011, ARCH PHYS MED REHAB, V92, P564, DOI 10.1016/j.apmr.2010.07.220; Heinemann AW, 2010, ARCH PHYS MED REHAB, V91, pS72, DOI 10.1016/j.apmr.2009.11.031; Hemmingsson H, 2005, AM J OCCUP THER, V59, P569, DOI 10.5014/ajot.59.5.569; Hollingsworth H, 2010, ARCH PHYS MED REHAB, V91, P1174, DOI 10.1016/j.apmr.2010.04.019; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; Institute of Medicine, 2007, FUTURE DISABILITY AM; Linacre J. M., 2009, WINSTEPS RASCH PROGR; Magasi S, 2010, ARCH PHYS MED REHAB, V91, pS17, DOI 10.1016/j.apmr.2010.07.011; Magasi S, 2009, J REHABIL MED, V41, P936, DOI 10.2340/16501977-0450; McColl MA, 2001, ARCH PHYS MED REHAB, V82, P429, DOI 10.1053/apmr.2001.22195; MCDONALD RP, 1981, BRIT J MATH STAT PSY, V34, P100, DOI 10.1111/j.2044-8317.1981.tb00621.x; Muthen B., 1997, ROBUST INFERENCE USI; Muthen L., 2006, MPLUS USERS GUIDE; O'Connor BP, 2000, BEHAV RES METH INS C, V32, P396, DOI 10.3758/BF03200807; Rasch G., 1980, PROBABILISTIC MODELS; Seekins T, 2012, DISABIL HEALTH J, V5, P224, DOI 10.1016/j.dhjo.2012.05.002; Sprangers MAG, 1999, SOC SCI MED, V48, P1507, DOI 10.1016/S0277-9536(99)00045-3; Tennant A, 2006, RASCH MEASUREMENT T, V20, P1048; Townley G, 2009, J COMMUNITY PSYCHOL, V37, P362, DOI 10.1002/jcop.20301; Ueda S, 2003, DISABIL REHABIL, V25, P596, DOI 10.1080/0963828031000137108; van de Ven L, 2005, DISABIL SOC, V20, P311, DOI 10.1080/09687590500060778; Vargus-Adams JN, 2012, DEV MED CHILD NEUROL, V54, P777, DOI 10.1111/j.1469-8749.2012.04353.x; Whiteneck G, 2006, WORKSH DIS AM NEW LO, P55; Whiteneck G, 2009, ARCH PHYS MED REHAB, V90, pS22, DOI 10.1016/j.apmr.2009.06.009; World Health Organization, 2001, INT CLASS FUNCT DIS; Wright B. D., 1999, MEASUREMENT ESSENTIA	34	42	42	0	21	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	NOV	2013	94	11					2157	2165		10.1016/j.apmr.2013.05.017			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	250KV	WOS:000326852600017	23769764				2021-06-18	
J	Schirmer, CM; Elder, JB; Roitberg, B; Lobel, DA				Schirmer, Clemens M.; Elder, J. Bradley; Roitberg, Ben; Lobel, Darlene A.			Virtual Reality-Based Simulation Training for Ventriculostomy: An Evidence-Based Approach	NEUROSURGERY			English	Article						Education; Neurotrauma; Residency; Simulation; Ventriculostomy; Virtual reality	CONSTRUCT-VALIDATION; TECHNICAL SKILL; CURRICULUM; PLACEMENT; EDUCATION	BACKGROUND: Virtual reality (VR) simulation-based technologies play an important role in ne resident training. The Congress of Neurological Surgeons (CNS) Simulation Committee developed a simulation-based curriculum incorporating VR simulators to train residents in the management of common neurosurgical C disorders. OBJECTIVE: To enhance neurosurgical resident training for ventriculostomy placement using simulation-based training. METHODS: A course-based neurosurgical simulation curriculum was introduced at the Neurosurgical Simulation Symposium at the 2011 and 2012 CNS annual meetings. A trauma module was developed to teach ventriculostomy placement as one of the neurosurgical procedures commonly performed in the management of traumatic brain injury. The course offered both didactic and simulator-based instruction, incorporating written and practical pretests and posttests and questionnaires to assess improvement in skill level and to validate the simulators as teaching tools. RESULTS: Fourteen trainees participated in the didactic component of the trauma module. Written scores improved significantly from pretest (75%) to posttest (87.5%; P < .05). Seven participants completed the ventriculostomy simulation. Significant improvements were observed in anatomy (P < .04), burr hole placement (P < .03), final location of the catheter (P = .05), and procedure completion time (P < .004). Senior residents planned a significantly better trajectory (P < .01); junior participants improved most in terms of identifying the relevant anatomy (P < .03) and the time required to complete the procedure (P < .04). CONCLUSION: VR ventriculostomy placement as part of the CNS simulation trauma module complements standard training techniques for residents in the management of neurosurgical trauma. Improvement in didactic and hands-on knowledge by course participants demonstrates the usefulness of the VR simulator as a training tool.	[Schirmer, Clemens M.] Baystate Med Ctr, Div Neurosurg, Springfield, MA USA; [Schirmer, Clemens M.] Tufts Univ, Sch Med, Dept Neurosurg, Springfield, MA 01107 USA; [Elder, J. Bradley] Ohio State Univ, Med Ctr, Dept Neurol Surg, Columbus, OH 43210 USA; [Roitberg, Ben] Univ Chicago, Neurosurg Sect, Chicago, IL 60637 USA; [Lobel, Darlene A.] Mayo Clin, Dept Neurol Surg, Rochester, MN USA	Schirmer, CM (corresponding author), Tufts Univ, Sch Med, Dept Neurosurg, Baystate Med Ctr Neurosurg, 2 Med Ctr Dr,Ste 503, Springfield, MA 01107 USA.	cmschirmer@gmail.com		Schirmer, Clemens/0000-0003-1743-8781			Abboudi H, 2013, BJU INT, V111, P194, DOI 10.1111/j.1464-410X.2012.11270.x; Accreditation Council for Graduate Medical Education (ACGME), COMM PROGR REQ; Banerjee PP, 2007, J NEUROSURG, V107, P515, DOI 10.3171/JNS-07/09/0515; Banerjee PP, 2007, SIMUL HEALTHC, V2, P145; Britt RC, 2007, AM SURGEON, V73, P680; Faulkner H, 1996, ACAD MED, V71, P1363, DOI 10.1097/00001888-199612000-00023; Gallagher AG, 2004, JAMA-J AM MED ASSOC, V292, P3024, DOI 10.1001/jama.292.24.3024; Hooten KG, 2012, C NEUR SURG CNS ANN; John N W, 2000, Stud Health Technol Inform, V70, P146; Kelly DC, 2012, UROLOGY, V79, P1068, DOI 10.1016/j.urology.2012.01.028; Khan MS, 2013, BJU INT, V111, P518, DOI 10.1111/j.1464-410X.2012.11204.x; Krombach G, 2000, MINIM INVAS NEUROSUR, V43, P171, DOI 10.1055/s-2000-11376; Larsen OV, 2001, ST HEAL T, V81, P256; Lemole GM, 2007, NEUROSURGERY, V61, P142, DOI 10.1227/01.neu.0000279734.22931.21; Liss MA, 2012, J ENDOUROL, V26, P1629, DOI 10.1089/end.2012.0328; Lobel DA, 2013, NEUROSURGERY; Luciano C., 2005, 11 INT C HUM COMP IN; Mazzola CA, 2010, NEUROSURGERY, V67, P225, DOI 10.1227/01.NEU.0000372206.41812.23; Palter VN, 2013, ANN SURG, V257, P224, DOI 10.1097/SLA.0b013e31827051cd; Panchaphongsaphak B, 2006, ST HEAL T, V119, P428; Phillips NI, 2000, NEUROSURGERY, V46, P933, DOI 10.1097/00006123-200004000-00031; Plooy AM, 2012, GASTROINTEST ENDOSC, V76, P144, DOI 10.1016/j.gie.2012.03.246; Popp AJ, 2008, J NEUROSURG, V109, P576, DOI 10.3171/JNS/2008/109/10/0576; Selden NR, 2012, NEUROSURGERY, V70, P971, DOI 10.1227/NEU.0b013e31823d7a45; Singapogu RB, 2013, SURG ENDOSC, V27, P1653, DOI 10.1007/s00464-012-2648-y; Yudkowsky R, 2013, SIMUL HEALTHC, V8, P25, DOI 10.1097/SIH.0b013e3182662c69	26	42	43	2	12	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	OCT	2013	73			1			66	73		10.1227/NEU.0000000000000074			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	300SG	WOS:000330483300013	24051886				2021-06-18	
J	Farook, JM; Shields, J; Tawfik, A; Markand, S; Sen, T; Smith, SB; Brann, D; Dhandapani, KM; Sen, N				Farook, J. M.; Shields, J.; Tawfik, A.; Markand, S.; Sen, T.; Smith, S. B.; Brann, D.; Dhandapani, K. M.; Sen, N.			GADD34 induces cell death through inactivation of Akt following traumatic brain injury	CELL DEATH & DISEASE			English	Article						Akt; GADD34; TBI; cell death; TRAF6	PROTEIN-KINASE B; OXIDATIVE STRESS; TRANSCRIPTION FACTOR; PHOSPHORYLATION; INHIBITION; SURVIVAL; INSULIN; DAMAGE; DEPHOSPHORYLATION; ACTIVATION	Neuronal cell death contributes significantly to the pathology of traumatic brain injury (TBI) irrespective of the mode or severity of the injury. Activation of a pro-survival protein, Akt, is known to be regulated by an E3 ligase TRAF6 through a process of ubiquitination-coupled phosphorylation at its T308 residue. Here we show that upregulation of a pro-apototic protein, GADD34, attenuates TRAF6-mediated Akt activation in a controlled cortical impact model of TBI in mice. TBI induces the expression of GADD34 by stimulating binding of a stress inducible transcription factor, ATF4, to the GADD34 promoter. GADD34 then binds with TRAF6 and prevents its interaction with Akt. This event leads to retention of Akt in the cytosol and prevents phosphorylation at the T308 position. Finally, in vivo depletion of GADD34 using a lentiviral knockdown approach leads to a rescue of Akt activation and markedly attenuates TBI-induced cell death.	[Farook, J. M.; Brann, D.; Sen, N.] Georgia Regents Univ, Inst Mol Med & Genet, Augusta, GA 30912 USA; [Shields, J.; Dhandapani, K. M.] Georgia Regents Univ, Dept Neurosurg, Augusta, GA 30912 USA; [Tawfik, A.; Markand, S.; Smith, S. B.] Georgia Regents Univ, Dept Cellular Biol & Anat, Augusta, GA 30912 USA; [Sen, T.] Georgia Regents Univ, Ctr Canc, Augusta, GA 30912 USA	Sen, N (corresponding author), Georgia Regents Univ, Dept Neurol, 1120 15th St,CA 2018, Augusta, GA 30912 USA.	nsen@gru.edu	Sen, Nilkantha/AAW-9788-2020; Tawfik, Amany/AAN-9902-2020	Tawfik, Amany/0000-0002-0245-8256; Dhandapani, Krishnan/0000-0001-7044-1117	Georgia Regents University; NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS065172, NS075774]; NEIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI);  [EY012830S];  [NS050730]; NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01EY012830] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS065172, R21NS075774, R01NS050730] Funding Source: NIH RePORTER	JMF and NS were supported by the startup package provided by Georgia Regents University. JS and KMD were supported by NS065172 and NS075774 sponsored by NINDS. AT, SM and SBS were supported by EY012830S sponsored by NEI. DB was sponsored by NS050730 and NINDS.	Adler HT, 1999, MOL CELL BIOL, V19, P7050; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Arden KC, 2004, MOL CELL, V14, P416, DOI 10.1016/S1097-2765(04)00213-8; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902; Breuleux M, 2009, MOL CANCER THER, V8, P742, DOI 10.1158/1535-7163.MCT-08-0668; Chakraborty A, 2010, CELL, V143, P897, DOI 10.1016/j.cell.2010.11.032; Chen SS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036784; Clark RSB, 2001, J NEUROTRAUM, V18, P675, DOI 10.1089/089771501750357627; Connor JH, 2001, MOL CELL BIOL, V21, P6841, DOI 10.1128/MCB.21.20.6841-6850.2001; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dawson VL, 2004, J BIOENERG BIOMEMBR, V36, P287, DOI 10.1023/B:JOBB.0000041755.22613.8d; delPeso L, 1997, SCIENCE, V278, P687; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Feng JH, 2004, J BIOL CHEM, V279, P41189, DOI 10.1074/jbc.M406731200; Filippa N, 2000, MOL CELL BIOL, V20, P5712, DOI 10.1128/MCB.20.15.5712-5721.2000; Gerriets T, 2003, STROKE, V34, P2234, DOI 10.1161/01.STR.0000087171.34637.A9; Han RZ, 2009, NEUROSCI BULL, V25, P367, DOI 10.1007/s12264-009-0608-x; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Kimbler DE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041229; Lange PS, 2008, J EXP MED, V205, P1227, DOI 10.1084/jem.20071460; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Marciniak SJ, 2004, GENE DEV, V18, P3066, DOI 10.1101/gad.1250704; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; Noshita N, 2002, NEUROBIOL DIS, V9, P294, DOI 10.1006/nbdi.2002.0482; Novoa I, 2001, J CELL BIOL, V153, P1011, DOI 10.1083/jcb.153.5.1011; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Reyes RC, 2012, J NEUROSCI, V32, P12973, DOI 10.1523/JNEUROSCI.1597-12.2012; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Schroder M, 2005, ANNU REV BIOCHEM, V74, P739, DOI 10.1146/annurev.biochem.73.011303.074134; Sen N, 2009, NEURON, V63, P81, DOI 10.1016/j.neuron.2009.05.024; Sokka AL, 2007, J NEUROSCI, V27, P901, DOI 10.1523/JNEUROSCI.4289-06.2007; Sood R, 2000, BIOCHEM J, V346, P281, DOI 10.1042/0264-6021:3460281; Srivastava AK, 1998, MOL CELL BIOCHEM, V182, P135, DOI 10.1023/A:1006857527588; Szegezdi E, 2006, EMBO REP, V7, P880, DOI 10.1038/sj.embor.7400779; Takayasu M, 2003, J NEUROSURG, V99, P132, DOI 10.3171/spi.2003.99.1.0132; Yang WL, 2009, SCIENCE, V325, P1134, DOI 10.1126/science.1175065; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; Zhang QG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034504; Zhang XC, 2005, EXP NEUROL, V191, P318, DOI 10.1016/j.expneurol.2004.10.011	43	42	46	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2041-4889			CELL DEATH DIS	Cell Death Dis.	AUG	2013	4								e754	10.1038/cddis.2013.280			9	Cell Biology	Cell Biology	214PK	WOS:000324146000011	23907468	DOAJ Gold, Green Published			2021-06-18	
J	Simpson, GK; Sabaz, M; Daher, M				Simpson, Grahame K.; Sabaz, Mark; Daher, Maysaa			Prevalence, Clinical Features, and Correlates of Inappropriate Sexual Behavior After Traumatic Brain Injury: A Multicenter Study	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						challenging behavior; inappropriate sexual behavior; Overt Behavior Scale; prevalence; traumatic brain injury	HEAD-INJURY; SCALE; PEOPLE; DISABILITY; DAMAGE; ABI	Objective: Investigate the prevalence and clinical features of inappropriate sexual behavior (ISB) among a community-based cohort of clients of the New South Wales Brain Injury Rehabilitation program. Setting: All 11 community-based rehabilitation services of the statewide network. Participants: Five hundred seven clients with severe traumatic brain injury. Design: Cross-sectional multicentre study. Main Measures: Overt Behavior Scale, Disability Rating Scale, Sydney Psychosocial Reintegration Scale-2, Health of the Nation Outcome Scale-Acquired Brain Injury, Care and Needs Scale. Results: The point prevalence rate of ISBs was 8.9% (45/507) over the previous 3 months. Inappropriate sexual talk comprised 57.9% of all ISBs, followed by genital and nongenital touching behaviors (29.8%) and exhibitionism/public masturbation (10.5%). In 43 of 45 cases, ISBs were accompanied by other challenging behaviors, most often inappropriate social behavior, and/or aggression. Individuals who sustained more severe injuries and who were younger were significantly more likely to display ISBs. People displaying ISBs were more likely to display higher levels of challenging behaviors overall, lower levels of social participation, and more neuropsychiatric sequelae than 2 other groups: people displaying no challenging behaviors and people displaying challenging behaviors but no ISBs respectively. Conclusions: ISBs pose a complex clinical challenge among a minority of individuals with severe TBI.	[Simpson, Grahame K.; Sabaz, Mark; Daher, Maysaa] Liverpool Hosp, Liverpool Brain Injury Rehabil Unit, Sydney, NSW, Australia; [Simpson, Grahame K.] Univ Sydney, Sydney Sch Med, Rehabil Studies Unit, Sydney, NSW 2006, Australia	Simpson, GK (corresponding author), Liverpool Hosp, Liverpool Brain Injury Rehabil Unit, Locked Bag 7279, Liverpool Bc, NSW 1871, Australia.	grahame.simpson@sswahs.nsw.gov.au	Simpson, Grahame K/W-1074-2019	Simpson, Grahame K/0000-0001-8156-9060	New South Wales Agency for Clinical Innovation	The New South Wales Agency for Clinical Innovation funded the project. Dr Mark Sabaz was employed by the Agency for Clinical Innovation when working on the project. The authors thank Dr Jeffrey Rogers, Inika Gillis, and the Project steering committee.	ALDERMAN N, 1991, Brain Injury, V5, P77, DOI 10.3109/02699059108998516; Bezeau SC, 2004, BRAIN INJURY, V18, P299, DOI 10.1080/02699050310001617398; Britton KR, 1998, BRAIN INJURY, V12, P703, DOI 10.1080/026990598122269; Coetzer R., 2001, PSYCHIAT B, V25, P421, DOI DOI 10.1192/pb.25.11.421; Elliott ML, 1996, BRAIN INJURY, V10, P703, DOI 10.1080/026990596123972; EMORY LE, 1995, J HEAD TRAUMA REHAB, V10, P47; Fleminger S, 2005, PSYCHIATR BULL, V29, P53, DOI 10.1192/pb.29.2.53; Guercio John M, 2002, Case Manager, V13, P55, DOI 10.1067/tcmg.2002.122043; Johnson C, 2006, BRAIN INJURY, V20, P687, DOI 10.1080/02699050600744137; Kelly G, 2006, BRAIN INJURY, V20, P307, DOI 10.1080/02699050500488074; Kelly G, 2008, BRAIN INJURY, V22, P457, DOI 10.1080/02699050802060647; Kelly G, 2011, SEX DISABIL, V29, P313, DOI 10.1007/s11195-011-9213-9; Knight C, 2008, NEUROPSYCHOL REHABIL, V18, P129, DOI 10.1080/09602010701822381; Koenigs M, 2007, NATURE, V446, P908, DOI 10.1038/nature05631; Lawrie B, 2012, REHABIL NURS, V29, P9; Lebel C, 2011, J NEUROSCI, V31, P10937, DOI 10.1523/JNEUROSCI.5302-10.2011; LEHNE G, 1986, SEX DISABIL, V7, P145; LISHMAN WA, 1968, BRIT J PSYCHIAT, V114, P373, DOI 10.1192/bjp.114.509.373; MONEY J, 1990, AM J PSYCHOTHER, V44, P26; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Sabaz M, J HEAD TRAU IN PRESS; SABHESAN S, 1989, ARCH SEX BEHAV, V18, P349, DOI 10.1007/BF01541953; Schlund MW, 1999, BRAIN INJURY, V13, P55; Simpson G, 2001, J HEAD TRAUMA REHAB, V16, P556, DOI 10.1097/00001199-200112000-00004; Simpson G, 1999, J HEAD TRAUMA REHAB, V14, P567, DOI 10.1097/00001199-199912000-00005; Simpson G., 2001, BRAIN IMPAIR, V2, P97, DOI [https://doi.org/10.1375/brim.2.2.97, DOI 10.1375/BRIM.2.2.97]; Sowell ER, 1999, NAT NEUROSCI, V2, P859, DOI 10.1038/13154; Stuss DT, 2002, ANNU REV PSYCHOL, V53, P401, DOI 10.1146/annurev.psych.53.100901.135220; Tate RL, 2004, BRAIN INJURY, V18, P445, DOI 10.1080/02699050310001641183; Tate RL, 2011, J REHABIL MED, V43, P609, DOI 10.2340/16501977-0829; Taylor LA, 2003, NEUROPSYCHOL REHABIL, V13, P165, DOI 10.1080/09602010244000336; TEASDALE GM, 1995, J NEUROL NEUROSUR PS, V58, P526, DOI 10.1136/jnnp.58.5.526; Thompson PM, 2000, NATURE, V404, P190, DOI 10.1038/35004593; Wood R. L., 1987, BRAIN INJURY REHABIL; ZENCIUS A, 1990, Brain Injury, V4, P175, DOI 10.3109/02699059009026163	35	42	42	0	18	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2013	28	3					202	210		10.1097/HTR.0b013e31828dc5ae			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	149PS	WOS:000319334000007	23661072				2021-06-18	
J	Macdonald, RL; Cusimano, MD; Etminan, N; Hanggi, D; Hasan, D; Ilodigwe, D; Jaja, B; Lantigua, H; Le Roux, P; Lo, B; Louffat-Olivares, A; Mayer, S; Molyneux, A; Quinn, A; Schweizer, TA; Schenk, T; Spears, J; Todd, M; Torner, J; Vergouwen, MDL; Wong, GKC				Macdonald, R. Loch; Cusimano, Michael D.; Etminan, Nima; Hanggi, Daniel; Hasan, David; Ilodigwe, Don; Jaja, Blessing; Lantigua, Hector; Le Roux, Peter; Lo, Benjamin; Louffat-Olivares, Ada; Mayer, Stephan; Molyneux, Andrew; Quinn, Audrey; Schweizer, Tom A.; Schenk, Thomas; Spears, Julian; Todd, Michael; Torner, James; Vergouwen, Mervyn D. L.; Wong, George K. C.		SAHIT Collaboration	Subarachnoid Hemorrhage International Trialists Data Repository (SAHIT)	WORLD NEUROSURGERY			English	Article						Cerebral aneurysm; Clinical trial; Outcome; Subarachnoid hemorrhage	TRAUMATIC BRAIN-INJURY; CEREBRAL INFARCTION; CLINICAL-TRIALS; INTENSIVE-CARE; DOUBLE-BLIND; VASOSPASM; STROKE; CLAZOSENTAN; ISCHEMIA; REGION	The outcome of patients with aneurysmal subarachnoid hemorrhage (SAH) has improved slowly over the past 25 years. This improvement may be due to early aneurysm repair by endovascular or open means, use of nimodipine, and better critical care management. Despite this improvement, mortality remains at about 40%, and many survivors have permanent neurologic, cognitive, and neuropsychologic deficits. Randomized clinical trials have tested pharmacologic therapies, but few have been successful. There are numerous explanations for the failure of these trials, including ineffective interventions, inadequate sample size, treatment side effects, and insensitive or inappropriate outcome measures. Outcome often is evaluated on a good-bad dichotomous scale that was developed for traumatic brain injury 40 years ago. To address these issues, we established the Subarachnoid Hemorrhage International Trialists (SAHIT) data repository. The primary aim of the SAHIT data repository is to provide a unique resource for prognostic analysis and for studies aimed at optimizing the design and analysis of phase III trials in aneurysmal SAH. With this aim in mind, we convened a multinational investigator meeting to explore merging individual patient data from multiple clinical trials and observational databases of patients with SAH and to create an agreement under which such a group of investigators could submit data and collaborate. We welcome collaboration with other investigators.	[Macdonald, R. Loch; Cusimano, Michael D.; Ilodigwe, Don; Jaja, Blessing; Lo, Benjamin; Louffat-Olivares, Ada; Schweizer, Tom A.; Spears, Julian] Univ Toronto, Toronto, ON, Canada; [Etminan, Nima; Hanggi, Daniel] Univ Dusseldorf, D-40225 Dusseldorf, Germany; [Hasan, David; Todd, Michael; Torner, James] Univ Iowa, Iowa City, IA USA; [Lantigua, Hector; Mayer, Stephan] Columbia Univ, New York, NY USA; [Le Roux, Peter] Univ Penn, Philadelphia, PA 19104 USA; [Molyneux, Andrew] Univ Oxford, Oxford, England; [Quinn, Audrey] Gen Infirm, Leeds LS1 3EX, W Yorkshire, England; [Schenk, Thomas] Kings Coll London, London WC2R 2LS, England; [Vergouwen, Mervyn D. L.] Univ Med Ctr Utrecht, Utrecht, Netherlands; [Wong, George K. C.] Chinese Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China	Macdonald, RL (corresponding author), Univ Toronto, Toronto, ON, Canada.		Wong, George KC/A-6378-2011; Cusimano, Michael/X-4059-2019; Wong, George Kwok Chu/L-4344-2016	Wong, George KC/0000-0002-6078-2548; Cusimano, Michael/0000-0002-9989-0650; hasan, david/0000-0002-8335-5442	Canadian Institutes for Health ResearchCanadian Institutes of Health Research (CIHR); Physicians Services Incorporated Foundation; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Brain Aneurysm Foundation; Heart and Stroke Foundation of CanadaHeart & Stroke Foundation of Canada; Canadian Stroke Network; Medical Research Council UKUK Research & Innovation (UKRI)Medical Research Council UK (MRC); Cerecyte Coil Trial; Ontario Ministry of Research and InnovationMinistry of Research and Innovation, Ontario; Netherlands Thrombosis Foundation; Netherlands Heart FoundationNetherlands Heart Foundation; Hong Kong Food and Health Bureau; Hong Kong University Grant Committee; Integra; Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9401611, G0700479] Funding Source: researchfish	This work was funded by a grant from the Canadian Institutes for Health Research. Michael D. Cusimano receives grant support from the Canadian Institutes for Health Research. Nima Etminan receives grant support from Physicians Services Incorporated Foundation. David Hasan receives grant funding from National Institutes of Health and Brain Aneurysm Foundation. Peter Le Roux receives research funding from the National Institutes of Health and Integra and is a consultant for Cadman, Integra and Edge Therapeutics. R. Loch Macdonald receives grant funding from the Canadian Institutes for Health Research, Heart and Stroke Foundation of Canada, Canadian Stroke Network, Brain Aneurysm Foundation, and Physicians Services Incorporated Foundation and is a consultant for Actelion Pharmaceuticals, Ltd., and Chief Scientific Officer of Edge Therapeutics, Inc. Stephan Mayer is a consultant for Actelion Pharmaceuticals, Ltd. Andrew Molyneux is a consultant for Micrus Endovascular and receives grant support from the Medical Research Council UK and Cerecyte Coil Trial. Tom A. Schweizer receives grant support from the Heart and Stroke Foundation of Canada, the Canadian Institutes of Health Research, and the Ontario Ministry of Research and Innovation. Michael Todd receives grant support from the National Institutes of Health. James Torner receives grant support from the National Institutes of Health. Mervyn D. I. Vergouwen receives grant support from the Netherlands Thrombosis Foundation and Netherlands Heart Foundation. George K. C. Wong receives grant support from the Hong Kong Food and Health Bureau and the Hong Kong University Grant Committee.	Al-Khindi T, 2010, STROKE, V41, pE519, DOI 10.1161/STROKEAHA.110.581975; Bath PMW, 2007, STROKE, V38, P1911, DOI 10.1161/STROKEAHA.106.474080; Deans KJ, 2007, CRIT CARE MED, V35, P1509, DOI 10.1097/01.CCM.0000266584.40715.A6; Dorhout Mees SM, 2007, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000277.PUB3; Etminan N, 2011, J CEREBR BLOOD F MET, V31, P1443, DOI 10.1038/jcbfm.2011.7; Frontera JA, 2006, NEUROSURGERY, V59, P21, DOI 10.1227/01.NEU.0000218821.34014.1B; JENNETT B, 1975, LANCET, V1, P480; KRAMER AH, 2011, ACTA NEUROCHIR SUPPL, V2, P193, DOI DOI 10.1007/978-3-7091-0356-2_36; Kreiter KT, 2009, STROKE, V40, P2362, DOI 10.1161/STROKEAHA.109.547331; Linn FHH, 1996, STROKE, V27, P625, DOI 10.1161/01.STR.27.4.625; Lovelock CE, 2010, NEUROLOGY, V74, P1494, DOI 10.1212/WNL.0b013e3181dd42b3; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Maas AIR, 2012, J NEUROTRAUM, V29, P32, DOI 10.1089/neu.2010.1599; Maas AIR, 2011, J NEUROTRAUM, V28, P177, DOI 10.1089/neu.2010.1617; Macdonald RL, 2008, STROKE, V39, P3015, DOI 10.1161/STROKEAHA.108.519942; Macdonald RL, 2011, LANCET NEUROL, V10, P618, DOI 10.1016/S1474-4422(11)70108-9; Molyneux A, 2002, LANCET, V360, P1267, DOI 10.1016/S0140-6736(02)11314-6; Nieuwkamp DJ, 2009, LANCET NEUROL, V8, P635, DOI 10.1016/S1474-4422(09)70126-7; Ospina-Tascon GA, 2008, CRIT CARE MED, V36, P1311, DOI 10.1097/CCM.0b013e318168ea3e; PICKARD JD, 1989, BRIT MED J, V298, P636, DOI 10.1136/bmj.298.6674.636; Sahs AL, 1969, INTRACRANIAL ANEURYS; Saver JL, 2007, STROKE, V38, P3055, DOI 10.1161/STROKEAHA.107.488536; Taylor TN, 1996, STROKE, V27, P1459, DOI 10.1161/01.STR.27.9.1459; Tobin MJ, 2008, CHEST, V133, P1071, DOI 10.1378/chest.08-0077; van der Schaaf IC, 2002, STROKE, V33, P2043, DOI 10.1161/01.STR.0000024110.82735.5A; Vergouwen MDI, 2011, J CEREBR BLOOD F MET, V31, P1545, DOI 10.1038/jcbfm.2011.56; Vincent JL, 2010, CRIT CARE MED, V38, pS534, DOI 10.1097/CCM.0b013e3181f208ac; Wong GKC, 2011, NEUROSURGERY, V68, P1556, DOI 10.1227/NEU.0b013e31820cd40d	28	42	42	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	MAR-APR	2013	79	3-4					418	422		10.1016/j.wneu.2013.01.006			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	135CC	WOS:000318262600005	23295631				2021-06-18	
J	Briones, TL; Woods, J; Rogozinska, M				Briones, Teresita L.; Woods, Julie; Rogozinska, Magdalena			Decreased neuroinflammation and increased brain energy homeostasis following environmental enrichment after mild traumatic brain injury is associated with improvement in cognitive function	ACTA NEUROPATHOLOGICA COMMUNICATIONS			English	Article						IL-beta; TNF-alpha; IL10; AMPK; Non-matching-to-sample task	ACTIVATED PROTEIN-KINASE; CEREBRAL-ISCHEMIA; MICROGLIA; RECOVERY; IMPAIRMENT; PLASTICITY; INFLAMMATION; STIMULATION; HIPPOCAMPUS; INVOLVEMENT	Background: Persistent neuroinflammation and disruptions in brain energy metabolism is commonly seen in traumatic brain injury (TBI). Because of the lack of success of most TBI interventions and the documented benefits of environmental enrichment (EE) in enhancing brain plasticity, here we focused our study on use of EE in regulating injury-induced neuroinflammation and disruptions in energy metabolism in the prefrontal cortex and hippocampus. Adult male Wistar rats were used in the study and randomly assigned to receive either: mild TBI (mTBI) using the controlled cortical injury model or sham surgery. Following surgery, rats from each group were further randomized to either: EE housing or standard laboratory housing (CON). After 4 weeks of recovery, cognitive testing was performed using the non-matching-to-sample and delayed non-matching-to-sample tasks. After completion of behavioral testing, levels of the pro-inflammatory cytokines IL-1 beta and TNF-alpha and the anti-inflammatory cytokine IL-10 were measured. In addition, levels of AMPK (adenosine monophosphate-activated protein kinase), phosphorylated AMPK and uMtCK (ubiquitous mitochondrial creatine kinase) were assessed as measures of brain energy homeostasis. Results: Our results showed that EE: (1) decreased the pro-inflammatory cytokines IL-1 beta and TNF-alpha and enhanced levels of the anti-inflammatory cytokine IL-10 after mTBI; (2) mitigated mTBI-induced cognitive impairment; and (3) attenuated mTBI-induced downregulation in pAMPK/AMPK ratio and uMtCK levels. Conclusions: Our data demonstrated the potential of EE to modulate the persistent: (1) neuroinflammatory response seen following mTBI, and (2) persistent disturbance in brain energy homeostasis. It is possible that through the mechanism of modulating neuroinflammation, EE housing was able to restore the disruption in energy metabolism and enhanced functional recovery after mTBI.	[Briones, Teresita L.] Wayne State Univ, Dept Adult Hlth, Cohn Bldg,Rm 344,5557 Cass Ave, Detroit, MI 48202 USA; [Woods, Julie; Rogozinska, Magdalena] Univ Illinois, Dept Biobehav Hlth Sci, Chicago, IL 60612 USA	Briones, TL (corresponding author), Wayne State Univ, Dept Adult Hlth, Cohn Bldg,Rm 344,5557 Cass Ave, Detroit, MI 48202 USA.	tbriones@wayne.edu			National Institutes of Health, NINRUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [RO1 NR007666]; University of Illinois at Chicago, College of Nursing Internal Research Program; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01NR007666] Funding Source: NIH RePORTER	This work was supported in part by the National Institutes of Health, NINR grant # RO1 NR007666 and the University of Illinois at Chicago, College of Nursing Internal Research Program. We are grateful for the assistance of Maggie Wadowska in animal handling.	Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; BACHYRITA P, 1990, NEUROPSYCHOLOGIA, V28, P547, DOI 10.1016/0028-3932(90)90033-K; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004; Boero J, 2003, MOL CELL BIOCHEM, V244, P69, DOI 10.1023/A:1022409101641; Briones T L, 2000, Biol Res Nurs, V1, P299, DOI 10.1177/109980040000100406; Briones Teresita L, 2005, Biol Res Nurs, V6, P167, DOI 10.1177/1099800404271328; Briones TL, 2009, J NEUROTRAUM, V26, P613, DOI 10.1089/neu.2008.0707; Briones TL, 2006, BEHAV BRAIN RES, V171, P17, DOI 10.1016/j.bbr.2006.03.011; Briones TL, 2006, BEHAV BRAIN RES, V168, P261, DOI 10.1016/j.bbr.2005.11.015; Briones TL, 2004, BRAIN RES, V997, P137, DOI 10.1016/j.brainres.2003.10.030; Carling D, 2004, TRENDS BIOCHEM SCI, V29, P18, DOI 10.1016/j.tibs.2003.11.005; Carling D, 2012, BIOCHEM J, V445, P11, DOI 10.1042/BJ20120546; Cheng JP, 2012, J NEUROTRAUM, V29, P2684, DOI 10.1089/neu.2012.2560; Cunningham C, 2008, BRAIN BEHAV IMMUN, V22, P1117, DOI 10.1016/j.bbi.2008.05.007; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Finnie JW, 2013, INFLAMMOPHARMACOLOGY, V21, P309, DOI 10.1007/s10787-012-0164-2; Fryer LGD, 2002, BIOCHEM J, V363, P167, DOI 10.1042/0264-6021:3630167; Huang ZB, 2010, NEUROSCI BULL, V26, P455, DOI 10.1007/s12264-010-6023-5; Israelsson C, 2008, J NEUROTRAUM, V25, P959, DOI 10.1089/neu.2008.0562; Johnson EM, 2013, FRONT BEHAV NEUROSCI, V7, DOI 10.3389/fnbeh.2013.00044; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Jurgens HA, 2012, BRAIN BEHAV IMMUN, V26, P1006, DOI 10.1016/j.bbi.2012.05.015; Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kleman AM, 2008, J NEUROSCI METH, V167, P292, DOI 10.1016/j.jneumeth.2007.08.028; Kline AE, 2010, J NEUROTRAUM, V27, P2021, DOI 10.1089/neu.2010.1535; Kovesdi E, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00042; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Lynch MA, 2009, MOL NEUROBIOL, V40, P139, DOI 10.1007/s12035-009-8077-9; Maegele M, 2005, EUR J NEUROSCI, V21, P2406, DOI 10.1111/j.1460-9568.2005.04070.x; Maesako M, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.10.028; Manwani B, 2013, J NEUROSCI RES, V91, P1018, DOI 10.1002/jnr.23207; Matter AM, 2011, NEUROREHAB NEURAL RE, V25, P558, DOI 10.1177/1545968310397206; McAfoose J, 2009, NEUROSCI BIOBEHAV R, V33, P355, DOI 10.1016/j.neubiorev.2008.10.005; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; Monaco CM, 2013, EXP NEUROL, V247, P410, DOI 10.1016/j.expneurol.2013.01.007; Nithianantharajah J, 2006, NAT REV NEUROSCI, V7, P697, DOI 10.1038/nrn1970; Passineau MJ, 2001, EXP NEUROL, V168, P373, DOI 10.1006/exnr.2000.7623; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Povlishock J T, 2000, Clin Neurosurg, V46, P113; Rijntjes M, 2002, PROG NEUROBIOL, V66, P109, DOI 10.1016/S0301-0082(01)00027-2; Smith JA, 2012, BRAIN RES BULL, V87, P10, DOI 10.1016/j.brainresbull.2011.10.004; Tonelli LH, 2005, FRONT BIOSCI, V10, P675, DOI 10.2741/1562; Will B, 2004, PROG NEUROBIOL, V72, P167, DOI 10.1016/j.pneurobio.2004.03.001; Wilson S, 2004, J NEUROTRAUM, V21, P239, DOI 10.1089/089771504322972031; Yao ZH, 2012, CURR NEUROVASC RES, V9, P176, DOI 10.2174/156720212801618974; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	51	42	43	0	0	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2051-5960			ACTA NEUROPATHOL COM	Acta Neuropathol. Commun.		2013	1								57	10.1186/2051-5960-1-57			10	Neurosciences	Neurosciences & Neurology	V9K2F	WOS:000422387200047	24252176	DOAJ Gold, Green Published			2021-06-18	
J	Hooft, A; Ronda, J; Schaeffer, P; Asnes, AG; Leventhal, JM				Hooft, Anneka; Ronda, Jocelyn; Schaeffer, Paula; Asnes, Andrea G.; Leventhal, John M.			Identification of Physical Abuse Cases in Hospitalized Children: Accuracy of International Classification of Diseases Codes	JOURNAL OF PEDIATRICS			English	Article							TRAUMATIC BRAIN-INJURY; MALTREATMENT; FRACTURES; SURVEILLANCE; DATABASE; RECORDS	Objective Hospital discharge databases are being increasingly used to track the incidence of child physical abuse in the United States. These databases use International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) codes to categorize illnesses and injuries in hospitalized patients. We assessed the accuracy of the assignment of these codes for cases of child physical abuse. Study design Participants were all children (N = 133) evaluated by a child abuse pediatrician (CAP) for suspicion of abuse at Yale-New Haven Children's Hospital from January 1, 2007-December 31, 2010. These children included both those judged to have injuries from abuse and those judged to have injuries accidental/medical in nature. We compared the ICD-9-CM codes entered in the hospital discharge database for each child with the decisions made by the CAPs, as documented in their child abuse registry. The CAPs' decisions were considered to be the gold standard. Sensitivity and specificity were calculated. Medical records were reviewed for cases in which the ICD-9-CM codes disagreed with the CAP's decision. Results In 133 cases of suspected child physical abuse, the sensitivity and specificity of ICD-9-CM codes for abuse were 76.7% (CI 61.4%, 88.2%) and 100% (CI 96.0%, 100%), respectively. Analysis of the 10 cases of abuse not receiving ICD-9-CM codes for abuse revealed that errors in physician documentation (n = 5) and in coding (n = 5) contributed to the reduction in sensitivity. Conclusions Despite high specificity in identifying child physical abuse, the sensitivity of ICD-9-CM codes is 77%, indicating that these codes underestimate the occurrence of abuse. (J Pediatr 2013;162:80-5).	[Hooft, Anneka; Schaeffer, Paula; Asnes, Andrea G.; Leventhal, John M.] Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06520 USA; [Ronda, Jocelyn] Johns Hopkins Sch Med, Dept Internal Med Pediat, Baltimore, MD USA	Leventhal, JM (corresponding author), Yale Univ, Sch Med, Dept Pediat, POB 208064,333 Cedar St, New Haven, CT 06520 USA.	john.leventhal@yale.edu			Child Abuse Funds, Department of Pediatrics; Office of Student Research, Yale School of Medicine; Doris Duke Foundation for Clinical Research for Child Abuse Prevention	Supported by the Child Abuse Funds, Department of Pediatrics and the Office of Student Research, Yale School of Medicine, and a grant from the Doris Duke Foundation for Clinical Research for Child Abuse Prevention. The authors declare no conflicts of interest.	Abellera J, 2005, STATES ARE COLLECTIN; American Hospital Association (AHA), AHA COD CLIN ICD 9 C; Barrett M, 2004, HCUP METHODS SERIES; Ellingson KD, 2008, AM J PREV MED, V34, pS157, DOI 10.1016/j.amepre.2007.12.021; Feng JY, 2011, CHILD ABUSE NEGLECT, V35, P655, DOI 10.1016/j.chiabu.2011.04.002; Gonzalez-Izquierdo A, 2010, ARCH DIS CHILD, V95, P918, DOI 10.1136/adc.2009.180216; Lane WG, 2011, PEDIATRICS, V127, pE1400, DOI 10.1542/peds.2010-2096; LANGLOIS JA, 1995, AM J PUBLIC HEALTH, V85, P1261, DOI 10.2105/AJPH.85.9.1261; Leventhal JM, 2008, PEDIATRICS, V122, P599, DOI 10.1542/peds.2007-1959; Leventhal JM, 2012, PEDIATRICS, V129, P458, DOI 10.1542/peds.2011-1277; Leventhal JM, 2010, PEDIATRICS, V126, pE104, DOI 10.1542/peds.2009-1076; Lindberg DM, 2008, PEDIATRICS, V121, pE945, DOI 10.1542/peds.2007-2485; National Center for Health Statistics, 2010, 2010 REL ICD 10 CM; National Center for Health Statistics, 2011, INT CLASS DIS, V1; Schnitzer PG, 2004, AM J PREV MED, V27, P379, DOI 10.1016/j.amepre.2004.08.007; Scott D, 2009, CHILD ABUSE NEGLECT, V33, P791, DOI 10.1016/j.chiabu.2009.08.005; THOMAS SA, 1991, PEDIATRICS, V88, P471; [U.S. Department of Health and Human Services Administration for Children and Families Administration on ChildrenYouth and Families Children's Bureau], 2011, CHILD MALTR 2010; US Department of Health and Human Services (USDHHS), 2010, ICD 9 CM OFF GUID CO; US Healthcare Cost and Utilization Project (HCUP), 2008, INTR HCUP KIDS INP D; WINN DG, 1995, PUBLIC HEALTH REP, V110, P277; Wirtz SJ, 2008, AM J PREV MED, V34, pS134, DOI 10.1016/j.amepre.2007.11.004; Wood JN, 2010, PEDIATRICS, V126, P408, DOI 10.1542/peds.2010-0031	23	42	42	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0022-3476			J PEDIATR-US	J. Pediatr.	JAN	2013	162	1					80	85		10.1016/j.jpeds.2012.06.037			6	Pediatrics	Pediatrics	062JK	WOS:000312915900019	22854329				2021-06-18	
J	Lebrun, CM; Mrazik, M; Prasad, AS; Tjarks, BJ; Dorman, JC; Bergeron, MF; Munce, TA; Valentine, VD				Lebrun, Constance M.; Mrazik, Martin; Prasad, Abhaya S.; Tjarks, B. Joel; Dorman, Jason C.; Bergeron, Michael F.; Munce, Thayne A.; Valentine, Verle D.			Sport concussion knowledge base, clinical practises and needs for continuing medical education: a survey of family physicians and cross-border comparison	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							SCHOOL FOOTBALL COACHES; INTERNATIONAL-CONFERENCE; AGREEMENT STATEMENT; ATHLETIC-TRAINERS; RUGBY PLAYERS; LINE VALUES; MANAGEMENT; HOCKEY; RETURN; PROFESSIONALS	Context Evolving concussion diagnosis/management tools and guidelines make Knowledge Transfer and Exchange (KTE) to practitioners challenging. Objective Identify sports concussion knowledge base and practise patterns in two family physician populations; explore current/preferred methods of KTE. Design A cross-sectional study. Setting Family physicians in Alberta, Canada (CAN) and North/South Dakota, USA. Participants CAN physicians were recruited by mail: 2.5% response rate (80/3154); US physicians through a database: 20% response rate (109/545). Intervention/instrument Online survey. Main and secondary outcome measures Diagnosis/management strategies for concussions, and current/preferred KTE. Results Main reported aetiologies: sports/recreation (52.5% CAN); organised sports (76.5% US). Most physicians used clinical examination (93.8% CAN, 88.1% US); far fewer used the Sport Concussion Assessment Tool (SCAT1/SCAT2) and balance testing. More US physicians initially used concussion-grading scales (26.7% vs 8.8% CAN, p=0.002); computerised neurocognitive testing (19.8% vs 1.3% CAN; p<0.001) and Standardised Assessment of Concussion (SAC) (21.8% vs 7.5% CAN; p=0.008). Most prescribed physical rest (83.8% CAN, 75.5% US), while fewer recommended cognitive rest (47.5% CAN, 28.4% US; p=0.008). Return-to-play decisions were based primarily on clinical examination (89.1% US, 73.8% CAN; p=0.007); US physicians relied more on neurocognitive testing (29.7% vs 5.0% CAN; p<0.001) and recognised guidelines (63.4% vs 23.8% CAN; p<0.001). One-third of Canadian physicians received KTE from colleagues, websites and medical school training. Leading KTE preferences included Continuing Medical Education (CME) courses and online CME. Conclusions Existing published recommendations regarding diagnosis/management of concussion are not always translated into practise, particularly the recommendation for cognitive rest; predicating enhanced, innovative CME initiatives.	[Lebrun, Constance M.] Univ Alberta, Dept Family Med, Fac Med & Dent, Glen Sather Sports Med Clin,Edmonton Clin, Edmonton, AB T6G 1Z1, Canada; [Mrazik, Martin] Univ Alberta, Dept Educ Psychol, Fac Educ, Edmonton, AB T6G 1Z1, Canada; [Prasad, Abhaya S.] Univ Alberta, Sch Publ Hlth, Edmonton, AB T6G 1Z1, Canada; [Tjarks, B. Joel] Univ S Dakota, Sanford Sch Med, Vermillion, SD 57069 USA; [Dorman, Jason C.; Bergeron, Michael F.; Munce, Thayne A.; Valentine, Verle D.] Sanford USD Med Ctr, Sioux Falls, SD USA	Lebrun, CM (corresponding author), Univ Alberta, Dept Family Med, Fac Med & Dent, Glen Sather Sports Med Clin,Edmonton Clin, Level 2,11400 Univ Ave, Edmonton, AB T6G 1Z1, Canada.	ConnieLebrun@med.ualberta.ca	Lebrun, Constance/K-6430-2013				Alla S, 2009, BRIT J SPORT MED, V43, pI3, DOI 10.1136/bjsm.2009.058339; [Anonymous], 2011, MED SCI SPORT EXER, V43, P2412, DOI 10.1249/MSS.0b013e3182342e64; [Anonymous], 2008, 3 INT C CONC SPORT Z; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bazarian JJ, 2001, CLIN PEDIATR, V40, P207, DOI 10.1177/000992280104000405; Boggild M, 2012, CAN J NEUROL SCI, V39, P361, DOI 10.1017/S0317167100013524; Canadian Institute for Health Information, HEAD INJ CAN DEC CHA; Canadian Medical Association (CMA), 2011, HEAD INJ SPORT; Canadian Pediatric Society, 2006, ID MAN CHILDR SPORT; Center for Disease Control (CDC) Atlanta, HEADS UP TOOLK PHYS; Chrisman SP, 2011, CLIN PEDIATR, V50, P1031, DOI 10.1177/0009922811410970; College of Family Physicians of Canada, 2012, ROL FAM PHYS MAN CON; Cook DJ, 2003, INJURY PREV, V9, P361, DOI 10.1136/ip.9.4.361; Covassin T, 2009, J ATHL TRAINING, V44, P639, DOI 10.4085/1062-6050-44.6.639; Covassin T, 2009, J ATHL TRAINING, V44, P400, DOI 10.4085/1062-6050-44.4.400; Cusimano MD, 2009, CAN J NEUROL SCI, V36, P315, DOI 10.1017/S0317167100007046; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Giebel S, 2011, J EMERG MED, V41, P649, DOI 10.1016/j.jemermed.2011.03.021; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Guilmette TJ, 2007, BRAIN INJURY, V21, P1039, DOI 10.1080/02699050701633080; Guskiewicz KM, 2011, PM&R, V3, P353, DOI 10.1016/j.pmrj.2010.12.006; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Harris AW, 2012, J SCI MED SPORT, V15, P298, DOI 10.1016/j.jsams.2011.12.005; Heck K, EVALUATING MILD HEAD; HODDINOTT SN, 1986, CAN FAM PHYSICIAN, V32, P2366; Jinguji TM, 2012, BRIT J SPORT MED, V46, P365, DOI 10.1136/bjsports-2011-090526; Kelly JP, 1997, NEUROLOGY, V48, P581; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lau BC, 2012, NEUROSURGERY, V70, P371, DOI 10.1227/NEU.0b013e31823150f0; Lau BC, 2011, AM J SPORT MED, V39, P1209, DOI 10.1177/0363546510392016; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2011, CLIN J SPORT MED, V21, P6, DOI 10.1097/JSM.0b013e318204db50; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; McGrath N, 2010, J ATHL TRAINING, V45, P492, DOI 10.4085/1062-6050-45.5.492; McLeod TCV, 2007, CLIN J SPORT MED, V17, P140; McLeod TCV, 2012, AM J SPORT MED, V40, P927, DOI 10.1177/0363546511431573; McLeod TCV, 2009, J ATHL TRAINING, V44, P663, DOI 10.4085/1062-6050-44.6.663; Meehan WP, 2012, PEDIATRICS, V129, P38, DOI 10.1542/peds.2011-1972; Meehan WP, 2011, CLIN SPORT MED, V30, P115, DOI 10.1016/j.csm.2010.08.003; Mrazik M, 2011, CLIN J SPORT MED, V21, P315, DOI 10.1097/JSM.0b013e31821e2b78; Murphy A, 2012, PM&R, V4, P419, DOI 10.1016/j.pmrj.2012.03.013; Piland SG, 2010, J ATHL TRAINING, V45, P273, DOI 10.4085/1062-6050-45.3.273; Pleacher MD, 2006, BRIT J SPORT MED, V40, DOI 10.1136/bjsm.2005.019067; Provvidenza CF, 2009, BRIT J SPORT MED, V43, pI68, DOI 10.1136/bjsm.2009.058180; Randolph C, 2011, CURR SPORT MED REP, V10, P21, DOI 10.1249/JSR.0b013e318207831d; Sarmiento K, 2012, J SCH HLTH, V80, P112; Sawyer RJ, 2012, HLTH PROMOT PRACT, V11, P34; Schatz P, 2011, NEUROSURGERY, V68, P1562, DOI 10.1227/NEU.0b013e31820e382e; Shehata N, 2009, BRIT J SPORT MED, V43, P730, DOI 10.1136/bjsm.2009.059832; Shrier I, 2012, CLIN J SPORT MED, V22, P211, DOI 10.1097/JSM.0b013e31824cc5f9; Shrier I, 2011, AM J SPORT MED, V39, pNP1, DOI 10.1177/0363546510391053; Sin DD, 2004, CAN FAM PHYSICIAN, V50, P1251; Sullivan SJ, 2009, CLIN J SPORT MED, V19, P228, DOI 10.1097/JSM.0b013e3181a41e43; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511; ThinkFirst-SportSmart Concussion Education and Awareness Committee, 2010, NEW CONC MAN GUID CO; Wesolowski K, 2010, NEUROLOGY TODAY, V10, P32	58	42	42	1	44	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	JAN	2013	47	1					54	59		10.1136/bjsports-2012-091480			6	Sport Sciences	Sport Sciences	073SF	WOS:000313762100015	23178923				2021-06-18	
J	Song, SX; Gao, JL; Wang, KJ; Li, R; Tian, YX; Wei, JQ; Cui, JZ				Song, Si-Xin; Gao, Jun-Ling; Wang, Kai-Jie; Li, Ran; Tian, Yan-Xia; Wei, Jian-Qiang; Cui, Jian-Zhong			Attenuation of brain edema and spatial learning deficits by the inhibition of NADPH oxidase activity using apocynin following diffuse traumatic brain injury in rats	MOLECULAR MEDICINE REPORTS			English	Article						diffuse brain injury; nicotinamide adenine dinucleotide phosphate oxidase; NOX2; secondary brain damage; learning and memory ability	CELL-DEATH; ACTIVATION; HEMORRHAGE; ISCHEMIA; STROKE; VOLUME; DAMAGE; MODEL; NOX2; BETA	Diffuse brain injury (DBI) is a leading cause of mortality and disability among young individuals and adults worldwide. In specific cases, DBI is associated with permanent spatial learning dysfunction and motor deficits due to primary and secondary brain damage. Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (NOX) is a major complex that produces reactive oxygen species (ROS) during the ischemic period. The complex aggravates brain damage and cell death following ischemia/reperfusion injury; however, its role in DBI remains unclear. The present study aimed to investigate the hypothesis that levels of NOX2 (a catalytic subunit of NOX) protein expression and the activation of NOX are enhanced following DBI induction in rats and are involved in aggravating secondary brain damage. A rat model of DBI was created using a modified weight-drop device. Our results demonstrated that NOX2 protein expression and NOX activity were enhanced in the CA1 subfield of the hippocampus at 48 and 72 h following DBI induction. Treatment with apocynin (50 mg/kg body weight), a specific inhibitor of NOX, injected intraperitoneally 30 min prior to DBI significantly attenuated NOX, protein expression and NOX activation. Moreover, treatment with apocynin reduced brain edema and improved spatial learning function assessed using the Morris water maze. These results reveal that treatment with apocynin may provide a new neuroprotective therapeutic strategy against DBI by diminishing the upregulation of NOX2 protein and NOX activity.	[Song, Si-Xin; Wei, Jian-Qiang; Cui, Jian-Zhong] Hebei Med Univ, Dept Surg, 361 E Zhongshan Rd, Shijiazhuang 050017, Peoples R China; [Gao, Jun-Ling; Li, Ran; Tian, Yan-Xia] Hebei United Univ, Sch Basic Med Sci, Tangshan, Hebei, Peoples R China; [Wang, Kai-Jie; Cui, Jian-Zhong] Tangshan Workers Hosp, Tangshan 063000, Peoples R China	Cui, JZ (corresponding author), Hebei Med Univ, Dept Surg, 361 E Zhongshan Rd, Shijiazhuang 050017, Peoples R China.	jzhcuidr2001@163.com			Natural Science Foundation of Hebei ProvinceNatural Science Foundation of Hebei Province [H2012401071]	The present study was supported by a grant from the Natural Science Foundation of Hebei Province (no. H2012401071).	Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005; Bobba A, 2008, INT J MOL MED, V21, P737; Cairns B, 2012, CURR DRUG TARGETS, V13, P199, DOI 10.2174/138945012799201676; Connell BJ, 2011, FOOD CHEM TOXICOL, V49, P3063, DOI 10.1016/j.fct.2011.09.010; Dohi K, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-41; Hur J, 2010, BIOCHEM BIOPH RES CO, V391, P1526, DOI 10.1016/j.bbrc.2009.12.114; Infanger DW, 2006, ANTIOXID REDOX SIGN, V8, P1583, DOI 10.1089/ars.2006.8.1583; Jackman KA, 2009, BRIT J PHARMACOL, V156, P680, DOI 10.1111/j.1476-5381.2008.00073.x; Jana A, 2004, J BIOL CHEM, V279, P51451, DOI 10.1074/jbc.M404635200; Kahles T, 2007, STROKE, V38, P3000, DOI 10.1161/STROKEAHA.107.489765; Kelly KA, 2009, BRAIN RES, V1292, P165, DOI 10.1016/j.brainres.2009.07.052; Kim MJ, 2005, BRAIN RES, V1040, P178, DOI 10.1016/j.brainres.2005.01.066; Lafeber FPJG, 1999, RHEUMATOLOGY, V38, P1088, DOI 10.1093/rheumatology/38.11.1088; Liu HG, 2010, SLEEP MED, V11, P205, DOI 10.1016/j.sleep.2009.05.015; Lo W, 2007, NEUROSCI LETT, V414, P228, DOI 10.1016/j.neulet.2006.12.055; Luo CL, 2011, NEUROSCIENCE, V184, P54, DOI 10.1016/j.neuroscience.2011.03.021; Mander PK, 2006, J IMMUNOL, V176, P1046, DOI 10.4049/jimmunol.176.2.1046; Murillo MM, 2007, BIOCHEM J, V405, P251, DOI 10.1042/BJ20061846; Sawauchi S, 2003, J NEUROTRAUM, V20, P613, DOI 10.1089/089771503322144536; Serrano F, 2003, BRAIN RES, V988, P193, DOI 10.1016/S0006-8993(03)03364-X; Sorce S, 2009, ANTIOXID REDOX SIGN, V11, P2481, DOI [10.1089/ars.2009.2578, 10.1089/ARS.2009.2578]; Tang JP, 2004, J CEREBR BLOOD F MET, V24, P1133, DOI 10.1097/01.WCB.0000135593.05952.DE; Tang LL, 2007, J INT MED RES, V35, P517, DOI 10.1177/147323000703500411; Vallet P, 2005, NEUROSCIENCE, V132, P233, DOI 10.1016/j.neuroscience.2004.12.038; Woodfin A, 2011, FREE RADICAL BIO MED, V50, P518, DOI 10.1016/j.freeradbiomed.2010.12.010; Yoshioka H, 2011, J CEREBR BLOOD F MET, V31, P868, DOI 10.1038/jcbfm.2010.166; Zhang QG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034504; Zhang QG, 2009, J NEUROSCI, V29, P13823, DOI 10.1523/JNEUROSCI.3574-09.2009; Zhang Y, 2005, AM J HYPERTENS, V18, P910, DOI 10.1016/j.amjhyper.2005.02.017; Zia MT, 2009, STROKE, V40, P2191, DOI 10.1161/STROKEAHA.108.544759	30	42	43	1	5	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1791-2997	1791-3004		MOL MED REP	Mol. Med. Rep.	JAN	2013	7	1					327	331		10.3892/mmr.2012.1147			5	Oncology; Medicine, Research & Experimental	Oncology; Research & Experimental Medicine	052ZA	WOS:000312238000057	23128834	Bronze			2021-06-18	
J	Waldron, B; Casserly, LM; O'Sullivan, C				Waldron, Brian; Casserly, Lisa Marie; O'Sullivan, Clodagh			Cognitive behavioural therapy for depression and anxiety in adults with acquired brain injury. What works for whom?	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Acquired brain injury; Traumatic brain injury; Cognitive behavioural therapy; Depression; Anxiety	OBSESSIVE-COMPULSIVE DISORDER; POSTTRAUMATIC-STRESS-DISORDER; HEAD-INJURY; SELF-ASSESSMENT; AXIS I; SKILLS; STROKE; TRIAL; SCALE; INDIVIDUALS	This paper reviews treatment outcome studies on cognitive behavioural therapy (CBT) for depression and anxiety following acquired brain injury (ABI), including traumatic brain injury (TBI), cerebral vascular accident (CVA), anoxia and neurosurgery. Studies are included for review when the published paper included an anxiety disorder or depression as the treatment focus, or as part of outcome measurement. Relaxed criteria were used to select studies including relevant single-cases, case series and single group studies along with studies that employed control groups. Twenty-four studies were identified. Twelve papers were of a single-case design (with or without replication). Two papers used uncontrolled single groups and ten studies used a control group. There were a total of 507 people in the various treatment and control groups, which ranged in size from 6 to 67 persons. All participants in the study had an ABI. Our review indicates CBT often shows a within-group pre- to post-treatment statistical difference for depression and anxiety problems, or a statistical difference between CBT-treated and non-treated groups. For studies that targeted the treatment of depression with CBT, effect-sizes ranged from 0 to 2.39 with an average effect-size of 1.15 for depression (large effect). For studies that targeted the treatment of anxiety with CBT, effect-sizes ranged from 0 to 3.47 with an average effect-size of 1.04 for anxiety (large effect). However, it was not possible to submit all twenty-four studies identified to effect-size analysis. Additionally, it is clear that CBT is not a panacea, as studies frequently indicate only partial reduction in anxiety and depression symptoms. This review suggests that if CBT is aimed at, for example, anger management or coping, it can be effective for anger or coping, but will not generalise to have an effect on anxiety or depression. CBT interventions that target anxiety and depression specifically appear to generate better therapeutic effects on anxiety and depression. Gaps in the literature are highlighted with suggestions for future research.	[Waldron, Brian; Casserly, Lisa Marie; O'Sullivan, Clodagh] ABI Ireland, Dun Laoghaire, Co Dublin, Ireland	Waldron, B (corresponding author), ABI Ireland, Northumberland Ave, Dun Laoghaire, Co Dublin, Ireland.	bwaldron@abiireland.ie					American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Anson K, 2006, BRAIN INJURY, V20, P1, DOI 10.1080/02699050500309791; Anson K, 2006, BRAIN INJURY, V20, P167, DOI 10.1080/02699050500442956; Arco L, 2008, NEUROPSYCHOL REHABIL, V18, P109, DOI 10.1080/09602010701656706; Arundine A, 2012, J HEAD TRAUMA REHAB, V27, P104, DOI 10.1097/HTR.0b013e3182125591; Batten SV, 2008, J CLIN PSYCHOL, V64, P928, DOI 10.1002/jclp.20513; Beck A. T., 1967, DEPRESSION CLIN EXPT; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Beck AT, 1993, MANUAL BECK ANXIETY; Beck AT., 1970, DEPRESSION CAUSES TR; Beck AT., 1996, BECK DEPRESSION INVE, V2; Bisson J, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003388.pub3; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Bradbury CL, 2008, ARCH PHYS MED REHAB, V89, pS61, DOI 10.1016/j.apmr.2008.08.210; Bryant RA, 2003, AM J PSYCHIAT, V160, P585, DOI 10.1176/appi.ajp.160.3.585; Chard KM, 2011, J TRAUMA STRESS, V24, P347, DOI 10.1002/jts.20644; Clark D.A., 1999, SCI FDN COGNITIVE TH; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; COOPERSMITH S, 1975, SELF ESTEEM INVENTOR; Corneil W, 1999, J Occup Health Psychol, V4, P131, DOI 10.1037/1076-8998.4.2.131; Derogatis L.R, 1994, SYMPTOM CHECKLIST 90; Fleminger S, 2003, NEUROPSYCHOL REHABIL, V13, P65, DOI 10.1080/09602010244000354; Frydenberg E., 1996, COPING SCALE ADULTS; Hackett ML, 2005, STROKE, V36, P1330, DOI 10.1161/01.STR.0000165928.19135.35; Heimberg RG, 2002, BIOL PSYCHIAT, V51, P101, DOI 10.1016/S0006-3223(01)01183-0; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hodgson J, 2005, BRAIN IMPAIR, V6, P169, DOI DOI 10.1375/BRIM.2005.6.3.169; HODGSON RJ, 1977, BEHAV RES THER, V15, P389, DOI 10.1016/0005-7967(77)90042-0; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; Khan-Bourne N, 2003, NEUROPSYCHOL REHABIL, V13, P89, DOI 10.1080/09602010244000318; King NS, 2002, BRAIN INJURY, V16, P65, DOI 10.1080/02699050110088263; Kneebone I, 2009, NEUROPSYCHOL REHABIL, V19, P86, DOI 10.1080/09602010802009623; Kneebone II, 2000, BRIT J CLIN PSYCHOL, V39, P53, DOI 10.1348/014466500163103; Koponen S, 2011, BRAIN INJURY, V25, P1029, DOI 10.3109/02699052.2011.607783; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Lincoln NB, 2003, STROKE, V34, P111, DOI 10.1161/01.STR.0000044167.44670.55; Lincoln NB, 1997, CLIN REHABIL, V11, P114, DOI 10.1177/026921559701100204; Lovibond S., 1996, MANUAL DEPRESSION AN; Maher CG, 2003, PHYS THER, V83, P713, DOI 10.1093/ptj/83.8.713; Malec JF, 2007, J HEAD TRAUMA REHAB, V22, P156, DOI 10.1097/01.HTR.0000271116.12028.af; Marks IM, 1986, BEHAV PSYCHOTHERAPY; Mateer CA, 2005, J HEAD TRAUMA REHAB, V20, P62, DOI 10.1097/00001199-200501000-00007; McDonald S, 2008, ARCH PHYS MED REHAB, V89, P1648, DOI 10.1016/j.apmr.2008.02.029; McGrath J, 1997, NEUROPSYCHOL REHABIL, V7, P231, DOI 10.1080/713755532; MCMILLAN TM, 1991, BRIT J PSYCHIAT, V159, P431, DOI 10.1192/bjp.159.3.431; McNeil J E, 1996, Cogn Neuropsychiatry, V1, P239, DOI 10.1080/135468096396532; Medd J, 2000, NEUROPSYCHOL REHABIL, V10, P185, DOI 10.1080/096020100389246; Novaco R.W., 1975, ANGER CONTROL DEV EV; Perdices M, 2009, NEUROPSYCHOL REHABIL, V19, P904, DOI 10.1080/09602010903040691; Prigatano G., 1989, TRAUMATIC BRAIN INJU, P175; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Rasquin SMC, 2009, NEUROPSYCHOL REHABIL, V19, P208, DOI 10.1080/09602010802091159; Resick P. A., 1993, COGNITIVE PROCESSING; Rosenberg M., 1965, SOC ADOLESCENT SELF, DOI 10.1126/science.148.3671.804; Salazar AM, 2000, JAMA-J AM MED ASSOC, V283, P3075, DOI 10.1001/jama.283.23.3075; Schneier FR., 1995, SOCIAL PHOBIA DIAGNO, P69, DOI DOI 10.1017/S1352465808004487; SNAITH RP, 1971, PSYCHOL MED, V1, P143, DOI 10.1017/S0033291700000064; Soo C, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005239.pub2; SooMeng K, 1997, INT J CLIN PRACT, V51, P336; Spielberger CD., 1988, STATE TRAIT ANGER EX; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Tiersky LA, 2005, ARCH PHYS MED REHAB, V86, P1565, DOI 10.1016/j.apmr.2005.03.013; Topolovec-Vranic J, 2010, BRAIN INJURY, V24, P762, DOI 10.3109/02699051003709599; Turner S.M., 1989, PSYCHOL ASSESSMENT, V1, P35; van Dam-Baggen R, 2000, J ANXIETY DISORD, V14, P437, DOI 10.1016/S0887-6185(00)00038-4; WALLANDER JL, 1985, BEHAV ASSESS, V7, P137; Williams W H, 2003, Cogn Neuropsychiatry, V8, P1, DOI 10.1080/713752238; Williams WH, 2003, NEUROPSYCHOL REHABIL, V13, P133, DOI 10.1080/09602010244000417; World Health Organization, 2008, ICD 10 INT STAT CLAS; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	71	42	44	1	70	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	JAN 1	2013	23	1					64	101		10.1080/09602011.2012.724196			38	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	096BD	WOS:000315377800004	23121258				2021-06-18	
J	Alwis, DS; Yan, EB; Morganti-Kossmann, MC; Rajan, R				Alwis, Dasuni S.; Yan, Edwin B.; Morganti-Kossmann, Maria-Cristina; Rajan, Ramesh			Sensory Cortex Underpinnings of Traumatic Brain Injury Deficits	PLOS ONE			English	Article							RAT BARREL CORTEX; VISUAL PROCESSING DEFICITS; DIFFUSE AXONAL INJURY; WHISKER VIBRATION; HIPPOCAMPAL CA1; CORTICAL INJURY; COMPLEX SOUNDS; LATE-ONSET; NEURONS; HYPEREXCITABILITY	Traumatic brain injury (TBI) can result in persistent sensorimotor and cognitive deficits including long-term altered sensory processing. The few animal models of sensory cortical processing effects of TBI have been limited to examination of effects immediately after TBI and only in some layers of cortex. We have now used the rat whisker tactile system and the cortex processing whisker-derived input to provide a highly detailed description of TBI-induced long-term changes in neuronal responses across the entire columnar network in primary sensory cortex. Brain injury (n = 19) was induced using an impact acceleration method and sham controls received surgery only (n = 15). Animals were tested in a range of sensorimotor behaviour tasks prior to and up to 6 weeks post-injury when there were still significant sensorimotor behaviour deficits. At 8-10 weeks post-trauma, in terminal experiments, extracellular recordings were obtained from barrel cortex neurons in response to whisker motion, including motion that mimicked whisker motion observed in awake animals undertaking different tasks. In cortex, there were lamina-specific neuronal response alterations that appeared to reflect local circuit changes. Hyper-excitation was found only in supragranular layers involved in intra-areal processing and long-range integration, and only for stimulation with complex, naturalistic whisker motion patterns and not for stimulation with simple trapezoidal whisker motion. Thus TBI induces long-term directional changes in integrative sensory cortical layers that depend on the complexity of the incoming sensory information. The nature of these changes allow predictions as to what types of sensory processes may be affected in TBI and contribute to post-trauma sensorimotor deficits.	[Alwis, Dasuni S.; Rajan, Ramesh] Monash Univ, Dept Physiol, Clayton, Vic 3168, Australia; [Alwis, Dasuni S.; Yan, Edwin B.; Morganti-Kossmann, Maria-Cristina] Alfred Hosp, Natl Trauma Res Inst, Prahran, Vic 3181, Australia	Rajan, R (corresponding author), Monash Univ, Dept Physiol, Clayton, Vic 3168, Australia.	Ramesh.Rajan@monash.edu	rajan, ramesh/L-4842-2019	Morganti-Kossmann, Cristina/0000-0002-0807-2063; Rajan, Ramesh/0000-0001-9862-0520	NHMRC of AustraliaNational Health and Medical Research Council of Australia [APP 1029311]	This study was funded by the NHMRC of Australia Grant No. APP 1029311. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adcock RA, 2009, SCHIZOPHRENIA BULL, V35, P1132, DOI 10.1093/schbul/sbp068; Akasu T, 2002, NEUROSCI LETT, V329, P305, DOI 10.1016/S0304-3940(02)00707-3; Andermann ML, 2004, NEURON, V42, P451, DOI 10.1016/S0896-6273(04)00198-9; Arabzadeh E, 2004, J NEUROSCI, V24, P6011, DOI 10.1523/JNEUROSCI.1389-04.2004; Arabzadeh E, 2003, J NEUROSCI, V23, P9146; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Arundine M, 2004, J NEUROSCI, V24, P8106, DOI 10.1523/JNEUROSCI.1362-04.2004; Arundine M, 2003, J NEUROTRAUM, V20, P1377, DOI 10.1089/089771503322686166; Boddaert N, 2004, AM J PSYCHIAT, V161, P2117, DOI 10.1176/appi.ajp.161.11.2117; Boddaert N, 2003, AM J PSYCHIAT, V160, P2057, DOI 10.1176/appi.ajp.160.11.2057; BOHNEN N, 1991, J NEUROL, V238, P443, DOI 10.1007/BF00314651; Bonislawski DP, 2007, NEUROBIOL DIS, V25, P163, DOI 10.1016/j.nbd.2006.09.002; Brosseau-Lachaine O, 2008, BRAIN INJURY, V22, P657, DOI 10.1080/02699050802203353; Butler PD, 2009, SCHIZOPHRENIA BULL, V35, P1095, DOI 10.1093/schbul/sbp109; Bye N, 2011, J NEUROSCI RES, V89, P986, DOI 10.1002/jnr.22635; Caeyenberghs K, 2009, BRAIN, V132, P684, DOI 10.1093/brain/awn344; Carmichael ST, 2012, ARCH NEUROL-CHICAGO, V69, P161, DOI 10.1001/archneurol.2011.1175; CARVELL GE, 1990, J NEUROSCI, V10, P2638; Chen SF, 2007, LIFE SCI, V81, P288, DOI 10.1016/j.lfs.2007.05.023; Chung S, 2002, NEURON, V34, P437, DOI 10.1016/S0896-6273(02)00659-1; Cohen AS, 2007, PROG BRAIN RES, V161, P143, DOI 10.1016/S0079-6123(06)61010-8; Cook NL, 2010, J MOL NEUROSCI, V42, P192, DOI 10.1007/s12031-010-9347-8; Corbo J, 2004, ANN EMERG MED, V44, P57, DOI 10.1016/j.annemergmed.2003.11.010; Davis AS, 2010, APPL NEUROPSYCHOL, V17, P104, DOI 10.1080/09084281003708951; Ding MC, 2008, NEUROSCIENCE, V154, P551, DOI 10.1016/j.neuroscience.2008.03.088; Ding MC, 2011, J NEUROSCI, V31, P14085, DOI 10.1523/JNEUROSCI.3572-11.2011; Donkin JJ, 2011, J NEUROTRAUM, V28, P217, DOI 10.1089/neu.2010.1632; DOSTER SK, 1991, NEURON, V6, P635, DOI 10.1016/0896-6273(91)90066-9; Draper K, 2009, NEUROPSYCHOL REHABIL, V19, P645, DOI 10.1080/17405620802613935; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Folmer RL, 2011, INT J PSYCHOPHYSIOL, V82, P4, DOI 10.1016/j.ijpsycho.2011.03.005; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Galvin J, 2009, AM J OCCUP THER, V63, P701, DOI 10.5014/ajot.63.6.701; Gao PH, 2001, J NEUROSCI, V21, P5374, DOI 10.1523/JNEUROSCI.21-14-05374.2001; Gibson JR, 2008, J NEUROPHYSIOL, V100, P2615, DOI 10.1152/jn.90752.2008; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; Greer JE, 2011, J NEUROSCI, V31, P5089, DOI 10.1523/JNEUROSCI.5103-10.2011; Griesemer D, 2007, J NEUROTRAUM, V24, P1823, DOI 10.1089/neu.2006.0237; Hall KD, 2010, BRAIN RES, V1323, P161, DOI 10.1016/j.brainres.2010.01.067; Hartmann MJ, 2003, J NEUROSCI, V23, P6510; Heath DL, 2001, J NEUROTRAUM, V18, P465, DOI 10.1089/089771501750171074; Hellewell SC, 2010, J NEUROTRAUM, V27, P1997, DOI 10.1089/neu.2009.1245; Higley MJ, 2003, J NEUROSCI, V23, P10190; Hoane MR, 2008, OXID MED CELL LONGEV, V1, P46, DOI 10.4161/oxim.1.1.6694; Horton HK, 2011, SCHIZOPHRENIA BULL, V37, P716, DOI 10.1093/schbul/sbr055; Hulsebosch CE, 1998, NEUROSCI LETT, V255, P83, DOI 10.1016/S0304-3940(98)00712-5; Imbrosci B, 2011, NEURAL PLAST, V2011, DOI 10.1155/2011/614329; Kalauzi Aleksandar, 2009, Nonlinear Biomed Phys, V3, P8, DOI 10.1186/1753-4631-3-8; Kim D, 2006, SCHIZOPHR RES, V82, P1, DOI 10.1016/j.schres.2005.10.008; Korostenskaja M, 2010, EPILEPSY RES, V92, P63, DOI 10.1016/j.eplepsyres.2010.08.008; Learoyd AE, 2012, BEHAV BRAIN RES, V226, P197, DOI 10.1016/j.bbr.2011.09.016; Leitman DI, 2007, AM J PSYCHIAT, V164, P474, DOI 10.1176/appi.ajp.164.3.474; Leitman DI, 2005, BIOL PSYCHIAT, V58, P56, DOI 10.1016/j.biopsych.2005.02.034; Lew HL, 2010, NEUROREHABILITATION, V26, P213, DOI 10.3233/NRE-2010-0557; Lew HL, 2009, J REHABIL RES DEV, V46, P819, DOI 10.1682/JRRD.2008.09.0129; Lew HL, 2004, AM J PHYS MED REHAB, V83, P428, DOI 10.1097/00002060-200406000-00004; Lewis DA, 2012, TRENDS NEUROSCI, V35, P57, DOI 10.1016/j.tins.2011.10.004; Li HF, 2002, J NEUROPHYSIOL, V88, P2, DOI 10.1152/jn.00507.2001; Li Y, 2011, J NEUROTRAUM, V28, P1767, DOI 10.1089/neu.2010.1687; Lifshitz J, 2007, J NEUROPATH EXP NEUR, V66, P218, DOI 10.1097/01.jnen.0000248558.75950.4d; Lifshitz J, 2012, BRAIN STRUCT FUNCT, V217, P49, DOI 10.1007/s00429-011-0323-z; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MANDELBROT BB, 1991, P ROY SOC LOND A MAT, V434, P79, DOI 10.1098/rspa.1991.0081; Marco EJ, 2011, PEDIATR RES, V69, p48R, DOI [10.1203/PDR.0b013e3182130c54, 10.1109/SPL.2011.5782616]; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McAllister Thomas W, 2011, Dialogues Clin Neurosci, V13, P287; McNamara KCS, 2010, J NEUROTRAUM, V27, P695, DOI 10.1089/neu.2009.1237; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Paluszkiewicz SM, 2011, DEV NEUROSCI-BASEL, V33, P349, DOI 10.1159/000329420; Patel R, 2011, OPTOMETRY, V82, P284, DOI 10.1016/j.optm.2010.10.012; Pinto DJ, 2000, J NEUROPHYSIOL, V83, P1158; Prince DA, 2009, EPILEPSIA, V50, P30, DOI 10.1111/j.1528-1167.2008.02008.x; Rafols JA, 2007, NEUROL RES, V29, P348, DOI 10.1179/016164107X204657; Raghavendra BS, 2009, PHYSIOL MEAS, V30, P795, DOI 10.1088/0967-3334/30/8/005; Rajan R, 1998, NAT NEUROSCI, V1, P138, DOI 10.1038/388; Rajan R, 2007, EUR J NEUROSCI, V25, P2383, DOI 10.1111/j.1460-9568.2007.05481.x; Rajan R, 2006, J NEUROSCI METH, V157, P103, DOI 10.1016/j.jneumeth.2006.04.008; Rajan R, 2001, CEREB CORTEX, V11, P171, DOI 10.1093/cercor/11.2.171; Rancan M, 2001, J NEUROSCI RES, V63, P438, DOI 10.1002/1097-4547(20010301)63:5<438::AID-JNR1039>3.0.CO;2-P; Raymond MJ, 1996, NEUROREHABILITATION, V6, P229, DOI 10.3233/NRE-1996-6309; Ritt JT, 2008, NEURON, V57, P599, DOI 10.1016/j.neuron.2007.12.024; Russo NM, 2008, CLIN NEUROPHYSIOL, V119, P1720, DOI 10.1016/j.clinph.2008.01.108; Schiene K, 1996, J CEREBR BLOOD F MET, V16, P906, DOI 10.1097/00004647-199609000-00014; Schmanke T, 1997, J NEUROTRAUM, V14, P459, DOI 10.1089/neu.1997.14.459; Schwarzbach E, 2006, HIPPOCAMPUS, V16, P541, DOI 10.1002/hipo.20183; Thomas TC, 2012, J NEUROTRAUM, V29, P187, DOI 10.1089/neu.2011.2091; Vink R, 2003, NEUROSCI LETT, V336, P41, DOI 10.1016/S0304-3940(02)01244-2; WADDELL PA, 1984, ACTA NEUROL SCAND, V69, P270, DOI 10.1111/j.1600-0404.1984.tb07812.x; Wang JH, 2003, BRAIN RES BULL, V60, P53, DOI 10.1016/S0361-9230(03)00026-1; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052; Wolf DH, 2008, BRAIN IMAGING BEHAV, V2, P132, DOI 10.1007/s11682-008-9022-7; Yan EB, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-147; Yang L, 2010, J NEUROTRAUM, V27, P1541, DOI 10.1089/neu.2009.1244; YU Z, 2009, EMBC 2009 ANN INT C, P1135	96	42	42	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 21	2012	7	12							e52169	10.1371/journal.pone.0052169			19	Multidisciplinary Sciences	Science & Technology - Other Topics	065OW	WOS:000313158800036	23284921	DOAJ Gold, Green Published			2021-06-18	
J	Shenaq, M; Kassem, H; Peng, CY; Schafer, S; Ding, JY; Fredrickson, V; Guthikonda, M; Kreipke, CW; Rafols, JA; Ding, YC				Shenaq, Mohammed; Kassem, Hassan; Peng, Changya; Schafer, Steven; Ding, Jamie Y.; Fredrickson, Vance; Guthikonda, Murali; Kreipke, Christian W.; Rafols, Jose A.; Ding, Yuchuan			Neuronal damage and functional deficits are ameliorated by inhibition of aquaporin and HIF1 alpha after traumatic brain injury (TBI)	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article						Marmarou's TBI model; Cerebral edema; Water channels; Cellular injury; FluoroJade; Functional deficits	HYPOXIA-INDUCIBLE-FACTOR; FLUORO-JADE; EDEMA; RAT; MODEL; ANGIOGENESIS; CHANNELS; MOTOR	The present study, using a rodent model of closed-head diffuse traumatic brain injury (TBI), investigated the role of dysregulated aquaporins (AQP) 4 and 9, as well as hypoxia inducible factor - 1 alpha(HIF-1 alpha) on brain edema formation, neuronal injury, and functional deficits. TBI was induced in adult (400-425 g), male Sprague-Dawley rats using a modified Marmarou's head impact-acceleration device (450 g weight dropped from 2 m height). Animals in each treatment group were administered intravenous anti-AQP4 or -AQP9 antibodies or 2-Methoxyestradiol (2ME2, an inhibitor of HIF-1 alpha) 30 min after injury. At 24 h post-TBI. animals (n = 6 each group) were sacrificed to examine the extent of brain edema by water content, as well as protein expression of AQP and HIF-1 alpha by Western immune-blotting. At 48-hours post-TBI, neuronal injury (n = 8 each group) was assessed by FluoroJade (FJ) histochemistry. Spatial learning and memory deficits were evaluated by radial arm maze (n=8 each group) up to 21 days post-TBI. Compared to non-injured controls, significant (p<0.05) increases in the expression of AQP4 and -9 were detected in the brains of injured animals. In addition, significant (p<0.05) brain edema after TBI was associated with increases (p<0.05) both in neuronal injury (9 labeling) and neurobehavioral deficits. Selective inhibition of either AQP4 or -9, or HIF-1 alpha significantly (p<0.05) decreased the expression of the proteins. In addition, inhibition of the AQPs and HIF-1 alpha significantly (p<0.05) ameliorated brain edema, as well as the number of injured neurons in cortical layers II/III and V/VI, striatum and hippocampal regions CA1/CA3. Finally, compared to the non-treated TBI animals, AQP or HIF-1 alpha inhibition significantly (p<0.01) improved neurobehavioral outcomes after TBI. Taken together, the present data supports a causal relation between HIF-AQP mediated cerebral edema, secondary neuronal injury, and tertiary behavioral deficits post-TBI. The data further suggests that upstream modulation of the molecular patho-trajectory effectively ameliorates both neuronal injury and behavioral deficits post-TBI. (C) 2012 Published by Elsevier B.V.	[Shenaq, Mohammed; Kassem, Hassan; Peng, Changya; Fredrickson, Vance; Guthikonda, Murali; Ding, Yuchuan] Wayne State Univ, Sch Med, Dept Neurol Surg, Detroit, MI 48201 USA; [Shenaq, Mohammed; Kassem, Hassan; Peng, Changya; Schafer, Steven; Fredrickson, Vance; Guthikonda, Murali; Kreipke, Christian W.; Rafols, Jose A.; Ding, Yuchuan] Coll Engn, Detroit, MI USA; [Schafer, Steven; Kreipke, Christian W.; Rafols, Jose A.] Wayne State Univ, Sch Med, Dept Anat & Cell Biol, Detroit, MI 48201 USA; [Shenaq, Mohammed] Wayne State Univ, Sch Med, Dept Biomed Engn, Detroit, MI 48201 USA; [Ding, Jamie Y.] Princeton Univ, Butler Coll, Princeton, NJ 08544 USA	Ding, YC (corresponding author), Wayne State Univ, Sch Med, Dept Neurol Surg, 550 E Canfield, Detroit, MI 48201 USA.	yding@med.wayne.edu			WSU Neurosurgery Fund; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS 39860, NS 064976]; VA RRD; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039860, R01NS064976] Funding Source: NIH RePORTER	This work was supported partially by the WSU Neurosurgery Fund (YD), NIH NS 39860 (JAR), and NIH NS 064976, VA RRD (CWK).	Agre P, 2004, NEUROSCIENCE, V129, P849, DOI 10.1016/j.neuroscience.2004.10.001; Badaut T, 2002, J CEREBR BLOOD F MET, V22, P367, DOI 10.1097/00004647-200204000-00001; Belli A, 2008, ACTA NEUROCHIR, V150, P461, DOI 10.1007/s00701-008-1580-3; Cernak I, 2010, DEV NEUROSCI-BASEL, V32, P442, DOI 10.1159/000320085; Ding JY, 2009, NEUROSCI LETT, V453, P68, DOI 10.1016/j.neulet.2009.01.077; Ding YC, 2001, NEUROL RES, V23, P193, DOI 10.1179/016164101101198334; Feldmann H, 1979, Acta Neurochir Suppl (Wien), V28, P74; Griesdale DEG, 2004, SURG NEUROL, V61, P418, DOI 10.1016/j.surneu.2003.10.047; Guo QM, 2006, EXP NEUROL, V198, P469, DOI 10.1016/j.expneurol.2005.12.013; Higashida T, 2011, CURR NEUROVASC RES, V8, P44, DOI 10.2174/156720211794520251; Higashida T, 2011, J NEUROSURG, V114, P92, DOI 10.3171/2010.6.JNS10207; Kaur C, 2006, GLIA, V54, P826, DOI 10.1002/glia.20420; Kawai N, 2010, J NEUROTRAUM, V27, P2131, DOI 10.1089/neu.2010.1464; Kimelberg HK, 2006, GLIA, V54, P747, DOI 10.1002/glia.20423; Kreipke CW, 2007, NEUROL RES, V29, P388, DOI 10.1179/016164107X204710; Langdon KD, 2008, EUR J NEUROSCI, V28, P2310, DOI 10.1111/j.1460-9568.2008.06513.x; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Lundby C, 2009, CELL MOL LIFE SCI, V66, P3615, DOI 10.1007/s00018-009-0146-8; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Marmarou Anthony, 2007, Neurosurg Focus, V22, pE1; Papadopoulos MC, 2007, PEDIATR NEPHROL, V22, P778, DOI 10.1007/s00467-006-0411-0; Papadopoulos MC, 2002, MT SINAI J MED, V69, P242; Poirier JL, 2000, NEUROSCIENCE, V97, P59, DOI 10.1016/S0306-4522(00)00026-9; Rafols JA, 2007, NEUROL RES, V29, P348, DOI 10.1179/016164107X204657; Sarabia R, 1988, Acta Neurochir Suppl (Wien), V42, P40; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Sun MC, 2003, J NEUROSURG, V98, P565, DOI 10.3171/jns.2003.98.3.0565; Swain RA, 2003, NEUROSCIENCE, V117, P1037, DOI 10.1016/S0306-4522(02)00664-4; Timofeeva OA, 2010, BRAIN RES, V1308, P147, DOI 10.1016/j.brainres.2009.10.040; Witt KA, 2005, J NEUROCHEM, V92, P203, DOI 10.1111/j.1471-4159.2004.02871.x	30	42	49	0	16	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-510X	1878-5883		J NEUROL SCI	J. Neurol. Sci.	DEC 15	2012	323	1-2					134	140		10.1016/j.jns.2012.08.036			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	037UT	WOS:000311132700023	23040263				2021-06-18	
J	Chamard, E; Theoret, H; Skopelja, EN; Forwell, LA; Johnson, AM; Echlin, PS				Chamard, Emilie; Theoret, Hugo; Skopelja, Elaine N.; Forwell, Lorie A.; Johnson, Andrew M.; Echlin, Paul S.			A prospective study of physician-observed concussion during a varsity university hockey season: metabolic changes in ice hockey players. Part 4 of 4	NEUROSURGICAL FOCUS			English	Article						concussion; ice hockey; magnetic resonance imaging; magnetic resonance spectroscopy; sex; Canada	TRAUMATIC BRAIN-INJURY; FOOTBALL PLAYERS; INTERNATIONAL-CONFERENCE; FUNCTIONAL CONNECTIVITY; SPORTS CONCUSSION; CORPUS-CALLOSUM; EPIDEMIOLOGY; MILD; ASSOCIATION; STATEMENT	Object. Despite negative neuroimaging findings using traditional neuroimaging methods such as MRI and CT, sports-related concussions have been shown to cause neurometabolic changes in both the acute and subacute phases of head injury. However, no prospective clinical study has used an independent physician-observer design in the monitoring of these changes. The objective of this study was to evaluate the effects of repetitive concussive and subconcussive head impacts on neurometabolic concentrations in a prospective study of two Canadian Interuniversity Sports (CIS) ice hockey teams using MR spectroscopy (MRS). Methods. Forty-five ice hockey players (25 men and 20 women) participated in this study. All participants underwent pre- and postseason MRI, including spectroscopy imaging, using a 3-T MRI machine. The linear combination model was used to quantify the following ratios: glutamate/creatine-phosphocreatine (Cr), myoinositol/Cr, and N-acetylaspartate (NAA)/Cr. Individuals sustaining a medically diagnosed concussion were sent for MRI at 72 hours, 2 weeks, and 2 months after injury. Results. No statistically significant differences were observed between athletes who were diagnosed with a concussion and athletes who were not clinically diagnosed as sustaining a concussion. Although no statistically significant longitudinal metabolic changes were observed among athletes who were diagnosed with a concussion, the results demonstrated a predictable pattern of initial impairment, followed by a gradual return to ratios that were similar to, but lower than, baseline ratios. No significant pre- to postseason changes were demonstrated among men who were not observed to sustain a concussion. However, a substantively significant decrease in the NAA/Cr ratio was noted among the female hockey players (t((13)) = 2.58, p = 0.02, eta(2) = 0.34). Conclusions. A key finding in this study, from the standpoint of future research design, is the demonstration of substantively significant metabolic changes among the players who were not diagnosed with a concussion. In addition, it may explain why there are few statistically significant differences demonstrated between players who were diagnosed with a concussion and players who were not diagnosed with a concussion (that is, the potency of the independent variable was diminished by the fact that the group of players not diagnosed with a concussion might be better described as a subgroup of the players who may have sustained a concussion but were not observed and diagnosed with a concussion). This result suggests that definitions of concussion may need to be revisited within sports with high levels of repetitive subconcussive head impacts. Future analysis of these data will examine the relationships between the modes of MRI (diffusion tensor imaging, MRS, and susceptibility-weighted MR imaging) used in this study, along with other more sensitive evaluative techniques. This type of intermodal comparison may improve the identification of concussions that were previously dependent on the unreliable self-reporting of recognized concussion symptomatology by the athlete or on poorly validated neuropsychological tests. (http://thejns.org/doi/abs/10.3171/2012.10.FOCUS12305)	[Echlin, Paul S.] Elliott Sports Med Clin, Burlington, ON L7N 2G3, Canada; [Chamard, Emilie; Theoret, Hugo] Univ Montreal, Dept Psychol, Montreal, PQ H3C 3J7, Canada; [Chamard, Emilie; Theoret, Hugo] CHU St Justine, Montreal, PQ, Canada; [Skopelja, Elaine N.] Indiana Univ, Sch Med Lib, Indianapolis, IN 46204 USA; [Forwell, Lorie A.] Univ Western Ontario, Fowler Kennedy Sport Med Clin, London, ON, Canada; [Forwell, Lorie A.] Univ Western Ontario, Sch Phys Therapy, London, ON, Canada; [Johnson, Andrew M.] Univ Western Ontario, Sch Hlth Studies, London, ON, Canada	Echlin, PS (corresponding author), Elliott Sports Med Clin, 1100 Walkers Line,Suite 2, Burlington, ON L7N 2G3, Canada.	psechlin@gmail.com	Johnson, Andrew M/B-2048-2012	Theoret, Hugo/0000-0002-7458-8797; Skopelja, Elaine/0000-0002-2847-8909; Johnson, Andrew M./0000-0002-7269-3016	Ontario Trillium Foundation; Dave Irwin Foundation for Brain Injury; Ontario Neurotrauma Foundation; Air Canada	Funding for this work was provided to the HCEP and Dr. Echlin by the Ontario Trillium Foundation, the Dave Irwin Foundation for Brain Injury, the Ontario Neurotrauma Foundation, and Air Canada.	Agel J, 2007, J ATHL TRAINING, V42, P249; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Brainard LL, 2012, MED SCI SPORT EXER, V44, P297, DOI 10.1249/MSS.0b013e31822b0ab4; Braun CMJ, 2002, LATERALITY, V7, P97, DOI 10.1080/13576500143000212; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Ducreux D, 2005, NEURORADIOLOGY, V47, P604, DOI 10.1007/s00234-005-1389-1; Echlin PS, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12286; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10186; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.10.FOCUS10222; Giza CC, 2001, J ATHL TRAINING, V36, P228; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Henry LC, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-105; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Johnson B, 2012, J NEUROTRAUM, V29, P2297, DOI 10.1089/neu.2011.2294; Johnson B, 2012, NEUROSCI LETT, V509, P5, DOI 10.1016/j.neulet.2011.11.013; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; PROVENCHER SW, 1993, MAGNET RESON MED, V30, P672, DOI 10.1002/mrm.1910300604; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Smits M, 2011, NEURORADIOLOGY, V53, P553, DOI 10.1007/s00234-010-0774-6; Sponheim SR, 2011, NEUROIMAGE, V54, pS21, DOI 10.1016/j.neuroimage.2010.09.007; Toga A.W., 2002, BRAIN MAPPING METHOD; Tremblay S, 2012, CEREB CORTEX; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54	32	42	43	0	25	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	DEC	2012	33	6							E4	10.3171/2012.10.FOCUS12305			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	048GI	WOS:000311898500005	23199427	Bronze			2021-06-18	
J	Honeybul, S; Ho, KM				Honeybul, Stephen; Ho, Kwok M.			How "Successful" Is Calvarial Reconstruction Using Frozen Autologous Bone?	PLASTIC AND RECONSTRUCTIVE SURGERY			English	Article							NEUROSURGICAL SITE INFECTIONS; TRAUMATIC BRAIN-INJURY; DECOMPRESSIVE CRANIECTOMY; HYDROXYAPATITE CEMENT; SURGICAL DECOMPRESSION; TITANIUM CRANIOPLASTY; CRANIAL DEFECTS; RISK-FACTORS; COMPLICATIONS; CRANIOTOMY	Background: The authors investigated the long-term outcome of frozen autologous bone cranioplasty in patients who had undergone decompressive craniectomy for severe traumatic brain injury. Methods: A retrospective analysis was undertaken of all patients who had undergone decompressive craniectomy at the two major trauma hospitals in Western Australia between 2004 and 2010. A specific note was made regarding "failure" of frozen autologous bone because of either infection or bone flap resorption. Results: A total of 194 patients required either unilateral or bilateral decompressive craniectomy for severe traumatic brain injury during the study period. Of these patients, 156 had had an autologous cranioplasty. Among these patients, the cranioplasty was judged a failure in 45 (29 percent). Thirteen (8.5 percent; 95 percent confidence interval, 5.0 to 14.0 percent) developed an infection requiring removal of the cranioplasty. Thirty-two (21 percent; 95 percent confidence interval, 15 to 28 percent) developed clinical symptoms or signs relating to resorption of the cranioplasty. Fourteen (9 percent) required secondary titanium cranioplasty, two were offered surgical augmentation but declined, and 16 (10 percent) developed significant bone resorption through both the inner and outer tables of the skull. Conclusions: This study has demonstrated that the use of frozen autologous bone is associated with a high long-term failure rate; however, this does not necessarily imply that alternative materials should be routinely used. Although a number are available, their efficacy over and above frozen autologous bone remains to be established and perhaps this will only be demonstrated in the setting of a formal clinical trial. (Plast. Reconstr. Surg. 130: 1110, 2012.)	[Honeybul, Stephen] Sir Charles Gairdner Hosp, Dept Neurosurg, Perth, WA, Australia; Royal Perth Hosp, Dept Intens Care, Perth, WA, Australia; Univ Western Australia, Sch Populat Hlth, Perth, WA 6009, Australia	Honeybul, S (corresponding author), Sir Charles Gairdner Hosp, Dept Neurosurg, Perth, WA, Australia.	stephen.honeybul@health.wa.gov.au	Ho, Kwok M./E-3546-2010	Ho, Kwok M./0000-0002-6705-6004			Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Adamo MA, 2008, J NEUROSURG, V108, P174, DOI 10.3171/JNS/2008/108/01/0174; Arnaud E, 2000, CHILD NERV SYST, V16, P659, DOI 10.1007/s003810000321; Beauchamp KM, 2010, J TRAUMA, V69, P270, DOI 10.1097/TA.0b013e3181e491c2; Bhaskar IP, 2011, J CLIN NEUROSCI, V18, P1690, DOI 10.1016/j.jocn.2011.02.046; Blum KS, 1997, PEDIATR NEUROSURG, V26, P33, DOI 10.1159/000121158; Cabraja M, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS091; Chang V, 2010, J NEUROSURG, V112, P1120, DOI 10.3171/2009.6.JNS09133; Costantino PD, 2000, OTOLARYNG HEAD NECK, V123, P409, DOI 10.1067/mhn.2000.107679; Dujovny M, 1997, NEUROL RES, V19, P311, DOI 10.1080/01616412.1997.11740818; Durham SR, 2003, NEUROSURGERY, V52, P842, DOI 10.1227/01.NEU.0000054220.01290.8E; Figaji AA, 2003, CHILD NERV SYST, V19, P666, DOI 10.1007/s00381-003-0804-3; FISHER CM, 1994, SURG NEUROL, V41, P65, DOI 10.1016/0090-3019(94)90210-0; FODSTAD H, 1984, ACTA NEUROCHIR, V70, P21, DOI 10.1007/BF01406039; Foster R, 2000, SCHMIDEK SWEET OPERA, P29; Gooch MR, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0962; Grant FC, 1939, ANN SURG, V110, P488, DOI 10.1097/00000658-193910000-00002; Grant GA, 2004, J NEUROSURG, V100, P163, DOI 10.3171/ped.2004.100.2.0163; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Hieu L C, 2002, Technol Health Care, V10, P413; Hofmeijer J, 2009, LANCET NEUROL, V8, P326, DOI 10.1016/S1474-4422(09)70047-X; Honeybul S, 2009, J CLIN NEUROSCI, V16, P727, DOI 10.1016/j.jocn.2008.06.015; Honeybul S, 2011, BRIT J NEUROSURG, V25, P343, DOI 10.3109/02688697.2011.568643; Honeybul S, 2011, J NEUROTRAUM, V28, P929, DOI 10.1089/neu.2010.1612; Honeybul S, 2010, J NEUROTRAUM, V27, P1225, DOI 10.1089/neu.2010.1316; Honeybul S, 2009, J NEUROTRAUM, V26, P2179, DOI 10.1089/neu.2009.0989; Iwama T, 2003, NEUROSURGERY, V52, P591, DOI 10.1227/01.NEU.0000047891.86938.46; Joffe J, 1999, BRIT J NEUROSURG, V13, P576, DOI 10.1080/02688699943088; JOFFE JM, 1992, BRIT J NEUROSURG, V6, P343, DOI 10.3109/02688699209023793; Kan P, 2006, J NEUROSURG, V105, P337, DOI 10.3171/ped.2006.105.5.337; Korinek AM, 2005, BRIT J NEUROSURG, V19, P155, DOI 10.1080/02688690500145639; Korinek AM, 1997, NEUROSURGERY, V41, P1073, DOI 10.1097/00006123-199711000-00010; Lu LC, 2001, J BONE JOINT SURG AM, V83A, pS82; MAAS CS, 1990, ARCH OTOLARYNGOL, V116, P551; Marchac D, 2008, J PLAST RECONSTR AES, V61, P744, DOI 10.1016/j.bjps.2007.10.055; Matic D, 2002, PLAST RECONSTR SURG, V110, P1, DOI 10.1097/00006534-200207000-00001; Matsuno A, 2006, ACTA NEUROCHIR, V148, P535, DOI 10.1007/s00701-006-0740-6; Moreira-Gonzalez A, 2003, J CRANIOFAC SURG, V14, P144, DOI 10.1097/00001665-200303000-00003; Neovius E, 2010, J PLAST RECONSTR AES, V63, P1615, DOI 10.1016/j.bjps.2009.06.003; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Phemister D, 1914, SURG GYNECOL OBS, V19, P303; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Prolo DJ, 1996, NEUROSURGERY, V2, P2783; RISH BL, 1979, NEUROSURGERY, V4, P381, DOI 10.1227/00006123-197905000-00002; Saringer W, 2002, ACTA NEUROCHIR, V144, P1193, DOI 10.1007/s00701-002-0995-5; Schaffler A, 2007, STEM CELLS, V25, P818, DOI 10.1634/stemcells.2006-0589; Scolozzi P, 2007, J CRANIOFAC SURG, V18, P224, DOI 10.1097/01.scs.0000249359.56417.7e; Sobani Zain A, 2011, Surg Neurol Int, V2, P123, DOI 10.4103/2152-7806.85055; Stiver SI, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.4.FOCUS0965; Sultan SM, 2011, PLAST RECONSTR SURG, V127, P1855, DOI 10.1097/PRS.0b013e31820e89a5; Thesleff T, 2011, NEUROSURGERY, V68, P1535, DOI 10.1227/NEU.0b013e31820ee24e; Verheggen R, 2001, ACTA NEUROCHIR, V143, P919, DOI 10.1007/s007010170022; Wen L, 2007, J CRANIOFAC SURG, V18, P526; Winkler PA, 2000, J NEUROSURG, V93, P53, DOI 10.3171/jns.2000.93.1.0053; Wong RK, 2011, J CRANIOFAC SURG, V22, P247, DOI 10.1097/SCS.0b013e3181f7b7db; YAMAURA A, 1977, Neurologia Medico-Chirurgica, V17, P43, DOI 10.2176/nmc.17pt1.43; Yang XF, 2008, ACTA NEUROCHIR, V150, P1241, DOI 10.1007/s00701-008-0145-9	57	42	44	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0032-1052	1529-4242		PLAST RECONSTR SURG	Plast. Reconstr. Surg.	NOV	2012	130	5					1110	1117		10.1097/PRS.0b013e318267d4de			8	Surgery	Surgery	030LL	WOS:000310572100059	23096611				2021-06-18	
J	Klein, P; Herr, D; Pearl, PL; Natale, J; Levine, Z; Nogay, C; Sandoval, F; Trzcinski, S; Atabaki, SM; Tsuchida, T; van den Anker, J; Soldin, SJ; He, JP; McCarter, R				Klein, Pavel; Herr, Daniel; Pearl, Phillip L.; Natale, JoAnne; Levine, Zachary; Nogay, Claude; Sandoval, Fabian; Trzcinski, Stacey; Atabaki, Shireen M.; Tsuchida, Tammy; van den Anker, John; Soldin, Steven J.; He, Jianping; McCarter, Robert			Results of Phase 2 Safety and Feasibility Study of Treatment With Levetiracetam for Prevention of Posttraumatic Epilepsy	ARCHIVES OF NEUROLOGY			English	Article							SEIZURES; EPILEPTOGENESIS	Objectives: To evaluate the safety and tolerability of treatment with levetiracetam and determine the trough levels of levetiracetam in patients with traumatic brain injury (TBI) who are at high risk for posttraumatic epilepsy (PTE). Design: Open-label, nonrandomized phase 2 study with 2 arms comparing levetiracetam treatment vs observation. Setting: Two level 1 trauma centers. Patients: A total of 422 participants 6 years or older with TBI who have a 20% risk for PTE were screened. Of these participants, 205 (48.6%) were eligible. A total of 126 participants were enrolled: 86 adults and 40 children. A total of 66 participants were in the treatment group (46 adults and 20 children), and a total of 60 participants were in the observation group (40 adults and 20 children). Participants presenting within 8 hours after TBI received treatment, and those presenting more than 8 to 24 hours after TBI did not. Intervention: Treatment with levetiracetam (55 mg/kg/d) for 30 days starting within 8 hours after injury. Main Outcome Measures: Number of adverse events, mood score, number of infections, trough level of levetiracetam, and PTE. Results: Of the 66 participants treated with levetiracetam, 2 (3%) stopped treatment owing to toxicity (somnolence). The most common adverse events were fatigue, headache, and somnolence. Mood scores and number of infections did not differ between the treatment and observation groups. Mean trough levels of levetiracetam on days 2 to 30 ranged from 19.6 to 26.7 mu g/mL. At 2 years, 13 of 86 adults (15.1%) and 1 of 40 children (2.5%) developed PTE. At 2 years, 5 of 46 treated adults (10.9%) and 8 of 40 untreated adults (20.0%) developed PTE (relative risk, 0.47; P = .18). Conclusion: Treatment with 55 mg/kg/d of levetiracetam (a dose with an antiepileptogenic effect on animals) for patients with TBI at risk for PTE is safe and well tolerated, with plasma levels similar to those in animal studies. The findings support further evaluation of levetiracetam treatment for the prevention of PTE.	[Klein, Pavel] Midatlantic Epilepsy & Sleep Ctr, Bethesda, MD 20817 USA; [Klein, Pavel; Herr, Daniel; Levine, Zachary; Nogay, Claude; Sandoval, Fabian] MedStar Res Inst, Dept Neurol, Washington, DC USA; [Pearl, Phillip L.; Natale, JoAnne; Trzcinski, Stacey; Tsuchida, Tammy; van den Anker, John; He, Jianping; McCarter, Robert] Childrens Natl Med Ctr, Dept Neurol, Washington, DC 20010 USA; [Atabaki, Shireen M.] Childrens Natl Med Ctr, Dept Emergency Med, Washington, DC 20010 USA	Klein, P (corresponding author), Midatlantic Epilepsy & Sleep Ctr, 6410 Rockledge Dr,Ste 410, Bethesda, MD 20817 USA.	kleinp@epilepsydc.com	Herr, Daniel/X-4215-2019	Herr, Daniel/0000-0001-8533-9000; Pearl, Phillip/0000-0002-6373-1068	UCB PharmaUCB Pharma SA; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS45656]; NIH grantUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS45656, R0158553]; General Clinical Research Center of Children's National Medical Center; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD058553] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045656] Funding Source: NIH RePORTER; CLINICAL CENTER [ZIACL010355] Funding Source: NIH RePORTER	Dr Klein received honoraria for serving on a scientific advisory board for UCB Pharma, has participated in clinical trials sponsored by UCB Pharma as the site principal investigator, and is on the speakers' bureau of UCB Pharma. He and Dr Herr received funding for this study from the National Institutes of Health (NIH; grant R01 NS45656). Dr Pearl also received funding for this study from NIH grant R01 NS45656 and receives funding from NIH grant R0158553. Dr Levine received honoraria for serving on a scientific advisory board for Medtronics and is on Medtronics' speakers' bureau. He and Drs van den Anker, Soldin, and McCarter also received funding for this study from NIH grant R01 NS45656.; This study was sponsored by the NIH (grant R01 NS45656). Study medication (levetiracetam) was provided free of charge by UCB Pharma. The study was supported by the NIH (grant R01 NS45656) and by the General Clinical Research Center of Children's National Medical Center.	[Anonymous], 1981, Epilepsia, V22, P489; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS83; Bratton SL, 2008, J NEUROTRAUM, V25, P276; Cramer JA, 2003, EPILEPSY BEHAV, V4, P124, DOI 10.1016/S1525-5050(03)00005-2; Crepeau AZ, 2010, EXPERT REV NEUROTHER, V10, P159, DOI [10.1586/ern.10.5, 10.1586/ERN.10.3]; Glauser TA, 2006, NEUROLOGY, V66, P1654, DOI 10.1212/01.wnl.0000217916.00225.3a; Harden C, 2001, EPILEPSIA, V42, P36, DOI 10.1046/j.1528-1157.2001.00008.x; Loscher W, 2010, PHARMACOL REV, V62, P668, DOI 10.1124/pr.110.003046; Pharma UCB Pharma Inc., 1999, DAT FIL; SILVER JM, 1991, ANN NEUROL, V29, P356, DOI 10.1002/ana.410290404; Statler KD, 2006, DEV NEUROSCI-BASEL, V28, P354, DOI 10.1159/000094162; Temkin NR, 2009, EPILEPSIA, V50, P10, DOI 10.1111/j.1528-1167.2008.02005.x; Temkin NR, 2003, EPILEPSIA, V44, P18, DOI 10.1046/j.1528-1157.44.s10.6.x	13	42	43	0	15	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0003-9942	1538-3687		ARCH NEUROL-CHICAGO	Arch. Neurol.	OCT	2012	69	10					1290	1295		10.1001/archneurol.2012.445			6	Clinical Neurology	Neurosciences & Neurology	016TC	WOS:000309541400007	22777131	Green Accepted, Bronze			2021-06-18	
J	Brekke, EMF; Walls, AB; Schousboe, A; Waagepetersen, HS; Sonnewald, U				Brekke, Eva M. F.; Walls, Anne B.; Schousboe, Arne; Waagepetersen, Helle S.; Sonnewald, Ursula			Quantitative importance of the pentose phosphate pathway determined by incorporation of C-13 from [2-C-13]- and [3-C-13]glucose into TCA cycle intermediates and neurotransmitter amino acids in functionally intact neurons	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						cell culture; energy metabolism; free radicals; MR spectroscopy; neurotransmitters	METABOLIC COMPARTMENTATION; GLUCOSE-METABOLISM; GABAERGIC NEURONS; ASTROCYTES; GLUTAMATE; GLUTATHIONE; EXPRESSION; RELEASE; ENZYMES; BRAIN	The brain is highly susceptible to oxidative injury, and the pentose phosphate pathway (PPP) has been shown to be affected by pathological conditions, such as Alzheimer's disease and traumatic brain injury. While this pathway has been investigated in the intact brain and in astrocytes, little is known about the PPP in neurons. The activity of the PPP was quantified in cultured cerebral cortical and cerebellar neurons after incubation in the presence of [2-C-13] glucose or [3-C-13] glucose. The activity of the PPP was several fold lower than glycolysis in both types of neurons. While metabolism of C-13-labeled glucose via the PPP does not appear to contribute to the production of releasable lactate, it contributes to labeling of tricarboxylic acid (TCA) cycle intermediates and related amino acids. Based on glutamate isotopomers, it was calculated that PPP activity accounts for similar to 6% of glucose metabolism in cortical neurons and similar to 4% in cerebellar neurons. This is the first demonstration that pyruvate generated from glucose via the PPP contributes to the synthesis of acetyl CoA for oxidation in the TCA cycle. Moreover, the fact that C-13 labeling from glucose is incorporated into glutamate proves that both the oxidative and the nonoxidative stages of the PPP are active in neurons. Journal of Cerebral Blood Flow & Metabolism (2012) 32, 1788-1799; doi:10.1038/jcbfm.2012.85; published online 20 June 2012	[Brekke, Eva M. F.; Walls, Anne B.; Sonnewald, Ursula] Norwegian Univ Sci & Technol NTNU, Fac Med, Dept Neurosci, N-7491 Trondheim, Norway; [Walls, Anne B.; Schousboe, Arne; Waagepetersen, Helle S.] Univ Copenhagen, Fac Hlth & Med Sci, Dept Drug Design & Pharmacol, Copenhagen, Denmark	Sonnewald, U (corresponding author), Norwegian Univ Sci & Technol NTNU, Fac Med, Dept Neurosci, PB 8905, N-7491 Trondheim, Norway.	ursula.sonnewald@ntnu.no		Waagepetersen, Helle/0000-0003-4583-8379; Schousboe, Arne/0000-0001-9600-402X	Danish Medical Research CouncilDanish Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [09-063393, 10-094362]	This work was funded by the Danish Medical Research Council (grant numbers 09-063393 and 10-094362).	Allaman I, 2010, J NEUROSCI, V30, P3326, DOI 10.1523/JNEUROSCI.5098-09.2010; Appel S H, 1970, J Neurochem, V17, P1619, DOI 10.1111/j.1471-4159.1970.tb11386.x; BADARGOFFER RS, 1990, BIOCHEM J, V266, P133, DOI 10.1042/bj2660133; Bakken IJ, 1997, NEUROSCI LETT, V237, P117, DOI 10.1016/S0304-3940(97)00834-3; BANKI K, 1994, J EXP MED, V180, P1649, DOI 10.1084/jem.180.5.1649; BAUER U, 1982, J NEUROCHEM, V39, P239, DOI 10.1111/j.1471-4159.1982.tb04725.x; BELHAGE B, 1993, NEUROSCIENCE, V54, P1019, DOI 10.1016/0306-4522(93)90592-4; BENYOSEPH O, 1995, J NEUROCHEM, V64, P1336; BenYoseph O, 1996, J NEUROCHEM, V66, P2329; Bolanos JP, 2010, IUBMB LIFE, V62, P14, DOI 10.1002/iub.280; Brekke E, 2012, GLIA, V60, P147, DOI 10.1002/glia.21265; CATALDO AM, 1986, J NEUROCYTOL, V15, P511, DOI 10.1007/BF01611733; DREJER J, 1985, NEUROCHEM RES, V10, P49, DOI 10.1007/BF00964771; DREJER J, 1987, J NEUROSCI, V7, P2910; DREJER J, 1989, NEUROCHEM RES, V14, P751, DOI 10.1007/BF00964953; Dringen R, 1999, J NEUROSCI, V19, P562, DOI 10.1523/jneurosci.19-02-00562.1999; Dusick JR, 2007, J CEREBR BLOOD F MET, V27, P1593, DOI 10.1038/sj.jcbfm.9600458; EHRHARTBORNSTEIN M, 1991, INT J DEV NEUROSCI, V9, P463, DOI 10.1016/0736-5748(91)90032-H; Filosa S, 2003, BIOCHEM J, V370, P935, DOI 10.1042/BJ20021614; GEDDES JW, 1984, J NEUROCHEM, V42, P16, DOI 10.1111/j.1471-4159.1984.tb09691.x; Herrero-Mendez A, 2009, NAT CELL BIOL, V11, P747, DOI 10.1038/ncb1881; HERTZ L, 1988, NEUROCHEM RES, V13, P605, DOI 10.1007/BF00973275; Hertz L, 1989, DISSECTION TISSUE CU; HERTZ L, 1982, NEUROSCIENCE APPROAC, V1, P175; HOSTETLE.KY, 1967, BIOCHEMISTRY-US, V6, P2961, DOI 10.1021/bi00862a001; HOTHERSALL JS, 1982, J NEUROCHEM, V39, P1325, DOI 10.1111/j.1471-4159.1982.tb12574.x; KATZ J, 1966, J BIOL CHEM, V241, P727; KATZ J, 1960, J BIOL CHEM, V235, P2165; KINGSLEYHICKMAN PB, 1990, ANAL BIOCHEM, V185, P235, DOI 10.1016/0003-2697(90)90285-H; LARSSON OM, 1985, INT J DEV NEUROSCI, V3, P177, DOI 10.1016/0736-5748(85)90008-5; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAWHINNEY TP, 1986, J CHROMATOGR, V358, P231, DOI 10.1016/S0021-9673(01)90333-4; McKenna MC, 2012, BASIC NEUROCHEMISTRY: PRINCIPLES OF MOLECULAR, CELLULAR, AND MEDICAL NEUROBIOLOGY, 8THEDITION, P200; Melo TM, 2006, NEUROCHEM INT, V48, P498, DOI 10.1016/j.neuint.2005.12.037; Obel LF, 2012, NEUROTOX RES, V21, P405, DOI 10.1007/s12640-011-9296-1; PATEL MS, 1974, J NEUROCHEM, V22, P717, DOI 10.1111/j.1471-4159.1974.tb04285.x; ROSS BD, 1994, BIOCHEM J, V302, P31, DOI 10.1042/bj3020031; SCHOUSBOE A, 1985, DEV NEUROSCI-BASEL, V7, P252, DOI 10.1159/000112294; Schousboe A, 1989, DISSECTION TISSUE CU, P183; Sickmann HM, 2005, NEUROCHEM RES, V30, P1295, DOI 10.1007/s11064-005-8801-4; Sonnewald U, 2004, NEUROCHEM INT, V45, P305, DOI 10.1016/j.neuint.2003.10.010; Takahashi S, 2012, ASN NEURO, V4, P71, DOI 10.1042/AN20120002; Vannucci SJ, 2003, AM J PHYSIOL-ENDOC M, V285, pE1127, DOI 10.1152/ajpendo.00187.2003; WHITE CW, 1988, J APPL PHYSIOL, V65, P2607; WOOD HG, 1963, BIOCHEM Z, V338, P809; YU ACH, 1983, J NEUROCHEM, V41, P1484, DOI 10.1111/j.1471-4159.1983.tb00849.x; ZUBAIRU S, 1983, J NEUROCHEM, V41, P76, DOI 10.1111/j.1471-4159.1983.tb11816.x	47	42	43	0	8	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	SEP	2012	32	9					1788	1799		10.1038/jcbfm.2012.85			12	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	000MR	WOS:000308390900013	22714050	Green Published, Bronze			2021-06-18	
J	Dennis, M; Simic, N; Taylor, HG; Bigler, ED; Rubin, K; Vannatta, K; Gerhardt, CA; Stancin, T; Roncadin, C; Yeates, KO				Dennis, Maureen; Simic, Nevena; Taylor, H. Gerry; Bigler, Erin D.; Rubin, Kenneth; Vannatta, Kathryn; Gerhardt, Cynthia A.; Stancin, Terry; Roncadin, Caroline; Yeates, Keith Owen			Theory of Mind in Children with Traumatic Brain Injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Intentionality; Childhood head injury; Glasgow Coma Scale; Social cognition; Social problem solving; Error monitoring	CLOSED-HEAD INJURY; INDIVIDUAL-DIFFERENCES; INHIBITORY CONTROL; SPEECH ACTS; DISCOURSE; LANGUAGE; MILD; ADOLESCENTS; PREDICTION; DISORDERS	Theory of mind (ToM) involves thinking about mental states and intentions to understand what other people know and to predict how they will act. We studied ToM in children with traumatic brain injury (TBI) and age-and gender-matched children with orthopedic injuries (OI), using a new three-frame Jack and Jill cartoon task that measures intentional thinking separate from contingent task demands. In the key ToM trials, which required intentional thinking, Jack switched a black ball from one hat to another of a different color, but Jill did not witness the switch; in the otherwise identical non-ToM trials, the switch was witnessed. Overall accuracy was higher in children with OI than in those with TBI. Children with severe TBI showed a larger decline in accuracy on ToM trials, suggesting a specific deficit in ToM among children with severe TBI. Accuracy was significantly higher on trials following errors than on trials following correct responses, suggesting that all groups monitored performance and responded to errors with increased vigilance. TBI is associated with poorer intentional processing in school-age children and adolescents relative to peers with OI; furthermore, children with TBI are challenged specifically by intentional demands, especially when their injury is severe. (JINS, 2012, 18, 908-916)	[Dennis, Maureen] Hosp Sick Children, Dept Psychol, Program Neurosci & Mental Hlth, Toronto, ON M5G 1X8, Canada; [Dennis, Maureen] Univ Toronto, Dept Surg, Toronto, ON, Canada; [Simic, Nevena] Univ Toronto, Dept Psychol, Toronto, ON M5S 1A1, Canada; [Taylor, H. Gerry; Stancin, Terry] Case Western Reserve Univ, Rainbow Babies & Childrens Hosp, Dept Pediat, Univ Hosp Case Med Ctr, Cleveland, OH 44106 USA; [Bigler, Erin D.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Bigler, Erin D.] Univ Utah, Dept Psychiat, Salt Lake City, UT USA; [Rubin, Kenneth] Univ Maryland, Dept Psychol, College Pk, MD 20742 USA; [Vannatta, Kathryn; Gerhardt, Cynthia A.; Yeates, Keith Owen] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; [Vannatta, Kathryn; Gerhardt, Cynthia A.; Yeates, Keith Owen] Nationwide Childrens Hosp, Res Inst, Ctr Biobehav Hlth, Columbus, OH USA; [Stancin, Terry] MetroHlth Med Ctr, Dept Psychiat, Cleveland, OH USA; [Roncadin, Caroline] Peel Childrens Ctr, Dept Psychol, Mississauga, ON, Canada	Dennis, M (corresponding author), Hosp Sick Children, Dept Psychol, Program Neurosci & Mental Hlth, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	maureen.dennis@sickkids.ca	Stancin, Terry/L-7993-2019; Vannatta, Kathryn/E-4237-2011; Rubin, Kenneth H/M-5276-2018; Gerhardt, Cynthia/E-3109-2011; Yeates, Keith/AAJ-4223-2020	Rubin, Kenneth H/0000-0002-2608-2484; Yeates, Keith/0000-0001-7680-2892	National Institute of Neurological Diseases and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1 RO1 HD 04946]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048946] Funding Source: NIH RePORTER	Preparation of this study was supported by National Institute of Neurological Diseases and Stroke Grant 1 RO1 HD 04946,"Social Outcomes in Pediatric Traumatic Brain Injury." We have no conflicts of interest to declare.	Astington J.W., 2003, INDIVIDUAL DIFFERENC; Astington JW, 1999, DEV PSYCHOL, V35, P1311, DOI 10.1037/0012-1649.35.5.1311; BARTSCH K, 1989, CHILD DEV, V60, P946, DOI 10.1111/j.1467-8624.1989.tb03526.x; Bibby H, 2005, NEUROPSYCHOLOGIA, V43, P99, DOI 10.1016/j.neuropsychologia.2004.04.027; Brown RL, 2010, CURR OPIN PEDIATR, V22, P321, DOI 10.1097/MOP.0b013e3283395f13; Carlson SM, 2004, J EXP CHILD PSYCHOL, V87, P299, DOI 10.1016/j.jecp.2004.01.002; Chapman SB, 2004, DEV NEUROPSYCHOL, V25, P37, DOI 10.1207/s15326942dn2501&2_4; Chevrier AD, 2007, HUM BRAIN MAPP, V28, P1347, DOI 10.1002/hbm.20355; Dennis M, 1998, BRAIN LANG, V61, P450, DOI 10.1006/brln.1997.1886; Dennis M, 1996, DEV NEUROPSYCHOL, V12, P77, DOI 10.1080/87565649609540641; Dennis M, 2001, BRAIN LANG, V78, P1, DOI 10.1006/brln.2000.2431; Dennis M, 2001, J INT NEUROPSYCH SOC, V7, P683, DOI 10.1017/S1355617701766040; Dennis M, 2001, BRAIN COGNITION, V47, P197; Dennis M, 2001, J HEAD TRAUMA REHAB, V16, P456, DOI 10.1097/00001199-200110000-00005; Dennis M, 2000, APHASIOLOGY, V14, P391, DOI 10.1080/026870300401423; DENNIS M, 1993, J PEDIATR PSYCHOL, V18, P639, DOI 10.1093/jpepsy/18.5.639; Dennis M, 2009, J INT NEUROPSYCH SOC, V15, P331, DOI 10.1017/S1355617709090481; Dennis M, 2009, J CLIN EXP NEUROPSYC, V31, P835, DOI 10.1080/13803390802572419; Filippova E, 2008, CHILD DEV, V79, P126, DOI 10.1111/j.1467-8624.2007.01115.x; Martin-Rodriguez JF, 2010, NEUROPSYCHOLOGIA, V48, P1181, DOI 10.1016/j.neuropsychologia.2010.02.009; Frith U, 2001, CURR DIR PSYCHOL SCI, V10, P151, DOI 10.1111/1467-8721.00137; Gordon ACL, 1998, J EXP CHILD PSYCHOL, V68, P70, DOI 10.1006/jecp.1997.2423; Greenbaum RL, 2009, ALCOHOL CLIN EXP RES, V33, P1656, DOI 10.1111/j.1530-0277.2009.01003.x; Hanten G, 2004, DEV NEUROPSYCHOL, V25, P85, DOI 10.1207/s15326942dn2501&2_6; Hein G, 2008, CURR OPIN NEUROBIOL, V18, P153, DOI 10.1016/j.conb.2008.07.012; Hein G, 2010, NEURON, V68, P149, DOI 10.1016/j.neuron.2010.09.003; Hill EL, 2003, PHILOS T R SOC B, V358, P281, DOI 10.1098/rstb.2002.1209; Howard I, 2005, ETHNIC DIS, V15, pS51; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Levin H, 2007, J DEV BEHAV PEDIATR, V28, P108, DOI 10.1097/01.DBP.0000267559.26576.cd; Levin HS, 2008, J NEUROSURG-PEDIATR, V1, P461, DOI 10.3171/PED/2008/1/6/461; Levin HS, 2004, J INT NEUROPSYCH SOC, V10, P305, DOI 10.1017/S1355617704102129; Max J. E., 2005, J AM ACAD CHILD ADOL, V44, P435; Max JE, 2006, J NEUROPSYCH CLIN N, V18, P21, DOI 10.1176/appi.neuropsych.18.1.21; Max JE, 2011, J NEUROPSYCH CLIN N, V23, P29, DOI 10.1176/appi.neuropsych.23.1.29; McKinlay A, 2010, INJURY PREV, V16, P31, DOI 10.1136/ip.2009.022483; MELTZOFF AN, 1995, J EXP CHILD PSYCHOL, V59, P497, DOI 10.1006/jecp.1995.1023; MELTZOFF AN, 1999, DEV THEORIES INTENTI; Moses LJ, 2001, CHILD DEV, V72, P688, DOI 10.1111/1467-8624.00306; Muscara F, 2009, NEUROPSYCHOL REHABIL, V19, P541, DOI 10.1080/09602010802365223; Olsson A, 2007, SOC COGN AFFECT NEUR, V2, P3, DOI 10.1093/scan/nsm005; Ornstein TJ, 2009, J CHILD PSYCHOL PSYC, V50, P506, DOI 10.1111/j.1469-7610.2008.01997.x; Parslow RC, 2005, ARCH DIS CHILD, V90, P1182, DOI 10.1136/adc.2005.072405; PREMACK D, 1978, SCIENCE, V202, P532, DOI 10.1126/science.705342; Robinson EJ, 2003, TRENDS COGN SCI, V7, P235, DOI 10.1016/S1364-6613(03)00102-5; Roncadin C, 2004, DEV NEUROPSYCHOL, V25, P21; Shamay-Tsoory SG, 2007, NEUROPSYCHOLOGIA, V45, P3054, DOI 10.1016/j.neuropsychologia.2007.05.021; Shammi P, 1999, BRAIN, V122, P657, DOI 10.1093/brain/122.4.657; Singer T, 2004, SCIENCE, V303, P1157, DOI 10.1126/science.1093535; SODIAN B, 1991, CHILD DEV, V62, P468, DOI 10.1111/j.1467-8624.1991.tb01545.x; Stuss DT, 2001, BRAIN, V124, P279, DOI 10.1093/brain/124.2.279; TEASDALE G, 1974, LANCET, V2, P81; Uekermann J, 2010, NEUROSCI BIOBEHAV R, V34, P734, DOI 10.1016/j.neubiorev.2009.10.009; Wellman HM, 2001, CHILD DEV, V72, P655, DOI 10.1111/1467-8624.00304; WIMMER H, 1983, COGNITION, V13, P103, DOI 10.1016/0010-0277(83)90004-5; Wobbrock J., 2011, P SIGCHI C HUM FACT, P143, DOI DOI 10.1145/1978942.1978963; Wu TC, 2010, DEV NEUROSCI-BASEL, V32, P361, DOI 10.1159/000317058; Yates PJ, 2006, J NEUROL NEUROSUR PS, V77, P699, DOI 10.1136/jnnp.2005.081901; Yeates KO, 2007, PSYCHOL BULL, V133, P535, DOI 10.1037/0033-2909.133.3.535; Yeates KO, 1997, J CLIN EXP NEUROPSYC, V19, P825, DOI 10.1080/01688639708403763; Yuh EL, 2012, J NEUROTRAUM, V29, P735, DOI 10.1089/neu.2011.2008	61	42	42	0	25	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	SEP	2012	18	5					908	916		10.1017/S1355617712000756			9	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	999KB	WOS:000308309100013	22846440	Green Accepted			2021-06-18	
J	Wang, B; Sun, L; Tian, Y; Li, ZY; Wei, HJ; Wang, D; Yang, Z; Chen, JL; Zhang, JN; Jiang, RC				Wang, Bin; Sun, Lin; Tian, Ye; Li, Zhanying; Wei, Huijie; Wang, Dong; Yang, Zhuo; Chen, Jieli; Zhang, Jianning; Jiang, Rongcai			Effects of atorvastatin in the regulation of circulating EPCs and angiogenesis in traumatic brain injury in rats	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article						Endothelial progenitor cell; Traumatic brain injury; Atorvastatin; Angiogenesis; Rat	ENDOTHELIAL PROGENITOR CELLS; REDUCES NEUROLOGICAL DEFICIT; CEREBRAL-ISCHEMIA; NITRIC-OXIDE; STATINS; STROKE; NEUROGENESIS; INCREASE; THERAPY; SYNAPTOGENESIS	Circulating endothelial progenitor cells (EPCs) play an important role in angiogenesis and vasculogenesis. Statins administered promote functional improvement in rats, independent of their capability to lower cholesterol. Whether statin treatment regulates circulating EPCs after traumatic brain injury (TBI) has not been investigated. We hypothesized that atorvastatin increases circulating EPCs and promotes angiogenesis in TBI rats. Wistar rats (20 months old) were subjected to TBI and treated with or without atorvastatin (orally administered, 1 mg/kg/day) starting 1 h after TBI and then daily for 14 consecutive days. Long term potentiation (LTP) in the cornu ammonis1 of the hippocampus as well as the Modified Neurological Severity Score (mNSS) and the Morris Water Maze (MWM) functional tests were performed. Blood circulating EPCs were identified by flow cytometry. Rats were sacrificed 25 days after TBI. vWF and CD31 immunostaining was performed. We found that atorvastatin administration significantly induced angiogenesis and increased circulating EPC levels as well as improved functional recovery when compared with non-treatment TBI-control rats (P<0.05). The circulating EPC level is correlated with vascular density (r = 0.878, P < 0.05) and CD31 positive cell number in the injured brain (r = 0.921, P < 0.05). The results suggest that increasing circulating EPCs with atorvastatin treatment may contribute to the observed increase in angiogenesis and improved functional outcome after TBI. (C) 2012 Elsevier B.V. All rights reserved.	[Wang, Bin; Sun, Lin; Tian, Ye; Li, Zhanying; Wei, Huijie; Wang, Dong; Zhang, Jianning; Jiang, Rongcai] Tianjin Med Univ, Gen Hosp, Dept Neurosurg, Tianjin 300052, Peoples R China; [Wang, Bin; Sun, Lin; Tian, Ye; Li, Zhanying; Wei, Huijie; Wang, Dong; Zhang, Jianning; Jiang, Rongcai] Tianjin Neurol Inst, Tianjin, Peoples R China; [Wang, Bin; Sun, Lin; Tian, Ye; Li, Zhanying; Wei, Huijie; Wang, Dong; Zhang, Jianning; Jiang, Rongcai] Minist Educ, Key Lab Posttrauma Neurorepair & Regenerat Cent N, Tianjin, Peoples R China; [Wang, Bin; Sun, Lin; Tian, Ye; Li, Zhanying; Wei, Huijie; Wang, Dong; Zhang, Jianning; Jiang, Rongcai] Tianjin Key Lab Injuries Variat & Regenerat Nervo, Tianjin, Peoples R China; [Li, Zhanying] Kailuan Hosp, N China Coal Med Sch, Dept Neurosurg, Tangshan, Peoples R China; [Yang, Zhuo] Nankai Univ, Coll Life Sci, Minist Educ, Sch Med,Key Lab Bioact Mat, Tianjin 300071, Peoples R China; [Chen, Jieli] Henry Ford Hosp, Dept Neurol, Detroit, MI 48202 USA	Zhang, JN (corresponding author), Tianjin Med Univ, Gen Hosp, Dept Neurosurg, Tianjin 300052, Peoples R China.	jianningzhang@hotmail.com; jianghope@gmail.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81100920]; Tianjin Research Program of Application Foundation and Advanced Technology [11JCZDJC18100]; Ontario-China Research and Innovation Fund (OCRIF) [2011DFG33430]	We acknowledge Weiyun Cui, Fanglian Chen, and Lei Zhou for their assistance with the technical aspects of experiments and data interpretation. The work is supported by the National Natural Science Foundation of China (grant 81100920), Tianjin Research Program of Application Foundation and Advanced Technology (grant 11JCZDJC18100) and Ontario-China Research and Innovation Fund (OCRIF, 2011DFG33430).	Beauchamp K, 2008, MOL MED, V14, P731, DOI 10.2119/2008-00050.Beauchamp; Buttmann M, 2007, J NEUROCHEM, V102, P1001, DOI 10.1111/j.1471-4159.2007.04563.x; Chen JL, 2003, ANN NEUROL, V53, P743, DOI 10.1002/ana.10555; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Dimmeler S, 2001, J CLIN INVEST, V108, P391, DOI 10.1172/JCI13152; Friedrich EB, 2006, CIRC RES, V98, pE20, DOI 10.1161/01.RES.0000205765.28940.93; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Hayashi T, 2005, BRAIN RES, V1037, P52, DOI 10.1016/j.brainres.2004.12.051; Hayward NMEA, 2010, J NEUROTRAUM, V27, P2203, DOI 10.1089/neu.2010.1448; Hixon ML, 2000, J CLIN INVEST, V106, P1011, DOI 10.1172/JCI8252; Ladhoff J, 2010, CARDIOVASC RES, V88, P121, DOI 10.1093/cvr/cvq109; Lam CF, 2008, ANESTH ANALG, V107, P686, DOI 10.1213/ane.0b013e31817e6719; Lara-Hernandez R, 2010, ANN VASC SURG, V24, P287, DOI 10.1016/j.avsg.2009.10.012; Laufs U, 2000, STROKE, V31, P2442, DOI 10.1161/01.STR.31.10.2442; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; Liu L, 2007, J NEUROTRAUM, V24, P936, DOI 10.1089/neu.2006.0250; Liu L, 2011, CRIT CARE MED, V39, P1760, DOI 10.1097/CCM.0b013e3182186cee; Llevadot J, 2001, J CLIN INVEST, V108, P399, DOI 10.1172/JCI13131; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Lu DY, 2004, J NEUROTRAUM, V21, P1756, DOI 10.1089/0897715042664885; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Lu DY, 2002, CELL TRANSPLANT, V11, P275; Lu DY, 2004, J NEUROSURG, V101, P813, DOI 10.3171/jns.2004.101.5.0813; Mahooti S, 2000, AM J PATHOL, V157, P75, DOI 10.1016/S0002-9440(10)64519-1; Matsumura M, 2009, J ATHEROSCLER THROMB, V16, P319, DOI 10.5551/jat.No026; Murohara T, 2002, ANTIOXID REDOX SIGN, V4, P825, DOI 10.1089/152308602760598981; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Ozdemir D, 2005, PHYSIOL RES, V54, P631; Seyfried D, 2004, J NEUROSURG, V101, P104, DOI 10.3171/jns.2004.101.1.0104; Thau-Zuchman O, 2010, J CEREBR BLOOD F MET, V30, P1008, DOI 10.1038/jcbfm.2009.271; Tsubokawa T, 2007, STROKE, V38, P1057, DOI 10.1161/01.STR.0000257978.70312.1d; Vasa M, 2001, CIRC RES, V89, pE1, DOI 10.1161/hh1301.093953; Vaughan CJ, 1999, STROKE, V30, P1969, DOI 10.1161/01.STR.30.9.1969; Vorhees CV, 2006, NAT PROTOC, V1, P848, DOI 10.1038/nprot.2006.116; Walter DH, 2002, CIRCULATION, V105, P3017, DOI 10.1161/01.CIR.0000018166.84319.55; Xiong Y, 2009, EXPERT OPIN EMERG DR, V14, P67, DOI [10.1517/14728210902769601, 10.1517/14728210902769601 ]; Zhang L, 2005, CIRCULATION, V112, P3486, DOI 10.1161/CIRCULATIONAHA.104.516757	37	42	49	0	9	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-510X			J NEUROL SCI	J. Neurol. Sci.	AUG 15	2012	319	1-2					117	123		10.1016/j.jns.2012.04.015			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	971ZS	WOS:000306246900023	22658532				2021-06-18	
J	Lange, RT; Brickell, TA; French, LM; Merritt, VC; Bhagwat, A; Pancholi, S; Iverson, GL				Lange, Rael T.; Brickell, Tracey A.; French, Louis M.; Merritt, Victoria C.; Bhagwat, Aditya; Pancholi, Sonal; Iverson, Grant L.			Neuropsychological Outcome from Uncomplicated Mild, Complicated Mild, and Moderate Traumatic Brain Injury in US Military Personnel	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Mild traumatic brain injury; Military service members; Personality Assessment Inventory	HEAD-INJURY; COGNITIVE PERFORMANCE; COMPUTED-TOMOGRAPHY; DIAGNOSIS THREAT; ABNORMALITIES; SYMPTOMS	This study compared the neuropsychological outcome in military personnel following mild-to-moderate traumatic brain injury (TBI). Participants were 83 service members divided into three injury severity groups: uncomplicated mild TBI (MTBI; n 24), complicated MTBI (n 17), and moderate TBI (n 42). Participants were evaluated within 6 months following injury (73 within 3 months) using neurocognitive testing and the Personality Assessment Inventory (PAI). There were no significant differences between the three groups on the majority of neurocognitive measures. Similarly, there were no significant differences between the three groups on the majority of PAI clinical scales (all p .05), with the exception of two scales. The uncomplicated MTBI group had significantly higher scores on the Anxiety-Related Disorders and Aggression scales compared with the complicated MTBI group, but not the moderate TBI group. Overall, these results suggest that within the first 6 months post injury, there were few detectable differences in the neuropsychological outcome following uncomplicated MTBI, complicated MTBI, or moderate TBI in this military sample.	[Lange, Rael T.; Brickell, Tracey A.; French, Louis M.; Bhagwat, Aditya; Pancholi, Sonal; Iverson, Grant L.] Def & Vet Brain Injury Ctr, Bethesda, MD 20852 USA; [Lange, Rael T.; Brickell, Tracey A.; French, Louis M.; Bhagwat, Aditya] Walter Reed Natl Mil Med Ctr, Silver Spring, MD USA; [Lange, Rael T.; Iverson, Grant L.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; [French, Louis M.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA; [Merritt, Victoria C.] Penn State Univ, University Pk, PA 16802 USA; [Pancholi, Sonal] Ft Belvoir Community Hosp, Ft Belvoir, VA USA	Lange, RT (corresponding author), Def & Vet Brain Injury Ctr, 11300 Rockville Pike,Suite 1100, Bethesda, MD 20852 USA.	rlange@dvbic.org	french, louis/AAB-2083-2020	french, louis/0000-0002-9451-0604; Merritt, Victoria/0000-0001-5683-4168; Iverson, Grant/0000-0001-7348-9570			BIGLER ED, 2005, TXB TRAUMATIC BRAIN, P79, DOI DOI 10.1007/S00417-005-0003-X; Bigler ED, 2007, BRAIN INJURY MED PRI, P201; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Borgaro SR, 2003, BRAIN INJURY, V17, P189, DOI 10.1080/0269905021000013183; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Conners K., 2002, CONNERS CONTINUOUS P; de Guise E, 2010, CLIN NEUROPSYCHOL, V24, P1113, DOI 10.1080/13854046.2010.506199; Delis DC, 2000, CALIFORNIA VERBAL LE; Department of Veterans Affairs and Department of Defense, 2009, VA DOD CLIN PRACT GU; FRENCH BN, 1977, SURG NEUROL, V7, P171; French LM, 2012, J HEAD TRAUMA REHAB, V27, P63, DOI 10.1097/HTR.0b013e3182248344; Goldstein FC, 2001, J INT NEUROPSYCH SOC, V7, P373, DOI 10.1017/S1355617701733115; Green P., 2003, GREENS WORD MEMORY T; Hanlon RE, 1999, BRAIN INJURY, V13, P873; Hartikainen KM, 2010, J CLIN EXP NEUROPSYC, V32, P767, DOI 10.1080/13803390903521000; Heaton RK, 2004, REVISED COMPREHENSIV; Hoffman SW, 2009, CLIN NEUROPSYCHOL, V23, P1400, DOI 10.1080/13854040903369433; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Iverson GL, 2000, BRAIN INJURY, V14, P1057; Iverson GL, 1999, CLIN NEUROPSYCHOL, V13, P437, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT437; Iverson GL, 2007, BRAIN INJURY MED PRI, P333; Iverson GL, 2006, BRAIN INJURY, V20, P1335, DOI 10.1080/02699050601082156; Iverson GL, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/415740; Iverson GL, 2011, LITTLE BLACK BOOK OF NEUROPSYCHOLOGY: A SYNDROME-BASED APPROACH, P697, DOI 10.1007/978-0-387-76978-3_22; JERET JS, 1993, NEUROSURGERY, V32, P9, DOI 10.1227/00006123-199301000-00002; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kennedy JE, 2010, NEUROREHABILITATION, V26, P191, DOI 10.3233/NRE-2010-0555; Kurca E, 2006, NEURORADIOLOGY, V48, P661, DOI 10.1007/s00234-006-0109-9; Lange RT, 2011, NATO SCI PEACE SEC, V86, P171, DOI 10.3233/978-1-60750-797-0-171; Lange RT, 2009, BRAIN INJURY, V23, P83, DOI 10.1080/02699050802635281; Lange RT, 2005, J CLIN EXP NEUROPSYC, V27, P897, DOI 10.1080/1380339049091290; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LIVINGSTON DH, 1991, J TRAUMA, V31, P483, DOI 10.1097/00005373-199104000-00006; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; Morey L. C., 1991, PERSONALITY ASSESSME; National Center for Injury Prevention and Control, 2003, C MILD TRAUM BRAIN I; Psychological Corporation, 2001, WECHSL TEST AD READ; Reitan R. M., 1992, TRAIL MAKING TEST MA; Sadowski-Cron C, 2006, BRAIN INJURY, V20, P1131, DOI 10.1080/02699050600832569; Suhr JA, 2005, J INT NEUROPSYCH SOC, V11, P23, DOI 10.1017/S1355617705050010; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P448, DOI 10.1076/jcen.24.4.448.1039; Tellier A, 1999, BRAIN INJURY, V13, P463; Temkin NR, 2003, J NEUROTRAUM, V20, P229, DOI 10.1089/089771503321532815; Thiruppathy SP, 2004, ACTA NEUROCHIR, V146, P1075, DOI 10.1007/s00701-004-0335-z; Thomas ML, 2009, CLIN NEUROPSYCHOL, V23, P1067, DOI 10.1080/13854040902795000; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 1997, WAIS 3 ADM SCORING M; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wilson J. T. L, 1996, RECOVERY TRAUMATIC B, P29	51	42	42	0	11	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	AUG	2012	27	5					480	494		10.1093/arclin/acs059			15	Psychology, Clinical; Psychology	Psychology	976UN	WOS:000306611300002	22766317	Bronze			2021-06-18	
J	Hoh, BL; Neal, DW; Kleinhenz, DT; Hoh, DJ; Mocco, J; Barker, FG				Hoh, Brian L.; Neal, Daniel W.; Kleinhenz, Dominic T.; Hoh, Daniel J.; Mocco, J.; Barker, Fred G., II			Higher Complications and No Improvement in Mortality in the ACGME Resident Duty-Hour Restriction Era: An Analysis of More Than 107000 Neurosurgical Trauma Patients in the Nationwide Inpatient Sample Database	NEUROSURGERY			English	Article						Complications; Medical errors; Mortality; Neurosurgery; Residency; Training; Trauma	STAFF WORKING HOURS; ACCREDITATION-COUNCIL; SLEEP-DEPRIVATION; INTERNAL-MEDICINE; SURGICAL RESIDENTS; HOURS REGULATIONS; IMPACT; CARE; EDUCATION; REFORM	BACKGROUND: The Accreditation Council for Graduate Medical Education resident duty-hour restrictions were implemented in July 2003 based on the supposition that resident fatigue contributes to medical errors. OBJECTIVE: To examine the effect of duty-hour restrictions on outcome in neurotrauma patients. METHODS: The Nationwide Inpatient Sample database was analyzed for a time period with no restrictions (years 1999-2002) compared with a period with restrictions (years 2005-2008) for (1) mortality and (2) complications. We analyzed both teaching and nonteaching hospitals to account for potential differences attributed to nonresident-related factors. RESULTS: There were 107 006 teaching hospital and 115 604 nonteaching hospital admissions for neurotrauma. Multivariate logistic regression demonstrated significantly more complications in the time period with restrictions in teaching hospitals. In nonteaching hospitals, there was no difference in complications. In both teaching and nonteaching hospitals, there was no difference in mortality between the 2 time periods. For teaching and nonteaching hospitals, there was no difference in hospital length of stay, but hospital charges were significantly higher in the period with restrictions. The occurrence of a complication was significantly associated with longer hospital length of stay and higher hospital charges in both time periods in both teaching and nonteaching hospitals. CONCLUSION: The implementation of the Accreditation Council for Graduate Medical Education resident duty-hour restrictions was associated with increased complications and no change in mortality for neurotrauma patients in teaching hospitals. In nonteaching hospitals, there was no change in complications and mortality. The occurrence of a complication was associated with longer length of stay and higher hospital charges in both time periods in both teaching and nonteaching hospitals.	[Hoh, Brian L.; Kleinhenz, Dominic T.; Hoh, Daniel J.; Mocco, J.] Univ Florida, Dept Neurosurg, Gainesville, FL 32610 USA; [Neal, Daniel W.] Univ Florida, Dept Biostat, Gainesville, FL 32610 USA; [Barker, Fred G., II] Massachusetts Gen Hosp, Neurosurg Serv, Boston, MA 02114 USA	Hoh, BL (corresponding author), Univ Florida, Dept Neurosurg, POB 100265, Gainesville, FL 32610 USA.	brian.hoh@neurosurgery.ufl.edu			Codman Neurovascular	Dr Mocco received an unrestricted educational grant from Codman Neurovascular and is a consultant to Actelion Pharmaceuticals, Nfocus, and Lazarus Effect. The other authors have no personal financial or institutional interest in any of the drugs, materials, or devices described in this article.	ACGME, 2003, REP ACGME WORK GROUP; Bailit JL, 2004, OBSTET GYNECOL, V103, P613, DOI 10.1097/01.AOG.0000119225.57285.c1; Basu CB, 2004, PLAST RECONSTR SURG, V114, P1878, DOI 10.1097/01.PRS.0000142768.07468.64; Browne JA, 2009, J BONE JOINT SURG AM, V91A, P2079, DOI 10.2106/JBJS.H.01240; Cohen-Gadol AA, 2005, NEUROSURGERY, V56, P398, DOI 10.1227/01.NEU.0000147999.64356.57; Damadi Amir, 2007, J Surg Educ, V64, P256, DOI 10.1016/j.jsurg.2007.07.008; Denisco R A, 1987, J Clin Monit, V3, P22, DOI 10.1007/BF00770879; Ellman PI, 2004, ANN THORAC SURG, V78, P906, DOI 10.1016/j.athoracsur.2004.04.006; Fletcher KE, 2005, JAMA-J AM MED ASSOC, V294, P1088, DOI 10.1001/jama.294.9.1088; Fletcher KE, 2004, ANN INTERN MED, V141, P851, DOI 10.7326/0003-4819-141-11-200412070-00009; Friedman WA, 2004, NEUROSURGERY, V54, P925, DOI 10.1227/01.NEU.0000115153.30283.F5; Gopaldas RR, 2009, J SURG RES, V157, P268, DOI 10.1016/j.jss.2009.03.042; Grady MS, 2009, J NEUROSURG, V110, P828, DOI 10.3171/2009.2.JNS081583; Horwitz LI, 2007, ANN INTERN MED, V147, P97, DOI 10.7326/0003-4819-147-2-200707170-00163; Horwitz LI, 2006, ARCH INTERN MED, V166, P1173, DOI 10.1001/archinte.166.11.1173; Howard DL, 2004, J GEN INTERN MED, V19, P1, DOI 10.1111/j.1525-1497.2004.30336.x; Hutter MM, 2006, ANN SURG, V243, P864, DOI 10.1097/01.sla.0000220042.48310.66; Irani JL, 2005, SURGERY, V138, P246, DOI 10.1016/j.surg.2005.06.010; JACQUES CHM, 1990, J FAM PRACTICE, V30, P223; Jagannathan J, 2009, J NEUROSURG, V110, P820, DOI 10.3171/2009.2.JNS081446; Kaafarani HMA, 2005, J SURG RES, V126, P167, DOI 10.1016/j.jss.2004.12.024; Kort KC, 2004, SURGERY, V136, P861, DOI 10.1016/j.surg.2004.07.005; LAINE C, 1993, JAMA-J AM MED ASSOC, V269, P374, DOI 10.1001/jama.269.3.374; Landrigan CP, 2008, PEDIATRICS, V122, P250, DOI 10.1542/peds.2007-2306; Landrigan CP, 2004, NEW ENGL J MED, V351, P1838, DOI 10.1056/NEJMoa041406; Lockley SW, 2004, NEW ENGL J MED, V351, P1829, DOI 10.1056/NEJMoa041404; Morrison CA, 2009, J SURG RES, V154, P157, DOI 10.1016/j.jss.2008.06.004; Mycyk MB, 2005, AM J HEALTH-SYST PH, V62, P1592, DOI 10.2146/ajhp040527; Myers JS, 2006, ACAD MED, V81, P1052, DOI 10.1097/01.ACM.0000246687.03462.59; PETERSEN LA, 1994, ANN INTERN MED, V121, P866, DOI 10.7326/0003-4819-121-11-199412010-00008; Poulose BK, 2005, ANN SURG, V241, P847, DOI 10.1097/01.sla.0000164075.18748.38; Prasad M, 2009, CRIT CARE MED, V37, P2564, DOI 10.1097/CCM.0b013e3181a93468; Privette AR, 2009, ANN SURG, V250, P316, DOI 10.1097/SLA.0b013e3181ae332a; Rosen AK, 2009, MED CARE, V47, P723, DOI 10.1097/MLR.0b013e31819a588f; SAMKOFF JS, 1991, ACAD MED, V66, P687, DOI 10.1097/00001888-199111000-00013; Schenarts P, 2005, AM J SURG, V190, P147, DOI 10.1016/j.amjsurg.2005.03.026; Shetty KD, 2007, ANN INTERN MED, V147, P73, DOI 10.7326/0003-4819-147-2-200707170-00161; Shonka DC, 2009, LARYNGOSCOPE, V119, P635, DOI 10.1002/lary.20144; Stamp Thomas, 2005, Curr Surg, V62, P117, DOI 10.1016/j.cursur.2004.09.013; Taffinder NJ, 1998, LANCET, V352, P1191, DOI 10.1016/S0140-6736(98)00034-8; Volpp KG, 2007, JAMA-J AM MED ASSOC, V298, P984, DOI 10.1001/jama.298.9.984; Volpp KG, 2007, JAMA-J AM MED ASSOC, V298, P975, DOI 10.1001/jama.298.9.975; Volpp KG, 2009, J GEN INTERN MED, V24, P1149, DOI 10.1007/s11606-009-1011-z; Watson JC, 2005, NEUROLOGY, V64, pE11, DOI 10.1212/01.WNL.0000152728.17155.41; Yaghoubian A, 2008, ARCH SURG-CHICAGO, V143, P847, DOI 10.1001/archsurg.143.9.847	45	42	42	1	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	JUN	2012	70	6					1369	1381		10.1227/NEU.0b013e3182486a75			13	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	946RV	WOS:000304372600020	22227483				2021-06-18	
J	Ponce, LL; Pillai, S; Cruz, J; Li, XQ; Julia, H; Gopinath, S; Robertson, CS				Ponce, Lucido L.; Pillai, Shibu; Cruz, Jovany; Li, Xiaoqi; Julia, H.; Gopinath, Shankar; Robertson, Claudia S.			Position of Probe Determines Prognostic Information of Brain Tissue PO2 in Severe Traumatic Brain Injury	NEUROSURGERY			English	Article						Brain tissue PO2; Head injury; PO2 monitoring; Traumatic brain injury	OXYGEN-TENSION; LICOX	BACKGROUND: Monitoring brain tissue PO2 (PbtO(2)) is part of multimodality monitoring of patients with traumatic brain injury (TBI). However, PbtO(2) measurement is a sampling of only a small area of tissue surrounding the sensor tip. OBJECTIVE: To examine the effect of catheter location on the relationship between PbtO(2) and neurological outcome. METHODS: A total of 405 patients who had PbtO(2) monitoring as part of standard management of severe traumatic brain injury were studied. The relationships between probe location and resulting PbtO(2) and outcome were examined. RESULTS: When the probe was located in normal brain, PbtO(2) averaged 30.8 +/- 18.2 compared with 25.6 +/- 14.8 mm Hg when placed in abnormal brain (P < .001). Factors related to neurological outcome in the best-fit logistic regression model were age, PbtO(2) probe position, postresuscitation motor Glasgow Coma Scale score, and PbtO(2) trend pattern. Although average PbtO(2) was significantly related to outcome in univariate analyses, it was not significant in the final logistic model. However, the interaction between PbtO(2) and probe position was statistically significant. When the PbtO(2) probe was placed in abnormal brain, the average PbtO(2) was higher in those with a favorable outcome, 28.8 +/- 12.0 mm Hg, compared with those with an unfavorable outcome, 19.5 +/- 13.7 mm Hg (P = .01). PbtO(2) and outcome were not related when the probe was placed in normal-appearing brain. CONCLUSION: These results suggest that the location of the PbtO(2) probe determines the PbtO2 values and the relationship of PbtO(2) to neurological outcome.	[Ponce, Lucido L.; Pillai, Shibu; Cruz, Jovany; Gopinath, Shankar; Robertson, Claudia S.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; [Li, Xiaoqi] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Julia, H.] Univ Houston, Houston, TX USA	Robertson, CS (corresponding author), Baylor Coll Med, Dept Neurosurg, 1 Baylor Plaza, Houston, TX 77030 USA.	claudiar@bcm.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P01-NS38660]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS038660] Funding Source: NIH RePORTER	This work was funded by National Institutes of Health grant P01-NS38660. The authors have no personal financial or institutional interest in any of the drugs, materials, or devices described in this article.	Bardt TF, 1998, ACT NEUR S, V71, P153; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS65; Bratton SL, 2007, J NEUROTRAUMA, V24, pS7; De Georgia MA, 2005, NEUROLOGIST, V11, P45, DOI 10.1097/01.nrl.0000149993.99956.09; Haitsma I, 2008, ACTA NEUROCHIR SUPPL, V102, P197, DOI 10.1007/978-3-211-85578-2_39; Hlatky R, 2004, J NEUROTRAUM, V21, P894, DOI 10.1089/0897715041526195; Kiening KL, 1998, ACT NEUR S, V71, P172; Longhi L, 2007, INTENS CARE MED, V33, P2136, DOI 10.1007/s00134-007-0845-2; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Martini RP, 2009, J NEUROSURG, V111, P644, DOI 10.3171/2009.2.JNS08998; Narotam PK, 2009, J NEUROSURG, V111, P672, DOI 10.3171/2009.4.JNS081150; Sarrafzadeh AS, 1998, ACT NEUR S, V71, P186; Spiotta AM, 2010, J NEUROSURG, V113, P571, DOI 10.3171/2010.1.JNS09506; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Timofeev I, 2011, J NEUROTRAUM, V28, P849, DOI 10.1089/neu.2010.1656; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; Wartenberg KE, 2007, CRIT CARE CLIN, V23, P507, DOI 10.1016/j.ccc.2007.06.002	18	42	42	0	2	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JUN	2012	70	6					1492	1502		10.1227/NEU.0b013e31824ce933			11	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	946RV	WOS:000304372600040	22289784	Green Accepted, Bronze			2021-06-18	
J	Kunio, NR; Differding, JA; Watson, KM; Stucke, RS; Schreiber, MA				Kunio, Nicholas R.; Differding, Jerome A.; Watson, Katherine M.; Stucke, Ryland S.; Schreiber, Martin A.			Thrombelastography-identified coagulopathy is associated with increased morbidity and mortality after traumatic brain injury	AMERICAN JOURNAL OF SURGERY			English	Article						Thrombelastography; Traumatic brain injury; Coagulopathy; Hypocoagulability	SEVERE HEAD-INJURY; INTRACEREBRAL HEMORRHAGE; PROGNOSIS; COAGULATION; THERAPY; DEATH	BACKGROUND: The purpose of this study was to determine the relationship between coagulopathy and outcome after traumatic brain injury. METHODS: Patients admitted with a traumatic brain injury were enrolled prospectively and admission blood samples were obtained for kaolin-activated thrombelastogram and standard coagulation assays. Demographic and clinical data were obtained for analysis. RESULTS: Sixty-nine patients were included in the analysis. A total of 8.7% of subjects showed hypocoagulability based on a prolonged time to clot formation (R time, > 9 min). The mortality rate was significantly higher in subjects with a prolonged R time at admission (50.0% vs 11.7%). Patients with a prolonged R time also had significantly fewer intensive care unit-free days (8 vs 27 d), hospital-free days (5 vs 24 d), and increased incidence of neurosurgical intervention (83.3% vs 34.9%). CONCLUSIONS: Hypocoagulability as shown by thrombelastography after traumatic brain injury is associated with worse outcomes and an increased incidence of neurosurgical intervention. (c) 2012 Elsevier Inc. All rights reserved.	[Kunio, Nicholas R.; Differding, Jerome A.; Watson, Katherine M.; Stucke, Ryland S.; Schreiber, Martin A.] Oregon Hlth & Sci Univ, Dept Surg, Portland, OR 97239 USA	Kunio, NR (corresponding author), Oregon Hlth & Sci Univ, Dept Surg, 3181 SW Sam Jackson Pk Rd,Mail Code L-223, Portland, OR 97239 USA.	kunion@ohsu.edu					Boto GR, 2006, J NEUROL NEUROSUR PS, V77, P1054, DOI 10.1136/jnnp.2005.087056; BRODERICK JP, 1993, STROKE, V24, P987, DOI 10.1161/01.STR.24.7.987; CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; Cohan MJ, 2007, J TRAUMA, V63, P1254, DOI 10.1097/TA.0b013e318156ee4c; COOPER PR, 1979, NEUROSURGERY, V5, P566, DOI 10.1227/00006123-197911000-00004; Gando S, 1999, J TRAUMA, V46, P1070, DOI 10.1097/00005373-199906000-00018; Hulka F, 1996, ARCH SURG-CHICAGO, V131, P923; Huttner HB, 2006, STROKE, V37, P1465, DOI 10.1161/01.STR.0000221786.81354.d6; Kaufmann CR, 1997, J TRAUMA, V42, P716, DOI 10.1097/00005373-199704000-00023; KOBAYASHI S, 1983, SURG NEUROL, V20, P25, DOI 10.1016/0090-3019(83)90101-5; Kothari U, 1996, STROKE, V27, P1304, DOI 10.1161/01.STR.27.8.1304; Lustenberger T, 2010, INJURY, V41, P924, DOI 10.1016/j.injury.2010.04.019; MCNICOL PL, 1994, ANAESTH INTENS CARE, V22, P659, DOI 10.1177/0310057X9402200603; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Scherer RU, 1998, CRIT CARE MED, V26, P149, DOI 10.1097/00003246-199801000-00031; SHACKFORD SR, 1993, ARCH SURG-CHICAGO, V128, P571, DOI 10.1001/archsurg.1993.01420170107016; SPIESS BD, 1995, J CARDIOTHOR VASC AN, V9, P168, DOI 10.1016/S1053-0770(05)80189-2; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; Stewart RM, 2003, J TRAUMA, V54, P66, DOI 10.1097/00005373-200301000-00009; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; Wafaisade A, 2010, NEUROCRIT CARE, V12, P211, DOI 10.1007/s12028-009-9281-1; Windelov NA, 2011, BLOOD COAGUL FIBRIN, V22, P416, DOI 10.1097/MBC.0b013e3283464f53; Zehtabchi S, 2008, RESUSCITATION, V76, P52, DOI 10.1016/j.resuscitation.2007.06.024	23	42	49	0	7	EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC	BRIDGEWATER	685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA	0002-9610	1879-1883		AM J SURG	Am. J. Surg.	MAY	2012	203	5					584	588		10.1016/j.amjsurg.2011.12.011			5	Surgery	Surgery	940ET	WOS:000303873500009	22425448				2021-06-18	
J	Sander, AM; Maestas, KL; Sherer, M; Malec, JF; Nakase-Richardson, R				Sander, Angelle M.; Maestas, Kacey Little; Sherer, Mark; Malec, James F.; Nakase-Richardson, Risa			Relationship of Caregiver and Family Functioning to Participation Outcomes After Postacute Rehabilitation for Traumatic Brain Injury: A Multicenter Investigation	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Caregivers; Rehabilitation; Treatment outcome	COMMUNITY INTEGRATION QUESTIONNAIRE; HEAD-INJURY; NEUROPSYCHOLOGICAL REHABILITATION; COGNITIVE REHABILITATION; COMMUNICATION ABILITIES; THERAPEUTIC ALLIANCE; SOCIAL INTEGRATION; ASSESSMENT DEVICE; FOLLOW-UP; VALIDITY	Sander AM, Maestas KL, Sherer M, Malec JF, Nakase-Richardson R. Relationship of caregiver and family functioning to participation outcomes after postacute rehabilitation for traumatic brain injury: a multicenter investigation. Arch Phys Med Rehabil 2012;93:842-8. Objective: To investigate the contribution of caregiver emotional functioning and family functioning to participation outcomes after postacute rehabilitation for traumatic brain injury (TBI). Design: Prospective cohort study. Setting: Three postacute comprehensive-integrated postacute rehabilitation programs associated with National Institute on Disability and Rehabilitation Research-funded TBI Model Systems Centers. Participants: Persons with medically documented TBI (N=136; 57% with severe TBI, 12% moderate, 31% mild), primarily men and 69% white. Interventions: Not applicable. Main Outcome Measures: Community Integration Questionnaire and Craig Handicap Assessment and Reporting Technique (CHART). Results: After accounting for age, education, sex, and race/ethnicity, there was a significant interaction between caregiver emotional functioning and time since injury for CHART Occupation and Social Integration Scale scores. Better emotional functioning in caregivers was associated with greater occupation and social integration outcomes for persons who entered the postacute rehabilitation program within 6 months of injury, but not for those >6 months postinjury. There was no relationship of family functioning to participation outcomes, and no interaction between family functioning and time since injury. Conclusions: Caregiver distress should be accounted for in studies investigating the effectiveness of postacute rehabilitation after TBI. Screening of caregivers early during postacute rehabilitation can target those who need assistance to improve their support of the person with TBI.	[Sander, Angelle M.; Maestas, Kacey Little; Sherer, Mark] TIRR Mem Hermann, Brain Injury Res Ctr, Houston, TX 77019 USA; [Sander, Angelle M.; Maestas, Kacey Little; Sherer, Mark] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Malec, James F.] Indiana Univ Sch Med, Dept Phys Med & Rehabil, Indianapolis, IN USA; [Malec, James F.] Rehabil Hosp Indiana, Indianapolis, IN USA; [Nakase-Richardson, Risa] James A Haley Vet Affairs Hosp, Tampa, FL USA; [Nakase-Richardson, Risa] Univ S Florida, Tampa, FL USA	Sander, AM (corresponding author), TIRR Mem Hermann, Brain Injury Res Ctr, 2323 S Shepherd Dr,Ste 907, Houston, TX 77019 USA.	asander@bcm.edu			National Institute on Disability and Rehabilitation Research, U.S. Department of EducationUS Department of Education [H133A70015, H133 B090023, H133A070043, H133P080007]	Supported in part by grants from the National Institute on Disability and Rehabilitation Research, U.S. Department of Education (grant nos. H133A70015, H133 B090023, H133A070043, H133P080007).	Anderson MI, 2002, BRAIN INJURY, V16, P743, DOI 10.1080/02699050210128906; BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P35, DOI DOI 10.1097/00001199-198703000-00007; Bier N, 2009, J HEAD TRAUMA REHAB, V24, P187, DOI 10.1097/HTR.0b013e3181a0b15a; Cantagallo A, 2000, EUROPA MED PHYS, V36, P171; Cicerone KD, 2004, ARCH PHYS MED REHAB, V85, P943, DOI 10.1016/j.apmr.2003.07.019; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; Cohen J., 2003, APPL MULTIPLE CORREL; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Derogatis L, 1993, BRIEF SYMPTOM INVENT; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; Evans CC, 2008, J HEAD TRAUMA REHAB, V23, P329, DOI 10.1097/01.HTR.0000336845.06704.bc; Goranson TE, 2003, BRAIN INJURY, V17, P759, DOI 10.1080/0269905031000088513; High WM, 2006, ARCH PHYS MED REHAB, V87, P334, DOI 10.1016/j.apmr.2005.11.028; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; KAPLAN SP, 1990, REHABIL COUNS BULL, V34, P16; Kersel DA, 2001, BRAIN INJURY, V15, P683, DOI 10.1080/02699050010013662; Klonoff PS, 2001, BRAIN INJURY, V15, P413, DOI 10.1080/02699050010005968; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Lefebvre H, 2008, BRAIN INJURY, V22, P535, DOI 10.1080/02699050802158243; Malec JF, 1996, ARCH PHYS MED REHAB, V77, P198, DOI 10.1016/S0003-9993(96)90168-9; Menard S., 1995, APPL LOGISTIC REGRES; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Myers R., 1990, CLASSICAL MODERN REG; PETERS L C, 1990, Brain Injury, V4, P39, DOI 10.3109/02699059009026147; Pledger C, 2003, AM PSYCHOL, V58, P279, DOI 10.1037/0003-066X.58.4.279; Ponsford J, 2010, J INT NEUROPSYCH SOC, V16, P306, DOI 10.1017/S1355617709991342; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; Prigatano G. P., 1994, J HEAD TRAUMA REHAB, V9, P91, DOI [DOI 10.1097/00001199-199403000-00011, 10.1097/00001199-199403000-00011]; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; Sady MD, 2010, ARCH PHYS MED REHAB, V91, P1542, DOI 10.1016/j.apmr.2010.07.012; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; Sander AM, 2003, ARCH PHYS MED REHAB, V84, P197, DOI 10.1053/apmr.2003.50105; Sander AM, 2002, BRAIN INJURY, V16, P649, DOI 10.1080/02699050210128889; Sander AM, 2001, J HEAD TRAUMA REHAB, V16, P356, DOI 10.1097/00001199-200108000-00006; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; Sander AM, 2009, NEUROREHABILITATION, V24, P15, DOI 10.3233/NRE-2009-0450; Sarajuuri JM, 2005, ARCH PHYS MED REHAB, V86, P2296, DOI 10.1016/j.apmr.2005.06.018; Sherer M, 2007, BRAIN INJURY, V21, P663, DOI 10.1080/02699050701481589; Struchen MA, 2011, J HEAD TRAUMA REHAB, V26, P30, DOI 10.1097/HTR.0b013e3182048f7c; Struchen MA, 2008, BRAIN INJURY, V22, P940, DOI 10.1080/02699050802425410; Svendsen HA, 2006, BRAIN INJURY, V20, P1295, DOI 10.1080/02699050601082123; Tabachnick BG, 2007, USING MULTIVARIATE S; TEASDALE G, 1974, LANCET, V2, P81; Temkin NR, 2009, J HEAD TRAUMA REHAB, V24, P460, DOI 10.1097/HTR.0b013e3181c13413; US Department of Education Office of Special Education and Rehabilitative Services National Institute on Disability and Rehabilitation Research, 2000, LONG RANG PLAN 1999; Uysal S, 1998, J HEAD TRAUMA REHAB, V13, P57, DOI 10.1097/00001199-199812000-00007; Vangel SJ, 2011, J HEAD TRAUMA REHAB, V26, P20, DOI 10.1097/HTR.0b013e318204a70d; West M., 1990, SUPPORTED EMPLOYMENT; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009; World Health Organization, 1980, INT CLASS IMP DIS HA; World Health Organization, 2001, INT CLASS FUNCT DIS; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617	61	42	43	1	24	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	2012	93	5					842	848		10.1016/j.apmr.2011.11.031			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	939DV	WOS:000303788500016	22417896				2021-06-18	
J	Kourbeti, IS; Vakis, AF; Papadakis, JA; Karabetsos, DA; Bertsias, G; Filippou, M; Ioannou, A; Neophytou, C; Anastasaki, M; Samonis, G				Kourbeti, I. S.; Vakis, A. F.; Papadakis, J. A.; Karabetsos, D. A.; Bertsias, G.; Filippou, M.; Ioannou, A.; Neophytou, C.; Anastasaki, M.; Samonis, G.			Infections in traumatic brain injury patients	CLINICAL MICROBIOLOGY AND INFECTION			English	Article						Head injury; infections; meningitis; trauma	VENTRICULOSTOMY-RELATED INFECTIONS; VENTILATOR-ASSOCIATED PNEUMONIA; RISK-FACTORS; SITE INFECTIONS; MENINGITIS; SURVEILLANCE; CRANIOTOMY; MANAGEMENT; CRITERIA; ADULT	Traumatic brain injury (TBI) victims are considered to be at high risk for infection. The purpose of this cohort study was to delineate the rates, types and risk factors for infection in TBI patients. Retrospective surveillance of infections was conducted for all TBI patients, aged =18 years, cared for at the Department of Neurosurgery of the University Hospital of Heraklion, Greece, between 1999 and 2005. A total of 760 patients (75% men) with a median age of 41 years were included. Most (59%) were injured in a motor vehicle accident. One third of them underwent a surgical procedure. Two hundred and fourteen infections were observed. The majority were infections of the lower respiratory tract (47%), followed by surgical site infections (SSI) (17%). Multivariate analysis showed that SSI development was independently associated with the performance of =2 surgical procedures (OR 16.7), presence of concomitant infections, namely VAP (OR 5.7) and UTI (OR 8.8), insertion of lumbar (OR 34.5) and ventricular drains (OR 4.0), and cerebrospinal fluid (CSF) leak (OR 3.8). Development of meningitis was associated with prolonged hospitalization (OR 1.02), especially >7 days ICU stay (OR 25.5), and insertion of lumbar (OR 297) and ventricular drains (OR 9.1). There was a notable predominance of Acinetobacter spp. as a VAP pathogen; gram-positive organisms remained the most prevalent in SSI cases. Respiratory tract infections were the most common among TBI patients. Device-related communication of the CSF with the environment and prolonged hospitalization, especially in the ICU setting, were independent risk factors for SSIs and meningitis cases.	[Kourbeti, I. S.; Papadakis, J. A.; Bertsias, G.; Samonis, G.] Univ Hosp Heraklion, Dept Internal Med Infect Dis, Iraklion, Greece; [Kourbeti, I. S.; Bertsias, G.; Ioannou, A.; Samonis, G.] Univ Crete, Sch Med, Grad Programme, Iraklion, Greece; [Vakis, A. F.; Karabetsos, D. A.; Filippou, M.; Ioannou, A.; Neophytou, C.] Univ Hosp Heraklion, Dept Neurosurg, Iraklion, Greece; [Anastasaki, M.] Univ Hosp Heraklion, Intens Care Unit, Iraklion, Greece	Kourbeti, IS (corresponding author), Community Hosp Chalkida, Dept Internal Med, 48 Gazepi St, Chalkida 34100, Greece.	irenekourbeti@hotmail.com	Karabetsos, Dimitris/AAA-2753-2021	Filippou-Frye, Maria/0000-0001-5516-0384; Karabetsos, Dimitris/0000-0003-1960-945X			Abadal-Centellas JM, 2007, J TRAUMA, V62, P282, DOI 10.1097/01.ta.0000199422.01949.78; BALTAS I, 1994, NEUROSURGERY, V35, P422, DOI 10.1227/00006123-199409000-00009; Boque M C, 2000, Semin Respir Infect, V15, P280; Bota DP, 2005, J NEUROSURG, V103, P468, DOI 10.3171/jns.2005.103.3.0468; BROWN EM, 1994, LANCET, V344, P1547; Coplin WM, 1999, J NEUROL NEUROSUR PS, V67, P468, DOI 10.1136/jnnp.67.4.468; Dziedzic T, 2004, CRIT CARE, V8, P266, DOI 10.1186/cc2828; Espinosa-Aguilar A, 2008, J TRAUMA, V64, P1327, DOI 10.1097/TA.0b013e3181469ebe; Harrison-Felix C, 2006, J HEAD TRAUMA REHAB, V21, P22, DOI 10.1097/00001199-200601000-00003; Hebb MO, 2007, CAN J SURG, V50, P187; Hoefnagel D, 2008, ACTA NEUROCHIR, V150, P209, DOI 10.1007/s00701-007-1458-9; Holloway KL, 1996, J NEUROSURG, V85, P419, DOI 10.3171/jns.1996.85.3.0419; Horan TC, 2008, AM J INFECT CONTROL, V36, P309, DOI 10.1016/j.ajic.2008.03.002; Kaufman B A, 1990, Infect Dis Clin North Am, V4, P677; Korinek AM, 1997, NEUROSURGERY, V41, P1073, DOI 10.1097/00006123-199711000-00010; Kourbeti IS, 2007, NEUROSURGERY, V60, P317, DOI 10.1227/01.NEU.0000249266.26322.25; Lozier AP, 2002, NEUROSURGERY, V51, P170, DOI 10.1097/00006123-200207000-00024; Lyke KE, 2001, CLIN INFECT DIS, V33, P2028, DOI 10.1086/324492; MAYHALL CG, 1984, NEW ENGL J MED, V310, P553, DOI 10.1056/NEJM198403013100903; MCRITCHIE DI, 1995, CLIN CHEST MED, V16, P135; MOLLMAN HD, 1986, J NEUROSURG, V64, P902, DOI 10.3171/jns.1986.64.6.0902; Papia G, 1999, J TRAUMA, V47, P923, DOI 10.1097/00005373-199911000-00018; PATIR R, 1992, ACTA NEUROCHIR, V119, P80, DOI 10.1007/BF01541786; Pelosi P, 2005, CURR OPIN CRIT CARE, V11, P37, DOI 10.1097/00075198-200502000-00006; Pelosi P, 2008, CHEST, V134, P101, DOI 10.1378/chest.07-2546; Reichert MCF, 2002, AM J INFECT CONTROL, V30, P158, DOI 10.1067/mic.2002.119925; RELLO J, 1992, CHEST, V102, P525, DOI 10.1378/chest.102.2.525; Roumbelaki M, 2008, AM J INFECT CONTROL, V36, P732, DOI 10.1016/j.ajic.2007.11.009; Zygun DA, 2006, NEUROCRIT CARE, V5, P108, DOI 10.1385/NCC:5:2:108	29	42	51	0	7	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1198-743X	1469-0691		CLIN MICROBIOL INFEC	Clin. Microbiol. Infect.	APR	2012	18	4					359	364		10.1111/j.1469-0691.2011.03625.x			6	Infectious Diseases; Microbiology	Infectious Diseases; Microbiology	910NJ	WOS:000301646100016	21851488	Bronze			2021-06-18	
J	Prevedello, LM; Raja, AS; Zane, RD; Sodickson, A; Lipsitz, S; Schneider, L; Hanson, R; Mukundan, S; Khorasani, R				Prevedello, Luciano M.; Raja, Ali S.; Zane, Richard D.; Sodickson, Aaron; Lipsitz, Stuart; Schneider, Louise; Hanson, Richard; Mukundan, Srinivasan; Khorasani, Ramin			Variation in Use of Head Computed Tomography by Emergency Physicians	AMERICAN JOURNAL OF MEDICINE			English	Article						Computed tomography; Emergency department; Head; Ordering; Variation	TRAUMATIC BRAIN-INJURY; SEVERITY INDEX; STROKE CARE; EXPERIENCE; DISPARITIES; RISK; PAIN	OBJECTIVE: Variation in emergency department head computed tomography (CT) use in patients with atraumatic headaches between hospitals is being measured nationwide. However, the magnitude of interphysician variation within a hospital is currently unknown. We hypothesized that there was significant variation in the rates of physician head CT use, both overall and for patients diagnosed with atraumatic headaches. METHODS: This cross-sectional study was conducted in the emergency department of a large urban academic hospital, and institutional review board approval was obtained. All emergency department visits from 2009 were analyzed, and the primary outcome measure was whether or not head CT was performed. Logistic regression was used to control for patient, physician, and visit characteristics potentially associated with head CT ordering. The degree of interphysician variability was tested, both before and after controlling for these variables. RESULTS: Of 55,286 emergency department patient encounters, 4919 (8.9%) involved head CT examinations. Unadjusted head CT ordering rates per physician ranged from 4.4% to 16.9% overall and from 15.2% to 61.7% in patients diagnosed with atraumatic headaches, with both rates varying significantly between physicians. Two-fold variation in head CT ordering overall (6.5%-13.5%) and approximately 3-fold variation in head CT ordering for atraumatic headaches (21.2%-60.1%) persisted even after controlling for pertinent variables. CONCLUSION: Emergency physicians vary significantly in their use of head CT both overall and in patients with atraumatic headaches. Further studies are needed to identify strategies to reduce interphysician variation in head CT use. (C) 2012 Elsevier Inc. All rights reserved. The American Journal of Medicine (2012) 125, 356-364	[Prevedello, Luciano M.; Sodickson, Aaron; Hanson, Richard; Mukundan, Srinivasan; Khorasani, Ramin] Brigham & Womens Hosp, Dept Radiol, Brookline, MA 02445 USA; [Raja, Ali S.; Zane, Richard D.; Schneider, Louise] Brigham & Womens Hosp, Dept Emergency Med, Brookline, MA 02445 USA; [Lipsitz, Stuart] Brigham & Womens Hosp, Ctr Surg & Publ Hlth, Brookline, MA 02445 USA; [Prevedello, Luciano M.; Raja, Ali S.; Zane, Richard D.; Sodickson, Aaron; Lipsitz, Stuart; Mukundan, Srinivasan; Khorasani, Ramin] Harvard Univ, Sch Med, Boston, MA USA; [Prevedello, Luciano M.; Raja, Ali S.; Zane, Richard D.; Sodickson, Aaron; Schneider, Louise; Hanson, Richard; Mukundan, Srinivasan; Khorasani, Ramin] Brigham & Womens Hosp, Ctr Evidence Based Imaging, Brookline, MA 02445 USA	Prevedello, LM (corresponding author), Brigham & Womens Hosp, Dept Radiol, 20 Kent St, Brookline, MA 02445 USA.	lprevedello@partners.org	Raja, Ali S./AAE-5103-2019; Khorasani, Ramin/AAM-8526-2021; Prevedello, Luciano/G-8650-2014	Prevedello, Luciano/0000-0002-6768-6452; Sodickson, Aaron/0000-0003-1275-681X	Marval Biosciences	Dr Sodickson is a consultant for Siemens and Toshiba CT. Dr Mukundan is the recipient of corporate-sponsored research grants on advanced visualization of CT scans and advanced magnetic resonance technique development, and a scientific consultant for Marval Biosciences (preclinical contrast agent). None of the other authors have any conflicts of interest associated with the work presented in this manuscript.	[Anonymous], QUALITYNET MEAS; Bhalla A, 2004, AGE AGEING, V33, P618, DOI 10.1093/ageing/afh219; Charlson ME, 2005, J GEN INTERN MED, V20, P497, DOI 10.1111/j.1525-1497.2005.0085.x; CHERKIN DC, 1994, ARTHRITIS RHEUM, V37, P15, DOI 10.1002/art.1780370104; Chisolm DJ, 2006, PEDIAT ALLERG IMM-UK, V17, P199, DOI 10.1111/j.1399-3038.2005.00362.x; Couchman GR, 2004, ACAD RADIOL, V11, P735, DOI 10.1016/j.acra.2004.03.050; DeLong ER, 1997, STAT MED, V16, P2645, DOI 10.1002/(SICI)1097-0258(19971215)16:23<2645::AID-SIM696>3.0.CO;2-D; Harris B, 2009, AM J EMERG MED, V27, P333, DOI 10.1016/j.ajem.2008.03.041; Iglehart JK, 2009, NEW ENGL J MED, V360, P1030, DOI 10.1056/NEJMhpr0808703; Kee YYK, 2009, POSTGRAD MED J, V85, P115, DOI 10.1136/pgmj.2008.070607; Khorasani R, 2001, RADIOGRAPHICS, V21, P1015, DOI 10.1148/radiographics.21.4.g01jl371015; Klassen TP, 2000, ACAD EMERG MED, V7, P739, DOI 10.1111/j.1553-2712.2000.tb02260.x; Mettler Fred A. Jr., 2000, Journal of Radiological Protection, V20, P353, DOI 10.1088/0952-4746/20/4/301; Pezzin LE, 2007, ACAD EMERG MED, V14, P149, DOI 10.1197/j.aem.2006.08.020; Raja AS, 2011, ARCH INTERN MED, V171, P260, DOI 10.1001/archinternmed.2010.520; Rosen MP, 1997, J GEN INTERN MED, V12, P407, DOI 10.1046/j.1525-1497.1997.00071.x; Rothschild J M, 2000, Diagn Imaging (San Franc), V22, P95; Rothschild JM, 2000, DIAGN IMAGING, V22, P101; Rothschild JM, 2000, DIAGNOSTIC IMAGING, V22, P99; Ryu WHA, 2009, CAN J NEUROL SCI, V36, P42, DOI 10.1017/S0317167100006296; Stiell IG, 1997, ANN EMERG MED, V30, P14, DOI 10.1016/S0196-0644(97)70104-5; Tanabe P, 2004, ACAD EMERG MED, V11, P59, DOI 10.1197/S1069-6563(03)00585-2; TANDBERG D, 1994, ANN EMERG MED, V23, P299, DOI 10.1016/S0196-0644(94)70044-3; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; van der Wulp I, 2009, EMERG MED J, V26, P506, DOI 10.1136/emj.2008.063768; van der Wulp I, 2010, EMERG MED J     1115; Verstappen WH, 2004, FAM PRACT, V21, P387, DOI 10.1093/fampra/cmh408; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690	28	42	42	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9343	1555-7162		AM J MED	Am. J. Med.	APR	2012	125	4					356	364		10.1016/j.amjmed.2011.06.023			9	Medicine, General & Internal	General & Internal Medicine	916RH	WOS:000302120400019	22325235				2021-06-18	
J	Heather, NL; Jefferies, C; Hofman, PL; Derraik, JGB; Brennan, C; Kelly, P; Hamill, JKM; Jones, RG; Rowe, DL; Cutfield, WS				Heather, Natasha L.; Jefferies, Craig; Hofman, Paul L.; Derraik, Jose G. B.; Brennan, Christine; Kelly, Patrick; Hamill, James K. M.; Jones, Rhys G.; Rowe, Deborah L.; Cutfield, Wayne S.			Permanent Hypopituitarism Is Rare after Structural Traumatic Brain Injury in Early Childhood	JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM			English	Article							ANEURYSMAL SUBARACHNOID HEMORRHAGE; GROWTH-HORMONE RESPONSE; BODY-MASS INDEX; PITUITARY-FUNCTION; YOUNG-CHILDREN; HEAD-INJURIES; COMA SCALE; CONSENSUS GUIDELINES; DYSFUNCTION; ADOLESCENTS	Background: Wesought to determine the incidence of permanent hypopituitarism in a potentially high-risk group: young children after structural traumatic brain injury (TBI). Methods: We conducted a cross-sectional study with longitudinal follow-up. Dynamic tests of pituitary function (GH and ACTH) were performed in all subjects and potential abnormalities critically evaluated. Puberty was clinically staged; baseline thyroid function, prolactin, IGF-I, serum sodium, and osmolality were compared with age-matched data. Diagnosis of GH deficiency was based on an integrated assessment of stimulated GH peak (<5 mu g/liter suggestive of deficiency), IGF-I, and growth pattern. ACTH deficiency was diagnosed based on a subnormal response to two serial Synacthen tests (peak cortisol <500 nmol/liter) and a metyrapone test. Results: We studied 198 survivors of structural TBI sustained in early childhood (112 male, age at injury 1.7 +/- 1.5 yr) 6.5 +/- 3.2 yr after injury. Sixty-four of the injuries (33%) were inflicted and 134 (68%) accidental. Two participants had developed precocious puberty, which is within the expected background population rate. Peak stimulated GH was subnormal in 16 participants (8%), in the context of normal IGF-I and normal growth. Stimulated peak cortisol was low in 17 (8%), but all had normal ACTH function on follow-up. One participant had a transient low serum T-4. Therefore, no cases of hypopituitarism were recorded. Conclusion: Permanenthypopituitarism is rare after both inflicted and accidental structural TBI in early childhood. Precocious puberty was the only pituitary hormone abnormality found, but the prevalence did not exceed that of the normal population. (J Clin Endocrinol Metab 97: 599-604, 2012)	[Heather, Natasha L.; Hofman, Paul L.; Derraik, Jose G. B.; Brennan, Christine; Rowe, Deborah L.; Cutfield, Wayne S.] Univ Auckland, Liggins Inst, Auckland, New Zealand; [Jones, Rhys G.] Univ Auckland, Fac Med & Hlth Sci, Sch Populat Hlth, Auckland 1020, New Zealand; Univ Auckland, Fac Med & Hlth Sci, Sch Nursing, Auckland 1020, New Zealand; [Jefferies, Craig; Kelly, Patrick; Hamill, James K. M.] Starship Childrens Hosp, Auckland Dist Hlth Board, Auckland 1142, New Zealand	Cutfield, WS (corresponding author), Univ Auckland, Liggins Inst, Private Bag 92019, Auckland, New Zealand.	w.cutfield@auckland.ac.nz	Heather, Natasha/AAV-8425-2020; Derraik, Jose Guilherme Behrensdorf/A-1925-2008	Derraik, Jose Guilherme Behrensdorf/0000-0003-1226-1956; Jefferies, Craig/0000-0002-0541-6094	Health Research Council of New ZealandHealth Research Council of New Zealand; Australasian Pediatric Endocrine Group; Starship Fellowship Foundation	The study was supported by grants from the Health Research Council of New Zealand and the Australasian Pediatric Endocrine Group. N.L.H. was supported by the Starship Fellowship Foundation.	Acerini CL, 2007, PITUITARY, V10, P373, DOI 10.1007/s11102-007-0052-8; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; *ASS ADV AUT MED, 2001, ABBR INJ SCAL; Barth JH, 2008, ANN CLIN BIOCHEM, V45, P598, DOI 10.1258/acb.2008.008074; Bechtel K, 2004, PEDIATRICS, V114, P165, DOI 10.1542/peds.114.1.165; Berneis K, 2002, J CLIN ENDOCR METAB, V87, P5470, DOI 10.1210/jc.2001-011959; Case ME, 2001, AM J FOREN MED PATH, V22, P112, DOI 10.1097/00000433-200106000-00002; COLE TJ, 1995, ARCH DIS CHILD, V73, P25, DOI 10.1136/adc.73.1.25; Dusick JR, 2008, PITUITARY       0515, DOI [10.1007/s11102-008-0130-6, DOI 10.1007/S11102-008-0130-6]; Einaudi S, 2006, J PEDIATR ENDOCR MET, V19, P691; Ghigo E, 2005, BRAIN INJURY, V19, P711, DOI 10.1080/02699050400025315; Ghigo E, 1996, J CLIN ENDOCR METAB, V81, P3323, DOI 10.1210/jc.81.9.3323; Gill MR, 2004, ANN EMERG MED, V43, P215, DOI 10.1016/S0196-0644(03)00814-X; Israel E, 2000, J CLIN ENDOCR METAB, V85, P3990; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Kaulfers AMD, 2010, J PEDIATR-US, V157, P894, DOI 10.1016/j.jpeds.2010.07.004; Kelly P, 2008, J PAEDIATR CHILD H, V44, P99, DOI 10.1111/j.1440-1754.2007.01234.x; Khadr SN, 2010, CLIN ENDOCRINOL, V73, P637, DOI 10.1111/j.1365-2265.2010.03857.x; Klose M, 2007, CLIN ENDOCRINOL, V67, P193, DOI 10.1111/j.1365-2265.2007.02860.x; Loche S, 2011, CLIN ENDOCRINOL, V74, P726, DOI 10.1111/j.1365-2265.2011.03988.x; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; McKinlay A, 2008, BRAIN INJURY, V22, P175, DOI 10.1080/02699050801888824; Moon RJ, 2010, J NEUROTRAUM, V27, P1827, DOI 10.1089/neu.2010.1408; Niederland T, 2007, J NEUROTRAUM, V24, P119, DOI 10.1089/neu.2005.369ER; Norwood KW, 2010, CLIN PEDIATR, V49, P1044, DOI 10.1177/0009922810376234; Poomthavorn P, 2008, ARCH DIS CHILD, V93, P133, DOI 10.1136/adc.2007.121137; Schneider HJ, 2011, J NEUROTRAUM, V28, P1693, DOI 10.1089/neu.2011.1887; Schneider HJ, 2007, JAMA-J AM MED ASSOC, V298, P1429, DOI 10.1001/jama.298.12.1429; SIMPSON DA, 1991, CHILD NERV SYST, V7, P183; TANNER JM, 1976, ARCH DIS CHILD, V51, P170, DOI 10.1136/adc.51.3.170; Tanriverdi F, 2008, CLIN ENDOCRINOL, V68, P573, DOI 10.1111/j.1365-2265.2007.03070.x; TASSONI P, 1990, J CLIN ENDOCR METAB, V71, P230, DOI 10.1210/jcem-71-1-230; TEASDALE G, 1974, LANCET, V2, P81; Teilmann G, 2005, PEDIATRICS, V116, P1323, DOI 10.1542/peds.2005-0012	35	42	44	0	4	ENDOCRINE SOC	CHEVY CHASE	8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA	0021-972X	1945-7197		J CLIN ENDOCR METAB	J. Clin. Endocrinol. Metab.	FEB	2012	97	2					599	604		10.1210/jc.2011-2284			6	Endocrinology & Metabolism	Endocrinology & Metabolism	904VP	WOS:000301226800057	22090267				2021-06-18	
J	Walter, KH; Kiefer, SL; Chard, KM				Walter, Kristen H.; Kiefer, Sarah L.; Chard, Kathleen M.			Relationship Between Posttraumatic Stress Disorder and Postconcussive Symptom Improvement After Completion of a Posttraumatic Stress Disorder/Traumatic Brain Injury Residential Treatment Program	REHABILITATION PSYCHOLOGY			English	Article						posttraumatic stress disorder; traumatic brain injury; postconcussive symptoms	MILITARY TBI; REHABILITATION; COMPLAINTS; VETERANS; IMPACT; PTSD	Objective: Research has demonstrated that veterans with a history of traumatic brain injury (TB!) may experience persistent symptoms following injury. These symptoms are frequently maintained or exacerbated by psychiatric symptoms, including posttraumatic stress disorder (PTSD). Studies suggest that decreasing PTSD symptoms may also reduce postconcussive symptoms. This study examined whether (a) PTSD and postconcussive symptoms decreased over the course of residential PTSD/TBI treatment and (b) a reduction in PTSD symptoms was associated with a reduction in postconcussive symptoms. Method: Twenty-eight veterans who met diagnostic criteria for PTSD and had a history of TBI were included in the study. Veterans received 8 weeks of treatment in a residential PTSD/TBI program and completed self-report measures of PTSD and postconcussive symptoms at pre- and posttreatment. Results: Results indicated that PTSD and postconcussive symptoms significantly decreased over the course of treatment. Furthermore, the decreases in PTSD and postconcussive symptoms were significantly positively related. Conclusions: The reduction in PTSD symptoms is positively associated with a reduction in postconcussive symptoms following residential treatment in a PTSD/TBI program. These findings suggest that PTSD and postconcussive symptoms are interdependent and mutually influence one another.	[Walter, Kristen H.; Chard, Kathleen M.] Cincinnati Vet Affairs Med Ctr, PTSD, Ft Thomas, KY 41075 USA; [Chard, Kathleen M.] Univ Cincinnati, Sch Med, Cincinnati, OH 45221 USA; [Walter, Kristen H.; Chard, Kathleen M.] Cincinnati Vet Affairs Med Ctr, Anxiety Disorders Div, Ft Thomas, KY 41075 USA	Chard, KM (corresponding author), Cincinnati Vet Affairs Med Ctr, PTSD, 1000 S Ft Thomas Ave, Ft Thomas, KY 41075 USA.	kathleen.chard@va.gov	Walter, Kristen H/S-1827-2019	Sautter, Frederic/0000-0001-6440-6358			ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Benge JF, 2009, REHABIL PSYCHOL, V54, P270, DOI 10.1037/a0016736; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Brenner LA, 2010, J HEAD TRAUMA REHAB, V25, P307, DOI 10.1097/HTR.0b013e3181cada03; Chard KM, 2011, J TRAUMA STRESS, V24, P347, DOI 10.1002/jts.20644; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Helmick K, 2010, NEUROREHABILITATION, V26, P239, DOI 10.3233/NRE-2010-0560; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Ivins BJ, 2003, J TRAUMA, V55, P617, DOI 10.1097/01.TA.0000052368.97573.D4; King NS, 2008, BRAIN INJURY, V22, P1, DOI 10.1080/02699050701829696; Lew HL, 2008, J REHABIL RES DEV, V45, pXI, DOI 10.1682/JRRD.2008.05.0064; Linehan MM., 1993, COGNITIVE BEHAV TREA; McCrea M, 2008, CLIN NEUROPSYCHOL, V22, P10, DOI 10.1080/13854040701760981; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Resick P. A, 2007, COGNITIVE PROCESSING; Resick PA, 2002, J CONSULT CLIN PSYCH, V70, P867, DOI 10.1037//0022-006X.70.4.867; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Twamley E. W., 2008, COGNITIVE SYMP UNPUB; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Weathers F. W., 1993, 9 ANN M INT SOC TRAU; Weathers FW, 1991, PCL S DSM 4	31	42	42	0	4	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550	1939-1544		REHABIL PSYCHOL	Rehabil. Psychol.	FEB	2012	57	1					13	17		10.1037/a0026254			5	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	901JX	WOS:000300964300003	22121935				2021-06-18	
J	de Sousa, A; McDonald, S; Rushby, J				de Sousa, Arielle; McDonald, Skye; Rushby, Jacqueline			Changes in emotional empathy, affective responsivity, and behavior following severe traumatic brain injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Emotional empathy; Emotional contagion; Emotional responsivity; Loss of emotional control; Loss of drive	ANXIETY STRESS SCALES; BLUNT HEAD-INJURY; CONSECUTIVE SERIES; FACIAL EXPRESSION; MIMICRY REACTIONS; SEX-DIFFERENCES; STATES; RECOGNITION; DYSFUNCTION; IMPAIRMENT	This study was designed to examine the relationship between deficits in empathy, emotional responsivity, and social behavior in adults with severe traumatic brain injury (TBI). A total of 21 patients with severe TBI and 25 control participants viewed six film clips containing pleasant, unpleasant, and neutral content whilst facial muscle responses, skin conductance, and valence and arousal ratings were measured. Emotional empathy (the Balanced Emotional Empathy Scale, BEES: self-report) and changes in drive and control in social situations (The Current Behaviour Scale, CBS: relative report) were also assessed. In comparison to control participants, those in the TBI group reported less ability to empathize emotionally and had reduced facial responding to both pleasant and unpleasant films. They also exhibited lowered autonomic arousal, as well as abnormal ratings of valence and arousal, particularly to unpleasant films. Relative reported loss of emotional control was significantly associated with heightened empathy, while there was a trend to suggest that impaired drive (or motivation) may be related to lower levels of emotional empathy. The results represent the first to suggest that level of emotional empathy post traumatic brain injury may be associated with behavioral manifestations of disorders of drive and control.	[de Sousa, Arielle; McDonald, Skye; Rushby, Jacqueline] Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia	de Sousa, A (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.	aydesous@bigpond.net.au	Rushby, Jacqueline/D-1820-2010; McDonald, Skye/G-4118-2014	Rushby, Jacqueline/0000-0002-5018-638X; McDonald, Skye/0000-0003-0723-6094			[Anonymous], 1996, BRIT MED J, V313, P1448; Antony MM, 1998, PSYCHOL ASSESSMENT, V10, P176, DOI 10.1037/1040-3590.10.2.176; Birkin J., 1992, MERRY CHRISTMAS BEAN; Blair RJR, 2005, CONSCIOUS COGN, V14, P698, DOI 10.1016/j.concog.2005.06.004; Blair RJR, 2000, BRAIN, V123, P1122, DOI 10.1093/brain/123.6.1122; Bradley MM, 2001, EMOTION, V1, P300, DOI 10.1037//1528-3542.1.3.300; Bruggemann JM, 2002, PERS INDIV DIFFER, V32, P1029, DOI 10.1016/S0191-8869(01)00108-8; Codispoti M, 2008, INT J PSYCHOPHYSIOL, V69, P90, DOI 10.1016/j.ijpsycho.2008.03.004; Croker V, 2005, BRAIN INJURY, V19, P787, DOI 10.1080/02699050500110033; Darwin C., 1872, EXPRESSION EMOTION M; de Sousa A, 2011, CORTEX, V47, P526, DOI 10.1016/j.cortex.2010.02.004; de Sousa A, 2010, NEUROPSYCHOLOGIA, V48, P3585, DOI 10.1016/j.neuropsychologia.2010.08.008; Decety Jean, 2004, Behav Cogn Neurosci Rev, V3, P71, DOI 10.1177/1534582304267187; DEVLIN D, 1980, MY BODYGUARD MOTION; DIMBERG U, 1982, PSYCHOPHYSIOLOGY, V19, P643, DOI 10.1111/j.1469-8986.1982.tb02516.x; Doherty RW, 1997, J NONVERBAL BEHAV, V21, P131, DOI 10.1023/A:1024956003661; ELSASS L, 1987, PSYCHOL MED, V17, P67, DOI 10.1017/S003329170001299X; Elsass L, 1989, P 14 ANN BRAIN IMP C, P124; Eslinger PJ, 2002, CURR OPIN NEUROL, V15, P91, DOI 10.1097/00019052-200202000-00014; ESLINGER PJ, 1996, J INT NEUROPSYCH SOC, V2, P15; Forster KI, 2003, BEHAV RES METH INS C, V35, P116, DOI 10.3758/BF03195503; FRIDLUND AJ, 1986, PSYCHOPHYSIOLOGY, V23, P567, DOI 10.1111/j.1469-8986.1986.tb00676.x; Gard MG, 2007, EMOTION, V7, P429, DOI 10.1037/1528-3542.7.2.429; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GERRARDSHESSE A, 1994, BRIT J PSYCHOL, V85, P55, DOI 10.1111/j.2044-8295.1994.tb02508.x; Gomez P, 2005, BIOL PSYCHOL, V68, P223, DOI 10.1016/j.biopsycho.2004.06.003; Grattan LM, 1989, NEUROPSYCHOLOGY, V3, P175, DOI 10.1037//0894-4105.3.3.175; GROSS JJ, 1995, COGNITION EMOTION, V9, P87, DOI 10.1080/02699939508408966; Hatfield E., 1994, EMOTION CONTAGION; Henry JD, 2005, BRIT J CLIN PSYCHOL, V44, P227, DOI 10.1348/014466505X29657; Hopkins MJ, 2002, BRAIN INJURY, V16, P245, DOI 10.1080/02699050110103346; HSEE CK, 1990, COGNITION EMOTION, V4, P327, DOI 10.1080/02699939008408081; HUBERT W, 1991, INT J PSYCHOPHYSIOL, V11, P131, DOI 10.1016/0167-8760(91)90005-I; JACKSON HF, 1987, CORTEX, V23, P293, DOI 10.1016/S0010-9452(87)80039-4; JENNETT B, 1976, J NEUROL NEUROSUR PS, V39, P647, DOI 10.1136/jnnp.39.7.647; Kemp D., 2008, EXTREME ALASKA DENAL; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; KINSELLA G, 1991, J NEUROL NEUROSUR PS, V54, P422, DOI 10.1136/jnnp.54.5.422; Lamm C, 2007, J COGNITIVE NEUROSCI, V19, P42, DOI 10.1162/jocn.2007.19.1.42; Lang P.J., 1980, TECHNOLOGY MENTAL HL, P119; Lang P.J., 1999, A4 U FLOR CTR RES PS; LOVIBOND PF, 1995, BEHAV RES THER, V33, P335, DOI 10.1016/0005-7967(94)00075-U; McDonald S., 1999, J HEAD TRAUMA REHAB, V16, P612; McDonald S, 2010, J CLIN EXP NEUROPSYC, V32, P855, DOI 10.1080/13803391003596405; McHugo G. J., 1982, MOTIVATION EMOTION, V6, P365, DOI DOI 10.1007/BF00998191; Mehrabian A., 2000, MANUAL BALANCED EMOT; Nakase-Richardson R, 2011, J NEUROL NEUROSUR PS, V82, P494, DOI 10.1136/jnnp.2010.222489; NEWTON A, 1985, BRIT J CLIN PSYCHOL, V24, P225, DOI 10.1111/j.2044-8260.1985.tb00655.x; OBRIEN RG, 1985, PSYCHOL BULL, V97, P316, DOI 10.1037/0033-2909.97.2.316; Pandya D. N., 1987, FRONTAL LOBES REVISI, P41; PHILIPPOT P, 1993, COGNITION EMOTION, V7, P171, DOI 10.1080/02699939308409183; Reiner R., 1989, HARRY MET SALLY MOTI; Reitan R. M, 1992, TRAIL MAKING TEST; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P16, DOI DOI 10.1001/ARCHNEUR.1961.00450130006002; Sanchez-Navarro JP, 2005, BEHAV NEUROSCI, V119, P87, DOI 10.1037/0735-7044.119.1.87; Saunders JC, 2006, NEUROPSYCHOLOGY, V20, P224, DOI 10.1037/0894-4105.20.2.224; Shallice, 1997, HAYLING BRIXTON TEST; Shamay-Tsoory SG, 2004, J CLIN EXP NEUROPSYC, V26, P1113, DOI 10.1080/13803390490515531; Shamay-Tsoory SG, 2009, BRAIN, V132, P617, DOI 10.1093/brain/awn279; Siegel S., 1956, NONPARAMETRIC STAT B; Sonnby-Borgstrom M, 2002, SCAND J PSYCHOL, V43, P433, DOI 10.1111/1467-9450.00312; Sonnby-Borgstrom M, 2003, J NONVERBAL BEHAV, V27, P3, DOI 10.1023/A:1023608506243; SPENCER N, 1987, CRY FREEDOM MOTION P; STUSS DT, 1992, J CONSULT CLIN PSYCH, V60, P349, DOI 10.1037/0022-006X.60.3.349; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; TATE RL, 1989, ACTA NEUROL SCAND, V79, P97, DOI 10.1111/j.1600-0404.1989.tb03719.x; Tate RL, 1999, CORTEX, V35, P39, DOI 10.1016/S0010-9452(08)70784-6; Wechsler D., 2001, WECHSLER TEST ADULT; Westermann R, 1996, EUR J SOC PSYCHOL, V26, P557, DOI 10.1002/(SICI)1099-0992(199607)26:4<557::AID-EJSP769>3.0.CO;2-4; Williams C, 2010, J CLIN EXP NEUROPSYC, V32, P259, DOI 10.1080/13803390902976940; Wood RL, 2008, J INT NEUROPSYCH SOC, V14, P289, DOI 10.1017/S1355617708080326	71	42	44	0	13	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2012	34	6					606	623		10.1080/13803395.2012.667067			18	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	970YM	WOS:000306168400006	22435955				2021-06-18	
J	Saltzherr, TP; Bakker, FC; Beenen, LFM; Dijkgraaf, MGW; Reitsma, JB; Goslings, JC				Saltzherr, T. P.; Bakker, F. C.; Beenen, L. F. M.; Dijkgraaf, M. G. W.; Reitsma, J. B.; Goslings, J. C.		REACT Study Grp	Randomized clinical trial comparing the effect of computed tomography in the trauma room versus the radiology department on injury outcomes	BRITISH JOURNAL OF SURGERY			English	Article; Proceedings Paper	11th European Congress of Trauma and Emergency Surgery of the European-Society-for-Trauma-and-Emergency-Surgery (ESTES)	MAY 15-18, 2010	Brussels, BELGIUM	European Soc Trauma & Emergency Surg (ESTES)			INTRAHOSPITAL TRANSPORT; MANAGEMENT	Background: Computed tomography (CT) of injured patients in the radiology department requires potentially dangerous and time-consuming patient transports and transfers. It was hypothesized that CT in the trauma room would improve patient outcome and workflow. Methods: A randomized trial compared the effect of locating a CT scanner in the trauma room versus the radiology department in two Dutch trauma hospitals. Injured patients aged at least 16 years were assigned randomly to one of these hospitals at the time of transport. The primary outcome measure was the number of non-institutionalized days within the first year after randomization. Subgroup analyses were performed in patients with multiple trauma or severe traumatic brain injury (TBI). Results: Some 1124 patients were included, of whom 1045 were available for analysis. The median number of non-institutionalized days was 360 days in the intervention group versus 362 days for the control group (P = 0.068). The time from arrival to the first CT imaging was 13 min shorter in the intervention group (36 versus 49 min; P < 0.001). Patient transfers and transports were reduced by more than half in the intervention group. For both multiple trauma (265 patients) and TBI (121) subgroups, differences in mortality and out-of-hospital days favoured the intervention group, but were not statistically significant. Conclusion: A CT scanner located in the trauma room reduces the time to acquire CT images and improves workflow, but does not lead to substantial improvements in clinical outcomes in a general trauma population. Observed beneficial effects on outcomes in patients with multiple trauma or severe TBI were not statistically significant. Registration number: ISRCTN55332315 (http://www.controlled-trials.com).	[Saltzherr, T. P.; Goslings, J. C.] Vrije Univ Amsterdam Med Ctr, Acad Med Ctr, Dept Surg, Trauma Unit, NL-1005 AZ Amsterdam, Netherlands; [Beenen, L. F. M.] Vrije Univ Amsterdam Med Ctr, Acad Med Ctr, Dept Radiol, NL-1005 AZ Amsterdam, Netherlands; [Dijkgraaf, M. G. W.; Reitsma, J. B.] Vrije Univ Amsterdam Med Ctr, Acad Med Ctr, Dept Clin Epidemiol Biostat & Bioinformat, NL-1005 AZ Amsterdam, Netherlands; [Bakker, F. C.] Vrije Univ Amsterdam Med Ctr, Dept Traumatol, NL-1005 AZ Amsterdam, Netherlands	Goslings, JC (corresponding author), Vrije Univ Amsterdam Med Ctr, Acad Med Ctr, Dept Surg, Trauma Unit, Meibergdreef 9, NL-1005 AZ Amsterdam, Netherlands.	j.c.goslings@amc.nl	Dijkgraaf, Marcel GW/G-6663-2011; Bossuyt, Patrick M./B-4557-2016; Beenen, Ludo F/AAA-3114-2021	Bossuyt, Patrick M./0000-0003-4427-0128; Beenen, Ludo F/0000-0001-9204-1026			Carpenter J, 2000, STAT MED, V19, P1141, DOI 10.1002/(SICI)1097-0258(20000515)19:9<1141::AID-SIM479>3.0.CO;2-F; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; Committee on Trauma American College of Surgeons, 2009, ADV TRAUM LIF SUPP A; CONSORT, CONSORT 2010 STAT; Exadaktylos AK, 2001, J TRAUMA, V51, P1173, DOI 10.1097/00005373-200112000-00025; Gaarder C, 2009, J TRAUMA, V67, P323, DOI 10.1097/TA.0b013e3181a4ed27; Gross T, 2010, BRIT J SURG, V97, P118, DOI 10.1002/bjs.6842; Hilbert P, 2007, INJURY, V38, P552, DOI 10.1016/j.injury.2006.12.023; Hoeymans N, 2005, QUAL LIFE RES, V14, P655, DOI 10.1007/s11136-004-1214-z; Holmes JF, 2005, J TRAUMA, V58, P902, DOI 10.1097/01.TA.0000162138.36519.2A; Jin PHPFK, 2008, J TRAUMA, V64, P1320, DOI 10.1097/TA.0b013e318059b9ae; Koerner M, 2008, RADIOGRAPHICS, V28, P225, DOI 10.1148/rg.281075047; Lee KL, 2009, INJURY, V40, P873, DOI 10.1016/j.injury.2008.12.001; Papson JPN, 2007, ACAD EMERG MED, V14, P574, DOI 10.1197/j.aem.2007.02.034; Saltzherr TP, 2008, INJURY, V39, P809, DOI 10.1016/j.injury.2008.01.010; Saltzherr TP, 2008, BMC EMERG MED, V8, DOI 10.1186/1471-227X-8-10; Waydhas C, 1999, CRIT CARE, V3, pR83, DOI 10.1186/cc362; Weninger P, 2007, J TRAUMA, V62, P584, DOI 10.1097/01.ta.0000221797.46249.ee	18	42	44	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0007-1323	1365-2168		BRIT J SURG	Br. J. Surg.	JAN	2012	99			1			105	113		10.1002/bjs.7705			9	Surgery	Surgery	930PG	WOS:000303151000017	22441863				2021-06-18	
J	Bruno, MA; Ledoux, D; Lambermont, B; Damas, F; Schnakers, C; Vanhaudenhuyse, A; Gosseries, O; Laureys, S				Bruno, Marie-Aurelie; Ledoux, Didier; Lambermont, Bernard; Damas, Francois; Schnakers, Caroline; Vanhaudenhuyse, Audrey; Gosseries, Olivia; Laureys, Steven			Comparison of the Full Outline of UnResponsiveness and Glasgow Liege Scale/Glasgow Coma Scale in an Intensive Care Unit Population	NEUROCRITICAL CARE			English	Article						Coma; Full Outline of UnResponsiveness; Glasgow Coma Scale; Glasgow Liege Scale; Vegetative state; Minimally conscious state; Neurological assessment; Intensive care	MINIMALLY CONSCIOUS STATE; TRAUMATIC BRAIN-INJURY; 4 SCORE; VEGETATIVE STATE; INTERRATER RELIABILITY; VALIDATION; PAIN; PREDICTION; PERCEPTION; ACTIVATION	The Full Outline of UnResponsiveness (FOUR) has been proposed as an alternative for the Glasgow Coma Scale (GCS)/Glasgow LiSge Scale (GLS) in the evaluation of consciousness in severely brain-damaged patients. We compared the FOUR and GLS/GCS in intensive care unit patients who were admitted in a comatose state. FOUR and GLS evaluations were performed in randomized order in 176 acutely (< 1 month) brain-damaged patients. GLS scores were transformed in GCS scores by removing the GLS brainstem component. Inter-rater agreement was assessed in 20% of the studied population (N = 35). A logistic regression analysis adjusted for age, and etiology was performed to assess the link between the studied scores and the outcome 3 months after injury (N = 136). GLS/GCS verbal component was scored 1 in 146 patients, among these 131 were intubated. We found that the inter-rater reliability was good for the FOUR score, the GLS/GCS. FOUR, GLS/GCS total scores predicted functional outcome with and without adjustment for age and etiology. 71 patients were considered as being in a vegetative/unresponsive state based on the GLS/GCS. The FOUR score identified 8 of these 71 patients as being minimally conscious given that these patients showed visual pursuit. The FOUR score is a valid tool with good inter-rater reliability that is comparable to the GLS/GCS in predicting outcome. It offers the advantage to be performable in intubated patients and to identify non-verbal signs of consciousness by assessing visual pursuit, and hence minimal signs of consciousness (11% in this study), not assessed by GLS/GCS scales.	[Bruno, Marie-Aurelie; Ledoux, Didier; Schnakers, Caroline; Vanhaudenhuyse, Audrey; Gosseries, Olivia; Laureys, Steven] Univ Liege, Coma Sci Grp, Cyclotron Res Ctr, B-4000 Liege, Belgium; [Bruno, Marie-Aurelie; Ledoux, Didier; Schnakers, Caroline; Vanhaudenhuyse, Audrey; Gosseries, Olivia; Laureys, Steven] Univ Liege, Dept Neurol, B-4000 Liege, Belgium; [Lambermont, Bernard] Univ Hosp Liege, Dept Intens Care, B-4000 Liege, Belgium; [Damas, Francois] Univ Liege, Dept Intens Care, Ctr Hosp Reg Citadelle, B-4000 Liege, Belgium	Laureys, S (corresponding author), Univ Liege, Coma Sci Grp, Cyclotron Res Ctr, Sart Tilman B30, B-4000 Liege, Belgium.	steven.laureys@ulg.ac.be	Laureys, Steven/AAN-2097-2021; Vanhaudenhuyse, Audrey/AAP-2455-2020; Laureys, Steven/A-3349-2011; Gosseries, Olivia/AAB-6469-2020	Laureys, Steven/0000-0002-3096-3807; Ledoux, Didier/0000-0002-9314-6564; Gosseries, Olivia/0000-0001-9011-7496			Akavipat P, 2009, NEUROL MED-CHIR, V49, P565, DOI 10.2176/nmc.49.565; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; BENZER A, 1991, LANCET, V338, P977, DOI 10.1016/0140-6736(91)91840-Q; Bernat JL, 2010, NEUROLOGY, V75, pS33, DOI 10.1212/WNL.0b013e3181fb35dd; Boly M, 2008, LANCET NEUROL, V7, P1013, DOI 10.1016/S1474-4422(08)70219-9; BORN JD, 1988, ACTA NEUROCHIR, V91, P1, DOI 10.1007/BF01400520; BORN JD, 1985, NEUROSURGERY, V16, P595, DOI 10.1227/00006123-198505000-00002; BORN JD, 1982, NEUROCHIRURGIE, V28, P1; Bruno MA, 2011, CURR OPIN CRIT CARE, V17, P146, DOI 10.1097/MCC.0b013e328343476d; Cohen J, 2009, J NEUROSCI NURS, V41, P261, DOI 10.1097/JNN.0b013e3181b2c766; Demertzi A, 2009, PROG BRAIN RES, V177, P329, DOI 10.1016/S0079-6123(09)17722-1; Eken C, 2009, EUR J EMERG MED, V16, P29, DOI 10.1097/MEJ.0b013e32830346ab; Fischer M, 2010, CRIT CARE, V14, DOI 10.1186/cc8963; Fugate JE, 2010, NEUROCRIT CARE, V13, P205, DOI 10.1007/s12028-010-9407-5; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Gill M, 2005, ANN EMERG MED, V45, P37, DOI 10.1016/j.annemergmed.2004.07.429; Gotoh O, 1996, NEUROSURGERY, V39, P19, DOI 10.1097/00006123-199607000-00005; Healey C, 2003, J TRAUMA, V54, P671, DOI 10.1097/01.TA.0000058130.30490.5D; Idrovo L, 2010, EUR NEUROL, V63, P364, DOI 10.1159/000292498; Iyer VN, 2009, MAYO CLIN PROC, V84, P694, DOI 10.1016/S0025-6196(11)60519-3; Jennett B, 2005, PROG BRAIN RES, V150, P537, DOI 10.1016/S0079-6123(05)50037-2; JENNETT B, 1972, LANCET, V1, P734; JENNETT B, 1975, LANCET, V1, P480; Laureys S, 2005, LANCET NEUROL, V4, P789, DOI 10.1016/S1474-4422(05)70230-1; Laureys S, 2005, PROG BRAIN RES, V150, P495, DOI 10.1016/S0079-6123(05)50034-7; Laureys S, 2007, CURR OPIN NEUROL, V20, P609, DOI 10.1097/WCO.0b013e3282f1d6dd; Laureys S, 2007, CONSCIOUS COGN, V16, P722, DOI 10.1016/j.concog.2007.04.004; Laureys S, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-68; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Rordorf G, 2000, CRIT CARE MED, V28, P1301, DOI 10.1097/00003246-200005000-00007; ROWLEY G, 1991, LANCET, V337, P535, DOI 10.1016/0140-6736(91)91309-I; Schiff ND, 2005, NEUROLOGY, V64, P514, DOI 10.1212/01.WNL.0000150883.10285.44; Schnakers C, 2007, CURR OPIN NEUROL, V20, P620, DOI 10.1097/WCO.0b013e3282f169d9; Schnakers C, 2010, EXPERT REV NEUROTHER, V10, P1725, DOI 10.1586/ERN.10.148; Schnakers C, 2010, PAIN, V148, P215, DOI 10.1016/j.pain.2009.09.028; Schnakers C, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-35; STARMARK JE, 1988, J NEUROSURG, V69, P699, DOI 10.3171/jns.1988.69.5.0699; Stead LG, 2009, NEUROCRIT CARE, V10, P50, DOI 10.1007/s12028-008-9145-0; Stocchetti N, 2008, INTENS CARE MED, V34, P1774, DOI 10.1007/s00134-008-1168-7; TEASDALE G, 1974, LANCET, V2, P81; Tien HC, 2006, J TRAUMA, V60, P274, DOI 10.1097/01.ta.0000197177.13379.f4; Wijdicks EFM, 2005, ANN NEUROL, V58, P585, DOI 10.1002/ana.20611; Wolf CA, 2007, MAYO CLIN PROC, V82, P435, DOI 10.4065/82.4.435	46	42	52	0	6	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	DEC	2011	15	3					447	453		10.1007/s12028-011-9547-2			7	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	852NT	WOS:000297365400014	21526394				2021-06-18	
J	Chen, SH; Chen, Y; Fang, WK; Huang, DW; Huang, KC; Tseng, SH				Chen, Shih-Han; Chen, Yun; Fang, Wen-Kuei; Huang, Da-Wei; Huang, Kuo-Chang; Tseng, Sheng-Hong			Comparison of Craniotomy and Decompressive Craniectomy in Severely Head-Injured Patients With Acute Subdural Hematoma	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Acute subdural hematoma; Complication; Craniotomy; Decompressive craniectomy; Outcome	TRAUMATIC BRAIN-INJURY; PROGNOSTIC-FACTORS; MANAGEMENT; MULTICENTER; LESIONS; COMA	Background: Decompressive craniectomy (DC) is helpful in lowering the intracranial pressure in patients with severe head injuries. However, it is still unclear which surgical approach (DC or craniotomy) is the optimal treatment strategy for severely head-injured patients with acute subdural hematoma (SDH). To clarify this point, we compared the outcomes and complications of the patients with acute SDH and low Glasgow Coma Scale (GCS) score treated with craniotomy or DC. Methods: We analyzed 102 patients with acute SDH and GCS scores of 4 to 8. Of them, 42 patients (41.2%) were treated with craniotomy and 60 (58.8%) treated with DC for evacuation of hematoma. The demographic and clinical data were analyzed including patient age, sex, injury mechanism, GCS score, pupil size and light reflex, time interval from injury to operation, types of surgical procedures, intracranial findings in pre- and postoperative computed tomography scan, intracranial pressure, complications, requirement of permanent cerebrospinal fluid diversion, and Glasgow Outcome Scale score after at least 1 year of follow-up. Results: The craniotomy and DC groups showed no difference in the demographic and clinical data. There was no difference in the outcomes and complication rates between these two groups except that the DC group had higher mortality than the craniotomy group (23.3% vs. 7.1%, p = 0.04). Conclusion: Both craniotomy and DC were feasible treatment strategies for acute SDH. The patients with acute SDH and low GCS score treated with craniotomy or DC showed no difference in the outcomes and complications.	[Tseng, Sheng-Hong] Natl Taiwan Univ Hosp, Dept Surg, Taipei 100, Taiwan; Natl Taiwan Univ, Coll Med, Taipei, Taiwan; [Chen, Shih-Han; Fang, Wen-Kuei; Huang, Da-Wei; Huang, Kuo-Chang] Chiayi Christian Hosp, Dept Surg, Chiayi, Taiwan; [Chen, Yun] Far Eastern Mem Hosp, Dept Surg, Taipei, Taiwan; [Chen, Yun] Yuan Ze Univ, Dept Chem Engn & Mat Sci, Tao Yuan, Taiwan	Tseng, SH (corresponding author), Natl Taiwan Univ Hosp, Dept Surg, 7 Chung Shan S Rd, Taipei 100, Taiwan.	tsh5110@ntu.edu.tw					Aarabi B, 2009, NEUROSURGERY, V64, P927, DOI 10.1227/01.NEU.0000341907.30831.D2; Akins PT, 2008, NEUROCRIT CARE, V9, P269, DOI 10.1007/s12028-007-9033-z; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; Bullock MR, 2006, NEUROSURGERY, V58, psi; Caroli M, 2001, SURG NEUROL, V56, P82, DOI 10.1016/S0090-3019(01)00540-7; Compagnone C, 2005, NEUROSURGERY, V57, P1183; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Coplin WM, 2001, J TRAUMA, V50, P1050, DOI 10.1097/00005373-200106000-00013; Honeybul S, 2011, J NEUROTRAUM, V28, P929, DOI 10.1089/neu.2010.1612; Hutchinson P J, 2004, Curr Opin Crit Care, V10, P101, DOI 10.1097/00075198-200404000-00004; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Jiang JY, 2005, J NEUROTRAUM, V22, P623, DOI 10.1089/neu.2005.22.623; Meier U, 2008, ACTA NEUROCHIR SUPPL, V102, P29, DOI 10.1007/978-3-211-85578-2_6; Morgalla MH, 2008, J NEUROSURG, V109, P685, DOI 10.3171/JNS/2008/109/10/0685; Paci GM, 2009, J TRAUMA, V67, P531, DOI 10.1097/TA.0b013e3181b840e8; Potts MB, 2008, ACTA NEUROCHIR SUPPL, V102, P109, DOI 10.1007/978-3-211-85578-2_22; Salvatore C, 2008, J NEUROSURG, V108, P74, DOI 10.3171/JNS/2008/108/01/0074; Schirmer CM, 2008, NEUROCRIT CARE, V8, P456, DOI 10.1007/s12028-008-9082-y; Stiver SI, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.4.FOCUS0965; TEASDALE G, 1974, LANCET, V2, P81; Timofeev I, 2008, J NEUROSURG, V108, P66, DOI 10.3171/JNS/2008/108/01/0066; Ucar T, 2005, J NEUROTRAUM, V22, P1311, DOI 10.1089/neu.2005.22.1311; Williams RF, 2009, J TRAUMA, V66, P1570, DOI 10.1097/TA.0b013e3181a594c4; Woertgen C, 2006, J CLIN NEUROSCI, V13, P718, DOI 10.1016/j.jocn.2005.08.019; Wong GKC, 2010, ACTA NEUROCHIR SUPPL, V106, P235, DOI 10.1007/978-3-211-98811-4_44	25	42	47	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	2011	71	6					1632	1636		10.1097/TA.0b013e3182367b3c			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	869RT	WOS:000298616400034	22027888				2021-06-18	
J	Garcia-Panach, J; Lull, N; Lull, JJ; Ferri, J; Martinez, C; Sopena, P; Robles, M; Chirivella, J; Noe, E				Garcia-Panach, Javier; Lull, Nuria; Jose Lull, Juan; Ferri, Joan; Martinez, Carlos; Sopena, Pablo; Robles, Montserrat; Chirivella, Javier; Noe, Enrique			A Voxel-Based Analysis of FDG-PET in Traumatic Brain Injury: Regional Metabolism and Relationship between the Thalamus and Cortical Areas	JOURNAL OF NEUROTRAUMA			English	Article						cerebral metabolism; consciousness; functional imaging; head injury; image analysis; positron emission tomography	DIFFUSE AXONAL INJURY; CEREBRAL GLUCOSE-METABOLISM; MINIMALLY CONSCIOUS STATES; VEGETATIVE STATE; POSTTRAUMATIC AMNESIA; DEFAULT MODE; HEAD-INJURY; RECOVERY; LESIONS; CONNECTIVITY	The objective was to study the correlations and the differences in glucose metabolism between the thalamus and cortical structures in a sample of severe traumatic brain injury (TBI) patients with different neurological outcomes. We studied 49 patients who had suffered a severe TBI and 10 healthy control subjects using 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET). The patients were divided into three groups: a vegetative or minimally-conscious state (MCS&VS) group (n=17), which included patients who were in a vegetative or a minimally conscious state; an In-post-traumatic amnesia (In-PTA) group (n=12), which included patients in PTA; and an Out-PTA group (n=20), which included patients who had recovered from PTA. SPM5 software was used to determine the metabolic differences between the groups. FDG-PET images were normalized and four regions of interest were generated around the thalamus, precuneus, and the frontal and temporal lobes. The groups were parameterized using Student's t-test. Principal component analysis was used to obtain an intensity-estimated-value per subject to correlate the function between the structures. Differences in glucose metabolism in all structures were related to the neurological outcome, and the most severe patients showed the most severe hypometabolism. We also found a significant correlation between the cortico-thalamocortical metabolism in all groups. Voxel-based analysis suggests a functional correlation between these four areas, and decreased metabolism was associated with less favorable outcomes. Higher levels of activation of the cortico-cortical connections appear to be related to better neurological condition. Differences in the thalamocortical correlations between patients and controls may be related to traumatic dysfunction due to focal or diffuse lesions.	[Garcia-Panach, Javier; Lull, Nuria; Jose Lull, Juan; Robles, Montserrat] Univ Politecn Valencia, Inst Aplicac Tecnol Informac & Comunicac Avanzada, Grp Informat Biomed, E-46071 Valencia, Spain; [Garcia-Panach, Javier; Ferri, Joan; Chirivella, Javier; Noe, Enrique] Fdn Hosp NISA, Serv Dano Cerebral Hosp NISA, Valencia, Spain; [Lull, Nuria] Univ CEU Cardenal Herrera, Valencia, Spain; [Martinez, Carlos; Sopena, Pablo] Hosp 9 Octubre, Serv PET Med Nucl, Valencia, Spain	Noe, E (corresponding author), Hosp NISA Valencia Mar, Serv Neurorehabil, C Rio Tajo 1, Valencia 46011, Spain.	enoe@comv.es	Sopena-Novales, Pablo/AAA-4427-2019; Lull, Juan Jose/AAB-5154-2019; Robles, Montserrat/A-6722-2016	Sopena-Novales, Pablo/0000-0002-0560-0051; Lull, Juan Jose/0000-0002-4399-950X; Noe Sebastian, Enrique/0000-0002-2547-8727; Robles, Montserrat/0000-0002-7705-1389	Official College of Physicians of Valladolid	A preliminary version of the manuscript presented here has obtained the 2nd award of IV Convocatoria de los Premios de Investigacion en Medicina del Colegio de Medicos de Valladolid (IV edition of the Medical Research Award of the Official College of Physicians of Valladolid).	Anderson CV, 1996, J NEUROTRAUM, V13, P35, DOI 10.1089/neu.1996.13.35; Ashburner J, 2000, NEUROIMAGE, V11, P805, DOI 10.1006/nimg.2000.0582; Bassett DS, 2009, CURR OPIN NEUROL, V22, P340, DOI 10.1097/WCO.0b013e32832d93dd; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bergsneider M, 2001, J HEAD TRAUMA REHAB, V16, P135, DOI 10.1097/00001199-200104000-00004; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; Boly M, 2008, ANN NY ACAD SCI, V1129, P119, DOI 10.1196/annals.1417.015; Cavanna AE, 2006, BRAIN, V129, P564, DOI 10.1093/brain/awl004; Cavanna AE, 2007, CNS SPECTRUMS, V12, P545, DOI 10.1017/S1092852900021295; Cruse D, 2010, CURR OPIN NEUROL, V23, P656, DOI 10.1097/WCO.0b013e32833fd4e7; EVANS AC, 1993, IEEE NUCL SCI S MED, P1813; Fernandez-Espejo D, 2010, J NEUROTRAUM, V27, P1187, DOI 10.1089/neu.2010.1297; Fransson P, 2008, NEUROIMAGE, V42, P1178, DOI 10.1016/j.neuroimage.2008.05.059; Fuster JM, 2006, INT J PSYCHOPHYSIOL, V60, P125, DOI 10.1016/j.ijpsycho.2005.12.015; Gennarelli T. A., 2005, TXB TRAUMATIC BRAIN, P27; Genovese CR, 2002, NEUROIMAGE, V15, P870, DOI 10.1006/nimg.2001.1037; Good CD, 2001, NEUROIMAGE, V14, P21, DOI 10.1006/nimg.2001.0786; Grados MA, 2001, J NEUROL NEUROSUR PS, V70, P350, DOI 10.1136/jnnp.70.3.350; Hattori N, 2003, J NUCL MED, V44, P1709; Kato T, 2007, J NEUROTRAUM, V24, P919, DOI 10.1089/neu.2006.0203; Kennedy MRT, 2008, NEUROPSYCHOL REHABIL, V18, P257, DOI 10.1080/09602010701748644; Laureys S, 2004, LANCET NEUROL, V3, P537, DOI 10.1016/S1474-4422(04)00852-X; Laureys S, 1999, NEUROIMAGE, V9, P377, DOI 10.1006/nimg.1998.0414; Laureys S, 1999, J NEUROL NEUROSUR PS, V67, P121, DOI 10.1136/jnnp.67.1.121; Laureys S, 2000, LANCET, V355, P1790, DOI 10.1016/S0140-6736(00)02271-6; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; Lull N, 2010, BRAIN INJURY, V24, P1098, DOI 10.3109/02699052.2010.494592; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Mitelman SA, 2006, BRAIN RES, V1114, P125, DOI 10.1016/j.brainres.2006.07.043; Nakashima T, 2007, AM J NEURORADIOL, V28, P236; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.080523; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Phillips CL, 2011, NEUROIMAGE, V56, P797, DOI 10.1016/j.neuroimage.2010.05.083; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Schiff ND, 2002, BRAIN, V125, P1210, DOI 10.1093/brain/awf131; Sporns O, 2006, P NATL ACAD SCI USA, V103, P19219, DOI 10.1073/pnas.0609523103; Tate RL, 2000, J NEUROL NEUROSUR PS, V68, P178, DOI 10.1136/jnnp.68.2.178; Tullberg M, 2004, NEUROLOGY, V63, P246, DOI 10.1212/01.WNL.0000130530.55104.B5; Turner-Stokes L, 2008, J REHABIL MED, V40, P691, DOI 10.2340/16501977-0265; WILSON JTL, 1994, J NEUROL NEUROSUR PS, V57, P198, DOI 10.1136/jnnp.57.2.198; WILSON JTL, 1995, J NEUROL NEUROSUR PS, V59, P328, DOI 10.1136/jnnp.59.3.328; Wu HM, 2004, J NEUROTRAUM, V21, P149, DOI 10.1089/089771504322778613; Zhang DY, 2008, J NEUROPHYSIOL, V100, P1740, DOI 10.1152/jn.90463.2008	43	42	43	0	9	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	SEP	2011	28	9					1707	1717		10.1089/neu.2011.1851			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	821AK	WOS:000294947000004	21770759	Green Published			2021-06-18	
J	Poljac, E; Montagne, B; de Haan, EHF				Poljac, Ervin; Montagne, Barbara; de Haan, Edward H. F.			Reduced recognition of fear and sadness in post-traumatic stress disorder	CORTEX			English	Article						Post-traumatic stress disorder, PTSD; Facial expression; Emotion recognition; Face perception	EVENT-RELATED POTENTIALS; FACIAL EXPRESSIONS; IMPAIRED RECOGNITION; HIPPOCAMPAL VOLUME; SEXUAL-ABUSE; BRAIN-INJURY; EMOTION; PERCEPTION; PTSD; DEPRESSION	Post-traumatic stress disorder (PTSD) is associated with impairments in emotional experience and expression. The current study examined the recognition of emotional facial expressions in PTSD patients and matched healthy controls, both in terms of accuracy and sensitivity. The task involved short video clips of a neutral face changing (morphing) into one of the six basic emotions (happiness, anger, fear, surprise, disgust and sadness). Clips differed in length, with short clips terminating at 20% of maximum emotional intensity, and the longest ones ending with a full-blown expression. We observed a specific impairment in the PTSD group for recognizing the emotions fear and sadness. This result was observed via a reduced accuracy and a decreased sensitivity for these emotions. We discuss the observed altered affective processing and its possible clinical implications. (C) 2010 Elsevier Srl. All rights reserved.	[Poljac, Ervin] Univ Leuven, Expt Psychol Lab, Louvain, Belgium; [Poljac, Ervin] Int Univ Sarajevo, Dept Psychol, Sarajevo, Bosnia & Herceg; [Montagne, Barbara] Radboud Univ Nijmegen, Med Ctr, Dept Psychiat, NL-6525 ED Nijmegen, Netherlands; [de Haan, Edward H. F.] Univ Amsterdam, Dept Psychol, NL-1012 WX Amsterdam, Netherlands	Poljac, E (corresponding author), Univ Leuven, Expt Psychol Lab, Tiensestr 102, Louvain, Belgium.	Ervin.Poljac@psy.kuleuven.be		de Haan, Edward/0000-0003-0312-3674			ADOLPHS R, 1994, NATURE, V372, P669, DOI 10.1038/372669a0; [Anonymous], 2000, DIAGNOSTIC STAT MANU; Avdibegovic E, 2008, PSYCHIAT DANUB, V20, P474; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BENSON PJ, 1991, IMAGE VISION COMPUT, V9, P123, DOI 10.1016/0262-8856(91)90022-H; Benton A. L., 1994, CONTRIBUTIONS NEUROP; Bowler RM, 1998, ARCH CLIN NEUROPSYCH, V13, P455, DOI 10.1016/S0887-6177(97)00092-9; Bremner JD, 2004, J NERV MENT DIS, V192, P643, DOI 10.1097/01.nmd.0000142027.52893.c8; Bremner JD, 1997, BIOL PSYCHIAT, V41, P23, DOI 10.1016/S0006-3223(96)00162-X; Bremner JD, 1999, BIOL PSYCHIAT, V45, P806, DOI 10.1016/S0006-3223(98)00297-2; Brewin CR, 2003, CLIN PSYCHOL REV, V23, P339, DOI 10.1016/S0272-7358(03)00033-3; Calder AJ, 2000, NAT NEUROSCI, V3, P1077, DOI 10.1038/80586; Calder AJ, 1996, VIS COGN, V3, P81, DOI 10.1080/713756735; Dalgleish T, 2004, PSYCHOL BULL, V130, P228, DOI 10.1037/0033-2909.130.2.228; DEHAAN EHF, 2002, ENCY HUMAN BRAIN, P67; DOLAN R, 2009, NEW OXFORD TXB PSYCH, P257; Ekman P, 1999, HDB COGNITION EMOTIO, DOI https://doi.org/10.1111%2F1467-9280.00147; Etkin A, 2007, AM J PSYCHIAT, V164, P1476, DOI 10.1176/appi.ajp.2007.07030504; FEINBERG TE, 1986, ARCH GEN PSYCHIAT, V43, P276; Felmingham KL, 2003, NEUROREPORT, V14, P777, DOI 10.1097/00001756-200304150-00024; Frewen PA, 2008, J TRAUMA STRESS, V21, P243, DOI 10.1002/jts.20320; Frewen PA, 2006, ANN NY ACAD SCI, V1071, P110, DOI 10.1196/annals.1364.010; Gilbertson MW, 2002, NAT NEUROSCI, V5, P1242, DOI 10.1038/nn958; Green REA, 2004, NEUROPSYCHOLOGIA, V42, P133, DOI 10.1016/j.neuropsychologia.2003.07.005; Hargrave R, 2002, J NEUROPSYCH CLIN N, V14, P64, DOI 10.1176/jnp.14.1.64; Kemp AH, 2007, PSYCHIAT RES-NEUROIM, V155, P265, DOI 10.1016/j.pscychresns.2007.01.010; Kemp AH, 2008, CNS SPECTRUMS, V13, P1066, DOI 10.1017/S1092852900017120; Lembke A, 2002, AM J PSYCHIAT, V159, P302, DOI 10.1176/appi.ajp.159.2.302; Liberzon I, 2006, ANN NY ACAD SCI, V1071, P87, DOI 10.1196/annals.1364.009; Mathersul D, 2009, J CLIN EXP NEUROPSYC, V31, P278, DOI 10.1080/13803390802043619; McClure EB, 2003, AM J PSYCHIAT, V160, P1172, DOI 10.1176/appi.ajp.160.6.1172; Montagne B, 2005, PERS INDIV DIFFER, V38, P5, DOI 10.1016/j.paid.2004.02.008; MONTAGNE B, 2005, J INT NEUROPSYCHO S2, V11; Montagne B, 2007, PERCEPT MOTOR SKILL, V104, P589, DOI 10.2466/PMS.104.2.589-598; Montagne Barbara, 2006, Cogn Neuropsychiatry, V11, P389, DOI 10.1080/13546800444000254; Montagne Barbara, 2005, Cogn Process, V6, P136, DOI 10.1007/s10339-005-0050-6; Montagne B, 2006, CORTEX, V42, P705, DOI 10.1016/S0010-9452(08)70408-8; Phan KL, 2002, NEUROIMAGE, V16, P331, DOI 10.1006/nimg.2002.1087; Phillips ML, 1999, PSYCHIAT RES-NEUROIM, V92, P11, DOI 10.1016/S0925-4927(99)00031-1; Rauch SL, 2006, BIOL PSYCHIAT, V60, P376, DOI 10.1016/j.biopsych.2006.06.004; Rauch SL, 2003, NEUROREPORT, V14, P913, DOI 10.1097/01.wnr.0000071767.24455.10; Reynolds M, 1999, BEHAV RES THER, V37, P201, DOI 10.1016/S0005-7967(98)00132-6; Shin LM, 2006, ANN NY ACAD SCI, V1071, P67, DOI 10.1196/annals.1364.007; SIFNEOS PE, 1973, PSYCHOTHER PSYCHOSOM, V22, P255, DOI 10.1159/000286529; SPEEDIE LJ, 1990, J NEUROL NEUROSUR PS, V53, P607, DOI 10.1136/jnnp.53.7.607; Stanford MS, 2001, PSYCHIAT RES, V102, P125, DOI 10.1016/S0165-1781(01)00236-0; Stephan BCM, 2006, J INT NEUROPSYCH SOC, V12, P884, DOI 10.1017/S1355617706061066; Taylor GJ, 2004, PSYCHOTHER PSYCHOSOM, V73, P68, DOI 10.1159/000075537; Vasterling JJ, 2002, NEUROPSYCHOLOGY, V16, P5, DOI 10.1037//0894-4105.16.1.5; Venn HR, 2006, INT J NEUROPSYCHOPH, V9, P229, DOI 10.1017/S1461145705006012; Venn HR, 2004, BIPOLAR DISORD, V6, P286, DOI 10.1111/j.1399-5618.2004.00121.x; Villarreal G, 2002, BIOL PSYCHIAT, V52, P119, DOI 10.1016/S0006-3223(02)01359-8; Williams LM, 2006, NEUROIMAGE, V29, P347, DOI 10.1016/j.neuroimage.2005.03.047; Woodward SH, 2006, BIOL PSYCHIAT, V59, P582, DOI 10.1016/j.biopsych.2005.07.033; Yehuda R, 2004, BIOL PSYCHIAT, V55, P291, DOI 10.1016/S0006-3223(03)00641-3	55	42	42	0	25	ELSEVIER MASSON	MILANO	VIA PALEOCAPA 7, 20121 MILANO, ITALY	0010-9452			CORTEX	Cortex	SEP	2011	47	8					974	980		10.1016/j.cortex.2010.10.002			7	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	797UJ	WOS:000293155300007	21075363				2021-06-18	
J	Shum, D; Levin, H; Chan, RCK				Shum, David; Levin, Harvey; Chan, Raymond C. K.			Prospective memory in patients with closed head injury: A review	NEUROPSYCHOLOGIA			English	Article						Traumatic brain injury; Closed head injury; Prospective memory	TRAUMATIC BRAIN-INJURY; SELF-AWARENESS; PERFORMANCE; MODERATE; ADULTS; EVENT; CHILDREN; COMPONENTS; RECOVERY; TASKS	This paper aimed to review the limited, but growing literature on prospective memory (PM) following closed head injury (CHI). Search of two commonly used databases yielded studies that could be classified as: self- or other-report of PM deficits; behavioral PM measures in adults with CHI, behavioral PM measures in children and adolescents with CHI, and treatment of PM in adults with CHI. The methodology and findings of these studies were critically reviewed and discussed. Because of the small number of studies, meta-analysis was only conducted for studies that used behavioral PM measures in adults to integrate findings. PM deficits were found to be commonly reported by patients with CHI and their significant others and they could be identified using behavioral measures in adults, children and adolescents with CHI. However, more work is needed to clarify the nature and mechanisms of these deficits. Although some promising results have been reported by studies that evaluated PM treatment, most studies lack tight experimental control and used only a small number of participants. The paper concluded with some suggestions for future research. (C) 2011 Elsevier Ltd. All rights reserved.	[Shum, David] Griffith Univ, Sch Psychol, Brisbane, Qld 4111, Australia; [Shum, David] Griffith Univ, Griffith Hlth Inst, Brisbane, Qld 4111, Australia; [Levin, Harvey] Univ Texas Houston Med Sch, Houston, TX USA; [Levin, Harvey] Baylor Coll Med, Houston, TX 77030 USA; [Chan, Raymond C. K.] Chinese Acad Sci, Inst Psychol, Beijing 100101, Peoples R China	Shum, D (corresponding author), Griffith Univ, Sch Psychol, Mt Gravatt Campus,176 Messines Ridge Rd, Mt Gravatt, Qld 4122, Australia.	d.shum@griffith.edu.au; rckchan@psych.ac.cn	Chan, Raymond CK/B-6717-2009; Shum, David/A-3914-2008	Chan, Raymond CK/0000-0002-3414-450X; Shum, David/0000-0002-4810-9262	Australian Academy of Science; Department of Veteran AffairsUS Department of Veterans Affairs; National Institute of Neurological Disorders And StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS056202]; Griffith UniversityGriffith University; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS056202] Funding Source: NIH RePORTER	Preparation of this manuscript was supported by an Australian Academy of Science, Scientific Visits to China Grant to David Shum, PhD; a Griffith Health Institute Distinguished Visiting Researcher Award, a Merit Review and Center of Excellence for Traumatic Brain Injury grants from the Department of Veteran Affairs, and Award Number P01NS056202 from the National Institute of Neurological Disorders And Stroke to Harvey Levin, PhD; and a Griffith University Allan Sewell Visiting Fellowship to Raymond Chan, PhD. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding bodies.	Borenstein M., 2005, COMPREHENSIVE METAAN; Burgess PW, 2001, NEUROPSYCHOLOGIA, V39, P545, DOI 10.1016/S0028-3932(00)00149-4; Carlesimo GA, 2004, J INT NEUROPSYCH SOC, V10, P679, DOI 10.1017/S1355617704105079; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fleming JM, 2005, BRAIN INJURY, V19, P1, DOI 10.1080/02699050410001720059; Fleming JM, 1996, BRAIN INJURY, V10, P1; GOLDSTEIN FC, 1995, HDB MEMORY DISORDERS, P187; Hannon R, 1995, REHABIL PSYCHOL, V40, P289, DOI 10.1037/0090-5550.40.4.289; Henry JD, 2007, J CLIN EXP NEUROPSYC, V29, P457, DOI 10.1080/13803390600762717; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Kim HJ, 2000, BRAIN INJURY, V14, P187, DOI 10.1080/026990500120844; Kinch J., 2001, BRAIN IMPAIR, V2, P119, DOI [10.1375/brim.2.2.119, DOI 10.1375/BRIM.2.2.119]; Kinsella G, 1996, BRAIN INJURY, V10, P499, DOI 10.1080/026990596124214; Kinsella GJ, 2009, BRAIN IMPAIR, V10, P45, DOI 10.1375/brim.10.1.45; Kirsch NL, 2004, BRAIN INJURY, V18, P725, DOI 10.1080/02699050310001646161; Kliegel M, 2004, BRAIN COGNITION, V56, P43, DOI 10.1016/j.bandc.2004.05.005; Kliegel M., 2008, PROSPECTIVE MEMORY C; Knight RG, 2006, J INT NEUROPSYCH SOC, V12, P8, DOI 10.1017/S1355617706060048; Knight RG, 2005, BRAIN INJURY, V19, P19, DOI 10.1080/02699050410001720022; Knight RG, 2009, BRAIN IMPAIR, V10, P3, DOI 10.1375/brim.10.1.3; KOTAPKA MJ, 1994, J NEUROTRAUM, V11, P317, DOI 10.1089/neu.1994.11.317; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Levin H., 2002, HDB MEMORY DISORDERS, P381; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; Mateer C.A., 1987, J HEAD TRAUMA REHAB, V2, P74, DOI [10.1097/00001199-198709000-00009, DOI 10.1097/00001199-198709000-00009]; Mathias JL, 2005, BRAIN INJURY, V19, P271, DOI 10.1080/02699050400005028; Maujean A., 2003, BRAIN IMPAIR, V4, P135, DOI DOI 10.1375/BRIM.4.2.135.27024; McCauley SR, 2004, DEV NEUROPSYCHOL, V25, P5, DOI 10.1207/s15326942dn2501&2_2; McCauley SR, 2010, DEV NEUROPSYCHOL, V35, P318, DOI 10.1080/87565641003696866; McCauley SR, 2010, J INT NEUROPSYCH SOC, V16, P335, DOI 10.1017/S135561770999138X; McCauley SR, 2009, NEUROPSYCHOLOGY, V23, P201, DOI 10.1037/a0014192; McKerracher G, 2005, NEUROPSYCHOL REHABIL, V15, P115, DOI 10.1080/09602010443000056; Okuda J, 1998, NEUROSCI LETT, V253, P127, DOI 10.1016/S0304-3940(98)00628-4; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Raskin SA, 1996, J HEAD TRAUMA REHAB, V11, P32, DOI 10.1097/00001199-199606000-00007; Raskin SA, 2009, BRAIN IMPAIR, V10, P76, DOI 10.1375/brim.10.1.76; Reynolds JR, 2009, CEREB CORTEX, V19, P1208, DOI 10.1093/cercor/bhn164; Roche NL, 2007, NEUROPSYCHOL REHABIL, V17, P314, DOI 10.1080/09602010600831004; Roche NL, 2002, BRAIN INJURY, V16, P931, DOI 10.1080/02699050210138581; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Schmitter-Edgecombe M, 2004, NEUROPSYCHOLOGY, V18, P353, DOI 10.1037/0894-4105.18.2.353; Shum D, 1999, J CLIN EXP NEUROPSYC, V21, P49, DOI 10.1076/jcen.21.1.49.943; Shum D., 2002, BRAIN IMPAIR, V3, DOI [https://doi.org/10.1375/brim.3.1.1, DOI 10.1375/BRIM.3.1.1]; Simons JS, 2006, NEUROPSYCHOLOGIA, V44, P1388, DOI 10.1016/j.neuropsychologia.2006.01.005; SOHLBERG M M, 1992, Brain Injury, V6, P129, DOI 10.3109/02699059209029651; Tay SY, 2010, J NEUROTRAUM, V27, P77, DOI 10.1089/neu.2009.1074; Vakil E, 2005, J CLIN EXP NEUROPSYC, V27, P977, DOI 10.1080/13803390490919245; Wang Y, 2009, SCHIZOPHR RES, V114, P64, DOI 10.1016/j.schres.2009.07.009; Ward H, 2004, BRAIN INJURY, V18, P471, DOI 10.1080/02699050310001646107; Ward H, 2007, CHILD NEUROPSYCHOL, V13, P219, DOI 10.1080/09297040600910003; Wilde EA, 2007, DEV MED CHILD NEUROL, V49, P294, DOI 10.1111/j.1469-8749.2007.00294.x; WILSON BA, 2002, HDB MEMORY DISORDERS	54	42	43	0	23	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932			NEUROPSYCHOLOGIA	Neuropsychologia	JUL	2011	49	8			SI		2156	2165		10.1016/j.neuropsychologia.2011.02.006			10	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	793FL	WOS:000292805700003	21315750				2021-06-18	
J	Turner, RJ; Helps, SC; Thornton, E; Vink, R				Turner, Renee J.; Helps, Stephen C.; Thornton, Emma; Vink, Robert			A substance P antagonist improves outcome when administered 4 h after onset of ischaemic stroke	BRAIN RESEARCH			English	Article						Ischaemic stroke; NK1 tachykinin receptor antagonist; Oedema; Neuropeptides; Neurogenic inflammation	MIDDLE CEREBRAL-ARTERY; SPINAL-CORD ASTROCYTES; NEUROGENIC INFLAMMATION; RECEPTOR ANTAGONIST; FUNCTIONAL DEFICITS; EDEMA FORMATION; BRAIN EDEMA; OCCLUSION; INJURY; TACHYKININ	Previous studies have suggested that substance P (SP) plays a critical role in the development of brain oedema and functional deficits following traumatic brain injury and that SP receptor antagonism may improve outcome. No studies have described such a role in ischemic stroke. The present study characterized the effects of the NK1 tachykinin receptor antagonist, n-acetyl-L-tryptophan (NAT), on blood-brain barrier (BBB) breakdown, oedema formation, infarct volume and functional outcome following reversible ischemic stroke in rats. Ischemia was induced using a reversible thread model of middle cerebral artery occlusion where occlusion was maintained for 2 h before reperfusion. Animals received either NAT or equal volume saline vehicle intravenously at 2 h post-reperfusion. Ischaemic stroke resulted in increased perivascular SP immunoreactivity at 24 h. Administration of NAT significantly reduced oedema formation and BBB permeability at 24 h post-ischemia and significantly improved functional outcome as assessed over 7 days. There was no effect on infarct volume. We conclude that inhibition of SP activity with a NK1 tachykinin receptor antagonist is effective in reducing cerebral oedema, BBB permeability and functional deficits following reversible ischemia and may therefore represent a novel therapeutic approach to the treatment of ischaemic stroke. (C) 2011 Elsevier B.V. All rights reserved.	[Turner, Renee J.] Univ Adelaide, Sch Med Sci, Discipline Anat & Pathol, Adelaide, SA 5005, Australia; Hanson Inst, Ctr Neurol Dis, Adelaide, SA, Australia	Turner, RJ (corresponding author), Univ Adelaide, Sch Med Sci, Discipline Anat & Pathol, Adelaide, SA 5005, Australia.	Renee.Turner@adelaide.edu.au	AM, Robert Vink/S-5616-2019; Vink, Robert/J-7351-2012	AM, Robert Vink/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667; Turner, Renee/0000-0003-4278-8302	National Health and Medical Research Council of AustraliaNational Health and Medical Research Council of AustraliaUK Research & Innovation (UKRI)Medical Research Council UK (MRC)	Supported, in part, by the National Health and Medical Research Council of Australia.	Alves RV, 1999, PEPTIDES, V20, P921, DOI 10.1016/S0196-9781(99)00082-0; Aronowski J, 1996, J CEREBR BLOOD F MET, V16, P705, DOI 10.1097/00004647-199607000-00022; Bakhai A, 2004, PHARMACOECONOMICS, V22, P11, DOI 10.2165/00019053-200422004-00004; Black PH, 2002, BRAIN BEHAV IMMUN, V16, P622, DOI 10.1016/S0889-1591(02)00021-1; Bondy B, 2003, BIOL PSYCHIAT, V53, P538, DOI 10.1016/S0006-3223(02)01544-5; Bruno G, 2003, INT J IMMUNOPATH PH, V16, P67, DOI 10.1177/039463200301600110; Cao T, 1999, AM J PHYSIOL-REG I, V277, pR476; Castro-Obregon S, 2002, CELL DEATH DIFFER, V9, P807, DOI 10.1038/sj.cdd.4401035; Donkin JJ, 2009, J CEREBR BLOOD F MET, V29, P1388, DOI 10.1038/jcbfm.2009.63; Fu D, 2004, NEUROSCIENCE, V125, P819, DOI 10.1016/j.neuroscience.2004.02.012; GROTTA JC, 1990, ANN NEUROL, V27, P612, DOI 10.1002/ana.410270605; HAFSTROM I, 1989, J RHEUMATOL, V16, P1033; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Harrison S, 2001, INT J BIOCHEM CELL B, V33, P555, DOI 10.1016/S1357-2725(01)00031-0; Hokfelt T, 2000, NEUROPHARMACOLOGY, V39, P1337, DOI 10.1016/S0028-3908(00)00010-1; Kaya M, 2001, CAN J PHYSIOL PHARM, V79, P793, DOI 10.1139/cjpp-79-9-793; Kramer JH, 1997, J MOL CELL CARDIOL, V29, P97, DOI 10.1006/jmcc.1996.0255; Lecrux C, 2008, STROKE, V39, P448, DOI 10.1161/STROKEAHA.107.492934; Li FH, 1997, J CEREBR BLOOD F MET, V17, P1132, DOI 10.1097/00004647-199710000-00016; Li Y, 2000, J CEREBR BLOOD F MET, V20, P1311, DOI 10.1097/00004647-200009000-00006; Lin RCS, 1995, NEUROREPORT, V7, P310, DOI 10.1097/00001756-199512290-00074; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; Malcangio M, 2000, EUR J NEUROSCI, V12, P397, DOI 10.1046/j.1460-9568.2000.00946.x; MARRIOTT D, 1991, ADV PROSTAG THROMB L, V21, P739; Modo M, 2000, J NEUROSCI METH, V104, P99, DOI 10.1016/S0165-0270(00)00329-0; Nimmo AJ, 2004, NEUROPEPTIDES, V38, P40, DOI 10.1016/j.npep.2003.12.003; NIMMO AJ, 2004, RECENT PAT CNS DRUG, V4, P86; Palma C, 1997, GLIA, V21, P183, DOI 10.1002/(SICI)1098-1136(199710)21:2<183::AID-GLIA2>3.0.CO;2-8; PERSSON MG, 1991, EUR J PHARMACOL, V205, P295, DOI 10.1016/0014-2999(91)90913-B; PRESTON E, 1993, NEUROSCI LETT, V149, P75, DOI 10.1016/0304-3940(93)90351-K; Ruifrok AC, 2001, ANAL QUANT CYTOL, V23, P291; SHARMA HS, 1993, NEUROPHARMACOLOGY, V32, P711, DOI 10.1016/0028-3908(93)90085-H; Stumm RK, 2001, J NEUROSCI, V21, P798; Turner RJ, 2006, ACTA NEUROCHIR SUPPL, V96, P263; Turner R, 2007, DRUG NEWS PERSPECT, V20, P221, DOI 10.1358/dnp.2007.20.4.1103527; vanderStaay FJ, 1996, BRAIN RES, V735, P271; Vink R, 2003, ACT NEUR S, V86, P257; Yu ZF, 1997, NEUROREPORT, V8, P2117, DOI 10.1097/00001756-199707070-00006	38	42	45	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JUN 1	2011	1393						84	90		10.1016/j.brainres.2011.03.066			7	Neurosciences	Neurosciences & Neurology	774JA	WOS:000291380300009	21466790				2021-06-18	
J	Werman, HA; Erskine, T; Caterino, J; Riebe, JF; Valasek, T				Werman, Howard A.; Erskine, Timothy; Caterino, Jeffrey; Riebe, Jane F.; Valasek, Tricia		State Ohio EMS Board	Development of Statewide Geriatric Patients Trauma Triage Criteria	PREHOSPITAL AND DISASTER MEDICINE			English	Article						emergency medical services; geriatric; Ohio; trauma; trauma center; trauma registry		Introduction: The geriatric population is unique in the type of traumatic injuries sustained, physiological responses to those injuries, and an overall higher mortality when compared to younger adults. No published, evidence-based, geriatric-specific field destination criteria exist as part of a statewide trauma system. The Trauma Committee of the Ohio Emergency Medical Services (EMS) Board sought to develop specific criteria for geriatric trauma victims. Methods: A literature search was conducted for all relevant literature to determine potential, geriatric-specific, field-destination criteria. Data from the Ohio Trauma Registry were used to compare elderly patients, defined as age >70 years, to all patients between the ages of 16 to 69 years with regards to mortality risk in the following areas: (1) Glasgow Coma Scale (GCS) score; (2) systolic blood pressure (SBP); (3) falls associated with head, chest, abdominal or spinal injury; (4) mechanism of injury; (5) involvement of more than one body system as defined in the Barell matrix; and (6) co-morbidities and motor vehicle collision with one or more long bone fracture. For GCS score and SBP, those cut-off points with equal or greater risk of mortality as compared to current values were chosen as proposed triage criteria. For other measures, any criterion demonstrating a statistically significant increase in mortality risk was included in the proposed criteria. Results: The following criteria were identified as geriatric-specific criteria: (1) GCS score <14 in the presence of known or suspected traumatic brain trauma; (2) SBP < 100 mmHg; (3) fall from any height with evidence of traumatic brain injury: (4) multiple body-system injuries; (5) struck by a moving vehicle; and (6) the presence of any proximal long bone fracture following motor vehicle trauma. In addition, these data suggested that elderly patients with specific co-morbidities be given strong consideration for evaluation in a trauma center. Conclusions: The state of Ohio is the first state to develop evidence-based geriatric-specific field-destination criteria using data from its state-mandated trauma registry. Further analysis of these criteria will help determine their effects on over-triage and under-triage of geriatric victims of traumatic injuries and the impact on the overall mortality in the elderly.	[Werman, Howard A.; Caterino, Jeffrey] Ohio State Univ, Columbus, OH 43210 USA; [Erskine, Timothy] Ohio Dept Publ Safety, Columbus, OH 43223 USA; [Riebe, Jane F.] Hosp Council Northwest Ohio, Toledo, OH USA; [Valasek, Tricia] Natl Assoc Local Boards Hlth, Bowling Green, OH USA	Erskine, T (corresponding author), Ohio Dept Publ Safety, EMS Div, 1970 West Broad St, Columbus, OH 43223 USA.	terskine@dps.state.oh.us					Baez AA, 2003, J TRAUMA, V54, P344, DOI 10.1097/01.TA.0000046258.81127.E1; Ballentine NH, 2008, CRIT CARE NURS Q, V31, P40, DOI 10.1097/01.CNQ.0000306395.86905.8b; Caterino JM, 2010, AM J EMERG MED, V28, P151, DOI 10.1016/j.ajem.2008.10.027; CDC. National Center for Health Statistics, BAR INJ DIAGN MATR C; CHAMPION HR, 1989, AM J PUBLIC HEALTH, V79, P1278, DOI 10.2105/AJPH.79.9.1278; Chang DC, 2008, ARCH SURG-CHICAGO, V143, P776, DOI 10.1001/archsurg.143.8.776; CLARK DE, NATL TRAUMA DATA BAN; Cushman JT, 2009, PREHOSP EMERG CARE, V13, P117; Demetriades D, 2001, J TRAUMA, V51, P754, DOI 10.1097/00005373-200110000-00022; FINELLI FC, 1989, J TRAUMA, V29, P541, DOI 10.1097/00005373-198905000-00001; Fulton Maryann M, 2005, J Am Acad Nurse Pract, V17, P123, DOI 10.1111/j.1041-2972.2005.0020.x; Gubler KD, 1997, ARCH SURG-CHICAGO, V132, P1010; Helling TS, 1999, J TRAUMA, V46, P453, DOI 10.1097/00005373-199903000-00019; Jacobs DG, 2003, J TRAUMA, V54, P391, DOI 10.1097/01.TA.0000042015.54022.BE; LONNER JH, 1995, CLIN ORTHOP RELAT R, P136; Ma MHM, 1999, J TRAUMA, V46, P168; McGwin G, 2004, J TRAUMA, V56, P1291, DOI 10.1097/01.TA.0000089354.02065.D0; MILZMAN DP, 1992, J TRAUMA, V32, P236, DOI 10.1097/00005373-199202000-00021; Mina AA, 2002, J TRAUMA, V53, P668, DOI 10.1097/00005373-200210000-00008; MORRIS JA, 1990, J TRAUMA, V30, P1476, DOI 10.1097/00005373-199012000-00006; MUELLER MS, 1976, SOC SECUR BULL, V39, P18; Mullins RJ, 1998, JAMA-J AM MED ASSOC, V279, P1727, DOI 10.1001/jama.279.21.1727; National Diabetes Statistics, 2007 NAT DIAB INF CL, P1; Ohio Department of Public Safety, 2004, OH TRAUM REG DICT 20; Perdue PW, 1998, J TRAUMA, V45, P805, DOI 10.1097/00005373-199810000-00034; Phillips S, 1996, J TRAUMA, V40, P278, DOI 10.1097/00005373-199602000-00018; Pieracci FM, 2007, J TRAUMA, V63, P525, DOI 10.1097/TA.0b013e31812e5216; Richmond TS, 2002, J AM GERIATR SOC, V50, P215, DOI 10.1046/j.1532-5415.2002.50051.x; Rosamond W, 2008, CIRCULATION, V117, pE25, DOI 10.1161/CIRCULATIONAHA.107.187998; Scheetz Linda J, 2003, J Emerg Nurs, V29, P109, DOI 10.1067/men.2003.59; SMITH DP, 1990, SOUTHERN MED J, V83, P171, DOI 10.1097/00007611-199002000-00010; Sugimoto K, 1999, Prehosp Disaster Med, V14, P186; Tornetta P, 1999, J TRAUMA, V46, P702, DOI 10.1097/00005373-199904000-00024; US Centers for Disease Control and Prevention (CDC), 2003, 10 LEAD CAUS INJ DEA; Victorino GP, 2003, ARCH SURG-CHICAGO, V138, P1093, DOI 10.1001/archsurg.138.10.1093; Zautcke JL, 2002, AM J EMERG MED, V20, P14, DOI 10.1053/ajem.2002.30107; ZIMMERGEMBECK MJ, 1995, J TRAUMA, V39, P922, DOI 10.1097/00005373-199511000-00017; 2007, COMMUNICATION	38	42	42	0	1	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1049-023X	1945-1938		PREHOSP DISASTER MED	Prehospital Disaster Med.	JUN	2011	26	3					170	179		10.1017/S1049023X11006315			10	Emergency Medicine	Emergency Medicine	VG0ZV	WOS:000445115900008	22107767				2021-06-18	
J	Hartholt, KA; van Lieshout, EMM; Polinder, S; Panneman, MJM; van der Cammen, TJM; Patka, P				Hartholt, Klaas A.; van Lieshout, Esther M. M.; Polinder, Suzanne; Panneman, Martien J. M.; van der Cammen, Tischa J. M.; Patka, Peter			Rapid Increase in Hospitalizations Resulting from Fall-Related Traumatic Head Injury in Older Adults in the Netherlands 1986-2008	JOURNAL OF NEUROTRAUMA			English	Article						guidelines; hospitalizations; older adults; time trend; traumatic head injuries	BRAIN-INJURIES; UNITED-STATES; TRENDS; MILD; PREVENTION; GUIDELINES; ADMISSIONS; MANAGEMENT; DISABILITY; PEOPLE	Falls occur frequently in older adults. With ageing populations worldwide, an increase in fall-related traumatic head injuries can be expected. The aim of our study was to determine trends in traumatic head-injury-related hospitalizations among older adults. Therefore, a secular trend analysis of fall-related traumatic head injuries in the older Dutch population between 1986 and 2008 was performed, using the National Hospital Discharge Registry. All significant fall-related traumatic head injury hospitalizations in persons aged >= 65 years were extracted from this database. During the study period, traumatic head-injury-related hospitalizations increased by 213% to 3,010 in 2008. The incidence rate increased annually by 1.2% (95% CI: 0.6; 1.9) between 1986 and 2000. Since 2001, the increase has accelerated up to 11.6% (95% CI: 9.5; 13.8) per year. Overall, the age-adjusted incidence rate increased from 53.1 in 1986 to 119.1 per 100,000 older persons in 2008. Age-specific incidence rates increased in all age groups, especially in persons aged >= 85 years. Despite an overall reduction in the length of hospital stay per admission, the total number of hospital-bed-days increased with 31.5% to 20,250 between 1991 and 2008. In conclusion, numbers and incidence rates of significant traumatic head-injury-related hospitalization after a fall are increasing rapidly in the older Dutch population, especially in the oldest old, resulting in an increased health care demand. The recent increase might be explained by the ageing population, but also other factors may have contributed to the increase, such as an increased awareness of traumatic head injuries, the implementation of renewed guidelines for traumatic head injuries, and improved radiographic tools.	[Hartholt, Klaas A.; van Lieshout, Esther M. M.; Patka, Peter] Univ Med Ctr Rotterdam, Erasmus MC, Dept Surg Traumatol, NL-3000 CA Rotterdam, Netherlands; [Hartholt, Klaas A.; van der Cammen, Tischa J. M.] Univ Med Ctr Rotterdam, Erasmus MC, Geriatr Med Sect, Dept Internal Med, NL-3000 CA Rotterdam, Netherlands; [Polinder, Suzanne] Univ Med Ctr Rotterdam, Erasmus MC, Dept Publ Hlth, NL-3000 CA Rotterdam, Netherlands; [Panneman, Martien J. M.] Consumer & Safety Inst, Amsterdam, Netherlands	van Lieshout, EMM (corresponding author), Univ Med Ctr Rotterdam, Erasmus MC, Dept Surg Traumatol, Room H822k,POB 2040, NL-3000 CA Rotterdam, Netherlands.	e.vanlieshout@erasmusmc.nl	Hartholt, Klaas A/Q-1782-2016	Hartholt, Klaas A/0000-0001-5019-9239	"The Netherlands Organization for Health Research and Development" (ZonMw)Netherlands Organization for Health Research and Development [170.885.607]	Klaas Hartholt is a research fellow at the Erasmus MC, appointed on a research grant from "The Netherlands Organization for Health Research and Development" (ZonMw), project number 170.885.607.	BRUGGINK JW, 2010, NATIONAAL KOMPAS VOL, P3; *COMM HEALTHC IMPR, 2001, GUID DIAGN TREATM PA; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Freedman VA, 2002, JAMA-J AM MED ASSOC, V288, P3137, DOI 10.1001/jama.288.24.3137; Gillespie LD., 2003, Cochrane Database Syst Rev, V4, DOI DOI 10.1002/14651858.CD007146.PUB2; HARTHOLT KA, 2010, J TRAUMA, DOI DOI 10.1097/TA.0B013E3181F6F5E5; Hartholt KA, 2010, ARCH INTERN MED, V170, P905, DOI 10.1001/archinternmed.2010.106; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; HOEYMANS N, 2009, NATIONAAL KOMPAS VOL; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; Jacobsson LJ, 2009, ACTA NEUROL SCAND, V120, P389, DOI 10.1111/j.1600-0404.2009.01238.x; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Jagoda AS, 2002, ANN EMERG MED, V40, P231, DOI 10.1016/j.jen.2008.12.010; Kannus P, 1999, JAMA-J AM MED ASSOC, V281, P1895, DOI 10.1001/jama.281.20.1895; Kannus P, 2005, LANCET, V366, P1885, DOI 10.1016/S0140-6736(05)67604-0; Kannus P, 2007, INJURY, V38, P81, DOI 10.1016/j.injury.2006.08.027; Logan PA, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2102; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MCNEIL DR, 1977, DEMOGRAPHY, V14, P245, DOI 10.2307/2060581; Polinder S, 2005, J TRAUMA, V59, P1283, DOI 10.1097/01.ta.0000195998.11304.5b; Scuffham P, 2003, J EPIDEMIOL COMMUN H, V57, P740, DOI 10.1136/jech.57.9.740; Stamatakis E, 2008, BRIT J SPORT MED, V42, P601; Statistics Netherlands, 2009, POP PROGN 1969 2040; Stevens J. A., 2006, Morbidity and Mortality Weekly Report, V55, P1221; Stevens JA, 2005, INJURY PREV, V11, P115, DOI 10.1136/ip.2004.005835; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; van der Stegen RPJ, 2009, DESCRIPTION METHODS; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x	28	42	42	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2011	28	5					739	744		10.1089/neu.2010.1488			6	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	762JI	WOS:000290472100274	21355818				2021-06-18	
J	Marion, DW; Curley, KC; Schwab, K; Hicks, RR				Marion, Donald W.; Curley, Kenneth C.; Schwab, Karen; Hicks, Ramona R.		mTBI Diagnostics Workgrp	Proceedings of the Military mTBI Diagnostics Workshop, St. Pete Beach, August 2010	JOURNAL OF NEUROTRAUMA			English	Article						concussion; diagnosis; mild traumatic brain injury; Neurocognitive Assessment Tool (NCAT); Military Acute Concussion Evaluation (MACE); Operation Iraqi Freedom (OIF); Operation Enduring Freedom (OEF); military mild traumatic brain injury	TRAUMATIC BRAIN-INJURY; COLLEGIATE FOOTBALL PLAYERS; BIOCHEMICAL MARKERS; HEAD-INJURY; CONCUSSION; SERUM; S-100B; DAMAGE; S100B; BIOMARKERS	Approximately 28,000 service members (SMs) sustain a traumatic brain injury (TBI) each year in the U. S. military. The majority of the injuries result either in a brief or no loss of consciousness, and are classified as a mild TBI (mTBI or concussion). Current evaluation guidelines of SMs suspected of having a mTBI rely heavily on self-reports. However, there is concern that SMs typically minimize or do not report their symptoms of mTBI for fear that doing so will result in being removed from the battlefield. Because mTBI often results in headaches, cognitive dysfunction, attention difficulties, and balance problems, returning to the battlefield before resolution of their symptoms can be dangerous for the SM and for their unit. Sustaining a second concussion before resolution of a previous mTBI also may make long-term neuronal injury more likely. The mTBI Diagnostics Workshop was designed as a forum where civilian and military experts from a variety of TBI-related clinical and basic science disciplines could meet to define the diagnostic tools, alone or in combination, that were most likely to result in an acute, objective diagnosis of mTBI. The premise of the meeting was that a small number of well-focused research projects conducted over the next 2-3 years could be done to validate the optimal test, or more likely combination of tests, that would be practical and reliable for the acute diagnosis of mTBI within 2-3 h of injury in theater. The recommendations of the Workshop are provided in this report.	[Marion, Donald W.; Schwab, Karen] Walter Reed Army Med Ctr, Def & Vet Brain Injury Ctr, Washington, DC 20307 USA; [Curley, Kenneth C.] USA, Combat Casualty Care Directorate, Med Res & Mat Command, Ft Detrick, MD USA; [Hicks, Ramona R.] NINDS, Bethesda, MD 20892 USA	Marion, DW (corresponding author), Walter Reed Army Med Ctr, Def & Vet Brain Injury Ctr, Bldg 1,Room B209 6900 Georgia Ave NW, Washington, DC 20307 USA.	Donald.Marion@us.army.mil	Marion, Donald/AAR-5749-2021		mTBI Diagnostics Workshop	Support for the mTBI Diagnostics Workshop was provided by Col. Dallas Hack, Director of the Combat Casualty Care Directorate, U.S. Army Medical Research and Materiel Command, and by Col. Jamie Grimes, National Director of the Defense and Veterans Brain Injury Center. Marithea Goberville, Ph.D., provided a transcript of the report-out session of the conference.	Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Begaz T, 2006, J NEUROTRAUM, V23, P1201, DOI 10.1089/neu.2006.23.1201; Bergsneider M, 2001, J HEAD TRAUMA REHAB, V16, P135, DOI 10.1097/00001199-200104000-00004; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Casscells SW, 2007, TRAUMATIC BRAIN INJU; Dash PK, 2010, J NEUROSCI RES, V88, P1719, DOI 10.1002/jnr.22336; Ellemberg D, 2009, J NEUROTRAUM, V26, P2365, DOI 10.1089/neu.2009.0906; Giljohann DA, 2009, NATURE, V462, P461, DOI 10.1038/nature08605; Giza CC, 2001, J ATHL TRAINING, V36, P228; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Hausmann R, 1999, INT J LEGAL MED, V112, P227, DOI 10.1007/s004140050241; Holli KK, 2010, ACAD RADIOL, V17, P1096, DOI 10.1016/j.acra.2010.04.009; Holli Kirsi K, 2010, BMC Med Imaging, V10, P8, DOI 10.1186/1471-2342-10-8; Holtkamp K, 2008, J NEURAL TRANSM, V115, P937, DOI 10.1007/s00702-008-0041-8; Iverson GL, 2008, BRAIN INJURY, V22, P147, DOI 10.1080/02699050701867407; Kochanek PM, 2008, CURR OPIN CRIT CARE, V14, P135, DOI 10.1097/MCC.0b013e3282f57564; Mao Q, 1995, Hua Xi Yi Ke Da Xue Xue Bao, V26, P135; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2009, PHYSICIAN SPORTSMED, V37, P141, DOI 10.3810/psm.2009.06.1721; *MTBI WORK GROUP, 2009, VA DOD CLIN PRACT GU; Mussack T, 2000, ACT NEUR S, V76, P393; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Parsons TD, 2008, STUD HEALTH TECHNOL, V132, P351; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Saatman KE, 2010, NEUROTHERAPEUTICS, V7, P31, DOI 10.1016/j.nurt.2009.11.002; Schatz P, 2006, APPL NEUROPSYCHOL, V13, P151, DOI 10.1207/s15324826an1303_2; Scherer MR, 2009, PHYS THER, V89, P980, DOI 10.2522/ptj.20080353; Stalnacke BM, 2004, BRAIN INJURY, V18, P899, DOI 10.1080/02699050410001671865; Stranjalis G, 2004, J NEUROTRAUM, V21, P1070, DOI 10.1089/0897715041651088; Tanielian T, 2008, INVISIBLE WOUNDS MEN; Tisdall MM, 2007, BRIT J ANAESTH, V99, P61, DOI 10.1093/bja/aem143; van Rossem K, 1999, ADV EXP MED BIOL, V471, P209; Wiesmann M, 2010, ACTA NEUROL SCAND, V121, P178, DOI 10.1111/j.1600-0404.2009.01196.x	36	42	44	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2011	28	4					517	526		10.1089/neu.2010.1638			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	746IW	WOS:000289240200003	21265587				2021-06-18	
J	Ballenger-Browning, KK; Schmitz, KJ; Rothacker, JA; Hammer, PS; Webb-Murphy, JA; Johnson, DC				Ballenger-Browning, Kara K.; Schmitz, Kimberly J.; Rothacker, John A.; Hammer, Paul S.; Webb-Murphy, Jennifer A.; Johnson, Douglas C.			Predictors of Burnout Among Military Mental Health Providers	MILITARY MEDICINE			English	Article							POSTTRAUMATIC-STRESS-DISORDER; NATIONAL COMORBIDITY SURVEY; JOB STRESS; SOCIAL SUPPORT; CAREER SATISFACTION; WORKERS; NURSES; STAFF; PSYCHOLOGISTS; PROFESSIONALS	Mental health treatment of military service members places unique demands on providers as their patients experience combat stress. This study assessed levels and predictors of burnout among mental health providers (N = 97) at military facilities, using a self-administered survey of demographic and work-related measures and the Maslach Burnout Inventory. Burnout levels were comparable to studies of civilian mental health providers but were less severe than those of the Maslach Burnout Inventory normative sample. Working more hours, having more patients with personality disorders, increased patient caseloads, female gender, and being a psychiatrist were predictive of higher burnout scores. Having more confidants at work, a greater percentage of patients with traumatic brain injury, more clinical experience, and being a psychologist predicted lower burnout scores. These findings suggest that burnout levels among military providers are similar to those among civilian providers and may be alleviated by interventions targeting general institutional risk factors.	[Ballenger-Browning, Kara K.; Schmitz, Kimberly J.; Rothacker, John A.; Hammer, Paul S.; Webb-Murphy, Jennifer A.] USN, San Diego Med Ctr, NCCOSC, San Diego, CA 92134 USA; [Johnson, Douglas C.] USN, Hlth Res Ctr, San Diego, CA 92106 USA	Ballenger-Browning, KK (corresponding author), USN, San Diego Med Ctr, NCCOSC, 34960 Bob Wilson Dr,Suite 400, San Diego, CA 92134 USA.						Abualrub RF, 2008, J NURS MANAGE, V16, P227, DOI 10.1111/j.1365-2834.2007.00810.x; ACKERLEY GD, 1988, PROF PSYCHOL-RES PR, V19, P624, DOI 10.1037/0735-7028.19.6.624; Agius RM, 1996, OCCUP ENVIRON MED, V53, P217, DOI 10.1136/oem.53.4.217; Ahola K, 2006, SOC PSYCH PSYCH EPID, V41, P11, DOI 10.1007/s00127-005-0011-5; Balogun Joseph A, 2002, J Allied Health, V31, P131; BROLLIER C, 1987, Occupational Therapy in Mental Health, V7, P39, DOI 10.1300/J004v07n01_03; Bystritsky A, 2005, GEN HOSP PSYCHIAT, V27, P313, DOI 10.1016/j.genhosppsych.2005.05.005; Carney J., 1993, PSYCHOSOC REHABIL, V16, P25, DOI DOI 10.1037/H0095654; Castelo-Branco C, 2007, BJOG-INT J OBSTET GY, V114, P94, DOI 10.1111/j.1471-0528.2006.01155.x; CHEDEKEL L, 2008, MENTAL HLTH PROVIDER; Coffey M, 2001, J ADV NURS, V34, P397, DOI 10.1046/j.1365-2648.2001.01770.x; Evans S, 2006, BRIT J PSYCHIAT, V188, P75, DOI 10.1192/bjp.188.1.75; Farber B. A., 1990, PSYCHOTHER PRIV PRAC, V8, P14, DOI 10.1300/J294v08n01_07; Finch E. S., 1991, PSYCHOSOC REHABIL, V14, P15; FIRTH H, 1987, INT J NURS STUD, V24, P227, DOI 10.1016/0020-7489(87)90005-8; FORT RS, 2009, LOS ANGELES TIMES; GARZOTTO N, 1992, NEW TRENDS EXPT CLIN, V8, P113; Hannigan B, 2000, J Psychiatr Ment Health Nurs, V7, P127, DOI 10.1046/j.1365-2850.2000.00279.x; Harper H, 1997, Ment Health Care, V1, P18; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Jenkins R, 2004, J ADV NURS, V48, P622, DOI 10.1111/j.1365-2648.2004.03240.x; Keeton K, 2007, OBSTET GYNECOL, V109, P949, DOI 10.1097/01.AOG.0000258299.45979.37; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P617, DOI 10.1001/archpsyc.62.6.617; Leiter MP, 1996, INT J SOC PSYCHIATR, V42, P90, DOI 10.1177/002076409604200203; LEITER MP, 1988, J ORGAN BEHAV, V9, P297, DOI 10.1002/job.4030090402; Lloyd C, 2004, SOC PSYCH PSYCH EPID, V39, P752, DOI 10.1007/s00127-004-0808-7; MASLACH C, 1988, REHABIL PSYCHOL, V33, P85, DOI 10.1037//0090-5550.33.2.85; Maslach C., 1996, MASLACH BURNOUT INVE, V3rd ed.; Maslach C, 1981, J OCCUPATIONAL BEHAV, V2, P15; MCDERMOTT D, 1984, J HUM STRESS, V10, P79, DOI 10.1080/0097840X.1984.9934962; McVicar A, 2003, J ADV NURS, V44, P633, DOI 10.1046/j.0309-2402.2003.02853.x; Nemeroff CB, 2006, J PSYCHIATR RES, V40, P1, DOI 10.1016/j.jpsychires.2005.07.005; ODRISCOLL MP, 1988, WORK STRESS, V2, P199, DOI 10.1080/02678378808259167; PINES A, 1978, HOSP COMMUNITY PSYCH, V29, P233; Pranger T, 1992, OCCUPATIONAL THERAPY, V12, P77; Prosser D, 1999, SOC PSYCH PSYCH EPID, V34, P295, DOI 10.1007/s001270050147; RAQUEPAW JM, 1989, PROF PSYCHOL-RES PR, V20, P5; Reid Y, 1999, SOC PSYCH PSYCH EPID, V34, P301, DOI 10.1007/s001270050148; ROSS RR, 1989, J COUNS PSYCHOL, V36, P464, DOI 10.1037/0022-0167.36.4.464; Rupert PA, 2005, PROF PSYCHOL-RES PR, V36, P544, DOI 10.1037/0735-7028.36.5.544; RUSSELL DW, 1987, J APPL PSYCHOL, V72, P269, DOI 10.1037/0021-9010.72.2.269; Shanafelt TD, 2009, ANN SURG, V250, P463, DOI 10.1097/SLA.0b013e3181ac4dfd; Sherring Simon, 2009, Br J Nurs, V18, P1234; SKORUPA J, 1993, PROF PSYCHOL-RES PR, V24, P281, DOI 10.1037/0735-7028.24.3.281; SNIBBE JR, 1989, PSYCHOL REP, V65, P775, DOI 10.2466/pr0.1989.65.3.775; TRACY EM, 1992, RES SOCIAL WORK PRAC, V2, P465, DOI 10.1177/104973159200200403; vanWijk C, 1997, MIL MED, V162, P707; WILCOXON SA, 1989, J RURAL COMMUNITY PS, V10, P3; Wykes T, 1997, SOC PSYCH PSYCH EPID, V32, P398; Zoroya G., 2007, US TODAY	51	42	43	2	22	ASSOC MILITARY SURG US	BETHESDA	9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA	0026-4075			MIL MED	Milit. Med.	MAR	2011	176	3					253	260		10.7205/MILMED-D-10-00269			8	Medicine, General & Internal	General & Internal Medicine	825BN	WOS:000295246000004	21456349	Bronze			2021-06-18	
J	Dore-Duffy, P; Wang, S; Mehedi, A; Katyshev, V; Cleary, K; Tapper, A; Reynolds, C; Ding, YC; Zhan, P; Rafols, J; Kreipke, CW				Dore-Duffy, Paula; Wang, Sherry; Mehedi, Afroza; Katyshev, Vladamir; Cleary, Kristen; Tapper, Alexander; Reynolds, Christian; Ding, Yuchuan; Zhan, Pang; Rafols, Jose; Kreipke, Christian W.			Pericyte-mediated vasoconstriction underlies TBI-induced hypoperfusion	NEUROLOGICAL RESEARCH			English	Article						Pericyte; Endothelin; Receptors	SMOOTH-MUSCLE; ENDOTHELIN RECEPTORS; CONTRACTILE PROTEINS; SCANNING-ELECTRON; BRAIN-INJURY; BLOOD-BRAIN; RAT MODEL; EXPRESSION; ACTIN; CELLS	Objectives: Endothelin-1 is a 21-amino acid peptide that together with specific receptors, A (ETrA) and B (ETrB) is induced following traumatic brain injury (TBI) and has been closely linked to regulation of cerebral vasospasm, oxidative stress, and hypoperfusion. Specific endothelin receptor antagonists have been shown to ameliorate early evidence of neuronal cell injury, activation of microglial cells, and hypoperfusion following TBI. The exact mechanism involved in TBI-induced hypoperfusion is still unclear; however, it is thought that endothelin-1 engagement of ETrA is primarily responsible for changes in blood flow. In this study we question the role of the microvascular pericyte in endothelin-1-mediated pathophysiology in TBI. Methods: Pericyte expression of endothelin-1, ETrA, and ETrB was examined in primary culture and in sham and impacted rat brain. Adult male rats were also given intracerebroventricular injections of ETrA (BQ-123) before being subjected to TBI using a closed head acceleration impact model. Results: Primary pericytes express both endothelin-1 and its receptors ETrA and ETrB. Following TBI, the number of alpha-smooth muscle actin (SMA) positive pericytes located in microvessels is significantly increased by 4 hours post-traumatic impact. Increases in pericyte expression of alpha-SMA correlated with evidence of a reduction in both arteriolar and capillary diameter. Capillary endothelin-1, ETrA, and ETrB transcript and protein was also increased. Increased endothelin-1 expression was seen by 2-4 hours post-impact. Upregulation of receptors was observed by 4-8 hours and maximum by 24 hours. ETrA antagonists decreased the number of alpha-SMA(+) pericytes as well as changes in microvascular diameter. Conclusion: These results suggest that decreased vasoconstriction following TBI may be due to an endothelin-1-induced pericyte-mediated regulation of microvessel blood flow following TBI. Furthermore, results suggest that ETrA antagonists ameliorate trauma induced hypoperfusion, in part, by inhibiting endothelin-1-mediated upregulation of alpha-SMA in pericytes.	[Dore-Duffy, Paula; Wang, Sherry; Mehedi, Afroza; Katyshev, Vladamir; Cleary, Kristen; Tapper, Alexander] Wayne State Univ, Sch Med, Dept Neurol, Detroit, MI 48201 USA; [Reynolds, Christian; Rafols, Jose; Kreipke, Christian W.] Wayne State Univ, Sch Med, Dept Neurol Surg, Detroit, MI 48201 USA; [Ding, Yuchuan; Zhan, Pang] Wayne State Univ, Sch Med, Dept Anat & Cell Biol, Detroit, MI 48201 USA; [Rafols, Jose; Kreipke, Christian W.] John D Dingell Vet Affairs Med Ctr, Detroit, MI USA	Dore-Duffy, P (corresponding author), Wayne State Univ, Sch Med, Dept Neurol, Room 9312 Scott Hall,540 E Canfield, Detroit, MI 48201 USA.	pdduffy@med.wayne.edu					ALI SS, 1984, CELL TISSUE RES, V235, P675; Andrawis NS, 1996, LIFE SCI, V59, P523, DOI 10.1016/0024-3205(96)00332-3; BALDI E, 1991, J PHARMACOL EXP THER, V256, P581; Bandopadhyay R, 2001, J NEUROCYTOL, V30, P35, DOI 10.1023/A:1011965307612; Bergmann MW, 2001, J MOL CELL CARDIOL, V33, P1223, DOI 10.1006/jmcc.2001.1385; Carloni V, 2000, HEPATOLOGY, V31, P131, DOI 10.1002/hep.510310121; CHAKRAVARTHY U, 1992, MICROVASC RES, V43, P241, DOI 10.1016/0026-2862(92)90022-H; Cushing MC, 2005, MATRIX BIOL, V24, P428, DOI 10.1016/j.matbio.2005.06.007; Dehouck MP, 1997, J CEREBR BLOOD F MET, V17, P464, DOI 10.1097/00004647-199704000-00012; DEHOUCK MP, 2001, J CEREB BLOOD FLOW M, V17, P464; DELARUBIA G, 1992, DIABETES, V41, P1533, DOI 10.2337/diabetes.41.12.1533; Dore SE, 1923, BRIT J DERMATOL SYPH, V35, P398, DOI 10.1111/j.1365-2133.1923.tb09069.x; Dore-Duffy P, 2000, MICROVASC RES, V60, P55, DOI 10.1006/mvre.2000.2244; Dore-Duffy P, 2008, CURR PHARM DESIGN, V14, P1581, DOI 10.2174/138161208784705469; Dore-Duffy P, 2007, NEUROL RES, V29, P395, DOI 10.1179/016164107X204729; Dore-Duffy Paula, 2003, Methods Mol Med, V89, P375; GAUDIO E, 1985, ANGIOLOGY, V36, P458, DOI 10.1177/000331978503600708; HAHN AWA, 1993, J VASC RES, V30, P192, DOI 10.1159/000158994; Hautmann MB, 1999, ARTERIOSCL THROM VAS, V19, P2049, DOI 10.1161/01.ATV.19.9.2049; ITO H, 1991, CIRC RES, V69, P209, DOI 10.1161/01.RES.69.1.209; Jones R, 1999, AM J RESP CELL MOL, V20, P582, DOI 10.1165/ajrcmb.20.4.3357; JOYCE NC, 1985, J CELL BIOL, V100, P1379, DOI 10.1083/jcb.100.5.1379; Kallakuri S, 2010, NEUROSCIENCE, V168, P820, DOI 10.1016/j.neuroscience.2010.01.018; Kallakuri S, 2007, NEUROL RES, V29, P362, DOI 10.1179/016164107X204675; KARIM OMA, 1992, J CELL BIOCHEM, V48, P373, DOI 10.1002/jcb.240480406; Kawamura H, 2002, INVEST OPHTH VIS SCI, V43, P882; Kreipke CW, 2010, NEUROL RES, V32, P209, DOI 10.1179/174313209X414515; Kreipke CW, 2009, J CELL MOL MED, V13, P262, DOI 10.1111/j.1582-4934.2008.00508.x; Kutcher ME, 2009, MICROVASC RES, V77, P235, DOI 10.1016/j.mvr.2009.01.007; Lam Hing-Chung, 2003, Current Vascular Pharmacology, V1, P243, DOI 10.2174/1570161033476600; Leung JWC, 2004, J CARDIOVASC PHARM, V44, pS293, DOI 10.1097/01.fjc.0000166277.70538.b0; Li Q, 2001, BRAIN RES, V907, P93, DOI 10.1016/S0006-8993(01)02607-5; Liu SQ, 1998, ATHEROSCLEROSIS, V140, P365, DOI 10.1016/S0021-9150(98)00143-9; LUNDBERG MS, 1995, IN VITRO CELL DEV-AN, V31, P595; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MCDONALD DM, 1995, INVEST OPHTH VIS SCI, V36, P1088; McDonald DM, 1996, INVEST OPHTH VIS SCI, V37, P1067; NEHLS V, 1991, J CELL BIOL, V113, P147, DOI 10.1083/jcb.113.1.147; Peppiatt CM, 2006, NATURE, V443, P700, DOI 10.1038/nature05193; Petrov T, 2002, NEUROSCIENCE, V115, P275, DOI 10.1016/S0306-4522(02)00345-7; Petrov T, 2001, NEUROL RES, V23, P139, DOI 10.1179/016164101101198479; Pinzani M, 1996, GASTROENTEROLOGY, V110, P534, DOI 10.1053/gast.1996.v110.pm8566602; Rafols JA, 2007, NEUROL RES, V29, P339, DOI 10.1179/016164107X204648; RAMACHANDRAN E, 1993, INVEST OPHTH VIS SCI, V34, P586; ROCKEY DC, 1995, BIOCHEM BIOPH RES CO, V207, P725, DOI 10.1006/bbrc.1995.1247; SIMONSON MS, 1990, J CLIN INVEST, V85, P790, DOI 10.1172/JCI114505; SPATZ M, 1993, PROSTAG LEUKOTR ESS, V49, P789, DOI 10.1016/0952-3278(93)90027-T; Takahashi A, 1997, ACTA NEUROPATHOL, V93, P354, DOI 10.1007/s004010050627; THOMAS CP, 1991, J CARDIOVASC PHARM, V17, pS79, DOI 10.1097/00005344-199100177-00022; Toribatake Y, 1997, SPINAL CORD, V35, P26, DOI 10.1038/sj.sc.3100348; WALLOW IHL, 1993, INVEST OPHTH VIS SCI, V34, P420; Yahiaoui L, 2006, CELL PHYSIOL BIOCHEM, V17, P37, DOI 10.1159/000091462; Yakubu MA, 1999, AM J PHYSIOL-CELL PH, V276, pC300; Yokota T, 2003, DIABETES, V52, P838, DOI 10.2337/diabetes.52.3.838	54	42	44	0	9	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.	MAR	2011	33	2					176	184		10.1179/016164111X12881719352372			9	Clinical Neurology; Neurosciences	Neurosciences & Neurology	723OM	WOS:000287516600009	21801592				2021-06-18	
J	Simblett, SK; Bateman, A				Simblett, Sara K.; Bateman, Andrew			Dimensions of the Dysexecutive Questionnaire (DEX) examined using Rasch analysis	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Dysexecutive Questionnaire; DEX; Acquired brain injury; Rasch analysis	TRAUMATIC BRAIN-INJURY; EXECUTIVE DYSFUNCTION; ECOLOGICAL VALIDITY; MEASUREMENT MODEL; GOAL MANAGEMENT; REHABILITATION; DEFICITS; PROGRAM; RATINGS; SKILLS	Executive dysfunction is very broad term used to capture a range of interacting high-level cognitive, emotional and behavioural difficulties, commonly seen after acquired brain injury (ABI). Many argue that the concept of executive functioning should be subdivided into several separate dimensions. In this study we explore the dimensional structure of a tool designed to assess level of executive functioning, the Dysexecutive (DEX) Questionnaire (Burgess, Alderman, Wilson, Evans, Emslie, 1996), in order to inform theoretical conceptualisations of executive functioning and improve measurement precision in rehabilitation centres. Rasch analysis was undertaken on the responses of 363 people with ABI to the DEX. Overall, the questionnaire did not perform as a unidimensional, interval-level scale of executive functioning, suggesting that it measures more than one psychological construct. Most subscales previously proposed using factor analysis, including those suggested in the DEX manual, did not perform as unidimensional interval-level scales either. Several new subscales in keeping with theoretical conceptualisations of the different dimensions of executive functioning are proposed, alongside suggestions for revision of the wording and scoring of some of the items in the DEX. These results provide a platform for future evaluation of executive function rehabilitation programmes.	[Simblett, Sara K.] Univ Cambridge, Dept Psychiat, Cambridge Intellectual & Dev Disabil Res Grp, Cambridge CB2 8AH, England; [Simblett, Sara K.] CLAHRC, NIHR, Peterborough, Cambs, England; [Bateman, Andrew] Oliver Zangwill Ctr Neuropsychol Rehabil, Ely, Cambs, England	Simblett, SK (corresponding author), Univ Cambridge, Dept Psychiat, Cambridge Intellectual & Dev Disabil Res Grp, Douglas House,18B,Trumpington Rd, Cambridge CB2 8AH, England.	ss879@medschl.cam.ac.uk		Simblett, Sara/0000-0002-8075-8238; Bateman, Andrew/0000-0002-2547-5921	NIHR CLAHRC for Cambridgeshire; Peterborough PhD award	The data reported here were collected by clinicians at the Oliver Zangwill Centre for Neuropsychological Rehabilitation. The preparation this paper was funded by an NIHR CLAHRC for Cambridgeshire and Peterborough PhD award to the first author; we are grateful for their support.	ALDERMAN N, 1995, NEUROPSYCHOL REHABIL, V5, P193, DOI 10.1080/09602019508401467; Alvarez JA, 2006, NEUROPSYCHOL REV, V16, P17, DOI 10.1007/s11065-006-9002-x; ANDRICH D, 1982, PSYCHOMETRIKA, V47, P105, DOI 10.1007/BF02293856; Andrich D., 2005, RUMM2020 VERSION 4 W; Anson K, 2006, BRAIN INJURY, V20, P167, DOI 10.1080/02699050500442956; Baghaei P., 2008, MELBOURNE PAPERS LAN, V13, P32; Bateman A, 2009, NEUROPSYCHOL REHABIL, V19, P941, DOI 10.1080/09602010903021170; Bennett PC, 2005, J INT NEUROPSYCH SOC, V11, P376, DOI 10.1017/S1355617705050423; BLAND JM, 1995, BRIT MED J, V310, P170, DOI 10.1136/bmj.310.6973.170; Bodenburg S, 2008, J NERV MENT DIS, V196, P75, DOI 10.1097/NMD.0b013e31815faa2b; Burgess P.W., 1996, BADS BEHAV ASSESSMEN, P18; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Chan RCK, 2008, J NEUROL NEUROSUR PS, V79, P86, DOI 10.1136/jnnp.2007.117184; Chan RCK, 2001, BRIT J PSYCHOL, V92, P551, DOI 10.1348/000712601162338; Chaytor N, 2006, ARCH CLIN NEUROPSYCH, V21, P217, DOI 10.1016/j.acn.2005.12.002; CRONBACH LJ, 1951, PSYCHOMETRIKA, V16, P297; Damasio A., 1994, DESCARTESERROR EMOTI; DZURILLA TJ, 1999, PROBLEM SOLVING THEA; Evans J. J., 1996, SELECTING ADM INTERP; Fish J, 2007, NEUROPSYCHOLOGIA, V45, P1318, DOI 10.1016/j.neuropsychologia.2006.09.015; Fisher WP., 1992, RASCH MEASUREMENT T, V6, P238; Gilbert SJ, 2010, BRAIN RES, V1312, P79, DOI 10.1016/j.brainres.2009.11.045; Hambleton R. K., 1991, FUNDAMENTALS ITEM RE; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P1030, DOI 10.1016/S0003-9993(99)90056-4; Hobart J, 2009, HEALTH TECHNOL ASSES, V13, P1, DOI 10.3310/hta13120; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; Linacre J, 2007, RASCH MEASUREMENT T, V21, P1096; Magar ECE, 2008, PERS INDIV DIFFER, V45, P153, DOI 10.1016/j.paid.2008.03.014; Mai N, 1991, NEUROPSYCHOL REHABIL, V1, P45, DOI DOI 10.1080/09602019108401379; Manly T, 2002, NEUROPSYCHOLOGIA, V40, P271, DOI 10.1016/S0028-3932(01)00094-X; MASTERS GN, 1982, PSYCHOMETRIKA, V47, P149, DOI 10.1007/BF02296272; McDonald BC, 2002, NEUROREHABILITATION, V17, P333; Medd J, 2000, NEUROPSYCHOL REHABIL, V10, P185, DOI 10.1080/096020100389246; NOVICK MR, 1966, J MATH PSYCHOL, V3, P1, DOI 10.1016/0022-2496(66)90002-2; Oikawa N., 2006, JPN J NEUROPSYCHOL, V22, P138; Pallant JF, 2007, BRIT J CLIN PSYCHOL, V46, P1, DOI 10.1348/014466506X96931; Rasch G., 1960, PROBABALISTIC MODELS; Rath JF, 2003, NEUROPSYCHOL REHABIL, V13, P461, DOI 10.1080/09602010343000039; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Smith Everett V Jr, 2002, J Appl Meas, V3, P205; Smith R. M., 2006, J APPL MEASUREMENT; Stuss D. T., 1983, LOCALIZATION NEUROPS; STUSS DT, 2007, HUMAN FRONTAL LOBES, P292; Tennant A, 2006, RASCH MEASUREMENT T, V20, P1048; Tennant A, 2007, ARTHRIT RHEUM-ARTHR, V57, P1358, DOI 10.1002/art.23108; Wilson BA, 1996, BEHAV ASSESSMENT DYS; WRIGHT BD, 1995, RASCH MEASUREMENT T, V9, P430	47	42	42	0	19	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2011	21	1					1	25	PII 931444558	10.1080/09602011.2010.531216			25	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	715RE	WOS:000286900800001	21919559				2021-06-18	
J	Strangman, GE; O'Neil-Pirozzi, TM; Supelana, C; Goldstein, R; Katz, DI; Glenn, MB				Strangman, Gary E.; O'Neil-Pirozzi, Therese M.; Supelana, Christina; Goldstein, Richard; Katz, Douglas I.; Glenn, Mel B.			Regional brain morphometry predicts memory rehabilitation outcome after traumatic brain injury	FRONTIERS IN HUMAN NEUROSCIENCE			English	Article						cognitive rehabilitation; memory; structural neuroimaging; behavioral neurology; morphometrics; semantic clustering; brain trauma	HUMAN CEREBRAL-CORTEX; COGNITIVE REHABILITATION; ALZHEIMERS-DISEASE; WORKING-MEMORY; PREFRONTAL CORTEX; HEAD TRAUMA; MODERATE; MILD; MRI; RECOVERY	Cognitive deficits following traumatic brain injury (TBI) commonly include difficulties with memory, attention, and executive dysfunction. These deficits are amenable to cognitive rehabilitation, but optimally selecting rehabilitation programs for individual patients remains a challenge. Recent methods for quantifying regional brain morphometry allow for automated quantification of tissue volumes in numerous distinct brain structures. We hypothesized that such quantitative structural information could help identify individuals more or less likely to benefit from memory rehabilitation. Fifty individuals with TBI of all severities who reported having memory difficulties first underwent structural MRI scanning. They then participated in a 12 session memory rehabilitation program emphasizing internal memory strategies (I-MEMS). Primary outcome measures (HVLT, RBMT) were collected at the time of the MRI scan, immediately following therapy, and again at 1-month post-therapy. Regional brain volumes were used to predict outcome, adjusting for standard predictors (e. g., injury severity, age, education, pretest scores). We identified several brain regions that provided significant predictions of rehabilitation outcome, including the volume of the hippocampus, the lateral prefrontal cortex, the thalamus, and several subregions of the cingulate cortex. The prediction range of regional brain volumes were in some cases nearly equal in magnitude to prediction ranges provided by pretest scores on the outcome variable. We conclude that specific cerebral networks including these regions may contribute to learning during I-MEMS rehabilitation, and suggest that morphometric measures may provide substantial predictive value for rehabilitation outcome in other cognitive interventions as well.	[Strangman, Gary E.; Supelana, Christina] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA; [Strangman, Gary E.; O'Neil-Pirozzi, Therese M.; Supelana, Christina; Goldstein, Richard; Glenn, Mel B.] Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Boston, MA USA; [O'Neil-Pirozzi, Therese M.] Northeastern Univ, Dept Speech Language Pathol & Audiol, Boston, MA 02115 USA; [Katz, Douglas I.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [Katz, Douglas I.] Braintree Rehabil Hosp, Braintree, MA USA; [Glenn, Mel B.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA	Strangman, GE (corresponding author), Dept Psychiat, Neural Syst Grp, 149 13th St,Suite 2651, Charlestown, MA 02129 USA.	strang@nmr.mgh.harvard.edu		Strangman, Gary/0000-0001-8896-2164; Katz, Douglas/0000-0002-7502-8505	National Institute on Disability and Rehabilitation Research, Department of Education [H133A020513]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NINDS: K25-NS046554]; National Institute on Disability and Rehabilitation Research [H133A020513]; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K25-NS046554]	We would like to thank Dana Christina, Kalika Kelkar, the Statewide Head Injury Program, and Community Rehabilitation Care for their help and support. The contents of this publication were developed under a grant from the National Institute on Disability and Rehabilitation Research, Department of Education (H133A020513). However, those contents do not necessarily represent the policy of the Department of Education, and you should not assume endorsement by the Federal Government. Funding for this project also came from the NIH (NINDS: K25-NS046554). Supported by National Institute on Disability and Rehabilitation Research (grant no. H133A020513), and the National Institute of Neurological Disorders and Stroke (grant no. K25-NS046554).	Ariza M, 2006, NEUROPSYCHOLOGIA, V44, P1956, DOI 10.1016/j.neuropsychologia.2005.11.007; Azouvi P, 2000, CURR OPIN NEUROL, V13, P665, DOI 10.1097/00019052-200012000-00009; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Bigler ED, 2010, NEUROIMAGE, V50, P1017, DOI 10.1016/j.neuroimage.2010.01.003; Burgess N, 2002, NEURON, V35, P625, DOI 10.1016/S0896-6273(02)00830-9; Chen KW, 2004, NEUROIMAGE, V22, P134, DOI 10.1016/j.neuroimage.2004.01.002; Cicerone KD, 2004, ARCH PHYS MED REHAB, V85, P943, DOI 10.1016/j.apmr.2003.07.019; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Cicerone K, 2006, J COGNITIVE NEUROSCI, V18, P1212, DOI 10.1162/jocn.2006.18.7.1212; Cramer SC, 2004, STROKE, V35, P2695, DOI 10.1161/01.STR.0000143326.36847.b0; de la Plata CAM, 2008, ARCH PHYS MED REHAB, V89, P896, DOI 10.1016/j.apmr.2007.12.030; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; Desikan RS, 2009, BRAIN, V132, P2048, DOI 10.1093/brain/awp123; Destrieux C, 2010, NEUROIMAGE, V53, P1, DOI 10.1016/j.neuroimage.2010.06.010; Dickerson BC, 2009, CEREB CORTEX, V19, P497, DOI 10.1093/cercor/bhn113; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Draper N. R., 1998, APPL REGRESSION ANAL, V326; Fischl B, 2004, CEREB CORTEX, V14, P11, DOI 10.1093/cercor/bhg087; Fischl B, 1999, NEUROIMAGE, V9, P195, DOI 10.1006/nimg.1998.0396; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Fjell AM, 2009, CEREB CORTEX, V19, P2001, DOI 10.1093/cercor/bhn232; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; Giles GM, 2001, BRAIN DAM B, P231; Han X, 2007, IEEE T MED IMAGING, V26, P479, DOI 10.1109/TMI.2007.893282; Hillary FG, 2006, HUM BRAIN MAPP, V27, P837, DOI 10.1002/hbm.20226; Jorge RE, 2007, BIOL PSYCHIAT, V62, P332, DOI 10.1016/j.biopsych.2006.07.024; Jovicich J, 2009, NEUROIMAGE, V46, P177, DOI 10.1016/j.neuroimage.2009.02.010; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; KENNEDY DN, 1989, IEEE T MED IMAGING, V8, P1, DOI 10.1109/42.20356; Kim YH, 2009, NEUROREHAB NEURAL RE, V23, P468, DOI 10.1177/1545968308328728; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; KRONMAL RA, 1993, J ROY STAT SOC A STA, V156, P379, DOI 10.2307/2983064; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; Logan JM, 2002, NEURON, V33, P827, DOI 10.1016/S0896-6273(02)00612-8; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; McCauley SR, 2010, DEV NEUROPSYCHOL, V35, P318, DOI 10.1080/87565641003696866; Mega MS, 2005, NEUROIMAGE, V26, P1009, DOI 10.1016/j.neuroimage.2005.03.031; Merkley TL, 2008, J NEUROTRAUM, V25, P1343, DOI 10.1089/neu.2008.0615; Messinger A, 2009, J NEUROSCI, V29, P5640, DOI 10.1523/JNEUROSCI.3857-08.2009; Ng K, 2008, ARCH PHYS MED REHAB, V89, pS35, DOI 10.1016/j.apmr.2008.07.006; O'Neil-Pirozzi TM, 2010, J HEAD TRAUMA REHAB, V25, P43, DOI 10.1097/HTR.0b013e3181bf24b1; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Ranganath C, 2003, NEUROPSYCHOLOGIA, V41, P378, DOI 10.1016/S0028-3932(02)00169-0; Rapoport MJ, 2000, BRAIN INJURY, V14, P749; Rossi AF, 2009, EXP BRAIN RES, V192, P489, DOI 10.1007/s00221-008-1642-z; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Salat DH, 2004, CEREB CORTEX, V14, P721, DOI 10.1093/cercor/bhh032; Salmond CH, 2005, BRAIN, V128, P189, DOI 10.1093/brain/awh352; SCHMANSKY N, 2010, DESTRIEUX ATLAS CHAN; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; Strangman GE, 2008, ARCH PHYS MED REHAB, V89, P974, DOI 10.1016/j.apmr.2008.02.011; Strangman GE, 2009, NEUROREHAB NEURAL RE, V23, P226, DOI 10.1177/1545968308324225; Taylor KS, 2009, HUM BRAIN MAPP, V30, P2731, DOI 10.1002/hbm.20705; TEMKIN NR, 1995, J NEUROSURG, V82, P764, DOI 10.3171/jns.1995.82.5.0764; Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092; Vogt BA, 2005, NAT REV NEUROSCI, V6, P533, DOI 10.1038/nrn1704; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412	61	42	43	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5161			FRONT HUM NEUROSCI	Front. Hum. Neurosci.	OCT 14	2010	4								182	10.3389/fnhum.2010.00182			11	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	747GR	WOS:000289308800001	21048895	DOAJ Gold, Green Published			2021-06-18	
J	Berry, C; Salim, A; Alban, R; Mirocha, J; Margulies, DR; Ley, EJ				Berry, Chersse; Salim, Ali; Alban, Rodrigo; Mirocha, James; Margulies, Daniel R.; Ley, Eric J.			Serum Ethanol Levels in Patients with Moderate to Severe Traumatic Brain Injury Influence Outcomes: A Surprising Finding	AMERICAN SURGEON			English	Article							ALCOHOL-INTOXICATION; HEAD-INJURY; MORTALITY; DEFICITS	Animal studies routinely demonstrate an alcohol (ETOH) -mediated increase in survival after experimental traumatic brain injury (TB!). Recent clinical studies also suggest ETOH plays a neuroprotective role in moderate to severe TBI. We sought to investigate the relationship between ETOH and outcomes in patients with moderate to severe TBI using a countywide database. The Los Angeles County Trauma System database was queried for all adult (older than 14 years) patients with isolated moderate to severe TBI trauma (head Abbreviated Injury Score [AIS] 3 or greater, all other AIS 3 or less) who had ETOH levels measured on admission between 1998 and 2005. A total of 7304 patients were evaluated with 3219 (44.1%) patients testing positive for serum ETOH. ETOH-positive patients with TBI had a significantly lower mortality rate compared with ETOH negative patients (8.5 vs 10.5%, P = 0.005). Even after logistic regression analysis, a positive ETOH was associated with reduced mortality (adjusted OR 0.82, 95% CI: 0.69-0.99, P = 0.035). Therefore, a positive serum ETOH level was independently associated with significantly improved survival in patients with isolated moderate to severe TBI. The neuroprotective role ETOH plays in TBI is in contrast to previous findings and deserves further attention as a potential therapeutic.	[Berry, Chersse; Salim, Ali; Alban, Rodrigo; Mirocha, James; Margulies, Daniel R.; Ley, Eric J.] Cedars Sinai Med Ctr, Dept Surg, Div Trauma & Crit Care, Los Angeles, CA 90048 USA	Salim, A (corresponding author), Cedars Sinai Med Ctr, Dept Surg, Div Trauma & Crit Care, 8700 Beverly Blvd,Suite 8215N, Los Angeles, CA 90048 USA.	ali.salim@cshs.org	Berry, Cherisse/AAO-5701-2020				Albrecht RF, 1998, MAYO CLIN PROC, V73, P629; Bombardier CH, 1998, BRAIN INJURY, V12, P725, DOI 10.1080/026990598122124; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; CHANDLER LJ, 1993, ALCOHOL CLIN EXP RES, V17, P54, DOI 10.1111/j.1530-0277.1993.tb00726.x; Gottesfeld Z, 2002, J NEUROTRAUM, V19, P317, DOI 10.1089/089771502753594882; HAMILL RW, 1987, ANN NEUROL, V21, P438, DOI 10.1002/ana.410210504; KELLY DF, 1995, J NEUROTRAUM, V12, P883, DOI 10.1089/neu.1995.12.883; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; O'Phelan K, 2008, J TRAUMA, V65, P674, DOI 10.1097/TA.0b013e31817db0a5; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Salim A, 2009, J TRAUMA, V67, P697, DOI 10.1097/TA.0b013e3181b5dcf2; Salim A, 2009, ARCH SURG-CHICAGO, V144, P865, DOI 10.1001/archsurg.2009.158; Sall JM, 1996, EXP NEUROL, V139, P257, DOI 10.1006/exnr.1996.0099; Taylor AN, 2002, J NEUROTRAUM, V19, P1597, DOI 10.1089/089771502762300256; WALTER PF, 1986, JAMA-J AM MED ASSOC, V256, P1461; WOOLF PD, 1990, ALCOHOL CLIN EXP RES, V14, P205, DOI 10.1111/j.1530-0277.1990.tb00473.x	16	42	44	0	3	SOUTHEASTERN SURGICAL CONGRESS	CUMMING	115 SAMARITAN DR, #200, CUMMING, GA 30040-2354 USA	0003-1348	1555-9823		AM SURGEON	Am. Surg.	OCT	2010	76	10					1067	1070					4	Surgery	Surgery	663AO	WOS:000282855600009	21105611				2021-06-18	
J	Oddo, M; Nduom, E; Frangos, S; MacKenzie, L; Chen, I; Maloney-Wilensky, E; Kofke, WA; Levine, JM; LeRoux, PD				Oddo, Mauro; Nduom, Edjah; Frangos, Suzanne; MacKenzie, Larami; Chen, Isaac; Maloney-Wilensky, Eileen; Kofke, W. Andrew; Levine, Joshua M.; LeRoux, Peter D.			Acute Lung Injury Is an Independent Risk Factor for Brain Hypoxia After Severe Traumatic Brain Injury	NEUROSURGERY			English	Article						Acute lung injury; Brain hypoxia; Brain tissue oxygen tension; Lung function; Systemic oxygenation; Traumatic brain injury	RESPIRATORY-DISTRESS-SYNDROME; SEVERE HEAD-INJURY; END-EXPIRATORY PRESSURE; TISSUE OXYGEN-TENSION; CEREBRAL PERFUSION-PRESSURE; HIGH TIDAL VOLUME; MECHANICAL VENTILATION; LONGITUDINAL DATA; INSPIRED OXYGEN; DELIVERY	BACKGROUND: Pulmonary complications are frequently observed after severe traumatic brain injury (TBI), but little is known about the consequences of lung injury on brain tissue oxygenation and metabolism. OBJECTIVE: We examined the association between lung function and brain tissue oxygen tension (PbtO(2)) in patients with severe TBI. METHODS: We analyzed data from 78 patients with severe, nonpenetrating TBI who underwent continuous PbtO(2) and intracranial pressure monitoring. Acute lung injury was defined by the presence of pulmonary infiltrates with a PaO2/FiO(2) (PF) ratio less than 300 and the absence of left ventricular failure. A total of 587 simultaneous measurements of PbtO(2) and PF ratio were examined using longitudinal data analysis. RESULTS: PbtO(2) correlated strongly with PaO2 and PF ratio (P < .05) independent of PaCO2, brain temperature, cerebral perfusion pressure, and hemoglobin. Acute lung injury was associated with lower PbtO(2) (34.6 +/- 13.8 mm Hg at PF ratio > 300 vs 30.2 +/- 10.8 mm Hg [ PF ratio 200-300], 28.9 +/- 9.8 mm Hg [ PF ratio 100-199], and 21.1 +/- 7.4 mm Hg [ PF ratio < 100], all P values <. 01). After adjusting for intracranial pressure, Marshall computed tomography score, and APACHE II (Acute Physiology and Chronic Health Evaluation) score, acute lung injury was an independent risk factor for compromised PbtO(2) (PbtO(2) < 20 mm Hg; adjusted odds ratio: 2.13, 95% confidence interval: 1.21-3.77; P < .01). CONCLUSION: After severe TBI, PbtO(2) correlates with PF ratio. Acute lung injury is associated with an increased risk of compromised PbtO(2), independent from intracerebral and systemic injuries. Our findings support the use of lung-protective strategies to prevent brain hypoxia in TBI patients.	[LeRoux, Peter D.] Univ Penn, Med Ctr, Div Clin Res, Dept Neurosurg, Philadelphia, PA 19107 USA; [MacKenzie, Larami; Levine, Joshua M.] Univ Penn, Med Ctr, Dept Neurol, Philadelphia, PA 19107 USA; [Kofke, W. Andrew; Levine, Joshua M.] Univ Penn, Med Ctr, Dept Anesthesiol & Crit Care, Philadelphia, PA 19107 USA	LeRoux, PD (corresponding author), Univ Penn, Med Ctr, Div Clin Res, Dept Neurosurg, 330 S 9th St, Philadelphia, PA 19107 USA.	Peter.LeRoux@uphs.upenn.edu	Oddo, Mauro/R-3370-2016; Nduom, Edjah/K-3171-2019	Oddo, Mauro/0000-0002-6155-2525; Nduom, Edjah/0000-0001-9882-0899	SICPA Foundation, Switzerland; Integra Foundation; Integra Neurosciences; Mary Elisabeth Groff Surgical and Medical Research Trust	Supported by research grants from the SICPA Foundation, Switzerland (M.O.), the Integra Foundation (P.D.L.R.), Integra Neurosciences (PDLR), and the Mary Elisabeth Groff Surgical and Medical Research Trust (P.D.L.R.). Dr. Le Roux is a member of Integra Neurosciences Speaker's Bureau. The authors have no personal financial or institutional interest in any of the drugs, materials, or devices described in this article.	BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Bratton SL, 1997, NEUROSURGERY, V40, P707, DOI 10.1097/00006123-199704000-00009; Brochard L, 1998, AM J RESP CRIT CARE, V158, P1831, DOI 10.1164/ajrccm.158.6.9801044; Bronchard G, 2004, ANESTHESIOLOGY, V100, P234, DOI 10.1097/00000542-200402000-00009; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Bullock RM, 2000, J NEUROTRAUM, V17, P449; BURCHIEL KJ, 1981, NEUROSURGERY, V8, P443, DOI 10.1227/00006123-198104000-00007; Chang JJJ, 2009, CRIT CARE MED, V37, P283, DOI 10.1097/CCM.0b013e318192fbd7; Coles Jonathan P, 2004, Curr Opin Crit Care, V10, P120, DOI 10.1097/00075198-200404000-00008; Coles JP, 2002, CRIT CARE MED, V30, P1950, DOI 10.1097/00003246-200209000-00002; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; Crossley DJ, 1997, CRIT CARE MED, V25, P1522, DOI 10.1097/00003246-199709000-00019; Dings J, 1998, NEUROL RES, V20, pS71; Gajic O, 2004, CRIT CARE MED, V32, P1817, DOI 10.1097/01.CCM.0000133019.52531.30; Hemphill JC, 2005, AM J NEURORADIOL, V26, P1095; Hemphill JC, 2001, NEUROSURGERY, V48, P377, DOI 10.1097/00006123-200102000-00028; Hlatky R, 2008, J NEUROSURG, V108, P53, DOI 10.3171/JNS/2008/108/01/0053; Holland MC, 2003, J TRAUMA, V55, P106, DOI 10.1097/01.TA.0000071620.27375.BE; Huynh T, 2002, J TRAUMA, V53, P488, DOI 10.1097/00005373-200209000-00016; Kalsotra A, 2007, J CEREBR BLOOD F MET, V27, P963, DOI 10.1038/sj.jcbfm.9600396; Lowe GJ, 2006, CURR OPIN CRIT CARE, V12, P3, DOI 10.1097/01.ccx.0000198055.29600.4b; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Mascia L, 2008, MINERVA ANESTESIOL, V74, P325; Mascia L, 2005, INTENS CARE MED, V31, P373, DOI 10.1007/s00134-004-2491-2; Mascia L, 2007, CRIT CARE MED, V35, P1815, DOI 10.1097/01.CCM.0000275269.77467.DF; Meixensberger J, 2003, J NEUROL NEUROSUR PS, V74, P760, DOI 10.1136/jnnp.74.6.760; Moore F, 2002, J TRAUMA, V53, P492; MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720; Nortje J, 2006, BRIT J ANAESTH, V97, P95, DOI 10.1093/bja/ael137; Oddo M, 2008, CRIT CARE MED, V36, P1984, DOI 10.1097/CCM.0b013e318176a9f6; Offner PJ, 2003, J TRAUMA, V55, P285, DOI 10.1097/01.TA.0000078695.35172.79; Pennings FA, 2008, J NEUROTRAUM, V25, P1173, DOI 10.1089/neu.2007.0402; Pinhu L, 2003, LANCET, V361, P332, DOI 10.1016/S0140-6736(03)12329-X; Ranieri VM, 1999, JAMA-J AM MED ASSOC, V282, P54, DOI 10.1001/jama.282.1.54; Reinert M, 2003, ACTA NEUROCHIR, V145, P341, DOI 10.1007/s00701-003-0027-0; ROGERS FB, 1995, J TRAUMA, V39, P860, DOI 10.1097/00005373-199511000-00009; Rosenthal G, 2008, CRIT CARE MED, V36, P1917, DOI 10.1097/CCM.0b013e3181743d77; Rosenthal G, 2008, J NEUROSURG, V108, P59, DOI 10.3171/JNS/2008/108/01/0059; Scheufler KM, 2002, ANESTH ANALG, V95, P1042, DOI 10.1097/00000539-200210000-00046; SHAPIRO HM, 1978, J TRAUMA, V18, P254, DOI 10.1097/00005373-197804000-00005; SPIOTTA A, 2010, J NEUROSURG     0423; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Tobin MJ, 2000, NEW ENGL J MED, V342, P1360, DOI 10.1056/NEJM200005043421808; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; van Santbrink H, 2003, ACTA NEUROCHIR, V145, P429, DOI 10.1007/s00701-003-0032-3; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; Yildirim E, 2004, EUR J CARDIO-THORAC, V25, P523, DOI 10.1016/j.ejcts.2003.12.021; ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734; ZEGER SL, 1992, STAT MED, V11, P1825, DOI 10.1002/sim.4780111406	51	42	45	0	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	AUG	2010	67	2					338	344		10.1227/01.NEU.0000371979.48809.D9			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	628HI	WOS:000280105800025	20644419				2021-06-18	
J	Preece, MHW; Horswill, MS; Geffen, GM				Preece, Megan H. W.; Horswill, Mark S.; Geffen, Gina M.			Driving After Concussion: The Acute Effect of Mild Traumatic Brain Injury on Drivers' Hazard Perception	NEUROPSYCHOLOGY			English	Article						mild traumatic brain injury; driving; fitness-to-drive; hazard perception skill	FIELD-OF-VIEW; HEAD-INJURY; OLDER-ADULTS; ACCIDENT INVOLVEMENT; EXPERIENCED DRIVERS; TRAFFIC ACCIDENT; WORD REPETITION; VISUAL-SEARCH; EYE-MOVEMENTS; RAPID SCREEN	Objective: No research has examined whether individuals recovering from a recent mild traumatic brain injury (MTBI) are safe to drive, despite cognitive impairment being a common consequence soon after MTBI. This study examined the acute effect of MTBI on drivers' hazard perception, which is defined as drivers' ability to search the road ahead to rapidly identify potentially dangerous traffic situations. Poorer hazard perception has been associated with higher crash rate's in a number of studies. Method: Forty-two patients with MTBI and 43 patients with minor orthopedic injuries were recruited from the emergency department of a large metropolitan hospital within 24 hours of injury. Participants completed a computerized hazard perception test, in which they watched videos of genuine traffic scenes filmed from the driver's point of view. They were required to use the computer mouse to click on potential traffic hazards as early as possible. Results: Participants with MTBI were significantly slower to respond to traffic hazards than participants with minor orthopedic injuries (p = .03, d = .48). Conclusions: This study provides the first indication that within the acute stage postinjury, MTBI is associated with impairment in a crash-related component of driving. This suggests that patients with MTBI should be advised to refrain from driving for at least the first 24 hours' postinjury.	[Preece, Megan H. W.; Horswill, Mark S.; Geffen, Gina M.] Univ Queensland, Sch Psychol, Brisbane, Qld 4072, Australia	Preece, MHW (corresponding author), Univ Queensland, Sch Psychol, Brisbane, Qld 4072, Australia.	m.preece@psy.uq.edu.au	Horswill, Mark/J-9029-2019; Preece, Megan/A-7186-2013	Horswill, Mark/0000-0002-0286-6292; Preece, Megan/0000-0003-4852-8712	Department of Emergency Medicine, Royal Brisbane & Women's Hospital	The research reported here forms part of the doctoral thesis of Megan H. W. Preece, to be submitted to The University of Queensland. These data were also presented in a poster session at the inaugural Mild Traumatic Brain Injury Conference. August. 2009, Vancouver. British Columbia. Canada. We thank Emmaline Falconer and Felicia Tay for testing some of the participants; Mark Wetton for preparing the Hazard Perception Test; and Dr Kevin Chu and staff from the Department of Emergency Medicine, Royal Brisbane & Women's Hospital for supporting the researchers to complete the study.	Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; BAILEY IL, 1993, OPTOMETRY VISION SCI, V70, P299, DOI 10.1097/00006324-199304000-00008; BAILEY IL, 1976, AM J OPTOM PHYS OPT, V53, P740; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bigler ED, 2004, J INT NEUROPSYCH SOC, V10, P794, DOI 10.1017/S1355617704105146; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Brewer TL, 2002, RES NURS HEALTH, V25, P269, DOI 10.1002/nur.10045; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chapman PR, 1998, PERCEPTION, V27, P951, DOI 10.1068/p270951; Comerford VE, 2002, J CLIN EXP NEUROPSYC, V24, P409, DOI 10.1076/jcen.24.4.409.1044; CRAWFORD JR, 1988, BRIT J PSYCHIAT, V153, P178, DOI 10.1192/bjp.153.2.178; Crundall D, 2003, J EXP PSYCHOL-APPL, V9, P163, DOI 10.1037/1076-898X.9.3.163; Crundall D, 1999, PERCEPTION, V28, P1075, DOI 10.1068/p2894; Crundall DE, 1998, ERGONOMICS, V41, P448, DOI 10.1080/001401398186937; Darby P, 2009, SAFETY SCI, V47, P436, DOI 10.1016/j.ssci.2008.05.004; De Monte VE, 2005, J CLIN EXP NEUROPSYC, V27, P224, DOI 10.1080/13803390490515766; De Monte VE., 2005, BRAIN IMPAIR, V6, P109, DOI [10.1375/brim.2005.6.2.109, DOI 10.1375/BRIM.2005.6.2.109]; De Monte VE, 2006, BRAIN INJURY, V20, P1345, DOI 10.1080/02699050601082073; Falconer EK, 2006, BRAIN INJURY, V20, P1251, DOI 10.1080/02699050601049601; Fisk GD, 1998, BRAIN INJURY, V12, P683; Formisano R, 2005, BRAIN INJURY, V19, P159, DOI 10.1080/02699050400017163; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Garay-Vega L, 2007, TRANSPORT RES REC, P1, DOI 10.3141/2009-01; Goode KT, 1998, J CLIN PSYCHOL MED S, V5, P425, DOI 10.1023/A:1026206927686; Graydon FX, 2004, TRANSPORT RES F-TRAF, V7, P271, DOI 10.1016/j.trf.2004.09.006; Hawley CA, 2001, J NEUROL NEUROSUR PS, V70, P761, DOI 10.1136/jnnp.70.6.761; Hirth VA, 2007, DEMENT GERIATR COGN, V24, P335, DOI 10.1159/000108606; Horikawa E, 2005, BRAIN COGNITION, V58, P166, DOI 10.1016/j.bandc.2004.10.002; Horswill M.S., 2004, COGNITIVE APPROACH S, P155; Horswill MS, 2008, J GERONTOL B-PSYCHOL, V63, pP212, DOI 10.1093/geronb/63.4.P212; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Kwapil KJ., 2003, BRAIN IMPAIR, V4, P155; Lawton R, 1997, J APPL SOC PSYCHOL, V27, P1258, DOI 10.1111/j.1559-1816.1997.tb01805.x; Leon-Carrion J, 2005, BRAIN INJURY, V19, P213, DOI 10.1080/02699050400017205; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lew HL, 2005, BRAIN INJURY, V19, P177, DOI 10.1080/02699050400017171; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Lovibond S.H., 1995, MANUAL DEPRESSION AN; Marrington SA, 2008, OPTOMETRY VISION SCI, V85, P1121, DOI 10.1097/OPX.0b013e31818e8d00; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; MCCULLOUGH CM, 2006, BRAIN IMPAIR, V7, P16; McKenna F.P., 1999, BEHAV RES ROAD SAFET; McKenna F.P., 1999, IATSS RES, V23, P26; McKenna FP, 2006, J EXP PSYCHOL-APPL, V12, P1, DOI 10.1037/1076-898X.12.1.1; McKenna FP., 1991, HAZARD PERCEPTION DR; Mesken J, 2002, ERGONOMICS, V45, P469, DOI 10.1080/00140130210129682; MILLS KL, 1998, EFFECTS HAZARD PERCE; Motor Accident Authorithies New South Wales, 2008, GUID MILD TRAUM BRAI; MOURANT RR, 1972, HUM FACTORS, V14, P325, DOI 10.1177/001872087201400405; Novack TA, 2006, BRAIN INJURY, V20, P455, DOI 10.1080/02699050600664541; Owsley C, 1998, JAMA-J AM MED ASSOC, V279, P1083, DOI 10.1001/jama.279.14.1083; PARKER D, 1995, ERGONOMICS, V38, P1036, DOI 10.1080/00140139508925170; PARKER D, 1995, ACCIDENT ANAL PREV, V27, P571, DOI 10.1016/0001-4575(95)00005-K; Peltz D.C., 1974, ACCIDENT ANAL PREV, V6, P45, DOI [10.1016/0001-4575(74)90015-3, DOI 10.1016/0001-4575(74)90015-3]; Pollatsek A, 2006, CURR DIR PSYCHOL SCI, V15, P255, DOI 10.1111/j.1467-8721.2006.00447.x; Pradhan AK, 2005, HUM FACTORS, V47, P840, DOI 10.1518/001872005775570961; Preacher KJ, 2004, BEHAV RES METH INS C, V36, P717, DOI 10.3758/BF03206553; Preece MHW, 2007, BRAIN INJURY, V21, P951, DOI 10.1080/02699050701481647; QUIMBY AR, 1986, PERCEPTUAL ABILITIES, V27; Renge K., 1998, IATSS RES, V22, P103; Rosser DA, 2001, BRIT J OPHTHALMOL, V85, P432, DOI 10.1136/bjo.85.4.432; Schneider JJ, 2005, APPL NEUROPSYCHOL, V12, P138, DOI 10.1207/S15324826AN1203_3; Smith SS, 2009, ACCIDENT ANAL PREV, V41, P729, DOI 10.1016/j.aap.2009.03.016; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; Underwood G, 2002, ERGONOMICS, V45, P1, DOI 10.1080/00140130110110610; Underwood G., 2002, TRANSPORTATION RES F, V5, P87, DOI [10.1016/S1369-8478(02)00008-6, DOI 10.1016/S1369-8478(02)00008-6]; VANZOMEREN AH, 1987, ARCH PHYS MED REHAB, V68, P697; Voller B, 1999, BRAIN INJURY, V13, P821, DOI 10.1080/026990599121214; Wald JL, 2000, CYBERPSYCHOL BEHAV, V3, P643, DOI 10.1089/109493100420232; Wallis TSA, 2007, ACCIDENT ANAL PREV, V39, P1177, DOI 10.1016/j.aap.2007.03.003; Watts G., 1979, DESIGN VALIDATION DR; Wechsler D, 1981, WESCHLER ADULT INTEL; WELLS P, 2008, COHORT 2 STUDY LEARN, V81; Wilson, 1991, NATL ADULT READING T	76	42	44	1	20	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	JUL	2010	24	4					493	503		10.1037/a0018903			11	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	619HN	WOS:000279420500008	20604623				2021-06-18	
J	O'Donnell, ML; Creamer, M; McFarlane, AC; Silove, D; Bryant, RA				O'Donnell, Meaghan L.; Creamer, Mark; McFarlane, Alexander C.; Silove, Derrick; Bryant, Richard A.			Should A2 be a diagnostic requirement for posttraumatic stress disorder in DSM-V?	PSYCHIATRY RESEARCH			English	Article						Traumatic injury; Criterion A	BRAIN INJURY; CRITERION; PTSD; IV; CONTROVERSIES	The requirement that trauma survivors experience fear, helplessness or horror (Criterion A2) as a part of their posttraumatic stress disorder (PTSD) diagnosis was introduced into DSM-IV. The imminent re-definition of PTSD in DSM-V highlights the need for empirical studies to validate the utility of the A2 requirement. We aimed to identify (i) how often A2 was associated with PTSD (B-F criteria) at 3 months after trauma and (ii) what was the peritraumatic emotional experience for those who met PTSD criteria but were A2 negative. In a prospective design cohort study we assessed the peritraumatic emotional experience of 535 injury patients in four Australian hospitals. These patients were followed up 3 months later and assessed for PTSD using a structured clinical interview. The majority of those who developed PTSD (B-F criterion) at 3 months met A2 criteria. A substantial minority, however (23%), did not meet A2 criteria. Those PTSD patients who were A2 negative fell into three groups: (i) those who experienced subthreshold levels of A2; (ii) those who experienced intense peritrauma emotional responses other than fear, helplessness or horror; and (iii) those who were amnesic to their peritrauma emotional experience. These findings do not support the inclusion of A2 as diagnostic requirement for DSM-V. (C) 2009 Elsevier Ireland Ltd. All rights reserved.	[O'Donnell, Meaghan L.; Creamer, Mark] Australian Ctr Posttraumat Mental Hlth, Melbourne, Vic 3002, Australia; [O'Donnell, Meaghan L.; Creamer, Mark] Univ Melbourne, Dept Psychiat, Parkville, Vic 3052, Australia; [O'Donnell, Meaghan L.] Natl Trauma Res Inst, Prahran, Vic, Australia; [Bryant, Richard A.] Univ New S Wales, Sch Psychol, Sydney, NSW, Australia; [Silove, Derrick] Univ New S Wales, Dept Psychiat, Sydney, NSW, Australia; [Silove, Derrick] Mental Hlth Ctr, Psychiat Res & Teaching Unit, Liverpool, NSW, Australia; [McFarlane, Alexander C.] Univ Adelaide, Dept Psychiat, Adelaide, SA 5005, Australia	O'Donnell, ML (corresponding author), Australian Ctr Posttraumat Mental Hlth, Level 1,340 Albert St, Melbourne, Vic 3002, Australia.	mod@unimelb.edu.au	Bryant, Richard/AAA-6479-2019	Bryant, Richard/0000-0002-9607-819X; O'Donnell, Meaghan/0000-0003-4349-0022	NHMRCNational Health and Medical Research Council of Australia [300304, 359284]; Victorian Trauma Foundation [V-11]	This study was supported by an NHMRC Program Grant (300304), a Victorian Trauma Foundation grant (#V-11), and a National Health and Medical Research Council Australian Clinical Research Fellowship (359284).	Adler AB, 2008, J TRAUMA STRESS, V21, P301, DOI 10.1002/jts.20336; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bedard-Gilligan M, 2008, BEHAV RES THER, V46, P1062, DOI 10.1016/j.brat.2008.06.009; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Breslau N, 2001, BIOL PSYCHIAT, V50, P699, DOI 10.1016/S0006-3223(01)01167-2; Brewin CR, 2000, J TRAUMA STRESS, V13, P499, DOI 10.1023/A:1007741526169; Brunet A, 2001, AM J PSYCHIAT, V158, P1480, DOI 10.1176/appi.ajp.158.9.1480; Bryant RA, 2001, CLIN PSYCHOL REV, V21, P931; Bryant RA, 2001, J CLIN EXP NEUROPSYC, V23, P718, DOI 10.1076/jcen.23.6.718.1024; Creamer M, 2001, PSYCHOL MED, V31, P1237, DOI 10.1017/S0033291701004287; DAVIDSON JRT, 1991, J ABNORM PSYCHOL, V100, P346, DOI 10.1037/0021-843X.100.3.346; Elhai JD, 2005, BRIT J PSYCHIAT, V187, P189, DOI 10.1192/bjp.187.2.189-a; Harvey AG, 2000, J NERV MENT DIS, V188, P602, DOI 10.1097/00005053-200009000-00007; KILPATRICK DG, 1997, DSM 4 SOURCEBOOK, V4; Long ME, 2009, PSYCHOL INJ LAW, V2, P167, DOI 10.1007/s12207-009-9043-6; O'Donnell ML, 2003, CLIN PSYCHOL REV, V23, P587, DOI 10.1016/S0272-7358(03)00036-9; ODONNELL ML, CLIN GUIDE SCI POSTT; Schnurr PP., 2002, J CLIN GEROPSYCHOL, V8, P175, DOI DOI 10.1023/A:1015992110544; Weathers FW, 2007, J TRAUMA STRESS, V20, P107, DOI 10.1002/jts.20210	20	42	44	0	5	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0165-1781			PSYCHIAT RES	Psychiatry Res.	APR 30	2010	176	2-3					257	260		10.1016/j.psychres.2009.05.012			4	Psychiatry	Psychiatry	585MP	WOS:000276830000030	20207009				2021-06-18	
J	Baratz, R; Rubovitch, V; Frenk, H; Pick, CG				Baratz, Renana; Rubovitch, Vardit; Frenk, Hanan; Pick, Chaim G.			The Influence of Alcohol on Behavioral Recovery after mTBI in Mice	JOURNAL OF NEUROTRAUMA			English	Article						alcohol and drug abuse; axonal injury; behavioral assessment; binge alcohol drinking; traumatic brain injury	TRAUMATIC BRAIN-INJURY; ACUTE ETHANOL INTOXICATION; ACUTE-PHASE RESPONSE; MINOR HEAD-INJURY; COGNITIVE DEFICITS; HOST-DEFENSE; ACETYLCHOLINE-RELEASE; BARRIER PERMEABILITY; HEMORRHAGIC-SHOCK; SPATIAL MEMORY	In the United States 258,000 people were injured in 2004 in motor vehicle accidents that were caused by drivers under the influence of alcohol. The majority of these drivers were binge drinkers, most notably young people who tend to drink heavily during the weekends, but rarely drink alcohol during the week. Since a large proportion of the injuries involved head injuries, the present study aimed at investigating the influence of binge alcohol drinking on mild traumatic brain injury (mTBI) in an animal model. Mice had access to 0%, 7.5%, 15%, or 30% alcohol solutions for 48 consecutive hours once a week for 4 weeks as the sole source of fluids (the remaining time they drank water). Three experiments were done. For the first one (alcohol-mTBI-alcohol) the animals were subjected to a controlled mTBI injury by applying a closed-head weight drop, or a sham procedure. After the mTBI/sham-mTBI the animals got alcohol and /water for the same regimen for 4 additional weeks. In the second experiment (alcohol only) after the 4 weeks of drinking blood samples were collected, at the same time as the animals that underwent sham-mTBI or mTBI procedures. In the third experiment (mTBI-alcohol) the mice were subjected to mTBI/sham-mTBI without any treatment, and after mTBI they had alcohol for 4 weeks in the same regimen as in the previous experiments. At the end of the pharmacological treatment all animals were assessed using different behavioral tests. mTBI mice exhibited lower memory ability in the Y-maze, higher anxiety in the elevated plus maze, and lower retention in the passive avoidance test than sham-mTBI animals. Alcohol reversed these effects at all doses. The results suggest that alcohol drinking before trauma might have a protective effect on recovery from brain trauma, but not if consumed after the trauma.	[Baratz, Renana; Rubovitch, Vardit; Pick, Chaim G.] Tel Aviv Univ, Sackler Fac Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel; [Frenk, Hanan] Tel Aviv Univ, Dept Psychol, IL-69978 Tel Aviv, Israel; [Frenk, Hanan] Acad Coll Tel Aviv Yafo, Tel Aviv, Israel	Pick, CG (corresponding author), Tel Aviv Univ, Sackler Fac Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel.	pickc@post.tau.ac.il					Alcalay RN, 2004, NEUROSCI LETT, V361, P128, DOI 10.1016/j.neulet.2003.12.005; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Alkana R. L., 1996, Society for Neuroscience Abstracts, V22, P814; Arican N, 2006, INT J NEUROSCI, V116, P1249, DOI 10.1080/00207450600550303; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; BRISMAR B, 1983, ACTA CHIR SCAND, V149, P11; BUNEGIN L, 1986, CRIT CARE MED, V14, P387, DOI 10.1097/00003246-198604000-00151; CASAMENTI F, 1993, NEUROSCIENCE, V56, P465, DOI 10.1016/0306-4522(93)90346-H; CHANDLER LJ, 1993, J NEUROCHEM, V60, P1578, DOI 10.1111/j.1471-4159.1993.tb03326.x; Conrad CD, 1996, BEHAV NEUROSCI, V110, P1321, DOI 10.1037/0735-7044.110.6.1321; de Kruijk JR, 2001, BRAIN INJURY, V15, P117, DOI 10.1080/026990501458353; DELLU F, 1992, BRAIN RES, V588, P132, DOI 10.1016/0006-8993(92)91352-F; Fadda F, 1999, BEHAV BRAIN RES, V103, P71, DOI 10.1016/S0166-4328(99)00025-X; FAN L, 1995, MOL BRAIN RES, V30, P125; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Flowers NT, 2008, ALCOHOL CLIN EXP RES, V32, P639, DOI 10.1111/j.1530-0277.2008.00622.x; GENNARELLI TA, 1994, J TRAUMA, V37, P962, DOI 10.1097/00005373-199412000-00016; GLUCKMAN SJ, 1978, BLOOD, V52, P551; Gottesfeld Z, 2002, J NEUROTRAUM, V19, P317, DOI 10.1089/089771502753594882; Greiffenstein P, 2007, ALCOHOL CLIN EXP RES, V31, P704, DOI 10.1111/j.1530-0277.2007.00355.x; GURNEY JG, 1992, J TRAUMA, V33, P709, DOI 10.1097/00005373-199211000-00020; Gururaj G, 2004, J Indian Med Assoc, V102, P157; Hanchar HJ, 2007, ALCOHOL CLIN EXP RES, V31, p290A; Iorio K., 1992, Society for Neuroscience Abstracts, V18, P978; Kang MH, 1996, BRAIN RES, V709, P221, DOI 10.1016/0006-8993(95)01274-5; KAPLAN C P, 1992, Brain Injury, V6, P337, DOI 10.3109/02699059209034948; Kelly DF, 2000, J NEUROTRAUM, V17, P261, DOI 10.1089/neu.2000.17.261; KELLY DF, 1995, J NEUROTRAUM, V12, P883, DOI 10.1089/neu.1995.12.883; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; KLAUBER MR, 1981, NEUROSURGERY, V9, P236, DOI 10.1227/00006123-198109000-00003; KOLLS JK, 1995, AM J PHYSIOL-LUNG C, V268, pL991; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; LEKER RR, 2002, C RES PUBL NEUR ANT; LEKER RR, 2001, C RES PUBL NEUR ANT; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Luke LC, 2002, EMERG MED J, V19, P542, DOI 10.1136/emj.19.6.542; Luo J, 2001, J NEUROCHEM, V76, P1354, DOI 10.1046/j.1471-4159.2001.00129.x; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Molina PE, 2004, ALCOHOL, V33, P217, DOI 10.1016/j.alcohol.2004.07.002; MOLLERMADSEN B, 1986, Z RECHTSMED, V97, P141; O'Phelan K, 2008, J TRAUMA, V65, P674, DOI 10.1097/TA.0b013e31817db0a5; OIKARINEN K, 1992, ALCOHOL ALCOHOLISM, V27, P189; Pan WH, 2003, EXP BRAIN RES, V149, P195, DOI 10.1007/s00221-002-1355-7; PERSSON L, 1977, ACTA NEUROL SCAND, V56, P7; Popovic M, 2004, NEUROSCI LETT, V357, P79, DOI 10.1016/j.neulet.2003.10.046; PORIES SE, 1992, J TRAUMA, V32, P60, DOI 10.1097/00005373-199201000-00013; Puljula J, 2007, ALCOHOL ALCOHOLISM, V42, P474, DOI 10.1093/alcalc/agm003; Schepens PJ, 1998, ANN EMERG MED, V31, P633, DOI 10.1016/S0196-0644(98)70210-0; Schreiber S, 2008, SLEEP MED, V9, P481, DOI 10.1016/j.sleep.2007.04.014; Schwarzbach E, 2006, HIPPOCAMPUS, V16, P541, DOI 10.1002/hipo.20183; Szabo G, 1999, ALCOHOL ALCOHOLISM, V34, P830, DOI 10.1093/alcalc/34.6.830; Tashlykov V, 2009, J MOL NEUROSCI, V37, P16, DOI 10.1007/s12031-008-9094-2; Tashlykov V, 2007, BRAIN RES, V1130, P197, DOI 10.1016/j.brainres.2006.10.032; Taylor AN, 2002, J NEUROTRAUM, V19, P1597, DOI 10.1089/089771502762300256; TULLOH BR, 1994, INJURY, V25, P539, DOI 10.1016/0020-1383(94)90097-3; Tweedie D, 2007, J NEUROSCI RES, V85, P805, DOI 10.1002/jnr.21160; VINSON RB, 1998, AM J PHYSIOL, V44, pR1049; Wang JY, 1998, LIFE SCI, V63, P1571, DOI 10.1016/S0024-3205(98)00424-X; Wright RL, 2006, EUR J NEUROSCI, V24, P595, DOI 10.1111/j.1460-9568.2006.04948.x; YOUNG AB, 1988, J NEUROSURG, V69, P375, DOI 10.3171/jns.1988.69.3.0375; Zambell KL, 2004, ALCOHOL CLIN EXP RES, V28, P635, DOI 10.1097/01.ALC.0000122104.85971.55; Zink BJ, 1998, J NEUROSURG, V89, P983, DOI 10.3171/jns.1998.89.6.0983; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	64	42	42	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2010	27	3					555	563		10.1089/neu.2009.0891			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	575PJ	WOS:000276079100009	20001584				2021-06-18	
J	Gu, Y; Wang, J; Ding, F; Hu, N; Wang, YX; Gu, XS				Gu, Yun; Wang, Jie; Ding, Fei; Hu, Nan; Wang, Yaxian; Gu, Xiaosong			Neurotrophic Actions of Bone Marrow Stromal Cells on Primary Culture of Dorsal Root Ganglion Tissues and Neurons	JOURNAL OF MOLECULAR NEUROSCIENCE			English	Article						Bone marrow stromal cells; Dorsal root ganglion; Coculture; Neurotrophic factor; Peripheral nerve regeneration	TRAUMATIC BRAIN-INJURY; MESENCHYMAL STEM-CELLS; PERIPHERAL-NERVE REGENERATION; ADULT RATS; FUNCTIONAL RECOVERY; GROWTH-FACTOR; SPINAL-CORD; CEREBRAL-ISCHEMIA; TRANSPLANTATION; DIFFERENTIATION	Application of adult bone marrow stromal cells (BMSCs) provides therapeutic benefits to the treatment of neurological insults. The aim of this study was to explore the potential of nonhematopoietic BMSCs to produce soluble factors and stimulate signaling pathways in neurons that mediate trophic effects. A combination of enzyme-linked immunosorbent assay and two-dimensional gel electrophoresis coupled with mass spectrometry showed that the BMSCs released into the culture medium an array of soluble factors such as nerve growth factor, brain-derived neurotrophic factor, basic fibroblast growth factor, and ciliary neurotrophic factor, which have been shown to exhibit potent neurotrophic effects on neural cells. Immunochemistry, cell viability assay, and quantitative real-time RT-PCR collectively showed that neurite outgrowth and neurogenesis in cultured rat dorsal root ganglion (DRG) explants and neurons were enhanced after they were cocultured with rat BMSCs. Western blot analysis revealed that BMSC-conditioned medium activated phosphorylation of mitogen-activated protein kinase/extracellular signal-regulated protein kinase and/or phosphoinositide 3-kinase/serine/threonine kinase (PI3K/Akt) in primary culture of rat DRG neurons, which suggested that BMSCs trigger endogenous survival signaling pathways in neurons through their secreted soluble factors. Our data help to elucidate the mechanisms by which BMSCs function as a cell therapy agent in peripheral nerve regeneration.	[Gu, Yun; Wang, Jie; Ding, Fei; Hu, Nan; Wang, Yaxian; Gu, Xiaosong] Nantong Univ, Jiangsu Key Lab Neuroregenerat, Nantong 226001, Jiangsu, Peoples R China	Gu, XS (corresponding author), Nantong Univ, Jiangsu Key Lab Neuroregenerat, 19 Qixiu Rd, Nantong 226001, Jiangsu, Peoples R China.	neurongu@public.nt.js.cn			Hi-Tech Research and Development Program of China (863 Program)National High Technology Research and Development Program of China [2006AA02A128]; Nature Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30670667]	The financial supports of the Hi-Tech Research and Development Program of China (863 Program, grant number 2006AA02A128) and the Nature Science Foundation of China (grant number 30670667) are gratefully acknowledged. We thank Professor Jie Liu for assistance in manuscript preparation.	ANTON ES, 1994, P NATL ACAD SCI USA, V91, P2795, DOI 10.1073/pnas.91.7.2795; Caplan AI, 2006, J CELL BIOCHEM, V98, P1076, DOI 10.1002/jcb.20886; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Chen JL, 2002, J NEUROL SCI, V199, P17, DOI 10.1016/S0022-510X(02)00075-8; Chen JL, 2003, CIRC RES, V92, P692, DOI 10.1161/01.RES.0000063425.51108.8D; Chen JL, 2001, J NEUROL SCI, V189, P49, DOI 10.1016/S0022-510X(01)00557-3; Chen XG, 2002, NEUROPATHOLOGY, V22, P275, DOI 10.1046/j.1440-1789.2002.00450.x; Chen Y, 2006, CELL MOL LIFE SCI, V63, P1649, DOI 10.1007/s00018-006-6019-5; Chen YS, 2000, BIOMATERIALS, V21, P1541, DOI 10.1016/S0142-9612(00)00028-4; Chen ZY, 2001, BRAIN RES, V902, P272, DOI 10.1016/S0006-8993(01)02395-2; Cheng YY, 2006, SOLID STATE PHENOMEN, V111, P115, DOI 10.4028/www.scientific.net/SSP.111.115; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; Coyne TM, 2006, STEM CELLS, V24, P2483, DOI 10.1634/stemcells.2006-0174; Crigler L, 2006, EXP NEUROL, V198, P54, DOI 10.1016/j.expneurol.2005.10.029; Cuevas P, 2002, NEUROL RES, V24, P634, DOI 10.1179/016164102101200564; Dezawa M, 2005, CURR MOL MED, V5, P723, DOI 10.2174/156652405774641070; EINHEBER S, 1993, J CELL BIOL, V123, P1223, DOI 10.1083/jcb.123.5.1223; Hetman M, 1999, J BIOL CHEM, V274, P22569, DOI 10.1074/jbc.274.32.22569; Hou SY, 2006, NEUROSCIENCE, V140, P101, DOI 10.1016/j.neuroscience.2006.01.066; Kocsis JD, 2002, J REHABIL RES DEV, V39, P287; Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711; Lee AC, 2003, EXP NEUROL, V184, P295, DOI 10.1016/S0014-4886(03)00258-9; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; Lu DY, 2002, J NEUROSURG, V97, P935, DOI 10.3171/jns.2002.97.4.0935; Lu DY, 2001, J NEUROTRAUM, V18, P813, DOI 10.1089/089771501316919175; Lu J, 2006, NEUROSCI LETT, V398, P12, DOI 10.1016/j.neulet.2005.12.053; Lu L, 2008, STEM CELLS, V26, P580, DOI 10.1634/stemcells.2007-0106; Mahmood A, 2006, J NEUROSURG, V104, P272, DOI 10.3171/jns.2006.104.2.272; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Marcol W, 2003, J NEUROSCI RES, V72, P417, DOI 10.1002/jnr.10560; Mimura T, 2004, J NEUROSURG, V101, P806, DOI 10.3171/jns.2004.101.5.0806; Munoz-Elias G, 2003, STEM CELLS, V21, P437, DOI 10.1634/stemcells.21-4-437; Neuhuber B, 2005, BRAIN RES, V1035, P73, DOI 10.1016/j.brainres.2004.11.055; Ohta M, 2004, EXP NEUROL, V187, P266, DOI 10.1016/j.expneurol.2004.01.021; Sun HL, 2006, J MUSCLE RES CELL M, V27, P241, DOI 10.1007/s10974-006-9067-4; Suzuki H, 2004, BIOCHEM BIOPH RES CO, V322, P918, DOI 10.1016/j.bbrc.2004.07.201; Sze SK, 2007, MOL CELL PROTEOMICS, V6, P1680, DOI 10.1074/mcp.M600393-MCP200; Wang D, 2008, BRAIN RES, V1188, P44, DOI 10.1016/j.brainres.2007.09.098; Wang J, 2009, BRAIN RES, V1262, P7, DOI 10.1016/j.brainres.2009.01.056; Wislet-Gendebien S, 2005, STEM CELLS, V23, P392, DOI 10.1634/stemcells.2004-0149; Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C; Wu SF, 2003, J NEUROSCI RES, V72, P343, DOI 10.1002/jnr.10587; Yang YM, 2007, BIOMATERIALS, V28, P1643, DOI 10.1016/j.biomaterials.2006.12.004; Zhong C, 2003, NEUROSCI LETT, V342, P93, DOI 10.1016/S0304-3940(03)00255-6	46	42	45	0	15	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0895-8696	1559-1166		J MOL NEUROSCI	J. Mol. Neurosci.	MAR	2010	40	3					332	341		10.1007/s12031-009-9304-6			10	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	557ZN	WOS:000274709700007	19894026				2021-06-18	
J	Butler, TR; Self, RL; Smith, KJ; Sharrett-Field, LJ; Berry, JN; Littleton, JM; Pauly, JR; Mulholland, PJ; Prendergast, MA				Butler, T. R.; Self, R. L.; Smith, K. J.; Sharrett-Field, L. J.; Berry, J. N.; Littleton, J. M.; Pauly, J. R.; Mulholland, P. J.; Prendergast, M. A.			SELECTIVE VULNERABILITY OF HIPPOCAMPAL CORNU AMMONIS 1 PYRAMIDAL CELLS TO EXCITOTOXIC INSULT IS ASSOCIATED WITH THE EXPRESSION OF POLYAMINE-SENSITIVE N-METHYL-D-ASPARATE-TYPE GLUTAMATE RECEPTORS	NEUROSCIENCE			English	Article						glutamate; calcium; head injury; amino acid; spermidine	CEREBELLAR GRANULE CELLS; D-ASPARTATE RECEPTOR; EXTRASYNAPTIC NMDA RECEPTORS; TRAUMATIC BRAIN-INJURY; SLICE CULTURES; ETHANOL WITHDRAWAL; RAT-BRAIN; CEREBRAL-ISCHEMIA; CALCIUM-CHANNELS; NEURONAL DEATH	Excess glutamate release and stimulation of postsynaptic glutamatergic receptors have been implicated in the pathophysiology of many neurological diseases. The hippocampus, and the pyramidal cell layer of the cornu ammonus 1 (CA1) region in particular, has been noted for its selective sensitivity to excitotoxic insults. The current studies examined the role of N-methyl-D-aspartate (NMDA) receptor subunit composition and sensitivity to stimulatory effects of the polyamine spermidine, an allosteric modulator of NMDA NR2 subunit activity, in hippocampal CA1 region sensitivity to excitotoxic insult. Organotypic hippocampal slice cultures of 8 day-old neonatal rat were obtained and maintained in vitro for 5 days. At this time, immunohistochemical analysis of mature neuron density (NeuN); microtubule associated protein-2(a,b) density (MAP-2); and NMDA receptor NR1 and NR2B subunit density in the primary cell layers of the dentate gyrus (DG), CA3, and CA1 regions, was conducted. Further, autoradiographic analysis of NMDA receptor distribution and density (i.e. [I-121]MK-801 binding) and spermidine (100 mu M)-potentiated [I-125]MK-801 binding in the primary cell layers of these regions was examined. A final series of studies examined effects of prolonged exposure to NMDA (0.1-10 mu M) on neurodegeneration in the primary cell layers of the DG, CA3, and CA1 regions, in the absence and presence of spermidine (100 mu M) or ifenprodil (100 mu M), an allosteric inhibitor of NR2B polypeptide subunit activity. The pyramidal cell layer of the CA1 region demonstrated significantly greater density of mature neurons, MAP-2, NR1 and NR2B subunits, and [I-125]MK-801 binding than the CA3 region or DG. Twenty-four hour NMDA (10 mu M) exposure produced marked neurodegeneration (similar to 350% of control cultures) in the CA1 pyramidal cell region that was significantly reduced by co-exposure to ifenprodil or DL-2-Amino-5-phosphonopentanoic acid (APV). The addition of spermidine significantly potentiated [I-125] MK-801 binding and neurodegeneration induced by exposure to a non-toxic concentration of NMDA, exclusively in the CA1 region. This neurodegeneration was markedly reduced with co-exposure to ifenprodil. These data suggest that selective sensitivity of the CA1 region to excitotoxic stimuli may be attributable to the density of mature neurons expressing polyamine-sensitive NR2B polypeptide subunits. (C) 2010 IBRO. Published by Elsevier Ltd. All rights reserved.	[Prendergast, M. A.] Univ Kentucky, Dept Psychol, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA; [Littleton, J. M.; Pauly, J. R.] Univ Kentucky, Dept Pharmaceut Sci, Lexington, KY 40536 USA	Prendergast, MA (corresponding author), Univ Kentucky, Dept Psychol, Spinal Cord & Brain Injury Res Ctr, B449 Biomed & Biol Sci Res Bldg,741 S Limestone S, Lexington, KY 40536 USA.	prender@uky.edu	Mulholland, Patrick J/L-9353-2017	Butler, Tracy/0000-0002-3849-7951	 [AA103561];  [AA013388];  [AA015676];  [AA014771]; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R56AA013388, F31AA014771, F31AA015676, R01AA013388] Funding Source: NIH RePORTER	The authors acknowledge the support of AA 103561, AA013388, AA015676, and AA014771.	Arundine M, 2004, CELL MOL LIFE SCI, V61, P657, DOI 10.1007/s00018-003-3319-x; Atlante A, 1997, J NEUROCHEM, V68, P2038, DOI 10.1046/j.1471-4159.1997.68052038.x; Baskys A, 2005, NEUROPHARMACOLOGY, V49, P146, DOI 10.1016/j.neuropharm.2005.04.029; Bonde C, 2005, NEUROSCIENCE, V136, P779, DOI 10.1016/j.neuroscience.2005.07.020; Bragin A, 1999, EPILEPSIA, V40, P1210, DOI 10.1111/j.1528-1157.1999.tb00849.x; Budd SL, 1996, J NEUROCHEM, V67, P2282; CASACCIABONNEFIL P, 1993, NEUROSCI LETT, V154, P5, DOI 10.1016/0304-3940(93)90157-G; Castilho RF, 1999, J NEUROCHEM, V72, P1394, DOI 10.1046/j.1471-4159.1999.721394.x; Cater HL, 2007, J NEUROCHEM, V101, P434, DOI 10.1111/j.1471-4159.2006.04379.x; Chen NS, 1999, J NEUROSCI, V19, P6844, DOI 10.1523/JNEUROSCI.19-16-06844.1999; Chizh BA, 2005, CURR PHARM DESIGN, V11, P2977, DOI 10.2174/1381612054865082; CHOI DW, 1988, J NEUROSCI, V8, P185; CHOI DW, 1987, J NEUROSCI, V7, P369; Gardoni F, 2006, EUR J PHARMACOL, V545, P2, DOI 10.1016/j.ejphar.2006.06.022; Gerencser AA, 2009, J NEUROCHEM, V110, P990, DOI 10.1111/j.1471-4159.2009.06194.x; Gibson DA, 2003, ALCOHOL CLIN EXP RES, V27, P1099, DOI 10.1097/01.ALC.0000075824.10502.DD; Gutierrez R, 1999, BRAIN RES, V815, P304, DOI 10.1016/S0006-8993(98)01101-9; Halpain S, 1998, J NEUROSCI, V18, P9835; Hardingham GE, 2002, BBA-PROTEINS PROTEOM, V1600, P148, DOI 10.1016/S1570-9639(02)00455-7; Hardingham GE, 2002, NAT NEUROSCI, V5, P405, DOI 10.1038/nn835; Harris AZ, 2007, J PHYSIOL-LONDON, V584, P509, DOI 10.1113/jphysiol.2007.137679; Heath PR, 2002, MUSCLE NERVE, V26, P438, DOI 10.1002/mus.10186; Henley CM, 1996, J NEUROTRAUM, V13, P487, DOI 10.1089/neu.1996.13.487; HERMAN MD, 1993, J PHYSIOL-LONDON, V462, P645, DOI 10.1113/jphysiol.1993.sp019574; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Holopainen IE, 2004, NEUROCHEM INT, V45, P1, DOI 10.1016/j.neuint.2004.01.005; Ikegaya Y, 2002, NEUROSCIENCE, V113, P253, DOI 10.1016/S0306-4522(02)00217-8; Janssen WGM, 2005, EXP NEUROL, V191, pS28, DOI 10.1016/j.expneurol.2004.08.020; Kim GH, 2009, CAN J NEUROL SCI, V36, P14, DOI 10.1017/S0317167100006247; Kristensen BW, 2003, BRAIN RES, V964, P264, DOI 10.1016/S0006-8993(02)04080-5; Lahtinen H, 2001, NEUROSCIENCE, V105, P131, DOI 10.1016/S0306-4522(01)00168-3; Laschet J, 1999, EPILEPSY RES, V35, P161, DOI 10.1016/S0920-1211(99)00009-1; Laurie DJ, 1997, MOL BRAIN RES, V51, P23, DOI 10.1016/S0169-328X(97)00206-4; Martens U, 2001, ANAT EMBRYOL, V203, P491, DOI 10.1007/s004290100174; MATTSON MP, 1989, BRAIN RES, V490, P110, DOI 10.1016/0006-8993(89)90436-8; MATTSON MP, 1991, BRAIN RES, V565, P94, DOI 10.1016/0006-8993(91)91740-R; MONAGHAN DT, 1985, J NEUROSCI, V5, P2909; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; Mulholland PJ, 2003, NEUROSCI RES, V46, P369, DOI 10.1016/S0168-0102(03)00102-0; NADLER JV, 1980, BRAIN RES, V195, P47; Obernier JA, 2002, ALCOHOL CLIN EXP RES, V26, P547, DOI 10.1111/j.1530-0277.2002.tb02573.x; Pelletier MR, 1999, J NEUROPHYSIOL, V81, P3054; Pivovarova NB, 2004, J NEUROSCI, V24, P5611, DOI 10.1523/JNEUROSCI.0531-04.2004; POLLARD H, 1994, NEUROSCIENCE, V63, P7, DOI 10.1016/0306-4522(94)90003-5; Prendergast MA, 2007, NEUROSCIENCE, V146, P330, DOI 10.1016/j.neuroscience.2007.01.023; Prendergast MA, 2004, NEUROSCIENCE, V124, P869, DOI 10.1016/j.neuroscience.2003.12.013; Prendergast MA, 2000, ALCOHOL CLIN EXP RES, V24, P1855, DOI 10.1111/j.1530-0277.2000.tb01990.x; Sattler R, 2000, J NEUROSCI, V20, P22, DOI 10.1523/JNEUROSCI.20-01-00022.2000; Scartabelli T, 2008, NEUROPHARMACOLOGY, V55, P509, DOI 10.1016/j.neuropharm.2008.06.019; Schuh RA, 2008, J NEUROSCI RES, V86, P3306, DOI 10.1002/jnr.21772; Self RL, 2004, BRAIN RES, V995, P39, DOI 10.1016/j.brainres.2003.09.052; SILVERSTEIN FS, 1991, PEDIATR RES, V30, P587, DOI 10.1203/00006450-199112000-00021; SIMAN R, 1988, NEURON, V1, P279, DOI 10.1016/0896-6273(88)90076-1; Stoll L, 2007, BIOPHYS J, V92, P1343, DOI 10.1529/biophysj.106.089896; STOLTENBURGDIDINGER G, 1994, NEUROTOXICOLOGY, V15, P445; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; Thomas CG, 2006, J NEUROPHYSIOL, V95, P1727, DOI 10.1152/jn.00771.2005; WALSH TJ, 1988, TOXICOLOGY, V49, P137, DOI 10.1016/0300-483X(88)90185-0; Wilkins LH, 2006, ALCOHOL CLIN EXP RES, V30, P1768, DOI 10.1111/j.1530-0277.2006.00210.x; WILLIAMS K, 1991, MOL PHARMACOL, V40, P774; WILLIAMS K, 1994, MOL PHARMACOL, V45, P803; Yamakura T, 1999, PROG NEUROBIOL, V59, P279, DOI 10.1016/S0301-0082(99)00007-6; Yan DH, 2005, J PHYSIOL-LONDON, V563, P713, DOI 10.1113/jphysiol.2004.077677; ZUKIN RS, 1995, TRENDS NEUROSCI, V18, P306, DOI 10.1016/0166-2236(95)93920-S	64	42	43	0	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	JAN 20	2010	165	2					525	534		10.1016/j.neuroscience.2009.10.018			10	Neurosciences	Neurosciences & Neurology	545IC	WOS:000273724700023	19837138	Green Accepted			2021-06-18	
J	Braden, C; Hawley, L; Newman, J; Morey, C; Gerber, D; Harrison-Felix, C				Braden, Cynthia; Hawley, Lenore; Newman, Jody; Morey, Clare; Gerber, Don; Harrison-Felix, Cynthia			Social communication skills group treatment: A feasibility study for persons with traumatic brain injury and comorbid conditions	BRAIN INJURY			English	Article						Traumatic brain injury; communication; group treatment; cognitive rehabilitation	CLOSED-HEAD INJURY; CONTROLLED-TRIAL; SELF-EFFICACY; UNITED-STATES; REHABILITATION; DEFICITS; AWARENESS; VALIDITY; QUESTIONNAIRE; ABILITY	Objectives: To evaluate the feasibility of improving impaired social communication skills in persons with traumatic brain injury (TBI) and concomitant neurological or psychiatric conditions, using an intervention with evidence of efficacy in a TBI cohort without such complications. Research design: Cohort study with pre-post intervention and follow-up assessments. Methods: Thirty individuals with TBI >= 1 year post-injury and identified social communication problems participated in a group intervention to improve social communication skills. Interventions: Group Interactive Structured Treatment (GIST) for Social Competence; 13 week, 1.5 hour manualized intervention. Outcome measures: Profile of Pragmatic Impairment in Communication (PPIC); Social Communication Skills Questionnaire-Adapted (SCSQ-A); LaTrobe Communication Questionnaire (LCQ); Goal Attainment Scale (GAS), Awareness Questionnaire (AQ), Satisfaction with Life Scale (SWLS); Participation Assessment with Recombined Tools (PART). Main outcomes and results: Participants made statistically significant gains on the SCSQ-A, GAS and SWLS post-treatment and at 6 months follow-up, using self and other ratings. Gains on the PPIC did not reach statistical significance but trended toward improvement. Treatment effects were not noted in analyses of the AQ or the PART. The LCQ showed statistically significant gains post-treatment and at follow-up. Conclusions: Participants showed improvement on subjective social communication skills measures post-treatment and at follow-up, demonstrating potential efficacy of the intervention in a broader population of persons with TBI, worthy of further investigation.	[Braden, Cynthia; Hawley, Lenore; Newman, Jody; Morey, Clare; Gerber, Don; Harrison-Felix, Cynthia] Craig Hosp, Englewood, CO USA	Braden, C (corresponding author), Craig Hosp, 3425 S Clarkson St, Englewood, CO USA.	cbraden@craighospital.org			Colorado Traumatic Brain Injury Trust	This research was supported by the Colorado Traumatic Brain Injury Trust Fund, a 2-year research award from 1 July through 30 June 2008. The opinions expressed in this manuscript are those of the authors and do not necessarily reflect the views of the Colorado Traumatic Brain Injury Trust Fund.	[Anonymous], 2008, GULF WAR HLTH, V7; BANDURA A, 1977, PSYCHOL REV, V84, P191, DOI 10.1037/0033-295X.84.2.191; Bellack A., 2004, SOCIAL SKILLS TRAINI; Benedict R., 1997, BRIEF VISUOSPATIAL M; Blais MC, 2005, BRAIN INJURY, V19, P1223, DOI 10.1080/02699050500309387; Brandt J., 2001, HOPKINS VERBAL LEARN; Brown M, 2004, J HEAD TRAUMA REHAB, V19, P459, DOI 10.1097/00001199-200411000-00004; Cicerone KD, 2007, J HEAD TRAUMA REHAB, V22, P257, DOI 10.1097/01.HTR.0000290970.56130.81; Cicerone KD, 2008, ARCH PHYS MED REHAB, V89, P2239, DOI 10.1016/j.apmr.2008.06.017; Corrigan J, 2003, TECHNICAL REPORT PRO; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; *CRAIG HOSP RES DE, 2004, TBI MOD SYST PART SP; *CTR TBIMSND, 2002, TRAUM BRAIN INJ MOD; Dahlberg C, 2006, BRAIN INJURY, V20, P425, DOI 10.1080/02699050600664574; Dahlberg CA, 2007, ARCH PHYS MED REHAB, V88, P1561, DOI 10.1016/j.apmr.2007.07.033; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; DIJKERS M, 2003, COMMUNITY INTERGRATI, V2; Douglas JM, 2007, J HEAD TRAUMA REHAB, V22, P31, DOI 10.1097/00001199-200701000-00004; Dowd T., 1992, TEACHING SOCIAL SKIL; Dumont C, 2004, J HEAD TRAUMA REHAB, V19, P431, DOI 10.1097/00001199-200411000-00002; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Fleming JM, 1996, BRAIN INJURY, V10, P1; Galski T, 1998, BRAIN INJURY, V12, P769, DOI 10.1080/026990598122160; Green REA, 2008, J CLIN EXP NEUROPSYC, V30, P163, DOI 10.1080/13803390701300524; HAGEN C, 1974, RANCHO AMIGOS SCALES; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P1030, DOI 10.1016/S0003-9993(99)90056-4; Hanks RA, 2008, ARCH PHYS MED REHAB, V89, P950, DOI 10.1016/j.apmr.2008.01.011; HANSEN DJ, 1989, BEHAV MODIF, V13, P4, DOI 10.1177/01454455890131001; Hawley L., 2008, GROUP INTERACTIVE ST; Hawley L, 2006, SOCIAL SKILLS TRAUMA; Hays SJ, 2004, APHASIOLOGY, V18, P693, DOI 10.1080/02687030444000183; HELFFENSTEIN DA, 1982, INT J CLIN NEUROPSYC, V4, P139; Kiresuk T., 1994, GOAL ATTAINMENT SCAL; LEZAK MD, 1978, AM J PHYS MED REHAB, V57, P9; LINSCOTT R, 2010, COMMUNICATION; Linscott RJ, 1996, BRAIN INJURY, V10, P397, DOI 10.1080/026990596124269; Lynch WJ, 2002, J HEAD TRAUMA REHAB, V17, P66, DOI 10.1097/00001199-200202000-00009; Malec James F., 1993, Brain Injury, V7, P15, DOI 10.3109/02699059309008153; MALEC JF, 1991, ARCH PHYS MED REHAB, V72, P138; Malec JF, 1999, NEUROPSYCHOL REHABIL, V9, P253, DOI 10.1080/096020199389365; Malec JF., 1994, J HEAD TRAUMA REHAB, V9, P1, DOI [10. 1097/ 00001199- 199412000- 00003, DOI 10.1097/00001199-199412000-00003]; Malec JF, 2003, MANUAL MAYOPORTLAND; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; McDonald S, 2008, ARCH PHYS MED REHAB, V89, P1648, DOI 10.1016/j.apmr.2008.02.029; McGann W, 1997, BRAIN INJURY, V11, P621, DOI 10.1080/026990597123179; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; Mesulam M., 2000, PRINCIPLES BEHAV COG; Mesulam M.-M., 2002, PRINCIPLES FRONTAL L, P8, DOI DOI 10.1093/ACPROF:OSO/9780195134971.003.0002; Morey CE, 2003, BRAIN INJURY, V17, P809, DOI 10.1080/0269905031000088586; NELSON DGK, 1988, MEM COGNITION, V16, P79, DOI 10.3758/BF03197748; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; *PREV CFDCA, 1998, BEH RISK FACT SURV S; PRIGATANO GP, 1989, B MENNINGER CLIN, V53, P414; RANKIN KP, 2006, HUMAN FRONTAL LOBES, P345; Reitan R. M., 1993, HALSTED REITAN NEURO; Sale P., 1991, J HEAD TRAUMA REHAB, V6, P1, DOI [DOI 10.1097/00001199-199109000-00004, 10.1097/00001199-199109000-00004.]; SanMiguel SK, 1996, LEARN DISABILITY Q, V19, P252; Sherer M, 1998, BRAIN INJURY, V12, P63, DOI 10.1080/026990598122863; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; Smith A., 1982, SYMBOL DIGIT MODALIT; Sohlberg MM, 1998, J HEAD TRAUMA REHAB, V13, P62, DOI 10.1097/00001199-199810000-00008; *SPSS INC, 2004, SPSS 13 0 WIND 13 0; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Struchen MA, 2008, BRAIN INJURY, V22, P940, DOI 10.1080/02699050802425410; Stuss D. T., 2006, HUMAN FRONTAL LOBES, P292; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; TROWER P, 1978, J ADOLESCENCE, V1, P319, DOI 10.1016/S0140-1971(78)80035-9; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; Wechsler D., 2001, WECHSLER TEST ADULT; WEHMAN P, 1993, AM J PHYS MED REHAB, V72, P355; Whiteneck G, 2001, COLORADO TRAUMATIC B; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; Ylvisaker M., 1998, COLLABORATIVE BRAIN; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	76	42	43	0	24	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2010	24	11					1298	1310		10.3109/02699052.2010.506859			13	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	667MY	WOS:000283198800004	20828228				2021-06-18	
J	Dobkin, BH				Dobkin, Bruce H.			Motor rehabilitation after stroke, traumatic brain, and spinal cord injury: common denominators within recent clinical trials	CURRENT OPINION IN NEUROLOGY			English	Article						functional electrical stimulation; gait training; robotics; spinal cord injury; stroke rehabilitation	CONSTRAINT-INDUCED MOVEMENT; TRANSCRANIAL MAGNETIC STIMULATION; UPPER EXTREMITY FUNCTION; MULTIPLE-SCLEROSIS; RANDOMIZED-TRIAL; CORTICAL STIMULATION; EXERCISE PROGRAM; AEROBIC CAPACITY; RECOVERY; THERAPY	Purpose of review Experimental studies and clinical trials that aim to improve motor function for use of the upper extremity and walking are traditionally separated by the category of neurological disease. This boundary may deter investigators from finding common denominators in the conceptual basis and deployment of rehabilitation interventions, especially across nonprogressive diseases in adults, such as stroke, brain trauma, and spinal cord injury. Recent findings The results of recent randomized clinical trials for walking by treadmill training and robotic devices and for the upper extremity by constraint-induced therapy, robotics, and brain stimulation suggest that more efficient strategies are needed to devise and prove the value of new therapies. Summary Investigators should consider working across disease platforms to develop and test the most optimal methods for training patients, the most practical trial designs, the best dose-response characteristics of interventions, the most meaningful outcome measures, and the likelihood of transfer of trained performance to real-world settings. Clinicians in the community may be more likely to adopt evidence-based practices drawn from positive trial results if these treatment strategies focus on key motor impairments and related disabilities, rather than on diseases.	Univ Calif Los Angeles, Geffen UCLA Sch Med, Dept Neurol, Los Angeles, CA 90095 USA	Dobkin, BH (corresponding author), Univ Calif Los Angeles, Geffen UCLA Sch Med, Dept Neurol, 710 Westwood Plaza, Los Angeles, CA 90095 USA.	bdobkin@mednet.ucla.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U01HD037439] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P41RR013642] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P41 RR013642] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U01 HD037439] Funding Source: Medline		Alaverdashvili M, 2008, BEHAV BRAIN RES, V188, P281, DOI 10.1016/j.bbr.2007.11.007; Alon G, 2007, NEUROREHAB NEURAL RE, V21, P207, DOI 10.1177/1545968306297871; Angevaren M., 2008, COCHRANE DATABASE SY; Askim T, 2009, NEUROREHAB NEURAL RE, V23, P295, DOI 10.1177/1545968308322840; Beer S, 2008, MULT SCLER J, V14, P231, DOI 10.1177/1352458507082358; Bestmann S, 2008, CEREB CORTEX, V18, P1281, DOI 10.1093/cercor/bhm159; Blesch A, 2009, TRENDS NEUROSCI, V32, P41, DOI 10.1016/j.tins.2008.09.008; Boake C, 2007, NEUROREHAB NEURAL RE, V21, P14, DOI 10.1177/1545968306291858; Byl NN, 2008, NEUROREHAB NEURAL RE, V22, P494, DOI 10.1177/1545968308317431; Carmichael ST, 2008, STROKE, V39, P1380, DOI 10.1161/STROKEAHA.107.499962; Cheeran B, 2009, NEUROREHAB NEURAL RE, V23, P97, DOI 10.1177/1545968308326636; Cramer SC, 2008, ANN NEUROL, V63, P272, DOI 10.1002/ana.21393; Criscimagna-Hemminger SE, 2008, J NEUROSCI, V28, P9610, DOI 10.1523/JNEUROSCI.3071-08.2008; Dobkin B, 2006, NEUROLOGY, V66, P484, DOI 10.1212/01.wnl.0000202600.72018.39; Dobkin BH, 2003, NEUROREHAB NEURAL RE, V17, P153, DOI 10.1177/0888439003255508; Dobkin BH, 2008, NEUROREHAB NEURAL RE, V22, P105, DOI 10.1177/1545968308315046; Dobkin BH, 2008, NAT CLIN PRACT NEURO, V4, P76, DOI 10.1038/ncpneuro0709; Dobkin BH, 2007, DEV NEUROBIOL, V67, P1133, DOI 10.1002/dneu.20514; Dobkin BH, 2009, NEUROREHAB NEURAL RE, V23, P197, DOI 10.1177/1545968309331863; Dobkin BH, 2009, NEUROREHAB NEURAL RE, V23, P633, DOI 10.1177/1545968309338290; Dobkin BH, 2007, NEUROREHAB NEURAL RE, V21, P3, DOI 10.1177/1545968306297329; Donaldson C, 2009, NEUROREHAB NEURAL RE, V23, P389, DOI 10.1177/1545968308326635; Dromerick AW, 2009, NEUROLOGY, V73, P195, DOI 10.1212/WNL.0b013e3181ab2b27; Duncan PW, 2007, BMC NEUROL, V7, DOI 10.1186/1471-2377-7-39; Enzinger C, 2009, STROKE, V40, P2460, DOI 10.1161/STROKEAHA.109.550053; Fawcett JW, 2009, BRAIN, V132, P1417, DOI 10.1093/brain/awp121; Franceschini M, 2009, STROKE, V40, P3079, DOI 10.1161/STROKEAHA.109.555540; French B, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006073.pub2; Fujiwara T, 2009, NEUROREHAB NEURAL RE, V23, P125, DOI 10.1177/1545968308321777; Furkiewicz MT, 2007, NEUROREHAB NEURAL RE, V21, P527, DOI 10.1177/1545968307301872; Goodman AD, 2009, LANCET, V373, P732, DOI 10.1016/S0140-6736(09)60442-6; Gueugneau N, 2009, NEUROREHAB NEURAL RE, V23, P237, DOI 10.1177/1545968308321775; Harvey RL, 2009, NEUROREHAB NEURAL RE, V23, P32, DOI 10.1177/1545968308317532; Hassett LM, 2009, J REHABIL MED, V41, P247, DOI 10.2340/16501977-0316; Hesse S, 2008, AM J PHYS MED REHAB, V87, P779, DOI 10.1097/PHM.0b013e318186b4bc; Hidler J, 2009, NEUROREHAB NEURAL RE, V23, P5, DOI 10.1177/1545968308326632; Hiscock A, 2008, NEUROREHAB NEURAL RE, V22, P228, DOI 10.1177/1545968307307115; Hoffman AN, 2008, NEUROSCI LETT, V431, P226, DOI 10.1016/j.neulet.2007.11.042; Hornby TG, 2008, STROKE, V39, P1786, DOI 10.1161/STROKEAHA.107.504779; Housman SJ, 2009, NEUROREHAB NEURAL RE, V23, P505, DOI 10.1177/1545968308331148; KERKOVICH D, 2009, NEUROREHABIL NEURAL; Kloosterman MGM, 2009, SPINAL CORD, V47, P196, DOI 10.1038/sc.2008.113; Kwakkel G, 2008, NEUROREHAB NEURAL RE, V22, P111, DOI 10.1177/1545968307305457; Levin MF, 2009, NEUROREHAB NEURAL RE, V23, P313, DOI 10.1177/1545968308328727; Lin KC, 2009, NEUROREHAB NEURAL RE, V23, P160, DOI 10.1177/1545968308320642; Lo AC, 2008, NEUROREHAB NEURAL RE, V22, P661, DOI 10.1177/1545968308318473; Lo AC, 2009, NEUROREHAB NEURAL RE, V23, P775, DOI 10.1177/1545968309338195; Luft AR, 2008, STROKE, V39, P3341, DOI 10.1161/STROKEAHA.108.527531; Mehrholz J, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006185.pub2; Mehrholz J, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006676.pub2; Morris ME, 2006, NEUROREHAB NEURAL RE, V20, P424, DOI 10.1177/1545968305285092; Pang MYC, 2006, CLIN REHABIL, V20, P97, DOI 10.1191/0269215506cr926oa; Plow EB, 2009, STROKE, V40, P1926, DOI 10.1161/STROKEAHA.108.540823; Pollock A, 2008, STROKE, V39, P519, DOI 10.1161/STROKEAHA.107.492710; Pomeroy VM, 2007, NEUROREHAB NEURAL RE, V21, P509, DOI 10.1177/1545968307300418; Quaney BM, 2009, NEUROREHAB NEURAL RE, V23, P879, DOI 10.1177/1545968309338193; Ridgel AL, 2009, NEUROREHAB NEURAL RE, V23, P600, DOI 10.1177/1545968308328726; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Sawaki L, 2008, NEUROREHAB NEURAL RE, V22, P505, DOI 10.1177/1545968308317531; Scheibel RS, 2007, NEUROREHAB NEURAL RE, V21, P36, DOI 10.1177/1545968306294730; Simmons L, 2008, NEUROREHAB NEURAL RE, V22, P458, DOI 10.1177/1545968308315597; Snaphaan L, 2009, BRAIN, V132, P1882, DOI 10.1093/brain/awp133; Snook EM, 2009, NEUROREHAB NEURAL RE, V23, P108, DOI 10.1177/1545968308320641; Sullivan KJ, 2007, PHYS THER, V87, P1580, DOI 10.2522/ptj.20060310; Tang A, 2009, NEUROREHAB NEURAL RE, V23, P398, DOI 10.1177/1545968308326426; Thrasher TA, 2008, NEUROREHAB NEURAL RE, V22, P706, DOI 10.1177/1545968308317436; van Praag H, 2009, TRENDS NEUROSCI, V32, P283, DOI 10.1016/j.tins.2008.12.007; Verma P, 2008, NEUROREHAB NEURAL RE, V22, P429, DOI 10.1177/1545968307313500; Volpe BT, 2008, NEUROREHAB NEURAL RE, V22, P305, DOI 10.1177/1545968307311102; Ward NS, 2008, CURR OPIN NEUROL, V21, P625, DOI 10.1097/WCO.0b013e32831997af; Westlake KP, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-18; Winchester P, 2005, NEUROREHAB NEURAL RE, V19, P313, DOI 10.1177/1545968305281515; Winstein CJ, 2003, NEUROREHAB NEURAL RE, V17, P137, DOI 10.1177/0888439003255511; Wolf SL, 2006, JAMA-J AM MED ASSOC, V296, P2095, DOI 10.1001/jama.296.17.2095	74	42	42	0	19	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1350-7540	1473-6551		CURR OPIN NEUROL	Curr. Opin. Neurol.	DEC	2009	22	6					563	569		10.1097/WCO.0b013e3283314b11			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	529UK	WOS:000272544100001	19724226	Green Accepted			2021-06-18	
J	Figaji, AA; Zwane, E; Fieggen, AG; Argent, AC; Le Roux, PD; Siesjo, P; Peter, JC				Figaji, Anthony A.; Zwane, Eugene; Fieggen, A. Graham; Argent, Andrew C.; Le Roux, Peter D.; Siesjo, Peter; Peter, Jonathan C.			Pressure autoregulation, intracranial pressure, and brain tissue oxygenation in children with severe traumatic brain injury	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						autoregulation; brain tissue oxygen tension; intracranial pressure; blood pressure; traumatic brain injury	CEREBRAL PERFUSION-PRESSURE; BLOOD-FLOW; HEAD-INJURY; INDUCED HYPERTENSION; REACTIVITY; METABOLISM; MANAGEMENT; RESPONSES; ARTERIES; HYPOXIA	Object. Cerebral pressure autoregulation is an important neuroprotective mechanism that stabilizes cerebral blood flow when blood pressure (BP) changes In this study the authors examined the association between autoregulation and clinical factors. BR. intracranial pressure (ICP), brain tissue oxygen tension (PbtO(2)), and outcome after pediatric severe traumatic brain injury (TBI). In particular we examined how the Status 01: autoregulation influenced the effect of BP changes on ICP and PbtO(2) Methods In this prospective observational study. 52 autoregulation tests were performed in 24 patients with severe. TBI. The patients had a mean age of 6.3 +/- 3.2 years. and a postresuscitation Glasgow Coma Scale score of 6 (range 3-8). All patients underwent continuous ICP and MID, monitoring. and transcranial Doppler ultrasonography was, used to examine the autoregulatory index (ARI) based on blood flow velocity of the middle cerebral artery after increasing mean arterial pressure by 20% of the baseline value Impaired autoregulation was defined as an ARI < 0 4 and intact autoregulation as an ART >= 0 4 The relationships between autoregulation (measured as both a Continuous and dichotomous variable), outcome, and clinical and physiological variables were examined using Multiple logistic regression analysis Results. Autoregulation was impaired (ART < 0 4) in 29% of patients (7 patients). The initial Glasgow Coma Scale score was significantly associated with the ARI (p = 0.02, r = 0.32) but no other clinical factors were associated with autoregulation Status. Baseline values at the time of testing for ICP, PbtO(2), the ratio PbtO(2)/PaO2, mean arterial pressure, and middle cerebral artery blood flow velocity were similar in the patients with impaired or intact autoregulation. There was an inverse relationship between ART (continuous and dichotomous) with a chancle in ICP (continuous ARI, p 0.005, dichotomous ARI, p = 0 02): that is. ICP increased with the BP increase when ARI was low (weak autoregulation) The ART (continuous and dichotomous) was also inversely associated with a change in PbtO(2). (continuous ART. p 0.002. dichotomous ARI, p = 0 02). The PbtO(2) increased when BP was increased in most patients, even when the ARI was relatively high (stronger autoregulation). but the magnitude of this response was still associated with the ART. There was no relationship between the ART and Outcome Conclusion. These data demonstrate the influence of the strength of autoregulation on the response of ICP and MO. to BP changes and the variability of this response between individuals The findings suggest that autoregulation testing may assist clinical decision-making in pediatric severe TBI and help better define optimal BP or cerebral perfusion pressure targets for individual patients. (DOI: 10.3171/2009.6.PEDS096)	[Figaji, Anthony A.; Fieggen, A. Graham; Peter, Jonathan C.] Univ Cape Town, Red Cross Childrens Hosp, Sch Child & Adolescent Hlth, Div Neurosurg, Cape Town, South Africa; [Argent, Andrew C.] Univ Cape Town, Red Cross Childrens Hosp, Sch Child & Adolescent Hlth, Div Pediat Crit Care, Cape Town, South Africa; [Zwane, Eugene] Univ Cape Town Observ, Sch Publ Hlth & Family Med, Infect Dis Epidemiol Unit Biostat, Cape Town, South Africa; [Le Roux, Peter D.] Hosp Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; [Siesjo, Peter] Lund Univ, Univ Lund Hosp, Dept Neurosurg, Lund, Sweden	Figaji, AA (corresponding author), Red Cross War Mem Childrens Hosp, Inst Child Hlth 617, Klipfontein Rd, ZA-7700 Rondebosch, South Africa.	AnthonyFigaji@uct.ac.za	Argent, Andrew/J-1605-2019	Argent, Andrew/0000-0001-9333-2036; Fieggen, Graham/0000-0001-6541-8377; Siesjo, Peter/0000-0002-5848-690X; Figaji, Anthony/0000-0002-3357-6490			Adelson P David, 2003, Pediatr Crit Care Med, V4, pS31; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS25; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS19; BOUMA GJ, 1990, J NEUROSURG, V73, P368, DOI 10.3171/jns.1990.73.3.0368; Bruzzone P, 1998, ACT NEUR S, V71, P111; Cherian L, 1999, CRIT CARE MED, V27, P2512, DOI 10.1097/00003246-199911000-00031; Coles JP, 2004, BRAIN, V127, P2479, DOI 10.1093/brain/awh268; Cremer OL, 2004, ANESTH ANALG, V99, P1211, DOI 10.1213/01.ANE.0000133917.67728.2A; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; Czosnyka M, 2008, ANESTH ANALG, V106, P234, DOI 10.1213/01.ane.0000295802.89962.13; Dings J, 1996, ACTA NEUROCHIR, V138, P425, DOI 10.1007/BF01420305; DURWARD QJ, 1983, J NEUROSURG, V59, P803, DOI 10.3171/jns.1983.59.5.0803; Figaji AA, 2008, NEUROSURGERY, V63, P83, DOI 10.1227/01.NEU.0000335074.39728.00; Fog M, 1938, J NEUROL PSYCHIATRY, V1, P187, DOI 10.1136/jnnp.1.3.187; Freeman SS, 2008, ANESTHESIOLOGY, V108, P588, DOI 10.1097/ALN.0b013e31816725d7; Hemphill JC, 2001, NEUROSURGERY, V48, P377, DOI 10.1097/00006123-200102000-00028; Hiler M, 2006, J NEUROSURG, V104, P731, DOI 10.3171/jns.2006.104.5.731; Hlatky R, 2005, NEUROSURGERY, V57, P917, DOI 10.1227/01.NEU.0000180025.43747.fc; Howells T, 2005, J NEUROSURG, V102, P311, DOI 10.3171/jns.2005.102.2.0311; Jaeger M, 2006, CRIT CARE MED, V34, P1783, DOI 10.1097/01.CCM.0000218413.51546.9E; Johnston AJ, 2005, CRIT CARE MED, V33, P189, DOI 10.1097/01.CCM.0000149837.09225.BD; KONTOS HA, 1978, AM J PHYSIOL, V234, pH371; Krejza J, 1999, AM J ROENTGENOL, V172, P213, DOI 10.2214/ajr.172.1.9888770; Lang EW, 2000, BRIT J NEUROSURG, V14, P117; Lang EW, 2003, CRIT CARE MED, V31, P267, DOI 10.1097/00003246-200301000-00042; LASSEN NA, 1959, PHYSIOL REV, V39, P183; Marin-Caballos A, 2005, CRIT CARE, V9, pR670, DOI 10.1186/cc3822; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Menzel M, 2003, J NEUROSURG ANESTH, V15, P33, DOI 10.1097/00008506-200301000-00006; Nordstrom Carl-Henrik, 2006, Neurosurgery, V58, pE590; Panerai RB, 2004, BRIT J NEUROSURG, V18, P471, DOI 10.1080/02688690400012343; Panerai RB, 1998, PHYSIOL MEAS, V19, P305, DOI 10.1088/0967-3334/19/3/001; PAULSON OB, 1990, CEREBROVAS BRAIN MET, V2, P161; Radolovich DK, 2009, NEUROCRIT CARE, V10, P274, DOI 10.1007/s12028-009-9190-3; Reinert M, 2003, ACTA NEUROCHIR, V145, P341, DOI 10.1007/s00701-003-0027-0; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Slater A, 2003, INTENS CARE MED, V29, P278, DOI 10.1007/s00134-002-1601-2; Steiner LA, 2003, J NEUROL NEUROSUR PS, V74, P765, DOI 10.1136/jnnp.74.6.765; Stocchetti N, 1998, ACT NEUR S, V71, P162; STREBEL S, 1995, ANESTHESIOLOGY, V83, P66, DOI 10.1097/00000542-199507000-00008; TEPAS JJ, 1988, J TRAUMA, V28, P425, DOI 10.1097/00005373-198804000-00001; The Brain Trauma Foundation. The American Association of Neurological Surgeons. The Joint Section on Neurotrauma and Critical Care, 2007, J NEUROTRAUMA S1, V24, pS59, DOI DOI 10.1089/NEU.2007.9987; Tontisirin N, 2007, CHILD NERV SYST, V23, P1163, DOI 10.1007/s00381-007-0339-0; Udomphorn Y, 2008, PEDIATR NEUROL, V38, P225, DOI 10.1016/j.pediatrneurol.2007.09.012; Unterberg AW, 1997, J TRAUMA, V42, pS32, DOI 10.1097/00005373-199705001-00006; URSINO M, 1991, ANN BIOMED ENG, V19, P15, DOI 10.1007/BF02368459; Vavilala MS, 2006, DEV NEUROSCI-BASEL, V28, P348, DOI 10.1159/000094161; Vavilala Monica S, 2004, Pediatr Crit Care Med, V5, P257, DOI 10.1097/01.PCC.0000123545.69133.C3; Zwienenberg M, 1999, J NEUROTRAUM, V16, P937, DOI 10.1089/neu.1999.16.937	50	42	42	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707	1933-0715		J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	NOV	2009	4	5					420	428		10.3171/2009.6.PEDS096			9	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	512JO	WOS:000271244400005	19877773				2021-06-18	
J	Scheibel, RS; Newsome, MR; Troyanskaya, M; Steinberg, JL; Goldstein, FC; Mao, H; Levin, HS				Scheibel, Randall S.; Newsome, Mary R.; Troyanskaya, Maya; Steinberg, Joel L.; Goldstein, Felicia C.; Mao, Hui; Levin, Harvey S.			Effects of Severity of Traumatic Brain Injury and Brain Reserve on Cognitive-Control Related Brain Activation	JOURNAL OF NEUROTRAUMA			English	Article						brain reserve; cognitive control; functional MRI; Glasgow Coma Scale; traumatic brain injury	WORKING-MEMORY LOAD; SEVERE HEAD-INJURY; SPATIAL ATTENTION; POSTERIOR CINGULATE; PRACTICAL SCALE; MOTOR SCORE; VALIDATION; PREDICTION; CLASSIFICATION; FMRI	Functional magnetic resonance imaging (fMRI) has revealed more extensive cognitive-control related brain activation following traumatic brain injury (TBI), but little is known about how activation varies with TBI severity. Thirty patients with moderate to severe TBI and 10 with orthopedic injury (OI) underwent fMRI at 3 months post-injury using a stimulus response compatibility task. Regression analyses indicated that lower total Glasgow Coma Scale (GCS) and GCS verbal component scores were associated with higher levels of brain activation. Brain-injured patients were also divided into three groups based upon their total GCS score (3-4, 5-8, or 9-15), and patients with a total GCS score of 8 or less produced increased, diffuse activation that included structures thought to mediate visual attention and cognitive control. The cingulate gyrus and thalamus were among the areas showing greatest increases, and this is consistent with vulnerability of these midline structures in severe, diffuse TBI. Better task performance was associated with higher activation, and there were differences in the over-activation pattern that varied with TBI severity, including greater reliance upon left-lateralized brain structures in patients with the most severe injuries. These findings suggest that over-activation is at least partially effective for improving performance and may be compensatory.	[Scheibel, Randall S.] Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Steinberg, Joel L.] Univ Texas Hlth Sci Ctr Houston, Dept Psychiat & Behav Sci, Houston, TX USA; [Goldstein, Felicia C.] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA; [Mao, Hui] Emory Univ, Sch Med, Dept Radiol, Atlanta, GA 30322 USA	Scheibel, RS (corresponding author), Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, 1709 Dryden Rd,Suite 725, Houston, TX 77030 USA.	scheibel@bcm.tmc.edu			 [NS-21889];  [NS-42772]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889, R01NS042772] Funding Source: NIH RePORTER	We thank Dr. Ronald A. Rauch for coding the anatomical image data, Xiaoqi Li for assisting with statistical analysis, and Candace Howell, Meghan Mitchell, and Tara Ravichandran for assisting with data acquisition. This research was supported by grants NS-21889 and NS-42772 awarded to Harvey S. Levin. The Michael E. DeBakey Veterans Affairs Medical Center (MEDVAMC) in Houston, TX, and the South Central Mental Illness Research, Education, and Clinical Center (MIRECC) provided access to equipment and facilities used for the acquisition and analysis of the image data.	Al-Salamah MA, 2004, ACAD EMERG MED, V11, P834, DOI 10.1197/j.aem.2004.03.008; BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; BRICOLO A, 1980, J NEUROSURG, V52, P625, DOI 10.3171/jns.1980.52.5.0625; Bryant RA, 2005, BIOL PSYCHIAT, V58, P111, DOI 10.1016/j.biopsych.2005.03.021; Cabeza R, 2002, PSYCHOL AGING, V17, P85, DOI 10.1037//0882-7974.17.1.85; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Cicerone K, 2006, J COGNITIVE NEUROSCI, V18, P1212, DOI 10.1162/jocn.2006.18.7.1212; Cremer OL, 2006, J TRAUMA, V61, P1484, DOI 10.1097/01.ta.0000195981.63776.ba; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Friston K., 1995, HUM BRAIN MAPP, V2, P189, DOI [10.1002/hbm.460020402, DOI 10.1002/HBM.460020402]; Garavan H, 2002, NEUROIMAGE, V17, P1820, DOI 10.1006/nimg.2002.1326; Haukoos JS, 2007, ANN EMERG MED, V50, P18, DOI 10.1016/j.annemergmed.2006.10.004; Kim J, 2008, NEUROIMAGE, V39, P1014, DOI 10.1016/j.neuroimage.2007.10.005; Kim YH, 1999, NEUROIMAGE, V9, P269, DOI 10.1006/nimg.1999.0408; Lancaster JL, 2000, HUM BRAIN MAPP, V10, P120, DOI 10.1002/1097-0193(200007)10:3<120::AID-HBM30>3.0.CO;2-8; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LEVIN HS, 2005, REHABILITATION TRAUM, P338; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McNett Molly, 2007, J Neurosci Nurs, V39, P68; Mesulam MM, 2001, NEUROIMAGE, V13, P1065, DOI 10.1006/nimg.2001.0768; Moore L, 2006, J TRAUMA, V60, P1238, DOI 10.1097/01.ta.0000195593.60245.80; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Nakashima T, 2007, AM J NEURORADIOL, V28, P236; Newsome MR, 2007, CORTEX, V43, P95, DOI 10.1016/S0010-9452(08)70448-9; Nielson KA, 2002, PSYCHOL AGING, V17, P56, DOI 10.1037//0882-7974.17.1.56; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; Price CJ, 2006, J MAGN RESON IMAGING, V23, P816, DOI 10.1002/jmri.20580; Price CJ, 2002, NEUROCASE, V8, P345, DOI 10.1076/neur.8.4.345.16186; Price CJ, 2001, HDB FUNCTIONAL NEURO, P379; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Ricker JH, 2001, J HEAD TRAUMA REHAB, V16, P191, DOI 10.1097/00001199-200104000-00007; Rovlias A, 2004, J NEUROTRAUM, V21, P886, DOI 10.1089/0897715041526249; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; Scheibel RS, 2007, NEUROREHAB NEURAL RE, V21, P36, DOI 10.1177/1545968306294730; Scheibel RS, 2003, BRAIN INJURY, V17, P919, DOI 10.1080/0269905031000110472; Shibata H, 2003, EUR J NEUROSCI, V18, P1615, DOI 10.1046/j.1460-9568.2003.02868.x; Small DM, 2003, NEUROIMAGE, V18, P633, DOI 10.1016/S1053-8119(02)00012-5; SOLEPADULLES C, 2009, NEUROBIOL A IN PRESS; TEASDALE G, 1974, LANCET, V2, P81; TEMKIN NR, 1995, J NEUROSURG, V82, P764, DOI 10.3171/jns.1995.82.5.0764; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yount R, 2002, J NEUROPSYCH CLIN N, V14, P416, DOI 10.1176/appi.neuropsych.14.4.416	44	42	43	0	4	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	SEP	2009	26	9					1447	1461		10.1089/neu.2008.0736			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	489NG	WOS:000269426200002	19645622	Green Published			2021-06-18	
J	Israelsson, C; Wang, Y; Kylberg, A; Pick, CG; Hoffer, BJ; Ebendal, T				Israelsson, Charlotte; Wang, Yun; Kylberg, Annika; Pick, Chaim G.; Hoffer, Barry J.; Ebendal, Ted			Closed Head Injury in a Mouse Model Results in Molecular Changes Indicating Inflammatory Responses	JOURNAL OF NEUROTRAUMA			English	Article						closed head injury; GeneChip array; inflammation; mild trauma; quantitative RT-PCR; weight drop impact	TRAUMATIC BRAIN-INJURY; RAT CEREBRAL-CORTEX; GENE-EXPRESSION; COGNITIVE DEFICITS; HYPOXIA-ISCHEMIA; MICE; MECHANISMS; CHEMOKINES; PATTERNS; SEQUELAE	Cerebral gene expression changes in response to traumatic brain injury will provide useful information in the search for future trauma treatment. In order to characterize the outcome of mild brain injury, we studied C57BL/6J mice in a weight-drop, closed head injury model. At various times post-injury, mRNA was isolated from neocortex and hippocampus and transcriptional alterations were studied using quantitative reverse transcriptase PCR and gene array analysis. At three days post-injury, the results showed unilateral injury responses, both in neocortex and hippocampus, with the main effect seen on the side of the skull hit by the dropping weight. Upregulated transcripts encoded products characterizing reactive astrocytes, phagocytes, microglia, and immune-reactive cells. Markers for oligodendrocytes and T-cells were not altered. Notably, strong differences in the responses among individual mice were seen (e. g., for the Gfap transcript expressed by reactive astrocytes and the chemokine Ccl3 transcript expressed by activated microglial cells). In conclusion, mild TBI chiefly activates transcripts leading to tissue signaling, inflammatory processes, and chemokine signaling, as in focal brain injury, suggesting putative targets for drug development.	[Israelsson, Charlotte; Kylberg, Annika; Ebendal, Ted] Uppsala Univ, Biomed Ctr, Dept Neurosci, SE-75124 Uppsala, Sweden; [Wang, Yun; Hoffer, Barry J.] Natl Inst Drug Abuse, Intramural Res Program, NIH, Baltimore, MD USA; [Pick, Chaim G.] Tel Aviv Univ, Sackler Fac Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel	Ebendal, T (corresponding author), Uppsala Univ, Biomed Ctr, Dept Neurosci, POB 593, SE-75124 Uppsala, Sweden.	Ted.Ebendal@neuro.uu.se	Pick, Chaim/D-4789-2009		Swedish Research CouncilSwedish Research CouncilEuropean Commission [2006-3014]; Swedish Brain Research Foundation; Sparbanksstiftelsen Upland; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NIDAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA); NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [ZIADA000429, ZIADA000461] Funding Source: NIH RePORTER	This work was supported by the Swedish Research Council (grant no. 2006-3014 [T. E.]), the Swedish Brain Research Foundation/Sparbanksstiftelsen Upland (T. E. and C. I.), and intramural grants from NIH/NIDA (B. J. H.). Hanna Goransson and Maria Rydaker carried out the GeneChip procedures.	Byrne E, 2000, J CLIN NEUROSCI, V7, P473, DOI 10.1054/jocn.2000.0779; Charo IF, 2006, NEW ENGL J MED, V354, P610, DOI 10.1056/NEJMra052723; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; Esche C, 2005, J INVEST DERMATOL, V125, P615, DOI 10.1111/j.0022-202X.2005.23841.x; Hausmann EHS, 1998, BRAIN RES, V788, P49, DOI 10.1016/S0006-8993(97)01160-8; Hedtjarn M, 2004, J CEREBR BLOOD F MET, V24, P1333, DOI 10.1097/01.WCB.0000141559.17620.36; Hedtjarn M, 2004, J CEREBR BLOOD F MET, V24, P1317, DOI 10.1097/01.WCB.0000141558.40491.75; Israelsson C, 2008, J NEUROTRAUM, V25, P959, DOI 10.1089/neu.2008.0562; Johnston Andrew J, 2002, Curr Opin Crit Care, V8, P121, DOI 10.1097/00075198-200204000-00006; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; Kobori N, 2002, MOL BRAIN RES, V104, P148, DOI 10.1016/S0169-328X(02)00331-5; Kury P, 2004, EUR J NEUROSCI, V19, P1708, DOI 10.1111/j.1460-9568.2004.03226.x; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Natale JE, 2003, J NEUROTRAUM, V20, P907, DOI 10.1089/089771503770195777; Pan WH, 2003, EXP BRAIN RES, V149, P195, DOI 10.1007/s00221-002-1355-7; Potts Mathew B, 2006, NeuroRx, V3, P143; Poulsen CB, 2005, J NEUROCHEM, V92, P417, DOI 10.1111/j.1471-4159.2004.02877.x; Rao VLR, 2003, J NEUROSCI RES, V71, P208, DOI 10.1002/jnr.10486; Tashlykov V, 2007, BRAIN RES, V1130, P197, DOI 10.1016/j.brainres.2006.10.032; Tweedie D, 2007, J NEUROSCI RES, V85, P805, DOI 10.1002/jnr.21160; von Gertten C, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-69; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	23	42	42	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2009	26	8					1307	1314		10.1089/neu.2008.0676			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	479AF	WOS:000268629900013	19317611	Green Published			2021-06-18	
J	Kwon, BK; Roy, J; Lee, JHT; Okon, E; Zhang, HB; Marx, JC; Kindy, MS				Kwon, Brian K.; Roy, Josee; Lee, Jae H. T.; Okon, Elena; Zhang, Hongbin; Marx, Jeffrey C.; Kindy, Mark S.			Magnesium Chloride in a Polyethylene Glycol Formulation as a Neuroprotective Therapy for Acute Spinal Cord Injury: Preclinical Refinement and Optimization	JOURNAL OF NEUROTRAUMA			English	Article						magnesium chloride; neuroprotection; polyethylene glycol; spinal cord injury	TRAUMATIC BRAIN-INJURY; RANDOMIZED CONTROLLED-TRIAL; ACUTE MYOCARDIAL-INFARCTION; ACUTE-STROKE-THERAPIES; INDUSTRY-ROUND-TABLE; INTRAVENOUS MAGNESIUM; PILOT TRIAL; SULFATE; RATS; METHYLPREDNISOLONE	Intravenously administered magnesium has been extensively investigated as a neuroprotective agent traumatic brain injuries and stroke. Numerous investigators have reported the neuroprotective benefits of magnesium in animal models of spinal cord injury (SCI) as well, but typically with doses that far exceed human tolerability. To develop magnesium into a clinically relevant therapy for SCI, further refinement and improvement of the magnesium formulation is necessary. In this series of experiments, we evaluated the neuroprotective efficacy of magnesium in a polyethylene glycol (PEG) formulation using an acute model of thoracic SCI. Following thoracic contusion (Infinite Horizon) rat SCI model, we independently confirmed the neuroprotective efficacy of the magnesium and PEG combination which had been previously reported in a thoracic clip compression model of SCI (Ditor et al., 2007). We established that the 254 mu mol/ kg dose of MgCl2 was superior to 127 mu mol/ kg MgCl2 with respect to tissue sparing and locomotor recovery. Additionally, the number of infusions (2, 4, or 6), time between infusions (6 vs 8 hours), and different magnesium salts (MgCl2 vs MgSO4) were evaluated to determine an "optimal" treatment regimen. We observed that an "optimized" regimen of MgCl2 within PEG conferred greater tissue neuroprotection and improved locomotor recovery compared to methylprednisolone. Further a 4 hour time window of histologic and behavioral efficacy was established. The goal of these experiments was to help guide the treatment parameters for a clinical trial of magnesium within a polyethylene glycol formulation in acute human spinal cord injury.	[Kwon, Brian K.] Univ British Columbia, Dept Orthopaed, CNOSP, Vancouver, BC V5Z 3J5, Canada; [Kwon, Brian K.; Lee, Jae H. T.; Okon, Elena; Zhang, Hongbin] Univ British Columbia, ICORD, Vancouver, BC V5Z 3J5, Canada; [Roy, Josee; Marx, Jeffrey C.] Medtron Spine & Biol, Memphis, TN USA; [Kindy, Mark S.] Med Univ S Carolina, Charleston, SC 29425 USA	Kwon, BK (corresponding author), Univ British Columbia, Dept Orthopaed, Vancouver Gen Hosp, D6 Heather Pavil,2733 Heather St, Vancouver, BC V5Z 3J5, Canada.	brian.kwon@vch.ca		Okon, Elena/0000-0001-8568-5771			Antman E, 2002, LANCET, V360, P1189, DOI 10.1016/S0140-6736(02)11278-5; Bareyre FM, 2000, J NEUROTRAUM, V17, P1029, DOI 10.1089/neu.2000.17.1029; Bareyre FM, 1999, J NEUROCHEM, V73, P271, DOI 10.1046/j.1471-4159.1999.0730271.x; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Borgens RB, 2000, FASEB J, V14, P27; Borgens RB, 2002, J EXP BIOL, V205, P1; Borgens RB, 2001, J NEUROSCI RES, V66, P1179; Cernak I, 2000, J NEUROTRAUM, V17, P53, DOI 10.1089/neu.2000.17.53; Chan MTV, 2005, ACT NEUR S, V95, P107; Demediuk P, 1990, Adv Neurol, V52, P225; Ditor DS, 2007, J NEUROSCI RES, V85, P1458, DOI 10.1002/jnr.21283; Dohi K, 2005, CRIT CARE MED, V33, P698, DOI 10.1097/01.CCM.0000155907.21185.C0; Duerstock BS, 2002, J EXP BIOL, V205, P13; Duley L, 2002, LANCET, V359, P1877, DOI 10.1016/s0140-6736(02)08778-0; Durlach J, 2005, MAGNESIUM RES, V18, P187; Eck JC, 2006, SPINE, V31, pE250, DOI 10.1097/01.brs.0000214886.21265.8c; Ferguson AR, 2004, J NEUROTRAUM, V21, P1601, DOI 10.1089/0897715042441747; Fisher M, 2005, STROKE, V36, P1808, DOI 10.1161/01.STR.0000173403.60553.27; Fisher M, 2003, STROKE, V34, P1539, DOI 10.1161/01.STR.0000072983.64326.53; Fisher M, 2007, STROKE, V38, P245, DOI 10.1161/01.STR.0000255951.37434.aa; Fu ES, 2005, CURR OPIN ANESTHESIO, V18, P181, DOI 10.1097/01.aco.0000162838.56344.88; Gok B, 2007, CHINESE J PHYSIOL, V50, P93; Gorio A, 2005, P NATL ACAD SCI USA, V102, P16379, DOI 10.1073/pnas.0508479102; Gowda RM, 2004, INT J CARDIOL, V96, P467, DOI 10.1016/j.ijcard.2003.04.067; Hausmann O, 2003, SPINAL CORD, V41, P369, DOI 10.1038/sj.sc.3101483; Heath DL, 1998, J NEUROTRAUM, V15, P183, DOI 10.1089/neu.1998.15.183; Hurlbert RJ, 2008, CAN J NEUROL SCI, V35, P41, DOI 10.1017/S031716710000754X; Hurlbert RJ, 2000, J NEUROSURG, V93, P1, DOI 10.3171/spi.2000.93.1.0001; Jellish WS, 2008, ANESTHESIOLOGY, V108, P78, DOI 10.1097/01.anes.0000296109.04010.82; Jiang S, 2004, INT J IMMUNOPATH PH, V17, P353, DOI 10.1177/039463200401700315; Kaptanoglu E, 2003, NEUROSURG REV, V26, P283, DOI 10.1007/s10143-003-0272-y; Kaptanoglu E, 2003, J CLIN NEUROSCI, V10, P329, DOI 10.1016/S0967-5868(03)00031-6; Kwon Brian K, 2004, Spine J, V4, P451, DOI 10.1016/j.spinee.2003.07.007; Lee JS, 2004, J NEUROTRAUM, V21, P549, DOI 10.1089/089771504774129883; Leeman L, 2008, AM FAM PHYSICIAN, V78, P93; Lees KR, 2004, LANCET, V363, P439; Li J, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002755.pub2; Luo J, 2004, NEUROSCI LETT, V359, P167, DOI 10.1016/j.neulet.2004.02.027; Mami A, 2006, NEUROCHEM RES, V31, P63, DOI 10.1007/s11064-005-9076-5; McKee JA, 2005, CRIT CARE MED, V33, P661, DOI 10.1097/01.ccm.0000156293.35868.b2; Memon ZI, 1995, SCAND J CLIN LAB INV, V55, P671, DOI 10.3109/00365519509075397; MORI H, 1992, NATURE, V358, P673, DOI 10.1038/358673a0; Mu XJ, 2000, J NEUROTRAUM, V17, P773, DOI 10.1089/neu.2000.17.773; MUIR KW, 1995, STROKE, V26, P1183, DOI 10.1161/01.STR.26.7.1183; O'Collins VE, 2006, ANN NEUROL, V59, P467, DOI 10.1002/ana.20741; Ozdemir M, 2005, MAGNESIUM RES, V18, P170; Poschel KA, 2000, KIDNEY INT, V58, P2478, DOI 10.1046/j.1523-1755.2000.00431.x; Rabchevsky AG, 2001, J NEUROTRAUM, V18, P513, DOI 10.1089/089771501300227314; Romani A, 2007, ARCH BIOCHEM BIOPHYS, V458, P90, DOI 10.1016/j.abb.2006.07.012; Saver JL, 2004, STROKE, V35, pE106, DOI 10.1161/01.STR.0000124458.98123.52; Savitz SI, 2007, EXP NEUROL, V205, P20, DOI 10.1016/j.expneurol.2007.03.003; Solaroglu I, 2005, SURG NEUROL, V64, P17, DOI 10.1016/j.surneu.2005.07.058; Stippler M, 2007, J NEUROTRAUM, V24, P1347, DOI 10.1089/neu.2007.0277; Suzer T, 1999, SPINAL CORD, V37, P480, DOI 10.1038/sj.sc.3100874; Tator CH, 2006, NEUROSURGERY, V59, P957, DOI 10.1227/01.NEU.0000245591.16087.89; Temkin NR, 2007, LANCET NEUROL, V6, P29, DOI 10.1016/S1474-4422(06)70630-5; Vink R, 2000, FRONT BIOSCI, V5, pD656, DOI 10.2741/Vink; VINK R, 1987, BIOCHEM BIOPH RES CO, V149, P594, DOI 10.1016/0006-291X(87)90409-8; Yang Y, 2000, NEUROSCI LETT, V285, P119, DOI 10.1016/S0304-3940(00)01048-X; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	60	42	42	2	15	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2009	26	8					1379	1393		10.1089/neu.2009.0884			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	479AF	WOS:000268629900021	19317592				2021-06-18	
J	Orsucci, D; Calsolaro, V; Mancuso, M; Siciliano, G				Orsucci, D.; Calsolaro, V.; Mancuso, M.; Siciliano, G.			Neuroprotective Effects of Tetracyclines: Molecular Targets, Animal Models and Human Disease	CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS			English	Article						Mitochondria; Neurodegeneration; PARP-1; ROS; Tetracyclines	FOCAL CEREBRAL-ISCHEMIA; SPINAL-CORD-INJURY; AMYOTROPHIC-LATERAL-SCLEROSIS; TRAUMATIC BRAIN-INJURY; CYTOCHROME-C RELEASE; RAT TEMPORAL CORTEX; MICROGLIAL ACTIVATION; MULTIPLE-SCLEROSIS; HUNTINGTONS-DISEASE; MOUSE MODEL	Tetracyclines are a class of antibiotics which could play a therapeutic role in several neurological disorders. Minocycline, extensively studied in animal models, decreased the size of ischaemic and haemorrhagic infarct. In Parkinson's disease models minocycline protected the nigrostriatal pathway, and in Huntington's disease and motoneuron disease models delayed the progression of disease extending the lifespan. Finally, in human diseases such as stroke and multiple sclerosis tetracyclines seem to play some neuroprotective role. The main biological effects of tetracyclines are the inhibition of microglial activation, the attenuation of apoptosis, and the suppression of reactive oxygen species production. These mechanisms are involved in the pathogenesis of several neurodegenerative disorders. Several reports showed that minocycline reduced mitochondrial Ca2+ uptake, stabilized mitochondrial membranes, and reduced the release into the cytoplasm of apoptotic factors. Other effects include upregulation of mitochondrial bcl-2 (an antiapoptotic protein), direct scavenging of reactive oxygen species, and inhibition of mitogen activated protein kinases. It is still unclear which of these mechanisms plays the pivotal role in neuroprotective properties of tetracyclines. The anti-apoptotic effect of tetracyclines probably involves the mitochondrion. The major target for tetracyclines in neurodegeneration could lie within the complex network that links mitochondria, oxidative stress, poly (ADP-ribose) polymerase-1 and apoptosis. Here, we review the neuroprotective effects of tetracyclines in animal models and in human disease, and we focus on their possible mechanism(s) of action, with special regard to mitochondrial dysfunction in neurodegeneration.	[Orsucci, D.; Calsolaro, V.; Mancuso, M.; Siciliano, G.] Univ Pisa, Neurol Clin, Dept Neurosci, I-56126 Pisa, Italy	Orsucci, D (corresponding author), Univ Pisa, Neurol Clin, Dept Neurosci, Via Roma 67, I-56126 Pisa, Italy.	d.orsucci@sssup.it	Mancuso, Michelangelo/K-4170-2016; Siciliano, Gabriele/K-7259-2016; Orsucci, Daniele/AAA-7576-2019	Mancuso, Michelangelo/0000-0003-2738-8562; Siciliano, Gabriele/0000-0002-6142-2384; Orsucci, Daniele/0000-0003-4847-7812			Alano CC, 2006, P NATL ACAD SCI USA, V103, P9685, DOI 10.1073/pnas.0600554103; Bilousova TV, 2009, J MED GENET, V46, P94, DOI 10.1136/jmg.2008.061796; Blum D, 2004, NEUROBIOL DIS, V17, P359, DOI 10.1016/j.nbd.2004.07.012; Bonelli RM, 2004, INT CLIN PSYCHOPHARM, V19, P337, DOI 10.1097/00004850-200411000-00004; Brundula V, 2002, BRAIN, V125, P1297, DOI 10.1093/brain/awf133; Burggraf D, 2007, NEUROBIOL DIS, V25, P506, DOI 10.1016/j.nbd.2006.10.013; Burgos-Ramos E, 2008, NEUROSCIENCE, V154, P1458, DOI 10.1016/j.neuroscience.2008.04.036; Burgos-Ramos E, 2009, LIFE SCI, V84, P205, DOI 10.1016/j.lfs.2008.11.019; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Cai Zhi-You, 2008, Neurosci Bull, V24, P305, DOI 10.1007/s12264-008-0324-y; Carty ML, 2008, INT J DEV NEUROSCI, V26, P477, DOI 10.1016/j.ijdevneu.2008.02.005; Chen M, 2000, NAT MED, V6, P797, DOI 10.1038/77528; Choi Y, 2007, NEUROPSYCHOPHARMACOL, V32, P2393, DOI 10.1038/sj.npp.1301377; Crack P, 2009, J NEURAL TRANSM, V116, P1, DOI 10.1007/s00702-008-0145-1; Davies JE, 2005, NAT MED, V11, P672, DOI 10.1038/nm1242; Diguet E, 2004, EUR J NEUROSCI, V19, P3266, DOI 10.1111/j.0953-816X.2004.03372.x; DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567; Du YS, 2001, P NATL ACAD SCI USA, V98, P14669, DOI 10.1073/pnas.251341998; Duan YT, 2007, J PHYSIOL-LONDON, V585, P741, DOI 10.1113/jphysiol.2007.145409; Fan LW, 2006, EUR J NEUROSCI, V24, P341, DOI 10.1111/j.1460-9568.2006.04918.x; Forloni G, 2002, P NATL ACAD SCI USA, V99, P10849, DOI 10.1073/pnas.162195499; Gieseler A, 2009, BIOCHEM PHARMACOL, V77, P888, DOI 10.1016/j.bcp.2008.11.003; Girgenrath M, 2009, ANN NEUROL, V65, P47, DOI 10.1002/ana.21523; Gordon PH, 2007, LANCET NEUROL, V6, P1045, DOI 10.1016/S1474-4422(07)70270-3; Haroon MF, 2007, NEUROBIOL DIS, V28, P237, DOI 10.1016/j.nbd.2007.07.021; Hayakawa K, 2008, STROKE, V39, P951, DOI 10.1161/STROKEAHA.107.495820; Hirsch EC, 2003, ANN NY ACAD SCI, V991, P214; Hu W, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004151; Jantzie LL, 2005, J CEREBR BLOOD F MET, V25, P314, DOI 10.1038/sj.jcbfm.9600025; Jiang SX, 2005, J BIOL CHEM, V280, P33811, DOI 10.1074/jbc.M503113200; Jordan J., 2007, Current Drug Delivery, V4, P225; Keilhoff G, 2008, EXP NEUROL, V212, P189, DOI 10.1016/j.expneurol.2008.03.028; Krantic S, 2005, TRENDS NEUROSCI, V28, P670, DOI 10.1016/j.tins.2005.09.011; Kraus RL, 2005, J NEUROCHEM, V94, P819, DOI 10.1111/j.1471-4159.2005.03219.x; LACKNER LL, 2009, BIOCH BIOPH IN PRESS; Lai Y, 2008, J NEUROCHEM, V104, P1700, DOI 10.1111/j.1471-4159.2007.05114.x; Lampl Y, 2007, NEUROLOGY, V69, P1404, DOI 10.1212/01.wnl.0000277487.04281.db; Ledeboer A, 2005, PAIN, V115, P71, DOI 10.1016/j.pain.2005.02.009; LEE H, NEUROBIOL D IN PRESS; Lee SM, 2003, J NEUROTRAUM, V20, P1017, DOI 10.1089/089771503770195867; Liu ZY, 2007, STROKE, V38, P146, DOI 10.1161/01.STR.0000251791.64910.cd; Luccanini I, 2008, EXP NEUROL, V211, P214, DOI 10.1016/j.expneurol.2008.01.022; Ludolph Albert C, 2007, Amyotroph Lateral Scler, V8, P217, DOI 10.1080/17482960701292837; Machado LS, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-56; Maier K, 2007, NEUROBIOL DIS, V25, P514, DOI 10.1016/j.nbd.2006.10.022; Malm TM, 2008, GLIA, V56, P1767, DOI 10.1002/glia.20726; Mancuso M, 2008, CURR ALZHEIMER RES, V5, P457, DOI 10.2174/156720508785908946; Mancuso M, 2006, J ALZHEIMERS DIS, V10, P59; Mancuso Michelangelo, 2008, Human Genomics, V3, P71; Metz LM, 2004, ANN NEUROL, V55, P756, DOI 10.1002/ana.20111; Minagar A, 2008, ARCH NEUROL-CHICAGO, V65, P199, DOI 10.1001/archneurol.2007.41; Mishra MK, 2008, J NEUROCHEM, V105, P1582, DOI 10.1111/j.1471-4159.2008.05238.x; Miyaoka T, 2008, CNS NEUROL DISORD-DR, V7, P376, DOI 10.2174/187152708786441858; Morimoto N, 2005, BRAIN RES, V1044, P8, DOI 10.1016/j.brainres.2005.02.062; Murata Y, 2008, STROKE, V39, P3372, DOI 10.1161/STROKEAHA.108.514026; Nagel S, 2008, BRAIN RES, V1188, P198, DOI 10.1016/j.brainres.2007.10.052; Nessler S, 2002, ANN NEUROL, V52, P689, DOI 10.1002/ana.10353; *NITS NET PD INV, 2006, NEUROLOGY, V66, P664; Noble W, 2009, FASEB J, V23, P739, DOI 10.1096/fj.08-113795; Noji H, 2001, J BIOL CHEM, V276, P1665, DOI 10.1074/jbc.R000021200; Omar A, 2007, NEUROLOGY, V68, P1159, DOI 10.1212/01.wnl.0000258659.21421.b0; Pontieri FE, 2005, NEUROL SCI, V26, P285, DOI 10.1007/s10072-005-0474-x; Popovic N, 2002, ANN NEUROL, V51, P215, DOI 10.1002/ana.10092; Power C, 2003, ANN NEUROL, V53, P731, DOI 10.1002/ana.10553; Raghavendra V, 2003, J PHARMACOL EXP THER, V306, P624, DOI 10.1124/jpet.103.052407; Ricci JE, 2004, CELL, V117, P773, DOI 10.1016/j.cell.2004.05.008; Rosa A, 2008, BMC MED GENET, V9, DOI 10.1186/1471-2350-9-57; Ruggieri M, 2008, J NEUROIMMUNOL, V197, P140, DOI 10.1016/j.jneuroim.2008.04.032; Schreiber V, 2006, NAT REV MOL CELL BIO, V7, P517, DOI 10.1038/nrm1963; Scovassi AI, 2004, BIOCHEM PHARMACOL, V68, P1041, DOI 10.1016/j.bcp.2004.04.023; Seabrook TJ, 2006, GLIA, V53, P776, DOI 10.1002/glia.20338; Shefer G, 2008, J CELL PHYSIOL, V215, P265, DOI 10.1002/jcp.21306; Smith DL, 2003, ANN NEUROL, V54, P186, DOI 10.1002/ana.10614; Teng YD, 2004, P NATL ACAD SCI USA, V101, P3071, DOI 10.1073/pnas.0306239101; Tikka TM, 2002, BRAIN, V125, P722, DOI 10.1093/brain/awf068; Tsuji M, 2004, EXP NEUROL, V189, P58, DOI 10.1016/j.expneurol.2004.01.011; Viscomi MT, 2008, CEREBELLUM, V7, P401, DOI 10.1007/s12311-008-0042-z; Wang HM, 2004, J NEUROSCI, V24, P10963, DOI 10.1523/JNEUROSCI.3461-04.2004; Wang X, 2003, P NATL ACAD SCI USA, V100, P10483, DOI 10.1073/pnas.1832501100; Wells JEA, 2003, BRAIN, V126, P1628, DOI 10.1093/brain/awg178; Wu JM, 2009, NEUROL RES, V31, P183, DOI 10.1179/174313209X385680; Xu L, 2004, BMC NEUROL, V4, DOI 10.1186/1471-2377-4-7; Yang LC, 2003, J NEUROSCI RES, V74, P278, DOI 10.1002/jnr.10709; Yong VW, 2004, LANCET NEUROL, V3, P744, DOI 10.1016/S1474-4422(04)00937-8; Yrjanheikki J, 1999, P NATL ACAD SCI USA, V96, P13496, DOI 10.1073/pnas.96.23.13496; Yrjanheikki J, 1998, P NATL ACAD SCI USA, V95, P15769, DOI 10.1073/pnas.95.26.15769; Yune TY, 2007, J NEUROSCI, V27, P7751, DOI 10.1523/JNEUROSCI.1661-07.2007; Zabad RK, 2007, MULT SCLER, V13, P517, DOI 10.1177/1352458506070319; Zhang ZY, 2009, J CELL MOL MED, V13, P341, DOI 10.1111/j.1582-4934.2008.00333.x; Zhu S, 2002, NATURE, V417, P74, DOI 10.1038/417074a	90	42	45	0	15	BENTHAM SCIENCE PUBL	BUSUM	PO BOX 294, BUSUM, 1400 AG, NETHERLANDS	1871-5273	1996-3181		CNS NEUROL DISORD-DR	CNS Neurol. Disord.-Drug Targets	JUL	2009	8	3					222	231					10	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	474BE	WOS:000268256400006	19601819				2021-06-18	
J	Scafidi, S; O'Brien, J; Hopkins, I; Robertson, C; Fiskum, G; McKenna, M				Scafidi, Susanna; O'Brien, Janet; Hopkins, Irene; Robertson, Courtney; Fiskum, Gary; McKenna, Mary			Delayed cerebral oxidative glucose metabolism after traumatic brain injury in young rats	JOURNAL OF NEUROCHEMISTRY			English	Article; Proceedings Paper	3rd International-Society-of-Neurochemistry-Special-Neurochemistry Conference/8th International Meeting on Brain Energy Metabolism	JUN 27-JUL 01, 2008	Beijing, PEOPLES R CHINA	Int Soc Neurochem		C-13-NMR spectroscopy; GABA; glucose; glutamate; immature brain; metabolism; PC; PDHC; traumatic brain injury	GLIAL-NEURONAL INTERACTIONS; CONTROLLED CORTICAL IMPACT; MITOCHONDRIAL DYSFUNCTION; IMMATURE RATS; ENERGY-METABOLISM; GLUTAMATE RELEASE; HEAD-INJURY; CYCLE; INCREASES; PYRUVATE	Traumatic brain injury (TBI) results in a cerebral metabolic crisis that contributes to poor neurologic outcome. The aim of this study was to characterize changes in oxidative glucose metabolism in early periods after injury in the brains of immature animals. At 5 h after controlled cortical impact TBI or sham surgery to the left cortex, 21-22 day old rats were injected intraperitoneally with [1,6-C-13]glucose and brains removed 15, 30 and 60 min later and studied by ex vivo C-13-NMR spectroscopy. Oxidative metabolism, determined by incorporation of C-13 into glutamate, glutamine and GABA over 15-60 min, was significantly delayed in both hemispheres of brain from TBI rats. The most striking delay was in labeling of the C4 position of glutamate from neuronal metabolism of glucose in the injured, ipsilateral hemisphere which peaked at 60 min, compared with the contralateral and sham-operated brains, where metabolism peaked at 30 and 15 min, respectively. Our findings indicate that (i) neuronal-specific oxidative metabolism of glucose at 5-6 h after TBI is delayed in both injured and contralateral sides compared with sham brain; (ii) labeling from metabolism of glucose via the pyruvate carboxylase pathway in astrocytes was also initially delayed in both sides of TBI brain compared with sham brain; (iii) despite this delayed incorporation, at 6 h after TBI, both sides of the brain showed apparent increased neuronal and glial metabolism, reflecting accumulation of labeled metabolites, suggesting impaired malate aspartate shuttle activity. The presence of delayed metabolism, followed by accumulation of labeled compounds is evidence of severe alterations in homeostasis that could impair mitochondrial metabolism in both ipsilateral and contralateral sides of brain after TBI. However, ongoing oxidative metabolism in mitochondria in injured brain suggests that there is a window of opportunity for therapeutic intervention up to at least 6 h after injury.	[Scafidi, Susanna; O'Brien, Janet; Hopkins, Irene; Robertson, Courtney; McKenna, Mary] Univ Maryland, Sch Med, Dept Pediat, Baltimore, MD 21201 USA; [Robertson, Courtney; Fiskum, Gary] Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA	McKenna, M (corresponding author), Univ Maryland, Sch Med, Dept Pediat, 655 W Baltimore St,R 13-019, Baltimore, MD 21201 USA.	mmckenna@umaryland.edu		Scafidi, Susanna/0000-0002-1229-8778	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P01HD016596] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P01 HD016596-24, HD16596, P01 HD016596-240001, P01 HD016596] Funding Source: Medline		Bartnik BL, 2005, J NEUROTRAUM, V22, P1052, DOI 10.1089/neu.2005.22.1052; Biagas KV, 1996, J NEUROTRAUM, V13, P189, DOI 10.1089/neu.1996.13.189; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Casey PA, 2008, J NEUROTRAUM, V25, P603, DOI 10.1089/neu.2007.0481; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; Haberg A, 2001, J CEREBR BLOOD F MET, V21, P1451, DOI 10.1097/00004647-200112000-00010; HASSEL B, 1995, J NEUROCHEM, V64, P2773; HASSEL B, 1995, J NEUROCHEM, V65, P2227; Haydon PG, 2006, PHYSIOL REV, V86, P1009, DOI 10.1152/physrev.00049.2005; HIGGINS JJ, 1994, J CHILD NEUROL, V9, P436, DOI 10.1177/088307389400900421; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; Keenan HT, 2006, DEV NEUROSCI-BASEL, V28, P256, DOI 10.1159/000094152; Kochanek AR, 2006, DEV NEUROSCI-BASEL, V28, P410, DOI 10.1159/000094167; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; Marcoux J, 2008, CRIT CARE MED, V36, P2871, DOI 10.1097/CCM.0b013e318186a4a0; McKenna MC, 2007, J NEUROSCI RES, V85, P3347, DOI 10.1002/jnr.21444; McKenna MC, 2006, BIOCHEM PHARMACOL, V71, P399, DOI 10.1016/j.bcp.2005.10.011; Montana V, 2004, J NEUROSCI, V24, P2633, DOI 10.1523/JNEUROSCI.3770-03.2004; Opii WO, 2007, J NEUROTRAUM, V24, P772, DOI 10.1089/neu.2006.0229; Oz G, 2004, J NEUROSCI, V24, P11273, DOI 10.1523/JNEUROSCI.3564-04.2004; Pandya JD, 2007, J NEUROTRAUM, V24, P798, DOI 10.1089/neu.2006.3673; Qu H, 2003, NEUROCHEM INT, V42, P101, DOI 10.1016/S0197-0186(02)00051-7; Richards EM, 2007, STROKE, V38, P1578, DOI 10.1161/STROKEAHA.106.473967; Robertson CL, 2006, EXP NEUROL, V197, P235, DOI 10.1016/j.expneurol.2005.09.014; Robertson CL, 2007, J NEUROCHEM, V101, P1248, DOI 10.1111/j.1471-4159.2007.04489.x; Robertson CL, 2006, DEV NEUROSCI-BASEL, V28, P432, DOI 10.1159/000094169; Samant UB, 2008, J NEUROTRAUM, V25, P495, DOI 10.1089/neu.2007.0491; Satrustegui J, 2007, J NEUROSCI RES, V85, P3359, DOI 10.1002/jnr.21299; Schroder ML, 1996, J NEUROTRAUM, V13, P17, DOI 10.1089/neu.1996.13.17; SIESJO BK, 1984, J NEUROSURG, V60, P883, DOI 10.3171/jns.1984.60.5.0883; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Soustiel JF, 2007, NEUROL RES, V29, P654, DOI 10.1179/016164107X240017; Starkov AA, 2004, J NEUROSCI, V24, P7779, DOI 10.1523/JNEUROSCI.1899-04.2004; TAKEUCHI H, 2008, EXP NEUROL; Thomas S, 2000, J NEUROTRAUM, V17, P649, DOI 10.1089/089771500415409; Verweij BH, 2007, PROG BRAIN RES, V161, P111, DOI 10.1016/S0079-6123(06)61008-X; Waagepetersen HS, 2000, NEUROCHEM INT, V36, P349, DOI 10.1016/S0197-0186(99)00143-6; Xiong Y, 1998, J NEUROTRAUM, V15, P531, DOI 10.1089/neu.1998.15.531; Xu Y, 2007, J NEUROCHEM, V101, P120, DOI 10.1111/j.1471-4159.2006.04349.x; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Zhong C, 2006, J NEUROCHEM, V97, P1015, DOI 10.1111/j.1471-4159.2006.03786.x	43	42	44	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	MAY	2009	109			1			189	197		10.1111/j.1471-4159.2009.05896.x			9	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	430UF	WOS:000265013900027	19393027	Green Accepted, Bronze			2021-06-18	
J	Sullivan, SJ; Bourne, L; Choie, S; Eastwood, B; Isbister, S; McCrory, P; Gray, A				Sullivan, S. John; Bourne, Liam; Choie, Sharon; Eastwood, Brigitte; Isbister, Sarah; McCrory, Paul; Gray, Andrew			Understanding of Sport Concussion by the Parents of Young Rugby Players: A Pilot Study	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						brain concussion; parents; pediatrics; rugby; signs and symptoms		Objective: Establish the knowledge and beliefs of the parents of high school rugby players about concussion. Design: Descriptive cross-sectional intercept style face-to-face pilot survey. Setting: The survey was conducted during high school rugby games. Participants: Two hundred parents of male high school rugby players who were attending their teenagers' games. Main Outcome Measures: Exploratory analysis of the closed- and open-ended questionnaire. Concussion signs and symptoms were subsequently mapped onto the framework of the Sport Concussion Assessment Tool. Results: Most parents (83%; 165 of 198) reported that they were able to recognize a concussion in their teenager and provide a list of well-accepted signs and symptoms. Nearly all (96%; 188 of 196) were aware of the risks of continuing to play while concussed, and approximately half (51%; 99 of 196) were aware of return-to-play guidelines/recommendations after a concussion. Conclusions: Parents of male high school rugby players reported having basic knowledge of concussion symptoms and the seriousness of concussion. Parents are potentially key figures in the detection of a possible concussion in the postgame/practice home environment.	[Sullivan, S. John; Bourne, Liam; Choie, Sharon; Eastwood, Brigitte; Isbister, Sarah] Univ Otago, Ctr Physiotherapy Res, Sch Physiotherapy, Dunedin 9054, New Zealand; [McCrory, Paul] Univ Melbourne, Ctr Hlth Exercise & Sports Med, Melbourne, Vic, Australia; [Gray, Andrew] Univ Otago, Dept Prevent & Social Med, Dunedin Sch Med, Dunedin 9054, New Zealand	Sullivan, SJ (corresponding author), Univ Otago, Ctr Physiotherapy Res, Sch Physiotherapy, POB 56, Dunedin 9054, New Zealand.	sjohn.sullivan@otago.ac.nz	McCrory, Paul/Q-8688-2019; Gray, Andrew Robert/L-9161-2015	Gray, Andrew Robert/0000-0003-4299-2194; McCrory, Paul/0000-0003-4850-0568			*ACC COMP CORP, ACC SPORTSSMART RES; Gagnon I, 2008, BRAIN INJURY, V22, P161, DOI 10.1080/02699050701867381; Gioia GA, 2008, J HEAD TRAUMA REHAB, V23, P230, DOI 10.1097/01.HTR.0000327255.38881.ca; Guilmette TJ, 2007, BRAIN INJURY, V21, P1039, DOI 10.1080/02699050701633080; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McLeod TCV, 2007, CLIN J SPORT MED, V17, P140; MILNE C, 1999, NZ J SPORTS MED, P15; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511	10	42	43	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	MAY	2009	19	3					228	230		10.1097/JSM.0b013e3181a41e43			3	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	443FN	WOS:000265895700006	19423976				2021-06-18	
J	Attix, DK; Story, TJ; Chelune, GJ; Ball, JD; Stutts, ML; Hart, RP; Barth, JT				Attix, Deborah K.; Story, Tyler J.; Chelune, Gordon J.; Ball, J. D.; Stutts, Michael L.; Hart, Robert P.; Barth, Jeffrey T.			THE PREDICTION OF CHANGE: NORMATIVE NEUROPSYCHOLOGICAL TRAJECTORIES	CLINICAL NEUROPSYCHOLOGIST			English	Article						Change; Trajectory; Normal change	POSTOPERATIVE COGNITIVE DYSFUNCTION; ANTERIOR TEMPORAL LOBECTOMY; RELIABLE CHANGE INDEXES; TRAUMATIC BRAIN-INJURY; WAIS-III/WMS-III; ALTERNATE FORMS; AGES 56; MEASURING RECOVERY; NORMAL INDIVIDUALS; TEST-PERFORMANCE	While the application of normative standards is vital to the practice of clinical neuropsychology, data regarding normative change remains scarce despite the frequency of serial assessments. Based on 285 normal individuals, we provide co-normed baseline data with demographic adjustments and test-retest standardized regression based (SRB) models for three time points for several measures. These models delineate normal, expected change across time, and yield standardized z-scores that are comparable across tests. Using a new approach, performance on any previous trial was accounted for in the subsequent models of change, yielding serial normative formulas that model change trajectories rather than simple change from point to point. These equations provide indices of deviation from expected baseline and change for use in clinical or research settings.	[Attix, Deborah K.; Story, Tyler J.] Duke Univ, Med Ctr, Div Neurol, Durham, NC 27710 USA; [Attix, Deborah K.; Story, Tyler J.] Duke Univ, Med Ctr, Div Med Psychol, Durham, NC 27710 USA; [Chelune, Gordon J.] Univ Utah, Hlth Sci Ctr, Salt Lake City, UT USA; [Ball, J. D.; Stutts, Michael L.] Eastern Virginia Med Sch, Norfolk, VA 23501 USA; [Hart, Robert P.] Virginia Commonwealth Univ, Richmond, VA USA; [Barth, Jeffrey T.] Univ Virginia, Sch Med, Charlottesville, VA 22908 USA	Attix, DK (corresponding author), Duke Univ, Med Ctr, Div Neurol, Box 3333, Durham, NC 27710 USA.	koltai@duke.edu	Ball, J.D./T-9440-2019	Koltai, Deborah/0000-0002-4254-9902			Andrew MJ, 2001, J CARDIOTHOR VASC AN, V15, P9, DOI 10.1053/jcan.2001.20210; Apa Pesidential Task Force, 2006, AM PSYCHOL, V61, P271, DOI 10.1037/0003-066X.61.4.271; Basso MR, 1999, CLIN NEUROPSYCHOL, V13, P283, DOI 10.1076/clin.13.3.283.1743; Beglinger LJ, 2005, ARCH CLIN NEUROPSYCH, V20, P517, DOI 10.1016/j.acn.2004.12.003; Benedict RHB, 1998, J CLIN EXP NEUROPSYC, V20, P339, DOI 10.1076/jcen.20.3.339.822; Benton AL, 1978, MULTILINGUAL APHASIA; Bruggemans EF, 1997, J CLIN EXP NEUROPSYC, V19, P543, DOI 10.1080/01688639708403743; Bruggemans EF, 1999, ANN THORAC SURG, V67, P297; Busch R, 2006, GERIATRIC NEUROPSYCH, P133; Chelune GJ, 2003, PREDICTION IN FORENSIC AND NEUROPSYCHOLOGY, P123; Chelune GJ, 2002, NEUROPSYCHOLOGY, V16, P422, DOI 10.1037//0894-4105.16.3.422; Chelune GJ, 1993, NEUROPSYCHOLOGY, V7, P41, DOI DOI 10.1037/0894-4105.7.1.41; CHELUNE GJ, 2007, J INT NEUROPSYCH SOC, V13, P107; CHELUNE GJ, 2006, ALZHEIMERS DEMENT, V2, P374; Chu BC, 2007, J CLIN EXP NEUROPSYC, V29, P617, DOI 10.1080/13803390600878893; Collie A, 2003, J INT NEUROPSYCH SOC, V9, P419, DOI 10.1017/S1355617703930074; Collie A, 2002, ANN THORAC SURG, V73, P2005, DOI 10.1016/S0003-4975(01)03375-6; Delis DC, 2000, CALIFORNIA VERBAL LE; Dikmen SS, 1999, J INT NEUROPSYCH SOC, V5, P346, DOI 10.1017/S1355617799544056; Duff K, 2005, ARCH CLIN NEUROPSYCH, V20, P281, DOI 10.1016/j.acn.2004.07.007; Farag E, 2006, ANESTH ANALG, V103, P633, DOI 10.1213/01.ane.0000228870.48028.b5; Ferland MB, 1998, J CLIN EXP NEUROPSYC, V20, P473, DOI 10.1076/jcen.20.4.473.1475; Golden C., 1978, STROOP COLOR WORD TE; Hawkins KA, 2003, CLIN INTERPRETATION, P211; Heaton R., 1993, WISCONSIN CARD SORTI; Heaton R.K., 2003, CLIN INTERPRETATION; Heaton RK, 2004, REVISED COMPREHENSIV; Hermann BP, 1996, EPILEPSIA, V37, P942, DOI 10.1111/j.1528-1157.1996.tb00531.x; Hermann BP, 1999, NEUROPSYCHOLOGY, V13, P3, DOI 10.1037/0894-4105.13.1.3; Hinton-Bayre A, 2005, PSYCHOL ASSESSMENT, V17, P237, DOI 10.1037/1040-3590.17.2.237; Iverson GL, 2001, ARCH CLIN NEUROPSYCH, V16, P183, DOI 10.1016/S0887-6177(00)00060-3; Ivnik R. J., 1990, PSYCHOL ASSESSMENT J, V2, P304, DOI [10.1037/1040-3590.2.3.304, DOI 10.1037/1040-3590.2.3.304]; Ivnik RJ, 2000, NEUROPSYCHOLOGY, V14, P163, DOI 10.1037/0894-4105.14.2.163; Ivnik RJ, 1997, J CLIN EXP NEUROPSYC, V19, P676, DOI 10.1080/01688639708403753; Ivnik RJ, 1996, CLIN NEUROPSYCHOL, V10, P262, DOI 10.1080/13854049608406689; Ivnik RJ, 1999, NEUROPSYCHOLOGY, V13, P121, DOI 10.1037/0894-4105.13.1.121; Ivnik RJ, 2001, CLIN NEUROPSYCHOL, V15, P114, DOI 10.1076/clin.15.1.114.1904; Ivnik RJ, 1992, CLIN NEUROPSYCHOL, V6, P49, DOI DOI 10.1080/13854049208401879; Ivnik RJ, 1992, CLIN NEUROPSYCHOL, V6, P83; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; KlOve H, 1963, MED CLIN N AM; Kneebone AC, 1998, ANN THORAC SURG, V65, P1320, DOI 10.1016/S0003-4975(98)00158-1; Knight RG, 2007, ARCH CLIN NEUROPSYCH, V22, P513, DOI 10.1016/j.acn.2007.03.005; Kurland, 1992, CLIN NEUROPSYCHOL, V6, P1, DOI DOI 10.1080/13854049208401877; Lehrner J, 2005, J CLIN EXP NEUROPSYC, V27, P859, DOI 10.1080/13803390490919083; Lewis M, 2004, NEUROSCI BIOBEHAV R, V28, P433, DOI 10.1016/j.neubiorev.2004.05.002; Lewis MS, 2006, ACTA ANAESTH SCAND, V50, P50, DOI 10.1111/j.1399-6576.2006.00893.x; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; LINEWEAVER TT, 2003, CLIN INTERPRETATION, P303; Lucas JA, 1998, J CLIN EXP NEUROPSYC, V20, P536, DOI 10.1076/jcen.20.4.536.1469; Martin R, 2002, EPILEPSIA, V43, P1551, DOI 10.1046/j.1528-1157.2002.23602.x; Maze M, 2007, ANESTHESIOLOGY, V106, P418, DOI 10.1097/00000542-200703000-00003; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; MCSWEENY AJ, 1993, CLIN NEUROPSYCHOL, V7, P460; Meyers J., 1995, REY COMPLEX FIGURE T; Mitchell AJ, 2008, CLIN NEUROPSYCHOL, V79, P1386, DOI DOI 10.1080/13854049208401878; Mitrushina M., 2005, HDB NORMATIVE DATA N; MOE C, 2004, FINAL REPORT N UNPUB; Murkin JM, 2001, J CARDIOTHOR VASC AN, V15, P1, DOI 10.1053/jcan.2001.2028; Powell DH, 1993, MICROCOG ASSESSMENT; Randolph C, 1998, REPEATABLE BATTERY A; Raymond PD, 2006, CLIN NEUROPSYCHOL, V20, P261, DOI 10.1080/13854040590947416; Ruff R. M., 1996, RUFF FIGURAL FLUENCY; Salthouse TA, 2007, NEUROPSYCHOLOGY, V21, P401, DOI 10.1037/0894-4105.21.4.401; Sawrie S M, 1996, J Int Neuropsychol Soc, V2, P556; Sawrie SM, 1999, J GERONTOL B-PSYCHOL, V54, pP116, DOI 10.1093/geronb/54B.2.P116; Schmidt M., 1996, REY AUDITORY VERBAL; SCHMIDT R, 1994, NEUROLOGY, V44, P964, DOI 10.1212/WNL.44.5.964; Seidenberg M, 1998, NEUROPSYCHOLOGY, V12, P303, DOI 10.1037/0894-4105.12.2.303; Smith A., 1982, SYMBOL DIGIT MODALIT; Stern R.A., 2001, NEUROPSYCHOLOGICAL A; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Taylor MJ, 2001, J INT NEUROPSYCH SOC, V7, P867, DOI 10.1017/S1355617701777107; Temkin NR, 1999, J INT NEUROPSYCH SOC, V5, P357, DOI 10.1017/S1355617799544068; Tombaugh TN, 2005, ARCH CLIN NEUROPSYCH, V20, P485, DOI 10.1016/j.acn.2004.11.004; Turf Elizabeth, 1999, Virginia Journal of Science, V50, P299; *US ARM, 1944, ARM IND TEST BATT; Vanderploeg RD, 2000, CLIN NEUROPSYCHOL, V14, P318, DOI 10.1076/1385-4046(200008)14:3;1-P;FT318; WAIS-III-WMS-III-WIAT-II Writer (Version 1.0), 2002, WAIS 3 WMS 3 WIAT 2; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wilkinson G. S., 1993, WIDE RANGE ACHIEVEME	81	42	42	0	9	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2009	23	1					21	38		10.1080/13854040801945078			18	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	399LR	WOS:000262801900003	18720272				2021-06-18	
J	Katz-Leurer, M; Rotem, H; Keren, O; Meyer, S				Katz-Leurer, Michal; Rotem, Hemda; Keren, Ofer; Meyer, Shirley			Balance abilities and gait characteristics in post-traumatic brain injury, cerebral palsy and typically developed children	DEVELOPMENTAL NEUROREHABILITATION			English	Article						Cerebral palsy; children; traumatic brain injury; step variability; balance		Objectives: To quantify the differences in gait variability and balance performance between children with cerebral palsy (CP), children with post-traumatic brain injury (TBI) and typically developed (TD) children and to determine the association between gait variability and functional balance in these groups. Design: Cross-sectional study. Setting: Physical therapy department of a paediatric and adolescent rehabilitation hospital. Participants: A convenience sample of 15 children post-TBI, 15 children with CP and 30 TD age-and sex-matched controls. Intervention: Not applicable. Main outcome measure: Step length and step time variability measured by an electronic walkway; timed up and go (TUG) test and functional reach test (FRT) were used as functional balance tests. Results: The functional balance abilities of children post-TBI and children with CP were significantly limited compared to TD children. Children post-TBI had significantly greater variability in step length in comparison to healthy controls. A significant linear inverse correlation between balance performance and step length variability was found only among children with TBI. Conclusion: Brain damage is associated with restricted balance performance and increased step variability. It might be that in a child born with brain damage, as opposed to acquired damage, the developmental process has a restraining effect on gait variability.	[Katz-Leurer, Michal] Tel Aviv Univ, Sackler Fac Med, Sch Hlth Profess, Phys Therapy Dept, IL-69978 Ramat Aviv, Israel; [Katz-Leurer, Michal; Rotem, Hemda; Keren, Ofer; Meyer, Shirley] Alyn Hosp, Pediat & Adolescent Rehabil Ctr, Jerusalem, Israel	Katz-Leurer, M (corresponding author), Tel Aviv Univ, Sackler Fac Med, Sch Hlth Profess, Phys Therapy Dept, IL-69978 Ramat Aviv, Israel.	michalkz@post.tau.ac.il					BRINK JD, 1970, DEV MED CHILD NEUROL, V12, P565; Donahoe B, 1994, PEDIAT PHYSICAL THER, V6, P189, DOI DOI 10.1097/00001577-199400640-00004; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; Hausdorff JM, 1999, J APPL PHYSIOL, V86, P1040; Hausdorff JM, 1997, ARCH PHYS MED REHAB, V78, P278, DOI 10.1016/S0003-9993(97)90034-4; Hausdorff JM, 1998, MOVEMENT DISORD, V13, P428, DOI 10.1002/mds.870130310; Katz-Leurer M, 2008, BRAIN INJURY, V22, P153, DOI 10.1080/02699050801895399; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; Kuhtz-Buschbeck JP, 2003, DEV MED CHILD NEUROL, V45, P821, DOI 10.1017/S001216220300152X; Lowes LP, 1996, PEDIAT PHYS THERAPY, V8, P176; LOWES LP, 1997, THESIS ALLEGHENY U H; Maki BE, 1997, J AM GERIATR SOC, V45, P313, DOI 10.1111/j.1532-5415.1997.tb00946.x; McDonough AL, 2001, ARCH PHYS MED REHAB, V82, P419, DOI 10.1053/apmr.2001.19778; Niznik Theresa M., 1995, Physical and Occupational Therapy in Pediatrics, V15, P1; Rosano C, 2007, NEUROEPIDEMIOLOGY, V29, P193, DOI 10.1159/000111582; TEASDALE G, 1974, LANCET, V2, P81; Thorpe DE, 2005, ARCH PHYS MED REHAB, V86, P2342, DOI 10.1016/j.apmr.2005.07.301; VanderSchaaf PJ, 1997, PEDIATR NEUROL, V16, P306, DOI 10.1016/S0887-8994(97)00025-8; Wade LD, 1997, ARCH PHYS MED REHAB, V78, P1107, DOI 10.1016/S0003-9993(97)90136-2	19	42	43	0	9	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	1751-8423			DEV NEUROREHABIL	Dev. Neurorehabil.		2009	12	2					100	105		10.1080/17518420902800928			6	Clinical Neurology; Pediatrics; Rehabilitation	Neurosciences & Neurology; Pediatrics; Rehabilitation	V15FM	WOS:000207787900005	19340662				2021-06-18	
J	Rossaint, J; Rossaint, R; Weis, J; Fries, M; Rex, S; Coburn, M				Rossaint, Jan; Rossaint, Rolf; Weis, Joachim; Fries, Michael; Rex, Steffen; Coburn, Mark			Propofol: neuroprotection in an in vitro model of traumatic brain injury	CRITICAL CARE			English	Article							ORGANOTYPIC HIPPOCAMPAL CULTURES; CEREBRAL-ISCHEMIA; CELL-DEATH; REGIONAL VULNERABILITY; OXIDATIVE STRESS; NEURONAL DEATH; SLICE CULTURES; INFARCT SIZE; GLUTAMATE; RAT	Introduction The anaesthetic agent propofol (2,6-diisopropylphenol) has been shown to be an effective neuroprotective agent in different in vitro models of brain injury induced by oxygen and glucose deprivation. We examined its neuroprotective properties in an in vitro model of traumatic brain injury. Methods In this controlled laboratory study organotypic hippocampal brain-slice cultures were gained from six-to eight-day-old mice pups. After 14 days in culture, hippocampal brain slices were subjected to a focal mechanical trauma and subsequently treated with different molar concentrations of propofol under both normo- and hypothermic conditions. After 72 hours of incubation, tissue injury assessment was performed using propidium iodide (PI), a staining agent that becomes fluorescent only when it enters damaged cells via perforated cell membranes. Inside the cell, PI forms a fluorescent complex with nuclear DNA. Results A dose-dependent reduction of both total and secondary tissue injury could be observed in the presence of propofol under both normo- and hypothermic conditions. This effect was further amplified when the slices were incubated at 32 degrees C after trauma. Conclusions When used in combination, the dose-dependent neuroprotective effect of propofol is additive to the neuroprotective effect of hypothermia in an in vitro model of traumatic brain injury.	[Rossaint, Jan; Rossaint, Rolf; Fries, Michael; Coburn, Mark] RWTH Aachen Univ Hosp, Dept Anesthesiol, D-52074 Aachen, Germany; [Weis, Joachim] Univ Hosp RWTH Aachen, Inst Neuropathol, D-52074 Aachen, Germany; [Rex, Steffen] Univ Hosp RWTH Aachen, Dept Surg Intens Care, D-52074 Aachen, Germany	Coburn, M (corresponding author), RWTH Aachen Univ Hosp, Dept Anesthesiol, Pauwelsstr 30, D-52074 Aachen, Germany.	mcoburn@ukaachen.de	Weis, Joachim/G-1984-2014	Weis, Joachim/0000-0003-3280-6773; Coburn, Mark/0000-0002-7930-0270; Rex, Steffen/0000-0002-3536-9321	START program of the Medical Faculty of the RWTH Aachen	This research was conducted with funding by the START program of the Medical Faculty of the RWTH Aachen. We would like to thank Rosemarie Blaumeiser-Debarry for help with data acquisition; the teams at the Departments of Neuropathology, Pathology and Animal Research at the University Hospital Aachen; Professor Nicholas P. Franks for expert laboratory advice, assistance and help; Christina Mutscher and Elfriede Arweiler for their statistical support; and Michelle Haager for helpful comments on the manuscript.	AbdelHamid KM, 1997, J NEUROSCI, V17, P3538; Adamchik Y, 2000, BRAIN RES PROTOC, V5, P153, DOI 10.1016/S1385-299X(00)00007-6; Adembri C, 2006, ANESTHESIOLOGY, V104, P80, DOI 10.1097/00000542-200601000-00014; Adembri C, 2004, J NEUROTRAUM, V21, P1103, DOI 10.1089/0897715041651079; Adembri C, 2008, CRIT CARE MED, V36, P975, DOI 10.1097/CCM.0B013E3181644343; Adembri C, 2007, CNS DRUG REV, V13, P333, DOI 10.1111/j.1527-3458.2007.00015.x; Alkire MT, 2001, BRIT J ANAESTH, V86, P618, DOI 10.1093/bja/86.5.618; Allen JW, 1999, FASEB J, V13, P1875; BAHR BA, 1995, J NEUROSCI RES, V42, P294, DOI 10.1002/jnr.490420303; Bayona NA, 2004, ANESTHESIOLOGY, V100, P1151, DOI 10.1097/00000542-200405000-00017; Coburn M, 2008, CRIT CARE MED, V36, P588, DOI 10.1097/01.CCM.0B013E3181611F8A6; Crain SM, 1998, METHODS, V16, P228, DOI 10.1006/meth.1998.0681; Daskalopoulos R, 2001, ANESTH ANALG, V93, P1199, DOI 10.1097/00000539-200111000-00030; De Riu PL, 2000, EUR J ANAESTH, V17, P18, DOI 10.1097/00003643-200001000-00004; Eberspacher E, 2006, ANESTH ANALG, V103, P1527, DOI 10.1213/01.ane.0000247803.30582.2d; Engdahl O, 1998, BRIT J ANAESTH, V81, P957; Feiner JR, 2005, ANESTH ANALG, V100, P215, DOI 10.1213/01.ANE.0000142129.17005.73; Finley M, 2004, BRAIN RES, V1001, P125, DOI 10.1016/j.brainres.2003.12.009; Fowler CJ, 2004, TRENDS PHARMACOL SCI, V25, P59, DOI 10.1016/j.tips.2003.12.001; Franks NP, 2006, BRIT J PHARMACOL, V147, pS72, DOI 10.1038/sj.bjp.0706441; Frantseva MV, 2002, J CEREBR BLOOD F MET, V22, P453, DOI 10.1097/00004647-200204000-00009; Gelb AW, 2002, ANESTHESIOLOGY, V96, P1183, DOI 10.1097/00000542-200205000-00023; Gredell JA, 2004, BRIT J ANAESTH, V93, P810, DOI 10.1093/bja/aeh272; Hollrigel GS, 1996, J NEUROPHYSIOL, V76, P2412; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; KOCHS E, 1992, ANESTHESIOLOGY, V76, P245, DOI 10.1097/00000542-199202000-00014; Lahtinen H, 2001, NEUROSCIENCE, V105, P131, DOI 10.1016/S0306-4522(01)00168-3; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Ludbrook GL, 2002, ANESTHESIOLOGY, V97, P1363, DOI 10.1097/00000542-200212000-00006; MACKLIS JD, 1990, J NEUROSCI METH, V31, P43, DOI 10.1016/0165-0270(90)90007-3; Moppett IK, 2007, BRIT J ANAESTH, V99, P18, DOI 10.1093/bja/aem128; Morrison B, 1998, J NEUROTRAUM, V15, P911, DOI 10.1089/neu.1998.15.911; Morrison B, 2000, NEUROSCIENCE, V96, P131, DOI 10.1016/S0306-4522(99)00537-0; MULLER D, 1993, DEV BRAIN RES, V71, P93, DOI 10.1016/0165-3806(93)90109-N; Noraberg J, 2005, CNS NEUROL DISORD-DR, V4, P435, DOI 10.2174/1568007054546108; Patel S, 2003, BRIT J PHARMACOL, V139, P1005, DOI 10.1038/sj.bjp.0705334; Pellegrini-Giampietro DE, 1999, EUR J NEUROSCI, V11, P3637, DOI 10.1046/j.1460-9568.1999.00786.x; Peters CE, 2001, ANESTHESIOLOGY, V94, P313, DOI 10.1097/00000542-200102000-00022; Pittman JE, 1997, ANESTHESIOLOGY, V87, P1139, DOI 10.1097/00000542-199711000-00018; Qi SH, 2002, ANESTH ANALG, V94, P655, DOI 10.1097/00000539-200203000-00032; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; RIDENOUR TR, 1992, ANESTHESIOLOGY, V76, P807, DOI 10.1097/00000542-199205000-00020; SHYR MH, 1995, NEUROSCI LETT, V184, P212, DOI 10.1016/0304-3940(94)11209-2; Sitar SM, 1999, ANESTHESIOLOGY, V90, P1446, DOI 10.1097/00000542-199905000-00030; Statler KD, 2006, J NEUROTRAUM, V23, P97, DOI 10.1089/neu.2006.23.97; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; Sundstrom L, 2005, DRUG DISCOV TODAY, V10, P993, DOI 10.1016/S1359-6446(05)03502-6; TASKER RC, 1992, J NEUROSCI, V12, P4298; Tisherman Samuel A, 2004, Curr Opin Crit Care, V10, P512; Trapani G, 2000, CURR MED CHEM, V7, P249, DOI 10.2174/0929867003375335; Tsai Y C, 1994, Acta Anaesthesiol Sin, V32, P99; Tsuchiya M, 2002, ACTA ANAESTH SCAND, V46, P1068, DOI 10.1034/j.1399-6576.2002.460903.x; Velly LJ, 2003, ANESTHESIOLOGY, V99, P368, DOI 10.1097/00000542-200308000-00018; VORNOV JJ, 1991, EXP NEUROL, V114, P11, DOI 10.1016/0014-4886(91)90079-R; Wilson JX, 2002, J NEUROSURG ANESTH, V14, P66, DOI 10.1097/00008506-200201000-00014; Zhu HC, 1997, ANESTHESIOLOGY, V87, P944, DOI 10.1097/00000542-199710000-00030	56	42	45	0	7	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care		2009	13	2							R61	10.1186/cc7795			8	Critical Care Medicine	General & Internal Medicine	453UN	WOS:000266638500033	19397790	DOAJ Gold, Green Published			2021-06-18	
J	Sander, AM; Pappadis, MR; Davis, LC; Clark, AN; Evans, G; Struchen, MA; Mazzei, DM				Sander, Angelle M.; Pappadis, Monique R.; Davis, Lynne Cole; Clark, Allison N.; Evans, Gina; Struchen, Margaret A.; Mazzei, Diana M.			Relationship of race/ethnicity and income to community integration following traumatic brain injury: Investigation in a non-rehabilitation trauma sample	NEUROREHABILITATION			English	Article						Traumatic brain injury; race/ethnicity; income; community integration	SEVERE HEAD-INJURY; ETHNIC DISPARITIES; PRACTICAL SCALE; OUTCOMES; WORK; TBI; QUESTIONNAIRE; EMPLOYMENT; VIOLENT; PEOPLE	The purpose of the current study was to determine the contribution of race/ethnicity and income to community integration at approximately 6 months following traumatic brain injury (TBI). Participants were 151 persons with mild to severe TBI (38% Black; 38% Hispanic; 24% White) recruited from consecutive admissions to the Neurosurgery service of a county Level I trauma center. A large number of participants had low income and low education. Community integration was assessed using the Community Integration Questionnaire (CIQ), Craig Handicap Assessment and Reporting Technique - Short Form (CHART-SF), and Community Integration Measure (CIM). Results of analysis of covariance (ANCOVA) indicated that, after accounting for injury severity, age, education, and income, race/ethnicity contributed significantly to the variance in CIQ Total score, Home Integration Scale, and Productive Activity Scale scores. Blacks had lower CIQ Total scores compared to Whites. Black and Hispanic participants had lower scores than Whites on the Home Integration Scale, and Blacks had lower scores than Whites and Hispanics on the CIQ Productive Activity Scale. Low income (<= $20,000) was related to lower scores on the CIQ and CHART-SF Social Integration Scales, and scores on the CIM Total, Belonging, and Independent Participation scales. These results indicate that racial/ethnic differences in community integration exist, even after accounting for income. However, income was more predictive than race/ethnicity for certain aspects of community integration, indicating that it should be accounted for in all studies investigating racial/ethnic differences in outcomes.	[Sander, Angelle M.; Pappadis, Monique R.; Davis, Lynne Cole; Clark, Allison N.; Struchen, Margaret A.; Mazzei, Diana M.] TIRR Mem Hermann, Brain Injury Res Ctr, Houston, TX 77019 USA; [Sander, Angelle M.; Davis, Lynne Cole; Clark, Allison N.; Evans, Gina; Struchen, Margaret A.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Sander, Angelle M.] Harris Cty Hosp Dist, Ctr Trauma Rehabil Res, Houston, TX USA; [Pappadis, Monique R.] Univ Houston, Dept Hlth & Human Performance, Houston, TX USA; [Evans, Gina] Baylor Coll Med, Chron Dis Prevent & Control Ctr, Dept Med, Houston, TX 77030 USA	Sander, AM (corresponding author), TIRR Mem Hermann, Brain Injury Res Ctr, 2323 S Shepherd Dr,Ste 907, Houston, TX 77019 USA.	asander@bcm.edu	Pappadis, Monique/Q-8639-2016	Pappadis, Monique/0000-0003-4742-4380	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [H133B031117, H133A070043] Funding Source: Medline		Albert SM, 2002, J HEAD TRAUMA REHAB, V17, P175, DOI 10.1097/00001199-200204000-00007; Arango-Lasprilla JC, 2007, ARCH PHYS MED REHAB, V88, P11, DOI 10.1016/j.apmr.2006.10.029; AXELROD D, 1986, HEAD INJURY NEW YORK; Blais MC, 2005, BRAIN INJURY, V19, P1223, DOI 10.1080/02699050500309387; Boake C, 1996, AM J PHYS MED REHAB, V75, P105, DOI 10.1097/00002060-199603000-00005; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Brown M, 2004, J HEAD TRAUMA REHAB, V19, P459, DOI 10.1097/00001199-200411000-00004; Chwalisz K, 1996, REHABIL PSYCHOL, V41, P91, DOI 10.1037/0090-5550.41.2.91; Cicerone KD, 2004, J HEAD TRAUMA REHAB, V19, P494, DOI 10.1097/00001199-200411000-00006; Coleman RD, 2002, ARCH PHYS MED REHAB, V83, P1415, DOI 10.1053/apmr.2002.35111; *CRAIG HOSP RES DE, 1999, CRAIG HAND ASS REP T; Cardoso EDS, 2007, J HEAD TRAUMA REHAB, V22, P85; Dikmen S, 2001, J NEUROTRAUM, V18, P127, DOI 10.1089/08977150150502578; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Eames P, 1996, BRAIN INJURY, V10, P631, DOI 10.1080/026990596124061; Goranson TE, 2003, BRAIN INJURY, V17, P759, DOI 10.1080/0269905031000088513; Gosling J, 1999, BRAIN INJURY, V13, P785; Hanks RA, 2003, ARCH PHYS MED REHAB, V84, P249, DOI 10.1053/apmr.2003.50096; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P158, DOI 10.1097/00001199-200503000-00004; Hoofien D, 2001, BRAIN INJURY, V15, P189; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Johnston MV, 2005, ARCH PHYS MED REHAB, V86, P735, DOI 10.1016/j.apmr.2004.10.031; Kozloff R, 1987, J HEAD TRAUMA REHAB, V2, P14, DOI DOI 10.1097/00001199-198709000-00004; KRAUS JF, 1999, REHABILITATION ADULT, P156; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Langlois JA, 2006, TRAUMATIC BRAIN INJU; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; de la Plata CM, 2007, J HEAD TRAUMA REHAB, V22, P113, DOI 10.1097/01.HTR.0000265099.29436.56; McColl MA, 2001, ARCH PHYS MED REHAB, V82, P429, DOI 10.1053/apmr.2001.22195; McColl MA, 1998, BRAIN INJURY, V12, P15, DOI 10.1080/026990598122827; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; ODDY M, 1984, CLOSED HEAD INJURY P; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Rapport L, 2006, J HEAD TRAUMA REHAB, V21, P34, DOI 10.1097/00001199-200601000-00004; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P353, DOI 10.1016/S0003-9993(97)90225-2; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; SANDER AM, 2007, INCLUSION MINORITIES; Schopp LH, 2006, J HEAD TRAUMA REHAB, V21, P213, DOI 10.1097/00001199-200605000-00002; Shafi S, 2007, J TRAUMA, V63, P1263, DOI 10.1097/TA.0b013e31815b8f00; Shafi S, 2007, J TRAUMA, V63, P1138, DOI 10.1097/TA.0b013e3181568cd4; Sherer M, 2003, J HEAD TRAUMA REHAB, V18, P408, DOI 10.1097/00001199-200309000-00003; SORENSON SB, 1991, J HEAD TRAUMA REHAB, V6, P1, DOI DOI 10.1097/00001199-199106000-00003; Staudenmayer KL, 2007, J TRAUMA, V63, P1364, DOI 10.1097/TA.0b013e31815b897b; Tabachnick BG, 2007, USING MULTIVARIATE S; Tamietto M, 2006, NEUROREHABILITATION, V21, P81; TEASDALE G, 1974, LANCET, V2, P81; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; Wehman P, 2005, J HEAD TRAUMA REHAB, V20, P115, DOI 10.1097/00001199-200503000-00001; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WHITMAN S, 1984, AM J EPIDEMIOL, V119, P570, DOI 10.1093/oxfordjournals.aje.a113774; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Willer B., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI DOI 10.1097/00001199-199308020-00009; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wood RL, 1997, BRAIN INJURY, V11, P491, DOI 10.1080/713802183	57	42	42	0	11	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2009	24	1					15	27		10.3233/NRE-2009-0450			13	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	412DS	WOS:000263704400003	19208954				2021-06-18	
J	Hassid, VJ; Schinco, MA; Tepas, JJ; Griffen, MM; Murphy, TL; Frykberg, ER; Kerwin, AJ				Hassid, Victor J.; Schinco, Miren A.; Tepas, Joseph J.; Griffen, Margaret M.; Murphy, Terri L.; Frykberg, Eric R.; Kerwin, Andrew J.			Definitive Establishment of Airway Control is Critical for Optimal Outcome in Lower Cervical Spinal Cord Injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Cervical spine; Cervical spinal cord injury; Intubation; Tracheostomy; Respiratory failure	RESPIRATORY COMPLICATIONS; TRAUMATIC QUADRIPLEGIA; PULMONARY-FUNCTION; DYSFUNCTION; MANAGEMENT; MECHANISM; LEVEL	Background: Respiratory complications can undermine outcome from low cervical spinal cord injury (SCI) (C5-T1). Most devastating of these is catastrophic loss of airway control. This study sought to determine the incidence and effect of catastrophic airway loss (CLA) and to define the need for elective intubation with subsequent tracheostomy to prevent potentially fatal outcomes. Methods: A database of 54,838 consecutive patients treated in a level I trauma center between January 1988 and December 2004 was queried to identify patients with low cervical SCI, without traumatic brain injury. Patients were then stratified into complete or incomplete SCI groups, based on clinical assessment of their SCI. Mortality, age, injury severity, need for intubation, and tracheostomy were analyzed for each group using Fisher's exact test or Student's t test, as appropriate, accepting p < 0.05 as significant. Results: One hundred eighty-six patients met inclusion criteria. The majority of low cervical spinal cord injuries were complete (58%). Overall, 127 (68%) patients required intubation, 88 (69%) required tracheostomy, and 27 died (15 % of study population). Between each group there were significant differences in age and Injury Severity Score, however, within each group there were no significant differences in either. Eleven CSCI patients were not intubated; four of whom were at family request. Six of the remaining seven patients encountered fatal catastrophic airway loss. One patient was discharged to rehabilitation. Patients with incomplete SCI required intubation less frequently (38%); however, 50% of those required tracheostomy for intractable pulmonary failure. Conclusions: These data indicate that regardless of severity of low cervical SCI, immediate, thorough evaluation for respiratory failure is necessary. Early intubation is mandatory for CSCI patients. For incomplete patients evidence of respiratory failure should prompt immediate airway intervention, half of whom will require tracheostomy.	[Hassid, Victor J.; Schinco, Miren A.; Tepas, Joseph J.; Griffen, Margaret M.; Murphy, Terri L.; Frykberg, Eric R.; Kerwin, Andrew J.] Univ Florida, Hlth Sci Ctr, Dept Surg, Jacksonville, FL 32209 USA	Schinco, MA (corresponding author), Univ Florida, Hlth Sci Ctr Jacksonville, Dept Surg, 655 W 8th St, Jacksonville, FL 32209 USA.	miren.schinco@jax.ufl.edu					American Spinal Injury Association, 2000, INT STAND NEUR CLASS; ANKE A, 1993, SCAND J REHABIL MED, V25, P73; Barinaga M, 1996, SCIENCE, V274, P1466; BELLAMY R, 1973, J NEUROSURG, V39, P596, DOI 10.3171/jns.1973.39.5.0596; BERGOFSKY EH, 1964, ANN INTERN MED, V61, P435, DOI 10.7326/0003-4819-61-3-435; Carter R E, 1979, Adv Neurol, V22, P261; CARTER RE, 1987, PARAPLEGIA, V25, P262, DOI 10.1038/sc.1987.48; Como JJ, 2005, J TRAUMA, V59, P912, DOI 10.1097/01.ta.0000187660.03742.a6; Croce MA, 2001, ANN SURG, V233, P851, DOI 10.1097/00000658-200106000-00016; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; DETROYER A, 1986, AM REV RESPIR DIS, V133, P1115; DETROYER A, 1986, NEW ENGL J MED, V314, P740, DOI 10.1056/NEJM198603203141203; DEVIVO MJ, 1989, ARCH INTERN MED, V149, P1761, DOI 10.1001/archinte.149.8.1761; DEVIVO MJ, 1980, ARCH NEUROL-CHICAGO, V37, P707, DOI 10.1001/archneur.1980.00500600055011; FUGL-MEYER A R, 1971, Scandinavian Journal of Rehabilitation Medicine, V3, P151; FUGL-MEYER A R, 1971, Scandinavian Journal of Rehabilitation Medicine, V3, P141; HULDTGREN AC, 1980, EUR J RESPIR DIS, V61, P347; KRAUS JF, 1985, CENTRAL NERVOUS SYST, P313; LEDSOME JR, 1981, AM REV RESPIR DIS, V124, P41; LEMONS VR, 1994, SPINE, V19, P2315, DOI 10.1097/00007632-199410150-00011; Lu K, 2000, SPINE, V25, P1332, DOI 10.1097/00007632-200006010-00003; MANSEL JK, 1990, CHEST, V97, P1446, DOI 10.1378/chest.97.6.1446; MCKINLEY AC, 1969, AM REV RESPIR DIS, V100, P526; MCMICHAN JC, 1980, JAMA-J AM MED ASSOC, V243, P528, DOI 10.1001/jama.243.6.528; MESARD L, 1978, ARCH NEUROL-CHICAGO, V35, P78, DOI 10.1001/archneur.1978.00500260016003; MONTERO JOSE C., 1967, ARCH PHYS MED REHABIL, V48, P650; Ohry A, 1975, Paraplegia, V13, P101; OSTERHOLM JL, 1974, J NEUROSURG, V40, P5, DOI 10.3171/jns.1974.40.1.0003; REINES HD, 1987, NEUROSURGERY, V21, P193, DOI 10.1227/00006123-198708000-00010; Roth EJ, 1997, AM J PHYS MED REHAB, V76, P262, DOI 10.1097/00002060-199707000-00002; SCHMITT J, 1991, NEUROL CLIN, V9, P779; STONE DJ, 1963, AM REV RESPIR DIS, V88, P621; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Velmahos GC, 2003, AM SURGEON, V69, P891	34	42	49	3	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	2008	65	6					1328	1332		10.1097/TA.0b013e31818d07e4			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	383WV	WOS:000261706000025	19077622				2021-06-18	
J	Huang, APH; Tu, YK; Tsai, YH; Chen, YS; Hong, WC; Yang, CC; Kuo, LT; Su, IC; Huang, SH; Huang, SJ				Huang, Abel Po-Hao; Tu, Yong-Kwang; Tsai, Yi-Hsin; Chen, Yuan-Shen; Hong, Wei-Chen; Yang, Chi-Cheng; Kuo, Lu-Ting; Su, I-Chang; Huang, She-Hao; Huang, Sheng-Jean			Decompressive Craniectomy as the Primary Surgical Intervention for Hemorrhagic Contusion	JOURNAL OF NEUROTRAUMA			English	Article						decompressive craniectomy; surgery; traumatic brain injury	SEVERE HEAD-INJURY; TRAUMATIC BRAIN-INJURY; REFRACTORY INTRACRANIAL HYPERTENSION; GLASGOW OUTCOME SCALE; CEREBRAL-BLOOD-FLOW; INTRACEREBRAL HEMATOMAS; MANAGEMENT; GUIDELINES; EXPERIENCE; PERFUSION	The standard surgical treatment of hemorrhagic cerebral contusion is craniotomy with evacuation of the focal lesion. We assessed the safety and feasibility of performing decompressive craniectomy and duraplasty as the primary surgical intervention in this group of patients. Fifty-four consecutive patients with Glasgow Coma Scale (GCS) scores of less than or equal to 8, a frontal or temporal hemorrhagic contusion greater than 20 cm(3) in volume, and a midline shift of at least 5 mm or cisternal compression on computer tomography (CT) scan were studied. Sixteen (29.7%) underwent traditional craniotomy with hematoma evacuation, and 38 (70.4%) underwent craniectomy as the primary surgical treatment. Mortality, reoperation rate, Glasgow Outcome Scale-Extended (GOSE) scores, and length of stay in both the acute care and rehabilitation phase were compared between these two groups. Mortality (13.2% vs. 25.0%) and reoperation rate (7.9% vs. 37.5%) were lower in the craniectomy group, whereas the length of stay in both the acute care setting and the rehabilitation phase were similar between these two groups. The craniectomy group also had better GOSE score (5.55 vs. 3.56) at 6 months. Decompressive craniectomy is safe and effective as the primary surgical intervention for treatment of hemorrhagic contusion. This study also suggests that patient with hemorrhagic contusion can possibly have better outcome after craniectomy than other subgroup of patients with severe traumatic brain injury.	[Huang, Abel Po-Hao; Tu, Yong-Kwang; Tsai, Yi-Hsin; Chen, Yuan-Shen; Hong, Wei-Chen; Yang, Chi-Cheng; Kuo, Lu-Ting; Su, I-Chang; Huang, She-Hao; Huang, Sheng-Jean] Natl Taiwan Univ Hosp, Dept Surg, Dept Neurosurg, Taipei 100, Taiwan; [Huang, Abel Po-Hao; Tu, Yong-Kwang; Tsai, Yi-Hsin; Chen, Yuan-Shen; Hong, Wei-Chen; Yang, Chi-Cheng; Kuo, Lu-Ting; Su, I-Chang; Huang, She-Hao; Huang, Sheng-Jean] Natl Taiwan Univ, Coll Med, Taipei 10764, Taiwan; [Chen, Yuan-Shen; Hong, Wei-Chen; Kuo, Lu-Ting; Huang, Sheng-Jean] Natl Taiwan Univ Hosp, Dept Surg, Yun Lin Branch, Yunlin, Taiwan; [Tsai, Yi-Hsin; Huang, Sheng-Jean] Natl Taiwan Univ, Natl Taiwan Univ Hosp, Dept Traumatol, Taipei 10764, Taiwan; [Yang, Chi-Cheng] Natl Taiwan Univ, Dept Psychol, Taipei 10764, Taiwan	Huang, SJ (corresponding author), Natl Taiwan Univ Hosp, Dept Surg, Dept Neurosurg, 7 Chung Shan S Rd, Taipei 100, Taiwan.	sjhuang@mail.ylh.gov.tw		Tu, Yong-kwang/0000-0003-2113-1176; Kuo, Lu-Ting/0000-0002-1405-8700; HUANG, ABEL PO-HAO/0000-0002-5689-6761			Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Bor-Seng-Shu E, 2006, J NEUROSURG, V104, P93, DOI 10.3171/jns.2006.104.1.93; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; BULLOCK R, 1989, SURG NEUROL, V32, P181, DOI 10.1016/0090-3019(89)90176-6; Chibbaro S, 2007, SURG NEUROL, V68, P632, DOI 10.1016/j.surneu.2006.12.046; Chieregato A, 2004, J NEUROTRAUM, V21, P655, DOI 10.1089/0897715041269669; Chieregato A, 2007, NEUROSURGERY, V60, P115, DOI 10.1227/01.NEU.0000249194.76527.28; Coplin WM, 2001, J TRAUMA, V50, P1050, DOI 10.1097/00005373-200106000-00013; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; Heppner P, 2006, J NEUROSURG, V104, P738, DOI 10.3171/jns.2006.104.5.738; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Jiang JY, 2005, J NEUROTRAUM, V22, P623, DOI 10.1089/neu.2005.22.623; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; Marion DW, 2006, NEUROSURGERY, V58, P655; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; Patel NY, 2000, J TRAUMA, V48, P367, DOI 10.1097/00005373-200003000-00001; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; SOLONIUK D, 1986, J TRAUMA, V26, P787, DOI 10.1097/00005373-198609000-00003; Stiefel MF, 2004, J NEUROSURG, V101, P241, DOI 10.3171/jns.2004.101.2.0241; TEASDALE G, 1974, LANCET, V2, P81; von Oettingen G, 2002, NEUROSURGERY, V50, P781, DOI 10.1097/00006123-200204000-00019; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wu JJ, 1999, J TRAUMA, V47, P39, DOI 10.1097/00005373-199907000-00009; Yamakami Iwao, 1993, Neurologia Medico-Chirurgica, V33, P616, DOI 10.2176/nmc.33.616	25	42	44	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2008	25	11					1347	1354		10.1089/neu.2008.0625			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	384BP	WOS:000261718900007	19061378				2021-06-18	
J	Schanke, AK; Rike, PO; Psychol, C; Molmen, A; Psychol, C; Osten, PE				Schanke, Anne-Kristine; Rike, Per-Ola; Psychol, Cand; Molmen, Anette; Psychol, Cand; Osten, Per Egil			DRIVING BEHAVIOUR AFTER BRAIN INJURY: A FOLLOW-UP OF ACCIDENT RATE AND DRIVING PATTERNS 6-9 YEARS POST-INJURY	JOURNAL OF REHABILITATION MEDICINE			English	Article						driving; brain injury; accidents	SIMULATOR; STROKE	Objective: A follow-up of accident rate and driving patterns of patients 6-9 years after brain injury. Design: Postal questionnaire sent to patients with brain injury who were assessed consecutively in the period 1997-2000 and who were re-issued. Subjects: A total of 93 persons, 69 men and 24 women, mean age 57 years, average 9 years post-injury, 65 persons with brain injury after cerebrovascular accidents and 28 with traumatic brain injury. Methods: The questionnaire covered self-reported driving accidents pre- and post-injury, yearly distance driven, behaviour in traffic and self-reported care taken in driving. Results: The cerebrovascular accident group had reduced their driving significantly post-injury and had also changed their driving patterns. No significant changes were found in distance driven and driving patterns for the group with traumatic brain injury. Compared with normative data, reported accidents post-injury in the cerebrovascular accident group showed no increased accident rate, while the accident rate in the traumatic brain injury-group was more than 2 times higher. Conclusion: Patients with traumatic brain injury represent a risk group for accidents post-injury, while those with brain injury after cerebrovascular accidents do not. Possible causes for this difference are discussed.	[Schanke, Anne-Kristine] Sunnaas Rehabil Hosp, Res Unit, N-1450 Nesoddtangen, Norway	Schanke, AK (corresponding author), Sunnaas Rehabil Hosp, Res Unit, N-1450 Nesoddtangen, Norway.	Anne-kristine.schanke@sunnaas.no					Akinwuntan AE, 2006, NEUROREHAB NEURAL RE, V20, P417, DOI 10.1177/1545968306287157; Bieliauskas LA, 2005, BRAIN INJURY, V19, P221, DOI 10.1080/02699050400017213; BJORNSKAU T, 6942003 I TRANSP EC; Coleman RD, 2002, ARCH PHYS MED REHAB, V83, P1415, DOI 10.1053/apmr.2002.35111; Formisano R, 2005, BRAIN INJURY, V19, P159, DOI 10.1080/02699050400017163; Goode KT, 1998, J CLIN PSYCHOL MED S, V5, P425, DOI 10.1023/A:1026206927686; Haselkorn JK, 1998, ARCH PHYS MED REHAB, V79, P738, DOI 10.1016/S0003-9993(98)90349-5; Leon-Carrion J, 2005, BRAIN INJURY, V19, P213, DOI 10.1080/02699050400017205; Lew HL, 2005, BRAIN INJURY, V19, P177, DOI 10.1080/02699050400017171; Lundberg C, 1998, ACCIDENT ANAL PREV, V30, P371, DOI 10.1016/S0001-4575(97)00111-5; Lundqvist A, 2000, APPL COGNITIVE PSYCH, V14, P135, DOI 10.1002/(SICI)1099-0720(200003/04)14:2<135::AID-ACP628>3.0.CO;2-S; MOSBERG A, 2000, J  NORWEGIAN MED ASS, V120, P3392; Pietrapiana P, 2005, BRAIN INJURY, V19, P197, DOI 10.1080/02699050400017197; Schanke AK, 2000, SCAND J PSYCHOL, V41, P113, DOI 10.1111/1467-9450.00179; Schultheis MT, 2002, J HEAD TRAUMA REHAB, V17, P38, DOI 10.1097/00001199-200202000-00006; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; VANZOMEREN AH, 1987, ARCH PHYS MED REHAB, V68, P697	17	42	44	0	9	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	OCT	2008	40	9					733	736		10.2340/16501977-0256			4	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	363VP	WOS:000260295300008	18843425	DOAJ Gold			2021-06-18	
J	Chen, SJ; Pipinos, I; Johanning, J; Radovic, M; Huisinga, JM; Myers, SA; Stergiou, N				Chen, Shing-Jye; Pipinos, Iraklis; Johanning, Jason; Radovic, Matija; Huisinga, Jessie M.; Myers, Sara A.; Stergiou, Nick			Bilateral claudication results in alterations in the gait biomechanics at the hip and ankle joints	JOURNAL OF BIOMECHANICS			English	Article						peripheral arterial disease; claudication; joint moment; biomechanics; gait	PERIPHERAL ARTERIAL-DISEASE; TRAUMATIC BRAIN-INJURY; QUALITY-OF-LIFE; INTERMITTENT CLAUDICATION; OCCLUSIVE DISEASE; PHYSICAL-ACTIVITY; WALKING IMPAIRMENT; TIBIAL ROTATION; MUSCLE; STRENGTH	claudication is the most common symptomatic manifestation of peripheral arterial disease (PAD), producing significant ambulatory compromise. The purpose of this study was to use advanced biomechanical gait analysis to determine the gait alterations occurring in claudicating patients both before and after onset of claudication pain in their legs. Hip, knee, and ankle joint moments were measured in claudicating patients (age: 64.46 +/- 8.47 years: body mass: 80.70 +/- 12.64 kg; body height: 1.72 +/- 0.08 m) and were compared to gender-age-body mass-height-matched healthy controls (age 66.27 +/- 9.22 years; body mass: 77.89 +/- 10.65kg; body height: 1.74 +/- 0.08 m). The claudicating patients were evaluated both before (pain-free (PF) condition) and after (pain condition) onset of claudication pain in their legs. Thirteen symptomatic PAD patients (26 claudicating limbs) with bilateral intermittent claudication (IC) and 11 healthy controls (22 control limbs) were tested during level walking at their self-selected speed. Compared to controls, PAD hip and ankle joints demonstrated significant angular kinematics and net internal moment changes. Alterations were present both in PF and pain conditions with several of them becoming worse in the pain condition. Both PF and pain conditions resulted in significantly reduced peak hip extensor moment (5.62 +/- 1.40 and 5.63 +/- 1.33% BW x BH, respectively) during early stance as compared to controls (7.53 +/- 1.16% BW x BH). In the pain condition, PAD patients had a significantly reduced ankle plantar flexor moment (7.56 +/- 1.41 % BW x BH) during late stance as compared to controls (8.65 +/- 1.27% BW x BH). Furthermore, when comparing PF to pain conditions, there was a decreased peak plantar flexor moment (PF condition: 8.23 +/- 1.37 vs. pain condition: 7.56 +/- 1.41% BW x BH) during late stance. The findings point to a weakness in the posterior compartment muscles of the hip and calf as being the key factor underlying the PAD gait adaptations. Our findings establish a detailed baseline description of the changes present in PAD patient's joint angles and moments during walking. Since IC is primarily a gait disability, better understanding of the abnormalities in joint and muscle function will enhance our understanding of the gait impairment and may lead to novel, gait-specific treatments. (c) 2008 Elsevier Ltd. All rights reserved.	[Chen, Shing-Jye; Radovic, Matija; Huisinga, Jessie M.; Myers, Sara A.; Stergiou, Nick] Univ Nebraska, HPER Biomech Lab, Sch Hlth Phys Educ & Recreat, Omaha, NE 68182 USA; [Pipinos, Iraklis; Johanning, Jason; Stergiou, Nick] Univ Nebraska Med Ctr, Omaha, NE USA; [Pipinos, Iraklis; Johanning, Jason] Vet Affairs Med Ctr, Omaha, NE USA	Chen, SJ (corresponding author), Univ Nebraska, HPER Biomech Lab, Sch Hlth Phys Educ & Recreat, 6001 Dodge St, Omaha, NE 68182 USA.	shingjychen@mail.unomaha.edu	Myers, Sara/E-1460-2015	Myers, Sara/0000-0002-2934-2624; Pipinos, Iraklis/0000-0001-6873-6346	American Geriatrics Society's Hartford Foundation Dennis W. Jahnigen Award; Nebraska Research Initiative; University of Community on Research and Creative Activity at UNO; AHA Scientific Councils' Student scholarshipAmerican Heart Association	We would like to acknowledge the support that was provided by the American Geriatrics Society's Hartford Foundation Dennis W. Jahnigen Award (to JMJ), the Nebraska Research Initiative (to NS), the University of Community on Research and Creative Activity at UNO (to SJC), and the AHA Scientific Councils' Student scholarship in cardiovascular disease and stroke (to SAM).	Atkins LM, 2004, ANGIOLOGY, V55, P347, DOI 10.1177/000331970405500401; Baker R, 2006, J NEUROENG REHABIL, V3, DOI 10.1186/1743-0003-3-4; Barker SP, 2006, GAIT POSTURE, V24, P448, DOI 10.1016/j.gaitpost.2005.09.008; Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; Bauman H C, 1997, J Vasc Nurs, V15, P21, DOI 10.1016/S1062-0303(97)90049-2; Benedetti MG, 1998, CLIN BIOMECH, V13, P204, DOI 10.1016/S0268-0033(97)00041-7; Bhat HK, 1999, CIRCULATION, V99, P807, DOI 10.1161/01.CIR.99.6.807; Brass EP, 2000, VASC MED, V5, P55, DOI 10.1177/1358836X0000500109; Chang FM, 2006, J PEDIATR ORTHOPED, V26, P612, DOI 10.1097/01.bpo.0000229970.55694.5c; Coyne KS, 2003, J VASC SURG, V38, P296, DOI 10.1016/S0741-5214(03)00312-4; Crowther RG, 2007, J VASC SURG, V45, P1172, DOI 10.1016/j.jvs.2007.01.060; DIBIANCO R, 1984, AM HEART J, V108, P1121, DOI 10.1016/0002-8703(84)90592-1; Fosang A, 2006, GAIT POSTURE, V24, P406, DOI 10.1016/j.gaitpost.2005.09.015; Gardner AW, 2006, ANGIOLOGY, V57, P539, DOI 10.1177/0003319706293114; Gardner AW, 1997, ANGIOLOGY, V48, P883, DOI 10.1177/000331979704801005; Gardner AW, 2001, VASC MED, V6, P31, DOI 10.1191/135886301677047365; Georgoalis AD, 2007, CLIN ORTHOP RELAT R, P89, DOI 10.1097/BLO.0b013e31802b4a0a; Green S, 2002, CLIN PHYSIOL FUNCT I, V22, P81, DOI 10.1046/j.1365-2281.2002.00400.x; Houck J, 2004, GAIT POSTURE, V19, P76, DOI 10.1016/S0966-6362(03)00033-X; Izquierdo-Porrera AM, 2005, J VASC SURG, V41, P625, DOI 10.1016/j.jvs.2005.01.012; Jobges M, 2004, J NEUROL NEUROSUR PS, V75, P1682, DOI 10.1136/jnnp.2003.016550; Judge JO, 1996, J GERONTOL A-BIOL, V51, pM303, DOI 10.1093/gerona/51A.6.M303; Kaufman KR, 2001, J BIOMECH, V34, P907, DOI 10.1016/S0021-9290(01)00036-7; Kemp GJ, 2004, MITOCHONDRION, V4, P629, DOI 10.1016/j.mito.2004.07.017; Kerrigan DC, 1998, ARCH PHYS MED REHAB, V79, P317, DOI 10.1016/S0003-9993(98)90013-2; Koopman JP, 1996, EUR J SURG, V162, P443; Liles DR, 2006, J SURG RES, V136, P294, DOI 10.1016/j.jss.2006.06.008; LUNDGREN F, 1988, AM J PHYSIOL, V255, pH1156; MARBINI A, 1986, ACTA NEUROL BELG, V86, P304; McDermott Mary McGrae, 2002, Am J Geriatr Cardiol, V11, P258, DOI 10.1111/j.1076-7460.2002.00031.x; McDermott MM, 2001, J AM GERIATR SOC, V49, P747, DOI 10.1046/j.1532-5415.2001.49151.x; McGibbon CA, 2001, CLIN BIOMECH, V16, P324, DOI 10.1016/S0268-0033(01)00004-3; McGinley JL, 2006, ARCH PHYS MED REHAB, V87, P779, DOI 10.1016/j.apmr.2006.02.022; MCKENNA M, 1991, ATHEROSCLEROSIS, V87, P119, DOI 10.1016/0021-9150(91)90014-T; Menard JR, 2004, J VASC SURG, V39, P1186, DOI 10.1016/j.jvs.2004.01.034; Meru AV, 2006, ATHEROSCLEROSIS, V187, P221, DOI 10.1016/j.atherosclerosis.2005.11.027; Neptune RR, 2001, J BIOMECH, V34, P1387, DOI 10.1016/S0021-9290(01)00105-1; Norgren L, 2007, J ENDOVASC THER, V14, P743, DOI 10.1583/1545-1550(2007)14[743:TISFOR]2.0.CO;2; Oka RK, 2005, VASC MED, V10, P265, DOI 10.1191/1358863x05vm637oa; Pipinos II, 2006, FREE RADICAL BIO MED, V41, P262, DOI 10.1016/j.freeradbiomed.2006.04.003; Riley PO, 2001, GAIT POSTURE, V14, P264, DOI 10.1016/S0966-6362(01)00133-3; Runge M., 2006, Journal of Musculoskeletal & Neuronal Interactions, V6, P167; Scott-Okafor HR, 2001, ANGIOLOGY, V52, P7, DOI 10.1177/000331970105200102; Scott-Pandorf MM, 2007, J VASC SURG, V46, P491, DOI 10.1016/j.jvs.2007.05.029; Stergiou N, 2007, SPORTS MED, V37, P601, DOI 10.2165/00007256-200737070-00004; Vallee M, 2006, ARCH PHYS MED REHAB, V87, P806, DOI 10.1016/j.apmr.2006.02.031; Weber F, 2002, MUSCLE NERVE, V26, P471, DOI 10.1002/mus.10235; Winter DA, 2005, BIOMECHANICS MOTOR C, P86; Yavuzer G, 2006, CLIN REHABIL, V20, P960, DOI 10.1177/0269215506070315	49	42	43	0	6	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290			J BIOMECH	J. Biomech.	AUG 7	2008	41	11					2506	2514		10.1016/j.jbiomech.2008.05.011			9	Biophysics; Engineering, Biomedical	Biophysics; Engineering	347GQ	WOS:000259129000022	18586253	Green Published			2021-06-18	
J	Jamieson, LM; Harrison, JE; Berry, JG				Jamieson, Lisa M.; Harrison, James E.; Berry, Jesia G.			Hospitalisation for head injury due to assault among Indigenous and non-Indigenous Australians, July 1999 to June 2005	MEDICAL JOURNAL OF AUSTRALIA			English	Article							TRAUMATIC BRAIN-INJURY; UNITED-STATES; CHILDREN	Objective: To describe rates of hospitalisation for head injury due to assault among Indigenous and non-Indigenous Australians. Design, setting and participants: Secondary analysis of routinely collected hospital morbidity. data for 42 874 inpatients at public and private hospitals in Queensland, Western Australia, South Australia and the Northern Territory for the 6-year period 1 July 1999 - 30 June 2005. Main outcome measures: Rates per 100000 population of head injury due to assault by Indigenous status, age, sex and location of residence. Results: The overall rate of head injury due to assault was 60.4 per 100000 population (95% CI, 59.8-60.9). The rate among the Indigenous population was 854.8 per 100000 (95% CI, 841.0-868.9), 21 times that among the non-Indigenous population (40.7 per 100000; 95% CI, 40.2-41.2). Most Indigenous (88%) and non-Indigenous (83%) victims of head injury due to assault were aged between 15 and 44 years. The peak incidence among the Indigenous population was in the 30-34-year age group, whereas that among the non-Indigenous population was in the 20-24-year age group. Indigenous females experienced 69 times the injury rate experienced by non-Indigenous females. Conclusions: Indigenous people, particularly women, were disproportionately represented among those hospitalised for head injury due to assault. Head injury imposes a substantial burden of care on individuals and communities. Along with the costs of treating head injury, these are good reasons to strengthen efforts to prevent head injury generally, with special attention to high-risk population segments.	[Harrison, James E.; Berry, Jesia G.] Flinders Univ S Australia, Res Ctr Injury Studies, Adelaide, SA, Australia; [Jamieson, Lisa M.] Univ Adelaide, Sch Dent, Adelaide, SA, Australia		lisa.jamieson@adelaide.edu.au	Harrison, James/B-8958-2009; Jamieson, Lisa M/M-5914-2014	Harrison, James/0000-0001-9893-8491; Berry, Jesia/0000-0002-4446-7927			*AUSTR I HLTH WELF, 2005, 101 AIHW HSE; *AUSTR I HLTH WELF, 2004, 53 AIHW PHE; Corso P, 2006, INJURY PREV, V12, P212, DOI 10.1136/ip.2005.010983; Cunningham J, 1996, MED J AUSTRALIA, V165, P309, DOI 10.5694/j.1326-5377.1996.tb124987.x; Davey TM, 2005, J PAEDIATR CHILD H, V41, P278, DOI 10.1111/j.1440-1754.2005.00611.x; Gruen RL, 2006, LANCET, V368, P130, DOI 10.1016/S0140-6736(06)68812-0; Helps YLM, 2006, INJURY TECHNICAL PAP; Kiely JM, 2006, J TRAUMA, V61, P791, DOI 10.1097/01.ta.0000239360.29852.1d; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; LEHOCZKY S, 2002, 47110 AUSTR BUR STAT; Max JE, 2000, J INT NEUROPSYCH SOC, V6, P279, DOI 10.1017/S1355617700633039; McIntyre PB, 2005, MED J AUSTRALIA, V182, P207, DOI 10.5694/j.1326-5377.2005.tb06667.x; MEMMOTT P, 2001, VIOLENCE INDIGENOUS; Moncrieff NJ, 2004, J CRANIOFAC SURG, V15, P686, DOI 10.1097/00001665-200407000-00030; National Public Health Partnership, 2004, NAT AB TORR STRAIT I; National Public Health Partnership, 2004, NAT INJ PREV SAF PRO; Peden M, 2000, INJURY LEADING CAUSE; Rothman K.J., 1998, MODERN EPIDEMIOLOGY, V2nd ed.; Ryb GE, 2006, J TRAUMA, V61, P799, DOI 10.1097/01.ta.0000196763.14289.4e; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Thurman DJ., 1995, GUIDELINES SURVEILLA; Turner-Stokes L, 2005, J NEUROL NEUROSUR PS, V76, P901, DOI 10.1136/jnnp.2005.066472; WILD R, 2007, NO TERR BOARD INQ PR	23	42	42	0	0	AUSTRALASIAN MED PUBL CO LTD	PYRMONT	LEVEL 2, 26-32 PYRMONT BRIDGE RD, PYRMONT, NSW 2009, AUSTRALIA	0025-729X			MED J AUSTRALIA	Med. J. Aust.	MAY 19	2008	188	10					576	579		10.5694/j.1326-5377.2008.tb01793.x			4	Medicine, General & Internal	General & Internal Medicine	319GA	WOS:000257150900007	18484929				2021-06-18	
J	Reddy, CC; Collins, MW; Gioia, GA				Reddy, Cara Camiolo; Collins, Michael W.; Gioia, Gerald A.			Adolescent-Sports Concussion	PHYSICAL MEDICINE AND REHABILITATION CLINICS OF NORTH AMERICA			English	Article							TRAUMATIC BRAIN-INJURY; NEUROPSYCHOLOGICAL TEST-PERFORMANCE; COLLEGIATE FOOTBALL PLAYERS; HIGH-SCHOOL; GENDER-DIFFERENCES; RECOVERY; GUIDELINES; MANAGEMENT; SYMPTOMS; HEADACHE	Approximately 2 million sports and recreation concussive injuries occur per year in the United States, which may be an underestimate because of inconsistent data reporting. The field of concussion management has evolved rapidly over the last 10 years, and with these advances comes new understanding of the significant symptomatic and cognitive impairments of concussion. These sequelae are more fully realized and may last longer than previously thought. Data have emerged regarding pathophysiology of concussion, risk factors, outcome, effects of repetitive injury, subtypes of concussive injury, and treatment protocols. This evidence calls for more conservative management of concussion, particularly in younger athletes, and demonstrates the shortcomings of concussion guidelines.	[Reddy, Cara Camiolo] Univ Pittsburgh, Dept Phys Med & Rehabil, Med Ctr, Pittsburgh, PA 15213 USA; [Collins, Michael W.] Univ Pittsburgh, Dept Orthopaed Surg, Med Ctr, Pittsburgh, PA 15203 USA; [Gioia, Gerald A.] George Washington Univ, Dept Pediat, Sch Med, Rockville, MD 20850 USA; [Gioia, Gerald A.] Childrens Natl Med Ctr, Rockville, MD 20850 USA; [Gioia, Gerald A.] George Washington Univ, Dept Psychiat, Sch Med, Rockville, MD 20850 USA	Reddy, CC (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, Med Ctr, 3471 5th Ave,LKB Suite 201, Pittsburgh, PA 15213 USA.	camioloce1@upmc.edu					Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Bergschneider M, 2003, J NEUROSURG, V86, P241; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; *C NEUR SURG COMM, 1996, CLIN NEUROSURG, V12, P386; CANTU RC, 1992, SPORTS MED, V14, P64, DOI 10.2165/00007256-199214010-00005; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; Cantu RC, 2001, J ATHL TRAINING, V36, P244; (CDC). National Center for Injury Prevention and Control, 2007, HEADS BRAIN INJ YOUR; Clinchot DM, 1998, AM J PHYS MED REHAB, V77, P291, DOI 10.1097/00002060-199807000-00006; Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P2283, DOI 10.1001/jama.282.24.2283; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; EMERSON CS, 1993, BRAIN RES, V608, P95, DOI 10.1016/0006-8993(93)90778-L; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Ernst A, 2005, OTOLARYNG HEAD NECK, V132, P554, DOI 10.1016/j.otohns.2004.09.034; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Fazio VC, 2007, NEUROREHABILITATION, V22, P207; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Giza CC, 2001, J ATHL TRAINING, V36, P228; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; GUSKIEWICZ KM, 2000, AM J SPORTS MED, V28, P1; Hovda DA, 1999, SPORTS-RELATED CONCUSSION, P12; Iverson GL, 2004, J INT NEUROPSYCH SOC, V10, P904, DOI 10.1017/S1355617704106139; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Iverson G, 2007, CLIN J SPORT MED, V17, P31; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, NEUROLOGY, V48, P581; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lew HL, 2006, AM J PHYS MED REHAB, V85, P619, DOI 10.1097/01.phm.0000223235.09931.c0; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; MAJERSKE CW, J ATHL TRAI IN PRESS; MATSER E, 1998, JAMA-J AM MED ASSOC, V282, P971; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; MCDONALD JW, 1990, BRAIN RES REV, V15, P41, DOI 10.1016/0165-0173(90)90011-C; Mihalik JP, 2005, J NEUROSURG, V102, P850, DOI 10.3171/jns.2005.102.5.0850; PARNES LS, 1993, ANN OTO RHINOL LARYN, V102, P325, DOI 10.1177/000348949310200501; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; PICKLES W, 1950, NEW ENGL J MED, V242, P607, DOI 10.1056/NEJM195004202421602; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; Rogers E, 2006, J HEAD TRAUMA REHAB, V21, P279, DOI 10.1097/00001199-200605000-00008; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Stein Donald G, 2003, Pediatr Rehabil, V6, P13, DOI 10.1080/1363849031000095279; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; WOJYTS ED, 1999, AM J SPORTS MED, V27, P676; Yang CC, 2007, J TRAUMA, V62, P657, DOI 10.1097/01.ta.0000203577.68764.b8	60	42	42	0	17	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1047-9651	1558-1381		PHYS MED REH CLIN N	Phys. Med. Rehabil. Clin. N. Am.	MAY	2008	19	2					247	+		10.1016/j.pmr.2007.12.002			24	Rehabilitation	Rehabilitation	437NB	WOS:000265493100006	18395647				2021-06-18	
J	Strangman, GE; O'Neil-Pirozzi, TM; Goldstein, R; Kelkar, K; Katz, DI; Burke, D; Rauch, SL; Savage, CR; Glenn, MB				Strangman, Gary E.; O'Neil-Pirozzi, Therese M.; Goldstein, Richard; Kelkar, Kalika; Katz, Douglas I.; Burke, David; Rauch, Scott L.; Savage, Cary. R.; Glenn, Mel B.			Prediction of memory rehabilitation outcomes in traumatic brain injury by using functional magnetic resonance imaging	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						magnetic resonance imaging; rehabilitation	COGNITIVE REHABILITATION; HEAD-INJURY; PREFRONTAL CORTEX; FOLLOW-UP; ACTIVATION; RECOVERY; MECHANISMS; RETRIEVAL; PERFORMANCE; FMRI	Objective: To evaluate the ability of functional magnetic resonance imaging (fMRI) measures collected from people with traumatic brain injury (TBI) to provide predictive value for rehabilitation outcomes over and above standard predictors. Design: Prospective study. Setting: Academic medical center. Participants: Persons (N=54) with TBI greater than I year postinjury. Intervention: A novel 12-session a up rehabilitation program focusing on internal strategies to improve memory, Main Outcome Measure: The Hopkins Verbal Learning Test-Revised (HVLT-R) delayed recall score. Results: fMRI measures were collected while participants performed a strategically directed word memorization task. Prediction models were multiple linear regressions with the following primary predictors of outcome: age, education, injury severity, preintervention HVLT-R, and task-related fMRI activation of the left dorsolateral and left ventrolateral prefrontal cortex (VLPFC). Baseline HVLT-R was a significant predictor of outcome (P = .007), as was injury severity (for severe vs mild. P = .049), We also found a significant quadratic (inverted-U) effect of fMRI in the VLPFC (P = .007). Conclusions: This Study Supports previous evidence that left prefrontal activity is related to strategic verbal learning, and the magnitude of this activation predicted success in response to cognitive memory rehabilitation strategies. Extreme under- or overactivation of VLPFC was associated with less successful learning after rehabilitation. Further study is necessary to clarify this relationship and to expand and optimize the possible uses of functional imaging to guide rehabilitation therapies.	[Strangman, Gary E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, Charlestown, MA USA; [Strangman, Gary E.; O'Neil-Pirozzi, Therese M.; Goldstein, Richard; Kelkar, Kalika; Glenn, Mel B.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Spaulding Rehabil Hosp, Boston, MA USA; [O'Neil-Pirozzi, Therese M.] Northeastern Univ, Dept Speech Language Pathol & Audiol, Boston, MA 02115 USA; [Katz, Douglas I.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [Katz, Douglas I.] Braintree Rehabil Hosp, Braintree, MA USA; [Burke, David] Emory Univ, Dept Rehabil Med, Atlanta, GA 30322 USA; [Rauch, Scott L.] Harvard Univ, McLean Hosp, Sch Med, Belmont, MA 02178 USA; [Savage, Cary. R.] Univ Kansas, Med Ctr, Hoglund Brain Imaging Ctr, Kansas City, KS 66103 USA	Strangman, GE (corresponding author), Neural Syst Grp, 149 13th St,Room 2651, Charlestown, MA 02129 USA.	strang@mmr.mgh.harvard.edu		Katz, Douglas/0000-0002-7502-8505; Strangman, Gary/0000-0001-8896-2164	National institute on Disability and Rehabilitation Research [H133A020513]; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K25-NS046554]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K25NS046554] Funding Source: NIH RePORTER	Supported by National institute on Disability and Rehabilitation Research (grant no. H133A020513) and the National Institute of Neurological Disorders and Stroke (grant no. K25-NS046554).	Badre D, 2005, NEURON, V47, P907, DOI 10.1016/j.neuron.2005.07.023; Badre D, 2004, NEURON, V41, P473, DOI 10.1016/S0896-6273(03)00851-1; Bajo A, 2002, BRAIN INJURY, V16, P385, DOI 10.1080/02699050110119826; Barr WB, 2003, ARCH CLIN NEUROPSYCH, V18, P91, DOI 10.1016/S0887-6177(01)00185-8; Bate AJ, 2001, CLIN NEUROPSYCHOL, V15, P405, DOI 10.1076/clin.15.3.405.10279; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Benedict RHB, 1998, CLIN NEUROPSYCHOL, V12, P43, DOI 10.1076/clin.12.1.43.1726; Berg I. J., 1991, NEUROPSYCHOL REHABIL, V1, P97, DOI [DOI 10.1080/09602019108401384, 10.1080/09602019108401384]; Brandt J., 2001, HOPKINS VERBAL LEARN; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; Bunge SA, 2004, BRAIN COGNITION, V56, P141, DOI 10.1016/j.bandc.2003.08.001; Bunge SA, 2003, J NEUROPHYSIOL, V90, P3419, DOI 10.1152/jn.00910.2002; Busch RM, 2005, J CLIN EXP NEUROPSYC, V27, P1022, DOI 10.1080/13803390490919263; Bush BA, 2003, ARCH PHYS MED REHAB, V84, P1803, DOI 10.1016/S0003-9993(03)00367-8; Cazalis F, 2001, J INT NEUROPSYCH SOC, V7, P795, DOI 10.1017/S1355617701777028; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Cicerone K, 2006, J COGNITIVE NEUROSCI, V18, P1212, DOI 10.1162/jocn.2006.18.7.1212; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Crinion J, 2007, NEUROIMAGE, V37, P866, DOI 10.1016/j.neuroimage.2007.04.065; Curtiss G, 2001, J INT NEUROPSYCH SOC, V7, P574, DOI 10.1017/S1355617701755051; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; GERSHBERG FB, 1995, NEUROPSYCHOLOGIA, V33, P1305, DOI 10.1016/0028-3932(95)00103-A; Greenspan AI, 1996, BRAIN INJURY, V10, P207, DOI 10.1080/026990596124520; Hewitt J, 2006, NEUROPSYCHOLOGIA, V44, P1468, DOI 10.1016/j.neuropsychologia.2005.11.016; Hoeft F, 2007, BEHAV NEUROSCI, V121, P602, DOI 10.1037/0735-7044.121.3.602; Kaschel R, 2002, NEUROPSYCHOL REHABIL, V12, P127, DOI 10.1080/09602010143000211; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; KENNEDY M, 2006, AHSA LEAD, V11, P8; Kennedy M, 2006, AHSA LEAD, V11, P34; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; Kirkby BS, 1996, NEUROPSYCHOLOGIA, V34, P689; Kuhl BA, 2007, NAT NEUROSCI, V10, P908, DOI 10.1038/nn1918; Laatsch LK, 2004, BRAIN INJURY, V18, P957, DOI 10.1080/02699050410001672369; Levine B, 2000, NEUROPSYCHOLOGY, V14, P491, DOI 10.1037/0894-4105.14.4.491; Little R, 2002, STAT ANAL MISSING DA, V2nd; Logan JM, 2002, NEURON, V33, P827, DOI 10.1016/S0896-6273(02)00612-8; Lombardi WJ, 1999, J CLIN EXP NEUROPSYC, V21, P2, DOI 10.1076/jcen.21.1.2.940; Loubinoux I, 2007, CEREB CORTEX, V17, P2980, DOI 10.1093/cercor/bhm023; MALEC J, 1990, J HEAD TRAUMA REHAB, V5, P60; Marchini JL, 2000, NEUROIMAGE, V12, P366, DOI 10.1006/nimg.2000.0628; Mcallister TW, 2004, BRAIN INJURY, V18, P331, DOI 10.1080/02699050310001617370; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; McKinlay W, 1999, REHABILITATION ADULT, V3, P74; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Miotto EC, 2006, HUM BRAIN MAPP, V27, P288, DOI 10.1002/hbm.20184; Musso M, 1999, BRAIN, V122, P1781, DOI 10.1093/brain/122.9.1781; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; OSHANICK GJ, 1994, NEUROPSYCHIATRY TRAU, P163; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Preece MHW, 2007, BRAIN INJURY, V21, P951, DOI 10.1080/02699050701481647; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Reber PJ, 2002, J NEUROSCI, V22, P9541; Ricker JH, 2001, J CLIN EXP NEUROPSYC, V23, P196, DOI 10.1076/jcen.23.2.196.1204; Royston P, 2005, STATA J, V5, P527, DOI 10.1177/1536867X0500500404; Ruff R. M., 1989, J HEAD TRAUMA REHAB, V4, P20, DOI [10.1097/00001199-198909000-00006, DOI 10.1097/00001199-198909000-00006]; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; RYAN T V, 1992, Brain Injury, V6, P175, DOI 10.3109/02699059209029656; Ryan T V, 1988, Arch Clin Neuropsychol, V3, P165, DOI 10.1016/0887-6177(88)90061-3; RYAN TV, 1986, THESIS CALIFORNIA SC; Savage CR, 2001, BRAIN, V124, P219, DOI 10.1093/brain/124.1.219; Schafer JL., 1997, ANAL INCOMPLETE MULT; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; SHIMAMURA AP, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P173; Small SL, 2002, BRAIN, V125, P1544, DOI 10.1093/brain/awf148; Strangman G, 2005, AM J PHYS MED REHAB, V84, P62, DOI 10.1097/01.PHM.0000150787.26860.12; Strauss E, 2006, COMPENDIUM NEUROSYCH; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; TEMKIN NR, 1995, J NEUROSURG, V82, P764, DOI 10.3171/jns.1995.82.5.0764; Vanderploeg RD, 2001, J CLIN EXP NEUROPSYC, V23, P185, DOI 10.1076/jcen.23.2.185.1210; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; WILSON B, 1989, J CLIN EXP NEUROPSYC, V11, P855, DOI 10.1080/01688638908400940; WILSON B, 2003, RIVERMEAD BEHAV ME S, V2; Ylvisaker M, 2002, J HEAD TRAUMA REHAB, V17, P191, DOI 10.1097/00001199-200206000-00002; ZENCIUS A, 1991, Brain Injury, V5, P321, DOI 10.3109/02699059109008102	76	42	42	0	13	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	2008	89	5					974	981		10.1016/j.apmr.2008.02.011			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	341ST	WOS:000258735900025	18452748				2021-06-18	
J	Milroy, G; Dorris, L; McMillan, TM				Milroy, G.; Dorris, L.; McMillan, T. M.			Brief report: Sleep disturbances following mild traumatic brain injury in childhood	JOURNAL OF PEDIATRIC PSYCHOLOGY			English	Article						brain injury; childhood; pediatrics; sleep	ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; MINOR HEAD-INJURY; DIFFICULTIES QUESTIONNAIRE; CHILDREN; ADOLESCENTS; PREVALENCE; STRENGTHS; SYMPTOMS; PATTERNS	Objective To examine objective and subjective reports of sleep disturbance in school-aged children who had sustained mild traumatic brain injury (TBI) at least 6 months prior to the study. Methods Eighteen children aged 7-12 years with a history of mild TBI (GCS 13-15. LOC <15 min) were compared to 30 children with orthopedic injuries using actigraphy and parental and self-report sleep questionnaires. Results Parents reported greater sleep disturbance in the mild TBI group. No significant differences were found in parental ratings of daytime sleepiness, child-reported sleep difficulties, or objective (actigraph) sleep measures. Conclusions The finding of greater parental reports of sleep disturbance following mild TBI 6 months after injury requires greater exploration and future research with a larger sample followed from the point of injury would seem appropriate.	[Milroy, G.; McMillan, T. M.] Univ Glasgow, Dept Psychol Med, Glasgow G12 0XH, Lanark, Scotland; [Dorris, L.] Royal Hosp Sick Children, Fraser Allander Neurosci Unit, Glasgow, Lanark, Scotland	McMillan, TM (corresponding author), Univ Glasgow, Gartnavel Royal Hosp, 1055 Great Western Rd, Glasgow G12 0XH, Lanark, Scotland.	t.m.mcmillan@clinmed.gla.ac.uk	Dorris, Liam/AAK-2273-2021; Sanguansri, Luz/B-6630-2011	Dorris, Liam/0000-0002-9502-3154; Sanguansri, Luz/0000-0003-1908-7604			Acebo C, 1999, SLEEP, V22, P95, DOI 10.1093/sleep/22.1.95; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Beebe DW, 2007, J PEDIATR PSYCHOL, V32, P845, DOI 10.1093/jpepsy/jsm003; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; Blunden SL, 2006, SLEEP MED REV, V10, P109, DOI 10.1016/j.smrv.2005.11.003; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Carstairs V, 1991, DEPRIVATION HLTH SCO; Corkum P, 2001, SLEEP, V24, P303, DOI 10.1093/sleep/24.3.303; Couturier JL, 2005, J AM ACAD CHILD PSY, V44, P815, DOI 10.1097/01.chi.0000166377.22651.87; Fallone G, 2002, SLEEP MED REV, V6, P287, DOI 10.1053/smrv.2001.0192; Goodman R, 1997, J CHILD PSYCHOL PSYC, V38, P581, DOI 10.1111/j.1469-7610.1997.tb01545.x; Goodman R, 1999, J ABNORM CHILD PSYCH, V27, P17, DOI 10.1023/A:1022658222914; Gruber R, 2000, J AM ACAD CHILD PSY, V39, P495, DOI 10.1097/00004583-200004000-00019; Hawley CA, 2002, BRAIN INJURY, V16, P969, DOI 10.1080/02699050210147239; Hooper SR, 2004, NEUROREHABILITATION, V19, P175; Kaufman Y, 2001, PEDIATR NEUROL, V24, P129, DOI 10.1016/S0887-8994(00)00254-X; Mulhern S, 2006, J PSYCHOSOM RES, V61, P439, DOI 10.1016/j.jpsychores.2006.03.004; Overweg-Plandsoen WCG, 1999, EUR J PEDIATR, V158, P249, DOI 10.1007/s004310051061; Owens JA, 2000, SLEEP, V23, P1043; Owens JA, 2000, ARCH PEDIAT ADOL MED, V154, P549, DOI 10.1001/archpedi.154.6.549; Pillar G, 2003, PEDIATR NEUROL, V29, P131, DOI 10.1016/S0887-8994(03)00149-8; Yeates Keith Owen, 2005, Pediatr Rehabil, V8, P5	22	42	42	0	8	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-8693	1465-735X		J PEDIATR PSYCHOL	J. Pediatr. Psychol.	APR	2008	33	3					242	247		10.1093/jpepsy/jsm099			6	Psychology, Developmental	Psychology	272JW	WOS:000253856700003	17967815				2021-06-18	
J	Genovese, T; Rossi, A; Mazzon, E; Di Paola, R; Muia, C; Caminiti, R; Bramanti, P; Sautebin, L; Cuzzocrea, S				Genovese, T.; Rossi, A.; Mazzon, E.; Di Paola, R.; Muia, C.; Caminiti, R.; Bramanti, P.; Sautebin, L.; Cuzzocrea, S.			Effects of zileuton and montelukast in mouse experimental spinal cord injury	BRITISH JOURNAL OF PHARMACOLOGY			English	Article						zileuton; montelukast; spinal cord injury; 5-lipoxygenase; cysteinyl-leukotrienes	NECROSIS-FACTOR-ALPHA; LEUKOTRIENE-B4 PRODUCES HYPERALGESIA; POLYMORPHONUCLEAR LEUKOCYTES; CELLULAR-LOCALIZATION; INFLAMMATORY RESPONSE; TRANSPLANTS SUPPORT; RECEPTOR ANTAGONIST; GM-1 GANGLIOSIDE; CONTROLLED TRIAL; MOTOR FUNCTION	Background and purpose: 5-lipoxygenase (5-LO) is the key enzyme in leukotriene (LT) biosynthesis from arachidonic acid (AA). Here, we examined the role of the 5-LO-product, cysteinyl-LT (Cys-LT), with a 5-LO inhibitor (zileuton) and a Cys-LT, receptor antagonist (montelukast), in the inflammatory response and tissue injury associated with spinal cord injury (SCI). Experimental approach: SCI was induced in mice by the application of vascular clips to the dura via a two-level T6 to T7 laminectomy for 1 min. Cord inflammation was assessed histologically and by measuring inflammatory mediators (ELISA) and apoptosis by annexin V, TUNEL, Fas ligand staining and Bax and Bcl-2 expression (immunohistochemistry and western blots). Motor function in hindlimbs was assessed by a locomotor rating scale, for 10 days after cord injury. Key results: SCI in mice resulted in tissue damage, oedema, neutrophil infiltration, apoptosis, tumour necrosis-alpha (TNF-alpha) and cyclooxygenase-2 (COX-2) expression, prostaglandin E-2 (PGE(2)) and leukotriene B-4 (LTB4) production, and extracellular signal-regulated kinase 1/2 (ERK1/2) phosphorylation in injured tissue. Treatment of the mice with zileuton or montelukast reduced the spinal cord inflammation and tissue injury, neutrophil infiltration, TNF-alpha, COX-2 and pERK1/2 expression, PGE2 and LTB4 production, and apoptosis. In separate experiments, zileuton or montelukast significantly improved the recovery of limb function over 10 days. Conclusions and implications: Zileuton and montelukast produced a substantial reduction of inflammatory events associated with experimental SCI. Our data underline the important role of 5-LO and Cys-LT in neurotrauma.	Univ Messina, Sch Med, Dept Clin & Expt Med & Pharmacol, I-98125 Messina 5, Italy; [Genovese, T.; Rossi, A.; Mazzon, E.; Di Paola, R.; Bramanti, P.; Cuzzocrea, S.] IRCCS, Ctr Neurolesi Bonino Pulejo, Messina, Italy; [Rossi, A.; Sautebin, L.] Univ Naples Federico II, Dept Expt Pharmacol, Naples, Italy; [Caminiti, R.] Univ Messina, Sch Med, Dept Human Pathol, Messina, Italy	Cuzzocrea, S (corresponding author), Univ Messina, Sch Med, Dept Clin & Expt Med & Pharmacol, Via C Valeria, I-98125 Messina 5, Italy.	salvator@unime.it	Mazzon, Emanuela/AAL-4334-2020; Bramanti, Placido/K-5117-2016; di paola, rosanna/U-4356-2019	di paola, rosanna/0000-0001-6725-8581; mazzon, emanuela/0000-0002-5073-717X; GENOVESE, Tiziana/0000-0002-3335-7327			Adachi K, 2005, NEUROSCI RES, V51, P73, DOI 10.1016/j.neures.2004.10.007; Anderson Aileen J, 2002, J Spinal Cord Med, V25, P70; Bao F, 2004, J NEUROCHEM, V90, P1194, DOI 10.1111/j.1471-4159.2004.02580.x; Bar-Peled O, 1999, J NEUROSCI RES, V55, P542, DOI 10.1002/(SICI)1097-4547(19990301)55:5<542::AID-JNR2>3.0.CO;2-7; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Beattie MS, 2002, PROG BRAIN RES, V137, P37; Beattie MS, 2004, TRENDS MOL MED, V10, P580, DOI 10.1016/j.molmed.2004.10.006; Bertolini A, 2002, CURR MED CHEM, V9, P1033, DOI 10.2174/0929867024606650; Bethea JR, 2002, CURR OPIN NEUROL, V15, P355, DOI 10.1097/00019052-200206000-00021; BISGAARD H, 1985, PROSTAGLANDINS, V30, P791, DOI 10.1016/0090-6980(85)90007-3; Blain JF, 2000, PROSTAG LEUKOTR ESS, V62, P361, DOI 10.1054/plef.2000.0167; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; Bregman B S, 1997, Adv Neurol, V72, P257; Bregman BS, 1998, EXP NEUROL, V149, P13, DOI 10.1006/exnr.1997.6669; Bregman BS, 1997, EXP NEUROL, V148, P475, DOI 10.1006/exnr.1997.6705; Carlson Gregory D, 2002, Spine J, V2, P116, DOI 10.1016/S1529-9430(01)00029-8; Carlson SL, 1998, EXP NEUROL, V151, P77, DOI 10.1006/exnr.1998.6785; Cheng H, 1996, SCIENCE, V273, P510, DOI 10.1126/science.273.5274.510; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; Cuzzocrea S, 2005, LAB INVEST, V85, P808, DOI 10.1038/labinvest.3700276; DEMOPOULOS HB, 1978, SCAN ELECTRON MICROS, V2, P677; Diener PS, 1998, J NEUROSCI, V18, P779; Diener PS, 1998, J NEUROSCI, V18, P763; Dietrich WD, 2004, ACTA NEUROCHIR SUPPL, V89, P69; Failla M, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-137; FORDHUTCHINSON AW, 1980, AGENTS ACTIONS, V10, P548, DOI 10.1007/BF02024162; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; GEISLER FH, 1991, NEW ENGL J MED, V324, P1829, DOI 10.1056/NEJM199106273242601; GEISLER FH, 1992, J NEUROTRAUM, V9, pS517; Genovese T, 2005, J NEUROIMMUNOL, V166, P55, DOI 10.1016/j.jneuroim.2005.05.009; Greene KA, 1996, J SPINAL DISORD, V9, P355; GREENE KA, 1994, CRIT REV NEUROSURG, V4, P254; Gris D, 2004, J NEUROSCI, V24, P4043, DOI 10.1523/JNEUROSCI.5343-03.2004; Hamada Y, 1996, J NEUROCHEM, V66, P1525; Hausmann O, 2003, SPINAL CORD, V41, P369, DOI 10.1038/sj.sc.3101483; Hensley K, 2006, ANTIOXID REDOX SIGN, V8, P2075, DOI 10.1089/ars.2006.8.2075; Ichiyama T, 2007, CLIN EXP ALLERGY, V37, P608, DOI 10.1111/j.1365-2222.2007.02692.x; Jacobs T P, 1987, Cent Nerv Syst Trauma, V4, P95; Joshi M, 2002, J NEUROTRAUM, V19, P175, DOI 10.1089/08977150252806947; Joshi M, 2002, J NEUROTRAUM, V19, P191, DOI 10.1089/08977150252806956; Jung SB, 2005, J CLIN IMMUNOL, V25, P482, DOI 10.1007/s10875-005-5431-1; King VR, 2006, J NEUROSCI, V26, P4672, DOI 10.1523/JNEUROSCI.5539-05.2006; Lee KS, 2007, J ALLERGY CLIN IMMUN, V119, P141, DOI 10.1016/j.jaci.2006.09.001; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; LEVINE JD, 1984, SCIENCE, V225, P743, DOI 10.1126/science.6087456; Marusic S, 2005, J EXP MED, V202, P841, DOI 10.1084/jem.20050665; Mazzon E, 2006, SHOCK, V25, P377, DOI 10.1097/01.shk.0000209530.30564.22; McTigue DM, 1998, J NEUROSCI RES, V53, P368, DOI 10.1002/(SICI)1097-4547(19980801)53:3<368::AID-JNR11>3.0.CO;2-1; MITSUHASHI T, 1994, PARAPLEGIA, V32, P524, DOI 10.1038/sc.1994.84; MULLANE KM, 1985, J PHARMACOL METHOD, V14, P157, DOI 10.1016/0160-5402(85)90029-4; Nesic-Taylor O, 2005, J NEUROSCI RES, V79, P628, DOI 10.1002/jnr.20400; Nishisho T, 1996, NEUROSURGERY, V39, P950, DOI 10.1097/00006123-199611000-00014; Profyris C, 2004, NEUROBIOL DIS, V15, P415, DOI 10.1016/j.nbd.2003.11.015; Rossi A, 2005, J LEUKOCYTE BIOL, V78, P985, DOI 10.1189/jlb.1004619; Saito H, 2004, IMMUNOLOGY, V113, P246, DOI 10.1111/j.1365-2567.2004.01944.x; Schutte B, 1998, J NEUROSCI METH, V86, P63, DOI 10.1016/S0165-0270(98)00147-2; SHEA TB, 1994, BIOTECHNIQUES, V16, P1126; SHOHAMI E, 1987, PROSTAG LEUKOTR ESS, V28, P169, DOI 10.1016/0262-1746(87)90161-2; STOVER SL, 1987, PARAPLEGIA, V25, P225, DOI 10.1038/sc.1987.40; Sugaya K, 2000, JPN J PHARMACOL, V82, P85, DOI 10.1254/jjp.82.85; SUTTORP N, 1987, INFECT IMMUN, V55, P104, DOI 10.1128/IAI.55.1.104-110.1987; Taoka Y, 1997, NEUROSCIENCE, V79, P1177, DOI 10.1016/S0306-4522(97)00011-0; TATOR CH, 1995, BRAIN PATHOL, V5, P407, DOI 10.1111/j.1750-3639.1995.tb00619.x; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Tugtepe H, 2007, EUR J PHARMACOL, V557, P69, DOI 10.1016/j.ejphar.2006.11.009; Virchow JC, 2001, CLIN EXP ALLERGY, V31, P836, DOI 10.1046/j.1365-2222.2001.01051.x; Wada K, 2006, FASEB J, V20, P1785, DOI 10.1096/fj.06-5809com; XU J, 1990, J NEUROCHEM, V55, P907, DOI 10.1111/j.1471-4159.1990.tb04577.x; Xu J, 2001, J NEUROTRAUM, V18, P523, DOI 10.1089/089771501300227323; Xu W, 2005, SPINAL CORD, V43, P204, DOI 10.1038/sj.sc.3101674; Yan P, 2001, J NEUROTRAUM, V18, P563, DOI 10.1089/089771501300227369; Yang LQ, 2004, SPINE, V29, P966, DOI 10.1097/00007632-200405010-00004	72	42	45	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0007-1188	1476-5381		BRIT J PHARMACOL	Br. J. Pharmacol.	FEB	2008	153	3					568	582		10.1038/sj.bjp.0707577			15	Pharmacology & Pharmacy	Pharmacology & Pharmacy	258QW	WOS:000252884000019	18059327	Green Published			2021-06-18	
J	Holland, MA; Tan, AA; Smith, DC; Hoane, MR				Holland, Michael A.; Tan, Arlene A.; Smith, Douglas C.; Hoane, Michael R.			Nicotinamide treatment provides acute neuroprotection and GFAP regulation following fluid percussion injury	JOURNAL OF NEUROTRAUMA			English	Article						fluoro-jade; GFAP; neuroprotection; nicotinamide; therapy; traumatic brain injury	TRAUMATIC BRAIN-INJURY; FOCAL CEREBRAL-ISCHEMIA; WISTAR RATS; REACTIVE ASTROCYTES; INFARCT VOLUME; UNITED-STATES; PROTECTION; LONGEVITY; RECOVERY	Previous studies in our laboratory have demonstrated the preclinical efficacy of nicotinamide (NAM; vitamin B3) treatment following fluid percussion injury (FPI). At a dose of 500 or 50 mg/kg, NAM significantly facilitated recovery of function on a variety of motor and sensorimotor tasks in rodents, and the 500 mg/kg dose improved cognitive performance. The purpose of the present study was to examine the acute neuroprotective ability of NAM following FPI. Rats were given a moderate FPI (1.8 atm) or sham injury. NAM (500 or 50 mg/kg) or saline was administered 15 min and 20 h after FPI. Rats were sacrificed at 24 h or 7 days following injury and prepared for histological analysis. Systematic volumetric measurements were conducted to examine cortical loss in a series of cresyl violet stained slices to examine the development of the injury cavity. To assess the extent of astrocytic activity and neurodegeneration, triple labeling with glial fibrillary acidic protein (GFAP), Fluoro-Jade B (FJ), and DAPI was performed. GFAP(+) astrocytes and FJ(+) neurons in the ipsilateral and contralateral cortex, and ipsilateral hippocampus and thalamus were assessed. While not significant at 24 h, NAM significantly attenuated cortical tissue loss at 7 days. At 24 h, the number of GFAP(+) astrocytes was significantly reduced by NAM. However, the inverse was observed at 7 days where NAM treatment significantly increased the number of GFAP(+) astrocytes. Both doses of NAM also significantly reduced FJ expression at the 24-h and 7-day time intervals. The results of this study suggest that NAM has strong neuroprotective abilities in the injured brain and may have therapeutic potential for brain injury.	[Holland, Michael A.; Tan, Arlene A.; Hoane, Michael R.] So Illinois Univ, Dept Psychol, Brain & Cognit Sci Program, Ctr Integrat Res Cognit & Neural Sci,Restorat Neu, Carbondale, IL 62901 USA; [Tan, Arlene A.; Smith, Douglas C.] So Illinois Univ, Dept Psychol, Brain & Cognit Sci Program, Ctr Integrat Res Cognit & Neural Sci,Neurotrauma, Carbondale, IL 62901 USA	Hoane, MR (corresponding author), So Illinois Univ, Dept Psychol, Brain & Cognit Sci Program, Ctr Integrat Res Cognit & Neural Sci,Restorat Neu, Carbondale, IL 62901 USA.	mhoane@siu.edu		Hoane, Michael/0000-0001-7779-2657	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R15NS045647, R01NS041551] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS041551, NS045647] Funding Source: Medline		Ayoub IA, 1999, NEUROSCI LETT, V259, P21, DOI 10.1016/S0304-3940(98)00881-7; Burkle A, 2001, CHEMBIOCHEM, V2, P725, DOI 10.1002/1439-7633(20011001)2:10<725::AID-CBIC725>3.0.CO;2-3; Davies SJA, 1996, EXP NEUROL, V142, P203, DOI 10.1006/exnr.1996.0192; Di Giovanni S, 2005, P NATL ACAD SCI USA, V102, P8333, DOI 10.1073/pnas.0500989102; Gondusky JS, 2005, MIL MED, V170, P546, DOI 10.7205/MILMED.170.6.546; GREENGARD P, 1967, J BIOL CHEM, V242, P152; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; Hoane MR, 2006, BRAIN RES, V1125, P185, DOI 10.1016/j.brainres.2006.10.019; Hoane MR, 2006, NEUROSCI LETT, V408, P35, DOI 10.1016/j.neulet.2006.07.011; Hoane MR, 2006, J NEUROTRAUM, V23, P1535, DOI 10.1089/neu.2006.23.1535; Hoane MR, 2003, J NEUROTRAUM, V20, P1189, DOI 10.1089/089771503770802871; Li FQ, 2006, CURR MED CHEM, V13, P883, DOI 10.2174/092986706776361058; Maiese K, 2003, TRENDS PHARMACOL SCI, V24, P228, DOI 10.1016/S0165-6147(03)00078-6; McGraw J, 2001, J NEUROSCI RES, V63, P109, DOI 10.1002/1097-4547(20010115)63:2<109::AID-JNR1002>3.0.CO;2-J; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Mokudai T, 2000, STROKE, V31, P1679, DOI 10.1161/01.STR.31.7.1679; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Paxinos G., 2005, RAT BRAIN STEREOTAXI; Sakakibara Y, 2000, NEUROSCI LETT, V281, P111, DOI 10.1016/S0304-3940(00)00854-5; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Smith DC, 2005, J NEUROTRAUM, V22, P1485, DOI 10.1089/neu.2005.22.1485; Sofroniew MV, 2005, NEUROSCIENTIST, V11, P400, DOI 10.1177/1073858405278321; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009	25	42	42	1	7	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	FEB	2008	25	2					140	152		10.1089/neu.2007.0312			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	266RZ	WOS:000253456000007	18260797				2021-06-18	
J	Grados, MA; Vasa, RA; Riddle, MA; Slomine, BS; Salorio, C; Christensen, J; Gerring, J				Grados, Marco A.; Vasa, Roma A.; Riddle, Mark A.; Slomine, Beth S.; Salorio, Cynthia; Christensen, James; Gerring, Joan			New onset obsessive-compulsive symptoms in children and adolescents with severe traumatic brain injury	DEPRESSION AND ANXIETY			English	Article						obsessive-compulsive disorder; traumatic brain injury; pediatric; anterior cingulate cortex; temporal lobe	TEMPORAL-LOBE EPILEPSY; CLOSED-HEAD INJURY; POSITRON-EMISSION-TOMOGRAPHY; CEREBRAL GLUCOSE-METABOLISM; ANTERIOR CINGULATE CORTEX; PSYCHIATRIC-DISORDERS; UNMEDICATED PATIENTS; PROVOCATION; COMORBIDITY; PERSONALITY	Traumatic brain injury (TBI) constitutes a major source of psychiatric morbidity and disability. This study examines new onset of obsessions and compulsions (OCS) within 1 year of severe pediatric TBI Eighty children and adolescents ages 6-18 years with severe TBI were interviewed by a child psychiatrist using the Diagnostic Interview for Children and Adolescents-Revised to diagnose OCS and comorbidities A brain magnetic resonance imaging used a 1.5 T scanner 3 months after injury with a T1-weighted spoiled gradient-recalled-echo sequence to provide high spatial resolution and T1- and T2*-contrast sensitivity. Race, sex, socioeconomic status, psychosocial adversity, and injury severity were used to predict new onset OCS. Psychiatric comorbidities and brain lesion volumes in orbitofrontal, mesial prefrontal, temporal lobe, basal ganglia, and thalamus were examined in relation to new onset OCS. Twenty-one children (21/72, 29.2%) had OCS after TBI. Most common were worries about disease, cleanliness, and inappropriate actions as well as excessive cleaning, doing things a certain way and ordering. Anxiety disorders, mania, dysthymia, depressive symptoms, and posttraumatic stress disorder were significantly associated with new onset OCS. Injury severity was not associated with new onset OCS. Greater psychosocial adversity (P = 0.009), and being female (P = 0.005) were associated with OCS while mesial prefrontal and temporal lobe lesions were associated with new onset obsessions (P<0.05). OCS are common after severe pediatric TBI and are associated with greater comorbidities. New onset obsessions are associated with female sex, psychosocial adversity, and mesial prefrontal and temporal lesions.	[Grados, Marco A.; Vasa, Roma A.; Riddle, Mark A.; Gerring, Joan] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21287 USA; [Vasa, Roma A.; Slomine, Beth S.; Salorio, Cynthia; Christensen, James; Gerring, Joan] Johns Hopkins Univ, Sch Med, Kennedy Krieger Res Inst, Baltimore, MD USA	Grados, MA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, 600 N Wolfe St,CMSC 346, Baltimore, MD 21287 USA.	mjgrados@jhmi.edu		Grados, Marco/0000-0002-6189-6264	NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K23MH066284] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K23MH066284] Funding Source: Medline		Adler CM, 2000, J PSYCHIATR RES, V34, P317, DOI 10.1016/S0022-3956(00)00022-4; ALEXANDER GE, 1986, ANNU REV NEUROSCI, V9, P357, DOI 10.1146/annurev.ne.09.030186.002041; Anderson VA, 2001, PEDIATR NEUROSURG, V34, P138, DOI 10.1159/000056009; Barbieri V, 2005, EPILEPSY BEHAV, V6, P617, DOI 10.1016/j.yebeh.2005.02.010; BAXTER LR, 1987, ARCH GEN PSYCHIAT, V44, P211; BAXTER LR, 1990, J CLIN PSYCHIAT, V51, P22; Berthier ML, 2001, NEUROPSY NEUROPSY BE, V14, P23; BIRD HR, 1992, J AM ACAD CHILD PSY, V31, P78, DOI 10.1097/00004583-199201000-00012; Bogetto F, 1999, EUR PSYCHIAT, V14, P434, DOI 10.1016/S0924-9338(99)00224-2; Botvinick MM, 2004, TRENDS COGN SCI, V8, P539, DOI 10.1016/j.tics.2004.10.003; Breiter HC, 1996, NEUROIMAGE, V4, pS127, DOI 10.1006/nimg.1996.0063; Busatto GF, 2001, J AM ACAD CHILD PSY, V40, P347, DOI 10.1097/00004583-200103000-00015; Carmichael ST, 1995, J COMP NEUROL, V363, P615, DOI 10.1002/cne.903630408; Childers MK, 1998, BRAIN INJURY, V12, P613; Damasio H., 1995, HUMAN BRAIN ANATOMY; DRUMMOND LM, 1988, BRIT J PSYCHIAT, V153, P839, DOI 10.1192/bjp.153.6.839; Gerring J, 2000, BRAIN INJURY, V14, P205; Gerring JP, 2002, J AM ACAD CHILD PSY, V41, P157, DOI 10.1097/00004583-200202000-00009; Grados MA, 2001, J NEUROL NEUROSUR PS, V70, P350, DOI 10.1136/jnnp.70.3.350; Herskovits EH, 1999, RADIOLOGY, V213, P389, DOI 10.1148/radiology.213.2.r99nv45389; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; INSEL TR, 1992, PSYCHIAT CLIN N AM, V15, P813; *ISG TECHN, 1995, ALL SOFTW; JENIKE M, 1984, J AFFECT DISORDERS, V2, P359; KANNER AM, 1993, NEUROPSY NEUROPSY BE, V6, P126; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; KROLL L, 1993, J NERV MENT DIS, V181, P457, DOI 10.1097/00005053-199307000-00011; Lensi P, 1996, BRIT J PSYCHIAT, V169, P101, DOI 10.1192/bjp.169.1.101; Max JE, 1998, J AM ACAD CHILD PSY, V37, P832, DOI 10.1097/00004583-199808000-00013; Max JE, 2000, J INT NEUROPSYCH SOC, V6, P279, DOI 10.1017/S1355617700633039; Max JE, 1997, J NERV MENT DIS, V185, P394, DOI 10.1097/00005053-199706000-00006; MAX JE, 1995, J AM ACAD CHILD PSY, V34, P45, DOI 10.1097/00004583-199501000-00012; Monaco F, 2005, EPILEPSY BEHAV, V7, P491, DOI 10.1016/j.yebeh.2005.07.003; Nestadt G, 2000, AM J HUM GENET, V67, P1611, DOI 10.1086/316898; Neumeister A, 2004, ARCH GEN PSYCHIAT, V61, P765, DOI 10.1001/archpsyc.61.8.765; NOSHIRVANI HF, 1991, BRIT J PSYCHIAT, V158, P260, DOI 10.1192/bjp.158.2.260; Paus T, 2001, NAT REV NEUROSCI, V2, P417, DOI 10.1038/35077500; Procyk E, 2000, NAT NEUROSCI, V3, P502, DOI 10.1038/74880; Pujol J, 2002, NEUROIMAGE, V15, P847, DOI 10.1006/nimg.2001.1004; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rauch SL, 1997, J NEUROPSYCH CLIN N, V9, P568; RAUCH SL, 1994, ARCH GEN PSYCHIAT, V51, P62; Reich W, 2000, J AM ACAD CHILD PSY, V39, P59, DOI 10.1097/00004583-200001000-00017; ROBINSON D, 1995, ARCH GEN PSYCHIAT, V52, P393; Rushworth MFS, 2004, TRENDS COGN SCI, V8, P410, DOI 10.1016/j.tics.2004.07.009; Sachdev PS, 2005, AUST NZ J PSYCHIAT, V39, P757, DOI 10.1080/j.1440-1614.2005.01680.x; Saxena S, 2004, AM J PSYCHIAT, V161, P1038, DOI 10.1176/appi.ajp.161.6.1038; Stein DJ, 2006, METAB BRAIN DIS, V21, P267, DOI 10.1007/s11011-006-9021-6; SWEDO SE, 1992, ARCH GEN PSYCHIAT, V49, P690; Szeszko PR, 1999, ARCH GEN PSYCHIAT, V56, P913, DOI 10.1001/archpsyc.56.10.913; Talairach J, 1988, CO PLANAR STEREOTAXI; TEASDALE G, 1974, LANCET, V2, P81; ValleniBasile LA, 1996, J AM ACAD CHILD PSY, V35, P898, DOI 10.1097/00004583-199607000-00015; Vasa RA, 2004, BIOL PSYCHIAT, V55, P208, DOI 10.1016/S0006-3223(03)00708-X; Weiss LA, 2006, NAT GENET, V38, P218, DOI 10.1038/ng1726	55	42	46	0	8	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1091-4269			DEPRESS ANXIETY	Depress. Anxiety		2008	25	5					398	407		10.1002/da.20398			10	Psychology, Clinical; Psychiatry; Psychology	Psychology; Psychiatry	304UH	WOS:000256134100004	17957806				2021-06-18	
J	Iverson, GL; Kaarto, ML; Koehle, MS				Iverson, Grant L.; Kaarto, Michelle L.; Koehle, Michael S.			Normative data for the balance error scoring system: Implications for brain injury evaluations	BRAIN INJURY			English	Article						balance; postural stability; concussion; traumatic brain injury; military	POSTURAL STABILITY; MOTOR-PERFORMANCE; CONCUSSION; DEFICITS; INSTABILITY	Primary objective: Patients who sustain traumatic brain injuries can experience temporary or permanent deficits in static or dynamic balance. The Balance Error Scoring System (BESS) is a brief, easily-administered test of static balance that recently has been recommended for use with military personnel who do not recover rapidly from a mild traumatic brain injury. However, the test lacks normative reference values for healthy adults, which greatly limits its clinical usefulness. The purpose of this study is to provide normative data for healthy men and women across the lifespan. Methods: Community-dwelling adults (n = 589) between the ages of 20-69 (M = 49.75, SD = 10.81) were administered the BESS. They did not have significant medical, neurological or lower extremity problems that might have an adverse effect on balance. Results: There was no relation between BESS and height and a very small correlation between BESS and weight. There was a small correlation between BESS and waist girth and body mass index. BESS performance was similar in men and women. BESS scores were consistent across the age groups until the 50s, when they worsened. Normative reference values stratified by age groups are presented. Conclusions: These normative data provide a frame of reference for interpreting BESS performance in civilians and military personnel who sustain traumatic brain injuries and adults with diverse neurological problems.	[Iverson, Grant L.; Koehle, Michael S.] Univ British Columbia, Dept Psychiat, Vancouver, BC V6T 2A1, Canada; [Iverson, Grant L.] British Columbia Mental Hlth & Addict Serv, Vancouver, BC, Canada; [Iverson, Grant L.] Copeman Neurosci Ctr, Vancouver, BC, Canada; [Kaarto, Michelle L.; Koehle, Michael S.] Copeman Healthcare Ctr, Vancouver, BC, Canada	Iverson, GL (corresponding author), Univ British Columbia, Dept Psychiat, 2255 Wesbrook Mall, Vancouver, BC V6T 2A1, Canada.	giverson@interchange.ubc.ca	Koehle, Michael S/C-7850-2013	Koehle, Michael S/0000-0001-7026-8422; Iverson, Grant/0000-0001-7348-9570			Bressel E, 2007, J ATHL TRAINING, V42, P42; Campbell M, 2005, BRAIN INJURY, V19, P1095, DOI 10.1080/02699050500188898; Choy NL, 2003, J GERONTOL A-BIOL, V58, P525; Collins M. W., 2007, BRAIN INJURY MED PRI, P407; Docherty CL, 2006, CLIN J SPORT MED, V16, P203, DOI 10.1097/00042752-200605000-00003; *DVBIC, 2006, DEF VET BRAIN INJ CT; Era P, 2006, GERONTOLOGY, V52, P204, DOI 10.1159/000093652; Gagnon I, 1998, BRAIN INJURY, V12, P843, DOI 10.1080/026990598122070; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; Gidlow C, 2006, HLTH ED J, V65, P338, DOI [10.1177/0017896906069378, DOI 10.1177/0017896906069378, 10. 1177/0017896906069378]; Greenwald BD, 2001, J HEAD TRAUMA REHAB, V16, P238, DOI 10.1097/00001199-200106000-00003; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Hopman WM, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-150; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2007, BRAIN INJURY MED PRI, P333; Kaufman KR, 2006, MED ENG PHYS, V28, P234, DOI 10.1016/j.medengphy.2005.05.005; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Patel AV, 2007, J ATHL TRAINING, V42, P66; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Register-Mihalik J, 2007, CLIN J SPORT MED, V17, P282, DOI 10.1097/JSM.0b013e31804ca68a; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Rinne MB, 2006, J REHABIL MED, V38, P224, DOI 10.1080/16501970600582989; Susco TM, 2004, J ATHL TRAINING, V39, P241; Valovich TC, 2003, J ATHL TRAINING, V38, P51; VALOVICH TC, 2004, J ATHL TRAINING, V14, P287; Wardle J, 2002, AM J PUBLIC HEALTH, V92, P1299, DOI 10.2105/AJPH.92.8.1299; Wilkins JC, 2004, J ATHL TRAINING, V39, P156	28	42	42	1	11	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2008	22	2					147	152		10.1080/02699050701867407			6	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	258DW	WOS:000252849600005	18240043				2021-06-18	
J	Safaz, I; Alaca, R; Yasar, E; Tok, F; Yilmaz, B				Safaz, Ismail; Alaca, Ridvan; Yasar, Evren; Tok, Fatih; Yilmaz, Bilge			Medical complications, physical function and communication skills in patients with traumatic brain injury: A single centre 5-year experience	BRAIN INJURY			English	Article						traumatic brain injury; complication; epilepsy; pressure ulcer; incontinence	HETEROTOPIC OSSIFICATION; VENOUS THROMBOEMBOLISM; RISK-FACTORS; SWALLOWING DISORDERS; VERBAL IMPAIRMENT; REHABILITATION; HEAD; INCONTINENCE; SEIZURES; OUTCOMES	Objective: The aim of this retrospective study was to review the medical complications of patients with traumatic brain injury (TBI) who were followed in 2000-2006. Methods and procedures: The demographic data, functional and cognitive status of 116 persons with TBI were noted. The presence of communication problems, swallowing disturbances, urinary and faecal incontinence, pressure ulcer, deep venous thrombosis (DVT), post-traumatic seizure (PTS) and heterotopic ossification (HO) were recorded at first admission and follow-up. Main outcome and results: This study detected aphasia in 19.0%, dysarthria in 30.2%, dysphagia in 17.2%, pressure ulcers in 6.9% and DVT in 2.6% the our patients with TBI. Urinary and faecal incontinence on admission were 32.7% and 26.7%, respectively. Patients with incontinence had poorer cognitive function than those with normal continence. HO rate was 18.1% and the ambulation levels of patients with HO were worse than those without HO. PTS was seen in 13.8% of the patients on admission and this ratio increased to 21.6% during the follow-up. In these patients, the aetiological risk factors for PTS were gunshot and fall injuries. Conclusions: Considering the wide spectrum of complications, this study advocates that these persons with TBI should be followed promptly by a multidisciplinary team.	[Safaz, Ismail; Alaca, Ridvan; Yasar, Evren; Tok, Fatih; Yilmaz, Bilge] Turkish Armed Force Rehabil Ctr, Dept Phys Med & Rehabil, Gulhane Mil Med Acad, Ankara, Turkey	Safaz, I (corresponding author), TSK Rehabil Merkezi Bilkent Ankara, TR-06530 Ankara, Turkey.	safazi@yahoo.com	YILMAZ, Bilge/A-7428-2013; YILMAZ, Bilge/W-6481-2019	YILMAZ, Bilge/0000-0003-1173-9399; YILMAZ, Bilge/0000-0003-1173-9399			Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Aras MD, 2004, INT J REHABIL RES, V27, P257, DOI 10.1097/00004356-200412000-00001; Boake C, 2000, PHYS MED REHABILITAT, P1073; Chua K, 2003, BRAIN INJURY, V17, P469, DOI 10.1080/02699050210154268; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P1182, DOI 10.1016/S0003-9993(96)90145-8; Connolly JF, 1999, ARCH PHYS MED REHAB, V80, P1309, DOI 10.1016/S0003-9993(99)90035-7; Cullen N, 2007, BRAIN INJURY, V21, P215, DOI 10.1080/02699050701202027; Demir SO, 2006, J REHABIL MED, V38, P68, DOI 10.1080/16501970510041262; Denson K, 2007, AM J SURG, V193, P380, DOI 10.1016/j.amjsurg.2006.12.004; Elhan AH, 2005, J REHABIL MED, V37, P306, DOI 10.1080/16501970510037573; Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022; Foxx-Orenstein A, 2003, ARCH PHYS MED REHAB, V84, P231, DOI 10.1053/apmr.2003.50095; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; GARLAND DE, 1980, J BONE JOINT SURG AM, V62, P1143, DOI 10.2106/00004623-198062070-00012; Gil M, 1996, BRAIN INJURY, V10, P39, DOI 10.1080/026990596124700; Gordon WA, 2006, AM J PHYS MED REHAB, V85, P343, DOI 10.1097/01.phm.0000202106.01654.61; HOLDEN MK, 1984, PHYS THER, V64, P35, DOI 10.1093/ptj/64.1.35; Johns JS, 1999, J HEAD TRAUMA REHAB, V14, P269, DOI 10.1097/00001199-199906000-00007; Kurtoglu M, 2004, WORLD J SURG, V28, P807, DOI 10.1007/s00268-004-7295-6; Lai JM, 1997, BRAIN INJURY, V11, P331, DOI 10.1080/026990597123485; Mackay LE, 1999, ARCH PHYS MED REHAB, V80, P365, DOI 10.1016/S0003-9993(99)90271-X; Mazaux JM, 2001, J REHABIL MED, V33, P99; Morgan AS, 1999, J HEAD TRAUMA REHAB, V14, P454, DOI 10.1097/00001199-199910000-00006; MOSCATO BS, 1994, J NEUROPSYCH CLIN N, V6, P134; Safaz I, 2008, J NEUROSURG, V108, P370, DOI 10.3171/JNS/2008/108/2/0370; Safaz I, 2008, AM J PHYS MED REHAB, V87, P65, DOI 10.1097/PHM.0b013e31815b5b4d; SARNO MT, 1986, ARCH PHYS MED REHAB, V67, P400; SARNO MT, 1980, J NERV MENT DIS, V168, P685, DOI 10.1097/00005053-198011000-00008; Simonsen LL, 2007, INJURY, V38, P1146, DOI 10.1016/j.injury.2007.03.019; Teasell R, 2007, BRAIN INJURY, V21, P201, DOI 10.1080/02699050701201854; Temkin NR, 2001, EPILEPSIA, V42, P515, DOI 10.1046/j.1528-1157.2001.28900.x; VARGHESE G, 1992, PHYS MED REH CLIN N, V3, P407; Wagner AK, 2003, AM J PHYS MED REHAB, V82, P526, DOI 10.1097/00002060-200307000-00006; Wang YT, 2005, J COMMUN DISORD, V38, P231, DOI 10.1016/j.jcomdis.2004.12.001; WATANABE TK, 2001, PHYS MED REHABILITAT, V15, P283	35	42	43	0	24	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2008	22	10					733	739		10.1080/02699050802304714			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	347MJ	WOS:000259145400002	18720099				2021-06-18	
J	Anderson, V; Catroppa, C				Anderson, Vicic; Catroppa, Cathy			Memory outcome at 5 years post-childhood traumatic brain injury	BRAIN INJURY			English	Article						traumatic brain injury; children memory	CLOSED-HEAD-INJURY; WORKING-MEMORY; CHILDREN; RECOVERY; SEVERITY; MILD	Primary objective: This study seeks to extend previous findings by documenting memory performance in a sample of 70 children at 5 years post-injury. It was anticipated that increasing injury severity would be associated with decreased performance on working and complex memory tasks. It was also expected that injury severity would significantly predict memory, but that the time from insult to subsequent testing would be associated with an increased relationship to non-injury factors. Research design: Participants were assessed at 5 years post-injury, aged between 6-14 years, using measures of immediate, working and complex memory. Methods and procedures: The sample comprised 18 children who had sustained a severe TBI, 24 with a moderate TBI, 11 with a mild TBI and 17 healthy controls, matched for age, gender and socio-economic-status. Results: Results indicated that severe TBI was associated with decreased complex auditory-verbal memory performance, although children with TBI did not display impairment on immediate, working or complex visual-spatial memory. While injury severity significantly predicted complex memory outcome, non-injury factors failed to significantly predict either working or complex memory performance. Conclusions: Future research should be engineered towards further clarifying what influences recovery from childhood TBI in the elongated post-injury period.	[Anderson, Vicic; Catroppa, Cathy] Royal Childrens Hosp, Melbourne, Vic, Australia; [Anderson, Vicic; Catroppa, Cathy] Univ Melbourne, Parkville, Vic 3052, Australia; [Anderson, Vicic; Catroppa, Cathy] Murdoch Childrens Res Inst, Melbourne, Vic, Australia	Catroppa, C (corresponding author), Royal Childrens Hosp, Dept Psychol, Flemington Rd, Parkville, Vic 3052, Australia.	cathy.catroppa@mcri.edu.au					AMACHER AL, 1988, PEDIAT HEAD INJURY; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2001, BRAIN DAM B, P125; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Anderson V.A., 1997, NEUROPSYCHOLOGICAL A; Anderson VA, 2000, BRAIN INJURY, V14, P679; Andrewes D., 2001, NEUROPSYCHOLOGY THEO; Baddeley A, 1990, HUMAN MEMORY THEORY; BADDELEY A, 2000, HUMAN MEMMORY THEORY; BASSETT SS, 1990, J PEDIATR PSYCHOL, V15, P225, DOI 10.1093/jpepsy/15.2.225; Bigler ED, 1999, J HEAD TRAUMA REHAB, V14, P406, DOI 10.1097/00001199-199908000-00009; Catroppa C, 2002, BRAIN INJURY, V16, P369, DOI 10.1080/02699050110104444; D'Esposito M, 2000, EXP BRAIN RES, V133, P3, DOI 10.1007/s002210000395; DANIEL A, 1983, POWER PRIVILEDGE PRE; Dennis M, 2004, DEV NEUROPSYCHOL, V25, P1, DOI 10.1207/s15326942dn2501&2_1; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; Farmer JE, 1999, DEV NEUROPSYCHOL, V15, P269, DOI 10.1080/87565649909540749; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GONZALEZ LM, IN PRESS J INT NEURO; Harris JR, 1996, J COMMUN DISORD, V29, P79, DOI 10.1016/0021-9924(94)00035-2; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; Lehnung M, 2003, BRAIN INJURY, V17, P855, DOI 10.1080/0269905031000089369; LENNENBURG EH, 1967, BIOL FDN LANGUAGE; LEVIN H, 1988, NEUROPSYCHOLOGY, V8, P171; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; Levin HS, 2004, NEUROPSYCHOLOGY, V18, P240, DOI 10.1037/0894-4105.18.2.240; Levin HS, 2002, ANN NEUROL, V52, P82, DOI 10.1002/ana.10252; Lowther JL, 2004, ARCH CLIN NEUROPSYCH, V19, P105, DOI 10.1016/S0887-6177(02)00222-6; MILNER B, 1971, BRIT MED BULL, V27, P272, DOI 10.1093/oxfordjournals.bmb.a070866; Ong LC, 1998, J PAEDIATR CHILD H, V34, P363, DOI 10.1046/j.1440-1754.1998.00239.x; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; Roman MJ, 1998, J CLIN EXP NEUROPSYC, V20, P245, DOI 10.1076/jcen.20.2.245.1168; Roncadin C, 2004, DEV NEUROPSYCHOL, V25, P21; Rourke BP, 1983, CHILD NEUROPSYCHOLOG; Sheslow D., 1990, WIDE RANGE ASSESSMEN; Sparrow S., 1984, VINELAND ADAPTIVE BE; Tabachnick B.G., 2000, USING MULTIVARIATE S, V4th; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TEASDALE G, 1974, LANCET, V2, P81; Tranel D., 2002, HDB MEMORY DISORDERS; Vakil E, 2004, CHILD NEUROPSYCHOL, V10, P57, DOI 10.1080/09297040490911078; Ward H, 2002, J CLIN EXP NEUROPSYC, V24, P458, DOI 10.1076/jcen.24.4.458.1032; WECHSLER D, 1991, MAN WECHSLER INTELLI; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78	47	42	42	0	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	DEC	2007	21	13-14					1399	1409		10.1080/02699050701785070			11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	253AA	WOS:000252488200008	18066942				2021-06-18	
J	Venneti, S; Wagner, AK; Wang, G; Slagel, SL; Chen, X; Lopresti, BJ; Mathis, CA; Wiley, CA				Venneti, Sriram; Wagner, Amy K.; Wang, Guoji; Slagel, Susan L.; Chen, Xiangbal; Lopresti, Brian J.; Mathis, Chester A.; Wiley, Clayton A.			The high affinity peripheral benzodiazepine receptor ligand DAA1106 binds specifically to microglia in a rat model of traumatic brain injury: Implications for PET imaging	EXPERIMENTAL NEUROLOGY			English	Article						peripheral benzodiazepine receptor; microglia; PET imaging; traumatic brain injury; DAA1106; PK11195	POSITRON-EMISSION-TOMOGRAPHY; CONTROLLED CORTICAL IMPACT; MILD COGNITIVE IMPAIRMENT; IN-VIVO; ISCHEMIC-STROKE; ACTIVATED MICROGLIA; MULTIPLE-SCLEROSIS; PARKINSONS-DISEASE; PK11195 BINDING; MOUSE-BRAIN	Traumatic brain injury (TBI) is a significant cause of mortality, morbidity, and disability. Microglial activation is commonly observed in response to neuronal injury which, when prolonged, is thought to be detrimental to neuronal survival. Activated microglia can be labeled using PK11195, a ligand that binds the peripheral benzodiazepine receptor (PBR), receptors which are increased in activated microglia and sparse in the resting brain. We compared the binding properties of two PBR ligands PK11195 and DAA1106 in rats using the controlled cortical impact (CCI) model of experimental TBI. While both ligands showed relative increases with specific binding in the cortex ipsitateral to injury compared to the contralateral side, [H-3]DAA1106 showed higher binding affinity compared with [H-3](R)-PK11195. Combined immunohistochemistry and autoradiography in brain tissues near the injury site showed that [H-3]DAA1106 binding co-registered with activated microglia more than astrocytes. Further, increased [H-3]DAA1106-specific binding positively correlated with the degree of microglial activation, and to a lesser degree with reactive astrocytosis. Finally, in vivo administration of each ligand in rats with TBI showed greater retention of [C-11]DAA1106 compared to [C-11](R)-PK11195 at the site of the contusion as assessed by ex vivo autoradiography. These results in a rat model of TBI indicate that [C-11] DAA1106 binds with higher affinity to microglia when compared with PK11195, suggesting that [C-11]DAA1106 may represent a better ligand than [C-11](R)-PK11195 for in vivo PET imaging of activated microglia in TBI. (c) 2007 Elsevier Inc. All rights reserved.	Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Radiol, Pittsburgh, PA 15213 USA	Wiley, CA (corresponding author), Presbyterian Univ Hosp, Div Neuropathol, 200 Lothrop St A515, Pittsburgh, PA 15213 USA.	wiley1@pitt.edu			NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K08 HD040833, K08HD40833] Funding Source: Medline; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01 MH064921, K24 MH001717-08, R01 MH64921, R01 MH071151, K24 MH001717, R01 MH071151-03, K24 MH01717] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K08HD040833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH071151, R01MH064921, K24MH001717] Funding Source: NIH RePORTER		Banati RB, 2002, GLIA, V40, P206, DOI 10.1002/glia.10144; Banati RB, 2000, BRAIN, V123, P2321, DOI 10.1093/brain/123.11.2321; Bellander BM, 2004, J NEUROTRAUM, V21, P605, DOI 10.1089/089771504774129937; Beschorner R, 2002, ACTA NEUROPATHOL, V103, P541, DOI 10.1007/s00401-001-0503-7; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; BONTKE CF, 1996, PHYS MED REHABILITAT, P1027; Cagnin A, 2002, EUR NEUROPSYCHOPHARM, V12, P581, DOI 10.1016/S0924-977X(02)00107-4; Cagnin A, 2001, LANCET, V358, P461, DOI 10.1016/S0140-6736(01)05625-2; Casellas P, 2002, NEUROCHEM INT, V40, P475, DOI 10.1016/S0197-0186(01)00118-8; Chaki S, 1999, EUR J PHARMACOL, V371, P197, DOI 10.1016/S0014-2999(99)00118-1; Chen MK, 2004, BRAIN, V127, P1379, DOI 10.1093/brain/awh161; Culty M, 2001, DRUG DEVELOP RES, V52, P475, DOI 10.1002/ddr.1149; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; Debruyne JC, 2003, EUR J NEUROL, V10, P257, DOI 10.1046/j.1468-1331.2003.00571.x; Dihne M, 2001, BRAIN RES, V902, P178, DOI 10.1016/S0006-8993(01)02378-2; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dommergues MA, 2003, NEUROSCIENCE, V121, P619, DOI 10.1016/S0306-4522(03)00558-X; Engel S, 2000, ACTA NEUROPATHOL, V100, P313, DOI 10.1007/s004019900172; Fetler L, 2005, SCIENCE, V309, P392, DOI 10.1126/science.1114852; Gerhard A, 2000, NEUROREPORT, V11, P2957, DOI 10.1097/00001756-200009110-00025; Gerhard A, 2005, NEUROIMAGE, V24, P591, DOI 10.1016/j.neuroimage.2004.09.034; Gerhard A, 2006, NEUROBIOL DIS, V21, P404, DOI 10.1016/j.nbd.2005.08.002; GIORDANA MT, 1994, NEUROPATH APPL NEURO, V20, P163, DOI 10.1111/j.1365-2990.1994.tb01175.x; GROOM GN, 1995, J NUCL MED, V36, P2207; Hammoud DA, 2005, J NEUROVIROL, V11, P346, DOI 10.1080/13550280500187351; Igarashi T, 2001, EXP NEUROL, V172, P332, DOI 10.1006/exnr.2001.7820; Ikoma Y, 2007, J CEREBR BLOOD F MET, V27, P173, DOI 10.1038/sj.jcbfm.9600325; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Kuhlmann AC, 2000, J NEUROCHEM, V74, P1694, DOI 10.1046/j.1471-4159.2000.0741694.x; Maeda J, 2004, SYNAPSE, V52, P283, DOI 10.1002/syn.20027; Mankowski JL, 2003, J NEUROVIROL, V9, P94, DOI 10.1080/13550280390173283; MINTUN MA, 1984, ANN NEUROL, V15, P217, DOI 10.1002/ana.410150302; MYERS R, 1991, J CEREBR BLOOD F MET, V11, P314, DOI 10.1038/jcbfm.1991.64; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Okuyama S, 1999, LIFE SCI, V64, P1455, DOI 10.1016/S0024-3205(99)00079-X; Ouchi Y, 2005, ANN NEUROL, V57, P168, DOI 10.1002/ana.20338; Pappata S, 2000, NEUROLOGY, V55, P1052, DOI 10.1212/WNL.55.7.1052; Park LCH, 2001, MECH AGEING DEV, V123, P21, DOI 10.1016/S0047-6374(01)00336-0; Pavese N, 2006, NEUROLOGY, V66, P1638, DOI 10.1212/01.wnl.0000222734.56412.17; Pedersen MD, 2006, EUR J NEUROSCI, V24, P991, DOI 10.1111/j.1460-9568.2006.04975.x; PETITTABOUE MC, 1991, EUR J PHARMACOL, V200, P347, DOI 10.1016/0014-2999(91)90594-G; Polazzi E, 2002, REV NEUROSCIENCE, V13, P221; Price CJS, 2006, STROKE, V37, P1749, DOI 10.1161/01.STR.0000226980.95389.0b; RAMSAY SC, 1992, LANCET, V339, P1054, DOI 10.1016/0140-6736(92)90576-O; Rao VLR, 2000, EXP NEUROL, V161, P102, DOI 10.1006/exnr.1999.7269; Schuitemaker A, 2004, NEUROBIOL AGING, V25, pS286, DOI 10.1016/S0197-4580(04)80947-3; Schuitemaker A, 2006, NEUROIMAGE, V31, pT159, DOI 10.1016/j.neuroimage.2006.04.142; SHAH SP, 1995, ADV CEM BASED MATER, V2, P1, DOI 10.1016/1065-7355(95)90032-2; STEPHENSON DT, 1995, J NEUROSCI, V15, P5263; Stoll G, 1999, PROG NEUROBIOL, V58, P233, DOI 10.1016/S0301-0082(98)00083-5; Streit WJ, 1996, NEUROTOXICOLOGY, V17, P671; Streit WJ, 2000, TOXICOL PATHOL, V28, P28, DOI 10.1177/019262330002800104; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Turner MR, 2004, NEUROBIOL DIS, V15, P601, DOI 10.1016/j.nbd.2003.12.012; Venneti S, 2004, J CLIN INVEST, V113, P981, DOI 10.1172/JCI200420227; Versijpt J, 2005, MULT SCLER J, V11, P127, DOI 10.1191/1352458505ms1140oa; Vowinckel E, 1997, J NEUROSCI RES, V50, P345, DOI 10.1002/(SICI)1097-4547(19971015)50:2<345::AID-JNR22>3.0.CO;2-5; Wagner AK, 2002, NEUROSCI LETT, V334, P165, DOI 10.1016/S0304-3940(02)01103-5; Wiley CA, 2006, J NEUROVIROL, V12, P262, DOI 10.1080/13550280600873868; Zhang MR, 2003, NUCL MED BIOL, V30, P513, DOI 10.1016/S0969-8051(03)00016-7	62	42	44	0	9	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	SEP	2007	207	1					118	127		10.1016/j.expneurol.2007.06.003			10	Neurosciences	Neurosciences & Neurology	210TB	WOS:000249477400013	17658516	Green Accepted			2021-06-18	
J	Atkins, CM; Oliva, AA; Alonso, OF; Chen, S; Bramlett, HM; Hu, BR; Dietrich, WD				Atkins, Coleen M.; Oliva, Anthony A., Jr.; Alonso, Ofelia F.; Chen, Shaoyi; Bramlett, Helen M.; Hu, Bing-Ren; Dietrich, W. Dalton			Hypothermia treatment potentiates ERK1/2 activation after traumatic brain injury	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						CREB; fluid-percussion; hypothermia; ERK1/2; traumatic brain injury	SIGNAL-REGULATED KINASE; FOCAL CEREBRAL-ISCHEMIA; FLUID PERCUSSION INJURY; MEK1 PROTEIN-KINASE; MODERATE HYPOTHERMIA; MILD HYPOTHERMIA; CELL-DEATH; THERAPEUTIC HYPOTHERMIA; SYNAPTIC PLASTICITY; NEURONAL SURVIVAL	Traumatic brain injury (TBI) results in significant hippocampal pathology and hippocampal-dependent memory loss, both of which are alleviated by hypothermia treatment. To elucidate the molecular mechanisms regulated by hypothermia after TBI, rats underwent moderate parasagittal fluid-percussion brain injury. Brain temperature was maintained at normothermic or hypothermic temperatures for 30 min prior and up to 4 h after TBI. The ipsilateral hippocampus was assayed with Western blotting. We found that hypothermia potentiated extracellular signal-regulated kinase 1/2 (ERK1/2) activation and its downstream effectors, p90 ribosomal S6 kinase (p90RSK) and the transcription factor cAMP response element-binding protein. Phosphorylation of another p90RSK substrate, Bad, also increased with hypothermia after TBI. ERK1/2 regulates mRNA translation through phosphorylation of mitogen-activated protein kinase-interacting kinase 1 (Mnk1) and the translation factor eukaryotic initiation factor 4E (eIF4E). Hypothermia also potentiated the phosphorylation of both Mnk1 and eIF4E. Augmentation of ERK1/2 activation and its downstream signalling components may be one molecular mechanism that hypothermia treatment elicits to improve functional outcome after TBI.	Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Miami, FL 33136 USA; Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami, FL 33152 USA; Univ Miami, Miller Sch Med, Neurotrauma Res Ctr, Miami, FL 33152 USA; Univ Miami, Miller Sch Med, Dept Neurol, Neurochem Lab Brain Injury, Miami, FL 33152 USA	Dietrich, WD (corresponding author), Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, POB 016960 R-48, Miami, FL 33136 USA.	ddietrich@miami.edu		Atkins, Coleen/0000-0003-4718-7493	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS42133, NS30291] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042133, P50NS030291] Funding Source: NIH RePORTER		Alessandrini A, 1999, P NATL ACAD SCI USA, V96, P12866, DOI 10.1073/pnas.96.22.12866; Arthur JSC, 2004, J NEUROSCI, V24, P4324, DOI 10.1523/JNEUROSCI.5227-03.2004; Atkins CM, 1998, NAT NEUROSCI, V1, P602, DOI 10.1038/2836; Atkins CM, 2006, J CEREBR BLOOD F MET, V26, P1507, DOI 10.1038/sj.jcbfm.9600301; Atwal JK, 2000, NEURON, V27, P265, DOI 10.1016/S0896-6273(00)00035-0; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Bito H, 2003, CELL CALCIUM, V34, P425, DOI 10.1016/S0143-4160(03)00140-4; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Bramlett HM, 1997, BRAIN RES, V762, P195, DOI 10.1016/S0006-8993(97)00387-9; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Brodhun M, 2001, ACTA NEUROPATHOL, V101, P424; Carbonell WS, 1998, J NEUROTRAUM, V15, P217, DOI 10.1089/neu.1998.15.217; Chan EYW, 1999, J CLIN INVEST, V103, P1337, DOI 10.1172/JCI5474; CHEN S, 2006, J CEREB BLOOD FLOW M, V27, P939; Choi JS, 2006, NEUROSCI LETT, V409, P187, DOI 10.1016/j.neulet.2006.09.053; Chu CT, 2004, EUR J BIOCHEM, V271, P2060, DOI 10.1111/j.1432-1033.2004.04132.x; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; D'Cruz BJ, 2005, BRAIN RES, V1064, P108, DOI 10.1016/j.brainres.2005.09.052; D'Cruz BJ, 2002, J CEREBR BLOOD F MET, V22, P843, DOI 10.1097/00004647-200207000-00009; Dash PK, 2002, NEUROSCIENCE, V114, P755, DOI 10.1016/S0306-4522(02)00277-4; DASH PK, 1995, J NEUROSCI, V15, P2030; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Dietrich WD, 1996, ADV NEUROL, V71, P177; Dinocourt C, 2006, EUR J NEUROSCI, V24, P1857, DOI 10.1111/j.1460-9568.2006.05067.x; Dirnagl U, 2003, TRENDS NEUROSCI, V26, P248, DOI 10.1016/S0166-2236(03)00071-7; Dixon CE, 1998, J NEUROTRAUM, V15, P95, DOI 10.1089/neu.1998.15.95; Eberspacher E, 2005, ACTA ANAESTH SCAND, V49, P477, DOI 10.1111/j.1399-6576.2005.00649.x; Ferreira A, 2002, CELL MOL LIFE SCI, V59, P589, DOI 10.1007/s00018-002-8451-5; Fritz HG, 2004, J NEUROSURG ANESTH, V16, P43, DOI 10.1097/00008506-200401000-00009; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Gurjar MV, 2001, AM J PHYSIOL-HEART C, V281, pH2568; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Haranishi Y, 2005, EUR J ANAESTH, V22, P140, DOI 10.1017/S0265021505000268; Harrington DK, 2007, ANN THORAC SURG, V83, pS799, DOI 10.1016/j.athoracsur.2006.11.018; Hausenloy DJ, 2006, CARDIOVASC RES, V70, P240, DOI 10.1016/j.cardiores.2006.01.017; Hausenloy DJ, 2005, TRENDS CARDIOVAS MED, V15, P69, DOI 10.1016/j.tcm.2005.03.001; Hetman M, 2004, EUR J BIOCHEM, V271, P2050, DOI 10.1111/j.1432-1033.2004.04133.x; Hicks SD, 2000, NEUROSCIENCE, V98, P677, DOI 10.1016/S0306-4522(00)00169-X; Hu BR, 2004, J CEREBR BLOOD F MET, V24, P934, DOI 10.1097/01.WCB.0000125888.56462.A1; Jiang JY, 2007, CURR OPIN CRIT CARE, V13, P153, DOI 10.1097/MCC.0b013e32807f2a80; Jiang JY, 2006, J CEREBR BLOOD F MET, V26, P771, DOI 10.1038/sj.jcbfm.9600253; Kinouchi T, 2002, BIOL GROW ANIM, V1, P203, DOI 10.1016/S1877-1823(09)70123-7; Kline AE, 2002, BRAIN RES, V937, P22, DOI 10.1016/S0006-8993(02)02458-7; Kornhauser JM, 2002, NEURON, V34, P221, DOI 10.1016/S0896-6273(02)00655-4; Kulich SM, 2003, J BIOSCIENCES, V28, P83, DOI 10.1007/BF02970136; Kushner SA, 2005, J NEUROSCI, V25, P9721, DOI 10.1523/JNEUROSCI.2836-05.2005; LANGLOIS JA, 2004, TRAUMATIC BRAIN INJU, P1; Lee KH, 2005, J BIOL CHEM, V280, P13179, DOI 10.1074/jbc.M410059200; Levati A, 2007, J NEUROSURG ANESTH, V19, P25, DOI 10.1097/01.ana.0000211022.96054.4d; Lin C.A., 2001, MASS COMMUNICATION S, V4, P19, DOI DOI 10.1207/S15327825MCS0401_03; Lipski J, 2006, BRAIN RES, V1077, P187, DOI 10.1016/j.brainres.2006.01.016; Liu HQ, 2006, NEUROCHEM RES, V31, P967, DOI 10.1007/s11064-006-9102-2; Liu LP, 2007, FRONT BIOSCI-LANDMRK, V12, P816, DOI 10.2741/2104; Lotocki G, 2006, EUR J NEUROSCI, V24, P2283, DOI 10.1111/j.1460-9568.2006.05123.x; LYETH BG, 1993, J NEUROTRAUM, V10, P57, DOI 10.1089/neu.1993.10.57; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Maier CM, 1998, STROKE, V29, P2171, DOI 10.1161/01.STR.29.10.2171; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Mathias JL, 2005, BRAIN INJURY, V19, P271, DOI 10.1080/02699050400005028; Matsumoto T, 2006, MOL CELL NEUROSCI, V31, P70, DOI 10.1016/j.mcn.2005.09.002; Maxwell WL, 2003, J NEUROPATH EXP NEUR, V62, P272, DOI 10.1093/jnen/62.3.272; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Mizushima T, 2006, NEUROSCIENCE, V140, P1337, DOI 10.1016/j.neuroscience.2006.03.024; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Murray B, 1998, P NATL ACAD SCI USA, V95, P11975, DOI 10.1073/pnas.95.20.11975; Namura S, 2001, P NATL ACAD SCI USA, V98, P11569, DOI 10.1073/pnas.181213498; Nishimoto S, 2006, EMBO REP, V7, P782, DOI 10.1038/sj.embor.7400755; Otani N, 2002, J CEREBR BLOOD F MET, V22, P327, DOI 10.1097/00004647-200203000-00010; Pernet V, 2005, J NEUROCHEM, V93, P72, DOI 10.1111/j.1471-4159.2005.03002.x; Phanithi PB, 2000, NEUROPATHOLOGY, V20, P273, DOI 10.1046/j.1440-1789.2000.00346.x; Polderman KH, 2002, INTENS CARE MED, V28, P1563, DOI 10.1007/s00134-002-1511-3; Pyronnet S, 2000, BIOCHEM PHARMACOL, V60, P1237, DOI 10.1016/S0006-2952(00)00429-9; Qiu WS, 2006, J CLIN NEUROSCI, V13, P995, DOI 10.1016/j.jocn.2006.02.027; Raghupathi R, 2003, EXP NEUROL, V183, P438, DOI 10.1016/S0014-4886(03)00166-3; RESNICK DK, 1994, NEUROSURGERY, V34, P252, DOI 10.1227/00006123-199402000-00007; Rothoerl Ralf Dirk, 2006, Neurosurg Focus, V20, pE5; Sananbenesi F, 2002, MOL CELL NEUROSCI, V21, P463, DOI 10.1006/mcne.2002.1188; Shann F, 2003, LANCET, V362, P1950, DOI 10.1016/S0140-6736(03)15083-0; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Stanciu M, 2000, J BIOL CHEM, V275, P12200, DOI 10.1074/jbc.275.16.12200; Stenzel-Poore MP, 2007, STROKE, V38, P680, DOI 10.1161/01.STR.0000251444.56487.4c; Subramaniam S, 2003, J BIOL CHEM, V278, P8904, DOI 10.1074/jbc.M210037200; Suh SW, 2006, J CEREBR BLOOD F MET, V26, P161, DOI 10.1038/sj.jcbfm.9600176; Sweatt JD, 2001, J NEUROCHEM, V76, P1, DOI 10.1046/j.1471-4159.2001.00054.x; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Tan Y, 1999, J BIOL CHEM, V274, P34859, DOI 10.1074/jbc.274.49.34859; Truettner JS, 2005, MOL BRAIN RES, V138, P124, DOI 10.1016/j.molbrainres.2005.04.006; Vitarbo EA, 2004, NEUROSURGERY, V55, P416, DOI 10.1227/01.NEU.0000130036.52521.2C; Waltereit R, 2003, MOL NEUROBIOL, V27, P99, DOI 10.1385/MN:27:1:99; Wang XK, 2003, J PHARMACOL EXP THER, V304, P172, DOI 10.1124/jpet.102.040246; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Xu RX, 1998, NEUROSURGERY, V43, P107, DOI 10.1097/00006123-199807000-00070; Yaglom J, 2003, MOL CELL BIOL, V23, P3813, DOI 10.1128/MCB.23.11.3813-3824.2003; Zhang ZJ, 2001, MOL BRAIN RES, V95, P75, DOI 10.1016/S0169-328X(01)00247-9; Zhao H, 2005, J NEUROSCI, V25, P9794, DOI 10.1523/JNEUROSCI.3163-05.2005; Zhao H, 2005, J CEREBR BLOOD F MET, V25, P1119, DOI 10.1038/sj.jcbfm.9600111; Zhu JH, 2002, AM J PATHOL, V161, P2087, DOI 10.1016/S0002-9440(10)64487-2	100	42	44	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	AUG	2007	26	4					810	819		10.1111/j.1460-9568.2007.05720.x			10	Neurosciences	Neurosciences & Neurology	203GP	WOS:000248963400002	17666079				2021-06-18	
J	Dvorak, J; McCrory, P; Kirkendall, DT				Dvorak, Jiri; McCrory, Paul; Kirkendall, Donald T.			Head injuries in the female football player: incidence, mechanisms, risk factors and management	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; SOCCER INJURIES; EUROPEAN FOOTBALL; SEX-DIFFERENCES; CONCUSSION; STATEMENT; SEASON; LEAGUE	Although all injuries in sports are a concern for participants, head injuries are particularly troublesome because of the potential for long-term cognitive deficits. To prevent any specific injury, it is important to understand the basic frequency and incidence of injury and then the mechanism of injury. Once these are established, prevention programmes can be tested to see if the rate of injury changes. A primary problem with head injuries is recognising that the injury has occurred. Many athletes are not aware of the seriousness of concussive injury, thus this type of injury is probably under-reported. Once the diagnosis of a concussion is made, the next difficult decision is when to return a player to the game. These two management issues dominate the continuing development of understanding of concussive head injury. This paper explores the known gender differences between head injuries and highlights the areas that need to be considered in future research.	Schulthess Klin, Zurich, Switzerland; FIFA Med Assessment & Res Ctr, Zurich, Switzerland; Univ Melbourne, Ctr Hlth Exercise & Sports Med, Parkville, Vic 3052, Australia	Dvorak, J (corresponding author), Schulthess Klin, Zurich, Switzerland.	jiri.dvorak@kws.ch	McCrory, Paul/Q-8688-2019				Andersen TE, 2004, BRIT J SPORT MED, V38, P690, DOI 10.1136/bjsm.2003.009357; Arnason A, 1996, SCAND J MED SCI SPOR, V6, P40, DOI 10.1111/j.1600-0838.1996.tb00069.x; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Balestreri M, 2003, J NEUROSURG, V99, P616; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; EKSTRAND J, 1983, AM J SPORT MED, V11, P63, DOI 10.1177/036354658301100203; ENGSTROM B, 1991, AM J SPORT MED, V19, P372, DOI 10.1177/036354659101900408; Farace E, 2000, Neurosurg Focus, V8, pe6; Faude O, 2006, BRIT J SPORT MED, V40, P785, DOI 10.1136/bjsm.2006.027540; Faude O, 2005, AM J SPORT MED, V33, P1694, DOI 10.1177/0363546505275011; Fuller CW, 2004, AM J SPORT MED, V32, p43S, DOI 10.1177/0363546503261248; Fuller CW, 2004, AM J SPORT MED, V32, p28S, DOI 10.1177/0363546503261247; Fuller CW, 2006, BRIT J SPORT MED, V40, P193, DOI 10.1136/bjsm.2005.025270; Fuller CW, 2005, BRIT J SPORT MED, V39, pI3, DOI 10.1136/bjsm.2005.018937; Hawkins RD, 2001, BRIT J SPORT MED, V35, P43, DOI 10.1136/bjsm.35.1.43; Junge A, 2004, BRIT J SPORT MED, V38, P168, DOI 10.1136/bjsm.2002.003020; Junge A, 2002, AM J SPORT MED, V30, P652, DOI 10.1177/03635465020300050401; Junge A, 2004, AM J SPORT MED, V32, p23S, DOI 10.1177/0363546503261246; Kirkendall DT, 2001, J ATHL TRAINING, V36, P328; Kirkness Catherine J, 2004, Biol Res Nurs, V5, P299, DOI 10.1177/1099800404263050; Kraus J F, 2000, Neurosurg Focus, V8, pe5; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; MCCRORY P, 2003, AMJ, V327, P352; Morgan BE, 2001, AM J SPORT MED, V29, P426, DOI 10.1177/03635465010290040701; Ostenberg A, 2000, SCAND J MED SCI SPOR, V10, P279, DOI 10.1034/j.1600-0838.2000.010005279.x; Slewa-Younan S, 2004, ARCH PHYS MED REHAB, V85, P376, DOI 10.1016/j.apmr.2003.05.007; Soderman K, 2001, SCAND J MED SCI SPOR, V11, P299, DOI 10.1034/j.1600-0838.2001.110508.x; SULLIVAN JA, 1980, AM J SPORT MED, V8, P325, DOI 10.1177/036354658000800505; Tierney RT, 2005, MED SCI SPORT EXER, V37, P272, DOI 10.1249/01.MSS.0000152734.47516.AA	31	42	42	1	16	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	AUG	2007	41			1			I44	I46	i44-i46	10.1136/bjsm.2007.037960			3	Sport Sciences	Sport Sciences	193DM	WOS:000248254400009	17496069	Green Published			2021-06-18	
J	Ent, DV; Lehn, H; Derks, EM; Hudziak, JJ; Van Strien, NM; Veltman, DJ; De Geus, EJC; Todd, RD; Boomsma, DI				Ent, D. Van 't; Lehn, H.; Derks, E. M.; Hudziak, J. J.; Van Strien, N. M.; Veltman, D. J.; De Geus, E. J. C.; Todd, R. D.; Boomsma, D. I.			A structural MRI study in monozygotic twins concordant or discordant for attention/hyperactivity problems: Evidence for genetic and environmental heterogeneity in the developing brain	NEUROIMAGE			English	Article						twin study; anatomical MRI; VBM; attention and hyperactivity problems; ADHD; genetic risk factors; environmental risk factors	DEFICIT HYPERACTIVITY DISORDER; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; VOXEL-BASED MORPHOMETRY; OPERATING CHARACTERISTIC ANALYSIS; CHILD-BEHAVIOR CHECKLIST; CLOSED-HEAD INJURY; GRAY-MATTER; HYPERKINETIC DISORDER; UNAFFECTED SIBLINGS; EXECUTIVE FUNCTIONS	Several structural brain abnormalities have been reported in patients with Attention Deficit Hyperactivity Disorder (ADHD). However, the etiology of these brain changes is still unclear. To investigate genetic and environmental influences on ADHD related neurobiological changes, we performed Voxel-Based Morphometry on MRI scans from monozygotic (MZ) twins selected from a large longitudinal population database to be highly concordant or highly discordant for ratings on the Child Behavior Checklist Attention Problem scale (CBCL-AP). Children scoring low on the CBCL-AP are at low risk for ADHD, whereas children scoring high on this scale are at high-risk for ADHD. Brain differences between concordant high-risk twin pairs and concordant low-risk twin pairs likely reflect the genetic risk for ADHD; brain differences between the low-risk and high-risk twins from discordant MZ twin pairs reflect the environmental risk for ADRD. A major difference between comparisons of high and low-risk twins from concordant pairs and high/low twins from discordant pairs was found for the prefrontal lobes. The concordant high-risk pairs showed volume loss in orbitofrontal subdivisions. High-risk members from the discordant twin pairs exhibited volume reduction in the right inferior dorsolateral prefontal cortex. In addition, the posterior corpus callosum was compromised in concordant high-risk pairs, only. Our findings indicate that inattention and hyperactivity symptoms are associated with anatomical abnormalities of a distributed action-attentional network. Different brain areas of this network appear to be affected in in attention/hyperactivity caused by genetic (i.e., high concordant MZ pairs) vs. environmental (i.e., high-low discordant MZ pairs) risk factors. These results provide clues that further our understanding of brain alterations in ADHD. (C) 2007 Elsevier Inc. All rights reserved.	Vrije Univ Amsterdam, Dept Biol Psychol, NL-1081 BT Amsterdam, Netherlands; Norwegian Univ Sci & Technol, Dept Circulat & Med Imaging, N-7034 Trondheim, Norway; Univ Vermont, Dept Psychiat, Burlington, VT USA; VU Med Ctr, Dept Psychiat, Amsterdam, Netherlands; VU Med Ctr, Clin PET Ctr, Amsterdam, Netherlands; Washington Univ, Sch Med, Dept Psychiat, St Louis, MO USA	Ent, DV (corresponding author), Vrije Univ Amsterdam, Dept Biol Psychol, Van Boechorststr 1, NL-1081 BT Amsterdam, Netherlands.	d.vant.ent@psy.vu.nl	de Geus, Eco J.C./M-9318-2015; Derks, Eske M/A-1652-2017	de Geus, Eco J.C./0000-0001-6022-2666; Derks, Eske M/0000-0002-6292-6883; van 't Ent, Dennis/0000-0003-2001-1375	NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R21 MH66148-01, R01 MH058799, R21 MH066148, R01 MH58799-03, R21 MH066148-01] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R21MH066148, R01MH058799] Funding Source: NIH RePORTER		American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Ashburner J, 2000, NEUROIMAGE, V11, P805, DOI 10.1006/nimg.2000.0582; Ashburner J, 2001, NEUROIMAGE, V14, P1238, DOI 10.1006/nimg.2001.0961; Ashburner J, 1999, HUM BRAIN MAPP, V7, P254, DOI 10.1002/(SICI)1097-0193(1999)7:4<254::AID-HBM4>3.0.CO;2-G; Ashburner J, 1997, NEUROIMAGE, V6, P344, DOI 10.1006/nimg.1997.0299; Auerbach JG, 2001, PSYCHIATR GENET, V11, P31, DOI 10.1097/00041444-200103000-00006; Barkley RA, 1997, PSYCHOL BULL, V121, P65, DOI 10.1037/0033-2909.121.1.65; Bhutta AT, 2001, TRENDS NEUROSCI, V24, P129, DOI 10.1016/S0166-2236(00)01747-1; Boomsma DI, 2002, TWIN RES, V5, P401, DOI 10.1375/twin.5.5.401; Brookes KJ, 2006, ARCH GEN PSYCHIAT, V63, P74, DOI 10.1001/archpsyc.63.1.74; Carmona S, 2005, NEUROSCI LETT, V389, P88, DOI 10.1016/j.neulet.2005.07.020; Castellanos FX, 2002, JAMA-J AM MED ASSOC, V288, P1740, DOI 10.1001/jama.288.14.1740; Castellanos FX, 2006, TRENDS COGN SCI, V10, P117, DOI 10.1016/j.tics.2006.01.011; Castellanos FX, 2003, AM J PSYCHIAT, V160, P1693, DOI 10.1176/appi.ajp.160.9.1693; Castellanos FX, 1996, ARCH GEN PSYCHIAT, V53, P607; CHEN WJ, 1994, J CONSULT CLIN PSYCH, V62, P1017, DOI 10.1037/0022-006X.62.5.1017; DEGEUS EJ, 2006, BIOL PSYCHIAT; Derks EM, 2006, COMPR PSYCHIAT, V47, P116, DOI 10.1016/j.comppsych.2005.05.006; DERKS EM, 2006, UNPUB GENETIC ENV IN; Durston S, 2005, MOL PSYCHIATR, V10, P678, DOI 10.1038/sj.mp.4001649; Durston S, 2004, J AM ACAD CHILD PSY, V43, P332, DOI 10.1097/00004583-200403000-00016; Durston S, 2003, MENT RETARD DEV D R, V9, P184, DOI 10.1002/mrdd.10079; Eaves LJ, 2005, TWIN RES HUM GENET, V8, P283, DOI 10.1375/1832427054936736; Eslinger PJ, 2004, BRAIN COGNITION, V55, P84, DOI 10.1016/s0278-2626(03)00281-1; Faraone SV, 2006, PSYCHOL MED, V36, P159, DOI 10.1017/S003329170500471X; Filipek PA, 1997, NEUROLOGY, V48, P589, DOI 10.1212/WNL.48.3.589; Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102; Fuster JM, 2002, J NEUROCYTOL, V31, P373, DOI 10.1023/A:1024190429920; Gerring J, 2000, BRAIN INJURY, V14, P205; Giedd JN, 2001, ANN NY ACAD SCI, V931, P33; Giuliani NR, 2005, SCHIZOPHR RES, V74, P135, DOI 10.1016/j.schres.2004.08.019; Goldman LS, 1998, JAMA-J AM MED ASSOC, V279, P1100, DOI 10.1001/jama.279.14.1100; Good CD, 2001, NEUROIMAGE, V14, P21, DOI 10.1006/nimg.2001.0786; Herskovits EH, 1999, RADIOLOGY, V213, P389, DOI 10.1148/radiology.213.2.r99nv45389; Hesslinger B, 2002, NEUROSCI LETT, V328, P319, DOI 10.1016/S0304-3940(02)00554-2; Hill DE, 2003, NEUROPSYCHOLOGY, V17, P496, DOI 10.1037/0894-4105.17.3.496; Hudziak JJ, 2004, J CHILD PSYCHOL PSYC, V45, P1299, DOI 10.1111/j.1469-7610.2004.00314.x; Hudziak JJ, 2000, J AM ACAD CHILD PSY, V39, P469, DOI 10.1097/00004583-200004000-00016; Hudziak JJ, 2003, J AM ACAD CHILD PSY, V42, P357, DOI 10.1097/00004583-200303000-00017; Hudziak JJ, 2005, AM J PSYCHIAT, V162, P1614, DOI 10.1176/appi.ajp.162.9.1614; Huizink AC, 2006, NEUROSCI BIOBEHAV R, V30, P24, DOI 10.1016/j.neubiorev.2005.04.005; HUTTENLOCHER PR, 1979, BRAIN RES, V163, P195; Kahn RS, 2003, J PEDIATR-US, V143, P104, DOI 10.1016/S0022-3476(03)00208-7; Kates WR, 2002, PSYCHIAT RES-NEUROIM, V116, P63, DOI 10.1016/S0925-4927(02)00066-5; KRAIN AL, 2006, CLIN PSYCHOL REV; Kubicki M, 2002, NEUROIMAGE, V17, P1711, DOI 10.1006/nimg.2002.1296; Lehn H, 2007, J AM ACAD CHILD PSY, V46, P83, DOI 10.1097/01.chi.0000242244.00174.d9; Linnet KM, 2003, AM J PSYCHIAT, V160, P1028, DOI 10.1176/appi.ajp.160.6.1028; Lou HC, 2004, DEV MED CHILD NEUROL, V46, P179; LOU HC, 1989, ARCH NEUROL-CHICAGO, V46, P48, DOI 10.1001/archneur.1989.00520370050018; Lyoo IK, 1996, BIOL PSYCHIAT, V40, P1060; Max JE, 2005, J AM ACAD CHILD PSY, V44, P1032, DOI 10.1097/01.chi.0000173293.05817.b1; Max JE, 2002, J AM ACAD CHILD PSY, V41, P563, DOI 10.1097/00004583-200205000-00014; Max JE, 2005, J AM ACAD CHILD PSY, V44, P443, DOI 10.1097/01.chi.0000156661.38576.0f; Mesulam MM, 1998, BRAIN, V121, P1013, DOI 10.1093/brain/121.6.1013; Neuman RJ, 1999, J AM ACAD CHILD PSY, V38, P25, DOI 10.1097/00004583-199901000-00016; Overmeyer S, 2001, PSYCHOL MED, V31, P1425, DOI 10.1017/S0033291701004706; Pennington BF, 1996, J CHILD PSYCHOL PSYC, V37, P51, DOI 10.1111/j.1469-7610.1996.tb01380.x; Peterson BS, 2000, ARCH GEN PSYCHIAT, V57, P364, DOI 10.1001/archpsyc.57.4.364; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; Powell AL, 1997, NEUROPSY NEUROPSY BE, V10, P151; Rietveld MJH, 2004, J CHILD PSYCHOL PSYC, V45, P577, DOI 10.1111/j.1469-7610.2004.00247.x; Rietveld MJH, 2003, AM J MED GENET B, V117B, P102, DOI 10.1002/ajmg.b.10024; Schubert R, 2005, PEDIATR NEUROL, V32, P1, DOI 10.1016/j.pediatrneurol.2004.06.007; Seidman LJ, 2005, BIOL PSYCHIAT, V57, P1263, DOI 10.1016/j.biopsych.2004.11.019; Semrud-Clikeman M, 2000, J AM ACAD CHILD PSY, V39, P477, DOI 10.1097/00004583-200004000-00017; SEMRUDCLIKEMAN M, 1994, J AM ACAD CHILD PSY, V33, P875, DOI 10.1097/00004583-199407000-00014; Sergeant JA, 2002, BEHAV BRAIN RES, V130, P3, DOI 10.1016/S0166-4328(01)00430-2; Sowell ER, 2003, LANCET, V362, P1699, DOI 10.1016/S0140-6736(03)14842-8; Thapar A, 1999, BRIT J PSYCHIAT, V174, P105, DOI 10.1192/bjp.174.2.105; Ungerleider Leslie G., 1994, Current Opinion in Neurobiology, V4, P157, DOI 10.1016/0959-4388(94)90066-3; Vaidya CJ, 1999, MOL PSYCHIATR, V4, P206, DOI 10.1038/sj.mp.4000533; Verhulst F. C., 1996, HANDLEIDING CBCL 4 1; Voeller KKS, 2004, J CHILD NEUROL, V19, P798, DOI 10.1177/08830738040190100901; Wait JWV, 2002, J TROP PEDIATRICS, V48, P294, DOI 10.1093/tropej/48.5.294; Worsley KJ, 1996, HUM BRAIN MAPP, V4, P58, DOI 10.1002/(SICI)1097-0193(1996)4:1<58::AID-HBM4>3.0.CO;2-O; Worsley KJ, 1999, HUM BRAIN MAPP, V8, P98, DOI 10.1002/(SICI)1097-0193(1999)8:2/3<98::AID-HBM5>3.0.CO;2-F; ZAMETKIN AJ, 1990, NEW ENGL J MED, V323, P1361, DOI 10.1056/NEJM199011153232001	78	42	42	0	16	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119			NEUROIMAGE	Neuroimage	APR 15	2007	35	3					1004	1020		10.1016/j.neuroimage.2007.01.037			17	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	160PZ	WOS:000245956100003	17346990	Green Published, Green Accepted			2021-06-18	
J	Swaine, BR; Tremblay, C; Platt, RW; Grimard, G; Zhang, X; Pless, IB				Swaine, Bonnie R.; Tremblay, Camille; Platt, Robert W.; Grimard, Guy; Zhang, Xun; Pless, I. Barry			Previous head injury is a risk factor for subsequent head injury in children: A longitudinal cohort study	PEDIATRICS			English	Article; Proceedings Paper	6th World Congress on Brain Injury	MAY 06-08, 2005	Melbourne, AUSTRALIA			children; recurrence; injury; head trauma; rehabilitation	TRAUMATIC BRAIN-INJURY; CONCUSSION MANAGEMENT; ACCIDENT-PRONENESS; 2ND IMPACT; MILD; EPIDEMIOLOGY; CHILDHOOD; SEQUELAE; SPORTS; TRENDS	OBJECTIVE. The objective of this study was to determine whether children who sought care for a head injury were at greater risk of having a subsequent head injury within the following 6 and 12 months compared with children who sought care for an injury other than to the head. DESIGN/SETTING. This was a longitudinal cohort study conducted in the emergency departments of 2 Montreal (Quebec, Canada) pediatric hospitals. PARTICIPANTS. The parents of 11 867 injured children aged 1 to 18 years were interviewed by telephone at 6 (n = 10 315) and 12 (n = 9486) months after their child's injury to ascertain outcome (ie, subsequent head injury) and to provide information on potential risk factors (age, gender, chronic medical condition, activity level, and socioeconomic status). MAIN OUTCOME MEASURE. The outcome of interest was a head injury requiring medical attention within the following year ascertained by parental recall or physician claims data. RESULTS. A total of 245 and 386 previously head-injured children sustained a subsequent head injury within 6 and 12 months, respectively. Children who sought care for an initial head injury (n = 3599) were at higher risk of having a subsequent head injury within 6 months than children who sought care for an injury not to the head (n = 6716). The adjusted odds ratio suggested weak confounding by age, gender, and history of previous head injury. Results were consistent on the basis of physician claims data and 12-month follow-up interview data. CONCLUSIONS. These results provide evidence that having a head injury increases a child's risk of having a subsequent head injury. Although age, gender, and history of previous head injury confound the relationship, the effect remains substantial.	Univ Montreal, Fac Med, Ecole Readaptat, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Sch Rehabil, Montreal, PQ H3C 3J7, Canada; Inst Readaptat Montreal, Montreal Metropolitain, Ctr Rech Interdisciplinaire Readaptat, Montreal, PQ, Canada; McGill Univ, Dept Pediat, Montreal, PQ H3A 2T5, Canada; McGill Univ, Dept Epidemiol & Biostat, Montreal, PQ H3A 2T5, Canada; McGill Univ, Montreal Childrens Hosp, Res Inst, Ctr Hlth, Montreal, PQ H3H 1P3, Canada; Hop St Justine, Montreal, PQ H3T 1C5, Canada	Swaine, BR (corresponding author), Univ Montreal, Fac Med, Ecole Readaptat, CP 6128,Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada.	bonnie.swaine@umontreal.ca		Platt, Robert/0000-0002-5981-8443			ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; BIJUR P, 1988, AM J DIS CHILD, V142, P1307, DOI 10.1001/archpedi.1988.02150120061041; BIJUR PE, 1990, PEDIATRICS, V86, P337; BIJUR PE, 1988, PEDIATRICS, V82, P707; Breslow NE, 1987, DESIGN ANAL COHORT S, V2; Brudvik C, 2000, INJURY, V31, P761, DOI 10.1016/S0020-1383(00)00093-0; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; CASEY R, 1986, PEDIATRICS, V78, P497; CERNAN J, 1996, HEAD INJURY POSTCONC, P441; Conn JM, 2003, INJURY PREV, V9, P117, DOI 10.1136/ip.9.2.117; COX DR, 1972, J R STAT SOC B, V34, P187; Dowd MD, 1996, AM J PUBLIC HEALTH, V86, P929, DOI 10.2105/AJPH.86.7.929; EMINSON CJ, 1986, J EPIDEMIOL COMMUN H, V40, P170, DOI 10.1136/jech.40.2.170; Gagnon I, 2004, ARCH PHYS MED REHAB, V85, P444, DOI 10.1016/j.apmr.2003.06.014; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; GRONWALL D, 1975, LANCET, V2, P995; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P681, DOI 10.1016/0003-9993(93)90024-5; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; JORDAN BD, 1990, JAMA-J AM MED ASSOC, V263, P1670, DOI 10.1001/jama.263.12.1670; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; King NS, 1997, CLIN REHABIL, V11, P13, DOI 10.1177/026921559701100104; KLONOFF H, 1971, AM J PUBLIC HEALTH N, V61, P2405, DOI 10.2105/AJPH.61.12.2405; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; Kostylova A, 2005, INJURY PREV, V11, P186, DOI 10.1136/ip.2004.006585; LANDIS JR, 1977, BIOMETRICS, V33, P174; Mackenzie S G, 1999, Inj Prev, V5, P208; MANTEL N, 1959, J NATL CANCER I, V22, P719; McCrory P, 1999, BRIT J SPORT MED, V33, P136, DOI 10.1136/bjsm.33.2.136; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; McCrory PR, 1997, MED SCI SPORT EXER, V29, pS207; PARTINGTON MW, 1960, ARCH DIS CHILD, V35, P215, DOI 10.1136/adc.35.181.215; PICKETT W, 2003, PEDIATRICS 1, V111; PLESS IB, 2000, UNINTENTIONAL INJURI; RIVARA FP, 1982, AM J DIS CHILD, V136, P399, DOI 10.1001/archpedi.1982.03970410017003; RIVARA FP, 1994, PEDIATR ANN, V23, P12, DOI 10.3928/0090-4481-19940101-06; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; SCHEIDT PC, 1995, AM J PUBLIC HEALTH, V85, P932, DOI 10.2105/AJPH.85.7.932; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; SWAINE B, 2002, 6 WORLD C INJ PREV C; Swaine BR, 2001, J HEAD TRAUMA REHAB, V16, P292, DOI 10.1097/00001199-200106000-00008; Swaine BR, 2000, AM J PHYS MED REHAB, V79, P412, DOI 10.1097/00002060-200009000-00002; SWAINE BR, 1999, 3 WORLD C BRAIN INJ; WARREN D, 1989, Pediatric Emergency Care, V5, P83, DOI 10.1097/00006565-198906000-00003; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003	46	42	42	0	16	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	APR	2007	119	4					749	758		10.1542/peds.2006-1186			10	Pediatrics	Pediatrics	153BH	WOS:000245406200037	17403846				2021-06-18	
J	Swartz, KR; Fee, DB; Joy, KM; Roberts, KN; Sun, S; Scheff, NN; Wilson, ME; Scheff, SW				Swartz, Karin R.; Fee, Dominic B.; Joy, Kelly M.; Roberts, Kelly N.; Sun, Sophie; Scheff, Nicole N.; Wilson, Melinda E.; Scheff, Stephen W.			Gender differences in spinal cord injury are not estrogen-dependent	JOURNAL OF NEUROTRAUMA			English	Article						estrogen; gender; neuroprotection; neurotrauma; spinal cord injury	TRAUMATIC BRAIN-INJURY; FUNCTIONAL RECOVERY; RATING-SCALE; RATS; OUTCOMES; LESION; MODEL; 17-BETA-ESTRADIOL; EPIDEMIOLOGY; RECEPTOR	Recent attention has been given to gender differences in neurotrauma, and the anecdotal suggestion is that females have better outcomes than males, suggesting that circulating levels of estrogen (ED may be neuroprotective. In order to address this issue, both young adult male and ovariectomized female rats were subjected to a T10 spinal cord injury (SCI), and E2 levels were maintained at chronic, constant circulating levels. Animals were clinically evaluated for locomotor changes using the Basso-Beattie-Bresnahan (BBB) scoring system. Morphologic differences were evaluated with unbiased stereology. Data analysis failed to reveal any significant benefit for the E2 therapy in either males or females. We did find a non-estrogen-dependent difference between male and female rats in length of injury, and percent of spared tissue, with female outcomes more favorable. These results suggest that E-2 does not provide a viable therapy following SCI.	Univ Kentucky, Med Ctr, Dept Surg, Div Neurosurg, Lexington, KY 40536 USA; Univ Kentucky, Med Ctr, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA; Univ Kentucky, Med Ctr, Dept Neurol, Lexington, KY 40536 USA; Univ Kentucky, Med Ctr, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; Univ Kentucky, Med Ctr, Dept Physiol, Lexington, KY 40536 USA	Swartz, KR (corresponding author), Univ Kentucky, Med Ctr, Dept Surg, Div Neurosurg, 800 Rose St,MS108, Lexington, KY 40536 USA.	krswar2@email.uky.edu					Baker KA, 2005, J NEUROTRAUM, V22, P415, DOI 10.1089/neu.2005.22.415; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; BRACKEN MB, 1985, J NEUROSURG, V63, P704, DOI 10.3171/jns.1985.63.5.0704; Chaovipoch P, 2006, J NEUROTRAUM, V23, P830, DOI 10.1089/neu.2006.23.830; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Farooque M, 2006, SPINAL CORD, V44, P182, DOI 10.1038/sj.sc.3101816; Furlan JC, 2005, J NEUROTRAUM, V22, P368, DOI 10.1089/neu.2005.22.368; Greenwald BD, 2001, ARCH PHYS MED REHAB, V82, P1181, DOI 10.1053/apmr.2001.24891; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Gunnarsson T, 2003, CURR OPIN NEUROL, V16, P717, DOI 10.1097/00019052-200312000-00012; Hall ED, 2005, J NEUROTRAUM, V22, P669, DOI 10.1089/neu.2005.22.669; Hauben E, 2002, EUR J NEUROSCI, V16, P1731, DOI 10.1046/j.1460-9568.2002.02241.x; Johnson ME, 2000, MAYO CLIN PROC, V75, P921, DOI 10.4065/75.9.921; Maggi A, 2004, ANNU REV PHYSIOL, V66, P291, DOI 10.1146/annurev.physiol.66.032802.154945; Morrison Wynne E, 2004, Pediatr Crit Care Med, V5, P145, DOI 10.1097/01.PCC.0000112373.71645.2A; Nobunaga AI, 1999, ARCH PHYS MED REHAB, V80, P1372, DOI 10.1016/S0003-9993(99)90247-2; Pleym H, 2003, ACTA ANAESTH SCAND, V47, P241, DOI 10.1034/j.1399-6576.2003.00036.x; PRICE C, 1994, AM J EPIDEMIOL, V139, P37, DOI 10.1093/oxfordjournals.aje.a116933; Rabchevsky AG, 2000, EXP NEUROL, V164, P280, DOI 10.1006/exnr.2000.7399; Rabchevsky AG, 2003, J NEUROTRAUM, V20, P659, DOI 10.1089/089771503322144572; Rabchevsky AG, 2001, J NEUROTRAUM, V18, P513, DOI 10.1089/089771501300227314; Regan RF, 1997, BRAIN RES, V764, P133, DOI 10.1016/S0006-8993(97)00437-X; Scheff SW, 2002, J NEUROTRAUM, V19, P1251, DOI 10.1089/08977150260338038; Scheff SW, 2003, J NEUROTRAUM, V20, P179, DOI 10.1089/08977150360547099; Sipski ML, 2004, ARCH PHYS MED REHAB, V85, P1826, DOI 10.1016/j.apmr.2004.04.031; Slewa-Younan S, 2004, ARCH PHYS MED REHAB, V85, P376, DOI 10.1016/j.apmr.2003.05.007; Sribnick EA, 2005, J NEUROSCI RES, V82, P283, DOI 10.1002/jnr.20622; Sribnick EA, 2003, ANN NY ACAD SCI, V993, P125, DOI 10.1111/j.1749-6632.2003.tb07521.x; Starkey ML, 2005, EXP NEUROL, V195, P524, DOI 10.1016/j.expneurol.2005.06.017; Stein Donald G, 2003, Pediatr Rehabil, V6, P13, DOI 10.1080/1363849031000095279; TATOR CH, 1993, SURG NEUROL, V40, P207, DOI 10.1016/0090-3019(93)90069-D; Thornton JW, 2001, P NATL ACAD SCI USA, V98, P5671, DOI 10.1073/pnas.091553298; Vegeto E, 2001, J NEUROSCI, V21, P1809, DOI 10.1523/JNEUROSCI.21-06-01809.2001; Wilson ME, 2002, MECH AGEING DEV, V123, P593, DOI 10.1016/S0047-6374(01)00406-7; WISE PM, 1981, BIOL REPROD, V24, P820, DOI 10.1095/biolreprod24.4.820; Yune TY, 2004, J NEUROTRAUM, V21, P293, DOI 10.1089/089771504322972086	37	42	43	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2007	24	3					473	480		10.1089/neu.2006.0167			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	152RQ	WOS:000245379900004	17402853				2021-06-18	
J	Yan, HQ; Ma, XC; Chen, XB; Li, Y; Shao, LF; Dixon, CE				Yan, Hong Qu; Ma, Xiecheng; Chen, Xianybai; Li, Youming; Shao, Lifang; Dixon, C. Edward			Delayed increase of tyrosine hydroxylase expression in rat nigrostriatal system after traumatic brain injury	BRAIN RESEARCH			English	Article						immunohistochemistry; nigrostriatal; rat; traumatic brain injury (TBI); tyrosine hydroxylase (TH); western blot	CONTROLLED CORTICAL IMPACT; NEOSTRIATAL DOPAMINE NEURONS; WORKING-MEMORY DEFICITS; PARKINSONS-DISEASE; SUBSTANTIA-NIGRA; GENE-EXPRESSION; COMPENSATORY RESPONSE; FRONTAL-CORTEX; LESIONS; STRIATUM	Tyrosine hydroxylase (TH) is the key enzyme for synthesizing dopamine (DA) in dopaminergic neurons and its terminals. Emerging experimental and clinical evidence support the hypothesis of a disturbance in dopamine neurotransmission following traumatic brain injury (TBI). However, the effect of controlled cortical impact (CCI) injury on TH in the nigrostriatal system is currently unknown. To determine if there is an alteration in TH after CCI injury, we examined TH levels at 1 day, 7 days, and 28 days post-injury by utilizing a commercially available antibody specific to TH. Rats were anesthetized and surgically prepared for CCI injury (4 m/s, 3.2 mm) or sham surgery. Injured (N=6) and sham animals (N=6) were sacrificed and coronally sectioned (35 mu m thick) through the striatum and substantia nigra (SN) for immunohistochemistry. Additionally, semiquantitative measurements of TH protein in striatal and SN homogenates from injured (N=6) and sham (N=6) rats sacrificed at the appropriate time post-surgery were assessed using Western blot analysis. TH protein is bilaterally increased at 28 days post-injury in nigrostriatal system revealed by immunohistochemistry in injured rats compared to sham controls. Western blot analysis confirms the findings of immunohistochemistry in both striatum and SN. We speculate that the increase in TH in the nigrostriatal system may reflect a compensatory response of dopaminergic neurons to upregulate their synthesizing capacity and a delayed increase in the efficiency of DA neurotransmission after TBI. (c) 2006 Elsevier B.V. All rights reserved.	Univ Pittsburgh, Safar Ctr, Brain Trauma Res Ctr, Dept Neurosurg, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15260 USA	Dixon, CE (corresponding author), Univ Pittsburgh, Safar Ctr, Brain Trauma Res Ctr, Dept Neurosurg, 201 Hill Bldg,3434 5th Ave, Pittsburgh, PA 15260 USA.	dixonec@upmc.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 33150, R01 NS040125, R01 NS079061, R01 NS033150, NS 40125, NS 30318, R01 NS060672, P01 NS030318, P50 NS030318] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030318, P01NS030318, R01NS060672, R01NS040125, R01NS033150, P50NS030318, R01NS079061] Funding Source: NIH RePORTER		ANDEN NE, 1964, LIFE SCI, V3, P523, DOI 10.1016/0024-3205(64)90161-4; Backman L, 1997, BRAIN, V120, P2207, DOI 10.1093/brain/120.12.2207; BANKIEWICZ KS, 1990, J NEUROSURG, V72, P231, DOI 10.3171/jns.1990.72.2.0231; BERNHEIMER H, 1973, J NEUROL SCI, V20, P415, DOI 10.1016/0022-510X(73)90175-5; BERTLER A, 1959, ACTA PHYSIOL SCAND, V47, P350; BLANCHARD V, 1995, J NEUROCHEM, V64, P1669; Blanchard V, 1996, BRAIN RES, V709, P319, DOI 10.1016/0006-8993(95)01391-1; CARLSSON A, 1959, PHARMACOL REV, V11, P490; Dietrich WD, 1998, NEUROSURGERY, V43, P585, DOI 10.1097/00006123-199809000-00105; Ding YC, 2001, NEUROL RES, V23, P193, DOI 10.1179/016164101101198334; DIVAC I, 1967, J COMP PHYSIOL PSYCH, V63, P184, DOI 10.1037/h0024348; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Doder M, 1999, J NEUROL NEUROSUR PS, V66, P380, DOI 10.1136/jnnp.66.3.380; Donnemiller E, 2000, EUR J NUCL MED, V27, P1410, DOI 10.1007/s002590000308; DRAVID A, 1984, BRAIN RES, V311, P361, DOI 10.1016/0006-8993(84)90101-X; DUNNMEYNELL A, 1994, BRAIN RES, V660, P88, DOI 10.1016/0006-8993(94)90842-7; DunnMeynell AA, 1997, BRAIN RES, V761, P25, DOI 10.1016/S0006-8993(97)00210-2; FIANDACA MS, 1988, EXP NEUROL, V102, P76, DOI 10.1016/0014-4886(88)90080-5; FRIEDMAN JH, 1989, SOUTHERN MED J, V82, P543, DOI 10.1097/00007611-198905000-00002; FRITSCHY JM, 1992, J COMP NEUROL, V321, P421, DOI 10.1002/cne.903210309; GILAD GM, 1979, BRAIN RES, V160, P17, DOI 10.1016/0006-8993(79)90597-3; Goldstein LB, 2003, BRAIN INJURY, V17, P685, DOI 10.1080/0269905031000107179; GUTERMAN A, 1987, SPORTS MED, V4, P194, DOI 10.2165/00007256-198704030-00004; HIRSCH EC, 1990, ANN NEUROL, V27, P676, DOI 10.1002/ana.410270615; HOKFELT T, 1977, MED BIOL, V55, P21; HOKFELT T, 1976, MED BIOL, V54, P427; HOKFELT T, 1969, ACTA PHYSIOL SCAND, V76, P415, DOI 10.1111/j.1748-1716.1969.tb04488.x; HORNYKIEWICZ O, 1993, ADV NEUROL, V60, P140; HOWELLS DW, 1993, BRAIN RES, V622, P285, DOI 10.1016/0006-8993(93)90830-G; JAEGER CB, 1983, J COMP NEUROL, V218, P74, DOI 10.1002/cne.902180105; JOH TH, 1975, BRAIN RES, V85, P146, DOI 10.1016/0006-8993(75)91021-5; Joyce JN, 1997, MOVEMENT DISORD, V12, P885, DOI 10.1002/mds.870120609; Kampfl A, 1996, EUR J NEUROSCI, V8, P344, DOI 10.1111/j.1460-9568.1996.tb01218.x; KATZMAN R, 1971, BRAIN RES, V25, P579, DOI 10.1016/0006-8993(71)90462-8; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Kobori N, 2006, J NEUROSCI, V26, P4236, DOI 10.1523/JNEUROSCI.4687-05.2006; KOPIN IJ, 1993, ADV NEUROL, V60, P707; KORDOWER JH, 1991, ANN NEUROL, V29, P405, DOI 10.1002/ana.410290411; Levin HS, 1998, CURR OPIN NEUROL, V11, P643, DOI 10.1097/00019052-199812000-00006; Lotocki G, 2003, J CEREBR BLOOD F MET, V23, P1129, DOI 10.1097/01.WCB.0000086938.68719.E0; Mcallister TW, 2004, BRAIN INJURY, V18, P331, DOI 10.1080/02699050310001617370; MCINTOSH TK, 1994, J NEUROCHEM, V63, P1426; Miyoshi E, 2002, BRAIN RES BULL, V58, P41, DOI 10.1016/S0361-9230(02)00754-2; Muller U, 2000, J NEURAL TRANSM, V107, P303, DOI 10.1007/s007020050025; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; ONN SP, 1986, BRAIN RES, V376, P8, DOI 10.1016/0006-8993(86)90894-2; OTTO D, 1990, J NEUROSCI, V10, P1912; PASINETTI GM, 1992, MOL BRAIN RES, V13, P63, DOI 10.1016/0169-328X(92)90045-D; PICKEL VM, 1975, J HISTOCHEM CYTOCHEM, V23, P1, DOI 10.1177/23.1.234988; Pifl C, 2006, NEUROCHEM INT, V49, P519, DOI 10.1016/j.neuint.2006.03.013; PLUNKETT RJ, 1990, J NEUROSURG, V73, P918, DOI 10.3171/jns.1990.73.6.0918; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; Posmantur RM, 1996, J NEUROPATH EXP NEUR, V55, P68, DOI 10.1097/00005072-199601000-00007; PRZEDBORSKI S, 1991, BRAIN RES, V550, P231, DOI 10.1016/0006-8993(91)91323-S; Ragnarsson KT, 2002, RESTOR NEUROL NEUROS, V20, P103; Rinne JO, 2000, ARCH NEUROL-CHICAGO, V57, P470, DOI 10.1001/archneur.57.4.470; ROSIN DL, 1992, NEUROSCIENCE, V48, P831, DOI 10.1016/0306-4522(92)90271-3; Sasajima H, 2002, EUR J BIOCHEM, V269, P3596, DOI 10.1046/j.1432-1033.2002.03052.x; Soriano MA, 1997, NEUROBIOL DIS, V4, P376, DOI 10.1006/nbdi.1997.0166; TOMAC A, 1995, NATURE, V373, P335, DOI 10.1038/373335a0; Von Voigtlander P F, 1971, J Pharm Pharmacol, V23, P381; Wagner AK, 2005, J NEUROCHEM, V95, P457, DOI 10.1111/j.1471-4159.2005.03382.x; White NM, 2002, NEUROBIOL LEARN MEM, V77, P125, DOI 10.1006/nlme.2001.4008; Williams AJ, 2006, NEUROCHEM INT, V49, P106, DOI 10.1016/j.neuint.2006.03.018; Wilson MS, 2005, J NEUROSCI RES, V80, P85, DOI 10.1002/jnr.20419; Yan HQ, 2002, NEUROREPORT, V13, P1899, DOI 10.1097/00001756-200210280-00013; Yan HQ, 2001, NEUROREPORT, V12, P2323, DOI 10.1097/00001756-200108080-00009; Yan HQ, 2000, BRAIN RES, V887, P134, DOI 10.1016/S0006-8993(00)03002-X; Yao XL, 2006, NEUROSCI LETT, V409, P65, DOI 10.1016/j.neulet.2006.09.015	69	42	45	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	FEB 23	2007	1134	1					171	179		10.1016/j.brainres.2006.11.087			9	Neurosciences	Neurosciences & Neurology	142GZ	WOS:000244638700020	17196177	Green Accepted			2021-06-18	
J	Chu, BC; Millis, S; Arango-Lasprilla, JC; Hanks, R; Novack, T; Hart, T				Chu, Bong-Chul; Millis, Scott; Arango-Lasprilla, Juan Carlos; Hanks, Robin; Novack, Thomas; Hart, Tessa			Measuring recovery in new learning and memory following traumatic brain injury: A mixed-effects modeling approach	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							HEAD-INJURY; PREDICTION; AWARENESS; 1-YEAR; LEVEL	Patterns of recovery from traumatic brain injury ( TBI) vary greatly across individuals. Using archival data from the Traumatic Brain Injury Model Systems, recovery of memory following TBI as measured by scores on the Rey Auditory Verbal Learning Test ( RAVLT) through 5 years postinjury was examined via mixed-effects modeling. Individual-level variables of age and posttraumatic amnesia duration were significant predictors of 1-year RAVLT total score. None of the variables examined predicted the trajectory of memory recovery after 1 year. Mixed-effects analyses can be helpful in determining the effect of intervention while allowing for missing data across time points.	Medstat Grp, Santa Barbara, CA USA; Wayne State Univ, Sch Med, Detroit, MI USA; Univ Med & Dent New Jersey, Dept Phys Med & Rehabil, W Orange, NJ 07052 USA; Kessler Med Rehabil Res & Educ Corp, W Orange, NJ USA; Univ Alabama Birmingham, Rehabil Inst Med, Birmingham, AL USA; Moss Rehabil Res Inst, Philadelphia, PA USA	Chu, BC (corresponding author), 5425 Hollister Ave,Suite 140, Santa Barbara, CA 93111 USA.	bongchul.chu@thomson.com					BOAKE C, 1995, BRAIN INJURY, V9, P273, DOI 10.3109/02699059509008198; Bushnik T, 2003, ARCH PHYS MED REHAB, V84, P151, DOI 10.1053/apmr.2003.50123; De Guise E, 2005, BRAIN INJURY, V19, P1087, DOI 10.1080/02699050500149882; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; DRUDGE OW, 1984, J CLIN PSYCHOL, V40, P259, DOI 10.1002/1097-4679(198401)40:1<259::AID-JCLP2270400149>3.0.CO;2-C; FINLAYSON MAJ, 1977, J CONSULT CLIN PSYCH, V45, P536, DOI 10.1037/0022-006X.45.4.536; FRANCIS DJ, 1991, J CONSULT CLIN PSYCH, V59, P27, DOI 10.1037/0022-006X.59.1.27; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P1030, DOI 10.1016/S0003-9993(99)90056-4; Kelly MP, 1997, BRAIN INJURY, V11, P391, DOI 10.1080/026990597123386; Lee D, 2004, REHABIL PSYCHOL, V49, P167, DOI 10.1037/0090-5550.49.2.167; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1982, NEUROBEHAV CONSEQUEN; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; McKinlay W, 1999, REHABILITATION ADULT, V3, P74; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Powell J B, 1991, Arch Clin Neuropsychol, V6, P241, DOI 10.1016/0887-6177(91)90001-P; Raudenbush SW., 2002, HIERARCHICAL LINEAR, V2nd ed; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Singer J.D., 2003, APPL LONGITUDINAL DA; Sohlberg M. M., 2001, COGNITIVE REHABILITA; Spikman JM, 1999, J CLIN EXP NEUROPSYC, V21, P585, DOI 10.1076/jcen.21.5.585.874; Stern Y, 2002, J INT NEUROPSYCH SOC, V8, P448, DOI 10.1017/S1355617702813248; THOMPSON NM, 1994, NEUROPSYCHOLOGY, V8, P333, DOI DOI 10.1037/0894-4105.8.3.333; Wong PP, 2001, BRAIN INJURY, V15, P519, DOI 10.1080/02699050010005995; Zwaagstra R, 1996, J CLIN EXP NEUROPSYC, V18, P383, DOI 10.1080/01688639608408995	28	42	42	0	11	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2007	29	6					617	625		10.1080/13803390600878893			9	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	208ZS	WOS:000249358500005	17691034				2021-06-18	
J	Pang, BC; Kuralmani, V; Joshi, R; Yin, HL; Lee, KK; Ang, BT; Li, JY; Leong, TY; Ng, I				Pang, Boon Chuan; Kuralmani, Vellaisamy; Joshi, Rohit; Yin Hongli; Lee, Kah Keow; Ang, Beng Ti; Li, Jinyan; Leong, Tze Yun; Ng, Ivan			Hybrid outcome prediction model for severe traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						adult brain injury; assessment tools; Bayesian network; decision tree; discriminant analysis; human studies; logistic regression; neural network; outcome measures; traumatic brain injuries	SEVERE HEAD-INJURY; VARIABLES; PROGNOSIS; CLASSIFICATION; TREE	Numerous studies addressing different methods of head injury prognostication have been published. Unfortunately, these studies often incorporate different head injury prognostication models and study populations, thus making direct comparison difficult, if not impossible. Furthermore, newer artiricial intelligence tools such as machine learning methods have evolved in the field of data analysis, alongside more traditional methods of analysis. This study targets the development of a set of integrated prognostication model combining different classes of outcome and prognostic factors. Methodologies such as discriminant analysis, logistic regression, decision tree, Bayesian network, and neural network were employed in the study. Several prognostication models were developed using prospectively collected data from 513 severe closed head-injured patients admitted to the Neurocritical Unit at National Neuroscience Institute of Singapore, from April 1999 to February 2003. The correlation between prognostic factors at admission and outcome at 6 months following injury was studied. Overritting error, which may falsely distinguish different outcomes, was compared graphically. Tenfold cross-validation technique, which reduces overfitting error, was used to validate outcome prediction accuracy. The overall prediction accuracy achieved ranged from 49.79% to 81.49%. Consistently high outcome prediction accuracy was seen with logistic regression and decision tree. Combining both logistic regression and decision tree models, a hybrid prediction model was then developed. This hybrid model would more accurately predict the 6-month post-severe head injury outcome using baseline admission parameters.	Natl Inst Neurosci, Dept Neurosurg, Acute Brain Injury Res Lab, Singapore 308433, Singapore; Inst Infocomm Res, Knowledge Discovery Dept, Data Mining Lab, Singapore, Singapore; Natl Univ Singapore, Sch Comp, Dept Comp Sci, Singapore 117548, Singapore	Ng, I (corresponding author), Natl Inst Neurosci, Dept Neurosurg, Acute Brain Injury Res Lab, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore.	ivan_ng@nni.com.sg	LEONG, Tze Yun/H-1142-2015; Yin, Hong/AAC-5784-2020	Leong, Tze Yun/0000-0002-1139-803X; Li, Jinyan/0000-0003-1833-7413			ABDELMONEN A, 2004, DISCRIMINANT ANAL CO; BOWERS SA, 1980, NEUROSURGERY, V6, P237; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; *BRAIN TRAUM FDN, 2002, MAN PROGN SEV TRAUM; Bullock Ross, 1996, Journal of Neurotrauma, V13, P639; CHENG J, 1997, P 6 ACM INT C INF KN; CHOI SC, 1994, J NEUROSURG, V81, P169, DOI 10.3171/jns.1994.81.2.0169; CHOI SC, 1983, J NEUROSURG, V59, P294, DOI 10.3171/jns.1983.59.2.0294; CHOI SC, 1991, J NEUROSURG, V75, P251, DOI 10.3171/jns.1991.75.2.0251; CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; CHOI SC, 1996, NEUROTRAUMA, V53, P779; CLIFTON GL, 1992, NEUROSURGERY, V31, P975, DOI 10.1227/00006123-199211000-00028; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; Gomez PA, 2000, ACTA NEUROCHIR, V142, P373, DOI 10.1007/s007010050445; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; JENNETT B, 1975, LANCET, V1, P480; Kelly DF, 1999, TRAUMATIC BRAIN INJU, P67; Langlois JA., 2004, TRAUMATIC BRAIN INJU; LOKKEBERG AR, 1984, J NEUROSURG, V61, P254, DOI 10.3171/jns.1984.61.2.0254; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; Marshall RM, 1991, APPL STAT-J ROY ST C, V40, P283; Morrison DF, 1990, MULTIVARIATE STAT ME; Mukherjee K, 2000, NEUROL INDIA, V48, P43; Ng I., 1998, Annals Academy of Medicine Singapore, V27, P332; OVERGAARD J, 1973, LANCET, V2, P631; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Pillai SV, 2003, NEUROL INDIA, V51, P345; Quinlan J. R., 1986, Machine Learning, V1, P81, DOI 10.1007/BF00116251; Rovlias A, 2004, J NEUROTRAUM, V21, P886, DOI 10.1089/0897715041526249; *SAS I INC, 2006, ENT MIN 9 1; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; *SPSS INC, 2006, SPSS 12 0 WIND; STABLEIN DM, 1980, NEUROSURGERY, V6, P243; Steinberg D, 1995, CART TREE STRUCTURED; Steinberg D., 1997, CART CLASSIFICATION; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Thurman DJ, 1999, TRAUMATIC BRAIN INJU; Wilson WJ, 2002, J NEUROSURG, V97, P1062, DOI 10.3171/jns.2002.97.5.1062; YONO J, 2001, J CLIN NUEUROSCI, V8, P120	41	42	43	0	5	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JAN	2007	24	1					136	146		10.1089/neu.2006.0113			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	131GX	WOS:000243858100013	17263677				2021-06-18	
J	Jiang, Y; Sun, XC; Xia, YX; Tang, WY; Cao, YQ; Gu, YJ				Jiang, Yong; Sun, Xiaochuan; Xia, Yuxian; Tang, Wenyuan; Cao, Yueqing; Gu, Yingjiang			Effect of APOE polymorphisms on early responses to traumatic brain injury	NEUROSCIENCE LETTERS			English	Article						APOE; polymorphism; traumatic brain injury; early response	APOLIPOPROTEIN-E GENOTYPE; HEAD-INJURY; E EPSILON-4; ASSOCIATION; RECOVERY; DEPOSITION; ALLELE; E4	To investigate the relationship between apolipoprotein E (APOE) polymorphisms and the severity of traumatic brain injury (TBI) in acute stage in the cohort of mainland Chinese patients. We prospectively identified admissions to the two neurosurgical departments for head injury. A total of 110 subjects with TBI (80 males and 30 females, with mean age of 43.87 years) were enrolled from December 2003 to May 2004, and demographic and clinical data were collected. Venous blood was collected from patients with TBI on admission to determine the APOE genotype polymorphisms. The APOE genotyping was performed by means of PCR-RFLP. The deterioration of patients' condition in acute stage (< 7 days after TBI) was judged by either of following criteria: decrease of GCS, increase in hematoma volume or delayed hematoma both detected by repeated CT scanning. chi(2)-test and logistic regression analyses were done by SPSS. The distributions of APOE genotypes and alleles matched Hardy-Weinberg law. In I 10 Chinese patients, 19 subjects presented with deteriorated clinical condition after hospitalization, and seven of 17 patients with APOE epsilon 4 (41.2%) had a deteriorated condition which was significantly different from those without APOE epsilon 4 (12 of 93 patients, 119%, P = 0.01). However, neither the presence of epsilon 2 nor of epsilon 3 was significantly different from those absent of it (P > 0.05). Logistic regression analyses showed that APOE epsilon 4 was a risk factor (OR = 4.836, P = 0.011, 95% CI 1.443-16.208) to predispose to clinical deterioration after adjusting for patient age, sex, smoking or not, alcohol-drinking or not, injury severity, injury mechanisms, treatments, and pattern of TBI. This finding suggests that the patients with APOE epsilon 4 predispose to clinical deterioration in acute phase after TBI and APOE polymorphisms play a role in early responses to TBI. (c) 2006 Elsevier Ireland Ltd. All rights reserved.	Chongqing Univ Med Sci, Dept Neurosurg, Affiliated Hosp 1, Chongqing 400016, Peoples R China; Luzhou Med Coll, Dept Neurosurg, Affiliated Hosp 1, Luzhou 646000, Peoples R China; Chongqing Univ, Ctr Gene Res, Chongqing 400044, Peoples R China	Sun, XC (corresponding author), Chongqing Univ Med Sci, Dept Neurosurg, Affiliated Hosp 1, Chongqing 400016, Peoples R China.	sunxch1445@gmail.com		sun, xiao chuan/0000-0001-6992-332X			ALLSOP D, 1990, AM J PATHOL, V136, P255; Chamelian L, 2004, BRAIN, V127, P2621, DOI 10.1093/brain/awh296; Chiang MF, 2003, ACTA NEUROCHIR, V145, P649, DOI 10.1007/s00701-003-0069-3; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Graham DI, 1999, ACT NEUR S, V73, P89; GRAVES AB, 1990, AM J EPIDEMIOL, V131, P491, DOI 10.1093/oxfordjournals.aje.a115523; Horsburgh K, 2000, NEUROBIOL AGING, V21, P245, DOI 10.1016/S0197-4580(00)00097-X; Liaquat I, 2002, J NEUROSURG, V96, P90, DOI 10.3171/jns.2002.96.1.0090; Liberman JN, 2002, NEUROLOGY, V58, P1038, DOI 10.1212/WNL.58.7.1038; Lichtman SW, 2000, NEUROLOGY, V55, P1536, DOI 10.1212/WNL.55.10.1536; Lynch JR, 2002, ANN NEUROL, V51, P113, DOI 10.1002/ana.10098; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Mauch DH, 2001, SCIENCE, V294, P1354, DOI 10.1126/science.294.5545.1354; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; McCarron MO, 2003, ACTA NEUROL SCAND, V107, P106, DOI 10.1034/j.1600-0404.2003.01365.x; Methia N, 2001, MOL MED, V7, P810, DOI 10.1007/BF03401973; Millar K, 2003, J NEUROL NEUROSUR PS, V74, P1047, DOI 10.1136/jnnp.74.8.1047; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; Nathoo N, 2003, J NEUROSURG, V98, P302, DOI 10.3171/jns.2003.98.2.0302; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; SHEARER MJ, 1995, LANCET, V345, P229, DOI 10.1016/S0140-6736(95)90227-9; Smith C, 2006, J NEUROL NEUROSUR PS, V77, P363, DOI 10.1136/jnnp.2005.074617; Sundstrom A, 2004, NEUROLOGY, V62, P1963, DOI 10.1212/01.WNL.0000129268.83927.A8; Teasdale GM, 2005, BRAIN, V128, P2556, DOI 10.1093/brain/awh595; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Tolar M, 1999, J NEUROSCI, V19, P7100, DOI 10.1523/JNEUROSCI.19-16-07100.1999; WENHAM PR, 1991, LANCET, V337, P1158, DOI 10.1016/0140-6736(91)92823-K; White F, 2001, EXP NEUROL, V169, P307, DOI 10.1006/exnr.2001.7655	32	42	58	0	5	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	NOV 13	2006	408	2					155	158		10.1016/j.neulet.2006.08.082			4	Neurosciences	Neurosciences & Neurology	102SW	WOS:000241834600016	16997460				2021-06-18	
J	Chibbaro, S; Tacconi, L				Chibbaro, S.; Tacconi, L.			Orbito-cranial injuries caused by penetrating non-missile foreign bodies. Experience with eighteen patients	ACTA NEUROCHIRURGICA			English	Article						non missile; orbito-facial; orbito-cranial; penetrating; angiography; cranio-cerebral	ANEURYSM SECONDARY; CRANIOCEREBRAL INJURIES; COMPUTED-TOMOGRAPHY; TRAUMATIC ANEURYSMS; INTRACRANIAL NAIL; BRAIN-ABSCESS; HEAD-INJURY; WOUNDS; PENCIL; WOOD	Background. Penetrating non-missile orbito-cranial injuries are uncommon civilian injuries which have some special features. Only limited case-reports are available in the international literature. Method. We present a retrospective review of 18 such in presumed trivial orbital injury. Early identification and removal of retained foreign body fragments was achieved within 36 hours. Findings. Patients were operated on and followed up for at least of 3 years. The final clinical outcome was excellent: 16 had a Glasgow Outcome Scale (GOS) of 5 while in the remaining 2 it was 4. Conclusion. The present report indicates that good results, in managing such injuries, can be achieved by a high index of suspicion and early diagnosis of intracranial injury in presumed trivial wounds and by the removal of every possible retained foreign body.	Univ Hosp Trieste, Dept Neurosurg, I-34100 Trieste, Italy	Chibbaro, S (corresponding author), Univ Hosp Trieste, Dept Neurosurg, Strada Fiume 447, I-34100 Trieste, Italy.	schibbaro@hotmail.com	Chibbaro, Salvatore/AAI-6368-2020	chibbaro, salvatore/0000-0003-1318-1245; tacconi, leonello/0000-0003-3915-5635			ACOSTA C, 1972, J NEUROSURG, V36, P531, DOI 10.3171/jns.1972.36.5.0531; Amirjamshidi A, 1996, J NEUROSURG, V84, P769, DOI 10.3171/jns.1996.84.5.0769; ASKENASY HM, 1961, J NEUROSURG, V18, P554, DOI 10.3171/jns.1961.18.4.0554; BAKAY L, 1977, ACTA NEUROCHIR, V39, P219, DOI 10.1007/BF01406732; BRAUN J, 1987, J COMPUT ASSIST TOMO, V11, P525, DOI 10.1097/00004728-198705000-00030; BURSICK DM, 1981, SURG NEUROL, V16, P427, DOI 10.1016/0090-3019(81)90235-4; Buxton N, 1997, J R Army Med Corps, V143, P112; CAROTHERS A, 1978, JAMA-J AM MED ASSOC, V239, P1151, DOI 10.1001/jama.239.12.1151; CHADDUCK WM, 1969, J NEUROSURG, V31, P77, DOI 10.3171/jns.1969.31.1.0077; CHAPMAN PH, 1985, CONCEPTS PEDIAT NEUR, V5, P1; CHAUDHRI KA, 1994, ACTA NEUROCHIR, V126, P120, DOI 10.1007/BF01476420; CLARK EC, 1986, J NEUROSURG, V6, P9; DOOLING JA, 1967, J NEUROSURG, V26, P636, DOI 10.3171/jns.1967.26.6.0636; DOUCET TW, 1983, ANN OPHTHALMOL, V15, P325; DUFFY GP, 1969, BRIT J SURG, V56, P685, DOI 10.1002/bjs.1800560912; DUJOVNY M, 1975, J TRAUMA, V15, P981, DOI 10.1097/00005373-197511000-00007; DUTREVOU MD, 1992, NEUROSURGERY, V31, P905, DOI 10.1227/00006123-199211000-00012; FANNING WL, 1976, J TRAUMA, V16, P919, DOI 10.1097/00005373-197611000-00011; FERRY DJ, 1972, J NEUROSURG, V36, P503, DOI 10.3171/jns.1972.36.4.0503; FOX JL, 1971, ACTA NEUROCHIR, V24, P315, DOI 10.1007/BF01405415; FOY P, 1980, LANCET, V2, P662; GLATT HJ, 1990, OPHTHALMIC PLAST REC, V6, P108, DOI 10.1097/00002341-199006000-00005; GREEN BF, 1990, OPHTHALMOLOGY, V97, P608; GREENE KA, 1993, SURG NEUROL, V40, P499, DOI 10.1016/0090-3019(93)90054-5; GUTHKELCH AN, 1960, BMJ-BRIT MED J, V5202, P842; HADDAD FS, 1991, NEUROSURGERY, V28, P1; HANSEN JE, 1988, J NEUROSURG, V68, P752, DOI 10.3171/jns.1988.68.5.0752; HORNER FA, 1964, NEW ENGL J MED, V271, P342, DOI 10.1056/NEJM196408132710703; IDE CH, 1971, AM J OPHTHALMOL, V71, P1037, DOI 10.1016/0002-9394(71)90571-X; Kahler RJ, 1998, NEUROSURGERY, V42, P1370, DOI 10.1097/00006123-199806000-00108; KAISER MC, 1983, NEURORADIOLOGY, V24, P229, DOI 10.1007/BF00399777; KICK CF, 1984, J NEUROSURG, V60, P42; MARKHAM JW, 1964, J NEUROSURG, V21, P1095, DOI 10.3171/jns.1964.21.12.1095; MILLER CF, 1977, SURG NEUROL, V7, P95; MOSDAL C, 1985, ACTA NEUROCHIR, V74, P31, DOI 10.1007/BF01413273; ONEILL OR, 1994, SURG NEUROL, V42, P494, DOI 10.1016/0090-3019(94)90079-5; Rahman NU, 1997, INT OPHTHALMOL, V21, P13, DOI 10.1023/A:1005834913614; Rao GP, 1998, BRIT J NEUROSURG, V12, P569; REZAI AR, 1994, SURG NEUROL, V42, P312, DOI 10.1016/0090-3019(94)90399-9; SOLOMON KD, 1993, J TRAUMA, V34, P285, DOI 10.1097/00005373-199302000-00020; Taylor AG, 1997, J NEUROSURG, V87, P512, DOI 10.3171/jns.1997.87.4.0512; Van der Heijden ECM, 1998, J ECON PSYCHOL, V19, P5, DOI 10.1016/S0167-4870(97)00035-4; WEISMAN RA, 1983, ARCH OTOLARYNGOL, V109, P265	43	42	47	0	3	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.	SEP	2006	148	9					937	942		10.1007/s00701-006-0794-5			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	081KK	WOS:000240316300003	16763734				2021-06-18	
J	Schiff, ND				Schiff, Nicholas D.			Multimodal neuroimaging approaches to disorders of consciousness	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article; Proceedings Paper	2nd Federal Interagency Conference on Traumatic Brain Injury	MAR 10, 2006	Bethesda, MD			axonal regrowth; minimally conscious state; traumatic brain injury; vegetative state	PERSISTENT VEGETATIVE STATE; BRAIN-INJURED PATIENTS; RECOVERY; COMA; NEUROPATHOLOGY; DIAGNOSIS; STIMULI	Advances in neuroimaging techniques hold significant promise for improving understanding of disorders of consciousness arising from severe brain injuries. We review neuroimaging studies of the vegetative state (VS) and minimally conscious state (MCS), and findings in an unusual case of late emergence from MCS. Multimodal neuroimaging studies using positron emission tomography techniques, functional magnetic resonance imaging, and quantitative electroencephalography and magnetoencephalography quantify variations of residual cerebral activity across these patient populations. The results suggest models to distinguish the pathophysiologic basis of VS and MCS. Less clear are potential brain mechanisms underlying late recovery of communication in rare MCS patients. Diffusion tensor magnetic resonance imaging studies and recent experimental findings suggest that structural remodeling of the brain following severe injury may play a role in late functional recoveries. More generally, relatively long time courses of recovery following severe brain injury emphasize the need to develop markers for identifying patients who may harbor potential for further meaningful recovery. Introduction of neuroimaging into the clinical evaluation process will require developing frameworks for longitudinal assessments of cerebral function. Although limited in number, available studies already provide important insights into underlying brain mechanisms that may help guide development of such assessment strategies.	Cornell Univ, Weill Med Coll, Dept Neurol & Neurosci, New York, NY 10021 USA	Schiff, ND (corresponding author), Cornell Univ, Weill Med Coll, Dept Neurol & Neurosci, 1300 York Ave,Room F610, New York, NY 10021 USA.	nds2001@med.cornell.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS043451] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS02172, NS43451] Funding Source: Medline		Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Bekinschtein T, 2004, J NEUROL NEUROSUR PS, V75, P788, DOI 10.1136/jnnp.2003.034876; Boly M, 2005, NEUROPSYCHOL REHABIL, V15, P283, DOI 10.1080/09602010443000371; Boly M, 2004, ARCH NEUROL-CHICAGO, V61, P233, DOI 10.1001/archneur.61.2.233; Burruss JW, 1999, J NEUROPSYCH CLIN N, V11, P100, DOI 10.1176/jnp.11.1.100; Chklovskii DB, 2004, NATURE, V431, P782, DOI 10.1038/nature03012; Clauss P, 2001, SAMJ S AFR MED J, V91, P788; Crone NE, 2001, CLIN NEUROPHYSIOL, V112, P565, DOI 10.1016/S1388-2457(00)00545-9; Danielsen ER, 2003, NEURORADIOLOGY, V45, P722, DOI 10.1007/s00234-003-1068-z; DEVOLDER AG, 1990, ARCH NEUROL-CHICAGO, V47, P197, DOI 10.1001/archneur.1990.00530020103022; Fins JJ, 2005, PROG BRAIN RES, V150, P565, DOI 10.1016/S0079-6123(05)50040-2; Fins JJ, 2004, ARCH NEUROL-CHICAGO, V61, P1354, DOI 10.1001/archneur.61.9.1354; Fins JJ, 2003, NAT REV NEUROSCI, V4, P323, DOI 10.1038/nrn1079; Giacino J, 2005, J HEAD TRAUMA REHAB, V20, P30, DOI 10.1097/00001199-200501000-00005; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; GIACINO JT, IN PRESS ARCH PHYS M; GOLDFINE AM, 2005, 35 ANN M NOV 12 16 2; Gusnard DA, 2001, NAT REV NEUROSCI, V2, P685, DOI 10.1038/35094500; Jennett B, 2001, NEUROLOGY, V56, P486, DOI 10.1212/WNL.56.4.486; JENNETT B, 2002, VEGETATIVE STATE; Kobylarz EJ, 2005, NEUROPSYCHOL REHABIL, V15, P323, DOI 10.1080/09602010443000605; Lammi MH, 2005, ARCH PHYS MED REHAB, V86, P746, DOI 10.1016/j.apmr.2004.11.004; Laureys S, 2004, LANCET NEUROL, V3, P537, DOI 10.1016/S1474-4422(04)00852-X; Laureys S, 2004, NEUROLOGY, V63, P916, DOI 10.1212/01.WNL.0000137421.30792.9B; Laureys S, 2002, NEUROIMAGE, V17, P732, DOI 10.1006/nimg.2002.1236; Laureys S, 2000, BRAIN, V123, P1589, DOI 10.1093/brain/123.8.1589; Leon-Carrion J, 2002, BRAIN INJURY, V16, P571, DOI 10.1080/02699050110119781; LEVY DE, 1987, ANN NEUROL, V22, P673, DOI 10.1002/ana.410220602; Macniven JA, 2003, BRAIN INJURY, V17, P525, DOI 10.1080/0269905031000086254; McMillan TM, 2004, BRAIN INJURY, V18, P935, DOI 10.1080/02699050410001675915; Menon DK, 1998, LANCET, V352, P1148, DOI 10.1016/S0140-6736(05)79795-6; Onofrj M, 1997, J NEUROL NEUROSUR PS, V63, P759, DOI 10.1136/jnnp.63.6.759; Owen AM, 2005, PROG BRAIN RES, V150, P457, DOI 10.1016/S0079-6123(05)50032-3; ROTHSTEIN TL, 1991, ELECTROEN CLIN NEURO, V79, P101, DOI 10.1016/0013-4694(91)90046-7; Schiff N, 1999, J COGNITIVE NEUROSCI, V11, P650, DOI 10.1162/089892999563715; Schiff ND, 2005, PROG BRAIN RES, V150, P473, DOI 10.1016/S0079-6123(05)50033-5; Schiff ND, 2005, NEUROLOGY, V64, P514, DOI 10.1212/01.WNL.0000150883.10285.44; Schiff ND, 2002, BRAIN, V125, P1210, DOI 10.1093/brain/awf131; Schirrmacher A, 2003, PHYS PERSPECT, V5, P4, DOI 10.1007/s000160300001; Shiel A, 2004, BRIT J NEUROSURG, V18, P5, DOI 10.1080/02688690410001660625; Tavalaro J, 1997, LOOK YES; TOMMASINO C, 1995, J NEUROSURG ANESTH, V7, P109, DOI 10.1097/00008506-199504000-00006; Voss HU, 2006, J CLIN INVEST, V116, P2005, DOI 10.1172/JCI27021; VOSS HU, 2005, ISMRM ABSTR; Wijdicks EFM, 2001, NEW ENGL J MED, V344, P1215, DOI 10.1056/NEJM200104193441606	47	42	44	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2006	21	5					388	397		10.1097/00001199-200609000-00003			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	084JM	WOS:000240529200003	16983224				2021-06-18	
J	Slobounov, S; Tutwiler, R; Sebastianelli, W; Slobounov, E				Slobounov, Semyon; Tutwiler, Rick; Sebastianelli, Wayne; Slobounov, Elena			Alteration of postural responses to visual field motion in mild traumatic brain injury	NEUROSURGERY			English	Article						balance; mild traumatic brain injury; virtual reality graphics; visual field motion	RECOVERY	OBJECTIVE: Balance deficits in individual's experiencing mild traumatic brain injury have been documented in numerous recent studies. However, long-lasting balance deficits and specific mechanisms causing these deficits have not been systematically examined. This article aimed to present empirical evidence showing destabilizing. effects of visual field motion in concussed individuals up to 30 days postinjury. METHODS: Sixty student athletes participated in the pilot (n = 12) and major experiments (n = 48) before injury. Eight of these 48 subjects who experienced mild traumatic brain injury in athletic events were tested again on Days 3, 10, and 30 after the incident. Postural responses to visual field motion were recorded using a virtual reality environment in conjunction with balance (AMTI force plate) and motion tracking (Flock of Birds) technologies. RESULTS: The area of the center of pressure during upright stance did not change from Day 3 to 30 postinjury with respect to pre-injury status (P > .05). However, balance deficits induced by visual field motion were present up to 30 days postinjury. Destabilizing effect of visual field motion was observed via significant increase of the center of pressure data (P < .05) and reduced coherence value. CONCLUSION: Our data suggest the presence of residual sensory integration dysfunction in concussed individuals at least 30 days postinjury and may indicate a lower threshold for brain reinjury.	Penn State Univ, Dept Kinesiol, University Pk, PA USA; Penn State Univ, Appl Res Lab, University Pk, PA 16802 USA; Penn State Univ, Ctr Sports Med, University Pk, PA USA; Penn State Univ, Visualizat Grp, University Pk, PA USA	Slobounov, S (corresponding author), 19 Recreat Hall, University Pk, PA 16802 USA.	sms18@psu.edu					Barth JT, 2001, J ATHL TRAINING, V36, P253; Beer J, 2002, EXP BRAIN RES, V143, P78, DOI 10.1007/s00221-001-0947-y; CANTU R, 2006, FDN SPORT RELATED BR, P88; Cantu RC, 2001, J ATHL TRAINING, V36, P244; CLEMENT G, 1983, EXP BRAIN RES, V52, P429; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; EHRENFRIED T, 2003, COGNITIVE BRAIN RES, V1, P34; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Hallett M, 2001, BRAIN RES REV, V36, P169, DOI 10.1016/S0165-0173(01)00092-3; HORAK FB, 1994, J NEUROPHYSIOL, V72, P479; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Ikeda T, 1997, ACTA OTO-LARYNGOL, V117, P815, DOI 10.3109/00016489709114206; KESHNER E, 2004, INT C DIS VIRT REAL; Keshner EA, 2004, ASSIST TECHNOL, V16, P54, DOI 10.1080/10400435.2004.10132074; Keshner EA, 2004, J VESTIBUL RES-EQUIL, V14, P307; KESHNER EA, 2000, J VESTIBUL RES-EQUIL, V7, P1; Kuno S, 1999, JPN J PHYSIOL, V49, P417, DOI 10.2170/jjphysiol.49.417; Lee D, 1975, J HUMAN MOVEMENT STU, V1, P87, DOI DOI 10.3758/BF03199297; LEE DN, 1974, PERCEPT PSYCHOPHYS, V15, P529, DOI 10.3758/BF03199297; LESTIENNE F, 1977, EXP BRAIN RES, V28, P363; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Mach E, 1875, GRUNDLINIEN LEHRE BE; Nakamura S, 1999, PERCEPTION, V28, P893, DOI 10.1068/p2939; PREVIC FH, 1991, J VESTIBUL RES-EQUIL, V1, P317; Randolph C, 2001, J ATHL TRAINING, V36, P288; RING C, 1988, ARCH PHYS MED REHAB, V69, P261; Slobounov S, 2005, NEUROSCI LETT, V383, P251, DOI 10.1016/j.neulet.2005.04.039; Slobounov S, 2002, CLIN NEUROPHYSIOL, V113, P185, DOI 10.1016/S1388-2457(01)00737-4; Stoffregen TA, 1998, BRAIN RES BULL, V47, P437, DOI 10.1016/S0361-9230(98)00102-6; THATCHER RW, 1989, ELECTROEN CLIN NEURO, V73, P94, DOI 10.1016/0013-4694(89)90188-0; Thompson J, 2005, NEUROSCI LETT, V377, P158, DOI 10.1016/j.neulet.2004.11.090; Thurrell AEI, 2002, EXP BRAIN RES, V147, P558, DOI 10.1007/s00221-002-1296-1; VANASTEN WNJC, 1988, EXP BRAIN RES, V73, P371, DOI 10.1007/BF00248230; WADE MG, 1995, J GERONTOL B-PSYCHOL, V50, pP51, DOI 10.1093/geronb/50B.1.P51; WARREN R, 1976, J EXP PSYCHOL HUMAN, V2, P448, DOI 10.1037/0096-1523.2.3.448; Wojtys EM, 1999, AM J SPORT MED, V27, P676, DOI 10.1177/03635465990270052401	37	42	42	0	5	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JUL	2006	59	1					134	139		10.1227/01.NEU.0000219197.33182.3F			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	061PV	WOS:000238885600031	16823309				2021-06-18	
J	Talvik, I; Metsvaht, T; Leito, K; Poder, H; Kool, P; Vali, M; Lintrop, M; Kolk, A; Talvik, T				Talvik, Inga; Metsvaht, Tuuli; Leito, Kaja; Poder, Haide; Kool, Pille; Vali, Marika; Lintrop, Mare; Kolk, Anneli; Talvik, Tiina			Inflicted traumatic brain injury (ITBI) or shaken baby syndrome (SBS) in Estonia	ACTA PAEDIATRICA			English	Article						inflicted brain injury; shaken baby syndrome; incidence; child abuse	SUBDURAL-HEMATOMA; INFANTS; OUTCOMES	Background: Inflicted traumatic brain injury (ITBI) or shaken baby syndrome (SBS) is recognized as a major cause of disability and death in the paediatric population. Aim: To find out the incidence of ITBI in Estonia. Methods: 26 cases of ITBI were recognized: four children died, 22 survived. Results: Of 26 children, 20 (77%) were boys and six (23%) were girls. Median age at admission to hospital was 3.9 mo, and the boys were younger than the girls.	Univ Tartu Hosp, Childrens Clin, Dept Neurol, EE-51014 Tartu, Estonia; Univ Tartu Hosp, Childrens Clin, Tartu, Estonia; Univ Tartu Hosp, Anaesthesiol & Intens Care Clin, Tartu, Estonia; Tallinn Childrens Hosp, Tallinn, Estonia; Tartu Univ Hosp, Radiol Dept, Tartu, Estonia; Univ Tartu, Dept Pathol Anat & Forens Med, Tartu, Estonia	Talvik, I (corresponding author), Univ Tartu Hosp, Childrens Clin, Dept Neurol, 6 Lunini Str, EE-51014 Tartu, Estonia.	inga.talvik@kliinikum.ee	Metsvaht, Tuuli/H-6897-2015	Metsvaht, Tuuli/0000-0003-3206-3092			Agran PF, 2003, PEDIATRICS, V111, pE683, DOI 10.1542/peds.111.6.e683; Barlow KM, 2005, PEDIATRICS, V116, pE174, DOI 10.1542/peds.2004-2739; Barlow KM, 2000, LANCET, V356, P1571, DOI 10.1016/S0140-6736(00)03130-5; CAFFEY J, 1972, AM J DIS CHILD, V124, P161, DOI 10.1001/archpedi.1972.02110140011001; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; Fung ELW, 2003, PEDIATR INT, V45, P497, DOI 10.1046/j.1442-200X.2003.01739.x; GUTHKELCH AN, 1971, BMJ-BRIT MED J, V2, P430, DOI 10.1136/bmj.2.5759.430; Haviland J, 1997, ARCH DIS CHILD, V77, P504, DOI 10.1136/adc.77.6.504; Jayawant S, 1998, BMJ-BRIT MED J, V317, P1558, DOI 10.1136/bmj.317.7172.1558; King WJ, 2003, CAN MED ASSOC J, V168, P155; Kivlin JD, 2000, OPHTHALMOLOGY, V107, P1246, DOI 10.1016/S0161-6420(00)00161-5; Kocher M S, 2000, J Am Acad Orthop Surg, V8, P10; Kujiraoka Y, 2004, NEUROL MED-CHIR, V44, P359, DOI 10.2176/nmc.44.359; Levin AV, 2000, RECENT ADV PAEDIAT, P151; Makaroff KL, 2003, DEV MED CHILD NEUROL, V45, P497, DOI 10.1017/S0012162203000926; Morad Y, 2004, J AAPOS, V8, P521, DOI 10.1016/j.jaapos.2004.07.009; Morad Y, 2002, AM J OPHTHALMOL, V134, P354, DOI 10.1016/S0002-9394(02)01628-8; Reijneveld SA, 2004, LANCET, V364, P1340, DOI 10.1016/S0140-6736(04)17191-2; van der Wal MF, 1998, ARCH DIS CHILD, V79, P312, DOI 10.1136/adc.79.4.312	19	42	44	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0803-5253	1651-2227		ACTA PAEDIATR	Acta Paediatr.	JUL	2006	95	7					799	804		10.1080/08035250500464923			6	Pediatrics	Pediatrics	057QL	WOS:000238610200007	16801174				2021-06-18	
J	Rapoport, MJ; Kiss, A; Feinstein, A				Rapoport, Mark J.; Kiss, Alexander; Feinstein, Anthony			The impact of major depression on outcome following mild-to-moderate traumatic brain injury in older adults	JOURNAL OF AFFECTIVE DISORDERS			English	Article; Proceedings Paper	18th Annual Meeting of the American-Association-for-Geriatric-Psychiatry	MAR 03-06, 2005	San Diego, CA	Amer Assoc Geriatr Psychiat		traumatic brain injury; older adults; major depression	HEAD-INJURY; QUESTIONNAIRE; DISORDERS; MORTALITY; SYMPTOMS	Background: Major depression is common following traumatic brain injury (TBI), yet no studies to date have explored its relationship to psychosocial outcome in older adults with TBI. Methods: A consecutive sample of seventy-seven older patients with mild-to-moderate TBI was assessed for the presence of major depression within 2 months of injury, and followed prospectively for 1 year. Those with major depression were compared with those without on measures of psychosocial outcome, instrumental activities of daily living (IADL). Results: Patients with major depression (15.6%) reported higher degrees of psychological distress, psychosocial dysfunction, and post-concussive symptoms than those without, and were rated as having poorer IADL performance. Limitations: The present study was limited to a clinical population, and there were significant attrition rates. Conclusions: Major depression in the first few months after TBI in older adults has persisting adverse effects on outcome, highlighting its significance in this population, and suggesting early attention to treatment. (c) 2006 Elsevier B.V. All rights reserved.	Univ Toronto, Hlth Sci Ctr, Sunnybrook & Womens Coll, Toronto, ON, Canada	Rapoport, MJ (corresponding author), Univ Toronto, Hlth Sci Ctr, Sunnybrook & Womens Coll, Toronto, ON, Canada.	mark.rapoport@sw.ca	Rapoport, Mark/AAD-8581-2020				Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; DIKMEN SS, 1993, J HEAD TRAUMA REHAB, V8, P30, DOI DOI 10.1097/00001199-199309000-00005; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; FIELDS RB, 1994, TXB GERIATRIC NEUROP, P479; First M.B., 1996, STRUCTURED CLIN INTE; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; Goldstein FC, 2001, J INT NEUROPSYCH SOC, V7, P373, DOI 10.1017/S1355617701733115; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; JORM AF, 1991, PSYCHOL MED, V21, P785, DOI 10.1017/S0033291700022418; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kilaru S, 1996, J TRAUMA, V41, P957, DOI 10.1097/00005373-199612000-00003; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Lyness JM, 2002, AM J GERIAT PSYCHIAT, V10, P275, DOI 10.1176/appi.ajgp.10.3.275; McCleary C, 1998, J CLIN EXP NEUROPSYC, V20, P270, DOI 10.1076/jcen.20.2.270.1172; MILLER MD, 1992, PSYCHIAT RES, V41, P237, DOI 10.1016/0165-1781(92)90005-N; PFEFFER RI, 1982, J GERONTOL, V37, P323, DOI 10.1093/geronj/37.3.323; Rapoport MJ, 2003, AM J GERIAT PSYCHIAT, V11, P365, DOI 10.1176/appi.ajgp.11.3.365; REGIER DA, 1988, ARCH GEN PSYCHIAT, V45, P977; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004	21	42	42	0	7	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0165-0327	1573-2517		J AFFECT DISORDERS	J. Affect. Disord.	JUN	2006	92	2-3					273	276		10.1016/j.jad.2005.05.022			4	Clinical Neurology; Psychiatry	Neurosciences & Neurology; Psychiatry	050ZS	WOS:000238130500016	16504305				2021-06-18	
J	Vallee, M; McFadyen, BJ; Swaine, B; Doyon, J; Cantin, JF; Dumas, D				Vallee, Marie; McFadyen, Bradford J.; Swaine, Bonnie; Doyon, Julien; Cantin, Jean-Francois; Dumas, Denyse			Effects of environmental demands on locomotion after traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						attention; gait; rehabilitation	DIVIDED ATTENTION; BALANCE; GAIT; RECOVERY; DEFICITS; TASK; SWAY; IDENTIFICATION; REHABILITATION; ADJUSTMENTS	Objective: To determine the effects of increasingly demanding environments related to simultaneous visual tasks and physical obstructions on the locomotor ability of people with traumatic brain injury (TBI). Design: Group comparison study. Setting: Gait analysis laboratory within a postacute rehabilitation facility. Participants: Volunteer sample of 9 people (8 men, 1 woman; age, 39.3 +/- 13.0 y) with moderate to severe TBI and a comparison group of 9 subjects without neurologic problems matched for age and sex (8 men, 1 woman; age, 39.7 +/- 12.3y). Interventions: Not applicable. Main Outcome Measures: Reading times for the Stroop bar and Stroop word tasks, walking speeds, stride lengths, and obstacle clearance margin. Results: The TBI group was slower than the control group in performing the Stroop bar task during sitting (P = .002), and while avoiding the narrow obstacle (P = .05), and in performing 9 the Stroop word task while avoiding the wide obstacle (P = .019). Despite their relatively normal gait speeds on level ground, subjects with TBI walked more slowly than control subjects for the narrow (P = .024) and the wide (P = .019) obstacle conditions and for the most complex dual task (P = .042). Greater lead-limb clearance margins were observed for the TBI group than for control subjects for all conditions whereas no differences were found for the trail limb except at the far end of the wide obstacle. Conclusions: Despite their good recovery of locomotor function, with respect to normal level walking speeds and ability to avoid obstacles, subjects with moderate and severe TBI showed residual deficits in relation to greater difficulties in dealing with environments that challenge their locomotor and attentional abilities. The use of such naturally based dual tasks may help identify some of the environmental obstructions to social participation after TBI.	Univ Laval, Ctr Interdisciplinary Res Rehabil & Social Integr, Fac Med, Quebec City, PQ G1M 2S8, Canada; Univ Laval, Dept Rehabil, Fac Med, Quebec City, PQ G1M 2S8, Canada; Ctr Rech Interdisciplinaire Readaptat, Montreal, PQ, Canada; Montreal Rehabil Inst, Montreal, PQ, Canada; Univ Montreal, Sch Rehabil, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Dept Psychol, Montreal, PQ H3C 3J7, Canada; Quebec Rehabil Inst, Quebec City, PQ, Canada	McFadyen, BJ (corresponding author), Univ Laval, Ctr Interdisciplinary Res Rehabil & Social Integr, Fac Med, 525 Hamel, Quebec City, PQ G1M 2S8, Canada.	brad.mcfadyen@rea.ulaval.ca		McFadyen, Bradford/0000-0003-1992-4927			Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; Brauer SG, 2004, HUM MOVEMENT SCI, V23, P489, DOI 10.1016/j.humov.2004.08.020; Chou LS, 2004, GAIT POSTURE, V20, P245, DOI 10.1016/j.gaitpost.2003.09.007; Dault MC, 2001, GAIT POSTURE, V14, P110, DOI 10.1016/S0966-6362(01)00113-8; Gadoury M, 2001, CADRE REFERENCE CLIN; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; GOLDEN CJ, 1976, J CLIN PSYCHOL, V32, P654, DOI 10.1002/1097-4679(197607)32:3<654::AID-JCLP2270320336>3.0.CO;2-Z; Katz DI, 2004, ARCH PHYS MED REHAB, V85, P865, DOI 10.1016/j.apmr.2003.11.020; Lajoie Y, 1996, EXP AGING RES, V22, P185, DOI 10.1080/03610739608254006; LAJOIE Y, 1993, EXP BRAIN RES, V97, P139; LEHMANN JF, 1990, ARCH PHYS MED REHAB, V71, P955; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; McFadyen BJ, 1997, EXP BRAIN RES, V114, P500, DOI 10.1007/PL00005659; MCFADYEN BJ, 1991, NEUROSCI RES COMMUN, V9, P37; McFadyen BJ, 2003, J HEAD TRAUMA REHAB, V18, P512, DOI 10.1097/00001199-200311000-00005; Mohagheghi AA, 2004, EXP BRAIN RES, V155, P459, DOI 10.1007/s00221-003-1751-7; Ochi F, 1999, J HEAD TRAUMA REHAB, V14, P105, DOI 10.1097/00001199-199904000-00002; Park NW, 1999, NEUROPSYCHOLOGIA, V37, P1119, DOI 10.1016/S0028-3932(99)00034-2; Parker TM, 2005, CLIN BIOMECH, V20, P389, DOI 10.1016/j.clinbiomech.2004.12.004; Patla AE, 1996, J MOTOR BEHAV, V28, P35, DOI 10.1080/00222895.1996.9941731; PATLA AE, 1991, J EXP PSYCHOL HUMAN, V17, P603, DOI 10.1037/0096-1523.17.3.603; PATLA AE, 1991, ADAPTABILITY HUMAN Q; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; SchmitterEdgecombe M, 1996, J HEAD TRAUMA REHAB, V11, P17, DOI 10.1097/00001199-199604000-00003; Stierwalt Julie A. G., 2002, Seminars in Speech and Language, V23, P129, DOI 10.1055/s-2002-24989; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Swaine BR, 1996, BRAIN INJURY, V10, P347, DOI 10.1080/026990596124368; Tappan RS, 2002, PHYS THER, V82, P473, DOI 10.1093/ptj/82.5.473; Wade LD, 1997, ARCH PHYS MED REHAB, V78, P1107, DOI 10.1016/S0003-9993(97)90136-2; Whyte J, 1998, J INT NEUROPSYCH SOC, V4, P127, DOI 10.1017/S1355617798001271; WHYTE J, 1995, NEUROPSYCHOLOGIA, V33, P797, DOI 10.1016/0028-3932(95)00029-3; Whyte J, 2000, J INT NEUROPSYCH SOC, V6, P1, DOI 10.1017/S1355617700611013; Williams G, 2004, AM J PHYS MED REHAB, V83, P910, DOI 10.1097/01.PHM.0000146503.25221.1D; WOBER C, 1993, ARCH PHYS MED REHAB, V74, P1151	35	42	43	0	5	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUN	2006	87	6					806	813		10.1016/j.apmr.2006.02.031			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	052AP	WOS:000238203100010	16731216				2021-06-18	
J	Keenan, HT; Runyan, DK; Nocera, M				Keenan, HT; Runyan, DK; Nocera, M			Longitudinal follow-up of families and young children with traumatic brain injury	PEDIATRICS			English	Article						traumatic brain injury; outcomes; child abuse; shaken baby syndrome	PEDIATRIC INTENSIVE-CARE; SCORES	OBJECTIVES. To examine the stability of functional outcomes 2 years after injury among children who sustained a traumatic brain injury (TBI) before 2 years of age and to examine the characteristics of the families caring for these children. METHODS. All North Carolina-resident children who were hospitalized between January 2000 and December 2001 in any of the state's 9 PICUs and survived a TBI that occurred on or before their second birthday were eligible to participate in the prospective cohort study. Child health status, use of ancillary medical resources, and family characteristics were assessed through maternal caregiver interviews similar to 2 years after injury. Comparisons were made among injury types ( inflicted versus noninflicted). RESULTS. There were 112 children who survived a TBI during the 2-year study period. Fifty-seven (79%) of the 72 maternal caregivers who had completed an interview 1 year after the child's injury participated in the year 2 interview. Most children (67%) had an outcome of mild disability or better at year 2, with 45% functioning at an age-appropriate level. Children's outcomes did not differ significantly at year 2 according to the mechanism of injury. The majority ( 67%) of children retained their Pediatric Overall Performance Category scores from year 1 to year 2. Children who changed were as likely to show improvement as deterioration. Children differed very little across time, as measured with the Stein-Jessup Functional Status II ( Revised) scale. Families tended to have multiple environmental factors that could put their children at risk for poor developmental outcomes, including living below the poverty level (22%) and low social capital (39%). CONCLUSIONS. The children in this cohort had relatively stable functional outcomes from year 1 to year 2 after injury. This population of children remains very vulnerable to poor developmental outcomes secondary to the effects of their TBI and environmental factors.	Univ Utah, Intermt Control Res Ctr, Salt Lake City, UT 84158 USA; Univ Utah, Dept Pediat, Salt Lake City, UT 84158 USA; Univ N Carolina, Dept Social Med, Chapel Hill, NC USA; Univ N Carolina, Dept Pediat, Chapel Hill, NC USA; Univ N Carolina, Univ N Carolina Canc Injury Prevent Res Ctr, Chapel Hill, NC USA	Keenan, HT (corresponding author), Univ Utah, Intermt Control Res Ctr, 295 Chipeta Way,POB 581289, Salt Lake City, UT 84158 USA.	heather.keenan@hsc.utah.edu	Runyan, Desmond/S-3974-2016	Runyan, Desmond/0000-0001-5571-9029	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23 HD041040, K23 HD041040-01A2, K23 HD041040-04] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR402444] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD041040] Funding Source: NIH RePORTER		COLEMAN JS, 1988, AM J SOCIOL, V94, pS95, DOI 10.1086/228943; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V26, P487, DOI 10.1207/s15326942dn2601_7; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Fiser DH, 2000, CRIT CARE MED, V28, P2616, DOI 10.1097/00003246-200007000-00072; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; Olds DL, 2004, PEDIATRICS, V114, P1550, DOI 10.1542/peds.2004-0962; POLITZ K, 2001, CONSUMERS GUIDE GETT; RUNYAN D, 2001, WELL BEING CHILDREN; Runyan DK, 1998, PEDIATRICS, V101, P12, DOI 10.1542/peds.101.1.12; Sameroff A J, 1998, Pediatrics, V102, P1287; SAMEROFF AJ, 1987, PEDIATRICS, V79, P343; STEIN REK, 1990, MED CARE, V28, P1041, DOI 10.1097/00005650-199011000-00006; TEASDALE G, 1974, LANCET, V2, P81; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110	17	42	43	0	3	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	APR	2006	117	4					1291	1297		10.1542/peds.2005-1883			7	Pediatrics	Pediatrics	029EA	WOS:000236540500062	16585326	Green Accepted			2021-06-18	
J	Rochkind, S; Shahar, A; Fliss, D; El-Ani, D; Astachov, L; Hayon, T; Alon, M; Zamostiano, R; Ayalon, O; Biton, I; Cohen, Y; Halperin, R; Schneider, D; Oron, A; Nevo, Z				Rochkind, S; Shahar, A; Fliss, D; El-Ani, D; Astachov, L; Hayon, T; Alon, M; Zamostiano, R; Ayalon, O; Biton, I; Cohen, Y; Halperin, R; Schneider, D; Oron, A; Nevo, Z			Development of a tissue-engineered composite implant for treating traumatic paraplegia in rats	EUROPEAN SPINE JOURNAL			English	Article						olfactory mucosa; spinal cord; transection; transplantation	NEURAL PROGENITOR CELLS; OLFACTORY ENSHEATHING CELLS; CENTRAL-NERVOUS-SYSTEM; SPINAL-CORD-INJURY; ADULT-RAT; AXONAL REGENERATION; FUNCTIONAL RECOVERY; STEM-CELLS; EXTRACELLULAR-MATRIX; DELAYED TRANSPLANTATION	This study was designed to assess a new composite implant to induce regeneration of injured spinal cord in paraplegic rats following complete cord transection. Neuronal xenogeneic cells from biopsies of adult nasal olfactory mucosa (NOM) of human origin, or spinal cords of human embryos, were cultured in two consecutive stages: stationary cultures in a viscous semi-solid gel (NVR-N-Gel) and in suspension on positively charged microcarriers (MCs). A tissue-engineered tubular scaffold, containing bundles of parallel nanofibers, was developed. Both the tube and the nanofibers were made of a biodegradable dextran sulphate-gelatin co-precipitate. The suturable scaffold anchored the implant at the site of injury and provided guidance for the regenerating axons. Implants of adult human NOM cells were implanted into eight rats, from which a 4 mm segment of the spinal cord had been completely removed. Another four rats whose spinal cords had also been transected were implanted with a composite implant of cultured human embryonic spinal cord cells. Eight other cord-transected rats served as a control group. Physiological and behavioral analysis, performed 3 months after implantation, revealed partial recovery of function in one or two limbs in three out of eight animals of the NOM implanted group and in all the four rats that were implanted with cultured human embryonic spinal cord cells. Animals of the control group remained completely paralyzed and did not show transmission of stimuli to the brain. The utilization of an innovative composite implant to bridge a gap resulting from the transection and removal of a 4 mm spinal cord segment shows promise, suggesting the feasibility of this approach for partial reconstruction of spinal cord lesions. Such an implant may serve as a vital bridging station in acute and chronic cases of paraplegia.	Neural & Vasc Reconstruct Labs, Ness Ziona, Israel; Tel Aviv Univ, Div Peripheral Nerve Reconstruct, Tel Aviv Sourasky Med Ctr, Dept Neurosurg, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Div Peripheral Nerve Reconstruct, Tel Aviv Sourasky Med Ctr, Dept Otolaryngol, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sackler Sch Med, Raymond & Beverly Sackler Fac Exact Sci, Sch Chem,Dept Clin Biochem, IL-69978 Tel Aviv, Israel; Assaf Harofeh Med Ctr, Dept Gynecol, IL-70300 Zerifin, Israel; Assaf Harofeh Med Ctr, Dept Obstet, IL-70300 Zerifin, Israel; Assaf Harofeh Med Ctr, Dept Orthoped, IL-70300 Zerifin, Israel	Shahar, A (corresponding author), Neural & Vasc Reconstruct Labs, Ness Ziona, Israel.	abrahams@nvrlab.com	Rochkind, Shimon/AAO-6447-2020	Shahar, Abraham/0000-0003-4894-2593			Assaf Y, 2000, MAGNET RESON MED, V43, P191, DOI 10.1002/(SICI)1522-2594(200002)43:2<191::AID-MRM5>3.0.CO;2-B; Assaf Y, 2000, MAGNET RESON MED, V44, P713, DOI 10.1002/1522-2594(200011)44:5<713::AID-MRM9>3.0.CO;2-6; Assaf Y, 2003, EXP NEUROL, V184, P726, DOI 10.1016/S0014-4886(03)00274-7; Bakshi A, 2004, J NEUROSURG-SPINE, V1, P322, DOI 10.3171/spi.2004.1.3.0322; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Bregman BS, 1997, EXP NEUROL, V148, P475, DOI 10.1006/exnr.1997.6705; CALOF AL, 2000, MICROSC RES TECHNIQ, V58, P176; Cohen Y, 2002, NMR BIOMED, V15, P516, DOI 10.1002/nbm.778; Condic ML, 2002, NEUROREPORT, V13, pA37, DOI 10.1097/00001756-200203040-00002; CORY DG, 1990, MAGNET RESON MED, V14, P435, DOI 10.1002/mrm.1910140303; Costa S, 2002, GLIA, V37, P105, DOI 10.1002/glia.10015; Coumans JV, 2001, J NEUROSCI, V21, P9334, DOI 10.1523/JNEUROSCI.21-23-09334.2001; Cunningham AM, 1999, NEUROSCIENCE, V93, P1301, DOI 10.1016/S0306-4522(99)00193-1; David S, 2002, NEUROSCIENTIST, V8, P33, DOI 10.1177/107385840200800108; Galvin KA, 2002, MED J AUSTRALIA, V177, P316, DOI 10.5694/j.1326-5377.2002.tb04791.x; GOLDMANSA, 1997, ANN NY ACAD SCI, V835, P30; Gorio A, 2004, NEUROSCIENCE, V125, P179, DOI 10.1016/j.neuroscience.2003.10.046; Hermanns S, 2001, RESTOR NEUROL NEUROS, V19, P139; HOULE JD, 1994, J NEURAL TRANSP PLAS, V5, P115, DOI 10.1155/NP.1994.115; Houweling DA, 1998, EXP NEUROL, V153, P49, DOI 10.1006/exnr.1998.6867; Jones LL, 2002, J NEUROSCI, V22, P2792, DOI 10.1523/JNEUROSCI.22-07-02792.2002; Kabos P, 2002, EXP NEUROL, V178, P288, DOI 10.1006/exnr.2002.8039; Karim F, 2001, BRAIN RES REV, V36, P204, DOI 10.1016/S0165-0173(01)00096-0; Kataoka K, 2004, TISSUE ENG, V10, P493, DOI 10.1089/107632704323061852; Keirstead HS, 2001, J NEUROSCI RES, V63, P233, DOI 10.1002/1097-4547(20010201)63:3<233::AID-JNR1016>3.0.CO;2-B; Keyvan-Fouladi N, 2003, J NEUROSCI, V23, P9428; Kisiday J, 2002, P NATL ACAD SCI USA, V99, P9996, DOI 10.1073/pnas.142309999; Krautstrunk M, 2002, ACTA NEUROPATHOL, V104, P592, DOI 10.1007/s00401-002-0589-6; Le Bihan D, 2003, NAT REV NEUROSCI, V4, P469, DOI 10.1038/nrn1119; Le Bihan D, 2002, NMR BIOMED, V15, P431, DOI 10.1002/nbm.798; Lee JB, 2004, BRAIN RES PROTOC, V14, P37, DOI 10.1016/j.brainresprot.2004.09.004; Loh NK, 2001, EXP NEUROL, V170, P72, DOI 10.1006/exnr.2001.7692; Lu J, 2002, BRAIN, V125, P14, DOI 10.1093/brain/awf014; Lu P, 2004, J NEUROSCI, V24, P6402, DOI 10.1523/JNEUROSCI.1492-04.2004; McDonald JW, 1999, NAT MED, V5, P1410, DOI 10.1038/70986; MCKEON RJ, 1995, EXP NEUROL, V136, P32, DOI 10.1006/exnr.1995.1081; Meijs MFL, 2004, J NEUROTRAUM, V21, P1415, DOI 10.1089/neu.2004.21.1415; Moon LDF, 2001, NAT NEUROSCI, V4, P465; Ogawa Y, 2002, J NEUROSCI RES, V69, P925, DOI 10.1002/jnr.10341; PEARSE AGE, 1972, HISTOCHEMISTRY THEOR, V1; Reubinoff BE, 2000, NAT BIOTECHNOL, V18, P399; Rochkind S, 2002, NEUROL RES, V24, P355, DOI 10.1179/016164102101200131; Roisen FJ, 2001, BRAIN RES, V890, P11, DOI 10.1016/S0006-8993(00)03016-X; Ruitenberg MJ, 2005, BRAIN, V128, P839, DOI 10.1093/brain/awh424; Schmidt CE, 2003, ANNU REV BIOMED ENG, V5, P293, DOI 10.1146/annurev.bioeng.5.011303.120731; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; Schuldiner M, 2001, BRAIN RES, V913, P201, DOI 10.1016/S0006-8993(01)02776-7; Schwartz Michal, 2003, J Spinal Cord Med, V26 Suppl 1, pS6; SHAHAR A, 1990, METHODS NEUROSCI, V2, P195; Silva GA, 2004, SCIENCE, V303, P1352, DOI 10.1126/science.1093783; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Stokols S, 2004, BIOMATERIALS, V25, P5839, DOI 10.1016/j.biomaterials.2004.01.041; Tatard VM, 2005, CURR DRUG TARGETS, V6, P81, DOI 10.2174/1389450053344885; Woerly S, 1999, TISSUE ENG, V5, P467, DOI 10.1089/ten.1999.5.467; Woerly S, 2001, J NEUROSCI RES, V66, P1187; Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C; Yoshii S, 2003, SPINE, V28, P2346, DOI 10.1097/01.BRS.0000085302.95413.16; Yoshii S, 2001, J BIOMED MATER RES, V56, P400, DOI 10.1002/1097-4636(20010905)56:3<400::AID-JBM1109>3.3.CO;2-Z; Zigova T, 2002, CELL TRANSPLANT, V11, P265	61	42	46	0	7	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0940-6719	1432-0932		EUR SPINE J	Eur. Spine J.	FEB	2006	15	2					234	245		10.1007/s00586-005-0981-8			12	Clinical Neurology; Orthopedics	Neurosciences & Neurology; Orthopedics	023CD	WOS:000236101900012	16292587	Green Published			2021-06-18	
J	Willison, J; Tombaugh, TN				Willison, J; Tombaugh, TN			Detecting simulation of attention deficits using reaction time tests	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						simulation; malingering; reaction time tests	INJURY	The current study examined if a newly developed series of reaction time tests, the Computerized Tests of Information Processing (CTIP) [Tombaugh, T. N., & Rees, L. (2000). Manual for the Computerized Tests of Information Processing (CTIP). Ottawa, Ontario: Carleton University (unpublished test)], were sensitive to simulation of attention deficits commonly caused by traumatic brain injury (TBI). The CTIP consists of three reaction time tests: Simple RT, Choice RT, and Semantic Search RT. These tests were administered to four groups: Control, Simulator, Mild TBI, and Severe TBI. Individuals attempting to simulate attention deficits produced longer reaction time scores, made more incorrect responses, and exhibited greater variability than cognitively-intact individuals and those with TBI. Sensitivity and specificity values were comparable or exceeded those obtained on the Test of Memory Malingering [Tombaugh, T. N. (1996). The Test of Memory Malingering (TOMM). Toronto, Canada: Multi-Health Systems Inc.]. As such, the CTIP offers considerable promise of serving as a viable malingering test that uses a distinctively different paradigm than the two-item, forced-choice procedure employed by traditional symptom validity tests. (c) 2005 National Academy of Neuropsychology. Published by Elsevier Ltd. All rights reserved.	Carleton Univ, Dept Psychol, Ottawa, ON K1S 5B6, Canada; Royal Ottawa Hosp, Ottawa, ON, Canada	Tombaugh, TN (corresponding author), Carleton Univ, Dept Psychol, 1125 Colonel By Dr, Ottawa, ON K1S 5B6, Canada.	ttombaug@ccs.carleton.ca					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; BAIRD BJ, 2004, THESIS OTTAWA ONTARI; Berry E., 2002, BOSTON GLOBE, pA1; BINDER LM, 1993, J CLIN EXP NEUROPSYC, V15, P170, DOI 10.1080/01688639308402555; Bolan B, 2002, J CLIN EXP NEUROPSYC, V24, P154, DOI 10.1076/jcen.24.2.154.1000; Collins LF, 1996, ARCH CLIN NEUROPSYCH, V11, P613, DOI 10.1016/0887-6177(97)81255-3; FAUST D, 1988, PROF PSYCHOL-RES PR, V19, P508, DOI 10.1037/0735-7028.19.5.508; Green P, 1999, BRAIN INJURY, V13, P813, DOI 10.1080/026990599121205; HISCOCK M, 1989, J CLIN EXP NEUROPSYC, V11, P967, DOI 10.1080/01688638908400949; IVERSON GL, 1991, LAW HUMAN BEHAV, V15, P667, DOI 10.1007/BF01065859; Iverson GL, 1996, J CLIN EXP NEUROPSYC, V18, P38, DOI 10.1080/01688639608408260; Langeluddecke PM, 2003, ARCH CLIN NEUROPSYCH, V18, P181, DOI 10.1016/S0887-6177(01)00195-0; Meyers J E, 1999, Appl Neuropsychol, V6, P208, DOI 10.1207/s15324826an0604_3; Meyers JE, 2003, ARCH CLIN NEUROPSYCH, V18, P261, DOI 10.1016/S0887-6177(02)00136-1; MITTENBERG W, 1993, PSYCHOL ASSESSMENT, V5, P34, DOI DOI 10.1037/1040-3590.5.1.34; NIES KJ, 1994, ARCH CLIN NEUROPSYCH, V9, P501, DOI 10.1016/0887-6177(94)90041-8; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PANKRATZ L, 1983, PERCEPT MOTOR SKILL, V57, P367, DOI 10.2466/pms.1983.57.2.367; PANKRATZ L, 1979, J CONSULT CLIN PSYCH, V47, P409, DOI 10.1037/0022-006X.47.2.409; Resnick P. J., 1988, CLIN ASSESSMENT MALI, P84; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; ROSE FE, 1995, CLIN NEUROPSYCHOL, V9, P124, DOI 10.1080/13854049508401594; Schagen S, 1997, J CLIN EXP NEUROPSYC, V19, P43, DOI 10.1080/01688639708403835; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Slick D., 1997, VICTORIA SYMPTOM VAL; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Strauss E, 2002, ARCH CLIN NEUROPSYCH, V17, P423, DOI 10.1016/S0887-6177(01)00126-3; STRAUSS E, 1994, ARCH CLIN NEUROPSYCH, V9, P483, DOI 10.1016/0887-6177(94)90039-6; Strauss E, 1999, CLIN NEUROPSYCHOL, V13, P420, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT420; Stuss D. T., 1989, CLIN NEUROPSYCHOL, V3, P145, DOI DOI 10.1080/13854048908403287; Stuss DT, 1994, NEUROPSYCHOLOGY, V8, P316, DOI DOI 10.1037/0894-4105.8.3.316; Suhr JA, 2000, ARCH CLIN NEUROPSYCH, V15, P415, DOI 10.1016/S0887-6177(99)00033-5; Tombaugh TN, 1996, TEST MEMORY MALINGER; Tombaugh TN, 2000, MANUAL COMPUTERIZED; TOMBAUGH TN, 1998, TEST MEMORY MALINGER; TRUEBLOOD W, 1993, J CLIN EXP NEUROPSYC, V15, P578, DOI 10.1080/01688639308402580; Trueblood W, 1997, ARCH CLIN NEUROPSYCH, V12, P13, DOI 10.1016/S0887-6177(96)00027-3; van Gorp WG, 1999, J CLIN EXP NEUROPSYC, V21, P245; VANZOMEREN AH, 1994, ASSESSMENT ATTENTION, P159; VANZOMEREN AH, 1989, NEUROBEHAVIORAL RECO, P398; Weschler D., 1997, WESCHLER ADULT INTEL; WESCHLER D, 1981, WESCHLER ADULT INTEL; Wogar MA, 1998, BRIT J CLIN PSYCHOL, V37, P327, DOI 10.1111/j.2044-8260.1998.tb01389.x	43	42	42	0	10	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	JAN	2006	21	1					41	52		10.1016/j.acn.2005.07.005			12	Psychology, Clinical; Psychology	Psychology	006EA	WOS:000234877100005	16280230	Bronze			2021-06-18	
J	Mendez, CV; Hurley, RA; Lassonde, M; Zhang, LY; Taber, KH				Mendez, CV; Hurley, RA; Lassonde, M; Zhang, LY; Taber, KH			Mild traumatic brain injury: Neuroimaging of sports-related concussion	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							HIGH-SCHOOL; PROFESSIONAL FOOTBALL; AXONAL INJURY; HEAD TRAUMA; COLLEGIATE; GUIDELINES; MR; MANAGEMENT; EVOLUTION; SYMPTOMS		Wake Forest Univ, Sch Med, Dept Psychiat, Vet Affairs Mid Atlantic Mentall Illness Res Educ, Winston Salem, NC 27109 USA; Salisbury Vet Affairs Med Ctr, Salisbury, NC USA; Wake Forest Univ, Sch Med, Dept Radiol, Winston Salem, NC 27109 USA; Baylor Coll Med, Meninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA; Univ Montreal, Ctr Rech Neuropsychol & Cognit, Montreal, PQ, Canada; Wayne State Univ, Ctr Bioengn, Detroit, MI USA	Hurley, RA (corresponding author), Hefner VA Med Ctr, 1601 Brenner Ave, Salisbury, NC 28144 USA.	Robin.Hurley@med.va.gov	Taber, Katherine H/B-8260-2011	Taber, Katherine H/0000-0001-7382-6151			ALVES WM, 1987, CLIN SPORT MED, V6, P211; [Anonymous], 2000, AM HERITAGE DICT ENG; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Bailes JE, 2001, NEUROSURGERY, V48, P26, DOI 10.1097/00006123-200101000-00005; Biasca N, 2002, BRIT J SPORT MED, V36, P410, DOI 10.1136/bjsm.36.6.410; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; Cantu RC, 1998, CLIN SPORT MED, V17, P45, DOI 10.1016/S0278-5919(05)70060-0; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Chen SHA, 2003, J NEUROL NEUROSUR PS, V74, P326, DOI 10.1136/jnnp.74.3.326; Covassin T, 2003, APPL NEUROPSYCHOL, V10, P12, DOI 10.1207/S15324826AN1001_3; Dupuis F, 2000, NEUROREPORT, V11, P4087, DOI 10.1097/00001756-200012180-00035; Easdon C, 2004, BRAIN COGNITION, V54, P136; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; FICK DS, 1995, POSTGRAD MED, V97, P53; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gaetz M, 2001, J HEAD TRAUMA REHAB, V16, P386, DOI 10.1097/00001199-200108000-00008; Gerberding J.L., 2003, REPORT C MILD TRAUMA; Giza CC, 2001, J ATHL TRAINING, V36, P228; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; HAYES RL, 1994, SEMIN NEUROL, V14, P25, DOI 10.1055/s-2008-1041055; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Hurley RA, 2004, J NEUROPSYCH CLIN N, V16, P1, DOI 10.1176/appi.neuropsych.16.1.1; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; KELLY AB, 1988, AM J NEURORADIOL, V9, P699; Kelly JP, 1998, J HEAD TRAUMA REHAB, V13, P53, DOI 10.1097/00001199-199804000-00008; Koh JO, 2002, J SPORT MED PHYS FIT, V42, P348; KOH JO, 2005, BRAIN INJURY, V17, P901; Lavoie ME, 2004, J CLIN EXP NEUROPSYC, V26, P55, DOI 10.1076/jcen.26.1.55.23936; Levy ML, 2004, NEUROSURGERY, V55, P656, DOI 10.1227/01.NEU.0000134599.01917.AA; Lewine JD, 1999, AM J NEURORADIOL, V20, P857; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2001, CLIN J SPORT MED, V11, P144, DOI 10.1097/00042752-200107000-00004; *NCAA, 2000, NCAA CENT SER 1; NOSEWORTHY JH, 1981, ARCH NEUROL-CHICAGO, V38, P275, DOI 10.1001/archneur.1981.00510050041004; Pellman EJ, 2004, NEUROSURGERY, V55, P1290, DOI 10.1227/01.NEU.0000149244.97560.91; Pellman EJ, 2004, NEUROSURGERY, V55, P1100, DOI 10.1227/01.NEU.0000147063.12873.F5; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pointinger H, 2002, BRAIN INJURY, V16, P799, DOI 10.1080/02699050210131911; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; Radelet MA, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.3.e28; Regner A, 2001, J NEUROTRAUM, V18, P783, DOI 10.1089/089771501316919148; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Sosin DM, 1996, BRAIN INJURY, V10, P47; STRAUSS I, 1934, ARCH NEUROL PSYCHIAT, V31, P955; Thompson J, 2005, NEUROSCI LETT, V377, P158, DOI 10.1016/j.neulet.2004.11.090; Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092; Wheless JW, 2004, NEUROLOGIST, V10, P138, DOI 10.1097/01.nrl.0000126589.21840.a1; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; 2005, NEWSLETTER VOLUNTEER, P1	57	42	44	1	9	AMER PSYCHIATRIC PUBLISHING, INC	WASHINGTON	800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA	0895-0172	1545-7222		J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	SUM	2005	17	3					297	303		10.1176/appi.neuropsych.17.3.297			7	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	962BB	WOS:000231704900001	16179650				2021-06-18	
J	Cohen, JE; Rajz, G; Itshayek, E; Shoshan, Y; Umansky, F; Gomori, JM				Cohen, JE; Rajz, G; Itshayek, E; Shoshan, Y; Umansky, F; Gomori, JM			Endovascular management of traumatic and iatrogenic aneurysms of the pericallosal artery - Report of two cases	JOURNAL OF NEUROSURGERY			English	Article						traumatic aneurysm; pericallosal artery; endovascular therapy; tumor; complication	MISSILE HEAD WOUNDS; INTRACRANIAL ANEURYSMS; CHILDHOOD; VESSELS	Traumatic intracranial aneurysms are rare complications of closed and penetrating head injuries and may also be related to a variety of neurosurgical procedures. The primary goals in the treatment of patients harboring these lesions are early identification and intervention to prevent bleeding. Traumatic aneurysms are fragile, prone to rupture, and represent a challenging subset of vascular lesions for either surgery or endovascular therapy. Surgical approaches to aneurysms located at the pericallosal arteries are associated with higher rates of morbidity and mortality than approaches to other supratentorial aneurysms. Current endovascular treatment most often involves occlusion of the parent artery with the potential of added morbidity. The authors present their experience in the endovascular management of traumatic and iatrogenic aneurysms of the pericallosal artery achieved by primary coil embolization with parent vessel preservation. For patients harboring traumatic pericallosal aneurysms with favorable anatomical characteristics, in which the morbidity caused by parent vessel occlusion is not acceptable, endosaccular coil placement may be a valuable option.	Hadassah Univ Hosp, Hadassah Stroke Ctr, Sect Endovasc Neurosurg & Intervent Neuroradiol, Dept Neurosurg, IL-91120 Jerusalem, Israel; Hadassah Univ Hosp, Hadassah Stroke Ctr, Sect Endovasc Neurosurg & Intervent Neuroradiol, Dept Radiol, IL-91120 Jerusalem, Israel	Cohen, JE (corresponding author), Hadassah Univ Hosp, Hadassah Stroke Ctr, Sect Endovasc Neurosurg & Intervent Neuroradiol, Dept Neurosurg, IL-91120 Jerusalem, Israel.	jcohenns@yahoo.com					AARABI B, 1995, NEUROSURG CLIN N AM, V6, P775; AARABI B, 1988, NEUROSURGERY, V22, P1056, DOI 10.1227/00006123-198806010-00014; Amirjamshidi A, 1996, J NEUROSURG, V84, P769, DOI 10.3171/jns.1996.84.5.0769; ASARI S, 1977, J NEUROSURG, V46, P795, DOI 10.3171/jns.1977.46.6.0795; BENOIT BG, 1973, J NEUROL NEUROSUR PS, V36, P127, DOI 10.1136/jnnp.36.1.127; BUCKINGHAM MJ, 1988, NEUROSURGERY, V22, P398, DOI 10.1227/00006123-198802000-00022; CASEY ATH, 1994, BRIT J NEUROSURG, V8, P97, DOI 10.3109/02688699409002401; de Sousa AA, 1999, SURG NEUROL, V52, P128, DOI 10.1016/S0090-3019(99)00066-X; HADDAD FS, 1991, NEUROSURGERY, V28, P1; Hentschel S, 2003, CAN J NEUROL SCI, V30, P63, DOI 10.1017/S0317167100002468; HOLMES B, 1993, J TRAUMA, V35, P855, DOI 10.1097/00005373-199312000-00009; Horowitz MB, 1999, SURG NEUROL, V51, P31, DOI 10.1016/S0090-3019(98)00029-9; Menovsky T, 2002, NEUROSURGERY, V50, P11, DOI 10.1097/00006123-200201000-00003; Pierot L, 1996, NEUROL RES, V18, P49, DOI 10.1080/01616412.1996.11740377; SORIA ED, 1988, ANGIOLOGY, V39, P609, DOI 10.1177/000331978803900708; Uzan M, 1998, NEUROSURGERY, V43, P1314, DOI 10.1097/00006123-199812000-00024; VENTUREYRA ECG, 1994, CHILD NERV SYST, V10, P361, DOI 10.1007/BF00335125	17	42	49	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	MAR	2005	102	3					555	557		10.3171/jns.2005.102.3.0555			3	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	911PR	WOS:000228017200026	15796396				2021-06-18	
J	Jones, NC; Constantin, D; Prior, MJW; Morris, PG; Marsden, CA; Murphy, S				Jones, NC; Constantin, D; Prior, MJW; Morris, PG; Marsden, CA; Murphy, S			The neuroprotective effect of progesterone after traumatic brain injury in male mice is independent of both the inflammatory response and growth factor expression	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						behaviour; cytokines; inflammation; oedema; trauma	CEREBRAL-ARTERY OCCLUSION; SPINAL-CORD; PREFRONTAL CORTEX; CELL-DEATH; MALE-RATS; G-CSF; GENDER; INTERLEUKIN-1-BETA; ESTROGEN; PROTECTS	Previous studies suggest that progesterone may possess neuroprotective properties after traumatic insult but, with the exception of reduced formation of cerebral oedema, limited experimental evidence has been presented to support this claim. In the present study we focused on the effect of progesterone treatment on structural and functional deficits in an experimental model of traumatic brain injury. Female mice exhibited significantly (P = 0.0445) reduced lesion volumes compared with males after aseptic cryogenic cerebral injury (ACI), suggesting that female sex steroids provide protection against this injury. In male mice, progesterone treatment after injury (three intraperitoneal doses of 8 mg/kg) reduced lesion volume (P = 0.0429) and improved performance in a spatial cognitive task (Morris water maze; P = 0.0014). However, progesterone had no demonstrable effect on the formation of oedema as measured using T-2-weighted magnetic resonance imaging, nor did it affect brain water content. The pro-inflammatory cytokines TNF-alpha and IL-1 beta, and growth factors BDNF and G-CSF, were all strongly transcriptionally activated after ACI. However, progesterone administration did not affect expression of these genes. This study provides strong evidence that progesterone possesses neuroprotective properties in a mouse model of traumatic brain injury, but suggests that the steroid achieves this effect through mechanism(s) independent of the inflammatory response or growth factor up-regulation.	Univ Nottingham, Inst Cell Signalling, Nottingham NG7 2UH, England; Univ Nottingham, Inst Neurosci, Nottingham NG7 2UH, England; Univ Nottingham, Sir Peter Mansfield Magnet Resonance Ctr, Nottingham NG7 2UH, England	Murphy, S (corresponding author), Univ Nottingham, Inst Cell Signalling, Clifton Blvd, Nottingham NG7 2UH, England.	sean.murphy@nottingham.ac.uk	Jones, Nigel C/K-7773-2012	Jones, Nigel/0000-0002-1080-8439			Asbury ET, 1998, BEHAV BRAIN RES, V97, P99, DOI 10.1016/S0166-4328(98)00031-X; AVITSUR R, 1995, BRAIN BEHAV IMMUN, V9, P234, DOI 10.1006/brbi.1995.1022; Bergeron R, 1996, J NEUROSCI, V16, P1193; Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; Cervantes M, 2002, ARCH MED RES, V33, P6, DOI 10.1016/S0188-4409(01)00347-2; Chen JL, 1999, J NEUROL SCI, V171, P24, DOI 10.1016/S0022-510X(99)00247-6; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Galani R, 2001, RESTOR NEUROL NEUROS, V18, P161; Gibson CL, 2004, J CEREBR BLOOD F MET, V24, P805, DOI 10.1097/01.WCB.0000125365.83980.00; Gibson CL, 2005, J CEREBR BLOOD F MET, V25, P431, DOI 10.1038/sj.jcbfm.9600033; Giralt M, 2002, EXP NEUROL, V173, P114, DOI 10.1006/exnr.2001.7772; Gonzalez SL, 2004, NEUROSCIENCE, V125, P605, DOI 10.1016/j.neuroscience.2004.02.024; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Grossman KJ, 2004, BRAIN RES, V1008, P29, DOI 10.1016/j.brainres.2004.02.022; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Hermann DM, 2000, ACTA NEUROPATHOL, V99, P147, DOI 10.1007/PL00007418; Hicks RR, 1999, J NEUROTRAUM, V16, P501, DOI 10.1089/neu.1999.16.501; Jain SK, 2004, CYTOKINE, V26, P102, DOI 10.1016/j.cyto.2004.01.002; Jones NC, 2004, J NEUROPATH EXP NEUR, V63, P708, DOI 10.1093/jnen/63.7.708; Knerlich F, 1999, MOL BRAIN RES, V68, P73, DOI 10.1016/S0169-328X(99)00064-9; KOENIG HL, 1995, SCIENCE, V268, P1500, DOI 10.1126/science.7770777; Kuebler JF, 2003, CRIT CARE MED, V31, P1786, DOI 10.1097/01.CCM.0000063441.41446.23; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Miller L, 1998, J IMMUNOL, V160, P5098; Mohammad S, 1998, EPILEPSY RES, V30, P195, DOI 10.1016/S0920-1211(98)00004-7; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; NAKAO N, 1995, EXP NEUROL, V131, P1, DOI 10.1016/0014-4886(95)90002-0; POLAN ML, 1989, J CLIN ENDOCR METAB, V69, P1200, DOI 10.1210/jcem-69-6-1200; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Sakamoto H, 2001, J NEUROSCI, V21, P6221; Schumacher M, 2004, GROWTH HORM IGF RES, V14, pS18, DOI 10.1016/j.ghir.2004.03.007; Sharma HS, 2003, ACT NEUR S, V86, P383; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; Stein Donald G, 2003, Pediatr Rehabil, V6, P13, DOI 10.1080/1363849031000095279; Thomas AJ, 1999, SPINE, V24, P2134, DOI 10.1097/00007632-199910150-00013; Vegeto E, 1999, FASEB J, V13, P793; Wiedermann FJ, 2001, WIEN KLIN WOCHENSCHR, V113, P90; Wright DW, 2001, J NEUROTRAUM, V18, P901, DOI 10.1089/089771501750451820	45	42	44	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	MAR	2005	21	6					1547	1554		10.1111/j.1460-9568.2005.03995.x			8	Neurosciences	Neurosciences & Neurology	918PM	WOS:000228560100009	15845082				2021-06-18	
J	Pietrapiana, P; Tamietto, M; Torrini, G; Mezzanato, T; Rago, R; Perino, C				Pietrapiana, P; Tamietto, M; Torrini, G; Mezzanato, T; Rago, R; Perino, C			Role of premorbid factors in predicting safe return to driving after severe TBI	BRAIN INJURY			English	Article						TBI; brain injury; driving safety; premorbid factors	TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; FUNCTIONAL INDEPENDENCE MEASURE; SPINAL-CORD-INJURY; ACCIDENT INVOLVEMENT; ALZHEIMERS-DISEASE; CEREBRAL-DAMAGE; RELATIVES VIEW; SELF-AWARENESS; REHABILITATION	Primary objective: The present study explored the possibility of predicting post- injury fitness to safe driving in patients with severe traumatic brain injury ( TBI) ( n = 66). Methods and procedure: Sixteen different measures, derived from four domains ( demo/ biographic, medico- functional, neuropsychological, and psychosocial) were used as predictor variables, whereas driving outcomes were assessed in terms of driving status ( post- TBI drivers versus non- drivers) and driving safety ( number of post- TBI car accidents and violations). Main outcomes and results: About 50% of the patients resumed driving after TBI. Compared to post- TBI non- drivers, post- injury drivers had shorter coma duration. With regard to driving safety, the final multiple regression model combined four predictors ( years post- injury, accidents and violations before TBI, pre- TBI- risky- personality- index, and pre- TBI- risky- driving- style- index) and explained 72.5% of variance in the outcome measure. Conclusions: Since the best three predictors of post- injury driving safety addressed patients' premorbid factors, the results suggest that in order to evaluate the actual possibility of safe driving after TBI, it would be advisable to consider carefully patients' pre- TBI histories.	Univ Turin, Dipartimento Psicol, I-10123 Turin, Italy; Ausiliatrice Hosp, Turin, Italy; Univ Turin, Ctr Cognit Sci, I-10124 Turin, Italy	Tamietto, M (corresponding author), Univ Turin, Dipartimento Psicol, Via Po 14, I-10123 Turin, Italy.	tamietto@psych.unito.it		Tamietto, Marco/0000-0002-8815-8499			American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Andersson S, 1999, BRAIN INJURY, V13, P393, DOI 10.1080/026990599121458; BALL K, 1991, HUM FACTORS, V33, P583; Bieliauskas LA, 1998, CLIN NEUROPSYCHOL, V12, P206, DOI 10.1076/clin.12.2.206.1994; Boake C., 1998, J INT NEUROPSYCH SOC, V4, P75; BROOKE MM, 1992, AM J PHYS MED REHAB, V71, P177, DOI 10.1097/00002060-199206000-00009; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brouwer WH, 1997, NEUROPSYCHOL REHABIL, V7, P177, DOI 10.1080/713755536; BROWER W, 1992, 2 INT C OBJ EV REH M; COLEMAN RD, 2002, ARCH PHYS MED REHAB, P83; CROFT D, 1987, BRIT J OCCUPATIONAL, V50, P357; DAVIDOFF GN, 1990, ARCH PHYS MED REHAB, V71, P326; DEBELLEIX X, 2001, EUROPA MEDICOPHYSICA, V37, P201; Dimarco F, 2001, EURA MEDICOPHYS, V37, P215; DITUNNO JF, 1995, SPINAL CORD INJURY C; ENGUM ES, 1989, COGNITIVE REHABILITA, V7, P22; Evans, 1991, TRAFFIC SAFETY DRIVE; FARMER J, 2000, BRAIN INJURY, P14; Finset A, 2000, BRAIN INJURY, V14, P887; Fisk GD, 1998, BRAIN INJURY, V12, P683; Fleming JM, 1996, BRAIN INJURY, V10, P1; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; FORMISANO R, 2001, EUROPA MEDICOPHYSICA, V37, P257; FOX G, 1993, ASTB C SEPT TOK, P1; Fox G K, 1992, Disabil Rehabil, V14, P140; FOX GK, 1998, ARCH PHYS MED REHAB, P79; GALSKI T, 1993, AM J OCCUP THER, V47, P391, DOI 10.5014/ajot.47.5.391; GALSKI T, 1990, AM J OCCUP THER, V44, P709, DOI 10.5014/ajot.44.8.709; GALSKI T, 1992, AM J OCCUP THER, V46, P324, DOI 10.5014/ajot.46.4.324; GOUVIER WD, 1989, ARCH PHYS MED REHAB, V70, P745; Granger CV, 1986, TOP GERIATR REHABIL, V1, P59, DOI 10.1097/00013614-198604000-00007; HALL K, 1997, J REHABIL OUTCOMES M, V1, P63; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; Hall KM, 1999, ARCH PHYS MED REHAB, V80, P1471, DOI 10.1016/S0003-9993(99)90260-5; Hartje W, 1991, NEUROPSYCHOL REHABIL, V3, P161; Hawley CA, 2001, J NEUROL NEUROSUR PS, V70, P761, DOI 10.1136/jnnp.70.6.761; HELLAWELL DJ, 1999, BRAIN INJURY, P13; HILLIER SL, 1997, BRAIN INJURY, P11; HOFMEIJER AMJ, 2002, EUROPA MEDICOPHYSICA, V38, P29; HUNT L, 1993, J AM GERIATR SOC, V71, P177; JONES MH, 1978, 783 U SO CAL; JONES R, 1983, AM J OCCUP THER, V37, P754, DOI 10.5014/ajot.37.11.754; Kapust L R, 1992, J Geriatr Psychiatry Neurol, V5, P210; KATZ RT, 1990, ARCH PHYS MED REHAB, V71, P133; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; KORTELING JE, 1990, HUM FACTORS, V32, P95, DOI 10.1177/001872089003200107; Korteling JE, 1996, ARCH PHYS MED REHAB, V77, P138, DOI 10.1016/S0003-9993(96)90158-6; Lishman W. A., 1987, ORGANIC PSYCHIAT; LISHMAN WA, 1973, PSYCHOL MED, V3, P304, DOI 10.1017/S003329170004959X; Lundqvist A, 2001, BRAIN INJURY, V15, P981, DOI 10.1080/02699050110065637; Max JE, 2001, J NEUROPSYCH CLIN N, V13, P161, DOI 10.1176/appi.neuropsych.13.2.161; Mazer BL, 1998, ARCH PHYS MED REHAB, V79, P743, DOI 10.1016/S0003-9993(98)90350-1; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; Meyers J E, 1999, Appl Neuropsychol, V6, P154, DOI 10.1207/s15324826an0603_3; MICHON JA, 1989, ACCIDENT ANAL PREV, V21, P341, DOI 10.1016/0001-4575(89)90025-0; Michon John A., 1979, 7901 VK U GRON TRAFF; MIHAL WL, 1976, J APPL PSYCHOL, V61, P229, DOI 10.1037/0021-9010.61.2.229; Nouri F M, 1987, Int Disabil Stud, V9, P110; Nouri F.M., 1992, CLIN REHABIL, V6, DOI [https://doi.org/10.1177/026921559200600402, DOI 10.1177/026921559200600402]; Novack TA, 2000, BRAIN INJURY, V14, P987; O'Shanick G J, 1989, Psychiatr Med, V7, P1; ODENHEIMER GL, 1994, J GERONTOL, V49, P153, DOI DOI 10.1093/GERONJ/49.4.M153; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Ott BR, 2000, DEMENT GERIATR COGN, V11, P153, DOI 10.1159/000017229; Parker RS, 1996, J CLIN PSYCHOL, V52, P32, DOI 10.1002/(SICI)1097-4679(199601)52:1<32::AID-JCLP5>3.0.CO;2-Y; PERINO C, 1997, GIORNALE ITALIANO RI, V1, P53; PRIDDY D A, 1990, Brain Injury, V4, P267, DOI 10.3109/02699059009026176; QUIGLEY FL, 1983, AM J OCCUP THER, V37, P474, DOI 10.5014/ajot.37.7.474; RANNEY TA, 1994, ACCIDENT ANAL PREV, V26, P733, DOI 10.1016/0001-4575(94)90051-5; RAPPORT LJ, 1993, ARCH PHYS MED REHAB, V74, P621, DOI 10.1016/0003-9993(93)90160-C; Rapport LJ, 1998, ARCH PHYS MED REHAB, V79, P629, DOI 10.1016/S0003-9993(98)90035-1; RAPPORT LJ, 1998, M AM PSYCH ASS SAN F; ROTHKE S, 1989, INT J CLIN NEUROPSYC, V11, P134; Schanke AK, 2000, SCAND J PSYCHOL, V41, P113, DOI 10.1111/1467-9450.00179; SCHWEITZER JR, 1994, ERGONOMICS REHABILIT, P85; SHORE D, 1980, ARCH PHYS MED REHAB, V61, P81; SIVAK M, 1981, ARCH PHYS MED REHAB, V62, P476; SPINNLER H, 1987, ITAL J NEUROL SCI S, P6; STORKX LC, 1986, J CLIN EXPT NEUROPSY, V8, P421; Tate RL, 1999, CORTEX, V35, P39, DOI 10.1016/S0010-9452(08)70784-6; Tate RL, 1998, NEUROPSYCHOL REHABIL, V8, P1, DOI 10.1080/713755554; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; TEASDALE G, 1974, LANCET, V2, P81; Trobe JD, 1996, ARCH NEUROL-CHICAGO, V53, P411, DOI 10.1001/archneur.1996.00550050033021; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; VANWOLFFELAAR P, 1988, ROAD USER BEHAVIOUR, P302; VANZOMEREN A, 1987, ARCH PHYS MED REHAB, V68, P607; VANZOMEREN AH, 1988, ARCH PHYS MED REHAB, V69, P90; WALLER PF, 1988, TRANSPORTATION AGING, V2, P72; Wechsler D., 1997, WAIS R WECHSLER ADUL; WILSON JTL, 1994, J NEUROL NEUROSUR PS, V57, P198, DOI 10.1136/jnnp.57.2.198; Wilson T, 1983, Int Rehabil Med, V5, P170	94	42	44	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAR	2005	19	3					197	211		10.1080/02699050400017197			15	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	906WJ	WOS:000227675000006	15832894				2021-06-18	
J	Jang, SH; Cho, SH; Kim, YH; You, SH; Kim, SH; Kim, O; Yang, DS; Son, SM				Jang, SH; Cho, SH; Kim, YH; You, SH; Kim, SH; Kim, O; Yang, DS; Son, SM			Motor recovery mechanism of diffuse axonal injury: A combined study of transcranial magnetic stimulation and functional MRI	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article						diffuse axonal injury; functional MRI; magnetic stimulation; motor recovery	TRAUMATIC BRAIN-INJURY; REORGANIZATION; CORTEX; STROKE; LOCALIZATION	Purpose: The purpose of this study was to investigate the motor recovery mechanism following diffuse axonal injury (DAI) using transcranial magnetic stimulation (TMS) and functional MRI (fMRI). Methods: Twenty-six hands of 13 control subjects and 14 affected hands of 8 patients (two hemiparetics and six quadriparetics) were evaluated. All the patients were initially diagnosed with DAI and were evaluated after they had reached their maximal motor recovery. fMRI was performed at 1.5 T using a hand grasp-release movement paradigm and TMS was applied with a round coil over the vertex. Results: fMRI revealed that both normal subjects and patients with DAI showed increased contralateral primary sensori-motor cortex activation during affected hand movement. The motor evoked potentials (MEPs) of the patient group was slightly delayed in latency and significantly increased in duration and turns. The relative MEP amplitude, phase, and excitatory threshold were not significantly different between the groups. Conclusions: These findings may indicate the heterogeneity of the axons in the recovery process of the corticospinal tract. It seems that the motor recovery in patients who had suffered DAI was attributable to the recovery of the corticospinal tract.	Yonsei Univ, Coll Hlth Sci, Dept Phys Therapy, Wonju 220710, Kangwondo, South Korea; Pochon Jungmoon Univ, Coll Med, Bundang CHA Gen Hosp, Dept Phys Med & Rehabil, Sungnam, South Korea; Hampton Univ, Phys Therapy Program, Hampton, VA 23668 USA	Cho, SH (corresponding author), Yonsei Univ, Coll Hlth Sci, Dept Phys Therapy, Wonju 220710, Kangwondo, South Korea.	davinci@dragon.yonsei.ac.kr					Abbott LF, 2000, NAT NEUROSCI, V3, P1178, DOI 10.1038/81453; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ALEXANDER GE, 1990, J NEUROPHYSIOL, V64, P133; Bastings EP, 1997, J NEUROL REHABIL, V11, P97; Cramer SC, 1997, STROKE, V28, P2518, DOI 10.1161/01.STR.28.12.2518; DARIANSMITH C, 1994, NATURE, V368, P737, DOI 10.1038/368737a0; HALLET M, 1996, J CLIN NEUROPHYSIOL, V13, P348; Hallett M, 1998, NEUROREHABILITATION, V10, P131, DOI 10.3233/NRE-1998-10205; Jang SH, 2002, AM J PHYS MED REHAB, V81, P844, DOI 10.1097/00002060-200211000-00007; Jang SH, 2001, ARCH PHYS MED REHAB, V82, P1733, DOI 10.1053/apmr.2001.25101; Katz DI, 1998, ARCH PHYS MED REHAB, V79, P488, DOI 10.1016/S0003-9993(98)90060-0; Macdonell RAL, 1999, NEUROLOGY, V53, P1462, DOI 10.1212/WNL.53.7.1462; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Rossini PM, 2003, LANCET NEUROL, V2, P493, DOI 10.1016/S1474-4422(03)00485-X; ROSSINI PM, 1994, ELECTROEN CLIN NEURO, V91, P79, DOI 10.1016/0013-4694(94)90029-9; SCHEFF S, 1977, SCIENCE, V197, P795, DOI 10.1126/science.887924; SELZER ME, 1995, J NEUROL REHABIL, V9, P73; Tao HZW, 2001, P NATL ACAD SCI USA, V98, P11009, DOI 10.1073/pnas.191351698; WEBER RJ, 1997, PRACTICAL ELECTROMYO, P131; Yousry TA, 1997, BRAIN, V120, P141, DOI 10.1093/brain/120.1.141	20	42	43	0	5	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0922-6028	1878-3627		RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.		2005	23	1					51	56					6	Neurosciences	Neurosciences & Neurology	944HG	WOS:000230417200006	15846032				2021-06-18	
J	Broglio, SP; Guskiewicz, KM; Sell, TC; Lephart, SM				Broglio, SP; Guskiewicz, KM; Sell, TC; Lephart, SM			No acute changes in postural control after soccer heading	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; COMPUTED-TOMOGRAPHY; PLAYERS; CONCUSSION; STABILITY; FOOTBALL; BALANCE; SWAY; DEFICITS; IMPACT	Background: Soccer heading has been proposed as a potential cause of cerebral dysfunction. Objective: To examine the acute effects of two types of soccer heading on postural control. Methods: Collegiate soccer players were randomly assigned to one of four groups: control, linear heading, simulated rotational heading, or rotational heading. Each subject completed a baseline postural stability assessment on day 1. On day 2 the same assessment was completed for the control subjects. The simulated rotational heading group completed a simulated heading drill before postural stability testing. The linear and rotational heading groups performed a heading drill with 20 balls at 88.71 km/h (55 mph), before postural stability testing. Separate one between (group), three within (surface, eyes, and day), mixed model, repeated measures analyses of variance were conducted on values for total sway and mean centre of pressure. Results: The mixed model analysis of variance of results showed no significant differences (p > 0.05) for the interactions of interest for either variable. Results suggest no acute changes in measures of postural control in soccer players completing either a linear or rotational soccer heading drill of 20 balls at a fixed speed. Conclusion: Non-significant interactions between surface, eyes, day, and group indicate that sensory interaction of the balance mechanism components are not be compromised by the heading drill. This research supports previous studies suggesting that there are no acute risks associated with routine soccer heading. A direct comparison between these findings and those suggesting long term chronic deficits, however, cannot be made. Other studies that report chronic cerebral deficits in soccer players may have resulted from factors other than soccer heading and warrant further examination.	Univ Pittsburgh, Pittsburgh, PA USA; Univ N Carolina, Chapel Hill, NC USA	Broglio, SP (corresponding author), Univ Georgia, Ramsey Ctr, 300 River Rd, Athens, GA 30602 USA.	sbroglio@coe.uga.edu		Guskiewicz, Kevin/0000-0002-8682-2130			Arbogast KB, 1999, J BIOMECH, V32, P865, DOI 10.1016/S0021-9290(99)00042-1; ATHA J, 1985, BRIT MED J, V291, P1756, DOI 10.1136/bmj.291.6511.1756; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; Brandt T. H., 1986, DISORDERS POSTURE GA, P157; BYL NN, 1991, SPINE, V16, P325, DOI 10.1097/00007632-199103000-00012; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Dvorak J, 2000, AM J SPORT MED, V28, pS3; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; GUSKIEWICZ KM, 1997, MED SCI SPORTS EXERC, V29, P213; GUYTON A, 2000, TXB MED PHYSL, P622; HORAK FB, 1990, EXP BRAIN RES, V82, P167; INGERSOLL CD, 1992, MED SCI SPORT EXER, V24, P739; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; Keselman HJ, 1998, PSYCHOPHYSIOLOGY, V35, P470, DOI 10.1111/1469-8986.3540470; Kirkendall DT, 2001, SPORTS MED, V31, P369, DOI 10.2165/00007256-200131050-00006; Kuo AD, 1998, EXP BRAIN RES, V122, P185, DOI 10.1007/s002210050506; Lewis LM, 2001, ACAD EMERG MED, V8, P604, DOI 10.1111/j.1553-2712.2001.tb00171.x; LOVELL M, 1989, CLIN J SPORT MED, V9, P193; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser EJT, 2000, PHYSICIAN SPORTSMED, V28, P87, DOI 10.3810/psm.2000.01.645; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; McCrea M, 2001, J ATHL TRAINING, V36, P274; NASHNER LM, 1982, J NEUROSCI, V2, P536; Naunheim RS, 2000, J TRAUMA, V48, P938, DOI 10.1097/00005373-200005000-00020; Putukian M, 2000, CLIN J SPORT MED, V10, P104, DOI 10.1097/00042752-200004000-00004; RICCIO GE, 1993, VARIABILITY AND MOTOR CONTROL, P317; Riemann BL, 2000, J ATHL TRAINING, V35, P19; ROSS RJ, 1987, CLIN SPORT MED, V6, P41; ROSS RJ, 1983, JAMA-J AM MED ASSOC, V249, P211, DOI 10.1001/jama.249.2.211; SHUMWAYCOOK A, 1986, PHYS THER, V66, P1548, DOI 10.1093/ptj/66.10.1548; SORTLAND O, 1989, NEURORADIOLOGY, V31, P44; TSYVAER AT, 1989, AM J SPORTS MED, V17, P573; Tsyvaer AT, 1981, BRIT J SPORT MED, V15, P163; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; 1976, LANCET          0221, P401	38	42	42	2	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674			BRIT J SPORT MED	Br. J. Sports Med.	OCT 1	2004	38	5					561	567		10.1136/bjsm.2003.004887			7	Sport Sciences	Sport Sciences	856PE	WOS:000224056300011	15388539	Green Published, Bronze			2021-06-18	
J	Hart, T; Buchhofer, R; Vaccaro, M				Hart, T; Buchhofer, R; Vaccaro, M			Portable electronic devices as memory and organizational aids after traumatic brain injury: A consumer survey study	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						assistive technology; cognitive compensations; traumatic brain injury	POCKET-COMPUTER; PEOPLE; REHABILITATION; SYSTEM	Objective: To ascertain consumer experiences and attitudes regarding the use of portable electronic devices as memory and organizational aids after traumatic brain injury (TBI). Design: Survey study. Setting: Post-acute TBI rehabilitation programs, research registries. Participants: Eighty persons with moderate to severe TBI interviewed a median of 3.7 years postinjury. Outcome Measure: Survey administered in structured interview format, analyzed both quantitatively and qualitatively. Results: Two thirds of participants reported regular use of computers, but fewer than one third had experience with handheld computers or similar devices. Interest in using portable devices for everyday memory and organizational tasks was higher than the expressed need for improvement in participants' current strategies. Respondents expressed reliable preferences for key device features, including simplicity of use, technical support, and long-lasting battery power. Preferred functions included keeping track of money spent, remembering things to do, and remembering what other people say. Conclusion: Portable electronic devices are acceptable or desirable by consumers with moderate to severe TBI for use as compensatory aids.	Thomas Jefferson Univ, Med Coll, Rehabil Res Inst, Philadelphia, PA 19141 USA; Thomas Jefferson Univ, Med Coll, Dept Rehabil Med, Philadelphia, PA 19141 USA	Hart, T (corresponding author), Thomas Jefferson Univ, Med Coll, Rehabil Res Inst, 1200 W Tabor Rd,Korman Suite 213, Philadelphia, PA 19141 USA.	thart@einstein.edu					Centers for Disease Control and Prevention, 1998, BEH RISK FACT SURV S; Davies DK, 2002, MENT RETARD, V40, P358, DOI 10.1352/0047-6765(2002)040<0358:EITMSO>2.0.CO;2; Evans JJ, 2003, J INT NEUROPSYCH SOC, V9, P925, DOI 10.1017/S1355617703960127; Hart T, 2003, BRAIN INJURY, V17, P401, DOI 10.1080/0269905021000038438; Hart T, 2002, J HEAD TRAUMA REHAB, V17, P556, DOI 10.1097/00001199-200212000-00007; HART T, 2004, ARCH PHYS MED RE SEP, P85; Hersh N A, 1994, NeuroRehabilitation, V4, P187, DOI 10.3233/NRE-1994-4309; KAYE HS, 2000, COOMPUTER INTERNET A; NELSON D, QUESTION APPRAISAL S; Oriani M, 2003, AGING MENT HEALTH, V7, P22, DOI 10.1080/1360786021000045863; Ricker JH, 2002, J HEAD TRAUMA REHAB, V17, P242, DOI 10.1097/00001199-200206000-00005; Scherer MJ., 2002, TRADIT DISCOV, V14, P125, DOI DOI 10.3233/TAD-2002-14308; van den Broek MD, 2000, BRAIN INJURY, V14, P455; WILSON BA, 1989, CORTEX, V25, P115, DOI 10.1016/S0010-9452(89)80011-5; Wilson BA, 2003, NEUROREHABILITATION, V18, P3; Wilson BA, 2001, J NEUROL NEUROSUR PS, V70, P477, DOI 10.1136/jnnp.70.4.477; Wright P, 2001, BRAIN INJURY, V15, P787, DOI 10.1080/02699050110045161; Wright P, 2001, INT J REHABIL RES, V24, P299, DOI 10.1097/00004356-200112000-00006	18	42	43	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2004	19	5					351	365		10.1097/00001199-200409000-00001			15	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	858UB	WOS:000224216300001	15597027				2021-06-18	
J	Roche, RAP; Dockree, PM; Garavan, H; Foxe, JJ; Robertson, IH; O'Mara, SM				Roche, RAP; Dockree, PM; Garavan, H; Foxe, JJ; Robertson, IH; O'Mara, SM			EEG alpha power changes reflect response inhibition deficits after traumatic brain injury (TBI) in humans	NEUROSCIENCE LETTERS			English	Article						event-related potentials; spectral power; desynchronisation; N2/P3 complex; inhibitory control	ATTENTION; SCHIZOPHRENIA; PERFORMANCE	Brain damage due to traumatic brain injury (TBI) has been associated with deficits in executive functions and the dynamic control of behaviour. Event-related brain potentials and spectral power data were recorded from eight TBI participants and eight matched controls while they completed a Go/NoGo response inhibition task. The TBI group was found to be significantly impaired at the task compared to controls, and exhibited abnormal N2 and P3 waveform components in response to NoGo stimuli relative to controls. Significant correlations were also found between alpha power, Go-trial RT and errors. We conclude that abnormal activity in the structures damaged in this group may render such patients less capable of maintaining a state of alpha desynchronisation compared to controls, resulting in poorer performance on the task. (C) 2004, Elsevier Ireland Ltd. All rights reserved.	Univ Dublin Trinity Coll, Dept Psychol, Dublin 2, Ireland; Univ Dublin Trinity Coll, Trinity Coll Inst Neurosci, Dublin 2, Ireland; Nathan S Kline Inst Psychiat Res, Orangeburg, NY 10962 USA	Roche, RAP (corresponding author), Univ Dublin Trinity Coll, Dept Psychol, Dublin 2, Ireland.	riroche@tcd.ie	Roche, Richard AP/C-4798-2009	Roche, Richard AP/0000-0001-6606-4187; Foxe, John/0000-0002-4300-3098; O'Mara, Shane/0000-0001-8087-8531; Robertson, Ian H/0000-0001-8637-561X	NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA014100] Funding Source: NIH RePORTER; NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA14100] Funding Source: Medline		Carter CS, 2001, AM J PSYCHIAT, V158, P1423, DOI 10.1176/appi.ajp.158.9.1423; Casey BJ, 1997, J AM ACAD CHILD PSY, V36, P374, DOI 10.1097/00004583-199703000-00016; Curtis CE, 2001, EXP BRAIN RES, V137, P228, DOI 10.1007/s002210000635; DASILVA FHL, 1980, ELECTROEN CLIN NEURO, V50, P449, DOI 10.1016/0013-4694(80)90011-5; Dias EC, 2003, CEREB CORTEX, V13, P701, DOI 10.1093/cercor/13.7.701; Foxe JJ, 1998, NEUROREPORT, V9, P3929, DOI 10.1097/00001756-199812010-00030; Garavan H, 2002, NEUROIMAGE, V17, P1820, DOI 10.1006/nimg.2002.1326; Garavan H, 1999, P NATL ACAD SCI USA, V96, P8301, DOI 10.1073/pnas.96.14.8301; Konrad KN, 2000, BRAIN INJURY, V14, P859; Levine B, 2000, NEUROPSYCHOLOGY, V14, P491, DOI 10.1037/0894-4105.14.4.491; Manly T, 2003, NEUROCASE, V9, P340, DOI 10.1076/neur.9.4.340.15553; Robertson I H, 1996, J Int Neuropsychol Soc, V2, P525; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; ROCHE RAP, UNPUB EXP BRAIN RES; Worden MS, 2000, J NEUROSCI, V20; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	16	42	46	0	13	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	MAY 13	2004	362	1					1	5		10.1016/j.neulet.2003.11.064			5	Neurosciences	Neurosciences & Neurology	822HZ	WOS:000221531100001	15147767				2021-06-18	
J	Hoofien, D; Gilboa, A; Vakil, E; Barak, O				Hoofien, D; Gilboa, A; Vakil, E; Barak, O			Unawareness of cognitive deficits and daily functioning among persons with traumatic brain injuries	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							MEMORY-METAMEMORY DISSOCIATIONS; SELF-AWARENESS; IMPAIRED AWARENESS; BEHAVIORAL LIMITATIONS; REHABILITATION; DYSFUNCTION; INFECTION; ADULTS	This study examines levels of unawareness of cognitive deficits and their relationship to functional outcome among persons with traumatic brain injury (TBI). Data from 61 persons with TBI and 34 family members consisting of various measures were used. The results suggest that awareness of cognitive deficits is not differentially distributed along a concrete-abstract continuum of cognitive domains. Awareness in this sample was significantly related to psychiatric symptomatology and partially associated with behavior disturbances and daily functioning, but not with vocational outcomes. Persons with TBI who over-estimated their cognitive abilities were found to function worse on most outcome measures, except vocation, than persons who did not overestimate their abilities.	Hebrew Univ Jerusalem, Dept Psychol, IL-91905 Jerusalem, Israel; Natl Inst Rehabil Brain Injured, Tel Aviv, Israel; Bar Ilan Univ, Ramat Gan, Israel	Hoofien, D (corresponding author), Hebrew Univ Jerusalem, Dept Psychol, Mt Scopus, IL-91905 Jerusalem, Israel.	mshoofi@mscc.huji.ac.il		Gilboa, Asaf/0000-0002-4530-7490			ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; Anderson S. W., 1989, CLIN NEUROPSYCHOL, V3, P327, DOI DOI 10.1080/13854048908401482; Bogod NM, 2003, J INT NEUROPSYCH SOC, V9, P450, DOI 10.1017/S1355617703930104; CAVALLO M M, 1992, Brain Injury, V6, P327, DOI 10.3109/02699059209034947; DEATON AV, 1986, REHABIL PSYCHOL, V31, P231, DOI 10.1037//0090-5550.31.4.231; Derogatis LR., 1977, SCL 90 MANUAL SCORIN; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; Fleming J, 1999, OCCUP THER J RES, V19, P3, DOI 10.1177/153944929901900101; Fleming JM, 1996, BRAIN INJURY, V10, P1; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; Hinkin CH, 1996, J CLIN EXP NEUROPSYC, V18, P431, DOI 10.1080/01688639608408999; Hoofien D, 2001, BRAIN INJURY, V15, P189; Langer KG, 1999, PSYCHOTHERAPEUTIC INTERVENTIONS FOR ADULTS WITH BRAIN INJURY OR STROKE: A CLINICIAN'S TREATMENT RESOURCE, P75; Malec JF, 2000, REHABIL PSYCHOL, V45, P227, DOI 10.1037/0090-5550.45.3.227; MAPOU RL, 1992, HDB HEAD TRAUMA ACUT, P75; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; Melamed S, 1999, SCAND J REHABIL MED, V31, P23; MELAMED S, 1985, SCAND J REHABIL MED, P129; Ownsworth TL, 2002, BRAIN INJURY, V16, P291, DOI 10.1080/02699050110103986; Port A, 2002, BRAIN INJURY, V16, P277, DOI 10.1080/02699050110103274; Prigatano G. P., 1990, CLIN NEUROPSYCHOL, V4, P163, DOI [10.1080/13854049008401509, DOI 10.1080/13854049008401509]; Prigatano GP, 1996, CLIN NEUROPSYCHOL, V10, P191, DOI 10.1080/13854049608406680; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Prigatano GP, 1998, J HEAD TRAUMA REHAB, V13, P29, DOI 10.1097/00001199-199810000-00005; Prigatano GP, 1991, AWARENESS DEFICIT BR, P111; PRIGATANO GP, 1999, COGNITIVE NEUROREHAB, P240; Rourke SB, 1999, J CLIN EXP NEUROPSYC, V21, P757, DOI 10.1076/jcen.21.6.757.852; SHALLICE T, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P125; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Sherer M, 1998, BRAIN INJURY, V12, P63, DOI 10.1080/026990598122863; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; Spreen O., 1998, COMPENDIUM NEUROPSYC; Strong J., 1995, BRIT J OCCUPATIONAL, V58, P55, DOI DOI 10.1177/030802269505800204; Stuss D.T., 1986, FRONTAL LOBES; Stuss DT., 1991, AWARENESS DEFICIT BR, P63; WALKER DE, 1987, J CLIN PSYCHOL, V43, P699, DOI 10.1002/1097-4679(198711)43:6<699::AID-JCLP2270430610>3.0.CO;2-9; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; WHYTE J, 1986, J HEAD TRAUMA REHAB, V1, P64	39	42	42	0	6	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	APR	2004	26	2					278	290		10.1076/jcen.26.2.278.28084			13	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	810QW	WOS:000220719800013	15202547				2021-06-18	
J	Marion, DW				Marion, DW			Controlled normothermia in neurologic intensive care	CRITICAL CARE MEDICINE			English	Article; Proceedings Paper	2nd Annual Safar Symposium	OCT   30, 2003	UNIV PITTSBURGH, PITTSBURGH, PENNSYLVANIA		UNIV PITTSBURGH	controlled normothermia; therapeutic hypothermia; traumatic brain injury	TRAUMATIC BRAIN-INJURY; PROGNOSTIC-SIGNIFICANCE; CARDIAC-ARREST; HYPOTHERMIA; HYPERTHERMIA; TEMPERATURE; FEVER; HEMORRHAGE; ISCHEMIA		Boston Univ, Sch Med, Dept Neurol Surg, Boston, MA 02118 USA; Boston Med Ctr, Boston, MA USA	Marion, DW (corresponding author), Boston Univ, Sch Med, Dept Neurol Surg, Boston, MA 02118 USA.		Marion, Donald/AAR-5749-2021	Marion, Donald/0000-0003-4627-7702			Albrecht RF, 1998, MAYO CLIN PROC, V73, P629; AZZIMINDI G, 1995, STROKE, V26, P2043; Baena RC, 1997, NEUROLOGY, V48, P768, DOI 10.1212/WNL.48.3.768; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; CASTILLO J, 1994, CEREBROVASC DIS, V4, P56; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Clifton GL, 2001, J NEUROSURG, V95, P751, DOI 10.3171/jns.2001.95.5.0751; DIETRICH WD, 1992, J NEUROTRAUMA, V9, P475; Hajat C, 2000, STROKE, V31, P410, DOI 10.1161/01.STR.31.2.410; Henker RA, 1998, NEUROSURGERY, V42, P1071, DOI 10.1097/00006123-199805000-00071; HINDFELT B, 1976, ACTA NEUROL SCAND, V53, P72, DOI 10.1111/j.1600-0404.1976.tb04326.x; Holzer M, 2002, NEW ENGL J MED, V346, P549; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; Kilpatrick MM, 2000, NEUROSURGERY, V47, P850, DOI 10.1097/00006123-200010000-00011; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Morimoto T, 1997, BRAIN RES, V746, P43, DOI 10.1016/S0006-8993(96)01154-7; Oliveira J, 2001, NEUROLOGY, V56, P1299, DOI 10.1212/WNL.56.10.1299; Rumana CS, 1998, CRIT CARE MED, V26, P562, DOI 10.1097/00003246-199803000-00032; Safar P, 2001, NEW ENGL J MED, V345, P66; Schwarz S, 2000, NEUROLOGY, V54, P354, DOI 10.1212/WNL.54.2.354	20	42	44	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0090-3493			CRIT CARE MED	Crit. Care Med.	FEB	2004	32	2		S			S43	S45		10.1097/01.CCM.0000110731.69637.16			3	Critical Care Medicine	General & Internal Medicine	775TP	WOS:000189077000008	15043227				2021-06-18	
J	Gyulkhandanyan, AV; Feeney, CJ; Pennefather, PS				Gyulkhandanyan, AV; Feeney, CJ; Pennefather, PS			Modulation of mitochondrial membrane potential and reactive oxygen species production by copper in astrocytes	JOURNAL OF NEUROCHEMISTRY			English	Article						antioxidants; astrocytes; copper; copper chelators; mitochondrial membrane potential; reactive oxygen species	TRAUMATIC BRAIN-INJURY; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; CELL-DEATH; PERMEABILITY TRANSITION; SUPEROXIDE DISMUTASES; LIVER-MITOCHONDRIA; NEURODEGENERATIVE DISEASES; ALZHEIMERS-DISEASE; HEART-MITOCHONDRIA	In monolayers of cultured rat astrocytes a number of agents that induce oxidative stress act synergistically with exposure to copper leading to rapid depolarization of the mitochondrial membrane potential (Psi(m)) and increased reactive oxygen species (ROS) production. Copper sensitized astrocytes to the action of menadione, an intracellular generator of superoxide anion radical, exogenous hydrogen peroxide (H2O2) and rotenone, an inhibitor of mitochondrial electron transport chain complex I. However, significant differences were observed in the ability to modulate the copper-enhanced oxidative stress depending on which stressor was used. The inhibitor of mitochondrial permeability transition cyclosporin A attenuated the effect of copper and rotenone, but had no protective action in the case of H2O2/copper and menadione/copper combinations. The H2O2 scavenger pyruvate was effective at protecting mitochondria against damage associated with the combined exposure to H2O2/copper and menadione/copper but not to the rotenone/copper combination. The antioxidant Trolox was ineffective at protecting against any of these actions and indeed had a damaging effect when combined with copper. The membrane-permeable copper chelator neocuproine combined with sensitizing concentrations of menadione caused a decrease in Psi(m), mimicking the action of copper. Penicillamine, a membrane-impermeable copper chelator, was effective at reducing copper sensitization. Endogenous copper, mobilized during periods of oxidative stress, may play a role in the pathophysiology of brain injury. Our results suggest that this might be particularly dangerous in dysfunctional conditions in which the mitochondrial electron transport chain is compromised.	Univ Toronto, Fac Pharm, Dept Pharmaceut Sci, Toronto, ON M5S 2S2, Canada; Univ Toronto, Dept Physiol, Toronto, ON M5S 2S2, Canada; Univ Toronto, Inst Med Sci, Toronto, ON M5S 2S2, Canada	Pennefather, PS (corresponding author), Univ Toronto, Fac Pharm, Dept Pharmaceut Sci, 19 Russell St, Toronto, ON M5S 2S2, Canada.						Albertini R, 1999, FREE RADICAL RES, V30, P181, DOI 10.1080/10715769900300201; Arnaiz SL, 1999, NITRIC OXIDE-BIOL CH, V3, P235, DOI 10.1006/niox.1999.0229; Atwood CS, 1998, J BIOL CHEM, V273, P12817, DOI 10.1074/jbc.273.21.12817; Bayol-Denizot C, 2000, BBA-MOL CELL RES, V1497, P115, DOI 10.1016/S0167-4889(00)00047-1; Beal MF, 2000, TRENDS NEUROSCI, V23, P298, DOI 10.1016/S0166-2236(00)01584-8; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; BOVERIS A, 1972, BIOCHEM J, V128, P617, DOI 10.1042/bj1280617; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brand KA, 1997, FASEB J, V11, P388; Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8; CADENAS E, 1977, ARCH BIOCHEM BIOPHYS, V180, P248, DOI 10.1016/0003-9861(77)90035-2; Camakaris J, 1999, BIOCHEM BIOPH RES CO, V261, P225, DOI 10.1006/bbrc.1999.1073; Cassarino DS, 1999, BRAIN RES REV, V29, P1, DOI 10.1016/S0165-0173(98)00046-0; Chan PH, 2001, J CEREBR BLOOD F MET, V21, P2, DOI 10.1097/00004647-200101000-00002; CHANCE B, 1979, PHYSIOL REV, V59, P527; CINO M, 1989, ARCH BIOCHEM BIOPHYS, V269, P623, DOI 10.1016/0003-9861(89)90148-3; Clarke G, 2000, NATURE, V406, P195, DOI 10.1038/35018098; CONSTANTINI P, 1996, J BIOL CHEM, V271, P6746; De Vizcaya-Ruiz A, 2000, TOXICOL IN VITRO, V14, P1, DOI 10.1016/S0887-2333(99)00082-X; Desagher S, 1997, J NEUROSCI, V17, P9060; DESAGHER S, 1996, J NEUROSCI, V16, P25; Feeney CJ, 2003, J NEUROSCI METH, V125, P13, DOI 10.1016/S0165-0270(03)00027-X; Ferruzza S, 2000, BIOMETALS, V13, P179, DOI 10.1023/A:1009271622356; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; FLINT DH, 1993, J BIOL CHEM, V268, P22369; Fontaine E, 1999, J BIOENERG BIOMEMBR, V31, P335, DOI 10.1023/A:1005475802350; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; Fridovich I, 1997, J BIOL CHEM, V272, P18515, DOI 10.1074/jbc.272.30.18515; Garcia N, 2000, MOL CELL BIOCHEM, V209, P119, DOI 10.1023/A:1007151511817; Gu M, 1996, ANN NEUROL, V39, P385, DOI 10.1002/ana.410390317; HALESTRAP AP, 1975, BIOCHEM J, V148, P85, DOI 10.1042/bj1480085; HALLIWELL B, 1999, FREE RADICALS BIOL; Han D, 2003, J BIOL CHEM, V278, P5557, DOI 10.1074/jbc.M210269200; Harrison MD, 1999, J BIOL INORG CHEM, V4, P145, DOI 10.1007/s007750050297; Heaton D, 2000, J BIOL CHEM, V275, P37582, DOI 10.1074/jbc.M006639200; Heininger K, 2000, HUM PSYCHOPHARM CLIN, V15, P1, DOI 10.1002/(SICI)1099-1077(200001)15:1<1::AID-HUP153>3.0.CO;2-1; Hempel SL, 1999, FREE RADICAL BIO MED, V27, P146, DOI 10.1016/S0891-5849(99)00061-1; Herrero A, 2000, J BIOENERG BIOMEMBR, V32, P609, DOI 10.1023/A:1005626712319; Hippeli S, 1999, FEBS LETT, V443, P1, DOI 10.1016/S0014-5793(98)01665-2; Hirrlinger J, 2002, J NEUROSCI RES, V69, P318, DOI 10.1002/jnr.10308; Kwong LK, 1998, ARCH BIOCHEM BIOPHYS, V350, P118, DOI 10.1006/abbi.1997.0489; LEBLONDEL G, 1984, J INORG BIOCHEM, V21, P241, DOI 10.1016/0162-0134(84)83007-X; Lenaz G, 1998, BBA-BIOENERGETICS, V1366, P53, DOI 10.1016/S0005-2728(98)00120-0; Lenaz G, 2001, IUBMB LIFE, V52, P159, DOI 10.1080/15216540152845957; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Liu YB, 2002, J NEUROCHEM, V80, P780, DOI 10.1046/j.0022-3042.2002.00744.x; Lovell MA, 1998, J NEUROL SCI, V158, P47, DOI 10.1016/S0022-510X(98)00092-6; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; Montal M, 1998, BBA-BIOENERGETICS, V1366, P113, DOI 10.1016/S0005-2728(98)00124-8; NAKATANI T, 1994, LIFE SCI, V54, P967, DOI 10.1016/0024-3205(94)00498-6; NATH KA, 1995, AM J PHYSIOL-CELL PH, V268, pC227; Nicholls DG, 2000, PHYSIOL REV, V80, P315; Nordberg J, 2001, FREE RADICAL BIO MED, V31, P1287, DOI 10.1016/S0891-5849(01)00724-9; Oikawa S, 1996, BIOCHEMISTRY-US, V35, P4584, DOI 10.1021/bi9527000; Okado-Matsumoto A, 2001, J BIOL CHEM, V276, P38388, DOI 10.1074/jbc.M105395200; Orth M, 2001, AM J MED GENET, V106, P27, DOI 10.1002/ajmg.1425; POOLE RC, 1993, AM J PHYSIOL, V264, P761; Raha S, 2000, TRENDS BIOCHEM SCI, V25, P502, DOI 10.1016/S0968-0004(00)01674-1; Rinaldi AC, 2000, BIOMETALS, V13, P9, DOI 10.1023/A:1009228824220; Rothstein JD, 1999, J NEUROCHEM, V72, P422, DOI 10.1046/j.1471-4159.1999.0720422.x; SARIS NEL, 1991, ACTA CHEM SCAND, V45, P1042, DOI 10.3891/acta.chem.scand.45-1042; SHEINBERG IH, 1981, J RHEUMATOL, V8, P90; Shimada H, 1998, ARCH BIOCHEM BIOPHYS, V351, P75, DOI 10.1006/abbi.1997.0557; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Swift LM, 2000, AM J PHYSIOL-HEART C, V278, pH982; Tanaka J, 1999, GLIA, V28, P85, DOI 10.1002/(SICI)1098-1136(199911)28:2<85::AID-GLIA1>3.0.CO;2-Y; THOR H, 1982, J BIOL CHEM, V257, P2419; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; Turrens JF, 1997, BIOSCIENCE REP, V17, P3, DOI 10.1023/A:1027374931887; Usuki F, 2001, NEUROSCI LETT, V304, P199, DOI 10.1016/S0304-3940(01)01764-5; VandenHoek TL, 1997, J MOL CELL CARDIOL, V29, P2571, DOI 10.1006/jmcc.1997.0497; Votyakova TV, 2001, J NEUROCHEM, V79, P266, DOI 10.1046/j.1471-4159.2001.00548.x; Wang XF, 2001, J NEUROSCI, V21, P3322, DOI 10.1523/JNEUROSCI.21-10-03322.2001; Wojtczak L, 1996, BIOCHEM BIOPH RES CO, V223, P468, DOI 10.1006/bbrc.1996.0917; Xiong Y, 2001, NEUROL RES, V23, P129, DOI 10.1179/016164101101198460; YOSHIDA Y, 1994, BBA-GEN SUBJECTS, V1200, P85, DOI 10.1016/0304-4165(94)90121-X; Zamzami N, 1997, J BIOENERG BIOMEMBR, V29, P185, DOI 10.1023/A:1022694131572; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	79	42	42	0	4	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0022-3042			J NEUROCHEM	J. Neurochem.	OCT	2003	87	2					448	460		10.1046/j.1471-4159.2003.02029.x			13	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	726JN	WOS:000185596100018	14511122	Bronze			2021-06-18	
J	Hlatky, R; Goodman, JC; Valadka, AB; Robertson, CS				Hlatky, R; Goodman, JC; Valadka, AB; Robertson, CS			Role of nitric oxide in cerebral blood flow abnormalities after traumatic brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						nitric oxide; cerebral blood flow; brain injury; intracerebral microdialysis	CEREBROSPINAL-FLUID; SYNTHASE; NITRATE; NO	Nitric oxide (NO) has important regulatory functions within the central nervous system. NO is oxidized in vivo to nitrate and nitrite (NOx). Measurement of these products gives an index of NO production. The purpose of this study was to examine the relation between the brain extracellular concentration of NO metabolites and cerebral blood flow (CBF) after severe traumatic brain injury. Using a chemiluminescence method, NOx concentrations were measured in 6,701 microdialysate samples obtained from 60 patients during the first 5 d after severe head injury. Regional and global values of CBF obtained by xenon-enhanced computed tomography were used for analyses. Dialysate NOx values were the highest within the first 24 h after brain trauma and gradually decreased over the 5 postinjury d (time effect, P < 0.001). Mean dialysate concentration of NOx was 15.5 +/- 17.6 mumol/L (minimum 0.3, maximum 461 mumol/L) and 65% of samples were between 5 and 20 mumol/L. There was a significant relation between regional CBF and dialysate NOx levels (r(2) = 0.316, P < 0.001). Dialysate NOx levels (9.5 +/- 2.2 mumol/L) in patients with critical reduction of regional CBF (<18 mL (.) 100 g(-1) (.) min(-1)) were significantly lower than in patients with normal CBF (18.6 +/- 8.1 mumol/L; P < 0.001). This relation between the dialysate concentration of NOx and regional CBF suggests some role for NO in the abnormalities of CBF that occur after traumatic brain injury.	Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Univ Hosp Hradec Kralove, Dept Neurosurg, Hradec Kralove, Czech Republic	Robertson, CS (corresponding author), Baylor Coll Med, Dept Neurosurg, 6560 Fannin,Ste 944, Houston, TX 77030 USA.	claudiar@bcm.tmc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS038660] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01 NS38660] Funding Source: Medline		ALBINA JE, 1993, J IMMUNOL, V150, P5080; BALCIOGLU A, 1993, J NEUROCHEM, V61, P2311, DOI 10.1111/j.1471-4159.1993.tb07475.x; Bullock RM, 2000, J NEUROTRAUM, V17, P449; CHAO CC, 1992, J IMMUNOL, V149, P2736; Cherian L, 2000, J NEUROPHYSIOL, V83, P2171; CLARK RS, 1994, CRIT CARE MED, V24, P1243; FARACI FM, 1994, STROKE, V25, P692, DOI 10.1161/01.STR.25.3.692; Gahm C, 2002, NEUROSURGERY, V50, P1319, DOI 10.1097/00006123-200206000-00024; Gahm C, 2000, NEUROSURGERY, V46, P169; Gebhard F, 1998, SHOCK, V10, P237, DOI 10.1097/00024382-199810000-00002; GOADSBY PJ, 1992, BRAIN RES, V595, P167, DOI 10.1016/0006-8993(92)91470-Y; Goodman JC, 2002, ACTA NEUROCHIR SUPPL, V81, P343; Iadecola C, 1996, AM J PHYSIOL-REG I, V271, pR990; Khaldi A, 2001, NEUROSURGERY, V49, P33; MALINSKI T, 1993, J CEREBR BLOOD F MET, V13, P355, DOI 10.1038/jcbfm.1993.48; MERRILL JE, 1993, J IMMUNOL, V151, P2132; Mesenge C, 1996, J NEUROTRAUM, V13, P209, DOI 10.1089/neu.1996.13.209; Sakowitz OW, 2002, ACT NEUR S, V81, P351; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Uzan M, 2001, SURG NEUROL, V56, P350, DOI 10.1016/S0090-3019(01)00633-4; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; White RP, 2000, CLIN SCI, V99, P555, DOI 10.1042/CS20000064; Zecca L, 1998, J NEURAL TRANSM, V105, P627, DOI 10.1007/s007020050084	24	42	42	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	MAY	2003	23	5					582	588		10.1097/01.WCB.0000059586.71206.F3			7	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	675RK	WOS:000182708900008	12771573	Bronze			2021-06-18	
J	Zhang, XP; Graham, SH; Kochanek, PM; Marion, DW; Nathaniel, PD; Watkins, SC; Clark, RSB				Zhang, XP; Graham, SH; Kochanek, PM; Marion, DW; Nathaniel, PD; Watkins, SC; Clark, RSB			Caspase-8 expression and proteolysis in human brain after severe head injury	FASEB JOURNAL			English	Article						apoptosis; cysteine protease; Fas; programmed cell death; traumatic brain injury	TUMOR-NECROSIS-FACTOR; CEREBROSPINAL-FLUID; NEURONAL APOPTOSIS; FAS LIGAND; CELL-DEATH; SIGNALING COMPLEX; ACTIVATION; MICE; CONTUSIONS; INDUCTION	Programmed cell death involves a complex and interrelated cascade of cysteine proteases termed caspases that are synthesized as inactive zymogens, which are proteolytically processed to active enzymes. Caspase-8 is an initiator caspase that becomes activated when Fas death receptor-Fas ligand (FasL) coupling on the cell surface leads to coalescence of a "death complex" perpetuating the programmed cell death cascade. In this study, brain tissue samples removed from adult patients during the surgical management of severe intracranial hypertension after traumatic brain injury (TBI; n=17) were compared with postmortem control brain tissue samples (n=6). Caspase-8 mRNA was measured by semiquantitative reverse transcription and polymerase chain reaction, and caspase-8 protein was examined by Western blot and immunocytochemistry. Fas and FasL were also examined using Western blot. Caspase-8 mRNA and protein were increased in TBI patients vs. controls, and caspase-8 protein was predominately expressed in neurons. Proteolysis of caspase-8 to 20-kDa fragments was seen only in TBI patients. Fas was also increased after TBI vs. control and was associated with relative levels of caspase-8, supporting formation of a death complex. These data identify additional steps in the programmed cell death cascade involving Fas death receptors and caspase-8 after TBI in humans.	Safar Ctr Resuscitat Res, Dept Crit Care Med, Pittsburgh, PA 15260 USA; Safar Ctr Resuscitat Res, Dept Neurol, Pittsburgh, PA USA; Safar Ctr Resuscitat Res, Dept Pediat, Pittsburgh, PA USA; Safar Ctr Resuscitat Res, Dept Neurol Surg, Pittsburgh, PA USA; Safar Ctr Resuscitat Res, Dept Cell Biol & Physiol, Pittsburgh, PA USA; Univ Pittsburgh, Brain Trauma Res Ctr, Pittsburgh, PA USA; VA Pittsburgh Hlth Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA	Clark, RSB (corresponding author), Safar Ctr Resuscitat Res, Dept Crit Care Med, 3434 5th Ave, Pittsburgh, PA 15260 USA.	clarkrs@ccm.upmc.edu	Marion, Donald/AAR-5749-2021; Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; watkins, simon/0000-0003-4092-1552			Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Beer R, 2001, J NEUROCHEM, V78, P862, DOI 10.1046/j.1471-4159.2001.00460.x; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Beer R, 2000, J CEREBR BLOOD F MET, V20, P669, DOI 10.1097/00004647-200004000-00004; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Buki A, 2000, J NEUROSCI, V20, P2825; Cheema ZF, 1999, J NEUROSCI, V19, P1754; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 1999, FASEB J, V13, P813; Clark RSB, 2000, J PEDIATR-US, V137, P197, DOI 10.1067/mpd.2000.106903; Eldadah BA, 2000, J NEUROTRAUM, V17, P811, DOI 10.1089/neu.2000.17.811; Ertel W, 1997, J NEUROIMMUNOL, V80, P93, DOI 10.1016/S0165-5728(97)00139-2; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; Harter L, 2001, J NEUROIMMUNOL, V121, P76, DOI 10.1016/S0165-5728(01)00409-X; Henshall DC, 2001, NEUROBIOL DIS, V8, P568, DOI 10.1006/nbdi.2001.0415; HOLMIN S, 2000, J NEUROSURG, V92; Jin KL, 2001, J CEREBR BLOOD F MET, V21, P1411, DOI 10.1097/00004647-200112000-00005; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; Lenzlinger PM, 2002, J NEUROIMMUNOL, V122, P167, DOI 10.1016/S0165-5728(01)00466-0; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Morishima Y, 2001, J NEUROSCI, V21, P7551; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Ng I, 2000, NEUROSURGERY, V46, P949, DOI 10.1097/00006123-200004000-00034; Noshita N, 2002, NEUROBIOL DIS, V9, P294, DOI 10.1006/nbdi.2002.0482; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Qiu JH, 2002, J NEUROSCI, V22, P3504; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; SEIDBERG N, 2002, IN PRESS J NEUROCHEM; Smith FM, 2000, ACTA NEUROPATHOL, V100, P537, DOI 10.1007/s004010000222; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Zhang XP, 2002, J NEUROCHEM, V82, P181, DOI 10.1046/j.1471-4159.2002.00975.x	33	42	46	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2003	17	8					1367	+		10.1096/fj.02-1067fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	WOS:000183165000027	12738800				2021-06-18	
J	Kuhtz-Buschbeck, JP; Stolze, H; Golge, M; Ritz, A				Kuhtz-Buschbeck, JP; Stolze, H; Golge, M; Ritz, A			Analyses of gait, reaching, and grasping in children after traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	Meeting on Neurotraumatology and Neuropsychological Rehabailitation	OCT   30, 2001	MANNHEIM, GERMANY			brain injuries; children; gait; hand; rehabilitation	MOTOR COORDINATION; FOLLOW-UP; REHABILITATION; PERFORMANCE; RELIABILITY; RECOVERY; COHORT; IDENTIFICATION; ADOLESCENTS; AGREEMENT	Objective: To evaluate motor behavior in children after traumatic brain injury (TBI) with quantitative instrumented measures of gait and of functional hand movements (reaching, grasping) and with clinical assessments. Design: Case-control study. Setting: Tertiary pediatric trauma rehabilitation center in Germany. Participants: Twenty children (age range, 6-13y) with moderate or severe TBI were examined 1+/-1.2 years (mean+/-standard deviation) postinjury. Fifteen were reexamined 2 months later. Control data were obtained from 20 healthy children and matched for age, gender, and school grade. Interventions: Not applicable Main Outcome Measures: Quantitative measures included 10 spatiotemporal gait parameters and 6 variables describing reaching and grasping. Qualitative scores of gait and upper-limb movements were also obtained. Results: Gait velocity and step and stride lengths were significantly smaller in children after TBI than in control subjects (Mann-Whitney U test, P<.05). Reach-to-grasp movements of the TBI children were characterized by a significantly longer reaction time (Mann-Whitney U test, P<.05) and movement duration, reduced velocity, and coordination deficits. The instrumented measures did not change significantly in 2 months. Several significant correlations between clinical and instrumented measures were obtained. Conclusion: Functional motor behavior is affected in children after moderate or severe TBI. To supplement clinical assessments with objective data, impairments of gait, reaching, and grasping movements can be recorded with instrumented measures.	Univ Kiel, Dept Physiol, Inst Physiol, D-24098 Kiel, Germany; Neurol Rehabil Zentrum Kinder & Jugendliche Fried, Bremen, Germany	Kuhtz-Buschbeck, JP (corresponding author), Univ Kiel, Dept Physiol, Inst Physiol, Olshaussenstr 40, D-24098 Kiel, Germany.		Kuhtz-Buschbeck, Johann/F-7745-2010	Kuhtz-Buschbeck, Johann P/0000-0002-4603-7103			BEHBEHANI K, 1990, ARCH PHYS MED REHAB, V71, P106; Bowen JM, 1997, DEV MED CHILD NEUROL, V39, P17; BRUININKS R, 1977, BRUININKSOSERETSKY T; CHAPLIN D, 1993, ARCH PHYS MED REHAB, V74, P161; COSTEFF H, 1990, J NEUROSURG, V73, P684, DOI 10.3171/jns.1990.73.5.0684; DISCALA C, 1992, AM J PHYS MED REHAB, V71, P145, DOI 10.1097/00002060-199206000-00004; Emanuelson I, 1996, CHILD NERV SYST, V12, P460, DOI 10.1007/BF00261625; Gagnon I, 1998, BRAIN INJURY, V12, P843, DOI 10.1080/026990598122070; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; HALEY SM, 1990, J HEAD TRAUMA REHAB, V5, P77; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; JEBSEN R H, 1969, Archives of Physical Medicine and Rehabilitation, V50, P311; Kuhtz-Buschbeck JP, 1999, GAIT POSTURE, V9, P184, DOI 10.1016/S0966-6362(99)00015-6; Kuhtz-Buschbeck JP, 1998, EXP BRAIN RES, V122, P424, DOI 10.1007/s002210050530; LEHMANN JF, 1990, ARCH PHYS MED REHAB, V71, P955; Masanic CA, 1998, ARCH PHYS MED REHAB, V79, P811, DOI 10.1016/S0003-9993(98)90361-6; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P223, DOI 10.1016/S0003-9993(96)90102-1; Melchers P, 1999, RESTOR NEUROL NEUROS, V14, P153; MELCHERS P, 1991, KAUFMAN ASSESSMENT B; Ochi F, 1999, J HEAD TRAUMA REHAB, V14, P105, DOI 10.1097/00001199-199904000-00002; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Quinn B, 2000, BRAIN INJURY, V14, P1063; Rossi C, 1996, ARCH PHYS MED REHAB, V77, P1062, DOI 10.1016/S0003-9993(96)90069-6; RUSSELL DJ, 1989, DEV MED CHILD NEUROL, V31, P341; Stolze H, 1998, GAIT POSTURE, V7, P125, DOI 10.1016/S0966-6362(97)00043-X; SULLIVAN SJ, 1994, BRAIN INJURY, V8, P613, DOI 10.3109/02699059409151014; Swaine BR, 1996, BRAIN INJURY, V10, P263, DOI 10.1080/026990596124449; Swaine BR, 1996, BRAIN INJURY, V10, P347, DOI 10.1080/026990596124368; SWAINE BR, 1992, ARCH PHYS MED REHAB, V73, P55; VanderSchaaf PJ, 1997, PEDIATR NEUROL, V16, P306, DOI 10.1016/S0887-8994(97)00025-8; Wade LD, 1997, ARCH PHYS MED REHAB, V78, P1107, DOI 10.1016/S0003-9993(97)90136-2; Wallen MA, 2001, ARCH PHYS MED REHAB, V82, P642, DOI 10.1053/apmr.2001.22620; WING AM, 1986, J MOTOR BEHAV, V18, P245	35	42	42	0	6	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAR	2003	84	3					424	430		10.1053/apmr.2003.50017			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	653KL	WOS:000181434300016	12638112				2021-06-18	
J	Reynolds, FD; Dietz, PA; Higgins, D; Whitaker, TS				Reynolds, FD; Dietz, PA; Higgins, D; Whitaker, TS			Time to deterioration of the elderly, anticoagulated, minor head injury patient who presents without evidence of neurologic abnormality	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						warfarin; Coumadin; anticoagulation; minor head injury; elderly; neurologic; decompensation	COMPUTED-TOMOGRAPHY; TRAUMA PATIENTS; BRAIN INJURY; WARFARIN	Background: Generally accepted guidelines regarding the care of the elderly, anticoagulated minor head injury patient do not exist within the trauma literature. Methods. Charts were reviewed on all anticoagulated, minor head injury patients older than 65 years between January 1993 and May 2000. Postinjury course was examined for neurologic changes, times, coagulation/radiographic studies, reversal, operative intervention, and outcome. Results. Thirty-two patients were identified. Twenty-four patients were discharged from the Emergency Department. Three of the remaining eight patients had initial Glasgow Coma Scale scores of 15, 15, and 14 but became comatose over a mean course of 3.83 hours. A fourth patient presented comatose 6 hours postinjury, down from "acting normal." Three of these four patients died. Conclusion. Elderly, anticoagulated patients with minor head trauma risk neurologic deterioration within 6 hours of injury, despite an initially normal neurologic examination. Early cranial computed tomographic scanning and close observation for a minimum of 6 hours are indicated.	Mary Imogene Bassett Hosp, Dept Surg, Cooperstown, NY 13326 USA; Mary Imogene Bassett Hosp, Dept Gen & Vasc Surg, Cooperstown, NY 13326 USA	Reynolds, FD (corresponding author), Mary Imogene Bassett Hosp, Dept Surg, 1 Atwell Rd, Cooperstown, NY 13326 USA.						Ferrera PC, 1999, AM J EMERG MED, V17, P154, DOI 10.1016/S0735-6757(99)90050-5; Garra G, 1999, ACAD EMERG MED, V6, P121, DOI 10.1111/j.1553-2712.1999.tb01048.x; Gomez PA, 1996, BRIT J NEUROSURG, V10, P453, DOI 10.1080/02688699647078; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Horton JD, 1999, AM FAM PHYSICIAN, V59, P635; *IMS, 1998, NAT PRESCR AUD PHYS; Inamasu J, 2000, AM J EMERG MED, V18, P810, DOI 10.1053/ajem.2000.18111; Kennedy DM, 2000, J TRAUMA, V48, P451, DOI 10.1097/00005373-200003000-00012; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Levine MN, 2001, CHEST, V119, p108S, DOI 10.1378/chest.119.1_suppl.108S; Li J, 2001, LANCET, V357, P771, DOI 10.1016/S0140-6736(00)04163-5; Livingston DH, 2000, ANN SURG, V232, P126, DOI 10.1097/00000658-200007000-00018; MATHIESEN T, 1995, ACTA NEUROL SCAND, V91, P208; Saab M, 1996, J ACCID EMERG MED, V13, P208; SIFTON DW, 2000, PHYSICIANS DESK REFE, P969; Snyder RW, 1997, AM J MED, V102, P488, DOI 10.1016/S0002-9343(97)89445-4; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Volans AP, 1998, J ACCID EMERG MED, V15, P159	19	42	47	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAR	2003	54	3					492	496		10.1097/01.TA.0000051601.60556.FC			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	660EA	WOS:000181819800010	12634528				2021-06-18	
J	Ahmed, SM; Weber, JT; Liang, S; Willoughby, KA; Sitterding, HA; Rzigalinski, BA; Ellis, EF				Ahmed, SM; Weber, JT; Liang, S; Willoughby, KA; Sitterding, HA; Rzigalinski, BA; Ellis, EF			NMDA receptor activation contributes to a portion of the decreased mitochondrial membrane potential and elevated intracellular free calcium in strain-injured neurons	JOURNAL OF NEUROTRAUMA			English	Article						APV; calcium; glutamate; mitochondria; MK-801; traumatic brain injury	STRETCH-INDUCED INJURY; ENERGY-METABOLISM; CORTICAL-NEURONS; BRAIN INJURY; IN-VITRO; GLUTAMATE EXCITOTOXICITY; DELAYED DEPOLARIZATION; SIGNAL-TRANSDUCTION; HEAD-INJURY; CELL INJURY	In our previous studies, we have shown that in vitro biaxial strain (stretch) injury of neurons in neuronal plus glial cultures increases intracellular free calcium ([Ca2+](i)) and decreases mitochondrial membrane potential (Deltapsi(m)). The goal of this study was to determine whether strain injury, without the addition of exogenous agents, causes glutamate release, and whether NMDA receptor antagonists affect the post-strain injury rise in [Ca2+](i) and decrease in Deltapsi(m). [Ca2+](i) and Deltapsi(m). were measured using the fluorescent indicators fura-2 AM and rhodamine-1,2,3 (rh123). Strain injury of neuronal plus glial cultures caused an immediate 100-200 nM elevation in neuronal [Ca2+](i) and a decline in neuronal Deltapsi(m) by 15 min post-injury. Pretreatment with the NMDA receptor antagonist MK-801 (10 muM) attenuated the [Ca2+](i) elevation after mild, but not moderate and severe injury. MK-801 pretreatment reduced the decline in Deltapsi(m) after mild and moderate, but not after severe injury. The NMDA receptor antagonist D-2-amino-5-phosphonopentanoic acid (APV; 100 muM) had effects similar to MK-801. Simultaneous measurement of [Ca2+](i) and Deltapsi(m). demonstrated a significant correlation and a temporal relationship between [Ca2+](i) elevation and depression of Deltapsi(m). We conclude that NMDA receptor stimulation contributes to some of the changes in [Ca2+](i) and Deltapsi(m) after less severe strain injury. However, after more pronounced injury other mechanisms appear to be more involved.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA; Erasmus Univ, Dept Anat, Rotterdam, Netherlands; Guilford Pharmaceut Res & Dev, Baltimore, MD USA; Univ Cent Florida, Dept Mol Biol & Microbiol, Coll Hlth & Publ Affairs, Orlando, FL 32816 USA	Ellis, EF (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, Campus Virginia Commonwealth Univ,POB 980613, Richmond, VA 23298 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS27214, NS07288] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027214] Funding Source: NIH RePORTER		Ahmed SM, 2000, J NEUROCHEM, V74, P1951, DOI 10.1046/j.1471-4159.2000.741951000000000.x; AMRUTHESH SC, 1993, J NEUROCHEM, V61, P150, DOI 10.1111/j.1471-4159.1993.tb03550.x; Babcock DF, 1997, J CELL BIOL, V136, P833, DOI 10.1083/jcb.136.4.833; Budd SL, 1996, J NEUROCHEM, V67, P2282; Bullock MR, 1999, ANN NY ACAD SCI, V890, P51, DOI 10.1111/j.1749-6632.1999.tb07980.x; BUNTING JR, 1992, BIOPHYS CHEM, V42, P163, DOI 10.1016/0301-4622(92)85006-P; Carriedo SG, 2000, J NEUROSCI, V20, P240, DOI 10.1523/JNEUROSCI.20-01-00240.2000; EHRENBERG B, 1988, BIOPHYS J, V53, P785, DOI 10.1016/S0006-3495(88)83158-8; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; ERECINSKA M, 1989, J CEREBR BLOOD F MET, V9, P2, DOI 10.1038/jcbfm.1989.2; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FAROOQUI AA, 1994, J NEUROSCI RES, V38, P6, DOI 10.1002/jnr.490380103; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAYES RL, 1992, J NEUROTRAUMA S1, V9, P173; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KIMELBERG HK, 1990, J NEUROSCI, V10, P1583; LaPlaca MC, 1998, J NEUROSCI RES, V52, P220, DOI 10.1002/(SICI)1097-4547(19980415)52:2<220::AID-JNR10>3.0.CO;2-B; MCCORMACK JG, 1994, NEWS PHYSIOL SCI, V9, P71; McKinney JS, 1996, STROKE, V27, P934, DOI 10.1161/01.STR.27.5.934; Morris GF, 1999, J NEUROSURG, V91, P737, DOI 10.3171/jns.1999.91.5.0737; Morrison B, 1998, J NEUROTRAUM, V15, P911, DOI 10.1089/neu.1998.15.911; Nicholls DG, 1998, BBA-BIOENERGETICS, V1366, P97, DOI 10.1016/S0005-2728(98)00123-6; Peng TI, 1998, MOL PHARMACOL, V53, P974; Peng TI, 1998, EXP NEUROL, V149, P1, DOI 10.1006/exnr.1997.6599; Peuchen S, 1996, NEUROSCIENCE, V71, P855, DOI 10.1016/0306-4522(95)00480-7; POENIE M, 1990, CELL CALCIUM, V11, P85, DOI 10.1016/0143-4160(90)90062-Y; Reynolds IJ, 1999, ANN NY ACAD SCI, V893, P33, DOI 10.1111/j.1749-6632.1999.tb07816.x; ROE MW, 1990, CELL CALCIUM, V11, P63, DOI 10.1016/0143-4160(90)90060-8; Rzigalinski BA, 1998, J NEUROCHEM, V70, P2377; RZIGALINSKI BA, 1998, J NEUROTRAUM, V15, P894; Schinder AF, 1996, J NEUROSCI, V16, P6125; Schreiber D., 1995, P 1995 INT RES C BIO, P233; Tavalin SJ, 1997, J NEUROPHYSIOL, V77, P632; Tavalin SJ, 1995, J NEUROPHYSIOL, V74, P2767; TRUMP BF, 1995, FASEB J, V9, P219; Vagnozzi R, 1999, J NEUROTRAUM, V16, P903, DOI 10.1089/neu.1999.16.903; Weber JT, 1999, CELL CALCIUM, V26, P289, DOI 10.1054/ceca.1999.0082; White RJ, 1997, J PHYSIOL-LONDON, V498, P31, DOI 10.1113/jphysiol.1997.sp021839; White RJ, 1996, J NEUROSCI, V16, P5688; WILLAN RL, 1990, MULTIPURPOSE TREE SP, V2, P11; Young W, 1992, J NEUROTRAUMA S1, V9, P9; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	42	42	43	0	2	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	DEC	2002	19	12					1619	1629		10.1089/089771502762300274			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	629UY	WOS:000180070700009	12542862				2021-06-18	
J	Ke, CS; Poon, WS; Ng, HK; Lai, FMM; Tang, NLS; Pang, JCS				Ke, CS; Poon, WS; Ng, HK; Lai, FMM; Tang, NLS; Pang, JCS			Impact of experimental acute hyponatremia on severe traumatic brain injury in rats: Influences on injuries, permeability of blood-brain barrier, ultrastructural features, and aquaporin-4 expression	EXPERIMENTAL NEUROLOGY			English	Article						head injury; hyponatremia; aquaporin-4; ultrastructure	AXONAL INJURY; MEMBRANE DOMAINS; WATER TRANSPORT; HEAD-INJURY; MODEL; CELLS; EDEMA; IMMUNOREACTIVITY; ENCEPHALOPATHY; DISEASE	The effects of acute hyponatremia on severe traumatic brain injury (TBI) in 35 adult male Sprague-Dawley rats were studied in a replicated focal and diffuse injury rat model. Such effects were assessed by the cerebral contusion volume and axonal injury (AI) densities, determined by quantitative immunoreactivity of beta-amyloid precursor protein, by blood-brain barrier (BBB) permeability based on endogenous IgG immunostaining, and by ultrastructural features. Significant increase of contusion volume (P < 0.05) and of AI in the segment of corpus callosum. beneath the contusion (P < 0.05) and ipsilateral thalamus (P < 0.05) were observed at 4 h postinjury during the hyponatremic phase. No change in BBB permeability was observed in the hyponatremia + TBI (HT) groups. Significant swelling of perivascular astrocytic foot processes in the HT groups was seen at 4 h (P < 0.01) and I day postinjury (P < 0.01) by quantitative image analysis of ultrastructures. However, attenuated swelling of perivascular astrocytic foot processes in severely edematous medulla oblongata with simultaneous swelling of perikaryal astrocytic processes was observed in the HT 1-day group. The ultrastructural features were also correlated with the down-regulation of aquaporin-4 (AQP4) mRNA expression (P < 0.05). Results suggest that acute hyponatremia acts as one of the secondary insults following severe TBI. Such exacerbation may not be attributable to further disruption of BBB permeability, but rather to the ischemia resulting from the swelling of perivascular astrocytic foot processes impeding microcirculation. Down-regulated AQP4 mRNA expression may be one of the molecular mechanisms maintaining water homeostasis in diffusely injured brain exposed to acute hyponatremia. (C) 2002 Elsevier Science (USA).	Chinese Univ Hong Kong, Prince Wales Hosp, Dept Surg, Div Neurosurg, Shatin, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anat & Cellular Pathol, Shatin, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Prince Wales Hosp, Dept Chem Pathol, Shatin, Hong Kong, Peoples R China	Ke, CS (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Surg, Div Neurosurg, Shatin, Hong Kong, Peoples R China.		Ng, Ho Keung/I-3952-2015; Tang, Nelson L/P-5018-2017; Poon, Wai Sang/F-1558-2011	Tang, Nelson L/0000-0002-3607-5819; 			AbouHamden A, 1997, J NEUROTRAUM, V14, P699, DOI 10.1089/neu.1997.14.699; ADLER S, 1993, NMR BIOMED, V6, P119, DOI 10.1002/nbm.1940060203; ADLER S, 1989, AM J PHYSIOL, V256, pF113; Agarwala S, 1998, J COMP NEUROL, V392, P252, DOI 10.1002/(SICI)1096-9861(19980309)392:2<252::AID-CNE7>3.0.CO;2-1; Arieff A I, 1987, Adv Intern Med, V32, P325; ARUOMA OI, 1988, BIOCHEM J, V256, P251, DOI 10.1042/bj2560251; Atchison James W., 1993, Brain Injury, V7, P347, DOI 10.3109/02699059309034961; Balabanov R, 2001, NEUROL RES, V23, P175, DOI 10.1179/016164101101198514; BOURKE RS, 1980, BIOL GLIAL SWELLING, V28, P98; Bussmann C, 2001, CHILD NERV SYST, V17, P58; Clark EC, 1996, KIDNEY INT, V49, P470, DOI 10.1038/ki.1996.66; CLUITMANS FHM, 1990, AM J MED, V88, P161, DOI 10.1016/0002-9343(90)90467-R; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; DOCZI T, 1982, NEUROSURGERY, V10, P685, DOI 10.1227/00006123-198206010-00001; Dohanics J, 1996, J NEUROSCI, V16, P2373; FOX JL, 1971, J NEUROSURG, V34, P506, DOI 10.3171/jns.1971.34.4.0506; HALLIWELL B, 1989, FREE RADICAL BIO MED, V2, P86; Hoshino S, 1996, BRAIN RES, V711, P73, DOI 10.1016/0006-8993(95)01329-6; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; JUNG JS, 1994, P NATL ACAD SCI USA, V91, P13052, DOI 10.1073/pnas.91.26.13052; Ke C, 2000, ACT NEUR S, V76, P405; Ke CS, 2001, NEUROSCI LETT, V301, P21, DOI 10.1016/S0304-3940(01)01589-0; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; KROLL M, 1992, J INTERN MED, V232, P291; Lammie GA, 1999, J NEUROTRAUM, V16, P603, DOI 10.1089/neu.1999.16.603; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MELTON JE, 1983, AM J PHYSIOL, V244, pR724; Mitrofanis J, 1999, J COMP NEUROL, V412, P173; Nagelhus EA, 1999, GLIA, V26, P47, DOI 10.1002/(SICI)1098-1136(199903)26:1<47::AID-GLIA5>3.0.CO;2-5; Nagelhus EA, 1996, NEUROSCIENCE, V72, P743, DOI 10.1016/0306-4522(96)00003-6; Neely JD, 1999, BIOCHEMISTRY-US, V38, P11156, DOI 10.1021/bi990941s; Nielsen S, 1997, J NEUROSCI, V17, P171; Petrov T, 2001, NEUROL RES, V23, P139, DOI 10.1179/016164101101198479; Pierce JES, 1996, J NEUROSCI, V16, P1083; ROJIANI AM, 1994, ACTA NEUROPATHOL, V88, P287; ROSS DT, 1990, NEUROSCIENCE, V35, P525, DOI 10.1016/0306-4522(90)90327-Z; Schuh-Hofer S, 2001, NEUROSCI LETT, V306, P61, DOI 10.1016/S0304-3940(01)01878-X; Soupart A, 1997, J LAB CLIN MED, V130, P226, DOI 10.1016/S0022-2143(97)90100-1; STERNS RH, 1989, KIDNEY INT, V35, P69, DOI 10.1038/ki.1989.9; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; Stys PK, 1998, J CEREBR BLOOD F MET, V18, P2, DOI 10.1097/00004647-199801000-00002; Vajda Z, 2000, BIOCHEM BIOPH RES CO, V270, P495, DOI 10.1006/bbrc.2000.2472; Verkman AS, 2000, AM J PHYSIOL-RENAL, V278, pF13; VEXLER ZS, 1994, J CLIN INVEST, V93, P256, DOI 10.1172/JCI116953	46	42	48	0	2	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	DEC	2002	178	2					194	206		10.1006/exnr.2002.8037			13	Neurosciences	Neurosciences & Neurology	628HX	WOS:000179988500005	12504879				2021-06-18	
J	Verbois, SL; Scheff, SW; Pauly, JR				Verbois, SL; Scheff, SW; Pauly, JR			Time-dependent changes in rat brain cholinergic receptor expression after experimental brain injury	JOURNAL OF NEUROTRAUMA			English	Article						alpha 7*nicotinic receptor; autoradiography; bungarotoxin; epibatidine; MK-801; neurotrauma; QNB	CENTRAL-NERVOUS-SYSTEM; NICOTINIC RECEPTORS; ACETYLCHOLINE-RECEPTORS; SELECTIVE AGONIST; BINDING; CALCIUM; MICE; INHIBITION; DISORDERS; SUBTYPES	Alterations in neurotransmitter receptor expression in the central nervous system may contribute to physiological and behavioral deficits that follow traumatic brain injury (TBI). Previous studies from our laboratory have demonstrated significant and widespread deficits in alpha7* nicotinic cholinergic receptor (alpha7* nAChr) expression 2 days following cortical contusion brain injury. The purpose of this study was to evaluate changes in alpha7* nAChr expression over a wider range of post-TBI recovery intervals. Animals were anesthetized and subjected to a moderate cortical contusion brain injury (2 mm cortical compression). Animals were euthanatized at various post-TBI time intervals, ranging from I h to 21 days, and quantitative autoradiography was used to evaluate cholinergic receptor subtype expression in the cerebral cortex and hippocampus. As previously reported, the alpha7* nAChr was the most sensitive target of TBI-induced plasticity. Significant decreases in alpha-[I-125]-bungarotoxin (BTX) binding occurred as early as I h post-TBI, and persisted in some brain regions for up to 21 days. A kinetic analysis of changes in BTX binding, performed 2 days following brain injury, indicated that the binding deficits are not due to significant changes in receptor affinity. TBI-induced changes in alpha3*/alpha4* nACh receptors, muscarinic cholinergic receptors, and NMDA-type glutamate receptor expression were lower in magnitude, restricted to fewer brain regions and more transient in nature. Persistent deficits in alpha7* nAChr expression following TBI may contribute to impaired functional outcome following brain injury.	Univ Kentucky, Coll Pharm, Div Pharmaceut Sci, Lexington, KY 40536 USA; Univ Kentucky, Coll Pharm, Sanders Brown Ctr Aging, Lexington, KY 40536 USA	Pauly, JR (corresponding author), Univ Kentucky, Coll Pharm, Div Pharmaceut Sci, 800 Rose St, Lexington, KY 40536 USA.	jpauly@uky.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042196, R01NS039828] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS39828, NS42196] Funding Source: Medline		Adams CE, 2001, BRAIN RES, V922, P180, DOI 10.1016/S0006-8993(01)03115-8; Adler LE, 1998, SCHIZOPHRENIA BULL, V24, P189, DOI 10.1093/oxfordjournals.schbul.a033320; Albuquerque EX, 1998, J PHYSIOLOGY-PARIS, V92, P309, DOI 10.1016/S0928-4257(98)80039-9; Alkondon M, 1997, EUR J NEUROSCI, V9, P2734, DOI 10.1111/j.1460-9568.1997.tb01702.x; Arciniegas D, 1999, BRAIN INJURY, V13, P1, DOI 10.1080/026990599121827; Arciniegas D, 2000, J NEUROPSYCH CLIN N, V12, P77, DOI 10.1176/jnp.12.1.77; Burnashev N, 1998, CELL CALCIUM, V24, P325, DOI 10.1016/S0143-4160(98)90056-2; Ciallella JR, 1998, EXP NEUROL, V152, P11, DOI 10.1006/exnr.1998.6831; Collins AC, 1996, DRUG DEVELOP RES, V38, P231, DOI 10.1002/(SICI)1098-2299(199607/08)38:3/4<231::AID-DDR12>3.0.CO;2-1; Dani JA, 2001, BIOL PSYCHIAT, V49, P166, DOI 10.1016/S0006-3223(00)01011-8; DEANGELIS MM, 1994, BRAIN RES, V653, P39, DOI 10.1016/0006-8993(94)90369-7; Delbono O, 1997, J PHARMACOL EXP THER, V280, P428; Eglen RM, 2001, TRENDS PHARMACOL SCI, V22, P409, DOI 10.1016/S0165-6147(00)01737-5; GORMAN LK, 1989, J NEUROTRAUM, V6, P203; Hillered L, 1999, SCAND J CLIN LAB INV, V59, P9, DOI 10.1080/00365519950185904; Hilmas C, 2001, J NEUROSCI, V21, P7463; Hoofien D, 2001, BRAIN INJURY, V15, P189; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; Hurley Robin A., 2002, Curr Treat Options Neurol, V4, P59, DOI 10.1007/s11940-002-0005-5; Lavine N, 1997, J COMP NEUROL, V380, P175, DOI 10.1002/(SICI)1096-9861(19970407)380:2<175::AID-CNE3>3.0.CO;2-0; Levin ED, 2000, EUR J PHARMACOL, V393, P141, DOI 10.1016/S0014-2999(99)00885-7; LIMBIRD LE, 1986, CELL SURFACE RECEPTO; Liu QS, 2001, P NATL ACAD SCI USA, V98, P4734, DOI 10.1073/pnas.081553598; Lukas RJ, 1999, PHARMACOL REV, V51, P397; LYETH BG, 1994, BRAIN RES, V640, P240, DOI 10.1016/0006-8993(94)91879-1; Maas AIR, 2001, EXPERT OPIN INV DRUG, V10, P753, DOI 10.1517/13543784.10.4.753; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; PAULY JR, 1990, PSYCHOPHARMACOLOGY, V101, P310, DOI 10.1007/BF02244047; PAXINOS G, 1997, RAT BRAIN STEREOTAXI; PERRY DC, 1995, J PHARMACOL EXP THER, V275, P1030; Perry E, 2000, EUR J PHARMACOL, V393, P215, DOI 10.1016/S0014-2999(00)00064-9; Perry EK, 2001, ALCOHOL, V24, P63, DOI 10.1016/S0741-8329(01)00130-6; Rao V, 2000, PSYCHOSOMATICS, V41, P95, DOI 10.1176/appi.psy.41.2.95; Rusted JM, 2000, BEHAV BRAIN RES, V113, P121, DOI 10.1016/S0166-4328(00)00207-2; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; SCHRODER W, 1998, ALZHEIMER DIS REV, V2, P61; SEGUELA P, 1993, J NEUROSCI, V13, P596; Sihver S, 2001, J NEUROCHEM, V78, P417, DOI 10.1046/j.1471-4159.2001.00428.x; Simosky JK, 2001, BIOL PSYCHIAT, V50, P493, DOI 10.1016/S0006-3223(01)01093-9; Sparks JA, 1999, PSYCHOPHARMACOLOGY, V141, P145, DOI 10.1007/s002130050818; Verbois SL, 2000, J NEUROTRAUM, V17, P1001, DOI 10.1089/neu.2000.17.1001; Waldo MC, 2000, BIOL PSYCHIAT, V47, P231, DOI 10.1016/S0006-3223(99)00272-3; Whiteaker P, 2000, EUR J PHARMACOL, V393, P123, DOI 10.1016/S0014-2999(00)00052-2; Wiley JL, 1996, BRAIN RES, V716, P47, DOI 10.1016/0006-8993(96)00045-5; Wonnacott S, 1997, TRENDS NEUROSCI, V20, P92, DOI 10.1016/S0166-2236(96)10073-4; Woodruff-Pak DS, 2001, P NATL ACAD SCI USA, V98, P2089, DOI 10.1073/pnas.031584398	46	42	43	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2002	19	12					1569	1585		10.1089/089771502762300238			17	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	629UY	WOS:000180070700005	12542858				2021-06-18	
J	Seale, GS; Caroselli, JS; High, WH; Becker, CL; Neese, LE; Scheibel, R				Seale, GS; Caroselli, JS; High, WH; Becker, CL; Neese, LE; Scheibel, R			Use of the Community Integration Questionnaire (CIQ) to characterize changes in functioning for individuals with traumatic brain injury who participated in a post-acute rehabilitation programme	BRAIN INJURY			English	Article							CLINICAL-SIGNIFICANCE; OUTCOME RESEARCH; RELIABILITY; IMPACT	Objective: Evaluate changes in community integration for survivors of traumatic brain injury (TBI) who participated in a post-acute rehabilitation programme. Design: Cohort, prospective study investigating change from admission to post-discharge. Participants: Individuals, the majority of whom were diagnosed with severe TBI, were placed into one of two groups as follows: (1) admitted for treatment less than 1 year post-injury (L1Y) or (2) admitted for treatment between 1-5 years post-injury (G1Y). Measure: The Community Integration Questionnaire (CIQ). Results: Both groups showed significant improvements from admission to follow-up; however, some CIQ findings were more pronounced for the L1Y group. Reliable change (RC) methodology was used to assess individual change. Results of this approach were consistent with group results, but tempered the perception of degree of change. Conclusions: Findings cannot simply be attributed to neurological recovery and individual factors are important to examine when assessing change.	Transit Learning Ctr, Galveston, TX 77550 USA; Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Inst Rehabil & Res, Sect Brain Injury Res Ctr, Houston, TX USA	Seale, GS (corresponding author), Transit Learning Ctr, 1528 Postoffice St, Galveston, TX 77550 USA.						Bontke C F, 1991, Neurosurg Clin N Am, V2, P473; BURKE DC, 1995, BRAIN INJURY, V9, P735, DOI 10.3109/02699059509008229; Chelune GJ, 1993, NEUROPSYCHOLOGY, V7, P41, DOI DOI 10.1037/0894-4105.7.1.41; COPE D N, 1991, Brain Injury, V5, P127, DOI 10.3109/02699059109008084; COPE D N, 1991, Brain Injury, V5, P111, DOI 10.3109/02699059109008083; COPE DN, 1995, BRAIN INJURY, V9, P649, DOI 10.3109/02699059509008224; Corrigan J D, 1994, NeuroRehabilitation, V4, P109, DOI 10.3233/NRE-1994-4207; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P41, DOI 10.1097/00001199-199508000-00005; Cusick CP, 2000, J HEAD TRAUMA REHAB, V15, P739, DOI 10.1097/00001199-200002000-00012; Dijkers M, 1997, J HEAD TRAUMA REHAB, V12, P74, DOI 10.1097/00001199-199712000-00007; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; Hermann BP, 1996, EPILEPSIA, V37, P942, DOI 10.1111/j.1528-1157.1996.tb00531.x; HIGH WM, 1995, J HEAD TRAUMA REHAB, V10, P14, DOI 10.1097/00001199-199502000-00004; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; JACOBSON NS, 1984, BEHAV THER, V15, P336, DOI 10.1016/S0005-7894(84)80002-7; Jennett B, 1981, MANAGEMENT HEAD INJU; JOHNSTON M V, 1991, Brain Injury, V5, P155, DOI 10.3109/02699059109008086; JOHNSTON M V, 1991, Brain Injury, V5, P141, DOI 10.3109/02699059109008085; Ling JS, 1997, J HEAD TRAUMA REHAB, V12, P51, DOI 10.1097/00001199-199702000-00009; Malec James F., 1993, Brain Injury, V7, P15, DOI 10.3109/02699059309008153; Malec JF, 1996, ARCH PHYS MED REHAB, V77, P198, DOI 10.1016/S0003-9993(96)90168-9; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P88, DOI 10.1097/00001199-199608000-00011; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P353, DOI 10.1016/S0003-9993(97)90225-2; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; Sawrie S M, 1996, J Int Neuropsychol Soc, V2, P556; SCHMIDT MF, 1995, J HEAD TRAUMA REHAB, V10, P14, DOI 10.1097/00001199-199508000-00003; Tepper S, 1996, BRAIN INJURY, V10, P575, DOI 10.1080/026990596124142; Thobaben JR, 1997, J HEAD TRAUMA REHAB, V12, P10, DOI 10.1097/00001199-199702000-00004; Willer B, 1999, ARCH PHYS MED REHAB, V80, P399, DOI 10.1016/S0003-9993(99)90276-9; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009; World Health Organization, 1993, INT CLASS IMP DIS HA	34	42	42	0	1	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	NOV	2002	16	11					955	967		10.1080/02699050210155258			13	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	609PQ	WOS:000178914500003	12455520				2021-06-18	
J	Prakash, KRC; Tang, Y; Kozikowski, AP; Flippen-Anderson, JL; Knoblach, SM; Faden, AI				Prakash, KRC; Tang, Y; Kozikowski, AP; Flippen-Anderson, JL; Knoblach, SM; Faden, AI			Synthesis and biological activity of novel neuroprotective diketopiperazines	BIOORGANIC & MEDICINAL CHEMISTRY			English	Article							THYROTROPIN-RELEASING-HORMONE; TRAUMATIC BRAIN INJURY; CELL-DEATH; TRH; CULTURES; GLYCINE; RAT; ALKYLATION; RECOVERY; CALCIUM	The cyclic dipeptide cyclo[His-Pro] (CHP) is synthesized endogenously de novo and as a breakdown product of thyrotropin-releasing hormone (TRH). a tripeptide with known neuroprotective activity. We synthesized two isomeric compounds based on the structure of CHP, in which the histidine residue was replaced by 3.5-di-tert-butyltyrosine (DBT), a phenolic amino acid that traps reactive oxygen species. These novel diketopiperazines prevented neuronal death in an in vitro model of traumatic injury. In addition, they dose-dependent prevented death caused by the direct induction of free radicals, and by calcium mobilization through an agent that evokes rapid. necrotic death. The drugs showed activity in the latter system at picomolar concentrations. The neuroprotective profile of these compounds suggests that they may be useful as treatments for neuronal degeneration in potentially through several different mechanisms. (C) 2002 Elsevier Science Ltd. All rights reserved.	Georgetown Univ, Ctr Med, Drug Discovery Program, Dept Neurol, Washington, DC 20007 USA; USN, Res Lab, Struct Matter Lab, Washington, DC 20375 USA; Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20007 USA	Kozikowski, AP (corresponding author), Georgetown Univ, Ctr Med, Drug Discovery Program, Dept Neurol, 3900 Reservoir Rd,NW, Washington, DC 20007 USA.	kozikowa@georgetown.edu					BEHRMANN DL, 1994, EXP NEUROL, V126, P61, DOI 10.1006/exnr.1994.1042; BREESE GR, 1975, J PHARMACOL EXP THER, V193, P11; DELAPENA P, 1992, BIOCHEM J, V284, P891, DOI 10.1042/bj2840891; Faden AI, 1999, AM J PHYSIOL-REG I, V277, pR1196; FADEN AI, 1981, NEW ENGL J MED, V305, P1063, DOI 10.1056/NEJM198110293051806; Faden AI, 2001, ARCH NEUROL-CHICAGO, V58, P1553, DOI 10.1001/archneur.58.10.1553; FADEN AI, 1993, J NEUROTRAUM, V10, P101, DOI 10.1089/neu.1993.10.101; FADEN AI, 1989, ANN NY ACAD SCI, V553, P380; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Koenig ML, 1996, BRAIN RES, V730, P143; KOH JY, 1995, EXP NEUROL, V135, P153, DOI 10.1006/exnr.1995.1074; KOLVASULO FI, 1979, ACTA PHYSL SCAND, V106, P83; LAHTI H, 1983, EXPERIENTIA, V39, P1338, DOI 10.1007/BF01990091; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; MATTSON MP, 1995, METHOD CELL BIOL, V46, P187; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; METCALF G, 1974, NATURE, V252, P310, DOI 10.1038/252310a0; Mukhin AG, 1998, J NEUROSCI RES, V51, P748, DOI 10.1002/(SICI)1097-4547(19980315)51:6<748::AID-JNR8>3.0.CO;2-B; ODONNELL MJ, 1988, J AM CHEM SOC, V110, P8520, DOI 10.1021/ja00233a031; ODONNELL MJ, 1994, TETRAHEDRON, V50, P4507, DOI 10.1016/S0040-4020(01)89382-0; PETERKOFSKY A, 1982, MOL CELL BIOCHEM, V42, P45; Prasad C, 1998, THYROID, V8, P969, DOI 10.1089/thy.1998.8.969; PRASAD C, 1987, NEUROCHEM RES, V12, P767, DOI 10.1007/BF00971513; PRASAD C, 1988, NEUROSCI BIOBEHAV R, V12, P19, DOI 10.1016/S0149-7634(88)80069-1; PRASAD C, 1989, ANN NY ACAD SCI, V553, P232; RAMARAO P, 1990, NEUROPEPTIDES, V15, P213, DOI 10.1016/0143-4179(90)90015-Q; Rauk A, 2000, J AM CHEM SOC, V122, P9761, DOI 10.1021/ja994436u; Shaikh ZA, 1999, TOXICOLOGY, V132, P139; STANISH C, 1989, AM ANTHROPOL, V91, P7, DOI 10.1525/aa.1989.91.1.02a00010; STANTON TL, 1980, BRAIN RES, V181, P470, DOI 10.1016/0006-8993(80)90632-0; TACHE Y, 1985, EUR J PHARMACOL, V107, P149, DOI 10.1016/0014-2999(85)90053-6; Tanaka K, 1997, REGUL PEPTIDES, V70, P173, DOI 10.1016/S0167-0115(97)01013-6; TECOMA ES, 1989, NEURON, V2, P1541, DOI 10.1016/0896-6273(89)90042-1; VINK R, 1988, BRAIN RES, V460, P184, DOI 10.1016/0006-8993(88)91221-8; Zhao X, 1999, NEUROCHEM RES, V24, P371, DOI 10.1023/A:1020933616351	35	42	45	0	12	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0968-0896	1464-3391		BIOORGAN MED CHEM	Bioorg. Med. Chem.	SEP	2002	10	9					3043	3048	PII S0968-0896(02)00132-3	10.1016/S0968-0896(02)00132-3			6	Biochemistry & Molecular Biology; Chemistry, Medicinal; Chemistry, Organic	Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry	584TL	WOS:000177484800026	12110327				2021-06-18	
J	Satoh, K; Ikeda, Y; Shioda, S; Tobe, T; Yoshikawa, T				Satoh, K; Ikeda, Y; Shioda, S; Tobe, T; Yoshikawa, T			Edarabone scavenges nitric oxide	REDOX REPORT			English	Article							PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; RADICALS; SYNTHASE; MIGRAINE; NO	Oxygen free radicals have been proposed to be major causative agents in secondary brain damage in traumatic and ischemic brain injury. Edarabone (3-methyl-1-phenyl-2-pyrazolin-5-one), a powerful antioxidative radical scavenger, is the only drug currently available in clinical practice for the treatment of cerebral infarction. There has been increasing interest in the role of nitric oxide (NO*) as a causative agent in brain injury. In the present study, we investigated the scavenging effect of Edarabone on nitric oxide (NO*), using an electron spin resonance (ESR) method. NO* was generated from 1-hydroxy-2-oxo-3-(N-3-methyl-3-aminopropyl)-3-methyl-1-triazene (NOC-7), and analyzed by 2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxy (carboxy-PTI) produced from the reaction between 2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxy-3-oxide (carboxy-PTIO) and NO*. Edarabone directly scavenged NO* in a dose-dependent manner. These ESR studies indicate that Edarabone has a direct NO* scavenging activity and the additional possibility of novel neuroprotective activities against brain injury and focal cerebral ischemia.	Showa Univ, Sch Pharmaceut Sci, Dept Med Informat, Shinagawa Ku, Tokyo 1428555, Japan; Showa Univ, Sch Med, Dept Neurosurg, Tokyo 1428555, Japan; Showa Univ, Sch Med, Dept Anat 1, Tokyo 1428555, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Kyoto, Japan; Kyoto Prefectural Univ Med, Dept Med 1, Kyoto, Japan	Satoh, K (corresponding author), Showa Univ, Sch Pharmaceut Sci, Dept Med Informat, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 1428555, Japan.	ksugar@pharm.showa-u.ac.jp					Akaike T, 1996, METHOD ENZYMOL, V268, P211; AKAIKE T, 1993, BIOCHEMISTRY-US, V32, P827, DOI 10.1021/bi00054a013; Asanuma M, 2001, J NEUROCHEM, V76, P1895, DOI 10.1046/j.1471-4159.2001.00205.x; Beal MF, 1998, ANN NEUROL, V44, pS110; DORHEIM MA, 1994, BIOCHEM BIOPH RES CO, V205, P659, DOI 10.1006/bbrc.1994.2716; Gatto EM, 2000, NITRIC OXIDE-BIOL CH, V4, P534, DOI 10.1006/niox.2000.0288; HOGG N, 1995, FREE RADICAL RES, V22, P47, DOI 10.3109/10715769509147527; IKEDA Y, 2001, J CLIN EXP MED, V199, P471; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P446, DOI 10.1016/0003-9861(92)90433-W; KIMURA E, 1996, AM J PHYSIOL, V270, pC748; KOSAKA H, 1989, CARCINOGENESIS, V10, P563, DOI 10.1093/carcin/10.3.563; Law A, 2001, BRAIN RES REV, V35, P73, DOI 10.1016/S0165-0173(00)00051-5; MITSUTA K, 1990, B CHEM SOC JPN, V63, P187, DOI 10.1246/bcsj.63.187; Nishibayashi S, 1996, J NEUROCHEM, V67, P2208; Noda Y, 1997, RES COMMUN MOL PATH, V96, P115; Olesen J, 2000, PATHOL BIOL, V48, P648; OLESEN J, 1994, TRENDS PHARMACOL SCI, V15, P149, DOI 10.1016/0165-6147(94)90075-2; OURESHI GA, 1995, NEUROREPORT, V6, P1642, DOI 10.1097/00001756-199508000-00013; WATANABE K, 1997, JPN PHARMACOL THER, V25, pS1691; WATANABE K, 1997, JPN PHARMACOL THER, V25, pS1699; Yamamoto Y, 1996, REDOX REP, V2, P333, DOI 10.1080/13510002.1996.11747069	21	42	55	0	0	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1351-0002	1743-2928		REDOX REP	Redox Rep.		2002	7	4					219	222		10.1179/135100002125000587			4	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	605PZ	WOS:000178687400005	12396667	Bronze			2021-06-18	
J	Fujii, DE; Ahmed, I				Fujii, DE; Ahmed, I			Risk factors in psychosis secondary to traumatic brain injury	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							SEX-DIFFERENCES; HEAD TRAUMA; SCHIZOPHRENIA; DISEASE; RECOVERY; APHASIA	Psychosis is a rare but devastating sequela of traumatic brain injury (TBI). This study examined risk factors for developing a psychosis secondary to TBI (PSTBI). Demographics of 25 inpatients with PSTBI were statistically analyzed for risk factors. Data from the PSTBI group were also compared with data from a control group of TBI patients without psychosis. Results indicate the PSTBI group was more likely to have had a previous congenital neurological disorder or to have sustained a head injury prior to adolescence. The PSTBI also had a higher proportion of males. Discussion focuses on potential models for developing PSTBI.	John A Burns Sch Med, Dept Psychiat, Honolulu, HI USA; Hawaii State Hosp, Dept Neuropsychol, Kaneohe, HI USA	Fujii, DE (corresponding author), Hawaii State Hosp, Dept Neuropsychol, 45-710 Keaahala Rd, Kaneohe, HI 96744 USA.						ACHTE K, 1991, PSYCHOPATHOLOGY, V24, P309, DOI 10.1159/000284731; ACHTE KA, 1969, ACTA PSYCHIAT SCAND, V45, P1, DOI 10.1111/j.1600-0447.1969.tb06197.x; Ahmed II, 1998, SEMIN CLIN NEUROPSYC, V3, P23; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; BASSO A, 1982, CORTEX, V18, P469, DOI 10.1016/S0010-9452(82)80044-0; CARLSSON GS, 1987, J NEUROSURG, V67, P197, DOI 10.3171/jns.1987.67.2.0197; CUMMINGS JL, 1988, PSYCHOSOMATICS, V29, P16, DOI 10.1016/S0033-3182(88)72418-4; Davison K, 1969, BRIT J PSYCHIATRY SP, V4, P113; FEINSTEIN A, 1990, PSYCHOL MED, V20, P793, DOI 10.1017/S0033291700036485; Feinstein A, 1998, J NEUROPSYCH CLIN N, V10, P448, DOI 10.1176/jnp.10.4.448; FLORHENRY P, 1969, EPILEPSIA, V10, P363, DOI 10.1111/j.1528-1157.1969.tb03853.x; Fujii DE, 1996, PROF PSYCHOL-RES PR, V27, P266; Fujii DEM, 1996, NEUROPSY NEUROPSY BE, V9, P133; GESCHWIND N, 1985, ARCH NEUROL-CHICAGO, V42, P428, DOI 10.1001/archneur.1985.04060050026008; Gualtari CT, 1991, BRAIN INJURY, V5, P219; GUR RC, 1982, SCIENCE, V217, P659, DOI 10.1126/science.7089587; GUREJE O, 1994, AM J PSYCHIAT, V151, P368; Harrington C R, 1997, Int Psychogeriatr, V9, P229, DOI 10.1017/S1041610297004390; Harwood DG, 1999, AM J GERIAT PSYCHIAT, V7, P119; HILIBOM E, 1960, ACTA PSYCHIAT NEUR S, V142, P1; Ingvar D., 1987, BIOL PERSPECTIVES SC, P201; Levy J., 1992, HDB BEHAVIORAL NEURO, P245; Lishman W. A., 1987, ORGANIC PSYCHIAT PSY; MCKENNA PJ, 1985, AM J PSYCHIAT, V142, P895; NASRALLAH HA, 1992, TXB NEUROPSYCHIATRY, P621; PIZZAMIGLIO L, 1985, BRAIN LANG, V25, P213, DOI 10.1016/0093-934X(85)90081-1; ROSSI A, 1990, BIOL PSYCHIAT, V27, P61, DOI 10.1016/0006-3223(90)90020-3; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; SHAPIRO LB, 1939, ILLINOIS MED J, V76, P250; Smeltzer Donald J., 1994, P251; The Mild Traumatic Brain Injury Committee of the Head Injury Interdisciplinary Special Interest Group of the American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86; VIOLON A, 1987, ACTA NEUROCHIR, V85, P96, DOI 10.1007/BF01456104; Waddington JL, 1998, PSYCHIAT CLIN N AM, V21, P123, DOI 10.1016/S0193-953X(05)70364-6; WEINBERGER DR, 1988, SCHIZOPHRENIA BULL, V14, P157, DOI 10.1093/schbul/14.2.157; WILCOX JA, 1987, PSYCHIAT RES, V21, P303, DOI 10.1016/0165-1781(87)90013-8; Woods BT, 1998, AM J PSYCHIAT, V155, P1661, DOI 10.1176/ajp.155.12.1661; YATES WR, 1990, NEUROPSY NEUROPSY BE, V3, P98	38	42	44	0	4	AMER PSYCHIATRIC PRESS, INC	WASHINGTON	1400 K ST, N W, STE 1101, WASHINGTON, DC 20005 USA	0895-0172			J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	WIN	2001	13	1					61	69		10.1176/appi.neuropsych.13.1.61			9	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	401TR	WOS:000166944800008	11207331				2021-06-18	
J	Adams, JH; Graham, DI; Jennett, B				Adams, JH; Graham, DI; Jennett, B			The structural basis of moderate disability after traumatic brain damage	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article						head injury; disability; neuropathology	DIFFUSE AXONAL INJURY; MISSILE HEAD-INJURY; ALZHEIMERS-DISEASE; RISK-FACTORS; NEUROPATHOLOGY; DIAGNOSIS	The objective was to discover the nature of brain damage in survivors of head injury who are left with moderate disability. Macroscopic and microscopic examination was carried out on the brains of 20 persons who had died long after a head injury that had been treated in a neurosurgical unit. All had become independent but had various disabilities (moderate disability on the Glasgow outcome scale) Most deaths had been sudden, which had led to their referral from forensic pathologists. Post-traumatic epilepsy was a feature in 75%. An intracranial haematoma had been evacuated in 75%, and in 11 of the 15 with epilepsy. Diffuse axonal injury was found in six patients, five of the mi est type (grade 1) and one of grade 2. No patient had diffuse thalamic damage but one had a small focal ischaemic lesion in the thalamus. No patient had severe ischaemic brain damage, but three had moderate lesions which were bilateral in only one. No patient had severe cortical contusions. In conclusion, the dominant lesion was focal damage from an evacuated intracranial haematoma. Severe diffuse damage was not found, with diffuse axonal injury only mild and thalamic damage in only one patient.	S Glasgow Univ Hosp NHS Trust, Inst Neurol Sci, Univ Dept Neuropathol, Glasgow G51 4TF, Lanark, Scotland; S Glasgow Univ Hosp NHS Trust, Inst Neurol Sci, Univ Dept Neurosurg, Glasgow G51 4TF, Lanark, Scotland	Graham, DI (corresponding author), S Glasgow Univ Hosp NHS Trust, Inst Neurol Sci, Univ Dept Neuropathol, 1345 Govan Rd, Glasgow G51 4TF, Lanark, Scotland.						ADAMS JH, 1976, NEUROPATH APPL NEURO, V2, P323, DOI 10.1111/j.1365-2990.1976.tb00506.x; ADAMS JH, 1985, MED SCI LAW, V25, P265, DOI 10.1177/002580248502500407; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ADAMS JH, 1985, NEUROPATH APPL NEURO, V11, P299, DOI 10.1111/j.1365-2990.1985.tb00027.x; CORSELLIS JAN, 1989, BRIT MED J, V298, P105, DOI 10.1136/bmj.298.6666.105; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Geddes JF, 1997, NEUROPATH APPL NEURO, V23, P339, DOI 10.1046/j.1365-2990.1997.4498044.x; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Griffin WST, 1998, BRAIN PATHOL, V8, P65; JENNETT B, 1975, LANCET, V1, P480; Jennett B, 2001, NEUROLOGY, V56, P486, DOI 10.1212/WNL.56.4.486; Kloster R, 1999, J NEUROL NEUROSUR PS, V67, P439, DOI 10.1136/jnnp.67.4.439; MAYEUX R, 1993, ANN NEUROL, V33, P494, DOI 10.1002/ana.410330513; Nashef L, 1997, EPILEPSIA, V38, pS6, DOI 10.1111/j.1528-1157.1997.tb06130.x; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; Thomas JD, 1997, FRESHWATER BIOL, V38, P1, DOI 10.1046/j.1365-2427.1997.00206.x	19	42	46	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	OCT	2001	71	4					521	524		10.1136/jnnp.71.4.521			4	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	478ZQ	WOS:000171379800019	11561038	Green Published, Bronze			2021-06-18	
J	Ruchholtz, S; Waydhas, C; Aufmkolk, M; Tager, G; Piepenbrink, K; Stolke, D; Nast-Kolb, D				Ruchholtz, S; Waydhas, C; Aufmkolk, M; Tager, G; Piepenbrink, K; Stolke, D; Nast-Kolb, D			A multidisciplinary quality management system (QMS) for the early treatment of severely injured patients in a trauma center in Germany	UNFALLCHIRURG			German	Article						quality management system; quality circle; trauma center; severely injured patients	ACUTE SUBDURAL-HEMATOMA; MULTIPLE INJURIES; MISSED INJURIES; PREVENTABLE DEATHS; COMATOSE PATIENTS; ABDOMINAL-TRAUMA; SEVERITY SCORE; CARE; IMPROVEMENT; MORTALITY	A multidisciplinary quality management system (QMS) for the early treatment of severely injured patients was validated in a trauma center in Germany. In the presented prospective study a QMS developed at another trauma center was implemented at the department of trauma surgery of the university of Essen for the presented study. The essential elements of the QMS were the establishment of (1) an adequate protocol for documentation, (2) 20 criteria for the assessment of treatment quality, (3) regular statistical analysis of treatment quality and (4) a quality circle comprising all medical specialties for data discussion. From 5/98-9/99 a cohort of 447 patients with an average injury severity score (ISS) of 22+/-17 was treated in the emergency department. The impact of the QMS was assessed in 4 periods (1: 5/1998-8/1998;2:9-12/1998; 3:1-4/1999; 4: 5-8/1999). The quality circle met 8 times. For the improvement of the process 16 long-term changes were introduced. In 60% (n=12) of the 20 assessment criteria significant improvements were detected. In diagnostics there were significant reductions of the time needed for basic radiological and sonographic check-up (from 24+/-12 min in the first to 14+/-8 min in the last period) and of the duration until performance of a cranial computed tomography in severe traumatic brain injury (sTBI; from 45+/-22 to 28+/-8 min). The rate of delayed diagnoses remained low (4% in the first, 5% in the last period). Further positive changes were the time savings in transfusion (from 35+/-20 to 20+/-4 min) and emergency operations (from 67+/-20 to 48+/-4 min) in hemorraghic shock as well as for craniotomies (77+/-41 to 54+/-19 min) in sTBI. Apart from the significant time reductions other improvements were found. Overall mortality was diminished from 17% in the first to 10% in the last observation period. In conclusion the study revealed that the quality of the early therapy of severely inured patients was significantly improved by implementation of a multidisciplinary quality management system especially with respect to treatment efficiency.	Univ Klinikum Essen, Klin & Poliklin Unfallchirurg, D-47145 Essen, Germany	Ruchholtz, S (corresponding author), Univ Klinikum Essen, Klin & Poliklin Unfallchirurg, Hufelandstr 55, D-47145 Essen, Germany.						*AM COLL SURG COMM, 1993, RES OPT CAR INJ PAT; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BISHOP M, 1991, AM SURGEON, V57, P736; BLUMENTHAL D, 1991, HOSPIMEDICA, V10, P26; BRAUN KH, 1993, HAV BIS MANAGER, V2, P77; CAMPBELL S, 1989, AM SURGEON, V55, P478; CAYTEN CG, 1991, ANN SURG, V214, P510, DOI 10.1097/00000658-199110000-00015; CHAMPION HR, 1992, ARCH SURG-CHICAGO, V127, P333; Cohen JE, 1996, J TRAUMA, V41, P120, DOI 10.1097/00005373-199607000-00019; *COMM INJ SCAL, 1999, ABBR INJ SCAL 1990 R; COPES WS, 1995, J TRAUMA, V38, P432, DOI 10.1097/00005373-199503000-00027; DAVIS JW, 1991, J TRAUMA, V31, P813, DOI 10.1097/00005373-199106000-00012; DAVIS JW, 1992, J TRAUMA, V32, P660, DOI 10.1097/00005373-199205000-00020; DEMING WE, 1985, OUT CRISIS; DONABEDIAN A, 1988, JAMA-J AM MED ASSOC, V260, P1743, DOI 10.1001/jama.260.12.1743; DRAAISMA JMT, 1989, J TRAUMA, V29, P1552; *DTSCH I NORM, 1990, QUAL EL QUAL; EASTHAM JN, 1993, JEMS, V1, P43; EKKERNKAMP A, 1992, UNFALLCHIRURG, V95, P380; HIRSHBERG A, 1994, AM J SURG, V168, P299, DOI 10.1016/S0002-9610(05)80152-7; HOYT DB, 1992, J TRAUMA, V33, P586, DOI 10.1097/00005373-199210000-00016; HOYT DB, 1988, J TRAUMA, V28, P435, DOI 10.1097/00005373-198804000-00003; HOYT DB, 1994, J TRAUMA, V36, P377, DOI 10.1097/00005373-199403000-00017; Ishikawa K, 1985, WHAT IS TOTAL QUALIT; IUA PT, 1998, AUST NZ J SURG, V68, P820; Juran J., 1989, JURAN LEADERSHIP QUA; KREIS DJ, 1986, J TRAUMA, V26, P649, DOI 10.1097/00005373-198607000-00010; LIEBIG, 1999, MFU MATERIALIEN, V9, P1; LIU M, 1988, CRIT CARE MED, V16, P1191, DOI 10.1097/00003246-198812000-00004; MACKENZIE EJ, 1992, J TRAUMA, V33, P292, DOI 10.1097/00005373-199208000-00021; MACKENZIE EJ, 1985, MED CARE, V23, P823, DOI 10.1097/00005650-198506000-00008; Massaro F, 1996, ACTA NEUROCHIR, V138, P185, DOI 10.1007/BF01411359; McDermott FT, 1996, J TRAUMA, V40, P520, DOI 10.1097/00005373-199604000-00003; MUCKART DJJ, 1991, AM J SURG, V162, P457, DOI 10.1016/0002-9610(91)90260-K; Nast-Kolb D, 1999, UNFALLCHIRURG, V102, P338, DOI 10.1007/s001130050415; NASTKOLB D, 1993, CHIRURG, V64, P552; NASTKOLB D, 1994, UNFALLCHIRURG, V97, P292; NERLICH ML, 1987, ZBL CHIR, V112, P1465; REEDER L, 1993, JEMS, V9, P46; REGEL G, 1993, UNFALLCHIRURG, V96, P350; Robertson R, 1996, AM J SURG, V172, P564, DOI 10.1016/S0002-9610(96)00247-4; Ruchholtz S, 1998, INJURY, V29, P115, DOI 10.1016/S0020-1383(97)00150-2; RUCHHOLTZ S, 1994, UNFALLCHIRURG, V97, P285; RUCHHOLTZ S, 1999, LANGENBECKS ARCH S, V116, P1029; SCHWARTZ ML, 1991, J TRAUMA, V31, P962, DOI 10.1097/00005373-199107000-00013; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; SHACKFORD SR, 1987, J TRAUMA, V27, P866, DOI 10.1097/00005373-198708000-00004; SHOEMAKER WC, 1988, CRIT CARE MED, V16, P1199, DOI 10.1097/00003246-198812000-00005; SMITH JS, 1990, J TRAUMA, V30, P1533, DOI 10.1097/00005373-199012000-00017; STOCCHETTI N, 1994, J TRAUMA, V36, P401, DOI 10.1097/00005373-199403000-00022; STOTHERT JC, 1990, J TRAUMA, V30, P1021, DOI 10.1097/00005373-199008000-00012; Sung CK, 1996, J TRAUMA, V41, P276, DOI 10.1097/00005373-199608000-00013; TRUNKEY D, 1991, NEW ENGL J MED, V324, P1259; WAYDHAS C, 1994, LANGENBECKS ARCH C S, V111, P1140; WENNEKER WW, 1990, AM J SURG, V160, P655, DOI 10.1016/S0002-9610(05)80768-8; WEST JG, 1979, ARCH SURG-CHICAGO, V114, P455; WILBERGER JE, 1990, J TRAUMA, V30, P733, DOI 10.1097/00005373-199006000-00014; WILSON DS, 1992, J TRAUMA, V32, P45, DOI 10.1097/00005373-199201000-00010; Zintl B, 1997, UNFALLCHIRURG, V100, P811, DOI 10.1007/s001130050198	59	42	44	0	1	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0177-5537			UNFALLCHIRURG	Unfallchirurg	OCT	2001	104	10					927	937		10.1007/s001130170033			11	Emergency Medicine; Surgery	Emergency Medicine; Surgery	483AF	WOS:000171611000003	11572129				2021-06-18	
J	Cusick, CP; Brooks, CA; Whiteneck, GG				Cusick, CP; Brooks, CA; Whiteneck, GG			The use of proxies in community integration research	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						disabled persons; health surveys; outcomes research; rehabilitation; reliability and validity	QUALITY-OF-LIFE; FUNCTIONAL STATUS; SIGNIFICANT OTHERS; PATIENT HEALTH; AGREEMENT; RELIABILITY; INJURY	Objective: To assess the level of agreement between persons with various disabilities and their proxies in reporting community integration outcomes using the Craig Handicap Assessment and Reporting Technique (CHART). Design: Reliability study. Setting: Participants living in the community for a minimum of 6 months after onset of disability or completion of inpatient rehabilitation. Participants: Persons (n = 983) with disability resulting from amputation, burn, multiple sclerosis, spinal cord injury (SCI), stroke, or traumatic brain injury and their self-selected proxies. Interventions: Telephone inter-view of subjects (FIM(TM) instrument, CHART); proxies (CHART). FIM instrument assesses the degree of assistance with physical and cognitive subscales; CHART measures community integration in 6 subscales: physical, cognitive, and economic independence, and mobility, social integration. and occupation. Main Outcome Measures: Intraclass correlation coefficients (ICCs) were used to assess participant-proxy agreement, and stepwise multiple regressions were used to identify patterns of difference in agreement based on disability type and demographic variables. Results: Thirty-seven of the 38 items examined for the entire sample yielded moderate to strong ICCs. Multiple regression analyses indicated that proxies overrated participants gr with severe functional cognitive disabilities on the mobility subscale (p <.001), overrated participants with less than a high school education on the total CHART score (p <.01), and underrated participants with SCIs on the occupation subscale (p <.01). Differences in all cases, however, were less than 6 points out of a possible score of 100 per subscale. Conclusions: Participant-proxy agreement across the 6 disability groups provided evidence in support of the inclusion of proxy data for persons with various types of disabilities in community integration research.	Craig Hosp, Dept Res, Englewood, CO 80110 USA	Cusick, CP (corresponding author), Craig Hosp, Dept Res, 3425 S Clarkson St, Englewood, CO 80110 USA.						American Spinal Injury Association International Medical Society of Paraplegia, 1996, INT STAND NEUR FUNCT; BASSETT SS, 1990, PSYCHOL AGING, V5, P127, DOI 10.1037/0882-7974.5.1.127; BLAND JM, 1990, COMPUT BIOL MED, V20, P337, DOI 10.1016/0010-4825(90)90013-F; CLARRIDGE BR, 1989, MED CARE, V27, P352, DOI 10.1097/00005650-198904000-00003; Cornoni-Huntley J., 1986, NIH PUBLICATION; Cusick CP, 2000, J HEAD TRAUMA REHAB, V15, P739, DOI 10.1097/00001199-200002000-00012; GRANGER CV, 1997, ASSESSING MED REHABI, P103; HAYS RD, 1995, QUAL LIFE RES, V4, P159, DOI 10.1007/BF01833609; KOLONEL LN, 1977, AM J EPIDEMIOL, V106, P476, DOI 10.1093/oxfordjournals.aje.a112494; KOONS DA, 1973, VITAL HLTH STAT SER, V2; MAGAZINER J, 1988, J CLIN EPIDEMIOL, V41, P1065, DOI 10.1016/0895-4356(88)90076-5; MCCUSKER J, 1984, MED CARE, V22, P789, DOI 10.1097/00005650-198409000-00002; ROTHMAN ML, 1991, MED CARE, V29, P115, DOI 10.1097/00005650-199102000-00004; RUBENSTEIN LZ, 1984, J GERONTOL, V39, P686, DOI 10.1093/geronj/39.6.686; Smith PM, 1996, ARCH PHYS MED REHAB, V77, P431, DOI 10.1016/S0003-9993(96)90029-5; Sneeuw KCA, 1997, MED CARE, V35, P490, DOI 10.1097/00005650-199705000-00006; SPRANGERS MAG, 1992, J CLIN EPIDEMIOL, V45, P743, DOI 10.1016/0895-4356(92)90052-O; *STAT U NY BUFF, 1996, GUID UN DAT SET MED; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; WEINBERGER M, 1992, J AM GERIATR SOC, V40, P585, DOI 10.1111/j.1532-5415.1992.tb02107.x; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WHITENECK GG, 1997, HANDICAP ASSESSMENT; World Health Organization, 1980, INT CLASS IMP DIS HA	23	42	42	0	5	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	2001	82	8					1018	1024		10.1053/apmr.2001.25098			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	459WT	WOS:000170275000002	11494179				2021-06-18	
J	Drescher, W; Schneider, T; Becker, C; Hobolth, J; Ruther, W; Hansen, ES; Bunger, C				Drescher, W; Schneider, T; Becker, C; Hobolth, J; Ruther, W; Hansen, ES; Bunger, C			Selective reduction of bone blood flow by short-term treatment with high-dose methylprednisolone - An experimental study in pigs	JOURNAL OF BONE AND JOINT SURGERY-BRITISH VOLUME			English	Article							STEROID-RELATED COMPLICATIONS; FEMORAL-HEAD; CYCLOSPORINE ERA; OSTEONECROSIS; NECROSIS; RABBITS	Treatment with corticosteroids is a risk factor for non-traumatic avascular necrosis of the femoral head, but the pathological mechanism is poorly understood, Short-term treatment with high doses of methylprednisolone is used in severe neurotrauma and after kidney and heart transplantation. We investigated the effect of such treatment on the pattern of perfusion of the femoral head and of bone in general in the pig, We allocated 15 immature pigs to treatment with high-dose methylprednisolone (20 mg/kg per day intramuscularly for three days, followed by 10 mg/kg intramuscularly for a further II days) and 15 to a control group. Perfusion of the systematically subdivided femoral head, proximal femur, acetabulum, humerus, and soft tissues was determined by the microsphere technique, Blood flow in bone was severely reduced in the steroid-treated group. The reduction of flow affected all the segments and the entire epiphysis of the femoral head. No changes in flow were found in non-osseous tissue, Short-term treatment with high-dose methylprednisolone causes reduction of osseous blood flow which may be the pathogenetic Factor in the early stage of steroid-induced osteonecrosis.	Aarhus Univ Hosp, DK-8000 Aarhus, Denmark	Drescher, W (corresponding author), Aarhus Univ, Dept Orthopaed, DK-8000 Aarhus C, Denmark.						BRADBURY G, 1994, J BONE JOINT SURG AM, V76A, P1385, DOI 10.2106/00004623-199409000-00014; BUNGER C, 1989, T ORS, P422; COOPER RR, 1966, J BONE JOINT SURG AM, VA 48, P1239, DOI 10.2106/00004623-196648070-00001; Cui Q, 1997, J BONE JOINT SURG AM, V79A, P1054, DOI 10.2106/00004623-199707000-00012; FRYER JP, 1994, CLIN TRANSPLANT, V8, P224; FRYER JP, 1994, TRANSPL P, V26, P91; Glueck CJ, 1998, CLIN ORTHOP RELAT R, P159; Glueck CJ, 1997, CLIN ORTHOP RELAT R, P43; GLUECK CJ, 1994, AM J HEMATOL, V45, P156, DOI 10.1002/ajh.2830450212; HANSEN ES, 1991, ACTA ORTHOP SCAND, V62, P268, DOI 10.3109/17453679108993608; Hirano K, 1997, CLIN ORTHOP RELAT R, P192; LANDMANN J, 1987, J BONE JOINT SURG AM, V69A, P1226, DOI 10.2106/00004623-198769080-00017; LAUSTEN GS, 1993, ACTA ORTHOP SCAND, V64, P533, DOI 10.3109/17453679308993686; Liesner RJ, 1999, J BONE JOINT SURG BR, V81B, P565; Nishimura T, 1997, CLIN ORTHOP RELAT R, P37; REMAGEN W, 1990, ORTHOPADE, V19, P174; SPENCER JD, 1988, CLIN ORTHOP RELAT R, P127; STERN PJ, 1979, J BONE JOINT SURG AM, V61, P851, DOI 10.2106/00004623-197961060-00008; Thomas DP, 1999, J BONE JOINT SURG BR, V81B, P691, DOI 10.1302/0301-620X.81B4.9438; TRUETA J, 1957, J BONE JOINT SURG BR, V39, P358; WANG GJ, 1977, J BONE JOINT SURG AM, V59, P729, DOI 10.2106/00004623-197759060-00003; WANG GJ, 1981, CLIN ORTHOP RELAT R, P274; WANG GJ, 1985, J BONE JOINT SURG AM, V67A, P121, DOI 10.2106/00004623-198567010-00015; Yamamoto T, 1997, ARTHRITIS RHEUM, V40, P2055, DOI 10.1002/art.1780401119	24	42	45	0	3	BRITISH EDITORIAL SOC BONE JOINT SURGERY	LONDON	22 BUCKINGHAM STREET, LONDON WC2N 6ET, ENGLAND	0301-620X			J BONE JOINT SURG BR	J. Bone Joint Surg.-Br. Vol.	MAR	2001	83B	2					274	277		10.1302/0301-620X.83B2.10323			4	Orthopedics; Surgery	Orthopedics; Surgery	415UM	WOS:000167742000025	11284580				2021-06-18	
J	Prueckner, S; Safar, P; Kentner, R; Stezoski, J; Tisherman, SA				Prueckner, S; Safar, P; Kentner, R; Stezoski, J; Tisherman, SA			Mild hypothermia increases survival from severe pressure-controlled hemorrhagic shock in rats	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	13th Annual Meeting of the Eastern-Association-for-the-Surgery-of-Trauma	JAN 10-15, 2000	SANIBEL, FL	Eastern Assoc Surg Trauma		hypothermia; rat model; fluid resuscitation; hemorrhage; hemorrhagic shock; hypotension; outcome; survival	TRAUMATIC BRAIN INJURY; CARDIAC-ARREST; MODERATE HYPOTHERMIA; OUTCOME MODEL; POSTTRAUMATIC HYPOTHERMIA; PROLONGS SURVIVAL; BODY-TEMPERATURE; RESUSCITATION; DOGS; OXYGEN	Background: In previous studies, mild hypothermia (34 degreesC) during uncontrolled hemorrhagic shock (HS) increased survival. Hypothermia also increased mean arterial pressure (MAP), which may have contributed to its beneficial effect, We hypothesized that hypothermia would improve survival in a pressure-controlled HS model and that prolonged hypothermia would further Improve survival, Methods: Thirty rats were prepared under light nitrous oxide/halothane anesthesia with spontaneous breathing, The rats underwent HS with an initial blood withdrawal of 2 mL/100 g over 10 minutes and pressure-controlled IIS at a MAP of 40 mm Ng over 90 minutes (without anticoagulation), followed by return of shed blood and additional lactated Ringer's solution to achieve normotension, Hemodynamic monitoring and anesthesia were continued to 1 hour, temperature control to 12 hours, and observation without anesthesia to 72 hours. After HS of 15 minutes, 10 rats each were randomized to group 1, with normothermia (38 degreesC) throughout; group 2, with brief mild hypothermia (34 degreesC during HS 15-90 minutes plus 30 minutes after reperfusion); and group 3, with prolonged mild hypothermia (same as group 2, then 35 degreesC [possible without shivering] from 30 minutes after reperfusion to 12 hours). Results: MAP during HS and initial resuscitation was the same in all three groups, but was higher in the hypothermia groups 2 and 3, compared with the normothermia group 1, at 15 and 60 minutes after reperfusion, Group 1 required less blood withdrawal to maintain MAP 40 mm Hg during HS and more lactated Ringer's solution for resuscitation, At end of IIS, lactate levels were higher in group 1 than in groups 2 and 3 (p < 0.02). Temperatures were according to protocol. Survival to 72 hours was achieved in group 1 by 3 of 10 rats, in group 2 by 7 of 10 rats (p = 0.18 vs. group 1), and in group 3 by 9 of 10 rats (p = 0.02 vs. group I,p = 0.58 vs. group 2), Survival time was longer in group 2 (p = 0.09) and group 3 (p = 0.007) compared with group 1. Conclusion: Brief hypothermia had physiologic benefit and a trend toward improved survival, Prolonged mild hypothermia significantly increased survival after severe HS even with controlled MAP. Extending the duration of hypothermia beyond the acute phases of shock and resuscitation may be needed to ensure improved outcome after prolonged HS.	Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Anesthesiol CCM, Pittsburgh, PA 15260 USA	Tisherman, SA (corresponding author), Univ Pittsburgh, Safar Ctr Resuscitat Res, 3434 5th Ave, Pittsburgh, PA 15260 USA.	tishermansa@msx.upmc.edu	Tisherman, Samuel A./AAK-9377-2020; Prueckner, Stephan/AAB-2280-2021	Tisherman, Samuel A./0000-0003-3810-3729; Prueckner, Stephan/0000-0002-5128-7625			Baiping Lei, 1994, Stroke, V25, P147; BIGELOW WG, 1950, ANN SURG, V132, P849, DOI 10.1097/00000658-195011000-00001; BRADER E, 1985, Annals of Emergency Medicine, V14, P510, DOI 10.1016/S0196-0644(85)80398-X; BUSTO R, 1989, STROKE, V20, P1113, DOI 10.1161/01.STR.20.8.1113; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; CAPONE A, 1995, RESUSCITATION, V29, P143, DOI 10.1016/0300-9572(95)00829-I; CAPONE AC, 1995, J AM COLL SURGEONS, V180, P49; CRIPPEN D, 1991, RESUSCITATION, V21, P271, DOI 10.1016/0300-9572(91)90052-Z; Davis JW, 1998, J TRAUMA, V44, P114, DOI 10.1097/00005373-199801000-00014; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DRIPPS RD, 1956, PHYSL INDUCED HYPOTH; EDMEYER U, 1998, J NEUROTRAUM, V15, P323; Gentilello LM, 1997, ANN SURG, V226, P439, DOI 10.1097/00000658-199710000-00005; GISVOLD SE, 1984, STROKE, V15, P803, DOI 10.1161/01.STR.15.5.803; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1250; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; GREGORY JS, 1991, J TRAUMA, V31, P795, DOI 10.1097/00005373-199106000-00009; GUBLER KD, 1994, J TRAUMA, V36, P847, DOI 10.1097/00005373-199406000-00015; HALMAGYI DF, 1973, SURGERY, V74, P370; Holzer M, 1997, Acta Anaesthesiol Scand Suppl, V111, P55; JURKOVICH GJ, 1988, J SURG RES, V44, P514, DOI 10.1016/0022-4804(88)90156-4; JURKOVICH GJ, 1987, J TRAUMA, V27, P1019, DOI 10.1097/00005373-198709000-00011; KATZ L, 1995, J CEREBR BLOOD F MET, V15, P1032, DOI 10.1038/jcbfm.1995.129; Kim SH, 1998, J TRAUMA, V44, P485, DOI 10.1097/00005373-199803000-00010; Kim SH, 1997, J TRAUMA, V42, P213, DOI 10.1097/00005373-199702000-00006; KRAMER RS, 1968, J THORAC CARDIOV SUR, V56, P699, DOI 10.1016/S0022-5223(19)42797-9; KUBOYAMA K, 1993, CRIT CARE MED, V21, P1348, DOI 10.1097/00003246-199309000-00019; Kurz A, 1996, NEW ENGL J MED, V334, P1209, DOI 10.1056/NEJM199605093341901; LEONOV Y, 1990, J CEREBR BLOOD F MET, V10, P57, DOI 10.1038/jcbfm.1990.8; LEONOV Y, 1990, STROKE, V21, P1600, DOI 10.1161/01.STR.21.11.1600; LEONOV Y, 1995, ACAD EMERG MED, V2, P401; LITTLE RA, 1981, BRIT J SURG, V68, P221, DOI 10.1002/bjs.1800680402; LUNA GK, 1987, J TRAUMA, V27, P1014, DOI 10.1097/00005373-198709000-00010; Mansfield RT, 1996, J CEREBR BLOOD F MET, V16, P244, DOI 10.1097/00004647-199603000-00009; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MEDEN P, 1994, BRAIN RES, V647, P131, DOI 10.1016/0006-8993(94)91407-9; MEYER D M, 1987, Current Surgery, V44, P399; MEYER DM, 1990, J SURG RES, V48, P61, DOI 10.1016/0022-4804(90)90147-T; MEYER DM, 1988, ANN SURG, V207, P462, DOI 10.1097/00000658-198804000-00015; MICHENFELDER JD, 1970, ANESTHESIOLOGY, V33, P430, DOI 10.1097/00000542-197010000-00013; Mizushima Y, 2000, J TRAUMA, V48, P58, DOI 10.1097/00005373-200001000-00010; *NAT CTR HLTH STAT, 1992, MONTHL VIT STAT REP, V43, P1; PATT A, 1988, SURG CLIN N AM, V68, P775; POMERANZ S, 1993, J NEUROSURG, V79, P241, DOI 10.3171/jns.1993.79.2.0241; POPE A, 1999, FLUID RESUSCITATION, P123; POSTEL AH, 1957, ANN SURG, V145, P311, DOI 10.1097/00000658-195703000-00003; REED RL, 1992, J TRAUMA, V33, P465, DOI 10.1097/00005373-199209000-00022; Rozenfeld RA, 1996, J APPL PHYSIOL, V81, P1834; SAFAR P, 1988, CRIT CARE MED, V16, P923, DOI 10.1097/00003246-198810000-00003; Safar P, 1996, STROKE, V27, P105, DOI 10.1161/01.STR.27.1.105; Scheibel RS, 1998, J NEUROTRAUM, V15, P685, DOI 10.1089/neu.1998.15.685; Schlichtig R, 1996, J CRIT CARE, V11, P51, DOI 10.1016/S0883-9441(96)90020-9; Smith SL, 1996, J NEUROTRAUM, V13, P1, DOI 10.1089/neu.1996.13.1; SORI AJ, 1987, AM SURGEON, V53, P706; STEINEMANN S, 1990, J TRAUMA, V30, P200, DOI 10.1097/00005373-199002000-00011; STERZ F, 1991, CRIT CARE MED, V19, P379, DOI 10.1097/00003246-199103000-00017; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101; Takasu A, 1999, CRIT CARE MED, V27, P1557, DOI 10.1097/00003246-199908000-00025; Takasu A, 2000, CRIT CARE MED, V28, P2465, DOI 10.1097/00003246-200007000-00047; Tanaka J, 1983, Adv Shock Res, V9, P219; WEINRAUCH V, 1992, STROKE, V23, P1454, DOI 10.1161/01.STR.23.10.1454; Whalen MJ, 1997, J NEUROTRAUM, V14, P561, DOI 10.1089/neu.1997.14.561	63	42	45	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	FEB	2001	50	2					253	261		10.1097/00005373-200102000-00010			9	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	404WL	WOS:000167125000018	11242289				2021-06-18	
J	Axelrod, BN; Fichtenberg, NL; Liethen, PC; Czarnota, MA; Stucky, K				Axelrod, BN; Fichtenberg, NL; Liethen, PC; Czarnota, MA; Stucky, K			Performance characteristics of postacute traumatic brain injury patients on the WAIS-III and WMS-III	CLINICAL NEUROPSYCHOLOGIST			English	Article								Publication of the third editions of the Wechsler intelligence and memory batteries in 1997 created a need for research identifying Wechsler Adult Intelligence Scale-Third Edition / Wechsler Memory Scale-Third Edition (WAIS-III/WMS-III) profile patterns associated with neuropathology. The WAIS-III/WMS-III Technical Manual offers data on various diagnostic groups, including traumatic brain injury (TBI). Hawkins (1998) employed Technical Manual data to propose certain diagnostic guidelines. In order to validate the conclusions put forth by Hawkins as they apply to brain injury, we examined WAIS-III and WMS-III profiles in an independent sample of 46 TBI cases. As expected, the WAIS-III Processing Speed Index (PSI) was more sensitive to brain injury than other WAIS-III composites; and specific WAIS-III scores were stronger than certain WMS-III scores. On the other hand, the predicted relationship for WMS-III auditory and visual indexes was not found. The lack of specificity for TBI of the proposed index comparisons confirms the need to validate such hypotheses in independent samples.	John D Dingell Dept Vet Affairs Med Ctr, Detroit, MI USA; Rehabil Inst Michigan, Detroit, MI USA; Wayne State Univ, Sch Med, Detroit, MI USA; Beaumont Hosp, Hlth & Rehabil Ctr, Royal Oak, MI USA; Lakeland Neurocare Ctr, Southfield, MI USA; Hurley Med Ctr, Flint, MI USA	Axelrod, BN (corresponding author), Psychol Sect 11MH PS, 4646 John R, Detroit, MI 48201 USA.						Cimino C. R., 2000, CLIN GUIDE NEUROPSYC, P69; Fisher D C, 2000, Appl Neuropsychol, V7, P126, DOI 10.1207/S15324826AN0703_2; Hawkins KA, 1998, CLIN NEUROPSYCHOL, V12, P535, DOI 10.1076/clin.12.4.535.7236; Keith TZ, 2000, SCHOOL PSYCHOL QUART, V15, P373, DOI 10.1037/h0088794; *PSYCH CORP, 1997, WAIS 3 ADM SCOR MAN; *PSYCH CORP, 1997, WMS 3 ADM SCOR MAN; Psychological Corporation, 1997, WAIS 3 WMS 3 TECHN M; VANDERPLOEG RD, 2000, CLIN GUIDE NEUROPSYC, P111	8	42	43	0	1	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	0920-1637			CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2001	15	4					516	520		10.1076/clin.15.4.516.1884			5	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	535QR	WOS:000174656100010	11935453				2021-06-18	
J	Bradshaw, DRS; Ivarsson, J; Morfey, CL; Viano, DC				Bradshaw, DRS; Ivarsson, J; Morfey, CL; Viano, DC			Simulation of acute subdural hematoma and diffuse axonal injury in coronal head impact	JOURNAL OF BIOMECHANICS			English	Article						brain injury; head impact; subdural hematoma; diffuse axonal injury; physical model	PRIMATE	Coronal head impacts were simulated in a physical model, based on the hypothesis that acute subdural hematoma (ASDH) is related to cerebral vertex displacement and diffuse axonal injury (DAI) to local Green-Lagrange strain. The geometry of the 2D model was based on anatomical measurements taken from the MRI scans of 10 adult males. Silicone gel modelled the cerebrum, paraffin the CSF and elastic membranes the trabeculae of the sulci. Pendulum impacts gave peak angular acceleration of 7800 rad s (- 2) in models with and without sulci. The motion of the gel and Green-Lagrange strain were calculated from tracked coordinates of Patrick markers. Worst-case bridging vein strains are produced on the contrecoup side and are approximately doubled by adding sulci. Given that axons in the corpus callosum are highly oriented, Green-Lagrange strain was resolved in the fibre direction. It is found to be close to the minimum principal strain, indicating a degree of natural, teleological protection for the axons. The data support the use of Delta (0) over dot (peak) as a suitable descriptor for the risk of DAT but not for ASDH. (C) 2000 Elsevier Science Ltd. All rights reserved.	Univ Southampton, Inst Sound & Vibrat Res, Fluid Dynam & Acoust Grp, Highfield SO17 1BJ, England; First Technol Safety Syst, Plymouth, MI 48170 USA; Chalmers Univ Technol, Dept Machine & Vehicle Design, SE-41296 Gothenburg, Sweden	Bradshaw, DRS (corresponding author), Univ Southampton, Inst Sound & Vibrat Res, Fluid Dynam & Acoust Grp, Highfield SO17 1BJ, England.						ALDMAN B, 1981, P HEAD NECK INJ CONS; BAIN AC, 1999, P 43 STAPP CAR CRASH; Donnelly BR, 1997, J BIOMECH ENG-T ASME, V119, P423, DOI 10.1115/1.2798289; FALLENSTEIN GT, 1969, J BIOMECH, V2, P217, DOI 10.1016/0021-9290(69)90079-7; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Holbourn AHS, 1943, LANCET, V2, P438; Ivarsson J, 2000, J BIOMECH, V33, P181, DOI 10.1016/S0021-9290(99)00144-X; IVARSSON J, 1999, THESIS CHALMERS U TE; LEE MC, 1989, J BIOMECH, V22, P537, DOI 10.1016/0021-9290(89)90005-5; LOWENHIELM P, 1978, J BIOENG, V2, P501; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; MARGULIES SS, 1987, THESIS U PENNSYLVANI; MEANEY DF, 1990, P INT IRCOBI C BIOM; Meaney DF, 1991, THESIS U PENNSYLVANI; Miller RT, 1998, P 42 STAPP CAR CRASH; SAUREN AAH, 1993, P INT IRCOBI C BIOM; Viano D. C., 1999, J CRASH PREVENTION I, V1, P35; VIANO DC, 1997, INT J CRASHWORTHINES, V2, P191; Zarkovic K, 1991, Neurol Croat, V40, P129	20	42	48	0	8	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290			J BIOMECH	J. Biomech.	JAN	2001	34	1					85	94		10.1016/S0021-9290(00)00135-4			10	Biophysics; Engineering, Biomedical	Biophysics; Engineering	392UV	WOS:000166431700010	11425084				2021-06-18	
J	Wahl, F; Grosjean-Piot, O; Bareyre, F; Uzan, A; Stutzmann, JM				Wahl, F; Grosjean-Piot, O; Bareyre, F; Uzan, A; Stutzmann, JM			Enoxaparin reduces brain edema, cerebral lesions, and improves motor and cognitive impairments induced by a traumatic brain injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						brain edema; enoxaparin; low-molecular-weight heparin; memory; neuroscore; neuroprotection; traumatic brain injury	MOLECULAR-WEIGHT HEPARIN; NITRIC-OXIDE SYNTHASE; INHIBIT LEUKOCYTE ACCUMULATION; POLYMORPHONUCLEAR LEUKOCYTES; REDUCTION; RILUZOLE; ISCHEMIA; REPERFUSION; RECRUITMENT; NEUTROPHILS	Traumatic brain injury (TBI) is often accompanied by secondary ischemia due, in part, to edema-induced blood vessel compression. Enoxaparin, a low-molecular weight heparin, which is efficacious in models of myocardial and brain ischemia was studied in lateral fluid percussion-induced TBI in rats. Enoxaparin was administered 2 h post-TBI at 0.5 mg/kg i.v. followed by 4 x 0.5, 4 x 1, or 4 x 2 mg/kg s.c. over 30 fi. Brain edema was measured in the hippocampus, temporal cortex and parietal cortex. Edema was reduced by enoxaparin (0.5 + 4 x 0.5 mg/kg) in the hippocampus (-53%, p = 0.07) and the parietal cortex (-39%, ns). At 0.5 + 4 x 1 mg/kg edema was reduced in the hippocampus (-63%, p < 0.05) and the parietal cortex (-47%, p = 0.06). At 0.5 + 4 x 2 mg/kg, the reduction was more important in the hippocampus (-69%, p < 0.01) and in the parietal cortex (-50%, p < 0.05). No reduction was seen in the temporal cortex. The lesion size was reduced by enoxaparin at 0.5 + 4 x 1 mg/kg (-50%,p < 0.05), and at 0.5 + 4 x 2 mg/kg (-35%, ns). The neurological deficit evaluated with a 9-point scale was also improved with enoxaparin at 0.5 + 4 x 1 mg/kg 1 week post-TBI (p < 0.05). The cognitive impairment evaluated with a Lashley maze task was improved with enoxaparin (0.5 + 4 x 1 mg/kg) from 48 h (p < 0.05) to 2 weeks post-TBI (p < 0.01). Our results demonstrate for the first time that enoxaparin significantly reduces the brain contusion and edema, and improves the functional outcomes induced by a TBI. Therefore, enoxaparin could be a candidate drug to treat acute brain-injured patients.	Aventis Pharma, CNS Res Dept, F-94400 Vitry Sur Seine, France; Aventis Pharma, Ischemia Trauma Dept, F-94400 Vitry Sur Seine, France; Aventis Pharma, Behav Pharmacol Dept, F-94400 Vitry Sur Seine, France	Wahl, F (corresponding author), Aventis Pharma, CNS Dept, 13 Quai Jules Guesde, F-94400 Vitry Sur Seine, France.	florence.wahl@aventis.com					Bareyre F, 1997, J NEUROTRAUM, V14, P839, DOI 10.1089/neu.1997.14.839; BAZZONI G, 1993, J LAB CLIN MED, V121, P268; BIAGAS KV, 1992, J NEUROTRAUM, V9, P363, DOI 10.1089/neu.1992.9.363; Bonmann E, 1998, NEUROSCI LETT, V253, P95, DOI 10.1016/S0304-3940(98)00613-2; CADE JF, 1984, THROMB RES, V35, P613, DOI 10.1016/0049-3848(84)90265-2; CARLOS TM, 1994, BLOOD, V84, P2068; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; CARNEY JM, 1992, PHARMACOLOGY OF CEREBRAL ISCHEMIA 1992, P321; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; CLARK WM, 1991, STROKE, V22, P877, DOI 10.1161/01.STR.22.7.877; Cohen M, 1997, NEW ENGL J MED, V337, P447, DOI 10.1056/NEJM199708143370702; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Dagenais P, 1997, FASEB J, V11, P1805; DELZOPPO GJ, 1991, STROKE, V22, P1276, DOI 10.1161/01.STR.22.10.1276; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Dietz BE, 1996, SOCIOL SPECTRUM, V16, P1, DOI 10.1080/02732173.1996.9982117; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Grady MS, 1999, J NEUROTRAUM, V16, P13, DOI 10.1089/neu.1999.16.13; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; HALL ED, 1993, RES P ARNMD, V71, P81; Hartl R, 1996, J CEREBR BLOOD F MET, V16, P1108; Jonas S, 1997, ANN NY ACAD SCI, V825, P389, DOI 10.1111/j.1749-6632.1997.tb48449.x; KOCHANEK PM, 1992, STROKE, V23, P1367, DOI 10.1161/01.STR.23.9.1367; Lafuente JV, 1999, J NEUROTRAUM, V16, P425, DOI 10.1089/neu.1999.16.425; Lashley KS, 1933, PHYSIOL REV, V13, P0001, DOI 10.1152/physrev.1933.13.1.1; Li PA, 1998, BRAIN RES, V801, P220, DOI 10.1016/S0006-8993(98)00559-9; Libersan D, 1998, CARDIOVASC RES, V37, P656, DOI 10.1016/S0008-6363(97)00292-7; Maeda T, 1997, ACT NEUR S, V70, P102; McIntosh TK, 1996, J NEUROTRAUM, V13, P767, DOI 10.1089/neu.1996.13.767; McIntosh TK, 1996, LAB INVEST, V74, P315; Mesenge C, 1996, J NEUROTRAUM, V13, P209, DOI 10.1089/neu.1996.13.209; Noble S, 1998, DRUGS, V56, P259, DOI 10.2165/00003495-199856020-00013; Obrenovitch TP, 1997, J NEUROTRAUM, V14, P677, DOI 10.1089/neu.1997.14.677; OYANAGUI Y, 1990, FREE RADICAL RES COM, V9, P87, DOI 10.3109/10715769009148576; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Pratt J, 1998, HAEMOSTASIS, V28, P78; Royo NC, 1999, NEUROREPORT, V10, P1363, DOI 10.1097/00001756-199904260-00038; ROYO NC, 1999, J CEREB BLOOD FLOW M, V19, pS389; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; Soares HD, 1995, J NEUROSCI, V15, P8223; Sugimori M., 1995, Society for Neuroscience Abstracts, V21, P2019; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; TOULMOND S, 1993, BRAIN RES, V620, P24, DOI 10.1016/0006-8993(93)90266-P; TYRRELL DJ, 1995, TRENDS PHARMACOL SCI, V16, P198, DOI 10.1016/S0165-6147(00)89022-7; Upchurch GR, 1997, CIRCULATION, V95, P2115, DOI 10.1161/01.CIR.95.8.2115; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; Wahl F, 1997, BRAIN RES, V756, P247, DOI 10.1016/S0006-8993(97)00144-3; WAHL F, 1999, J CEREB BLOOD FLOW M, V19, pS379; WARD PA, 1988, FREE RADICAL BIO MED, V5, P403, DOI 10.1016/0891-5849(88)90114-1; Yanaka K, 1996, J NEUROSURG, V85, P1108, DOI 10.3171/jns.1996.85.6.1108; Yanaka K, 1996, J NEUROSURG, V85, P1102, DOI 10.3171/jns.1996.85.6.1102	54	42	43	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2000	17	11					1055	1065		10.1089/neu.2000.17.1055			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	374KY	WOS:000165345400005	11101208				2021-06-18	
J	Nath, R; Huggins, M; Glantz, SB; Morrow, JS; McGinnis, K; Nadimpalli, R; Wang, KKW				Nath, R; Huggins, M; Glantz, SB; Morrow, JS; McGinnis, K; Nadimpalli, R; Wang, KKW			Development and characterization of antibodies specific to caspase-3-produced alpha II-spectrin 120 kDa breakdown product: marker for neuronal apoptosis	NEUROCHEMISTRY INTERNATIONAL			English	Article						caspase; excitotoxicity; neuronal death; fodrin; necrosis; apoptosis	FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN INJURY; PROGRAMMED CELL-DEATH; CEREBELLAR GRANULE NEURONS; SPINAL-CORD INJURY; DNA FRAGMENTATION; RAT-BRAIN; INTERLEUKIN-1-BETA-CONVERTING ENZYME; PROTEASE ACTIVATION; NEUROBLASTOMA-CELLS	Alpha II-spectrin (alpha-fodrin) is a demonstrated endogenous substrate for caspase-3 in neurons undergoing unscheduled apoptotic death. We have previously identified the caspase cleavage site that yields the distinctive 120 kDa spectrin breakdown product (SBDP120) as (DSLD(1478*)SVEAL). Here, by using a synthetic peptide (NH2-SVEALC) mimicking the neo-N-terminal of SBDP120 as antigen, we report the development of chicken antibodies that specifically recognize the SBDP120 generated by in vitro caspase-3 digestion of bovine alpha-spectrin on Western blot. These anti-SBDP120 antibodies recognize SBDP120 generated by two apoptotic challenges (staurosporine, EGTA) to human neuroblastoma SH-SY5Y cells. Yet they neither react with intact alpha-spectrin nor its other fragments on Western blots. These anti-SBDP120 work equally well in detecting SBDP120 generated in rat cerebellar granule neurons undergoing potassium withdrawal-induced apoptosis. In immunocytochemical studies, these antibodies also specifically stained apoptotic SH-SY5Y or CGN's undergoing apoptosis in a caspase- inhibitor-sensitive manner. These anti-SBDP120s might become powerful markers for apoptotic neurons in various neurological or neurodegenerative conditions in vivo. (C) 2000 Elsevier Science Ltd. All rights reserved.	Warner Lambert Parke Davis, Parke Davis Pharmaceut Res, Dept Neurosci Therapeut, Lab Neurobiochem, Ann Arbor, MI 48105 USA; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA; Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA	Nath, R (corresponding author), Warner Lambert Parke Davis, Parke Davis Pharmaceut Res, Dept Neurosci Therapeut, Lab Neurobiochem, 2800 Plymouth Rd, Ann Arbor, MI 48105 USA.	rathna.nath@wl.com; kevin.wang@wl.com		Wang, Kevin/0000-0002-9343-6473			Armstrong RC, 1997, J NEUROSCI, V17, P553; BAHR BA, 1995, J PHARMACOL EXP THER, V273, P902; Campagne MV, 1996, NEUROSCI LETT, V213, P111, DOI 10.1016/0304-3940(96)12839-1; CharriautMarlangue C, 1995, NEUROREPORT, V7, P61, DOI 10.1097/00001756-199512000-00014; CHARRIAUTMARLANGUE C, 1995, J CEREBR BLOOD F MET, V15, P385, DOI 10.1038/jcbfm.1995.48; Chen J, 1997, J NEUROCHEM, V69, P232; COTMAN CW, 1995, MOL NEUROBIOL, V10, P19, DOI 10.1007/BF02740836; DELCOSTE MC, 1992, NEUROSCIENCE, V18, P558; DESSI F, 1993, J NEUROCHEM, V60, P1953, DOI 10.1111/j.1471-4159.1993.tb13427.x; DOLLE RE, 1994, J MED CHEM, V37, P563, DOI 10.1021/jm00031a003; Emery E, 1998, J NEUROSURG, V89, P911, DOI 10.3171/jns.1998.89.6.0911; Endres H, 1998, J CEREBR BLOOD F MET, V18, P238, DOI 10.1097/00004647-199803000-00002; FILIPKOWSKI RK, 1994, NEUROREPORT, V5, P1538, DOI 10.1097/00001756-199407000-00032; Guo-Ross S, 1998, NEUROCHEM INT, V33, P277, DOI 10.1016/S0197-0186(98)00032-1; HARRIS AS, 1988, J BIOL CHEM, V263, P15754; HERON A, 1993, J NEUROCHEM, V61, P1973, DOI 10.1111/j.1471-4159.1993.tb09843.x; HILL IE, 1995, BRAIN RES, V676, P398, DOI 10.1016/0006-8993(95)00145-G; HONG WJ, 1989, J BIOL CHEM, V264, P12758; Juan TSC, 1997, GENOMICS, V40, P86, DOI 10.1006/geno.1996.4548; KERR JFR, 1991, APOPTOSIS MOL BASIS, P5; KOH JY, 1995, EXP NEUROL, V135, P153, DOI 10.1006/exnr.1995.1074; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Leist M, 1998, EXP CELL RES, V239, P183, DOI 10.1006/excr.1997.4026; LI Y, 1995, MOL BRAIN RES, V28, P164, DOI 10.1016/0169-328X(94)00220-9; LINNIK MD, 1993, STROKE, V24, P2002, DOI 10.1161/01.STR.24.12.2002; Loddick SA, 1996, NEUROREPORT, V7, P1465, DOI 10.1097/00001756-199606170-00004; Lou J, 1998, SPINAL CORD, V36, P683, DOI 10.1038/sj.sc.3100632; MA YP, 1993, MOL BRAIN RES, V18, P87, DOI 10.1016/0169-328X(93)90176-P; MACMANUS JP, 1993, NEUROSCI LETT, V164, P89, DOI 10.1016/0304-3940(93)90864-H; Marks N, 1999, NEUROCHEM INT, V35, P195, DOI 10.1016/S0197-0186(99)00061-3; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; McGinnis KM, 1999, J NEUROCHEM, V72, P1853, DOI 10.1046/j.1471-4159.1999.0721853.x; MCMAHON AP, 1987, DIFFERENTIATION, V34, P68, DOI 10.1111/j.1432-0436.1987.tb00052.x; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; Nath R, 1998, J NEUROCHEM, V71, P186; Ni BH, 1997, J NEUROSCI, V17, P1561; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Pike BR, 1998, J NEUROSCI RES, V52, P505, DOI 10.1002/(SICI)1097-4547(19980601)52:5<505::AID-JNR3>3.3.CO;2-Y; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; PORTERACAILLIAU C, 1995, J NEUROSCI, V15, P3775, DOI 10.1523/jneurosci.15-05-03775.1995; Posmantur R, 1997, J NEUROCHEM, V68, P2328; RINK A, 1995, AM J PATHOL, V147, P1575; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; SAIDO TC, 1993, J BIOL CHEM, V268, P25239; Scott RJ, 1997, NEUROPATH APPL NEURO, V23, P307; Siman R, 1999, NEUROSCIENCE, V92, P1425, DOI 10.1016/S0306-4522(99)00034-2; Vanags DM, 1996, J BIOL CHEM, V271, P31075, DOI 10.1074/jbc.271.49.31075; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; Wiesner DA, 1996, J NEUROCHEM, V66, P1418; Yakovlev AG, 1997, J NEUROSCI, V17, P7415	51	42	42	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0197-0186	1872-9754		NEUROCHEM INT	Neurochem. Int.	OCT	2000	37	4					351	361		10.1016/S0197-0186(00)00040-1			11	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	350AT	WOS:000089078800003	10825575				2021-06-18	
J	Palmese, CA; Raskin, SA				Palmese, CA; Raskin, SA			The rehabilitation of attention in individuals with mild traumatic brain injury, using the APT-II programme	BRAIN INJURY			English	Article							HEAD-INJURY	Traumatic brain injury (TBI) is a prevalent cause of cognitive impairments and dysfunctions and affects over 2 million individuals each year. Mild traumatic brain injury (MTBI) is generally defined by a brief loss of consciousness, and post-traumatic amnesia that lasts for less than 24 hours. One region of the brain that is likely affected in patients with MTBI is the pre-frontal cortex. This region mediates several functions, including those required for adequate attention. Three individuals, diagnosed with MTBI and difficulties with attention, volunteered to participate in the study. Individuals were presented with 10 weeks of cognitive retraining with the Attention Process Training-II (APT-II) programme, followed by 6 or 7 weeks of educational and applicational programmes. Cognitive tests were administered both pre- and post-training to assess the effectiveness of the programme. Analysis of the results showed that the APT-II programme improved attention and performance speed in each of the three individuals. In addition, any rehabilitated cognitive skills remained stable in each individual in the absence of the rehabilitation programme for at least 6 weeks.	Trinity Coll, Program Neurosci, Hartford, CT 06106 USA; Trinity Coll, Dept Psychol, Hartford, CT 06106 USA; CUNY Queens Coll, Neuropsychol Program, Flushing, NY 11367 USA	Palmese, CA (corresponding author), CUNY Coll Staten Isl, PSAS Dept, Bldg 4S,Rm223,2800 Victory Blvd, Staten Isl, NY 10314 USA.		Raskin, Sarah/T-1420-2019	Raskin, Sarah/0000-0002-4310-4278			Anderson SD, 1996, B AM ACAD PSYCH LAW, V24, P493; BRUCKNER P, 1996, AUSTR FAMILY PHYSICI, V25, P1445; Chambers J, 1996, J TRAUMA, V41, P976, DOI 10.1097/00005373-199612000-00006; Cicerone KD, 1996, BRAIN INJURY, V10, P277, DOI 10.1080/026990596124458; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; Diamond M. C., 1988, ENRICHING HEREDITY I; FARMER JE, 1988, BRAIN INJURY, V4, P323; GIARDI PA, 1994, FINAL REPORT FINDING; GRONWALL DM, 1977, PERCEPT MOTOR SKILL, V55, P367; JOHNSTONE B, 1998, RECOVERY TRAUMATIC B, P115; KAY T, 1986, MINOR HEAD INJURY IN; Kolb B., 1996, FUNDAMENTALS HUMAN N; LEWINE JD, 1998, RECOVERY TRAUMATIC B, P1; LEWIS R, 1996, MANUAL REPEATABLE CO; MERSKEY H, 1972, BRAIN, V95, P521, DOI 10.1093/brain/95.3.521; PETERSON LR, 1959, J EXP PSYCHOL, V58, P193, DOI 10.1037/h0049234; RAICHLE ME, 1994, CEREB CORTEX, V4, P8, DOI 10.1093/cercor/4.1.8; Raskin S., 1992, NEUROREHABILITATION, V2, P38; Raskin SA, 1998, CLIN NEUROPSYCHOL, V12, P21, DOI 10.1076/clin.12.1.21.1724; Raskin SA, 1994, HDB NEUROREHABILITAT, P243; SINDEN JD, 1992, ADV EXPT MED BIOL RE, P35; Smith A., 1993, SYMBOL DIGIT MODALIT; SOHLBERG M, 1989, ATTENTION PROCESS TE; SOHLBERG M, ATTENTION PROCESS TR, V2; Sohlberg M. M., 1989, INTRO COGNITIVE REHA; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; TSUBOKAWA T, 1998, RECOVERY TRAUMATIC B, P83; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY	29	42	42	0	7	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JUN	2000	14	6					535	548					14	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	325WN	WOS:000087699600004	10887887				2021-06-18	
J	Victorov, IV; Prass, K; Dirnagl, U				Victorov, IV; Prass, K; Dirnagl, U			Improved selective, simple, and contrast staining of acidophilic neurons with vanadium acid fuchsin	BRAIN RESEARCH PROTOCOLS			English	Article						acidophilia; brain pathology; neuron; vanadium acid fuchsin; toluidine blue; Gill's hematoxylin	HYPOGLYCEMIC BRAIN-DAMAGE; RAT-BRAIN; ISCHEMIA; DEGENERATION; OCCLUSION; NECROSIS; CORTEX; INJURY; TRAUMA	Acidophilia is one of the hallmarks of acute neuronal damage and death in brain ischemia, excitotoxic and traumatic lesions and epileptic seizures. We here describe a novel and simple method for visualizing acidophilic neurons on paraffin sections, using vanadium acid fuchsin (VAF) staining and toluidine blue or hematoxylin counterstaining. Paraffin sections of the brain fixed in ethanol-formalin-acetic acid mixture are stained in 0.1% acid fuchsin containing 0.125% of ammonium metavanadate and 1% of glacial acetic acid, differentiated if overstained in 0.01% of borax solution, and counterstained with 0.05-0.025% of toluidine blue in acetate buffer (pH 3.3) or Gill's II hematoxylin. The sections are dehydrated, cleared in xylene and mounted in Canada balsam or any synthetic mounting media for light microscopy. VAF combined with toluidine blue or hematoxylin results in highly selective and reproducible color contrast staining of acidophilic neurons as well as glial nuclei and hyperchromatic neurons. As a progressive method, acid fuchsin staining usually does not require differentiation. The red acidophilic neurons are clearly visible on the background of non-damaged cells, which significantly facilitates the identification, and localization of damaged neurons, even at low magnification under the light microscope. (C) 2000 Elsevier Science B.V. All rights reserved.	Brain Res Inst, Lab Expt Neurocytol, Moscow 103064, Russia; Humboldt Univ, Charite, D-10098 Berlin, Germany	Victorov, IV (corresponding author), Brain Res Inst, Lab Expt Neurocytol, Pereulok Obukha 5, Moscow 103064, Russia.		Victorov, Ilya/C-4680-2012	Dirnagl, Ulrich/0000-0003-0755-6119			AUER RN, 1984, ACTA NEUROPATHOL, V64, P177, DOI 10.1007/BF00688108; AUER RN, 1985, ACTA NEUROPATHOL, V67, P13, DOI 10.1007/BF00688120; AUER RN, 1988, ANN NEUROL, V24, P699, DOI 10.1002/ana.410240602; Brown A W, 1977, J Clin Pathol Suppl (R Coll Pathol), V11, P155; BROWN AW, 1972, J NEUROL SCI, V16, P59, DOI 10.1016/0022-510X(72)90102-5; BUCHAN AM, 1990, BRAIN RES, V512, P7, DOI 10.1016/0006-8993(90)91163-B; CAMMERMEYER J, 1978, HISTOCHEMISTRY, V56, P97, DOI 10.1007/BF00508437; CAMMERMEYER J, 1960, EXP NEUROL, V2, P379, DOI 10.1016/0014-4886(60)90022-4; CAMMERMEYER JAN, 1961, ACTA NEUROPATHOL, V1, P245; CHANG D, 1994, DEV BRAIN RES, V77, P133, DOI 10.1016/0165-3806(94)90220-8; DEOLMOS JS, 1994, NEUROTOXICOL TERATOL, V16, P545, DOI 10.1016/0892-0362(94)90033-7; Dreier JP, 1998, J CEREBR BLOOD F MET, V18, P978; GARCIA JH, 1995, STROKE, V26, P636, DOI 10.1161/01.STR.26.4.636; GARCIA JH, NEURONAL ISCHEMIC IN, P43; GARCIA JH, 1986, NATO ASI SERIES A, V115, P65; KAWAI K, 1992, J CEREBR BLOOD F MET, V12, P238, DOI 10.1038/jcbfm.1992.34; Kiernan JA, 1998, BIOTECH HISTOCHEM, V73, P244, DOI 10.3109/10520299809141118; KIRINO T, 1985, PROG BRAIN RES, V63, P39; LEES GJ, 1989, ACTA NEUROPATHOL, V77, P519, DOI 10.1007/BF00687254; Lillie RD, 1965, HISTOPATHOLOGIC TECH; ROBBINS SL, 1979, PATHOLOGIC BASIS DIS, P22; ROSENBLUM WI, 1997, J NEUROTRAUM, V14, P311; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; SMITH ML, 1984, ACTA NEUROL SCAND, V69, P385, DOI 10.1111/j.1600-0404.1984.tb07822.x; SPIELMEYER W, 1922, HISTOPATHOLOGIC NERV, pS74; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; VICTOROV IV, 1993, PATHOL PHYSL EXP THE, V2, P53	27	42	52	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1385-299X			BRAIN RES PROTOC	Brain Res. Protoc.	APR	2000	5	2					135	139		10.1016/S1385-299X(00)00004-0			5	Biochemical Research Methods; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	311VV	WOS:000086907300003	10775832				2021-06-18	
J	Read, SJ; Smith, MI; Hunter, AJ; Upton, N; Parsons, AA				Read, SJ; Smith, MI; Hunter, AJ; Upton, N; Parsons, AA			SB-220453, a potential novel antimigraine agent, inhibits nitric oxide release following induction of cortical spreading depression in the anaesthetized cat	CEPHALALGIA			English	Article						migraine; novel therapeutics; nitric oxide; SB-220453	CEREBRAL BLOOD-FLOW; TRIGEMINAL NUCLEUS CAUDALIS; ANESTHETIZED CAT; MIGRAINE; METABOLISM; MECHANISMS; HEADACHE; EXPRESSION; RAT	Profound nitric oxide release associated with cortical spreading depression (SD), has been implicated in stroke, traumatic brain injury and migraine pathophysiology. SB-220453 represents a mechanistically novel, well-tolerated class of compounds which may have therapeutic potential in the treatment of conditions associated with neuronal hyperexcitability and inflammation. The aim of the present study was to investigate the effects of SB-220453 on the nitric oxide (NO) release associated with SD in the anaesthetized cat. In vehicle treated animals, KCl application for 6 min to the cortical surface produced repeated changes in extracellular direct current field potential with associated NO release. This activity was sustained for a median duration of 55 min (25-75% range, 32-59 min) and 59 min (25-75% range, 34-59 min), respectively. SB-220453 (1, 3 and 10 mg/kg i.p.) produced a dose-related inhibition of this activity and at the highest dose tested, the median duration of changes in extracellular field potential and NO release were reduced to 9 min (25-75% range, 4-5min) and 5 min (25-75% range, 5-5min), respectively. No effect was observed on basal systemic haemodynamic parameters or resting cerebral laser Doppler blood flux at any of the doses of SB-220453 tested. SB-220453 therefore represents a novel compound to assess the potential benefit of inhibiting SD associated nitric oxide release in neurological disease.	SmithKline Beecham Pharmaceut, Neurosci Res, Harlow CM19 5AD, Essex, England; SmithKline Beecham Pharmaceut, Cardiovasc Pharmacol, King Of Prussia, PA 19406 USA	Read, SJ (corresponding author), SmithKline Beecham Pharmaceut, Neurosci Res, New Frontiers Sci Pk, Harlow CM19 5AD, Essex, England.						Andersson JLR, 1997, CEPHALALGIA, V17, P570, DOI 10.1046/j.1468-2982.1997.1705570.x; Aurora SK, 1998, CURR OPIN NEUROL, V11, P205, DOI 10.1097/00019052-199806000-00003; CAO Y, 1997, J CEREB BLOOD FLOW M, V17, pS176; Chan WN, 1999, BIOORG MED CHEM LETT, V9, P285, DOI 10.1016/S0960-894X(98)00728-8; FABRICIUS M, 1995, AM J PHYSIOL-HEART C, V269, pH23; Ferrari MD, 1998, LANCET, V351, P1043, DOI 10.1016/S0140-6736(97)11370-8; GOADSBY PJ, 1992, BRAIN RES, V595, P167, DOI 10.1016/0006-8993(92)91470-Y; Ingvardsen BK, 1997, PAIN, V72, P407, DOI 10.1016/S0304-3959(97)00069-9; IVERSEN HK, 1989, PAIN, V38, P17, DOI 10.1016/0304-3959(89)90067-5; Lambert GA, 1999, CEPHALALGIA, V19, P631, DOI 10.1046/j.1468-2982.1999.019007631.x; Lassen LH, 1997, LANCET, V349, P401, DOI 10.1016/S0140-6736(97)80021-9; LAURITZEN M, 1987, TRENDS NEUROSCI, V10, P8, DOI 10.1016/0166-2236(87)90115-9; LAURITZEN M, 1984, BRAIN, V107, P447, DOI 10.1093/brain/107.2.447; Leao AAP, 1944, J NEUROPHYSIOL, V7, P359; LEI SZ, 1992, NEURON, V8, P1087, DOI 10.1016/0896-6273(92)90130-6; MOSKOWITZ MA, 1993, CEREBROVAS BRAIN MET, V5, P159; MOSKOWITZ MA, 1993, J NEUROSCI, V13, P1167, DOI 10.1523/jneurosci.13-03-01167.1993; OLESEN J, 1993, NEUROREPORT, V4, P1027, DOI 10.1097/00001756-199308000-00008; Ophoff RA, 1996, CELL, V87, P543, DOI 10.1016/S0092-8674(00)81373-2; Read SJ, 1999, BRAIN RES, V847, P1, DOI 10.1016/S0006-8993(99)01985-X; Read SJ, 1997, CEPHALALGIA, V17, P826, DOI 10.1046/j.1468-2982.1997.1708826.x; Read SJ, 1999, CEPHALALGIA, V19, P403; Read SJ, 1997, NEUROSCI LETT, V232, P127, DOI 10.1016/S0304-3940(97)00604-6; Read SJ, 1998, NEUROSCI LETT, V250, P115, DOI 10.1016/S0304-3940(98)00442-X; READ SJ, EXP HEADACHE MODELS, P81; READ SJ, 1997, HEADACHE PATHOGENESI; Savchenko A, 1997, NATURE, V390, P694; Welch KMA, 1998, CURR OPIN NEUROL, V11, P193, DOI 10.1097/00019052-199806000-00001; WELCH KMA, 1995, J NEUROL SCI, V134, P9, DOI 10.1016/0022-510X(95)00196-1; WELCH KMA, 1989, NEUROLOGY, V39, P538, DOI 10.1212/WNL.39.4.538; WOODS RP, 1994, NEW ENGL J MED, V331, P1689, DOI 10.1056/NEJM199412223312505; WOOLF CJ, 1996, MIGRAINE 2000 DEV NE, V12, P173; ZHANG ZG, 1994, J CEREBR BLOOD F MET, V14, P939, DOI 10.1038/jcbfm.1994.125	33	42	45	0	0	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	0333-1024			CEPHALALGIA	Cephalalgia	MAR	2000	20	2					92	99		10.1046/j.1468-2982.2000.00022.x			8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	347BD	WOS:000088905600004	10961764				2021-06-18	
J	Quinto, C; Gellido, C; Chokroverty, S; Masdeu, J				Quinto, C; Gellido, C; Chokroverty, S; Masdeu, J			Posttraumatic delayed sleep phase syndrome	NEUROLOGY			English	Article						sleep disorders; delayed sleep phase syndrome	DISORDERS	Circadian rhythm sleep disorders may occur after traumatic brain injury. We describe a 48-year-old man who presented with sleep onset insomnia and cognitive dysfunction after a car accident. A diagnosis of delayed sleep phase syndrome (DSPS) was confirmed by sleep logs and actigraphy, which revealed sleep onset in the early morning hours and awakening around noon.	New York Med Coll, St Vincents Hosp, Dept Neurol, New York, NY 10011 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Neurol, New Brunswick, NJ 08903 USA; Albert Einstein Coll Med, Dept Neurol, Bronx, NY 10467 USA	Quinto, C (corresponding author), New York Med Coll, St Vincents Hosp, Dept Neurol, 153 W 11th St, New York, NY 10011 USA.		Masdeu, Joseph C/B-5052-2010				*AM SLEEP DIS ASS, 1997, INT CLASS SLEEP DIS, P132; ANDO K, 1995, SLEEP RES, V24, P509; KLEIN DC, 1991, SUPRACHIASMATIC NUCL; PATTEN SB, 1992, J AM ACAD CHILD PSY, V31, P100, DOI 10.1097/00004583-199201000-00015; PELAYO RP, 1988, SLEEP RES, V17, P392; Richardson GS, 1996, J CLIN NEUROPHYSIOL, V13, P17, DOI 10.1097/00004691-199601000-00003; SCHREIBER S, 1997, J NEUROPSYCHIAT, V9, P640; Wagner DR, 1996, NEUROL CLIN, V14, P651, DOI 10.1016/S0733-8619(05)70278-4; WEITZMAN ED, 1981, ARCH GEN PSYCHIAT, V38, P737	9	42	42	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0028-3878			NEUROLOGY	Neurology	JAN 11	2000	54	1					250	252		10.1212/WNL.54.1.250			3	Clinical Neurology	Neurosciences & Neurology	273VE	WOS:000084727900049	10636163				2021-06-18	
J	Morrow, TJ; Paulson, PE; Brewer, KL; Yezierski, RP; Casey, KL				Morrow, TJ; Paulson, PE; Brewer, KL; Yezierski, RP; Casey, KL			Chronic, selective forebrain responses to excitotoxic dorsal horn injury	EXPERIMENTAL NEUROLOGY			English	Article						spinal cord injury; regional cerebral blood flow; plasticity; somatosensory; diencephalon; cortex; quisqualic acid	SPINAL-CORD INJURY; HYPOTHALAMIC ARCUATE NUCLEUS; INDUCED NOXIOUS-STIMULATION; CHRONIC CENTRAL PAIN; BLOOD-FLOW; FUNCTIONAL-ACTIVITY; SPINOHYPOTHALAMIC TRACT; INTRASPINAL INJECTIONS; QUISQUALIC ACID; AMINO-ACIDS	Intraspinal injection of the AMPA/metabotropic receptor agonist quisqualic acid (QUIS) results in excitotoxic injury which develops pathological characteristics similar to those associated with ischemic and traumatic spinal cord injury (SCI) (R. P. Yezierski et at, 1998, Pain 75: 141-155; R, P. Yezierski ct at, 1993, J. Neurotrauma 10: 445-456), Since spinal injury can lead to partial or complete deafferentation of ascending supraspinal structures, it is likely that secondary to the disruption of spinal pathways these regions could undergo significant reorganization. Recently, T. J. Morrow et at. (Pain 75: 355-365) showed that autoradiographic estimates of regional cerebral blood flow (rCBF) can be used to simultaneously identify alterations in the activation of multiple forebrain structures responsive to noxious formalin stimulation. Accordingly, we examined whether excitotoxic SCI produced alterations in the activation of supraspinal structures using rCBF as a marker of neuronal activity. Twenty-four to 41 days after unilateral injection of QUIS into the T12 to L3 spinal segments, we found significant increases in the activation of 7 of 22 supraspinal structures examined. As compared to controls, unstimulated SCI rats exhibited a significant bilateral increase in rCBF within the arcuate nucleus (ARC), the hindlimb region of S1 cortex (HL), parietal cortex (PAR), and the thalamic posterior (PO), ventral lateral (VL), ventral posterior lateral (VPL), and ventral posterior medial (VPM) nuclei. All structures showing significantly altered rCBF are associated with the processing of somatosensory information. These changes constitute remote responses to injury and suggest that widespread functional changes occur within cortical and subcortical regions following injury to the spinal cord. (C) 2000 Academic Press.	VA Med Ctr, Neurol Res Lab, Ann Arbor, MI 48105 USA; Univ Michigan, Dept Neurol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Physiol, Ann Arbor, MI 48109 USA; E Carolina Univ, Dept Anat & Cell Biol, Greenville, NC 27858 USA; Univ Miami, Miami Project, Miami, FL 33136 USA	Morrow, TJ (corresponding author), VA Med Ctr, Neurol Res Lab, Ann Arbor, MI 48105 USA.				NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P01-HD33986] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P01HD033986] Funding Source: NIH RePORTER		Bach FW, 1997, ACTA ANAESTH SCAND, V41, P133, DOI 10.1111/j.1399-6576.1997.tb04627.x; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; Brewer K. L., 1997, Society for Neuroscience Abstracts, V23, P438; BUNGE MB, 1994, EXP NEUROL, V127, P76, DOI 10.1006/exnr.1994.1082; Burstein R, 1996, J COMP NEUROL, V373, P549, DOI 10.1002/(SICI)1096-9861(19960930)373:4<549::AID-CNE6>3.0.CO;2-1; BURSTEIN R, 1991, J NEUROPHYSIOL, V66, P261; CASEY KL, 1994, J NEUROPHYSIOL, V71, P802; Christensen MD, 1997, J NEUROTRAUM, V14, P517, DOI 10.1089/neu.1997.14.517; Christensen MD, 1996, PAIN, V68, P97, DOI 10.1016/S0304-3959(96)03224-1; COGHILL RC, 1994, J NEUROSCI, V14, P4095; Faggin BM, 1997, P NATL ACAD SCI USA, V94, P9428, DOI 10.1073/pnas.94.17.9428; HAMBA M, 1988, BRAIN RES BULL, V21, P757, DOI 10.1016/0361-9230(88)90043-3; HAO JX, 1992, J NEUROPHYSIOL, V68, P384; Iadecola C, 1996, J NEUROPHYSIOL, V75, P940; Jain N, 1998, NEWS PHYSIOL SCI, V13, P143; KOYAMA S, 1993, BRAIN RES, V612, P345, DOI 10.1016/0006-8993(93)91684-K; LENZ FA, 1994, J NEUROPHYSIOL, V72, P1570; LIU DX, 1991, BRAIN RES, V547, P344, DOI 10.1016/0006-8993(91)90984-4; Liu SL, 1997, BRAIN RES, V756, P160, DOI 10.1016/S0006-8993(97)00137-6; LOMBARD MC, 1979, ADV PAIN RES THER, V3, P767; LOU HC, 1987, ANN NEUROL, V22, P289, DOI 10.1002/ana.410220302; MADSEN PW, 1994, J NEUROTRAUM, V11, P241, DOI 10.1089/neu.1994.11.241; Malonek D, 1996, SCIENCE, V272, P551, DOI 10.1126/science.272.5261.551; MARSALA M, 1994, J CEREBR BLOOD F MET, V14, P604, DOI 10.1038/jcbfm.1994.75; Morrow T. J., 1998, Society for Neuroscience Abstracts, V24, P2083; Morrow TJ, 1998, PAIN, V75, P355, DOI 10.1016/S0304-3959(98)00016-5; Ness TJ, 1998, PAIN, V78, P139, DOI 10.1016/S0304-3959(98)00153-5; *NIH, 1996, NIH GUID CAR US LAB; PALKOVITS M, 1986, BRAIN RES, V373, P252, DOI 10.1016/0006-8993(86)90339-2; Paxinos G, 1986, RAT BRAIN STEREOTAXI; PORRO CA, 1991, NEUROSCIENCE, V41, P667, DOI 10.1016/0306-4522(91)90358-U; PORRO CA, 1991, NEUROSCIENCE, V41, P655, DOI 10.1016/0306-4522(91)90357-T; Price DD, 1988, PSYCHOL NEURAL MECH, Vx; SIDDALL P, 1995, NEUROREPORT, V6, P1241, DOI 10.1097/00001756-199506090-00003; SIMPSON RK, 1990, NEUROCHEM RES, V15, P635, DOI 10.1007/BF00973755; SOKOLOFF L, 1981, FED PROC, V40, P2311; TAKESHIGE C, 1991, BRAIN RES BULL, V26, P779, DOI 10.1016/0361-9230(91)90175-J; TALBOT JD, 1991, SCIENCE, V251, P1355, DOI 10.1126/science.2003220; WANG Q, 1990, BRAIN RES, V526, P221, DOI 10.1016/0006-8993(90)91225-6; Willis WD, 1997, J CLIN NEUROPHYSIOL, V14, P2, DOI 10.1097/00004691-199701000-00002; WILLIS WD, 1985, PAIN SYSTEM NEURAL M; XU XJ, 1994, PAIN, V56, P271, DOI 10.1016/0304-3959(94)90165-1; Yezierski RP, 1996, PAIN, V68, P185, DOI 10.1016/S0304-3959(96)03178-8; Yezierski RP, 1998, PAIN, V75, P141, DOI 10.1016/S0304-3959(97)00216-9; Yezierski RP, 1996, J CEREBR BLOOD F MET, V16, P996, DOI 10.1097/00004647-199609000-00025; YEZIERSKI RP, 1993, NEUROSCI LETT, V157, P115, DOI 10.1016/0304-3940(93)90656-6; YEZIERSKI RP, 1993, J NEUROTRAUM, V10, P445, DOI 10.1089/neu.1993.10.445	47	42	42	0	1	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	JAN	2000	161	1					220	226		10.1006/exnr.1999.7246			7	Neurosciences	Neurosciences & Neurology	290FU	WOS:000085666300020	10683288				2021-06-18	
J	Sarrafzadeh, AS; Thomale, UW; Kroppenstedt, SN; Unterberg, AW				Sarrafzadeh, AS; Thomale, UW; Kroppenstedt, SN; Unterberg, AW			Neuroprotective effect of melatonin on cortical impact injury in the rat	ACTA NEUROCHIRURGICA			English	Article						melatonin; antioxidant; cortical impact injury; brain contusion	PINEAL HORMONE MELATONIN; TRAUMATIC BRAIN-INJURY; LIPID-PEROXIDATION; PROTECTION; KAINATE; DAMAGE; LIGHT; RADICALS; MODEL	The pineal hormone melatonin is a highly efficient physiological scavenger of free radicals involved in secondary brain damage. A variety of experimental studies have demonstrated a neuroprotective effect for melatonin, based on its antioxidant activity. The purpose of the present study was to investigate the time-dependency and a possible protective effect of exogenous melatonin in the cortical impact model in rats. The protective effect was quantified determining contusion volume, brain edema and brain water content. 45 anesthetized male Sprague-Dawley rats (250-350 mg) were subjected to cortical impact injury of moderate severity (7 mis, deformation 2 mm). Melatonin (100 mg/kg bw i.p.), or a vehicle was injected 20 min before trauma, immediately after, and 1 and 2 hours after trauma during daytime and nighttime. Posttraumatic lesion volume using hematoxylin-eosin staining, hemispheric swelling, brain water content, cerebral perfusion pressure and intracranial pressure 24 hours after injury were investigated. Melatonin, given during nighttime, significantly reduced contusion volume corresponding to a mean reduction of contusion volume of 27% (placebo, n = 7: 41.9 +/- 5.2 mm(3), melatonin, n = 8: 30.5 +/- 4.2 mm(3), p < 0.05). Given during daytime, the reduction in contusion volume was not significant (placebo, n = 8: 42.1 <plus/minus> 5.1 mm(3), melatonin, n = 8: 35.9 +/- 2.2 mm(3), reduction of 15%, p = 0.08, n.s.). Hemispheric swelling was unchanged by melatonin treatment. Mean arterial blood pressure and rectal temperature remained stable before and after the cortical impact injury and injection of melatonin. This study shows that melatonin significantly reduces contusion volume with major effects during night.	Humboldt Univ, Virchow Med Ctr, Charite, Dept Neurosurg, D-13353 Berlin, Germany	Sarrafzadeh, AS (corresponding author), Humboldt Univ, Virchow Med Ctr, Charite, Dept Neurosurg, Augustenburger Pl 1, D-13353 Berlin, Germany.						Arendt J, 1997, J BIOL RHYTHM, V12, P604, DOI 10.1177/074873049701200616; CIPOLLANETO J, 1993, J NEURAL TRANSM-GEN, V92, P117, DOI 10.1007/BF01244871; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Guerrero JM, 1997, J PINEAL RES, V23, P24, DOI 10.1111/j.1600-079X.1997.tb00331.x; HARDELAND R, 1995, J PINEAL RES, V18, P104, DOI 10.1111/j.1600-079X.1995.tb00147.x; IANAS O, 1991, ROM J ENDOCRINOL, V29, P147; ILLNEROVA H, 1971, LIFE SCI, V10, P955, DOI 10.1016/0024-3205(71)90360-2; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; Krauchi K, 1997, AM J PHYSIOL-REG I, V272, pR1178, DOI 10.1152/ajpregu.1997.272.4.R1178; Kroppenstedt SN, 1998, J NEUROTRAUM, V15, P191, DOI 10.1089/neu.1998.15.191; LEWY AJ, 1980, SCIENCE, V210, P1267, DOI 10.1126/science.7434030; LIGHTHALL J W, 1989, Journal of Neurotrauma, V6, P83, DOI 10.1089/neu.1989.6.83; Manev H, 1996, RESTOR NEUROL NEUROS, V9, P251, DOI 10.3233/RNN-1996-9408; Manev H, 1997, ANN NY ACAD SCI, V825, P85, DOI 10.1111/j.1749-6632.1997.tb48417.x; Melchiorri D, 1996, EUR J PHARMACOL, V305, P239, DOI 10.1016/0014-2999(96)00241-5; Mesenge C, 1998, J PINEAL RES, V25, P41, DOI 10.1111/j.1600-079X.1998.tb00384.x; Pablos MI, 1998, NEUROCHEM INT, V32, P69, DOI 10.1016/S0197-0186(97)00043-0; Pappolla MA, 1997, J NEUROSCI, V17, P1683; Pierre C., 1994, LIFE SCI, V55, P271; Reiter RJ, 1998, PROG NEUROBIOL, V56, P359, DOI 10.1016/S0301-0082(98)00052-5; Reiter RJ, 1997, HORM METAB RES, V29, P363, DOI 10.1055/s-2007-979057; Scaiano JC, 1995, J PINEAL RES, V19, P189, DOI 10.1111/j.1600-079X.1995.tb00188.x; Smith SL, 1996, J NEUROTRAUM, V13, P1, DOI 10.1089/neu.1996.13.1; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; Uz T, 1996, NEUROSCIENCE, V73, P631, DOI 10.1016/0306-4522(96)00155-8; Viswanathan Mohan, 1993, Biological Signals, V2, P221; WirzJustice A, 1996, J AFFECT DISORDERS, V37, P109, DOI 10.1016/0165-0327(95)00081-X; YERESWARAM K, 1997, J PINEAL RES, V22, P45	28	42	45	0	1	SPRINGER-VERLAG WIEN	VIENNA	SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.		2000	142	11					1293	1299		10.1007/s007010070028			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	387GW	WOS:000166115700030	11201646				2021-06-18	
J	McKinley, WO; Kolakowsky, SA; Kreutzer, JS				McKinley, WO; Kolakowsky, SA; Kreutzer, JS			Substance abuse, violence, and outcome after traumatic spinal cord injury	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						spinal cord injury; violence; substance abuse; outcome	BRAIN INJURY; ALCOHOL; MODEL	Alcohol and drug use have been shown to contribute to the onset of traumatic spinal cord injury and to be a marker for later onset substance abuse issues. Admission toxicology (drug and alcohol) screens were collected from 87 consecutive rehabilitation medicine patients with a diagnosis of acute traumatic spinal cord injury. Forty-six patients (53%) presented with positive screens (44% alcohol only, 30% drug only, 26% both). Seventy-five percent of those with positive alcohol screens met state criteria for alcohol intoxication (blood alcohol level, greater than or equal to 0.08 mg/dl). Compared with individuals with negative screens, those with positive screens were significantly (P < 0.05) younger and unmarried. Compared with nonviolence-related spinal cord injury, patients with violence-related spinal cores injury (gunshot wound and assault) were significantly (P < 0.01) more likely to have positive admission toxicology screens (76% v 41%), drug screens (62% v 14%), and intoxication screens (72% v 34%). Rehabilitation outcome comparisons between those with positive and negative screens revealed similar length of stay, admission and discharge Functional independence Measure (FIM(TM)) scores, FIM change scores, and FIM efficiency scores. This study has important implications with regard to substance abuse issues and their impact on traumatic spinal cord injury outcome, which may assist in better targeting prevention.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Phys Med & Rehabil, Richmond, VA 23298 USA	McKinley, WO (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Phys Med & Rehabil, POB 980661, Richmond, VA 23298 USA.						*AM SPIN INJ ASS, 1996, INT STAND NEUR FUNCT; BURNEY RE, 1993, ARCH SURG-CHICAGO, V128, P596; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; DeVivo MJ, 1997, SPINAL CORD, V35, P509, DOI 10.1038/sj.sc.3100430; DEVIVO MJ, 1980, ARCH NEUROL-CHICAGO, V37, P707, DOI 10.1001/archneur.1980.00500600055011; Ditunnio John F. Jr., 1995, P170; Dunnegan SW, 1997, J PSYCHOACTIVE DRUGS, V29, P345, DOI 10.1080/02791072.1997.10400561; Frisbie J H, 1984, J Am Paraplegia Soc, V7, P71; FULLERTON DT, 1981, ARCH GEN PSYCHIAT, V38, P1369; GO BK, 1995, SPINAL CORD INJURY C; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; Hall KM., 1993, J HEAD TRAUMA REHAB, V8, DOI [DOI 10.1097/00001199-199308020-00008, 10.1097/00001199-199308020-00008]; HALLKM, 1994, ARCH PHYS MED RE S12, V75, pSC10; Harrison-Felix C, 1998, ARCH PHYS MED REHAB, V79, P730, DOI 10.1016/S0003-9993(98)90348-3; Hawkins DA, 1998, REHABIL PSYCHOL, V43, P219, DOI 10.1037/0090-5550.43.3.219; HEINEMANN AW, 1995, REHABIL PSYCHOL, V40, P125; HEINEMANN AW, 1988, ARCH PHYS MED REHAB, V69, P619; HEINEMANN AW, 1988, ALCOHOL CLIN EXP RES, V12, P815, DOI 10.1111/j.1530-0277.1988.tb01352.x; HEINEMANN AW, 1989, REHABIL PSYCHOL, V34, P191, DOI 10.1037//0090-5550.34.3.191; HEINEMANN AW, 1991, ARCH PHYS MED REHAB, V72, P482; HICKMAN JK, 1993, SPINAL CORD INJURY V; Higgins JP, 1996, AM J EMERG MED, V14, P265, DOI 10.1016/S0735-6757(96)90172-2; JOHNSON DC, 1985, ALCOHOL USE PERSONS; KRAUS JF, 1975, J CHRON DIS, V28, P471, DOI 10.1016/0021-9681(75)90057-0; MEYERS JK, 1984, ARCH GEN PSYCHIAT, V41, P959; *NAT I ALC AB ALC, 1981, DHHS PUBL ADM; PRICE C, 1994, AM J EPIDEMIOL, V139, P37, DOI 10.1093/oxfordjournals.aje.a116933; Soderstrom CA, 1997, J TRAUMA, V42, P67, DOI 10.1097/00005373-199701000-00012; Spain DA, 1997, J TRAUMA, V43, P423, DOI 10.1097/00005373-199709000-00006; Sparadeo F. R., 1989, J HEAD TRAUMA REHAB, V4, P75, DOI DOI 10.1097/00001199-198903000-00010; Stein DJ, 1997, S AFR MED J, V87, P996; STOVER SL, 1986, SPINAL CORD INJURY F; WOODRUFF BA, 1994, AM J PREV MED, V10, P10	33	42	43	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	JUL-AUG	1999	78	4					306	312		10.1097/00002060-199907000-00002			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	216AP	WOS:000081418600002	10418834				2021-06-18	
J	Triyoso, DH; Good, TA				Triyoso, DH; Good, TA			Pulsatile shear stress leads to DNA fragmentation in human SH-SU5Y neuroblastoma cell line	JOURNAL OF PHYSIOLOGY-LONDON			English	Article							FINITE-ELEMENT ANALYSIS; NITRIC-OXIDE PRODUCTION; TRAUMATIC BRAIN INJURY; ENDOTHELIAL-CELLS; G-PROTEINS; EXPERIMENTAL GLAUCOMA; OXIDATIVE STRESS; MESSENGER-RNA; PC12 CELLS; C-FOS	1. Using an in vitro model of shear stress-induced cell injury we demonstrate that application of shear to differentiated human SH-SY5Y cells leads to cell death characterized by DNA fragmentation. Controlled shear stress was applied to cells via a modified cone and plate viscometer. 2. We show that pulsatile shear stress leads to DNA fragmentation, as determined via flow cytometry of fluorescein-12-dUTP nick-end labelled cells, in 45 +/- 4% of cells. No lactate dehydrogenase (LDH) release was observed immediately after injury; however, 24 h after injury significant LDH release was observed. 3. Nitric oxide production by cells subjected tu pulsatile shear increased two- to threefold over that in unsheared control cells. 4. Inhibition of protein synthesis, nitric oxide production, Ca(2+) entry into cells, and pertussis toxin-sensitive G protein activation attenuated the shear stress-induced cell injury. 5. Our results show for the first time that application of pulsatile shear stress to a neuron-like cell in vitro leads to nitric oxide-dependent cell death.	Texas A&M Univ, Dept Chem Engn, College Stn, TX 77843 USA	Good, TA (corresponding author), Texas A&M Univ, Dept Chem Engn, College Stn, TX 77843 USA.	tgood@tamu.edu					ALEVRIADOU BR, 1993, ANN BIOMED ENG, V21, P1, DOI 10.1007/BF02368159; BERTHIAUME F, 1992, FEBS LETT, V308, P277, DOI 10.1016/0014-5793(92)81292-T; Bird R.B., 2007, TRANSPORT PHENOMENA, V2nd; Brubaker RF, 1996, AM J OPHTHALMOL, V121, P473, DOI 10.1016/S0002-9394(14)75421-2; CAHANE M, 1992, OPHTHALMIC RES, V24, P280, DOI 10.1159/000267179; Cargill RS, 1996, J NEUROTRAUM, V13, P395, DOI 10.1089/neu.1996.13.395; CHEN SS, 1987, J FLUIDS STRUCTURES, V1, P35, DOI DOI 10.1016/S0889-9746(87)90170-8; CHU CS, 1994, J BIOMECH, V27, P187, DOI 10.1016/0021-9290(94)90208-9; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; Desole MS, 1997, NEUROCHEM INT, V31, P169, DOI 10.1016/S0197-0186(96)00146-5; Ehrich M, 1998, J TOXICOL ENV HEAL A, V53, P385, DOI 10.1080/009841098159240; FECHTNER RD, 1994, SURV OPHTHALMOL, V39, P23, DOI 10.1016/S0039-6257(05)80042-6; Frangos JA, 1996, BIOCHEM BIOPH RES CO, V224, P660, DOI 10.1006/bbrc.1996.1081; GARCIAVALENZUELA E, 1995, EXP EYE RES, V61, P33, DOI 10.1016/S0014-4835(95)80056-5; Helmlinger G, 1996, J VASC RES, V33, P360, DOI 10.1159/000159164; HILL JO, 1993, REV INORG CHEM, V13, P183; HONG MS, 1997, THESIS TEXAS A M U; HSIEH HJ, 1993, J CELL PHYSIOL, V154, P143, DOI 10.1002/jcp.1041540118; KOTAPKA MJ, 1993, NEUROPATH APPL NEURO, V19, P128, DOI 10.1111/j.1365-2990.1993.tb00417.x; Kruman I, 1997, J NEUROSCI, V17, P5089; KUCHAN MJ, 1994, AM J PHYSIOL, V267, pC753; LAN QX, 1994, BIOCHEM BIOPH RES CO, V201, P950, DOI 10.1006/bbrc.1994.1794; Lee HF, 1997, TELECOMMUN SYST, V7, P355, DOI 10.1023/A:1019188715963; Lindsberg PJ, 1996, J CEREBR BLOOD F MET, V16, P82, DOI 10.1097/00004647-199601000-00010; LOWENSTEIN DH, 1994, MOL BRAIN RES, V22, P299, DOI 10.1016/0169-328X(94)90058-2; Mackrill JJ, 1997, BIOCHEM J, V327, P251, DOI 10.1042/bj3270251; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; MATTSON MP, 1992, ANN NY ACAD SCI, V679, P1; McConkey DJ, 1996, MOL ASPECTS MED, V17, P1, DOI 10.1016/0098-2997(95)00006-2; MIKAWA S, 1995, MOL BRAIN RES, V33, P288, DOI 10.1016/0169-328X(95)00146-J; Miller SW, 1996, J NEUROCHEM, V67, P1897; Nikonorov IM, 1998, ANESTH ANALG, V86, P885, DOI 10.1097/00000539-199804000-00038; Nilsson P, 1996, J CEREBR BLOOD F MET, V16, P262, DOI 10.1097/00004647-199603000-00011; Papadaki M, 1997, BIOTECHNOL PROGR, V13, P209, DOI 10.1021/bp970029f; Prince JA, 1997, BRAIN RES BULL, V43, P515, DOI 10.1016/S0361-9230(97)00328-6; QUIGLEY HA, 1995, INVEST OPHTH VIS SCI, V36, P774; Reich KM, 1997, ENDOCRINOLOGY, V138, P1014, DOI 10.1210/en.138.3.1014; Ridge J, 1996, IN VITRO CELL DEV-AN, V32, P238; Satoh T, 1996, J BIOCHEM-TOKYO, V120, P540; Takahashi M, 1997, J VASC RES, V34, P212, DOI 10.1159/000159225; UENO K, 1995, J NEUROTRAUM, V12, P695, DOI 10.1089/neu.1995.12.695; WHITE BC, 1993, ANN EMERG MED, V22, P970, DOI 10.1016/S0196-0644(05)82737-4; YAN DB, 1994, BRIT J OPHTHALMOL, V78, P643, DOI 10.1136/bjo.78.8.643; YAN GM, 1995, J NEUROCHEM, V65, P2425	45	42	42	0	3	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0022-3751			J PHYSIOL-LONDON	J. Physiol.-London	MAR 1	1999	515	2					355	365		10.1111/j.1469-7793.1999.355ac.x			11	Neurosciences; Physiology	Neurosciences & Neurology; Physiology	182VQ	WOS:000079519200004	10050003	Bronze, Green Published			2021-06-18	
J	Chiaretti, A; De Benedictis, R; Langer, A; Di Rocco, C; Bizzarri, C; Iannelli, A; Polidori, G				Chiaretti, A; De Benedictis, R; Langer, A; Di Rocco, C; Bizzarri, C; Iannelli, A; Polidori, G			Prognostic implications of hyperglycaemia in paediatric head injury	CHILDS NERVOUS SYSTEM			English	Article						children; head injury; hyperglycaemia; outcome	ADMISSION HYPERGLYCEMIA; CEREBRAL-ISCHEMIA; BRAIN; GLUCOSE; ACIDOSIS; CHILDREN; INSULIN	Fifty children with head injury were evaluated in an attempt to estabilish a correlation between post-traumatic hyperglycaemia and long-term outcome. In all the patients, the blood glucose level was measured on admission and on the days following the trauma (threshold of normal value set at 150 mg/dl). Hyperglycaemia was seen more frequently in children with severe head injury than in those with mild and moderate head injury. It was present in 87.5% of the patients with a Glasgow Coma Score (GCS) less than or equal to 8 (the average blood glucose level on admission was 237.8+/-92 mg/dl), in 60% of the patients with a GCS of 9-12 (178+/-78.7 mg/dl) and only in 25% of those with a GCS of 13-15 (131.5+/-39 mg/dl). A close correlation was also seen between the outcome and the blood glucose level. In fact, the blood glucose on admission was higher in the patients with a poor outcome, i.e. in those having a Glasgow Outcome Score (COS) of 2 or 3 and in those who died (GOS 1), than in the patients with a good outcome (GOS of 4 or 5). Finally, hyperglycaemia persisted beyond the first 24 h after trauma in all the children who died or who survived with a poor outcome. Hyperglycaemia, and especially its persistence over time, appears to be an important negative prognostic factor in children with head injury.	Univ Cattolica Sacro Cuore, Inst Paediat, Paediat Intens Care Unit, I-00168 Rome, Italy; Univ Cattolica Sacro Cuore, Dept Paediat Neurosurg, I-00168 Rome, Italy	Chiaretti, A (corresponding author), Univ Cattolica Sacro Cuore, Inst Paediat, Paediat Intens Care Unit, Largo A Gemelli 8, I-00168 Rome, Italy.		Bizzarri, Carla/AAI-2429-2019	Bizzarri, Carla/0000-0002-5616-9185			DESALLES AAF, 1986, J NEUROSURG, V65, P615, DOI 10.3171/jns.1986.65.5.0615; FLAKALL PJ, 1995, AM J PHYSIOL, V269, P636; FUKUOKA S, 1989, STROKE, V20, P396, DOI 10.1161/01.STR.20.3.396; ISSEKUTZ B, 1965, AM J PHYSIOL, V209, P1137; JEEVANANDAM M, 1990, J TRAUMA, V30, P582, DOI 10.1097/00005373-199005000-00010; KUSHNER M, 1990, ANN NEUROL, V28, P129, DOI 10.1002/ana.410280204; LAM AM, 1991, J NEUROSURG, V75, P545, DOI 10.3171/jns.1991.75.4.0545; LEMAY DR, 1988, STROKE, V19, P1411, DOI 10.1161/01.STR.19.11.1411; MERGUERIAN PA, 1981, CRIT CARE MED, V9, P838, DOI 10.1097/00003246-198112000-00007; MICHAUD LJ, 1991, J TRAUMA, V31, P1356, DOI 10.1097/00005373-199110000-00007; PARISH RA, 1988, J TRAUMA, V28, P517, DOI 10.1097/00005373-198804000-00017; Pentelenyi T, 1979, Acta Neurochir Suppl (Wien), V28, P103; REHNCRONA S, 1980, ACTA PHYSIOL SCAND, V110, P435, DOI 10.1111/j.1748-1716.1980.tb06692.x; ROLIH CA, 1995, MED CLIN N AM, V79, P211, DOI 10.1016/S0025-7125(16)30093-1; ROSE J, 1977, BRIT MED J, V2, P615, DOI 10.1136/bmj.2.6087.615; SIEBER FE, 1992, CRIT CARE MED, V20, P104, DOI 10.1097/00003246-199201000-00022; Yang SY, 1995, SURG NEUROL, V44, P373, DOI 10.1016/0090-3019(96)80243-6; YOUNG B, 1989, ANN SURG, V210, P466, DOI 10.1097/00000658-198910000-00007	18	42	44	0	2	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0256-7040			CHILD NERV SYST	Childs Nerv. Syst.	SEP	1998	14	9					455	459		10.1007/s003810050259			5	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	126BK	WOS:000076272700006	9808254				2021-06-18	
J	Kant, R; Smith-Seemiller, L; Zeiler, D				Kant, R; Smith-Seemiller, L; Zeiler, D			Treatment of aggression and irritability after head injury	BRAIN INJURY			English	Article; Proceedings Paper	8th Annual Meeting of the American-Neuropsychiatric-Association	FEB 02-04, 1997	ORLANDO, FLORIDA	Amer Neuropsychiat Assoc			DISORDERS	Thirteen patients who experienced problems with irritability and aggression following closed head injury (CHI) participated in a non-blind, 8 week open trial of sertraline Hcl. Significant reduction in irritability and aggressive outbursts was observed. No significant changes were observed in depressive symptomatology. Results suggest that serotonergic agents may be useful in treating aggression and irritability after head injury. Further placebo-controlled studies using serotonergic agents are indicated.	St Francis Med Ctr, Head Injury Clin, Pittsburgh, PA 15524 USA; St Francis Med Ctr, Dept Psychiat, Pittsburgh, PA 15524 USA; Allegheny Gen Hosp, Pittsburgh, PA 15212 USA	Kant, R (corresponding author), St Francis Med Ctr, Head Injury Clin, 4608 Penn Ave, Pittsburgh, PA 15524 USA.		Kant, Ravi/F-7025-2013	Kant, Ravi/0000-0003-3878-9775			BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; COCCARO EF, 1992, INT CLIN PSYCHOPHARM, V7, P3, DOI 10.1097/00004850-199200710-00001; COCCARO EF, 1991, J NEUROPSYCHIAT, V3, P544; JOHNSON D, 1993, BRIT J NEUROSURG, V7, P53, DOI 10.3109/02688699308995056; LINNOILA VMI, 1992, J CLIN PSYCHIAT, V53, P46; LOPEZIBOR JJ, 1992, INT CLIN PSYCHOPHARM, V7, P5, DOI 10.1097/00004850-199210002-00003; MARKOVITZ PJ, 1991, AM J PSYCHIAT, V148, P1064; MOSS HB, 1990, BIOL PSYCHIAT, V28, P325, DOI 10.1016/0006-3223(90)90660-T; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; SPOTZER RL, 1978, SCHEDULE AFFECTIVE D; VANPRAAG HM, 1986, SUICIDE LIFE-THREAT, V16, P103; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; YUDOFSKY SC, 1986, AM J PSYCHIAT, V143, P35	13	42	42	1	2	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	AUG	1998	12	8					661	666		10.1080/026990598122223			6	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	108AN	WOS:000075243800003	9724837				2021-06-18	
J	Dutcher, SA; Underwood, BD; Walker, PD; Diaz, FG; Michael, DB				Dutcher, SA; Underwood, BD; Walker, PD; Diaz, FG; Michael, DB			Patterns of heat-shock protein 70 biosynthesis following human traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						cerebral cortex; gene expression; hsp70; human brain injury	FOCAL CEREBRAL-ISCHEMIA; RAT-BRAIN; GENE-EXPRESSION; C-FOS; TRANSIENT ISCHEMIA; HYPOXIA-ISCHEMIA; KAINIC ACID; INDUCTION; HIPPOCAMPUS; CELLS	Heat-shock protein 70 (hsp70) is activated upon cellular stress/injury and participates in the folding and intracellular transport of damaged proteins, The expression of hsp70 following CNS trauma has been speculated to be part of a cellular response which is involved in the repair of damaged proteins, In this study, we measured hsp70 mRNA and protein levels within human cerebral cortex subjected to traumatic brain injury. Specimens were obtained during routine neurosurgery for trauma and processed for Northern mRNA and Western protein analysis, The largest increase in hsp70 mRNA levels was detected in trauma tissue obtained 4-6 h following injury. By 24 h, hsp70 mRNA levels were similar to nontrauma comparison tissues, hsp70 protein expression exhibited its greatest increases at 12-20 h post-injury, Immunocytological techniques revealed hsp70 protein expression in cells with neuronal-like morphology at 12 h after injury, These results suggest a role for hsp70 in human cortex following TBI, Moreover, since the temporal induction pattern of hsp70 biosynthesis is similar to that reported in the rodent, our observations validate the importance of rodent brain injury models in providing useful information directly applicable to human brain injury.	Wayne State Univ, Sch Med, Dept Neurol Surg, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Anat & Cell Biol, Detroit, MI 48201 USA	Dutcher, SA (corresponding author), Wayne State Univ, Sch Med, Dept Neurol Surg, Detroit, MI 48201 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS030550] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30550] Funding Source: Medline		Amin V, 1996, NEUROSCI LETT, V206, P45, DOI 10.1016/0304-3940(96)12421-6; Bellmann K, 1996, FEBS LETT, V391, P185, DOI 10.1016/0014-5793(96)00730-2; BROWN IR, 1989, NEURON, V2, P1559, DOI 10.1016/0896-6273(89)90044-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CURRAN T, 1983, MOL CELL BIOL, V3, P914, DOI 10.1128/MCB.3.5.914; CURRIE RW, 1981, SCIENCE, V214, P72, DOI 10.1126/science.7280681; DIENEL GA, 1986, J CEREBR BLOOD F MET, V6, P505, DOI 10.1038/jcbfm.1986.86; DRAGUNOW M, 1988, BRAIN RES, V455, P295, DOI 10.1016/0006-8993(88)90088-1; DRAGUNOW M, 1994, MOL BRAIN RES, V25, P19, DOI 10.1016/0169-328X(94)90274-7; DWYER BE, 1989, EXP NEUROL, V104, P28, DOI 10.1016/0014-4886(89)90005-8; FERRIERO DM, 1990, DEV BRAIN RES, V53, P145, DOI 10.1016/0165-3806(90)90136-M; GONZALEZ MF, 1989, MOL BRAIN RES, V6, P93, DOI 10.1016/0169-328X(89)90033-8; HUNT C, 1985, P NATL ACAD SCI USA, V82, P6455, DOI 10.1073/pnas.82.19.6455; JACEWICZ M, 1986, J CEREBR BLOOD F MET, V6, P263, DOI 10.1038/jcbfm.1986.48; KASOF GM, 1995, J NEUROSCI, V15, P4238; KONOPKA D, 1995, NEUROSCI LETT, V185, P167, DOI 10.1016/0304-3940(95)11252-R; LEWIS SA, 1984, P NATL ACAD SCI-BIOL, V81, P2743, DOI 10.1073/pnas.81.9.2743; LOWENSTEIN DH, 1990, BRAIN RES, V531, P173, DOI 10.1016/0006-8993(90)90771-3; NOWAK TS, 1990, J NEUROCHEM, V54, P451, DOI 10.1111/j.1471-4159.1990.tb01893.x; PHILLIPS LL, 1992, J NEUROTRAUM, V9, P323, DOI 10.1089/neu.1992.9.323; Sall JM, 1996, EXP NEUROL, V139, P257, DOI 10.1006/exnr.1996.0099; SATOH J, 1992, BRAIN RES, V573, P37, DOI 10.1016/0006-8993(92)90111-L; SIESJO BK, 1992, J NEUROSURG, V77, P337, DOI 10.3171/jns.1992.77.3.0337; TANNO H, 1993, J CEREBR BLOOD F MET, V13, P116, DOI 10.1038/jcbfm.1993.14; UNEY JB, 1988, FEBS LETT, V235, P215, DOI 10.1016/0014-5793(88)81265-1; VASS K, 1988, ACTA NEUROPATHOL, V77, P128; WALKER PD, 1993, J NEUROSCI RES, V36, P588, DOI 10.1002/jnr.490360511; WALKER PD, 1993, NEUROREPORT, V4, P699, DOI 10.1097/00001756-199306000-00024	28	42	46	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUN	1998	15	6					411	420		10.1089/neu.1998.15.411			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	ZR931	WOS:000074030700003	9624626				2021-06-18	
J	Lancon, JA; Haines, DE; Parent, AD				Lancon, JA; Haines, DE; Parent, AD			Anatomy of the shaken baby syndrome	ANATOMICAL RECORD			English	Article						shaken baby syndrome; traumatic injuries; child abuse	PERMANENT BRAIN-DAMAGE; MENTAL-RETARDATION; INFANTS; INJURIES; SHAKING; FALLS	Shaken baby syndrome refers to the constellation of nonaccidental injuries occurring in infants and young children as a consequence of violent shaking, The typical victim of shaken baby syndrome is a male infant younger than six months of age who is alone with the perpetrator at the time of injury, Occurrence of the syndrome is unrelated to race, gender, socioeconomic status, or education, The characteristic injuries observed in shaken baby syndrome include subdural hemorrhages, retinal hemorrhages, and fractures of the ribs or long bones. Although each of these injuries may result from violent shaking of the victim, the most severe brain injuries result from the addition of a forceful impact of the infant's or child's head against a firm surface, The unique anatomic features of the infant's head and skeletal system, which account for the type and pattern of injuries observed in shaken baby syndrome, are emphasized in this article. (C) 1998 Wiley-Liss, Inc.	Univ Mississippi, Med Ctr, Dept Neurosurg, Jackson, MS 39216 USA; Univ Mississippi, Med Ctr, Dept Anat, Jackson, MS 39216 USA	Lancon, JA (corresponding author), Univ Mississippi, Med Ctr, Dept Neurosurg, Jackson, MS 39216 USA.						BRUCE DA, 1989, PEDIATR ANN, V18, P482, DOI 10.3928/0090-4481-19890801-07; CAFFEY J, 1974, PEDIATRICS, V54, P396; CAFFEY J, 1946, AM J ROENTGENOL, V56, P163; CAFFEY J, 1972, AM J DIS CHILD, V124, P161, DOI 10.1001/archpedi.1972.02110140011001; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; Giardino A.P., 1997, PRACTICAL GUIDE EVAL; HALL JR, 1989, J TRAUMA, V29, P1273, DOI 10.1097/00005373-198909000-00015; HELFER RE, 1977, PEDIATRICS, V60, P533; KLEINMAN PK, 1986, AM J ROENTGENOL, V146, P895, DOI 10.2214/ajr.146.5.895; KLEINMAN PK, 1989, NEW ENGL J MED, V320, P507, DOI 10.1056/NEJM198902233200807; Levin AV, 1990, OPHTHALMOL CLIN N AM, V3, P249; MONTELEONE JA, 1994, CHILD MALTREATMENT C; WILLIAMS RA, 1991, J TRAUMA, V31, P1350, DOI 10.1097/00005373-199110000-00005; WILSON EF, 1977, PEDIATRICS, V60, P751	14	42	43	0	6	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	0003-276X			ANAT REC	Anat. Rec.	FEB	1998	253	1					13	18		10.1002/(SICI)1097-0185(199802)253:1<13::AID-AR8>3.0.CO;2-F			6	Anatomy & Morphology	Anatomy & Morphology	ZF467	WOS:000072900400008	9556020				2021-06-18	
J	Koiv, L; Merisalu, E; Zilmer, K; Tomberg, T; Kaasik, AE				Koiv, L; Merisalu, E; Zilmer, K; Tomberg, T; Kaasik, AE			Changes of sympatho-adrenal and hypothalamo-pituitary-adrenocortical system in patients with head injury	ACTA NEUROLOGICA SCANDINAVICA			English	Article						head injury; brain injury; catecholamines; adrenocorticotropic hormone; cortisol; prognosis	TRAUMATIC BRAIN INJURY; CATECHOLAMINES; CORTISOL	To determine the role of the sympatho-adrenal (SAS) and hypothalamo-pituitary-adrenocortical system (HPAS) after head injury, the relationship between venous blood epinephrine (E), norepinephrine (NE), adrenocorticotropic hormone (ACTH), cortisol levels, and clinical condition was examined in 55 patients. These observations suggest that head injury causes mainly activation of the above-mentioned systems depending on the severity of trauma. An inverse correlation between the levels of E, NE and Glasgow Coma Scale score, indicating the severity of head injury was revealed. ACTH and cortisol were similarly related to the clinical condition, although the observed correlation was less expressed. The changes in hormonal levels were present during the whole research period (1 week), although a certain shift to normalization was observed. However, catecholamines and ACTH levels in plasma were relatively low in severely head-injured patients whose CT scans revealed serious alterations in the mesencephalic-diencephalic area. At the same time their cortisol levels obtained maximal values and their chance to survive was diminutive. The results of this study indicate that investigation of hormones of SAS and HPAS might be useful as an additional method in the complex of ordinary examinations in establishing early prognosis in patients with brain injury.	TARTU STATE UNIV,DEPT PUBL HLTH,EE-202400 TARTU,ESTONIA; TARTU STATE UNIV,DEPT BIOCHEM,EE-202400 TARTU,ESTONIA	Koiv, L (corresponding author), TARTU STATE UNIV,DEPT NEUROL & NEUROSURG,2 L PUUSEPP ST,EE-2400 TARTU,ESTONIA.						ARITA K, 1993, ACTA NEUROCHIR, V123, P64, DOI 10.1007/BF01476288; CHIOLERO R, 1988, J TRAUMA, V28, P1368, DOI 10.1097/00005373-198809000-00011; CHIOLERO R, 1989, JPEN-PARENTER ENTER, V13, P5, DOI 10.1177/014860718901300105; COLGAN FJ, 1983, CRIT CARE MED, V11, P368, DOI 10.1097/00003246-198305000-00010; CROMPTON MR, 1971, BRAIN, V94, P165, DOI 10.1093/brain/94.1.165; Damianova G, 1989, Neurol Psychiatr (Bucur), V27, P127; DOLECEK R, 1990, ENDOCRINOLOGY THERMA; DUNN AJ, 1989, STRESS NEUROCHEMISTR, P108; FELDMAN Z, 1993, J TRAUMA, V34, P806, DOI 10.1097/00005373-199306000-00010; HADFIELD JM, 1992, INJURY, V23, P177, DOI 10.1016/S0020-1383(05)80040-3; HAMILL RW, 1987, ANN NEUROL, V21, P438, DOI 10.1002/ana.410210504; HANSSON L, 1991, AM J CARDIOL, V67, pB43, DOI 10.1016/0002-9149(91)90819-7; HARRUFF RC, 1993, AM J FOREN MED PATH, V14, P284, DOI 10.1097/00000433-199312000-00003; JENKINS A, 1986, LANCET, V2, P445; KAUFMAN HH, 1993, MED CLIN N AM, V77, P43, DOI 10.1016/S0025-7125(16)30271-1; KING LR, 1970, ANN SURG, V172, P975, DOI 10.1097/00000658-197012000-00008; KOIDE T, 1986, J CEREBR BLOOD F MET, V6, P559, DOI 10.1038/jcbfm.1986.102; LINDVALL O, 1988, EXP BRAIN RES, V73, P219, DOI 10.1007/BF00279676; OTT L, 1987, JPEN-PARENTER ENTER, V11, P488, DOI 10.1177/0148607187011005488; PAJU AJ, 1979, LAB DELO, V5, P297; PAYEN D, 1990, CRIT CARE MED, V18, P392, DOI 10.1097/00003246-199004000-00008; Pentelenyi T, 1992, Acta Neurochir Suppl (Wien), V55, P21; Pfenninger E, 1991, Anaesthesiol Reanim, V16, P243; PITTS LH, 1990, HDB CLIN NEUROLOGY, V13, P65; RATGE D, 1982, ACTA ENDOCRINOL-COP, V101, P428, DOI 10.1530/acta.0.1010428; ROSNER MJ, 1984, J NEUROSURG, V61, P76, DOI 10.3171/jns.1984.61.1.0076; ROSS DA, 1989, J NEUROSURG, V71, P498, DOI 10.3171/jns.1989.71.4.0498; Selye H., 1956, STRESS LIFE; SHAPIRA Y, 1988, J CEREBR BLOOD F MET, V8, P395, DOI 10.1038/jcbfm.1988.75; SHENKIN HA, 1971, J NEUROSURG, V34, P657, DOI 10.3171/jns.1971.34.5.0657; SHIBATA M, 1993, J NEUROSURG, V79, P696, DOI 10.3171/jns.1993.79.5.0696; SILVER JM, 1990, J CLIN PSYCHIAT, V51, P33; SNOW RB, 1986, NEUROSURGERY, V18, P45, DOI 10.1227/00006123-198601000-00008; *STATSOFT INC, 1994, STAT WIND OP SYST; Takahashi H, 1989, Neurol Med Chir (Tokyo), V29, P192, DOI 10.2176/nmc.29.192; TOUTANT SM, 1984, J NEUROSURG, V61, P691, DOI 10.3171/jns.1984.61.4.0691; VANLOON J, 1993, J NEUROSURG, V79, P705, DOI 10.3171/jns.1993.79.5.0705; WOOLF PD, 1987, J NEUROSURG, V66, P875, DOI 10.3171/jns.1987.66.6.0875; WOOLF PD, 1988, AM J MED, V84, P201, DOI 10.1016/0002-9343(88)90414-7; WOOLF PD, 1988, AM J PHYSIOL, V254, P287; WURTMAN RJ, 1974, J NEUROSURG, V40, P34, DOI 10.3171/jns.1974.40.1.0034	41	42	42	0	1	MUNKSGAARD INT PUBL LTD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0001-6314			ACTA NEUROL SCAND	Acta Neurol. Scand.	JUL	1997	96	1					52	58					7	Clinical Neurology	Neurosciences & Neurology	XM194	WOS:A1997XM19400009	9262133				2021-06-18	
J	Lang, EW; Pitts, LH; Damron, SL; Rutledge, R				Lang, EW; Pitts, LH; Damron, SL; Rutledge, R			Outcome after severe head injury: An analysis of prediction based upon comparison of neural network versus logistic regression analysis	NEUROLOGICAL RESEARCH			English	Article; Proceedings Paper	10th European Congress of Neurosurgery	MAY 07-12, 1995	BERLIN, GERMANY			neural network; prognosis; outcome prediction; severe head injury	CEREBRAL BLOOD-FLOW; GLASGOW COMA SCALE; BRAIN INJURY; PERFUSION-PRESSURE; EVOKED-POTENTIALS; LACTIC-ACIDOSIS; TRAUMATIC COMA; RESUSCITATION; MANAGEMENT; PROGNOSIS	More reliable prediction of outcome would be helpful for clinicians who treat severely head-injured patients. To determine if neural network modeling would improve outcome prediction compared with standard logistic regression analysis and to determine if data available 24 h after severe head injury allows better prediction than data obtained within 6 h, we tested the ability of both techniques at these two times to predict outcome (dead versus alive) at 6 months. One thousand sixty-six consecutive patients with Glasgow Coma Scale scores of 8 or less during the first 24 h after injury were randomly divided into two groups. Data from the first group (n = 799) were used to develop the models; data from the second group (n = 267) were used to test the accuracy, sensitivity, and specificity of the models by comparing predicted and actual outcomes. The 6-month mortality race was 63.5%. Our findings confirm the importance of age, Glasgow Coma Scale scores, and hypotension in predicting outcome. Using data available al 24 h improved the predictive power of both models compared with admission data; at both time points, however, the differences in the results obtained with the two models were negligible. We conclude that outcome (dead versus alive) at 6 months after severe head injury can be predicted with logistic regression or neural network models based on data available at 24 h. Critical therapeutic decisions, such as cessation of therapy should be based on the patient's status 1 day after injury and only rarely on admission status alone.	UNIV CALIF SAN FRANCISCO, SCH MED, SAN FRANCISCO GEN HOSP, DEPT NEUROL SURG, SAN FRANCISCO, CA USA; UNIV N CAROLINA, SCH MED, DEPT SURG, DIV GEN SURG, CHAPEL HILL, NC USA							BARLOW P, 1986, NEUROSURGERY, V19, P989, DOI 10.1227/00006123-198612000-00014; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BORN JD, 1985, NEUROSURGERY, V16, P595, DOI 10.1227/00006123-198505000-00002; Braakman R, 1986, Acta Neurochir Suppl (Wien), V36, P112; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; BRAAKMAN R, 1992, ACTA NEUROCHIR, V116, P161, DOI 10.1007/BF01540870; BURKE HB, 1994, SEMIN SURG ONCOL, V10, P73, DOI 10.1002/ssu.2980100111; CHANGARIS DG, 1987, J TRAUMA, V27, P1007, DOI 10.1097/00005373-198709000-00009; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; COLOHAN ART, 1989, J NEUROSURG, V71, P202, DOI 10.3171/jns.1989.71.2.0202; CORDOBES F, 1986, ACTA NEUROCHIR, V81, P27, DOI 10.1007/BF01456261; DESALLES AAF, 1986, J NEUROSURG, V65, P615, DOI 10.3171/jns.1986.65.5.0615; DOYLE HR, 1994, ANN SURG, V219, P408, DOI 10.1097/00000658-199404000-00012; EBELL MH, 1993, J FAM PRACTICE, V36, P297; EIDE PK, 1992, ACTA NEUROL SCAND, V86, P194, DOI 10.1111/j.1600-0404.1992.tb05065.x; FACCO E, 1986, CHILD NERV SYST, V2, P67; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; FOLTZ EL, 1988, SURG NEUROL, V30, P273, DOI 10.1016/0090-3019(88)90298-4; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; Green DM, 1974, SIGNAL DETECTION THE; GREENBERG RP, 1981, J NEUROSURG, V55, P227, DOI 10.3171/jns.1981.55.2.0227; GREENWOOD D, 1991, BEHAV SCI, V36, P1, DOI 10.1002/bs.3830360102; HANS P, 1987, BRIT J HOSP MED, V37, P535; HARTUNG HJ, 1992, ANAESTHESIST, V41, P468; HILL DA, 1993, AUST NZ J SURG, V63, P604, DOI 10.1111/j.1445-2197.1993.tb00466.x; HOULDEN DA, 1990, NEUROSURGERY, V27, P701, DOI 10.1227/00006123-199011000-00006; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; JENNETT B, 1975, LANCET, V1, P480; KAPPEN HJ, 1993, ANN ONCOL         S4, V4, pS31; Katz S, 1994, J Heart Valve Dis, V3, P49; KAUFMANN MA, 1992, RESUSCITATION, V23, P199, DOI 10.1016/0300-9572(92)90003-U; LAM AM, 1991, J NEUROSURG, V75, P545, DOI 10.3171/jns.1991.75.4.0545; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MARMAROU A, 1992, J NEUROTRAUM, V9, pS327; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; OLSON JD, 1989, NEUROSURGERY, V24, P825, DOI 10.1227/00006123-198906000-00007; PENNINGS JL, 1993, ARCH SURG-CHICAGO, V128, P787; Pentelenyi T, 1992, Acta Neurochir Suppl (Wien), V55, P21; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; RABOW L, 1986, J NEUROSURG, V65, P625, DOI 10.3171/jns.1986.65.5.0625; ROBERTSON CS, 1992, J NEUROL NEUROSUR PS, V55, P594, DOI 10.1136/jnnp.55.7.594; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; SHUFFLEBARGER CM, 1992, ANN EMERG MED, V21, P1461, DOI 10.1016/S0196-0644(05)80060-5; STABLEIN DM, 1980, NEUROSURGERY, V6, P243; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P140; TEASDALE G, 1974, LANCET, V2, P81; THOMAS DGT, 1977, LANCET, V1, P113; TOUTANT SM, 1984, J NEUROSURG, V61, P691, DOI 10.3171/jns.1984.61.4.0691; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; WALD SL, 1993, J TRAUMA, V34, P377, DOI 10.1097/00005373-199303000-00012; WAXMAN K, 1991, ARCH SURG-CHICAGO, V126, P1237; WEBER M, 1990, NEUROSURGERY, V27, P106, DOI 10.1227/00006123-199007000-00015	61	42	43	0	2	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.	JUN	1997	19	3					274	280		10.1080/01616412.1997.11740813			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	XC468	WOS:A1997XC46800012	9192380				2021-06-18	
J	Prigatano, GP; Ogano, M; Amakusa, B				Prigatano, GP; Ogano, M; Amakusa, B			A cross-cultural study on impaired self-awareness in Japanese patients with brain dysfunction	NEUROPSYCHIATRY NEUROPSYCHOLOGY AND BEHAVIORAL NEUROLOGY			English	Article						brain dysfunction; cerebrovascular accident; Japanese; traumatic brain injury; self-awareness	BEHAVIORAL LIMITATIONS; HEAD-INJURY; ANOSOGNOSIA	Japanese patients with brain dysfunction (21 with severe traumatic brain injury [TBI], 21 with right, and 21 with left cerebral vascular accidents [CVA]) were asked to make behavioral ratings regarding their competencies in several areas, Relatives of patients and physical therapists who treated them also rated each patient's behavioral competency. Japanese patients with TBI overestimated their behavioral competencies compared with therapists' ratings, but not relatives' ratings. Japanese patients with TBI overestimated self-care skills but not their ability to interact in socioemotional situations. Patients who had right and left CVA did not differ in their mean ratings of behavioral competency. Among all patient groups, there was no correlation between self-reported competencies and performance on a neuropsychological test. Family ratings of patients' behavioral competencies correlated with the patients' neuropsychological test performance. Post hoc analyses of patients with TBI suggest that speed of finger tapping related to an impaired self-awareness. Whereas cultural factors may influence self reports of behavioral competency, patients across cultures with brain dysfunction seem to have reduced insight into their actual level of neuropsychological functioning.	ST JOSEPHS HOSP,BARROW NEUROL INST,DIV NEUROL,PHOENIX,AZ							CUTTING J, 1978, J NEUROL NEUROSUR PS, V41, P548, DOI 10.1136/jnnp.41.6.548; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; GAINOTTI G, 1975, PSYCHIAT CLIN, V8, P99, DOI 10.1159/000283622; HAALAND KY, 1994, J CLIN EXP NEUROPSYC, V16, P448, DOI 10.1080/01688639408402655; HANDA T, 1983, PHYS THER C NAT HOSP; JOHNSON MK, 1951, J BONE JOINT SURG AM, V33, P623; LEBRUN Y, 1987, CORTEX, V23, P251, DOI 10.1016/S0010-9452(87)80035-7; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; MIZUNO M, 1991, Keio Journal of Medicine, V40, P221; MORIYAMA S, 1987, P JOINT JAP CHIN STR; OTA T, 1974, NEUROSURGERY, V2, P623; Prigatano G. P., 1991, AWARENESS DEFICIT BR; Prigatano G. P., 1990, CLIN NEUROPSYCHOL, V4, P163, DOI [10.1080/13854049008401509, DOI 10.1080/13854049008401509]; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; Prigatano George P, 1993, Clin Neuropsychol, V7, P123, DOI 10.1080/13854049308401514; Prigatano GP, 1996, CLIN NEUROPSYCHOL, V10, P191, DOI 10.1080/13854049608406680; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Prigatano GP, 1996, NEUROPSYCHOL REHABIL, V6, P305, DOI 10.1080/713755515; PRIGATANO GP, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P381; Prigatano GP, 1996, CLIN NEUROPSYCHOL, V10, P342; Prigatano GP, 1995, PSYCHOL ASSESSMENT, V7, P396; PRIGATANO GP, 1997, IN PRESS CLIN NEUROP; Prigatano GP, 1995, ADM SCORING MANUAL B; ROMANO MD, 1974, SCAND J REHABIL MED, V6, P1; STARKSTEIN SE, 1993, NEUROPSY NEUROPSY BE, V6, P43; Walker A E, 1972, Scand J Rehabil Med, V4, P5; WEILLER C, 1993, ANN NEUROL, V33, P181; Weinstein E. A., 1955, DENIAL ILLNESS SYMBO	28	42	43	0	3	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0894-878X			NEUROPSY NEUROPSY BE	Neuropsychiatr. Neuropsychol. Behav. Neurol.	APR	1997	10	2					135	143					9	Clinical Neurology; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	WY139	WOS:A1997WY13900009	9150515				2021-06-18	
J	Ferraro, FR				Ferraro, FR			Cognitive slowing in closed-head injury	BRAIN AND COGNITION			English	Article; Proceedings Paper	22nd Annual Meeting of the International-Neuropsychological-Society	FEB 02-06, 1994	CINCINNATI, OH	Int Neuropsychol Soc			REACTION-TIME; PERFORMANCE; RECOVERY; DEFICITS; SPEED	Mean response times (RTs) from a sample of 13 simple- and choice-reaction time studies (which included 353 Closed-Head Injury (CHI) subjects at various stages of injury and 329 Control, non-CHI, subjects; mean age of both groups, approximately 28 years) were analyzed using Brinley Plot/multiple regression analysis techniques to provide support for the observation that CHI results in a slowing of basic cognitive information processing. Across 101 experimental conditions, the best-fit equation that resulted from regressing the CHI data onto the Control data for matched conditions was Y (CHI) = 1.54 X (Control) - 59, and this specific regression equation accounted for approximately 89% of the variance (based on R(2)). These results suggest that the basic cognition processes involved in simple- and choice-reaction time performance were approximately 1.54 times slower in CHI individuals in this sample as compared to non-CHI individuals. This pattern of performance substantiates the observation the CHI results in a slowing of even very basic cognition information processes. (C) 1996 Academic Press, Inc.		Ferraro, FR (corresponding author), UNIV N DAKOTA,DEPT PSYCHOL,BOX 8380,GRAND FORKS,ND 58202, USA.						BENTON AL, 1958, J ABNORMAL SOCIAL PS, V54, P109; Birren J. E., 1965, BEHAV AGING NERVOUS, P191; BLACKBURN H L, 1955, Confin Neurol, V15, P327; BLEIBERG J, 1994, INCONSISTENCY MARKER; Brinley J. F., 1965, BEHAV AGING NERVOUS, P114; CERELLA J, 1985, PSYCHOL BULL, V98, P67, DOI 10.1037/0033-2909.98.1.67; Cerella J., 1980, AGING 1980S PSYCHOL, P332, DOI DOI 10.1037/10050-024; DEACON D, 1991, ELECTROEN CLIN NEURO, V78, P133, DOI 10.1016/0013-4694(91)90113-I; DENCKER SJ, 1958, ACTA PSYCHIAT NEUROL, V33, P122; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; HALE S, 1990, CHILD DEV, V61, P653, DOI 10.2307/1130951; Haut M W, 1990, Arch Clin Neuropsychol, V5, P299, DOI 10.1016/0887-6177(90)90028-N; HAUT MW, 1991, BRAIN COGNITION, V17, P31, DOI 10.1016/0278-2626(91)90064-F; KAIL R, 1992, AM J MENT RETARD, V97, P333; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; Mahurin RK, 1986, DEV NEUROPSYCHOL, V2, P345, DOI 10.1080/87565648609540353; MATTSON AJ, 1994, J NEUROL NEUROSUR PS, V57, P818, DOI 10.1136/jnnp.57.7.818; Miller E, 1970, Cortex, V6, P121; MUNTE TF, 1994, ARCH NEUROL-CHICAGO, V51, P482, DOI 10.1001/archneur.1994.00540170058017; MYERSON J, 1992, PSYCHOL AGING, V7, P257, DOI 10.1037/0882-7974.7.2.257; MYERSON J, 1994, J GERONTOL, V49, pP72, DOI 10.1093/geronj/49.2.P72; NEBES RD, 1992, J CLIN EXP NEUROPSYC, V14, P317, DOI 10.1080/01688639208402831; NORMAN B, 1961, ACTA PSYCHIAT SCAND, V37, P236; PERFECT TJ, 1994, J GERONTOL, V49, pP60, DOI 10.1093/geronj/49.2.P60; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Salthouse T. A., 1985, HDB AGING HDB PSYCHO, P400; SALTHOUSE TA, 1982, J GERONTOL, V37, P59, DOI 10.1093/geronj/37.1.59; SANDERSON J, 1988, COGNITIVE APPROACHES; Schmitter-Edgecombe M., 1993, NEUROPSYCHOLOGY, V7, P136, DOI DOI 10.1037/0894-4105.7.2.136; SCHMITTEREDGECOMBE ME, 1992, J CLIN EXP NEUROPSYC, V14, P717, DOI 10.1080/01688639208402858; SHUM DHK, 1994, J CLIN EXP NEUROPSYC, V16, P547, DOI 10.1080/01688639408402666; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; STUSS DT, 1986, CANADIAN J NEUROLOGI, V16, P161; Stuss DT, 1994, NEUROPSYCHOLOGY, V8, P316, DOI DOI 10.1037/0894-4105.8.3.316; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; VANZOMEREN AH, 1978, J NEUROL NEUROSUR PS, V41, P452, DOI 10.1136/jnnp.41.5.452	36	42	42	0	1	ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495	0278-2626			BRAIN COGNITION	Brain Cogn.	DEC	1996	32	3					429	440		10.1006/brcg.1996.0075			12	Neurosciences; Psychology, Experimental	Neurosciences & Neurology; Psychology	WD489	WOS:A1996WD48900005	8975681				2021-06-18	
J	Warren, L; Wrigley, JM; Yoels, WC; Fine, PR				Warren, L; Wrigley, JM; Yoels, WC; Fine, PR			Factors associated with life satisfaction among a sample of persons with neurotrauma	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						life satisfaction; rehabilitation; spinal cord injury; traumatic brain injury	SPINAL-CORD INJURY; HEAD-INJURY; REHABILITATION; HANDICAP; OUTCOMES	Factors were examined that are associated with life satisfaction one year post-discharge for persons with a spinal cord (SCI) or traumatic brain injury (TBI). Findings show persons with SCI or TBI should be considered as two distinct groups with regard to factors affecting life satisfaction. Different strategies might be considered to affect either group. Three psychosocial variables significantly increased life satisfaction for persons with SCI: closeness to family, the level of family activities, and blaming oneself for the injury. For persons with TBI, total family satisfaction, blaming oneself for the injury, being employed, being married, and having memory and bowel independence significantly increased life satisfaction, For persons with TBI, there was a difference in the number of factors affecting life satisfaction dependent on whether the persons blamed themselves or not. Those who do not blame themselves show a greater number of functional activities as indicators for their self-satisfaction.	UNIV ALABAMA, INJURY CONTROL RES CTR, BIRMINGHAM, AL 35294 USA; ALABAMA DEPT ENVIRONM MANAGEMENT, MONTGOMERY, AL 36130 USA			Warren, Lorraine/P-3967-2017	Warren, Lorraine/0000-0001-7459-0136			BACH JR, 1994, ARCH PHYS MED REHAB, V75, P626, DOI 10.1016/0003-9993(94)90183-X; BULMAN RJ, 1977, J PERS SOC PSYCHOL, V35, P351, DOI 10.1037/0022-3514.35.5.351; Chase B W, 1990, Int J Rehabil Res, V13, P325, DOI 10.1097/00004356-199012000-00006; CRISP R, 1992, PARAPLEGIA, V30, P420, DOI 10.1038/sc.1992.92; DEVIVO MJ, 1987, ARCH PHYS MED REHAB, V68, P494; Drewes A M, 1989, Int Disabil Stud, V11, P178; FUHRER MJ, 1992, ARCH PHYS MED REHAB, V73, P552; KANELLOS MC, 1985, AM J OCCUP THER, V39, P726, DOI 10.5014/ajot.39.11.726; Keith R A, 1987, Adv Clin Rehabil, V1, P6; Koehler M L, 1989, Rehabil Nurs, V14, P9; Liss M, 1990, Int J Rehabil Res, V13, P309, DOI 10.1097/00004356-199012000-00004; MCGOWAN MB, 1987, PARAPLEGIA, V25, P357, DOI 10.1038/sc.1987.64; MCMORDIE W R, 1991, Brain Injury, V5, P43, DOI 10.3109/02699059108998510; MELAMED S, 1992, Brain Injury, V6, P233, DOI 10.3109/02699059209029665; NAKAJIMA A, 1988, PARAPLEGIA, V26, P165, DOI 10.1038/sc.1988.27; NEUGARTEN BL, 1961, J GERONTOL, V16, P134, DOI 10.1093/geronj/16.2.134; Nieves C C, 1991, Rehabil Nurs, V16, P129; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; OLSON DH, 1979, FAM PROCESS, V18, P3, DOI 10.1111/j.1545-5300.1979.00003.x; SHOLOMSKAS DE, 1990, J APPL SOC PSYCHOL, V20, P548, DOI 10.1111/j.1559-1816.1990.tb00427.x; STAMBROOK M, 1991, PARAPLEGIA, V29, P318, DOI 10.1038/sc.1991.46; STAMBROOK M, 1991, J CLIN EXP NEUROPSYC, V13, P521, DOI 10.1080/01688639108401068; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WRIGLEY JM, 1994, ARCH PHYS MED REHAB, V75, P149; YARKONY G, AM J PHSY MED REHABI, V67, P73	25	42	42	0	0	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.	OCT	1996	33	4					404	408					5	Rehabilitation	Rehabilitation	VL572	WOS:A1996VL57200007	8895135				2021-06-18	
J	Leathem, J; Heath, E; Woolley, C				Leathem, J; Heath, E; Woolley, C			Relatives' perceptions of role change, social support and stress after traumatic brain injury	BRAIN INJURY			English	Article							SEVERE HEAD-INJURY; PATIENT; IMPACT; VIEW; MOOD	There is general agreement between researchers and clinicians alike that relatives of people with head injuries experience heightened stress as a result of the injury and its consequences. In the present study a single structured interview, including both verbally administered and written response questionnaires, was completed by 1.8 parents and 11 partners. Measures included the Daily Hassles and Uplifts Scale, the Arizona Social Support Interview Schedule and questions regarding role change and health problems. The combined parents and partners group indicated that they experienced moderate levels of stress and role change. A relatively small proportion of participants reported experiencing health problems. Partners indicated a slightly higher degree of stress and a greater degree of role change than parents, and a larger proportion of partners indicated the presence of health problems. Qualitative differences between the two groups were found in terms of sources of stress. There was little quantitative or qualitative difference between the two groups in sources, utilization of and satisfaction with social support. Positive correlations were found between stress and role change and stress and health problems.	OPT COMMUNITY LIVING, PALMERSTON NORTH, NEW ZEALAND	Leathem, J (corresponding author), MASSEY UNIV, DEPT PSYCHOL, PALMERSTON NORTH, NEW ZEALAND.						Barrera Jr M, 1981, SOCIAL NETWORKS SOCI, P69; BIGLER ED, 1988, BRAIN INJURY, V3, P73; BLYTH B, 1981, NEW ZEAL MED J, V93, P267; BOND MR, 1986, NEUROPSYCHOLOGICAL A, P347; BOND MR, 1983, REHABILITATION HEAD, P209; Brooks D N, 1979, Int Rehabil Med, V1, P160; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROOKS DN, 1984, HEAD INJURY PSYCHOL, P123; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; CRAWFORD C, 1983, NEW ZEAL MED J, V96, P972; DELONGIS A, 1988, J PERS SOC PSYCHOL, V54, P486, DOI 10.1037/0022-3514.54.3.486; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; KANNER AD, J BEHAV MED, V4, P1; KANTER AD, 1981, J BEHAV MED, V4, P1; Kaplan B H, 1977, Med Care, V15, P47, DOI 10.1097/00005650-197705001-00006; LEFCOURT HM, 1985, SOCIAL SUPPORT THEOR, P155; Lezak M.D., 1983, NEUROPSYCHOLOGICAL A; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; LEZAK MD, 1986, REHABIL PSYCHOL, V31, P241, DOI 10.1037//0090-5550.31.4.241; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; LONG CJ, 1984, J REHABIL, V50, P39; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; PANTING A, 1982, REHABILITATION, V38, P33; Prigatano GP, 1986, NEUROPSYCHOL REHABIL, P1; RICHARDSON JTE, 1990, CLIN NEUROPSYCHOLOGI; RIMEL RW, 1983, REHABILITATION HEAD, P9; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; ZEIGLER EA, 1987, J REHABIL, V53, P50	34	42	46	0	5	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN	1996	10	1					27	38					12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	TY049	WOS:A1996TY04900003	8680390				2021-06-18	
J	Tchelingerian, JL; LeSaux, F; Jacque, C				Tchelingerian, JL; LeSaux, F; Jacque, C			Identification and topography of neuronal cell populations expressing TNF alpha and IL-1 alpha in response to hippocampal lesion	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						brain trauma; cytokines; TNF alpha; IL-1 alpha; neurons	NERVE GROWTH-FACTOR; CORTICOTROPIN-RELEASING FACTOR; CULTURED SYMPATHETIC NEURONS; RAT-BRAIN; HYPOTHALAMUS INVIVO; CYTOKINE REGULATION; MESSENGER-RNA; INTERLEUKIN-1; LOCALIZATION; FOREBRAIN	In previous studies, we have shown that a traumatic lesion to the hippocampus of adult mice induces the transitory expression of TNF alpha and IL-1 alpha. by neurons of different brain areas and also by glial cells at the site of injury, The aim of the present study was to establish whether the expression of TNF alpha and IL-1 alpha is restricted to defined subpopulations, or else is common to most of the central neuronal populations, Using polyclonal anti-GAD 67, anti-TH and monoclonal anti-ChAT, and anti-5-HT antibodies in a double-labeling immunohistochemical procedure in combination with murine anti-TNF alpha and anti-IL-1 alpha polyclonal antibodies, we show that most GABAergic, catecholaminergic, and serotoninergic neurons, and a subgroup of the cholinergic neurons, express these cytokines, Although not immunohistochemically characterized, neurons in some glutamatergic structures such as the hippocampus and the prefrontal cortex also express these cytokines. Thus, we conclude that the capacity of central neurons to express cytokines like TNF alpha and IL-1 alpha in reaction to a brain injury is not restricted to peculiar neuronal subtypes, but could include most of the neuronal populations of the brain. (C) 1996 Wiley-Liss, Inc.		Tchelingerian, JL (corresponding author), HOP LA PITIE SALPETRIERE, INSERM U134, 47 BLD HOP, F-75651 PARIS 13, FRANCE.						ALHEIM K, 1991, P NATL ACAD SCI USA, V88, P9302, DOI 10.1073/pnas.88.20.9302; BANDTLOW CE, 1990, J CELL BIOL, V111, P1701, DOI 10.1083/jcb.111.4.1701; BARTFAI T, 1993, NEUROCHEM INT, V22, P435, DOI 10.1016/0197-0186(93)90038-7; BERKENBOSCH F, 1987, SCIENCE, V238, P524, DOI 10.1126/science.2443979; BREDER CD, 1993, J COMP NEUROL, V337, P543, DOI 10.1002/cne.903370403; BREDER CD, 1988, SCIENCE, V240, P321, DOI 10.1126/science.3258444; BRENNEMAN DE, 1992, J NEUROCHEM, V58, P454, DOI 10.1111/j.1471-4159.1992.tb09743.x; BUTTINI M, 1994, MOL BRAIN RES, V23, P126, DOI 10.1016/0169-328X(94)90218-6; CHENG B, 1994, NEURON, V12, P139, DOI 10.1016/0896-6273(94)90159-7; CUNNINGHAM ET, 1993, IMMUNOL TODAY, V14, P171; ELENKOV IJ, 1992, J NEUROIMMUNOL, V41, P117, DOI 10.1016/0165-5728(92)90203-W; FREIDIN M, 1992, P NATL ACAD SCI USA, V89, P10440, DOI 10.1073/pnas.89.21.10440; KATSUKI H, 1990, EUR J PHARMACOL, V181, P323, DOI 10.1016/0014-2999(90)90099-R; LECHAN RM, 1990, BRAIN RES, V514, P135, DOI 10.1016/0006-8993(90)90445-H; LI ZH, 1992, NEUROREPORT, V3, P91, DOI 10.1097/00001756-199201000-00024; MEHLER MF, 1993, NATURE, V362, P62, DOI 10.1038/362062a0; MILENKOVIC L, 1989, P NATL ACAD SCI USA, V86, P2418, DOI 10.1073/pnas.86.7.2418; MILLER LG, 1991, MOL PHARMACOL, V39, P105; MINAMI M, 1992, J NEUROCHEM, V58, P390, DOI 10.1111/j.1471-4159.1992.tb09324.x; MOHANKUMAR PS, 1991, LIFE SCI, V48, P925, DOI 10.1016/0024-3205(91)90040-I; MOHANKUMAR PS, 1993, BRAIN RES BULL, V31, P745, DOI 10.1016/0361-9230(93)90151-Z; POUSSET F, 1994, DEV BRAIN RES, V81, P143, DOI 10.1016/0165-3806(94)90078-7; ROTHWELL NJ, 1991, TRENDS PHARMACOL SCI, V12, P430, DOI 10.1016/0165-6147(91)90623-Z; SAPOLSKY R, 1987, SCIENCE, V238, P522, DOI 10.1126/science.2821621; SCARBOROUGH DE, 1989, ENDOCRINOLOGY, V124, P549, DOI 10.1210/endo-124-1-549; SCHETTINI G, 1990, PROG NEUROENDOCRINIM, V3, P157; SHINTANI F, 1993, J NEUROSCI, V13, P3574; SOLIVEN B, 1992, J NEUROSCI, V12, P2665; TANCREDI V, 1992, NEUROSCI LETT, V146, P176, DOI 10.1016/0304-3940(92)90071-E; TCHELINGERIAN JL, 1994, NEUROREPORT, V5, P585, DOI 10.1097/00001756-199401000-00013; TCHELINGERIAN JL, 1993, NEURON, V10, P213, DOI 10.1016/0896-6273(93)90312-F; YOSHIDA K, 1992, BRAIN RES, V569, P14, DOI 10.1016/0006-8993(92)90364-F	32	42	42	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	JAN 1	1996	43	1					99	106		10.1002/jnr.490430113			8	Neurosciences	Neurosciences & Neurology	TT360	WOS:A1996TT36000012	8838580				2021-06-18	
J	HAMM, RJ; PIKE, BR; TEMPLE, MD; ODELL, DM; LYETH, BG				HAMM, RJ; PIKE, BR; TEMPLE, MD; ODELL, DM; LYETH, BG			THE EFFECT OF POSTINJURY KINDLED SEIZURES ON COGNITIVE PERFORMANCE OF TRAUMATICALLY BRAIN-INJURED RATS	EXPERIMENTAL NEUROLOGY			English	Article							PROPHYLACTICALLY ADMINISTERED PHENYTOIN; CLOSED HEAD-INJURY; POSTTRAUMATIC SEIZURES; PENTYLENETETRAZOL; MK-801; IMPAIRMENT; RECOVERY; DEFICITS; FAILURE; ACID	The purpose of this experiment was to examine the consequences of postinjury seizures on cognitive performance after experimental traumatic brain injury (TBI). Rats either were injured at a moderate (2.1 atm) level of central fluid percussion TBI (n = 16) or were surgically prepared but did not receive a fluid pulse (sham-injured control, n = 16). Beginning 24 h after TBI, injured animals were injected (ip) once daily (Days 1-24 postinjury) with either saline (n = 8) or 25 mg/kg pentylenetetrazol (PTZ) (n = 8). Sham-injured rats were injected with an equal volume of saline (n = 8) or PTZ (n = 8). In both injured and sham injured animals, daily injections of PTZ resulted in an increase in the severity of behavioral seizures over days. On Days 25-29 after injury or sham injury, all animals were tested in the Morris water maze (MWM). Analysis of maze performance indicated that in sham injured animals PTZ-produced seizures had a detrimental effect on performance. In injured animals, however, PTZ-treated animals exhibited significantly faster acquisition and better terminal performance in the MWM than did untreated injured animals. These results show that posttraumatic kindled seizures do not exacerbate behavioral deficits after TBI and may, in fact, improve recovery following injury. The findings of this experiment are consistent with the hypothesis that post-TBI neuronal depression may contribute to behavioral morbidity following injury. (C) 1995 Academic Press, Inc.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DIV NEUROSURG,RICHMOND,VA 23284	HAMM, RJ (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PSYCHOL,RICHMOND,VA 23284, USA.			Lyeth, Bruce/0000-0003-4811-1474	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 12587] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS012587, P50NS012587] Funding Source: NIH RePORTER		ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; BARKAI E, 1994, J NEUROPHYSIOL, V72, P72; BARTH TM, 1990, STROKE, V21, P153; BECKER A, 1992, BEHAV NEURAL BIOL, V57, P37, DOI 10.1016/0163-1047(92)90735-M; BRAILOWSKY S, 1986, BRAIN RES, V362, P322, DOI 10.1016/0006-8993(86)90457-9; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879; CHOU C-L, 1991, Society for Neuroscience Abstracts, V17, P722; CORDA MG, 1992, J PHARMACOL EXP THER, V262, P792; CORDA MG, 1991, PHARMACOL BIOCHEM BE, V40, P329, DOI 10.1016/0091-3057(91)90562-G; DEWITT DS, 1988, ANESTHESIOLOGY REV, V15, P31; DIETRICH WD, 1994, J NEUROTRAUM, V6, P629; DIKMEN SS, 1991, JAMA-J AM MED ASSOC, V265, P1271, DOI 10.1001/jama.265.10.1271; DIXON CE, 1994, J NEUROTRAUM, V11, P275, DOI 10.1089/neu.1994.11.275; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Dugan Ellen M., 1994, Emergency Medicine Clinics of North America, V12, P1081; Feeney D M, 1987, Brain Inj, V1, P27, DOI 10.3109/02699058709034441; FEENEY DM, 1991, J NEUROL REHABIL, V5, P113; FOY PM, 1992, J NEUROL NEUROSUR PS, V77, P753; GIORGI O, 1991, EUR J PHARMACOL, V193, P363, DOI 10.1016/0014-2999(91)90152-G; GODDARD GV, 1969, EXP NEUROL, V25, P295, DOI 10.1016/0014-4886(69)90128-9; GRECKSCH G, 1991, PHARMACOL BIOCHEM BE, V39, P825, DOI 10.1016/0091-3057(91)90174-Z; HAMM RJ, 1992, NEUROSURGERY, V31, P1072, DOI 10.1227/00006123-199212000-00013; HAMM RJ, 1994, J NEUROSURG, V81, P267, DOI 10.3171/jns.1994.81.2.0267; HERNANDEZ TD, 1988, EXP NEUROL, V103, P318; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; HUMPEL C, 1993, NEUROSCIENCE, V53, P909, DOI 10.1016/0306-4522(93)90476-V; KENNEDY CR, 1986, J HEAD TRAUMA REHAB, V1, P66; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; KULKARNI SK, 1994, METHOD FIND EXP CLIN, V16, P735; LEE ST, 1992, J NEUROSURG, V76, P435, DOI 10.3171/jns.1992.76.3.0435; LEONARD JR, 1994, J NEUROTRAUM, V11, P379, DOI 10.1089/neu.1994.11.379; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MASSAGLI TL, 1991, ARCH PHYS MED REHAB, V72, P219; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; OHNO K, 1993, J NEUROL NEUROSUR PS, V56, P1231, DOI 10.1136/jnnp.56.11.1231; PAZDERNIK TL, 1985, NEUROSCIENCE, V14, P823, DOI 10.1016/0306-4522(85)90146-0; PIERCE JES, 1993, BRAIN RES, V624, P199, DOI 10.1016/0006-8993(93)90078-2; SCHALLERT T, 1986, BRAIN RES, V379, P104, DOI 10.1016/0006-8993(86)90261-1; SMITH DB, 1991, ADV NEUROLOGY, V55; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SMITH KR, 1994, ARCH NEUROL-CHICAGO, V51, P653, DOI 10.1001/archneur.1994.00540190029012; Temkin N R, 1991, Neurosurg Clin N Am, V2, P425; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; VOIGT JP, 1990, BIOMED BIOCHIM ACTA, V49, P143; WATSON CW, 1945, J NEUROPHYSIOL, V8, P221; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; YOUNG B, 1983, J NEUROSURG, V58, P236, DOI 10.3171/jns.1983.58.2.0236; YOUNG B, 1983, J NEUROSURG, V58, P231, DOI 10.3171/jns.1983.58.2.0231	50	42	42	0	1	ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS	SAN DIEGO	525B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495	0014-4886			EXP NEUROL	Exp. Neurol.	DEC	1995	136	2					143	148		10.1006/exnr.1995.1091			6	Neurosciences	Neurosciences & Neurology	TK258	WOS:A1995TK25800006	7498404				2021-06-18	
J	CHOE, BY; SUH, TS; CHOI, KH; SHINN, KS; PARK, CK; KANG, JK				CHOE, BY; SUH, TS; CHOI, KH; SHINN, KS; PARK, CK; KANG, JK			NEURONAL DYSFUNCTION IN PATIENTS WITH CLOSED-HEAD INJURY EVALUATED BY IN-VIVO H-1 MAGNETIC-RESONANCE SPECTROSCOPY	INVESTIGATIVE RADIOLOGY			English	Article						MAGNETIC RESONANCE SPECTROSCOPY; CLOSED HEAD INJURY	DIFFUSE AXONAL INJURY; STIMULATED ECHOES; NMR-SPECTROSCOPY; MR SPECTROSCOPY; CONSCIOUSNESS; INVIVO; TUMORS; MILD; COMA	RATIONALE AND OBJECTIVES. With the use of localized, water-suppressed in vivo H-1 magnetic resonance spectroscopy (MRS), the proton metabolic alterations of white matter in patients with closed head injury (CHI) and healthy controls are evaluated, and metabolic alterations with Glasgow Outcome Scale (GOS) scores are compared, METHODS. Patients with CHI (n = 10) and healthy control subjects (n = 10) underwent MRS examinations using a stimulated-echo acquisition mode pulse sequence that provided 2 X 2 X 2 cm(3) volume of interest in the left frontoparietal white matter, Proton metabolite ratios relative to creatine were obtained using a Marquart algorithm, RESULTS. The specific feature in patients with CHI was significant decrease of N-acetylaspartate (NAA)/creatine ratio compared with normal controls, No clear correlation of other metabolite ratios such as choline/creatine and inositols creatine was established, The level of NAA/creatine ratio was significantly correlated with GOS, CONCLUSIONS. Results of this preliminary study suggest that the reduction of NAA/creatine ratio may indicate neuronal loss in patients with CHI. The NAA/creatine ratio may serve as a metabolic criterion to predict the GOS of patients with CHI, Thus, in vivo H-1 MRS may be a useful modality in the clinical evaluation of patients with CHI based on the proton metabolite concentrations of cerebral white matter.	CATHOLIC UNIV, KANGNAM ST MARYS HOSP, COLL MED, DEPT NEUROSURG, SEOUL 137040, SOUTH KOREA	CHOE, BY (corresponding author), CATHOLIC UNIV, KANGNAM ST MARYS HOSP,COLL MED,DEPT RADIOL, SEOUCHO KU, 505 BANPO DONG, SEOUL 137040, SOUTH KOREA.						ADAMS JH, 1984, GREENFIELDS NEUROPAT, P85; AUE WP, 1987, ANN NY ACAD SCI, V508, P360, DOI 10.1111/j.1749-6632.1987.tb32917.x; BOTTOMLEY PA, 1989, RADIOLOGY, V170, P1; BREITER SN, 1992, SOC MAGNETIC RESONAN, V1, P644; CROOKS DA, 1991, J PATHOL, V165, P5, DOI 10.1002/path.1711650103; CROOKS DA, 1991, NEUROPATH APPL NEURO, V17, P421, DOI 10.1111/j.1365-2990.1991.tb00742.x; FRAHM J, 1987, J MAGN RESON, V72, P502, DOI 10.1016/0022-2364(87)90154-5; FRAHM J, 1989, MAGNET RESON MED, V9, P79, DOI 10.1002/mrm.1910090110; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTRY LR, 1988, AM J NEURORADIOL, V9, P101, DOI 10.2214/ajr.150.3.663; HARDY CJ, 1988, MAGNET RESON MED, V8, P104, DOI 10.1002/mrm.1910080113; JARVIK JG, 1993, RADIOLOGY, V186, P739, DOI 10.1148/radiology.186.3.8430182; JENNETT B, 1975, LANCET, V1, P480; KREIS R, 1991, NMR BIOMED, V4, P109, DOI 10.1002/nbm.1940040214; KUGEL H, 1992, RADIOLOGY, V183, P701, DOI 10.1148/radiology.183.3.1584924; LEVIN HS, 1988, J NEUROSURG, V69, P861, DOI 10.3171/jns.1988.69.6.0861; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; NADJMI MR, 1981, KRANIELLE COMPUTER T; NADLER JV, 1972, J NEUROCHEM, V19, P313, DOI 10.1111/j.1471-4159.1972.tb01341.x; Ordidge R., 1985, MAGNETIC RESONANCE B, P387; PETROFF OAC, 1992, NEUROLOGY, V42, P1349, DOI 10.1212/WNL.42.7.1349; Pilz P, 1983, Acta Neurochir Suppl (Wien), V32, P119; POSNER MI, 1987, NEUROBEHAVIORAL RECO, P390; PRAYER L, 1993, ACTA RADIOL, V34, P593; ROSS B, 1992, EUR J RADIOL, V14, P128, DOI 10.1016/0720-048X(92)90226-Y; TEASDALE G, 1974, LANCET, V2, P81; Wilson JTL, 1989, NEUROPSYCHOLOGY, V3, P255, DOI 10.1037//0894-4105.3.4.255; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391; ZOMEREN AHV, 1987, NEUROBEHAVIORAL RECO, P398	30	42	44	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0020-9996	1536-0210		INVEST RADIOL	Invest. Radiol.	AUG	1995	30	8					502	506		10.1097/00004424-199508000-00008			5	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	RW469	WOS:A1995RW46900008	8557517				2021-06-18	
J	LEVIN, HS				LEVIN, HS			NEUROBEHAVIORAL OUTCOME OF CLOSED-HEAD INJURY - IMPLICATIONS FOR CLINICAL-TRIALS	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	Head Injury 1994 - International Symposium on Head Injury Research	OCT 12-14, 1994	WASHINGTON, DC	Natl Highway Traff Safety Adm, Head Injury Res Program, George Washington Univ		CLOSED HEAD INJURY; GLASGOW OUTCOME SCALE; POSTTRAUMATIC AMNESIA; NEUROBEHAVIORAL SEQUELAE	TRAUMATIC BRAIN INJURY; BEHAVIORAL SEQUELAE; RATING-SCALE; MEMORY; RECOVERY; DISABILITY; ADOLESCENTS; ORIENTATION; COGNITION; SYMPTOMS	This review encompasses the neurobehavioral sequelae of moderate to severe closed head injury (CHI). Following a discussion of posttraumatic amnesia and its measurement, the paper discusses assessment of the global outcome of CHI using the Glasgow Outcome Scale, Domains of residual neurobehavioral sequelae that are reviewed include attention/information processing speed, memory, language, intellectual ability, executive functions, and motor speed. The contribution of behavioral disturbance and psychosocial maladjustment to overall outcome is reviewed, as is the impact on the family, Finally, the neurobehavioral outcome measures for clinical trials involving moderate to severe head-injured patients are presented, Caveats for completing clinical trials that involve assessment of neurobehavioral functioning are provided.		LEVIN, HS (corresponding author), UNIV MARYLAND,MED SYST,DIV NEUROSURG,22 S GREEN ST,12TH FLOOR,BALTIMORE,MD 21201, USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS21889] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER		ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; [Anonymous], 1944, ARMY INDIVIDUAL TEST; Benton A., 1976, MULTILINGUAL APHASIA; BENTON AL, 1968, NEUROPSYCHOLOGIA, V6, P53, DOI 10.1016/0028-3932(68)90038-9; BOHNEN N, 1992, ACTA NEUROL SCAND, V85, P116, DOI 10.1111/j.1600-0404.1992.tb04009.x; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; CHOI SC, 1994, J NEUROSURG, V81, P169, DOI 10.3171/jns.1994.81.2.0169; CLIFTON GL, 1992, NEUROSURGERY, V31, P975, DOI 10.1227/00006123-199211000-00028; CLIFTON GL, 1993, NEUROSURGERY, V33, P34; DAMASIO H, 1994, SCIENCE, V264, P1102, DOI 10.1126/science.8178168; EWERT J, 1989, ARCH NEUROL-CHICAGO, V46, P911, DOI 10.1001/archneur.1989.00520440105027; GOLDSTEIN FC, 1991, BRAIN COGNITION, V17, P23, DOI 10.1016/0278-2626(91)90063-E; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; GRONWALL D, 1975, LANCET, V2, P995; GRONWALL D, 1980, Journal of Clinical Neuropsychology, V2, P51, DOI 10.1080/01688638008403780; GRONWALL D, 1974, LANCET, V2, P605; HANNAY HJ, 1985, J CLIN EXP NEUROPSYC, V7, P251, DOI 10.1080/01688638508401258; HEILMAN KM, 1971, J NEUROL NEUROSUR PS, V34, P265, DOI 10.1136/jnnp.34.3.265; HIGH WM, 1990, J CLIN EXP NEUROPSYC, V12, P703, DOI 10.1080/01688639008401013; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; JENNETT WB, 1969, CURRENT PROBLEMS NEU; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; JORGE RE, 1994, J AFFECT DISORDERS, V27, P233; KLOVE H, 1963, MED CLIN N AM, P1647; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; LEVIN HS, 1986, J CLIN EXP NEUROPSYC, V8, P643, DOI 10.1080/01688638608405185; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P1294, DOI 10.1136/jnnp.51.10.1294; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LEVIN HS, 1991, NEUROSURGERY, V28, P196, DOI 10.1227/00006123-199102000-00004; LEVIN HS, 1976, J NEUROL NEUROSUR PS, V39, P1062, DOI 10.1136/jnnp.39.11.1062; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LEVIN HS, 1994, NEUROPSYCHOLOGY, V8, P171, DOI DOI 10.1037/0894-4105.8.2.171; LEVIN HS, 1989, MILD MODERATE HEAD I, P153; LEVIN HS, 1982, NEUROBEHAVIORAL CONS, P63; LEWIS RJ, 1990, ANN EMERG MED, V19, P1047, DOI 10.1016/S0196-0644(05)82570-3; MAAS AIR, 1983, J NEUROSURG, V58, P321, DOI 10.3171/jns.1983.58.3.0321; MANDELSOHN D, 1992, CHILD NERV SYST, V8, P445; MANDLEBERG IA, 1975, J NEUROL NEUROSUR PS, V38, P1121, DOI 10.1136/jnnp.38.11.1121; MATTSON AJ, 1994, J NEUROL NEUROSUR PS, V57, P818, DOI 10.1136/jnnp.57.7.818; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; REITAN RM, 1985, HALSTEAD REITAN NEUR, P10; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROBINSON RG, 1981, ANN NEUROL, V9, P447, DOI 10.1002/ana.410090506; STARKSTEIN SE, 1991, BIOL PSYCHIAT, V29, P149, DOI 10.1016/0006-3223(91)90043-L; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; TATE RL, 1991, J NERV MENT DIS, V179, P117, DOI 10.1097/00005053-199103000-00001; VANZOMEREN AH, 1978, J NEUROL NEUROSUR PS, V41, P452, DOI 10.1136/jnnp.41.5.452; Wechsler D., 2008, WECHSLER ADULT INTEL	60	42	43	0	2	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	AUG	1995	12	4					601	610		10.1089/neu.1995.12.601			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	RY920	WOS:A1995RY92000011	8683611				2021-06-18	
J	SIEGEL, JH				SIEGEL, JH			THE EFFECT OF ASSOCIATED INJURIES, BLOOD-LOSS, AND OXYGEN DEBT ON DEATH AND DISABILITY IN BLUNT TRAUMATIC BRAIN INJURY - THE NEED FOR EARLY PHYSIOLOGICAL PREDICTORS OF SEVERITY	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	Head Injury 1994 - International Symposium on Head Injury Research	OCT 12-14, 1994	WASHINGTON, DC	Natl Highway Traff Safety Adm, Head Injury Res Program, George Washington Univ		TRAUMATIC BRAIN INJURY; SECONDARY INSULT; HYPOVOLEMIA; MORBIDITY	MORTALITY; VOLUME; SHOCK	Studies of 4590 patients with blunt trauma injuries admitted to a Level I Trauma Center, have shown that 37% had a blunt traumatic brain injury (BTBI). Of these brain injured patients 60% has an associated other injury, Examination of mortality has shown that those with an isolated brain injury had an 11% mortality compared with 21.8% in those with an associated systemic injury, Further investigation demonstrated that the cause of the increased mortality was related to the blood loss associated with the injuries and that when hypovolemic shock resulted, mortality rose from 12.8 to 62%. The severity of the associated injuries effect on the brain injured patient could be estimated by a parameter of oxygen debt, the base deficit and this allowed for a quantitative estimate of the probability of death as an index of severity, A combined linear logistic model using the admission Glasgow Coma Score (GCS) as a measure of brain injury and the base deficit as a measure of physiologic injury provides such a predictive score, The effect of associated injuries in patients with moderate brain injury (AIS 2,3) was to increase the average total cost of medical care in the first year of injury by three-fold ($12,489 to $36,177) and for severe brain injury (AIS 4,5) to increase average cost from $59,000 in isolated BTBI to $90,000 in BTBI with associated injury, The high incidence of brain injuries in motor vehicle crashes (MVC) caused by lateral impacts and their association with other side-impact injuries (lungs, spleen, kidney, and pelvic fractures) in which large blood volume losses are common, focuses attention on the need for side impact protection standards that simultaneously protect brain, thoracoabdominal viscera, and pelvis as a means of reducing the severity and cost of lateral impact MVCs.	UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT ANAT CELL BIOL & INJURY SCI,NEWARK,NJ 07103	SIEGEL, JH (corresponding author), UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,NEW JERSEY TRAUMA CTR,DEPT SURG,185 S ORANGE AVE,NEWARK,NJ 07103, USA.						ADDIS MD, 1994, UNPUB J TRAUMA; COOPER PJ, 1987, HEAD INJURY, P1; CROWELL JW, 1991, AM J PHYSIOL, V206, P313; DUNHAM CM, 1991, CRIT CARE MED, V19, P231, DOI 10.1097/00003246-199102000-00020; GENNARELLI TA, 1989, J TRAUMA, V29, P1193, DOI 10.1097/00005373-198909000-00002; LANGFITT TW, 1978, J NEUROSURG, V48, P673, DOI 10.3171/jns.1978.48.5.0673; LAWLESS JF, 1992, STATISTICAL MODELS M; RIVKIND AI, 1989, ANN SURG, V210, P355, DOI 10.1097/00000658-198909000-00012; SACHS L, 1992, APPLIED STATISTICS H; SCHMOKER JD, 1993, J TRAUMA, V35, P627; SIEGEL JH, 1993, J TRAUMA, V34, P736, DOI 10.1097/00005373-199305000-00017; SIEGEL JH, 1993, J TRAUMA, V35, P920, DOI 10.1097/00005373-199312000-00019; SIEGEL JH, 1991, CRIT CARE MED, V19, P1252, DOI 10.1097/00003246-199110000-00007; SIEGEL JH, 1990, ARCH SURG-CHICAGO, V125, P498; SIEGEL JH, 1993, PATHOPHYSIOLOGY SHOC, P626; SIEGEL JH, 1987, TRAUMA EMERGENCY SUR, P201; SOSIN DM, 1986, JAMA-J AM MED ASSOC, V262, P2251; TEASDALE G, 1974, LANCET, V2, P81	18	42	43	0	2	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	AUG	1995	12	4					579	590		10.1089/neu.1995.12.579			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	RY920	WOS:A1995RY92000009	8683609				2021-06-18	
J	DUNN, JT; LEESHALEY, PR; BROWN, RS; WILLIAMS, CW; ENGLISH, LT				DUNN, JT; LEESHALEY, PR; BROWN, RS; WILLIAMS, CW; ENGLISH, LT			NEUROTOXIC COMPLAINT BASE RATES OF PERSONAL-INJURY CLAIMANTS - IMPLICATIONS FOR NEUROPSYCHOLOGICAL ASSESSMENT	JOURNAL OF CLINICAL PSYCHOLOGY			English	Article							CLOSED HEAD-INJURY; IMPAIRMENT	This study reports base rate data for 113 family practice patients with no history of head trauma or toxic exposure, 68 family practice patients with a history of head trauma or toxic exposure, and 156 personal injury claimants with no history of toxic exposure or head trauma who presented for a psychological evaluation due to emotional distress. Personal injury claimants reported suffering from significantly more neurotoxic and neuropsychologic symptoms than subjects with a reported history of head trauma and/or toxic exposure. The authors urge that evaluating psychologists consider the base rate of these symptoms in litigating populations and use caution in relying on self-reported symptoms as evidence of injury when patients are in litigation.	LEES HALEY PSYCHOL CORP, ENCINO, CA USA							Anger W.K., 1985, NEUROTOXICITY IND CO, P51; ANGER WK, 1990, BEHAVIORAL MEASURES, P69; BAKER EL, 1988, ANNU REV PUBL HEALTH, V9, P223; BEAUMONT JG, 1990, BEHAVIORAL MEASURES, P86; COOK PB, 1989, OCCUPATIONAL HLTH HA; COTTROL C, 1993, HOSP COMMUNITY PSYCH, V44, P715; ELWOOD RW, 1993, CLIN PSYCHOL REV, V13, P409, DOI 10.1016/0272-7358(93)90012-B; Fischman M. L., 1988, CHEM HAZARDS WORKPLA; FOX DD, 1994, ARCH CLIN NEUROPSYCH, V9, P211, DOI 10.1016/0887-6177(94)90026-4; GASS CS, 1991, J CLIN PSYCHOL, V47, P100, DOI 10.1002/1097-4679(199101)47:1<100::AID-JCLP2270470116>3.0.CO;2-H; Gibbs MS, 1986, ADV ENVIRON PSYCHOL, V6, P47; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; Hartman DE, 1988, NEUROPSYCHOLOGICAL T; JAMES RC, 1985, IND TOXICOLOGY, P123; Johnson BL, 1990, ADV NEUROBEHAVIORAL; LAVE LB, 1987, CHEM HLTH ENV; Lees-Haley P. R., 1992, FORENSIC REPORTS, V5, P385; LEESHALEY P, 1990, FORENSIC REPORTS, V3, P421; LEESHALEY P, 1989, DEFENSE COUNSEL J, V56, P110; LEESHALEY PR, 1990, PERCEPT MOTOR SKILL, V70, P1379, DOI 10.2466/PMS.70.3.1379-1382; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; Lezak M.D., 1983, NEUROPSYCHOLOGICAL A; MARKOWITZ JS, 1986, ADV ENVIRON PSYCHOL, V6, P89; MARQUIS JK, 1989, GUIDE GENERAL TOXICO; MATARAZZO J. D., 1989, PSYCHOL ASSESSMENT J, V1, P186, DOI DOI 10.1037/1040-3590.1.3.186; Matarazzo J. D., 1987, CLIN NEUROPSYCHOL, V1, P307; MATARAZZO JD, 1990, AM PSYCHOL, V45, P999, DOI 10.1037/0003-066X.45.9.999; MATARAZZO JD, 1988, J CLIN PSYCHOL, V44, P940, DOI 10.1002/1097-4679(198811)44:6<940::AID-JCLP2270440615>3.0.CO;2-A; MEEHL PE, 1960, AM PSYCHOL, V15, P19, DOI 10.1037/h0041744; MEEHL PE, 1955, PSYCHOL ASSESSMENT, V4, P190; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; ODONNELL WE, 1993, J CLIN PSYCHOL, V49, P372, DOI 10.1002/1097-4679(199305)49:3<372::AID-JCLP2270490311>3.0.CO;2-K; REITAN RM, 1992, CLIN NEUROPSYCHOLOGY; RUSSELL RW, 1990, BEHAVIORAL MEASURES, P359; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; RUTHERFORD WH, 1977, LANCET, V1, P1; VANDERKILK BA, 1987, PSYCHOL TRAUMA; WEISBESKI D, 1989, J TRAUMA, V29, P940, DOI 10.1097/00005373-198907000-00006; Weissman HN., 1990, BEHAV SCI LAW, V8, P67, DOI [10.1002/bsl.2370080108, DOI 10.1002/BSL.2370080108]; WILLIAMSON AM, 1990, BEHAVIORAL MEASURES, P56; ZISKIN J, 1988, COPING PSYCHIATRIC P; 1991, INT CLASS DIS	43	42	42	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0021-9762	1097-4679		J CLIN PSYCHOL	J. Clin. Psychol.	JUL	1995	51	4					577	584		10.1002/1097-4679(199507)51:4<577::AID-JCLP2270510418>3.0.CO;2-E			8	Psychology, Clinical	Psychology	RQ994	WOS:A1995RQ99400017	7593681				2021-06-18	
J	KROPFL, A; NAGLIK, H; PRIMAVESI, C; HERTZ, H				KROPFL, A; NAGLIK, H; PRIMAVESI, C; HERTZ, H			UNREAMED INTRAMEDULLARY NAILING OF FEMORAL FRACTURES	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article							SHAFT FRACTURES; MULTIPLE INJURIES; FEMUR; FIXATION; DOG	Seventy-five patients with 81 femoral shaft fractures were treated with unreamed antegrade intramedullary nailing using a titanium alloy implant (AIM femoral nail, ACE Medical) with static interlocking. There were 73 closed fractures and 8 open fractures. Six patients had bilateral femoral shaft fractures. In two cases there was an ipsilateral fracture of the femoral neck, two patients had an ipsilateral intertrochanteric fracture, in one case there was a concomitant subtrochanteric fracture, and four patients had sustained an ipsilateral fracture of the acetabulum in addition to their femoral shaft fractures. In 43 cases (53%) the fracture of the femoral shaft was a comminuted type fracture. Thirty-nine patients (52%) had suffered multiple injuries; the mean Injury Severity Score was 41.2. Sixty-nine fractures were stabilized primarily within 8 hours after admission and 12 fractures were treated secondarily, in a mean of 5.8 days after injury. Closed intramedullary nailing was performed in 73 femora and open nailing with cerclage wiring was done in 8. All 81 nails were implanted unreamed and static was used in every case. The diameters of the nails used were 9 mm (n = 68) and 10 mm (n = 13). Proximal interlocking was distally directed in 76 cases and proximally directed in 5 cases. Two patients died of severe head injuries and one patient died of multiple organ failure. The infection rate was 0%, and uneventful consolidation of the fractures was seen in all cases within a mean of 3.8 months. Neither in the case of nails nor in the case of interlocking bolts did an implant failure occur.		KROPFL, A (corresponding author), UNFALLKRANKENHAUS,TRAUMA CTR SALZBURG,DR FRANZ REHRL PL 5,A-5010 SALZBURG,AUSTRIA.						ALHO A, 1991, J TRAUMA, V31, P49, DOI 10.1097/00005373-199101000-00011; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BUCHOLZ RW, 1987, J BONE JOINT SURG AM, V69A, P1391; CUBBERLY WH, 1988, METALS HDB, V3, P389; FRANKLIN JL, 1988, J BONE JOINT SURG AM, V70A, P1463, DOI 10.2106/00004623-198870100-00004; HAAS N, 1993, INJURY, V24, P49, DOI 10.1016/0020-1383(93)90084-J; HEIM D, 1993, INJURY S3, V24, P56; KEMPF I, 1985, J BONE JOINT SURG AM, V67A, P709, DOI 10.2106/00004623-198567050-00005; KLEIN MPM, 1990, ARCH ORTHOP TRAUM SU, V109, P314, DOI 10.1007/BF00636168; Kuntscher G., 1967, PRACTICE INTRAMEDULL; KYLE RF, 1991, CLIN ORTHOP RELAT R, V267, P169; LATTA L, 1992, S CURR CONC TRAUM CA, P55; MANNING JB, 1983, J TRAUMA, V23, P322, DOI 10.1097/00005373-198304000-00009; OBRIEN PJ, 1991, J TRAUMA, V31, P113, DOI 10.1097/00005373-199101000-00022; PAPE HC, 1992, J TRAUMA, V33, P574, DOI 10.1097/00005373-199210000-00014; PAPE HC, 1993, J TRAUMA, V34, P540, DOI 10.1097/00005373-199304000-00010; PAPE HC, 1992, UNFALLCHIRURG, V95, P634; PELL ACH, 1993, J BONE JOINT SURG BR, V75, P921; Piccioni L, 1992, Orthop Rev, V21, P1213; PRATT DJ, 1987, INJURY, V18, P177, DOI 10.1016/0020-1383(87)90131-8; RHINELANDER FW, 1974, CLIN ORTHOP RELAT R, V105, P34; SCHANDELMAIER P, 1991, CHIRURGISCHES FORUM, P251; STROMBERG L, 1978, ACTA ORTHOP SCAND, V49, P448, DOI 10.3109/17453677808993261; STURMER KM, 1980, UNFALLHEILKUNDE, V83, P346; UHTHOFF HK, 1981, J BONE JOINT SURG BR, V63, P427; WENDA K, 1990, UNFALLCHIRURG, V93, P56; Wenda K, 1993, INJURY S3, V24, P73; WHITE GM, 1986, J BONE JOINT SURG AM, V68A, P865, DOI 10.2106/00004623-198668060-00008; WHITTLE AP, 1992, J BONE JOINT SURG AM, V74A, P1162, DOI 10.2106/00004623-199274080-00005; WINQUIST RA, 1984, J BONE JOINT SURG AM, V66A, P529, DOI 10.2106/00004623-198466040-00006; Wiss D A, 1992, J Orthop Trauma, V6, P159, DOI 10.1097/00005131-199206000-00005; WOZASEK GE, 1994, J TRAUMA, V36, P202, DOI 10.1097/00005373-199402000-00010; ZIMMERMAN KW, 1983, J BONE JOINT SURG BR, V65, P274	33	42	45	0	2	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1079-6061			J TRAUMA	J. Trauma-Injury Inf. Crit. Care	MAY	1995	38	5					717	726					10	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	RD569	WOS:A1995RD56900007	7760398				2021-06-18	
J	BIGLER, ED; SNYDER, JL				BIGLER, ED; SNYDER, JL			NEUROPSYCHOLOGICAL OUTCOME AND QUANTITATIVE NEUROIMAGING IN MILD HEAD-INJURY	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article; Proceedings Paper	Meeting of the National-Academy-of-Neuropsychology	NOV, 1992	PITTSBURGH, PA	NATL ACAD NEUROPSYCHOL			TRAUMATIC BRAIN INJURY; DEGENERATIVE CHANGES; SYMPTOMS; SEQUELAE	Four cases of well-documented mild traumatic brain injury (Glasgow Coma scares greater than or equal to 13) in whom preinjury neuroimaging studies were available (three with computerized tomography and one with magnetic resonance [MR] imaging) were examined in terms of postinjury MR imaging and neuropsychological outcome. All scans were subjected to quantitative analysis by measuring ventricular volumes and calculating a ventricle-to-brain ratio Since ventricular measurements provide an index of parenchymal integrity, any systematic increase in postinjury ventricle size would be an indication of tissue loss. In addition to using the preinjury scan for a within-subject design in comparing postinjury changes, similar MR measures were obtained on a group of medical controls. Despite neuropsychological findings that suggested significant sequelae, quantitative postinjury MR studies did not shot; differences between preinjury neuroimaging or medical control subjects. These findings show no major anatomic abnormalities in mild TBI. Results are discussed in terms of metabolic and/or neurophysiological factors as the basis for persistent neuropsychological sequelae in most cares of mild TBI.	UTAH VALLEY REG MED CTR, REHABIL UNIT, PROVO, UT USA	BIGLER, ED (corresponding author), BRIGHAM YOUNG UNIV, DEPT PSYCHOL, 1086 SWKT, PROVO, UT 84602 USA.						ADAMS KM, 1991, J CLIN EXP NEUROPSYC, V13, P388, DOI 10.1080/01688639108401053; Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; ANDERSON CV, 1994, BRAIN INJURY, V8, P565, DOI 10.3109/02699059409151008; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; Bigler E D, 1991, Arch Clin Neuropsychol, V6, P113, DOI 10.1016/0887-6177(91)90028-8; Bigler E. D., 1990, TRAUMATIC BRAIN INJU; BIGLER ED, 1992, BRAIN RES BULL, V28, P651, DOI 10.1016/0361-9230(92)90119-I; BIGLER ED, 1992, ARCH CLIN NEUROPSYCH, V7, P449, DOI 10.1016/0887-6177(92)90158-J; BIGLER ED, 1988, DIAGNOSTIC CLIN NEUR; Bigler Erin D., 1993, Brain Injury, V7, P125, DOI 10.3109/02699059309008166; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BLATTER DD, IN PRESS AM J NEUROR; BOHNEN N, 1992, J NERV MENT DIS, V180, P683, DOI 10.1097/00005053-199211000-00002; BORNSTEIN RA, 1989, J NEUROSURG, V70, P509, DOI 10.3171/jns.1989.70.4.0509; DACEY R, 1991, J TRAUMA, V31, P217, DOI 10.1097/00005373-199131020-00011; DIKMEN SS, 1989, MILD HEAD INJURY, P229; Eisenberg H. M., 1989, MILD HEAD INJURY, P133; EVANS RW, 1992, PHYSICAL MED REHAB C, V3, P427; FASCHINGBAUER TR, 1974, J CONSULT CLIN PSYCH, V42, P645, DOI 10.1037/h0037049; GENARELLI T, 1986, J HEAD TRAUMA REHAB, V1, P23; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gronwall D, 1989, MILD HEAD INJURY, P153; Heaton R., 1992, COMPREHENSIVE NORMS; Heaton R.K., 1991, COMPREHENSIVE NORMS; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; Lezak M.D., 1983, NEUROPSYCHOLOGICAL A; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MARGULIES S S, 1989, Journal of Biomechanical Engineering, V111, P241; MILLER H, 1961, BRIT MED J, V1, P919, DOI 10.1136/bmj.1.5230.919; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; MOHANTY SK, 1991, J TRAUMA, V31, P801, DOI 10.1097/00005373-199106000-00010; Pawlik G, 1989, NEUROPSYCHOLOGICAL F, P65; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; RADANOV BP, 1993, ARCH NEUROL-CHICAGO, V50, P87, DOI 10.1001/archneur.1993.00540010081022; ROSS DT, 1993, J NEUROTRAUM, V10, P151, DOI 10.1089/neu.1993.10.151; Ruff R. M., 1989, NEUROPSY NEUROPSY BE, V2, P103; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; Ruff RM, 1989, NEUROPSYCHOLOGICAL F, P161; SALAZAR AM, 1992, CHALLENGES NEUROLOGY, P55; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; Spreen O., 1991, COMPENDIUM NEUROPSYC; THATCHER RW, 1989, ELECTROEN CLIN NEURO, V73, P94, DOI 10.1016/0013-4694(89)90188-0; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; YOKOTA H, 1991, J TRAUMA, V31, P351, DOI 10.1097/00005373-199103000-00007; ZAPPALA G, 1992, ARCH CLIN NEUROPSYCH, V7, P145, DOI 10.1016/0887-6177(92)90008-B	51	42	42	0	10	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	MAR-APR	1995	10	2					159	174		10.1016/0887-6177(94)E0003-8			16	Psychology, Clinical; Psychology	Psychology	QJ432	WOS:A1995QJ43200008	14589737	Bronze			2021-06-18	
J	WONG, CW				WONG, CW			CRITERIA FOR CONSERVATIVE TREATMENT OF SUPRATENTORIAL ACUTE SUBDURAL HEMATOMAS	ACTA NEUROCHIRURGICA			English	Article						SUBDURAL HEMATOMA; HEAD INJURY; CONSERVATIVE TREATMENT	TRAUMATIC INTRACEREBRAL HEMATOMAS; EXTRADURAL HEMATOMAS; EPIDURAL HEMATOMAS; HEAD-INJURY; MULTIPLE TRAUMA; HEMORRHAGE; MANAGEMENT; MORTALITY; CHILDREN; PATIENT	Without mortality, 31 patients underwent conservative treatment for traumatic supratentorial acute subdural haematoma (SDH). Later on six of them had the haematoma surgically evacuated mainly because of a deterioration of the Glasgow Coma Scale (GCS)scores. It was found that patients with a midline shift of less than 10 mm on the computed tomography (CT) scans and with a GCS score of 15 initially might be treated conservatively under close observation, reserving urgent craniotomy and evacuation of the SDH for those with deteriorating neurological conditions. A smaller degree of midline shift was tolerated by patients with an GCS score of less than 15: a shift of more than 5 mm on the initial CT scans predicted an exhaustion of the cerebral compensatory mechanism within 3 days of injury. In such cases the GCS score worsened, and surgical evacuation of the SDH became necessary. A total hospital stay of 6 to 7 days may suffice for those who have become fully conscious. Repeal CT studies before discharge should be done and a close follow-up during the first 3 to 4 weeks is advisable.	CHANG GUNG MEM HOSP & MED COLL,DEPT SURG,DIV NEUROSURG,TAIPEI,TAIWAN							AMBROSETTO C, 1962, ARCH NEUROL-CHICAGO, V6, P287, DOI 10.1001/archneur.1962.00450220029005; BENDER MB, 1974, ARCH NEUROL-CHICAGO, V31, P73, DOI 10.1001/archneur.1974.00490380021001; BROWN FD, 1978, J NEUROSURG, V48, P1019, DOI 10.3171/jns.1978.48.6.1019; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; BUCCI MN, 1986, NEUROSURGERY, V19, P65, DOI 10.1227/00006123-198607000-00009; CHEN TY, 1993, NEUROSURGERY, V32, P176, DOI 10.1227/00006123-199302000-00004; ELSNER H, 1990, J NEUROSURG, V72, P813, DOI 10.3171/jns.1990.72.5.0813; GANNON WE, 1962, J NEUROSURG, V19, P865, DOI 10.3171/jns.1962.19.10.0865; INZELBERG R, 1989, CLIN NEUROL NEUROSUR, V91, P85, DOI 10.1016/S0303-8467(89)80014-9; KNUCKEY NW, 1989, J NEUROSURG, V70, P392, DOI 10.3171/jns.1989.70.3.0392; KOBRINE AI, 1977, J NEUROSURG, V46, P256, DOI 10.3171/jns.1977.46.2.0256; LEE ST, 1991, ACTA NEUROCHIR, V113, P121, DOI 10.1007/BF01403196; LOBATO RD, 1991, J NEUROSURG, V75, P256, DOI 10.3171/jns.1991.75.2.0256; LUSINS JO, 1989, MT SINAI J MED, V56, P68; MATHEW P, 1993, ACTA NEUROCHIR, V121, P100, DOI 10.1007/BF01809258; MENDELOW AD, 1985, J NEUROSURG, V63, P43, DOI 10.3171/jns.1985.63.1.0043; MILLER JD, 1990, NEUROSURGERY, V27, P433, DOI 10.1227/00006123-199009000-00016; Miller JD, 1992, NEUROSURG QUART, V2, P28; PANG D, 1983, J NEUROSURG, V59, P958, DOI 10.3171/jns.1983.59.6.0958; PETERSEN OF, 1984, NEURORADIOLOGY, V26, P363, DOI 10.1007/BF00327488; POZZATI E, 1986, NEUROSURGERY, V18, P696, DOI 10.1227/00006123-198606000-00003; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; SERVADEI F, 1989, ACTA NEUROCHIR, V96, P39, DOI 10.1007/BF01403493; SOLONIUK D, 1986, J TRAUMA, V26, P787, DOI 10.1097/00005373-198609000-00003; STONE JL, 1983, SURG NEUROL, V19, P216, DOI 10.1016/S0090-3019(83)80005-6; TANAKA T, 1988, J NEUROSURG, V69, P203, DOI 10.3171/jns.1988.69.2.0203; TEASDALE G, 1974, LANCET, V2, P81; VERLOOY P, 1987, J NEUROL, V234, P254, DOI 10.1007/BF00618260; WAGA S, 1979, SURG NEUROL, V11, P191; WEAVER D, 1981, J NEUROSURG, V54, P248, DOI 10.3171/jns.1981.54.2.0248; WILBERGER JE, 1991, J NEUROSURG, V74, P212, DOI 10.3171/jns.1991.74.2.0212; WONG CW, 1994, ACTA NEUROCHIR, V126, P124, DOI 10.1007/BF01476421; WONG CW, 1995, ACTA NEUROCHIR, V135, P131, DOI 10.1007/BF02187756	33	42	44	0	0	SPRINGER-VERLAG WIEN	VIENNA	SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.		1995	135	1-2					38	43		10.1007/BF02307412			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	RL342	WOS:A1995RL34200006	8748790				2021-06-18	
J	WEHMAN, P; SHERRON, P; KREGEL, J; KREUTZER, J; TRAN, S; CIFU, D				WEHMAN, P; SHERRON, P; KREGEL, J; KREUTZER, J; TRAN, S; CIFU, D			RETURN TO WORK FOR PERSONS FOLLOWING SEVERE TRAUMATIC BRAIN INJURY - SUPPORTED EMPLOYMENT OUTCOMES AFTER 5 YEARS	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						BRAIN; INJURY; WORK; EMPLOYMENT	HEAD-INJURY	Supported employment is a recently developed rehabilitation alternative that is being used to assist individuals with traumatic brain injury to return to work. The present study reports the results of a supported employment program that has placed 80 individuals into competitive employment during a 5-year time period. All individuals had sustained a severe traumatic brain injury; 72% of the injuries involved a motor vehicle. A mean of 6.1 years had passed since injury for all participants, who had been unconscious an average of 48 days. Neuropsychologic evaluation revealed defective cognitive functioning, which contributed to diminished employment potential. A key outcome indicator used to assess return to work capacity is the monthly employment ratio, which is computed by dividing the number of months employed during an employment phase (i.e., pre/post injury) by the total possible months an individual would have the opportunity to be employed. The monthly employment ratio increased from 13% after injury with no supported employment to 67% with supported employment services. The majority of individuals were employed in warehouse, clerical and service-related occupations. A mean of 250 staff intervention hours were required to train and provide follow-up services to program participants.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,CTR TRAUMAT BRAIN INJURY,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PHYS MED & REHABIL,RICHMOND,VA 23298	WEHMAN, P (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DIV REHABIL RES,RICHMOND,VA, USA.			Cifu, David/0000-0003-1600-9387			BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P35, DOI DOI 10.1097/00001199-198703000-00007; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Burke W H, 1988, Brain Inj, V2, P313, DOI 10.3109/02699058809150902; DRESSER AC, 1973, PSYCH MED, V12, P286; KREGEL J, 1992, UNPUB IMPACT BEHAVIO; Lezak M. D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI [10.1097/00001199-198703000-00009, DOI 10.1097/00001199-198703000-00009]; MCMORDIE W R, 1990, Brain Injury, V4, P57, DOI 10.3109/02699059009026149; PECK G, 1984, ANN M INT NEUROPSYCH; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; Sale P., 1991, J HEAD TRAUMA REHAB, V6, P1, DOI [DOI 10.1097/00001199-199109000-00004, 10.1097/00001199-199109000-00004.]; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; Wehman P, 1989, Brain Inj, V3, P397, DOI 10.3109/02699058909004563; Wehman P., 1988, J HEAD TRAUMA REHAB, V3, P82, DOI DOI 10.1097/00001199-198812000-00012; WEHMAN PH, 1990, ARCH PHYS MED REHAB, V71, P1047; WEST M, 1991, ARCH PHYS MED REHAB, V72, P127; 1987, DATA MANAGEMENT SYST	17	42	42	0	4	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	DEC	1993	72	6					355	363					9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	MP702	WOS:A1993MP70200004	8260128				2021-06-18	
J	LYETH, BG; LIU, SL; HAMM, RJ				LYETH, BG; LIU, SL; HAMM, RJ			COMBINED SCOPOLAMINE AND MORPHINE TREATMENT OF TRAUMATIC BRAIN INJURY IN THE RAT	BRAIN RESEARCH			English	Article						OPIOID; SCOPOLAMINE; MORPHINE; TRAUMATIC BRAIN INJURY; FLUID PERCUSSION	ENDOGENOUS OPIOIDS; RESPONSES; BEHAVIOR; NEURONS; FLUID	Previous studies have indicated that either scopolamine (1.0 mg/kg) or morphine (10.0 mg/kg) administered to rats prior to or soon after moderate fluid percussion traumatic brain injury (TBI) reduces behavioral deficits associated with injury. In this study, a series of experiments examined the effects of a combination of these drugs, as well as each drug individually, on behavioral outcome, brain temperature, and systemic physiological responses to TBI. Experiment I: a single systemic bolus injection of scopolamine (n = 10), morphine (n = 11), scopolamine plus morphine (n = 11), or saline (n = 10) was administered to rats 15 min prior to TBI. Animals were assessed on beam-walking behavioral performance for 5 days after injury. Scopolamine alone or morphine alone significantly reduced (P < 0.05) deficits produced by injury. Treatment with a combination of scopolamine and morphine provided greater protection on beam-walking behavioral measures than either drug alone. Experiment II: morphine raised brain temperature in uninjured rats (n = 5) to a mean of 39.3-degrees-C +/- 0.3 by 60 min post-injection. Neither scopolamine (n = 5) nor scopolamine plus morphine (n = 5) altered brain temperature. Experiment III: scopolamine (n = 7) significantly raised heart rate for 5 min after injury. Saline (n = 8), morphine (n = 9) and scopolamine plus morphine (n = 7) significantly lowered heart rate after injury. All four groups had similar hypertensive responses to TBI which peaked at 10 s after injury. The results confirm that pharmacological blockade of muscarinic receptors or stimulation of A opioid receptors reduces functional deficits associated with TBI. The greater protection observed with the combined drug treatment indicates that a cocktail of pharmacological treatments has the potential for providing greater benefit than single drug strategies.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PSYCHOL,DIV NEUROSURG,RICHMOND,VA 23298	LYETH, BG (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT SURG,BOX 693,MCV STN,RICHMOND,VA 23298, USA.			Lyeth, Bruce/0000-0003-4811-1474	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 29995, NS 12587] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS012587, P01NS012587, R01NS029995] Funding Source: NIH RePORTER		BRADLEY PB, 1984, BRIT J PHARMACOL, V83, P763, DOI 10.1111/j.1476-5381.1984.tb16231.x; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; DELAHUNTY TM, 1992, BRAIN RES, V594, P307, DOI 10.1016/0006-8993(92)91140-A; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GORMAN LK, 1989, J NEUROTRAUM, V6, P203; HAYES RL, 1983, J NEUROSURG, V58, P720, DOI 10.3171/jns.1983.58.5.0720; HAYES RL, 1990, J NEUROSURG, V72, P252, DOI 10.3171/jns.1990.72.2.0252; HAYES RL, 1988, J NEUROTRAUM, V5, P287; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; LAPCHAK P A, 1987, Society for Neuroscience Abstracts, V13, P1192; LYETH BG, 1992, BRAIN RES, V569, P281, DOI 10.1016/0006-8993(92)90640-U; LYETH BG, 1988, BRAIN RES, V448, P88, DOI 10.1016/0006-8993(88)91104-3; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; LYETH BG, 1990, 8TH ANN NEUR S; MCINTOSH T K, 1988, Society for Neuroscience Abstracts, V14, P1152; MCINTOSH TK, 1987, AM J PHYSIOL, V253, pE565; MCINTOSH TK, 1987, BRAIN RES, V425, P225, DOI 10.1016/0006-8993(87)90505-1; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; NICOLL RA, 1977, P NATL ACAD SCI USA, V74, P2584, DOI 10.1073/pnas.74.6.2584; NORTH RA, 1979, LIFE SCI, V24, P1527, DOI 10.1016/0024-3205(79)90014-6; OLENIAK L D, 1988, Society for Neuroscience Abstracts, V14, P1151; PERRY DC, 1992, MOL CHEM NEUROPATHOL, V16, P95, DOI 10.1007/BF03159963; ROBINSON S E, 1991, Society for Neuroscience Abstracts, V17, P721; ROBINSON SE, 1989, BRAIN RES, V503, P32, DOI 10.1016/0006-8993(89)91699-5; ROBINSON SE, 1990, BRAIN RES, V511, P141, DOI 10.1016/0006-8993(90)90233-2; ROBINSON SE, 1990, BRAIN RES, V509, P41, DOI 10.1016/0006-8993(90)90306-V; SACHS E, 1957, J NEUROSURG, V14, P22, DOI 10.3171/jns.1957.14.1.0022; SIMONDS WF, 1988, ENDOCR REV, V9, P200, DOI 10.1210/edrv-9-2-200; TOWER DB, 1949, CAN J RES E, V27, P105, DOI 10.1139/cjr49e-016; YAO JJ, 1988, NEUROPEPTIDES, V12, P177, DOI 10.1016/0143-4179(88)90051-0; ZIMMERMAN RS, 1990, NEUROSURGERY, V26, P764, DOI 10.1227/00006123-199005000-00005	34	42	42	1	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	JUL 16	1993	617	1					69	75		10.1016/0006-8993(93)90614-S			7	Neurosciences	Neurosciences & Neurology	LL526	WOS:A1993LL52600010	8374747				2021-06-18	
J	BEHRMANN, DL; BRESNAHAN, JC; BEATTIE, MS				BEHRMANN, DL; BRESNAHAN, JC; BEATTIE, MS			A COMPARISON OF YM-14673, U-50488H, AND NALMEFENE AFTER SPINAL-CORD INJURY IN THE RAT	EXPERIMENTAL NEUROLOGY			English	Article							THYROTROPIN-RELEASING-HORMONE; RECEPTOR ANTAGONIST NALMEFENE; TRAUMATIC BRAIN INJURY; CENTRAL-NERVOUS-SYSTEM; TRH-ANALOG; OPIATE ANTAGONIST; CEREBRAL-ISCHEMIA; MOTOR FUNCTION; PHARMACOLOGICAL ACTIONS; NEUROLOGICAL DEFICITS		OHIO STATE UNIV, NEUROSCI GRAD STUDIES PROGRAM, COLUMBUS, OH 43210 USA	BEHRMANN, DL (corresponding author), OHIO STATE UNIV, DEPT CELL BIOL NEUROBIOL & ANAT, 333 W 10TH AVE, COLUMBUS, OH 43210 USA.		Beattie, Michael S/A-8953-2009		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-10165, NS-07291] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS010165] Funding Source: NIH RePORTER		ARIAS MJ, 1985, SURG NEUROL, V23, P440, DOI 10.1016/0090-3019(85)90226-5; ASKANAS V, 1989, ANN NY ACAD SCI, V553, P325; BAKSHI R, 1990, J NEUROSCI, V10, P3793; BANDA R W, 1987, Neurology, V37, P285; BANDA RW, 1989, ANN NY ACAD SCI, V553, P588; BEATTIE MS, 1989, C P CRITERIA ASSESSI, P16; BEATTIE MS, 1988, PHARM APPROACHES TRE, P43; BEHRMANN DL, 1992, J NEUROTRAUM, V9, P197, DOI 10.1089/neu.1992.9.197; BEHRMANN DL, 1991, SOC NEUR ABSTR, P163; BERMAN D, 1982, PAIN, V13, P307, DOI 10.1016/0304-3959(82)90020-3; BHARGAVA HN, 1986, BRAIN RES, V368, P262, DOI 10.1016/0006-8993(86)90570-6; Black P, 1991, J NEUROTRAUM, V8, P157, DOI 10.1089/neu.1991.8.157; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; BRACKEN MB, 1992, J NEUROSURG, V76, P23, DOI 10.3171/jns.1992.76.1.0023; Bresnahan JC, 1991, J NEUROTRAUM, V8, P91, DOI 10.1089/neu.1991.8.91; BRESNAHAN JC, 1987, EXP NEUROL, V95, P548, DOI 10.1016/0014-4886(87)90299-8; CLARK JA, 1989, J PHARMACOL EXP THER, V251, P461; CONTRERAS PC, 1991, BRAIN RES, V546, P79, DOI 10.1016/0006-8993(91)91161-S; DAS S, 1987, GEN PHARMACOL, V18, P99, DOI 10.1016/0306-3623(87)90178-9; DECOSTA BR, 1989, J MED CHEM, V32, P1996, DOI 10.1021/jm00128a050; DEMEDINACELI L, 1982, EXP NEUROL, V77, P634, DOI 10.1016/0014-4886(82)90234-5; FADEN AI, 1981, SCIENCE, V211, P493, DOI 10.1126/science.7455690; FADEN AI, 1990, ANN NEUROL, V27, P67, DOI 10.1002/ana.410270111; FADEN AI, 1983, PEPTIDES, V4, P631, DOI 10.1016/0196-9781(83)90009-8; FADEN AI, 1990, J PHARMACOL EXP THER, V255, P608; FADEN AI, 1988, BRAIN RES, V448, P287, DOI 10.1016/0006-8993(88)91265-6; FADEN AI, 1989, BRAIN RES, V486, P228, DOI 10.1016/0006-8993(89)90509-X; FADEN AI, 1990, J PHARMACOL EXP THER, V255, P451; FADEN AI, 1988, J PHARMACOL EXP THER, V245, P742; FLAMM ES, 1982, NEUROSURGERY, V10, P227, DOI 10.1227/00006123-198202000-00009; FONE KCF, 1988, BRAIN RES, V455, P157, DOI 10.1016/0006-8993(88)90126-6; GOMEZPINILLA F, 1989, EXP NEUROL, V104, P118, DOI 10.1016/S0014-4886(89)80004-4; HALL ED, 1987, BRAIN RES, V435, P174, DOI 10.1016/0006-8993(87)91599-X; HAYES AG, 1988, J PHARM PHARMACOL, V40, P718, DOI 10.1111/j.2042-7158.1988.tb07002.x; HENSCHEN A, 1988, EXP NEUROL, V102, P125, DOI 10.1016/0014-4886(88)90085-4; HOLADAY JW, 1978, LIFE SCI, V22, P1537, DOI 10.1016/0024-3205(78)90009-7; HOLTZ A, 1989, ACTA NEUROL SCAND, V80, P215, DOI 10.1111/j.1600-0404.1989.tb03865.x; IWASAKI Y, 1989, NEUROSCI LETT, V101, P316, DOI 10.1016/0304-3940(89)90552-1; KIM JP, 1987, EUR J PHARMACOL, V138, P133, DOI 10.1016/0014-2999(87)90349-9; KOREH K, 1981, BIOCHEM BIOPH RES CO, V102, P1317, DOI 10.1016/S0006-291X(81)80155-6; KOSKINEN LOD, 1989, ANN NY ACAD SCI, V553, P353; LUX WE, 1983, NATURE, V302, P822, DOI 10.1038/302822a0; LUX WE, 1983, CIRC SHOCK, V10, P262; MARTINEZARIZALA A, 1988, BRAIN RES, V473, P385, DOI 10.1016/0006-8993(88)90871-2; MCINTOSH TK, 1988, AM J PHYSIOL, V254, pR785; MEANS ED, 1981, J NEUROSURG, V55, P200, DOI 10.3171/jns.1981.55.2.0200; MICHEL ME, 1985, METHOD FIND EXP CLIN, V7, P175; NOYES DH, 1987, EXP NEUROL, V95, P535, DOI 10.1016/0014-4886(87)90298-6; NOYES DH, 1987, MED BIOL ENG COMPUT, V25, P335, DOI 10.1007/BF02447434; Puniak MA, 1991, J NEUROTRAUM, V8, P193, DOI 10.1089/neu.1991.8.193; RIVLIN AS, 1977, J NEUROSURG, V47, P577, DOI 10.3171/jns.1977.47.4.0577; SCHMIDTACHERT KM, 1984, J NEUROCHEM, V43, P586, DOI 10.1111/j.1471-4159.1984.tb00939.x; SILVIA RC, 1987, BRAIN RES, V403, P52, DOI 10.1016/0006-8993(87)90121-1; STOKES BT, 1992, EXP NEUROL, V116, P1, DOI 10.1016/0014-4886(92)90171-L; STOKES BT, 1984, BRAIN RES, V290, P187, DOI 10.1016/0006-8993(84)90753-4; STOKES BT, 1992, J NEUROTRAUM, V9, P187, DOI 10.1089/neu.1992.9.187; TANG A H, 1986, Society for Neuroscience Abstracts, V12, P64; TANG AH, 1985, LIFE SCI, V37, P1475, DOI 10.1016/0024-3205(85)90178-X; TARLOV IM, 1954, AMA ARCH NEUROL PSY, V71, P271, DOI 10.1001/archneurpsyc.1954.02320390001001; VANDENBERGH P, 1988, NEUROLOGY, V38, P452, DOI 10.1212/WNL.38.3.452; VINK R, 1988, BRAIN RES, V460, P184, DOI 10.1016/0006-8993(88)91221-8; VINK R, 1990, J NEUROSCI, V10, P3524; VONVOIGTLANDER PF, 1982, PROG NEURO-PSYCHOPH, V6, P467, DOI 10.1016/S0278-5846(82)80130-9; VONVOIGTLANDER PF, 1983, J PHARMACOL EXP THER, V224, P7; VONVOIGTLANDER PF, 1986, FASEB J, V45, P677; VONVOIGTLANDER PF, 1987, MOL MECHANISMS NEURO, P345; WALLACE MC, 1986, NEUROSURGERY, V19, P489; WEILL C L, 1984, Society for Neuroscience Abstracts, V10, P641; WINER BJ, 1962, STATISTICAL PRINCIPL; YAMAMOTO M, 1989, ARCH INT PHARMACOD T, V300, P29; YAMAMOTO M, 1990, CURR THER RES CLIN E, V47, P781; YAMAMOTO M, 1989, ARCH INT PHARMACOD T, V299, P55; YAMAMOTO M, 1990, ARCH INT PHARMACOD T, V306, P5; YAMAMOTO M, 1991, EUR J PHARMACOL, V192, P165, DOI 10.1016/0014-2999(91)90084-4; YAMAMOTO M, 1989, STROKE, V20, P1089, DOI 10.1161/01.STR.20.8.1089; YAMAMOTO M, 1989, STROKE, V20, P362, DOI 10.1161/01.STR.20.3.362; YAMAMOTO M, 1987, N-S ARCH PHARMACOL, V336, P561; YAMAMOTO M, 1990, EUR J PHARMACOL, V181, P207, DOI 10.1016/0014-2999(90)90080-P; YOUNG W, 1981, J NEUROSURG, V55, P209, DOI 10.3171/jns.1981.55.2.0209; YUM SW, 1990, ARCH NEUROL-CHICAGO, V47, P277, DOI 10.1001/archneur.1990.00530030043014; ZUKIN RS, 1988, P NATL ACAD SCI USA, V85, P4061, DOI 10.1073/pnas.85.11.4061	81	42	46	0	0	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	FEB	1993	119	2					258	267		10.1006/exnr.1993.1028			10	Neurosciences	Neurosciences & Neurology	KL778	WOS:A1993KL77800013	8432363				2021-06-18	
J	WU, AHB; WANG, XM; GORNET, TG; ORDONEZLLANOS, J				WU, AHB; WANG, XM; GORNET, TG; ORDONEZLLANOS, J			CREATINE-KINASE MB ISOFORMS IN PATIENTS WITH SKELETAL-MUSCLE INJURY - RAMIFICATIONS FOR EARLY DETECTION OF ACUTE MYOCARDIAL-INFARCTION	CLINICAL CHEMISTRY			English	Article						THROMBOLYTIC THERAPY; EXERCISE, EFFECTS OF; STROKE; CLOSED HEAD INJURY; SCLERODERMA; ISOENZYMES	ISOENZYME-MB; EARLY DIAGNOSIS; TROPONIN-T; SERUM; MASS; MM; MYOGLOBIN; SUBFORMS; DAMAGE; ASSAY	We measured total creatine kinase (CK), CK-MB isoenzyme, and the MB isoforms in 202 serum and plasma samples from nine groups of patients and normal individuals: 39 with acute myocardial infarction (MI), divided according to time between the onset of chest pain and blood collection (1-6 h, 7-12 h, and 13-48 h); 26 with chest pain for whom an MI was ruled out, sampled at admission; 17 undergoing bypass surgery or cardiac catheterization, sampled within 6 h after either procedure; 17 with acute skeletal muscle injury, sampled within 8 h after injury; 30 marathon runners immediately after a race; 17 runners and other athletes >12 h after training or a race; 12 with cerebral injury or seizures, sampled at admission; 8 with closed head injury, sampled at admission; and 38 normal subjects. CK-MB (relative index) and MB isoforms (MB2/MB1) were respectively increased in 15% and 75% of MI patients 1-6 h after onset, 94% and 94% after 7-12 h, and 88% and 8% after 12 h, and in 87% and 82% of cardiac surgery patients. MB isoforms were increased in most patients with acute skeletal muscle trauma and in subjects examined after exercise, but were within normal limits in patients for whom MI was ruled out, patients with cerebral trauma, and normal individuals. The relative index of MB/total CK was normal in essentially all individuals in the last groups, including those with acute skeletal muscle trauma. We concluded that the CK-MB isoform ratio is increased in both acute skeletal muscle injury and MI. The isoform ratio is most useful for distinguishing recent from old (>12 h) injury.	UNIV TEXAS,SCH MED,DEPT PATHOL,HOUSTON,TX 77030; HUNAN MED UNIV,DEPT BIOCHEM,CHANGSHA,PEOPLES R CHINA; HOSP ST CRUE & ST PAU,SERVEI BIOQUIM,BARCELONA,SPAIN			Ordonez-Llanos, Jordi/B-4961-2011; Ordonez-Llanos, Jorge/N-1126-2019; Ordonez-Llanos, Jorge/A-9335-2010; Ordonez-Llanos, Jorge/AAE-3088-2020	Ordonez-Llanos, Jordi/0000-0003-4896-5832; Ordonez-Llanos, Jorge/0000-0003-4896-5832; Ordonez-Llanos, Jorge/0000-0003-4896-5832			ANNESLEY TM, 1985, CLIN CHEM, V31, P402; BODOR G, 1990, CLIN CHEM, V36, P1103; BRUNS DE, 1989, CLIN CHEM, V35, P705; CHAPELLE JP, 1981, CLIN CHIM ACTA, V115, P255, DOI 10.1016/0009-8981(81)90239-4; ELALLAF M, 1986, CLIN CHEM, V32, P291; GERHARDT W, 1991, CLIN CHEM, V37, P1405; GIBLER WB, 1987, ANN EMERG MED, V16, P851; GRAEBER GM, 1985, SURG CLIN N AM, V65, P539; GULBIS B, 1990, CLIN CHEM, V36, P1784; HARKER CC, 1990, CLIN CHEM, V36, P1128; JACKOWSKI G, 1989, CIRCULATION, V30, P854; KESHGEGIAN AA, 1988, CLIN CHEM, V34, P1067; KOCH TR, 1986, CLIN CHEM, V32, P186; KONNIGS CH, 1989, ANN CLIN BIOCHEM, V26, P254; LIU N, 1992, Clinical Chemistry, V38, P984; MAIR J, 1991, CLIN CHEM, V37, P845; NEUIER D, 1981, CREATINE KINASE ISOE, P85; PANTEGHINI M, 1986, CLIN CHIM ACTA, V155, P1, DOI 10.1016/0009-8981(86)90093-8; PULEO P R, 1992, Journal of the American College of Cardiology, V19, p303A; PULEO PR, 1990, CIRCULATION, V82, P759, DOI 10.1161/01.CIR.82.3.759; PULEO PR, 1989, CLIN CHEM, V35, P1452; SCHULTZ A, 1986, AM HEART J, V112, P609, DOI 10.1016/0002-8703(86)90529-6; SCHWARTZ JG, 1989, CLIN CHEM, V35, P651; SCHWARZ F, 1982, AM J CARDIOL, V50, P933, DOI 10.1016/0002-9149(82)90398-8; SIEGEL AJ, 1981, JAMA-J AM MED ASSOC, V246, P2049, DOI 10.1001/jama.246.18.2049; THOMPSON WG, 1988, CLIN CHEM, V34, P2208; WANG J, 1989, CLIN CHIM ACTA, V181, P325, DOI 10.1016/0009-8981(89)90238-6; WU AHB, 1989, CLIN CHEM, V35, P1752; WU AHB, 1987, CLIN CHEM, V33, P359; 1985, NEW ENGL J MED, V312, P923	30	42	42	0	1	AMER ASSOC CLINICAL CHEMISTRY	WASHINGTON	2101 L STREET NW, SUITE 202, WASHINGTON, DC 20037-1526	0009-9147			CLIN CHEM	Clin. Chem.	DEC	1992	38	12					2396	2400					5	Medical Laboratory Technology	Medical Laboratory Technology	KD011	WOS:A1992KD01100007	1458574				2021-06-18	
J	CITTAPIETROLUNGO, TJ; ALEXANDER, MA; STEG, NL				CITTAPIETROLUNGO, TJ; ALEXANDER, MA; STEG, NL			EARLY DETECTION OF HETEROTOPIC OSSIFICATION IN YOUNG-PATIENTS WITH TRAUMATIC BRAIN INJURY	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						BONE SCANS; HETEROTOPIC OSSIFICATION; TRAUMATIC BRAIN INJURY	DISODIUM ETIDRONATE; HEAD-INJURY; THERAPY	Heterotopic ossification (HO) is frequently a complication in patients with severe head injury, impeding the rehabilitation process. Detection of HO is often delayed until the appearance of clinical manifestations. To better characterize the frequency and distribution of HO, a three-year prospective study at a pediatric brain injury rehabilitation unit was done. Triple-phase bone scans were performed routinely on all patients. Early intervention followed, with intensive physical therapy and indomethacin. We report an incidence of HO in 25 of 111 cases (22.5%). Of 55 sites identified, the hip was most commonly affected. Clinically significant heterotopic bone impeded the rehabilitation process in five patients (20%), although none of these patients required surgical intervention. Bone scanning identified HO in patients whose symptoms were clinically silent, as well as in those who were symptomatic. In addition, multiple sites of involvement were found in areas not clinically suspect. This study suggests that HO may be more prevalent in young, traumatically brain injured patients than previously suspected.	ALFRED I DUPONT INST,DIV REHABIL,1600 ROCKLAND RD,WILMINGTON,DE 19899; ALFRED I DUPONT INST,DIV PEDIAT REHABIL,WILMINGTON,DE 19899							CHIODO AE, 1987, ARCH PHYS MED REHAB, V68, P645; FREED JH, 1982, PARAPLEGIA, V20, P208, DOI 10.1038/sc.1982.39; GARLAND DE, 1980, J BONE JOINT SURG AM, V62, P1143, DOI 10.2106/00004623-198062070-00012; GARLAND DE, 1988, CLIN ORTHOP RELAT R, V233, P86; Hagen C., 1979, LEVELS COGNITIVE FUN; HARCKE HT, 1986, DIAGNOSTIC RADIOLOGY, P2197; HOFFER MM, 1975, CLIN ORTHOPAEDICS, V110, P244; KALISKY Z, 1985, ARCH PHYS MED REHAB, V66, P25; MITAL MA, 1987, J PEDIATR ORTHOPED, V7, P83, DOI 10.1097/01241398-198701000-00017; RITTER MA, 1985, CLIN ORTHOP RELAT R, V196, P217; ROBERTS P H, 1968, Journal of Bone and Joint Surgery British Volume, V50B, P70; ROGERS JG, 1977, J PEDIATR-US, V91, P1011, DOI 10.1016/S0022-3476(77)80918-9; Rogers R C, 1988, Brain Inj, V2, P169, DOI 10.3109/02699058809150941; SPIELMAN G, 1983, ARCH PHYS MED REHAB, V64, P539; Stover S L, 1976, Paraplegia, V14, P146; STOVER SL, 1975, ARCH PHYS MED REHAB, V56, P199	16	42	45	0	0	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAR	1992	73	3					258	262					5	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	HH123	WOS:A1992HH12300010	1543430				2021-06-18	
J	HEINEMANN, AW; DOLL, MD; ARMSTRONG, KJ; SCHNOLL, S; YARKONY, GM				HEINEMANN, AW; DOLL, MD; ARMSTRONG, KJ; SCHNOLL, S; YARKONY, GM			SUBSTANCE USE AND RECEIPT OF TREATMENT BY PERSONS WITH LONG-TERM SPINAL-CORD INJURIES	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						SPINAL CORD INJURIES; SUBSTANCE ABUSE; SUBSTANCE-USE DISORDERS	HEAD-INJURY; PROBLEM DRINKING; ALCOHOL ABUSERS; SELF-REPORTS; FOLLOW-UP; DRUG; RELIABILITY; ADULTHOOD; VETERANS	The purpose of this study was to assess the rate of self-reported substance use, consequent problems, perceived need for treatment, and receipt of treatment by persons with long-term spinal cord injury (SCI). Information was obtained from 86 persons with traumatic SCI who were between 13 and 58 years of age at injury, cognitively intact, injured more than two years earlier, English speaking, and recruited from two SCI organizations. The mean age of the sample was 39.5 years at recruitment: 69% were men. Participants reported substance use information across four periods covering six months before injury to an average of 13 years after injury. All participants reported use of substances with abuse potential at some time in their lives; the time of greatest use was injury to six months before first interview. The duration of this period ranged from 18 months to 43 years. Problems resulting from substance use were reported by 70%; more than half (52%) the sample reported problems during this postinjury period. Sixteen percent of the sample believed they needed treatment at some time; the time of greatest perceived need was in the period after injury. Treatment for substance abuse was received by 7%. Problems attributable to abuse of both prescription and nonprescription medication were reported, suggesting the importance of close monitoring of substance-use patterns in persons with SCI who are prescribed sedating or narcotic medications. Timely assessment of problems related to substance use and provision of treatment services to persons with traumatic injury are indicated to prevent a potential dual disability.	IIT,DEPT PSYCHOL,CHICAGO,IL 60616; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,RICHMOND,VA 23298	HEINEMANN, AW (corresponding author), NORTHWESTERN UNIV,SCH MED,REHABIL INST CHICAGO,DEPT REHABIL MED,345 E SUPER ST,CHICAGO,IL 60611, USA.		Heinemann, Allen W/K-6283-2012	Heinemann, Allen W/0000-0003-2782-7326	NIAAA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R01 AAO711] Funding Source: Medline		Anderson P, 1980, ALCOHOL HEALTH RES W, V5, P37; BROOKS DN, 1972, J NERV MENT DIS, V155, P350; BUSS A, 1989, INCIDENCE ALCOHOL US; DEAN JC, 1985, INT J ADDICT, V20, P629, DOI 10.3109/10826088509044942; DiClemente C.C., 1985, COPING SUBSTANCE USE, P319; DICLEMENTE CC, 1982, ADDICT BEHAV, V7, P133, DOI 10.1016/0306-4603(82)90038-7; DONOVAN JE, 1983, J STUD ALCOHOL, V44, P109, DOI 10.15288/jsa.1983.44.109; FILLMORE KM, 1974, Q J STUD ALCOHOL, V35, P819; Frisbie J H, 1984, J Am Paraplegia Soc, V7, P71; FULLETON D, 1981, ARCH GEN PSYCHIAT, V28, P1369; GALBRAITH S, 1976, BRIT J SURG, V63, P128, DOI 10.1002/bjs.1800630210; GALE JL, 1983, NEUROSURGERY, V12, P487, DOI 10.1227/00006123-198305000-00001; HEINEMANN AW, 1989, REHABIL PSYCHOL, V34, P191, DOI 10.1037//0090-5550.34.3.191; KIRUBAKARAN VR, 1986, J STUD ALCOHOL, V47, P223, DOI 10.15288/jsa.1986.47.223; Lowenthal A, 1980, ALCOHOL HEALTH RES W, V5, P16; MAISTO SA, 1979, J BEHAV ASSESS, V1, P315, DOI DOI 10.1007/BF01321373; MARLATT GA, 1988, ANNU REV PSYCHOL, V39, P223, DOI 10.1146/annurev.psych.39.1.223; O'Donnell JJ, 1981, ALCOHOL HEALTH RES W, V6, P27; Rasmussen GA, 1980, ALCOHOL HEALTH RES W, V5, P48; RUSSELL WR, 1971, TRAUMATIC AMNESIAS; SOBELL LC, 1988, J STUD ALCOHOL, V49, P225, DOI 10.15288/jsa.1988.49.225; SWEENEY TT, 1982, INT J ADDICT, V17, P897, DOI 10.3109/10826088209056336; 1987, DIAGNOSTIC STATISTIC; 1989, HOUSEHOLD SURVEY DRU	24	42	43	0	2	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUN	1991	72	7					482	487					6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	FP702	WOS:A1991FP70200008	2059120				2021-06-18	
J	LEVIN, HS; EISENBERG, HM; GARY, HE; MARMAROU, A; FOULKES, MA; JANE, JA; MARSHALL, LF; PORTMAN, SM				LEVIN, HS; EISENBERG, HM; GARY, HE; MARMAROU, A; FOULKES, MA; JANE, JA; MARSHALL, LF; PORTMAN, SM			INTRACRANIAL HYPERTENSION IN RELATION TO MEMORY FUNCTIONING DURING THE 1ST YEAR AFTER SEVERE HEAD-INJURY	NEUROSURGERY			English	Article						HEAD INJURY; INTRACRANIAL PRESSURE; MEMORY	INTRA-CRANICAL PRESSURE; COMA	The relationship between intracranial hypertension and residual memory deficit after closed head injury was evaluated using the 6-month and 1-year neurobehavioral outcome data obtained by the Traumatic Coma Data Bank. Intracranial pressure was analyzed using the percentage of time that it exceeded 20 mm Hg and the maximum value recorded during the first 72 hours after injury. Memory measures included recall of word lists, prose recall, and visual memory for designs that were obtained 6 months (n = 149) and 1 year (n = 132) after injury. Intracranial hypertension occurred in more than half of the Traumatic Coma Data Bank cohort who met the criteria for the neurobehavioral follow-up study. Linear regression analysis disclosed an effect of elevated intracranial pressure on some, but not all, measures of memory at 6 months, whereas the results were negative for the 1-year follow-up examination. We conclude that the elevation of intracranial pressure exerts little if any effect on later memory functioning, and that any effect it does have diminishes over 1 year in survivors of severe head injury.	UNIV TEXAS,MED BRANCH,DEPT NEUROL,GALVESTON,TX 77550; CTR DIS CONTROL,ATLANTA,GA 30333; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT NEUROSURG,RICHMOND,VA 23298; UNIV CALIF SAN DIEGO,DIV NEUROSURG,LA JOLLA,CA 92093; NIH,OFF BIOMETRY,BETHESDA,MD 20892; UNIV VIRGINIA,DEPT NEUROSURG,CHARLOTTESVILLE,VA 22903	LEVIN, HS (corresponding author), UNIV TEXAS,MED BRANCH,DIV NEUROSURG D-73,GALVESTON,TX 77550, USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [N01-NS-3-2341, N01-NS-3-2339, N01-NS-3-2340] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [N01NS032341, N01NS032340, N01NS032339] Funding Source: NIH RePORTER		ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; Benton AL, 1974, VISUAL RETENTION TES; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; TEASDALE G, 1974, LANCET, V2, P81; UZZELL BP, 1986, J NEUROSURG, V65, P630, DOI 10.3171/jns.1986.65.5.0630; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wechsler D., 1945, WECHSLER MEMORY SCAL	12	42	43	0	2	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery	FEB	1991	28	2					196	200		10.1227/00006123-199102000-00004			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	EU430	WOS:A1991EU43000004	1997886				2021-06-18	
J	ZWIMPFER, TJ; BERNSTEIN, M				ZWIMPFER, TJ; BERNSTEIN, M			SPINAL-CORD CONCUSSION	JOURNAL OF NEUROSURGERY			English	Article									UNIV TORONTO,DIV NEUROSURG,25 LEONARD AVE,SUITE 211,TORONTO M5T 2R2,ONTARIO,CANADA							BARR ML, 1979, HUMAN NERVOUS SYSTEM, P106; BELL HS, 1970, J NEUROSURG, V33, P376, DOI 10.3171/jns.1970.33.4.0376; Countee R W, 1979, J Natl Med Assoc, V71, P257; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; GROAT RA, 1945, SURG GYNECOL OBSTET, V81, P63; Gurdjian ES, 1966, CLIN NEUROSURG, V12, P386; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; HOLDSWORTH F, 1970, J BONE JOINT SURG AM, VA 52, P1534, DOI 10.2106/00004623-197052080-00002; Holmes G, 1915, Br Med J, V2, P769; JANE JA, 1982, HEAD INJURY BASIC CL, P229; Kobrine A I, 1975, Surg Neurol, V3, P261; KOBRINE AI, 1979, J NEUROSURG, V50, P639, DOI 10.3171/jns.1979.50.5.0639; MARBURG O, 1936, HDB NEUROLOGIE; MEYER JS, 1970, J NEUROSURG, V32, P304, DOI 10.3171/jns.1970.32.3.0304; NILSSON B, 1977, J NEUROSURG, V47, P252, DOI 10.3171/jns.1977.47.2.0252; NILSSON B, 1977, J NEUROSURG, V47, P262, DOI 10.3171/jns.1977.47.2.0262; NILSSON B, 1977, J NEUROSURG, V47, P241, DOI 10.3171/jns.1977.47.2.0241; OBERSTEINER H, 1879, WEIN MED JB, V34, P531; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; OSTERHOLM JL, 1974, J NEUROSURG, V40, P5, DOI 10.3171/jns.1974.40.1.0003; PARKINSON D, 1983, SURG NEUROL, V20, P456, DOI 10.1016/0090-3019(83)90027-7; PARKINSON D, 1981, SURG NEUROL, V16, P347, DOI 10.1016/0090-3019(81)90272-X; RICHARDSON PM, 1979, J NEUROSURG, V51, P178, DOI 10.3171/jns.1979.51.2.0178; SANDLER AN, 1976, J NEUROSURG, V45, P638, DOI 10.3171/jns.1976.45.6.0638; Schneider R C, 1973, Clin Neurosurg, V20, P424; Shetter A G, 1979, Adv Neurol, V22, P5; TORG JS, 1986, J BONE JOINT SURG AM, V68A, P1354, DOI 10.2106/00004623-198668090-00008; Walker AE, 1944, J NEUROSURG, V1, P103, DOI 10.3171/jns.1944.1.2.0103	28	42	48	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.	JUN	1990	72	6					894	900		10.3171/jns.1990.72.6.0894			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	DF001	WOS:A1990DF00100010	2338574				2021-06-18	
J	KIMELBERG, HK; ROSE, JW; BARRON, KD; WANIEWSKI, RA; CRAGOE, EJ				KIMELBERG, HK; ROSE, JW; BARRON, KD; WANIEWSKI, RA; CRAGOE, EJ			ASTROCYTIC SWELLING IN TRAUMATIC-HYPOXIC BRAIN INJURY - BENEFICIAL-EFFECTS OF AN INHIBITOR OF ANION-EXCHANGE TRANSPORT AND GLUTAMATE UPTAKE IN GLIAL-CELLS	MOLECULAR AND CHEMICAL NEUROPATHOLOGY			English	Article									UNION UNIV ALBANY MED COLL, DEPT NEUROL, ALBANY, NY 12208 USA; VET ADM MED CTR, ALBANY, NY 12208 USA; NEW YORK STATE DEPT HLTH, WADSWORTH CTR LABS & RES, ALBANY, NY 12208 USA; MERCK SHARP & DOHME RES LABS, West Point, PA 19486 USA	KIMELBERG, HK (corresponding author), UNION UNIV ALBANY MED COLL, DEPT NEUROSURG, ALBANY, NY 12208 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS023750] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS23750] Funding Source: Medline		BAKAY L, 1977, J NEUROSURG, V47, P525, DOI 10.3171/jns.1977.47.4.0525; BAKAY L, 1968, BRAIN, V91, P697, DOI 10.1093/brain/91.4.697; BARRON KD, 1988, ACTA NEUROPATHOL, V75, P295, DOI 10.1007/BF00690538; BEVAN S, 1985, PROC R SOC SER B-BIO, V225, P299, DOI 10.1098/rspb.1985.0063; BONTING SL, 1970, MEMBRANES TRANSPORT, V1, P258; BOURKE RS, 1983, NEUROCHEM RES, V8, P5, DOI 10.1007/BF00965650; BOURKE RS, 1966, J NEUROCHEM, V13, P1099, DOI 10.1111/j.1471-4159.1966.tb04268.x; BOURKE RS, 1979, NEURAL TRAUMA, P95; BOWMAN CL, 1984, NATURE, V311, P656, DOI 10.1038/311656a0; BRAZY PC, 1976, J GEN PHYSIOL, V68, P583, DOI 10.1085/jgp.68.6.583; CABANTCHIK ZI, 1978, BIOCHIM BIOPHYS ACTA, V515, P239; CASPER DS, 1982, J COMP NEUROL, V209, P79, DOI 10.1002/cne.902090108; CHAN PH, 1982, J NEUROCHEM, V38, P525, DOI 10.1111/j.1471-4159.1982.tb08659.x; CHAN PH, 1988, BIOCH PATHOLOGY ASTR, P327; Coles J. A., 1981, Ion-selective microelectrodes and their use in excitable tissues, P345; CRAGOE EJ, 1986, J MED CHEM, V29, P825, DOI 10.1021/jm00155a038; CRAGOE EJ, 1982, J MED CHEM, V25, P567, DOI 10.1021/jm00347a017; DIETZEL I, 1980, EXP BRAIN RES, V40, P432; Duffy PE, 1983, ASTROCYTES NORMAL RE; FRANCK G, 1983, ADV CELL NEUROBIOL, V4, P133; FRANGAKIS MV, 1984, NEUROCHEM RES, V9, P1689, DOI 10.1007/BF00968079; FRELIN C, 1986, BIOCHEM BIOPH RES CO, V134, P326, DOI 10.1016/0006-291X(86)90566-8; GARAY RP, 1986, N-S ARCH PHARMACOL, V334, P202, DOI 10.1007/BF00505823; GARCIA JH, 1977, VIRCHOWS ARCH B, V25, P191; GARCIA JH, 1979, CEREBROVASC DIS, P125; GRAY PTA, 1986, PROC R SOC SER B-BIO, V228, P267, DOI 10.1098/rspb.1986.0055; GRIFFITHS IR, 1978, ACTA NEUROPATHOL, V41, P33, DOI 10.1007/BF00689554; HERNDON RM, 1980, NEUROSCIENCE, V5, P1015, DOI 10.1016/0306-4522(80)90182-7; HERTZ L, 1979, PROG NEUROBIOL, V13, P277, DOI 10.1016/0301-0082(79)90018-2; HIRANO A, 1981, GUIDE NEUROPATHOLOGY, P204; HIRATA H, 1983, BRAIN RES, V270, P358, DOI 10.1016/0006-8993(83)90614-5; HODGKIN AL, 1959, J PHYSIOL-LONDON, V148, P127, DOI 10.1113/jphysiol.1959.sp006278; Jenkins L.W., 1984, RECENT PROGR STUDY T, P523; JENKINS LW, 1979, ACTA NEUROPATHOL, V48, P113, DOI 10.1007/BF00691152; KALIMO H, 1981, J CEREBR BLOOD F MET, V1, P313, DOI 10.1038/jcbfm.1981.35; Kimelberg H K, 1987, Cent Nerv Syst Trauma, V4, P3; Kimelberg H.K., 1982, HEAD INJURY BASIC CL, P31; KIMELBERG HK, 1986, ANN NY ACAD SCI, V481, P334, DOI 10.1111/j.1749-6632.1986.tb27162.x; KIMELBERG HK, 1979, BRAIN RES, V177, P533, DOI 10.1016/0006-8993(79)90470-0; KIMELBERG HK, 1989, J NEUROSCI, V9, P1141; KIMELBERG HK, 1985, BRAIN RES, V361, P125, DOI 10.1016/0006-8993(85)91282-X; KIMELBERG HK, 1979, BRAIN RES, V173, P111; KIMELBERG HK, 1981, BIOCHIM BIOPHYS ACTA, V646, P179, DOI 10.1016/0005-2736(81)90285-6; KIMELBERG HK, 1987, J PHYSIOL-PARIS, V82, P294; KIMELBERG HK, 1979, NEURAL TRAUMA, P137; KIMELBERG HK, 1986, ASTROCYTES, V3, P129; KIMELBERG HK, 1986, ADV BIOSCI, V61, P177; KIMELBERG HK, IN PRESS SOC NEUR AB; Klatzo I, 1980, Adv Neurol, V28, P359; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; Klatzo I, 1984, RECENT PROGR STUDY T, P1; KLETZIEN RF, 1975, ANAL BIOCHEM, V68, P537, DOI 10.1016/0003-2697(75)90649-1; KOECHEL DA, 1981, ANNU REV PHARMACOL, V21, P265, DOI 10.1146/annurev.pa.21.040181.001405; KRAIG RP, 1985, BRAIN RES, V342, P281, DOI 10.1016/0006-8993(85)91127-8; KRAIG RP, 1985, PROG BRAIN RES, V63, P155; KREGENOW FM, 1981, ANNU REV PHYSIOL, V43, P493, DOI 10.1146/annurev.ph.43.030181.002425; LOWE AG, 1982, BIOCHIM BIOPHYS ACTA, V694, P353, DOI 10.1016/0304-4157(82)90002-8; LUNDANDERSEN H, 1970, EXP BRAIN RES, V11, P199; MARTIN DL, 1979, J BIOL CHEM, V254, P7076; MATAKAS F, 1978, ACTA NEUROPATHOL, V41, P207, DOI 10.1007/BF00690437; MATYJA E, 1986, EXP NEUROL, V92, P609, DOI 10.1016/0014-4886(86)90303-1; NELSON LR, 1979, NEURAL TRAUMA, P297; NELSON LR, 1982, HEAD INJURY BASIC CL, P117; NORENBERG MD, 1974, J NEUROPATH EXP NEUR, V33, P422, DOI 10.1097/00005072-197407000-00008; NORENBERG MD, 1986, ASTROCYTES, V3, P425; PAPPIUS HM, 1956, CAN J BIOCHEM PHYS, V34, P1053; PLUM F, 1983, NEUROLOGY, V33, P222, DOI 10.1212/WNL.33.2.222; SIESJO BK, 1981, J CEREBR BLOOD F MET, V1, P155, DOI 10.1038/jcbfm.1981.18; SIESJO BK, 1984, CEREBRAL ISCHEMIA, P157; SONTHEIMER H, 1988, GLIA, V1, P328, DOI 10.1002/glia.440010505; SYKOVA E, 1983, PROG BIOPHYS MOL BIO, V42, P135, DOI 10.1016/0079-6107(83)90006-8; Trachtenberg MC., 1982, HEAD INJURY BASIC CL, P169; VANHARREVELD A, 1982, J NEUROBIOL, V13, P519, DOI 10.1002/neu.480130607; VANHARREVELD A, 1971, EXP MOL PATHOL, V15, P61, DOI 10.1016/0014-4800(71)90019-0; WALZ W, 1985, BRAIN RES, V343, P44, DOI 10.1016/0006-8993(85)91156-4; WALZ W, 1984, J CEREBR BLOOD F MET, V4, P301, DOI 10.1038/jcbfm.1984.42; WANIEWSKI RA, 1983, BRAIN RES, V268, P390, DOI 10.1016/0006-8993(83)90511-5; WANIEWSKI RA, 1984, J NEUROSCI, V4, P2237; WARNOCK DG, 1984, FED PROC, V43, P2473; YU MC, 1972, ACTA NEUROPATHOL, V22, P222, DOI 10.1007/BF00684525	80	42	42	0	1	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1044-7393			MOL CHEM NEUROPATHOL	Mol. Chem. Neuropathol.	AUG	1989	11	1					1	31		10.1007/BF03160036			31	Neurosciences; Pathology	Neurosciences & Neurology; Pathology	AP450	WOS:A1989AP45000001	2570584				2021-06-18	
J	FOLTZ, EL; JENKNER, FL; WARD, AA				FOLTZ, EL; JENKNER, FL; WARD, AA			EXPERIMENTAL CEREBRAL CONCUSSION	JOURNAL OF NEUROSURGERY			English	Article																BORNSTEIN MB, 1946, J NEUROPHYSIOL, V9, P349; de No RL, 1938, AM J PHYSIOL, V121, P331; Denny-Brown D, 1940, J PHYSIOL-LONDON, V99, P153, DOI 10.1113/jphysiol.1940.sp003887; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; DENNYBROWN D, 1945, PHYSIOL REV, V25, P296; EICHELBERGER L, 1949, AM J PHYSIOL, V156, P129; Miller GG, 1927, ARCH SURG-CHICAGO, V14, P891, DOI 10.1001/archsurg.1927.01130160100005; RHINES R, 1946, AM J PHYSIOL, V146, P344; SPIEGEL EA, 1948, J NEUROPATH EXP NEUR, V7, P162, DOI 10.1097/00005072-194804000-00004; TOWER DB, 1948, J CLIN INVEST, V27, P558; Walker AE, 1944, J NEUROSURG, V1, P103, DOI 10.3171/jns.1944.1.2.0103; WARD A, 1950, J NEUROSURG, V7, P398, DOI 10.3171/jns.1950.7.5.0398; Webster JE, 1941, ANN SURG, V113, P556, DOI 10.1097/00000658-194104000-00009; WHITE JC, 1943, ANN SURG, V118, P619; Williams D, 1941, BRAIN, V64, P223, DOI 10.1093/brain/64.4.223	15	42	43	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.		1953	10	4					342	352		10.3171/jns.1953.10.4.0342			11	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	YD698	WOS:A1953YD69800003	13070057				2021-06-18	
J	Benabid, AL; Costecalde, T; Eliseyev, A; Charvet, G; Verney, A; Karakas, S; Foerster, M; Lambert, A; Moriniere, B; Abroug, N; Schaeffer, MC; Moly, A; Sauter-Starace, F; Ratel, D; Moro, C; Torres-Martinez, N; Langar, ML; Oddoux, M; Polosan, M; Pezzani, S; Auboiroux, V; Aksenova, T; Mestais, C; Chabardes, S				Benabid, Alim Louis; Costecalde, Thomas; Eliseyev, Andrey; Charvet, Guillaume; Verney, Alexandre; Karakas, Serpil; Foerster, Michael; Lambert, Aurelien; Moriniere, Boris; Abroug, Neil; Schaeffer, Marie-Caroline; Moly, Alexandre; Sauter-Starace, Fabien; Ratel, David; Moro, Cecile; Torres-Martinez, Napoleon; Langar, Lilia; Oddoux, Manuela; Polosan, Mircea; Pezzani, Stephane; Auboiroux, Vincent; Aksenova, Tetiana; Mestais, Corinne; Chabardes, Stephan			An exoskeleton controlled by an epidural wireless brain-machine interface in a tetraplegic patient: a proof-of-concept demonstration	LANCET NEUROLOGY			English	Article							CORTICAL CONTROL; MOTOR; RESTORATION; MOVEMENT	Background Approximately 20% of traumatic cervical spinal cord injuries result in tetraplegia. Neuroprosthetics are being developed to manage this condition and thus improve the lives of patients. We aimed to test the feasibility of a semi-invasive technique that uses brain signals to drive an exoskeleton. Methods We recruited two participants at Clinatec research centre, associated with Grenoble University Hospital, Grenoble, France, into our ongoing clinical trial. Inclusion criteria were age 18-45 years, stability of neurological deficits, a need for additional mobility expressed by the patient, ambulatory or hospitalised monitoring, registration in the French social security system, and signed informed consent. The exclusion criteria were previous brain surgery, anticoagulant treatments, neuropsychological sequelae, depression, substance dependence or misuse, and contraindications to magnetoencephalography (MEG), EEG, or MRI. One participant was excluded because of a technical problem with the implants. The remaining participant was a 28-year-old man, who had tetraplegia following a C4-C5 spinal cord injury. Two bilateral wireless epidural recorders, each with 64 electrodes, were implanted over the upper limb sensorimotor areas of the brain. Epidural electrocorticographic (ECoG) signals were processed online by an adaptive decoding algorithm to send commands to effectors (virtual avatar or exoskeleton). Throughout the 24 months of the study, the patient did various mental tasks to progressively increase the number of degrees of freedom. Findings Between June 12,2017, and July 21,2019, the patient cortically controlled a programme that simulated walking and made bimanual, multi-joint, upper-limb movements with eight degrees of freedom during various reach-andtouch tasks and wrist rotations, using a virtual avatar at home (64.0% [SD 5.1] success) or an exoskeleton in the laboratory (70.9% [11.6] success). Compared with rnicroelectrodes, epidural ECoG is semi-invasive and has similar efficiency. The decoding models were reusable for up to approximately 7 weeks without recalibration. Interpretation These results showed long-term (24-month) activation of a four-limb neuroprosthetic exoskeleton by a complete brain-machine interface system using continuous, online epidural ECoG to decode brain activity in a tetraplegic patient. Up to eight degrees of freedom could be simultaneously controlled using a unique model, which was reusable without recalibration for up to about 7 weeks. Copyright (C) 2019 Elsevier Ltd. All rights reserved.	[Benabid, Alim Louis; Costecalde, Thomas; Eliseyev, Andrey; Charvet, Guillaume; Verney, Alexandre; Foerster, Michael; Lambert, Aurelien; Moriniere, Boris; Abroug, Neil; Schaeffer, Marie-Caroline; Moly, Alexandre; Sauter-Starace, Fabien; Ratel, David; Moro, Cecile; Torres-Martinez, Napoleon; Langar, Lilia; Oddoux, Manuela; Pezzani, Stephane; Auboiroux, Vincent; Aksenova, Tetiana; Mestais, Corinne; Chabardes, Stephan] Univ Grenoble, Clinatec, LETI, CEA, MINATEC Campus, F-38000 Grenoble, France; [Benabid, Alim Louis; Langar, Lilia; Oddoux, Manuela; Polosan, Mircea; Pezzani, Stephane; Chabardes, Stephan] CHU Grenoble Alpes, Grenoble, France; [Verney, Alexandre; Moriniere, Boris; Abroug, Neil] CEA, LIST, DIASI, SRI, Gif Sur Yvette, France	Benabid, AL (corresponding author), Univ Grenoble, Clinatec, LETI, CEA, MINATEC Campus, F-38000 Grenoble, France.	alimlouis@sfr.fr	Eliseyev, Andrey/I-1434-2019; SAUTER-STARACE, Fabien/AAY-9542-2020; Torres, Napoleon R/H-6182-2015	Torres, Napoleon R/0000-0003-3067-4172; CHARVET, Guillaume/0000-0003-4938-9419; Eliseyev, Andrey/0000-0002-0312-889X; Aksenova, Tetiana/0000-0003-4007-2343	CEAFrench Atomic Energy Commission; French Ministry of Health [PHRC-15-15-0124]; Fondation Motrice; Fondation Nanosciences; Institut Carnot; Fonds de Dotation Clinatec	CLINATEC is a Laboratory of CEA-Grenoble and has statutory links with the University Hospital of Grenoble (CHUGA) and with University Grenoble Alpes (UGA). This study was funded by CEA (recurrent funding) and the French Ministry of Health (Grant PHRC-15-15-0124), Fondation Motrice, Fondation Nanosciences, Institut Carnot, Fonds de Dotation Clinatec. Fondation Philanthropique Edmond J Safra is a major founding institution of the Clinatec Edmond J Safra Biomedical Research Center. We thank Maighed Gallagher Gambarelly for English language editing.	Ajiboye AB, 2017, LANCET, V389, P1821, DOI 10.1016/S0140-6736(17)30601-3; Bouton CE, 2016, NATURE, V533, P247, DOI 10.1038/nature17435; Capogrosso M, 2016, NATURE, V539, P284, DOI 10.1038/nature20118; Donati ARC, 2016, SCI REP-UK, V6, DOI 10.1038/srep30383; Eliseyev A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16579-9; Eliseyev A, 2011, J NEURAL ENG, V8, DOI 10.1088/1741-2560/8/4/046012; Elnady AM, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00168; Felton EA, 2007, J NEUROSURG, V106, P495, DOI 10.3171/jns.2007.106.3.495; Friggeri A., 2006, INFLUENCE TYPE NIVEA; Frolov AA, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00400; Gamble, 2006, HUMAN WALKING; Hatsopoulos NG, 2011, NEURON, V72, P477, DOI 10.1016/j.neuron.2011.10.020; Hochberg LR, 2012, NATURE, V485, P372, DOI 10.1038/nature11076; Kennedy PR, 1998, NEUROREPORT, V9, P1707, DOI 10.1097/00001756-199806010-00007; Kennefick M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113563; Mestais CS, 2015, IEEE T NEUR SYS REH, V23, P10, DOI 10.1109/TNSRE.2014.2333541; Milekovic T, 2018, J NEUROPHYSIOL, V120, P343, DOI 10.1152/jn.00493.2017; Moriniere B, 2015, 2015 IEEE RSJ INT C; Mushahwar VK, 2006, IEEE T NEUR SYS REH, V14, P198, DOI 10.1109/TNSRE.2006.875532; Pfurtscheller G, 2000, NEUROSCI LETT, V292, P211, DOI 10.1016/S0304-3940(00)01471-3; Roux FE, 2003, NEUROSURGERY, V53, P1342, DOI 10.1227/01.NEU.0000093424.71086.8F; Sauter-Starace F, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00847; Schaeffer Marie-Caroline, 2016, J Physiol Paris, V110, P348, DOI 10.1016/j.jphysparis.2017.03.002; Simeral JD, 2011, J NEURAL ENG, V8, DOI 10.1088/1741-2560/8/2/025027; Skelsey P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075892; Sussillo D, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13749; Taylor DM, 2002, SCIENCE, V296, P1829, DOI 10.1126/science.1070291; Vansteensel MJ, 2016, NEW ENGL J MED, V375, P2060, DOI 10.1056/NEJMoa1608085; Wang W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055344; Wodlinger B, 2015, J NEURAL ENG, V12, DOI 10.1088/1741-2560/12/1/016011; Yousry TA, 1997, BRAIN, V120, P141, DOI 10.1093/brain/120.1.141	31	41	41	5	37	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2019	18	12					1112	1122		10.1016/S1474-4422(19)30321-7			11	Clinical Neurology	Neurosciences & Neurology	JM0CO	WOS:000495892200017	31587955				2021-06-18	
J	Bhowmick, S; D'Mello, V; Caruso, D; Wallerstein, A; Abdul-Muneer, PM				Bhowmick, Saurav; D'Mello, Veera; Caruso, Danielle; Wallerstein, Alex; Abdul-Muneer, P. M.			Impairment of pericyte-endothelium crosstalk leads to blood-brain barrier dysfunction following traumatic brain injury	EXPERIMENTAL NEUROLOGY			English	Article						Traumatic brain injury; Blood-brain barrier; Pericytes; Endothelial cells; PDGF-B/PDGFR-beta signaling; Vasogenic edema	VESSEL FORMATION; ANIMAL-MODEL; N-CADHERIN; PDGF-B; BETA; NEUROINFLAMMATION; ADHESION; ANGIOGENESIS; RECRUITMENT; DISRUPTION	The blood-brain barrier (BBB) constitutes a neurovascular unit formed by microvascular endothelial cells, pericytes, and astrocytes. Brain pericytes are important regulators of BBB integrity, permeability, and blood flow. Pericyte loss has been implicated in injury; however, how the crosstalk among pericytes, endothelial cells, and astrocytes ultimately leads to BBB dysfunction in traumatic brain injury (TBI) remains elusive. In this study, we demonstrate the importance of pericyte-endothelium interaction in maintaining the BBB function. TBI causes the platelet-derived growth factor-B (PDGF-B)/PDGF receptor-beta signaling impairment that results in loss of interaction with endothelium and leads to neurovascular dysfunction. Using in vivo mild (7 psi) and moderate (15 psi) fluid percussion injury (FPI) in mice, we demonstrate the expression of various pericyte markers including PDGFR-beta, NG2 and CD13 that were significantly reduced with a subsequent reduction in the expression of various integrins; adherent junction protein, N-cadherin; gap junction protein, connexin-43; and tight junction proteins such as occludin, claudin-5, ZO-1, and JAM-a. Impairment of pericyte-endothelium interaction increases the BBB permeability to water that is marked by a significant increase in aquaporin4 expression in injured animals. Similarly, pericyte-endothelium integrity impairment in FPI animals greatly increases the permeability of small-molecular-weight sodium fluorescein and high-molecular-weight-tracer Evans blue across the BBB. In addition, the injury-inflicted animals show significantly higher levels of S100 beta and NSE in the blood samples compared with controls. In conclusion, our data provide an insight that brain trauma causes an early impairment of pericyte-endothelium integrity and results in BBB dysregulation that initiates pathological consequences associated with TBI.	[Bhowmick, Saurav; D'Mello, Veera; Caruso, Danielle; Wallerstein, Alex; Abdul-Muneer, P. M.] Hackensack Meridian Hlth JFK Med Ctr, JFK Neurosci Inst, Lab CNS Injury & Mol Therapy, 65 James St, Edison, NJ 08820 USA	Abdul-Muneer, PM (corresponding author), Hackensack Meridian Hlth JFK Med Ctr, JFK Neurosci Inst, Lab CNS Injury & Mol Therapy, 65 James St, Edison, NJ 08820 USA.	Mohammed.Muneer@hackensackmeridian.org	Bhowmick, Saurav/Y-6011-2019	Abdul-Muneer, P. M/0000-0001-8231-4385	Neuroscience Institute at Hackensack Meridian Health JFK Medical Center, Edison, NJ	This work was supported by the Neuroscience Institute at Hackensack Meridian Health JFK Medical Center, Edison, NJ to P.M. Abdul-Muneer.	Abdul-Muneer PM, 2018, MOL NEUROBIOL, V55, P5901, DOI 10.1007/s12035-017-0812-z; Abdul-Muneer PM, 2017, MOL NEUROBIOL, V54, P3964, DOI 10.1007/s12035-016-9949-4; Abdul-Muneer PM, 2017, BRAIN BEHAV IMMUN, V62, P291, DOI 10.1016/j.bbi.2017.02.014; Abdul-Muneer PM, 2017, BRAIN BEHAV IMMUN, V59, P190, DOI 10.1016/j.bbi.2016.09.002; Abdul-Muneer PM, 2013, FREE RADICAL BIO MED, V60, P282, DOI 10.1016/j.freeradbiomed.2013.02.029; ALBELDA SM, 1989, J CLIN INVEST, V83, P1992, DOI 10.1172/JCI114109; Alikunju S, 2011, BRAIN BEHAV IMMUN, V25, pS129, DOI 10.1016/j.bbi.2011.01.007; Arimura K, 2012, CURR NEUROVASC RES, V9, P1; Armulik A, 2005, CIRC RES, V97, P512, DOI 10.1161/01.RES.0000182903.16652.d7; Armulik A, 2011, DEV CELL, V21, P193, DOI 10.1016/j.devcel.2011.07.001; Armulik A, 2010, NATURE, V468, P557, DOI 10.1038/nature09522; Bankhead P., 2014, AN FLUOR MICR IM IMA; Bell RD, 2010, NEURON, V68, P409, DOI 10.1016/j.neuron.2010.09.043; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Bergers G, 2005, NEURO-ONCOLOGY, V7, P452, DOI 10.1215/S1152851705000232; Bhowmick S, 2019, MOL NEUROBIOL, V56, P1124, DOI 10.1007/s12035-018-1132-7; Bhowmick S, 2018, BRAIN SCI, V8, DOI 10.3390/brainsci8010011; Bjarnegard M, 2004, DEVELOPMENT, V131, P1847, DOI 10.1242/dev.01080; Chew SSL, 2010, EXP NEUROL, V225, P250, DOI 10.1016/j.expneurol.2010.07.014; Daneman R, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a020412; Daneman R, 2010, NATURE, V468, P562, DOI 10.1038/nature09513; Del Maschio A, 1999, J EXP MED, V190, P1351, DOI 10.1084/jem.190.9.1351; Diaz-Flores L, 2009, HISTOL HISTOPATHOL, V24, P909, DOI 10.14670/HH-24.909; Enge M, 2002, EMBO J, V21, P4307, DOI 10.1093/emboj/cdf418; Fisher M, 2009, STROKE, V40, pS13, DOI 10.1161/STROKEAHA.108.533117; Francesca B, 2010, CURR NEUROPHARMACOL, V8, P92, DOI 10.2174/157015910791233132; Geraldes P, 2009, NAT MED, V15, P1298, DOI 10.1038/nm.2052; Gerhardt H, 2000, DEV DYNAM, V218, P472, DOI 10.1002/1097-0177(200007)218:3<472::AID-DVDY1008>3.0.CO;2-#; Gonzalez-Mariscal L, 2000, SEMIN CELL DEV BIOL, V11, P315, DOI 10.1006/scdb.2000.0178; Harris AL, 2007, PROG BIOPHYS MOL BIO, V94, P120, DOI 10.1016/j.pbiomolbio.2007.03.011; Hellstrom M, 1999, DEVELOPMENT, V126, P3047; Huang FJ, 2010, DEV BIOL, V344, P1035, DOI 10.1016/j.ydbio.2010.06.023; Krueger M, 2010, GLIA, V58, P1, DOI 10.1002/glia.20898; KUNZ J, 1994, J NEUROCHEM, V62, P2375; Lebrin F, 2010, NAT MED, V16, P420, DOI 10.1038/nm.2131; Li FF, 2011, DEV CELL, V20, P291, DOI 10.1016/j.devcel.2011.01.011; Lindahl P, 1999, CURR TOPICS PATHOL, V93, P27; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; Luissint AC, 2012, FLUIDS BARRIERS CNS, V9, DOI 10.1186/2045-8118-9-23; Muneer PMA, 2012, ARTERIOSCL THROM VAS, V32, P1167, DOI 10.1161/ATVBAHA.112.247668; Nag S, 2009, ACTA NEUROPATHOL, V118, P197, DOI 10.1007/s00401-009-0541-0; Obermeier B, 2013, NAT MED, V19, P1584, DOI 10.1038/nm.3407; Osada T, 2011, J CEREBR BLOOD F MET, V31, P1972, DOI 10.1038/jcbfm.2011.99; Patel RK, 2017, BRAIN BEHAV IMMUN, V64, P244, DOI 10.1016/j.bbi.2017.04.012; Sengillo JD, 2013, BRAIN PATHOL, V23, P303, DOI 10.1111/bpa.12004; Shultz SR, 2011, BEHAV BRAIN RES, V224, P326, DOI 10.1016/j.bbr.2011.06.012; Simard M, 2003, J NEUROSCI, V23, P9254; Smith LL, 1996, J BIOL CHEM, V271, P28485, DOI 10.1074/jbc.271.45.28485; Stratman AN, 2009, BLOOD, V114, P5091, DOI 10.1182/blood-2009-05-222364; Sweeney MD, 2016, NAT NEUROSCI, V19, P771, DOI 10.1038/nn.4288; Takata F, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-106; Tallquist MD, 2003, PLOS BIOL, V1, P288, DOI 10.1371/journal.pbio.0000052; Tallquist MD, 2003, DEVELOPMENT, V130, P507, DOI 10.1242/dev.00241; Thanabalasundaram G, 2011, INT J BIOCHEM CELL B, V43, P1284, DOI 10.1016/j.biocel.2011.05.002; Winkler EA, 2011, NAT NEUROSCI, V14, P1398, DOI 10.1038/nn.2946; Winkler EA, 2010, MOL NEURODEGENER, V5, DOI 10.1186/1750-1326-5-32; Zehendner CM, 2015, SCI REP-UK, V5, DOI 10.1038/srep13497; Zhao Z, 2015, CELL, V163, P1064, DOI 10.1016/j.cell.2015.10.067; Zlokovic BV, 2008, NEURON, V57, P178, DOI 10.1016/j.neuron.2008.01.003	59	41	42	1	20	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JUL	2019	317						260	270		10.1016/j.expneurol.2019.03.014			11	Neurosciences	Neurosciences & Neurology	IC2PY	WOS:000470803400024	30926390				2021-06-18	
J	Yang, YX; Ye, YQ; Kong, CG; Su, XH; Zhang, X; Bai, W; He, XS				Yang, Yongxiang; Ye, Yuqin; Kong, Chuiguang; Su, Xinhong; Zhang, Xin; Bai, Wei; He, Xiaosheng			MiR-124 Enriched Exosomes Promoted the M2 Polarization of Microglia and Enhanced Hippocampus Neurogenesis After Traumatic Brain Injury by Inhibiting TLR4 Pathway	NEUROCHEMICAL RESEARCH			English	Article						Traumatic brain injury; Exosome; MiR-124; Microglia; Neurogenesis; TLR4	INTERLEUKIN-1 RECEPTOR ANTAGONIST; FUNCTIONAL RECOVERY; ADULT NEUROGENESIS; CONTRIBUTES; MACROPHAGES; ACTIVATION; PROTECTION; REGULATOR; ABLATION; DELIVERY	MicroRNA-124 (miR-124) is a brain specific miRNA that is highly expressed in microglia. The upregulation of miR-124 contributes to M2 polarization of microglia, which is beneficial to neurogenesis. Exosomes are lipid membrane vesicles that can deliver miR-124 into the brain. However, whether miR-124 enriched exosomes (Exo-miR-124) can regulate the polarization of microglia and affect hippocampus neurogenesis after traumatic brain injury (TBI) is unknown. To clarify this, the Exo-miR-124 was first constructed, and then was intravenously administrated into rats via tail vein with the dose of 3x10(9) particles/each rat at 24h post TBI. The polarization of microglia in hippocampus was evaluated through measuring the signature genes and cytokines of M1/M2 phenotype by reverse transcription-polymerase chain reaction (RT-PCR) and enzyme-linked immune sorbent assay (ELISA) at 7/14/21/28 days after TBI. Hippocampus neurogenesis was evaluated through detecting the proliferation marker BrdU/SOX2 and differentiation marker BrdU/NeuN by immunofluorescence (IF) at 7 and 28days after TBI respectively. Neurological function was evaluated by neurological severity score (NSS) and morris water maze (MWM) at 7/14/21/28 and 24-28days after TBI respectively. To explore the underlying mechanisms, the mRNA expression of TLR4 pathway molecules in hippocampus were measured by RT-PCR, and the polarization of microglia and the activation of TLR4 pathway in BV2 cells were measured after exosome treatment as well. Results demonstrated that Exo-miR-124 treatment promoted the M2 polarization of microglia, enhanced neurogenesis in hippocampus, and improved function recovery after TBI. The M2 polarization effect of Exo-miR-124 was produced through inhibiting TLR4 pathway, which was verified in hippocampus and BV2 microglia. In conclusion, Exo-miR-124 treatment promoted M2 polarization of microglia and improved hippocampal neurogenesis and functional recovery after brain injury, which might be a strategy to improve the outcome of TBI.	[Yang, Yongxiang; Ye, Yuqin; Kong, Chuiguang; Su, Xinhong; Zhang, Xin; Bai, Wei; He, Xiaosheng] Fourth Mil Med Univ, Airforce Mil Med Univ, Xijing Hosp, Dept Neurosurg, Xian 710032, Shaanxi, Peoples R China; [Yang, Yongxiang] PLA 422nd Hosp, Dept Neurosurg, Zhanjiang 524005, Peoples R China; [Ye, Yuqin] Hunan Normal Univ, Affiliated Hosp 2, PLA 163rd Hosp, Dept Neurosurg, Changsha 410000, Hunan, Peoples R China	He, XS (corresponding author), Fourth Mil Med Univ, Airforce Mil Med Univ, Xijing Hosp, Dept Neurosurg, Xian 710032, Shaanxi, Peoples R China.	hexiaos@fmmu.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81471264]; Science and Technology Development Fund of Airforce Military Medical University (Fourth Military Medical University) [2016XC178, 2016XC210]	The present work was supported by Grants from National Natural Science Foundation of China (81471264 to XH), Science and Technology Development Fund of Airforce Military Medical University (Fourth Military Medical University) (2016XC178 and 2016XC210 to XH).	Ahmad A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057208; Albert-WeiSSenberger Christiane, 2012, Exp Transl Stroke Med, V4, P1, DOI 10.1186/2040-7378-4-1; Alvarez-Erviti L, 2011, NAT BIOTECHNOL, V29, P341, DOI 10.1038/nbt.1807; Amici SA, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01520; Battista D, 2006, EUR J NEUROSCI, V23, P83, DOI 10.1111/j.1460-9568.2005.04539.x; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Braccioli L, 2014, MOL NEUROBIOL, V49, P113, DOI 10.1007/s12035-013-8504-9; Braicu C, 2015, CELL DEATH DIFFER, V22, P34, DOI 10.1038/cdd.2014.130; Butovsky O, 2006, MOL CELL NEUROSCI, V31, P149, DOI 10.1016/j.mcn.2005.10.006; de Miranda AS, 2017, J NEUROL SCI, V372, P482, DOI 10.1016/j.jns.2016.10.052; Helmy A, 2014, J CEREBR BLOOD F MET, V34, P845, DOI 10.1038/jcbfm.2014.23; Huang S, 2018, FASEB J, V32, P2315, DOI 10.1096/fj.201700673RERR; Iosif RE, 2006, J NEUROSCI, V26, P9703, DOI 10.1523/JNEUROSCI.2723-06.2006; Kalani A, 2014, MOL NEUROBIOL, V49, P590, DOI 10.1007/s12035-013-8544-1; Keene CD, 2009, AM J PATHOL, V174, P2300, DOI 10.2353/ajpath.2009.081153; Kiyota T, 2012, GENE THER, V19, P724, DOI 10.1038/gt.2011.126; Lee ST, 2017, J MOV DISORD, V10, P45, DOI 10.14802/jmd.16054; McDonald SJ, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0555-1; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Monje ML, 2003, SCIENCE, V302, P1760, DOI 10.1126/science.1088417; Moore CS, 2013, ANN NEUROL, V74, P709, DOI 10.1002/ana.23967; Mouihate A, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00173; Ning RZ, 2017, ONCOTARGET, V8, P95481, DOI 10.18632/oncotarget.20751; Periyasamy P, 2018, MOL NEUROBIOL, V55, P3196, DOI 10.1007/s12035-017-0584-5; Pinto S, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00273; Ponomarev ED, 2013, GLIA, V61, P91, DOI 10.1002/glia.22363; Ponomarev ED, 2011, NAT MED, V17, P64, DOI 10.1038/nm.2266; Raposo G, 2013, J CELL BIOL, V200, P373, DOI 10.1083/jcb.201211138; Richardson RM, 2007, NEUROSURG CLIN N AM, V18, P169, DOI 10.1016/j.nec.2006.10.007; Seong KJ, 2016, KOREAN J PHYSIOL PHA, V20, P41, DOI 10.4196/kjpp.2016.20.1.41; Sun D, 2016, EXP NEUROL, V275, P405, DOI 10.1016/j.expneurol.2015.04.017; Sun MJ, 2018, BRAIN BEHAV IMMUN, V69, P618, DOI 10.1016/j.bbi.2018.01.007; Sun MJ, 2017, BRAIN BEHAV IMMUN, V66, P359, DOI 10.1016/j.bbi.2017.08.005; Sun Y, 2013, CELL RES, V23, P1270, DOI 10.1038/cr.2013.116; Svahn AJ, 2016, DEV NEUROBIOL, V76, P507, DOI 10.1002/dneu.22328; Taupin P, 2007, BRAIN RES REV, V53, P198, DOI 10.1016/j.brainresrev.2006.08.002; Veremeyko T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081774; Vorhees CV, 2006, NAT PROTOC, V1, P848, DOI 10.1038/nprot.2006.116; Vorhees CV, 2014, NEUROTOXICOL TERATOL, V45, P75, DOI 10.1016/j.ntt.2014.07.003; Wojtowicz JM, 2006, NAT PROTOC, V1, P1399, DOI 10.1038/nprot.2006.224; Wu MD, 2012, BRAIN BEHAV IMMUN, V26, P292, DOI 10.1016/j.bbi.2011.09.012; Xin HQ, 2017, STROKE, V48, P747, DOI 10.1161/STROKEAHA.116.015204; Xiong Y, 2017, NEURAL REGEN RES, V12, P19, DOI 10.4103/1673-5374.198966; Xue F, 2015, TUMORI, V101, P542, DOI 10.5301/tj.5000226; Yang JL, 2017, MOL THER-NUCL ACIDS, V7, P278, DOI 10.1016/j.omtn.2017.04.010; Yang YX, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00055; Yao XL, 2017, J NEUROIMMUNOL, V310, P38, DOI 10.1016/j.jneuroim.2017.06.006; YE Y, 2017, STEM CELLS INT, V2017, DOI DOI 10.1155/2017/5841814; Ye Y, 2016, NEURAL PLAST, V2016, DOI DOI 10.1155/2016/8072156280186795153466; Yu AY, 2017, IMMUNOL LETT, V182, P1, DOI 10.1016/j.imlet.2016.12.003; Zhang YL, 2017, NEUROCHEM INT, V111, P69, DOI 10.1016/j.neuint.2016.08.003; Zhang YL, 2015, J NEUROSURG, V122, P856, DOI 10.3171/2014.11.JNS14770	52	41	46	3	37	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190	1573-6903		NEUROCHEM RES	Neurochem. Res.	APR	2019	44	4					811	828		10.1007/s11064-018-02714-z			18	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	HR2TP	WOS:000462990500007	30628018				2021-06-18	
J	DePadilla, L; Miller, GF; Jones, SE; Peterson, AB; Breiding, MJ				DePadilla, Lara; Miller, Gabrielle F.; Jones, Sherry Everett; Peterson, Alexis B.; Breiding, Matthew J.			Self-Reported Concussions from Playing a Sport or Being Physically Active Among High School Students - United States, 2017	MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT			English	Article									[DePadilla, Lara; Peterson, Alexis B.; Breiding, Matthew J.] CDC, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA; [Miller, Gabrielle F.] CDC, Div Anal Res & Practice Integrat, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA; [Jones, Sherry Everett] CDC, Div Adolescent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA; [Jones, Sherry Everett] CDC, Sch Hlth, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA	DePadilla, L (corresponding author), CDC, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA.	ldepadilla@cdc.gov					Bell JM, 2017, J SAFETY RES, V62, P253, DOI 10.1016/j.jsr.2017.04.002; Brener ND, 2013, MMWR RECOMM REP, V62, P1; CDC, 2015, FACT SHEET YOUTH SPO; Coronado VG, 2015, J HEAD TRAUMA REHAB, V30, P185, DOI 10.1097/HTR.0000000000000156; DePadilla L, 2018, 4 FED INT C TRAUM BR; Institute of Medicine and National Research Council, 2014, SPORTS RELATED CONCU; JOBE JB, 1993, APPL COGNITIVE PSYCH, V7, P567, DOI 10.1002/acp.2350070703; Mailer BJ, 2008, J SPORT REHABIL, V17, P11, DOI 10.1123/jsr.17.1.11; Marshall Stephen W, 2015, Inj Epidemiol, V2, P13; Rivara FP, 2014, AM J SPORT MED, V42, P1197, DOI 10.1177/0363546514521774	10	41	41	2	3	CENTERS  DISEASE CONTROL & PREVENTION	ATLANTA	1600 CLIFTON RD, ATLANTA, GA 30333 USA	0149-2195	1545-861X		MMWR-MORBID MORTAL W	MMWR-Morb. Mortal. Wkly. Rep.	JUN 22	2018	67	24					682	685		10.15585/mmwr.mm6724a3			4	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	GK5VO	WOS:000436247500003	29927909	Green Published, Bronze			2021-06-18	
J	Morton, RP; Abecassis, IJ; Hanson, JF; Barber, JK; Chen, MM; Kelly, CM; Nerva, JD; Emerson, SN; Ene, CI; Levitt, MR; Chowdhary, MM; Ko, AL; Chesnut, RM				Morton, Ryan P.; Abecassis, Isaac Josh; Hanson, Josiah F.; Barber, Jason K.; Chen, Mimi; Kelly, Cory M.; Nerva, John D.; Emerson, Samuel N.; Ene, Chibawanye I.; Levitt, Michael R.; Chowdhary, Michelle M.; Ko, Andrew L.; Chesnut, Randall M.			Timing of cranioplasty: a 10.75-year single-center analysis of 754 patients	JOURNAL OF NEUROSURGERY			English	Article						cranioplasty; timing; infection; resorption; complication; traumatic brain injury	DECOMPRESSIVE CRANIECTOMY; CLINICAL ARTICLE; CRANIAL BONES; SKULL BONE; COMPLICATIONS; PREDICTORS; EXPERIENCE; PRESERVATION; GRAFTS	OBJECTIVE Despite their technical simplicity, cranioplasty procedures carry high reported morbidity rates. The authors here present the largest study to date on complications after cranioplasty, focusing specifically on the relationship between complications and timing of the operation. METHODS The authors retrospectively reviewed all cranioplasty cases performed at Harborview Medical Center over the past 10.75 years. In addition to relevant clinical and demographic characteristics, patient morbidity and mortality data were abstracted from the electronic medical record. Cox proportional-hazards models were used to analyze variables potentially associated with the risk of infection, hydrocephalus, seizure, hematoma, and bone flap resorption. RESULTS Over the course of 10.75 years, 754 cranioplasties were performed at a single institution. Sixty percent of the patients who underwent these cranioplasties were male, and the median follow-up overall was 233 days. The 30-day mortality rate was 0.26% (2 cases, both due to postoperative epidural hematoma). Overall, 24.6% percent of the patients experienced at least 1 complication including infection necessitating explantation of the flap (6.6%), postoperative hydrocephalus requiring a shunt (9.0%), resorption of the flap requiring synthetic cranioplasty (6.3%), seizure (4.1%), postoperative hematoma requiring evacuation (2.3%), and other (1.6%). The rate of infection was significantly higher if the cranioplasty had been performed < 14 days after the initial craniectomy (p = 0.007, Holm-Bonferroni-adjusted p = 0.028). Hydrocephalus was significantly correlated with time to cranioplasty (OR 0.92 per 10-day increase, p < 0.001) and was most common in patients whose cranioplasty had been performed < 90 days after initial craniectomy. New-onset seizure, however, only occurred in patients who had undergone their cranioplasty > 90 days after initial craniectomy. Bone flap resorption was the least likely complication for patients whose cranioplasty had been performed between 15 and 30 days after initial craniectomy. Resorption was also correlated with patient age, with a hazard ratio of 0.67 per increase of 10 years of age (p = 0.001). CONCLUSIONS Cranioplasty performed between 15 and 30 days after initial craniectomy may minimize infection, seizure, and bone flap resorption, whereas waiting > 90 days may minimize hydrocephalus but may increase the risk of seizure.	[Morton, Ryan P.; Abecassis, Isaac Josh; Hanson, Josiah F.; Barber, Jason K.; Chen, Mimi; Kelly, Cory M.; Nerva, John D.; Emerson, Samuel N.; Ene, Chibawanye I.; Levitt, Michael R.; Chowdhary, Michelle M.; Ko, Andrew L.; Chesnut, Randall M.] Univ Washington, Sch Med, Dept Neurol Surg, Seattle, WA 98195 USA; [Levitt, Michael R.] Univ Washington, Sch Med, Dept Radiol, Seattle, WA 98195 USA; [Levitt, Michael R.] Univ Washington, Dept Mech Engn, Sch Med, Seattle, WA 98195 USA	Morton, RP (corresponding author), Univ Washington, Neurosci Publicat, Box 359924,325 9th Ave, Seattle, WA 98104 USA.	publications@neurosurgery.washington.edu		Ko, Andrew/0000-0002-6253-9891; Chesnut, Randall/0000-0001-6377-3666			Chang V, 2010, J NEUROSURG, V112, P1120, DOI 10.3171/2009.6.JNS09133; Chibbaro S, 2011, WORLD NEUROSURG, V75, P558, DOI 10.1016/j.wneu.2010.10.020; De Bonis P, 2012, J NEUROTRAUM, V29, P1071, DOI 10.1089/neu.2011.2116; Gooch MR, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0962; Grossman N., 2007, Cell and Tissue Banking, V8, P243, DOI 10.1007/s10561-006-9032-x; Iwama T, 2003, NEUROSURGERY, V52, P591, DOI 10.1227/01.NEU.0000047891.86938.46; Jho DH, 2007, J NEUROSURG, V107, P440, DOI 10.3171/JNS-07/08/0440; Kriegel RJ, 2007, ZBL NEUROCHIR, V68, P182, DOI 10.1055/s-2007-985857; Liao CC, 2002, J CLIN NEUROSCI, V9, P553, DOI 10.1054/jocn.2002.1116; Lu Y, 2012, BRIT J NEUROSURG, V26, P216, DOI 10.3109/02688697.2011.629699; Morina Arsim, 2011, Surg Neurol Int, V2, P72, DOI 10.4103/2152-7806.81735; Morton RP, 2016, J NEUROSURG, V125, P766, DOI 10.3171/2015.8.JNS151390; Movassaghi K, 2006, PLAST RECONSTR SURG, V117, P202, DOI 10.1097/01.prs.0000187152.48402.17; Piedra MP, 2012, J NEUROSURG-PEDIATR, V10, P268, DOI 10.3171/2012.6.PEDS1268; Sobani Zain A, 2011, Surg Neurol Int, V2, P123, DOI 10.4103/2152-7806.85055; Staffa G, 2007, ACTA NEUROCHIR, V149, P161, DOI 10.1007/s00701-006-1078-9; Stephens FL, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.2.FOCUS1026; Walcott BP, 2013, J NEUROSURG, V118, P757, DOI 10.3171/2013.1.JNS121626; Wen L, 2007, J CRANIOFAC SURG, V18, P526; Wiggins A, 2013, NEUROSURGERY, V72, P248, DOI 10.1227/NEU.0b013e31827b98f3; Wurm G, 2004, SURG NEUROL, V62, P510, DOI 10.1016/j.surneu.2004.01.025; Yadla S, 2011, NEUROSURGERY, V68, P1124, DOI 10.1227/NEU.0b013e31820a5470; Zanaty M, 2015, J NEUROSURG, V123, P182, DOI 10.3171/2014.9.JNS14405	23	41	44	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JUN	2018	128	6					1648	1652		10.3171/2016.11.JNS161917			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	GP2IM	WOS:000440653000006	28799868	Bronze			2021-06-18	
J	Evered, L; Silbert, B; Scott, DA; Zetterberg, H; Blennow, K				Evered, Lisbeth; Silbert, Brendan; Scott, David A.; Zetterberg, Henrik; Blennow, Kaj			Association of Changes in Plasma Neurofilament Light and Tau Levels With Anesthesia and Surgery Results From the CAPACITY and ARCADIAN Studies	JAMA NEUROLOGY			English	Article							POSTOPERATIVE COGNITIVE DYSFUNCTION; TRAUMATIC BRAIN-INJURY; GENERAL-ANESTHESIA; ALZHEIMERS-DISEASE; FLUID BIOMARKER; MECHANISMS; PROTEIN; NEURODEGENERATION	IMPORTANCE Anesthesia and surgery are believed to act on the central nervous system by a fully reversible mechanism innocuous to nerve cells. Evidence that neurological sequelae may follow would challenge this belief and would thereby suggest a need to reassess theories of the mechanism of anesthetic action or the response of the central nervous system to surgery. OBJECTIVE To measure 2 biomarkers of neurological injury (neurofilament light and tau) in plasma in a series of timed collections before and after anesthesia and surgery. DESIGN, SETTING, AND PARTICIPANTS These 2 related observational studies (CAPACITY and ARCADIAN) recruited patients 60 years and older who were undergoing general anesthesia for surgeries performed within a tertiary hospital. Blood samples were taken immediately before surgical anesthesia was administered and then sequentially after surgery at 30-minute, 6-hour, 24-hour, and 48-hour intervals. Sampling took place from January 2014 to August 2015. Data analysis took place from October 2016 to February 2017. MAIN OUTCOMES AND MEASURES Plasma neurofilament light and tau. RESULTS A total of 30 patients were enrolled (13 from the CAPACITY study and 17 from the ARCADIAN study). The mean (SD) age was 69.1(7.0) years, and 18 members (59%) of the participant group were female; 22 (73%) were undergoing joint arthroplasty. Mean neurofilament light increased at each measurement from a combined baseline mean (SD) of 22.3 (20.4) pg/mL to a maximal combined mean (SD) level of 35.1(28.7) pg/mL, a maximum increase of 67% (95% CI, 45%-89%; P < .001), at 48 hours postoperatively. The level of tau increased significantly from baseline at every measurement, from a combined baseline mean (SD) of 3.1(1.3) pg/mL to a maximal combined mean (SD) of 10.8 (9.5) pg/mL, a peak increase of 257% (95% CI, 154%-361%; P < .001), at 6 hours postoperatively. After 6 hours, the mean level began to return to baseline but remained elevated after 48 hours. CONCLUSIONS AND RELEVANCE Neurofilament light is a specific marker of axonal injury and has been shown to indicate neuronal damage in a number of diseases. Tau proteins are an integral component of axonal integrity, and increased tau indicates neuronal damage. The increases in both neurofilament light and tau over 48 hours after surgery suggest that general anesthesia and surgery may be associated with neuronal damage in the short term. Further investigations will be required to study any association with clinical outcomes. These preliminary findings demand that we question the prevailing assumption that anesthesia and surgery are innocuous, transient, and without injurious changes to the central nervous system.	[Evered, Lisbeth; Silbert, Brendan; Scott, David A.] St Vincents Hosp, Dept Anaesthesia & Acute Pain Med, Ctr Anaesthesia & Cognit Funct, Melbourne, Vic, Australia; [Evered, Lisbeth; Silbert, Brendan; Scott, David A.] Univ Melbourne, Melbourne Med Sch, Anaesthesia Perioperat & Pain Med Unit, Melbourne, Vic, Australia; [Zetterberg, Henrik; Blennow, Kaj] Univ Gothenburg, Sahlgrenska Univ Hosp, Sahlgrenska Acad, Clin Neurochem Lab,Inst Neurosci & Physiol, Molndal, Sweden; [Zetterberg, Henrik] UCL, Dept Mol Neurosci, Inst Neurol, London, England	Silbert, B (corresponding author), St Vincents Hlth, Dept Anaesthesia & Acute Pain Med, POB 2900, Fitzroy, Vic 3065, Australia.	brendan.silbert@svha.org.au			Department of Health National Health and Medical Research Council [1027178]; Australian and New Zealand College of Anaesthetists grant [15/026]; Department of Health/National Health and Medical Research Council Dementia Research Fellowship [1102462]; Svenska Forskningsradet Formas (Swedish Research Council Formas)Swedish Research Council Formas [2013-2546]; European Research CouncilEuropean Research Council (ERC)European Commission [681712]; Swedish State Support for Clinical Research grant [ALFGBG-441051]; Swedish Alzheimer's Foundation [AF-553101, AF-646211]; Research Council Sweden grant [14002]; Swedish Brain Foundation [FO2015-0021]; LUA/ALF-medel Vastra Gotalandsregionen grant [ALFGBG-139671]	Drs Evered, Silbert, and Scott are supported by Department of Health National Health and Medical Research Council grant 1027178 and Australian and New Zealand College of Anaesthetists grant 15/026. Dr Evered is supported by Department of Health/National Health and Medical Research Council Dementia Research Fellowship grant 1102462. Dr Zetterberg is supported by Svenska Forskningsradet Formas (Swedish Research Council Formas) grant 2013-2546, European Research Council grant 681712, and Swedish State Support for Clinical Research grant ALFGBG-441051. Dr Blennow is supported by Swedish Alzheimer's Foundation grants AF-553101 and AF-646211, Research Council Sweden grant 14002, Swedish Brain Foundation grant FO2015-0021, and LUA/ALF-medel Vastra Gotalandsregionen grant ALFGBG-139671.	Al Nimer F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132177; Andreasson Ulf, 2016, Alzheimers Dement (Amst), V3, P98, DOI 10.1016/j.dadm.2016.05.005; Andropoulos DB, 2017, NEW ENGL J MED, V376, P905, DOI 10.1056/NEJMp1700196; Berger M, 2016, J ALZHEIMERS DIS, V52, P1299, DOI 10.3233/JAD-151190; Evered L, 2016, ANESTHESIOLOGY, V124, P353, DOI 10.1097/ALN.0000000000000953; Fodale V, 2006, BRIT J ANAESTH, V97, P445, DOI 10.1093/bja/ael233; Franks NP, 2006, BRIT J PHARMACOL, V147, pS72, DOI 10.1038/sj.bjp.0706441; Gisslen M, 2016, EBIOMEDICINE, V3, P135, DOI 10.1016/j.ebiom.2015.11.036; Hogue CW, 2006, ANESTH ANALG, V103, P21, DOI 10.1213/01.ANE.0000220035.82989.79; Lambert DG, 2017, ANAEST INTENS CARE M, V18, P344, DOI 10.1016/j.mpaic.2017.04.008; Mattsson N, 2016, NEUROLOGY, V87, P1827, DOI 10.1212/WNL.0000000000003246; Moller JT, 1998, LANCET, V351, P857, DOI 10.1016/S0140-6736(97)07382-0; Paredes S, 2016, ACTA ANAESTH SCAND, V60, P1043, DOI 10.1111/aas.12724; POCOCK G, 1991, BRIT J ANAESTH, V66, P116, DOI 10.1093/bja/66.1.116; Randall J, 2013, RESUSCITATION, V84, P351, DOI 10.1016/j.resuscitation.2012.07.027; Rappaport BA, 2015, NEW ENGL J MED, V372, P796, DOI 10.1056/NEJMp1414786; Rohrer JD, 2016, NEUROLOGY, V87, P1329, DOI 10.1212/WNL.0000000000003154; Rojas JC, 2016, ANN CLIN TRANSL NEUR, V3, P216, DOI 10.1002/acn3.290; Shahim P, 2017, NEUROLOGY, V88, P1788, DOI 10.1212/WNL.0000000000003912; Shahim P, 2016, SCI REP-UK, V6, DOI 10.1038/srep36791; Spillantini MG, 2013, LANCET NEUROL, V12, P609, DOI 10.1016/S1474-4422(13)70090-5; Strom C, 2014, ANAESTHESIA, V69, P35, DOI 10.1111/anae.12493; Tang JXX, 2011, ANESTHESIOLOGY, V115, P727, DOI 10.1097/ALN.0b013e31822e9306; van Harten AE, 2012, ANAESTHESIA, V67, P280, DOI 10.1111/j.1365-2044.2011.07008.x; Vutskits L, 2016, NAT REV NEUROSCI, V17, P705, DOI 10.1038/nrn.2016.128; Westermann D, 2017, NAT REV CARDIOL, V14, P472, DOI 10.1038/nrcardio.2017.48; Xie ZC, 2006, ANESTHESIOLOGY, V104, P988, DOI 10.1097/00000542-200605000-00015; Zetterberg H, 2016, NEURON, V91, P1, DOI 10.1016/j.neuron.2016.06.030	28	41	45	1	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6149	2168-6157		JAMA NEUROL	JAMA Neurol.	MAY	2018	75	5					542	547		10.1001/jamaneurol.2017.4913			6	Clinical Neurology	Neurosciences & Neurology	GF9RL	WOS:000432316000007	29459944	Green Published, Bronze			2021-06-18	
J	Li, H; Sun, J; Du, J; Wang, F; Fang, R; Yu, C; Xiong, J; Chen, W; Lu, Z; Liu, J				Li, H.; Sun, J.; Du, J.; Wang, F.; Fang, R.; Yu, C.; Xiong, J.; Chen, W.; Lu, Z.; Liu, J.			Clostridium butyricum exerts a neuroprotective effect in a mouse model of traumatic brain injury via the gut-brain axis	NEUROGASTROENTEROLOGY AND MOTILITY			English	Article						Clostridium butyricum; glucagon-like peptide-1; gut brain axis; neuroprotection; traumatic brain injury	GLUCAGON-LIKE PEPTIDE-1; CEREBRAL ISCHEMIA/REPERFUSION INJURY; DEPENDENT INSULINOTROPIC POLYPEPTIDE; BARRIER INTEGRITY; INTESTINAL PERMEABILITY; SODIUM-BUTYRATE; MICE; MICROBIOTA; EDEMA; GLP-1	Background: Traumatic brain injury (TBI) is a common occurrence following gastrointestinal dysfunction. Recently, more and more attentions are being focused on gut microbiota in brain and behavior. Glucagon-like peptide-1 (GLP-1) is considered as a mediator that links the gut-brain axis. The aim of this study was to explore the neuroprotective effects of Clostridium butyricum (Cb) on brain damage in a mouse model of TBI. Methods: Male C57BL/6 mice were subjected to a model of TBI-induced by weight-drop impact head injury and were treated intragastrically with Cb. The cognitive deficits, brain water content, neuronal death, and blood-brain barrier (BBB) permeability were evaluated. The expression of tight junction (TJ) proteins, Bcl-2, Bax, GLP-1 receptor (GLP-1R), and phosphorylation of Akt (p-Akt) in the brain were also measured. Moreover, the intestinal barrier permeability, the expression of TJ protein and GLP-1, and IL-6 level in the intestine were detected. Results: Cb treatment significantly improved neurological dysfunction, brain edema, neurodegeneration, and BBB impairment. Meanwhile, Cb treatment also significantly increased the expression of TJ proteins (occludin and zonula occluden-1), p-Akt and Bcl-2, but decreased expression of Bax. Moreover, Cb treatment exhibited more prominent effects on decreasing the levels of plasma d-lactate and colonic IL-6, up-regulating expression of Occludin, and protecting intestinal barrier integrity. Furthermore, Cb-treated mice showed increased the secretion of intestinal GLP-1 and upregulated expression of cerebral GLP-1R. Conclusions: Our findings demonstrated the neuroprotective effect of Cb in TBI mice and the involved mechanisms were partially attributed to the elevating GLP-1 secretion through the gut-brain axis.	[Li, H.; Lu, Z.] Wenzhou Med Univ, Affiliated Hosp 1, Dept Emergency Med, Wenzhou, Zhejiang, Peoples R China; [Sun, J.] Wenzhou Med Univ, Affiliated Hosp 2, Dept Neurol, Wenzhou, Zhejiang, Peoples R China; [Du, J.] Wenzhou Med Univ, Dept Clin Microbiol & Immunol, Wenzhou, Zhejiang, Peoples R China; [Wang, F.] Wenzhou Med Univ, Dept Pathophysiol, Wenzhou, Zhejiang, Peoples R China; [Fang, R.; Yu, C.; Xiong, J.; Chen, W.; Liu, J.] Wenzhou Med Univ, Dept Prevent Med, Wenzhou, Zhejiang, Peoples R China	Liu, J (corresponding author), Wenzhou Med Univ, Dept Prevent Med, Wenzhou, Zhejiang, Peoples R China.	wzjiaming_liu@163.com			Zhejiang Province Traditional Chinese medicine scientific research funds [2017ZA096]; Zhejiang Medical and Health General Research [2018254915, 2017173424]; Wenzhou Science and Technology Research [Y20170145]	Zhejiang Province Traditional Chinese medicine scientific research funds, Grant/Award Number: 2017ZA096; Zhejiang Medical and Health General Research, Grant/Award Number: 2018254915 and 2017173424; Wenzhou Science and Technology Research, Grant/Award Number: Y20170145	Ait-Belgnaoui A, 2014, NEUROGASTROENT MOTIL, V26, P510, DOI 10.1111/nmo.12295; Alahmadi H, 2010, J NEUROSURG, V112, P1139, DOI 10.3171/2009.5.JNS081369; Alvarez JI, 2011, SCIENCE, V334, P1727, DOI 10.1126/science.1206936; Alves JL, 2014, J NEUROSCI RES, V92, P141, DOI 10.1002/jnr.23300; Araki Y, 2002, INT J MOL MED, V9, P53; Bansal V, 2009, J NEUROTRAUM, V26, P1353, DOI 10.1089/neu.2008-0858; Barton W, 2018, GUT, V67, P625, DOI 10.1136/gutjnl-2016-313627; Blixt J, 2015, BRAIN RES, V1611, P18, DOI 10.1016/j.brainres.2015.03.004; Carabotti M, 2015, ANN GASTROENTEROL, V28, P203; DeKosky ST, 2013, NAT REV NEUROL, V9, P192, DOI 10.1038/nrneurol.2013.36; DellaValle B, 2014, ANN CLIN TRANSL NEUR, V1, P721, DOI 10.1002/acn3.99; Ding K, 2015, J SURG RES, V194, P239, DOI 10.1016/j.jss.2014.09.026; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Dube PE, 2004, HORM METAB RES, V36, P755, DOI 10.1055/s-2004-826159; Faivre E, 2011, J NEUROPHYSIOL, V105, P1574, DOI 10.1152/jn.00866.2010; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Feighery L, 2008, J TRAUMA, V64, P131, DOI 10.1097/TA.0b013e3181568d9f; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Fukuda S, 2016, J MOL NEUROSCI, V59, P211, DOI 10.1007/s12031-015-0696-1; Gao ZG, 2009, DIABETES, V58, P1509, DOI 10.2337/db08-1637; Greiner TU, 2016, MOL METAB, V5, P753, DOI 10.1016/j.molmet.2016.05.012; Higashida T, 2011, J NEUROSURG, V114, P92, DOI 10.3171/2010.6.JNS10207; Iwai T, 2006, NEUROSCI RES, V55, P352, DOI 10.1016/j.neures.2006.04.008; Jiang CM, 2017, J ALZHEIMERS DIS, V58, P1, DOI 10.3233/JAD-161141; Jin W, 2008, CYTOKINE, V44, P135, DOI 10.1016/j.cyto.2008.07.005; Juengst SB, 2015, REHABIL PSYCHOL, V60, P353, DOI 10.1037/rep0000056; Jung SY, 2014, EXP THER MED, V7, P587, DOI 10.3892/etm.2013.1451; Katzenberger RJ, 2015, FLY, V9, P68, DOI 10.1080/19336934.2015.1085623; Kharrazian D, 2015, ALTERN THER HEALTH M, V21, P28; Li HX, 2016, BRAIN RES, V1642, P70, DOI 10.1016/j.brainres.2016.03.031; Li W, 2016, J NUTR, V146, P964, DOI 10.3945/jn.115.228312; Li YZ, 2009, P NATL ACAD SCI USA, V106, P1285, DOI 10.1073/pnas.0806720106; Liu JK, 2015, BRAIN RES, V1610, P1, DOI 10.1016/j.brainres.2015.03.044; Livingston EM, 2017, J AM ACAD CHILD PSY, V56, P895, DOI 10.1016/j.jaac.2017.07.787; MacFabe Derrick F., 2012, Microbial Ecology in Health and Disease, V23, P19260, DOI 10.3402/mehd.v23i0.19260; Macfarlane S, 2003, P NUTR SOC, V62, P67, DOI 10.1079/PNS2002207; Mark KS, 2002, AM J PHYSIOL-HEART C, V282, pH1485, DOI 10.1152/ajpheart.00645.2001; Mullonkal CJ, 2007, J INVEST SURG, V20, P195, DOI 10.1080/08941930701366471; Nyberg J, 2007, J NEUROSCI RES, V85, P2099, DOI 10.1002/jnr.21349; Parashar A, 2017, PARKINSONISM RELAT D, V38, P1, DOI 10.1016/j.parkreldis.2017.02.002; Puddu A, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/975032; Rachmany L, 2013, AGE, V35, P1621, DOI 10.1007/s11357-012-9464-0; Ragaisis Vytautas, 2002, Medicina (Kaunas), V38, P243; Rahner C, 2001, GASTROENTEROLOGY, V120, P411, DOI 10.1053/gast.2001.21736; Rojo D, 2017, FEMS MICROBIOL REV, V41, P453, DOI 10.1093/femsre/fuw046; Rosenfeld JV, 2012, LANCET, V380, P1088, DOI 10.1016/S0140-6736(12)60864-2; Rupprecht LE, 2013, AM J PHYSIOL-ENDOC M, V305, pE751, DOI 10.1152/ajpendo.00367.2013; Salcedo I, 2012, BRIT J PHARMACOL, V166, P1586, DOI 10.1111/j.1476-5381.2012.01971.x; Santos A, 2008, BASIC CLIN PHARMACOL, V103, P247, DOI 10.1111/j.1742-7843.2008.00272.x; Savignac HM, 2015, BEHAV BRAIN RES, V287, P59, DOI 10.1016/j.bbr.2015.02.044; Savignac HM, 2014, NEUROGASTROENT MOTIL, V26, P1615, DOI 10.1111/nmo.12427; Schmued LC, 2005, BRAIN RES, V1035, P24, DOI 10.1016/j.brainres.2004.11.054; Sun J, 2016, BRAIN RES, V1642, P180, DOI 10.1016/j.brainres.2016.03.042; Sun J, 2016, NEUROSCI LETT, V618, P159, DOI 10.1016/j.neulet.2016.03.003; Sun J, 2016, NEUROSCI LETT, V613, P30, DOI 10.1016/j.neulet.2015.12.047; Sundman MH, 2017, BRAIN BEHAV IMMUN, V66, P31, DOI 10.1016/j.bbi.2017.05.009; Szalay L, 2003, SHOCK, V20, P245, DOI 10.1097/00024382-200309000-00008; Tolhurst G, 2012, DIABETES, V61, P364, DOI 10.2337/db11-1019; Tweedie D, 2013, EXP NEUROL, V239, P170, DOI 10.1016/j.expneurol.2012.10.001; Umeda K, 2006, CELL, V126, P741, DOI 10.1016/j.cell.2006.06.043; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Yang Y, 2014, NEUROSCI LETT, V568, P44, DOI 10.1016/j.neulet.2014.03.037; Yuan J, 2016, BRAIN RES BULL, V127, P171, DOI 10.1016/j.brainresbull.2016.09.010; Zhao YZ, 2015, NEURAL REGEN RES, V10, P1076, DOI 10.4103/1673-5374.160097; Zhu KJ, 2014, WORLD J GASTROENTERO, V20, P9585, DOI 10.3748/wjg.v20.i28.9585	66	41	45	1	32	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1350-1925	1365-2982		NEUROGASTROENT MOTIL	Neurogastroenterol. Motil.	MAY	2018	30	5							e13260	10.1111/nmo.13260			12	Gastroenterology & Hepatology; Clinical Neurology; Neurosciences	Gastroenterology & Hepatology; Neurosciences & Neurology	GE1XM	WOS:000431010100002	29193450				2021-06-18	
J	Main, BS; Villapol, S; Sloley, SS; Barton, DJ; Parsadanian, M; Agbaegbu, C; Stefos, K; McCann, MS; Washington, PM; Rodriguez, OC; Burns, MP				Main, Bevan S.; Villapol, Sonia; Sloley, Stephanie S.; Barton, David J.; Parsadanian, Maia; Agbaegbu, Chinyere; Stefos, Kathryn; McCann, Mondona S.; Washington, Patricia M.; Rodriguez, Olga C.; Burns, Mark P.			Apolipoprotein E4 impairs spontaneous blood brain barrier repair following traumatic brain injury	MOLECULAR NEURODEGENERATION			English	Article						Apolipoprotein E; Blood brain barrier; Neurovascular unit; Pericyte; MMP-9; CD31; Lectin; TBI	CONTROLLED CORTICAL IMPACT; CLOSED-HEAD INJURY; CEREBROSPINAL-FLUID; AMYLOID-BETA; NEUROINFLAMMATORY RESPONSE; KERATAN SULFATE; DISRUPTION; PERMEABILITY; EDEMA; MICE	Background: Traumatic Brain Injury (TBI) is a major cause of disability and mortality, to which there is currently no comprehensive treatment. Blood Brain Barrier (BBB) dysfunction is well documented in human TBI patients, yet the molecular mechanisms that underlie this neurovascular unit (NVU) pathology remains unclear. The apolipoprotein-E (apoE) protein has been implicated in controlling BBB integrity in an isoform dependent manner, via suppression of Cyclophilin A (CypA)-Matrix metallopeptidase-9 (MMP-9) signaling cascades, however the contribution of this pathway in TBI-induced BBB permeability is not fully investigated. Methods: We exposed C57Bl/6 mice to controlled cortical impact and assessed NVU and BBB permeability responses up to 21 days post-injury. We pharmacologically probed the role of the CypA-MMP-9 pathway in BBB permeability after TBI using Cyclosporin A (CsA, 20 mg/kg). Finally, as the apoE4 protein is known to be functionally deficient compared to the apoE3 protein, we used humanized APOE mice as a clinically relevant model to study the role of apoE on BBB injury and repair after TBI. Results: In C57Bl/6 mice there was an inverse relationship between soluble apoE and BBB permeability, such that damaged BBB stabilizes as apoE levels increase in the days following TBI. TBI mice displayed acute pericyte loss, increased MMP-9 production and activity, and reduced tight-junction expression. Treatment with the CypA antagonist CsA in C57Bl/6 mice attenuates MMP-9 responses and enhances BBB repair after injury, demonstrating that MMP-9 plays an important role in the timing of spontaneous BBB repair after TBI. We also show that apoe mRNA is present in both astrocytes and pericytes after TBI. We report that APOE3 and APOE4 mice have similar acute BBB responses to TBI, but APOE3 mice display faster spontaneous BBB repair than APOE4 mice. Isolated microvessel analysis reveals delayed pericyte repopulation, augmented and sustained MMP-9 expression at the NVU, and impaired stabilization of Zonula Occludens-1, Occludin and Claudin-5 expression at tight junctions in APOE4 mice after TBI compared to APOE3 mice. Conclusions: These data confirm apoE as an important modulator of spontaneous BBB stabilization following TBI, and highlights the APOE4 allele as a risk factor for poor outcome after TBI.	[Rodriguez, Olga C.] Georgetown Univ, Med Ctr, Dept Oncol, Washington, DC 20057 USA; [Main, Bevan S.; Villapol, Sonia; Sloley, Stephanie S.; Barton, David J.; Parsadanian, Maia; Agbaegbu, Chinyere; Stefos, Kathryn; McCann, Mondona S.; Washington, Patricia M.; Burns, Mark P.] Georgetown Univ, Med Ctr, Dept Neurosci, Lab Brain Injury & Dementia, Washington, DC 20007 USA; [Burns, Mark P.] Georgetown Univ, Med Ctr, Dept Neurosci, New Res Buld EG11,3970 Reservoir Rd,NW, Washington, DC 20057 USA	Burns, MP (corresponding author), Georgetown Univ, Med Ctr, Dept Neurosci, Lab Brain Injury & Dementia, Washington, DC 20007 USA.; Burns, MP (corresponding author), Georgetown Univ, Med Ctr, Dept Neurosci, New Res Buld EG11,3970 Reservoir Rd,NW, Washington, DC 20057 USA.	mpb37@georgetown.edu	Villapol, Sonia/D-1949-2014; Barton, David J/C-9282-2011	Barton, David J/0000-0003-0976-0383; Villapol, Sonia/0000-0002-6174-4113; McCann, Mondona/0000-0002-6520-7956; Burns, Mark P/0000-0003-4750-2000	National Institute for Neurological Disorders and Stroke (NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS067417, R03NS095038]; Department of Health and Human Services [90AR5005]; Neural Injury and Plasticity pre-doctoral fellowship [T32 NS041218]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS041218, R03NS095038, R01NS081068, R03NS067417] Funding Source: NIH RePORTER	This work was supported by R01NS067417 (MPB) and R03NS095038 (SV) from the National Institute for Neurological Disorders and Stroke (NINDS). The Advanced Rehabilitation Research and Training Program (90AR5005) funded by The Department of Health and Human Services provided fellowship support for BSM and a T32 NS041218 Neural Injury and Plasticity pre-doctoral fellowship supported SSS.	Alata W, 2015, J CEREBR BLOOD F MET, V35, P86, DOI 10.1038/jcbfm.2014.172; Alves JL, 2014, J NEUROSCI RES, V92, P141, DOI 10.1002/jnr.23300; Armulik A, 2010, NATURE, V468, P557, DOI 10.1038/nature09522; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Beaumont A, 2006, ACTA NEUROCHIR SUPPL, V96, P171; Bell RD, 2012, NATURE, V485, P512, DOI 10.1038/nature11087; Bell RD, 2010, NEURON, V68, P409, DOI 10.1016/j.neuron.2010.09.043; Blyth BJ, 2009, J NEUROTRAUM, V26, P1497, DOI [10.1089/neu.2008.0738, 10.1089/neu.2008-0738]; Cao F, 2016, J NEUROTRAUM, V33, P175, DOI 10.1089/neu.2015.3887; Cartagena CM, 2008, J NEUROTRAUM, V25, P1087, DOI 10.1089/neu.2007.0444; Casey CS, 2015, J BIOL CHEM, V290, P14208, DOI 10.1074/jbc.M114.625251; Chen CC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030294; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; Cherian L, 2011, J PHARMACOL EXP THER, V337, P451, DOI 10.1124/jpet.110.176602; COLTON CA, 1992, J HISTOCHEM CYTOCHEM, V40, P505, DOI 10.1177/40.4.1372634; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Dash PK, 2016, J NEUROSCI, V36, P2809, DOI 10.1523/JNEUROSCI.3197-15.2016; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Dore-Duffy P, 2000, MICROVASC RES, V60, P55, DOI 10.1006/mvre.2000.2244; Enerson BE, 2006, J CEREBR BLOOD F MET, V26, P959, DOI 10.1038/sj.jcbfm.9600249; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Glushakova OY, 2014, J NEUROTRAUM, V31, P1180, DOI 10.1089/neu.2013.3080; Hafezi-Moghadam A, 2007, AM J PHYSIOL-CELL PH, V292, pC1256, DOI 10.1152/ajpcell.00563.2005; Halliday MR, 2016, J CEREBR BLOOD F MET, V36, P216, DOI 10.1038/jcbfm.2015.44; Halliday MR, 2013, JAMA NEUROL, V70, P1198, DOI 10.1001/jamaneurol.2013.3841; Hay JR, 2015, J NEUROPATH EXP NEUR, V74, P1147, DOI [10.1093/jnen/74.12.1147, 10.1097/NEN.0000000000000261]; Higashida T, 2011, J NEUROSURG, V114, P92, DOI 10.3171/2010.6.JNS10207; Ho KM, 2014, J NEUROSURG, V121, P674, DOI 10.3171/2014.6.JNS132838; Horsburgh K, 2000, J CEREBR BLOOD F MET, V20, P458, DOI 10.1097/00004647-200003000-00003; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Kay AD, 2003, J NEUROTRAUM, V20, P943, DOI 10.1089/089771503770195795; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Kenney K, 2016, EXP NEUROL, V275, P353, DOI 10.1016/j.expneurol.2015.05.019; Lanfranco MF, 2017, BIO-PROTOCOL, V7, DOI 10.21769/BioProtoc.2608; Li HX, 2016, BRAIN RES, V1642, P70, DOI 10.1016/j.brainres.2016.03.031; Li SJ, 2015, J TRAUMA ACUTE CARE, V79, P78, DOI 10.1097/TA.0000000000000697; Lin Y, 2012, LAB INVEST, V92, P1623, DOI 10.1038/labinvest.2012.118; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Loane DJ, 2011, J NEUROTRAUM, V28, P225, DOI 10.1089/neu.2010.1595; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Main BS, 2017, J NEUROCHEM, V141, P75, DOI 10.1111/jnc.13940; Main BS, 2016, GLIA, V64, P1590, DOI 10.1002/glia.23028; Mannix RC, 2011, J CEREBR BLOOD F MET, V31, P351, DOI 10.1038/jcbfm.2010.99; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; Meng QY, 2017, EBIOMEDICINE, V16, P184, DOI 10.1016/j.ebiom.2017.01.046; Methia N, 2001, MOL MED, V7, P810, DOI 10.1007/BF03401973; Namjoshi DR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053529; Neuwelt E, 2008, LANCET NEUROL, V7, P84, DOI 10.1016/S1474-4422(07)70326-5; Park E, 2009, J CEREBR BLOOD F MET, V29, P575, DOI 10.1038/jcbfm.2008.151; Price L., 2016, TRANSLATIONAL RES TR; Rodriguez-Baeza A, 2003, ANAT REC PART A, V273A, P583, DOI 10.1002/ar.a.10069; Sabo T, 2000, NEUROSCIENCE, V101, P879, DOI 10.1016/S0306-4522(00)00438-3; Sangiorgi S, 2013, J NEUROSURG, V118, P763, DOI 10.3171/2012.11.JNS12627; Saw MM, 2014, NEUROCRIT CARE, V20, P209, DOI 10.1007/s12028-013-9933-z; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Si DW, 2014, EXP THER MED, V8, P1010, DOI 10.3892/etm.2014.1840; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; Stahel PF, 2001, J NEUROTRAUM, V18, P773, DOI 10.1089/089771501316919139; Storck SE, 2016, J CLIN INVEST, V126, P123, DOI 10.1172/JCI81108; Suehiro E, 2004, J NEUROTRAUM, V21, P1706, DOI 10.1089/0897715042664957; Sullivan PG, 2000, NEUROSCIENCE, V101, P289, DOI 10.1016/S0306-4522(00)00380-8; Takata F, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-106; Tao X, 2015, NEUROSCIENCE, V291, P26, DOI 10.1016/j.neuroscience.2015.01.070; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Teng ZP, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06932-3; Tomkins Oren, 2011, Cardiovasc Psychiatry Neurol, V2011, P765923, DOI 10.1155/2011/765923; Tsuji D, 2005, J NEUROCHEM, V92, P1497, DOI 10.1111/j.1471-4159.2005.02986.x; Vilalta A, 2008, INTENS CARE MED, V34, P1384, DOI 10.1007/s00134-008-1056-1; Villapol S, 2017, GLIA, V65, P1423, DOI 10.1002/glia.23171; Villapol S, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00082; Washington PM, 2014, J NEUROTRAUM, V31, P125, DOI 10.1089/neu.2013.3017; Washington PM, 2016, J NEUROPATHOL EXP NE; Wilhelmus MMM, 2005, J NEUROSCI, V25, P3621, DOI 10.1523/JNEUROSCI.4213-04.2005; Winer J, 1999, ANAL BIOCHEM, V270, P41, DOI 10.1006/abio.1999.4085; Winkler EA, 2012, J CEREBR BLOOD F MET, V32, P1841, DOI 10.1038/jcbfm.2012.113; Xu Q, 2006, J NEUROSCI, V26, P4985, DOI 10.1523/JNEUROSCI.5476-05.2006; Yamakawa H, 2003, J CEREBR BLOOD F MET, V23, P371, DOI 10.1097/01.WCB.0000047369.05600.03; Yamamoto T, 1988, J NEUROTRAUM, V5, P69, DOI 10.1089/neu.1988.5.69; Yao XM, 2015, J NEUROTRAUM, V32, P1458, DOI 10.1089/neu.2014.3675; Yuan F, 2016, J NEUROCHEM, V136, P581, DOI 10.1111/jnc.13423; Zehendner CM, 2015, SCI REP-UK, V5, DOI 10.1038/srep13497; Zhang HQ, 2006, ANN NY ACAD SCI, V1086, P81, DOI 10.1196/annals.1377.014; Zhang HQ, 2006, GLYCOBIOLOGY, V16, P702, DOI 10.1093/glycob/cwj115; Zozulya A, 2008, BRAIN RES, V1189, P1, DOI 10.1016/j.brainres.2007.10.099	87	41	42	0	8	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1750-1326			MOL NEURODEGENER	Mol. Neurodegener.	APR 4	2018	13								17	10.1186/s13024-018-0249-5			18	Neurosciences	Neurosciences & Neurology	GC6AZ	WOS:000429873800002	29618365	DOAJ Gold, Green Published			2021-06-18	
J	Geeraerts, T; Velly, L; Abdennour, L; Asehnoune, K; Audibert, G; Bouzat, P; Bruder, N; Carrillon, R; Cottenceau, V; Cotton, F; Courtil-Teyssedre, S; Dahyot-Fizelier, C; Dailler, F; David, JS; Engrand, N; Fletcher, D; Francony, G; Gergele, L; Ichai, C; Javouhey, E; Leblanc, PE; Lieutaud, T; Meyer, P; Mirek, S; Orliaguet, G; Proust, F; Quintard, H; Ract, C; Srairi, M; Tazarourte, K; Vigue, B; Payen, JF				Geeraerts, Thomas; Velly, Lionel; Abdennour, Lamine; Asehnoune, Karim; Audibert, Gerard; Bouzat, Pierre; Bruder, Nicolas; Carrillon, Romain; Cottenceau, Vincent; Cotton, Francois; Courtil-Teyssedre, Sonia; Dahyot-Fizelier, Claire; Dailler, Frederic; David, Jean-Stephane; Engrand, Nicolas; Fletcher, Dominique; Francony, Gilles; Gergele, Laurent; Ichai, Carole; Javouhey, Etienne; Leblanc, Pierre-Etienne; Lieutaud, Thomas; Meyer, Philippe; Mirek, Sebastien; Orliaguet, Gilles; Proust, Francois; Quintard, Herve; Ract, Catherine; Srairi, Mohamed; Tazarourte, Karim; Vigue, Bernard; Payen, Jean-Francois		French Soc Anaesthesia Intensive C; Assoc Neuro Anesthesie Reanimation; French Soc Emergency Med; Soc Francaise Neurochirurgie; Grp Francophone Reanimation Urgenc; Assoc Anesthesistes Reanimateurs P	Management of severe traumatic brain injury (first 24 hours)	ANAESTHESIA CRITICAL CARE & PAIN MEDICINE			English	Article							CEREBRAL PERFUSION-PRESSURE; GLASGOW-COMA-SCALE; SEVERE HEAD-INJURY; SIMPLIFIED MOTOR SCORE; INTENSIVE INSULIN THERAPY; SYSTOLIC BLOOD-PRESSURE; INTRA-CRANICAL PRESSURE; REFRACTORY INTRACRANIAL HYPERTENSION; EARLY DECOMPRESSIVE CRANIECTOMY; RANDOMIZED CONTROLLED-TRIALS	The latest French Guidelines for the management in the first 24 hours of patients with severe traumatic brain injury (TBI) were published in 1998. Due to recent changes (intracerebral monitoring, cerebral perfusion pressure management, treatment of raised intracranial pressure), an update was required. Our objective has been to specify the significant developments since 1998. These guidelines were conducted by a group of experts for the French Society of Anesthesia and Intensive Care Medicine (Societe francaise d'anesthesie et de reanimation [SFAR]) in partnership with the Association de neuro-anesthesie-reanimation de langue francaise (ANARLF), The French Society of Emergency Medicine (Societe francaise de medecine d'urgence (SFMU), the Societe francaise de neurochirurgie (SFN), the Groupe francophone de reanimation et d'urgences pediatriques (GFRUP) and the Association des anesthesistes-reanimateurs pediatriques d'expression francaise (ADARPEF). The method used to elaborate these guidelines was the Grade (R) method. After two Delphi rounds, 32 recommendations were formally developed by the experts focusing on the evaluation the initial severity of traumatic brain injury, the modalities of prehospital management, imaging strategies, indications for neurosurgical interventions, sedation and analgesia, indications and modalities of cerebral monitoring, medical management of raised intracranial pressure, management of multiple trauma with severe traumatic brain injury, detection and prevention of post-traumatic epilepsia, biological homeostasis (osmolarity, glycaemia, adrenal axis) and paediatric specificities. (C) 2017 The Authors. Published by Elsevier Masson SAS on behalf of Societe francaise d'anesthesie et de reanimation (Sfar).	[Geeraerts, Thomas; Srairi, Mohamed] Univ Toulouse 3, Paul Sabatier, CHU Toulouse,Pole Anesthesie Reanimat, ToNIC,Toulouse Neuroimaging Ctr,UMR 1214,Inserm, F-31059 Toulouse, France; [Velly, Lionel; Bruder, Nicolas] Univ Aix Marseille, CHU Timone, AP HM, Serv Anesthesie Reanimat, F-13005 Marseille, France; [Abdennour, Lamine] Grp Hosp Pitie Salpetriere, AP HP, Dept Anesthesie Reanimat, F-75013 Paris, France; [Asehnoune, Karim] CHU Nantes, Hotel Dieu, Serv Anesthesie & Reanimat Chirurgicale, F-44093 Nantes 1, France; [Audibert, Gerard] CHU Nancy, Hop Cent, Dept Anesthesie & Reanimat, F-54000 Nancy, France; [Bouzat, Pierre; Francony, Gilles; Payen, Jean-Francois] CHU Grenoble Alpes, Pole Anesthesie Reanimat, F-38043 Grenoble 9, France; [Carrillon, Romain; Dailler, Frederic] Hosp civils Lyon, Grp Hosp Est, Hop Neurol Pierre Wertheimer, Serv Anesthesie & Reanimat, F-69677 Bron, France; [Cottenceau, Vincent] CHU Bordeaux, Hop Pellegrin, SAR 1, Serv Reanimat Cirurgicale & Traumatol, Bordeaux, France; [Cotton, Francois] Hosp Civils Lyon, Ctr Hosp Lyon Sud, Serv Imagerie, F-69495 Pierre Benite, France; [Courtil-Teyssedre, Sonia; Javouhey, Etienne] Hosp Civils Lyon, Hop Femme Mere Enfant, Serv Reanimat Pediat, F-69677 Bron, France; [Dahyot-Fizelier, Claire] CHU Poitiers, Dept Anesthesie & Reanimat, F-86021 Poitiers, France; [David, Jean-Stephane] Ctr Hosp Lyon Sud, Hospices Civils Lyon, Serv Anesthesie Reanimat, F-69495 Pierre Benite, France; [Engrand, Nicolas] Fdn Ophtalmol Adolphe Rothschild, Serv Anesthesie Reanimat, F-75940 Paris 19, France; [Fletcher, Dominique] Univ Versailles St Quentin, Hop Raymond Poincare, AP HP, Serv Anesthesie Reanimat Chirurgicale, Garches, France; [Gergele, Laurent] CHU St Etienne, Dept Anesthesie & Reanimat, F-42055 St Etienne, France; [Ichai, Carole; Quintard, Herve] CHU Nice, Hop Pasteur, CNRS, UMR 7275,Serv Anesthesie Reanimat Med Chirurgical, F-06000 Nice, France; [Leblanc, Pierre-Etienne; Ract, Catherine; Vigue, Bernard] Hop Univ Paris Sud, Hop Bicetre, AP HP, Dept Anesthesie & Reanimat, Le Kremlin Bicetre, France; [Leblanc, Pierre-Etienne; Ract, Catherine; Vigue, Bernard] Ctr Rech Neurosci, Ctr Hosp Bourg Bresse, Serv Anesthesie, Inserm 5288,CNRS 1072,Equipe TIGER, Lyon, France; [Lieutaud, Thomas] Univ Claude Bernard Lyon, IFSTTAR, UMR T9405, UMRESTTE, Lyon, France; [Lieutaud, Thomas] Univ Paris 05, Hop Univ Necker Enfants Malades, Serv Anesthesie Reanimat, AP HP, Paris, France; [Meyer, Philippe; Orliaguet, Gilles] Serv Pharmacol & Evaluat Therapeut Chez Enfant En, EA Paris Descartes 08, F-75743 Paris 15, France; [Mirek, Sebastien] CHU Dijon, Serv Anesthesie Reanimat, Dijon, France; [Proust, Francois] CHU Strasbourg, Serv Neurochirurgie, Hop Hautepierre, F-67098 Strasbourg, France; [Tazarourte, Karim] Hop Edouard Herriot, Hosp civils Lyon, SAMU SMUR Serv Urgences, F-69437 Lyon 03, France	Geeraerts, T (corresponding author), CHU Toulouse, Pole Anesthesie Reanimat, F-31059 Toulouse 9, France.	geeraerts.t@chu-toulouse.fr	cotton, francois/F-4762-2013; David, Jean Stephane/H-9399-2019; Bouzat, Pierre/AAC-4105-2019; Meyer, Philippe/ABE-4242-2020; Bouzat, Pierre/L-6881-2014; Payen, Jean-Francois/L-6667-2014	cotton, francois/0000-0003-0046-2478; David, Jean Stephane/0000-0001-6274-7044; Bouzat, Pierre/0000-0003-4667-6738; Meyer, Philippe/0000-0002-3829-6631; Srairi, Mohamed/0000-0001-7219-501X; tazarourte, karim/0000-0002-3376-1258; Orliaguet, Gilles/0000-0003-0930-2251; GERGELE, Laurent/0000-0002-7283-6793			Adelson P David, 2003, Pediatr Crit Care Med, V4, pS5; Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Al-Salamah MA, 2004, ACAD EMERG MED, V11, P834, DOI 10.1197/j.aem.2004.03.008; Alahmadi H, 2010, J NEUROSURG, V112, P1139, DOI 10.3171/2009.5.JNS081369; Albanese J, 1999, CRIT CARE MED, V27, P407, DOI 10.1097/00003246-199902000-00050; Algarra NN, 2016, J NEUROSURG ANESTHES; Alkhoury F, 2014, JAMA SURG, V149, P544, DOI 10.1001/jamasurg.2013.4329; Allen BB, 2014, PEDIATR CRIT CARE ME, V15, P62, DOI 10.1097/PCC.0b013e3182a556ea; Ananda A, 1999, ACTA NEUROCHIR SUPPL, V73, P99; Anderson RCE, 2004, J NEUROSURG, V101, P53, DOI 10.3171/ped.2004.101.2.0053; Andrews PJD, 2002, J NEUROSURG, V97, P326, DOI 10.3171/jns.2002.97.2.0326; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; [Anonymous], 1999, Ann Fr Anesth Reanim, V18, P15; [Anonymous], 2008, GUIDELINES MILD TRAU; Aries MJH, 2012, CRIT CARE MED, V40, P2456, DOI 10.1097/CCM.0b013e3182514eb6; Aufderheide TP, 2004, CIRCULATION, V109, P1960, DOI 10.1161/01.CIR.0000126594.79136.61; Augustes R, 2011, ANAESTH INTENS CARE, V39, P401, DOI 10.1177/0310057X1103900310; Badri S, 2012, INTENS CARE MED, V38, P1800, DOI 10.1007/s00134-012-2655-4; Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; Balestreri M, 2006, NEUROCRIT CARE, V4, P8, DOI 10.1385/NCC:4:1:008; Barlow KM, 2005, PEDIATRICS, V116, pE174, DOI 10.1542/peds.2004-2739; Barlow KM, 1999, DEV MED CHILD NEUROL, V41, P220, DOI 10.1017/S0012162299000481; Barr J, 2013, CRIT CARE MED, V41, P263, DOI 10.1097/CCM.0b013e3182783b72; Bechir M, 2010, MINERVA ANESTESIOL, V76, P896; Behrens A, 2011, NEUROSURGERY, V69, pE1033, DOI 10.1227/NEU.0b013e31822999b7; Bekelis K, 2015, ANN SURG, V261, P579, DOI 10.1097/SLA.0000000000000672; Bennett TD, 2012, ARCH PEDIAT ADOL MED, V166, P641, DOI 10.1001/archpediatrics.2012.322; Bernard SA, 2010, ANN SURG, V252, P959, DOI 10.1097/SLA.0b013e3181efc15f; Berry C, 2012, INJURY, V43, P1833, DOI 10.1016/j.injury.2011.08.014; Bhullar IS, 2014, J TRAUMA ACUTE CARE, V76, P54, DOI 10.1097/TA.0b013e3182aafd15; Biersteker HAR, 2012, CRIT CARE MED, V40, P1914, DOI 10.1097/CCM.0b013e3182474bde; Bilotta F, 2008, NEUROCRIT CARE, V9, P159, DOI 10.1007/s12028-008-9084-9; Bilotta F, 2009, ANESTHESIOLOGY, V110, P611, DOI 10.1097/ALN.0b013e318198004b; Blaha M, 2003, PEDIATR NEUROSURG, V39, P27, DOI 10.1159/000070877; Bochicchio GV, 2005, J TRAUMA, V58, P921, DOI 10.1097/01.TA.0000162141.26392.07; Bodanapally UK, 2015, RADIOL CLIN N AM, V53, P695, DOI 10.1016/j.rcl.2015.02.011; Bouzat P, 2011, NEUROSURGERY, V68, P1603, DOI 10.1227/NEU.0b013e31820cd43e; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS7; Brenner M, 2012, J TRAUMA ACUTE CARE, V72, P1135, DOI 10.1097/TA.0b013e31824af90b; Brophy GM, 2011, J NEUROTRAUM, V28, P861, DOI 10.1089/neu.2010.1564; Bulger EM, 2010, JAMA-J AM MED ASSOC, V304, P1455, DOI 10.1001/jama.2010.1405; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Butcher I, 2007, J NEUROTRAUM, V24, P294, DOI 10.1089/neu.2006.0032; Caballero G Christina, 2013, Hosp Pharm, V48, P757, DOI 10.1310/hpj4809-757; Caputo ND, 2014, J TRAUMA ACUTE CARE, V77, P534, DOI 10.1097/TA.0000000000000414; Cariou A, 2017, ANAESTH CRIT CARE PA; Carter BG, 2008, CHILD NERV SYST, V24, P245, DOI 10.1007/s00381-007-0461-z; Caterino JM, 2012, EMERG MED J, V29, P492, DOI 10.1136/emj.2010.110437; Caulfield EV, 2009, J TRAUMA, V66, P1577, DOI 10.1097/TA.0b013e3181a3931d; Chaiwat O, 2009, J NEUROTRAUM, V26, P657, DOI 10.1089/neu.2008.0770; Chambers IR, 2006, J NEUROL NEUROSUR PS, V77, P234, DOI 10.1136/jnnp.2005.072215; Chambers IR, 2001, J NEUROSURG, V94, P412, DOI 10.3171/jns.2001.94.3.0412; CHAN KH, 1992, J NEUROL NEUROSUR PS, V55, P787, DOI 10.1136/jnnp.55.9.787; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Chi JH, 2006, J TRAUMA, V61, P1134, DOI 10.1097/01.ta.0000196644.64653.d8; Cinotti R, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0498-9; CLARK WC, 1989, NEUROSURGERY, V25, P20; Clifton GL, 2002, CRIT CARE MED, V30, P739, DOI 10.1097/00003246-200204000-00003; Cnossen MC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161367; Coester A, 2010, J TRAUMA, V68, P904, DOI 10.1097/TA.0b013e3181c9afc2; Coles JP, 2007, CRIT CARE MED, V35, P568, DOI 10.1097/01.CCM.0000254066.37187.88; Coles JP, 2002, CRIT CARE MED, V30, P1950, DOI 10.1097/00003246-200209000-00002; Compagnone C, 2009, NEUROSURGERY, V64, P690, DOI 10.1227/01.NEU.0000340796.18738.F7; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Cooper DJ, 2004, JAMA-J AM MED ASSOC, V291, P1350, DOI 10.1001/jama.291.11.1350; Cremer OL, 2005, CRIT CARE MED, V33, P2207, DOI 10.1097/01.CCM.0000181300.99078.B5; Cruz J, 2002, NEUROSURGERY, V50, P774, DOI 10.1097/00006123-200204000-00017; Czosnyka M, 1996, J NEUROSURG, V84, P79, DOI 10.3171/jns.1996.84.1.0079; Davis DP, 2011, PREHOSP EMERG CARE, V15, P184, DOI 10.3109/10903127.2010.545473; Davis DP, 2005, ANN EMERG MED, V46, P115, DOI 10.1016/j.annemergmed.2005.01.024; Davis DP, 2003, J TRAUMA, V54, P444, DOI 10.1097/01.TA.0000053396.02126.CD; Debenham S, 2011, CAN J NEUROL SCI, V38, P896, DOI 10.1017/S031716710001249X; Densmore JC, 2006, J PEDIATR SURG, V41, P92, DOI 10.1016/j.jpedsurg.2005.10.013; Depreitere B, 2014, J NEUROSURG, V120, P1451, DOI 10.3171/2014.3.JNS131500; Dias C, 2015, NEUROCRIT CARE, V23, P92, DOI 10.1007/s12028-014-0103-8; DiCocco JM, 2011, ANN SURG, V253, P444, DOI 10.1097/SLA.0b013e31820d946b; DIKMEN SS, 1991, JAMA-J AM MED ASSOC, V265, P1271, DOI 10.1001/jama.265.10.1271; Diringer MN, 2002, J NEUROSURG, V96, P103, DOI 10.3171/jns.2002.96.1.0103; Diringer MN, 2000, J NEUROSURG, V92, P7, DOI 10.3171/jns.2000.92.1.0007; Downard C, 2000, J TRAUMA, V49, P654, DOI 10.1097/00005373-200010000-00012; Dumont TM, 2010, J NEUROTRAUM, V27, P1233, DOI 10.1089/neu.2009.1216; Duranteau J, 2015, ANESTH REANIM, V1, P62, DOI 10.1016/j.anrea.2014.12.007; Egerod I, 2010, CRIT CARE, V14, DOI 10.1186/cc8978; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Elf K, 2005, NEUROSURGERY, V56, P962, DOI 10.1227/01.NEU.0000158317.00603.40; Farahvar A, 2011, J NEUROSURG, V114, P1471, DOI 10.3171/2010.11.JNS101116; Figaji AA, 2009, J NEUROSURG-PEDIATR, V4, P420, DOI 10.3171/2009.6.PEDS096; Finfer S, 2004, NEW ENGL J MED, V350, P2247; Finfer S, 2009, NEW ENGL J MED, V360, P1283, DOI 10.1056/NEJMoa0810625; Finfer S, 2015, INTENS CARE MED, V41, P1037, DOI 10.1007/s00134-015-3757-6; Flierl MA, 2010, J ORTHOP TRAUMA, V24, P107, DOI 10.1097/BOT.0b013e3181b6bdfc; Fortune JB, 1995, J TRAUMA, V39, P1091, DOI 10.1097/00005373-199512000-00014; Fuller G, 2014, BRIT J NEUROSURG, V28, P452, DOI 10.3109/02688697.2013.865708; Fuller G, 2014, INJURY, V45, P612, DOI 10.1016/j.injury.2013.09.008; Gabriel WM, 2014, ANN PHARMACOTHER, V48, P1440, DOI 10.1177/1060028014549013; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; Gelabert-Gonzalez M, 2006, ACTA NEUROCHIR, V148, P435, DOI 10.1007/s00701-005-0683-3; Ghajar J, 1995, New Horiz, V3, P395; Gill M, 2005, ANN EMERG MED, V45, P37, DOI 10.1016/j.annemergmed.2004.07.429; Gill M, 2006, ACAD EMERG MED, V13, P968, DOI 10.1197/j.aem.2006.05.019; GIULIONI M, 1988, NEUROSURGERY, V22, P807, DOI 10.1227/00006123-198805000-00001; Goyal A, 2012, J NEUROTRAUMA; Griesdale DEG, 2009, NEUROCRIT CARE, V11, P311, DOI 10.1007/s12028-009-9249-1; Grinkeviciute DE, 2008, MEDICINA-LITHUANIA, V44, P119, DOI 10.3390/medicina44020015; Guiza F, 2015, INTENS CARE MED, V41, P1067, DOI 10.1007/s00134-015-3806-1; Gura M, 2011, TURK NEUROSURG, V21, P210, DOI 10.5137/1019-5149.JTN.3574-10.1; Guzel A, 2008, NEUROSURG REV, V31, P439, DOI 10.1007/s10143-008-0148-2; Haitsma Iain K, 2002, Curr Opin Crit Care, V8, P115, DOI 10.1097/00075198-200204000-00005; Hall JR, 1996, J PEDIATR SURG, V31, P72, DOI 10.1016/S0022-3468(96)90322-X; Haltiner AM, 1999, J NEUROSURG, V91, P588, DOI 10.3171/jns.1999.91.4.0588; Hara M, 1998, NEUROL RES, V20, P225, DOI 10.1080/01616412.1998.11740510; Hartl R, 2006, J TRAUMA, V60, P1250, DOI 10.1097/01.ta.0000203717.57821.8d; Hasler RM, 2012, RESUSCITATION, V83, P476, DOI 10.1016/j.resuscitation.2011.10.018; Haukoos JS, 2007, ANN EMERG MED, V50, P18, DOI 10.1016/j.annemergmed.2006.10.004; Healey C, 2003, J TRAUMA, V54, P671, DOI 10.1097/01.TA.0000058130.30490.5D; Helbok R, 2012, CRIT CARE, V16, DOI 10.1186/cc11880; HOLLIDAY PO, 1982, NEUROSURGERY, V10, P25, DOI 10.1227/00006123-198201000-00005; Howells T, 2005, J NEUROSURG, V102, P311, DOI 10.3171/jns.2005.102.2.0311; HUANG MS, 1995, J TRAUMA, V38, P154, DOI 10.1097/00005373-199501000-00035; Huang SJ, 2006, J CLIN NEUROSCI, V13, P818, DOI 10.1016/j.jocn.2005.11.034; Huang YH, 2016, WORLD NEUROSURG, V88, P59, DOI 10.1016/j.wneu.2015.12.041; Huang YH, 2015, SEIZURE-EUR J EPILEP, V25, P150, DOI 10.1016/j.seizure.2014.10.008; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; Hulka F, 1997, J TRAUMA, V42, P514, DOI 10.1097/00005373-199703000-00020; Hutchinson PJ, 2016, N ENGL J MED; Ilves P, 2010, ACTA PAEDIATR, V99, P1329, DOI 10.1111/j.1651-2227.2010.01820.x; Inaba K, 2013, J TRAUMA ACUTE CARE, V74, P766, DOI 10.1097/TA.0b013e3182826e84; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; Jaffres P, 2005, INTENS CARE MED, V31, P785, DOI 10.1007/s00134-005-2630-4; Jagannathan J, 2007, J NEUROSURG, V106, P268, DOI 10.3171/ped.2007.106.4.268; Jakola AS, 2014, WORLD NEUROSURG, V82, DOI 10.1016/j.wneu.2013.08.021; Javouhey E, 2009, PEDIATR CRIT CARE ME, V10, P472, DOI 10.1097/PCC.0b013e318198b1cb; Jeremitsky E, 2005, J TRAUMA, V58, P47, DOI 10.1097/01.TA.0000135158.42242.B1; Jiang JY, 2005, J NEUROTRAUM, V22, P623, DOI 10.1089/neu.2005.22.623; Jiang LB, 2014, SCAND J TRAUMA RESUS, V22, DOI 10.1186/s13049-014-0054-2; Johnson DL, 1996, PEDIATR NEUROSURG, V25, P309, DOI 10.1159/000121145; Johnson U, 2011, NEUROSURGERY, V68, P714, DOI 10.1227/NEU.0b013e3182077313; Jones KE, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E3; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; Jourdan C, 2013, BRAIN INJURY, V27, P1000, DOI 10.3109/02699052.2013.794971; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Kalb DC, 1998, SURGERY, V124, P739, DOI 10.1067/msy.1998.91395; Kamel H, 2011, CRIT CARE MED, V39, P554, DOI 10.1097/CCM.0b013e318206b9be; Kapapa T, 2010, J CHILD NEUROL, V25, P274, DOI 10.1177/0883073809332699; Karamanos E, 2014, AM J SURG, V208, P363, DOI 10.1016/j.amjsurg.2013.10.026; Keenan Heather T, 2005, Pediatr Crit Care Med, V6, P537, DOI 10.1097/01.PCC.0000164638.44600.67; Kim DR, 2014, J KOREAN NEUROSURG S, V55, P26, DOI 10.3340/jkns.2014.55.1.26; Kim JJ, 2011, NEUROTHERAPEUTICS, V8, P39, DOI 10.1007/s13311-010-0003-3; KISHORE PRS, 1981, AM J ROENTGENOL, V137, P829, DOI 10.2214/ajr.137.4.829; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Kosty JA, 2013, ANESTH ANALG, V117, P694, DOI 10.1213/ANE.0b013e31829cc765; Kouvarellis AJ, 2011, CHILD NERV SYST, V27, P1139, DOI 10.1007/s00381-011-1464-3; Kramer AH, 2012, CRIT CARE, V16, DOI 10.1186/cc11812; Kruer RM, 2013, J CRIT CARE, V28, DOI 10.1016/j.jcrc.2012.11.020; Lazaridis C, 2014, J NEUROSURG, V120, P893, DOI 10.3171/2014.1.JNS131292; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Lescot T, 2006, CRIT CARE MED, V34, P3029, DOI 10.1097/01.CCM.0000243797.42346.64; Liliang PC, 2010, J SURG RES, V160, P302, DOI 10.1016/j.jss.2008.12.022; Liu-DeRyke X, 2009, NEUROCRIT CARE, V11, P151, DOI 10.1007/s12028-009-9228-6; LOBATO RD, 1986, J NEUROSURG, V65, P784, DOI 10.3171/jns.1986.65.6.0784; LOBATO RD, 1988, J NEUROSURG, V68, P48, DOI 10.3171/jns.1988.68.1.0048; Lozier AP, 2002, NEUROSURGERY, V51, P170, DOI 10.1097/00006123-200207000-00024; Ma CY, 2010, CHIN J TRAUMATOL, V13, P293, DOI 10.3760/cma.j.issn.1008-1275.2010.05.008; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; Maguire M, 2010, J TRAUMA, V68, P250, DOI 10.1097/TA.0b013e3181c45479; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; Marin-Caballos A, 2005, CRIT CARE, V9, pR670, DOI 10.1186/cc3822; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; Matsushima K, 2012, J CRIT CARE, V27, P125, DOI 10.1016/j.jcrc.2011.08.012; McQuire JC, 1998, J NEUROSURG, V89, P526, DOI 10.3171/jns.1998.89.4.0526; Mehta A, 2010, DEV NEUROSCI-BASEL, V32, P413, DOI 10.1159/000316804; Meierhans R, 2010, CRIT CARE, V14, DOI 10.1186/cc8869; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; Miller PR, 2002, ANN SURG, V236, P386, DOI 10.1097/00000658-200209000-00015; Mirski MA, 2001, J NEUROSURG ANESTH, V13, P83, DOI 10.1097/00008506-200104000-00004; MIZUTANI T, 1990, SURG NEUROL, V33, P178, DOI 10.1016/0090-3019(90)90181-N; Mondello S, 2011, NEUROSURG; Mondello S, 2010, J NEUROTRAUM, V27, P1203, DOI 10.1089/neu.2010.1278; Morris KP, 2006, INTENS CARE MED, V32, P1606, DOI 10.1007/s00134-006-0285-4; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Mrozek S, 2013, ANN FR ANESTH, V32, P510, DOI 10.1016/j.annfar.2013.07.010; Mrozek S, 2014, CRIT CARE, V18, DOI 10.1186/cc13841; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; Myburgh J, 2007, NEW ENGL J MED, V357, P874; NAKAYAMA DK, 1992, J PEDIATR SURG, V27, P427, DOI 10.1016/0022-3468(92)90328-5; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; Narotam PK, 2006, J PEDIATR SURG, V41, P505, DOI 10.1016/j.jpedsurg.2005.11.069; Narotam PK, 2009, J NEUROSURG, V111, P672, DOI 10.3171/2009.4.JNS081150; National Institute for Health and Clinical Excellence (NICE), 2014, HEAD INJ ASS EARL MA; Newgard CD, 2010, ANN EMERG MED, V55, P235, DOI 10.1016/j.annemergmed.2009.07.024; Oddo M, 2008, CURR OPIN CLIN NUTR, V11, P134, DOI 10.1097/MCO.0b013e3282f37b43; Oddo M, 2008, CRIT CARE MED, V36, P3233, DOI 10.1097/CCM.0b013e31818f4026; Ono J, 2001, J CLIN NEUROSCI, V8, P120, DOI 10.1054/jocn.2000.0732; Orliaguet G, 2001, INTENS CARE MED, V27, P743, DOI 10.1007/s001340100905; Osler TM, 2001, J TRAUMA, V50, P96, DOI 10.1097/00005373-200101000-00017; Ost M, 2006, NEUROLOGY, V67, P1600, DOI 10.1212/01.wnl.0000242732.06714.0f; OSULLIVAN MG, 1994, J NEUROSURG, V80, P46, DOI 10.3171/jns.1994.80.1.0046; Oyetunji TA, 2011, AM J SURG, V201, P445, DOI 10.1016/j.amjsurg.2010.10.006; Panczykowski DM, 2012, J NEUROTRAUM, V29, P47, DOI 10.1089/neu.2010.1482; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; PAPAZIAN L, 1993, BRIT J ANAESTH, V71, P267, DOI 10.1093/bja/71.2.267; Parks Nancy A, 2012, Adv Surg, V46, P205; Patel HC, 2005, LANCET, V366, P1538, DOI 10.1016/S0140-6736(05)67626-X; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Paulus EM, 2014, J TRAUMA ACUTE CARE, V76, P279, DOI 10.1097/TA.0000000000000101; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Pepe Paul E, 2004, Crit Care Med, V32, pS414, DOI 10.1097/01.CCM.0000134264.88332.37; Pepe PE, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0808-x; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Pfenninger J, 2002, SWISS MED WKLY, V132, P116; PIETROPAOLI JA, 1992, J TRAUMA, V33, P403, DOI 10.1097/00005373-199209000-00011; Pineda JA, 2007, J NEUROTRAUM, V24, P354, DOI 10.1089/neu.2006.003789; Pineda JA, 2013, LANCET NEUROL, V12, P45, DOI 10.1016/S1474-4422(12)70269-7; Poca MA, 1998, ACT NEUR S, V71, P27; Potoka DA, 2001, J TRAUMA, V51, P824, DOI 10.1097/00005373-200111000-00002; Potoka DA, 2000, J TRAUMA, V49, P237, DOI 10.1097/00005373-200008000-00009; Pracht EE, 2008, J PEDIATR SURG, V43, P212, DOI 10.1016/j.jpedsurg.2007.09.047; Qiu WS, 2009, CRIT CARE, V13, DOI 10.1186/cc8178; Ract C, 2007, INTENS CARE MED, V33, P645, DOI 10.1007/s00134-007-0558-6; Radic JAE, 2014, NEUROCRIT CARE, V21, P228, DOI 10.1007/s12028-013-9951-x; Ramakrishnan Vivek, 2015, Surg Neurol Int, V6, P8, DOI 10.4103/2152-7806.149613; Rao V, 2013, SCAND J TRAUMA RESUS, V21, DOI 10.1186/1757-7241-21-78; Ratanalert S, 2002, J CLIN NEUROSCI, V9, P640, DOI 10.1054/jocn.2002.1085; Reinhart K, 2012, INTENS CARE MED, V38, P368, DOI 10.1007/s00134-012-2472-9; REYNOLDS MA, 1995, ANN SURG, V222, P470; Rhine T, 2012, J TRAUMA ACUTE CARE, V73, pS248, DOI 10.1097/TA.0b013e31826b0062; Rickard AC, 2014, EMERG MED J, V31, P679, DOI 10.1136/emermed-2013-202679; Roberts DJ, 2013, ANN SURG, V257, P621, DOI 10.1097/SLA.0b013e318288c514; Roberts I, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000033.pub2; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Roquilly A, 2011, CRIT CARE, V15, DOI 10.1186/cc10522; Rossi-Mossuti F, 2016, J NEUROL SURG PART A, V77, P36, DOI 10.1055/s-0035-1563556; Rovlias A, 2000, NEUROSURGERY, V46, P335, DOI 10.1097/00006123-200002000-00015; SADHU VK, 1979, RADIOLOGY, V133, P507, DOI 10.1148/133.2.507; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; Schreiber MA, 2002, ARCH SURG-CHICAGO, V137, P285, DOI 10.1001/archsurg.137.3.285; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; Shafi S, 2008, J TRAUMA, V64, P335, DOI 10.1097/TA.0b013e31815dd017; Shea Kenneth, 2012, Emerg Med Pract, V14, P1; Sierink JC, 2012, BRIT J SURG, V99, P52, DOI 10.1002/bjs.7760; Sigurta A, 2013, INTENS CARE MED, V39, P129, DOI 10.1007/s00134-012-2748-0; Simma B, 1998, CRIT CARE MED, V26, P1265, DOI 10.1097/00003246-199807000-00032; Singh B, 2013, BRAIN INJURY, V27, P293, DOI 10.3109/02699052.2012.743182; Sonneville R, 2015, INTENS CARE MED, V41, P192, DOI 10.1007/s00134-014-3577-0; Sorrentino E, 2012, NEUROCRIT CARE, V16, P258, DOI 10.1007/s12028-011-9630-8; Soustiel JF, 2006, ACTA NEUROCHIR, V148, P845, DOI 10.1007/s00701-006-0792-7; Spiotta AM, 2010, J NEUROSURG, V113, P571, DOI 10.3171/2010.1.JNS09506; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; Stein SC, 2010, J NEUROSURG, V112, P1105, DOI 10.3171/2009.8.JNS09738; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Stippler M, 2012, J NEUROSURG-PEDIATR, V10, P383, DOI 10.3171/2012.8.PEDS12165; Stocchetti N, 1996, J TRAUMA, V40, P764, DOI 10.1097/00005373-199605000-00014; Stocchetti N, 2014, ACTA NEUROCHIR, V156, P1615, DOI 10.1007/s00701-014-2127-4; Stocchetti N, 2014, NEW ENGL J MED, V370, P2121, DOI 10.1056/NEJMra1208708; Sung J, 2005, J TRAUMA, V59, P80, DOI 10.1097/01.TA.0000171452.96585.84; Szaflarski JP, 2010, NEUROCRIT CARE, V12, P165, DOI 10.1007/s12028-009-9304-y; Talving P, 2013, J NEUROSURG, V119, P1248, DOI 10.3171/2013.7.JNS122255; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; TEASDALE G, 1983, LANCET, V2, P678; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; Temkin NR, 2003, EPILEPSIA, V44, P18, DOI 10.1046/j.1528-1157.44.s10.6.x; THOMAS D G T, 1978, Lancet, V1, P113; Thompson DO, 2011, ANN EMERG MED, V58, P417, DOI 10.1016/j.annemergmed.2011.05.033; Thompson K, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009900.pub2; Timmons SD, 2011, J TRAUMA, V71, P1172, DOI 10.1097/TA.0b013e31822b0f4b; TOUTANT SM, 1984, J NEUROSURG, V61, P691, DOI 10.3171/jns.1984.61.4.0691; Townsend RN, 1998, J TRAUMA, V44, P977, DOI 10.1097/00005373-199806000-00008; Trabold F, 2004, INTENS CARE MED, V30, P108, DOI 10.1007/s00134-003-2057-8; Treggiari MM, 2007, NEUROCRIT CARE, V6, P104, DOI 10.1007/s12028-007-0012-1; Melo JRT, 2009, CHILD NERV SYST, V25, P1077, DOI 10.1007/s00381-009-0924-5; Unden J, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-50; Utomo WK, 2009, INJURY, V40, P973, DOI 10.1016/j.injury.2009.05.034; Van den Berghe G, 2005, NEUROLOGY, V64, P1348, DOI 10.1212/01.WNL.0000158442.08857.FC; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; Vavilala MS, 2014, CRIT CARE MED, V42, P2258, DOI 10.1097/CCM.0000000000000507; Vernon DD, 2005, PEDIATR EMERG CARE, V21, P18, DOI 10.1097/01.pec.0000150983.96357.83; Vespa P, 2006, CRIT CARE MED, V34, P850, DOI 10.1097/01.CCM.0000201875.12245.6F; Vespa P, 2012, CRIT CARE MED, V40, P1923, DOI 10.1097/CCM.0b013e31824e0fcc; Vik A, 2008, J NEUROSURG, V109, P678, DOI 10.3171/JNS/2008/109/10/0678; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Voulgaris SG, 2005, MED SCI MONITOR, V11, pCR49; Wahlstrom MR, 2005, INTENS CARE MED, V31, P832, DOI 10.1007/s00134-005-2632-2; Wakerley BR, 2015, J NEUROIMAGING, V25, P111, DOI 10.1111/jon.12100; Wang NE, 2013, J TRAUMA ACUTE CARE, V75, P704, DOI 10.1097/TA.0b013e31829a0a65; WELCH K, 1980, J NEUROSURG, V52, P693, DOI 10.3171/jns.1980.52.5.0693; Wells DL, 2012, CRIT CARE, V16, DOI 10.1186/cc11678; White JRM, 2001, CRIT CARE MED, V29, P534, DOI 10.1097/00003246-200103000-00011; WILBERGER JE, 1991, J NEUROSURG, V74, P212, DOI 10.3171/jns.1991.74.2.0212; YAMAZAKI Y, 1995, SURG NEUROL, V43, P267, DOI 10.1016/0090-3019(95)80012-6; Yang M, 2009, INT J NURS STUD, V46, P753, DOI 10.1016/j.ijnurstu.2009.01.004; Yang SY, 1995, SURG NEUROL, V44, P373, DOI 10.1016/0090-3019(96)80243-6; Yu A, 2013, CRIT CARE MED, V41, P2002, DOI 10.1097/CCM.0b013e31828e96c0; Yuan Q, 2013, BRAIN INJURY, V27, P664, DOI 10.3109/02699052.2013.775497; Zafar SN, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-30; Zhao HX, 2015, BMC SURG, V15, DOI 10.1186/s12893-015-0100-7	304	41	43	0	12	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	2352-5568			ANAESTH CRIT CARE PA	Anaesth. Crit. Care Pain Med.	APR	2018	37	2					171	186		10.1016/j.accpm.2017.12.001			16	Anesthesiology; Critical Care Medicine	Anesthesiology; General & Internal Medicine	GA8WW	WOS:000428623300015	29288841	Other Gold, Green Published			2021-06-18	
J	Ma, EL; Smith, AD; Desai, N; Cheung, LM; Hanscom, M; Stoica, BA; Loane, DJ; Shea-Donohue, T; Faden, AI				Ma, Elise L.; Smith, Allen D.; Desai, Neemesh; Cheung, Lumei; Hanscom, Marie; Stoica, Bogdan A.; Loane, David J.; Shea-Donohue, Terez; Faden, Alan I.			Bidirectional brain-gut interactions and chronic pathological changes after traumatic brain injury in mice	BRAIN BEHAVIOR AND IMMUNITY			English	Article						Traumatic brain injury; Mucosal barrier function; Enteric glial cells; Brain-gut axis; Neuroinflammation; Neurodegeneration; Citrobacter rodentium	SPINAL-CORD-INJURY; INCREASED INTESTINAL PERMEABILITY; MUSCARINIC RECEPTORS CONTRIBUTE; CITROBACTER-RODENTIUM INFECTION; ENTERIC NERVOUS-SYSTEM; BARRIER FUNCTION; GLIAL-CELLS; CHRONIC NEUROINFLAMMATION; MICROGLIAL ACTIVATION; EPITHELIAL BARRIER	Objectives: Traumatic brain injury (TBI) has complex effects on the gastrointestinal tract that are associated with TBI-related morbidity and mortality. We examined changes in mucosal barrier properties and enteric glial cell response in the gut after experimental TBI in mice, as well as effects of the enteric pathogen Citrobacter rodentium (Cr) on both gut and brain after injury. Methods: Moderate-level TBI was induced in C57BL/6 mice by controlled cortical impact (CCI). Mucosal barrier function was assessed by transepithelial resistance, fluorescent-labelled dextran flux, and quantification of tight junction proteins. Enteric glial cell number and activation were measured by Sox10 expression and GFAP reactivity, respectively. Separate groups of mice were challenged with Cr infection during the chronic phase of TBI, and host immune response, barrier integrity, enteric glial cell reactivity, and progression of brain injury and inflammation were assessed. Results: Chronic CCI induced changes in colon morphology, including increased mucosal depth and smooth muscle thickening. At day 28 post-CCI, increased paracellular permeability and decreased claudin-1 mRNA and protein expression were observed in the absence of inflammation in the colon. Colonic glial cell GFAP and Sox10 expression were significantly increased 28 days after brain injury. Clearance of Cr and upregulation of Th1/Th17 cytokines in the colon were unaffected by CCI; however, colonic paracellular flux and enteric glial cell GFAP expression were significantly increased. Importantly, Cr infection in chronically-injured mice worsened the brain lesion injury and increased astrocyte- and microglial-mediated inflammation. Conclusion: These experimental studies demonstrate chronic and bidirectional brain-gut interactions after TBI, which may negatively impact late outcomes after brain injury. (C) 2017 Elsevier Inc. All rights reserved.	[Ma, Elise L.; Hanscom, Marie; Stoica, Bogdan A.; Loane, David J.; Faden, Alan I.] Univ Maryland, Dept Anesthesiol, Sch Med, 20 Penn St,S247, Baltimore, MD 21201 USA; [Ma, Elise L.; Hanscom, Marie; Stoica, Bogdan A.; Loane, David J.; Faden, Alan I.] Univ Maryland, Shock Trauma & Anesthesiol Res STAR Ctr, Sch Med, 20 Penn St,S247, Baltimore, MD 21201 USA; [Smith, Allen D.; Cheung, Lumei] ARS, Beltsville Human Nutr Res Ctr, Diet Gen & Immunol Lab, USDA, Beltsville, MD USA; [Desai, Neemesh; Shea-Donohue, Terez] Univ Maryland, Sch Med, Dept Radiat Oncol, Baltimore, MD 21201 USA; [Desai, Neemesh; Shea-Donohue, Terez] Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA	Faden, AI (corresponding author), Univ Maryland, Dept Anesthesiol, Sch Med, 20 Penn St,S247, Baltimore, MD 21201 USA.; Faden, AI (corresponding author), Univ Maryland, Shock Trauma & Anesthesiol Res STAR Ctr, Sch Med, 20 Penn St,S247, Baltimore, MD 21201 USA.; Shea-Donohue, T (corresponding author), Univ Maryland, Sch Med, Dept Radiat Oncol & Med, 10 S Pine St,7-00C, Baltimore, MD 21201 USA.	tdonohue@medicine.umaryland.edu; afaden@anes.umm.edu	STOICA, BOGDAN/H-9782-2013	STOICA, BOGDAN/0000-0002-2501-6434; Hanscom, Marie/0000-0001-8308-135X; Loane, David/0000-0003-0393-3503; Faden, Alan I./0000-0003-0128-2348	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [4R01NS052568, 5R01NS037313-16, 5R01DK083418-05, R01NS082308, T32DK067872]; USDA CRIS project [8040-51000-058]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK083418, T32DK067872] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS052568, R01NS037313, R01NS082308] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health [4R01NS052568 (A.I.F.); 5R01NS037313-16 (A.I.F.); 5R01DK083418-05 (T.S-D.); R01NS082308 (DJ.L.); T32DK067872(E.L.M.)]; and the USDA CRIS project [8040-51000-058 (A.S.)].	Anthony DC, 2014, EXP NEUROL, V258, P105, DOI 10.1016/j.expneurol.2014.03.013; Aungst SL, 2014, J CEREBR BLOOD F MET, V34, P1223, DOI 10.1038/jcbfm.2014.75; Bansal V, 2009, J NEUROTRAUM, V26, P1353, DOI 10.1089/neu.2008-0858; Benakis C, 2016, NAT MED, V22, P516, DOI 10.1038/nm.4068; Berg DJ, 1996, J CLIN INVEST, V98, P1010, DOI 10.1172/JCI118861; Bischoff SC, 2014, BMC GASTROENTEROL, V14, DOI 10.1186/s12876-014-0189-7; Bush TG, 1998, CELL, V93, P189, DOI 10.1016/S0092-8674(00)81571-8; Buzza MS, 2010, P NATL ACAD SCI USA, V107, P4200, DOI 10.1073/pnas.0903923107; Byrnes KR, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-43; Machado MCC, 2016, CURR PHARM DESIGN, V22, P4645, DOI 10.2174/1381612822666160510125331; Clairembault T, 2014, J NEUROCHEM, V130, P805, DOI 10.1111/jnc.12742; Da Franceschi R. Cunha, 2017, NEUROSCI RES, V2; Doig CJ, 1998, AM J RESP CRIT CARE, V158, P444, DOI 10.1164/ajrccm.158.2.9710092; El Asmar R, 2002, GASTROENTEROLOGY, V123, P1607, DOI 10.1053/gast.2002.36578; Faden AI, 2016, BRIT J PHARMACOL, V173, P681, DOI 10.1111/bph.13179; Faden AI, 2015, NEUROTHERAPEUTICS, V12, P143, DOI 10.1007/s13311-014-0319-5; Faries PL, 1998, J TRAUMA, V44, P1031, DOI 10.1097/00005373-199806000-00016; Fasano A, 2005, NAT CLIN PRACT GASTR, V2, P416, DOI 10.1038/ncpgasthep0259; Feighery L, 2008, J TRAUMA, V64, P131, DOI 10.1097/TA.0b013e3181568d9f; Fuhrich DG, 2013, ANAL QUANT CYTOL, V35, P210; Gaddam Samson Sujit Kumar, 2015, Handb Clin Neurol, V127, P205, DOI 10.1016/B978-0-444-52892-6.00014-3; Griffin GD, 2011, MIL MED, V176, P364, DOI 10.7205/MILMED-D-10-00021; Gulbransen BD., 2014, C SERIES NEUROGLIA B, V1, P1, DOI [10.4199/C00113ED1V01Y201407NGL002, DOI 10.4199/C00113ED1V01Y201407NGL002]; Gulbransen BD, 2012, NAT REV GASTRO HEPAT, V9, P625, DOI 10.1038/nrgastro.2012.138; Hang CH, 2003, WORLD J GASTROENTERO, V9, P2776; Harrison-Felix CL, 2009, ARCH PHYS MED REHAB, V90, P1506, DOI 10.1016/j.apmr.2009.03.015; Hazeldine J, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00235; Houlden A., 2016, BRAIN BEHAV IMMUN; Jin W, 2008, CYTOKINE, V44, P135, DOI 10.1016/j.cyto.2008.07.005; Joseph NM, 2011, J CLIN INVEST, V121, P3398, DOI 10.1172/JCI58186; Kabouridis PS, 2015, NEURON, V85, P289, DOI 10.1016/j.neuron.2014.12.037; Kao CH, 1998, AM J GASTROENTEROL, V93, P1108; Katzenberger R., 2015, LIFE, V4; Kharrazian D, 2015, ALTERN THER HEALTH M, V21, P28; Kiesler P, 2015, CELL MOL GASTROENTER, V1, P154, DOI 10.1016/j.jcmgh.2015.01.006; Kigerl KA, 2016, J EXP MED, V213, P2603, DOI 10.1084/jem.20151345; Klein SL, 2016, NAT REV IMMUNOL, V16, P626, DOI 10.1038/nri.2016.90; Krakau K, 2006, BRAIN INJURY, V20, P345, DOI 10.1080/02699050500487571; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; Laranjeira C, 2011, J CLIN INVEST, V121, P3412, DOI 10.1172/JCI58200; Liao YL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068963; Lim HB, 2007, ANAESTHESIA, V62, P474, DOI 10.1111/j.1365-2044.2007.04998.x; Loane DJ, 2016, EXP NEUROL, V275, P316, DOI 10.1016/j.expneurol.2015.08.018; Loane D, 2014, NEUROTHERAPEUTICS, V11, P857, DOI 10.1007/s13311-014-0298-6; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Lopetuso LR, 2015, EUR REV MED PHARMACO, V19, P1068; Mackos AR, 2013, INFECT IMMUN, V81, P3253, DOI 10.1128/IAI.00278-13; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; McClain JL, 2014, GASTROENTEROLOGY, V146, P497, DOI 10.1053/j.gastro.2013.10.061; McLean LP, 2016, AM J PHYSIOL-GASTR L, V311, pG130, DOI 10.1152/ajpgi.00461.2014; McLean LP, 2015, INFLAMM BOWEL DIS, V21, P1860, DOI 10.1097/MIB.0000000000000408; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Neunlist M, 2007, AM J PHYSIOL-GASTR L, V292, pG231, DOI 10.1152/ajpgi.00276.2005; Olsen AB, 2013, NEUROGASTROENT MOTIL, V25, DOI 10.1111/nmo.12121; Sandiego CM, 2015, P NATL ACAD SCI USA, V112, P12468, DOI 10.1073/pnas.1511003112; Savidge TC, 2007, LAB INVEST, V87, P731, DOI 10.1038/labinvest.3700600; Savidge TC, 2007, GASTROENTEROLOGY, V132, P1344, DOI 10.1053/j.gastro.2007.01.051; Schwab JM, 2014, EXP NEUROL, V258, P121, DOI 10.1016/j.expneurol.2014.04.023; Sender R, 2016, CELL, V164, P337, DOI 10.1016/j.cell.2016.01.013; Sharkey KA, 2015, J CLIN INVEST, V125, P918, DOI 10.1172/JCI76303; Shen L, 2011, ANNU REV PHYSIOL, V73, P283, DOI 10.1146/annurev-physiol-012110-142150; Singh V, 2016, J NEUROSCI, V36, P7428, DOI 10.1523/JNEUROSCI.1114-16.2016; Smith AD, 2011, BIOL TRACE ELEM RES, V144, P965, DOI 10.1007/s12011-011-9071-4; Smith AD, 2011, INFECT IMMUN, V79, P1471, DOI 10.1128/IAI.01017-10; Snoek S., 2014, EXPERT REV GASTROENT, V4, P637; Sundman M., 2017, BRAIN BEHAV IMMUNITY, V2; Tan M, 2011, BRIT J NEUROSURG, V25, P2, DOI 10.3109/02688697.2010.522745; Turner JR, 2009, NAT REV IMMUNOL, V9, P799, DOI 10.1038/nri2653; Uesaka T, 2015, J NEUROSCI, V35, P9879, DOI 10.1523/JNEUROSCI.1239-15.2015; Vallance BA, 2003, INFECT IMMUN, V71, P3443, DOI 10.1128/IAI.71.6.3443-3453.2003; Winek K, 2016, J CEREBR BLOOD F MET, V36, P891, DOI 10.1177/0271678X16636890; Yu YB, 2014, WORLD J GASTROENTERO, V20, P11273, DOI 10.3748/wjg.v20.i32.11273; Zhao ZR, 2013, J CEREBR BLOOD F MET, V33, P1897, DOI 10.1038/jcbfm.2013.144	74	41	49	1	8	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0889-1591	1090-2139		BRAIN BEHAV IMMUN	Brain Behav. Immun.	NOV	2017	66						56	69		10.1016/j.bbi.2017.06.018			14	Immunology; Neurosciences; Psychiatry	Immunology; Neurosciences & Neurology; Psychiatry	FL4YE	WOS:000414236600007	28676351	Green Accepted			2021-06-18	
J	McGlinchey, RE; Milberg, WP; Fonda, JR; Fortier, CB				McGlinchey, Regina E.; Milberg, William P.; Fonda, Jennifer R.; Fortier, Catherine Brawn			A methodology for assessing deployment trauma and its consequences in OEF/OIF/OND veterans: The TRACTS longitudinal prospective cohort study	INTERNATIONAL JOURNAL OF METHODS IN PSYCHIATRIC RESEARCH			English	Article						blast; co-morbidity; concussion; neuroimaging; post-traumatic stress disorder	POSTTRAUMATIC-STRESS-DISORDER; NEUROPSYCHOLOGICAL TEST-PERFORMANCE; REDUCED CORTICAL THICKNESS; MENTAL-HEALTH PROBLEMS; BRAIN-INJURY; BLAST EXPOSURE; BOSTON ASSESSMENT; PTSD; COMBAT; SYMPTOMS	Many US veterans of Afghanistan and Iraq have multiple physical and psychiatric problems. A major focus of research has been on determining the effects of mild Traumatic Brain Injury (mTBI), but mTBI is rarely diagnosed in the absence of co-occurring conditions such as blast exposure, post-traumatic stress disorder (PTSD), depression, substance abuse, etc. These potentially interactive psychological and physical conditions produce complex patterns of cognitive, psychological, and physical symptoms that impede civilian reintegration and complicate efficient and effective treatment planning. The Translational Research Center for TBI and Stress Disorders (TRACTS) has developed a multidisciplinary approach to the assessment of deployment trauma and its consequences in veterans of these wars. The prospective TRACTS longitudinal cohort study conducts state-of-the-art assessments in the domains of biomedical function, lifetime head trauma, psychological function encompassing deployment experience and lifetime exposure to traumatic events, neuropsychological function, and structural and functional neuroimaging. The TRACTS longitudinal cohort study is the first of its kind to comprehensively evaluate lifetime incidence of TBI and PTSD in these veterans, in addition to those incurred during military deployment. The protocol has begun to reveal information that will help improve understanding of the complex pathophysiology associated with co-occurring mTBI and related stress disorders.	[McGlinchey, Regina E.; Milberg, William P.; Fonda, Jennifer R.; Fortier, Catherine Brawn] VA Boston Healthcare Syst, Geriatr Res Educ & Clin Ctr GRECC, Boston, MA USA; [McGlinchey, Regina E.; Milberg, William P.; Fonda, Jennifer R.; Fortier, Catherine Brawn] VA Boston Healthcare Syst, Translat Res Ctr TBI & Stress Disorders TRACTS, Boston, MA USA; [McGlinchey, Regina E.; Milberg, William P.; Fortier, Catherine Brawn] Harvard Med Sch, Dept Psychiat, Boston, MA USA	McGlinchey, RE (corresponding author), VA Boston Healthcare Syst, GRECC TRACTS 182 JP, 150 South Huntington Ave, Boston, MA 02130 USA.	regina_mcglinchey@hms.harvard.edu			Translational Research Center for TBI and Stress Disorders (TRACTS); VA Rehabilitation Research and Development Traumatic Brain Injury National Network Research Center [B9254-C]; National Center for Complementary & Integrative HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21AT009430] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I50RX003001, I01CX001327] Funding Source: NIH RePORTER	Translational Research Center for TBI and Stress Disorders (TRACTS); VA Rehabilitation Research and Development Traumatic Brain Injury National Network Research Center (B9254-C)	Amick MM, 2013, J INT NEUROPSYCH SOC, V19, P792, DOI 10.1017/S1355617713000544; Bailes JE, 2001, NEUROSURGERY, V48, P26, DOI 10.1097/00006123-200101000-00005; Bailie JM, 2016, J HEAD TRAUMA REHAB, V31, P2, DOI 10.1097/HTR.0000000000000142; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Belmont PJ, 2012, J TRAUMA ACUTE CARE, V73, P3, DOI 10.1097/TA.0b013e318250bfb4; Benedict R., 1997, BRIEF VISUOSPATIAL M; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Corbo V, 2014, PSYCHIAT RES-NEUROIM, V223, P53, DOI 10.1016/j.pscychresns.2014.04.013; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; Delis D., 2001, D KEFS EXAMINERS TEC; Delis DC, 2000, CALIFORNIA VERBAL LE; Esterman M, 2013, J INT NEUROPSYCH SOC, V19, P835, DOI 10.1017/S135561771300057X; Esterman M, 2013, CEREB CORTEX, V23, P2712, DOI 10.1093/cercor/bhs261; First M., 1997, USERS GUIDE STRUCTUR; Fischl B, 2004, NEUROIMAGE, V23, pS69, DOI 10.1016/j.neuroimage.2004.07.016; Fortier CB, 2015, J HEAD TRAUMA REHAB, V30, pE1, DOI 10.1097/HTR.0000000000000008; Fortier CB, 2014, J HEAD TRAUMA REHAB, V29, P89, DOI 10.1097/HTR.0b013e3182865859; French LM, 2014, J REHABIL RES DEV, V51, P933, DOI 10.1682/JRRD.2013.10.0226; Green, 2004, GREENS MED SYMPTOM V; HEATHERTON TF, 1991, BRIT J ADDICT, V86, P1119; Henry GK, 2005, CLIN NEUROPSYCHOL, V19, P121, DOI 10.1080/13854040490516604; Henry JD, 2005, BRIT J CLIN PSYCHOL, V44, P227, DOI 10.1348/014466505X29657; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; King LA, 2006, MIL PSYCHOL, V18, P89, DOI 10.1207/s15327876mp1802_1; Kubany ES, 2000, PSYCHOL ASSESSMENT, V12, P210, DOI 10.1037//1040-3590.12.2.210; Lindemer ER, 2013, NEUROIMAGE-CLIN, V2, P601, DOI 10.1016/j.nicl.2013.04.009; Lippa SM, 2015, J TRAUMA STRESS, V28, P25, DOI 10.1002/jts.21979; MacGregor AJ, 2010, J HEAD TRAUMA REHAB, V25, P1, DOI 10.1097/HTR.0b013e3181c2993d; Maksimovskiy Arkadiy L, 2014, J Alcohol Drug Depend, V2, P144; McGlinchey R. E., 2016, 11 WORLD C BRAIN INJ; MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5; Miller MW, 2015, PSYCHONEUROENDOCRINO, V62, P359, DOI 10.1016/j.psyneuen.2015.09.003; Morissette SB, 2011, REHABIL PSYCHOL, V56, P340, DOI 10.1037/a0025462; O'Neil M.E., 2013, COMPLICATIONS MILD T; Pickering TG, 2005, CIRCULATION, V111, P697, DOI [10.1161/01.CIR.0000154900.76284.F6, 10.1161/01.HYP.0000150859.47929.8e]; Robinson ME, 2015, HUM BRAIN MAPP, V36, P911, DOI 10.1002/hbm.22675; Sadeh N, 2016, MOL PSYCHIATR, V21, P357, DOI 10.1038/mp.2015.134; Sadeh N, 2016, Mol Psychiatry, V21, P299, DOI 10.1038/mp.2016.10; Sadeh N, 2015, HUM BRAIN MAPP, V36, P3076, DOI 10.1002/hbm.22829; Seal KH, 2009, AM J PUBLIC HEALTH, V99, P1651, DOI 10.2105/AJPH.2008.150284; SELZER ML, 1975, J STUD ALCOHOL, V36, P117, DOI 10.15288/jsa.1975.36.117; SKINNER HA, 1982, J STUD ALCOHOL, V43, P1157, DOI 10.15288/jsa.1982.43.1157; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Soble JR, 2013, J CLIN EXP NEUROPSYC, V35, P551, DOI 10.1080/13803395.2013.798398; Spielberg JM, 2015, BIOL PSYCHIAT, V78, P210, DOI 10.1016/j.biopsych.2015.02.013; Storzbach D, 2015, J INT NEUROPSYCH SOC, V21, P353, DOI 10.1017/S1355617715000326; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Thomas JL, 2010, ARCH GEN PSYCHIAT, V67, P614, DOI 10.1001/archgenpsychiatry.2010.54; Tiffen J., 1968, PURDUE PEGBOARD EXAM; Trotter BB, 2015, BRAIN, V138, P2278, DOI 10.1093/brain/awv139; Ustun TB, 2010, B WORLD HEALTH ORGAN, V88, P815, DOI 10.2471/BLT.09.067231; Ustun TB, 2010, MEASURING HLTH DISAB; Vasterling JJ, 2012, BRIT J PSYCHIAT, V201, P186, DOI 10.1192/bjp.bp.111.096461; Verfaellie M, 2014, NEUROPSYCHOLOGY, V28, P337, DOI 10.1037/neu0000027; Warrington E., 1991, VISUAL OBJECT SPACE; Weathers FW, 1991, PCL C FOR DSM 4; Wechsler D., 2001, WECHSLER TEST ADULT; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th ed; Wolf EJ, 2016, BIOL PSYCHIAT, V80, P363, DOI 10.1016/j.biopsych.2015.11.023; Wolf EJ, 2016, PSYCHONEUROENDOCRINO, V63, P155, DOI 10.1016/j.psyneuen.2015.09.020; Woods SP, 2006, ARCH CLIN NEUROPSYCH, V21, P413, DOI 10.1016/j.acn.2006.06.002	64	41	41	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1049-8931	1557-0657		INT J METH PSYCH RES	Int. J. Methods Psychiatr. Res.	SEP	2017	26	3							e1556	10.1002/mpr.1556			15	Psychiatry	Psychiatry	FI2RF	WOS:000411789400010	28211592	Green Published, Green Accepted			2021-06-18	
J	Schwab, K; Terrio, HP; Brenner, LA; Pazdan, RM; McMillan, HP; MacDonald, M; Hinds, SR; Scher, AI				Schwab, Karen; Terrio, Heidi P.; Brenner, Lisa A.; Pazdan, Renee M.; McMillan, Henry P.; MacDonald, Margaret; Hinds, Sidney R., II; Scher, Ann I.			Epidemiology and prognosis of mild traumatic brain injury in returning soldiers A cohort study	NEUROLOGY			English	Article							POSTTRAUMATIC-STRESS-DISORDER; PERSISTENT POSTCONCUSSIVE SYMPTOMS; US MILITARY PERSONNEL; CHRONIC PAIN; IRAQ; AFGHANISTAN; VETERANS; COMBAT; DEPLOYMENT; VALIDITY	Objective: Mild traumatic brain injury (mTBI; concussion) is common in returning service members yet limited definitive evidence exists on its prognosis. Methods: Almost 25,000 non-medically evacuated soldiers returning from Afghanistan or Iraq to 2 military bases between 2009 and 2014 were screened for mTBI. We invited a random sample to participate in the present study, oversampling those screening positive, resulting in 557 mTBI cases and 1,010 controls, of whom 366 cases and 599 controls completed 3-month follow-up evaluations. The criterion measure of screened mTBI was the Ohio State University Traumatic Brain Injury Identification Method. Postconcussive symptoms (PCS) were measured at follow-up with the Neurobehavioral SymptomInventory. Symptoms reported at a severe or very severe level were considered clinically relevant. Results: About half (47%) of soldiers who had sustained an mTBI during this latest deployment reported PCS at 3-month follow-up vs 25% of controls: adjusted odds ratio 2.4 (1.8-3.2). The most commonly reported symptoms (cases vs controls) were sleep problems (30% vs 14%), forgetfulness (21% vs 9%), irritability (17% vs 8%), and headaches (15% vs 5%). mTBI cases were about twice as likely as controls to report receiving rehabilitative services and fair or poor health. Other predictors of PCS included posttraumatic stress, combat exposure, and noncephalic pain. A majority of both cases and controls reported traumatic brain injuries predating this latest deployment. Conclusions: In this nonclinical population of recently deployed soldiers, a substantial proportion of those who had sustained an mTBI were symptomatic 3 months postdeployment. Future studies need to include longer follow-up to measure symptom resolution.	[Schwab, Karen; Terrio, Heidi P.; Pazdan, Renee M.; MacDonald, Margaret; Hinds, Sidney R., II] Def & Vet Brain Injury Ctr, Silver Spring, MD 20910 USA; [Schwab, Karen; Scher, Ann I.] Uniformed Serv Univ Hlth Sci, Dept Prevent Med & Biostat, Bethesda, MD 20814 USA; [Terrio, Heidi P.; Pazdan, Renee M.; MacDonald, Margaret] Evans Army Community Hosp, Ft Carson, NC USA; [Brenner, Lisa A.] Rocky Mt Mental Illness Res Educ & Clin Ctr, Denver, CO USA; [Brenner, Lisa A.] Univ Colorado, Anschutz Med Campus, Aurora, CO USA; [McMillan, Henry P.] Def & Vet Brain Injury Ctr, Intrepid Spirit, Ft Bragg, NC USA; [McMillan, Henry P.] Bur Prison Fed Med Ctr, Butner, NC USA; [Hinds, Sidney R., II] US Army Med Res & Mat Command, Ft Detrick, MD USA	Schwab, K (corresponding author), Def & Vet Brain Injury Ctr, Silver Spring, MD 20910 USA.; Schwab, K (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Prevent Med & Biostat, Bethesda, MD 20814 USA.	Karen.Schwab@usuhs.edu	Brenner, Lisa A./AAG-2442-2019	Scher, Ann/0000-0003-4599-9834	Congressionally Directed Medical Research ProgramsUnited States Department of Defense; Center for Neuroscience and Regenerative Medicine, Defense Medical Research and Development Program; Defense and Veterans Brain Injury CenterUS Department of Veterans Affairs	Primary funding for the study was provided by the Congressionally Directed Medical Research Programs. Additional support was provided by the Center for Neuroscience and Regenerative Medicine, Defense Medical Research and Development Program, and the Defense and Veterans Brain Injury Center.	Baldassarre M, 2015, PM&R, V7, P845, DOI 10.1016/j.pmrj.2015.03.003; Belanger HG, 2012, ARCH PHYS MED REHAB, V93, P1234, DOI 10.1016/j.apmr.2012.03.003; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Bliese PD, 2008, J CONSULT CLIN PSYCH, V76, P272, DOI 10.1037/0022-006X.76.2.272; Boyle Eleanor, 2014, Arch Phys Med Rehabil, V95, pS230, DOI 10.1016/j.apmr.2013.08.297; Brenner LA, 2010, J HEAD TRAUMA REHAB, V25, P307, DOI 10.1097/HTR.0b013e3181cada03; Cassidy J David, 2014, Arch Phys Med Rehabil, V95, pS132, DOI 10.1016/j.apmr.2013.08.299; Chase RP, 2015, J HEAD TRAUMA REHAB, V30, pE57, DOI 10.1097/HTR.0000000000000061; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; IOM, 2010, RET HOM IR AFGH PREL; Iverson GL, 2009, CLIN NEUROPSYCHOL, V23, P1299, DOI 10.1080/13854040903153902; Kashluba S, 2004, ARCH CLIN NEUROPSYCH, V19, P805, DOI 10.1016/j.acn.2003.09.005; Katz Douglas I, 2015, Handb Clin Neurol, V127, P131, DOI 10.1016/B978-0-444-52892-6.00009-X; Kennedy JE, 2010, NEUROREHABILITATION, V26, P191, DOI 10.3233/NRE-2010-0555; King PR, 2012, J REHABIL RES DEV, V49, P879, DOI 10.1682/JRRD.2011.03.0051; Kontos AP, 2013, J NEUROTRAUM, V30, P680, DOI 10.1089/neu.2012.2506; Lange RT, 2015, J CLIN EXP NEUROPSYC, V37, P853, DOI 10.1080/13803395.2015.1064864; Lange RT, 2014, ARCH CLIN NEUROPSYCH, V29, P329, DOI 10.1093/arclin/acu013; Lew HL, 2008, J REHABIL RES DEV, V45, pXI, DOI 10.1682/JRRD.2008.05.0064; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Ling G, 2015, Handb Clin Neurol, V127, P173, DOI 10.1016/B978-0-444-52892-6.00011-8; Mac Donald CL, 2015, BRAIN, V138, P1314, DOI 10.1093/brain/awv038; Mac Donald CL, 2014, JAMA NEUROL, V71, P994, DOI 10.1001/jamaneurol.2014.1114; McCrea HJ, 2013, SPORTS HEALTH, V5, P160, DOI 10.1177/1941738112462203; Miller KJ, 2013, J HEAD TRAUMA REHAB, V28, P31, DOI 10.1097/HTR.0b013e318255ceae; ONeil ME, J INT NEUROPSYCHOL S; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Scholten JD, 2012, BRAIN INJURY, V26, P1177, DOI 10.3109/02699052.2012.661914; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Stein MB, 2016, J NEUROTRAUM, V33, P2125, DOI 10.1089/neu.2015.4320; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Terrio HP, 2011, REHABIL PSYCHOL, V56, P26, DOI 10.1037/a0022685; Von Korff M, 2005, PAIN, V117, P304, DOI 10.1016/j.pain.2005.06.017; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Wilk JE, 2012, PSYCHOSOM MED, V74, P249, DOI 10.1097/PSY.0b013e318244c604	40	41	42	0	23	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	APR 18	2017	88	16					1571	1579		10.1212/WNL.0000000000003839			9	Clinical Neurology	Neurosciences & Neurology	ES1NF	WOS:000399293600016	28314862				2021-06-18	
J	Crompton, EM; Lubomirova, I; Cotlarciuc, I; Han, TS; Sharma, SD; Sharma, P				Crompton, Ellie M.; Lubomirova, Irina; Cotlarciuc, Ioana; Han, Thang S.; Sharma, Sapna D.; Sharma, Pankaj			Meta-Analysis of Therapeutic Hypothermia for Traumatic Brain Injury in Adult and Pediatric Patients	CRITICAL CARE MEDICINE			English	Article						adult; hypothermia; morbidity; mortality; pediatric; traumatic brain injury	RANDOMIZED CONTROLLED-TRIAL; MILD HYPOTHERMIA; MODERATE HYPOTHERMIA; INTRACRANIAL-PRESSURE; CEREBRAL HYPOTHERMIA; HEAD-INJURY; PHASE-II; CEREBROSPINAL-FLUID; ENERGY-EXPENDITURE; PROTEIN-LEVELS	Objective: Therapeutic hypothermia has been used to attenuate the effects of traumatic brain injuries. However, the required degree of hypothermia, length of its use, and its timing are uncertain. We undertook a comprehensive meta-analysis to quantify benefits of hypothermia therapy for traumatic brain injuries in adults and children by analyzing mortality rates, neurologic outcomes, and adverse effects. Data Sources: Electronic databases PubMed, Google Scholar, Web of Science, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov and manual searches of studies were conducted for relevant publications up until February 2016. Study Selection: Forty-one studies in adults (n= 3,109; age range, 18-81 yr) and eight studies in children (n = 454; age range, 3 mo to 18 yr) met eligibility criteria. Data Extraction: Baseline patient characteristics, enrollment time, methodology of cooling, target temperature, duration of hypothermia, and rewarming protocols were extracted. Data Synthesis: Risk ratios with 95% Cls were calculated. Compared with adults who were kept normothermic, those who underwent therapeutic hypothermia were associated with 18% reduction in mortality (risk ratio, 0.82; 95% CI, 0.70-0.96; p = 0.01) and a 35% improvement in neurologic outcome (risk ratio, 1.35; 95% CI, 1.18-1.54; p < 0.00001). The optimal management strategy for adult patients included cooling patients to a minimum of 33 degrees C for 72 hours, followed by spontaneous, natural rewarming. In contrast, adverse outcomes were observed in children who underwent hypothermic treatment with a 66% increase in mortality (risk ratio, 1.66; 95% CI, 1.06-2.59; p= 0.03) and a marginal deterioration of neurologic outcome (risk ratio, 0.90; 95% CI, 0.80-1.01; p= 0.06). Conclusions: Therapeutic hypothermia is likely a beneficial treatment following traumatic brain injuries in adults but cannot be recommended in children. (Crit Care Med 2017; 45:575-583)	[Crompton, Ellie M.; Cotlarciuc, Ioana; Han, Thang S.; Sharma, Sapna D.; Sharma, Pankaj] Royal Holloway Univ London ICR2UL, Inst Cardiovasc Res, Egham, Surrey, England; [Lubomirova, Irina] Imperial Coll London, Dept Med, London, England; [Han, Thang S.; Sharma, Pankaj] Ashford & St Peters NHS Fdn Trust, Chertsey, Surrey, England	Sharma, P (corresponding author), Royal Holloway Univ London ICR2UL, Inst Cardiovasc Res, Egham, Surrey, England.; Sharma, P (corresponding author), Ashford & St Peters NHS Fdn Trust, Chertsey, Surrey, England.	pankaj.sharma@rhul.ac.uk	Crompton, Ellie/M-3164-2015	Han, Thang/0000-0003-2570-0938; Crompton, Ellie/0000-0002-8362-8850			Adelson PD, 2013, LANCET NEUROL, V12, P546, DOI 10.1016/S1474-4422(13)70077-2; Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Aibiki M, 2000, CRIT CARE MED, V28, P3902, DOI 10.1097/00003246-200012000-00029; Andrews PJD, 2015, NEW ENGL J MED, V373, P2403, DOI 10.1056/NEJMoa1507581; Beca J, 2015, CRIT CARE MED, V43, P1458, DOI 10.1097/CCM.0000000000000947; Bergman KS, 2015, CRIT CARE NURS CLIN, V27, P225, DOI 10.1016/j.cnc.2015.02.009; Biswas AK, 2002, CRIT CARE MED, V30, P2742, DOI 10.1097/00003246-200212000-00020; BORZOTTA AP, 1994, J TRAUMA, V37, P459, DOI 10.1097/00005373-199409000-00022; Bourdages M, 2010, PEDIATR CRIT CARE ME, V11, P408, DOI 10.1097/PCC.0b013e3181c51dea; Brain Trauma Foundation, 2007, J NEUROTRAUM, V24, pS21; Chen L, 2001, Chin J Traumatol, V4, P164; Clark RSB, 1996, CRIT CARE MED, V24, P1243, DOI 10.1097/00003246-199607000-00030; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CLIFTON GL, 1992, J NEUROTRAUM, V9, pS487; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; Clifton GL, 2011, LANCET NEUROL, V10, P131, DOI 10.1016/S1474-4422(10)70300-8; DEMPSEY DT, 1985, SURG GYNECOL OBSTET, V160, P128; Dennis L J, 2001, Neurol India, V49 Suppl 1, pS37; Dietrich WD, 2010, NEUROTHERAPEUTICS, V7, P43, DOI 10.1016/j.nurt.2009.10.015; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Frieden T. R., 2015, REPORT C TRAUMATIC B; Gal R, 2002, CLIN NEUROL NEUROSUR, V104, P318, DOI 10.1016/S0303-8467(02)00023-9; Galvin IM, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006638.pub3; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; Gururaj G, 2002, NEUROL RES, V24, P24, DOI 10.1179/016164102101199503; Harris OA, 2009, J NEUROSURG, V110, P1256, DOI 10.3171/2009.1.JNS081320; Hashiguchi N, 2003, J TRAUMA, V55, P1054, DOI 10.1097/01.TA.0000033252.43742.8B; Hayashi S, 2005, ACT NEUR S, V95, P269; Hayashi S, 2002, ACT NEUR S, V81, P83; Hirayama TKY, 1994, INTRACRANIAL PRESSUR, VIX, P233; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; Idris Zamzuri, 2014, Asian J Neurosurg, V9, P115, DOI 10.4103/1793-5482.142690; Ishikawa K, 2000, J TRAUMA, V49, P912, DOI 10.1097/00005373-200011000-00020; Jiang Jiyao, 1998, Chin J Traumatol, V1, P17; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; Jiang JY, 2004, NEUROSURGERY, V54, P713, DOI 10.1227/01.NEU.0000109535.58429.49; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; Kinoshita K, 2002, NEUROSURGERY, V51, P195, DOI 10.1097/00006123-200207000-00027; Lee HC, 2010, WORLD NEUROSURG, V74, P654, DOI 10.1016/j.wneu.2010.06.019; Li H, 2009, J NEUROTRAUM, V26, P1905, DOI 10.1089/neu.2008-0828; Li PC, 2014, BRAIN INJURY, V28, P1036, DOI 10.3109/02699052.2014.910609; Liu J, 1999, CHIN J TRAUMATOL, V15, P35; Liu WG, 2006, J INT MED RES, V34, P58, DOI 10.1177/147323000603400107; Lotocki G, 2006, EUR J NEUROSCI, V24, P2283, DOI 10.1111/j.1460-9568.2006.05123.x; LYETH BG, 1993, MOL CHEM NEUROPATHOL, V18, P247, DOI 10.1007/BF03160117; Ma CK, 2013, CHILD NERV SYST, V29, P979, DOI 10.1007/s00381-013-2076-x; Maekawa T, 2015, J NEUROTRAUM, V32, P422, DOI 10.1089/neu.2013.3197; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; McIntyre LA, 2003, JAMA-J AM MED ASSOC, V289, P2992, DOI 10.1001/jama.289.22.2992; Meissner W, 2003, INTENS CARE MED, V29, P44, DOI 10.1007/s00134-002-1556-3; Mtaweh H, 2014, PEDIATR CRIT CARE ME, V15, P242, DOI 10.1097/PCC.0000000000000041; Nara I, 1997, ACTA NEUROCHIR WIE S, V71, P22; Papile LA, 2014, PEDIATRICS, V133, P1146, DOI 10.1542/peds.2014-0899; Peterson K, 2008, J NEUROTRAUM, V25, P62, DOI 10.1089/neu.2007.0424; Polderman KH, 2004, INTENS CARE MED, V30, P556, DOI 10.1007/s00134-003-2152-x; Polderman KH, 2002, INTENS CARE MED, V28, P1563, DOI 10.1007/s00134-002-1511-3; Puvanachandra P., 2009, PAK J NEUROL SCI, V4, P27; Qiu Wu-si, 2005, Chin J Traumatol, V8, P27; Qiu W, 2007, J CRIT CARE, V22, P229, DOI 10.1016/j.jcrc.2006.06.011; ROBERTSON CS, 1984, NEUROSURGERY, V15, P307, DOI 10.1227/00006123-198409000-00003; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; ROSOMOFF HL, 1954, AM J PHYSIOL, V179, P85; ROSOMOFF HL, 1956, SURGERY, V40, P328; Salonia R, 2010, J NEUROTRAUM, V27, P1819, DOI 10.1089/neu.2010.1402; Shamseer L, 2015, BMJ-BRIT MED J, V349, DOI [10.1136/bmj.g7647, 10.1136/bmj.i4086]; Shiozaki T, 1999, J NEUROSURG, V91, P185, DOI 10.3171/jns.1999.91.2.0185; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; Shiozaki T, 2001, J NEUROSURG, V94, P50, DOI 10.3171/jns.2001.94.1.0050; Smrcka M, 2005, ACT NEUR S, V95, P273; Soukup J, 2002, J NEUROTRAUM, V19, P559, DOI 10.1089/089771502753754046; Suehiro E, 2014, J NEUROTRAUM, V31, P315, DOI 10.1089/neu.2013.3057; Tagin MA, 2012, ARCH PEDIAT ADOL MED, V166, P558, DOI 10.1001/archpediatrics.2011.1772; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Tisherman SA, 1999, SURG CLIN N AM, V79, P1269, DOI 10.1016/S0039-6109(05)70077-3; Tokutomi T, 2004, NEUROCRIT CARE, V1, P171, DOI 10.1385/NCC:1:2:171; Tokutomi T, 2003, NEUROSURGERY, V52, P102, DOI 10.1097/00006123-200301000-00013; Vitarbo EA, 2004, NEUROSURGERY, V55, P416, DOI 10.1227/01.NEU.0000130036.52521.2C; Whiteneck G, 2001, COLORADO TRAUMATIC B; Wu TC, 2013, LANCET NEUROL, V12, P275, DOI 10.1016/S1474-4422(13)70013-9; Wu X, 2008, J TRAUMA, V64, P1313, DOI 10.1097/TA.0b013e318165c803; Yamamoto T, 2002, NEUROL RES, V24, P789, DOI 10.1179/016164102101200906; Yan Y, 2010, J CLIN NEUROSCI, V17, P196, DOI 10.1016/j.jocn.2009.05.022; YOUNG B, 1985, NEUROSURGERY, V17, P784, DOI 10.1227/00006123-198511000-00010; Zhang BF, 2015, WORLD NEUROSURG, V83, P567, DOI 10.1016/j.wneu.2014.12.010; Zhang XW, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-1133-0; Zhao QJ, 2011, J CRIT CARE, V26, P311, DOI 10.1016/j.jcrc.2010.08.014; Zhi DS, 2003, SURG NEUROL, V59, P381, DOI 10.1016/S0090-3019(03)00148-4; Zhu Yan-xiang, 2003, Chin J Traumatol, V6, P152	89	41	45	1	23	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	APR	2017	45	4					575	583		10.1097/CCM.0000000000002205			9	Critical Care Medicine	General & Internal Medicine	EO6JQ	WOS:000396798700002	27941370				2021-06-18	
J	Rivera-Lara, L; Zorrilla-Vaca, A; Geocadin, R; Ziai, W; Healy, R; Thompson, R; Smielewski, P; Czosnyka, M; Hogue, CW				Rivera-Lara, Lucia; Zorrilla-Vaca, Andres; Geocadin, Romer; Ziai, Wendy; Healy, Ryan; Thompson, Richard; Smielewski, Peter; Czosnyka, Marek; Hogue, Charles W.			Predictors of Outcome With Cerebral Autoregulation Monitoring: A Systematic Review and Meta-Analysis	CRITICAL CARE MEDICINE			English	Article						cerebral blood flow; cerebrovascular autoregulation; intracranial pressure monitoring; neuromonitoring; transcranial Doppler	CEREBROVASCULAR PRESSURE REACTIVITY; TRAUMATIC BRAIN-INJURY; BLOOD-FLOW AUTOREGULATION; INTRACRANIAL-PRESSURE; TISSUE OXYGENATION; PERFUSION-PRESSURE; CARDIOPULMONARY BYPASS; VASOMOTOR REACTIVITY; HEAD-INJURY; CHILDREN	Objective: To compare cerebral autoregulation indices as predictors of patient outcome and their dependence on duration of monitoring. Data Sources: Systematic literature search and meta-analysis using PubMed, EM BASE, and the Cochrane Library from January 1990 to October 2015. Study Selection: We chose articles that assessed the association between cerebral autoregulation indices and dichotomized or continuous outcomes reported as standardized mean differences or correlation coefficients (R), respectively. Animal and validation studies were excluded. Data Extraction: Two authors collected and assessed the data independently. The studies were grouped into two sets according to the type of analysis used to assess the relationship between cerebral autoregulation indices and predictors of outcome (standardized mean differences or R). Data Synthesis: Thirty-three studies compared cerebral autoregulation indices and patient outcomes using standardized mean differences, and 20 used Rs. The only data available for meta-analysis were from patients with traumatic brain injury or subarachnoid hemorrhage. Based on z score analysis, the best three cerebral autoregulation index predictors of mortality or Glasgow Outcome Scale for patients with traumatic brain injury were the pressure reactivity index, transcranial Doppler-derived mean velocity index based on cerebral perfusion pressure, and autoregulation reactivity index (z scores: 8.97, 6.01, 3.94, respectively). Mean velocity index based on arterial blood pressure did not reach statistical significance for predicting outcome measured as a continuous variable (p = 0.07) for patients with traumatic brain injury. For patients with subarachnoid hemorrhage, autoregulation reactivity index was the only cerebral autoregulation index that predicted patient outcome measured with the Glasgow Outcome Scale as a continuous outcome (R = 0.82; p = 0.001; z score, 3.39). We found a significant correlation between the duration of monitoring and predictive value for mortality (R = 0.78; p < 0.001). Conclusions: Three cerebral autoregulation indices, pressure reactivity index, mean velocity index based on cerebral perfusion pressure, and autoregulation reactivity index were the best outcome predictors for patients with traumatic brain injury. For patients with subarabhnoid hemorrhage, autoregulation reactivity index was the only cerebral autoregulation index predictor of Glasgow Outcome Scale. Continuous assessment of cerebral autoregulation predicted outcome better than intermittent monitoring. (Crit Care Med 2017; 45:695-704)	[Rivera-Lara, Lucia; Geocadin, Romer; Ziai, Wendy] Johns Hopkins Sch Med, Dept Neurol, Baltimore, MD 21205 USA; [Rivera-Lara, Lucia; Zorrilla-Vaca, Andres; Geocadin, Romer; Ziai, Wendy; Healy, Ryan; Hogue, Charles W.] Johns Hopkins Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21205 USA; [Zorrilla-Vaca, Andres] Univ Valle, Sch Med, Dept Anesthesiol, Cali, Colombia; [Thompson, Richard] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD USA; [Smielewski, Peter; Czosnyka, Marek] Univ Cambridge, Div Neurosurg, Dept Clin Neurosci, Cambridge, England	Rivera-Lara, L (corresponding author), Johns Hopkins Sch Med, Dept Neurol, Baltimore, MD 21205 USA.; Rivera-Lara, L (corresponding author), Johns Hopkins Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21205 USA.	Iriver14@jhmi.edu	Rivera-Lara, Lucia/AAX-8233-2020; Vaca, Andres Zorrilla/I-9274-2014	Rivera-Lara, Lucia/0000-0002-9053-2283; Vaca, Andres Zorrilla/0000-0001-8140-8486; Smielewski, Peter/0000-0001-5096-3938	Johns Hopkins Institute for Clinical and Translational Research (ICTR); National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1 TR 000424-06]; NIH Roadmap for Medical ResearchUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 HL 92259]; American Academy of Neurology/American Brain Foundation; Covidien; Medtronic/Covidien, Dublin, IR; Cambridge Enterprise; Integra Speakers Bureau; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600986] Funding Source: researchfish	Supported by the Johns Hopkins Institute for Clinical and Translational Research (ICTR), which is funded in part by Grant Number UL1 TR 000424-06 from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of the Johns Hopkins ICTR, NCATS, or NIH.; Dr. Rivera-Lara received support for article research from the National Institutes of Health (NIH). Her institution received funding (Dr. Hogue is the PI on an NIH-sponsored clinical study [R01 HL 92259]; Dr. Rivera-Lara is the PI on an American Academy of Neurology/American Brain Foundation and Covidien grant; and Dr. Hogue receives research funding from Medtronic/Covidien, Dublin, IR, and he serves as a consultant to Medtronic/Covidien and Ornim Medical, Foxborough, MA). Dr. Healy received support for article research from the NIH. Dr. Thompson received support for article research from the NIH. Dr. Smielewski disclosed other support (The author receives part of licensing fees of the software ICM+ used for data collection and partial analysis). Dr. Czosnyka received support for article research from Research Councils UK and received funding from Cambridge Enterprise and from Integra Speakers Bureau. Dr. Hogue received support for article research from the NIH and disclosed off-label product use (The autoregulation methods described are investigational but derived from Food and Drug Administration approved monitors). The remaining authors have disclosed that they do not have any potential conflicts of interest.	Ang BT, 2007, J NEUROL NEUROSUR PS, V78, P298, DOI 10.1136/jnnp.2005.082735; Aries MJH, 2012, CRIT CARE MED, V40, P2456, DOI 10.1097/CCM.0b013e3182514eb6; Aries MJH, 2012, NEUROCRIT CARE, V17, P67, DOI 10.1007/s12028-012-9687-z; Barth Martin, 2012, Acta Neurochir Suppl, V114, P157, DOI 10.1007/978-3-7091-0956-4_29; Bochicchio M, 1996, INTENS CARE MED, V22, P1070, DOI 10.1007/BF01699230; Brady KM, 2007, STROKE, V38, P2818, DOI 10.1161/STROKEAHA.107.485706; Brady KM, 2010, STROKE, V41, P1957, DOI 10.1161/STROKEAHA.109.575167; Budohoski KP, 2012, STROKE, V43, P3230, DOI 10.1161/STROKEAHA.112.669788; Budohoski KP, 2012, NEUROSURGERY, V71, P652, DOI 10.1227/NEU.0b013e318260feb1; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Cooper H., 1994, HDB RES SYNTHESIS; Czosnyka M, 2006, ACTA NEUROCHIR SUPPL, V96, P114; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Czosnyka M, 1999, J NEUROL NEUROSUR PS, V66, P606, DOI 10.1136/jnnp.66.5.606; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Dohmen C, 2007, STROKE, V38, P56, DOI 10.1161/01.STR.0000251642.18522.b6; Eide PK, 2007, NEUROL RES, V29, P578, DOI 10.1179/016164107X172167; Figaji AA, 2009, J NEUROSURG-PEDIATR, V4, P420, DOI 10.3171/2009.6.PEDS096; GILPIN AR, 1993, EDUC PSYCHOL MEAS, V53, P87, DOI 10.1177/0013164493053001007; Higgins JTP., 2008, COCHRANE HDB SYSTEMA, V5; Hiler M, 2006, J NEUROSURG, V104, P731, DOI 10.3171/jns.2006.104.5.731; Hollingsworth KG, 2010, LIVER INT, V30, P878, DOI 10.1111/j.1478-3231.2010.02259.x; Howells T, 2015, J CLIN MONIT COMPUT, V29, P97, DOI 10.1007/s10877-014-9573-7; Hozo Stela Pudar, 2005, BMC Med Res Methodol, V5, P13, DOI 10.1186/1471-2288-5-13; Jaeger M, 2006, CRIT CARE MED, V34, P1783, DOI 10.1097/01.CCM.0000218413.51546.9E; Jaeger M, 2012, STROKE, V43, P2097, DOI 10.1161/STROKEAHA.112.659888; Johnson U, 2011, NEUROSURGERY, V68, P714, DOI 10.1227/NEU.0b013e3182077313; Joshi B, 2010, ANESTH ANALG, V110, P321, DOI 10.1213/ANE.0b013e3181c6fd12; Kirkness C J, 2001, Biol Res Nurs, V2, P175, DOI 10.1177/109980040100200303; Lang EW, 2003, J NEUROL NEUROSUR PS, V74, P1053, DOI 10.1136/jnnp.74.8.1053; Lang EW, 2003, J NEUROTRAUM, V20, P69, DOI 10.1089/08977150360517191; LASSEN NA, 1959, PHYSIOL REV, V39, P183; Lewis PM, 2007, ACTA NEUROCHIR, V149, P549, DOI 10.1007/s00701-007-1160-y; Lewis Philip M, 2012, Acta Neurochir Suppl, V114, P147, DOI 10.1007/978-3-7091-0956-4_27; Liberati Alessandro, 2009, J Clin Epidemiol, V62, pe1, DOI 10.1016/j.jclinepi.2009.06.006; Liu XY, 2015, J CEREBR BLOOD F MET, V35, P248, DOI 10.1038/jcbfm.2014.192; Ma L, 2014, PEDIATR CRIT CARE ME, V15, P742, DOI 10.1097/PCC.0000000000000197; Ono M, 2012, BRIT J ANAESTH, V109, P391, DOI 10.1093/bja/aes148; Ono M, 2013, CRIT CARE MED, V41, P464, DOI 10.1097/CCM.0b013e31826ab3a1; Panerai RB, 2004, BRIT J NEUROSURG, V18, P471, DOI 10.1080/02688690400012343; PAULSON OB, 1990, CEREBROVAS BRAIN MET, V2, P161; Pham P, 2015, RESUSCITATION, V96, P192, DOI 10.1016/j.resuscitation.2015.08.007; Radolovich DK, 2011, NEUROCRIT CARE, V15, P379, DOI 10.1007/s12028-011-9553-4; Ragauskas A, 2005, ACTA NEUROCHIR SUPPL, V95, P367; Reinhard M, 2012, ACTA NEUROL SCAND, V125, P156, DOI 10.1111/j.1600-0404.2011.01515.x; Reinhard M, 2010, INTENS CARE MED, V36, P264, DOI 10.1007/s00134-009-1698-7; Santos E, 2011, ACTA NEUROCHIR, V153, P2189, DOI 10.1007/s00701-011-1148-5; Schmidt B, 2016, J CLIN MONIT COMPUT, V30, P367, DOI 10.1007/s10877-015-9726-3; Shaw M, 2008, ACT NEUR S, V102, P33, DOI 10.1007/978-3-211-85578-2_7; Soehle M, 2004, ANESTH ANALG, V98, P1133, DOI 10.1213/01.ANE.0000111101.41190.99; Sorrentino E, 2011, NEUROCRIT CARE, V14, P188, DOI 10.1007/s12028-010-9492-5; Steiner LA, 2003, J NEUROL NEUROSUR PS, V74, P765, DOI 10.1136/jnnp.74.6.765; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; STRANDGAARD S, 1984, STROKE, V15, P413, DOI 10.1161/01.STR.15.3.413; Tisdall MM, 2009, ANESTH ANALG, V109, P906, DOI 10.1213/ane.0b013e3181aedcdc; Tontisirin N, 2007, CHILD NERV SYST, V23, P1163, DOI 10.1007/s00381-007-0339-0; Vavilala MS, 2008, NEUROCRIT CARE, V9, P45, DOI 10.1007/s12028-007-9036-9; Vavilala MS, 2007, J NEUROTRAUM, V24, P87, DOI 10.1089/neu.2006.0058; Vavilala Monica S, 2004, Pediatr Crit Care Med, V5, P257, DOI 10.1097/01.PCC.0000123545.69133.C3; Wells G, 2012, NEWCASTLE OTTAWA SCA; Zheng YY, 2012, NEUROCRIT CARE, V17, P77, DOI 10.1007/s12028-012-9721-1; Zweifel C, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E2	63	41	41	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	APR	2017	45	4					695	704		10.1097/CCM.0000000000002251			10	Critical Care Medicine	General & Internal Medicine	EO6JQ	WOS:000396798700017	28291094				2021-06-18	
J	Yu, FS; Shukla, DK; Armstrong, RC; Marion, CM; Radomski, KL; Selwyn, RG; Dardzinski, BJ				Yu, Fengshan; Shukla, Dinesh K.; Armstrong, Regina C.; Marion, Christina M.; Radomski, Kryslaine L.; Selwyn, Reed G.; Dardzinski, Bernard J.			Repetitive Model of Mild Traumatic Brain Injury Produces Cortical Abnormalities Detectable by Magnetic Resonance Diffusion Imaging, Histopathology, and Behavior	JOURNAL OF NEUROTRAUMA			English	Article						concussion; diffusion kurtosis imaging; diffusion tensor imaging; microglia; Thy1-YFP	WHITE-MATTER; AXONAL INJURY; DIFFERENTIAL DETECTION; CHRONIC DEMYELINATION; COGNITIVE IMPAIRMENT; CORPUS-CALLOSUM; GLUCOSE-UPTAKE; MOUSE MODEL; HEAD-INJURY; TRACK-TBI	Noninvasive detection of mild traumatic brain injury (mTBI) is important for evaluating acute through chronic effects of head injuries, particularly after repetitive impacts. To better detect abnormalities from mTBI, we performed longitudinal studies (baseline, 3, 6, and 42 days) using magnetic resonance diffusion tensor imaging (DTI) and diffusion kurtosis imaging (DKI) in adult mice after repetitive mTBI (r-mTBI; daily x 5) or sham procedure. This r-mTBI produced righting reflex delay and was first characterized in the corpus callosum to demonstrate low levels of axon damage, astrogliosis, and microglial activation, without microhemorrhages. High-resolution DTI-DKI was then combined with post-imaging pathological validation along with behavioral assessments targeted for the impact regions. In the corpus callosum, only DTI fractional anisotropy at 42 days showed significant change post-injury. Conversely, cortical regions under the impact site (M1-M2, anterior cingulate) had reduced axial diffusivity (AD) at all time points with a corresponding increase in axial kurtosis (K-a) at 6 days. Post-imaging neuropathology showed microglial activation in both the corpus callosum and cortex at 42 days after r-mTBI. Increased cortical microglial activation correlated with decreased cortical AD after r-mTBI (r=-0.853; n = 5). Using Thy1-YFP-16 mice to fluorescently label neuronal cell bodies and processes revealed low levels of axon damage in the cortex after r-mTBI. Finally, r-mTBI produced social deficits consistent with the function of this anterior cingulate region of cortex. Overall, vulnerability of cortical regions is demonstrated after mild repetitive injury, with underlying differences of DTI and DKI, microglial activation, and behavioral deficits.	[Yu, Fengshan; Shukla, Dinesh K.; Armstrong, Regina C.; Marion, Christina M.; Radomski, Kryslaine L.; Selwyn, Reed G.; Dardzinski, Bernard J.] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA; [Yu, Fengshan; Radomski, Kryslaine L.] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA; [Armstrong, Regina C.; Marion, Christina M.] Uniformed Serv Univ Hlth Sci, Program Neurosci, Bethesda, MD 20814 USA; [Dardzinski, Bernard J.] Uniformed Serv Univ Hlth Sci, Dept Radiol & Radiol Sci, Bethesda, MD 20814 USA; [Shukla, Dinesh K.] Univ Maryland, Sch Med, Dept Psychiat, Baltimore, MD 21201 USA; [Selwyn, Reed G.] Univ New Mexico, Dept Radiol, Albuquerque, NM 87131 USA	Yu, FS (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Ctr Neurosci & Regenerat Med, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	fengshan.yu.ctr@usuhs.edu	Marion, Christina M/B-8120-2015	Marion, Christina M/0000-0003-0381-4109; Dardzinski, Bernard/0000-0001-7098-9131; Radomski, Kryslaine/0000-0001-9624-623X; Yu, Fengshan/0000-0001-8620-3084	Department of Defense within the Center for Neuroscience and Regenerative Medicine	This study was funded by the Department of Defense within the Center for Neuroscience and Regenerative Medicine. We appreciate the assistance of Dr. Amanda Mierzwa, Laurel Beer, Tuan Le, and the Pre-clinical Core and Translational Imaging Core of the Center for Neuroscience and Regenerative Medicine. We thank Drs. R. P. Gullapalli and J. Zhuo (University of Maryland, Baltimore, MD) for providing the MATLAB code for DKI processing.	Adam O, 2015, NEUROLOGY, V85, P219, DOI 10.1212/WNL.0000000000001758; Alexander AL, 2007, NEUROTHERAPEUTICS, V4, P316, DOI 10.1016/j.nurt.2007.05.011; Allen B, 2002, J NEUROSCI, V22, P9340; Armstrong RC, 2002, J NEUROSCI, V22, P8574; Armstrong RC, 2006, J NEUROPATH EXP NEUR, V65, P245, DOI 10.1097/01.jnen.0000205142.08716.7e; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Bennett RE, 2012, NEUROSCI LETT, V513, P160, DOI 10.1016/j.neulet.2012.02.024; Bouix S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066205; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; Davenport EM, 2016, J NEUROTRAUM, V33, P2133, DOI 10.1089/neu.2015.4267; Delano-Wood L, 2015, BRAIN IMAGING BEHAV, V9, P500, DOI 10.1007/s11682-015-9432-2; Edlow BL, 2016, BMC NEUROL, V16, DOI 10.1186/s12883-015-0525-8; Eierud C, 2014, NEUROIMAGE-CLIN, V4, P283, DOI 10.1016/j.nicl.2013.12.009; Gardner RC, 2015, MOL CELL NEUROSCI, V66, P75, DOI 10.1016/j.mcn.2015.03.001; Glenn GR, 2016, AM J NEURORADIOL, V37, P1216, DOI 10.3174/ajnr.A4714; Grossman EJ, 2013, AM J NEURORADIOL, V34, P951, DOI 10.3174/ajnr.A3358; Grossman EJ, 2012, J NEUROTRAUM, V29, P2318, DOI 10.1089/neu.2011.1763; Harris NG, 2016, NEUROIMAGE, V133, P129, DOI 10.1016/j.neuroimage.2016.03.012; HENNIG J, 1986, MAGNET RESON MED, V3, P823, DOI 10.1002/mrm.1910030602; Hernandez A, 2016, J NEUROCHEM, V136, P18, DOI 10.1111/jnc.13402; Hibbits N, 2009, ASN NEURO, V1, DOI 10.1042/AN20090032; Hong S, 2016, CURR OPIN NEUROBIOL, V36, P128, DOI 10.1016/j.conb.2015.12.004; Huang L, 2013, BRAIN RES, V1499, P109, DOI 10.1016/j.brainres.2012.12.038; Hughes EG, 2013, NAT NEUROSCI, V16, P668, DOI 10.1038/nn.3390; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; Jensen JH, 2010, NMR BIOMED, V23, P698, DOI 10.1002/nbm.1518; Jensen JH, 2005, MAGNET RESON MED, V53, P1432, DOI 10.1002/mrm.20508; Kenney K, 2016, EXP NEUROL, V275, P353, DOI 10.1016/j.expneurol.2015.05.019; Klemenhagen KC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074510; Kou Z, 2010, GLIA, V62, P1831; Lavin Claudio, 2013, Front Neurosci, V7, P64, DOI 10.3389/fnins.2013.00064; LEVINE JM, 1994, J NEUROSCI, V14, P4716; Lindner M, 2008, NEUROPATH APPL NEURO, V34, P105, DOI 10.1111/j.1365-2990.2007.00879.x; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Mannix R, 2013, ANN NEUROL, V74, P65, DOI 10.1002/ana.23858; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKenzie IA, 2014, SCIENCE, V346, P318, DOI 10.1126/science.1254960; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; Meehan WP, 2012, NEUROSURGERY, V71, P885, DOI 10.1227/NEU.0b013e318265a439; Meier TB, 2016, J NEUROTRAUM, V33, P330, DOI 10.1089/neu.2015.3919; Mierzwa AJ, 2015, J NEUROPATH EXP NEUR, V74, P218, DOI 10.1097/NEN.0000000000000165; Mierzwa AJ, 2014, ASN NEURO, V6, DOI 10.1177/1759091414551782; Mierzwa AJ, 2013, NEUROSCI LETT, V548, P280, DOI 10.1016/j.neulet.2013.05.010; Moy SS, 2004, GENES BRAIN BEHAV, V3, P287, DOI 10.1111/j.1601-1848.2004.00076.x; Nadler JJ, 2004, GENES BRAIN BEHAV, V3, P303, DOI 10.1111/j.1601-183X.2004.00071.x; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Ojo JO, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00213; Olmos-Alonso A, 2016, BRAIN, V139, P891, DOI 10.1093/brain/awv379; Pajevic S, 1999, MAGNET RESON MED, V42, P526, DOI 10.1002/(SICI)1522-2594(199909)42:3<526::AID-MRM15>3.0.CO;2-J; Petraglia Anthony L, 2014, Surg Neurol Int, V5, P184, DOI 10.4103/2152-7806.147566; Pierpaoli C., 2010, ISMRM 18 ANN M STOCK, P1597; Robinson S, 2017, J NEUROSCI RES, V95, P1025, DOI 10.1002/jnr.23848; Sekar A, 2016, NATURE, V530, P177, DOI 10.1038/nature16549; Selwyn R, 2013, J NEUROTRAUM, V30, P1943, DOI 10.1089/neu.2013.2928; Selwyn RG, 2016, J NEUROTRAUM, V33, P1479, DOI 10.1089/neu.2015.4129; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Silverman JL, 2010, NAT REV NEUROSCI, V11, P490, DOI 10.1038/nrn2851; Singh K, 2016, EXP NEUROL, V275, P427, DOI 10.1016/j.expneurol.2015.07.016; Smits M, 2011, NEURORADIOLOGY, V53, P553, DOI 10.1007/s00234-010-0774-6; Song SK, 2005, NEUROIMAGE, V26, P132, DOI 10.1016/j.neuroimage.2005.01.028; Srivastava DP, 2012, J NEUROSCI, V32, P11864, DOI 10.1523/JNEUROSCI.1349-12.2012; STEJSKAL EO, 1965, J CHEM PHYS, V42, P288, DOI 10.1063/1.1695690; Stemper BD, 2015, ANN BIOMED ENG, V43, P1071, DOI 10.1007/s10439-014-1171-9; Stokum JA, 2015, BRAIN INJURY, V29, P47, DOI 10.3109/02699052.2014.947628; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Sullivan GM, 2013, J NEUROPATH EXP NEUR, V72, P1106, DOI 10.1097/NEN.0000000000000009; Susarla BTS, 2014, ASN NEURO, V6, DOI 10.1042/AN20130034; Tobin JE, 2011, J NEUROPATH EXP NEUR, V70, P157, DOI 10.1097/NEN.0b013e31820937e4; Tu TW, 2016, ANN NEUROL, V79, P907, DOI 10.1002/ana.24641; Ware JB, 2016, RADIOLOGY, V280, P212, DOI 10.1148/radiol.2016151013; Yang ST, 2015, J NEUROL SCI, V349, P99, DOI 10.1016/j.jns.2014.12.032; Yuh EL, 2014, J NEUROTRAUM, V31, P1457, DOI 10.1089/neu.2013.3171; Zhou YX, 2013, RADIOLOGY, V267, P880, DOI 10.1148/radiol.13122542; Zhuo JC, 2012, NEUROIMAGE, V59, P467, DOI 10.1016/j.neuroimage.2011.07.050	76	41	42	2	19	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2017	34	7					1364	1381		10.1089/neu.2016.4569			18	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	ER0FB	WOS:000398461600007	27784203	Green Published, Bronze			2021-06-18	
J	Llinas-Regla, J; Vilalta-Franch, J; Lopez-Pousa, S; Calvo-Perxas, L; Torrents Rodas, D; Garre-Olmo, J				Llinas-Regla, Jordi; Vilalta-Franch, Joan; Lopez-Pousa, Secundino; Calvo-Perxas, Laia; Torrents Rodas, David; Garre-Olmo, Josep			The Trail Making Test: Association With Other Neuropsychological Measures and Normative Values for Adults Aged 55 Years and Older From a Spanish-Speaking Population-Based Sample	ASSESSMENT			English	Article						Trail Making Test; psychometrics; neuropsychological tests; executive function; reference standards; cognition	TRAUMATIC BRAIN-INJURY; MILD COGNITIVE IMPAIRMENT; ORAL WORD-ASSOCIATION; ALZHEIMERS-DISEASE; EXECUTIVE FUNCTIONS; CONSTRUCT-VALIDITY; ELDERLY-PEOPLE; VISUAL-SEARCH; STROOP TEST; PART-B	The Trail Making Test (TMT) is used as an indicator of visual scanning, graphomotor speed, and executive function. The aim of this study was to examine the TMT relationships with several neuropsychological measures and to provide normative data in community-dwelling participants of 55 years and older. A population-based Spanish-speaking sample of 2,564 participants was used. The TMT, Symbol Digit Test, Stroop Color-Word Test, Digit Span Test, Verbal Fluency tests, and the MacQuarrie Test for Mechanical Ability tapping subtest were administered. Exploratory factor analyses and regression lineal models were used. Normative data for the TMT scores were obtained. A total of 1,923 participants (76.3%) participated, 52.4% were women, and the mean age was 66.5 years (Digit Span = 8.0). The Symbol Digit Test, MacQuarrie Test for Mechanical Ability tapping subtest, Stroop Color-Word Test, and Digit Span Test scores were associated in the performance of most TMT scores, but the contribution of each measure was different depending on the TMT score. Normative tables according to significant factors such as age, education level, and sex were created. Measures of visual scanning, graphomotor speed, and visuomotor processing speed were more related to the performance of the TMT-A score, while working memory and inhibition control were mainly associated with the TMT-B and derived TMT scores..	[Llinas-Regla, Jordi; Vilalta-Franch, Joan; Lopez-Pousa, Secundino] Hosp Santa Caterina, Memory Clin, Salt, Spain; [Llinas-Regla, Jordi; Vilalta-Franch, Joan; Lopez-Pousa, Secundino; Garre-Olmo, Josep] Univ Girona, Dept Med Sci, Girona, Spain; [Vilalta-Franch, Joan; Lopez-Pousa, Secundino; Calvo-Perxas, Laia; Garre-Olmo, Josep] Girona Biomed Res Inst IDIBGI, Salt, Spain; [Torrents Rodas, David] Univ Autonoma Barcelona, Dept Psychiat & Forens Med, Barcelona, Spain	Garre-Olmo, J (corresponding author), Girona Biomed Res Inst, Edifici Mancomunitat 1,Parc Hosp Marti & Julia, Girona 17190, Catalonia, Spain.	josep.garre@ias.scs.es	Garre-Olmo, Josep/D-8460-2011; Calvo-Perxas, Laia/H-9931-2013	Garre-Olmo, Josep/0000-0002-7817-0814; Vilalta-Franch, Joan/0000-0002-5306-437X; Calvo-Perxas, Laia/0000-0001-8618-504X; Torrents-Rodas, David/0000-0003-0222-7770; Lopez-Pousa, Secundino/0000-0002-2818-3473	Instituto de Salud Carlos IIIInstituto de Salud Carlos IIIEuropean Commission [PI09/02591]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Instituto de Salud Carlos III under Grant number PI09/02591.	Arbuthnott K, 2000, J CLIN EXP NEUROPSYC, V22, P518, DOI 10.1076/1380-3395(200008)22:4;1-0;FT518; Armitage SG, 1946, PSYCHOL MONOGR, V60, P1; Army Individual Tests Battery, 1944, MAN DIR SCOR; Ashendorf L, 2008, ARCH CLIN NEUROPSYCH, V23, P129, DOI 10.1016/j.acn.2007.11.005; Bell-McGinty S, 2002, INT J GERIATR PSYCH, V17, P828, DOI 10.1002/gps.646; Belsley D, 1980, REGRESSION DIAGNOSTI; Bezdicek O, 2012, ARCH CLIN NEUROPSYCH, V27, P906, DOI 10.1093/arclin/acs084; BORNSTEIN RA, 1988, DEV NEUROPSYCHOL, V4, P17, DOI 10.1080/87565648809540386; BORNSTEIN RA, 1985, J CLIN PSYCHOL, V41, P651, DOI 10.1002/1097-4679(198509)41:5<651::AID-JCLP2270410511>3.0.CO;2-C; Cangoz B, 2009, J NEUROL SCI, V283, P73, DOI 10.1016/j.jns.2009.02.313; Cavaco S, 2013, ARCH CLIN NEUROPSYCH, V28, P189, DOI 10.1093/arclin/acs115; Chapman RM, 2011, J CLIN EXP NEUROPSYC, V33, P187, DOI 10.1080/13803395.2010.499356; Chen PJ, 2001, ARCH GEN PSYCHIAT, V58, P853, DOI 10.1001/archpsyc.58.9.853; Cook R.D., 1982, RESIDUALS INFLUENCE; CORRIGAN JD, 1987, J CLIN PSYCHOL, V43, P402, DOI 10.1002/1097-4679(198707)43:4<402::AID-JCLP2270430411>3.0.CO;2-E; Crowe SF, 1998, J CLIN PSYCHOL, V54, P585, DOI 10.1002/(SICI)1097-4679(199808)54:5<585::AID-JCLP4>3.0.CO;2-K; Dawson JD, 2009, NEUROLOGY, V72, P521, DOI 10.1212/01.wnl.0000341931.35870.49; EHRENSTEIN WH, 1982, ARCH PSYCHIAT NERVEN, V231, P333, DOI 10.1007/BF00345589; Emerson JL, 2012, PSYCHOL AGING, V27, P550, DOI 10.1037/a0026359; Ernst J, 1987, Arch Clin Neuropsychol, V2, P1, DOI 10.1016/0887-6177(87)90030-8; Ewers M, 2012, NEUROBIOL AGING, V33, P1203, DOI 10.1016/j.neurobiolaging.2010.10.019; Ferman TJ, 2006, CLIN NEUROPSYCHOL, V20, P623, DOI 10.1080/13854040500376831; Fernandez AL, 2008, SCAND J PSYCHOL, V49, P239, DOI 10.1111/j.1467-9450.2008.00637.x; Fruchter B., 1973, FUNDAMENTAL STAT PSY; Giovagnoli AR, 1996, ITAL J NEUROL SCI, V17, P305, DOI 10.1007/BF01997792; Golden C. J., 1994, STROOP TEST COLORES; Gomar JJ, 2011, ARCH GEN PSYCHIAT, V68, P961, DOI 10.1001/archgenpsychiatry.2011.96; Grau M, 2007, EUR J CARDIOV PREV R, V14, P653, DOI 10.1097/HJR.0b013e3281764429; Hanks RA, 2008, ARCH PHYS MED REHAB, V89, P950, DOI 10.1016/j.apmr.2008.01.011; Hashimoto R, 2006, PSYCHIAT CLIN NEUROS, V60, P422, DOI 10.1111/j.1440-1819.2006.01526.x; Heled E, 2012, J CLIN EXP NEUROPSYC, V34, P151, DOI 10.1080/13803395.2011.625351; Hester RL, 2005, CLIN NEUROPSYCHOL, V19, P45, DOI 10.1080/13854040490524137; Horton A. M., 2003, ARCH CLIN NEUROPSYCH, V18, P310; Ivnik RJ, 1996, CLIN NEUROPSYCHOL, V10, P262, DOI 10.1080/13854049608406689; Jacobson SC, 2011, BRAIN COGNITION, V77, P60, DOI 10.1016/j.bandc.2011.06.001; Jurado MB, 2007, NEUROPSYCHOL REV, V17, P213, DOI 10.1007/s11065-007-9040-z; Koziol L.F., 2014, MYTH EXECUTIVE FUNCT; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Lange RT, 2005, J CLIN EXP NEUROPSYC, V27, P897, DOI 10.1080/1380339049091290; Larrabee GJ, 2008, CLIN NEUROPSYCHOL, V22, P813, DOI 10.1080/13854040701625846; Lemiere J, 2004, J NEUROL, V251, P935, DOI 10.1007/s00415-004-0461-9; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Lopez-Pousa S, 2004, NEUROEPIDEMIOLOGY, V23, P170, DOI 10.1159/000078502; LOWE C, 1997, METHODOLOGY FRONTAL, P39; Lucas JA, 2005, CLIN NEUROPSYCHOL, V19, P243, DOI 10.1080/13854040590945337; MacQuarrie T. W., 1925, MACQUARRIE TEST MECH; Manea L, 2015, GEN HOSP PSYCHIAT, V37, P67, DOI 10.1016/j.genhosppsych.2014.09.009; MATARAZZO JD, 1974, J NERV MENT DIS, V158, P37, DOI 10.1097/00005053-197401000-00006; McCurry SM, 2001, ARCH CLIN NEUROPSYCH, V16, P447, DOI 10.1016/S0887-6177(00)00056-1; Misdraji EL, 2010, J CLIN EXP NEUROPSYC, V32, P159, DOI 10.1080/13803390902881942; Mitrushina M., 2005, HDB NORMATIVE DATA N; MORRIS JC, 1989, NEUROLOGY, V39, P1159, DOI 10.1212/wnl.43.12.2457; O'Rourke JJF, 2011, J CLIN EXP NEUROPSYC, V33, P567, DOI 10.1080/13803395.2010.541228; ODONNELL JP, 1994, J CLIN PSYCHOL, V50, P596, DOI 10.1002/1097-4679(199407)50:4<596::AID-JCLP2270500416>3.0.CO;2-S; Oosterman JM, 2010, CLIN NEUROPSYCHOL, V24, P203, DOI 10.1080/13854040903482848; Partington JE., 1949, PSYCHOL SERV CTR J, V1, P11; PAUKER JD, 1988, J CLIN PSYCHOL, V44, P930, DOI 10.1002/1097-4679(198811)44:6<930::AID-JCLP2270440613>3.0.CO;2-H; Pena-Casanova J, 2009, ARCH CLIN NEUROPSYCH, V24, P321, DOI 10.1093/arclin/acp038; Pena-Casanova J, 2009, ARCH CLIN NEUROPSYCH, V24, P307, DOI 10.1093/arclin/acp027; Perianez JA, 2007, ARCH CLIN NEUROPSYCH, V22, P433, DOI 10.1016/j.acn.2007.01.022; Potter GG, 2013, AM J GERIAT PSYCHIAT, V21, P297, DOI 10.1016/j.jagp.2012.12.009; Quijano TD, 2004, MED CLIN-BARCELONA, V122, P727, DOI 10.1157/13062190; Rabbitt P., 1997, METHODOLOGY FRONTAL, P1; Rasmusson DX, 1998, CLIN NEUROPSYCHOL, V12, P169, DOI 10.1076/clin.12.2.169.2005; Reitan R. M., 1955, NEUROPSYCHOLOGICAL T; Reitan RM, 1955, J CONSULT PSYCHOL, V19, P393, DOI 10.1037/h0044509; REITAN RM, 1959, J CLIN PSYCHOL, V15, P281, DOI 10.1002/1097-4679(195907)15:3<281::AID-JCLP2270150314>3.0.CO;2-D; Rios M, 2004, BRAIN INJURY, V18, P257, DOI 10.1080/02699050310001617442; Salthouse TA, 2005, NEUROPSYCHOLOGY, V19, P532, DOI 10.1037/0894-4105.19.4.532; Salthouse TA, 2000, NEUROPSYCHOLOGY, V14, P102, DOI 10.1037/0894-4105.14.1.102; Salthouse TA, 2011, INTELLIGENCE, V39, P222, DOI 10.1016/j.intell.2011.03.001; Sanchez-Cubillo I, 2009, J INT NEUROPSYCH SOC, V15, P438, DOI 10.1017/S1355617709090626; Seo EH, 2006, INT J GERIATR PSYCH, V21, P844, DOI 10.1002/gps.1570; Soukup V M, 1998, Appl Neuropsychol, V5, P65, DOI 10.1207/s15324826an0502_2; Spreen O., 1998, COMPENDIUM NEUROPSYC; Steinberg BA, 2005, CLIN NEUROPSYCHOL, V19, P329, DOI 10.1080/13854040590945210; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Stuss D. T., 1989, CLIN NEUROPSYCHOL, V3, P145, DOI DOI 10.1080/13854048908403287; Stuss D.T., 1987, CLIN NEUROPSYCHOL, V1, P139, DOI DOI 10.1080/13854048708520046; Terada S, 2013, PSYCHIAT RES-NEUROIM, V213, P249, DOI 10.1016/j.pscychresns.2013.03.006; Tombaugh TN, 2004, ARCH CLIN NEUROPSYCH, V19, P203, DOI 10.1016/S0887-6177(03)00039-8; Van Breukelen GJP, 2005, PSYCHOL ASSESSMENT, V17, P336, DOI 10.1037/1040-3590.17.3.336; Van der Elst W, 2006, ASSESSMENT, V13, P62, DOI 10.1177/1073191105283427; Vazzana R, 2010, J AM GERIATR SOC, V58, P719, DOI 10.1111/j.1532-5415.2010.02780.x; Wasserman T, 2013, APPL NEUROPSYCH-CHIL, V2, P88, DOI 10.1080/21622965.2013.748394; Wechsler D, 1999, WECHSLER ADULT INTEL; Wecker NS, 2000, NEUROPSYCHOLOGY, V14, P409, DOI 10.1037//0894-4105.14.3.409; Weiskrantz L., 1992, NEUROPSYCHOLOGY CONS, P1; Wiberg B, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2011-000458; WIEDERHOLT WC, 1993, J AM GERIATR SOC, V41, P639, DOI 10.1111/j.1532-5415.1993.tb06738.x; Wolfson D., 1993, HALSTEAD REITAN NEUR; ZACHARY RA, 1985, J CLIN PSYCHOL, V41, P86, DOI 10.1002/1097-4679(198501)41:1<86::AID-JCLP2270410115>3.0.CO;2-W; Zalonis I., 2010, ANN GEN PSYCHIAT S, V9, pS145	93	41	42	0	12	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1073-1911	1552-3489		ASSESSMENT	Assessment	MAR	2017	24	2					183	196		10.1177/1073191115602552			14	Psychology, Clinical	Psychology	EL9SF	WOS:000394959700004	26318386				2021-06-18	
J	Vergara, VM; Mayer, AR; Damaraju, E; Kiehl, KA; Calhoun, V				Vergara, Victor M.; Mayer, Andrew R.; Damaraju, Eswar; Kiehl, Kent A.; Calhoun, Vince			Detection of Mild Traumatic Brain Injury by Machine Learning Classification Using Resting State Functional Network Connectivity and Fractional Anisotropy	JOURNAL OF NEUROTRAUMA			English	Article						diffusion tensor imaging; magnetic resonance imaging; traumatic brain injury	STRUCTURAL CONNECTIVITY; MRI; FMRI; SCHIZOPHRENIA; ABNORMALITIES; DISRUPTION; COGNITION; DISORDER; THERAPY; TIME	Traumatic brain injury (TBI) may adversely affect a person's thinking, memory, personality, and behavior. While mild TBI (mTBI) diagnosis is challenging, there is a risk for long-term psychiatric, neurologic, and psychosocial problems in some patients that motivates the search for new and better biomarkers. Recently, diffusion magnetic resonance imaging (dMRI) has shown promise in detecting mTBI, but its validity is still being investigated. Resting state functional network connectivity (rsFNC) is another approach that is emerging as a promising option for the diagnosis of mTBI. The present work investigated the use of rsFNC for mTBI detection compared with dMRI results on the same cohort. Fifty patients with mTBI (25 males) and age-sex matched healthy controls were recruited. Features from dMRI were obtained using all voxels, the enhanced Z-score microstructural assessment for pathology, and the distribution corrected Z-score. Features based on rsFNC were obtained through group independent component analysis and correlation between pairs of resting state networks. A linear support vector machine was used for classification and validated using leave-one-out cross validation. Classification achieved a maximum accuracy of 84.1% for rsFNC and 75.5% for dMRI and 74.5% for both combined. A t test analysis revealed significant increase in rsFNC between cerebellum versus sensorimotor networks and between left angular gyrus versus precuneus in subjects with mTBI. These outcomes suggest that inclusion of both common and unique information is important for classification of mTBI. Results also suggest that rsFNC can yield viable biomarkers that might outperform dMRI and points to connectivity to the cerebellum as an important region for the detection of mTBI.	[Vergara, Victor M.; Mayer, Andrew R.; Damaraju, Eswar; Kiehl, Kent A.; Calhoun, Vince] Mind Res Network, 1101 Yale Blvd NE, Albuquerque, NM 87106 USA; [Vergara, Victor M.; Mayer, Andrew R.; Damaraju, Eswar; Kiehl, Kent A.; Calhoun, Vince] Lovelace Biomed & Environm Res Inst, Albuquerque, NM USA; [Mayer, Andrew R.] Univ New Mexico, Sch Med, Dept Neurol, Albuquerque, NM 87131 USA; [Damaraju, Eswar; Calhoun, Vince] Univ New Mexico, Dept ECE, Albuquerque, NM 87131 USA; [Kiehl, Kent A.] Univ New Mexico, Dept Psychol, Albuquerque, NM 87131 USA	Vergara, VM (corresponding author), Mind Res Network, 1101 Yale Blvd NE, Albuquerque, NM 87106 USA.	vvergara@mrn.org	Kiehl, Kent A./AAK-3290-2020		NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R24HD050836/R21NS064464/3R21 NS064464, P20GM103472/1R01EB006841]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24HD050836] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB006841] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P20GM103472] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS064464] Funding Source: NIH RePORTER; Office Of The DirectorNational Science Foundation (NSF)NSF - Office of the Director (OD) [1539067] Funding Source: National Science Foundation	The authors thank Joseph Ling, Jill Fries, Vikram Rao, Prashanth Nyalakanti, and Sandeep Panta for help with preprocessing the data. This work was funded by the following NIH grants: R24HD050836/R21NS064464/3R21 NS064464 to A.M. and P20GM103472/1R01EB006841 to V.C.	Allen EA, 2011, FRONT SYST NEUROSCI, V5, DOI 10.3389/fnsys.2011.00002; Arenth PM, 2014, J HEAD TRAUMA REHAB, V29, pE1, DOI 10.1097/HTR.0b013e318289ede5; Bharath RD, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00513; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Calhoun VD, 2001, HUM BRAIN MAPP, V14, P140, DOI 10.1002/hbm.1048; Calhoun Vince D, 2016, Biol Psychiatry Cogn Neurosci Neuroimaging, V1, P230; Calhoun Vince D, 2012, IEEE Rev Biomed Eng, V5, P60, DOI 10.1109/RBME.2012.2211076; Damaraju E., 2014, 4 BIENN C REST STAT; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Friston KJ., 2003, NEUROSCIENCE DATABAS, P237, DOI [10.1007/978-1-4615-1079-6_16, DOI 10.1007/978-1-4615-1079-6_16]; Hahn T, 2015, JAMA PSYCHIAT, V72, P68, DOI 10.1001/jamapsychiatry.2014.1741; Hillary FG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104021; Himberg J, 2004, NEUROIMAGE, V22, P1214, DOI 10.1016/j.neuroimage.2004.03.027; Holli KK, 2010, ACAD RADIOL, V17, P1096, DOI 10.1016/j.acra.2010.04.009; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Huston JM, 2013, MAGN RESON IMAGING C, V21, P279, DOI 10.1016/j.mric.2012.12.003; Kasahara M, 2010, NEUROLOGY, V75, P168, DOI 10.1212/WNL.0b013e3181e7ca58; Kim N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059382; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Koch MA, 2002, NEUROIMAGE, V16, P241, DOI 10.1006/nimg.2001.1052; Leech R, 2014, BRAIN, V137, P12, DOI 10.1093/brain/awt162; Ling JM, 2012, BRAIN, V135, P1281, DOI 10.1093/brain/aws073; Lipton ML, 2012, BRAIN IMAGING BEHAV, V6, P329, DOI 10.1007/s11682-012-9175-2; Liu JY, 2009, HUM BRAIN MAPP, V30, P241, DOI 10.1002/hbm.20508; Ma S, 2011, IEEE T BIO-MED ENG, V58, P3406, DOI 10.1109/TBME.2011.2167149; Mayer A., 2014, J NEUROTRAUMA; Mayer AR, 2015, NEUROSCI BIOBEHAV R, V49, P8, DOI 10.1016/j.neubiorev.2014.11.016; Mayer AR, 2014, HUM BRAIN MAPP, V35, P5457, DOI 10.1002/hbm.22563; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; Narayana PA, 2015, NEUROIMAGE-CLIN, V7, P87, DOI 10.1016/j.nicl.2014.07.010; Nathan DE, 2015, BRAIN CONNECT, V5, P102, DOI 10.1089/brain.2014.0273; Power JD, 2012, NEUROIMAGE, V59, P2142, DOI 10.1016/j.neuroimage.2011.10.018; Rocca MA, 2013, NEUROTHERAPEUTICS, V10, P511, DOI 10.1007/s13311-013-0189-2; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Schmahmann JD, 2006, BRAIN, V129, P290, DOI 10.1093/brain/awh729; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Shen H, 2010, NEUROIMAGE, V49, P3110, DOI 10.1016/j.neuroimage.2009.11.011; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Slobounov SM, 2011, NEUROIMAGE, V55, P1716, DOI 10.1016/j.neuroimage.2011.01.024; Sours C, 2013, BRAIN RES, V1537, P201, DOI 10.1016/j.brainres.2013.08.034; Stevens MC, 2012, BRAIN IMAGING BEHAV, V6, P293, DOI 10.1007/s11682-012-9157-4; Sui J, 2011, NEUROIMAGE, V57, P839, DOI 10.1016/j.neuroimage.2011.05.055; Tang L, 2011, RADIOLOGY, V260, P831, DOI 10.1148/radiol.11110014; Timmann D, 2007, CEREBELLUM, V6, P159, DOI 10.1080/14734220701496448; Vakhtin AA, 2013, BRAIN INJURY, V27, P1304, DOI 10.3109/02699052.2013.823561; van den Heuvel MP, 2009, HUM BRAIN MAPP, V30, P3127, DOI 10.1002/hbm.20737; Vergara V. M., 2016, NEUROIMAGE; Whelan R, 2014, NATURE, V512, P185, DOI 10.1038/nature13402; Yuan K, 2016, BRAIN STRUCT FUNCT, V221, P1427, DOI 10.1007/s00429-014-0982-7; Yuh EL, 2014, J NEUROTRAUM, V31, P1457, DOI 10.1089/neu.2013.3171; Zhou YX, 2014, J MAGN RESON IMAGING, V39, P1558, DOI 10.1002/jmri.24310; Zhou YX, 2012, RADIOLOGY, V265, P882, DOI 10.1148/radiol.12120748	53	41	42	2	20	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR 1	2017	34	5					1045	1053		10.1089/neu.2016.4526			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	EM6EI	WOS:000395405200009	27676221	Green Published			2021-06-18	
J	Churchill, N; Hutchison, M; Richards, D; Leung, G; Graham, S; Schweizer, TA				Churchill, Nathan; Hutchison, Michael; Richards, Doug; Leung, General; Graham, Simon; Schweizer, Tom A.			Brain Structure and Function Associated with a History of Sport Concussion: A Multi-Modal Magnetic Resonance Imaging Study	JOURNAL OF NEUROTRAUMA			English	Article						blood flow; concussion; diffusion tensor imaging; MRI; traumatic brain injury	COLLEGIATE FOOTBALL PLAYERS; RESTING-STATE FMRI; RECURRENT CONCUSSION; NCAA CONCUSSION; HEAD TRAUMA; INJURY; RECOVERY; MRI; TRACTOGRAPHY; DEPRESSION	There is growing concern about the potential long-term consequences of sport concussion for young, currently active athletes. However, there remains limited information about brain abnormalities associated with a history of concussion and how they relate to clinical factors. In this study, advanced MRI was used to comprehensively describe abnormalities in brain structure and function associated with a history of sport concussion. Forty-three athletes (21 male, 22 female) were recruited from interuniversity teams at the beginning of the season, including 21 with a history of concussion and 22 without prior concussion; both groups also contained a balanced sample of contact and noncontact sports. Multi-modal MRI was used to evaluate abnormalities in brain structure and function. Athletes with a history of concussion showed frontal decreases in brain volume and blood flow. However, they also demonstrated increased posterior cortical volume and elevated markers of white matter microstructure. A greater number of prior concussions was associated with more extensive decreases in cerebral blood flow and insular volume, whereas recovery time from most recent concussion was correlated with reduced frontotemporal volume. White matter showed limited correlations with clinical factors, predominantly in the anterior corona radiata. This study provides the first evidence of the long-term effects of concussion on gray matter volume, blood flow, and white matter microstructure within a single athlete cohort. This was examined for a mixture of male and female athletes in both contact and noncontact sports, demonstrating the relevance of these findings for the overall sporting community.	[Churchill, Nathan; Leung, General; Schweizer, Tom A.] St Michaels Hosp, Keenan Res Ctr, Toronto, ON, Canada; [Hutchison, Michael; Richards, Doug] Univ Toronto, Fac Kinesiol & Phys Educ, Toronto, ON, Canada; [Leung, General] Univ Toronto, Dept Med Imaging, Toronto, ON, Canada; [Graham, Simon] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; [Schweizer, Tom A.] Univ Toronto, Fac Med Neurosurg, Toronto, ON, Canada; [Schweizer, Tom A.] Univ Toronto, Inst Biomat & Biomed Engn, Toronto, ON, Canada; [Graham, Simon] Sunnybrook Res Inst, Phys Sci, Toronto, ON, Canada	Churchill, N (corresponding author), St Michaels Hosp, Li Ka Shing Knowledge Inst, Keenan Res Ctr, 209 Victoria St, Toronto, ON M5B 1M8, Canada.	nchurchill.research@gmail.com			Siemens Canada Ltd.; Defence Research & Development Canada (DRDC); Canadian Institutes of Military and Veterans Health (CIMVHR)	This study was conducted with partial support from Siemens Canada Ltd.; This research received funding from the Defence Research & Development Canada (DRDC) and the Canadian Institutes of Military and Veterans Health (CIMVHR). This study was approved by the Canadian Forces Surgeon General's Health Research Program.	Albaugh MD, 2015, J PEDIATR-US, V166, P394, DOI 10.1016/j.jpeds.2014.10.016; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; Chamard E, 2013, BRAIN INJURY, V27, P1038, DOI 10.3109/02699052.2013.794968; Chappell MH, 2006, J MAGN RESON IMAGING, V24, P537, DOI 10.1002/jmri.20656; Conti AC, 1998, J NEUROSCI, V18, P5663; Dancause N, 2005, J NEUROSCI, V25, P10167, DOI 10.1523/JNEUROSCI.3256-05.2005; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Efron B., 1994, INTRO BOOTSTRAP; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Fischl B, 2012, NEUROIMAGE, V62, P774, DOI 10.1016/j.neuroimage.2012.01.021; Frost SB, 2003, J NEUROPHYSIOL, V89, P3205, DOI 10.1152/jn.01143.2002; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Graham D I, 2002, GREENFIELDS NEUROPAT, P823; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2013, BRIT J SPORT MED, V47, P289, DOI 10.1136/bjsports-2013-092225; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hart J, 2013, JAMA NEUROL, V70, P326, DOI 10.1001/2013.jamaneurol.340; Henry LC, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-105; Hutchison M, 2009, CLIN J SPORT MED, V19, P13, DOI 10.1097/JSM.0b013e318190ba06; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Kim J, 2008, NEUROIMAGE, V39, P1014, DOI 10.1016/j.neuroimage.2007.10.005; Len TK, 2011, CLIN PHYSIOL FUNCT I, V31, P85, DOI 10.1111/j.1475-097X.2010.00990.x; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2010, J HEAD TRAUMA REHAB, V25, P283, DOI 10.1097/HTR.0b013e3181e67923; McCrory P, 2013, BRIT J SPORT MED, V47, P327, DOI 10.1136/bjsports-2013-092248; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meier TB, 2016, J NEUROTRAUM, V33, P330, DOI 10.1089/neu.2015.3919; Meier TB, 2015, JAMA NEUROL, V72, P530, DOI 10.1001/jamaneurol.2014.4778; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Mukherjee P, 2008, AM J NEURORADIOL, V29, P843, DOI 10.3174/ajnr.A1052; Murugavel M, 2014, J NEUROTRAUM, V31, P1860, DOI 10.1089/neu.2014.3368; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Sasaki Takeshi, 2014, J Neurosurg, V120, P882, DOI 10.3171/2013.12.JNS132092; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Singh R, 2014, JAMA-J AM MED ASSOC, V311, P1883, DOI 10.1001/jama.2014.3313; Slobounov S, 2012, BRAIN IMAGING BEHAV, V6, P224, DOI 10.1007/s11682-012-9167-2; Terry DP, 2012, BRAIN INJURY, V26, P1684, DOI 10.3109/02699052.2012.722259; Thayer JF, 2012, NEUROSCI BIOBEHAV R, V36, P747, DOI 10.1016/j.neubiorev.2011.11.009; Tremblay S, 2014, BRAIN, V137, P2997, DOI 10.1093/brain/awu236; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Zhang H, 2012, NEUROIMAGE, V61, P1000, DOI 10.1016/j.neuroimage.2012.03.072; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3; Zhu DC, 2015, J NEUROTRAUM, V32, P327, DOI 10.1089/neu.2014.3413	48	41	41	1	23	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB 15	2017	34	4					765	771		10.1089/neu.2016.4531			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	EL0XD	WOS:000394344200002	27246317				2021-06-18	
J	Iverson, GL				Iverson, Grant L.			Suicide and Chronic Traumatic Encephalopathy	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							MILD COGNITIVE IMPAIRMENT; STRESSFUL LIFE EVENTS; MAJOR DEPRESSION; BRAIN-INJURY; CHRONIC PAIN; ALZHEIMERS-DISEASE; RISK-FACTORS; PSYCHIATRIC-DISORDERS; COMPLETED SUICIDE; ADULT DEPRESSION	For nearly 80 years, suicidality was not considered to be a core clinical feature of chronic traumatic encephalopathy (CTE). In recent years, suicide has been widely cited as being associated with CTE, and now depression has been proposed to be one of three core diagnostic features alongside cognitive impairment and anger control problems. This evolution of the clinical features has been reinforced by thousands of media stories reporting a connection between mental health problems in former athletes and military veterans, repetitive neurotrauma, and CTE. At present, the science underlying the causal assumption between repetitive neurotrauma, depression, suicide, and the neuropathology believed to be unique to CTE is inconclusive. Epidemiological evidence indicates that former National Football League players, for example, are at lower, not greater, risk for suicide than men in the general population. This article aims to discuss the critical issues and literature relating to these possible relationships.	[Iverson, Grant L.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA; [Iverson, Grant L.] Spaulding Rehabil Hosp, Boston, MA USA; [Iverson, Grant L.] MassGen Hosp Children Sports Concuss Program, Boston, MA USA; [Iverson, Grant L.] Red Sox Fdn, Boston, MA USA; [Iverson, Grant L.] Massachusetts Gen Hosp, Home Base Program, Boston, MA 02114 USA	Iverson, GL (corresponding author), Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA.; Iverson, GL (corresponding author), Spaulding Rehabil Hosp, Boston, MA USA.; Iverson, GL (corresponding author), MassGen Hosp Children Sports Concuss Program, Boston, MA USA.; Iverson, GL (corresponding author), Red Sox Fdn, Boston, MA USA.; Iverson, GL (corresponding author), Massachusetts Gen Hosp, Home Base Program, Boston, MA 02114 USA.	giverson@mgh.harvard.edu		Iverson, Grant/0000-0001-7348-9570			Almeida OP, 2014, J PSYCHIATR NEUROSCI, V39, P200, DOI 10.1503/jpn.130158; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Anderson RJ, 2001, DIABETES CARE, V24, P1069, DOI 10.2337/diacare.24.6.1069; Arsenault-Lapierre G, 2004, BMC PSYCHIATRY, V4, DOI 10.1186/1471-244X-4-37; ATKINSON JH, 1991, PAIN, V45, P111, DOI 10.1016/0304-3959(91)90175-W; Ayerbe L, 2013, BRIT J PSYCHIAT, V202, P14, DOI 10.1192/bjp.bp.111.107664; Banks SM, 1996, PSYCHOL BULL, V119, P95, DOI 10.1037/0033-2909.119.1.95; Barnes DE, 2006, ARCH GEN PSYCHIAT, V63, P273, DOI 10.1001/archpsyc.63.3.273; Baron SL, 2012, AM J CARDIOL, V109, P889, DOI 10.1016/j.amjcard.2011.10.050; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; BECK AT, 1990, AM J PSYCHIAT, V147, P190; BECK AT, 1985, AM J PSYCHIAT, V142, P559; Binder EB, 2010, MOL PSYCHIATR, V15, P574, DOI 10.1038/mp.2009.141; Blosnich J, 2013, ARCH SUICIDE RES, V17, P52, DOI 10.1080/13811118.2013.748415; Bodenmann G, 2013, CURR OPIN PSYCHIATR, V26, P464, DOI 10.1097/YCO.0b013e3283642de7; Bradley RG, 2008, ARCH GEN PSYCHIAT, V65, P190, DOI 10.1001/archgenpsychiatry.2007.26; Breslau N, 2000, NEUROLOGY, V54, P308, DOI 10.1212/WNL.54.2.308; Breslau N, 2003, NEUROLOGY, V60, P1308, DOI 10.1212/01.WNL.0000058907.41080.54; BRESLAU N, 1994, HEADACHE, V34, P387, DOI 10.1111/j.1526-4610.1994.hed3407387.x; Brown GK, 2014, CONCISE GUIDE TO UNDERSTANDING SUICIDE: EPIDEMIOLOGY, PATHOPHYSIOLOGY, AND PREVENTION, P42; Bruce JM, 2008, J GERIATR PSYCH NEUR, V21, P34, DOI 10.1177/0891988707311032; Bruffaerts R, 2010, BRIT J PSYCHIAT, V197, P20, DOI 10.1192/bjp.bp.109.074716; Bulloch A, 2012, DEPRESS ANXIETY, V29, P1058, DOI 10.1002/da.22001; Bulloch AG, 2009, DEPRESS ANXIETY, V26, P1172, DOI 10.1002/da.20618; Busch FN, 2009, ADV PSYCHIAT TREAT, V15, P271, DOI DOI 10.1192/APT.BP.107.004937; Campbell LC, 2003, BIOL PSYCHIAT, V54, P399, DOI 10.1016/S0006-3223(03)00545-6; Castellani RJ, 2015, J NEUROPATH EXP NEUR, V74, P493, DOI 10.1097/NEN.0000000000000193; Cheng QJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108724; Conner KR, 2012, DRUG ALCOHOL DEPEN, V120, P155, DOI 10.1016/j.drugalcdep.2011.07.013; Conner KR, 2004, AM J GERIAT PSYCHIAT, V12, P37, DOI 10.1176/appi.ajgp.12.1.37; Conner KR, 2001, SUICIDE LIFE-THREAT, V31, P367, DOI 10.1521/suli.31.4.367.22048; Conwell Y, 2010, INT J GERIATR PSYCH, V25, P371, DOI 10.1002/gps.2348; Cottler LB, 2011, DRUG ALCOHOL DEPEN, V116, P188, DOI 10.1016/j.drugalcdep.2010.12.003; Critchley M, 1949, PUNCH DRUNK SYNDROME; Davis DS, 2014, J MED ETHICS, V40, P543, DOI 10.1136/medethics-2012-101022; Davis GA, 2015, NEUROSURGERY, V76, P643, DOI 10.1227/NEU.0000000000000722; Diamond J., 2005, IRRITABLE MALE SYNDR; Djamshidian A, 2014, CURR TREAT OPTION NE, V16, DOI 10.1007/s11940-014-0285-6; Draper B, 2010, ALZHEIMERS DEMENT, V6, P75, DOI 10.1016/j.jalz.2009.04.1229; Farmer AE, 2003, PSYCHOL MED, V33, P1169, DOI 10.1017/S0033291703008419; Fassberg MM, 2012, INT J ENV RES PUB HE, V9, P722, DOI 10.3390/ijerph9030722; Fava M, 2010, MOL PSYCHIATR, V15, P856, DOI 10.1038/mp.2009.20; Fazel S, 2014, JAMA PSYCHIAT, V71, P326, DOI 10.1001/jamapsychiatry.2013.3935; Fishbain DA, 1997, CLIN J PAIN, V13, P116, DOI 10.1097/00002508-199706000-00006; Foster T, 2011, ARCH SUICIDE RES, V15, P1, DOI 10.1080/13811118.2011.540213; Friis RH, 2002, EUR PSYCHIAT, V17, P241, DOI 10.1016/S0924-9338(02)00682-X; Gatt JM, 2009, MOL PSYCHIATR, V14, P681, DOI 10.1038/mp.2008.143; Gavett BE, 2011, CURR OPIN NEUROL, V24, P525, DOI 10.1097/WCO.0b013e32834cd477; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Gonzalez HM, 2010, J PSYCHIATR RES, V44, P1043, DOI 10.1016/j.jpsychires.2010.03.017; Gothe F, 2012, PANMINERVA MED, V54, P161; Gvion Y, 2011, ARCH SUICIDE RES, V15, P93, DOI 10.1080/13811118.2011.565265; Halpin M, 2012, OMEGA-J DEATH DYING, V65, P317, DOI 10.2190/OM.65.4.e; Hassett AL, 2014, CURR PAIN HEADACHE R, V18, DOI 10.1007/s11916-014-0436-1; Hauger RL, 2009, ANN NY ACAD SCI, V1179, P120, DOI 10.1111/j.1749-6632.2009.05011.x; Heim C, 2008, PSYCHONEUROENDOCRINO, V33, P693, DOI 10.1016/j.psyneuen.2008.03.008; Heim C, 2009, FRONT BEHAV NEUROSCI, V3, DOI 10.3389/neuro.08.041.2009; Hooley JM, 2014, CURR PAIN HEADACHE R, V18, DOI 10.1007/s11916-014-0435-2; Hung CI, 2006, CEPHALALGIA, V26, P26, DOI 10.1111/j.1468-2982.2005.00985.x; Ilgen MA, 2008, GEN HOSP PSYCHIAT, V30, P521, DOI 10.1016/j.genhosppsych.2008.09.003; Iverson GL, 2015, NEUROSCI BIOBEHAV R, V56, P276, DOI 10.1016/j.neubiorev.2015.05.008; Iverson GL, 2014, BRIT J SPORT MED, V48, P162, DOI 10.1136/bjsports-2013-092935; Jaremka LM, 2013, DEPRESS ANXIETY, V30, P288, DOI 10.1002/da.22078; Ji NJ, 2014, J AFFECT DISORDERS, V156, P56, DOI 10.1016/j.jad.2013.11.015; Jopson NM, 2003, J PSYCHOSOM RES, V54, P503, DOI 10.1016/S0022-3999(02)00455-5; Kendler KS, 2000, AM J PSYCHIAT, V157, P1243, DOI 10.1176/appi.ajp.157.8.1243; Kendler KS, 2003, ARCH GEN PSYCHIAT, V60, P789, DOI 10.1001/archpsyc.60.8.789; Kendler KS, 2001, AM J PSYCHIAT, V158, P582, DOI 10.1176/appi.ajp.158.4.582; Kendler KS, 1999, AM J PSYCHIAT, V156, P837, DOI 10.1176/ajp.156.6.837; Khera M, 2013, ARCH ESP UROL, V66, P729; Kosteniuk JG, 2014, DEMENT GER COGN D EX, V4, P209, DOI 10.1159/000363226; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Lee AR, 2014, PSYCHIAT RES, V219, P518, DOI 10.1016/j.psychres.2014.06.037; Lee GJ, 2012, BIOL PSYCHIAT, V71, P814, DOI 10.1016/j.biopsych.2011.12.024; Leung YW, 2012, PSYCHOSOM MED, V74, P786, DOI 10.1097/PSY.0b013e31826ddbed; Levin HS, 2005, ARCH GEN PSYCHIAT, V62, P523, DOI 10.1001/archpsyc.62.5.523; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; Lin EHB, 2010, DIABETES CARE, V33, P264, DOI 10.2337/dc09-1068; Luppino FS, 2010, ARCH GEN PSYCHIAT, V67, P220, DOI 10.1001/archgenpsychiatry.2010.2; Mackelprang JL, 2014, AM J PUBLIC HEALTH, V104, pE100, DOI 10.2105/AJPH.2013.301794; Mackin RS, 2012, INT J GERIATR PSYCH, V27, P355, DOI 10.1002/gps.2713; Maroon JC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117338; Martin LA, 2013, JAMA PSYCHIAT, V70, P1100, DOI 10.1001/jamapsychiatry.2013.1985; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; McAuliffe C, 2002, BEHAV COGN PSYCHOTH, V30, P385, DOI 10.1017/S1352465802004010; McCarthy TC, 2015, NEWSDAY; McGirr Alexander, 2007, Curr Psychiatry Rep, V9, P460, DOI 10.1007/s11920-007-0062-2; McGuffin P, 2005, HUM MOL GENET, V14, P3337, DOI 10.1093/hmg/ddi363; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McWilliams LA, 2003, PAIN, V106, P127, DOI 10.1016/S0304-3959(03)00301-4; Medici M, 2014, J CLIN ENDOCR METAB, V99, P1213, DOI 10.1210/jc.2013-3589; Meng L, 2012, J HYPERTENS, V30, P842, DOI 10.1097/HJH.0b013e32835080b7; Millspaugh J., 1937, US NAVAL MED B, V35, P297; Modrego PJ, 2004, ARCH NEUROL-CHICAGO, V61, P1290, DOI 10.1001/archneur.61.8.1290; Monroe SM, 2005, PSYCHOL REV, V112, P417, DOI 10.1037/0033-295X.112.2.417; Mooney G, 2001, BRAIN INJURY, V15, P865, DOI 10.1080/02699050110065286; Mormont E, 2014, J GERIATR PSYCH NEUR, V27, P231, DOI 10.1177/0891988714532021; Naarding P, 2011, EXPERT REV NEUROTHER, V11, P77, DOI 10.1586/ERN.10.92; Naranjo DM, 2011, ANN FAM MED, V9, P115, DOI 10.1370/afm.1212; National Institute of Neurological Disorders and Stroke, 2015, 1 NIH CONS C DEF NEU; Nock MK, 2010, MOL PSYCHIATR, V15, P868, DOI 10.1038/mp.2009.29; Ohayon MM, 2004, ENCEPHALE, V30, P222; Olin JT, 2002, AM J GERIAT PSYCHIAT, V10, P125; Omalu B, 2014, PROG NEUROL SURG, V28, P38, DOI 10.1159/000358761; Omalu Bennet I, 2010, J Forensic Nurs, V6, P40, DOI 10.1111/j.1939-3938.2009.01064.x; Omalu BI, 2010, AM J FOREN MED PATH, V31, P130, DOI 10.1097/PAF.0b013e3181ca7f35; Palmer K, 2010, J ALZHEIMERS DIS, V20, P175, DOI 10.3233/JAD-2010-1352; Parker HL, 1934, J NEUROL PSYCHOPATHO, V15, P20; Perlis RH, 2009, ACTA PSYCHIAT SCAND, V119, P282, DOI 10.1111/j.1600-0447.2008.01298.x; Pollack WS, 1998, NEW PSYCHOTHERAPY ME; Raskind MA, 2008, AM J MED, V121, P28, DOI 10.1016/j.amjmed.2008.09.011; Ravven S, 2013, HARVARD REV PSYCHIAT, V21, P59, DOI 10.1097/HRP.0b013e31828a3612; Richard E, 2013, JAMA NEUROL, V70, P383, DOI 10.1001/jamaneurol.2013.603; Richardson T, 2013, CLIN PSYCHOL REV, V33, P1148, DOI 10.1016/j.cpr.2013.08.009; Roberts AH., 1969, BRAIN DAMAGE BOXERS; Schwenk TL, 2007, MED SCI SPORT EXER, V39, P599, DOI 10.1249/mss.0b013e31802fa679; Scott KM, 2010, PSYCHOSOM MED, V72, P712, DOI 10.1097/PSY.0b013e3181e3333d; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Sheftell FD, 2002, HEADACHE, V42, P934, DOI 10.1046/j.1526-4610.2002.02217.x; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Simmons RD, 2010, NAT REV NEUROL, V6, P603, DOI 10.1038/nrneurol.2010.143; Simpson G, 2007, BRAIN INJURY, V21, P1335, DOI 10.1080/02699050701785542; Sisask M, 2012, INT J ENV RES PUB HE, V9, P123, DOI 10.3390/ijerph9010123; Steinberg M, 2008, INT J GERIATR PSYCH, V23, P170, DOI 10.1002/gps.1858; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Sullivan PF, 2000, AM J PSYCHIAT, V157, P1552, DOI 10.1176/appi.ajp.157.10.1552; Tang NKY, 2006, PSYCHOL MED, V36, P575, DOI 10.1017/S0033291705006859; Van der Mussele S, 2014, J ALZHEIMERS DIS, V42, P1239, DOI 10.3233/JAD-140405; Van Orden KA, 2005, CURR PSYCHIATRY REV, V1, P187, DOI 10.2174/1573400054065541; Ventura T, 2010, ARCH PHYS MED REHAB, V91, P20, DOI 10.1016/j.apmr.2009.08.151; Weir Dr, 2009, NATL FOOTBALL LEAGUE; Wilcox HC, 2004, DRUG ALCOHOL DEPEN, V76, pS11, DOI 10.1016/j.drugalcdep.2004.08.003; Wilson KG, 2002, CLIN J PAIN, V18, P77, DOI 10.1097/00002508-200203000-00002; Winkler D, 2005, PSYCHOTHER PSYCHOSOM, V74, P303, DOI 10.1159/000086321; Wortzel HS, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/424280; Yang AC, 2013, SOC PSYCH PSYCH EPID, V48, P427, DOI 10.1007/s00127-012-0562-1; Yeap BB, 2014, MATURITAS, V79, P227, DOI 10.1016/j.maturitas.2014.05.015; Zarrour FA, 2009, J PSYCHIATR PRACT, V15, P289, DOI 10.1097/01.pra.0000358315.88931.fc	140	41	42	3	295	AMER PSYCHIATRIC PUBLISHING, INC	WASHINGTON	800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA	0895-0172	1545-7222		J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	WIN	2016	28	1					9	16		10.1176/appi.neuropsych.15070172			8	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	DM0PB	WOS:000376046800013	26449269	Bronze			2021-06-18	
J	Zhang, B; Bailey, WM; McVicar, AL; Gensel, JC				Zhang, Bei; Bailey, William M.; McVicar, Anna Leigh; Gensel, John C.			Age increases reactive oxygen species production in macrophages and potentiates oxidative damage after spinal cord injury	NEUROBIOLOGY OF AGING			English	Article						Aging; Arginase-1; Microglia; Macrophage polarization; Dihydroethidium; gp91(phox)	TRAUMATIC BRAIN-INJURY; NADPH OXIDASE; ACTIVATED MACROPHAGES; MICROGLIAL ACTIVATION; INFLAMMATORY RESPONSE; ANTIOXIDANT THERAPIES; LIPID-PEROXIDATION; CNS INJURY; STRESS; RECOVERY	Age potentiates neurodegeneration and impairs recovery from spinal cord injury (SCI). Previously, we observed that age alters the balance of destructive (M1) and protective (M2) macrophages; however, the age-related pathophysiology in SCI is poorly understood. Nicotinamide adenine dinucleotide phosphate oxidase (NOX) contributes to reactive oxygen species (ROS)-mediated damage and macrophage activation in neurotrauma. Further, NOX and ROS increase with central nervous system age. Here, we found significantly higher ROS generation in 14 versus 4-month-old (MO) mice after contusion SCI. Notably, NOX2 increased in 14 MO ROS-producing macrophages suggesting that macrophages and NOX contribute to SCI oxidative stress. Indicators of lipid peroxidation, a downstream cytotoxic effect of ROS accumulation, were significantly higher in 14 versus 4 MO SCI mice. We also detected a higher percentage of ROS-producing M2 (Arginase-1-positive) macrophages in 14 versus 4 MO mice, a previously unreported SCI phenotype, and increased M1 (CD16/32-positive) macrophages with age. Thus, NOX and ROS are age-related mediators of SCI pathophysiology and normally protective M2 macrophages may potentiate secondary injury through ROS generation in the aged injured spinal cord. (C) 2016 Elsevier Inc. All rights reserved.	[Zhang, Bei; Bailey, William M.; McVicar, Anna Leigh; Gensel, John C.] Univ Kentucky, Dept Physiol, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA	Gensel, JC (corresponding author), Univ Kentucky, B463 Biomed & Biol Sci Res Bldg BBSRB, Lexington, KY 40536 USA.	gensel.1@uky.edu		, John/0000-0001-8980-108X	Craig H. Neilsen Foundation; National Institute of Neurological DisordersUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS091582, P30 NS051220]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS091582, P30NS051220] Funding Source: NIH RePORTER	The authors would like to thank Dr Edward Hall, Dr Indrapal Singh, and Linda Simmerman for technical support and advice. The current work was supported by the Craig H. Neilsen Foundation and by the National Institute of Neurological Disorders with grants R01 NS091582 and P30 NS051220.	Angeloni C, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/370312; Aoyama T, 2008, NEUROL MED-CHIR, V48, P539, DOI 10.2176/nmc.48.539; Bains M, 2012, BBA-MOL BASIS DIS, V1822, P675, DOI 10.1016/j.bbadis.2011.10.017; BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; Bastani NE, 2012, ARCH PHYS MED REHAB, V93, P2223, DOI 10.1016/j.apmr.2012.06.021; Brandes RP, 2014, FREE RADICAL BIO MED, V76, P208, DOI 10.1016/j.freeradbiomed.2014.07.046; BRAUGHLER JM, 1992, J NEUROTRAUM, V9, pS1; Brune B, 2013, ANTIOXID REDOX SIGN, V19, P595, DOI 10.1089/ars.2012.4785; Bylund J, 2010, FREE RADICAL BIO MED, V49, P1834, DOI 10.1016/j.freeradbiomed.2010.09.016; Carrico KM, 2009, J NEUROTRAUM, V26, P1369, DOI [10.1089/neu.2008.0870, 10.1089/neu.2008-0870]; Choi SH, 2012, J NEUROCHEM, V120, P292, DOI 10.1111/j.1471-4159.2011.07572.x; Cooney SJ, 2014, FREE RADICAL RES, V48, P929, DOI 10.3109/10715762.2014.927578; Cooney SJ, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-155; Cui K, 2004, PROG NEURO-PSYCHOPH, V28, P771, DOI 10.1016/j.pnpbp.2004.05.023; Damani MR, 2011, AGING CELL, V10, P263, DOI 10.1111/j.1474-9726.2010.00660.x; David S, 2011, NAT REV NEUROSCI, V12, P388, DOI 10.1038/nrn3053; Devasagayam TPA, 2003, INDIAN J BIOCHEM BIO, V40, P300; DeVivo MJ, 2011, ARCH PHYS MED REHAB, V92, P332, DOI 10.1016/j.apmr.2010.08.031; Dohi K, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-41; Donnelly DJ, 2011, J NEUROSCI, V31, P9910, DOI 10.1523/JNEUROSCI.2114-11.2011; Fenn AM, 2014, J NEUROSCI, V34, P8904, DOI 10.1523/JNEUROSCI.1146-14.2014; Ferger AI, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-45; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Fleming JC, 2006, BRAIN, V129, P3249, DOI 10.1093/brain/awl296; Furlan JC, 2009, J NEUROTRAUM, V26, P1707, DOI [10.1089/neu.2009.0888, 10.1089/neu.2009-0888]; Genovese T, 2006, NEUROSCI LETT, V393, P141, DOI 10.1016/j.neulet.2005.09.060; Ghosh M, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-015-0463-9; Greenhalgh AD, 2016, BRAIN BEHAV IMMUN, V56, P61, DOI 10.1016/j.bbi.2016.04.013; Hall ED, 2011, NEUROTHERAPEUTICS, V8, P152, DOI 10.1007/s13311-011-0026-4; Hooshmand MJ, 2014, IMMUN AGEING, V11, DOI 10.1186/1742-4933-11-15; Horn KP, 2008, J NEUROSCI, V28, P9330, DOI 10.1523/JNEUROSCI.2488-08.2008; Jakob W, 2009, J NEUROTRAUM, V26, P2037, DOI 10.1089/neu.2008.0824; Jia Z, 2012, SPINAL CORD, V50, P264, DOI 10.1038/sc.2011.111; Johnstone JT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080975; Khayrullina G, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0391-8; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Kim D, 2010, P NATL ACAD SCI USA, V107, P14851, DOI 10.1073/pnas.1009926107; Kroner A, 2014, NEURON, V83, P1098, DOI 10.1016/j.neuron.2014.07.027; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Mahbub S, 2012, J INTERF CYTOK RES, V32, P18, DOI 10.1089/jir.2011.0058; Nazarewicz RR, 2013, J BIOMOL SCREEN, V18, P498, DOI 10.1177/1087057112468765; NSCISC S, 2016, FIG AT A GLANC; Ordonez FJ, 2013, ARCH PHYS MED REHAB, V94, P2336, DOI 10.1016/j.apmr.2013.05.029; Padgett LE, 2015, DIABETES, V64, P937, DOI 10.2337/db14-0929; Pawate S, 2004, J NEUROSCI RES, V77, P540, DOI 10.1002/jnr.20180; Qin LY, 2013, GLIA, V61, P855, DOI 10.1002/glia.22479; Qin LY, 2005, GLIA, V52, P78, DOI 10.1002/glia.20225; Quinn R, 2005, NUTRITION, V21, P775, DOI 10.1016/j.nut.2005.04.002; Sareila O, 2011, ANTIOXID REDOX SIGN, V15, P2197, DOI 10.1089/ars.2010.3635; Scheff SW, 2003, J NEUROTRAUM, V20, P179, DOI 10.1089/08977150360547099; Siegenthaler MM, 2008, EXP NEUROL, V213, P363, DOI 10.1016/j.expneurol.2008.06.015; Slegenthaler MM, 2008, EXP NEUROL, V210, P207, DOI 10.1016/j.expneurol.2007.10.019; Trivedi A, 2006, CLIN NEUROSCI RES, V6, P283, DOI 10.1016/j.cnr.2006.09.007; van Tits LJH, 2011, ATHEROSCLEROSIS, V214, P345, DOI 10.1016/j.atherosclerosis.2010.11.018; Xiong YQ, 2007, J NEUROCHEM, V100, P639, DOI 10.1111/j.1471-4159.2006.04312.x; Zhang B, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0440-3; Zhang B, 2015, EXP NEUROL, V273, P83, DOI 10.1016/j.expneurol.2015.08.001; Zhang Y, 2013, CELL RES, V23, P898, DOI 10.1038/cr.2013.75	59	41	41	2	15	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0197-4580	1558-1497		NEUROBIOL AGING	Neurobiol. Aging	NOV	2016	47						157	167		10.1016/j.neurobiolaging.2016.07.029			11	Geriatrics & Gerontology; Neurosciences	Geriatrics & Gerontology; Neurosciences & Neurology	EA9PO	WOS:000386976500017	27596335	Green Accepted			2021-06-18	
J	Oresic, M; Posti, JP; Kamstrup-Nielsen, MH; Takala, RSK; Lingsma, HF; Mattila, I; Jantti, S; Katila, AJ; Carpenter, KLH; Ala-Seppala, H; Kyllonen, A; Maanpaa, HR; Tallus, J; Coles, JP; Heino, I; Frantzen, J; Hutchinson, PJ; Menon, DK; Tenovuo, O; Hyotylainen, T				Oresic, Matej; Posti, Jussi P.; Kamstrup-Nielsen, Maja H.; Takala, Riikka S. K.; Lingsma, Hester F.; Mattila, Ismo; Jantti, Sirkku; Katila, Ari J.; Carpenter, Keri L. H.; Ala-Seppala, Henna; Kyllonen, Anna; Maanpaa, Henna-Riikka; Tallus, Jussi; Coles, Jonathan P.; Heino, Iiro; Frantzen, Janek; Hutchinson, Peter J.; Menon, David K.; Tenovuo, Olli; Hyotylainen, Tuulia			Human Serum Metabolites Associate With Severity and Patient Outcomes in Traumatic Brain Injury	EBIOMEDICINE			English	Article						Biomarkers; Mass spectrometry; Metabolomics; Traumatic brain injury	CEREBRAL-ISCHEMIA; DAMAGE; HEAD; BARRIER; MARKERS; PROTEIN; S100B; ACIDS; PREDICTORS; DISRUPTION	Traumatic brain injury (TBI) is a major cause of death and disability worldwide, especially in children and young adults. TBI is an example of a medical condition where there are still major lacks in diagnostics and outcome prediction. Here we apply comprehensive metabolic profiling of serum samples from TBI patients and controls in two independent cohorts. The discovery study included 144 TBI patients, with the samples taken at the time of hospitalization. The patients were diagnosed as severe (sTBI; n=22), moderate (moTBI; n=14) or mild TBI (mTBI; n=108) according to Glasgow Coma Scale. The control group (n=28) comprised of acute orthopedic non-brain injuries. The validation study included sTBI (n=23), moTBI (n=7), mTBI (n=37) patients and controls (n=27). We show that two medium-chain fatty acids (decanoic and octanoic acids) and sugar derivatives including 2,3-bisphosphoglyceric acid are strongly associated with severity of TBI, and most of them are also detected at high concentrations in brain microdialysates of TBI patients. Based on metabolite concentrations from TBI patients at the time of hospitalization, an algorithm was developed that accurately predicted the patient outcomes (AUC=0.84 in validation cohort). Addition of the metabolites to the established clinical model (CRASH), comprising clinical and computed tomography data, significantly improved prediction of patient outcomes. The identified 'TBI metabotype' in serum, that may be indicative of disrupted blood-brain barrier, of protective physiological response and altered metabolism due to head trauma, offers a new venue for the development of diagnostic and prognostic markers of broad spectrum of TBIs. (C) 2016 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).	[Oresic, Matej; Hyotylainen, Tuulia] Univ Turku, Turku Ctr Biotechnol, FI-20520 Turku, Finland; [Oresic, Matej; Hyotylainen, Tuulia] Abo Akad Univ, FI-20520 Turku, Finland; [Oresic, Matej; Kamstrup-Nielsen, Maja H.; Mattila, Ismo; Hyotylainen, Tuulia] Steno Diabet Ctr A S, DK-2820 Gentofte, Denmark; [Posti, Jussi P.; Hyotylainen, Tuulia] VTT, VTT Tech Res Ctr Finland, FI-02044 Espoo, Finland; [Posti, Jussi P.; Frantzen, Janek] Turku Univ Hosp, Dept Neurosurg, Div Clin Neurosci, FI-20521 Turku, Finland; [Posti, Jussi P.; Ala-Seppala, Henna; Kyllonen, Anna; Maanpaa, Henna-Riikka; Tallus, Jussi; Heino, Iiro; Frantzen, Janek; Tenovuo, Olli] Turku Univ Hosp, Dept Rehabil & Brain Trauma, Div Clin Neurosci, FI-20521 Turku, Finland; [Posti, Jussi P.; Maanpaa, Henna-Riikka; Tallus, Jussi; Coles, Jonathan P.; Heino, Iiro; Frantzen, Janek; Tenovuo, Olli] Univ Turku, Dept Neurol, FI-20014 Turku, Finland; [Katila, Ari J.] Turku Univ Hosp, Perioperat Serv Intens Care Med & Pain Management, FI-20521 Turku, Finland; [Lingsma, Hester F.] Erasmus MC Univ Med Ctr, Dept Publ Hlth, Rotterdam, Netherlands; [Carpenter, Keri L. H.; Hutchinson, Peter J.] Univ Cambridge, Dept Clin Neurosci, Div Neurosurg, Box 167,Cambridge Biomed Campus, Cambridge CB2 0QQ, England; [Coles, Jonathan P.; Menon, David K.] Univ Cambridge, Dept Med, Div Anaesthesia, Box 93,Cambridge Biomed Campus, Cambridge CB2 0QQ, England; [Hyotylainen, Tuulia] Univ Helsinki, Cent Hosp, Clin Res Inst, FI-00290 Helsinki, Finland; [Hyotylainen, Tuulia] Univ Orebro, Dept Chem, S-70281 Orebro, Sweden	Oresic, M; Hyotylainen, T (corresponding author), Univ Turku, Turku Ctr Biotechnol, FI-20520 Turku, Finland.; Oresic, M; Hyotylainen, T (corresponding author), Abo Akad Univ, FI-20520 Turku, Finland.; Oresic, M; Hyotylainen, T (corresponding author), Steno Diabet Ctr A S, DK-2820 Gentofte, Denmark.; Hyotylainen, T (corresponding author), VTT, VTT Tech Res Ctr Finland, FI-02044 Espoo, Finland.; Tenovuo, O (corresponding author), Turku Univ Hosp, Dept Rehabil & Brain Trauma, Div Clin Neurosci, FI-20521 Turku, Finland.; Tenovuo, O (corresponding author), Univ Turku, Dept Neurol, FI-20014 Turku, Finland.; Menon, DK; Hyotylainen, T (corresponding author), Univ Cambridge, Dept Med, Div Anaesthesia, Box 93,Cambridge Biomed Campus, Cambridge CB2 0QQ, England.; Hyotylainen, T (corresponding author), Univ Helsinki, Cent Hosp, Clin Res Inst, FI-00290 Helsinki, Finland.; Hyotylainen, T (corresponding author), Univ Orebro, Dept Chem, S-70281 Orebro, Sweden.; Oresic, M (corresponding author), Turku Ctr Biotechnol, Tykistokatu 6, FI-20520 Turku, Finland.	matej.oresic@utu.fi; dkm13@wbic.cam.ac.uk; olli.tenovuo@tyks.fi; tuulia.hyotylainen@oru.se	Posti, Jussi P./Y-2908-2019; Oresic, Matej/K-7673-2016; Oresic, Matej/AAV-3978-2020; Hyotylainen, Tuulia/AAP-6266-2020	Posti, Jussi P./0000-0002-5925-5193; Oresic, Matej/0000-0002-2856-9165; Mattila, Ismo/0000-0001-9597-7831; Heino, Iiro/0000-0002-5293-9859; Hyotylainen, Tuulia/0000-0002-1389-8302; Ala-Seppala, Henna/0000-0002-1577-3028; Carpenter, Keri/0000-0001-8236-7727	EU FP7 project TBIcare [270259]; GE-NFL Head Health Challenge I Award [7620]; EVO (Finland); Maire Taponen Foundation; National Institute for Health Research (NIHR) Research Professorship; NIHR Biomedical Research Centre (NIHR BRC) Cambridge; NIHR BRC Cambridge; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NIHR-RP-R3-12-013, NF-SI-0512-10090] Funding Source: researchfish	This work was supported by the EU FP7 project TBIcare (Project ref. 270259; to M.O., D.M., and O.T.), by the GE-NFL Head Health Challenge I Award (grant no. 7620 to M.O. and T.H.), by personal EVO funding (Finland) (to J.P.P and R.S.K.T.), and by personal grant from Maire Taponen Foundation (to J.P.P.). Support for P.J.H. - National Institute for Health Research (NIHR) Research Professorship; NIHR Biomedical Research Centre (NIHR BRC) Cambridge (Neuroscience Theme; Brain Injury and Repair Theme). Support for K.L.H.C. - NIHR BRC Cambridge (Neuroscience Theme; Brain Injury and Repair Theme).	Anderson VA, 2001, PEDIATR NEUROSURG, V34, P138, DOI 10.1159/000056009; Berger RP, 2006, PEDIATRICS, V117, P325, DOI 10.1542/peds.2005-0711; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Castillo S, 2011, ANAL CHEM, V83, P3058, DOI 10.1021/ac103308x; Chyan YJ, 1999, J BIOL CHEM, V274, P21937, DOI 10.1074/jbc.274.31.21937; Clausen F, 2011, ACTA NEUROCHIR, V153, P653, DOI 10.1007/s00701-010-0871-7; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; de Assis DR, 2004, BRAIN RES, V1030, P141, DOI 10.1016/j.brainres.2004.10.010; Ebert D, 2003, J NEUROSCI, V23, P5928; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Harrell Frank E., 2001, REGRESSION MODELING; Hartonen M., 2013, J CHROMATOGR A; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; Hsia CCW, 1998, NEW ENGL J MED, V338, P239, DOI 10.1056/NEJM199801223380407; Hwang IK, 2009, J NEUROSCI RES, V87, P2126, DOI 10.1002/jnr.22030; Ingebrigtsen T, 2002, J TRAUMA, V52, P798, DOI 10.1097/00005373-200204000-00038; Jeter CB, 2013, J NEUROTRAUM, V30, P671, DOI 10.1089/neu.2012.2491; Karbownik M, 2001, J CELL BIOCHEM, V81, P507, DOI 10.1002/1097-4644(20010601)81:3<507::AID-JCB1064>3.3.CO;2-D; Koh SXT, 2014, SPORTS MED, V44, P369, DOI 10.1007/s40279-013-0119-9; Kopka J, 2005, BIOINFORMATICS, V21, P1635, DOI 10.1093/bioinformatics/bti236; Lakshmanan R, 2010, NEUROCRIT CARE, V12, P324, DOI 10.1007/s12028-010-9342-5; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Maas AIR, 2015, NEUROSURGERY, V76, P67, DOI 10.1227/NEU.0000000000000575; Menon DK, 2004, CRIT CARE MED, V32, P1384, DOI 10.1097/01.CCM.0000127777.16609.08; Mondello S, 2011, CRIT CARE, V15, DOI 10.1186/cc10286; OLDENDORF WH, 1973, AM J PHYSIOL, V224, P1450; Paik MJ, 2009, CLIN CHIM ACTA, V402, P25, DOI 10.1016/j.cca.2008.12.022; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Savola O, 2004, J TRAUMA, V56, P1229, DOI 10.1097/01.TA.0000096644.08735.72; Saw MM, 2014, NEUROCRIT CARE, V20, P209, DOI 10.1007/s12028-013-9933-z; Schuck PF, 2009, NEUROCHEM INT, V54, P519, DOI 10.1016/j.neuint.2009.02.009; Schuck PF, 2009, BRAIN RES, V1296, P117, DOI 10.1016/j.brainres.2009.08.053; SPECTOR R, 1988, J NEUROCHEM, V50, P639, DOI 10.1111/j.1471-4159.1988.tb02958.x; Storey JD, 2002, J ROY STAT SOC B, V64, P479, DOI 10.1111/1467-9868.00346; Takala RSK, 2016, WORLD NEUROSURG, V87, P8, DOI 10.1016/j.wneu.2015.10.066; Timofeev I, 2011, BRAIN, V134, P484, DOI 10.1093/brain/awq353; Torabian S, 2005, CURR OPIN ONCOL, V17, P167, DOI 10.1097/01.cco.0000154039.07466.5d; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Wikoff WR, 2009, P NATL ACAD SCI USA, V106, P3698, DOI 10.1073/pnas.0812874106; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wolf A, 2001, LANCET, V357, P606, DOI 10.1016/S0140-6736(00)04064-2	45	41	44	0	10	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	2352-3964			EBIOMEDICINE	EBioMedicine	OCT	2016	12						118	126		10.1016/j.ebiom.2016.07.015			9	Medicine, General & Internal; Medicine, Research & Experimental	General & Internal Medicine; Research & Experimental Medicine	EA8IM	WOS:000386878500026	27665050	DOAJ Gold, Green Published			2021-06-18	
J	Stahon, KE; Bastian, C; Griffith, S; Kidd, GJ; Brunet, S; Baltan, S				Stahon, Katharine E.; Bastian, Chinthasagar; Griffith, Shelby; Kidd, Grahame J.; Brunet, Sylvain; Baltan, Selva			Age-Related Changes in Axonal and Mitochondrial Ultrastructure and Function in White Matter	JOURNAL OF NEUROSCIENCE			English	Article						aging; axon; mitochondrial dynamic; myelin; neurodegeneration; three-dimensional electron microscopy	MYELINATED NERVE-FIBERS; RAT OPTIC-NERVE; ISCHEMIC-INJURY; SODIUM-CHANNELS; RHESUS-MONKEY; FUSION; CONDUCTION; APOPTOSIS; ATP; EXCITOTOXICITY	The impact of aging on CNS white matter (WM) is of general interest because the global effects of aging on myelinated nerve fibers are more complex and profound than those in cortical gray matter. It is important to distinguish between axonal changes created by normal aging and those caused by neurodegenerative diseases, including multiple sclerosis, stroke, glaucoma, Alzheimer's disease, and traumatic brain injury. Using three-dimensional electron microscopy, weshow that in mouse optic nerve, which is a pure and fully myelinated WMtract, aging axons are larger, have thicker myelin, and are characterized by longer and thicker mitochondria, which are associated with altered levels of mitochondrial shaping proteins. These structural alterations in aging mitochondria correlate with lower ATP levels and increased generation of nitric oxide, protein nitration, and lipid peroxidation. Moreover, mitochondria-smooth endoplasmic reticulum interactions are compromised due to decreased associations and decreased levels of calnexin and calreticulin, suggesting a disruption in Ca2+ homeostasis and defective unfolded protein responses in aging axons. Despite these age-related modifications, axon function is sustained in aging WM, which suggests that age-dependent changes do not lead to irreversible functional decline under normal conditions, as is observed in neurodegenerative diseases.	[Stahon, Katharine E.; Bastian, Chinthasagar; Griffith, Shelby; Kidd, Grahame J.; Brunet, Sylvain; Baltan, Selva] Cleveland Clin Fdn, Dept Neurosci, 9500 Euclid Ave, Cleveland, OH 44195 USA	Baltan, S (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Neurosci, 9500 Euclid Ave NB30, Cleveland, OH 44195 USA.	baltans@ccf.org	Baltan, Selva/AAO-8237-2021	Kidd, Grahame/0000-0003-3956-2206; Bastian, Chinthasagar/0000-0001-5759-5496	NIAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG033720]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R56AG033720, R01AG033720] Funding Source: NIH RePORTER	This work was supported by NIA Grant AG033720 to S.B. We thank Dr. Chris Nelson for his help in editing this paper.	Baltan S, 2014, WHITE MATTER INJURY, P373; Baltan S, 2008, J NEUROSCI, V28, P1479, DOI 10.1523/JNEUROSCI.5137-07.2008; Baltan S, 2016, NEUROPHARMACOLOGY, V110, P626, DOI 10.1016/j.neuropharm.2015.09.015; Baltan S, 2012, J NEUROCHEM, V123, P108, DOI 10.1111/j.1471-4159.2012.07949.x; Baltan S, 2011, J NEUROSCI, V31, P3990, DOI 10.1523/JNEUROSCI.5379-10.2011; Baltan S, 2010, J NEUROSCI, V30, P5644, DOI 10.1523/JNEUROSCI.5956-09.2010; Baltan S, 2009, NEUROSCIENTIST, V15, P126, DOI 10.1177/1073858408324788; Bay V, 2012, GLIA, V60, P651, DOI 10.1002/glia.22299; Black JA, 2002, MOL BRAIN RES, V105, P19, DOI 10.1016/S0169-328X(02)00385-6; Blalock EM, 2003, J NEUROSCI, V23, P3807; Boiko T, 2001, NEURON, V30, P91, DOI 10.1016/S0896-6273(01)00265-3; Bowley MP, 2010, J COMP NEUROL, V518, P3046, DOI 10.1002/cne.22379; Camacho P, 2003, CALNEXIN CALRETICULI, P126; Cavallotti C, 2003, ANAT HISTOL EMBRYOL, V32, P12, DOI 10.1046/j.1439-0264.2003.00431.x; Cavallotti C, 2002, CAN J OPHTHALMOL, V37, P389, DOI 10.1016/S0008-4182(02)80040-0; Chen HC, 2005, J BIOL CHEM, V280, P26185, DOI 10.1074/jbc.M503062200; Cipolat S, 2004, P NATL ACAD SCI USA, V101, P15927, DOI 10.1073/pnas.0407043101; Coe H, 2009, GEN PHYSIOL BIOPHYS, V28, pF96; Craner MJ, 2004, P NATL ACAD SCI USA, V101, P8168, DOI 10.1073/pnas.0402765101; CUMMINS KL, 1979, ELECTROEN CLIN NEURO, V46, P634, DOI 10.1016/0013-4694(79)90101-9; de Brito OM, 2008, NATURE, V456, P605, DOI 10.1038/nature07534; Feldman ML, 1998, J NEUROCYTOL, V27, P605, DOI 10.1023/A:1006926428699; Fiala JC, 2001, J AM MED INFORM ASSN, V8, P1; Fiala JC, 2005, J MICROSC-OXFORD, V218, P52, DOI 10.1111/j.1365-2818.2005.01466.x; FOSTER RE, 1982, DEV BRAIN RES, V3, P371, DOI 10.1016/0165-3806(82)90005-0; Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7; Friedman JR, 2011, SCIENCE, V334, P358, DOI 10.1126/science.1207385; Graier WF, 2007, PFLUG ARCH EUR J PHY, V455, P375, DOI 10.1007/s00424-007-0296-1; Griffiths EJ, 2009, BBA-BIOENERGETICS, V1787, P1324, DOI 10.1016/j.bbabio.2009.01.019; Guedes Guilherme, 2011, Curr Aging Sci, V4, P110; Heflin M, 2008, PATHOBIOLOGY OCULAR, P361; Hinman JD, 2006, J COMP NEUROL, V495, P351, DOI 10.1002/cne.20886; HODGKIN AL, 1949, J PHYSIOL-LONDON, V108, P37, DOI 10.1113/jphysiol.1949.sp004310; Jahani-Asl A, 2007, J BIOL CHEM, V282, P23788, DOI 10.1074/jbc.M703812200; Jouaville LS, 1999, P NATL ACAD SCI USA, V96, P13807, DOI 10.1073/pnas.96.24.13807; Kaplan MR, 2001, NEURON, V30, P105, DOI 10.1016/S0896-6273(01)00266-5; Kemper T. L., 1994, CLIN NEUROLOGY AGING, P3; Khan HA, 2003, J BIOSCIENCES, V28, P379, DOI 10.1007/BF02705114; Kirichok Y, 2004, NATURE, V427, P360, DOI 10.1038/nature02246; Lasiene J, 2009, AGING CELL, V8, P201, DOI 10.1111/j.1474-9726.2009.00462.x; Misgeld T, 2007, NAT METHODS, V4, P559, DOI 10.1038/NMETH1055; Murphy SP, 2014, J NEUROCHEM, V129, P509, DOI 10.1111/jnc.12498; Neuspiel M, 2005, J BIOL CHEM, V280, P25060, DOI 10.1074/jbc.M501599200; Olichon A, 2003, J BIOL CHEM, V278, P7743, DOI 10.1074/jbc.C200677200; Parpura V, 2017, NEUROCHEM RES, V42, P19, DOI 10.1007/s11064-016-1848-6; Peters A, 2000, J COMP NEUROL, V419, P364, DOI 10.1002/(SICI)1096-9861(20000410)419:3<364::AID-CNE8>3.0.CO;2-R; Peters A, 1999, CEREB CORTEX, P49; Peters A, 2009, FRONT NEUROANAT, V3, DOI 10.3389/neuro.05.011.2009; Ross MH, 2016, HISTOLOGY TEXT ATLAS, P356; Sandell JH, 2002, J COMP NEUROL, V445, P13, DOI 10.1002/cne.10162; Sasaki T, 2011, SCIENCE, V331, P599, DOI 10.1126/science.1197598; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Skulachev VP, 2001, TRENDS BIOCHEM SCI, V26, P23, DOI 10.1016/S0968-0004(00)01735-7; STYS PK, 1991, ANN NEUROL, V30, P375, DOI 10.1002/ana.410300309; Szabadkai G, 2008, PHYSIOLOGY, V23, P84, DOI 10.1152/physiol.00046.2007; Tondera D, 2009, EMBO J, V28, P1589, DOI 10.1038/emboj.2009.89; Uo T, 2009, J NEUROSCI, V29, P2824, DOI 10.1523/JNEUROSCI.6186-08.2009; Westermann B, 2010, NAT REV MOL CELL BIO, V11, P872, DOI 10.1038/nrm3013	58	41	42	0	7	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	SEP 28	2016	36	39					9990	10001		10.1523/JNEUROSCI.1316-16.2016			12	Neurosciences	Neurosciences & Neurology	EC8BB	WOS:000388363800002	27683897	Green Published, Bronze			2021-06-18	
J	Chrisman, SPD; Mac Donald, CL; Friedman, S; Andre, J; Rowhani-Rahbar, A; Drescher, S; Stein, E; Holm, M; Evans, N; Poliakov, AV; Ching, RP; Schwien, CC; Vavilala, MS; Rivara, FP				Chrisman, Sara P. D.; Mac Donald, Christine L.; Friedman, Seth; Andre, Jalal; Rowhani-Rahbar, Ali; Drescher, Sara; Stein, Elizabeth; Holm, Matthew; Evans, Nicole; Poliakov, Andrew V.; Ching, Randal P.; Schwien, Christina C.; Vavilala, Monica S.; Rivara, Frederick P.			Head Impact Exposure During a Weekend Youth Soccer Tournament	JOURNAL OF CHILD NEUROLOGY			English	Article						soccer; child; adolescent; heading; sport; concussion	WHITE-MATTER INTEGRITY; NEUROPSYCHOLOGICAL CONSEQUENCE; NEUROCOGNITIVE PERFORMANCE; POSTURAL CONTROL; PLAYERS; CONCUSSION; FOOTBALL; SYMPTOMS; FEMALE; SEASON	Concussion is a known risk in youth soccer, but little is known about subconcussive head impacts. The authors provided a prospective cohort study measuring frequency and magnitude of subconcussive head impacts using accelerometry in a middle school-age soccer tournament, and association between head impacts and changes in (1) symptoms, (2) cognitive testing, and (3) advanced neuroimaging. A total of 17 youth completed the study (41% female, mean 12.6 years). There were 73 head impacts >15g measured (45% headers) and only 2 had a maximum peak linear acceleration >50g. No youth reported symptoms consistent with concussion. After correction for multiple comparisons and a sensitivity analysis excluding clear outliers, no significant associations were found between head impact exposure and neuropsychological testing or advanced neuroimaging. The authors conclude that head impacts were relatively uncommon and low in acceleration in youth playing a weekend soccer tournament. This study adds to the limited data regarding head impacts in youth soccer.	[Chrisman, Sara P. D.; Mac Donald, Christine L.; Friedman, Seth; Andre, Jalal; Rowhani-Rahbar, Ali; Ching, Randal P.; Vavilala, Monica S.; Rivara, Frederick P.] Univ Washington, Harborview Injury Prevent & Res Ctr, Seattle, WA 98195 USA; [Chrisman, Sara P. D.] Seattle Childrens Hosp, Adolescent Med, Seattle, WA USA; [Chrisman, Sara P. D.; Drescher, Sara; Stein, Elizabeth; Holm, Matthew; Schwien, Christina C.; Rivara, Frederick P.] Seattle Childrens Res Inst, Ctr Child Hlth Behav & Dev, POB 5371,Mailstop CW8-6, Seattle, WA 98145 USA; [Mac Donald, Christine L.; Evans, Nicole] Univ Washington, Neurosurg, Seattle, WA 98195 USA; [Friedman, Seth; Poliakov, Andrew V.] Seattle Childrens Hosp, Radiol, Seattle, WA USA; [Friedman, Seth] Seattle Childrens Res Inst, Ctr Clin & Translat Res, POB 5371,Mailstop CW8-6, Seattle, WA 98145 USA; [Andre, Jalal] Univ Washington, Neuroradiol, Seattle, WA 98195 USA; [Rowhani-Rahbar, Ali] Univ Washington, Epidemiol, Seattle, WA 98195 USA; [Ching, Randal P.] Univ Washington, Appl Biomech Lab, Seattle, WA 98195 USA; [Vavilala, Monica S.] Univ Washington, Anesthesiol & Pain Med, Seattle, WA 98195 USA	Chrisman, SPD (corresponding author), Seattle Childrens Res Inst, Ctr Child Hlth Behav & Dev, POB 5371,Mailstop CW8-6, Seattle, WA 98145 USA.	sara.chrisman@seattlechildrens.org		Andre, Jalal/0000-0002-0896-183X; Chrisman, Sara/0000-0001-5373-7223; friedman, seth/0000-0001-8785-7215; Stein, Elizabeth/0000-0002-1820-3821	Seattle Pediatric Concussion Research Collaborative, Seattle Children's Research Institute	The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was funded by the Seattle Pediatric Concussion Research Collaborative, Seattle Children's Research Institute.	Abbas K, 2015, BRAIN CONNECT, V5, P91, DOI 10.1089/brain.2014.0279; Bazarian JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094734; Camarillo DB, 2013, ANN BIOMED ENG, V41, P1939, DOI 10.1007/s10439-013-0801-y; Cantu RC, 2014, NEUROLOGICAL CONSEQU; Chun IY, 2015, DEV NEUROPSYCHOL, V40, P92, DOI 10.1080/87565641.2015.1020945; Cobb BR, 2013, ANN BIOMED ENG, V41, P2463, DOI 10.1007/s10439-013-0867-6; Comstock RD, 2015, JAMA PEDIATR, V169, P830, DOI 10.1001/jamapediatrics.2015.1062; Daniel RW, 2014, J BIOMECH ENG-T ASME, V136, DOI 10.1115/1.4027872; Davenport EM, 2014, J NEUROTRAUM, V31, P1617, DOI 10.1089/neu.2013.3233; FIFA Communications Division, 2007, FIFA DAT BIG COUNT 2, DOI 10.1177/0883073816634857; Hanlon EM, 2012, MED SCI SPORT EXER, V44, P1102, DOI 10.1249/MSS.0b013e3182444d7d; Haran FJ, 2013, INT J SPORTS MED, V34, P350, DOI 10.1055/s-0032-1304647; Hendrie HC, 2009, ALZHEIMERS DEMENT, V5, pP218, DOI [10.1016/j.jalz.2009.04.146, DOI 10.1016/J.JALZ.2009.04.146]; Janda David H, 2002, Inj Control Saf Promot, V9, P25, DOI 10.1076/icsp.9.1.25.3324; Kaminski TW, 2007, J CLIN EXP NEUROPSYC, V29, P742, DOI 10.1080/13825580600976911; Kim J, 2010, J NEUROTRAUM, V27, P1399, DOI 10.1089/neu.2009.1215; Koerte IK, 2012, JAMA-J AM MED ASSOC, V308, P1859, DOI 10.1001/jama.2012.13735; Kontos AP, 2011, BRAIN INJURY, V25, P1234, DOI 10.3109/02699052.2011.608209; Krustrup P, 2010, SCAND J MED SCI SPOR, V20, P1, DOI 10.1111/j.1600-0838.2010.01108.x; Leong Danielle F, 2015, J Optom, V8, P131, DOI 10.1016/j.optom.2014.12.005; Lipton ML, 2013, RADIOLOGY, V268, P850, DOI 10.1148/radiol.13130545; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Matser JT, 2001, J CLIN EXP NEUROPSYC, V23, P770, DOI 10.1076/jcen.23.6.770.1029; McAllister TW, 2012, NEUROLOGY, V78, P1777, DOI 10.1212/WNL.0b013e3182582fe7; McAllister TW, 2014, NEUROLOGY, V82, P63, DOI 10.1212/01.wnl.0000438220.16190.42; Munce TA, 2014, J CHILD NEUROL, V29, P1601, DOI 10.1177/0883073813509887; Rieder C, 2011, ARCH CLIN NEUROPSYCH, V26, P583, DOI 10.1093/arclin/acr055; Rosenthal JA, 2014, AM J SPORT MED, V42, P1710, DOI 10.1177/0363546514530091; Schmitt DM, 2004, INT J SPORTS MED, V25, P326, DOI 10.1055/s-2004-819941; Stephens R, 2010, J NEUROPSYCH CLIN N, V22, P295, DOI 10.1176/appi.neuropsych.22.3.295; Straume-Naesheim TM, 2009, NEUROSURGERY, V64, P719, DOI 10.1227/01.NEU.0000340681.12949.6D; Tenforde AS, 2011, PM&R, V3, P861, DOI 10.1016/j.pmrj.2011.05.019; US Youth Soccer, 2014, US YOUTH SOCC ANN RE; Webbe FM, 2003, APPL NEUROPSYCHOL, V10, P31, DOI 10.1207/S15324826AN1001_5; Witol AD, 2003, ARCH CLIN NEUROPSYCH, V18, P397, DOI 10.1016/S0887-6177(02)00151-8; Zhang MR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057364	36	41	41	0	14	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0883-0738	1708-8283		J CHILD NEUROL	J. Child Neurol.	JUL	2016	31	8					971	978		10.1177/0883073816634857			8	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	DQ0GL	WOS:000378876900003	26951540				2021-06-18	
J	Haus, DL; Lopez-Velazquez, L; Gold, EM; Cunningham, KM; Perez, H; Anderson, AJ; Cummings, BJ				Haus, Daniel L.; Lopez-Velazquez, Luci; Gold, Eric M.; Cunningham, Kelly M.; Perez, Harvey; Anderson, Aileen J.; Cummings, Brian J.			Transplantation of human neural stem cells restores cognition in an immunodeficient rodent model of traumatic brain injury	EXPERIMENTAL NEUROLOGY			English	Article						Traumatic brain injury; Human neural stem cell; Cell transplantation; Spatial memory; Emotional memory; Hippocampal neuron survival; Stereology; Cell therapy; Neurotrauma	SPINAL-CORD-INJURY; CONTROLLED CORTICAL IMPACT; DELAYED NEURONAL DEATH; MORRIS WATER MAZE; LONG-TERM; PROGENITOR CELLS; RAT MODEL; STEM/PROGENITOR CELLS; THERAPEUTIC STRATEGY; REPEATED CONCUSSION	Traumatic brain injury (TBI) in humans can result in permanent tissue damage and has been linked to cognitive impairment that lasts years beyond the initial insult. Clinically effective treatment strategies have yet to be developed. Transplantation of human neural stem cells (hNSCs) has the potential to restore cognition lost due to injury, however, the vast majority of rodent TBI/hNSC studies to date have evaluated cognition only at early time points, typically <1 month post-injury and cell transplantation. Additionally, human cell engraftment and long-term survival in rodent models of TBI has been difficult to achieve due to host immunorejection of the transplanted human cells, which confounds conclusions pertaining to transplant-mediated behavioral improvement. To overcome these shortfalls, we have developed a novel TBI xenotransplantation model that utilizes immunodeficient athymic nude (ATN) rats as the host recipient for the post-TBI transplantation of human embryonic stem cell (hESC) derived NSCs and have evaluated cognition in these animals at long-term (>= 2 months) time points post-injury. We report that immunodeficient ATN rats demonstrate hippocampal-dependent spatial memory deficits (Novel Place, Morris Water Maze), but not non-spatial (Novel Object) or emotional/anxiety-related (Elevated Plus Maze, Conditioned Taste Aversion) deficits, at 2-3 months post-TBI, confirming that ATN rats recapitulate some of the cognitive deficits found in immunosufficient animal strains. Approximately 9-25% of transplanted hNSCs survived for at least 5 months post-transplantation and differentiated into mature neurons (NeuN, 18-38%), astrocytes (GFAP, 13-16%), and oligodendrocytes (Olig2, 11-13%). Furthermore, while this model of TBI (cortical impact) targets primarily cortex and the underlying hippocampus and generates a large lesion cavity, hNSC transplantation facilitated cognitive recovery without affecting either lesion volume or total spared cortical or hippocampal tissue volume. Instead, we have found an overall increase in host hippocampal neuron survival in hNSC transplanted animals and demonstrate that a correlation exists between hippocampal neuron survival and cognitive performance. Together, these findings support the use of immunodeficient rodents in models of TBI that involve the transplantation of human cells, and suggest that hNSC transplantation may be a viable, long-term therapy to restore cognition after brain injury. (C) 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).	[Haus, Daniel L.; Gold, Eric M.; Anderson, Aileen J.; Cummings, Brian J.] Univ Calif Irvine, Sue & Bill Gross Stem Cell Ctr, Irvine, CA 92697 USA; [Haus, Daniel L.; Gold, Eric M.; Anderson, Aileen J.; Cummings, Brian J.] Univ Calif Irvine, Anat & Neurobiol, Irvine, CA 92697 USA; [Anderson, Aileen J.; Cummings, Brian J.] Univ Calif Irvine, Phys & Med Rehabil, Irvine, CA 92697 USA; [Lopez-Velazquez, Luci; Cunningham, Kelly M.; Perez, Harvey; Anderson, Aileen J.; Cummings, Brian J.] Univ Calif Irvine, UCI Inst Memory Impairments & Neurol Disorders MI, Irvine, CA 92697 USA	Cummings, BJ (corresponding author), Univ Calif Irvine, Room 2026 Gross Hall,845 Hlth Sci Rd, Irvine, CA 92697 USA.	cummings@uci.edu	Cummings, Brian J/C-9180-2012	Cummings, Brian J/0000-0003-3628-5290	California Institute for Regenerative Medicine (CIRM)California Institute for Regenerative Medicine [TR2-01767, TG2-01152, TB1-01182]	The preceding studies were supported by grants from the California Institute for Regenerative Medicine (CIRM): Early Translational Award TR2-01767 awarded to BJC, Predoctoral Fellowship in Stem Cell Biology TG2-01152 awarded to DLH, and a Bridges Training Program Award TB1-01182 awarded to KMC and HP. The authors wish to thank the following individuals for their technical contributions to the manuscript: Diane Su and Rebecca Nishi for assistance with TBI and cell transplantation surgical procedures, and Janae Bustos, George Lacuesta (TB1-01182), and Daniel Ho for assistance with animal behavioral testing and analysis. The authors would also like to thank Dr. Stephen Scheff (University of Kentucky) for training on CCI TBI models and surgical procedures.	Acharya MM, 2009, P NATL ACAD SCI USA, V106, P19150, DOI 10.1073/pnas.0909293106; Aertker B.M., 2015, EXP NEUROL; Al Nimer F, 2004, NEUROREPORT, V15, P1871, DOI 10.1097/00001756-200408260-00007; Anderson AJ, 2011, REGEN MED, V6, P367, DOI [10.2217/RME.11.22, 10.2217/rme.11.22]; Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; Bakshi A, 2006, EUR J NEUROSCI, V23, P2119, DOI 10.1111/j.1460-9568.2006.04743.x; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Brunson KL, 2001, P NATL ACAD SCI USA, V98, P8856, DOI 10.1073/pnas.151224898; BRUTKOWSKI S, 1965, PHYSIOL REV, V45, P721; Chen JL, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00382; Chen TX, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00275; CONRAD CD, 1993, J NEUROSCI, V13, P2582; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Cummings BJ, 2005, P NATL ACAD SCI USA, V102, P14069, DOI 10.1073/pnas.0507063102; Ebert AD, 2008, EXP NEUROL, V209, P213, DOI 10.1016/j.expneurol.2007.09.022; Gao JL, 2006, EXP NEUROL, V201, P281, DOI 10.1016/j.expneurol.2006.04.039; Gold EM, 2013, REGEN MED, V8, P483, DOI 10.2217/rme.13.41; Gowing G, 2014, NEUROREPORT, V25, P367, DOI 10.1097/WNR.0000000000000092; Griesbach GS, 2015, J NEUROTRAUM, V32, P704, DOI 10.1089/neu.2014.3754; Hagan M, 2003, NEUROSCI LETT, V351, P149, DOI 10.1016/j.neulet.2003.07.021; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hartman RE, 2005, BRAIN RES, V1043, P48, DOI 10.1016/j.brainres.2005.02.030; Haus DL, 2014, STEM CELL RES, V13, P214, DOI 10.1016/j.scr.2014.06.008; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hooshmand MJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005871; Huang L, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt519; KIRINO T, 1982, BRAIN RES, V239, P57, DOI 10.1016/0006-8993(82)90833-2; KOLB B, 1984, BRAIN RES REV, V8, P65, DOI 10.1016/0165-0173(84)90018-3; Levy M., 2015, BRAIN RES; Li GM, 2013, NEUROL SCI, V34, P963, DOI 10.1007/s10072-012-1173-z; Li Y, 2009, NEUROSCI LETT, V456, P120, DOI 10.1016/j.neulet.2008.03.096; Lindvall O, 2012, CELL STEM CELL, V10, P660, DOI [10.1016/j.stem.2012.04.004, 10.1016/j.stem.2012.01.009]; Longhi L, 2004, J NEUROTRAUM, V21, P1723, DOI 10.1089/0897715042664876; Lopez-Velazquez L, 2007, NEUROSCIENCE, V144, P808, DOI 10.1016/j.neuroscience.2006.09.063; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Lu J, 2012, BRAIN INJURY, V26, P1523, DOI 10.3109/02699052.2012.722257; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; Mattis VB, 2014, EXP NEUROL, V254, P90, DOI 10.1016/j.expneurol.2014.01.007; McCullers D, 2002, NEUROSCIENCE, V109, P219, DOI 10.1016/S0306-4522(01)00477-8; Milman A, 2008, EUR NEUROPSYCHOPHARM, V18, P181, DOI 10.1016/j.euroneuro.2007.05.007; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Muir JK, 1999, J NEUROTRAUM, V16, P403, DOI 10.1089/neu.1999.16.403; Mumby DG, 2002, LEARN MEMORY, V9, P49, DOI 10.1101/lm.41302; Myczek K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106009; Nakamura M, 2013, CELL RES, V23, P70, DOI 10.1038/cr.2012.171; Nasonkin I, 2009, STEM CELLS, V27, P2414, DOI 10.1002/stem.177; Nudo RJ, 1999, CURR OPIN NEUROBIOL, V9, P740, DOI 10.1016/S0959-4388(99)00027-6; Okano H, 2003, SEMIN CELL DEV BIOL, V14, P191, DOI 10.1016/S1084-9521(03)00011-9; Philips MF, 2001, J NEUROSURG, V94, P765, DOI 10.3171/jns.2001.94.5.0765; Piltti KM, 2013, STEM CELL TRANSL MED, V2, P961, DOI 10.5966/sctm.2013-0064; Piltti KM, 2013, STEM CELL TRANSL MED, V2, P204, DOI 10.5966/sctm.2012-0110; Poltavtseva RA, 2012, B EXP BIOL MED+, V153, P586, DOI 10.1007/s10517-012-1772-y; Redmond DE, 2007, P NATL ACAD SCI USA, V104, P12175, DOI 10.1073/pnas.0704091104; Rekha J, 2009, BEHAV NEUROSCI, V123, P1197, DOI 10.1037/a0017655; Riess P, 2002, NEUROSURGERY, V51, P1043, DOI 10.1097/00006123-200210000-00035; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Rosser A, 2014, MOVEMENT DISORD, V29, P1446, DOI 10.1002/mds.26026; Salazar DL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012272; Scheff SW, 2005, J NEUROTRAUM, V22, P719, DOI 10.1089/neu.2005.22.719; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Schouten JW, 2004, J NEUROTRAUM, V21, P1501, DOI 10.1089/neu.2004.21.1501; Seminatore C, 2010, STROKE, V41, P153, DOI 10.1161/STROKEAHA.109.563015; Shear DA, 2011, RESTOR NEUROL NEUROS, V29, P215, DOI 10.3233/RNN-2011-0593; Shultz SR, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-26; Shultz SR, 2012, J NEUROTRAUM, V29, P281, DOI 10.1089/neu.2011.2123; Silva AF, 2013, BRAIN RES, V1491, P23, DOI 10.1016/j.brainres.2012.10.063; Skardelly M, 2011, J NEUROTRAUM, V28, P401, DOI 10.1089/neu.2010.1526; Snyder EY, 2004, J NEUROSCI RES, V76, P157, DOI 10.1002/jnr.20033; Sontag CJ, 2014, STEM CELL REP, V2, P620, DOI 10.1016/j.stemcr.2014.03.005; Tang HL, 2013, CELL REPROGRAM, V15, P435, DOI 10.1089/cell.2012.0081; Teng YD, 2011, CURR NEUROPHARMACOL, V9, P574, DOI 10.2174/157015911798376299; Tetzlaff W, 2011, J NEUROTRAUM, V28, P1611, DOI 10.1089/neu.2009.1177; Thomsen GM, 2014, EXP NEUROL, V262, P127, DOI 10.1016/j.expneurol.2014.02.021; Tsai YC, 2015, STEM CELLS, V33, P2537, DOI 10.1002/stem.2032; Vaysse L, 2015, BIOMATERIALS, V58, P46, DOI 10.1016/j.biomaterials.2015.04.019; VOLPE BT, 1992, BEHAV NEUROSCI, V106, P457, DOI 10.1037/0735-7044.106.3.457; Vorhees CV, 2006, NAT PROTOC, V1, P848, DOI 10.1038/nprot.2006.116; Vorhees CV, 2014, ILAR J, V55, P310, DOI 10.1093/ilar/ilu013; Walker PA, 2009, DIS MODEL MECH, V2, P23, DOI 10.1242/dmm.001198; Wang EY, 2012, J NEUROTRAUM, V29, P295, DOI 10.1089/neu.2011.2043; Wang QJ, 2016, ADV EXP MED BIOL, V854, P543, DOI 10.1007/978-3-319-17121-0_72; Watson DJ, 2003, J NEUROPATH EXP NEUR, V62, P368, DOI 10.1093/jnen/62.4.368; Wennersten A, 2004, J NEUROSURG, V100, P88, DOI 10.3171/jns.2004.100.1.0088; Wennersten A, 2006, EXP NEUROL, V199, P339, DOI 10.1016/j.expneurol.2005.12.035; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Xiong Y, 2009, EXPERT OPIN EMERG DR, V14, P67, DOI [10.1517/14728210902769601, 10.1517/14728210902769601 ]; Xu LY, 2006, TRANSPLANTATION, V82, P865, DOI 10.1097/01.tp.0000235532.00920.7a; Xu LY, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0087-0; Yamasaki TR, 2007, J NEUROSCI, V27, P11925, DOI 10.1523/JNEUROSCI.1627-07.2007; Zhang C, 2005, J NEUROTRAUM, V22, P1456, DOI 10.1089/neu.2005.22.1456; Zhang ZG, 2009, LANCET NEUROL, V8, P491, DOI 10.1016/S1474-4422(09)70061-4	92	41	43	1	16	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JUL	2016	281						1	16		10.1016/j.expneurol.2016.04.008			16	Neurosciences	Neurosciences & Neurology	DN4RO	WOS:000377055100001	27079998	Other Gold			2021-06-18	
J	Li, HX; Sun, J; Wang, FY; Ding, GQ; Chen, WQ; Fang, RC; Yao, Y; Pang, MQ; Lu, ZQ; Liu, JM				Li, Haixiao; Sun, Jing; Wang, Fangyan; Ding, Guoqiang; Chen, Wenqian; Fang, Renchi; Yao, Ye; Pang, Mengqi; Lu, Zhong-Qiu; Liu, Jiaming			Sodium butyrate exerts neuroprotective effects by restoring the blood-brain barrier in traumatic brain injury mice	BRAIN RESEARCH			English	Article						Traumatic brain injury; Blood-brain barrier; Sodium butyrate; Neuronal degeneration; Brain oedema	CLOSED-HEAD INJURY; PARKINSONS-DISEASE; RAT MODEL; EDEMA; PERMEABILITY; DISRUPTION; INHIBITION; INTEGRITY; DYSFUNCTION; LEUKOCYTE	Sodium butyrate (SB) has been widely used to treat cerebral diseases. The aim of the present study is to examine the neuroprotective effects of SB on early TBI in mice and to explore the underlying mechanisms of these effects. TBI was induced using a modified weight-drop method. Neurological deficits were evaluated according to the neurological severity score (NSS), brain oedema was measured by brain water content, and blood-brain barrier (BBB) permeability was evaluated by Evans blue (EB) dye extravasation. Neuronal injury was assessed by hematoxylin and eosin (H&E) staining and Fluoro-jade C staining. The expression of tight junction-associated proteins, such as occludin and zonula occludens-1 (ZO-1), was analysed by western blotting and immunofluorescence. Our results showed that mice subjected to TBI exhibited worsened NSS, brain oedema, neuronal damage and BBB permeability. However, these were all attenuated by SB. Moreover, SB reversed the decrease in occludin and ZO-1 expression induced by TBI. These findings suggest that SB might attenuate neurological deficits, brain oedema, neuronal change and BBB damage, as well as increase occludin and ZO-1 expression in the brain to protect against TBI. The protective effect of SB may be correlated with restoring the BBB following its impairment. (C) 2016 Elsevier B.V. All rights reserved.	[Li, Haixiao; Lu, Zhong-Qiu] Wenzhou Med Univ, Dept Emergency Med, Affiliated Hosp 1, Wenzhou 325000, Zhejiang, Peoples R China; [Sun, Jing] Wenzhou Med Univ, Dept Neurol, Affiliated Hosp 2, 109 Coll West Rd, Wenzhou 325027, Zhejiang, Peoples R China; [Wang, Fangyan] Wenzhou Med Univ, Dept Pathophysiol, 1210 Univ Town, Wenzhou 325035, Zhejiang, Peoples R China; [Ding, Guoqiang] Wenzhou Med Univ, Dept Stomatol, Affiliated Yiwu Hosp, Yiwu 322000, Zhejiang, Peoples R China; [Chen, Wenqian; Fang, Renchi; Yao, Ye; Pang, Mengqi; Lu, Zhong-Qiu; Liu, Jiaming] Wenzhou Med Univ, Sch Environm Sci & Publ Hlth, 1210 Univ Town, Wenzhou 325035, Zhejiang, Peoples R China	Lu, ZQ (corresponding author), Wenzhou Med Univ, Dept Emergency Med, Affiliated Hosp 1, Wenzhou 325000, Zhejiang, Peoples R China.; Liu, JM (corresponding author), Wenzhou Med Univ, Sch Environm Sci & Publ Hlth, 1210 Univ Town, Wenzhou 325035, Zhejiang, Peoples R China.			LU, Zhongqiu/0000-0002-0569-4182	Zhejiang Science and Technology Development Funds [2015C37010]; Zhejiang Province Medical and Health Science and Technology Funds [2016136369]	The research was supported by Zhejiang Science and Technology Development Funds (2015C37010), Zhejiang Province Medical and Health Science and Technology Funds (2016136369).	Al-Asmakh M, 2015, TISSUE BARRIERS, V3, DOI 10.1080/21688370.2015.1039691; Alvarez JI, 2011, SCIENCE, V334, P1727, DOI 10.1126/science.1206936; Alves JL, 2014, J NEUROSCI RES, V92, P141, DOI 10.1002/jnr.23300; Bartels AL, 2008, J NEURAL TRANSM, V115, P1001, DOI 10.1007/s00702-008-0030-y; Blixt J, 2015, BRAIN RES, V1611, P18, DOI 10.1016/j.brainres.2015.03.004; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; Dash PK, 2009, NEUROSCIENCE, V163, P1, DOI 10.1016/j.neuroscience.2009.06.028; Ding K, 2015, J SURG RES, V194, P239, DOI 10.1016/j.jss.2014.09.026; Fabene PF, 2013, MOL IMMUNOL, V55, P100, DOI 10.1016/j.molimm.2012.12.009; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Friedman A, 2015, SEMIN CELL DEV BIOL, V38, P1, DOI 10.1016/j.semcdb.2015.03.006; Griseri P, 2003, GUT, V52, P1154, DOI 10.1136/gut.52.8.1154; Harrison JL, 2014, EXP BRAIN RES, V232, P2709, DOI 10.1007/s00221-014-3948-3; Higashida T, 2011, J NEUROSURG, V114, P92, DOI 10.3171/2010.6.JNS10207; Hurst RD, 1999, NEUROCHEM INT, V35, P261, DOI 10.1016/S0197-0186(99)00069-8; Istvan Pregun, 2007, Orvosi Hetilap, V148, P923, DOI 10.1556/OH.2007.27995; Janigro D, 2012, EPILEPSIA, V53, P26, DOI 10.1111/j.1528-1167.2012.03472.x; Katz PS, 2015, J NEUROTRAUM, V32, P297, DOI 10.1089/neu.2014.3508; Kotunia A., 2004, J PHYSIOL PHARMACOL, V55, P559; Lenzlinger PM, 2002, J NEUROIMMUNOL, V122, P167, DOI 10.1016/S0165-5728(01)00466-0; Li SS, 2015, NEUROPSYCH DIS TREAT, V11, P1573, DOI 10.2147/NDT.S65816; Li W, 2008, NEUROSCIENCE, V151, P1198, DOI 10.1016/j.neuroscience.2007.11.020; Lu M, 2012, CLIN EXP PHARMACOL P, V39, P577, DOI 10.1111/j.1440-1681.2011.05650.x; Lucke-Wold BP, 2015, MOL NEUROBIOL, V52, P1119, DOI 10.1007/s12035-014-8902-7; Luh C, 2010, J NEUROCHEM, V112, P1015, DOI 10.1111/j.1471-4159.2009.06514.x; Lundblad C, 2004, J NEUROTRAUM, V21, P741, DOI 10.1089/0897715041269614; Ma X, 2012, J ANIM SCI, V90, P266, DOI 10.2527/jas.50965; Mark KS, 2002, AM J PHYSIOL-HEART C, V282, pH1485, DOI 10.1152/ajpheart.00645.2001; Moretti R, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00040; Mustafa AG, 2013, NEUROSCIENCES, V18, P222; Obermeier B, 2013, NAT MED, V19, P1584, DOI 10.1038/nm.3407; QUARLESS SA, 1987, MOL BRAIN RES, V2, P235, DOI 10.1016/0169-328X(87)90030-1; Ragaisis Vytautas, 2002, Medicina (Kaunas), V38, P243; Schmued LC, 2005, BRAIN RES, V1035, P24, DOI 10.1016/j.brainres.2004.11.054; Schwarzmaier SM, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00358; Shi H, 2015, CNS NEUROSCI THER, V21, P374, DOI 10.1111/cns.12366; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Si DW, 2014, EXP THER MED, V8, P1010, DOI 10.3892/etm.2014.1840; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Sun J, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/395895; Thal SC, 2014, ARCH MED RES, V45, P698, DOI 10.1016/j.arcmed.2014.11.006; Tomkins Oren, 2011, Cardiovasc Psychiatry Neurol, V2011, P765923, DOI 10.1155/2011/765923; Umeda K, 2006, CELL, V126, P741, DOI 10.1016/j.cell.2006.06.043; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Varela RB, 2015, J PSYCHIATR RES, V61, P114, DOI 10.1016/j.jpsychires.2014.11.003; Wang HB, 2012, DIGEST DIS SCI, V57, P3126, DOI 10.1007/s10620-012-2259-4; Wang ZF, 2011, J CEREBR BLOOD F MET, V31, P52, DOI 10.1038/jcbfm.2010.195; Wen JF, 2014, EXP THER MED, V8, P881, DOI 10.3892/etm.2014.1818; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yeoh S, 2013, ANN BIOMED ENG, V41, P2206, DOI 10.1007/s10439-013-0805-7; Yu Qiong, 2011, Front Biosci (Elite Ed), V3, P978; Zhao YZ, 2015, NEURAL REGEN RES, V10, P1076, DOI 10.4103/1673-5374.160097	54	41	42	1	13	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JUL 1	2016	1642						70	78		10.1016/j.brainres.2016.03.031			9	Neurosciences	Neurosciences & Neurology	DP7EI	WOS:000378661600008	27017959				2021-06-18	
J	Bonsack, F; Alleyne, CH; Sukumari-Ramesh, S				Bonsack, Frederick; Alleyne, Cargill H., Jr.; Sukumari-Ramesh, Sangeetha			Augmented expression of TSPO after intracerebral hemorrhage: a role in inflammation?	JOURNAL OF NEUROINFLAMMATION			English	Article						Microglial activation; ICH; TSPO	PROTEIN 18 KDA; PERIPHERAL BENZODIAZEPINE-RECEPTOR; DIAZEPAM-BINDING INHIBITOR; INTERDISCIPLINARY-WORKING-GROUP; ASSOCIATION-STROKE-COUNCIL; AMERICAN-HEART-ASSOCIATION; PRESSURE-RESEARCH-COUNCIL; TRAUMATIC BRAIN-INJURY; QUALITY-OF-CARE; TRANSLOCATOR PROTEIN	Background: Intracerebral hemorrhage (ICH) is a potentially fatal stroke subtype accounting for 10-15 % of all strokes. Despite neurosurgical intervention and supportive care, the 30-day mortality rate remains 30-50 % with ICH survivors frequently displaying neurological impairment and requiring long-term assisted care. Although accumulating evidence demonstrates the role of neuroinflammation in secondary brain injury and delayed fatality after ICH, the molecular regulators of neuroinflammation remain poorly defined after ICH. Methods: In the present study, ICH was induced in CD1 male mice by collagenase injection method and given the emerging role of TSPO (18-kDa translocator protein) in neuroinflammation, immunofluorescence staining of brain sections was performed to characterize the temporal expression pattern and cellular and subcellular localization of TSPO after ICH. Further, both genetic and pharmacological studies were employed to assess the functional role of TSPO in neuroinflammation. Results: The expression of TSPO was found to be increased in the peri-hematomal brain region 1 to 7 days post-injury, peaking on day 3 to day 5 in comparison to sham. Further, the TSPO expression was mostly observed in microglia/macrophages, the inflammatory cells of the central nervous system, suggesting an unexplored role of TSPO in neuroinflammatory responses after ICH. Further, the subcellular localization studies revealed prominent perinuclear expression of TSPO after ICH. Moreover, both genetic and pharmacological studies revealed a regulatory role of TSPO in the release of pro-inflammatory cytokines in a macrophage cell line, RAW 264.7. Conclusions: Altogether, the data suggest that TSPO induction after ICH could be an intrinsic mechanism to prevent an exacerbated inflammatory response and raise the possibility of targeting TSPO for the attenuation of secondary brain injury after ICH.	[Bonsack, Frederick; Alleyne, Cargill H., Jr.; Sukumari-Ramesh, Sangeetha] Augusta Univ, Med Coll Georgia, Dept Neurosurg, 1120 15th St,CA1010, Augusta, GA 30912 USA	Sukumari-Ramesh, S (corresponding author), Augusta Univ, Med Coll Georgia, Dept Neurosurg, 1120 15th St,CA1010, Augusta, GA 30912 USA.	sramesh@gru.edu			American Heart AssociationAmerican Heart Association [14SDG18730034]	This work was supported by a grant from the American Heart Association (14SDG18730034) to SSR. None of the funding bodies had a role in the study design, data collection, data analysis, data interpretation, or writing of the manuscript.	Aguilar MI, 2010, SEMIN NEUROL, V30, P555, DOI 10.1055/s-0030-1268865; ANHOLT RRH, 1986, J BIOL CHEM, V261, P576; Aronowski J, 2005, NEUROL RES, V27, P268, DOI 10.1179/016164105X25225; Aronowski J, 2011, STROKE, V42, P1781, DOI 10.1161/STROKEAHA.110.596718; Babu R, 2012, NEUROSURG FOCUS, V32, DOI 10.3171/2012.1.FOCUS11366; Banati RB, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6452; BRAESTRUP C, 1977, NATURE, V269, P702, DOI 10.1038/269702a0; Broderick J, 2007, CIRCULATION, V116, pE391, DOI 10.1161/CIRCULATIONAHA.107.183689; Broderick J, 2007, STROKE, V38, P2001, DOI 10.1161/STROKEAHA.107.183689; Broderick JP, 1999, STROKE, V30, P905, DOI 10.1161/01.STR.30.4.905; Carmichael ST, 2008, J CEREBR BLOOD F MET, V28, P1860, DOI 10.1038/jcbfm.2008.77; Casellas P, 2002, NEUROCHEM INT, V40, P475, DOI 10.1016/S0197-0186(01)00118-8; CHANG YJ, 1992, DNA CELL BIOL, V11, P471, DOI 10.1089/dna.1992.11.471; Chen MK, 2008, PHARMACOL THERAPEUT, V118, P1, DOI 10.1016/j.pharmthera.2007.12.004; Cosenza-Nashat M, 2009, NEUROPATH APPL NEURO, V35, P306, DOI 10.1111/j.1365-2990.2008.01006.x; COSTA E, 1994, J STEROID BIOCHEM, V49, P385, DOI 10.1016/0960-0760(94)90284-4; DIRINGER MN, 1993, CRIT CARE MED, V21, P1591, DOI 10.1097/00003246-199310000-00032; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Emsley HCA, 2002, J CEREBR BLOOD F MET, V22, P1399, DOI 10.1097/01.WCB.0000037880.62590.28; FERRERO P, 1986, P NATL ACAD SCI USA, V83, P827, DOI 10.1073/pnas.83.3.827; Ferzaz B, 2002, J PHARMACOL EXP THER, V301, P1067, DOI 10.1124/jpet.301.3.1067; GANTER S, 1992, J NEUROSCI RES, V33, P218, DOI 10.1002/jnr.490330205; GARNIER M, 1994, MOL PHARMACOL, V45, P201; Gomez-Nicola D, 2013, J NEUROSCI, V33, P2481, DOI 10.1523/JNEUROSCI.4440-12.2013; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Hirsch T, 1998, EXP CELL RES, V241, P426, DOI 10.1006/excr.1998.4084; Hong SH, 2006, J NEUROSCI RES, V83, P1293, DOI 10.1002/jnr.20829; Karlstetter M, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-3; Kloss CUA, 1997, J NEUROSCI RES, V49, P248; Kobayashi K, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.54; KRUEGER KE, 1990, J BIOL CHEM, V265, P15015; Kuhlmann AC, 2000, J NEUROCHEM, V74, P1694, DOI 10.1046/j.1471-4159.2000.0741694.x; Lacapere JJ, 2003, STEROIDS, V68, P569, DOI 10.1016/S0039-128X(03)00101-6; Laird MD, 2010, J NEUROCHEM, V113, P637, DOI 10.1111/j.1471-4159.2010.06630.x; LETARTE PB, 1993, J NEUROSURG, V79, P252, DOI 10.3171/jns.1993.79.2.0252; Liao B, 2012, EXP NEUROL, V237, P147, DOI 10.1016/j.expneurol.2012.06.011; Lin S, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-46; Liu GJ, 2014, BRAIN PATHOL, V24, P631, DOI 10.1111/bpa.12196; Liu J, 2006, J BIOL CHEM, V281, P38879, DOI 10.1074/jbc.M608820200; Ma L, 2016, BRAIN RES BULL, V121, P192, DOI 10.1016/j.brainresbull.2016.02.001; Maeda J, 2007, BRAIN RES, V1157, P100, DOI 10.1016/j.brainres.2007.04.054; Mander PK, 2006, J IMMUNOL, V176, P1046, DOI 10.4049/jimmunol.176.2.1046; Moller T, 2000, J NEUROCHEM, V75, P1539, DOI 10.1046/j.1471-4159.2000.0751539.x; Morohaku K, 2014, ENDOCRINOLOGY, V155, P89, DOI 10.1210/en.2013-1556; MUKHIN AG, 1989, P NATL ACAD SCI USA, V86, P9813, DOI 10.1073/pnas.86.24.9813; Nilsson OG, 2002, J NEUROSURG, V97, P531, DOI 10.3171/jns.2002.97.3.0531; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Nothdurfter C, 2012, EUR ARCH PSY CLIN N, V262, pS107, DOI 10.1007/s00406-012-0352-5; O'Donnell MJ, 2010, LANCET, V376, P112, DOI 10.1016/S0140-6736(10)60834-3; Papadopoulos V, 2006, TRENDS PHARMACOL SCI, V27, P402, DOI 10.1016/j.tips.2006.06.005; PAROLA AL, 1991, J BIOL CHEM, V266, P14082; Politis M, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00096; Ponomarev ED, 2007, J NEUROSCI, V27, P10714, DOI 10.1523/JNEUROSCI.1922-07.2007; Qureshi AI, 2001, CRIT CARE MED, V29, P152, DOI 10.1097/00003246-200101000-00030; Qureshi AI, 2001, NEW ENGL J MED, V344, P1450, DOI 10.1056/NEJM200105103441907; Ribo M, 2006, CURR NEUROL NEUROSCI, V6, P17, DOI 10.1007/s11910-996-0004-0; RIOND J, 1991, EUR J BIOCHEM, V195, P305, DOI 10.1111/j.1432-1033.1991.tb15707.x; ROMEO E, 1993, J PHARMACOL EXP THER, V267, P462; Rupprecht R, 2010, NAT REV DRUG DISCOV, V9, P971, DOI 10.1038/nrd3295; Ryu JK, 2005, NEUROBIOL DIS, V20, P550, DOI 10.1016/j.nbd.2005.04.010; Scholz R, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0431-4; SPRENGEL R, 1989, J BIOL CHEM, V264, P20415; Sukumari-Ramesh S, 2016, J MOL NEUROSCI, V58, P525, DOI 10.1007/s12031-016-0722-y; Sukumari-Ramesh S, 2016, TRANSL STROKE RES, V7, P141, DOI 10.1007/s12975-015-0421-y; Sukumari-Ramesh S, 2012, J NEUROTRAUM, V29, P2798, DOI 10.1089/neu.2011.2243; Sukumari-Ramesh S, 2012, TRANSL STROKE RES, V3, pS80, DOI 10.1007/s12975-012-0165-x; Tu LN, 2014, J BIOL CHEM, V289, P27444, DOI 10.1074/jbc.M114.578286; van Asch CJJ, 2010, LANCET NEUROL, V9, P167, DOI 10.1016/S1474-4422(09)70340-0; van Rossum D, 2004, METAB BRAIN DIS, V19, P393, DOI 10.1023/B:MEBR.0000043984.73063.d8; Veenman L, 2002, J NEUROCHEM, V80, P917, DOI 10.1046/j.0022-3042.2002.00769.x; Veenman L, 2007, CURR PHARM DESIGN, V13, P2385; Veiga S, 2005, J NEUROSCI RES, V80, P129, DOI 10.1002/jnr.20430; Veiga S, 2007, GLIA, V55, P1426, DOI 10.1002/glia.20558; Venneti S, 2013, GLIA, V61, P10, DOI 10.1002/glia.22357; Wang J, 2003, ANN NEUROL, V54, P655, DOI 10.1002/ana.10750; Wang J, 2007, J CEREBR BLOOD F MET, V27, P894, DOI 10.1038/sj.jcbfm.9600403; Wang JA, 2010, PROG NEUROBIOL, V92, P463, DOI 10.1016/j.pneurobio.2010.08.001; Wang MH, 2014, J NEUROSCI, V34, P3793, DOI 10.1523/JNEUROSCI.3153-13.2014; Xi GH, 2006, LANCET NEUROL, V5, P53, DOI 10.1016/S1474-4422(05)70283-0; Yanase H, 2002, ARCH HISTOL CYTOL, V65, P27, DOI 10.1679/aohc.65.27; Zhang D, 2009, TOXICOL APPL PHARM, V238, P64, DOI 10.1016/j.taap.2009.04.015; Zhao Yan-Yin, 2011, Neuron Glia Biol, V7, P187, DOI 10.1017/S1740925X12000129; Zurcher NR, 2015, NEUROIMAGE-CLIN, V7, P409, DOI 10.1016/j.nicl.2015.01.009	83	41	42	1	4	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	JUN 17	2016	13								151	10.1186/s12974-016-0619-2			14	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	DQ0BF	WOS:000378861600001	27315802	DOAJ Gold, Green Published			2021-06-18	
J	Debski, KJ; Pitkanen, A; Puhakka, N; Bot, AM; Khurana, I; Harikrishnan, KN; Ziemann, M; Kaspi, A; El-Osta, A; Lukasiuk, K; Kobow, K				Debski, Konrad J.; Pitkanen, Asla; Puhakka, Noora; Bot, Anna M.; Khurana, Ishant; Harikrishnan, K. N.; Ziemann, Mark; Kaspi, Antony; El-Osta, Assam; Lukasiuk, Katarzyna; Kobow, Katja			Etiology matters - Genomic DNA Methylation Patterns in Three Rat Models of Acquired Epilepsy	SCIENTIFIC REPORTS			English	Article							TEMPORAL-LOBE EPILEPSY; TRAUMATIC BRAIN-INJURY; DIFFERENTIAL EXPRESSION ANALYSIS; EPIGENETIC MECHANISMS; PROMOTER METHYLATION; STATUS EPILEPTICUS; GENE LISTS; EPILEPTOGENESIS; THERAPIES; PROFILES	This study tested the hypothesis that acquired epileptogenesis is accompanied by DNA methylation changes independent of etiology. We investigated DNA methylation and gene expression in the hippocampal CA3/dentate gyrus fields at 3 months following epileptogenic injury in three experimental models of epilepsy: focal amygdala stimulation, systemic pilocarpine injection, or lateral fluid-percussion induced traumatic brain injury (TBI) in rats. In the models studies, DNA methylation and gene expression profiles distinguished controls from injured animals. We observed consistent increased methylation in gene bodies and hypomethylation at non-genic regions. We did not find a common methylation signature in all three different models and few regions common to any two models. Our data provide evidence that genome-wide alteration of DNA methylation signatures is a general pathomechanism associated with epileptogenesis and epilepsy in experimental animal models, but the broad pathophysiological differences between models (i.e. pilocarpine, amygdala stimulation, and post-TBI) are reflected in distinct etiology-dependent DNA methylation patterns.	[Debski, Konrad J.; Bot, Anna M.; Lukasiuk, Katarzyna] Polish Acad Sci, M Nencki Inst Expt Biol, Dept Mol & Cellular Neurobiol, Lab Epileptogenesis, Warsaw, Poland; [Pitkanen, Asla; Puhakka, Noora] Univ Eastern Finland, Epilepsy Res Lab, AI Virtanen Inst Mol Sci, POB 1627, FIN-70211 Kuopio, Finland; [Khurana, Ishant; Harikrishnan, K. N.; Ziemann, Mark; Kaspi, Antony; El-Osta, Assam] Alfred Med Res & Educ Precinct, Baker IDI Heart & Diabet Inst, Epigenet Human Hlth & Dis, Melbourne, Vic, Australia; [Kobow, Katja] Univ Hosp Erlangen, Dept Neuropathol, Schwabachanlage 6, D-91054 Erlangen, Germany	Kobow, K (corresponding author), Univ Hosp Erlangen, Dept Neuropathol, Schwabachanlage 6, D-91054 Erlangen, Germany.	katja.kobow@uk-erlangen.de	Ziemann, Mark Daniel/AAE-8466-2019; Lukasiuk, Katarzyna/F-4636-2010	El-Osta, Assam/0000-0003-2969-9137; Ziemann, Mark/0000-0002-7688-6974; Lukasiuk, Katarzyna/0000-0002-1582-0920; Bot, Anna/0000-0003-1811-3647; Debski, Konrad/0000-0001-5949-9211; Khurana, Ishant/0000-0001-9050-2749; El-Osta, Assam/0000-0001-7968-7375; Kaspi, Antony/0000-0001-6576-5862	Polish Ministry of Science and Higher EducationMinistry of Science and Higher Education, Poland [888/N-ESF-EuroEPINOMICS/10/2011/0]; National Science Centre, PolandNational Science Centre, Poland [2014/13/N/NZ2/00587]; Academy of Finland ESF-EuroEPINOMICS/grantAcademy of Finland; University of Eastern Finland Spearhead Funding; German Research Foundation (DFG) within the EUROCORES Programme EuroEPINOMICS/EpiGENet of the European Science Foundation [BL 421/3-1]	This work was supported by Polish Ministry of Science and Higher Education grant 888/N-ESF-EuroEPINOMICS/10/2011/0 (AB, KD, KL); the National Science Centre, Poland grant 2014/13/N/NZ2/00587 (KD); the Academy of Finland ESF-EuroEPINOMICS/2012 grant (AP), the University of Eastern Finland Spearhead Funding (AP); and the German Research Foundation (DFG, grant BL 421/3-1) within the EUROCORES Programme EuroEPINOMICS/EpiGENet of the European Science Foundation (KK).	Belhedi N, 2014, EPILEPSY RES, V108, P144, DOI 10.1016/j.eplepsyres.2013.10.007; Curia G, 2008, J NEUROSCI METH, V172, P143, DOI 10.1016/j.jneumeth.2008.04.019; Galanopoulou AS, 2012, EPILEPSIA, V53, P571, DOI 10.1111/j.1528-1167.2011.03391.x; Golzenleuchter M, 2015, EPIGENETICS-US, V10, P200, DOI 10.1080/15592294.2015.1006493; Guzik-Kornacka A, 2011, ACTA NEUROBIOL EXP, V71, P193; Hayward NMEA, 2010, J NEUROTRAUM, V27, P2203, DOI 10.1089/neu.2010.1448; Karolchik D, 2004, NUCLEIC ACIDS RES, V32, pD493, DOI 10.1093/nar/gkh103; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kobow K, 2014, PROG BRAIN RES, V213, P279, DOI 10.1016/B978-0-444-63326-2.00014-4; Kobow K, 2013, ACTA NEUROPATHOL, V126, P741, DOI 10.1007/s00401-013-1168-8; Kobow K, 2013, EPILEPSIA, V54, P41, DOI 10.1111/epi.12183; Kobow K, 2009, J NEUROPATH EXP NEUR, V68, P356, DOI 10.1097/NEN.0b013e31819ba737; Kolde Raivo, 2015, F1000Res, V4, P574, DOI 10.12688/f1000research.6925.1; Krzywinski M, 2009, GENOME RES, V19, P1639, DOI 10.1101/gr.092759.109; Laxer KD, 2014, EPILEPSY BEHAV, V37, P59, DOI 10.1016/j.yebeh.2014.05.031; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Lim ASP, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004792; Lister R, 2009, NATURE, V462, P315, DOI 10.1038/nature08514; Loscher W, 2013, NAT REV DRUG DISCOV, V12, P757, DOI 10.1038/nrd4126; Lukasiuk K, 2006, PROG BRAIN RES, V158, P223, DOI 10.1016/S0079-6123(06)58011-2; Machnes ZM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076299; Malousi A, 2012, MOL GENET GENOMICS, V287, P631, DOI 10.1007/s00438-012-0703-y; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Miller-Delaney SFC, 2015, BRAIN, V138, P616, DOI 10.1093/brain/awu373; Miller-Delaney SFC, 2012, J NEUROSCI, V32, P1577, DOI 10.1523/JNEUROSCI.5180-11.2012; Murphy GG, 2013, EPILEPSY CURR, V13, P26, DOI 10.5698/1535-7511-13.1.26; Ngugi AK, 2010, EPILEPSIA, V51, P883, DOI 10.1111/j.1528-1167.2009.02481.x; Nissinen J, 2000, EPILEPSY RES, V38, P177, DOI 10.1016/S0920-1211(99)00088-1; Oberdoerffer S, 2012, TRANSCR-AUSTIN, V3, P106, DOI 10.4161/trns.19816; Parrish RR, 2015, ANN CLIN TRANSL NEUR, V2, P401, DOI 10.1002/acn3.183; Parrish RR, 2013, NEUROSCIENCE, V248, P602, DOI 10.1016/j.neuroscience.2013.06.029; Paxinos G., 2007, RAT BRAIN STEREOTAXI, V6th ed.; Pirola L, 2011, GENOME RES, V21, P1601, DOI 10.1101/gr.116095.110; Pitkanen A, 2013, EPILEPSIA, V54, P35, DOI 10.1111/epi.12297; Pitkanen A, 2011, NEUROSCI LETT, V497, P163, DOI 10.1016/j.neulet.2011.02.033; Pitkanen A, 2011, LANCET NEUROL, V10, P173, DOI 10.1016/S1474-4422(10)70310-0; Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033; R Core Team, 2013, R LANG ENV STAT COMP; R Core Team, 2013, GPLOTS VAR R PROGR T; Reimand J, 2007, NUCLEIC ACIDS RES, V35, pW193, DOI 10.1093/nar/gkm226; Reimand J, 2011, NUCLEIC ACIDS RES, V39, pW307, DOI 10.1093/nar/gkr378; Robinson MD, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-3-r25; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Rodrigues GM, 2015, BEHAV BRAIN RES, V279, P123, DOI 10.1016/j.bbr.2014.11.023; Roopra A, 2012, EPILEPSIA, V53, P2, DOI 10.1111/epi.12030; Sati S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031621; Schor IE, 2013, EMBO J, V32, P2264, DOI 10.1038/emboj.2013.167; Shultz SR, 2013, EPILEPSIA, V54, P1240, DOI 10.1111/epi.12223; Simonato M, 2014, LANCET NEUROL, V13, P949, DOI 10.1016/S1474-4422(14)70076-6; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Urdinguio RG, 2009, LANCET NEUROL, V8, P1056, DOI 10.1016/S1474-4422(09)70262-5; Williams-Karnesky RL, 2013, J CLIN INVEST, V123, P3552, DOI 10.1172/JCI65636; Xiao YH, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0095875, 10.1371/journal.pone.0086344]; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137; Zhu Q, 2012, J MOL NEUROSCI, V46, P420, DOI 10.1007/s12031-011-9602-7	55	41	42	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	MAY 9	2016	6								25668	10.1038/srep25668			14	Multidisciplinary Sciences	Science & Technology - Other Topics	DL1WD	WOS:000375422600001	27157830	DOAJ Gold, Green Published			2021-06-18	
J	Liu, T; Zhao, DX; Cui, H; Chen, L; Bao, YH; Wang, Y; Jiang, JY				Liu, Tao; Zhao, Dong-xu; Cui, Hua; Chen, Lei; Bao, Ying-hui; Wang, Yong; Jiang, Ji-yao			Therapeutic hypothermia attenuates tissue damage and cytokine expression after traumatic brain injury by inhibiting necroptosis in the rat	SCIENTIFIC REPORTS			English	Article							TUMOR-NECROSIS-FACTOR; CELL-DEATH; PROGRAMMED NECROSIS; MEDIATES NECROPTOSIS; CORTICAL IMPACT; UP-REGULATION; IN-VIVO; PROTEIN; KINASE; APOPTOSIS	Necroptosis has been shown as an alternative form of cell death in many diseases, but the detailed mechanisms of the neuron loss after traumatic brain injury (TBI) in rodents remain unclear. To investigate whether necroptosis is induced after TBI and gets involved in the neuroprotecton of therapeutic hypothermia on the TBI, we observed the pathological and biochemical change of the necroptosis in the fluid percussion brain injury (FPI) model of the rats. We found that receptor-interacting protein (RIP) 1 and 3, and mixed lineage kinase domain-like protein (MLKL), the critical downstream mediators of necroptosis recently identified in vivo, as well as HMGB1 and the pro-inflammation cytokines TNF-alpha, IL-6 and IL-18, were increased at an early phase (6 h) in cortex after TBI. Posttraumatic hypothermia (33 degrees C) led to the decreases in the necroptosis regulators, inflammatory factors and brain tissue damage in rats compared with normothermia-treated TBI animals. Immunohistochemistry studies showed that posttraumatic hypothermia also decreased the necroptosis-associated proteins staining in injured cortex and hippocampal CA1. Therefore, we conclude that the RIP1/RIP3-MLKL-mediated necroptosis occurs after experimental TBI and therapeutic hypothermia may protect the injured central nervous system from tissue damage and the inflammatory responses by targeting the necroptosis signaling after TBI.	[Liu, Tao; Zhao, Dong-xu; Cui, Hua; Bao, Ying-hui; Wang, Yong; Jiang, Ji-yao] Shanghai Jiao Tong Univ, Sch Med, Dept Neurosurg, Ren Ji Hosp, Shanghai 200030, Peoples R China; [Chen, Lei] Peoples Hosp Pu Dong New Area, Dept Neurol Srgery, Shanghai, Peoples R China	Bao, YH (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Dept Neurosurg, Ren Ji Hosp, Shanghai 200030, Peoples R China.	bombbao@126.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81070988, 81171166]; Science and Technology Committee of ShanghaiShanghai Science & Technology Committee [0852 nm04900, 11 nm0503200, 11JC1408602]	This research was supported by grants from the National Natural Science Foundation of China (#81070988 and #81171166) and Science and Technology Committee of Shanghai (#0852 nm04900, #11 nm0503200, and #11JC1408602).	Andersen JL, 2013, MOL CELL, V49, P399, DOI 10.1016/j.molcel.2012.12.026; Bao YH, 2011, J NEUROTRAUM, V28, P35, DOI 10.1089/neu.2010.1383; Bonnet MC, 2011, IMMUNITY, V35, P572, DOI 10.1016/j.immuni.2011.08.014; Chan FKM, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008805; CLIFTON GL, 1992, J NEUROTRAUM, V9, pS487; Cohen-Yeshurun A, 2011, J CEREBR BLOOD F MET, V31, P1768, DOI 10.1038/jcbfm.2011.53; Corps KN, 2015, JAMA NEUROL, V72, P355, DOI 10.1001/jamaneurol.2014.3558; Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711; Dietrich WD, 2010, NEUROTHERAPEUTICS, V7, P43, DOI 10.1016/j.nurt.2009.10.015; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Dixon CE, 1998, J NEUROTRAUM, V15, P95, DOI 10.1089/neu.1998.15.95; Feng M, 2014, J STEROID BIOCHEM, V144, P455, DOI 10.1016/j.jsbmb.2014.09.005; Fritz HG, 2004, EXP TOXICOL PATHOL, V56, P91, DOI 10.1016/j.etp.2004.04.001; Galluzzi L, 2014, CELL RES, V24, P139, DOI 10.1038/cr.2014.8; He SD, 2009, CELL, V137, P1100, DOI 10.1016/j.cell.2009.05.021; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Jia F, 2010, J NEUROTRAUM, V27, P1059, DOI 10.1089/neu.2009.1067; Jia F, 2009, J NEUROTRAUM, V26, P243, DOI 10.1089/neu.2008.0670; Jouan-Lanhouet S, 2014, SEMIN CELL DEV BIOL, V35, P2, DOI 10.1016/j.semcdb.2014.08.010; Kanakura H, 2007, J ANESTH, V21, P354, DOI 10.1007/s00540-007-0533-y; Khuman J, 2011, J CEREBR BLOOD F MET, V31, P778, DOI 10.1038/jcbfm.2010.172; Kim JH, 2013, CURR PROTEIN PEPT SC, V14, P51; Lai YC, 2008, J CEREBR BLOOD F MET, V28, P540, DOI 10.1038/sj.jcbfm.9600551; Li JX, 2012, CELL, V150, P339, DOI 10.1016/j.cell.2012.06.019; Linkermann A, 2013, P NATL ACAD SCI USA, V110, P12024, DOI 10.1073/pnas.1305538110; Linkermann A, 2012, KIDNEY INT, V81, P751, DOI 10.1038/ki.2011.450; Longhi L, 2013, J CEREBR BLOOD F MET, V33, P1182, DOI 10.1038/jcbfm.2013.65; Lotocki G, 2006, EUR J NEUROSCI, V24, P2283, DOI 10.1111/j.1460-9568.2006.05123.x; Luedde M, 2014, CARDIOVASC RES, V103, P206, DOI 10.1093/cvr/cvu146; Mandal P, 2014, MOL CELL, V56, P481, DOI 10.1016/j.molcel.2014.10.021; Moujalled DM, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2012.201; Murakami Y, 2014, CELL DEATH DIFFER, V21, P270, DOI 10.1038/cdd.2013.109; Murphy JM, 2013, IMMUNITY, V39, P443, DOI 10.1016/j.immuni.2013.06.018; Newton K, 2014, SCIENCE, V343, P1357, DOI 10.1126/science.1249361; O'Donnell MA, 2011, NAT CELL BIOL, V13, P1437, DOI 10.1038/ncb2362; Okuma Y, 2012, ANN NEUROL, V72, P373, DOI 10.1002/ana.23602; Orozco S, 2014, CELL DEATH DIFFER, V21, P1511, DOI 10.1038/cdd.2014.76; Pasparakis M, 2015, NATURE, V517, P311, DOI 10.1038/nature14191; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Sun LM, 2012, CELL, V148, P213, DOI 10.1016/j.cell.2011.11.031; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Trichonas G, 2010, P NATL ACAD SCI USA, V107, P21695, DOI 10.1073/pnas.1009179107; Urbano LA, 2012, CURR NEUROL NEUROSCI, V12, P580, DOI 10.1007/s11910-012-0304-5; Vandenabeele P, 2010, NAT REV MOL CELL BIO, V11, P700, DOI 10.1038/nrm2970; Varfolomeev EE, 2004, CELL, V116, P491, DOI 10.1016/S0092-8674(04)00166-7; Vieira M, 2014, NEUROBIOL DIS, V68, P26, DOI 10.1016/j.nbd.2014.04.002; Vitner EB, 2014, NAT MED, V20, P204, DOI 10.1038/nm.3449; Wang L, 2008, CELL, V133, P693, DOI 10.1016/j.cell.2008.03.036; Wang YQ, 2012, NEUROCHEM RES, V37, P1849, DOI 10.1007/s11064-012-0791-4; Wu JF, 2013, CELL RES, V23, P994, DOI 10.1038/cr.2013.91; Wu XN, 2014, CELL DEATH DIFFER, V21, P1709, DOI 10.1038/cdd.2014.77; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008; Yenari MA, 2012, NAT REV NEUROSCI, V13, P267, DOI 10.1038/nrn3174; Yin B, 2015, BRAIN RES, V1609, P63, DOI 10.1016/j.brainres.2015.03.024; You ZR, 2008, J CEREBR BLOOD F MET, V28, P1564, DOI 10.1038/jcbfm.2008.44; Zhang DW, 2009, SCIENCE, V325, P332, DOI 10.1126/science.1172308; ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4	57	41	44	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	APR 15	2016	6								24547	10.1038/srep24547			11	Multidisciplinary Sciences	Science & Technology - Other Topics	DJ5BE	WOS:000374221000001	27080932	DOAJ Gold, Green Published			2021-06-18	
J	Zhao, HL; Zhang, X; Dai, ZQ; Feng, Y; Li, Q; Zhang, JH; Liu, X; Chen, YJ; Feng, H				Zhao, Hengli; Zhang, Xuan; Dai, Zhiqiang; Feng, Yang; Li, Qiang; Zhang, John H.; Liu, Xin; Chen, Yujie; Feng, Hua			P2X7 Receptor Suppression Preserves Blood-Brain Barrier through Inhibiting RhoA Activation after Experimental Intracerebral Hemorrhage in Rats	SCIENTIFIC REPORTS			English	Article							CENTRAL-NERVOUS-SYSTEM; P2X(7) RECEPTORS; SUBARACHNOID HEMORRHAGE; INTRAVENTRICULAR HEMORRHAGE; HEMATOMA VOLUME; KINASE; MICE; INTEGRITY; STROKE; INJURY	Blockading P2X7 receptor(P2X7R) provides neuroprotection toward various neurological disorders, including stroke, traumatic brain injury, and subarachnoid hemorrhage. However, whether and how P2X7 receptor suppression protects blood-brain barrier(BBB) after intracerebral hemorrhage(ICH) remains unexplored. In present study, intrastriatal autologous-blood injection was used to mimic ICH in rats. Selective P2X7R inhibitor A438079, P2X7R agonist BzATP, and P2X7R siRNA were administrated to evaluate the effects of P2X7R suppression. Selective RhoA inhibitor C3 transferase was administered to clarify the involvement of RhoA. Post-assessments, including neurological deficits, Fluoro-Jade C staining, brain edema, Evans blue extravasation and fluorescence, western blot, RhoA activity assay and immunohistochemistry were performed. Then the key results were verified in collagenase induced ICH model. We found that endogenous P2X7R increased at 3 hrs after ICH with peak at 24 hrs, then returned to normal at 72 hrs after ICH. Enhanced immunoreactivity was observed on the neurovascular structure around hematoma at 24 hrs after ICH, along with perivascular astrocytes and endothelial cells. Both A438079 and P2X7R siRNA alleviated neurological deficits, brain edema, and BBB disruption after ICH, in association with RhoA activation and down-regulated endothelial junction proteins. However, BzATP abolished those effects. In addition, C3 transferase reduced brain injury and increased endothelial junction proteins' expression after ICH. These data indicated P2X7R suppression could preserve BBB integrity after ICH through inhibiting RhoA activation.	[Zhao, Hengli; Zhang, Xuan; Dai, Zhiqiang; Feng, Yang; Li, Qiang; Liu, Xin; Chen, Yujie; Feng, Hua] Third Mil Med Univ, Southwest Hosp, Dept Neurosurg, Chongqing, Peoples R China; [Zhang, John H.] Loma Linda Univ, Dept Anesthesiol Neurosurg & Physiol, Loma Linda, CA 92350 USA	Chen, YJ; Feng, H (corresponding author), Third Mil Med Univ, Southwest Hosp, Dept Neurosurg, Chongqing, Peoples R China.	yujiechen6886@foxmail.com; fenghua8888@vip.163.com		Chen, Yujie/0000-0002-9905-9138	National Basic Research Program of China (973 Program)National Basic Research Program of China [2014CB541600]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81501002, 81220108009]	This study was supported by the National Basic Research Program of China (973 Program, No. 2014CB541600) and the National Natural Science Foundation of China (Grant No. 81501002, 81220108009).	Abbott NJ, 2010, NEUROBIOL DIS, V37, P13, DOI 10.1016/j.nbd.2009.07.030; Allen C, 2010, STROKE, V41, P2056, DOI 10.1161/STROKEAHA.109.574939; Anderson CM, 2006, TRENDS NEUROSCI, V29, P257, DOI 10.1016/j.tins.2006.03.003; Arbeloa J, 2012, NEUROBIOL DIS, V45, P954, DOI 10.1016/j.nbd.2011.12.014; Beckel JM, 2014, GLIA, V62, P1486, DOI 10.1002/glia.22695; Chen QW, 2015, TRANSL STROKE RES, V6, P125, DOI 10.1007/s12975-014-0367-5; Chen S, 2013, CRIT CARE MED, V41, pE466, DOI 10.1097/CCM.0b013e31829a8246; Chen S, 2013, NEUROBIOL DIS, V58, P296, DOI 10.1016/j.nbd.2013.06.011; Chen YJ, 2015, NEUROSCI LETT, V588, P131, DOI 10.1016/j.neulet.2015.01.005; Chen YJ, 2015, STROKE, V46, P529, DOI 10.1161/STROKEAHA.114.007265; Chen Z, 2014, NEUROREPORT, V25, P635, DOI 10.1097/WNR.0000000000000050; Chrovian CC, 2014, PROGR MED CHEM, V53, P65, DOI 10.1016/B978-0-444-63380-4.00002-0; Daneman R, 2012, ANN NEUROL, V72, P648, DOI 10.1002/ana.23648; Duan SM, 2006, GLIA, V54, P738, DOI 10.1002/glia.20397; Fang JQ, 2015, CANCER BIOL THER, V16, P498, DOI 10.1080/15384047.2015.1016663; Feng L, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0409-2; Fu ZH, 2014, INT J CLIN EXP PATHO, V7, P7844; Fujita Y, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00338; Henriquez M, 2011, J CELL SCI, V124, P1581, DOI 10.1242/jcs.073171; Hirayama Y, 2015, J NEUROSCI, V35, P3794, DOI 10.1523/JNEUROSCI.4218-14.2015; Huang B, 2012, NEUROBIOL DIS, V46, P204, DOI 10.1016/j.nbd.2012.01.008; Kang SS, 2013, TRANSL STROKE RES, V4, P533, DOI 10.1007/s12975-013-0265-2; Li Q, 2015, SCI REP-UK, V5, DOI 10.1038/srep11357; LoPresti MA, 2014, J NEUROL SCI, V345, P3, DOI 10.1016/j.jns.2014.06.057; Ma QY, 2014, ANN NEUROL, V75, P209, DOI 10.1002/ana.24070; Ma QY, 2011, ANN NEUROL, V70, P920, DOI 10.1002/ana.22549; MacLellan CL, 2010, STROKE, V41, pS95, DOI 10.1161/STROKEAHA.110.594457; Marzal M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097321; Mendelow A. D., 1993, STROKE S, V24, pI118; Mendelow A. D., 1993, STROKE S1, V24, pI115; Murthy SB, 2015, STROKE, V46, P3088, DOI 10.1161/STROKEAHA.115.010054; North RA, 2013, MOL PHARMACOL, V83, P759, DOI 10.1124/mol.112.083758; Obermeier B, 2013, NAT MED, V19, P1584, DOI 10.1038/nm.3407; Roth TL, 2014, NATURE, V505, P223, DOI 10.1038/nature12808; Rubio-Araiz A, 2014, INT J NEUROPSYCHOPH, V17, P1243, DOI 10.1017/S1461145714000145; Sandoval KE, 2008, NEUROBIOL DIS, V32, P200, DOI 10.1016/j.nbd.2008.08.005; Sathanoori R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125111; Sperlagh B, 2006, PROG NEUROBIOL, V78, P327, DOI 10.1016/j.pneurobio.2006.03.007; Sperlagh B, 2014, TRENDS PHARMACOL SCI, V35, P537, DOI 10.1016/j.tips.2014.08.002; Stockton RA, 2010, J EXP MED, V207, P881, DOI 10.1084/jem.20091258; Urday S, 2015, NAT REV NEUROL, V11, P111, DOI 10.1038/nrneurol.2014.264; Volonte C, 2012, CNS NEUROL DISORD-DR, V11, P705, DOI 10.2174/187152712803581137; Vose LR, 2013, J NEUROSCI, V33, P17232, DOI 10.1523/JNEUROSCI.2713-13.2013; Wang LX, 2013, ANN NEUROL, V73, P189, DOI 10.1002/ana.23762; Wiley JS, 2011, TISSUE ANTIGENS, V78, P321, DOI 10.1111/j.1399-0039.2011.01780.x; Xi GH, 2014, PROG NEUROBIOL, V115, P45, DOI 10.1016/j.pneurobio.2013.09.007; Yang F., 2015, STROKE J CEREBRAL CI, DOI [10.1161/STROKEAHA.114.008336, DOI 10.1161/STROKEAHA.114.008336]; Yu Y, 2014, INT J MOL MED, V33, P661, DOI 10.3892/ijmm.2014.1618; Zhang Y, 2015, STROKE, V46, P2637, DOI 10.1161/STROKEAHA.115.009792; Zheng Y, 2015, STROKE, V46, P485, DOI 10.1161/STROKEAHA.114.006372; Zhou Y, 2014, PROG NEUROBIOL, V115, P25, DOI 10.1016/j.pneurobio.2013.11.003	51	41	43	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	MAR 16	2016	6								23286	10.1038/srep23286			14	Multidisciplinary Sciences	Science & Technology - Other Topics	DG4QB	WOS:000372055700002	26980524	DOAJ Gold, Green Published			2021-06-18	
J	Harris, NG; Verley, DR; Gutman, BA; Thompson, PM; Yeh, HJ; Brown, JA				Harris, N. G.; Verley, D. R.; Gutman, B. A.; Thompson, P. M.; Yeh, H. J.; Brown, J. A.			Disconnection and hyper-connectivity underlie reorganization after TBI: A rodent functional connectomic analysis	EXPERIMENTAL NEUROLOGY			English	Article						Plasticity; Reorganization; Bold; Resting state fMRI; Connectivity; Controlled cortical impact; Rat	TRAUMATIC BRAIN-INJURY; CONTROLLED CORTICAL IMPACT; AXONAL INJURY; NETWORK; RAT; EXPRESSION; RECOVERY; ORGANIZATION; EXCITATION; PLASTICITY	While past neuroimaging methods have contributed greatly to our understanding of brain function after traumatic brain injury (TBI), resting state functional MRI (rsfMRl) connectivity methods have more recently provided a far more unbiased approach with which to monitor brain circuitry compared to task-based approaches. However, current knowledge on the physiologic underpinnings of the correlated blood oxygen level dependent signal, and how changes in functional connectivity relate to reorganizational processes that occur following injury is limited. The degree and extent of this relationship remain to be determined in order that rsfMRI methods can be fully adapted for determining the optimal timing and type of rehabilitative interventions that can be used post-TBI to achieve the best outcome. Very few rsfMRl studies exist after experimental TBI and therefore we chose to acquire rsfMRl data before and at 7, 14 and 28 days after experimental TBI using a well-known, clinically-relevant, unilateral controlled cortical impact injury (CCI) adult rat model of TBI. This model was chosen since it has widespread axonal injury, a well-defined time-course of reorganization including spine, dendrite, axonal and cortical map changes, as well as spontaneous recovery of sensorimotor function by 28 d post-injury from which to interpret alterations in functional connectivity. Data were co-registered to a parcellated rat template to generate adjacency matrices for network analysis by graph theory. Making no assumptions about direction of change, we used two-tailed statistical analysis over multiple brain regions in a data-driven approach to access global and regional changes in network topology in order to assess brain connectivity in an unbiased way. Our main hypothesis was that deficits in functional connectivity would become apparent in regions known to be structurally altered or deficient in axonal connectivity in this model. The data show the loss of functional connectivity predicted by the structural deficits, not only within the primary sensorimotor injury site and pericontused regions, but the normally connected homotopic cortex, as well as subcortical regions, all of which persisted chronically. Especially novel in this study is the unanticipated finding of widespread increases in connection strength that dwarf both the degree and extent of the functional disconnections, and which persist chronically in some sensorimotor and subcortically connected regions. Exploratory global network analysis showed changes in network parameters indicative of possible acutely increased random connectivity and temporary reductions in modularity that were matched by local increases in connectedness and increased efficiency among more weakly connected regions. The global network parameters: shortest path-length, clustering coefficient and modularity that were most affected by trauma also scaled with the severity of injury, so that the corresponding regional measures were correlated to the injury severity most notably at 7 and 14 days and especially within, but not limited to, the contralateral cortex. These changes in functional network parameters are discussed in relation to the known time-course of physiologic and anatomic data that underlie structural and functional reorganization in this experiment model of TBI. (C) 2015 Elsevier Inc. All rights reserved.	[Harris, N. G.; Verley, D. R.] Univ Calif Los Angeles, Dept Neurosurg, UCLA Brain Res Ctr, Los Angeles, CA 90095 USA; [Gutman, B. A.] Univ So Calif, Keck USC Sch Med, Inst Neuroimaging & Informat, Imaging Genet Ctr,Dept Neurol, Los Angeles, CA USA; [Thompson, P. M.] Univ So Calif, Keck USC Sch Med, Dept Psychiat, Los Angeles, CA USA; [Thompson, P. M.] Univ So Calif, Keck USC Sch Med, Dept Engn, Los Angeles, CA USA; [Thompson, P. M.] Univ So Calif, Keck USC Sch Med, Dept Radiol, Los Angeles, CA USA; [Thompson, P. M.] Univ So Calif, Dept Ophthalmol, Keck USC Sch Med, Los Angeles, CA 90089 USA; [Yeh, H. J.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90095 USA; [Brown, J. A.] Univ Calif San Francisco, Sch Med, Dept Neurol, San Francisco, CA USA	Harris, NG (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, UCLA Brain Injury Res Ctr, 300 Stein Plaza,Ste 535,Box 956901, Los Angeles, CA 90095 USA.	ngharris@mednet.ucla.edu	Thompson, Paul M/C-4194-2018; Verley, Derek/J-4550-2015	Thompson, Paul M/0000-0002-4720-8867; Verley, Derek/0000-0002-2670-6568; Harris, Neil/0000-0002-1965-6750	UCLA Brain Injury Research Center; NIH NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS091222];  [NS27544]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027544, R01NS091222] Funding Source: NIH RePORTER	UCLA Brain Injury Research Center; NIH NINDS NS091222; NS27544; NGH is a fellow of the Center for Neuroskills, Bakersfield, California.	Abdelnour F, 2014, NEUROIMAGE, V90, P335, DOI 10.1016/j.neuroimage.2013.12.039; Benali A, 2008, J NEUROSCI, V28, P12284, DOI 10.1523/JNEUROSCI.1952-08.2008; BISWAL B, 1995, MAGNET RESON MED, V34, P537, DOI 10.1002/mrm.1910340409; Blondel VD, 2008, J STAT MECH-THEORY E, DOI 10.1088/1742-5468/2008/10/P10008; Cantu D., 2014, CEREB CORTEX; Celio MR, 1998, TRENDS NEUROSCI, V21, P510, DOI 10.1016/S0166-2236(98)01298-3; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Chen S., 2002, J NEUROTRAUM, V19, P1300; Chen SF, 2004, J CEREBR BLOOD F MET, V24, P1025, DOI 10.1097/01.WCB.0000129415.34520.47; Crum WR, 2013, J NEUROSCI METH, V218, P170, DOI 10.1016/j.jneumeth.2013.05.009; David O, 2008, PLOS BIOL, V6, P2683, DOI 10.1371/journal.pbio.0060315; de Arcangelis L, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00062; Ding MC, 2011, J NEUROSCI, V31, P14085, DOI 10.1523/JNEUROSCI.3572-11.2011; DINSE HR, 1993, NEUROREPORT, V5, P173, DOI 10.1097/00001756-199311180-00020; Donovan V, 2014, J CEREBR BLOOD F MET, V34, P715, DOI 10.1038/jcbfm.2014.6; Drexel M, 2015, NEUROPHARMACOLOGY, V88, P122, DOI 10.1016/j.neuropharm.2014.08.023; Fukushima M, 2009, J NEUROTRAUM, V26, P1095, DOI 10.1089/neu.2008.0771; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Han K, 2014, NEUROIMAGE, V84, P76, DOI 10.1016/j.neuroimage.2013.08.017; Harris NG, 2009, J NEUROSCI RES, V87, P2937, DOI 10.1002/jnr.22115; Harris N.G., 2003, J CEREB METAB BLOOD, V21, P1318; Harris N, 2009, J NEUROTRAUM, V26, pA37; Harris NG, 2013, J NEUROTRAUM, V30, P1257, DOI 10.1089/neu.2012.2737; Harris NG, 2013, J NEUROTRAUM, V30, P1137, DOI 10.1089/neu.2012.2785; Harris NG, 2012, J NEUROTRAUM, V29, P1469, DOI 10.1089/neu.2011.2161; Harris NG, 2010, J NEUROTRAUM, V27, P1971, DOI 10.1089/neu.2010.1470; Harris NG, 2010, J NEUROPATH EXP NEUR, V69, P139, DOI 10.1097/NEN.0b013e3181cb5bee; Hebb D.O., 1949, ORG BEHAV NEUROPSYCH; Hillary FG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104021; Holschneider DP, 2013, J NEUROTRAUM, V30, P907, DOI 10.1089/neu.2012.2657; Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132; Jenkinson M, 2001, MED IMAGE ANAL, V5, P143, DOI 10.1016/S1361-8415(01)00036-6; Jones TA, 2012, J NEUROTRAUM, V29, P1455, DOI 10.1089/neu.2011.2207; Kalthoff D, 2011, NEUROIMAGE, V54, P2828, DOI 10.1016/j.neuroimage.2010.10.053; Kasahara M, 2010, NEUROLOGY, V75, P168, DOI 10.1212/WNL.0b013e3181e7ca58; Kasahara M, 2011, BRAIN INJURY, V25, P1170, DOI 10.3109/02699052.2011.608210; Lee S, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.16; Liang ZF, 2012, J NEUROSCI, V32, P10183, DOI 10.1523/JNEUROSCI.1020-12.2012; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Magnuson ME, 2014, BRAIN CONNECT, V4, P15, DOI 10.1089/brain.2013.0167; Magnuson ME, 2014, NMR BIOMED, V27, P291, DOI 10.1002/nbm.3062; Mayer AR, 2014, J NEUROTRAUM, V31, P189, DOI 10.1089/neu.2013.3069; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; MERZENICH MM, 1984, J COMP NEUROL, V224, P591, DOI 10.1002/cne.902240408; Mishra AM, 2011, J NEUROSCI, V31, P15053, DOI 10.1523/JNEUROSCI.0101-11.2011; Mishra AK, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0086852, 10.1371/journal.pone.0095280]; Mix A, 2010, EUR J NEUROSCI, V32, P1575, DOI 10.1111/j.1460-9568.2010.07425.x; Nakamura T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008220; Pan WJ, 2013, NEUROIMAGE, V74, P288, DOI 10.1016/j.neuroimage.2013.02.035; Pandit AS, 2013, NEUROLOGY, V80, P1826, DOI 10.1212/WNL.0b013e3182929f38; PAXINOS G, 1997, RAT BRAIN STEREOTAXI; Raible DJ, 2012, J NEUROTRAUM, V29, P2548, DOI 10.1089/neu.2012.2483; Rehme AK, 2011, NEUROIMAGE, V55, P1147, DOI 10.1016/j.neuroimage.2011.01.014; Reyt S, 2010, NEUROIMAGE, V52, P1456, DOI 10.1016/j.neuroimage.2010.05.021; RICHARDS HK, 1995, CHILD NERV SYST, V11, P288, DOI 10.1007/BF00301762; Rubinov M, 2010, NEUROIMAGE, V52, P1059, DOI 10.1016/j.neuroimage.2009.10.003; Shattuck DW, 2002, MED IMAGE ANAL, V6, P129, DOI 10.1016/S1361-8415(02)00054-3; SHAW NA, 1984, AUST J EXP BIOL MED, V62, P361, DOI 10.1038/icb.1984.36; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Stemper BD, 2014, ANN BIOMED ENG; Stevens MC, 2012, BRAIN IMAGING BEHAV, V6, P293, DOI 10.1007/s11682-012-9157-4; Valdes-Hernandez Pedro Antonio, 2011, Front Neuroinform, V5, P26, DOI 10.3389/fninf.2011.00026; van Meer MPA, 2010, J NEUROSCI, V30, P3964, DOI 10.1523/JNEUROSCI.5709-09.2010; Verley DR, 2013, J NEUROTRAUM, V30, pA121; Wang L, 2010, BRAIN, V133, P1224, DOI 10.1093/brain/awq043; Williams KA, 2010, MAGN RESON IMAGING, V28, P995, DOI 10.1016/j.mri.2010.03.007; Winston CN, 2013, J NEUROTRAUM, V30, P1966, DOI 10.1089/neu.2013.2960; Xia MR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068910; Yushkevich PA, 2006, NEUROIMAGE, V31, P1116, DOI 10.1016/j.neuroimage.2006.01.015; Zhou Y., 2013, J MAGN RESON IMAGING; Zhuo JC, 2012, NEUROIMAGE, V59, P467, DOI 10.1016/j.neuroimage.2011.07.050	74	41	41	2	16	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	MAR	2016	277						124	138		10.1016/j.expneurol.2015.12.020			15	Neurosciences	Neurosciences & Neurology	DF2ST	WOS:000371194800014	26730520	Green Accepted			2021-06-18	
J	Cruz, LJ; Stammes, MA; Que, I; van Beek, ER; Knol-Blankevoort, VT; Snoeks, TJA; Chan, A; Kaijzel, EL; Lowik, CWGM				Cruz, Luis J.; Stammes, Marieke A.; Que, Ivo; van Beek, Ermond R.; Knol-Blankevoort, Vicky T.; Snoeks, Thomas J. A.; Chan, Alan; Kaijzel, Eric L.; Lowik, Clemens W. G. M.			Effect of PLGA NP size on efficiency to target traumatic brain injury	JOURNAL OF CONTROLLED RELEASE			English	Article						Imaging; Targeting; Contrast agents; Nanoparticles; PLGA; Brain injury	IN-VITRO; NANOPARTICLES; CELLS	Necrotic cell death occurs exclusively under pathological conditions, such as ischemic diseases. Necrosis imaging is of diagnostic value and enables early measurement of treatment efficiency in ischemic patients. Here we explored the targeted delivery of particles, with diameters of approximately 100 nm, 200 nm and 800 nm, consisting of a poly(lactic-co-glycolic acid) (PLGA) nanoparticle (NP) core coated with a polyethylene glycollipid (PEG) layer. Targeted delivery was facilitated by coupling the amino end group of the polyethylene glycol-layer to 800CW imaging agent, which specifically binds to intracellular proteins of cells that have lost membrane integrity, thus revealing the extent of the damaged area. We found that smaller NPs (100 nm), with an appropriate coating, diffuse throughout the traumatic brain injury (TBI) in mice. Optical imaging revealed that smaller (100-nm) PEG-coated NPs carrying 800CW penetrated deeper into the mouse brain than large 800CW containing NPs (800 nm). The importance of the 800CW as a ligand to target the necrotic tissue was further confirmed in living mice. The ability to achieve brain penetration with smaller NPs is expected to allow more uniform, longer-lasting, and effective delivery of drugs within the brain, and may find application in the treatment of stroke, brain tumors, neuroinflammation, and other brain diseases where the blood-brain barrier is compromised or where local delivery strategies are feasible. (C) 2015 Elsevier B.V. All rights reserved.	[Cruz, Luis J.; Que, Ivo; Knol-Blankevoort, Vicky T.; Snoeks, Thomas J. A.; Kaijzel, Eric L.; Lowik, Clemens W. G. M.] Leiden Univ, Med Ctr, Dept Radiol, Nanomed & Mol Imaging, Albinusdreef 2, NL-2300 RC Leiden, Netherlands; [Stammes, Marieke A.; van Beek, Ermond R.; Chan, Alan] Percuros, Enschede, Netherlands	Cruz, LJ (corresponding author), Leiden Univ, Med Ctr, Dept Radiol, Nanomed & Mol Imaging, Albinusdreef 2, NL-2333 ZA Leiden, Netherlands.; Lowik, CWGM (corresponding author), Leiden Univ, Med Ctr, Dept Radiol, Expt Mol Imaging, Albinusdreef 2, NL-2333 ZA Leiden, Netherlands.	l.j.cruz_ricondo@lumc.nl; C.W.G.M.Lowik@lumc.nl		Chan, Alan/0000-0001-6949-9274; Kaijzel, Eric/0000-0003-3118-9910	VIDI personal grant [723.012.110]; European UnionEuropean Commission [612360]; CTMM project Cancer Vaccine Tracking [03O-302]	The authors wish to thank the technicians of the LUMC Radiology Department for assistance. This work was financially supported by the VIDI personal grant (project number 723.012.110) L.J.C, the FP7 European Union Marie Curie IAPP program, BRAINPATH, under grant number 612360 and the CTMM project Cancer Vaccine Tracking (03O-302).	Barichello JM, 1999, DRUG DEV IND PHARM, V25, P471, DOI 10.1081/DDC-100102197; BAZILE D, 1995, J PHARM SCI, V84, P493, DOI 10.1002/jps.2600840420; CHIGNELL CF, 1970, MOL PHARMACOL, V6, P1; Cruz LJ, 2014, MOL PHARMACEUT, V11, P4299, DOI 10.1021/mp400717r; Cruz LJ, 2011, MOL PHARMACEUT, V8, P520, DOI 10.1021/mp100356k; Cruz LJ, 2010, J CONTROL RELEASE, V144, P118, DOI 10.1016/j.jconrel.2010.02.013; Fagan SC, 2004, STROKE, V35, P2220, DOI 10.1161/01.STR.0000138023.60272.9e; GREF R, 1994, SCIENCE, V263, P1600, DOI 10.1126/science.8128245; Ishii T, 2013, BIOCHEM BIOPH RES CO, V430, P1201, DOI 10.1016/j.bbrc.2012.12.080; Ishii T, 2010, BRAIN RES, V1321, P164, DOI 10.1016/j.brainres.2010.01.039; Jain S, 2012, BRIT J RADIOL, V85, P101, DOI 10.1259/bjr/59448833; Lakhan SE, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00032; Langer R, 1998, NATURE, V392, P5; Li SD, 2008, MOL PHARMACEUT, V5, P496, DOI 10.1021/mp800049w; Mc Carthy DJ, 2015, PHARM RES-DORDR, V32, P1161, DOI 10.1007/s11095-014-1545-6; Mosqueira VCF, 2001, BIOMATERIALS, V22, P2967, DOI 10.1016/S0142-9612(01)00043-6; Mozaffarian D, 2015, CIRCULATION, V131, pE29, DOI [10.1161/01.cir.0000441139.02102.80, 10.1161/CIR.0000000000000152, 10.1161/CIR.0b013e31828124ad]; Nance EA, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003594; Nobs L, 2003, INT J PHARM, V250, P327, DOI 10.1016/S0378-5173(02)00542-2; Panagiotou S, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00182; Pogue B.W., 2015, P SPIE INT SOC OPT E, V9311; Ruozi B., 2015, MOL NEUROBIOL; Sierra S, 2011, J ALZHEIMERS DIS, V23, P307, DOI 10.3233/JAD-2010-101179; Tassa C, 2010, BIOCONJUGATE CHEM, V21, P14, DOI 10.1021/bc900438a; Togashi DM, 2008, J FLUORESC, V18, P519, DOI 10.1007/s10895-007-0294-x; Veronese FM, 2005, DRUG DISCOV TODAY, V10, P1451, DOI 10.1016/S1359-6446(05)03575-0; Xie B., 2015, ONCOTARGET; Zehendner CM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016760; Zhang P.L., 2015, CELL BIOCH BIOPHYS	29	41	41	1	45	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0168-3659	1873-4995		J CONTROL RELEASE	J. Control. Release	FEB 10	2016	223						31	41		10.1016/j.jconrel.2015.12.029			11	Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Chemistry; Pharmacology & Pharmacy	DB8TG	WOS:000368788900004	26708021				2021-06-18	
J	Margulies, S; Anderson, G; Atif, F; Badaut, J; Clark, R; Empey, P; Guseva, M; Hoane, M; Huh, J; Pauly, J; Raghupathi, R; Scheff, S; Stein, D; Tang, HL; Hicks, M				Margulies, Susan; Anderson, Gail; Atif, Fahim; Badaut, Jerome; Clark, Robert; Empey, Philip; Guseva, Maria; Hoane, Michael; Huh, Jimmy; Pauly, Jim; Raghupathi, Ramesh; Scheff, Stephen; Stein, Donald; Tang, Huiling; Hicks, Mona			Combination Therapies for Traumatic Brain Injury: Retrospective Considerations	JOURNAL OF NEUROTRAUMA			English	Article						pharmacological interventions; preclinical therapeutic development; treatments	N-TERMINAL KINASE; IMPROVES FUNCTIONAL RECOVERY; GLYCINE-PROLINE-GLUTAMATE; VITAMIN-D HORMONE; GENE-EXPRESSION; IMMATURE RAT; INTRAVENOUS-INFUSION; CLINICAL-TRIAL; AXONAL INJURY; HEAD-INJURY	Patients enrolled in clinical trials for traumatic brain injury (TBI) may present with heterogeneous features over a range of injury severity, such as diffuse axonal injury, ischemia, edema, hemorrhage, oxidative damage, mitochondrial and metabolic dysfunction, excitotoxicity, inflammation, and other pathophysiological processes. To determine whether combination therapies might be more effective than monotherapy at attenuating moderate TBI or promoting recovery, the National Institutes of Health funded six preclinical studies in adult and immature male rats to evaluate promising acute treatments alone and in combination. Each of the studies had a solid rationale for its approach based on previous research, but only one reported significant improvements in long-term outcomes across a battery of behavioral tests. Four studies had equivocal results because of a lack of sensitivity of the outcome assessments. One study demonstrated worse results with the combination in comparison with monotherapies. While specific research findings are reported elsewhere, this article provides an overview of the study designs, insights, and recommendations for future research aimed at therapy development for TBI.	[Margulies, Susan] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; [Anderson, Gail] Univ Washington, Dept Pharm Pharmaceut & Neurol Surg, Seattle, WA 98195 USA; [Atif, Fahim; Stein, Donald; Tang, Huiling] Emory Univ, Dept Emergency Med, Atlanta, GA 30322 USA; [Badaut, Jerome] Univ Bordeaux, INCIA, Bordeaux, France; [Clark, Robert] Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Pittsburgh, PA USA; [Clark, Robert] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA USA; [Empey, Philip] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15261 USA; [Guseva, Maria] Fresenius Kabi USA LLC, Lake Zurich, IL USA; [Hoane, Michael] So Illinois Univ, Dept Psychol, Carbondale, IL 62901 USA; [Huh, Jimmy] Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA; [Pauly, Jim] Univ Kentucky, Dept Pharmaceut Sci, Lexington, KY USA; [Raghupathi, Ramesh] Drexel Univ, Coll Med, Dept Neurobiol & Anat, Philadelphia, PA 19104 USA; [Scheff, Stephen] Univ Kentucky, Ctr Aging, Lexington, KY USA; [Hicks, Mona] One Mind, Seattle, WA USA	Margulies, S (corresponding author), Univ Penn, Dept Bioengn, 210 S 33rd St,240 Skirkanich Hall, Philadelphia, PA 19104 USA.	margulie@seas.upenn.edu	Stein, Donald/AAJ-5139-2020; Empey, Philip/L-9604-2019	Empey, Philip/0000-0001-7474-2339; Hoane, Michael/0000-0001-7779-2657	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 HD061944, R01 HD061946, R01 HD061963, R01 HD061966, R01 HD061971, R01 NS069247, U01 NS069545]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD061946, R01HD061971, R01HD061963, R01HD061944] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS069247, U01NS069545] Funding Source: NIH RePORTER	We thank Beth Ansel and Michael Weinrich of the NIH for their leadership in developing and administering the research initiative that supported these studies. We also thank Stephen Ashwal, Richard Hartman, and Andre Obenaus of Loma Linda University for their thoughtful discussions. The research was supported by NIH grants R01 HD061944, R01 HD061946, R01 HD061963, R01 HD061966, R01 HD061971, R01 NS069247, and U01 NS069545.	Ajao D., 2011, SOC NEUROSCIENCE ABS, V41; Ajao DO, 2012, J NEUROTRAUM, V29, P2060, DOI 10.1089/neu.2011.1883; ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; Aminmansour Bahram, 2012, Adv Biomed Res, V1, P58, DOI 10.4103/2277-9175.100176; Anderson GD, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00021; Anderson GD, 2013, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00129; Anderson GD, 2011, J NEUROTRAUM, V28, P1827, DOI 10.1089/neu.2011.1911; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Arima H, 2003, J BIOL CHEM, V278, P44525, DOI 10.1074/jbc.M304368200; Armstead William M, 2005, Pathophysiology, V12, P5, DOI 10.1016/j.pathophys.2005.01.002; Armstead WM, 2011, NEUROL RES, V33, P726, DOI 10.1179/016164110X12807570509853; Arvin KL, 2002, ANN NEUROL, V52, P54, DOI 10.1002/ana.10242; Atif F, 2013, NEUROPHARMACOLOGY, V67, P78, DOI 10.1016/j.neuropharm.2012.10.004; Atif F, 2009, MOL MED, V15, P328, DOI 10.2119/molmed.2009.00016; Badaut J, 2011, J CEREBR BLOOD F MET, V31, P819, DOI 10.1038/jcbfm.2010.163; Baki SGA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012490; Bateman DN, 2014, LANCET, V383, P697, DOI 10.1016/S0140-6736(13)62062-0; Bazarian JJ, 2010, J NEUROTRAUM, V27, P527, DOI 10.1089/neu.2009.1068; Behan LA, 2007, HORM RES, V68, P18, DOI 10.1159/000110466; Bonny C, 2001, DIABETES, V50, P77, DOI 10.2337/diabetes.50.1.77; Borsello T, 2003, NAT MED, V9, P1180, DOI 10.1038/nm911; Brustovetsky N, 2001, J NEUROCHEM, V76, P425, DOI 10.1046/j.1471-4159.2001.00052.x; Buller KM, 2009, J NEUROSCI RES, V87, P599, DOI 10.1002/jnr.21890; BURNELL JM, 1951, J CLIN INVEST, V30, P697, DOI 10.1172/JCI102482; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Cekic M, 2011, NEUROBIOL AGING, V32, P864, DOI 10.1016/j.neurobiolaging.2009.04.017; Cekic M, 2009, FRONT NEUROENDOCRIN, V30, P158, DOI 10.1016/j.yfrne.2009.04.002; Chow SC, 2014, ANNU REV MED, V65, P405, DOI 10.1146/annurev-med-092012-112310; CRAWFORD IL, 1979, J PHYSIOL-LONDON, V287, P519, DOI 10.1113/jphysiol.1979.sp012674; Cruchaga C, 2013, NEURON, V78, P256, DOI 10.1016/j.neuron.2013.02.026; Cutler SM, 2007, J NEUROTRAUM, V24, P1475, DOI 10.1089/neu.2007.0294; Deutsch ER, 2013, BRAIN RES, V1530, P82, DOI 10.1016/j.brainres.2013.07.014; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P135, DOI 10.1089/neu.2013.3019; DiLeonardi AM, 2012, J NEUROPATH EXP NEUR, V71, P959, DOI 10.1097/NEN.0b013e31826f5876; DiLeonardi AM, 2009, BRAIN RES, V1263, P174, DOI 10.1016/j.brainres.2009.01.021; Doppenberg EMR, 2004, J NEUROSURG ANESTH, V16, P87, DOI 10.1097/00008506-200401000-00019; Empey PE, 2013, CRIT CARE MED, V41, P2379, DOI 10.1097/CCM.0b013e318292316c; Fukuda AM, 2012, NEUROSCIENCE, V222, P366, DOI 10.1016/j.neuroscience.2012.06.033; Fukuda AM, 2013, GENES-BASEL, V4, P435, DOI 10.3390/genes4030435; Fukuda AM, 2013, J CEREBR BLOOD F MET, V33, P1621, DOI 10.1038/jcbfm.2013.118; Fukuda AM, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-279; Gagne JJ, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g6802; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Guan J, 2004, NEUROPHARMACOLOGY, V47, P892, DOI 10.1016/j.neuropharm.2004.07.002; Guerrero-Ontiveros ML, 1998, MOL CELL BIOCHEM, V184, P427, DOI 10.1023/A:1006895414925; Guseva MV, 2008, J NEUROTRAUM, V25, P975, DOI 10.1089/neu.2008.0516; Haber M, 2013, EXP NEUROL, V249, P169, DOI 10.1016/j.expneurol.2013.09.002; Hammond CL, 2007, J BIOL CHEM, V282, P14337, DOI 10.1074/jbc.M611019200; Hartz AMS, 2011, CURR PHARM BIOTECHNO, V12, P656; Heard K, 2012, CURR PHARM BIOTECHNO, V13, P1917, DOI 10.2174/138920112802273146; Hirt L, 2004, STROKE, V35, P1738, DOI 10.1161/01.STR.0000131480.03994.b1; Hoffer ME, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054163; Hua F, 2012, HORM BEHAV, V61, P642, DOI 10.1016/j.yhbeh.2012.02.017; Huh JW, 2008, EXP NEUROL, V213, P84, DOI 10.1016/j.expneurol.2008.05.009; Kamper JE, 2013, EXP NEUROL, V250, P8, DOI 10.1016/j.expneurol.2013.09.016; Karatas H, 2013, SCIENCE, V339, P1092, DOI 10.1126/science.1231897; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; Li B, 2009, NEUROSURGERY, V65, P179, DOI 10.1227/01.NEU.0000346272.76537.DC; Lu XCM, 2009, J NEUROTRAUM, V26, P141, DOI 10.1089/neu.2008.0629; Mahmood A, 2009, NEUROSURGERY, V65, P187, DOI 10.1227/01.NEU.0000343540.24780.D6; Margulies S, 2009, J NEUROTRAUM, V26, P925, DOI [10.1089/neu.2008.0794, 10.1089/neu.2008-0794]; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; Marmarou CR, 2006, EXP NEUROL, V197, P353, DOI 10.1016/j.expneurol.2005.10.003; McAllister Thomas W, 2011, Dialogues Clin Neurosci, V13, P287; Mejia ROS, 2001, NEUROSURGERY, V48, P1393; Michel-Monigadon D, 2010, CEREBROVASC DIS, V29, P564, DOI 10.1159/000306643; Norman AW, 2007, J STEROID BIOCHEM, V103, P204, DOI 10.1016/j.jsbmb.2006.12.071; Ortolano F, 2009, J NEUROPATH EXP NEUR, V68, P964, DOI 10.1097/NEN.0b013e3181b20670; Peterson TC, 2015, J NEUROTRAUM, V32, P765, DOI 10.1089/neu.2014.3530; Peterson TC, 2012, J NEUROTRAUM, V29, P2823, DOI 10.1089/neu.2012.2471; Plane JM, 2010, ARCH NEUROL-CHICAGO, V67, P1442, DOI 10.1001/archneurol.2010.191; Potts Mathew B, 2006, NeuroRx, V3, P143; Prins ML, 2003, J NEUROTRAUM, V20, P123, DOI 10.1089/08977150360547053; Raghupathi R, 2003, EXP NEUROL, V183, P438, DOI 10.1016/S0014-4886(03)00166-3; Raghupathi R, 2007, J NEUROTRAUM, V24, P1596, DOI 10.1089/neu.2007.3790; Reeves TM, 2007, BRAIN RES, V1154, P225, DOI 10.1016/j.brainres.2007.04.002; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Samuni Y, 2013, BBA-GEN SUBJECTS, V1830, P4117, DOI 10.1016/j.bbagen.2013.04.016; Sanders Lisa M, 2007, Nutr Today, V42, P181, DOI 10.1097/01.NT.0000286155.55343.fa; Saporito MS, 1998, NEUROSCIENCE, V86, P461, DOI 10.1016/S0306-4522(98)00059-1; SARA VR, 1993, ANN NY ACAD SCI, V692, P183; Scheff SW, 2004, NEUROCHEM RES, V29, P469, DOI 10.1023/B:NERE.0000013753.22615.59; Setkowicz Z, 2004, EPILEPSY RES, V61, P63, DOI 10.1016/j.eplepsyres.2004.06.001; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Silverman WR, 2009, J BIOL CHEM, V284, P18143, DOI 10.1074/jbc.M109.004804; Singleton RH, 2001, J NEUROTRAUM, V18, P607, DOI 10.1089/089771501750291846; Sizonenko SV, 2001, BRAIN RES, V922, P42, DOI 10.1016/S0006-8993(01)03148-1; Skolnick BE, 2014, NEW ENGL J MED, V371, P2467, DOI 10.1056/NEJMoa1411090; Smith DH, 2013, J NEUROTRAUM, V30, P307, DOI 10.1089/neu.2012.2825; Staal JA, 2010, J NEUROCHEM, V112, P1147, DOI 10.1111/j.1471-4159.2009.06531.x; Sullivan PG, 2000, ANN NEUROL, V48, P723, DOI 10.1002/1531-8249(200011)48:5&lt;723::AID-ANA5&gt;3.0.CO;2-W; Tang HL, 2013, HORM BEHAV, V64, P527, DOI 10.1016/j.yhbeh.2013.06.009; Tarnopolsky MA, 2001, ANN NEUROL, V49, P561, DOI 10.1002/ana.1028.abs; Temkin NR, 2007, LANCET NEUROL, V6, P29, DOI 10.1016/S1474-4422(06)70630-5; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; Vonder Haar C, 2014, J NEUROTRAUM, V31, P961, DOI 10.1089/neu.2013.3119; WALLIMANN T, 1994, MOL CELL BIOCHEM, V133, P193, DOI 10.1007/BF01267955; Wei HH, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-19; Wiegler K, 2008, CEREBROVASC DIS, V26, P360, DOI 10.1159/000151639; Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304; Wright DW, 2005, J CLIN PHARMACOL, V45, P640, DOI 10.1177/0091270005276201; Xiong Y, 1999, J NEUROTRAUM, V16, P1067, DOI 10.1089/neu.1999.16.1067; Yatsushige H, 2007, J NEUROSCI RES, V85, P1436, DOI 10.1002/jnr.21281; Yeatts SD, 2013, STROKE, V44, pS116, DOI 10.1161/STROKEAHA.111.000031; Zafonte RD, 2012, JAMA-J AM MED ASSOC, V308, P1993, DOI 10.1001/jama.2012.13256; Zwienenberg M, 1999, J NEUROTRAUM, V16, P937, DOI 10.1089/neu.1999.16.937	107	41	42	1	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 1	2016	33	1					101	112		10.1089/neu.2014.3855			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CZ4EW	WOS:000367057200013	25970337	Green Published			2021-06-18	
J	Miller, DR; Hayes, JP; Lafleche, G; Salat, DH; Verfaellie, M				Miller, Danielle R.; Hayes, Jasmeet P.; Lafleche, Ginette; Salat, David H.; Verfaellie, Mieke			White Matter Abnormalities are Associated With Chronic Postconcussion Symptoms in Blast-Related Mild Traumatic Brain Injury	HUMAN BRAIN MAPPING			English	Article						diffusion tensor imaging; OEF/OIF; PTSD; loss of consciousness	POSTTRAUMATIC-STRESS-DISORDER; HIPPOCAMPAL VOLUME; WAR VETERANS; HEAD-INJURY; COMBAT; CONCUSSION; IRAQ; PTSD; PERSISTENT; AFGHANISTAN	Blast-related mild traumatic brain injury (mTBI) is a common injury among Iraq and Afghanistan military veterans due to the frequent use of improvised explosive devices. A significant minority of individuals with mTBI report chronic postconcussion symptoms (PCS), which include physical, emotional, and cognitive complaints. However, chronic PCS are nonspecific and are also associated with mental health disorders such as posttraumatic stress disorder (PTSD). Identifying the mechanisms that contribute to chronic PCS is particularly challenging in blast-related mTBI, where the incidence of comorbid PTSD is high. In this study, we examined whether blast-related mTBI is associated with diffuse white matter changes, and whether these neural changes are associated with chronic PCS. Ninety Operation Enduring Freedom/Operation Iraqi Freedom (OEF/OIF) veterans were assigned to one of three groups including a blast-exposed no - TBI group, a blast-related mTBI without loss of consciousness (LOC) group (mTBI - LOC), and a blast-related mTBI with LOC group (mTBI + LOC). PCS were measured with the Rivermead Postconcussion Questionnaire. Results showed that participants in the mTBI + LOC group had more spatially heterogeneous white matter abnormalities than those in the no - TBI group. These white matter abnormalities were significantly associated with physical PCS severity even after accounting for PTSD symptoms, but not with cognitive or emotional PCS severity. A mediation analysis revealed that mTBI + LOC significantly influenced physical PCS severity through its effect on white matter integrity. These results suggest that white matter abnormalities are associated with chronic PCS independent of PTSD symptom severity and that these abnormalities are an important mechanism explaining the relationship between mTBI and chronic physical PCS. Published 2015. This article is a U.S. Government work and is in the public domain in the USA.	[Miller, Danielle R.] Boston Univ, Sch Med, Dept Anat & Neurobiol, Boston, MA 02118 USA; [Miller, Danielle R.; Lafleche, Ginette; Verfaellie, Mieke] VA Boston Healthcare Syst, Memory Disorders Res Ctr, 151A,150 South,Huntington Ave, Boston, MA 02130 USA; [Hayes, Jasmeet P.] VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA 02130 USA; [Hayes, Jasmeet P.; Lafleche, Ginette; Verfaellie, Mieke] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA; [Hayes, Jasmeet P.; Salat, David H.] VA Boston Healthcare Syst, Neuroimaging Res Vet Ctr, Boston, MA 02130 USA; [Salat, David H.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA; [Salat, David H.] Harvard Univ, Sch Med, Boston, MA USA	Miller, DR (corresponding author), VA Boston Healthcare Syst, Memory Disorders Res Ctr, 151A,150 South,Huntington Ave, Boston, MA 02130 USA.	dmiller3@bu.edu	Hayes, Jasmeet/AAN-4150-2020	Hayes, Jasmeet/0000-0002-5157-0666; Sullivan, Danielle R./0000-0002-0141-5887; Verfaellie, Mieke/0000-0001-5535-4584	VA Rehabilitation Research Development [RX000216]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K23MH084013]; National Center for PTSD; VA Clinical Science Research and Development Service; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K23MH084013] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX000216] Funding Source: NIH RePORTER	Contract grant sponsor: VA Rehabilitation Research & Development; Contract grant number: RX000216; Contract grant sponsor: NIH; Contract grant number: K23MH084013; Contract grant sponsor: National Center for PTSD; Contract grant sponsor: VA Clinical Science Research and Development Service.	Bartnik-Olson BL, 2014, J NEUROTRAUM, V31, P1497, DOI 10.1089/neu.2013.3213; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bazarian JJ, 2013, J HEAD TRAUMA REHAB, V28, P1, DOI 10.1097/HTR.0b013e318256d3d3; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Bouix S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066205; BREMNER JD, 1995, AM J PSYCHIAT, V152, P973; Bremner JD, 1999, BIOL PSYCHIAT, V45, P806, DOI 10.1016/S0006-3223(98)00297-2; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Corbo V, 2005, BIOL PSYCHIAT, V58, P119, DOI 10.1016/j.biopsych.2005.02.032; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P315, DOI 10.1097/01.HTR.0000300226.67748.3e; Daniels JK, 2010, J PSYCHIATR NEUROSCI, V35, P258, DOI 10.1503/jpn.090010; Davenport ND, 2015, HUM BRAIN MAPP, V36, P1053, DOI 10.1002/hbm.22685; Davenport ND, 2012, NEUROIMAGE, V59, P2017, DOI 10.1016/j.neuroimage.2011.10.050; Donnell AJ, 2012, CLIN NEUROPSYCHOL, V26, P1092, DOI 10.1080/13854046.2012.713984; Fear NT, 2009, PSYCHOL MED, V39, P1379, DOI 10.1017/S0033291708004595; Hayes AF, 2014, BRIT J MATH STAT PSY, V67, P451, DOI 10.1111/bmsp.12028; Hayes JP, 2015, NEUROIMAGE-CLIN, V8, P148, DOI 10.1016/j.nicl.2015.04.001; Hayes JP, 2011, J PSYCHIATR RES, V45, P660, DOI 10.1016/j.jpsychires.2010.10.007; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Jorge RE, 2012, AM J PSYCHIAT, V169, P1284, DOI 10.1176/appi.ajp.2012.12050600; Kasai K, 2008, BIOL PSYCHIAT, V63, P550, DOI 10.1016/j.biopsych.2007.06.022; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Landre N, 2006, ARCH CLIN NEUROPSYCH, V21, P255, DOI 10.1016/j.acn.2005.12.007; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Ling JM, 2012, BRAIN, V135, P1281, DOI 10.1093/brain/aws073; Lippa SM, 2010, J INT NEUROPSYCH SOC, V16, P856, DOI 10.1017/S1355617710000743; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Matthews SC, 2012, PSYCHIAT RES-NEUROIM, V204, P149, DOI 10.1016/j.pscychresns.2012.04.018; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2008, MILD TRAUMATIC BRAIN; Messe A, 2012, BRAIN IMAGING BEHAV, V6, P283, DOI 10.1007/s11682-012-9159-2; Milad MR, 2009, BIOL PSYCHIAT, V66, P1075, DOI 10.1016/j.biopsych.2009.06.026; Morey RA, 2013, HUM BRAIN MAPP, V34, P2986, DOI 10.1002/hbm.22117; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; O'Doherty DCM, 2015, PSYCHIAT RES-NEUROIM, V232, P1, DOI 10.1016/j.pscychresns.2015.01.002; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Petrie EC, 2014, J NEUROTRAUM, V31, P425, DOI [10.1089/NEU.2013.2952, 10.1089/neu.2013.2952]; Sadeh N, 2015, HUM BRAIN MAPP, V36, P3076, DOI 10.1002/hbm.22829; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Shin LM, 2010, NEUROPSYCHOPHARMACOL, V35, P169, DOI 10.1038/npp.2009.83; Shin LM, 2004, ARCH GEN PSYCHIAT, V61, P168, DOI 10.1001/archpsyc.61.2.168; Smith ME, 2005, HIPPOCAMPUS, V15, P798, DOI 10.1002/hipo.20102; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Sorg SF, 2014, J HEAD TRAUMA REHAB, V29, P21, DOI 10.1097/HTR.0b013e31828a1aa4; St Jacques PL, 2013, COGN AFFECT BEHAV NE, V13, P554, DOI 10.3758/s13415-013-0157-7; Taber KH, 2015, J HEAD TRAUMA REHAB, V30, pE15, DOI 10.1097/HTR.0000000000000030; Tombaugh TN, 1996, TEST MEMORY MALINGER; van Wingen GA, 2012, P NATL ACAD SCI USA, V109, P15508, DOI 10.1073/pnas.1206330109; Verfaellie M, 2013, J INT NEUROPSYCH SOC, V19, P1, DOI 10.1017/S1355617712000902; Wechsler D., 2001, WECHSLER TEST ADULT; White T, 2009, PSYCHIAT RES-NEUROIM, V174, P110, DOI 10.1016/j.pscychresns.2009.04.014; Xydakis MS, 2012, ANN NEUROL, V72, P673, DOI 10.1002/ana.23757; Yeh PH, 2014, HUM BRAIN MAPP, V35, P2652, DOI 10.1002/hbm.22358	61	41	41	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1065-9471	1097-0193		HUM BRAIN MAPP	Hum. Brain Mapp.	JAN	2016	37	1					220	229		10.1002/hbm.23022			10	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	DC3WU	WOS:000369150500015	26497829	Green Accepted, Green Published			2021-06-18	
J	Osier, ND; Carlson, SW; DeSana, A; Dixon, CE				Osier, Nicole D.; Carlson, Shaun W.; DeSana, Anthony; Dixon, C. Edward			Chronic Histopathological and Behavioral Outcomes of Experimental Traumatic Brain Injury in Adult Male Animals	JOURNAL OF NEUROTRAUMA			English	Article						behavior; chronic; function; histopathology; TBI	CONTROLLED CORTICAL IMPACT; DIFFUSE AXONAL INJURY; LATERAL FLUID-PERCUSSION; CLOSED-HEAD-INJURY; POSTTRAUMATIC-STRESS-DISORDER; MARROW STROMAL CELLS; ACUTE NEURONAL DEGENERATION; SYMPATHETIC NERVOUS-SYSTEM; MEDIAL PREFRONTAL CORTEX; CHRONIC-STAGE CONTUSION	The purpose of this review is to survey the use of experimental animal models for studying the chronic histopathological and behavioral consequences of traumatic brain injury (TBI). The strategies employed to study the long-term consequences of TBI are described, along with a summary of the evidence available to date from common experimental TBI models: fluid percussion injury; controlled cortical impact; blast TBI; and closed-head injury. For each model, evidence is organized according to outcome. Histopathological outcomes included are gross changes in morphology/histology, ventricular enlargement, gray/white matter shrinkage, axonal injury, cerebrovascular histopathology, inflammation, and neurogenesis. Behavioral outcomes included are overall neurological function, motor function, cognitive function, frontal lobe function, and stress-related outcomes. A brief discussion is provided comparing the most common experimental models of TBI and highlighting the utility of each model in understanding specific aspects of TBI pathology. The majority of experimental TBI studies collect data in the acute postinjury period, but few continue into the chronic period. Available evidence from long-term studies suggests that many of the experimental TBI models can lead to progressive changes in histopathology and behavior. The studies described in this review contribute to our understanding of chronic TBI pathology.	[Osier, Nicole D.; Carlson, Shaun W.; DeSana, Anthony; Dixon, C. Edward] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; [Carlson, Shaun W.; Dixon, C. Edward] Univ Pittsburgh, Dept Neurol Surg, Brain Trauma Res Ctr, Pittsburgh, PA 15260 USA; [Dixon, C. Edward] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA; [Osier, Nicole D.] Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15260 USA; [DeSana, Anthony] Seton Hill Univ, Greensburg, PA USA	Dixon, CE (corresponding author), Univ Pittsburgh, Dept Neurol Surg, 201 Hill Bldg,3434 Fifth Ave, Pittsburgh, PA 15260 USA.	dixonec@upmc.edu	Osier, Nicole/Q-7913-2017	Osier, Nicole/0000-0002-2903-6774; Carlson, Shaun/0000-0002-1413-5075	National Institutes of Health (NIH)-NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS079061, 5T32HD040686-14]; Department of Veterans AffairsUS Department of Veterans Affairs [RRD B1127-I]; NIH-NINRUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [1F31NR014957-01, T32NR009759]; Pittsburgh Foundation; Sigma Theta Tau International Eta Chapter; International Society for Nurses in Genetics; American Association of Neuroscience Nursing/Neuroscience Nursing Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F32NS090748, R01NS079061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [T32NR009759, F31NR014957] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX001127] Funding Source: NIH RePORTER	This work was supported by three federally sponsored grants: National Institutes of Health (NIH)-NINDS grants R01-NS079061 and 5T32HD040686-14, Department of Veterans Affairs grant RR&D B1127-I, and NIH-NINR grants 1F31NR014957-01 and T32NR009759. Additional support for this work was provided by grants from the following foundations and professional societies: The Pittsburgh Foundation, Sigma Theta Tau International Eta Chapter, International Society for Nurses in Genetics, and the American Association of Neuroscience Nursing/Neuroscience Nursing Foundation. The authors thank Michael Farmer for his time and assistance with the figures, Marilyn Farmer for her editorial support, as well as Lori Beck, Emad Madha, Lan Pham, and Amanda Savarese for their assistance in identifying and managing the long-term publications cited in this review.	Abdul-Muneer PM, 2013, FREE RADICAL BIO MED, V60, P282, DOI 10.1016/j.freeradbiomed.2013.02.029; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Ahmed F, 2012, ELECTROPHORESIS, V33, P3705, DOI 10.1002/elps.201200299; ALLEN IV, 1982, INJURY, V14, P183, DOI 10.1016/0020-1383(82)90057-2; Alves JL, 2014, J NEUROSCI RES, V92, P141, DOI 10.1002/jnr.23300; Anderson MI, 2002, BRAIN INJURY, V16, P743, DOI 10.1080/02699050210128906; Andruszkow H, 2014, HEALTH QUAL LIFE OUT, V12, DOI 10.1186/1477-7525-12-26; Arciniegas D, 1999, BRAIN INJURY, V13, P1, DOI 10.1080/026990599121827; Bailes JE, 2010, J NEUROTRAUM, V27, P1617, DOI 10.1089/neu.2009.1239; Bao F, 2012, J NEUROTRAUM, V29, P2375, DOI 10.1089/neu.2012.2408; Baratz R, 2010, J NEUROTRAUM, V27, P555, DOI 10.1089/neu.2009.0891; Barlow KM, 2005, PEDIATRICS, V116, pE174, DOI 10.1542/peds.2004-2739; BARNES CA, 1979, J COMP PHYSIOL PSYCH, V93, P74, DOI 10.1037/h0077579; Barth M, 2000, ACTA NEUROCHIR SUPPL, V76, P121; Baskin YK, 2003, J NEUROSCI METH, V129, P87, DOI 10.1016/S0165-0270(03)00212-7; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI 10.1089/neu.2009-0898; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Birrell JM, 2000, J NEUROSCI, V20, P4320; Blaiss CA, 2011, J NEUROSCI, V31, P4906, DOI 10.1523/JNEUROSCI.5265-10.2011; Bolzenius JD, 2015, APPL NEUROPSYCH-ADUL, V22, P79, DOI 10.1080/23279095.2013.845823; Bondi CO, 2008, NEUROPSYCHOPHARMACOL, V33, P320, DOI 10.1038/sj.npp.1301410; Bondi CO, 2014, J NEUROTRAUM, V31, P926, DOI 10.1089/neu.2013.3295; Bondi CO, 2010, PROG NEURO-PSYCHOPH, V34, P913, DOI 10.1016/j.pnpbp.2010.04.016; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Briones TL, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-57; Buccafusco JJ, 2009, FRONT NEUROSCI, P1; Bye N, 2011, J NEUROSCI RES, V89, P986, DOI 10.1002/jnr.22635; Byrnes KR, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-43; Cai WK, 2012, J NEUROSCI, V32, P9887, DOI 10.1523/JNEUROSCI.0375-12.2012; Cao AH, 2012, BEHAV BRAIN FUNCT, V8, DOI 10.1186/1744-9081-8-10; Carbonell WS, 1998, J NEUROTRAUM, V15, P217, DOI 10.1089/neu.1998.15.217; Carbonnel WS, 1999, ACTA NEUROPATHOL, V98, P396, DOI 10.1007/s004010051100; CAREY ME, 1989, J NEUROSURG, V71, P754, DOI 10.3171/jns.1989.71.5.0754; Carlson SW, 2014, J NEUROPATH EXP NEUR, V73, P734, DOI 10.1097/NEN.0000000000000092; Cederberg D, 2010, CHILD NERV SYST, V26, P221, DOI 10.1007/s00381-009-1029-x; Centers for Disease Control and Prevention, 2010, TRAUMATIC BRAIN INJU; Cernak I, 2004, NEUROBIOL DIS, V17, P29, DOI 10.1016/j.nbd.2004.05.011; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Chauhan NB, 2011, RESTOR NEUROL NEUROS, V29, P23, DOI 10.3233/RNN-2011-0573; Chauhan NB, 2010, BRAIN RES, V1360, P177, DOI 10.1016/j.brainres.2010.09.010; Chayer C, 2001, Curr Neurol Neurosci Rep, V1, P547, DOI 10.1007/s11910-001-0060-4; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Chen SF, 2004, J CEREBR BLOOD F MET, V24, P1025, DOI 10.1097/01.WCB.0000129415.34520.47; Chen T, 2011, BRAIN RES BULL, V84, P163, DOI 10.1016/j.brainresbull.2010.11.015; Cheng JP, 2012, J NEUROTRAUM, V29, P2684, DOI 10.1089/neu.2012.2560; Cho HJ, 2013, NEUROSCIENCE, V253, P9, DOI 10.1016/j.neuroscience.2013.08.037; Clelland CD, 2009, SCIENCE, V325, P210, DOI 10.1126/science.1173215; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Conti AC, 1998, J NEUROSCI, V18, P5663; Cook LG, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00087; Cooper DJ, 2004, JAMA-J AM MED ASSOC, V291, P1350, DOI 10.1001/jama.291.11.1350; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; d'Avila JC, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-31; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; de Lanerolle NC, 2011, J NEUROPATH EXP NEUR, V70, P1046, DOI 10.1097/NEN.0b013e318235bef2; Deng W, 2010, NAT REV NEUROSCI, V11, P339, DOI 10.1038/nrn2822; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; DeWitt DS, 2009, J NEUROTRAUM, V26, P877, DOI 10.1089/neu.2007.0439; Dias C, 2014, J NEUROTRAUM, V31, P1872, DOI 10.1089/neu.2014.3376; Dietrich WD, 1999, J NEUROTRAUM, V16, P567, DOI 10.1089/neu.1999.16.567; DIXON CE, 1994, J NEUROTRAUM, V11, P275, DOI 10.1089/neu.1994.11.275; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Donovan V, 2014, J CEREBR BLOOD F MET, V34, P715, DOI 10.1038/jcbfm.2014.6; Elder GA, 2012, J NEUROTRAUM, V29, P2564, DOI 10.1089/neu.2012.2510; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; Ellingson Benjamin M., 2005, V41, P86; Emery DL, 2005, J NEUROTRAUM, V22, P978, DOI 10.1089/neu.2005.22.978; ERB DE, 1988, ACTA NEUROPATHOL, V76, P347, DOI 10.1007/BF00686971; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Esler M, 2000, J CARDIOVASC PHARM, V35, pS1, DOI 10.1097/00005344-200000004-00001; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Flygt J, 2013, EUR J NEUROSCI, V38, P2153, DOI 10.1111/ejn.12179; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Fox GB, 1998, J NEUROSCI RES, V53, P718, DOI 10.1002/(SICI)1097-4547(19980915)53:6<718::AID-JNR9>3.0.CO;2-8; Fox GB, 1998, J NEUROTRAUM, V15, P1037, DOI 10.1089/neu.1998.15.1037; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Fox GB, 1999, J NEUROTRAUM, V16, P377, DOI 10.1089/neu.1999.16.377; Friess SH, 2009, J NEUROTRAUM, V26, P1111, DOI [10.1089/neu.2008.0845, 10.1089/neu.2008-0845]; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Fujita M, 2012, J NEUROTRAUM, V29, P2172, DOI 10.1089/neu.2012.2357; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; Gao X, 2008, J NEUROSCI RES, V86, P2258, DOI 10.1002/jnr.21677; Gao X, 2009, EXP NEUROL, V219, P516, DOI 10.1016/j.expneurol.2009.07.007; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Genovese RF, 2013, NEUROSCIENCE, V254, P120, DOI 10.1016/j.neuroscience.2013.09.021; Glaesser J, 2004, BMC PSYCHIATRY, V4, DOI 10.1186/1471-244X-4-5; Glushakova OY, 2014, J NEUROTRAUM, V31, P1180, DOI 10.1089/neu.2013.3080; Godbolt Alison K, 2014, Arch Phys Med Rehabil, V95, pS245, DOI 10.1016/j.apmr.2013.06.036; Gold EM, 2013, REGEN MED, V8, P483, DOI 10.2217/rme.13.41; Gonzalez MMC, 2013, J NEUROTRAUM, V30, P119, DOI 10.1089/neu.2012.2499; Graham DI, 2000, ACTA NEUROPATHOL, V99, P117, DOI 10.1007/PL00007414; Graner J, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00016; Greer JE, 2011, J NEUROSCI, V31, P5089, DOI 10.1523/JNEUROSCI.5103-10.2011; Guo XB, 2009, J NEUROTRAUM, V26, P1337, DOI [10.1089/neu.2008.0733, 10.1089/neu.2008-0733]; Gurkoff GG, 2006, BRAIN RES, V1077, P24, DOI 10.1016/j.brainres.2006.01.011; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; Halldorsson JG, 2013, BRAIN INJURY, V27, P1106, DOI 10.3109/02699052.2013.765599; HAMM RJ, 1995, EXP NEUROL, V136, P143, DOI 10.1006/exnr.1995.1091; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; Han RZ, 2009, NEUROSCI BULL, V25, P367, DOI 10.1007/s12264-009-0608-x; Hanell A, 2010, J NEUROTRAUM, V27, P1297, DOI 10.1089/neu.2009.1255; Hannay HJ, 1999, J NEUROTRAUM, V16, P1103, DOI 10.1089/neu.1999.16.1103; Hayes R. L., 1994, BRAIN INJURY, V1, P93; Hayward NMEA, 2010, J NEUROTRAUM, V27, P2203, DOI 10.1089/neu.2010.1448; Hilton GD, 2008, J CEREBR BLOOD F MET, V28, P1845, DOI 10.1038/jcbfm.2008.75; Hines-Beard J, 2012, EXP EYE RES, V99, P63, DOI 10.1016/j.exer.2012.03.013; Hoane MR, 2005, RESTOR NEUROL NEUROS, V23, P67; HOEHNSARIC R, 1988, PSYCHIAT CLIN N AM, V11, P375; HOFFMAN SW, 1994, J NEUROTRAUM, V11, P417, DOI 10.1089/neu.1994.11.417; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holmin S, 1999, NEUROREPORT, V10, P1889, DOI 10.1097/00001756-199906230-00017; Hoover RC, 2004, J NEUROTRAUM, V21, P501, DOI 10.1089/089771504774129847; Hoover S, 2014, INT J PSYCHOPHYSIOL, V91, P139, DOI 10.1016/j.ijpsycho.2013.12.009; Immonen RJ, 2009, NEUROIMAGE, V45, P1, DOI 10.1016/j.neuroimage.2008.11.022; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Jessberger S, 2009, LEARN MEMORY, V16, P147, DOI 10.1101/lm.1172609; Johnson EM, 2013, FRONT BEHAV NEUROSCI, V7, DOI 10.3389/fnbeh.2013.00044; Johnson SC, 1994, NEUROPSYCHOLOGY, V8, P307, DOI DOI 10.1037/0894-4105.8.3.301; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kabadi SV, 2010, NAT PROTOC, V5, P1552, DOI 10.1038/nprot.2010.112; Kagan VE, 2005, NAT CHEM BIOL, V1, P223, DOI 10.1038/nchembio727; Keck CA, 2007, RESTOR NEUROL NEUROS, V25, P77; Kee N, 2002, J NEUROSCI METH, V115, P97, DOI 10.1016/S0165-0270(02)00007-9; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; King NS, 2008, BRAIN INJURY, V22, P1, DOI 10.1080/02699050701829696; Klein E, 2003, CAN J PSYCHIAT, V48, P28; Kleindienst A, 2005, J NEUROTRAUM, V22, P645, DOI 10.1089/neu.2005.22.645; Knoblach SM, 2004, J CEREBR BLOOD F MET, V24, P1119, DOI 10.1097/01.WCB.0000138664.17682.32; Kobeissy F, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00186; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; Kovesdi Erzsebet, 2012, Front Neurol, V3, P111, DOI 10.3389/fneur.2012.00111; Kovesdi E, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00042; Kramer S P, 1896, Ann Surg, V23, P163, DOI 10.1097/00000658-189601000-00031; Kreuter M, 1998, BRAIN INJURY, V12, P349, DOI 10.1080/026990598122494; Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150; Krpan KM, 2013, NEUROREHABILITATION, V32, P721, DOI 10.3233/NRE-130897; Kwon Sook-Kyung C, 2011, Front Neurol, V2, P12, DOI 10.3389/fneur.2011.00012; Lam TI, 2013, NEUROREHAB NEURAL RE, V27, P889, DOI 10.1177/1545968313491003; Lapiz MDS, 2006, NEUROSCIENCE, V137, P1039, DOI 10.1016/j.neuroscience.2005.09.031; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Lee LL, 2004, EXP NEUROL, V190, P70, DOI 10.1016/j.expneurol.2004.07.003; Lenzlinger PM, 2005, NEUROSCIENCE, V134, P1047, DOI 10.1016/j.neuroscience.2005.04.048; Leung LY, 2014, ANN BIOMED ENG, V42, P1618, DOI 10.1007/s10439-014-1014-8; LEVIN HS, 1981, ARCH NEUROL-CHICAGO, V38, P623, DOI 10.1001/archneur.1981.00510100051007; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Li Y, 2000, J CEREBR BLOOD F MET, V20, P1311, DOI 10.1097/00004647-200009000-00006; Lifshitz J, 2007, J NEUROPATH EXP NEUR, V66, P218, DOI 10.1097/01.jnen.0000248558.75950.4d; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Lima FD, 2008, BEHAV BRAIN RES, V193, P306, DOI 10.1016/j.bbr.2008.05.013; LINDGREN STEN, 1965, BIOPHYSIK, V2, P320; Lindner MD, 1998, J NEUROTRAUM, V15, P199, DOI 10.1089/neu.1998.15.199; Liston C, 2006, J NEUROSCI, V26, P7870, DOI 10.1523/JNEUROSCI.1184-06.2006; Liu CL, 2008, J CEREBR BLOOD F MET, V28, P674, DOI 10.1038/sj.jcbfm.9600587; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Long JB, 1996, J NEUROTRAUM, V13, P149, DOI 10.1089/neu.1996.13.149; Longhi L, 2004, J NEUROTRAUM, V21, P1723, DOI 10.1089/0897715042664876; Longhi L, 2011, J CEREBR BLOOD F MET, V31, P1919, DOI 10.1038/jcbfm.2011.42; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu DY, 2007, NEUROSURGERY, V61, P596, DOI 10.1227/01.NEU.0000290908.38438.B2; Lu J, 2012, J NEUROTRAUM, V29, P1434, DOI 10.1089/neu.2010.1591; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Lyeth BG, 2001, EXP NEUROL, V169, P191, DOI 10.1006/exnr.2001.7643; Mackie AR, 2011, TEX HEART I J, V38, P474; Majka M, 2001, BLOOD, V97, P3075, DOI 10.1182/blood.V97.10.3075; Mannix R, 2013, ANN NEUROL, V74, P65, DOI 10.1002/ana.23858; Mannix RC, 2011, J CEREBR BLOOD F MET, V31, P351, DOI 10.1038/jcbfm.2010.99; Marklund N, 2007, J NEUROSURG, V107, P844, DOI 10.3171/JNS-07/10/0844; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Maruichi K, 2009, NEUROPATHOLOGY, V29, P422, DOI 10.1111/j.1440-1789.2008.00995.x; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; Meng YL, 2011, J NEUROSURG, V115, P550, DOI 10.3171/2011.3.JNS101721; MEYERS CA, 1983, J NEUROL NEUROSUR PS, V46, P1092, DOI 10.1136/jnnp.46.12.1092; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Ming GL, 2011, NEURON, V70, P687, DOI 10.1016/j.neuron.2011.05.001; Miyamoto Kazuyuki, 2013, Acta Neurochir Suppl, V118, P103, DOI 10.1007/978-3-7091-1434-6_18; Muir KW, 2006, CURR OPIN PHARMACOL, V6, P53, DOI 10.1016/j.coph.2005.12.002; Muradashvili N, 2013, BRAIN INJURY, V27, P1508, DOI 10.3109/02699052.2013.823562; Murray CK, 2005, MIL MED, V170, P516, DOI 10.7205/MILMED.170.6.516; Nagamoto-Combs K, 2007, J NEUROTRAUM, V24, P1719, DOI 10.1089/neu.2007.0377; Nekludov M, 2007, J NEUROTRAUM, V24, P174, DOI 10.1089/neu.2006.0173; NEVIN NC, 1967, J NEUROPATH EXP NEUR, V26, P77, DOI 10.1097/00005072-196701000-00006; Nochi M, 1998, QUAL HEALTH RES, V8, P665, DOI 10.1177/104973239800800507; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; O'Connor CA, 2007, EXP NEUROL, V205, P145, DOI 10.1016/j.expneurol.2007.01.034; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Ohry A, 1996, BRAIN INJURY, V10, P687, DOI 10.1080/026990596124106; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Pandey DK, 2009, BEHAV BRAIN RES, V205, P436, DOI 10.1016/j.bbr.2009.07.027; Pascual JL, 2013, AM J SURG, V206, P840, DOI 10.1016/j.amjsurg.2013.07.016; Passineau MJ, 2001, EXP NEUROL, V168, P373, DOI 10.1006/exnr.2000.7623; Patel AD, 2010, J NEUROPATH EXP NEUR, V69, P1177, DOI 10.1097/NEN.0b013e3181fbf6d6; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; Piao CS, 2013, NEUROBIOL DIS, V54, P252, DOI 10.1016/j.nbd.2012.12.017; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Poca MA, 2005, J NEUROTRAUM, V22, P1303, DOI 10.1089/neu.2005.22.1303; Ponsford J, 2003, NEUROPSYCHOL REHABIL, V13, P275, DOI 10.1080/09602010244000363; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Rafaels K, 2011, J NEUROTRAUM, V28, P2319, DOI 10.1089/neu.2009.1207; Rafaels KA, 2012, J TRAUMA ACUTE CARE, V73, P895, DOI 10.1097/TA.0b013e31825a760e; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; RAND CW, 1946, ARCH NEURO PSYCHIATR, V55, P79, DOI 10.1001/archneurpsyc.1946.02300130003001; Ratcliff JJ, 2007, BRAIN INJURY, V21, P1023, DOI 10.1080/02699050701633072; Rau TF, 2012, J TRAUMA ACUTE CARE, V73, pS165, DOI 10.1097/TA.0b013e318260896a; Reger ML, 2012, BIOL PSYCHIAT, V71, P335, DOI 10.1016/j.biopsych.2011.11.007; Riess P, 2001, RESTOR NEUROL NEUROS, V18, P1; Rigby P., 2011, SURVEY BLAST INJURY; RIGOR, IMPR QUAL NINDS SUPP; RINDER L, 1968, ACTA NEUROPATHOL, V11, P183; Risling M, 2011, NEUROIMAGE, V54, pS89, DOI 10.1016/j.neuroimage.2010.05.031; Risling Marten, 2012, Front Neurol, V3, P30, DOI 10.3389/fneur.2012.00030; Rodriguez-Paez AC, 2005, ACTA NEUROPATHOL, V109, P603, DOI 10.1007/s00401-005-1010-z; Rola R, 2006, EXP NEUROL, V202, P189, DOI 10.1016/j.expneurol.2006.05.034; Rubovitch V, 2011, EXP NEUROL, V232, P280, DOI 10.1016/j.expneurol.2011.09.018; Sahay A, 2011, NATURE, V472, P466, DOI 10.1038/nature09817; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; Sanai N, 2004, NATURE, V427, P740, DOI 10.1038/nature02301; Sanders MJ, 1999, J NEUROTRAUM, V16, P915, DOI 10.1089/neu.1999.16.915; Sauerbeck A, 2011, EXP NEUROL, V227, P128, DOI 10.1016/j.expneurol.2010.10.003; SCHALEN W, 1994, BRAIN INJURY, V8, P49, DOI 10.3109/02699059409150958; Schmidt RH, 1999, J NEUROTRAUM, V16, P1139, DOI 10.1089/neu.1999.16.1139; Schutz C, 2006, CRIT CARE MED, V34, P492, DOI 10.1097/01.CCM.0000198326.32049.7F; Scott A, 2004, BRIT J SPORT MED, V38, P248, DOI 10.1136/bjsm.2003.011221; Seguin JR, 2009, EUR J DEV PSYCHOL, V6, P100, DOI 10.1080/17405620701669871; Semple BD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103386; Semple BD, 2012, J NEUROTRAUM, V29, P2672, DOI 10.1089/neu.2012.2595; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; Shear DA, 2011, RESTOR NEUROL NEUROS, V29, P215, DOI 10.3233/RNN-2011-0593; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; Shultz SR, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-26; Shultz SR, 2012, J NEUROTRAUM, V29, P281, DOI 10.1089/neu.2011.2123; SILVA MRE, 1994, AGENTS ACTIONS, V43, P86; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Slewa-Younan S, 2004, ARCH PHYS MED REHAB, V85, P376, DOI 10.1016/j.apmr.2003.05.007; Smith DC, 2005, J NEUROTRAUM, V22, P1485, DOI 10.1089/neu.2005.22.1485; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Smith DH, 2013, J NEUROTRAUM, V30, P307, DOI 10.1089/neu.2012.2825; Sosa MAG, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/2051-5960-2-67; Spain A, 2010, J NEUROTRAUM, V27, P1429, DOI 10.1089/neu.2010.1288; Stern SA, 2000, J NEUROSURG, V93, P305, DOI 10.3171/jns.2000.93.2.0305; Steward O, 1999, EXP NEUROL, V157, P19, DOI 10.1006/exnr.1999.7040; Strauss KI, 2000, J NEUROTRAUM, V17, P695, DOI 10.1089/089771500415436; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; Sullivan S, 2013, J NEUROTRAUM, V30, P538, DOI 10.1089/neu.2012.2594; Sun D, 2007, EXP NEUROL, V204, P264, DOI 10.1016/j.expneurol.2006.11.005; Sun D, 2009, EXP NEUROL, V216, P56, DOI 10.1016/j.expneurol.2008.11.011; Tait DS, 2007, EUR J NEUROSCI, V25, P3719, DOI 10.1111/j.1460-9568.2007.05612.x; Takeuchi Satoru, 2013, Acta Neurochir Suppl, V118, P99, DOI 10.1007/978-3-7091-1434-6_17; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Tate RL, 1999, PSYCHOL MED, V29, P713, DOI 10.1017/S0033291799008466; Taupin P, 2007, BRAIN RES REV, V53, P198, DOI 10.1016/j.brainresrev.2006.08.002; Thau-Zuchman O, 2012, J MOL NEUROSCI, V47, P166, DOI 10.1007/s12031-012-9706-8; Thau-Zuchman O, 2010, J CEREBR BLOOD F MET, V30, P1008, DOI 10.1038/jcbfm.2009.271; Thompson HJ, 2006, RESTOR NEUROL NEUROS, V24, P109; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; Tomasevic G, 2012, J NEUROSURG, V116, P1368, DOI 10.3171/2012.2.JNS11888; Truelle JL, 2010, BRAIN INJURY, V24, P1272, DOI 10.3109/02699052.2010.506865; Turner RC, 2013, EXP NEUROL, V248, P520, DOI 10.1016/j.expneurol.2013.07.008; Urrea C, 2007, RESTOR NEUROL NEUROS, V25, P65; Varsos GV, 2014, NEUROCRIT CARE, V21, P266, DOI 10.1007/s12028-014-9971-1; Voikar V, 2001, PHYSIOL BEHAV, V72, P271, DOI 10.1016/S0031-9384(00)00405-4; Wagner AK, 2004, BRAIN RES, V998, P113, DOI 10.1016/j.brainres.2003.11.027; Whalen MJ, 1997, J NEUROTRAUM, V14, P561, DOI 10.1089/neu.1997.14.561; Williams AJ, 2005, J NEUROTRAUM, V22, P313, DOI 10.1089/neu.2005.22.313; Williams AJ, 2006, J NEUROTRAUM, V23, P1828, DOI 10.1089/neu.2006.23.1828; Williams WH, 2002, BRAIN INJURY, V16, P673, DOI 10.1080/02699050210128861; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Xiong Y, 2011, TRANSL STROKE RES, V2, P619, DOI 10.1007/s12975-011-0120-2; Xiong Y, 2012, J NEUROSURG, V116, P1081, DOI 10.3171/2012.1.JNS111729; Xiong Y, 2011, J NEUROSURG, V114, P102, DOI 10.3171/2010.4.JNS10118; Xiong Y, 2011, J NEUROSURG, V114, P549, DOI 10.3171/2010.10.JNS10925; Xiong Y, 2010, J NEUROSURG, V113, P598, DOI 10.3171/2009.9.JNS09844; Yamaki T, 1998, BRAIN RES PROTOC, V3, P100, DOI 10.1016/S1385-299X(98)00030-0; Yamaki T, 1997, BRAIN RES, V752, P151, DOI 10.1016/S0006-8993(96)01469-2; Yoshioka T, 2005, STEM CELLS, V23, P355, DOI 10.1634/stemcells.2004-0200; Young JW, 2010, COGN AFFECT BEHAV NE, V10, P243, DOI 10.3758/CABN.10.2.243; Yu TS, 2008, J NEUROSCI, V28, P12901, DOI 10.1523/JNEUROSCI.4629-08.2008; Zhang JY, 2009, STAPP CAR CRASH JO, V53, P215; Zhang YL, 2012, EXP NEUROL, V235, P336, DOI 10.1016/j.expneurol.2012.02.015; Zhang YL, 2009, BRAIN RES, V1294, P153, DOI 10.1016/j.brainres.2009.07.077; Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033; Zhao CM, 2006, J NEUROSCI, V26, P3, DOI 10.1523/JNEUROSCI.3648-05.2006; Zhao ZR, 2012, J NEUROTRAUM, V29, P2475, DOI 10.1089/neu.2012.2511; Zheng WM, 2013, J NEUROTRAUM, V30, P1872, DOI 10.1089/neu.2010.1579; Zhou HZ, 2012, J NEUROPATH EXP NEUR, V71, P348, DOI 10.1097/NEN.0b013e31824ea078; ZINK BJ, 1993, J NEUROTRAUM, V10, P275, DOI 10.1089/neu.1993.10.275	309	41	42	0	15	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC 1	2015	32	23			SI		1861	1882		10.1089/neu.2014.3680			22	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CX4TW	WOS:000365694200004	25490251	Green Published			2021-06-18	
J	Rowson, B; Rowson, S; Duma, SM				Rowson, Bethany; Rowson, Steven; Duma, Stefan M.			Hockey STAR: A Methodology for Assessing the Biomechanical Performance of Hockey Helmets	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Concussion; Linear; Rotational; Acceleration; Risk; Impact	CHRONIC TRAUMATIC ENCEPHALOPATHY; INJURY SURVEILLANCE SYSTEM; HEAD IMPACT BIOMECHANICS; SCHOOL FOOTBALL PLAYERS; ICE HOCKEY; DESCRIPTIVE EPIDEMIOLOGY; PROFESSIONAL FOOTBALL; CONCUSSION EDUCATION; RISK; SPORT	Optimizing the protective capabilities of helmets is one of several methods of reducing brain injury risk in sports. This paper presents the experimental and analytical development of a hockey helmet evaluation methodology. The Summation of Tests for the Analysis of Risk (STAR) formula combines head impact exposure with brain injury probability over the broad range of 227 head impacts that a hockey player is likely to experience during one season. These impact exposure data are mapped to laboratory testing parameters using a series of 12 impact conditions comprised of three energy levels and four head impact locations, which include centric and non-centric directions of force. Injury risk is determined using a multivariate injury risk function that incorporates both linear and rotational head acceleration measurements. All testing parameters are presented along with exemplar helmet test data. The Hockey STAR methodology provides a scientific framework for manufacturers to optimize hockey helmet design for injury risk reduction, as well as providing consumers with a meaningful metric to assess the relative performance of hockey helmets.	[Rowson, Bethany; Rowson, Steven; Duma, Stefan M.] Virginia Tech, Dept Biomed Engn & Mech, Blacksburg, VA 24061 USA	Rowson, B (corresponding author), Virginia Tech, Dept Biomed Engn & Mech, 313 Kelly Hall,325 Stanger St, Blacksburg, VA 24061 USA.	bethmv2@vt.edu	Rowson, Steven/B-1270-2012; Duma, Stefan/A-8368-2012	Rowson, Steven/0000-0002-3227-0596; 	Virginia Tech Department of Biomedical Engineering and Mechanics; Virginia Tech Institute of Critical Technologies and Applied Sciences	The authors appreciate the support and assistance from the faculty, students, and staff at the Virginia Tech - Wake Forest Center for Injury Biomechanics. We are also grateful for the financial support from the Virginia Tech Department of Biomedical Engineering and Mechanics, and the Virginia Tech Institute of Critical Technologies and Applied Sciences.	Agel J, 2007, J ATHL TRAINING, V42, P241; Agel J, 2007, J ATHL TRAINING, V42, P249; Allison MA, 2014, MED SCI SPORT EXER, V46, P115, DOI 10.1249/MSS.0b013e3182a32d0d; Baugh CM, 2015, J NEUROTRAUM, V32, P314, DOI 10.1089/neu.2014.3582; Benson BW, 2013, BRIT J SPORT MED, V47, P321, DOI 10.1136/bjsports-2013-092216; Biasca N, 2002, BRIT J SPORT MED, V36, P410, DOI 10.1136/bjsm.36.6.410; Brainard LL, 2012, MED SCI SPORT EXER, V44, P297, DOI 10.1249/MSS.0b013e31822b0ab4; Chamard E, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12305; Clay MB, 2013, J CHIROPR MED, V12, P230, DOI 10.1016/j.jcm.2012.11.005; Cobb B. R., 2014, P I MECH ENG P-J SPO; Council N.R., 2014, SPORTS REL CONC YOUT; Covassin T, 2012, J SCHOOL HEALTH, V82, P233, DOI 10.1111/j.1746-1561.2012.00692.x; Davenport EM, 2014, J NEUROTRAUM, V31, P1617, DOI 10.1089/neu.2013.3233; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10186; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10210; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10187; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.10.FOCUS10222; Echlin PS, 2012, NEUROSURG FOCUS, V33, P1, DOI DOI 10.3171/2012.10.F0CUS12286; Funk JR, 2012, ANN BIOMED ENG, V40, P79, DOI 10.1007/s10439-011-0400-8; Gadd C.W., 1966, PROCEEDINGS OF THE 1; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Gennarelli T.A., 1971, P 15 STAPP CAR CRASH, V39, P797; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; GURDJIAN ES, 1966, J TRAUM, V6, P600, DOI 10.1097/00005373-196609000-00005; Gwin J. T., 2009, J ASTM INT, V6, P1; Hackney J.R, 1995, SAE TECHNICAL PAPER; Hardy WN, 2007, STAPP CAR CRASH JO, V51, P17; HARDY WN, 1994, INT J IMPACT ENG, V15, P561, DOI 10.1016/0734-743X(94)80034-7; Hershman L. L., 2001, ENHANCED SAFETY VEHI, P1; Hootman JM, 2007, J ATHL TRAINING, V42, P311; King A.I., 2003, P INT RES C BIOM IMP; Koerte IK, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12303; Langburt W, 2001, J CHILD NEUROL, V16, P83, DOI 10.1177/088307380101600203; Macpherson A, 2006, PEDIATRICS, V117, pE143, DOI 10.1542/peds.2005-1163; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mihalik JP, 2012, ANN BIOMED ENG, V40, P141, DOI 10.1007/s10439-011-0405-3; Odelgard B, 1989, ASTM STP; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; OMMAYA AK, 1971, J BIOMECH, V4, P13, DOI 10.1016/0021-9290(71)90011-X; Pellman EJ, 2006, NEUROSURGERY, V58, P78, DOI 10.1227/01.NEU.0000196265.35238.7C; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Roberts WO, 1996, ARCH PEDIAT ADOL MED, V150, P140, DOI 10.1001/archpedi.1996.02170270022003; Rowson S., 2014, VIRGINIA TECH HELMET; Rowson S, 2014, J NEUROSURG, V120, P919, DOI 10.3171/2014.1.JNS13916; Rowson S, 2013, J NEUROSURG, V119, P805, DOI 10.3171/2013.3.JNS121735; Rowson S, 2013, P I MECH ENG P-J SPO, V227, P12, DOI 10.1177/1754337112442620; Rowson S, 2013, ANN BIOMED ENG, V41, P873, DOI 10.1007/s10439-012-0731-0; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Rowson S, 2011, ANN BIOMED ENG, V39, P2130, DOI 10.1007/s10439-011-0322-5; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Unterharnscheidt F. J, 1971, P 15 STAPP CAR CRASH; Versace J., 1971, SAE TECHNICAL PAPER; Wilcox BJ, 2014, J BIOMECH, V47, P109, DOI 10.1016/j.jbiomech.2013.10.004; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	58	41	41	0	23	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	OCT	2015	43	10					2429	2443		10.1007/s10439-015-1278-7			15	Engineering, Biomedical	Engineering	CR5NS	WOS:000361390400011	25822907	Green Published, Other Gold			2021-06-18	
J	Ellis, MJ; Leiter, J; Hall, T; McDonald, PJ; Sawyer, S; Silver, N; Bunge, M; Essig, M				Ellis, Michael J.; Leiter, Jeff; Hall, Thomas; McDonald, Patrick J.; Sawyer, Scott; Silver, Norm; Bunge, Martin; Essig, Marco			Neuroimaging findings in pediatric sports-related concussion	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						neuroimaging; sports-related concussion; pediatric patients; computed tomography; magnetic resonance imaging; trauma	CRANIAL COMPUTED-TOMOGRAPHY; DIFFUSE AXONAL INJURY; DECISION RULE; HEAD-INJURY; INTERNATIONAL-CONFERENCE; ARACHNOID CYSTS; CHILDREN; RISK; STATEMENT; RETURN	OBJECT The goal in this review was to summarize the results of clinical neuroimaging studies performed in patients with sports-related concussion (SRC) who were referred to a multidisciplinary pediatric concussion program. METHODS The authors conducted a retrospective review of medical records and neuroimaging findings for all patients referred to a multidisciplinary pediatric concussion program between September 2013 and July 2014. Inclusion criteria were as follows: 1) age 19 years; and 2) physician-diagnosed SRC. All patients underwent evaluation and follow-up by the same neurosurgeon. The 2 outcomes examined in this review were the frequency of neuroimaging studies performed in this population (including CT and MRI) and the findings of those studies. Clinical indications for neuroimaging and the impact of neuroimaging findings on clinical decision making were summarized where available. This investigation was approved by the local institutional ethics review board. RESULTS A total of 151 patients (mean age 14 years, 59% female) were included this study. Overall, 36 patients (24%) underwent neuroimaging studies, the results of which were normal in 78% of cases. Sixteen percent of patients underwent CT imaging; results were normal in 79% of cases. Abnormal CT findings included the following: arachnoid cyst (1 patient), skull fracture (2 patients), suspected intracranial hemorrhage (1 patient), and suspected hemorrhage into an arachnoid cyst (1 patient). Eleven percent of patients underwent MRI; results were normal in 75% of cases. Abnormal MRI findings included the following: intraparenchymal hemorrhage and sylvian fissure arachnoid cyst (1 patient); nonhemorrhagic contusion (1 patient); demyelinating disease (1 patient); and posterior fossa arachnoid cyst, cerebellar volume loss, and nonspecific white matter changes (1 patient). CONCLUSIONS Results of clinical neuroimaging studies are normal in the majority of pediatric patients with SRC. However, in selected cases neuroimaging can provide information that impacts decision making about return to play and retirement from the sport.	[Ellis, Michael J.; Leiter, Jeff; McDonald, Patrick J.] Univ Manitoba, Dept Surg, Winnipeg, MB R3T 2N2, Canada; [Ellis, Michael J.; McDonald, Patrick J.; Sawyer, Scott; Silver, Norm] Univ Manitoba, Dept Pediat & Child Hlth, Winnipeg, MB R3T 2N2, Canada; [Bunge, Martin; Essig, Marco] Univ Manitoba, Dept Diagnost Imaging, Winnipeg, MB, Canada; [Leiter, Jeff; McDonald, Patrick J.] Univ Manitoba, Sect Neurosurg, Winnipeg, MB, Canada; [Sawyer, Scott; Silver, Norm] Hlth Sci Ctr Childrens Hosp, Winnipeg, MB, Canada; [Ellis, Michael J.; Leiter, Jeff; Hall, Thomas; McDonald, Patrick J.] Pan Am Clin, Winnipeg, MB R3M 3E4, Canada; [Ellis, Michael J.; McDonald, Patrick J.] Canada North Concuss Network, Childrens Hosp Res Inst Manitoba, Winnipeg, MB, Canada	Ellis, MJ (corresponding author), Pan Am Clin, 75 Poseidon Bay, Winnipeg, MB R3M 3E4, Canada.	mellis3@panamclinic.com		essig, marco/0000-0002-7964-2297	Pan Am Clinic Foundation	We thank the Pan Am Clinic Foundation for their financial support of this study.	Al-Holou WN, 2010, J NEUROSURG-PEDIATR, V5, P578, DOI 10.3171/2010.2.PEDS09464; Ashwal S, 2006, ARCH PHYS MED REHAB, V87, pS50, DOI 10.1016/j.apmr.2006.07.275; Atabaki SM, 2008, ARCH PEDIAT ADOL MED, V162, P439, DOI 10.1001/archpedi.162.5.439; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Babikian T, 2005, PEDIATR NEUROL, V33, P184, DOI 10.1016/j.pediatrneurol.2005.03.015; Beauchamp MH, 2013, CORTEX, V49, P591, DOI 10.1016/j.cortex.2012.08.015; Beauchamp MH, 2011, J NEUROTRAUM, V28, P915, DOI 10.1089/neu.2010.1712; Bodensteiner JB, 1998, J CHILD NEUROL, V13, P120, DOI 10.1177/088307389801300305; Brenner DJ, 2001, AM J ROENTGENOL, V176, P289, DOI 10.2214/ajr.176.2.1760289; Cantu RC, 2003, CLIN SPORT MED, V22, P593, DOI 10.1016/S0278-5919(02)00095-9; Cantu RC, 2011, PM&R, V3, pS440, DOI 10.1016/j.pmrj.2011.07.013; Choe MC, 2012, CURR OPIN PEDIATR, V24, P689, DOI 10.1097/MOP.0b013e32835a1a44; Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; Cress M, 2013, NEUROSURGERY, V72, P716, DOI 10.1227/NEU.0b013e318285b3a4; DAVIS RL, 1994, ANN EMERG MED, V24, P640, DOI 10.1016/S0196-0644(94)70273-X; Dunning J, 2006, ARCH DIS CHILD, V91, P885, DOI 10.1136/adc.2005.083980; Eisenberg MA, 2014, PEDIATRICS, V133, P999, DOI 10.1542/peds.2014-0158; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Hall P, 2004, BMJ-BRIT MED J, V328, P19, DOI 10.1136/bmj.328.7430.19; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Klassen TP, 2000, ACAD EMERG MED, V7, P739, DOI 10.1111/j.1553-2712.2000.tb02260.x; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Kutcher JS, 2010, CURR SPORT MED REP, V9, P16, DOI 10.1249/JSR.0b013e3181caa89d; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Maguire JL, 2009, PEDIATRICS, V124, pE145, DOI 10.1542/peds.2009-0075; Makdissi M, 2013, BRIT J SPORT MED, V47, P314, DOI 10.1136/bjsports-2013-092256; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; Mayer AR, 2012, J NEUROSCI, V32, P17961, DOI 10.1523/JNEUROSCI.3379-12.2012; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meehan WP, 2013, J PEDIATR-US, V163, P721, DOI 10.1016/j.jpeds.2013.03.012; Oman JA, 2006, PEDIATRICS, V117, pE238, DOI 10.1542/peds.2005-1063; Osmond MH, 2010, CAN MED ASSOC J, V182, P341, DOI 10.1503/cmaj.091421; Palchak MJ, 2003, ANN EMERG MED, V42, P492, DOI 10.1067/S0196-0644(03)00425-6; Parsch CS, 1997, NEUROSURGERY, V40, P483, DOI 10.1097/00006123-199703000-00010; Scopaz KA, 2013, SPORTS HEALTH, V5, P537, DOI 10.1177/1941738112473059; Tator CH, 2013, CAN MED ASSOC J, V185, P975, DOI 10.1503/cmaj.120039; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Yang Z, 2012, J NEUROTRAUM, V29, P2124, DOI 10.1089/neu.2012.2395	43	41	41	0	15	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707	1933-0715		J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	SEP	2015	16	3					241	247		10.3171/2015.1.PEDS14510			7	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	CP6VY	WOS:000360027500001	26031620	Bronze			2021-06-18	
J	Wilde, EA; Bouix, S; Tate, DF; Lin, AP; Newsome, MR; Taylor, BA; Stone, JR; Montier, J; Gandy, SE; Biekman, B; Shenton, ME; York, G				Wilde, Elisabeth A.; Bouix, Sylvain; Tate, David F.; Lin, Alexander P.; Newsome, Mary R.; Taylor, Brian A.; Stone, James R.; Montier, James; Gandy, Samuel E.; Biekman, Brian; Shenton, Martha E.; York, Gerald			Advanced neuroimaging applied to veterans and service personnel with traumatic brain injury: state of the art and potential benefits	BRAIN IMAGING AND BEHAVIOR			English	Article						Traumatic brain injury; Magnetic resonance imaging; Diffusion tensor imaging; fMRI; Positron emission tomography; Magnetic resonance spectroscopy; Veteran	MAGNETIC-RESONANCE-SPECTROSCOPY; PROTON MR SPECTROSCOPY; POSTTRAUMATIC-STRESS-DISORDER; CEREBRAL-BLOOD-FLOW; DIFFUSE AXONAL INJURY; SPORTS-RELATED CONCUSSION; WHITE-MATTER ABNORMALITIES; AFGHANISTAN WAR VETERANS; MEDIAL TEMPORAL-LOBES; PITTSBURGH COMPOUND-B	Traumatic brain injury (TBI) remains one of the most prevalent forms of morbidity among Veterans and Service Members, particularly for those engaged in the conflicts in Iraq and Afghanistan. Neuroimaging has been considered a potentially useful diagnostic and prognostic tool across the spectrum of TBI generally, but may have particular importance in military populations where the diagnosis of mild TBI is particularly challenging, given the frequent lack of documentation on the nature of the injuries and mixed etiologies, and highly comorbid with other disorders such as post-traumatic stress disorder, depression, and substance misuse. Imaging has also been employed in attempts to understand better the potential late effects of trauma and to evaluate the effects of promising therapeutic interventions. This review surveys the use of structural and functional neuroimaging techniques utilized in military studies published to date, including the utilization of quantitative fluid attenuated inversion recovery (FLAIR), susceptibility weighted imaging (SWI), volumetric analysis, diffusion tensor imaging (DTI), magnetization transfer imaging (MTI), positron emission tomography (PET), magnetoencephalography (MEG), task-based and resting state functional MRI (fMRI), arterial spin labeling (ASL), and magnetic resonance spectroscopy (MRS). The importance of quality assurance testing in current and future research is also highlighted. Current challenges and limitations of each technique are outlined, and future directions are discussed.	[Wilde, Elisabeth A.; Newsome, Mary R.; Taylor, Brian A.] Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA; [Wilde, Elisabeth A.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; [Wilde, Elisabeth A.] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; [Wilde, Elisabeth A.; Newsome, Mary R.; Biekman, Brian] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Shenton, Martha E.] Harvard Univ, Brigham & Womens Hosp, Dept Psychiat, Sch Med, Boston, MA 02115 USA; [Tate, David F.] Univ Missouri St Louis, Missouri Inst Mental Hlth, Berkeley, MO USA; [Lin, Alexander P.] Harvard Univ, Brigham & Womens Hosp, Ctr Clin Spect, Sch Med, Boston, MA 02115 USA; [Lin, Alexander P.; Shenton, Martha E.] Harvard Univ, Brigham & Womens Hosp, Dept Radiol, Sch Med, Boston, MA 02115 USA; [Montier, James] Univ Virginia Hlth Syst, Dept Radiol & Med Imaging, Dept Neurol Surg, Charlottesville, VA USA; [Gandy, Samuel E.] Icahn Sch Med, Ctr Cognit Hlth, New York, NY USA; [Gandy, Samuel E.] Icahn Sch Med, NFL Neurol Ctr, New York, NY USA; [Gandy, Samuel E.] James J Peters VA Med Ctr, Div Neurol, New York, NY USA; [Shenton, Martha E.] Vet Affairs Boston Healthcare Syst, Dept Psychiat, Brockton Div, Brockton, MA USA; [York, Gerald] San Antonio Mil Med Ctr, Def Vet Brain Injury Ctr, Ft Sam Houston, TX USA	Wilde, EA (corresponding author), Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA.	ewilde@bcm.edu	Tate, David F/I-3963-2013; Shenton, Martha/V-8780-2019	Tate, David F/0000-0003-0213-1920; Taylor, Brian/0000-0001-9745-1075	US Department of Veterans AffairsUS Department of Veterans Affairs; VA MERIT review grant programUS Department of Veterans Affairs [1I01RX000684-01A2, 1I01RX001062-01A1, 1 I01 RX000928:]; VA SPIRE program [VA 1 I21RX001565, VA 1 I21RX001608]; Department of Defense Office of the Congressionally Directed Medical Research Programs (CDMRP) [W81XWH-10-1-0835, X81XWH-07-CC-CSDoD]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-NS078337]; Telemedicine and Advanced Technology Research Center (TATRC) at the U.S. Army Medical Research and Material Command (USAMRMC)U.S. Army Medical Research & Materiel Command (USAMRMC) [W81XWH-13-2-0025]; United States Army Medical Research Acquisition Activity (USAMRAA) [W81XWH-09-2-0160]; Chronic Effects Neurotrauma Consortium (CENC) [PT108802-SC106187, 1W81XWH-13-2-0095]; Alzheimer's Drug Discovery Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS078337] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG005138] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX000684, I01RX002174, I21RX001608] Funding Source: NIH RePORTER	The authors recognize the support of the US Department of Veterans Affairs (EAW, BAT, SG, MRN, MES, SG), the VA MERIT review grant program (1I01RX000684-01A2: SG, 1I01RX001062-01A1: EAW, MRN, and 1 I01 RX000928: MES, SB), and VA SPIRE program (VA 1 I21RX001565 BAT, and VA 1 I21RX001608 MRN); the Department of Defense Office of the Congressionally Directed Medical Research Programs (CDMRP) (W81XWH-10-1-0835: APL; X81XWH-07-CC-CSDoD: MES, SB), the National Institutes of Health (R01-NS078337: APL, MES, SB), Telemedicine and Advanced Technology Research Center (TATRC) at the U.S. Army Medical Research and Material Command (USAMRMC; W81XWH-13-2-0025: DFT), United States Army Medical Research Acquisition Activity (USAMRAA; W81XWH-09-2-0160: JRS, SG), the Chronic Effects Neurotrauma Consortium (CENC; PT108802-SC106187 and 1W81XWH-13-2-0095), and the Alzheimer's Drug Discovery Foundation (SG). We also wish to thank Rhonda O'Donovan for her assistance in manuscript preparation.	Allen EA, 2011, FRONT SYST NEUROSCI, V5, DOI 10.3389/fnsys.2011.00002; Alsop DC, 2015, MAGN RESON MED, V73, P102, DOI 10.1002/mrm.25197; Amann M, 2015, NEUROIMAGE, V108, P87, DOI 10.1016/j.neuroimage.2014.12.045; Aoki Y, 2012, J NEUROL NEUROSUR PS, V83, P870, DOI 10.1136/jnnp-2012-302742; Aron AR, 2003, NAT NEUROSCI, V6, P115, DOI 10.1038/nn1003; Ashwal S, 2004, PEDIATR RES, V56, P630, DOI 10.1203/01.PDR.0000139928.60530.7D; Ashwal S, 2006, ARCH PHYS MED REHAB, V87, pS50, DOI 10.1016/j.apmr.2006.07.275; Bagley LJ, 2000, J MAGN RESON IMAGING, V11, P1, DOI 10.1002/(SICI)1522-2586(200001)11:1<1::AID-JMRI1>3.0.CO;2-H; Barker JW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117101; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI 10.1089/neu.2009-0898; Bazarian JJ, 2013, J HEAD TRAUMA REHAB, V28, P1, DOI 10.1097/HTR.0b013e318256d3d3; Beauchamp MH, 2013, CORTEX, V49, P591, DOI 10.1016/j.cortex.2012.08.015; Beckmann CF, 2005, PHILOS T R SOC B, V360, P1001, DOI 10.1098/rstb.2005.1634; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; Bigler ED, 2013, NEUROPSYCHOLOGY, V27, P438, DOI 10.1037/a0032837; BISWAL B, 1995, MAGNET RESON MED, V34, P537, DOI 10.1002/mrm.1910340409; Bouix S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066205; Brown S, 2003, J NEUROPSYCH CLIN N, V15, P367, DOI 10.1176/appi.neuropsych.15.3.367; Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011; Budde MD, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00154; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; Byrnes Kimberly R, 2014, Front Neuroenergetics, V5, P13, DOI 10.3389/fnene.2013.00013; Calabrese E, 2014, J NEUROTRAUM, V31, P938, DOI 10.1089/neu.2013.3144; Callaghan MF, 2014, NEUROBIOL AGING, V35, P1862, DOI 10.1016/j.neurobiolaging.2014.02.008; Castellanos NP, 2011, NEUROIMAGE, V55, P1189, DOI 10.1016/j.neuroimage.2010.12.046; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Chamard E, 2013, BRAIN INJURY, V27, P1038, DOI 10.3109/02699052.2013.794968; Chamard E, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12305; Choe AS, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00290; Cohen BA, 2007, AM J NEURORADIOL, V28, P907; Corbo V, 2014, PSYCHIAT RES-NEUROIM, V223, P53, DOI 10.1016/j.pscychresns.2014.04.013; Coughlin JM, 2015, NEUROBIOL DIS, V74, P58, DOI 10.1016/j.nbd.2014.10.019; Crary JF, 2014, ACTA NEUROPATHOL, V128, P755, DOI 10.1007/s00401-014-1349-0; da Costa L, 2015, J NEUROL NEUROSUR PS, V86, P1008, DOI 10.1136/jnnp-2014-308571; Davenport ND, 2015, HUM BRAIN MAPP, V36, P1053, DOI 10.1002/hbm.22685; Davenport ND, 2012, NEUROIMAGE, V59, P2017, DOI 10.1016/j.neuroimage.2011.10.050; de la Plata CM, 2007, J NEUROTRAUM, V24, P591, DOI 10.1089/neu.2006.0214; Descoteaux M, 2011, MED IMAGE ANAL, V15, P603, DOI 10.1016/j.media.2010.07.001; DETRE JA, 1992, MAGNET RESON MED, V23, P37, DOI 10.1002/mrm.1910230106; Ding K, 2008, J NEUROTRAUM, V25, P1433, DOI 10.1089/neu.2008.0683; Dortch RD, 2013, NEUROIMAGE, V64, P640, DOI 10.1016/j.neuroimage.2012.08.047; Doshi H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118061; Ennis DB, 2006, MAGN RESON MED, V55, P136, DOI 10.1002/mrm.20741; Farbota KDM, 2012, J INT NEUROPSYCH SOC, V18, P1006, DOI 10.1017/S1355617712000835; Fischer BL, 2014, J NEUROTRAUM, V31, P169, DOI 10.1089/neu.2013.2877; Folkersma H, 2011, J NUCL MED, V52, P1235, DOI 10.2967/jnumed.110.084061; Folkersma H, 2009, J NUCL MED, V50, P1975, DOI 10.2967/jnumed.109.067512; Fox MD, 2005, P NATL ACAD SCI USA, V102, P9673, DOI 10.1073/pnas.0504136102; Franklin TR, 2012, DRUG ALCOHOL DEPEN, V125, P60, DOI 10.1016/j.drugalcdep.2012.03.016; Freeman TW, 1998, MAGNET RESON MED, V40, P66, DOI 10.1002/mrm.1910400110; Friedman L, 2006, J MAGN RESON IMAGING, V23, P827, DOI 10.1002/jmri.20583; GANDY SE, 1984, ANN NEUROL, V16, P254, DOI 10.1002/ana.410160217; Garcia-Panach J, 2011, J NEUROTRAUM, V28, P1707, DOI 10.1089/neu.2011.1851; Gardner A, 2014, J NEUROTRAUM, V31, P1, DOI 10.1089/neu.2013.3079; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Gasparovic C, 2009, J NEUROTRAUM, V26, P1635, DOI [10.1089/neu.2009.0896, 10.1089/neu.2009-0896]; Gholipour A, 2011, IEEE ENG MED BIO, P6997, DOI 10.1109/IEMBS.2011.6091769; Guskiewicz KM, 2011, PM&R, V3, P353, DOI 10.1016/j.pmrj.2010.12.006; Haacke E.M., 2013, CEREBRAL BLOOD FLOW, P75; Han K, 2014, NEUROIMAGE, V84, P76, DOI 10.1016/j.neuroimage.2013.08.017; Hariri AR, 2002, NEUROIMAGE, V17, P317, DOI 10.1006/nimg.2002.1179; Harrison NA, 2015, BIOL PSYCHIAT, V78, P49, DOI 10.1016/j.biopsych.2014.09.023; Hartkamp NS, 2014, CURR OPIN NEUROL, V27, P42, DOI 10.1097/WCO.0000000000000051; Haseler LJ, 1997, PEDIATRICS, V99, P4, DOI 10.1542/peds.99.1.4; Helmick KM, 2015, BRAIN IMAGING BEHAV, V9, P358, DOI 10.1007/s11682-015-9399-z; Henry LC, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-105; Hetherington HP, 2014, MAGN RESON MED, V71, P1358, DOI 10.1002/mrm.24814; Holshouser BA, 2005, AM J NEURORADIOL, V26, P1276; Hong YT, 2014, JAMA NEUROL, V71, P23, DOI 10.1001/jamaneurol.2013.4847; Huang H, 2008, MAGN RESON IMAGING, V26, P1294, DOI 10.1016/j.mri.2008.03.005; Huang MX, 2014, NEUROIMAGE-CLIN, V5, P109, DOI 10.1016/j.nicl.2014.06.004; Huang MX, 2012, NEUROIMAGE, V61, P1067, DOI 10.1016/j.neuroimage.2012.04.029; Hunter JV, 2012, J NEUROTRAUM, V29, P654, DOI 10.1089/neu.2011.1906; Isaac L, 2015, BIOL PSYCHOL, V105, P20, DOI 10.1016/j.biopsycho.2014.12.011; Ito R, 2002, NEUROIMAG CLIN N AM, V12, P1, DOI 10.1016/S1052-5149(03)00067-4; Johnson B, 2012, J NEUROTRAUM, V29, P2297, DOI 10.1089/neu.2011.2294; Jorge RE, 2012, AM J PSYCHIAT, V169, P1284, DOI 10.1176/appi.ajp.2012.12050600; Kawai N, 2013, BRAIN INJURY, V27, P1026, DOI 10.3109/02699052.2013.794963; Kim J, 2012, NEUROREHAB NEURAL RE, V26, P870, DOI 10.1177/1545968311434553; Kim J, 2012, PSYCHOPHARMACOLOGY, V222, P47, DOI 10.1007/s00213-011-2622-8; Kim N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059382; Kimbrell T, 2005, PSYCHIAT RES-NEUROIM, V140, P91, DOI 10.1016/j.pscychresns.2005.07.001; Kirov I, 2007, BRAIN INJURY, V21, P1147, DOI 10.1080/02699050701630383; Kirov II, 2013, J NEUROTRAUM, V30, P1200, DOI 10.1089/neu.2012.2696; Kirov II, 2013, J NEUROL, V260, P242, DOI 10.1007/s00415-012-6626-z; Koerte IK, 2015, J NEUROTRAUM, V32, P1287, DOI 10.1089/neu.2014.3715; Koerte IK, 2015, BRAIN PATHOL, V25, P318, DOI 10.1111/bpa.12249; LaConte SM, 2007, HUM BRAIN MAPP, V28, P1033, DOI 10.1002/hbm.20326; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Lewine JD, 1999, AM J NEURORADIOL, V20, P857; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; Lin AP, 2012, BRAIN IMAGING BEHAV, V6, P208, DOI 10.1007/s11682-012-9181-4; Lin A. P., 2010, 96 SCI ASS ANN M RAD; Lin A, 2012, SEMIN NEUROL, V32, P432, DOI 10.1055/s-0032-1331814; Lin AP, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0094-5; Lin YC, 2015, BRAIN CONNECT, V5, P401, DOI 10.1089/brain.2014.0245; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Logan G. D., 2000, ATTENTION PERFORM, P653; Lopez-Larson Melissa, 2013, Front Psychiatry, V4, P83, DOI 10.3389/fpsyt.2013.00083; Luo Q, 2013, J NEUROTRAUM, V30, P1702, DOI 10.1089/neu.2012.2679; Mac Donald C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055823; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Maikusa N, 2013, MED PHYS, V40, DOI 10.1118/1.4801913; Makoroff KL, 2005, PEDIATR RADIOL, V35, P668, DOI 10.1007/s00247-005-1441-7; Maksimovskiy Arkadiy L, 2014, J Alcohol Drug Depend, V2, P144; Mamere AE, 2009, AM J NEURORADIOL, V30, P947, DOI 10.3174/ajnr.A1477; Marino S, 2011, NEUROCRIT CARE, V14, P127, DOI 10.1007/s12028-010-9406-6; Mascalchi M, 2014, J MAGN RESON IMAGING, V40, P360, DOI 10.1002/jmri.24355; Matthews S, 2011, PSYCHIAT RES-NEUROIM, V191, P76, DOI 10.1016/j.pscychresns.2010.09.013; Matthews SC, 2011, NEUROIMAGE, V54, pS69, DOI 10.1016/j.neuroimage.2010.04.269; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; Mayer AR, 2014, HUM BRAIN MAPP, V35, P5457, DOI 10.1002/hbm.22563; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; McGowan JC, 2000, AM J NEURORADIOL, V21, P875; Mendez MF, 2013, NEUROREHABILITATION, V32, P397, DOI 10.3233/NRE-130861; Mitsis EM, 2014, TRANSL PSYCHIAT, V4, DOI 10.1038/tp.2014.91; Moffett John R, 2013, Front Neuroenergetics, V5, P11, DOI 10.3389/fnene.2013.00011; Morey RA, 2013, HUM BRAIN MAPP, V34, P2986, DOI 10.1002/hbm.22117; Mutsaerts HJMM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104108; Narayana PA, 2015, NEUROIMAGE-CLIN, V7, P87, DOI 10.1016/j.nicl.2014.07.010; Nathan DE, 2015, BRAIN CONNECT, V5, P102, DOI 10.1089/brain.2014.0273; Newbould RD, 2014, NEUROIMAGE-CLIN, V4, P641, DOI 10.1016/j.nicl.2014.02.004; Newsome MR, 2015, NEUROIMAGE-CLIN, V8, P543, DOI 10.1016/j.nicl.2015.04.024; Ng TSC, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt239; Niedermeyer E, 2005, ELECTROENCEPHALOGRAP; OGAWA S, 1992, P NATL ACAD SCI USA, V89, P5951, DOI 10.1073/pnas.89.13.5951; Oz G, 2014, RADIOLOGY, V270, P658, DOI 10.1148/radiol.13130531; Pagani E, 2008, NEUROL SCI, V29, pS290, DOI 10.1007/s10072-008-1001-7; Pasternak O, 2009, MAGN RESON MED, V62, P717, DOI 10.1002/mrm.22055; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; Petrie EC, 2014, J NEUROTRAUM, V31, P425, DOI [10.1089/NEU.2013.2952, 10.1089/neu.2013.2952]; Poole VN, 2015, DEV NEUROPSYCHOL, V40, P12, DOI 10.1080/87565641.2014.984810; Poole VN, 2014, DEV NEUROPSYCHOL, V39, P459, DOI 10.1080/87565641.2014.940619; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Raymont V, 2010, NEUROLOGY, V75, P224, DOI 10.1212/WNL.0b013e3181e8e6d0; Reider-Groswasser II, 2002, BRAIN INJURY, V16, P517, DOI 10.1080/02699050110119141; Robinson ME, 2015, HUM BRAIN MAPP, V36, P911, DOI 10.1002/hbm.22675; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; Rubovitch V, 2011, EXP NEUROL, V232, P280, DOI 10.1016/j.expneurol.2011.09.018; Ruthotto L, 2012, PHYS MED BIOL, V57, P5715, DOI 10.1088/0031-9155/57/18/5715; Scheibel RS, 2012, J INT NEUROPSYCH SOC, V18, P89, DOI 10.1017/S1355617711001433; Scheibel RS, 2009, J NEUROTRAUM, V26, P1447, DOI 10.1089/neu.2008.0736; Scheibel RS, 2007, NEUROREHAB NEURAL RE, V21, P36, DOI 10.1177/1545968306294730; Schuff N, 2008, PSYCHIAT RES-NEUROIM, V162, P147, DOI 10.1016/j.pscychresns.2007.04.011; Selwyn R, 2013, J NEUROTRAUM, V30, P1943, DOI 10.1089/neu.2013.2928; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Shutter L, 2004, J NEUROTRAUM, V21, P1693, DOI 10.1089/neu.2004.21.1693; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; Sinson G, 2001, AM J NEURORADIOL, V22, P143; Sokunbi MO, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00392; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Song SK, 2005, NEUROIMAGE, V26, P132, DOI 10.1016/j.neuroimage.2005.01.028; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Spielberg JM, 2015, BIOL PSYCHIAT, V78, P210, DOI 10.1016/j.biopsych.2015.02.013; Sponheim SR, 2011, NEUROIMAGE, V54, pS21, DOI 10.1016/j.neuroimage.2010.09.007; Sporns O, 2004, TRENDS COGN SCI, V8, P418, DOI 10.1016/j.tics.2004.07.008; STERNBERG S, 1966, SCIENCE, V153, P652, DOI 10.1126/science.153.3736.652; Stevens MC, 2012, BRAIN IMAGING BEHAV, V6, P293, DOI 10.1007/s11682-012-9157-4; Stocker RPJ, 2014, NEUROIMAGE, V99, P207, DOI 10.1016/j.neuroimage.2014.05.067; Symms M, 2004, J NEUROL NEUROSUR PS, V75, P1235, DOI 10.1136/jnnp.2003.032714; Taber KH, 2015, J HEAD TRAUMA REHAB, V30, pE15, DOI 10.1097/HTR.0000000000000030; Tarapore PE, 2013, J NEUROSURG, V118, P1306, DOI 10.3171/2013.3.JNS12398; Tate DF, 2014, BRAIN IMAGING BEHAV, V8, P102, DOI 10.1007/s11682-013-9257-9; Tompkins P, 2013, J NEUROTRAUM, V30, P1888, DOI 10.1089/neu.2012.2674; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Tormenti M, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12282; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vakhtin AA, 2013, BRAIN INJURY, V27, P1304, DOI 10.3109/02699052.2013.823561; Wang DJJ, 2013, NEUROIMAGE-CLIN, V3, P1, DOI 10.1016/j.nicl.2013.06.017; Wang XJ, 2014, NMR BIOMED, V27, P843, DOI 10.1002/nbm.3129; Wang Y, 2015, DEV NEUROPSYCHOL, V40, P40, DOI 10.1080/87565641.2014.979927; Wang Y, 2015, BRAIN, V138, P1223, DOI 10.1093/brain/awv046; Wang Z, 2014, HUM BRAIN MAPP, V35, P2869, DOI 10.1002/hbm.22445; Wedeen VJ, 2008, NEUROIMAGE, V41, P1267, DOI 10.1016/j.neuroimage.2008.03.036; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Wolf ME, 2014, J NEUROIMAGING, V24, P453, DOI 10.1111/jon.12064; Yeo RA, 2011, J NEUROTRAUM, V28, P1, DOI 10.1089/neu.2010.1578; Yoo RE, 2015, STROKE, V46, P564, DOI 10.1161/STROKEAHA.114.007797; Yuan H, 2014, BRAIN CONNECT, V4, P690, DOI 10.1089/brain.2014.0262; Yurgelun-Todd DA, 2011, J HEAD TRAUMA REHAB, V26, P276, DOI 10.1097/HTR.0b013e31822251dc; Zaharchuk G, 2010, MAGN RESON MED, V63, P1548, DOI 10.1002/mrm.22329; Zhang H, 2012, NEUROIMAGE, V61, P1000, DOI 10.1016/j.neuroimage.2012.03.072; Zhang J, 2010, J NEUROTRAUM, V27, P35, DOI 10.1089/neu.2009.1049; Zhang K, 2014, J CEREBR BLOOD F MET, V34, P1373, DOI 10.1038/jcbfm.2014.92; Zhang S, 2012, HUM BRAIN MAPP, V33, P89, DOI 10.1002/hbm.21197; Zivadinov R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091098	191	41	41	0	31	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1931-7557	1931-7565		BRAIN IMAGING BEHAV	Brain Imaging Behav.	SEP	2015	9	3					367	402		10.1007/s11682-015-9444-y			36	Neuroimaging	Neurosciences & Neurology	CR8LQ	WOS:000361604300003	26350144	Green Accepted			2021-06-18	
J	Hendricks, S; O'connor, S; Lambert, M; Brown, J; Burger, N; Mc Fie, S; Readhead, C; Viljoen, W				Hendricks, Sharief; O'connor, Sam; Lambert, Michael; Brown, James; Burger, Nicholas; Mc Fie, Sarah; Readhead, Clint; Viljoen, Wayne			Contact technique and concussions in the South African under-18 Coca-Cola Craven Week Rugby tournament	EUROPEAN JOURNAL OF SPORT SCIENCE			English	Article						measurement; concussion; team sport; Skill; injury and prevention	CONSENSUS STATEMENT; TACKLING TECHNIQUE; INJURY RISK; SPORT; EPIDEMIOLOGY; PERFORMANCE; STRATEGIES	In rugby union, understanding the techniques and events leading to concussions is important because of the nature of the injury and the severity and potential long-term consequences, particularly in junior players. Proper contact technique is a prerequisite for successful participation in rugby and is a major factor associated with injury. However, the execution of proper contact technique and its relationship to injury has yet to be studied in matches. Therefore, the aim of this study was to compare contact techniques leading to concussion with a representative sample of similarly matched non-injury (NI) contact events. Injury surveillance was conducted at the 2011-2013 under-18 Craven Week Rugby tournaments. Video footage of 10 concussive events (5 tackle, 4 ruck and 1 aerial collision) and 83 NI events were identified (19 tackle, 61 ruck and 3 aerial collisions). Thereafter, each phase of play was analysed using standardised technical proficiency criteria. Overall score for ruck proficiency in concussive events was 5.67 (out of a total of 15) vs. 6.98 for NI events (n = 54) (effect size = 0.52, small). Overall average score for tackler proficiency was 7.25 (n = 4) and 6.67 (n = 15) for injury and NI tackles, respectively (out of 16) (effect size = 0.19, trivial). This is the first study to compare concussion injury contact technique to a player-matched sample of NI contact techniques. Certain individual technical criteria had an effect towards an NI outcome, and others had an effect towards a concussive event, highlighting that failure to execute certain techniques may substantially increase the opportunity for concussion.	[Hendricks, Sharief; O'connor, Sam; Lambert, Michael; Brown, James; Burger, Nicholas; Mc Fie, Sarah; Readhead, Clint; Viljoen, Wayne] Univ Cape Town, Div Exercise Sci & Sports Med, Dept Human Biol, Fac Hlth Sci, ZA-7725 Cape Town, South Africa; [Readhead, Clint; Viljoen, Wayne] South African Rugby Union SARU, Cape Town, South Africa	Hendricks, S (corresponding author), Univ Cape Town, Div Exercise Sci & Sports Med, Dept Human Biol, Fac Hlth Sci, POB 115, ZA-7725 Cape Town, South Africa.	sharief.hendricks01@gmail.com	Brown, James Craig/H-7637-2019; Hendricks, Sharief/U-3278-2019	Brown, James Craig/0000-0002-7778-7783; Hendricks, Sharief/0000-0002-3416-6266; Viljoen, Wayne/0000-0002-9432-6153			Bird YN, 1998, BRIT J SPORT MED, V32, P319, DOI 10.1136/bjsm.32.4.319; Brooks JHM, 2008, CLIN SPORT MED, V27, P51, DOI 10.1016/j.csm.2007.09.001; Brown JC, 2012, S AFR J SPORTS MED, V24, P49; Buzzini SRR, 2006, CURR OPIN PEDIATR, V18, P376, DOI 10.1097/01.mop.0000236385.26284.ec; Chadwick S., 2011, EC IMPACT REPORT GLO, P1; Fuller CW, 2007, BRIT J SPORT MED, V41, P328, DOI 10.1136/bjsm.2006.033282; Fuller CW, 2010, BRIT J SPORT MED, V44, P159, DOI 10.1136/bjsm.2008.050864; Gabbett T, 2009, INT J SPORTS SCI COA, V4, P521, DOI 10.1260/174795409790291402; Gabbett TJ, 2008, J STRENGTH COND RES, V22, P625, DOI 10.1519/JSC.0b013e3181635a6a; Gabbett TJ., 2007, INT J SPORTS SCI COA, V2, P467, DOI DOI 10.1260/174795407783359731; Gardner AJ, 2014, SPORTS MED, V44, P1717, DOI 10.1007/s40279-014-0233-3; HENDRICKS S, 2012, S AFR J SPORTS MED, V24, P122, DOI DOI 10.7196/SAJSM.357; Hendricks S, 2014, EUR J SPORT SCI, V14, P753, DOI 10.1080/17461391.2014.905982; Hendricks S, 2014, J SPORT SCI MED, V13, P715; Hendricks S, 2012, SAFETY SCI, V50, P266, DOI 10.1016/j.ssci.2011.08.061; Hendricks S, 2010, INT J SPORTS SCI COA, V5, P117, DOI 10.1260/1747-9541.5.1.117; Hopkins WG, 2009, MED SCI SPORT EXER, V41, P3, DOI 10.1249/MSS.0b013e31818cb278; Kemp SPT, 2008, CLIN J SPORT MED, V18, P227, DOI 10.1097/JSM.0b013e31816a1c9a; McCrory P, 2009, J ATHL TRAINING, P36; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Mcintosh AS, 2010, MED SCI SPORT EXER, V42, P977, DOI 10.1249/MSS.0b013e3181c07b5b; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Quarrie KL, 2008, AM J SPORT MED, V36, P1705, DOI 10.1177/0363546508316768; Verhagen E., 2010, SPORTS INJURY RES, P117; Viljoen W, 2012, BRIT J SPORT MED, V46, P692, DOI 10.1136/bjsports-2012-091278; Wheeler KW, 2010, EUR J SPORT SCI, V10, P237, DOI 10.1080/17461391.2010.482595; Williams S, 2013, SPORTS MED, V43, P1043, DOI 10.1007/s40279-013-0078-1	27	41	42	0	16	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1746-1391	1536-7290		EUR J SPORT SCI	Eur. J. Sport Sci.	AUG 18	2015	15	6			SI		557	564		10.1080/17461391.2015.1046192			8	Sport Sciences	Sport Sciences	CR5EQ	WOS:000361363600014	26223002				2021-06-18	
J	Hammond, FM; Sherer, M; Malec, JF; Zafonte, RD; Whitney, M; Bell, K; Dikmen, S; Bogner, J; Mysiw, J; Pershad, R				Hammond, Flora M.; Sherer, Mark; Malec, James F.; Zafonte, Ross D.; Whitney, Marybeth; Bell, Kathleen; Dikmen, Sureyya; Bogner, Jennifer; Mysiw, Jerry; Pershad, Rashmi		Amantadine Irritability Multisite	Amantadine Effect on Perceptions of Irritability after Traumatic Brain Injury: Results of the Amantadine Irritability Multisite Study	JOURNAL OF NEUROTRAUMA			English	Article						agitation; aggression; amantadine; brain injuries; irritability	NEUROPSYCHIATRIC INVENTORY; BEHAVIOR-CHANGE; ALLIANCE; DISEASE; TRIALS; SCALE	This study examines the effect of amantadine on irritability in persons in the post-acute period after traumatic brain injury (TBI). There were 168 persons 6 months post-TBI with irritability who were enrolled in a parallel-group, randomized, double-blind, placebo-controlled trial receiving either amantadine 100mg twice daily or equivalent placebo for 60 days. Subjects were assessed at baseline and days 28 (primary end-point) and 60 of treatment using observer-rated and participant-rated Neuropsychiatric Inventory (NPI-I) Most Problematic item (primary outcome), NPI Most Aberrant item, and NPI-I Distress Scores, as well as physician-rated Clinical Global Impressions (CGI) scale. Observer ratings between the two groups were not statistically significantly different at day 28 or 60; however, observers rated the majority in both groups as having improved at both intervals. Participant ratings for day 60 demonstrated improvements in both groups with greater improvement in the amantadine group on NPI-I Most Problematic (p<0.04) and NPI-I Distress (p<0.04). These results were not significant with correction for multiple comparisons. CGI demonstrated greater improvement for amantadine than the placebo group (p<0.04). Adverse event occurrence did not differ between the two groups. While observers in both groups reported large improvements, significant group differences were not found for the primary outcome (observer ratings) at either day 28 or 60. This large placebo or nonspecific effect may have masked detection of a treatment effect. The result of this study of amantadine 100mg every morning and noon to reduce irritability was not positive from the observer perspective, although there are indications of improvement at day 60 from the perspective of persons with TBI and clinicians that may warrant further investigation.	[Hammond, Flora M.; Malec, James F.] Indiana Univ Sch Med, Dept Phys Med & Rehabil, Indianapolis, IN 46254 USA; [Hammond, Flora M.; Malec, James F.] Rehabil Hosp Indiana, Indianapolis, IN USA; [Hammond, Flora M.; Whitney, Marybeth; Pershad, Rashmi] Carolinas HealthCare Syst, Carolinas Rehabil, Dept Phys Med & Rehabil, Charlotte, NC USA; [Sherer, Mark] TIRR Mem Hermann, Houston, TX USA; [Zafonte, Ross D.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Spaulding Rehabil Hosp, Boston, MA USA; [Zafonte, Ross D.] Brigham & Womens Hosp, Boston, MA 02115 USA; [Bell, Kathleen; Dikmen, Sureyya] Univ Washington, Seattle, WA 98195 USA; [Bogner, Jennifer; Mysiw, Jerry] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; [Bell, Kathleen] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA	Hammond, FM (corresponding author), Indiana Univ Sch Med, Rehabil Hosp Indiana, Carolinas Rehabil, 4141 Shore Dr, Indianapolis, IN 46254 USA.	Flora.hammond@rhin.com		Bell, Kathleen/0000-0002-0928-2046	US Department of Education, Office of Special Education and Rehabilitative Services, National Institute on Disability and Rehabilitation ResearchUS Department of Education [H133A080035]	The research reported in this article was supported by US Department of Education, Office of Special Education and Rehabilitative Services, National Institute on Disability and Rehabilitation Research grant H133A080035. This support included the funds to purchase amantadine. The study sponsor had no role in the design and conduct of this study; the collection, management, analysis, and interpretation of the data; or the preparation review, or approval of the manuscript.	Beck AT., 1996, BECK DEPRESSION INVE, V2; Berry DA, 1996, J NATL CANCER I, V88, P1606, DOI 10.1093/jnci/88.22.1606; Bird EL, 2013, HEALTH PSYCHOL, V32, P829, DOI 10.1037/a0032078; Ciurli P, 2011, J HEAD TRAUMA REHAB, V26, P116, DOI 10.1097/HTR.0b013e3181dedd0e; Cumming G., 2012, UNDERSTANDING NEW ST; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; Ehde D., 2014, 42 ANN S INT NEUR SO; Eknoyan D, 2013, J NEUROPSYCH CLIN N, V25, P250; Evans CC, 2008, J HEAD TRAUMA REHAB, V23, P329, DOI 10.1097/01.HTR.0000336845.06704.bc; Fava M, 2003, PSYCHOTHER PSYCHOSOM, V72, P115, DOI 10.1159/000069738; Gualtieri C T, 1988, Brain Inj, V2, P273, DOI 10.3109/02699058809150898; Hammond FM, 2014, J HEAD TRAUMA REHAB, V29, P391, DOI 10.1097/01.HTR.0000438116.56228.de; Hammond FM, 2011, J HEAD TRAUMA REHAB, V26, P69, DOI 10.1097/HTR.0b013e318205174d; HOLM S, 1979, SCAND J STAT, V6, P65; Kaufer DI, 1998, J AM GERIATR SOC, V46, P210, DOI 10.1111/j.1532-5415.1998.tb02542.x; Kilmer RP, 2006, REHABIL PSYCHOL, V51, P232, DOI 10.1037/0090-5550.51.3.232; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Miciak M, 2012, SCAND J CARING SCI, V26, P394, DOI 10.1111/j.1471-6712.2011.00923.x; Peeters M, 2003, NEUROSCI LETT, V343, P205, DOI 10.1016/S0304-3940(03)00398-7; PETO R, 1995, J CLIN EPIDEMIOL, V48, P23, DOI 10.1016/0895-4356(94)00150-O; Rief W, 2009, J AFFECT DISORDERS, V118, P1, DOI 10.1016/j.jad.2009.01.029; Schonberger M, 2006, BRAIN INJURY, V20, P445, DOI 10.1080/02699050600664772; Silver JM, 2006, NEUROLOGY, V67, P748, DOI 10.1212/01.wnl.0000234062.98062.e9; Spahn JM, 2010, J AM DIET ASSOC, V110, P879, DOI 10.1016/j.jada.2010.03.021; Wampold B. E., 2001, GREAT PSYCHOTHERAPY; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	26	41	41	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG 15	2015	32	16					1230	1238		10.1089/neu.2014.3803			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CU9RU	WOS:000363883400007	25774566	Bronze, Green Published			2021-06-18	
J	Sours, C; Zhuo, JC; Roys, S; Shanmuganathan, K; Gullapalli, RP				Sours, Chandler; Zhuo, Jiachen; Roys, Steven; Shanmuganathan, Kathirkamanthan; Gullapalli, Rao P.			Disruptions in Resting State Functional Connectivity and Cerebral Blood Flow in Mild Traumatic Brain Injury Patients	PLOS ONE			English	Article							NEUROPSYCHOLOGICAL ASSESSMENT METRICS; MODE NETWORK CONNECTIVITY; DEFAULT-MODE; HEAD-INJURY; PERFUSION; DEFICITS; RELIABILITY; PERFORMANCE; TASK; RECOVERY	Mild traumatic brain injury (mTBI) is often occult to conventional imaging techniques. However, there is growing evidence that mTBI patients who lack evidence of structural intracranial injury may develop post-concussive syndrome (PCS). We investigated longitudinal alterations in resting state functional connectivity (rs-FC) in brain networks in a population of 28 patients compared to 28 matched control participants. Rs-FC and cerebral blood flow (CBF) within the nodes of the Default Mode Network (DMN) and Task Positive Network (TPN) were assessed at three time points including acute, sub-acute, and chronic stages following mTBI. Participants received the Automated Neuropsychological Assessment Metrics (ANAM) to assess cognitive performance. Main findings indicate that despite normalized cognitive performance, chronic mTBI patients demonstrate increased rs-FC between the DMN and regions associated with the salience network (SN) and TPN compared to the control populations, as well as reduced strength of rs-FC within the DMN at the acute stage of injury. In addition, chronic mTBI patients demonstrate an imbalance in the ratio of CBF between nodes of the DMN and TPN. Furthermore, preliminary exploratory analysis suggests that compared to those without chronic PCS, patients with chronic PCS reveal an imbalance in the ratio of CBF between the DMN nodes and TPN nodes across multiple stages of recovery. Findings suggest that the altered network perfusion with the associated changes in rs-FC may be a possible predictor of which mTBI patients will develop chronic PCS.	[Sours, Chandler; Zhuo, Jiachen; Roys, Steven; Gullapalli, Rao P.] Univ Maryland, Sch Med, Magnet Resonance Res Ctr, Baltimore, MD 21201 USA; [Sours, Chandler; Zhuo, Jiachen; Roys, Steven; Shanmuganathan, Kathirkamanthan; Gullapalli, Rao P.] Univ Maryland, Sch Med, Dept Diagnost Radiol & Nucl Med, Baltimore, MD 21201 USA	Sours, C (corresponding author), Univ Maryland, Sch Med, Magnet Resonance Res Ctr, Baltimore, MD 21201 USA.	csours001@umm.edu			Department of DefenseUnited States Department of Defense [W81XWH-08-1-0725, W81XWH-12-1-0098]; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1F31NS081984]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F31NS081984] Funding Source: NIH RePORTER	Support for this work was in part provided by the Department of Defense (W81XWH-08-1-0725 & W81XWH-12-1-0098 to RPG). CS was supported by an predoctoral grant from the National Institute of Neurological Disorders and Stroke (1F31NS081984). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bonne O, 2003, PSYCHIAT RES-NEUROIM, V124, P141, DOI 10.1016/S0925-4927(03)00109-4; Bonnelle V, 2012, P NATL ACAD SCI USA, V109, P4690, DOI 10.1073/pnas.1113455109; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; Castellanos FX, 2008, BIOL PSYCHIAT, V63, P332, DOI 10.1016/j.biopsych.2007.06.025; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; D'Esposito M, 2007, PHILOS T R SOC B, V362, P761, DOI 10.1098/rstb.2007.2086; Daniels JK, 2010, J PSYCHIATR NEUROSCI, V35, P258, DOI 10.1503/jpn.090010; De Havas JA, 2012, NEUROIMAGE, V59, P1745, DOI 10.1016/j.neuroimage.2011.08.026; de la Plata CDM, 2011, ARCH NEUROL-CHICAGO, V68, P74, DOI 10.1001/archneurol.2010.342; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fox MD, 2005, P NATL ACAD SCI USA, V102, P9673, DOI 10.1073/pnas.0504136102; Franco AR, 2013, BRAIN CONNECT, V3, P363, DOI 10.1089/brain.2012.0134; FRISTON KJ, 1993, J CEREBR BLOOD F MET, V13, P5, DOI 10.1038/jcbfm.1993.4; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; Greicius MD, 2003, P NATL ACAD SCI USA, V100, P253, DOI 10.1073/pnas.0135058100; Gusnard DA, 2001, P NATL ACAD SCI USA, V98, P4259, DOI 10.1073/pnas.071043098; Hayward NMEA, 2010, J NEUROTRAUM, V27, P2203, DOI 10.1089/neu.2010.1448; Hillary FG, 2011, INT J PSYCHOPHYSIOL, V82, P115, DOI 10.1016/j.ijpsycho.2011.03.011; Iraji A, 2015, J NEUROTRAUM, V32, P1031, DOI 10.1089/neu.2014.3610; Iverson GL, 2000, BRAIN INJURY, V14, P1057; Ivins BJ, 2009, J HEAD TRAUMA REHAB, V24, P24, DOI 10.1097/HTR.0b013e3181957042; Jann K, 2013, BRAIN TOPOGR, V26, P569, DOI 10.1007/s10548-013-0280-3; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Kane RL, 2007, ARCH CLIN NEUROPSYCH, V22, pS115, DOI 10.1016/j.acn.2006.10.006; Kasahara M, 2010, NEUROLOGY, V75, P168, DOI 10.1212/WNL.0b013e3181e7ca58; Kim J, 2010, J NEUROTRAUM, V27, P1399, DOI 10.1089/neu.2009.1215; Kindler J, 2013, SCHIZOPHR B; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kwok FY, 2008, BRAIN INJURY, V22, P740, DOI 10.1080/02699050802336989; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; Li ZJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044556; Liu TT, 2013, NEUROIMAGE, V80, P339, DOI 10.1016/j.neuroimage.2013.04.071; Liu W, 2013, NMR BIOMED, V26, P651, DOI 10.1002/nbm.2910; Mannfolk P, 2011, J MAGN RESON IMAGING, V34, P511, DOI 10.1002/jmri.22654; Maruishi M, 2007, J NEUROL NEUROSUR PS, V78, P168, DOI 10.1136/jnnp.2006.097345; Mayer AR, 2015, J NEUROTRAUM, V32, P1046, DOI 10.1089/neu.2014.3542; Mayer AR, 2012, BRAIN IMAGING BEHAV, V6, P343, DOI 10.1007/s11682-012-9178-z; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; McCrea M., 2000, STANDARDIZED ASSESSM; Menon V, 2010, BRAIN STRUCT FUNCT, V214, P655, DOI 10.1007/s00429-010-0262-0; Ponsford J, 2013, J NEUROTRAUMA; Ponsford J, 2013, NEUROREHABILITATION, V32, P803, DOI 10.3233/NRE-130904; Pop V, 2011, TRANSL STROKE RES, V2, P533, DOI 10.1007/s12975-011-0126-9; Prakash RS, 2012, BEHAV BRAIN RES, V230, P192, DOI 10.1016/j.bbr.2012.01.058; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Reeves DL, 2006, MIL MED, V171, P982, DOI 10.7205/MILMED.171.10.982; Reich S, 2005, VALIDATION ANAM TEST; Sambataro F, 2010, NEUROBIOL AGING, V31, P839, DOI 10.1016/j.neurobiolaging.2008.05.022; Schonberger M, 2009, J NEUROTRAUM, V26, P2157, DOI 10.1089/neu.2009.0939; Seeley WW, 2007, J NEUROSCI, V27, P2349, DOI 10.1523/JNEUROSCI.5587-06.2007; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Shumskaya E, 2012, NEUROLOGY, V79, P175, DOI 10.1212/WNL.0b013e31825f04fb; Slobounov SM, 2011, NEUROIMAGE, V55, P1716, DOI 10.1016/j.neuroimage.2011.01.024; Sonuga-Barke EJS, 2007, NEUROSCI BIOBEHAV R, V31, P977, DOI 10.1016/j.neubiorev.2007.02.005; Sours C, 2014, BRAIN IMAGING BEHAV; Sours C, 2015, BRAIN CONNECT, V5, P442, DOI 10.1089/brain.2014.0333; Sours C, 2013, BRAIN RES, V1537, P201, DOI 10.1016/j.brainres.2013.08.034; Sridharan D, 2008, P NATL ACAD SCI USA, V105, P12569, DOI 10.1073/pnas.0800005105; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Wang JJ, 2003, J MAGN RESON IMAGING, V18, P404, DOI 10.1002/jmri.10372; Weissman DH, 2006, NAT NEUROSCI, V9, P971, DOI 10.1038/nn1727; Williams WH, 2010, J NEUROL NEUROSUR PS, V81, P1116, DOI 10.1136/jnnp.2008.171298; Woodward ND, 2011, SCHIZOPHR RES, V130, P86, DOI 10.1016/j.schres.2011.03.010; World Health Organization, 2010, INT CLASS DIS; Zhou YX, 2012, RADIOLOGY, V265, P882, DOI 10.1148/radiol.12120748; Zhuo JC, 2012, NEUROIMAGE, V59, P467, DOI 10.1016/j.neuroimage.2011.07.050	67	41	42	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 4	2015	10	8							e0134019	10.1371/journal.pone.0134019			20	Multidisciplinary Sciences	Science & Technology - Other Topics	CO1VB	WOS:000358942700032	26241476	DOAJ Gold, Green Published			2021-06-18	
J	Bosarge, PL; Shoultz, TH; Griffin, RL; Kerby, JD				Bosarge, Patrick L.; Shoultz, Thomas H.; Griffin, Russell L.; Kerby, Jeffrey D.			Stress-induced hyperglycemia is associated with higher mortality in severe traumatic brain injury	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Stress-induced hyperglycemia; traumatic brain injury; glycosylated hemoglobin A; HgA1c; stress response; physiologic wounds and injuries; complications; mortality	INTENSIVE INSULIN THERAPY; CRITICALLY-ILL PATIENTS; CARE-UNIT PATIENTS; GLYCEMIC CONTROL; ADMISSION HYPERGLYCEMIA; BLOOD-GLUCOSE; MYOCARDIAL-INFARCTION; DIABETIC STATUS; IMPACT; METABOLISM	BACKGROUND An association between stress-induced hyperglycemia (SIH) and increased mortality has been demonstrated following trauma. Experimental animal model data regarding the association between hyperglycemia and outcomes following traumatic brain injury (TBI) are inconsistent, suggesting that hyperglycemia may be harmful, neutral, or beneficial. The purpose of this study was to examine the effects of SIH versus diabetic hyperglycemia (DH) on severe TBI. METHODS Admission glycosylated hemoglobin (HbA1c), glucose levels, and comorbidity data were collected during a 4-year period from September 2009 to December 2013 for patients with severe TBI (i.e., admission Glasgow Coma Scale [GCS] score of 3-8 and head Abbreviated Injury Scale [AIS] score 3). Diabetes mellitus was determined by patient history or admission HbA1c of 6.5% or greater. SIH was determined by the absence of diabetes mellitus and admission glucose of 200 mg/dL or greater. A Cox proportional hazards model adjusted for age, sex, injury mechanism, and Injury Severity Score (ISS) was used to calculate hazard ratios (HRs) and associated 95% confidence intervals (CIs) for the association between SIH and the outcomes of interest. RESULTS During the study period, a total of 626 patients were included in the study group, having severe TBI defined by both GCS score of 3 to 8 and head AIS score being 3 or greater and also had available HbA1c and admission glucose levels. A total of 184 patients were admitted with hyperglycemia; 152 patients (82.6%) were diagnosed with SIH, and 32 patients (17.4%) were diagnosed with DH. When comparing patients with severe TBI adjusted for age, sex, injury mechanism, ISS, Revised Trauma Score (RTS), and lactic acid greater than 2.5 mmol/L, patients with SIH had a 50% increased mortality (HR, 1.49; 95% CI, 1.13-1.95) compared with the nondiabetic normoglycemia patients. DH patients did not have a significant increase in mortality (HR, 0.94; 95% CI, 0.56-1.58). CONCLUSION SIH is associated with higher mortality after severe TBI. This association was not observed among patients with DH, which suggests that hyperglycemia related to diabetes is of less importance compared with SIH in terms of mortality in the acute trauma and TBI patient. Further research is warranted to identify mechanisms causing SIH and subsequent worse outcomes after TBI. LEVEL OF EVIDENCE Prognostic/epidemiologic study, leve III.	[Bosarge, Patrick L.; Shoultz, Thomas H.; Griffin, Russell L.; Kerby, Jeffrey D.] Univ Alabama Birmingham, Div Trauma Burns & Surg Crit Care, Birmingham, AL USA	Bosarge, PL (corresponding author), Univ Birmingham, Univ Alabama, Alabama Med Ctr, Div Trauma Burns & Surg Crit Care, 112 Lyons Harrison Res Bldg,701 19th St, South Birmingham, AL 35294 USA.	pbosarge@uabmc.edu					Ahmad R, 2007, ARCH SURG-CHICAGO, V142, P613, DOI 10.1001/archsurg.142.7.613; Alessandri B, 2000, ACTA NEUROCHIR SUPPL, V76, P425; Alves OL, 2005, J NEUROTRAUM, V22, P733, DOI 10.1089/neu.2005.22.733; Amer Diabet Assoc, 2012, DIABETES CARE, V35, pS64, DOI [10.2337/dc09-S062, 10.2337/dc12-s064, 10.2337/dc12-S064, 10.2337/dc11-S062]; BELLODI G, 1989, AM J CARDIOL, V64, P885, DOI 10.1016/0002-9149(89)90836-9; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; Bochicchio GV, 2007, J TRAUMA, V63, P1353, DOI 10.1097/TA.0b013e31815b83c4; Bochicchio GV, 2005, J TRAUMA, V58, P921, DOI 10.1097/01.TA.0000162141.26392.07; Bosarge Patrick L, 2013, Adv Surg, V47, P287; Bruno A, 2002, NEUROLOGY, V59, P669, DOI 10.1212/WNL.59.5.669; Capes SE, 2000, LANCET, V355, P773, DOI 10.1016/S0140-6736(99)08415-9; Capes SE, 2001, STROKE, V32, P2426, DOI 10.1161/hs1001.096194; Centers for Disease Control and Prevention (CDC), 2014, NAT DIAB STAT REP; Cherian L, 1997, CRIT CARE MED, V25, P1378, DOI 10.1097/00003246-199708000-00027; Cherian L, 1998, J NEUROTRAUM, V15, P307, DOI 10.1089/neu.1998.15.307; Egi M, 2008, CRIT CARE MED, V36, P2249, DOI 10.1097/CCM.0b013e318181039a; Finfer S, 2009, NEW ENGL J MED, V360, P1283, DOI 10.1056/NEJMoa0810625; Griesdale DEG, 2009, NEUROCRIT CARE, V11, P311, DOI 10.1007/s12028-009-9249-1; Griesdale DEG, 2009, CAN MED ASSOC J, V180, P821, DOI 10.1503/cmaj.090206; Hill J, 2010, J NEUROTRAUM, V27, P1439, DOI 10.1089/neu.2010.1328; Hurt RT, 2012, JPEN-PARENTER ENTER, V36, P721, DOI 10.1177/0148607112436978; Jeremitsky E, 2005, J TRAUMA, V58, P47, DOI 10.1097/01.TA.0000135158.42242.B1; Kerby JD, 2012, ANN SURG, V256, P446, DOI 10.1097/SLA.0b013e3182654549; Krinsley JS, 2006, SEMIN THORAC CARDIOV, V18, P317, DOI 10.1053/j.semtcvs.2006.12.003; Krinsley JS, 2012, CURR OPIN CLIN NUTR, V15, P151, DOI 10.1097/MCO.0b013e32834f0009; Kutcher ME, 2011, J TRAUMA, V71, P1108, DOI 10.1097/TA.0b013e318232e35b; Laird AM, 2004, J TRAUMA, V56, P1058, DOI 10.1097/01.TA.0000123267.39011.9F; Lee SM, 1999, ANN NY ACAD SCI, V893, P337, DOI 10.1111/j.1749-6632.1999.tb07849.x; Liu-DeRyke X, 2009, NEUROCRIT CARE, V11, P151, DOI 10.1007/s12028-009-9228-6; McCowen KC, 2001, CRIT CARE CLIN, V17, P107, DOI 10.1016/S0749-0704(05)70154-8; Moro N, 2013, BRAIN RES, V1535, P124, DOI 10.1016/j.brainres.2013.08.044; Nathan DM, 2007, DIABETOLOGIA, V50, P2239, DOI 10.1007/s00125-007-0803-0; Peppa M, 2011, CURR DIABETES REV, V7, P416, DOI 10.2174/157339911797579188; Rady MY, 2005, MAYO CLIN PROC, V80, P1558, DOI 10.4065/80.12.1558; Rovlias A, 2000, NEUROSURGERY, V46, P335, DOI 10.1097/00006123-200002000-00015; Saudek CD, 2006, JAMA-J AM MED ASSOC, V295, P1688, DOI 10.1001/jama.295.14.1688; Scalea TM, 2007, ANN SURG, V246, P605, DOI 10.1097/SLA.0b013e318155a789; Sung J, 2005, J TRAUMA, V59, P80, DOI 10.1097/01.TA.0000171452.96585.84; SUTTON RL, 1994, ACTA NEUROCHIR, P446; Toschlog EA, 2007, J TRAUMA, V62, P1370, DOI 10.1097/TA.0b013e318047b7dc; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Vogelzang M, 2006, J TRAUMA, V60, P873, DOI 10.1097/01.ta.0000195715.63978.80; Wahl WL, 2008, J TRAUMA, V65, P42, DOI 10.1097/TA.0b013e318176c54e; Yendamuri S, 2003, J TRAUMA, V55, P33, DOI 10.1097/01.TA.0000074434.39928.72; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; YOUNG B, 1989, ANN SURG, V210, P466, DOI 10.1097/00000658-198910000-00007	46	41	49	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	AUG	2015	79	2					289	294		10.1097/TA.0000000000000716			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	CS2II	WOS:000361892800019	26218699				2021-06-18	
J	Losoi, H; Silverberg, ND; Waljas, M; Turunen, S; Rosti-Otajarvi, E; Helminen, M; Luoto, TMA; Julkunen, J; Ohman, J; Iverson, GL				Losoi, Heidi; Silverberg, Noah D.; Waljas, Minna; Turunen, Senni; Rosti-Otajarvi, Eija; Helminen, Mika; Luoto, Teemu Miikka Artturi; Julkunen, Juhani; Oehman, Juha; Iverson, Grant L.			Resilience Is Associated with Outcome from Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						head injury; patient outcome assessment; resilience; traumatic brain injury	BNI FATIGUE SCALE; QUALITY-OF-LIFE; HEAD-INJURY; PSYCHOMETRIC PROPERTIES; ILLNESS PERCEPTIONS; RELIABILITY; SYMPTOMS; GUIDELINES; VALIDITY; VERSION	Resilient individuals manifest adaptive behavior and are better able to recover from adversity. The association between resilience and outcome from mild traumatic brain injury (mTBI) is examined, and the reliability and validity of the Resilience Scale and its short form in mTBI research is evaluated. Patients with mTBI (n=74) and orthopedic controls (n=39) completed the Resilience Scale at one, six, and 12 months after injury. Additionally, self-reported post-concussion symptoms, fatigue, insomnia, pain, post-traumatic stress, and depression, as well as quality of life, were evaluated. The internal consistency of the Resilience Scale and the short form ranged from 0.91 to 0.93 for the mTBI group and from 0.86 to 0.95 for controls. The test-retest reliability ranged from 0.70 to 0.82. Patients with mTBI and moderate-to-high resilience reported significantly fewer post-concussion symptoms, less fatigue, insomnia, traumatic stress, and depressive symptoms, and better quality of life, than the patients with low resilience. No association between resilience and time to return to work was found. Resilience was associated with self-reported outcome from mTBI, and based on this preliminary study, can be reliably evaluated with Resilience Scale and its short form in those with mTBIs.	[Losoi, Heidi; Waljas, Minna; Turunen, Senni; Rosti-Otajarvi, Eija; Luoto, Teemu Miikka Artturi; Oehman, Juha] Tampere Univ Hosp, Dept Neurosci & Rehabil, FI-33521 Tampere, Finland; [Losoi, Heidi; Julkunen, Juhani] Univ Helsinki, Inst Behav Sci, FIN-00014 Helsinki, Finland; [Silverberg, Noah D.] Univ British Columbia, Div Phys Med & Rehabil, Vancouver, BC V5Z 1M9, Canada; [Silverberg, Noah D.] GF Strong Rehab Ctr, Vancouver, BC, Canada; [Helminen, Mika] Univ Tampere & Sci Ctr, Sch Hlth Sci, Tampere, Finland; [Iverson, Grant L.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Charlestown, MA USA; [Iverson, Grant L.] MassGen Hosp Children, Sports Concuss Program, Boston, MA USA; [Iverson, Grant L.] Red Sox Fdn, Boston, MA USA; [Iverson, Grant L.] Massachusetts Gen Hosp, Home Base Program, Boston, MA 02114 USA	Losoi, H (corresponding author), Tampere Univ Hosp, POB 2000, FI-33521 Tampere, Finland.	heidi.losoi@gmail.com	Luoto, Teemu/W-6468-2018; Helminen, Mika T/I-3900-2016	Luoto, Teemu/0000-0002-7329-3284; Helminen, Mika T/0000-0001-5695-2084; Iverson, Grant/0000-0001-7348-9570; Ohman, Juha/0000-0002-6592-1367	INTRuST Posttraumatic Stress Disorder and Traumatic Brain Injury Clinical Consortium - Department of Defense Psychological Health/Traumatic Brain Injury Research Program [X81XWH-07-CC-CSDoD]	The authors thank research assistants Anne sSimi and Marika Suopanki-Ervasti for their contribution in data collection. GLI notes that he was supported in part by the INTRuST Posttraumatic Stress Disorder and Traumatic Brain Injury Clinical Consortium funded by the Department of Defense Psychological Health/Traumatic Brain Injury Research Program (X81XWH-07-CC-CSDoD). This study was done as part of the first author's PhD thesis research program.	Abiola Tajudeen, 2011, BMC Res Notes, V4, P509, DOI 10.1186/1756-0500-4-509; Aroian K J, 1997, J Nurs Meas, V5, P151; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Beck AT., 1996, BECK DEPRESSION INVE, V2; Borgaro SR, 2004, BRAIN INJURY, V18, P685, DOI 10.1080/02699050310001646080; Cancelliere C, 2014, ARCH PHYS MED REHAB, V95, P201; Cassidy J David, 2014, Arch Phys Med Rehabil, V95, pS132, DOI 10.1016/j.apmr.2013.08.299; Earvolino-Ramirez M, 2007, NURS FORUM, V42, P73, DOI 10.1111/j.1744-6198.2007.00070.x; Garden N, 2010, NEUROPSYCHOLOGY, V24, P168, DOI 10.1037/a0017431; Godwin EE, 2013, BRAIN INJURY, V27, P637, DOI 10.3109/02699052.2012.750745; Heilemann MarySue V, 2003, J Nurs Meas, V11, P61, DOI 10.1891/106137403780954976; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Hou RH, 2012, J NEUROL NEUROSUR PS, V83, P217, DOI 10.1136/jnnp-2011-300767; Humphreys Janice, 2003, Issues Ment Health Nurs, V24, P137, DOI 10.1080/01612840305293; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Loprinzi CE, 2011, CLIN BREAST CANCER, V11, P364, DOI 10.1016/j.clbc.2011.06.008; Losoi H., 2013, PSYCHOL COMMUN HLTH, V2, P1, DOI [10.5964/pch.v2i1.40, DOI 10.5964/PCH.V2I1.40, 10.23668/psycharchives.2244, DOI 10.23668/PSYCHARCHIVES.2244]; Losoi H., 2014, RESILIENCE IS ASS FA; Lundman B, 2007, SCAND J CARING SCI, V21, P229, DOI 10.1111/j.1471-6712.2007.00461.x; Luoto TM, 2013, J NEUROTRAUM, V30, P11, DOI 10.1089/neu.2012.2611; Luthar SS, 2000, CHILD DEV, V71, P543, DOI 10.1111/1467-8624.00164; Macedo T, 2014, BMC PSYCHIATRY, V14, DOI 10.1186/s12888-014-0227-6; Mak WWS, 2011, J COUNS PSYCHOL, V58, P610, DOI 10.1037/a0025195; McCauley SR, 2013, J NEUROTRAUM, V30, P642, DOI 10.1089/neu.2012.2393; Morin CM, 2011, SLEEP, V34, P601, DOI 10.1093/sleep/34.5.601; Neenan M, 2009, DEV RESILIENCE COGNI; Nishi Daisuke, 2010, BMC Res Notes, V3, P310, DOI 10.1186/1756-0500-3-310; Nygren B, 2005, AGING MENT HEALTH, V9, P354, DOI 10.1080/1360500114415; Ruff R. M., 2003, RUFF NEUROBEHAVIORAL; Ruggiero KJ, 2003, J TRAUMA STRESS, V16, P495, DOI 10.1023/A:1025714729117; Snell DL, 2011, BRAIN INJURY, V25, P1126, DOI 10.3109/02699052.2011.607786; Steinhardt M, 2008, J AM COLL HEALTH, V56, P445, DOI 10.3200/JACH.56.44.445-454; Stulemeijer M, 2007, J PSYCHOSOM RES, V63, P637, DOI 10.1016/j.jpsychores.2007.06.023; Tugade MM, 2004, J PERS SOC PSYCHOL, V86, P320, DOI 10.1037/0022-3514.86.2.320; van Veldhoven LM, 2011, J NEUROL NEUROSUR PS, V82, P782, DOI 10.1136/jnnp.2010.228254; von Steinbuchel N, 2010, J NEUROTRAUM, V27, P1167, DOI 10.1089/neu.2009.1076; von Steinbuchel N, 2010, J NEUROTRAUM, V27, P1157, DOI 10.1089/neu.2009.1077; Wagnild G, 2009, RESILIENCE SCALE USE; Wagnild G M, 1993, J Nurs Meas, V1, P165; Wagnild Gail, 2003, J Gerontol Nurs, V29, P42; Wagnild G, 2009, J NURS MEAS, V17, P105, DOI 10.1891/1061-3749.17.2.105; Waljas M, 2014, J HEAD TRAUMA REHAB, V29, P443, DOI 10.1097/HTR.0000000000000002; Waljas M, 2012, BRAIN INJURY, V26, P972, DOI 10.3109/02699052.2012.660511; Weathers F.W., 1993, 9 ANN C ISTSS SAN AN; White B, 2008, REHABIL PSYCHOL, V53, P9, DOI 10.1037/0090-5550.53.1.9; Whittaker R, 2007, J NEUROL NEUROSUR PS, V78, P644, DOI 10.1136/jnnp.2006.101105	47	41	42	0	19	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL 1	2015	32	13					942	949		10.1089/neu.2014.3799			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CV0SU	WOS:000363964200002	25764398				2021-06-18	
J	Rose, SC; Fischer, AN; Heyer, GL				Rose, Sean C.; Fischer, Anastasia N.; Heyer, Geoffrey L.			How long is too long? The lack of consensus regarding the post-concussion syndrome diagnosis	BRAIN INJURY			English	Article						Concussion; head injury; mild brain injury; post-concussion syndrome; traumatic brain injury	TRAUMATIC BRAIN-INJURY; SPORT-RELATED CONCUSSION; DSM-IV CRITERIA; HIGH-SCHOOL; POSTCONCUSSIONAL DISORDER; PROLONGED RECOVERY; FOOTBALL; STATEMENT; SEVERITY; AGE	Background/aim: A standard definition of Post-concussion Syndrome (PCS) does not exist. The objective was to determine consensus regarding the definition of PCS among physician members of the American College of Sports Medicine (ACSM). Methods: Physician members of the ACSM were sent an electronic survey to determine opinions regarding the PCS diagnosis. Results: Five hundred and ninety-seven physicians completed the survey. When asked the minimum duration of symptoms required to diagnose PCS, respondents answered: <2 weeks (26.6%), 2 weeks to 1 month (20.4%), 1-3 months (33%) and >3 months (11.1%). Physicians who see >= 10% concussion patients in their practise, as well as physicians whose concussion population consists of >50% paediatric patients, were more likely to require >1 month of symptoms (p<0.001). When asked the minimum number of symptoms required to diagnose PCS, responses varied: one symptom (55.9%), two symptoms (17.6%), three symptoms (14.6%) and four or more symptoms (3.2%). Respondents from the US were more likely than non-US respondents to require only one symptom for the PCS diagnosis (p = 0.01). Conclusions: There is a lack of consensus regarding the definition of PCS among physician members of the ACSM. A standard definition would improve consistency in concussion research and in clinical practise.	[Rose, Sean C.; Fischer, Anastasia N.; Heyer, Geoffrey L.] Nationwide Childrens Hosp, Dept Pediat, Columbus, OH 43205 USA; [Rose, Sean C.; Heyer, Geoffrey L.] Nationwide Childrens Hosp, Dept Neurol, Columbus, OH 43205 USA; [Fischer, Anastasia N.] Nationwide Childrens Hosp, Dept Sports Med, Columbus, OH 43205 USA; Ohio State Univ, Columbus, OH 43210 USA	Heyer, GL (corresponding author), Nationwide Childrens Hosp, Dept Neurol, 700 Childrens Dr, Columbus, OH 43205 USA.	geoffrey.heyer@nationwidechildrens.org		Heyer, Geoffrey/0000-0001-9334-3739; Rose, Sean/0000-0001-5177-7715			American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Blume HK, 2012, PEDIATRICS, V129, pE31, DOI 10.1542/peds.2011-1742; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Boake C, 2004, J NEUROPSYCH CLIN N, V16, P493, DOI 10.1176/appi.neuropsych.16.4.493; Brown NJ, 2014, PEDIATRICS, V133, pE299, DOI 10.1542/peds.2013-2125; Chrisman SP, 2013, BRAIN INJURY, V27, P1, DOI 10.3109/02699052.2012.722251; Eisenberg MA, 2014, PEDIATRICS, V133, P999, DOI 10.1542/peds.2014-0158; Eisenberg MA, 2013, PEDIATRICS, V132, P8, DOI 10.1542/peds.2013-0432; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gibson S, 2013, BRAIN INJURY, V27, P839, DOI 10.3109/02699052.2013.775494; Harmon KG, 2013, CLIN J SPORT MED, V23, P1, DOI 10.1097/JSM.0b013e31827f5f93; Kashluba S, 2006, J INT NEUROPSYCH SOC, V12, P111, DOI 10.1017/S1355617706060036; Kaye AJ, 2010, J TRAUMA, V68, P1396, DOI 10.1097/TA.0b013e3181cf7d1b; Kraus JF, 2014, BRAIN INJURY, V28, P1248, DOI 10.3109/02699052.2014.916420; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Makdissi M, 2013, BRIT J SPORT MED, V47, P308, DOI 10.1136/bjsports-2013-092255; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; McCauley SR, 2005, J NERV MENT DIS, V193, P540, DOI 10.1097/01.nmd.0000172592.05801.71; McCauley SR, 2008, J CLIN EXP NEUROPSYC, V30, P360, DOI 10.1080/13803390701416635; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meehan WP, 2013, J PEDIATR-US, V163, P721, DOI 10.1016/j.jpeds.2013.03.012; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Piland SG, 2006, MED SCI SPORT EXER, V38, P27, DOI 10.1249/01.mss.0000183186.98212.d5; Torelli P, 2004, CEPHALALGIA, V24, P29, DOI 10.1111/j.1468-2982.2004.00633.x; World Health Organisation, 1993, ICD 10 CLASSIFICATIO; Zemek R, 2013, ACAD EMERG MED, V20, P1041, DOI 10.1111/acem.12220	30	41	41	0	21	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUL	2015	29	7-8					798	803		10.3109/02699052.2015.1004756			6	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	CO0BJ	WOS:000358814800002	25870975				2021-06-18	
J	Yan, EB; Frugier, T; Lim, CK; Heng, B; Sundaram, G; Tan, M; Rosenfeld, JV; Walker, DW; Guillemin, GJ; Morganti-Kossmann, MC				Yan, Edwin B.; Frugier, Tony; Lim, Chai K.; Heng, Benjamin; Sundaram, Gayathri; Tan, May; Rosenfeld, Jeffrey V.; Walker, David W.; Guillemin, Gilles J.; Morganti-Kossmann, Maria Cristina			Activation of the kynurenine pathway and increased production of the excitotoxin quinolinic acid following traumatic brain injury in humans	JOURNAL OF NEUROINFLAMMATION			English	Article						Patients; Traumatic brain injury; Kynurenine pathway; Tryptophan metabolism; Quinolinic acid	INDOLEAMINE 2,3-DIOXYGENASE EXPRESSION; AMYOTROPHIC-LATERAL-SCLEROSIS; ALZHEIMERS-DISEASE; HUNTINGTONS-DISEASE; CEREBROSPINAL-FLUID; TRYPTOPHAN DEGRADATION; LIPID-PEROXIDATION; OXIDATIVE STRESS; HUMAN NEURONS; RAT-BRAIN	During inflammation, the kynurenine pathway (KP) metabolises the essential amino acid tryptophan (TRP) potentially contributing to excitotoxicity via the release of quinolinic acid (QUIN) and 3-hydroxykynurenine (3HK). Despite the importance of excitotoxicity in the development of secondary brain damage, investigations on the KP in TBI are scarce. In this study, we comprehensively characterised changes in KP activation by measuring numerous metabolites in cerebrospinal fluid (CSF) from TBI patients and assessing the expression of key KP enzymes in brain tissue from TBI victims. Acute QUIN levels were further correlated with outcome scores to explore its prognostic value in TBI recovery. Methods: Twenty-eight patients with severe TBI (GCS <= 8, three patients had initial GCS = 9-10, but rapidly deteriorated to <= 8) were recruited. CSF was collected from admission to day 5 post-injury. TRP, kynurenine (KYN), kynurenic acid (KYNA), QUIN, anthranilic acid (AA) and 3-hydroxyanthranilic acid (3HAA) were measured in CSF. The Glasgow Outcome Scale Extended (GOSE) score was assessed at 6 months post-TBI. Post-mortem brains were obtained from the Australian Neurotrauma Tissue and Fluid Bank and used in qPCR for quantitating expression of KP enzymes (indoleamine 2,3-dioxygenase-1 (IDO1), kynurenase (KYNase), kynurenine amino transferase-II (KAT-II), kynurenine 3-monooxygenase (KMO), 3-hydroxyanthranilic acid oxygenase (3HAO) and quinolinic acid phosphoribosyl transferase (QPRTase) and IDO1 immunohistochemistry. Results: In CSF, KYN, KYNA and QUIN were elevated whereas TRP, AA and 3HAA remained unchanged. The ratios of QUIN: KYN, QUIN: KYNA, KYNA: KYN and 3HAA: AA revealed that QUIN levels were significantly higher than KYN and KYNA, supporting increased neurotoxicity. Amplified IDO1 and KYNase mRNA expression was demonstrated on post-mortem brains, and enhanced IDO1 protein coincided with overt tissue damage. QUIN levels in CSF were significantly higher in patients with unfavourable outcome and inversely correlated with GOSE scores. Conclusion: TBI induced a striking activation of the KP pathway with sustained increase of QUIN. The exceeding production of QUIN together with increased IDO1 activation and mRNA expression in brain-injured areas suggests that TBI selectively induces a robust stimulation of the neurotoxic branch of the KP pathway. QUIN's detrimental roles are supported by its association to adverse outcome potentially becoming an early prognostic factor post-TBI.	[Yan, Edwin B.] Monash Univ, Dept Physiol, Clayton, Vic 3800, Australia; [Frugier, Tony] Univ Melbourne, Dept Pharmacol & Therapeut, Melbourne, Vic, Australia; [Lim, Chai K.; Heng, Benjamin; Guillemin, Gilles J.] Macquarie Univ, Fac Med & Hlth Sci, Neuroinflammat Grp, Sydney, NSW 2109, Australia; [Sundaram, Gayathri] St Vincents Ctr Appl Med Res, Peter Duncan Neurosci Res Unit, Appl Neurosci Program, Sydney, NSW, Australia; [Tan, May] Hosp Queen Elizabeth, Kota Kinabalu 88586, Sabah, Malaysia; [Rosenfeld, Jeffrey V.] Alfred Hosp, Dept Neurosurg, Melbourne, Vic, Australia; [Rosenfeld, Jeffrey V.] Monash Univ, Cent Clin Sch, Dept Surg, Melbourne, Vic 3004, Australia; [Rosenfeld, Jeffrey V.] Monash Univ, Monash Inst Med Engn, Melbourne, Vic 3004, Australia; [Walker, David W.] Monash Med Ctr, Hudson Inst Med Res, Ritchie Ctr, Melbourne, Vic, Australia; [Morganti-Kossmann, Maria Cristina] Monash Univ, Dept Epidemiol & Prevent Med, Australian New Zealand Intens Care Res Ctr, Melbourne, Vic 3004, Australia; [Morganti-Kossmann, Maria Cristina] Univ Arizona, Barrow Neurol Inst, Dept Child Hlth, Phoenix, AZ USA	Yan, EB (corresponding author), Monash Univ, Dept Physiol, Clayton, Vic 3800, Australia.	edwin.yan@monash.edu	Heng, Ruiwen benjamin/U-7383-2019; Lim, Edwin/R-5001-2019; Guillemin, Gilles J/C-3878-2015; Sundaram, Gayathri/AAN-3599-2020	Heng, Ruiwen benjamin/0000-0002-0247-2920; Lim, Edwin/0000-0003-3526-8405; Guillemin, Gilles J/0000-0001-8105-4470; Sundaram, Gayathri/0000-0001-8610-1598; Frugier, Tony/0000-0002-1275-5158; Morganti-Kossmann, Cristina/0000-0002-0807-2063	Victorian Neurotrauma Initiative/Traffic Accident Commission [D009]; National Health Medical Research CouncilNational Health and Medical Research Council of Australia [436815]; Australian Research Council (Future Fellowship)Australian Research Council; Florey Institute of Neuroscience and Mental Health; Alfred and the Victorian Forensic Institute of Medicine; Australia's National Health & Medical Research Council; Parkinson's VictoriaParkinson's UK	This study was funded by the Victorian Neurotrauma Initiative/Traffic Accident Commission project grant D009 and Research Fellowships to EBY and MCM.-K and National Health Medical Research Council Project Grant #436815. GJG is funded by the Australian Research Council (Future Fellowship). Post-mortem brain tissues were received from the Victorian Brain Bank Network, supported by The Florey Institute of Neuroscience and Mental Health, The Alfred and the Victorian Forensic Institute of Medicine and funded by Australia's National Health & Medical Research Council and Parkinson's Victoria.	Baratte S, 1998, MOL BRAIN RES, V59, P50, DOI 10.1016/S0169-328X(98)00136-3; BEAL MF, 1986, NATURE, V321, P168, DOI 10.1038/321168a0; Bell MJ, 1999, CRIT CARE MED, V27, P493, DOI 10.1097/00003246-199903000-00023; Braidy N, 2009, NEUROTOX RES, V16, P77, DOI 10.1007/s12640-009-9051-z; Chen YQ, 2011, J NEUROCHEM, V118, P816, DOI 10.1111/j.1471-4159.2010.07159.x; Chen YQ, 2010, NEUROTOX RES, V18, P132, DOI 10.1007/s12640-009-9129-7; CHRISTENSEN HN, 1994, J EXP BIOL, V196, P51; Costantino G, 2014, FUTURE MED CHEM, V6, P841, DOI [10.4155/FMC.14.35, 10.4155/fmc.14.35]; Darlington LG, 2007, EUR J NEUROSCI, V26, P2211, DOI 10.1111/j.1460-9568.2007.05838.x; Darlington LG, 2010, INT J TRYPTOPHAN RES, V3, P51; Fallarino F, 2012, EUR J IMMUNOL, V42, P1932, DOI 10.1002/eji.201242572; Forrest CM, 2006, CLIN EXP PHARMACOL P, V33, P1078, DOI 10.1111/j.1440-1681.2006.04490.x; Forrest CM, 2010, J NEUROCHEM, V112, P112, DOI 10.1111/j.1471-4159.2009.06442.x; FOSTER AC, 1984, NEUROSCI LETT, V48, P273, DOI 10.1016/0304-3940(84)90050-8; Frugier T, 2012, J NEUROPATH EXP NEUR, V71, P242, DOI 10.1097/NEN.0b013e3182496149; Frugier T, 2011, CELL MOL NEUROBIOL, V31, P569, DOI 10.1007/s10571-011-9650-0; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; Goda K, 1996, ADV EXP MED BIOL, V398, P247; Guillemin GJ, 2007, J NEUROSCI, V27, P12884, DOI 10.1523/JNEUROSCI.4101-07.2007; Guillemin GJ, 2012, FEBS J, V279, P1355, DOI 10.1111/j.1742-4658.2012.08493.x; Guillemin GJ, 2012, FEBS J, V279, P1356, DOI 10.1111/j.1742-4658.2012.08485.x; Guillemin GJ, 2005, NEUROPATH APPL NEURO, V31, P395, DOI 10.1111/j.1365-2990.2005.00655.x; Guillemin GJ, 2003, ADV EXP MED BIOL, V527, P167; Guillemin GJ, 2002, REDOX REP, V7, P199, DOI 10.1179/135100002125000550; HABERNY KA, 1992, NEUROSCI LETT, V146, P187, DOI 10.1016/0304-3940(92)90074-H; Han Q, 2008, BIOSCIENCE REP, V28, P205, DOI 10.1042/BSR20080085; Han Q, 2010, CELL MOL LIFE SCI, V67, P353, DOI 10.1007/s00018-009-0166-4; HEYES MP, 1991, ANN NEUROL, V29, P202, DOI 10.1002/ana.410290215; HEYES MP, 1992, BRAIN, V115, P1249, DOI 10.1093/brain/115.5.1249; Iwahashi H, 1999, CHEM-BIOL INTERACT, V118, P201, DOI 10.1016/S0009-2797(99)00080-0; Kalonia Harikesh, 2009, Inflammopharmacology, V17, P211, DOI 10.1007/s10787-009-0012-1; Kerr SJ, 1998, AIDS, V12, P355, DOI 10.1097/00002030-199804000-00003; Kheramin S, 2002, PSYCHOPHARMACOLOGY, V165, P9, DOI 10.1007/s00213-002-1228-6; Mackay GM, 2009, CLIN EXP PHARMACOL P, V36, P425, DOI 10.1111/j.1440-1681.2008.05077.x; MARTIN A, 1992, J NEUROPSYCH CLIN N, V4, P270; MCMENAMY RH, 1965, J BIOL CHEM, V240, P4235; Meisel R, 2004, BLOOD, V103, P4619, DOI 10.1182/blood-2003-11-3909; MILLER JD, 1993, J NEUROL NEUROSUR PS, V56, P440, DOI 10.1136/jnnp.56.5.440; Moroni F, 1999, EUR J PHARMACOL, V375, P87, DOI 10.1016/S0014-2999(99)00196-X; Nemeth H, 2005, CURR NEUROVASC RES, V2, P249, DOI 10.2174/1567202054368326; Pellegrin K, 2005, SHOCK, V23, P209, DOI 10.1097/01.shk.000150773.16613.d3; PFEFFERKORN ER, 1984, P NATL ACAD SCI-BIOL, V81, P908, DOI 10.1073/pnas.81.3.908; Ploder M, 2009, CLIN SCI, V116, P593, DOI 10.1042/CS20080319; Salazar C, 2009, FEBS J, V276, P3177, DOI 10.1111/j.1742-4658.2009.07027.x; Santamaria A, 2001, NEUROREPORT, V12, P2693, DOI 10.1097/00001756-200108280-00020; Santamaria A, 2001, NEUROREPORT, V12, P871, DOI 10.1097/00001756-200103260-00049; Sarkhosh K, 2003, WOUND REPAIR REGEN, V11, P337, DOI 10.1046/j.1524-475X.2003.11505.x; Sarkhosh K, 2003, J CELL BIOCHEM, V90, P206, DOI 10.1002/jcb.10593; SCHWARCZ R, 1983, SCIENCE, V219, P316, DOI 10.1126/science.6849138; Schwarcz R, 2012, NAT REV NEUROSCI, V13, P465, DOI 10.1038/nrn3257; Sinz EH, 1998, J CEREBR BLOOD F MET, V18, P610, DOI 10.1097/00004647-199806000-00002; Smythe GA, 2002, ANAL BIOCHEM, V301, P21, DOI 10.1006/abio.2001.5490; Stone TW, 2001, PROG NEUROBIOL, V64, P185, DOI 10.1016/S0301-0082(00)00032-0; STONE TW, 1981, EUR J PHARMACOL, V72, P411, DOI 10.1016/0014-2999(81)90587-2; Stoy N, 2005, J NEUROCHEM, V93, P611, DOI 10.1111/j.1471-4159.2005.03070.x; Swanson KA, 2004, AM J RESP CELL MOL, V30, P311, DOI 10.1165/rcmb.2003-0268OC; Ting KK, 2007, NEUROTOX RES, V12, P247, DOI 10.1007/BF03033908; Vandresen-Filho S, 2015, NEUROL SCI; VONRUECKER AA, 1989, BIOCHEM BIOPH RES CO, V163, P836, DOI 10.1016/0006-291X(89)92298-5; Wang YX, 2010, BRAIN BEHAV IMMUN, V24, P201, DOI 10.1016/j.bbi.2009.06.152; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; WHETSELL WO, 1989, NEUROSCI LETT, V97, P271, DOI 10.1016/0304-3940(89)90609-5; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Yamada A, 2009, J NEUROCHEM, V110, P791, DOI 10.1111/j.1471-4159.2009.06175.x; Yan E, 2005, NEUROSCIENCE, V134, P867, DOI 10.1016/j.neuroscience.2005.04.056; Yan EB, 2014, J NEUROTRAUM, V31, P618, DOI 10.1089/neu.2013.3087; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016; Zwilling D, 2011, CELL, V145, P863, DOI 10.1016/j.cell.2011.05.020	69	41	41	0	7	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	MAY 30	2015	12								110	10.1186/s12974-015-0328-2			17	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	CK1OO	WOS:000355976800001	26025142	DOAJ Gold, Green Published			2021-06-18	
J	Laitinen, T; Sierra, A; Bolkvadze, T; Pitkanen, A; Grohn, O				Laitinen, Teemu; Sierra, Alejandra; Bolkvadze, Tamuna; Pitkanen, Asla; Grohn, Olli			Diffusion tensor imaging detects chronic microstructural changes in white and gray matter after traumatic brain injury in rat	Frontiers in Neuroscience			English	Article						diffusion tensor imaging; traumatic brain injury; microstructure; animal models; histology	FLUID PERCUSSION INJURY; AXONAL INJURY; MRI; ANISOTROPY; MODERATE; IMAGES; MODEL; WATER; OPTIMIZATION; REGISTRATION	Traumatic brain injury (TBI) is a major cause of disability and death in people of all ages worldwide. An initial brain injury caused by external mechanical forces triggers a cascade of tissue changes that lead to a wide spectrum of symptoms and disabilities, such as cognitive deficits, mood or anxiety disorders, motor impairments, chronic pain, and epilepsy. We investigated the detectability of secondary injury at a chronic time-point using ex vivo diffusion tensor imaging (DTI) in a rat model of TBI, lateral fluid percussion (LFP) injury. Our analysis of ex vivo DTI data revealed persistent microstructural tissue changes in white matter tracts, such as the splenium of the corpus callosum, angular bundle, and internal capsule. Histologic examination revealed mainly loss of myelinated axons and/or iron accumulation. Gray matter areas in the thalamus exhibited an increase in fractional anisotropy associated with neurodegeneration, myelinated fiber loss, and/or calcifications at the chronic phase. In addition, we examined whether these changes could also be detected with in vivo settings at the same chronic time-point. Our results provide insight into DTI detection of microstructural changes in the chronic phase of TBI, and elucidate how these changes correlate with cellular level alterations.	[Laitinen, Teemu; Sierra, Alejandra; Bolkvadze, Tamuna; Pitkanen, Asla; Grohn, Olli] Univ Eastern Finland, AI Virtanen Inst Mol Sci, Dept Neurobiol, FI-70211 Kuopio, Finland; [Pitkanen, Asla] Kuopio Univ Hosp, Dept Neurol, SF-70210 Kuopio, Finland	Sierra, A (corresponding author), Univ Eastern Finland, AI Virtanen Inst Mol Sci, POB1627,Neulaniementie 2, FI-70211 Kuopio, Finland.	alejandra.sierralopez@uef.fi		Sierra Lopez, Alejandra/0000-0001-5399-2056	Academy of FinlandAcademy of FinlandEuropean Commission; Sigrid Juselius FoundationSigrid Juselius Foundation; Finnish Cultural FoundationFinnish Cultural Foundation; University of Eastern Finland	This study was supported by the Academy of Finland (AS, OG, AP), Sigrid Juselius Foundation (AP), Finnish Cultural Foundation (AS), and UEF-Brain strategic funding from the University of Eastern Finland. We thank Ms. Maarit Pulkkinen for assistance with the histology.	Aquino C, 2015, EMERG RADIOL, V22, P65, DOI 10.1007/s10140-014-1226-0; Basser PJ, 1998, MAGNET RESON MED, V39, P928, DOI 10.1002/mrm.1910390610; BASSER PJ, 1994, BIOPHYS J, V66, P259, DOI 10.1016/S0006-3495(94)80775-1; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Flygt J, 2013, EUR J NEUROSCI, V38, P2153, DOI 10.1111/ejn.12179; Gallagher CN, 2007, CURR OPIN NEUROL, V20, P403, DOI 10.1097/WCO.0b013e32821b987b; Graham DI, 2000, ACTA NEUROPATHOL, V99, P117, DOI 10.1007/PL00007414; Gurkoff GG, 2013, J NEUROTRAUM, V30, P292, DOI 10.1089/neu.2012.2463; Hayward NMEA, 2010, J NEUROTRAUM, V27, P2203, DOI 10.1089/neu.2010.1448; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Hylin MJ, 2013, J NEUROTRAUM, V30, P702, DOI 10.1089/neu.2012.2630; Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132; Jenkinson M, 2001, MED IMAGE ANAL, V5, P143, DOI 10.1016/S1361-8415(01)00036-6; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kharatishvili I, 2007, BRAIN, V130, P3155, DOI 10.1093/brain/awm268; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Laitinen T, 2010, NEUROIMAGE, V51, P521, DOI 10.1016/j.neuroimage.2010.02.077; Lehto LJ, 2012, NEUROIMAGE, V61, P761, DOI 10.1016/j.neuroimage.2012.03.002; Lifshitz J, 2007, J NEUROPATH EXP NEUR, V66, P218, DOI 10.1097/01.jnen.0000248558.75950.4d; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Makinen S, 2008, J CEREBR BLOOD F MET, V28, P263, DOI 10.1038/sj.jcbfm.9600529; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Mori S, 2006, NEURON, V51, P527, DOI 10.1016/j.neuron.2006.08.012; Okubo Shuichi, 2013, Acta Neurochir Suppl, V118, P83, DOI 10.1007/978-3-7091-1434-6_14; Pajevic S, 1999, MAGNET RESON MED, V42, P526, DOI 10.1002/(SICI)1522-2594(199909)42:3<526::AID-MRM15>3.0.CO;2-J; Rodriguez-Paez AC, 2005, ACTA NEUROPATHOL, V109, P603, DOI 10.1007/s00401-005-1010-z; ROSS DT, 1990, NEUROSCIENCE, V35, P525, DOI 10.1016/0306-4522(90)90327-Z; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Savander V, 1996, J COMP NEUROL, V374, P291, DOI 10.1002/(SICI)1096-9861(19961014)374:2<291::AID-CNE10>3.0.CO;2-Y; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; SLOVITER RS, 1982, BRAIN RES BULL, V8, P771, DOI 10.1016/0361-9230(82)90104-6; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Sun SW, 2005, MAGN RESON MED, V53, P1447, DOI 10.1002/mrm.20488; Sun SW, 2003, MAGN RESON MED, V50, P743, DOI 10.1002/mrm.10605; van der Zwaag W, 2009, J MAGN RESON IMAGING, V30, P1171, DOI 10.1002/jmri.21951	42	41	43	0	10	FRONTIERS RESEARCH FOUNDATION	LAUSANNE	PO BOX 110, LAUSANNE, 1015, SWITZERLAND	1662-453X			FRONT NEUROSCI-SWITZ	Front. Neurosci.	APR 22	2015	9								128	10.3389/fnins.7015.00128			12	Neurosciences	Neurosciences & Neurology	CG9OY	WOS:000353647200001	25954146	DOAJ Gold			2021-06-18	
J	Fan, W; Zhu, X; Wu, L; Wu, Z; Li, D; Huang, F; He, H				Fan, W.; Zhu, X.; Wu, L.; Wu, Z.; Li, D.; Huang, F.; He, H.			Propofol: an anesthetic possessing neuroprotective effects	EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES			English	Article						Propofol; Neuroprotection; Cerebral ischemia; Brain injury	FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; REDUCES INFARCT SIZE; PROTEIN-KINASE-C; RAT CEREBROCORTICAL NEURONS; OXYGEN-GLUCOSE DEPRIVATION; NECROSIS-FACTOR-ALPHA; SPINAL-CORD-INJURY; OXIDATIVE STRESS; CULTURED ASTROCYTES	Propofol is a short-acting intravenous anaesthetic agent and widely used not only in operating rooms but also in the intensive care unit (ICU). Apart from its multiple anaesthetic advantages, the neuroprotective effect of propofol has been demonstrated in diverse models of neuronal injury. The effect of propofol results from activation of gamma-aminobutyric acid (GABA) receptor, modulation excitatory amino acid transmitter system and protecting brain cells against oxidative stress. Moreover, propofol is able to supress apoptosis and inflammation and to regulate neuroprotection-associated proteins or ion homeostasis to act its neuroprotective effects. This review focuses on the research progress of the neuroprotective effects of propofol and its mechanisms of action to date. The implications for possible use for the clinical setting are also discussed.	[Fan, W.; Wu, L.; Wu, Z.; Huang, F.; He, H.] Guangdong Prov Key Lab Stomatol, Guangzhou, Guangdong, Peoples R China; [Fan, W.] Sun Yat Sen Univ, Affiliated Hosp Stomatol, Dept Anesthesiol, Guangzhou 510275, Guangdong, Peoples R China; [Zhu, X.] Guangdong Med Coll, Guangdong Prov Key Lab Med Mol Diag, Dongguan, Guangdong, Peoples R China; [Li, D.] Georgia Regents Univ, Inst Mol Med & Genet, Augusta, GA USA	He, H (corresponding author), Guangdong Prov Key Lab Stomatol, Guangzhou, Guangdong, Peoples R China.	HeHW@mail.sysu.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81271166, 81371107]; Natural Science Foundation of Guangdong ProvinceNational Natural Science Foundation of Guangdong Province [10451008901006145]; Fundamental Research Funds for the Central UniversitiesFundamental Research Funds for the Central Universities [11ykpy50]	This work is supported in part by the National Natural Science Foundation of China (No. 81271166, 81371107), Natural Science Foundation of Guangdong Province (No. 10451008901006145) and Fundamental Research Funds for the Central Universities (No. 11ykpy50).	AARTS L, 1995, FEBS LETT, V357, P83, DOI 10.1016/0014-5793(94)01337-Z; Acquaviva R, 2005, CURR NEUROVASC RES, V2, P141, DOI 10.2174/1567202053586820; Acquaviva R, 2004, ANESTHESIOLOGY, V101, P1363; Adembri C, 2006, ANESTHESIOLOGY, V104, P80, DOI 10.1097/00000542-200601000-00014; Adembri C, 2007, CNS DRUG REV, V13, P333, DOI 10.1111/j.1527-3458.2007.00015.x; Andrews DT, 2012, ANAESTH INTENS CARE, V40, P46, DOI 10.1177/0310057X1204000106; Bayona NA, 2004, ANESTHESIOLOGY, V100, P1151, DOI 10.1097/00000542-200405000-00017; Berns M, 2009, J INT MED RES, V37, P680, DOI 10.1177/147323000903700311; Boland A, 2000, EUR J PHARMACOL, V404, P21, DOI 10.1016/S0014-2999(00)00496-9; Bowery NG, 2006, BRIT J PHARMACOL, V147, pS109, DOI 10.1038/sj.bjp.0706443; Cai JS, 2011, NEUROCHEM RES, V36, P1724, DOI 10.1007/s11064-011-0487-1; Chen L, 2008, ACTA ANAESTH SCAND, V52, P413, DOI 10.1111/j.1399-6576.2007.01560.x; Chen LH, 2003, CHINESE MED J-PEKING, V116, P292; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; Cui DR, 2013, NEUROSCIENCE, V246, P117, DOI 10.1016/j.neuroscience.2013.04.054; Cui DR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035324; Dietrich WD, 1996, J NEUROTRAUM, V13, P309, DOI 10.1089/neu.1996.13.309; Ding ZY, 2013, CELL BIOCHEM BIOPHYS, V67, P615, DOI 10.1007/s12013-013-9549-0; Do SH, 2003, NEUROSCI LETT, V343, P113, DOI 10.1016/S0304-3940(03)00358-6; Engelhard K, 2004, ANESTHESIOLOGY, V101, P912, DOI 10.1097/00000542-200410000-00016; Engelhard K, 2004, EUR J ANAESTH, V21, P530, DOI 10.1017/S0265021504007057; Engelhard K, 2003, ANESTH ANALG, V97, P1155, DOI 10.1213/01.ANE.0000078576.93190.6F; Engelhard K, 2006, CURR OPIN ANESTHESIO, V19, P504, DOI 10.1097/01.aco.0000245275.76916.87; Ergun R, 2002, NEUROSURG REV, V25, P95, DOI 10.1007/s101430100171; Feiner JR, 2005, ANESTH ANALG, V100, P215, DOI 10.1213/01.ANE.0000142129.17005.73; Feng C S, 2004, CHIN MED J, V84, P2110; Gelb AW, 2002, ANESTHESIOLOGY, V96, P1183, DOI 10.1097/00000542-200205000-00023; Gill R, 2010, FREE RADICAL BIO MED, V48, P1121, DOI 10.1016/j.freeradbiomed.2010.01.006; Grasshoff C, 2005, EUR J ANAESTH, V22, P467, DOI 10.1017/S0265021505000803; Grasshoff C, 2002, ANESTH ANALG, V95, P920, DOI 10.1213/01.ANE.0000025705.93185.09; Gui B, 2012, INFLAMMATION, V35, P1632, DOI 10.1007/s10753-012-9478-x; Haeseler G, 2008, BRIT J PHARMACOL, V155, P265, DOI 10.1038/bjp.2008.255; Hans P, 1997, J NEUROSURG ANESTH, V9, P234, DOI 10.1097/00008506-199707000-00006; HANS P, 1994, J NEUROSURG ANESTH, V6, P249; Hans P, 2006, CURR OPIN ANESTHESIO, V19, P498, DOI 10.1097/01.aco.0000245274.69292.ad; Harman F, 2012, CHILD NERV SYST, V28, P1055, DOI 10.1007/s00381-012-1782-0; He JG, 2013, NEUROL SCI, V34, P165, DOI 10.1007/s10072-012-0978-0; Hollrigel GS, 1996, J NEUROPHYSIOL, V76, P2412; Huang WC, 2009, IMMUNOLOGY, V128, pe275, DOI 10.1111/j.1365-2567.2008.02959.x; Hutchens MP, 2006, NEUROCRIT CARE, V4, P54, DOI 10.1385/NCC:4:1:054; Ichinose K, 2006, RESUSCITATION, V70, P275, DOI 10.1016/j.resuscitation.2005.12.011; Iijima T, 2006, BRAIN RES, V1099, P25, DOI 10.1016/j.brainres.2006.04.117; Ishii H, 2002, BRIT J ANAESTH, V88, P412, DOI 10.1093/bja/88.3.412; ISHII H, 1994, ACTA NEUROCHIR, P238; Ito H, 1999, ACTA ANAESTH SCAND, V43, P153, DOI 10.1034/j.1399-6576.1999.430206.x; Jevtovic-Todorovic V, 2001, BRAIN RES, V913, P185, DOI 10.1016/S0006-8993(01)02800-1; JevtovicTodorovic V, 1997, J CEREBR BLOOD F MET, V17, P168, DOI 10.1097/00004647-199702000-00006; Jiao S, 2007, J NEUROCHEM, V100, P979, DOI 10.1111/j.1471-4159.2006.04261.x; Kanbak M, 2004, CAN J ANAESTH, V51, P712, DOI 10.1007/BF03018431; Kaptanoglu E, 2002, J NEUROSURG ANESTH, V14, P114, DOI 10.1097/00008506-200204000-00005; Karen T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064480; Kawaguchi Masahiko, 2005, J Anesth, V19, P150, DOI 10.1007/s00540-005-0305-5; Kitamura Y, 2003, J NEUROSCI RES, V71, P544, DOI 10.1002/jnr.10514; Kobayashi K, 2008, ANESTHESIOLOGY, V109, P426, DOI 10.1097/ALN.0b013e318182a903; Kobayashi M, 2007, J NEUROSURG ANESTH, V19, P171, DOI 10.1097/ANA.0b013e318051743d; KOCHS E, 1992, ANESTHESIOLOGY, V76, P245, DOI 10.1097/00000542-199202000-00014; Koerner IP, 2006, CURR OPIN ANESTHESIO, V19, P481, DOI 10.1097/01.aco.0000245271.84539.4c; Kotani Y, 2008, CNS NEUROSCI THER, V14, P95, DOI 10.1111/j.1527-3458.2008.00043.x; Kotani Y, 2008, J CEREBR BLOOD F MET, V28, P354, DOI 10.1038/sj.jcbfm.9600532; Krasowski MD, 2001, J PHARMACOL EXP THER, V297, P338; Kubo K, 2011, BRAIN RES, V1387, P125, DOI 10.1016/j.brainres.2011.02.079; Kumagai H, 2006, EUR J CARDIO-THORAC, V29, P714, DOI 10.1016/j.ejcts.2006.01.042; Larsson M, 2011, NEUROSCIENTIST, V17, P256, DOI 10.1177/1073858409349913; Lee B, 2005, J NEUROSCI, V25, P1137, DOI 10.1523/JNEUROSCI.4288-04.2005; Lee H, 2005, J NEUROSURG ANESTH, V17, P144, DOI 10.1097/01.ana.0000167143.67673.53; Lee SR, 1999, NEUROL RES, V21, P225, DOI 10.1080/01616412.1999.11740922; Lee Y, 2000, J KOREAN MED SCI, V15, P627, DOI 10.3346/jkms.2000.15.6.627; Li Q, 2002, EXP NEUROL, V177, P531, DOI 10.1006/exnr.2002.7994; Liang C, 2013, J NEUROSURG ANESTH, V25, P311, DOI 10.1097/ANA.0b013e31828c6af5; Lingamaneni R, 2001, ANESTHESIOLOGY, V95, P1460, DOI 10.1097/00000542-200112000-00027; Liu J, 2012, CLIN EXP MED, V12, P31, DOI 10.1007/s10238-011-0139-4; Ma G, 2013, J CARDIOTHOR VASC AN, V27, P510, DOI 10.1053/j.jvca.2012.10.013; Ma Jie, 2009, Yaoxue Xuebao, V44, P344; Maines MD, 2004, ANTIOXID REDOX SIGN, V6, P797, DOI 10.1089/ars.2004.6.797; Manataki AD, 2001, SURG ENDOSC, V15, P950, DOI 10.1007/s004640090104; Menku A, 2010, TURK NEUROSURG, V20, P57; Minami K, 1996, N-S ARCH PHARMACOL, V353, P572; Morris DR, 2013, CURR OPIN CLIN NUTR, V16, P708, DOI 10.1097/MCO.0b013e328364f39c; Nakanishi M, 2007, ANESTH ANALG, V104, P1136, DOI 10.1213/01.ane.0000260615.12553.4e; Ouyang W, 2003, MOL PHARMACOL, V64, P373, DOI 10.1124/mol.64.2.373; Pittman JE, 1997, ANESTHESIOLOGY, V87, P1139, DOI 10.1097/00000542-199711000-00018; Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476; Qin X, 2013, J PHYSIOL BIOCHEM, V69, P707, DOI 10.1007/s13105-013-0247-6; Raivich G, 2008, J NEUROCHEM, V107, P898, DOI 10.1111/j.1471-4159.2008.05684.x; Ratnakumari L, 1996, BRIT J PHARMACOL, V119, P1498, DOI 10.1111/j.1476-5381.1996.tb16064.x; Ratnakumari L, 1997, ANESTHESIOLOGY, V86, P428, DOI 10.1097/00000542-199702000-00018; Ribeiro MD, 2006, J NEUROSCI RES, V83, P1231, DOI 10.1002/jnr.20819; Rossaint J, 2009, CRIT CARE, V13, DOI 10.1186/cc7795; Sagara Y, 1999, J NEUROCHEM, V73, P2524, DOI 10.1046/j.1471-4159.1999.0732524.x; Schlunzen L, 2012, ACTA ANAESTH SCAND, V56, P248, DOI 10.1111/j.1399-6576.2011.02561.x; Schoen J, 2011, BRIT J ANAESTH, V106, P840, DOI 10.1093/bja/aer091; Shu LW, 2012, NEUROCHEM RES, V37, P49, DOI 10.1007/s11064-011-0582-3; SIESJO BK, 1992, J NEUROSURG, V77, P169, DOI 10.3171/jns.1992.77.2.0169; Singh S, 2012, EUR REV MED PHARMACO, V16, P1651; Sitar SM, 1999, ANESTHESIOLOGY, V90, P1446, DOI 10.1097/00000542-199905000-00030; Snyder GL, 2007, NEUROPHARMACOLOGY, V53, P619, DOI 10.1016/j.neuropharm.2007.07.008; Solaroglu I, 2004, BIOL NEONATE, V85, P221, DOI 10.1159/000075835; Song CY, 2011, EUR J PHARMACOL, V653, P16, DOI 10.1016/j.ejphar.2010.10.072; Stratford N, 1998, EUR J ANAESTH, V15, P158, DOI 10.1046/j.1365-2346.1998.00261.x; Suh SW, 2000, BRAIN RES, V852, P268, DOI 10.1016/S0006-8993(99)02095-8; Szewczyk B, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00033; Tanaka T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029378; Tawfeeq NA, 2009, INJURY, V40, pS75, DOI 10.1016/j.injury.2009.10.040; Traber MG, 2007, FREE RADICAL BIO MED, V43, P4, DOI 10.1016/j.freeradbiomed.2007.03.024; Trapani G, 2000, CURR MED CHEM, V7, P249, DOI 10.2174/0929867003375335; Vasileiou I, 2009, EUR J PHARMACOL, V605, P1, DOI 10.1016/j.ejphar.2009.01.007; Velly LJ, 2003, ANESTHESIOLOGY, V99, P368, DOI 10.1097/00000542-200308000-00018; Wang HY, 2009, BRAIN RES, V1297, P177, DOI 10.1016/j.brainres.2009.08.054; Wang HY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065187; Wang HY, 2011, J NEUROCHEM, V119, P210, DOI 10.1111/j.1471-4159.2011.07400.x; Wang JP, 2002, EUR J PHARMACOL, V452, P303, DOI 10.1016/S0014-2999(02)02332-4; Wang L, 2008, J NEUROSURG ANESTH, V20, P124, DOI 10.1097/ANA.0b013e3181667c27; Wang MJ, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-99; Wang P, 2013, EUR REV MED PHARMACO, V17, P1722; WERNER C, 1992, J NEUROSURG ANESTH, V4, P41, DOI 10.1097/00008506-199201000-00008; Wu GJ, 2011, BRAIN RES, V1384, P42, DOI 10.1016/j.brainres.2011.02.004; Wu XJ, 2007, ACTA PHARMACOL SIN, V28, P1123, DOI 10.1111/j.1745-7254.2007.00610.x; Xi HJ, 2011, BRAIN RES, V1410, P24, DOI 10.1016/j.brainres.2011.06.060; Xue QS, 2004, ACTA PHARMACOL SIN, V25, P115; Yamaguchi S, 1999, CAN J ANAESTH, V46, P593, DOI 10.1007/BF03013553; Yamasaki T, 1999, EUR J ANAESTH, V16, P320, DOI 10.1046/j.1365-2346.1999.00478.x; Yano T, 2000, BRAIN RES, V883, P69, DOI 10.1016/S0006-8993(00)02889-4; Young Y, 1997, EUR J ANAESTH, V14, P320, DOI 10.1046/j.1365-2346.1997.00130.x; Yun JY, 2007, EUR J PHARMACOL, V565, P83, DOI 10.1016/j.ejphar.2007.02.045; Zhan RZ, 2001, CRIT CARE MED, V29, P808, DOI 10.1097/00003246-200104000-00026; Zhang YY, 2012, MED GAS RES, V2, DOI 10.1186/2045-9912-2-20; Zhao XC, 2013, NEUROCHEM RES, V38, P530, DOI 10.1007/s11064-012-0945-4; Zheng YY, 2008, ANESTH ANALG, V107, P2009, DOI 10.1213/ane.0b013e318187c313; Zhu SM, 2009, ANESTH ANALG, V109, P1493, DOI 10.1213/ANE.0b013e3181b893f3	129	41	43	0	6	VERDUCI PUBLISHER	ROME	VIA GREGORIO VII, ROME, 186-00165, ITALY	1128-3602			EUR REV MED PHARMACO	Eur. Rev. Med. Pharmacol. Sci.	APR	2015	19	8					1520	1529					10	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CI1WG	WOS:000354535200027	25967729				2021-06-18	
J	Rubovitch, V; Barak, S; Rachmany, L; Goldstein, RB; Zilberstein, Y; Pick, CG				Rubovitch, Vardit; Barak, Shani; Rachmany, Lital; Goldstein, Renana Baratz; Zilberstein, Yael; Pick, Chaim G.			The Neuroprotective Effect of Salubrinal in a Mouse Model of Traumatic Brain Injury	NEUROMOLECULAR MEDICINE			English	Article						Brain trauma; Recognition memory; Spatial memory; Cell death mechanisms; Neuroprotection; Integrated stress response; Salubrinal	ENDOPLASMIC-RETICULUM STRESS; UNFOLDED PROTEIN RESPONSE; GROWTH-FACTOR-I; ER STRESS; TRANSLATIONAL CONTROL; CELL-DEATH; MICE; PHOSPHORYLATION; INITIATION; MEMORY	We have previously reported that mild traumatic brain injury (mTBI) induced cognitive deficits as well as apoptotic changes in the brains of mice. Apoptosis may be caused by severe, prolonged accumulation of misfolded proteins, and protein aggregation in the endoplasmic reticulum (ER stress). In an additional study, we have reported that mTBI activated the pro-apoptotic arm of the integrated stress response (ISR). The main goal of the present study was to test the involvement of the adaptive eIF2 alpha/ATF4 pathway in mTBI-affected brains. Head injury was induced with a noninvasive, closed-head weight drop (30 g) to ICR mice. Salubrinal, the selective phosphatase inhibitor of p-eIF2 alpha, was injected immediately and 24 h after mTBI (1 mg/kg, ip). Y-maze and novel object recognition tests to assess spatial and visual memories, respectively, were conducted either 7 or 30 days post-trauma. Salubrinal administration significantly improved memory deficits following mTBI. Slaubrinal also prevented the elevation of degenerating neurons and the reduction of mature neurons in the cortex (as seen by immunofluorescent staining with Fluoro-Jade-B and NeuN antibodies, 72 h and 1 week post-mTBI, respectively). Western blot analysis revealed that salubrinal prevented the significant reduction in eIF2 alpha and ATF4 phosphorylation in mTBI brains 72 h post-injury. Immunofluorescence staining revealed that although the reduction in p-eIF2 alpha did not reach significance, salubrinal administration elevated it dramatically. Our results show that targeting the translational/adaptive arm of the ISR with salubrinal may serve as a therapeutic strategy for brain damage.	[Rubovitch, Vardit; Barak, Shani; Rachmany, Lital; Goldstein, Renana Baratz; Pick, Chaim G.] Tel Aviv Univ, Sackler Fac Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel; [Zilberstein, Yael] Tel Aviv Univ, Sackler Fac Med, Sackler Cellular & Mol Imaging Ctr, IL-69978 Tel Aviv, Israel; [Pick, Chaim G.] Tel Aviv Univ, Sagol Sch Neurosci, IL-69978 Tel Aviv, Israel	Rubovitch, V (corresponding author), Tel Aviv Univ, Sackler Fac Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel.	rubovitc@post.tau.ac.il					Aleman A, 2009, PROG NEUROBIOL, V89, P256, DOI 10.1016/j.pneurobio.2009.07.008; Baird TD, 2012, ADV NUTR, V3, P307, DOI 10.3945/an.112.002113; Begum G, 2014, J NEUROSCI, V34, P3743, DOI 10.1523/JNEUROSCI.2872-13.2014; Boyce M, 2006, CELL DEATH DIFFER, V13, P363, DOI 10.1038/sj.cdd.4401817; Cai XH, 2014, EXP NEUROL, V257, P148, DOI 10.1016/j.expneurol.2014.04.029; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Chang HC, 2011, MED SCI SPORT EXER, V43, P2274, DOI 10.1249/MSS.0b013e318223b5d9; Chen CM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040801; Cohen E, 2009, CELL, V139, P1157, DOI 10.1016/j.cell.2009.11.014; Colla E, 2012, J NEUROSCI, V32, P3301, DOI 10.1523/JNEUROSCI.5368-11.2012; Conrad CD, 1996, BEHAV NEUROSCI, V110, P1321, DOI 10.1037/0735-7044.110.6.1321; DELLU F, 1992, BRAIN RES, V588, P132, DOI 10.1016/0006-8993(92)91352-F; Dix SL, 1999, BEHAV BRAIN RES, V99, P191, DOI 10.1016/S0166-4328(98)00079-5; Frerichs KU, 1998, P NATL ACAD SCI USA, V95, P14511, DOI 10.1073/pnas.95.24.14511; Gao B, 2013, ACTA PHARMACOL SIN, V34, P657, DOI 10.1038/aps.2013.34; Gow A, 2009, CURR OPIN NEUROBIOL, V19, P505, DOI 10.1016/j.conb.2009.08.007; Guan J, 2003, PROG NEUROBIOL, V70, P443, DOI 10.1016/j.pneurobio.2003.08.002; Harding HP, 1999, NATURE, V397, P271; Harding HP, 2002, ANNU REV CELL DEV BI, V18, P575, DOI 10.1146/annurev.cellbio.18.011402.160624; Hetz CA, 2006, CURR MOL MED, V6, P1, DOI 10.2174/156652406775574532; Hetz C, 2012, NAT REV MOL CELL BIO, V13, P89, DOI 10.1038/nrm3270; Huang XM, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.10.007; LaRocque JJ, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00005; Li TF, 2014, OSTEOARTHR CARTILAGE, V22, P481, DOI 10.1016/j.joca.2013.12.020; McAllister Thomas W, 2011, Dialogues Clin Neurosci, V13, P287; Messier C, 1997, NEUROBIOL LEARN MEM, V67, P172, DOI 10.1006/nlme.1996.3755; Methippara M, 2012, NEUROSCIENCE, V209, P108, DOI 10.1016/j.neuroscience.2012.02.016; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Myers SA, 2014, EXP NEUROL, V256, P25, DOI 10.1016/j.expneurol.2014.03.016; Nakka VP, 2010, NEUROTOX RES, V17, P189, DOI 10.1007/s12640-009-9110-5; Nashine S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063205; Nee DE, 2011, NEUROIMAGE, V54, P1540, DOI 10.1016/j.neuroimage.2010.09.002; O'Connor T, 2008, NEURON, V60, P988, DOI 10.1016/j.neuron.2008.10.047; Rachmany L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079837; Ron D, 2002, J CLIN INVEST, V110, P1383, DOI 10.1172/JCI200216784; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Rubovitch V, 2011, NEUROCHEM INT, V58, P443, DOI 10.1016/j.neuint.2011.01.009; Rubovitch V, 2010, NEUROBIOL DIS, V38, P299, DOI 10.1016/j.nbd.2010.01.021; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; Saxena S, 2009, NAT NEUROSCI, V12, P627, DOI 10.1038/nn.2297; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Segev Y, 2013, NEUROBIOL AGING, V34, P863, DOI 10.1016/j.neurobiolaging.2012.06.020; Slemmer JE, 2008, AM J PATHOL, V173, P1795, DOI 10.2353/ajpath.2008.080168; Sokka AL, 2007, J NEUROSCI, V27, P901, DOI 10.1523/JNEUROSCI.4289-06.2007; Tan S, 2001, J CELL BIOL, V152, P997, DOI 10.1083/jcb.152.5.997; Tang BL, 2006, NEUROBIOL AGING, V27, P501, DOI 10.1016/j.neurobiolaging.2005.02.001; Tashlykov V, 2009, J MOL NEUROSCI, V37, P16, DOI 10.1007/s12031-008-9094-2; Tashlykov V, 2007, BRAIN RES, V1130, P197, DOI 10.1016/j.brainres.2006.10.032; Tweedie D, 2007, J NEUROSCI RES, V85, P805, DOI 10.1002/jnr.21160; Vaccaro A, 2013, NEUROBIOL DIS, V55, P64, DOI 10.1016/j.nbd.2013.03.015; Zhu Y, 2008, J NEUROSCI, V28, P2168, DOI 10.1523/JNEUROSCI.5232-07.2008; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	52	41	43	0	10	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1535-1084	1559-1174		NEUROMOL MED	Neuromol. Med.	MAR	2015	17	1					58	70		10.1007/s12017-015-8340-3			13	Neurosciences	Neurosciences & Neurology	CB8VW	WOS:000349910700006	25582550				2021-06-18	
J	Bledsoe, BE; Casey, MJ; Feldman, J; Johnson, L; Diel, S; Forred, W; Gorman, C				Bledsoe, Bryan E.; Casey, Michael J.; Feldman, Jay; Johnson, Larry; Diel, Scott; Forred, Wes; Gorman, Codee			Glasgow Coma Scale Scoring is Often Inaccurate	PREHOSPITAL AND DISASTER MEDICINE			English	Article						emergency care; Emergency Medical Services; Glasgow Coma Score; trauma care	TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; EMERGENCY-DEPARTMENT; INTERRATER RELIABILITY; SCORES; CONSCIOUSNESS	Introduction: The Glasgow Coma Scale (GCS) is widely applied in the emergency setting; it is used to guide trauma triage and for the application of essential interventions such as endotracheal intubation. However, inter-rater reliability of GCS scoring has been shown to be low for inexperienced users, especially for the motor component. Concerns regarding the accuracy and validity of GCS scoring between various types of emergency care providers have been expressed. Hypothesis/Problem: The objective of this study was to determine the degree of accuracy of GCS scoring between various emergency care providers within a modern Emergency Medical Services (EMS) system. Methods: This was a prospective observational study of the accuracy of GCS scoring using a convenience sample of various types of emergency medical providers using standardized video vignettes. Ten video vignettes using adults were prepared and scored by two board-certified neurologists. Inter-rater reliability was excellent (Cohen's kappa = 1). Subjects viewed the video and then scored each scenario. The scoring of subjects was compared to expert scoring of the two board-certified neurologists. Results: A total of 217 emergency providers watched 10 video vignettes and provided 2,084 observations of GCS scoring. Overall total GCS scoring accuracy was 33.1% (95% CI, 30.2-36.0). The highest accuracy was observed on the verbal component of the GCS (69.2%; 95% CI, 67.8-70.4). The eye-opening component was the second most accurate (61.2%; 95% CI, 59.5-62.9). The least accurate component was the motor component (59.8%; 95% CI, 58.1-61.5). A small number of subjects (9.2%) assigned GCS scores that do not exist in the GCS scoring system. Conclusions: Glasgow Coma Scale scoring should not be considered accurate. A more simplified scoring system should be developed and validated.	[Bledsoe, Bryan E.; Casey, Michael J.; Feldman, Jay; Johnson, Larry; Forred, Wes; Gorman, Codee] Univ Nevada, Sch Med, Dept Emergency Med, Las Vegas, NV 89106 USA; [Bledsoe, Bryan E.; Casey, Michael J.; Feldman, Jay; Johnson, Larry; Forred, Wes; Gorman, Codee] Univ Nevada, Sch Med, Dept Trauma Surg, Las Vegas, NV 89106 USA; [Bledsoe, Bryan E.; Johnson, Larry; Diel, Scott] MedicWest Ambulance Amer Med Response, Las Vegas, NV USA	Bledsoe, BE (corresponding author), Univ Nevada, Sch Med, Dept Emergency Med, 901 Ranch Lane,Suite 135, Las Vegas, NV 89106 USA.	bbledsoe@medicine.nevada.edu					Bazarian JJ, 2003, BRAIN INJURY, V17, P553, DOI 10.1080/0269905031000070260; BRAAKMAN R, 1977, CLIN NEUROL NEUROSUR, V80, P104; Brain Trauma Foundation, 2007, PREHOSP EMERG CAR S1, V12, pS14; Gill M, 2007, ANN EMERG MED, V49, P403, DOI 10.1016/j.annemergmed.2006.03.031; Gill M, 2006, ACAD EMERG MED, V13, P968, DOI 10.1197/j.aem.2006.05.019; Gill MR, 2004, ANN EMERG MED, V43, P215, DOI 10.1016/S0196-0644(03)00814-X; Heron R, 2001, Aust Crit Care, V14, P100, DOI 10.1016/S1036-7314(01)80026-6; Holdgate Anna, 2006, Emerg Med Australas, V18, P379, DOI 10.1111/j.1742-6723.2006.00867.x; JENNETT B, 1977, LANCET, V1, P878; JENNETT B, 1976, LANCET, V1, P1031; Juarez V J, 1995, J Neurosci Nurs, V27, P283; Kerby JD, 2007, J TRAUMA, V63, P1026, DOI 10.1097/TA.0b013e318157d9e8; Lane Peter L, 2002, Prehosp Disaster Med, V17, P142; MENEGAZZI JJ, 1993, J TRAUMA, V34, P46, DOI 10.1097/00005373-199301000-00008; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Prasad K, 1996, J CLIN EPIDEMIOL, V49, P755, DOI 10.1016/0895-4356(96)00013-3; SEGATORE M, 1992, HEART LUNG, V21, P548; Stevens RD, 2013, CRIT CARE MED, V41, P1104, DOI 10.1097/CCM.0b013e318287ee79; TEASDALE G, 1974, LANCET, V2, P81; Tuijn S, 2012, J EVAL CLIN PRACT, V18, P887, DOI 10.1111/j.1365-2753.2011.01705.x	21	41	45	0	10	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1049-023X	1945-1938		PREHOSP DISASTER MED	Prehospital Disaster Med.	FEB	2015	30	1					46	53		10.1017/S1049023X14001289			8	Emergency Medicine	Emergency Medicine	CN4NP	WOS:000358407200008	25489727				2021-06-18	
J	Donders, J; Strong, CAH				Donders, Jacobus; Strong, Carrie-Ann H.			Clinical Utility of the Wechsler Adult Intelligence Scale-Fourth Edition After Traumatic Brain Injury	ASSESSMENT			English	Article						assessment; processing speed; sensitivity; specificity	WAIS-IV; CRITERION VALIDITY; NEUROPSYCHOLOGICAL TESTS; SAMPLE; SCORES	The performance of 100 patients with traumatic brain injury (TBI) on the Wechsler Adult Intelligence Scale-Fourth Edition (WAIS-IV) was compared with that of 100 demographically matched neurologically healthy controls. Processing Speed was the only WAIS-IV factor index that was able to discriminate between persons with moderate-severe TBI on the one hand and persons with either less severe TBI or neurologically healthy controls on the other hand. The Processing Speed index also had acceptable sensitivity and specificity when differentiating between patients with TBI who either did or did not have scores in the clinically significant range on the Trail Making Test. It is concluded that WAIS-IV Processing Speed has acceptable clinical utility in the evaluation of patients with moderate-severe TBI but that it should be supplemented with other measures to assure sufficient accuracy in the diagnostic process.	[Donders, Jacobus; Strong, Carrie-Ann H.] Mary Free Bed Rehabil Hosp, Grand Rapids, MI 49503 USA	Donders, J (corresponding author), Mary Free Bed Rehabil Hosp, Psychol Serv, 235 Wealthy SE, Grand Rapids, MI 49503 USA.	jacobus.donders@maryfreebed.com					Axelrod BN, 2001, CLIN NEUROPSYCHOL, V15, P516, DOI 10.1076/clin.15.4.516.1884; Bagiella E, 2010, J HEAD TRAUMA REHAB, V25, P375, DOI 10.1097/HTR.0b013e3181d27fe3; Benson N, 2010, PSYCHOL ASSESSMENT, V22, P121, DOI 10.1037/a0017767; Binder LM, 2011, CLIN NEUROPSYCHOL, V25, P62, DOI 10.1080/13854046.2010.533195; Brooks BL, 2011, ASSESSMENT, V18, P156, DOI 10.1177/1073191110385316; Canivez GL, 2010, PSYCHOL ASSESSMENT, V22, P827, DOI 10.1037/a0020429; Cullen N, 2014, BRAIN INJURY, V28, P38, DOI 10.3109/02699052.2013.849005; Donders J, 2001, J INT NEUROPSYCH SOC, V7, P892, DOI 10.1017/S1355617701777132; Donders J, 2008, J INT NEUROPSYCH SOC, V14, P651, DOI 10.1017/S1355617708080752; Donders J, 2012, ARCH CLIN NEUROPSYCH, V27, P440, DOI 10.1093/arclin/acs043; Green P., 2003, GREENS WORD MEMORY T; Grimes DA, 2005, LANCET, V365, P1500, DOI 10.1016/S0140-6736(05)66422-7; Heyanka DJ, 2013, INT J NEUROSCI, V123, P526, DOI 10.3109/00207454.2013.771261; Holdnack JA, 2011, ASSESSMENT, V18, P178, DOI 10.1177/1073191110393106; HOLM S, 1979, SCAND J STAT, V6, P65; Loring DW, 2010, NEUROLOGY, V74, P685, DOI 10.1212/WNL.0b013e3181d0cd12; Martin TA, 2000, REHABIL PSYCHOL, V45, P402, DOI 10.1037/0090-5550.45.4.402; Martin TA, 2003, APPL NEUROPSYCHOL, V10, P163, DOI 10.1207/S15324826AN1003_05; Michel NM, 2013, ASSESSMENT, V20, P462, DOI 10.1177/1073191113478153; Munnoz-Moreno JA, 2013, JAIDS-J ACQ IMM DEF, V63, P585, DOI 10.1097/QAI.0b013e31829e1408; Nelson JM, 2013, PSYCHOL ASSESSMENT, V25, P618, DOI 10.1037/a0032086; Pandharipande PP, 2013, NEW ENGL J MED, V369, P1306, DOI 10.1056/NEJMoa1301372; Ryan JJ, 2012, J CLIN EXP NEUROPSYC, V34, P571, DOI 10.1080/13803395.2012.666229; Stucky KJ, 2014, NEUROPSYCHOLOGY STUD, P432; Tombaugh TN, 1996, TEST MEMORY MALINGER; Ward LC, 2012, PSYCHOL ASSESSMENT, V24, P328, DOI 10.1037/a0025614; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th ed; Weissberger GH, 2013, NEUROPSYCHOLOGY, V27, P343, DOI 10.1037/a0032399; Wolfson D., 1993, HALSTEAD REITAN NEUR	30	41	41	0	27	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1073-1911	1552-3489		ASSESSMENT	Assessment	FEB	2015	22	1					17	22		10.1177/1073191114530776			6	Psychology, Clinical	Psychology	AX0LZ	WOS:000346645100002	24752385				2021-06-18	
J	Genova, HM; Rajagopalan, V; Chiaravalloti, N; Binder, A; Deluca, J; Lengenfelder, J				Genova, Helen M.; Rajagopalan, Venkateswaran; Chiaravalloti, Nancy; Binder, Allison; Deluca, John; Lengenfelder, Jeannie			Facial affect recognition linked to damage in specific white matter tracts in traumatic brain injury	SOCIAL NEUROSCIENCE			English	Article						Inferior-fronto-occipital fasciculus; Emotional processing; Facial affect recognition; Traumatic brain injury; Inferior longitudinal fasciculus; Diffusion tensor imaging	EMOTION RECOGNITION; EXPRESSIONS; IMAGES; METAANALYSIS; ASSOCIATION; EXTRACTION; DISORDER; FACES; FSL; SAD	Emotional processing deficits have recently been identified in individuals with traumatic brain injury (TBI), specifically in the domain of facial affect recognition. However, the neural networks underlying these impairments have yet to be identified. In the current study, 42 individuals with moderate to severe TBI and 23 healthy controls performed a task of facial affect recognition (Facial Emotion Identification Test (FEIT)) in order to assess their ability to identify and discriminate six emotions: happiness, sadness, anger, surprise, shame, and fear. These individuals also underwent structural neuroimaging including diffusion tensor imaging to examine white matter (WM) integrity. Correlational analyses were performed to determine where in the brain WM damage was associated with performance on the facial affect recognition task. Reduced performance on the FEIT was associated with reduced WM integrity (fractional anisotropy, mean diffusivity, axial diffusivity, and radial diffusivity) in the inferior longitudinal fasciculus and inferior-fronto-occipital fasciculus in individuals with TBI. Poor performance on the task was additionally associated with reduced gray matter (GM) volume in lingual gyrus and parahippocampal gyrus. The results implicate a pattern of WM and GM damage in TBI that may play a role in emotional processing impairments.	[Genova, Helen M.; Rajagopalan, Venkateswaran; Chiaravalloti, Nancy; Deluca, John; Lengenfelder, Jeannie] Kessler Fdn Res Ctr, Neuropsychol & Neurosci Lab, W Orange, NJ 07052 USA; [Genova, Helen M.; Rajagopalan, Venkateswaran; Chiaravalloti, Nancy; Deluca, John; Lengenfelder, Jeannie] Rutgers New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ USA; [Binder, Allison] Univ Massachusetts, Dept Psychol, Amherst, MA 01003 USA; [Binder, Allison] Suffolk Univ, Dept Clin Psychol, Boston, MA 02114 USA	Genova, HM (corresponding author), Kessler Fdn Res Ctr, Neuropsychol & Neurosci Lab, W Orange, NJ 07052 USA.	hgenova@kesslerfoundation.org		Chiaravalloti, Nancy/0000-0003-2943-7567	New Jersey Commission on Brain Injury Research (NJCBIR) [10-3218-BIR-E-0, CBIR13IRG026]	This work was supported by the New Jersey Commission on Brain Injury Research (NJCBIR), Research Grants [10-3218-BIR-E-0] to JL and [CBIR13IRG026] to JL and HG.	Adolphs R, 2010, ANN NY ACAD SCI, V1191, P42, DOI 10.1111/j.1749-6632.2010.05445.x; Aldinger M, 2013, PSYCHIAT RES, V205, P59, DOI 10.1016/j.psychres.2012.08.032; Andriessen TMJC, 2010, J CELL MOL MED, V14, P2381, DOI 10.1111/j.1582-4934.2010.01164.x; Ashburner J, 2000, NEUROIMAGE, V11, P805, DOI 10.1006/nimg.2000.0582; Babbage DR, 2011, NEUROPSYCHOLOGY, V25, P277, DOI 10.1037/a0021908; Baggio HC, 2012, NEUROPSYCHOLOGIA, V50, P2121, DOI 10.1016/j.neuropsychologia.2012.05.020; Bessette KL, 2014, BRAIN IMAGING BEHAV, V8, P531, DOI 10.1007/s11682-013-9274-8; Catani M, 2003, BRAIN, V126, P2093, DOI 10.1093/brain/awg203; Fu CHY, 2008, BIOL PSYCHIAT, V64, P505, DOI 10.1016/j.biopsych.2008.04.033; Fusar-Poli P, 2009, NEUROSCI LETT, V452, P262, DOI 10.1016/j.neulet.2009.01.065; Good CD, 2001, NEUROIMAGE, V14, P21, DOI 10.1006/nimg.2001.0786; Green REA, 2008, J CLIN EXP NEUROPSYC, V30, P163, DOI 10.1080/13803390701300524; Grieve SM, 2013, NEUROIMAGE-CLIN, V3, P332, DOI 10.1016/j.nicl.2013.08.016; Gur RC, 2002, NEUROIMAGE, V16, P651, DOI 10.1006/nimg.2002.1097; Jenkinson M, 2001, MED IMAGE ANAL, V5, P143, DOI 10.1016/S1361-8415(01)00036-6; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Jou RJ, 2011, AUST NZ J PSYCHIAT, V45, P153, DOI 10.3109/00048674.2010.534069; Kennedy DP, 2012, TRENDS COGN SCI, V16, P559, DOI 10.1016/j.tics.2012.09.006; KERR SL, 1993, J ABNORM PSYCHOL, V102, P312, DOI 10.1037/0021-843X.102.2.312; Martino J, 2010, CORTEX, V46, P691, DOI 10.1016/j.cortex.2009.07.015; Mike A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082422; Miyahara M, 2013, SOC COGN AFFECT NEUR, V8, P181, DOI 10.1093/scan/nsr085; Nyenhuis DL, 1998, J PERS ASSESS, V70, P386, DOI 10.1207/s15327752jpa7002_14; Philippi CL, 2009, J NEUROSCI, V29, P15089, DOI 10.1523/JNEUROSCI.0796-09.2009; Polyack S., 1957, VERTEBRATE VISUAL SY; Popescu V, 2012, NEUROIMAGE, V61, P1484, DOI 10.1016/j.neuroimage.2012.03.074; Puce A, 1996, J NEUROSCI, V16, P5205; Shukla DK, 2011, J CHILD PSYCHOL PSYC, V52, P286, DOI 10.1111/j.1469-7610.2010.02342.x; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Surguladze S, 2005, BIOL PSYCHIAT, V57, P201, DOI 10.1016/j.biopsych.2004.10.028; Suslow T, 2010, BIOL PSYCHIAT, V67, P155, DOI 10.1016/j.biopsych.2009.07.023; Trautmann SA, 2009, BRAIN RES, V1284, P100, DOI 10.1016/j.brainres.2009.05.075; Wechsler D., 2001, WECHSLER TEST ADULT; Yim J, 2013, BRAIN INJURY, V27, P1155, DOI 10.3109/02699052.2013.804203; Zhang YY, 2001, IEEE T MED IMAGING, V20, P45, DOI 10.1109/42.906424	37	41	41	0	18	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND	1747-0919	1747-0927		SOC NEUROSCI-UK	Soc. Neurosci.	JAN 2	2015	10	1					27	34		10.1080/17470919.2014.959618			8	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	AU3GW	WOS:000345501400004	25223759				2021-06-18	
J	Bao, HJ; Zhang, L; Han, WC; Dai, DK				Bao, Hai-Jun; Zhang, Lin; Han, Wen-Can; Dai, Ding-Kun			Apelin-13 Attenuates Traumatic Brain Injury-Induced Damage by Suppressing Autophagy	NEUROCHEMICAL RESEARCH			English	Article						Apelin-13; Traumatic brain injury (TBI); Autophagy	CONTROLLED CORTICAL IMPACT; TRANSCRIPTION FACTOR NRF2; SELECTIVE AUTOPHAGY; TISSUE DISTRIBUTION; CELL-DEATH; P62/SQSTM1; RECEPTOR; PEPTIDE; APJ; P62	The adipocytokine apelin is a peptide, Apelin and its receptor are abundantly expressed in the nervous and cardiovascular systems. Previous studies had found apelin-13 reduces brain injuries and postischemic cerebral edema through blocking programmed cell death, Apelin-13 is also able to inhibit glucose deprivation induced cardiomyocyte autophagy in a concentration dependent fashion. To observe the effect of Apelin-13 on the brain injury induced by traumatic brain injury (TBI), and explore the effect of Apelin-13 on autophagy in TBI, We performed The neurological test, and the numbers of TBI-induced neural cell death were also counted by propidium iodide labeling. At last, the autophagy associated proteins LC3, Beclin-1, Bcl-2, p62 were also assessed with western-blotting. Compared with saline vehicle groups, the neural cell death, lesion volume, and neural dysfunction were attenuated by apelin-13 after TBI. In additionally, Apelin-13 also reversed TBI induced downregulation of LC3, Beclin-1, Bcl-2, p62 expression, compared with saline vehicle groups, at 24 and 48 h post TBI. Apelin-13 attenuates TBI induced brain damage by suppressing autophagy. All these results revealed that Apelin-13 suppressed autophagy. The autophagy may be involved in the mechanism of Apelin-13 rescue the subsequent damaged neuron in TBI.	[Bao, Hai-Jun; Zhang, Lin; Han, Wen-Can] Xuzhou Med Coll, Dept Pathol, 209 Tongshan Rd,Xuzhou Yunlong Town, Xuzhou, Peoples R China; [Dai, Ding-Kun] Peoples Hosp Subei, Dept Forens Identificat, Yangzhou, Peoples R China	Bao, HJ (corresponding author), Xuzhou Med Coll, Dept Pathol, 209 Tongshan Rd,Xuzhou Yunlong Town, Xuzhou, Peoples R China.	bahajun@163.com			National Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81302612]	The work was supported by the National Science Foundation of China (No 81302612).	Bao HJ, 2012, NEUROCHEM RES, V37, P2856, DOI 10.1007/s11064-012-0880-4; Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002; Choe W, 2000, J NEUROVIROL, V6, pS61; Clark RSB, 2008, AUTOPHAGY, V4, P88, DOI 10.4161/auto.5173; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Hosoya M, 2000, J BIOL CHEM, V275, P21061, DOI 10.1074/jbc.M908417199; Ichimura Y, 2008, J BIOL CHEM, V283, P22847, DOI 10.1074/jbc.M802182200; Jain A, 2010, J BIOL CHEM, V285, P22576, DOI 10.1074/jbc.M110.118976; Jiao H, 2013, EXP THER MED, V5, P797, DOI 10.3892/etm.2013.902; Kawamata Y, 2001, BBA-MOL CELL RES, V1538, P162, DOI 10.1016/S0167-4889(00)00143-9; Khaksari M, 2012, J MOL NEUROSCI, V48, P201, DOI 10.1007/s12031-012-9808-3; Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496; Komatsu M, 2007, P NATL ACAD SCI USA, V104, P14489, DOI 10.1073/pnas.0701311104; Komatsu M, 2010, FEBS LETT, V584, P1374, DOI 10.1016/j.febslet.2010.02.017; Komatsu M, 2010, NAT CELL BIOL, V12, P213, DOI 10.1038/ncb2021; Lamark T, 2009, CELL CYCLE, V8, P1986, DOI 10.4161/cc.8.13.8892; Liu CL, 2008, J CEREBR BLOOD F MET, V28, P674, DOI 10.1038/sj.jcbfm.9600587; Luo CL, 2011, NEUROSCIENCE, V184, P54, DOI 10.1016/j.neuroscience.2011.03.021; Mbye LH, 2012, J CEREBR BLOOD F MET, V32, P515, DOI 10.1038/jcbfm.2011.158; Mizushima N, 2004, INT J BIOCHEM CELL B, V36, P2491, DOI 10.1016/j.biocel.2004.02.005; Mizushima N, 2004, MOL BIOL CELL, V15, P1101, DOI 10.1091/mbc.E03-09-0704; Nagley P, 2010, BBA-MOL BASIS DIS, V1802, P167, DOI 10.1016/j.bbadis.2009.09.004; Norman JM, 2010, AUTOPHAGY, V6, P1042, DOI 10.4161/auto.6.8.13337; O'Donnell LA, 2007, J NEUROCHEM, V102, P1905, DOI 10.1111/j.1471-4159.2007.04645.x; ODOWD BF, 1993, GENE, V136, P355, DOI 10.1016/0378-1119(93)90495-O; Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06; Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Pattingre S, 2006, CANCER RES, V66, P2885, DOI 10.1158/0008-5472.CAN-05-4412; Pozuelo RM, 2011, AUTOPHAGY, V7, P240; Puyal J, 2009, AUTOPHAGY, V5, P1060, DOI 10.4161/auto.5.7.9728; Qin ZH, 1999, J NEUROSCI, V19, P4023; Shankar S, 2008, BIOCHEM BIOPH RES CO, V373, P478; Simpkin JC, 2007, BASIC RES CARDIOL, V102, P518, DOI 10.1007/s00395-007-0671-2; Smith CM, 2011, NEUROBIOL DIS, V43, P52, DOI 10.1016/j.nbd.2010.09.014; Susaki E, 2005, REGUL PEPTIDES, V129, P37, DOI 10.1016/j.regpep.2005.01.013; Tatemoto K, 1998, BIOCHEM BIOPH RES CO, V251, P471, DOI 10.1006/bbrc.1998.9489; Wei YJ, 2008, MOL CELL, V30, P678, DOI 10.1016/j.molcel.2008.06.001; Whalen MJ, 2008, J CEREBR BLOOD F MET, V28, P490, DOI 10.1038/sj.jcbfm.9600544; Zeng XJ, 2010, EXP CELL RES, V316, P1773, DOI 10.1016/j.yexcr.2010.02.005; Zheng YT, 2009, J IMMUNOL, V183, P5909, DOI 10.4049/jimmunol.0900441	41	41	43	0	18	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190	1573-6903		NEUROCHEM RES	Neurochem. Res.	JAN	2015	40	1					89	97		10.1007/s11064-014-1469-x			9	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	AZ7DH	WOS:000348378100010	25362565				2021-06-18	
J	Dimitriadis, SI; Zouridakis, G; Rezaie, R; Babajani-Feremi, A; Papanicolaou, AC				Dimitriadis, Stavros I.; Zouridakis, George; Rezaie, Roozbeh; Babajani-Feremi, Abbas; Papanicolaou, Andrew C.			Functional connectivity changes detected with magnetoencephalography after mild traumatic brain injury	NEUROIMAGE-CLINICAL			English	Article						Mild traumatic brain injury; MEG; Tensors; Computational connectomics; Biomarkers; Diagnosis	RESTING-STATE ACTIVITY; SMALL-WORLD NETWORKS; IMAGING APPROACH; MEG; DYNAMICS; SCALE; CLASSIFICATION; FLUCTUATIONS; CONCUSSION; BIOMARKERS	Mild traumatic brain injury (mTBI) may affect normal cognition and behavior by disrupting the functional connectivity networks that mediate efficient communication among brain regions. In this study, we analyzed brain connectivity profiles from resting state Magnetoencephalographic (MEG) recordings obtained from 31 mTBI patients and 55 normal controls. We used phase-locking value estimates to compute functional connectivity graphs to quantify frequency-specific couplings between sensors at various frequency bands. Overall, normal controls showed a dense network of strong local connections and a limited number of long-range connections that accounted for approximately 20% of all connections, whereas mTBI patients showed networks characterized by weak local connections and strong long-range connections that accounted for more than 60% of all connections. Comparison of the two distinct general patterns at different frequencies using a tensor representation for the connectivity graphs and tensor subspace analysis for optimal feature extraction showed that mTBI patients could be separated from normal controls with 100% classification accuracy in the alpha band. These encouraging findings support the hypothesis that MEG-based functional connectivity patterns may be used as biomarkers that can provide more accurate diagnoses, help guide treatment, and monitor effectiveness of intervention in mTBI. (C) 2015 The Authors. Published by Elsevier Inc.	[Dimitriadis, Stavros I.] Aristotle Univ Thessaloniki, Dept Informat, Artificial Intelligence & Informat Anal Lab, Thessaloniki 54124, Greece; [Dimitriadis, Stavros I.] Aristotle Univ Thessaloniki, NeuroInformat Grp, Thessaloniki, Greece; [Zouridakis, George] Basque Ctr Cognit Brain & Language BCBL, Paseo Mikeletegi 69, Donostia San Sebastian 20009, Spain; [Rezaie, Roozbeh; Babajani-Feremi, Abbas; Papanicolaou, Andrew C.] Univ Tennessee, Ctr Hlth Sci, Dept Pediat, Div Clin Neurosci, Memphis, TN 38163 USA; [Rezaie, Roozbeh; Babajani-Feremi, Abbas; Papanicolaou, Andrew C.] Le Bonheur Children3s Hosp, Neurosci Inst, Memphis, TN USA; [Papanicolaou, Andrew C.] Univ Tennessee, Ctr Hlth Sci, Dept Anat & Neurobiol, Memphis, TN 38163 USA; [Zouridakis, George] Univ Houston, Biomed Imaging Lab, Dept Engn Technol, Houston, TX 77204 USA; [Zouridakis, George] Univ Houston, Biomed Imaging Lab, Dept Comp Sci Elect & Comp Engn, Houston, TX 77204 USA; [Zouridakis, George] Univ Houston, Biomed Imaging Lab, Dept Biomed Engn, Houston, TX 77204 USA	Zouridakis, G (corresponding author), Univ Houston, Biomed Imaging Lab, 4730 Calhoun Rd Room 300, Houston, TX 77204 USA.	zouridakis@uh.edu	Zouridakis, George/R-8876-2019; DIMITRIADIS, STAVROS I/AAN-8992-2020	Zouridakis, George/0000-0002-7770-9857; DIMITRIADIS, STAVROS I/0000-0002-0000-5392; Basque Center on Cognition, Brain and Language, BCBL./0000-0002-8345-6892; Rezaie, Roozbeh/0000-0002-7494-339X	U.S. Department of Defense Congressionally Directed Medical Research ProgramUnited States Department of Defense [W81XWH-08-2-0131, W81XWH-08-2-0138, W81XWH-08-2-0132, W81XWH-08-2-0149, W81XWH-08-2-0133, W81XWH-08-2-0140, W81XWH-08-2-0135, W81XWH-08-2-0142]	This project is part of a larger study, the Integrated Clinical Protocol, conducted by the Investigators and staff of The Mission Connect Mild Traumatic Brain Injury Translational Research Consortium and supported by the U.S. Department of Defense Congressionally Directed Medical Research Program: W81XWH-08-2-0131, J. J. McCarthy, MD; W81XWH-08-2-0138, Brent Masel, MD; W81XWH-08-2-0132, C. S. Robertson, MD; W81XWH-08-2-0149, Eli Mizrahi, MD; W81XWH-08-2-0133, H. Levin, PhD; W81XWH-08-2-0140, Ponnada Narayana, PhD; W81XWH-08-2-0135, A. Papanicolaou, PhD and W81XWH-08-2-0142, Paul Swank, PhD.	Achard S, 2007, PLOS COMPUT BIOL, V3, P174, DOI 10.1371/journal.pcbi.0030017; AERTSEN AMHJ, 1989, J NEUROPHYSIOL, V61, P900; Akil H, 2011, SCIENCE, V331, P708, DOI 10.1126/science.1199305; ALTMAN NS, 1992, AM STAT, V46, P175, DOI 10.2307/2685209; Assistant Secretary D.o.D., TRAUM BRAIN INJ DEF; Bardouille T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048682; Bassett DS, 2009, P NATL ACAD SCI USA, V106, P11747, DOI 10.1073/pnas.0903641106; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bigler ED, 2013, NEUROPSYCHOL REV, V23, P169, DOI 10.1007/s11065-013-9237-2; Boccaletti S, 2006, PHYS REP, V424, P175, DOI 10.1016/j.physrep.2005.10.009; Borst C, 1999, ICRA '99: IEEE INTERNATIONAL CONFERENCE ON ROBOTICS AND AUTOMATION, VOLS 1-4, PROCEEDINGS, P1890, DOI 10.1109/ROBOT.1999.770384; Brookes MJ, 2012, NEUROIMAGE, V63, P910, DOI 10.1016/j.neuroimage.2012.03.048; Bullmore ET, 2009, NAT REV NEUROSCI, V10, P186, DOI 10.1038/nrn2575; Buzsaki G, 2004, SCIENCE, V304, P1926, DOI 10.1126/science.1099745; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Castellanos NP, 2011, NEUROIMAGE, V55, P1189, DOI 10.1016/j.neuroimage.2010.12.046; Castellanos NP, 2010, BRAIN, V133, P2365, DOI 10.1093/brain/awq174; Congedo M, 2010, INT J PSYCHOPHYSIOL, V78, P89, DOI 10.1016/j.ijpsycho.2010.06.003; CORTES C, 1995, MACH LEARN, V20, P273, DOI 10.1023/A:1022627411411; Daubechies I., 1992, 10 LECT WAVELETS; de Pasquale F, 2012, NEURON, V74, P753, DOI 10.1016/j.neuron.2012.03.031; de Pasquale F, 2010, P NATL ACAD SCI USA, V107, P6040, DOI 10.1073/pnas.0913863107; Delorme A, 2004, J NEUROSCI METH, V134, P9, DOI 10.1016/j.jneumeth.2003.10.009; Delorme A, 2007, J NEUROSCI, V27, P11949, DOI 10.1523/JNEUROSCI.3477-07.2007; Delorme A, 2007, NEUROIMAGE, V34, P1443, DOI 10.1016/j.neuroimage.2006.11.004; Dimitriadis SI, 2013, NEUROIMAGE, V83, P307, DOI 10.1016/j.neuroimage.2013.06.036; Dimitriadis SI, 2012, IEEE T BIO-MED ENG, V59, P1302, DOI 10.1109/TBME.2012.2186568; Dimitriadis S. I., 2013, 35 ANN INT C IEEE EM; Dimitriadis S. I., 2015, CLIN NEUROPHYSIOL; Dimitriadis SI, 2015, ANN BIOMED ENG, V43, P977, DOI 10.1007/s10439-014-1143-0; Dimitriadis SI, 2010, J NEUROSCI METH, V193, P145, DOI 10.1016/j.jneumeth.2010.08.027; Eierud C, 2014, NEUROIMAGE-CLIN, V4, P283, DOI 10.1016/j.nicl.2013.12.009; Engel AK, 2013, NEURON, V80, P867, DOI 10.1016/j.neuron.2013.09.038; Fisher RA, 1936, ANN EUGENIC, V7, P179, DOI 10.1111/j.1469-1809.1936.tb02137.x; Florin E, 2015, NEUROIMAGE, V111, P26, DOI 10.1016/j.neuroimage.2015.01.054; Fox MD, 2007, NAT REV NEUROSCI, V8, P700, DOI 10.1038/nrn2201; Golub G. H., 1996, MATRIX COMPUTATIONS; Guggisberg AG, 2008, ANN NEUROL, V63, P193, DOI 10.1002/ana.21224; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hamalainen Matti S., 1995, Brain Topography, V7, P283, DOI 10.1007/BF01195254; Hastie T., 2003, ELEMENTS STAT LEARNI; He X., 2005, ADV NEURAL INFORM PR, V18; He Y, 2010, CURR OPIN NEUROL, V23, P341, DOI 10.1097/WCO.0b013e32833aa567; Helmer KG, 2014, J NEUROSURG, V120, P864, DOI [10.3171/2013.12.JNS132093, 10.3171/2013.12.JNS132090]; Hillebrand A, 2012, NEUROIMAGE, V59, P3909, DOI 10.1016/j.neuroimage.2011.11.005; Hipp JF, 2012, NAT NEUROSCI, V15, P884, DOI 10.1038/nn.3101; Hipp JF, 2011, NEURON, V69, P387, DOI 10.1016/j.neuron.2010.12.027; HORN RA, 1990, SIAM J MATRIX ANAL A, V11, P481, DOI 10.1137/0611034; Huang GB, 2006, NEUROCOMPUTING, V70, P489, DOI 10.1016/j.neucom.2005.12.126; Huang MX, 2014, NEUROIMAGE-CLIN, V5, P109, DOI 10.1016/j.nicl.2014.06.004; Huang MX, 2012, NEUROIMAGE, V61, P1067, DOI 10.1016/j.neuroimage.2012.04.029; Huang MX, 2009, J NEUROTRAUM, V26, P1213, DOI 10.1089/neu.2008.0672; Hunter JV, 2012, J NEUROTRAUM, V29, P654, DOI 10.1089/neu.2011.1906; Iakovidou N., 2013, 13 IEEE INT C BIOINF; Iakovidou ND, 2013, J NEUROSCI METH, V213, P204, DOI 10.1016/j.jneumeth.2012.12.018; Ioannides AA, 2012, COMPUT MATH METHOD M, V2012, DOI 10.1155/2012/452503; Irimia Andrei, 2012, Front Neurol, V3, P10, DOI 10.3389/fneur.2012.00010; Jirsa VK, 2010, ARCH ITAL BIOL, V148, P189; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kim J, 2009, BIOMED ENG ONLINE, V8, DOI 10.1186/1475-925X-8-31; Kou ZF, 2010, J HEAD TRAUMA REHAB, V25, P267, DOI 10.1097/HTR.0b013e3181e54793; Lachaux JP, 1999, HUM BRAIN MAPP, V8, P194, DOI 10.1002/(SICI)1097-0193(1999)8:4<194::AID-HBM4>3.0.CO;2-C; Latora V, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.198701; Levin H. S., 2009, MISSION CONNECT MILD; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lewine JD, 1999, AM J NEURORADIOL, V20, P857; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; Li Qiang, 2013, Journal of Highway and Transportation Research and Development (Chinese Edition), V30, P1, DOI 10.3969/j.issn.1002-0268.2013.12.001; Lu H., 2013, MULTILINEAR SUBSPACE, P2013; Luo Q, 2013, J NEUROTRAUM, V30, P1702, DOI 10.1089/neu.2012.2679; Mallat S, 2008, WAVELET TOUR SIGNAL; Mantini D, 2011, BRAIN CONNECT, V1, P49, DOI 10.1089/brain.2011.0001; Martino J, 2011, ANN NEUROL, V69, P521, DOI 10.1002/ana.22167; Marzetti L, 2013, NEUROIMAGE, V79, P172, DOI 10.1016/j.neuroimage.2013.04.062; Micheloyannis S, 2006, SCHIZOPHR RES, V87, P60, DOI 10.1016/j.schres.2006.06.028; Onton J, 2006, NEUROSCI BIOBEHAV R, V30, P808, DOI 10.1016/j.neubiorev.2006.06.007; Oostenveld R, 2011, COMPUT INTEL NEUROSC, V2011, DOI 10.1155/2011/156869; Pollonini L, 2010, IEEE ENG MED BIO, P1730, DOI 10.1109/IEMBS.2010.5626702; Quigley M, 2001, AM J NEURORADIOL, V22, P294; Richiardi J, 2011, NEUROIMAGE, V56, P616, DOI 10.1016/j.neuroimage.2010.05.081; Romero S, 2008, COMPUT BIOL MED, V38, P348, DOI 10.1016/j.compbiomed.2007.12.001; Rubinov M, 2013, TRENDS COGN SCI, V17, P641, DOI 10.1016/j.tics.2013.10.007; Salvador R, 2005, CEREB CORTEX, V15, P1332, DOI 10.1093/cercor/bhi016; Sasaki Takeshi, 2014, J Neurosurg, V120, P882, DOI 10.3171/2013.12.JNS132092; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; Shen H, 2010, NEUROIMAGE, V49, P3110, DOI 10.1016/j.neuroimage.2009.11.011; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; Sireci SG, 2003, J EDUC MEAS, V40, P277, DOI 10.1111/j.1745-3984.2003.tb01108.x; Sporns O, 2005, PLOS COMPUT BIOL, V1, P245, DOI 10.1371/journal.pcbi.0010042; Sporns O, 2012, DISCOVERING HUMAN CO; Stam CJ, 2007, CEREB CORTEX, V17, P92, DOI 10.1093/cercor/bhj127; Stam CJ, 2010, INT J PSYCHOPHYSIOL, V77, P186, DOI 10.1016/j.ijpsycho.2010.06.024; Tarapore PE, 2013, J NEUROSURG, V118, P1306, DOI 10.3171/2013.3.JNS12398; TEASDALE G, 1974, LANCET, V2, P81; THEILER J, 1992, PHYSICA D, V58, P77, DOI 10.1016/0167-2789(92)90102-S; van Dellen E, 2013, NEUROIMAGE-CLIN, V2, P1, DOI 10.1016/j.nicl.2012.10.007; van Walsum AMV, 2003, CLIN NEUROPHYSIOL, V114, P1034, DOI 10.1016/S1388-2457(03)00072-5; Zhu GW, 2009, J INT MED RES, V37, P983, DOI 10.1177/147323000903700402; Zouridakis G, 2012, J MECH MED BIOL, V12, DOI 10.1142/S0219519412400064	99	41	41	0	7	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	2213-1582			NEUROIMAGE-CLIN	NeuroImage-Clin.		2015	9						519	531		10.1016/j.nicl.2015.09.011			13	Neuroimaging	Neurosciences & Neurology	DI0LR	WOS:000373188400056	26640764	DOAJ Gold, Green Published			2021-06-18	
J	Winklewski, PJ; Radkowski, M; Demkow, U				Winklewski, Pawel J.; Radkowski, Marek; Demkow, Urszula			Cross-talk between the inflammatory response, sympathetic activation and pulmonary infection in the ischemic stroke	JOURNAL OF NEUROINFLAMMATION			English	Article						Stroke; Brain injury; Immune response; Sympathetic nervous system; Lung injury; Pneumonia	COMMUNITY-ACQUIRED PNEUMONIA; PITUITARY-ADRENAL AXIS; TRAUMATIC BRAIN-INJURY; ACUTE LUNG INJURY; CEREBRAL-ISCHEMIA; T-LYMPHOCYTES; NERVOUS-SYSTEM; SUBARACHNOID HEMORRHAGE; IMMUNE-SYSTEM; UP-REGULATION	The immune system response and inflammation play a key role in brain injury during and after a stroke. The acute immune response is responsible for secondary brain tissue damage immediately after the stroke, followed by immunosuppression due to sympathetic nervous system activation. The latter increases risk of infection complications, such as pneumonia. The pneumonia-related inflammatory state can release a bystander autoimmune response against central nervous system antigens, thereby initiating a vicious circle. The aim of this review is to summarize the relationship between ischemic stroke, sympathetic nervous system activation and pulmonary infection.	[Winklewski, Pawel J.] Med Univ Gdansk, Inst Human Physiol, PL-80210 Gdansk, Poland; [Radkowski, Marek] Med Univ Warsaw, Dept Immunopathol Infect & Parasit Dis, Warsaw, Poland; [Demkow, Urszula] Med Univ Warsaw, Dept Lab Diagnost & Clin Immunol Dev Age, Warsaw, Poland	Winklewski, PJ (corresponding author), Med Univ Gdansk, Inst Human Physiol, Tuwima St 15, PL-80210 Gdansk, Poland.	pawelwinklewski@wp.pl	; Radkowski, Marek/V-3860-2018	Winklewski, Pawel/0000-0002-1671-2163; Radkowski, Marek/0000-0003-1808-679X			Ahnstedt H, 2012, ACTA PHYSIOL, V205, P266, DOI 10.1111/j.1748-1716.2011.02392.x; Ainslie Philip N, 2014, F1000Prime Rep, V6, P14, DOI 10.12703/P6-14; Ajmo CT, 2009, EXP NEUROL, V218, P47, DOI 10.1016/j.expneurol.2009.03.044; Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; Armstead WM, 2013, J NEUROTRAUM, V30, P1898, DOI 10.1089/neu.2013.2962; Arumugam TV, 2005, NEUROMOL MED, V7, P229, DOI 10.1385/NMM:7:3:229; Avlonitis VS, 2005, AM J TRANSPLANT, V5, P684, DOI 10.1111/j.1600-6143.2005.00755.x; Bakovic D, 2013, CLIN PHYSIOL FUNCT I, V33, P30, DOI 10.1111/j.1475-097X.2012.01156.x; BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; Barry M, 2002, NAT REV IMMUNOL, V2, P401, DOI 10.1038/nri819; Becker KJ, 2005, J CEREBR BLOOD F MET, V25, P1634, DOI 10.1038/sj.jcbfm.9600160; Becker KJ, 2011, STROKE, V42, P2763, DOI 10.1161/STROKEAHA.111.619593; Bellinger DL, 2008, CELL IMMUNOL, V252, P27, DOI 10.1016/j.cellimm.2007.09.005; Brait VH, 2012, J CEREBR BLOOD F MET, V32, P598, DOI 10.1038/jcbfm.2012.6; Brait VH, 2010, J CEREBR BLOOD F MET, V30, P1306, DOI 10.1038/jcbfm.2010.14; Cassaglia PA, 2008, AM J PHYSIOL-REG I, V294, pR1255, DOI 10.1152/ajpregu.00332.2007; Chamorro A, 2007, STROKE, V38, P1097, DOI 10.1161/01.STR.0000258346.68966.9d; Chang LL, 2011, BRAIN BEHAV IMMUN, V25, P260, DOI 10.1016/j.bbi.2010.09.017; Chao HJ, 2005, J NEUROIMMUNOL, V158, P159, DOI 10.1016/j.jneuroim.2004.09.008; Chiarella SE, 2014, J CLIN INVEST, V124, P2935, DOI 10.1172/JCI75157; Cobelens PM, 2010, CRIT CARE, V14, DOI 10.1186/cc9232; COLICE GL, 1985, CLIN CHEST MED, V6, P473; Davenport RJ, 1996, STROKE, V27, P415, DOI 10.1161/01.STR.27.3.415; Davison DL, 2012, CRIT CARE, V16, DOI 10.1186/cc11226; DEMLING R, 1990, CRIT CARE MED, V18, P768, DOI 10.1097/00003246-199007000-00019; Denes A, 2007, J CEREBR BLOOD F MET, V27, P1941, DOI 10.1038/sj.jcbfm.9600495; Dziedzic T, 2007, J NEUROL SCI, V252, P53, DOI 10.1016/j.jns.2006.10.007; Dziewas R, 2004, J NEUROL NEUROSUR PS, V75, P852, DOI 10.1136/jnnp.2003.019075; Emsley HC, 2008, LANCET NEUROL, V7, P341, DOI 10.1016/S1474-4422(08)70061-9; Faraco G, 2013, HYPERTENSION, V62, P759, DOI 10.1161/HYPERTENSIONAHA.113.01761; Flierl MA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004414; Gelderblom M, 2009, STROKE, V40, P1849, DOI 10.1161/STROKEAHA.108.534503; Gendron A, 2002, BRAIN RES, V955, P85, DOI 10.1016/S0006-8993(02)03368-1; Gur AY, 2007, J NEUROL SCI, V257, P121, DOI 10.1016/j.jns.2007.01.024; Hamner JW, 2010, STROKE, V41, P102, DOI 10.1161/STROKEAHA.109.557132; Hannawi Y, 2013, CEREBROVASC DIS, V35, P430, DOI 10.1159/000350199; HARDY J, 1994, AM J VET RES, V55, P1570; Holland MC, 2003, J TRAUMA, V55, P106, DOI 10.1097/01.TA.0000071620.27375.BE; Iadecola C, 2011, NAT MED, V17, P796, DOI 10.1038/nm.2399; Immink RV, 2005, STROKE, V36, P2595, DOI 10.1161/01.STR.0000189624.06836.03; Ishikawa M, 2003, STROKE, V34, P1777, DOI 10.1161/01.STR.0000074921.17767.F2; JANDER S, 1995, J CEREBR BLOOD F MET, V15, P42, DOI 10.1038/jcbfm.1995.5; Kahn JM, 2006, CRIT CARE MED, V34, P196, DOI 10.1097/01.CCM.0000194540.44020.8E; Kalsotra A, 2007, J CEREBR BLOOD F MET, V27, P963, DOI 10.1038/sj.jcbfm.9600396; Kamel H, 2012, ARCH NEUROL-CHICAGO, V69, P576, DOI 10.1001/archneurol.2011.3590; Katzan IL, 2003, NEUROLOGY, V60, P620, DOI 10.1212/01.WNL.0000046586.38284.60; Konoeda F, 2010, BIOCHEM BIOPH RES CO, V402, P500, DOI 10.1016/j.bbrc.2010.10.058; Kriz Jasna, 2006, Critical Reviews in Neurobiology, V18, P145; Lalancette-Hebert M, 2007, J NEUROSCI, V27, P2596, DOI 10.1523/JNEUROSCI.5360-06.2007; Langhorne P, 2000, STROKE, V31, P1223, DOI 10.1161/01.STR.31.6.1223; Liesz A, 2011, BRAIN, V134, P704, DOI 10.1093/brain/awr008; Lopez-Aguilar J, 2005, CRIT CARE MED, V33, P1077, DOI 10.1097/01.CCM.0000162913.72479.F7; Macrez R, 2011, LANCET NEUROL, V10, P471, DOI 10.1016/S1474-4422(11)70066-7; Maddahi A, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-107; Maddahi A, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-14; MARRIE TJ, 1994, CLIN INFECT DIS, V18, P501, DOI 10.1093/clinids/18.4.501; Martin A, 2008, MOL IMAGING, V7, P157, DOI 10.2310/7290.2008.00016; Mascia L, 2009, NEUROCRIT CARE, V11, P417, DOI 10.1007/s12028-009-9242-8; Meisel C, 2011, NEW ENGL J MED, V365, P2134, DOI 10.1056/NEJMcibr1112454; Mracsko E, 2014, BRAIN BEHAV IMMUN, V41, P200, DOI 10.1016/j.bbi.2014.05.015; Nakajima K, 2001, J BIOCHEM-TOKYO, V130, P169, DOI 10.1093/oxfordjournals.jbchem.a002969; Nieswandt B, 2011, J PHYSIOL-LONDON, V589, P4115, DOI 10.1113/jphysiol.2011.212886; Offner H, 2006, J CEREBR BLOOD F MET, V26, P654, DOI 10.1038/sj.jcbfm.9600217; Offner H, 2006, J IMMUNOL, V176, P6523, DOI 10.4049/jimmunol.176.11.6523; Pelosi P, 2005, CURR OPIN CRIT CARE, V11, P37, DOI 10.1097/00075198-200502000-00006; Planas AM, 2012, J IMMUNOL, V188, P2156, DOI 10.4049/jimmunol.1102289; Prass K, 2003, J EXP MED, V198, P725, DOI 10.1084/jem.20021098; Prass K, 2006, STROKE, V37, P2607, DOI 10.1161/01.STR.0000240409.68739.2b; Pun PBL, 2009, FREE RADICAL RES, V43, P348, DOI 10.1080/10715760902751902; Rassler B, 2012, SCI CAIRO, V2012; Riquelme R, 1996, AM J RESP CRIT CARE, V154, P1450, DOI 10.1164/ajrccm.154.5.8912763; Sammani S, 2011, AM J RESP CELL MOL, V45, P1022, DOI 10.1165/rcmb.2010-0267OC; Shichita T, 2009, NAT MED, V15, P946, DOI 10.1038/nm.1999; Stoll G, 2010, ANN NY ACAD SCI, V1207, P149, DOI 10.1111/j.1749-6632.2010.05730.x; Tanzi P, 2011, NEUROCRIT CARE, V14, P244, DOI 10.1007/s12028-010-9490-7; ter Laan M, 2013, BRIT J ANAESTH, V111, P361, DOI 10.1093/bja/aet122; Teramoto S, 2009, EXPERT REV NEUROTHER, V9, P1187, DOI [10.1586/ern.09.72, 10.1586/ERN.09.72]; THEODORE J, 1975, LANCET, V2, P749; Toung TJK, 2005, CRIT CARE MED, V33, P203, DOI 10.1097/01.CCM.0000150659.15558.23; Walter U, 2013, EUR J NEUROL, V20, P153, DOI 10.1111/j.1468-1331.2012.03818.x; Wang JP, 2015, BRAIN BEHAV IMMUN, V43, P172, DOI 10.1016/j.bbi.2014.07.022; Winklewski PJ, 2013, BLOOD PRESSURE, V22, P27, DOI 10.3109/08037051.2012.701407; Woiciechowsky C, 1999, BRAIN RES, V816, P563, DOI 10.1016/S0006-8993(98)01238-4; Wong CHY, 2011, SCIENCE, V334, P101, DOI 10.1126/science.1210301; Wu S, 2006, EXP NEUROL, V200, P245, DOI 10.1016/j.expneurol.2006.01.027; Yenari MA, 2006, STROKE, V37, P1087, DOI 10.1161/01.STR.0000206281.77178.ac; Yilmaz G, 2008, NEUROL RES, V30, P783, DOI 10.1179/174313208X341085; Zierath D, 2010, NEUROCRIT CARE, V12, P274, DOI 10.1007/s12028-009-9270-4	88	41	53	2	16	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	DEC 24	2014	11								213	10.1186/s12974-014-0213-4			8	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	CA6SA	WOS:000349044600001	25539803	DOAJ Gold, Green Published			2021-06-18	
J	Wu, QB; Jing, YL; Yuan, XC; Zhang, XY; Li, BW; Liu, MM; Wang, B; Li, HW; Liu, SY; Xiu, RJ				Wu, Qingbin; Jing, Yingli; Yuan, Xiaochen; Zhang, Xiaoyan; Li, Bingwei; Liu, Mingming; Wang, Bing; Li, Hongwei; Liu, Shuying; Xiu, Ruijuan			Melatonin Treatment Protects Against Acute Spinal Cord Injury-Induced Disruption of Blood Spinal Cord Barrier in Mice	JOURNAL OF MOLECULAR NEUROSCIENCE			English	Article						Spinal cord injury; Microcirculation; Blood spinal cord barrier; Permeability; Melatonin	BRAIN-BARRIER; FUNCTIONAL RECOVERY; MATRIX METALLOPROTEINASES; TRAUMATIC INJURY; OXIDATIVE DAMAGE; GENE-EXPRESSION; RATS; PERMEABILITY; COMPRESSION; IMPACT	The spinal cord microcirculation plays a critically important role in maintaining the normal function of spinal cord neurons, glial cells, and axons. Previous researches were largely focused on improved neurological manifestations of spinal cord injury (SCI) while ignoring to improve spinal cord microcirculation disorder after melatonin treatment. Therefore, the mechanism of melatonin that affects blood spinal cord barrier (BSCB) integrity and microcirculation in SCI remains unclear. The present study was performed to investigate the effect of melatonin on the BSCB in a SCI mice model. Melatonin (5, 10, 25, 50, 100 mg/kg i.p.) was administered to mice immediately following SCI. Compared to the 48 h post-SCI group, mice treated with melatonin (50 mg/kg) exhibited significantly reduced BSCB permeability. Additionally, melatonin treatment restrained microvessel loss; attenuated edema; protected the tight junction proteins, endothelial cells, and pericytes; decreased the number of cell apoptosis; and reduced MMP3/AQP4/HIF-1 alpha/VEGF/VEGFR2 expression after SCI. Above all, our results clearly demonstrated that melatonin could stabilize microvascular barrier function and microcirculation of SCI, whose mechanism was to promote the repair of the damaged BSCB.	[Wu, Qingbin; Jing, Yingli; Yuan, Xiaochen; Zhang, Xiaoyan; Li, Bingwei; Liu, Mingming; Wang, Bing; Li, Hongwei; Liu, Shuying; Xiu, Ruijuan] Chinese Acad Med Sci, Inst Microcirculat, Key Lab Microcirculat, Minist Natl Hlth China, Beijing 100005, Peoples R China; [Wu, Qingbin; Jing, Yingli; Yuan, Xiaochen; Zhang, Xiaoyan; Li, Bingwei; Liu, Mingming; Wang, Bing; Li, Hongwei; Liu, Shuying; Xiu, Ruijuan] Peking Union Med Coll, Beijing 100005, Peoples R China	Xiu, RJ (corresponding author), Chinese Acad Med Sci, Inst Microcirculat, Key Lab Microcirculat, Minist Natl Hlth China, 5 Dong Dan San Tiao, Beijing 100005, Peoples R China.	xiurj@aliyun.com	LIU, Mingming/ABA-6770-2020	Liu, Mingming/0000-0002-6750-5068; Xiu, Ruijuan/0000-0002-1446-2711	Chinese Academy of Medical Sciences; Peking Union Medical College [1012012X17]	This work was supported by the innovation fund of Chinese Academy of Medical Sciences and Peking Union Medical College (No. 1012012X17).	Allen A.R., 1911, JAMA-J AM MED ASSOC, V57, P878, DOI DOI 10.1001/JAMA.1911.04260090100008; Allen AR, 1914, J NERV MENT DIS, V41, P141, DOI 10.1097/00005053-191403000-00002; Alvarez C, 2007, HUM REPROD, V22, P3210, DOI 10.1093/humrep/dem315; Casella GTB, 2006, EXP NEUROL, V202, P8, DOI 10.1016/j.expneurol.2006.05.028; Chen HY, 2006, J PINEAL RES, V41, P175, DOI 10.1111/j.1600-079X.2006.00351.x; Daneman R, 2010, NATURE, V468, P562, DOI 10.1038/nature09513; Dulmovits BM, 2012, INT J BIOCHEM CELL B, V44, P1800, DOI 10.1016/j.biocel.2012.06.031; Echeverry S, 2011, J NEUROSCI, V31, P10819, DOI 10.1523/JNEUROSCI.1642-11.2011; Ersahin M, 2009, J PINEAL RES, V46, P324, DOI 10.1111/j.1600-079X.2009.00664.x; Espino J, 2010, FERTIL STERIL, V94, P1915, DOI 10.1016/j.fertnstert.2009.12.082; Esposito E, 2008, J PINEAL RES, V45, P149, DOI 10.1111/j.1600-079X.2008.00569.x; Fan ZK, 2013, J MOL NEUROSCI, V51, P986, DOI 10.1007/s12031-013-0083-8; Fan ZK, 2013, J NEUROTRAUM, V30, P473, DOI 10.1089/neu.2012.2574; Furuse M, 2006, TRENDS CELL BIOL, V16, P181, DOI 10.1016/j.tcb.2006.02.006; Goldberg AL, 2010, J SPINAL CORD MED, V33, P105, DOI 10.1080/10790268.2010.11689685; GRIFFITHS IR, 1978, ACTA NEUROPATHOL, V41, P33, DOI 10.1007/BF00689554; Haddadi G, 2013, CELL J, V14, P246; HAPPEL RD, 1981, BRAIN RES, V211, P476, DOI 10.1016/0006-8993(81)90976-8; Imaizumi T, 1997, J NEUROTRAUM, V14, P299, DOI 10.1089/neu.1997.14.299; Josko J, 2004, MED SCI MONITOR, V10, pRA89; Jung F, 2010, CLIN HEMORHEOL MICRO, V45, P79, DOI 10.3233/CH-2010-1312; Kaur C, 2008, CURR NEUROVASC RES, V5, P71, DOI 10.2174/156720208783565645; Lee JY, 2012, J NEUROCHEM, V121, P818, DOI 10.1111/j.1471-4159.2012.07731.x; Liebner S, 2011, INT J DEV BIOL, V55, P467, DOI 10.1387/ijdb.103224sl; Morita K, 1999, P NATL ACAD SCI USA, V96, P511, DOI 10.1073/pnas.96.2.511; NOBLE LJ, 1989, BRAIN RES, V482, P57, DOI 10.1016/0006-8993(89)90542-8; Noble LJ, 2002, J NEUROSCI, V22, P7526; Oudega M, 2012, CELL TISSUE RES, V349, P269, DOI 10.1007/s00441-012-1440-6; Oyinbo CA, 2011, ACTA NEUROBIOL EXP, V71, P281; Park K, 2010, J PINEAL RES, V48, P270, DOI 10.1111/j.1600-079X.2010.00751.x; Qiu J, 2009, LANCET NEUROL, V8, P606, DOI 10.1016/S1474-4422(09)70162-0; Ray SK, 2003, BRAIN RES REV, V42, P169, DOI 10.1016/S0165-0173(03)00152-8; Ray SK, 2011, NEUROTHERAPEUTICS, V8, P180, DOI 10.1007/s13311-011-0037-1; Saadoun S, 2008, BRAIN, V131, P1087, DOI 10.1093/brain/awn014; Samantaray S, 2008, J PINEAL RES, V44, P348, DOI 10.1111/j.1600-079X.2007.00534.x; Schiaveto-de-Souza A, 2013, BRAZ J MED BIOL RES, V46, P348, DOI 10.1590/1414-431X20132322; Semenza GL, 2004, PHYSIOLOGY, V19, P176, DOI 10.1152/physiol.00001.2004; Sharma HS, 2011, J NEURAL TRANSM, V118, P155, DOI 10.1007/s00702-010-0514-4; SHARMA HS, 1990, NEUROSCIENCE, V36, P725, DOI 10.1016/0306-4522(90)90014-U; SHARMA HS, 1993, ACTA NEUROPATHOL, V85, P145; Shibuya Masaubmi, 2006, Angiogenesis, V9, P225, DOI 10.1007/s10456-006-9055-8; Sommansson A, 2013, J PINEAL RES, V54, P282, DOI 10.1111/jpi.12013; Strazielle N, 2013, MOL PHARMACEUT, V10, P1473, DOI 10.1021/mp300518e; Wolburg H, 2002, VASC PHARMACOL, V38, P323, DOI 10.1016/S1537-1891(02)00200-8; Xiong YQ, 2007, J NEUROCHEM, V100, P639, DOI 10.1111/j.1471-4159.2006.04312.x; Xu WB, 2008, BRAIN RES, V1246, P11, DOI 10.1016/j.brainres.2008.09.087; Ye S, 1996, J BIOL CHEM, V271, P13055, DOI 10.1074/jbc.271.22.13055; Yuan XC, 2011, J PINEAL RES, V51, P220, DOI 10.1111/j.1600-079X.2011.00882.x	48	41	44	3	18	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0895-8696	1559-1166		J MOL NEUROSCI	J. Mol. Neurosci.	DEC	2014	54	4					714	722		10.1007/s12031-014-0430-4			9	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	AW0PP	WOS:000345995700013	25303856				2021-06-18	
J	Neuhaus, W; Gaiser, F; Mahringer, A; Franz, J; Riethmuller, C; Forster, C				Neuhaus, Winfried; Gaiser, Fabian; Mahringer, Anne; Franz, Jonas; Riethmueller, Christoph; Foerster, Carola			The pivotal role of astrocytes in an in vitro stroke model of the blood-brain barrier	FRONTIERS IN CELLULAR NEUROSCIENCE			English	Article						blood-brain barrier; in vitro; stroke; oxygen/glucose deprivation; ischemia; traumatic brain injury; cerebEND; C6	CAPILLARY ENDOTHELIAL-CELLS; BINDING CASSETTE TRANSPORTERS; PLASMINOGEN ACTIVATOR TPA; TIGHT JUNCTION COMPLEXES; P-GLYCOPROTEIN; GLIAL-CELLS; MATRIX METALLOPROTEINASES; CEREBRAL-ISCHEMIA; UP-REGULATION; EXPRESSION	Stabilization of the blood-brain barrier during and after stroke can lead to less adverse outcome. For elucidation of underlying mechanisms and development of novel therapeutic strategies validated in vitro disease models of the blood-brain barrier could be very helpful. To mimic in vitro stroke conditions we have established a blood-brain barrier in vitro model based on mouse cell line cerebEND and applied oxygen/glucose deprivation (OGD). The role of astrocytes in this disease model was investigated by using cell line C6. Transwell studies pointed out that addition of astrocytes during OGD increased the barrier damage significantly in comparison to the endothelial monoculture shown by changes of transendothelial electrical resistance as well as fluorescein permeability data. Analysis on mRNA and protein levels by qPCR, western blotting and immunofluorescence microscopy of tight junction molecules claudin-3,-5,-12, occludin and ZO-1 revealed that their regulation and localisation is associated with the functional barrier breakdown. Furthermore, soluble factors of astrocytes, OGD and their combination were able to induce changes of functionality and expression of ABC-transporters Abcb1a (P-gp), Abcg2 (bcrp), and Abcc4 (mrp4). Moreover, the expression of proteases (matrixmetalloproteinases MMP-2, MMP-3, MMP-9, and t-PA) as well as of their endogenous inhibitors (TIMP-1, TIMP-3, PAI-1) was altered by astrocyte factors and OGD which resulted in significant changes of total MMP and t-PA activity. Morphological rearrangements induced by OGD and treatment with astrocyte factors were confirmed at a nanometer scale using atomic force microscopy. In conclusion, astrocytes play a major role in blood-brain barrier breakdown during OGD in vitro.	[Neuhaus, Winfried] Univ Vienna, Dept Pharmaceut Chem, A-1090 Vienna, Austria; [Neuhaus, Winfried; Gaiser, Fabian; Foerster, Carola] Univ Hosp Wurzburg, Dept Anesthesia & Crit Care, Wurzburg, Germany; [Mahringer, Anne] Heidelberg Univ, Inst Pharm & Mol Biotechnol, Dept Pharmaceut Technol & Biopharm, Heidelberg, Germany; [Franz, Jonas; Riethmueller, Christoph] Serend Ip GmbH, Ctr Nanotechnol, Munster, Germany	Neuhaus, W (corresponding author), Univ Vienna, Dept Pharmaceut Chem, Althanstr 14, A-1090 Vienna, Austria.	winfried.neuhaus@univie.ac.at; foerster_c@ukw.de		Franz, Jonas/0000-0001-7523-6622; Neuhaus, Winfried/0000-0002-6552-7183	European Union Seventh Framework Programme (FP7) [HEALTH-F2-2009- 241778]	The research leading to these results has received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under Grant agreement No. HEALTH-F2-2009- 241778 to Carola Forster. We are very grateful to Anja Neuhoff for her excellent technical support. The funding organization has no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; Adibhatla RM, 2008, CNS NEUROL DISORD-DR, V7, P243, DOI 10.2174/187152708784936608; Andras IE, 2007, J CEREBR BLOOD F MET, V27, P1431, DOI 10.1038/sj.jcbfm.9600445; Ballabh P, 2004, NEUROBIOL DIS, V16, P1, DOI 10.1016/j.nbd.2003.12.016; Bauer AT, 2010, J CEREBR BLOOD F MET, V30, P837, DOI 10.1038/jcbfm.2009.248; Berezowski V, 2004, BRAIN RES, V1018, P1, DOI 10.1016/j.brainres.2004.05.092; Berezowski Vincent, 2012, Int J Cell Biol, V2012, P176287, DOI 10.1155/2012/176287; Boveri M, 2005, GLIA, V51, P187, DOI 10.1002/glia.20189; BRIGHTMA.MW, 1969, J CELL BIOL, V40, P648, DOI 10.1083/jcb.40.3.648; Brillault J, 2002, J NEUROCHEM, V83, P807, DOI 10.1046/j.1471-4159.2002.01186.x; Brouns R, 2011, EUR NEUROL, V65, P23, DOI 10.1159/000321965; Cecchelli R, 2007, NAT REV DRUG DISCOV, V6, P650, DOI 10.1038/nrd2368; Ceruti S, 2011, NEUROCHEM INT, V59, P259, DOI 10.1016/j.neuint.2011.05.013; Culot M, 2008, TOXICOL IN VITRO, V22, P799, DOI 10.1016/j.tiv.2007.12.016; Cunningham LA, 2005, GLIA, V50, P329, DOI 10.1002/glia.20169; Dazert P, 2006, NEUROSCIENCE, V142, P1071, DOI 10.1016/j.neuroscience.2006.07.056; Deli Maria A., 1996, Keio Journal of Medicine, V45, P183; Doyle KP, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-62; ElHafny B, 1997, NEUROSCI LETT, V236, P107, DOI 10.1016/S0304-3940(97)00679-4; Engelhardt S, 2014, J CELL PHYSIOL, V229, P1096, DOI 10.1002/jcp.24544; Gaillard PJ, 2000, PHARMACEUT RES, V17, P1198, DOI 10.1023/A:1026406528530; JANZER RC, 1987, NATURE, V325, P253, DOI 10.1038/325253a0; Jiao HX, 2011, J MOL NEUROSCI, V44, P130, DOI 10.1007/s12031-011-9496-4; Jin R, 2010, NEUROBIOL DIS, V38, P376, DOI 10.1016/j.nbd.2010.03.008; Joo F, 1996, PROG NEUROBIOL, V48, P255, DOI 10.1016/0301-0082(95)00046-1; Jungmann P, 2008, PFLUG ARCH EUR J PHY, V455, P1007, DOI 10.1007/s00424-007-0352-x; Kleinschnitz C, 2011, STROKE, V42, P1081, DOI 10.1161/STROKEAHA.110.592238; Krafft PR, 2013, STROKE, V44, P1743, DOI 10.1161/STROKEAHA.111.000427; Lau LT, 2001, J NEUROTRAUM, V18, P351, DOI 10.1089/08977150151071035; Lazarowski A, 2007, J NEUROL SCI, V258, P84, DOI 10.1016/j.jns.2007.03.004; Lee SR, 2007, NEUROSCI LETT, V417, P1, DOI 10.1016/j.neulet.2007.01.017; Lenglet S, 2014, THROMB HAEMOSTASIS, V112, P363, DOI 10.1160/TH14-01-0007; Lundquist S, 2002, PHARMACEUT RES, V19, P976, DOI 10.1023/A:1016462205267; Mathiisen TM, 2010, GLIA, V58, P1094, DOI 10.1002/glia.20990; Mysiorek C, 2009, CURR NEUROVASC RES, V6, P181, DOI 10.2174/156720209788970081; Nakagawa S, 2009, NEUROCHEM INT, V54, P253, DOI 10.1016/j.neuint.2008.12.002; NEUHAUS J, 1991, ANN NY ACAD SCI, V633, P578; Neuhaus W, 2006, PHARM RES, V23, P1491, DOI 10.1007/s11095-006-0256-z; Neuhaus W, 2012, DIFFERENTIATION, V84, P294, DOI 10.1016/j.diff.2012.08.006; Neuhaus W, 2012, NEUROSCI LETT, V506, P44, DOI 10.1016/j.neulet.2011.10.045; Neuhaus W, 2008, J PHARM SCI-US, V97, P5158, DOI 10.1002/jps.21371; Novakova I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086806; Patak P, 2011, CURR PHARM DESIGN, V17, P2787, DOI 10.2174/138161211797440195; Pfefferkorn T, 2003, STROKE, V34, P2025, DOI 10.1161/01.STR.0000083051.93319.28; Piontek J, 2011, CELL MOL LIFE SCI, V68, P3903, DOI 10.1007/s00018-011-0680-z; Poller B, 2010, CELL MOL NEUROBIOL, V30, P63, DOI 10.1007/s10571-009-9431-1; Redzic ZB, 2015, INT J STROKE, V10, P407, DOI 10.1111/ijs.12197; Reichel V, 2010, J NEUROCHEM, V115, P200, DOI 10.1111/j.1471-4159.2010.06915.x; Ronaldson PT, 2012, CURR PHARM DESIGN, V18, P3624; Shin JA, 2015, BRAIN STRUCT FUNCT, V220, P13, DOI 10.1007/s00429-013-0632-5; Silwedel C, 2006, J NEUROIMMUNOL, V179, P37, DOI 10.1016/j.jneuroim.2006.06.019; Spudich A, 2006, NAT NEUROSCI, V9, P487, DOI 10.1038/nn1676; Strecker JK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025863; Takeshita T, 2014, MOL CELL NEUROSCI, V60, P1, DOI 10.1016/j.mcn.2014.01.006; Thal SC, 2013, CRIT CARE MED, V41, P1305, DOI 10.1097/CCM.0b013e31827ca494; Thoelking G, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/26/265102; Torok M, 2003, EXP BRAIN RES, V153, P356, DOI 10.1007/s00221-003-1620-4; Tsuji K, 2005, STROKE, V36, P1954, DOI 10.1161/01.STR.0000177517.01203.eb; Ueno M, 2009, NEUROPATH APPL NEURO, V35, P147, DOI 10.1111/j.1365-2990.2008.00966.x; VanGilder RL, 2011, PHARMACOL THERAPEUT, V130, P239, DOI 10.1016/j.pharmthera.2010.12.004; Wang YMF, 1998, NAT MED, V4, P228, DOI 10.1038/nm0298-228; Willis CL, 2013, NEUROSCIENCE, V250, P773, DOI 10.1016/j.neuroscience.2013.06.061; Willis CL, 2004, GLIA, V48, P1, DOI 10.1002/glia.20049; Witt KA, 2003, AM J PHYSIOL-HEART C, V285, pH2820, DOI 10.1152/ajpheart.00589.2003; Yang Y, 2011, STROKE, V42, P3323, DOI 10.1161/STROKEAHA.110.608257; Yeh WL, 2008, MOL PHARMACOL, V73, P170, DOI 10.1124/mol.107.038851	66	41	43	0	24	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND		1662-5102		FRONT CELL NEUROSCI	Front. Cell. Neurosci.	OCT 28	2014	8								352	10.3389/fncel.2014.00352			16	Neurosciences	Neurosciences & Neurology	AS9AW	WOS:000344536800004	25389390	DOAJ Gold, Green Published			2021-06-18	
J	Te Ao, B; Brown, P; Tobias, M; Ameratunga, S; Barker-Collo, S; Theadom, A; McPherson, K; Starkey, N; Dowell, A; Jones, K; Feigin, VL				Te Ao, Braden; Brown, Paul; Tobias, Martin; Ameratunga, Shanthi; Barker-Collo, Suzanne; Theadom, Alice; McPherson, Kathryn; Starkey, Nicola; Dowell, Anthony; Jones, Kelly; Feigin, Valery L.		BIONIC Study Grp	Cost of traumatic brain injury in New Zealand Evidence from a population-based study	NEUROLOGY			English	Article							HEAD-INJURY; OUTCOMES; CHILDREN; SCALE; CARE; BURDEN	Objective: We aimed to estimate from a societal perspective the 1-year and lifetime direct and indirect costs of traumatic brain injury (TBI) for New Zealand (NZ) in 2010 projected to 2020. Methods: An incidence-based cost of illness model was developed using data from the Brain Injury Outcomes New Zealand in the Community Study. Details of TBI-related resource use during the first 12 months after injury were obtained for 725 cases using resource utilization information from participant surveys and medical records. Total costs are presented in US dollars year 2010 value. Results: In 2010, 11,301 first-ever TBI cases were estimated to have occurred in NZ; total first-year cost of all new TBI cases was estimated to be US $47.9 million with total prevalence costs of US $101.4 million. The average cost per new TBI case during the first 12 months and over a lifetime was US $5,922 (95% confidence interval [CI] $4,777-$7,858), varying from US $4,636 (95% CI $3,756-$5,561) for mild cases to US $36,648 (95% CI $16,348-$65,350) for moderate/severe cases. Because of the unexpectedly large number of mild TBI cases (95% of all TBI cases), the total cost of treating these cases is nearly 3 times that of moderate/severe. The total lifetime cost of all TBI survivors in 2010 was US $146.5 million and is expected to increase to US $177.1 million in 2020. Conclusion: The results suggest that there is an urgent need to develop effective interventions to prevent both mild and moderate/severe TBI.	[Te Ao, Braden; Theadom, Alice; Jones, Kelly; Feigin, Valery L.] AUT Univ, Natl Inst Stroke & Appl Neurosci, Fac Hlth & Environm Studies, Auckland, New Zealand; [McPherson, Kathryn] AUT Univ, Hlth & Rehabil Res Inst, Fac Hlth & Environm Studies, Auckland, New Zealand; [Brown, Paul] Univ Calif, Sch Social Sci Humanities & Arts, Merced, CA USA; [Tobias, Martin] Minist Hlth, Publ Hlth Intelligence, Wellington, New Zealand; [Ameratunga, Shanthi] Univ Auckland, Sch Populat Hlth, Fac Med & Hlth Sci, Auckland 1, New Zealand; [Barker-Collo, Suzanne] Univ Auckland, Dept Psychol, Auckland 1, New Zealand; [Starkey, Nicola] Univ Waikato, Dept Psychol, Fac Arts & Social Sci, Hamilton, New Zealand; [Dowell, Anthony] Univ Otago, Wellington, New Zealand	Te Ao, B (corresponding author), AUT Univ, Natl Inst Stroke & Appl Neurosci, Fac Hlth & Environm Studies, Auckland, New Zealand.	braden.teao@aut.ac.nz	Jones, Kelly/I-5199-2019; Starkey, Nicola/AAJ-3795-2020; Feigin, Valery/AAF-2313-2019	Starkey, Nicola/0000-0002-4370-8186; Ameratunga, Shanthi/0000-0001-8042-2251; Theadom, Alice/0000-0003-0351-6216; McPherson, Kath/0000-0003-0487-8497; Te Ao, Braden/0000-0002-1050-200X; McPherson, Kathryn/0000-0003-1240-8882; Feigin, Valery L./0000-0002-6372-1740	Health Research Council of New ZealandHealth Research Council of New Zealand; Waikato Tainui doctoral grant	The study was funded by the Health Research Council of New Zealand. Braden Te Ao was supported by a PhD fellowship from the Health Research Council of New Zealand and a Waikato Tainui doctoral grant.	Access Economics, 2009, EC COST SPIN CORD IN; Aitken ME, 2009, PEDIATRICS, V123, P199, DOI 10.1542/peds.2008-0607; Barendregt Jan J, 2003, Popul Health Metr, V1, P4, DOI 10.1186/1478-7954-1-4; Barendregt JJ, 2005, EUR J EPIDEMIOL, V20, P827, DOI 10.1007/s10654-005-2227-9; Brener I, 2004, J HEAD TRAUMA REHAB, V19, P405, DOI 10.1097/00001199-200409000-00005; Cadilhac DA, 2011, INT J BEHAV NUTR PHY, V8, DOI 10.1186/1479-5868-8-99; Chen A, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-76; Davis KL, 2007, J TRAUMA, V62, P622, DOI 10.1097/TA.0b013e318031afe3; DisMod II, 2013, EPIGEAR INT SOFTW DO; Farhad K, 2013, J NEUROTRAUM, V30, P84, DOI 10.1089/neu.2011.2283; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; GRABOW JD, 1984, AM J PUBLIC HEALTH, V74, P710, DOI 10.2105/AJPH.74.7.710; KOOPMANSCHAP MA, 1993, PHARMACOECONOMICS, V4, P446, DOI 10.2165/00019053-199304060-00006; KOOPMANSCHAP MA, 1992, SOC SCI MED, V34, P1005, DOI 10.1016/0277-9536(92)90131-9; McGarry LJ, 2002, J TRAUMA, V53, P1152, DOI 10.1097/00005373-200212000-00020; McGregor K, 1997, SOC SCI MED, V45, P295, DOI 10.1016/S0277-9536(96)00345-0; Ministry of Health, 2010, NZ CAS FRAM PUBL FUN; Ministry of Health. New Zealand Health Information Services, 2010, NAT MIN DAT HOSP EV; Mock C, 2004, LANCET, V363, P2172, DOI 10.1016/S0140-6736(04)16510-0; Morris S, 2008, ANAESTHESIA, V63, P499, DOI 10.1111/j.1365-2044.2007.05432.x; New Zealand Ministry of Health, OV NZ HLTH SYST; New Zealand Treasury, 2005, COST BEN AN PRIM; Organisation for Economic Co-operation and Development, PRIC PURCH POW PAR P; PHARMAC, 2012, PRESCR PHARM AN METH; Ponsford J, 2004, BRAIN INJURY, V18, P603, DOI 10.1080/02699050310001646152; Schootman M, 2003, BRAIN INJURY, V17, P983, DOI 10.1080/0269905031000110427; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Statistics New Zealand, 2010, INC WORK; TEASDALE G, 1974, LANCET, V2, P81; Theadom A, 2012, NEUROEPIDEMIOLOGY, V38, P18, DOI 10.1159/000334746; Tilford JM, 2005, CRIT CARE MED, V33, P2074, DOI 10.1097/01.CCM.0000171839.65687.F5; Wren J, 2010, COSTS INJURY NZ METH	32	41	41	0	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	OCT 28	2014	83	18					1645	1652		10.1212/wnl.0000000000000933			8	Clinical Neurology	Neurosciences & Neurology	AT3RU	WOS:000344852200014	25261503				2021-06-18	
J	Bean, CN; Fortier, M; Post, C; Chima, K				Bean, Corliss N.; Fortier, Michelle; Post, Courtney; Chima, Karam			Understanding How Organized Youth Sport May Be Harming Individual Players within the Family Unit: A Literature Review	INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH			English	Article						sport; negative; family; youth; parent; sibling; review	TRAUMATIC BRAIN-INJURY; JUNIOR TENNIS PLAYERS; ILLICIT DRUG-USE; PHYSICAL-ACTIVITY; EATING-DISORDERS; MENTAL-HEALTH; HIGH-SCHOOL; MOTIVATIONAL CLIMATE; POSITION STATEMENT; PSYCHOMETRIC PROPERTIES	Within the United States, close to 45 million youths between the ages of 6 and 18 participate in some form of organized sports. While recent reviews have shown the positive effects of youth sport participation on youth health, there are also several negative factors surrounding the youth sport environment. To date, a comprehensive review of the negative physical and psychological effects of organized sport on youth has not been done and little thus far has documented the effect organized sport has on other players within a family, particularly on parents and siblings. Therefore the purpose of this paper is to conduct a review of studies on the negative effects of organized sport on the youth athlete and their parents and siblings. Articles were found by searching multiple databases (Physical Education Index and Sociology, Psychology databases (Proquest), SPORTDiscus and Health, History, Management databases (EBSCOhost), Science, Social Science, Arts and Humanities on Web of Science (ISI), SCOPUS and Scirus (Elsevier). Results show the darker side of organized sport for actors within the family unit. A model is proposed to explain under which circumstances sport leads to positive versus negative outcomes, ideas for future research are drawn and recommendations are made to optimize the youth sport experience and family health.	[Bean, Corliss N.; Fortier, Michelle; Post, Courtney; Chima, Karam] Univ Ottawa, Sch Human Kinet, Ottawa, ON K1N 6N5, Canada	Fortier, M (corresponding author), Univ Ottawa, Sch Human Kinet, 125 Univ Private, Ottawa, ON K1N 6N5, Canada.	cbean@uottawa.ca; mfortier@uottawa.ca; cpost015@uottawa.ca; kchima@rogers.com					Adirim TA, 2003, SPORTS MED, V33, P75, DOI 10.2165/00007256-200333010-00006; Alexander K., 2011, EXPERIENCES CHILDREN; Amorose AJ, 2009, RES Q EXERCISE SPORT, V80, P386, DOI 10.1080/02701367.2009.10599575; Anderson JR, 2005, FAM RELAT, V54, P654, DOI 10.1111/j.1741-3729.2005.00349.x; Arendell Teresa, 2001, MINDING TIME FAMILY, P163; Bailey R, 2006, J SCHOOL HEALTH, V76, P397, DOI 10.1111/j.1746-1561.2006.00132.x; Baillargeon A, 2012, BRAIN INJURY, V26, P211, DOI 10.3109/02699052.2012.654590; Baker J, 2003, HIGH ABIL STUD, V14, P85, DOI 10.1080/13598130304091; Balish SM, 2014, PSYCHOL SPORT EXERC, V15, P429, DOI 10.1016/j.psychsport.2014.04.003; Barber H., 1999, J SPORT BEHAV, V22, P1; Barnett LA, 2008, J PARK RECREAT ADM, V26, P28; Bartholomew K., 2011, SPORT EXERCISE PSYCH, V7, P23, DOI DOI 10.1123/jsep.33.1.75; Basak W.A., CONCUSSION EPIDEMIC; Baxter-Jones ADG, 2003, J SPORT MED PHYS FIT, V43, P250; Bean C.N., 2014, WOMEN SPORT IN PRESS; Bean C.N., 2014, DOES SPORT HEL UNPUB; Bernhardt D.T., 2014, PREPARTICIPATION PHY, P179; Biddle SJH, 2011, BRIT J SPORT MED, V45, P886, DOI 10.1136/bjsports-2011-090185; Bloom G, 2010, ENGL LITERARY RENAIS, V40, P329, DOI 10.1111/j.1475-6757.2010.01071.x; Boyer C, 2011, OBSERVATIONAL ANAL I; Bratland-Sanda S, 2013, EUR J SPORT SCI, V13, P499, DOI 10.1080/17461391.2012.740504; Bridge MW, 2013, J SPORT SCI, V31, P87, DOI 10.1080/02640414.2012.721560; Brown WJ, 2005, AM J PREV MED, V29, P265, DOI 10.1016/j.amepre.2005.06.009; BUHRMESTER D, 1990, CHILD DEV, V61, P1387, DOI 10.1111/j.1467-8624.1990.tb02869.x; Busser J. A., 2010, Managing Leisure, V15, P128, DOI 10.1080/13606710903448210; Cairney J., 2014, INT REV SPO IN PRESS; Camire M, 2011, J SPORT PSYCHOL ACTI, V2, P92, DOI 10.1080/21520704.2011.584246; Campbell K., 2013, SELLING DREAM; Canada Hockey, HOCK CAN 94 ANN GEN; Capranica L, 2011, INT J SPORT PHYSIOL, V6, P572, DOI 10.1123/ijspp.6.4.572; Carter JC, 2001, BEHAV RES THER, V39, P625, DOI 10.1016/S0005-7967(00)00033-4; CASHER BB, 1977, RES QUART, V48, P33, DOI 10.1080/10671315.1977.10762146; Chircop A, 2015, HEALTH PROMOT INT, V30, P418, DOI 10.1093/heapro/dat056; Chircop A, 2015, CRIT PUBLIC HEALTH, V25, P178, DOI 10.1080/09581596.2014.887831; Cicirelli VG, 1995, SIBLING RELATIONSHIP; Clark W., KIDS SPORTS; Coakley J., 2006, Leisure Studies, V25, P153, DOI 10.1080/02614360500467735; Cobb KL, 2003, MED SCI SPORT EXER, V35, P711, DOI 10.1249/01.MSS.0000064935.68277.E7; Coble C.J., 2010, FEMALE PARENT COACH; Collins CL, 2008, ARCH PEDIAT ADOL MED, V162, P49, DOI 10.1001/archpediatrics.2007.1; Cote J, 1999, SPORT PSYCHOL, V13, P395, DOI 10.1123/tsp.13.4.395; Cote J., 2007, SPORT PSYCHOL CANADI, P270; Cote J, COACHING YOUTH M CHA; Cote J, 2009, INT J SPORT EXERC PS, V7, P7, DOI 10.1080/1612197X.2009.9671889; Cote J, 2008, INT STUD PHYS EDUC Y, P34; Cotunga Nancy, 2005, J Sch Nurs, V21, P323; Cowdery RS, 2005, FAM RELAT, V54, P335, DOI 10.1111/j.1741-3729.2005.00321.x; Crowe K., BODYCHECKING RISKS Y; Crowe LM, 2010, EMERG MED AUSTRALAS, V22, P56, DOI 10.1111/j.1742-6723.2009.01249.x; Cuskelly G., 2006, SPORT MANAG REV, V9, P141, DOI DOI 10.1016/S1441-3523(06)70023-7; Daly M., 2004, WELFARE STATE CHANGE, P135; Danish S., 2004, World Leisure Journal, V46, P38; Datko K, HIGH COST YOUTH SPOR; Coelho GMD, 2010, APPETITE, V55, P379, DOI 10.1016/j.appet.2010.08.003; Ferreira JED, 2008, APPETITE, V51, P249, DOI 10.1016/j.appet.2008.02.015; Deci E., 1985, INTRINSIC MOTIVATION, DOI DOI 10.1007/978-1-4899-2271-7; Deci EL, 2000, PSYCHOL INQ, V11, P227, DOI 10.1207/S15327965PLI1104_01; DiFiori JP, 2014, CLIN J SPORT MED, V24, P3, DOI 10.1097/JSM.0000000000000060; Dixon MA, 2009, SPORT MANAG REV, V12, P34, DOI DOI 10.1016/J.SMR.2008.09.002; Dixon MA, 2008, SOCIOL SPORT J, V25, P538, DOI 10.1123/ssj.25.4.538; Donnelly P., SOCHI INSPIRATION WO; Dorsch T.E., 2013, PARENT SPORT SOCIALI; Dorsch TE, 2009, J SPORT EXERCISE PSY, V31, P444, DOI 10.1123/jsep.31.4.444; Duda J. L, 2014, INT J SPORT EXER PSY, P1; Duda JL., 2005, ORG ACTIVITIES CONTE, P311, DOI DOI 10.4324/9781410612748; Dyck V., 2006, Leisure Studies, V25, P201, DOI 10.1080/02614360500418589; Eccles J., 2002, COMMUNITY PROGRAMS P, P66; Eime RM, 2013, INT J BEHAV NUTR PHY, V10, DOI 10.1186/1479-5868-10-98; Eklund R.C., 2007, HDB SPORT PSYCHOL, P621; Emery CA, 2006, CLIN J SPORT MED, V16, P20, DOI 10.1097/01.jsm.0000184638.72075.b7; Emrich E, 2009, INT REV SOCIOL SPORT, V44, P151, DOI 10.1177/1012690209104797; Engh F., 2002, WHY JOHNNY HATES SPO; Ericsson K. A., 2003, P49; Ewing M., 1990, PRESIDENTS COUNCIL P, V2, P1; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Finch CF, 2011, SPORTS MED, V41, P59, DOI 10.2165/11537260-000000000-00000; Flintoff, 2002, GENDER SPORT READER; Fogelholm M, 1999, MED SCI SPORT EXER, V31, P229, DOI 10.1097/00005768-199902000-00005; FORTIER MS, 1995, INT J SPORT PSYCHOL, V26, P24; Fraser-Thomas J., 2013, CONDITIONS CHILDRENS, P179; Fraser-Thomas J. L., 2005, Physical Education and Sport Pedagogy, V10, P19, DOI 10.1080/1740898042000334890; Fraser-Thomas J, 2008, PSYCHOL SPORT EXERC, V9, P645, DOI 10.1016/j.psychsport.2007.08.003; Fraser-Thomas J, 2009, SPORT PSYCHOL, V23, P3, DOI 10.1123/tsp.23.1.3; Fredricks JA, 2005, J SPORT EXERCISE PSY, V27, P3, DOI 10.1123/jsep.27.1.3; Fredricks JA, 2002, DEV PSYCHOL, V38, P519, DOI 10.1037/0012-1649.38.4.519; Fredricks JA., 2004, DEV SPORT EXERCISE P, P145, DOI DOI 10.1016/J.PSYCHSPORT.2010.05.001; Fredricks JA, 2006, DEV PSYCHOL, V42, P698, DOI 10.1037/0012-1649.42.4.698; Gagne M, 2007, INTRINSIC MOTIVATION, P243; Gillis C., NEW HOCKEY FIGHTS; Goldberg S, QUITTING ACTIVITIES; Goodger K, 2007, SPORT PSYCHOL, V21, P127, DOI 10.1123/tsp.21.2.127; Gottschalk AW, 2011, SPORTS MED ARTHROSC, V19, P2, DOI 10.1097/JSA.0b013e31820b95fc; Gould D., 2008, INT REV SPORT EXER P, V1, P58, DOI [10.1080/17509840701834573, DOI 10.1080/17509840701834573]; Gould D., 1988, CHILDREN SPORT, P161; Gould D, 2008, SPORT PSYCHOL, V22, P18, DOI 10.1123/tsp.22.1.18; Gould D, 2010, J PHYS EDUC RECREAT, V81, P33, DOI 10.1080/07303084.2010.10598525; Government of Canada, 2013, ORG SPORT CAN; Griffin B.M., 2014, ONLY 6 WORDS PARENTS; Grundtner Koch C.E., 2012, THESIS U ST THOMAS S; Guevremont Anne, 2008, Health Rep, V19, P65; Gustafsson H, 2008, PSYCHOL SPORT EXERC, V9, P800, DOI 10.1016/j.psychsport.2007.11.004; Gustafsson H, 2007, SPORT PSYCHOL, V21, P21, DOI 10.1123/tsp.21.1.21; Hageman W., STUDY FINDS PARENTAL; Halldorsson V, 2014, INT REV SOCIOL SPORT, V49, P311, DOI 10.1177/1012690213507718; Harris BS, 2014, J CLIN SPORT PSYCHOL, V8, P1, DOI 10.1123/jcsp.2014-0009; Harvey HH, 2013, AM J PUBLIC HEALTH, V103, P1249, DOI 10.2105/AJPH.2012.301107; Harwood C, 2009, J SPORT SCI, V27, P339, DOI 10.1080/02640410802603871; Harwood C, 2009, PSYCHOL SPORT EXERC, V10, P447, DOI 10.1016/j.psychsport.2009.01.005; Harwood CG, 2015, PSYCHOL SPORT EXERC, V16, P24, DOI 10.1016/j.psychsport.2014.03.001; Hausenblas HA, 1999, J SPORT EXERCISE PSY, V21, P230, DOI 10.1123/jsep.21.3.230; Hedstrom R, 2004, RES YOUTH SPORTS CRI; Helliker K, PROBLEM SPORTS PAREN; Hemond C, 2012, CAN MED ASSOC J, V184, P861, DOI 10.1503/cmaj.109-4167; Herron R.M., 2013, MEDIA IMPACT MENTAL; Hodge K, 2009, SPORT PSYCHOL, V23, P186, DOI 10.1123/tsp.23.2.186; Hoefer WR, 2001, AM J PREV MED, V21, P48, DOI 10.1016/S0749-3797(01)00314-2; Hohepa M, 2007, INT J BEHAV NUTR PHY, V4, DOI 10.1186/1479-5868-4-54; Holder MD, 2009, J HEALTH PSYCHOL, V14, P378, DOI 10.1177/1359105308101676; Hollander D. B., 1995, Journal of Sport Behavior, V18, P3; Holt NL, 2008, PSYCHOL SPORT EXERC, V9, P663, DOI 10.1016/j.psychsport.2007.08.001; Holt NL, 2008, INT STUD PHYS EDUC Y, P122; Howell A.J., 2013, RES APPL INTERVENTIO, P59, DOI [10.1007/978-94-007-6398-2_5, DOI 10.1007/978-94-007-6398-2_5]; Hyman M., 2012, MOST EXPENSIVE GAME; Institute of Medicine, 2013, SPORTS REL CONC YOUT; Janssen I, 2010, INT J BEHAV NUTR PHY, V7, DOI 10.1186/1479-5868-7-40; Jayanthi N., 2011, J MED SCI TENNIS, V16, P14; Jayanthi N, 2013, SPORTS HEALTH, V5, P251, DOI 10.1177/1941738112464626; Johnson JN, 2013, BRIT J SPORT MED, V47, P28, DOI 10.1136/bjsports-2012-091751; Johnson LSM, 2012, J SCHOOL HEALTH, V82, P180, DOI 10.1111/j.1746-1561.2011.00684.x; Johnson LSM, 2011, CAN MED ASSOC J, V183, P921, DOI 10.1503/cmaj.110282; Kaleth AS, 2010, J PHYS EDUC RECREAT, V81, P29, DOI 10.1080/07303084.2010.10598524; Kanters M. A., 2008, Journal of Sport Behavior, V31, P64; Kay T., 2000, European Physical Education Review, V6, P151, DOI 10.1177/1356336X000062004; Keegan R, 2010, J APPL SPORT PSYCHOL, V22, P87, DOI 10.1080/10413200903421267; Keyes CLM, 2005, J CONSULT CLIN PSYCH, V73, P539, DOI 10.1037/0022-006X.73.3.539; Keyes CLM., 2013, MENTAL WELL BEING IN, P3, DOI [10.1007/978-94-007-5195-8_1, DOI 10.1007/978-94-007-5195-8_1]; Keyes CLM, 2010, CORSINI ENCY PSYCHOL; Keyes CLM, 2006, AM J ORTHOPSYCHIAT, V76, P395, DOI 10.1037/0002-9432.76.3.395; King WJ, 2006, CAN MED ASSOC J, V175, P163, DOI 10.1503/cmaj.060620; Kirk D., 1997, EUR J PHYS ED, V20, P51, DOI DOI 10.1080/1740898970020105; Kutcher JS, 2013, BRIT J SPORT MED, V47, P299, DOI 10.1136/bjsports-2013-092257; Kwan M, 2014, ADDICT BEHAV, V39, P497, DOI 10.1016/j.addbeh.2013.11.006; Lally P, 2008, J APPL SPORT PSYCHOL, V20, P42, DOI 10.1080/10413200701788172; Lamers SMA, 2012, EUR J PSYCHOL ASSESS, V28, P290, DOI 10.1027/1015-5759/a000109; Lamers SMA, 2011, J CLIN PSYCHOL, V67, P99, DOI 10.1002/jclp.20741; Lauer L, 2010, J CLIN SPORT PSYCHOL, V4, P69, DOI 10.1123/jcsp.4.1.69; LaVoi N. M., 2012, SPORTS COACH REV, V1, P17, DOI DOI 10.1080/21640629.2012.695891; Lemon J., PARENT PARENT SPEND; Lindstrom Bremer K., 2012, J FAM THEOR REV, V4, P235, DOI [10.1111/j.1756-2589.2012.00129.x, DOI 10.1111/J.1756-2589.2012.00129.X]; Lisha NE, 2010, ADDICT BEHAV, V35, P399, DOI 10.1016/j.addbeh.2009.12.032; Lisha NE, 2014, J DRUG ISSUES, V44, P83, DOI 10.1177/0022042613491107; Lonsdale C, 2009, J SPORT SCI, V27, P785, DOI 10.1080/02640410902929366; Luke A, 2011, CLIN J SPORT MED, V21, P307, DOI 10.1097/JSM.0b013e3182218f71; MacDonald DJ, 2011, SPORT PSYCHOL, V25, P32, DOI 10.1123/tsp.25.1.32; MAFFULLI N, 1992, BRIT MED BULL, V48, P561, DOI 10.1093/oxfordjournals.bmb.a072563; Maffulli N, 2010, PHYSICIAN SPORTSMED, V38, P29, DOI 10.3810/psm.2010.06.1780; Malina RM, 2010, CURR SPORT MED REP, V9, P364, DOI 10.1249/JSR.0b013e3181fe3166; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Marsiglio W, 2000, J MARRIAGE FAM, V62, P1173, DOI 10.1111/j.1741-3737.2000.01173.x; Martens MP, 2006, J APPL SPORT PSYCHOL, V18, P136, DOI 10.1080/10413200600653758; Martinsen M, 2013, MED SCI SPORT EXER, V45, P1188, DOI 10.1249/MSS.0b013e318281a939; Maslach C, 2001, ANNU REV PSYCHOL, V52, P397, DOI 10.1146/annurev.psych.52.1.397; Maslach C., 1984, APPL SOC PSYCHOL, V5, P133; Mazer C., 2013, PARENTAL INVOLVEMENT; McArdle W., 2007, EXERCISE PHYSL ENERG, V7th; McCann S., 2005, OLYMP COACH, V1, P17; McCarthy PJ, 2008, PSYCHOL SPORT EXERC, V9, P142, DOI 10.1016/j.psychsport.2007.01.005; McIntosh AS, 2005, BRIT J SPORT MED, V39, P2, DOI 10.1136/bjsm.2004.016188; McLean JA, 2003, APPETITE, V40, P185, DOI 10.1016/S0195-6663(02)00125-3; McLeod TCV, 2011, J ATHL TRAINING, V46, P206, DOI 10.4085/1062-6050-46.2.206; Merglen A., 2013, ARCH DIS CHILD; Merkel DL, 2013, OPEN ACCESS J SPORTS, V4, P151, DOI 10.2147/OAJSM.S33556; Metzl JD, 2001, PEDIATRICS, V108, P421, DOI 10.1542/peds.108.2.421; Meyers D., HAPPY GIRL SAD GIRL; Moore MJ, 2005, J ADOLESCENT HEALTH, V36, P486, DOI 10.1016/j.jadohealth.2004.02.031; Mostafavifar AM, 2013, BRIT J SPORT MED, V47, P1060, DOI 10.1136/bjsports-2012-092005; Nattiv Aurelia, 2007, Med Sci Sports Exerc, V39, P1867; Nelson TF, 2011, CURR SPORT MED REP, V10, P360, DOI 10.1249/JSR.0b013e318237bf74; Newhouse-Bailey M.J., UNDERSTANDING IMPACT; Newton M, 2000, J SPORT SCI, V18, P275, DOI 10.1080/026404100365018; Nicholls J.G., 1989, LEARN INDIVID DIFFER, V1, P63, DOI DOI 10.1016/1041-6080(89)90010-1; NICHOLLS JG, 1984, PSYCHOL REV, V91, P328, DOI 10.1037/0033-295X.91.3.328; Norman L, 2012, INT REV SOCIOL SPORT, V47, P705, DOI 10.1177/1012690211420487; Ntoumanis N, 2012, DEV PSYCHOL, V48, P213, DOI 10.1037/a0024934; Ommundsen Y., 2014, HDB CHILD WELL BEING, P911; Paiement CA, 2007, RES Q EXERCISE SPORT, V78, pA84; Partridge J. A., 2008, ADV SPORT PSYCH, P269; Patel DR, 2003, J ADOLESCENT RES, V18, P280, DOI 10.1177/0743558403018003006; Paterno MV, 2013, ORTHOP CLIN N AM, V44, P553, DOI 10.1016/j.ocl.2013.06.009; Pelletier LG, 2001, MOTIV EMOTION, V25, P279, DOI 10.1023/A:1014805132406; Petersen I., 2013, ACTA PSYCHIAT SCAND, V15, P411; Petitpas AJ, 2005, SPORT PSYCHOL, V19, P63, DOI 10.1123/tsp.19.1.63; Pike A., 2009, CHILDHOOD, V79, P217; Popay J., 2006, MOVING EFFECTIVENESS; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Quested E, 2011, PSYCHOL SPORT EXERC, V12, P159, DOI 10.1016/j.psychsport.2010.09.003; Raedeke TD, 2001, J SPORT EXERCISE PSY, V23, P281, DOI 10.1123/jsep.23.4.281; Rajabali F., CONCUSSION CHILDREN; Raudsepp L, 2000, EUR J PHYS ED, V5, P169, DOI DOI 10.1080/1740898000050205; Ricciardelli LA, 2004, PSYCHOL BULL, V130, P179, DOI 10.1037/0033-2909.130.2.179; ROTELLA RJ, 1991, ELEM SCHOOL J, V91, P421, DOI 10.1086/461664; Russell W. D., 2013, Journal of Sport Behavior, V36, P82; Ryan J., 1995, LITTLE GIRLS PRETTY; Sallis JF, 1999, HEALTH PSYCHOL, V18, P410, DOI 10.1037/0278-6133.18.4.410; Sandle T., CONCUSSIONS YOUTH SP; Sanlier N, 2008, APPETITE, V51, P641, DOI 10.1016/j.appet.2008.05.058; Sarrazin P, 2002, EUR J SOC PSYCHOL, V32, P395, DOI 10.1002/ejsp.98; SCANLAN TK, 1993, J SPORT EXERCISE PSY, V15, P1, DOI 10.1123/jsep.15.1.1; Schaufeli WB, 2009, CAREER DEV INT, V14, P204, DOI 10.1108/13620430910966406; Schtscherbyna A, 2009, NUTRITION, V25, P634, DOI 10.1016/j.nut.2008.11.029; Scool and Sports, MUCH DO PAR REALL SP; Sebire SJ, 2009, J SPORT EXERCISE PSY, V31, P189, DOI 10.1123/jsep.31.2.189; Seligman MEP, 2005, AM PSYCHOL, V60, P410, DOI 10.1037/0003-066X.60.5.410; Seligman MEP, 2000, AM PSYCHOL, V55, P5, DOI 10.1037/0003-066X.55.1.5; Shearer C, 2012, CAN J PUBLIC HEALTH, V103, pS55, DOI 10.1007/BF03403836; Small EW, 2007, PEDIATRICS, V119, P1242, DOI 10.1542/peds.2007-0887; Smink FRE, 2012, CURR PSYCHIAT REP, V14, P406, DOI 10.1007/s11920-012-0282-y; Smith RE, 2007, J SPORT EXERCISE PSY, V29, P39, DOI 10.1123/jsep.29.1.39; Smoll F., 2002, CHILD YOUTH SPORT, V2, P211; Alvarez MS, 2012, J CLIN SPORT PSYCHOL, V6, P166, DOI 10.1123/jcsp.6.2.166; Sonderlund AL, 2014, J SCI MED SPORT, V17, P2, DOI 10.1016/j.jsams.2013.03.011; Statistics Canada, 2011, GEN SOC SURV 2010 OV; Stein CJ, 2014, SPINAL INJURIES COND, P47; Stoneman Z., 1982, FAMILY STRENGTHS, P113; STOP Sport Injuries, AB STOP SPORTS INJ; Strachan L, 2009, J APPL SPORT PSYCHOL, V21, P340, DOI 10.1080/10413200903018667; Sundgot-Borgen J, 2004, CLIN J SPORT MED, V14, P25, DOI 10.1097/00042752-200401000-00005; Sundgot-Borgen J, 2013, BRIT J SPORT MED, V47, P1012, DOI 10.1136/bjsports-2013-092966; Superville D., OBAMA DRAW ATTENTION; Surya M., 2012, PHENEX J, V4, P1; Taliaferro LA, 2010, J SCHOOL HEALTH, V80, P399, DOI 10.1111/j.1746-1561.2010.00520.x; Tenenbaum, 2007, HDB SPORT PSYCHOL, P184, DOI DOI 10.1002/9781118270011.CH8; Terry-McElrath YM, 2011, AM J PREV MED, V40, P530, DOI 10.1016/j.amepre.2010.12.021; Theisen D, 2013, J SCI MED SPORT, V16, P200, DOI 10.1016/j.jsams.2012.07.007; Thompson S.M., 1999, MOTHERS TAXI SPORT W; Thorsteinsdottir G, 2008, EUR J PSYCHIAT, V22, P107, DOI 10.4321/s0213-61632008000200007; Timperio AF, 2013, INT J BEHAV NUTR PHY, V10, DOI 10.1186/1479-5868-10-15; Tomlin D.L., 2013, J INT SOC SPORT NUTR, V10, DOI [10.1186/1550-2738-10-38, DOI 10.1186/1550-2738-10-38]; Townsend M., 2001, ACHPER Healthy Lifestyles Journal, V48, P10; Trussell D.E., 2009, ORG YOUTH SPORT PARE; Trussell DE, 2007, J LEISURE RES, V39, P366; Turocy P.S., 2011, J ATHL TRAINING, V46, P206; Ullrich-French S, 2009, PSYCHOL SPORT EXERC, V10, P87, DOI 10.1016/j.psychsport.2008.06.007; Vardar Erdal, 2007, Eat Behav, V8, P143, DOI 10.1016/j.eatbeh.2006.03.002; Venning A, 2013, AUST PSYCHOL, V48, P299, DOI 10.1111/j.1742-9544.2012.00068.x; Wall M., 2007, Physical Education and Sport Pedagogy, V12, P77, DOI 10.1080/17408980601060358; WANKEL LM, 1989, J SPORT EXERCISE PSY, V11, P355, DOI 10.1123/jsep.11.4.355; Warsh JM, 2009, CLIN J SPORT MED, V19, P134, DOI 10.1097/JSM.0b013e3181987783; Weiss MR, 2001, PEDIATR EXERC SCI, V13, P131, DOI 10.1123/pes.13.2.131; Weiss MR, 2005, RES Q EXERCISE SPORT, V76, P286; WEISS MR, 1995, PEDIATR EXERC SCI, V7, P36; Wichstrom T, 2009, ADDICTION, V104, P138, DOI 10.1111/j.1360-0443.2008.02422.x; Wiersma LD, 2000, PEDIATR EXERC SCI, V12, P13, DOI 10.1123/pes.12.1.13; Wiersma LD, 2008, J LEISURE RES, V40, P505; Wilson L.L., WEIGHTY MATTERS; Wolfenden LE, 2005, J APPL SPORT PSYCHOL, V17, P108, DOI 10.1080/10413200590932416; World Health Organization, NUTR AD ISS CHALL HL; Wuerth S, 2004, PSYCHOL SPORT EXERC, V5, P21, DOI 10.1016/S1469-0292(02)00047-X; Yard EE, 2006, J ATHL TRAINING, V41, P441; YIANNAKIS A, 1976, RES QUART, V47, P62, DOI 10.1080/10671315.1976.10615341	260	41	41	0	53	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND	1660-4601			INT J ENV RES PUB HE	Int. J. Environ. Res. Public Health	OCT	2014	11	10					10226	10268		10.3390/ijerph111010226			43	Environmental Sciences; Public, Environmental & Occupational Health	Environmental Sciences & Ecology; Public, Environmental & Occupational Health	AS6FA	WOS:000344358700019	25275889	DOAJ Gold, Green Published			2021-06-18	
J	Rodrigues, EM; Simon, D; Ikuta, N; Klovan, C; Dannebrock, FA; de Oliveira, CO; Regner, A				Rodrigues Filho, Edison Moraes; Simon, Daniel; Ikuta, Nilo; Klovan, Caroline; Dannebrock, Fernando Augusto; de Oliveira, Carla Oliveira; Regner, Andrea			Elevated Cell-Free Plasma DNA Level as an Independent Predictor of Mortality in Patients with Severe Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						biomarkers; outcome; plasma DNA; real-time PCR; traumatic brain injury	SEVERE HEAD-INJURY; SERUM S-100B PROTEIN; GLASGOW COMA SCALE; MATERNAL PLASMA; FETAL DNA; INTRACRANIAL-PRESSURE; PROGNOSTIC MARKER; MULTIPLE TRAUMA; CANCER-PATIENTS; CARDIAC-ARREST	Trauma is the leading cause of death in individuals less than 45 years old worldwide, and up to 50% of trauma fatalities are because of brain injury. Prediction of outcome is one of the major problems associated with severe traumatic brain injury (TBI), and research efforts have focused on the investigation of biomarkers with prognostic value after TBI. Therefore, our aim was to investigate whether cell-free DNA concentrations correlated to short-term primary outcome (survival or death) and Glasgow Coma Scale (GCS) scores after severe TBI. A total of 188 patients with severe TBI were enrolled in this prospective study; outcome variables comprised survival and neurological assessment using the GCS at intensive care unit (ICU) discharge. Control blood samples were obtained from 25 healthy volunteers. Peripheral venous blood was collected at admission to the ICU. Plasma DNA was measured using a real-time quantitative polymerase chain reaction (PCR) assay for the beta-globin gene. There was correlation between higher DNA levels and both fatal outcome and lower hospital admission GCS scores. Plasma DNA concentrations at the chosen cutoff point (>= 171,381 kilogenomes-equivalents/L) predicted mortality with a specificity of 90% and a sensitivity of 43%. Logistic regression analysis showed that elevated plasma DNA levels were independently associated with death (p < 0.001). In conclusion, high cell-free DNA concentration was a predictor of short-term mortality after severe TBI.	[Rodrigues Filho, Edison Moraes; Simon, Daniel; Ikuta, Nilo; de Oliveira, Carla Oliveira; Regner, Andrea] Univ Luterana Brasil, Lab Biomarcadores Trauma, Canoas, Brazil; [Simon, Daniel; Ikuta, Nilo; Regner, Andrea] Univ Luterana Brasil, Programa Posgrad Biol Celular & Mol Aplicada Saud, Canoas, Brazil; [Ikuta, Nilo] Simbios Biotecnol, Canoas, RS, Brazil; [Klovan, Caroline; Dannebrock, Fernando Augusto; Regner, Andrea] Univ Luterana Brasil, Curso Med, Canoas, Brazil	Regner, A (corresponding author), Univ Luterana Brasil, Ctr Pesquisa Ciencias Med, Ave Farroupilha,8001 Predio 22,5 Andar, BR-92425900 Canoas, RS, Brazil.	regner@uol.com.br	Regner, Andrea/M-2596-2014; Simon, Daniel/A-9087-2011	Regner, Andrea/0000-0002-6657-7991; Simon, Daniel/0000-0003-1122-8468; Dannebrock, Fernando Augusto/0000-0002-7640-8956	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ) [568691/2008-3]; Fundacao de Amparo a Pesquisa do Estado do Rio Grande do Sul (FAPERGS)Fundacao de Amparo a Ciencia e Tecnologia do Estado do Rio Grande do Sul (FAPERGS) [PPSUS 09/0041-5]	The present study received financial support from the Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq; research Grant 568691/2008-3) and Fundacao de Amparo a Pesquisa do Estado do Rio Grande do Sul (FAPERGS; research Grant PPSUS 09/0041-5).	Andriessen TMJC, 2011, J NEUROTRAUM, V28, P2019, DOI 10.1089/neu.2011.2034; Arnalich F, 2010, CRIT CARE, V14, DOI 10.1186/cc8934; Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; BOOM R, 1990, J CLIN MICROBIOL, V28, P495, DOI 10.1128/JCM.28.3.495-503.1990; Coplin WM, 2001, NEUROL RES, V23, P277, DOI 10.1179/016164101101198433; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Da Rocha AB, 2005, J NEUROTRAUM, V22, P966, DOI 10.1089/neu.2005.22.966; da Rocha AB, 2006, CLIN CHEM LAB MED, V44, P1234, DOI 10.1515/CCLM.2006.218; De Oliveira CO, 2007, J NEUROTRAUM, V24, P1331, DOI 10.1089/neu.2006.0159; Diringer MN, 1997, ARCH NEUROL-CHICAGO, V54, P606, DOI 10.1001/archneur.1997.00550170078017; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Gahan PB, 2008, ANN NY ACAD SCI, V1137, P7, DOI 10.1196/annals.1448.046; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hergenroeder GW, 2008, MOL DIAGN THER, V12, P345, DOI 10.2165/1250444-200812060-00002; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; HOLLAND PM, 1991, P NATL ACAD SCI USA, V88, P7276, DOI 10.1073/pnas.88.16.7276; Jahr S, 2001, CANCER RES, V61, P1659; Johnson PJ, 2002, CLIN CHEM, V48, P1186; Lam NYL, 2004, CLIN CHEM, V50, P213, DOI 10.1373/clinchem.2003.025783; Lam NYL, 2003, CLIN CHEM, V49, P1286, DOI 10.1373/49.8.1286; Lo YMD, 1998, LANCET, V351, P1329, DOI 10.1016/S0140-6736(05)79055-3; Lo YMD, 2000, CLIN CHEM, V46, P319; Lo YMD, 1999, AM J HUM GENET, V64, P218, DOI 10.1086/302205; Lo YMD, 1998, AM J HUM GENET, V62, P768, DOI 10.1086/301800; Lo YMD, 1997, LANCET, V350, P485, DOI 10.1016/S0140-6736(97)02174-0; Macher H, 2012, CLIN CHIM ACTA, V414, P12, DOI 10.1016/j.cca.2012.08.001; MANDEL P, 1948, C R Seances Soc Biol Fil, V142, P241; Mussack T, 2002, CRIT CARE MED, V30, P2669, DOI 10.1097/00003246-200212000-00010; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Pelinka LE, 2003, SHOCK, V19, P195, DOI 10.1097/00024382-200303000-00001; Petzold A, 2002, CRIT CARE MED, V30, P2705, DOI 10.1097/00003246-200212000-00015; Crespo ART, 2007, BRAIN INJURY, V21, P441, DOI 10.1080/02699050701311125; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Raabe A, 2003, RESTOR NEUROL NEUROS, V21, P159; Rainer TH, 2003, CLIN CHEM, V49, P562, DOI 10.1373/49.4.562; Rainer TH, 2006, CLIN CHIM ACTA, V368, P110, DOI 10.1016/j.cca.2005.12.021; Regner A, 2001, NEUROREPORT, V12, P691, DOI 10.1097/00001756-200103260-00015; Rhodes A, 2006, CRIT CARE, V10, DOI 10.1186/cc4894; Rodrigues E., 2008, BRAIN INJ S1, V22, P165; Saukkonen K, 2008, CLIN CHEM, V54, P1000, DOI 10.1373/clinchem.2007.101030; Savola O, 2004, J TRAUMA, V56, P1229, DOI 10.1097/01.TA.0000096644.08735.72; Soares FMS, 2012, NEUROIMMUNOMODULAT, V19, P377, DOI 10.1159/000342141; Svetlov SI, 2009, J NEUROTRAUM, V26, P913, DOI 10.1089/neu.2008.0609; TEASDALE G, 1974, LANCET, V2, P81; Toschlog EA, 2003, AM SURGEON, V69, P491; Townend WJ, 2002, J NEUROL NEUROSUR PS, V73, P542, DOI 10.1136/jnnp.73.5.542; van der Vaart M, 2008, ANN NY ACAD SCI, V1137, P18, DOI 10.1196/annals.1448.022; van Leeuwen N, 2012, NEUROSURGERY, V70, P811, DOI 10.1227/NEU.0b013e318235d640; Wang BG, 2003, CANCER RES, V63, P3966; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026; Yurgel VC, 2007, J NEUROTRAUM, V24, P1172, DOI 10.1089/neu.2006.0160; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P364, DOI 10.1097/00002060-199609000-00012; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	55	41	42	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT 1	2014	31	19					1639	1646		10.1089/neu.2013.3178			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AP5VI	WOS:000342146400006	24827371	Green Published			2021-06-18	
J	Quintard, H; Lorivel, T; Gandin, C; Lazdunski, M; Heurteaux, C				Quintard, H.; Lorivel, T.; Gandin, C.; Lazdunski, M.; Heurteaux, C.			MLC901, A TRADITIONAL CHINESE MEDICINE INDUCES NEUROPROTECTIVE AND NEUROREGENERATIVE BENEFITS AFTER TRAUMATIC BRAIN INJURY IN RATS	NEUROSCIENCE			English	Article						NeuroAid; traumatic brain injury; neurogenesis; cognitive deficits; aquaporins; VEGF	EPISODIC-LIKE MEMORY; NEUROAID EFFICACY; STROKE RECOVERY; TEMPORAL-ORDER; DOUBLE-BLIND; MLC601 NEUROAID(R); CELLULAR EDEMA; RECOGNITION; MODERATE; DAMAGE	Traumatic brain injury (TBI) is a frequent and clinically highly heterogeneous neurological disorder with large socioeconomic consequences. NeuroAid (MLC601 and MLC901), a Traditional Medicine used in China for patients after stroke has been previously reported to induce neuroprotection and neuroplasticity. This study was designed to evaluate the neuroprotective and neuroregenerative effects of MLC901 in a rat model of TBI. TBI was induced by a moderate lateral fluid percussion applied to the right parietal cortex. MLC901 was injected intraperitoneally at 2 h post-TBI, and then administered in drinking water at a concentration of 10 mg/ml until sacrifice of the animals. The cognitive deficits induced by TBI were followed by using the "what-where-when'' task, which allows the measurement of episodic-like memory. MLC901 treatment decreased brain lesions induced by TBI. It prevented the serum increase of S-100 beta (S100B) and neuron-specific enolase (NSE), which may be markers to predict the neurologic outcome in human patients with TBI. MLC901 reduced the infarct volume when injected up to 2 h post-TBI, prevented edema formation and assisted its resolution, probably via the regulation of aquaporin 4. These positive MLC901 effects were associated with an upregulation of vascular endothelial growth factor (VEGF) as well as an increase of endogenous hippocampal neurogenesis and gliogenesis around the lesion. Furthermore, MLC901 reduced cognitive deficits induced by TBI. Rats subjected to TBI displayed a suppression of temporal order memory, which was restored by MLC901. This work provides evidence that MLC901 has neuroprotective and neurorestorative actions, which lead to an improvement in the recovery of cognitive functions in a model of traumatic brain injury. (C) 2014 The Authors. Published by Elsevier Ltd. on behalf of IBRO. This is an open access article under the CC BY-NC-ND license.	[Quintard, H.; Lorivel, T.; Gandin, C.; Lazdunski, M.; Heurteaux, C.] Univ Nice Sophia Antipolis, CNRS, Inst Pharmacol Mol & Cellulaire, F-06560 Valbonne, France; [Quintard, H.] CHU Nice, Hop St Roch, F-06000 Nice, France	Heurteaux, C (corresponding author), Univ Nice Sophia Antipolis, CNRS, Inst Pharmacol Mol & Cellulaire, 660 Route Lucioles, F-06560 Valbonne, France.	heurteau@ipmc.cnrs.fr	HEURTEAUX, Catherine/M-4947-2016	HEURTEAUX, Catherine/0000-0002-9741-9777	Centre National de la Recherche Scientifique (CNRS)Centre National de la Recherche Scientifique (CNRS); CNRS/CHU NiceCentre National de la Recherche Scientifique (CNRS)	The authors are very grateful to D. Picard (Moleac Singapore) for discussions concerning the program and the follow-up of the clinical effects of MLC601 and for providing MLC901 capsules. They are grateful to P. Ferrari for NSE and S100B dosing in the Biochemistry department of the Nice University Hospital (CHU). We are grateful to Dr A. Patel for carefully reading the manuscript. This work is supported by the Centre National de la Recherche Scientifique (CNRS). HQ is very grateful for the financial support of CNRS/CHU Nice.	Andriessen TMJC, 2010, J CELL MOL MED, V14, P2381, DOI 10.1111/j.1582-4934.2010.01164.x; Arenth PM, 2012, J CLIN EXP NEUROPSYC, V34, P333, DOI 10.1080/13803395.2011.633896; Badaut J, 2011, CEREBROVASC DIS, V31, P521, DOI 10.1159/000324328; Barbosa FF, 2010, BEHAV BRAIN RES, V215, P326, DOI 10.1016/j.bbr.2009.11.028; Barker GRI, 2011, J NEUROSCI, V31, P10721, DOI 10.1523/JNEUROSCI.6413-10.2011; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Berger RP, 2006, PEDIATRICS, V117, P325, DOI 10.1542/peds.2005-0711; Bittner S, 2009, BRAIN, V132, P2501, DOI 10.1093/brain/awp163; Bloomfield SM, 2007, NEUROCRIT CARE, V6, P121, DOI 10.1007/s12028-007-0008-x; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Chen C, 2009, STROKE, V40, P859, DOI 10.1161/STROKEAHA.108.531616; Chen CLH, 2013, STROKE, V44, P3580, DOI 10.1161/STROKEAHA.113.003226; Chen CLH, 2013, STROKE, V44, P2093, DOI 10.1161/STROKEAHA.113.002055; Chen XR, 2008, J PHARMACOL EXP THER, V326, P966, DOI 10.1124/jpet.108.140368; Chopp M, 2009, STROKE, V40, pS143, DOI 10.1161/STROKEAHA.108.533141; Conte V., 2003, EUR J TRAUMA, V29, P335; Davis AR, 2010, J NEUROSCI METH, V189, P84, DOI 10.1016/j.jneumeth.2010.03.012; Dere E, 2005, NEUROBIOL LEARN MEM, V84, P214, DOI 10.1016/j.nlm.2005.07.002; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Du AL, 2013, CHINESE MED J-PEKING, V126, P2934, DOI 10.3760/cma.j.issn.0366-6999.20121193; Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027; Fukuda AM, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-279; Gan R, 2008, CEREBROVASC DIS, V25, P450, DOI 10.1159/000126919; Garthe A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005464; Giacoppo S, 2012, NEUROCRIT CARE, V16, P470, DOI 10.1007/s12028-012-9707-z; Greenberg DA, 2005, NATURE, V438, P954, DOI 10.1038/nature04481; Gurkoff GG, 2013, J NEUROTRAUM, V30, P292, DOI 10.1089/neu.2012.2463; Harandi AA, 2011, STROKE RES TREAT, V2011, DOI 10.4061/2011/721613; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Heurteaux C, 2006, NEUROSCIENCE, V137, P241, DOI 10.1016/j.neuroscience.2005.08.083; Heurteaux C, 2013, CEREBROVASC DIS, V35, P1, DOI 10.1159/000346228; Heurteaux C, 2010, NEUROPHARMACOLOGY, V58, P987, DOI 10.1016/j.neuropharm.2010.01.001; Howland JG, 2008, HIPPOCAMPUS, V18, P251, DOI 10.1002/hipo.20396; JOHNSON GVW, 1992, J NEUROSCI RES, V33, P505, DOI 10.1002/jnr.490330402; Kart-Teke E, 2006, NEUROBIOL LEARN MEM, V85, P173, DOI 10.1016/j.nlm.2005.10.002; Ke CS, 2001, NEUROSCI LETT, V301, P21, DOI 10.1016/S0304-3940(01)01589-0; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Khaksari M, 2013, IRAN J BASIC MED SCI, V16, P858; Kovesdi E, 2010, ACTA NEUROCHIR, V152, P1, DOI 10.1007/s00701-009-0463-6; Kong KH, 2009, CEREBROVASC DIS, V28, P514, DOI 10.1159/000247001; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Maati HMO, 2012, NEUROPHARMACOLOGY, V63, P692, DOI 10.1016/j.neuropharm.2012.05.035; Marmarou A, 2006, J NEUROSURG, V104, P720, DOI 10.3171/jns.2006.104.5.720; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Murphy TH, 2009, NAT REV NEUROSCI, V10, P861, DOI 10.1038/nrn2735; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; Navarro JC, 2014, SESS AC STROK NEW TR; Navarro JC, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/506387; Ozawa T, 2014, BEHAV BRAIN RES, V263, P210, DOI 10.1016/j.bbr.2014.01.034; Quintard H, 2011, NEUROPHARMACOLOGY, V61, P622, DOI 10.1016/j.neuropharm.2011.05.003; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; Richardson RM, 2010, J NEUROSURG, V112, P1125, DOI 10.3171/2009.4.JNS081087; Ross SA, 1996, BRIT J NEUROSURG, V10, P471, DOI 10.1080/02688699647104; Rothermundt M, 2003, MICROSC RES TECHNIQ, V60, P614, DOI 10.1002/jemt.10303; Ruttan L, 2008, ARCH PHYS MED REHAB, V89, pS69, DOI 10.1016/j.apmr.2008.07.007; Sahay A, 2011, NATURE, V472, P466, DOI 10.1038/nature09817; Schmitter-Edgecombe M, 2012, J CLIN EXP NEUROPSYC, V34, P256, DOI 10.1080/13803395.2011.633497; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schoch KM, 2012, NEUROTHERAPEUTICS, V9, P323, DOI 10.1007/s13311-012-0107-z; Shahripour RB, 2011, EUR J INTERN MED, V22, P509, DOI 10.1016/j.ejim.2011.01.002; Shenaq M, 2012, J NEUROL SCI, V323, P134, DOI 10.1016/j.jns.2012.08.036; Siddiqui FJ, 2013, CEREBROVASC DIS, V35, P8, DOI 10.1159/000346231; Siow CHC, 2008, EUR NEUROL, V60, P264, DOI 10.1159/000155220; Sun D, 2007, EXP NEUROL, V204, P264, DOI 10.1016/j.expneurol.2006.11.005; Taniguchi M, 2000, MOL BRAIN RES, V78, P131, DOI 10.1016/S0169-328X(00)00084-X; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Tulving E, 2001, PHILOS T R SOC B, V356, P1505, DOI 10.1098/rstb.2001.0937; Venketasubramanian N, 2009, INT J STROKE, V4, P54, DOI 10.1111/j.1747-4949.2009.00237.x; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Wang L, 2008, P NATL ACAD SCI USA, V105, P4826, DOI 10.1073/pnas.0712365105; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026; Xiong Y, 2009, EXPERT OPIN EMERG DR, V14, P67, DOI [10.1517/14728210902769601, 10.1517/14728210902769601 ]; Young SHY, 2010, CEREBROVASC DIS, V30, P1, DOI 10.1159/000313398	76	41	42	0	14	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	SEP 26	2014	277						72	86		10.1016/j.neuroscience.2014.06.047			15	Neurosciences	Neurosciences & Neurology	AO6VA	WOS:000341488700008	24993477	Other Gold			2021-06-18	
J	Macauley, SL; Wong, AMS; Shyng, C; Augner, DP; Dearborn, JT; Pearse, Y; Roberts, MS; Fowler, SC; Cooper, JD; Watterson, DM; Sands, MS				Macauley, Shannon L.; Wong, Andrew M. S.; Shyng, Charles; Augner, David P.; Dearborn, Joshua T.; Pearse, Yewande; Roberts, Marie S.; Fowler, Stephen C.; Cooper, Jonathan D.; Watterson, D. Martin; Sands, Mark S.			An Anti-Neuroinflammatory That Targets Dysregulated Glia Enhances the Efficacy of CNS-Directed Gene Therapy in Murine Infantile Neuronal Ceroid Lipofuscinosis	JOURNAL OF NEUROSCIENCE			English	Article						Batten disease; lysosomal storage disease; neurodegeneration; neuroinflammation; neuronal ceroid lipofuscinosis	ATTENUATES SYNAPTIC DYSFUNCTION; BONE-MARROW-TRANSPLANTATION; CYTOKINE UP-REGULATION; MOUSE MODEL; BRAIN; DISEASE; ACTIVATION; PATHOLOGY; SURVIVAL; SEIZURES	Infantile neuronal ceroid lipofuscinosis (INCL) is an inherited neurodegenerative lysosomal storage disease (LSD) caused by a deficiency in palmitoyl protein thioesterase-1 (PPT1). Studies in Ppt1(-/-) mice demonstrate that glial activation is central to the pathogenesis of INCL. Astrocyte activation precedes neuronal loss, while cytokine upregulation associated with microglial reactivity occurs before and concurrent with neurodegeneration. Therefore, we hypothesized that cytokine cascades associated with neuroinflammation are important therapeutic targets for the treatment of INCL. MW01-2-151SRM (MW151) is a blood-brain barrier penetrant, small-molecule anti-neuroinflammatory that attenuates glial cytokine upregulation in models of neuroinflammation such as traumatic brain injury, Alzheimer's disease, and kainic acid toxicity. Thus, we used MW151, alone and in combination with CNS-directed, AAV-mediated gene therapy, as a possible treatment for INCL. MW151 alone decreased seizure susceptibility. When combined with AAV-mediated gene therapy, treated INCL mice had increased life spans, improved motor performance, and eradication of seizures. Combination-treated INCL mice also had decreased brain atrophy, astrocytosis, and microglial activation, as well as intermediary effects on cytokine upregulation. These data suggest that MW151 can attenuate seizure susceptibility but is most effective when used in conjunction with a therapy that targets the primary genetic defect.	[Macauley, Shannon L.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; [Macauley, Shannon L.; Shyng, Charles; Dearborn, Joshua T.; Roberts, Marie S.; Sands, Mark S.] Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA; [Sands, Mark S.] Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA; [Fowler, Stephen C.] Univ Kansas, Dept Pharmacol, Lawrence, KS 66045 USA; [Fowler, Stephen C.] Univ Kansas, Dept Toxicol, Lawrence, KS 66045 USA; [Wong, Andrew M. S.; Augner, David P.; Pearse, Yewande; Cooper, Jonathan D.] Kings Coll London, Inst Psychiat, MRC Ctr Neurodegenerat Res, Dept Neurosci,Ctr Cellular Basis Behav, London SE5 9NU, England; [Watterson, D. Martin] Northwestern Univ, Feinberg Sch Med, Dept Pharmacol, Chicago, IL 60611 USA	Sands, MS (corresponding author), Washington Univ, Sch Med, Dept Internal Med, Campus Box 8007,660 South Euclid Ave, St Louis, MO 63110 USA.	msands@dom.wustl.edu	Shyng, Charles/P-3197-2016; Shyng, Charles/K-6224-2014; Cooper, Jonathan/V-9962-2019	Shyng, Charles/0000-0001-6451-2847; Shyng, Charles/0000-0001-6451-2847; Cooper, Jonathan/0000-0003-1339-4750; Sands, Mark/0000-0002-5559-0832; Macauley, Shannon/0000-0002-4292-2703; Dearborn, Joshua/0000-0003-0335-1087	BDSRA postdoctoral research fellowship;  [NS043205];  [NS056728];  [R01NS056051];  [HD002528]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS043205] Funding Source: NIH RePORTER	This work was supported by the following grants: NS043205 (M.S.S.), NS056728 (S.L.M.), R01NS056051 (D.M.W.), HD002528 (S.C.F.), and a BDSRA postdoctoral research fellowship (S.L.M.).	Bachstetter AD, 2012, J NEUROSCI, V32, P10201, DOI 10.1523/JNEUROSCI.1496-12.2012; Chang M, 2008, MOL THER, V16, P649, DOI 10.1038/mt.2008.9; Chen YH, 2009, NAT MED, V15, P1215, DOI 10.1038/nm.2025; Chrzaszcz M, 2010, J NEUROTRAUM, V27, P1283, DOI 10.1089/neu.2009.1227; Glover LE, 2012, TRANSL STROKE RES, V3, P90, DOI 10.1007/s12975-011-0127-8; Griffey M, 2004, NEUROBIOL DIS, V16, P360, DOI 10.1016/j.nbd.2004.03.005; Griffey MA, 2006, MOL THER, V13, P538, DOI 10.1016/j.ymthe.2005.11.008; Groh J, 2013, BRAIN, V136, P1083, DOI 10.1093/brain/awt020; Gupta P, 2001, P NATL ACAD SCI USA, V98, P13566, DOI 10.1073/pnas.251485198; Hofmann SL, 1999, MOL GENET METAB, V66, P234, DOI 10.1006/mgme.1999.2803; Hu J, 2012, MOL GENET METAB, V107, P213, DOI 10.1016/j.ymgme.2012.05.009; Hu WH, 2007, BIOORG MED CHEM LETT, V17, P414, DOI 10.1016/j.bmcl.2006.10.028; Karpus WJ, 2008, J NEUROIMMUNOL, V203, P73, DOI 10.1016/j.jneuroim.2008.06.039; Kielar C, 2007, NEUROBIOL DIS, V25, P150, DOI 10.1016/j.nbd.2006.09.001; Kielar C, 2009, HUM MOL GENET, V18, P4066, DOI 10.1093/hmg/ddp355; Macauley SL, 2012, ANN NEUROL, V71, P797, DOI 10.1002/ana.23545; Macauley SL, 2011, J NEUROSCI, V31, P15575, DOI 10.1523/JNEUROSCI.3579-11.2011; Macauley SL, 2009, EXP NEUROL, V217, P124, DOI 10.1016/j.expneurol.2009.01.022; Oswald MJ, 2005, NEUROBIOL DIS, V20, P49, DOI 10.1016/j.nbd.2005.01.025; Qiao X, 2007, BMC NEUROSCI, V8, DOI 10.1186/1471-2202-8-95; Reddy AS, 2011, J NEUROSCI, V31, P9945, DOI 10.1523/JNEUROSCI.1802-11.2011; Roberts MS, 2012, J INHERIT METAB DIS, V35, P847, DOI 10.1007/s10545-011-9446-x; Somera-Molina KC, 2007, EPILEPSIA, V48, P1785, DOI 10.1111/j.1528-1167.2007.01135.x; VESA J, 1995, NATURE, V376, P584, DOI 10.1038/376584a0; Weimer JM, 2009, BRAIN RES, V1266, P93, DOI 10.1016/j.brainres.2009.02.009	25	41	41	0	8	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	SEP 24	2014	34	39					13077	13082		10.1523/JNEUROSCI.2518-14.2014			6	Neurosciences	Neurosciences & Neurology	AQ9CR	WOS:000343140000013	25253854	Green Published, Bronze			2021-06-18	
J	Bourgeois, FT; Monuteaux, MC; Stack, AM; Neuman, MI				Bourgeois, Florence T.; Monuteaux, Michael C.; Stack, Anne M.; Neuman, Mark I.			Variation in Emergency Department Admission Rates in US Children's Hospitals	PEDIATRICS			English	Article						hospitalization rates; variation in care; emergency department	GEOGRAPHIC VARIATIONS; REGIONAL-VARIATIONS; MANAGEMENT; CARE; OUTCOMES; TRENDS	OBJECTIVE: To measure the hospital-level variation in admission rates for children receiving treatment of common pediatric illnesses across emergency departments (EDs) in US children's hospitals. METHODS: We performed a multi-center cross sectional study of children presenting to the EDs of 35 pediatric tertiary-care hospitals participating in the Pediatric Health Information System (PHIS). Admission rates were calculated for visits occurring between January 1, 2009, and December 31, 2012, associated with 1 of 7 common conditions, and corrected to adjust for hospital-level severity of illness. Conditions were selected systematically based on frequency of visits and admission rates. RESULTS: A total of 1 288 706 ED encounters (13.8% of all encounters) were associated with 1 of the 7 conditions of interest. After adjusting for hospital-level severity, the greatest variation in admission rates was observed for concussion (range 5%-72%), followed by pneumonia (19%-69%), and bronchiolitis (19%-65%). The least variation was found among patients presenting with seizures (7%-37%) and kidney and urinary tract infections (6%-37%). Although variability existed in disease-specific admission rates, certain hospitals had consistently higher, and others consistently lower, admission rates. CONCLUSIONS: We observed greater than threefold variation in severity-adjusted admission rates for common pediatric conditions across US children's hospitals. Although local practices and hospital-level factors may partly explain this variation, our findings highlight the need for greater focus on the standardization of decisions regarding admission.	[Bourgeois, Florence T.] Childrens Hosp Boston, Div Emergency Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA USA	Bourgeois, FT (corresponding author), Childrens Hosp Boston, Div Emergency Med, 300 Longwood Ave, Boston, MA 02115 USA.	florence.bourgeois@childrens.harvard.edu	Bourgeois, Florence/H-6710-2016; Monuteaux, Michael C/O-5032-2018	Bourgeois, Florence/0000-0001-7798-4560; 	National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [1R21HD072382]; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R21HD072382] Funding Source: NIH RePORTER	Dr. Bourgeois was supported by a grant from the National Institute of Child Health and Human Development (1R21HD072382), National Institutes of Health. Funded by the National Institutes of Health (NIH).	Abualenain J, 2013, ANN EMERG MED, V61, P638, DOI 10.1016/j.annemergmed.2013.01.016; Alessandrini EA, 2012, ACAD EMERG MED, V19, P70, DOI 10.1111/j.1553-2712.2011.01250.x; Ashton CM, 1999, NEW ENGL J MED, V340, P32, DOI 10.1056/NEJM199901073400106; Averill R., 2003, WHAT ARE APR DRGS IN; Child Health Corporation of America, 2014, CHILD HLTH CORP AM B; Conway PH, 2009, J PEDIATR-US, V154, P789, DOI 10.1016/j.jpeds.2009.01.010; Feudtner C, 2001, PEDIATRICS, V107, DOI 10.1542/peds.107.6.e99; Fisher ES, 2003, ANN INTERN MED, V138, P288, DOI 10.7326/0003-4819-138-4-200302180-00007; Fisher ES, 2003, ANN INTERN MED, V138, P273, DOI 10.7326/0003-4819-138-4-200302180-00006; Florin TA, 2013, PEDIATRICS, V132, P237, DOI 10.1542/peds.2013-0179; Freedman SB, 2011, PEDIATRICS, V127, pE287, DOI 10.1542/peds.2010-2214; Hampers LC, 2000, ACAD EMERG MED, V7, P21, DOI 10.1111/j.1553-2712.2000.tb01886.x; Jain S, 2014, PEDIATRICS, V133, P187, DOI 10.1542/peds.2013-1820; Katz DA, 2005, ANN EMERG MED, V46, P525, DOI 10.1016/j.annemergmed.2005.04.016; Kharbanda AB, 2013, J PEDIATR-US, V163, P230, DOI 10.1016/j.jpeds.2012.12.013; Knapp JF, 2010, PEDIATR EMERG CARE, V26, P364, DOI 10.1097/PEC.0b013e3181db2262; Lu S, 2012, ACAD PEDIATR, V12, P436, DOI 10.1016/j.acap.2012.06.006; Macy ML, 2012, J HOSP MED, V7, P530, DOI 10.1002/jhm.1923; Macy ML, 2012, J HOSP MED, V7, P287, DOI 10.1002/jhm.949; Mannix R, 2013, ANN EMERG MED, V62, P327, DOI 10.1016/j.annemergmed.2013.02.027; Neuman MI, 2012, PEDIATRICS, V130, P823, DOI 10.1542/peds.2012-1285; Nigrovic LE, 2013, PEDIATRICS, V131, P670, DOI 10.1542/peds.2012-3077; O'Cathain A, 2014, BMJ QUAL SAF, V23, P47, DOI 10.1136/bmjqs-2013-002003; PEARSON SD, 1995, J GEN INTERN MED, V10, P557, DOI 10.1007/BF02640365; Pines JM, 2013, MED CARE RES REV, V70, P218, DOI 10.1177/1077558712470565; Pines JM, 2009, AM J EMERG MED, V27, P552, DOI 10.1016/j.ajem.2008.04.031; Sabbatini AK, 2013, ACAD EMERG MED S1, V20, pS183; Sheridan DC, 2013, J PEDIATR-US, V163, P1634, DOI 10.1016/j.jpeds.2013.07.006; Tieder JS, 2009, PEDIATRICS, V124, pE1081, DOI 10.1542/peds.2009-0473; Todd J, 2002, ARCH PEDIAT ADOL MED, V156, P1086, DOI 10.1001/archpedi.156.11.1086; Wennberg JE, 1999, NEW ENGL J MED, V340, P52, DOI 10.1056/NEJM199901073400111; Wennberg JE, 2002, BRIT MED J, V325, P961, DOI 10.1136/bmj.325.7370.961; Wennberg John E, 2004, Manag Care, V13, P3; Wood JN, 2012, PEDIATRICS, V130, P853, DOI 10.1542/peds.2012-0244	34	41	41	0	3	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	SEP	2014	134	3					539	545		10.1542/peds.2014-1278			7	Pediatrics	Pediatrics	AO5DN	WOS:000341362600055	25113291	Green Published			2021-06-18	
J	McDonald, S; Gowland, A; Randall, R; Fisher, A; Osborne-Crowley, K; Honan, C				McDonald, Skye; Gowland, Alison; Randall, Rebekah; Fisher, Alana; Osborne-Crowley, Katie; Honan, Cynthia			Cognitive Factors Underpinning Poor Expressive Communication Skills After Traumatic Brain Injury: Theory of Mind or Executive Function?	NEUROPSYCHOLOGY			English	Article						traumatic brain injury; communication; theory of mind; executive function	CLOSED-HEAD-INJURY; PRAGMATIC LANGUAGE-SKILLS; MEDIAL PREFRONTAL CORTEX; SOCIAL COGNITION; FOLLOW-UP; EMOTION RECOGNITION; PERSPECTIVE-TAKING; VERBAL IMPAIRMENT; ECOLOGICAL VALIDITY; CLINICAL TOOL	Objective: The ability to see things from another's perspective, that is, have a theory of mind (ToM), is essential to effective communication. So too is the ability to regulate verbal output, that is, to exercise executive control. People with traumatic brain injuries (TBIs) have impaired communication abilities, but the extent to which this reflects ToM versus executive dysfunction is unclear. This study explored the relative contributions of executive abilities, specifically flexibility and inhibition and ToM abilities in language production post-TBI. Method: Twenty-five adults (18 males: mean age of 48.2 years, SD = 12.0 years) with moderate to severe TBI (posttraumatic amnesia = 69.2, SD = 54.6 days) and 28 noninjured adults (19 males: mean age 49.0, SD = 12.2 years) completed three sets of communication tasks with low executive demands, high flexibility, and high inhibition demands. Within each, parallel versions had low or high ToM requirements. Results: For low executive and high flexibility tasks, scores on the high ToM versions were predicted by scores on the low ToM versions, suggesting that poor performance was explained by the executive demands the parallel tasks had in common. The exception was the high inhibition task. In this case, speakers with TBI had differential difficulty with the high ToM version, that is, they had specific difficulty inhibiting self-referential thoughts in order to cater for another's perspective. Conclusion: We found problems with inhibiting the self-perspective accords with descriptive accounts of the egocentric nature of some communication patterns following TBI, which points to potential targets for remediation.	[McDonald, Skye; Gowland, Alison; Randall, Rebekah; Fisher, Alana; Osborne-Crowley, Katie; Honan, Cynthia] Univ New S Wales, Sch Psychol, Kensington Campus, Sydney, NSW 2052, Australia; [McDonald, Skye; Fisher, Alana; Osborne-Crowley, Katie; Honan, Cynthia] Moving Ahead Ctr Res Excellence Brain Recovery, Sydney, NSW, Australia	McDonald, S (corresponding author), Univ New S Wales, Sch Psychol, Kensington Campus, Sydney, NSW 2052, Australia.	s.mcdonald@unsw.edu.au	McDonald, Skye/G-4118-2014; Fisher, Alana/T-1869-2019; Honan, Cynthia/O-6332-2017	McDonald, Skye/0000-0003-0723-6094; Osborne-Crowley, Katherine/0000-0003-0295-1849; Fisher, Alana/0000-0002-6027-659X; Gowland, Alison/0000-0002-6578-4112; Honan, Cynthia/0000-0001-5735-4270	Australian Research CouncilAustralian Research Council	This study was supported by a research grant from the Australian Research Council. We thank all the people with traumatic brain injuries and community controls who willingly donated their time to participate in this research. The authors have no competing or conflicts of interest to report.	Bara BG, 2001, BRAIN LANG, V77, P72, DOI 10.1006/brln.2000.2430; Baron-Cohen S, 2001, J CHILD PSYCHOL PSYC, V42, P241, DOI 10.1017/S0021963001006643; BARONCOHEN S, 1985, COGNITION, V21, P37, DOI 10.1016/0010-0277(85)90022-8; Benton A., 1994, MULTILINGUAL APHASIA; Bibby H, 2005, NEUROPSYCHOLOGIA, V43, P99, DOI 10.1016/j.neuropsychologia.2004.04.027; Bigler ED, 2007, NEUROPSYCHOLOGY, V21, P515, DOI 10.1037/0894-4105.21.5.515; Bigler ED, 2011, NEUROREHABILITATION, V28, P63, DOI 10.3233/NRE-2011-0633; Body R, 2005, CLIN LINGUIST PHONET, V19, P379, DOI 10.1080/02699200400027189; Body R, 1998, BRAIN INJURY, V12, P963, DOI 10.1080/026990598122016; Bond F, 1997, BRAIN INJURY, V11, P319, DOI 10.1080/026990597123476; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; Brookshire BL, 2000, J INT NEUROPSYCH SOC, V6, P741, DOI 10.1017/S1355617700677019; Channon Shelley, 2003, Cogn Neuropsychiatry, V8, P243, DOI 10.1080/135468000344000002; Channon S, 2010, NEUROPSYCHOL REHABIL, V20, P739, DOI 10.1080/09602011003794583; Cicerone KD, 1997, ARCH CLIN NEUROPSYCH, V12, P173, DOI 10.1016/S0887-6177(96)00022-4; Collette F, 2001, NEUROIMAGE, V14, P258, DOI 10.1006/nimg.2001.0846; CROSSON B, 1987, CLIN NEUROPSYCHOL, V1, P335, DOI DOI 10.1080/13854048708520069; D'Argembeau A, 2007, J COGNITIVE NEUROSCI, V19, P935, DOI 10.1162/jocn.2007.19.6.935; Davis GA, 2004, BRAIN LANG, V89, P508, DOI 10.1016/j.bandl.2004.01.003; Davis M.H, 1980, J PERS SOC PSYCHOL, V10, P85; de Sousa A, 2010, NEUROPSYCHOLOGIA, V48, P3585, DOI 10.1016/j.neuropsychologia.2010.08.008; Decety Jean, 2004, Behav Cogn Neurosci Rev, V3, P71, DOI 10.1177/1534582304267187; Dennis M, 2009, J CLIN EXP NEUROPSYC, V31, P835, DOI 10.1080/13803390802572419; ELSASS L, 1987, PSYCHOL MED, V17, P67, DOI 10.1017/S003329170001299X; FLANAGAN S, 1995, BRAIN INJURY, V9, P321, DOI 10.3109/02699059509005773; Galski T, 1998, BRAIN INJURY, V12, P769, DOI 10.1080/026990598122160; Geraci A, 2010, BRAIN INJURY, V24, P978, DOI 10.3109/02699052.2010.487477; GODFREY H P D, 1991, Brain Injury, V5, P207, DOI 10.3109/02699059109008091; HAPPE FGE, 1993, COGNITION, V48, P101, DOI 10.1016/0010-0277(93)90026-R; HARTLEY L L, 1991, Brain Injury, V5, P267, DOI 10.3109/02699059109008097; Havet-Thomassin V, 2006, BRAIN INJURY, V20, P83, DOI 10.1080/02699050500340655; HEILMAN KM, 1971, J NEUROL NEUROSUR PS, V34, P265, DOI 10.1136/jnnp.34.3.265; Henry JD, 2006, NEUROPSYCHOLOGIA, V44, P1623, DOI 10.1016/j.neuropsychologia.2006.03.020; Hynes CA, 2011, SOC NEUROSCI-UK, V6, P599, DOI 10.1080/17470919.2011.584447; Kendall E, 1997, J HEAD TRAUMA REHAB, V12, P68, DOI 10.1097/00001199-199706000-00007; KINSELLA G, 1991, J NEUROL NEUROSUR PS, V54, P422, DOI 10.1136/jnnp.54.5.422; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LEVIN HS, 1976, J NEUROL NEUROSUR PS, V39, P1062, DOI 10.1136/jnnp.39.11.1062; LOVIBOND PF, 1995, BEHAV RES THER, V33, P335, DOI 10.1016/0005-7967(94)00075-U; Marini A, 2011, NEUROPSYCHOLOGIA, V49, P2904, DOI 10.1016/j.neuropsychologia.2011.06.017; Marsh NV, 1991, NEUROPSYCHOLOGY, V5, P107, DOI 10.1037/0894-4105.5.2.107; Martin I, 2005, APHASIOLOGY, V19, P712, DOI 10.1080/02687030500172203; Mathias JL, 2007, BRIT J CLIN PSYCHOL, V46, P457, DOI 10.1348/014466507X190197; McDonald S, 1998, BRAIN LANG, V61, P88, DOI 10.1006/brln.1997.1846; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; McDonald S, 2003, J HEAD TRAUMA REHAB, V18, P219, DOI 10.1097/00001199-200305000-00001; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; McDonald S, 2004, NEUROPSYCHOL REHABIL, V14, P285, DOI 10.1080/09602010343000237; MCDONALD S, 1995, BRAIN INJURY, V9, P255, DOI 10.3109/02699059509008197; McDonald S, 2006, DISABIL REHABIL, V28, P1529, DOI 10.1080/09638280600646185; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; Milders M, 2008, J INT NEUROPSYCH SOC, V14, P318, DOI 10.1017/S1355617708080351; Milders M, 2006, NEUROPSYCHOLOGY, V20, P400, DOI 10.1037/0894-4105.20.4.400; Mitchell JP, 2005, J COGNITIVE NEUROSCI, V17, P1306, DOI 10.1162/0898929055002418; Morris PG, 2005, BRIT J CLIN PSYCHOL, V44, P209, DOI 10.1348/014466505X34174; Muller F, 2010, CORTEX, V46, P1088, DOI 10.1016/j.cortex.2009.08.014; Nigg JT, 2001, PSYCHOL BULL, V127, P571, DOI 10.1037//0033-2909.127.5.571; Northoff G, 2006, NEUROIMAGE, V31, P440, DOI 10.1016/j.neuroimage.2005.12.002; Prigatano G. P., 1985, LANG SCI, V7, P217, DOI [10.1016/S0388-0001(85)80020-6, DOI 10.1016/S0388-0001(85)80020-6]; Prince S, 2002, J MED SPEECH-LANG PA, V10, P19; Reitan R. M, 1992, TRAIL MAKING TEST; Rowe AD, 2001, BRAIN, V124, P600, DOI 10.1093/brain/124.3.600; Ruby P, 2004, J COGNITIVE NEUROSCI, V16, P988, DOI 10.1162/0898929041502661; SARNO MT, 1986, ARCH PHYS MED REHAB, V67, P400; SARNO MT, 1980, J NERV MENT DIS, V168, P685, DOI 10.1097/00005053-198011000-00008; SARNO MT, 1988, SCAND J REHABIL MED, P55; SARNO MT, 1984, J NERV MENT DIS, V172, P475, DOI 10.1097/00005053-198408000-00006; Shallice, 1997, HAYLING BRIXTON TEST; Shamay-Tsoory SG, 2009, BRAIN, V132, P617, DOI 10.1093/brain/awn279; Snow PC, 1999, APHASIOLOGY, V13, P529, DOI 10.1080/026870399401993; SPIERS MV, 1994, BRAIN INJURY, V8, P463, DOI 10.3109/02699059409150998; Spikman JM, 2012, J NEUROTRAUM, V29, P101, DOI 10.1089/neu.2011.2084; Stone VE, 1998, J COGNITIVE NEUROSCI, V10, P640, DOI 10.1162/089892998562942; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Turkstra LS, 2004, NEUROREHABILITATION, V19, P245; Turkstra LS, 2008, BRAIN INJURY, V22, P397, DOI 10.1080/02699050802027059; Turkstra LS, 2008, NEUROREHABILITATION, V23, P501; Wechsler D., 2001, WECHSLER TEST ADULT; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wechsler D, 1997, WAIS 3 ADM SCORING M; Winner E, 1998, BRAIN LANG, V62, P89, DOI 10.1006/brln.1997.1889; WINNER E, 1991, BRIT J DEV PSYCHOL, V9, P257, DOI 10.1111/j.2044-835X.1991.tb00875.x; Youse KM, 2005, BRAIN INJURY, V19, P1001, DOI 10.1080/02699050500109951	83	41	42	2	54	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	SEP	2014	28	5					801	811		10.1037/neu0000089			11	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	AO4FO	WOS:000341291800014	24819067				2021-06-18	
J	Liu, X; Zhang, X; Zhang, J; Kang, N; Zhang, N; Wang, H; Xue, J; Yu, J; Yang, Y; Cui, H; Cui, L; Wang, L; Wang, X				Liu, X.; Zhang, X.; Zhang, J.; Kang, N.; Zhang, N.; Wang, H.; Xue, J.; Yu, J.; Yang, Y.; Cui, H.; Cui, L.; Wang, L.; Wang, X.			DIOSMIN PROTECTS AGAINST CEREBRAL ISCHEMIA/REPERFUSION INJURY THROUGH ACTIVATING JAK2/STAT3 SIGNAL PATHWAY IN MICE	NEUROSCIENCE			English	Article						cerebral ischemia/reperfusion; diosmin; apoptosis; JAK2/STAT3	CHRONIC VENOUS INSUFFICIENCY; TRAUMATIC BRAIN-INJURY; DAFLON 500 MG; ISCHEMIA-REPERFUSION; NEURONAL APOPTOSIS; STAT3 ACTIVATION; OXIDATIVE STRESS; ARTERY OCCLUSION; ALPHA EXPRESSION; GENE-EXPRESSION	Background and object: Apoptosis is a major form of cell death in cerebral ischemia/reperfusion (I/R) pathogenesis and may represent a target for treatment. Diosmin (DM), a micronized purified flavonoid drug, possesses an anti-apoptotic effect in the treatment of varicose veins and renal injury. However, the effect of DM in the acute phase of cerebral I/R is not clear. This study investigated DM's role in cerebral I/R and its potential mechanism. Methods: Male CD-1 mice were subjected to transient middle cerebral artery occlusion (tMCAO). Experiment 1 was used to evaluate the time course expression of Janus tyrosine kinase-2 (JAK2), signal transducer and activator of transcription-3 (STAT3), phosphorylated JAK2 (pJAK2) and phosphorylated STAT3 (pSTAT3) after cerebral I/R, and six time points were included. In experiment 2, DM was given orally at doses of 50 mg/kg or 100 mg/kg for 6 consecutive days before receiving tMCAO. At 24 h after reperfusion, neurological deficit, Nissl staining, brain water content and infarct volume were examined. Bcl-2, Bax, pJAK2, and pSTAT3 were detected by immunohistochemistry, qRT-PCR and Western blot. Confocal microscope was used to observe the location of pSTAT3 in the cerebral cortex. Results: Compared with Vehicle group, the high dose of DM significantly alleviated neurological deficit, brain water content, infarct volume, increased the Nissl-positive cells, upregulated the expression of pJAK2, pSTAT3 and Bcl-2 and downregulated Bax (P < 0.05). Conclusion: These results showed that DM protected against cerebral I/R injury through activating JAK2/STAT3 signal pathway. (C) 2014 IBRO. Published by Elsevier Ltd. All rights reserved.	[Liu, X.; Zhang, X.; Zhang, J.; Kang, N.; Zhang, N.; Wang, H.; Xue, J.; Yu, J.; Yang, Y.; Cui, H.; Cui, L.; Wang, L.] Hebei Med Univ, Hosp 2, Dept Neurol, Shijiazhuang 050000, Hebei, Peoples R China; [Zhang, X.; Cui, L.; Wang, L.; Wang, X.] Hebei Collaborat Innovat Ctr Cardiocerebrovasc Di, Shijiazhuang 050000, Hebei, Peoples R China; [Zhang, X.; Cui, L.; Wang, L.] Hebei Key Lab Neurol, Shijiazhuang 050000, Hebei, Peoples R China	Zhang, X (corresponding author), Hebei Med Univ, Hosp 2, Dept Neurol, 215 Hepingxi Rd, Shijiazhuang 050000, Hebei, Peoples R China.	zhang6xj@aliyun.com; wangxl2014@yahoo.com		Zhang, Xiangjian/0000-0003-0114-1668; Zhang, Nan/0000-0002-6814-214X	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81371287]; Natrural Science Foundation of Hebei Province [10276104D]	This work was funded by the National Natural Science Foundation of China (Grant No. 81371287) and Natrural Science Foundation of Hebei Province (Grant No. 10276104D). We thank technicians Ruichun Liu, Zhongyao Li and Hongran Wu for their technical assistance and Prof. Yansu Guo M.D. PhD. and Weisong Duan M.D. PhD. for providing valuable suggestions.	Amantea D, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.125; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; Benavente-Garcia O, 2008, J AGR FOOD CHEM, V56, P6185, DOI 10.1021/jf8006568; Bergan JJ, 2001, ANGIOLOGY, V52, pS43; Bjorbaek C, 2004, RECENT PROG HORM RES, V59, P305, DOI 10.1210/rp.59.1.305; Bjornstrom L, 2002, MOL ENDOCRINOL, V16, P2202, DOI 10.1210/me.2002-0072; Buckshee K, 1997, INT J GYNECOL OBSTET, V57, P145, DOI 10.1016/S0020-7292(97)02889-0; BUTTINI M, 1994, MOL BRAIN RES, V23, P126, DOI 10.1016/0169-328X(94)90218-6; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chen LY, 2012, BRAIN RES, V1475, P80, DOI 10.1016/j.brainres.2012.07.052; Chiba T, 2009, EXPERT OPIN THER TAR, V13, P1155, DOI 10.1517/14728220903213426; Choi DW, 1996, CURR OPIN NEUROBIOL, V6, P667, DOI 10.1016/S0959-4388(96)80101-2; Clark WM, 1997, NEUROL RES, V19, P641; COVA D, 1992, INT J CLIN PHARM TH, V30, P29; Cui LL, 2010, PHARMACOL BIOCHEM BE, V96, P469, DOI 10.1016/j.pbb.2010.07.007; Dholakiya SL, 2011, TOXICOL IN VITRO, V25, P1039, DOI 10.1016/j.tiv.2011.04.003; Di Domenico F, 2012, J NEUROCHEM, V121, P680, DOI 10.1111/j.1471-4159.2012.07721.x; Dirnagl U, 2004, E SCHERING RES FDN W, V47, P87; Dong LP, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/370804; Du YY, 2012, NEUROSCI LETT, V509, P110, DOI 10.1016/j.neulet.2011.12.054; Dziennis S, 2007, J NEUROSCI, V27, P7268, DOI 10.1523/JNEUROSCI.1558-07.2007; Forte R, 2013, J OCUL PHARMACOL TH, V29, P733, DOI 10.1089/jop.2013.0010; Friesenecker B, 1995, INT J MICROCIRC, V15, P17, DOI 10.1159/000179090; Haga S, 2003, J CLIN INVEST, V112, P989, DOI 10.1172/JCI200317970; HATASHITA S, 1988, J CEREBR BLOOD F MET, V8, P552, DOI 10.1038/jcbfm.1988.96; Iriz E, 2008, VASA-J VASCULAR DIS, V37, P233, DOI 10.1024/0301-1526.37.3.233; Ji H, 2012, BRAIN RES BULL, V87, P50, DOI 10.1016/j.brainresbull.2011.09.021; Jiang CJ, 2013, INT J NEUROSCI, V123, P684, DOI 10.3109/00207454.2013.817409; Korthuis RJ, 1997, INT J MICROCIRC, V17, P11, DOI 10.1159/000179261; Le Devehat C, 1997, INT J MICROCIRC, V17, P27, DOI 10.1159/000179264; Lin SB, 2006, MOL ENDOCRINOL, V20, P3376, DOI 10.1210/me.2006-0177; LINNIK MD, 1995, STROKE, V26, P1670, DOI 10.1161/01.STR.26.9.1670; Liu GY, 2013, BEHAV BRAIN FUNCT, V9, DOI 10.1186/1744-9081-9-36; Liu HC, 2012, BRAIN RES, V1474, P73, DOI 10.1016/j.brainres.2012.07.028; Liu J, 2005, STROKE, V36, P1264, DOI 10.1161/01.STR.0000166180.91042.02; LIU T, 1994, STROKE, V25, P1481, DOI 10.1161/01.STR.25.7.1481; Loddick SA, 1998, J CEREBR BLOOD F MET, V18, P176, DOI 10.1097/00004647-199802000-00008; Lyseng-Williamson KA, 2003, DRUGS, V63, P71, DOI 10.2165/00003495-200363010-00005; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; Oliva AA, 2012, J NEUROCHEM, V120, P710, DOI 10.1111/j.1471-4159.2011.07610.x; Ramelet AA, 2001, ANGIOLOGY, V52, pS49; Rehman MU, 2013, BRIT J NUTR, V110, P699, DOI 10.1017/S0007114512005752; Satriotomo I, 2006, J NEUROCHEM, V98, P1353, DOI 10.1111/j.1471-4159.2006.04051.x; Sehara Y, 2013, J NEUROSCI, V33, P12364, DOI 10.1523/JNEUROSCI.1852-13.2013; Sepulveda P, 2007, CELL DEATH DIFFER, V14, P378, DOI 10.1038/sj.cdd.4402007; Shyu WC, 2004, NEUROBIOL AGING, V25, P935, DOI 10.1016/j.neurobiolaging.2003.10.012; Smith C, 1999, J VASC RES, V36, P24; Solaroglu I, 2006, NEUROSCIENCE, V143, P965, DOI 10.1016/j.neuroscience.2006.09.014; Stephanou A, 2000, CELL DEATH DIFFER, V7, P329, DOI 10.1038/sj.cdd.4400656; Suzuki S, 2001, EXP NEUROL, V170, P63, DOI 10.1006/exnr.2001.7701; Tanrikulu Y, 2013, BOSNIAN J BASIC MED, V13, P218, DOI 10.17305/bjbms.2013.2305; Dung TD, 2012, FOOD CHEM TOXICOL, V50, P1802, DOI 10.1016/j.fct.2012.01.021; Wang G, 2008, INT J BIOCHEM CELL B, V40, P461, DOI 10.1016/j.biocel.2007.08.008; Wen TC, 2001, NEUROSCI LETT, V303, P153, DOI 10.1016/S0304-3940(01)01711-6; Wrighting DM, 2006, BLOOD, V108, P3204, DOI 10.1182/blood-2006-06-027631; Xia DY, 2013, BRAZ J MED BIOL RES, V46, P580, DOI 10.1590/1414-431X20133161; Xu XS, 2006, STROKE, V37, P2613, DOI 10.1161/01.STR.0000242772.94277.1f; Yamashita T, 2005, J NEUROCHEM, V94, P459, DOI 10.1111/j.1471-4159.2005.03227.x; Yang CH, 2009, BRAIN RES, V1282, P133, DOI 10.1016/j.brainres.2009.05.009; Yao XL, 2005, J NEUROTRAUM, V22, P656, DOI 10.1089/neu.2005.22.656; Zhang L, 2013, BRAIN RES BULL, V96, P45, DOI 10.1016/j.brainresbull.2013.04.009; Zhu HB, 2013, EUR J PHARMACOL, V714, P23, DOI 10.1016/j.ejphar.2013.05.043; Zushi SI, 1998, INT J CANCER, V78, P326, DOI 10.1002/(SICI)1097-0215(19981029)78:3<326::AID-IJC12>3.0.CO;2-4	63	41	51	2	21	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	MAY 30	2014	268						318	327		10.1016/j.neuroscience.2014.03.032			10	Neurosciences	Neurosciences & Neurology	AG6AX	WOS:000335501900029	24680937				2021-06-18	
J	Mata-Mbemba, D; Mugikura, S; Nakagawa, A; Murata, T; Ishii, K; Li, L; Takase, K; Kushimoto, S; Takahashi, S				Mata-Mbemba, Daddy; Mugikura, Shunji; Nakagawa, Atsuhiro; Murata, Takaki; Ishii, Kiyoshi; Li, Li; Takase, Kei; Kushimoto, Shigeki; Takahashi, Shoki			Early CT Findings to Predict Early Death in Patients with Traumatic Brain Injury: Marshall and Rotterdam CT Scoring Systems Compared in the Major Academic Tertiary Care Hospital in Northeastern Japan	ACADEMIC RADIOLOGY			English	Article						CT; Marshall; Rotterdam; early death; traumatic brain injury	MINOR HEAD-INJURY; COMPUTED-TOMOGRAPHY; PROGNOSTIC VALUE; CLASSIFICATION; VALIDATION; VOLUME	Rationale and Objectives: Computed tomography (CT) plays a crucial role in early assessment of patients with traumatic brain injury (TBI). Marshall and Rotterdam are the mostly used scoring systems, in which CT findings are grouped differently. We sought to determine the scoring system and initial CT findings predicting the death at hospital discharge (early death) in patients with TBI. Materials and Methods: We included 245 consecutive adult patients with mild-to-severe TB!. Their initial CT and status at hospital discharge (dead or alive) were reviewed, and both CT scores were calculated. We examined whether each score was related to early death; compared the two scoring systems' performance in predicting early death, and identified the CT findings that are independent predictors of early death. Results: More deaths occurred among patients with higher Marshall and Rotterdam scores (both P <.05, Mann-Whitney U test). The areas under the receiver operating characteristic curve (AUCs) indicated that both scoring systems had similarly good discriminative power in predicting early death (Marshall, AUC 0. 85 vs. Rotterdam, AUC =0.85). Basal cistern absence (odds ratio [OR] = 771.5, P <.0001), positive midline shift (OR =56.2, P=.0011), hemorrhagic mass volume >= 25 mL (OR = 12.9, P=.0065), and intraventricular or subarachnoid hemorrhage (OR = 3.8, P =.0395) were independent predictors of early death. Conclusions: Both Marshall and Rotterdam scoring systems can be used to predict early death in patients with TBI. The performance of the Marshall score is-at least equal to that of the Rotterdam score. Thus, although older, the Marshall score-remains useful in predicting patients' prognosis.	[Mata-Mbemba, Daddy; Mugikura, Shunji; Murata, Takaki; Li, Li; Takase, Kei; Takahashi, Shoki] Tohoku Univ, Grad Sch Med, Dept Diagnost Radiol, Aoba Ku, Sendai, Miyagi 9808574, Japan; [Nakagawa, Atsuhiro] Tohoku Univ, Grad Sch Med, Dept Neurosurg, Sendai, Miyagi 9808574, Japan; [Kushimoto, Shigeki] Tohoku Univ, Grad Sch Med, Div Emergency Med, Sendai, Miyagi 9808574, Japan; [Ishii, Kiyoshi] Sendai City Hosp, Dept Radiol, Sendai, Miyagi, Japan	Mugikura, S (corresponding author), Tohoku Univ, Grad Sch Med, Dept Diagnost Radiol, Aoba Ku, 1-1 Seiryo Machi, Sendai, Miyagi 9808574, Japan.	mugi@rad.med.tohoku.ac.jp	Mata-Mbemba, Daddy/AAP-3184-2020	Mata-Mbemba, Daddy/0000-0002-0031-6473	Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [13F03410] Funding Source: KAKEN		Chun KA, 2010, J NEUROTRAUM, V27, P325, DOI 10.1089/neu.2009.1115; Goldschlager T, 2007, J CLIN NEUROSCI, V14, P618, DOI 10.1016/j.jocn.2006.02.018; Harrell Frank E., 2001, REGRESSION MODELING; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Hilario A, 2012, AM J NEURORADIOL, V33, P1925, DOI 10.3174/ajnr.A3092; Huang YH, 2012, NEUROSURGERY, V71, P80, DOI 10.1227/NEU.0b013e3182517aa1; Jacobs B, 2011, J NEUROTRAUM, V28, P203, DOI 10.1089/neu.2010.1558; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; Katsnelson M, 2012, NEUROSURGERY, V70, P1095, DOI 10.1227/NEU.0b013e318240c1ed; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; National Center for Injury Prevention and Control, 2003, C MILD TRAUM BRAIN I; Nelson DW, 2010, J NEUROTRAUM, V27, P51, DOI 10.1089/neu.2009.0986; Smits M, 2010, RADIOLOGY, V254, P532, DOI 10.1148/radiol.2541081672; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Stiell IG, 2001, ANN EMERG MED, V38, P317, DOI 10.1067/mem.2001.116795; Stocchetti N, 2000, J NEUROL NEUROSUR PS, V68, P14, DOI 10.1136/jnnp.68.1.14	20	41	45	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1076-6332	1878-4046		ACAD RADIOL	Acad. Radiol.	MAY	2014	21	5					605	611		10.1016/j.acra.2014.01.017			7	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	AF2RH	WOS:000334559200007	24703472				2021-06-18	
J	Ayton, S; Zhang, M; Roberts, BR; Lam, LQ; Lind, M; McLean, C; Bush, AI; Frugier, T; Crack, PJ; Duce, JA				Ayton, Scott; Zhang, Moses; Roberts, Blaine R.; Lam, Linh Q.; Lind, Monica; McLean, Catriona; Bush, Ashley I.; Frugier, Tony; Crack, Peter J.; Duce, James A.			Ceruloplasmin and beta-amyloid precursor protein confer neuroprotection in traumatic brain injury and lower neuronal iron	FREE RADICAL BIOLOGY AND MEDICINE			English	Article						Traumatic brain injury; Iron; Mouse models; Amyloid precursor protein; Ceruloplasmin; Free radicals	OXIDATIVE STRESS; FERROXIDASE ACTIVITY; CEREBRAL-ISCHEMIA; SYNAPTIC PROTEINS; FERROUS IRON; SPINAL-CORD; RAT MODEL; ACCUMULATION; MICE; EXPRESSION	Traumatic brain injury (TBI) is in part complicated by pro-oxidant iron elevation independent of brain hemorrhage. Ceruloplasmin (CP) and beta-amyloid protein precursor (APP) are known neuroprotective proteins that reduce oxidative damage through iron regulation. We surveyed iron, CP, and APP in brain tissue from control and TBI-affected patients who were stratified according to time of death following injury. We observed CP and APP induction after TBI accompanying iron accumulation. Elevated APP and CP expression was also observed in a mouse model of focal cortical contusion injury concomitant with iron elevation. To determine if changes in APP or CP were neuroprotective we employed the same TBI model on APP(-/-) and CP-/- mice and found that both exhibited exaggerated infarct volume and iron accumulation postinjury. Evidence supports a regulatory role of both proteins in defence against iron-induced oxidative damage after TBI, which presents as a tractable therapeutic target. (C) 2014 Elsevier Inc. All rights reserved.	[Ayton, Scott; Roberts, Blaine R.; Lam, Linh Q.; Lind, Monica; Bush, Ashley I.; Duce, James A.] Univ Melbourne, Oxidat Biol Unit, Florey Inst Neurosci & Mental Hlth, Parkville, Vic 3010, Australia; [Zhang, Moses; Crack, Peter J.] Univ Melbourne, Dept Pharmacol & Therapeut, Parkville, Vic 3010, Australia; [McLean, Catriona; Bush, Ashley I.] Univ Melbourne, Dept Pathol, Parkville, Vic 3010, Australia; [Frugier, Tony] Univ Melbourne, Dept Anat & Cell Biol, Parkville, Vic 3010, Australia; [Duce, James A.] Univ Leeds, Sch Mol & Cellular Biol, Fac Biol Sci, Leeds LS2 9JT, N Yorkshire, England	Duce, JA (corresponding author), Univ Leeds, Sch Mol & Cellular Biol, Fac Biol Sci, Leeds LS2 9JT, N Yorkshire, England.	james.duce@florey.edu.au	Bush, Ashley/Y-2457-2019; Crack, Peter/ABE-2065-2020; Bush, Ashley I/A-1186-2007; Ayton, Scott/AAJ-3414-2021; Ayton, Scott/J-8000-2015	Bush, Ashley/0000-0001-8259-9069; Crack, Peter/0000-0002-5030-0330; Bush, Ashley I/0000-0001-8259-9069; Ayton, Scott/0000-0002-3479-2427; Duce, James/0000-0002-8762-2245; Roberts, Blaine/0000-0001-5466-0053; Frugier, Tony/0000-0002-1275-5158	Australian Research CouncilAustralian Research Council; Australian National Health AMP; Medical Research Council; University of MelbourneUniversity of Melbourne; Florey Institute of Neuroscience and Mental Health; Alfred Hospital; Victorian Forensic Institute of Medicine; Alzheimers Research UKAlzheimer&apos;s Research UK (ARUK) [ART-SRF2011-1] Funding Source: researchfish	This work was supported by funds from the Australian Research Council, the Australian National Health & Medical Research Council, and Operational Infrastructure Support from the Victorian State Government. The Victorian Brain Bank Network is supported by The University of Melbourne, The Florey Institute of Neuroscience and Mental Health, The Alfred Hospital and the Victorian Forensic Institute of Medicine. Dr. Bush is a shareholder in Prana Biotechnology Pty Ltd., Eucalyptus Pty Ltd., and Mesoblast Pty Ltd. and a paid consultant for Collaborative Medicinal Developments LLC.	Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Ansari MA, 2008, J NEUROTRAUM, V25, P513, DOI 10.1089/neu.2007.0451; Asano Y, 2012, J HISTOCHEM CYTOCHEM, V60, P229, DOI 10.1369/0022155411431734; Auriat AM, 2012, EXP NEUROL, V234, P136, DOI 10.1016/j.expneurol.2011.12.030; Ayton S, 2013, ANN NEUROL, V73, P554, DOI 10.1002/ana.23817; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Caliaperumal J, 2012, EXP NEUROL, V237, P363, DOI 10.1016/j.expneurol.2012.07.001; Carbonell T, 2007, CURR MED CHEM, V14, P857, DOI 10.2174/092986707780363014; Corrigan F, 2014, J NEUROCHEM, V128, P196, DOI 10.1111/jnc.12391; Corrigan F, 2012, J NEUROCHEM, V122, P208, DOI 10.1111/j.1471-4159.2012.07761.x; Corrigan F, 2012, BRAIN RES, V1451, P87, DOI 10.1016/j.brainres.2012.02.045; Corrigan F, 2011, BRAIN RES, V1378, P137, DOI 10.1016/j.brainres.2010.12.077; Crack P, 2009, J NEURAL TRANSM, V116, P1, DOI 10.1007/s00702-008-0145-1; Dash PK, 2010, J NEUROSCI RES, V88, P1719, DOI 10.1002/jnr.22336; De Domenico I, 2007, EMBO J, V26, P2823, DOI 10.1038/sj.emboj.7601735; Downes CE, 2010, BRIT J PHARMACOL, V160, P1872, DOI 10.1111/j.1476-5381.2010.00864.x; Duce JA, 2010, CELL, V142, P857, DOI 10.1016/j.cell.2010.08.014; Frugier T, 2012, J NEUROPATH EXP NEUR, V71, P242, DOI 10.1097/NEN.0b013e3182496149; Frugier T, 2011, CELL MOL NEUROBIOL, V31, P569, DOI 10.1007/s10571-011-9650-0; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; Gonzalez-Cuyar LF, 2008, NEUROPATHOLOGY, V28, P466, DOI 10.1111/j.1440-1789.2008.00901.x; Hare D, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00034; Harris ZL, 1999, P NATL ACAD SCI USA, V96, P10812, DOI 10.1073/pnas.96.19.10812; Hawkins BE, 2013, J BIOL CHEM, V288, P17042, DOI 10.1074/jbc.M113.472746; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Justicia C, 2008, STROKE, V39, P1541, DOI 10.1161/STROKEAHA.107.503565; Kuhlow CJ, 2003, GLIA, V44, P76, DOI 10.1002/glia.10273; Lei P, 2012, NAT MED, V18, P291, DOI 10.1038/nm.2613; Liu HD, 2013, NEUROL SCI, V34, P1173, DOI 10.1007/s10072-012-1214-7; Liuzzi JP, 2006, P NATL ACAD SCI USA, V103, P13612, DOI 10.1073/pnas.0606424103; Long DA, 1996, BRAIN RES, V717, P109, DOI 10.1016/0006-8993(95)01500-0; Maynard CJ, 2006, J INORG BIOCHEM, V100, P952, DOI 10.1016/j.jinorgbio.2006.02.010; McNeill A, 2008, EUR NEUROL, V60, P200, DOI 10.1159/000148691; Meguro R, 2007, ARCH HISTOL CYTOL, V70, P1, DOI 10.1679/aohc.70.1; Millerot-Serrurot E, 2008, NEUROCHEM INT, V52, P1442, DOI 10.1016/j.neuint.2008.04.002; Moos T, 2007, J NEUROCHEM, V103, P1730, DOI 10.1111/j.1471-4159.2007.04976.x; Okubo Shuichi, 2013, Acta Neurochir Suppl, V118, P83, DOI 10.1007/978-3-7091-1434-6_14; PANTER SS, 1992, J NEUROTRAUM, V9, P47, DOI 10.1089/neu.1992.9.47; Patel BN, 1997, J BIOL CHEM, V272, P20185, DOI 10.1074/jbc.272.32.20185; Patel BN, 2002, J NEUROSCI, V22, P6578; Pierce JES, 1996, J NEUROSCI, V16, P1083; Ramos P, 2014, J TRACE ELEM MED BIO, V28, P13, DOI 10.1016/j.jtemb.2013.08.001; Rathore KI, 2008, J NEUROSCI, V28, P12736, DOI 10.1523/JNEUROSCI.3649-08.2008; Raz E, 2011, AM J NEURORADIOL, V32, P1851, DOI 10.3174/ajnr.A2637; Sashindranath M, 2011, LAB INVEST, V91, P1079, DOI 10.1038/labinvest.2011.67; Sauerbeck A, 2013, EXP NEUROL, V248, P53, DOI 10.1016/j.expneurol.2013.05.011; Smith C, 2003, NEUROPATH APPL NEURO, V29, P496, DOI 10.1046/j.1365-2990.2003.00488.x; Smith MA, 1997, P NATL ACAD SCI USA, V94, P9866, DOI 10.1073/pnas.94.18.9866; Thornton E, 2006, BRAIN RES, V1094, P38, DOI 10.1016/j.brainres.2006.03.107; Van den Heuvel C, 1999, EXP NEUROL, V159, P441, DOI 10.1006/exnr.1999.7150; Weinreb O, 2013, FREE RADICAL BIO MED, V62, P52, DOI 10.1016/j.freeradbiomed.2013.01.017; Wong CHY, 2008, J NEUROCHEM, V107, P241, DOI 10.1111/j.1471-4159.2008.05605.x; Zecca L, 2004, NAT REV NEUROSCI, V5, P863, DOI 10.1038/nrn1537; Zhang AS, 2009, J BIOL CHEM, V284, P711, DOI 10.1074/jbc.R800017200; Zhang LJ, 2013, NEUROL SCI, V34, P639, DOI 10.1007/s10072-012-1090-1; Zhang QG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034504; ZHENG H, 1995, CELL, V81, P525, DOI 10.1016/0092-8674(95)90073-X	57	41	41	0	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0891-5849	1873-4596		FREE RADICAL BIO MED	Free Radic. Biol. Med.	APR	2014	69						331	337		10.1016/j.freeradbiomed.2014.01.041			7	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Biochemistry & Molecular Biology; Endocrinology & Metabolism	AD8BC	WOS:000333490500035	24509156				2021-06-18	
J	Cook, JM; Dinnen, S; Simiola, V; Thompson, R; Schnurr, PP				Cook, Joan M.; Dinnen, Stephanie; Simiola, Vanessa; Thompson, Richard; Schnurr, Paula P.			VA Residential Provider Perceptions of Dissuading Factors to the Use of Two Evidence-Based PTSD Treatments	PROFESSIONAL PSYCHOLOGY-RESEARCH AND PRACTICE			English	Article						evidence-based treatment; posttraumatic stress disorder; provider perspectives	POSTTRAUMATIC-STRESS-DISORDER; COGNITIVE PROCESSING THERAPY; TRAUMATIC BRAIN-INJURY; PROLONGED EXPOSURE; PSYCHOLOGICAL TREATMENTS; PERSONALITY-DISORDERS; VETERANS; PSYCHOTHERAPY; TRIAL; SURVIVORS	Providers (N = 198) from 38 Department of Veterans Affairs residential posttraumatic stress disorder treatment programs across the United States completed qualitative interviews regarding implementation of 2 evidence-based treatments: prolonged exposure and cognitive processing therapy. As part of this investigation, providers were asked how they decide which patients are appropriate for these treatments. Many indicated that they did not perceive any patient factors that dissuade their use of either evidence-based treatment. However, 3 broad categories emerged surrounding reasons that patients were perceived to be less suitable candidates for the treatments: the presence of psychiatric comorbidities, cognitive limitations, and low levels of patient motivation. Interestingly, providers' perceived reasons for limited or nonuse of a treatment did not correspond entirely to those espoused by treatment developers. Possible solutions to address provider concerns, including educational and motivational interventions, are noted.	[Cook, Joan M.] Yale Univ, Sch Med, Dept Psychiat, West Haven, CT 06516 USA; [Dinnen, Stephanie; Simiola, Vanessa] Yale Univ, Sch Med, West Haven, CT 06516 USA; [Cook, Joan M.; Dinnen, Stephanie; Simiola, Vanessa] Natl Ctr PTSD, West Haven, CT USA; [Thompson, Richard] Univ Illinois, Chicago, IL USA; [Schnurr, Paula P.] Natl Ctr PTSD, White River Jct, VT USA; [Schnurr, Paula P.] Dartmouth Coll, Geisel Sch Med, Hanover, NH 03755 USA	Cook, JM (corresponding author), Yale Univ, Sch Med, Northeast Program Evaluat Ctr 182, 950 Campbell Ave, West Haven, CT 06516 USA.	joan.cook@yale.edu			NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [RC1 MH088454] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [RC1MH088454] Funding Source: NIH RePORTER		Alvarez J, 2011, J CONSULT CLIN PSYCH, V79, P590, DOI 10.1037/a0024466; Bass JK, 2013, NEW ENGL J MED, V368, P2182, DOI 10.1056/NEJMoa1211853; Beck AT, 1985, ANXIETY DISORDERS PH; Becker CB, 2004, BEHAV RES THER, V42, P277, DOI 10.1016/S0005-7967(03)00138-4; Chard KM, 2011, J TRAUMA STRESS, V24, P347, DOI 10.1002/jts.20644; Cloitre M, 2010, AM J PSYCHIAT, V167, P915, DOI 10.1176/appi.ajp.2010.09081247; Cook JM, 2013, J TRAUMA STRESS, V26, P56, DOI 10.1002/jts.21769; Cook JM, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-59; Desai R, 2010, LONG JOURNEY HOME; Foa E., 1986, PSYCHOL BULL, V132, P20, DOI DOI 10.1037/0033-2909.99.1.20; Foa E. B., 2009, EFFECTIVE TREATMENTS; Foa EB, 2005, J CONSULT CLIN PSYCH, V73, P953, DOI 10.1037/0022-006X.73.5.953; Foa EB, 2002, J CONSULT CLIN PSYCH, V70, P1022, DOI 10.1037//0022-006X.70.4.1022; Foa EB, 2007, PROLONGED EXPOSURE T; Foa EB, 2013, JAMA-J AM MED ASSOC, V310, P488, DOI 10.1001/jama.2013.8268; Frueh BC, 2009, J ANXIETY DISORD, V23, P665, DOI 10.1016/j.janxdis.2009.02.005; Glasgow RE, 2013, HEALTH EDUC BEHAV, V40, P257, DOI 10.1177/1090198113486805; Greenhalgh T, 2005, DIFFUSION INNOVATION, DOI [10.1002/9780470987407, DOI 10.1002/9780470987407]; Hembree EA, 2004, J PERS DISORD, V18, P117, DOI 10.1521/pedi.18.1.117.32767; Hembree EA, 2003, J TRAUMA STRESS, V16, P555, DOI 10.1023/B:JOTS.0000004078.93012.7d; Jaycox LH, 1996, CLIN PSYCHOL PSYCHOT, V3, P176; Karlin BE, 2010, J TRAUMA STRESS, V23, P663, DOI 10.1002/jts.20588; LITZ BT, 1990, BEHAV THERAPIST, V13, P91; McCarthy E, 2011, J TRAUMA STRESS, V24, P474, DOI 10.1002/jts.20660; Murphy RT, 2009, PSYCHOL SERV, V6, P264, DOI 10.1037/a0017577; Rauch SAM, 2009, J TRAUMA STRESS, V22, P60, DOI 10.1002/jts.20380; Resick P. A., 1993, COGNITIVE PROCESSING; Resick PA, 2008, COGNITIVE PROCESSING; Resick PA, 2008, J CONSULT CLIN PSYCH, V76, P243, DOI 10.1037/0022-006X.76.2.243; Rosenheck R, 1997, J TRAUMA STRESS, V10, P407, DOI 10.1023/A:1024837220247; Sayer NA, 2009, J REHABIL RES DEV, V46, P703, DOI 10.1682/JRRD.2009.01.0008; Schottenbauer MA, 2008, PSYCHIATRY, V71, P134, DOI 10.1521/psyc.2008.71.2.134; Shiner B, 2013, ADM POLICY MENT HLTH, V40, P311, DOI 10.1007/s10488-012-0421-0; Sripada RK, 2013, J TRAUMA STRESS, V26, P369, DOI 10.1002/jts.21813; Steenkamp MM, 2013, CLIN PSYCHOL REV, V33, P45, DOI 10.1016/j.cpr.2012.10.002; Tuerk PW, 2011, J ANXIETY DISORD, V25, P397, DOI 10.1016/j.janxdis.2010.11.002; U.S. Department of Veterans Affairs, 2010, VET HLTH ADM HDB VHA, V1160; United States Department of Veterans Affairs Department of Defense and The American Heart Association/American Stroke Association, 2010, VA DOD CLIN PRACT GU; van Dam D, 2012, CLIN PSYCHOL REV, V32, P202, DOI 10.1016/j.cpr.2012.01.004; van Minnen A, 2012, EUR J PSYCHOTRAUMATO, V3, DOI 10.3402/ejpt.v3i0.18805; Walter KH, 2012, COGNITIVE THER RES, V36, P576, DOI 10.1007/s10608-011-9393-8	41	41	42	0	11	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0735-7028	1939-1323		PROF PSYCHOL-RES PR	Prof. Psychol.-Res. Pract.	APR	2014	45	2					136	142		10.1037/a0036183			7	Psychology, Multidisciplinary	Psychology	AF7AF	WOS:000334865100008	25309031	Green Accepted			2021-06-18	
J	Tzekov, R; Quezada, A; Gautier, M; Biggins, D; Frances, C; Mouzon, B; Jamison, J; Mullan, M; Crawford, F				Tzekov, Radouil; Quezada, Alexandra; Gautier, Megan; Biggins, Davida; Frances, Candice; Mouzon, Benoit; Jamison, Jeff; Mullan, Michael; Crawford, Fiona			Repetitive Mild Traumatic Brain Injury Causes Optic Nerve and Retinal Damage in a Mouse Model	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						Electroretinography; Ganglion cells; Mild traumatic brain injury; Optic nerve; Retina; Spectral-domain optical coherence tomography	PHOTOPIC NEGATIVE RESPONSE; INDUCED AXONAL INJURY; GANGLION-CELL DEATH; WALLERIAN DEGENERATION; VISUAL IMPAIRMENTS; FIBER LAYER; RAT; ELECTRORETINOGRAM; MYELIN; ACTIVATION	There is increasing evidence that long-lasting morphologic and functional consequences can be present in the human visual system after repetitive mild traumatic brain injury (r-mTBI). The exact location and extent of the damage in this condition are not well understood. Using a recently developed mouse model of r-mTBI, we assessed the effects on the retina and optic nerve using histology and immunohistochemistry, electroretinography (ERG), and spectral-domain optical coherence tomography (SD-OCT) at 10 and 13 weeks after injury. Control mice received repetitive anesthesia alone (r-sham). We observed decreased optic nerve diameters and increased cellularity and areas of demyelination in optic nerves in r-mTBI versus r-sham mice. There were concomitant areas of decreased cellularity in the retinal ganglion cell layer and approximately 67% decrease in brain-specific homeobox/POU domain protein 3A-positive retinal ganglion cells in retinal flat mounts. Furthermore, SD-OCT demonstrated a detectable thinning of the inner retina; ERG demonstrated a decrease in the amplitude of the photopic negative response without any change in a- or b-wave amplitude or timing. Thus, the ERG and SD-OCT data correlated well with changes detected by morphometric, histologic, and immunohistochemical methods, thereby supporting the use of these noninvasive methods in the assessment of visual function and morphology in clinical cases of mTBI.	[Tzekov, Radouil; Quezada, Alexandra; Gautier, Megan; Biggins, Davida; Frances, Candice; Mouzon, Benoit; Mullan, Michael; Crawford, Fiona] Roskamp Inst, Tampa, FL USA; [Tzekov, Radouil] Univ S Florida, Tampa, FL USA; [Jamison, Jeff] Ophthy DS Inc, Kalamazoo, MI USA; [Tzekov, Radouil; Mouzon, Benoit; Mullan, Michael; Crawford, Fiona] James A Haley Vet Adm, Tampa, FL USA	Tzekov, R (corresponding author), Roskamp Inst, 2040 Whitfield Ave, Sarasota, FL 34243 USA.	rtzekov@roskampinstitute.net	Frances, Candice/K-3359-2018	Frances, Candice/0000-0002-2741-628X; Tzekov, Radouil/0000-0002-3662-9818	Department of DefenseUnited States Department of Defense [W81XWH-10-1-0759]; Roskamp Foundation	This work was supported by Department of Defense award W81XWH-10-1-0759 (to Fiona Crawford) and by the Roskamp Foundation.	Alarcon-Martinez L, 2010, VISION RES, V50, P2176, DOI 10.1016/j.visres.2010.08.014; Atkins Edward J, 2008, Rev Neurol Dis, V5, P73; Barnard AR, 2011, EXP EYE RES, V93, P771, DOI 10.1016/j.exer.2011.07.004; BERKELAAR M, 1994, J NEUROSCI, V14, P4368, DOI 10.1523/jneurosci.14-07-04368.1994; Bien A, 1999, J NEUROTRAUM, V16, P153, DOI 10.1089/neu.1999.16.153; Binder S, 2005, J HEAD TRAUMA REHAB, V20, P189, DOI 10.1097/00001199-200505000-00002; Brahm KD, 2009, OPTOMETRY VISION SCI, V86, P817, DOI 10.1097/OPX.0b013e3181adff2d; Brigell M, 2005, DOC OPHTHALMOL, V110, P3, DOI 10.1007/s10633-005-7338-9; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Camp AS, 2011, INVEST OPHTH VIS SCI, V52, P5226, DOI 10.1167/iovs.10-6307; Chrysostomou V, 2013, INVEST OPHTH VIS SCI, V54, P4691, DOI 10.1167/iovs.13-12415; CROMPTON M R, 1970, Brain Behavior and Evolution, V93, P785, DOI 10.1093/brain/93.4.785; Dibas A, 2010, MOL VIS, V16, P330; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Domleo A, 2002, NUROPATH APPL NEUROB, V28, P161; Dratviman-Storobinsky O, 2008, MOL VIS, V14, P2171; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fijalkowski RJ, 2007, J NEUROTRAUM, V24, P1387, DOI 10.1089/neu.2007.0268; Fortune B, 2008, INVEST OPHTH VIS SCI, V49, P4444, DOI 10.1167/iovs.08-2255; Galindo-Romero C, 2011, EXP EYE RES, V92, P377, DOI 10.1016/j.exer.2011.02.008; GENNARELLI TA, 1989, J NEUROSURG, V71, P244, DOI 10.3171/jns.1989.71.2.0244; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; Gotoh Y, 2004, ARCH OPHTHALMOL-CHIC, V122, P341, DOI 10.1001/archopht.122.3.341; Greenwald BD, 2012, BRAIN INJURY, V26, P1338, DOI 10.3109/02699052.2012.706356; Grubenhoff JA, 2011, BRAIN INJURY, V25, P943, DOI 10.3109/02699052.2011.597043; Hoyt CS, 2007, EYE, V21, P1285, DOI 10.1038/sj.eye.6702849; Huber G, 2009, INVEST OPHTH VIS SCI, V50, P5888, DOI 10.1167/iovs.09-3724; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Johnson EC, 2007, INVEST OPHTH VIS SCI, V48, P3161, DOI 10.1167/iovs.06-1282; Kilbourne M, 2009, J NEUROTRAUM, V26, P2233, DOI 10.1089/neu.2009.0968; Knox D L, 2000, Trans Am Ophthalmol Soc, V98, P203; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Leung CKS, 2011, INVEST OPHTH VIS SCI, V52, P1539, DOI 10.1167/iovs.10-6012; Lew HL, 2009, J REHABIL RES DEV, V46, P819, DOI 10.1682/JRRD.2008.09.0129; Li B, 2005, DOC OPHTHALMOL, V111, P23, DOI 10.1007/S10633-005-2629-8; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Maxwell WL, 2013, BRAIN SCI, V3, P1374, DOI 10.3390/brainsci3031374; Maxwell WL, 1999, J NEUROTRAUM, V16, P273, DOI 10.1089/neu.1999.16.273; MAXWELL WL, 1994, J NEUROCYTOL, V23, P379, DOI 10.1007/BF01666527; Moalem G, 1999, NAT MED, V5, P49, DOI 10.1038/4734; Moalem G, 1999, FASEB J, V13, P1207; Mohan K, 2013, INVEST OPHTH VIS SCI, V54, P3440, DOI 10.1167/iovs.12-11522; Mouzon BC, 2013, ANN NEUROL, DOI 10.1002/ana.24064; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Nadal-Nicolas FM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049830; O'Connor WT, 2011, PHARMACOL THERAPEUT, V130, P106, DOI 10.1016/j.pharmthera.2011.01.001; Ojo JO, 2013, J NEUROPATH EXP NEUR, V72, P137, DOI 10.1097/NEN.0b013e3182814cdf; PeinadoRamon P, 1996, INVEST OPHTH VIS SCI, V37, P489; Perunovic B, 2001, J NEUROL SCI, V185, P55, DOI 10.1016/S0022-510X(01)00463-4; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Prilloff S, 2012, INVEST OPHTH VIS SCI, V53, P1460, DOI 10.1167/iovs.11-8306; Rangaswamy NV, 2004, INVEST OPHTH VIS SCI, V45, P3827, DOI 10.1167/iovs.04-0458; Rasband W. S, 2012, IMAGEJ; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; Saleh M, 2007, INVEST OPHTH VIS SCI, V48, P4564, DOI 10.1167/iovs.07-0483; Salinas-Navarro M, 2009, MOL VIS, V15, P2578; Sanchez-Migallon MC, 2011, EXP EYE RES, V92, P260, DOI 10.1016/j.exer.2011.02.001; SHELDON WG, 1995, LAB ANIM SCI, V45, P508; Shindler KS, 2008, EXP EYE RES, V87, P208, DOI 10.1016/j.exer.2008.05.017; STOLL G, 1989, J NEUROSCI, V9, P2327; Suchoff Irwin B, 2008, Optometry, V79, P259, DOI 10.1016/j.optm.2007.10.012; Sulaiman AM, 2011, J NEUROTRAUM, V28, P383, DOI 10.1089/neu.2010.1707; Viswanathan S, 1999, INVEST OPHTH VIS SCI, V40, P1124; Wang CH, 2013, EXP THER MED, V5, P621, DOI 10.3892/etm.2012.844; Wang JQ, 2013, J NEUROPATH EXP NEUR, V72, P768, DOI 10.1097/NEN.0b013e31829d8d9d; Wang J, 2012, INVEST OPHTH VIS SCI, V53, P1315, DOI 10.1167/iovs.11-8461; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yoles E, 1998, EXP NEUROL, V153, P1, DOI 10.1006/exnr.1998.6811; ZIMMERMAN LORENZ E., 1967, INVEST OPHTHALMOL, V6, P109	72	41	42	0	7	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	APR	2014	73	4					345	361		10.1097/NEN.0000000000000059			17	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	AD7UA	WOS:000333471100007	24607965	Bronze			2021-06-18	
J	Madinier, A; Quattromani, MJ; Sjolund, C; Ruscher, K; Wieloch, T				Madinier, Alexandre; Quattromani, Miriana Jlenia; Sjolund, Carin; Ruscher, Karsten; Wieloch, Tadeusz			Enriched Housing Enhances Recovery of Limb Placement Ability and Reduces Aggrecan-Containing Perineuronal Nets in the Rat Somatosensory Cortex after Experimental Stroke	PLOS ONE			English	Article							CHONDROITIN SULFATE PROTEOGLYCANS; INDUCED MOVEMENT THERAPY; TRAUMATIC BRAIN-INJURY; FORCED ARM USE; ENVIRONMENTAL ENRICHMENT; PHOTOTHROMBOTIC STROKE; EXTRACELLULAR-MATRIX; GENE-EXPRESSION; NEUROTROPHIC FACTOR; MOTOR RECOVERY	Stroke causes life long disabilities where few therapeutic options are available. Using electrical and magnetic stimulation of the brain and physical rehabilitation, recovery of brain function can be enhanced even late after stroke. Animal models support this notion, and housing rodents in an enriched environment (EE) several days after experimental stroke stimulates lost brain function by multisensory mechanisms. We studied the dynamics of functional recovery of rats with a lesion to the fore and hind limb motor areas induced by photothrombosis (PT), and with subsequent housing in either standard (STD) or EE. In this model, skilled motor function is not significantly enhanced by enriched housing, while the speed of recovery of sensori-motor function substantially improves over the 9-week study period. In particular, this stroke lesion completely obliterates the fore and hind limb placing ability when visual and whisker guidance is prevented, a deficit that persists for up to 9 weeks of recovery, but that is markedly restored within 2 weeks by enriched housing. Enriched housing after stroke also leads to a significant loss of perineuronal net (PNN) immunoreactivity; detection of aggrecan protein backbone with AB1031 antibody was decreased by 13-22%, and labelling of a glycan moiety of aggrecan with Cat-315 antibody was reduced by 25-30% in the peri-infarct area and in the somatosensory cortex, respectively. The majority of these cells are parvalbumin/GABA inhibitory interneurons that are important in sensori-information processing. We conclude that damage to the fore and hind limb motor areas provides a model of loss of limb placing response without visual guidance, a deficit also seen in more than 50% of stroke patients. This loss is amenable to recovery induced by multiple sensory stimulation and correlates with a decrease in aggrecan-containing PNNs around inhibitory interneurons. Modulating the PNN structure after ischemic damage may provide new therapies enhancing tactile/proprioceptive function after stroke.	[Madinier, Alexandre; Quattromani, Miriana Jlenia; Sjolund, Carin; Ruscher, Karsten; Wieloch, Tadeusz] Lund Univ, Dept Clin Sci, Expt Brain Res Lab, Div Neurosurg, Lund, Sweden	Wieloch, T (corresponding author), Lund Univ, Dept Clin Sci, Expt Brain Res Lab, Div Neurosurg, Lund, Sweden.	tadeusz.wieloch@med.lu.se		Wieloch, Tadeusz/0000-0002-7669-2520	Swedish Research CouncilSwedish Research CouncilEuropean Commission [2011-2652, 2011-2684]; EU through the European Stroke Network [201024]; Hans-Christian and Alice Wachtmeister Foundation; Swedish Brain Fund; Greta och Johan Kocks Stiftelser; Thorsten och Elsa Segerfalk Stiftelse; Crafoord Foundation	This study was supported by the Swedish Research Council grants no. 2011-2652 (TW) and no. 2011-2684 (KR), the EU 7th work program through the European Stroke Network grant no. 201024, the Hans-Christian and Alice Wachtmeister Foundation (TW, KR), the Swedish Brain Fund (TW), the Greta och Johan Kocks Stiftelser (KR), the Thorsten och Elsa Segerfalk Stiftelse (KR) and the Crafoord Foundation (KR). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arendash GW, 2004, NEUROREPORT, V15, P1751, DOI 10.1097/01.wnr.0000137183.68847.4e; Ballermann M, 2001, J NEUROSCI METH, V106, P39, DOI 10.1016/S0165-0270(01)00326-0; Bandtlow CE, 2000, PHYSIOL REV, V80, P1267; Bezard E, 2003, J NEUROSCI, V23, P10999; Biernaskie J, 2001, J NEUROSCI, V21, P5272, DOI 10.1523/JNEUROSCI.21-14-05272.2001; Carey LM, 2011, NEUROREHAB NEURAL RE, V25, P443, DOI 10.1177/1545968310395777; Carey LM, 1996, ARCH PHYS MED REHAB, V77, P1271, DOI 10.1016/S0003-9993(96)90192-6; Carmichael ST, 2005, EXP NEUROL, V193, P291, DOI 10.1016/j.expneurol.2005.01.004; Carmichael ST, 2006, ANN NEUROL, V59, P735, DOI 10.1002/ana.20845; Celio MR, 1998, TRENDS NEUROSCI, V21, P510, DOI 10.1016/S0166-2236(98)01298-3; Dahlqvist P, 2003, NEUROSCIENCE, V119, P643, DOI 10.1016/S0306-4522(03)00195-7; Dancause N, 2006, REV NEUROSCIENCE, V17, P561; DERYCK M, 1992, BRAIN RES, V573, P44; DERYCK M, 1989, STROKE, V20, P1383, DOI 10.1161/01.STR.20.10.1383; Diederich K, 2012, STROKE, V43, P185, DOI 10.1161/STROKEAHA.111.622159; Dino MR, 2006, NEUROSCIENCE, V142, P1055, DOI 10.1016/j.neuroscience.2006.07.054; DONOGHUE JP, 1994, J CLIN NEUROPHYSIOL, V11, P382; DUNCAN PW, 1992, STROKE, V23, P1084, DOI 10.1161/01.STR.23.8.1084; Edwardson MA, 2013, EXP BRAIN RES, V224, P335, DOI 10.1007/s00221-012-3315-1; Encarnacion A, 2011, J NEUROSCI METH, V196, P247, DOI 10.1016/j.jneumeth.2011.01.010; Foscarin S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016666; Freund TF, 2007, NEURON, V56, P33, DOI 10.1016/j.neuron.2007.09.012; Frischknecht R, 2012, ADV EXP MED BIOL, V970, P153, DOI 10.1007/978-3-7091-0932-8_7; Gherardini L., 2013, CEREB CORTEX; Giamanco KA, 2010, NEUROSCIENCE, V170, P1314, DOI 10.1016/j.neuroscience.2010.08.032; GUIMARAES A, 1990, J NEUROSCI, V10, P3014; HALL RD, 1974, BRAIN RES, V66, P23, DOI 10.1016/0006-8993(74)90076-6; Harris NG, 2009, J NEUROSCI RES, V87, P2937, DOI 10.1002/jnr.22115; Harris NG, 2010, J NEUROPATH EXP NEUR, V69, P139, DOI 10.1097/NEN.0b013e3181cb5bee; HARTIG W, 1994, BRAIN RES, V635, P307, DOI 10.1016/0006-8993(94)91452-4; Hebb D. O., 1947, AM PSYCHOL, V2, P306, DOI DOI 10.1037/H0028720; Hill JJ, 2012, P NATL ACAD SCI USA, V109, P9155, DOI 10.1073/pnas.1205697109; Hobohm C, 2005, J NEUROSCI RES, V80, P539, DOI 10.1002/jnr.20459; HOCKFIELD S, 1990, COLD SH Q B, V55, P505; HOCKFIELD S, 1983, P NATL ACAD SCI-BIOL, V80, P5758, DOI 10.1073/pnas.80.18.5758; Hockly E, 2002, ANN NEUROL, V51, P235, DOI 10.1002/ana.10094; Hua Y, 2002, STROKE, V33, P2478, DOI 10.1161/01.STR.0000032302.91894.0F; Inacio AR, 2011, NEUROBIOL DIS, V41, P270, DOI 10.1016/j.nbd.2010.09.015; Jablonka JA, 2010, NEUROSCIENCE, V165, P90, DOI 10.1016/j.neuroscience.2009.09.074; Janssen H, 2010, NEUROREHAB NEURAL RE, V24, P802, DOI 10.1177/1545968310372092; Jin Z, 2010, BRAIN RES, V1363, P191, DOI 10.1016/j.brainres.2010.09.081; Johansson BB, 2002, J CEREBR BLOOD F MET, V22, P89, DOI 10.1097/00004647-200201000-00011; JONES TA, 1992, BEHAV BRAIN RES, V51, P1, DOI 10.1016/S0166-4328(05)80306-7; JORGENSEN HS, 1995, ARCH PHYS MED REHAB, V76, P399, DOI 10.1016/S0003-9993(95)80567-2; Karetko-Sysa M, 2011, EXP NEUROL, V231, P113, DOI 10.1016/j.expneurol.2011.05.022; Katsman D, 2003, J CEREBR BLOOD F MET, V23, P997, DOI 10.1097/01.WCB.0000084252.20114.BE; Keyvani K, 2004, J NEUROPATH EXP NEUR, V63, P598, DOI 10.1093/jnen/63.6.598; Kitago T, 2013, NEUROREHAB NEURAL RE, V27, P99, DOI 10.1177/1545968312452631; Knieling M, 2009, NEUROSCIENCE, V163, P759, DOI 10.1016/j.neuroscience.2009.07.004; Kovesdi E, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00042; Lander C, 1997, J NEUROSCI, V17, P1928; Lendvai D, 2013, ACTA NEUROPATHOL, V125, P215, DOI 10.1007/s00401-012-1042-0; Lenzlinger PM, 2004, RESTOR NEUROL NEUROS, V22, P73; Lo EH, 2003, NAT REV NEUROSCI, V4, P399, DOI 10.1038/nrn1106; Martinez-Cue C, 2005, BEHAV BRAIN RES, V163, P174, DOI 10.1016/j.bbr.2005.04.016; Matthews RT, 2002, J NEUROSCI, V22, P7536; McRae PA, 2007, J NEUROSCI, V27, P5405, DOI 10.1523/JNEUROSCI.5425-06.2007; Moon SK, 2009, EXP NEUROL, V218, P145, DOI 10.1016/j.expneurol.2009.04.021; Morawski M, 2012, INT J BIOCHEM CELL B, V44, P690, DOI 10.1016/j.biocel.2012.01.010; Muller HD, 2008, STROKE, V39, P1012, DOI 10.1161/STROKEAHA.107.495069; Muntner P, 2002, STROKE, V33, P1209, DOI 10.1161/01.STR.0000015031.57955.D1; Murphy TH, 2009, NAT REV NEUROSCI, V10, P861, DOI 10.1038/nrn2735; Nithianantharajah J, 2006, NAT REV NEUROSCI, V7, P697, DOI 10.1038/nrn1970; OHLSSON AL, 1995, STROKE, V26, P644, DOI 10.1161/01.STR.26.4.644; Overman JJ, 2014, NEUROSCIENTIST, V20, P15, DOI 10.1177/1073858413491146; Pizzorusso T, 2002, SCIENCE, V298, P1248, DOI 10.1126/science.1072699; Rampon C, 2000, P NATL ACAD SCI USA, V97, P12880, DOI 10.1073/pnas.97.23.12880; Restivo L, 2005, P NATL ACAD SCI USA, V102, P11557, DOI 10.1073/pnas.0504984102; Roger VL, 2012, CIRCULATION, V125, pE2, DOI 10.1161/CIR.0b013e31823ac046; Rogers DC, 1997, PHARMACOL BIOCHEM BE, V56, P747, DOI 10.1016/S0091-3057(96)00430-3; Rosell A, 2008, CURR OPIN PHARMACOL, V8, P82, DOI 10.1016/j.coph.2007.12.001; Ruscher K, 2011, BRAIN, V134, P732, DOI 10.1093/brain/awq367; Ruscher K, 2009, J CEREBR BLOOD F MET, V29, P1796, DOI 10.1038/jcbfm.2009.96; Sale A, 2007, NAT NEUROSCI, V10, P679, DOI 10.1038/nn1899; Schabitz WR, 2004, STROKE, V35, P992, DOI 10.1161/01.STR.0000119754.85848.0D; Schulz R, 2013, NEUROPHARMACOLOGY, V64, P579, DOI 10.1016/j.neuropharm.2012.05.016; Shanina EV, 2006, NEUROSCIENCE, V139, P1495, DOI 10.1016/j.neuroscience.2006.01.016; Sigler A, 2008, J NEUROSCI METH, V170, P35, DOI 10.1016/j.jneumeth.2007.12.015; Soleman S, 2013, NEUROSCIENCE, V253, P194, DOI 10.1016/j.neuroscience.2013.08.050; Starkey ML, 2012, BRAIN, V135, P3265, DOI 10.1093/brain/aws270; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; Vandeputte C, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-92; Viapiano MS, 2006, TRENDS MOL MED, V12, P488, DOI 10.1016/j.molmed.2006.08.007; Wang DF, 2012, CELL TISSUE RES, V349, P147, DOI 10.1007/s00441-012-1375-y; Wang YG, 2008, J CEREBR BLOOD F MET, V28, P1936, DOI 10.1038/jcbfm.2008.82; Wieloch T, 2006, CURR OPIN NEUROBIOL, V16, P258, DOI 10.1016/j.conb.2006.05.011; Wood NI, 1996, BEHAV BRAIN RES, V78, P113, DOI 10.1016/0166-4328(95)00237-5; Yamaguchi Y, 2000, CELL MOL LIFE SCI, V57, P276, DOI 10.1007/PL00000690	89	41	42	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 24	2014	9	3							e93121	10.1371/journal.pone.0093121			14	Multidisciplinary Sciences	Science & Technology - Other Topics	AD7QO	WOS:000333459900155	24664200	DOAJ Gold, Green Published			2021-06-18	
J	Forbes, CE; Poore, JC; Krueger, F; Barbey, AK; Solomon, J; Grafman, J				Forbes, Chad E.; Poore, Joshua C.; Krueger, Frank; Barbey, Aron K.; Solomon, Jeffrey; Grafman, Jordan			The role of executive function and the dorsolateral prefrontal cortex in the expression of neuroticism and conscientiousness	SOCIAL NEUROSCIENCE			English	Article						Personality; DLPC; Executive function; Neuroticism; Conscientiousness; Self-control	GENERAL INTELLIGENCE; PERSONALITY-TRAITS; EMOTION REGULATION; BRAIN VOLUME; EXTROVERSION; FMRI; METAANALYSIS; SOFTWARE; AMYGDALA; INJURY	The current study examined how specific neurological systems contribute to the expression of multiple personality dimensions. We used individuals with traumatic brain injuries to examine the contribution of the dorsolateral prefrontal cortex (DLPFC)a region important for executive function and attentionto the expression of neuroticism and conscientiousness factors and facets. Results from Voxel-Based Lesion-Symptom Mapping analyses revealed that focal damage to the left DLPFC (Brodmann's area 9) was associated with high neuroticism and low conscientious factor and facet scores (anxiety and self-discipline, respectively). Compared with lesioned and normal controls, veterans with damage in left DLPFC also reported higher neuroticism and lower conscientiousness facet scores, slower reaction times on the California Computerized Assessment Package assessment, and lower scores on the Delis-Kaplan executive function battery. Findings suggest that while neuroticism and conscientiousness remain psychometrically independent personality dimensions, their component facets may rely on a common neurocognitive infrastructure and executive function resources in general.	[Forbes, Chad E.; Poore, Joshua C.; Krueger, Frank; Barbey, Aron K.; Solomon, Jeffrey; Grafman, Jordan] NINDS, Cognit Neurosci Sect, NIH, Bethesda, MD 20892 USA; [Forbes, Chad E.] Univ Delaware, Dept Psychol, Newark, DE 19716 USA; [Forbes, Chad E.] Ctr Clin, Bethesda, MD USA; [Forbes, Chad E.] Natl Inst Biomed Imaging & Bioengn, NIH, Bethesda, MD USA; [Poore, Joshua C.] Charles Stark Draper Lab Inc, Boston, MA USA; [Krueger, Frank] George Mason Univ, Dept Mol Neurosci, Fairfax, VA 22030 USA; [Solomon, Jeffrey] Expert Image Anal LLC, Potomac, MD USA; [Grafman, Jordan] Rehabil Inst Chicago, Chicago, IL 60611 USA; [Grafman, Jordan] Northwestern Univ, Feinberg Sch Med, Alzheimers Dis Res Ctr, Dept Phys Med & Rehabil, Evanston, IL 60208 USA; [Grafman, Jordan] Northwestern Univ, Feinberg Sch Med, Alzheimers Dis Res Ctr, Dept Psychiat & Behav Sci, Evanston, IL 60208 USA; [Grafman, Jordan] Northwestern Univ, Feinberg Sch Med, Alzheimers Dis Res Ctr, Dept Cognit Neurol, Evanston, IL 60208 USA; [Grafman, Jordan] Northwestern Univ, Dept Psychol, Evanston, IL 60208 USA	Forbes, CE (corresponding author), Univ Delaware, Dept Psychol, 111 Wolf Hall, Newark, DE 19716 USA.	cforbes@psych.udel.edu; jgrafman@northwestern.edu	Barbey, Aron/L-7312-2015	Barbey, Aron/0000-0002-6092-0912; Grafman, Jordan H./0000-0001-8645-4457	Intramural Research Training Program of the National Institute of Neurological Disorders and Stroke, National Institutes of Health; US Army Medical Research and Material CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [DAMD17-01-1-0675]	This work was supported by the Intramural Research Training Program of the National Institute of Neurological Disorders and Stroke, National Institutes of Health, and a project grant from the US Army Medical Research and Material Command administrated by the Henry M. Jackson Foundation [Vietnam Head Injury Study Phase III: A 30-year post-injury follow-up study: Grant number: DAMD17-01-1-0675]. The authors are grateful to all the Vietnam veterans who participated in this study.	Badre D, 2008, TRENDS COGN SCI, V12, P193, DOI 10.1016/j.tics.2008.02.004; Banich MT, 2009, CURR DIR PSYCHOL SCI, V18, P89, DOI 10.1111/j.1467-8721.2009.01615.x; Banks SJ, 2007, SOC COGN AFFECT NEUR, V2, P303, DOI 10.1093/scan/nsm029; Barbey AK, 2014, SOC COGN AFFECT NEUR, V9, P265, DOI 10.1093/scan/nss124; Barbey AK, 2012, BRAIN, V135, P1154, DOI 10.1093/brain/aws021; Barrett LF, 2006, CURR DIR PSYCHOL SCI, V15, P79, DOI 10.1111/j.0963-7214.2006.00411.x; Barrett LF, 2009, PERSPECT PSYCHOL SCI, V4, P326, DOI 10.1111/j.1745-6924.2009.01134.x; Bates E, 2003, NAT NEUROSCI, V6, P448, DOI 10.1038/nn1050; Blankstein U, 2009, NEUROPSYCHOLOGIA, V47, P599, DOI 10.1016/j.neuropsychologia.2008.10.014; Costa PT, 1992, NEO PI R PROFESSIONA; Deckersbach T, 2006, DEPRESS ANXIETY, V23, P133, DOI 10.1002/da.20152; Defense Do, 1960, ARMED FORCES QUALIF; Delis D.C., 2001, DELIS KAPLAN EXECUTI; DeYoung CG, 2010, PSYCHOL SCI, V21, P820, DOI 10.1177/0956797610370159; DeYoung CG, 2009, CAMBRIDGE HANDBOOK OF PERSONALITY PSYCHOLOGY, P323; Eisenberger NI, 2005, COGN AFFECT BEHAV NE, V5, P169, DOI 10.3758/CABN.5.2.169; FUSTER JM, 1997, PREFRONTAL CORTEX AN; Giedd JN, 2010, NEURON, V67, P728, DOI 10.1016/j.neuron.2010.08.040; Glascher J, 2010, P NATL ACAD SCI USA, V107, P4705, DOI 10.1073/pnas.0910397107; GRAFMAN J, 1988, BRAIN, V111, P169, DOI 10.1093/brain/111.1.169; Gross JJ, 2003, J PERS SOC PSYCHOL, V85, P348, DOI 10.1037/0022-3514.85.2.348; Jackson J, 2011, NEUROBIOL AGING, V32, P2162, DOI 10.1016/j.neurobiolaging.2009.12.009; John OP., 2008, PARAD SHIFT INT BIG, P114; Knutson B, 2001, BIOL PSYCHIAT, V50, P685, DOI 10.1016/S0006-3223(01)01220-3; Kotov R, 2010, PSYCHOL BULL, V136, P768, DOI 10.1037/a0020327; Krueger F, 2011, J NEUROSCI, V31, P598, DOI 10.1523/JNEUROSCI.1399-10.2011; Krueger F, 2009, P NATL ACAD SCI USA, V106, P22486, DOI 10.1073/pnas.0912568106; Kumari V, 2007, BEHAV NEUROSCI, V121, P643, DOI 10.1037/0735-7044.121.4.643; Lancaster JL, 2000, HUM BRAIN MAPP, V10, P120, DOI 10.1002/1097-0193(200007)10:3<120::AID-HBM30>3.0.CO;2-8; Lewis MD, 2007, COGNITIVE DEV, V22, P406, DOI 10.1016/j.cogdev.2007.08.004; Lieberman MD, 2009, SOC COGN AFFECT NEUR, V4, P423, DOI 10.1093/scan/nsp052; Lindquist KA, 2012, BEHAV BRAIN SCI, V35, P121, DOI 10.1017/S0140525X11000446; Makale M, 2002, BEHAV RES METH INS C, V34, P6, DOI 10.3758/BF03195419; Maldjian JA, 2003, NEUROIMAGE, V19, P1233, DOI 10.1016/S1053-8119(03)00169-1; McCrae R.R., 2008, HDB PERSONALITY THEO, V3rd ed, P159, DOI DOI 10.3905/JPE.2000.319978; MCCRAE RR, 1992, J PERS, V60, P175, DOI 10.1111/j.1467-6494.1992.tb00970.x; Miller E. N., 1990, CALIFORNIA COMPUTERI; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Muller D, 2005, J PERS SOC PSYCHOL, V89, P852, DOI 10.1037/0022-3514.89.6.852; Murphy FC, 2003, COGN AFFECT BEHAV NE, V3, P207, DOI 10.3758/CABN.3.3.207; Naragon-Gainey K, 2011, PSYCHOL MED, V41, P1437, DOI 10.1017/S0033291710002096; Omura K, 2005, NEUROREPORT, V16, P1905, DOI 10.1097/01.wnr.0000186596.64458.76; Roberts BW, 2000, PSYCHOL BULL, V126, P3, DOI 10.1037/0033-2909.126.1.3; Solomon J, 2007, COMPUT METH PROG BIO, V86, P245, DOI 10.1016/j.cmpb.2007.02.006; Vul E, 2009, PERSPECT PSYCHOL SCI, V4, P274, DOI 10.1111/j.1745-6924.2009.01125.x; Wager TD, 2003, NEUROIMAGE, V19, P513, DOI 10.1016/S1053-8119(03)00078-8; Wagner AD, 2001, NEUROIMAGE, V14, P1337, DOI 10.1006/nimg.2001.0936; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wood JN, 2003, NAT REV NEUROSCI, V4, P139, DOI 10.1038/nrn1033; Wright CI, 2007, NEUROIMAGE, V35, P263, DOI 10.1016/j.neuroimage.2006.11.039; Wright CI, 2006, CEREB CORTEX, V16, P1809, DOI 10.1093/cercor/bhj118; Zuckerman M., 1991, PERSONALITY INDIVIDU, V54, P96	52	41	43	0	46	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND	1747-0919	1747-0927		SOC NEUROSCI-UK	Soc. Neurosci.	MAR 4	2014	9	2					139	151		10.1080/17470919.2013.871333			13	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	AA2NZ	WOS:000330932600004	24405294				2021-06-18	
J	Nadrop, B; Soreq, H				Nadrop, Bettina; Soreq, Hermona			Predicted overlapping microRNA regulators of acetylcholine packaging and degradation in neuroinflammation-related disorders	FRONTIERS IN MOLECULAR NEUROSCIENCE			English	Article						acetlycholinesterase; butyrylcholinesterase; choline acetyltransferase; vesicular acetylcholine transporter; microRNA-186; cholinergic signaling; primate-specific microRNAs	INFLAMMATORY-BOWEL-DISEASE; ACUTE MYOCARDIAL-INFARCTION; CORONARY-ARTERY-DISEASE; BLOOD MONONUCLEAR-CELLS; CHOLINERGIC GENE LOCUS; TRAUMATIC BRAIN-INJURY; HEART-FAILURE; ALZHEIMERS-DISEASE; PERIPHERAL-BLOOD; STROKE PATIENTS	MicroRNAs (miRNAs) can notably control many targets each and regulate entire cellular pathways, but whether miRNAs can regulate complete neurotransmission processes is largely unknown. Here, we report that miRNAs with complementary sequence motifs to the key genes involved in acetylcholine (ACh) synthesis and/or packaging show massive overlap with those regulating ACh degradation. To address this topic, we first searched for miRNAs that could target the 3'-untranslated regions of the choline acetyltransferase (ChAT) gene that controls ACh synthesis; the vesicular ACh transporter (VAChT), encoded from an intron in the ChAT gene and the ACh hydrolyzing genes acetyl- and/or butyrylcholinesterase (AChE, BChE). Intriguingly, we found that many of the miRNAs targeting these genes are primate-specific, and that changes in their levels associate with inflammation, anxiety, brain damage, cardiac, neurodegenerative, or pain-related syndromes. To validate the in vivo relevance of this dual interaction, we selected the evolutionarily conserved miR-186, which targets both the stress-inducible soluble "readthrough" variant AChE-R and the major peripheral cholinesterase BChE. We exposed mice to predator scent stress and searched for potential associations between consequent changes in their miR-186, AChE-R, and BChE levels. Both intestinal miR-186 as well as BChE and AChE-R activities were conspicuously elevated 1 week post-exposure, highlighting the previously unknown involvement of miR-186 and BChE in psychological stress responses. Overlapping miRNA regulation emerges from our findings as a recently evolved surveillance mechanism over cholinergic neurotransmission in health and disease; and the corresponding miRNA details and disease relevance may serve as a useful resource for studying the molecular mechanisms underlying this surveillance.	[Soreq, Hermona] Hebrew Univ Jerusalem, Edmond & Lily Safra Ctr Brain Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel; [Soreq, Hermona] Hebrew Univ Jerusalem, Edmond & Lily Safra Ctr Brain Sci, Ctr Bioengn, IL-91904 Jerusalem, Israel	Soreq, H (corresponding author), Hebrew Univ Jerusalem, Edmond & Lily Safra Ctr Brain Sci, Dept Biol Chem, Edmond J Safra Campus, IL-91904 Jerusalem, Israel.	hermona.soreq@mail.huji.ac.il		Soreq, Hermona/0000-0002-0955-526X; Nadorp, Bettina/0000-0003-1974-8425	European Research CouncilEuropean Research Council (ERC)European Commission [321501]; European CommissionEuropean CommissionEuropean Commission Joint Research Centre [602133]; Hebrew University's Bioengineering program	The authors are grateful to Dr. Shani Shenhar-Tsarfaty, Mr. Yochai Wolf and Mr. Uriya Bekenstein, Jerusalem for helpful advice and discussions. This study was supported by a European Research Council Advanced Research Award 321501(to Hermona Soreq) and The European Commission FP-7 Health-2013-Innovation grant number 602133(to Hermona Soreq). Bettina Nadorp is an incumbent of a PhD fellowship from The Hebrew University's Bioengineering program.	Abdellatif M, 2011, PEDIATR CARDIOL, V32, P311, DOI 10.1007/s00246-010-9882-7; Arbel Y, 2014, MOL MED, V20, P38, DOI 10.2119/molmed.2013.00139; Archacki SR, 2003, PHYSIOL GENOMICS, V15, P65, DOI 10.1152/physiolgenomics.00181.2002; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Ben Assayag E, 2010, MOL MED, V16, P278, DOI 10.2119/molmed.2010.00015; Berson A, 2012, EMBO MOL MED, V4, P730, DOI 10.1002/emmm.201100995; Bhattacharyya M, 2013, MOL BIOSYST, V9, P457, DOI 10.1039/c2mb25434d; Bostjancic E, 2009, DIS MARKERS, V27, P255, DOI 10.3233/DMA-2009-0671; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; Chen YW, 2012, INT J MOL MED, V29, P601, DOI 10.3892/ijmm.2012.894; Chen-Plotkin AS, 2012, J NEUROSCI, V32, P11213, DOI 10.1523/JNEUROSCI.0521-12.2012; Cohen O, 2002, MOL PSYCHIATR, V7, P874, DOI 10.1038/sj.mp.4001103; Danielsson K, 2012, J ORAL PATHOL MED, V41, P90, DOI 10.1111/j.1600-0714.2011.01084.x; Diaz-Prado S, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471-2474-13-144; Dickinson BA, 2013, EUR J HEART FAIL, V15, P650, DOI 10.1093/eurjhf/hft018; Doeppner TR, 2013, ACTA NEUROPATHOL, V126, P251, DOI 10.1007/s00401-013-1142-5; Dutta R, 2013, ANN NEUROL, V73, P637, DOI 10.1002/ana.23860; Eiden LE, 1998, J NEUROCHEM, V70, P2227; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; ERICKSON JD, 1994, J BIOL CHEM, V269, P21929; Eskildsen TV, 2013, INT J MOL SCI, V14, P11190, DOI 10.3390/ijms140611190; Etoh M, 2013, ARCH DERMATOL RES, V305, P9, DOI 10.1007/s00403-012-1287-4; Goren Y, 2012, EUR J HEART FAIL, V14, P147, DOI 10.1093/eurjhf/hfr155; Gupta MK, 2013, J MOL CELL CARDIOL, V62, P131, DOI 10.1016/j.yjmcc.2013.05.011; Hanieh H, 2013, EUR J IMMUNOL, V43, P2771, DOI 10.1002/eji.201343486; Hanin G, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00028; Hoekstra M, 2010, BIOCHEM BIOPH RES CO, V394, P792, DOI 10.1016/j.bbrc.2010.03.075; Iborra M, 2013, CLIN EXP IMMUNOL, V173, P250, DOI 10.1111/cei.12104; Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014; Imai S, 2011, J NEUROSCI, V31, P15294, DOI 10.1523/JNEUROSCI.0921-11.2011; Jeyapalan Z, 2011, NUCLEIC ACIDS RES, V39, P3026, DOI 10.1093/nar/gkq1003; Jin W, 2012, J BIOL CHEM, V287, P15672, DOI 10.1074/jbc.M111.322669; Junn E, 2009, P NATL ACAD SCI USA, V106, P13052, DOI 10.1073/pnas.0906277106; Kang JG, 2011, J PATHOL, V225, P378, DOI 10.1002/path.2962; Katare R, 2011, CIRC RES, V109, P894, DOI 10.1161/CIRCRESAHA.111.251546; Kaufer D, 1998, NATURE, V393, P373, DOI 10.1038/30741; Kefas B, 2008, CANCER RES, V68, P3566, DOI 10.1158/0008-5472.CAN-07-6639; Keller A, 2011, NAT METHODS, V8, P841, DOI [10.1038/nmeth.1682, 10.1038/NMETH.1682]; Khaitovich P, 2006, NAT REV GENET, V7, P693, DOI 10.1038/nrg1940; Kress M, 2013, FRONT MOL NEUROSCI, V6, DOI 10.3389/fnmol.2013.00033; Kynast KL, 2013, PAIN, V154, P368, DOI 10.1016/j.pain.2012.11.010; Lau P, 2013, EMBO MOL MED, V5, P1613, DOI 10.1002/emmm.201201974; Lee ST, 2010, STROKE, V41, P1646, DOI 10.1161/STROKEAHA.110.579649; Lerman G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020916; Levy C, 2010, MOL CELL, V40, P841, DOI 10.1016/j.molcel.2010.11.020; Liu DZ, 2010, J CEREBR BLOOD F MET, V30, P92, DOI 10.1038/jcbfm.2009.186; Lu TX, 2012, J ALLERGY CLIN IMMUN, V129, P1064, DOI 10.1016/j.jaci.2012.01.060; Lukiw WJ, 2012, MOL NEUROBIOL, V46, P11, DOI 10.1007/s12035-012-8234-4; Lungu G, 2013, NEUROSCI LETT, V553, P153, DOI 10.1016/j.neulet.2013.08.001; Lupini Laura, 2013, Frontiers in Genetics, V4, P64, DOI 10.3389/fgene.2013.00064; Lusardi TA, 2010, J CEREBR BLOOD F MET, V30, P744, DOI 10.1038/jcbfm.2009.253; Maharshak N, 2013, INFLAMM BOWEL DIS, V19, P1346, DOI 10.1097/MIB.0b013e318281f47d; Manca S, 2011, EXP DERMATOL, V20, P932, DOI 10.1111/j.1600-0625.2011.01359.x; Martino S, 2009, J BIOMED BIOTECHNOL, DOI 10.1155/2009/654346; Matsukawa T, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4164; Matsumoto S, 2013, CIRC RES, V113, P322, DOI 10.1161/CIRCRESAHA.113.301209; MCGEER PL, 1984, NEUROLOGY, V34, P741, DOI 10.1212/WNL.34.6.741; Meder B, 2011, BASIC RES CARDIOL, V106, P13, DOI 10.1007/s00395-010-0123-2; Meshorer E, 2005, MOL PSYCHIATR, V10, P985, DOI 10.1038/sj.mp.4001735; Meshorer E, 2006, TRENDS NEUROSCI, V29, P216, DOI 10.1016/j.tins.2006.02.005; Monastyrskaya K, 2013, AM J PATHOL, V182, P431, DOI 10.1016/j.ajpath.2012.10.020; Muinos-Gimeno M, 2009, HUM MUTAT, V30, P1062, DOI 10.1002/humu.21005; Murata K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069118; Murata K, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3013; Naumann T, 2002, J NEUROSCI, V22, P2409, DOI 10.1523/JNEUROSCI.22-07-02409.2002; Oliveira-Carvalho V, 2013, MOL BIOL REP, V40, P2663, DOI 10.1007/s11033-012-2352-y; Oshikawa Y, 2013, ACTA DERM-VENEREOL, V93, P273, DOI 10.2340/00015555-1459; Papagiannakopoulos T, 2008, CANCER RES, V68, P8164, DOI 10.1158/0008-5472.CAN-08-1305; Paraskevi A, 2012, J CROHNS COLITIS, V6, P900, DOI 10.1016/j.crohns.2012.02.006; Redell JB, 2010, J NEUROTRAUM, V27, P2147, DOI 10.1089/neu.2010.1481; Rink C, 2011, PHYSIOL GENOMICS, V43, P521, DOI 10.1152/physiolgenomics.00158.2010; Sakai A, 2013, BRAIN, V136, P2738, DOI 10.1093/brain/awt191; Santini P, 2014, RHEUMATOL INT, V34, P711, DOI 10.1007/s00296-013-2754-8; Schipper HM, 2007, GENE REGUL SYST BIO, V1, P263; Shaked I, 2009, IMMUNITY, V31, P965, DOI 10.1016/j.immuni.2009.09.019; Shaltiel G, 2013, BRAIN STRUCT FUNCT, V218, P59, DOI 10.1007/s00429-011-0376-z; Shenhar-Tsarfaty S, 2013, EUR J NEUROL, V20, P891, DOI 10.1111/ene.12074; Shenhar-Tsarfaty S, 2014, J MOL NEUROSCI, V53, P298, DOI 10.1007/s12031-013-0176-4; Sklan EH, 2004, P NATL ACAD SCI USA, V101, P5512, DOI 10.1073/pnas.0307659101; SOREQ H, 1990, P NATL ACAD SCI USA, V87, P9688, DOI 10.1073/pnas.87.24.9688; Soreq H, 2001, NAT REV NEUROSCI, V2, P294, DOI 10.1038/35067589; Sun Y, 2013, CNS NEUROSCI THER, V19, P813, DOI 10.1111/cns.12142; Takagi T, 2010, J GASTROEN HEPATOL, V25, pS129, DOI 10.1111/j.1440-1746.2009.06216.x; Tan KS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007689; Tracey KJ, 2010, NAT IMMUNOL, V11, P561, DOI 10.1038/ni0710-561; Valiyaveettil M, 2013, CHEM-BIOL INTERACT, V203, P371, DOI 10.1016/j.cbi.2012.10.022; van Rooij E, 2008, P NATL ACAD SCI USA, V105, P13027, DOI 10.1073/pnas.0805038105; Villa C, 2011, REJUV RES, V14, P275, DOI 10.1089/rej.2010.1123; Voellenkle C, 2010, PHYSIOL GENOMICS, V42, P420, DOI 10.1152/physiolgenomics.00211.2009; Wang HJ, 2012, J TRAUMA ACUTE CARE, V73, P850, DOI 10.1097/TA.0b013e31825a7560; Wang HJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038885; Wang J, 2012, J CELL MOL MED, V16, P2150, DOI 10.1111/j.1582-4934.2012.01523.x; Wang WX, 2011, ACTA NEUROPATHOL, V121, P193, DOI 10.1007/s00401-010-0756-0; Wong HKA, 2013, HUM MOL GENET, V22, P3077, DOI 10.1093/hmg/ddt164; Wong MS, 2013, CELL REP, V3, P1028, DOI 10.1016/j.celrep.2013.03.011; Xie YF, 2011, INT J ORAL SCI, V3, P125, DOI 10.4248/IJOS11046; Xu N, 2011, J INVEST DERMATOL, V131, P1521, DOI 10.1038/jid.2011.55; Yu SQ, 2011, AM J RHINOL ALLERGY, V25, pE242, DOI 10.2500/ajra.2011.25.3682; Yuan M, 2013, ATHEROSCLEROSIS, V226, P447, DOI 10.1016/j.atherosclerosis.2012.11.026; Zhang HB, 2013, CARDIOVASC RES, V98, P269, DOI 10.1093/cvr/cvt030; Zhu HY, 2012, CARDIOVASC RES, V94, P284, DOI 10.1093/cvr/cvr291; Zimmerman G, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.4	102	41	41	0	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5099			FRONT MOL NEUROSCI	Front. Molec. Neurosci.	FEB 10	2014	7								9	10.3389/fnmol.2014.00009			11	Neurosciences	Neurosciences & Neurology	AZ0UN	WOS:000347960400002	24574962	DOAJ Gold, Green Published			2021-06-18	
J	Goddard, L; Dritschel, B; Robinson, S; Howlin, P				Goddard, Lorna; Dritschel, Barbara; Robinson, Sally; Howlin, Patricia			Development of autobiographical memory in children with autism spectrum disorders: Deficits, gains, and predictors of performance	DEVELOPMENT AND PSYCHOPATHOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; EXECUTIVE FUNCTION; EPISODIC MEMORY; EMOTION RECOGNITION; OVERGENERAL MEMORY; ASPERGER-SYNDROME; SELF-RECOGNITION; ADULTS; AMNESIA; MIND	Autobiographical memory (AM) was assessed in 63 children (aged 8-17 years) with an autism spectrum disorder (ASD) and compared with 63 typically developing children matched for age, gender, IQ, and verbal ability. A range of methodologies was employed for eliciting past experience with particular focus on the ability to recall (a) specific events, (b) the recent and remote past, and (c) semantic versus episodic memories across different lifetime periods. Results indicated that the ASD group manifested difficulties in retrieving specific memories to word cues and had poorer access to the remote past. Deficits were found in the context of intact recent memory and preserved general memory abilities, with some impairment of visual memory. Problems in retrieving episodic and semantic AMs across the life span were also evident. Qualitative analysis of memory reports suggested that the ASD group was less likely to refer to emotion in their remote memories but more likely to describe emotions in their recent memories. Important predictors of AM performance in the ASD group were central executive abilities, in particular cognitive flexibility and verbal fluency.	[Goddard, Lorna] Univ London, London SE14 6NW, England; [Dritschel, Barbara] Univ St Andrews, St Andrews KY16 9AJ, Fife, Scotland; [Robinson, Sally; Howlin, Patricia] Kings Coll London, London WC2R 2LS, England	Goddard, L (corresponding author), Univ London, Dept Psychol, London SE14 6NW, England.	l.goddard@gold.ac.uk	Howlin, Patricia/A-7622-2011; Goddard, Lorna/R-8635-2016	Goddard, Lorna/0000-0001-8884-3253; Howlin, Patricia/0000-0002-1804-6053; Dritschel, Barbara/0000-0002-0909-6323	Economic and Social Research CouncilUK Research & Innovation (UKRI)Economic & Social Research Council (ESRC) [ES/E004954/1] Funding Source: researchfish		Anderson DK, 2009, J ABNORM CHILD PSYCH, V37, P1019, DOI 10.1007/s10802-009-9326-0; Baron-Cohen S, 2001, INT REV RES MENT RET, V23, P169; Bekerian D., 2001, 3 INT C MEM VAL SPAI; Ben Shalom D, 2003, CORTEX, V39, P1129; Berument SK, 1999, BRIT J PSYCHIAT, V175, P444, DOI 10.1192/bjp.175.5.444; Bowler DM, 2004, J AUTISM DEV DISORD, V34, P533, DOI 10.1007/s10803-004-2548-7; Bowler DM, 2000, J AUTISM DEV DISORD, V30, P295, DOI 10.1023/A:1005575216176; Brewer W. F., 1986, AUTOBIOGRAPHICAL MEM, P25; BRITTLEBANK AD, 1993, BRIT J PSYCHIAT, V162, P118, DOI 10.1192/bjp.162.1.118; Brown BT, 2012, J AUTISM DEV DISORD, V42, P441, DOI 10.1007/s10803-011-1246-5; Bruck M, 2007, DEV PSYCHOPATHOL, V19, P73, DOI 10.1017/S0954579407070058; Cohen M.J., 1997, CHILDRENS MEMORY SCA; COLTHEART M, 1981, Q J EXP PSYCHOL-A, V33, P497, DOI 10.1080/14640748108400805; Conway MA, 2000, PSYCHOL REV, V107, P261, DOI 10.1037//0033-295X.107.2.261; Conway MA, 2001, J MEM LANG, V45, P493, DOI 10.1006/jmla.2001.2781; Conway MA, 2000, INT J PSYCHOL, V35, P113; Crane L, 2008, J AUTISM DEV DISORD, V38, P498, DOI 10.1007/s10803-007-0420-2; Crane L, 2010, J AUTISM DEV DISORD, V40, P383, DOI 10.1007/s10803-009-0875-4; Crane L, 2009, MEMORY, V17, P557, DOI 10.1080/09658210902960211; CROVITZ HF, 1974, B PSYCHONOMIC SOC, V4, P517; Culbertson W. C., 2005, TOWER LONDON DX; Dalgleish T, 2007, J EXP PSYCHOL GEN, V136, P23, DOI 10.1037/0096-3445.136.1.23; Dissanayake C, 2010, AUTISM, V14, P495, DOI 10.1177/1362361310366569; Dritschel B, 2010, AUTISM, V14, P509, DOI 10.1177/1362361310368407; Dunn L.M., 1997, BRIT PICTURE VOCABUL; Fivush R, 2006, BRIT J DEV PSYCHOL, V24, P235, DOI 10.1348/026151005X57747; Friedman NP, 2004, J EXP PSYCHOL GEN, V133, P101, DOI 10.1037/0096-3445.133.1.101; Gilboa A, 2004, CEREB CORTEX, V14, P1214, DOI 10.1093/cercor/bhh082; Goddard L, 1996, J ABNORM PSYCHOL, V105, P609, DOI 10.1037/0021-843X.105.4.609; Goddard L, 2007, J AUTISM DEV DISORD, V37, P291, DOI 10.1007/s10803-006-0168-0; Goldman S, 2008, J AUTISM DEV DISORD, V38, P1982, DOI 10.1007/s10803-008-0588-0; Gunter HL, 2002, J AUTISM DEV DISORD, V32, P263, DOI 10.1023/A:1016326701439; Heaton R. K., 2003, WCST 64 COMPUTERIZED; Heeren A, 2009, BEHAV RES THER, V47, P403, DOI 10.1016/j.brat.2009.01.017; Hewitt J, 2006, NEUROPSYCHOLOGIA, V44, P1468, DOI 10.1016/j.neuropsychologia.2005.11.016; Hill EL, 2004, TRENDS COGN SCI, V8, P26, DOI 10.1016/j.tics.2003.11.003; Hill EL, 2006, NEUROPSYCHOLOGIA, V44, P2822, DOI 10.1016/j.neuropsychologia.2006.06.007; Howe ML, 1997, PSYCHOL REV, V104, P499, DOI 10.1037/0033-295X.104.3.499; Howlin P, 2004, J CHILD PSYCHOL PSYC, V45, P212, DOI 10.1111/j.1469-7610.2004.00215.x; Klein SB, 1999, SOC COGNITION, V17, P413, DOI 10.1521/soco.1999.17.4.413; Kleinhans NM, 2010, NEUROPSYCHOLOGIA, V48, P3665, DOI 10.1016/j.neuropsychologia.2010.07.022; Lee LC, 2007, RES AUTISM SPECT DIS, V1, P126, DOI 10.1016/j.rasd.2006.08.004; Lee SJ, 2009, PSYCHIAT INVEST, V6, P156, DOI 10.4306/pi.2009.6.3.156; Lind SE, 2009, J AUTISM DEV DISORD, V39, P643, DOI 10.1007/s10803-008-0670-7; Lord, 2003, SOCIAL COMMUNICATION; Losh M, 2003, J AUTISM DEV DISORD, V33, P239, DOI 10.1023/A:1024446215446; McDowd J, 2011, NEUROPSYCHOLOGY, V25, P210, DOI 10.1037/a0021531; Milders M, 2008, J INT NEUROPSYCH SOC, V14, P318, DOI 10.1017/S1355617708080351; Millward C, 2000, J AUTISM DEV DISORD, V30, P15, DOI 10.1023/A:1005455926727; Mitchell P, 2008, J AUTISM DEV DISORD, V38, P1591, DOI 10.1007/s10803-007-0530-x; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; NELSON K, 1993, PSYCHOL SCI, V4, P7, DOI 10.1111/j.1467-9280.1993.tb00548.x; Nelson K., 2000, OXFORD HDB MEMORY, P283; O'Shea AG, 2005, DEV NEUROPSYCHOL, V27, P337, DOI 10.1207/s15326942dn2703_3; OCONNOR M, 1992, J CLIN EXP NEUROPSYC, V14, P159, DOI 10.1080/01688639208402821; OGDEN JA, 1993, NEUROPSYCHOLOGIA, V31, P571, DOI 10.1016/0028-3932(93)90053-3; OZONOFF S, 1991, J CHILD PSYCHOL PSYC, V32, P1081, DOI 10.1111/j.1469-7610.1991.tb00351.x; Perner J, 2005, SCIENCE, V308, P214, DOI 10.1126/science.1111656; Perner J, 2007, INFANT CHILD DEV, V16, P471, DOI 10.1002/icd.517; Peterson C, 2011, CHILD DEV, V82, P1092, DOI 10.1111/j.1467-8624.2011.01597.x; Rabbitt P., 1988, PRACTICAL ASPECTS ME, V1, P301; Raes F, 2010, J CLIN CHILD ADOLESC, V39, P276, DOI 10.1080/15374410903532684; Reese E, 1999, NARRAT INQ, V9, P215, DOI 10.1075/ni.9.2.02ree; Robinson S, 2009, BRAIN COGNITION, V71, P362, DOI 10.1016/j.bandc.2009.06.007; Rutter M., 2003, AUTISTIC DIAGNOSTIC; Shallice T, 1996, PHILOS T R SOC B, V351, P1405, DOI 10.1098/rstb.1996.0124; Shallice T, 2002, DEV NEUROPSYCHOL, V21, P43, DOI 10.1207/S15326942DN2101_3; St Jacques PL, 2007, MEMORY, V15, P129, DOI 10.1080/09658210601119762; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Valentino K, 2012, J CLIN CHILD ADOLESC, V41, P491, DOI 10.1080/15374416.2012.660689; Wechsler D., 2011, WECHLSER ABBREVIATED; WelchRoss MK, 1997, DEV PSYCHOL, V33, P618, DOI 10.1037/0012-1649.33.4.618; Williams D, 2010, AUTISM, V14, P474, DOI 10.1177/1362361310366314; WILLIAMS JMG, 1992, NATO ADV SCI INST SE, V65, P391; Williams JMG, 1999, Q J EXP PSYCHOL-A, V52, P555, DOI 10.1080/713755828	75	41	42	1	33	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	0954-5794	1469-2198		DEV PSYCHOPATHOL	Dev. Psychopathol.	FEB	2014	26	1					215	228		10.1017/S0954579413000904			14	Psychology, Developmental	Psychology	AD0UV	WOS:000332950500015	24284059	Green Accepted			2021-06-18	
J	Bhullar, IS; Johnson, D; Paul, JP; Kerwin, AJ; Tepas, JJ; Frykberg, ER				Bhullar, Indermeet S.; Johnson, Donald; Paul, Julia P.; Kerwin, Andrew J.; Tepas, Joseph J., III; Frykberg, Eric R.			More harm than good: Antiseizure prophylaxis after traumatic brain injury does not decrease seizure rates but may inhibit functional recovery	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	72nd Annual Meeting of the American-Association-for-the-Surgery-of-Trauma / Clinical Congress of Acute Care Surgery	SEP 18-23, 2013	San Francisco, CA	Amer Assoc Surg Trauma		Phenytoin; antiseizure prophylaxis; functional outcome; traumatic brain injury	SEVERE HEAD-INJURY; POSTTRAUMATIC EPILEPSY; PHENYTOIN	BACKGROUND: The purposes of this study were to examine the current Brain Trauma Foundation recommendation for antiseizure prophylaxis with phenytoin during the first 7 days after traumatic brain injury (TBI) in preventing seizures and to determine if this medication affects functional recovery at discharge. METHODS: The records of adult (age >= 18 years) patients with blunt severe TBI who remained in the hospital at least 7 days after injury were retrospectively reviewed from January 2008 to January 2010. Clinical seizure rates during the first 7 days after injury and functional outcome at discharge were compared for the two groups based on antiseizure prophylaxis, no prophylaxis (NP) versus phenytoin prophylaxis (PP). Statistical analysis was performed using chi(2). RESULTS: A total of 93 adult patients who met the previously mentioned criteria were identified (43 [46%] NP group vs. 50 [54%] PP group). The two groups were well matched. Contrary to expectation, more seizures occurred in the PP group as compared with the NP group; however, this did not reach significance (PP vs. NP, 2 [4%] vs. 1 [2.3%], p = 1). There was no significant difference in the two groups (PP vs. NP) as far as disposition are concerned, mortality caused by head injury (4 [8%] vs. 3 [7%], p = 1), discharge home (16 [32%] vs. 17 [40%], p = 0.7), and discharge to rehabilitation (30 [60%] vs. 23 [53%], p = 0.9). However, with PP, there was a significantly longer hospital stay (PP vs. NP, 36 vs. 25 days, p = 0.04) and significantly worse functional outcome at discharge based on Glasgow Outcome Scale (GOS) score (PP vs. NP, 2.9 vs. 3.4, p < 0.01) and modified Rankin Scale score (2.3 +/- 1.7 vs. 3.1 +/- 1.5, p = 0.02). CONCLUSION: PP may not decrease early posttraumatic seizure and may suppress functional outcome after blunt TBI. These results need to be verified with randomized studies before recommending changes in clinical practice and do not apply to penetrating trauma. (Copyright (C) 2014 by Lippincott Williams & Wilkins)	[Bhullar, Indermeet S.; Paul, Julia P.; Kerwin, Andrew J.; Frykberg, Eric R.] Univ Florida, Coll Med, Div Acute Care Surg, Jacksonville, FL 32209 USA; [Johnson, Donald] Univ Florida, Coll Med, Div Pharm, Jacksonville, FL 32209 USA; [Tepas, Joseph J., III] Univ Florida, Coll Med, Div Pediat, Jacksonville, FL 32209 USA	Bhullar, IS (corresponding author), Univ Florida, Coll Med, Surg Intens Care Unit, 655 West 8th St, Jacksonville, FL 32209 USA.	Indermeet.bhullar@jax.ufl.edu					Ascroft PB, 1941, BMJ-BRIT MED J, V1941, P739, DOI 10.1136/bmj.1.4193.739; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS83; Dauch WA, 1996, ZBL NEUROCHIR, V57, P190; Debenham S, 2011, CAN J NEUROL SCI, V38, P896, DOI 10.1017/S031716710001249X; DIKMEN SS, 1991, JAMA-J AM MED ASSOC, V265, P1271, DOI 10.1001/jama.265.10.1271; Faul M.D., 2010, TRAUMATIC BRAIN INJU; GLOTZNER FL, 1983, NEUROCHIRURGIA, V26, P66; Haltiner AM, 1999, J NEUROSURG, V91, P588, DOI 10.3171/jns.1999.91.4.0588; HARUDA F, 1979, NEUROLOGY, V29, P1480, DOI 10.1212/WNL.29.11.1480; HENDRICK EB, 1968, J TRAUM, V8, P547; Jacka MJ, 2007, CAN J NEUROL SCI, V34, P307, DOI 10.1017/S0317167100006727; JENNETT WB, 1960, J NEUROL NEUROSUR PS, V23, P295, DOI 10.1136/jnnp.23.4.295; JONES GL, 1983, MED RES REV, V3, P383, DOI 10.1002/med.2610030403; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MCQUEEN JK, 1983, J NEUROL NEUROSUR PS, V46, P899, DOI 10.1136/jnnp.46.10.899; Messe S, 2009, NEUROCRIT CARE, V11, P38, DOI 10.1007/s12028-009-9207-y; Naidech AM, 2005, STROKE, V36, P583, DOI 10.1161/01.STR.0000141936.36596.1e; Naidech AM, 2009, STROKE, V40, P3810, DOI 10.1161/STROKEAHA.109.559948; NORTH JB, 1983, J NEUROSURG, V58, P672, DOI 10.3171/jns.1983.58.5.0672; PHILLIPS G, 1954, J NEUROL NEUROSUR PS, V17, P1, DOI 10.1136/jnnp.17.1.1; RAPPORT RL, 1973, J NEUROSURG, V38, P159, DOI 10.3171/jns.1973.38.2.0159; RISH BL, 1973, J NEUROSURG, V38, P155, DOI 10.3171/jns.1973.38.2.0155; Rowbotham GF, 1942, ACUTE INJURIES HEAD; Sahin S, 2008, CLIN NEUROPHARMACOL, V31, P93, DOI 10.1097/WNF.0b013e31806ad6cb; Szaflarski JP, 2010, NEUROCRIT CARE, V12, P165, DOI 10.1007/s12028-009-9304-y; Temkin N R, 1991, Neurosurg Clin N Am, V2, P425; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; YABLON SA, 1993, ARCH PHYS MED REHAB, V74, P983; YOUNG B, 1983, J NEUROSURG, V58, P236, DOI 10.3171/jns.1983.58.2.0236; Zhao YQ, 2012, SEIZURE-EUR J EPILEP, V21, P322, DOI 10.1016/j.seizure.2012.02.007	30	41	42	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	JAN	2014	76	1					54	60		10.1097/TA.0b013e3182aafd15			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	AH8JN	WOS:000336384200012	24368357				2021-06-18	
J	Marklund, N; Farrokhnia, N; Hanell, A; Vanmechelen, E; Enblad, P; Zetterberg, H; Blennow, K; Hillered, L				Marklund, Niklas; Farrokhnia, Nina; Hanell, Anders; Vanmechelen, Eugeen; Enblad, Per; Zetterberg, Henrik; Blennow, Kaj; Hillered, Lars			Monitoring of beta-Amyloid Dynamics after Human Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						A; APP; axonal injury; cerebral MD; energy metabolism; TBI	ALZHEIMERS-DISEASE; HEAD-INJURY; CEREBROSPINAL-FLUID; PRECURSOR PROTEIN; A-BETA; INTRACEREBRAL MICRODIALYSIS; APOLIPOPROTEIN-E; WHITE-MATTER; PEPTIDE; ACCUMULATION	Epidemiological evidence links severe or repeated traumatic brain injury (TBI) to the development of Alzheimer's disease (AD). Accumulation of amyloid precursor protein (APP) occurs with high frequency after TBI, particularly in injured axons, and APP may be cleaved to amyloid- (A) peptides playing key pathophysiological roles in AD. We used cerebral microdialysis (MD) to test the hypothesis that interstitial A levels are altered following TBI and are related to the injury type, cerebral energy metabolism, age of the patient, and level of consciousness. In the present report, we evaluated 10 mechanically ventilated patients (7 male, 3 female, ages 18-76 years) with a severe TBI, who had intracranial pressure and MD monitoring. Each MD sample was analyzed for hourly routine energy metabolic biomarkers (MD-lactate, MD-pyruvate, MD-glucose, and MD-lactate/pyruvate ratio), cellular distress biomarkers (MD-glutamate, MD-glycerol), and MD-urea. The remaining MD samples were analyzed for A1-40 (A40; n=765 samples) and A1-42 (A42; n=765 samples) in pooled 2h fractions up to 14 days post-injury, using the Luminex xMAP technique, allowing detection with high temporal resolution of the key A peptides A40 and A42. Data are presented using medians and 25th and 75th percentiles. Both A40 and A42 were consistently higher in patients with predominately diffuse axonal injury compared with patients with focal TBI at days 1-6 post- injury, A42 being significantly increased at 113-116h post-injury (p<0.05). The A levels did not correlate with the interstitial energy metabolic situation, age of the patient, or the level of consciousness. These results support that interstitial generation of potentially toxic A species may occur following human TBI, particularly related to axonal injury.	[Marklund, Niklas; Farrokhnia, Nina; Hanell, Anders; Enblad, Per; Hillered, Lars] Uppsala Univ, Div Neurosurg, Dept Neurosurg, Uppsala, Sweden; [Vanmechelen, Eugeen] ADx NeuroSci, Ghent, Belgium; [Zetterberg, Henrik; Blennow, Kaj] Univ Gothenburg, Sahlgrenska Acad, Dept Psychiat & Neurochem, Inst Neurosci & Physiol, Molndal, Sweden; [Zetterberg, Henrik] UCL, Inst Neurol, London, England	Marklund, N (corresponding author), Univ Uppsala Hosp, Dept Neurosurg, SE-75185 Uppsala, Sweden.	Niklas.Marklund@neuro.uu.se	Vanmechelen, Eugeen/AAA-8005-2019; Hanell, Anders/E-4776-2011	Marklund, Niklas/0000-0002-9797-5626; Hillered, Lars/0000-0002-2808-9292; Hanell, Anders/0000-0001-9369-3886; Vanmechelen, Eugeen/0000-0002-9466-5366	Swedish Medical Research CouncilSwedish Medical Research Council (SMRC)European Commission; Swedish Brain Foundation; Selander Foundation; Ahlen Foundation; Uppsala University Hospital	The authors thank Per Bondegard and Inger Stahl-Myllyaho for technical assistance. This work was supported by funds from the Swedish Medical Research Council, Swedish Brain Foundation, Selander Foundation, and Ahlen Foundation, and by funds from the Uppsala University Hospital.	Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Badan I, 2004, EUR J NEUROSCI, V19, P2270, DOI 10.1111/j.0953-816X.2004.03323.x; Bellander BM, 2004, INTENS CARE MED, V30, P2166, DOI 10.1007/s00134-004-2461-8; Bibl M, 2004, ELECTROPHORESIS, V25, P2912, DOI 10.1002/elps.200305992; Bjerke M., 2010, INT J ALZHEIMERS DIS, V15; Blennow K, 2006, LANCET, V368, P387, DOI 10.1016/S0140-6736(06)69113-7; Brody DL, 2008, SCIENCE, V321, P1221, DOI 10.1126/science.1161591; Broersen K, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt36; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; Cirrito JR, 2008, NEURON, V58, P42, DOI 10.1016/j.neuron.2008.02.003; Cirrito JR, 2005, NEURON, V48, P913, DOI 10.1016/j.neuron.2005.10.028; Claeysen S, 2012, CELL SIGNAL, V24, P1831, DOI 10.1016/j.cellsig.2012.05.008; CLINTON J, 1991, NEUROPATH APPL NEURO, V17, P69, DOI 10.1111/j.1365-2990.1991.tb00695.x; DeKosky ST, 2007, ARCH NEUROL-CHICAGO, V64, P541, DOI 10.1001/archneur.64.4.541; Elf K, 2002, CRIT CARE MED, V30, P2129, DOI 10.1097/00003246-200209000-00029; Emmerling MR, 2000, ANN NY ACAD SCI, V903, P118, DOI 10.1111/j.1749-6632.2000.tb06357.x; Enblad P, 2001, STROKE, V32, P1574, DOI 10.1161/01.STR.32.7.1574; Esparza TJ, 2013, ANN NEUROL, V73, P104, DOI 10.1002/ana.23748; Franz G, 2003, NEUROLOGY, V60, P1457, DOI 10.1212/01.WNL.0000063313.57292.00; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Haacke EM, 2010, J MAGN RESON IMAGING, V32, P516, DOI 10.1002/jmri.22259; Hansson O, 2010, NEUROBIOL AGING, V31, P357, DOI 10.1016/j.neurobiolaging.2008.03.027; Hillered L, 2006, CURR OPIN CRIT CARE, V12, P112, DOI 10.1097/01.ccx.0000216576.11439.df; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; Hong SY, 2011, J NEUROSCI, V31, P15861, DOI 10.1523/JNEUROSCI.3272-11.2011; Hutchinson PJ, 2002, J CEREBR BLOOD F MET, V22, P735, DOI 10.1097/00004647-200206000-00012; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; Kamenetz F, 2003, NEURON, V37, P925, DOI 10.1016/S0896-6273(03)00124-7; Kang JE, 2007, P NATL ACAD SCI USA, V104, P10673, DOI 10.1073/pnas.0700148104; Kang JE, 2009, SCIENCE, V326, P1005, DOI 10.1126/science.1180962; Kay AD, 2003, J NEUROTRAUM, V20, P943, DOI 10.1089/089771503770195795; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Koffie RM, 2012, BRAIN, V135, P2155, DOI 10.1093/brain/aws127; Koike MA, 2010, AM J PATHOL, V177, P300, DOI 10.2353/ajpath.2010.090750; Lachno DR, 2009, J NUTR HEALTH AGING, V13, P220, DOI 10.1007/s12603-009-0062-5; Lachno DR, 2012, J ALZHEIMERS DIS, V32, P905, DOI 10.3233/JAD-2012-121075; Lagares A, 2009, ACTA NEUROCHIR, V151, P341, DOI 10.1007/s00701-009-0194-8; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; Li J, 2010, J TRAUMA, V69, P1610, DOI 10.1097/TA.0b013e3181f5a9ed; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Magnoni S, 2012, BRAIN, V135, P1268, DOI 10.1093/brain/awr286; Magnoni S, 2010, ARCH NEUROL-CHICAGO, V67, P1068, DOI 10.1001/archneurol.2010.214; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; Marklund N, 2009, J NEUROSURG, V110, P1227, DOI 10.3171/2008.9.JNS08584; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Masters CL, 2006, J NEUROCHEM, V97, P1700, DOI 10.1111/j.1471-4159.2006.03989.x; MAYEUX R, 1993, ANN NEUROL, V33, P494, DOI 10.1002/ana.410330513; McAllister Thomas W, 2011, Dialogues Clin Neurosci, V13, P287; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Nunan J, 2000, FEBS LETT, V483, P6, DOI 10.1016/S0014-5793(00)02076-7; Olsson A, 2004, J NEUROL, V251, P870, DOI 10.1007/s00415-004-0451-y; Osler T, 1997, J TRAUMA, V43, P922, DOI 10.1097/00005373-199712000-00009; Pierce JES, 1996, J NEUROSCI, V16, P1083; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; PRICE DL, 1995, CURR OPIN NEUROL, V8, P268, DOI 10.1097/00019052-199508000-00004; Qi JP, 2007, J ALZHEIMERS DIS, V12, P335; Raby CA, 1998, J NEUROCHEM, V71, P2505; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; Ronne-Engstrom E, 2001, J NEUROSURG, V94, P397, DOI 10.3171/jns.2001.94.3.0397; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; Schipke CG, 2011, J ALZHEIMERS DIS, V26, P255, DOI 10.3233/JAD-2011-110329; Schulz MK, 2000, J NEUROSURG, V93, P808, DOI 10.3171/jns.2000.93.5.0808; Schwetye KE, 2010, NEUROBIOL DIS, V40, P555, DOI 10.1016/j.nbd.2010.06.018; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Servadei F, 2000, NEUROSURGERY, V46, P70; Skandsen T, 2010, J NEUROSURG, V113, P556, DOI 10.3171/2009.9.JNS09626; Skoglund K, 2009, NEUROCRIT CARE, V11, P135, DOI 10.1007/s12028-009-9255-3; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Smith DH, 2003, J NEUROSURG, V98, P1072, DOI 10.3171/jns.2003.98.5.1072; Tanzi RE, 2004, NEURON, V43, P605, DOI 10.1016/j.neuron.2004.08.024; Texido L, 2011, NEUROCHEM INT, V59, P954, DOI 10.1016/j.neuint.2011.07.006; Timofeev I, 2011, BRAIN, V134, P484, DOI 10.1093/brain/awq353; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Vanderstichele H, 2000, AMYLOID, V7, P245, DOI 10.3109/13506120009146438; Wang XJ, 2010, J ALZHEIMERS DIS, V21, P813, DOI 10.3233/JAD-2010-100216; Wen Y, 2004, BRAIN RES, V1009, P1, DOI 10.1016/j.brainres.2003.09.086; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wisniewski HM, 1996, FOLIA NEUROPATHOL, V34, P65; Yam PS, 1997, BRAIN RES, V760, P150, DOI 10.1016/S0006-8993(97)00290-4; Zetterberg H, 2006, ARCH NEUROL-CHICAGO, V63, P1277, DOI 10.1001/archneur.63.9.1277; Zetterberg H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028263	88	41	44	0	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 1	2014	31	1					42	55		10.1089/neu.2013.2964			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	302WJ	WOS:000330635500005	23829439				2021-06-18	
J	Neumann, D; Zupan, B; Malec, JF; Hammond, F				Neumann, Dawn; Zupan, Barbra; Malec, James F.; Hammond, Flora			Relationships Between Alexithymia, Affect Recognition, and Empathy After Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						alexithymia; empathy; traumatic brain injury; rehabilitation; emotion recognition	FACIAL AFFECT RECOGNITION; EMOTION PERCEPTION; NONVERBAL-COMMUNICATION; INDIVIDUAL-DIFFERENCES; SOCIAL-PERCEPTION; COGNITIVE EMPATHY; DEFICITS; IMPAIRMENT; NEUROBIOLOGY; COMPETENCE	Objectives: To determine (1) alexithymia, affect recognition, and empathy differences in participants with and without traumatic brain injury (TBI); (2) the amount of affect recognition variance explained by alexithymia; and (3) the amount of empathy variance explained by alexithymia and affect recognition. Participants: Sixty adults with moderate-to-severe TBI; 60 age and gender-matched controls. Procedures: Participants were evaluated for alexithymia (difficulty identifying feelings, difficulty describing feelings, and externally-oriented thinking); facial and vocal affect recognition; and affective and cognitive empathy (empathic concern and perspective-taking, respectively). Results: Participants with TBI had significantly higher alexithymia; poorer facial and vocal affect recognition; and lower empathy scores. For TBI participants, facial and vocal affect recognition variances were significantly explained by alexithymia (12% and 8%, respectively); however, the majority of the variances were accounted for by externally-oriented thinking alone. Affect recognition and alexithymia significantly accounted for 16.5% of cognitive empathy. Again, the majority of the variance was primarily explained by externally-oriented thinking. Affect recognition and alexithymia did not explain affective empathy. Conclusions: Results suggest that people who have a tendency to avoid thinking about emotions (externally-oriented thinking) are more likely to have problems recognizing others' emotions and assuming others' points of view. Clinical implications are discussed.	[Neumann, Dawn; Malec, James F.; Hammond, Flora] Indiana Univ Sch Med, Dept Phys Med & Rehabil, Indianapolis, IN 46254 USA; [Neumann, Dawn; Malec, James F.; Hammond, Flora] Rehabil Hosp Indiana, Indianapolis, IN 46254 USA; [Zupan, Barbra] Brock Univ, Dept Appl Linguist, St Catharines, ON L2S 3A1, Canada	Neumann, D (corresponding author), Indiana Univ Sch Med, Dept Phys Med & Rehabil, 4141 Shore Dr, Indianapolis, IN 46254 USA.	dmneuman@iupui.edu		Barbra, Zupan/0000-0002-4603-333X	Cannon Research Center at Carolinas Rehabilitation in Charlotte, North Carolina; Humanity Research Institute at Brock University	This work was supported by Cannon Research Center at Carolinas Rehabilitation in Charlotte, North Carolina, and the Humanity Research Institute at Brock University.	Adolphs R, 2000, J NEUROSCI, V20, P2683; Adolphs R, 2002, CURR OPIN NEUROBIOL, V12, P169, DOI 10.1016/S0959-4388(02)00301-X; Babbage DR, 2011, NEUROPSYCHOLOGY, V25, P277, DOI 10.1037/a0021908; BAGBY RM, 1994, J PSYCHOSOM RES, V38, P33, DOI 10.1016/0022-3999(94)90006-X; BAGBY RM, 1994, J PSYCHOSOM RES, V38, P23, DOI 10.1016/0022-3999(94)90005-1; Bird G, 2010, BRAIN, V133, P1515, DOI 10.1093/brain/awq060; Brooks N., 1984, CLOSED HEAD INJURY P; Cox CL, 2012, SOC COGN AFFECT NEUR, V7, P727, DOI 10.1093/scan/nsr051; Davis M.H, 1980, J PERS SOC PSYCHOL, V10, P85; DAVIS MH, 1983, J PERS SOC PSYCHOL, V44, P113, DOI 10.1037/0022-3514.44.1.113; de Sousa A, 2011, CORTEX, V47, P526, DOI 10.1016/j.cortex.2010.02.004; de Sousa A, 2010, NEUROPSYCHOLOGIA, V48, P3585, DOI 10.1016/j.neuropsychologia.2010.08.008; ELSASS L, 1987, PSYCHOL MED, V17, P67, DOI 10.1017/S003329170001299X; Eslinger PJ, 2002, CURR OPIN NEUROL, V15, P91, DOI 10.1097/00019052-200202000-00014; Franz M, 2008, SOC PSYCH PSYCH EPID, V43, P54, DOI 10.1007/s00127-007-0265-1; GomezHernandez R, 1997, ARCH PHYS MED REHAB, V78, P1321, DOI 10.1016/S0003-9993(97)90304-X; Green REA, 2004, NEUROPSYCHOLOGIA, V42, P133, DOI 10.1016/j.neuropsychologia.2003.07.005; Grynberg D, 2010, PERS INDIV DIFFER, V49, P845, DOI 10.1016/j.paid.2010.07.013; Henry JD, 2006, NEUROPSYCHOLOGIA, V44, P62, DOI 10.1016/j.neuropsychologia.2005.04.011; Hornak J, 2003, BRAIN, V126, P1691, DOI 10.1093/brain/awg168; Jessimer M, 1997, BRAIN COGNITION, V34, P246, DOI 10.1006/brcg.1997.0900; Koponen S, 2005, PSYCHOSOM MED, V67, P807, DOI 10.1097/01.psy.0000181278.92249.e5; Lane RD, 1996, PSYCHOSOM MED, V58, P203, DOI 10.1097/00006842-199605000-00002; Lane RD, 2000, PSYCHOSOM MED, V62, P492, DOI 10.1097/00006842-200007000-00007; Larsen JK, 2003, J PSYCHOSOM RES, V54, P533, DOI 10.1016/S0022-3999(02)00466-X; Lawrence EJ, 2006, NEUROIMAGE, V29, P1173, DOI 10.1016/j.neuroimage.2005.09.001; LEZAK MD, 1988, J LEARN DISABIL, V21, P456, DOI 10.1177/002221948802100802; Lough S, 2006, NEUROPSYCHOLOGIA, V44, P950, DOI 10.1016/j.neuropsychologia.2005.08.009; Malec JF, 2007, J NEUROTRAUM, V24, P1417, DOI 10.1089/neu.2006.0245; MAYER JD, 1990, J PERS ASSESS, V54, P772, DOI 10.1207/s15327752jpa5403&4_29; MCDONALD PW, 1990, PSYCHOSOM MED, V52, P199, DOI 10.1097/00006842-199003000-00007; McDonald S, 2005, J INT NEUROPSYCH SOC, V11, P392, DOI 10.1017/S1355617705050447; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; McDonald S, 2011, BRAIN IMPAIR, V12, P165; MEHRABIAN A, 1972, J PERS, V40, P525, DOI 10.1111/j.1467-6494.1972.tb00078.x; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; Nowicki S, 1998, GENET SOC GEN PSYCH, V124, P39; NOWICKI S, 1994, J NONVERBAL BEHAV, V18, P9, DOI 10.1007/BF02169077; NOWICKI S, 1989, J GENET PSYCHOL, V150, P39, DOI 10.1080/00221325.1989.9914572; PARKER JDA, 1993, PSYCHOTHER PSYCHOSOM, V59, P197, DOI 10.1159/000288664; Parker JDA, 2001, PERS INDIV DIFFER, V30, P107, DOI 10.1016/S0191-8869(00)00014-3; Pelphrey KA, 2004, J COGNITIVE NEUROSCI, V16, P1706, DOI 10.1162/0898929042947900; Phillips ML, 2003, BIOL PSYCHIAT, V54, P504, DOI 10.1016/S0006-3223(03)00168-9; Phillips ML, 2003, BRIT J PSYCHIAT, V182, P190, DOI 10.1192/bjp.182.3.190; Radice-Neumann D, 2007, BRAIN INJURY, V21, P807, DOI 10.1080/02699050701504281; Radice-Neumann D, 2009, J HEAD TRAUMA REHAB, V24, P313, DOI 10.1097/HTR.0b013e3181b09160; RIGGIO RE, 1989, PERS INDIV DIFFER, V10, P93, DOI 10.1016/0191-8869(89)90184-0; Shamay-Tsoory SG, 2004, J CLIN EXP NEUROPSYC, V26, P1113, DOI 10.1080/13803390490515531; Shamay-Tsoory SG, 2003, J COGNITIVE NEUROSCI, V15, P324, DOI 10.1162/089892903321593063; Shamay-Tsoory SG, 2009, BRAIN, V132, P617, DOI 10.1093/brain/awn279; SIFNEOS PE, 1973, PSYCHOTHER PSYCHOSOM, V22, P255, DOI 10.1159/000286529; Spell LA, 2000, J NONVERBAL BEHAV, V24, P285, DOI 10.1023/A:1006675230193; Taylor G. J., 1997, DISORDERS AFFECT REG; Watts AJ, 2006, APHASIOLOGY, V20, P707, DOI 10.1080/02687030500489953; Williams C, 2010, J CLIN EXP NEUROPSYC, V32, P259, DOI 10.1080/13803390902976940; Wood RL, 2005, BRAIN INJURY, V19, P845, DOI 10.1080/02699050500058778; Wood RL, 2008, J INT NEUROPSYCH SOC, V14, P289, DOI 10.1017/S1355617708080326; YIRMIYA N, 1992, CHILD DEV, V63, P150, DOI 10.1111/j.1467-8624.1992.tb03603.x	58	41	41	1	38	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2014	29	1					E18	E27		10.1097/HTR.0b013e31827fb0b5			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AH1OC	WOS:000335889400005	23407425				2021-06-18	
J	Brown, FL; Whittingham, K; Sofronoff, K; Boyd, RN				Brown, Felicity L.; Whittingham, Koa; Sofronoff, Kate; Boyd, Roslyn N.			Parenting a child with a traumatic brain injury: Experiences of parents and health professionals	BRAIN INJURY			English	Article						Family; focus group; parent; qualitative research; traumatic brain injury	FAMILY OUTCOMES; YOUNG-CHILDREN; REHABILITATION; PREDICTORS; ADOLESCENTS; DISTRESS; BURDEN; TBI; DISSEMINATION; DISABILITIES	Objective: To qualitatively explore the experiences, challenges and needs of parents of children with traumatic brain injury (TBI) in order to inform future intervention research through incorporation of participant knowledge and experience. Methods: Parents of children with TBI (n = 10) and experienced health professionals in paediatric rehabilitation (n = 5) took part in focus groups or individual interviews. Audio recordings were transcribed verbatim and an inductive thematic analysis performed. Findings: Participants reported that, beyond the impact of the injury on the child, TBI affects the entire family. Parents need to adjust to and manage their child's difficulties and can also experience significant emotional distress, relationship discord and burden of care, further adding to the challenges of the parenting role. Parents can feel isolated and the importance of empowerment, support and information was emphasized. Coping styles of disengagement and avoidance were often reported, despite acknowledgement that these were not beneficial. Conclusions: Parenting interventions may provide essential support for parents in adjusting to and managing their child's difficulties and the efficacy of existing programmes needs evaluation. Addressing parent emotional adjustment and coping strategies is vital following paediatric TBI, given the impact on parent well-being and the potential negative effects on child outcomes through reduced parenting effectiveness. Group programmes may enable connection and support.	[Brown, Felicity L.; Whittingham, Koa; Sofronoff, Kate] Univ Queensland, Sch Psychol, Fac Social & Behav Sci, Brisbane, Qld, Australia; [Brown, Felicity L.; Whittingham, Koa; Boyd, Roslyn N.] Univ Queensland, Sch Med, Queensland Cerebral Palsy & Rehabil Res Ctr, Brisbane, Qld, Australia; [Brown, Felicity L.] Univ Queensland, Fac Hlth Sci, Queensland Childrens Med Res Inst, Brisbane, Qld, Australia	Brown, FL (corresponding author), Univ Queensland, Dept Psychol, St Lucia, Qld 4072, Australia.	f.brown@psy.uq.edu.au	Whittingham, Koa L/C-6766-2009; Boyd, Roslyn N/A-4498-2011	Whittingham, Koa L/0000-0002-5344-9907; Boyd, Roslyn N/0000-0002-4919-5975; Brown, Felicity/0000-0001-6800-1657	QCMRI [50002]; NHMRCNational Health and Medical Research Council of Australia [631712, 1037220]; Smart State Fellowship; University of Queensland FoundationUniversity of Queensland	The authors acknowledge a QCMRI PhD Scholarship (50002) (FB), an NHMRC postdoctoral fellowship (631712) (KW) and an NHMRC Career Development Fellowship (1037220), Smart State Fellowship and the University of Queensland Foundation support (RB). The authors report no conflicts of interest.	Aitken ME, 2009, PEDIATRICS, V123, P199, DOI 10.1542/peds.2008-0607; Anderson V, 2006, AM J PHYS MED REHAB, V85, P767, DOI 10.1097/01.phm.0000233176.08480.22; Anderson VA, 2001, PEDIATR NEUROSURG, V34, P138, DOI 10.1159/000056009; Anderson V, 2012, INT J DEV NEUROSCI, V30, P217, DOI 10.1016/j.ijdevneu.2011.09.008; Anderson V, 2011, NEUROPSYCHOLOGY, V25, P176, DOI 10.1037/a0021217; Blackledge JT, 2006, CHILD FAM BEHAV THER, V28, P1, DOI 10.1300/J019v28n01_01; Boschen K, 2007, NEUROREHABILITATION, V22, P19; Braga LW, 2005, BRAIN INJURY, V19, P819, DOI 10.1080/02699050500110165; Braun V., 2006, QUALITATIVE RES PSYC, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706qp063oa]; Brown FL, 2012, J HEAD TRAUMA REHABI; Catroppa C, 2008, J PEDIATR PSYCHOL, V33, P707, DOI 10.1093/jpepsy/jsn006; Catroppa C, 2009, DEV NEUROREHABIL, V12, P53, DOI 10.1080/17518420802634476; Clark Alex, 2008, Clin Child Psychol Psychiatry, V13, P565, DOI 10.1177/1359104508090607; Cole WR, 2009, DEV DISABIL RES REV, V15, P159, DOI 10.1002/ddrr.58; Eakes G G, 1998, Image J Nurs Sch, V30, P179; Eyberg S., 1988, CHILD FAM BEHAV THER, V10, P33, DOI [DOI 10.1300/J019V10N01_04, 10.1300/J019v10n01_04]; Fay TB, 2009, NEUROPSYCHOLOGY, V23, P271, DOI 10.1037/a0014936; Ganesalingam K, 2008, J PEDIATR PSYCHOL, V33, P621, DOI 10.1093/jpepsy/jsm133; Gerrard-Morris A, 2010, J INT NEUROPSYCH SOC, V16, P157, DOI 10.1017/S1355617709991135; Glidden LM, 2006, J INTELL DISABIL RES, V50, P949, DOI 10.1111/j.1365-2788.2006.00929.x; Greco LA, 2005, BEHAV THER, V36, P177, DOI 10.1016/S0005-7894(05)80066-8; Hawley CA, 2003, BRAIN INJURY, V17, P1, DOI 10.1080/0269905021000010096; Hayes SC, 2006, BEHAV RES THER, V44, P1, DOI 10.1016/j.brat.2005.06.006; Helgeson VS, 2006, J CONSULT CLIN PSYCH, V74, P797, DOI 10.1037/0022-006X.74.5.797; Kinsella G, 1999, J CONSULT CLIN PSYCH, V67, P116, DOI 10.1037/0022-006X.67.1.116; Kurowski BG, 2011, PM&R, V3, P836, DOI 10.1016/j.pmrj.2011.05.016; Lloyd T, 2008, J INTELL DISABIL RES, V52, P37, DOI 10.1111/j.1365-2788.2007.00974.x; Micklewright JL, 2012, J INT NEUROPSYCH SOC, V18, P343, DOI 10.1017/S1355617711001792; Morse J.M., 2008, INT J QUAL METHODS, V1, P13, DOI [10.1177/160940690200100202, DOI 10.1177/160940690200100202]; Prigatano GP, 2007, BRAIN INJURY, V21, P721, DOI 10.1080/02699050701481605; Ross KA, 2011, DEV MED CHILD NEUROL, V53, P692, DOI 10.1111/j.1469-8749.2011.03976.x; Rotondi AJ, 2007, J HEAD TRAUMA REHAB, V22, P14, DOI 10.1097/00001199-200701000-00002; Samios C, 2009, RES AUTISM SPECT DIS, V3, P358, DOI 10.1016/j.rasd.2008.08.003; Sanders MR, 2012, ANNU REV CLIN PSYCHO, V8, P345, DOI 10.1146/annurev-clinpsy-032511-143104; Sanders MR, 2012, BEHAV THER, V43, P236, DOI 10.1016/j.beth.2011.01.005; Stancin T, 2008, J DEV BEHAV PEDIATR, V29, P253, DOI 10.1097/DBP.0b013e31816b6b0f; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; Verhaeghe S, 2005, J CLIN NURS, V14, P1004, DOI 10.1111/j.1365-2702.2005.01126.x; Wade SL, 2011, DEV PSYCHOL, V47, P119, DOI 10.1037/a0021028; Wade SL, 2010, NEUROREHABILITATION, V27, P63, DOI 10.3233/NRE-2010-0581; Wade SL, 2004, J CONSULT CLIN PSYCH, V72, P776, DOI 10.1037/0022-006X.72.5.776; Wade SL, 2001, J CONSULT CLIN PSYCH, V69, P406, DOI 10.1037//0022-006X.69.3.406; WEBSTERSTRATTON C, 1990, BEHAV THER, V21, P319, DOI 10.1016/S0005-7894(05)80334-X; Whittingham K, 2013, CHILD CARE HLTH DEV, V39, P366, DOI 10.1111/j.1365-2214.2012.01396.x; Yeates KO, 2002, J PEDIATR PSYCHOL, V27, P393, DOI 10.1093/jpepsy/27.4.393; Ylvisaker M, 2005, J HEAD TRAUMA REHAB, V20, P95, DOI 10.1097/00001199-200501000-00009; Zinner ES, 1997, ARCH CLIN NEUROPSYCH, V12, P435, DOI 10.1016/S0887-6177(96)00034-0	47	41	41	1	23	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	DEC	2013	27	13-14					1570	1582		10.3109/02699052.2013.841996			13	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	259BW	WOS:000327503400011	24111604				2021-06-18	
J	Sommerauer, M; Valko, PO; Werth, E; Baumann, CR				Sommerauer, Michael; Valko, Philipp O.; Werth, Esther; Baumann, Christian R.			Excessive sleep need following traumatic brain injury: a case-control study of 36 patients	JOURNAL OF SLEEP RESEARCH			English	Article						excessive daytime sleepiness; hypersomnia; raumatic brain injury	FOCAL CEREBRAL-ISCHEMIA; CLOSED HEAD INJURY; PRACTICE PARAMETERS; DAYTIME SLEEPINESS; LESIONS; SCALE; RECOVERY; RAT	Increased sleep need following traumatic brain injury, referred to in this study as post-traumatic pleiosomnia, is common, but so far its clinical impact and therapeutic implications have not been characterized. We present a case-control study of 36 patients with post-traumatic pleiosomnia, defined by an increased sleep need of at least 2h per 24h after traumatic brain injury, compared to 36 controls. We assessed detailed history, sleep-activity patterns with sleep logs and actigraphy, nocturnal sleep with polysomnography and daytime sleep propensity with multiple sleep latency tests. Actigraphy recordings revealed that traumatic brain injury (TBI) patients had longer estimated sleep durations than controls (10.8h per 24h, compared to 7.3h). When using sleep logs, TBI patients underestimated their sleep need. During nocturnal sleep, patients had higher amounts of slow-wave sleep than controls (20 versus 13.8%). Multiple sleep latency tests revealed excessive daytime sleepiness in 15 patients (42%), and 10 of them had signs of chronic sleep deprivation. We conclude that post-traumatic pleiosomnia may be even more frequent than reported previously, because affected patients often underestimate their actual sleep need. Furthermore, these patients exhibit an increase in slow-wave sleep which may reflect recovery mechanisms, intrinsic consequences of diffuse brain damage or relative sleep deprivation.	[Sommerauer, Michael; Valko, Philipp O.; Werth, Esther; Baumann, Christian R.] Univ Zurich Hosp, Dept Neurol, CH-8091 Zurich, Switzerland	Sommerauer, M (corresponding author), Univ Zurich Hosp, Dept Neurol, Frauenklinikstr 26, CH-8091 Zurich, Switzerland.	michael.sommerauer@rwth-aachen.de	Werth, E/AAN-7955-2021	Baumann, Christian/0000-0003-3417-1978; Werth, Esther/0000-0002-5099-3122	Swiss National Science Foundation (SNF)Swiss National Science Foundation (SNSF) [32003B-125504]; Schweizerischer Versicherungs-verband (SVV)	This work was supported by the Swiss National Science Foundation (SNF; 32003B-125504 to C. B.; www.snf.ch) and an unrestricted grant of the Schweizerischer Versicherungs-verband (SVV). The SNF is an independent national non-profit funding organization. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	American Academy of Sleep Medicine, 2005, ICSD 2 INT CLASS SLE; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Baumann CR, 2009, ANN NEUROL, V66, P555, DOI 10.1002/ana.21836; Baumann CR, 2005, NEUROLOGY, V65, P147, DOI 10.1212/01.wnl.0000167605.02541.f2; Bloch KE, 1999, RESPIRATION, V66, P440, DOI 10.1159/000029408; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Carmichael ST, 2002, J NEUROSCI, V22, P6062; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; CROMPTON MR, 1971, LANCET, V1, P669; CROMPTON MR, 1971, BRAIN, V94, P165, DOI 10.1093/brain/94.1.165; Dijk Derk-Jan, 2009, J Clin Sleep Med, V5, pS6; Fronczek R, 2007, BRAIN, V130, P1577, DOI 10.1093/brain/awm090; Gao B, 2008, CEREBROVASC DIS, V26, P413, DOI 10.1159/000151683; Gao B, 2010, SLEEP, V33, P879, DOI 10.1093/sleep/33.7.879; Gerashchenko D, 2003, EXP NEUROL, V184, P1010, DOI 10.1016/S0014-4886(03)00388-1; Iber C, 2007, AASM MANUAL SCORING; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Kaiser PR, 2010, NEUROLOGY, V75, P1780, DOI 10.1212/WNL.0b013e3181fd62a2; Kempf J, 2010, J NEUROL NEUROSUR PS, V81, P1402, DOI 10.1136/jnnp.2009.201913; Littner MR, 2005, SLEEP, V28, P113, DOI 10.1093/sleep/28.1.113; Morgenthaler T, 2007, SLEEP, V30, P519, DOI 10.1093/sleep/30.4.519; Pizza F, 2013, J SLEEP RES, V22, P32, DOI 10.1111/j.1365-2869.2012.01032.x; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Stickgold R, 2001, SCIENCE, V294, P1052, DOI 10.1126/science.1063530; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Valko PO, 2008, SLEEP, V31, P1601, DOI 10.1093/sleep/31.11.1601; Verma A, 2007, J CLIN SLEEP MED, V3, P357; Zunzunegui C, 2011, SLEEP, V34, P1261, DOI 10.5665/SLEEP.1252	28	41	43	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0962-1105	1365-2869		J SLEEP RES	J. Sleep Res.	DEC	2013	22	6					634	639		10.1111/jsr.12068			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	250VI	WOS:000326884000005	23837871	Bronze			2021-06-18	
J	Shakeri, M; Boustani, MR; Pak, N; Panahi, F; Salehpour, F; Lotfinia, I; Meshkini, A; Daghighi, S; Vahedi, P; Khani, M; Taghiloo, D				Shakeri, Moslem; Boustani, Mohammad Reza; Pak, Neda; Panahi, Farid; Salehpour, Firouz; Lotfinia, Iraj; Meshkini, Ali; Daghighi, Shadi; Vahedi, Payman; Khani, Mehdi; Taghiloo, Dariush			Effect of progesterone administration on prognosis of patients with diffuse axonal injury due to severe head trauma	CLINICAL NEUROLOGY AND NEUROSURGERY			English	Article						Glasgow coma scale; Traumatic brain injury; Progesterone; Diffuse axonal injury; Neuro-protective agent	BRAIN-INJURY; CEREBRAL-ISCHEMIA; CONTUSION INJURY; RATS; PROTECTS; DAMAGE; TRIAL; DEATH	Objective: Severe traumatic brain injury (TBI) has a major role in mortality rate among the other types of trauma. The aim of this clinical study was to assess the effect of progesterone on the improvement of neurologic outcome in patients with acute severe TBI. Methods: A total of 76 patients who had arrived within 8 h of injury with a Glasgow Coma Score <= 8 were enrolled in the study. In a randomized style 38 received progesterone (1 mg/kg per 12 h for 5 days) and 38 did not. Results: There was a better recovery rate and GOS score for the patients who were given progesterone than for those in the control group in a 3-months follow-up period (50% vs. 21%); subgroup analysis showed a significant difference in the percentage of favorable outcome between the two groups with GCS of 5-8 (p = 0.03). Conclusion: The use of progesterone may significantly improve neurologic outcome of patients suffering severe TBI up to 3 months after injury, especially those with 5 <= GCS <= 8, providing a potential benefit to the treatment of acute severe TBI patients. Considering this drug had no significant side effects, so progesterone could be used in patients with severe TBI as a neuro-protective drug. (C) 2013 Elsevier B.V. All rights reserved.	[Shakeri, Moslem; Boustani, Mohammad Reza; Salehpour, Firouz; Lotfinia, Iraj; Meshkini, Ali] Tabriz Univ Med Sci, Sch Med, Imam Reza Teaching Hosp, Dept Neurosurg, Tabriz, Iran; [Pak, Neda] Univ Tehran Med Sci, Childrens Hosp, Med Ctr, Dept Radiol, Tehran, Iran; [Panahi, Farid] Tabriz Univ Med Sci, Sch Med, Imam Reza Teaching Hosp, Neurosci Res Ctr, Tabriz, Iran; [Daghighi, Shadi; Khani, Mehdi] Tabriz Univ Med Sci, Sch Med, Tabriz, Iran; [Vahedi, Payman] Mashhad Univ Med Sci, Nishabour Fac Med, Dept Neurosurg, Mashhad, Iran; [Panahi, Farid] Tabriz Univ Med Sci, Sch Med, Student Div, Res Dev & Coordinat Ctr, Tabriz, Iran; [Taghiloo, Dariush] Tabriz Univ Med Sci, Sch Med, Imam Reza Teaching Hosp, Dept Emergency Med, Tabriz, Iran	Panahi, F (corresponding author), Tabriz Univ Med Sci, Sch Med, Imam Reza Teaching Hosp, Neurosci Res Ctr, Golgasht Ave,POB 5166859188, Tabriz, Iran.	mb_np_dr@yahoo.com; Farid.Panahi@gmail.com	Taghiloo, Dariush/N-8244-2016; Panahi, Farid/K-3021-2012; MESHKINI, ALI -/M-1009-2017; salehpour, firooz/L-8833-2017	Taghiloo, Dariush/0000-0002-1101-2627; Panahi, Farid/0000-0002-8237-6989; MESHKINI, ALI -/0000-0001-6996-5028; salehpour, firooz/0000-0003-0693-6400	Tabriz University of Medical Sciences	Source of Support: Research Deputy of Tabriz University of Medical Sciences.	Asbury ET, 1998, BEHAV BRAIN RES, V97, P99, DOI 10.1016/S0166-4328(98)00031-X; Cervantes M, 2002, ARCH MED RES, V33, P6, DOI 10.1016/S0188-4409(01)00347-2; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Feeser VR, 2011, J NEUROIMMUNOL, V237, P4, DOI 10.1016/j.jneuroim.2011.06.007; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; JENNETT B, 1975, LANCET, V1, P480; Kumon Y, 2000, J NEUROSURG, V92, P848, DOI 10.3171/jns.2000.92.5.0848; O'Connor CA, 2007, EXP NEUROL, V205, P145, DOI 10.1016/j.expneurol.2007.01.034; Pan DS, 2007, BIOMED ENVIRON SCI, V20, P432; Ransohoff RM, 1998, TRENDS NEUROSCI, V21, P154, DOI 10.1016/S0166-2236(97)01198-3; ROOF RL, 1992, RESTOR NEUROL NEUROS, V4, P425, DOI 10.3233/RNN-1992-4608; ROOF RL, 1993, BEHAV BRAIN RES, V57, P47, DOI 10.1016/0166-4328(93)90060-4; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; XIAO GM, 2007, ZHONGHUA WAI KE ZA Z, V4, P106; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887	20	41	44	0	10	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0303-8467	1872-6968		CLIN NEUROL NEUROSUR	Clin. Neurol. Neurosurg.	OCT	2013	115	10					2019	2022		10.1016/j.clineuro.2013.06.013			4	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	236XQ	WOS:000325833200016	23871679				2021-06-18	
J	Treble, A; Hasan, KM; Iftikhar, A; Stuebing, KK; Kramer, LA; Cox, CS; Swank, PR; Ewing-Cobbs, L				Treble, Amery; Hasan, Khader M.; Iftikhar, Amal; Stuebing, Karla K.; Kramer, Larry A.; Cox, Charles S., Jr.; Swank, Paul R.; Ewing-Cobbs, Linda			Working Memory and Corpus Callosum Microstructural Integrity after Pediatric Traumatic Brain Injury: A Diffusion Tensor Tractography Study	JOURNAL OF NEUROTRAUMA			English	Article						axonal injury; cognitive function; diffusion tensor imaging; pediatric brain injury	WHITE-MATTER INTEGRITY; MEDIAL TEMPORAL-LOBE; CLOSED-HEAD-INJURY; INTRUSION ERRORS; WATER DIFFUSION; AXONAL INJURY; CHILDREN; INFORMATION; MODERATE; DEFICITS	Deficits in working memory (WM) are a common consequence of pediatric traumatic brain injury (TBI) and are believed to contribute to difficulties in a range of cognitive and academic domains. Reduced integrity of the corpus callosum (CC) after TBI may disrupt the connectivity between bilateral frontoparietal neural networks underlying WM. In the present investigation, diffusion tensor imaging (DTI) tractography of eight callosal subregions (CC1-CC8) was examined in relation to measures of verbal and visuospatial WM in 74 children sustaining TBI and 49 typically developing comparison children. Relative to the comparison group, children with TBI demonstrated poorer visuospatial WM, but comparable verbal WM. Microstructure of the CC was significantly compromised in brain-injured children, with lower fractional anisotropy (FA) and higher axial and radial diffusivity metrics in all callosal subregions. In both groups of children, lower FA and/or higher radial diffusivity in callosal subregions connecting anterior and posterior parietal cortical regions predicted poorer verbal WM, whereas higher radial diffusivity in callosal subregions connecting anterior and posterior parietal, as well as temporal, cortical regions predicted poorer visuospatial WM. DTI metrics, especially radial diffusivity, in predictive callosal subregions accounted for significant variance in WM over and above remaining callosal subregions. Reduced microstructural integrity of the CC, particularly in subregions connecting parietal and temporal cortices, may act as a neuropathological mechanism contributing to long-term WM deficits. The future clinical use of neuroanatomical biomarkers may allow for the early identification of children at highest risk for WM deficits and earlier provision of interventions for these children.	[Treble, Amery] Univ Houston, Dept Psychol, Houston, TX USA; [Hasan, Khader M.; Iftikhar, Amal] Univ Texas Hlth Sci Ctr Houston, Dept Diagnost Imaging, Houston, TX 77030 USA; [Stuebing, Karla K.] Univ Houston, Texas Inst Measurement Evaluat & Stat, Houston, TX USA; [Kramer, Larry A.] Univ Texas Hlth Sci Ctr Houston, Dept Diagnost & Intervent Imaging, Houston, TX 77030 USA; [Cox, Charles S., Jr.] Univ Texas Hlth Sci Ctr Houston, Dept Pediat Surg, Houston, TX 77030 USA; [Swank, Paul R.; Ewing-Cobbs, Linda] Univ Texas Hlth Sci Ctr Houston, Childrens Learning Inst, Houston, TX 77030 USA	Ewing-Cobbs, L (corresponding author), Univ Texas Hlth Sci Ctr Houston, Childrens Learning Inst, 7000 Fannin,Suite 2401, Houston, TX 77030 USA.	linda.ewing-cobbs@uth.tmc.edu	Hasan, Khader M./ABB-5767-2020		National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NIH-R01 NS046308, NIH-R01 NS052505]; Dunn Research Fund; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [S10-RR19186]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000371] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [S10RR019186] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS052505, R01NS046308] Funding Source: NIH RePORTER	This work was funded by the National Institutes of Health (NIH-R01 NS046308 [awarded to L. E. C.] and NIH-R01 NS052505) and the Dunn Research Fund (to K. M. H.). The purchase of the 3.0 T MRI Clinical Scanner was partially funded by the NIH (grant no.: S10-RR19186; to Dr. Ponnada A. Narayana). The content is solely the responsibility of the authors and does not necessarily represent the official views of the granting institutes. The authors thank Vipul Kumar Patel for helping in data acquisition.	Aboitiz F, 2003, BRAZ J MED BIOL RES, V36, P409, DOI 10.1590/S0100-879X2003000400002; ABOITIZ F, 1992, BRAIN RES, V598, P143, DOI 10.1016/0006-8993(92)90178-C; Alexander AL, 2007, NEUROTHERAPEUTICS, V4, P316, DOI 10.1016/j.nurt.2007.05.011; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2010, J PEDIATR PSYCHOL, V35, P716, DOI 10.1093/jpepsy/jsp100; Anderson V, 2010, NEUROPSYCHOLOGIA, V48, P2041, DOI 10.1016/j.neuropsychologia.2010.03.025; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Baddeley A, 2003, NAT REV NEUROSCI, V4, P829, DOI 10.1038/nrn1201; Baddeley A.D., 1999, MODELS WORKING MEMOR, P28, DOI DOI 10.1017/CBO9781139174909.005; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782; Benavidez DA, 1999, CORTEX, V35, P315, DOI 10.1016/S0010-9452(08)70803-7; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Burzynska AZ, 2011, CEREB CORTEX, V21, P2261, DOI 10.1093/cercor/bhq293; Caeyenberghs K, 2011, J NEUROTRAUM, V28, P897, DOI 10.1089/neu.2010.1721; CASEY BJ, 1995, NEUROIMAGE, V2, P221, DOI 10.1006/nimg.1995.1029; Charlton RA, 2008, NEUROBIOL AGING, V29, P1547, DOI 10.1016/j.neurobiolaging.2007.03.017; Charlton RA, 2010, CORTEX, V46, P474, DOI 10.1016/j.cortex.2009.07.005; Conklin HM, 2008, BRAIN INJURY, V22, P847, DOI 10.1080/02699050802403565; Cornoldi C, 2006, MEMORY, V14, P176, DOI 10.1080/09658210544000033; Cornoldi C, 2001, CHILD NEUROPSYCHOL, V7, P230, DOI 10.1076/chin.7.4.230.8735; Curtis CE, 2006, HDB FUNCTIONAL NEURO, P269; DANEMAN M, 1980, J VERB LEARN VERB BE, V19, P450, DOI 10.1016/S0022-5371(80)90312-6; De Beni R, 1998, Q J EXP PSYCHOL-A, V51, P305, DOI 10.1080/713755761; de la Plata CDM, 2011, J INT NEUROPSYCH SOC, V17, P24, DOI 10.1017/S1355617710001189; Eluvathingal TJ, 2007, CEREB CORTEX, V17, P2760, DOI 10.1093/cercor/bhm003; Engle RW, 2002, CURR DIR PSYCHOL SCI, V11, P19, DOI 10.1111/1467-8721.00160; Ewing-Cobbs L, 2006, AM J NEURORADIOL, V27, P879; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V26, P487, DOI 10.1207/s15326942dn2601_7; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Ewing-Cobbs L, 2006, J NEUROSURG, V105, P287, DOI 10.3171/ped.2006.105.4.287; Farbota KD, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00160; Fay TB, 2009, NEUROPSYCHOLOGY, V23, P271, DOI 10.1037/a0014936; Gathercole SE, 2004, DEV PSYCHOL, V40, P177, DOI 10.1037/0012-1649.40.2.177; Gennarelli T. A., 1998, SEM CLIN NEUR, V3, P160; Gorman S, 2012, J INT NEUROPSYCH SOC, V18, P29, DOI 10.1017/S1355617711001251; Graham KS, 2010, NEUROPSYCHOLOGIA, V48, P831, DOI 10.1016/j.neuropsychologia.2010.01.001; Hasan KM, 2007, MAGN RESON IMAGING, V25, P1196, DOI 10.1016/j.mri.2007.02.011; Hasan KM, 2009, BRAIN RES, V1249, P91, DOI 10.1016/j.brainres.2008.10.026; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; Huang H, 2005, NEUROIMAGE, V26, P195, DOI 10.1016/j.neuroimage.2005.01.019; Jiang HY, 2006, COMPUT METH PROG BIO, V81, P106, DOI 10.1016/j.cmpb.2005.08.004; Kaplan GB, 2010, BEHAV PHARMACOL, V21, P427, DOI 10.1097/FBP.0b013e32833d8bc9; Karlsgodt KH, 2008, BIOL PSYCHIAT, V63, P512, DOI 10.1016/j.biopsych.2007.06.017; Klingberg T, 2002, J COGNITIVE NEUROSCI, V14, P1, DOI 10.1162/089892902317205276; Klingberg T, 2006, NEUROPSYCHOLOGIA, V44, P2171, DOI 10.1016/j.neuropsychologia.2005.11.019; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kwon H, 2002, P NATL ACAD SCI USA, V99, P13336, DOI 10.1073/pnas.162486399; Levin HS, 2008, J HEAD TRAUMA REHAB, V23, P197, DOI 10.1097/01.HTR.0000327252.54128.7c; Levin HS, 2004, NEUROPSYCHOLOGY, V18, P240, DOI 10.1037/0894-4105.18.2.240; Levin HS, 2002, ANN NEUROL, V52, P82, DOI 10.1002/ana.10252; Levin HS, 2000, NEUROLOGY, V54, P647, DOI 10.1212/WNL.54.3.647; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mathias JL, 2004, J INT NEUROPSYCH SOC, V10, P286, DOI 10.1017/S1355617704102117; MENDELSOHN DB, 1992, NEURORADIOLOGY, V34, P384, DOI 10.1007/BF00596495; Miyake A., 1999, MODELS WORKING MEMOR; Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3; Moseley M, 2002, BRAIN COGNITION, V50, P396, DOI 10.1016/S0278-2626(02)00524-9; Nagy Z, 2004, J COGNITIVE NEUROSCI, V16, P1227, DOI 10.1162/0898929041920441; Nelson CA, 2000, DEV PSYCHOL, V36, P109, DOI 10.1037/0012-1649.36.1.109; O'Hare ED, 2008, NEUROIMAGE, V42, P1678, DOI 10.1016/j.neuroimage.2008.05.057; Olesen PJ, 2003, COGNITIVE BRAIN RES, V18, P48, DOI 10.1016/j.cogbrainres.2003.09.003; Owen AM, 2005, HUM BRAIN MAPP, V25, P46, DOI 10.1002/hbm.20131; Palacios EM, 2012, NEUROLOGY, V78, P852, DOI 10.1212/WNL.0b013e31824c465a; Palacios EM, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-24; Park HJ, 2008, HUM BRAIN MAPP, V29, P503, DOI 10.1002/hbm.20314; Passolunghi MC, 1999, MEM COGNITION, V27, P779; Pierpaoli C, 2001, NEUROIMAGE, V13, P1174, DOI 10.1006/nimg.2001.0765; Pollmann S, 2004, NEUROPSYCHOLOGY, V18, P710, DOI 10.1037/0894-4105.18.4.710; Ranganath C, 2005, TRENDS COGN SCI, V9, P374, DOI 10.1016/j.tics.2005.06.009; Ranganath C, 2001, NEURON, V31, P865, DOI 10.1016/S0896-6273(01)00411-1; Roncadin C, 2004, DEV NEUROPSYCHOL, V25, P21; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Schulte T, 2005, CEREB CORTEX, V15, P1384, DOI 10.1093/cercor/bhi020; Sesma HW, 2008, PEDIATRICS, V121, pE1686, DOI 10.1542/peds.2007-2461; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Sun SW, 2006, MAGN RESON MED, V55, P302, DOI 10.1002/mrm.20774; Tasker RC, 2006, DEV NEUROSCI-BASEL, V28, P302, DOI 10.1159/000094156; TEASDALE G, 1974, LANCET, V2, P81; Thomas KM, 1999, NEUROIMAGE, V10, P327, DOI 10.1006/nimg.1999.0466; Vallat-Azouvi C, 2007, J INT NEUROPSYCH SOC, V13, P770, DOI 10.1017/S1355617707070993; Wager TD, 2003, COGN AFFECT BEHAV NE, V3, P255, DOI 10.3758/CABN.3.4.255; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wilde EA, 2012, BRAIN IMAGING BEHAV, V6, P404, DOI 10.1007/s11682-012-9150-y; WITELSON SF, 1989, BRAIN, V112, P799, DOI 10.1093/brain/112.3.799; Wu TC, 2010, DEV NEUROSCI-BASEL, V32, P361, DOI 10.1159/000317058; Zaidel E., 2003, PARALLEL BRAIN COGNI	95	41	41	1	26	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT 1	2013	30	19					1609	1619		10.1089/neu.2013.2934			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	227WQ	WOS:000325146800001	23627735	Green Published			2021-06-18	
J	Classen, S; Wang, YN; Crizzle, AM; Winter, SM; Lanford, DN				Classen, Sherrilene; Wang, Yanning; Crizzle, Alexander M.; Winter, Sandra M.; Lanford, Desiree N.			Predicting Older Driver On-Road Performance by Means of the Useful Field of View and Trail Making Test Part B	AMERICAN JOURNAL OF OCCUPATIONAL THERAPY			English	Article						aging; automobile driving; cognition; ROC curve; vision tests	TRAUMATIC BRAIN-INJURY; DRIVING PERFORMANCE; PARKINSONS-DISEASE; VEHICLE CRASHES; VISUAL-SEARCH; ADULTS; IMPAIRMENT; CURVES; STROKE; RISK	The Useful Field of View(R) (UFOV) and Trail Making Test Part B (Trails B) are measures of divided attention. We determined which measure was more accurate in predicting on-road outcomes among drivers (N = 198, mean age = 73.86, standard deviation = 6.05). Receiver operating characteristic curves for the UFOV (Risk Index [RI] and Subtests 1-3) and Trails B significantly predicted on-road outcomes. Contrasting Trails B with the UFOV RI and subtests, the only difference was found between the UFOV RI and Trails B, indicating the UFOV RI was the best predictor of on-road outcomes. Misclassifications of drivers totaled 28 for the UFOV RI, 62 for Trails B, and 58 for UFOV Subtest 2. The UFOV RI is a superior test in predicting on-road outcomes, but the Trails B has acceptable accuracy and is comparable to the other UFOV subtests.	[Classen, Sherrilene] Univ Western Ontario, Sch Occupat Therapy, Elborn Coll, London, ON N6A 5B9, Canada; [Classen, Sherrilene; Crizzle, Alexander M.; Winter, Sandra M.; Lanford, Desiree N.] Univ Florida, Coll Publ Hlth & Hlth Profess, Inst Mobil Act & Participat, Gainesville, FL USA; [Classen, Sherrilene; Crizzle, Alexander M.; Winter, Sandra M.; Lanford, Desiree N.] Univ Florida, Coll Publ Hlth & Hlth Profess, Dept Occupat Therapy, Gainesville, FL USA; [Wang, Yanning] Univ Florida, Coll Publ Hlth & Hlth Profess, Dept Epidemiol, Gainesville, FL USA	Classen, S (corresponding author), Univ Western Ontario, Sch Occupat Therapy, Elborn Coll, London, ON N6A 5B9, Canada.	sclassen@uwo.ca		Crizzle, Alexander/0000-0002-5289-7257; Tilahin, Shimelis/0000-0001-8975-8026			BALL K, 1993, INVEST OPHTH VIS SCI, V34, P3110; Ball K, 1993, J Am Optom Assoc, V64, P71; Ball K, 2002, JAMA-J AM MED ASSOC, V288, P2271, DOI 10.1001/jama.288.18.2271; BALL KK, 1988, J OPT SOC AM A, V5, P2210, DOI 10.1364/JOSAA.5.002210; Bedard M, 2010, AM J OCCUP THER, V64, P336, DOI 10.5014/ajot.64.2.336; Classen S, 2011, AM J OCCUP THER, V65, P579, DOI 10.5014/ajot.2011.001073; Classen S, 2008, TRAFFIC INJ PREV, V9, P456, DOI 10.1080/15389580802260026; Clay OJ, 2005, OPTOMETRY VISION SCI, V82, P724, DOI 10.1097/01.opx.0000175009.08626.65; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Duchek JM, 1998, J GERONTOL B-PSYCHOL, V53, pP130, DOI 10.1093/geronb/53B.2.P130; Edwards JD, 2006, ARCH CLIN NEUROPSYCH, V21, P275, DOI 10.1016/j.acn.2006.03.001; Fisk GD, 2002, J HEAD TRAUMA REHAB, V17, P16, DOI 10.1097/00001199-200202000-00004; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Goode KT, 1998, J CLIN PSYCHOL MED S, V5, P425, DOI 10.1023/A:1026206927686; Hunt LA, 2010, AM J OCCUP THER, V64, P105, DOI 10.5014/ajot.64.1.105; Justiss MD, 2006, TOP GERIATR REHABIL, V22, P121; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Mackworth NH, 1965, PSYCHON SCI, V3, P67, DOI [10.3758/BF03343023, DOI 10.3758/BF03343023]; Marcotte TD, 2004, NEUROLOGY, V63, P1417, DOI 10.1212/01.WNL.0000141920.33580.5D; Marshall SC, 2007, TOP STROKE REHABIL, V14, P98, DOI 10.1310/tsr1401-98; Mazer BL, 2003, ARCH PHYS MED REHAB, V84, P541, DOI 10.1053/apmr.2003.50085; MILNER B, 1963, ARCH NEUROL-CHICAGO, V9, P90, DOI 10.1001/archneur.1963.00460070100010; Mullen NW, 2010, AM J OCCUP THER, V64, P288, DOI 10.5014/ajot.64.2.288; Novack TA, 2006, BRAIN INJURY, V20, P455, DOI 10.1080/02699050600664541; Owsley C, 1998, JAMA-J AM MED ASSOC, V279, P1083, DOI 10.1001/jama.279.14.1083; Posse S, 2006, TOP GERIATR REHABIL, V22, P113; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Reynolds C.R., 2002, COMPREHENSIVE TRAIL; Rubin GS, 2007, INVEST OPHTH VIS SCI, V48, P1483, DOI 10.1167/iovs.06-0474; Stav WB, 2008, J SAFETY RES, V39, P1, DOI 10.1016/j.jsr.2007.10.004; Streiner DL, 2007, CAN J PSYCHIAT, V52, P121, DOI 10.1177/070674370705200210; Uc EY, 2006, ANN NEUROL, V60, P407, DOI 10.1002/ana.20958	32	41	42	1	20	AMER OCCUPATIONAL THERAPY ASSOC, INC	BETHESDA	4720 MONTGOMERY LANE, BETHESDA, MD 20814-3425 USA	0272-9490	1943-7676		AM J OCCUP THER	Am. J. Occup. Ther.	SEP-OCT	2013	67	5					574	582		10.5014/ajot.2013.008136			9	Rehabilitation	Rehabilitation	220EQ	WOS:000324565400011	23968796	Bronze, Green Published			2021-06-18	
J	Noe, N; Dillon, L; Lellek, V; Diaz, F; Hida, A; Moraes, CT; Wenz, T				Noe, Natalie; Dillon, Lloye; Lellek, Veronika; Diaz, Francisca; Hida, Aline; Moraes, Carlos T.; Wenz, Tina			Bezafibrate improves mitochondrial function in the CNS of a mouse model of mitochondrial encephalopathy	MITOCHONDRION			English	Article						Bezafibrate; CNS; PPAR/PGC-1 alpha; Mitochondrial encephalopathy	GAMMA AGONIST ROSIGLITAZONE; RECEPTOR-ALPHA ACTIVATION; TRAUMATIC BRAIN-INJURY; PGC-1-ALPHA; FENOFIBRATE; BIOGENESIS; NEUROPROTECTION; RESVERATROL; DEFICIENCY; MICROGLIA	Mitochondrial dysfunction frequently affects the central nervous system. Here, we investigated the effect of bezafibrate treatment on neuronal mitochondrial function and its impact on the progression of a mitochondrial encephalopathy. We used a murine model with a forebrain-specific cytochrome c oxidase deficiency caused by conditional deletion of the COX10 gene. In this mouse model, bezafibrate-administration improved the phenotype of the mice associated with an increase in mitochondrial proteins and mitochondrial ATP generating capacity. Bezafibrate-treatment also attenuated astrogliosis and decreased the level of inflammatory markers in the affected tissues. Overall, bezafibrate had a neuroprotective effect in this mouse model of mitochondrial encephalopathy. These findings imply that bezafibrate might be a promising therapeutic agent for the treatment of neurodegenerative disease associated with mitochondrial dysfunction. (C) 2012 Elsevier B.V. and Mitochondria Research Society. All rights reserved.	[Noe, Natalie; Lellek, Veronika; Wenz, Tina] Univ Cologne, Inst Genet, D-50674 Cologne, Germany; [Noe, Natalie; Lellek, Veronika; Wenz, Tina] Univ Cologne, Cluster Excellence Cellular Stress Responses Agi, D-50674 Cologne, Germany; [Dillon, Lloye; Diaz, Francisca; Hida, Aline; Moraes, Carlos T.; Wenz, Tina] Univ Miami, Sch Med, Dept Neurol, Miami, FL 33136 USA; [Moraes, Carlos T.; Wenz, Tina] Univ Miami, Sch Med, Dept Cell Biol & Anat, Miami, FL 33136 USA	Wenz, T (corresponding author), Univ Cologne, Inst Genet, Zulpicher Str 47A, D-50674 Cologne, Germany.	tina.wenz@uni-koeln.de		Dillon, Lloye/0000-0002-5118-1126	Public Health ServiceUnited States Department of Health & Human ServicesUnited States Public Health Service [AG036871, EY10804, NS079965]; Muscular Dystrophy AssociationMuscular Dystrophy Association; United Mitochondrial Disease Foundation; Emmy-Nother-Programme of the German Research Society (DFG)German Research Foundation (DFG) [WE4108/3-1]; Cluster of Excellence: Cellular Stress Responses in Aging-Associated Diseases (CECAD); NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01EY010804] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS079965] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG036871] Funding Source: NIH RePORTER	Our work is supported by the Public Health Service grants AG036871, EY10804, and NS079965 and by the Muscular Dystrophy Association. Dr. Wenz was supported by a fellowship from the United Mitochondrial Disease Foundation, the Emmy-Nother-Programme of the German Research Society (DFG, WE4108/3-1) as well as the Cluster of Excellence: Cellular Stress Responses in Aging-Associated Diseases (CECAD).	Ates O, 2007, MOL CELL BIOCHEM, V294, P137, DOI 10.1007/s11010-006-9253-0; Beal M Flint, 2007, Novartis Found Symp, V287, P183; Besson VC, 2005, NEUROSCI LETT, V388, P7, DOI 10.1016/j.neulet.2005.06.019; Canto C, 2009, CURR OPIN LIPIDOL, V20, P98, DOI 10.1097/MOL.0b013e328328d0a4; Deplanque D, 2003, J NEUROSCI, V23, P6264; Diaz F, 2005, HUM MOL GENET, V14, P2737, DOI 10.1093/hmg/ddi307; Diaz F, 2012, HUM MOL GENET, V21, P5066, DOI 10.1093/hmg/dds350; Dillon LM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044335; Dillon LM, 2012, HUM MOL GENET, V21, P2288, DOI 10.1093/hmg/dds049; DiMauro S, 2008, ANNU REV NEUROSCI, V31, P91, DOI 10.1146/annurev.neuro.30.051606.094302; DiMauro S, 2009, BBA-MOL BASIS DIS, V1792, P1159, DOI 10.1016/j.bbadis.2008.10.015; Djouadi F, 2011, CELL METAB, V14, P715, DOI 10.1016/j.cmet.2011.11.003; Dumont M, 2012, HUM MOL GENET, V21, P5091, DOI 10.1093/hmg/dds355; Feinstein Douglas L, 2003, Diabetes Technol Ther, V5, P67, DOI 10.1089/152091503763816481; Fukui H, 2007, P NATL ACAD SCI USA, V104, P14163, DOI 10.1073/pnas.0705738104; Gonzalez-Scarano F, 1999, ANNU REV NEUROSCI, V22, P219, DOI 10.1146/annurev.neuro.22.1.219; Izawa Y, 2009, BRAIN RES, V1305, P64, DOI 10.1016/j.brainres.2009.09.098; Johri A, 2012, HUM MOL GENET, V21, P1124, DOI 10.1093/hmg/ddr541; Kapadia R, 2008, FRONT BIOSCI-LANDMRK, V13, P1813, DOI 10.2741/2802; Kreisler A, 2007, BRAIN RES, V1135, P77, DOI 10.1016/j.brainres.2006.12.011; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; Luo YM, 2006, J NEUROCHEM, V97, P435, DOI 10.1111/j.1471-4159.2006.03758.x; Matsui HR, 1997, DIABETES, V46, P348, DOI 10.2337/diabetes.46.3.348; McGill JK, 2006, CELL, V127, P465, DOI 10.1016/j.cell.2006.10.023; Miglio G, 2009, NEUROCHEM INT, V55, P496, DOI 10.1016/j.neuint.2009.05.001; Minghetti L, 1998, PROG NEUROBIOL, V54, P99, DOI 10.1016/S0301-0082(97)00052-X; Mudo G, 2012, CELL MOL LIFE SCI, V69, P1153, DOI 10.1007/s00018-011-0850-z; Mysiorek C, 2009, CURR NEUROVASC RES, V6, P181, DOI 10.2174/156720209788970081; O'Rourke F, 2004, CAN MED ASSOC J, V170, P1123, DOI 10.1503/cmaj.1031185; Pallas M, 2009, CURR NEUROVASC RES, V6, P70, DOI 10.2174/156720209787466019; Ramanan S, 2009, INT J RADIAT ONCOL, V75, P870, DOI 10.1016/j.ijrobp.2009.06.059; Ryan MJ, 2004, HYPERTENSION, V43, P661, DOI 10.1161/01.HYP.0000116303.71408.c2; Scarpulla RC, 2008, PHYSIOL REV, V88, P611, DOI 10.1152/physrev.00025.2007; St-Pierre J, 2006, CELL, V127, P397, DOI 10.1016/j.cell.2006.09.024; Tenenbaum A, 2005, CARDIOVASC DIABETOL, V4, DOI 10.1186/1475-2840-4-14; Viscomi C, 2011, CELL METAB, V14, P80, DOI 10.1016/j.cmet.2011.04.011; Wareski P, 2009, J BIOL CHEM, V284, P21379, DOI 10.1074/jbc.M109.018911; Wenz T, 2008, CELL METAB, V8, P249, DOI 10.1016/j.cmet.2008.07.006; Yatsuga S, 2012, HUM MOL GENET, V21, P526, DOI 10.1093/hmg/ddr482; Yi JH, 2008, BRAIN RES, V1244, P164, DOI 10.1016/j.brainres.2008.09.074; Zhao W, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-51	41	41	41	0	9	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1567-7249	1872-8278		MITOCHONDRION	Mitochondrion	SEP	2013	13	5			SI		417	426		10.1016/j.mito.2012.12.003			10	Cell Biology; Genetics & Heredity	Cell Biology; Genetics & Heredity	210YF	WOS:000323870600005	23261681	Green Accepted			2021-06-18	
J	Pearl, PL; McCarter, R; McGavin, CL; Yu, YZ; Sandoval, F; Trzcinski, S; Atabaki, SM; Tsuchida, T; van den Anker, J; He, JP; Klein, P				Pearl, Phillip L.; McCarter, Robert; McGavin, Colleen L.; Yu, Yuezhou; Sandoval, Fabian; Trzcinski, Stacey; Atabaki, Shireen M.; Tsuchida, Tammy; van den Anker, John; He, Jianping; Klein, Pavel			Results of phase II levetiracetam trial following acute head injury in children at risk for posttraumatic epilepsy	EPILEPSIA			English	Article						Posttraumatic epilepsy; Levetiracetam; Pediatric	TRAUMATIC BRAIN-INJURY; SEIZURES; ADULTS	Posttraumatic seizures develop in up to 20% of children following severe traumatic brain injury (TBI). Children ages 6-17 years with one or more risk factors for the development of posttraumatic epilepsy, including presence of intracranial hemorrhage, depressed skull fracture, penetrating injury, or occurrence of posttraumatic seizure were recruited into this phase II study. Treatment subjects received levetiracetam 55 mg/kg/day, b. i. d., for 30 days, starting within 8 h postinjury. The recruitment goal was 20 treated patients. Twenty patients who presented within 8-24 h post-TBI and otherwise met eligibility criteria were recruited for observation. Follow-up was for 2 years. Forty-five patients screened within 8 h of head injury met eligibility criteria and 20 were recruited into the treatment arm. The most common risk factor present for pediatric inclusion following TBI was an imme-diate seizure. Medication compliance was 95%. No patients died; 19 of 20 treatment patients were retained and one observation patient was lost to follow-up. The most common severe adverse events in treatment subjects were headache, fatigue, drowsiness, and irritability. There was no higher incidence of infection, mood changes, or behavior problems among treatment subjects compared to observation subjects. Only 1 (2.5%) of 40 subjects developed posttraumatic epilepsy (defined as seizures > 7 days after trauma). This study demonstrates the feasibility of a pediatric posttraumatic epilepsy prevention study in an at-risk traumatic brain injury population. Levetiracetam was safe and well tolerated in this population. This study sets the stage for implementation of a prospective study to prevent posttraumatic epilepsy in an at-risk population.	[Pearl, Phillip L.; McGavin, Colleen L.; Yu, Yuezhou; Sandoval, Fabian; Trzcinski, Stacey; Tsuchida, Tammy] Childrens Natl Med Ctr, Dept Neurol, Washington, DC 20010 USA; [McCarter, Robert; He, Jianping] Childrens Natl Med Ctr, Dept Biostat, Washington, DC 20010 USA; [Atabaki, Shireen M.] Childrens Natl Med Ctr, Dept Emergency Med, Washington, DC 20010 USA; [van den Anker, John] Childrens Natl Med Ctr, Dept Pharmacol, Washington, DC 20010 USA; [Klein, Pavel] Midatlantic Epilepsy & Sleep Ctr, Bethesda, MD USA	Pearl, PL (corresponding author), Childrens Natl Med Ctr, Dept Neurol, 111 Michigan Ave NW, Washington, DC 20010 USA.	ppearl@childrensnational.org			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1 R01 NS45656]; GCRC of Children's National Medical Center; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045656] Funding Source: NIH RePORTER	The study was supported by the NIH, Grant 1 R01 NS45656, and the GCRC of Children's National Medical Center. Levetiracetam was provided by UCB Pharma, Inc.	Aitken ME, 2009, PEDIATRICS, V123, P199, DOI 10.1542/peds.2008-0607; Christensen J, 2009, LANCET, V373, P1105, DOI 10.1016/S0140-6736(09)60214-2; Klein P., 2012, ARCH NEUROL-CHICAGO, V9, P1; Liesemer K, 2011, J NEUROTRAUM, V28, P755, DOI 10.1089/neu.2010.1518; Mazzola CA, 2002, CRIT CARE MED, V30, pS393, DOI 10.1097/00003246-200211001-00003; Statler KD, 2006, DEV NEUROSCI-BASEL, V28, P354, DOI 10.1159/000094162; Temkin NR, 2009, EPILEPSIA, V50, P10, DOI 10.1111/j.1528-1167.2008.02005.x; Temkin NR, 2003, EPILEPSIA, V44, P18, DOI 10.1046/j.1528-1157.44.s10.6.x; YOUNG B, 1983, CHILD BRAIN, V10, P185	9	41	43	0	18	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0013-9580			EPILEPSIA	Epilepsia	SEP	2013	54	9					e135	e137		10.1111/epi.12326			3	Clinical Neurology	Neurosciences & Neurology	213BW	WOS:000324029400005	23876024	Green Accepted			2021-06-18	
J	Coppi, E; Maraula, G; Fumagalli, M; Failli, P; Cellai, L; Bonfanti, E; Mazzoni, L; Coppini, R; Abbracchio, MP; Pedata, F; Pugliese, AM				Coppi, Elisabetta; Maraula, Giovanna; Fumagalli, Marta; Failli, Paola; Cellai, Lucrezia; Bonfanti, Elisabetta; Mazzoni, Luca; Coppini, Raffaele; Abbracchio, Maria P.; Pedata, Felicita; Pugliese, Anna Maria			UDP-glucose enhances outward K plus currents necessary for cell differentiation and stimulates cell migration by activating the GPR17 receptor in oligodendrocyte precursors	GLIA			English	Article						GPR17; K plus currents; migration; Ca2+currents; purinergic receptors; myelination	GLIAL PROGENITOR CELLS; CHANNEL EXPRESSION; MEMBRANE DEPOLARIZATION; POTASSIUM CURRENTS; GROWTH-FACTORS; IN-VITRO; MYELINATION; PROLIFERATION; LINEAGE; CA2+	In the developing and mature central nervous system, NG2 expressing cells comprise a population of cycling oligodendrocyte progenitor cells (OPCs) that differentiate into mature, myelinating oligodendrocytes (OLGs). OPCs are also characterized by high motility and respond to injury by migrating into the lesioned area to support remyelination. K+ currents in OPCs are developmentally regulated during differentiation. However, the mechanisms regulating these currents at different stages of oligodendrocyte lineage are poorly understood. Here we show that, in cultured primary OPCs, the purinergic G-protein coupled receptor GPR17, that has recently emerged as a key player in oligodendrogliogenesis, crucially regulates K+ currents. Specifically, receptor stimulation by its agonist UDP-glucose enhances delayed rectifier K+ currents without affecting transient K+ conductances. This effect was observed in a subpopulation of OPCs and immature pre-OLGs whereas it was absent in mature OLGs, in line with GPR17 expression, that peaks at intermediate phases of oligodendrocyte differentiation and is thereafter downregulated to allow terminal maturation. The effect of UDP-glucose on K+ currents is concentration-dependent, blocked by the GPR17 antagonists MRS2179 and cangrelor, and sensitive to the K+ channel blocker tetraethyl-ammonium, which also inhibits oligodendrocyte maturation. We propose that stimulation of K+ currents is responsible for GPR17-induced oligodendrocyte differentiation. Moreover, we demonstrate, for the first time, that GPR17 activation stimulates OPC migration, suggesting an important role for this receptor after brain injury. Our data indicate that modulation of GPR17 may represent a strategy to potentiate the post-traumatic response of OPCs under demyelinating conditions, such as multiple sclerosis, stroke, and brain trauma.	[Coppi, Elisabetta; Maraula, Giovanna; Failli, Paola; Cellai, Lucrezia; Mazzoni, Luca; Coppini, Raffaele; Pedata, Felicita; Pugliese, Anna Maria] Univ Florence, Div Pharmacol & Toxicol, Dept Neurosci Psychol Drug Res & Child Hlth Neuro, I-50139 Florence, Italy; [Fumagalli, Marta; Bonfanti, Elisabetta; Abbracchio, Maria P.] Univ Milan, Dept Pharmacol & Biomol Sci, Lab Mol & Cellular Pharmacol Purinerg Transmiss, I-20133 Milan, Italy; [Mazzoni, Luca] Univ Florence, Dept Clin & Expt Med, I-50139 Florence, Italy	Coppi, E (corresponding author), Univ Florence, Dept Hlth Sci, Viale Pieraccini 6, I-50139 Florence, Italy.	elisabetta.coppi@unifi.it	Abbracchio, Maria Pia/B-9342-2014; Coppini, Raffaele/K-4841-2016; Coppi, Elisabetta/K-6705-2016	Abbracchio, Maria Pia/0000-0002-7833-3388; Failli, Paola/0000-0003-3879-9068; Fumagalli, Marta/0000-0002-0158-842X; Pedata, Felicita/0000-0002-6841-3712; Bonfanti, Elisabetta/0000-0003-1280-9109; PUGLIESE, ANNA MARIA/0000-0001-7554-5740	University of Florence; PRIN-COFINMinistry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN); Fondazione Italiana Sclerosi MultiplaFondazione Italiana Sclerosi Multipla (FISM) [FISM 2010/R2]	Grant sponsors: University of Florence, PRIN-COFIN 2008; Grant sponsor: Fondazione Italiana Sclerosi Multipla; Grant number: FISM 2010/R2.	Agresti C, 2005, GLIA, V50, P132, DOI 10.1002/glia.20160; ARMSTRONG RC, 1990, J NEUROSCI RES, V27, P400, DOI 10.1002/jnr.490270319; Attali B, 1997, J NEUROSCI, V17, P8234; BARRES BA, 1990, NEURON, V4, P507, DOI 10.1016/0896-6273(90)90109-S; BERGER T, 1992, EUR J NEUROSCI, V4, P1271, DOI 10.1111/j.1460-9568.1992.tb00153.x; Boda E, 2011, GLIA, V59, P1958, DOI 10.1002/glia.21237; Butt AM, 2002, J NEUROCYTOL, V31, P551, DOI 10.1023/A:1025751900356; Ceruti S, 2011, GLIA, V59, P363, DOI 10.1002/glia.21107; Ceruti S, 2009, BRAIN, V132, P2206, DOI 10.1093/brain/awp147; Chavalmane AK, 2010, J SEX MED, V7, P2698, DOI 10.1111/j.1743-6109.2010.01811.x; Chen Y, 2009, NAT NEUROSCI, V12, P1398, DOI 10.1038/nn.2410; Chittajallu R, 2002, P NATL ACAD SCI USA, V99, P2350, DOI 10.1073/pnas.042698399; Ciana P, 2006, EMBO J, V25, P4615, DOI 10.1038/sj.emboj.7601341; Ciceri P, 2001, BRIT J PHARMACOL, V133, P1323, DOI 10.1038/sj.bjp.0704189; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; Dawson MRL, 2003, MOL CELL NEUROSCI, V24, P476, DOI 10.1016/S1044-7431(03)00210-0; DUBOISDALCQ M, 1987, EMBO J, V6, P2587, DOI 10.1002/j.1460-2075.1987.tb02549.x; DUNLAP K, 1985, PFLUG ARCH EUR J PHY, V403, P170, DOI 10.1007/BF00584096; Franklin RJM, 2002, NAT REV NEUROSCI, V3, P705, DOI 10.1038/nrn917; Fulton D, 2010, GLIA, V58, P1292, DOI 10.1002/glia.21008; Fumagalli M, 2011, J BIOL CHEM, V286, P10593, DOI 10.1074/jbc.M110.162867; Gallo V, 1996, J NEUROSCI, V16, P2659, DOI 10.1523/jneurosci.16-08-02659.1996; GARD AL, 1989, DEVELOPMENT, V106, P119; Ghiani CA, 1999, J NEUROSCI, V19, P5380; GREGA DS, 1987, SCIENCE, V235, P345, DOI 10.1126/science.2432663; Hampton DW, 2004, NEUROSCIENCE, V127, P813, DOI 10.1016/j.neuroscience.2004.05.028; HENRY PD, 1980, AM J CARDIOL, V46, P1047, DOI 10.1016/0002-9149(80)90366-5; Hibino H, 2010, PHYSIOL REV, V90, P291, DOI 10.1152/physrev.00021.2009; Horner PJ, 2000, J NEUROSCI, V20, P2218; KETTENMANN H, 1991, ANN NY ACAD SCI, V633, P64; KIERNAN BW, 1993, DEVELOPMENT, P219; Knutson P, 1997, J NEUROSCI, V17, P2669, DOI 10.1523/jneurosci.17-08-02669.1997; Lecca D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003579; Levine JM, 2001, TRENDS NEUROSCI, V24, P39, DOI 10.1016/S0166-2236(00)01691-X; Mann SA, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-39; McMorris FA, 1996, BRAIN PATHOL, V6, P313, DOI 10.1111/j.1750-3639.1996.tb00858.x; Melani A, 2005, NEUROCHEM INT, V47, P442, DOI 10.1016/j.neuint.2005.05.014; Melani A, 2012, EXP NEUROL, V233, P193, DOI 10.1016/j.expneurol.2011.09.036; Miller RH, 2002, PROG NEUROBIOL, V67, P451, DOI 10.1016/S0301-0082(02)00058-8; Milner R, 1997, GLIA, V19, P85, DOI 10.1002/(SICI)1098-1136(199701)19:1<85::AID-GLIA9>3.0.CO;2-9; Nawrath H, 1997, N-S ARCH PHARMACOL, V355, P79; Nishisho T, 1996, NEUROSURGERY, V39, P950, DOI 10.1097/00006123-199611000-00014; Nishiyama A, 2002, J NEUROCYTOL, V31, P437, DOI 10.1023/A:1025783412651; Nishiyama A, 2009, NAT REV NEUROSCI, V10, P9, DOI 10.1038/nrn2495; Paez PM, 2009, J NEUROSCI RES, V87, P3259, DOI 10.1002/jnr.21938; Paez PM, 2010, J NEUROSCI, V30, P6422, DOI 10.1523/JNEUROSCI.5086-09.2010; Paez PM, 2009, ASN NEURO, V1, DOI 10.1042/AN20090003; Paez PM, 2009, J NEUROSCI, V29, P6663, DOI 10.1523/JNEUROSCI.5806-08.2009; Pugliese AM, 2009, AM J PHYSIOL-CELL PH, V297, pC1028, DOI 10.1152/ajpcell.00658.2008; Schmidt C, 1997, GLIA, V20, P284; SHRAGER P, 1995, DEV BRAIN RES, V88, P68, DOI 10.1016/0165-3806(95)00081-N; Simon C, 2011, GLIA, V59, P869, DOI 10.1002/glia.21156; SOLIVEN B, 1989, DEV NEUROSCI-BASEL, V11, P118, DOI 10.1159/000111893; Soliven B, 2001, MICROSC RES TECHNIQ, V52, P672, DOI 10.1002/jemt.1051; SOLIVEN B, 1988, J NEUROSCI, V8, P2131; SONTHEIMER H, 1988, GLIA, V1, P415, DOI 10.1002/glia.440010609; SONTHEIMER H, 1989, NEURON, V2, P1135, DOI 10.1016/0896-6273(89)90180-3; Stevens B, 2002, NEURON, V36, P855, DOI 10.1016/S0896-6273(02)01067-X; STRONG JA, 1984, J NEUROSCI, V4, P2772; Tanaka K, 2003, BRAIN RES, V989, P172, DOI 10.1016/S0006-8993(03)03317-1; Temporini C, 2009, ANAL BIOCHEM, V384, P123, DOI 10.1016/j.ab.2008.09.010; Tiwari-Woodruff S, 2006, AM J PHYSIOL-CELL PH, V291, pC687, DOI 10.1152/ajpcell.00510.2005; Vautier F, 2004, GLIA, V48, P337, DOI 10.1002/glia.20088; VERKHRATSKY AN, 1990, NEUROSCI LETT, V112, P194, DOI 10.1016/0304-3940(90)90202-K; von Kugelgen I, 2006, PHARMACOL THERAPEUT, V110, P415, DOI 10.1016/j.pharmthera.2005.08.014; VONBLANKENFELD G, 1992, EUR J NEUROSCI, V4, P1035; Wake H, 2011, SCIENCE, V333, P1647, DOI 10.1126/science.1206998; Wang XH, 2004, NAT MED, V10, P821, DOI 10.1038/nm1082; WARRINGTON AE, 1993, J NEUROSCI RES, V34, P1, DOI 10.1002/jnr.490340102; Watanabe M, 2002, J NEUROSCI RES, V69, P826, DOI 10.1002/jnr.10338; Williamson AV, 1997, EUR J NEUROSCI, V9, P706, DOI 10.1111/j.1460-9568.1997.tb01419.x	71	41	42	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	JUL	2013	61	7					1155	1171		10.1002/glia.22506			17	Neurosciences	Neurosciences & Neurology	171NK	WOS:000320935900013	23640798				2021-06-18	
J	Kirov, II; Tal, A; Babb, JS; Reaume, J; Bushnik, T; Ashman, TA; Flanagan, S; Grossman, RI; Gonen, O				Kirov, Ivan I.; Tal, Assaf; Babb, James S.; Reaume, Joseph; Bushnik, Tamara; Ashman, Teresa A.; Flanagan, Steven; Grossman, Robert I.; Gonen, Oded			Proton MR Spectroscopy Correlates Diffuse Axonal Abnormalities with Post-Concussive Symptoms in Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						diffuse axonal injury; magnetic resonance spectroscopy; mild traumatic brain injury; N-acetyl-aspartate; post-concussive symptoms	HEAD-INJURY; RECOVERY	There are no established biomarkers for mild traumatic brain injury (mTBI), in part because post-concussive symptoms (PCS) are subjective and conventional imaging is typically unremarkable. To test whether diffuse axonal abnormalities quantified with three-dimensional (3D) proton magnetic resonance spectroscopic imaging (H-1-MRSI) correlated with patients' PCS, we retrospectively studied 26 mTBI patients (mean Glasgow Coma Scale [GCS] score of 14.7), 18- to 56-year-olds and 13 controls three to 55 days post-injury. All were scanned at 3 Tesla with T1- and T2-weighted MRI and 3D H-1-MRSI (480 voxels over 360 cm(3), similar to 30% of the brain). On scan day, patients completed a symptom questionnaire, and those who indicated at least one of the most common subacute mTBI symptoms (headache, dizziness, sleep disturbance, memory deficits, blurred vision) were grouped as PCS-positive. Global gray matter and white matter (GM/WM) absolute concentrations of N-acetylaspartate (NAA), choline (Cho), creatine (Cr) and myo-inositol (mI) in PCS-positive and PCS-negative patients were compared to age-and gender-matched controls using two-way analysis of variance. The results showed that the PCS-negative group (n = 11) and controls (n = 8) did not differ in any GM or WM metabolite level. The PCS-positive patients (n = 15) had lower WM NAA than the controls (n = 12; 7.0 +/- 0.6 versus 7.9 +/- 0.5mM; p = 0.0007). Global WM NAA, therefore, showed sensitivity to the TBI sequelae associated with common PCS in patients with mostly normal neuroimaging, as well as GCS scores. This suggests a potential biomarker role in a patient population in which objective measures of injury and symptomatology are currently lacking.	[Kirov, Ivan I.; Tal, Assaf; Babb, James S.; Reaume, Joseph; Grossman, Robert I.; Gonen, Oded] NYU, Sch Med, Dept Radiol, New York, NY 10016 USA; [Bushnik, Tamara; Ashman, Teresa A.; Flanagan, Steven] NYU, Sch Med, Rusk Inst Rehabil Med, New York, NY 10016 USA	Gonen, O (corresponding author), NYU, Sch Med, Dept Radiol, 660 1st Ave,4th Floor, New York, NY 10016 USA.	oded.gonen@med.nyu.edu	Kirov, Ivan/I-2792-2019	Kirov, Ivan/0000-0001-5641-8578; Tal, Assaf/0000-0001-6718-6522; Bushnik, Tamara/0000-0003-3328-257X; Flanagan, Steven/0000-0001-9005-5897; Babb, James/0000-0003-1798-1186; Gonen, Oded/0000-0002-3148-2028	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [EB01015, NS39135, NS29029, NS0050520]; Human Frontiers Science Project; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB001015] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039135, R01NS029029, R37NS029029, R01NS050520, R56NS050520] Funding Source: NIH RePORTER	This work was supported by NIH Grants EB01015, NS39135, NS29029 and NS0050520. Dr. Tal acknowledges the support of the Human Frontiers Science Project.	Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Biasca N, 2007, PROG BRAIN RES, V161, P263, DOI 10.1016/S0079-6123(06)61019-4; Bigler ED, 2012, NEUROSCI LETT, V509, P1, DOI 10.1016/j.neulet.2011.12.009; Blyth BJ, 2010, EMERG MED CLIN N AM, V28, P571, DOI 10.1016/j.emc.2010.03.003; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; Dischinger PC, 2009, J TRAUMA, V66, P289, DOI 10.1097/TA.0b013e3181961da2; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Grossman RI, 2012, NMR BIOMED; Johnson VE, 2012, EXP NEUROL; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kirov II, 2013, J NEUROL, V260, P242, DOI 10.1007/s00415-012-6626-z; Kirov II, 2012, MAGN RESON MED, V67, P27, DOI 10.1002/mrm.23001; Lin AP, 2012, BRAIN IMAGING BEHAV, V6, P208, DOI 10.1007/s11682-012-9181-4; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; Messe A, 2012, BRAIN IMAGING BEHAV, V6, P283, DOI 10.1007/s11682-012-9159-2; Paling D, 2011, J NEUROL, V258, P2113, DOI 10.1007/s00415-011-6117-7; Ruff RM, 2011, NEUROREHABILITATION, V28, P167, DOI 10.3233/NRE-2011-0646; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5	20	41	44	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2013	30	13					1200	1204		10.1089/neu.2012.2696			5	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	174WB	WOS:000321186400011	23339670	Green Published			2021-06-18	
J	Sayed, N; Culver, C; Dams-O'Connor, K; Hammond, F; Diaz-Arrastia, R				Sayed, Nasreen; Culver, Carlee; Dams-O'Connor, Kristen; Hammond, Flora; Diaz-Arrastia, Ramon			Clinical Phenotype of Dementia after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						Alzheimer's disease; chronic traumatic encephalopathy; National Alzheimer's Coordinating Center	ALZHEIMERS-DISEASE; HEAD-INJURY; RISK	Traumatic brain injury (TBI) in early to mid-life is associated with an increased risk of dementia in late life. It is unclear whether TBI results in acceleration of Alzheimer's disease (AD)-like pathology or has features of another dementing condition, such as chronic traumatic encephalopathy, which is associated with more-prominent mood, behavior, and motor disturbances than AD. Data from the National Alzheimer's Coordinating Center (NACC) Uniform Data Set was obtained over a 5-year period. Categorical data were analyzed using Fisher's exact test. Continuous parametric data were analyzed using the Student's t-test. Nonparametric data were analyzed using Mann-Whitney's test. Overall, 877 individuals with dementia who had sustained TBI were identified in the NACC database. Only TBI with chronic deficit or dysfunction was associated with increased risk of dementia. Patients with dementia after TBI (n = 62) were significantly more likely to experience depression, anxiety, irritability, and motor disorders than patients with probable AD. Autopsy data were available for 20 of the 62 TBI patients. Of the patients with TBI, 62% met National Institute of Aging-Reagan Institute "high likelihood'' criteria for AD. We conclude that TBI with chronic deficit or dysfunction is associated with an increased odds ratio for dementia. Clinically, patients with dementia associated with TBI were more likely to have symptoms of depression, agitation, irritability, and motor dysfunction than patients with probable AD. These findings suggest that dementia in individuals with a history of TBI may be distinct from AD.	[Sayed, Nasreen; Diaz-Arrastia, Ramon] Univ Texas SW Med Ctr Dallas, Dept Neurol, Dallas, TX 75390 USA; [Culver, Carlee; Diaz-Arrastia, Ramon] Uniformed Serv Univ Hlth Sci, Dept Neurol, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA; [Dams-O'Connor, Kristen] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA; [Hammond, Flora] Indiana Univ Sch Med, Dept Phys Med & Rehabil, Indianapolis, IN 46202 USA	Diaz-Arrastia, R (corresponding author), Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, 12725 Twinbrook Pkwy, Rockville, MD 20852 USA.	Ramon.Diaz-Arrastia@usuhs.mil		Diaz-Arrastia, Ramon/0000-0001-6051-3594	NIDRR [H133A020526, U01 AG16976];  [P30 AG12300];  [R01 HD048179]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048179] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [ZIANS003138] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG012300, U01AG016976] Funding Source: NIH RePORTER	This work was supported by P30 AG12300 (Core B), R01 HD048179, and NIDRR H133A020526 (to R.D.-A.) and U01 AG16976 (NACC).	Beekly DL, 2004, ALZ DIS ASSOC DIS, V18, P270; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Faul M., TRAUMATIC BRAIN INJU, P1; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Institute of Medicine Committee on Gulf War Health, 2009, GULF WAR HLTH; Jack CR, 2011, ARCH NEUROL-CHICAGO, V68, P1526, DOI 10.1001/archneurol.2011.183; MARTLAND HS, 1928, JAMA-J AM MED ASSOC, V91, P1103, DOI DOI 10.1001/JAMA.1928.02700150029009; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Morris JC, 2006, ALZ DIS ASSOC DIS, V20, P210, DOI 10.1097/01.wad.0000213865.09806.92; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Savonenko AV, 2012, NEUROPSYCHOPHARMACOL, V37, P261, DOI 10.1038/npp.2011.211; Shively S, 2012, ARCH NEUROL-CHICAGO, V69, P1245, DOI 10.1001/archneurol.2011.3747; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Thurman DJ, 2007, BRAIN INJURY MED PRI, P45; Villareal DT, 2003, NEUROLOGY, V61, P661, DOI 10.1212/WNL.61.5.661	18	41	41	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2013	30	13					1117	1122		10.1089/neu.2012.2638			6	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	174WB	WOS:000321186400002	23374007	Green Published			2021-06-18	
J	Campolo, M; Ahmad, A; Crupi, R; Impellizzeri, D; Morabito, R; Esposito, E; Cuzzocrea, S				Campolo, Michela; Ahmad, Akbar; Crupi, Rosalia; Impellizzeri, Daniela; Morabito, Rossana; Esposito, Emanuela; Cuzzocrea, Salvatore			Combination therapy with melatonin and dexamethasone in a mouse model of traumatic brain injury	JOURNAL OF ENDOCRINOLOGY			English	Article						melatonin; dexamethasone; TBI; inflammation; cell death; motor function	REDUCES SECONDARY INJURY; NITRIC-OXIDE SYNTHASE; KAPPA-B ACTIVITY; OXIDATIVE STRESS; ANTIINFLAMMATORY ACTIVITY; NEUROVASCULAR UNIT; MICE MODEL; RAT MODEL; NEUROPROTECTION; RECOVERY	Traumatic brain injury (TBI) is a major cause of preventable death and morbidity in young adults. This complex condition is characterized by a significant blood-brain barrier leakage that stems from cerebral ischemia, inflammation, and redox imbalances in the traumatic penumbra of the injured brain. Recovery of function after TBI is partly through neuronal plasticity. In order to test whether combination therapy with melatonin and dexamethasone (DEX) might improve functional recovery, a controlled cortical impact (CCI) was performed in adult mice, acting as a model of TBI. Once trauma has occurred, combating these exacerbations is the keystone of an effective TBI therapy. The therapy with melatonin (10 mg/kg) and DEX (0.025 mg/kg) is able to reduce edema and brain infractions as evidenced by decreased 2,3,5-triphenyltetrazoliumchloride staining across the brain sections. Melatonin- and DEX-mediated improvements in tissue histology shown by the reduction in lesion size and an improvement in apoptosis level further support the efficacy of combination therapy. The combination therapy also blocked the infiltration of astrocytes and reduced CCI-mediated oxidative stress. In addition, we have also clearly demonstrated that the combination therapy significantly ameliorated neurological scores. Taken together, our results clearly indicate that combination therapy with melatonin and DEX presents beneficial synergistic effects, and we consider it an avenue for further development of novel combination therapeutic agents in the treatment of TBI that are more effective than a single effector molecule.	[Campolo, Michela; Ahmad, Akbar; Crupi, Rosalia; Impellizzeri, Daniela; Esposito, Emanuela; Cuzzocrea, Salvatore] Univ Messina, Dept Biol & Environm Sci, I-98100 Messina, Italy; [Morabito, Rossana] Univ Messina, Dept Human & Social Sci, I-98100 Messina, Italy; [Cuzzocrea, Salvatore] Univ Manchester, Manchester Royal Infirm, Manchester Biomed Res Ctr, Sch Med, Manchester M13 9WL, Lancs, England	Cuzzocrea, S (corresponding author), Univ Messina, Dept Biol & Environm Sci, Policlin Univ Via C Valeria, I-98100 Messina, Italy.	salvator@unime.it	Campolo, Michela/K-6432-2016; Crupi, Rosalia/U-4364-2019	Cuzzocrea, Salvatore/0000-0001-6131-3690; MORABITO, Rossana/0000-0003-4904-4963; Ahmad, Akbar/0000-0003-1841-9670; Crupi, Rosalia/0000-0002-7629-3132; Impellizzeri, Daniela/0000-0001-9492-3161			Afanas'ev IB, 2007, MOL BIOTECHNOL, V37, P2, DOI 10.1007/s12033-007-0056-7; Ahmad A, 2012, BRAIN BEHAV IMMUN, V26, P1310, DOI 10.1016/j.bbi.2012.07.021; Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Antunes F, 1999, FREE RADICAL BIO MED, V26, P117, DOI 10.1016/S0891-5849(98)00168-3; Bethea JR, 1998, J NEUROSCI, V18, P3251; Borlongan CV, 2000, FASEB J, V14, P1307, DOI 10.1096/fj.14.10.1307; Cabrera J, 2000, NEUROPHARMACOLOGY, V39, P507, DOI 10.1016/S0028-3908(99)00128-8; Cevc G, 2004, BBA-BIOMEMBRANES, V1663, P61, DOI 10.1016/j.bbamem.2004.01.006; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Crisafulli C, 2006, J PINEAL RES, V41, P228, DOI 10.1111/j.1600-079X.2006.00358.x; Cuzzocrea S, 2005, ARTHRITIS RHEUM-US, V52, P1929, DOI 10.1002/art.21044; Cuzzocrea S, 2008, MOL PHARMACOL, V73, P323, DOI 10.1124/mol.107.041475; Di Bella L, 2006, NEUROENDOCRINOL LETT, V27, P425; Dundar K, 2005, CLIN EXP PHARMACOL P, V32, P926, DOI 10.1111/j.1440-1681.2005.04286.x; Esposito E, 2008, J PINEAL RES, V45, P149, DOI 10.1111/j.1600-079X.2008.00569.x; Esposito E, 2010, CURR NEUROPHARMACOL, V8, P228, DOI 10.2174/157015910792246155; Fowler G, 2003, FREE RADICAL BIO MED, V34, P77, DOI 10.1016/S0891-5849(02)01186-3; Genovese T, 2005, J PINEAL RES, V38, P198, DOI 10.1111/j.1600-079X.2004.00194.x; Genovese T, 2007, NEUROSCIENCE, V150, P168, DOI 10.1016/j.neuroscience.2007.06.059; Genovese T, 2007, J PINEAL RES, V43, P140, DOI 10.1111/j.1600-079X.2007.00454.x; Gilgun-Sherki Y, 2002, PHARMACOL REV, V54, P271, DOI 10.1124/pr.54.2.271; Hang CH, 2005, NEUROL INDIA, V53, P312, DOI 10.4103/0028-3886.16930; Hang CH, 2005, J SURG RES, V123, P188, DOI 10.1016/j.jss.2004.08.002; Hoffman AN, 2008, LIFE SCI, V83, P602, DOI 10.1016/j.lfs.2008.08.007; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Ismailoglu O, 2012, TURK NEUROSURG, V22, P740, DOI 10.5137/1019-5149.JTN.6197-12.1; Jain KK, 2008, DRUG DISCOV TODAY, V13, P1082, DOI 10.1016/j.drudis.2008.09.006; Jeanneteau F, 2008, P NATL ACAD SCI USA, V105, P4862, DOI 10.1073/pnas.0709102105; Jennekens N, 2010, J CLIN NURS, V19, P1198, DOI 10.1111/j.1365-2702.2009.03114.x; Jin W, 2008, ANN CLIN LAB SCI, V38, P221; Kaptanoglu E, 2000, J NEUROSURG, V93, P77, DOI 10.3171/spi.2000.93.1.0077; Kelso ML, 2011, NEUROSCI LETT, V488, P60, DOI 10.1016/j.neulet.2010.11.003; Khan M, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-32; Kline AE, 2007, BEHAV BRAIN RES, V177, P186, DOI 10.1016/j.bbr.2006.11.036; Kline AE, 2008, NEUROSCI LETT, V448, P263, DOI 10.1016/j.neulet.2008.10.076; Lambert AJ, 2009, METHODS MOL BIOL, V554, P165, DOI 10.1007/978-1-59745-521-3_11; Li ZQ, 2009, BRAIN RES, V1264, P98, DOI 10.1016/j.brainres.2009.01.055; Livrea MA, 1997, FREE RADICAL BIO MED, V23, P706, DOI 10.1016/S0891-5849(97)00018-X; MCEWEN BS, 1987, ENVIRON HEALTH PERSP, V74, P177, DOI 10.2307/3430447; Mesenge C, 1998, J PINEAL RES, V25, P41, DOI 10.1111/j.1600-079X.1998.tb00384.x; Mohr S, 1997, BIOCHEM BIOPH RES CO, V238, P387, DOI 10.1006/bbrc.1997.7304; Nichols NR, 2005, BRAIN RES REV, V48, P287, DOI 10.1016/j.brainresrev.2004.12.019; Orihara Y, 2001, FORENSIC SCI INT, V123, P142, DOI 10.1016/S0379-0738(01)00537-0; Ozawa Hitoshi, 2005, Journal of Nippon Medical School, V72, P316, DOI 10.1272/jnms.72.316; Reiter RJ, 2000, J BIOMED SCI, V7, P444, DOI 10.1159/000025480; Reiter RJ, 1997, HORM METAB RES, V29, P363, DOI 10.1055/s-2007-979057; Singh IN, 2007, J NEUROSCI RES, V85, P2216, DOI 10.1002/jnr.21360; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Sullivan PG, 2011, J NEUROTRAUM, V28, P311, DOI 10.1089/neu.2010.1646; Venegas C, 2012, J PINEAL RES, V52, P217, DOI 10.1111/j.1600-079X.2011.00931.x; Zohar O, 2011, ACTA NEUROBIOL EXP, V71, P36	53	41	42	0	9	BIOSCIENTIFICA LTD	BRISTOL	EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT, ENGLAND	0022-0795	1479-6805		J ENDOCRINOL	J. Endocrinol.	JUN	2013	217	3					291	301		10.1530/JOE-13-0022			11	Endocrinology & Metabolism	Endocrinology & Metabolism	151JU	WOS:000319457600009	23532863	Bronze			2021-06-18	
J	Torbic, H; Forni, AA; Anger, KE; Degrado, JR; Greenwood, BC				Torbic, Heather; Forni, Allison A.; Anger, Kevin E.; Degrado, Jeremy R.; Greenwood, Bonnie C.			Use of antiepileptics for seizure prophylaxis after traumatic brain injury	AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY			English	Article							PROPHYLACTICALLY ADMINISTERED PHENYTOIN; INTRAVENOUS LEVETIRACETAM; POSTTRAUMATIC EPILEPSY; RISK-FACTORS; PREVENTION; VALPROATE; FAILURE	Purpose. Antiepileptics used for seizure prophylaxis after traumatic brain injury (TBI) are reviewed. Summary. Of the 275,000 people who are hospitalized with TBI each year, approximately 5-7% experience a posttraumatic seizure (PIS). According to the latest guidelines issued by the Brain Trauma Foundation and the American Academy of Neurology (AAN) for the management of severe TBI, PTS prophylaxis is recommended only during the first seven days after TBI. Of the available antiepileptic drugs, phenytoin has been the most extensively studied for the prophylaxis of PTS. Phenobarbital, valproate, and carbamazepine have not been as extensively researched, and, given their adverse-effect profiles and pharmacodynamic properties, there is no advantage to using these agents over phenytoin. Levetiracetam has demonstrated comparable efficacy to phenytoin for PTS prophylaxis and is associated with fewer adverse effects and monitoring considerations; it may be a reasonable alternative to phenytoin. However, levetiracetam has been associated with an increased seizure tendency. The Brain Trauma Foundation recommends using phenytoin for early PTS prophylaxis. The guidelines also state that valproate has demonstrated similar efficacy to phenytoin but warn that its use may be associated with increased mortality. Conclusion. The available literature supports the use of antiepileptics for early PTS prophylaxis during the first week after a TBI. Phenytoin has been extensively studied for this indication and is recommended by the AAN and Brain Trauma Foundation guidelines for early PTS prophylaxis. Levetiracetam has demonstrated comparable efficacy to phenytoin for early PTS prophylaxis and may be a reasonable alternative to consider in this patient population.	[Torbic, Heather; Anger, Kevin E.; Degrado, Jeremy R.; Greenwood, Bonnie C.] Brigham & Womens Hosp, Boston, MA 02115 USA; [Forni, Allison A.] UMass Mem Med Ctr, Worcester, MA USA	Torbic, H (corresponding author), Brigham & Womens Hosp, Dept Pharm, 75 Francis St, Boston, MA 02115 USA.	htorbic@partners.org	Anger, Kevin/AAW-8108-2020; DeGrado, Jeremy/AAF-3482-2021	Anger, Kevin/0000-0002-3202-3421; DeGrado, Jeremy/0000-0002-0141-7137; Greenwood, Bonnie/0000-0002-7472-9043			[Anonymous], 2009, KEPPR LEV PACK INS; [Anonymous], 2011, DIL PHEN PACK INS; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Chang BS, 2003, NEUROLOGY, V60, P10, DOI 10.1212/01.WNL.0000031432.05543.14; Dennis KC, CURRENT PERSPECTIVES; Diaz-Arrastia R, 2009, EPILEPSIA, V50, P14, DOI 10.1111/j.1528-1167.2008.02006.x; Dikmen SS, 2000, NEUROLOGY, V54, P895, DOI 10.1212/WNL.54.4.895; DIKMEN SS, 1991, JAMA-J AM MED ASSOC, V265, P1271, DOI 10.1001/jama.265.10.1271; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Frend V, 2007, CLIN NEUROPHARMACOL, V30, P362, DOI 10.1097/WNF.0b013e318059ae1c; GLOTZNER FL, 1983, NEUROCHIRURGIA, V26, P66; Haltiner AM, 1999, J NEUROSURG, V91, P588, DOI 10.3171/jns.1999.91.4.0588; Jensen FE, 2009, EPILEPSIA S2, V50, P1; Jones KE, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E3; Kraus J, 2000, HEAD INJURY, P1; MANAKA S, 1992, JPN J PSYCHIAT NEUR, V46, P311; Marik PE, 2002, CHEST, V122, P699, DOI 10.1378/chest.122.2.699; MCQUEEN JK, 1983, J NEUROL NEUROSUR PS, V46, P899, DOI 10.1136/jnnp.46.10.899; Patsalos PN, 2004, CLIN PHARMACOKINET, V43, P707, DOI 10.2165/00003088-200443110-00002; RISH BL, 1973, J NEUROSURG, V38, P155, DOI 10.3171/jns.1973.38.2.0155; Ruegg S, 2008, EPILEPSY BEHAV, V12, P477, DOI 10.1016/j.yebeh.2008.01.004; Szaflarski JP, 2010, NEUROCRIT CARE, V12, P165, DOI 10.1007/s12028-009-9304-y; TEASDALE G, 1974, LANCET, V2, P81; Temkin N R, 1991, Neurosurg Clin N Am, V2, P425; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; Temkin NR, 2003, EPILEPSIA, V44, P18, DOI 10.1046/j.1528-1157.44.s10.6.x; von Winckelmann SL, 2008, PHARMACOTHERAPY, V28, P1391, DOI 10.1592/phco.28.11.1391; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; YABLON SA, 1993, ARCH PHYS MED REHAB, V74, P983; YOUNG B, 1983, J NEUROSURG, V58, P236, DOI 10.3171/jns.1983.58.2.0236; YOUNG B, 1983, J NEUROSURG, V58, P231, DOI 10.3171/jns.1983.58.2.0231	33	41	43	1	9	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	1079-2082	1535-2900		AM J HEALTH-SYST PH	Am. J. Health-Syst. Pharm.	MAY 1	2013	70	9					759	766		10.2146/ajhp120203			8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	137WQ	WOS:000318469300008	23592358				2021-06-18	
J	White, TE; Ford, GD; Surles-Zeigler, MC; Gates, AS; LaPlaca, MC; Ford, BD				White, Todd E.; Ford, Gregory D.; Surles-Zeigler, Monique C.; Gates, Alicia S.; LaPlaca, Michelle C.; Ford, Byron D.			Gene expression patterns following unilateral traumatic brain injury reveals a local pro-inflammatory and remote anti-inflammatory response	BMC GENOMICS			English	Article						Bioinformatics; Cytokine; Gene interaction hierarchy; Inflammation; Microarray; Rat; Traumatic brain injury	CENTRAL-NERVOUS-SYSTEM; LONG-TERM DISABILITY; RAT CEREBRAL-CORTEX; UNITED-STATES; FOCAL STROKE; ISCHEMIA; NEUROPROTECTION; NEUREGULIN-1; HIPPOCAMPUS; CYTOKINES	Background: Traumatic brain injury (TBI) results in irreversible damage at the site of impact and initiates cellular and molecular processes that lead to secondary neural injury in the surrounding tissue. We used microarray analysis to determine which genes, pathways and networks were significantly altered using a rat model of TBI. Adult rats received a unilateral controlled cortical impact (CCI) and were sacrificed 24 h post-injury. The ipsilateral hemi-brain tissue at the site of the injury, the corresponding contralateral hemi-brain tissue, and naive (control) brain tissue were used for microarray analysis. Ingenuity Pathway Analysis (IPA) software was used to identify molecular pathways and networks that were associated with the altered gene expression in brain tissues following TBI. Results: Inspection of the top fifteen biological functions in IPA associated with TBI in the ipsilateral tissues revealed that all had an inflammatory component. IPA analysis also indicated that inflammatory genes were altered on the contralateral side, but many of the genes were inversely expressed compared to the ipsilateral side. The contralateral gene expression pattern suggests a remote anti-inflammatory molecular response. We created a network of the inversely expressed common (i.e., same gene changed on both sides of the brain) inflammatory response (IR) genes and those IR genes included in pathways and networks identified by IPA that changed on only one side. We ranked the genes by the number of direct connections each had in the network, creating a gene interaction hierarchy (GIH). Two well characterized signaling pathways, toll-like receptor/NF-kappaB signaling and JAK/STAT signaling, were prominent in our GIH. Conclusions: Bioinformatic analysis of microarray data following TBI identified key molecular pathways and networks associated with neural injury following TBI. The GIH created here provides a starting point for investigating therapeutic targets in a ranked order that is somewhat different than what has been presented previously. In addition to being a vehicle for identifying potential targets for post-TBI therapeutic strategies, our findings can also provide a context for evaluating the potential of therapeutic agents currently in development.	[White, Todd E.; Surles-Zeigler, Monique C.; Gates, Alicia S.; Ford, Byron D.] Morehouse Sch Med, Inst Neurosci, Dept Neurobiol, Atlanta, GA 30310 USA; [Ford, Gregory D.] Morehouse Coll, Dept Biol, Atlanta, GA 30314 USA; [LaPlaca, Michelle C.] Georgia Inst Technol, Dept Biomed Engn, Atlanta, GA 30332 USA	Ford, BD (corresponding author), Morehouse Sch Med, Inst Neurosci, Dept Neurobiol, 720 Westview Dr SW, Atlanta, GA 30310 USA.	bford@msm.edu		Surles-Zeigler, Monique/0000-0002-2308-8813	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [U01 NS 057993, U54 NS060659]; Department of DefenseUnited States Department of Defense [W81XWH-10-2-0055]; W.M. Keck FoundationW.M. Keck Foundation; BRIC NIH grant [5P20M006131-02]; NIH, National Center for Research Resources (NCRR)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1 RR025008, KL2 RR025009, TL1 RR025010]; Morehouse School of Medicine Grants from the NCRR, a component of NIH [U54 RR026137, G12RR003034, S21MD000101]; Howard Hughes Medical InstituteHoward Hughes Medical Institute [52006306]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [KL2TR000455, UL1TR000454, TL1TR000456] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [U54RR026137, G12RR003034, KL2RR025009, TL1RR025010, UL1RR025008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U54NS060659, U01NS057993] Funding Source: NIH RePORTER; National Institute on Minority Health and Health DisparitiesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD) [S21MD000101] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM) [T15LM007056] Funding Source: NIH RePORTER	The authors would like to thank Brock Wester, Kaelin Brewster, and Samantha Simon for their technical assistance. This work was supported by National Institutes of Health (NIH) grants U01 NS 057993 (BDF), U54 NS060659 (BDF), Department of Defense Contract #W81XWH-10-2-0055 (BDF), the W.M. Keck Foundation (BDF); BRIC NIH grant #5P20M006131-02 (GDF), Howard Hughes Medical Institute grant #52006306 (GDF) and PHS Grant (UL1 RR025008, KL2 RR025009 or TL1 RR025010) from the Clinical and Translational Science Award program, NIH, National Center for Research Resources (NCRR) (MCL). The project described was supported by Morehouse School of Medicine Grants Number U54 RR026137, G12RR003034 and S21MD000101 from the NCRR, a component of NIH, and its contents are solely the responsibility of the authors and do not necessarily represent the official views of NCRR or NIH.	Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Chavarria A, 2004, AUTOIMMUN REV, V3, P251, DOI 10.1016/j.autrev.2003.09.006; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Di Pietro V, 2010, J NEUROTRAUM, V27, P349, DOI 10.1089/neu.2009.1095; Fahlenkamp AV, 2011, INFLAMM RES, V60, P379, DOI 10.1007/s00011-010-0281-6; FAN L, 1995, MOL BRAIN RES, V30, P125; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Feuerstein GZ, 1997, ANN NY ACAD SCI, V825, P179, DOI 10.1111/j.1749-6632.1997.tb48428.x; Ford G, 2006, BRAIN RES, V1071, P226, DOI 10.1016/j.brainres.2005.11.090; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; Hang CH, 2004, BRAIN RES, V1026, P23, DOI 10.1016/j.brainres.2004.07.090; Herx LM, 2000, J IMMUNOL, V165, P2232, DOI 10.4049/jimmunol.165.4.2232; Israelsson C, 2008, J NEUROTRAUM, V25, P959, DOI 10.1089/neu.2008.0562; Khan M, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-32; Kobori N, 2002, MOL BRAIN RES, V104, P148, DOI 10.1016/S0169-328X(02)00331-5; Kochanek PM, 2008, CURR OPIN CRIT CARE, V14, P135, DOI 10.1097/MCC.0b013e3282f57564; Kong Y, 2011, INT IMMUNOPHARMACOL, V11, P1407, DOI 10.1016/j.intimp.2011.04.025; Laird MD, 2008, NEUROSIGNALS, V16, P154, DOI 10.1159/000111560; Ley EJ, 2011, J SURG RES, V170, P253, DOI 10.1016/j.jss.2011.03.006; Li HH, 2004, J NEUROTRAUM, V21, P1141, DOI 10.1089/0897715041953777; Li YG, 2011, TOXICOL APPL PHARM, V253, P261, DOI 10.1016/j.taap.2011.03.026; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Poulsen CB, 2005, J NEUROCHEM, V92, P417, DOI 10.1111/j.1471-4159.2004.02877.x; Rall JM, 2003, NEUROPATH APPL NEURO, V29, P118, DOI 10.1046/j.1365-2990.2003.00439.x; Rostworowski M, 1997, J NEUROSCI, V17, P3664; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Shojo H, 2010, NEUROSCIENCE, V171, P1273, DOI 10.1016/j.neuroscience.2010.10.018; Sturn A, 2002, BIOINFORMATICS, V18, P207, DOI 10.1093/bioinformatics/18.1.207; von Gertten C, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-69; Wang Q, 2007, J NEUROIMMUNOL, V184, P53, DOI 10.1016/j.jneuroim.2006.11.014; Xu ZF, 2005, NEUROBIOL DIS, V19, P461, DOI 10.1016/j.nbd.2005.01.027; Xu ZF, 2004, BIOCHEM BIOPH RES CO, V322, P440, DOI 10.1016/j.bbrc.2004.07.149; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	36	41	41	0	4	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-2164			BMC GENOMICS	BMC Genomics	APR 25	2013	14								282	10.1186/1471-2164-14-282			20	Biotechnology & Applied Microbiology; Genetics & Heredity	Biotechnology & Applied Microbiology; Genetics & Heredity	156KB	WOS:000319819600001	23617241	DOAJ Gold, Green Published			2021-06-18	
J	Luo, CL; Chen, XP; Li, LL; Li, QQ; Li, BX; Xue, AM; Xu, HF; Dai, DK; Shen, YW; Tao, LY; Zhao, ZQ				Luo, Cheng-Liang; Chen, Xi-Ping; Li, Li-Liang; Li, Qian-Qian; Li, Bei-Xu; Xue, Ai-Min; Xu, Hong-Fei; Dai, Ding-Kun; Shen, Yi-Wen; Tao, Lu-Yang; Zhao, Zi-Qin			Poloxamer 188 Attenuates in vitro Traumatic Brain Injury-Induced Mitochondrial and Lysosomal Membrane Permeabilization Damage in Cultured Primary Neurons	JOURNAL OF NEUROTRAUMA			English	Article						cultured primary neurons; mitochondrial and lysosomal membrane permeability; poloxamer 188; traumatic brain injury; in vitro cell shearing device	CATHEPSIN-B CONTRIBUTES; INDUCED CELL-DEATH; CYTOCHROME-C; INDUCED APOPTOSIS; CORTICAL-NEURONS; RECEPTOR; NEUROPROTECTION; AUTOPHAGY; PROTEASE; RELEASE	Acute membrane damage due to traumatic brain injury (TBI) is a critical precipitating event. However, the subsequent effects of the mechanical trauma, including mitochondrial and lysosomal membrane permeability (MOMP and LMP) remain elusive. The main objective of the current study was to assess the role of a putative membrane-resealing agent poloxamer 188 (P188) in MOMP and LMP in response to a well-defined mechanical insult. Using an in vitro cell shearing device (VCSD), mechanical injury resulted in immediate disruption of membrane integrity in cultured primary neurons, and neurons were treated with P188 or a cathepsin B inhibitor (CBI) after VCSD 10 min. The protective effect of P188 on cultured primary neurons was first detected visually with a light microscope, and measured by MTT assay and LDH assay. The validity of monitoring changes in mitochondrial membrane potential (Delta Psi m) was measured by JC-1 staining, and Western blot for cytochrome c and truncated Bid (tBid) in purified mitochondria was also performed. In addition, lysosomal integrity was detected by blotting for cathepsin B and tBid in purified lysosomes. Our results showed post-injury P188 treatment moderated the dissipation of Delta Psi m in mitochondria, and inhibited VCSD-induced cytochrome c release from mitochondria as well as cathepsin B from lysosomes. Cathepsin B inhibition (CBI) could also increase cell viability, maintain mitochondrial membrane potential, and repress VCSD-induced release of cytochrome c from mitochondria to cytosol. Both P188 and CBI treatment decreased the cytosolic accumulation of tBid in supernatant of purified lysosomes, and the amount of mitochondrial localized tBid. These data indicate injured neurons have undergone mitochondrial and lysosomal membrane permeability damage, and the mechanism can be exploited with pharmacological interventions. P188's neuroprotection appears to involve a relationship between cathepsin B and tBid-mediated mitochondrial initiation of cell death.	[Luo, Cheng-Liang; Li, Li-Liang; Li, Bei-Xu; Xue, Ai-Min; Shen, Yi-Wen; Zhao, Zi-Qin] Fudan Univ, Dept Forens Med, Shanghai Med Coll, Shanghai 200032, Peoples R China; [Luo, Cheng-Liang; Chen, Xi-Ping; Xu, Hong-Fei; Dai, Ding-Kun; Tao, Lu-Yang] Soochow Univ, Dept Forens Med, Suzhou 215123, Peoples R China; [Li, Qian-Qian] Wannan Med Coll, Dept Forens Med, Wuhu, Peoples R China	Tao, LY (corresponding author), Soochow Univ, Dept Forens Med, 199 Renai Rd, Suzhou 215123, Peoples R China.	luyang.tao@163.com; zqzhao@shmu.edu.cn	Li, Liliang/AAQ-9877-2020	Li, Liliang/0000-0002-1933-134X	National Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81271379, 81172911, 81172897]; Shanghai Forensic Key Laboratory Foundation [KF1005]	This work was supported by the National Science Foundation of China (No. 81271379, No. 81172911, No. 81172897), and the Shanghai Forensic Key Laboratory Foundation (No. KF1005).	Alexandratou E, 2005, FREE RADICAL BIO MED, V39, P1119, DOI 10.1016/j.freeradbiomed.2005.06.006; Blackman BR, 2000, ANN BIOMED ENG, V28, P363, DOI 10.1114/1.286; Blomgran R, 2007, J LEUKOCYTE BIOL, V81, P1213, DOI 10.1189/jlb.0506359; Boya P, 2003, J EXP MED, V197, P1323, DOI 10.1084/jem.20021952; Chwieralski CE, 2006, APOPTOSIS, V11, P143, DOI 10.1007/s10495-006-3486-y; Eghwrudjakpor P O, 2010, Niger J Med, V19, P14; Foghsgaard L, 2001, J CELL BIOL, V153, P999, DOI 10.1083/jcb.153.5.999; Galluzzi L, 2008, CELL DEATH DIFFER, V15, P1113, DOI 10.1038/cdd.2008.28; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Guicciardi ME, 2000, J CLIN INVEST, V106, P1127, DOI 10.1172/JCI9914; Hunt WT, 2010, J NEUROCHEM, V115, P123, DOI 10.1111/j.1471-4159.2010.06908.x; Ji J, 2012, J NEUROTRAUM, V29, P776, DOI 10.1089/neu.2010.1602; Kilinc D, 2008, EXP NEUROL, V212, P422, DOI 10.1016/j.expneurol.2008.04.025; Kilinc D, 2009, EXP NEUROL, V219, P553, DOI 10.1016/j.expneurol.2009.07.014; Kim R, 2006, CANCER CHEMOTH PHARM, V57, P545, DOI 10.1007/s00280-005-0111-7; LaPlaca MC, 1998, J NEUROSCI RES, V52, P220, DOI 10.1002/(SICI)1097-4547(19980415)52:2<220::AID-JNR10>3.0.CO;2-B; Lenz A, 2007, INJURY, V38, P1336, DOI 10.1016/j.injury.2007.10.003; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Luo CL, 2011, NEUROSCIENCE, V184, P54, DOI 10.1016/j.neuroscience.2011.03.021; Luo CL, 2010, J NEUROSCI RES, V88, P2847, DOI 10.1002/jnr.22453; Marks Jeremy D., 2001, FASEB Journal, V15, P1107; Maskarinec SA, 2002, BIOPHYS J, V82, P1453, DOI 10.1016/S0006-3495(02)75499-4; Mbye LH, 2012, J CEREBR BLOOD F MET, V32, P515, DOI 10.1038/jcbfm.2011.158; McNeil PL, 2003, ANNU REV CELL DEV BI, V19, P697, DOI 10.1146/annurev.cellbio.19.111301.140101; Nicholls DG, 2000, PHYSIOL REV, V80, P315; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Prado GR, 2005, J NEURAL ENG, V2, P148, DOI 10.1088/1741-2560/2/4/011; Repnik U, 2010, MITOCHONDRION, V10, P662, DOI 10.1016/j.mito.2010.07.008; Salvioli S, 2000, CYTOMETRY, V40, P189, DOI 10.1002/1097-0320(20000701)40:3<189::AID-CYTO3>3.0.CO;2-6; Schouten JW, 2007, CURR OPIN CRIT CARE, V13, P134, DOI 10.1097/MCC.0b013e3280895d5c; Serbest G, 2005, J NEUROTRAUM, V22, P119, DOI 10.1089/neu.2005.22.119; Serbest G, 2006, FASEB J, V20, P308, DOI 10.1096/fj.05-4024fje; Sharma S, 2010, J NEUROSCI RES, V88, P2869, DOI 10.1002/jnr.22452; Sung DK, 2010, J NEUROSCI METH, V193, P232, DOI 10.1016/j.jneumeth.2010.08.020; Taguchi T, 2000, Environ Health Prev Med, V4, P217, DOI 10.1007/BF02931261; Wang X, 2011, J NEUROSCI, V31, P14496, DOI 10.1523/JNEUROSCI.3059-11.2011; Wang Y, 2008, AUTOPHAGY, V4, P214, DOI 10.4161/auto.5369; Xin H, 2009, EUR J PHARMACOL, V612, P75, DOI 10.1016/j.ejphar.2009.03.067; Xu ZM, 2008, REV OCCIDENTE, P133; Zhang HL, 2011, NEUROSCIENCE, V176, P381, DOI 10.1016/j.neuroscience.2010.12.029; Zhang XD, 2009, AUTOPHAGY, V5, P339, DOI 10.4161/auto.5.3.8174	41	41	41	0	19	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	APR	2013	30	7					597	607		10.1089/neu.2012.2425			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	133PD	WOS:000318150300011	23186154				2021-06-18	
J	McCarthy, MM; Voos, JE; Nguyen, JT; Callahan, L; Hannafin, JA				McCarthy, Moira M.; Voos, James E.; Nguyen, Joseph T.; Callahan, Lisa; Hannafin, Jo A.			Injury Profile in Elite Female Basketball Athletes at the Women's National Basketball Association Combine	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						ACL; meniscus; ankle sprain; WNBA	ANTERIOR CRUCIATE LIGAMENT; GENERALIZED JOINT LAXITY; HIGH-SCHOOL BASKETBALL; PROFESSIONAL BASKETBALL; RISK-FACTORS; PROSPECTIVE COHORT; MENSTRUAL-CYCLE; ANKLE INJURIES; ACL INJURIES; KNEE INJURY	Background: Anterior cruciate ligament (ACL) and meniscus injuries are common in female athletes participating in cutting and pivoting sports such as basketball. The epidemiological characteristics of injury in athletes seen at the Women's National Basketball Association (WNBA) combine and the effect of ACL reconstruction and meniscus surgery on longevity in the WNBA are unknown. Purpose: To evaluate the details and spectrum of injuries in athletes entering the WNBA combine and to assess the potential effect of specific injuries on the round drafted into the WNBA and career length. Study Design: Descriptive epidemiology study. Methods: Demographic data and the documented collegiate injury profile were reviewed from the WNBA database for all players entering the WNBA combine in 2000-2008. The study included injury data on 506 athletes. Complete demographic data were available for 496 players. Results: Of the athletes taking part in the combine, 45.2% were guards, 33.7% were forwards, and 21.1% were centers. Ankle sprain (47.8% of players), hand injury (20.8%), patellar tendinitis (17.0%), ACL injury (15.0%), meniscus injury (10.5%), stress fracture (7.3%), and concussion (7.1%) were the most common injuries reported. Seventy-three athletes (14.4%) reported ACL reconstruction before entering the WNBA combine, and meniscus surgery was the next most common surgery (n = 50 players; 9.9%). There were no differences in ACL or meniscus surgery when analyzed by player position or round drafted. History of ACL or meniscus surgery did not affect career length in the WNBA. Excluding ACL and meniscus surgery, other reported surgical procedures were knee arthroscopic surgery (11.7%), ankle reconstruction (2.6%), and shoulder stabilization (2.0%). Conclusion: The ankle is the most common site of injury and ACL reconstruction is the most common surgery in elite female athletes participating in the WNBA combine. A history of injury or surgery did not affect the round drafted or career length.	[McCarthy, Moira M.; Voos, James E.; Nguyen, Joseph T.; Callahan, Lisa; Hannafin, Jo A.] Hosp Special Surg, New York, NY 10021 USA	McCarthy, MM (corresponding author), Hosp Special Surg, 310 East 71st St,Suite 2E, New York, NY 10021 USA.	mccarthymo@hss.edu					Agel J, 2005, AM J SPORT MED, V33, P524, DOI 10.1177/0363546504269937; Alentorn-Geli E, 2009, KNEE SURG SPORT TR A, V17, P705, DOI 10.1007/s00167-009-0813-1; ARENDT E, 1995, AM J SPORT MED, V23, P694, DOI 10.1177/036354659502300611; Arendt EA, 1999, J ATHL TRAINING, V34, P86; Barrett G R, 1992, J Miss State Med Assoc, V33, P279; Boden BP, 2000, ORTHOPEDICS, V23, P573, DOI 10.3928/0147-7447-20000601-15; Brophy RH, 2009, AM J SPORT MED, V37, P2102, DOI 10.1177/0363546509349035; Deitch JR, 2006, AM J SPORT MED, V34, P1077, DOI 10.1177/0363546505285383; DeMorat G, 2004, AM J SPORT MED, V32, P477, DOI 10.1177/0363546503258928; DUFEK JS, 1991, SPORTS MED, V12, P326, DOI 10.2165/00007256-199112050-00005; Everhart JS, 2010, AM J SPORT MED, V38, P1667, DOI 10.1177/0363546510367424; FERRETTI A, 1992, AM J SPORT MED, V20, P203, DOI 10.1177/036354659202000219; Gomez E, 1996, AM J SPORT MED, V24, P684, DOI 10.1177/036354659602400521; GRAY J, 1985, INT J SPORTS MED, V6, P314, DOI 10.1055/s-2008-1025861; Gwinn DE, 2000, AM J SPORT MED, V28, P98, DOI 10.1177/03635465000280012901; Hashemi J, 2008, J BONE JOINT SURG AM, V90A, P2724, DOI 10.2106/JBJS.G.01358; HENRY JH, 1982, AM J SPORT MED, V10, P16, DOI 10.1177/036354658201000104; HERSKOWITZ A, 1993, CLIN SPORT MED, V12, P293; Hewett TE, 2006, AM J SPORT MED, V34, P299, DOI 10.1177/0363546505284183; Hewett TE, 2005, AM J SPORT MED, V33, P492, DOI 10.1177/0363546504269591; Hewett TE, 2008, ORTHOPEDICS, V31, P26, DOI 10.3928/01477447-20080101-18; Hewett TE, 2007, AM J SPORT MED, V35, P659, DOI 10.1177/0363546506295699; Hickey GJ, 1997, CLIN J SPORT MED, V7, P252, DOI 10.1097/00042752-199710000-00002; Hosea TM, 2000, CLIN ORTHOP RELAT R, P45; Huston LJ, 1996, AM J SPORT MED, V24, P427, DOI 10.1177/036354659602400405; Ireland ML, 2002, ORTHOP CLIN N AM, V33, P637, DOI 10.1016/S0030-5898(02)00028-7; Kofotolis N, 2007, J ATHL TRAINING, V42, P388; KRINSKY MB, 1992, AM J SPORT MED, V20, P17, DOI 10.1177/036354659202000105; LaPrade RF, 1994, AM J SPORTS MED, V22, P203; Li G, 1999, J BIOMECH, V32, P395, DOI 10.1016/S0021-9290(98)00181-X; McKay G, 2001, J SCI MED SPORT, V4, P196, DOI 10.1016/S1440-2440(01)80030-X; McKay GD, 2001, BRIT J SPORT MED, V35, P103, DOI 10.1136/bjsm.35.2.103; Meeuwisse WH, 2003, AM J SPORT MED, V31, P379, DOI 10.1177/03635465030310030901; Messina DF, 1999, AM J SPORT MED, V27, P294, DOI 10.1177/03635465990270030401; Mihata LCS, 2006, AM J SPORT MED, V34, P899, DOI 10.1177/0363546505285582; Myer GD, 2008, AM J SPORT MED, V36, P1073, DOI 10.1177/0363546507313572; Myer GD, 2009, CLIN J SPORT MED, V19, P3, DOI 10.1097/JSM.0b013e318190bddb; Myklebust G, 1998, SCAND J MED SCI SPOR, V8, P149, DOI 10.1111/j.1600-0838.1998.tb00185.x; Owens BD, 2007, MIL MED, V172, P90, DOI 10.7205/MILMED.172.1.90; Powell JW, 1999, J ATHL TRAINING, V34, P277; Powell JW, 2000, AM J SPORT MED, V28, P385, DOI 10.1177/03635465000280031801; Ramesh R, 2005, J BONE JOINT SURG BR, V87B, P800, DOI 10.1302/0301-620X.87B6.15833; Renstrom P, 2008, BRIT J SPORT MED, V42, P394, DOI 10.1136/bjsm.2008.048934; Rozzi SL, 1999, AM J SPORT MED, V27, P312, DOI 10.1177/03635465990270030801; Schmitz RJ, 2008, AM J SPORT MED, V36, P1380, DOI 10.1177/0363546508317411; SHAMBAUGH JP, 1991, MED SCI SPORT EXER, V23, P522; Silvers Holly J, 2005, Curr Sports Med Rep, V4, P341; Starkey C, 2000, J ATHL TRAINING, V35, P161; Trojian TH, 2006, AM J SPORT MED, V34, P895, DOI 10.1177/0363546505284384; Uhorchak JM, 2003, AM J SPORT MED, V31, P831, DOI 10.1177/03635465030310061801; Vauhnik R, 2011, J ATHL TRAINING, V46, P92, DOI 10.4085/1062-6050-46.1.92; Wojtys EM, 1998, AM J SPORT MED, V26, P614, DOI 10.1177/03635465980260050301; ZAGELBAUM BM, 1995, ARCH OPHTHALMOL-CHIC, V113, P749, DOI 10.1001/archopht.1995.01100060075035; Zazulak BT, 2007, AM J SPORT MED, V35, P368, DOI 10.1177/0363546506297909; ZELISKO JA, 1982, AM J SPORT MED, V10, P297, DOI 10.1177/036354658201000507	55	41	44	1	66	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465			AM J SPORT MED	Am. J. Sports Med.	MAR	2013	41	3					645	651		10.1177/0363546512474223			7	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	098QG	WOS:000315563200023	23378506				2021-06-18	
J	Griessenauer, CJ; Fleming, JB; Richards, BF; Cava, LP; Cure, JK; Younan, DS; Zhao, LM; Alexandrov, AV; Barlinn, K; Taylor, T; Harrigan, MR				Griessenauer, Christoph J.; Fleming, J. Brett; Richards, Boyd F.; Cava, Luis P.; Cure, Joel K.; Younan, Duraid S.; Zhao, Limin; Alexandrov, Andrei V.; Barlinn, Kristian; Taylor, Tracy; Harrigan, Mark R.			Timing and mechanism of ischemic stroke due to extracranial blunt traumatic cerebrovascular injury	JOURNAL OF NEUROSURGERY			English	Article						carotid artery; vertebral artery; blunt trauma; ischemic stroke; vascular disorders	INTERNAL CAROTID-ARTERY; VASCULAR NECK INJURIES; EARLY-DIAGNOSIS; FOLLOW-UP; OUTCOMES; THERAPY; ANGIOGRAPHY; DISSECTION; ANTICOAGULATION; HEAD	Object. Extracranial cerebrovascular injury is believed to be an important cause of neurological injury in patients who have suffered blunt trauma. The authors sought to determine the timing and mechanisms of ischemic stroke in patients who suffered traumatic cerebrovascular injury (TCVI). Methods. This is a prospective study of all patients with TCVI who were admitted to a Level I trauma center during a 28-month period. All patients who suffered blunt trauma and had risk factors for TCVI underwent screening CT angiography (CTA) of the head and neck on admission. All patients with either an ischemic stroke or CTA suggesting TCVI underwent confirmatory digital subtraction angiography (DSA). Patients with DSA-confirmed TCVI were treated with 325 mg aspirin daily; all patients were observed during their hospitalization for the occurrence of new ischemic stroke. In addition, a subset of patients with TCVI underwent transcranial Doppler ultrasonography monitoring for microembolic signals. Results. A total of 112 patients had CTA findings suggestive of TCVI; 68 cases were confirmed by DSA. Overall, 7 patients had an ischemic stroke in the territory of the affected artery prior to or during admission. Four of the patients had their event prior to diagnosis with CTA and 2 occurred prior to DSA. In 1 patient the ischemic stroke was found to be due to an extracranial atherosclerotic carotid plaque, and this patient was excluded from further analysis. All patients with ischemic stroke had brain CT findings consistent with an embolic mechanism. Two (8.7%) of 23 monitored patients with TCVI had microembolic signals on transcranial Doppler ultrasonography. Conclusions. Most ischemic strokes due to TCVI are embolic in nature and occur prior to screening CTA and initiation of treatment with aspirin. (http://thejns.org/doi/abs/10.3171/2012.11.JNS121038)	[Griessenauer, Christoph J.; Fleming, J. Brett; Richards, Boyd F.; Younan, Duraid S.; Taylor, Tracy; Harrigan, Mark R.] Univ Birmingham, Dept Surg, Birmingham, AL USA; [Cava, Luis P.; Cure, Joel K.] Univ Birmingham, Dept Radiol, Birmingham, AL USA; [Zhao, Limin; Alexandrov, Andrei V.; Barlinn, Kristian] Univ Birmingham, Dept Neurol, Birmingham, AL USA	Harrigan, MR (corresponding author), Fac Off Tower 1005,510 20th St S, Birmingham, AL 35294 USA.	mharrigan@uabmc.edu	Barlinn, Kristian/AAL-9340-2021	Griessenauer, Christoph/0000-0002-2952-3812; Alexandrov, Andrei V/0000-0001-8871-1023			Arthurs ZM, 2008, INJURY, V39, P1232, DOI 10.1016/j.injury.2008.02.042; Beletsky V, 2003, STROKE, V34, P2856, DOI 10.1161/01.STR.0000098649.39767.BC; Berne JD, 2009, J TRAUMA, V67, P1333, DOI 10.1097/TA.0b013e31818888c7; Biffl WL, 2002, ANN SURG, V235, P699, DOI 10.1097/00000658-200205000-00012; Biffl WL, 1998, ANN SURG, V228, P462, DOI 10.1097/00000658-199810000-00003; Biffl WL, 2000, ANN SURG, V231, P672, DOI 10.1097/00000658-200005000-00007; Biffl WL, 1999, J TRAUMA, V47, P845, DOI 10.1097/00005373-199911000-00004; Biffl WL, 1999, AM J SURG, V178, P517, DOI 10.1016/S0002-9610(99)00245-7; Bromberg WJ, 2010, J TRAUMA, V68, P471, DOI 10.1097/TA.0b013e3181cb43da; Carrillo EH, 1999, J TRAUMA, V46, P1120, DOI 10.1097/00005373-199906000-00030; COGBILL TH, 1994, J TRAUMA, V37, P473, DOI 10.1097/00005373-199409000-00024; Cothren CC, 2009, ARCH SURG-CHICAGO, V144, P685, DOI 10.1001/archsurg.2009.111; Cothren CC, 2004, ARCH SURG-CHICAGO, V139, P540, DOI 10.1001/archsurg.139.5.540; Diaz-Daza O, 2003, CARDIOVASC INTER RAD, V26, P213, DOI 10.1007/s00270-002-2619-0; DiPerna CA, 2002, AM SURGEON, V68, P441; Droste DW, 2001, CEREBROVASC DIS, V12, P181, DOI 10.1159/000047701; Eachempati SR, 1998, J TRAUMA, V45, P997, DOI 10.1097/00005373-199812000-00004; Eastman AL, 2009, J TRAUMA, V67, P551, DOI 10.1097/TA.0b013e3181b84408; Edwards NM, 2007, J AM COLL SURGEONS, V204, P1007, DOI 10.1016/j.jamcollsurg.2006.12.041; Fabian TC, 1996, ANN SURG, V223, P513, DOI 10.1097/00000658-199605000-00007; FABIAN TC, 1990, J TRAUMA, V30, P953, DOI 10.1097/00005373-199008000-00003; Fleck SK, 2011, NEUROSURGERY, V69, P615, DOI 10.1227/NEU.0b013e31821a8701; Franz RW, 2010, VASC ENDOVASC SURG, V44, P198, DOI 10.1177/1538574409359429; Harrigan MR, 2011, WORLD J EMERG SURG, V6, DOI 10.1186/1749-7922-6-11; KRAJEWSKI LP, 1980, ANN SURG, V191, P341, DOI 10.1097/00000658-198003000-00014; Mayberry JC, 2004, ARCH SURG-CHICAGO, V139, P609, DOI 10.1001/archsurg.139.6.609; McKevitt EC, 2002, J TRAUMA, V53, P472, DOI 10.1097/00005373-200209000-00013; Miller PR, 2002, ANN SURG, V236, P386, DOI 10.1097/00000658-200209000-00015; Miller PR, 2001, J TRAUMA, V51, P279, DOI 10.1097/00005373-200108000-00009; MOKRI B, 1988, J NEUROSURG, V68, P189, DOI 10.3171/jns.1988.68.2.0189; Molina CA, 2000, NEUROLOGY, V55, P1738, DOI 10.1212/WNL.55.11.1738; PERRY MO, 1980, ANN SURG, V192, P74, DOI 10.1097/00000658-198007000-00013; Redekop GJ, 2008, CAN J NEUROL SCI, V35, P146, DOI 10.1017/S0317167100008556; Ringelstein EB, 1998, STROKE, V29, P725; Rodriguez M, 2001, ACTA NEUROCHIR, V143, P939, DOI 10.1007/s007010170025; Schneidereit NP, 2006, J TRAUMA, V60, P209, DOI 10.1097/01.ta.0000195651.60080.2c; Sliker CW, 2008, RADIOGRAPHICS, V28, P1689, DOI 10.1148/rg.286085521; Sliker CW, 2008, AM J ROENTGENOL, V190, P790, DOI 10.2214/AJR.07.2378; Srinivasan J, 1996, STROKE, V27, P1226, DOI 10.1161/01.STR.27.7.1226; Stein DM, 2009, J TRAUMA, V66, P132, DOI 10.1097/TA.0b013e318142d146; Wahl WL, 2002, J TRAUMA, V52, P896, DOI 10.1097/00005373-200205000-00012	41	41	44	0	9	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	FEB	2013	118	2					397	404		10.3171/2012.11.JNS121038			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	076DY	WOS:000313937900025	23216467				2021-06-18	
B	Iverson, GL; Silverberg, N; Lange, RT; Zasler, ND		Zasler, ND; Katz, DI; Zafonte, RD		Iverson, Grant L.; Silverberg, Noah; Lange, Rael T.; Zasler, Nathan D.			Conceptualizing Outcome From Mild Traumatic Brain Injury	BRAIN INJURY MEDICINE: PRINCIPLES AND PRACTICE, SECOND EDITION			English	Article; Book Chapter							POSTTRAUMATIC-STRESS-DISORDER; POST-CONCUSSION SYMPTOMS; QUALITY-OF-LIFE; WHITE-MATTER HYPERINTENSITIES; COGNITIVE-BEHAVIORAL THERAPY; CHRONIC-FATIGUE-SYNDROME; MINOR HEAD-INJURY; GOOD-OLD-DAYS; PERSISTENT POSTCONCUSSION SYNDROME; SOCIAL ANXIETY DISORDER		[Iverson, Grant L.; Lange, Rael T.] Univ British Columbia, Dept Psychiat, Vancouver, BC, Canada; [Silverberg, Noah] Univ British Columbia, Dept Acquired Brain Injury, GF Strong Rehab Ctr, Vancouver, BC, Canada; [Silverberg, Noah] Univ British Columbia, Dept Med, Div Phys Med & Rehabil, Vancouver, BC, Canada; [Lange, Rael T.] Walter Reed Natl Mil Med Ctr, Def & Vet Brain Injury Ctr, Bethesda, MD USA; [Zasler, Nathan D.] Concuss Care Ctr Virginia Ltd, Richmond, VA USA; [Zasler, Nathan D.] Tree Life Serv Inc, Richmond, VA USA; [Zasler, Nathan D.] Sheltering Arms Hosp, iWalk Program, Richmond, VA USA; [Zasler, Nathan D.] VCU Dept Phys Med & Rehabil, Richmond, VA USA; [Zasler, Nathan D.] Univ Virginia, Dept Phys Med & Rehabil, Charlottesville, VA USA	Iverson, GL (corresponding author), Univ British Columbia, Dept Psychiat, Vancouver, BC, Canada.						Acarturk C, 2009, PSYCHOL MED, V39, P241, DOI 10.1017/S0033291708003590; Al Sayegh A, 2010, J NEUROL NEUROSUR PS, V81, P1128, DOI 10.1136/jnnp.2008.170092; Alla S, 2009, BRIT J SPORT MED, V43, pI3, DOI 10.1136/bjsm.2009.058339; ALQURAINY IA, 1995, BRIT J ORAL MAX SURG, V33, P71, DOI 10.1016/0266-4356(95)90203-1; Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Andersson G, 2008, INT J AUDIOL, V47, pS106, DOI 10.1080/14992020802301670; Antepohl W, 2003, NEUROREHABILITATION, V18, P307; Asmundson GJG, 2009, DEPRESS ANXIETY, V26, P888, DOI 10.1002/da.20600; ATKINSON JH, 1991, PAIN, V45, P111, DOI 10.1016/0304-3959(91)90175-W; Austin MP, 1999, PSYCHOL MED, V29, P73, DOI 10.1017/S0033291798007788; Babyak M, 2000, PSYCHOSOM MED, V62, P633, DOI 10.1097/00006842-200009000-00006; Bachar E, 2005, J NERV MENT DIS, V193, P762, DOI 10.1097/01.nmd.0000185874.31672.a5; Balla JI, 1988, HEADACHE CERVICAL DI, P256; Barbour KA, 2007, J CARDIOPULM REHABIL, V27, P359, DOI 10.1097/01.HCR.0000300262.69645.95; Barker MJ, 2005, J INT NEUROPSYCH SOC, V11, P281, DOI 10.1017/S1355617705050332; Barker MJ, 2004, ARCH CLIN NEUROPSYCH, V19, P437, DOI 10.1016/S0887-6177(03)00096-9; Barsky AJ, 2002, JAMA-J AM MED ASSOC, V287, P622, DOI 10.1001/jama.287.5.622; Bay E, 2011, J HEAD TRAUMA REHAB, V26, P355, DOI 10.1097/HTR.0b013e3181f20146; Bedard M, 2003, DISABIL REHABIL, V25, P722, DOI 10.1080/0963828031000090489; Bedard M, 2005, J COGN REHABIL, V23, P8, DOI DOI 10.1080/0963828031000090489; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Beltman MW, 2010, BRIT J PSYCHIAT, V197, P11, DOI 10.1192/bjp.bp.109.064675; Benedetti F, 2003, J NEUROSCI, V23, P4315; BENOIT G, 1992, CAN J PSYCHOL, V46, P41, DOI 10.1037/h0084314; Benson H, 1997, PREV MED, V26, P612, DOI 10.1006/pmed.1997.0228; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Bigler ED, 2010, PSYCHOL INJ LAW, V3, P36, DOI 10.1007/s12207-010-9064-1; Binder EB, 2010, MOL PSYCHIATR, V15, P574, DOI 10.1038/mp.2009.141; Binder LM, 2009, ARCH CLIN NEUROPSYCH, V24, P31, DOI 10.1093/arclin/acn001; Bisson J, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003388.pub3; BLACK FO, 1990, NEUROL CLIN, V8, P361, DOI 10.1016/S0733-8619(18)30361-X; Blackledge JT, 2006, CHILD FAM BEHAV THER, V28, P1, DOI 10.1300/J019v28n01_01; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Bond F W, 2000, J Occup Health Psychol, V5, P156, DOI 10.1037/1076-8998.5.1.156; Bond FW, 2003, J APPL PSYCHOL, V88, P1057, DOI 10.1037/0021-9010.88.6.1057; Boniver Raymond, 2002, Int Tinnitus J, V8, P129; Boone KB, 2009, CLIN NEUROPSYCHOL, V23, P1016, DOI 10.1080/13854040802441135; Bootzin RR, 2005, J CLIN PSYCHOL, V61, P871, DOI 10.1002/jclp.20131; Borgaro SR, 2003, BRAIN INJURY, V17, P189, DOI 10.1080/0269905021000013183; Bortolotti B, 2008, GEN HOSP PSYCHIAT, V30, P293, DOI 10.1016/j.genhosppsych.2008.04.001; Bourgeois B, 2005, Ann Otolaryngol Chir Cervicofac, V122, P181, DOI 10.1016/S0003-438X(05)82346-1; Brady KT, 2005, SUBST USE MISUSE, V40, P2021, DOI 10.1080/10826080500294924; Brandt T., 1991, VERTIGO ITS MULTISEN; Brenner LA, 2010, J HEAD TRAUMA REHAB, V25, P307, DOI 10.1097/HTR.0b013e3181cada03; Breslau N, 2000, NEUROLOGY, V54, P308, DOI 10.1212/WNL.54.2.308; Breslau N, 2003, NEUROLOGY, V60, P1308, DOI 10.1212/01.WNL.0000058907.41080.54; Brewin CR, 2000, J CONSULT CLIN PSYCH, V68, P748, DOI 10.1037/0022-006X.68.5.748; Brown RJ, 2004, PSYCHOL BULL, V130, P793, DOI 10.1037/0033-2909.130.5.793; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Bryant RA, 2009, J INT NEUROPSYCH SOC, V15, P862, DOI 10.1017/S1355617709990671; Budd RJ, 1996, J PSYCHOSOM RES, V41, P327, DOI 10.1016/S0022-3999(96)00171-7; Campbell LC, 2003, BIOL PSYCHIAT, V54, P399, DOI 10.1016/S0006-3223(03)00545-6; Carlson KF, 2011, J HEAD TRAUMA REHAB, V26, P103, DOI 10.1097/HTR.0b013e3181e50ef1; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Carter J E, 1983, Child Abuse Negl, V7, P279, DOI 10.1016/0145-2134(83)90005-4; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Channon S, 1999, J NEUROL NEUROSUR PS, V66, P162, DOI 10.1136/jnnp.66.2.162; Channon S, 1996, J AFFECT DISORDERS, V39, P107, DOI 10.1016/0165-0327(96)00027-4; CHAOULOFF F, 1989, ACTA PHYSIOL SCAND, V137, P1, DOI 10.1111/j.1748-1716.1989.tb08715.x; Chapman EH, 1999, J HEAD TRAUMA REHAB, V14, P521, DOI 10.1097/00001199-199912000-00002; Chen SHA, 2003, J NEUROL NEUROSUR PS, V74, P326, DOI 10.1136/jnnp.74.3.326; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; Cook J B, 1972, Scand J Rehabil Med, V4, P27; Cooper DB, 2011, BRAIN INJURY, V25, P1, DOI 10.3109/02699052.2010.531692; Costanzo RM, 1992, J HEAD TRAUMA REHAB, V7, P15, DOI DOI 10.1097/00001199-199203000-00005; Cote P, 2011, SPINE, V36, pS275, DOI 10.1097/BRS.0b013e3182388d32; Croft AC, 2002, WHIPLASH INJURIES CE, P335; Cytowic R, 1988, NEUROPSYCHOLOGICAL S, P226; Dahl J, 2004, BEHAV THER, V35, P785, DOI 10.1016/S0005-7894(04)80020-0; DAILY L, 1979, ARCH OPHTHALMOL-CHIC, V97, P360; Daley A, 2008, J CLIN PSYCHOL MED S, V15, P140, DOI 10.1007/s10880-008-9105-z; Dalrymple KL, 2007, BEHAV MODIF, V31, P543, DOI 10.1177/0145445507302037; Davis CH, 2002, AM J PHYS MED REHAB, V81, P609, DOI 10.1097/00002060-200208000-00009; de Guise E, 2010, CLIN NEUROPSYCHOL, V24, P1113, DOI 10.1080/13854046.2010.506199; Dean PJA, 2012, BRAIN INJURY, V26, P14, DOI 10.3109/02699052.2011.635354; Degl'Innocenti A, 1998, ACTA PSYCHIAT SCAND, V97, P182, DOI 10.1111/j.1600-0447.1998.tb09985.x; Delis DC, 2007, ARCH CLIN NEUROPSYCH, V22, P589, DOI 10.1016/j.acn.2007.04.001; Devine JM, 2009, PM&R, V1, P560, DOI 10.1016/j.pmrj.2009.03.015; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Dischinger PC, 2009, J TRAUMA, V66, P289, DOI 10.1097/TA.0b013e3181961da2; Drake AI, 2000, J HEAD TRAUMA REHAB, V15, P1103, DOI 10.1097/00001199-200010000-00004; Dunn AL, 2005, AM J PREV MED, V28, P1, DOI 10.1016/j.amepre.2004.09.003; DUNN JT, 1995, J CLIN PSYCHOL, V51, P577, DOI 10.1002/1097-4679(199507)51:4<577::AID-JCLP2270510418>3.0.CO;2-E; EDNA TH, 1987, ACTA NEUROCHIR, V86, P12, DOI 10.1007/BF01419498; Ekeland E, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003683.PUB2; Ekers D, 2008, PSYCHOL MED, V38, P611, DOI 10.1017/S0033291707001614; ELLIS HC, 1991, J EXP PSYCHOL GEN, V120, P310, DOI 10.1037/0096-3445.120.3.310; Ericsson M, 2002, DISABIL REHABIL, V24, P334, DOI 10.1080/09638280110096241; Ernst A, 2005, OTOLARYNG HEAD NECK, V132, P554, DOI 10.1016/j.otohns.2004.09.034; Ettenhofer ML, 2009, J CLIN EXP NEUROPSYC, V31, P363, DOI 10.1080/13803390802175270; Evans RW, 2010, HEADACHE, V50, P716, DOI 10.1111/j.1526-4610.2010.01645.x; Evans RW, 2003, HEADACHE, V43, P1113, DOI 10.1046/j.1526-4610.2003.03216.x; Evered L, 2003, ASSESSMENT, V10, P420, DOI 10.1177/1073191103259539; Feder A, 2009, NAT REV NEUROSCI, V10, P446, DOI 10.1038/nrn2649; FEE CRA, 1988, ARCH EMERG MED, V5, P12; Ferguson R. J., 1996, SOURCEBOOK PSYCHOL T, P615; Ferrari R, 2001, MED HYPOTHESES, V56, P372, DOI 10.1054/mehy.2000.1215; Ferrari R, 2001, CLIN NEUROL NEUROSUR, V103, P184, DOI 10.1016/S0303-8467(01)00143-3; Festinger L., 1957, THEORY COGNITIVE DIS; Fishbain DA, 1997, CLIN J PAIN, V13, P116, DOI 10.1097/00002508-199706000-00006; FLOR H, 1987, J PSYCHOSOM RES, V31, P251, DOI 10.1016/0022-3999(87)90082-1; Foa EB, 1997, PSYCHOL ASSESSMENT, V9, P445, DOI 10.1037/1040-3590.9.4.445; Forman EM, 2007, BEHAV MODIF, V31, P772, DOI 10.1177/0145445507302202; FOX DD, 1995, CLIN NEUROPSYCHOL, V9, P89, DOI 10.1080/13854049508402064; Franklin CL, 2001, J NERV MENT DIS, V189, P548, DOI 10.1097/00005053-200108000-00008; Frisher M, 2005, J EPIDEMIOL COMMUN H, V59, P847, DOI 10.1136/jech.2004.030833; Gagnon I, 2009, BRAIN INJURY, V23, P956, DOI 10.3109/02699050903373477; Garden N, 2010, APPL NEUROPSYCHOL, V17, P1, DOI 10.1080/09084280903297495; Gasquoine P G, 2000, Appl Neuropsychol, V7, P83, DOI 10.1207/S15324826AN0702_3; Geary EK, 2010, J INT NEUROPSYCH SOC, V16, P506, DOI 10.1017/S135561771000010X; Gil S, 2005, AM J PSYCHIAT, V162, P963, DOI 10.1176/appi.ajp.162.5.963; Gladstone J, 2009, HEADACHE, V49, P1097, DOI 10.1111/j.1526-4610.2009.01461.x; Gottshall K, 2011, NEUROREHABILITATION, V29, P167, DOI 10.3233/NRE-2011-0691; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Grant BF, 2004, ARCH GEN PSYCHIAT, V61, P807, DOI 10.1001/archpsyc.61.8.807; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Greenwood BN, 2008, NEUROMOL MED, V10, P81, DOI 10.1007/s12017-008-8029-y; Greiffenstein MF, 2001, CLIN NEUROPSYCHOL, V15, P162, DOI 10.1076/clin.15.2.162.1895; Griesbach GS, 2008, NEUROSCIENCE, V154, P530, DOI 10.1016/j.neuroscience.2008.04.003; Griesbach GS, 2007, J NEUROTRAUM, V24, P1161, DOI 10.1089/neu.2006.0255; Griesbach GS, 2009, J NEUROSCI RES, V87, P795, DOI 10.1002/jnr.21893; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; GRIMM RJ, 1989, ACTA OTO-LARYNGOL, P1, DOI 10.3109/00016488909138632; Grothues J, 2005, ALCOHOL ALCOHOLISM, V40, P394, DOI 10.1093/alcalc/agh182; Guez M, 2005, J CLIN EXP NEUROPSYC, V27, P151, DOI 10.1080/13803390490515487; Gunstad J, 2004, ARCH CLIN NEUROPSYCH, V19, P391, DOI 10.1016/S0887-6177(03)00073-8; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; Gutierrez O, 2004, BEHAV THER, V35, P767, DOI 10.1016/S0005-7894(04)80019-4; Hagger MS, 2003, PSYCHOL HEALTH, V18, P141, DOI 10.1080/088704403100081321; Hahn RA, 1997, PREV MED, V26, P607, DOI 10.1006/pmed.1996.0124; Haldorsen T, 2003, APPL NEUROPSYCHOL, V10, P170, DOI 10.1207/S15324826AN1003_06; Hanna-Pladdy B, 2001, CLIN NEUROPSYCHOL, V15, P289, DOI 10.1076/clin.15.3.289.10272; Harch PG, 2012, J NEUROTRAUM, V29, P168, DOI 10.1089/neu.2011.1895; Hart RP, 2000, NEUROPSYCHOL REV, V10, P131, DOI 10.1023/A:1009020914358; Hart T, 2007, REHABIL PSYCHOL, V52, P152, DOI 10.1037/0090-5550.52.2.152; Hayes, 2005, CLIN CASE STUD, V4, DOI [https://doi.org/10.1177/1534650103259689, DOI 10.1177/1534650103259689, 10.1177/1534650103259689]; Hayes S.C., 1999, ACCEPTANCE COMMITMEN; Hayes SC, 2004, BEHAV THER, V35, P35, DOI 10.1016/S0005-7894(04)80003-0; HEALY GB, 1982, NEW ENGL J MED, V306, P1029, DOI 10.1056/NEJM198204293061705; Heim C, 2008, PSYCHONEUROENDOCRINO, V33, P693, DOI 10.1016/j.psyneuen.2008.03.008; Heinrichs M, 2005, AM J PSYCHIAT, V162, P2276, DOI 10.1176/appi.ajp.162.12.2276; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; Herring MP, 2010, ARCH INTERN MED, V170, P321, DOI 10.1001/archinternmed.2009.530; Hesser H, 2011, CLIN PSYCHOL REV, V31, P545, DOI 10.1016/j.cpr.2010.12.006; Hesser H, 2009, BEHAV RES THER, V47, P523, DOI 10.1016/j.brat.2009.02.002; HILDINGSSON C, 1990, ACTA ORTHOP SCAND, V61, P357, DOI 10.3109/17453679008993536; Hilsabeck RC, 1998, J CLIN EXP NEUROPSYC, V20, P328, DOI 10.1076/jcen.20.3.328.813; HIRSCHFELD RMA, 1983, ARCH GEN PSYCHIAT, V40, P993; Hoffman JM, 2012, ARCH PHYS MED REHAB, V93, P287, DOI 10.1016/j.apmr.2011.08.041; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge EA, 2007, DEPRESS ANXIETY, V24, P139, DOI 10.1002/da.20175; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Holroyd KA, 2000, HEADACHE, V40, P3, DOI 10.1046/j.1526-4610.2000.00001.x; Hopkins RO, 2006, J NEUROIMAGING, V16, P243, DOI 10.1111/j.1552-6569.2006.00047.x; Hou RH, 2012, J NEUROL NEUROSUR PS, V83, P217, DOI 10.1136/jnnp-2011-300767; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Hung CI, 2006, CEPHALALGIA, V26, P26, DOI 10.1111/j.1468-2982.2005.00985.x; Hunot V, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001848; ILSLEY JE, 1995, J AFFECT DISORDERS, V35, P1, DOI 10.1016/0165-0327(95)00032-I; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; Iverson G.L., 2001, J FORENSIC NEUROPSYC, V2, P19, DOI [https://doi.org/10.1300/J151v02n01_02, DOI 10.1300/J151v02n01_02]; Iverson G.L., 2007, BRAIN INJURY MED PRI, P373; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Iverson GL, 2006, BRAIN INJURY, V20, P1335, DOI 10.1080/02699050601082156; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Iverson GL, 2010, BRAIN INJURY, V24, P1246, DOI 10.3109/02699052.2010.490513; Iverson GL, 2010, J HEAD TRAUMA REHAB, V25, P23, DOI 10.1097/HTR.0b013e3181b4b6ab; Iverson GL, 2010, CLIN NEUROPSYCHOL, V24, P17, DOI 10.1080/13854040903190797; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; JAMISON RN, 1988, INT J PSYCHIAT MED, V18, P183; Jamora CW, 2012, BRAIN INJURY, V26, P36, DOI 10.3109/02699052.2011.635352; Johnston M, 2010, CLIN J PAIN, V26, P393, DOI 10.1097/AJP.0b013e3181cf59ce; Jolliffe CD, 2004, PAIN, V107, P167, DOI 10.1016/j.pain.2003.10.015; Kangas M, 2011, NEUROPSYCHOL REHABIL, V21, P250, DOI 10.1080/09602011.2010.540920; Kant R, 1997, BRAIN INJURY, V11, P115, DOI 10.1080/026990597123700; Kashluba S, 2006, J INT NEUROPSYCH SOC, V12, P111, DOI 10.1017/S1355617706060036; Kashluba S, 2008, CLIN NEUROPSYCHOL, V22, P195, DOI 10.1080/13854040701263655; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; KENDLER KS, 1993, ARCH GEN PSYCHIAT, V50, P853; Kendler KS, 2001, AM J PSYCHIAT, V158, P587, DOI 10.1176/appi.ajp.158.4.587; Kendrick D, ACQUIRED BR IN PRESS; KENNEDY W P, 1961, Med World, V95, P203; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; King NS, 2011, BRAIN INJURY, V25, P462, DOI 10.3109/02699052.2011.558042; KISCHKA U, 1991, EUR NEUROL, V31, P136, DOI 10.1159/000116663; Konrad C, 2011, PSYCHOL MED, V41, P1197, DOI 10.1017/S0033291710001728; Kouyanou K, 1998, PAIN, V76, P417, DOI 10.1016/S0304-3959(98)00074-8; Kowacs F, 2003, CEPHALALGIA, V23, P79, DOI 10.1046/j.1468-2982.2003.00461.x; KOWAL L, 1992, AUST NZ J OPHTHALMOL, V20, P35, DOI 10.1111/j.1442-9071.1992.tb00701.x; Kraus J, 2005, J HEAD TRAUMA REHAB, V20, P239, DOI 10.1097/00001199-200505000-00007; Kraus J, 2009, J HEAD TRAUMA REHAB, V24, P344, DOI 10.1097/HTR.0b013e3181ae35fd; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Kurca E, 2006, NEURORADIOLOGY, V48, P661, DOI 10.1007/s00234-006-0109-9; LANCMAN ME, 1994, ANN NEUROL, V35, P359, DOI 10.1002/ana.410350319; Lange RT, 2010, J CLIN EXP NEUROPSYC, V32, P961, DOI 10.1080/13803391003645657; Lange RT, 2011, J HEAD TRAUMA REHAB, V26, P127, DOI 10.1097/HTR.0b013e3181e4622a; Lange RT, 2010, ARCH CLIN NEUROPSYCH, V25, P442, DOI 10.1093/arclin/acq031; Lange RT, 2009, BRAIN INJURY, V23, P83, DOI 10.1080/02699050802635281; Lange RT, J HEAD TRAUMA REHABI; Lawlor DA, 2001, BMJ-BRIT MED J, V322, P763, DOI 10.1136/bmj.322.7289.763; Leddy JJ, 2007, NEUROREHABILITATION, V22, P199; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Lees-Haley PR, 2001, ARCH CLIN NEUROPSYCH, V16, P689, DOI 10.1016/S0887-6177(00)00092-5; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; LeesHaley PR, 1996, PSYCHOL REP, V79, P811, DOI 10.2466/pr0.1996.79.3.811; LeesHaley PR, 1997, BRAIN INJURY, V11, P791; Lemelin S, 1997, J NERV MENT DIS, V185, P542, DOI 10.1097/00005053-199709000-00002; Leonard KN, 2004, INT NEUR SOC M FEBR; Leventhal H., 2003, SELF REGULATION HLTH; Lipton RB, 2000, NEUROLOGY, V55, P629, DOI 10.1212/WNL.55.5.629; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Lo C, 2009, J COMPUT ASSIST TOMO, V33, P293, DOI 10.1097/RCT.0b013e31817579d1; Locke DEC, 2008, NEUROREHABILITATION, V23, P273; Lojovich JM, 2010, J HEAD TRAUMA REHAB, V25, P184, DOI 10.1097/HTR.0b013e3181dc78cd; Luis CA, 2003, J INT NEUROPSYCH SOC, V9, P1001, DOI 10.1017/S1355617703970044; LUPARELLO T, 1968, PSYCHOSOM MED, V30, P819, DOI 10.1097/00006842-196811000-00002; Ma M, 2008, AM J EMERG MED, V26, P763, DOI 10.1016/j.ajem.2007.10.029; Machulda MM, 1998, ARCH CLIN NEUROPSYCH, V13, P415, DOI 10.1016/S0887-6177(97)00031-0; Magnusson JE, 2003, HEADACHE, V43, P1049, DOI 10.1046/j.1526-4610.2003.03206.x; MAIER W, 1992, J AFFECT DISORDERS, V24, P153, DOI 10.1016/0165-0327(92)90063-C; Maitland C G, 2001, Curr Neurol Neurosci Rep, V1, P486, DOI 10.1007/s11910-001-0111-x; Malouff JA, 2008, CLIN PSYCHOL REV, V28, P736, DOI 10.1016/j.cpr.2007.10.004; Malouff JM, 2011, CURR PSYCHIAT REP, V13, P31, DOI 10.1007/s11920-010-0163-1; Marzo SJ, 2004, LARYNGOSCOPE, V114, P1720, DOI 10.1097/00005537-200410000-00008; McCauley SR, 2005, J NERV MENT DIS, V193, P540, DOI 10.1097/01.nmd.0000172592.05801.71; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McCauley SR, 2008, J CLIN EXP NEUROPSYC, V30, P360, DOI 10.1080/13803390701416635; McCracken LA, 2003, PAIN, V105, P197, DOI 10.1016/S0304-3959(03)00202-1; McCracken LM, 2005, BEHAV RES THER, V43, P1335, DOI 10.1016/j.brat.2004.10.003; McCracken LM, 1998, PAIN, V74, P21, DOI 10.1016/S0304-3959(97)00146-2; McCracken LM, 2001, J PAIN SYMPTOM MANAG, V21, P392, DOI 10.1016/S0885-3924(01)00267-6; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; McCullagh S, 2003, J NEUROL NEUROSUR PS, V74, P39, DOI 10.1136/jnnp.74.1.39; McDermott LM, 2009, J AFFECT DISORDERS, V119, P1, DOI 10.1016/j.jad.2009.04.022; McLean SA, 2004, MED HYPOTHESES, V63, P653, DOI 10.1016/j.mehy.2004.03.022; McLean SA, 2009, AM J EMERG MED, V27, P182, DOI 10.1016/j.ajem.2008.01.054; McNally RJ, 2003, BIOL PSYCHIAT, V53, P779, DOI 10.1016/S0006-3223(02)01663-3; McWilliams LA, 2003, PAIN, V106, P127, DOI 10.1016/S0304-3959(03)00301-4; Mead GE, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004366.pub3; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Merom D, 2008, J ANXIETY DISORD, V22, P959, DOI 10.1016/j.janxdis.2007.09.010; Merriam EP, 1999, AM J PSYCHIAT, V156, P780; Michelini LC, 2009, EXP PHYSIOL, V94, P947, DOI 10.1113/expphysiol.2009.047449; Mickeviciene D, 2004, EUR J NEUROL, V11, P411, DOI 10.1111/j.1468-1331.2004.00816.x; Mickeviciene D, 2002, EUR J NEUROL, V9, P581, DOI 10.1046/j.1468-1331.2002.00497.x; Miller L J, 1998, Appl Neuropsychol, V5, P172, DOI 10.1207/s15324826an0504_2; Mitsikostas DD, 1999, CEPHALALGIA, V19, P211, DOI 10.1046/j.1468-2982.1999.019004211.x; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Mols F, 2010, GEN HOSP PSYCHIAT, V32, P66, DOI 10.1016/j.genhosppsych.2009.09.010; Molteni R, 2002, EUR J NEUROSCI, V16, P1107, DOI 10.1046/j.1460-9568.2002.02158.x; Monroe SM, 2005, PSYCHOL REV, V112, P417, DOI 10.1037/0033-295X.112.2.417; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; Mooney G, 2001, BRAIN INJURY, V15, P865, DOI 10.1080/02699050110065286; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; Mossberg KA, 2010, J HEAD TRAUMA REHAB, V25, P173, DOI 10.1097/HTR.0b013e3181dc98ff; Munoz M, 2005, CLIN J PAIN, V21, P287; NEEPER SA, 1995, NATURE, V373, P109, DOI 10.1038/373109a0; Nemiah J.C., 1970, MODERN TRENDS PSYCHO, P26, DOI 10.1017/; Newman S, 2004, LANCET, V364, P1523, DOI 10.1016/S0140-6736(04)17277-2; Nijs J, 2008, J REHABIL MED, V40, P241, DOI 10.2340/16501977-0185; Nolin P, 2006, BRAIN INJURY, V20, P1147, DOI 10.1080/02699050601049247; Nolte S, 2007, PATIENT EDUC COUNS, V65, P351, DOI 10.1016/j.pec.2006.08.016; Norrie J, 2010, BRAIN INJURY, V24, P1528, DOI 10.3109/02699052.2010.531687; Nunes EV, 2004, JAMA-J AM MED ASSOC, V291, P1887, DOI 10.1001/jama.291.15.1887; Ontario Neurotrauma Foundation, 2011, GUID MILD TRAUM BRAI; Ormel J, 2004, ARCH GEN PSYCHIAT, V61, P990, DOI 10.1001/archpsyc.61.10.990; Ozen LJ, 2011, J INT NEUROPSYCH SOC, V17, P219, DOI 10.1017/S135561771000144X; PACKARD RC, 1992, HEADACHE, V32, P496, DOI 10.1111/j.1526-4610.1992.hed3210496.x; Panayiotou A, 2011, AUST PSYCHOL, P1; PARMELEE PA, 1993, J AM GERIATR SOC, V41, P517, DOI 10.1111/j.1532-5415.1993.tb01888.x; Patil VK, 2011, HEADACHE, V51, P1112, DOI 10.1111/j.1526-4610.2011.01946.x; PEARCE JMS, 1989, J NEUROL NEUROSUR PS, V52, P1329, DOI 10.1136/jnnp.52.12.1329; Penninx BWJH, 2002, J GERONTOL B-PSYCHOL, V57, pP124, DOI 10.1093/geronb/57.2.P124; Petersen CL, 2009, PSYCHOL REC, V59, P521, DOI 10.1007/BF03395679; Pine DS, 1996, J CHILD ADOL PSYCHOP, V6, P153, DOI 10.1089/cap.1996.6.153; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Potter S, 2012, NEUROPSYCHOL REHABIL, V22, P1, DOI 10.1080/09602011.2011.630883; Powell T, 2007, BRAIN INJURY, V21, P31, DOI 10.1080/02699050601106245; Price JR, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001027.pub2; RADANOV BP, 1992, SPINE, V17, P127, DOI 10.1097/00007632-199202000-00001; Rajkowska G, 1999, BIOL PSYCHIAT, V45, P1085, DOI 10.1016/S0006-3223(99)00041-4; RASMUSSEN BK, 1991, J CLIN EPIDEMIOL, V44, P1147, DOI 10.1016/0895-4356(91)90147-2; Rasmussen BK, 2001, CEPHALALGIA, V21, P774, DOI 10.1046/j.1468-2982.2001.00248.x; Rees PM, 2003, ARCH PHYS MED REHAB, V84, P1885, DOI 10.1016/j.apmr.2003.03.001; Rethorst CD, 2009, SPORTS MED, V39, P491, DOI 10.2165/00007256-200939060-00004; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; Roe C, 2009, DISABIL REHABIL, V31, P1235, DOI 10.1080/09638280802532720; Roesch SC, 2001, J PSYCHOSOM RES, V50, P205, DOI 10.1016/S0022-3999(01)00188-X; Rohling ML, 2012, CLIN NEUROPSYCHOL, V26, P197, DOI 10.1080/13854046.2011.647085; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Roth RS, 2005, ARCH PHYS MED REHAB, V86, P1147, DOI 10.1016/j.apmr.2004.10.041; RUBIN W, 1990, NEUROL CLIN, V8, P225, DOI 10.1016/S0733-8619(18)30352-9; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Ruff RM, 1999, STUD NEUROPSYCHOL DE, P315; Ruff RM, 1999, BRAIN INJURY, V13, P943; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Ruff RM, 2011, NEUROREHABILITATION, V28, P167, DOI 10.3233/NRE-2011-0646; Rush BK, 2004, REHABIL PSYCHOL, V49, P275, DOI 10.1037/0090-5550.49.4.275; RUTHERFORD WH, 1977, LANCET, V1, P1; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Sadowski-Cron C, 2006, BRAIN INJURY, V20, P1131, DOI 10.1080/02699050600832569; Satz P, 1999, J CLIN EXP NEUROPSYC, V21, P620, DOI 10.1076/jcen.21.5.620.870; Sawchyn JM, 2000, ARCH CLIN NEUROPSYCH, V15, P1, DOI 10.1016/S0887-6177(98)00041-9; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; SCHNURR RF, 1995, CLIN J PAIN, V11, P103, DOI 10.1097/00002508-199506000-00004; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; SCHWEIGER A, 1981, PAVLOVIAN J BIOL SCI, V16, P140; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Shalev AY, 1998, AM J PSYCHIAT, V155, P630, DOI 10.1176/ajp.155.5.630; Sheftell FD, 2002, HEADACHE, V42, P934, DOI 10.1046/j.1526-4610.2002.02217.x; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; Silverberg ND, 2011, NEUROREHABILITATION, V29, P317, DOI 10.3233/NRE-2011-0708; Slattery EL, 2011, NEUROREHABILITATION, V29, P143, DOI 10.3233/NRE-2011-0688; Smith PJ, 2010, PSYCHOSOM MED, V72, P239, DOI 10.1097/PSY.0b013e3181d14633; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Smits JAJ, 2008, DEPRESS ANXIETY, V25, P689, DOI 10.1002/da.20411; Smits M, 2011, NEURORADIOLOGY, V53, P553, DOI 10.1007/s00234-010-0774-6; Snell DL, 2011, BRAIN INJURY, V25, P1126, DOI 10.3109/02699052.2011.607786; Snell DL, 2011, J HEAD TRAUMA REHAB, V26, P468, DOI 10.1097/HTR.0b013e3181fc5e1e; Snell DL, 2010, BRAIN INJURY, V24, P1595, DOI 10.3109/02699052.2010.523048; Snell D, 2009, J CLIN EXP NEUROPSYC, V31, P20, DOI 10.1080/13803390801978849; Southwick SM, 2005, ANNU REV CLIN PSYCHO, V1, P255, DOI 10.1146/annurev.clinpsy.1.102803.143948; Spiegel H, 1997, PREV MED, V26, P616, DOI 10.1006/pmed.1997.0229; Spinos P, 2010, J TRAUMA, V69, P789, DOI 10.1097/TA.0b013e3181edea67; Stalnacke BM, 2005, J REHABIL MED, V37, P300, DOI 10.1080/16501970510032910; STEELE CM, 1995, J PERS SOC PSYCHOL, V69, P797, DOI 10.1037/0022-3514.69.5.797; STERNBERG DE, 1976, ARCH GEN PSYCHIAT, V33, P219; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; Strosahl KD, 2004, PRACTICAL GUIDE TO ACCEPTANCE AND COMMITMENT THERAPY, P31; Stulemeijer M, 2008, J NEUROL NEUROSUR PS, V79, P936, DOI 10.1136/jnnp.2007.131250; Stulemeijer M, 2007, J PSYCHOSOM RES, V63, P637, DOI 10.1016/j.jpsychores.2007.06.023; Stulemeijer M, 2007, BRAIN INJURY, V21, P309, DOI 10.1080/02699050701209980; Stulemeijer M, 2006, J NEUROTRAUM, V23, P1561, DOI 10.1089/neu.2006.23.1561; Suhr JA, 2005, J INT NEUROPSYCH SOC, V11, P23, DOI 10.1017/S1355617705050010; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P981, DOI 10.1076/jcen.24.8.981.8372; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P448, DOI 10.1076/jcen.24.4.448.1039; Sullivan MJL, 2008, J OCCUP REHABIL, V18, P249, DOI 10.1007/s10926-008-9140-5; Sullivan Michael J L, 2002, Pain Res Manag, V7, P120; Sullivan PF, 2000, AM J PSYCHIAT, V157, P1552, DOI 10.1176/appi.ajp.157.10.1552; Symonds Charles, 1937, GUYS HOSP GAZ, V51, P461; The Management of Concussion/mTBI Working Group, 2009, VA DOD CLIN PRACT GU; Tiersky LA, 2005, ARCH PHYS MED REHAB, V86, P1565, DOI 10.1016/j.apmr.2005.03.013; TOLLISON CD, 1992, PAINFUL CERVICAL TRA; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; UOMOTO JM, 1993, ARCH PHYS MED REHAB, V74, P61; Van Damme S, 2006, J PSYCHOSOM RES, V61, P595, DOI 10.1016/j.jpsychores.2006.04.015; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Van Os J, 1999, PSYCHOL MED, V29, P1055, DOI 10.1017/S0033291799001026; van Praag H, 2008, NEUROMOL MED, V10, P128, DOI 10.1007/s12017-008-8028-z; van Straten A, 2010, J PSYCHOSOM RES, V69, P23, DOI 10.1016/j.jpsychores.2010.01.019; van Veldhoven LM, 2011, J NEUROL NEUROSUR PS, V82, P782, DOI 10.1136/jnnp.2010.228254; van Wilgen CP, 2010, DISABIL REHABIL, V32, P1576, DOI 10.3109/09638281003596857; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Vanderploeg RD, 2003, J HEAD TRAUMA REHAB, V18, P148, DOI 10.1097/00001199-200303000-00006; Veale D., 2008, ADV PSYCHIAT TREATME, V14, P29, DOI [10.1192/apt.bp.107.004051, DOI 10.1192/APT.BP.107.004051, DOI 10.1192/apt.bp.107.004051]; Venable VL, 2001, HEADACHE, V41, P21, DOI 10.1046/j.1526-4610.2001.111006021.x; Vowels KE, 2008, COGN BEHAV PRACT, V16, P49; Wacogne C, 2003, CEPHALALGIA, V23, P451, DOI 10.1046/j.1468-2982.2003.00550.x; Wang CC, 2010, BMC COMPLEM ALTERN M, V10, DOI 10.1186/1472-6882-10-23; WATSON MR, 1995, BRIT J PSYCHIAT, V167, P514, DOI 10.1192/bjp.167.4.514; WEINGARTNER H, 1981, ARCH GEN PSYCHIAT, V38, P42; Weissman HN., 1990, BEHAV SCI LAW, V8, P67, DOI [10.1002/bsl.2370080108, DOI 10.1002/BSL.2370080108]; Wen W, 2009, HUM BRAIN MAPP, V30, P1155, DOI 10.1002/hbm.20586; Westin V, 2008, BEHAV RES THER, V46, P1259, DOI 10.1016/j.brat.2008.08.008; Whittaker R, 2007, J NEUROL NEUROSUR PS, V78, P644, DOI 10.1136/jnnp.2006.101105; Wicksell RK, 2009, PAIN, V141, P248, DOI 10.1016/j.pain.2008.11.006; Willer Barry, 2006, Curr Treat Options Neurol, V8, P415, DOI 10.1007/s11940-006-0031-9; Williams GH, 1989, TXB HEAD INJURY, P367; Wilson KG, 2002, CLIN J PAIN, V18, P77, DOI 10.1097/00002508-200203000-00002; WOLFE J, 1987, J AFFECT DISORDERS, V13, P83, DOI 10.1016/0165-0327(87)90077-2; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906; Woodrome SE, 2011, J INT NEUROPSYCH SOC, V17, P317, DOI 10.1017/S1355617710001700; WOOLEY SC, 1978, PSYCHOSOM MED, V40, P379, DOI 10.1097/00006842-197808000-00003; World Health Organization, 1992, ICD 10 CLASS MENT BE; World Health Organization, 1992, ICD 10 INT STAT CLAS; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3; Yang CC, 2009, BRAIN INJURY, V23, P299, DOI 10.1080/02699050902788543; Yardley L, 2001, J ANXIETY DISORD, V15, P107, DOI 10.1016/S0887-6185(00)00045-1; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056; YLIKOSKI A, 1995, STROKE, V26, P1171, DOI 10.1161/01.STR.26.7.1171; Youngstedt SD, 2005, CLIN SPORT MED, V24, P355, DOI 10.1016/j.csm.2004.12.003; YOUNGSTEDT SD, 2005, CLIN SPORTS MED, V24, pR11; Zakzanis KK, 1998, NEUROPSY NEUROPSY BE, V11, P111; Zasler ND, 2011, J HEAD TRAUMA REHAB, V26, P397, DOI 10.1097/HTR.0b013e31822721f8; Zasler ND, 2011, MANUAL OF TRAUMATIC BRAIN INJURY MANAGEMENT, P125; Zasler Nathan D., 1992, Archives of Physical Medicine and Rehabilitation, V73, P963; Zasler ND, 1991, J HEAD TRAUMA REHAB, V6, P78; Zasler ND, 1996, MED REHABILITATION T, P133; Zasler ND, CLIN MANUAL IN PRESS; Zeitzer JM, 2008, SLEEP DISORDERS CONT; Zwart JA, 2003, EUR J NEUROL, V10, P147, DOI 10.1046/j.1468-1331.2003.00551.x	407	41	41	0	16	DEMOS MEDICAL PUBLICATIONS	NEW YORK	11 WEST 42ND STREET, 15TH FLOOR, NEW YORK, NY 10036 USA			978-1-936287-27-7				2013							470	497					28	Clinical Neurology	Neurosciences & Neurology	BDJ25	WOS:000313536100030					2021-06-18	
J	Bao, HJ; Wang, T; Zhang, MY; Liu, R; Dai, DK; Wang, YQ; Wang, L; Zhang, L; Gao, YZ; Qin, ZH; Chen, XP; Tao, LY				Bao, Hai-Jun; Wang, Tao; Zhang, Ming-Yang; Liu, Ran; Dai, Ding-Kun; Wang, Yao-Qi; Wang, Long; Zhang, Lu; Gao, Yu-Zhen; Qin, Zheng-Hong; Chen, Xi-Ping; Tao, Lu-Yang			Poloxamer-188 Attenuates TBI-Induced Blood-Brain Barrier Damage Leading to Decreased Brain Edema and Reduced Cellular Death	NEUROCHEMICAL RESEARCH			English	Article						Traumatic brain injury; Poloxamer 188; Brain edema; Apoptosis; Neurovascular unit	CONTROLLED CORTICAL IMPACT; NF-KAPPA-B; WATER TRANSPORT; INJURY MODEL; AQUAPORIN-4; CELLS; PERMEABILITY; MECHANISMS; INHIBITION; CONTUSION	Plasmalemma permeability plays an important role in the secondary neuronal death induced by traumatic brain injury (TBI). Previous works showed that Poloxamer 188 (P188) could restore the intactness of the plasma membrane and play a cytoprotective action. However, the roles of P188 in blood-brain barrier (BBB) integrity and TBI-induced neural cell death are still not clear. In this study, mice were induced TBI by controlled cortical impact (CCI), and cerebral water content was measured to explore the profile of brain edema after CCI. Further, the regimen of P188 in mouse CCI models was optimized. The neurological test and BBB integrity assessment were performed, and the numbers of TBI-induced neural cell death were counted by propidium iodide (PI) labeling. The expression of apoptotic pathway associated proteins (Bax, cyt-c, caspase-8, caspase-9, caspase-3, P53) and aquaporin-4 (AQP4) was assessed by RT-PCR or immunoblotting. The data showed that the brain edema peaked at 24 h after TBI in untreated animals. Tail intravenous injection of P188 (4 mg/ml, 100 mu l) 30 min before TBI or within 30 min after TBI could attenuate TBI-induced brain edema. P188 pre-treatment restored BBB integrity, suppressed TBI-induced neural cell death, and improved neurological function. TBI induced an up-regulation of Bax, cyt-c, caspase-8, caspase-9, caspase-3, and the expression of p53 was down-regulated by P188 pre-treatment. AQP4 mainly located on endothelial cells and astrocytes, and its expression was also regulated by P188 pretreatment. All these results revealed that P188 attenuates TBI-induced brain edema by resealing BBB and regulating AQP4 expression, and suppressed apoptosis through extrinsic or intrinsic pathway. Plasmalemma permeability may be a potential target for TBI treatment.	[Bao, Hai-Jun; Wang, Tao; Zhang, Ming-Yang; Liu, Ran; Dai, Ding-Kun; Wang, Yao-Qi; Wang, Long; Zhang, Lu; Gao, Yu-Zhen; Chen, Xi-Ping; Tao, Lu-Yang] Soochow Univ, Inst Forens Sci, Suzhou 215123, Jiangsu, Peoples R China; [Zhang, Ming-Yang] Nantong Univ, Coll Med, Dept Forens Sci, Nantong 226001, Jiangsu, Peoples R China; [Qin, Zheng-Hong] Soochow Univ, Dept Pharmacol, Suzhou 215123, Jiangsu, Peoples R China	Chen, XP (corresponding author), Soochow Univ, Inst Forens Sci, Suzhou 215123, Jiangsu, Peoples R China.	xiping.chen@163.com; luyang.tao@163.com	Mingyang, Zhang/J-7412-2019	Mingyang, Zhang/0000-0001-7084-6237	National Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81271379, 81172911, 30872666]	The work was supported by the National Science Foundation of China (No. 81271379, No. 81172911, No. 30872666). We thank Dr. Changhong Xing who polished this paper.	Abbott NJ, 2002, J ANAT, V200, P629, DOI 10.1046/j.1469-7580.2002.00064.x; Baars DC, 2006, BIOMECH MODEL MECHAN, V5, P133, DOI 10.1007/s10237-006-0024-3; Bierbach B, 2008, STROKE, V39, P213, DOI 10.1161/STROKEAHA.107.496620; Cullen DK, 2011, J NEUROTRAUM, V28, P2219, DOI 10.1089/neu.2011.1841; Curry DJ, 2004, J NEUROSURG, V101, P91, DOI 10.3171/ped.2004.101.2.0091; Doelken M, 2007, DIAGN INTERV RADIOL, V13, P125; Donkin JJ, 2010, CURR OPIN NEUROL, V23, P293, DOI 10.1097/WCO.0b013e328337f451; Eghwrudjakpor PO, 2010, LIBYAN J MED, V5, DOI [10.4176/091104, 10.3402/ljm.v5i0.4620]; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Greenebaum B, 2004, BURNS, V30, P539, DOI 10.1016/j.burns.2004.02.009; Hunter RL, 2010, ANN CLIN LAB SCI, V40, P115; Ke CS, 2001, NEUROSCI LETT, V301, P21, DOI 10.1016/S0304-3940(01)01589-0; LaPlaca MC, 2009, IEEE ENG MED BIO, P1113, DOI 10.1109/IEMBS.2009.5334457; Lentsch AB, 1999, CLIN CHEM LAB MED, V37, P205, DOI 10.1515/CCLM.1999.038; Lescot T, 2010, J NEUROTRAUM, V27, P1069, DOI 10.1089/neu.2009.1188; Luo CL, 2011, NEUROSCIENCE, V184, P54, DOI 10.1016/j.neuroscience.2011.03.021; Luo CL, 2010, NEURAL REGEN RES, V5, P706, DOI 10.3969/j.issn.1673-5374.2010.09.012; Marmarou A, 2003, ACT NEUR S, V86, P7; Marmarou Anthony, 2007, Neurosurg Focus, V22, pE1; Matsumoto Y, 2004, STROKE, V35, P185, DOI 10.1161/01.STR.0000106910.42815.C2; Nicchia GP, 2004, NEUROSCIENCE, V129, P935, DOI 10.1016/j.neuroscience.2004.07.055; Nielsen S, 1997, J NEUROSCI, V17, P171; Oliva AA, 2011, NEUROSCIENCE, V180, P272, DOI 10.1016/j.neuroscience.2011.02.020; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Plesnila N, 2007, CELL DEATH DIFFER, V14, P1529, DOI 10.1038/sj.cdd.4402159; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Rangel-Castilla L, 2008, NEUROL CLIN, V26, px; Rangel-Castillo L, 2008, NEUROL CLIN, V26, P521, DOI 10.1016/j.ncl.2008.02.003; Rao KVR, 2011, J NEUROTRAUM, V28, P371, DOI 10.1089/neu.2010.1705; Robbins MA, 2003, ENDOCRINOLOGY, V144, P4616, DOI 10.1210/en.2003-0266; Saadoun S, 2003, J CLIN PATHOL, V56, P972, DOI 10.1136/jcp.56.12.972; Serbest G, 2005, J NEUROTRAUM, V22, P119, DOI 10.1089/neu.2005.22.119; Serbest G, 2006, FASEB J, V20, P308, DOI 10.1096/fj.05-4024fje; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; SHOHAMI E, 1993, J NEUROTRAUM, V10, P109, DOI 10.1089/neu.1993.10.109; Sun MC, 2003, J NEUROSURG, V98, P565, DOI 10.3171/jns.2003.98.3.0565; Tomkins O, 2011, CARDIOVASC PSYCHIAT, V2011; Unal-Cevik I, 2004, STROKE, V35, P2189, DOI 10.1161/01.STR.0000136149.81831.c5; Van Putten HP, 2005, J NEUROTRAUM, V22, P857; Venero JL, 2001, PROG NEUROBIOL, V63, P321, DOI 10.1016/S0301-0082(00)00035-6; Verkman AS, 2000, AM J PHYSIOL-RENAL, V278, pF13; Whalen MJ, 2008, J CEREBR BLOOD F MET, V28, P490, DOI 10.1038/sj.jcbfm.9600544; Yang BX, 2008, J BIOL CHEM, V283, P15280, DOI 10.1074/jbc.M801425200; Yang Xiao-feng, 2005, Chin J Traumatol, V8, P96; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4; Zweckberger K, 2003, J NEUROTRAUM, V20, P1307, DOI 10.1089/089771503322686102	48	41	43	0	17	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190	1573-6903		NEUROCHEM RES	Neurochem. Res.	DEC	2012	37	12					2856	2867		10.1007/s11064-012-0880-4			12	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	043IW	WOS:000311537300023	23011204				2021-06-18	
J	Hall, ED; Wang, JA; Miller, DM				Hall, Edward D.; Wang, Juan A.; Miller, Darren M.			Relationship of nitric oxide synthase induction to peroxynitrite-mediated oxidative damage during the first week after experimental traumatic brain injury	EXPERIMENTAL NEUROLOGY			English	Article						Traumatic brain injury; Peroxynitrite; Oxidative damage; 3-Nitrotyrosine; Nitric oxide synthase	TYROSINE NITRATION; DEFICIENT MICE; MOUSE MODEL; SUPEROXIDE; NEURODEGENERATION; ANTIOXIDANT; EXPRESSION; REDUCTION; CONTUSION; TEMPOL	We have previously shown the pathophysiological importance of the reactive nitrogen species peroxynitrite (PN) formed from the reaction of nitric oxide (center dot NO) and superoxide (O-2(center dot-)) radicals and its involvement in lipid peroxidation (LP) and protein nitration damage in brain tissue following traumatic brain injury (TBI). Nitric oxide is produced by at least three isoforms of the enzyme nitric oxide synthase (NOS) including: endothelial NOS (eNOS) in the CNS vasculature, neuronal NOS (nNOS), and inducible NOS (iNOS) in macrophages/microglia. In view of the requirement of center dot NO synthesis for PN formation, we sought to address the time course of NOS expression (mRNA by real time quantitative PCR and protein by western blot) after TBI in comparison with the time course of PN-mediated protein nitration (3-nitrotyrosine, 3-NT) in ipsilateral cortex (CTX) and hippocampus (HIPP) between 3 hours and 1 week post-injury using a controlled cortical impact (CCI) mouse model of TBI in young adult CF-1 mice. Protein nitration showed a progressive posttraumatic increase that became significant in CTX at 24 hours and then peaked at 72 hours in both CTX and HIPP. During the increase in PN-derived 3-NT, there was no increase in either CTX or HIPP eNOS mRNA levels, whereas eNOS protein levels were significantly (p<0.05) increased at 48 and 72 hours in both brain regions. There was a significant decrease in HIPP, but not CTX nNOS mRNA; however, nNOS protein did not change except for a significant increase in CTX at 1 week. There was significantly increased CTX and HIPP iNOS mRNA levels at 24, 48, and 72 hours (p<.05) post-injury. In contrast, no change was seen in CTX or HIPP iNOS protein at any timepoint. Taken together, eNOS protein expression and iNOS mRNA appear to bear a coincident temporal relationship to the time course of PN-mediated protein nitrative damage after CCI-TBI suggesting that both constitutive and inducible NOS isoforms contribute center dot NO for PN formation and 3-NT protein modification after TBI. (C) 2012 Elsevier Inc. All rights reserved.	[Hall, Edward D.] Univ Kentucky, Med Ctr, SCoBIRC, Lexington, KY 40536 USA; Univ Kentucky, Med Ctr, Dept Anat & Neurobiol, Lexington, KY 40536 USA	Hall, ED (corresponding author), Univ Kentucky, Med Ctr, SCoBIRC, Room B483,Biomed & Biol Sci Res Bldg,741 S Limest, Lexington, KY 40536 USA.	edhall@uky.edu; jawang@uky.edu; darren.miller@uky.edu	Hall, Edward D/F-8930-2013		Kentucky Spinal Cord and Head Injury Research Trust; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1T32 DA022738];  [1R01 NSO46566];  [2P01 NS058484];  [5P30 NS051220]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS046566, P01NS058484, P30NS051220] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [T32DA022738] Funding Source: NIH RePORTER	This work was supported by 1R01 NSO46566, 2P01 NS058484, 5P30 NS051220 and the Kentucky Spinal Cord and Head Injury Research Trust. Darren M. Miller was supported by fellowship funds from the NIH Blueprint Translational Neuroscience Training Grant 1T32 DA022738.	Alvarez B, 2003, AMINO ACIDS, V25, P295, DOI 10.1007/s00726-003-0018-8; Bayir H, 2005, J CEREBR BLOOD F MET, V25, P673, DOI 10.1038/sj.jcbfm.9600068; Bayir H, 2007, J NEUROCHEM, V101, P168, DOI 10.1111/j.1471-4159.2006.04353.x; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BECKMAN JS, 1991, J DEV PHYSIOL, V15, P53; Carroll RT, 2000, CHEM RES TOXICOL, V13, P294, DOI 10.1021/tx990159t; Deng Y, 2007, EXP NEUROL, V205, P154, DOI 10.1016/j.expneurol.2007.01.023; Deng-Bryant Y, 2008, J CEREBR BLOOD F MET, V28, P1114, DOI 10.1038/jcbfm.2008.10; Denicola A, 1996, ARCH BIOCHEM BIOPHYS, V333, P49, DOI 10.1006/abbi.1996.0363; Elfering SL, 2002, J BIOL CHEM, V277, P38079, DOI 10.1074/jbc.M205256200; Gahm C, 2002, NEUROSURGERY, V50, P1319, DOI 10.1097/00006123-200206000-00024; Gahm C, 2000, NEUROSURGERY, V46, P169; Ghafourifar P, 2005, TRENDS PHARMACOL SCI, V26, P190, DOI 10.1016/j.tips.2005.02.005; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Hummel SG, 2006, FREE RADICAL BIO MED, V40, P501, DOI 10.1016/j.freeradbiomed.2005.08.047; KOBZIK L, 1995, BIOCHEM BIOPH RES CO, V211, P375, DOI 10.1006/bbrc.1995.1824; Lacza Z, 2003, FREE RADICAL BIO MED, V35, P1217, DOI 10.1016/S0891-5849(03)00510-0; Lundblad C, 2009, J NEUROTRAUM, V26, P1953, DOI 10.1089/neu.2009.0955; Mesenge C, 1998, EUR J PHARMACOL, V353, P53, DOI 10.1016/S0014-2999(98)00432-4; Mesenge C, 1996, J NEUROTRAUM, V13, P209, DOI 10.1089/neu.1996.13.209; Radi R, 2001, FREE RADICAL BIO MED, V30, P463, DOI 10.1016/S0891-5849(00)00373-7; Radi R, 1998, CHEM RES TOXICOL, V11, P720, DOI 10.1021/tx980096z; Radi R, 2004, P NATL ACAD SCI USA, V101, P4003, DOI 10.1073/pnas.0307446101; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Wada K, 1999, J NEUROTRAUM, V16, P203, DOI 10.1089/neu.1999.16.203; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807	29	41	44	0	10	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	DEC	2012	238	2					176	182		10.1016/j.expneurol.2012.08.024			7	Neurosciences	Neurosciences & Neurology	046KE	WOS:000311763100014	22960186	Green Accepted			2021-06-18	
J	Heltemes, KJ; Holbrook, TL; MacGregor, AJ; Galarneau, MR				Heltemes, Kevin J.; Holbrook, Troy L.; MacGregor, Andrew J.; Galarneau, Michael R.			Blast-related mild traumatic brain injury is associated with a decline in self-rated health amongst US military personnel	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Mild traumatic brain injury; Self-rated health; Military; Combat casualty	QUALITY-OF-LIFE; OPERATION-IRAQI-FREEDOM; WHITEHALL-II; AFGHANISTAN; DEPLOYMENT; MORTALITY; SYMPTOMS; VALIDITY	Introduction: Mild traumatic brain injury (MTBI) has emerged as the preeminent injury of combat from the recent conflicts in Iraq and Afghanistan. Very little is known about short-and long-term outcomes after combat-related MTBI. As a measure of outcome after injury, self-rated health is a reliable, widely used measure that assesses perceived health. The primary aim of this study was to determine the effect of combat-related MTBI on self-reported health status after return from deployment. The secondary objective was to examine predictors of a decline in self-reported health status amongst US service members with MTBI, as compared to those service members with other minor non-TBI injuries. Patients and methods: MTBI cases and an injured comparison group were identified from the Expeditionary Medical Encounter Database records of 1129 male, US service members who experienced blast-related injuries in Iraq from March 2004 to March 2008. Self-rated health was assessed from the routinely administered pre- and post-deployment health assessment questionnaires by the following question, "Overall, how would you rate your health during the past month?" Possible responses were "poor", "fair", "good", "very good", or "excellent." A distinction was made between minor and major negative changes in health (i.e., very good to fair) based on these self-rated health outcomes captured post-injury. Results: For all personnel, post-injury levels of self-rated health were statistically significantly worse than pre-injury health rating. At 6 months post-injury, service members with MTBI were 5 times more likely to report a major negative change in health as compared to members with other mild injuries. This association was independent of age, rank, branch of service, Injury Severity Score, mental health diagnosis prior to injury, and having been referred to a health care professional. Discussion: Blast-related injuries, specifically MTBI, during deployment have negative consequences on service members' perception of health. Future research is needed to improve our understanding of the overall effects of MTBI on health and quality of life. (C) 2011 Elsevier Ltd. All rights reserved.	[Heltemes, Kevin J.; Holbrook, Troy L.; MacGregor, Andrew J.; Galarneau, Michael R.] USN, Hlth Res Ctr, Dept Med Modeling Simulat & Mission Support, San Diego, CA 92106 USA	Heltemes, KJ (corresponding author), USN, Hlth Res Ctr, Dept Med Modeling Simulat & Mission Support, 140 Sylvester Rd, San Diego, CA 92106 USA.	kevin.heltemes@med.navy.mil		MacGregor, Andrew/0000-0003-1020-7390	US Army Medical Research and Materiel Command, Telemedicine and Advanced Technology Research CenterU.S. Army Medical Research & Materiel Command (USAMRMC)	The authors thank Dr. Mary Clouser for her assistance with data analysis and manuscript revision. The authors thank Science Applications International Corporation for its contributions to this work. Funding support for this research was provided through the US Army Medical Research and Materiel Command, Telemedicine and Advanced Technology Research Center. The views expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Department of the Navy, Department of Defense, or the US Government. Approved for public release; distribution is unlimited. This research has been conducted in compliance with all applicable federal regulations governing the protection of human subjects in research (Protocol NHRC.2003.0025).	BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bullinger M, 2002, RESTOR NEUROL NEUROS, V20, P111; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; CHANDLER D, 2006, ASHA LEADER, V11, P8; Emanuelson I, 2003, ACTA NEUROL SCAND, V108, P332, DOI 10.1034/j.1600-0404.2003.00155.x; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Haddock CK, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-57; Hawthorne G, 2009, J NEUROTRAUM, V26, P1623, DOI [10.1089/neu.2008.0735, 10.1089/neu.2008-0735]; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Larson GE, 2008, AM J EPIDEMIOL, V167, P1269, DOI 10.1093/aje/kwn084; Larsson D, 2002, SCAND J PUBLIC HEALT, V30, P259, DOI 10.1080/14034940210133997; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; McCrea M, 2008, MILD TRAUMATIC BRAIN; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; REISTER FA, 1973, BATTLE CASUALTIES ME, pCH3; REVICKI DA, 1989, J FAM PRACTICE, V29, P377; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Singh-Manoux A, 2006, J EPIDEMIOL COMMUN H, V60, P364, DOI 10.1136/jech.2005.039883; Singh-Manoux A, 2007, PSYCHOSOM MED, V69, P138, DOI 10.1097/PSY.0b013e318030483a; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; Voelker MD, 2002, AM J EPIDEMIOL, V155, P899, DOI 10.1093/aje/155.10.899; Wade AL, 2007, J TRAUMA, V63, P836, DOI 10.1097/01.ta.0000251453.54663.66; Zhang SR, 2009, J REHABIL MED, V41, P1062, DOI 10.2340/16501977-0462	26	41	41	0	11	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383			INJURY	Injury-Int. J. Care Inj.	DEC	2012	43	12					1990	1995		10.1016/j.injury.2011.07.021			6	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	028XM	WOS:000310458600004	21855064				2021-06-18	
J	Kalonia, H; Mishra, J; Kumar, A				Kalonia, Harikesh; Mishra, Jitendriya; Kumar, Anil			Targeting Neuro-Inflammatory Cytokines and Oxidative Stress by Minocycline Attenuates Quinolinic-Acid-Induced Huntington's Disease-Like Symptoms in Rats	NEUROTOXICITY RESEARCH			English	Article						Minocycline; Neurotoxicity; Oxidative stress; Proinflammatory cytokines; Quinolinic acid	FOCAL CEREBRAL-ISCHEMIA; TRANSGENIC MOUSE MODEL; TRAUMATIC BRAIN-INJURY; NEURODEGENERATIVE DISEASES; MICROGLIAL ACTIVATION; CELL-DEATH; MITOCHONDRIAL DYSFUNCTION; BEHAVIORAL ALTERATIONS; MOLECULAR-MECHANISMS; PARKINSONS-DISEASE	Recent experimental and clinical reports support the fact that the minocycline exhibits significant neuroprotective activity in neurodegenerative diseases. However, its mechanism of neuroprotection is still far from our understanding. Besides, minocycline does not always produce neuroprotective effect. Therefore, this study has been designed to explore the possible mechanism of minocycline in experimental model of HD in rats. Intrastriatal administration of quinolinic acid caused a significant reduction in body weight, motor dysfunction (impaired locomotor activity, rotarod performance, and beam walk test), oxidative damage (as evidenced by increase in lipid peroxidation, nitrite concentration, and depletion of super oxide dismutase and catalase), increased TNF-alpha and IL-6 levels as compared to the sham-treated animals. Minocycline (25, 50, and 100 mg/kg) treatment (for 21 days) significantly improved body weight, locomotor activity, rotarod performance, balance beam walk performance, oxidative defense, attenuated TNF-alpha and IL-6 levels as compared to quinolinic-acid (QA)-treated animals. This study provides evidence that minocycline might have neuroprotective effect against QA-induced Huntington-like behavioral, biochemical alterations, and neuroinflammation in rats.	[Kalonia, Harikesh; Mishra, Jitendriya; Kumar, Anil] Panjab Univ, Univ Inst Pharmaceut Sci, UGC Ctr Adv Study, Div Pharmacol, Chandigarh 160014, India	Kumar, A (corresponding author), Panjab Univ, Univ Inst Pharmaceut Sci, UGC Ctr Adv Study, Div Pharmacol, Chandigarh 160014, India.	kumaruips@yahoo.com	KUMAR, ANIL -/D-7471-2011	KUMAR, ANIL -/0000-0002-9506-6197	University Grant Commission (U.G.C.), New DelhiUniversity Grants Commission, India	The Research Fellowship in Science for Meritorious Student (Harikesh Kalonia) of the University Grant Commission (U.G.C.), New Delhi, is gratefully acknowledged.	Amin AR, 1996, P NATL ACAD SCI USA, V93, P14014, DOI 10.1073/pnas.93.24.14014; Amori L, 2009, NEUROSCIENCE, V159, P196, DOI 10.1016/j.neuroscience.2008.11.055; Appel SH, 2009, J CLIN INVEST, V119, P13, DOI 10.1172/JCI38096; Beal MF, 2000, TRENDS NEUROSCI, V23, P298, DOI 10.1016/S0166-2236(00)01584-8; BEAL MF, 1986, NATURE, V321, P168, DOI 10.1038/321168a0; BEAL MF, 1995, ANN NEUROL, V38, P357, DOI 10.1002/ana.410380304; Bizat N, 2003, J NEUROSCI, V23, P5020; Blum D, 2004, NEUROBIOL DIS, V17, P359, DOI 10.1016/j.nbd.2004.07.012; Blum D, 2003, LANCET NEUROL, V2, P366, DOI 10.1016/S1474-4422(03)00411-3; Braidy N, 2009, NEUROTOX RES, V16, P77, DOI 10.1007/s12640-009-9051-z; Brouillet E, 1999, PROG NEUROBIOL, V59, P427, DOI 10.1016/S0301-0082(99)00005-2; Browne SE, 2002, INT REV NEUROBIOL, V53, P243; Cai ZY, 2010, NEUROSCI BULL, V26, P28, DOI 10.1007/s12264-010-0818-2; Cai Zhi-You, 2008, Neurosci Bull, V24, P305, DOI 10.1007/s12264-008-0324-y; Cha JHJ, 2000, TRENDS NEUROSCI, V23, P387, DOI 10.1016/S0166-2236(00)01609-X; Chen M, 2000, NAT MED, V6, P797, DOI 10.1038/77528; Chu LS, 2010, LIFE SCI, V86, P170, DOI 10.1016/j.lfs.2009.12.001; Diguet E, 2004, EUR J NEUROSCI, V19, P3266, DOI 10.1111/j.0953-816X.2004.03372.x; Dong XX, 2009, ACTA PHARMACOL SIN, V30, P379, DOI 10.1038/aps.2009.24; Du YS, 2001, P NATL ACAD SCI USA, V98, P14669, DOI 10.1073/pnas.251341998; Eikelenboom P, 2006, J NEURAL TRANSM, V113, P1685, DOI 10.1007/s00702-006-0575-6; Gafni J, 2004, J BIOL CHEM, V279, P20211, DOI 10.1074/jbc.M401267200; Gafni J, 2002, J NEUROSCI, V22, P4842, DOI 10.1523/JNEUROSCI.22-12-04842.2002; Ganzella M, 2006, NEUROSCI RES, V55, P397, DOI 10.1016/j.neures.2006.05.003; GORNALL AG, 1949, J BIOL CHEM, V177, P751; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Gunawardena S, 2003, NEURON, V40, P25, DOI 10.1016/S0896-6273(03)00594-4; Hardingham GE, 2009, BIOCHEM SOC T, V37, P1147, DOI 10.1042/BST0371147; He Y, 2001, BRAIN RES, V909, P187, DOI 10.1016/S0006-8993(01)02681-6; Homsi S, 2009, BRAIN RES, V1291, P122, DOI 10.1016/j.brainres.2009.07.031; Jiang WL, 2009, NEUROCHEM INT, V55, P601, DOI 10.1016/j.neuint.2009.06.001; Kalonia H, 2010, NEUROTOXICOLOGY, V31, P195, DOI 10.1016/j.neuro.2009.12.008; Kalonia H, 2009, NEUROSCI BULL, V25, P343, DOI 10.1007/s12264-009-0513-3; Kalonia H, 2009, INDIAN J EXP BIOL, V47, P880; KONO Y, 1978, ARCH BIOCHEM BIOPHYS, V186, P189, DOI 10.1016/0003-9861(78)90479-4; Kulkarni SK., 1999, HDB EXPT PHARM, V3; Leblhuber F, 1998, CLIN CHEM LAB MED, V36, P747, DOI 10.1515/CCLM.1998.132; Lim D, 2008, J BIOL CHEM, V283, P5780, DOI 10.1074/jbc.M704704200; Lin CH, 2001, LIFE SCI, V69, P2503, DOI 10.1016/S0024-3205(01)01330-3; Liu XD, 2009, ARCH ORAL BIOL, V54, P1143, DOI 10.1016/j.archoralbio.2009.09.006; Luck H., 1971, METHODS ENZYMATIC AN; Garcia-Martinez EM, 2010, BIOCHEM PHARMACOL, V79, P239, DOI 10.1016/j.bcp.2009.07.028; Mattson MP, 2003, NEUROMOL MED, V3, P65, DOI 10.1385/NMM:3:2:65; McGeer PL, 2004, ANN NY ACAD SCI, V1035, P104, DOI 10.1196/annals.1332.007; Mejia ROS, 2001, NEUROSURGERY, V48, P1393; Milakovic T, 2006, J BIOL CHEM, V281, P34785, DOI 10.1074/jbc.M603845200; Minghetti L, 2007, J NEUROPATH EXP NEUR, V66, P363, DOI 10.1097/nen.0b013e3180517477; Mishra MK, 2009, NEUROCHEM INT, V54, P464, DOI 10.1016/j.neuint.2009.01.022; Panov AV, 2002, NAT NEUROSCI, V5, P731, DOI 10.1038/nn884; Pavese N, 2006, NEUROLOGY, V66, P1638, DOI 10.1212/01.wnl.0000222734.56412.17; Paxinos G., 2007, RAT BRAIN STEREOTAXI, V6th ed.; Rossato JI, 2002, NEUROSCI LETT, V318, P137, DOI 10.1016/S0304-3940(01)02504-6; Sanchez AME, 2008, ARCH MED RES, V39, P265, DOI 10.1016/j.arcmed.2007.11.011; Sapp E, 2001, J NEUROPATH EXP NEUR, V60, P161, DOI 10.1093/jnen/60.2.161; Sattler R, 2001, MOL NEUROBIOL, V24, P107, DOI 10.1385/MN:24:1-3:107; Scarabelli TM, 2004, J AM COLL CARDIOL, V43, P865, DOI 10.1016/j.jacc.2003.09.050; Smith DL, 2003, ANN NEUROL, V54, P186, DOI 10.1002/ana.10614; Song C, 2003, J BIOL CHEM, V278, P33364, DOI 10.1074/jbc.M304240200; Stolp HB, 2009, NEUROPATH APPL NEURO, V35, P132, DOI 10.1111/j.1365-2990.2008.01005.x; Szebenyi G, 2003, NEURON, V40, P41, DOI 10.1016/S0896-6273(03)00569-5; Tai YF, 2007, BRAIN, V130, P1759, DOI 10.1093/brain/awm044; Tang MK, 2010, J CEREBR BLOOD F MET, V30, P119, DOI 10.1038/jcbfm.2009.194; Tang TS, 2003, NEURON, V39, P227, DOI 10.1016/S0896-6273(03)00366-0; Tikka T, 2001, J NEUROSCI, V21, P2580, DOI 10.1523/JNEUROSCI.21-08-02580.2001; Tikka TM, 2002, BRAIN, V125, P722, DOI 10.1093/brain/awf068; Tikka TM, 2001, J IMMUNOL, V166, P7527, DOI 10.4049/jimmunol.166.12.7527; Tsuji M, 2004, EXP NEUROL, V189, P58, DOI 10.1016/j.expneurol.2004.01.011; Turmaine M, 2000, P NATL ACAD SCI USA, V97, P8093, DOI 10.1073/pnas.110078997; Tzeng Shun-Fen, 2005, Current Drug Targets - Inflammation and Allergy, V4, P335, DOI 10.2174/1568010054022051; Wang JZ, 2004, J BIOL CHEM, V279, P19948, DOI 10.1074/jbc.M313629200; Wang X, 2003, P NATL ACAD SCI USA, V100, P10483, DOI 10.1073/pnas.1832501100; Wang XM, 2006, BIOCHEM BIOPH RES CO, V340, P1023, DOI 10.1016/j.bbrc.2005.12.125; Wellington CL, 2003, CLIN NEUROSCI RES, V3, P129, DOI 10.1016/S1566-2772(03)00055-0; WILLS ED, 1966, BIOCHEM J, V99, P667, DOI 10.1042/bj0990667; Wu DC, 2002, J NEUROSCI, V22, P1763, DOI 10.1523/JNEUROSCI.22-05-01763.2002; Yang LC, 2003, J NEUROSCI RES, V74, P278, DOI 10.1002/jnr.10709; Yrjanheikki J, 1999, P NATL ACAD SCI USA, V96, P13496, DOI 10.1073/pnas.96.23.13496; Yrjanheikki J, 1998, P NATL ACAD SCI USA, V95, P15769, DOI 10.1073/pnas.95.26.15769; Zeron MM, 2002, NEURON, V33, P849, DOI 10.1016/S0896-6273(02)00615-3; Zhu S, 2002, NATURE, V417, P74, DOI 10.1038/417074a; Zilka N, 2009, J NEUROIMMUNOL, V209, P16, DOI 10.1016/j.jneuroim.2009.01.013; Zuccato C, 2003, NAT GENET, V35, P76, DOI 10.1038/ng1219	82	41	41	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1029-8428			NEUROTOX RES	Neurotox. Res.	NOV	2012	22	4					310	320		10.1007/s12640-012-9315-x			11	Neurosciences	Neurosciences & Neurology	008OM	WOS:000308966400006	22392362				2021-06-18	
J	Salinsky, M; Evrard, C; Storzbach, D; Pugh, MJ				Salinsky, Martin; Evrard, Collette; Storzbach, Daniel; Pugh, Mary Jo			Psychiatric comorbidity in veterans with psychogenic seizures	EPILEPSY & BEHAVIOR			English	Article						Epilepsy; Psychogenic seizures; Veterans; Post-traumatic stress disorder	POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; NONEPILEPTIC SEIZURES; VIDEO-EEG; EPILEPSY; HEALTH; PREVALENCE; DIAGNOSIS; SYMPTOMS; HISTORY	Psychogenic non-epileptic seizures (PNES) are frequently encountered in epilepsy monitoring units (EMU) at Veterans Affairs Medical Centers (VAMCs) and cause significant long-term disability. An understanding of psychiatric factors associated with PNES could aid in earlier diagnosis and treatment. We studied 50 consecutive veterans diagnosed with PNES and 37 veterans diagnosed with epileptic seizures (ES), evaluated at a VAMC EMU. We reviewed all available mental health evaluations prior to EMU evaluation. Univariate comparisons included axis I diagnoses, axis II diagnoses, and psychiatric hospitalizations. Predictive models of seizure classification were evaluated by logistic regression. A diagnosis of post-traumatic stress disorder (PTSD) preceded the diagnosis of PNES in 58% of patients and the diagnosis of ES in 13.5% (p<0.001). On logistic regression, PTSD was the only significant psychiatric diagnosis (odds ratio 9.2). Major depression and alcohol abuse were common diagnoses but did not differentiate PNES and ES groups. Published by Elsevier Inc.	[Salinsky, Martin; Evrard, Collette; Storzbach, Daniel] Portland VA Med Ctr, Portland, OR USA; [Salinsky, Martin] Oregon Hlth & Sci Univ, Portland, OR 97201 USA; [Pugh, Mary Jo] San Antonio Vet Affairs Med Ctr, San Antonio, TX USA	Salinsky, M (corresponding author), 3181 SW Sam Jackson Pk Rd,CR 120, Portland, OR 97239 USA.	Salinsky@ohsu.edu	Pugh, Mary Jo/K-5336-2019	Pugh, Mary Jo/0000-0003-4196-7763	Portland VA Medical CenterUS Department of Veterans Affairs; Veterans AffairsUS Department of Veterans Affairs [I01HX000717] Funding Source: NIH RePORTER	This material is the result of work supported with resources and the use of facilities at the Portland VA Medical Center.	ALPER K, 1993, NEUROLOGY, V43, P1950, DOI 10.1212/WNL.43.10.1950; Andreski P, 1998, PSYCHIAT RES, V79, P131, DOI 10.1016/S0165-1781(98)00026-2; Arnold LM, 1996, PSYCHOSOMATICS, V37, P438, DOI 10.1016/S0033-3182(96)71531-1; Asmussen SB, 2009, SEIZURE-EUR J EPILEP, V18, P564, DOI 10.1016/j.seizure.2009.05.006; Benbadis SR, 2004, EPILEPSIA, V45, P1150, DOI 10.1111/j.0013-9580.2004.14504.x; Benbadis SR, 2001, NEUROLOGY, V57, P915, DOI 10.1212/WNL.57.5.915; Bowman ES, 1996, AM J PSYCHIAT, V153, P57; Buchanan N, 1993, Seizure, V2, P141, DOI 10.1016/S1059-1311(05)80119-0; D'Alessio L, 2006, SEIZURE-EUR J EPILEP, V15, P333, DOI 10.1016/j.seizure.2006.04.003; Dikel TN, 2003, EPILEPSY BEHAV, V4, P644, DOI 10.1016/j.yebeh.2003.08.006; Dworetzky BA, 2005, EPILEPSIA, V46, P1418, DOI 10.1111/j.1528-1167.2005.13004.x; Ettinger AB, 1999, EPILEPSIA, V40, P1292, DOI 10.1111/j.1528-1157.1999.tb00860.x; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2007, AM J PSYCHIAT, V164, P150, DOI 10.1176/appi.ajp.164.1.150; Kessler R., 1995, ARCH GEN PSYCHIAT, V51, P1048, DOI DOI 10.1001/ARCHPSYC.1995.03950240066012; LaFrance WC, 2008, INT REV NEUROBIOL, V83, P347, DOI 10.1016/S0074-7742(08)00020-2; LEMPERT T, 1990, J NEUROL, V237, P35, DOI 10.1007/BF00319665; Marchetti R, 2010, SEIZURE, V17, P247; Martin R, 2003, NEUROLOGY, V61, P1791, DOI 10.1212/01.WNL.0000098890.13946.F5; Martin RC, 1998, SEIZURE-EUR J EPILEP, V7, P385, DOI 10.1016/S1059-1311(05)80007-X; McKenzie P, 2010, NEUROLOGY, V74, P64, DOI 10.1212/WNL.0b013e3181c7da6a; Pierelli F, 1989, EPILEPSIA, V30, P512; Pietrzak RH, 2009, J NERV MENT DIS, V197, P748, DOI 10.1097/NMD.0b013e3181b97a75; Raymont V, 2010, NEUROLOGY, V75, P224, DOI 10.1212/WNL.0b013e3181e8e6d0; Reuber M, 2003, ANN NEUROL, V53, P305, DOI 10.1002/ana.3000; Rosenberg HJ, 2000, EPILEPSIA, V41, P447, DOI 10.1111/j.1528-1157.2000.tb00187.x; Salinsky M, 2011, NEUROLOGY, V77, P945, DOI 10.1212/WNL.0b013e31822cfc46; SCHLENGER WE, 1992, J TRAUMA STRESS, V5, P333, DOI 10.1002/jts.2490050303; Selwa LM, 2000, EPILEPSIA, V41, P1330, DOI 10.1111/j.1528-1157.2000.tb04613.x; WALCZAK TS, 1995, EPILEPSIA, V36, P1131, DOI 10.1111/j.1528-1157.1995.tb00472.x	30	41	42	0	10	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1525-5050			EPILEPSY BEHAV	Epilepsy Behav.	NOV	2012	25	3					345	349		10.1016/j.yebeh.2012.07.013			5	Behavioral Sciences; Clinical Neurology; Psychiatry	Behavioral Sciences; Neurosciences & Neurology; Psychiatry	035BM	WOS:000310917000009	23103308				2021-06-18	
J	Whyte, J; Barrett, AM				Whyte, John; Barrett, A. M.			Advancing the Evidence Base of Rehabilitation Treatments: A Developmental Approach	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Rehabilitation; Translational medical research	TRAUMATIC BRAIN-INJURY; ATTENTION RATING-SCALE; CLINICAL-RESEARCH; THERAPY; TRIALS; NEUROREHABILITATION; CONSCIOUSNESS; DISORDERS; AROUSAL; PATIENT	Translational research refers to the development of new scientific discoveries into evidence-based treatments for human diseases and conditions. This developmental process requires that a number of scientific, as well as social and psychological obstacles, be overcome during a sequence of research stages that address different goals. Rehabilitation, like other biomedical disciplines, requires this kind of developmental process. For a variety of reasons, however, development of rehabilitation treatments is less linear than the familiar phases of pharmaceutical research. In addition, research on treatments intended to address impairments (body structure/function, in terms of the International Classification of Functioning, Disability and Health), faces the challenge of determining the likely impact of an impairment-level treatment on the multifaceted activities and aspects of participation that are the typical goals of rehabilitation treatments. This article describes the application of treatment theory and enablement theory to the development of new impairment-based treatments, and examines similarities and differences between the developmental sequence needed for rehabilitation treatment research versus pharmaceutical research in other areas of medicine.	[Whyte, John] Moss Rehabil Res Inst, Elkins Pk, PA 19027 USA; [Barrett, A. M.] Kessler Fdn Res Ctr, W Orange, NJ USA; [Barrett, A. M.] Univ Med & Dent New Jersey, NJ Med Sch, Newark, NJ 07103 USA	Whyte, J (corresponding author), Moss Rehabil Res Inst, 50 Township Line Rd, Elkins Pk, PA 19027 USA.	jwhyte@einstein.edu		Whyte, John/0000-0002-4381-1474; Barrett, A.M./0000-0002-0789-2887	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HD050836, HD062647]; National Institute on Disability and Rehabilitation Research [H133A080053]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K24HD062647] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24HD050836] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K02NS047099, R01NS055808] Funding Source: NIH RePORTER	Supported in part by the National Institutes of Health (grant nos. HD050836 and HD062647) and National Institute on Disability and Rehabilitation Research (cooperative agreement no. H133A080053).	Barrett AM, 1999, ARCH PHYS MED REHAB, V80, P600, DOI 10.1016/S0003-9993(99)90205-8; BARRETT AM, 2004, PRINCIPLES PRACTICE, P409; Barrett AM, 2007, AM J PHYS MED REHAB, V86, P694, DOI 10.1097/PHM.0b013e31813e6280; Barrett AM, 2009, BEHAV NEUROL, V22, P17, DOI 10.3233/BEN-2009-0250; Contopoulos-Ioannidis DG, 2003, AM J MED, V114, P477, DOI 10.1016/S0002-9343(03)00013-5; Edlund W, 2004, CLIN PRACTICE GUIDEL; Foundas A L, 1995, J Int Neuropsychol Soc, V1, P62; French J, 2008, NEUROLOGY, V71, P1634, DOI 10.1212/01.wnl.0000336533.19610.1b; Gonzalez-Rothi LJ, 2006, J HEAD TRAUMA REHAB, V21, P194, DOI 10.1097/00001199-200603000-00011; GUYATT G, 1986, NEW ENGL J MED, V314, P889, DOI 10.1056/NEJM198604033141406; Horn SD, 2010, MED CARE, V48, pS17, DOI 10.1097/MLR.0b013e3181d57473; Kummar S, 2008, CANCER J, V14, P133, DOI 10.1097/PPO.0b013e318172d6f3; Kwok OM, 2008, REHABIL PSYCHOL, V53, P370, DOI 10.1037/a0012765; Poeck K, 1985, ADV PSYCHOL, P99, DOI DOI 10.1016/S0166-4115(08)61138-3; Raudenbush SW., 2002, HIERARCHICAL LINEAR, V2nd ed; Robey RR, 1999, APHASIOLOGY, V13, P445, DOI 10.1080/026870399402028; Rosnow R.L., 2009, ARTIFACTS BEHAV RES, P138; Rothi LJG, 2006, J INT NEUROPSYCH SOC, V12, P812, DOI 10.1017/S1355617706060991; Rothi LJG, 1992, FLORIDA APRAXIA BATT; Sohlberg MM, 2000, J CLIN EXP NEUROPSYC, V22, P656, DOI 10.1076/1380-3395(200010)22:5;1-9;FT656; Stucki G, 2005, AM J PHYS MED REHAB, V84, P733, DOI 10.1097/01.phm.0000179521.70639.83; Sung NS, 2003, JAMA-J AM MED ASSOC, V289, P1278, DOI 10.1001/jama.289.10.1278; TAUB E, 1993, ARCH PHYS MED REHAB, V74, P347; Tunis SR, 2003, JAMA-J AM MED ASSOC, V290, P1624, DOI 10.1001/jama.290.12.1624; Whyte J, 2006, J HEAD TRAUMA REHAB, V21, P99, DOI 10.1097/00001199-200603000-00003; Whyte J, 2003, ARCH PHYS MED REHAB, V84, P268, DOI 10.1053/apmr.2003.50108; Whyte J, 1996, J Int Neuropsychol Soc, V2, P274; Whyte J, 1998, J INT NEUROPSYCH SOC, V4, P127, DOI 10.1017/S1355617798001271; Whyte J, 1997, NEUROPSYCHOLOGIA, V35, P313, DOI 10.1016/S0028-3932(96)00092-9; WHYTE J, 1995, NEUROPSYCHOLOGIA, V33, P797, DOI 10.1016/0028-3932(95)00029-3; Whyte J, 2000, J INT NEUROPSYCH SOC, V6, P1, DOI 10.1017/S1355617700611013; Whyte J, 2005, ARCH PHYS MED REHAB, V86, P453, DOI 10.1016/j.apmr.2004.05.016; Whyte J, 2008, ARCH PHYS MED REHAB, V89, P966, DOI 10.1016/j.apmr.2007.12.031; Whyte J, 2008, ARCH PHYS MED REHAB, V89, P203, DOI 10.1016/j.apmr.2007.11.026; Whyte J, 2007, AM J PHYS MED REHAB, V86, P86, DOI 10.1097/PHM.0b013e31802f0434; Whyte J, 2006, NEUROPSYCHOLOGIA, V44, P2007, DOI 10.1016/j.neuropsychologia.2006.02.012; Whyte J, 2009, NEUROPSYCHOL REHABIL, V19, P807, DOI 10.1080/09602010903031146; Whyte J, 2009, ARCH PHYS MED REHAB, V90, pS3, DOI 10.1016/j.apmr.2009.07.008; Whyte J, 2009, AM J PHYS MED REHAB, V88, P410, DOI 10.1097/PHM.0b013e3181a0e3a0; Wolf SL, 2006, JAMA-J AM MED ASSOC, V296, P2095, DOI 10.1001/jama.296.17.2095; Woolf SH, 2008, JAMA-J AM MED ASSOC, V299, P211, DOI 10.1001/jama.2007.26	41	41	42	0	18	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	2012	93	8		2			S101	S110		10.1016/j.apmr.2011.11.040			10	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	983XL	WOS:000307151900002	22683206	Green Accepted			2021-06-18	
J	Chen, CM; Yi, HY; Yoon, YH; Dong, CH				Chen, Chiung M.; Yi, Hsiao-Ye; Yoon, Young-Hee; Dong, Chuanhui			Alcohol Use at Time of Injury and Survival Following Traumatic Brain Injury: Results From the National Trauma Data Bank	JOURNAL OF STUDIES ON ALCOHOL AND DRUGS			English	Article							ACUTE ETHANOL INTOXICATION; HEAD-INJURY; PATIENT MORTALITY; OUTCOMES; ASSOCIATION; CONSUMPTION; SEVERITY; MODERATE; MECHANISM; CULTURES	Objective: Premised on biological evidence from animal research, recent clinical studies have, for the most part, concluded that elevated blood alcohol concentration levels are independently associated with higher survival or decreased mortality in patients with moderate to severe traumatic brain injury (TBI). This study aims to provide some counterevidence to this claim and to further future investigations. Method: Incident data were drawn from the largest U.S. trauma registry, the National Trauma Data Bank, for emergency department admission years 2002-2006. TBI was identified according to the National Trauma Data Bank's definition using international Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), codes. To eliminate confounding, the exact matching method was used to match alcohol-positive with alcohol-negative incidents on sex, age, race/ethnicity, and facility. Logistic regression compared in-hospital mortality between 44,043 alcohol-positive and 59,817 matched alcohol-negative TBI incidents, with and without causes and intents of TBI and Injury Severity Score as covariates. A sensitivity analysis was performed within a subsample of isolated moderate to severe TBI incidents. Results: Alcohol use at the time of injury was found to be significantly associated with an increased risk for TBI. Including varied causes and intents of TBI and Injury Severity Score as potential confounders in the regression model explained away the statistical significance of the seemingly protective effect of alcohol against TBI mortality for all TBIs and for isolated moderate to severe TBIs. Conclusions: The null finding shows that the purported reduction in TBI mortality attributed to positive blood alcohol likely is attributable to residual confounding. Accordingly, the risk of TBI associated with alcohol use should not be overlooked. (J. Stud. Alcohol Drugs, 73.531-541, 2012)	[Chen, Chiung M.; Yi, Hsiao-Ye; Yoon, Young-Hee; Dong, Chuanhui] CSR Inc, Alcohol Epidemiol Data Syst, Arlington, VA 22201 USA	Chen, CM (corresponding author), CSR Inc, Alcohol Epidemiol Data Syst, 2107 Wilson Blvd,Suite 1000, Arlington, VA 22201 USA.	cchen@csrincorporated.com			National Institute on Alcohol Abuse and Alcoholism, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [HH-SN267200800023C]	This article is based on a study conducted for the Alcohol Epidemiologic Data System project funded by the National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, through Contract No. HH-SN267200800023C to CSR, Incorporated. The views and opinions expressed in this report are those of the authors and should not be construed to represent the views of the sponsoring agency or the federal government.	[Anonymous], 2010, INT CLASS DIS 9 REV; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Berry C, 2011, AM SURGEON, V77, P1416; Berry C, 2010, AM SURGEON, V76, P1067; Cebere A, 2003, NEUROCHEM RES, V28, P1193, DOI 10.1023/A:1024228412198; Centers for Disease Control and Prevention, 1997, MMWR-MORBID MORTAL W, V46, P1; CHANDLER LJ, 1993, ALCOHOL CLIN EXP RES, V17, P54, DOI 10.1111/j.1530-0277.1993.tb00726.x; CLARK D, 2007, NATL TRAUMA DATA BAN; Committee on Trauma American College of Surgeons, 2008, NAT TRAUM DAT BANK N; Cummings P, 2003, EPIDEMIOL REV, V25, P43, DOI 10.1093/epirev/mxg002; Fantus Richard J, 2008, Bull Am Coll Surg, V93, P48; Faul M., 2010, TRAUMATIC BRAIN INJU, P1; Gottesfeld Z, 2002, J NEUROTRAUM, V19, P317, DOI 10.1089/089771502753594882; Hadjizacharia P, 2011, EUR J TRAUMA EMERG S, V37, P169, DOI 10.1007/s00068-010-0038-5; Hahn D.R, 2009, ICDPIC STATA MODULE; Haider AH, 2009, J SURG RES, V153, P138, DOI 10.1016/j.jss.2008.04.011; Ho Daniel E., 2011, J STAT SOFTW, V42, P1, DOI DOI 10.18637/JSS.V042.I08; Is M, 2005, NEUROSURG QUART, V15, P60, DOI 10.1097/01.wnq.0000152407.39871.c7; JURKOVICH GJ, 1993, JAMA-J AM MED ASSOC, V270, P51, DOI 10.1001/jama.270.1.51; Kelly DF, 2000, J NEUROTRAUM, V17, P261, DOI 10.1089/neu.2000.17.261; Kim YJ, 2011, J CLIN NURS, V20, P1518, DOI 10.1111/j.1365-2702.2010.03618.x; Lange RT, 2008, ARCH CLIN NEUROPSYCH, V23, P809, DOI 10.1016/j.acn.2008.07.004; McMillan TM, 2007, BRAIN, V130, P2520, DOI 10.1093/brain/awm185; Morgan SL, 2006, SOCIOL METHOD RES, V35, P3, DOI 10.1177/0049124106289164; O'Phelan K, 2008, J TRAUMA, V65, P674, DOI 10.1097/TA.0b013e31817db0a5; Opreanu RC, 2010, J AM COLL SURGEONS, V210, P997, DOI 10.1016/j.jamcollsurg.2010.01.036; Parry-Jones BL, 2006, NEUROPSYCHOL REHABIL, V16, P537, DOI 10.1080/09602010500231875; Plurad D, 2010, J EMERG MED, V38, P12, DOI 10.1016/j.jemermed.2007.09.048; Roudsari B, 2008, INJURY PREV, V14, P96, DOI 10.1136/ip.2007.017129; Royston P, 2008, Multivariable model-building. A pragmatic approach to regression analysis based on fractional polynomials for modelling continuous variables; Safaz I, 2008, BRAIN INJURY, V22, P733, DOI 10.1080/02699050802304714; Salim A, 2009, J TRAUMA, V67, P697, DOI 10.1097/TA.0b013e3181b5dcf2; Salim A, 2009, ARCH SURG-CHICAGO, V144, P865, DOI 10.1001/archsurg.2009.158; Shandro JR, 2009, J TRAUMA, V66, P1584, DOI 10.1097/TA.0b013e318182af96; Talving P, 2010, J TRAUMA, V68, P357, DOI 10.1097/TA.0b013e3181bb80bf; Taylor AN, 2002, J NEUROTRAUM, V19, P1597, DOI 10.1089/089771502762300256; Tien HCN, 2006, ARCH SURG-CHICAGO, V141, P1185, DOI 10.1001/archsurg.141.12.1185; Tureci E, 2004, NEUROL RES, V26, P108, DOI 10.1179/016164104225013699; Watt K, 2006, J STUD ALCOHOL, V67, P14, DOI 10.15288/jsa.2006.67.14; Winqvist S, 2008, BRAIN INJURY, V22, P780, DOI 10.1080/02699050802339397; Yaghoubian A, 2009, AM SURGEON, V75, P950; Zeckey C, 2011, ALCOHOL, V45, P245, DOI 10.1016/j.alcohol.2010.08.004	42	41	41	0	6	ALCOHOL RES DOCUMENTATION INC CENT ALCOHOL STUD RUTGERS UNIV	PISCATAWAY	C/O DEIRDRE ENGLISH, 607 ALLISON RD, PISCATAWAY, NJ 08854-8001 USA	1937-1888			J STUD ALCOHOL DRUGS	J. Stud. Alcohol Drugs	JUL	2012	73	4					531	541		10.15288/jsad.2012.73.531			11	Substance Abuse; Psychology	Substance Abuse; Psychology	971KJ	WOS:000306202500003	22630791	Green Published			2021-06-18	
J	Lange, RT; Pancholi, S; Brickell, TA; Sakura, S; Bhagwat, A; Merritt, V; French, LM				Lange, Rael T.; Pancholi, Sonal; Brickell, Tracey A.; Sakura, Sara; Bhagwat, Aditya; Merritt, Victoria; French, Louis M.			Neuropsychological Outcome from Blast versus Non-blast: Mild Traumatic Brain Injury in US Military Service Members	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Mild traumatic brain injury; Blast injury; Military; Service members; Neurocognitive; Psychological outcome	POSTTRAUMATIC-STRESS-DISORDER; POSTCONCUSSIVE SYMPTOMS; WAR; OVERPRESSURE; MECHANISMS; DIAGNOSIS; MODEL; IRAQ; TBI	The purpose of this study was to compare the neuropsychological outcome from blast-related versus non-blast related mild traumatic brain injury (MTBI). Participants were 56 U.S. military service members who sustained an MTBI, divided into two groups based on mechanism of injury: (a) non-blast related (Non-blast; n = 21), and (b) blast plus secondary blunt trauma (Blast Plus; n = 35). All participants had sustained their injury in theatre whilst deployed during Operation Iraqi Freedom or Operation Enduring Freedom. Patients had been seen for neuropsychological evaluation at Walter Reed Army Medical Center on average 4.4 months (SD = 4.1) post-injury. Measures included 14 clinical scales from the Personality Assessment Inventory (PAL) and 12 common neurocognitive measures. For the PAI, there were no significant differences between groups on all scales (p > .05). However, medium effect sizes were found for the Depression (d = .49) and Stress (d = .47) scales (i.e., Blast Plus > Non-blast). On the neurocognitive measures, after controlling for the influence of psychological distress (i.e., Depression, Stress), there were no differences between the Non-blast and Blast Plus groups on all measures. These findings provide little evidence to suggest that blast exposure plus secondary blunt trauma results in worse cognitive or psychological recovery than blunt trauma alone. (JINS, 2012, 18, 595-605)	[Lange, Rael T.; Pancholi, Sonal; Brickell, Tracey A.; Sakura, Sara; Bhagwat, Aditya; French, Louis M.] Def & Vet Brain Injury Ctr, Dept Res, Bethesda, MD 20852 USA; [Lange, Rael T.; Brickell, Tracey A.; Sakura, Sara; Bhagwat, Aditya; French, Louis M.] Walter Reed Natl Mil Med Ctr, Dept Orthopaed & Rehabil, Bethesda, MD USA; [Lange, Rael T.] Univ British Columbia, Dept Psychiat, Vancouver, BC, Canada; [Pancholi, Sonal] Ft Belvoir Community Hosp, Ft Belvoir, VA USA; [Bhagwat, Aditya] US PHS, Bethesda, MD USA; [Merritt, Victoria] Penn State Univ, Dept Psychol, State Coll, PA USA; [French, Louis M.] Uniformed Serv Univ Hlth Sci, Dept Neurol, Bethesda, MD 20814 USA	Lange, RT (corresponding author), Def & Vet Brain Injury Ctr, Dept Res, 11300 Rockville Pike,Suite 1100, Bethesda, MD 20852 USA.	rlange@dvbic.org	french, louis/AAB-2083-2020	french, louis/0000-0002-9451-0604; Merritt, Victoria/0000-0001-5683-4168			Alley MD, 2011, NEUROIMAGE, V54, pS45, DOI 10.1016/j.neuroimage.2010.05.030; Anderson-Barnes VC, 2011, CLIN NEUROPSYCHOL, V25, P517; Belanger HG, 2011, CLIN NEUROPSYCHOL, V25, P702, DOI 10.1080/13854046.2011.566892; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Bochicchio GV, 2008, AM SURGEON, V74, P267; Brenner LA, 2009, REHABIL PSYCHOL, V54, P239, DOI 10.1037/a0016908; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Chafi MS, 2010, ANN BIOMED ENG, V38, P490, DOI 10.1007/s10439-009-9813-z; Cheng JM, 2010, J NEUROL SCI, V294, P23, DOI 10.1016/j.jns.2010.04.010; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Conners K., 2002, CONNERS CONTINUOUS P; Courtney MW, 2011, NEUROIMAGE, V54, pS55, DOI 10.1016/j.neuroimage.2010.05.025; Delis DC, 2000, CALIFORNIA VERBAL LE; Desmoulin GT, 2009, J TRAUMA, V67, P1113, DOI 10.1097/TA.0b013e3181bb8e84; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Green P., 2003, GREENS WORD MEMORY T; Heaton RK, 2004, REVISED COMPREHENSIV; Iverson GL, 2007, BRAIN INJURY MED PRI, P333; Jaffee CMS, 2009, CLIN NEUROPSYCHOL, V23, P1291, DOI 10.1080/13854040903307250; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kennedy JE, 2010, NEUROREHABILITATION, V26, P223, DOI 10.3233/NRE-2010-0558; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Lippa SM, 2010, J INT NEUROPSYCH SOC, V16, P856, DOI 10.1017/S1355617710000743; Lockhart P, 2011, J TRAUMA, V70, pE29, DOI 10.1097/TA.0b013e3181de3f4b; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; Managment of Concussion/nTBI Working Group, 2009, VA DOD CLIN PRACT GU; Mayorga M., 2010, NEUROIMAGE S1, V54, pS83; Morey L. C., 1991, PERSONALITY ASSESSME; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Psychological Corporation, 2001, WECHSL TEST AD READ; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Reitan R. M., 1992, TRAIL MAKING TEST MA; Salijo A., 2010, J NEUROTRAUM, V27, P283; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Snell FI, 2010, J PSYCHOSOC NURS MEN, V48, P22, DOI [10.3928/02793695-20100108-02, 10.3928/02793695-20100107-01]; Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885; Taylor PA, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3118765; Wallace D, 2009, AUSTRALAS PSYCHIATRY, V17, P218, DOI 10.1080/10398560902878679; Warden DL, 2009, NEUROIMAGE, V47, pT152, DOI 10.1016/j.neuroimage.2009.01.060; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f; Yilmaz S, 2007, AM J EMERG MED, V25, P97, DOI 10.1016/j.ajem.2006.04.014	46	41	42	0	12	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAY	2012	18	3					595	605		10.1017/S1355617712000239			11	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	937VG	WOS:000303690500021	22459022				2021-06-18	
J	Chen, T; Zhang, L; Qu, Y; Huo, K; Jiang, XF; Fei, Z				Chen, Tao; Zhang, Lei; Qu, Yan; Huo, Kai; Jiang, Xiaofan; Fei, Zhou			The selective mGluR5 agonist CHPG protects against traumatic brain injury in vitro and in vivo via ERK and Akt pathway	INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE			English	Article						apoptosis; neuroprotective effect; traumatic brain injury; extracellular signal-regulated kinase; Akt	METABOTROPIC GLUTAMATE ANTAGONIST; SIGNAL-REGULATED KINASE; ELEMENT-BINDING PROTEIN; EXCITATORY AMINO-ACIDS; INDUCED CELL-DEATH; NEURONAL INJURY; BEHAVIORAL DEFICITS; RAT HIPPOCAMPUS; NMDA RECEPTORS; CYTOCHROME-C	Group I metabotropic glutamate receptors (mGluRs) have been implicated in the pathophysiology of central nervous system injury, but the role of mGluR5 in traumatic brain injury (TB!) remains unclear. In the present study, we investigated the neuroprotective potency of (R,S)-2-chloro-5-hydroxyphenylglycine (CHPG), a selective mGluR5 agonist, for protecting against TBI in both in vitro and in vivo models. Primary cortical neurons were treated with 1 mM CHPG in an in vitro preparation 30 min before TBI, and 250 nM CHPG was injected into the right lateral ventricle of rats 30 min before TBI was induced in in vivo studies. The results showed that CHPG significantly attenuated lactate dehydrogenase (LDH) release and neuronal apoptosis and reduced lesion volume. Compared to the control or vehicle group, the phosphorylation levels of extracellular signal-regulated kinase (ERK) and Akt were increased in the presence of CHPG, even following the induction of TBI. Furthermore, treatment with either the ERK inhibitor PD98059 or Akt inhibitor LY294002 partially reversed the CHPG's neuroprotective effects. These data suggest that CHPG minimizes brain damage after induction of TBI both in vitro and in vivo, and that these protective effects were possibly mediated by activation of the ERK and Akt signaling pathways. Thus, potentiating mGluR5 activity with selective agonists such as CHPG may be useful for the treatment of traumatic brain injury.	[Chen, Tao; Zhang, Lei; Qu, Yan; Huo, Kai; Jiang, Xiaofan; Fei, Zhou] Fourth Mil Med Univ, Xijing Inst Clin Neurosci, Dept Neurosurg, Xijing Hosp, Xian 710032, Shannxi, Peoples R China; [Chen, Tao] 123th Hosp PLA, Dept Surg, Bengbu 233000, Anhui, Peoples R China	Jiang, XF (corresponding author), Fourth Mil Med Univ, Xijing Inst Clin Neurosci, Dept Neurosurg, Xijing Hosp, Xian 710032, Shannxi, Peoples R China.	fmmujiangxiaofan@163.com; muzhoufei@163.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30670796, 30930093, 81071034]	This study was financially supported by the National Natural Science Foundation of China (nos. 30670796, 30930093 and 81071034).	Atkins CM, 2007, EUR J NEUROSCI, V26, P810, DOI 10.1111/j.1460-9568.2007.05720.x; Belayev L, 2001, J NEUROTRAUM, V18, P1031, DOI 10.1089/08977150152693728; Bullock R, 1995, ANN NY ACAD SCI, V765, P290, DOI 10.1111/j.1749-6632.1995.tb16586.x; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Choe ES, 2001, MOL BRAIN RES, V94, P75, DOI 10.1016/S0169-328X(01)00217-0; Chong ZZ, 2005, HISTOL HISTOPATHOL, V20, P299, DOI 10.14670/HH-20.299; COPANI A, 1995, MOL PHARMACOL, V47, P890; Copani A, 1998, EUR J NEUROSCI, V10, P2173, DOI 10.1046/j.1460-9568.1998.00230.x; Dash PK, 2002, NEUROSCIENCE, V114, P755, DOI 10.1016/S0306-4522(02)00277-4; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Doherty AJ, 1997, NEUROPHARMACOLOGY, V36, P265, DOI 10.1016/S0028-3908(97)00001-4; Faden AI, 2001, EXP NEUROL, V167, P435, DOI 10.1006/exnr.2000.7577; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fei Z, 2006, J CLIN NEUROSCI, V13, P1023, DOI 10.1016/j.jocn.2005.11.042; Finnie JW, 2002, VET PATHOL, V39, P679, DOI 10.1354/vp.39-6-679; Fukunaga K, 2003, J PHARMACOL SCI, V92, P317; Fukushima M, 2009, J NEUROTRAUM, V26, P1095, DOI 10.1089/neu.2008.0771; GONG QZ, 1995, BRAIN RES, V700, P299, DOI 10.1016/0006-8993(95)01081-6; Guerra B, 2004, J NEUROCHEM, V91, P99, DOI 10.1111/j.1471-4159.2004.02695.x; Homayoun H, 2010, EUR J PHARMACOL, V639, P33, DOI 10.1016/j.ejphar.2009.12.042; Hou LF, 2004, J NEUROSCI, V24, P6352, DOI 10.1523/JNEUROSCI.0995-04.2004; Huang WD, 2005, NEUROSCI LETT, V389, P46, DOI 10.1016/j.neulet.2005.07.014; Kuroki Y, 2001, EUR J NEUROSCI, V13, P472, DOI 10.1046/j.0953-816x.2000.01409.x; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Leinninger GM, 2004, FASEB J, V18, P1544, DOI 10.1096/fj.04-1581fje; Liu F, 2005, J NEUROCHEM, V95, P1363, DOI 10.1111/j.1471-4159.2005.03474.x; Lujan R, 1996, EUR J NEUROSCI, V8, P1488, DOI 10.1111/j.1460-9568.1996.tb01611.x; Lyeth BG, 2001, EXP NEUROL, V169, P191, DOI 10.1006/exnr.2001.7643; MAJNO G, 1995, AM J PATHOL, V146, P3; Mammis A, 2009, SURG NEUROL, V71, P527, DOI 10.1016/j.surneu.2008.02.040; McAllister TW, 2009, CLIN NEUROPSYCHOL, V23, P1338, DOI 10.1080/13854040903277289; Morin N, 2010, NEUROPHARMACOLOGY, V58, P981, DOI 10.1016/j.neuropharm.2009.12.024; Movsesyan VA, 2004, J NEUROCHEM, V89, P1528, DOI 10.1111/j.1471-4159.2004.02451.x; Movsesyan VA, 2001, J PHARMACOL EXP THER, V296, P41; Mukhin A, 1996, J NEUROSCI, V16, P6012; Mullonkal CJ, 2007, J INVEST SURG, V20, P195, DOI 10.1080/08941930701366471; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Pugazhenthi S, 2000, J BIOL CHEM, V275, P10761, DOI 10.1074/jbc.275.15.10761; Redmond L, 2002, NEURON, V34, P999, DOI 10.1016/S0896-6273(02)00737-7; ROMANO C, 1995, J COMP NEUROL, V355, P455, DOI 10.1002/cne.903550310; Schumann J, 2008, J NEUROTRAUM, V25, P945, DOI 10.1089/neu.2008.0521; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; Xu XS, 2008, BRAIN RES, V1227, P12, DOI 10.1016/j.brainres.2008.06.018; Yang L, 2004, J NEUROSCI, V24, P10846, DOI 10.1523/JNEUROSCI.2496-04.2004; Yu SJ, 2009, BRAIN RES, V1287, P157, DOI 10.1016/j.brainres.2009.06.067; Yurkewicz L, 2005, J NEUROTRAUM, V22, P1428, DOI 10.1089/neu.2005.22.1428; Zhu Y, 2002, J NEUROSCI, V22, P3898, DOI 10.1523/JNEUROSCI.22-10-03898.2002	48	41	41	0	7	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1107-3756	1791-244X		INT J MOL MED	Int. J. Mol. Med.	APR	2012	29	4					630	636		10.3892/ijmm.2011.870			7	Medicine, Research & Experimental	Research & Experimental Medicine	911XI	WOS:000301757300017	22211238	Green Published, Bronze			2021-06-18	
J	Lincoln, AE; Caswell, SV; Almquist, JL; Dunn, RE; Clough, MV; Dick, RW; Hinton, RY				Lincoln, Andrew E.; Caswell, Shane V.; Almquist, Jon L.; Dunn, Reginald E.; Clough, Mark V.; Dick, Randall W.; Hinton, Richard Y.			Effectiveness of the Women's Lacrosse Protective Eyewear Mandate in the Reduction of Eye Injuries	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						women's lacrosse; eye injuries; protective eyewear; injury prevention	HEAD; PLAYERS; FACE	Background: In an effort to minimize the risk of catastrophic eye injury, US Lacrosse initiated mandatory use of protective eyewear in women's lacrosse in the 2004-2005 season. Purpose: The authors compared eye injury rates in girls' scholastic lacrosse before and after implementation of protective eyewear. They also compared head/face injury rates, concussion rates, and overall injury rates before and after the rule change to assess possible unintended consequences of the change. Study Design: Cohort study; Level of evidence, 3. Methods: The study group included female scholastic lacrosse players in the 25 public high schools in Fairfax County, Virginia, during the 2004-2009 spring seasons. Injury rates were compared with those from the same data source for the 2000-2003 seasons. Premandate versus postmandate injury rates were adjusted for athlete exposures, or total opportunities for injury throughout the season. Results: The rate of eye injuries was reduced from 0.10 injuries per 1000 athlete exposures (AEs) in 2000 through 2003 before the use of protective eyewear to 0.016 injuries per 1000 AEs in 2004 through 2009 (incident rate ratio [IRR], 0.16; 95% confidence interval [CI], 0.06-0.42). The rate ratio of head/face injuries excluding concussion also decreased (IRR, 0.44; 95% CI, 0.26-0.76). There was no change in the rate ratio of total injuries involving all body parts (IRR, 0.93; 95% CI, 0.82-1.1) after introduction of protective eyewear. However, the rate ratio of concussion increased (IRR, 1.6; 95% CI, 1.1-2.3). Conclusion: The use of protective eyewear in women's lacrosse was associated with a reduction in the number of eye injuries. The number of head/face injuries decreased in this study group after introduction of protective eyewear, and there was no change in overall injury rates. The reason for the increase in concussion rate cannot be determined conclusively based on this study, but the authors speculate that this increase resulted largely from increased recognition and diagnosis because overall injury rates do not indicate rougher play with introduction of protective equipment.	[Lincoln, Andrew E.; Caswell, Shane V.; Almquist, Jon L.; Dunn, Reginald E.; Clough, Mark V.; Dick, Randall W.; Hinton, Richard Y.] MedStar Sports Med Res Ctr, Baltimore, MD USA	Lincoln, AE (corresponding author), Care of Camire L, Union Mem Orthopaed, Johnston Profess Bldg,Suite 400,3333 N Calvert St, Baltimore, MD 21218 USA.	lyn.camire@medstar.net			US Lacrosse Sports Science and Safety Committee	One or more of the authors has declared the following potential conflict of interest or source of funding: A nonrestrictive research support was provided by the US Lacrosse Sports Science and Safety Committee. The funding source had no other role in the study.	Caraffa A, 1996, Knee Surg Sports Traumatol Arthrosc, V4, P19, DOI 10.1007/BF01565992; Diamond PT, 2001, BRAIN INJURY, V15, P537, DOI 10.1080/02699050010007362; Goldenberg Michael S., 1995, Journal of Athletic Training, V30, P37; Hinton RY, 2005, AM J SPORT MED, V33, P1305, DOI 10.1177/0363546504274148; Junge A, 2002, AM J SPORT MED, V30, P652, DOI 10.1177/03635465020300050401; LAPIDUS CS, 1992, J TRAUMA, V32, P555, DOI 10.1097/00005373-199205000-00003; Lincoln AE, 2007, AM J SPORT MED, V35, P207, DOI 10.1177/0363546506293900; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Livingston LA, 1996, J TRAUMA, V40, P144, DOI 10.1097/00005373-199601000-00030; Matthews LS, 2001, SPORTS INJURIES MECH, P568; Perna FM, 2003, ANN BEHAV MED, V25, P66, DOI 10.1207/S15324796ABM2501_09; Schwarz A., 2011, NY TIMES        0216; Tyler TF, 2002, AM J SPORT MED, V30, P680, DOI 10.1177/03635465020300050801; Webster DA, 1999, MED SCI SPORT EXER, V31, P938, DOI 10.1097/00005768-199907000-00004	14	41	41	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465			AM J SPORT MED	Am. J. Sports Med.	MAR	2012	40	3					611	614		10.1177/0363546511428873			4	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	902TV	WOS:000301065100016	22156171				2021-06-18	
J	Noe, E; Olaya, J; Navarro, MD; Noguera, P; Colomer, C; Garcia-Panach, J; Rivero, S; Moliner, B; Ferri, J				Noe, Enrique; Olaya, Jose; Dolores Navarro, M.; Noguera, Paloma; Colomer, Carolina; Garcia-Panach, Javier; Rivero, Sandra; Moliner, Belen; Ferri, Joan			Behavioral Recovery in Disorders of Consciousness: A Prospective Study With the Spanish Version of the Coma Recovery Scale-Revised	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Consciousness; Rehabilitation; Treatment outcome; Vegetative state	PERSISTENT VEGETATIVE STATE; BRAIN-INJURY; FOLLOW-UP; RECOMMENDATIONS; REHABILITATION; PREDICTORS; ACCURACY	Noe E, Olaya J, Navarro MD, Noguera P, Colomer C, Garcia-Panach J, Rivero S, Moliner B, Ferri J. Behavioral recovery in disorders of consciousness: a prospective study with the Spanish version of the Coma Recovery Scale Revised. Arch Phys Med Rehabil 2012;93:428-33. Objective: To describe the clinical characteristics and short-term pattern of evolution of a sample of patients within I year after acquiring a brain injury that led to a vegetative state (VS) or a minimally conscious state (MCS). Design: Cohort study. Setting: Inpatient brain injury rehabilitation program. Participants: Patients with acquired brain injury (N=32; 47% traumatic, 37.5% hemorrhagic, 15.5% anoxic) who were in a VS or an MCS according to Coma Recovery Scale Revised (CRS-R) scores. Intervention: Integrative multisensory program comprising daily physical rehabilitation procedures and multimodal sensory stimulation. Main Outcome Measure: All patients were assessed with a Spanish version of the CRS-R at admission and then monthly for at least 6 months or until emergence from MCS. Results: At the time of admission, 12 patients were diagnosed as being in a VS and 20 as being in an MCS. Eight patients were able to emerge from their MCS during follow-up. Seven of these 8 patients were diagnosed as being in an MCS at inclusion, and only 1 was diagnosed as being in a VS. Emergence from an MCS was mostly associated with improvement in both the communication and motor function scales (n=4). Lesser chronicity (P=.01) and the presence of more than visual behavioral responses at admission (P=.05) were both significant predictors of emergence from an MCS. Conclusions: The CRS-R seems appropriate for establishing an immediate prognosis in this population. A quick referral of these patients for specialized assessment and rehabilitation facilities is recommended.	Hosp NISA, Serv NeuroRehabil & Dano Cerebral, Valencia, Spain; Fdn Hosp NISA, Valencia, Spain	Noe, E (corresponding author), Hosp NISAValencia Mar, Serv NeuroRehabil & Dano Cerebral, C Rio Tajo 1, Valencia 46011, Spain.	enoe@comv.es		Noe Sebastian, Enrique/0000-0002-2547-8727			Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; CHILDS NL, 1993, NEUROLOGY, V43, P1465, DOI 10.1212/WNL.43.8.1465; Dolce G, 2008, BRAIN INJURY, V22, P617, DOI 10.1080/02699050802132503; Dolce G, 2011, J NEUROTRAUM, V28, P1149, DOI 10.1089/neu.2010.1405; Estraneo A, 2010, NEUROLOGY, V75, P239, DOI 10.1212/WNL.0b013e3181e8e8cc; Giacino J, 2005, J HEAD TRAUMA REHAB, V20, P30, DOI 10.1097/00001199-200501000-00005; Giacino J, 1995, J HEAD TRAUMA REHAB, V10, P44; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P36, DOI 10.1097/00001199-199708000-00005; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P79, DOI 10.1097/00001199-199708000-00008; Giacino JT, 2005, PROG BRAIN RES, V150, P381, DOI 10.1016/S0079-6123(05)50027-X; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; GIACINO JT, 1991, ARCH PHYS MED REHAB, V72, P897, DOI 10.1016/0003-9993(91)90008-7; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; GIACINO JT, 1995, ARCH PHYS MED REHAB, V76, P205; JENNETT B, 1972, LANCET, V1, P734; Katz DI, 2009, PROG BRAIN RES, V177, P73, DOI 10.1016/S0079-6123(09)17707-5; Lammi MH, 2005, ARCH PHYS MED REHAB, V86, P746, DOI 10.1016/j.apmr.2004.11.004; Laureys S, 2004, LANCET NEUROL, V3, P537, DOI 10.1016/S1474-4422(04)00852-X; Laureys S, 2000, LANCET, V355, P1790, DOI 10.1016/S0140-6736(00)02271-6; Luaute J, 2010, NEUROLOGY, V75, P246, DOI 10.1212/WNL.0b013e3181e8e8df; Schnakers C, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-35; Seel RT, 2010, ARCH PHYS MED REHAB, V91, P1795, DOI 10.1016/j.apmr.2010.07.218; Taylor CM, 2007, ARCH PHYS MED REHAB, V88, P521, DOI 10.1016/j.apmr.2007.01.013; Whyte J, 2009, PROG BRAIN RES, V177, P63, DOI 10.1016/S0079-6123(09)17706-3; Whyte J, 2005, ARCH PHYS MED REHAB, V86, P453, DOI 10.1016/j.apmr.2004.05.016	26	41	43	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAR	2012	93	3					428	433		10.1016/j.apmr.2011.08.048			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	902GW	WOS:000301027600008	22277244				2021-06-18	
J	Campbell, JN; Register, D; Churn, SB				Campbell, John N.; Register, David; Churn, Severn B.			Traumatic Brain Injury Causes an FK506-Sensitive Loss and an Overgrowth of Dendritic Spines in Rat Forebrain	JOURNAL OF NEUROTRAUMA			English	Article						calcineurin; cofilin; epilepsy; epileptogenesis; traumatic brain injury	LONG-TERM DEPRESSION; IN-VIVO; AREA CA1; GLUTAMATE; SYNAPTOGENESIS; NEURONS; MODEL; POLO-LIKE-KINASE-2; DEPHOSPHORYLATION; HYPEREXCITABILITY	Traumatic brain injury (TBI) causes both an acute loss of tissue and a progressive injury through reactive processes such as excitotoxicity and inflammation. These processes may worsen neural dysfunction by altering neuronal circuitry beyond the focally-damaged tissue. One means of circuit alteration may involve dendritic spines, micron-sized protuberances of dendritic membrane that support most of the excitatory synapses in the brain. This study used a modified Golgi-Cox technique to track changes in spine density on the proximal dendrites of principal cells in rat forebrain regions. Spine density was assessed at 1 h, 24h, and 1 week after a lateral fluid percussion TBI of moderate severity. At 1 h after TBI, no changes in spine density were observed in any of the brain regions examined. By 24h after TBI, however, spine density had decreased in ipsilateral neocortex in layer and III and dorsal dentate gyrus (dDG). This apparent loss of spines was prevented by a single, post-injury administration of the calcineurin inhibitor FK506. These results; together with those of a companion study, indicate an FK506-sensitive mechanism of dendritic spine loss in the TBI model. Furthermore, by 1 week after TBI, spine density had increased substantially above control levels, bilaterally in CA1 and CA3 and ipsilaterally in dDG. The apparent overgrowth of spines in CA1 is of particular interest, as it may explain previous reports of abnormal and potentially epileptogenic activity in this brain region.	[Campbell, John N.; Churn, Severn B.] Virginia Commonwealth Univ, Dept Anat & Neurobiol, Richmond, VA 23298 USA; [Register, David; Churn, Severn B.] Virginia Commonwealth Univ, Dept Neurol, Richmond, VA 23298 USA; [Churn, Severn B.] Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA	Churn, SB (corresponding author), Virginia Commonwealth Univ, Dept Anat, POB 980599, Richmond, VA 23298 USA.	schurn@vcu.edu			Commonwealth Neurotrauma Initiative [07-302E]	This research was funded by a grant from the Commonwealth Neurotrauma Initiative (#07-302E) to S.B.C. The authors gratefully acknowledge Dr. Robert Hamm for the use of the fluid percussion injury device, Dr. M. Alex Meredith for the use of the microscope and Neurolucida system, and Dr. John Povlishock for the use of the vibratome.	Akasu T, 2002, NEUROSCI LETT, V329, P305, DOI 10.1016/S0304-3940(02)00707-3; ANDERSON KJ, 1986, J COMP NEUROL, V252, P374, DOI 10.1002/cne.902520306; Ansari MA, 2008, J NEUROTRAUM, V25, P513, DOI 10.1089/neu.2007.0451; Bourne J, 2007, CURR OPIN NEUROBIOL, V17, P381, DOI 10.1016/j.conb.2007.04.009; Campbell JN, 2011, J NEUROTRAUMA; Campbell JN, 2009, DENDRITIC SPINES: BIOCHEMISTRY, MODELING AND PROPERTIES, P45; Cesa R, 2005, EUR J NEUROSCI, V22, P579, DOI 10.1111/j.1460-9568.2005.04244.x; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; Corbett D, 2006, EXP NEUROL, V202, P133, DOI 10.1016/j.expneurol.2006.05.020; Dietrich WD, 1998, NEUROSURGERY, V43, P585, DOI 10.1097/00006123-199809000-00105; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Esclapez M, 1999, J COMP NEUROL, V408, P449, DOI 10.1002/(SICI)1096-9861(19990614)408:4<449::AID-CNE1>3.0.CO;2-R; Fiala JC, 2008, DENDRITES, P1; Groth RD, 2003, BIOCHEM BIOPH RES CO, V311, P1159, DOI 10.1016/j.bbrc.2003.09.002; Grutzendler J, 2002, NATURE, V420, P812, DOI 10.1038/nature01276; Halpain S, 1998, J NEUROSCI, V18, P9835; HALPAIN S, 1990, NATURE, V343, P369, DOI 10.1038/343369a0; Hasbani MJ, 2001, J NEUROSCI, V21, P2393; Hoskison MM, 2009, NEUROSCIENCE, V159, P483, DOI 10.1016/j.neuroscience.2008.12.050; Isokawa M, 2000, EPILEPSIA, V41, pS14, DOI 10.1111/j.1528-1157.2000.tb01550.x; JONES EG, 1969, J CELL SCI, V5, P509; Kirov SA, 2004, NEUROSCIENCE, V127, P69, DOI 10.1016/j.neuroscience.2004.04.053; Kurz JE, 2008, EPILEPSIA, V49, P1696, DOI 10.1111/j.1528-1167.2008.01616.x; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; McKinney RA, 1999, NAT NEUROSCI, V2, P44, DOI 10.1038/4548; Megias M, 2001, NEUROSCIENCE, V102, P527, DOI 10.1016/S0306-4522(00)00496-6; Monfils MH, 2004, SYNAPSE, V53, P114, DOI 10.1002/syn.20039; Nimchinsky EA, 2002, ANNU REV PHYSIOL, V64, P313, DOI 10.1146/annurev.physiol.64.081501.160008; Niwa R, 2002, CELL, V108, P233, DOI 10.1016/S0092-8674(01)00638-9; Norris CM, 2009, J NEUROTRAUM, V26, P2269, DOI 10.1089/neu.2009.1029; Pak DTS, 2003, SCIENCE, V302, P1368, DOI 10.1126/science.1082475; Park JS, 1996, NEUROBIOL DIS, V3, P215, DOI 10.1006/nbdi.1996.0022; PARNAVELAS JG, 1974, NATURE, V248, P71, DOI 10.1038/248071a0; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Petrak LJ, 2005, J COMP NEUROL, V484, P183, DOI 10.1002/cne.20468; Pitkanen A, 2006, J NEUROTRAUM, V23, P241, DOI 10.1089/neu.2006.23.241; Ruan YW, 2009, J NEUROSCI RES, V87, P61, DOI 10.1002/jnr.21816; Sarmiere PD, 2004, J NEUROBIOL, V58, P103, DOI 10.1002/neu.10267; Scheff SW, 2005, J NEUROTRAUM, V22, P719, DOI 10.1089/neu.2005.22.719; Schwartz N, 2009, NEURON, V62, P655, DOI 10.1016/j.neuron.2009.05.007; Schwarzbach E, 2006, HIPPOCAMPUS, V16, P541, DOI 10.1002/hipo.20183; Seeburg DP, 2008, J NEUROSCI, V28, P6583, DOI 10.1523/JNEUROSCI.1853-08.2008; Seeburg DP, 2008, NEURON, V58, P571, DOI 10.1016/j.neuron.2008.03.021; Shankar GM, 2007, J NEUROSCI, V27, P2866, DOI 10.1523/JNEUROSCI.4970-06.2007; Shao LR, 2005, J NEUROPHYSIOL, V93, P3007, DOI 10.1152/jn.00877.2004; Spires-Jones TL, 2011, NEUROSCI LETT, V487, P260, DOI 10.1016/j.neulet.2010.10.033; Spruston N, 2007, HIPPOCAMPUS BOOK, P133; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Wang Y, 2005, J BIOL CHEM, V280, P12683, DOI 10.1074/jbc.M411494200; Wu GY, 1999, J NEUROSCI, V19, P4472; Wu LX, 2007, BRAIN RES, V1168, P38, DOI 10.1016/j.brainres.2007.06.082; Xu HT, 2007, NAT NEUROSCI, V10, P549, DOI 10.1038/nn1883; Zeng LH, 2007, J NEUROSCI, V27, P11604, DOI 10.1523/JNEUROSCI.0983-07.2007; Zhou Q, 2004, NEURON, V44, P749, DOI 10.1016/j.neuron.2004.11.011; Zipfel GJ, 2000, J NEUROTRAUM, V17, P857, DOI 10.1089/neu.2000.17.857	56	41	41	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 20	2012	29	2					201	217		10.1089/neu.2011.1761			17	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	885SO	WOS:000299801300002	21517673				2021-06-18	
J	Ozdemir, D; Baykara, B; Aksu, I; Kiray, M; Sisman, AR; Cetin, F; Dayi, A; Gurpinar, T; Uysal, N; Arda, MN				Ozdemir, Durgul; Baykara, Basak; Aksu, Ilkay; Kiray, Muge; Sisman, Ali Riza; Cetin, Ferihan; Dayi, Ayfer; Gurpinar, Tugba; Uysal, Nazan; Arda, M. Nuri			Relationship between circulating IGF-1 levels and traumatic brain injury-induced hippocampal damage and cognitive dysfunction in immature rats	NEUROSCIENCE LETTERS			English	Article						Hippocampus; Immature rat; Insulin-like growth factor (IGF)-1; Spatial memory; Traumatic brain injury	GROWTH-FACTOR-I; HEAD-INJURY; MOUSE-BRAIN; CHILDREN; MEMORY; APOPTOSIS; ADOLESCENTS; INVOLVEMENT; EXPRESSION; CORTEX	It is well known that traumatic brain injury (TBI) induces the cognitive dysfunction resulting from hippocampal damage. In the present study, we aimed to assess whether the circulating IGF-I levels are associated with cognition and hippocampal damage in 7-day-old rat pups subjected to contusion injury. Hippocampal damage was examined by cresyl violet staining and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay. Spatial memory performance was assessed in the Morris water maze. Serum IGF-1 levels decreased in both early and late period of TBI. Decreased levels of serum IGF-1 were correlated with hippocampal neuron loss and spatial memory deficits. Circulating IGF-1 levels may be predictive of cognitive dysfunction resulted from hippocampal damage following traumatic injury in developing brain. Therapy strategies that increase circulating IGF-1 may be highly promising for preventing the unfavorable outcomes of traumatic damage in young children. (C) 2011 Elsevier Ireland Ltd. All rights reserved.	[Ozdemir, Durgul] Dokuz Eylul Univ, Fac Med, Dept Pediat, Izmir, Turkey; [Baykara, Basak] Dokuz Eylul Univ, High Sch Phys Therapy & Rehabil, Izmir, Turkey; [Aksu, Ilkay; Kiray, Muge; Cetin, Ferihan; Dayi, Ayfer; Uysal, Nazan] Dokuz Eylul Univ, Fac Med, Dept Physiol, Izmir, Turkey; [Sisman, Ali Riza] Dokuz Eylul Univ, Fac Med, Dept Biochem, Izmir, Turkey; [Gurpinar, Tugba] Celal Bayar Univ, Fac Med, Dept Pharmacol, Izmir, Turkey; [Arda, M. Nuri] Dokuz Eylul Univ, Fac Med, Dept Neurosurg, Izmir, Turkey	Ozdemir, D (corresponding author), Dokuz Eylul Univ, Fac Med, Dept Pediat, Izmir, Turkey.	durgul.ozdemir@deu.edu.tr	Baykara, Basak/AAC-6504-2019; dayi, ayfer/O-9503-2019	Baykara, Basak/0000-0002-4178-2235; dayi, ayfer/0000-0002-4102-1399; Uysal, Nazan/0000-0002-2348-7427			Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; Aleman A, 2009, PROG NEUROBIOL, V89, P256, DOI 10.1016/j.pneurobio.2009.07.008; Amaral David G., 1995, P443; Anderson MF, 2002, DEV BRAIN RES, V134, P115; Arwert LI, 2005, GROWTH HORM IGF RES, V15, P416, DOI 10.1016/j.ghir.2005.09.001; Bayir H, 2003, CRIT CARE CLIN, V19, P529, DOI 10.1016/S0749-0704(03)00014-9; BEERS SR, 1992, NEUROPSYCHOL REV, V3, P281, DOI 10.1007/BF01108414; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Bittigau P, 2004, EXP TOXICOL PATHOL, V56, P83, DOI 10.1016/j.etp.2004.04.006; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Carro E, 2000, J NEUROSCI, V20, P2926; DOBBING J, 1979, EARLY HUM DEV, V3, P79, DOI 10.1016/0378-3782(79)90022-7; Felderhoff-Mueser Ursula, 2000, Current Opinion in Neurology, V13, P141, DOI 10.1097/00019052-200004000-00005; Frankland PW, 2004, SCIENCE, V304, P881, DOI 10.1126/science.1094804; Gunnell D, 2005, PEDIATRICS, V116, pE681, DOI 10.1542/peds.2004-2390; Guthrie E, 1999, CHILD ADOL PSYCH CL, V8, P807; Jo YS, 2007, J NEUROSCI, V27, P13567, DOI 10.1523/JNEUROSCI.3589-07.2007; Kazanis I, 2003, BRAIN RES, V991, P34, DOI 10.1016/S0006-8993(03)03525-X; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Leoni MJ, 2000, EXP NEUROL, V166, P442, DOI 10.1006/exnr.2000.7513; Madathil SK, 2010, J NEUROTRAUM, V27, P95, DOI 10.1089/neu.2009.1002; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Ozdemir D, 2005, NEUROSCI LETT, V385, P234, DOI 10.1016/j.neulet.2005.05.055; Paxinos G., 1982, RAT BRAIN STEREOTAXI; REINHARDT RR, 1994, ENDOCRINOLOGY, V135, P1753, DOI 10.1210/en.135.5.1753; Rendeiro C, 2009, GENES NUTR, V4, P251, DOI 10.1007/s12263-009-0137-2; Rubovitch V, 2010, NEUROBIOL DIS, V38, P299, DOI 10.1016/j.nbd.2010.01.021; Russell JW, 1998, J NEUROBIOL, V36, P455, DOI 10.1002/(SICI)1097-4695(19980915)36:4<455::AID-NEU1>3.0.CO;2-V; Sanus GZ, 2007, ULUS TRAVMA ACIL CER, V13, P281; Schober ME, 2010, J NEUROTRAUM, V27, P2011, DOI 10.1089/neu.2009.1226; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; Sonntag WE, 2005, AGEING RES REV, V4, P195, DOI 10.1016/j.arr.2005.02.001; Tamatani M, 1998, CELL DEATH DIFFER, V5, P911, DOI 10.1038/sj.cdd.4400439; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; Torres-Aleman I, 2010, DEV NEUROBIOL, V70, P384, DOI 10.1002/dneu.20778; Trejo JI, 2007, MOL PSYCHIATR, V12, P1118, DOI 10.1038/sj.mp.4002076; Yan H, 2011, J ENDOCRINOL, V211, P27, DOI 10.1530/JOE-11-0200	37	41	45	1	21	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	JAN 17	2012	507	1					84	89		10.1016/j.neulet.2011.11.059			6	Neurosciences	Neurosciences & Neurology	892GN	WOS:000300274800017	22172933				2021-06-18	
J	Anderson, V; Le Brocque, R; Iselin, G; Eren, S; Dob, R; Davern, TJ; McKinlay, L; Kenardy, J				Anderson, Vicki; Le Brocque, Robyne; Iselin, Greg; Eren, Senem; Dob, Rian; Davern, Timothy J.; McKinlay, Lynne; Kenardy, Justin			Adaptive ability, behavior and quality of life pre and posttraumatic brain injury in childhood	DISABILITY AND REHABILITATION			English	Article						Adaptive behavior; behavior; child; executive function; quality of life; traumatic brain injury	CLOSED HEAD-INJURY; CHILDREN; EPIDEMIOLOGY; PREDICTORS; RECOVERY; EXPERIENCE; SEVERITY; SEQUELAE; OUTCOMES; TERM	Context: Traumatic brain injury (TBI) is a common, acquired childhood disability, which has been shown to have a significant impact on children's cognitive and educational function. While behavioral problems are also noted, there is ongoing debate about the contribution of preinjury factors in this domain. Few studies have attempted to measure the impact of these preinjury functions on postinjury behavior. Objective: To compare pre and postinjury adaptive ability, behavior, executive function and quality of life (QOL) and to identify factors that contribute to outcomes in these domains including injury severity, socio-demographic and preinjury characteristics. Design: Consecutive recruitments to a prospective, longitudinal study, utilizing a between factor design, with injury severity as the independent variable. Participants and methods: Children admitted to hospital with a diagnosis of TBI aged between 6 and 14 years (n = 205) were divided according to injury severity (mild, moderate and severe). Adaptive behavior (Vineland Adaptive Behavior Scales), child behavior (Child Behavior Checklist), everyday executive functions (Behavior Rating Inventory of Executive Function) and QOL (Child Health Questionnaire) assessed at 6 months post-TBI. Results and conclusions: Severity by time interactions were identified across a range of outcome domains demonstrating that more severe injury is associated with a decrease in functional ability at 6 months post-TBI. This effect was most pronounced for everyday executive skills, social function and internalizing aspects of child behavior. Preinjury function was a consistent predictor of postinjury status. Injury severity contributed little to the prediction of functional outcomes once preinjury functioning was accounted for in the model. Age at injury and family cohesion were relevant to specific outcome domains only. Socio-economic status did not contribute significantly to outcome at 6 months. Preinjury functioning as reported by parents in the acute phase may be a useful predictive tool for identifying children who may be at risk of functioning difficulties 6 months post-TBI.	[Anderson, Vicki; Eren, Senem] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Anderson, Vicki] Royal Childrens Hosp, Dept Psychol, Melbourne, Vic, Australia; [Anderson, Vicki; Eren, Senem] Univ Melbourne, Melbourne, Vic, Australia; [Le Brocque, Robyne; Iselin, Greg; Kenardy, Justin] Univ Queensland, Sch Med, Ctr Natl Res Disabil & Rehabil Med, Brisbane, Qld, Australia; [Dob, Rian] Univ Queensland, Sch Psychol, Brisbane, Qld, Australia; [Davern, Timothy J.] Monash Univ, Melbourne, Vic 3004, Australia; [McKinlay, Lynne] Royal Childrens Hosp, Queensland Paediat Rehabil Serv, Brisbane, Qld, Australia	Anderson, V (corresponding author), Royal Childrens Hosp, Dept Psychol, Parkville, Vic 3052, Australia.	vicki.anderson@rch.org.au	Kenardy, Justin A/H-6603-2014; Le Brocque, Robyne/F-4848-2010; Kenardy, Justin/F-2085-2010	Kenardy, Justin A/0000-0001-9475-8450; Le Brocque, Robyne/0000-0002-4574-1254; McKinlay, Lynne/0000-0002-6677-0628	NHMRCNational Health and Medical Research Council of Australia	NHMRC project grant (Kenardy, Anderson, Bellamy & McKinlay).	Achenbach T. M., 1991, MANUAL CHILD BEHAV C; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Anderson VA, 2005, J NEUROL NEUROSUR PS, V76, P401, DOI 10.1136/jnnp.2003.019174; Anderson VA, 2004, BRAIN, V127, P2608, DOI 10.1093/brain/awh320; Asarnow R, 1995, TRAUMATIC BRAIN INJU, P117; Braga L, 2000, BRAIN INJURY, V17, P1; Butler RW, 2002, J INT NEUROPSYCH SOC, V8, P115, DOI 10.1017/S1355617701020112; Catroppa C, 2008, J PEDIATR PSYCHOL, V33, P707, DOI 10.1093/jpepsy/jsn006; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CRAFT AW, 1972, BMJ-BRIT MED J, V4, P200, DOI 10.1136/bmj.4.5834.200; DALBY PR, 1991, DEV NEUROPSYCHOL, V7, P35, DOI 10.1080/87565649109540476; Ducrocq SC, 2006, PEDIATR CRIT CARE ME, V7, P461, DOI 10.1097/01.PCC.0000235245.49129.27; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Gioia G.A., 2000, BEHAV RATING INVENTO; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; Johnson AR, 2009, DEV DISABIL RES REV, V15, P124, DOI 10.1002/ddrr.63; Keenan HT, 2006, DEV NEUROSCI-BASEL, V28, P256, DOI 10.1159/000094152; Kinsella G J, 1997, J Int Neuropsychol Soc, V3, P608; KLONOFF H, 1971, AM J PUBLIC HEALTH N, V61, P2405, DOI 10.2105/AJPH.61.12.2405; LANDGRAF JM, 1996, CHQ USERS MANUAL; McCarthy ML, 2006, ARCH PEDIAT ADOL MED, V160, P252, DOI 10.1001/archpedi.160.3.252; McKinlay A, 2010, INJURY PREV, V16, P31, DOI 10.1136/ip.2009.022483; McLennan W., 1997, AUSTR STANDARD CLASS; Mitra B, 2007, J PAEDIATR CHILD H, V43, P154, DOI 10.1111/j.1440-1754.2007.01035.x; MOYES CD, 1980, CHILD CARE HLTH DEV, V6, P1, DOI 10.1111/j.1365-2214.1980.tb00791.x; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; RUTTER M, 1981, AM J PSYCHIAT, V138, P1533; Rutter M, 1983, DEV NEUROPSYCHIATRY, P83; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Sparrow S., 1984, VINELAND ADAPTIVE BE; Taylor H.G., 1995, TRAUMATIC HEAD INJUR, P188; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; TEASDALE G, 1974, LANCET, V2, P81; TOMPKINS CA, 1990, BRAIN COGNITION, V13, P86, DOI 10.1016/0278-2626(90)90042-M; Van't Hooft I, 2005, BRAIN INJURY, V19, P511, DOI 10.1080/02699050400025224; van 't Hooft I, 2007, NEUROREHABILITATION, V22, P109; Wade SL, 2006, J HEAD TRAUMA REHAB, V21, P57, DOI 10.1097/00001199-200601000-00006; Wechsler D., 2011, WECHLSER ABBREVIATED; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Ylvisaker Mark, 2002, Pediatr Rehabil, V5, P51, DOI 10.1080/1363849021000041891	42	41	41	1	26	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0963-8288	1464-5165		DISABIL REHABIL	Disabil. Rehabil.		2012	34	19					1639	1647		10.3109/09638288.2012.656789			9	Rehabilitation	Rehabilitation	979VS	WOS:000306850400006	22416951				2021-06-18	
J	Schroeder, RW; Baade, LE; Peck, CP; VonDran, EJ; Brockman, CJ; Webster, BK; Heinrichs, RJ				Schroeder, Ryan W.; Baade, Lyle E.; Peck, Caleb P.; VonDran, Emanuel J.; Brockman, Callie J.; Webster, Blake K.; Heinrichs, Robin J.			Validation of MMPI-2-RF Validity Scales in Criterion Group Neuropsychological Samples	CLINICAL NEUROPSYCHOLOGIST			English	Article						Validity scales; Minnesota Multiphasic Personality Inventory-2 Restructured Form; MMPI-2-RF; Malingering; Forensic neuropsychology	MALINGERED NEUROCOGNITIVE DYSFUNCTION; FAKE BAD SCALE; RESPONSE BIAS; UTILITY; RBS	This study utilized multiple criterion group neuropsychological samples to evaluate the "over-reporting" and "under-reporting" MMPI-2-RF validity scales. The five criterion groups included in this study were (1) litigating traumatic brain injury patients who failed Slick et al. criteria for probable malingering, (2) litigating traumatic brain injury patients who passed Slick et al. criteria, (3) mixed neuropsychological outpatients who passed SVTs and were diagnosed with primary neurological conditions, (4) mixed neuropsychological outpatients who passed SVTs and were diagnosed with primary psychiatric conditions, and (5) epileptic seizure disorder inpatients who were diagnosed via video-EEG. Using the data from these groups, cumulative percentages for all possible T-scores and sensitivity and specificity rates for optimal cutoff scores were determined. When specificity rates were set at 90% across all non-malingering neurological condition groups, sensitivity rates ranged from 48% (FBS-r) to 10% (K-r).	[Schroeder, Ryan W.; Baade, Lyle E.; Peck, Caleb P.; VonDran, Emanuel J.; Brockman, Callie J.; Webster, Blake K.; Heinrichs, Robin J.] Univ Kansas, Sch Med Wichita, Wichita, KS 67206 USA	Schroeder, RW (corresponding author), Univ Kansas, Sch Med Wichita, Room 105,7829 E Rockhill, Wichita, KS 67206 USA.	Ryan.W.Schroeder.PsyD@hotmail.com					Ben-Porath Y. S., 2008, MMPI 2 RESTRUCTURED; Bortnik KE, 2010, CLIN NEUROPSYCHOL, V24, P344, DOI 10.1080/13854040903307268; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Butcher, 1989, MINNESOTA MULTIPHASI; Camara WJ, 2000, PROF PSYCHOL-RES PR, V31, P141, DOI 10.1037/0735-7028.31.2.141; Delis DC, 1987, CALIFORNIA VERBAL LE; Frederick R.I., 1997, VALIDITY INDICATOR P; Gervais RO, 2007, ASSESSMENT, V14, P196, DOI 10.1177/1073191106295861; Gervais RO, 2010, ARCH CLIN NEUROPSYCH, V25, P274, DOI 10.1093/arclin/acq018; Green, 2004, GREENS MED SYMPTOM V; Green P., 2003, GREENS WORD MEMORY T; Green P., 2004, MEMORY COMPLAINTS IN; Greiffenstein M.F., 2007, ASSESSMENT FEIGNED C, P210; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2006, CLIN NEUROPSYCHOL, V20, P491, DOI 10.1080/13854040590967144; Heilbronner RL, 2007, CLIN NEUROPSYCHOL, V21, P209, DOI 10.1080/13825580601025932; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; LEESHALEY PR, 1991, PSYCHOL REP, V68, P203, DOI 10.2466/PR0.68.1.203-210; LEESHALEY PR, 1992, J CLIN PSYCHOL, V48, P681, DOI 10.1002/1097-4679(199209)48:5<681::AID-JCLP2270480516>3.0.CO;2-Q; Locke DEC, 2010, EPILEPSY BEHAV, V17, P252, DOI 10.1016/j.yebeh.2009.12.004; Mathias CW, 2002, ASSESSMENT, V9, P301, DOI 10.1177/1073191102009003009; Miller JB, 2011, CLIN NEUROPSYCHOL, V25, P160, DOI 10.1080/13854046.2010.533197; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Nelson NW, 2007, J CLIN EXP NEUROPSYC, V29, P67, DOI 10.1080/13803390500488546; Nelson NW, 2010, CLIN NEUROPSYCHOL, V24, P701, DOI 10.1080/13854040903482863; Pearson, 2009, ADV CLIN SOL WAIS 4; Rogers R, 2011, J PSYCHOPATHOL BEHAV, V33, P355, DOI 10.1007/s10862-011-9222-0; Sellbom M, 2010, PSYCHOL ASSESSMENT, V22, P757, DOI 10.1037/a0020825; Sellbom M, 2010, PSYCHOL ASSESSMENT, V22, P22, DOI 10.1037/a0018222; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Tombaugh TN, 1996, TEST MEMORY MALINGER; Wechsler D., 2009, WECHSLER MEMORY SCAL; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wygant D. B., 2010, PSYCHOL ASSESSMENT, V22, P1; Wygant DB, 2009, ARCH CLIN NEUROPSYCH, V24, P671, DOI 10.1093/arclin/acp073; Youngjohn JR, 2011, CLIN NEUROPSYCHOL, V25, P463, DOI [10.1080/13854046.2011.554444, 10.1080/13854046.2010.550635]	37	41	41	1	12	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2012	26	1					129	146		10.1080/13854046.2011.639314			18	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	922JN	WOS:000302543300011	22150551				2021-06-18	
J	Theadom, A; Barker-Collo, S; Feigin, VL; Starkey, NJ; Jones, K; Jones, A; Ameratunga, S; Barber, PA				Theadom, A.; Barker-Collo, S.; Feigin, V. L.; Starkey, N. J.; Jones, K.; Jones, A.; Ameratunga, S.; Barber, P. A.		BIONIC Res Grp	The Spectrum Captured: A Methodological Approach to Studying Incidence and Outcomes of Traumatic Brain Injury on a Population Level	NEUROEPIDEMIOLOGY			English	Article						Traumatic brain injury; Epidemiology; Longitudinal; Outcomes; Assessment; Methods; New Zealand; Incidence	MILD HEAD-INJURY; YOUNG-CHILDREN; NEW-ZEALAND; COMA SCALE; FOLLOW-UP; QUESTIONNAIRE; RECOVERY; CONSCIOUSNESS; EPIDEMIOLOGY; RELIABILITY	Objective: Drawing on the experience of conducting the Brain Injury Incidence and Outcomes New Zealand in the Community study, this article aims to identify the issues arising from the implementation of proposed guidelines for population-based studies of incidence and outcomes in traumatic brain injury (TBI). Study Design and Setting: All new cases of TBI (all ages and severities) were ascertained over a 1-year period, using overlapping prospective and retrospective sources of case ascertainment in New Zealand. All eligible TBI cases were invited to participate in a comprehensive assessment at baseline and at 1-month follow-up. Results: Our experience to date has revealed the feasibility of case ascertainment methods. Consultation with community health services and professionals resulted in feasible referral pathways to support the identification of TBI cases. 'Hot pursuit' methods of recruitment were essential to ensure complete case ascertainment for this population with few additional cases of TBI identified through cross-checks. Conclusion: This review of proposed guidelines in relation to practical study methodology provides a framework for future comparable population-based epidemiological studies of TBI incidence and outcomes in developed countries. Copyright (C) 2011 S. Karger AG, Basel	[Theadom, A.] Auckland Univ Technol, Fac Hlth & Environm Sci, Sch Rehabil & Occupat Studies, Natl Inst Stroke & Appl Neurosci, Auckland 1142, New Zealand; [Barker-Collo, S.] Univ Auckland, Dept Psychol, Fac Sci, Auckland, New Zealand; [Ameratunga, S.] Univ Auckland, Sch Populat Hlth, Auckland 1, New Zealand; [Barber, P. A.] Univ Auckland, Dept Med, Auckland, New Zealand; [Starkey, N. J.] Univ Waikato, Fac Arts & Social Sci, Sch Psychol, Hamilton, New Zealand	Theadom, A (corresponding author), Auckland Univ Technol, Fac Hlth & Environm Sci, Sch Rehabil & Occupat Studies, Natl Inst Stroke & Appl Neurosci, AUT N Shore Campus,AA254C,90 Akoranga Dr,Private, Auckland 1142, New Zealand.	alice.theadom@aut.ac.nz	Feigin, Valery/AAF-2313-2019; Jones, Kelly/I-5199-2019; Starkey, Nicola/AAJ-3795-2020; Jones, Kelly/G-4127-2015	Starkey, Nicola/0000-0002-4370-8186; Feigin, Valery L./0000-0002-6372-1740; Theadom, Alice/0000-0003-0351-6216; Ameratunga, Shanthi/0000-0001-8042-2251; Jones, Kelly/0000-0001-5692-653X; Barber, P Alan/0000-0003-2469-9023	Health Research Council of New Zealand (HRC)Health Research Council of New Zealand [09/063A]; ABI Rehabilitation Management, NZ	This study is funded by the Health Research Council of New Zealand (HRC 09/063A). The lead author's position is supported by ABI Rehabilitation Management, NZ. The authors would also like to thank all those who have supported the study through advertising and referring eligible participants, the research assistants working on the BIONIC study and all participants for taking part. Without their contribution this study would not have been possible.	Anderson CS, 2005, STROKE, V36, P2087, DOI 10.1161/01.STR.0000181079.42690.bf; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Bakas T, 1999, NURS RES, V48, P250, DOI 10.1097/00006199-199909000-00005; Barker-Collo SL, 2009, NEUROEPIDEMIOLOGY, V32, P32, DOI 10.1159/000170090; Barker-Collo SL, 2009, NEUROEPIDEMIOLOGY, V32, P1, DOI 10.1159/000170084; Beck A. T., 1996, BECK DEPRESSION INVE, VII; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Broadbent E, 2006, J PSYCHOSOM RES, V60, P631, DOI 10.1016/j.jpsychores.2005.10.020; BROADHEAD WE, 1988, MED CARE, V26, P709, DOI 10.1097/00005650-198807000-00006; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Coen AS, 1996, EVAL PROGRAM PLANN, V19, P309, DOI 10.1016/S0149-7189(96)00024-9; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Donders J, 2007, J HEAD TRAUMA REHAB, V22, P296, DOI 10.1097/01.HTR.0000290974.01872.82; Feigin V. L., 2007, HDB CLIN NEUROEPIDEM, P197; Fletcher JM, 1990, VARIABILITY OUTCOMES; Foa EB, 1997, PSYCHOL ASSESSMENT, V9, P445, DOI 10.1037/1040-3590.9.4.445; GRIGSBY J, 1992, PERCEPT MOTOR SKILL, V74, P883, DOI 10.2466/PMS.74.3.883-892; Gualtieri CT, 2006, ARCH CLIN NEUROPSYCH, V21, P623, DOI 10.1016/j.acn.2006.05.007; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; Harrison P., 2003, ADAPTIVE BEHAV ASSES; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; JENNETT B, 1975, LANCET, V1, P480; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; King N, 1997, BRIT J CLIN PSYCHOL, V36, P161, DOI 10.1111/j.2044-8260.1997.tb01405.x; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kroenke K, 2003, MED CARE, V41, P1284, DOI 10.1097/01.MLR.0000093487.78664.3C; Langley J, 2010, BRAIN INJURY, V24, P939, DOI 10.3109/02699052.2010.491494; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lin MR, 2010, ARCH PHYS MED REHAB, V91, P474, DOI 10.1016/j.apmr.2009.10.031; McKinlay A, 2010, CHILD CARE HLTH DEV, V36, P3, DOI 10.1111/j.1365-2214.2009.01006.x; *NZ GUID GROUP, 2005, DIAGN AC MAN REH PEO; Petrie KJ, 2007, CURR OPIN PSYCHIATR, V20, P163, DOI 10.1097/YCO.0b013e328014a871; Ponsford J, 2004, BRAIN INJURY, V18, P603, DOI 10.1080/02699050310001646152; REILLY PL, 1988, CHILD NERV SYST, V4, P30; Reynolds CR., 2002, CLIN GUIDE BEHAV ASS; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Silver JM, 2005, TXB TRAUMATIC BRAIN; SIMPSON DA, 1991, CHILD NERV SYST, V7, P183; *STAT NZ, 2006, NZ CENS 2006; TEASDALE G, 1974, LANCET, V2, P81; Temkin NR, 2009, J HEAD TRAUMA REHAB, V24, P460, DOI 10.1097/HTR.0b013e3181c13413; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Torner JC, 1996, HEAD INJURY POSTCONC; Van de Voorde P, 2008, RESUSCITATION, V76, P175, DOI 10.1016/j.resuscitation.2007.07.007; van Velzen JM, 2009, BRAIN INJURY, V23, P473, DOI 10.1080/02699050902970737; Varni J. W., 1999, J CLIN OUTCOMES MANA, V6, P33; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Willer B., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI DOI 10.1097/00001199-199308020-00009; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; WOODCOCK RW, 2001, WOODCOCKJOHNSON III; World Health Organization, 2005, 55 SESS WHO REG COMM; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	56	41	42	0	12	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0251-5350	1423-0208		NEUROEPIDEMIOLOGY	Neuroepidemiology		2012	38	1					18	29		10.1159/000334746			12	Public, Environmental & Occupational Health; Clinical Neurology	Public, Environmental & Occupational Health; Neurosciences & Neurology	879DI	WOS:000299309500002	22179412	Bronze			2021-06-18	
J	Datta, A; Qian, JR; Khor, TH; Teo, MT; Heese, K; Sze, SK				Datta, Arnab; Qian Jingru; Khor, Tze Hsin; Teo, Muh Tyng; Heese, Klaus; Sze, Siu Kwan			Quantitative Neuroproteomics of an In Vivo Rodent Model of Focal Cerebral Ischemia/Reperfusion Injury Reveals a Temporal Regulation of Novel Pathophysiological Molecular Markers	JOURNAL OF PROTEOME RESEARCH			English	Article						cerebral ischemia; iTRAQ; MCAO model; neuroproteomics; temporal profiling; glutamate excitotoxicity; neuro-inflammation; transferrin; stroke	TRAUMATIC BRAIN-INJURY; FIBRILLARY ACIDIC PROTEIN; ACUTE ISCHEMIC-STROKE; ARTERY OCCLUSION; GLUTAMATE-DEHYDROGENASE; INTRALUMINAL SUTURE; PROTEOMICS APPROACH; UP-REGULATION; RATS; IDENTIFICATION	Cerebral ischemia or stroke, an acute neurological injury lacking an effective therapy, is the second leading cause of death globally. The unmet need in stroke research is to identify viable targets and to understand their interplay during the temporal evolution of ischemia/reperfusion (I/R) injury. Here we report a temporal signature of the ischemic hemisphere revealed by the isobaric tag for relative and absolute quantification (iTRAQ)-based 2D-LC-MS/MS strategy in an in vivo middle cerebral artery occlusion (MCAO) model of focal cerebral I/R injury. To recapitulate clinical stroke, two hours of MCAO was followed by 0, 4, and 24 h of reperfusion to capture ischemia with an acute and subacute durations of reperfusion injury. The subsequent iTRAQ experiment identified 2242 proteins from the ischemic hemisphere with <1.0% false discovery rate. Data mining revealed that (1) about 2.7% of detected proteins were temporally perturbed having an involvement in the energy metabolism (Pygb, Atp5b), glutamate excitotoxicity (Slc1a3, Glud1), neuro-inflammation (Tf, C3, Alb), and cerebral plasticity (Gfap, Vim, Gap43); (2) astrocytes participated actively in the neurometabolic coupling underlining the importance of a cerebro-protective rather than a neuro-protective approach; and (3) hyper-acute yet progressive opening of the blood brain barrier (BBB), accompanied by stimulation of an innate immune response and late activation of a regenerative response, which provides an extended therapeutic window for intervention. Several regulated proteins (Caskin1, Shank3, Kpnb1, Uchl1, Mtap6, Epb4.1l1, Apba1, and Ube1x) novel in the context of stroke were also discovered. In conclusion, our result supports a dynamic multitarget therapy rather than the traditional approach of a unilateral and sustained modulation of a single target to address the phasic regulation of an ischemic proteome.	[Datta, Arnab; Qian Jingru; Khor, Tze Hsin; Teo, Muh Tyng; Heese, Klaus; Sze, Siu Kwan] Nanyang Technol Univ, Sch Biol Sci, Singapore 637551, Singapore	Sze, SK (corresponding author), Nanyang Technol Univ, Sch Biol Sci, 60 Nanyang Dr, Singapore 637551, Singapore.	sksze@ntu.edu.sg	Sze, Siu Kwan/AAO-3342-2020; Datta, Arnab/H-2755-2013; Heese, Klaus/H-3128-2013; Sze, Siu_kwan Newman/A-2199-2011	Sze, Siu Kwan/0000-0002-5652-1687; Datta, Arnab/0000-0002-9220-7812; Heese, Klaus/0000-0002-0027-6993; Sze, Siu_kwan Newman/0000-0002-5652-1687	Agency for Science, Technology and Research of SingaporeAgency for Science Technology & Research (ASTAR) [BMRC: 08/1/22/19/575]; Nanyang Technological UniversityNanyang Technological University [AcRF: RG 51/10]	We thank Lokesh Bhatt, Prashant Jamadarkhana, Anookh Mohanan, Salil Kumar Bose, Jung Eun Park, Xin Li, Anindya Basu for the experimental assistance and/or critical reading of the manuscript. The work was supported by grants from the Agency for Science, Technology and Research of Singapore (BMRC: 08/1/22/19/575) and Nanyang Technological University (AcRF: RG 51/10).	AIGNER L, 1995, CELL, V83, P269, DOI 10.1016/0092-8674(95)90168-X; Altamura C, 2009, STROKE, V40, P1282, DOI 10.1161/STROKEAHA.108.536714; AOKI C, 1987, J NEUROSCI RES, V18, P305, DOI 10.1002/jnr.490180207; Arikkath J, 2009, J NEUROSCI, V29, P5435, DOI 10.1523/JNEUROSCI.0835-09.2009; Arranz AM, 2010, NEUROBIOL DIS, V37, P156, DOI 10.1016/j.nbd.2009.09.019; Bao XD, 2009, J NEUROSCI, V29, P13929, DOI 10.1523/JNEUROSCI.4413-09.2009; Bayes A, 2009, NAT REV NEUROSCI, V10, P635, DOI 10.1038/nrn2701; Belayev L, 1996, STROKE, V27, P1616, DOI 10.1161/01.STR.27.9.1616; Belayev L, 1999, BRAIN RES, V833, P181, DOI 10.1016/S0006-8993(99)01528-0; Bosc C, 2003, BIOCHEMISTRY-US, V42, P12125, DOI 10.1021/bi0352163; Brown AM, 2005, J NEUROSCI RES, V79, P74, DOI 10.1002/jnr.20335; Carmichael S Thomas, 2005, NeuroRx, V2, P396; Chemerinski E, 2006, MT SINAI J MED, V73, P1006; Chen A, 2007, NEUROCHEM INT, V50, P1078, DOI 10.1016/j.neuint.2006.11.008; Chong PK, 2006, J PROTEOME RES, V5, P1232, DOI 10.1021/pr060018u; Cid C, 2007, PROTEOMICS, V7, P3207, DOI 10.1002/pmic.200700214; Datta A, 2010, J PROTEOME RES, V9, P472, DOI 10.1021/pr900829h; DELZOPPO GJ, 1994, CEREBROVAS BRAIN MET, V6, P47; Dhodda VK, 2004, J NEUROCHEM, V89, P73, DOI 10.1111/j.1471-4159.2004.02316.x; Dittmar M, 2003, STROKE, V34, P2252, DOI 10.1161/01.STR.0000083625.54851.9A; Dominguez C, 2010, STROKE, V41, P653, DOI 10.1161/STROKEAHA.109.571935; Duan SM, 1999, J NEUROSCI, V19, P10193; Fisher M, 2009, STROKE, V40, P2244, DOI 10.1161/STROKEAHA.108.541128; Foley LM, 2010, TRANSL STROKE RES, V1, P220, DOI 10.1007/s12975-010-0032-6; Gong YS, 2009, BRAIN RES, V1292, P191, DOI 10.1016/j.brainres.2009.07.056; Gygi SP, 1999, NAT BIOTECHNOL, V17, P994, DOI 10.1038/13690; Haigis MC, 2006, CELL, V126, P941, DOI 10.1016/j.cell.2006.06.057; Herrmann M, 2000, STROKE, V31, P2670, DOI 10.1161/01.STR.31.11.2670; Honda M, 2010, J TRAUMA, V69, P104, DOI 10.1097/TA.0b013e3181bbd485; Horonchik L, 2008, CHEM BIOL, V15, P647, DOI 10.1016/j.chembiol.2008.05.011; Huang PY, 2009, J NEUROL, V256, P625, DOI 10.1007/s00415-009-0133-x; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; Ishii T, 2010, BRAIN RES, V1321, P164, DOI 10.1016/j.brainres.2010.01.039; Joshi CN, 2004, BRAIN RES PROTOC, V13, P11, DOI 10.1016/j.brainresprot.2003.12.001; Kersey PJ, 2004, PROTEOMICS, V4, P1985, DOI 10.1002/pmic.200300721; Koh PO, 2010, J VET MED SCI, V72, P181, DOI 10.1292/jvms.09-0364; Leiser SF, 2010, MOL CELL, V38, P779, DOI 10.1016/j.molcel.2010.06.015; Li FH, 1999, STROKE, V30, P2464, DOI 10.1161/01.STR.30.11.2464; LIPTON P, 1989, J NEUROSCI METH, V28, P147, DOI 10.1016/0165-0270(89)90019-8; Liu F, 2009, J NEUROSCI METH, V179, P1, DOI 10.1016/j.jneumeth.2008.12.028; Liu MC, 2010, EUR J NEUROSCI, V31, P722, DOI 10.1111/j.1460-9568.2010.07097.x; Lo EH, 2005, STROKE, V36, P189, DOI 10.1161/01.STR.0000153069.96296.fd; Lo EH, 2008, NAT MED, V14, P497, DOI 10.1038/nm1735; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; Luo YM, 2006, J NEUROCHEM, V97, P435, DOI 10.1111/j.1471-4159.2006.03758.x; Magistretti PJ, 2009, AM J CLIN NUTR, V90, p875S, DOI 10.3945/ajcn.2009.27462CC; Moskowitz MA, 2010, NEURON, V67, P181, DOI 10.1016/j.neuron.2010.07.002; Nagaraja TN, 2008, MICROCIRCULATION, V15, P1, DOI 10.1080/10739680701409811; Park JE, 2010, MOL CELL PROTEOMICS, V9, P1085, DOI 10.1074/mcp.M900381-MCP200; Pekny M, 2005, GLIA, V50, P427, DOI 10.1002/glia.20207; Pendlebury ST, 2009, MATURITAS, V64, P165, DOI 10.1016/j.maturitas.2009.09.010; Prajapati KD, 2010, BRAIN RES, V1327, P118, DOI 10.1016/j.brainres.2010.02.063; Schroeder JM, 2003, AM J PHYSIOL-RENAL, V285, pF258, DOI 10.1152/ajprenal.00422.2002; Sung JH, 2009, J PINEAL RES, V46, P300, DOI 10.1111/j.1600-079X.2008.00661.x; Swistowski A, 2009, J NEUROSCI, V29, P15703, DOI 10.1523/JNEUROSCI.4351-09.2009; Tabuchi K, 2002, J NEUROSCI, V22, P4264, DOI 10.1523/JNEUROSCI.22-11-04264.2002; Thomas PD, 2003, GENOME RES, V13, P2129, DOI 10.1101/gr.772403; Vaslin A, 2009, ANN NEUROL, V65, P337, DOI 10.1002/ana.21584; Wang XY, 2003, MOL NEUROBIOL, V28, P229, DOI 10.1385/MN:28:3:229; Wardlaw JM, 2010, J INTERN MED, V267, P172, DOI 10.1111/j.1365-2796.2009.02200.x; Washburn MP, 2001, NAT BIOTECHNOL, V19, P242, DOI 10.1038/85686; Weinstein PR, 2004, STROKE, V35, P2666, DOI 10.1161/01.STR.0000144052.10644.ed; Whiteley W, 2009, STROKE, V40, pE380, DOI 10.1161/STROKEAHA.108.528752; YAMADA K, 1994, ACTA NEUROPATHOL, V88, P553; Yamamoto H, 2007, MOL ENDOCRINOL, V21, P1745, DOI 10.1210/me.2007-0079; Zaleska MM, 2009, NEUROPHARMACOLOGY, V56, P329, DOI 10.1016/j.neuropharm.2008.10.006; Zausinger S, 2000, BRAIN RES, V863, P94, DOI 10.1016/S0006-8993(00)02100-4; Zhang XM, 2010, BRAIN RES, V1343, P143, DOI 10.1016/j.brainres.2010.04.027; Zhang ZJ, 2009, NEUROCHEM INT, V54, P488, DOI 10.1016/j.neuint.2009.02.005	69	41	41	0	15	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	1535-3893	1535-3907		J PROTEOME RES	J. Proteome Res.	NOV	2011	10	11					5199	5213		10.1021/pr200673y			15	Biochemical Research Methods	Biochemistry & Molecular Biology	840CA	WOS:000296414700028	21950801				2021-06-18	
J	Ehrenreich, H; Kastner, A; Weissenborn, K; Streeter, J; Sperling, S; Wang, KK; Worthmann, H; Hayes, RL; von Ahsen, N; Kastrup, A; Jeromin, A; Herrmann, M				Ehrenreich, Hannelore; Kaestner, Anne; Weissenborn, Karin; Streeter, Jackson; Sperling, Swetlana; Wang, Kevin K.; Worthmann, Hans; Hayes, Ronald L.; von Ahsen, Nico; Kastrup, Andreas; Jeromin, Andreas; Herrmann, Manfred			Circulating Damage Marker Profiles Support a Neuroprotective Effect of Erythropoietin in Ischemic Stroke Patients	MOLECULAR MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; TISSUE-PLASMINOGEN ACTIVATOR; FIBRILLARY ACIDIC PROTEIN; CENTRAL-NERVOUS-SYSTEM; C-TERMINAL HYDROLASE; NEUROBIOCHEMICAL MARKERS; OUTCOME PREDICTION; BIOMARKER; COMBINATION; HEMORRHAGE	The German Multicenter EPO Stroke Trial, which investigated safety and efficacy of erythropoietin (EPO) treatment in ischemic stroke, was formally declared a negative study. Exploratory subgroup analysis, however, revealed that patients not receiving thrombolysis most likely benefited from EPO during clinical recovery, a result demonstrated in the findings of the Gottingen EPO Stroke Study The present work investigated whether the positive signal on clinical outcome in this patient subgroup was mirrored by respective poststroke biomarker profiles. All patients of the German Multicenter EPO Stroke Trial nonqualifying for thrombolysis were included if they (a) were treated per protocol and (b) had at least two of the five follow-up blood samples for circulating damage markers drawn (n = 163). The glial markers S100B and glial fibrillary acid protein (GFAP) and the neuronal marker ubiquitin C-terminal hydrolase (UCH-L1) were measured by enzyme-linked immunosorbent assay in serum on d 1, 2, 3, 4 and 7 poststroke. All biomarkers increased poststroke. Overall, EPO-treated patients had significantly lower concentrations (area under the curve) over 7 d of observation, as reflected by the composite score of all three markers (Cronbach alpha = 0.811) and by UCH-L1. S100B and GFAP showed a similar tendency. To conclude, serum biomarker profiles, as an outcome measure of brain damage, corroborate an advantageous effect of EPO in ischemic stroke. In particular, reduction in the neuronal damage marker UCH-L1 may reflect neuroprotection by EPO. (C) 2011 The Feinstein Institute for Medical Research, www.feinsteininstitute.org Online address: http://www.molmed.org doi: 10.2119/molmed.2011.00259	[Ehrenreich, Hannelore] Max Planck Inst Expt Med, Div Clin Neurosci, D-37075 Gottingen, Germany; [Weissenborn, Karin; Worthmann, Hans] Hannover Med Sch, Dept Neurol, D-3000 Hannover, Germany; [Streeter, Jackson; Hayes, Ronald L.; Jeromin, Andreas] Banyan Biomarkers Inc, Alachua, FL USA; [von Ahsen, Nico] Univ Gottingen, Dept Clin Chem, Gottingen, Germany; [Kastrup, Andreas] Klinikum Bremen Ost & Bremen Mitte, Dept Neurol, Bremen, Germany; [Herrmann, Manfred] Univ Bremen, Dept Neuropsychol & Behav Neurobiol, D-28359 Bremen, Germany	Ehrenreich, H (corresponding author), Max Planck Inst Expt Med, Div Clin Neurosci, Hermann Rein Str 3, D-37075 Gottingen, Germany.	ehrenreich@em.mpg.de; ajeromin@banyanbio.com	Herrmann, Manfred/H-3931-2011	Herrmann, Manfred/0000-0003-1872-8406; Wang, Kevin/0000-0002-9343-6473; Ehrenreich, Hannelore/0000-0001-8371-5711	Max Planck Society and Banyan Biomarkers, Inc.	This study was supported by the Max Planck Society and Banyan Biomarkers, Inc.	Brines M, 2005, NAT REV NEUROSCI, V6, P484, DOI 10.1038/nrn1687; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; Ehrenreich H, 2009, STROKE, V40, pE647, DOI 10.1161/STROKEAHA.109.564872; Eng LF, 2000, NEUROCHEM RES, V25, P1439, DOI 10.1023/A:1007677003387; Heizmann CW, 1999, NEUROCHEM RES, V24, P1097, DOI 10.1023/A:1020700117665; Herrmann M, 2000, STROKE, V31, P645, DOI 10.1161/01.STR.31.3.645; Herrmann M, 2003, RESTOR NEUROL NEUROS, V21, P177; Herrmann M, 2000, STROKE, V31, P2670, DOI 10.1161/01.STR.31.11.2670; Jia LF, 2010, STROKE, V41, P2071, DOI 10.1161/STROKEAHA.110.586198; Lewis SB, 2010, J NEUROSCI RES, V88, P1475, DOI 10.1002/jnr.22323; Liu MC, 2010, EUR J NEUROSCI, V31, P722, DOI 10.1111/j.1460-9568.2010.07097.x; Marchi N, 2003, RESTOR NEUROL NEUROS, V21, P109; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Sargin D, 2010, BEST PRACT RES-CLIN, V24, P573, DOI 10.1016/j.bpa.2010.10.005; Siman R, 2008, BRAIN RES, V1213, P1, DOI 10.1016/j.brainres.2008.03.034; Siman R, 2009, J NEUROTRAUM, V26, P1867, DOI 10.1089/neu.2009.0882; Wunderlich MT, 1999, STROKE, V30, P1190, DOI 10.1161/01.STR.30.6.1190; Zechariah A, 2010, STROKE, V41, P1008, DOI 10.1161/STROKEAHA.109.574418	19	41	43	0	7	FEINSTEIN INST MED RES	MANHASSET	350 COMMUNITY DR, MANHASSET, NY 11030 USA	1076-1551			MOL MED	Mol. Med.	NOV-DEC	2011	17	11-12					1306	1310		10.2119/molmed.2011.00259			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	860OY	WOS:000297958800021	21912808	DOAJ Gold, Green Published			2021-06-18	
J	Widome, R; Laska, MN; Gulden, A; Fu, SS; Lust, K				Widome, Rachel; Laska, Melissa Nelson; Gulden, Ashley; Fu, Steven S.; Lust, Katherine			Health Risk Behaviors of Afghanistan and Iraq War Veterans Attending College	AMERICAN JOURNAL OF HEALTH PROMOTION			English	Article						Veterans; Young Adult; Tobacco; Substance Abuse; Obesity; Safety; Prevention Research	TRAUMATIC BRAIN-INJURY; PHYSICAL-ACTIVITY; CIGARETTE-SMOKING; YOUNG-ADULTS; BODY-WEIGHT; UNITED-STATES; ALCOHOL-USE; TOBACCO USE; OBESITY; PREVALENCE	Purpose. The population of military veterans attending college is rapidly growing as veterans return from Operation Enduring Freedom and Operation Iraqi Freedom (OEF/OIF). We sought to describe patterns of student veterans' health-related behaviors and how they might differ from their nonveteran peers. Design. We analyzed data from the 2008 Boynton College Student Health Survey (CSHS). Setting. CSHS participants completed an anonymous online survey. Subjects. The CSHS sampled students (n = 8651) attending public, private, 2-year, and 4-year postsecondary educational institutions in Minnesota. Measures. The CSHS included items on substance use (including alcohol and tobacco), safety, nutrition, and physical activity. Analysis. We described demographics of OEF/OIF veteran, non-OEF/OIF veteran, and nonveteran students and used Poisson regression to compute adjusted relative risks (ARRs) with 95 % confidence intervals (CIs) to characterize associations between veteran status and health behaviors. Results. After controlling for demographics, veteran students reported more safety-, tobacco-, and alcohol-related risk behaviors compared to nonveteran students. For instance, compared to the nonveteran reference group, the ARR for past year smokeless tobacco use and physical fighting among for OEF/OIF veterans was 1.76 (95 % CI = 1.31-2.35) and 1.48 (95 % CI = 1.22-1.79) respectively. Veteran and nonveteran students display similar weight-related behaviors, though OEF/OIF veteran students were more likely to engage in strengthening exercises. Conclusions. There are specific health risk behaviors that are particularly relevant for veterans attending postsecondary institutions. As veterans enroll in postsecondary education, there is a unique window of opportunity far health promotion in this population. (Am J Health Promot 2011;26[2]:101-108.)	[Widome, Rachel; Gulden, Ashley; Fu, Steven S.] Minneapolis VA Med Ctr, CCDOR, Minneapolis, MN 55417 USA; [Widome, Rachel; Fu, Steven S.] Univ Minnesota, Sch Med, Dept Med, Minneapolis, MN 55455 USA; [Laska, Melissa Nelson] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN USA; [Lust, Katherine] Univ Minnesota, Boynton Hlth Serv, Minneapolis, MN USA	Widome, R (corresponding author), Minneapolis VA Med Ctr, CCDOR, 1 Vet Dr 152-2E, Minneapolis, MN 55417 USA.	chel@umn.edu		Laska, Melissa/0000-0002-3836-0269	NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [U54CA116849] Funding Source: NIH RePORTER; NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [U54 CA116849, U54CA116849] Funding Source: Medline		Almond N, 2008, MIL MED, V173, P544, DOI 10.7205/MILMED.173.6.544; Bondurant S, 2009, COMB TOB US MIL VET; BRAY RM, 2006, RTI7841106FR; Butler SM, 2004, AM J HEALTH BEHAV, V28, P24, DOI 10.5993/AJHB.28.1.3; Centers for Disease Control and Prevention, 2009 STAT LOC YOUTH; COOK A, 2005, PYRAMID SERVINGS INT; DALTON A, 2006, HLTH SERVICES VA SUB; DeBate RD, 2001, ADOLESCENCE, V36, P819; Driskell JA, 2005, J AM DIET ASSOC, V105, P798, DOI 10.1016/j.jada.2005.02.004; FEIGELMAN W, 1994, PREV MED, V23, P235, DOI 10.1006/pmed.1994.1032; Ferreira I, 2005, ARCH INTERN MED, V165, P42, DOI 10.1001/archinte.165.1.42; Forgas LB, 1996, MIL MED, V161, P165; Gordon-Larsen P, 2004, AM J PREV MED, V27, P277, DOI 10.1016/j.amepre.2004.07.006; Hajhosseini L, 2006, J AM COLL NUTR, V25, P123, DOI 10.1080/07315724.2006.10719522; Hammond D, 2005, TOB CONTROL, V14, P181, DOI 10.1136/tc.2004.009621; Heron M, NAT VIT STAT REP, V58, P1; Hoffman DJ, 2006, J AM COLL HEALTH, V55, P41, DOI 10.3200/JACH.55.1.41-46; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holm-Denoma JM, 2008, HEALTH PSYCHOL, V27, pS3, DOI 10.1037/0278-6133.27.1.S3; Huang TTK, 2003, J AM COLL HEALTH, V52, P83, DOI 10.1080/07448480309595728; Jacobson IG, 2008, JAMA-J AM MED ASSOC, V300, P663, DOI 10.1001/jama.300.6.663; Jacobson IG, 2009, AM J EPIDEMIOL, V169, P415, DOI 10.1093/aje/kwn366; Kaly PW, 2002, J COLL STUDENT DEV, V43, P838; Kang H., 2009, ANAL VA HLTH CARE UT; Karney BR., 2008, INVISIBLE WOUNDS WAR, P119; Kiefe CI, 2001, AM J PUBLIC HEALTH, V91, P213, DOI 10.2105/AJPH.91.2.213; Killgore WDS, 2008, J PSYCHIATR RES, V42, P1112, DOI 10.1016/j.jpsychires.2008.01.001; KLEVENS RM, 1995, AM J PREV MED, V11, P245; LaBrie JW, 2008, ARCH SEX BEHAV, V37, P330, DOI 10.1007/s10508-007-9195-y; Lloyd-Richardson EE, 2009, PREV MED, V48, P256, DOI 10.1016/j.ypmed.2008.12.009; McCracken Melissa, 2007, Prev Chronic Dis, V4, pA25; McKinney WP, 1997, PUBLIC HEALTH REP, V112, P212; McNutt LA, 2003, AM J EPIDEMIOL, V157, P940, DOI 10.1093/aje/kwg074; Mokdad AH, 1999, JAMA-J AM MED ASSOC, V282, P1519, DOI 10.1001/jama.282.16.1519; Morrell HER, 2008, AM J ADDICTION, V17, P181, DOI 10.1080/10550490802019899; Morrow ML, 2006, OBESITY, V14, P1438, DOI 10.1038/oby.2006.163; Nelson KM, 2006, J GEN INTERN MED, V21, P915, DOI 10.1007/BF02743137; Nelson MC, 2008, OBESITY, V16, P2205, DOI 10.1038/oby.2008.365; Nielsen SJ, 2004, AM J PREV MED, V27, P205, DOI 10.1016/j.amepre.2004.05.005; Office of Statistics and Programming NCfIPaCCfDCaP, 2009, WISQUARS 2006 UN INJ; Ogden CL, 2006, JAMA-J AM MED ASSOC, V295, P1549, DOI 10.1001/jama.295.13.1549; Paeratakul S, 2003, J AM DIET ASSOC, V103, P1332, DOI 10.1016/S0002-8223(03)01086-1; Peterson AL, 2007, MIL MED, V172, P1300, DOI 10.7205/MILMED.172.12.1300; Pi-Sunyer FX, 1998, OBES RES, V6, p51S; Racette SB, 2005, J AM COLL HEALTH, V53, P245, DOI 10.3200/JACH.53.6.245-251; Racette SB, 2008, J NUTR EDUC BEHAV, V40, P39, DOI 10.1016/j.jneb.2007.01.001; Raudenbush S., 2002, HIERACHICAL LINEAR M; Rigotti NA, 2000, JAMA-J AM MED ASSOC, V284, P699, DOI 10.1001/jama.284.6.699; Romero-Corral A, 2008, INT J OBESITY, V32, P959, DOI 10.1038/ijo.2008.11; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Sewall M., 2010, CHRON HIGHER EDUC, V56, pA20; Smith B, 2008, AM J PREV MED, V35, P539, DOI 10.1016/j.amepre.2008.07.009; Sutfin EL, 2009, NICOTINE TOB RES, V11, P444, DOI 10.1093/ntr/ntp006; Taylor DH, 2002, AM J PUBLIC HEALTH, V92, P990, DOI 10.2105/AJPH.92.6.990; Vander Weg MW, 2008, ADDICT BEHAV, V33, P69, DOI 10.1016/j.addbeh.2007.07.005; WAGNER TH, 2007, PSYCHOL SERVICES, V0004; Wechsler H, 1998, JAMA-J AM MED ASSOC, V280, P1673, DOI 10.1001/jama.280.19.1673	57	41	41	0	24	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0890-1171	2168-6602		AM J HEALTH PROMOT	Am. J. Health Promot.	NOV-DEC	2011	26	2					101	108		10.4278/ajhp.090826-QUAN-278			8	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	846WR	WOS:000296934400006	22040391	Green Accepted			2021-06-18	
J	Berry, C; Ley, EJ; Margulies, DR; Mirocha, J; Bukur, M; Malinoski, D; Salim, A				Berry, Cherisse; Ley, Eric J.; Margulies, Daniel R.; Mirocha, James; Bukur, Marko; Malinoski, Darren; Salim, Ali			Correlating the Blood Alcohol Concentration with Outcome after Traumatic Brain Injury: Too Much Is Not a Bad Thing	AMERICAN SURGEON			English	Article; Proceedings Paper	22nd Annual Scientific Meeting of the Southern California Chapter of the American-College-of-Surgeons	JAN 21-23, 2011	Santa Barbara, CA	Amer Coll Surg			SERUM ETHANOL LEVELS; MORTALITY; LEVEL; RISK; INTOXICATION; ASSOCIATION; SEVERITY; MODERATE; RAT	Although recent evidence suggests a beneficial effect of alcohol for patients with traumatic brain injury (TB!), the level of alcohol that confers the protective effect is unknown. Our objective was to investigate the relationship between admission blood alcohol concentration (BAC) and outcomes in patients with isolated moderate to severe TBI. From 2005 to 2009, the Los Angeles County Trauma Database was queried for all patients >= 14 years of age with isolated moderate to severe TBI and admission serum alcohol levels. Patients were then stratified into four levels based on admission BAC: None (0 mg/dL), low (0-100 mg/dL), moderate (100-230 mg/dL), and high (>= 230 mg/dL). Demographics, patient characteristics, and outcomes were compared across levels. In evaluating 3794 patients, the mortality rate decreased with increasing BAC levels (linear trend P < 0.0001). In determining the relationship between BAC and mortality, multivariable logistic regression analysis demonstrated a high BAC level was significantly protective (adjusted odds ratio 0.55; 95% confidence interval: 0.38-0.8; P = 0.002). In the largest study to date, a high (>= 230 mg/dL) admission BAC was independently associated with improved survival in patients with isolated moderate to severe TBI. Additional research is warranted to investigate the potential therapeutic implications.	[Berry, Cherisse; Ley, Eric J.; Margulies, Daniel R.; Mirocha, James; Bukur, Marko; Malinoski, Darren; Salim, Ali] Cedars Sinai Med Ctr, Dept Surg, Div Trauma & Crit Care, Los Angeles, CA 90048 USA	Salim, A (corresponding author), Cedars Sinai Med Ctr, Dept Surg, Div Trauma & Crit Care, 8700 Beverly Blvd,Suite 8215N, Los Angeles, CA 90048 USA.	ali.salim@cshs.org	Berry, Cherisse/AAO-5701-2020	Bukur, Marko/0000-0002-1850-7147			Albrecht RF, 1998, MAYO CLIN PROC, V73, P629; Alexander S, 2004, J NEUROTRAUM, V21, P575, DOI 10.1089/089771504774129900; Berry C, 2010, AM SURGEON, V76, P1067; CHANDLER LJ, 1993, ALCOHOL CLIN EXP RES, V17, P54, DOI 10.1111/j.1530-0277.1993.tb00726.x; Gottesfeld Z, 2002, J NEUROTRAUM, V19, P317, DOI 10.1089/089771502753594882; HAMILL RW, 1987, ANN NEUROL, V21, P438, DOI 10.1002/ana.410210504; Katada R, 2009, J NEUROTRAUM, V26, P2015, DOI 10.1089/neu.2008.0552; Li GH, 1997, J TRAUMA, V42, P562, DOI 10.1097/00005373-199703000-00032; Li GH, 2001, JAMA-J AM MED ASSOC, V285, P893, DOI 10.1001/jama.285.7.893; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; O'Phelan K, 2008, J TRAUMA, V65, P674, DOI 10.1097/TA.0b013e31817db0a5; Opreanu RC, 2010, J AM COLL SURGEONS, V210, P997, DOI 10.1016/j.jamcollsurg.2010.01.036; Salim A, 2009, J TRAUMA, V67, P697, DOI 10.1097/TA.0b013e3181b5dcf2; Salim A, 2009, ARCH SURG-CHICAGO, V144, P865, DOI 10.1001/archsurg.2009.158; Shandro JR, 2009, J TRAUMA, V66, P1584, DOI 10.1097/TA.0b013e318182af96; Talving P, 2010, J TRAUMA, V68, P357, DOI 10.1097/TA.0b013e3181bb80bf; Taylor AN, 2002, J NEUROTRAUM, V19, P1597, DOI 10.1089/089771502762300256; Tien HCN, 2006, ARCH SURG-CHICAGO, V141, P1185, DOI 10.1001/archsurg.141.12.1185; TULLOH BR, 1994, INJURY, V25, P539, DOI 10.1016/0020-1383(94)90097-3; WOOLF PD, 1990, ALCOHOL CLIN EXP RES, V14, P205, DOI 10.1111/j.1530-0277.1990.tb00473.x; YAMAKAMI I, 1995, J NEUROSURG, V82, P813, DOI 10.3171/jns.1995.82.5.0813	21	41	41	0	8	SOUTHEASTERN SURGICAL CONGRESS	ATLANTA	141 WEST WIEUCA RD, STE B100, ATLANTA, GA 30342 USA	0003-1348			AM SURGEON	Am. Surg.	OCT	2011	77	10					1416	1419					4	Surgery	Surgery	829ED	WOS:000295558600033	22127102				2021-06-18	
J	Feng, K; Hu, YT; Ma, ZZ				Feng, Kang; Hu, Yun Tao; Ma, Zhizhong			Prognostic Indicators for No Light Perception After Open-Globe Injury: Eye Injury Vitrectomy Study	AMERICAN JOURNAL OF OPHTHALMOLOGY			English	Article							MASSIVE SUPRACHOROIDAL HEMORRHAGE; TRAUMATIC CHOROIDAL RUPTURE; PARS-PLANA VITRECTOMY; SYMPATHETIC OPHTHALMIA; OCULAR SURVIVAL; CLASSIFICATION; SURGERY; EPIDEMIOLOGY; MANAGEMENT; SECONDARY	PURPOSE: To describe ocular characteristics, surgical interventions, and anatomic and visual outcomes of traumatized eyes with no light perception (NLP) following open-globe injury and to investigate prognostic predictors for NLP cases after open-globe injury. DESIGN: Interventional case series study. METHODS: Thirty-three traumatized eyes with NLP were selected from the Eye Injury Vitrectomy Study database, a hospital-based multicenter prospective cohort study. Inclusion criteria were NLP cases following open-globe injury with outcomes of anatomic restoration, phthisis bulbi, or enucleation. Exclusion criteria were cases with missing records, undergoing vitrectomy after injury at nonparticipating hospitals, direct optic head injury, endophthalmitis, and hypotonous or silicone oil-sustained eyes. All cases underwent vitreoretinal surgery or enucleation after exploratory surgery and were followed up for at least 6 months. Two outcomes were assessed: favorable outcome (anatomically restored eye globes with light perception [LP] or better vision) and unfavorable outcome (NLP, phthisis bulbi, or enucleation). RESULTS: The following 7 risk factors were significant between the 2 groups: rupture (P = .021); open globe III (P = .046); scleral wound >= 10 mm (P = .001); ciliary body damage (P < .001); severe intraocular hemorrhage (P = .005); closed funnel retinal detachment or retinal prolapse (P = .005); and choroidal damage (P =.001). CONCLUSIONS: These 7 risk factors are possible predictors of poor prognosis. Traumatized eyes with NLP can be anatomically restored with LP or better vision if vitreoretinal surgery is attempted, and a favorable anatomic and visual outcome is increased by having a decreased number of these risk factors. (Am J Ophthalmol 2011;152:654-662. (C) 2011 by Elsevier Inc. All rights reserved.)	[Feng, Kang; Hu, Yun Tao; Ma, Zhizhong] Peking Univ, Hosp 3, Ctr Eye, Beijing 100191, Peoples R China	Ma, ZZ (corresponding author), Peking Univ, Hosp 3, Ctr Eye, Huayuan N St 49, Beijing 100191, Peoples R China.	puh3_yk@bjmu.edu.cn		Feng, Kang/0000-0002-8923-932X	PEKING UNIVERSITY HEALTH SCIENCE CENTER; 211 Evidence-Based Medicine Discipline Groups, Beijing, China [03-9-02]	PUBLICATION OF THIS ARTICLE WAS FUNDED BY A GRANT FROM THE PEKING UNIVERSITY HEALTH SCIENCE CENTER, 211 Evidence-Based Medicine Discipline Groups, Beijing, China (No.03-9-02). The funding organization had no role in the design or conduct of this research. The authors indicate no financial conflict of interest. Involved in design of the study (Z.Z.M.); conduct of the study (K.F., Z.Z.M., Y.T.H.); collection of the data (Z.Z.M., Y.T.H., K.F.); analysis and interpretation of the data (K.F.); and review and approval of the manuscript (Z.Z.M.). This study was approved by the review board/ethics committee of the Peking University Third Hospital. Informed consent was obtained from every patient.	ALBERT DM, 1989, SURV OPHTHALMOL, V34, P1, DOI 10.1016/0039-6257(89)90125-2; Ament CS, 2006, ARCH OPHTHALMOL-CHIC, V124, P957, DOI 10.1001/archopht.124.7.957; Larque-Daza AB, 2010, EUR J OPHTHALMOL, V20, P578; Casson RJ, 2002, CLIN EXP OPHTHALMOL, V30, P15, DOI 10.1046/j.1442-9071.2002.00484.x; COLEMAN DJ, 1995, RETINA-J RET VIT DIS, V15, P312, DOI 10.1097/00006982-199515040-00008; du Toit N, 2008, BRIT J OPHTHALMOL, V92, P61, DOI 10.1136/bjo.2007.120600; Entezari M, 2006, INJURY, V37, P633, DOI 10.1016/j.injury.2006.02.043; Feretis E, 2006, EUR J OPHTHALMOL, V16, P835; FRENKEL REP, 1986, ARCH OPHTHALMOL-CHIC, V104, P1459; Gotzaridis EV, 2003, EYE, V17, P790, DOI 10.1038/sj.eye.6700472; Gurdal C, 2002, OCUL IMMUNOL INFLAMM, V10, P223, DOI 10.1076/ocii.10.3.223.15600; INGRAHAM HJ, 1989, AM J OPHTHALMOL, V108, P670, DOI 10.1016/0002-9394(89)90859-3; Kuhn F, 1996, GRAEF ARCH CLIN EXP, V234, P399, DOI 10.1007/BF00190717; Kuhn F, 2004, INJURY, V35, P690, DOI 10.1016/j.injury.2004.03.008; LAKHANPAL V, 1990, OPHTHALMOLOGY, V97, P1114; Matthews GP, 1998, OPHTHALMIC SURG LAS, V29, P48; Mei HF, 2009, RETINA-J RET VIT DIS, V29, P473, DOI 10.1097/IAE.0b013e318196b189; Morris R, 1999, VITREORETINAL SURG I, P113; Moshfeghi DM, 2000, SURV OPHTHALMOL, V44, P277, DOI 10.1016/S0039-6257(99)00112-5; Pieramici DJ, 1997, AM J OPHTHALMOL, V123, P820, DOI 10.1016/S0002-9394(14)71132-8; Rahman I, 2006, EYE, V20, P1336, DOI 10.1038/sj.eye.6702099; Raman SV, 2004, CAN J OPHTHALMOL, V39, P260, DOI 10.1016/S0008-4182(04)80123-6; Rofail M, 2006, CLIN EXP OPHTHALMOL, V34, P783, DOI 10.1111/j.1442-9071.2006.01309.x; Salehi-Had H, 2009, GRAEF ARCH CLIN EXP, V247, P477, DOI 10.1007/s00417-009-1035-4; Savar A, 2009, AM J OPHTHALMOL, V147, P595, DOI 10.1016/j.ajo.2008.10.017; Schepens C, 1983, RETINAL DETACHMENT A, P1006; Schmidt GW, 2008, OPHTHALMOLOGY, V115, P202, DOI 10.1016/j.ophtha.2007.04.008; Sobaci G, 2000, AM J OPHTHALMOL, V129, P47, DOI 10.1016/S0002-9394(99)00254-8; SPEAKER MG, 1991, OPHTHALMOLOGY, V98, P202; WELCH JC, 1988, OPHTHALMOLOGY, V95, P1202; WOLTER JR, 1988, OPHTHALMIC SURG LAS, V19, P344; Yang SS, 2003, RETINA-J RET VIT DIS, V23, P139, DOI 10.1097/00006982-200304000-00001	32	41	50	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9394			AM J OPHTHALMOL	Am. J. Ophthalmol.	OCT	2011	152	4					654	662		10.1016/j.ajo.2011.04.004			9	Ophthalmology	Ophthalmology	830LF	WOS:000295657800019	21726850				2021-06-18	
J	Robinson, RJ; Bhuta, S				Robinson, Richard J.; Bhuta, Sandeep			Susceptibility-Weighted Imaging of the Brain: Current Utility and Potential Applications	JOURNAL OF NEUROIMAGING			English	Article						Susceptibility-Weighted Imaging; Cerebrovascular disease; Traumatic brain injury; Venous Sinus Thrombosis; Minimum Intensity Projection; Cerebrospinal fluid; Fluid attenuated inversion recovery; Magnetic Resonance Imaging; Diffuse axonal injury; Computed Tomography; Subdural Hematoma; Subarachnoid Hemorrhage; Cerebral amyloid angiopathy; Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy; Developmental Venous Anomalies; Neurodegeneration with brain iron accumulation; Pantothenate kinase associated neurodegeneration; Multiple Sclerosis; Glioblastoma Multiforme; World Health Organization	CEREBRAL AMYLOID ANGIOPATHY; DIFFUSE AXONAL INJURY; MRI; CHILDREN; LESIONS	BACKGROUND AND PURPOSE Susceptibility-Weighted Imaging (SWI) is a relatively new magnetic resonance imaging (MRI) sequence relying on susceptibility differences between adjacent tissues to produce an image. It is extremely sensitive for detection of blood products (hemosiderin, ferritin), deoxygenated blood, calcium, iron, and small vein depiction. Little information is available in the literature to describe common findings seen using this imaging sequence. This article is an comprehensive review of appearances across the spectrum of brain pathology encountered in routine clinical practice. MATERIALS AND METHODS A retrospective review of 400 MRI Brain examinations was performed by one fellowship trained Neuroradiologist with 5 years experience (SB) and one general radiologist (RR). Agreement was by consensus observing normal and pathological imaging features seen in SWI sequences. RESULTS Results are presented as a comprehensive pictorial review highlighting the key imaging findings observed and new directions using SWI. CONCLUSION SWI is an extremely useful adjunct to current MRI sequences of the brain and is advocated for inclusion into routine Neuroimaging protocols.	[Robinson, Richard J.; Bhuta, Sandeep] Griffith Univ, Sch Med, Gold Coast Hosp, Dept Med Imaging, Gold Coast, Qld 4215, Australia	Bhuta, S (corresponding author), Griffith Univ, Sch Med, Gold Coast Hosp, Dept Med Imaging, 108 Nerang St, Gold Coast, Qld 4215, Australia.	sandeepbhuta@gmail.com	S, Bhuta/H-5454-2019	S, Bhuta/0000-0002-7292-9658			Adachi M, 1999, AM J NEURORADIOL, V20, P1500; Babikian T, 2005, PEDIATR NEUROL, V33, P184, DOI 10.1016/j.pediatrneurol.2005.03.015; Boukobza M, 2009, AM J NEURORADIOL, V30, P344, DOI 10.3174/ajnr.A1332; Chastain CA, 2009, J NEUROTRAUM, V26, P1183, DOI 10.1089/neu.2008.0650; Cooper AD, 2008, NEUROLOGY, V71, P382, DOI 10.1212/01.wnl.0000319659.86629.c8; de Souza JM, 2008, AM J NEURORADIOL, V29, P154, DOI 10.3174/ajnr.A0748; DRAYER B, 1986, AM J ROENTGENOL, V147, P103, DOI 10.2214/ajr.147.1.103; Duncan IC, 2005, AM J ROENTGENOL, V184, P1317, DOI 10.2214/ajr.184.4.01841317; Erdag N, 2001, AM J ROENTGENOL, V176, P1319, DOI 10.2214/ajr.176.5.1761319; Fushimi Y, 2010, J NEUROIMAGING, V20, P255, DOI 10.1111/j.1552-6569.2008.00348.x; Gao TL, 2008, NEUROL RES, V30, P272, DOI 10.1179/016164107X251556; Ghostine S, 2009, NEUROPATH APPL NEURO, V35, P116, DOI 10.1111/j.1365-2990.2008.00976.x; Haacke EM, 2007, AM J NEURORADIOL, V28, P316; Haacke EM, 2009, AM J NEURORADIOL, V30, P19, DOI 10.3174/ajnr.A1400; Haacke EM, 2009, J MAGN RESON IMAGING, V29, P537, DOI 10.1002/jmri.21676; HAIMES AB, 1989, AM J ROENTGENOL, V152, P1073, DOI 10.2214/ajr.152.5.1073; Hayflick SJ, 2006, AM J NEURORADIOL, V27, P1230; Kesavadas C, 2008, AJNR Am J Neuroradiol, V29, pe71, DOI 10.3174/ajnr.A1083; Kim HS, 2009, AJNR AM J NEURORADIO; Mittal S, 2009, AM J NEURORADIOL, V30, P232, DOI 10.3174/ajnr.A1461; Pinker K, 2007, AM J NEURORADIOL, V28, P1280, DOI 10.3174/ajnr.A0540; Rauscher A, 2005, AM J NEURORADIOL, V26, P736; Thomas B, 2008, NEURORADIOLOGY, V50, P105, DOI 10.1007/s00234-007-0316-z; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Wu Z, 2009, J MAGN RESON IMAGING, V29, P177, DOI 10.1002/jmri.21617	26	41	47	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1051-2284	1552-6569		J NEUROIMAGING	J. Neuroimaging	OCT	2011	21	4					E189	E204		10.1111/j.1552-6569.2010.00516.x			16	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	834OF	WOS:000295970700001	21281380				2021-06-18	
J	Krajewska, M; You, ZR; Rong, J; Kress, C; Huang, XS; Yang, JS; Kyoda, T; Leyva, R; Banares, S; Hu, Y; Sze, CH; Whalen, MJ; Salmena, L; Hakem, R; Head, BP; Reed, JC; Krajewski, S				Krajewska, Maryla; You, Zerong; Rong, Juan; Kress, Christina; Huang, Xianshu; Yang, Jinsheng; Kyoda, Tiffany; Leyva, Ricardo; Banares, Steven; Hu, Yue; Sze, Chia-Hung; Whalen, Michael J.; Salmena, Leonardo; Hakem, Razqallah; Head, Brian P.; Reed, John C.; Krajewski, Stan			Neuronal Deletion of Caspase 8 Protects against Brain Injury in Mouse Models of Controlled Cortical Impact and Kainic Acid-Induced Excitotoxicity	PLOS ONE			English	Article							PROGRAMMED CELL-DEATH; FOCAL CEREBRAL-ISCHEMIA; C-JUN; HEAD-INJURY; IN-VITRO; ORGANOTYPIC CULTURES; NERVOUS-SYSTEM; JNK ACTIVATION; APOPTOSIS; MICE	Background: Acute brain injury is an important health problem. Given the critical position of caspase 8 at the crossroads of cell death pathways, we generated a new viable mouse line (Ncasp8(-/-)), in which the gene encoding caspase 8 was selectively deleted in neurons by cre-lox system. Methodology/Principal Findings: Caspase 8 deletion reduced rates of neuronal cell death in primary neuronal cultures and in whole brain organotypic coronal slice cultures prepared from 4 and 8 month old mice and cultivated up to 14 days in vitro. Treatments of cultures with recombinant murine TNF alpha (100 ng/ml) or TRAIL (250 ng/mL) plus cyclohexamide significantly protected neurons against cell death induced by these apoptosis-inducing ligands. A protective role of caspase 8 deletion in vivo was also demonstrated using a controlled cortical impact (CCI) model of traumatic brain injury (TBI) and seizure-induced brain injury caused by kainic acid (KA). Morphometric analyses were performed using digital imaging in conjunction with image analysis algorithms. By employing virtual images of hundreds of brain sections, we were able to perform quantitative morphometry of histological and immunohistochemical staining data in an unbiased manner. In the TBI model, homozygous deletion of caspase 8 resulted in reduced lesion volumes, improved post-injury motor performance, superior learning and memory retention, decreased apoptosis, diminished proteolytic processing of caspases and caspase substrates, and less neuronal degeneration, compared to wild type, homozygous cre, and caspase 8-floxed control mice. In the KA model, Ncasp8(-/-) mice demonstrated superior survival, reduced seizure severity, less apoptosis, and reduced caspase 3 processing. Uninjured aged knockout mice showed improved learning and memory, implicating a possible role for caspase 8 in cognitive decline with aging. Conclusions: Neuron-specific deletion of caspase 8 reduces brain damage and improves post-traumatic functional outcomes, suggesting an important role for this caspase in pathophysiology of acute brain trauma.	[Krajewska, Maryla; Rong, Juan; Kress, Christina; Huang, Xianshu; Kyoda, Tiffany; Leyva, Ricardo; Banares, Steven; Sze, Chia-Hung; Reed, John C.; Krajewski, Stan] Sanford Burnham Med Res Inst, La Jolla, CA 92037 USA; [You, Zerong; Yang, Jinsheng; Whalen, Michael J.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Neurosci, Charlestown, MA USA; [Hu, Yue; Head, Brian P.] Univ Calif San Diego, Dept Anesthesiol, La Jolla, CA 92093 USA; [Hu, Yue] VA San Diego Healthcare Syst, San Diego, CA USA; [Salmena, Leonardo; Hakem, Razqallah] Ontario Canc Inst, Dept Med Biophys, Toronto, ON M4X 1K9, Canada	Krajewska, M (corresponding author), Sanford Burnham Med Res Inst, La Jolla, CA 92037 USA.	jreed@sanfordburnham.org; stan@sanfordburnham.org		Hakem, Razq/0000-0001-5948-7931; Salmena, Leonardo/0000-0003-4023-658X	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS36821, CA69381]; DoDUnited States Department of Defense [W81XWH-08-2-0067, W81XWH-07-1-0569]; VA CDA-2; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P01CA069381] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS036821, R01NS064545] Funding Source: NIH RePORTER	Supported by the NIH grants (NS36821 [SK]; CA69381 [JCR]) and DoD grants (W81XWH-08-2-0067 [SK]; W81XWH-07-1-0569 [JCR]); VA CDA-2 [BPH]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahlemeyer B, 2005, J NEUROSCI METH, V149, P110, DOI 10.1016/j.jneumeth.2005.05.022; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bagnoli M, 2010, INT J BIOCHEM CELL B, V42, P210, DOI 10.1016/j.biocel.2009.11.015; Banares S, 2005, GENESIS, V42, P6, DOI 10.1002/gene.20117; Beer R, 2001, J NEUROCHEM, V78, P862, DOI 10.1046/j.1471-4159.2001.00460.x; Beer R, 2000, J CEREBR BLOOD F MET, V20, P669, DOI 10.1097/00004647-200004000-00004; Ben Moshe T, 2008, CYTOKINE GROWTH F R, V19, P209, DOI 10.1016/j.cytogfr.2008.04.012; Bermpohl D, 2007, J CEREB BLOOD FLOW M; Bermpohl D, 2006, J CEREBR BLOOD F MET, V26, P625, DOI 10.1038/sj.jcbfm.9600258; Bredesen DE, 2006, NATURE, V443, P796, DOI 10.1038/nature05293; Casha S, 2005, EXP NEUROL, V196, P390, DOI 10.1016/j.expneurol.2005.08.020; Cho S, 2007, CURR NEUROPHARMACOL, V5, P19, DOI 10.2174/157015907780077105; Chowdhury I, 2008, COMP BIOCHEM PHYS B, V151, P10, DOI 10.1016/j.cbpb.2008.05.010; Collombet JM, 2006, NEUROSCI LETT, V398, P337, DOI 10.1016/j.neulet.2006.01.029; Djavaheri-Mergny M, 2010, ONCOGENE, V29, P1717, DOI 10.1038/onc.2009.519; Escartin C, 2008, MOL NEUROBIOL, V38, P231, DOI 10.1007/s12035-008-8043-y; Eskelinen EL, 2009, BBA-MOL CELL RES, V1793, P664, DOI 10.1016/j.bbamcr.2008.07.014; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; Falschlehner C, 2007, INT J BIOCHEM CELL B, V39, P1462, DOI 10.1016/j.biocel.2007.02.007; Feng YZ, 2003, EUR J PHARMACOL, V481, P169, DOI 10.1016/j.ejphar.2003.09.016; FERKANY JW, 1984, NATURE, V308, P561, DOI 10.1038/308561a0; Finley M, 2004, BRAIN RES, V1001, P125, DOI 10.1016/j.brainres.2003.12.009; Fox GB, 1998, J NEUROSCI RES, V53, P718, DOI 10.1002/(SICI)1097-4547(19980915)53:6<718::AID-JNR9>3.0.CO;2-8; Fujikawa DG, 2005, EPILEPSY BEHAV, V7, pS3, DOI 10.1016/j.yebeh.2005.08.003; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Gervais FG, 2002, NAT CELL BIOL, V4, P95, DOI 10.1038/ncb735; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; Hanger DP, 2009, TRENDS MOL MED, V15, P112, DOI 10.1016/j.molmed.2009.01.003; Harrison DC, 2001, MOL BRAIN RES, V89, P133, DOI 10.1016/S0169-328X(01)00058-4; Henshall DC, 2001, P NATL ACAD SCI USA, V98, P15318; Hou W, 2010, AUTOPHAGY, V6, P891, DOI 10.4161/auto.6.7.13038; Igarashi T, 2001, EXP NEUROL, V172, P332, DOI 10.1006/exnr.2001.7820; Johnson V. E., 2010, NAT REV NEUROSCI; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; Kim YE, 2010, NAT PROTOC, V5, P1396, DOI 10.1038/nprot.2010.101; Krajewska M, 2008, AM J PATHOL, V172, P1312, DOI 10.2353/ajpath.2008.070594; Krajewska M, 2009, J HISTOCHEM CYTOCHEM, V57, P649, DOI 10.1369/jhc.2009.952812; Krajewski S, 2009, METHODS MOL BIOL, V536, P473, DOI 10.1007/978-1-59745-542-8_48; Kumar S, 1997, INT J BIOCHEM CELL B, V29, P393, DOI 10.1016/S1357-2725(96)00146-X; Li SH, 2000, MOL CELL NEUROSCI, V16, P168, DOI 10.1006/mcne.2000.0858; Li TF, 2006, BRAIN RES, V1098, P204, DOI 10.1016/j.brainres.2006.04.131; Liu CL, 2008, J CEREBR BLOOD F MET, V28, P674, DOI 10.1038/sj.jcbfm.9600587; Liu D, 2009, NEUROMOL MED, V11, P28, DOI 10.1007/s12017-009-8058-1; Liu J, 2005, CELL RES, V15, P36, DOI 10.1038/sj.cr.7290262; Love S, 2003, PROG NEURO-PSYCHOPH, V27, P267, DOI 10.1016/S0278-5846(03)00022-8; MATUS A, 1988, ANNU REV NEUROSCI, V11, P29, DOI 10.1146/annurev.neuro.11.1.29; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Neumann J, 2006, FASEB J, V20, P714, DOI 10.1096/fj.05-4882fje; Ng FWH, 1997, J CELL BIOL, V139, P327, DOI 10.1083/jcb.139.2.327; Okuno S, 2004, J NEUROSCI, V24, P7879, DOI 10.1523/JNEUROSCI.1745-04.2004; OLNEY JW, 1989, SCIENCE, V244, P1360, DOI 10.1126/science.2660263; Paxinos G., 2001, MOUSE BRAIN STEREOTA; Qiu JH, 2002, J NEUROSCI, V22, P3504; Romito-DiGiacomo RR, 2007, J NEUROSCI, V27, P8496, DOI 10.1523/JNEUROSCI.1008-07.2007; ROSEN GD, 1990, J NEUROSCI METH, V35, P115, DOI 10.1016/0165-0270(90)90101-K; Roth W, 2003, CELL DEATH DIFFER, V10, P1178, DOI 10.1038/sj.cdd.4401287; Ruifrok AC, 2001, ANAL QUANT CYTOL, V23, P291; Salmena L, 2003, GENE DEV, V17, P883, DOI 10.1101/gad.1063703; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Staal JA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022040; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Stoica B, 2009, NEUROTHERAPEUTICS, V6, P14, DOI 10.1016/j.nurt.2008.10.029; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; Sugawara T, 2002, J NEUROTRAUM, V19, P85, DOI 10.1089/089771502753460268; Taoufik E, 2007, J NEUROSCI, V27, P6633, DOI 10.1523/JNEUROSCI.1091-07.2007; Turk B, 2002, CURR PHARM DESIGN, V8, P1623, DOI 10.2174/1381612023394124; Unal-Cevik I, 2004, BRAIN RES, V1015, P169, DOI 10.1016/j.brainres.2004.04.032; Vandenabeele Peter, 2006, Sci STKE, V2006, ppe44, DOI 10.1126/stke.3582006pe44; Vandenabeele P, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3115re4; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Velier JJ, 1999, J NEUROSCI, V19, P5932, DOI 10.1523/JNEUROSCI.19-14-05932.1999; Vink R, 2009, NEUROTHERAPEUTICS, V6, P28, DOI 10.1016/j.nurt.2008.10.036; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2; Wullaert A, 2006, BIOCHEM PHARMACOL, V72, P1090, DOI 10.1016/j.bcp.2006.07.003; Xiang ZM, 2000, J NEUROSCI METH, V98, P145, DOI 10.1016/S0165-0270(00)00197-7; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Yoon JJ, 2010, BRAIN RES, V1353, P194, DOI 10.1016/j.brainres.2010.07.005; You ZR, 2008, J CEREBR BLOOD F MET, V28, P1564, DOI 10.1038/jcbfm.2008.44; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645; Yu L, 2006, P NATL ACAD SCI USA, V103, P4952, DOI 10.1073/pnas.0511288103; Zemlan FP, 1999, J NEUROCHEM, V72, P741, DOI 10.1046/j.1471-4159.1999.0720741.x; Zhang H, 2000, P NATL ACAD SCI USA, V97, P2597, DOI 10.1073/pnas.97.6.2597; Zhang JH, 2001, BIOCHEM BIOPH RES CO, V285, P1143, DOI 10.1006/bbrc.2001.5313; Zhang XP, 2003, FASEB J, V17, P1367, DOI 10.1096/fj.02-1067fje; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	89	41	44	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 16	2011	6	9							e24341	10.1371/journal.pone.0024341			21	Multidisciplinary Sciences	Science & Technology - Other Topics	824BI	WOS:000295173800020	21957448	DOAJ Gold, Green Published			2021-06-18	
J	Lustenberger, T; Inaba, K; Barmparas, G; Talving, P; Plurad, D; Lam, L; Konstantinidis, A; Demetriades, D				Lustenberger, Thomas; Inaba, Kenji; Barmparas, Galinos; Talving, Peep; Plurad, David; Lam, Lydia; Konstantinidis, Agathoklis; Demetriades, Demetrios			Ethanol Intoxication Is Associated with a Lower Incidence of Admission Coagulopathy in Severe Traumatic Brain Injury Patients	JOURNAL OF NEUROTRAUMA			English	Article						adrenergic response; alcohol; coagulopathy; morbidity; mortality; severe traumatic brain injury	MOTOR-VEHICLE CRASHES; ALCOHOL-CONSUMPTION; PENTOBARBITAL COMA; HEAD TRAUMA; OUTCOMES; MORTALITY; FIBRINOLYSIS; RISK; PREVALENCE; FIBRINOGEN	The aim of this study was to determine the impact of ethanol (ETOH) on the incidence of severe traumatic brain injury (sTBI)-associated coagulopathy and to examine the effect of ETOH on in-hospital outcomes in patients sustaining sTBI. Patients admitted to the surgical intensive care unit from June 2005 through December 2008 following sTBI, defined as a head Abbreviated Injury Scale (AIS) score >= 3, were retrospectively identified. Patients with a chest, abdomen, or extremity AIS score > 3 were excluded to minimize the impact of extracranial injuries. Criteria for sTBI-associated coagulopathy included thrombocytopenia and/or elevated International Normalized Ratio (INR) and/or prolonged activated partial thromboplastin time (aPTT). The incidence of admission coagulopathy, in-hospital complications, and mortality were compared between patients who were ETOH positive [ETOH (+)] and ETOH negative [ETOH (-)]. During the study period, there were 439 patients with ETOH levels available for analysis. Overall, 46.5% (n = 204) of these patients were ETOH (+), while 53.5% (n = 235) were ETOH (-). Coagulopathy was significantly less frequent in the ETOH (+) patients compared to their ETOH (-) counterparts (5.4% versus 15.3%; adjusted p < 0.001). In the forward logistic regression analysis, a positive ETOH level proved to be an independent protective factor for admission coagulopathy [OR (95% CI) = 0.24 (0.10,0.54; p = 0.001]. ETOH (+) patients had a significantly lower in-hospital mortality rate than ETOH (-) patients [9.8% versus 16.6%; adjusted p = 0.011; adjusted OR (95% CI) = 0.39 (0.19,0.81)]. For brain-injured patients arriving alive to the hospital, ETOH intoxication is associated with a significantly lower incidence of early coagulopathy and in-hospital mortality. Further research to establish the pathophysiologic mechanisms underlying any potential beneficial effect of ETOH on the coagulation system following sTBI is warranted.	[Lustenberger, Thomas; Inaba, Kenji; Barmparas, Galinos; Talving, Peep; Plurad, David; Lam, Lydia; Konstantinidis, Agathoklis; Demetriades, Demetrios] Univ So Calif, Keck Sch Med, Div Acute Care Surg Trauma Emergency Surg & Surg, Los Angeles, CA 90033 USA	Inaba, K (corresponding author), Univ So Calif, Keck Sch Med, Div Acute Care Surg Trauma Emergency Surg & Surg, Los Angeles Cty Gen Hosp LAC USC, 1200 N State St,IPT,C5L100, Los Angeles, CA 90033 USA.	kinaba@surgery.usc.edu	Talving, Peep/G-8621-2015; INABA, KENJI/AAC-8532-2020; Talving, Peep/E-6015-2013; Barmparas, Galinos/L-6530-2019	Talving, Peep/0000-0002-9741-2073; 			Brooks N, 1989, Brain Inj, V3, P235, DOI 10.3109/02699058909029638; Cormio M, 1999, J NEUROTRAUM, V16, P927, DOI 10.1089/neu.1999.16.927; Dash PK, 2004, J NEUROTRAUM, V21, P1573, DOI 10.1089/neu.2004.21.1573; de Lange DW, 2004, ALCOHOL CLIN EXP RES, V28, P1562, DOI 10.1097/01.ALC.0000141808.62230.75; Demetriades D, 2004, J AM COLL SURGEONS, V199, P687, DOI 10.1016/j.jamcollsurg.2004.07.017; Dunser Martin W, 2009, J Intensive Care Med, V24, P293, DOI 10.1177/0885066609340519; El-Sayed MS, 2000, BLOOD COAGUL FIBRIN, V11, P359, DOI 10.1097/00001721-200006000-00007; Engstrom M, 2006, BLOOD COAGUL FIBRIN, V17, P661, DOI 10.1097/MBC.0b013e32801010b7; Erstad B L, 1999, Am J Ther, V6, P299; ERSTAD BL, 1993, ANN PHARMACOTHER, V27, P889, DOI 10.1177/106002809302700716; Field CA, 2001, J TRAUMA, V50, P13, DOI 10.1097/00005373-200101000-00002; Foley N, 2008, J NEUROTRAUM, V25, P1415, DOI 10.1089/neu.2008.0628; Grenett HE, 2000, THROMB RES, V97, P247, DOI 10.1016/S0049-3848(99)00172-3; Janis LS, 1998, J NEUROTRAUM, V15, P105, DOI 10.1089/neu.1998.15.105; Kelly DF, 2000, J NEUROTRAUM, V17, P261, DOI 10.1089/neu.2000.17.261; Kelly DF, 1997, J NEUROSURG, V86, P876, DOI 10.3171/jns.1997.86.5.0876; Kiviniemi TO, 2009, EUR J CARDIOV PREV R, V16, P161, DOI 10.1097/HJR.0b013e328320ad1b; Lacoste L, 2001, AM J CARDIOL, V87, P82, DOI 10.1016/S0002-9149(00)01277-7; Li GH, 1997, J TRAUMA, V42, P562, DOI 10.1097/00005373-199703000-00032; LUNA GK, 1984, J TRAUMA, V24, P695, DOI 10.1097/00005373-198408000-00001; Marshall GT, 2010, J TRAUMA, V69, P275, DOI 10.1097/TA.0b013e3181de74c7; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Parry-Jones BL, 2006, NEUROPSYCHOL REHABIL, V16, P537, DOI 10.1080/09602010500231875; Plurad D, 2006, J AM COLL SURGEONS, V202, P919, DOI 10.1016/j.jamcollsurg.2006.02.024; Plurad D, 2010, J EMERG MED, V38, P12, DOI 10.1016/j.jemermed.2007.09.048; PORIES SE, 1992, J TRAUMA, V32, P60, DOI 10.1097/00005373-199201000-00013; Salim A, 2009, J TRAUMA, V67, P697, DOI 10.1097/TA.0b013e3181b5dcf2; Salim A, 2009, ARCH SURG-CHICAGO, V144, P865, DOI 10.1001/archsurg.2009.158; Shandro JR, 2009, J TRAUMA, V66, P1584, DOI 10.1097/TA.0b013e318182af96; Stein SC, 2004, NEUROCRIT CARE, V1, P479, DOI 10.1385/NCC:1:4:479; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; Tabengwa EM, 2002, ALCOHOL CLIN EXP RES, V26, P1121, DOI 10.1097/01.ALC.0000024358.83124.6B; Talving P, 2010, J TRAUMA, V68, P357, DOI 10.1097/TA.0b013e3181bb80bf; Tien HCN, 2006, ARCH SURG-CHICAGO, V141, P1185, DOI 10.1001/archsurg.141.12.1185; van de Wiel A, 2001, EUR J CLIN INVEST, V31, P164, DOI 10.1046/j.1365-2362.2001.00773.x; White CL, 2009, J TRAUMA, V67, P508, DOI 10.1097/TA.0b013e3181b2519f; Wilde EA, 2004, J NEUROTRAUM, V21, P137, DOI 10.1089/089771504322778604; WOOLF PD, 1990, ALCOHOL CLIN EXP RES, V14, P917, DOI 10.1111/j.1530-0277.1990.tb01838.x; WOOLF PD, 1991, J TRAUMA, V31, P1271, DOI 10.1097/00005373-199109000-00012; WOOLF PD, 1990, ALCOHOL CLIN EXP RES, V14, P205, DOI 10.1111/j.1530-0277.1990.tb00473.x; Zink BJ, 1996, ALCOHOL CLIN EXP RES, V20, P1518, DOI 10.1111/j.1530-0277.1996.tb01693.x	41	41	43	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2011	28	9					1699	1706		10.1089/neu.2011.1866			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	821AK	WOS:000294947000003	21902539				2021-06-18	
J	Catroppa, C; Anderson, V; Godfrey, C; Rosenfeld, JV				Catroppa, Cathy; Anderson, Vicki; Godfrey, Celia; Rosenfeld, Jeffrey V.			Attentional skills 10 years post-paediatric traumatic brain injury (TBI)	BRAIN INJURY			English	Article						Traumatic brain injury; paediatric; attentional outcome	HEAD-INJURY; SUSTAINED ATTENTION; SELF-REGULATION; FRONTAL LOBES; CHILDREN; CHILDHOOD; TERM; RECOVERY; SEVERITY; DEFICITS	Objective: To date no study has reported findings regarding attentional deficits following pre-school paediatric traumatic brain injury (TBI), as long as 10 years post-injury. It was predicted that more severe TBI would be associated with generalized deficits at 10 years post-TBI, particularly for skills not mastered at time of injury. Research design: The sample comprised 40 prospectively-recruited children (42%% of the original sample) who had sustained a mild, moderate or severe traumatic brain injury (TBI) between the ages of 1--7 years and 19 non-injured control participants. Children were assessed 10 years post-TBI, with a focus on measures of attentional ability. Outcomes/results: While attentional deficits were not evident across all components of attentional ability, both early- and later-established attention skills were compromised, particularly following severe TBI. Environmental predictors were generally not successful predictors of attentional outcome at 10 years post-TBI. Age at injury and acute IQ were identified as contributing to attention at 10 years. Conclusions/implications: The present study shows that attentional deficits do occur and persist to 10 years following serious TBI. Clinicians may be able to screen for such deficits and so intervene in order to prevent or lessen the consequences of such difficulties.	[Catroppa, Cathy] Royal Childrens Hosp, Dept Psychol, Parkville, Vic 3052, Australia; [Catroppa, Cathy; Anderson, Vicki; Godfrey, Celia] Australian Ctr Child Neuropsychol Studies, Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Catroppa, Cathy; Anderson, Vicki] Univ Melbourne, Melbourne, Vic 3010, Australia; [Rosenfeld, Jeffrey V.] Alfred Hosp, Melbourne, Vic, Australia; [Rosenfeld, Jeffrey V.] Monash Univ, Melbourne, Vic 3004, Australia	Catroppa, C (corresponding author), Royal Childrens Hosp, Dept Psychol, Flemington Rd, Parkville, Vic 3052, Australia.	cathy.catroppa@mcri.edu.au	Rosenfeld, Jeffrey V/B-7249-2011				Anderson V, 1998, NEUROPSYCHOL REHABIL, V8, P283; Anderson V, 2005, BRAIN INJURY, V19, P699, DOI 10.1080/02699050400025281; Anderson V, 2005, BRAIN INJURY, V19, P459, DOI 10.1080/02699050400004823; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson VA, 2001, DEV NEUROPSYCHOL, V20, P385, DOI 10.1207/S15326942DN2001_5; Betts J, 2006, CHILD NEUROPSYCHOL, V12, P205, DOI 10.1080/09297040500488522; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Catale C, 2009, J CLIN EXP NEUROPSYC, V31, P331, DOI 10.1080/13803390802134616; Catroppa C, 1999, J INT NEUROPSYCH SOC, V5, P48, DOI 10.1017/S1355617799511077; Catroppa C, 2005, J INT NEUROPSYCH SOC, V11, P84, DOI 10.1017/S1355617705050101; Catroppa C, 2003, DEV NEUROPSYCHOL, V23, P359, DOI 10.1207/S15326942DN2303_3; Catroppa C, 1999, CHILD NEUROPSYCHOL, V5, P251, DOI 10.1076/0929-7049(199912)05:04;1-R;FT251; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; COOLEY EL, 1990, DEV NEUROPSYCHOL, V6, P239, DOI 10.1080/87565649009540465; Daniel A. E., 1983, POWER PRIVILEGE PRES; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Dennis M, 1995, TRAUMATIC HEAD INJUR; Dennis M, 1989, CLIN NEUOROPSYCHOLOG; Ewing-Cobbs L, 2006, J NEUROSURG, V105, P287, DOI 10.3171/ped.2006.105.4.287; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; Ganesalingam K, 2007, J INT NEUROPSYCH SOC, V13, P298, DOI 10.1017/S1355617707070324; Ganesalingam K, 2006, J INT NEUROPSYCH SOC, V12, P609, DOI 10.1017/S1355617706060796; Gioia G.A., 2000, BEHAV RATING INVENTO; Gogtay N, 2010, BRAIN COGNITION, V72, P6, DOI 10.1016/j.bandc.2009.08.009; Goldstein FC, 1992, COGNITIVE DISORDERS; Gronwall D, 1997, J Int Neuropsychol Soc, V3, P592; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; HAAS JF, 1987, J NEUROL NEUROSUR PS, V50, P52, DOI 10.1136/jnnp.50.1.52; HALPERIN JM, 1991, INT J NEUROSCI, V58, P171, DOI 10.3109/00207459108985433; Harrison P., 2003, ADAPTIVE BEHAV ASSES; Hsiang JNK, 1997, J NEUROSURG, V87, P234, DOI 10.3171/jns.1997.87.2.0234; KAIL R, 1986, CHILD DEV, V57, P969, DOI 10.2307/1130372; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; Kramer ME, 2008, J INT NEUROPSYCH SOC, V14, P424, DOI 10.1017/S1355617708080545; Lachar D, 1992, PERSONALITY INVENTOR; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P1294, DOI 10.1136/jnnp.51.10.1294; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; Mangeot S, 2002, CHILD NEUROPSYCHOL, V8, P271, DOI 10.1076/chin.8.4.271.13503; Manly T., 1999, TEST EVERYDAY ATTENT; MCKAY KE, 1994, DEV NEUROPSYCHOL, V10, P121, DOI 10.1080/87565649409540572; MIRSKY A F, 1991, Neuropsychology Review, V2, P109, DOI 10.1007/BF01109051; Muscara F, 2008, DEV NEUROPSYCHOL, V33, P623, DOI 10.1080/87565640802171162; Muscara F, 2009, NEUROPSYCHOL REHABIL, V19, P541, DOI 10.1080/09602010802365223; Noller P, 1988, ICPS FAMILY FU UNPUB; Park BS, 2009, APPL NEUROPSYCHOL, V16, P1, DOI 10.1080/09084280802636371; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; Power T, 2007, BRAIN INJURY, V21, P279, DOI 10.1080/02699050701253095; Rebok GW, 1997, CHILD NEUROPSYCHOL, V3, P28, DOI 10.1080/09297049708401366; Reynolds C.R., 1992, BEHAV ASSESSMENT SYS; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; RUIJS MBM, 1994, NEUROPEDIATRICS, V25, P73, DOI 10.1055/s-2008-1071589; Sisk CL, 2005, FRONT NEUROENDOCRIN, V26, P163, DOI 10.1016/j.yfrne.2005.10.003; Sparrow S., 1984, VINELAND ADAPTIVE BE; Stein SC, 1995, PEDIATR NEUROSURG, V23, P299, DOI 10.1159/000120975; Stuss DT, 2006, J INT NEUROPSYCH SOC, V12, P261, DOI 10.1017/S1355617706060358; Stuss DT, 1995, STRUCTURE FUNCTION H; Taylor GH, 1992, ADV CLIN NEUROPSYCHO, V1, P50; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TEASDALE G, 1974, LANCET, V2, P81; Timmermans SR, 1991, COGNITIVE REHABILITA, V9, P26; Van Heughten CM, 2008, BRAIN INJURY, V20, P895; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; Wassenberg R, 2004, BRAIN INJURY, V18, P751, DOI 10.1080/02699050410001671775; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wechsler D., 1991, MANUAL WECHSLER INTE; Yeates KO, 2005, J AM ACAD CHILD PSY, V44, P574, DOI 10.1097/01.chi.0000159947.50523.64; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093	68	41	41	1	12	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	AUG	2011	25	9					858	869		10.3109/02699052.2011.589794			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	790CY	WOS:000292567300006	21714623				2021-06-18	
J	Cao, C; Slobounov, S				Cao, Cheng; Slobounov, Semyon			Application of a novel measure of EEG non-stationarity as 'Shannon-entropy of the peak frequency shifting' for detecting residual abnormalities in concussed individuals	CLINICAL NEUROPHYSIOLOGY			English	Article						EEG; Non-stationarity; Mild traumatic brain injury (mTBI)	POSTURAL CONTROL; CEREBRAL CONCUSSION; SPECTRAL-ANALYSIS; BRAIN-INJURY; COLLEGIATE; DEFICITS	Objective: The aim of this report was to propose a novel measure of non-stationarity of EEG signals, named Shannon-entropy of the peak frequency shifting (SEPFS). The feasibility of this method was documented comparing this measure with traditional time domain assessment of non-stationarity and its application to EEG data sets obtained from student-athletes before and after suffering a single episode of mild traumatic brain injury (mTBI) with age-matched normal controls. Methods: Instead of assessing the power density distribution on the time-frequency plane, like previously proposed measures of signal non-stationarity, this new measure is based on the shift of the dominant frequency of the EEG signal over time. We applied SEPFS measure to assess the properties of EEG non-stationarity in subjects before and shortly after they suffered mTBI. Student-athletes at high risk for mTBI (n = 265) were tested prior to concussive episodes as a baseline. From this subject pool, 30 athletes who suffered from mTBI were retested on day 30 post-injury. Additional subjects pool (student-athletes without history of concussion, n = 30) were recruited and test-re-tested within the same 30 day interval. Thirty-two channels EEG signals were acquired in sitting eyes closed condition. Results: The results showed that the SEPFS values significantly decreased in subjects suffering from mTBI. Specifically, reduced EEG non-stationarity was observed in occipital, temporal and central brain areas, indicating the possibility of residual brain dysfunctions in concussed individuals. A similar but less statistically significant trend was observed using traditional time domain analysis of EEG non-stationarity. Conclusions: The proposed measure has at least two merits of interest: (1) it is less affected by the limited resolution of time-frequency representation of the EEG signal; (2) it takes into account the neural characteristics of the EEG signal that have not been considered in previously proposed measures of non-stationarity. Significance: This new method may potentially be used as a complementary tool to assess the alteration of brain functions as a result of mTBI. Published by Elsevier Ltd. on behalf of International Federation of Clinical Neurophysiology.	[Cao, Cheng; Slobounov, Semyon] Penn State Univ, Dept Kinesiol, University Pk, PA 16802 USA	Slobounov, S (corresponding author), Penn State Univ, Dept Kinesiol, 19 Recreat Bldg, University Pk, PA 16802 USA.	sms18@psu.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 NS056227-01A2]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS056227] Funding Source: NIH RePORTER	This study was supported by NIH Grant RO1 NS056227-01A2 "Identification of Athletes at Risk for Traumatic Brain Injury".	BERGER H, 1969, ELECTROENCEPHALOGR S, V28; BIGLER E, 2010, DIFFUSION TENSOR IMA; Bluml S, 2006, FOUNDATIONS OF SPORT-RELATED BRAIN INJURIES, P197, DOI 10.1007/0-387-32565-4_9; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Cantu R, 2006, Foundations of Sport-Related Brain Injuries, P87, DOI 10.1007/0-387-32565-4_5; Cao C, 2010, IEEE T NEUR SYS REH, V18, P11, DOI 10.1109/TNSRE.2009.2027704; Cao C, 2008, IEEE T NEUR SYS REH, V16, P327, DOI 10.1109/TNSRE.2008.918422; Cavanaugh JT, 2006, J ATHL TRAINING, V41, P305; Cavanaugh JT, 2005, SPORTS MED, V35, P935, DOI 10.2165/00007256-200535110-00002; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Delaney JS, 2006, CLIN J SPORT MED, V16, P162, DOI 10.1097/00042752-200603000-00013; Delorme A, 2004, J NEUROSCI METH, V134, P9, DOI 10.1016/j.jneumeth.2003.10.009; Gabor D., 1946, Journal of the Institution of Electrical Engineers. III. Radio and Communication Engineering, V93, P429; Goryunova A V, 2007, Neurosci Behav Physiol, V37, P761, DOI 10.1007/s11055-007-0079-3; GROSSMANN A, 1984, SIAM J MATH ANAL, V15, P723, DOI 10.1137/0515056; Holschneider Daniel P., 1995, Brain Topography, V8, P169, DOI 10.1007/BF01199780; Klem G H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P3; Klimesch W, 1999, BRAIN RES REV, V29, P169, DOI 10.1016/S0165-0173(98)00056-3; Levin HS, 2003, BRAIN INJURY, V17, P665, DOI 10.1080/0269905031000107151; Li XL, 2005, J NEURAL ENG, V2, P11, DOI 10.1088/1741-2560/2/2/002; Mantini D, 2007, P NATL ACAD SCI USA, V104, P13170, DOI 10.1073/pnas.0700668104; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; Meyer Y., 1993, SIAM; Nuwer MR, 2005, CLIN NEUROPHYSIOL, V116, P2001, DOI 10.1016/j.clinph.2005.05.008; Ptito A, 2007, NEUROREHABILITATION, V22, P217; Randolph C, 2001, J ATHL TRAINING, V36, P288; RANDOLPH C, 1988, NEUROPSYCHOBIOLOGY, V20, P43, DOI 10.1159/000118471; Slobounov S, 2005, NEUROSCI LETT, V383, P251, DOI 10.1016/j.neulet.2005.04.039; Slobounov S, 2002, CLIN NEUROPHYSIOL, V113, P185, DOI 10.1016/S1388-2457(01)00737-4; SLOBOUNOV S, 2006, FDN SPORT RELATED BR; Slobounov S, 2008, CLIN NEUROPHYSIOL, V119, P281, DOI 10.1016/j.clinph.2007.10.006; Slobounov S, 2007, NEUROSURGERY, V61, P338, DOI 10.1227/01.NEU.0000280001.03578.FF; Slobounov S, 2006, CYBERPSYCHOL BEHAV, V9, P188, DOI 10.1089/cpb.2006.9.188; Slobounov S, 2006, NEUROSURGERY, V59, P134, DOI 10.1227/01.NEU.0000219197.33182.3F; Slobounov S, 2009, CLIN NEUROPHYSIOL, V120, P862, DOI 10.1016/j.clinph.2009.03.009; Slobounov SM, 2010, EXP BRAIN RES, V202, P341, DOI 10.1007/s00221-009-2141-6; TEBANO MT, 1988, ELECTROEN CLIN NEURO, V70, P185, DOI 10.1016/0013-4694(88)90118-6; THATCHER RW, 1989, ELECTROEN CLIN NEURO, V73, P94, DOI 10.1016/0013-4694(89)90188-0; Tong S, 2003, P ANN INT IEEE EMBS, V25, P2570; TONG S, 2007, IEEE T BIOMED ENG, V54, P129; Trouillas P, 1997, J NEUROL SCI, V145, P205, DOI 10.1016/S0022-510X(96)00231-6	42	41	42	2	9	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1388-2457	1872-8952		CLIN NEUROPHYSIOL	Clin. Neurophysiol.	JUL	2011	122	7					1314	1321		10.1016/j.clinph.2010.12.042			8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	770PZ	WOS:000291102300009	21216191	Green Accepted			2021-06-18	
J	Reeves, RR; Panguluri, RL				Reeves, Roy R.; Panguluri, Rajeev L.			Neuropsychiatric Complications of Traumatic Brain Injury	JOURNAL OF PSYCHOSOCIAL NURSING AND MENTAL HEALTH SERVICES			English	Article							POSTTRAUMATIC-STRESS-DISORDER; PSYCHIATRIC-DISORDERS; MAJOR DEPRESSION; HEAD-INJURIES; SEQUELAE; SUICIDE; INDIVIDUALS; MANAGEMENT; MORTALITY; SECONDARY	Traumatic brain injury (TBI) may be defined as any extracranial mechanical force to the brain that results in any period of loss of consciousness, any loss of memory for events immediately before or after the event, or any alteration in mental status at the time of the event. The major causes are automobile accidents, falls, sporting injuries, and assaults. Many soldiers returning from combat in Afghanistan and Iraq have also experienced TBI. This article provides an overview of the neuropsychiatric complications of TBI, including impairment of consciousness, posttraumatic amnesia, cognitive disorders and dementia, posttraumatic epilepsy, aphasia, depression, mania, psychosis, anxiety disorders, personality changes, aggression, behavioral dyscontrol, fatigue/apathy, and increased risk of suicide. Discussion will focus primarily on issues affecting mental health clinicians. Because mental health providers are more involved in care of chronic issues related to TBI, these issues will be discussed in more detail, although acute neuropsychiatric complications of TBI will be briefly explained.	[Reeves, Roy R.; Panguluri, Rajeev L.] GV Sonny Montgomery VA Med Ctr, Jackson, MS 39216 USA; [Reeves, Roy R.; Panguluri, Rajeev L.] Univ Mississippi, Sch Med, Jackson, MS 39216 USA	Reeves, RR (corresponding author), GV Sonny Montgomery VA Med Ctr, 11M,1500 E Woodrow Wilson Dr, Jackson, MS 39216 USA.	roy.reeves@va.gov					American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Bruns JJ, 2009, MT SINAI J MED, V76, P129, DOI 10.1002/msj.20101; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Chew E, 2009, J REHABIL RES DEV, V46, P851, DOI 10.1682/JRRD.2008.09.0120; Deb S, 1999, AM J PSYCHIAT, V156, P374; DUFFY JD, 1994, J NEUROPSYCH CLIN N, V6, P379; Epstein Richard S., 1994, P285; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Flanagan S, 1999, MT SINAI J MED, V66, P152; Fleminger S, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003299.pub2; Fujii D, 2002, J NEUROPSYCH CLIN N, V14, P130, DOI 10.1176/appi.neuropsych.14.2.130; Gavett BE, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt42; Graham DP, 2008, ANN NY ACAD SCI, V1141, P148, DOI 10.1196/annals.1441.029; Guerreiro DF, 2009, BRAIN INJURY, V23, P358, DOI 10.1080/02699050902800918; Harrison-Felix C, 2006, J HEAD TRAUMA REHAB, V21, P22, DOI 10.1097/00001199-200601000-00003; Hesdorffer DC, 2009, J HEAD TRAUMA REHAB, V24, P452, DOI 10.1097/HTR.0b013e3181c133fd; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Jellinger KA, 2004, CURR OPIN NEUROL, V17, P719, DOI 10.1097/00019052-200412000-00012; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1993, AM J PSYCHIAT, V150, P916; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; Kavanagh DO, 2010, CASE REP MED, V2010, DOI 10.1155/2010/678060; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; Khan F, 2003, MED J AUSTRALIA, V178, P290, DOI 10.5694/j.1326-5377.2003.tb05199.x; Kharatishvili I, 2010, CURR OPIN NEUROL, V23, P183, DOI 10.1097/WCO.0b013e32833749e4; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; Kosch Y, 2010, BRAIN INJURY, V24, P479, DOI 10.3109/02699051003610417; Lane-Brown AT, 2009, NEUROPSYCHOL REHABIL, V19, P481, DOI 10.1080/09602010902949207; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Malec JF, 2010, ARCH PHYS MED REHAB, V91, P1087, DOI 10.1016/j.apmr.2010.04.002; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; Nakase-Richardson R, 2009, NEUROLOGY, V73, P1120, DOI 10.1212/WNL.0b013e3181bacf34; Opreanu RC, 2010, J AM COLL SURGEONS, V210, P997, DOI 10.1016/j.jamcollsurg.2010.01.036; Rao V, 2000, PSYCHOSOMATICS, V41, P95, DOI 10.1176/appi.psy.41.2.95; Rao V, 2010, J NEUROPSYCH CLIN N, V22, P166, DOI 10.1176/appi.neuropsych.22.2.166; Rapoport M, 2002, NEUROPSY NEUROPSY BE, V15, P123, DOI 10.1097/01.WNN.0000016801.80266.36; Reeves RR, 2009, TERROR HOT SPOTS CON, P105; Ropper AH, 2008, HARRISONS PRINCIPLES, P2596; Sachdev P, 2001, PSYCHOL MED, V31, P231, DOI 10.1017/S0033291701003336; Salim A, 2009, ARCH SURG-CHICAGO, V144, P865, DOI 10.1001/archsurg.2009.158; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; Seel RT, 2010, J HEAD TRAUMA REHAB, V25, P99, DOI 10.1097/HTR.0b013e3181ce3966; Seifert TD, 2010, CURR PAIN HEADACHE R, V14, P292, DOI 10.1007/s11916-010-0117-7; Shavelle RM, 2001, AM J PHYS MED REHAB, V80, P510, DOI 10.1097/00002060-200107000-00009; Silver J. M., 2008, AM PSYCHIAT PUBLISHI, P595; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Simpson G, 2002, PSYCHOL MED, V32, P687, DOI 10.1017/S0033291702005561; STARKSTEIN SE, 1990, ANN NEUROL, V27, P652, DOI 10.1002/ana.410270612; Suchy Y, 2007, BRAIN INJURY, V21, P69, DOI 10.1080/02699050601149088; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Vaishnavi S, 2009, PSYCHOSOMATICS, V50, P198, DOI 10.1176/appi.psy.50.3.198; Warriner Erin M, 2006, Curr Psychiatry Rep, V8, P73, DOI 10.1007/s11920-006-0083-2; Wasserman L, 2008, BRAIN INJURY, V22, P811, DOI 10.1080/02699050802372166; Wilgus J, 2009, J HIST NEUROSCI, V18, P340, DOI 10.1080/09647040903018402; Yeates GN, 2008, NEUROPSYCHOL REHABIL, V18, P566, DOI 10.1080/09602010802151532; Zeitzer JM, 2009, J REHABIL RES DEV, V46, P827, DOI 10.1682/JRRD.2008.08.0099	56	41	44	1	43	SLACK INC	THOROFARE	6900 GROVE RD, THOROFARE, NJ 08086 USA	0279-3695			J PSYCHOSOC NURS MEN	J. Psychosoc. Nurs. Ment. Health Serv.	MAR	2011	49	3					42	50		10.3928/02793695-20110201-03			9	Nursing	Nursing	742UA	WOS:000288969300016	21323264				2021-06-18	
J	Riggio, S				Riggio, Silvana			Traumatic Brain Injury and Its Neurobehavioral Sequelae	NEUROLOGIC CLINICS			English	Article						Traumatic brain injury; Postconcussive syndrome; Neuropsychiatric disorders; Frontal lobe seizures	POSTTRAUMATIC-STRESS-DISORDER; HEAD-INJURY; CHRONIC PAIN; PSYCHIATRIC-DISORDERS; SYMPTOMS; FATIGUE; ASSOCIATION; PREVALENCE; CONCUSSION; DISABILITY	The neurobehavioral sequelae of TBI consist of a spectrum of somatic, neurologic, and psychiatric symptoms. The challenge for clinicians lies in understanding the interface of the various symptoms and how they interrelate with other entities. Specifically, the challenge is differentiating post-TBI-related symptoms from preexisting or de novo psychiatric, neurologic, and/or systemic disorders. A comprehensive evaluation and a multidisciplinary approach to evaluating patients are essential to be able to develop the differential diagnosis needed to design a management plan that maximizes recovery.	[Riggio, Silvana] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA; [Riggio, Silvana] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA; [Riggio, Silvana] James J Peters VA Med Ctr, Bronx, NY USA	Riggio, S (corresponding author), Mt Sinai Sch Med, Dept Psychiat, 1 Gustave L Levy Pl,Box 1230, New York, NY 10029 USA.	silvana.riggio@mssm.edu					Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Anstey KJ, 2004, J CLIN EPIDEMIOL, V57, P1202, DOI 10.1016/j.jclinepi.2003.11.011; Ashman TA, 2008, J HEAD TRAUMA REHAB, V23, P33, DOI 10.1097/01.HTR.0000308719.70288.22; Baandrup L, 2005, CEPHALALGIA, V25, P132, DOI 10.1111/j.1468-2982.2004.00818.x; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Borg J, 2004, J REHABIL MED, V36, P76, DOI 10.1080/16501960410023840; Bryant RA, 2001, CLIN PSYCHOL REV, V21, P931; Bryant RA, 2000, BRAIN INJURY, V14, P175, DOI 10.1080/026990500120826; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Bushnik T, 2008, J HEAD TRAUMA REHAB, V23, P17, DOI 10.1097/01.HTR.0000308717.80590.22; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Chamelian L, 2004, ARCH PHYS MED REHAB, V85, P1662, DOI 10.1016/j.apmr.2004.02.012; Clinchot DM, 1998, AM J PHYS MED REHAB, V77, P291, DOI 10.1097/00002060-199807000-00006; Couch JR, 2001, HEADACHE, V41, P559, DOI 10.1046/j.1526-4610.2001.041006559.x; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Gil S, 2005, AM J PSYCHIAT, V162, P963, DOI 10.1176/appi.ajp.162.5.963; Greve KW, 2001, BRAIN INJURY, V15, P255; Hart RP, 2000, NEUROPSYCHOL REV, V10, P131, DOI 10.1023/A:1009020914358; Harvey AG, 1998, BRAIN INJURY, V12, P147, DOI 10.1080/026990598122773; Hesdorffer DC, 2009, J HEAD TRAUMA REHAB, V24, P452, DOI 10.1097/HTR.0b013e3181c133fd; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; King NS, 1997, J NEUROL NEUROSUR PS, V62, P82, DOI 10.1136/jnnp.62.1.82; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; McCracken LM, 2001, J PAIN SYMPTOM MANAG, V21, P392, DOI 10.1016/S0885-3924(01)00267-6; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Paniak C, 2002, ARCH CLIN NEUROPSYCH, V17, P319, DOI 10.1016/S0887-6177(01)00115-9; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Popovic Vera, 2005, Pituitary, V8, P239, DOI 10.1007/s11102-006-6047-z; Quesney LF, 1986, RECENT ADV EPILEPSY, V3, P81; Rao Vani, 2002, Curr Treat Options Neurol, V4, P77, DOI 10.1007/s11940-002-0006-4; RIGGIO S, 1995, ADV NEUROL, V66, P153; Rogers JM, 2007, BRAIN INJURY, V21, P1321, DOI 10.1080/02699050701765700; Ruff RM, 1996, BRAIN INJURY, V8, P61; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Simpson G, 2007, BRAIN INJURY, V21, P1335, DOI 10.1080/02699050701785542; Tateno A, 2003, J NEUROPSYCH CLIN N, V15, P155, DOI 10.1176/appi.neuropsych.15.2.155; Turnbull SJ, 2001, BRAIN INJURY, V15, P775, DOI 10.1080/02699050110034334; UOMOTO JM, 1993, ARCH PHYS MED REHAB, V74, P61; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316	46	41	42	1	9	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0733-8619	1557-9875		NEUROL CLIN	Neurol. Clin.	FEB	2011	29	1					35	+		10.1016/j.ncl.2010.10.008			14	Clinical Neurology; Neurosciences	Neurosciences & Neurology	714BA	WOS:000286780700004	21172569				2021-06-18	
J	Green, P				Green, Paul			Comparison Between the Test of Memory Malingering (TOMM) and the Nonverbal Medical Symptom Validity Test (NV-MSVT) in Adults With Disability Claims	APPLIED NEUROPSYCHOLOGY			English	Article						effort; malingering; NV-MSVT; SVT; TOMM	TEST-PERFORMANCE; CHILDREN; DAMAGE	In this study, the Nonverbal Medical Symptom Validity Test (NV-MSVT; Green, 2008) and the Test of Memory Malingering (TOMM; Tombaugh, 1996) were given to a consecutive series of outpatients undergoing disability assessment. No cases of moderate to severe traumatic brain injury (TBI) failed the easy NV-MSVT subtests or the TOMM. However, 26% of the mild TBI group failed the NV-MSVT and 10% failed the TOMM. More than 10% of the whole sample passed the TOMM but failed the NV-MSVT. Using profile analysis, the NV-MSVT has been shown to have a zero false-positive rate in three independent groups of patients with severe cognitive impairment arising from dementia. The more severe the actual cognitive impairment, the more likely it is that false positives for poor effort will occur. Therefore, using the same criteria, we would also expect zero false positives in people with much less severe impairment, such as mild TBI. Those in the current study who passed the TOMM and failed the NV-MSVT had profiles that were not characteristic of people with actual severe impairment. Instead, they were of the paradoxical type seen in simulators. The results suggest that the NV-MSVT is considerably more sensitive to poor effort than the TOMM, if the conventional cutoff is used to define TOMM failure.		Green, P (corresponding author), 17010 103 Ave, Edmonton, AB T5S 1K7, Canada.	paulgreen@shaw.ca					Ashendorf L, 2004, ARCH CLIN NEUROPSYCH, V19, P125, DOI 10.1016/S0887-6177(02)00218-4; Blaskewitz N, 2008, ARCH CLIN NEUROPSYCH, V23, P379, DOI 10.1016/j.acn.2008.01.008; Brockhaus R, 2004, NERVENARZT, V75, P882, DOI 10.1007/s00115-003-1592-4; Carone DA, 2008, BRAIN INJURY, V22, P960, DOI 10.1080/02699050802491297; Goodrich-Hunsaker NJ, 2009, NEUROPSYCHOLOGY, V23, P529, DOI 10.1037/a0015444; Green P, 2003, CHILD NEUROPSYCHOL, V9, P189, DOI 10.1076/chin.9.3.189.16460; Green P, 2009, BRAIN INJURY, V23, P741, DOI 10.1080/02699050903133962; Green P., 2005, MANUAL WORD MEMORY T; Green P., 2008, MANUAL NONVERBAL MED; Green P., 2004, MANUAL MED SYMPTOM V; Green P., 2010, ADV INTERPRETATION P; Green P., DETECTION M IN PRESS; Green P., 1995, MANUAL ORAL WORD MEM; Henry M, 2010, J CLIN EXP NEUROPSYC, V32, P19, DOI 10.1080/13803390902791653; Merten T, 2007, J CLIN EXP NEUROPSYC, V29, P308, DOI 10.1080/13803390600693607; Singhal A, 2009, ARCH CLIN NEUROPSYCH, V24, P721, DOI 10.1093/arclin/acp074; Tombaugh TN, 1996, TEST MEMORY MALINGER	17	41	41	0	11	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0908-4282			APPL NEUROPSYCHOL	Appl. Neuropsychol.		2011	18	1					18	26	PII 934413787	10.1080/09084282.2010.523365			9	Clinical Neurology; Psychology	Neurosciences & Neurology; Psychology	733MC	WOS:000288265800003	21390896				2021-06-18	
J	Miller, JB; Millis, SR; Rapport, LJ; Bashem, JR; Hanks, RA; Axelrod, BN				Miller, Justin B.; Millis, Scott R.; Rapport, Lisa J.; Bashem, Jesse R.; Hanks, Robin A.; Axelrod, Bradley N.			Detection of Insufficient Effort Using the Advanced Clinical Solutions for the Wechsler Memory Scale, Fourth Edition	CLINICAL NEUROPSYCHOLOGIST			English	Article						Effort; Malingering; Assessment; Neuropsychology; Logistic regression	TRAUMATIC BRAIN-INJURY; VERBAL-LEARNING TEST; RESPONSE BIAS; PERFORMANCE; INDICATORS; NAN	This study investigated the ability of the Wechsler Memory Scale-4th Edition (WMS-IV) and the Advanced Clinical Solutions (ACS) package including the new Word Choice test (WCT) to distinguish poor performance due to intentional response bias among simulators of traumatic brain injury (TBI) from poor performance due to actual TBI. Participants were 45 survivors of moderate to severe TBI and 39 healthy adult coached to simulate TBI. Logistic regression indicated that a five-variable model containing all the ACS variables and a single-variable model using only the WCT were statistically reliable. Comparing predictive accuracy of each model found that adding the WCT to the ACS increased predictive accuracy. Diagnostic efficiency for the full ACS model was considered "excellent" according to interpretive guidelines.	[Miller, Justin B.; Hanks, Robin A.] Wayne State Univ, Sch Med, Detroit, MI 48202 USA; [Axelrod, Bradley N.] Vet Affairs Med Ctr, John D Dingell Dept, Detroit, MI USA	Miller, JB (corresponding author), Wayne State Univ, Sch Med, 7th Floor,5057 Woodward Ave, Detroit, MI 48202 USA.	Justin.b.miller@gmail.com		Miller, Justin B./0000-0002-4439-6604	National Institute on Disability and Rehabilitation Research [H133A080044]; US Department of EducationUS Department of Education; Del Harder foundation, Detroit, Michigan	The study was supported in part by grant number H133A080044 through the National Institute on Disability and Rehabilitation Research, the US Department of Education, and the Del Harder foundation, Detroit, Michigan.	Axelrod BN, 2007, INT J NEUROSCI, V117, P1591, DOI 10.1080/00207450600941189; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Coleman RD, 1998, J CLIN EXP NEUROPSYC, V20, P201, DOI 10.1076/jcen.20.2.201.1164; Delis DC, 2000, CALIFORNIA VERBAL LE; Delis DC, 2007, ARCH CLIN NEUROPSYCH, V22, P589, DOI 10.1016/j.acn.2007.04.001; DenBoer JW, 2007, CLIN NEUROPSYCHOL, V21, P943, DOI 10.1080/13854040601020783; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Flaro L, 2007, BRAIN INJURY, V21, P373, DOI 10.1080/02699050701311133; Green P., 2008, NONVERBAL MED SYMPTO; Green P., 2005, MED SYMPTOM VALIDITY; GREIFFENSTEIN MF, 1995, CLIN NEUROPSYCHOL, V9, P230, DOI 10.1080/13854049508400485; Greve KW, 2009, CLIN NEUROPSYCHOL, V23, P534, DOI 10.1080/13854040802232690; Hanks RA, 2007, NEUROREHABILITATION, V22, P43; Hardin JW, 2007, GEN LINEAR MODELS EX; Harrell Frank E., 2001, REGRESSION MODELING; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Hosmer D. W., 2000, APPL LOGISTIC REGRES; Kim MS, 2010, ARCH CLIN NEUROPSYCH, V25, P60, DOI 10.1093/arclin/acp088; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Larrabee G. J., 2007, ASSESSMENT MALINGERE, P3; Larrabee GJ, 2008, CLIN NEUROPSYCHOL, V22, P666, DOI 10.1080/13854040701494987; MILGRAM S, 1963, J ABNORM PSYCHOL, V67, P371, DOI 10.1037/h0040525; Millis S., 2008, NEUROPSYCHOLOGY MALI, P21; MILLIS SR, 1994, J CLIN PSYCHOL, V50, P601, DOI 10.1002/1097-4679(199407)50:4<601::AID-JCLP2270500417>3.0.CO;2-9; Millis SR, 1995, PSYCHOL ASSESSMENT, V7, P463; MILLIS SR, 1992, CLIN NEUROPSYCHOL, V6, P406; Ord JS, 2008, CLIN NEUROPSYCHOL, V22, P689, DOI 10.1080/13854040701425437; *PEARS ED I, 2008, WECHSL MEM SCAL CLIN; Rabin LA, 2005, ARCH CLIN NEUROPSYCH, V20, P33, DOI 10.1016/j.acn.2004.02.005; Rogers R., 1997, CLIN ASSESSMENT MALI, P398; Steyerberg EW., 2009, CLIN PREDICTION MODE; SUHR JA, 2007, ASSESSMENT MALINGERE, P287; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; Tombaugh TN, 1996, TEST MEMORY MALINGER; Victor T, 2009, CLIN NEUROPSYCHOL, V23, P297, DOI 10.1080/13854040802232682; Warrington EK., 1984, RECOGNITION MEMORY T; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th ed; Wolfe PL, 2010, CLIN NEUROPSYCHOL, V24, P153, DOI 10.1080/13854040903107791	38	41	41	1	11	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2011	25	1					160	172		10.1080/13854046.2010.533197			13	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	722FM	WOS:000287417100011	21253964				2021-06-18	
J	Ribbe, K; Friedrichs, H; Begemann, M; Grube, S; Papiol, S; Kastner, A; Gerchen, MF; Ackermann, V; Tarami, A; Treitz, A; Flogel, M; Adler, L; Aldenhoff, JB; Becker-Emner, M; Becker, T; Czernik, A; Dose, M; Folkerts, H; Freese, R; Gunther, R; Herpertz, S; Hesse, D; Kruse, G; Kunze, H; Franz, M; Lohrer, F; Maier, W; Mielke, A; Muller-Isberner, R; Oestereich, C; Pajonk, FG; Pollmacher, T; Schneider, U; Schwarz, HJ; Kroner-Herwig, B; Havemann-Reinecke, U; Frahm, J; Stuhmer, W; Falkai, P; Brose, N; Nave, KA; Ehrenreich, H				Ribbe, Katja; Friedrichs, Heidi; Begemann, Martin; Grube, Sabrina; Papiol, Sergi; Kaestner, Anne; Gerchen, Martin F.; Ackermann, Verena; Tarami, Asieh; Treitz, Annika; Floegel, Marlene; Adler, Lothar; Aldenhoff, Josef B.; Becker-Emner, Marianne; Becker, Thomas; Czernik, Adelheid; Dose, Matthias; Folkerts, Here; Freese, Roland; Guenther, Rolf; Herpertz, Sabine; Hesse, Dirk; Kruse, Gunther; Kunze, Heinrich; Franz, Michael; Loehrer, Frank; Maier, Wolfgang; Mielke, Andreas; Mueller-Isberner, Ruediger; Oestereich, Cornelia; Pajonk, Frank-Gerald; Pollmaecher, Thomas; Schneider, Udo; Schwarz, Hans-Joachim; Kroener-Herwig, Birgit; Havemann-Reinecke, Ursula; Frahm, Jens; Stuehmer, Walter; Falkai, Peter; Brose, Nils; Nave, Klaus-Armin; Ehrenreich, Hannelore			The cross-sectional GRAS sample: A comprehensive phenotypical data collection of schizophrenic patients	BMC PSYCHIATRY			English	Article							TRAUMATIC BRAIN-INJURY; GENDER-DIFFERENCES; RATING-SCALE; COGNITIVE PERFORMANCE; PSYCHOTIC DISORDERS; SEX-DIFFERENCES; 1ST-EPISODE; NEUROCOGNITION; DETERMINANTS; ASSOCIATION	Background: Schizophrenia is the collective term for an exclusively clinically diagnosed, heterogeneous group of mental disorders with still obscure biological roots. Based on the assumption that valuable information about relevant genetic and environmental disease mechanisms can be obtained by association studies on patient cohorts of >= 1000 patients, if performed on detailed clinical datasets and quantifiable biological readouts, we generated a new schizophrenia data base, the GRAS (Gottingen Research Association for Schizophrenia) data collection. GRAS is the necessary ground to study genetic causes of the schizophrenic phenotype in a 'phenotype-based genetic association study' (PGAS). This approach is different from and complementary to the genome-wide association studies (GWAS) on schizophrenia. Methods: For this purpose, 1085 patients were recruited between 2005 and 2010 by an invariable team of traveling investigators in a cross-sectional field study that comprised 23 German psychiatric hospitals. Additionally, chart records and discharge letters of all patients were collected. Results: The corresponding dataset extracted and presented in form of an overview here, comprises biographic information, disease history, medication including side effects, and results of comprehensive cross-sectional psychopathological, neuropsychological, and neurological examinations. With >3000 data points per schizophrenic subject, this data base of living patients, who are also accessible for follow-up studies, provides a wide-ranging and standardized phenotype characterization of as yet unprecedented detail. Conclusions: The GRAS data base will serve as prerequisite for PGAS, a novel approach to better understanding 'the schizophrenias' through exploring the contribution of genetic variation to the schizophrenic phenotypes.	[Ribbe, Katja; Friedrichs, Heidi; Begemann, Martin; Grube, Sabrina; Papiol, Sergi; Kaestner, Anne; Gerchen, Martin F.; Ackermann, Verena; Tarami, Asieh; Treitz, Annika; Floegel, Marlene; Ehrenreich, Hannelore] Max Planck Inst Expt Med, Div Clin Neurosci, D-37075 Gottingen, Germany; [Aldenhoff, Josef B.] Hosp Psychiat & Psychotherapy, Ctr Integrat Psychiat, Kiel, Germany; [Becker-Emner, Marianne] Karl Jaspers Hosp, Bad Zwischenahn, Germany; [Becker, Thomas] Univ Ulm, Dist Hosp Gunzburg, Dept Psychiat 2, D-89069 Ulm, Germany; [Czernik, Adelheid] Hosp Fulda, Dept Psychiat & Psychotherapy, Fulda, Germany; [Dose, Matthias] Isar Amper Hosp, Dept Psychiat & Psychotherapy, Taufkirchen, Vils, Germany; [Folkerts, Here] Reinhard Nieter Hosp, Dept Psychiat & Psychotherapy, Wilhelmshaven, Germany; [Freese, Roland] Vitos Hosp Forens Psychiat Eltville, Eltville, Germany; [Guenther, Rolf] Vitos Hosp Psychiat & Psychotherapy Merxhausen, Kassel, Germany; [Herpertz, Sabine] Univ Rostock, Dept Psychiat & Psychotherapy, D-2500 Rostock 1, Germany; [Hesse, Dirk] Hosp Forens Psychiat, Moringen, Germany; [Kruse, Gunther] Reg Hosp Hannover, Hosp Psychiat & Psychotherapy Langenhagen, Hannover, Germany; [Kunze, Heinrich; Franz, Michael] Vitos Hosp Psychiat & Psychotherapy, Bad Emstal Merxhausen, Germany; [Loehrer, Frank] Addict Hosp Am Waldsee, Rieden, Germany; [Maier, Wolfgang] Univ Med Ctr Bonn, Dept Psychiat & Psychotherapy, Bonn, Germany; [Mielke, Andreas] Vitos Hosp Psychiat & Psychotherapy Merxhausen, Hofgeismar, Germany; [Mueller-Isberner, Ruediger] Vitos Haina Forens Psychiat Hosp, Haina, Germany; [Oestereich, Cornelia] Reg Hosp Hannover, Dept Psychiat & Psychotherapy, Wunstorf, Germany; [Pajonk, Frank-Gerald] Dr K Fontheims Hosp Mental Hlth, Liebenburg, Germany; [Pollmaecher, Thomas] Hosp Ingolstadt, Dept Psychiat & Psychotherapy, Ingolstadt, Germany; [Schneider, Udo] Hosp Lubbecke, Dept Psychiat & Psychotherapy, Lubeck, Germany; [Schwarz, Hans-Joachim] Hosp Psychiat & Psychotherapy, Rickling, Germany; [Kroener-Herwig, Birgit] Univ Gottingen, Georg Elias Muller Inst Psychol, D-37075 Gottingen, Germany; [Havemann-Reinecke, Ursula; Falkai, Peter] Univ Med Ctr Gottingen, Dept Psychiat & Psychotherapy, Gottingen, Germany; [Frahm, Jens] Max Planck Inst Biophys Chem, Biomed NMR Res GmbH, D-37075 Gottingen, Germany; [Stuehmer, Walter] Max Planck Inst Expt Med, Dept Mol Biol Neuronal Signals, D-37075 Gottingen, Germany; [Brose, Nils] Max Planck Inst Expt Med, Dept Mol Neurobiol, D-37075 Gottingen, Germany; [Nave, Klaus-Armin] Max Planck Inst Expt Med, Dept Neurogenet, D-37075 Gottingen, Germany	Ehrenreich, H (corresponding author), Max Planck Inst Expt Med, Div Clin Neurosci, Hermann Rein Str 3, D-37075 Gottingen, Germany.	ehrenreich@em.mpg.de	Stuehmer, Walter/A-2176-2009; Falkai, Peter/E-3273-2017; Becker, Thomas/O-9769-2014; Nave, Klaus-Armin/C-8883-2011; Herpertz, Sabine C/AAW-4885-2020	Falkai, Peter/0000-0003-2873-8667; Becker, Thomas/0000-0001-8179-1219; Herpertz, Sabine C/0000-0001-9676-1928; Papiol, Sergi/0000-0001-9366-8728; Ehrenreich, Hannelore/0000-0001-8371-5711; Gerchen, Martin Fungisai/0000-0003-3071-5296	Max Planck SocietyMax Planck SocietyFoundation CELLEX; DFG-Research Center for Molecular Physiology of the Brain (CMBP)German Research Foundation (DFG)	This study was supported by the Max Planck Society and the DFG-Research Center for Molecular Physiology of the Brain (CMBP). We are indebted to all patients for their participation in the GRAS (Gottingen Research Association for Schizophrenia) study and to all colleagues in the collaborating centers who contributed to the GRAS data collection.	Aleman A, 2003, ARCH GEN PSYCHIAT, V60, P565, DOI 10.1001/archpsyc.60.6.565; Allen NC, 2008, NAT GENET, V40, P827, DOI 10.1038/ng.171; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Aschenbrenner S, 2000, REGENSBURGER WORTFLU; AYLWARD E, 1984, SCHIZOPHRENIA BULL, V10, P430, DOI 10.1093/schbul/10.3.430; BARNES TRE, 1989, BRIT J PSYCHIAT, V154, P672, DOI 10.1192/bjp.154.5.672; Barnes TRE, 2003, J PSYCHOPHARMACOL, V17, P365, DOI 10.1177/0269881103174013; Bartels C, 2008, NEUROMUSCULAR DISORD, V18, P398, DOI 10.1016/j.nmd.2008.02.005; Begemann M, 2010, ARCH GEN PSYCHIAT, V67, P879, DOI 10.1001/archgenpsychiatry.2010.107; Blom G., 1958, STAT ESTIMATES TRANS; Calkins ME, 2007, SCHIZOPHRENIA BULL, V33, P33, DOI 10.1093/schbul/sbl044; Cardno AG, 1999, ARCH GEN PSYCHIAT, V56, P162, DOI 10.1001/archpsyc.56.2.162; Cardno AG, 2000, AM J MED GENET, V97, P12, DOI 10.1002/(SICI)1096-8628(200021)97:1<12::AID-AJMG3>3.3.CO;2-L; CASTLE DJ, 1994, PSYCHOL MED, V24, P41, DOI 10.1017/S0033291700026817; CHAPMAN RL, 1948, PSYCHOMETRIKA, V13, P175; CHEN EYH, 1995, PSYCHIAT RES, V56, P183, DOI 10.1016/0165-1781(95)02535-2; Crowley JJ, 2008, AM J MED GENET B, V147B, P1298, DOI 10.1002/ajmg.b.30727; DAVIS JM, 1976, ARCH GEN PSYCHIAT, V33, P858; Dominguez MD, 2009, PSYCHOL BULL, V135, P157, DOI 10.1037/a0014415; DUAN J, BRAIN RES B; Ehrenreich H, 2001, EUR ARCH PSY CLIN N, V251, P149, DOI 10.1007/s004060170034; Fleischhacker WW, 2005, SCHIZOPHR RES, V78, P147, DOI 10.1016/j.schres.2005.06.004; Franke G. H., 2000, BRIEF SYMPTOM INVENT; Franzek E, 1998, AM J PSYCHIAT, V155, P76, DOI 10.1176/ajp.155.1.76; Gaite L, 2005, COMPR PSYCHIAT, V46, P440, DOI 10.1016/j.comppsych.2005.03.006; Gold JM, 1997, ARCH GEN PSYCHIAT, V54, P159; GOTTESMAN II, 1967, P NATL ACAD SCI USA, V58, P199, DOI 10.1073/pnas.58.1.199; Green REA, 2008, J CLIN EXP NEUROPSYC, V30, P163, DOI 10.1080/13803390701300524; Guy, 1976, ECDEU ASSESSMENT MAN; Hafner H, 2000, ACTA PSYCHIAT SCAND, V102, P44, DOI 10.1034/j.1600-0447.2000.00008.x; Hafner H, 1998, SOC PSYCH PSYCH EPID, V33, P380, DOI 10.1007/s001270050069; Haro JM, 2003, ACTA PSYCHIAT SCAND, V107, P222, DOI 10.1034/j.1600-0447.2003.00064.x; Helmstaedter C., 2001, VERBALER LERN MERKFA; Henry JM, 2010, PSYCHIAT SERV, V61, P264, DOI 10.1176/ps.2010.61.3.264; Hoff AL, 1998, AM J PSYCHIAT, V155, P1437, DOI 10.1176/ajp.155.10.1437; Horn W, 1983, LEISTUNGSPRUFSYSTEM; Israel N, 2010, AM J COMMUN PSYCHOL, V46, P49, DOI 10.1007/s10464-010-9326-9; Jablensky A, 1992, Psychol Med Monogr Suppl, V20, P1; Jablensky A, 2000, AUST NZ J PSYCHIAT, V34, P221, DOI 10.1046/j.1440-1614.2000.00728.x; Karayiorgou M, 2004, AM J MED GENET B, V124B, P20, DOI 10.1002/ajmg.b.20090; KAY SR, 1987, SCHIZOPHRENIA BULL, V13, P261, DOI 10.1093/schbul/13.2.261; Kern RS, 2008, AM J PSYCHIAT, V165, P214, DOI 10.1176/appi.ajp.2007.07010043; KESSLER J, 1999, DEMEZ TEST DT; Kraepelin E., 1899, PSYCHIAT LEHRBUCH ST; Krampe H, 2008, AMYOTROPH LATERAL SC, V9, P99, DOI 10.1080/17482960701875805; Kupfer J., 2001, TORONTO ALEXITHYMIE; Larsen TK, 1996, SCHIZOPHRENIA BULL, V22, P257, DOI 10.1093/schbul/22.2.257; Laux L., 1981, STATE TRAIT ANGSTINV; LEHRL S, 1995, ACTA NEUROL SCAND, V91, P335, DOI 10.1111/j.1600-0404.1995.tb07018.x; Lehrl S, 1999, MEHRFACH WORTSCHATZ; Leung A, 2000, ACTA PSYCHIAT SCAND, V101, P3; Lichtenstein P, 2009, LANCET, V373, P234, DOI 10.1016/S0140-6736(09)60072-6; Lieberman JA, 2005, NEW ENGL J MED, V353, P1209, DOI 10.1056/NEJMoa051688; LOUGHLAND C, AUSTR NZ J PSYCHIAT; Loughland CM, 2004, PSYCHIAT RES, V125, P117, DOI 10.1016/j.psychres.2003.11.002; Loughland CM, 2001, AUST NZ J PSYCHIAT, V35, P660, DOI 10.1080/0004867010060516; McGrath J, 2008, EPIDEMIOL REV, V30, P67, DOI 10.1093/epirev/mxn001; Moriarty PJ, 2001, SCHIZOPHRENIA BULL, V27, P103, DOI 10.1093/oxfordjournals.schbul.a006850; Perianez JA, 2007, ARCH CLIN NEUROPSYCH, V22, P433, DOI 10.1016/j.acn.2007.01.022; PINHEIRO AP, 2009, AUSTR NZ J PSYCHIAT, V41, P169; Price GW, 2006, BIOL PSYCHIAT, V60, P1, DOI 10.1016/j.biopsych.2005.09.010; Puig O, 2008, PSYCHIAT RES, V158, P11, DOI 10.1016/j.psychres.2007.04.017; Riecher-Rossler A, 2000, ACTA PSYCHIAT SCAND, V102, P58, DOI 10.1034/j.1600-0447.2000.00011.x; RILEY B, 2003, SCHIZOPHRENIA; Schennach-Wolff R, 2009, SCHIZOPHR RES, V113, P210, DOI 10.1016/j.schres.2009.05.032; Seeman MV, 2009, SCHIZOPHRENIA BULL, V35, P937, DOI 10.1093/schbul/sbn023; Seeman MV, 2004, AM J PSYCHIAT, V161, P1324, DOI 10.1176/appi.ajp.161.8.1324; SEEMAN MV, 1990, SCHIZOPHRENIA BULL, V16, P185, DOI 10.1093/schbul/16.2.185; Simpson G.M., 1970, ACTA PSYCHIAT SCAND, V212, pS11; SIMPSON GM, 1979, PSYCHOPHARMACOLOGY, V64, P171, DOI 10.1007/BF00496058; Stroup TS, 2003, SCHIZOPHRENIA BULL, V29, P15, DOI 10.1093/oxfordjournals.schbul.a006986; Sullivan PF, 2008, MOL PSYCHIATR, V13, P570, DOI 10.1038/mp.2008.25; Sullivan PF, 2007, BIOL PSYCHIAT, V61, P902, DOI 10.1016/j.biopsych.2006.07.036; Tewes U., 1991, HAMBURG WECHSLER INT, V2; Thorup A, 2007, J NERV MENT DIS, V195, P396, DOI 10.1097/01.nmd.0000253784.59708.dd; TORO PA, 1995, J CONSULT CLIN PSYCH, V63, P280, DOI 10.1037/0022-006X.63.2.280; War Department, 1944, ARM IND TEST BATT MA; Weiser M, 2000, SCHIZOPHR RES, V45, P185, DOI 10.1016/S0920-9964(99)00190-5; Wittchen H.-.U., 1997, SKID I STRUKTURIERTE; World Health Organization, 1992, ICD 10 CLASS MENT BE; Zimmermann P, 1993, TESTBATTERIE AUFMERK	81	41	41	0	6	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1471-244X		BMC PSYCHIATRY	BMC Psychiatry	NOV 10	2010	10								91	10.1186/1471-244X-10-91			20	Psychiatry	Psychiatry	695DM	WOS:000285350800001	21067598	DOAJ Gold, Green Published			2021-06-18	
J	Morton, N; Barker, L				Morton, Nicholas; Barker, Lynne			The contribution of injury seventy, executive and implicit functions to awareness of deficits after traumatic brain injury (TBI)	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Tacit; Conscious; Control processes; Impairment; Neuropathology	CLOSED-HEAD-INJURY; IMPAIRED SELF-AWARENESS; COGNITION; INSIGHT; DISEASE; ADULTS; PERFORMANCE; ADJUSTMENT; KNOWLEDGE; LESIONS	Deficits in self-awareness are commonly seen after Traumatic Brain Injury (TBI) and adversely affect rehabilitative efforts, independence and quality of life (Ponsford, 2004) Awareness models predict that executive and implicit functions are important cognitive components of awareness though the putative relationship between implicit and awareness processes has not been subject to empirical investigation (Crosson et al, 1989, Ownsworth, Clare & Morris 2006 Toglia & Kirk, 2000) Severity of injury, also thought to be a crucial determinant of awareness outcome post insult is under-explored in awareness studies (Sherer Boake Levin Silver Ringholz & Walter 1998) The present study measured the contribution of injury seventy, IQ, mood state executive and implicit functions to awareness in head-injured patients assigned to moderate/severe head-injured groups using several awareness executive, and implicit measures Severe injuries resulted in greater impairments across most awareness executive and implicit measures compared with moderate injuries although deficits were still seen in the moderate group Hierarchical regression results showed that severity of injury, IQ, mood state executive and implicit functions made significant unique contributions to selective aspects of awareness Future models of awareness should account for both implicit and executive contributions to awareness and the possibility that both are vulnerable to disruption after neuropathology (JINS 2010 16 1089-1098)	[Morton, Nicholas] Rotherham Doncaster & S Humber Mental Hlth NHS Tr, Tickhill Rd Hosp, Neurorehabil Serv, Doncaster DN4 8QL, S Yorkshire, England; [Barker, Lynne] Sheffield Hallam Univ, Dept Psychol, Sheffield S1 1WB, S Yorkshire, England	Morton, N (corresponding author), Rotherham Doncaster & S Humber Mental Hlth NHS Tr, Tickhill Rd Hosp, Neurorehabil Serv, Doncaster DN4 8QL, S Yorkshire, England.		Morton, NICHOLAS/ABF-3774-2020				ALLOY LB, 1979, J EXP PSYCHOL GEN, V108, P441, DOI 10.1037/0096-3445.108.4.441; Andres P, 2002, NEUROPSYCHOLOGIA, V40, P835, DOI 10.1016/S0028-3932(01)00182-8; Banks SJ, 2009, J NEUROPSYCH CLIN N, V21, P299, DOI 10.1176/appi.neuropsych.21.3.299; Barker LA, 2006, NEUROPSYCHOLOGIA, V44, P1413, DOI 10.1016/j.neuropsychologia.2005.12.005; Barker LA, 2010, NEUROPSYCHOLOGIA, V48, P2550, DOI 10.1016/j.neuropsychologia.2010.05.001; Barker LA, 2004, NEUROCASE, V10, P233, DOI 10.1080/13554790490495096; Beldarrain MG, 2002, EXP BRAIN RES, V142, P529, DOI 10.1007/s00221-001-0935-2; Benton A, 1989, MULTILINGUAL APHASIA; Bogod NM, 2003, J INT NEUROPSYCH SOC, V9, P450, DOI 10.1017/S1355617703930104; Crosson B., 1989, J HEAD TRAUMA REHAB, V4, P46, DOI [10.1097/00001199-198909000-00008, DOI 10.1097/00001199-198909000-00008]; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Flashman LA, 2002, NEUROREHABILITATION, V17, P285; Fleming J, 1999, OCCUP THER J RES, V19, P3, DOI 10.1177/153944929901900101; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; Fleming JM, 1996, BRAIN INJURY, V10, P1; Forgas JP, 1998, J PERS SOC PSYCHOL, V75, P318, DOI 10.1037/0022-3514.75.2.318; Frith CD, 2008, NEURON, V60, P503, DOI 10.1016/j.neuron.2008.10.032; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P333, DOI 10.1097/00001199-200507000-00005; HART T, 1999, NEUROPSYCHOL REHABIL, V19, P161; KIHLSTROM JF, 1991, AWARENESS DEFICIT BR; King N, 1997, BRIT J CLIN PSYCHOL, V36, P161, DOI 10.1111/j.2044-8260.1997.tb01405.x; Kouider S, 2007, PHILOS T R SOC B, V362, P857, DOI 10.1098/rstb.2007.2093; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Lieberman MD, 2000, PSYCHOL BULL, V126, P109, DOI 10.1037/0033-2909.126.1.109; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; Mild Traumatic Brain Injury Committee, 1993, J HEAD TRAUMA REHAB, V8, P86; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Morris R., 2004, COGNITIVE NEUROPSYCH, V2nd; NISSEN MJ, 1987, COGNITIVE PSYCHOL, V19, P1, DOI 10.1016/0010-0285(87)90002-8; O'Keeffe F, 2007, J INT NEUROPSYCH SOC, V13, P38, DOI 10.1017/S1355617707070075; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Ownsworth T, 2006, REHABIL PSYCHOL, V51, P50, DOI 10.1037/0090-5550.51.1.50; Ownsworth T, 2005, J HEAD TRAUMA REHAB, V20, P315, DOI 10.1097/00001199-200507000-00004; Ownsworth T, 2006, NEUROPSYCHOL REHABIL, V16, P415, DOI 10.1080/09602010500505641; Ownsworth TL, 2000, CLIN NEUROPSYCHOL, V14, P76, DOI 10.1076/1385-4046(200002)14:1;1-8;FT076; PETRIDES M, 1982, NEUROPSYCHOLOGIA, V20, P263; Ponsford J, 2004, COGNITIVE BEHAV REHA; Prigatano G. P., 1991, AWARENESS DEFICIT BR; PRIGATANO GP, 2010, ADV STUDY ANOSOGNOSI; Psychological Corporation, 2001, WECHSL TEST AD READ; REBER AS, 2002, IMPLICIT LEARNING CO; Rich JB, 1996, NEUROPSY NEUROPSY BE, V9, P99; Rosen HJ, 2010, NEUROIMAGE, V49, P3358, DOI 10.1016/j.neuroimage.2009.11.041; SCHACTER DL, 1990, J CLIN EXP NEUROPSYC, V12, P155, DOI 10.1080/01688639008400962; Schmitz TW, 2006, NEUROPSYCHOLOGIA, V44, P762, DOI 10.1016/j.neuropsychologia.2005.07.012; Seger CA, 1997, CONSCIOUS COGN, V6, P108, DOI 10.1006/ccog.1996.0285; Seidler RD, 2005, EXP BRAIN RES, V165, P114, DOI 10.1007/s00221-005-2284-z; Shallice, 1997, HAYLING BRIXTON TEST; Sherer M, 2005, J HEAD TRAUMA REHAB, V20, P287, DOI 10.1097/00001199-200507000-00002; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Sherer M, 2003, BRAIN INJURY, V17, P25, DOI 10.1080/0269905021000010113; Stuss DT, 2007, PHILOS T R SOC B, V362, P901, DOI 10.1098/rstb.2007.2096; Toglia J, 2000, NEUROREHABILITATION, V15, P57; Trahan E, 2006, J HEAD TRAUMA REHAB, V21, P226, DOI 10.1097/00001199-200605000-00003; Wechsler D., 2011, WECHLSER ABBREVIATED; Wilson BA, 1996, BEHAV ASSESSMENT DYS; Wise K, 2005, BRAIN INJURY, V19, P765, DOI 10.1080/0269905050019977; Wong PS, 1997, CONSCIOUS COGN, V6, P519, DOI 10.1006/ccog.1997.0322; ZAJONC RB, 1968, J PERS SOC PSYCHOL, V9, P1, DOI 10.1037/h0025848; ZAJONC RB, 1980, AM PSYCHOL, V35, P151, DOI 10.1037/0003-066X.35.2.151; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	62	41	42	0	12	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	NOV	2010	16	6					1089	1098		10.1017/S1355617710000925			10	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	690RL	WOS:000285023200016	20735889	Green Accepted			2021-06-18	
J	Defrin, R; Gruener, H; Schreiber, S; Pick, CG				Defrin, Ruth; Gruener, Hila; Schreiber, Shaul; Pick, Chaim G.			Quantitative somatosensory testing of subjects with chronic post-traumatic headache: Implications on its mechanisms	EUROPEAN JOURNAL OF PAIN			English	Article						Chronic pain; Traumatic head injury; Quantitative somatosensory testing (QST)	TRAUMATIC BRAIN-INJURY; TENSION-TYPE HEADACHE; CHRONIC PAIN; WHIPLASH INJURY; STRESS-DISORDER; MIGRAINE; PTSD; NECK; EXCITOTOXICITY; SENSITIZATION	Background: Chronic headache is one of the most prominent symptoms among subjects with traumatic head injury (THI). Despite the relatively high prevalence of chronic post-traumatic headache (CPTHA) and its enormous effect on the already poor quality of life of subjects with THI, its mechanisms has not been studied in depth. Objective: To conducted quantitative somatosensory testing in THI subjects with and without chronic post-traumatic headache (CPTHA) in order to shed light on the yet, unknown pathophysiology of CPTHA. Methods: THI subjects with and without CPTHA and healthy controls underwent thermal and mechanical threshold measurements in painful and pain-free regions in the head and in their hands (a remote pain-free region) and filled out and the post-traumatic stress disorder (PTSD) inventory. In addition, the THI and CPTHA filled out the Mc'Gill pain questionnaire (MPQ). Results: THI subjects with CPTHA had significantly higher thermal thresholds in both the head and hand indicating central damage to the pain and temperature system and in addition, a significantly lower pressure- pain threshold in the head as well as more severe PTSD symptomatology than the pain-free THI subjects and healthy controls. Conclusions: The sensory profile of subjects with CPTHA suggests that CPTHA may be a form of central pain. The cranial mechanical hyperalgesia may originate from peripheral tissue damage accompanying the THI. Psychological factors may contribute to the development, and maintenance of CPTHA in susceptible individuals. (C) 2010 European Federation of International Association for the Study of Pain Chapters. Published by Elsevier Ltd. All rights reserved.	[Defrin, Ruth] Tel Aviv Univ, Sackler Fac Med, Dept Phys Therapy, Sch Allied Hlth Profess, IL-69978 Tel Aviv, Israel; [Gruener, Hila; Pick, Chaim G.] Tel Aviv Univ, Sackler Fac Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel; [Schreiber, Shaul] Tel Aviv Univ, Dept Psychiat, Tel Aviv Sourasky Med Ctr, IL-69978 Tel Aviv, Israel	Defrin, R (corresponding author), Tel Aviv Univ, Sackler Fac Med, Dept Phys Therapy, Sch Allied Hlth Profess, IL-69978 Tel Aviv, Israel.	rutidef@post.tau.ac.il	Schreiber, Shaul/E-5821-2010	Schreiber, Shaul/0000-0002-2189-0693			Andary MT, 1997, CLIN J PAIN, V13, P244, DOI 10.1097/00002508-199709000-00010; Ashina M, 2000, CEPHALALGIA, V20, P919, DOI 10.1046/j.1468-2982.2000.00150.x; Asmundson GJG, 2002, CAN J PSYCHIAT, V47, P930; Baandrup L, 2005, CEPHALALGIA, V25, P132, DOI 10.1111/j.1468-2982.2004.00818.x; Barcellos Sue, 1996, P139; Bartsch T, 2002, BRAIN, V125, P1496, DOI 10.1093/brain/awf166; Bendtsen L, 2000, CEPHALALGIA, V20, P486, DOI 10.1046/j.1468-2982.2000.00070.x; Boivi J, 1999, TXB PAIN, P879; BOVIM G, 1992, PAIN, V51, P169, DOI 10.1016/0304-3959(92)90258-D; Bowsher D, 1999, Am J Hosp Palliat Care, V16, P593, DOI 10.1177/104990919901600408; Brown AW, 2008, ARCH PHYS MED REHAB, V89, pS3, DOI 10.1016/j.apmr.2007.12.001; Bryant RA, 1999, J HEAD TRAUMA REHAB, V14, P588, DOI 10.1097/00001199-199912000-00007; Buchgreitz L, 2006, PAIN, V123, P19, DOI 10.1016/j.pain.2006.01.040; Burstein R, 2000, ANN NEUROL, V47, P614, DOI 10.1002/1531-8249(200005)47:5<614::AID-ANA9>3.0.CO;2-N; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; DE TOMMASO M, 2003, PAIN, V104, P111; Defrin R, 2001, PAIN, V89, P253, DOI 10.1016/S0304-3959(00)00369-9; Defrin R, 2008, PAIN, V138, P450, DOI 10.1016/j.pain.2008.05.006; *DSM 4 TR, 1994, DIAGN STAT MAN MENT; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Faux S, 2008, PAIN MED, V9, P1001, DOI 10.1111/j.1526-4637.2007.00404.x; Fernandez-De-Las-Penas C, 2007, CEPHALALGIA, V27, P383, DOI 10.1111/j.1468-2982.2007.01295.x; Finnerup NB, 2003, BRAIN, V126, P57, DOI 10.1093/brain/awg007; Gilkey SJ, 1997, HEADACHE, V37, P583, DOI 10.1046/j.1526-4610.1997.3709583.x; GOBEL H, 1992, CEPHALALGIA, V12, P142, DOI 10.1046/j.1468-2982.1992.1203142.x; Hansson P, 2004, EUR J NEUROL, V11, P22, DOI 10.1111/j.1471-0552.2004.00793.x; Hao JX, 1998, EXP BRAIN RES, V118, P259, DOI 10.1007/s002210050280; Jensen R, 1999, CEPHALALGIA, V19, P602, DOI 10.1046/j.1468-2982.1999.019006602.x; JENSEN R, 1993, PAIN, V52, P193, DOI 10.1016/0304-3959(93)90131-8; Johansen MK, 1999, PAIN, V83, P229, DOI 10.1016/S0304-3959(99)00106-2; Kasch H, 2001, CEPHALALGIA, V21, P189, DOI 10.1046/j.1468-2982.2001.00179.x; Keidel M, 2001, PAIN, V92, P319, DOI 10.1016/S0304-3959(01)00272-X; King NS, 2008, BRAIN INJURY, V22, P1, DOI 10.1080/02699050701829696; Lahz S, 1996, ARCH PHYS MED REHAB, V77, P889, DOI 10.1016/S0003-9993(96)90275-0; Lew HL, 2006, AM J PHYS MED REHAB, V85, P619, DOI 10.1097/01.phm.0000223235.09931.c0; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; Lipton P, 1999, PHYSIOL REV, V79, P1431; MCINTOSH TK, 1987, BRAIN RES, V425, P225, DOI 10.1016/0006-8993(87)90505-1; McMahon S B, 1993, Curr Opin Neurobiol, V3, P602, DOI 10.1016/0959-4388(93)90062-4; MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5; Merskey H, 1994, CLASSIFICATION CHRON; NICOLODI M, 1994, HEADACHE, V34, P12, DOI 10.1111/j.1526-4610.1994.hed3401012.x; Obrenovitch TP, 1997, J NEUROTRAUM, V14, P677, DOI 10.1089/neu.1997.14.677; Ofek H, 2007, PAIN, V131, P330, DOI 10.1016/j.pain.2007.06.015; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; PACKARD RC, 1993, HEADACHE, V33, P133, DOI 10.1111/j.1526-4610.1993.hed3303133.x; Packard RC, 2008, CURR PAIN HEADACHE R, V12, P67, DOI 10.1007/s11916-008-0013-6; Packard Russell C, 2005, Curr Pain Headache Rep, V9, P59, DOI 10.1007/s11916-005-0076-6; Packard Russell C, 2002, Curr Pain Headache Rep, V6, P301, DOI 10.1007/s11916-002-0051-4; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Radanov BP, 2001, EUR SPINE J, V10, P403, DOI 10.1007/s005860000227; Sandrini G, 2006, CEPHALALGIA, V26, P782, DOI 10.1111/j.1468-2982.2006.01130.x; Sandrini G, 2002, NEUROSCI LETT, V317, P135, DOI 10.1016/S0304-3940(01)02447-8; Scott D, 2005, CLIN J PAIN, V21, P175, DOI 10.1097/00002508-200503000-00009; Sharp TJ, 2001, CLIN PSYCHOL REV, V21, P857, DOI 10.1016/S0272-7358(00)00071-4; Sheftell FD, 2007, NEUROL SCI, V28, pS203, DOI 10.1007/s10072-007-0777-1; Sherman Kristen Brewer, 2006, Phys Med Rehabil Clin N Am, V17, P473, DOI 10.1016/j.pmr.2005.11.007; Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x; Solomon S, 2005, HEADACHE, V45, P53, DOI 10.1111/j.1526-4610.2005.05011.x; SOLOMON Z, 1993, ISRAEL J PSYCHIAT, V30, P110; STURZENEGGER M, 1994, NEUROLOGY, V44, P688, DOI 10.1212/WNL.44.4.688; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; UOMOTO JM, 1993, ARCH PHYS MED REHAB, V74, P61; VOGELBAUM MA, 1998, CLIN NEUROL, V3, P1; WALKER R, 2004, 200401 CDAR KENT DEP; Walker WC, 2005, ARCH PHYS MED REHAB, V86, P1793, DOI 10.1016/j.apmr.2004.12.042; Walker WC, 2004, J HEAD TRAUMA REHAB, V19, P72, DOI 10.1097/00001199-200401000-00007; Weissman-Fogel I, 2003, PAIN, V104, P693, DOI 10.1016/S0304-3959(03)00159-3; WOOLF CJ, 1983, NATURE, V306, P686, DOI 10.1038/306686a0	70	41	41	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1090-3801	1532-2149		EUR J PAIN	Eur. J. Pain	OCT	2010	14	9					924	931		10.1016/j.ejpain.2010.03.004			8	Anesthesiology; Clinical Neurology; Neurosciences	Anesthesiology; Neurosciences & Neurology	651ZH	WOS:000281967400006	20363652				2021-06-18	
J	Sady, MD; Sander, AM; Clark, AN; Sherer, M; Nakase-Richardson, R; Malec, JF				Sady, Maegan D.; Sander, Angelle M.; Clark, Allison N.; Sherer, Mark; Nakase-Richardson, Risa; Malec, James F.			Relationship of Preinjury Caregiver and Family Functioning to Community Integration in Adults With Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; traumatic; Family; Caregivers; Rehabilitation	SOCIAL SUPPORT; HEAD-INJURY; PREDICTING RETURN; WORK; RELIABILITY; PARTICIPATION; QUESTIONNAIRE; DISABILITY; SURVIVORS; OUTCOMES	Sady MD, Sander AM, Clark AN, Sherer M, Nakase-Richardson R, Malec JF. Relationship of preinjury caregiver and family functioning to community integration in adults with traumatic brain injury. Arch Phys Med Rehabil 2010;91:1542-50. Objective: To investigate the relationship of preinjury caregiver and family functioning to community integration outcomes in persons with traumatic brain injury (TBI). Design: Inception cohort. Setting: Three TBI Model Systems inpatient rehabilitation facilities. Participants: Persons with TBI (N=141) and their caregivers admitted to inpatient rehabilitation and followed up at 1 to 2 years after injury. Interventions: Not applicable. Main Outcome Measures: Community Integration Questionnaire and the Social and Occupation scales of the Craig Handicap Assessment and Reporting Technique. Results: There were significant interactions of several preinjury caregiver and family variables with injury severity. For persons with complicated mild/moderate injury, better family functioning was associated with greater home integration, and less caregiver distress was associated with better social integration. For persons with severe injuries, greater caregiver perceived social support was associated with better outcomes in productivity and social integration. Conclusions: Preinjury caregiver and family characteristics interact with injury severity to affect outcomes in persons with injury. Research on outcomes should include measures of caregiver and family functioning. Early interventions targeted toward decreasing caregiver distress, increasing support, and improving family functioning may have a positive impact on later outcomes.	[Sady, Maegan D.; Sander, Angelle M.; Clark, Allison N.; Sherer, Mark] TIRR Mem Hermann, Brain Injury Res Ctr, Houston, TX 77019 USA; [Sady, Maegan D.] Univ Houston, Dept Psychol, Houston, TX USA; [Sander, Angelle M.; Clark, Allison N.; Sherer, Mark] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Nakase-Richardson, Risa] James A Haley Vet Hosp, Psychol Serv, Tampa, FL 33612 USA; [Nakase-Richardson, Risa] Methodist Rehabil Ctr, Dept Neuropsychol, Jackson, MS USA; [Malec, James F.] Rehabil Hosp Indiana, Indianapolis, IN USA	Sander, AM (corresponding author), TIRR Mem Hermann, Brain Injury Res Ctr, 2323 S Shepherd Dr,Ste 907, Houston, TX 77019 USA.	asander@bcm.edu		Sady, Maegan/0000-0002-1438-4477			Bier N, 2009, J HEAD TRAUMA REHAB, V24, P187, DOI 10.1097/HTR.0b013e3181a0b15a; Brandt E. N., 1997, ENABLING AM ASSESSIN; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; Cusick CP, 2000, J HEAD TRAUMA REHAB, V15, P739, DOI 10.1097/00001199-200002000-00012; Derogatis L, 1993, BRIEF SYMPTOM INVENT; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; DIKMEN S, 1995, J INT NEUROPSYCH SOC, V1, P66; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; Ergh TC, 2003, J CLIN EXP NEUROPSYC, V25, P1090, DOI 10.1076/jcen.25.8.1090.16735; FRASER R, 1988, REHABIL COUNS BULL, V31, P276; Gollaher K, 1998, BRAIN INJURY, V12, P255, DOI 10.1080/026990598122557; GRAVETTER FJ, 2007, STAT BEHAV SCI, P291; Hanks RA, 2007, NEUROREHABILITATION, V22, P43; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; KAPLAN SP, 1990, REHABIL COUNS BULL, V34, P16; KAZARIAN SS, 1991, J COMMUNITY PSYCHOL, V19, P150, DOI 10.1002/1520-6629(199104)19:2<150::AID-JCOP2290190206>3.0.CO;2-J; Kersel DA, 2001, BRAIN INJURY, V15, P683, DOI 10.1080/02699050010013662; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Lefebvre H, 2008, BRAIN INJURY, V22, P535, DOI 10.1080/02699050802158243; MCMORDIE W R, 1990, Brain Injury, V4, P57, DOI 10.3109/02699059009026149; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Muthen L., 2006, MPLUS USERS GUIDE; Oddy M, 2008, PSYCHOL APPROACHES R, P431; Perlesz A, 1999, REHABIL PSYCHOL, V44, P6, DOI 10.1037/0090-5550.44.1.6; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; RAO N, 1990, Brain Injury, V4, P49, DOI 10.3109/02699059009026148; RAO N, 1992, ARCH PHYS MED REHAB, V73, P911; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; Sander AM, 1997, BRAIN INJURY, V11, P235, DOI 10.1080/026990597123548; Sander AM, 2003, ARCH PHYS MED REHAB, V84, P197, DOI 10.1053/apmr.2003.50105; Sander AM, 2002, BRAIN INJURY, V16, P649, DOI 10.1080/02699050210128889; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P353, DOI 10.1016/S0003-9993(97)90225-2; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; Schafer JL, 2002, PSYCHOL METHODS, V7, P147, DOI 10.1037//1082-989X.7.2.147; SCHMIDT MF, 1995, J HEAD TRAUMA REHAB, V10, P14, DOI 10.1097/00001199-199508000-00003; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; Son AHPWV, 2007, CLIN REHABIL, V21, P1024, DOI 10.1177/0269215507077603; Tate DG, 2003, AM PSYCHOL, V58, P289, DOI 10.1037/0003-066X.58.4.289; TEASDALE G, 1974, LANCET, V2, P81; Tepper S, 1996, BRAIN INJURY, V10, P575, DOI 10.1080/026990596124142; Uysal S, 1998, J HEAD TRAUMA REHAB, V13, P57, DOI 10.1097/00001199-199812000-00007; WEST M, 1990, VOCATIONAL REHABILIT, P201; WHITENECK G, 1988, GUIDE USE CHART CRAI; Whiteneck G, 2009, ARCH PHYS MED REHAB, V90, pS22, DOI 10.1016/j.apmr.2009.06.009; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Willer B., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI DOI 10.1097/00001199-199308020-00009; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; World Health Organization, 1980, INT CLASS IMP DIS HA; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; ZARSKI J, 1988, J HEAD TRAUMA REHAB, V3, P31; ZIMET GD, 1988, J PERS ASSESS, V52, P30, DOI 10.1207/s15327752jpa5201_2	60	41	41	0	18	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	2010	91	10					1542	1550		10.1016/j.apmr.2010.07.012			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	661IT	WOS:000282720300009	20875512				2021-06-18	
J	Schroeppel, TJ; Fischer, PE; Zarzaur, B; Magnotti, LJ; Clement, LP; Fabian, TC; Croce, MA				Schroeppel, Thomas J.; Fischer, Peter E.; Zarzaur, Ben L.; Magnotti, Louis J.; Clement, L. Paige; Fabian, Timothy C.; Croce, Martin A.			Beta-Adrenergic Blockade and Traumatic Brain Injury: Protective?	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	68th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	OCT 01-03, 2009	Pittsburgh, PA	Amer Assoc Surg Trauma		Traumatic brain injury; Beta-blocker	WALL-MOTION ABNORMALITIES; FACTOR-ALPHA PRODUCTION; SUBARACHNOID HEMORRHAGE; HEAD-INJURY; MYOCARDIAL DAMAGE; IMPROVED OUTCOMES; NERVOUS-SYSTEM; CATECHOLAMINES; MODULATION; NECROSIS	Background: Catecholamine surge after traumatic brain injury (TBI) is associated with infectious morbidity and potentially preventable mortality. Previous studies have supported the protective effect of beta-adrenergic blockade in patients with TBI. We hypothesize that suppression of the catecholamine surge in multiple-injured TBI patients with beta-adrenergic blockade decreases mortality. Methods: The trauma registry at an urban Level I trauma center was queried for blunt TBI from June 1, 2003, to December 31, 2007. Patients who received more than one dose of beta-blockers (BB) were identified by a review of the hospital pharmacy order database. chi(2) and Student's t tests were used where appropriate. After adjusting for age, injury severity score, admission Glasgow Coma Score, and transfusions multivariable logistic regression was performed to analyze whether receiving BB was protective in patients sustaining TBI. Results: A total of 2,601 patients were admitted with blunt TBI during the study period. Of these, 506 patients (20%) received BB. Despite higher age (51 years vs. 38 years, p < 0.0001) and more severe head injury (head Abbreviated Injury Scale score 4.14 vs. 3.81, p < 0.0001), there was no difference in mortality (15% vs. 16%). Multivariable logistic regression identified BB as protective in patients sustaining head injury (odds ratio, 0.347; confidence interval, 0.246-0.490), when compared with those who did not receive BB, reducing mortality by 65%. Conclusions: BB are associated with significantly reduced mortality in patients with TBI. This simple, inexpensive intervention may have a profound effect on mortality in this population of injured patients and requires further prospective study.	[Schroeppel, Thomas J.; Fischer, Peter E.; Zarzaur, Ben L.; Magnotti, Louis J.; Clement, L. Paige; Fabian, Timothy C.; Croce, Martin A.] Univ Tennessee, Hlth Sci Ctr, Dept Surg, Memphis, TN 38163 USA	Schroeppel, TJ (corresponding author), Univ Tennessee, Hlth Sci Ctr, Dept Surg, 910 Madison Bldg,2nd Floor,220, Memphis, TN 38163 USA.	tschroep@utmem.edu	Zarzaur, Ben/S-6572-2019				Acosta JA, 1998, J AM COLL SURGEONS, V186, P528, DOI 10.1016/S1072-7515(98)00082-9; Amory DW, 2002, J CARDIOTHOR VASC AN, V16, P270, DOI 10.1053/jcan.2002.124132; Arbabi S, 2004, J TRAUMA, V56, P265, DOI 10.1097/01.TA.0000109859.91202.C8; Arbabi S, 2007, J TRAUMA, V62, P56, DOI 10.1097/TA.0b013e31802d972b; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; CONNOR RCR, 1969, AM HEART J, V78, P145, DOI 10.1016/0002-8703(69)90001-5; Cotton BA, 2007, J TRAUMA, V62, P26, DOI 10.1097/TA.0b013e31802d02d0; Deng JP, 2004, AM J PHYSIOL-CELL PH, V287, pC730, DOI 10.1152/ajpcell.00562.2003; ELENKOV IJ, 1995, J NEUROIMMUNOL, V61, P123, DOI 10.1016/0165-5728(95)00080-L; Freibel JH, 1981, ANN NEUROL, V9, P340; Fukuzawa M, 2000, IMMUNOPHARMACOLOGY, V48, P65, DOI 10.1016/S0162-3109(00)00179-X; GREENHOO.JH, 1969, J NEUROSURG, V30, P521, DOI 10.3171/jns.1969.30.5.0521; Grunsfeld Alexander, 2005, Curr Neurol Neurosci Rep, V5, P488, DOI 10.1007/s11910-005-0039-7; HAMILL RW, 1987, ANN NEUROL, V21, P438, DOI 10.1002/ana.410210504; HAWKINS WE, 1971, CARDIOVASC RES, V5, P524, DOI 10.1093/cvr/5.4.524; Herndon DN, 2001, NEW ENGL J MED, V345, P1223, DOI 10.1056/NEJMoa010342; HORTNAGL H, 1980, INTENS CARE MED, V6, P169, DOI 10.1007/BF01757299; Inaba K, 2008, J AM COLL SURGEONS, V206, P432, DOI 10.1016/j.jamcollsurg.2007.10.005; JAATTELA A, 1975, BRIT J SURG, V62, P177, DOI 10.1002/bjs.1800620303; Kalinichenko VV, 1999, J IMMUNOL, V163, P2492; KONO T, 1994, J AM COLL CARDIOL, V24, P636, DOI 10.1016/0735-1097(94)90008-6; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Mangano DT, 1996, NEW ENGL J MED, V335, P1713, DOI 10.1056/NEJM199612053352301; MCLEOD AA, 1982, BRIT HEART J, V47, P221; Naredi S, 2000, STROKE, V31, P901, DOI 10.1161/01.STR.31.4.901; NEILDWYER G, 1981, BRIT J CLIN PHARMACO, V11, P549, DOI 10.1111/j.1365-2125.1981.tb01169.x; NEILDWYER G, 1978, BRIT MED J, V2, P990, DOI 10.1136/bmj.2.6143.990; NEILDWYER G, 1985, EUR J CLIN PHARMACOL, V28, P25, DOI 10.1007/BF00543706; POLLICK C, 1988, J AM COLL CARDIOL, V12, P600, DOI 10.1016/S0735-1097(88)80044-5; Prass K, 2003, J EXP MED, V198, P725, DOI 10.1084/jem.20021098; Randell T, 1999, J NEUROSURG ANESTH, V11, P163, DOI 10.1097/00008506-199907000-00001; Riordan WP, 2007, J TRAUMA, V63, P503, DOI 10.1097/TA.0b013e3181271c34; Rossitch E Jr, 1988, Br J Neurosurg, V2, P471, DOI 10.3109/02688698809029601; SHACKFORD SR, 1993, ARCH SURG-CHICAGO, V128, P571, DOI 10.1001/archsurg.1993.01420170107016; SOLENSKI NJ, 1995, CRIT CARE MED, V23, P1007, DOI 10.1097/00003246-199506000-00004; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Wallace A, 1998, ANESTHESIOLOGY, V88, P7, DOI 10.1097/00000542-199801000-00005; WEIR BK, 1978, J NEUROSURG, V49, P502, DOI 10.3171/jns.1978.49.4.0502; Woiciechowsky C, 1998, NAT MED, V4, P808, DOI 10.1038/nm0798-808; WOOLF PD, 1987, J NEUROSURG, V66, P875, DOI 10.3171/jns.1987.66.6.0875; WOOLF PD, 1992, ARCH SURG-CHICAGO, V127, P899	41	41	42	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	OCT	2010	69	4					776	780		10.1097/TA.0b013e3181e981b8			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	664KP	WOS:000282959100021	20938265				2021-06-18	
J	Armstead, WM; Kiessling, JW; Kofke, WA; Vavilala, MS				Armstead, William M.; Kiessling, J. Willis; Kofke, W. Andrew; Vavilala, Monica S.			Impaired cerebral blood flow autoregulation during posttraumatic arterial hypotension after fluid percussion brain injury is prevented by phenylephrine in female but exacerbated in male piglets by extracellular signal-related kinase mitogen-activated protein kinase upregulation	CRITICAL CARE MEDICINE			English	Article						cerebral circulation; pediatric; traumatic brain injury; signal transduction; autoregulation	INTRACRANIAL-PRESSURE; PERFUSION-PRESSURE; ISCHEMIC BRAIN; ADRENOMEDULLIN; GENDER; CHILDREN; AGE; NEWBORN; OCCLUSION; MEMORY	Objective: Traumatic brain injury contributes to morbidity and mortality in children and boys are disproportionately represented. Hypotension is common and worsens outcome after traumatic brain injury. Extracellular signal-related kinase mitogen-activated protein kinase is upregulated and reduces cerebral blood flow after fluid percussion brain injury in piglets. We hypothesized that increased cerebral perfusion pressure through phenylephrine sex dependently reduces impairment of cerebral autoregulation during hypotension after fluid percussion brain injury through modulation of extracellular signal-related kinase mitogen-activated protein kinase. Design: Prospective, randomized animal study. Setting: University laboratory. Subjects: Newborn (1-to 5-day-old) pigs. Interventions: Cerebral blood flow, pial artery diameter, intracranial pressure, and autoregulatory index were determined before and after fluid percussion brain injury in untreated, preinjury, and postinjury phenylephrine (1 mu g/kg/min intravenously) treated male and female pigs during normotension and hemorrhagic hypotension. Cerebrospinal fluid extracellular signal-related kinase mitogen-activated protein kinase was determined by enzyme-linked immunosorbent assay. Measurements and Main Results: Reductions in pial artery diameter, cerebral blood flow, cerebral perfusion pressure, and elevated intracranial pressure after fluid percussion brain injury were greater in males, which were blunted by phenylephrine pre- or postfluid percussion brain injury. During hypotension and fluid percussion brain injury, pial artery dilation was impaired more in males. Phenylephrine decreased impairment of hypotensive pial artery dilation after fluid percussion brain injury in females, but paradoxically caused vasoconstriction after fluid percussion brain injury in males. Papaverine-induced pial artery vasodilation was unchanged by fluid percussion brain injury and phenylephrine. Cerebral blood flow, cerebral perfusion pressure, and autoregulatory index decreased markedly during hypotension and fluid percussion brain injury in males but less in females. Phenylephrine prevented reductions in cerebral blood flow, cerebral perfusion pressure, and autoregulatory index during hypotension in females but increased reductions in males. Cerebrospinal fluid extracellular signal-related kinase mitogen-activated protein kinase was increased more in males than females after fluid percussion brain injury. Phenylephrine blunted extracellular signal-related kinase mitogen-activated protein kinase upregulation in females but increased extracellular signal-related kinase mitogen-activated protein kinase upregulation in males after fluid percussion brain injury. Conclusions: These data indicate that elevation of cerebral perfusion pressure with phenylephrine sex dependently prevents impairment of cerebral autoregulation during hypotension after fluid percussion brain injury through modulation of extracellular signal-related kinase mitogen-activated protein kinase. These data suggest the potential role for sex-dependent mechanisms in cerebral autoregulation after pediatric traumatic brain injury. (Crit Care Med 2010; 38:1868-1874)	[Armstead, William M.; Kiessling, J. Willis; Kofke, W. Andrew] Univ Penn, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA; [Armstead, William M.] Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Washington, Dept Anesthesiol Pediat & Neurol Surg, Seattle, WA 98195 USA	Armstead, WM (corresponding author), Univ Penn, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA.	armsteaw@uphs.upenn.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HD57355]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD057355] Funding Source: NIH RePORTER	Supported by grant HD57355 from the National Institutes of Health.	Adelson P David, 2003, Pediatr Crit Care Med, V4, pS31; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS12; Alkayed NJ, 1998, STROKE, V29, P159, DOI 10.1161/01.STR.29.1.159; Armstead WM, 2007, J CEREBR BLOOD F MET, V27, P1702, DOI 10.1038/sj.jcbfm.9600473; Armstead WM, 2010, J NEUROTRAUM, V27, P391, DOI 10.1089/neu.2009.1094; Armstead WM, 2009, J CEREBR BLOOD F MET, V29, P524, DOI 10.1038/jcbfm.2008.142; ARMSTEAD WM, 1994, J NEUROTRAUM, V11, P487, DOI 10.1089/neu.1994.11.487; Armstead WM, 1999, AM J PHYSIOL-HEART C, V277, pH1884; Armstead WM, 2000, MICROCIRCULATION, V7, P225, DOI 10.1038/sj.mn.7300110; BASKAYA MK, 1995, J CEREBR BLOOD F MET, V15, P827, DOI 10.1038/jcbfm.1995.103; Bratton SL, 2007, J NEUROTRAUMA, V24, pS7; BRATTON SL, 2007, J NEUROTRAUMA S1, V24, pS5; Catala-Temprano A, 2007, J NEUROSURG, V106, P463, DOI 10.3171/ped.2007.106.6.463; Chaiwat O, 2009, J NEUROTRAUM, V26, P657, DOI 10.1089/neu.2008.0770; Coates BM, 2005, CRIT CARE MED, V33, P2645, DOI 10.1097/01.CCM.0000186417.19199.9B; Cremer OL, 2005, CRIT CARE MED, V33, P2207, DOI 10.1097/01.CCM.0000181300.99078.B5; Davis DP, 2006, J NEUROTRAUM, V23, P140, DOI 10.1089/neu.2006.23.140; DOBBING J, 1974, PEDIATRICS, V53, P2; Dogan A, 1997, J CEREBR BLOOD F MET, V17, P19, DOI 10.1097/00004647-199701000-00004; Donders J, 2003, J HEAD TRAUMA REHAB, V18, P106, DOI 10.1097/00001199-200303000-00002; Donders J, 2002, NEUROPSYCHOLOGY, V16, P491, DOI 10.1037//0894-4105.16.4.491; Du LN, 2004, J BIOL CHEM, V279, P38563, DOI 10.1074/jbc.M405461200; Freeman SS, 2008, ANESTHESIOLOGY, V108, P588, DOI 10.1097/ALN.0b013e31816725d7; Ishikawa S, 2009, ANESTH ANALG, V108, P1631, DOI 10.1213/ane.0b013e31819d94e3; Juhl L, 2006, EUR J PHARMACOL, V538, P101, DOI 10.1016/j.ejphar.2006.03.005; Khanna S, 2000, CRIT CARE MED, V28, P1144, DOI 10.1097/00003246-200004000-00038; Laher I, 2001, J CEREBR BLOOD F MET, V21, P887, DOI 10.1097/00004647-200108000-00001; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Liu MY, 2007, J CEREBR BLOOD F MET, V27, P135, DOI 10.1038/sj.jcbfm.9600331; Miyashita K, 2006, ENDOCRINOLOGY, V147, P1642, DOI 10.1210/en.2005-1038; Morrison Wynne E, 2004, Pediatr Crit Care Med, V5, P145, DOI 10.1097/01.PCC.0000112373.71645.2A; O'Connor CA, 2005, BRAIN RES, V1062, P171, DOI 10.1016/j.brainres.2005.09.011; Philip S, 2009, CRIT CARE MED, V37, P2973, DOI 10.1097/CCM.0b013e3181a963f6; Robertson CL, 2001, J NEUROTRAUM, V18, P861, DOI 10.1089/089771501750451785; Vavilala MS, 2006, DEV NEUROSCI-BASEL, V28, P348, DOI 10.1159/000094161; WANG XK, 1995, P NATL ACAD SCI USA, V92, P11480, DOI 10.1073/pnas.92.25.11480	36	41	41	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	SEP	2010	38	9					1868	1874		10.1097/CCM.0b013e3181e8ac1a			7	Critical Care Medicine	General & Internal Medicine	646RK	WOS:000281559500014	20562700	Green Accepted			2021-06-18	
J	Dellavalle, B; Hempel, C; Kurtzhals, JAL; Penkowa, M				Dellavalle, Brian; Hempel, Casper; Kurtzhals, Jorgen A. L.; Penkowa, Milena			In Vivo Expression of Neuroglobin in Reactive Astrocytes During Neuropathology in Murine Models of Traumatic Brain Injury, Cerebral Malaria, and Autoimmune Encephalitis	GLIA			English	Article						neuroglobin; astrocytes; cerebral malaria; traumatic brain injury; EAE; kainic acid; inflammation	INFLAMMATORY RESPONSE; OXIDATIVE STRESS; METALLOTHIONEIN-I; TISSUE-REPAIR; NEURODEGENERATION; PROTECTS; ENCEPHALOMYELITIS; OVEREXPRESSION; LOCALIZATION; CYTOGLOBIN	Neuroglobin (Ngb) is proposed to be a neuron-specific, hypoxia-responsive, neuroprotective protein. However, results are conflicting concerning both Ngb's physiological and pathological significance. This study was designed to investigate the in vivo localization and regulation of Ngb in different neuropathological models representing traumatic injury, infectious, autoimmune, and excitotoxic pathogeneses. We profiled Ngb immunohistochemistry in murine models of traumatic brain injury, cerebral malaria, experimental autoimmune encephalitis, and kainic acid (KA)-mediated epileptic seizures that, to our knowledge, have not been studied in the context of Ngb. In control mice Ngb was expressed exclusively in neurons. In all pathological models except KA, in addition to neurons Ngb was present in reactive astrocytes. Ngb positive astrocytes were found within regions associated with most severe pathology and the astroglial scar. This is the first report of Ngb present in reactive astroglia and in scar-forming astrocytes in response to different pathological conditions relevant to human disease. In light of previously reported cyto-protective properties of Ngb, further insight may result in therapeutic ramifications. (C) 2010 Wiley-Liss, Inc.	[Dellavalle, Brian; Hempel, Casper; Penkowa, Milena] Univ Copenhagen, Panum Inst, Sect Neuroprotect, Dept Neurosci & Pharmacol, DK-2200 Copenhagen, Denmark; [Dellavalle, Brian; Hempel, Casper; Kurtzhals, Jorgen A. L.] Copenhagen Univ Hosp, Ctr Med Parasitol, Dept Clin Microbiol, Copenhagen, Denmark; [Dellavalle, Brian; Hempel, Casper; Kurtzhals, Jorgen A. L.] Univ Copenhagen, Dept Int Hlth Immunol & Microbiol, DK-2200 Copenhagen, Denmark	Dellavalle, B (corresponding author), Univ Copenhagen, Panum Inst, Sect Neuroprotect, Dept Neurosci & Pharmacol, Bld 18-1-38, DK-2200 Copenhagen, Denmark.	briandellavalle@gmail.com	Kurtzhals, Jorgen AL/I-8921-2012; Kurtzhals, Jorgen/Y-3799-2019; Hempel, Casper/ABE-7065-2020; Hempel, Casper/C-9511-2013	Kurtzhals, Jorgen/0000-0003-2760-8713; Hempel, Casper/0000-0002-9816-4673; Hempel, Casper/0000-0002-9816-4673; DellaValle, Brian/0000-0002-1427-8244	NovoNordisk foundationNovo Nordisk Foundation; Faculty of Health Sciences at University of Copenhagen; Lundbeck FondenLundbeckfonden; IMK Almene Fond; Direktor Jacob Madsen og Hustru Olga Madsens Fond; Horsley Fonden; Vera og Carl Michaelsens Legat; Fonden til Laegevidenskabens Fremme; Eva & Henry Fraenkels Mindefond; Dir. Leo Nielsens Legat; Kathrine og Vigo Skovgaards Fond; Kong Christian d. X's fond; Th. Maigaard's Eftf. Fru Lily Benthine Lunds Fond [1/6 1978]; Toyota Fonden; Hotelejer Edvard Johnsen og hustrus fond; Karen A. Tolstrups Fond; Direktor Kurt Bonnelyckes Fond; Laegeforeningens Forskningsfond; Direktor Ib Henriksens Fond; Fonden [af 17-12-1981]; Laererinde Karen Svankjaer Ydes Fond; Laegernes Forsikringsforening; Kong Christian den Tiendes Fond	Grant sponsors: NovoNordisk foundation, Faculty of Health Sciences at University of Copenhagen, Lundbeck Fonden, IMK Almene Fond, Direktor Jacob Madsen og Hustru Olga Madsens Fond, Horsley Fonden, Vera og Carl Michaelsens Legat, Fonden til Laegevidenskabens Fremme, Eva & Henry Fraenkels Mindefond, Dir. Leo Nielsens Legat, Kathrine og Vigo Skovgaards Fond, Kong Christian d. X's fond, Th. Maigaard's Eftf. Fru Lily Benthine Lunds Fond of 1/6 1978, Toyota Fonden, Hotelejer Edvard Johnsen og hustrus fond, Karen A. Tolstrups Fond, Direktor Kurt Bonnelyckes Fond, Laegeforeningens Forskningsfond, Direktor Ib Henriksens Fond, Fonden af 17-12-1981, Laererinde Karen Svankjaer Ydes Fond, Laegernes Forsikringsforening, Kong Christian den Tiendes Fond.	Baxter AG, 2007, NAT REV IMMUNOL, V7, P904, DOI 10.1038/nri2190; Burmester T, 2000, NATURE, V407, P520, DOI 10.1038/35035093; Burmester T, 2009, J EXP BIOL, V212, P1423, DOI 10.1242/jeb.000729; Carrasco J, 2000, EUR J NEUROSCI, V12, P2311, DOI 10.1046/j.1460-9568.2000.00128.x; Casado Begona, 2005, Proteome Sci, V3, P2, DOI 10.1186/1477-5956-3-2; Chen XQ, 2005, GLIA, V50, P182, DOI 10.1002/glia.20147; Cowley MA, 2003, NEURON, V37, P649, DOI 10.1016/S0896-6273(03)00063-1; Espejo C, 2005, NEUROSCIENCE, V132, P1135, DOI 10.1016/j.neuroscience.2005.01.057; Fago A, 2008, IUBMB LIFE, V60, P398, DOI 10.1002/iub.35; Fordel E, 2006, NEUROSCI LETT, V410, P146, DOI 10.1016/j.neulet.2006.09.027; Hankeln T, 2004, IUBMB LIFE, V56, P671, DOI 10.1080/15216540500037794; Hein-Kristensen L, 2009, EXP PARASITOL, V123, P152, DOI 10.1016/j.exppara.2009.06.010; Herold S, 2004, J BIOL CHEM, V279, P22841, DOI 10.1074/jbc.M313732200; Hundahl CA, 2008, NEUROENDOCRINOLOGY, V88, P183, DOI 10.1159/000135617; Hunt NH, 2003, TRENDS IMMUNOL, V24, P491, DOI 10.1016/S1471-4906(03)00229-1; Jin KL, 2008, NEUROSCI LETT, V430, P135, DOI 10.1016/j.neulet.2007.10.031; Khan AA, 2006, P NATL ACAD SCI USA, V103, P17944, DOI 10.1073/pnas.0607497103; Lackner P, 2006, NEUROPATH APPL NEURO, V32, P177, DOI 10.1111/j.1365-2990.2006.00706.x; Lafon-Cazal M, 2003, J BIOL CHEM, V278, P24438, DOI 10.1074/jbc.M211980200; Li RC, 2008, NEUROBIOL AGING, V29, P1815, DOI 10.1016/j.neurobiolaging.2007.05.001; Linker RA, 2005, J AUTOIMMUN, V25, P199, DOI 10.1016/j.jaut.2005.09.019; Masmoudi-Kouki O, 2007, PEPTIDES, V28, P1753, DOI 10.1016/j.peptides.2007.05.015; Mills SY, 2007, COMPLEMENT THER MED, V15, P1, DOI [10.1016/j.ctim.2007.01.003, 10.1002/0471142735.im1501s77]; Minagar A, 2003, MULT SCLER J, V9, P540, DOI 10.1191/1352458503ms965oa; Mitz SA, 2009, NEUROSCIENCE, V163, P552, DOI 10.1016/j.neuroscience.2009.06.058; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Penkowa M, 2000, GLIA, V32, P271, DOI 10.1002/1098-1136(200012)32:3<271::AID-GLIA70>3.0.CO;2-5; Penkowa M, 2003, J NEUROSCI RES, V72, P574, DOI 10.1002/jnr.10615; Penkowa M, 1999, GLIA, V25, P343; Penkowa M, 2001, NEUROSCIENCE, V102, P805, DOI 10.1016/S0306-4522(00)00515-7; Penkowa M, 1999, J NEUROSCI, V19, P2535; Reuss S, 2002, NEUROSCIENCE, V115, P645, DOI 10.1016/S0306-4522(02)00536-5; Schmidt M, 2003, J BIOL CHEM, V278, P1932, DOI 10.1074/jbc.M209909200; Shang AJ, 2006, BRAIN RES, V1078, P219, DOI 10.1016/j.brainres.2006.01.064; SMITH ME, 1987, J NEUROSCI RES, V18, P203, DOI 10.1002/jnr.490180129; Valassi E, 2008, NUTR METAB CARDIOVAS, V18, P158, DOI 10.1016/j.numecd.2007.06.004; Wakasugi K, 2003, J BIOL CHEM, V278, P36505, DOI 10.1074/jbc.M305519200; Wang Q, 2005, MOL NEUROBIOL, V31, P3, DOI 10.1385/MN:31:1-3:003; Wang XY, 2008, STROKE, V39, P1869, DOI 10.1161/STROKEAHA.107.506022; Wiese L, 2006, EXP NEUROL, V200, P216, DOI 10.1016/j.expneurol.2006.02.011; Wystub S, 2003, NEUROSCI LETT, V346, P114, DOI 10.1016/S0304-3940(03)00563-9; Yu ZY, 2009, NEUROL RES, V31, P122, DOI 10.1179/174313209X389866	42	41	43	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	AUG 1	2010	58	10					1220	1227		10.1002/glia.21002			8	Neurosciences	Neurosciences & Neurology	618XJ	WOS:000279389100008	20544857				2021-06-18	
J	Matousek, SB; Hein, AM; Shaftel, SS; Olschowka, JA; Kyrkanides, S; O'Banion, MK				Matousek, Sarah B.; Hein, Amy M.; Shaftel, Solomon S.; Olschowka, John A.; Kyrkanides, Stephanos; O'Banion, M. Kerry			Cyclooxygenase-1 mediates prostaglandin E-2 elevation and contextual memory impairment in a model of sustained hippocampal interleukin-1 beta expression	JOURNAL OF NEUROCHEMISTRY			English	Article						cyclooxygenase-1; hippocampus; interleukin-1; neuroinflammation; prostaglandin E-2	AMYOTROPHIC-LATERAL-SCLEROSIS; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; ALZHEIMER-DISEASE; MOUSE-BRAIN; CEREBRAL-ISCHEMIA; COX-2; NEUROINFLAMMATION; INHIBITION; ACCUMULATION	P>Interleukin (IL)-1 beta is a proinflammatory cytokine implicated in several neurodegenerative disorders. Downstream actions of IL-1 beta include production of prostaglandin (PG) E-2 by increasing expression of cyclooxygenase (COX) enzymes and prostaglandin E synthase (PGES) isoforms. We recently developed a transgenic mouse carrying a dormant human IL-1 beta eXcisional Activation Transgene (XAT) for conditional and chronic up-regulation of IL-1 beta in selected brain regions. This model is characterized by regionally specific glial activation, immune cell recruitment, and induction of cytokines and chemokines. Here, we aimed to elucidate the effects of long-term IL-1 beta expression on the PGE(2) synthetic pathway and to determine the effects of PGs on inflammation and memory in our model. As expected, PGE(2) levels were significantly elevated after IL-1 beta up-regulation. Quantitative real-time PCR analysis indicated significant induction of mRNAs for COX-1 and membranous PGES-1, but not COX-2 or other PGES isoforms. Immunohistochemistry revealed elevation of COX-1 but no change in COX-2 following sustained IL-1 beta production. Furthermore, pharmacological inhibition of COX-1 and use of COX-1 knockout mice abrogated IL-1 beta-mediated PGE(2) increases. Although COX-1 deficient mice did not present a dramatically altered neuroinflammatory phenotype, they did exhibit improved contextual fear memory. This data suggests a unique role for COX-1 in mediating chronic neuroinflammatory effects through PGE(2) production.	[O'Banion, M. Kerry] Univ Rochester, Med Ctr, Dept Neurobiol & Anat, Sch Med & Dent, Rochester, NY 14642 USA; [Kyrkanides, Stephanos] SUNY Stony Brook, Med Ctr, Dept Orthodont & Pediat Dent, Stony Brook, NY 11794 USA	O'Banion, MK (corresponding author), Univ Rochester, Med Ctr, Dept Neurobiol & Anat, Sch Med & Dent, 601 Elmwood Ave,Box 603, Rochester, NY 14642 USA.	kerry_obanion@urmc.rochester.edu		O'Banion, M. Kerry/0000-0003-1246-3363	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 NS33553, R21 NS048522, RO1 AG030149, F31 AG031667]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS048522, R01NS033553] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG030149, F31AG031667] Funding Source: NIH RePORTER	This work was supported by NIH RO1 NS33553, R21 NS048522 and RO1 AG030149 to MKO, and F31 AG031667 to SBM. The authors would like to thank Jen-nie Miller for FIV packaging, Jack Walter and Mallory Olschowka for animal colony maintenance and aid with experiments, Renee Johnson for ELISA expertise, and Linda Callahan for assistance with confocal microscopy.	Aisen PS, 2003, JAMA-J AM MED ASSOC, V289, P2819, DOI 10.1001/jama.289.21.2819; Basu A, 2004, J NEUROSCI RES, V78, P151, DOI 10.1002/jnr.20266; BREDER CD, 1995, J COMP NEUROL, V355, P296, DOI 10.1002/cne.903550208; Cakala M, 2007, PHARMACOL REP, V59, P164; Candelario-Jalil E, 2003, J NEUROCHEM, V86, P545, DOI 10.1046/j.1471-4159.2003.01812.x; Candelario-Jalil E, 2006, J NEUROIMMUNOL, V174, P39, DOI 10.1016/j.jneuroim.2006.01.003; Cernak I, 2002, EXP BRAIN RES, V147, P193, DOI 10.1007/s00221-002-1245-z; Choi SH, 2008, FASEB J, V22, P1491, DOI 10.1096/fj.07-9411com; Choi SH, 2006, J NEUROCHEM, V98, P801, DOI 10.1111/j.1471-4159.2006.03926.x; Choi SH, 2009, TRENDS PHARMACOL SCI, V30, P174, DOI 10.1016/j.tips.2009.01.002; Cudkowicz ME, 2006, ANN NEUROL, V60, P22, DOI 10.1002/ana.20903; Deininger MH, 2000, J NEUROIMMUNOL, V106, P198, DOI 10.1016/S0165-5728(00)00187-9; Dore S, 2003, ANN NEUROL, V54, P155, DOI 10.1002/ana.10612; Hauss-Wegrzyniak B, 1999, NEUROBIOL AGING, V20, P305, DOI 10.1016/S0197-4580(99)00028-7; Hein AM, 2007, NEUROSCIENCE, V150, P754, DOI 10.1016/j.neuroscience.2007.10.003; Hein AM, 2010, BRAIN BEHAV IMMUN, V24, P243, DOI 10.1016/j.bbi.2009.10.002; Hein AM, 2009, MOL NEUROBIOL, V40, P15, DOI 10.1007/s12035-009-8066-z; Hoozemans JJM, 2005, CNS NEUROL DISORD-DR, V4, P307, DOI 10.2174/1568007054038201; Jin DQ, 2008, PHARMACOL BIOCHEM BE, V89, P404, DOI 10.1016/j.pbb.2008.01.016; Kaufmann WE, 1996, P NATL ACAD SCI USA, V93, P2317, DOI 10.1073/pnas.93.6.2317; Kaufmann WE, 1997, PROSTAG OTH LIPID M, V54, P601, DOI 10.1016/S0090-6980(97)00128-7; Kelso ML, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-108; Kiaei M, 2005, J NEUROCHEM, V93, P403, DOI 10.1111/j.1471-4159.2005.03024.x; Kyrkanides S, 2002, MOL BRAIN RES, V104, P159, DOI 10.1016/S0169-328X(02)00353-4; Lai YC, 2006, ARTHRITIS RHEUM-US, V54, P1184, DOI 10.1002/art.21771; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Matsumoto Y, 2004, NEUROPHARMACOLOGY, V46, P1195, DOI 10.1016/j.neuropharm.2004.02.012; McGeer PL, 2007, NEUROBIOL AGING, V28, P639, DOI 10.1016/j.neurobiolaging.2006.03.013; Mckee AC, 2008, BRAIN RES, V1207, P225, DOI 10.1016/j.brainres.2008.01.095; Moore AH, 2009, NEUROSCIENCE, V164, P1484, DOI 10.1016/j.neuroscience.2009.08.073; Moore AH, 2004, RADIAT RES, V161, P153, DOI 10.1667/RR3116; Moore AH, 2005, INT J RADIAT ONCOL, V62, P267, DOI 10.1016/j.ijrobp.2005.01.035; Moore AH, 2004, J NEUROIMMUNOL, V148, P32, DOI 10.1016/j.jneuroim.2003.11.001; Nakayama M, 1998, P NATL ACAD SCI USA, V95, P10954, DOI 10.1073/pnas.95.18.10954; O'Banion MK, 2010, PROSTAG OTH LIPID M, V91, P113, DOI 10.1016/j.prostaglandins.2009.04.008; O'Banion MK, 1999, CRIT REV NEUROBIOL, V13, P45, DOI 10.1615/CritRevNeurobiol.v13.i1.30; OBanion MK, 1996, J NEUROCHEM, V66, P2532; OITZL MS, 1993, BRAIN RES, V613, P160, DOI 10.1016/0006-8993(93)90468-3; Pepicelli O, 2005, J NEUROCHEM, V93, P1561, DOI 10.1111/j.1471-4159.2005.03150.x; Pugh CR, 1998, BRAIN BEHAV IMMUN, V12, P212, DOI 10.1006/brbi.1998.0524; Rajakariar R, 2007, P NATL ACAD SCI USA, V104, P20979, DOI 10.1073/pnas.0707394104; Resnick DK, 1998, J NEUROTRAUM, V15, P1005, DOI 10.1089/neu.1998.15.1005; Schwab JM, 2000, ACTA NEUROPATHOL, V99, P609, DOI 10.1007/s004010051170; Schwab JM, 2002, J NEUROSURG, V96, P892, DOI 10.3171/jns.2002.96.5.0892; Shaftel SS, 2007, J NEUROSCI, V27, P9301, DOI 10.1523/JNEUROSCI.1418-07.2007; Shaftel SS, 2007, J CLIN INVEST, V117, P1595, DOI 10.1172/JCI31450; Shaw KN, 2005, BRAIN RES, V1038, P231, DOI 10.1016/j.brainres.2005.01.035; Takemiya T, 2003, PROSTAG OTH LIPID M, V71, P205, DOI 10.1016/S1098-8823(03)00040-6; Takemiya T, 2007, NEUROCHEM INT, V51, P112, DOI 10.1016/j.neuint.2007.05.009; Teeling JL, 2010, BRAIN BEHAV IMMUN, V24, P409, DOI 10.1016/j.bbi.2009.11.006; Vlad SC, 2008, NEUROLOGY, V70, P1672, DOI 10.1212/01.wnl.0000311269.57716.63; Yermakova AV, 1999, J NEUROPATH EXP NEUR, V58, P1135, DOI 10.1097/00005072-199911000-00003; Yermakova AV, 2001, NEUROBIOL AGING, V22, P823, DOI 10.1016/S0197-4580(01)00303-7; Zhang D, 2009, TOXICOL APPL PHARM, V238, P64, DOI 10.1016/j.taap.2009.04.015	54	41	42	0	1	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0022-3042			J NEUROCHEM	J. Neurochem.	JUL	2010	114	1					247	258		10.1111/j.1471-4159.2010.06759.x			12	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	608FA	WOS:000278567100023	20412387	Bronze, Green Accepted			2021-06-18	
J	Dahlin, AP; Wetterhall, M; Caldwell, KD; Larsson, A; Bergquist, J; Hillered, L; Hjort, K				Dahlin, Andreas P.; Wetterhall, Magnus; Caldwell, Karin D.; Larsson, Anders; Bergquist, Jonas; Hillered, Lars; Hjort, Klas			Methodological Aspects on Microdialysis Protein Sampling and Quantification in Biological Fluids: An In Vitro Study on Human Ventricular CSF	ANALYTICAL CHEMISTRY			English	Article							TRAUMATIC BRAIN-INJURY; HUMAN SKELETAL-MUSCLE; SURFACE INTERACTIONS; CEREBRAL MICRODIALYSIS; CEREBROSPINAL-FLUID; POLYETHYLENE OXIDE; RELATIVE RECOVERY; HUMAN SKIN; MEMBRANE; MACROMOLECULES	There is growing interest in sampling of protein biomarkers from the interstitial compartment of the brain and other organs using high molecular cutoff membrane microdialysis (MD) catheters. However, recent data suggest that protein sampling across such MD membranes is a highly complex process that needs to be further studied. Here, we report three major improvements for microdialysis sampling of proteins in complex biological matrixes. The improvements in this in vitro study using human ventricular cerebrospinal fluid as the sample matrix include increased fluid recovery control, decreased protein adsorption on the microdialysis membrane and materials, and novel quantitative mass spectrometry analysis. Dextrans in different concentrations and sizes were added to the perfusion fluid. It was found that dextrans with molecular mass 250 and 500 kDa provided a fluid recovery close to 100%. An improved fluid recovery precision could be obtained by self-assembly triblock polymer surface modification of the MD catheters. The modified catheters also delivered a significantly increased extraction efficiency for some of the investigated proteins. The final improvement was to analyze the dialysates with isobaric tagged (iTRAQ) proteomics, followed by tandem mass spectrometric analysis. By using this technique, 48 proteins could be quantified and analyzed with respect to their extraction efficiencies. The novel aspects of microdialysis protein sampling, detection, and quantification in biological fluids presented in this study should be considered as a first step toward better understanding and handling of the challenges associated with microdialysis sampling of proteins. The next step is to optimize the developed methodology in vivo.	[Dahlin, Andreas P.; Hjort, Klas] Uppsala Univ, Dept Engn Sci, SE-75121 Uppsala, Sweden; [Wetterhall, Magnus; Caldwell, Karin D.; Bergquist, Jonas] Uppsala Univ, Dept Phys & Analyt Chem, SE-75124 Uppsala, Sweden; [Larsson, Anders] Uppsala Univ, Univ Uppsala Hosp, Dept Med Sci, SE-75185 Uppsala, Sweden; [Hillered, Lars] Uppsala Univ, Univ Uppsala Hosp, Dept Neurosci, SE-75185 Uppsala, Sweden	Dahlin, AP (corresponding author), Uppsala Univ, Dept Engn Sci, Box 534, SE-75121 Uppsala, Sweden.	andreas.dahlin@angstrom.uu.se	Dahlin, Andreas P/F-7210-2010; Bergquist, Jonas/C-5894-2015	Bergquist, Jonas/0000-0002-4597-041X; Dahlin, Andreas/0000-0002-0041-0902; Hillered, Lars/0000-0002-2808-9292	Uppsala Berzelii Technology Centre for Neurodiagnostics [P29797-1]; Swedish Research CouncilSwedish Research CouncilEuropean Commission; Uppsala University Hospital; Selander Foundation; Ahlen Foundation	We acknowledge Inger Stahl Myllyaho for collecting vCSF sample material and Uppsala Berzelii Technology Centre for Neurodiagnostics P29797-1 for financial and expertise support. We also acknowledge CMA Microdialysis and Pharmacosmos AC for sharing their knowledge and for material support. Additional sources of financial support were the Swedish Research Council, Uppsala University Hospital, the Selander Foundation, and the Ahlen Foundation.	ALEXANDRIDIS P, 1995, COLLOID SURFACE A, V96, P1, DOI 10.1016/0927-7757(94)03028-X; Anderson JM, 2008, SEMIN IMMUNOL, V20, P86, DOI 10.1016/j.smim.2007.11.004; Ao XP, 2006, METHODS, V38, P331, DOI 10.1016/j.ymeth.2005.11.012; Brody DL, 2008, SCIENCE, V321, P1221, DOI 10.1126/science.1161591; Bungay PM, 2010, J MEMBRANE SCI, V348, P131, DOI 10.1016/j.memsci.2009.10.050; Buttler T, 1996, J CHROMATOGR A, V725, P41, DOI 10.1016/0021-9673(95)01120-X; Chen H, 2008, PROG POLYM SCI, V33, P1059, DOI 10.1016/j.progpolymsci.2008.07.006; Choe L, 2007, PROTEOMICS, V7, P3651, DOI 10.1002/pmic.200700316; Clough GF, 2007, J INVEST DERMATOL, V127, P2799, DOI 10.1038/sj.jid.5700930; Clough GF, 2005, AAPS J, V7, pE686, DOI 10.1208/aapsj070369; Dumortier G, 2006, PHARM RES-DORDR, V23, P2709, DOI 10.1007/s11095-006-9104-4; Gerber SA, 2003, P NATL ACAD SCI USA, V100, P6940, DOI 10.1073/pnas.0832254100; Hanrieder J, 2009, J NEUROSCI METH, V177, P469, DOI 10.1016/j.jneumeth.2008.10.038; Helmy A, 2007, CURR MED CHEM, V14, P1525, DOI 10.2174/092986707780831113; Helmy A, 2009, J NEUROTRAUM, V26, P549, DOI 10.1089/neu.2008.0719; Hillered L, 2006, CURR OPIN CRIT CARE, V12, P112, DOI 10.1097/01.ccx.0000216576.11439.df; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; Hillman J, 2005, NEUROSURGERY, V56, P1264, DOI 10.1227/01.NEU.0000159711.93592.8D; JEON SI, 1991, J COLLOID INTERF SCI, V142, P159, DOI 10.1016/0021-9797(91)90044-9; JEON SI, 1991, J COLLOID INTERF SCI, V142, P149, DOI 10.1016/0021-9797(91)90043-8; KAZUHIKO I, 2002, BIOMEDICAL DIAGNOSTI, P367; Kjellstrom S, 1999, CHROMATOGRAPHIA, V50, P539, DOI 10.1007/BF02493658; Lee GJ, 2008, NEUROL RES, V30, P661, DOI 10.1179/174313208X289570; Li JT, 1996, ADV CHEM SER, V248, P61; Li ZH, 2008, J MEMBRANE SCI, V310, P237, DOI 10.1016/j.memsci.2007.10.051; Marklund N, 2009, J NEUROSURG, V110, P1227, DOI 10.3171/2008.9.JNS08584; Maurer Martin H, 2003, Proteome Sci, V1, P7, DOI 10.1186/1477-5956-1-7; McAdoo DJ, 2008, PHARMACOL BIOCHEM BE, V90, P282, DOI 10.1016/j.pbb.2008.03.001; Nejadnik MR, 2009, LANGMUIR, V25, P6245, DOI 10.1021/la9001169; Pan S, 2009, J PROTEOME RES, V8, P787, DOI 10.1021/pr800538n; Plock N, 2005, EUR J PHARM SCI, V25, P1, DOI 10.1016/j.ejps.2005.01.017; Roche S, 2008, PROTEOM CLIN APPL, V2, P428, DOI 10.1002/prca.200780040; Rosdahl H, 1997, ACTA PHYSIOL SCAND, V159, P261, DOI 10.1046/j.1365-201X.1997.123358000.x; Rosdahl H, 2000, INT J BIOL MACROMOL, V28, P69, DOI 10.1016/S0141-8130(00)00148-3; Rosenbloom AJ, 2006, J IMMUNOL METHODS, V309, P55, DOI 10.1016/j.jim.2005.11.013; Rosenbloom AJ, 2005, J NEUROSCI METH, V148, P147, DOI 10.1016/j.jneumeth.2005.04.018; Ross PL, 2004, MOL CELL PROTEOMICS, V3, P1154, DOI 10.1074/mcp.M400129-MCP200; Schutte RJ, 2004, ANAL CHEM, V76, P6058, DOI 10.1021/ac0493626; Singh-Joy SD, 2008, INT J TOXICOL, V27, P93, DOI 10.1080/10915810802244595; Stenken JA, 2010, AAPS J, V12, P73, DOI 10.1208/s12248-009-9163-7; Sun SD, 2003, J MEMBRANE SCI, V222, P3, DOI 10.1016/S0376-7388(03)00313-2; Torto N, 1998, J CHROMATOGR A, V806, P265, DOI 10.1016/S0021-9673(98)00063-6; Torto N, 2004, PURE APPL CHEM, V76, P879, DOI 10.1351/pac200476040879; Torto N, 1997, J MEMBRANE SCI, V130, P239, DOI 10.1016/S0376-7388(97)00030-6; Trickler W, 2003, J PHARM SCI-US, V92, P1419, DOI 10.1002/jps.10410; UNGERSTEDT U, 1991, J INTERN MED, V230, P365, DOI 10.1111/j.1365-2796.1991.tb00459.x; Wang XD, 2007, ANAL CHEM, V79, P1816, DOI 10.1021/ac061503b; Wisniewski N, 2001, J BIOMED MATER RES, V57, P513, DOI 10.1002/1097-4636(20011215)57:4<513::AID-JBM1197>3.0.CO;2-E	48	41	41	2	32	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0003-2700			ANAL CHEM	Anal. Chem.	JUN 1	2010	82	11					4376	4385		10.1021/ac1007706			10	Chemistry, Analytical	Chemistry	601MD	WOS:000278062800014	20465223				2021-06-18	
J	Stephens, R; Rutherford, A; Potter, D; Fernie, G				Stephens, Richard; Rutherford, Andrew; Potter, Douglas; Fernie, Gordon			Neuropsychological Consequence of Soccer Play in Adolescent UK School Team Soccer Players	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							HEAD-INJURY; FOOTBALL SOCCER	To assess mild head injury effects in adolescent soccer players, neuropsychological performance across school team soccer players, rugby players and noncontact sport players was assessed in a quasi-experimental cross-sectional design. One hundred eighty-five males were tested (ages 13-16; response rate 55%) and 86 contributed data to the analyses after exclusion for recent concussion and overlapping sports participation. Soccer players showed lower premorbid intellectual functioning, but neither soccer players nor rugby players showed neuropsychological decrement compared with noncontact sport players. Cumulative heading did not predict neuropsychological performance. While no specific attribute of soccer was linked with neuropsychological impairment, head injury predicted reduced attention for all participants. (The Journal of Neuropsychiatry and Clinical Neurosciences 2010; 22:295-303)	[Stephens, Richard; Rutherford, Andrew] Univ Keele, Sch Psychol, Keele ST5 5BG, Staffs, England; [Potter, Douglas] Univ Dundee, Sch Psychol, Dundee, Scotland; [Fernie, Gordon] Univ Liverpool, Sch Psychol, Liverpool L69 3BX, Merseyside, England	Stephens, R (corresponding author), Univ Keele, Sch Psychol, Keele ST5 5BG, Staffs, England.	r.stephens@psy.keele.ac.uk	Stephens, Richard/C-4062-2009	Stephens, Richard/0000-0002-5851-8975	Wellcome TrustWellcome TrustEuropean Commission [054248]	Funded by the Wellcome Trust, grant reference 054248. This research was approved by the Keele University Department of Psychology Research Ethics Committee.	Aiken L.S., 1991, MULTIPLE REGRESSION; Bailes JE, 2001, NEUROSURGERY, V48, P26, DOI 10.1097/00006123-200101000-00005; BANGSBO J, 1991, CAN J SPORT SCI, V16, P110; Barth J T, 2000, Dent Clin North Am, V44, P67; Barth JT., 1989, MILD HEAD INJURY, P257; BODEN B, 1988, AM J SPORTS MED, V26, P238; CHRISTENSEN PR, 1960, ALTERNATE USES FORM; Cohen J, 1988, STAT POWER BEHAV SCI; Cohen J., 2003, APPL MULTIPLE CORREL; EKBLOM B, 1986, SPORTS MED, V3, P50, DOI 10.2165/00007256-198603010-00005; Ellemberg D, 2007, CLIN J SPORT MED, V17, P369, DOI 10.1097/JSM.0b013e31814c3e3e; Erlanger DM, 1999, CLIN NEUROPSYCHOL, V13, P193, DOI 10.1076/clin.13.2.193.1963; Fox K, 2004, SPORT LEISURE RESULT; Golden C., 1978, STROOP COLOR WORD TE; Green GA, 1998, CLIN SPORT MED, V17, P795, DOI 10.1016/S0278-5919(05)70120-4; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; HOCHBERG Y, 1995, J STAT PLAN INFER, V48, P141, DOI 10.1016/0378-3758(95)00005-T; HOCHBERG Y, 1988, BIOMETRIKA, V75, P800, DOI 10.1093/biomet/75.4.800; Iverson G L, 2000, Appl Neuropsychol, V7, P247, DOI 10.1207/S15324826AN0704_7; Jaeger RG, 1998, HERPETOLOGICA, V54, pS64; Kaminski TW, 2007, J CLIN EXP NEUROPSYC, V29, P742, DOI 10.1080/13825580600976911; KOVACS M, 1982, CHILDHOOD DEPRESSION; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Putukian M, 2000, CLIN J SPORT MED, V10, P104, DOI 10.1097/00042752-200004000-00004; ROM DM, 1990, BIOMETRIKA, V77, P663, DOI 10.2307/2337008; Rutherford A, 2005, J CLIN EXP NEUROPSYC, V27, P299, DOI 10.1080/13803390490515504; Rutherford A, 2003, NEUROPSYCHOL REV, V13, P153, DOI 10.1023/A:1025525613477; RUTHERFORD A, 1992, BRIT J MATH STAT PSY, V45, P197, DOI 10.1111/j.2044-8317.1992.tb00988.x; Rutherford A., 2001, INTRO ANOVA ANCOVA G; Rutherford A, 2009, J CLIN EXP NEUROPSYC, V31, P664, DOI 10.1080/13803390802484755; Satz P, 2001, CURR DIR PSYCHOL SCI, V10, P106, DOI 10.1111/1467-8721.00127; SHAFFER JP, 1986, J AM STAT ASSOC, V81, P826, DOI 10.2307/2289016; SHAFFER JP, 1995, ANNU REV PSYCHOL, V46, P561, DOI 10.1146/annurev.ps.46.020195.003021; *SOCC ASS FED INT, 2007, FIFA BIG COUNT 2006; Stephens R, 2005, CHILD NEUROPSYCHOL, V11, P513, DOI 10.1080/092970490959629; Straume-Naesheim TM, 2005, BRIT J SPORT MED, V39, pI70, DOI 10.1136/bjsm.2005.019646; Tysvaer A, 1981, Br J Sports Med, V15, P163; Webbe FM, 2003, CLIN SPORT MED, V22, P577, DOI 10.1016/S0278-5919(02)00103-5; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D., 1974, MANUAL WECHSLER INTE; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Westfall P. H, 1993, RESAMPLING BASED MUL; WITHERS R T, 1982, Journal of Human Movement Studies, V8, P159; Zetterberg H, 2007, BRIT J SPORT MED, V41, DOI 10.1136/bjsm.2007.037143; ZIMMERMAN P, 1995, ATTENTIONAL PERFORMA	45	41	41	0	14	AMER PSYCHIATRIC PUBLISHING, INC	WASHINGTON	800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA	0895-0172	1545-7222		J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	SUM	2010	22	3					295	303		10.1176/appi.neuropsych.22.3.295			9	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	635IM	WOS:000280648800006	20686136				2021-06-18	
J	Padayachy, LC; Figaji, AA; Bullock, MR				Padayachy, Llewellyn C.; Figaji, Anthony A.; Bullock, M. R.			Intracranial pressure monitoring for traumatic brain injury in the modern era	CHILDS NERVOUS SYSTEM			English	Article						Traumatic brain injury; Intracranial pressure; Brain monitoring; Children; Neurocritical care	SEVERE HEAD-INJURY; CEREBRAL PERFUSION-PRESSURE; INTRA-CRANICAL PRESSURE; AGGRESSIVE TREATMENT; CLINICAL-EVALUATION; CRITICAL THRESHOLDS; OXYGEN-CONSUMPTION; INTENSIVE-CARE; BLOOD-PRESSURE; TISSUE OXYGEN	Intracranial pressure (ICP) has become a cornerstone of care in adult and pediatric patients with traumatic brain injury (TBI). Despite the fact that continuous monitoring of ICP in TBI was described almost 60 years ago, there are no randomized trials confirming the benefit of ICP monitoring and treatment in TBI. There is, however, a large body of clinical evidence showing that ICP monitoring influences treatment and leads to better outcomes if part of protocol-driven therapy. However, treatment of ICP has adverse effects, and there are several questions about ICP management that have yet to be definitively answered, particularly in pediatric TBI. This review examines the history and evolution of ICP monitoring, pathophysiological concepts that influence ICP interpretation, ongoing controversies, and the place of ICP monitoring in modern neurocritical care.	[Figaji, Anthony A.] Red Cross Childrens Hosp, ZA-7700 Cape Town, South Africa; [Bullock, M. R.] Univ Miami, Miller Sch Med, Dept Neurosurg, Miami, FL 33136 USA; [Padayachy, Llewellyn C.; Figaji, Anthony A.] Univ Cape Town, Red Cross Childrens Hosp, Sch Child & Adolescent Hlth, Div Neurosurg, ZA-7925 Cape Town, South Africa	Figaji, AA (corresponding author), Red Cross Childrens Hosp, 617 ICH Bldg,Klipfontein Rd, ZA-7700 Cape Town, South Africa.	Anthony.Figaji@uct.ac.za	Padayachy, Llewellyn/AAD-3821-2019	Figaji, Anthony/0000-0002-3357-6490	National Research Foundation [GUN 2072790]	This work was supported in part by a grant from the South Africa-Swedish Links Program/National Research Foundation (GUN 2072790).	Adelson P David, 2003, Pediatr Crit Care Med, V4, pS31; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS2, DOI 10.1097/01.CCM.0000066600.71233.01; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS25; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS19; Akopian G, 2007, AM SURGEON, V73, P447; Andrews PJD, 2008, INTENS CARE MED, V34, P1362, DOI 10.1007/s00134-008-1103-y; ASGEIRSSON B, 1994, INTENS CARE MED, V20, P260, DOI 10.1007/BF01708961; ASTRUP J, 1981, STROKE, V12, P723, DOI 10.1161/01.STR.12.6.723; Balestreri M, 2004, ACTA NEUROCHIR, V146, P131, DOI 10.1007/s00701-003-0187-y; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS65; BRATTON SL, 2007, J NEUROTRAUMA S1, V24, pS87; Bratton SL, 2007, J NEUROTRAUMA S1, V24, P555, DOI DOI 10.1089/NEU.2007.9988; BRUCE DA, 1979, CHILD BRAIN, V5, P174; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Cantais E, 2001, INTENS CARE MED, V27, P1511, DOI 10.1007/s001340101039; Catala-Temprano A, 2007, J NEUROSURG, V106, P463, DOI 10.3171/ped.2007.106.6.463; Chambers IR, 2006, J NEUROL NEUROSUR PS, V77, P234, DOI 10.1136/jnnp.2005.072215; Chesnut RM, 2008, J TRAUMA, V65, P500, DOI 10.1097/TA.0b013e31818020b3; Chesnut RM, 2006, CRIT CARE MED, V34, P2262, DOI 10.1097/01.CCM.0000229885.76483.F7; Citerio G, 2008, NEUROSURGERY, V63, P1152, DOI 10.1227/01.NEU.0000335148.87042.D7; Coles JP, 2007, CRIT CARE MED, V35, P568, DOI 10.1097/01.CCM.0000254066.37187.88; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; Cremer OL, 2005, CRIT CARE MED, V33, P2207, DOI 10.1097/01.CCM.0000181300.99078.B5; Czosnyka Marek, 2007, Neurosurg Focus, V22, pE10; Dean NP, 2007, J NEUROSURG, V107, P387, DOI 10.3171/PED-07/11/387; Enriquez P, 2004, CURR PHARM DESIGN, V10, P2131; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; Figaji AA, 2008, NEUROSURGERY, V63, P83, DOI 10.1227/01.NEU.0000335074.39728.00; Figaji AA, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E4; Figaji AA, 2009, SURG NEUROL, V72, P389, DOI 10.1016/j.surneu.2009.02.012; Figaji AA, 2009, CHILD NERV SYST, V25, P1325, DOI 10.1007/s00381-009-0822-x; Figaji AA, 2009, AM SURGEON, V75, P441; Fodstad H, 2006, NEUROSURGERY, V59, P1132, DOI 10.1227/01.NEU.0000245582.08532.7C; Fog M, 1938, J NEUROL PSYCHIATRY, V1, P187, DOI 10.1136/jnnp.1.3.187; Gelabert-Gonzalez M, 2006, ACTA NEUROCHIR, V148, P435, DOI 10.1007/s00701-005-0683-3; GOSLING RG, 1974, P ROY SOC MED, V67, P447, DOI 10.1177/00359157740676P113; Grinkeviciute DE, 2008, MEDICINA-LITHUANIA, V44, P119, DOI 10.3390/medicina44020015; GUILLAUME J, 1951, REV NEUROL, V84, P131; Hackbarth RM, 2002, CRIT CARE MED, V30, P1630, DOI 10.1097/00003246-200207000-00038; Howells T, 2005, J NEUROSURG, V102, P311, DOI 10.3171/jns.2005.102.2.0311; Huschak G, 2009, J NEUROSURG ANESTH, V21, P155, DOI 10.1097/ANA.0b013e31818f2eac; Jagannathan J, 2008, J NEUROSURG-PEDIATR, V2, P240, DOI 10.3171/PED.2008.2.10.240; JONES TH, 1981, J NEUROSURG, V54, P773, DOI 10.3171/jns.1981.54.6.0773; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Keenan Heather T, 2005, Pediatr Crit Care Med, V6, P537, DOI 10.1097/01.PCC.0000164638.44600.67; Kellie George, 1824, Trans Med Chir Soc Edinb, V1, P84; Kohta M, 2007, J CLIN NEUROSCI, V14, P167, DOI 10.1016/j.jocn.2006.01.042; KONTOS HA, 1978, AM J PHYSIOL, V234, pH371; Koskinen LOD, 2005, NEUROSURGERY, V56, P693, DOI 10.1227/01.NEU.0000156609.95596.24; Lang EW, 2000, BRIT J NEUROSURG, V14, P117; Lang JM, 2003, NEUROSURGERY, V52, P1455, DOI 10.1227/01.NEU.0000065136.70455.6F; LANGFITT TW, 1964, J NEUROSURG, V21, P989, DOI 10.3171/jns.1964.21.11.0989; LASSEN NA, 1959, PHYSIOL REV, V39, P183; Lescot T, 2005, ACTA NEUROCHIR, V147, P125, DOI 10.1007/s00701-004-0355-8; Levasseur JE, 2006, NEUROSURGERY, V59, P1122, DOI 10.1227/01.NEU.0000245581.00908.AF; Luerssen T G, 1997, Semin Pediatr Neurol, V4, P146, DOI 10.1016/S1071-9091(97)80033-2; LUNDBERG N, 1960, Acta Psychiatr Scand Suppl, V36, P1; LUNDBERG N, 1965, J NEUROSURG, V22, P581, DOI 10.3171/jns.1965.22.6.0581; LUNDBERG N, 1965, ACTA NEUROL SCAND, VS 41, P115; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Maas AI, 2008, J TRAUMA, V65, P966, DOI 10.1097/TA.0b013e318184ee7b; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; Marmarou A, 1997, ACT NEUR S, V70, P68; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; Martini RP, 2009, J NEUROSURG, V111, P644, DOI 10.3171/2009.2.JNS08998; Monro A, 1823, OBSERVATIONS STRUCTU; Morris KP, 2006, INTENS CARE MED, V32, P1606, DOI 10.1007/s00134-006-0285-4; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; Narotam PK, 2009, J NEUROSURG, V111, P672, DOI 10.3171/2009.4.JNS081150; Nordstrom Carl-Henrik, 2006, Neurosurgery, V58, pE590; O'Phelan KH, 2009, NEUROCRIT CARE, V10, P280, DOI 10.1007/s12028-008-9183-7; Oertel M, 2002, J NEUROSURG, V97, P1045, DOI 10.3171/jns.2002.97.5.1045; Palmer S, 2001, J TRAUMA, V50, P657, DOI 10.1097/00005373-200104000-00010; Panerai RB, 1998, PHYSIOL MEAS, V19, P305, DOI 10.1088/0967-3334/19/3/001; PAULSON OB, 1990, CEREBROVAS BRAIN MET, V2, P161; Pietrini D, 2004, Minerva Anestesiol, V70, P549; Plotz FB, 2007, INTENS CARE MED, V33, P1675, DOI 10.1007/s00134-007-0643-x; POPLE IK, 1995, PEDIATR NEUROSURG, V23, P64, DOI 10.1159/000120938; Procaccio F, 2000, J Neurosurg Sci, V44, P1; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Rossi S, 1998, ACT NEUR S, V71, P91; RYDER HW, 1953, J LAB CLIN MED, V41, P428; Salim A, 2008, AM SURGEON, V74, P1088; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; Shafi S, 2008, J TRAUMA, V64, P335, DOI 10.1097/TA.0b013e31815dd017; SHAPIRO K, 1982, J NEUROSURG, V56, P819, DOI 10.3171/jns.1982.56.6.0819; SHARPLES PM, 1995, J NEUROL NEUROSUR PS, V58, P145, DOI 10.1136/jnnp.58.2.145; SIESJO BK, 1992, J NEUROSURG, V77, P169, DOI 10.3171/jns.1992.77.2.0169; Steiner LA, 2003, STROKE, V34, P2404, DOI 10.1161/01.STR.0000089014.59668.04; Wiegand C, 2007, DEV MED CHILD NEUROL, V49, P935, DOI 10.1111/j.1469-8749.2007.00935.x; Yau YH, 2005, ACT NEUR S, V95, P289; Young Jeffrey S, 2003, Neurosurg Focus, V15, pE2; Zauner A, 2002, NEUROSURGERY, V51, P289, DOI 10.1097/00006123-200208000-00003; Zwienenberg M, 1999, J NEUROTRAUM, V16, P937, DOI 10.1089/neu.1999.16.937	98	41	42	1	6	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0256-7040	1433-0350		CHILD NERV SYST	Childs Nerv. Syst.	APR	2010	26	4					441	452		10.1007/s00381-009-1034-0			12	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	568QI	WOS:000275537100006	19937249				2021-06-18	
J	Melcer, T; Walker, GJ; Galarneau, M; Belnap, B; Konoske, P				Melcer, Ted; Walker, G. Jay; Galarneau, Michael; Belnap, Brian; Konoske, Paula			Midterm Health and Personnel Outcomes of Recent Combat Amputees	MILITARY MEDICINE			English	Article							POSTTRAUMATIC-STRESS-DISORDER; OPERATION ENDURING FREEDOM; TRAUMATIC BRAIN-INJURY; FOLLOW-UP; HETEROTOPIC OSSIFICATION; MILITARY PERSONNEL; IRAQI-FREEDOM; VIETNAM-WAR; AMPUTATIONS; AFGHANISTAN	Objective: Warfighters who sustained combat amputations in Operation Enduring Freedom or Operation Iraqi Freedom (OEF/OIF) have unique challenges during rehabilitation. This study followed their outcomes. Methods: Subjects were 382 U.S. warfighters with major limb amputations utter combat injury in OEF/OIF between 2001 and 2005. Outcome measures were diagnoses, treatment codes, and personnel events captured by health and personnel data-bases during 24 months postinjury. Results: Most patients had multiple complications generally within 30 days postinjury (e.g., infections, anemia), with important exceptions (e.g., heterotopic ossification). Lower limb amputees had 50% more complications than upper limb amputees. Two-thirds of patients had a mental health disorder (e.g.. adjustment, post-traumatic stress disorder), with rates of major disorder categories between 18% and 25%. Over 80% of patients used physical and occupational therapy. prosthetic/orthotic services. and psychiatric care. Conclusions: Combat amputees had a complex set of outcomes supporting the continued need for military amputee care programs.	[Melcer, Ted; Galarneau, Michael; Konoske, Paula] USN, Hlth Res Ctr, San Diego, CA 92106 USA; [Walker, G. Jay] Sci Applicat Int Corp, San Diego, CA 92121 USA; [Belnap, Brian] USN, San Diego Med Ctr, Comprehens Combat & Complex Casualty Care Naval M, San Diego, CA 92134 USA	Melcer, T (corresponding author), USN, Hlth Res Ctr, Dept 161,Bldg 331,140 Sylvester Rd, San Diego, CA 92106 USA.				Office of the Assistant Secretary of Defense (Health Affairs); U.S. Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC); Marine Corps Systems Command; Office of Naval ResearchOffice of Naval Research	This work was funded by the Office of the Assistant Secretary of Defense (Health Affairs), U.S. Army Medical Research and Materiel Command, Marine Corps Systems Command, and the Office of Naval Research.	Andersen Romney C, 2006, J Am Acad Orthop Surg, V14, pS24; Balboni TA, 2006, INT J RADIAT ONCOL, V65, P1289, DOI 10.1016/j.ijrobp.2006.03.053; Bosse MJ, 2002, NEW ENGL J MED, V347, P1924, DOI 10.1056/NEJMoa012604; Centers for Disease Control and Prevention, TRAUM BRAIN INJ US R; COPES WS, 1988, J TRAUMA, V28, P69, DOI 10.1097/00005373-198801000-00010; COVEY D, 2005, INSTR COURSE LECT, V57, P65; Dohrenwend BP, 2006, SCIENCE, V313, P979, DOI 10.1126/science.1128944; Dougherty PJ, 2003, J TRAUMA, V54, P718, DOI 10.1097/01.TA.0000046260.16866.A9; Dougherty PJ, 2001, J BONE JOINT SURG AM, V83A, P383, DOI 10.2106/00004623-200103000-00010; FISCHER H, CRS REPORT C OPERATI; FRANKLIN A, 2006, ARCH PHYS MED REHAB, V87, pE30; GAJEWSKI G, 2006, J AM ACAD ORTHOP S S, V14, pS183; Galarneau MR, 2006, MIL MED, V171, P691, DOI 10.7205/MILMED.171.8.691; Grieger TA, 2006, AM J PSYCHIAT, V163, P1777, DOI 10.1176/appi.ajp.163.10.1777; Gunawardena NS, 2006, MIL MED, V171, P283, DOI 10.7205/MILMED.171.4.283; Gunderson EKE, 2005, MIL MED, V170, P172; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Hospenthal DR, 2008, J TRAUMA, V64, pS211, DOI 10.1097/TA.0b013e318163c421; Ketz Ann Kobiela, 2008, Crit Care Nurs Clin North Am, V20, P51, DOI 10.1016/j.ccell.2007.10.006; KISBAUGH D, 1995, MIL MED, V160, P82; Larson GE, 2008, AM J EPIDEMIOL, V167, P1269, DOI 10.1093/aje/kwn084; Lin DL, 2004, J ORTHOP TRAUMA, V18, pS48, DOI 10.1097/00005131-200409001-00008; MacGregor AJ, 2009, MIL MED, V174, P224, DOI 10.7205/MILMED-D-03-9107; MacKenzie EJ, 2005, J BONE JOINT SURG AM, V87A, P1801, DOI 10.2106/JBJS.E.00032; Masini BD, 2009, J ORTHOP TRAUMA, V23, P261, DOI 10.1097/BOT.0b013e31819dfa04; McCarthy ML, 2003, J BONE JOINT SURG AM, V85A, P1689, DOI 10.2106/00004623-200309000-00006; Murray CK, 2008, J TRAUMA, V64, pS239, DOI 10.1097/TA.0b013e318163cd14; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Pasquina PF, 2006, ARCH PHYS MED REHAB, V87, pS34, DOI 10.1016/j.apmr.2005.11.026; Pezzin LE, 2000, ARCH PHYS MED REHAB, V81, P292, DOI 10.1053/apmr.2000.0810292; Potter Benjamin K, 2006, J Am Acad Orthop Surg, V14, pS188; Potter BK, 2007, J BONE JOINT SURG AM, V89A, P476, DOI 10.2106/JBJS.F.00412; Rybarczyk B, 2000, HANDBOOK OF REHABILITATION PSYCHOLOGY, P29, DOI 10.1037/10361-002; Smurr LM, 2008, J HAND THER, V21, P160, DOI 10.1197/j.jht.2007.09.006; Stansbury LG, 2008, J ORTHOP TRAUMA, V22, P43, DOI 10.1097/BOT.0b013e31815b35aa; Starr AJ, 2004, J BONE JOINT SURG AM, V86A, P1115, DOI 10.2106/00004623-200406000-00001; Toomey R, 2008, AM J EPIDEMIOL, V167, P1277, DOI 10.1093/aje/kwn083; Yun HC, 2008, J TRAUMA, V64, pS163, DOI 10.1097/TA.0b013e318160868c; Zouris JM, 2006, MIL MED, V171, P246, DOI 10.7205/MILMED.171.3.246	40	41	42	1	12	ASSOC MILITARY SURG US	BETHESDA	9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA	0026-4075			MIL MED	Milit. Med.	MAR	2010	175	3					147	154		10.7205/MILMED-D-09-00120			8	Medicine, General & Internal	General & Internal Medicine	582GT	WOS:000276585400005	20358702	Bronze			2021-06-18	
J	LaPlaca, MC; Prado, GR				LaPlaca, Michelle C.; Prado, Gustavo R.			Neural mechanobiology and neuronal vulnerability to traumatic loading	JOURNAL OF BIOMECHANICS			English	Article						Traumatic brain injury; Traumatic spinal cord injury; Injury biomechanics; Cellular models; Mechanoporation; Plasma membrane permeability	IN-VITRO MODEL; EXPERIMENTAL BRAIN-INJURY; NERVOUS-SYSTEM INJURY; SPINAL-CORD-INJURY; AXONAL INJURY; PLASMA-MEMBRANE; MECHANICAL STRETCH; WHITE-MATTER; CEREBRAL CONCUSSION; CORTICAL-NEURONS	In order to understand the physical tolerance of neurons to traumatic insults, engineers and neuroscientists have attempted to reproduce the biomechanical environment during a traumatic event using in vitro injury systems with isolated components of the nervous system. This approach allows one to begin to unravel the underlying molecular and biochemical mechanisms that lead to cell dysfunction and death as a function of mechanical inputs. Excess mechanical force and deformation causes structural and functional breakdown, including several key deleterious cellular processes, such as membrane damage, an upset of calcium homeostasis, glutamate release, cell death, and caspase-mediated proteolysis. Understanding of the mechanotransduction events, however, that lead to cellular failure and dysfunction, are not well understood. Mechanically characterized cellular models of traumatic loading are critical to the improved understanding of mechanotransduction in the context of neural injury, the improvement of protective systems, and to provide a controlled setting for testing therapeutic interventions. In this review of the cellular mechanics of traumatic neural loading. we focus on the backdrop and motivation for studying mechanical thresholds in neurons and glial cells and discuss some of the acute responses that may help elucidate improved tolerance criteria and illuminate future research directions. (C) 2009 Elsevier Ltd. All rights reserved.	[LaPlaca, Michelle C.; Prado, Gustavo R.] Emory Univ, Wallace H Coulter Dept Biomed Engn, Neural Injury Biomech & Repair Lab, Georgia Inst Technol,Inst Bioengn & Biosci, Atlanta, GA 30322 USA	LaPlaca, MC (corresponding author), Emory Univ, Wallace H Coulter Dept Biomed Engn, Neural Injury Biomech & Repair Lab, Georgia Inst Technol,Inst Bioengn & Biosci, 313 Ferst Dr, Atlanta, GA 30322 USA.	michelle.laplaca@bme.gatech.edu			Whitaker Foundation; Institute for Bioengineering and Bioscience; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [EB000786]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB000786] Funding Source: NIH RePORTER	The authors acknowledge Dr. Mark R. Prausnitz and Dr. Donna M. Geddes-Klein for technical advice, Dr. Robert P. Apkarian (deceased) for generous electron microscopy assistance, and the Whitaker Foundation, the Institute for Bioengineering and Bioscience, and the NIH (EB000786) for funding.	Adelson PD, 2000, J NEUROTRAUM, V17, P273, DOI 10.1089/neu.2000.17.273; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; BALENTINE JD, 1988, LAB INVEST, V58, P93; Barbee KA, 2005, ANN NY ACAD SCI, V1066, P67, DOI 10.1196/annals.1363.006; Borgens RB, 2000, FASEB J, V14, P27; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Cargill RS, 1996, J NEUROTRAUM, V13, P395, DOI 10.1089/neu.1996.13.395; Cater HL, 2006, J BIOMECH, V39, P2810, DOI 10.1016/j.jbiomech.2005.09.023; Choo AM, 2007, J NEUROSURG-SPINE, V6, P255, DOI 10.3171/spi.2007.6.3.255; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Conti AC, 1998, J NEUROSCI, V18, P5663; Cukierman E, 2001, SCIENCE, V294, P1708, DOI 10.1126/science.1064829; Cullen DK, 2006, J NEUROTRAUM, V23, P1304, DOI 10.1089/neu.2006.23.1304; CULLEN DK, 2007, BRAIN RES; Eddleman CS, 1997, P NATL ACAD SCI USA, V94, P4745, DOI 10.1073/pnas.94.9.4745; Elkin BS, 2007, J NEUROTRAUM, V24, P812, DOI 10.1089/neu.2006.0169; Elkin BS, 2007, STAPP CAR CRASH JO, V51, P127; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Farkas O, 2006, J NEUROSCI, V26, P3130, DOI 10.1523/JNEUROSCI.5119-05.2006; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Galle B, 2007, J BIOMECH, V40, P3029, DOI 10.1016/j.jbiomech.2007.03.014; Geddes DM, 2003, J NEUROTRAUM, V20, P1039, DOI 10.1089/089771503770195885; Geddes DM, 2001, J BIOMECH ENG-T ASME, V123, P247, DOI 10.1115/1.1374201; Geddes-Klein DM, 2006, J NEUROTRAUM, V23, P193, DOI 10.1089/neu.2006.23.193; Gennarelli TA, 1997, NEUROSCIENTIST, V3, P73, DOI 10.1177/107385849700300117; Gennarelli TA, 1972, P 16 STAPP CAR CRASH; Graham DI, 2000, ACTA NEUROPATHOL, V99, P117, DOI 10.1007/PL00007414; Grembowicz KP, 1999, MOL BIOL CELL, V10, P1247, DOI 10.1091/mbc.10.4.1247; GURDJIAN ES, 1966, J TRAUM, V6, P600, DOI 10.1097/00005373-196609000-00005; HAYES RL, 1995, J NEUROTRAUM, V12, P933, DOI 10.1089/neu.1995.12.933; Holbourn AHS, 1943, LANCET, V2, P438; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kilinc D, 2008, EXP NEUROL, V212, P422, DOI 10.1016/j.expneurol.2008.04.025; KING AI, 2003, P 2003 IRCOBI C LISB; Kumaria A, 2008, BRIT J NEUROSURG, V22, P200, DOI 10.1080/02688690701772413; LaPlaca MC, 2007, PROG BRAIN RES, V161, P13, DOI 10.1016/S0079-6123(06)61002-9; LaPlaca MC, 2005, J BIOMECH, V38, P1093, DOI 10.1016/j.jbiomech.2004.05.032; LaPlaca MC, 1997, ANN BIOMED ENG, V25, P665, DOI 10.1007/BF02684844; LaPlaca MC, 1997, J NEUROTRAUM, V14, P355, DOI 10.1089/neu.1997.14.355; LaPlaca MC, 1998, J NEUROSCI RES, V52, P220, DOI 10.1002/(SICI)1097-4547(19980415)52:2<220::AID-JNR10>3.0.CO;2-B; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; Lusardi TA, 2004, ANN BIOMED ENG, V32, P1546, DOI 10.1114/B:ABME.0000049038.75368.75; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McNeil PL, 2002, J CELL SCI, V115, P873; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; Morrison B, 1998, J NEUROTRAUM, V15, P911, DOI 10.1089/neu.1998.15.911; Morrison B, 2006, J NEUROSCI METH, V150, P192, DOI 10.1016/j.jneumeth.2005.06.014; Morrison B, 1998, ANN BIOMED ENG, V26, P381, DOI 10.1114/1.61; Morrison B., 2003, STAPP CAR CRASH J, V47, P93; NAWASHIRO H, 1995, NEUROL RES, V17, P455, DOI 10.1080/01616412.1995.11740363; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Pfister BJ, 2003, ANN BIOMED ENG, V31, P589, DOI 10.1114/1.1566445; POVISHLOK J, 1996, ACTA NEUROCHIR SUPP, V66, P81; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Prado GR, 2005, J NEURAL ENG, V2, P148, DOI 10.1088/1741-2560/2/4/011; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; RAGHUPATHI R, 1995, BRAIN PATHOL, V5, P437, DOI 10.1111/j.1750-3639.1995.tb00622.x; REGAN RF, 1994, BRAIN RES, V633, P236, DOI 10.1016/0006-8993(94)91544-X; RINK A, 1995, AM J PATHOL, V147, P1575; RZIGALINSKI BA, 1996, J NEUROTRAUM, V13, P609; SAHAY KB, 1992, J BIOMECH, V25, P319, DOI 10.1016/0021-9290(92)90029-Z; Schindler M, 2006, CELL BIOCHEM BIOPHYS, V45, P215, DOI 10.1385/CBB:45:2:215; Serbest G, 2006, FASEB J, V20, P308, DOI 10.1096/fj.05-4024fje; Shi R, 2006, J NEUROPHYSIOL, V95, P3384, DOI 10.1152/jn.00350.2005; Shi RY, 2004, J NEUROCYTOL, V33, P203, DOI 10.1023/B:NEUR.0000030695.76840.19; SHIELDS M, 1987, BIOCHIM BIOPHYS ACTA, V905, P181, DOI 10.1016/0005-2736(87)90022-8; Simon CM, 2009, J NEUROTRAUM, V26, P563, DOI 10.1089/neu.2008.0523; Singleton RH, 2004, J NEUROSCI, V24, P3543, DOI 10.1523/JNEUROSCI.5048-03.2004; Smith DH, 1999, J NEUROSCI, V19, P4263; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Stone JR, 2001, EXP NEUROL, V172, P320, DOI 10.1006/exnr.2001.7818; Teasell R, 2007, BRAIN INJURY, V21, P201, DOI 10.1080/02699050701201854; Terasaki M, 1997, J CELL BIOL, V139, P63, DOI 10.1083/jcb.139.1.63; Togo T, 1999, J CELL SCI, V112, P719; Tymianski M, 1996, NEUROSURGERY, V38, P1176; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; Weber JT, 2001, J BIOL CHEM, V276, P1800, DOI 10.1074/jbc.M009209200; Weber JT, 1999, CELL CALCIUM, V26, P289, DOI 10.1054/ceca.1999.0082; WHALEN MJ, 2007, J CEREB BLOOD FLOW M; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Zhang JY, 2006, BIOMED SCI INSTRUM, V42, P501	86	41	42	1	30	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290	1873-2380		J BIOMECH	J. Biomech.	JAN 5	2010	43	1			SI		71	78		10.1016/j.jbiomech.2009.09.011			8	Biophysics; Engineering, Biomedical	Biophysics; Engineering	547SL	WOS:000273909400011	19811784				2021-06-18	
J	Bortnik, KE; Boone, KB; Marion, SD; Amano, S; Ziegler, E; Cottingham, ME; Victor, TL; Zeller, MA				Bortnik, Kirsty E.; Boone, Kyle B.; Marion, Sarah D.; Amano, Stacy; Ziegler, Elizabeth; Cottingham, Maria E.; Victor, Tara L.; Zeller, Michelle A.			EXAMINATION OF VARIOUS WMS-III LOGICAL MEMORY SCORES IN THE ASSESSMENT OF RESPONSE BIAS	CLINICAL NEUROPSYCHOLOGIST			English	Article						Logical Memory; Wechsler Memory Scale - III; Malingering; Rarely Missed Index; Effort	RARELY MISSED INDEX; TRAUMATIC BRAIN-INJURY; SUSPECT EFFORT; RECOGNITION TRIAL; SENSITIVITY; SPECIFICITY; PERFORMANCE; VALIDITY; SCALE	The assessment of response validity during neuropsychological evaluation is an integral part of the testing process. Research has increasingly focused on the use of "embedded'' effort measures (derived from standard neuropsychological tasks) because they do not require additional administration time and are less likely to be identified as effort indicators by test takers because of their primary focus as measures of cognitive function. The current study examined the clinical utility of various WMS-III Logical Memory scores in detecting response bias, as well as the Rarely Missed Index, an embedded effort indicator derived from the WMS-III Logical Memory Delayed Recognition subtest. The Rarely Missed Index cut-off only identified 24.1% of 63 non-credible participants (at >= 90% specificity in 125 credible patients), and cut-offs for other Logical Memory variables were in fact found to be more sensitive to non-credible performance. A new indicator, consisting of the weighted combination of the two most sensitive Logical Memory subtest scores (Logical Memory II raw score and Logical Memory Delayed Recognition raw score), was associated with 53% to 60% sensitivity, and thus may be an effective adjunct when utilized in conjunction with other validated effort indicators and collateral information in identifying non-credible performance.	[Bortnik, Kirsty E.; Marion, Sarah D.; Amano, Stacy] Fuller Grad Sch Psychol, Pasadena, CA USA; [Boone, Kyle B.] Alliant Int Univ, Los Angeles, CA USA; [Ziegler, Elizabeth] Spokane VA Med Ctr, Spokane, WA USA; [Victor, Tara L.] Calif State Univ Dominguez Hills, Carson, CA 90747 USA; [Zeller, Michelle A.] W LA VA Med Ctr, Los Angeles, CA USA	Bortnik, KE (corresponding author), Fuller Grad Sch Psychol, Pasadena, CA USA.	kirstybortnik@fuller.edu	Victor, Tara/K-6581-2019				Arnold G, 2005, CLIN NEUROPSYCHOL, V19, P105, DOI 10.1080/13854040490888567; Arnold G., 2007, ASSESSMENT FEIGNED C, P178; Babikian T, 2006, CLIN NEUROPSYCHOL, V20, P145, DOI 10.1080/13854040590947362; Babikian T., 2007, ASSESSMENT FEIGNED C, P103; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P19, DOI 10.1076/clin.15.1.19.1907; Boone K., 2002, DOT COUNTING TEST; Boone K., CLIN NEUROP IN PRESS; Boone K. B., 2002, B TEST; Boone K. B., 2007, ASSESSMENT FEIGNED C, P29; Boone KB, 2005, ARCH CLIN NEUROPSYCH, V20, P301, DOI 10.1016/j.acn.2004.08.001; Boone KB, 2002, ARCH CLIN NEUROPSYCH, V17, P625, DOI 10.1016/S0887-6177(01)00166-4; Boone KB, 2002, J CLIN EXP NEUROPSYC, V24, P561, DOI 10.1076/jcen.24.5.561.1004; BOONE KB, 2007, ASSESSMENT MALINGERE, P27; BRANDT J, 1988, CLIN ASSESSMENT MALI, P65; Dean AC, 2008, CLIN NEUROPSYCHOL, V22, P705, DOI 10.1080/13854040701440493; Dean AC, 2009, CLIN NEUROPSYCHOL, V23, P133, DOI 10.1080/13854040701819050; Greve KW, 2008, CLIN NEUROPSYCHOL, V22, P896, DOI 10.1080/13854040701565208; Greve KW, 2009, ASSESSMENT, V16, P237, DOI 10.1177/1073191108326227; Haines ME, 2001, CLIN NEUROPSYCHOL, V15, P171, DOI 10.1076/clin.15.2.171.1891; Iverson GL, 1998, BRAIN INJURY, V12, P275, DOI 10.1080/026990598122575; Killgore WDS, 2000, J CLIN EXP NEUROPSYC, V22, P761; Lange RT, 2006, J CLIN EXP NEUROPSYC, V28, P294, DOI 10.1080/13803390490918156; Lange RT, 2005, J CLIN EXP NEUROPSYC, V27, P412, DOI 10.1080/13803390490520319; Langeluddecke PM, 2003, ARCH CLIN NEUROPSYCH, V18, P181, DOI 10.1016/S0887-6177(01)00195-0; Larrabee G. J., 2007, ASSESSMENT MALINGERE, P3; Larrabee G. J., 2007, ASSESSMENT MALINGERE, P80; Larrabee GJ, 1990, NEUROPSYCHOLOGY, V4, P239, DOI 10.1037/0894-4105.4.4.239; Lu P. H., 2007, ASSESSMENT FEIGNED C, P128; Lu PH, 2003, CLIN NEUROPSYCHOL, V17, P426, DOI 10.1076/clin.17.3.426.18083; Mittenberg W, 2001, CLIN NEUROPSYCHOL, V15, P440; Nelson NW, 2003, CLIN NEUROPSYCHOL, V17, P263, DOI 10.1076/clin.17.2.263.16511; NIES KJ, 1994, ARCH CLIN NEUROPSYCH, V9, P501, DOI 10.1016/0887-6177(94)90041-8; Nitch S, 2006, CLIN NEUROPSYCHOL, V20, P873, DOI 10.1080/13854040590967603; Ord JS, 2008, CLIN NEUROPSYCHOL, V22, P689, DOI 10.1080/13854040701425437; ROGERS R, 1993, CLIN PSYCHOL REV, V13, P255, DOI 10.1016/0272-7358(93)90023-F; Root JC, 2006, J INT NEUROPSYCH SOC, V12, P688, DOI 10.1017/S1355617706060838; Ross SR, 1999, CLIN NEUROPSYCHOL, V13, P112, DOI 10.1076/clin.13.1.112.1973; Sherman DS, 2002, CLIN NEUROPSYCHOL, V16, P242, DOI 10.1076/clin.16.3.242.13860; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Suhr J. A., 2007, ASSESSMENT MALINGERE; Swihart AA, 2008, J CLIN EXP NEUROPSYC, V30, P120, DOI 10.1080/13803390701249044; Tombaugh TN, 1996, TEST MEMORY MALINGER; Wechsler D., 1997, WMS 3 WECHSLER MEMOR	43	41	41	0	7	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1385-4046			CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2010	24	2					344	357		10.1080/13854040903307268			14	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	566HR	WOS:000275361200011	19921593				2021-06-18	
J	Kikuchi, K; Tancharoen, S; Matsuda, F; Biswas, KK; Ito, T; Morimoto, Y; Oyama, Y; Takenouchi, K; Miura, N; Arimura, N; Nawa, Y; Meng, XJ; Shrestha, B; Arimura, S; Iwata, M; Mera, K; Sameshima, H; Ohno, Y; Maenosono, R; Tajima, Y; Uchikado, H; Kuramoto, T; Nakayama, K; Shigemori, M; Yoshida, Y; Hashiguchi, T; Maruyama, I; Kawahara, K				Kikuchi, Kiyoshi; Tancharoen, Salunya; Matsuda, Fumiyo; Biswas, Kamal Krishna; Ito, Takashi; Morimoto, Yoko; Oyama, Yoko; Takenouchi, Kazunori; Miura, Naoki; Arimura, Noboru; Nawa, Yuko; Meng, Xiaojie; Shrestha, Binita; Arimura, Shinichiro; Iwata, Masahiro; Mera, Kentaro; Sameshima, Hisayo; Ohno, Yoshiko; Maenosono, Ryuichi; Tajima, Yutaka; Uchikado, Hisaaki; Kuramoto, Terukazu; Nakayama, Kenji; Shigemori, Minoru; Yoshida, Yoshihiro; Hashiguchi, Teruto; Maruyama, Ikuro; Kawahara, Ko-ichi			Edaravone attenuates cerebral ischemic injury by suppressing aquaporin-4	BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS			English	Article						Edaravone; Aquaporin-4; Cerebral ischemic injury	FREE-RADICAL SCAVENGER; TRANSIENT FOCAL ISCHEMIA; BRAIN EDEMA; ARTERY OCCLUSION; STROKE; RATS; MCI-186; MICE; MODEL; ASTROCYTES	Aquaporin-4 (AQP4) plays a role in the generation of post-ischemic edema, Pharmacological modulation of AQP4 function may thus provide a novel therapeutic strategy for the treatment of stroke, tumor-associated edema, epilepsy, traumatic brain injury, and other disorders of the central nervous system (CNS) associated with altered brain water balance. Edaravone, a free radical scavenger, is used for the treatment of acute ischemic stroke (AIS) in Japan. In this study, edaravone significantly reduced the infarct area and improved the neurological deficit scores at 24 h after reperfusion in a rat transient focal ischemia model. Furthermore, edaravone markedly reduced AQP4 immunoreactivity and protein levels in the cerebral infarct area. In light of observations that edaravone specifically inhibited AQP4 in a rat transient focal ischemia model, we propose that edaravone might reduce cerebral edema through the inhibition of AQP4 expression following cerebral infarction. (C) 2009 Elsevier Inc. All rights reserved.	[Kikuchi, Kiyoshi; Biswas, Kamal Krishna; Ito, Takashi; Oyama, Yoko; Takenouchi, Kazunori; Arimura, Noboru; Nawa, Yuko; Meng, Xiaojie; Shrestha, Binita; Arimura, Shinichiro; Sameshima, Hisayo; Ohno, Yoshiko; Maenosono, Ryuichi; Hashiguchi, Teruto; Maruyama, Ikuro; Kawahara, Ko-ichi] Kagoshima Univ, Div Lab & Vasc Med, Field Cardiovasc & Resp Disorders, Dept Adv Therapeut,Grad Sch Med & Dent Sci, Kagoshima 8908520, Japan; [Kikuchi, Kiyoshi; Tajima, Yutaka; Kuramoto, Terukazu; Nakayama, Kenji] Omuta City Gen Hosp, Dept Neurosurg, Fukuoka 8368567, Japan; [Tancharoen, Salunya] Mahidol Univ, Fac Dent, Dept Pharmacol, Bangkok 10400, Thailand; [Matsuda, Fumiyo; Yoshida, Yoshihiro] Kagoshima Univ, Div Phys Therapy, Sch Hlth Sci, Fac Med, Kagoshima 8908560, Japan; [Morimoto, Yoko] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Restorat Dent & Endodontol, Kagoshima 8908544, Japan; [Miura, Naoki] Kagoshima Univ, Lab Vet Diagnost Imaging, Dept Vet Med, Fac Agr, Kagoshima 8900065, Japan; [Iwata, Masahiro; Mera, Kentaro] Kagoshima Univ, Dept Dermatol, Grad Sch Med & Dent Sci, Kagoshima 8908520, Japan; [Uchikado, Hisaaki; Shigemori, Minoru] Kurume Univ, Fac Med, Sch Med, Fukuoka 8300011, Japan	Kawahara, K (corresponding author), Kagoshima Univ, Div Lab & Vasc Med, Field Cardiovasc & Resp Disorders, Dept Adv Therapeut,Grad Sch Med & Dent Sci, 8-35-1 Sakuragaoka, Kagoshima 8908520, Japan.	telo@m3.kufm.kagoshima-u.ac.jp	Miura, Naoki/O-6997-2016; tancharoen, salunya/AAJ-4765-2020; Miura, Naoki/A-5734-2010	Miura, Naoki/0000-0002-4625-5231; Miura, Naoki/0000-0002-4625-5231; Takenouchi, Kazunori/0000-0003-1946-457X; TANCHAROEN, SALUNYA/0000-0002-2952-7952	Ministry of Education, Culture, Sports, Science, and Technology of JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [21390483]; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [21700539] Funding Source: KAKEN	We thank Nobue Uto, Tomoka Nagasato and Tomomi Morizono for their excellent technical assistance. This study was supported by Research Grants from the Ministry of Education, Culture, Sports, Science, and Technology of Japan, by Grant-in-Aid 21390483 (to K.K.).	ABE K, 1988, STROKE, V19, P480, DOI 10.1161/01.STR.19.4.480; Abe S, 2004, CHEM PHARM BULL, V52, P186, DOI 10.1248/cpb.52.186; Amemiya S, 2005, EUR J PHARMACOL, V516, P125, DOI 10.1016/j.ejphar.2005.04.036; Arima H, 2003, J BIOL CHEM, V278, P44525, DOI 10.1074/jbc.M304368200; Cuzzocrea S, 2000, J PINEAL RES, V29, P217, DOI 10.1034/j.1600-0633.2002.290404.x; Diener HC, 2008, STROKE, V39, P1751, DOI 10.1161/STROKEAHA.107.503334; Green AR, 2006, DRUG DISCOV TODAY, V11, P681, DOI 10.1016/j.drudis.2006.06.001; Haberg A, 2001, J CEREBR BLOOD F MET, V21, P1451, DOI 10.1097/00004647-200112000-00010; Kaur C, 2006, GLIA, V54, P826, DOI 10.1002/glia.20420; Kawai H, 1997, J PHARMACOL EXP THER, V281, P921; Kikuchi K, 2009, J PHARMACOL EXP THER, V329, P865, DOI 10.1124/jpet.108.149484; Kikuchi K, 2009, BIOCHEM BIOPH RES CO, V385, P132, DOI 10.1016/j.bbrc.2009.04.041; Lapchak PA, 2009, EXP NEUROL, V215, P95, DOI 10.1016/j.expneurol.2008.09.004; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Manley GT, 2004, NEUROSCIENCE, V129, P983, DOI 10.1016/j.neuroscience.2004.06.088; MENZIES SA, 1992, NEUROSURGERY, V31, P100, DOI 10.1227/00006123-199207000-00014; MENZIES SA, 1992, NEUROSURGERY, V31, P106; Nakamura T, 2008, STROKE, V39, P463, DOI 10.1161/STROKEAHA.107.486654; NISHI H, 1989, STROKE, V20, P1236, DOI 10.1161/01.STR.20.9.1236; Noor JI, 2005, STROKE, V36, P2468, DOI 10.1161/01.STR.0000185653.49740.c6; Otomo E, 2003, CEREBROVASC DIS, V15, P222, DOI 10.1159/000069318; Papadopoulos MC, 2002, MT SINAI J MED, V69, P242; Shichinohe H, 2004, BRAIN RES, V1029, P200, DOI 10.1016/j.brainres.2004.09.055; Shuaib A, 2007, NEW ENGL J MED, V357, P562, DOI 10.1056/NEJMoa070240; Tanimura Y, 2009, J STRUCT BIOL, V166, P16, DOI 10.1016/j.jsb.2008.11.010; Torii K, 2004, J PINEAL RES, V36, P18, DOI 10.1046/j.1600-079X.2003.00097.x; van der Worp HB, 2002, NEUROLOGY, V58, P133, DOI 10.1212/WNL.58.1.133; Wang CX, 2007, DRUG AGING, V24, P537, DOI 10.2165/00002512-200724070-00002; Watanabe T, 2004, YAKUGAKU ZASSHI, V124, P99, DOI 10.1248/yakushi.124.99; Zhang N, 2005, STROKE, V36, P2220, DOI 10.1161/01.STR.0000182241.07096.06; Zhu C, 2007, CELL DEATH DIFFER, V14, P775, DOI 10.1038/sj.cdd.4402053	31	41	45	0	10	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0006-291X	1090-2104		BIOCHEM BIOPH RES CO	Biochem. Biophys. Res. Commun.	DEC 25	2009	390	4					1121	1125		10.1016/j.bbrc.2009.09.015			5	Biochemistry & Molecular Biology; Biophysics	Biochemistry & Molecular Biology; Biophysics	531GB	WOS:000272650800009	19737535				2021-06-18	
J	Zafonte, R; Friedewald, WT; Lee, SM; Levin, B; Diaz-Arrastia, R; Ansel, B; Eisenberg, H; Timmons, SD; Temkin, N; Novack, T; Ricker, J; Merchant, R; Jallo, J				Zafonte, Ross; Friedewald, William T.; Lee, Shing M.; Levin, Bruce; Diaz-Arrastia, Ramon; Ansel, Beth; Eisenberg, Howard; Timmons, Shelly D.; Temkin, Nancy; Novack, Thomas; Ricker, Joseph; Merchant, Randall; Jallo, Jack			The Citicoline Brain Injury Treatment (COBRIT) Trial: Design and Methods	JOURNAL OF NEUROTRAUMA			English	Article						citicoline; clinical trial; COBRIT; therapy; traumatic brain injury	ACUTE ISCHEMIC-STROKE; RANDOMIZED EFFICACY TRIAL; CDP-CHOLINE; HIPPOCAMPAL; SCALE; DISORDERS; PRECURSOR; EDEMA; TBI	Traumatic brain injury (TBI) is a major cause of death and disability. In the United States alone approximately 1.4 million sustain a TBI each year, of which 50,000 people die, and over 200,000 are hospitalized. Despite numerous prior clinical trials no standard pharmacotherapy for the treatment of TBI has been established. Citicoline, a naturally occurring endogenous compound, offers the potential of neuroprotection, neurorecovery, and neurofacilitation to enhance recovery after TBI. Citicoline has a favorable side-effect profile in humans and several meta-analyses suggest a benefit of citicoline treatment in stroke and dementia. COBRIT is a randomized, double-blind, placebo-controlled, multi-center trial of the effects of 90 days of citicoline on functional outcome in patients with complicated mild, moderate, and severe TBI. In all, 1292 patients will be recruited over an estimated 32 months from eight clinical sites with random assignment to citicoline (1000mg twice a day) or placebo (twice a day), administered enterally or orally. Functional outcomes are assessed at 30, 90, and 180 days after the day of randomization. The primary outcome consists of a set of measures that will be analyzed as a composite measure using a global test procedure at 90 days. The measures comprise the following core battery: the California Verbal Learning Test II; the Controlled Oral Word Association Test; Digit Span; Extended Glasgow Outcome Scale; the Processing Speed Index; Stroop Test part 1 and Stroop Test part 2; and Trail Making Test parts A and B. Secondary outcomes include survival, toxicity, and rate of recovery.	[Lee, Shing M.; Levin, Bruce] Columbia Univ, Dept Biostat, Mailman Sch Publ Hlth, New York, NY 10032 USA; [Zafonte, Ross] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Phys Med & Rehabil,Spaulding Rehabil Hosp, Boston, MA USA; [Friedewald, William T.] Columbia Univ, Dept Epidemiol, New York, NY USA; [Diaz-Arrastia, Ramon] Univ Texas SW Med Ctr Dallas, Dept Neurol, Dallas, TX 75390 USA; [Ansel, Beth] NICHHD, TBI & Stroke Rehabil Res Program, Natl Ctr Med Rehabil Res, Bethesda, MD 20892 USA; [Eisenberg, Howard] Univ Maryland Hosp S, Dept Neurosurg, Baltimore, MD USA; [Timmons, Shelly D.] Univ Tennessee, Ctr Hlth Sci, Dept Neurosurg, Memphis, TN 38163 USA; [Timmons, Shelly D.] Univ Tennessee, Ctr Hlth Sci, Neurotrauma Div, Semmes Murphey Clin, Memphis, TN 38163 USA; [Temkin, Nancy] Univ Washington, Dept Neurol Surg & Biostat, Seattle, WA 98195 USA; [Novack, Thomas] Univ Alabama Birmingham, Dept Phys Med & Rehabil, Birmingham, AL USA; [Ricker, Joseph] Univ Pittsburgh, Sch Med, Dept Phys Med & Rehabil, Pittsburgh, PA USA; [Merchant, Randall] Virginia Commonwealth Univ, Dept Anat & Neurobiol, Richmond, VA USA; [Jallo, Jack] Thomas Jefferson Univ, Dept Neurosurg, Philadelphia, PA 19107 USA	Friedewald, WT (corresponding author), Columbia Univ, Dept Biostat, Mailman Sch Publ Hlth, Room 647,722 W 168th St, New York, NY 10032 USA.	wtf1@columbia.edu	Friedewald, William T/C-8034-2011	Diaz-Arrastia, Ramon/0000-0001-6051-3594; Ricker, Joseph/0000-0003-3415-991X; Jallo, Jack/0000-0002-5512-1729	National Institute AwardUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [U01HD042823, U01HD042738, U01HD042687, U01HD042736, U01HD042678, U01HD042686, U01HD042653, U01HD042689, U01HD042652]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U01HD042652] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U01HD042687, U01HD042689, U01HD042678, U01HD042736, U01HD042653, U01HD042738, U01HD042823, U01HD042686] Funding Source: NIH RePORTER	The study is supported in part by National Institute Award numbers NICHD U01HD042823, U01HD042738, U01HD 042687, U01HD042736, U01HD042678, U01HD042686, U01H D042653, U01HD042689, and U01HD042652, to eight clinical sites and a data coordinating center.	Adibhatla RM, 2006, J BIOL CHEM, V281, P6718, DOI 10.1074/jbc.M512112200; Adibhatla RM, 2002, J NEUROSCI RES, V70, P133, DOI 10.1002/jnr.10403; Adibhatla RM, 2001, STROKE, V32, P2376, DOI 10.1161/hs1001.096010; Alexandrov A V, 2001, Curr Opin Investig Drugs, V2, P1757; Ali R, 2002, ADDICTION, V97, P1183; Alkan T., 2001, Archives of Physiology and Biochemistry, V109, P161, DOI 10.1076/apab.109.2.161.4273; Allen JP, 1997, ALCOHOL CLIN EXP RES, V21, P613, DOI 10.1097/00000374-199706000-00008; Babb SM, 2002, PSYCHOPHARMACOLOGY, V161, P248, DOI 10.1007/s00213-002-1045-y; BAGIELLA E, MEASURING OUTC UNPUB; Barrachina M, 2003, J NEUROL SCI, V215, P105, DOI 10.1016/S0022-510X(03)00204-1; Baskaya MK, 2000, J NEUROSURG, V92, P448, DOI 10.3171/jns.2000.92.3.0448; Benton A. L., 1994, CONTRIBUTIONS NEUROP; Chua R, 2007, CEREBROVASC DIS, V23, P73; Clark WM, 1999, STROKE, V30, P2592, DOI 10.1161/01.STR.30.12.2592; Clark WM, 1997, NEUROLOGY, V49, P671, DOI 10.1212/WNL.49.3.671; Clark WM, 2001, NEUROLOGY, V57, P1595, DOI 10.1212/WNL.57.9.1595; COHADON F, 1982, NEUROCHIRURGIE, V28, P287; Davalos A, 2002, STROKE, V33, P2850, DOI 10.1161/01.STR.0000038691.03334.71; De la Cruz JP, 2000, N-S ARCH PHARMACOL, V361, P47; Delis DC, 2000, CALIFORNIA VERBAL LE; Dempsey RJ, 2003, J NEUROSURG, V98, P867, DOI 10.3171/jns.2003.98.4.0867; Derogatis L, 1993, BRIEF SYMPTOM INVENT; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dixon CE, 1997, J NEUROTRAUM, V14, P161, DOI 10.1089/neu.1997.14.161; DODRILL CB, 1978, EPILEPSIA, V19, P611, DOI 10.1111/j.1528-1157.1978.tb05041.x; Fioravanti M, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000269.pub3; FIORAVANTI M, 2000, COCHRANE DB SYST REV; IKEDA Y, 1990, NEUROSURGERY, V27, P1; KENNEDY EP, 1956, J BIOL CHEM, V222, P185; Kline AE, 2004, J NEUROTRAUM, V21, P1712, DOI 10.1089/0897715042664849; KONTOS CD, 1992, AM J PHYSIOL, V263, pH1234; Leon-Carrion J, 2000, NEUROREHABILITATION, V14, P33; LEVIN HS, 1991, J NEUROL SCI, V103, pS39; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Little R, 1996, BIOMETRICS, V52, P1324, DOI 10.2307/2532847; MALDONADO VC, 1991, J NEUROL SCI, V103, pS15; OBRIEN PC, 1984, BIOMETRICS, V40, P1079, DOI 10.2307/2531158; Ovbiagele Bruce, 2003, Curr Treat Options Cardiovasc Med, V5, P441, DOI 10.1007/s11936-003-0033-9; POCOCK SJ, 1987, BIOMETRICS, V43, P487, DOI 10.2307/2531989; Rao AM, 2001, BRAIN RES, V893, P268, DOI 10.1016/S0006-8993(00)03280-7; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Reitan R. M., 1992, TRAIL MAKING TEST MA; REITAN RM, 1993, HALSTEAD REITH NEURO; Rejdak R, 2002, OPHTHALMIC RES, V34, P146, DOI 10.1159/000063658; Ross BM, 2001, NEUROSCIENCE, V102, P899, DOI 10.1016/S0306-4522(00)00501-7; Rubin D.B., 1997, MULTIPLE IMPUTATION; Sample PL, 2004, BRAIN INJURY, V18, P1177, DOI 10.1080/02699050410001719925; Saver Jeffrey L, 2008, Rev Neurol Dis, V5, P167; SECADES JJ, 1995, METHOD FIND EXP CLIN, V17, P1; TANG DI, 1993, BIOMETRICS, V49, P23, DOI 10.2307/2532599; TAZAKI Y, 1988, STROKE, V19, P211, DOI 10.1161/01.STR.19.2.211; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tilley BC, 1996, STROKE, V27, P2136, DOI 10.1161/01.STR.27.11.2136; Warach S, 2000, ANN NEUROL, V48, P713, DOI 10.1002/1531-8249(200011)48:5<713::AID-ANA4>3.0.CO;2-#; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yan HQ, 2001, NEUROREPORT, V12, P2323, DOI 10.1097/00001756-200108080-00009	57	41	43	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2009	26	12					2207	2216		10.1089/neu.2009.1015			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	536AI	WOS:000273013200008	19803786	Green Published			2021-06-18	
J	Adamides, AA; Cooper, DJ; Rosenfeldt, FL; Bailey, MJ; Pratt, N; Tippett, N; Vallance, S; Rosenfeld, JV				Adamides, A. A.; Cooper, D. J.; Rosenfeldt, F. L.; Bailey, M. J.; Pratt, N.; Tippett, N.; Vallance, S.; Rosenfeld, J. V.			Focal cerebral oxygenation and neurological outcome with or without brain tissue oxygen-guided therapy in patients with traumatic brain injury	ACTA NEUROCHIRURGICA			English	Article						Brain; Oxygen; Traumatic brain injury	SEVERE HEAD-INJURY; PERFUSION-PRESSURE; HYPERVENTILATION; REACTIVITY	In patients with severe traumatic brain injury (TBI), the depth and duration of cerebral hypoxia are independent predictors of outcome. This study aimed to evaluate the efficacy of brain oxygen-guided therapy in improving cerebral oxygenation and neurological outcome in severe TBI patients. Thirty TBI patients had brain oxygen monitors placed contralateral to the side of mass lesions, or to the non-dominant side if injury was diffuse. The first 10 patients (Group 1, observational) had brain tissue oxygen (PbrO(2)) monitored, but not treated. The next 20 patients (Group 2, interventional) were treated according to brain tissue oxygen-guided algorithms aiming to improve cerebral oxygen availability. The 6-month neurological outcome of Group 2 patients was compared with that of Group 1 patients and with contemporary control patients (Group 3) treated without the use of brain oxygen monitoring. The mean duration of brain hypoxic episodes (PbrO(2) < 15 mmHg) was 106 minutes in Group 1, and 34 minutes in Group 2 (p=0.01). Brain tissue oxygen was < 15 mmHg for 10% of monitoring time in Group 1 and 2.8% in Group 2 (p=0.12). The peak incidence of cerebral hypoxic events in both groups occurred during post-injury day 5. The mean Injury Severity Score (ISS) of patients experiencing cerebral hypoxia was higher than that of patients without cerebral hypoxic episodes (33.7 vs 24.2, p=0.04). There was no statistically significant difference in neurological outcome between those patients treated with and those without brain oxygen-guided therapy. In TBI patients, brain tissue oxygen-guided therapy is associated with decreased duration of episodes of cerebral hypoxia. Larger studies are indicated to determine the effects of this therapy on neurological outcome.	[Adamides, A. A.; Rosenfeld, J. V.] Alfred Hosp, Dept Neurosurg, Prahran, Vic 3181, Australia; [Cooper, D. J.; Pratt, N.; Tippett, N.; Vallance, S.] Alfred Hosp, Dept Intens Care, Melbourne, Vic, Australia; [Pratt, N.; Tippett, N.] Alfred Hosp, Dept Trauma Surg, Melbourne, Vic, Australia; [Adamides, A. A.; Rosenfeldt, F. L.; Rosenfeld, J. V.] Monash Univ, Dept Surg, Melbourne, Vic 3004, Australia; [Cooper, D. J.; Bailey, M. J.] Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia; [Adamides, A. A.; Cooper, D. J.; Pratt, N.; Tippett, N.; Vallance, S.] Natl Trauma Res Inst, Melbourne, Vic, Australia	Rosenfeld, JV (corresponding author), Alfred Hosp, Dept Neurosurg, POB 315, Prahran, Vic 3181, Australia.	j.rosenfeld@alfred.org.au	Rosenfeld, Jeffrey V/B-7249-2011; Cooper, D. James/G-7961-2013; Bailey, Michael J/A-4499-2012	Cooper, D. James/0000-0002-5872-9051; Bailey, Michael J/0000-0002-5551-1401	Victorian Trauma Foundation	The study was funded by a Victorian Trauma Foundation best practice grant. We acknowledge the efforts of the neurosurgical and ICU staff. We are grateful to Philip M. Lewis, John Iacono, Christina Lowe and Philippa Marks for efficient and reliable technical support and to Rachael Nevill for assistance with data collection.	Andrews Peter J D, 2003, Curr Opin Crit Care, V9, P83, DOI 10.1097/00075198-200304000-00001; *BRAIN TRAUM FDN, 2007, J NEUROTRAUMA S1, V24, P87, DOI DOI 10.1089/NEU.2006.0058; Coles JP, 2004, BRAIN, V127, P2479, DOI 10.1093/brain/awh268; Coles JP, 2002, CRIT CARE MED, V30, P1950, DOI 10.1097/00003246-200209000-00002; Imberti R, 2002, J NEUROSURG, V96, P97, DOI 10.3171/jns.2002.96.1.0097; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Johnston AJ, 2003, BRIT J ANAESTH, V90, P774, DOI 10.1093/bja/aeg104; Kiening KL, 1997, NEUROL RES, V19, P233, DOI 10.1080/01616412.1997.11740805; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Meixensberger J, 2003, J NEUROL NEUROSUR PS, V74, P760, DOI 10.1136/jnnp.74.6.760; Menon DK, 2003, ANESTHESIOLOGY, V98, P805, DOI 10.1097/00000542-200304000-00002; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; Pagano A, 2003, ANN NY ACAD SCI, V1010, P405, DOI 10.1196/annals.1299.074; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Suazo JAC, 2000, CRIT CARE MED, V28, P3268, DOI 10.1097/00003246-200009000-00024; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; The Brain Trauma Foundation. The American Association of Neurological Surgeons. The Joint Section on Neurotrauma and Critical Care, 2007, J NEUROTRAUMA S1, V24, pS59, DOI DOI 10.1089/NEU.2007.9987; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018	19	41	43	0	3	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	NOV	2009	151	11					1399	1409		10.1007/s00701-009-0398-y			11	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	514NQ	WOS:000271402000008	19727549				2021-06-18	
J	Belmont, A; Agar, N; Azouvi, P				Belmont, Angelique; Agar, Nathalie; Azouvi, Philippe			Subjective Fatigue, Mental Effort, and Attention Deficits After Severe Traumatic Brain Injury	NEUROREHABILITATION AND NEURAL REPAIR			English	Article						Traumatic brain injury; Mental fatigue; Attention deficits	CLOSED-HEAD INJURY; 1ST 2 YEARS; PRACTICAL SCALE; DEPRESSION; PERFORMANCE; RECOVERY; DAMAGE	Objective. Although fatigue is one of the most frequent complaints of individuals with traumatic brain injury (TBI), its mechanisms remain poorly understood. The objective of this study was to assess the relationships between subjective mental fatigue, mental effort, attention deficits, and mood after severe TBI. Methods and participants. A total of 27 patients with subacute/chronic severe TBI were compared with matched controls. Patients first rated their baseline subjective fatigue on the Fatigue Severity Scale (FSS) and on the Visual Analog Scale for Fatigue (VAS-F). Mood was assessed with the Montgomery and Asberg Depression Rating Scale (MADRS). Then, they performed a long-duration selective attention task, separated in 2 parts. Fatigue on the VAS-F was assessed again between the 2 parts and at the end of the attention task. Patients were also asked to rate on the VAS the level of subjective mental effort devoted to the task. Results. Patients reported a higher baseline fatigue than controls. They performed significantly poorer on the selective attention task. Significant correlations were found in the group with TBI between attention performance, mental effort, and subjective fatigue. Depression did not significantly correlate with fatigue. Discussion and conclusions. These findings suggest that patients with more severe attention deficits have to produce higher levels of mental effort to manage a complex task, which may increase subjective fatigue, in line with the coping hypothesis.	[Belmont, Angelique; Agar, Nathalie; Azouvi, Philippe] Hop Raymond Poincare, AP HP, Serv Med Phys & Readaptat, F-92380 Garches, France; [Belmont, Angelique; Azouvi, Philippe] INSERM, U731, Paris, France; [Belmont, Angelique; Azouvi, Philippe] Fac Med, Lab Physiol & Physiopathol Motricite, Paris, France; [Azouvi, Philippe] Univ Versailles St Quentin, Versailles, France	Azouvi, P (corresponding author), Hop Raymond Poincare, AP HP, Serv Med Phys & Readaptat, F-92380 Garches, France.	philippe.azouvi@rpc.aphp.fr		BELMONT, Angelique/0000-0002-4700-8582			ARCINIEGAS DB, 2000, CURRENT TREATMENT OP, V2, P169; Ashman TA, 2008, J HEAD TRAUMA REHAB, V23, P33, DOI 10.1097/01.HTR.0000308719.70288.22; Azouvi P, 2004, NEUROPSYCHOLOGIA, V42, P1260, DOI 10.1016/j.neuropsychologia.2004.01.001; Bay E, 2008, BRAIN INJURY, V22, P233, DOI 10.1080/02699050801953073; Borgaro SR, 2005, J HEAD TRAUMA REHAB, V20, P416, DOI 10.1097/00001199-200509000-00003; Bushnik T, 2008, J HEAD TRAUMA REHAB, V23, P25, DOI 10.1097/01.HTR.0000308718.88214.bb; Bushnik T, 2008, J HEAD TRAUMA REHAB, V23, P17, DOI 10.1097/01.HTR.0000308717.80590.22; Bushnik T, 2007, BRAIN INJURY, V21, P559, DOI 10.1080/02699050701426915; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; Chaumet G, 2008, NEUROLOGY, V71, P1609, DOI 10.1212/01.wnl.0000334753.49193.48; Clinchot DM, 1998, AM J PHYS MED REHAB, V77, P291, DOI 10.1097/00002060-199807000-00006; De Vries J, 2003, OCCUP ENVIRON MED, V60, P10; Dijkers MPJM, 2008, J HEAD TRAUMA REHAB, V23, P3, DOI 10.1097/01.HTR.0000308716.80590.6b; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; JENNETT B, 1975, LANCET, V1, P480; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; LaChapelle DL, 1998, BRAIN INJURY, V12, P649, DOI 10.1080/026990598122214; Leclercq M, 2000, J CLIN EXP NEUROPSYC, V22, P339, DOI 10.1076/1380-3395(200006)22:3;1-V;FT339; LEE KA, 1991, PSYCHIAT RES, V36, P291, DOI 10.1016/0165-1781(91)90027-M; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Meek PM, 2000, NURS RES, V49, P181, DOI 10.1097/00006199-200007000-00001; MONTGOMERY SA, 1979, BRIT J PSYCHIAT, V134, P382, DOI 10.1192/bjp.134.4.382; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Ouellet MC, 2004, ARCH PHYS MED REHAB, V85, P1298, DOI 10.1016/j.apmr.2003.11.036; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; Riese H, 1999, NEUROPSYCHOL REHABIL, V9, P189, DOI 10.1080/713755600; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; Stulemeijer M, 2006, J NEUROL, V253, P1041, DOI 10.1007/s00415-006-0156-5; Van Zomeren A. H., 1984, CLOSED HEAD INJURY P, P74; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; WALKER GC, 1991, ARCH PHYS MED REHAB, V72, P469; Winstead-Fry P, 1998, J Nurs Meas, V6, P111; Ziino C, 2006, J INT NEUROPSYCH SOC, V12, P100, DOI 10.1017/S1355617706060139; Ziino C, 2005, J INT NEUROPSYCH SOC, V11, P416, DOI 10.1017/S1355617705050472; Ziino C, 2006, NEUROPSYCHOLOGY, V20, P383, DOI 10.1037/0894-4105.20.3.383	36	41	41	0	10	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1545-9683	1552-6844		NEUROREHAB NEURAL RE	Neurorehabil. Neural Repair	NOV-DEC	2009	23	9					939	944		10.1177/1545968309340327			6	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	508NQ	WOS:000270939300007	19574545	Green Published			2021-06-18	
J	Wu, Z; Hao, SY; Zhang, JT; Zhang, LW; Jia, GJ; Tang, J; Mao, XR; Wang, L; Wang, ZC				Wu, Zhen; Hao, Shuyu; Zhang, Junting; Zhang, Liwei; Jia, Guijun; Tang, Jie; Mao, Xinru; Wang, Liang; Wang, Zhongcheng			Foramen magnum meningiomas: experiences in 114 patients at a single institute over 15 years	SURGICAL NEUROLOGY			English	Article						Foramen magnum; Meningioma; Surgical approach; Microsurgery	TRAUMATIC BRAIN-INJURY; FAR-LATERAL APPROACH; INTRADURAL LESIONS; CERVICAL-SPINE; BENIGN-TUMORS; ANTERIOR; HYPOPITUITARISM; RESECTION; MIDLINE	Background: Although there has been great development in the anatomical understanding and operative techniques for skull base tumors, controversy still exists regarding the optimal surgical strategies for the FMMs. We report clinical and radiologic features as well as the surgical findings and outcome for patients with FMM treated at our institution over the last 15 years. Methods: We reviewed 114 consecutive cases of FMM operated between May 1993 and June 2008 in the neurosurgery department at Beijing Tiantan Hospital. Results: There were 68 female and 46 male patients (mean age, 52.3 years; range, 28-76 years). Foramen magnum meningiomas were classified as anterior (80 cases), anterolateral (24 cases), and posterolateral (10 cases). Mean duration of symptoms was 11.7 months (ranging from 1.5 to 240 months). Cervico-occipital pain (80.7%) and headache and dizziness (42.1%) were the most common presenting symptoms. The preoperative KPS was 72.5 +/- 8.3. Mean maximum diameter of the tumors on MRI was 3.35 cm (range, 1.5-4.7 cm). Posterior midline approach was performed in 10 cases, far-lateral retrocondylar approach in 97 cases, and extended far-lateral approach in 7 cases. Gross total resection was achieved in 86.0% of patients and subtotal resection in 14.0%. Surgical mortality was 1.8%. Follow-up data were available for 93 patients, with a mean follow-up of 90.3 months (range, 1-180 months), of which 59 (63.4%) lived a normal life (KPS, 80-100). Conclusion: Our experience suggests that most anterior and anterolateral FMMs can be completely resected by a far-lateral retrocondylar approach without resection of the occipital condyle. Complete resection of the tumor should be attempted at the first operation. Postoperative management of FMM is important for the prognosis. Crown Copyright (C) 2009 Published by Elsevier Inc. All rights reserved.	[Wu, Zhen; Zhang, Junting; Zhang, Liwei; Jia, Guijun; Tang, Jie; Mao, Xinru; Wang, Liang] Capital Med Univ, Beijing Tiantan Hosp, Dept Neurosurg, Beijing 100050, Peoples R China; [Hao, Shuyu; Wang, Zhongcheng] Capital Med Univ, Beijing Neurosurg Inst, Beijing 100050, Peoples R China	Zhang, JT (corresponding author), Capital Med Univ, Beijing Tiantan Hosp, Dept Neurosurg, Beijing 100050, Peoples R China.	zhangjunting2003@yahoo.com.cn			Capital Medical Development Foundation	We gratefully acknowledge grant No. 2007-2064 from the Capital Medical Development Foundation.	ABE H, 1983, SHINKEI GEKA, V11, P353; Agha A, 2007, BRIT J NEUROSURG, V21, P210, DOI 10.1080/02688690701253331; Arnaldo E, 2002, NEUROL MED-CHIR, V42, P472, DOI 10.2176/nmc.42.472; Arnautovic KI, 2000, J NEUROSURG, V92, P71, DOI 10.3171/spi.2000.92.1.0071; Bassiouni H, 2006, NEUROSURGERY, V59, P1177, DOI 10.1227/01.NEU.0000245629.77968.37; Bertalanffy H, 1996, Acta Neurochir Suppl, V65, P82; Boulton Melfort R, 2003, Neurosurg Focus, V14, pe10; Bruneau M, 2008, NEUROSURG REV, V31, P19, DOI 10.1007/s10143-007-0097-1; CHONO Y, 1985, Neurological Surgery, V13, P109; David C A, 1997, Clin Neurosurg, V44, P467; de Tella OI, 2006, ARQ NEURO-PSIQUIAT, V64, P437, DOI 10.1590/S0004-282X2006000300016; George B, 1997, SURG NEUROL, V47, P371, DOI 10.1016/S0090-3019(96)00204-2; GEORGE B, 1988, SURG NEUROL, V29, P484, DOI 10.1016/0090-3019(88)90145-0; Goel A, 2001, NEUROSURGERY, V49, P102, DOI 10.1097/00006123-200107000-00016; Gupta SK, 2004, BRIT J NEUROSURG, V18, P164, DOI 10.1080/02688690410001681028; HUSAG L, 1983, COMPUTERTOM SONOGRAP, V3, P149; KENNING TJ, 2008, J NEUROONCOL; KIM KS, 1982, SURG NEUROL, V17, P287, DOI 10.1016/0090-3019(82)90124-0; KRATIMENOS GP, 1993, BRIT J NEUROSURG, V7, P129, DOI 10.3109/02688699309103469; Menezes AH, 2008, CHILD NERV SYST, V24, P1203, DOI 10.1007/s00381-008-0597-5; MEYER FB, 1984, J NEUROSURG, V61, P136, DOI 10.3171/jns.1984.61.1.0136; Muthukumar N, 1999, SURG NEUROL, V51, P268, DOI 10.1016/S0090-3019(98)00099-8; Nanda A, 2002, J NEUROSURG, V96, P302, DOI 10.3171/jns.2002.96.2.0302; Pamir MN, 2004, J CLIN NEUROSCI, V11, P863, DOI 10.1016/j.jocn.2004.02.007; Rhoton A L Jr, 1994, Neurosurg Clin N Am, V5, P349; Schneider HJ, 2007, LANCET, V369, P1461, DOI 10.1016/S0140-6736(07)60673-4; Schneider HJ, 2006, ACTA NEUROCHIR, V148, P449, DOI 10.1007/s00701-005-0724-y; Sekhar LN, 1996, J NEURO-ONCOL, V29, P249, DOI 10.1007/BF00165655; SEN CN, 1990, NEUROSURGERY, V27, P197, DOI 10.1227/00006123-199008000-00004; Sharma BS, 1999, NEUROL INDIA, V47, P268; Tsao GJ, 2008, J GEN INTERN MED, V23, P206, DOI 10.1007/s11606-007-0474-z; Wang Zhen-yu, 2004, Beijing Da Xue Xue Bao Yi Xue Ban, V36, P634	32	41	45	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0090-3019			SURG NEUROL	Surg. Neurol.	OCT	2009	72	4					376	382		10.1016/j.surneu.2009.05.006			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	498YW	WOS:000270183900012	19608233				2021-06-18	
J	Kraus, J; Hsu, P; Schaffer, K; Vaca, F; Ayers, K; Kennedy, F; Afifi, AA				Kraus, Jess; Hsu, Paul; Schaffer, Kathryn; Vaca, Federico; Ayers, Kathl; Kennedy, Frank; Afifi, Abdelmonem A.			Preinjury Factors and 3-Month Outcomes Following Emergency Department Diagnosis of Mild Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						cohort study; mild traumatic brain injury; outcomes assessment; Pittsburgh Sleep Quality Index; Rivermead Post-Concussion Symptoms Questionnaire	POST-CONCUSSION SYMPTOMS; MINOR HEAD-INJURY; POSTCONCUSSION-LIKE SYMPTOMS; SLEEP QUALITY; QUESTIONNAIRE; RECOVERY; INSOMNIA; VALIDITY; SEQUELAE	Objective: To investigate the sequelae of mild traumatic brain injury (MTBI) by comparing selected outcomes of emergency department-diagnosed patients with mild head injuries to those with non-head injuries. Setting: Five emergency departments in southern California. Participants: Two cohorts, one with MTBI (n = 689 at initial assessment) and another with non-head injuries (n = 1318). Main Measures: Rivermead Post-Concussion Symptoms Questionnaire and Pittsburgh Sleep Quality Index at 3 months postinjury. Results: Postconcussion symptom rates and summary Rivermead Post-Concussion Symptoms Questionnaire scores were significantly higher for persons with MTBI than for the comparison cohort. Women reported significantly more symptoms than men. Complaints about sleep quality overall (and also sleep latency and daytime dysfunction subcomponents) were significantly more frequent among those with MTBI. Conclusion: Patients with MTBI have significantly more negative outcomes than patients in the comparison cohort and should be clinically managed with these prevalent outcomes in mind. Further study of follow-up medical management and the development of treatment guidelines for this group of patients are both warranted.	[Kraus, Jess; Hsu, Paul; Schaffer, Kathryn; Afifi, Abdelmonem A.] Univ Calif Los Angeles, So Calif Injury Prevent Res Ctr, Los Angeles, CA 90024 USA; [Vaca, Federico] Univ Calif Irvine, Ctr Trauma & Injury Prevent Res, Dept Emergency Med, Irvine, CA USA; [Ayers, Kathl; Kennedy, Frank] Sharp Mem Hosp & Rehabil Ctr, San Diego, CA USA	Kraus, J (corresponding author), Univ Calif Los Angeles, So Calif Injury Prevent Res Ctr, 10960 Wilshire Blvd,Ste 1550, Los Angeles, CA 90024 USA.	jkraus3637@adelphia.net		SCHAFFER, KATHRYN/0000-0002-3550-1679; Hsu, Paul/0000-0002-6153-364X	Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49/CCR922432]	This project was supported by the Centers for Disease Control and Prevention (grant #R49/CCR922432).	Afifi A., 2004, COMPUTER AIDED MULTI; Afifi AA, 2007, ANNU REV PUBL HEALTH, V28, P95, DOI 10.1146/annurev.publhealth.28.082206.094100; Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; CASSIDY JD, 2004, J REHABIL MED S, V43, P126; Chan RCK, 2001, CLIN REHABIL, V15, P266, DOI 10.1191/026921501675253420; Deb S, 1998, J NEUROL NEUROSUR PS, V65, P899, DOI 10.1136/jnnp.65.6.899; *DEP HLTH HUM SERV, 1989, INT CLASS DIS 9 REV; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; Feinstein A, 2000, CAN J PUBLIC HEALTH, V91, P325, DOI 10.1007/BF03404799; Fichtenberg NL, 2002, BRAIN INJURY, V16, P197, DOI 10.1080/02699050110103940; Fichtenberg NL, 2001, AM J PHYS MED REHAB, V80, P339, DOI 10.1097/00002060-200105000-00003; Gunstad J, 2002, J INT NEUROPSYCH SOC, V8, P37, DOI 10.1017/S1355617701020045; Heitger MH, 2006, BRAIN INJURY, V20, P807, DOI 10.1080/02699050600676354; Hosmer D. W., 2001, APPL LOGISTIC REGRES, V2nd; Ingebrigtsen T, 1999, NEUROSURGERY, V45, P468, DOI 10.1097/00006123-199909000-00010; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; Masel BE, 2001, ARCH PHYS MED REHAB, V82, P1526, DOI 10.1053/apmr.2001.26093; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Nolin P, 2006, J HEAD TRAUMA REHAB, V21, P514, DOI 10.1097/00001199-200611000-00006; Parcell DL, 2008, ARCH PHYS MED REHAB, V89, P843, DOI 10.1016/j.apmr.2007.09.057; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Potter S, 2006, J NEUROL, V253, P1603, DOI 10.1007/s00415-006-0275-z; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; *SAS I INC, 2003, VERS 9 1 3 SP4 COMP; Sheedy J, 2006, J CLIN EXP NEUROPSYC, V28, P755, DOI 10.1080/13803390591000864; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Stulemeijer M, 2006, J NEUROL, V253, P1041, DOI 10.1007/s00415-006-0156-5; TEASDALE G, 1974, LANCET, V2, P81; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; Wang Y, 2006, ARCH CLIN NEUROPSYCH, V21, P339, DOI 10.1016/j.acn.2006.03.006	44	41	42	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2009	24	5					344	354		10.1097/HTR.0b013e3181ae35fd			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	509WG	WOS:000271049300005	19858968				2021-06-18	
J	Leder, SB; Suiter, DM; Warner, HL				Leder, Steven B.; Suiter, Debra M.; Warner, Heather Lisitano			Answering Orientation Questions and Following Single-Step Verbal Commands: Effect on Aspiration Status	DYSPHAGIA			English	Article						Deglutition; Deglutition disorders; Cognition; Aspiration	FIBEROPTIC ENDOSCOPIC EVALUATION; DYSPHAGIA; VIDEOFLUOROSCOPY	In the acute-care setting patients with altered mental status as a result of such diverse etiologies as stroke, traumatic brain injury, degenerative neurologic impairments, dementia, or alcohol/drug abuse are routinely referred for dysphagia testing. A protocol for dysphagia testing was developed that began with verbal stimuli to determine patient orientation status and ability to follow single-step verbal commands. Although unknown, it would be beneficial to ascertain if this information on mental status was predictive of aspiration risk. The purpose of this investigation was to determine if there was a difference in odds for aspiration based upon correctly answering specific orientation questions, i.e., 1. What is your name? 2. Where are you right now? and 3. What year is it?, and following specific single-step verbal commands, i.e., 1. Open your mouth. 2. Stick out your tongue. and 3. Smile. In a consecutive retrospective manner data from 4070 referred patients accrued between 1 December 1999 and 1 January 2007 were analyzed. The odds of liquid aspiration were 31% greater for patients not oriented to person, place, and time (odds ratio [OR] = 1.305, 95% CI = 1.134-1.501). The odds of liquid aspiration (OR = 1.566, 95% CI = 1.307-1.876), puree aspiration (OR = 1.484, 95% CI = 1.202-1.831), and being deemed unsafe for any oral intake (OR = 1.688, 95% CI = 1.387-2.054) were, respectively, 57, 48, and 69% greater for patients unable to follow single-step verbal commands. Being able to answer orientation questions and follow single-step verbal commands provides information on odds of aspiration for liquid and puree food consistencies as well as overall eating status prior to dysphagia testing. Knowledge of potential increased odds of aspiration allows for individualization of dysphagia testing thereby optimizing swallowing success.	[Leder, Steven B.] Yale Univ, Sch Med, Otolaryngol Sect, Dept Surg, New Haven, CT 06520 USA; [Suiter, Debra M.] Univ Memphis, Sch Audiol & Speech Language Pathol, Memphis, TN 38105 USA; [Warner, Heather Lisitano] Yale New Haven Med Ctr, Speech & Swallow Ctr, New Haven, CT USA	Leder, SB (corresponding author), Yale Univ, Sch Med, Otolaryngol Sect, Dept Surg, POB 208041, New Haven, CT 06520 USA.	steven.leder@yale.edu					BARER DH, 1989, J NEUROL NEUROSUR PS, V52, P236, DOI 10.1136/jnnp.52.2.236; Daniels SK, 2007, AM J SPEECH-LANG PAT, V16, P140, DOI 10.1044/1058-0360(2007/018); FEINBERG M J, 1990, Dysphagia, V5, P61, DOI 10.1007/BF02412646; Fleiss JL, 1981, STAT METHODS RATES P, V2nd; Kelly AM, 2006, CLIN OTOLARYNGOL, V31, P425, DOI 10.1111/j.1749-4486.2006.01292.x; Kelly AM, 2007, LARYNGOSCOPE, V117, P1723, DOI 10.1097/MLG.0b013e318123ee6a; Kuhlemeier KV, 2001, DYSPHAGIA, V16, P119, DOI 10.1007/s004550011003; Langmore S E, 1988, Dysphagia, V2, P216, DOI 10.1007/BF02414429; LANGMORE SE, 1991, ANN OTO RHINOL LARYN, V100, P678; Leder SB, 2005, DYSPHAGIA, V20, P157, DOI 10.1007/s00455-005-0009-x; Leder SB, 1997, J SPEECH LANG HEAR R, V40, P1352, DOI 10.1044/jslhr.4006.1352; Leder SB, 1998, ARCH PHYS MED REHAB, V79, P1264, DOI 10.1016/S0003-9993(98)90273-8; Logemann J. A., 1998, EVALUATION TREATMENT; MARTIN BJW, 1990, J SPEECH HEAR DISORD, V55, P28, DOI 10.1044/jshd.5501.28; McCullough GH, 2005, J SPEECH LANG HEAR R, V48, P1280, DOI 10.1044/1092-4388(2005/089); Sackett DL, 1996, BRIT MED J, V312, P71, DOI 10.1136/bmj.312.7023.71; STANCZAK DE, 1984, J NEUROSURG, V60, P955, DOI 10.3171/jns.1984.60.5.0955	17	41	42	0	13	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0179-051X			DYSPHAGIA	Dysphagia	SEP	2009	24	3					290	295		10.1007/s00455-008-9204-x			6	Otorhinolaryngology	Otorhinolaryngology	486HW	WOS:000269187900006	19263106				2021-06-18	
J	Sander, AM; Clark, AN; Atchison, TB; Rueda, M				Sander, Angelle M.; Clark, Allison N.; Atchison, Timothy B.; Rueda, Misty			A Web-Based Videoconferencing Approach to Training Caregivers in Rural Areas to Compensate for Problems Related to Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						caregivers; traumatic brain injury; Web-based videoconferencing	EXPRESSIVE VOCABULARY DELAYS; RANDOMIZED CONTROLLED-TRIAL; SEVERE HEAD-INJURY; LONG-TERM; COGNITIVE REHABILITATION; PRELIMINARY EFFICACY; FAMILY INTERVENTION; TELEREHABILITATION; SUPERVISION; DISTRESS	Objective: To describe the development and the implementation of a Web-based, videoconferencing training program for caregivers of adults with traumatic brain injury in rural areas to manage cognitive and behavioral changes in the person with the injury. Design: Feasibility study, with satisfaction and perceived utility assessed. Intervention: Six Web-based videoconference sessions, combining didactic education and problem-solving. Participants: Fifteen caregivers of persons with complicated mild, moderate, or severe traumatic brain injury, who were admitted to a level III trauma center in a rural area of Texas. Measures: Satisfaction survey and perceived utility questions conducted immediately following training and at an average of 18 months after training. Results: Participants' overall satisfaction and comfort with the training was high. They perceived that they gained knowledge that was applicable to the everyday problems being experienced. At follow-up, all participants reported having used the knowledge gained to help cope with problems and all had referred to the written materials at least once since the training. Conclusions: Web-based videoconferencing can be used to provide training to caregivers to manage cognitive and behavioral problems resulting from traumatic brain injury. However, there are obstacles related to willingness to seek help among persons in rural areas that must be overcome.	[Sander, Angelle M.; Clark, Allison N.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Sander, Angelle M.; Clark, Allison N.] Harris Cty Hosp Dist, Houston, TX USA; [Atchison, Timothy B.; Rueda, Misty] W Texas A&M Univ, Dept Psychol Sociol & Social Work, Canyon, TX USA; [Sander, Angelle M.; Clark, Allison N.] TIRR Mem Hermann, Brain Injury Res Ctr, Houston, TX USA	Sander, AM (corresponding author), Brain Injury Res Ctr, TIRR, 2323 S Shepherd Ste 907, Houston, TX 77019 USA.	asander@bcm.tmc.edu			National Institute on Disability and Rehabilitation Research; U.S. Department of EducationUS Department of Education [H133B031117]	This work was supported by a grant from the National Institute on Disability and Rehabilitation Research, U.S. Department of Education (grant no. H133B031117 Rehabilitation Research and Training Center on Community Integration in Persons With Traumatic Brain Injury). The authors thank staff at the West Texas A&M Interactive T V Center; Deann Hoececk, MA, Laura Rosas, MA, and Delisa West, PhD for contributing to the development of the sessions; and Jason and Susannah Terguson for consumer review of the sessions.	Anderson MI, 2002, BRAIN INJURY, V16, P743, DOI 10.1080/02699050210128906; Atchison TB, 2004, CLIN NEUROPSYCHOL, V18, P249, DOI 10.1080/13854040490501475; Bell KR, 2008, J NEUROL NEUROSUR PS, V79, P1275, DOI 10.1136/jnnp.2007.141762; Bell KR, 2005, ARCH PHYS MED REHAB, V86, P851, DOI 10.1016/j.apmr.2004.09.015; Bell KR, 2003, J HEAD TRAUMA REHAB, V18, P504, DOI 10.1097/00001199-200311000-00004; BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P35, DOI DOI 10.1097/00001199-198703000-00007; Boake C, 1996, ARCH PHYS MED REHAB, V77, P765, DOI 10.1016/S0003-9993(96)90254-3; Bourgeois MS, 2007, BRAIN INJURY, V21, P1245, DOI 10.1080/02699050701727452; Bradbury CL, 2008, ARCH PHYS MED REHAB, V89, pS61, DOI 10.1016/j.apmr.2008.08.210; Braga LW, 2005, BRAIN INJURY, V19, P819, DOI 10.1080/02699050500110165; Brennan DM, 2004, TELEMED J E-HEALTH, V10, P147, DOI 10.1089/1530562041641237; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Bushy Angeline, 2008, Annu Rev Nurs Res, V26, P221; Carnevale GJ, 2006, ARCH PHYS MED REHAB, V87, P1289, DOI 10.1016/j.apmr.2006.06.010; Carnevale GJ, 2002, J HEAD TRAUMA REHAB, V17, P83, DOI 10.1097/00001199-200204000-00002; Carr E.G., 1999, POSITIVE BEHAV SUPPO; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Cicerone KD, 2008, ARCH PHYS MED REHAB, V89, P2239, DOI 10.1016/j.apmr.2008.06.017; Curl RM, 1996, J HEAD TRAUMA REHAB, V11, P75, DOI 10.1097/00001199-199602000-00009; Diamond BJ, 2003, NEUROREHABILITATION, V18, P171; Forducey PG, 2003, NEUROREHABILITATION, V18, P103; Gabella B, 1997, ANN EPIDEMIOL, V7, P207, DOI 10.1016/S1047-2797(96)00150-0; Girolametto L, 1999, AM J SPEECH-LANG PAT, V8, P364, DOI 10.1044/1058-0360.0804.364; Girolametto L, 1996, J SPEECH HEAR RES, V39, P1274, DOI 10.1044/jshr.3906.1274; Goldberg D.P, 1972, DETECTION PSYCHIAT I; Hanlon RE, 1999, BRAIN INJURY, V13, P873; Hart T, 2003, ARCH PHYS MED REHAB, V84, P221, DOI 10.1053/apmr.2003.50023; Hart-Hester S, 2003, SOUTH MED J, V96, P149, DOI 10.1097/01.SMJ.0000051180.92828.DD; Hauber RP, 2002, J HEAD TRAUMA REHAB, V17, P535, DOI 10.1097/00001199-200212000-00005; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; Johnson ME, 2006, ADM POLICY MENT HLTH, V33, P504, DOI 10.1007/s10488-005-0001-7; Johnstone B, 2002, J RURAL HEALTH, V18, P109, DOI 10.1111/j.1748-0361.2002.tb00882.x; Kaiser AP, 1996, TOP EARLY CHILD SPEC, V16, P375, DOI 10.1177/027112149601600307; KAY T, 1995, J HEAD TRAUMA REHAB, V10, P12, DOI 10.1097/00001199-199504000-00004; LAWTON MP, 1989, J GERONTOL, V44, pP61, DOI 10.1093/geronj/44.3.P61; LEVIN HS, 1993, HEAD INJURY, P525; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; Loftin WA, 2005, DIABETES EDUCATOR, V31, P251, DOI 10.1177/0145721705275517; Long K A, 1989, Sch Inq Nurs Pract, V3, P113; MALEC JF, 1993, BRAIN INJURY, V7, P383, DOI 10.3109/02699059309029682; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; McGrath N, 2008, J HEAD TRAUMA REHAB, V23, P388, DOI 10.1097/01.HTR.0000341434.74875.c8; MCLINLAY WW, 1999, REHABILITATION ADULT, P74; Millis S R, 1994, Int J Neurosci, V79, P165; Ponsford J, 2003, BRAIN INJURY, V17, P453, DOI 10.1080/0269905031000070143; PRESSLEY M, 1995, EDUC PSYCHOL, V30, P207, DOI 10.1207/s15326985ep3004_6; Prigatano G. P., 1994, J HEAD TRAUMA REHAB, V9, P91, DOI [DOI 10.1097/00001199-199403000-00011, 10.1097/00001199-199403000-00011]; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; Prigatano GP., 1999, PRINCIPLES NEUROPSYC; Sander AM, 2001, J HEAD TRAUMA REHAB, V16, P356, DOI 10.1097/00001199-200108000-00006; Savard L, 2003, NEUROREHABILITATION, V18, P93; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; SMITH L, 1995, RAMILY SUPPORT PROGR; Sohlberg M. M., 2001, COGNITIVE REHABILITA; Struchen MA, 2002, J HEAD TRAUMA REHAB, V17, P132, DOI 10.1097/00001199-200204000-00005; TEASDALE G, 1974, LANCET, V2, P81; Wade SL, 2006, J CONSULT CLIN PSYCH, V74, P445, DOI 10.1037/0022-006X.74.3.445; Wade SL, 2008, J HEAD TRAUMA REHAB, V23, P369, DOI 10.1097/01.HTR.0000341432.67251.48; Wade SL, 2005, J PEDIATR PSYCHOL, V30, P437, DOI 10.1093/jpepsy/jsi067; Wells R, 2005, BRAIN INJURY, V19, P1105, DOI 10.1080/02699050500150062; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Winters JM, 2002, ANNU REV BIOMED ENG, V4, P287, DOI 10.1146/annurev.bioeng.4.112801.121923; WOODWARD A, 1984, MED J AUSTRALIA, V141, P13, DOI 10.5694/j.1326-5377.1984.tb132660.x; Ylvisaker M, 2002, J HEAD TRAUMA REHAB, V17, P191, DOI 10.1097/00001199-200206000-00002	66	41	41	1	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2009	24	4					248	261		10.1097/HTR.0b013e3181ad593a			14	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	506SK	WOS:000270796000004	19625864				2021-06-18	
J	Malcolm, D				Malcolm, Dominic			Medical Uncertainty and Clinician-Athlete Relations: The Management of Concussion Injuries in Rugby Union	SOCIOLOGY OF SPORT JOURNAL			English	Article							SPORT; RISK; PAIN	This article addresses clinical practice in sport medicine. Combining notions of medical uncertainty with a figurational sociological emphasis oil interdependence. the article illustrates how uncertainty characterizes the medical understanding, clinical treatment, and patient experience of concussion. Faced With uncertainty, the clinician's desire for recognition and validation through athletes' dependence oil them enables medically based diagnostic and treatment guidelines to be replaced by the understanding and definition of concussion dominant in file sport subculture. Clinicians further invoke strategies that protect their professional status and therefore Secure their interdependence with others in the sport club figuration. The study advances Our understanding by illuminating the basis Oil which clinicians and athletes negotiate treatment and the impact of these experiences oil clinicians' actions and beliefs.	Loughborough Univ Technol, Sch Sport & Exercise Sci, Loughborough LE11 3TU, Leics, England	Malcolm, D (corresponding author), Loughborough Univ Technol, Sch Sport & Exercise Sci, Loughborough LE11 3TU, Leics, England.			Malcolm, Dominic/0000-0002-5898-2911			Adamson C, 1997, SOCIOL HEALTH ILL, V19, P133, DOI 10.1111/1467-9566.ep10934391; CALNAN M, 1984, SOCIOL HEALTH ILL, V6, P74, DOI 10.1111/1467-9566.ep10777367; COCKERHAM WC, 2004, MED SOCIOLOGY; Conrad P, 1987, RES SOCIOLOGY HLTH C, V6, P1; CURRY TJ, 1993, SYMB INTERACT, V16, P273, DOI 10.1525/si.1993.16.3.273; de Vaus D.A., 1996, SURVEYS SOCIAL RES, V4th ed.; Elias, 1978, WHAT IS SOCIOLOGY; Fox RC., 2000, HDB SOCIAL STUDIES H, P409, DOI DOI 10.4135/9781848608412.N26; Fox RC., 1957, STUDENT PHYS INTRO S, P207; Howe PD, 2004, SPORT PROFESSIONALIS; HUGHES R, 1991, SOCIOL SPORT J, V8, P307, DOI 10.1123/ssj.8.4.307; *IRB, 2008, REG REL GAM; LIGHT D, 1979, J HEALTH SOC BEHAV, V20, P310, DOI 10.2307/2955407; Malcolm D, 2002, SOCIOL SPORT J, V19, P149, DOI 10.1123/ssj.19.2.149; MALCOLM D, 2004, SPORT SOC, V7, P95; MALCOLM D, 2005, FOOTBALL STUDIES, V8, P58; Malcolm D, 2006, SOCIOL SPORT J, V23, P376, DOI 10.1123/ssj.23.4.376; Malcolm D, 2005, ETHICS SPORT, P165; May T., 2001, SOCIAL RES ISSUES ME; McCrory P, 2001, BRIT J SPORT MED, V35, P81, DOI 10.1136/bjsm.35.2.81; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2001, BRIT J SPORT MED, V35, P380, DOI 10.1136/bjsm.35.6.380; McCrory PR, 1999, BRIT J SPORT MED, V33, P297; Messner M., 1992, POWER PLAY SPORT PRO; Murphy P., 2008, MATTERS SPORT ESSAYS, P40; Nixon H.L., 1992, J SPORT SOCIAL ISSUE, V16, P127, DOI [DOI 10.1177/019372359201600208, 10.1177/019372359201600208]; Pike ECJ, 2003, SOCIOL SPORT J, V20, P232, DOI 10.1123/ssj.20.3.232; Rafalovich A, 2005, SOCIOL HEALTH ILL, V27, P305, DOI 10.1111/j.1467-9566.2005.00444.x; *RFU, 1998, RFU HDB SAF RUGB; Roderick M., 2000, International Review for the Sociology of Sport, V35, P165, DOI 10.1177/101269000035002003; Roderick M., 2006, WORK PROFESSIONAL FO; Roderick M, 2005, ETHICS SPORT, P17; Roderick Martin, 2004, SPORTING BODIES DAMA, P137; Safai P, 2003, SOCIOL SPORT J, V20, P127, DOI 10.1123/ssj.20.2.127; Safai P, 2004, SPORTING BODIES DAMA, P269; SCHWARZ A, 2007, NY TIMES        0915; Stroh M, 2000, RES TRAINING SOCIAL, P196, DOI DOI 10.4135/9780857028051.D23; Theberge N, 2008, SOCIOL HEALTH ILL, V30, P19, DOI 10.1111/j.1467-9566.2007.01026.x; Theberge N, 2007, ROUTL CRIT STUD SPOR, P176; Waddington I, 2002, BRIT J SPORT MED, V36, P118, DOI 10.1136/bjsm.36.2.118; Waddington Ivan., 2000, SPORT HLTH DRUGS CRI; Walk SR, 1997, SOCIOL SPORT J, V14, P22, DOI 10.1123/ssj.14.1.22; Yair G, 2007, SOCIOLOGY, V41, P681, DOI 10.1177/0038038507078923; YOUNG K, 1993, SOCIOL SPORT J, V10, P373, DOI 10.1123/ssj.10.4.373; Young K, 2004, SPORTING BODIES DAMA, P1, DOI DOI 10.1016/S1476-2854(04)02023-0; Young K., 2000, MASCULINITIES GENDER, P108, DOI DOI 10.4135/9781452233963	46	41	41	1	20	HUMAN KINETICS PUBL INC	CHAMPAIGN	1607 N MARKET ST, PO BOX 5076, CHAMPAIGN, IL 61820-2200 USA	0741-1235	1543-2785		SOCIOL SPORT J	Sociol. Sport J.	JUN	2009	26	2					191	210		10.1123/ssj.26.2.191			20	Hospitality, Leisure, Sport & Tourism; Sociology; Sport Sciences	Social Sciences - Other Topics; Sociology; Sport Sciences	465GV	WOS:000267571700001		Green Accepted			2021-06-18	
J	Miller, WJ; Leventhal, I; Scarsella, D; Haydon, PG; Janmey, P; Meaney, DF				Miller, William J.; Leventhal, Ilya; Scarsella, David; Haydon, Philip G.; Janmey, Paul; Meaney, David F.			Mechanically Induced Reactive Gliosis Causes ATP-Mediated Alterations in Astrocyte Stiffness	JOURNAL OF NEUROTRAUMA			English	Article						glia cell response to injury; in vitro studies; traumatic brain injury	FIBRILLARY ACIDIC PROTEIN; ATOMIC-FORCE MICROSCOPY; STRETCH-INDUCED INJURY; VISCOELASTIC PROPERTIES; PURINERGIC RECEPTORS; CULTURED ASTROCYTES; EXTRACELLULAR ATP; KINASE; CELLS; ELASTICITY	Reactive gliosis is a process triggered in astrocytes after traumatic injury, yet the exact consequences of gliosis on cellular survival and neural regenerative processes in the injured brain remain only partly understood. One recently discovered feature influencing neuronal growth and differentiation is the physical stiffness of the environment surrounding pioneering neurites. In this study, the mechanical properties of cultured cortical astrocytes are measured following a mechanical stretch injury that induces reactive gliosis. In mechanically injured cultures, there was a significant increase in glial fibrillary acidic protein (GFAP) immunoreactivity 24 h following a rapid, transient 15% strain. In these same cultures, astrocytes in the surrounding region-the "mechanical penumbra''-also exhibited increased GFAP immunoreactivity compared to naive cultures. Correlated with these changes in GFAP was a general softening of the non-nuclear regions of the astrocytes, both in the injured and penumbra cells, as measured by atomic force microscopy (AFM). The elastic modulus in naive cultures was observed to be 57.7 +/- 5.8 kPa in non-nuclear regions of naive cultures, while 24 h after injury the modulus was observed to be 26.4 +/- 4.9 kPa in the same region of injured cells. In the penumbra of injured cultures, the modulus was 23.7 +/- 3.6 kPa. Alterations in astrocyte stiffness in the area of injury and mechanical penumbra were ameliorated by pretreating cultures with a nonselective P2 receptor antagonist (PPADS). Since neuronal cells generally prefer softer substrates for growth and neurite extension, these findings may indicate that the mechanical characteristics of reactive astrocytes are favorable for neuronal recovery after traumatic brain injury.	[Miller, William J.; Leventhal, Ilya; Scarsella, David; Janmey, Paul; Meaney, David F.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; [Meaney, David F.] Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; [Janmey, Paul] Univ Penn, Dept Physiol, Philadelphia, PA 19104 USA; [Janmey, Paul] Univ Penn, Inst Med & Engn, Philadelphia, PA 19104 USA; [Haydon, Philip G.] Tufts Univ, Dept Neurosci, Boston, MA 02111 USA	Meaney, DF (corresponding author), 240 Skirkanich Hall,210 S 33rd St, Philadelphia, PA 19104 USA.	dmeaney@seas.upenn.edu		Meaney, David/0000-0002-0954-4122	National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 HD41699, NS35712]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD041699] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS035712] Funding Source: NIH RePORTER	Funds were provided by the National Institute of Health ( grants RO1 HD41699 and NS35712).	Abbracchio MP, 1996, CIBA F SYMP, V198, P142; AbdElBasset EM, 1997, J NEUROSCI RES, V49, P608, DOI 10.1002/(SICI)1097-4547(19970901)49:5<608::AID-JNR11>3.0.CO;2-R; Ahmed SM, 2000, J NEUROCHEM, V74, P1951, DOI 10.1046/j.1471-4159.2000.741951000000000.x; Alonso JL, 2003, LIFE SCI, V72, P2553, DOI 10.1016/S0024-3205(03)00165-6; Araque A, 2000, J NEUROSCI, V20, P666, DOI 10.1523/JNEUROSCI.20-02-00666.2000; Araque A, 1998, J NEUROSCI, V18, P6822; Araque A, 1998, EUR J NEUROSCI, V10, P2129, DOI 10.1046/j.1460-9568.1998.00221.x; Balgude AP, 2001, BIOMATERIALS, V22, P1077, DOI 10.1016/S0142-9612(00)00350-1; Brambilla R, 2002, J NEUROCHEM, V83, P1285, DOI 10.1046/j.1471-4159.2002.01239.x; Caille N, 2002, J BIOMECH, V35, P177, DOI 10.1016/S0021-9290(01)00201-9; Chang L, 2004, NAT REV MOL CELL BIO, V5, P601, DOI 10.1038/nrm1438; Collinsworth AM, 2002, AM J PHYSIOL-CELL PH, V283, pC1219, DOI 10.1152/ajpcell.00502.2001; Costa KD, 1999, J BIOMECH ENG-T ASME, V121, P462, DOI 10.1115/1.2835074; Dahl KN, 2005, BIOPHYS J, V89, P2855, DOI 10.1529/biophysj.105.062554; Discher DE, 2005, SCIENCE, V310, P1139, DOI 10.1126/science.1116995; Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044; Fiacco TA, 2004, J NEUROSCI, V24, P722, DOI 10.1523/JNEUROSCI.2859-03.2004; Flanagan LA, 2002, NEUROREPORT, V13, P2411, DOI 10.1097/00001756-200212200-00007; Floyd CL, 2004, J NEUROTRAUM, V21, P205, DOI 10.1089/089771504322778668; Georges PC, 2006, BIOPHYS J, V90, P3012, DOI 10.1529/biophysj.105.073114; Halassa MM, 2007, J NEUROSCI, V27, P6473, DOI 10.1523/JNEUROSCI.1419-07.2007; Hanbury R, 2003, J COMP NEUROL, V461, P307, DOI 10.1002/cne.10667; HOH JH, 1994, J CELL SCI, V107, P1105; Kang J, 1998, NAT NEUROSCI, V1, P683, DOI 10.1038/3684; Landau L., 1970, THEORY ELASTICITY; Lenz G, 2000, BRIT J PHARMACOL, V129, P927, DOI 10.1038/sj.bjp.0703138; Li WL, 2008, DEV NEUROBIOL, V68, P1474, DOI 10.1002/dneu.20674; Lo CM, 2000, BIOPHYS J, V79, P144, DOI 10.1016/S0006-3495(00)76279-5; Lu YB, 2006, P NATL ACAD SCI USA, V103, P17759, DOI 10.1073/pnas.0606150103; Lusardi TA, 2004, ANN BIOMED ENG, V32, P1546, DOI 10.1114/B:ABME.0000049038.75368.75; Martens JC, 2008, PFLUG ARCH EUR J PHY, V456, P95, DOI 10.1007/s00424-007-0419-8; Mathur AB, 2001, J BIOMECH, V34, P1545, DOI 10.1016/S0021-9290(01)00149-X; McKeon RJ, 1999, J NEUROSCI, V19, P10778; Moreels M, 2008, NEUROPATH APPL NEURO, V34, P532, DOI 10.1111/j.1365-2990.2007.00910.x; Munsch N, 1998, BIOMED PHARMACOTHER, V52, P180, DOI 10.1016/S0753-3322(98)80208-4; Neary JT, 2005, J NEUROTRAUM, V22, P491, DOI 10.1089/neu.2005.22.491; Neary JT, 1999, J NEUROSCI, V19, P4211, DOI 10.1523/jneurosci.19-11-04211.1999; Neary JT, 1998, NEUROSCI LETT, V242, P159, DOI 10.1016/S0304-3940(98)00067-6; Neary JT, 2003, J NEUROSCI, V23, P2348, DOI 10.1523/jneurosci.23-06-02348.2003; Otani N, 2003, ACTA NEUROCHIR SUPPL, V86, P267; Otani N, 2006, J CLIN NEUROSCI, V13, P934, DOI 10.1016/j.jocn.2005.10.018; PARPURA V, 1994, NATURE, V369, P744, DOI 10.1038/369744a0; Pekny M, 2005, GLIA, V50, P427, DOI 10.1002/glia.20207; Pekny M, 1999, J CELL BIOL, V145, P503, DOI 10.1083/jcb.145.3.503; Pekny M, 2001, Prog Brain Res, V132, P23; Pelham RJ, 1997, P NATL ACAD SCI USA, V94, P13661, DOI 10.1073/pnas.94.25.13661; Powell EM, 1997, CELL TISSUE RES, V290, P385, DOI 10.1007/s004410050945; Radmacher M, 1996, BIOPHYS J, V70, P556, DOI 10.1016/S0006-3495(96)79602-9; Ricci D, 1997, MICROSC RES TECHNIQ, V36, P165, DOI 10.1002/(SICI)1097-0029(19970201)36:3<165::AID-JEMT4>3.0.CO;2-O; Rotsch C, 1997, CELL BIOL INT, V21, P685, DOI 10.1006/cbir.1997.0213; Rotsch C, 2000, BIOPHYS J, V78, P520, DOI 10.1016/S0006-3495(00)76614-8; Sandvig A, 2004, GLIA, V46, P225, DOI 10.1002/glia.10315; Sato M, 2000, J BIOMECH, V33, P127, DOI 10.1016/S0021-9290(99)00178-5; SATO M, 1990, J BIOMECH ENG-T ASME, V112, P263, DOI 10.1115/1.2891183; SHREIBER DI, 1997, 41 STAPP CAR CRASH C; Sneddon I.N., 1965, INT J ENG SCI, V3, P47, DOI [DOI 10.1016/0020-7225(65)90019-4, 10.1016/0020-7225(65)90019-4]; Sofroniew MV, 2005, NEUROSCIENTIST, V11, P400, DOI 10.1177/1073858405278321; Trickey WR, 2004, J ORTHOPAED RES, V22, P131, DOI 10.1016/S0736-0266(03)00150-5; Ventura R, 1999, J NEUROSCI, V19, P6897, DOI 10.1523/JNEUROSCI.19-16-06897.1999; Wagner B, 2006, P NATL ACAD SCI USA, V103, P13974, DOI 10.1073/pnas.0510190103; Wang HB, 2001, P NATL ACAD SCI USA, V98, P11295, DOI 10.1073/pnas.201201198; Wilhelmsson U, 2004, J NEUROSCI, V24, P5016, DOI 10.1523/JNEUROSCI.0820-04.2004; Yamane Y, 2000, J ELECTRON MICROSC, V49, P463, DOI 10.1093/oxfordjournals.jmicro.a023830; Yiu G, 2006, NAT REV NEUROSCI, V7, P617, DOI 10.1038/nrn1956	64	41	41	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2009	26	5					789	797		10.1089/neu.2008.0727			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	452XM	WOS:000266574500013	19331521	Green Accepted			2021-06-18	
J	Almaguel, FG; Liu, JW; Pacheco, FJ; Casiano, CA; De Leon, M				Almaguel, Frankis G.; Liu, Jo-Wen; Pacheco, Fabio J.; Casiano, Carlos A.; De Leon, Marino			Activation and Reversal of Lipotoxicity in PC12 and Rat Cortical Cells Following Exposure to Palmitic Acid	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						ASCOS; DHA; hypoxia/ischemia; lipotoxicity; neurotoxicity; traumatic brain injury	POLYUNSATURATED FATTY-ACIDS; FOCAL CEREBRAL-ISCHEMIA; PERCUSSION BRAIN-INJURY; DOCOSAHEXAENOIC ACID; GENE-EXPRESSION; HUMAN-ALBUMIN; NEUROTROPHIC FACTOR; LIPID-PEROXIDATION; OXIDATIVE STRESS; PRIMARY CULTURE	Lipotoxicity involves a series of pathological cellular responses after exposure to elevated levels of fatty acids. This process may be detrimental to normal cellular homeostasis and cell viability. The present study shows that nerve growth factor-differentiated PC12 cells (NGFDPC12) and rat cortical cells (RCC) exposed to high levels of palmitic acid (PA) exhibit significant lipotoxicity and death linked to an "augmented state of cellular oxidative stress" (ASCOS). The ASCOS response includes generation of reactive oxygen species (ROS), alterations in the mitochondrial transmembrane potential, and increase in the mRNA levels of key cell death/survival regulatory genes. The observed cell death was apoptotic based on nuclear morphology, caspase-3 activation, and cleavage of lamin B and PARR Quantitative real-time PCR measurements showed that cells undergoing lipotoxicity exhibited an increase in the expression of the mRNAs encoding the cell death-associated proteins BNIP3 and FAS receptor. Cotreatment of NGFDPC12 and RCC cells undergoing lipotoxicity with docosahexaenoic acid (DHA) and bovine serum albumin (BSA) significantly reduced cell death within the first 2 hr following the initial exposure to PA. The data suggest that lipotoxicity in NGFDPC12 and cortical neurons triggers a strong cell death apoptotic response. Results with NGFDPC12 cells suggest a linkage between induction of ASCOS and the apoptotic process and exhibit a temporal window that is sensitive to DHA and BSA interventions. (C) 2008 Wiley-Liss, Inc.	[Almaguel, Frankis G.; Liu, Jo-Wen; Pacheco, Fabio J.; Casiano, Carlos A.; De Leon, Marino] Loma Linda Univ, Ctr Hlth Disparties & Mol Med, Sch Med, Loma Linda, CA 92350 USA; [Almaguel, Frankis G.; Liu, Jo-Wen; Pacheco, Fabio J.; Casiano, Carlos A.; De Leon, Marino] Loma Linda Univ, Dept Basic Sci, Sch Med, Loma Linda, CA 92350 USA; [Pacheco, Fabio J.] Ctr Univ Adventista Sao Paulo, Dept Biol Sci, Sao Paulo, Brazil	De Leon, M (corresponding author), Loma Linda Univ, Ctr Hlth Disparties & Mol Med, Sch Med, Loma Linda, CA 92350 USA.	madeleon@llu.edu	De Leon, Marino/A-6922-2009	De Leon, Marino/0000-0001-6576-785X	NATIONAL CENTER ON MINORITY HEALTH AND HEALTH DISPARITIESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD) [P20MD001632] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R25GM060507] Funding Source: NIH RePORTER; National Institute on Minority Health and Health DisparitiesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD) [P20MD006988] Funding Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R25 GM060507, R25 GM060507-08, R25 GM060507-07, R25 GM060507-02, R25 GM060507-01A1] Funding Source: Medline; NIMHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD) [P20 MD001632, P20 MD006988, P20 MD001632-04, P20 MD001632-03] Funding Source: Medline		ABE K, 1987, J NEUROCHEM, V48, P503, DOI 10.1111/j.1471-4159.1987.tb04121.x; Aid S, 2003, J LIPID RES, V44, P1545, DOI 10.1194/jlr.M300079-JLR200; Arab K, 2006, BRIT J NUTR, V95, P18, DOI 10.1079/BJN20051626; AUESTAD N, 1991, J NEUROCHEM, V56, P1376, DOI 10.1111/j.1471-4159.1991.tb11435.x; Bazan NG, 2005, ANN NY ACAD SCI, V1053, P137, DOI 10.1196/annals.1344.011; Bazan NG, 2005, BRAIN PATHOL, V15, P159; BAZAN NG, 1970, BIOCHIM BIOPHYS ACTA, V218, P1, DOI 10.1016/0005-2760(70)90086-X; Bazan NG, 2006, CELL MOL NEUROBIOL, V26, P901, DOI 10.1007/s10571-006-9064-6; Belayev L, 2005, STROKE, V36, P118, DOI 10.1161/01.STR.0000149620.74770.2e; Belayev L, 1999, J NEUROTRAUM, V16, P445, DOI 10.1089/neu.1999.16.445; Belayev L, 2002, STROKE, V33, P1077, DOI 10.1161/hs0402.105555; Belayev L, 2001, STROKE, V32, P553, DOI 10.1161/01.STR.32.2.553; Belayev L, 2004, BRAIN RES, V998, P243, DOI 10.1016/j.brainres.2003.11.015; Belayev L, 1997, J NEUROSURG, V87, P595, DOI 10.3171/jns.1997.87.4.0595; Blazquez C, 2000, FASEB J, V14, P2315, DOI 10.1096/fj.00-0122com; CAVANAGH ME, 1985, ANAT EMBRYOL, V172, P345, DOI 10.1007/BF00318983; de Turco EBR, 2002, J NEUROCHEM, V83, P515, DOI 10.1046/j.1471-4159.2002.01121.x; Dhillon HS, 1997, EXP NEUROL, V146, P240, DOI 10.1006/exnr.1997.6524; DYKENS JA, 1994, J NEUROCHEM, V63, P584; EDMOND J, 1987, J NEUROSCI RES, V18, P551, DOI 10.1002/jnr.490180407; FUKUDA K, 1995, J NEUROTRAUM, V12, P315, DOI 10.1089/neu.1995.12.315; Garcia MC, 1998, J NEUROCHEM, V70, P24; Ginsberg MD, 2003, STROKE, V34, P214, DOI 10.1161/01.STR.0000048846.09677.62; Guajardo MH, 2002, BBA-MOL CELL BIOL L, V1581, P65, DOI 10.1016/S1388-1981(02)00121-X; HALLIWELL B, 1991, AM J MED, V91, pS14, DOI 10.1016/0002-9343(91)90279-7; Hannun YA, 1997, BIOCHEM SOC T, V25, P1171, DOI 10.1042/bst0251171; Hartfield PJ, 1997, FEBS LETT, V401, P148, DOI 10.1016/S0014-5793(96)01460-3; Homayoun P, 1997, J NEUROCHEM, V69, P199; Horrocks LA, 2004, PROSTAG LEUKOTR ESS, V70, P361, DOI 10.1016/j.plefa.2003.12.011; Hulbert AJ, 2003, J EXP BIOL, V206, P2303, DOI 10.1242/jeb.00399; JESBERGER JA, 1991, INT J NEUROSCI, V57, P1, DOI 10.3109/00207459109150342; Kilkus JP, 2008, J NEUROCHEM, V106, P1745, DOI 10.1111/j.1471-4159.2008.05490.x; Kim HY, 2004, BIOCHEMISTRY-US, V43, P1030, DOI 10.1021/bi035197x; Kim HY, 2000, J BIOL CHEM, V275, P35215, DOI 10.1074/jbc.M004446200; Lauritzen I, 2000, EMBO J, V19, P1784, DOI 10.1093/emboj/19.8.1784; LEE Y, 1994, P NATL ACAD SCI USA, V91, P10878, DOI 10.1073/pnas.91.23.10878; Lengqvist J, 2004, MOL CELL PROTEOMICS, V3, P692, DOI 10.1074/mcp.M400003-MCP200; Listenberger LL, 2003, P NATL ACAD SCI USA, V100, P3077, DOI 10.1073/pnas.0630588100; Marcheselli VL, 2003, J BIOL CHEM, V278, P43807, DOI 10.1074/jbc.M305841200; Matsumura H, 2000, J CELL BIOL, V151, P1247, DOI 10.1083/jcb.151.6.1247; Mattson MP, 1998, TRENDS NEUROSCI, V21, P53, DOI 10.1016/S0166-2236(97)01188-0; Mukherjee PK, 2004, P NATL ACAD SCI USA, V101, P8491, DOI 10.1073/pnas.0402531101; REHNCRONA S, 1982, J NEUROCHEM, V38, P84, DOI 10.1111/j.1471-4159.1982.tb10857.x; Remmers M, 1999, BRAIN RES, V827, P237, DOI 10.1016/S0006-8993(99)01304-9; Rokyta R, 1996, Cesk Fysiol, V45, P4; Schmidt-Kastner R, 2004, BRAIN RES, V1001, P133, DOI 10.1016/j.brainres.2003.11.065; Singh SK, 2007, GROWTH FACTORS, V25, P363, DOI 10.1080/08977190801886905; SODERBERG M, 1991, LIPIDS, V26, P421, DOI 10.1007/BF02536067; Stillwell W, 2005, REPROD NUTR DEV, V45, P559, DOI 10.1051/rnd:2005046; SUN DD, 1994, J NEUROCHEM, V62, P1921; Tabernero A, 2002, J BIOL CHEM, V277, P4240, DOI 10.1074/jbc.M108760200; Ulloth JE, 2003, J NEUROCHEM, V84, P655, DOI 10.1046/j.1471-4159.2003.01571.x; Unger RH, 2003, TRENDS ENDOCRIN MET, V14, P398, DOI 10.1016/j.tem.2003.09.008; Unger RH, 2000, INT J OBESITY, V24, pS28, DOI 10.1038/sj.ijo.0801498; Valentine RC, 2004, PROG LIPID RES, V43, P383, DOI 10.1016/j.plipres.2004.05.004; Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000; Vercammen D, 1998, J EXP MED, V188, P919, DOI 10.1084/jem.188.5.919; Wu A, 2003, NEUROSCIENCE, V119, P365, DOI 10.1016/S0306-4522(03)00154-4; Yehuda S, 2002, NEUROBIOL AGING, V23, P843, DOI 10.1016/S0197-4580(02)00074-X; Yu-Poth S, 2005, J NUTR, V135, P2541; Yu-Poth S, 2004, J NUTR, V134, P68	61	41	41	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	APR	2009	87	5					1207	1218		10.1002/jnr.21918			12	Neurosciences	Neurosciences & Neurology	416DF	WOS:000263984700017	18951473	Green Accepted			2021-06-18	
J	Reed, TT; Owen, J; Pierce, WM; Sebastian, A; Sullivan, PG; Butterfield, DA				Reed, Tanea T.; Owen, Joshua; Pierce, William M.; Sebastian, Andrea; Sullivan, Patrick G.; Butterfield, D. Allan			Proteomic Identification of Nitrated Brain Proteins in Traumatic Brain-Injured Rats Treated Postinjury With Gamma-Glutamylcysteine Ethyl Ester: Insights Into the Role of Elevation of Glutathione as a Potential Therapeutic Strategy for Traumatic Brain Injury	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						oxidative stress; brain; antioxidant	ALZHEIMERS-DISEASE BRAIN; MANGANESE SUPEROXIDE-DISMUTASE; OXIDATIVELY MODIFIED PROTEINS; MILD COGNITIVE IMPAIRMENT; LIPID-PEROXIDATION; TRANSGENIC MICE; NITRIC-OXIDE; PEROXYNITRITE; STRESS; CALPAIN	Traumatic brain injury (TBI) occurs suddenly and has damaging effects to the brain that are dependent on the severity of insult. Symptoms can be mild, moderate, or severe. Oxidative damage is associated with traumatic brain injury through reactive oxygen/nitrogen species production. One such species, peroxynitrite, is elevated in TBI brain tissue (Orihara et al. [2001] Forensic Sci. Int. 123:142-149; Deng et al. [2007] Exp. Neurol. 205:154-165). Peroxynitrite can react with carbon dioxide and decompose to produce NO2 and carbonate radicals, which in turn can lead to 3-nitrotyrosine, an index of protein nitration. Gamma-glutamylcysteine ethyl ester (GCEE) is an ethyl ester moiety of gamma-glutamylcysteine, an agent that up-regulates glutathione (GSH) production in brain (Drake et al. (2002] J. Neurosci. Res. 68:776-784). Many preclinical studies of TBI have employed pretreatment of animals with proposed beneficial agents prior to the injury itself. However, in the real world of TBI, treatment begins postinjury. Hence, insights into agents that improve outcome following injury are desperately needed. This study is one of the first to investigate a potential GSH-based therapy for TBI postinjury. Protein carbonyls, an index of protein oxidation, were significantly elevated in brain of animals subjected to TBI. However, if, after TBI, GCEE was administered i.p., protein carbonyl levels were significantly reduced. Similarly, 3-nitrotyrosine levels were elevated in brain following TBI but significantly decreased following TBI if GCEE was administered i.p. Redox proteomics analysis showed that several brain proteins were nitrated after TBI. However, if GCEE was given i.p. following TBI, many of these proteins were protected from nitration. The results are	[Butterfield, D. Allan] Univ Kentucky, Dept Chem, Ctr Membrane Sci, Lexington, KY 40506 USA; [Pierce, William M.] Univ Louisville, Dept Pharmacol, Louisville, KY 40292 USA; [Sebastian, Andrea; Sullivan, Patrick G.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40506 USA	Butterfield, DA (corresponding author), Univ Kentucky, Dept Chem, Ctr Membrane Sci, Lexington, KY 40506 USA.	dabens@uky.edu		Reed, Tanea/0000-0003-2642-3100	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AG-10836]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG010836] Funding Source: NIH RePORTER	Contract grant sponsor NIH: Contract grant number: AG-10836 (to D.A.B.).	Alvarez B, 2004, FREE RADICAL BIO MED, V37, P813, DOI 10.1016/j.freeradbiomed.2004.06.006; Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Ansari MA, 2008, J NEUROTRAUM, V25, P513, DOI 10.1089/neu.2007.0451; Aoyama K, 2000, ANN NEUROL, V47, P524, DOI 10.1002/1531-8249(200004)47:4<524::AID-ANA19>3.3.CO;2-X; Bedell EA, 2002, CRIT CARE MED, V30, P710, DOI 10.1097/00003246-200203000-00041; Botti H, 2005, IUBMB LIFE, V57, P407, DOI 10.1080/15216540500137701; BOWLING AC, 1995, LIFE SCI, V56, P1151, DOI 10.1016/0024-3205(95)00055-B; Boyd-Kimball D, 2005, BRAIN RES, V1044, P206, DOI 10.1016/j.brainres.2005.02.086; Boyd-Kimball D, 2005, NEUROSCIENCE, V132, P313, DOI 10.1016/j.neuroscience.2004.12.022; Boyd-Kimball D, 2005, J NEUROSCI RES, V79, P700, DOI 10.1002/jnr.20394; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Butterfield DA, 2006, ANTIOXID REDOX SIGN, V8, P1971, DOI 10.1089/ars.2006.8.1971; Butterfield DA, 2003, J NEUROCHEM, V86, P1313, DOI 10.1046/j.1471-4159.2003.01948.x; Castegna A, 2004, J NEUROCHEM, V88, P1540, DOI 10.1046/j.1471-4159.2003.02288.x; Castegna A, 2002, J NEUROCHEM, V82, P1524, DOI 10.1046/j.1471-4159.2002.01103.x; Castegna A, 2002, FREE RADICAL BIO MED, V33, P562, DOI 10.1016/S0891-5849(02)00914-0; Cooper AJL, 1997, BIOL CHEM, V378, P793; Da Rocha AB, 2005, J NEUROTRAUM, V22, P966, DOI 10.1089/neu.2005.22.966; Deng Y, 2007, EXP NEUROL, V205, P154, DOI 10.1016/j.expneurol.2007.01.023; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Dohi K, 2006, J NEUROTRAUM, V23, P1591, DOI 10.1089/neu.2006.23.1591; Drake J, 2002, J NEUROSCI RES, V68, P776, DOI 10.1002/jnr.10266; Ekegren T, 2006, J PROTEOME RES, V5, P2364, DOI 10.1021/pr060237f; Gahm C, 2005, NEUROSURGERY, V57, P1272, DOI 10.1227/01.NEU.0000187317.32529.06; Ginsberg MD, 2002, CRIT CARE MED, V30, P935, DOI 10.1097/00003246-200204000-00040; Gorska D, 2000, Neurol Neurochir Pol, V34, P573; Grasso G, 2007, BRAIN RES, V1182, P99, DOI 10.1016/j.brainres.2007.08.078; HALL ED, 1994, ANN NY ACAD SCI, V738, P15; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Hoane MR, 2008, NEUROSCIENCE, V154, P861, DOI 10.1016/j.neuroscience.2008.04.044; Jackson RM, 1998, FREE RADICAL BIO MED, V25, P463, DOI 10.1016/S0891-5849(98)00101-4; Joshi G, 2007, J NEUROSCI RES, V85, P497, DOI 10.1002/jnr.21158; Kiang JG, 1998, PHARMACOL THERAPEUT, V80, P183, DOI 10.1016/S0163-7258(98)00028-X; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; Kupina NC, 2003, EXP NEUROL, V180, P55, DOI 10.1016/S0014-4886(02)00048-1; Lai YC, 2004, J NEUROTRAUM, V21, P229, DOI 10.1089/089771504322972022; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Marklund N, 2006, NEUROCHEM RES, V31, P1085, DOI 10.1007/s11064-006-9120-0; Masuda M, 2002, CHEM-BIOL INTERACT, V139, P187, DOI 10.1016/S0009-2797(01)00299-X; Mostert JP, 2008, CNS NEUROSCI THER, V14, P153, DOI 10.1111/j.1527-3458.2008.00040.x; Onofri F, 2000, J BIOL CHEM, V275, P29857, DOI 10.1074/jbc.M006018200; Onofri F, 2007, J BIOL CHEM, V282, P15754, DOI 10.1074/jbc.M701051200; Opii WO, 2007, J NEUROTRAUM, V24, P772, DOI 10.1089/neu.2006.0229; Orihara Y, 2001, FORENSIC SCI INT, V123, P142, DOI 10.1016/S0379-0738(01)00537-0; Otori T, 2004, J NEUROTRAUM, V21, P707, DOI 10.1089/0897715041269623; Ozdemir D, 2005, PHYSIOL RES, V54, P631; Perluigi M, 2005, FREE RADICAL BIO MED, V38, P960, DOI 10.1016/j.freeradbiomed.2004.12.021; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Polderman KH, 2004, INTENS CARE MED, V30, P757, DOI 10.1007/s00134-003-2151-y; Poon HF, 2005, J NEUROCHEM, V94, P380, DOI 10.1111/j.1471-4159.2005.03215.x; Poon HF, 2005, NEUROBIOL DIS, V18, P492, DOI 10.1016/j.nbd.2004.12.009; Poon HF, 2004, NEUROSCIENCE, V126, P915, DOI 10.1016/j.neuroscience.2004.04.046; Qiu W, 2007, J CRIT CARE, V22, P229, DOI 10.1016/j.jcrc.2006.06.011; Reed T, 2008, NEUROBIOL DIS, V30, P107, DOI 10.1016/j.nbd.2007.12.007; Reid WM, 2008, J NEUROTRAUM, V25, P248, DOI 10.1089/neu.2007.0389; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Sawyer E, 2008, ANN PHARMACOTHER, V42, P247, DOI 10.1345/aph.1K284; Schonberger SJ, 2001, PROTEOMICS, V1, P1519, DOI 10.1002/1615-9861(200111)1:12<1519::AID-PROT1519>3.0.CO;2-L; Schwarzbach E, 2006, HIPPOCAMPUS, V16, P541, DOI 10.1002/hipo.20183; Singh IN, 2007, J NEUROSCI RES, V85, P2216, DOI 10.1002/jnr.21360; Sonmez U, 2007, NEUROSCI LETT, V420, P133, DOI 10.1016/j.neulet.2007.04.070; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; Sultana R, 2006, NEUROBIOL DIS, V22, P76, DOI 10.1016/j.nbd.2005.10.004; Sultana R, 2007, J CELL MOL MED, V11, P839, DOI 10.1111/j.1582-4934.2007.00065.x; Sultana R, 2006, NEUROBIOL AGING, V27, P918, DOI 10.1016/j.neurobiolaging.2005.05.005; Szabo C, 2003, TOXICOL LETT, V140, P105, DOI 10.1016/S0378-4274(02)00507-6; Szabo C, 1996, P NATL ACAD SCI USA, V93, P1753, DOI 10.1073/pnas.93.5.1753; Tangpong J, 2007, J NEUROCHEM, V100, P191, DOI 10.1111/j.1471-4159.2006.04179.x; Thongboonkerd V, 2002, J BIOL CHEM, V277, P16599, DOI 10.1074/jbc.M200746200; Tisherman SA, 1999, SURG CLIN N AM, V79, P1269, DOI 10.1016/S0039-6109(05)70077-3; Wendt S, 2003, J BIOL CHEM, V278, P1125, DOI 10.1074/jbc.M208572200; Yu CG, 2007, NEUROCHEM RES, V32, P2046, DOI 10.1007/s11064-007-9347-4	74	41	42	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	FEB 1	2009	87	2					408	417		10.1002/jnr.21872			10	Neurosciences	Neurosciences & Neurology	403JQ	WOS:000263079300012	18803298				2021-06-18	
J	Sarnowska, A; Braun, H; Sauerzweig, S; Reymann, KG				Sarnowska, Anna; Braun, Holger; Sauerzweig, Steven; Reymann, Klaus G.			The neuroprotective effect of bone marrow stem cells is not dependent on direct cell contact with hypoxic injured tissue	EXPERIMENTAL NEUROLOGY			English	Article						Neuroprotection; Transplantation; Bone marrow stem cells; Stem cell therapy; Hippocampal slice culture; Serum deprivation; Oxygen-glucose deprivation; Cortical primary culture	TRAUMATIC BRAIN-INJURY; GROWTH-FACTOR PRODUCTION; STROMAL CELLS; IN-VITRO; INDUCED NEUROGENESIS; FUNCTIONAL RECOVERY; ISCHEMIC-STROKE; RAT HIPPOCAMPUS; CULTURES; EXPRESSION	Bone marrow stem cells (BMSCs) are able to confer beneficial effects after transplantation into animals with ischemic brain injuries. This effect is probably mainly caused by the release of trophic factors, though the possibility of dead neural cells being replaced by BMSCs cannot be excluded. The aim of this study was to determine whether the neuroprotective effects in question are dependent on direct cell-cell contacts between BMSCs and injured tissue. We therefore investigated that interplay in an in vitro model of hippocampal organotypic slice Cultures (OHCs), in order to avoid the interference due to immunological rejection processes following transplantation in vivo. To perform ischemic injury in vitro, OHCs were made subject to oxygen-glucose deprivation (OGD). The possible direct or indirect neuroprotective effects induced by BMSCs were evaluated 24 h after injury by reference to two experimental paradigms using ischemic injured hippocampal slices: (i) cell transplantation on the top of OGD-treated OHC (ii) co-cultivation of cell culture with OHC space separated for 24 h. In both paradigms, the BMSC treatment induced comparable and significant neuroprotection in OGD-injured OHCs. This effect increased after treatment with serum-deprived BMSCs, enriched with cells expressing nestin and GFAR Comparing cell transplantation and cell co-cultivation with injured tissue, we concluded that the neuroprotective effect of BMSCs evoked shortly after ischemia (24 h) does not depend on cell-cell contacts. Additionally OGD-treated OHC was found to stimulate co-cultured BMSCs into expressing higher levels of bFGF and NGF. Finally, ischemic hippocampal slices increased the expression of nestin and GFAP in co-cultivated BMSCs, as well as changing their morphology. (c) 2008 Elsevier Inc. All rights reserved.	[Sarnowska, Anna; Reymann, Klaus G.] FAN GmbH, Res Inst Appl Neurosci, D-39120 Magdeburg, Germany; [Braun, Holger; Sauerzweig, Steven; Reymann, Klaus G.] Leibniz Inst Neurobiol, D-39118 Magdeburg, Germany; [Sarnowska, Anna] Polish Acad Sci, Med Res Inst, NeuroRepair Dept, Warsaw, Poland	Sarnowska, A (corresponding author), FAN GmbH, Res Inst Appl Neurosci, Leipziger Str 44, D-39120 Magdeburg, Germany.	a_sarnowska@tlen.pl			Marie Curie development host fellowshipEuropean Commission [MCFH-2001-00639]	Our work was supported by the Marie Curie development host fellowship program (MCFH-2001-00639).	Abe K, 2000, J CEREBR BLOOD F MET, V20, P1393, DOI 10.1097/00004647-200010000-00001; Alvarez-Dolado M, 2003, NATURE, V425, P968, DOI 10.1038/nature02069; Bonthius DJ, 2003, DEV BRAIN RES, V140, P15, DOI 10.1016/S0165-3806(02)00549-7; Braun H, 2006, J NEUROSCI METH, V157, P32, DOI 10.1016/j.jneumeth.2006.03.019; Buhnemann C, 2006, BRAIN, V129, P3238, DOI 10.1093/brain/awl261; Cavaliere F, 2005, NEUROSCIENCE, V136, P615, DOI 10.1016/j.neuroscience.2005.04.038; Chen XG, 2002, J NEUROSCI RES, V69, P687, DOI 10.1002/jnr.10334; Chen XG, 2002, NEUROPATHOLOGY, V22, P275, DOI 10.1046/j.1440-1789.2002.00450.x; Darsalia V, 2005, STROKE, V36, P1790, DOI 10.1161/01.STR.0000173151.36031.be; Dempsey RJ, 2007, NEUROSURG CLIN N AM, V18, P183, DOI 10.1016/j.nec.2006.10.011; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Dluzniewska J, 2005, FASEB J, V19, P1896, DOI 10.1096/fj.05-3786fje; Golbs A, 2007, J NEUROSCI METH, V161, P234, DOI 10.1016/j.jneumeth.2006.11.011; Haynesworth SE, 1996, J CELL PHYSIOL, V166, P585, DOI 10.1002/(SICI)1097-4652(199603)166:3<585::AID-JCP13>3.0.CO;2-6; Jaworski J, 2005, J NEUROSCI, V25, P11300, DOI 10.1523/JNEUROSCI.2270-05.2005; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Johnson-Farley NN, 2007, BRAIN RES, V1154, P40, DOI 10.1016/j.brainres.2007.04.026; Kokaia Z, 2003, CURR OPIN NEUROBIOL, V13, P127, DOI 10.1016/S0959-4388(03)00017-5; Kozlowska H, 2007, STEM CELLS DEV, V16, P481, DOI 10.1089/scd.2007.9993; Kumar V, 2005, J NEUROSCI, V25, P11288, DOI 10.1523/JNEUROSCI.2284-05.2005; Lei ZG, 2006, NEUROSCI LETT, V407, P224, DOI 10.1016/j.neulet.2006.06.019; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; Lindvall O, 2004, NAT MED, V10, pS42, DOI 10.1038/nm1064; Liu YB, 2006, J SURG RES, V136, P336, DOI 10.1016/j.jss.2006.07.037; Lu J, 2006, NEUROSCI LETT, V398, P12, DOI 10.1016/j.neulet.2005.12.053; Mahmood A, 2006, J NEUROSURG, V104, P272, DOI 10.3171/jns.2006.104.2.272; Mahmood A, 2005, NEUROSURGERY, V57, P1026, DOI 10.1227/01.NEU.0000181369.76323.50; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; MILLER LDP, 1994, NEUROSCIENCE, V63, P471, DOI 10.1016/0306-4522(94)90544-4; Neumann J, 2006, FASEB J, V20, P714, DOI 10.1096/fj.05-4882fje; Nighoghossian N, 2007, STROKE, V38, P303, DOI 10.1161/01.STR.0000254548.30258.f2; Ortiz-Gonzalez XR, 2004, CURR NEUROVASC RES, V1, P207, DOI 10.2174/1567202043362342; Pforte C, 2005, NEUROSCIENCE, V136, P1133, DOI 10.1016/j.neuroscience.2005.08.043; Pisati F, 2007, CELL TRANSPLANT, V16, P41, DOI 10.3727/000000007783464443; Sanchez-Ramos J, 2000, EXP NEUROL, V164, P247, DOI 10.1006/exnr.2000.7389; Sauerzweig S, 2009, EXP CELL RES, V315, P50, DOI 10.1016/j.yexcr.2008.10.007; Schulman A, 2005, STEM CELL REV, V1, P291, DOI 10.1385/SCR:1:4:291; Steiner B, 2006, GLIA, V54, P805, DOI 10.1002/glia.20407; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; Tabakman R, 2005, ANN NY ACAD SCI, V1053, P84, DOI 10.1196/annals.1344.008; Zaman V, 2003, EXP NEUROL, V183, P11, DOI 10.1016/S0014-4886(03)00167-5; Zaman V, 2003, HIPPOCAMPUS, V13, P618, DOI 10.1002/hipo.10091; Zhang J, 2004, BRAIN RES, V1030, P19, DOI 10.1016/j.brainres.2004.09.061	44	41	44	0	5	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	FEB	2009	215	2					317	327		10.1016/j.expneurol.2008.10.023			11	Neurosciences	Neurosciences & Neurology	400TG	WOS:000262890900014	19063882				2021-06-18	
J	Yu, WR; Liu, TY; Fehlings, TK; Fehlings, MG				Yu, Wen Ru; Liu, Tianyi; Fehlings, Tara K.; Fehlings, Michael G.			Involvement of mitochondrial signaling pathways in the mechanism of Fas-mediated apoptosis after spinal cord injury	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						apoptosis; Bcl-2 family proteins; Fas; mitochondrial dysfunction; spinal cord injury	BCL-2 FAMILY PROTEINS; NEURONAL CELL-DEATH; FUNCTIONAL RECOVERY; CYTOCHROME-C; GRADED MODEL; CASPASE 8; ACTIVATION; MOUSE; RECEPTOR; LIGAND	Activation of the Fas receptor has been recently linked to apoptotic cell death after spinal cord injury (SCI). Although it is generally considered that Fas activation mediates apoptosis predominantly through the extrinsic pathway, we hypothesized that intrinsic mitochondrial signaling could be involved in the underlying mechanism of Fas-induced apoptosis after SCI. In the present study, we utilized the Fejota(TM) clip compression model of SCI at T5-6 in C57BL/6 Fas-deficient (lpr) and wild-type mice. Complementary studies were conducted using an in vitro model of trauma or a Fas-activating antibody to induce apoptosis in primary neuronal-glial mixed spinal cord cultures. After in vivo SCI, lpr mice, in comparison with wild-type mice, exhibited reduced numbers of terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)-positive cells at the lesion, reduced expression of truncation of Bid (tBid), apoptosis-inducing factor, activated caspase-9 and activated caspase-3, and increased expression of the antiapoptotic proteins Bcl-2 and Bcl-xL. After in vitro neurotrauma or the induction of Fas signaling by the Jo2 activating antibody, lpr spinal cord cultures showed an increased proportion of cells retaining mitochondrial membrane integrity and a reduction of tBid expression, caspase-9 and caspase-3 activation, and TUNEL-positive cells as compared to wild-type spinal cord cultures. The neutralization of Fas ligand (FasL) protected against traumatically induced or Fas-mediated caspase-3 activation and the loss of mitochondrial membrane potential and tBid expression in wild-type spinal cord cultures. However, in lpr spinal cord cultures, FasL neutralization had no protective effects. In summary, these data provide direct evidence for the induction of intrinsic mitochondrial signaling pathways following Fas activation after SCI.	[Fehlings, Michael G.] Toronto Western Hosp, Univ Hlth Network, Krembil Chair Neural Repair & Regenerat, Toronto Western Res Inst,Div Genet & Dev & Neuros, Toronto, ON M5T 2S8, Canada; Toronto Western Hosp, Univ Hlth Network, Krembil Neurosci Ctr, Toronto, ON M5T 2S8, Canada	Fehlings, MG (corresponding author), Toronto Western Hosp, Univ Hlth Network, Krembil Chair Neural Repair & Regenerat, Toronto Western Res Inst,Div Genet & Dev & Neuros, Room 4W-449,399 Bathurst St, Toronto, ON M5T 2S8, Canada.	michael@uhnres.utoronto.ca		Fehlings, Michael/0000-0002-5722-6364	PSI Foundation; Krembil Chair in Neural Repair and Regeneration	This work was supported by an operating grant received from the PSI Foundation. M. G. Fehlings is supported by the Krembil Chair in Neural Repair and Regeneration.	Ackery A, 2006, J NEUROTRAUM, V23, P604, DOI 10.1089/neu.2006.23.604; Adachi S, 1997, J BIOL CHEM, V272, P21878, DOI 10.1074/jbc.272.35.21878; Aggarwal S, 1999, CLIN EXP IMMUNOL, V117, P285; Beattie MS, 2002, PROG BRAIN RES, V137, P37; Beattie MS, 2004, TRENDS MOL MED, V10, P580, DOI 10.1016/j.molmed.2004.10.006; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; Casha S, 2005, EXP NEUROL, V196, P390, DOI 10.1016/j.expneurol.2005.08.020; Casha S, 2001, NEUROSCIENCE, V103, P203, DOI 10.1016/S0306-4522(00)00538-8; Castiglione M, 2004, NEUROSCIENCE, V126, P889, DOI 10.1016/j.neuroscience.2004.04.038; Chandler JM, 1998, J BIOL CHEM, V273, P10815, DOI 10.1074/jbc.273.18.10815; Citron BA, 1997, NEUROSCI LETT, V230, P25, DOI 10.1016/S0304-3940(97)00468-0; Cittelly DM, 2008, EXP NEUROL, V210, P295, DOI 10.1016/j.expneurol.2007.03.001; Colak A, 2005, J NEUROSURG-SPINE, V2, P327, DOI 10.3171/spi.2005.2.3.0327; Cregan SP, 2002, J CELL BIOL, V158, P507, DOI 10.1083/jcb.200202130; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Cruise MW, 2005, J LEUKOCYTE BIOL, V78, P412, DOI 10.1189/jlb.0105005; Demjen D, 2004, NAT MED, V10, P389, DOI 10.1038/nm1007; Desbarats J, 2003, NAT CELL BIOL, V5, P118, DOI 10.1038/ncb916; Diguet E, 2004, EXP NEUROL, V189, P1, DOI 10.1016/j.expneurol.2004.05.016; Emery E, 1998, J NEUROSURG, V89, P911, DOI 10.3171/jns.1998.89.6.0911; Felderhoff-Mueser U, 2000, BRAIN PATHOL, V10, P17; GONZALEZGARCIA M, 1995, P NATL ACAD SCI USA, V92, P4304, DOI 10.1073/pnas.92.10.4304; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; Joshi M, 2002, J NEUROTRAUM, V19, P175, DOI 10.1089/08977150252806947; Joshi M, 2002, J NEUROTRAUM, V19, P191, DOI 10.1089/08977150252806956; Keane RW, 2001, J NEUROPATH EXP NEUR, V60, P422, DOI 10.1093/jnen/60.5.422; Kim TH, 2000, J BIOL CHEM, V275, P39474, DOI 10.1074/jbc.M003370200; Kuwana T, 1998, J BIOL CHEM, V273, P16589, DOI 10.1074/jbc.273.26.16589; Li GL, 1996, J NEUROPATH EXP NEUR, V55, P280, DOI 10.1097/00005072-199603000-00003; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liu SS, 1996, SCI CHINA SER C, V39, P168; Lou J, 1998, SPINAL CORD, V36, P683, DOI 10.1038/sj.sc.3100632; Martin-Villalba A, 2001, CELL DEATH DIFFER, V8, P679, DOI 10.1038/sj.cdd.4400882; Matsushita K, 2000, J NEUROSCI, V20, P6879, DOI 10.1523/JNEUROSCI.20-18-06879.2000; Nesic-Taylor O, 2005, J NEUROSCI RES, V79, P628, DOI 10.1002/jnr.20400; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; Park H, 2005, J IMMUNOL, V175, P7193, DOI 10.4049/jimmunol.175.11.7193; Pasquini LA, 2000, J NEUROSCI RES, V59, P601, DOI 10.1002/(SICI)1097-4547(20000301)59:5<601::AID-JNR3>3.0.CO;2-1; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Sekhon LHS, 2001, SPINE, V26, pS2, DOI 10.1097/00007632-200112151-00002; Seki T, 2003, NEUROSURGERY, V53, P192, DOI 10.1227/01.NEU.0000068988.28788.2C; Seko Y, 2002, J AM COLL CARDIOL, V39, P1399, DOI 10.1016/S0735-1097(02)01776-X; Shiraishi H, 2002, LAB INVEST, V82, P1121, DOI 10.1097/01.LAB.0000029148.88524.CE; Springer JE, 1999, NAT MED, V5, P943, DOI 10.1038/11387; Springer JE, 2000, J NEUROSCI, V20, P7246; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Tsujimoto Y, 2003, J CELL PHYSIOL, V195, P158, DOI 10.1002/jcp.10254; Tsujimoto Y, 1998, GENES CELLS, V3, P697, DOI 10.1046/j.1365-2443.1998.00223.x; Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wang HM, 2003, ANN NY ACAD SCI, V991, P132; Wang L, 2001, P NATL ACAD SCI USA, V98, P13884, DOI 10.1073/pnas.241358198; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; Wu KLH, 2007, J NEUROCHEM, V101, P1552, DOI 10.1111/j.1471-4159.2006.04445.x; Yin XM, 2000, CELL RES, V10, P161, DOI 10.1038/sj.cr.7290045; Yin XM, 2000, J MOL MED-JMM, V78, P203, DOI 10.1007/s001090000099; Yoshino O, 2004, SPINE, V29, P1394, DOI 10.1097/01.BRS.0000129894.34550.48; YU ACH, 1993, J NEUROSCI RES, V34, P295, DOI 10.1002/jnr.490340306; Yu FS, 2006, J NEUROTRAUM, V23, P595, DOI 10.1089/neu.2006.23.595; Yu SW, 2006, P NATL ACAD SCI USA, V103, P18314, DOI 10.1073/pnas.0606528103	63	41	46	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	JAN	2009	29	1					114	131		10.1111/j.1460-9568.2008.06555.x			18	Neurosciences	Neurosciences & Neurology	387OO	WOS:000261961700012	19120440				2021-06-18	
J	Wennberg, RA; Tator, CH				Wennberg, Richard A.; Tator, Charles H.			Concussion Incidence and Time Lost from Play in the NHL During the Past Ten Years	CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES			English	Article							CONSENSUS INJURY DEFINITIONS; TEAM SPORTS; ICE HOCKEY; HEAD; DEBATE; FOCUS; SIZE	Background: The problem of concussions in professional hockey has attracted Much recent attention. To evaluate file current state of this injury in the National Hockey League (NHL), we analyzed the Concussion incidence and time lost from play Clue to Concussions during the past tell NHL seasons. Methods: Data were obtained from a complete review of injury reports in two different sports media sources covering the NFIL seasons 1997-98 through 2007-08. Time lost from play was measured in missed games per concussion. Results: The incidence of concussions reported in the regular season ranged from it high of 1.81/1000 athlete exposures in 1998-99 to a low of 1.04/1000 athlete exposures in 2005-06. There was if downward trend ill the number Of Concussions reported per season during the past tell years (p=0.01). However, average time lost from play per concussion increased over the same period (p < 0.0005). Forwards suffered a disproportionately high percentage of concussions (p < 0.0001). Conclusions: Possibly related to injury reduction efforts. the number of concussions reported per season in the NHL has trended downward in recent years. However. the incidence of concussion remains high and the average time lost from play per concussion has increased. This may reflect increased injury severity in recent years or, alternatively, increased adherence to modern management guidelines preventing premature return to play.	[Wennberg, Richard A.] Univ Toronto, Toronto Western Hosp, Div Neurol, Krembil Neurosci Ctr, Toronto, ON M5T 2S8, Canada; [Tator, Charles H.] Univ Toronto, Toronto Western Hosp, Div Neurosurg, Krembil Neurosci Ctr, Toronto, ON M5T 2S8, Canada; [Wennberg, Richard A.; Tator, Charles H.] ThinkFirst, Toronto, ON, Canada	Wennberg, RA (corresponding author), Univ Toronto, Toronto Western Hosp, Div Neurol, Krembil Neurosci Ctr, 399 Bathurst St,Suite 5W444, Toronto, ON M5T 2S8, Canada.						Agel J, 2007, J ATHL TRAINING, V42, P241; Carson J, 2006, CAN FAM PHYSICIAN, V52, P756; Goodman D, 2001, MED SCI SPORT EXER, V33, P2004, DOI 10.1097/00005768-200112000-00005; Hodgson L, 2007, CLIN J SPORT MED, V17, P188, DOI 10.1097/JSM.0b013e3180547513; McCrory Paul, 2005, Clin J Sport Med, V15, P48; MEEUWISSE W, 2001, BRIT J SPORT MED, V35, P375; MENDOZA M, 2006, COLUMBIAN       1206, pB1; MOORE M, 2006, SAVING GAME; Orchard J, 2002, BRIT J SPORT MED, V36, P16, DOI 10.1136/bjsm.36.1.16; Orchard J, 2007, CLIN J SPORT MED, V17, P192, DOI 10.1097/JSM.0b013e3180547527; Pashby T, 2001, CLIN J SPORT MED, V11, P211, DOI 10.1097/00042752-200110000-00001; REID SM, 2007, ORANGE COUNTY R 0923, P1; STARKMAN R, 2007, TORONTO STAR    1223, pS1; Stevens ST, 2006, J SCI MED SPORT, V9, P238, DOI 10.1016/j.jsams.2006.03.025; Wennberg R, 2005, CLIN J SPORT MED, V15, P67, DOI 10.1097/01.jsm.0000152712.27968.fe; Wennberg R, 2004, CAN J NEUROL SCI, V31, P373, DOI 10.1017/S0317167100003474; WENNBERG R, 2004, GLOBE MAIL      0826, pA17; Wennberg RA, 2003, CAN J NEUROL SCI, V30, P206, DOI 10.1017/S0317167100002596; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832	19	41	41	1	13	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	0317-1671	2057-0155		CAN J NEUROL SCI	Can. J. Neurol. Sci.	NOV	2008	35	5					647	651		10.1017/S031716710000946X			5	Clinical Neurology	Neurosciences & Neurology	379JZ	WOS:000261393800017	19235451	Bronze			2021-06-18	
J	Finnerup, NB				Finnerup, Nanna B.			A review of central neuropathic pain states	CURRENT OPINION IN ANESTHESIOLOGY			English	Article						central pain; multiple sclerosis; Parkinson's disease; poststroke pain; spinal cord injury; traumatic brain injury	SPINAL-CORD-INJURY; DOUBLE-BLIND; LAMOTRIGINE; VALIDATION; MODULATION; MICROGLIA; LEVODOPA; TRIAL	Purpose of review Central neuropathic pain is an important and disabling but often neglected problem following central nervous system lesions. The present review highlights recent advances in the understanding of the underlying mechanisms and in the diagnosis and treatment of central pain. Recent findings Within the past year, the field of central pain has moved toward a more integrative understanding of central pain. The involvement of nonneuronal cells and interaction between multiple areas of the central nervous system has been recognized as important in the underlying mechanisms. The interest for conditions other than spinal cord injury, multiple sclerosis, and stroke has increased, and continued discussions on clear clinical diagnostic criteria are needed. The treatment of central pain is still a great challenge, but recent evidence points to tricyclic antidepressants, gabapentin and pregabalin, and selective serotonin-noradrenaline reuptake inhibitors as first-line drugs in central pain. An increased understanding of the psychosocial aspects of central pain also has implications for the treatment. Summary Increased insight into the mechanisms of central pain will hopefully lead to increased efforts to study mechanism-based treatment of central pain.	[Finnerup, Nanna B.] Aarhus Univ Hosp, Danish Pain Res Ctr, DK-8000 Aarhus C, Denmark; [Finnerup, Nanna B.] Viborg Hosp, Spinal Cord Unit, Viborg, Denmark	Finnerup, NB (corresponding author), Aarhus Univ Hosp, Danish Pain Res Ctr, Norrebrogade 44,Bldg 1A, DK-8000 Aarhus C, Denmark.	finnerup@ki.au.dk	Finnerup, Nanna Brix/ABA-8219-2020	Finnerup, Nanna Brix/0000-0001-5541-0240	Ludvig and Sara Elsass Foundation	The present work was supported by a grant from Ludvig and Sara Elsass Foundation.	Bennett MI, 2007, PAIN, V127, P199, DOI 10.1016/j.pain.2006.10.034; BOIVIE J, 2006, TXB PAIN, P1057; Boord P, 2008, SPINAL CORD, V46, P118, DOI 10.1038/sj.sc.3102077; Breuer B, 2007, CLIN THER, V29, P2022, DOI 10.1016/j.clinthera.2007.09.023; Bryce TN, 2007, J SPINAL CORD MED, V30, P421, DOI 10.1080/10790268.2007.11753405; Budh CN, 2007, CLIN REHABIL, V21, P89, DOI 10.1177/0269215506070313; Canavero S, 2007, ACTA NEUROCHIR SUPPL, V97, P27; Defrin R, 2007, ARCH PHYS MED REHAB, V88, P1574, DOI 10.1016/j.apmr.2007.07.025; Djaldetti R, 2007, CLIN NEUROPHARMACOL, V30, P201, DOI 10.1097/WNF.0B013E3180340319; Dworkin RH, 2007, PAIN, V132, P237, DOI 10.1016/j.pain.2007.08.033; Ertas M, 1998, PAIN, V75, P257, DOI 10.1016/S0304-3959(98)00003-7; Finnerup NB, 2007, EXP NEUROL, V207, P139, DOI 10.1016/j.expneurol.2007.06.001; Finnerup NB, 2005, PAIN, V118, P289, DOI 10.1016/j.pain.2005.08.013; Galer BS, 1997, NEUROLOGY, V48, P332, DOI 10.1212/WNL.48.2.332; Gerdelat-Mas A, 2007, J NEUROL NEUROSUR PS, V78, P1140, DOI 10.1136/jnnp.2007.120212; Kim JH, 2007, J NEUROSCI, V27, P4995, DOI 10.1523/JNEUROSCI.0716-07.2007; Knerlich-Lukoschus F, 2008, J NEUROTRAUM, V25, P427, DOI 10.1089/neu.2007.0431; Merskey H, 1994, CLASSIFICATION CHRON; Ofek H, 2007, PAIN, V131, P330, DOI 10.1016/j.pain.2007.06.015; PERTOVAARA A, 2007, PAIN; Rintala DH, 2007, ARCH PHYS MED REHAB, V88, P1547, DOI 10.1016/j.apmr.2007.07.038; Rog DJ, 2007, CLIN J PAIN, V23, P473, DOI 10.1097/AJP.0b013e31805d0c5d; Schestatsky P, 2007, NEUROLOGY, V69, P2162, DOI 10.1212/01.wnl.0000295669.12443.d3; Silver M, 2007, J PAIN SYMPTOM MANAG, V34, P446, DOI 10.1016/j.jpainsymman.2006.12.015; Tracey I, 2007, NEURON, V55, P377, DOI 10.1016/j.neuron.2007.07.012; Treede RD, 2008, NEUROLOGY, V70, P1630, DOI 10.1212/01.wnl.0000282763.29778.59; Veldhuijzen Dieuwke S, 2007, Curr Pain Headache Rep, V11, P183, DOI 10.1007/s11916-007-0189-1; Vinik AI, 2007, PAIN, V128, P169, DOI 10.1016/j.pain.2006.09.040; Vranken JH, 2008, PAIN, V136, P150, DOI 10.1016/j.pain.2007.06.033; Widerstrom-Noga EG, 2007, ARCH PHYS MED REHAB, V88, P1628, DOI 10.1016/j.apmr.2007.09.013; Yezierski RP, 2006, HAND CLINIC, V81, P293, DOI 10.1016/S0072-9752(06)80025-4; Zhao P, 2007, J NEUROSCI, V27, P8893, DOI 10.1523/JNEUROSCI.2209-07.2007; Zhao P, 2007, J NEUROSCI, V27, P2357, DOI 10.1523/JNEUROSCI.0138-07.2007	33	41	47	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0952-7907	1473-6500		CURR OPIN ANESTHESIO	Curr. Opin. Anesthesiol.	OCT	2008	21	5					586	589		10.1097/ACO.0b013e32830a4c11			4	Anesthesiology	Anesthesiology	398ER	WOS:000262715900010	18784483				2021-06-18	
J	Ayer, RE; Sugawara, T; Chen, W; Tong, W; Zhang, JH				Ayer, Robert E.; Sugawara, Takashi; Chen, Wanqiu; Tong, Wenni; Zhang, John H.			Melatonin decreases mortality following severe subarachnoid hemorrhage	JOURNAL OF PINEAL RESEARCH			English	Article						acute brain injury; lipid peroxidation; melatonin; mortality; oxidative stress; subarachnoid hemorrhage	CEREBRAL-ARTERY OCCLUSION; TRAUMATIC BRAIN-INJURY; HYDROXYL RADICAL SCAVENGER; VEHICLE-CONTROLLED TRIAL; DOSE TIRILAZAD MESYLATE; DOUBLE-BLIND; INDUCED NEUROPROTECTION; REDUCES VOLUME; RAT; ISCHEMIA	Aneurysmal subarachnoid hemorrhage (SAH) is a devastating disease that is associated with significant morbidity and mortality. There is substantial evidence to suggest that oxidative stress is significant in the development of acute brain injury following SAH. Melatonin is a strong antioxidant that has low toxicity and easily passes through the blood-brain barrier. Previous studies have shown that melatonin provides neuroprotection in animal models of ischemic stroke. This study hypothesizes that melatonin will provide neuroprotection when administered 2 hr after SAH. The filament perforation model of SAH was performed in male Sprague-Dawley rats weighing between 300 and 380 g. Melatonin (15 or 150 mg/kg), or vehicle was given via intraperitoneal injection 2 hr after SAH. Mortality and neurologic deficits were assessed 24 hr after SAH. A significant reduction in 24-hr mortality was seen following treatment with high dose melatonin. There was no improvement in neurologic scores with treatment. Brain water content and lipid peroxidation were measured following the administration of high dose melatonin to identify a mechanism for the increased survival. High dose melatonin tended to reduce brain water content following SAH, but had no effect on the lipid peroxidation of brain samples. Large doses of melatonin significantly reduces mortality and brain water content in rats following SAH through a mechanism unrelated to oxidative stress.	[Zhang, John H.] Loma Linda Univ, Med Ctr, Dept Neurosurg, Loma Linda, CA 92350 USA; [Ayer, Robert E.; Sugawara, Takashi; Chen, Wanqiu; Tong, Wenni; Zhang, John H.] Loma Linda Univ, Dept Physiol & Pharmacol, Loma Linda, CA 92350 USA; [Zhang, John H.] Loma Linda Univ, Dept Anesthesiol, Loma Linda, CA 92350 USA	Zhang, JH (corresponding author), Loma Linda Univ, Med Ctr, Dept Neurosurg, 11234 Anderson St, Loma Linda, CA 92350 USA.	johnzhang3910@yahoo.com	Sugawara, Takashi/ABI-3295-2020		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS043338, R01NS045694, R01NS053407] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS43338, NS45694, NS53407] Funding Source: Medline		Asano T, 1999, CRIT REV NEUROSURG, V9, P303, DOI 10.1007/s003290050147; Asano T, 1996, J NEUROSURG, V84, P792, DOI 10.3171/jns.1996.84.5.0792; Aydin MV, 2005, NEUROL RES, V27, P77, DOI 10.1179/016164105X18331; Badaut J, 2003, ACTA NEUROCHIR SUPPL, V86, P495; BAENA RRY, 1988, ACTA NEUROCHIR S, V43, P177; BARCHAS J, 1967, NATURE, V214, P919, DOI 10.1038/214919a0; Beni SM, 2004, FASEB J, V18, P149, DOI 10.1096/fj.03-0323fje; Biros MH, 1999, ACAD EMERG MED, V6, P1088, DOI 10.1111/j.1553-2712.1999.tb00109.x; BRODERICK JP, 1994, STROKE, V25, P1342, DOI 10.1161/01.STR.25.7.1342; Busch E, 1998, STROKE, V29, P2155, DOI 10.1161/01.STR.29.10.2155; Cahill J, 2007, NEUROSURGERY, V60, P531, DOI 10.1227/01.NEU.0000249287.99878.9B; Cheung RTF, 2006, J PINEAL RES, V41, P337, DOI 10.1111/j.1600-079X.2006.00372.x; Cheung RTF, 2003, J PINEAL RES, V34, P153, DOI 10.1034/j.1600-079X.2003.00034.x; Claassen J, 2002, STROKE, V33, P1225, DOI 10.1161/01.STR.0000015624.29071.1F; DOCZI T, 1985, ACTA NEUROCHIR, V77, P110, DOI 10.1007/BF01476215; Gaetani P, 1992, J Neurosurg Sci, V36, P1; Gaetani P, 1998, J NEUROSURG, V89, P748, DOI 10.3171/jns.1998.89.5.0748; GARCIA JH, 1995, STROKE, V26, P627, DOI 10.1161/01.STR.26.4.627; Germano A, 1998, J NEUROSURG, V88, P1075, DOI 10.3171/jns.1998.88.6.1075; Gorgulu AK, 2001, NEUROSURGERY, V49, P1434; Gul S, 2005, SURG NEUROL, V64, P355, DOI 10.1016/j.surneu.2005.03.036; Haley EC, 1997, J NEUROSURG, V86, P467, DOI 10.3171/jns.1997.86.3.0467; Handa Y, 2000, SURG NEUROL, V53, P323, DOI 10.1016/S0090-3019(00)00168-3; Imperatore C, 2000, LIFE SCI, V66, P779, DOI 10.1016/S0024-3205(99)00651-7; Josko J, 2001, FOLIA NEUROPATHOL, V39, P243; Kassell NF, 1996, J NEUROSURG, V84, P221, DOI 10.3171/jns.1996.84.2.0221; KASSELL NF, 1990, J NEUROSURG, V73, P18, DOI 10.3171/jns.1990.73.1.0018; Kaur C, 2006, GLIA, V54, P826, DOI 10.1002/glia.20420; Kaynar MY, 2005, NEUROL RES, V27, P562, DOI 10.1179/016164105X17288; Kilic U, 2005, J PINEAL RES, V38, P67, DOI 10.1111/j.1600-079X.2004.00178.x; Kondoh T, 2002, LIFE SCI, V72, P583, DOI 10.1016/S0024-3205(02)02256-7; Kusaka G, 2004, J CEREBR BLOOD F MET, V24, P916, DOI 10.1097/01.WCB.0000125886.48838.7E; Kusaka I, 2004, AM J PHYSIOL-HEART C, V286, pH2442, DOI 10.1152/ajpheart.01169.2003; Lanzino G, 1999, J NEUROSURG, V90, P1011, DOI 10.3171/jns.1999.90.6.1011; Lanzino G, 1999, J NEUROSURG, V90, P1018, DOI 10.3171/jns.1999.90.6.1018; Leon J, 2005, J PINEAL RES, V38, P1, DOI 10.1111/j.1600-079X.2004.00181.x; Lima ACP, 2003, NEUROTOX RES, V5, P323, DOI 10.1007/BF03033152; Maldonado MD, 2007, J PINEAL RES, V42, P1, DOI 10.1111/j.1600-079X.2006.00376.x; Martinez-Cruz F, 2002, NEUROSCI LETT, V331, P208, DOI 10.1016/S0304-3940(02)00884-4; Mayberg MR, 1998, NEUROSURG CLIN N AM, V9, P615; Mayhan WG, 1999, AM J PHYSIOL-CELL PH, V276, pC1148; MCCORMICK WF, 1965, J NEUROSURG, V22, P155, DOI 10.3171/jns.1965.22.2.0155; Orakcioglu B, 2005, EXP NEUROL, V193, P369, DOI 10.1016/j.expneurol.2005.01.017; Ostrowski RP, 2006, NEUROL RES, V28, P399, DOI 10.1179/016164106X115008; Ozdemir D, 2005, NEUROSCI LETT, V385, P234, DOI 10.1016/j.neulet.2005.05.055; Ozdemir D, 2005, PHYSIOL RES, V54, P631; Pei Z, 2002, J PINEAL RES, V32, P168, DOI 10.1034/j.1600-079x.2002.1o847.x; Pei Z, 2003, J PINEAL RES, V34, P110, DOI 10.1034/j.1600-079X.2003.00014.x; Pei Z, 2002, NEUROSCI LETT, V318, P141, DOI 10.1016/S0304-3940(01)02503-4; Rosen J, 2006, J PINEAL RES, V41, P374, DOI 10.1111/j.1600-079X.2006.00379.x; Sack RL, 1997, SLEEP, V20, P908, DOI 10.1093/sleep/20.10.908; Schievink WI, 2004, NEUROEPIDEMIOLOGY, V23, P299, DOI 10.1159/000080096; Schievink WI, 1997, NEW ENGL J MED, V336, P28, DOI 10.1056/NEJM199701023360106; Schwartz AY, 2000, J NEUROSCI METH, V96, P161, DOI 10.1016/S0165-0270(00)00156-4; Sehba FA, 2006, NEUROL RES, V28, P381, DOI 10.1179/016164106X114991; Sibon I, 2004, EUR J NEUROL, V11, P497, DOI 10.1111/j.1468-1331.2004.00847.x; Tan DX, 2007, J PINEAL RES, V42, P28, DOI 10.1111/j.1600-079X.2006.00407.x; Taylor AN, 2002, J NEUROTRAUM, V19, P1597, DOI 10.1089/089771502762300256; Titova E, 2007, CLIN EXP PHARMACOL P, V34, P845, DOI 10.1111/j.1440-1681.2007.04664.x; Torii K, 2004, J PINEAL RES, V36, P18, DOI 10.1046/j.1600-079X.2003.00097.x; Tureci E, 2004, NEUROL RES, V26, P108, DOI 10.1179/016164104225013699; Watanabe T, 1997, NEUROL RES, V19, P563, DOI 10.1080/01616412.1997.11740859; Yamamoto S, 2000, J NEUROSURG, V92, P1009, DOI 10.3171/jns.2000.92.6.1009; Yatsushige H, 2007, J NEUROSCI RES, V85, P1436, DOI 10.1002/jnr.21281; Yon JH, 2006, NEUROBIOL DIS, V21, P522, DOI 10.1016/j.nbd.2005.08.011	65	41	42	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0742-3098	1600-079X		J PINEAL RES	J. Pineal Res.	MAR	2008	44	2					197	204		10.1111/j.1600-079X.2007.00508.x			8	Endocrinology & Metabolism; Neurosciences; Physiology	Endocrinology & Metabolism; Neurosciences & Neurology; Physiology	264AK	WOS:000253257400012	18289172				2021-06-18	
J	Brichtova, E; Kozak, L				Brichtova, Eva; Kozak, Libor			Apolipoprotein E genotype and traumatic brain injury in children - association with neurological outcome	CHILDS NERVOUS SYSTEM			English	Article						brain injuries; child; Apolipoprotein E4; association; Glasgow Coma Scale; Glasgow Outcome Scale	WITHIN-PERSON COMPARISONS; MILD HEAD-INJURY; ALZHEIMERS-DISEASE; NEUROPSYCHOLOGICAL FUNCTION; APOE-EPSILON-4 ALLELE; APOE INFLUENCES; E POLYMORPHISM; EPSILON-4; RECOVERY	Objective To determine whether the presence of Apolipoprotein E epsilon 4 genotype (ApoE epsilon 4) is associated with outcomes of traumatic brain injury in children. Materials and methods The ApoE genotype was examined in the group of 70 pediatric patients who suffered from traumatic brain injury. The group consists of 48 boys and 22 girls, and the most frequent was the E3 isoform of ApoE. Polymerase chain reaction/restriction fragment length polymorphism method was used for the ApoE genotype assessment. The severity of trauma was assessed by Glasgow Coma Scale and graded into three categories. The presence of focal neurology signs, comparing the admission and dimission status, and duration of hospital care were observed. The neurological outcome after 1 year was assessed by Glasgow Outcome Scale. Trauma severity was compared with the neurological outcome, according to different ApoE genotypes. For statistical processing, t test, nonparametric Wilcoxon test, Fisher, and chi(2) tests were used. Conclusion Our results suggest the association between the ApoE genotype and outcome of traumatic brain injury in children. Patients with ApoE epsilon 4 genotype were more likely to have severe clinical symptomatology and unfavorable neurological outcome after traumatic brain injury compared to significantly better outcome with other ApoE genotype.	[Brichtova, Eva] Brno Fac Hosp, Clin Pediat Surg Orthopaed & Traumatol, Brno, Czech Republic; [Kozak, Libor] Brno Fac Hosp, Mol Biol & Gene Therapy Ctr, Brno, Czech Republic	Brichtova, E (corresponding author), Brno Fac Hosp, Clin Pediat Surg Orthopaed & Traumatol, Brno, Czech Republic.	brichtovae@seznam.cz					Chamelian L, 2004, BRAIN, V127, P2621, DOI 10.1093/brain/awh296; Chiang MF, 2003, ACTA NEUROCHIR, V145, P649, DOI 10.1007/s00701-003-0069-3; Collie A, 2004, NEUROLOGY, V63, P2460, DOI 10.1212/WNL.63.12.2460; Diaz-Arrastia R, 2003, ARCH NEUROL-CHICAGO, V60, P818, DOI 10.1001/archneur.60.6.818; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Graham DI, 1999, ACT NEUR S, V73, P89; Horsburgh K, 2000, NEUROBIOL AGING, V21, P245, DOI 10.1016/S0197-4580(00)00097-X; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Kerr M E, 1998, AACN Clin Issues, V9, P524, DOI 10.1097/00044067-199811000-00007; Krupa Mariusz, 2003, Neurol Neurochir Pol, V37, P1223; Laskowitz DT, 1998, J CEREBR BLOOD F MET, V18, P465, DOI 10.1097/00004647-199805000-00001; Leclercq PD, 2005, J NEUROL NEUROSUR PS, V76, P229, DOI 10.1136/jnnp.2003.025528; Lucotte G, 1997, HUM BIOL, V69, P253; Lynch JR, 2002, ANN NEUROL, V51, P113, DOI 10.1002/ana.10098; Nathoo N, 2003, J CLIN PATHOL-MOL PA, V56, P132, DOI 10.1136/mp.56.3.132; NICOLL JA, 1996, ANN NY ACAD SCI, V17, P271; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Sabo T, 2000, NEUROSCIENCE, V101, P879, DOI 10.1016/S0306-4522(00)00438-3; Samatovicz RA, 2000, J HEAD TRAUMA REHAB, V15, P869, DOI 10.1097/00001199-200006000-00002; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; Schiefermeier M, 2000, STROKE, V31, P2068, DOI 10.1161/01.STR.31.9.2068; Seliger G, 1997, NEUROLOGY, V48, P28001; Smith G, 2002, DRUG DEV IND PHARM, V28, P151, DOI 10.1081/DDC-120002448; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; Sundstrom A, 2004, NEUROLOGY, V62, P1963, DOI 10.1212/01.WNL.0000129268.83927.A8; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; UEKI A, 1993, NEUROSCI LETT, V163, P166, DOI 10.1016/0304-3940(93)90373-S; Veinbergs I, 2002, J NEUROSCI RES, V67, P379, DOI 10.1002/jnr.10138	28	41	42	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0256-7040	1433-0350		CHILD NERV SYST	Childs Nerv. Syst.	MAR	2008	24	3					349	356		10.1007/s00381-007-0459-6			8	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	258RV	WOS:000252888100011	17932679				2021-06-18	
J	Tabelow, K; Polzehl, J; Spokoiny, V; Voss, HU				Tabelow, Karsten; Polzehl, Joerg; Spokoiny, Vladimir; Voss, Henning U.			Diffusion tensor imaging: Structural adaptive smoothing	NEUROIMAGE			English	Article						diffusion tenser imaging; spatially adaptive smoothing	TRAUMATIC BRAIN-INJURY; WHITE-MATTER; B-MATRIX; ANISOTROPY; MRI; NOISE; REDUCTION; SPACE	Diffusion Tensor Imaging (DTI) data is characterized by a high noise level. Thus, estimation errors of quantities like anisotropy indices or the main diffusion direction used for fiber tracking are relatively large and may significantly confound the accuracy of DTI in clinical or neuroscience applications. Besides pulse sequence optimization, noise reduction by smoothing the data can be pursued as a complementary approach to increase the accuracy of DTI. Here, we suggest an anisotropic structural adaptive smoothing procedure, which is based on the Propagation-Separation method and preserves the structures seen in DTI and their different sizes and shapes. It is applied to artificial phantom data and a brain scan. We show that this method significantly improves the quality of the estimate of the diffusion tensor, by means of both bias and variance reduction, and hence enables one either to reduce the number of scans or to enhance the input for subsequent analysis such as fiber tracking. (C) 2007 Elsevier Inc. All rights reserved.	[Tabelow, Karsten; Polzehl, Joerg; Spokoiny, Vladimir] Weierstrass Inst Appl Anal & Stochast, D-10117 Berlin, Germany; [Voss, Henning U.] Cornell Univ, Weill Med Coll, Citigrp Biomed Imaging Ctr, New York, NY 10021 USA	Tabelow, K (corresponding author), Weierstrass Inst Appl Anal & Stochast, Mohrenstr 39, D-10117 Berlin, Germany.	tabelow@wias-berlin.de	Spokoiny, Vladimir G./L-5441-2015; Voss, Henning/C-2194-2009; Spokoiny, Vladimir/AAF-4942-2021; Tabelow, Karsten/AAI-4490-2021	Spokoiny, Vladimir G./0000-0002-2040-3427; Voss, Henning/0000-0003-2811-2074; Spokoiny, Vladimir/0000-0002-2040-3427; Tabelow, Karsten/0000-0003-1274-9951; Polzehl, Joerg/0000-0001-7471-2658			Alexander AL, 2000, MAGNET RESON MED, V44, P283, DOI 10.1002/1522-2594(200008)44:2<283::AID-MRM16>3.0.CO;2-V; Arsigny V, 2006, MAGN RESON MED, V56, P411, DOI 10.1002/mrm.20965; BASSER PJ, 1994, BIOPHYS J, V66, P259, DOI 10.1016/S0006-3495(94)80775-1; BASSER PJ, 1994, J MAGN RESON SER B, V103, P247, DOI 10.1006/jmrb.1994.1037; Basser PJ, 2000, MAGNET RESON MED, V44, P41, DOI 10.1002/1522-2594(200007)44:1<41::AID-MRM8>3.0.CO;2-O; Basu S, 2006, LECT NOTES COMPUT SC, V4190, P117; Bengtsson SL, 2005, NAT NEUROSCI, V8, P1148, DOI 10.1038/nn1516; Carbon M, 2004, ANN NEUROL, V56, P283, DOI 10.1002/ana.20177; CARR HY, 1954, PHYS REV, V94, P630, DOI 10.1103/PhysRev.94.630; CHUNG MK, 2005, TR1109 U WISC DEP ST; Clark CA, 2000, MAGN RESON MED, V44, P852, DOI 10.1002/1522-2594(200012)44:6<852::AID-MRM5>3.0.CO;2-A; Ding ZH, 2005, MAGN RESON MED, V53, P485, DOI 10.1002/mrm.20339; Fan JQ, 1996, J AM STAT ASSOC, V91, P674; Fillard P, 2007, IEEE T MED IMAGING, V26, P1472, DOI 10.1109/TMI.2007.899173; Fletcher P.T., 2004, THESIS U N CAROLINA; Fletcher PT, 2007, SIGNAL PROCESS, V87, P250, DOI 10.1016/j.sigpro.2005.12.018; Frank LR, 2001, MAGN RESON MED, V45, P935, DOI 10.1002/mrm.1125; GUDBJARTSSON H, 1995, MAGNET RESON MED, V34, P910, DOI 10.1002/mrm.1910340618; HAHN KR, 2006, VISUALIZATION IMAGE; Heim S, 2007, COMPUT STAT DATA AN, V51, P6212, DOI 10.1016/j.csda.2007.01.005; Jones DK, 2004, MAGN RESON MED, V52, P979, DOI 10.1002/mrm.20283; Jones DK, 2004, MAGNET RESON MED, V51, P807, DOI 10.1002/mrm.20033; JONES DK, 2003, P INT SOC MAGN RESON, V11, P2118; Khong PL, 2006, J CLIN ONCOL, V24, P884, DOI 10.1200/JCO.2005.02.4505; Kingsley PB, 2006, CONCEPT MAGN RESON A, V28A, P155, DOI 10.1002/cmr.a.20050; LEBIHAN D, 1985, CR ACAD SCI II, V301, P1109; LEE JH, 2005, P 13 ANN M ISMRM, P2253; Leung LHT, 2004, NEUROIMAGE, V21, P261, DOI 10.1016/j.neuroimage.2003.09.020; Liston C, 2006, CEREB CORTEX, V16, P553, DOI 10.1093/cercor/bhj003; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; MATTIELLO J, 1994, J MAGN RESON SER A, V108, P131, DOI 10.1006/jmra.1994.1103; Mattiello J, 1997, MAGNET RESON MED, V37, P292, DOI 10.1002/mrm.1910370226; McKinstry RC, 2002, CEREB CORTEX, V12, P1237, DOI 10.1093/cercor/12.12.1237; Melhem ER, 2002, AM J ROENTGENOL, V178, P3, DOI 10.2214/ajr.178.1.1780003; MERBOLDT KD, 1985, J MAGN RESON, V64, P479, DOI 10.1016/0022-2364(85)90111-8; Mori S, 2006, NEURON, V51, P527, DOI 10.1016/j.neuron.2006.08.012; Mukherjee P, 2006, NEUROIMAG CLIN N AM, V16, P19, DOI 10.1016/j.nic.2005.11.004; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Neyman J, 1937, SKAND AKTUARIETIDSKR, V20, P149; O'Sullivan M, 2005, NEUROLOGY, V65, P1584, DOI 10.1212/01.wnl.0000184480.07394.fb; Parker GJM, 2000, J MAGN RESON IMAGING, V11, P702, DOI 10.1002/1522-2586(200006)11:6<702::AID-JMRI18>3.0.CO;2-A; Pennec X, 2006, INT J COMPUT VISION, V66, P41, DOI 10.1007/s11263-005-3222-z; PERONA P, 1990, IEEE T PATTERN ANAL, V12, P629, DOI 10.1109/34.56205; Polzehl J, 2006, PROBAB THEORY REL, V135, P335, DOI 10.1007/s00440-005-0464-1; Schneider JFL, 2004, NEURORADIOLOGY, V46, P258, DOI 10.1007/s00234-003-1154-2; Schwartzman A, 2005, MAGN RESON MED, V53, P1423, DOI 10.1002/mrm.20503; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; STEJSKAL EO, 1965, J CHEM PHYS, V42, P288, DOI 10.1063/1.1695690; Sundgren PC, 2004, NEURORADIOLOGY, V46, P339, DOI 10.1007/s00234-003-1114-x; TABELOW K, IN PRESS IEEE T MED; Tabelow K, 2006, NEUROIMAGE, V33, P55, DOI 10.1016/j.neuroimage.2006.06.029; TAYLOR DG, 1985, PHYS MED BIOL, V30, P345, DOI 10.1088/0031-9155/30/4/009; Tuch D.S., 1999, P 7 ANN M ISMRM PHIL, P321; Voss HU, 2007, P NATL ACAD SCI USA, V104, P10667, DOI 10.1073/pnas.0611515104; Weickert J., 1998, ANISOTROPIC DIFFUSIO, Vvol 1; Westin CF, 1999, LECT NOTES COMPUT SC, V1679, P441; Yoshiura T, 2003, NEUROIMAGE, V20, P413, DOI 10.1016/S1053-8119(03)00342-2; ZHANG F, 2006, MED IMAGE COMPUTING, V2, P234; Zhang F, 2006, LECT NOTES COMPUT SC, V4109, P83	59	41	41	0	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	FEB 15	2008	39	4					1763	1773		10.1016/j.neuroimage.2007.10.024			11	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	263UK	WOS:000253241800025	18060811				2021-06-18	
J	Poomthavorn, P; Maixner, W; Zacharin, M				Poomthavorn, P.; Maixner, W.; Zacharin, M.			Pituitary function in paediatric survivors of severe traumatic brain injury	ARCHIVES OF DISEASE IN CHILDHOOD			English	Article							GROWTH-HORMONE DEFICIENCY; HEAD TRAUMA; NEUROENDOCRINE DYSFUNCTION; SUBARACHNOID HEMORRHAGE; PRACTICAL SCALE; HYPOPITUITARISM; CHILDHOOD; CHILDREN	Background: Traumatic brain injury (TBI)-mediated hypopituitarism is an increasingly recognised problem. Paediatric survivors of TBI may be vulnerable to the possible effects of pituitary deficits as pituitary hormones control normal growth and development. Research concerning pituitary dysfunction following childhood TBI is limited. Aim To identify pituitary dysfunction in paediatric survivors of severe TBI. Methods: Of 1020 children who sustained a TBI and were admitted to the Royal Children's Hospital, Melbourne, Australia over 10 years, 117 were identified as survivors of severe TBI. 54 patients (31 males) were enrolled and administered questionnaires regarding quality of life and possible endocrine dysfunction. Where indicated, hormone testing was performed. Results: 29 of the 54 patients underwent hormonal investigations, while 21 who had satisfactory questionnaires did not (four patients had already been diagnosed with pituitary deficiencies). In those 29 patients, TBI occurred at ages ranging from 0.25 to 16.80 years (median 9.7 years). Time from TBI to study ranged from 0.9 to 8.5 years (median 4.5 years). Of the 54 patients, nine had pituitary dysfunction, of whom four had multiple pituitary hormone deficiencies. Conclusions: Our study that confirms that paediatric survivors of severe TBI may develop pituitary dysfunction. Pituitary function should therefore be determined in these patients.	[Poomthavorn, P.; Zacharin, M.] Royal Childrens Hosp, Dept Endocrinol & Diabet, Parkville, Vic 3052, Australia; [Poomthavorn, P.] Ramathibodi Hosp, Fac Med, Dept Pediat, Div Endocrinol & Metab, Bangkok, Thailand; [Maixner, W.] Royal Childrens Hosp, Dept Neurosurg, Melbourne, Vic, Australia	Zacharin, M (corresponding author), Royal Childrens Hosp, Dept Endocrinol & Diabet, Flemington Rd, Parkville, Vic 3052, Australia.	margaret.zacharin@rch.org.au					Acerini CL, 2006, EUR J ENDOCRINOL, V155, P663, DOI 10.1530/eje.1.02284; Agha A, 2006, CLIN ENDOCRINOL, V64, P481, DOI 10.1111/j.1365-2265.2006.02517.x; Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Agha Amar, 2005, Pituitary, V8, P245, DOI 10.1007/s11102-005-3463-4; Agha Amar, 2005, Am J Med, V118, P1416; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Bondanelli M, 2005, EUR J ENDOCRINOL, V152, P679, DOI 10.1530/eje.1.01895; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Dogru O, 2005, NEUROENDOCRINOL LETT, V26, P311; EICHLER I, 1988, J ENDOCRINOL INVEST, V11, P409, DOI 10.1007/BF03349069; Einaudi S, 2006, J PEDIATR ENDOCR MET, V19, P691; Giordano Giulio, 2005, Pituitary, V8, P227, DOI 10.1007/s11102-006-6045-1; JENNETT B, 1975, LANCET, V1, P480; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Kraus J., 1995, TRAUMATIC HEAD INJUR, P117; Landgraf JM, 1996, CHILD HLTH QUESTIONN, V1st; LEE SC, 1994, BRAIN INJURY, V8, P571; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Lim H S, 1990, Ann Acad Med Singap, V19, P851; McKenna SP, 1999, QUAL LIFE RES, V8, P373, DOI 10.1023/A:1008987922774; Mitra B, 2007, J PAEDIATR CHILD H, V43, P154, DOI 10.1111/j.1440-1754.2007.01035.x; Niederland T, 2007, J NEUROTRAUM, V24, P119, DOI 10.1089/neu.2005.369ER; Poomthavorn P, 2007, EUR J PEDIATR, V166, P1163, DOI 10.1007/s00431-006-0406-7; SHAH A, 1992, BRIT MED J, V304, P173, DOI 10.1136/bmj.304.6820.173; TANNER JM, 1976, ARCH DIS CHILD, V51, P170, DOI 10.1136/adc.51.3.170; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; TEASDALE G, 1974, LANCET, V2, P81; YAMANAKA C, 1993, EUR J PEDIATR, V152, P99, DOI 10.1007/BF02072482	32	41	42	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0003-9888	1468-2044		ARCH DIS CHILD	Arch. Dis. Child.	FEB	2008	93	2					133	137		10.1136/adc.2007.121137			5	Pediatrics	Pediatrics	253GX	WOS:000252507800010	17986604				2021-06-18	
J	Field, EL; Norman, P; Barton, J				Field, Emma Louise; Norman, Paul; Barton, Jane			Cross-sectional and prospective associations between cognitive appraisals and posttraumatic stress disorder symptoms following stroke	BEHAVIOUR RESEARCH AND THERAPY			English	Article						PTSD; anxiety; depression; cognitive appraisals; stroke	TRAUMATIC BRAIN-INJURY; SEXUAL ASSAULT; PTSD; VALIDATION; SCALE	This study examined cross-sectional and prospective associations between cognitive appraisals and posttraumatic stress disorder (PTSD) symptoms following stroke. While in hospital, stroke patients (n = 81) completed questionnaires assessing cognitive appraisals (i.e., negative cognitions about the self, negative cognitions about the world, and self-blame) and PTSD symptoms. PTSD symptoms were assessed again 3 months later when all patients had been discharged from hospital (n = 70). Significant correlations were found between the time 1 measures of negative cognitions about the self and the world, but not self-blame, and the severity of PTSD symptoms measured at time 1 and at time 2. Regression analyses revealed that cognitive appraisals explained a significant amount of variance in the severity of PTSD symptoms at time 1, with negative cognitions about the self-emerging as a significant predictor. In contrast, time 1 cognitive appraisals were unable to explain additional variance in time 2 PTSD severity over and above that explained by time I PTSD severity. The findings therefore provide only weak support for Ehlers and Clark's cognitive model of PTSD. (c) 2007 Elsevier Ltd. All rights reserved.	[Norman, Paul] Univ Sheffield, Dept Psychol, Sheffield S10 2TP, S Yorkshire, England; [Field, Emma Louise] Univ Sheffield, Clin Psychol Unit, Sheffield S10 2TP, S Yorkshire, England; [Barton, Jane] Nether Edge Hosp, Sheffield Care Trust, Sheffield S11 9BJ, S Yorkshire, England	Norman, P (corresponding author), Univ Sheffield, Dept Psychol, Sheffield S10 2TP, S Yorkshire, England.	p.norman@sheffield.ac.uk					Agar E, 2006, BEHAV COGN PSYCHOTH, V34, P437, DOI 10.1017/S1352465806002943; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Berry E, 1998, BRIT J CLIN PSYCHOL, V37, P365, DOI 10.1111/j.2044-8260.1998.tb01392.x; Bruggimann L, 2006, NEUROLOGY, V66, P513, DOI 10.1212/01.wnl.0000194210.98757.49; Bryant RA, 2001, J CLIN EXP NEUROPSYC, V23, P718, DOI 10.1076/jcen.23.6.718.1024; Caspi Y, 2005, J LOSS TRAUMA, V10, P319, DOI 10.1080/15325020590956756; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Dunmore E, 1999, BEHAV RES THER, V37, P809, DOI 10.1016/S0005-7967(98)00181-8; Dunmore E, 2001, BEHAV RES THER, V39, P1063, DOI 10.1016/S0005-7967(00)00088-7; Ehlers A, 2000, BEHAV RES THER, V38, P319, DOI 10.1016/S0005-7967(99)00123-0; Fairbrother N, 2006, J BEHAV THER EXP PSY, V37, P74, DOI 10.1016/j.jbtep.2004.08.004; Foa EB, 1999, PSYCHOL ASSESSMENT, V11, P303, DOI 10.1037/1040-3590.11.3.303; Foa EB, 1997, PSYCHOL ASSESSMENT, V9, P445, DOI 10.1037/1040-3590.9.4.445; Foa EB., 1998, TREATING TRAUMA RAPE; Harvey AG, 2003, J INT NEUROPSYCH SOC, V9, P663, DOI 10.1017/S1355617703940069; Kangas M, 2005, HEALTH PSYCHOL, V24, P579, DOI 10.1037/0278-6133.24.6.579; KUTZ I, 1994, ISRAEL J PSYCHIAT, V31, P48; Marshall GN, 2006, J ABNORM PSYCHOL, V115, P624, DOI 10.1037/0021-843X.115.3.624; Mayou RA, 2002, BEHAV RES THER, V40, P665, DOI 10.1016/S0005-7967(01)00069-9; Merriman Charlotte, 2007, Psychol Health Med, V12, P592, DOI 10.1080/13548500601162747; *NAT I CLIN EXC, 2005, POST TRAUM STRESS DI; Nemeroff CB, 2006, J PSYCHIATR RES, V40, P1, DOI 10.1016/j.jpsychires.2005.07.005; Sembi S, 1998, INT J GERIATR PSYCH, V13, P315, DOI 10.1002/(SICI)1099-1166(199805)13:5<315::AID-GPS766>3.0.CO;2-P; SHALEV AY, 1993, BRIT J CLIN PSYCHOL, V32, P247, DOI 10.1111/j.2044-8260.1993.tb01052.x; Shemesh E, 2001, GEN HOSP PSYCHIAT, V23, P215, DOI 10.1016/S0163-8343(01)00150-5; *STROK ASS, 2006, INF; Tabachnick BG, 2013, USING MULTIVARIATE S; Tedstone JE, 2003, CLIN PSYCHOL REV, V23, P409, DOI 10.1016/S0272-7358(03)00031-X; WILLIAMS GN, 1997, SCI PSYCHOSOCIAL PRO, V10, P40; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	30	41	42	0	11	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0005-7967			BEHAV RES THER	Behav. Res. Ther.	JAN	2008	46	1					62	70		10.1016/j.brat.2007.10.006			9	Psychology, Clinical	Psychology	264GQ	WOS:000253276200005	18005937	Green Accepted			2021-06-18	
J	Katz-Leurer, M; Rotem, H; Lewitus, H; Keren, O; Meyer, S				Katz-Leurer, Michal; Rotem, Hemda; Lewitus, Hana; Keren, Ofer; Meyer, Shirley			Relationship between balance abilities and gait characteristics in children with post-traumatic brain injury	BRAIN INJURY			English	Article						children; traumatic brain injury; gait; variability; balance	OLDER-ADULTS; ELECTRONIC WALKWAY; STEP WIDTH; VARIABILITY; PARAMETERS; VALIDITY; MOTOR; ADOLESCENTS; PERFORMANCE; RECOVERY	Objectives: To quantify the differences in gait variability and balance performance between typically developed (TD) children and children with post-traumatic brain injury (TBI) and to determine the association between gait variability and functional balance in both groups. Design: Cross-sectional study. Setting: Physical therapy department of a paediatric and adolescent rehabilitation hospital. Participants: A convenience sample of 24 children post-TBI and 24 TD age and sex matched controls. Intervention: Not applicable. Main outcome measure: Step length, step time and base width variability measured with an electronic walkway; timed up and go (TUG) test and functional reach test (FRT) as a functional balance test. Results: Base width and step time variability showed no significant difference between the groups. However, children post-TBI had significantly greater variability in step length in comparison to healthy controls. The functional balance abilities of children post-TBI were significantly limited compared to TD children. A significant linear inverse correlation was found between balance performance and step length variability only among children with a TBI. Conclusion: Ambulatory children post-severe TBI had decreased balance performance, decreased gait speed and increased step length variability as compared to age-matched healthy controls.	[Katz-Leurer, Michal] Tel Aviv Univ, Sch Hlth Profess, Dept Phys Therapy, Sackler Fac Med, Ramat Aviv, Israel; [Katz-Leurer, Michal; Rotem, Hemda; Lewitus, Hana; Keren, Ofer; Meyer, Shirley] Alyn Hosp, Pediat & Adolescent Rehabil Ctr, Jerusalem, Israel	Katz-Leurer, M (corresponding author), Tel Aviv Univ, Sch Hlth Profess, Dept Phys Therapy, Sackler Fac Med, Ramat Aviv, Israel.	michalkz@post.tau.ac.il					Bilney B, 2003, GAIT POSTURE, V17, P68, DOI 10.1016/S0966-6362(02)00053-X; Bowen JM, 1997, DEV MED CHILD NEUROL, V39, P17; BRINK JD, 1970, DEV MED CHILD NEUROL, V12, P565; Burton CL, 2002, CLIN NEUROPSYCHOL, V16, P264, DOI 10.1076/clin.16.3.264.13854; Chesnin KJ, 2000, GAIT POSTURE, V12, P128, DOI 10.1016/S0966-6362(00)00071-0; Cutlip RG, 2000, GAIT POSTURE, V12, P134, DOI 10.1016/S0966-6362(00)00062-X; Donahoe B, 1994, PEDIAT PHYSICAL THER, V6, P189, DOI DOI 10.1097/00001577-199400640-00004; Dusing SC, 2007, GAIT POSTURE, V25, P135, DOI 10.1016/j.gaitpost.2006.06.003; Emanuelson I, 1998, Pediatr Rehabil, V2, P65; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; HALEY SM, 1990, J HEAD TRAUMA REHAB, V5, P77; Hausdorff JM, 2001, ARCH PHYS MED REHAB, V82, P1050, DOI 10.1053/apmr.2001.24893; Hausdorff JM, 1999, J APPL PHYSIOL, V86, P1040; Hausdorff JM, 1997, ARCH PHYS MED REHAB, V78, P278, DOI 10.1016/S0003-9993(97)90034-4; Hausdorff JM, 1998, MOVEMENT DISORD, V13, P428, DOI 10.1002/mds.870130310; HEITMANN DK, 1989, PHYS THER, V69, P923, DOI 10.1093/ptj/69.11.923; Ivanenko YP, 2005, J NEUROPHYSIOL, V94, P754, DOI 10.1152/jn.00088.2004; Jordan K, 2007, GAIT POSTURE, V26, P128, DOI 10.1016/j.gaitpost.2006.08.010; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; Kuhtz-Buschbeck JP, 2003, DEV MED CHILD NEUROL, V45, P821, DOI 10.1017/S001216220300152X; LEITNER Y, 2007, J NEUROLOGY     0402; Lowes LP, 1996, PEDIAT PHYS THERAPY, V8, P176; LOWES LP, 1997, THESIS ALLEGHENY U H; Maki BE, 1997, J AM GERIATR SOC, V45, P313, DOI 10.1111/j.1532-5415.1997.tb00946.x; McDonough AL, 2001, ARCH PHYS MED REHAB, V82, P419, DOI 10.1053/apmr.2001.19778; Niechwiej-Szwedo E, 2007, GAIT POSTURE, V25, P70, DOI 10.1016/j.gaitpost.2006.01.002; Niznik Theresa M., 1995, Physical and Occupational Therapy in Pediatrics, V15, P1; Ochi F, 1999, J HEAD TRAUMA REHAB, V14, P105, DOI 10.1097/00001199-199904000-00002; Owings TM, 2004, J BIOMECH, V37, P935, DOI 10.1016/j.jbiomech.2003.11.012; Provost Beth, 2007, Pediatr Phys Ther, V19, P2, DOI 10.1097/01.pep.0000249418.25913.a3; Rossi C, 1996, ARCH PHYS MED REHAB, V77, P1062, DOI 10.1016/S0003-9993(96)90069-6; Thorpe DE, 2005, ARCH PHYS MED REHAB, V86, P2342, DOI 10.1016/j.apmr.2005.07.301; van Emmerik REA, 2002, EXERC SPORT SCI REV, V30, P177, DOI 10.1097/00003677-200210000-00007; VanderSchaaf PJ, 1997, PEDIATR NEUROL, V16, P306, DOI 10.1016/S0887-8994(97)00025-8; Wade LD, 1997, ARCH PHYS MED REHAB, V78, P1107, DOI 10.1016/S0003-9993(97)90136-2	35	41	42	0	7	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2008	22	2					153	159		10.1080/02699050801895399			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	258DW	WOS:000252849600006	18240044				2021-06-18	
J	Turkstra, LS; Williams, WH; Tonks, J; Frampton, I				Turkstra, Lyn S.; Williams, W. Huw; Tonks, James; Frampton, Ian			Measuring social cognition in adolescents: Implications for students with TBI returning to school	NEUROREHABILITATION			English	Article						Social cognition; theory of mind; adolescent; emotion recognition	TRAUMATIC BRAIN-INJURY; FACIAL EXPRESSION; CHILDREN; MIND; EMOTION; COMPREHENSION; RECOGNITION; LANGUAGE; BELIEFS; SKILLS	In everyday adolescent communication, the ability to empathise with the mental state of others, recognise or infer intentions, or make judgements about emotional state, is a non-conscious but vital prerequisite of relating. Execution of these skills in social interactions supports both the exchange of social knowledge and also the development and maintenance of personal relationships. Thus, adolescents with impairments in these skills are at risk for a variety of negative outcomes. In this paper, we present data to illustrate that adolescents with traumatic brain injury (TBI) are likely to have impairments in processes such as emotion recognition and mental state attribution, and that these might not be identified on standardised tests. This is considered from the perspective of clinical assessment and intervention in school contexts.	[Turkstra, Lyn S.] Univ Wisconsin, Dept Commun Disorders, Madison, WI 53706 USA; [Williams, W. Huw; Tonks, James] Univ Exeter, Exeter, Devon, England; [Frampton, Ian] Cornwall Partnership NHS Trust, Cornwall, England	Turkstra, LS (corresponding author), Univ Wisconsin, Dept Commun Disorders, 1975 Willow Dr, Madison, WI 53706 USA.	lsturkstra@wisc.edu		williams, huw/0000-0003-0670-2620; Tonks, James/0000-0003-3930-9294			ASHER SR, 1986, SOCIAL WORK ED, V8, P205; Bach LJ, 2006, BRAIN COGNITION, V60, P196; Baron-Cohen S, 1999, J AUTISM DEV DISORD, V29, P407, DOI 10.1023/A:1023035012436; Baron-Cohen S, 2000, NEUROSCI BIOBEHAV R, V24, P355, DOI 10.1016/S0149-7634(00)00011-7; Baron-Cohen S, 2001, J DEV LEARNING DISOR, V5, P47, DOI DOI 10.1111/J.1467-7687.2008.00720.X; BARONCOHEN S, 1985, COGNITION, V21, P37, DOI 10.1016/0010-0277(85)90022-8; Bernet W, 1999, J AM ACAD CHILD PSY, V38, p1S, DOI 10.1016/S0890-8567(99)80001-X; Bibby H, 2005, NEUROPSYCHOLOGIA, V43, P99, DOI 10.1016/j.neuropsychologia.2004.04.027; Blakemore SJ, 2006, J CHILD PSYCHOL PSYC, V47, P296, DOI 10.1111/j.1469-7610.2006.01611.x; BLAZYK S, 1983, SOC WORK HEALTH CARE, V8, P55, DOI 10.1300/J010v08n04_05; BURGESS S, 2008, SOCIAL COGNITI UNPUB; Carrow-Woolfolk E., 1999, COMPREHENSIVE ASSESS; CHERULNIK PD, 1978, J SOC PSYCHOL, V104, P263, DOI 10.1080/00224545.1978.9924068; Choudhury S, 2006, SOC COGN AFFECT NEUR, V1, P165, DOI 10.1093/scan/nsl024; Coleman J. C., 1999, NATURE ADOLESCENCE; Damasio A. R., 2003, LOOKING SPINOZA JOY; DAMASIO AR, 1990, BEHAV BRAIN RES, V41, P81, DOI 10.1016/0166-4328(90)90144-4; DAWSON G, 2001, NEURAL BASES SOCIAL; Drevets WC, 1998, COGNITION EMOTION, V12, P353, DOI 10.1080/026999398379646; FINSET A, 1995, BRAIN INJURY, V9, P141, DOI 10.3109/02699059509008187; Fiske S.T., 1991, SOC COGNITION; FLAVELL JH, 1968, DEV ROLE TAKING COMM; Goodman R, 1997, J CHILD PSYCHOL PSYC, V38, P581, DOI 10.1111/j.1469-7610.1997.tb01545.x; Gregory C, 2002, BRAIN, V125, P752, DOI 10.1093/brain/awf079; Hansen DJ, 1996, BEHAV MODIF, V20, P281, DOI 10.1177/01454455960203003; HAPPE FGE, 1994, J AUTISM DEV DISORD, V24, P129, DOI 10.1007/BF02172093; Havet-Thomassin V, 2006, BRAIN INJURY, V20, P83, DOI 10.1080/02699050500340655; HENRY JD, 2006, NEUROPSYCHOLOGIA; HOMBERG V, 1993, NEUROSCI LETT, V150, P187, DOI 10.1016/0304-3940(93)90532-P; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; KOLB B, 1992, BRAIN COGNITION, V20, P74, DOI 10.1016/0278-2626(92)90062-Q; LENO AB, 2004, SALLY ANDY TASK; LILES BZ, 1993, J SPEECH HEAR RES, V36, P868, DOI 10.1044/jshr.3605.868; Linscott RJ, 1996, BRAIN INJURY, V10, P397, DOI 10.1080/026990596124269; Lough S, 2006, NEUROPSYCHOLOGIA, V44, P950, DOI 10.1016/j.neuropsychologia.2005.08.009; McColl MA, 1998, BRAIN INJURY, V12, P15, DOI 10.1080/026990598122827; McDonald S, 2005, J INT NEUROPSYCH SOC, V11, P392, DOI 10.1017/S1355617705050447; MCDONALD S, 2005, BRAIN IMPAIR, V6, P58; McDonald S, 2007, CLINICAL APHASIOLOGY: FUTURE DIRECTIONS, P42; McGivern RF, 2002, BRAIN COGNITION, V50, P73, DOI 10.1016/S0278-2626(02)00012-X; Milders M, 2006, NEUROPSYCHOLOGY, V20, P400, DOI 10.1037/0894-4105.20.4.400; Miller CA, 2006, AM J SPEECH-LANG PAT, V15, P142, DOI 10.1044/1058-0360(2006/014); Morton JB, 2001, CHILD DEV, V72, P834, DOI 10.1111/1467-8624.00318; *NFER NELS, 2005, EM LIT ASS INT; Ninio Anat, 1996, PRAGMATIC DEV; Nippold MA, 2003, J SPEECH LANG HEAR R, V46, P788, DOI 10.1044/1092-4388(2003/062); Nippold MA, 2000, J SPEECH LANG HEAR R, V43, P621, DOI 10.1044/jslhr.4303.621; Nippold MA, 1996, J SPEECH HEAR RES, V39, P166, DOI 10.1044/jshr.3901.166; Nippold MA, 2000, TOP LANG DISORD, V20, P15, DOI 10.1097/00011363-200020020-00004; Onishi KH, 2007, ACTA PSYCHOL, V124, P106, DOI 10.1016/j.actpsy.2006.09.009; PARENTE R, 1996, J VOCATIONAL REHABIL, V7, P181; PLACE KS, 1991, DISCOURSE PROCESS, V14, P227, DOI 10.1080/01638539109544783; SHATZ M, 1973, MONOGR SOC RES CHILD, V38, P1, DOI 10.2307/1165783; SHATZ M, 1978, J CHILD LANG, V5, P39, DOI 10.1017/S0305000900001926; Stallard P., 2002, THINK GOOD FEEL GOOD; Stone VE, 1998, J COGNITIVE NEUROSCI, V10, P640, DOI 10.1162/089892998562942; STRONACH ST, 2007, REVISION; Surian L, 2007, PSYCHOL SCI, V18, P580, DOI 10.1111/j.1467-9280.2007.01943.x; Tchanturia Kate, 2007, Ann Gen Psychiatry, V6, P14, DOI 10.1186/1744-859X-6-14; TONKS J, 2007, BRAIN IMPAIR, V8, P143, DOI DOI 10.1375/BRIM.8.2.143; Tonks J, 2007, BRAIN INJURY, V21, P623, DOI 10.1080/02699050701426865; Tonks J, 2007, BRAIN INJURY, V21, P731, DOI 10.1080/02699050701426899; TURKSTRA L, 2007, NEUROPHYSIOLOGY NEUR, V17, P15, DOI DOI 10.1044/NNSLD17.3.15; Turkstra LS, 2004, NEUROREHABILITATION, V19, P245; Turkstra LS, 2001, J HEAD TRAUMA REHAB, V16, P469, DOI 10.1097/00001199-200110000-00006; Watts AJ, 2006, APHASIOLOGY, V20, P707, DOI 10.1080/02687030500489953; Wehman Paul, 1993, Brain Injury, V7, P31, DOI 10.3109/02699059309008154; Williams WH, 2003, STUD NEUROPSYCHOL DE, P115; WIMMER H, 1983, COGNITION, V13, P103, DOI 10.1016/0010-0277(83)90004-5; Wykes T, 2005, COGNITIVE REMEDIATIO; Ylvisaker M., 1989, MILD MODERATE HEAD I, P203	71	41	41	0	19	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2008	23	6					501	509					9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	391CI	WOS:000262210200006	19127003				2021-06-18	
J	Hoffman, JM; Pagulayan, KF; Zawaideh, N; Dikmen, S; Temkin, N; Bell, KR				Hoffman, Jeanne M.; Pagulayan, Kathleen F.; Zawaideh, Nadya; Dikmen, Sureyya; Temkin, Nancy; Bell, Kathleen R.			Understanding pain after traumatic brain injury - Impact on community participation	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						pain; traumatic brain injury; rehabilitation	PRACTICAL SCALE; HEAD-INJURY; QUESTIONNAIRE; DISABILITY; TBI; INTEGRATION; MANAGEMENT; COGNITION; DISORDER	Objective: To examine the prevalence of pain 1 yr after moderate to severe traumatic brain injury (TBI) and identify predictors from the time of injury. Additionally, factors related to pain at 1 yr after injury were examined along with the impact of pain on community participation. Design: Prospective cohort study of 146 individuals enrolled during acute inpatient rehabilitation for TBI and community follow-up at 1 yr after injury. Results: Higher reports of depressive symptoms during inpatient rehabilitation and at 1 yr after injury were significantly related to reports of pain at 1 yr when controlling for demographic and injury characteristics. Being female and nonwhite were also factors related to increased reports of pain. Pain and community participation were significantly related until depression was entered into the model. Depression is a significant factor in the relationship between pain and community participation. Conclusion: Whereas pain was frequently reported 1 yr after injury, injury-related factors were surprisingly unrelated. Further evaluation of the role that depression plays in the relationship between pain and community participation will be important to determine appropriate management of pain and depression and to optimize participation in individuals with TBI.	Univ Washington, Sch Med, Dept Rehabil Med, Seattle, WA 98195 USA; Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA	Hoffman, JM (corresponding author), Univ Washington, Sch Med, Dept Rehabil Med, Seattle, WA 98195 USA.		Pagulayan, Kati/AAR-9225-2020	Bell, Kathleen/0000-0002-0928-2046			Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; BELL KR, 2005, REHABILITATION TRAUM; Benjamin S, 2000, ARTHRITIS RHEUM-US, V43, P561, DOI 10.1002/1529-0131(200003)43:3<561::AID-ANR12>3.0.CO;2-O; Branca B, 2004, J HEAD TRAUMA REHAB, V19, P40, DOI 10.1097/00001199-200401000-00005; Bryant RA, 1999, J HEAD TRAUMA REHAB, V14, P588, DOI 10.1097/00001199-199912000-00007; Chiu TT, 2005, ARCH PHYS MED REHAB, V86, P534, DOI 10.1016/j.apmr.2004.02.030; Cook AKR, 1999, INT J GERIATR PSYCH, V14, P421, DOI 10.1002/(SICI)1099-1166(199906)14:6<421::AID-GPS932>3.0.CO;2-Y; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; Dudgeon BJ, 2005, ARCH PHYS MED REHAB, V86, P109, DOI 10.1016/j.apmr.2004.01.034; Edwards RR, 2005, PAIN MED, V6, P88, DOI 10.1111/j.1526-4637.2005.05007.x; Ehde DM, 2003, CLIN J PAIN, V19, P3, DOI 10.1097/00002508-200301000-00002; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; GALE JL, 1983, NEUROSURGERY, V12, P487, DOI 10.1227/00006123-198305000-00001; Gunstad J, 2004, ARCH CLIN NEUROPSYCH, V19, P391, DOI 10.1016/S0887-6177(03)00073-8; Hecht JS, 2004, J HEAD TRAUMA REHAB, V19, P58, DOI 10.1097/00001199-200401000-00006; Ivanhoe CB, 2004, J HEAD TRAUMA REHAB, V19, P29, DOI 10.1097/00001199-200401000-00004; Lahz S, 1996, ARCH PHYS MED REHAB, V77, P889, DOI 10.1016/S0003-9993(96)90275-0; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; MacKinnon D P, 2000, Prev Sci, V1, P173, DOI 10.1023/A:1026595011371; MacKinnon DP, 2002, PSYCHOL METHODS, V7, P83, DOI 10.1037/1082-989X.7.1.83; Martelli M. F., 2007, BRAIN INJURY MED PRI, P723; Martelli MF, 2004, J HEAD TRAUMA REHAB, V19, P10, DOI 10.1097/00001199-200401000-00003; Martelli MF, 1999, J HEAD TRAUMA REHAB, V14, P49, DOI 10.1097/00001199-199902000-00007; Mihalik JP, 2005, J NEUROSURG, V102, P850, DOI 10.3171/jns.2005.102.5.0850; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; Nicholson K, 2004, J HEAD TRAUMA REHAB, V19, P2, DOI 10.1097/00001199-200401000-00002; Nicholson K, 2000, NEUROREHABILITATION, V14, P95; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; TEASDALE G, 1974, LANCET, V2, P81; Von Korff M, 2000, SPINE, V25, P3140, DOI 10.1097/00007632-200012150-00009; Walker WC, 2005, ARCH PHYS MED REHAB, V86, P1793, DOI 10.1016/j.apmr.2004.12.042; Walker WC, 2004, J HEAD TRAUMA REHAB, V19, P72, DOI 10.1097/00001199-200401000-00007; Ware JE., 1993, SF 36 HLTH SURVEY MA; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; ZASLER ND, 2007, BRAIN INJURY MED PRI, P697	35	41	41	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	DEC	2007	86	12					962	969		10.1097/PHM.0b013e31815b5ee5			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	237DG	WOS:000251352600002	18090437				2021-06-18	
J	Song, SJ; Song, SJ; Zhang, HL; Cuevas, J; Sanchez-Ramos, J				Song, Shijie; Song, Shuojing; Zhang, Hongling; Cuevas, Javier; Sanchez-Ramos, Juan			Comparison of neuron-like cells derived from bone marrow stem cells to those differentiated from adult brain neural stem cells	STEM CELLS AND DEVELOPMENT			English	Article							MAMMALIAN SUBSTANTIA-NIGRA; STROMAL CELLS; NEUROECTODERMAL DIFFERENTIATION; PROGENITOR CELLS; IN-VITRO; NEUROGENESIS; FUSION; MICE; PROLIFERATION; INDUCTION	Bone marrow-derived stem/progenitor cells have been shown by independent investigators to give rise to neural-like cells (neurons and glia) both in vitro and in vivo. The objective of the present study was to determine whether nestin-enriched cells derived from bone marrow can differentiate into cells with the same morphological and functional characteristics as neurons derived from adult brain neurogenic zones. Cell culture methods were used for generation of adult bone marrow and brain stem/progenitor cells and for studying their differentiation into neural-like cells. The proportion of cells expressing neuronal markers was greater in cultures derived from adult hippocampal neural stem cells than in the bone marrow-derived cells, but the electrophysiological and functional characteristics of the cells were similar. Action potentials with electrical characteristics corresponding to those exhibited by adult neural stem cell-derived neurons were recorded from approximately 2.5% of patched neuron-like cells differentiated from bone marrow cells. The active uptake of tritium-labeled neurotransmitters gamma-aminobutyric acid ([H-3] GABA) and dopamine ([H-3] DA) was measured in both sets of cultures. [H-3] GABA uptake, but not [H-3] DA, was significantly increased in differentiated neurons in both neural stem cell cultures and bone marrow-derived cultures. [H-3] GABA uptake was greater in differentiated neurons derived from brain neural stem cells. In summary, both the nestin-expressing bone marrow and the adult brain neural stem/progenitors developed into cells with morphological, immunocytochemical, and functional characteristics of neurons. Even though a smaller proportion of neuron-like cells was generated from bone marrow-derived progenitors than from brain-derived neural stem cells, these cells may be useful in the cellular therapy of neurodegenerative diseases and traumatic brain and spinal cord injury.	Univ S Florida, Dept Neurol, MDC 55, Tampa, FL 33612 USA; Univ S Florida, Dept Pharmacol & Therapeut, Tampa, FL 33612 USA; MIT, Sch Engn, Cambridge, MA 02139 USA; James Haley VA Hosp, Tampa, FL 33612 USA	Sanchez-Ramos, J (corresponding author), Univ S Florida, Dept Neurol, MDC 55, 12901 Bruce B Downs Blvd, Tampa, FL 33612 USA.	jsramos@health.usf.edu	Mordwinkin, Nicholas M/A-4347-2010; Sanchez-Ramos, Juan/O-7870-2014; Cuevas, Javier/I-4941-2012; Sanchez-Ramos, Juan/A-1188-2009	Sanchez-Ramos, Juan/0000-0002-3391-7857			Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908; Black IB, 2001, BLOOD CELL MOL DIS, V27, P632, DOI 10.1006/bcmd.2001.0423; Blau HM, 2002, NATURE, V419, P437, DOI 10.1038/419437a; Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775; Caplice NM, 2003, P NATL ACAD SCI USA, V100, P4754, DOI 10.1073/pnas.0730743100; Cho KJ, 2005, STEM CELLS, V23, P383, DOI 10.1634/stemcells.2004-0251; D'Ippolito G, 2004, J CELL SCI, V117, P2971, DOI 10.1242/jcs.01103; Deb A, 2003, CIRCULATION, V107, P1247, DOI 10.1161/01.CIR.0000061910.39145.F0; Deng WW, 2001, BIOCHEM BIOPH RES CO, V282, P148, DOI 10.1006/bbrc.2001.4570; Eglitis MA, 1997, P NATL ACAD SCI USA, V94, P4080, DOI 10.1073/pnas.94.8.4080; Egusa H, 2005, J BIOL CHEM, V280, P23691, DOI 10.1074/jbc.M413796200; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; Frielingsdorf H, 2004, P NATL ACAD SCI USA, V101, P10177, DOI 10.1073/pnas.0401229101; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Gould E, 1999, SCIENCE, V286, P548, DOI 10.1126/science.286.5439.548; Hermann A, 2004, J CELL SCI, V117, P4411, DOI 10.1242/jcs.01307; Hermann A, 2006, J NEUROSCI RES, V83, P1502, DOI 10.1002/jnr.20840; Jackson KA, 2001, J CLIN INVEST, V107, P1395, DOI 10.1172/JCI12150; Jiang YH, 2003, P NATL ACAD SCI USA, V100, P11854, DOI 10.1073/pnas.1834196100; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Jin KL, 2003, EXP NEUROL, V184, P78, DOI 10.1016/S0014-4886(03)00133-X; Kabos P, 2002, EXP NEUROL, V178, P288, DOI 10.1006/exnr.2002.8039; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Kempermann G, 2002, ANN NEUROL, V52, P135, DOI 10.1002/ana.10262; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Kohyama J, 2001, DIFFERENTIATION, V68, P235, DOI 10.1046/j.1432-0436.2001.680411.x; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; Magavi SS, 2000, NATURE, V405, P951; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; Munoz-Elias G, 2004, J NEUROSCI, V24, P4585, DOI 10.1523/JNEUROSCI.5060-03.2004; Orlic D, 2001, P NATL ACAD SCI USA, V98, P10344, DOI 10.1073/pnas.181177898; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Petersen BE, 1999, SCIENCE, V284, P1168, DOI 10.1126/science.284.5417.1168; Sanai N, 2004, NATURE, V427, P740, DOI 10.1038/nature02301; Sanchez-Ramos J, 2000, EXP NEUROL, V164, P247, DOI 10.1006/exnr.2000.7389; SANCHEZRAMOS JR, 1992, J NEUROCHEM, V58, P328, DOI 10.1111/j.1471-4159.1992.tb09314.x; Scheffler B, 2005, P NATL ACAD SCI USA, V102, P9353, DOI 10.1073/pnas.0503965102; SONG S, 2002, PROTOCOLS NEURAL STE, P79; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Tondreau T, 2004, CYTOTHERAPY, V6, P372, DOI 10.1080/14653240410004943; Tondreau T, 2004, DIFFERENTIATION, V72, P319, DOI 10.1111/j.1432-0436.2004.07207003.x; van Praag H, 1999, NAT NEUROSCI, V2, P266; Vassilopoulos G, 2003, NATURE, V422, P901, DOI 10.1038/nature01539; Wang X, 2003, NATURE, V422, P897, DOI 10.1038/nature01531; Weimann JM, 2003, P NATL ACAD SCI USA, V100, P2088, DOI 10.1073/pnas.0337659100; Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C; Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729; Zhao M, 2003, P NATL ACAD SCI USA, V100, P7925, DOI 10.1073/pnas.1131955100	50	41	44	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1547-3287	1557-8534		STEM CELLS DEV	Stem Cells Dev.	OCT	2007	16	5					747	756		10.1089/scd.2007.0027			10	Cell & Tissue Engineering; Hematology; Medicine, Research & Experimental; Transplantation	Cell Biology; Hematology; Research & Experimental Medicine; Transplantation	235XF	WOS:000251266900006	17999596				2021-06-18	
J	Ives, JC; Alderman, M; Stred, SE				Ives, Jeffrey C.; Alderman, Mark; Stred, Susan E.			Hypopituitarism after multiple concussions: A retrospective case study in an adolescent male	JOURNAL OF ATHLETIC TRAINING			English	Article						neuroendocrinology; mild traumatic brain injury; sports	TRAUMATIC BRAIN-INJURY; GROWTH-HORMONE DEFICIENCY; SPORT-RELATED CONCUSSION; SCHOOL FOOTBALL PLAYERS; POSTCONCUSSION SYNDROME; HEAD TRAUMA; HIGH-RISK; CHILDREN; DYSFUNCTION; PERFORMANCE	Objective: To describe the development of hypopituitarism in an adolescent athlete after multiple concussions and to raise awareness among sports medicine clinicians concerning the growing concern of hypopituitarism in concussion injury surveillance and management. Background: A 14-year-old, previously healthy male athlete suffered 4 head traumas over a 4-month period. The first 3 traumas were considered by the athlete to be minor and were not reported to medical personnel. The fourth trauma was a medically diagnosed concussion suffered during soccer play. Over the next year, the patient noted a decline in strength and conditioning and a failure to grow. Differential Diagnosis: After physical examination and a full battery of endocrine tests, the patient, then 16.5 years old, was diagnosed with hypopituitarism. Follow-up interviews provided evidence that at least 2 of the 3 head injuries suffered before the last concussion could also be considered concussions, which may have contributed to the severity of the last head injury. Treatment: The patient is currently being treated with physiologic replacement hormones (growth hormone, cortisol, and thyroxine), with resumption of linear growth and strength. He is progressing well. Uniqueness: In the past few years in the medical literature, increased attention has been drawn to the occult occurrence of hypopituitarism after traumatic brain injury in adults. Initial reports indicate that children are also at risk. To our knowledge, this is the first reported case of hypopituitarism after mild traumatic brain injury in the sports medicine literature. Conclusions: Symptoms of hypopituitarism are often masked by trauma and postconcussion symptoms and may not appear until months or years after the trauma incident, which can lead to significant delay in proper diagnosis and treatment. We urge greater vigilance by, and training of, sports medicine clinicians toward the goal of recognizing the possibility of pituitary disorders after sports concussion.	Ithaca Coll, Ithaca, NY 14850 USA; Upstate Med Univ, Syracuse, NY USA	Ives, JC (corresponding author), Ithaca Coll, Ithaca, NY 14850 USA.	jives@ithaca.edu					Acerini CL, 2006, EUR J ENDOCRINOL, V155, P663, DOI 10.1530/eje.1.02284; Agrawal D, 2005, J NEUROSURG, V102, P167, DOI 10.3171/jns.2005.102.2.0167; Aimaretti G, 2005, J ENDOCRINOL INVEST, V28, P984, DOI 10.1007/BF03345336; Aimaretti G, 2004, GROWTH HORM IGF RES, V14, pS114, DOI 10.1016/j.ghir.2004.03.025; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Bazarian JJ, 2006, ACAD EMERG MED, V13, P199, DOI 10.1197/j.aem.2005.07.031; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Bruce JM, 2004, NEUROLOGY, V63, P1516; Casanueva FF, 2005, ARCH PHYS MED REHAB, V86, P463, DOI 10.1016/j.apmr.2004.05.018; Casanueva FF, 2004, J ENDOCRINOL INVEST, V27, P793, DOI 10.1007/BF03347526; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Einaudi S, 2006, J PEDIATR ENDOCR MET, V19, P691; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Gagnon I, 2005, J HEAD TRAUMA REHAB, V20, P436, DOI 10.1097/00001199-200509000-00005; Gagnon I, 2004, J HEAD TRAUMA REHAB, V19, P391, DOI 10.1097/00001199-200409000-00004; Gagnon I, 2004, ARCH PHYS MED REHAB, V85, P444, DOI 10.1016/j.apmr.2003.06.014; Gagnon I, 1998, BRAIN INJURY, V12, P843, DOI 10.1080/026990598122070; Ghigo E, 2005, BRAIN INJURY, V19, P711, DOI 10.1080/02699050400025315; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Kelestimur F, 2004, J ENDOCRINOL INVEST, V27, pRC28, DOI 10.1007/BF03345299; Kelestimur Fahrettin, 2005, Pituitary, V8, P259, DOI 10.1007/s11102-006-6051-3; Killam C, 2005, ARCH CLIN NEUROPSYCH, V20, P599, DOI 10.1016/j.acn.2005.02.001; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; LaBotz M, 2005, CLIN J SPORT MED, V15, P73, DOI 10.1097/01.jsm.0000157649.99867.fc; Langburt W, 2001, J CHILD NEUROL, V16, P83, DOI 10.1177/088307380101600203; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Massagli TL, 2004, ARCH PHYS MED REHAB, V85, P1428, DOI 10.1016/j.apmr.2003.12.036; McCauley SR, 2004, DEV NEUROPSYCHOL, V25, P5, DOI 10.1207/s15326942dn2501&2_2; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory Paul, 2005, Clin J Sport Med, V15, P48; McKeever CK, 2003, APPL NEUROPSYCHOL, V10, P4, DOI 10.1207/S15324826AN1001_2; McLean JP, 2006, MED SCI SPORT EXER, V38, pS132, DOI 10.1249/00005768-200605001-01481; Miller L J, 1998, Appl Neuropsychol, V5, P172, DOI 10.1207/s15324826an0504_2; Mittenberg W, 1997, NEUROPSYCHOLOGY, V11, P447, DOI 10.1037/0894-4105.11.3.447; Patel DR, 2005, SPORTS MED, V35, P671, DOI 10.2165/00007256-200535080-00002; POLISSAR NL, 1994, BRAIN INJURY, V8, P249, DOI 10.3109/02699059409150977; Popovic V, 2004, J ENDOCRINOL INVEST, V27, P1048, DOI 10.1007/BF03345308; Rosenfeld RG, 1997, J CLIN ENDOCR METAB, V82, P349, DOI 10.1210/jc.82.2.349; Schneider M, 2005, J NEUROTRAUM, V22, P937, DOI 10.1089/neu.2005.22.937; Stewart PM, 2001, HORM RES, V56, P1, DOI 10.1159/000048126; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; Thompson J, 2005, NEUROSCI LETT, V377, P158, DOI 10.1016/j.neulet.2004.11.090; Urban RJ, 2005, BRAIN INJURY, V19, P349, DOI 10.1080/02699050400004807; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Wall SE, 2006, J NEUROL NEUROSUR PS, V77, P518, DOI 10.1136/jnnp.2004.061044; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003	51	41	41	0	13	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	JUL-SEP	2007	42	3					431	439					9	Sport Sciences	Sport Sciences	220FG	WOS:000250141800017	18060001				2021-06-18	
J	Marcotte, AL; Osterman, AL				Marcotte, Anthony L.; Osterman, A. Lee			Longitudinal radioulnar dissociation: Identification and treatment of acute and chronic injuries	HAND CLINICS			English	Article							ONE-BONE FOREARM; TRIANGULAR FIBROCARTILAGE COMPLEX; SYMPTOMATIC PROXIMAL TRANSLATION; RADIAL HEAD FRACTURES; INTEROSSEOUS MEMBRANE; CLOSED FRACTURE; LOAD-TRANSFER; ULNAR JOINT; RECONSTRUCTION; EXCISION	In this article we describe the fundamental concepts that were established by Essex-Lopresti over 50 years ago and explore the current concepts in anatomy, biomechanics, diagnosis, and treatment for longitudinal radioulnar dissociation. Moreover, we present encouraging results for treating chronic injuries to the IOM achieved by bone-ligament-bone (BLB) reconstruction using a patellar tendon graft, giving hope for this seemingly unforgiving injury. A treatment algorithm is also provided to aid in the management of acute and chronic longitudinal radioulnar dissociation.	Philadelphia Hand Ctr, King Of Prussia, PA 19406 USA; Ohio Univ, Dept Orthopaed, Grandview Med Ctr, Dayton, OH 45405 USA; Thomas Jefferson Univ, Philadelphia, PA 19107 USA	Osterman, AL (corresponding author), Philadelphia Hand Ctr, Merion Bldg,Suite 200,700 S Henderson Rd, King Of Prussia, PA 19406 USA.	alosterman@handcenters.com					Allende C, 2004, J BONE JOINT SURG AM, V86A, P364, DOI 10.2106/00004623-200402000-00022; Birkbeck DP, 1997, J HAND SURG-AM, V22A, P975, DOI 10.1016/S0363-5023(97)80035-4; Boulas H J, 1998, Chir Main, V17, P314; Brockman E P, 1931, Proc R Soc Med, V24, P904; CASTLE ME, 1974, J BONE JOINT SURG AM, VA 56, P1223, DOI 10.2106/00004623-197456060-00014; Chandler JW, 2003, J HAND SURG-AM, V28A, P111, DOI 10.1053/jhsu.2003.50033; Chen F, 2001, Am J Orthop (Belle Mead NJ), V30, P486; Chen F, 1998, J HAND SURG-AM, V23A, P1091, DOI 10.1016/S0363-5023(98)80021-X; COLEMAN DA, 1987, J BONE JOINT SURG AM, V69A, P385; CURR JF, 1946, BRIT J SURG, V34, P74, DOI 10.1002/bjs.18003413312; EDWARDS GS, 1988, CLIN ORTHOP RELAT R, P61; ESSEXLOPRESTI P, 1951, J BONE JOINT SURG BR, V33, P244; Failla JM, 1999, J HAND SURG-AM, V24A, P257; Fester EW, 2002, J HAND SURG-AM, V27A, P418, DOI 10.1053/jhsu.2002.32961; Geel C W, 1990, J Orthop Trauma, V4, P270, DOI 10.1097/00005131-199004030-00006; GEEL CW, 1992, CLIN ORTHOP RELAT R, P79; GOLDBERG I, 1986, J BONE JOINT SURG AM, V68A, P675, DOI 10.2106/00004623-198668050-00006; HALLS AA, 1964, ANAT REC, V150, P243, DOI 10.1002/ar.1091500305; Harman TW, 2005, CURR OPIN ORTHOP, V16, P285; Hotchkiss, 1997, J Am Acad Orthop Surg, V5, P1; HOTCHKISS RN, 1989, J HAND SURG-AM, V14, P256, DOI 10.1016/0363-5023(89)90017-8; Jaakkola JI, 2001, J HAND SURG-AM, V26A, P1053, DOI 10.1053/jhsu.2001.27187; Karlstad R, 2005, J BONE JOINT SURG AM, V87A, P1828, DOI 10.2106/JBJS.D.02351; KUZMA G, 2003, AAHS 33 AN M KAUI HI; Manson TT, 2000, J HAND SURG-AM, V25A, P1058, DOI 10.1053/jhsu.2000.17869; MCDOUGALL A, 1957, J BONE JOINT SURG BR, V39, P278; McGinley JC, 2006, SKELETAL RADIOL, V35, P275, DOI 10.1007/s00256-005-0069-x; McGinley JC, 2001, CLIN ORTHOP RELAT R, P108, DOI 10.1097/00003086-200102000-00013; Moro JK, 2001, J BONE JOINT SURG AM, V83A, P1201, DOI 10.2106/00004623-200108000-00010; MORREY BF, 1981, J BONE JOINT SURG AM, V63, P872, DOI 10.2106/00004623-198163060-00002; MORREY BF, 1979, J BONE JOINT SURG AM, V61, P63, DOI 10.2106/00004623-197961010-00012; PALMER AK, 1981, J HAND SURG-AM, V6, P153, DOI 10.1016/S0363-5023(81)80170-0; PALMER AK, 1984, CLIN ORTHOP RELAT R, P26; PETERSON CA, 1995, J HAND SURG-AM, V20A, P609, DOI 10.1016/S0363-5023(05)80277-1; Pfaeffle HJ, 2005, J HAND SURG-AM, V30A, P319, DOI 10.1016/j.jhsa.2004.10.005; Pfaeffle HJ, 2000, J HAND SURG-AM, V25A, P683, DOI 10.1053/jhsu.2000.9416; RABINOWITZ RS, 1994, J HAND SURG-AM, V19A, P385, DOI 10.1016/0363-5023(94)90050-7; RADIN EL, 1966, J BONE JOINT SURG AM, VA 48, P1055, DOI 10.2106/00004623-196648060-00003; Ring D, 2002, J BONE JOINT SURG AM, V84A, P1811, DOI 10.2106/00004623-200210000-00011; SELLMAN DC, 1995, J ORTHOP TRAUMA, V9, P516, DOI 10.1097/00005131-199509060-00010; Skahen JR, 1997, J HAND SURG-AM, V22A, P986, DOI 10.1016/S0363-5023(97)80037-8; Skahen JR, 1997, J HAND SURG-AM, V22A, P981, DOI 10.1016/S0363-5023(97)80036-6; Smith AM, 2002, J BONE JOINT SURG AM, V84A, P1970, DOI 10.2106/00004623-200211000-00010; Smith G R, 1996, J Shoulder Elbow Surg, V5, P113, DOI 10.1016/S1058-2746(96)80005-X; SOWA DT, 1995, CLIN ORTHOP RELAT R, P106; Stabile KJ, 2002, HAND CLIN, V18, P195, DOI 10.1016/S0749-0712(02)00003-3; Starch DW, 2001, J BONE JOINT SURG AM, V83A, P235, DOI 10.2106/00004623-200102000-00011; STEPHEN IBM, 1981, ACTA ORTHOP SCAND, V52, P409, DOI 10.3109/17453678109050121; SWANSON AB, 1981, J BONE JOINT SURG AM, V63, P1039, DOI 10.2106/00004623-198163070-00001; Szabo RM, 1997, J HAND SURG-AM, V22A, P269, DOI 10.1016/S0363-5023(97)80163-3; TAYLOR TKF, 1964, J BONE JOINT SURG BR, V46, P83; Tomaino MM, 2003, J HAND SURG-BRIT EUR, V28B, P267, DOI 10.1016/S0266-7681(03)00012-3; TROUSDALE RT, 1992, J BONE JOINT SURG AM, V74A, P1486, DOI 10.2106/00004623-199274100-00007; Wallace AL, 1997, J BONE JOINT SURG BR, V79B, P422, DOI 10.1302/0301-620X.79B3.7142	54	41	48	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0749-0712	1558-1969		HAND CLIN	Hand Clin.	MAY	2007	23	2					195	+		10.1016/j.hcl.2007.01.005			15	Orthopedics	Orthopedics	182XF	WOS:000247536600007	17548011				2021-06-18	
J	Deb, S; Burns, J				Deb, Shoumitro; Burns, James			Neuropsychiatric consequences of traumatic brain injury: A comparison between two age groups	BRAIN INJURY			English	Article						psychiatric disorders; neurobehavioural symptoms; traumatic brain injury; old age; young age	HEAD-INJURY; UNITED-STATES; OLDER-ADULTS; MILD; QUESTIONNAIRE; DISABILITY; DISORDERS; SYMPTOMS; SCALE	Background: Neurobehavioural symptoms and certain psychiatric disorders are common after a traumatic brain injury ( TBI). Relatively few studies have investigated the effect of age upon these outcomes. Aim: Our aim was to compare the rates of neurobehavioural symptoms and psychiatric disorders between 18 - 65 year old and over 65 year old patients with TBI. Method: 120 adults aged 18 to 65 years and 45 adults over 65 years of age who were admitted to a hospital following a TBI were assessed for neurobehavioural symptoms and psychiatric disorders one year after the injury. Results: Our estimate suggested that a higher proportion of 18 - 65 year old patients ( 32%) had ICD- 10 psychiatric disorders according to the Schedule for Clinical Assessment in Neuropsychiatry ( SCAN) interview compared with patients over 65 years of age ( 16%). Similarly, the ICD- 10 depressive disorder was more common among the younger patients ( 16%) than the older group of patients ( 11%). None of these differences were statistically significant. However, a multiple regression analysis revealed that among other risk factors, a younger age was significantly associated with the presence of a psychiatric disorder. Also, a significantly higher rate of psychiatric caseness was detected among the younger age group using screening instruments such as the General Health Questionniare- 28 ( GHQ- 28) ( p < 0.01) and the Clinical Interview Schedule- Revised ( CIS- R) ( p < 0.01). The rates of individual neurobehavioural symptoms varied significantly between the two age groups. The most prevalent symptoms in 18 - 65 year olds were irritability ( 37%) and sleep problems ( 37%). In the older group of patients the most prevalent symptoms were poor memory ( 40%), dependence ( 38%) and slowness in thinking ( 33%). Conclusion: 18 - 65 year old patients are likely to be at a greater risk of psychiatric morbidity following TBI than over 65 year olds whereas neurobehavioural symptoms are prevalent in both age groups.	Univ Birmingham, Queen Elizabeth Psychiat Hosp, Div Nueropsychiat, Birmingham B15 2QZ, W Midlands, England; Univ Birmingham, Sch Med, Birmingham, W Midlands, England	Deb, S (corresponding author), Univ Birmingham, Queen Elizabeth Psychiat Hosp, Div Nueropsychiat, Mindelsohn Way, Birmingham B15 2QZ, W Midlands, England.	s.deb@bham.ac.uk		Deb, Shoumitro/0000-0002-1300-8103			AFFLECK JW, 1988, LANCET, V1, P230; BEBBINGTON P, 1995, INT J METHOD PSYCH, V5, P11; Breed ST, 2004, ARCH PHYS MED REHAB, V85, pS61, DOI 10.1016/j.apmr.2003.08.115; Deb S, 1999, AM J PSYCHIAT, V156, P374; Deb S, 1999, BRAIN INJURY, V13, P369, DOI 10.1080/026990599121557; Deb S, 1999, BRIT J PSYCHIAT, V174, P360, DOI 10.1192/bjp.174.4.360; Ferraro FR, 1996, BRAIN COGNITION, V32, P429, DOI 10.1006/brcg.1996.0075; Fichtenberg NL, 2002, BRAIN INJURY, V16, P197, DOI 10.1080/02699050110103940; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; FOLSTEIN MF, 1975, J PSYCHIATR RES, V12, P198; Goldberg D., 1978, MANUAL GEN HLTH QUES; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Kannus P, 1999, AM J EPIDEMIOL, V149, P143; LEWIS G, 1992, PSYCHOL MED, V22, P465, DOI 10.1017/S0033291700030415; Luukinen H, 1999, NEUROLOGY, V52, P557, DOI 10.1212/WNL.52.3.557; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Mathias JL, 1999, J CLIN EXP NEUROPSYC, V21, P200, DOI 10.1076/jcen.21.2.200.930; MYERSON J, 1992, PSYCHOL AGING, V7, P57; O'Keeffe FM, 2004, COGNITIVE BRAIN RES, V22, P101, DOI 10.1016/j.cogbrainres.2004.07.012; Rapoport MJ, 2003, AM J GERIAT PSYCHIAT, V11, P365, DOI 10.1176/appi.ajgp.11.3.365; REGIER DA, 1993, ACTA PSYCHIAT SCAND, V88, P35, DOI 10.1111/j.1600-0447.1993.tb03411.x; SINGLETON N, 2000, PSYCHIAT MORBIDITY A; Teasdale TW, 1997, BRAIN INJURY, V11, P543, DOI 10.1080/026990597123250; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; WING JK, 1990, ARCH GEN PSYCHIAT, V47, P586; World Health Organization (WHO), 1978, MENT DIS GLOSS GUID	29	41	42	0	5	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2007	21	3					301	307		10.1080/02699050701253137			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	168IW	WOS:000246518400005	17453758				2021-06-18	
J	Fischer, FR; Peduzzi, JD				Fischer, Florence R.; Peduzzi, Jean D.			Functional recovery in rats with chronic spinal cord injuries after exposure to an enriched environment	JOURNAL OF SPINAL CORD MEDICINE			English	Article						spinal cord injuries; rats; motor score; locomotor testing; enriched environment; exercise; rehabilitation	EARLY-ONSET STIMULATION; TRAUMATIC BRAIN-INJURY; ADULT-RAT; NEUROTROPHIC FACTOR; SPATIAL MEMORY; MESSENGER-RNA; DENTATE GYRUS; CELL-PROLIFERATION; LOCOMOTOR RECOVERY; HOUSING CONDITIONS	Background/Objective: The objective of this study was to determine the effect of environmental enrichment on the sensorimotor function of rats with chronic spinal cord injuries. Design: Adult Sprague-Dawley rats received a contusive injury of moderate severity at vertebral level T8 using a weight-drop device. Three months after injury, 1 randomized group (n = 16) of rats was placed in an enriched environment, whereas the control group (n = 16) remained housed in standard laboratory cages (2/cage). Methods: Animals were placed in an enriched environment for 4 weeks beginning at 3 months after injury. The enriched environment consisted of a large cage (5-6 rats/cage) with access to items such as tubes, ramps, and running wheel, with items changed daily. Main Outcome Measures: Functional evaluation consisted of the open field Basso, Beattie and Bresnahan (BBB) locomotor test and the tests that form the combined behavioral score (CBS). The CBS includes motor score, toe spread, placing, withdrawal, righting, inclined plane, hot plate, and swim tests. Behavioral testing was repeated 7 times before and after the period of intervention. Results: The group placed in the enriched environment scored significantly better on the BBB (ANOVA repeated-measures, P < 0.01) test and CBS (ANOVA repeated-measures, P < 0.01). Conclusions: Environmental enrichment results in significant functional improvement in animals with spinal cord injury even with a substantial delay in initiating treatment after injury. The features of an enriched environment that may be responsible for the improvement include social interactions, exercise, and novel items in an interesting environment. These findings suggest a continued plasticity of the chronically injured rat spinal cord and a possible therapeutic intervention for people with spinal cord injury.	Wayne State Univ, Sch Med, Dept Anat & Cell Biol, Detroit, MI 48201 USA	Peduzzi, JD (corresponding author), Wayne State Univ, Sch Med, Dept Anat & Cell Biol, 8137 Scott Hall, Detroit, MI 48201 USA.	jpeduzzi@med.wayne.edu					Aberg E, 2005, NEUROREPORT, V16, P1419; Bareyre FM, 2004, NAT NEUROSCI, V7, P269, DOI 10.1038/nn1195; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Bennett E.L, 1970, MOL APPROACHES LEARN, P55; Biernaskie J, 2004, J NEUROSCI, V24, P1245, DOI 10.1523/JNEUROSCI.3834-03.2004; Biernaskie J, 2001, J NEUROSCI, V21, P5272, DOI 10.1523/JNEUROSCI.21-14-05272.2001; Briones TL, 2004, BRAIN RES, V1018, P130, DOI 10.1016/j.brainres.2004.06.001; Chen R, 2002, NEUROSCIENCE, V111, P761, DOI 10.1016/S0306-4522(02)00025-8; Dahlqvist P, 2003, NEUROSCIENCE, V119, P643, DOI 10.1016/S0306-4522(03)00195-7; Dobrossy MD, 2005, REV NEUROSCIENCE, V16, P1; Dobrossy MD, 2000, EXP NEUROL, V165, P172, DOI 10.1006/exnr.2000.7462; Elphick GF, 2003, J APPL PHYSIOL, V94, P660, DOI 10.1152/japplphysiol.00547.2002; Erschbamer MK, 2006, EXP NEUROL, V201, P154, DOI 10.1016/j.expneurol.2006.04.003; FALKENBERG T, 1992, NEUROSCI LETT, V138, P153, DOI 10.1016/0304-3940(92)90494-R; FERCHMIN PA, 1970, BRAIN RES, V20, P49, DOI 10.1016/0006-8993(70)90153-8; Fernandez CI, 2004, ANN NY ACAD SCI, V1019, P53, DOI 10.1196/annals.1297.012; Fischer F. R., 1997, Society for Neuroscience Abstracts, V23, P2188; GALE K, 1985, EXP NEUROL, V88, P123, DOI 10.1016/0014-4886(85)90118-9; GENTILE AM, 1987, BEHAV NEURAL BIOL, V47, P321, DOI 10.1016/S0163-1047(87)90435-3; Gobbo OL, 2005, BEHAV BRAIN RES, V159, P21, DOI 10.1016/j.bbr.2004.09.021; Goshgarian HG, 2003, J APPL PHYSIOL, V94, P795, DOI 10.1152/japplphysiol.00847.2002; GRABOWSKI M, 1995, EXP NEUROL, V133, P96, DOI 10.1006/exnr.1995.1011; GREENOUGH WT, 1975, AM SCI, V63, P37; Harkema SJ, 1997, J NEUROPHYSIOL, V77, P797; Hebb D. O., 1947, AM PSYCHOL, V2, P306, DOI DOI 10.1037/H0028720; HELD JM, 1985, BEHAV NEUROSCI, V99, P678, DOI 10.1037/0735-7044.99.4.678; Hicks RR, 2002, NEUROSCIENCE, V112, P631, DOI 10.1016/S0306-4522(02)00104-5; Himes BT, 2006, NEUROREHAB NEURAL RE, V20, P278, DOI 10.1177/1545968306286976; Iuvone L, 1996, EXP NEUROL, V139, P25, DOI 10.1006/exnr.1996.0077; Ji BX, 2005, EUR J NEUROSCI, V22, P587, DOI 10.1111/j.1460-9568.2005.04241.x; Johansson BB, 1996, EXP NEUROL, V139, P322, DOI 10.1006/exnr.1996.0106; Johansson BB, 1996, STROKE, V27, P324, DOI 10.1161/01.STR.27.2.324; Johansson BB, 1997, MATURATION PHENOMENON IN CEREBRAL ISCHEMIA II, P159; KELCHE C, 1982, BRAIN RES, V245, P107, DOI 10.1016/0006-8993(82)90343-2; KELCHE C, 1995, NEUROBIOL LEARN MEM, V63, P155, DOI 10.1006/nlme.1995.1016; KELCHE C, 1988, BEHAV BRAIN RES, V28, P287, DOI 10.1016/0166-4328(88)90131-3; Kempermann G, 1999, HIPPOCAMPUS, V9, P321, DOI 10.1002/(SICI)1098-1063(1999)9:3<321::AID-HIPO11>3.0.CO;2-C; Kempermann G, 1998, CURR BIOL, V8, P939, DOI 10.1016/S0960-9822(07)00377-6; KERASIDIS H, 1987, J NEUROSCI METH, V20, P167, DOI 10.1016/0165-0270(87)90048-3; Komitova M, 2005, EUR J NEUROSCI, V21, P2397, DOI 10.1111/j.1460-9568.2005.04072.x; Koopmans GC, 2006, EUR J NEUROSCI, V23, P1035, DOI 10.1111/j.1460-9568.2006.04627.x; KUENZLE CC, 1974, PHYSIOL BEHAV, V13, P205, DOI 10.1016/0031-9384(74)90036-5; Lambert TJ, 2005, NEUROBIOL LEARN MEM, V83, P206, DOI 10.1016/j.nlm.2004.12.001; Lankhorst AJ, 1999, NEUROSCI RES COMMUN, V24, P135; Lankhorst AJ, 2001, J NEUROTRAUM, V18, P203, DOI 10.1089/08977150150502622; Li LZ, 2005, BIOCHEM BIOPH RES CO, V334, P293, DOI 10.1016/j.bbrc.2005.05.162; Maegele M, 2005, J NEUROTRAUM, V22, P772, DOI 10.1089/neu.2005.22.772; Maegele M, 2005, EUR J NEUROSCI, V21, P2406, DOI 10.1111/j.1460-9568.2005.04070.x; Martinez-Cue C, 2002, BEHAV BRAIN RES, V134, P185, DOI 10.1016/S0166-4328(02)00026-8; Mattsson B, 1997, STROKE, V28, P1225, DOI 10.1161/01.STR.28.6.1225; MCCALL RB, 1969, J COMP PHYSIOL PSYCH, V69, P644, DOI 10.1037/h0028198; Mohammed AH, 2002, PROG BRAIN RES, V138, P109, DOI 10.1016/S0079-6123(02)38074-9; Nantwi KD, 2003, J SPINAL CORD MED, V26, P364, DOI 10.1080/10790268.2003.11753707; NOBLE LJ, 1987, EXP NEUROL, V95, P530, DOI 10.1016/0014-4886(87)90162-2; PANJABI MM, 1988, SPINE, V13, P1365, DOI 10.1097/00007632-198812000-00007; Pikov V, 2001, J NEUROSCI, V21, P559, DOI 10.1523/JNEUROSCI.21-02-00559.2001; Pinaud R, 2001, MOL BRAIN RES, V91, P50, DOI 10.1016/S0169-328X(01)00121-8; Puurunen K, 2001, EXP NEUROL, V167, P348, DOI 10.1006/exnr.2000.7563; Puurunen K, 1997, STROKE, V28, P623, DOI 10.1161/01.STR.28.3.623; Puurunen K, 2001, NEUROPHARMACOLOGY, V40, P440, DOI 10.1016/S0028-3908(00)00172-6; Rema V, 1999, J NEUROSCI, V19, P10993; Risedal A, 2002, BRAIN RES BULL, V58, P315, DOI 10.1016/S0361-9230(02)00796-7; ROSENZWE.MR, 1966, AM PSYCHOL, V21, P321, DOI 10.1037/h0023555; ROSENZWEIG MR, 1984, AM PSYCHOL, V39, P365, DOI 10.1037/0003-066X.39.4.365; Roy RR, 1998, MUSCLE NERVE, V21, P63, DOI 10.1002/(SICI)1097-4598(199801)21:1<63::AID-MUS9>3.0.CO;2-E; Schrott LM, 1997, ACTA PAEDIATR, V86, P45; SCHWARTZ S, 1964, J COMP PHYSIOL PSYCH, V57, P72, DOI 10.1037/h0045518; Svensson J, 2005, AM J PHYSIOL-ENDOC M, V289, pE466, DOI 10.1152/ajpendo.00425.2004; Takami T, 2002, J NEUROSCI, V22, P6670; Taub E, 2002, NAT REV NEUROSCI, V3, P228, DOI 10.1038/nrn754; Torasdotter M, 1996, NEUROSCI LETT, V218, P107, DOI 10.1016/S0304-3940(96)13127-X; Tuszynski MH, 2003, EXP NEUROL, V181, P47, DOI 10.1016/S0014-4886(02)00055-9; Van Meeteren NLU, 2003, J NEUROTRAUM, V20, P1029, DOI 10.1089/089771503770195876; van Praag H, 1999, NAT NEUROSCI, V2, P266; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; Wernig A, 2000, PROG BRAIN RES, V128, P89; WHISHAW IQ, 1984, BEHAV NEURAL BIOL, V42, P183, DOI 10.1016/S0163-1047(84)91046-X; Will B, 2004, PROG NEUROBIOL, V72, P167, DOI 10.1016/j.pneurobio.2004.03.001; Woerly S, 2001, J NEUROSCI RES, V66, P1187; Young D, 1999, NAT MED, V5, P448; Zhao LR, 2001, NEUROSCI LETT, V305, P169, DOI 10.1016/S0304-3940(01)01837-7	81	41	44	1	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1079-0268	2045-7723		J SPINAL CORD MED	J. Spinal Cord. Med.		2007	30	2					147	155		10.1080/10790268.2007.11753926			9	Clinical Neurology	Neurosciences & Neurology	171BO	WOS:000246710100012	17591227	Green Published			2021-06-18	
J	Jensen, T; Jensen, J; Norholt, SE; Dahl, M; Lenk-Hansen, L; Svensson, P				Jensen, Thomas; Jensen, John; Norholt, Sven Erik; Dahl, Martin; Lenk-Hansen, Lone; Svensson, Peter			Open reduction and rigid internal fixation of mandibular condylar fractures by an intraoral approach: A long-term follow-up study of 15 patients	JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY			English	Article							SUBCONDYLAR FRACTURES; NECK FRACTURES; CLOSED TREATMENT; BITE FORCES; OSTEOSYNTHESIS; MANAGEMENT; REPAIR	Purpose: To evaluate the long-term results obtained with open reduction and rigid internal fixation of mandibular condylar fractures by an intraoral approach. Patients and Methods: Fifteen patients with 24 mandibular condylar fractures were retrospectively examined with an average follow-up of 23 months (range, 6-63 months). Clinical and radiographic examination was conducted according to the Research Diagnostic Criteria for Temporomandibular Disorders (RDC/TMD), including an evaluation of maximum voluntary bite force measurements and facial nerve function. Statistical analysis was performed on maximum voluntary bite force measurements and maximum pressure pain threshold. Results: Two patients fulfilled the criteria for a RDC/TMD diagnosis. Myofacial pain (group 1) and bilateral arthralgia (group III), combined with a moderate nonspecific physical symptom score, was diagnosed in 1 patient and 1 patient received a diagnosis of disc displacement with reduction (group H). Satisfying radiographic fracture healing was seen in 12 joints. However, miniplate fracture occurred in 3 patients and severe bone resorption of the condylar head was seen in one patient. Minor adjustment of the postoperative occlusion was necessary in 6 patients. No significant difference between maximum voluntary isometric bite force measurements or maximum pressure pain threshold was found between the fracture side and the opposite side in unilateral cases or between the operated and nonoperated side in bilateral cases. None of the patients showed facial nerve injury or visible facial scars. Conclusion: Within the limitations of a retrospective study, the present study emphasized that optimal management of dislocated bilateral condylar injuries combined with other fractures of the facial skeleton constitute a challenging issue in maxillofacial trauma. Moreover, open reduction and rigid internal fixation of mandibular condylar fractures by an intraoral approach is a technically demanding surgical procedure associated with a high risk of postoperative complications in these injuries. (C) 2006 American Association of Oral and Maxillofacial Surgeons.	Aarhus Univ Hosp, Aalborg Hosp, Dept Oral & Maxillofacial Surg, DK-9000 Aalborg, Denmark; Univ Aarhus, Fac Hlth Sci, Sch Dent, Dept Clin Oral Physiol, DK-8000 Aarhus C, Denmark	Jensen, T (corresponding author), Aarhus Univ Hosp, Aalborg Hosp, Dept Oral & Maxillofacial Surg, Hobrovej 18-22, DK-9000 Aalborg, Denmark.	u00250@aas.nja.dk	Svensson, Peter/H-6735-2012				Banks P, 1998, INT J ORAL MAX SURG, V27, P244, DOI 10.1016/S0901-5027(05)80504-1; Chen CT, 1999, PLAST RECONSTR SURG, V103, P60, DOI 10.1097/00006534-199901000-00011; Choi BH, 2001, INT J ORAL MAX SURG, V30, P296, DOI 10.1054/ijom.2001.0054; Choi BH, 1999, ORAL SURG ORAL MED O, V88, P292, DOI 10.1016/S1079-2104(99)70030-2; DAHLSTROM L, 1989, INT J ORAL MAX SURG, V18, P18, DOI 10.1016/S0901-5027(89)80009-8; Derogatis L.R., 1983, SCL90R CLIN PSYCH RE; Dworkin Samuel F., 1992, Journal of Craniomandibular Disorders, V6, P301; Ellis E, 2000, J ORAL MAXIL SURG, V58, P950, DOI 10.1053/joms.2000.8734; ELLIS E, 1993, ORAL SURG ORAL MED O, V76, P6, DOI 10.1016/0030-4220(93)90285-C; ELLIS E, 1985, ORAL SURG ORAL MED O, V59, P586; Ellis ED, 2001, J ORAL MAXIL SURG, V59, P389, DOI 10.1053/joms.2001.21873; Hammer B, 1997, BRIT J ORAL MAX SURG, V35, P288, DOI 10.1016/S0266-4356(97)90050-4; Haug RH, 2002, J ORAL MAXIL SURG, V60, P73, DOI 10.1053/joms.2002.29078; Hovinga J, 1999, INT J ORAL MAX SURG, V28, P429, DOI 10.1034/j.1399-0020.1999.280606.x; IIZUKA T, 1991, ORAL SURG ORAL MED O, V72, P400, DOI 10.1016/0030-4220(91)90547-P; JETER TS, 1988, J ORAL MAXIL SURG, V46, P1113, DOI 10.1016/0278-2391(88)90462-4; Kellman Robert M, 2003, Arch Facial Plast Surg, V5, P244, DOI 10.1001/archfaci.5.3.244; KONSTANTINOVIC VS, 1992, J ORAL MAXIL SURG, V50, P349, DOI 10.1016/0278-2391(92)90395-G; LACHNER J, 1991, ORAL SURG ORAL MED O, V71, P257, DOI 10.1016/0030-4220(91)90295-N; LINDAHL L, 1977, INT J ORAL MAXILLOF, V6, P12, DOI 10.1016/S0300-9785(77)80067-7; LINDAHL L, 1977, INT J ORAL MAXILLOF, V6, P195, DOI 10.1016/S0300-9785(77)80009-4; LINDSAY KW, 1997, NEUROLOGY NEUROSURGE; Miloro M, 2003, ORAL SURG ORAL MED O, V96, P387, DOI 10.1016/j.tripleo.2003.07.004; Mitchell DA, 1997, BRIT J PLAST SURG, V50, P67, DOI 10.1016/S0007-1226(97)91286-8; Motamedi MHK, 2003, J ORAL MAXIL SURG, V61, P61, DOI 10.1053/joms.2003.50049; Newman L, 1998, BRIT J ORAL MAX SURG, V36, P176, DOI 10.1016/S0266-4356(98)90492-2; Schon R, 2002, INT J ORAL MAX SURG, V31, P237, DOI 10.1054/ijom.2001.0213; Silvennoinen U, 1998, INT J ORAL MAX SURG, V27, P280, DOI 10.1016/S0901-5027(05)80615-0; SILVENNOINEN U, 1992, J ORAL MAXIL SURG, V50, P1032, DOI 10.1016/0278-2391(92)90484-H; Suzuki T, 2004, J ORAL MAXIL SURG, V62, P919, DOI 10.1016/j.joms.2004.01.016; Svensson Peter, 1995, Journal of Orofacial Pain, V9, P347; TATE GS, 1994, J ORAL MAXIL SURG, V52, P734, DOI 10.1016/0278-2391(94)90489-8; Undt G, 1999, ORAL SURG ORAL MED O, V88, P534, DOI 10.1016/S1079-2104(99)70082-X; Widmark G, 1996, INT J ORAL MAX SURG, V25, P107, DOI 10.1016/S0901-5027(96)80052-X; WORSAAE N, 1994, J ORAL MAXIL SURG, V52, P353, DOI 10.1016/0278-2391(94)90436-7; Yang WG, 2002, J TRAUMA, V52, P498, DOI 10.1097/00005373-200203000-00014; Zou Z J, 1987, Dentomaxillofac Radiol, V16, P91	37	41	44	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0278-2391	1531-5053		J ORAL MAXIL SURG	J. Oral Maxillofac. Surg.	DEC	2006	64	12					1771	1779		10.1016/j.joms.2005.12.069			9	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	112ZV	WOS:000242567800011	17113444				2021-06-18	
J	Vergouwen, MDI; Vermeulen, M; Roos, YBWEM				Vergouwen, Mervyn D. I.; Vermeulen, Marinus; Roos, Yvo B. W. E. M.			Effect of nimodipine on outcome in patients with traumatic subarachnoid haemorrhage: a systematic review	LANCET NEUROLOGY			English	Article							HEAD-INJURY; TRIAL	Background Despite several randomised controlled trials, there is still much debate whether nimodipine improves outcome in patients with traumatic subarachnoid haemorrhage. A 2003 Cochrane review reported improved outcome with nimodipine in these patients; however, because the results of Head Injury Trial (HIT) 4 were only partly presented there is still discussion whether patients with traumatic subarachnoid haemorrhage should be treated with this drug. Here, we present data from all head-injury trials, including previously unpublished results from HIT 4. Methods We systematically searched PubMed and EMBASE databases using the following combinations of variables "nimodipine" or "calcium antagonist" with "traumatic subarachnoid haemorrhage", "head injury", "head trauma", "brain injury", or "brain trauma". Bayer AG and all principal investigators or corresponding authors of the identified studies were contacted for additional information. Findings Five manuscripts were identified, describing the results of four trials. We obtained additional data from HIT 1, 2, and 4. In total, 1074 patients with traumatic subarachnoid haemorrhage were included. The occurrence of poor outcome was similar in patients treated with nimodipine (39%) and those treated with placebo (40%); odds ratio was 0.88 (95% CI 0.51-1.54). Mortality rates did not differ between nimodipine (26%) and placebo (27%) treated patients (odds ratio 0.95; 95% CI 0.71-1.26). Interpretation Our results do not lend support to the finding of a beneficial effect of nimodipine on outcome in patients with traumatic subarachnoid haemorrhage as reported in an earlier Cochrane review.	Univ Amsterdam, Acad Med Ctr, Dept Neurol, NL-1105 AZ Amsterdam, Netherlands	Vergouwen, MDI (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Neurol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	m.d.vergouwen@amc.uva.nl	Roos, Yvo BWEM/B-9843-2013				BAILEY I, 1991, ACTA NEUROCHIR, V110, P97, DOI 10.1007/BF01400674; BRAAKMAN R, 1994, J NEUROSURG, V80, P797; Fukuda T, 1998, NEUROSURGERY, V43, P1040, DOI 10.1097/00006123-199811000-00022; Harders A, 1996, J NEUROSURG, V85, P82, DOI 10.3171/jns.1996.85.1.0082; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; JENNETT B, 1975, LANCET, V2, P480; KOSTRON H, 1984, Neurological Research, V6, P29; Langham J, 2003, COCHRANE DB SYST REV; Murray GD, 1996, ACTA NEUROCHIR, V138, P1163, DOI 10.1007/BF01809745; Pillai SV, 2003, NEUROL INDIA, V51, P361; RINKEL GJ, 2005, COCHRANE DB SYST REV, V1; Roos YBWEM, 2001, STROKE, V32, P1860, DOI 10.1161/01.STR.32.8.1860; STEIGER HJ, 1994, NEUROSURGERY, V34, P79	13	41	45	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	DEC	2006	5	12					1029	1032		10.1016/S1474-4422(06)70582-8			4	Clinical Neurology	Neurosciences & Neurology	108VA	WOS:000242266100032	17110283				2021-06-18	
J	Gibson, LJ				Gibson, L. J.			Woodpecker pecking: how woodpeckers avoid brain injury	JOURNAL OF ZOOLOGY			English	Article						woodpeckers; pecking; brain injury; biomechanics	CONCUSSION; IMPACT	Woodpeckers are capable of repeated pecking on a tree at remarkably high decelerations (on the order of 10 000 m s(-2) or 1000 g). In this paper, I re-examine previous studies of pecking and scaling effects in brain injury. I find that there are three keys to woodpeckers' ability to withstand high decelerations: their small size, which reduces the stress on the brain for a given acceleration; the short duration of the impact, which increases the tolerable acceleration; and the orientation of the brain within the skull, which increases the area of contact between the brain and the skull.	MIT, Dept Mat Sci & Engn, Cambridge, MA 02139 USA	Gibson, LJ (corresponding author), MIT, Dept Mat Sci & Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	ljgibson@mit.edu	Gibson, Lorna J/K-4738-2012	/0000-0001-7559-7815			Bock WJ, 1999, ZOOL ANZ, V238, P27; BOCK WJ, 1964, J MORPHOL, V114, P1, DOI 10.1002/jmor.1051140102; Bock WJ, 1999, OSTRICH, V70, P23, DOI 10.1080/00306525.1999.9639746; BOCK WJ, 1966, AUK, V83, P10, DOI 10.2307/4082976; ELPHICK C, 2001, SIBLEY GUIDE BIRD LI; Hirschman A., 1976, LANCET, V307, P454, DOI [10.1016/s0140-6736(76)91477-x, DOI 10.1016/S0140-6736(76)91477-X]; Holbourn AHS, 1943, LANCET, V2, P438; MAY PRA, 1979, ARCH NEUROL-CHICAGO, V36, P370, DOI 10.1001/archneur.1979.00500420080011; McLean A. J., 1997, HEAD INJURY, P25; MLIKOVSKY J, 1989, Vestnik Ceskoslovenske Spolecnosti Zoologicke, V53, P252; Ommaya A. K., 1967, P 11 STAPP CAR CRASH, V670906; OMMAYA AK, 1971, J BIOMECH, V4, P13, DOI 10.1016/0021-9290(71)90011-X; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; ONO K, 1980, P 24 STAPP CAR CRASH, P101; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; SPRING LOWELL W., 1965, CONDOR, V67, P457, DOI 10.2307/1365612; Winkler H., 1995, WOODPECKERS GUIDE WO	18	41	47	2	78	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0952-8369			J ZOOL	J. Zool.	NOV	2006	270	3					462	465		10.1111/j.1469-7998.2006.00166.x			4	Zoology	Zoology	094MR	WOS:000241244000009		Green Published			2021-06-18	
J	Cragar, DE; Berry, DTR; Fakhoury, TA; Cibula, JE; Schmitt, FA				Cragar, Dona E.; Berry, David T. R.; Fakhoury, Toufic A.; Cibula, Jean E.; Schmitt, Frederick A.			Performance of patients with epilepsy or psychogenic non-epileptic seizures on four measures of effort	CLINICAL NEUROPSYCHOLOGIST			English	Article; Proceedings Paper	29th Annual Meeting of the International-Neuropsychological-Society	FEB 14-17, 2001	CHICAGO, IL	Int Neuropsychol Soc			MEMORY; DEPRESSION; IMPAIRMENT; VALIDATION; DIAGNOSIS; INJURY; TOMM	Exaggeration of cognitive symptoms or poor effort on cognitive testing has been addressed primarily in the traumatic brain injury literature. The present investigation aims to extend the evaluation of effort to the epilepsy monitoring setting, where base rates of failure on effort testing remain unknown for patients with intractable epilepsy (ES), psychogenic nonepileptic seizures (PNES), or both conditions (ES+PNES). In addition, this investigation explores how well four measures of effort (DMT, LMT, TOMM, PDRT) distinguish between these diagnostic groups. Results show that 20% of the combined sample failed one or more effort measure. When examining failure rates for each diagnostic group, 22% of epilepsy patients, 24% of PNES patients, and 11% of ES+PNES patients performed suboptimally on one or more measure of effort. The utility of these effort measures to differentiate between these diagnostic groups appears limited. Further research is needed to clarify the base rate of poor effort in the epilepsy monitoring unit setting in general and in these three diagnostic groups specifically.	Univ Kentucky, Dept Psychol, Lexington, KY 40506 USA; Univ Kentucky, Dept Neurol, Lexington, KY 40506 USA; Univ Kentucky, Dept Psychiat, Lexington, KY 40506 USA; Univ Kentucky, Dept Behav Sci, Lexington, KY 40506 USA; Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40506 USA	Cragar, DE (corresponding author), Mayo Clin, Div Psychol, 13400 E Shea Blvd, Scottsdale, AZ 85259 USA.	locke.dona@mayo.edu		Locke, Dona/0000-0002-1966-7716			Allen L.M., 1997, CARB 97 MANUAL COMPU; Ashendorf L, 2004, ARCH CLIN NEUROPSYCH, V19, P125, DOI 10.1016/S0887-6177(02)00218-4; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P19, DOI 10.1076/clin.15.1.19.1907; Bigler ED, 2003, ARCH CLIN NEUROPSYCH, V18, P595; Binder Laurence M, 1990, Clin Neuropsychol, V4, P25, DOI 10.1080/13854049008401494; BINDER LM, 1994, J CLIN EXP NEUROPSYC, V16, P524, DOI 10.1080/01688639408402663; Binder LM, 1998, ARCH CLIN NEUROPSYCH, V13, P513, DOI 10.1016/S0887-6177(97)00042-5; BINDER LM, 2002, J FORENSIC NEUROPSYC, V2, P27; Cragar DE, 2003, J CLIN EXP NEUROPSYC, V25, P793, DOI 10.1076/jcen.25.6.793.16471; Cragar DE, 2002, NEUROPSYCHOL REV, V12, DOI 10.1023/A:1015491123070; D'Arcy RCN, 2000, BRAIN COGNITION, V44, P54; DEVINSKY O, 1995, NEUROL CLIN, V13, P299; Green P, 2003, ARCH CLIN NEUROPSYCH, V18, P625, DOI 10.1016/S0887-6177(03)00094-5; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; GREEN P, 1996, WORD MEMORY TEST MAN; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; GUILMETTE TJ, 1994, CLIN NEUROPSYCHOL, V8, P283, DOI 10.1080/13854049408404135; Hill SK, 2003, J FORENSIC NEUROPSYC, V3, P1; HISCOCK M, 1989, J CLIN EXP NEUROPSYC, V11, P967, DOI 10.1080/01688638908400949; Inman TH, 1998, PSYCHOL ASSESSMENT, V10, P128, DOI 10.1037/1040-3590.10.2.128; Inman TH, 2002, ARCH CLIN NEUROPSYCH, V17, P1, DOI 10.1016/S0887-6177(00)00073-1; Martin R, 2003, NEUROLOGY, V61, P1791, DOI 10.1212/01.WNL.0000098890.13946.F5; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Orey SA, 2000, ARCH CLIN NEUROPSYCH, V15, P335, DOI 10.1016/S0887-6177(99)00024-4; Rees LM, 2001, ARCH CLIN NEUROPSYCH, V16, P501, DOI 10.1016/S0887-6177(00)00064-0; Reynolds CR, 1998, CRIT ISS NE, P261; SMIGIELSKI JS, 2004, 24 ANN NAT AC NEUR C; Teichner G, 2004, ARCH CLIN NEUROPSYCH, V19, P455, DOI 10.1016/S0887-6177(03)00078-7; Tombaugh T.N., 1996, TOMM TEST MEMORY MAL; Vickery CD, 2004, ARCH CLIN NEUROPSYCH, V19, P37, DOI 10.1016/S0887-6177(02)00170-1; Vickery CD, 2001, ARCH CLIN NEUROPSYCH, V16, P45, DOI 10.1016/S0887-6177(99)00058-X; Williamson David J., 2003, Epilepsia, V44, P13; Willis SC., 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI [10.1037/1040-3590.3.2.175, DOI 10.1037/1040-3590.3.2.175]	33	41	41	1	11	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	SEP	2006	20	3					552	566		10.1080/13854040590947380			15	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	071MT	WOS:000239607000015	16895866				2021-06-18	
J	Muller, K; Elverland, A; Romner, B; Waterloo, K; Langbakk, B; Unden, J; Ingebrigtsen, T				Muller, Kay; Elverland, Astrid; Romner, Bertil; Waterloo, Knut; Langbakk, Bodil; Unden, Johan; Ingebrigtsen, Tor			Analysis of protein S-100B in serum: a methodological study	CLINICAL CHEMISTRY AND LABORATORY MEDICINE			English	Article						methods; protein S-100B; serum analysis; serum markers; traumatic brain injury	TRAUMATIC BRAIN-DAMAGE; SEX-RELATED CHANGES; MINOR HEAD-INJURY; S100B; BLOOD; S100-BETA; STABILITY; MARKERS; STORAGE; DISEASE	Background: Dysfunction and damage of the human central nervous system can be detected with biochemical markers, and protein S-100B is the best-established such marker. The aim of this study was to evaluate whether the protein is stable during longterm storage, to establish reference values for the new Elecsys((R)) S100 test and to compare this new method with the Liaison((R)) Sangtec((R)) 100 test. Methods: We analysed blood samples from 118 blood donors and 196 patients with subarachnoid haemorrhage or head injury. The long-term stability of S-100B in frozen serum samples was evaluated with repeated analysis in 1997 and 2003 using an immunoradiometric assay. Method comparison between the Liaison((R)) Sangtec((R)) 100 and Elecsys((R)) S100 tests was performed using Bland-Altman difference plots. Results: Serum concentrations increased significantly during long-term storage (mean difference 0.15 mu g/L; +/- 2 SD, 0.55 mu g/L). Serum measurements using the Elecsys ((R)) S100 method in 118 healthy blood donors showed S-100B levels between 0.02 and 0.08 mu g/L (mean 0.05). The 95th percentile was 0.07 mu g/L. The Liaison ((R)) Sangtec((R)) 100 test usually measured higher concentrations than the Elecsys((R)) S100 method, and the difference between the two methods increased with increasing concentrations. The mean difference between the methods was 0.14 mu g/L (+/- 2 SD, 0.39 mu g/L). Conclusions: Protein S-100B is not stable during longterm storage and the two analytical methods are not interchangeable.	Univ Hosp N Norway, Dept Neurosurg, N-9038 Tromso, Norway; Univ Hosp N Norway, Dept Neurol, N-9038 Tromso, Norway; Univ Hosp N Norway, Dept Clin Chem, N-9038 Tromso, Norway; Univ Lund Hosp, Dept Neurosurg, Lund, Sweden; Univ Tromso, Inst Clin Med, Dept Neurosurg, Tromso, Norway	Muller, K (corresponding author), Univ Hosp N Norway, Dept Neurosurg, N-9038 Tromso, Norway.	kay.muller@unn.no		Ingebrigtsen, Tor/0000-0001-5966-9786			Buttner T, 1997, STROKE, V28, P1961, DOI 10.1161/01.STR.28.10.1961; Dewitte K, 2002, CLIN CHEM, V48, P799; Djukanovic D, 2001, BRIT J DERMATOL, V145, P1030, DOI 10.1046/j.1365-2133.2001.04545.x; Fassbender K, 1997, J NEUROL SCI, V148, P101, DOI 10.1016/S0022-510X(96)05351-8; Gazzolo D, 2003, CLIN CHEM, V49, P967, DOI 10.1373/49.6.967; GRIFFIN WST, 1995, J NEUROCHEM, V65, P228; Ingebrigtsen T, 1999, NEUROSURGERY, V45, P468, DOI 10.1097/00006123-199909000-00010; Ingebrigtsen T, 2002, J TRAUMA, V52, P798, DOI 10.1097/00005373-200204000-00038; Ingebrigtsen T, 1997, J CLIN NEUROSCI, V4, P29, DOI 10.1016/S0967-5868(97)90007-2; Nygaard O, 1997, CLIN CHEM, V43, P541; Portela LVC, 2002, CLIN CHEM, V48, P950; Raabe A, 1998, J NEUROL NEUROSUR PS, V65, P930, DOI 10.1136/jnnp.65.6.930; Raabe A, 2003, CLIN CHEM LAB MED, V41, P700, DOI 10.1515/CCLM.2003.106; Reynolds MA, 2003, CLIN CHEM, V49, P1733, DOI 10.1373/49.10.1733; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; Unden J, 2004, SCAND J INFECT DIS, V36, P10, DOI 10.1080/00365540310017294; VANELDIK LJ, 1994, BBA-MOL CELL RES, V1223, P398, DOI 10.1016/0167-4889(94)90101-5; Wiesmann M, 1997, ACTA NEUROCHIR, V139, P1155, DOI 10.1007/BF01410976; Wiesmann M, 1998, CLIN CHEM, V44, P1056	19	41	42	0	0	WALTER DE GRUYTER & CO	BERLIN	GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY	1434-6621			CLIN CHEM LAB MED	Clin. Chem. Lab. Med.	SEP	2006	44	9					1111	1114		10.1515/CCLM.2006.211			4	Medical Laboratory Technology	Medical Laboratory Technology	093TT	WOS:000241193800013	16958605				2021-06-18	
J	Cutler, SM; VanLandingham, JW; Stein, DG				Cutler, Sarah M.; VanLandingham, Jacob W.; Stein, Donald G.			Tapered progesterone withdrawal promotes long-term recovery following brain trauma	EXPERIMENTAL NEUROLOGY			English	Article							CEREBRAL-ARTERY OCCLUSION; NEUROACTIVE STEROIDS; NEUROTROPHIC FACTOR; INFLAMMATORY RESPONSE; GABA(A) RECEPTOR; SPINAL-CORD; INJURY; RATS; EXPRESSION; NEUROSTEROIDS	We previously demonstrated that after traumatic brain injury (TBI), acute progesterone withdrawal (AW) causes an increase in anxiety behaviors and cerebro-cellular inflammation compared to tapered progesterone withdrawal (TW). Our current study investigates the behavioral and cellular effects of AW two weeks after termination of treatments to determine the longer-term influence of withdrawal after injury. Adult, male Sprague-Dawley rats received either bilateral frontal cortex contusion (L) or sham (S) surgery. Rats were injected at I and 6 h post-injury, then every 24 h for six days. Vehicle (V)-treated rats Were given 9 injections of 22.5% cyclodextrin, whereas AW rats received 9 injections of 16 mg/kg progesterone and TW rats received 7 injections of P at 16 mg/kg, followed by one at 8 mg/kg and one at 4 mg/kg. On day 8, sensory neglect and locomotor activity tests were initiated. Animals were killed 22 days post-TBI and the brains prepared for either molecular or histological analysis. Western blotting revealed increased brain-derived neurotrophic factor (BDNF) and heat shock protein 70 (HSP70) in TW vs. AW animals. P53 was increased in VL animals, whereas all progesterone-treated groups were equivalent to shams. TW animals had markedly decreased sensory neglect compared to AW animals and increased center time in locomotor activity assays. In addition, lesion reconstruction revealed a decreased lesion size for TWL over AWL over VL animals. Glial fibrillary acidic protein (GFAP) immunofluorescent staining followed this pattern as well. In conclusion, after TBI, AW affects select behaviors and molecular markers in the chronic recovery period. (c) 2006 Elsevier Inc. All rights reserved.	Emory Univ, Dept Emergency Med, Atlanta, GA USA	Cutler, SM (corresponding author), 1365B Clifton Rd,Emory Clin Suite 5100,Room 5301, Atlanta, GA 30322 USA.	scutler@emory.edu	Stein, Donald/AAJ-5139-2020		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1R01NS540825, 1R01NS538664] Funding Source: Medline		Acarin L, 1999, J NEUROPATH EXP NEUR, V58, P389, DOI 10.1097/00005072-199904000-00009; AKWA Y, 1991, J STEROID BIOCHEM, V40, P71, DOI 10.1016/0960-0760(91)90169-6; Asbury ET, 1998, BEHAV BRAIN RES, V97, P99, DOI 10.1016/S0166-4328(98)00031-X; ATTELLA MJ, 1987, BEHAV NEURAL BIOL, V48, P352, DOI 10.1016/S0163-1047(87)90918-6; Binder DK, 2004, GROWTH FACTORS, V22, P123, DOI 10.1080/08977190410001723308; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Burleson MH, 1998, PSYCHOSOM MED, V60, P17, DOI 10.1097/00006842-199801000-00004; CDC, 2004, TRAUM BRAIN INJ US, P1; Chen JL, 1999, J NEUROL SCI, V171, P24, DOI 10.1016/S0022-510X(99)00247-6; Chuang De-Maw, 2004, Critical Reviews in Neurobiology, V16, P83, DOI 10.1615/CritRevNeurobiol.v16.i12.90; Cutler SM, 2005, EXP NEUROL, V195, P423, DOI 10.1016/j.expneurol.2005.06.003; de Leme RJ, 2001, ARQ NEURO-PSIQUIAT, V59, P483; DELCERRO S, 1995, GLIA, V14, P65; DelCerro S, 1996, GLIA, V18, P293, DOI 10.1002/(SICI)1098-1136(199612)18:4<293::AID-GLIA4>3.0.CO;2-Z; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Driscoll I, 2005, HORM BEHAV, V47, P326, DOI 10.1016/j.yhbeh.2004.11.013; Feinstein DL, 1996, J BIOL CHEM, V271, P17724, DOI 10.1074/jbc.271.30.17724; Foldvary-Schaefer Nancy, 2004, Cleve Clin J Med, V71 Suppl 2, pS11; Galani R, 2001, RESTOR NEUROL NEUROS, V18, P161; GARCIAESTRADA J, 1993, BRAIN RES, V628, P271, DOI 10.1016/0006-8993(93)90964-O; Gibson CL, 2005, EXP NEUROL, V193, P522, DOI 10.1016/j.expneurol.2005.01.009; Gibson CL, 2004, J CEREBR BLOOD F MET, V24, P805, DOI 10.1097/01.WCB.0000125365.83980.00; Gonzalez SL, 2004, NEUROSCIENCE, V125, P605, DOI 10.1016/j.neuroscience.2004.02.024; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Grossman KJ, 2004, BRAIN RES, V1008, P29, DOI 10.1016/j.brainres.2004.02.022; Gulinello M, 2003, EUR J NEUROSCI, V17, P641, DOI 10.1046/j.1460-9568.2003.02479.x; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; HATTEN ME, 1991, GLIA, V4, P233, DOI 10.1002/glia.440040215; Horvath KM, 2000, EUR J PHARMACOL, V405, P33, DOI 10.1016/S0014-2999(00)00539-2; Kempermann G, 2000, Prog Brain Res, V127, P35; Kleim JA, 2003, NEUROCHEM RES, V28, P1757, DOI 10.1023/A:1026025408742; Kulkarni S. K., 1995, Drugs of Today, V31, P433; Kumon Y, 2000, J NEUROSURG, V92, P848, DOI 10.3171/jns.2000.92.5.0848; Legrand A, 1998, BRAIN RES, V802, P125, DOI 10.1016/S0006-8993(98)00580-0; Lukasiuk K, 2000, J NEUROCHEM, V74, P2445, DOI 10.1046/j.1471-4159.2000.0742445.x; Mattson MP, 2003, NEUROMOL MED, V3, P65, DOI 10.1385/NMM:3:2:65; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; ROOF RL, 1994, 21 ANN M SOC NEUR MI, P191; Rupprecht R, 2003, PSYCHONEUROENDOCRINO, V28, P139, DOI 10.1016/S0306-4530(02)00064-1; Rupprecht R, 2001, BRAIN RES REV, V37, P59, DOI 10.1016/S0165-0173(01)00123-0; Rupprecht R, 2001, INT REV NEUROBIOL, V46, P461; Schumacher M, 2003, PROG NEUROBIOL, V71, P3, DOI 10.1016/j.pneurobio.2003.09.004; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; Smith SS, 2002, STEROIDS, V67, P519, DOI 10.1016/S0039-128X(01)00170-2; vandenPol AN, 1996, NEUROSCIENCE, V74, P653, DOI 10.1016/0306-4522(96)00153-4; Vink R, 2004, EXPERT OPIN INV DRUG, V13, P1263, DOI 10.1517/13543784.13.10.1263; Will B, 2004, PROG NEUROBIOL, V72, P167, DOI 10.1016/j.pneurobio.2004.03.001	48	41	41	1	9	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	AUG	2006	200	2					378	385		10.1016/j.expneurol.2006.02.137			8	Neurosciences	Neurosciences & Neurology	072BH	WOS:000239647100011	16797538				2021-06-18	
J	Paparrigopoulos, T; Melissaki, A; Tsekou, H; Efthymiou, A; Kribeni, G; Baziotis, N; Geronikola, X				Paparrigopoulos, Thomas; Melissaki, Antigoni; Tsekou, Hara; Efthymiou, Anna; Kribeni, Georgia; Baziotis, Nikos; Geronikola, Xenia			Melatonin secretion after head injury: A pilot study	BRAIN INJURY			English	Article						melatonin; traumatic brain injury; intensive care unit	INTENSIVE-CARE-UNIT; TRAUMATIC BRAIN-INJURY; CRITICALLY ILL PATIENTS; CIRCADIAN-RHYTHM; SLEEP QUALITY; PATTERNS; SURGERY; INSOMNIA; ICU	Primary objective: To investigate the circadian rhythm of serum melatonin in patients with traumatic brain injury (TBI) during Intensive Care Unit (ICU) stay and its relationship with core body temperature fluctuations and measures of severity of their condition. Methods and procedures: The pilot study was conducted in the ICU of a general hospital in Athens, Greece. Blood melatonin was determined in eight patients consecutively admitted at the ICU following severe head injury, eight times per day during the first and second day following admission. Core body temperature was recorded at hourly intervals. Patients were also assessed with the Glasgow Coma Score (GCS) and the APACHE II score. Results: Melatonin concentrations were lower than the normally reported values. Mean night-time melatonin levels were higher than mean daytime levels both on the first and second days, although not statistically significant. Diurnal variation of melatonin was associated with the GCS. Thus, patients with low GCS (n=4) did not exhibit a consistent diurnal variation of melatonin, whereas those with high GCS (n = 4) retained the normally expected fluctuations. Conclusions: ICU-treated TBI patients exhibit reduced melatonin levels and a circadian secretion profile which is related to the severity of the injury. Patients with more severe head trauma exhibit a clearly disrupted pattern of melatonin secretion, whereas those with less severe trauma preserve a relatively intact diurnal rhythm. Furthermore, the diurnal secretion pattern of melatonin appeared to be dissociated from the circadian rhythm of core body temperature. These preliminary findings may have implications for the management of TBI patients.	Univ Athens, Eginit Hosp, Sch Med, Sleep Res Unit,Dept Psychiat, GR-11528 Athens, Greece; Agios Savvas Gen Hosp, ICU, Athens, Greece; Agios Savvas Gen Hosp, Dept Nucl Med, Athens, Greece	Paparrigopoulos, T (corresponding author), Univ Athens, Eginit Hosp, Sch Med, Sleep Res Unit,Dept Psychiat, 74 Vas Sofias Ave, GR-11528 Athens, Greece.	tompaparrigopoulos@teledomenet.gr					AURELL J, 1985, BRIT MED J, V290, P1029, DOI 10.1136/bmj.290.6474.1029; Beni SM, 2004, FASEB J, V18, P149, DOI 10.1096/fj.03-0323fje; BENTLEY S, 1977, BRIT MED J, V2, P1503, DOI 10.1136/bmj.2.6101.1503; Borlongan CV, 2000, FASEB J, V14, P1307, DOI 10.1096/fj.14.10.1307; BREZINSKI A, 1997, NEW ENGL J MED, V336, P186, DOI DOI 10.1056/NEJM199701163360306; BURNS AM, 1992, DRUGS, V43, P507, DOI 10.2165/00003495-199243040-00007; Cabrera J, 2000, NEUROPHARMACOLOGY, V39, P507, DOI 10.1016/S0028-3908(99)00128-8; Castriotta RJ, 2001, ARCH PHYS MED REHAB, V82, P1403, DOI 10.1053/apmr.2001.26081; Clinchot DM, 1998, AM J PHYS MED REHAB, V77, P291, DOI 10.1097/00002060-199807000-00006; COHEN M, 1992, J NEUROL NEUROSUR PS, V55, P313, DOI 10.1136/jnnp.55.4.313; Cronin AJ, 2000, LANCET, V356, P1244, DOI 10.1016/S0140-6736(00)02795-1; Dagan Y, 2002, SLEEP MED REV, V6, P45, DOI 10.1053/smrv.2001.0190; Fichtenberg NL, 2002, BRAIN INJURY, V16, P197, DOI 10.1080/02699050110103940; Fichtenberg NL, 2001, AM J PHYS MED REHAB, V80, P339, DOI 10.1097/00002060-200105000-00003; Frisk U, 2004, CLIN SCI, V107, P47, DOI 10.1042/CS20030374; Gabor J Y, 2001, Curr Opin Crit Care, V7, P21, DOI 10.1097/00075198-200102000-00004; Geoffriau M, 1998, HORM RES, V49, P136, DOI 10.1159/000023160; Goscinski I, 2001, Neurol Neurochir Pol, V35, P63; Herdegen JJ, 2002, CRIT CARE MED, V30, P709, DOI 10.1097/00003246-200203000-00040; Hilton B A, 1976, J Adv Nurs, V1, P453, DOI 10.1111/j.1365-2648.1976.tb00932.x; Kaptanoglu E, 2000, J NEUROSURG, V93, P77, DOI 10.3171/spi.2000.93.1.0077; Karkela J, 2002, ACTA ANAESTH SCAND, V46, P30, DOI 10.1034/j.1399-6576.2002.460106.x; Kemp S, 2004, BRAIN INJURY, V18, P911, DOI 10.1080/02699050410001671892; KRACHMAN SL, 1995, CHEST, V107, P1713, DOI 10.1378/chest.107.6.1713; Mesenge C, 1998, J PINEAL RES, V25, P41, DOI 10.1111/j.1600-079X.1998.tb00384.x; MEYER TJ, 1994, CHEST, V105, P1211, DOI 10.1378/chest.105.4.1211; Miyazaki T, 2003, SURGERY, V133, P662, DOI 10.1067/msy.2003.149; Moskala Marek, 2004, Neurol Neurochir Pol, V38, P401; Mundigler G, 2002, CRIT CARE MED, V30, P536, DOI 10.1097/00003246-200203000-00007; Nishimura S, 1998, J PINEAL RES, V25, P73, DOI 10.1111/j.1600-079X.1998.tb00542.x; Olofsson K, 2004, ACTA ANAESTH SCAND, V48, P679, DOI 10.1111/j.0001-5172.2004.00401.x; PARSONS LC, 1982, NURS RES, V31, P260; RICHARDS KC, 1988, HEART LUNG, V17, P35; ROSENTHAL NE, 1991, J CLIN ENDOCR METAB, V73, P227; Shilo L, 1999, AM J MED SCI, V317, P278, DOI 10.1097/00000441-199905000-00002; THORPY MJ, 1990, ICSD INT CLASSIFICAT; TreggiariVenzi M, 1996, INTENS CARE MED, V22, P1186, DOI 10.1007/s001340050236; WEITZMAN ED, 1978, J NEUROL TRANSM    S, V13, P325	38	41	41	0	2	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUL	2006	20	8					873	878		10.1080/02699050600832114			6	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	081ZO	WOS:000240356300010	17060154				2021-06-18	
J	Schroth, M; Plank, C; Meissner, U; Eberle, KP; Weyand, M; Cesnjevar, R; Dotsch, J; Rascher, W				Schroth, Michael; Plank, Christian; Meissner, Udo; Eberle, Klaus-Peter; Weyand, Michael; Cesnjevar, Robert; Doetsch, Joerg; Rascher, Wolfgang			Hypertonic-hyperoncotic solutions improve cardiac function in children after open-heart surgery	PEDIATRICS			English	Article						hypertonic-hyperoncotic solutions; pediatrics; capillary leakage; low-output failure; cardiopulmonary bypass	TRAUMATIC BRAIN-INJURY; LEUKOCYTE-ENDOTHELIUM INTERACTION; SMALL-VOLUME RESUSCITATION; HYDROXYETHYL-STARCH; CAPILLARY LEAKAGE; HEMORRHAGIC-SHOCK; SALINE INFUSION; DEXTRAN; OUTPUT; HYPERNATREMIA	OBJECTIVES. Hypertonic-hyperoncotic solutions are used for the improvement of micro- and macrocirculation in various types of shock. In pediatric intensive care medicine, controlled, randomized studies with hypertonic-hyperoncotic solutions are lacking. Hypertonic-hyperoncotic solutions may improve cardiac function in children. The primary objective of this controlled, randomized, blinded study was to evaluate the hemodynamic effects and safety of hypertonic-hyperoncotic solution infusions in children shortly after open-heart surgery for congenital cardiac disease. The secondary objective was to determine whether the administration of hypertonic-hyperoncotic solutions could be a potential and effective therapeutic option for preventing a probable capillary leakage syndrome that frequently occurs in children after open-heart surgery. METHODS. The children were randomly assigned to 2 groups of 25. The hypertonic-hyperoncotic solution group received Poly-(O-2)-hydroxyethyl-starch 60.0 g, with molecular weight of 200 kDa, Na+ 1232 mmol/L and osmolality of 2464 mOsmol/L (7.2% sodium chloride with 6% hydroxyethyl-starch 200 kDa). The isotonic saline solution group received isotonic saline solution (0.9% sodium chloride). Atrial and ventricular septal defects were corrected using a homograft patch. Monitoring consisted of an arterial, a central venous, and a thermodilution catheter (PULSIOCATH). Cardiac index, extravascular lung water index, stroke volume index, mean arterial blood pressure, and systemic vascular resistance index were measured (Pulse Contour Cardiac Output technique). Immediately after surgery, patients were loaded either with hypertonic-hyperoncotic solution or with isotonic saline solution (4 mL/kg). Blood samples (sodium concentration, osmolality, thrombocyte count, fibrinogen, and arterial blood gases) were drawn directly before; immediately after; 15 minutes after; and, 1, 4, 12, and 24 hours after the end of volume loading. Hemodynamic parameters were registered at the same time. The total amount of dobutamine required was documented, as well as the 24- and 48-hour fluid balances. RESULTS. In the hypertonic-hyperoncotic solution group, cardiac index was 3.6 +/- 0.26 L/min per m(2) before volume administration and increased to 5.96 +/- 0.27 after the administration of the study solution (64%). Fifteen and 60 minutes after administration, the cardiac index remained significantly elevated (5.55 +/- 0.29 L/min per m(2) and 4.65 +/- 0.18 L/min per m2, respectively) and returned to preadministration values after 4 hours. In the isotonic saline solution group, the cardiac index did not change during the entire observation period (3.39 +/- 0.21 before and 3.65 +/- 0.23 L/min per m(2) after isotonic saline solution). The systemic vascular resistance index decreased in the hypertonic-hyperoncotic solution group after administration from 1396 +/- 112 to 868 +/- 63 dyn/sec per cm(-5)/m(2). The decrease of systemic vascular resistance index in the hypertonic-hyperoncotic solution group was transiently significant within 60 minutes after administration but stayed lower than before volume load (999 +/- 70 dyn/sec per cm(-5)/m(2)). In the isotonic saline solution group, we found no statistically relevant change in systemic vascular resistance index. Stroke volume index significantly increased after hypertonic-hyperoncotic solution infusion (53.9 +/- 3.0 mL/m(2) directly after, 48.8 +/- 2.46 mL/m(2) 15 minutes after, and 41.4 +/- 2.2 mL/m(2) 60 minutes after) when compared with stroke volume index before administration (32.4 +/- 2.6 mL/m(2)). In the hypertonic-hyperoncotic solution group, an increase in mean arterial blood pressure remained transiently significant within 60 minutes after administration when compared with the isotonic saline solution group, in which the mean arterial blood pressure remained unchanged. Both central venous pressure and heart rate were unchanged during the whole time of observation in both groups. In the hypertonic-hyperoncotic solution group, extravascular lung water index decreased from 10.6 +/- 1.2 to 5.6 +/- 1.2 mL/kg and remained significantly decreased 15 minutes after (6.5 +/- 1.2 mL/kg) when compared with before volume administration. In the isotonic saline solution group, extravascular lung water index increased from 12.3 +/- 1.1 mL/kg to 18.1 +/- 1.7 mL/kg directly after administration and remained elevated for 60 minutes after volume loading (15.6 +/- 1.5 mL/kg). In all patients, no hypoxia (Pao(2) < 60 mm Hg) or hypercapnia (Paco(2) > 60 mm Hg) was observed. Arterial blood gas analysis showed pH and base excess within physiologic range, and this did not change throughout the whole period of observation. After infusion of hypertonic-hyperoncotic solution, sodium concentration increased from 139.2 +/- 0.7 to 147.5 +/- 0.7 mmol/L. The maximum sodium concentration was 153 mmol/L, measured immediately after hypertonic-hyperoncotic solution in 1 patient. The total amount of fluid infused was similar in both groups. The postoperative need for infused dobutamine in the patients in the hypertonic-hyperoncotic solution group was decreased compared with the isotonic saline solution group 46.9 +/- 8.8 mu g/kg vs 308.2 +/- 46.6 mu g/kg). No patient presented with severe bleeding. Short- and long-term cardiac and neurologic outcome was not reduced and all patients left the hospital in a clinically sufficient state. DISCUSSION. This study demonstrates a profound increase of cardiac index after the administration of hypertonic-hyperoncotic solution in children after uncomplicated open-heart surgery, suggesting a positive inotropic effect. The total amount of catecholamine was lower, assuming that hypertonic-hyperoncotic solution reduces the need for positive inotropic support. The observed positive cardiac effect of hypertonic-hyperoncotic solution may even be intensified by the decreased afterload (decreased systemic vascular resistance index). According to the Frank-Starling relation, an effective tool in the treatment of low cardiac output are an elevated preload while afterload is diminished. Therefore, we postulate that hypertonic-hyperoncotic solution may be helpful in preventing or attenuating low cardiac output failure in childhood. Capillary leakage syndrome also is a frequent problem after cardiopulmonary bypass. For quantification of edema formation, extravascular lung water index measurement is a useful tool. Using this approach, we provided evidence that the infusion of hypertonic-hyperoncotic solution is transiently able to reduce extravascular lung water index. This reduction was transient but might prevent the triggering of a clinically relevant capillary leakage syndrome. This is in line with in vitro studies demonstrating that hypertonic-hyperoncotic solution improves microcirculation by reducing vascular permeability. The single administration of hypertonic-hyperoncotic solution infusion was safe, and no adverse effects, such as hemostatic disturbances, were observed. CONCLUSIONS. A single infusion of hypertonic-hyperoncotic saline solution after cardiac surgery is safe despite the hypertonicity and the colloid component of the hypertonic-hyperoncotic saline solution. In children after cardiopulmonary bypass surgery, the administration of hypertonic-hyperoncotic saline solution increased cardiac index by elevating stroke volume index in combination with a lowered systemic vascular resistance index. Extravascular lung water index transiently decreased, suggesting that hypertonic-hyperoncotic saline solution effectively counteracts the capillary leakage that often occurs after cardiac surgery in children. Additional investigations might elucidate whether the temporary effects of hypertonic-hyperoncotic saline solution are beneficial in the treatment of severe capillary leakage after complicated cardiac surgery. It has to be shown that hypertonic-hyperoncotic saline solution is a long-lasting, effective treatment strategy for low cardiac output failure in children that is caused by sepsis, multiorgan failure, and endothelial edema. We have provided evidence to pediatric intensive care clinicians that the single administration of hypertonic-hyperoncotic saline solution might be a useful and safe treatment in the amelioration of contractility, inotropy, and the possible treatment of early-onset capillary leakage.	Univ Erlangen Nurnberg, Kinder & Jugendklin, Dept Pediat, Pediat Intens Care Unit, D-91054 Erlangen, Germany; Univ Erlangen Nurnberg, Dept Anesthesiol, D-91054 Erlangen, Germany; Univ Erlangen Nurnberg, Dept Cardiac Surg, D-91054 Erlangen, Germany	Schroth, M (corresponding author), Univ Erlangen Nurnberg, Kinder & Jugendklin, Dept Pediat, Pediat Intens Care Unit, Loschgestr 15, D-91054 Erlangen, Germany.	michael_schroth@yahoo.de	Cesnjevar, Robert/AAD-6215-2019	Cesnjevar, Robert/0000-0002-3575-6647			ALBRECHT MD, 1995, SHOCK, V3, P152, DOI 10.1097/00024382-199503020-00011; BERG RA, 1993, J PHARMACOL EXP THER, V265, P1232; BOLDT J, 1994, CRIT CARE MED, V22, P1913; BOLDT J, 1993, BRIT J ANAESTH, V70, P661, DOI 10.1093/bja/70.6.661; Carli P, 2004, LANCET, V363, P584, DOI 10.1016/S0140-6736(04)15626-2; Cecchetti C, 2003, Minerva Anestesiol, V69, P907; Christ F, 1997, ACTA ANAESTH SCAND, V41, P62, DOI 10.1111/j.1399-6576.1997.tb04614.x; Corso CO, 1999, J TRAUMA, V46, P417, DOI 10.1097/00005373-199903000-00011; de Kleijn ED, 1998, EUR J PEDIATR, V157, P869, DOI 10.1007/s004310050958; DEFELIPPE J, 1980, LANCET, V2, P1002; ELLINGER K, 1995, SHOCK, V3, P167, DOI 10.1097/00024382-199503000-00002; Hartl R, 1997, J TRAUMA, V42, pS41, DOI 10.1097/00005373-199705001-00008; Hazelzet JA, 1998, INFECT IMMUN, V66, P5350, DOI 10.1128/IAI.66.11.5350-5356.1998; KAPIOTIS S, 1994, CRIT CARE MED, V22, P606, DOI 10.1097/00003246-199404000-00016; Khabar KSA, 1997, CLIN IMMUNOL IMMUNOP, V85, P97, DOI 10.1006/clin.1997.4413; Khanna S, 2000, CRIT CARE MED, V28, P1144, DOI 10.1097/00003246-200004000-00038; KIEN ND, 1991, ANESTH ANALG, V73, P597; KREIMEIER U, 1995, LANCET, V346, P49, DOI 10.1016/S0140-6736(95)92677-1; KREIMEIER U, 1990, J SURG RES, V49, P493, DOI 10.1016/0022-4804(90)90174-Z; Kreimeier U, 2002, ACTA ANAESTH SCAND, V46, P625, DOI 10.1034/j.1399-6576.2002.460601.x; LANG RM, 1986, CIRCULATION, V74, P1114, DOI 10.1161/01.CIR.74.5.1114; Levy RJ, 2004, ANESTH ANALG, V99, P1642, DOI 10.1213/01.ANE.0000136952.85278.99; MATTOX KL, 1991, MULTICENTER TRIAL AN, V213, P482; Michard F, 2003, CHEST, V124, P1900, DOI 10.1378/chest.124.5.1900; MODER KG, 1990, MAYO CLIN PROC, V65, P1587, DOI 10.1016/S0025-6196(12)62194-6; Moritz ML, 1999, PEDIATRICS, V104, P435, DOI 10.1542/peds.104.3.435; NOLTE D, 1991, AM J PHYSIOL, V261, pH651; NOLTE D, 1992, N-S ARCH PHARMACOL, V346, P234, DOI 10.1007/BF00165307; Nurnberger W, 1997, ANN HEMATOL, V75, P95, DOI 10.1007/s002770050321; Pickelmann S, 1998, AM J PHYSIOL-HEART C, V275, pH361; PRIEN T, 1993, ZBL CHIR, V118, P257; PRIEN T, 1993, ZENTRALBL CHIR, V118, P264; Rocha-e-Silva R, 2003, SHOCK, V20, P427, DOI 10.1097/01.SHK.0000094037.09886.d2; ROCHAESILVA M, 1986, CIRC SHOCK, V19, P165; Scheingraber S, 1999, ANESTHESIOLOGY, V90, P1265, DOI 10.1097/00000542-199905000-00007; Schimetta W, 2002, WIEN KLIN WOCHENSCHR, V114, P89; SCHRANZ D, 1994, Z KARDIOL, V83, P83; Simma B, 1998, CRIT CARE MED, V26, P1265, DOI 10.1097/00003246-199807000-00032; TAKEDA A, 1995, J VET MED SCI, V57, P481, DOI 10.1292/jvms.57.481; Tollofsrud S, 1998, ACTA ANAESTH SCAND, V42, P154, DOI 10.1111/j.1399-6576.1998.tb05101.x; VASSAR MJ, 1990, ARCH SURG-CHICAGO, V125, P1309; VOLLMAR B, 1994, AM J PHYSIOL, V266, pH1927; White PA, 1997, AM J PHYSIOL-HEART C, V273, pH295	43	41	53	0	9	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	JUL	2006	118	1					E76	E84		10.1542/peds.2005-2795			9	Pediatrics	Pediatrics	059II	WOS:000238726100073	16751617				2021-06-18	
J	Mazzeo, AT; Kunene, NK; Gilman, CB; Hamm, RJ; Hafez, N; Bullock, MR				Mazzeo, Anna Teresa; Kunene, Niki K.; Gilman, Charlotte B.; Hamm, Robert J.; Hafez, Naiel; Bullock, M. Ross			Severe human traumatic brain injury, but not cyclosporin A treatment, depresses activated T lymphocytes early after injury	JOURNAL OF NEUROTRAUMA			English	Article						cyclosporin A; immunity; immunosuppression; infection; severe head injury; T cells	MITOCHONDRIAL PERMEABILITY TRANSITION; TRANSIENT FOREBRAIN ISCHEMIA; HEAD-INJURY; IMMUNE FUNCTION; CELL FUNCTION; DAMAGE; PHARMACOKINETICS; AUTOIMMUNITY; DYSFUNCTION; IMPAIRMENT	Severe traumatic brain injury (TBI) leads to an immunocompromised state responsible for an increased morbidity and mortality. Our understanding of the mechanisms responsible for this brain damage is incomplete. Damage maybe mediated by a complex cascade of neuroinflammation, and cytokine activation. In addition, translocation and accumulation of T cells in the brain parenchyma could take place and be related to detrimental effects. Our aims in this prospective randomized pilot study, were to detect the early effect of severe TBI upon cell-mediated immunity, to verify if early immunologic impairment correlates with neurologic outcome, and finally, to test the effect of early administration of iv infusion of cyclosporin A upon cell-mediated immunologic function. Forty-nine patients with severe TBI were studied. Thirty-six of these patients received a 24-h intravenous infusion of Cyclosporin A, or two 24-h infusions of the drug. 10 patients were in the placebo group. Three patients, not enrolled in the cyclosporin trial, were studied only for the relationship between cellular immunity, neurological outcome, and infection rate. T cell counts and microbiological cultures were performed in all patients. Sixty-five percent of patients demonstrated reduced T lymphocyte counts on admission. Furthermore, reduction of T cell numbers was related with significantly worse neurologic outcome and an increase in pulmonary infection. There was no significant difference between the placebo and CsA treated patients for the studied immunological parameters, or for incidence of infection. We also observed sequestration/diapedesis of T cells into the brain parenchyma, around contusions, after human TBI and we speculate that this could be responsible for further brain damage.	Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, Richmond, VA 23298 USA; Univ Messina, Dept Neurosci Psychiat & Anesthesiol Sci, Messina, Italy; Virginia Commonwealth Univ, Dept Informat Syst, Richmond, VA USA; Virginia Commonwealth Univ, Dept Psychol, Richmond, VA 23284 USA; Virginia Commonwealth Univ, Div Neuropathol, Dept Pathol, Richmond, VA 23284 USA	Bullock, MR (corresponding author), West Hosp, 1200 E Broad St,8th Fl,S Wing,POB 980631, Richmond, VA 23298 USA.	robulloc@hsc.vcu.edu		Mazzeo, Anna Teresa/0000-0002-8454-7243	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [12587] Funding Source: Medline		Alessandri B, 2002, J NEUROTRAUM, V19, P829, DOI 10.1089/08977150260190429; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Boddie DE, 2003, BRIT J NEUROSURG, V17, P405, DOI 10.1080/02688690310001611198; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Czura CJ, 2005, J INTERN MED, V257, P156, DOI 10.1111/j.1365-2796.2004.01442.x; Danovitch GM, 2005, HDB KIDNEY TRANSPLAN, P72; DEITCH EA, 1997, SCI FDN TRAUMA, P729; Fee D, 2003, J NEUROIMMUNOL, V136, P54, DOI 10.1016/S0165-5728(03)00008-0; Ferrand-Drake M, 2003, J NEUROCHEM, V85, P1431, DOI 10.1046/j.1471-4159.2003.01794.x; Foradori A, 1998, TRANSPLANT P, V30, P1685, DOI 10.1016/S0041-1345(98)00393-5; Friberg H, 1998, J NEUROSCI, V18, P5151; HELLING TS, 1988, J TRAUMA, V28, P1575, DOI 10.1097/00005373-198811000-00009; Hensler T, 2000, INFLAMM RES, V49, P524, DOI 10.1007/s000110050626; HOYT DB, 1990, J TRAUMA, V30, P759, DOI 10.1097/00005373-199007000-00001; Jones TE, 1997, CLIN PHARMACOKINET, V32, P357, DOI 10.2165/00003088-199732050-00002; Kipnis J, 2002, P NATL ACAD SCI USA, V99, P15620, DOI 10.1073/pnas.232565399; Kipnis J, 2002, J NEUROIMMUNOL, V130, P78, DOI 10.1016/S0165-5728(02)00219-9; KROCZEK RA, 1987, J IMMUNOL, V139, P3597; Li PA, 2000, EXP NEUROL, V165, P153, DOI 10.1006/exnr.2000.7459; Lown KS, 1997, CLIN PHARMACOL THER, V62, P248, DOI 10.1016/S0009-9236(97)90027-8; Matsumoto S, 1999, J CEREBR BLOOD F MET, V19, P736, DOI 10.1097/00004647-199907000-00002; McLachlan AJ, 1998, THER DRUG MONIT, V20, P390, DOI 10.1097/00007691-199808000-00007; MEERT KL, 1995, CRIT CARE MED, V23, P822, DOI 10.1097/00003246-199505000-00008; MILLER AC, 1999, RADIAT RES, V1, P117; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; MORGANTIKOSSMANN MC, 2001, MO CL BI CC, V2, P99; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; QUATTROCCHI K B, 1991, Neurological Research, V13, P13; QUATTROCCHI K B, 1990, Journal of Neurotrauma, V7, P77, DOI 10.1089/neu.1990.7.77; QUATTROCCHI KB, 1992, J NEUROTRAUM, V9, P1, DOI 10.1089/neu.1992.9.1; QUATTROCCHI KB, 1991, J NEUROSURG, V75, P766, DOI 10.3171/jns.1991.75.5.0766; QUATTROCCHI KB, 1992, J NEUROSURG, V77, P694, DOI 10.3171/jns.1992.77.5.0694; Rieves R. Dwaine, 1997, P303; SACKS GS, 1995, JPEN-PARENTER ENTER, V19, P387, DOI 10.1177/0148607195019005387; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; SHIGA Y, 1992, BRAIN RES, V595, P145, DOI 10.1016/0006-8993(92)91465-Q; Shohami E, 1999, J NEUROTRAUM, V16, P365, DOI 10.1089/neu.1999.16.365; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; Uchino H, 1995, ACTA PHYSIOL SCAND, V155, P469, DOI 10.1111/j.1748-1716.1995.tb09999.x; Uchino H, 1998, BRAIN RES, V812, P216, DOI 10.1016/S0006-8993(98)00902-0; WIEDERRECHT G, 1993, ANN NY ACAD SCI, V696, P9, DOI 10.1111/j.1749-6632.1993.tb17137.x; Woiciechowsky C, 2002, J TRAUMA, V52, P339, DOI 10.1097/00005373-200202000-00021; Woiciechowsky C, 1998, NAT MED, V4, P808, DOI 10.1038/nm0798-808; Yoles E, 2001, J NEUROSCI, V21, P3740, DOI 10.1523/JNEUROSCI.21-11-03740.2001; Yoshimoto T, 1999, BRAIN RES, V839, P283, DOI 10.1016/S0006-8993(99)01733-3; ZENKE G, 1993, ANN NY ACAD SCI, V685, P330, DOI 10.1111/j.1749-6632.1993.tb35882.x	48	41	44	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2006	23	6					962	975		10.1089/neu.2006.23.962			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	056TW	WOS:000238549000012	16774480				2021-06-18	
J	Schonberger, M; Humle, F; Zeeman, P; Teasdale, TW				Schonberger, M; Humle, F; Zeeman, P; Teasdale, TW			Working alliance and patient compliance in brain injury rehabilitation and their relation to psychosocial outcome	NEUROPSYCHOLOGICAL REHABILITATION			English	Article								Employment and physical activity at follow up of 98 patients who underwent a holistic neuropsychological outpatient rehabilitation programme were examined in relation to therapeutic process factors. The patients had suffered a traumatic brain injury (n = 26), a cerebrovascular accident ( n 58) or another neurological insult (n = 14). Two staff members, a neuropsychologist and a physiotherapist, retrospectively rated patients' compliance with the therapeutic regime and their working alliances. They completed the ratings separately, but had some degree of common knowledge about the patients. While the compliance ratings were closely associated, working alliance ratings differed between the raters. The working alliance ratings were predictive of employment, but not physical activity. Both compliance ratings predicted physical training, but only the neuropsychologist's compliance rating was associated with follow-up employment. Post-hoc analysis showed that high compliance ratings given by the physiotherapist were also a predictor of employment. Overall, there was a tendency for the neuropsychologist's ratings to be more closely associated with employment than the physiotherapist's ratings. These results indicate that employment and physical activity are differentially predictable from different process measures rated from different professional perspectives.	Univ Copenhagen, Ctr Rehabil Brain Injury, DK-2300 Copenhagen S, Denmark	Schonberger, M (corresponding author), Univ Copenhagen, Ctr Rehabil Brain Injury, Njalsgade 88, DK-2300 Copenhagen S, Denmark.	michael.schoenberger@psy.ku.dk					BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P33; CAETANO C, 2000, INT HDB NEUROPSYCHOL; CHRISTENSEN AL, 1992, ACTA NEUROL SCAND, V85, P32; CHRISTENSEN AL, 1999, COGNITIVE NEUROREHAB; Constantino M. J., 2002, COUNSELING BASED PRO; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; Hilsenroth MJ, 2002, PSYCHOTHERAPY, V39, P309, DOI 10.1037//0033-3204.39.4.309; HORVATH AO, 1989, J COUNS PSYCHOL, V36, P223, DOI 10.1037/0022-0167.36.2.223; HORVATH AO, 1994, WORKING ALLIANCE THE, P259; Klonoff PS, 2001, BRAIN INJURY, V15, P413, DOI 10.1080/02699050010005968; Lambert M.J., 2002, PSYCHOTHERAPY RELATI, P17; Malec JF, 1996, ARCH PHYS MED REHAB, V77, P198, DOI 10.1016/S0003-9993(96)90168-9; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; Meichenbaum D., 1987, FACILITATING TREATME; PETERMANN F, 1998, COMPLIANCE SELBSTMAN, P73; Prigatano G. P., 1994, J HEAD TRAUMA REHAB, V9, P91, DOI [DOI 10.1097/00001199-199403000-00011, 10.1097/00001199-199403000-00011]; Prigatano GP., 1999, PRINCIPLES NEUROPSYC; RASMUSSESN G, 1994, BRAIN INJURY NEUROPS; Rogers CR., 1952, SCI AM, V187, P66, DOI [10.1038/scientificamerican1152-66, DOI 10.1038/SCIENTIFICAMERICAN1152-66]; Shirk SR, 2003, J CONSULT CLIN PSYCH, V71, P452, DOI 10.1037/0022-006X.71.3.452; Thomsen I V, 1987, Brain Inj, V1, P131, DOI 10.3109/02699058709034452; VOLMER T, 1998, COMPLIANCE SELBSTMAN, P45	22	41	42	0	11	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	JUN	2006	16	3					298	314		10.1080/09602010500176476			17	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	054XR	WOS:000238412400004	16835153				2021-06-18	
J	Rapoport, MJ; Herrmann, N; Shammi, P; Kiss, A; Phillips, A; Feinstein, A				Rapoport, MJ; Herrmann, N; Shammi, P; Kiss, A; Phillips, A; Feinstein, A			Outcome after traumatic brain injury sustained in older adulthood: A one-year longitudinal study	AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY			English	Article; Proceedings Paper	11th Congress of the International-Psychogeriatric-Association	AUG 17-22, 2003	Chicago, IL	Int Psychogeriatr Assoc		traumatic brain injury; cognition; major depression	CLOSED-HEAD INJURY; NEUROBEHAVIORAL CONSEQUENCES; ALZHEIMERS-DISEASE; RISK-FACTOR; MILD; QUESTIONNAIRE; SYMPTOMS; DEPRESSION	Objective: The objective of this study was to explore the effects of traumatic brain injury (TBI) on cognition and functioning in older adults in a one-year longitudinal study. Methods: Participants with mild-to-moderate TBI were compared with an age-, gender-, and education-matched healthy comparison group on aspects of cognition. Neuropsychologic tests were administered at one year. Self-reported measures of functioning were completed at baseline, six months, and one year. Informants rated instrumental functioning at one year. Results: Sixty-nine subjects aged 50 years and over (mean: 67 years; standard deviation: 7.9) and a comparison group of 79 participants were assessed. Patients with TBI had poorer processing speed, verbal memory, language, and executive function; they self-reported more psychologic distress, psychosocial dysfunction, and postconcussive symptoms; and they were rated as more impaired in functioning than the comparison group. TBI of moderate severity accounted for most of the between-group differences. Conclusion: TBI, particularly of moderate severity, led to poorer cognitive and psychosocial functioning one year postinjury among older adults. The clinical significance of this may become more evident with time in this vulnerable population.	Univ Toronto, Sunnybrook & Womens Coll Hlth Sci, Toronto, ON, Canada	Rapoport, MJ (corresponding author), FRCPC, FG37-2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.		Rapoport, Mark/AAD-8581-2020				AharonPeretz J, 1997, BRAIN INJURY, V11, P871; CORWIN J, 1993, CLIN NEUROPSYCHOL, V7, P3, DOI 10.1080/13854049308401883; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; Delis DC, 1989, CALIFORNIA VERBAL LE; DIKMEN SS, 1993, J HEAD TRAUMA REHAB, V8, P30, DOI DOI 10.1097/00001199-199309000-00005; First M.B., 1996, STRUCTURED CLIN INTE; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; GOLDSTEIN FC, 1994, J NEUROL NEUROSUR PS, V57, P961, DOI 10.1136/jnnp.57.8.961; Goldstein FC, 2001, J INT NEUROPSYCH SOC, V7, P373, DOI 10.1017/S1355617701733115; Goldstein FC, 1999, J NEUROPSYCH CLIN N, V11, P38, DOI 10.1176/jnp.11.1.38; Heaton R., 1993, WISCONSIN CARD SORTI; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORM AF, 1991, PSYCHOL MED, V21, P785, DOI 10.1017/S0033291700022418; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Lavretsky H, 2002, AM J GERIAT PSYCHIAT, V10, P239, DOI 10.1176/appi.ajgp.10.3.239; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; Mattis S, 1976, GERIATRIC PSYCHIAT, P77; MAZZUCCHI A, 1992, J NEUROL, V239, P256; McCullagh S, 2003, J NEUROL NEUROSUR PS, V74, P39, DOI 10.1136/jnnp.74.1.39; MCCULLAGH S, 2004, NEUROPSYCHIAT TBI; MCCULLAGH S, 2002, J NEUROPSYCH CLIN N, V14, P116; MILLER MD, 1992, PSYCHIAT RES, V41, P237, DOI 10.1016/0165-1781(92)90005-N; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; NAYAK AK, 1980, J NEUROL SCI, V47, P211, DOI 10.1016/0022-510X(80)90005-2; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; PFEFFER RI, 1982, J GERONTOL, V37, P323, DOI 10.1093/geronj/37.3.323; *PSYCH CORP, 1997, WECHSL ADULT INT SCA; Rapoport M, 2002, NEUROPSY NEUROPSY BE, V15, P123, DOI 10.1097/01.WNN.0000016801.80266.36; Rapoport MJ, 2003, AM J GERIAT PSYCHIAT, V11, P365, DOI 10.1176/appi.ajgp.11.3.365; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; Rothweiler B, 1998, ARCH PHYS MED REHAB, V79, P881, DOI 10.1016/S0003-9993(98)90082-X; SILVER JM, 1994, SYNOPSIS NEUROPSYCHI, P279; SOSIN DM, 1991, BRAIN INJURY, V10, P47, DOI DOI 10.1080/026990596124719; Spreen O., 1998, COMPENDIUM NEUROPSYC; Tabert MH, 2002, NEUROLOGY, V58, P758, DOI 10.1212/WNL.58.5.758	40	41	44	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1064-7481	1545-7214		AM J GERIAT PSYCHIAT	Am. J. Geriatr. Psychiatr.	MAY	2006	14	5					456	465		10.1097/01.JGP.0000199339.79689.8a			10	Geriatrics & Gerontology; Gerontology; Psychiatry	Geriatrics & Gerontology; Psychiatry	038RC	WOS:000237239700009	16670250				2021-06-18	
J	Peleg, K; Rivkind, A; Aharonson-Damel, L				Peleg, K; Rivkind, A; Aharonson-Damel, L		Israeli Trauma Grp	Does body armor protect from firearm injuries?	JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS			English	Article							PERSONAL ARMOR; BATTLEFIELD; CASUALTIES; WARFARE; WOUNDS; IRAQ	BACKGROUND: Bullet-p roof vests and helmets protect from harm in combat and military engagements. The use of armor against shrapnel has been studied, yet little has been documented as to how they protect from high velocity, gunshots. This study aims to describe the medical consequences of high velocity Firearm Injuries and to differentiate between patients injured while using protective wear and those injured unprotected. STUDY DESIGN: National trauma registry, data oil injury, characteristics, treatment and outcomes between October 1, 2000 and December 31, 2003 were retrieved and analyzed. RESULTS: There were 669 terror-related Firearm injuries recorded: 236 (37.8%) in soldiers (protected) and 433 (62.2%) In civilians (unprotected). Injury severity was notably, higher in civilian patients (31% versus 16% with Injury, Severity Score 16). Civilians had more ICU care (26% versus 20%, p = 0.06), and double the inpatient mortality (8.6% [n = 37] versus 3.4% (n = 81 patients). Protected body, regions Such as abdomen, chest, and brain, were injured less frequently Once a traumatic brain injury was sustained, no statistical differences were found ill severity distribution, ICU stay, or inpatient death between protected and unprotected patients. But injury, severity, in patients with chest Injuries was Much higher in those who were unprotected (Injury Severity Score >= 25, 41% versus 23%, respectively, p = 0.08). This increased severity could be attributed partly to more multiple injuries involving the chest. Abdominal injuries showed a similar pattern. CONCLUSIONS: Body armor has a protective effect on victims of high velocity, gunshot wounds; lower rates of head, brain, chest, and abdominal injuries are seen. In addition, armor reduces the severity of injuries to the chest and the abdomen. (J Am Coll Surg 2006;202:643-648. (c) 2006 by the American College of Surgeons).	Chaim Sheba Med Ctr, Gertner Inst Epidemiol & Hlth Policy Res, Israel Natl Ctr Trauma & Emergency Med Res, IL-52621 Tel Hashomer, Israel; Hadassah Hebrew Univ Hosp, Dept Gen Surg, Jerusalem, Israel; Hadassah Hebrew Univ Hosp, Shock Trauma Unit, Jerusalem, Israel	Peleg, K (corresponding author), Chaim Sheba Med Ctr, Gertner Inst Epidemiol & Hlth Policy Res, Israel Natl Ctr Trauma & Emergency Med Res, IL-52621 Tel Hashomer, Israel.		Aharonson-Daniel, Limor/F-1998-2012	Aharonson-Daniel, Limor/0000-0003-4585-6892			BELLAMY RF, 1984, MIL MED, V149, P55; Gofrit ON, 1996, INJURY, V27, P577, DOI 10.1016/S0020-1383(96)00072-1; Gondusky JS, 2005, MIL MED, V170, P546, DOI 10.7205/MILMED.170.6.546; Kosashvili Y, 2005, J TRAUMA, V58, P1236, DOI 10.1097/01.TA.0000169804.17603.76; LEITH RA, 1997, ANAL CASUALTY RATES; Mabry RL, 2000, J TRAUMA, V49, P515, DOI 10.1097/00005373-200009000-00021; MAUGHON JS, 1970, MIL MED, V135, P8; Xydakis MS, 2005, OTOLARYNG HEAD NECK, V133, P497, DOI 10.1016/j.otohns.2005.07.003; ZAJTCHUK BG, 1997, TXB MILITARY MED	9	41	44	0	12	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1072-7515			J AM COLL SURGEONS	J. Am. Coll. Surg.	APR	2006	202	4					643	648		10.1016/j.jamcollsurg.2005.12.019			6	Surgery	Surgery	028HE	WOS:000236476900014	16571436				2021-06-18	
J	Preusser, M; Strobel, T; Gelpi, E; Eiler, M; Broessner, G; Schmutzhard, E; Budka, H				Preusser, M; Strobel, T; Gelpi, E; Eiler, M; Broessner, G; Schmutzhard, E; Budka, H			Alzheimer-type neuropathology in a 28 year old patient with iatrogenic Creutzfeldt-Jakob disease after dural grafting	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							HEAD-INJURY; AMYLOID PLAQUES; BETA-PROTEIN; BRAIN-INJURY; COEXISTENCE; INFECTIONS; DEPOSITION; PATHOLOGY; DEMENTIA; OVERLAP	We report the case of a 28 year old man who had received a cadaverous dura mater graft after a traumatic open skull fracture with tearing of the dura at the age of 5 years. A clinical suspicion of Creutzfeldt-Jakob disease (CJD) was confirmed by a brain biopsy 5 months prior to death and by autopsy, thus warranting the diagnosis of iatrogenic CJD (iCJD) according to WHO criteria. Immunohistochemistry showed widespread cortical depositions of disease associated prion protein (PrPsc) in a synaptic pattern, and western blot analysis identified PrPsc of type 2A according to Parchi et al. Surprisingly, we found Alzheimer-type senile plaques and cerebral amyloid angiopathy in widespread areas of the brain. Plaque-type and vascular amyloid was immunohistochemically identified as deposits of beta-A4 peptide. CERAD criteria for diagnosis of definite Alzheimer's disease ( AD) were met in the absence of neurofibrillar tangles or alpha-synuclein immunoreactive inclusions. There was no family history of AD, CJD, or any other neurological disease, and genetic analysis showed no disease specific mutations of the prion protein, presenilin 1 and 2, or amyloid precursor protein genes. This case represents (a) the iCJD case with the longest incubation time after dural grafting reported so far, (b) the youngest documented patient with concomitant CJD and Alzheimer-type neuropathology to date, (c) the first description of Alzheimer-type changes in iCJD, and (d) the second case of iCJD in Austria. Despite the young patient age, the Alzheimer-type changes may be an incidental finding, possibly related to the childhood trauma.	Med Univ Vienna, Inst Neurol, A-1097 Vienna, Austria; Gen Hosp Vienna, Austrian Reference Ctr Human Prion Dis, Vienna, Austria; LKH Rankweil, Dept Neurol, Rankweil, Austria; Med Univ Innbruck, Dept Neurol, Innsbruck, Austria	Budka, H (corresponding author), Med Univ Vienna, Inst Neurol, Waehringer Guertel 18-20,4J, A-1097 Vienna, Austria.	herbert.budka@kin.at	Preusser, Matthias/C-8530-2011; Budka, Herbert/I-3486-2019	Budka, Herbert/0000-0002-1933-1577; Preusser, Matthias/0000-0003-3541-2315			BARCIKOWSKA M, 1995, HISTOPATHOLOGY, V26, P445; Braak H, 1997, NEUROBIOL AGING, V18, P351, DOI 10.1016/S0197-4580(97)00056-0; Brown P, 2000, NEUROLOGY, V55, P1075, DOI 10.1212/WNL.55.8.1075; BROWN P, 1990, NEUROLOGY, V40, P226, DOI 10.1212/WNL.40.2.226; BUGIANI O, 1993, J NEUROPATH EXP NEUR, V52, P64, DOI 10.1097/00005072-199301000-00008; Castellani RJ, 2004, ACTA NEUROBIOL EXP, V64, P11; Cruts M, 1998, HUM MOL GENET, V7, P43, DOI 10.1093/hmg/7.1.43; DEARMOND SJ, 1993, CURR OPIN NEUROL, V6, P872, DOI 10.1097/00019052-199312000-00008; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; GAJDUSEK DC, 1994, ANN NY ACAD SCI, V724, P173, DOI 10.1111/j.1749-6632.1994.tb38909.x; Gentleman SM, 1997, NEUROREPORT, V8, P1519, DOI 10.1097/00001756-199704140-00039; GRAY F, 1994, ACTA NEUROPATHOL, V88, P106, DOI 10.1007/BF00294366; Hainfellner JA, 1998, ACTA NEUROPATHOL, V96, P116, DOI 10.1007/s004010050870; Horsburgh K, 2000, NEUROPATH APPL NEURO, V26, P124, DOI 10.1046/j.1365-2990.2000.026002124.x; Hyman BT, 1997, J NEUROPATH EXP NEUR, V56, P1095, DOI 10.1097/00005072-199710000-00002; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Jellinger KA, 2004, CURR OPIN NEUROL, V17, P719, DOI 10.1097/00019052-200412000-00012; Jellinger KA, 2001, EUR J NEUROL, V8, P707, DOI 10.1046/j.1468-1331.2001.00322.x; Kretzschmar HA, 2003, BRAIN PATHOL, V13, P245; LIBERSKI PP, 1987, ACTA NEUROL SCAND, V76, P428, DOI 10.1111/j.1600-0404.1987.tb03598.x; MASTERS CL, 1988, CIBA F SYMP, V135, P24; MASTERS CL, 1981, BRAIN, V104, P535, DOI 10.1093/brain/104.3.535; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; MIYAZONO M, 1992, ACTA NEUROPATHOL, V83, P333, DOI 10.1007/BF00713522; MURAMOTO T, 1992, ACTA NEUROPATHOL, V84, P686; Parchi P, 1999, ANN NEUROL, V46, P224, DOI 10.1002/1531-8249(199908)46:2<224::AID-ANA12>3.0.CO;2-W; POWERS JM, 1991, ACTA NEUROPATHOL, V83, P95, DOI 10.1007/BF00294437; Radbauer C, 1998, WIEN KLIN WOCHENSCHR, V110, P496; Revesz T, 2003, J NEUROPATH EXP NEUR, V62, P885, DOI 10.1093/jnen/62.9.885; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Rocchi A, 2003, BRAIN RES BULL, V61, P1, DOI 10.1016/S0361-9230(03)00067-4; WATSON CP, 1979, ANN NEUROL, V6, P368, DOI 10.1002/ana.410060415; WONG CW, 1985, P NATL ACAD SCI USA, V82, P8729, DOI 10.1073/pnas.82.24.8729	33	41	41	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	MAR	2006	77	3					413	416		10.1136/jnnp.2005.070805			4	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	016WK	WOS:000235651900034	16484658	Green Published			2021-06-18	
J	Saunders, JC; McDonald, S; Richardson, R				Saunders, JC; McDonald, S; Richardson, R			Loss of emotional experience after traumatic brain injury: Findings with the startle probe procedure	NEUROPSYCHOLOGY			English	Article						traumatic brain injury; affective processing; startle reflex	HEAD-INJURY; AFFECTIVE MODULATION; REFLEX MODIFICATION; FACIAL EXPRESSIONS; SOCIAL-PERCEPTION; LOBE DAMAGE; RECOGNITION; ATTENTION; BLINK; FACES	The authors used affective modulation of the eyeblink startle response to examine the impact of traumatic brain injury (TBI) on emotional reactions to pictures. Participants were 13 individuals with severe TBI and 24 controls. Participants were presented with pictures that differed in affective valence (e.g., mutilated bodies, erotic couples, and household objects) while the eyeblink startle response to an acoustic probe was measured. Startle amplitude was used to assess valence of emotional response, and startle latency was used to index interest in the pictures. Subjective ratings of the affect and arousal elicited by the various pictures were also obtained. TBI impaired startle potentiation to unpleasant pictures but not startle attenuation to pleasant pictures. Further, subjective ratings indicated that TBI participants found unpleasant pictures less arousing than did controls. The results are consistent with recent evidence of differential impairment in negative versus positive emotions after TBI and are discussed in relation to 2 competing explanations of startle modulation.	Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia	McDonald, S (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.	s.mcdonald@unsw.edu.au	McDonald, Skye/G-4118-2014	McDonald, Skye/0000-0003-0723-6094; Richardson, Rick/0000-0003-1833-9777			Adolphs R, 1996, J NEUROSCI, V16, P7678; ADOLPHS R, 1995, J NEUROSCI, V15, P5879; Adolphs Ralph, 2002, Behav Cogn Neurosci Rev, V1, P21, DOI 10.1177/1534582302001001003; Angrilli A, 1996, BRAIN, V119, P1991, DOI 10.1093/brain/119.6.1991; ANTHONY BJ, 1985, BIOL PSYCHOL, V21, P43, DOI 10.1016/0301-0511(85)90052-3; BERG WK, 1999, STARTLE MODIFICATION, P21, DOI DOI 10.1017/CB09780511665523.004; Borod J., 1993, NEUROPSYCHOLOGY, V7, P445, DOI DOI 10.1037/0894-4105.7.4.445; BOROD JC, 1992, J CONSULT CLIN PSYCH, V60, P339, DOI 10.1037/0022-006X.60.3.339; BRADLEY MM, 1990, PSYCHOPHYSIOLOGY, V27, P513, DOI 10.1111/j.1469-8986.1990.tb01966.x; Bradley MM, 1999, STARTLE MODIFICATION, DOI DOI 10.1017/CBO9780511665523.010; Buchanan TW, 2004, BEHAV NEUROSCI, V118, P429, DOI 10.1037/0735-7044.118.2.429; Calder AJ, 2000, NAT NEUROSCI, V3, P1077, DOI 10.1038/80586; Cook E.W., 1999, STARTLE MODIFICATION, P187; COOK EW, 1991, J ABNORM PSYCHOL, V100, P3; COURVILLE CB, 1945, PATHLOGY NERVOUS SYS; Croker V, 2005, BRAIN INJURY, V19, P787, DOI 10.1080/02699050500110033; DAMASIO AR, 1990, BEHAV BRAIN RES, V41, P81, DOI 10.1016/0166-4328(90)90144-4; Davidson RJ, 1999, TRENDS COGN SCI, V3, P11, DOI 10.1016/S1364-6613(98)01265-0; Davis M, 1999, STARTLE MODIFICATION, P95, DOI [10.1017/CB09780511665523.007, DOI 10.1017/CBO9780511665523.007]; DIMBERG U, 1990, PSYCHOPHYSIOLOGY, V27, P481, DOI 10.1111/j.1469-8986.1990.tb01962.x; Ekman P., 1976, PICTURES FACIAL AFFE; FRIDLUND AJ, 1986, PSYCHOPHYSIOLOGY, V23, P567, DOI 10.1111/j.1469-8986.1986.tb00676.x; Funayama ES, 2001, J COGNITIVE NEUROSCI, V13, P721, DOI 10.1162/08989290152541395; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; Green REA, 2004, NEUROPSYCHOLOGIA, V42, P133, DOI 10.1016/j.neuropsychologia.2003.07.005; Grillon C, 2003, CLIN NEUROPHYSIOL, V114, P1557, DOI 10.1016/S1388-2457(03)00202-5; HADLEY DM, 1988, CLIN RADIOL, V39, P131; Hamm AO, 1997, PSYCHOPHYSIOLOGY, V34, P97, DOI 10.1111/j.1469-8986.1997.tb02420.x; Harmer CJ, 2001, NAT NEUROSCI, V4, P17, DOI 10.1038/82854; Hopkins MJ, 2002, BRAIN INJURY, V16, P245, DOI 10.1080/02699050110103346; Hornak J, 1996, NEUROPSYCHOLOGIA, V34, P247, DOI 10.1016/0028-3932(95)00106-9; JACKSON HF, 1987, CORTEX, V23, P293, DOI 10.1016/S0010-9452(87)80039-4; Koch M, 1996, NEUROREPORT, V7, P1442, DOI 10.1097/00001756-199605310-00024; Lacey J.I., 1967, PSYCHOL STRESS ISSUE, P4; Lang P. J., 1997, INT AFFECTIVE PICTUR; LANG PJ, 1990, PSYCHOL REV, V97, P377, DOI 10.1037/0033-295X.97.3.377; LANG PJ, 1995, AM PSYCHOL, V50, P372, DOI 10.1037/0003-066X.50.5.372; LANG PJ, 1999, A4 CTR RES PSYCH U F; LeDoux JE, 2000, ANNU REV NEUROSCI, V23, P155, DOI 10.1146/annurev.neuro.23.1.155; Levenston GK, 2000, J ABNORM PSYCHOL, V109, P373, DOI 10.1037//0021-843X.109.3.373; LEY RG, 1979, BRAIN LANG, V7, P127, DOI 10.1016/0093-934X(79)90010-5; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; McDonald S, 2003, J HEAD TRAUMA REHAB, V18, P219, DOI 10.1097/00001199-200305000-00001; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; PATRICK CJ, 1993, J ABNORM PSYCHOL, V102, P82, DOI 10.1037/0021-843X.102.1.82; Phillips ML, 2003, BIOL PSYCHIAT, V54, P504, DOI 10.1016/S0006-3223(03)00168-9; Prigatano GP, 1986, NEUROPSYCHOL REHABIL, P29; REUTERLORENZ P, 1981, NEUROPSYCHOLOGIA, V19, P609, DOI 10.1016/0028-3932(81)90030-0; SCHLENKER R, 1995, EUR ARCH PSY CLIN N, V245, P309, DOI 10.1007/BF02191873; Spell LA, 2000, J NONVERBAL BEHAV, V24, P285, DOI 10.1023/A:1006675230193; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; Vanman EJ, 1998, PERS SOC PSYCHOL B, V24, P994, DOI 10.1177/0146167298249007; VRANA SR, 1988, J ABNORM PSYCHOL, V97, P487, DOI 10.1037/0021-843X.97.4.487; Wild B, 2001, PSYCHIAT RES, V102, P109, DOI 10.1016/S0165-1781(01)00225-6; Yeomans JS, 1995, BRAIN RES REV, V21, P301, DOI 10.1016/0165-0173(96)00004-5	56	41	41	0	3	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	MAR	2006	20	2					224	231		10.1037/0894-4105.20.2.224			8	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	031IW	WOS:000236699000010	16594783				2021-06-18	
J	Sinha, K; Karimi-Abdolrezaee, S; Velumian, AA; Fehlings, MG				Sinha, K; Karimi-Abdolrezaee, S; Velumian, AA; Fehlings, MG			Functional changes in genetically dysmyelinated spinal cord axons of shiverer mice: Role of juxtaparanodal Kv1 family K+ channels	JOURNAL OF NEUROPHYSIOLOGY			English	Article							MYELIN BASIC-PROTEIN; GATED POTASSIUM CHANNELS; CENTRAL-NERVOUS-SYSTEM; MAJOR DENSE LINE; MUTANT MOUSE; HYPOMYELINATED AXONS; PARANODAL JUNCTIONS; CONDUCTION-BLOCK; XENOPUS OOCYTES; SCHWANN-CELLS	Axonal dysfunction after spinal cord injury (SCI) and other types of neurotrauma is associated with demyelination and exposure of juxtaparanodal K+ channels. In this study, sucrose gap electrophysiology using selective and nonselective K+ channel blockers, confocal immunohistochemistry, and Western blotting were used to study the role of Kv1.1 and Kv1.2 K+ channel subunits in dysmyelination-induced spinal cord axonal dysfunction in shiverer mice, which lack the gene encoding myelin basic protein (MBP) and exhibit incomplete myelin sheath formation on CNS axons. The shiverer spinal cord axons exhibited smaller amplitude of compound action potentials (CAPs), reduced conduction velocity, reduced excitability, and greater degree of high-frequency conduction failure. The "fast" K+ channel blocker 4-aminopyridine, the toxin DTX-I, which targets the Kv1.1 and Kv1.2, but not DTX-K, which has higher selectivity for Kv1.1, increased the amplitude and area of CAPs of shiverer mice spinal cord axons but had insignificant effects in wild-type mice. Confocal immunohistochemistry showed that, unlike wild-type mice, which have a precise juxtaparanodal localization of the Kv1.l and Kv1.2 K+ channel subunits, shiverer mouse axons displayed a dispersed distribution of these subunits along the internodes. In contrast, the Kv1. l and Kv1.2 subunits, Na+ channels remained highly localized to the nodal regions. Western blotting showed an increased expression of Kv 1.1 and 1.2 in the shiverer mouse spinal cord. These results provide evidence that the neurological deficits associated with myelin deficiency reflect the altered distribution and expression of the K+ channel subunits Kv1. l and Kv1.2 along the internodes of spinal cord axons associated with the biophysical consequences caused by alterations in the myelin sheaths.	Univ Toronto, Toronto Western Hosp, Univ Hlth Network,Toronto Western Res Inst, Krembil Neurosci Ctr,Div Cell & Mol Biol, Toronto, ON M5T 2S8, Canada; Univ Toronto, Dept Surg, Div Neurosurg, Toronto, ON M5T 2S8, Canada; Univ Toronto, Inst Med Sci, Toronto, ON M5T 2S8, Canada	Fehlings, MG (corresponding author), Univ Toronto, Toronto Western Hosp, Univ Hlth Network, Div Neurosurg, Rm 4W-449,399 Bathurst St, Toronto, ON M5T 2S8, Canada.	michael.fehlings@uhn.on.ca		Karimi-Abdolrezaee, Soheila/0000-0002-0683-2663; Fehlings, Michael/0000-0002-5722-6364			Agrawal SK, 1996, J NEUROSCI, V16, P545; Arroyo EJ, 2002, J NEUROSCI, V22, P1726, DOI 10.1523/JNEUROSCI.22-05-01726.2002; BAKER M, 1987, J PHYSIOL-LONDON, V383, P45; Baumann N, 2001, PHYSIOL REV, V81, P871; BEMENT SL, 1969, EXP NEUROL, V24, P147, DOI 10.1016/0014-4886(69)90012-0; Bhat MA, 2001, NEURON, V30, P369, DOI 10.1016/S0896-6273(01)00294-X; BLIGHT AR, 1989, BRAIN RES BULL, V22, P47, DOI 10.1016/0361-9230(89)90126-3; BLIGHT AR, 1986, NEUROSCIENCE, V19, P321, DOI 10.1016/0306-4522(86)90025-4; Boiko T, 2001, NEURON, V30, P91, DOI 10.1016/S0896-6273(01)00265-3; Boyle MET, 2001, NEURON, V30, P385, DOI 10.1016/S0896-6273(01)00296-3; CHERNOFF GF, 1981, J HERED, V72, P128, DOI 10.1093/oxfordjournals.jhered.a109442; Chiu S Y, 1981, Adv Neurol, V31, P313; CHIU SY, 1980, NATURE, V284, P170, DOI 10.1038/284170a0; Coetzee T, 1996, CELL, V86, P209, DOI 10.1016/S0092-8674(00)80093-8; Devaux JJ, 2005, J NEUROSCI, V25, P1470, DOI 10.1523/JNEUROSCI.3328-04.2005; Dodson PD, 2003, J PHYSIOL-LONDON, V550, P27, DOI 10.1113/jphysiol.2003.046250; DUBOIS JM, 1981, J PHYSIOL-LONDON, V318, P297; DUPOUEY P, 1979, NEUROSCI LETT, V12, P113, DOI 10.1016/0304-3940(79)91490-3; Eftekharpour E, 2005, EXP NEUROL, V193, P334, DOI 10.1016/j.expneurol.2005.01.019; Einheber S, 1997, J CELL BIOL, V139, P1495, DOI 10.1083/jcb.139.6.1495; ERLANGER JGH, 1937, ELECT SIGNS NERVOUS, P1221; Fehlings MG, 1997, J NEUROSCI METH, V71, P215, DOI 10.1016/S0165-0270(96)00147-1; Fehlings MG, 1996, BRAIN RES, V736, P135, DOI 10.1016/0006-8993(96)00667-1; HANSEBOUT RR, 1993, J NEUROTRAUM, V10, P1, DOI 10.1089/neu.1993.10.1; HAYES KC, 1994, J NEUROTRAUM, V11, P433, DOI 10.1089/neu.1994.11.433; Honmou O, 1996, J NEUROSCI, V16, P3199; Hopkins WF, 1998, J PHARMACOL EXP THER, V285, P1051; HUDSON LD, 1990, SEMIN NEUROSCI, V2, P483; Ishibashi T, 2002, J NEUROSCI, V22, P6507; Jenkins SM, 2002, P NATL ACAD SCI USA, V99, P2303, DOI 10.1073/pnas.042601799; Jensen JM, 2003, J NEUROPHYSIOL, V90, P2334, DOI 10.1152/jn.00868.2002; Karimi-Abdolrezaee S, 2004, EUR J NEUROSCI, V19, P577, DOI 10.1111/j.0953-816X.2004.03164.x; KATSUKI M, 1988, SCIENCE, V241, P593, DOI 10.1126/science.2456614; KIRSCHNER DA, 1980, NATURE, V283, P207, DOI 10.1038/283207a0; MACKLIN WB, 1987, FEBS LETT, V223, P417, DOI 10.1016/0014-5793(87)80331-9; Marcus J, 2002, BBA-GEN SUBJECTS, V1573, P406, DOI 10.1016/S0304-4165(02)00410-5; Marcus J, 2002, J CELL BIOL, V156, P567, DOI 10.1083/jcb.200111047; Mathis C, 2001, DEVELOPMENT, V128, P4881; McDonald JW, 2000, NAT MED, V6, P358, DOI 10.1038/74759; MEDIRATTA NK, 1983, J PHYSIOL-LONDON, V336, P545, DOI 10.1113/jphysiol.1983.sp014597; Menegoz M, 1997, NEURON, V19, P319, DOI 10.1016/S0896-6273(00)80942-3; MOLINEAUX SM, 1986, P NATL ACAD SCI USA, V83, P7542, DOI 10.1073/pnas.83.19.7542; NADON NL, 1990, DEVELOPMENT, V110, P529; Nashmi R, 2000, EUR J NEUROSCI, V12, P491, DOI 10.1046/j.1460-9568.2000.00926.x; Nashmi R, 2001, NEUROSCIENCE, V104, P235, DOI 10.1016/S0306-4522(01)00009-4; Nashmi R, 2001, BRAIN RES REV, V38, P165, DOI 10.1016/S0165-0173(01)00134-5; Nie DY, 2003, EMBO J, V22, P5666, DOI 10.1093/emboj/cdg570; NOEBELS JL, 1991, NATURE, V352, P431, DOI 10.1038/352431a0; Peles E, 2000, CURR OPIN NEUROBIOL, V10, P558, DOI 10.1016/S0959-4388(00)00122-7; Poliak S, 2003, J CELL BIOL, V162, P1149, DOI 10.1083/jcb.200305018; Poliak S, 2003, NAT REV NEUROSCI, V4, P968, DOI 10.1038/nrn1253; PRIVAT A, 1979, NEUROSCI LETT, V12, P107, DOI 10.1016/0304-3940(79)91489-7; Rasband M, 1998, J NEUROSCI, V18, P36; Rasband MN, 1999, J NEUROCYTOL, V28, P319, DOI 10.1023/A:1007057512576; Rasband MN, 1999, J NEUROSCI, V19, P7516, DOI 10.1523/JNEUROSCI.19-17-07516.1999; READHEAD C, 1987, CELL, V48, P703, DOI 10.1016/0092-8674(87)90248-0; READHEAD C, 1991, HUM REPROD, V6, P93, DOI 10.1093/oxfordjournals.humrep.a137265; Rios JC, 2000, J NEUROSCI, V20, P8354, DOI 10.1523/JNEUROSCI.20-22-08354.2000; ROACH A, 1985, CELL, V42, P1049; Robertson B, 1996, FEBS LETT, V383, P26, DOI 10.1016/0014-5793(96)00211-6; ROSENBLUTH J, 1980, J COMP NEUROL, V194, P639, DOI 10.1002/cne.901940310; Rosenbluth J, 2003, GLIA, V41, P318, DOI 10.1002/glia.10179; Shi RY, 1997, EXP NEUROL, V148, P495, DOI 10.1006/exnr.1997.6706; Sobko A, 1998, J NEUROSCI, V18, P10398; Tait S, 2000, J CELL BIOL, V150, P657, DOI 10.1083/jcb.150.3.657; TARG EF, 1985, BRAIN RES, V328, P358, DOI 10.1016/0006-8993(85)91049-2; TYTGAT J, 1995, J BIOL CHEM, V270, P24776, DOI 10.1074/jbc.270.42.24776; UTZSCHNEIDER DA, 1994, P NATL ACAD SCI USA, V91, P53, DOI 10.1073/pnas.91.1.53; VIGNAIS L, 1993, INT J DEV NEUROSCI, V11, P603, DOI 10.1016/0736-5748(93)90049-J; Vitry S, 2003, J NEUROSCI, V23, P10724; Wang H, 1995, NEURON, V15, P1337, DOI 10.1016/0896-6273(95)90012-8; WEST DC, 1983, J PHYSIOL-LONDON, V337, P37, DOI 10.1113/jphysiol.1983.sp014610; WESTENBROEK RE, 1992, J NEUROSCI, V12, P2259, DOI 10.1523/jneurosci.12-06-02259.1992	73	41	41	0	10	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-3077	1522-1598		J NEUROPHYSIOL	J. Neurophysiol.	MAR	2006	95	3					1683	1695		10.1152/jn.00899.2005			13	Neurosciences; Physiology	Neurosciences & Neurology; Physiology	014KE	WOS:000235477900036	16319208				2021-06-18	
J	Staszewski, RD; Yamamoto, BK				Staszewski, RD; Yamamoto, BK			Methamphetamine-induced spectrin proteolysis in the rat striatum	JOURNAL OF NEUROCHEMISTRY			English	Article						calpain; excitotoxicity; glutamate; methamphetamine; spectrin	INDUCED DOPAMINERGIC NEUROTOXICITY; TRANSIENT FOREBRAIN ISCHEMIA; FOCAL CEREBRAL-ISCHEMIA; EXCITATORY AMINO-ACIDS; TRAUMATIC BRAIN-INJURY; ALPHA-II-SPECTRIN; GLUTAMATE RECEPTORS; GLOBAL-ISCHEMIA; EXTRACELLULAR CONCENTRATIONS; SEPTOHIPPOCAMPAL CULTURES	Methamphetamine (METH) is a widely abused psychostimulant. Multiple high doses of METH cause long-term toxicity to dopamine (DA) and serotonin (5-HT) nerve terminals in the brain, as evidenced by decreases in DA and 5-HT content, decreases in tyrosine and tryptophan hydroxylase activities, decreases in DA and 5-HT re-uptake sites, and nerve terminal degeneration. Multiple high doses of METH are known to elicit a rapid increase in DA release and hyperthermia. Although METH also produces a delayed and sustained rise in glutamate, no studies have shown whether METH produces structural evidence of excitotoxicity in striatum, or identified the receptors that mediate this toxicity directly, independent of alterations in METH-induced hyperthermia. These experiments investigated whether METH can cause excitotoxicity as evidenced by cytoskeletal protein breakdown in a glutamate receptor-dependent manner. METH increased calpain-mediated spectrin proteolysis in the rat striatum 5 and 7 days after METH administration without affecting caspase 3-dependent spectrin breakdown. This effect was completely blocked with the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist, GYKI 52466, but not the NMDA receptor antagonist, MK-801. However, AMPA or NMDA receptor antagonism did not attenuate the METH-induced depletions of the dopamine transporter (DAT). Independent mechanisms involved in mediating spectrin proteolysis and DAT protein loss are discussed.	Boston Univ, Sch Med, Dept Pharmacol, Neurochem Lab, Boston, MA 02118 USA	Yamamoto, BK (corresponding author), Boston Univ, Sch Med, Dept Pharmacol, Neurochem Lab, Boston, MA 02118 USA.	bkyam@bu.edu	Yamamoto, Bryan/Z-1050-2019		NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA007606] Funding Source: NIH RePORTER; NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA07606] Funding Source: Medline		ABEKAWA T, 1994, BRAIN RES, V643, P276, DOI 10.1016/0006-8993(94)90033-7; Abellan MT, 2000, EUR NEUROPSYCHOPHARM, V10, P455, DOI 10.1016/S0924-977X(00)00118-8; Albers DS, 1995, J PHARMACOL EXP THER, V275, P1104; ALI SF, 1994, BRAIN RES, V658, P33, DOI 10.1016/S0006-8993(09)90007-5; ARVIN B, 1994, J NEUROCHEM, V62, P1458; BAKHIT C, 1981, NEUROPHARMACOLOGY, V20, P1135, DOI 10.1016/0028-3908(81)90053-8; Bartus RT, 1998, BRAIN RES, V790, P1, DOI 10.1016/S0006-8993(97)01414-5; Battaglia G, 2002, J NEUROSCI, V22, P2135, DOI 10.1523/JNEUROSCI.22-06-02135.2002; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Betarbet R, 1999, EXP NEUROL, V159, P401, DOI 10.1006/exnr.1999.7154; Block F, 1996, J NEUROL SCI, V139, P167; BOWYER JF, 1994, J PHARMACOL EXP THER, V268, P1571; Buki A, 1999, EXP NEUROL, V159, P319, DOI 10.1006/exnr.1999.7139; Burrows Kristan B., 2003, P211; Chapman DE, 2001, J PHARMACOL EXP THER, V296, P520; Dunah AW, 2000, MOL PHARMACOL, V57, P342; Fan XD, 1999, BRAIN RES, V850, P79, DOI 10.1016/S0006-8993(99)02106-X; Fleckenstein AE, 1997, EUR J PHARMACOL, V334, P111, DOI 10.1016/S0014-2999(97)01175-8; Fleckenstein AE, 1997, J PHARMACOL EXP THER, V283, P281; GIBB JW, 1979, N-S ARCH PHARMACOL, V310, P185, DOI 10.1007/BF00500283; Golembiowska K, 2003, NEUROPHARMACOLOGY, V45, P484, DOI 10.1016/S0028-3908(03)00209-0; GREEN AR, 1992, NEUROPHARMACOLOGY, V31, P315, DOI 10.1016/0028-3908(92)90062-T; Harold C, 2000, EUR J PHARMACOL, V400, P99, DOI 10.1016/S0014-2999(00)00392-7; HARRIS AS, 1988, J NEUROSCI, V8, P2640; Hernandez LF, 2003, NEUROCHEM RES, V28, P1819, DOI 10.1023/A:1026115607216; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; HOTCHKISS AJ, 1979, LIFE SCI, V25, P1373, DOI 10.1016/0024-3205(79)90414-4; Itzhak Y, 2000, NEUROREPORT, V11, P2943, DOI 10.1097/00001756-200009110-00022; Jayanthi S, 2004, FASEB J, V18, P238, DOI 10.1096/fj.03-0295com; KEEFE KA, 1993, J NEURAL TRANSM-GEN, V91, P223, DOI 10.1007/BF01245233; Kitagawa K, 1999, J NEUROSCI RES, V55, P643, DOI 10.1002/(SICI)1097-4547(19990301)55:5<643::AID-JNR11>3.0.CO;2-V; Lai SK, 2003, NEUROCHEM INT, V43, P639, DOI 10.1016/S0197-0186(03)00080-9; LaVoie MJ, 1999, J NEUROSCI, V19, P1484, DOI 10.1523/jneurosci.19-04-01484.1999; LEE KS, 1991, P NATL ACAD SCI USA, V88, P7233, DOI 10.1073/pnas.88.16.7233; LEPEILLET E, 1992, BRAIN RES, V571, P115; Lu T, 2002, BBA-MOL CELL RES, V1590, P16, DOI 10.1016/S0167-4889(02)00193-3; McGinnis KM, 1998, J BIOL CHEM, V273, P19993, DOI 10.1074/jbc.273.32.19993; Minger SL, 1998, BRAIN RES, V810, P181, DOI 10.1016/S0006-8993(98)00921-4; Morimoto T, 1997, BRAIN RES, V746, P43, DOI 10.1016/S0006-8993(96)01154-7; NASH JF, 1992, BRAIN RES, V581, P237, DOI 10.1016/0006-8993(92)90713-J; ODELL SJ, 1991, BRAIN RES, V564, P256, DOI 10.1016/0006-8993(91)91461-9; OHTA K, 1994, NEUROSCI RES, V21, P83, DOI 10.1016/0168-0102(94)90071-X; Pike BR, 2004, J CEREBR BLOOD F MET, V24, P98, DOI 10.1097/01.WCB.0000098520.11962.37; Pike BR, 2001, J NEUROCHEM, V78, P1297, DOI 10.1046/j.1471-4159.2001.00510.x; Pike BR, 1998, J NEUROSCI RES, V52, P505, DOI 10.1002/(SICI)1097-4547(19980601)52:5<505::AID-JNR3>3.3.CO;2-Y; RICAURTE GA, 1982, BRAIN RES, V235, P93, DOI 10.1016/0006-8993(82)90198-6; Sakai K, 1997, NEUROCHEM INT, V30, P329, DOI 10.1016/S0197-0186(96)00047-2; SCHMIDT CJ, 1985, NEUROCHEM RES, V10, P637, DOI 10.1007/BF00964403; Segovia G, 1997, J NEUROCHEM, V69, P1476; SEIDEN LS, 1988, ANN NY ACAD SCI, V537, P161, DOI 10.1111/j.1749-6632.1988.tb42104.x; SEUBERT P, 1988, BRAIN RES, V460, P189, DOI 10.1016/0006-8993(88)91222-X; SEUBERT P, 1988, BRAIN RES, V459, P226, DOI 10.1016/0006-8993(88)90638-5; SIMAN R, 1988, NEURON, V1, P279, DOI 10.1016/0896-6273(88)90076-1; SIMAN R, 1989, J NEUROSCI, V9, P1579; SONSALLA PK, 1991, J PHARMACOL EXP THER, V256, P506; Stephans S, 1996, NEUROSCIENCE, V72, P593, DOI 10.1016/0306-4522(95)00587-0; STEPHANS SE, 1994, SYNAPSE, V17, P203, DOI 10.1002/syn.890170310; WAGNER GC, 1985, RES COMMUN CHEM PATH, V47, P221; WAGNER GC, 1980, BRAIN RES, V181, P151, DOI 10.1016/0006-8993(80)91265-2; Wallace TL, 2003, NEUROSCIENCE, V116, P1063, DOI 10.1016/S0306-4522(02)00795-9; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Yamamoto BK, 1998, J PHARMACOL EXP THER, V287, P107; Zhang C, 2002, NEUROBIOL DIS, V10, P289, DOI 10.1006/nbdi.2002.0526; Zhao X, 1999, NEUROCHEM RES, V24, P371, DOI 10.1023/A:1020933616351	65	41	42	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	MAR	2006	96	5					1267	1276		10.1111/j.1471-4159.2005.03618.x			10	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	012IR	WOS:000235332600005	16417574	Bronze			2021-06-18	
J	Fingerhut, LA; Warner, M				Fingerhut, LA; Warner, M			The ICD-10 injury mortality diagnosis matrix	INJURY PREVENTION			English	Article								Objective: To standardize the presentation of the more than 1200 ICD-10 "S'' and "T'' codes from Chapter XIX by cross classifying the body region of injury by the nature of injury using the ICD-10 injury mortality diagnosis matrix. This paper explains the rationale for decisions made when developing the matrix and presents mortality data using the matrix. Design: ICD-10 codes are organized by diagnosis groups and body regions of injury for the purpose of standardizing presentation. The categories can be collapsed to facilitate analysis at varying levels of detail. Findings from the United States 2002 injury mortality data are used as an example. Main outcome measures: All injury diagnoses mentioned in deaths with an underlying cause of injury. Results: There were a total of 247,195 injury diagnoses mentioned in the 161,269 deaths with an underlying cause of injury in 2002 in the United States. The matrix can be used to show that 30% of all injury diagnoses mentioned were to the head and neck region; 28% were system wide injuries, 17% were to the torso. Open wounds accounted for 17% of all injury diagnoses mentioned, and close to half of all open wounds were traumatic brain injuries. Twenty eight percent of injury diagnoses mentioned were unspecified as to their nature and 9.5% had no body region specified. Conclusions: Multiple cause of death data are a rich but underused source of injury data often due to the complexity of the data and of the ICD classification system. Analytic techniques will need to be refined to accommodate deaths with multiple contributing injury diagnoses. The injury mortality diagnosis matrix will facilitate analysis as it is a useful tool for summarizing diagnosis data associated with injury deaths.	Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA	Fingerhut, LA (corresponding author), Natl Ctr Hlth Stat, 3311 Toledo Rd, Hyattsville, MD 20782 USA.	LFingerhut@cdc.gov					Aharonson-Daniel L, 2005, INJURY PREV, V11, P197, DOI 10.1136/ip.2005.008227; Aharonson-Daniel L, 2003, INJURY PREV, V9, P156, DOI 10.1136/ip.9.2.156; Anderson Robert N, 2004, Natl Vital Stat Rep, V52, P1; Barell V, 2002, INJ PREV, V8, P91, DOI 10.1136/ip.8.2.91; FINKELSTEIN EA, 2005, INCIDENCE EC BURDEN; HEINEN M, 2005, NATL TRENDS INJURY H; Langlois JA., 2004, TRAUMATIC BRAIN INJU; MARIETTA GA, 2003, STATE TERRITORIAL IN; MININO AM, 2006, IN PRESS NATL VITAL; *NCHS, COMP CAUS DEATH BETW; *NCHS, 2005, COMP ED MORT DAT INC; *US DEP HHS, 2004, US DHHS CDCP; WHO, 1977, MAN INT STAT CLASS D; World Health Organization, 1992, ICD 10 INT STAT CLAS	14	41	41	1	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1353-8047			INJURY PREV	Inj. Prev.	FEB	2006	12	1					24	29		10.1136/ip.2005.009076			6	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	009BK	WOS:000235085900008	16461416	Green Published			2021-06-18	
J	Kompanje, EJO; Bakker, J; Slieker, FJA; Ijzermans, JNM; Maas, AIR				Kompanje, EJO; Bakker, J; Slieker, FJA; Ijzermans, JNM; Maas, AIR			Organ donations and unused potential donations in traumatic brain injury, subarachnoid haemorrhage and intracerebral haemorrhage	INTENSIVE CARE MEDICINE			English	Article						brain death; ethics; potential organ donor; intracerebral haemorrhage; non-heart-beating organ donation; subarachnoid haemorrhage; traumatic brain injury	HIGH-RISK; DEATH; IDENTIFICATION; TRANSPLANTATION; DONORS; CARE	Objective:To obtain insight into the occurrence of brain death and the potential for brain dead and controlled non-heart-beating organ donors (CNHB) in patients with traumatic brain injury (TBI), subarachnoid haemorrhage (SAH) and intracerebral haemorrhage (ICH) in a large neurosurgical serving area (2.1 million inhabitants). Design:Retrospective analysis of data concerning patients with TBI, SAH and ICH who died during the course of ICU treatment during 1999-2003. Setting:A 16-bed neuro-intensive care unit. Patients: Patients with TBI, SAH or ICH who died during the course of ICU treatment. Measurements and results:The number of ICU deaths in patients with TBI, SAH and ICH declined from 111 in 1999 to 64 in 2003. In total, 476 deaths occurred. Of these, 177 patients were not included in the analysis. Two hundred ninety-nine (299) ventilated patients had two or more absent brainstem reflexes (ABSR) and a Glasgow Coma Score of 3-4 at the moment of treatment withdrawal and formed the potential for organ donation; 61 of these patients were treated until full brain death. Organs of 57 patients could be harvested. We analysed the reasons that organs were not procured in the 242 remaining patients. The most important reasons were family refusal (32%), medical contraindications (14%), and the treating physician not considering potential organ donation (20%). The missed potential is 162/299 (54%). Conclusion:The number of actual and potential organ donors is declining, but a considerable number of potential CNHB donors exists. Refusal by relatives is the most important reason for failure to procure organs.	Erasmus Univ, Med Ctr, Dept Intens Care, NL-3000 CA Rotterdam, Netherlands; Erasmus MC Univ, Med Ctr, Dept Intens Care, NL-3000 CA Rotterdam, Netherlands; Erasmus MC Univ, Med Ctr, Dept Surg, NL-3000 CA Rotterdam, Netherlands	Kompanje, EJO (corresponding author), Erasmus Univ, Med Ctr, Dept Intens Care, POB 2040, NL-3000 CA Rotterdam, Netherlands.	e.j.o.kompanje@erasmusmc.nl	Maas, Andrew IR/C-5584-2013; Bakker, Jan/A-4011-2009	Maas, Andrew IR/0000-0003-1612-1264; Bakker, Jan/0000-0003-2236-7391			Altinors N, 1998, TRANSPLANT P, V30, P771, DOI 10.1016/S0041-1345(98)00041-4; BRODERICK JP, 1994, STROKE, V25, P1342, DOI 10.1161/01.STR.25.7.1342; Chiara O, 2002, INJURY, V33, P553, DOI 10.1016/S0020-1383(02)00123-7; Cohen B, 2005, NEPHROL DIAL TRANSPL, V20, P34, DOI 10.1093/ndt/gfh506; Dominguez-Roldan JM, 1999, TRANSPL P, V31, P2595, DOI 10.1016/S0041-1345(99)00516-3; Dominguez-Roldan JM, 2002, TRANSPLANT P, V34, P9, DOI 10.1016/S0041-1345(01)02646-X; Dosemeci L, 2004, TRANSPL P, V36, P20, DOI 10.1016/j.transproceed.2003.11.050; FALTIN DL, 1992, TRANSPLANTATION, V54, P85, DOI 10.1097/00007890-199207000-00015; GORE SM, 1989, BRIT MED J, V299, P1193, DOI 10.1136/bmj.299.6709.1193; Kleindienst A, 1999, ACTA NEUROCHIR, V141, P641, DOI 10.1007/s007010050354; Matesanz R, 2002, J NEPHROL, V15, P22; Morris PJ, 1999, LANCET, V354, P1147, DOI 10.1016/S0140-6736(99)01104-6; Navarro A, 1996, TRANSPLANT P, V28, P103; Opdam HI, 2004, INTENS CARE MED, V30, P1390, DOI 10.1007/s00134-004-2185-9; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Pratschke J, 2004, TRANSPLANTATION, V77, P43, DOI 10.1097/01.TP.0000092003.02115.95; Procaccio F, 2001, Minerva Anestesiol, V67, P71; Pugliese MR, 2003, TRANSPL INT, V16, P21, DOI 10.1111/j.1432-2277.2003.tb00218.x; SALIH MAM, 1991, BRIT MED J, V302, P1053, DOI 10.1136/bmj.302.6784.1053; Schaeffer M J, 1998, J Transpl Coord, V8, P9; Senouci K, 2004, INTENS CARE MED, V30, P38, DOI 10.1007/s00134-003-1923-8; Sheehy E, 2003, NEW ENGL J MED, V349, P667, DOI 10.1056/NEJMsa021271; Siminoff LA, 2001, JAMA-J AM MED ASSOC, V286, P71, DOI 10.1001/jama.286.1.71; SPRUNG CL, 2004, JAMA-J AM MED ASSOC, V290, P790; Tullius SG, 2001, TRANSPLANTATION, V72, P1341, DOI 10.1097/00007890-200110270-00001	25	41	42	0	1	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	FEB	2006	32	2					217	222		10.1007/s00134-005-0001-9			6	Critical Care Medicine	General & Internal Medicine	011EH	WOS:000235250300006	16432680				2021-06-18	
J	Suh, SW; Frederickson, CJ; Danscher, G				Suh, SW; Frederickson, CJ; Danscher, G			Neurotoxic zinc translocation into hippocampal neurons is inhibited by hypothermia and is aggravated by hyperthermia after traumatic brain injury in rats	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						hippocampus; hyperthermia; hypothermia; rats; traumatic brain injury; zinc	CONTROLLED CORTICAL IMPACT; ACID-INDUCED SEIZURES; PROTEIN-KINASE-II; MODERATE HYPOTHERMIA; CEREBRAL-ISCHEMIA; POSTTRAUMATIC HYPOTHERMIA; CELL-DEATH; CALCIUM ACCUMULATION; FOREBRAIN ISCHEMIA; RADICAL PRODUCTION	Hypothermia reduces excitotoxic neuronal damage after seizures, cerebral ischemia and traumatic brain injury (TBI), while hyperthermia exacerbates damage from these insults. Presynaptic release of ionic zinc (Zn2+), translocation and accumulation of Zn2+ ions in postsynaptic neurons are important mechanisms of excitotoxic neuronal injury. We hypothesized that temperature-dependent modulation of excitotoxicity is mediated in part by temperature-dependent changes in the synaptic release and translocation of Zn2+. In the present studies, we used autometallographic (AMG) and fluorescent imaging of N-(6-methoxy-8-quinolyl)-para-toluenesulfonamide (TSQ) staining to quantify the influence of temperature on translocation of Zn2+ into hippocampal neurons in adult rats after weight drop-induced TBI. The central finding was that TBI- induced Zn2+ translocation is strongly influenced by brain temperature. Vesicular Zn2+ release was detected by AMG staining 1 h after TBI. At 30 degrees C, hippocampus showed almost no evidence of vesicular Zn2+ release from presynaptic terminals; at 36.5 degrees C, the hippocampus showed around 20% to 30% presynaptic vesicular Zn2+ release; and at 39 degrees C vesicular Zn2+ release was significantly greater (40% to 60%) than at 36.5 degrees C. At 6 h after TBI, intracellular Zn2+ accumulation was detected by the TSQ staining method, which showed that Zn2+ translocation also paralleled the vesicular Zn2+ release. Neuronal injury, assessed by counting eosinophilic neurons, also paralleled the translocation of Zn2+, being minimal at 30 degrees C and maximal at 39 degrees C. We conclude that pathological Zn2+ translocation in brain after TBI is temperature-dependent and that hypothermic neuronal protection might be mediated in part by reduced Zn2+ translocation.	Univ Calif San Francisco, Vet Adm Med Ctr, Dept Neurol 127, San Francisco, CA 94121 USA; NeuroBioTex Inc, Galveston, TX USA; Univ Aarhus, Inst Anat, Dept Neurobiol, Aarhus C, Denmark	Suh, SW (corresponding author), Univ Calif San Francisco, Vet Adm Med Ctr, Dept Neurol 127, 4150 Clement St, San Francisco, CA 94121 USA.	swsuh@itsa.ucsf.edu					ARAI H, 1993, NEUROSCI LETT, V163, P132, DOI 10.1016/0304-3940(93)90363-P; ASSAF SY, 1984, NATURE, V308, P734, DOI 10.1038/308734a0; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; BUSTO R, 1989, NEUROSCI LETT, V101, P299, DOI 10.1016/0304-3940(89)90549-1; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; CHURN SB, 1990, STROKE, V21, P1715, DOI 10.1161/01.STR.21.12.1715; Clark RSB, 1996, J CEREBR BLOOD F MET, V16, P253, DOI 10.1097/00004647-199603000-00010; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; CRAWFORD IL, 1972, J NEUROCHEM, V19, P1451, DOI 10.1111/j.1471-4159.1972.tb05088.x; Danscher G, 1996, HISTOCHEM J, V28, P361, DOI 10.1007/BF02331399; DANSCHER G, 1975, BRAIN RES, V94, P167, DOI 10.1016/0006-8993(75)90887-2; DANSCHER G, 1973, EXP BRAIN RES, V16, P521, DOI 10.1007/BF00234478; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIETRICH WD, 1992, J NEUROTRAUM, V9, pS475; DIETRICH WD, 1993, J CEREBR BLOOD F MET, V13, P541, DOI 10.1038/jcbfm.1993.71; FREDERICKSON CJ, 1990, PROG BRAIN RES, V83, P71; Frederickson CJ, 2000, J NUTR, V130, p1471S, DOI 10.1093/jn/130.5.1471S; FREDERICKSON CJ, 1987, J NEUROSCI METH, V20, P91, DOI 10.1016/0165-0270(87)90042-2; Frederickson CJ, 2002, J HISTOCHEM CYTOCHEM, V50, P1659, DOI 10.1177/002215540205001210; FREDERICKSON CJ, 1988, BRAIN RES, V446, P383, DOI 10.1016/0006-8993(88)90899-2; FREDERICKSON CJ, 1989, BRAIN RES, V480, P317, DOI 10.1016/0006-8993(89)90199-6; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; Haug F M, 1975, J Hirnforsch, V16, P151; HOWELL GA, 1984, NATURE, V308, P736, DOI 10.1038/308736a0; HU BR, 1995, NEUROSCIENCE, V68, P1003, DOI 10.1016/0306-4522(95)00213-3; ITO U, 1975, ACTA NEUROPATHOL, V32, P209, DOI 10.1007/BF00696570; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; JOHANSEN FF, 1993, MOL CHEM NEUROPATHOL, V18, P161, DOI 10.1007/BF03160030; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kil HY, 1996, J CEREBR BLOOD F MET, V16, P100, DOI 10.1097/00004647-199601000-00012; Koh JY, 1996, SCIENCE, V272, P1013, DOI 10.1126/science.272.5264.1013; Koizumi H, 1997, BRAIN RES, V747, P304, DOI 10.1016/S0006-8993(96)01240-1; Lee JY, 2000, J NEUROSCI, V20; LIU Z, 1993, BRAIN RES, V631, P51, DOI 10.1016/0006-8993(93)91185-U; LUNDGREN J, 1994, EXP BRAIN RES, V99, P43; LYETH BG, 1993, MOL CHEM NEUROPATHOL, V18, P247, DOI 10.1007/BF03160117; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Matsushita Y, 2000, ACTA NEUROCHIR SUPPL, V76, P207; MINAMISAWA H, 1990, J CEREBR BLOOD F MET, V10, P365, DOI 10.1038/jcbfm.1990.66; MINAMISAWA H, 1990, ANN NEUROL, V28, P26, DOI 10.1002/ana.410280107; MITANI A, 1991, BRAIN RES, V562, P159, DOI 10.1016/0006-8993(91)91201-B; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; Palmiter RD, 1996, P NATL ACAD SCI USA, V93, P14934, DOI 10.1073/pnas.93.25.14934; ROSOMOFF HL, 1959, J NEUROSURG, V16, P177, DOI 10.3171/jns.1959.16.2.0177; SLOVITER RS, 1985, BRAIN RES, V330, P150, DOI 10.1016/0006-8993(85)90017-4; Suh SW, 2000, BRAIN RES, V879, P7, DOI 10.1016/S0006-8993(00)02675-5; Suh SW, 2004, NEUROBIOL DIS, V16, P538, DOI 10.1016/j.nbd.2004.04.017; Suh SW, 1999, J HISTOCHEM CYTOCHEM, V47, P969, DOI 10.1177/002215549904700715; Suh SW, 2000, BRAIN RES, V852, P268, DOI 10.1016/S0006-8993(99)02095-8; TANIMOTO M, 1987, BRAIN RES, V417, P239, DOI 10.1016/0006-8993(87)90448-3; TIMM F, 1958, Dtsch Z Gesamte Gerichtl Med, V46, P706, DOI 10.1007/BF00665092; TONDER N, 1990, NEUROSCI LETT, V109, P247, DOI 10.1016/0304-3940(90)90002-Q; Tsuchiya D, 2002, J CEREBR BLOOD F MET, V22, P1231; Yamamoto M, 1999, J NEUROTRAUM, V16, P487, DOI 10.1089/neu.1999.16.487; ZAUNER A, 1995, J NEUROTRAUM, V12, P547, DOI 10.1089/neu.1995.12.547; ZORNOW MH, 1995, J NEUROSURG ANESTH, V7, P148, DOI 10.1097/00008506-199504000-00022	62	41	43	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	FEB	2006	26	2					161	169		10.1038/sj.jcbfm.9600176			9	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	021HZ	WOS:000235975600002	15988476	Bronze			2021-06-18	
J	Empey, PE; McNamara, PJ; Young, B; Rosbolt, MB; Hatton, J				Empey, PE; McNamara, PJ; Young, B; Rosbolt, MB; Hatton, J			Cyclosporin A disposition following acute traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						cyclosporin A; dosing; human; neuroprotection; pharmacokinetics; traumatic brain injury	SEVERE HEAD-INJURY; ACUTE-PHASE RESPONSE; AMINO-ACID RELEASE; AXONAL DAMAGE; INTERLEUKIN-6; KINETICS; FLUID; PHARMACOKINETICS; TRANSPLANTATION; METABOLISM	Although the precise mechanism of action remains to be defined, Cyclosporin A (CsA) has demonstrated potential for neuroprotection in animal models. Predictive dosing strategies for CsA in acute traumatic brain injured (TBI) patients must account for the influence of the acute phase response on drug disposition. To characterize CsA pharmacokinetic parameters early following acute TBI, serial blood samples from patients enrolled into a Phase II dose-escalation trial were analyzed. Within eight hours of injury, thirty patients admitted with acute severe TBI were prospectively randomized into three cohorts (n = 8 CsA; n = 2 placebo per cohort) in this dose-escalation trial. Patients received one of three doses (I = 0.625 mg/kg/dose; II = 1.25 mg/kg/dose; III = 2.5 mg/kg/dose) or placebo intravenously every 12 h for 72 h. Serial blood collection began prior to dose I and continued for 72 h following the completion of six doses. Whole blood concentrations were determined by high-performance liquid chromatography (HPLC) with ultraviolet (UV) detection. Pharmacokinetic parameters were determined for each patient by fitting the concentration-time profile to a two-compartmental model with first order elimination. Mean area under the curve and predicted maximal blood concentration increased with each dosing cohort (I = 9840 h*mu g/L, 398 mu g/L; II = 18300 h*mu g/L, 645 mu g/L; III = 32500 h*mu g/L, 1300 /mu g/L). Whole blood clearance, steady state volume of distribution, and beta half-life were independent of dose and higher than published reports from other populations: 0.420 L/h/kg, 5.91 L/kg, and 17.3 h, respectively. These, data show patients with acute severe TBI demonstrate a more rapid clearance and a larger distribution volume of CsA. Pharmacokinetic parameters derived from this study will guide dosing strategies for future prospective clinical trials evaluating CsA therapy following acute TBI.	Univ Kentucky, Coll Pharm, Dept Pharm & Neurosurg, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA; Univ Kentucky, Coll Med, Dept Pharmaceut Sci, Lexington, KY USA; Univ Kentucky, Coll Med, Div Neurosurg, Lexington, KY USA	Hatton, J (corresponding author), Univ Kentucky, Coll Pharm, Dept Pharm & Neurosurg, Spinal Cord & Brain Injury Res Ctr, B357 Biol Basic Sci Res Bldg,741 S Limestone, Lexington, KY 40536 USA.	jhatt1@email.uky.edu	Empey, Philip/L-9604-2019	Empey, Philip/0000-0001-7474-2339	NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR002602] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS041239] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01 RR02602] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1R01NS41239-01, 5R01NS041239] Funding Source: Medline		Akhlaghi F, 2002, CLIN PHARMACOKINET, V41, P615, DOI 10.2165/00003088-200241090-00001; Alessandri B, 2002, J NEUROTRAUM, V19, P829, DOI 10.1089/08977150260190429; AWEEKA FT, 1994, J CLIN PHARMACOL, V34, P60, DOI 10.1002/j.1552-4604.1994.tb03967.x; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Boucher BA, 1998, CLIN PHARMACOKINET, V35, P209, DOI 10.2165/00003088-199835030-00004; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; BURCKART GJ, 1986, J CLIN PHARMACOL, V26, P647, DOI 10.1002/j.1552-4604.1986.tb02966.x; CHEN SZ, 1994, REAL-TIME SYST, V6, P55, DOI 10.1007/BF01245299; Clausen T, 2001, CURR PHARM DESIGN, V7, P1517, DOI 10.2174/1381612013397267; Doppenberg EMR, 1999, ACT NEUR S, V75, P31; EDWARDS DJ, 1982, CLIN PHARMACOL THER, V31, P62, DOI 10.1038/clpt.1982.10; Enriquez P, 2004, CURR PHARM DESIGN, V10, P2131; FOLLATH F, 1983, CLIN PHARMACOL THER, V34, P638, DOI 10.1038/clpt.1983.226; GUPTA SK, 1990, J CLIN PHARMACOL, V30, P643, DOI 10.1002/j.1552-4604.1990.tb01868.x; Hatton J, 2004, J NEUROSURG, V100, P784; Kalsotra A, 2003, J NEUROTRAUM, V20, P1339, DOI 10.1089/089771503322686139; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Koura SS, 1998, ACT NEUR S, V71, P244; KRONBACH T, 1988, CLIN PHARMACOL THER, V43, P630, DOI 10.1038/clpt.1988.87; LEGG B, 1987, J PHARM PHARMACOL, V39, P599, DOI 10.1111/j.2042-7158.1987.tb03436.x; LEMAIRE M, 1982, J PHARM PHARMACOL, V34, P715, DOI 10.1111/j.2042-7158.1982.tb06206.x; Maas AIR, 1999, NEUROSURGERY, V44, P1286, DOI 10.1097/00006123-199906000-00076; MCCLAIN C, 1991, J LAB CLIN MED, V118, P225; MCCLAIN CJ, 1988, J NEUROSURG, V69, P386, DOI 10.3171/jns.1988.69.3.0386; Morris GF, 1999, J NEUROSURG, V91, P737, DOI 10.3171/jns.1999.91.5.0737; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; PTACHCINSKI RJ, 1985, CLIN PHARMACOL THER, V38, P296, DOI 10.1038/clpt.1985.174; PTACHCINSKI RJ, 1987, J CLIN PHARMACOL, V27, P243, DOI 10.1002/j.1552-4604.1987.tb02193.x; Riess P, 2001, RESTOR NEUROL NEUROS, V18, P1; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Singleton RH, 2001, J NEUROTRAUM, V18, P607, DOI 10.1089/089771501750291846; Suehiro E, 2001, J NEUROSURG, V94, P493, DOI 10.3171/jns.2001.94.3.0493; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; The Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P463; TOLER SM, 1993, DRUG METAB DISPOS, V21, P1064; Wilcockson DC, 2002, J CEREBR BLOOD F MET, V22, P318, DOI 10.1097/00004647-200203000-00009; Yamamoto T, 1999, ACT NEUR S, V75, P17	39	41	41	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2006	23	1					109	116		10.1089/neu.2006.23.109			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	009GP	WOS:000235100100009	16430377				2021-06-18	
J	Boschen, KA; Tonack, M; Gargaro, J				Boschen, KA; Tonack, M; Gargaro, J			The impact of being a support provider to a person living in the community with a spinal cord injury	REHABILITATION PSYCHOLOGY			English	Article						support provider; caregivers; spinal cord injury; community integration; quality of life	SEVERE PHYSICAL-DISABILITIES; PROBLEM-SOLVING ABILITIES; TRAUMATIC BRAIN INJURY; SOCIAL SUPPORT; FAMILY CAREGIVERS; QUALITY; LIFE; ADJUSTMENT; REINTEGRATION; OUTCOMES	Objective: To examine the personal impact of being I support provider (SP) to a community-dwelling person with a spinal cord injury (SCI). Study Design: Quantitative phase (interview-completed questionnaire; n = 100), followed by qualitative phase (8 focus groups; n = 46). Participants: Convenience sample; self-selected subsample in focus groups. Main Outcome Measures: Productivity status, satisfaction with community integration, quality of life. Results: Supporting a person with SCI brings significant life change. Greater support provision was related to lower productivity and community integration of the SPs. They felt underserved and unprepared emotionally and cognitively for their new, unanticipated role. Conclusions: More attention, understanding, and service directed to SPs are required to reduce trial-and-error learning and emotional and physical burden. Enhanced injury resource materials, peer networks, and knowledge-building opportunities may ameliorate SP difficulties.	Toronto Rehabil Inst, Lyndhurst Ctr, Dept Res, Toronto, ON M4G 3V9, Canada; Univ Toronto, Dept Occupat Therapy, Toronto, ON, Canada; Univ Toronto, Grad Dept Rehabil Sci, Toronto, ON, Canada	Boschen, KA (corresponding author), Toronto Rehabil Inst, Lyndhurst Ctr, Dept Res, 520 Sutherland Dr, Toronto, ON M4G 3V9, Canada.	boschen.kathy@torontorehab.on.ca					ALLEN K, 1994, REHABIL PSYCHOL, V39, P29, DOI 10.1037/h0080313; BOSCHEN K, 1998, CAN J REHABIL, V11, P184; Boschen KA, 1998, INT J REHABIL RES, V21, P285, DOI 10.1097/00004356-199809000-00004; Boschen KA, 2003, INT J REHABIL RES, V26, P157, DOI 10.1097/00004356-200309000-00001; BOSCHEN KA, 1999, J REHABILITATION OUT, V3, P1; BOSCHEN KA, 1997, CANADIAN J REHABILIT, V10, P125; BROOKINGS JB, 1988, AM J COMMUN PSYCHOL, V16, P137, DOI 10.1007/BF00906076; Canam C, 1999, Rehabil Nurs, V24, P192; CHARMAZ K, 1990, SOC SCI MED, V30, P1161, DOI 10.1016/0277-9536(90)90256-R; Christy MA, 1999, PARAPLEGIA NEWS, V53, P8; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Cresswell J, 1998, QUALITATIVE INQUIRY; DEJONG G, 1982, ARCH PHYS MED REHAB, V63, P68; Dijkers M, 1997, SPINAL CORD, V35, P829, DOI 10.1038/sj.sc.3100571; Elliott T. R., 1998, J VOCATIONAL REHABIL, V10, P123, DOI DOI 10.1016/S1052-2263(98)00007-5; Elliott TR, 2002, J CLIN PSYCHOL MED S, V9, P65, DOI 10.1023/A:1014931924809; Elliott TR, 2001, J COUNS PSYCHOL, V48, P223, DOI 10.1037//0022-0167.48.2.223; Erlandson D.A., 1993, DOING NATURALISTIC I; FLANAGAN JC, 1978, AM PSYCHOL, V33, P138, DOI 10.1037/0003-066X.33.2.138; FLANAGAN JC, 1982, ARCH PHYS MED REHAB, V63, P56; Fougeyrollas P., 2002, TOP SPINAL CORD INJ, V7, P1, DOI DOI 10.1310/QDNN-8FN0-NJMG-TVWB; FRIEDLAND J, 1987, ARCH PHYS MED REHAB, V68, P475; Gillen R, 1998, J HEAD TRAUMA REHAB, V13, P31, DOI 10.1097/00001199-199806000-00004; Glaser B. G., 1967, DISCOVERY GROUNDED T; Grant JS, 2001, REHABIL PSYCHOL, V46, P44, DOI 10.1037/0090-5550.46.1.44; Kolakowsky-Hayner SA, 2001, J HEAD TRAUMA REHAB, V16, P374, DOI 10.1097/00001199-200108000-00007; Kurylo MF, 2001, J COUNS DEV, V79, P275, DOI 10.1002/j.1556-6676.2001.tb01972.x; Levenson H., 1981, RES LOCUS CONTROL CO, V1, P15, DOI DOI 10.1016/B978-0-12-443201-7.50006-3; MCCOLL MA, 1989, OCCUP THER J RES, V9, P218, DOI 10.1177/153944928900900403; McMillen JC, 2003, REHABIL PSYCHOL, V48, P77, DOI 10.1037/0090-5550.48.2.77; Meade MA, 2004, REHABIL PSYCHOL, V49, P150, DOI 10.1037/0090-5550.49.2.150; MINTZ S, 1997, PARAPLEGIA NEWS, V51, P14; MINTZ S, 1999, PARAPLEGIA NEWS, V53, P12; MINTZ S, 1996, PARAPLEGIA NEWS, V50, P79; Noreau L., 2002, TOPICS SPINAL CORD I, V7, P56, DOI DOI 10.1310/1UGA-EY2T-N6XP-1PHE; NOSEK MA, 1992, REHABIL COUNS BULL, V36, P21; Rivera P, 2003, TOP SPINAL CORD INJ, V9, P53, DOI [DOI 10.1310/G82F-BR2R-T69L-3QX8, 10.1310/G82F-BR2R-T69L-3QX8]; Sarason, 1985, SOCIAL SUPPORT THEOR, P73, DOI DOI 10.1007/978-94-009-5115-0_5; Shewchuk RM, 2004, J CLIN PSYCHOL MED S, V11, P141, DOI 10.1023/B:JOCS.0000037608.55768.df; Shewchuk RM, 1998, HEALTH PSYCHOL, V17, P125, DOI 10.1037/0278-6133.17.2.125; *STAT CAN, 2004, LAB FORC EMPL UN MEM; Strauss A., 1990, BASICS QUALITATIVE R; Tashakkori Abbas, 1998, MIXED METHODOLOGY CO; Taylor S. J., 1984, INTRO QUALITATIVE ME; WOODDAUPHINEE SL, 1988, ARCH PHYS MED REHAB, V69, P583	45	41	42	0	3	EDUCATIONAL PUBLISHING FOUNDATION	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550			REHABIL PSYCHOL	Rehabil. Psychol.	NOV	2005	50	4					397	407		10.1037/0090-5550.50.4.397			11	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	990KL	WOS:000233741700010					2021-06-18	
J	Holbrook, TL; Hoyt, DB; Coimbra, R; Potenza, B; Sise, M; Anderson, JP				Holbrook, TL; Hoyt, DB; Coimbra, R; Potenza, B; Sise, M; Anderson, JP			High rates of acute stress disorder impact quality-of-life outcomes in injured adolescents: Mechanism and gender predict acute stress disorder risk	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	34th Annual Meeting of the Western-Trauma-Association	FEB 22-27, 2004	Steamboat Springs, CO	Western Trauma Assoc		acute stress disorder; adolescents; quality-of-life outcomes; posttraumatic stress disorder	MOTOR-VEHICLE ACCIDENTS; TRAUMA RECOVERY PROJECT; POSTTRAUMATIC-STRESS; MAJOR TRAUMA; MULTIPLE TRAUMA; GENERAL HEALTH; CHILDREN; WOMEN; MEN; CONSEQUENCES	Background: Injury is the leading cause of death and functional disability in adolescent children. Little is known about quality of life and psychological outcomes after trauma in adolescents. The Trauma Recovery Project in Adolescents is a prospective epidemiologic study designed to examine multiple outcomes after major trauma in adolescents aged 12 to 19 years, including quality of life (QoL) and psychological sequelae such as acute stress disorder (ASD) and posttraumatic stress disorder (PTSD). The specific objectives of the present report are to examine ASD rates and the association of ASD with QoL outcomes in injured adolescents. Methods: Between April 26, 1999, and November 13, 2002, 401 eligible trauma patients aged 12 to 19 years triaged to five participating trauma center hospitals in a regionalized trauma system were enrolled in the study. The admission criteria for patients were as follows: (1) age 12 to 19 years and (2) injury diagnoses excluding severe traumatic brain injury (TBI) or spinal cord injury. QoL after trauma was measured using the Quality of Well-being (QWB) scale, a sensitive and well-validated functional index (range, 0 = death to 1.000 = optimum functioning). ASD (before discharge) was diagnosed with the Impact of Events Scale-Revised. Scores of 24+ were used to diagnose ASD. Patient outcomes were assessed at discharge and at 3, 6, 12, 18, and 24 months after discharge. Results: ASD before discharge was diagnosed in 40% of adolescent trauma survivors. ASD status was associated with large QoL deficits during follow-up, as follows: 3-month, ASD-positive QWB score = 0.667 vs. ASD-negative QWB score = 0.710, p < 0.01; 6-month, ASD-positive QWB score 0.704 vs. ASD-negative QWB score 0.742, p < 0.001; 12-month: ASD-positive QWB score = 0.718 vs. ASD-negative QWB score = 0.757, p < 0.01; 24-month, ASD-positive QWB score = 0.725 vs. ASD-negative QWB score = 0.769, p < 0.01. Female sex and violent mechanism predicted ASD risk (47% female vs. 36% male; odds ratio, 1.6; p < 0.05; violence 54% vs. 38%; odds ratio, 1.9; p < 0.01). Conclusions: Adolescent trauma survivors have high rates of ASD. ASD severely impacts QoL outcomes and is associated with female sex and mechanism of injury in adolescents. Early recognition and treatment of ASD in seriously injured adolescents will improve QoL outcomes.	Univ Calif San Diego, Med Ctr, Dept Family & Prevent Med, San Diego, CA 92103 USA; Univ Calif San Diego, Dept Surg, Div Trauma, San Diego, CA 92103 USA; Mercy Hosp, Ctr Trauma, San Diego, CA USA	Holbrook, TL (corresponding author), Univ Calif San Diego, Med Ctr, Dept Family & Prevent Med, 8896,200 W Arbor Dr, San Diego, CA 92103 USA.	tholbrook@ucsd.edu	Coimbra, Raul/AAP-3019-2020	Coimbra, Raul/0000-0002-3759-6851	AHRQ HHSUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [R01 HS 07611] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITYUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [R01HS007611] Funding Source: NIH RePORTER		ANDERSON JP, 1986, MED CARE, V24, P454, DOI 10.1097/00005650-198605000-00008; ANDERSON JP, 1988, J CLIN EPIDEMIOL, V41, P127, DOI 10.1016/0895-4356(88)90087-X; Anke AGW, 1997, J TRAUMA, V42, P54, DOI 10.1097/00005373-199701000-00010; BLANCHARD EB, 1995, J NERV MENT DIS, V183, P495, DOI 10.1097/00005053-199508000-00001; BLANCHARD EB, 1995, BEHAV RES THER, V33, P529, DOI 10.1016/0005-7967(94)00079-Y; Bouillon B, 2002, RESTOR NEUROL NEUROS, V20, P125; Breslau N, 1997, ARCH GEN PSYCHIAT, V54, P1044; Brown ES, 2000, COMPR PSYCHIAT, V41, P19, DOI 10.1016/S0010-440X(00)90126-3; Bryant RA, 1996, J TRAUMA STRESS, V9, P223, DOI 10.1002/jts.2490090206; Butcher JL, 1996, J TRAUMA, V41, P4, DOI 10.1097/00005373-199607000-00002; Caffo E, 2003, CHILD ADOL PSYCH CL, V12, P493, DOI 10.1016/S1056-4993(03)00004-X; Chaffin M, 2001, CHILD ABUSE NEGLECT, V25, P401, DOI 10.1016/S0145-2134(00)00257-X; Daviss WB, 2000, J AM ACAD CHILD PSY, V39, P576, DOI 10.1097/00004583-200005000-00011; GREEN BL, 1991, J AM ACAD CHILD PSY, V30, P945, DOI 10.1097/00004583-199111000-00012; Holbrook TL, 2002, J TRAUMA, V53, P882, DOI 10.1097/00005373-200211000-00012; Holbrook TL, 2001, J TRAUMA, V51, P287, DOI 10.1097/00005373-200108000-00010; Holbrook TL, 1998, J TRAUMA, V45, P315, DOI 10.1097/00005373-199808000-00018; Holbrook TL, 1999, J TRAUMA, V46, P765, DOI 10.1097/00005373-199905000-00003; Holbrook TL, 2004, J TRAUMA, V56, P284, DOI 10.1097/01.TA.0000109758.75406.F8; Holbrook TL, 2001, J TRAUMA, V50, P91, DOI 10.1097/00005373-200101000-00016; Holbrook TL, 2001, J TRAUMA, V50, P270, DOI 10.1097/00005373-200102000-00012; KAPLAN J, 2000, WORKING PREVENT CONT; KAPLAN RM, 1984, J CHRON DIS, V37, P85, DOI 10.1016/0021-9681(84)90050-X; KAPLAN RM, 1988, J CONSULT CLIN PSYCH, V56, P1; Kaplan RM, 1982, HEALTH PSYCHOL, V1, P61, DOI DOI 10.1037/0278-6133.1.1.61; KAPLAN RM, 1978, P AM STAT ASSOC, P704; LANDSMAN IS, 1990, J BEHAV MED, V13, P561, DOI 10.1007/BF00844735; MacKenzie EJ, 1996, J TRAUMA, V41, P799, DOI 10.1097/00005373-199611000-00006; MALT U, 1988, BRIT J PSYCHIAT, V153, P810, DOI 10.1192/bjp.153.6.810; Michaels AJ, 1998, J TRAUMA, V44, P644, DOI 10.1097/00005373-199804000-00013; Michaels AJ, 1999, J TRAUMA, V47, P867, DOI 10.1097/00005373-199911000-00009; Michaels AJ, 2000, J TRAUMA, V48, P841, DOI 10.1097/00005373-200005000-00007; Michaels AJ, 1999, J TRAUMA, V47, P460, DOI 10.1097/00005373-199909000-00005; Ott R, 1996, UNFALLCHIRURG, V99, P267; PYNOOS RS, 1993, BRIT J PSYCHIAT, V163, P239, DOI 10.1192/bjp.163.2.239; Richmond TS, 1998, J TRAUMA, V44, P635, DOI 10.1097/00005373-199804000-00012; SCHLESSELMAN JJ, 1982, CASE CONTROL STUDIES; Seekamp A, 1996, INJURY, V27, P133, DOI 10.1016/0020-1383(95)00178-6; Shalev AY, 1996, AM J PSYCHIAT, V153, P219; Stein MB, 1997, AM J PSYCHIAT, V154, P1114; Winston FK, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.6.e90	41	41	42	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	NOV	2005	59	5					1126	1130		10.1097/01.ta.0000196433.61423.f2			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	001DO	WOS:000234514000018	16385290				2021-06-18	
J	Kissick, J; Johnston, KM				Kissick, J; Johnston, KM			Return to play after concussion - Principles and practice	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussion; return to play; rehabilitation	SPORT-RELATED CONCUSSION; FOOTBALL PLAYERS; HEAD-INJURY; MANAGEMENT; EXERCISE; STATEMENT; SCIENCE	Objective: The sport medicine team is increasingly being asked to manage concussed athletes and to provide written clearance for return to play postconcussion, making it critical to have a good understanding of concussion recognition, assessment, and management. Data Sources/Synthesis: A handy way to think of concussion management is the four Rs: recognition, response, rehabilitation, and return. Results: Athletes, coaches, parents, therapists, and physicians need a thorough understanding of concussion signs and symptoms. An athlete suspected of having sustained a concussion should be removed from the game or practice and assessed by a member of the sideline medical team. All athletes who sustain a concussion should be evaluated by a medical doctor. Rehabilitation has similarities to but also differs from the traditional orthopedic model in that the first step is rest, both physical and cognitive. Once asymptomatic at rest, a step-wise return to activity is undertaken. Conclusions: This protocol has been adapted for various sports. It may be used for children, although it is prudent to be more conservative and to progress more slowly than in an older age group.	Ottawa Sport Med Ctr, Ottawa, ON, Canada; McGill Univ, Dept Neurosurg, Montreal, PQ H3A 2T5, Canada; McGill Univ, Dept Kinesiol, Montreal, PQ H3A 2T5, Canada; McGill Univ, Dept Phys Educ, Montreal, PQ H3A 2T5, Canada	Kissick, J (corresponding author), 39 Goulding Cr, Ottawa, ON K2K 2N9, Canada.	jkissick@sympatico.ca					Asplund CA, 2004, CLIN J SPORT MED, V14, P339, DOI 10.1097/00042752-200411000-00003; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bloom GA, 2004, BRIT J SPORT MED, V38, P519, DOI 10.1136/bjsm.2004.011999; Braham RA, 2004, BRIT J SPORT MED, V38, P426, DOI 10.1136/bjsm.2002.004051; Cantu RC, 2003, CLIN SPORT MED, V22, P593, DOI 10.1016/S0278-5919(02)00095-9; Collie A, 2004, BRIT J SPORT MED, V38, P273, DOI 10.1136/bjsm.2003.000293; Collie A, 2003, CLIN J SPORT MED, V13, P28, DOI 10.1097/00042752-200301000-00006; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Gall B, 2004, BRIT J SPORT MED, V38, P773, DOI 10.1136/bjsm.2003.009530; Gall B, 2004, MED SCI SPORT EXER, V36, P1269, DOI 10.1249/01.MSS.0000135787.73757.4D; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Haykowsky MJ, 2003, MED SCI SPORT EXER, V35, P65, DOI 10.1097/00005768-200301000-00011; Horton A., 2002, MED SCI SPORTS EXERC, V34, P99; Iverson GL, 2004, J INT NEUROPSYCH SOC, V10, P904, DOI 10.1017/S1355617704106139; Johnston Karen M, 2004, Curr Sports Med Rep, V3, P316; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; Johnston KM, 2001, CLIN J SPORT MED, V11, P166, DOI 10.1097/00042752-200107000-00007; Johnston KM, 2000, CLIN J SPORT MED, V10, P209; JOHNSTON KM, 2004, THINK 1 SPORT SMART; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; Lovell M, 2004, CLIN SPORT MED, V23, P421, DOI 10.1016/j.csm.2004.04.001; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McCrory P, 2001, CLIN J SPORT MED, V11, P160, DOI 10.1097/00042752-200107000-00006; McCrory P, 2001, CLIN J SPORT MED, V11, P190, DOI 10.1097/00042752-200107000-00010; McCrory P, 2001, CLIN J SPORT MED, V11, P144, DOI 10.1097/00042752-200107000-00004; McCrory Paul, 2005, Clin J Sport Med, V15, P48; McCrory PR, 2000, CLIN J SPORT MED, V10, P235, DOI 10.1097/00042752-200010000-00002; Pellman EJ, 2005, NEUROSURGERY, V56, P79, DOI 10.1227/01.NEU.0000150180.16552.8D; Podlog L, 2004, CLIN J SPORT MED, V14, P257, DOI 10.1097/00042752-200409000-00001; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304	37	41	41	0	19	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	NOV	2005	15	6					426	431		10.1097/01.jsm.0000186683.59158.8b			6	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	012BL	WOS:000235313100007	16278546				2021-06-18	
J	Simpson, G; Tate, R				Simpson, G; Tate, R			Clinical features of suicide attempts after traumatic brain injury	JOURNAL OF NERVOUS AND MENTAL DISEASE			English	Article						suicide attempts; traumatic brain injury; suicide prevention	PREVENTION; LETHALITY; SCALE; RISK	This study documents demographic, clinical and temporal parameters for suicide attempts after traumatic brain injury (TBI). Clinical interviews and a medical file review were conducted with an outpatient sample (N = 172), identifying 45 clients (26.2%) who had collectively made a lifetime total of 80 suicide attempts. Data were collected on postinjury psychopathology, current hopelessness, and suicide ideation, as well as historical data about the attempts. The sample (N = 43, missing data N = 2) had a lifetime prevalence of 1.86 attempts, with 19 clients (44.2%) making repeat attempts. The majority (70%) of the attempts were made postinjury. Medical attention was provided in 60.7% of attempts. The odds ratio found that respondents with a comorbid postinjury history of psychiatric/emotional disturbance and substance abuse were 21 times more likely to have made an attempt post-TBI compared with respondents with no such history. The findings can inform suicide prevention initiatives among people with TBI.	Liverpool Hosp, Brain Injury Rehabil Unit, Liverpool BC, NSW 1871, Australia; Univ Sydney, Rehabil Studies Unit, Sydney, NSW 2006, Australia; Royal Rehabil Ctr Sydney, Sydney, NSW, Australia	Simpson, G (corresponding author), Liverpool Hosp, Brain Injury Rehabil Unit, Locked Bag 7103, Liverpool BC, NSW 1871, Australia.		Simpson, Grahame K/W-1074-2019	Simpson, Grahame K/0000-0001-8156-9060			ACHTE KA, 1971, ACTA PSYCHIAT SCAN S, V225, P1; Beck A., 1993, BECK SCALE SUICIDE I; Beck A.T., 1993, BECK HOPELESSNESS SC; BECK AT, 1979, J CONSULT CLIN PSYCH, V47, P343, DOI 10.1037/0022-006X.47.2.343; BECK AT, 1975, AM J PSYCHIAT, V132, P285; BONGAR B, 1991, SUICIDAL PATIENT CLI; GUNNELL D, 1994, BMJ-BRIT MED J, V308, P1227, DOI 10.1136/bmj.308.6938.1227; HAWTON K, 1982, BRIT J PSYCHIAT, V140, P118, DOI 10.1192/bjp.140.2.118; JACOBS D, 1989, SUICIDE UNDERSTANDIN, P363; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KLONOFF PS, 1995, J HEAD TRAUMA REHAB, V10, P16, DOI 10.1097/00001199-199512000-00005; MALONE KM, 1995, J AFFECT DISORDERS, V34, P173, DOI 10.1016/0165-0327(95)00015-F; Mann JJ, 1999, AM J PSYCHIAT, V156, P181; MARIS RW, 1981, PATHWAYS SUICIDE SUR; MORGAN HG, 1993, BRIT J PSYCHIAT, V163, P111, DOI 10.1192/bjp.163.1.111; MOSCICKI EK, 1995, SUICIDE PREVENTION Y, P22; MURPHY GE, 1987, PSYCHIATRY, V1, P1; ROBINSON RG, 2000, SYNOPSIS NEUROPSYCHI, P289; Shavelle RM, 2001, AM J PHYS MED REHAB, V80, P510, DOI 10.1097/00002060-200107000-00009; Shneidman EdwinS., 1985, DEFINITION SUICIDE; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Simpson G, 2003, J HEAD TRAUMA REHAB, V18, P445, DOI 10.1097/00001199-200309000-00006; Simpson G, 2002, PSYCHOL MED, V32, P687, DOI 10.1017/S0033291702005561; SIMPSON GK, 2001, SUICIDE PREVENTION T; SMITH K, 1984, SUICIDE LIFE-THREAT, V14, P215; Tate R, 1997, J HEAD TRAUMA REHAB, V12, P16, DOI 10.1097/00001199-199712000-00003; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436	27	41	42	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA	0022-3018			J NERV MENT DIS	J. Nerv. Ment. Dis.	OCT	2005	193	10					680	685		10.1097/01.nmd.0000180743.65943.c8			6	Clinical Neurology; Psychiatry	Neurosciences & Neurology; Psychiatry	973VD	WOS:000232549800007	16208164				2021-06-18	
J	Striedinger, K; Petrasch-Parwez, E; Zoidl, G; Napirei, M; Meier, C; Eysel, UT; Dermietzel, R				Striedinger, K; Petrasch-Parwez, E; Zoidl, G; Napirei, M; Meier, C; Eysel, UT; Dermietzel, R			Loss of connexin36 increases retinal cell vulnerability to secondary cell loss	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						gap junction; infrared laser photocoagulation; mouse; neuronal survival	GAP JUNCTIONAL COMMUNICATION; MOUSE RETINA; NEURONAL CONNEXIN36; EFFECTIVE REDUCTION; MAMMALIAN RETINA; GENE CONNEXIN36; NERVOUS-SYSTEM; RODENT MODEL; ATP RELEASE; TUNEL ASSAY	Accruing evidence indicates that gap junctions are involved in neuronal survival after brain injury. The present study was aimed at clarifying the contribution of the neuronal gap-junction protein connexin36 (Cx36) to secondary cell loss after injury in the mouse retina. A focal retinal lesion was induced by infrared laser photocoagulation. Remarkably, this model allowed spatial and temporal definition of the lesion with high reproducibility. Moreover, Cx36 is abundantly expressed in the retina and plays an essential role in the visual transmission process. Taking advantage of these features, cell death was assessed using TUNEL assay and light and electron microscopy, and the extent of Cx36 expression was studied by immunohistochemistry, Western blot, in situ hybridization and real-time RT-PCR. Secondary cell loss was most prominent between 24 and 48 h after lesioning. This peak was accompanied by an increase in Cx36 expression. When cultured explanted retinas were subjected to gap-junction blockers a significant increase in the extent of secondary cell loss after laser photocoagulation became evident. Using the same experimental paradigm we compared the incidence of cell death in wild-type and Cx36(-/-) mice. A significant increase in total number of TUNEL-positive cells occurred in the Cx36(-/-) mice compared to controls. From these data we conclude that Cx36 contributes to the survival and resistance against damage of retinal cells and thus constitutes a protective factor after traumatic injury of the retina.	Ruhr Univ Bochum, Dept Neuroanat & Mol Brain Res, D-44801 Bochum, Germany; Ruhr Univ Bochum, Dept Anat & Embryol, D-4630 Bochum, Germany; Ruhr Univ Bochum, Dept Neurophysiol, D-4630 Bochum, Germany; Ruhr Univ Bochum, Int Grad Sch Neurosci, D-4630 Bochum, Germany	Dermietzel, R (corresponding author), Ruhr Univ Bochum, Dept Neuroanat & Mol Brain Res, Univ Str 150,MA 6-159, D-44801 Bochum, Germany.	rolf.dermietzel@ruhr-uni-bochum.de		Eysel, Ulf/0000-0001-6087-957X			Adamchik Y, 2000, BRAIN RES PROTOC, V5, P153, DOI 10.1016/S1385-299X(00)00007-6; Al-Ubaidi MR, 2000, J NEUROSCI RES, V59, P813, DOI 10.1002/(SICI)1097-4547(20000315)59:6<813::AID-JNR14>3.0.CO;2-#; BENSASSON SA, 1995, METHOD CELL BIOL, V46, P29; Berger JW, 1997, LASER SURG MED, V20, P409, DOI 10.1002/(SICI)1096-9101(1997)20:4<409::AID-LSM6>3.0.CO;2-U; Blanc EM, 1998, J NEUROCHEM, V70, P958; Contreras JE, 2002, P NATL ACAD SCI USA, V99, P495, DOI 10.1073/pnas.012589799; Cotrina ML, 1998, P NATL ACAD SCI USA, V95, P15735, DOI 10.1073/pnas.95.26.15735; Cusato K, 2003, J NEUROSCI, V23, P6413; De Maio A, 2002, J CELL PHYSIOL, V191, P269, DOI 10.1002/jcp.10108; Deans MR, 2001, NEURON, V31, P477, DOI 10.1016/S0896-6273(01)00373-7; Dermietzel R, 1998, BRAIN RES REV, V26, P176, DOI 10.1016/S0165-0173(97)00031-3; DOWLING JE, 1987, RETINA APPROACHABLE; Eysel UT, 1999, RESTOR NEUROL NEUROS, V15, P153; FAWCETT J, 2001, BRAIN DAMAGE BRAIN; Feigenspan A, 2004, J NEUROSCI, V24, P3325, DOI 10.1523/JNEUROSCI.5598-03.2004; Feigenspan A, 2001, J NEUROSCI, V21, P230, DOI 10.1523/JNEUROSCI.21-01-00230.2001; Frantseva MV, 2002, J NEUROSCI, V22, P644, DOI 10.1523/JNEUROSCI.22-03-00644.2002; Frantseva MV, 2002, J CEREBR BLOOD F MET, V22, P453, DOI 10.1097/00004647-200204000-00009; Gillen C, 1996, EUR J NEUROSCI, V8, P405, DOI 10.1111/j.1460-9568.1996.tb01223.x; Glickman RD, 2002, INT J TOXICOL, V21, P473, DOI 10.1080/10915810290169909; GRASLKRAUPP B, 1995, HEPATOLOGY, V21, P1465, DOI 10.1016/0270-9139(95)90071-3; Guldenagel M, 2001, J NEUROSCI, V21, P6036, DOI 10.1523/JNEUROSCI.21-16-06036.2001; Guldenagel M, 2000, J COMP NEUROL, V425, P193; Jerome KR, 2000, PATHOLOGY, V32, P186; Kelly KJ, 2003, AM J PHYSIOL-CELL PH, V284, pC1309, DOI 10.1152/ajpcell.00353.2002; Kermer P, 1999, CELL TISSUE RES, V298, P383, DOI 10.1007/s004410050061; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Leybaert L, 2003, CELL COMMUN ADHES, V10, P251, DOI 10.1080/15419060390262985; Lin JHC, 2003, J NEUROSCI, V23, P430; Lin JHC, 1998, NAT NEUROSCI, V1, P494, DOI 10.1038/2210; LYNCH DR, 1994, CURR OPIN NEUROL, V7, P510, DOI 10.1097/00019052-199412000-00007; MALCHOW RP, 1994, J GEN PHYSIOL, V104, P1039, DOI 10.1085/jgp.104.6.1039; Meier C, 2002, HISTOCHEM CELL BIOL, V117, P461, DOI 10.1007/s00418-002-0417-z; Mills SL, 2001, J COMP NEUROL, V436, P336; Naus CCG, 2001, CELL COMMUN ADHES, V8, P325, DOI 10.3109/15419060109080747; Ogilvie JM, 1999, J NEUROSCI METH, V87, P57; Oguro K, 2001, J NEUROSCI, V21, P7534; Ozog MA, 2002, J NEUROPATH EXP NEUR, V61, P132, DOI 10.1093/jnen/61.2.132; Petrasch-Parwez E, 2004, J COMP NEUROL, V479, P181, DOI 10.1002/cne.20327; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Rami A, 2000, EXP NEUROL, V170, P297, DOI 10.1006/exnr.2001.7712; Rawanduzy A, 1997, J NEUROSURG, V87, P916, DOI 10.3171/jns.1997.87.6.0916; Rozental R, 2001, METH MOL B, V154, P447; Schmittgen TD, 2000, J BIOCHEM BIOPH METH, V46, P69, DOI 10.1016/S0165-022X(00)00129-9; Siushansian R, 2001, J COMP NEUROL, V440, P387, DOI 10.1002/cne.1392; Sohl G, 1998, FEBS LETT, V428, P27, DOI 10.1016/S0014-5793(98)00479-7; Sohl G, 2000, BRAIN RES REV, V32, P138, DOI 10.1016/S0165-0173(99)00074-0; Srinivas M, 2001, P NATL ACAD SCI USA, V98, P10942, DOI 10.1073/pnas.191206198; Vaney DI, 1998, J NEUROSCI, V18, P10594; Velazquez JLP, 2003, NEUROSCIENTIST, V9, P5, DOI 10.1177/1073858402239586; WHEELER CB, 1976, PHYS MED BIOL, V21, P616, DOI 10.1088/0031-9155/21/4/012; Xia YQ, 2003, VISUAL NEUROSCI, V20, P429, DOI 10.1017/S0952523803204089; Zoidl G, 2002, J NEUROSCI RES, V69, P448, DOI 10.1002/jnr.10284	53	41	42	1	1	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0953-816X			EUR J NEUROSCI	Eur. J. Neurosci.	AUG	2005	22	3					605	616		10.1111/j.1460-9568.2005.04228.x			12	Neurosciences	Neurosciences & Neurology	954IE	WOS:000231147700007	16101742				2021-06-18	
J	Rappaport, M				Rappaport, M			The Disability Rating and Coma/Near-Coma scales in evaluating severe head injury	NEUROPSYCHOLOGICAL REHABILITATION			English	Article; Proceedings Paper	Conference of the International-Neuropsychological-Society	JUL 16-19, 2003	Berlin, GERMANY	Int Neuropsychol Soc			TRAUMATIC BRAIN INJURY; EVOKED-POTENTIALS; RECOVERY; VALIDITY; STATES	The Disability Rating (DR) and Coma/Near-Coma (C/NC) scales for evaluating severe head injury are described. Scales are related to patient status, course and outcome and also underlying electroneurophysiological dysfunction. They lend themselves to high inter-rater reliability with brief training and can be completed in minutes, conserving staff time and energy.		Rappaport, M (corresponding author), 1185 McKendrie St, San Jose, CA 95126 USA.	rappapor@ix.netcom.com					ELIASON MR, 1984, PHYS THER, V64, P1357, DOI 10.1093/ptj/64.9.1357; FLEMING JM, 1994, ARCH PHYS MED REHAB, V75, P156; FRYER LJ, 1987, J HEAD TRAUMA REHAB, V2, P51, DOI DOI 10.1097/00001199-198709000-00007; GIACINO JT, 1995, J HEAD TRAUMA REHAB, V10, P40; GOODIN DS, 1983, NEUROLOGY, V33, P1215, DOI 10.1212/WNL.33.9.1215; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; Hall KM., 1993, J HEAD TRAUMA REHAB, V8, DOI [DOI 10.1097/00001199-199308020-00008, 10.1097/00001199-199308020-00008]; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P258; RAPPAPORT M, 1977, ARCH PHYS MED REHAB, V58, P333; Rappaport M, 1991, J Neuropsychiatry Clin Neurosci, V3, P180; RAPPAPORT M, 1985, CLIN ELECTROENCEPHAL, V16, P183, DOI 10.1177/155005948501600404; RAPPAPORT M, 1992, ARCH PHYS MED REHAB, V73, P628; RAPPAPORT M, 1981, CLIN ELECTROENCEPHAL, V12, P154, DOI 10.1177/155005948101200402; RAPPAPORT M, 1981, CLIN ELECTROENCEPHAL, V12, P167, DOI 10.1177/155005948101200403; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; RAPPAPORT M, 1990, CLIN ELECTROENCEPHAL, V21, P188, DOI 10.1177/155005949002100406; Rappaport M, 1996, MED REHABILITATION T, P271; RAPPAPORT M, 1994, J HEAD TRAUMA REHAB, V9, P94; RAPPAPORT M, 1986, J HEAD TRAUMA REHABI, P00015, DOI DOI 10.1097/00001199-198603000-00005; SCRANTON J, 1970, Archives of Physical Medicine and Rehabilitation, V51, P1; TEASDALE G, 1974, LANCET, V2, P81	23	41	41	0	0	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	JUL-SEP	2005	15	3-4					442	453		10.1080/09602010443000335			12	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	965PE	WOS:000231961900029	16350985				2021-06-18	
J	af Geijerstam, JL; Britton, M				af Geijerstam, JL; Britton, M			Mild head injury: reliability of early computed tomographic findings in triage for admission	EMERGENCY MEDICINE JOURNAL			English	Article							TRAUMATIC BRAIN-INJURY; DELAYED EPIDURAL HEMATOMA; EXTRADURAL HEMATOMAS; SUBDURAL-HEMATOMA; EMERGENCY-DEPARTMENT; NEUROLOGIC EXAMINATION; PEDIATRIC-PATIENTS; CT SCANS; MANAGEMENT; MORTALITY	Objective: To search the literature for case reports on adverse outcomes in patients with mild head injury where acute computed tomography (CT) findings had been normal. Methods: Mild head injury was defined as head trauma involving amnesia or loss of consciousness, but where neurological findings are normal on arrival at hospital (GCS 15). The scientific literature was systematically searched for case reports where an early CT was normal and the patient deteriorated within two days. In these cases, early discharge despite a normal CT head scan would have been hazardous. Results: Two prospective studies were found that investigated the safety of early CT in 3300 patients with mild head injury, as were 39 reports on adverse outcomes describing 821 patients. In addition, 52 studies containing over 62 000 patients with mild head injury were reviewed. In total, only three cases were deemed to have experienced an early adverse outcome despite a normal CT and GCS 15 on initial presentation. In another eight cases with incomplete descriptions, the interpretation was doubtful. Many reports of complications were not relevant to our question and excluded. These reports included cases with more severe head injury/not GCS 15 at presentation, complications that occurred after more than two days, or initial CT findings that were not fully normal. Conclusion: Very few cases were found where an early adverse event occurred after normal acute CT in patients with mild head injury. The strongest scientific evidence available at this time shows that a CT strategy is a safe way to triage patients for admission.	Karolinska Univ Hosp, Dept Med, Clin Epidemiol Unit, SE-17176 Stockholm, Sweden; Swedish Council Technol Assessment Hlth Care SBU, Stockholm, Sweden	af Geijerstam, JL (corresponding author), Karolinska Univ Hosp, Dept Med N4 01, Clin Epidemiol Unit, SE-17176 Stockholm, Sweden.	jean-luc.af.geijerstam@medks.ki.se					af Geijerstam JL, 2000, EUR J SURG, V166, P526; ALFARO D, 1995, ANN EMERG MED, V25, P169, DOI 10.1016/S0196-0644(95)70319-5; Arendts Glenn, 2003, Australas Radiol, V47, P368, DOI 10.1046/j.1440-1673.2003.01204.x; Arienta C, 1997, SURG NEUROL, V48, P213, DOI 10.1016/S0090-3019(97)00019-0; Atkinson JLD, 2003, J MAGN RESON IMAGING, V17, P484, DOI 10.1002/jmri.10275; Bor-Seng-Shu E, 1997, CHILD NERV SYST, V13, P605, DOI 10.1007/s003810050151; Borczuk Pierre, 1997, Emergency Medicine Clinics of North America, V15, P563, DOI 10.1016/S0733-8627(05)70318-7; BOROVICH B, 1985, J NEUROSURG, V63, P30, DOI 10.3171/jns.1985.63.1.0030; BRUNETTI J, 1979, NEURORADIOLOGY, V18, P43, DOI 10.1007/BF00346211; CERVANTES LA, 1983, J NEUROSURG, V59, P351, DOI 10.3171/jns.1983.59.2.0351; Chang JH, 2002, CHILD NERV SYST, V18, P712, DOI 10.1007/s00381-002-0664-2; CIQUINI JO, 1992, ARQ NEURO-PSIQUIAT, V50, P361; Cook L S, 1994, Acad Emerg Med, V1, P227; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; Cushman JG, 2001, J TRAUMA, V51, P1016, DOI 10.1097/00005373-200111000-00034; DAVIES KG, 1990, BRIT J CLIN PRACT, V44, P420; DAVIES RL, 1995, PEDIATRICS, V95, P345; de Kruijk JR, 2001, BRAIN INJURY, V15, P117, DOI 10.1080/026990501458353; DEITCH D, 1989, NEUROLOGY, V39, P985, DOI 10.1212/WNL.39.7.985; DIROCCO A, 1991, NEURORADIOLOGY, V33, P253, DOI 10.1007/BF00588229; DOMENICUCCI M, 1995, NEUROSURG REV, V18, P109, DOI 10.1007/BF00417668; Dunn LT, 2003, J TRAUMA, V54, P497, DOI 10.1097/01.TA.0000030627.71453.CD; Egger M, 2003, Health Technol Assess, V7, P1; Fabbri A, 2004, J NEUROL NEUROSUR PS, V75, P410, DOI 10.1136/jnnp.2003.016113; Fabbri A, 2004, EUR J EMERG MED, V11, P65, DOI 10.1097/00063110-200404000-00002; FANKHAUSER H, 1983, NEUROCHIRURGIE, V29, P255; FANKHAUSER H, 1982, ACTA NEUROCHIR, V60, P29, DOI 10.1007/BF01401747; Ferrera PC, 1997, AM J EMERG MED, V15, P76, DOI 10.1016/S0735-6757(97)90055-3; FEUERMAN T, 1988, NEUROSURGERY, V22, P449, DOI 10.1227/00006123-198803000-00001; FUKAMACHI A, 1984, COMPUT RADIOL, V8, P197, DOI 10.1016/0730-4862(84)90123-9; Geijerstam JLA, 2003, ACTA NEUROCHIR, V145, P843, DOI 10.1007/s00701-003-0115-1; Glasziou P, 2004, BMJ-BRIT MED J, V328, P39, DOI 10.1136/bmj.328.7430.39; HAHN YS, 1993, PEDIATR NEUROSURG, V19, P135, DOI 10.1159/000120718; Hemphill RR, 1999, ACAD EMERG MED, V6, P957, DOI 10.1111/j.1553-2712.1999.tb01248.x; Inamasu J, 2001, AM J EMERG MED, V19, P324, DOI 10.1053/ajem.2001.24480; Ingebrigtsen T, 1997, ACTA NEUROL SCAND, V95, P51, DOI 10.1111/j.1600-0404.1997.tb00068.x; Jagoda AS, 2002, ANN EMERG MED, V40, P231, DOI 10.1016/j.jen.2008.12.010; JAIMOVICH R, 1992, PEDIATR NEUROSURG, V17, P25, DOI 10.1159/000120562; Kamerling SN, 2003, PEDIATR EMERG CARE, V19, P431, DOI 10.1097/01.pec.0000092590.40174.1f; KESKIL IS, 1995, CHILD NERV SYST, V11, P467, DOI 10.1007/BF00334967; KLAUBER MR, 1989, NEUROSURGERY, V24, P31, DOI 10.1227/00006123-198901000-00005; Lal NR, 2000, AM J NEURORADIOL, V21, P124; LEE ST, 1991, ACTA NEUROCHIR, V113, P121, DOI 10.1007/BF01403196; LEE ST, 1992, J NEUROSURG, V76, P435, DOI 10.3171/jns.1992.76.3.0435; LIVINGSTON DH, 1991, AM SURGEON, V57, P14; Livingston DH, 2000, ANN SURG, V232, P126, DOI 10.1097/00000658-200007000-00018; LOBATO RD, 1991, J NEUROSURG, V75, P256, DOI 10.3171/jns.1991.75.2.0256; Mandavia DP, 2001, PEDIATR EMERG CARE, V17, P193, DOI 10.1097/00006565-200106000-00011; MERTOL T, 1991, British Journal of Neurosurgery, V5, P491, DOI 10.3109/02688699108998478; MILO R, 1987, ACTA NEUROCHIR, V84, P13, DOI 10.1007/BF01456345; Nagy KK, 1999, J TRAUMA, V46, P268, DOI 10.1097/00005373-199902000-00012; Newman TB, 2003, BRIT MED J, V327, P1424, DOI 10.1136/bmj.327.7429.1424; Peloso PM, 2004, J REHABIL MED, V36, P106, DOI 10.1080/16501960410023868; POON WS, 1992, NEUROSURGERY, V30, P681; Riesgo P, 1997, SURG NEUROL, V48, P226, DOI 10.1016/S0090-3019(97)00194-8; RIVARA F, 1987, PEDIATRICS, V80, P579; ROCKSWOLD GL, 1993, ANN EMERG MED, V22, P1004, DOI 10.1016/S0196-0644(05)82742-8; Schunk JE, 1996, PEDIATR EMERG CARE, V12, P160, DOI 10.1097/00006565-199606000-00004; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; SERVADEI F, 1995, ACTA NEUROCHIR, V133, P50, DOI 10.1007/BF01404947; Shu EBS, 2000, PEDIATR NEUROSURG, V32, P176, DOI 10.1159/000028930; SMITH HK, 1991, NEUROSURGERY, V29, P258, DOI 10.1227/00006123-199108000-00016; SNOEY ER, 1994, ANN EMERG MED, V23, P1127, DOI 10.1016/S0196-0644(94)70115-6; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; STEIN SC, 1990, NEUROSURGERY, V26, P638, DOI 10.1227/00006123-199004000-00012; *SWED COUNC TECHN, 2000, 153 SBU SWED COUNC T; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; TEASDALE G, 1974, LANCET, V2, P81; TEASDALE GM, 1995, J NEUROL NEUROSUR PS, V58, P526, DOI 10.1136/jnnp.58.5.526; Von Wild K, 2001, BRAIN INJURY, V15, P273; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; WILLIAMS RJL, 1994, J ROY SOC MED, V87, P83; YOUNG HA, 1984, NEUROSURGERY, V14, P22, DOI 10.1227/00006123-198401000-00006	74	41	42	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1472-0205	1472-0213		EMERG MED J	Emerg. Med. J.	FEB 1	2005	22	2					103	107		10.1136/emj.2004.015396			5	Emergency Medicine	Emergency Medicine	892DQ	WOS:000226630400007	15662058	Bronze, Green Published			2021-06-18	
J	Zygun, DA; Laupland, KB; Hader, WJ; Kortbeek, JB; Findlay, C; Doig, CJ; Hameed, SM				Zygun, DA; Laupland, KB; Hader, WJ; Kortbeek, JB; Findlay, C; Doig, CJ; Hameed, SM			Severe traumatic brain injury in a large Canadian health region	CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES			English	Article							SEVERE HEAD-INJURY; EMERGENCY CARE; POPULATION; EPIDEMIOLOGY; TRENDS; MANAGEMENT; COMMUNITY; MORTALITY; OUTCOMES; COUNTY	Background: Although severe traumatic brain injury (sTBI) is a devastating condition with tremendous public health implications, the epidemiology of this disease has not previously been described in Canada. We Sought to define the incidence, risk factors and outcome of patients suffering sTBI in a large Canadian region. Methods: A population-based surveillance cohort design was utilized to identify all Calgary Heath Region residents who were victims of trauma with an injury severity score greater than or equal to12. Subsequent application of a specific sTBI case definition defined the final cohort. Results: The annual incidence of sTBI was 11.4 per 100,000 population. The incidence of sTBI was significantly higher for males as compared to females [17.1 vs. 5.9 per 100,000; relative risk (RR) = 2.91, 95% confidence interval; 2.17, 3.94; p<0.0001]. There was a striking increase in the annual age specific population incidence of sTBI observed among those older than 74 years of age. The relative risk among the highest risk group of elderly (>85 years) males as compared to the lowest risk female group (50-64 years) was 19.78 (95% CI; 6.27, 62.3; p<0.0001). One hundred and eight patients died prior to hospital discharge for a mortality rate of 5.1 per 100,000 per year. Conclusions: Severe traumatic brain injury is common among residents of the Calgary Health Region and is associated with a high mortality rate. Males and the elderly are at the highest risk for acquiring sTBI and may represent target groups for preventive efforts.	Univ Calgary, Dept Crit Care Med, Calgary, AB, Canada; Univ Calgary, Dept Med, Calgary, AB, Canada; Univ Calgary, Dept Pathol & Lab Med, Calgary, AB, Canada; Univ Calgary, Dept Clin Neurosci, Calgary, AB, Canada; Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada; Univ Calgary, Dept Surg, Calgary, AB, Canada; Calgary Hlth Res, Calgary, AB, Canada	Hameed, SM (corresponding author), Vancouver Gen Hosp, Trauma Serv, 855 W 12th Ave, Vancouver, BC V5Z 1M9, Canada.		Laupland, Kevin/AAG-3656-2020; Doig, Christopher/AAC-7949-2020; Laupland, kevin/AAJ-6339-2020; Kortbeek, John B/AAO-5298-2020	Doig, Christopher/0000-0002-8576-9139; Laupland, kevin/0000-0002-1205-5354; 			Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bouillon B, 1999, RESTOR NEUROL NEUROS, V14, P85; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; BULLOCK MR, 2000, J NEUROTRAUM, V17, P450; FOULKES MA, 1991, J NEUROSURG, V75, pS1, DOI 10.3171/sup.1991.75.1s.00s1; Foulkes MA, 1991, J NEUROSURG S, V75, P8, DOI 10.3171/sup.1991.75.1s.00s8; GENNARELLI TA, 1994, J TRAUMA, V37, P962, DOI 10.1097/00005373-199412000-00016; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; Khan S, 2002, BRAIN INJURY, V16, P537, DOI 10.1080/02699050110119862; KLAUBER MR, 1981, AM J EPIDEMIOL, V113, P500, DOI 10.1093/oxfordjournals.aje.a113125; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; Lane PL, 2000, CAN J SURG, V43, P442; MACKENZIE EJ, 1988, J TRAUMA, V28, P281, DOI 10.1097/00005373-198803000-00003; Masson F, 1997, J CLIN EPIDEMIOL, V50, P595, DOI 10.1016/S0895-4356(97)00012-7; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; McGarry LJ, 2002, J TRAUMA, V53, P1152, DOI 10.1097/00005373-200212000-00020; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; PARKINSON D, 1985, CAN J SURG, V28, P79; Pickett W, 2001, CAN MED ASSOC J, V165, P288; SNOW WG, 1988, CAN J SURG, V31, P191; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; *STAT CAN, 2001, CAN NAT POP CENS; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; TIRET L, 1990, INT J EPIDEMIOL, V19, P133, DOI 10.1093/ije/19.1.133; Winchell RJ, 1997, ARCH SURG-CHICAGO, V132, P592; Wong Pauline P., 1993, Brain Injury, V7, P283, DOI 10.3109/02699059309034955	29	41	42	0	5	CANADIAN J NEUROL SCI INC	CALGARY	PO BOX 4220, STATION C EDITORIAL & SUBSCRIPTION SERV, CALGARY, AB T2T 5N1, CANADA	0317-1671			CAN J NEUROL SCI	Can. J. Neurol. Sci.	FEB	2005	32	1					87	92		10.1017/S0317167100016930			6	Clinical Neurology	Neurosciences & Neurology	901DY	WOS:000227264400013	15825552	Bronze			2021-06-18	
J	Davis, DP; Heister, R; Poste, JC; Hoyt, DB; Ochs, M; Dunford, JV				Davis, DP; Heister, R; Poste, JC; Hoyt, DB; Ochs, M; Dunford, JV			Ventilation patterns in patients with severe traumatic brain injury following paramedic rapid sequence intubation	NEUROCRITICAL CARE			English	Article						paramedic; rapid sequence intubation; ventilation; hyperventilation; traumatic brain injury; intubation; head injury; airway management	TIDAL CARBON-DIOXIDE; CEREBRAL-BLOOD-FLOW; INDUCED LUNG INJURY; SEVERE HEAD-INJURY; MECHANICAL VENTILATION; INTRAHOSPITAL TRANSPORT; TISSUE PO2; HYPERVENTILATION; ARTERIAL; CYTOKINES	Introduction: Inadvertent hyperventilation has been documented during aeromedical transports but has not been studied following paramedic rapid sequence intubation (RSI). The San Diego Paramedic RST Trial was designed to study the impact of paramedic RSI on outcome inpatients with severe head injury. This analysis explores ventilation patterns in a cohort of trial patients undergoing end-tidal CO2 (ETCO2) monitoring. Methods: Adult patients with severe head injury (Glasgow Coma Score: 3-8) unable to be intubated without RSI were prospectively enrolled in the trial. Midazolam and succinylcholine were used for RSI; rocuronium was administered following tube confirmation. Standardized ventilation protocols were used by most paramedics; however, one agency instituted ETCO2 monitoring during the second trial year, with paramedics instructed to target ETCO, values of 30 to 35 mmHg. The incidence and duration of inadvertent hyperventilation (ETCO2: < 30 mmHg) and severe hyperventilation (ETCO2: < 25 mmHg) were explored for patients undergoing ETCO2 monitoring. The initial, final, minimum, and maximum values for ETCO2 and the maximum and minimum ventilatory rate values were also calculated using descriptive statistics (95% confidence interval). The pattern of ETCO2 values over time and distribution of recorded ventilatory rate values were explored graphically. Results: A total of 76 trial patients had adequate ETCO, data for this analysis. The mean values for initial, final, maximum, and minimum ETCO2 were 40.8 (range: 37.5-44.2),28.4 (range: 25.4-31.4),45.1 (range: 41.4-48.8), and 23.5 mmHg (range: 21.4-25.5), respectively. The mean maximum and minimum ventilatory rate values were 36.0/minute (range: 33.5-38.5) and 12.8/minute (range: 11.9-13.7), respectively. ETCO2 values less than 30 and 25 mmHg were documented in 79% and 59% of patients, respectively, with mean durations of 485 (range: 378-592) and 390 seconds (range: 285-494). Conclusion: Inadvertent hyperventilation is common following paramedic RSI, despite ETCO2 monitoring and target parameters.	Univ Calif San Diego, Dept Emergency Med, San Diego, CA 92103 USA; Univ Calif San Diego, Div Trauma, San Diego, CA 92103 USA; San Diego Cty EMS, San Diego, CA USA	Davis, DP (corresponding author), UCSD Emergency Med, 200 W Arbor Dr,8676, San Diego, CA 92103 USA.	davismd@cox.net					Ali SS, 2002, MED PRIN PRACT, V11, P35, DOI 10.1159/000048658; Ausina A, 1998, ACT NEUR S, V71, P1; Bao Yinghui, 2000, Chin J Traumatol, V3, P210; BRAMAN SS, 1987, ANN INTERN MED, V107, P469, DOI 10.7326/0003-4819-107-4-469; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; BUXTON RL, 1970, LANCET, V2, P498; Casati A, 1997, Minerva Anestesiol, V63, P177; Chiumello D, 1999, AM J RESP CRIT CARE, V160, P109, DOI 10.1164/ajrccm.160.1.9803046; Coles JP, 2002, CRIT CARE MED, V30, P1950, DOI 10.1097/00003246-200209000-00002; CRUZ J, 1993, CRIT CARE MED, V21, P1225, DOI 10.1097/00003246-199308000-00025; Davis DP, 2004, J TRAUMA, V57, P1, DOI 10.1097/01.TA.0000135503.71684.C8; Davis DP, 2004, J TRAUMA, V56, P808, DOI 10.1097/01.TA.0000100217.05066.87; Davis DP, 2003, J TRAUMA, V54, P444, DOI 10.1097/01.TA.0000053396.02126.CD; Diringer MN, 2002, J NEUROSURG, V96, P103, DOI 10.3171/jns.2002.96.1.0103; Dunford JV, 2003, ANN EMERG MED, V42, P721, DOI 10.1016/S0196-0644(03)00660-7; Forbes ML, 1998, J NEUROSURG, V88, P549, DOI 10.3171/jns.1998.88.3.0549; GERVAIS HW, 1987, CRIT CARE MED, V15, P761, DOI 10.1097/00003246-198708000-00010; Grenier B, 1999, ANESTH ANALG, V88, P43, DOI 10.1097/00000539-199901000-00009; Hardman JG, 2003, ANESTH ANALG, V97, P1846, DOI 10.1213/01.ANE.0000090316.46604.89; Helm M, 2002, BRIT J ANAESTH, V88, P345, DOI 10.1093/bja/88.3.345; HURST JM, 1989, J TRAUMA, V29, P1637, DOI 10.1097/00005373-198912000-00008; Imai Y, 2003, JAMA-J AM MED ASSOC, V289, P2104, DOI 10.1001/jama.289.16.2104; Imberti R, 2002, J NEUROSURG, V96, P97, DOI 10.3171/jns.2002.96.1.0097; Manley GT, 2000, J TRAUMA, V48, P1025, DOI 10.1097/00005373-200006000-00005; Marion DW, 2002, CRIT CARE MED, V30, P2619, DOI 10.1097/00003246-200212000-00001; McLaughlin MR, 1996, J NEUROSURG, V85, P871, DOI 10.3171/jns.1996.85.5.0871; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; PEPE PE, 2002, EMERGENCY VENTILATOR, P80; ROSSANDA M, 1968, SCAND J CLIN LAB I S, V102; RUSSELL GB, 1994, J TRAUMA, V36, P317, DOI 10.1097/00005373-199403000-00006; Sarrafzadeh AS, 2002, ACTA NEUROCHIR SUPPL, V81, P319; Schneider GH, 1998, ACT NEUR S, V71, P62; Sitzwohl C, 1998, ANESTH ANALG, V86, P1131, DOI 10.1097/00000539-199805000-00043; Skippen P, 1997, CRIT CARE MED, V25, P1402, DOI 10.1097/00003246-199708000-00031; Slutsky A S, 2000, Respir Res, V1, P73, DOI 10.1186/rr15; STRINGER WA, 1993, AM J NEURORADIOL, V14, P475; The Brain Trauma Foundation. The American Association of Neurological Surgeons, 2000, J Neurotrauma, V17, P563, DOI 10.1089/neu.2000.17.563; Thomas SH, 2002, J TRAUMA, V52, P47, DOI 10.1097/00005373-200201000-00010; Tobias JD, 1996, PEDIATR EMERG CARE, V12, P249, DOI 10.1097/00006565-199608000-00003; Tremblay L, 1997, J CLIN INVEST, V99, P944, DOI 10.1172/JCI119259; Tremblay LN, 2002, CRIT CARE MED, V30, P1693, DOI 10.1097/00003246-200208000-00003; Uhlig S, 2002, AM J PHYSIOL-LUNG C, V282, pL892, DOI 10.1152/ajplung.00124.2001; van Santbrink H, 2003, ACTA NEUROCHIR, V145, P429, DOI 10.1007/s00701-003-0032-3; Weinger M B, 1987, J Clin Monit, V3, P73, DOI 10.1007/BF00858353; WHITWAM JG, 1966, BRIT J ANAESTH, V38, P846, DOI 10.1093/bja/38.11.846; Wilson MR, 2003, J APPL PHYSIOL, V95, P1385, DOI 10.1152/japplphysiol.00213.2003; Zhang HB, 2002, ANESTHESIOLOGY, V97, P1426, DOI 10.1097/00000542-200212000-00014; Zornow MH, 2002, CRIT CARE MED, V30, P2774, DOI 10.1097/00003246-200212000-00026	48	41	41	0	2	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care		2005	2	2					165	171		10.1385/NCC:2:2:165			7	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	947JI	WOS:000230639100009	16159059				2021-06-18	
J	Starkstein, SE; Jorge, R				Starkstein, SE; Jorge, R			Dementia after traumatic brain injury	INTERNATIONAL PSYCHOGERIATRICS			English	Article						traumatic brain injury; dementia; cognition; Alzheimer's disease	AMYLOID PROTEIN DEPOSITION; CHILDHOOD HEAD-INJURY; ALZHEIMERS-DISEASE; RISK-FACTOR; CEREBROSPINAL-FLUID; EPISODIC MEMORY; WORKING-MEMORY; MILD; PERFORMANCE; ATTENTION	Early retrospective studies suggested that individuals with a history of a traumatic brain injury (TBI) had a higher risk for dementia than those without a history of TBI. Two meta-analyses demonstrated that the risk for dementia is higher among men, but not women, with a history of TBI. More recent prospective studies, however, are providing discrepant findings, probably due to important methodological differences. TBI is usually associated with significant neuropsychological deficits, primarily in the domains of attention, executive functioning and memory. These deficits may not improve with time. TBI may also lower the threshold for the clinical expression of dementia among predisposed individuals, and the onset of Alzheimer's disease (AD)like neuropathological and biochemical changes immediately after severe TBI may play an important role in this mechanism.	Fremantle Hosp, Fremantle, WA 6959, Australia; Univ Western Australia, Sch Psychiat & Clin Neurosci, Nedlands, WA 6009, Australia; Univ Iowa, Dept Psychiat, Iowa City, IA 52242 USA	Starkstein, SE (corresponding author), Fremantle Hosp, Educ Bldg T-7, Fremantle, WA 6959, Australia.	ses@cyllene.uwa.edu.au					Alexander MP, 2003, BRAIN, V126, P1493, DOI 10.1093/brain/awg128; Alexander MP, 2000, SEMIN NEUROL, V20, P427, DOI 10.1055/s-2000-13175; Anderson VA, 2004, BRAIN, V127, P2608, DOI 10.1093/brain/awh320; Arciniegas D, 1999, BRAIN INJURY, V13, P1, DOI 10.1080/026990599121827; Arciniegas David B, 2003, Curr Psychiatry Rep, V5, P391, DOI 10.1007/s11920-003-0074-5; Burke R, 2004, BRAIN INJURY, V18, P497, DOI 10.1080/02699050310001645784; Chamelian L, 2004, BRAIN, V127, P2621, DOI 10.1093/brain/awh296; Chiang MF, 2003, ACTA NEUROCHIR, V145, P649, DOI 10.1007/s00701-003-0069-3; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; Dritschel BH, 1998, BRAIN INJURY, V12, P875; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Franz G, 2003, NEUROLOGY, V60, P1457, DOI 10.1212/01.WNL.0000063313.57292.00; Galski T, 1998, BRAIN INJURY, V12, P769, DOI 10.1080/026990598122160; Goldstein FC, 2001, J CLIN EXP NEUROPSYC, V23, P739, DOI 10.1076/jcen.23.6.739.1028; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Hawley CA, 2004, BRAIN INJURY, V18, P645, DOI 10.1080/02699050310001646189; Hawley CA, 2004, J NEUROL NEUROSUR PS, V75, P737, DOI 10.1136/jnnp.2003.020651; Henry JD, 2004, NEUROPSYCHOLOGY, V18, P284, DOI 10.1037/0894-4105.18.2.284; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Isaki E, 2000, BRAIN INJURY, V14, P441; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; Jellinger KA, 2001, EUR J NEUROL, V8, P707, DOI 10.1046/j.1468-1331.2001.00322.x; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Jurado MA, 2000, BRAIN INJURY, V14, P789; KATZMAN R, 1989, ANN NEUROL, V25, P317, DOI 10.1002/ana.410250402; Kersel DA, 2001, BRAIN INJURY, V15, P283, DOI 10.1080/02699050010005887; Koponen S, 2004, NEUROLOGY, V63, P749, DOI 10.1212/01.WNL.0000134603.57107.2F; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; Levin HS, 2002, ANN NEUROL, V52, P82, DOI 10.1002/ana.10252; Levin HS, 2001, NEUROPSYCHOLOGIA, V39, P122, DOI 10.1016/S0028-3932(00)00111-1; Levine B, 1998, BRAIN, V121, P1951, DOI 10.1093/brain/121.10.1951; Levine B, 2000, NEUROPSYCHOLOGY, V14, P491, DOI 10.1037/0894-4105.14.4.491; Liberman JN, 2002, NEUROLOGY, V58, P1038, DOI 10.1212/WNL.58.7.1038; Luukinen H, 1999, NEUROLOGY, V52, P557, DOI 10.1212/WNL.52.3.557; Luukinen H, 2005, EUR J NEUROL, V12, P86, DOI 10.1111/j.1468-1331.2004.00953.x; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; Mangels JA, 2002, NEUROPSYCHOLOGIA, V40, P2369, DOI 10.1016/S0028-3932(02)00084-2; Martin I, 2003, BRAIN LANG, V85, P451, DOI 10.1016/S0093-934X(03)00070-1; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; MAYEUX R, 1993, ANN NEUROL, V33, P494, DOI 10.1002/ana.410330513; Mcallister TW, 2004, BRAIN INJURY, V18, P331, DOI 10.1080/02699050310001617370; MCDOWELL I, 1994, NEUROLOGY, V44, P2073; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; Millar K, 2003, J NEUROL NEUROSUR PS, V74, P1047, DOI 10.1136/jnnp.74.8.1047; Moran C, 2004, BRAIN INJURY, V18, P273, DOI 10.1080/02699050310001617415; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Newell KL, 1999, J NEUROPATH EXP NEUR, V58, P1147, DOI 10.1097/00005072-199911000-00004; Olsson A, 2004, J NEUROL, V251, P870, DOI 10.1007/s00415-004-0451-y; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; RASMUSSON DX, 1995, BRAIN INJURY, V9, P213, DOI 10.3109/02699059509008194; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Salmond CH, 2005, BRAIN, V128, P189, DOI 10.1093/brain/awh352; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; Smith C, 2003, NEUROPATH APPL NEURO, V29, P496, DOI 10.1046/j.1365-2990.2003.00488.x; Smith EE, 1999, SCIENCE, V283, P1657, DOI 10.1126/science.283.5408.1657; Snow P, 1998, BRAIN INJURY, V12, P911, DOI 10.1080/026990598121981; Sundstrom A, 2004, NEUROLOGY, V62, P1963, DOI 10.1212/01.WNL.0000129268.83927.A8; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; TULVING E, 1988, BRAIN COGNITION, V8, P3, DOI 10.1016/0278-2626(88)90035-8; Wheeler MA, 2003, CORTEX, V39, P827, DOI 10.1016/S0010-9452(08)70866-9; Zemlan FP, 1999, J NEUROCHEM, V72, P741, DOI 10.1046/j.1471-4159.1999.0720741.x; Zhang L, 2004, ARCH PHYS MED REHAB, V85, P1050, DOI 10.1016/j.apmr.2003.10.014; Zhukareva V, 2001, ACTA NEUROPATHOL, V101, P518	73	41	41	0	12	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1041-6102	1741-203X		INT PSYCHOGERIATR	Int. Psychogeriatr.		2005	17			1			S93	S107		10.1017/S1041610205001973			15	Psychology, Clinical; Geriatrics & Gerontology; Gerontology; Psychiatry; Psychology	Psychology; Geriatrics & Gerontology; Psychiatry	977WH	WOS:000232833700009	16240486				2021-06-18	
J	Yi, JH; Pow, DV; Hazell, AS				Yi, JH; Pow, DV; Hazell, AS			Early loss of the glutamate transporter splice-variant GLT-1v in rat cerebral cortex following lateral fluid-percussion injury	GLIA			English	Article						traumatic brain injury; glutamate transporter; excitoxicity; GLT-1; fluid percussion injury	TRAUMATIC BRAIN-INJURY; CORTICAL EXTRACELLULAR LEVELS; AMINO-ACID TRANSPORTER; HUMAN HEAD-INJURY; DOWN-REGULATION; ANTISENSE KNOCKDOWN; NEURONAL DAMAGE; BLOOD-FLOW; CELL-DEATH; EXPRESSION	Glutamate transporter proteins are essential for the control of interstitial glutamate levels, with an impairment of their function or levels being a major potential contributor to excitotoxicity. We have investigated the effects of lateral fluid percussion on the levels of the glutamate transporter proteins GLT-1alpha, its splice variant GLT-1v, GLAST, and EAAC1 in the rat in order to evaluate their pathogenetic role in this model of traumatic brain injury (TBI). Immunoblot analysis revealed neuronal loss in the cerebral cortex was accompanied by a 54% decrease in GLT-1v 6 h following the insult which progressed to an 83% loss of the transporter after 24 h. No changes in GLT-1alpha, GLAST, or EAAC1 were observed in this brain region at either time point. GLT-1v content was also decreased by 55% and 68% in the hippocampus and thalamus, respectively, at 6 h post-injury, but recovered fully after 24 h in both brain regions. In contrast, levels of GLT-1alpha were increased in the hippocampus at 6 h and 24 h post-TBI. These alterations in transporter protein content were also confirmed using immunohistochemical methods. Our results show for the first time a pattern of early, dynamic changes in the levels of GLT-1 transporter splice variants in different brain regions in this trauma model. In addition, correlation of GLT-1v levels with both neuronal cell loss and a-internexin content in the injured cortex suggests that loss of this novel glutamate transporter may be a key factor in determining cerebral vulnerability following this type of brain injury. (C) 2004 Wiley-Liss, Inc.	Univ Montreal, Dept Med, Hop St Luc, Montreal, PQ H2X 3J4, Canada; Univ Queensland, Dept Physiol & Pharmacol, Brisbane, Qld 4072, Australia	Hazell, AS (corresponding author), Univ Montreal, Dept Med, Hop St Luc, 1058 St Denis St, Montreal, PQ H2X 3J4, Canada.	alan.stewart.hazell@umontreal.ca	Pow, David/F-8198-2010; Pow, David V/A-2064-2016	Pow, David V/0000-0001-8522-4465			Arriza JL, 1997, P NATL ACAD SCI USA, V94, P4155, DOI 10.1073/pnas.94.8.4155; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Chan SO, 1998, NEUROCHEM RES, V23, P393, DOI 10.1023/A:1022417819356; Chen WZ, 2002, J NEUROSCI, V22, P2142, DOI 10.1523/JNEUROSCI.22-06-02142.2002; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; Clausen T, 2001, CURR PHARM DESIGN, V7, P1517, DOI 10.2174/1381612013397267; Danbolt NC, 1998, PROG BRAIN RES, V116, P23, DOI 10.1016/S0079-6123(08)60428-8; DANBOLT NC, 1992, NEUROSCIENCE, V51, P295, DOI 10.1016/0306-4522(92)90316-T; Di X, 1999, J NEUROTRAUM, V16, P195, DOI 10.1089/neu.1999.16.195; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; Fountoulakis M, 2001, EXP NEUROL, V167, P86, DOI 10.1006/exnr.2000.7529; GELGELASHVILI G, 1997, J NEUROCHEM, V69, P2612; Haugeto O, 1996, J BIOL CHEM, V271, P27715, DOI 10.1074/jbc.271.44.27715; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; Hazell AS, 2003, GLIA, V43, P175, DOI 10.1002/glia.10241; Hazell AS, 2001, J NEUROCHEM, V78, P560, DOI 10.1046/j.1471-4159.2001.00436.x; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; Kanai Y, 1997, CURR OPIN CELL BIOL, V9, P565, DOI 10.1016/S0955-0674(97)80035-X; KANTHAN R, 1995, J NEUROL NEUROSUR PS, V59, P326, DOI 10.1136/jnnp.59.3.326; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Knecht K, 1997, NEUROSCI LETT, V229, P201, DOI 10.1016/S0304-3940(97)00444-8; Koizumi H, 1997, BRAIN RES, V747, P304, DOI 10.1016/S0006-8993(96)01240-1; LEHRE KP, 1995, J NEUROSCI, V15, P1835; LEVY LM, 1995, EUR J NEUROSCI, V7, P2036, DOI 10.1111/j.1460-9568.1995.tb00626.x; Li S, 1997, J NEUROPATH EXP NEUR, V56, P901, DOI 10.1097/00005072-199708000-00008; Matsushita Y, 2000, J NEUROTRAUM, V17, P143, DOI 10.1089/neu.2000.17.143; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; Miller HP, 1997, J NEUROCHEM, V68, P1564; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Okiyama K, 1998, BRAIN RES, V792, P291, DOI 10.1016/S0006-8993(98)00158-9; PAXINOS G, 1998, AT BRAIN STEREOTAXIC; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; Pow DV, 1999, CELL TISSUE RES, V297, P57, DOI 10.1007/s004410051333; Rao VLR, 2001, BRAIN RES, V911, P96; Rao VLR, 1998, J NEUROCHEM, V70, P2020; Rao VLR, 2001, NEUROCHEM RES, V26, P497; Rao VLR, 2001, EUR J NEUROSCI, V13, P119, DOI 10.1046/j.1460-9568.2001.01367.x; Rao VLR, 2001, J NEUROSCI, V21, P1876, DOI 10.1523/JNEUROSCI.21-06-01876.2001; Reye P, 2002, GLIA, V38, P246, DOI 10.1002/glia.10059; ROTHSTEIN JD, 1994, NEURON, V13, P713, DOI 10.1016/0896-6273(94)90038-8; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; ROTHSTEIN JD, 1995, ANN NEUROL, V38, P73, DOI 10.1002/ana.410380114; Schmitt A, 2002, NEUROSCIENCE, V109, P45, DOI 10.1016/S0306-4522(01)00451-1; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; Sullivan R, 2004, GLIA, V45, P155, DOI 10.1002/glia.10317; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699; TORP R, 1995, EXP BRAIN RES, V103, P51; UtsunomiyaTate N, 1997, FEBS LETT, V416, P312, DOI 10.1016/S0014-5793(97)01232-5; Van Landeghem FKH, 2001, GLIA, V35, P167, DOI 10.1002/glia.1082; Wilson JMB, 2003, NEUROMOL MED, V3, P105, DOI 10.1385/NMM:3:2:105; Wong NKY, 2000, J NEUROPATH EXP NEUR, V59, P972, DOI 10.1093/jnen/59.11.972; Zauner A, 1996, ACT NEUR S, V67, P40	55	41	41	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	JAN 1	2005	49	1					121	133		10.1002/glia.20099			13	Neurosciences	Neurosciences & Neurology	879CW	WOS:000225695000011	15390098				2021-06-18	
J	Bruce, JM; Echemendia, RJ				Bruce, JM; Echemendia, RJ			Concussion history predicts self-reported symptoms before and following a concussive event	NEUROLOGY			English	Article; Proceedings Paper	50th Annual Meeting of the American-College-of-Sports-Medicine	MAY 28-31, 2003	San Francisco, CA	Amer Coll Sports Med				The authors evaluated how history of concussion affects symptom reporting prior to and after sustaining a concussion. At baseline, athletes with a positive concussion history reported more current symptomatology than athletes who had never been concussed. At 2 hours postinjury, concussed athletes with a history of previous concussion (PC) reported fewer symptoms than concussed athletes with no previous concussion history (NPC). By 1 week postinjury, however, PC athletes reported more symptoms than NPC athletes.	Penn State Univ, Coll Liberal Arts, Dept Psychol, University Pk, PA 16802 USA; Psychol & Neurobehav Associates, University Pk, PA USA	Bruce, JM (corresponding author), Penn State Univ, Coll Liberal Arts, Dept Psychol, 314 Bruce V Moore Bldg, University Pk, PA 16802 USA.	jmb518@psu.edu	Echemendia, Ruben/R-6939-2019	Echemendia, Ruben/0000-0001-6116-8462			Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Cantu RC, 1998, CLIN SPORT MED, V17, P45, DOI 10.1016/S0278-5919(05)70060-0; Echemendia RJ, 2004, STUD NEUROPSYCHOL DE, P479; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Kelly JP, 1997, NEUROLOGY, V48, P581; ROSENBAUM AM, 2003, THESIS PENNSYLVANIA	6	41	41	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	OCT 26	2004	63	8					1516	1518					3	Clinical Neurology	Neurosciences & Neurology	865VN	WOS:000224732400037	15505180				2021-06-18	
J	Harradine, PG; Winstanley, JB; Tate, R; Cameron, ID; Baguley, IJ; Harris, RD				Harradine, PG; Winstanley, JB; Tate, R; Cameron, ID; Baguley, IJ; Harris, RD			Severe traumatic brain injury in New South Wales: comparable outcomes for rural and urban residents	MEDICAL JOURNAL OF AUSTRALIA			English	Article							SCALE	Objective: To compare differences in functional outcomes between urban and rural patients with traumatic brain injury (TBI). Design: A longitudinal, prospective, multicentre study of a 2-year cohort from the Brain Injury Rehabilitation Program (BIRP) for New South Wales, with follow-up at 18 months after injury. Participants: 198 patients (147 urban, 51 rural) with severe TBI from the 11 participating rehabilitation units. Main outcome measures: Demographic and injury details collected prospectively using a standardised questionnaire, and measures from five validated instruments (Disability Rating Scale, Mayo-Portland Adaptability Inventory, Sydney Psychosocial Reintegration Scale, Medical Outcomes Study Short Form and the General Health Questionnaire -28-item version) administered at follow-up to document functional, psychosocial, emotional and vocational outcomes. Results: Demographic details, injury severity, lengths of stay in intensive and acute care wards were similar for both rural and urban groups. There were no significant group differences in functional outcomes, including return to work, at follow-up. Conclusions: Our findings contrast with previous research that has reported poorer outcomes after TBI for rural residents, and suggest that the integrated network of inpatient, outpatient and outreach services provided throughout NSW through the BIRP provides effective rehabilitation for people with severe TBI regardless of where they live.	Tamworth Base Hosp, New England Brain Injury Rehabil Program, Tamworth, NSW, Australia; Univ Sydney, Fac Med, Rehabil Studies Unit, Sydney, NSW 2006, Australia; Westmead Hosp, Brain Injury Rehabil Serv, Westmead, NSW 2145, Australia; Univ Sydney, Pain Management & Res Ctr, St Leonards, NSW 2065, Australia	Harradine, PG (corresponding author), Univ Sydney, Fac Med, Rehabil Studies Unit, POB 6, Ryde, NSW 1680, Australia.	jwin6139@mail.usyd.edu.au	Baguley, Ian J/K-6878-2013; Baguley, Ian/AAM-5828-2021	Baguley, Ian J/0000-0001-5650-3705; Winstanley, Julie/0000-0002-9353-6757			Commonwealth Department of Health and Aged Care, 2001, MEAS REM ACC REM IND; Department of Primary Industries and Energy and Department of Human Services and Health, 1994, RUR REM METR AR CLAS; Doherty SR, 2001, MED J AUSTRALIA, V175, P585, DOI 10.5694/j.1326-5377.2001.tb143735.x; ELASHOF JD, 2002, NQUERY ADVISIOR VERS; Farmer JE, 2003, J HEAD TRAUMA REHAB, V18, P116, DOI 10.1097/00001199-200303000-00003; GLABELLA B, 1997, ANN EPIDEMIOL, V7, P207; Goldberg D. P., 1988, USERS GUIDE GENERAL; Johnstone B, 2002, J RURAL HEALTH, V18, P109, DOI 10.1111/j.1748-0361.2002.tb00882.x; Malec JF., 1994, J HEAD TRAUMA REHAB, V9, P1, DOI [10. 1097/ 00001199- 199412000- 00003, DOI 10.1097/00001199-199412000-00003]; NORUSIS M, 1986, STAT PACKAGE SOC SCI; *NSW HLTH, 2002, NSW RUR HLTH REP REP; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Sample PL, 1998, BRAIN INJURY, V12, P855, DOI 10.1080/026990598122089; Schootman M, 1999, BRAIN INJURY, V13, P995; Schopp LH, 2000, J TELEMED TELECARE, V6, P146, DOI 10.1258/1357633001934474; Siegel S., 1956, NONPARAMETRIC STAT B; Tate R, 1999, J HEAD TRAUMA REHAB, V14, P543, DOI 10.1097/00001199-199912000-00003; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WARE JE, 2001, SF36 PHYS MENTAL HLT; WOODWARD A, 1984, MED J AUSTRALIA, V141, P13, DOI 10.5694/j.1326-5377.1984.tb132660.x	20	41	41	1	1	AUSTRALASIAN MED PUBL CO LTD	PYRMONT	LEVEL 2, 26-32 PYRMONT BRIDGE RD, PYRMONT, NSW 2009, AUSTRALIA	0025-729X	1326-5377		MED J AUSTRALIA	Med. J. Aust.	AUG 2	2004	181	3					130	134		10.5694/j.1326-5377.2004.tb06202.x			5	Medicine, General & Internal	General & Internal Medicine	848RW	WOS:000223485800004	15287829				2021-06-18	
J	de boussard, CN; Fredman, P; Lundin, A; Andersson, K; Edman, G; Borg, J				de boussard, CN; Fredman, P; Lundin, A; Andersson, K; Edman, G; Borg, J			S100 in mild traumatic brain injury	BRAIN INJURY			English	Article							NEURON-SPECIFIC ENOLASE; POST-CONCUSSION SYMPTOMS; CALCIUM-BINDING PROTEINS; MINOR HEAD TRAUMA; S-100 PROTEIN; COMPUTED-TOMOGRAPHY; SERUM-LEVELS; OUTCOME PREDICTION; DAMAGE; FAMILY	Primary objectives : To examine the diagnostic value of S100 in mild traumatic brain injury (MTBI). Research design : Prospective cohort study. Methods and procedures : S100B, S100A1B and S100BB concentrations were examined in sera from patients with MTBI with an arrival Glasgow Coma Scale score of 15 or 14, patients with orthopaedic injuries and non-injured subjects. Main outcome and results : Mean values and proportions of subjects above cut-off limits for S100B and S100A1B were significantly higher in each trauma group than in non-injured controls, but only for S100A1B when patients with MTBI were compared with controls with orthopaedic injuries. Using a 97.5 percentile cut-off limit, the sensitivity of S100A1B for MTBI vs orthopaedic injury was 61% (95% confidence interval (CI) 49-73%), specificity 77% (95% CI 62-93%). The area under the ROC curve did not approach 0.9 for any cut off limit. Conclusions : Diagnostic validity of S100 in acute MTBI was not demonstrated. S100A1B has merits for long-term prognostic studies.	Danderyd Hosp, Karolinska Inst, Dept Rehabil Med, SE-18288 Stockholm, Sweden; Univ Gothenburg, Sahlgrenska Acad, Inst Clin Neurosci, Sect Expt Neurosci, SU Molndal, Sweden; Danderyd Hosp, Karolinska Inst, Dept Psychiat, R&D Unit, Stockholm, Sweden; Uppsala Univ, Dept Neurosci, Uppsala, Sweden	de boussard, CN (corresponding author), Danderyd Hosp, Karolinska Inst, Dept Rehabil Med, SE-18288 Stockholm, Sweden.	catharina.nygren@reh.ds.sll.se		Borg, Jorgen/0000-0002-2372-7478			Ali MS, 2000, BRIT J ANAESTH, V85, P287, DOI 10.1093/bja/85.2.287; Anderson RE, 2000, ANN THORAC SURG, V69, P847, DOI 10.1016/S0003-4975(99)01526-X; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Anderson RE, 2001, ANN THORAC SURG, V71, P1512, DOI 10.1016/S0003-4975(01)02399-2; Biberthaler P, 2002, EUR J MED RES, V7, P164; Biberthaler P, 2000, ACT NEUR S, V76, P177; Biberthaler P, 2001, SHOCK, V16, P97, DOI 10.1097/00024382-200116020-00002; Blockzjil A, 1998, TUMOR BIOL, V19, P46, DOI 10.1159/000056504; BRITTON M, 2000, 2000 SBU; de Kruijk JR, 2001, ACTA NEUROL SCAND, V103, P175, DOI 10.1034/j.1600-0404.2001.103003175.x; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; FANO G, 1995, PROG NEUROBIOL, V46, P71, DOI 10.1016/0301-0082(94)00062-M; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Heizmann CW, 1999, NEUROCHEM RES, V24, P1097, DOI 10.1023/A:1020700117665; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Ingebrigtsen T, 2000, BRAIN INJURY, V14, P1047; ISOBE T, 1984, J NEUROCHEM, V43, P1494, DOI 10.1111/j.1471-4159.1984.tb05415.x; Johnsson P, 2000, SCAND CARDIOVASC J, V34, P548, DOI 10.1080/140174300750064459; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; Livingston DH, 2000, ANN SURG, V232, P126, DOI 10.1097/00000658-200007000-00018; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Miller EC, 1996, ANN EMERG MED, V27, P290, DOI 10.1016/S0196-0644(96)70261-5; Miller Erik C., 1997, Journal of Emergency Medicine, V15, P453, DOI 10.1016/S0736-4679(97)00071-1; Missler U, 1997, STROKE, V28, P1956, DOI 10.1161/01.STR.28.10.1956; NYBERG L, 1996, 24 M INT SOC ONC BIO; PERSSON L, 1987, STROKE, V18, P911, DOI 10.1161/01.STR.18.5.911; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Raabe A, 1999, BRIT J NEUROSURG, V13, P56, DOI 10.1080/02688699944195; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Rothoerl RD, 1998, J TRAUMA, V45, P765, DOI 10.1097/00005373-199810000-00025; Savola O, 2003, EUR J NEUROL, V10, P175, DOI 10.1046/j.1468-1331.2003.00552.x; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; SERVADEI F, 1988, ITAL J NEUROL SCI, V9, P449, DOI 10.1007/BF02337162; SINDIC CJM, 1982, J NEUROL NEUROSUR PS, V45, P1130, DOI 10.1136/jnnp.45.12.1130; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Stigbrand T, 2000, INT J BIOL MARKER, V15, P33; Teasdale TW, 1997, BRIT MED J, V315, P569; Townend WJ, 2002, J NEUROL NEUROSUR PS, V73, P542, DOI 10.1136/jnnp.73.5.542; USUI A, 1989, CLIN CHEM, V35, P1942; Waterloo K, 1997, ACTA NEUROCHIR, V139, P26, DOI 10.1007/BF01850864; Wiesmann M, 1997, ACTA NEUROCHIR, V139, P1155, DOI 10.1007/BF01410976; Woertgen C, 2002, BRAIN INJURY, V16, P807, DOI 10.1080/02699050210128933; Wrightson P, 1998, NEW ZEAL MED J, V111, P99; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	48	41	41	0	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUL	2004	18	7					671	683		10.1080/02699050310001646215			13	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	821HJ	WOS:000221450700004	15204328				2021-06-18	
J	Suzuki, T; Bramlett, HM; Ruenes, G; Dietrich, WD				Suzuki, T; Bramlett, HM; Ruenes, G; Dietrich, WD			The effects of early post-traumatic hyperthermia in female and ovariectomized rats	JOURNAL OF NEUROTRAUMA			English	Article						fever; gender; hyperthermia; traumatic brain injury	TRAUMATIC BRAIN-INJURY; INDUCED AXONAL INJURY; CEREBRAL-BLOOD-FLOW; MODERATE HYPOTHERMIA; FOREBRAIN ISCHEMIA; PROTEIN; DAMAGE; PROGESTERONE; TEMPERATURE; GENDER	Episodes of post-traumatic hyperthermia commonly occur in the head-injured patient population. Although post-traumatic hyperthermia has been shown to worsen outcome in experimental studies using male rats, the consequences of secondary hyperthermia following traumatic brain injury (TBI) have not been investigated in female animals. Thus, the purpose of this study was to examine the effects of post-traumatic hyperthermia after fluid-percussion (F-P) brain injury in intact and ovariectomized female rats. Thirty-eight female Sprague-Dawley rats were used in these experiments. Intact female rats underwent TBI followed 30 min later by a 4-h period of normothermia (37degreesC) or brain hyperthermia (40degreesC). Female rats that had been ovariectomized 10 days prior to TBI were also traumatized and followed by a period of normothermia or hyperthermia. At 72 h after TBI, rats were perfusion-fixed for quantitative histopathological and immunocytochemical evaluation. Following normothermic TBI, intact female rats demonstrated significantly smaller contusion volumes, decreased frequency of axonal beta-amyloid precursor protein (beta-APP) profiles, and greater numbers of NeuN-positive cortical neurons compared to traumatized ovariectomized females. Although post-traumatic hyperthermia increased contusion volume, cortical neuronal cell death and axonal damage in both intact and ovariectomized female groups, the effects of the induced hyperthermic period were more pronounced in ovariectomized animals. These findings demonstrate for the first time that post-traumatic hyperthermia worsens histopathological outcome in female rats, and that neural hormones, including estrogen and progesterone, may protect against secondary hyperthermic insults.	Univ Miami, Sch Med, Dept Neurol Surg, Miami Project Cure Paralysis, Miami, FL 33152 USA	Dietrich, WD (corresponding author), Univ Miami, Sch Med, Dept Neurol Surg, Miami Project Cure Paralysis, POB 016960,R-48, Miami, FL 33152 USA.	ddietrich@miami.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30291, NS42133] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030291, R01NS042133] Funding Source: NIH RePORTER		Albrecht RF, 1998, MAYO CLIN PROC, V73, P629; Baena RC, 1997, NEUROLOGY, V48, P768, DOI 10.1212/WNL.48.3.768; Behr R, 1997, ANN NY ACAD SCI, V813, P722, DOI 10.1111/j.1749-6632.1997.tb51774.x; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; Cairns Chris J S, 2002, Curr Opin Crit Care, V8, P106, DOI 10.1097/00075198-200204000-00003; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; CROMPTON MR, 1971, BRAIN, V94, P165, DOI 10.1093/brain/94.1.165; D'Cruz BJ, 2002, J CEREBR BLOOD F MET, V22, P843, DOI 10.1097/00004647-200207000-00009; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; DIETRICH WD, 1990, J NEUROPATH EXP NEUR, V49, P486, DOI 10.1097/00005072-199009000-00004; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIETRICH WD, 1992, J NEUROTRAUM, V9, pS475; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Enomoto S, 1996, ANESTHESIOLOGY, V84, P1392, DOI 10.1097/00000542-199606000-00016; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1250; Graham DI, 1996, NEUROTRAUMA, P43; HURN PD, 1995, J CEREBR BLOOD F MET, V15, P666, DOI 10.1038/jcbfm.1995.82; Kamme F, 1996, ADV NEUROL, V71, P199; Kilpatrick MM, 2000, NEUROSURGERY, V47, P850, DOI 10.1097/00006123-200010000-00011; Kim Y, 1996, STROKE, V27, P2274, DOI 10.1161/01.STR.27.12.2274; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; Kumar K, 1996, MOL BRAIN RES, V42, P337, DOI 10.1016/S0169-328X(96)00181-7; Kupina NC, 2003, EXP NEUROL, V180, P55, DOI 10.1016/S0014-4886(02)00048-1; Marion DW, 2001, CURR PHARM DESIGN, V7, P1533, DOI 10.2174/1381612013397302; Matsushita Y, 2001, CRIT CARE MED, V29, P2060, DOI 10.1097/00003246-200111000-00004; MINAMISAWA H, 1990, ANN NEUROL, V28, P26, DOI 10.1002/ana.410280107; Morimoto T, 1997, BRAIN RES, V746, P43, DOI 10.1016/S0006-8993(96)01154-7; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Nakamura T, 1999, J NEUROSURG, V91, P114, DOI 10.3171/jns.1999.91.1.0114; Natale JE, 2000, CRIT CARE MED, V28, P2608, DOI 10.1097/00003246-200007000-00071; Paxinos G., 1982, RAT BRAIN STEREOTAXI; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Segatore M, 1992, J Neurosci Nurs, V24, P104; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Suehiro E, 2003, J NEUROTRAUM, V20, P381, DOI 10.1089/089771503765172336; Suehiro E, 2001, J NEUROSURG, V94, P493, DOI 10.3171/jns.2001.94.3.0493; Suzuki T, 2003, EXP NEUROL, V184, P1017, DOI 10.1016/S0014-4886(03)00389-3; Thompson HJ, 2003, NEUROBIOL DIS, V12, P163, DOI 10.1016/S0969-9961(02)00030-X; Toyoda T, 1996, NEUROSURGERY, V39, P1200, DOI 10.1097/00006123-199612000-00024; Wagner AK, 2003, J NEUROTRAUM, V20, P1121; WIDMANN R, 1993, J NEUROCHEM, V61, P200, DOI 10.1111/j.1471-4159.1993.tb03556.x; Zhang ZJ, 2001, MOL BRAIN RES, V95, P75, DOI 10.1016/S0169-328X(01)00247-9; ZILLES L, 1985, CORTEX RAT STEREOTAX	51	41	42	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2004	21	7					842	853		10.1089/0897715041526186			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	842AE	WOS:000222973800002	15307897				2021-06-18	
J	Mathias, CW; Stanford, MS; Houston, RJ				Mathias, CW; Stanford, MS; Houston, RJ			The physiological experience of the Paced Auditory Serial Addition Task (PASAT): Does the PASAT induce autonomic arousal?	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						arousal; Paced Auditory Serial Attention Task; heart rate; blood pressure	TRAUMATIC BRAIN-INJURY; BLOOD-PRESSURE; HEAD-INJURY; PERFORMANCE; ASSOCIATION; DISEASE; SCORES	Previous research suggests that the Paced Auditory Serial Attention Task (PASAT) alters mood states, which may induce performance changes and complicate interpretation test scores. In the current design, we examined arousal as one mechanism moderating PASAT performance. It was expected that arousal level would increase during the test, and performance on the test would be related to arousal level. Heart rate and blood pressure (systolic and diastolic) were recorded from 42 healthy adult men during rest and PASAT challenge. Heart rate and blood pressure were significantly higher and stable across the PASAT procedure, while performance scores showed a steady decrease in correct responses. No association of arousal level and performance was found. Although, PASAT induced arousal changes were not significantly related to performance among healthy adults, the observed arousal changes do raise concerns about interpretation of PASAT performance among more sensitive populations and indicate new areas of application of the procedure. (C) 2003 National Academy of Neuropsychology. Published by Elsevier Ltd. All rights reserved.	Baylor Univ, Dept Psychol & Neurosci, Waco, TX 76798 USA; Univ Texas, Hlth Sci Ctr, Neurobehav Res Lab & Clin, Houston, TX USA; Univ Connecticut, Sch Med, Dept Psychiat, Farmington, CT USA	Stanford, MS (corresponding author), Baylor Univ, Dept Psychol & Neurosci, Waco, TX 76798 USA.	Matthew_Stanford@baylor.edu		Mathias, Charles/0000-0003-1902-673X			AlAbsi M, 1997, PSYCHOPHYSIOLOGY, V34, P266, DOI 10.1111/j.1469-8986.1997.tb02397.x; ANDERSON CA, 1995, PERS SOC PSYCHOL B, V21, P434, DOI 10.1177/0146167295215002; Brooks J, 1999, J TRAUMA, V46, P159, DOI 10.1097/00005373-199901000-00027; Catipovic-Veselica K, 1999, PSYCHOL REP, V84, P433, DOI 10.2466/PR0.84.2.433-442; Chen Y, 1998, INT J OBESITY, V22, P771, DOI 10.1038/sj.ijo.0800658; Chronicle EP, 1998, NEUROPSYCHOL REHABIL, V8, P273; Cicerone KD, 1997, CLIN NEUROPSYCHOL, V11, P266, DOI 10.1080/13854049708400455; Cohen R. A., 1993, NEUROPSYCHOLOGY ATTE; DEARY IJ, 1991, PERS INDIV DIFFER, V12, P983, DOI 10.1016/0191-8869(91)90027-9; EGAN V, 1988, PERS INDIV DIFFER, V9, P179, DOI 10.1016/0191-8869(88)90046-3; Fos L A, 2000, Appl Neuropsychol, V7, P140, DOI 10.1207/S15324826AN0703_4; GEISSER S, 1958, ANN MATH STAT, V29, P885, DOI 10.1214/aoms/1177706545; Graham RE, 1996, PSYCHOPHYSIOLOGY, V33, P566, DOI 10.1111/j.1469-8986.1996.tb02433.x; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; HEBB DO, 1955, PSYCHOL REV, V62, P243, DOI 10.1037/h0041823; Holdwick DJ, 1999, ARCH CLIN NEUROPSYCH, V14, P273, DOI 10.1016/S0887-6177(98)00021-3; HUMPHREYS MS, 1984, PSYCHOL REV, V91, P153, DOI 10.1037/0033-295X.91.2.153; *JOHN JOHN MED INC, 1997, DINAMAP MPS SEL PORT; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; MANOLIO TA, 1988, AM J HYPERTENS, V1, pS161, DOI 10.1093/ajh/1.3.161S; Mathias CW, 2003, PERS INDIV DIFFER, V35, P355, DOI 10.1016/S0191-8869(02)00195-2; Matthews G., 1998, PERSONALITY TRAITS; PAPILLO JF, 1990, PRINCIPLES PSYCHOPHY; *PSYCH CORP, 1998, PASAT PAS AUD SER AT; Roman DD, 1991, CLIN NEUROPSYCHOL, V5, P33; SCHACHTER S, 1962, PSYCHOL REV, V69, P379, DOI 10.1037/h0046234; Sherman EMS, 1997, CLIN NEUROPSYCHOL, V11, P34, DOI 10.1080/13854049708407027; Sjogren P, 2000, J PAIN SYMPTOM MANAG, V19, P100, DOI 10.1016/S0885-3924(99)00143-8; Snyder PJ, 2001, NEUROPSYCHOLOGY, V15, P617, DOI 10.1037//0894-4105.15.4.617; Spreen O., 1991, COMPENDIUM NEUROPSYC; Stevens J., 1996, APPL MULTIVARIATE ST; Weersink EJM, 1997, AM J RESP CRIT CARE, V156, P1144, DOI 10.1164/ajrccm.156.4.9701001; Yerkes RM, 1908, J COMP NEUROL PSYCHO, V18, P459, DOI 10.1002/cne.920180503; ZANZOMERAN AH, 1994, CLIN NEUROPSYCHOLOGY	35	41	42	0	2	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	JUN	2004	19	4					543	554		10.1016/j.acn.2003.08.001			12	Psychology, Clinical; Psychology	Psychology	830DL	WOS:000222101700008	15163455	Bronze			2021-06-18	
J	Campbell, CGN; Kuehn, SM; Richards, PMP; Ventureyra, E; Hutchison, JS				Campbell, CGN; Kuehn, SM; Richards, PMP; Ventureyra, E; Hutchison, JS			Medical and cognitive outcome in children with traumatic brain injury	CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES			English	Article							SEVERE HEAD-INJURY; ADOLESCENTS; SURVIVAL; SEQUELAE; COHORT	Background: Head injury is an important cause of morbidity and mortality in pediatrics. Comprehensive studies on outcome are scarce despite significant clinical concern that multiple areas of functioning may be impaired following moderate to severe head injury. The literature suggests that sequelae include not only medical problems but also impairments in cognitive functioning. Methods: A retrospective medical and psychology chart review of patients, age 1-18 years, admitted to the Children's Hospital of Eastern Ontario with moderate (Glasgow Coma Scale [GCS] 9-12) or severe head injury (GCS :5 8) from November 1, 1993 until December 31, 1998 was conducted. Correlations were performed between medical variables (i.e., GCS, Pediatric Risk of Mortality [PRISM] III score, duration of ICU and hospital stay) and measures of intelligence and memory functioning. Results: Eighty-three children age I to 18 were included. Seventy percent of the children were classified as having a severe head injury. There was a mortality rate of thirteen percent. Younger age at injury, lower GCS, and higher PRISM III scores predicted higher mortality. Medical complications were documented systematically. Forty-four patients underwent at least one cognitive assessment and 17 of these children had intelligence testing at three points in time: baseline (< four months), early recovery (five to 15 months) and follow-up (16 to 38 months). The mean intelligence and memory scores fell within the average range at the latest point in follow-up. For those children who underwent three serial assessments, the mean verbal and performance IQ fell within the low average range at baseline improving significantly to fall within the average range by early recovery. Continued improvements were apparent in verbal memory beyond early recovery, with the mean obtained at follow-up falling within 1 SD of the normative mean. Despite the return to normal ranges for the group means the proportion of scores falling below 1.5 standard deviations from the mean was greater than population norms for verbal IQ, performance IQ and verbal memory. Lower GCS scores and longer duration of stay in ICU or hospital were predictive of lower nonverbal intelligence. Lower GCS was also predictive of lower visual memory scores. Conclusions: This study describes a population of Canadian children who suffered moderate or severe traumatic brain injury. Initial GCS was the best predictor of mortality and cognitive outcome. These children demonstrated a temporal improvement in intelligence and memory functioning, with their mean performance on these cognitive measures failing within the average range at 16 to 38 months postinjury, although there was considerable variability in the outcomes between individuals.	Univ Toronto, Hosp Sick Children, Dept Crit Care, Fac Med, Toronto, ON M5G 1X8, Canada; Univ Toronto, Hosp Sick Children, Dept Pediat, Fac Med, Toronto, ON M5G 1X8, Canada; Carleton Univ, Fac Psychol, Ottawa, ON K1S 5B6, Canada; Univ Ottawa, Fac Med, Ottawa, ON, Canada; Childrens Hosp Eastern Ontario, Dept Pediat, Ottawa, ON K1H 8L1, Canada; Childrens Hosp Eastern Ontario, Dept Mental Hlth, Ottawa, ON K1H 8L1, Canada; Childrens Hosp Eastern Ontario, Dept Surg, Ottawa, ON K1H 8L1, Canada; Childrens Hosp Eastern Ontario, Div Neurosurg, Ottawa, ON K1H 8L1, Canada; Childrens Hosp Eastern Ontario, Div Neurol, Ottawa, ON K1H 8L1, Canada; Childrens Hosp Eastern Ontario, Discipline Psychol, Ottawa, ON K1H 8L1, Canada	Hutchison, JS (corresponding author), Univ Toronto, Hosp Sick Children, Dept Crit Care, Fac Med, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.						Adelson P David, 2003, Pediatr Crit Care Med, V4, pS19; Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; BEHRMAN RE, 1996, NELSON TXB PEDIAT, P1; BROWN S, 1994, J NEUROPSYCHIATRY CL, V16, P15; BUSCHKE H, 1974, J EXP CHILD PSYCHOL, V18, P488, DOI 10.1016/0022-0965(74)90126-X; CHADWICK O, 1981, J CHILD PSYCHOL PSYC, V22, P117, DOI 10.1111/j.1469-7610.1981.tb00538.x; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; Chesnut RM, 1998, J TRAUMA, V44, P958, DOI 10.1097/00005373-199806000-00003; Clark E, 1996, J LEARN DISABIL, V29, P549, DOI 10.1177/002221949602900509; DAVIS RJ, 1992, TXB PEDIAT INTENSIVE, P805; DISCALA C, 1991, ARCH PHYS MED REHAB, V72, P662; Emanuelson IM, 1997, DEV MED CHILD NEUROL, V39, P502; Ewing-Cobbs L, 2000, CHILD NERV SYST, V16, P25, DOI 10.1007/s003810050006; EWINGCOBBS L, 1990, NEUROSURGERY, V26, P638; EWINGCOBBS L, 1998, TRAUMATIC BRAIN INJU, P11; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; Greenspan A I, 1996, Curr Probl Pediatr, V26, P170, DOI 10.1016/S0045-9380(96)80004-1; Helfaer Mark A., 1993, Current Opinion in Pediatrics, V5, P303; HUN SS, 1997, CHILD NERV SYST, V13, P82; JOHNSON DA, 1992, BRIT J EDUC PSYCHOL, V62, P404, DOI 10.1111/j.2044-8279.1992.tb01033.x; KNIGHTS R M, 1991, Brain Injury, V5, P339, DOI 10.3109/02699059109008107; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P223, DOI 10.1016/S0003-9993(96)90102-1; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P125, DOI 10.1016/S0003-9993(96)90156-2; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; MICHAUD LJ, 1993, PEDIATR CLIN N AM, V40, P553; Pollack MM, 1996, CRIT CARE MED, V24, P743, DOI 10.1097/00003246-199605000-00004; PRIOER M, 1994, AUST PSYCHOL, V29, P116, DOI 10.1080/00050069408257334; RUIJS MBM, 1990, CLIN NEUROL NEUROSUR, V92, P323, DOI 10.1016/0303-8467(90)90058-D; Semple PL, 1998, S AFR MED J, V88, P440; Sheslow D., 1990, WIDE RANGE ASSESSMEN; Thakker JC, 1997, CRIT CARE MED, V25, P1396, DOI 10.1097/00003246-199708000-00030; Wechsler D., 1989, WECHSLER PRESCHOOL P; Wechsler D., 1997, WECHSLER INTELLIGENC; WECHSLER D, 1974, INTELLIGENCE SCALE C; Wechsler D, 1981, ADULT INTELLIGENCE S; YLVISAKER M, 1990, REHABILITATION ADULT	41	41	45	0	3	CANADIAN J NEUROL SCI INC	CALGARY	PO BOX 4220, STATION C EDITORIAL & SUBSCRIPTION SERV, CALGARY, AB T2T 5N1, CANADA	0317-1671			CAN J NEUROL SCI	Can. J. Neurol. Sci.	MAY	2004	31	2					213	219		10.1017/S0317167100053853			7	Clinical Neurology	Neurosciences & Neurology	820IY	WOS:000221383600014	15198446	Bronze			2021-06-18	
J	Giacino, JT; Trott, CT				Giacino, JT; Trott, CT			Rehabilitative management of patients with disorders of consciousness grand rounds	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						coma; diagnosis; minimally conscious state; prognosis; rehabilitation; vegetative state	TRAUMATIC BRAIN-INJURY; VEGETATIVE STATE; SENSORY STIMULATION; AMANTADINE; RECOVERY; COMA	Background: There are no standards of care to guide the selection of rehabilitation assessment and treatment procedures for patients with disorders of consciousness. Recently, consensus-based recommendations for management of patients in the vegetative and minimally conscious states have been developed and disseminated in neurology and neurorehabilitation. This is an important first step toward achieving evidence-based guidelines of care. Objective: Using a "Grand Rounds" format, we illustrate the application of consensus-based diagnostic, prognostic, and treatment recommendations in a patient who sustained severe traumatic brain injury with prolonged alteration in consciousness. After discussing the salient features of the case, we summarize the basic tenets of clinical care for this population.	New Jersey Neurosci Inst, JFK Med Ctr, Edison, NJ 08818 USA; JFK Johnson Rehabil Inst, Ctr Head Injuries, Edison, NJ USA	Giacino, JT (corresponding author), New Jersey Neurosci Inst, JFK Med Ctr, 65 James St, Edison, NJ 08818 USA.	jgiacino@solarishs.org	Giacino, Joseph/AAF-1952-2021	Giacino, Joseph/0000-0002-7916-9698			Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; ANSELL BJ, 1989, ARCH PHYS MED REHAB, V70, P104; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; *ASP NEUR C WORKGR, 1996, P ASP NEUR C MARCH 1; CHATHAMSHOWALTE.PE, 2000, BRAIN INJURY, V14, P997; CHILDS NL, 1993, NEUROLOGY, V43, P1465, DOI 10.1212/WNL.43.8.1465; DiPasquale MC, 1996, J HEAD TRAUMA REHAB, V11, P9, DOI 10.1097/00001199-199612000-00004; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P36, DOI 10.1097/00001199-199708000-00005; GIACINO JT, 1991, ARCH PHYS MED REHAB, V72, P897, DOI 10.1016/0003-9993(91)90008-7; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; GIACINO JT, 1995, J HEAD TRAUMA REHAB, V10, P40; Giacino JT, 1996, NEUROREHABILITATION, V6, P69, DOI 10.3233/NRE-1996-6108; GIACINO JT, REHABILITATION INTER; JENNETT B, 1972, LANCET, V1, P734; Jennett B, 2001, NEUROLOGY, V56, P486, DOI 10.1212/WNL.56.4.486; Kampfl A, 1998, LANCET, V351, P1763, DOI 10.1016/S0140-6736(97)10301-4; KANNO T, 1987, PACE, V10, P207, DOI 10.1111/j.1540-8159.1987.tb05949.x; Katz DI, 2002, NEUROLOGY, V58, pA6; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; Meythaler JM, 2002, J HEAD TRAUMA REHAB, V17, P300, DOI 10.1097/00001199-200208000-00004; Ottenbacher KJ, 1999, AM J PHYS MED REHAB, V78, P169, DOI 10.1097/00002060-199903000-00021; Passler MA, 2001, ARCH PHYS MED REHAB, V82, P311, DOI 10.1053/apmr.2001.20831; Plum F, 1982, DIAGNOSIS STUPOR COM; Powell JH, 1996, J NEUROL NEUROSUR PS, V60, P416, DOI 10.1136/jnnp.60.4.416; RAPPAPORT M, 1992, ARCH PHYS MED REHAB, V73, P628; Reinhard DL, 1996, ARCH PHYS MED REHAB, V77, P80, DOI 10.1016/S0003-9993(96)90225-7; ROCKSWOLD GL, 1992, J NEUROSURG, V76, P929, DOI 10.3171/jns.1992.76.6.0929; Schneider WN, 1999, BRAIN INJURY, V13, P863; SHIFF N, 2002, BRAIN, V125, P1; TRESCH DD, 1991, ARCH INTERN MED, V151, P930, DOI 10.1001/archinte.151.5.930; Tsubokawa T, 1990, Brain Inj, V4, P315; Worzniak M, 1997, J FAM PRACTICE, V44, P495; Zafonte RD, 1998, BRAIN INJURY, V12, P617	34	41	44	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2004	19	3					254	265		10.1097/00001199-200405000-00006			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	826JB	WOS:000221824300006	15247847				2021-06-18	
J	Colletti, V; Carner, M; Miorelli, V; Colletti, L; Guida, M; Fiorino, F				Colletti, V; Carner, M; Miorelli, V; Colletti, L; Guida, M; Fiorino, F			Auditory brainstem implant in posttraumatic cochlear nerve avulsion	AUDIOLOGY AND NEURO-OTOLOGY			English	Article; Proceedings Paper	Conference on Candidacy for Implantable Hearing Devices	JUN 27-29, 2002	Utrecht, NETHERLANDS			auditory brainstem implant; profound hearing loss; head injury	SENSORINEURAL HEARING-LOSS; TEMPORAL BONE-FRACTURE; ELECTRICAL-STIMULATION; ROUND-WINDOW; CANDIDATES; EXPERIENCE; SURVIVAL	Patients aged over 12 years with neurofibromatosis type 2 are considered candidates for an auditory brainstem implant (ABI). This study extends the indication criteria of ABI to subjects with profound hearing loss due to damaged cochleas and/or cochlear nerves (CNs) following head injuries. In our department, over the period from April 1997 to November 2002, 32 patients, 23 adults and 9 children, were fitted with ABIs. Their ages ranged from 14 months to 70 years. These patients were suffering from a variety of tumor (13 subjects) and nontumor CN or cochlear diseases (19 subjects). Six patients, 5 adults and 1 child, had profound hearing loss following head injury. Their mean age was 25 years (range: 16-48 years). Five were male and 1 female. The retrosigmoid approach was used in all 6 patients. The electrode array was inserted into the lateral recess of the fourth ventricle and correct electrode positioning was monitored with the aid of electrically evoked auditory brainstem responses and neural response telemetry. Correct implantation was achieved in all patients. No complications were observed due to implantation surgery or related to ABI activation and stimulation of the cochlear nuclei. At activation, an average of 9.8 electrodes (range 5-13) were switched on without side effects. One to 6 electrodes were activated in the following sessions after time periods ranging from 2 to 16 months. All patients achieved auditory-alone-mode closed-set word recognition scores ranging from 40 to 100%; 3 had auditory-alone-mode open-set sentence recognition scores of 60 100%; 2 of these even had speech-tracking performance scores of 38 and 43 words, respectively, showing an ability to engage in normal conversation and converse over the phone. The present study demonstrates that the ABI is a useful rehabilitation instrument in subjects with damaged cochleas and/or CN avulsion following head injury who are unamenable or poorly responsive to auditory rehabilitation using cochlear implants. Copyright (C) 2004 S. Karger AG, Basel.	Univ Verona, ENT Dept, IT-37100 Verona, Italy	Colletti, V (corresponding author), Univ Verona, ENT Dept, Ple LA Scuro 10, IT-37100 Verona, Italy.	vittoriocolletti@yahoo.com		COLLETTI, Liliana/0000-0001-8089-5681			Brown CJ, 1998, AM J OTOL, V19, P320; Camilleri AE, 1999, J LARYNGOL OTOL, V113, P454, DOI 10.1017/S0022215100144202; COHEN NL, 1988, ANN OTOL RHINOL LA S, V135, P8; COLIGADO EJ, 1993, ARCH PHYS MED REHAB, V74, P653, DOI 10.1016/0003-9993(93)90166-8; Colletti V, 2002, OTOLARYNG HEAD NECK, V127, P84, DOI 10.1067/mhn.2002.126723; Colletti V, 2001, INT J PEDIATR OTORHI, V60, P99, DOI 10.1016/S0165-5876(01)00465-7; COLLETTI V, IN PRESS OTOL NEUROT; DESAUVAGE RC, 1983, J ACOUST SOC AM, V73, P616, DOI 10.1121/1.388872; FIFER RC, 1991, AM J OTOL, V12, P350; GANTZ BJ, 1993, ADV OTO-RHINO-LARYNG, V48, P153; GRAY RF, 1990, CLIN OTOLARYNGOL, V15, P29, DOI 10.1111/j.1365-2273.1990.tb00428.x; GRIFFITHS MV, 1979, J LARYNGOL OTOL, V93, P253, DOI 10.1017/S0022215100086990; *ISTAT, 2000, STAT INC STRAD ANN 2; KILENY PR, 1992, EAR HEARING, V13, P294, DOI 10.1097/00003446-199210000-00006; KILENY PR, 1987, ARCH OTOLARYNGOL, V113, P1072; KOCKHAR MS, 1990, ENT-EAR NOSE THROAT, V69, P537; KOEFOEDNIELSEN B, 1982, ORL J OTO-RHINO-LARY, V44, P206, DOI 10.1159/000275594; LYOS AT, 1995, ARCH OTOLARYNGOL, V121, P795; MAKISHIMA K, 1976, LARYNGOSCOPE, V86, P1303, DOI 10.1288/00005537-197609000-00002; Mason SM, 1997, AM J OTOL, V18, P466; MECKLENBURG DJ, 1997, MANUAL AUDITORY REHA; Moore A, 1999, J LARYNGOL OTOL, V113, P34, DOI 10.1017/S0022215100146079; MORGAN WE, 1994, LARYNGOSCOPE, V104, P426; Nikolopoulos TP, 2000, EAR HEARING, V21, P236, DOI 10.1097/00003446-200006000-00007; SEKIYA T, 1988, ACTA NEUROCHIR, V90, P45, DOI 10.1007/BF01541266; SMITH L, 1983, ANN OTO RHINOL LARYN, V92, P19, DOI 10.1177/000348948309200105	26	41	46	0	7	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1420-3030			AUDIOL NEURO-OTOL	Audiol. Neuro-Otol.		2004	9	4					247	255		10.1159/000078394			9	Audiology & Speech-Language Pathology; Neurosciences; Otorhinolaryngology	Audiology & Speech-Language Pathology; Neurosciences & Neurology; Otorhinolaryngology	830CH	WOS:000222098700008	15205552				2021-06-18	
J	Li, JF; Li, WY; Su, J; Liu, WM; Altura, BT; Altura, BM				Li, JF; Li, WY; Su, J; Liu, WM; Altura, BT; Altura, BM			Hydrogen peroxide induces apoptosis in cerebral vascular smooth muscle cells: possible relation to neurodegenerative diseases and strokes	BRAIN RESEARCH BULLETIN			English	Article						hydrogen peroxide (H2O2); apoptosis; cerebral vascular smooth muscle cells; brain injury; strokes	HUMAN HEPATOMA-CELLS; OXIDATIVE STRESS; ENDOTHELIAL-CELLS; DNA FRAGMENTATION; INJURY; DEATH; MECHANISMS; NECROSIS; MEDIATOR; CALCIUM	Recently, reactive oxygen species (ROS) have been suggested as important mediators of brain damage in a number of disease states, including traumatic brain injury, neurodegenerative diseases and strokes. Apoptosis has been suggested to play an important role in neurodegenerative diseases, traumatic brain injury and strokes. The aim of this study was to determine whether or not cerebral vascular smooth muscle cells (CVSMCs) undergo apoptosis following treatment with hydrogen peroxide (H2O2). Herein, we demonstrate, for the first time, that H2O2 can induce apoptosis in a concentration-dependent manner in primary cultured CVSMCs, as measured by several morphological and biochemical criteria. H2O2-induced apoptosis may be initiated by stimulating Ca2+-dependent endonuclease activity. The present new data suggest that apoptosis in cerebral VSMCs, induced by ROS, such as H2O2, could play important roles in nemodegenerative processes, traumatic brain injury and strokes. (C) 2003 Elsevier Inc. All rights reserved.	SUNY Hlth Sci Ctr, Dept Physiol & Pharmacol, Brooklyn, NY 11203 USA; SUNY Hlth Sci Ctr, Dept Anat & Cell Biol, Brooklyn, NY 11203 USA; SUNY Hlth Sci Ctr, Dept Med, Brooklyn, NY 11203 USA; SUNY Hlth Sci Ctr, Ctr Cardiovasc & Muscle Res, Brooklyn, NY 11203 USA	Li, JF (corresponding author), SUNY Hlth Sci Ctr, Dept Physiol & Pharmacol, Brooklyn, NY 11203 USA.				NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R01AA008674] Funding Source: NIH RePORTER; NIAAA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [AA-08674] Funding Source: Medline		Altura BM, 1996, NEUROSCI LETT, V220, P207, DOI 10.1016/S0304-3940(96)13268-7; Barbouti A, 2002, FREE RADICAL BIO MED, V33, P691, DOI 10.1016/S0891-5849(02)00967-X; Bennett MR, 1999, CARDIOVASC RES, V41, P361, DOI 10.1016/S0008-6363(98)00212-0; Bondy SC, 2002, NEUROCHEM INT, V40, P123, DOI 10.1016/S0197-0186(01)00084-5; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; Curtin JF, 2002, J IMMUNOL METHODS, V265, P49, DOI 10.1016/S0022-1759(02)00070-4; de Klaver MJM, 2002, ANESTHESIOLOGY, V97, P24, DOI 10.1097/00000542-200207000-00005; Deshpande SS, 2002, HUM EXP TOXICOL, V21, P63, DOI 10.1191/0960327102ht211oa; Diez J, 1998, CURR OPIN CARDIOL, V13, P317, DOI 10.1097/00001573-199809000-00005; Fairbairn DW, 1996, SCANNING, V18, P407; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GENG YJ, 1995, AM J PATHOL, V147, P251; Gilgun-Sherki Y, 2002, PHARMACOL REV, V54, P271, DOI 10.1124/pr.54.2.271; Groc L, 2001, NEUROCHEM INT, V39, P127, DOI 10.1016/S0197-0186(01)00013-4; HAN DKM, 1995, AM J PATHOL, V147, P267; He JL, 2001, J PHARMACOL EXP THER, V298, P180; Hetts SW, 1998, JAMA-J AM MED ASSOC, V279, P300, DOI 10.1001/jama.279.4.300; Jin N, 2000, FREE RADICAL BIO MED, V29, P736, DOI 10.1016/S0891-5849(00)00376-2; Kalyankrishna S, 2002, PROSTAG OTH LIPID M, V70, P13, DOI 10.1016/S0090-6980(02)00010-2; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KOLBER MA, 1990, FASEB J, V4, P3021; KONTOS HA, 1981, AM J PHYSIOL, V240, P511; Labat-Moleur F, 1998, J HISTOCHEM CYTOCHEM, V46, P327, DOI 10.1177/002215549804600306; Li J, 2000, CELL BIOL INT, V24, P9, DOI 10.1006/cbir.1999.0438; Li JF, 2001, CELL BIOL INT, V25, P1213, DOI 10.1006/cbir.2001.0792; Li PF, 1997, FEBS LETT, V404, P249, DOI 10.1016/S0014-5793(97)00093-8; Li PF, 1997, CIRCULATION, V96, P3602; LING YH, 1993, CANCER RES, V53, P1845; Liu XM, 2002, CARDIOVASC RES, V55, P396, DOI 10.1016/S0008-6363(02)00410-8; Mallat Z, 2000, BRIT J PHARMACOL, V130, P947, DOI 10.1038/sj.bjp.0703407; MALLAT Z, 2001, BRIT J PHARMACOL, V133, P967; Orzechowski A, 2002, LIFE SCI, V71, P1793, DOI 10.1016/S0024-3205(02)01942-2; Peiro C, 2001, BRIT J PHARMACOL, V133, P967, DOI 10.1038/sj.bjp.0704184; Rollet-Labelle E, 1998, FREE RADICAL BIO MED, V24, P563, DOI 10.1016/S0891-5849(97)00292-X; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; WEI EP, 1981, CIRC RES, V48, P95, DOI 10.1161/01.RES.48.1.95; Yang ZW, 1999, N-S ARCH PHARMACOL, V360, P646, DOI 10.1007/s002109900128; ZHANG A, 1992, ALCOHOL CLIN EXP RES, V16, P55, DOI 10.1111/j.1530-0277.1992.tb00635.x; Zhang AM, 1997, ALCOHOL, V14, P367, DOI 10.1016/S0741-8329(96)00185-1	40	41	43	1	7	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0361-9230			BRAIN RES BULL	Brain Res. Bull.	DEC 15	2003	62	2					101	106		10.1016/j.brainresbull.2003.08.011			6	Neurosciences	Neurosciences & Neurology	750JG	WOS:000186987100003	14638383				2021-06-18	
J	Hlatky, R; Lui, H; Cherian, L; Goodman, JC; O'Brien, WE; Contant, CF; Robertson, CS				Hlatky, R; Lui, H; Cherian, L; Goodman, JC; O'Brien, WE; Contant, CF; Robertson, CS			The role of endothelial nitric oxide synthase in the cerebral hemodynamics after controlled cortical impact injury in mice	JOURNAL OF NEUROTRAUMA			English	Article						cerebral blood flow; endothelial NOS; nitric oxide; traumatic brain injury	TRAUMATIC BRAIN-INJURY; L-ARGININE; DEFICIENT; HYPERTENSION; RESPONSES; LACKING; GENE; RATS	Traumatic brain injury causes a reduction in cerebral blood flow, which may cause additional damage to the brain. The purpose of this study was to examine the role of nitric oxide produced by endothelial nitric oxide synthase (eNOS) in these vascular effects of trauma. To accomplish this, cerebral hemodynamics were monitored in mice deficient in eNOS and wild-type control mice that underwent lateral controlled cortical impact injury followed by administration of either L-arginine, 300 mg/kg, or saline at 5 min after the impact injury. The eNOS deficient mice had a greater reduction in laser Doppler flow (LDF) in the contused brain tissue at the impact site after injury, despite maintaining a higher blood pressure. L-Arginine administration increased LDF post-injury only in the wild-type mice. L-Arginine administration also resulted in a reduction in contusion volume, from 2.4 +/- 1.5 to 1.1 +/- 1.2 mm(3) in wild-type mice. Contusion volume in the eNOS deficient mice was not significantly altered by L-arginine administration. These differences in cerebral hemodynamics between the eNOS-deficient and the wild-type mice suggest an important role for nitric oxide produced by eNOS in the preservation of cerebral blood flow in contused brain following traumatic injury, and in the improvement in cerebral blood flow with L-arginine administration.	Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Genet & Mol Biol, Houston, TX 77030 USA; Charles Univ Prague, Univ Hosp, Dept Neurosurg, Hradec Kralove, Czech Republic; W China Univ Med Sci, Univ Hosp 1, Dept Surg, Chengdu 610041, Peoples R China	Robertson, CS (corresponding author), Baylor Coll Med, Dept Neurosurg, 6560 Fannin St 944, Houston, TX 77030 USA.	claudiar@bcm.tmc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS038660] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS38660] Funding Source: Medline		Champion HC, 2000, AM J PHYSIOL-HEART C, V278, pH8; Cherian L, 1999, CRIT CARE MED, V27, P2512, DOI 10.1097/00003246-199911000-00031; Cherian L, 2000, J NEUROPHYSIOL, V83, P2171; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; DALKARA T, 1995, J CEREBR BLOOD F MET, V15, P631, DOI 10.1038/jcbfm.1995.78; Goldstein H, 1995, MULTILEVEL STAT MODE; Gregg AR, 1998, AM J PHYSIOL-HEART C, V275, pH2319; Grima G, 2001, EUR J NEUROSCI, V14, P1762, DOI 10.1046/j.0953-816x.2001.01799.x; Hefler LA, 2001, BIOL REPROD, V64, P666, DOI 10.1095/biolreprod64.2.666; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; Huang ZH, 1996, J CEREBR BLOOD F MET, V16, P981, DOI 10.1097/00004647-199609000-00023; Kurihara N, 1998, HYPERTENSION, V32, P856, DOI 10.1161/01.HYP.32.5.856; Liu H, 2002, J NEUROTRAUM, V19, P327, DOI 10.1089/089771502753594891; Lo EH, 1996, STROKE, V27, P1381, DOI 10.1161/01.STR.27.8.1381; Lu YC, 1997, MOL CHEM NEUROPATHOL, V30, P125, DOI 10.1007/BF02815154; Michael LH, 1995, AM J PHYSIOL-HEART C, V269, pH2147; RASBASH J, 2002, MLWIN VERSION 1 20 M; Rehman A, 1997, BRIT J PHARMACOL, V122, P1702, DOI 10.1038/sj.bjp.0701556; Shesely EG, 1996, P NATL ACAD SCI USA, V93, P13176, DOI 10.1073/pnas.93.23.13176; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Wada K, 1999, J NEUROTRAUM, V16, P203, DOI 10.1089/neu.1999.16.203; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; WADA K, 1997, J NEUROTRAUM, V14, P760; WU CC, 1995, BRIT J PHARMACOL, V114, P1666, DOI 10.1111/j.1476-5381.1995.tb14955.x; Yamada M, 2000, J CEREBR BLOOD F MET, V20, P709, DOI 10.1097/00004647-200004000-00008	26	41	43	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2003	20	10					995	1006		10.1089/089771503770195849			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	734RX	WOS:000186072300008	14588116				2021-06-18	
J	Ip, EY; Zanier, ER; Moore, AH; Lee, SM; Hovda, DA				Ip, EY; Zanier, ER; Moore, AH; Lee, SM; Hovda, DA			Metabolic, neurochemical, and histologic responses to vibrissa motor cortex stimulation after traumatic brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						cortex; fluid percussion injury; fluorodeoxyglucose autoradiography; microdialysis; stimulation; vibrissa	LONG-TERM POTENTIATION; CEREBRAL GLUCOSE-UTILIZATION; FLUID-PERCUSSION INJURY; BLOOD-FLOW; EVOKED-POTENTIALS; HEAD-INJURY; RAT; ISCHEMIA; ACTIVATION; DEPRESSION	During the prolonged metabolic depression after traumatic brain injury (TBI), neurons are less able to respond metabolically to peripheral stimulation. Because this decreased responsiveness has been attributed to circuit dysfunction, the present study examined the metabolic, neurochemical, and histologic responses to direct cortical stimulation after lateral fluid percussion injury (LFPI). This study addressed three specific hypotheses: that neurons, if activated after LFPI, will increase their utilization of glucose even during a period of posttraumatic metabolic depression; that this secondary activation results in an increase in the production of lactate and a depletion of extracellular glucose; and that because cells are known to be in a state of energy crisis after traumatic brain injury, additional energy demands resulting from activation can result in their death. The results indicate that stimulating to levels eliciting a vibrissa twitch resulted in an increase in the cerebral metabolic rate for glucose (CMRglc; mumol. 100 g(-1).min(-1)) of 34% to 61% in the sham-operated, 1-hour LFPI, and 7-day LFPI groups. However, in the 1-day LFPI group, stimulation induced a 161 % increase in CMRglc and a 35% decrease in metabolic activation volume. Extracellular lactate concentrations during stimulation significantly increased from 23% in the sham-injured group to 55% to 63% in the 1-day and 7-day LFPI groups. Extracellular glucose concentrations during stimulation remained unchanged in the sham-injured and 7-day LFPI groups, but decreased 17% in the 1-day LFPI group. The extent of cortical degeneration around the stimulating electrode in the 1-day LFPI group nearly doubled when compared with controls. These results indicate that at I day after LFPI, the cortex can respond to stimulation with an increase in anaerobic glycolysis; however, this metabolic response to levels eliciting a vibrissa response via direct cortical stimulation appears to constitute a secondary injury in the TBI brain.	Univ Calif Los Angeles, Sch Med, Div Neurosurg, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Neurosci Interdept PhD Program, Los Angeles, CA USA; Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Dept Med & Mol Pharmacol, Los Angeles, CA USA; Univ Rochester, Dept Neurobiol & Anat M&D, Rochester, NY USA; Osped Maggiore, Policlin IRRCS, Dept Anesthesia & Crit Care Med, Milan, Italy	Hovda, DA (corresponding author), Univ Calif Los Angeles, Sch Med, Div Neurosurg, Box 957039, Los Angeles, CA 90095 USA.	dhovda@mednet.ucla.edu	Zanier, Elisa/AAA-8095-2020	Zanier, Elisa/0000-0002-3011-8718	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30308, NS27544] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030308, R01NS027544] Funding Source: NIH RePORTER		Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; Bramlett HM, 1999, J NEUROSURG, V91, P653, DOI 10.3171/jns.1999.91.4.0653; Cherian L, 1996, J NEUROTRAUM, V13, P371, DOI 10.1089/neu.1996.13.371; COLLE LM, 1986, BRAIN RES, V397, P27, DOI 10.1016/0006-8993(86)91366-1; DESALLES AAF, 1987, J NEUROSURG, V66, P102, DOI 10.3171/jns.1987.66.1.0102; DIETRICH WD, 1994, J NEUROTRAUM, V11, P629, DOI 10.1089/neu.1994.11.629; DIETRICH WD, 1986, J CEREBR BLOOD F MET, V6, P405, DOI 10.1038/jcbfm.1986.73; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; GINSBERG MD, 1989, J CEREBR BLOOD F MET, V9, P329, DOI 10.1038/jcbfm.1989.51; Ginsberg MD, 1997, AM J PHYSIOL-HEART C, V272, pH2859; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; HOVDA DA, 1996, NEUROTRAUMA, P1459; ISHIGE N, 1987, NEUROSURGERY, V20, P854, DOI 10.1227/00006123-198706000-00006; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; Jiang XB, 1999, NEUROL MED-CHIR, V39, P649, DOI 10.2176/nmc.39.649; Jiang XB, 2000, NEUROL MED-CHIR, V40, P16, DOI 10.2176/nmc.40.16; Kozlowski DA, 1996, J NEUROSCI, V16, P4776; Lee SM, 1999, ANN NY ACAD SCI, V893, P337, DOI 10.1111/j.1749-6632.1999.tb07849.x; Matsushita Y, 2001, J CEREBR BLOOD F MET, V21, P847, DOI 10.1097/00004647-200107000-00010; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; Moore AH, 2000, J CEREBR BLOOD F MET, V20, P1492, DOI 10.1097/00004647-200010000-00011; NAWASHIRO H, 1995, NEUROL RES, V17, P455, DOI 10.1080/01616412.1995.11740363; NUDO RJ, 1990, SOMATOSENS MOT RES, V7, P463, DOI 10.3109/08990229009144720; Passineau MJ, 2000, AM J PHYSIOL-HEART C, V279, pH924; Reeves TM, 2000, J NEUROSCI RES, V60, P370, DOI 10.1002/(SICI)1097-4547(20000501)60:3<370::AID-JNR12>3.3.CO;2-2; REEVES TM, 1995, EXP BRAIN RES, V106, P248; Risedal A, 1999, J CEREBR BLOOD F MET, V19, P997, DOI 10.1097/00004647-199909000-00007; Sanders MJ, 2000, BRAIN RES, V861, P69, DOI 10.1016/S0006-8993(00)01986-7; Schiene K, 1999, J NEUROL SCI, V162, P6, DOI 10.1016/S0022-510X(98)00292-5; SHARP FR, 1982, J COMP NEUROL, V208, P255, DOI 10.1002/cne.902080305; SHAW NA, 1986, J NEUROL SCI, V74, P257, DOI 10.1016/0022-510X(86)90111-5; Sick TJ, 1998, BRAIN RES, V785, P287, DOI 10.1016/S0006-8993(97)01418-2; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; UEKI M, 1988, J CEREBR BLOOD F MET, V8, P486, DOI 10.1038/jcbfm.1988.89; Vink R, 1988, J NEUROTRAUM, V5, P315, DOI 10.1089/neu.1988.5.315; Vink R, 1990, J NEUROTRAUM, V7, P21, DOI 10.1089/neu.1990.7.21; WAGNER KR, 1990, J CEREBR BLOOD F MET, V10, P417, DOI 10.1038/jcbfm.1990.72; Wiley JL, 1996, BRAIN RES, V716, P47, DOI 10.1016/0006-8993(96)00045-5; Yamaki T, 1996, J TRAUMA, V40, P50, DOI 10.1097/00005373-199601000-00010; YOSHINO A, 1992, J CEREBR BLOOD F MET, V12, P996, DOI 10.1038/jcbfm.1992.137; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	44	41	41	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	AUG	2003	23	8					900	910		10.1097/01.WCB.0000076702.71231.F2			11	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	709BJ	WOS:000184604600003	12902834	Bronze			2021-06-18	
J	Walker, R; Hiller, M; Staton, M; Leukefeld, CG				Walker, R; Hiller, M; Staton, M; Leukefeld, CG			Head injury among drug abusers: An indicator of co-occurring problems	JOURNAL OF PSYCHOACTIVE DRUGS			English	Article; Proceedings Paper	63rd Annual Meeting of the College-on-Problems-of-Drug-Dependence	JUN 16-21, 2001	SCOTTSDALE, AZ	Coll Problems Drug Dependence		co-occurring disorders; head injury; substance abuse	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; SHORT-TERM-MEMORY; SUBSTANCE-ABUSE; FORENSIC ISSUES; CHRONIC PAIN; IMPAIRMENT; ALCOHOL; USERS; RISK	Alcohol and other drug use has been associated with traumatic brain injury both as a contributing factor to the injury and as a complicating factor for rehabilitation. Brain injury is associated with an increase in mental health and other problems that may be related to drug and alcohol abuse and that may influence recovery. This study examined self-reports of 661 drug-abusing inmates with self-reported head injury, health problems and mental health problems. Three groups were examined for this study: those having no head injury, one head injury, and two or more head injuries. Results indicate that inmates with head injuries had a significantly greater number of health problems, higher levels of alcohol and marijuana use, and significantly more mental health problems including depression, anxiety, suicidal thinking, and difficulties in concentrating and controlling violent behavior. This study suggests that questions regarding head injuries during assessment may identify drug abusers who need a treatment approach that accommodates their co-occurring problems and difficulties with processing and complying with treatment interventions.	Univ Kentucky, Ctr Drug & Alcohol Res, Lexington, KY 40536 USA	Walker, R (corresponding author), Univ Kentucky, Ctr Drug & Alcohol Res, Bowman Hall,Room 333, Lexington, KY 40536 USA.				NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA011309] Funding Source: NIH RePORTER; NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA 11309] Funding Source: Medline		Amen DG, 1997, J PSYCHOACTIVE DRUGS, V29, P307, DOI 10.1080/02791072.1997.10400557; BOND MR, 1986, NEUROPSYCHOLOGICAL A; BOYLE MJ, 1991, J ROY SOC MED, V84, P608; BREMNER JD, 1993, AM J PSYCHIAT, V150, P1015; Bremner JD, 1995, PSYCHIAT RES, V59, P97; BREMNER JD, 1995, AM J PSYCHIAT, V152, P973; BROWN BS, 1997, TREATING DRUG ABUSER; Chitwood DD, 1999, SUBST USE MISUSE, V34, P727, DOI 10.3109/10826089909037240; COLLINS JG, 1990, 911503 DHHS PUBL; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; DAVIS M, 1992, AMYGDALA NEUROBIOLOG; DIKMEN SS, 1993, J HEAD TRAUMA REHAB, V8, P30, DOI DOI 10.1097/00001199-199309000-00005; Dixon CE, 1993, J HEAD TRAUMA REHAB, V8, P1, DOI [10.1097/00001199-199309000-00003, DOI 10.1097/00001199-199309000-00003]; DUFFY JD, 1994, J NEUROPSYCH CLIN N, V6, P379; EDWARDSLEE TA, 1999, HUMAN FRONTAL LOBES; FOGLE BS, 1994, J NEUROPSYCHIAT, V6, P343; Gao BL, 2000, J NEUROPSYCH CLIN N, V12, P385, DOI 10.1176/appi.neuropsych.12.3.385; Gazzaniga M.S., 1998, COGNITIVE NEUROSCIEN; Giancola PR, 1996, ALCOHOL CLIN EXP RES, V20, P740, DOI 10.1111/j.1530-0277.1996.tb01680.x; Giancola PR, 1999, PSYCHOL SCI, V10, P203, DOI 10.1111/1467-9280.00135; GOLDMANRAKIC PS, 1990, BRAIN ORG MEMORY CEL; GOLDMANRAKIE PS, 1998, PREFRONTAL CORTEX EX; HALGREN E, 1995, COGNITIVE NEUROSCIEN; HARDEN PW, 1995, ADDICTIVE BEHAV READ; HART T, 1999, EVALUATION TREATMENT; HESTAD K, 1995, SCAND J PSYCHOL, V36, P246, DOI 10.1111/j.1467-9450.1995.tb00984.x; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Kaplan H.I, 1998, SYNOPSIS PSYCHIAT BE, V8th; Kelly JP, 1999, JAMA-J AM MED ASSOC, V282, P989, DOI 10.1001/jama.282.10.989; Kelly MP, 1997, BRAIN INJURY, V11, P391, DOI 10.1080/026990597123386; Koechlin E, 1999, NATURE, V399, P148; KRAUS J, 1994, NEUROPSYCHIATRY TRAU; KRAUS JF, 1989, AM J PUBLIC HEALTH, V79, P294, DOI 10.2105/AJPH.79.3.294; LeDoux J., 1996, EMOTIONAL BRAIN MYST; Leukefeld CG, 2002, INT J OFFENDER THER, V46, P715, DOI 10.1177/0306624X02238164; LEUKEFELD CG, 1992, NIDA MONOGRAPH, V118; LITVAN I, 1999, HUMAN FRONTAL LOBES; MALEC JF, 1999, EVALUATION TREATMENT; MATEER CA, 2000, NEUROPSYCHOLOGICAL M; MCALLISTER TW, 1999, EVALUATION TREATMENT; MCLELLAN AT, 1992, J SUBST ABUSE TREAT, V9, P119; MEEK PS, 1989, J PSYCHOACTIVE DRUGS, V21, P153, DOI 10.1080/02791072.1989.10472155; MICHELSON D, 1995, NEUROBIOLOGY CLIN CO; MILLER L, 1992, INT J LAW PSYCHIAT, V15, P303, DOI 10.1016/0160-2527(92)90005-L; MOES EJ, 1994, PSYCHOTHERAPISTS GUI; Morgan AB, 2000, CLIN PSYCHOL REV, V20, P113, DOI 10.1016/S0272-7358(98)00096-8; MORSE PA, 1994, PSYCHOTHERAPISTS GUI; Nixon SJ, 1999, PSYCHOL SCI, V10, P181, DOI 10.1111/1467-9280.00130; PIHL RO, 1995, ALCOHOL HEALTH RES W, V19, P142; Prigatano GP., 1999, PRINCIPLES NEUROPSYC; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Raine A., 1993, PSYCHOPATHOLOGY CRIM; ROLLS ET, 1995, COGNITIVE NEUROSCIEN; SAPOLSKY RM, 1990, MOL CELLULAR MECH NE; SCHNIDER A, 1999, HUMAN FRONTAL LOBES; Shallice T., 1998, PREFRONTAL CORTEX EX; Silver JM, 1997, J NEUROPSYCH CLIN N, V9, P102; SILVER JM, 1997, AM PSYCHIAT PRESS TX; Sohlberg M. M., 1989, INTRO COGNITIVE REHA; SOLOMON D, 1992, NEUROREHABILITATION, V2, P16; Sparadeo F. R., 1989, J HEAD TRAUMA REHAB, V4, P75, DOI DOI 10.1097/00001199-198903000-00010; SPARADEO FR, 1992, NEUROREHABILITATION, V2, P65; Spreen O., 1998, COMPENDIUM NEUROPSYC; STRICKLAND TL, 1993, J NEUROPSYCH CLIN N, V5, P419; UOMOTO JM, 1993, ARCH PHYS MED REHAB, V74, P61; VOLAVKA J, 1995, NEUROBIOLOGY VIOLENC; Walker R, 2001, SUBST USE MISUSE, V36, P757, DOI 10.1081/JA-100104089	69	41	41	0	8	HAIGHT-ASHBURY PUBL	SAN FRANCISCO	409 CLAYTON ST, SAN FRANCISCO, CA 94117 USA	0279-1072			J PSYCHOACTIVE DRUGS	J. Psychoact. Drugs	JUL-SEP	2003	35	3					343	353		10.1080/02791072.2003.10400017			11	Psychology, Clinical; Substance Abuse	Psychology; Substance Abuse	732ZL	WOS:000185975400005	14621132				2021-06-18	
J	Pelinka, LE; Bahrami, S; Szalay, L; Umar, F; Redl, H				Pelinka, LE; Bahrami, S; Szalay, L; Umar, F; Redl, H			Hemorrhagic shock induces an S100Bincrease associated with shock severity	SHOCK			English	Article						traumatic brain injury; extracerebral trauma; soft tissue injury; laparotomy; acidosis; rats	TRAUMATIC BRAIN INJURY; SERUM S-100 PROTEIN; HEAD-INJURY; CARDIAC-SURGERY; NERVOUS-SYSTEM; DAMAGE; RELEASE; RESUSCITATION; MARKERS; ENOLASE	S 100 B is a glial marker of cerebral injury. In a previous clinical study, we found an S 100 B increase within the first 24 h in patients with multiple trauma and hemorrhagic shock but without cerebral trauma. The aim of our current experimental study was to determine whether this posttraumatic S 100 B increase is caused by extracerebral soft tissue injury or by hemorrhagic shock and whether it is associated with the severity of hemorrhagic shock. Hemorrhagic shock was achieved by bleeding anesthetized rats to a mean arterial pressure (MAP) of 30-35 mmHg through a femoral catheter and maintaining this MAP until incipient decompensation. At incipient decompensation, MAP was either increased immediately to 40-45 mmHg (moderate shock) or was maintained until 40% of shed blood had been returned (severe shock), and then increased to 40-45 mmHg. Resuscitation was provided after 40-45 mmHg MAP had been maintained for 40 min. Soft tissue injury was achieved by midline laparotomy performed at the onset of hemorrhagic shock or without shock and was maintained for 30 min. Hemorrhagic shock caused an early S 100 B increase at the onset of decompensation. S 100 B remained increased for 24 h and was significantly higher after severe than after moderate shock. In contrast, soft tissue injury without hemorrhagic shock caused no S 100 B increase. The data presented demonstrate for the first time that the S 100 B increase is induced by hemorrhagic shock and is associated with the severity of shock.	Ludwig Boltzmann Inst Expt & Clin Traumatol, A-1200 Vienna, Austria; Allgemeine Unfallversicherungsanstalt, Res Ctr, Vienna, Austria	Pelinka, LE (corresponding author), Ludwig Boltzmann Inst Expt & Clin Traumatol, Donaueschingenstr 13, A-1200 Vienna, Austria.		Redl, Heinz/AAD-8157-2019	Bahrami, Soheyl/0000-0002-4563-6251			Abraha HD, 1997, ANN CLIN BIOCHEM, V34, P366, DOI 10.1177/000456329703400405; Ali MS, 2000, BRIT J ANAESTH, V85, P936; Anderson RE, 2000, ANN THORAC SURG, V69, P847, DOI 10.1016/S0003-4975(99)01526-X; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Biberthaler P, 2001, SHOCK, V16, P97, DOI 10.1097/00024382-200116020-00002; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; Ingebrigtsen T, 1999, NEUROSURGERY, V45, P468, DOI 10.1097/00006123-199909000-00010; ISOBE T, 1984, J NEUROCHEM, V43, P1494, DOI 10.1111/j.1471-4159.1984.tb05415.x; Kilminster S, 1999, STROKE, V30, P1869, DOI 10.1161/01.STR.30.9.1869; Manley GT, 1999, J TRAUMA, V46, P261, DOI 10.1097/00005373-199902000-00011; Missler U, 2002, CLIN CHIM ACTA, V321, P29, DOI 10.1016/S0009-8981(02)00061-X; Novak L, 1999, J TRAUMA, V47, P834, DOI 10.1097/00005373-199911000-00003; PELINKA G, 2000, RECONSTR NEUROL NEUR, V16, P282; PERSSON L, 1987, STROKE, V18, P911, DOI 10.1161/01.STR.18.5.911; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Raabe A, 2000, NEUROSURG REV, V23, P136, DOI 10.1007/PL00011944; Rosen H, 1998, STROKE, V29, P473, DOI 10.1161/01.STR.29.2.473; Wiesmann M, 1997, ACTA NEUROCHIR, V139, P1155, DOI 10.1007/BF01410976; Wong CH, 1999, ANN THORAC SURG, V67, P1911, DOI 10.1016/S0003-4975(99)00425-7; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	20	41	48	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1073-2322			SHOCK	Shock	MAY	2003	19	5					422	426		10.1097/01.shk.0000055345.58165.52			5	Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease	General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology	669RZ	WOS:000182365400005	12744484				2021-06-18	
J	Thompson, HJ; Pinto-Martin, J; Bullock, MR				Thompson, HJ; Pinto-Martin, J; Bullock, MR			Neurogenic fever after traumatic brain injury: an epidemiological study	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							CRITICAL CARE; HEAD-INJURY; HYPERTHERMIA; REHABILITATION; CONSCIOUSNESS; TEMPERATURE; STATE; RATS	Objectives: To determine the incidence of neurogenic fever (NF) in a population of patients in the acute phase following severe traumatic brain injury (TBI); to identify factors associated with the development of NF following severe TBI in adults. Methods: Charts of patients admitted from 1996 to 1999 with severe TBI at a large, urban mid-Atlantic teaching hospital were retrospectively evaluated based on diagnostic criteria for each episode of hyperthermia to determine the diagnosis of NF. Data were collected regarding mechanism and area of injury, severity of injury, and demographic factors to determine potential predictors of NF. Results: Diffuse axonal injury (DAI) ( OR 9.06, 95% CI 0.99 to 82.7) and frontal lobe injury of any type (OR 6.68, 95% CI 1.1 to 39.3) are independently predictive of an increased risk of development of NF following severe TBI. The presence of a skull fracture and lower initial Glasgow Coma Score (GCS) were individual predictors of development of NF, but did not contribute to the final model. Conclusions: These findings examine known and novel risk factors for this phenomenon in comparison to previously published literature on NF. A set of predictor variables was identified to help clinicians target patients at high risk for development of NF following severe TBI. It is hoped that earlier diagnosis and appropriate intervention for fever in the TBI patient will lead to improved outcomes.	Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA; Virginia Commonwealth Univ Hlth Syst, Div Neurosurg, Richmond, VA USA	Thompson, HJ (corresponding author), Univ Penn, Dept Neurosurg, 105C Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.				NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [F31NR007694] Funding Source: NIH RePORTER; NINR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [NR 7694] Funding Source: Medline		Albrecht RF, 1998, MAYO CLIN PROC, V73, P629; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BENEDEK G, 1987, CAN J NEUROL SCI, V14, P145; BRITT RH, 1983, MED INSTRUM, V17, P172; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; CHILDERS MK, 1994, BRAIN INJURY, V8, P335, DOI 10.3109/02699059409150984; Clinchot DM, 1997, AM J PHYS MED REHAB, V76, P323, DOI 10.1097/00002060-199707000-00012; CROMPTON MR, 1971, BRAIN, V94, P165, DOI 10.1093/brain/94.1.165; CUNHA BA, 1984, HEART LUNG, V13, P460; CUNHA BA, 1988, HEART LUNG, V17, P608; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; DIETRICH WD, 1990, STROKE, V21, P1318, DOI 10.1161/01.STR.21.9.1318; DIETRICH WD, 1992, J NEUROTRAUMA, V9, P475; Heindl UT, 1996, NEUROPEDIATRICS, V27, P94, DOI 10.1055/s-2007-973756; HOLTZCLAW BJ, 1992, HEART LUNG, V21, P482; KAKUDA W, 1997, J CEREB BLOOD FLO S1, V17, pS43; KERN KB, 1984, J TRAUMA, V24, P69, DOI 10.1097/00005373-198401000-00012; Kilpatrick MM, 2000, NEUROSURGERY, V47, P850, DOI 10.1097/00006123-200010000-00011; KUROIWA T, 1990, J CEREBR BLOOD F MET, V10, P550, DOI 10.1038/jcbfm.1990.97; Lausberg G, 1971, Cah Anesthesiol, V19, P315; MEYTHALER JM, 1994, ARCH PHYS MED REHAB, V75, P816; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Powers JH, 1996, INFECT DIS CLIN N AM, V10, P45, DOI 10.1016/S0891-5520(05)70285-3; SAZBON L, 1990, J NEUROSURG, V72, P75, DOI 10.3171/jns.1990.72.1.0075; Segatore M, 1992, J Neurosci Nurs, V24, P104; Soukup J, 2002, J NEUROTRAUM, V19, P559, DOI 10.1089/089771502753754046; TEASDALE G, 1974, LANCET, V2, P81; THOMPSON HJ, 1997, P 29 ANN M AM ASS NE, P10; WHYTE J, 1993, AM J PHYS MED REHAB, V72, P281, DOI 10.1097/00002060-199310000-00006	29	41	41	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	MAY	2003	74	5					614	619		10.1136/jnnp.74.5.614			6	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	668GC	WOS:000182281100016	12700304	Green Published, Bronze			2021-06-18	
J	Khan-Bourne, N; Brown, RG				Khan-Bourne, N; Brown, RG			Cognitive behaviour therapy for the treatment of depression in individuals with brain injury	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							CLOSED-HEAD-INJURY; FOLLOW-UP; MULTIPLE-SCLEROSIS; COPING STRATEGIES; MOOD DISORDERS; REHABILITATION; LONG; COMORBIDITY; PREVALENCE; POSTSTROKE	This article focuses on depression and its psychological management following brain injury or stroke in the adult population. The presentation of depression in the context of brain injury is discussed and a summary of the psychosocial aetiological factors for the development of depression in this context is provided. The links between depression and neuropsychological functioning are explored and the significant impact of depression on neurorehabilitation outcome highlights the need for the development of effective interventions in this area. Cognitive behaviour therapy (CBT) is presented as a potentially suitable treatment: The model is described with ideas for the clinician on how to adapt the delivery of CBT for clients with neuropsychological impairment. To date, there have been a very small number of studies evaluating CBT for the treatment of depression in brain injury, however their results have been promising. It is concluded that further research is necessary.	Kings Coll London, Dept Psychol, Inst Psychiat, London SE5 8AF, England; Maudsley Hosp & Inst Psychiat, Lishman Brain Injury Unit, S London, England; Maudsley NHS Trust, London, England	Brown, RG (corresponding author), Kings Coll London, Dept Psychol, Inst Psychiat, PO77,De Crespigny Pk, London SE5 8AF, England.		Brown, Richard G/A-9599-2010	Brown, Richard G/0000-0001-9021-0172			Al-Adawi S, 1998, NEUROPSYCHOLOGY, V12, P115, DOI 10.1037/0894-4105.12.1.115; Angst J, 1996, BRIT J PSYCHIAT, V168, P31, DOI 10.1192/S0007125000298383; Asikainen I, 1996, BRAIN INJURY, V10, P883, DOI 10.1080/026990596123864; Asvall J. E., 2001, DEPRESSION SOCIAL EC; BECK AT, 1970, BEHAV THER, V1, P184, DOI 10.1016/S0005-7894(70)80030-2; Bellus SB, 1998, BRAIN INJURY, V12, P139, DOI 10.1080/026990598122764; Bernstein DM, 2000, BRAIN COGNITION, V44, P50, DOI 10.1006/brcg.1999.1209; Bowen A, 1999, BRAIN INJURY, V13, P547; BROTHERTON FA, 1988, ARCH PHYS MED REHAB, V69, P827; BROWN RG, 1994, PSYCHOL MED, V24, P829, DOI 10.1017/S0033291700028932; BURGHLEIGH SA, 1998, AM J OCCUPATIONAL TH, V52, P45; Chisholm D, 2001, DEPRESSION SOCIAL EC; Clark D.A., 1999, SCI FDN COGNITIVE TH; Coyne JC, 1999, J CONSULT CLIN PSYCH, V67, P76, DOI 10.1037/0022-006X.67.1.76; Curran CA, 2000, J HEAD TRAUMA REHAB, V15, P1256, DOI 10.1097/00001199-200012000-00006; DAVIS GR, 1984, J CLIN PSYCHOL, V40, P930, DOI 10.1002/1097-4679(198407)40:4<930::AID-JCLP2270400410>3.0.CO;2-Q; DRUMMOND A, 1996, BR J OCCUP THER, V59, P330; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; Fennell M., 1999, OVERCOMING LOW SELF; Finset A, 2000, BRAIN INJURY, V14, P887; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; GUTH PE, 2000, DISS ABSTR INT B, V61, P1803; Hawton K.E., 1989, COGNITIVE BEHAV THER; Hoofien D, 2001, BRAIN INJURY, V15, P189; HOUSE A, 1992, OX MED PUBL, P51; Jacobson NS, 1996, J CONSULT CLIN PSYCH, V64, P295, DOI 10.1037/0022-006X.64.2.295; Jean-Bay E, 2000, J Neurosci Nurs, V32, P169; Kersel DA, 2001, BRAIN INJURY, V15, P683, DOI 10.1080/02699050010013662; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; LARCOMBE NA, 1984, BRIT J PSYCHIAT, V145, P366, DOI 10.1192/bjp.145.4.366; LEUNG M, 1997, CLIN PSYCHOL, V10, P2002; Lewinsohn PM., 1974, PSYCHOL DEPRESSION C; Lincoln NB, 1997, CLIN REHABIL, V11, P114, DOI 10.1177/026921559701100204; LINN RT, 1994, BRAIN INJURY, V8, P135, DOI 10.3109/02699059409150965; Lishman W. A., 1987, ORGANIC PSYCHIAT; MALIA K, 1995, BRAIN INJURY, V9, P607, DOI 10.3109/02699059509008219; Marin RS, 1997, PSYCHIAT ANN, V27, P30, DOI 10.3928/0048-5713-19970101-08; MAZZUCA SA, 1982, J CHRON DIS, V35, P521, DOI 10.1016/0021-9681(82)90071-6; Mohr DC, 2001, J CONSULT CLIN PSYCH, V69, P942, DOI 10.1037//0022-006X.69.6.942; MONTGOMERY GK, 1995, BRAIN INJURY, V9, P453, DOI 10.3109/02699059509008205; MOORE AD, 1995, BRAIN INJURY, V9, P109, DOI 10.3109/02699059509008185; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Ohayon MM, 1999, BIOL PSYCHIAT, V45, P300, DOI 10.1016/S0006-3223(98)00011-0; Ownsworth TL, 1998, BRAIN INJURY, V12, P735, DOI 10.1080/026990598122133; PARIKH RM, 1990, ARCH NEUROL-CHICAGO, V47, P785, DOI 10.1001/archneur.1990.00530070083014; Perino C, 2001, BRAIN INJURY, V15, P139, DOI 10.1080/026990501458371; PERSONS J, 1997, HDB PSYCHOTHERAPY CA; PICCINELLI M, 1994, BRIT J PSYCHIAT, V164, P297, DOI 10.1192/bjp.164.3.297; Pohjasvaara T, 2001, EUR J NEUROL, V8, P315, DOI 10.1046/j.1468-1331.2001.00182.x; Ponsford J., 1995, TRAUMATIC BRAIN INJU; Reischies FM, 2000, EUR ARCH PSY CLIN N, V250, P186, DOI 10.1007/s004060070023; ROSENTHAL TL, 1971, COND REFLEX, V6, P22; Sandin K, 1994, ARCH PHYS MED REHAB, V75, P52; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; Schlund MW, 1999, BRAIN INJURY, V13, P889; Tate RL, 1999, PSYCHOL MED, V29, P713, DOI 10.1017/S0033291799008466; TENNANT A, 1995, BRAIN INJURY, V9, P595, DOI 10.3109/02699059509008218; TERI L, 1997, J GERONTOL B-PSYCHOL, V52, P159, DOI DOI 10.1093/GER0NB/52B.4.P159; Wallace CA, 2000, BRAIN INJURY, V14, P549; WALLACE CA, 2000, DISS ABSTR INT B, V60, P4257; Watkins E, 2002, J NEUROL NEUROSUR PS, V72, P400, DOI 10.1136/jnnp.72.3.400; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; Wilson BA, 1997, J INT NEUROPSYCH SOC, V3, P487, DOI 10.1017/S1355617797004876; Wood R, 2000, NEUROBEHAVIOURAL DIS	65	41	42	1	12	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	MAR-MAY	2003	13	1-2			SI		89	107		10.1080/09602010244000318			19	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	665EK	WOS:000182106500006	21854329				2021-06-18	
J	Langeluddecke, PM; Lucas, SK				Langeluddecke, PM; Lucas, SK			Quantitative measures of memory malingering on the Wechsler Memory Scale - Third edition in mild head injury litigants	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						malingered neurocognitive dysfunction; traumatic brain injury; neuropsychological assessment	PERFORMANCE; INCENTIVES; DEFICITS; SUBTEST	Wechsler Memory Scale-Third edition (WMS-III) performance in 25 mild traumatic brain injury (TBI) litigants who met the criteria for probable malingered neurocognitive dysfunction (MND) was compared with 50 nonmalingering subjects. The base rate for probable MND in the population studied was 27%. Overall, malingerers showed globally depressed memory function. They returned significantly poorer scores than nonmalingerers on all WMS-III indexes and subtests, and on selected WMS-III index difference scores and intelligence-memory difference scores. Using the minimum score returned in the nonmalingerers as the cut-off for malingering, the delayed auditory recognition memory tasks were highly effective in detecting malingering. Raw scores below 43 on the auditory recognition-delayed (AR-D) subtest or below 18 on word list II-recognition, identified around 80% of the malingerers. In a group of 50 severe TBI litigants, only a very small proportion (i.e., <10%) returned scores below the cut-offs for malingering for the mild TBI subjects. (C) 2002 National Academy of Neuropsychology. Published by Elsevier Science Ltd. All rights reserved.	Westmead Hosp, Dept Med Psychol, Westmead, NSW 2145, Australia	Langeluddecke, PM (corresponding author), Suite 1003,37 Bligh St, Sydney, NSW 2000, Australia.	langeluddecke@bigpond.com					ALLEN LM, 1999, CARB 97 COMPUTERIZED; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; ARNETT PA, 1995, CLIN NEUROPSYCHOL, V9, P17, DOI 10.1080/13854049508402052; BEETAR JT, 1995, ARCH CLIN NEUROPSYCH, V10, P57, DOI 10.1016/0887-6177(94)E0005-A; BERNARD LC, 1993, ARCH CLIN NEUROPSYCH, V8, P539, DOI 10.1016/0887-6177(93)90054-5; BERNARD LC, 1990, J CLIN EXP NEUROPSYC, V12, P715, DOI 10.1080/01688639008401014; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P19, DOI 10.1076/clin.15.1.19.1907; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Camara WJ, 2000, PROF PSYCHOL-RES PR, V31, P141, DOI 10.1037/0735-7028.31.2.141; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Fisher D C, 2000, Appl Neuropsychol, V7, P126, DOI 10.1207/S15324826AN0703_2; Gouvier WD, 1998, CRIT ISS NE, P55; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Haines ME, 1995, NEUROPSYCHOL REV, V5, P125, DOI 10.1007/BF02208438; Iverson G.L., 1994, ASSESSMENT, V1, P323, DOI [DOI 10.1177/1073191, https://doi.org/10.1177/107319119400100401, DOI 10.1177/107319119400100401]; Iverson GL, 1998, BRAIN INJURY, V12, P275, DOI 10.1080/026990598122575; Killgore WDS, 2000, PSYCHOL REP, V86, P851, DOI 10.2466/PR0.86.3.851-857; Lee G.P., 1992, PSYCHOL ASSESSMENT, V4, P43, DOI [10.1037/1040-3590.4.1.43, DOI 10.1037/1040-3590.4.1.43]; LeesHaley PR, 1996, ARCH CLIN NEUROPSYCH, V11, P45, DOI 10.1016/0887-6177(95)00011-9; Millis SR, 1996, NEUROREHABILITATION, V7, P55, DOI 10.3233/NRE-1996-7106; MITTENBERG W, 1993, PSYCHOL ASSESSMENT, V5, P34, DOI DOI 10.1037/1040-3590.5.1.34; NELSON HD, 1991, REVISED NAWTL ADULT; NIES KJ, 1994, ARCH CLIN NEUROPSYCH, V9, P501, DOI 10.1016/0887-6177(94)90041-8; Reitan RM, 1998, CRIT ISS NE, P163; Rey A., 1964, EXAMEN CLIN PSYCHOL, P121; Reynolds CR, 1998, CRIT ISS NE, P261; Schretlen D., 1991, PSYCHOL ASSESSMENT J, V3, P667, DOI [10.1037/1040-3590.3.4.667, DOI 10.1037/1040-3590.3.4.667]; Schwartz SM, 1998, INT J LAW PSYCHIAT, V21, P261, DOI 10.1016/S0160-2527(98)00004-1; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Spreen O., 1998, COMPENDIUM NEUROPSYC; Suchy Y, 2000, CLIN NEUROPSYCHOL, V14, P56, DOI 10.1076/1385-4046(200002)14:1;1-8;FT056; Suhr J, 1997, J CLIN EXP NEUROPSYC, V19, P500, DOI 10.1080/01688639708403740; TEASDALE GM, 1995, J NEUROL NEUROSUR PS, V58, P526, DOI 10.1136/jnnp.58.5.526; Tombaugh TN, 1996, TEST MEMORY MALINGER; TRUEBLOOD W, 1993, J CLIN EXP NEUROPSYC, V15, P578, DOI 10.1080/01688639308402580; Vickery CD, 2001, ARCH CLIN NEUROPSYCH, V16, P45, DOI 10.1016/S0887-6177(99)00058-X; Warrington EK., 1984, RECOGNITION MEMORY T; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wechsler D, 1945, J PSYCHOL, V19, P87, DOI 10.1080/00223980.1945.9917223; Williams JM, 1998, CRIT ISS NE, P105; Wynkoop T.F., 2001, J FORENSIC NEUROPSYC, V2, P71	44	41	42	0	4	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	MAR	2003	18	2					181	197	PII S0887-6177(01)00195-0	10.1016/S0887-6177(01)00195-0			17	Psychology, Clinical; Psychology	Psychology	648LC	WOS:000181152000008	14591470	Bronze			2021-06-18	
J	Chan, RCK; Hoosain, R; Lee, TMC; Fan, YW; Fong, D				Chan, RCK; Hoosain, R; Lee, TMC; Fan, YW; Fong, D			Are there sub-types of attentional deficits in patients with persisting post-concussive symptoms? A cluster analytical study	BRAIN INJURY			English	Article; Proceedings Paper	29th Annual Meeting of the International-Neuropsychological-Society	FEB 14-17, 2001	CHICAGO, IL	Int Neuropsychol Soc			CLOSED-HEAD-INJURY; NEUROPSYCHOLOGICAL DEFICITS; SUSTAINED ATTENTION; QUESTIONNAIRE; PERFORMANCE; FAILURES; RECOVERY; AROUSAL	Aim : The present study aimed to examine attentional deficits in patients with persisting post-concussive symptoms using a multi-componential framework of attention. Design : A cross-sectional investigation using standardized tests and questionnaires of attention including 92 patients. Method : Participants were administered comprehensive measures of attention assessing sustained attention (Sustained Attention Response to Task, Backward Digit Span), selective attention (Stroop Word-Colour Test, Colour Trails Test), divided attention (Paced Auditory Serial Addition Test, Symbol Digit Modalities Test), and attentional control (Tower of Hanoi, Six Elements Test). Ecological tests of attention were used to validate the cluster solution. Main outcome : Three clusters of patients with different combinations of attentional deficits were identified. They were mild sustained attentional deficits, selective and divided attentional deficits, and general attentional deficit. A MANOVA indicated that these three clusters were statistically and clinically different from one another in terms of different attentional components proposed. Conclusion : This study provides preliminary evidence suggesting that sub-types of attentional impairments exit in patients with post-concussive symptoms.	Univ Hong Kong, Dept Psychiat, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Dept Psychol, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Dept Surg, Div Neurosurg, Hong Kong, Hong Kong, Peoples R China; Tuen Mun Hosp, Dept Neurosurg, Hong Kong, Hong Kong, Peoples R China	Chan, RCK (corresponding author), Univ Hong Kong, Dept Psychiat, Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.	rckchan@hkucc.hku.hk	Lee, Tatia Mei Chun/D-4922-2009; Chan, Raymond CK/B-6717-2009	Chan, Raymond CK/0000-0002-3414-450X			Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BINDER LM, 1997, J CLIN EXPT NEUROPSY, V19, P529; BLASHFIELD RK, 1980, J CONSULT CLIN PSYCH, V48, P456; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Burgess P. W., 1996, BEHAV ASSESSMENT DYS; Cabeza R, 1997, J COGNITIVE NEUROSCI, V9, P1, DOI 10.1162/jocn.1997.9.1.1; Chan RCK, 1999, ARCH CLIN NEUROPSYCH, V14, P735, DOI 10.1016/S0887-6177(99)80228-5; Chan RCK, 2001, BRAIN INJURY, V15, P71, DOI 10.1080/02699050118215; Chan RCK, 2001, BRIT J PSYCHOL, V92, P551, DOI 10.1348/000712601162338; Chan RCK, 2001, CLIN REHABIL, V15, P266, DOI 10.1191/026921501675253420; CHAN RCK, IN PRESS J CLIN EXPT; CHAN RCK, IN PRESS CLIN REHABI; DELIA LF, 1996, COLOUR TRAILS TEST P; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; Gronwall D.M., 1974, PSYCHOL EFFECTS CONC; Hair J.F., 1995, MULTIVARIATE DATA AN, V4th ed.; Humes GE, 1997, ASSESSMENT, V4, P249, DOI 10.1177/107319119700400305; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Lee TMC, 2000, J CLIN EXP NEUROPSYC, V22, P465, DOI 10.1076/1380-3395(200008)22:4;1-0;FT465; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; MIRSKY A F, 1991, Neuropsychology Review, V2, P109, DOI 10.1007/BF01109051; MORRIS RD, 1980, J CLIN EXPT NEUROPSY, V10, P640; Morris RG, 1997, COGN NEUROPSYCHOL, V14, P1007, DOI 10.1080/026432997381330; PARASURAMAN R, 1991, J CLIN EXP NEUROPSYC, V13, P789, DOI 10.1080/01688639108401090; Park NW, 1999, NEUROPSYCHOL REHABIL, V9, P135, DOI 10.1080/713755595; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; REZAI K, 1993, ARCH NEUROL-CHICAGO, V50, P636, DOI 10.1001/archneur.1993.00540060066020; Robertson I. H., 1994, TEST EVERYDAY ATTENT; Robertson IH, 1997, NEUROPSYCHOLOGY, V11, P290, DOI 10.1037/0894-4105.11.2.290; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Sohlberg M. M., 1989, INTRO COGNITIVE REHA; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; Spreen O., 1998, COMPENDIUM NEUROPSYC; Sturm W, 1997, NEUROPSYCHOL REHABIL, V7, P81, DOI 10.1080/713755526; Stuss D.T., 1986, FRONTAL LOBES; Stuss DT, 1995, ANN NY ACAD SCI, V769, P191, DOI 10.1111/j.1749-6632.1995.tb38140.x; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Stuss DT, 1994, NEUROPSYCHOLOGY, V8, P316, DOI DOI 10.1037/0894-4105.8.3.316; Van Zomeren A. H., 1984, CLOSED HEAD INJURY P, P74; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; WECHSLER D, 1981, WAISR MANUAL WECHSLE; WHYTE J, 1992, ARCH PHYS MED REHAB, V73, P940; Whyte J, 1996, J Int Neuropsychol Soc, V2, P274; WHYTE J, 1995, NEUROPSYCHOLOGIA, V33, P797, DOI 10.1016/0028-3932(95)00029-3; Wilson BA, 1996, BEHAV ASSESSMENT DYS	49	41	41	0	10	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2003	17	2					131	148		10.1080/0269905021000010168			18	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	633LL	WOS:000180284700003	12519640				2021-06-18	
J	Vinchon, M; Noizet, O; Defoort-Dhellemmes, S; Soto-Ares, G; Dhellemmes, P				Vinchon, M; Noizet, O; Defoort-Dhellemmes, S; Soto-Ares, G; Dhellemmes, P			Infantile subdural hematomas due to traffic accidents	PEDIATRIC NEUROSURGERY			English	Article						subdural hematoma; traffic accident; pathophysiology	NONACCIDENTAL HEAD-INJURY; SHAKEN-BABY SYNDROME; IMPACT SYNDROME; TRAUMA; HEMORRHAGE; ABUSE; HYDROCEPHALUS; CHILDREN; INFANCY	The most common cause of subdural hematomas (SDH) in infants is shaken-baby syndrome (SBS). The pathogenesis and natural history of infantile SDH (ISDH) are poorly documented, because in SBS, the date of shaking is usually imprecise and the assault is often repeated. Victims of traffic accidents (TA) form a study group close to experimental conditions, because the trauma is unique, witnessed and dated. We reviewed 18 cases of SDH due to TA in infants under the age of 24 months. Our goal was to investigate the clinical and radiological data and natural history of SDH. A subdural collection was found on the day of trauma in 7 cases. In 3 of these, the collection was already hypodense. The perifalcine region was the most frequent site of intracranial bleeding. Blood hyperdensity was always found on CT scans performed during the first week, and turned hypodense on about the 9th day. Three patients had retinal hemorrhage, of a type distinct from that found in SBS. Drainage of the SDH was required in 14 cases after a mean delay of 13.5 +/- 5.8 days after trauma. Four patients also required a ventriculoperitoneal shunt because of associated hydrocephalus. Our data suggest that impaired CSF drainage plays a large role in the pathogenesis of ISDH. The fact that a single and recent trauma can result in mixeddensity ISDH can be of great importance in forensic medicine. (C) 2002 S. Karger AG, Basel	CHRU, Dept Pediat Neurosurg, F-59037 Lille, France; CHRU, Dept Pediat Intens Care, F-59037 Lille, France; CHRU, Dept Neuroophthalmol, F-59037 Lille, France; CHRU, Dept Neuroradiol, F-59037 Lille, France	Vinchon, M (corresponding author), CHRU, Dept Pediat Neurosurg, F-59037 Lille, France.			Vinchon, Matthieu/0000-0002-9122-6165			AOKI N, 1984, J NEUROSURG, V61, P273, DOI 10.3171/jns.1984.61.2.0273; Barlow KM, 1999, ACTA PAEDIATR, V88, P734; Bruce DA, 2000, CHILD NERV SYST, V16, P755, DOI 10.1007/PL00013720; Dias MS, 1998, PEDIATR NEUROSURG, V29, P77, DOI 10.1159/000028694; Duhaime AC, 1996, PEDIATR NEUROSURG, V24, P292, DOI 10.1159/000121058; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; Duhaime AC, 1996, PEDIATR NEUROSURG, V25, P116, DOI 10.1159/000121108; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; DUNCAN CC, 1989, CONCEPTS PEDIAT NEUR, V9, P211; Durkin MS, 1998, NEUROSURGERY, V42, P300, DOI 10.1097/00006123-199802000-00052; Ewing-Cobbs L, 2000, CHILD NERV SYST, V16, P25, DOI 10.1007/s003810050006; Friede RL, 1989, DEV NEUROPATHOLOGY, P198; HADLEY MN, 1989, NEUROSURGERY, V24, P536, DOI 10.1227/00006123-198904000-00008; HAINES DE, 1993, NEUROSURGERY, V32, P111, DOI 10.1227/00006123-199301000-00017; Hwang SK, 2000, CHILD NERV SYST, V16, P590, DOI 10.1007/s003810000312; IKEDA A, 1987, CHILD NERV SYST, V3, P19, DOI 10.1007/BF00707188; JOHNSON DL, 1993, NEUROSURGERY, V33, P231; Kaptain GJ, 2001, J NEUROSURG, V94, P538, DOI 10.3171/jns.2001.94.3.0538; Lasjaunias P, 1997, VASCULAR DIS NEONATE, P31; LEESTMA JE, 1995, PEDIAT NEUROPATHOLOG, P234; MACDONALD RL, 1994, PEDIATR NEUROSURG, V20, P73; Massicotte EM, 1999, J NEUROSURG, V91, P80, DOI 10.3171/jns.1999.91.1.0080; MORI K, 1993, CHILD NERV SYST, V9, P282, DOI 10.1007/BF00306274; Morris MW, 2000, PEDIATRICS, V105, P549, DOI 10.1542/peds.105.3.549; Papasian NC, 2000, PEDIATR NEUROSURG, V33, P188, DOI 10.1159/000055951; Sargent S, 1996, J FORENSIC SCI, V41, P314; SUNDERLAND R, 1997, ARCH DIS CHILD, V76, P397; Tibbs RE, 1998, ANAT REC, V253, P167; Vinchon M, 2001, J NEUROSURG, V95, P249, DOI 10.3171/jns.2001.95.2.0249; Wilkins B, 1997, ARCH DIS CHILD, V76, P393, DOI 10.1136/adc.76.5.393	30	41	41	1	3	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1016-2291			PEDIATR NEUROSURG	Pediatr. Neurosurg.	NOV	2002	37	5					245	253		10.1159/000066216			9	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	616EC	WOS:000179287900007	12411716				2021-06-18	
J	Dirette, D				Dirette, D			The development of awareness and the use of compensatory strategies for cognitive deficits	BRAIN INJURY			English	Article							TRAUMATIC BRAIN INJURY; SELF-AWARENESS; ADULTS; REHABILITATION; INTERVENTION	Background: Cognitive rehabilitation often involves teaching individuals with acquired brain injuries (ABI) to use compensatory strategies for cognitive deficits. The use of compensatory strategies is frequently limited by reduced awareness of deficits. The process through which a person with ABI develops awareness and begins to use compensatory strategies is rarely explored from the clients' perspectives. Objective: To explore the development of awareness and the use of compensatory strategies by adults with ABI. Setting: A cognitive rehabilitation day treatment programme. Method: A critical incidents, qualitative inquiry was conducted with three clients who had made good recovery. The development of awareness and the use of compensatory strategies is examined from the clients' perspectives. Their perspectives are compared to the perspectives of the therapists with whom they worked during the cognitive rehabilitation process. Results: Clients described the development of deficit awareness as a slow process with occasional 'aha' moments. These moments involved a comparison of current performance to pre-morbid performance on functional tasks. There was agreement among clients and therapists on the cognitive deficits manifested and on the strategies used to compensate for those deficits. The description of the process of developing awareness, however, was different. Conclusion: In-depth qualitative exploration of the experiences of clients has the potential to provide guidance for more effective cognitive rehabilitation interventions.	Western Michigan Univ, Occupat Therapy Dept, Kalamazoo, MI 49008 USA	Dirette, D (corresponding author), Western Michigan Univ, Occupat Therapy Dept, 1903 W Michigan Ave, Kalamazoo, MI 49008 USA.						Abreu BC, 2001, ARCH PHYS MED REHAB, V82, P49, DOI 10.1053/apmr.2001.9167; BENYISHAY Y, 1993, ARCH PHYS MED REHAB, V74, P204; Birnboim S, 1995, BRIT J OCCUPATIONAL, V58, P61; Carney N, 1999, J HEAD TRAUMA REHAB, V14, P277, DOI 10.1097/00001199-199906000-00008; Crosson B., 1989, J HEAD TRAUMA REHAB, V4, P46, DOI [10.1097/00001199-198909000-00008, DOI 10.1097/00001199-198909000-00008]; Dirette DK, 1999, OCCUP THER J RES, V19, P223, DOI 10.1177/153944929901900401; Dirette DK, 1999, J HEAD TRAUMA REHAB, V14, P595, DOI 10.1097/00001199-199912000-00008; FLANAGAN JC, 1954, PSYCHOL BULL, V51, P327, DOI 10.1037/h0061470; Fleming J, 1999, OCCUP THER J RES, V19, P3, DOI 10.1177/153944929901900101; FLEMING J, 1997, BRIT J OCCUPATIONAL, V60, P295, DOI DOI 10.1177/030802269706000703; Fleming JM, 1996, BRAIN INJURY, V10, P1; Katz N., 1997, CANADIAN J OCCUPATIO, V64, P53, DOI DOI 10.1177/000841749706400201; KREFTING L, 1991, AM J OCCUP THER, V45, P214, DOI 10.5014/ajot.45.3.214; KREFTING L, 1989, OCCUP THER J RES, V9, P67, DOI 10.1177/153944928900900201; LAATSCH L, 2001, J COGNITIVE REHA SPR, P10; Mosey, 1996, APPL SCI INQUIRY HLT; Prigatano GP, 1986, NEUROPSYCHOL REHABIL, P1; PRIGATANO GP, 1986, AWARENESS DEFICIT BR, P1; Sohlberg MM, 1998, J HEAD TRAUMA REHAB, V13, P62, DOI 10.1097/00001199-199810000-00008; Strong J., 1995, BRIT J OCCUPATIONAL, V58, P55, DOI DOI 10.1177/030802269505800204; TEHAN G, 1995, MEM COGNITION, V23, P181, DOI 10.3758/BF03197220; Toglia J, 2000, NEUROREHABILITATION, V15, P57; TOGLIA JP, 1991, AM J OCCUP THER, V45, P505, DOI 10.5014/ajot.45.6.505	23	41	41	0	5	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	OCT	2002	16	10					861	871		10.1080/02699050210131902			11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	599VG	WOS:000178355400003	12418999				2021-06-18	
J	Sellal, FO; Manning, L; Seegmuller, C; Scheiber, C; Schoenfelder, F				Sellal, FO; Manning, L; Seegmuller, C; Scheiber, C; Schoenfelder, F			Pure retrograde amnesia following a mild head trauma: A neuropsychological and metabolic study	CORTEX			English	Article						retrograde amnesia; recovery; SPECT; procedural memory	TRANSIENT GLOBAL AMNESIA; LONG-TERM-MEMORY; ELECTROCONVULSIVE-THERAPY; ATTRIBUTION; CAUSALITY; ACCOUNT; DISEASE	After a minor closed head injury, a 33-year-old man acquired extensive retrograde amnesia (RA) covering the previous ten years and concerning autobiographical, semantic and procedural memories. The patient's learning abilities remained excellent and he recovered considerable information from his wife, the media and personal documents. This relearned information did not, however, provide a sense of personal experience in the first weeks. CT and MRI failed to show brain damage, but EEG and SPECT examination showed a marked right temporal dysfunction. After three months the patient had almost completely recovered from RA. Interestingly, a parallel recovery was observed in the second SPECT obtained at this period. There was clearly a blockade of retrieval, while the stored engrams were probably intact. The mechanisms underlying such a functional amnesia are discussed in the light of previous reports of amnesia without brain lesions.	Hop Univ Strasbourg, Serv Neurol Neuropsychol & Explorat Fonctionnelle, F-67091 Strasbourg, France; Univ Strasbourg 1, UMR 7521, Lab Neurosci Comportementales & Cognit, F-67083 Strasbourg, France; Hop Univ Strasbourg, Inst Biol Phys, F-67091 Strasbourg, France	Sellal, FO (corresponding author), Hop Univ Strasbourg, Serv Neurol Neuropsychol & Explorat Fonctionnelle, 1 Pl Hop, F-67091 Strasbourg, France.			Manning, Liliann/0000-0001-5027-8551			DAMASIO AR, 1989, COGNITION, V33, P25, DOI 10.1016/0010-0277(89)90005-X; DeRenzi E, 1997, NEUROPSYCHOLOGIA, V35, P781, DOI 10.1016/S0028-3932(97)00018-3; DERENZI E, 1993, CORTEX, V29, P449, DOI 10.1016/S0010-9452(13)80253-5; DERENZI E, 1995, CORTEX, V31, P531, DOI 10.1016/S0010-9452(13)80064-0; Evans JJ, 1996, NEUROCASE, V2, P1; FINCK G, 1996, J NEUROSCI, V16, P4275; Fujii T, 1999, CORTEX, V35, P599, DOI 10.1016/S0010-9452(08)70822-0; GLOOR P, 1990, BRAIN, V113, P1673, DOI 10.1093/brain/113.6.1673; GOLDBERG E, 1981, SCIENCE, V213, P1392, DOI 10.1126/science.7268442; HAAS DC, 1990, TRANSIENT GLOBAL AMN, P79; HODGES JR, 1989, BRAIN, V112, P595, DOI 10.1093/brain/112.3.595; HUNKIN NM, 1995, NEUROPSYCHOLOGIA, V33, P509, DOI 10.1016/0028-3932(94)00136-D; Kapur N, 2000, COGN NEUROPSYCHOL, V17, P623, DOI 10.1080/026432900750002181; Kapur N, 1997, MEMORY, V5, P115, DOI 10.1080/741941152; KAPUR N, 1993, CORTEX, V29, P217, DOI 10.1016/S0010-9452(13)80177-3; KAPUR N, 1992, BRAIN, V115, P73, DOI 10.1093/brain/115.1.73; Kapur N, 1999, PSYCHOL BULL, V125, P800, DOI 10.1037/0033-2909.125.6.800; Kopelman MD, 2000, COGNITIVE NEUROPSYCH, V17, P585, DOI 10.1080/026432900750002172; KOPELMAN MD, 1989, J CLIN EXP NEUROPSYC, V11, P724, DOI 10.1080/01688638908400928; KRITCHEVSKY M, 1989, NEUROLOGY, V39, P213, DOI 10.1212/WNL.39.2.213; LUCCHELLI F, 1995, BRAIN, V118, P167, DOI 10.1093/brain/118.1.167; Markowitsch HJ, 1996, NEUROCASE, V2, P357; Markowitsch HJ, 1997, PSYCHIAT RES-NEUROIM, V74, P119, DOI 10.1016/S0925-4927(97)03041-2; Mattioli F, 1996, CORTEX, V32, P121, DOI 10.1016/S0010-9452(96)80021-9; Ribot T-A., 1881, MALADIES MEMOIRE; ROUSSEAUX M, 1984, CORTEX, V20, P575, DOI 10.1016/S0010-9452(84)80060-X; Rumelhart D.E., 1986, PARALLEL DISTRIBUTED, V1; RUSSELL WR, 1946, BRAIN, V69, P280, DOI 10.1093/brain/69.4.280; SCHACTER DL, 1982, NEUROPSYCHOLOGIA, V20, P523, DOI 10.1016/0028-3932(82)90026-4; SCHACTER DL, 1989, HDB NEUROPSYCHOLOGY, V3, P209; SELTZER B, 1974, NEUROLOGY, V24, P527, DOI 10.1212/WNL.24.6.527; Spinnler H, 1996, BRAIN, V119, P1403, DOI 10.1093/brain/119.4.1403; SQUIRE LR, 1975, SCIENCE, V187, P77, DOI 10.1126/science.1109228; SQUIRE LR, 1981, ARCH GEN PSYCHIAT, V38, P89; STUSS D, 1988, BRAIN COGNITION, V7, P21; Thomas-Anterion C., 1994, Annales de Readaptation et de Medecine Physique, V37, P381; WECHSLER D, 1991, ECHELLE CLIN MEMOIRE	37	41	44	1	8	MASSON DIVISIONE PERIODICI	MILAN	VIA FRATELLI BRESSAN 2, 20126 MILAN, ITALY	0010-9452			CORTEX	Cortex	SEP	2002	38	4					499	509		10.1016/S0010-9452(08)70019-4			11	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	623RE	WOS:000179716000005	12465665				2021-06-18	
J	Meldrum, B				Meldrum, B			Do preclinical seizure models preselect certain adverse effects of antiepileptic drugs	EPILEPSY RESEARCH			English	Article; Proceedings Paper	Workshop on New Horizons in the Development of Antiepileptic Drugs	NOV 28-29, 2001	PHILADELPHIA, PENNSYLVANIA			epilepsy; antiepileptic drugs; sodium channels; GABA(A) receptors; side effects; benzodiazepines	LEVETIRACETAM UCB L059; SODIUM-CHANNEL; ANTICONVULSANT ACTIVITY; RECEPTOR SUBTYPES; ALPHA-SUBUNIT; PAPIO-PAPIO; DBA/2 MICE; RAT-BRAIN; D-CPP; EPILEPSY	Classical screening tests (maximal electroshock, MES, and threshold pentylenetetrazol, PTZ) employ non-epileptic rodents and identify antiepileptic drugs (AEDs) with mechanisms of action associated with significant CNS side effects. Thus MES identifies drugs acting on Na+ channels that produce cerebellar toxicity. It may be possible to produce novel AEDs more selectively targeted at voltage-sensitive (VS) ion channels. There is little specific evidence for the likely success of this strategy with subunit selective agents targeted at the different VS Na+ channels. Drugs targeted at specific VS Ca++ channels J, N, P/Q types) may be useful in generalised seizures. There are many as yet unexplored possibilities relating to K + channels. GABA related drugs acting on PTZ clonic seizures tend to induce sedation and muscle hypotonia. Studies in mice, particularly with knock-in mutations, but also with subunit selective agents acting via the GABA(A) benzodiazepine site, suggest that it is possible to produce agents which do or do not induce particular side effects (sedative, hypnotic, anxiolytic, muscle relaxant, amnesia, anaesthesia). Whether these findings transfer to man has yet to be established. Acquired epilepsy in rodents (e.g. kindling or spontaneous seizures following chemically- or electrically-induced status epilepticus) or acquired epilepsy in man (following prolonged febrile seizures or traumatic brain injury) is associated with multiple changes in the function and subunit composition of ion channels and receptor molecules. Optimal screening of novel AEDs, both for efficacy and side effects, requires models with receptor and ion channel changes similar to those in the target human syndrome. (C) 2002 Elsevier Science B.V. All rights reserved.	GKT Sch Biomed Sci, London SE1 1UL, England	Meldrum, B (corresponding author), GKT Sch Biomed Sci, Henriette Raphael House,Guys Campus,London Bridge, London SE1 1UL, England.						BENESKI DA, 1980, P NATL ACAD SCI-BIOL, V77, P639, DOI 10.1073/pnas.77.1.639; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; CHAPMAN AG, 1991, EPILEPSIA, V32, P578, DOI 10.1111/j.1528-1157.1991.tb04695.x; CHAPMAN AG, 1990, EUR J PHARMACOL, V178, P97, DOI 10.1016/0014-2999(90)94798-3; COULTER DA, 1990, BRIT J PHARMACOL, V100, P800, DOI 10.1111/j.1476-5381.1990.tb14095.x; Goldin AL, 2001, ANNU REV PHYSIOL, V63, P871, DOI 10.1146/annurev.physiol.63.1.871; GOWER AJ, 1992, EUR J PHARMACOL, V222, P193, DOI 10.1016/0014-2999(92)90855-X; HARTSHORNE RP, 1982, J BIOL CHEM, V257, P3888; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; HONACK D, 1995, EPILEPSIA, V36, P763, DOI 10.1111/j.1528-1157.1995.tb01613.x; Hosford DA, 1997, EPILEPSIA, V38, P408, DOI 10.1111/j.1528-1157.1997.tb01729.x; Klapstein GJ, 1999, NEUROPHARMACOLOGY, V38, P927, DOI 10.1016/S0028-3908(99)00016-7; KRALL RL, 1978, EPILEPSIA, V19, P404; Leresche N, 1998, J NEUROSCI, V18, P4842; Lombardo AJ, 1996, MOL BRAIN RES, V35, P84, DOI 10.1016/0169-328X(95)00194-W; Loscher W, 1998, J PHARMACOL EXP THER, V284, P474; McKernan RM, 2000, NAT NEUROSCI, V3, P587, DOI 10.1038/75761; Meadows HJ, 1998, BRIT J PHARMACOL, V123, P1253, DOI 10.1038/sj.bjp.0701721; Merritt HH, 1938, J AMER MED ASSOC, V111, P1068, DOI 10.1001/jama.1938.02790380010004; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; NOYER M, 1995, EUR J PHARMACOL, V286, P137, DOI 10.1016/0014-2999(95)00436-O; PATEL S, 1990, EPILEPSY RES, V7, P3, DOI 10.1016/0920-1211(90)90049-2; Ragsdale DS, 1998, BRAIN RES REV, V26, P16, DOI 10.1016/S0165-0173(97)00054-4; Richards R.K., 1944, FED PROC, V3, P39; ROGAWSKI MA, 2002, ANTIEPILEPTIC DRUGS, P3; Rudolph U, 2001, TRENDS PHARMACOL SCI, V22, P188, DOI 10.1016/S0165-6147(00)01646-1; Rudolph U, 1999, NATURE, V401, P796, DOI 10.1038/44579; SASHIHARA S, 1994, NEUROSCIENCE, V62, P803, DOI 10.1016/0306-4522(94)90478-2; Skradski SL, 2001, NEURON, V31, P537, DOI 10.1016/S0896-6273(01)00397-X; Smith AJ, 2001, MOL PHARMACOL, V59, P1108; SMITH SE, 1992, EUR J PHARMACOL, V211, P109, DOI 10.1016/0014-2999(92)90270-E; SVEINBJORNSDOTTIR S, 1993, EPILEPSY RES, V16, P165, DOI 10.1016/0920-1211(93)90031-2; TURSKI L, 1990, J PHARMACOL EXP THER, V253, P344; White H. S., 2002, ANTIEPILEPTIC DRUGS; Yarov-Yarovoy V, 2001, J BIOL CHEM, V276, P20, DOI 10.1074/jbc.M006992200	35	41	42	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0920-1211			EPILEPSY RES	Epilepsy Res.	JUN	2002	50	1-2					33	40	PII S0920-1211(02)00066-9	10.1016/S0920-1211(02)00066-9			8	Clinical Neurology	Neurosciences & Neurology	592LU	WOS:000177939800005	12151115				2021-06-18	
J	Pfenninger, J; Santi, A				Pfenninger, J; Santi, A			Severe traumatic brain injury in children are the results improving?	SWISS MEDICAL WEEKLY			English	Article						head injury; miltiple injury; computerized tomography; consukption coagulopathy; intracranial pressure	SEVERE HEAD-INJURY; INTRACRANIAL-PRESSURE; INSULTS; CARE	Questions under study: Traumatic brain injury (TBI) remains an important cause of mortality and morbidity in children. Medical management is constantly being refined, and thus results should improve. The aim of the present study was to analyse our data of recent years and to compare them with previous series (1978-83 and 1988-92). Patients and methods: The data of 51 children (1 month to 16 years old) with severe blunt TBI treated in our unit from 1994 to 1998 were analyzed retrospectively. Severe TBI was defined by immediate loss of consciousness and an admission Glasgow coma scale (GCS) <8. Outcome,,vas classified by using the Glasgow outcome scale (GOS) 6 to 12 months after injury. Results: 35 patients (69%) showed a good outcome (GOS 4 and 5), 14 died (GOS 1), one survived in a permanent vegetative state (GOS 2), and another was severely disabled (GOS 3) (GOS 1-3 = bad outcome, 31%). Bad outcome was associated with low GCS (i.e. 3 and 4), fixed and dilated pupils at admission, invisible basal cisterns on first computerized tomography, and presence of coagulopathy. Moderate to severe intracranial hypertension was also significantly related to bad outcome in the 26 patients with intracranial pressure monitoring. Compared to our first series severity of TBI was unchanged, and the incidence of multiple injury and consumption coagulopathy was less frequent. Intubation rate prior to admission to the centre increased from 3 5% to 94%. Intensive care measures (duration of mechanical ventilation, use of hypothermia, mannitol, thiopentone etc.) were less aggressive. The rate of good outcome remained unchanged (69% vs. 60%). Conclusions: Despite changing management policies, results were comparable with those of our former series. This fact underlines the importance of primary injury and the secondary role of intensive care management on final outcome.	Univ Bern, Inselspital, Univ Childrens Hosp, Pediat Intens Care Unit, CH-3010 Bern, Switzerland	Pfenninger, J (corresponding author), Univ Bern, Inselspital, Univ Kinderklin, Abt Padiatr Intens Behandlung, CH-3010 Bern, Switzerland.						BRUCE DA, 1979, CHILD BRAIN, V5, P174; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESNUT RM, 1997, YB INTENSIVE CARE EM, P749; Chiaretti A, 2001, PEDIATR NEUROSURG, V34, P131, DOI 10.1159/000056008; DYKES EH, 1989, J TRAUMA, V29, P724, DOI 10.1097/00005373-198906000-00004; FISHER B, 1992, J NEUROSURG ANESTH, V4, P4, DOI 10.1097/00008506-199201000-00002; JENNETT B, 1995, LANCET, V345, P480; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; PFENNINGER J, 1993, INTENS CARE MED, V19, P243, DOI 10.1007/BF01690543; PFENNINGER J, 1984, Z KINDERCHIR, V39, P223; PFENNINGER J, 1982, EUR J PEDIATR SURG, V37, P53; PFENNINGER J, 1997, YB INTENSIVE CARE EM, P766; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Sarrafzadeh AS, 2001, CRIT CARE MED, V29, P1116, DOI 10.1097/00003246-200106000-00004; Segal S, 2001, INTENS CARE MED, V27, P236, DOI 10.1007/s001340000717; Souter MJ, 1996, INTENSIVE CARE WORLD, V13, P32; Suominen P, 2000, Eur J Emerg Med, V7, P3; THOMAS D G T, 1978, Lancet, V1, P113; Tilford JM, 2001, CRIT CARE MED, V29, P1056, DOI 10.1097/00003246-200105000-00037; Vavilala MS, 2001, J NEUROSURG ANESTH, V13, P13, DOI 10.1097/00008506-200101000-00003; VOS LJM, 1972, EUR J PEDIAT SURG S, V11, P334; Zornow M H, 1995, New Horiz, V3, P488	23	41	43	0	2	E M H SWISS MEDICAL PUBLISHERS LTD	BASEL	STEINENTORSTRASSE 13, CH-4-10 BASEL, SWITZERLAND	1424-7860			SWISS MED WKLY	Swiss Med. Wkly.	MAR 9	2002	132	9-10					116	120					7	Medicine, General & Internal	General & Internal Medicine	560RJ	WOS:000176094800002	12045999	DOAJ Gold			2021-06-18	
J	Saljo, A; Bao, F; Shi, JS; Hamberger, A; Hansson, HA; Haglid, KG				Saljo, A; Bao, F; Shi, JS; Hamberger, A; Hansson, HA; Haglid, KG			Expression of c-Fos and c-Myc and deposition of beta-APP in neurons in the adult rat brain as a result of exposure to short-lasting impulse noise	JOURNAL OF NEUROTRAUMA			English	Article						acoustic energy; degeneration; pressure waves; traumatic brain injury	AMYLOID PRECURSOR PROTEIN; IMMEDIATE-EARLY GENES; FATAL HEAD-INJURY; ALZHEIMERS-DISEASE; MESSENGER-RNA; JUN; NEUROTOXICITY; ACCUMULATION; EVOLUTION; APOPTOSIS	There is increasing evidence that impulse noise causes brain damage, but little is known about the mechanisms and extent of the response. Here, rat brains were investigated immunohistochemically for the expression of c-Fos, c-Myc, and beta-APP during the first 3 weeks postexposure to impulse noise of 198 or 202 dB. The expression of c-Fos and c-Myc increased at 2 h after exposure in neurons of the cerebral cortex, thalamus, and hippocampus; and this c-Fos immunoreactivity remained elevated for the entire observation period. The c-Myc immunoreactivity peaked at 18 h in both neurons and astrocytes but returned to control levels at 7 days. Abnormal deposition of beta-APP was evident within 6 h in the same brain regions. The beta-APP immunoreactivity was most prominent at 18 h and remained increased over the 21-day period assessed. The observed effects were similar to those described in humans following traumatic brain injury and in Alzheimer's disease. We conclude that impulse noise influences the brain in a fashion similar to that in cases with progressive CNS degeneration.	Univ Gothenburg, Dept Anat & Cell Biol, SE-40530 Gothenburg, Sweden; China Med Univ, Inst Brain Res, Shenyang, Peoples R China; Zunyi Med Coll, Dept Pharmacol, Zunyi, Peoples R China	Saljo, A (corresponding author), Univ Gothenburg, Dept Anat & Cell Biol, Box 420, SE-40530 Gothenburg, Sweden.	annette.saljo@anatcell.gu.se					Aubry S, 2000, DNA CELL BIOL, V19, P353, DOI 10.1089/10445490050043326; Cernak I, 1999, J TRAUMA, V47, P96, DOI 10.1097/00005373-199907000-00021; CERNAK I, 1997, INT REV ARMED FORCES, V70, P114; Chen XH, 1999, J NEUROPATH EXP NEUR, V58, P588, DOI 10.1097/00005072-199906000-00003; CLEMEDSON CARL-JOHAN, 1955, JOUR AVIATION MED, V26, P373; Cunningham K, 2000, J ACCID EMERG MED, V17, P139; CURRAN T, 1995, J NEUROBIOL, V26, P403, DOI 10.1002/neu.480260312; Dancer A, 1998, SCAND AUDIOL, V27, P123; Duma SM, 1996, J TRAUMA, V41, P114, DOI 10.1097/00005373-199607000-00018; Dutcher SA, 1999, NEUROL RES, V21, P234, DOI 10.1080/01616412.1999.11740924; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Elsayed NM, 1997, TOXICOLOGY, V121, P1, DOI 10.1016/S0300-483X(97)03651-2; Emmerling MR, 2000, ANN NY ACAD SCI, V903, P118, DOI 10.1111/j.1749-6632.2000.tb06357.x; Estus S, 1997, J NEUROSCI, V17, P7736; Fuhrmann G, 1999, MUTAT RES-REV MUTAT, V437, P205, DOI 10.1016/S1383-5742(99)00084-8; FUKUCHI K, 1992, BIOCHEM BIOPH RES CO, V182, P165, DOI 10.1016/S0006-291X(05)80126-3; Gass P, 1995, PROG NEUROBIOL, V47, P257, DOI 10.1016/0301-0082(95)00022-4; Gillardon F, 1996, BRAIN RES, V706, P169, DOI 10.1016/0006-8993(95)01332-6; Graham DI, 1999, CELL MOL NEUROBIOL, V19, P19, DOI 10.1023/A:1006937205905; Griffin WST, 1998, BRAIN PATHOL, V8, P65; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; Horsburgh K, 2000, NEUROBIOL AGING, V21, P245, DOI 10.1016/S0197-4580(00)00097-X; Hotti A, 2000, ONCOGENE, V19, P2354, DOI 10.1038/sj.onc.1203567; HUGHES P, 1995, PHARMACOL REV, V47, P133; *ISO, 1992, AC QUANT UN; Lodish H., 1999, MOL CELL BIOL; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; McFeely WJ, 1999, OTOLARYNG HEAD NECK, V121, P367, DOI 10.1016/S0194-5998(99)70222-6; MILWARD EA, 1992, NEURON, V9, P129, DOI 10.1016/0896-6273(92)90228-6; Murakami N, 1998, J NEUROTRAUM, V15, P993, DOI 10.1089/neu.1998.15.993; Price GR, 1999, J ACOUST SOC AM, V106, P2629, DOI 10.1121/1.428092; Ryan KM, 1996, BIOCHEM J, V314, P713, DOI 10.1042/bj3140713; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; SALJO A, 2002, IN PRESS J NEUROTRAU; Saljo Annette, 2001, Pathophysiology, V8, P105, DOI 10.1016/S0928-4680(01)00067-0; SASSONECORSI P, 1988, COLD SPRING HARB SYM, V53, P749, DOI 10.1101/SQB.1988.053.01.085; Saunders JE, 1998, OTOLARYNG HEAD NECK, V118, P228, DOI 10.1016/S0194-5998(98)80021-1; Selkoe Dennis J., 1994, Current Opinion in Neurobiology, V4, P708, DOI 10.1016/0959-4388(94)90014-0; Sheng JG, 1997, ACTA NEUROPATHOL, V94, P1, DOI 10.1007/s004010050664; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Van den Heuvel C, 2000, J CLIN NEUROSCI, V7, P140; Walton M, 1998, J NEUROSCI RES, V53, P330, DOI 10.1002/(SICI)1097-4547(19980801)53:3<330::AID-JNR7>3.0.CO;2-B; Whitfield PC, 2000, NEUROL RES, V22, P138, DOI 10.1080/01616412.2000.11741050; Wu KJ, 1999, SCIENCE, V283, P676, DOI 10.1126/science.283.5402.676; YANG QN, 1995, BRAIN RES, V696, P49, DOI 10.1016/0006-8993(95)00755-F; YOSHIKAWA K, 1992, NATURE, V359, P64, DOI 10.1038/359064a0	47	41	44	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2002	19	3					379	385		10.1089/089771502753594945			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	534BC	WOS:000174563900009	11939505				2021-06-18	
J	Bode, RK; Heinemann, AW				Bode, RK; Heinemann, AW			Course of functional improvement after stroke, spinal cord injury, and traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	Annual Meeting of the American-Congress-of-Rehabilitation-Medicine	SEP, 1998	SEATTLE, WASHINGTON	Amer Congress Rehabil Med		brain injuries; length of stay; rehabilitation; stroke; spinal cord injuries; treatment outcome	INPATIENT REHABILITATION; MEDICAL REHABILITATION; DISABILITY; OUTCOMES; LENGTH; STAY	Objective: To examine functional improvement patterns of persons with stroke. traumatic brain injury (TBI), and spinal cord injury (SCI). Design: Statistical analysis of data from a multisite study evaluating rehabilitation outcomes. Setting: Eight inpatient rehabilitation facilities. Participants: A total of 314 consecutive admissions of persons with stroke, SCI, and TBI who received acute medical rehabilitation between 1994 and 1998. Intervention: Calibration of motor and cognitive items from the FIM(TM) instrument. grouping of cases by number of weeks of rehabilitation (length of stay [LOS] groups). and plotting of weekly averages across time. Main Outcome Measures: Weekly motor and cognitive functional status. Results: With the exception of cognitive functioning for persons with SCI, LOS was related to initial functional status, with patients with greater disability having longer LOS (eg, initial motor status for persons with stroke was 48.3 for those with a 2-week stay. 36.8 for a 6-week stay, with the averages between decreasing monotonically). With the exception of cognitive gains for person with TBIs, the amount of functional C gain during rehabilitation was essentially the same for all LOS group, (eg, the overall average total motor gain for persons with SCI is 22.3. with no patterns of increase or decrease across LOS groups) however, the rate of improvement in motor (but not cognitive) functioning differed across LOS groups, with patients with shorter stays having the greater rates of improvement leg, the overall average weekly motor gain for persons with SCI was 3.6, with the averages by LOS group monotonically decreasing from 6.4 for those with 4-week stays to 2.7 for those with 9-week stays). Conclusions: When examined separately for persons grouped by LOS, functional status improved linearly during the rehabilitation stay. with differences in rate of improvement depending on initial functional status.	Rehabil Inst Chicago, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Phys Med & Rehabil, Chicago, IL USA	Bode, RK (corresponding author), Rehabil Inst Chicago, 345 E Super St,Rm 1378, Chicago, IL 60611 USA.		Heinemann, Allen W/K-6283-2012; Heinemann, Allen W./AAI-2790-2021	Heinemann, Allen W/0000-0003-2782-7326; Heinemann, Allen W./0000-0003-2782-7326			Bryk A.S., 1992, HIERARCHICAL LINEAR; BRYK AS, 1987, PSYCHOL BULL, V101, P47; CAREY RG, 1988, ARCH PHYS MED REHAB, V69, P337; Fuhrer MJ, 1987, REHABILITATION OUTCO, P137; GRANGER CV, 1989, ARCH PHYS MED REHAB, V70, P100; GRANGER CV, 1988, ARCH PHYS MED REHAB, V69, P506; HEINEMANN AW, 1987, ARCH NEUROL-CHICAGO, V44, P1167, DOI 10.1001/archneur.1987.00520230051013; HEINEMANN AW, 1989, ARCH NEUROL-CHICAGO, V46, P1098, DOI 10.1001/archneur.1989.00520460084017; HEINEMANN AW, 1994, ARCH PHYS MED REHAB, V75, P133; HEINEMANN AW, 2000, J REHABIL OUTCOMES M, V4, P18; Heinemann AW, 1994, TOP STROKE REHABIL, V1, P1; Leiter P, 1997, MED CARE, V35, pJS113, DOI 10.1097/00005650-199706001-00021; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; Rasch G., 1980, PROBABILISTIC MODELS; ROGOSA DR, 1985, PSYCHOMETRIKA, V50, P203, DOI 10.1007/BF02294247; SCHULZ EM, 1992, OBJECTIVE MEASUREMEN, V1, P138; SETLZER MH, 1994, EDUC EVAL POLICY AN, V16, P41; Stineman M G, 1995, Am J Med Qual, V10, P190, DOI 10.1177/0885713X9501000405; STINEMAN MG, 1994, MED CARE, V32, P366, DOI 10.1097/00005650-199404000-00005; Stineman MG, 1998, ARCH PHYS MED REHAB, V79, P241, DOI 10.1016/S0003-9993(98)90001-6; Stineman MG, 1996, AM J PHYS MED REHAB, V75, P68, DOI 10.1097/00002060-199601000-00018; STINEMAN MG, 1994, ARCH PHYS MED REHAB, V75, P1277; STINEMAN MG, 1990, ARCH PHYS MED REHAB, V71, P881; WILLETT JB, 1988, REV RES EDUC, V15, P345; Wilson M., 1997, OBJECTIVE MEASUREMEN, V4, P297; Wright B.D., 1996, RASCH MEASUREMENT T, V10, P506; Wright B. D., 1982, RATING SCALE ANAL RA; WRIGHT BD, 1996, RASCH MEAS T, V10, P478; WRIGHT BD, 2000, WINSTEPS COMPUTER PR; YARKONY GM, 1988, ARCH PHYS MED REHAB, V69, P111	30	41	58	0	4	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JAN	2002	83	1					100	106		10.1053/apmr.2002.26073			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	509JU	WOS:000173145300016	11782839				2021-06-18	
J	Piot-Grosjean, O; Wahl, F; Gobbo, O; Stutzmann, JM				Piot-Grosjean, O; Wahl, F; Gobbo, O; Stutzmann, JM			Assessment of sensorimotor and cognitive deficits induced by a moderate traumatic injury in the right parietal cortex of the rat	NEUROBIOLOGY OF DISEASE			English	Article						traumatic brain injury; rat; sensorimotor function; cognitive function; functional recovery	CONTROLLED CORTICAL IMPACT; EXPERIMENTAL BRAIN INJURY; CLOSED-HEAD-INJURY; FLUID-PERCUSSION MODEL; LONG-TERM; HIPPOCAMPAL DAMAGE; CEREBRAL EDEMA; SPATIAL MEMORY; TIME-COURSE; MAZE	The purpose of this study was to set-up a battery of behavioral tests to assess sensorimotor and cognitive deficits following a moderate traumatic brain injury (TBI) in rats. Coordinated walking ability was evaluated in an accelerated rotarod test. Vestibulomotor function and fine motor coordination were assessed by using a beam-walking task. Rotarod and beam-walking performances were both altered in injured rats compared to sham-operated and control rats. A more pronounced and longer-lasting deficit was measured in the beam-walking test. Cognitive function was studied by using the Lashley maze paradigm. A spatial localization deficit was significant for 4 weeks posttrauma in TBI rats. The beam-walking task and the Lashley maze are robust and sensitive methods in detecting sensorimotor and cognitive impairment after TBI in rats, respectively. These tests are proposed for evaluating the ability of new pharmacological agents to improve the functional recovery after a TBI in rats. (C) 2001 Elsevier Science.	Aventis Pharma, Neurodegenerat Dis Grp, CRVA, F-94403 Vitry Sur Seine, France	Piot-Grosjean, O (corresponding author), Aventis Pharma, Neurodegenerat Dis Grp, CRVA, 13 Quai Jules Guesde, F-94403 Vitry Sur Seine, France.		Gobbo, Oliviero/R-1763-2016; Gobbo, Oliviero/S-2043-2019	Gobbo, Oliviero/0000-0003-4629-9485; Gobbo, Oliviero/0000-0003-4629-9485			Adelson PD, 1997, J NEUROTRAUM, V14, P99, DOI 10.1089/neu.1997.14.99; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Bareyre F, 1997, J NEUROTRAUM, V14, P839, DOI 10.1089/neu.1997.14.839; Cervos-Navarro J., 1991, J NEUROL SCI, V103, P3; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DENENBERG VH, 1991, PHYSIOL BEHAV, V50, P857, DOI 10.1016/0031-9384(91)90031-I; DIXON CE, 1995, BEHAV BRAIN RES, V70, P125, DOI 10.1016/0166-4328(95)80002-6; DIXON CE, 1994, J NEUROTRAUM, V11, P275, DOI 10.1089/neu.1994.11.275; Dixon CE, 1996, PHARMACOL BIOCHEM BE, V53, P679, DOI 10.1016/0091-3057(95)02069-1; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DUNHAM NW, 1957, J AM PHARM ASSOC, V46, P208, DOI 10.1002/jps.3030460322; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Fox GB, 1998, J NEUROTRAUM, V15, P1037, DOI 10.1089/neu.1998.15.1037; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GOLDSTEIN LB, 1990, J NEUROSCI METH, V31, P101, DOI 10.1016/0165-0270(90)90154-8; GORMAN LK, 1993, BRAIN RES, V614, P29, DOI 10.1016/0006-8993(93)91014-J; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; Gualtari CT, 1991, BRAIN INJURY, V5, P219; Hamm RJ, 1996, J NEUROTRAUM, V13, P317, DOI 10.1089/neu.1996.13.317; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Holmin S, 1999, NEUROREPORT, V10, P1889, DOI 10.1097/00001756-199906230-00017; JONES BJ, 1968, J PHARM PHARMACOL, V20, P302, DOI 10.1111/j.2042-7158.1968.tb09743.x; JUCKER M, 1990, PHYSIOL BEHAV, V47, P207, DOI 10.1016/0031-9384(90)90062-9; Lashley KS, 1933, PHYSIOL REV, V13, P0001, DOI 10.1152/physrev.1933.13.1.1; Levin H S, 1991, Neurosurg Clin N Am, V2, P457; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LIGHTHALL J W, 1989, Journal of Neurotrauma, V6, P83, DOI 10.1089/neu.1989.6.83; Lindner MD, 1998, J NEUROTRAUM, V15, P199, DOI 10.1089/neu.1998.15.199; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MAIER NRF, 1934, J COMP NEUROL, V61, P395; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MCDANIEL WF, 1995, BEHAV BRAIN RES, V70, P165, DOI 10.1016/0166-4328(95)80006-9; McIntosh TK, 1996, LAB INVEST, V74, P315; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MOSER MB, 1994, P NATL ACAD SCI USA, V91, P12673, DOI 10.1073/pnas.91.26.12673; Newton R, 1989, Brain Inj, V3, P335, DOI 10.3109/02699058909004558; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; OKEEFE J, 1979, BEHAV BRAIN SCI, V2, P487, DOI 10.1017/S0140525X00063949; OLTON DS, 1976, J EXP PSYCHOL-ANIM B, V2, P97, DOI 10.1037/0097-7403.2.2.97; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; SCHROTT LM, 1992, PHYSIOL BEHAV, V52, P1085, DOI 10.1016/0031-9384(92)90463-C; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Soblosky JS, 1996, BEHAV BRAIN RES, V79, P79, DOI 10.1016/0166-4328(95)00264-2; Soblosky JS, 1996, BEHAV BRAIN RES, V80, P185, DOI 10.1016/0166-4328(96)00034-4; TOULMOND S, 1993, BRAIN RES, V620, P24, DOI 10.1016/0006-8993(93)90266-P; Wahl F, 1997, BRAIN RES, V756, P247, DOI 10.1016/S0006-8993(97)00144-3; WAHL F, 1992, STROKE, V23, P267, DOI 10.1161/01.STR.23.2.267	56	41	44	0	2	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961			NEUROBIOL DIS	Neurobiol. Dis.	DEC	2001	8	6					1082	1093		10.1006/nbdi.2001.0450			12	Neurosciences	Neurosciences & Neurology	505BV	WOS:000172892100016	11741403				2021-06-18	
J	Vink, R; Nimmo, AJ; Cernak, I				Vink, R; Nimmo, AJ; Cernak, I			An overview of new and novel pharmacotherapies for use in traumatic brain injury	CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY			English	Article; Proceedings Paper	34th Annual Meeting of the Australasian-Society-of-Clinical-and-Experimental-Pharmacologists-and-Toxicologists	DEC 03-06, 2000	NEWCASTLE, AUSTRALIA	Australasian Soc Clin & Exptl Pharmacologists & Toxicologists		apoptosis; brain injury; gender; neurotrauma; tachykinin; therapy	FREE MAGNESIUM CONCENTRATION; CYCLOSPORINE-A; PHARMACOLOGICAL STRATEGIES; PERMEABILITY TRANSITION; RECEPTOR ANTAGONIST; CORTICAL DAMAGE; CNS TRAUMA; RATS; MITOCHONDRIA; ESTROGEN	1. Although a number of interventional pharmacotherapies have undergone clinical trial in traumatic brain injury (TBI), none has shown considerable promise. The present short review will examine some of the more novel compounds that have been proposed recently as potential therapeutic agents for use in TBI. 2. Previous experimental studies have demonstrated that brain intracellular free magnesium significantly declines following TBI and that the administration of magnesium salts attenuates the post-traumatic neurological deficits. More recent studies have established that magnesium salts administered after trauma enter the brain intracellular space and reduce the size of the lesion volume. Such protection could be afforded through attenuation of both necrotic and apoptotic cell death. Magnesium salts are currently on clinical trial in TBI. 3. Cyclosporine A is known to inhibit opening of the mitochondrial permeability transition pore. Administration of cyclosporine A after TBI has been shown to attenuate axonal injury and decrease the resultant lesion volume. Therefore, inhibitors of mitochondrial transition pore opening and resultant attenuation of apoptosis show some promise as neuroprotective agents. 4. Recent evidence has shown that substance P antagonists may decrease lesion volume and improve neurological outcome after ischaemia. Similar findings have recently been reported in TBI. The fact that substance P antagonists are known to reduce neurogenic inflammation, oedema formation and are clinically being trialed as both antidepressants and antinociceptive agents suggests that these agents warrant further investigation as therapeutic agents following TBI. 5. There are numerous contradictions in the literature regarding the potential neuroprotective effects of the hormones oestrogen and progesterone. Recent studies suggest that both hormones are protective in TBI and further studies are required to ascertain the mechanisms associated with this protection and any potential for clinical application.	James Cook Univ N Queensland, Dept Physiol & Pharmacol, Townsville, Qld 4811, Australia	Vink, R (corresponding author), Univ Adelaide, Dept Pathol, Adelaide, SA 5005, Australia.		Cernak, Ibolja/A-6399-2008; AM, Robert Vink/S-5616-2019; Vink, Robert/J-7351-2012	AM, Robert Vink/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667; Ibolja, Cernak/0000-0003-3214-698X; Nimmo, Alan/0000-0002-0718-7934			Bareyre FM, 2000, J NEUROTRAUM, V17, P1029, DOI 10.1089/neu.2000.17.1029; BIBAN C, 1995, BIOCHEM PHARMACOL, V50, P497, DOI 10.1016/0006-2952(95)00165-V; BIRCH NJ, 1993, MAGNESIUM CELL; Brustovetsky N, 2000, J NEUROSCI, V20, P8229, DOI 10.1523/JNEUROSCI.20-22-08229.2000; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Doppenberg EMR, 1997, J NEUROTRAUM, V14, P71, DOI 10.1089/neu.1997.14.71; Ema M, 1998, ALCOHOL, V15, P95, DOI 10.1016/S0741-8329(97)00102-X; EMERSON CS, 1993, BRAIN RES, V608, P95, DOI 10.1016/0006-8993(93)90778-L; Faden AI, 1996, JAMA-J AM MED ASSOC, V276, P569, DOI 10.1001/jama.276.7.569; FADEN AI, 1992, TRENDS PHARMACOL SCI, V13, P29, DOI 10.1016/0165-6147(92)90013-V; GITTER BD, 1995, EUR J PHARM-MOLEC PH, V289, P439, DOI 10.1016/0922-4106(95)90152-3; Heath DL, 1996, BRAIN RES, V738, P150, DOI 10.1016/0006-8993(96)00957-2; Heath DL, 1999, J PHARMACOL EXP THER, V288, P1311; Heath DL, 1999, J NEUROSURG, V90, P504, DOI 10.3171/jns.1999.90.3.0504; Kowaltowski AJ, 1998, ARCH BIOCHEM BIOPHYS, V359, P77, DOI 10.1006/abbi.1998.0870; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; McIntosh TK, 1988, J NEUROTRAUM, V5, P17, DOI 10.1089/neu.1988.5.17; Muir JK, 1999, EXP NEUROL, V159, P584, DOI 10.1006/exnr.1999.7187; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Rupniak NMJ, 1999, TRENDS PHARMACOL SCI, V20, P485, DOI 10.1016/S0165-6147(99)01396-6; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; SHIGA Y, 1992, BRAIN RES, V595, P145, DOI 10.1016/0006-8993(92)91465-Q; SMITH DH, 1993, NEUROSCI LETT, V157, P211, DOI 10.1016/0304-3940(93)90739-8; Smith DH, 1998, J NEUROTRAUM, V15, P665, DOI 10.1089/neu.1998.15.665; Suzuki M, 1997, GEN PHARMACOL, V28, P119, DOI 10.1016/S0306-3623(96)00148-6; SZABO I, 1991, J BIOL CHEM, V266, P3376; Uchino H, 1995, ACTA PHYSIOL SCAND, V155, P469, DOI 10.1111/j.1748-1716.1995.tb09999.x; VINK R, 1988, J BIOL CHEM, V263, P757; VINK R, 2000, REST NEUROL NEUROSCI, V16, P164; Yu ZF, 1997, NEUROREPORT, V8, P2117, DOI 10.1097/00001756-199707070-00006; ZHANG C, 1998, J NEUROTRAUM, V15, P904	33	41	48	1	3	BLACKWELL PUBLISHING ASIA	CARLTON	54 UNIVERSITY ST, P O BOX 378, CARLTON, VICTORIA 3053, AUSTRALIA	0305-1870			CLIN EXP PHARMACOL P	Clin. Exp. Pharmacol. Physiol.	NOV	2001	28	11					919	921		10.1046/j.1440-1681.2001.03548.x			3	Pharmacology & Pharmacy; Physiology	Pharmacology & Pharmacy; Physiology	548PA	WOS:000175396000013	11703396				2021-06-18	
J	Chapman, SB; McKinnon, L; Levin, HS; Song, J; Meier, MC; Chiu, S				Chapman, SB; McKinnon, L; Levin, HS; Song, J; Meier, MC; Chiu, S			Longitudinal outcome of verbal discourse in children with traumatic brain injury: Three-year follow-up	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							WRITTEN LANGUAGE PRODUCTION; DEVELOPMENTAL PLASTICITY; HEAD-INJURY; RECOVERY	Purpose: This study compared changes in discourse ability between two groups of children age 5 to 10 years after brain injury: those with severe traumatic brain injury (TBI) and those with mild/moderate injury over 3-year follow-up testing. Materials and Methods: Forty-three children with TBI were recruited from a larger research project examining cognitive and linguistic recovery after injury. Twenty-two of these patients had severe injuries and 21 sustained mild/moderate injuries. AD children were presented an ordered sequence of pictures and asked to verbally produce a story/narrative discourse. Each child was then asked to produce a lesson relating to the story. Results: The severe group performed significantly worse than the mild/moderate group when performance across all four discourse domains was considered. Both groups improved across time on selected discourse measures. Qualitative analysis suggested that the severe group showed differential rates of improvement across the individual discourse variables over the 3-year interval. Conclusions: Severe TBI can have a pernicious effect on discourse abilities in children years after injury compared with children with mild/moderate injuries. The major caveat is that the discourse measures must be sufficiently challenging when used to assess older children and children with milder forms of TBI.	Univ Texas, Dept Human Dev, Dallas, TX 75230 USA; Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA	Chapman, SB (corresponding author), Univ Texas, Ctr BrainHlth, 1966 Inwood Rd, Dallas, TX 75235 USA.	schapman@utdallas.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889] Funding Source: Medline		Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Applebee A., 1978, CHILDS CONCEPT STORY; ASARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; Biddle KR, 1996, J COMMUN DISORD, V29, P447, DOI 10.1016/0021-9924(95)00038-0; BIJUR PE, 1990, PEDIATRICS, V86, P337; Brookshire BL, 2000, J INT NEUROPSYCH SOC, V6, P741, DOI 10.1017/S1355617700677019; Chapman S. B., 1997, AM J SPEECH-LANG PAT, V6, P66; Chapman SB, 1998, BRAIN LANG, V61, P420, DOI 10.1006/brln.1997.1885; Chapman SB, 2000, J COMMUN DISORD, V33, P333, DOI 10.1016/S0021-9924(00)00029-0; CHAPMAN SB, 1995, J HEAD TRAUMA REHAB, V10, P36, DOI 10.1097/00001199-199510000-00006; CHAPMAN SB, 1997, AM J SPEECH-LANG PAT, V6, P50, DOI DOI 10.1044/1058-0360.0602.50; CHAPMAN SB, UNPUB NEUROIMAGING D; CHAPMAN SB, 1996, DIAGNOZA ITERAPIS OS; CHAPMAN SB, 1999, ADV SPEECH LANGUAGE, V1, P19; CHAPMAN SB, 1999, BRAIN DAM B, P235; DELIS DC, 1988, J CONSULT CLIN PSYCH, V56, P123, DOI 10.1037/0022-006X.56.1.123; DELIS DC, 1990, ADV PSYCHOL ASSESS, P101; Dennis M, 2000, J COMMUN DISORD, V33, P321, DOI 10.1016/S0021-9924(00)00028-9; Dunn L., 1981, PEABODY PICTURE VOCA; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P225; EWINGCOBBS L, 1992, BRAIN LANG, V43, P42; FAY GC, 1993, ARCH PHYS MED REHAB, V74, P895; Frederiksen C. H., 1990, DISCOURSE ABILITY BR; Hunt K. W., 1965, 3 NAT COUNC TEACH EN; Jackendoff R. S., 1992, LANGUAGES MIND ESSAY; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; Joanette Y., 1990, DISCOURSE ABILITY BR; LABOV W, 1972, LANGUAGE CITY STUDIE; Levin H S, 1997, J Int Neuropsychol Soc, V3, P598; Levin HS, 1996, DEV NEUROPSYCHOL, V12, P17, DOI 10.1080/87565649609540638; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; MROSS EF, 1990, DISCOURSE ABILITY BR; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Sparrow S.S., 1989, MAJOR PSYCHOL ASSESS, V2, P199; Stein N. L., 1979, NEW DIRECTIONS DISCO, V2, P53; SUTTONSMITH B, 1976, HUM DEV, V19, P1, DOI 10.1159/000271510; TEASDALE G, 1974, LANCET, V2, P81; Westby C. E., 1984, LANGUAGE LEARNING DI, P103; Yorkston KM, 1997, ARCH PHYS MED REHAB, V78, P1096, DOI 10.1016/S0003-9993(97)90134-9; Yorkston KM, 1999, APHASIOLOGY, V13, P691, DOI 10.1080/026870399401803	40	41	41	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	OCT	2001	16	5					441	455		10.1097/00001199-200110000-00004			15	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	483JF	WOS:000171631700004	11574040				2021-06-18	
J	Harris, LK; Black, RT; Golden, KM; Reeves, TM; Povlishock, JT; Phillips, LL				Harris, LK; Black, RT; Golden, KM; Reeves, TM; Povlishock, JT; Phillips, LL			Traumatic brain injury-induced changes in gene expression and functional activity of mitochondrial cytochrome c oxidase	JOURNAL OF NEUROTRAUMA			English	Article						cytochrome c oxidase; deafferentation; neuroexcitation; plasticity; traumatic brain injury	FLUID-PERCUSSION INJURY; MESSENGER-RNA; DIFFERENTIAL DISPLAY; RAT; METABOLISM; HIPPOCAMPUS; SUBUNIT; DISEASE; AMELIORATION; PROTEOLYSIS	Traumatic brain injury (TBI) is documented to have detrimental effects on CNS metabolism, including alterations in glucose utilization and the depression of mitochondrial oxidative phosphorylation. Studies on mitochondrial metabolism have also provided evidence for reduced activity of the cytochrome oxidase complex of the electron transport chain (complex IV) after TBI and an immediate (1hr) reduction in mitochondrial state 3 respiratory rate, which can persist for up to 14 days postinjury. Using differential display methods to screen for differences in gene expression, we have found that cytochrome c oxidase H (COII), a mitochondrial encoded subunit of complex IV, is upregulated following TBI. Since COH carries a binding site for cytochrome c in the respiratory chain, and since it is required for the passage of chain electrons to molecular oxygen, driving the production of ATP, we hypothesized that metabolic dysfunction resulting from TBI alters COII gene expression directly, perhaps influencing the synaptic plasticity that occurs during postinjury recovery processes. To test this hypothesis, we documented COII mRNA expression and complex IV (cytochrome c oxidase) functional activity at 7 days postinjury, focusing on the long-term postinjury period most closely associated with synaptic reorganization. Both central fluid percussion TBI and combined TBI and bilateral entorhinal cortical lesion were examined. At 7 days survival, differential display, RT-PCR, and Northern blot analysis of hippocampal RNA from both TBI and combined insult models showed a significant induction of COII mRNA. This long-term elevation in COII gene expression was supported by increases in COII immunobinding. By contrast, cytochrome oxidase histochemical activity within tissue sections from injured brains suggested a reduction of complex IV activity within the TBI cases, but not within animals subjected to the combined insult. These differences in cytochrome c oxidase activity were supported by in vitro assay of complex IV using cerebral cortical and hippocampal tissues. Our present results support the hypothesis that COH is selectively vulnerable to TBI and that COII differences may indicate the degree of metabolic dysfunction induced by different pathologies. Taken together, such data will better define the role of metabolic function in long-term recovery after TBI.	Virginia Commonwealth Univ, MCV Stn, Dept Anat, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Div Neurosurg, Richmond, VA 23298 USA	Harris, LK (corresponding author), Virginia Commonwealth Univ, MCV Stn, Dept Anat, 1217 E Marshall St Rm 7-36,POB 980709, Richmond, VA 23298 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS012587, P01NS012587, R01NS020193] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 12587, NS 20193] Funding Source: Medline		Ahmed SM, 2000, J NEUROCHEM, V74, P1951, DOI 10.1046/j.1471-4159.2000.741951000000000.x; Bates TE, 1996, NEUROREPORT, V7, P1397, DOI 10.1097/00001756-199605310-00014; BAUDRY M, 1982, SCIENCE, V216, P411, DOI 10.1126/science.7071588; BENNETT MC, 1992, BEHAV NEURAL BIOL, V58, P72, DOI 10.1016/0163-1047(92)90967-9; Bentzer P, 2000, J NEUROTRAUM, V17, P441, DOI 10.1089/neu.2000.17.441; BOROWSKY IW, 1989, NEUROSCIENCE, V33, P253, DOI 10.1016/0306-4522(89)90204-2; Cassarino DS, 1999, BBA-MOL BASIS DIS, V1453, P49, DOI 10.1016/S0925-4439(98)00083-0; CHAN PH, 1992, J NEUROTRAUM, V9, pS417; CHAN PH, 1995, J NEUROTRAUM, V12, P815, DOI 10.1089/neu.1995.12.815; Chandrasekaran K, 1998, BRAIN RES, V796, P13, DOI 10.1016/S0006-8993(98)00248-0; Chen T, 2000, J NEUROTRAUM, V17, P135, DOI 10.1089/neu.2000.17.135; Cherian L, 2000, J NEUROPHYSIOL, V83, P2171; CHOI DW, 1987, J NEUROSCI, V7, P357; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Doppenberg EMR, 1997, J NEUROTRAUM, V14, P71, DOI 10.1089/neu.1997.14.71; DOUGLASS J, 1995, J NEUROSCI, V15, P2471; DUGAN LL, 1995, J NEUROSCI, V15, P6377; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; FUKUHARA T, 1994, BRAIN RES, V657, P333, DOI 10.1016/0006-8993(94)90987-3; Ginsberg MD, 1997, AM J PHYSIOL-HEART C, V272, pH2859; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; HAMM RJ, 1993, COGNITIVE BRAIN RES, V1, P223, DOI 10.1016/0926-6410(93)90006-Q; Harris L. K., 1998, Society for Neuroscience Abstracts, V24, P739; HARRIS LK, 1997, J NEUROTRAUM, V14, P794; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HEALES SJR, 1995, NEUROCHEM RES, V20, P31; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; Inokuchi K, 1996, BIOCHEM BIOPH RES CO, V221, P430, DOI 10.1006/bbrc.1996.0612; Inokuchi K, 1996, FEBS LETT, V382, P48, DOI 10.1016/0014-5793(96)00135-4; Jiang XB, 1999, NEUROL MED-CHIR, V39, P649, DOI 10.2176/nmc.39.649; KAGEYAMA GH, 1988, J COMP NEUROL, V278, P521, DOI 10.1002/cne.902780405; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Keppel, 1991, DESIGN ANAL RES HDB; Kitahara T, 1996, NEUROL RES, V18, P329; LAND PW, 1987, J COMP NEUROL, V262, P78, DOI 10.1002/cne.902620107; Levasseur JE, 2000, J NEUROTRAUM, V17, P101, DOI 10.1089/neu.2000.17.101; LEVINE G, 1991, GUIDE SPSS ANAL VARI; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; MELLGREN SI, 1967, Z ZELLFORSCH MIK ANA, V78, P167, DOI 10.1007/BF00334762; Mikawa S, 1996, J NEUROSURG, V85, P885, DOI 10.3171/jns.1996.85.5.0885; MJAATVEDT AE, 1988, J COMP NEUROL, V277, P155, DOI 10.1002/cne.902770202; NELSON C, 1994, PEDIATR RES, V36, P12, DOI 10.1203/00006450-199407001-00003; Norusis M., 1993, SPSS WINDOWS ADV STA; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; OKONKWO DO, 1999, J CEREB BLOOD FLOW M, V19, P332; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PARKER WD, 1994, NEUROLOGY, V44, P1090, DOI 10.1212/WNL.44.6.1090; PHILLIPS LL, 1994, J NEUROTRAUM, V11, P641, DOI 10.1089/neu.1994.11.641; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Reeves TM, 1997, BRAIN RES, V757, P119, DOI 10.1016/S0006-8993(97)00170-4; Schapira AHV, 1999, BBA-BIOENERGETICS, V1410, P159, DOI 10.1016/S0005-2728(98)00164-9; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; STEWARD O, 1973, BRAIN RES, V54, P65, DOI 10.1016/0006-8993(73)90034-6; Vink R, 1990, J NEUROTRAUM, V7, P21, DOI 10.1089/neu.1990.7.21; WAGNER KR, 1990, J NEUROL SCI, V100, P142, DOI 10.1016/0022-510X(90)90025-I; Wharton D., 1967, METHODS ENZYMOL, V10, P245, DOI [10.1016/0076-6879(67)10048-7, DOI 10.1016/0076-6879(67)10048-7]; WongRiley MTT, 1997, NEUROSCIENCE, V76, P1035, DOI 10.1016/S0306-4522(96)00410-1; Xiong Y, 1997, J NEUROTRAUM, V14, P907, DOI 10.1089/neu.1997.14.907; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	63	41	43	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2001	18	10					993	1009		10.1089/08977150152693692			17	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	484NG	WOS:000171696000003	11686499				2021-06-18	
J	Cristofori, L; Tavazzi, B; Gambin, R; Vagnozzi, R; Vivenza, C; Amorini, AM; Di Pierro, D; Fazzina, G; Lazzarino, G				Cristofori, L; Tavazzi, B; Gambin, R; Vagnozzi, R; Vivenza, C; Amorini, AM; Di Pierro, D; Fazzina, G; Lazzarino, G			Early onset of lipid peroxidation after human traumatic brain injury: A fatal limitation for the free radical scavenger pharmacological therapy?	JOURNAL OF INVESTIGATIVE MEDICINE			English	Article						human traumatic brain injury; reactive oxygen species; lipid peroxidation; malondialdehyde; cerebrospinal fluid	SEVERE HEAD-INJURY; OXIDATIVE STRESS; MITOCHONDRIAL DYSFUNCTION; CEREBROSPINAL-FLUID; ENERGY-METABOLISM; RATS; MALONDIALDEHYDE; MULTICENTER; ISCHEMIA; TRIAL	Background: On the basis of the contradiction between data on experimental head trauma showing oxidative stress-mediated cerebral tissue damage and failure of the majority of clinical trials using free radical scavenger drugs, we monitored the time-course changes of malondialdehyde (MDA, an index of cell lipid peroxidation), ascorbate, and dephosphorylated ATP catabolites in cerebrospinal fluid (CSF) of traumatic brain-injured patients. Methods: CSF samples were obtained from 20 consecutive patients suffering from severe brain injury. All patients were comatose, with a Glasgow Coma Scale on admission of 6 +/-1. The first CSF sample for each patient was collected within a mean value of 2.95 hours from trauma (SD=1.98), after the insertion of a ventriculostomy catheter for the continuous monitoring of intracranial pressure. During the next 48 hours, CSF was withdrawn from each patient once every 6 hours. All samples were analyzed by an ion-pairing high-performance liquid chromatographic method for the simultaneous determination of MDA, ascorbic acid, hypoxanthine, xanthine, uric acid, inosine, and adenosine. Results: In comparison with values recorded in 10 herniated-lumbar-disk, noncerebral control patients, data showed that all CSF samples of brain-injured patients had high values (0.226 mu moL/1,; SD=0.196) of MDA (undetectable in samples of control patients) and decreased ascorbate levels (96.25 mu mol/L; SD=31.74), already at the time of first withdrawal at the time of hospital admission. MDA was almost constant in the next two withdrawals and tended to decrease thereafter, although 48 hours after hospital admission, a mean level of 0.072 mu mol/L CSF (SD=0.026) was still recorded. The ascorbate level was normalized 42 hours after hospital admission. Changes in the CSF values of ATP degradation products (oxypurines and nucleosides) suggested a dramatic alteration of neuronal energy metabolism after traumatic brain injury. Conclusions: On the whole, these data demonstrate the early onset of oxygen radical-mediated oxidative stress, proposing a valid explanation for the failure of clinical trials based on the administration of oxygen free radical scavenger drugs and suggesting a possible rationale for testing the efficacy of lipid peroxidation "chain breakers" in future clinical trials.	Univ Catania, Biochem Lab, Dept Chem Sci, I-95125 Catania, Italy; Univ Roma Tor Vergata, Dept Neurosci, Chair Neurosurg, Rome, Italy; Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, Rome, Italy; Univ Hosp Verona, Dept Neurosurg, Verona, Italy	Lazzarino, G (corresponding author), Univ Catania, Biochem Lab, Dept Chem Sci, Viale A Doria 6, I-95125 Catania, Italy.		TAVAZZI, BARBARA/AAB-9830-2019; lazzarino, giuseppe/K-2277-2015	TAVAZZI, BARBARA/0000-0001-8743-0895; lazzarino, giuseppe/0000-0002-5917-7279; AMORINI, Angela Maria/0000-0003-3525-9955			Alderson P, 1997, BRIT MED J, V314, P1855, DOI 10.1136/bmj.314.7098.1855; Ammar RF, 2000, CARDIOVASC RES, V47, P595, DOI 10.1016/S0008-6363(00)00094-8; Awasthi D, 1997, SURG NEUROL, V47, P575, DOI 10.1016/S0090-3019(96)00461-2; BRAAKMAN R, 1994, J NEUROSURG, V80, P797; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8; Calabrese V, 1998, DRUG EXP CLIN RES, V24, P125; Cernak I, 2000, J NEUROTRAUM, V17, P53, DOI 10.1089/neu.2000.17.53; Doppenberg EMR, 1997, J NEUROTRAUM, V14, P71, DOI 10.1089/neu.1997.14.71; GIARDINA B, 1993, AM J CARDIOL, V71, P788, DOI 10.1016/0002-9149(93)90825-W; GRUMME T, 1995, RES EXP MED, V195, P217, DOI 10.1007/BF02576791; HAMVAS A, 1992, J APPL PHYSIOL, V72, P621; JENNETT B, 1975, LANCET, V1, P480; LAZZARINO G, 1991, ANAL BIOCHEM, V197, P191, DOI 10.1016/0003-2697(91)90378-7; LAZZARINO G, 1994, CIRCULATION, V90, P291, DOI 10.1161/01.CIR.90.1.291; Maas AIR, 1999, NEUROSURGERY, V44, P1286, DOI 10.1097/00006123-199906000-00076; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MARMAROU A, 1991, J NEUROSURG S, V75, P59; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Obrenovitch TP, 1997, J NEUROTRAUM, V14, P677, DOI 10.1089/neu.1997.14.677; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; Soto-Otero R, 2000, J NEUROCHEM, V74, P1605, DOI 10.1046/j.1471-4159.2000.0741605.x; Stover JF, 2000, NEUROSCI LETT, V288, P25, DOI 10.1016/S0304-3940(00)01187-3; Tak PP, 2000, IMMUNOL TODAY, V21, P78, DOI 10.1016/S0167-5699(99)01552-2; Tavazzi B, 1998, FREE RADICAL RES, V28, P25, DOI 10.3109/10715769809097873; Tavazzi B, 2000, EUR J BIOCHEM, V267, P684, DOI 10.1046/j.1432-1327.2000.01042.x; THOM SR, 1991, FREE RADICAL BIO MED, V10, P413, DOI 10.1016/0891-5849(91)90050-D; Treitinger A, 2000, EUR J CLIN INVEST, V30, P454; Vagnozzi R, 1999, J NEUROTRAUM, V16, P903, DOI 10.1089/neu.1999.16.903; Wang YX, 2000, NEUROBIOL AGING, V21, P525, DOI 10.1016/S0197-4580(00)00114-7; Watson BD, 1998, CELL MOL NEUROBIOL, V18, P581, DOI 10.1023/A:1020209616428; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Young B, 1996, JAMA-J AM MED ASSOC, V276, P538, DOI 10.1001/jama.276.7.538	34	41	43	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1081-5589			J INVEST MED	J. Invest. Med.	SEP	2001	49	5					450	458		10.2310/6650.2001.33790			9	Medicine, General & Internal; Medicine, Research & Experimental	General & Internal Medicine; Research & Experimental Medicine	464QQ	WOS:000170543600010	11523701				2021-06-18	
J	Finnie, JW				Finnie, JW			Animal models of traumatic brain injury: a review	AUSTRALIAN VETERINARY JOURNAL			English	Article						animal models; traumatic brain injury; neuropathology	DIFFUSE AXONAL INJURY; HEAD-INJURY; CEREBRAL CONCUSSION; CHILDREN; IMPACT; LAMBS; SHEEP; AGE	Objective To review the main types of animal models of traumatic brain injury (TBI), their desirable characteristics and limitations, the major structural changes in the brain modelled, and special features of paediatric TBI modelling. Conclusion Animal models have contributed substantially to our understanding of the mechanisms of TBI in humans, but many aspects of closed head injury remain to be elucidated and effective neuroprotective agents are few. Many of the advances in the pathogenesis of human TBI also have application in veterinary medicine and there is ample opportunity for veterinarians to contribute to the selection, development and characterisation of potential animal models of neurotrauma and other disorders and ensure that animal welfare standards are maintained.	Inst Med & Vet Sci, Vet Serv Div, Gilles Plains, SA 5086, Australia	Finnie, JW (corresponding author), Inst Med & Vet Sci, Vet Serv Div, 101 Blacks Rd, Gilles Plains, SA 5086, Australia.						Adams J. H., 1982, HEAD INJURY BASIC CL, P141; Adelson PD, 1999, EXP TOXICOL PATHOL, V51, P130; ANDERSON TE, 1996, NEUROTRAUMA, P1357; Blumbergs P. C., 1997, HEAD INJURY PATHOPHY, P39; Blumbergs PC, 1998, J CLIN NEUROSCI, V5, P123, DOI 10.1016/S0967-5868(98)90026-1; Bullock MR, 1999, NEUROSURGERY, V45, P207, DOI 10.1097/00006123-199908000-00001; DELAHUNTA A, 1983, VET NEUROANATOMY CLI, P356; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; DENNYBROWN D, 1945, PHYSIOL REV, V25, P296; DOBBING J, 1981, SCI FDN PAEDIAT, P745; DUHAIME AC, 1999, TRAUMATIC BRAIN INJU, P257; Fearnside MR, 1997, HEAD INJURY PATHOPHY, P3; Finnie J, 1999, J CLIN NEUROSCI, V6, P38, DOI 10.1016/S0967-5868(99)90601-X; Finnie JW, 2001, J COMP PATHOL, V124, P159, DOI 10.1053/jcpa.2000.0446; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENNARELLI TA, 1985, CENTRAL NERVOUS SYST, P392; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; GRAHAM DI, 1989, J CLIN PATHOL, V42, P18, DOI 10.1136/jcp.42.1.18; Graham DI, 1996, NEUROTRAUMA, P43; GRAHAM DI, 1997, GREENFIELDS NEUROPAT, V1, P197; Jubb KVF, 1993, PATHOLOGY DOMESTIC A, P267; Kochanek PM, 1999, TRAUMATIC BRAIN INJU, P233; KRIEL RL, 1989, PEDIATR NEUROL, V5, P296, DOI 10.1016/0887-8994(89)90021-0; Laurer HL, 1999, CURR OPIN NEUROL, V12, P715, DOI 10.1097/00019052-199912000-00010; Lewis SB, 1996, J NEUROTRAUM, V13, P505, DOI 10.1089/neu.1996.13.505; LIGHTHALL J W, 1989, Journal of Neurotrauma, V6, P83, DOI 10.1089/neu.1989.6.83; Lighthall J.W., 1994, NEUROBIOLOGY CENTRAL, P3; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MCINTOSH GH, 1979, NEUROPATH APPL NEURO, V5, P103, DOI 10.1111/j.1365-2990.1979.tb00664.x; MURPHY EJ, 1994, NEUROBIOLOGY CENTRAL, P216; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; OMMAYA AK, 1966, HEAD INJURY C P, P3211; Povlishock J.T., 1994, NEUROBIOLOGY CENTRAL, P109; POVLISHOCK JT, 1994, J NEUROTRAUM, V11, P723, DOI 10.1089/neu.1994.11.723; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Povlishock JT., 1996, NEUROTRAUMA, P1325; Rajtova V, 1976, Gegenbaurs Morphol Jahrb, V122, P927; ROSS DT, 1994, EXP NEUROL, V126, P291, DOI 10.1006/exnr.1994.1067; SHAPIRO K, 1993, HEAD INJURY, P427; SUMMERS BA, 1995, VET NEUROPATHOLOGY, P15; TORNHEIM PA, 1983, J NEUROSURG, V59, P431, DOI 10.3171/jns.1983.59.3.0431; Ward JD, 1996, NEUROTRAUMA, P859	44	41	44	0	12	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0005-0423			AUST VET J	Aust. Vet. J.	SEP	2001	79	9					628	633		10.1111/j.1751-0813.2001.tb10785.x			6	Veterinary Sciences	Veterinary Sciences	475EB	WOS:000171148200036	11702936				2021-06-18	
J	Bailes, JE; Hudson, V				Bailes, JE; Hudson, V			Classification of sport-related head trauma: A spectrum of mild to severe injury	JOURNAL OF ATHLETIC TRAINING			English	Article						diffuse brain injury; hematoma	CHRONIC SUBDURAL-HEMATOMA; EXTRACELLULAR POTASSIUM; EXTRADURAL HEMATOMA; BRAIN-INJURY; CONCUSSION; MANAGEMENT	Objective: To identify the types of injuries the human brain incurs as a result of traumatic forces applied to the cranium. In athletic events and endeavors, the full spectrum of intracranial hemorrhages in various compartments, raised intracranial pressure, and diffuse nonhemorrhagic damage may be seen. In this review, we describe these serious injuries and the more common mild traumatic brain injury in their clinical presentations and relate concussion classification to the overall picture of traumatic brain injury. Methods: Our cumulative experience with athletic injuries, both at the catastrophic and mild traumatic brain injury levels, has led us to a management paradigm that serves to guide us in the classification and treatment of these athletes. Discussion: The occurrence of intracranial injuries in sports has now been well documented. Intracranial hematomas (epidural, subdural, and parenchymal) and cerebral contusions can result from head injury. Many patients sustain a diffuse brain injury, resulting in elevated intracranial pressures, without a blood clot or mass lesion. The classification of concussion and the use of concussion guidelines are not uniform. However, the major emphases are agreed upon: the close and careful scrutiny of the athlete, an expeditious but reliable neurologic examination, and proper on-field management. Return-to-play decisions are based on many factors that affect normal functioning, both on and off the playing field. Conclusions: Sufficient knowledge now exists to allow us to carefully evaluate the injured athlete, to place him or her in the management scheme to minimize the potential for permanent cerebral dysfunction, and to know when the athlete can safely return to contact sport participation.	W Virginia Univ, Dept Neurosurg, Sch Med, Morgantown, WV 26506 USA; Univ Cent Florida, Orlando, FL 32816 USA	Bailes, JE (corresponding author), W Virginia Univ, Dept Neurosurg, Sch Med, POB 9183, Morgantown, WV 26506 USA.	jbailes@hsc.wvu.edu					Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; BRICOLO AP, 1984, NEUROSURGERY, V14, P8, DOI 10.1227/00006123-198401000-00003; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P224; *COL MED SOC, 1991, GUID MAN CONC SPORTS; Gennarelli TA, 1993, HEAD INJURY, P137; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; Hovda DA, 1999, SPORTS-RELATED CONCUSSION, P12; HUBSCHMANN OR, 1983, J NEUROSURG, V59, P289, DOI 10.3171/jns.1983.59.2.0289; *INT TASK FORC APP, 2001, PREH CAR SPIN INJ AT; JAMIESON KG, 1968, J NEUROSURG, V29, P13, DOI 10.3171/jns.1968.29.1.0013; KASTE M, 1979, ACTA NEUROCHIR, V48, P231, DOI 10.1007/BF02056971; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kelly JP, 1997, NEUROLOGY, V48, P581; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVI L, 1990, NEUROSURGERY, V27, P429, DOI 10.1227/00006123-199009000-00015; Meek T D, 1970, Tex Med, V66, P58; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Pilz P, 1983, Acta Neurochir Suppl (Wien), V32, P119; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; ROBINSON RG, 1984, J NEUROSURG, V61, P263, DOI 10.3171/jns.1984.61.2.0263; Rutherford W. H., 1989, MILD HEAD INJURY, P217; SATO S, 1975, J NEUROSURG, V43, P569, DOI 10.3171/jns.1975.43.5.0569; SCHNEIDER K, 1988, INT J SPORT BIOMECH, V4, P358, DOI 10.1123/ijsb.4.4.358; Schonauer M, 1979, J Neurosurg Sci, V23, P279; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Servadei F, 1997, ACTA NEUROCHIR, V139, P273, DOI 10.1007/BF01808821; STRICH SJ, 1961, LANCET, V2, P443; SWEET RC, 1978, NEUROSURGERY, V3, P16, DOI 10.1227/00006123-197807000-00003; TAKAHASHI H, 1981, J NEUROSURG, V55, P708, DOI 10.3171/jns.1981.55.5.0708; ZIMMERMAN RA, 1978, RADIOLOGY, V127, P393, DOI 10.1148/127.2.393	34	41	41	0	7	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	JUL-SEP	2001	36	3					236	243					8	Sport Sciences	Sport Sciences	557NC	WOS:000175913800004	12937490				2021-06-18	
J	Kelly, JP				Kelly, JP			Loss of consciousness: Pathophysiology and implications in grading and safe return to play	JOURNAL OF ATHLETIC TRAINING			English	Article						concussion; mild traumatic brain injury; sport concussion guidelines	TRAUMATIC BRAIN-INJURY; HEAD-INJURY; CONCUSSION; MILD; GUIDELINES; PREDICTION; MANAGEMENT; SEQUELAE; LESIONS; SPORTS	Objective: To provide historical background and current concepts regarding the importance of loss of consciousness (LOC) in the evaluation of concussion and athletes. Data Sources: A MEDLINE search identified scientific and clinical articles on sport concussion management published from 1966 to present. Discussions were held with authors of selected reports. Recent research findings reported at national meetings were reviewed. Data Synthesis: The relative importance of LOC in the evaluation of concussion was reviewed in light of scientific and clinical evidence in the literature. Comments made by authors of concussion grading scales were considered in the development of expert consensus statements. Conclusions/Recommendations: The observation of LOC at the time of concussion must be viewed as reflecting a potentially worrisome traumatic brain injury. LOC is followed by more severe acute mental status abnormalities and carries a greater risk of intracranial pathology than concussion without LOC. Prolonged LOC represents a neurologic emergency, which may require neurosurgical intervention. Lingering symptoms of concussion, even without LOC, should be monitored closely and managed according to established guidelines for safe return to play.	Chicago Neurol Inst, Chicago, IL 60611 USA	Kelly, JP (corresponding author), Chicago Neurol Inst, 233 E Erie St,Suite 704, Chicago, IL 60611 USA.	jpk070@northwestern.edu					American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; BROOKS DN, 1980, J NEUROL NEUROSUR PS, V43, P529, DOI 10.1136/jnnp.43.6.529; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; *COL MED SOC, 1991, GUID MAN CONC SPORTS; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; FISHER CM, 1966, NEUROLOGY, V16, P826, DOI 10.1212/WNL.16.8.826; Gennarelli TA, 1993, HEAD INJURY, P137; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P79, DOI 10.1097/00001199-199708000-00008; Giza CC, 2000, NEUROLOGIC ATHLETIC, P80; JENKINS A, 1986, LANCET, V2, P445; JENNETT B, 1975, LANCET, V1, P480; Kelly JP, 2000, NEUROLOGY, V54, pA243; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kelly JP, 1997, NEUROLOGY, V48, P581; Kelly JP, 1999, JAMA-J AM MED ASSOC, V282, P989, DOI 10.1001/jama.282.10.989; Lee SM, 1999, ANN NY ACAD SCI, V893, P337, DOI 10.1111/j.1749-6632.1999.tb07849.x; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVI L, 1990, NEUROSURGERY, V27, P429, DOI 10.1227/00006123-199009000-00015; LEVIN HS, 1988, J NEUROSURG, V69, P861, DOI 10.3171/jns.1988.69.6.0861; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1985, ARCH NEUROL-CHICAGO, V42, P963, DOI 10.1001/archneur.1985.04060090045012; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; LOVELL MR, 2000, NEUROLOGIC ATHLETIC, P109; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McIntosh TK, 1996, LAB INVEST, V74, P315; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PLUM F, 1982, DIAGNOSIS STUPOR COM, P3; Povlishock J T, 1985, Cent Nerv Syst Trauma, V2, P285; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; TEASDALE G, 1974, LANCET, V2, P81; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; WAGSTYL J, 1987, J PEDIATR SURG, V22, P127, DOI 10.1016/S0022-3468(87)80427-X; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; WOLJTYS EM, 1999, AM J SPORTS MED, V27, P676; YARNELL PR, 1970, LANCET, V1, P863; 1987, NEW LEXICON WEBSTERS, P1072	41	41	41	0	2	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	JUL-SEP	2001	36	3					249	252					4	Sport Sciences	Sport Sciences	557NC	WOS:000175913800006	12937492				2021-06-18	
J	Server, A; Dullerud, R; Haakonsen, M; Nakstad, PH; Johnsen, ULH; Magnaes, B				Server, A; Dullerud, R; Haakonsen, M; Nakstad, PH; Johnsen, ULH; Magnaes, B			Post-traumatic cerebral infarction - Neuroimaging findings, etiology and outcome	ACTA RADIOLOGICA			English	Article						brain injuries; cerebral infarction; carotid artery dissection; CT; MR imaging; angiography; comparative investigation	CAROTID-ARTERY DISSECTION; ISCHEMIC BRAIN-DAMAGE; SEVERE HEAD-INJURY; SUBARACHNOID HEMORRHAGE; ANGIOGRAPHIC FINDINGS; EARLY DIAGNOSIS; CT; HERNIATION; THERAPY; BLOOD	Purpose. To assess the radiological characteristics of post-traumatic cerebral infarctions (PTCIs), the etiology and site of infarction, and to provide neuroimaging indicators of a poor clinical outcome. Material and Methods. A retrospective study of 16 patients with the neuroimaging-based diagnosis of PTCI was carried out. Ah CT, MR examinations, cerebral angiograms and medical records of the patients were reviewed. Results: Infarcts were diagnosed in the territory of the posterior cerebral artery in 9 patients, in the middle cerebral artery in 5, in the anterior cerebral artery in 3, lenticulostriate-thalamoperforating in 2, vertebrobasilar in 3, and cortical infarcts in 2 patients. Neuroimaging studies suggested focal mass effect and/or acquired intracranial herniations as the cause of infarction in 13/16 patients (81.2%). In 3/16 patients (18.8%), PTCI was due to vascular injury of which 2 were angiographically documented (carotid artery dissection). Eight of the 16 patients in this study died or were left in a persistent vegetative state. Patients with associated subdural hematoma, brain swelling/edema and traumatic subarachnoid hemorrhage (tSAH) exhibited the worst outcome. Conclusion. Gross mechanical shift of the brain and herniation across the fair and/or tentorium accounted for infarction in a majority of cases in our study. The overall death rate was 43.8% and this result suggests that PTCI is an indication of a poor clinical outcome, especially among patients with associated subdural hematoma, brain swelling/edema and tSAH.	Univ Oslo, Ulleval Hosp, Div Radiol, Dept Neuroradiol, N0-0407 Oslo, Norway; Aker Hosp, Dept Radiol, Oslo, Norway; Natl Hosp Oslo, Dept Neuroradiol, Oslo, Norway; Univ Oslo, Ulleval Hosp, Dept Neurosurg, N0-0407 Oslo, Norway	Server, A (corresponding author), Univ Oslo, Ulleval Hosp, Div Radiol, Dept Neuroradiol, N0-0407 Oslo, Norway.						BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BERMAN SA, 1984, AM J ROENTGENOL, V142, P1035, DOI 10.2214/ajr.142.5.1035; BERMAN SA, 1980, AM J NEURORADIOL, V1, P259; BUI LN, 1993, STROKE, V24, P126, DOI 10.1161/01.STR.24.1.126; DANIEL W, 1995, BIOSTATISTICS FDN AN; Fabian TC, 1996, ANN SURG, V223, P513, DOI 10.1097/00000658-199605000-00007; FERNANDEZFRESNO LF, 1997, RADIOLOGIA, V39, P545; Fukuda T, 1998, NEUROSURGERY, V43, P1040, DOI 10.1097/00006123-199811000-00022; GENTRY LR, 1994, RADIOLOGY, V191, P1; Gentry LR., 1996, MAGNETIC RESONANCE I, P611; Graham DI, 1996, NEUROPATH APPL NEURO, V22, P505, DOI 10.1111/j.1365-2990.1996.tb01125.x; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; HART RG, 1983, NEUROL CLIN N AM, V1, P255; HOSOYA T, 1996, JAPAN RAD MED, V14, P241; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; KAKARIEKA A, 1994, ACTA NEUROCHIR, V129, P1, DOI 10.1007/BF01400864; KEARNE JR, 1986, ANN NEUROL, V8, P186; LAINE FJ, 1995, AM J ROENTGENOL, V165, P967, DOI 10.2214/ajr.165.4.7677003; Laitt RD, 1996, CLIN RADIOL, V51, P117, DOI 10.1016/S0009-9260(96)80268-6; LOBATO RD, 1988, J NEUROSURG, V68, P417, DOI 10.3171/jns.1988.68.3.0417; Macmillan CSA, 1999, NEUROSURGERY, V45, P188, DOI 10.1097/00006123-199907000-00047; MACPHERSON P, 1978, J NEUROL NEUROSUR PS, V41, P122, DOI 10.1136/jnnp.41.2.122; MARTIN NA, 1992, J NEUROSURG, V77, P575, DOI 10.3171/jns.1992.77.4.0575; Meyer A, 1920, ARCH NEURO PSYCHIATR, V4, P387, DOI 10.1001/archneurpsyc.1920.02180220036003; MILLER JD, 1985, BRIT J ANAESTH, V57, P120, DOI 10.1093/bja/57.1.120; MIRVIS SE, 1990, AJNR, V11, P335; MORGAN MK, 1987, J NEUROSURG, V66, P192, DOI 10.3171/jns.1987.66.2.0192; Mulloy JP, 1998, RADIOLOGY, V207, P571, DOI 10.1148/radiology.207.3.9609876; Osborn AG, 1991, NEUORIMAGING CLIN N, V1, P461; OSBORN AG, 1996, HDB NEURORADIOLOGY B, P198; OSULLIVAN RM, 1990, AM J NEURORADIOL, V11, P1150; Ozdoba C, 1996, RADIOLOGY, V199, P191, DOI 10.1148/radiology.199.1.8633145; PASQUALIN A, 1984, NEUROSURGERY, V15, P855, DOI 10.1227/00006123-198412000-00015; REICH JB, 1993, ANN NEUROL, V33, P159, DOI 10.1002/ana.410330205; ROTHFUS WE, 1987, AM J NEURORADIOL, V8, P1073; SAHUQUILLOBARRIS J, 1988, J NEUROSURG, V68, P894, DOI 10.3171/jns.1988.68.6.0894; SALAMON G, 1976, RADIOLOGIC ANATOMY B, P48; SATO M, 1986, NEUROSURGERY, V18, P300, DOI 10.1227/00006123-198603000-00007; SCHIEVINK WI, 1994, NEW ENGL J MED, V330, P393, DOI 10.1056/NEJM199402103300604; SMIRNIOTOPOULOS JG, 1992, IMAGING TRAUMA CRITI, P23; SUWANWELA C, 1972, J NEUROSURG, V36, P314, DOI 10.3171/jns.1972.36.3.0314; Taneda M, 1996, J NEUROSURG, V84, P762, DOI 10.3171/jns.1996.84.5.0762; TAVERAS JM, 1976, CEREBRAL ANGIOGRAPHY, V2, P543; Teasdale GM, 1998, NEUROSURGERY, V43, P723, DOI 10.1097/00006123-199810000-00001; WEISBERG LA, 1979, COMPUT TOMOGR, V3, P15, DOI 10.1016/0363-8235(75)90004-6	45	41	46	0	4	MUNKSGAARD INT PUBL LTD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0284-1851			ACTA RADIOL	Acta Radiol.	MAY	2001	42	3					254	260					7	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	435WZ	WOS:000168906300002	11350282				2021-06-18	
J	Lin, B; Ginsberg, MD; Zhao, WH; Alonso, OF; Belayev, L; Busto, R				Lin, B; Ginsberg, MD; Zhao, WH; Alonso, OF; Belayev, L; Busto, R			Quantitative analysis of microvascular alterations in traumatic brain injury by endothelial barrier antigen immunohistochemistry	JOURNAL OF NEUROTRAUMA			English	Article						blood-brain barrier; edema; endothelium; fluid-percussion brain injury; image-analysis; microvasculature; rat	EXCITATORY AMINO-ACIDS; REDUCES HISTOPATHOLOGICAL DAMAGE; SPINAL-CORD; CEREBRAL CONTUSION; RATS; EXPRESSION; IMMUNOREACTIVITY; ALBUMIN; EDEMA; ANGIOGENESIS	Endothelial barrier antigen (EBA) is a protein triplet located in the plasma membrane of microvascular endothelium and selectively expressed in the normal nervous system. In this study, microvascular alterations following traumatic brain injury were studied using EBA immunohistochemistry. Anesthetized, physiologically regulated, normothermic Sprague-Dawley rats received moderate (1.5-2.0 atm) parieto-occipital parasagittal fluid-percussion traumatic brain injury (TBI). Control rats were subjected to similar anesthesia and physiological monitoring. Seven days after operative procedures, brains were perfusion-fixed, and coronal sections were reacted for EBA immunohistochemistry using a monoclonal antibody to rat EBA. Selected sections were reacted for isolectin B-4 histochemistry. Computerized image analysis was used to compute numbers of EBA-immunopositive vascular profiles and mean vascular profile areas. In control brains, virtually all brain microvessels were clearly and positively immunostained, acid antibody binding was specific for blood vessels. In rats with TBI, EBA immunoreactivity was greatly reduced in the zone of cortical contusion. Within the core contusion, fractional areas occupied by vascular profiles were markedly reduced (on average, by 57%), vascular profile counts were diminished, and lectin histochemistry revealed a robust inflammatory response with abundant macrophages. Taken together, these findings were thought to indicate frank microvascular destruction. At adjacent peri-contusional sites, the intensity of EBA immunostaining was also diminished; and vascular profile counts were reduced at adjacent cortical sites and homologous contralateral sites. The latter findings were interpreted as sublethal microvascular alterations possibly related to cerebral edema. The present results confirm that EBA is a specific immunohistochemical marker of normal central nervous system microvessels; that it is suitable for use in formaldehyde-fixed material; and that it is useful in quantitatively assessing microvascular alterations observed at contusional, peri-contusional and more remote sites following traumatic brain injury.	Univ Miami, Sch Med, Dept Neurol D4 5, Cerebral Vasc Dis Res Ctr, Miami, FL 33101 USA; Univ Miami, Sch Med, Dept Neurol D4 5, Neurotrauma Res Ctr, Miami, FL 33101 USA	Lin, B (corresponding author), Univ Miami, Sch Med, Dept Neurol D4 5, Cerebral Vasc Dis Res Ctr, POB 016960, Miami, FL 33101 USA.			Lin, Binshan/0000-0002-8481-302X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030291] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 30291] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [05820] Funding Source: Medline		BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; Barzo P, 1997, ACT NEUR S, V70, P119; Belayev L, 1999, J NEUROTRAUM, V16, P445, DOI 10.1089/neu.1999.16.445; Bullock R, 1995, ANN NY ACAD SCI, V765, P290, DOI 10.1111/j.1749-6632.1995.tb16586.x; Bullock R, 1992, Acta Neurochir Suppl (Wien), V55, P14; Bullock R, 1992, Acta Neurochir Suppl (Wien), V55, P49; Daneyemez M, 1999, NEUROSCIENCE, V92, P783, DOI 10.1016/S0306-4522(99)00035-4; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; FAROOQUE M, 1992, ACTA NEUROPATHOL, V84, P613; Hartl R, 1997, ACT NEUR S, V70, P240; Jaeger CB, 1997, EXP NEUROL, V144, P381, DOI 10.1006/exnr.1996.6405; Kadota E, 1997, ACT NEUR S, V70, P141; KRUM JM, 1991, EXP NEUROL, V111, P152, DOI 10.1016/0014-4886(91)90002-T; Krum JM, 1997, EXP NEUROL, V146, P33, DOI 10.1006/exnr.1997.6528; Lin BW, 1998, ACTA NEUROPATHOL, V95, P511, DOI 10.1007/s004010050832; Lin BW, 2000, BRAIN RES, V865, P237, DOI 10.1016/S0006-8993(00)02228-9; Maeda T, 1997, ACT NEUR S, V70, P102; Matsushita Y, 2000, J NEUROTRAUM, V17, P143, DOI 10.1089/neu.2000.17.143; Murakami K, 1998, J NEUROTRAUM, V15, P825, DOI 10.1089/neu.1998.15.825; Nishigaya K, 2000, ACTA NEUROPATHOL, V99, P231, DOI 10.1007/PL00007432; PAXINOS G, 1997, RAT BRAIN STEREOTAXI; Perdiki M, 1998, ACTA NEUROPATHOL, V96, P8, DOI 10.1007/s004010050854; RISAU W, 1995, FASEB J, V9, P926; ROSENSTEIN JM, 1992, DEV BRAIN RES, V66, P47, DOI 10.1016/0165-3806(92)90138-M; Shreiber DI, 1999, J NEUROPATH EXP NEUR, V58, P153, DOI 10.1097/00005072-199902000-00005; Si QS, 1997, GLIA, V21, P413, DOI 10.1002/(SICI)1098-1136(199712)21:4<413::AID-GLIA9>3.0.CO;2-3; STERNBERGER NH, 1989, RES IMMUNOL, V140, P187, DOI 10.1016/0923-2494(89)90084-9; STERNBERGER NH, 1987, P NATL ACAD SCI USA, V84, P8169, DOI 10.1073/pnas.84.22.8169; STERNBERGER NH, 1989, J NEUROIMMUNOL, V21, P241, DOI 10.1016/0165-5728(89)90180-X; Strasser A, 1997, ACT NEUR S, V70, P8; Unterberg AW, 1997, ACT NEUR S, V70, P106; VANDENBRINK WA, 1994, ACT NEUR S, V60, P456; Vaz R, 1997, ACTA NEUROCHIR, V139, P215, DOI 10.1007/BF01844754; ZAUNER A, 1995, J NEUROTRAUM, V12, P547, DOI 10.1089/neu.1995.12.547; Zhang RL, 1998, BRAIN RES, V785, P207, DOI 10.1016/S0006-8993(97)01343-7; Zilles K., 1985, CORTEX RAT	37	41	45	0	2	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	APR	2001	18	4					389	397		10.1089/089771501750170958			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	425TP	WOS:000168308000003	11336440				2021-06-18	
J	Lu, J; Moochhala, S; Kaur, C; Ling, EA				Lu, J; Moochhala, S; Kaur, C; Ling, EA			Cellular inflammatory response associated with breakdown of the blood-brain barrier after closed head injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						blood-brain barrier; closed head injury; IgG; MHC class II antigen; microglia; NOS; rat; RhIc	NITRIC-OXIDE SYNTHASE; COMPLEX ANTIGEN EXPRESSION; AMEBOID MICROGLIAL CELLS; CENTRAL-NERVOUS-SYSTEM; CLASS-II EXPRESSION; INTRACEREBRAL INJECTION; LATERAL VENTRICLES; ENDOTHELIAL-CELLS; EPIPLEXUS CELLS; SPINAL-CORD	This study reports a widespread microglial response characterized by an upregulation of surface antigens, such as complement type 3 receptors (CR3) and major histocompatibility complex (MHC) class II antigens on these cells following closed head injury. Increased expression of CR3 (OX-42) and MHC class II antigens (OX-6) was observed in rats killed at 1, 3, and 5 days after injury. Intense OX-42 immunoreactivity was observed in microglial cells throughout the brain with a smaller number of them being OX-6 positive. In addition to microglial reaction, astrocytic activation reflected in cellular hypertrophy and increased immunoreactivity for glial fibrillary acidic protein (GFAP) was observed at 5 days after head injury. Together with the above, a diffuse perivascular and intraneuronal immunostaining for immunoglobulin G (IgG) was observed primarily in the cerebral cortex. This was accompanied by an enhanced expression of both endothelial nitric oxide synthase (eNOS) in blood vessels and inducible nitric oxide synthase (iNOS) in brain macrophages. In rats subjected to closed head injury followed by a single intraperitoneal (i.p.) injection of rhodamine isothiocyanate (RhIc), seepage of the fluorescent dye into the neuropil was observed. This had resulted in the labelling of the cortical neurons dearly demonstrating a breakdown of the blood-brain barrier (BBB). In the latter, it is conceivable that the ensuing leakage of plasma immunoglobulins and other serum-derived materials could induce the expression of MHC class II antigens on microglia. The mechanism causing the BBB dysfunction is not clear, although present results suggest that excessive release of nitric oxide (NO) may be a contributory factor. The widespread activation of microglia in rats after head injury suggests their involvement in increased endocytosis and immunological responses.	Def Sci & Technol Agcy, Def Med Res Inst, Singapore 109681, Singapore; Natl Univ Singapore, Fac Med, Dept Anat, Singapore 117548, Singapore	Moochhala, S (corresponding author), Def Sci & Technol Agcy, Def Med Res Inst, Def Technol Tower B,20-04 Depot Rd, Singapore 109681, Singapore.	nmiv19@nus.edu.sg		MOOCHHALA, SHABBIR/0000-0003-4521-3192			ABRAHAMSON DR, 1983, LAB INVEST, V48, P162; AIHARA N, 1994, J COMP NEUROL, V342, P481, DOI 10.1002/cne.903420402; AKIYAMA H, 1988, J NEUROSCI RES, V20, P147, DOI 10.1002/jnr.490200202; Boje KMK, 1996, BRAIN RES, V720, P75, DOI 10.1016/0006-8993(96)00142-4; BUTTINI M, 1994, MOL BRAIN RES, V23, P126, DOI 10.1016/0169-328X(94)90218-6; CHI OZ, 1994, PHARMACOLOGY, V48, P367, DOI 10.1159/000139202; Cobbs CS, 1997, BRAIN RES, V751, P336, DOI 10.1016/S0006-8993(96)01429-1; DEGROOT CJA, 1991, INT J NEUROSCI, V59, P53, DOI 10.3109/00207459108985449; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Engel S, 1996, ACT NEUR S, V66, P87; Folkerts MM, 1998, J NEUROTRAUM, V15, P349, DOI 10.1089/neu.1998.15.349; FREI K, 1994, J IMMUNOL, V152, P2720; Gahm C, 2000, NEUROSURGERY, V46, P169; GEHRMANN J, 1991, ACTA NEUROPATHOL, V82, P442, DOI 10.1007/BF00293378; Giovannoni G, 1998, MULT SCLER J, V4, P212, DOI 10.1177/135245859800400323; GIULIAN D, 1986, J EXP MED, V164, P594, DOI 10.1084/jem.164.2.594; Hooper DC, 2000, FASEB J, V14, P691; Hoshino S, 1996, BRAIN RES, V711, P73, DOI 10.1016/0006-8993(95)01329-6; HOWARDJONES N, 1985, WHO CHRON, V39, P51; Htain WW, 1997, NEUROSCI LETT, V223, P53; JANIGRO D, 1994, CIRC RES, V75, P528, DOI 10.1161/01.RES.75.3.528; Jensen MB, 1997, EXP NEUROL, V143, P103, DOI 10.1006/exnr.1996.6337; KAUR C, 1992, J ANAT, V180, P333; KLATZO I, 1987, ACTA NEUROPATHOL, V72, P236, DOI 10.1007/BF00691095; KOBARI M, 1994, BRAIN RES, V667, P255, DOI 10.1016/0006-8993(94)91503-2; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Lehrmann E, 1997, J COMP NEUROL, V386, P461; LU J, 1993, J ANAT, V183, P405; LU J, 1995, BRAIN RES, V699, P275, DOI 10.1016/0006-8993(95)00919-H; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MAYHAN WG, 1995, BRAIN RES, V686, P99, DOI 10.1016/0006-8993(95)00460-8; MCGEER PL, 1993, GLIA, V7, P84, DOI 10.1002/glia.440070114; MORIOKA T, 1992, ACTA NEUROPATHOL, V83, P149, DOI 10.1007/BF00308474; MORIOKA T, 1991, J NEUROIMMUNOL, V35, P21, DOI 10.1016/0165-5728(91)90158-4; Nakano S, 1996, CANCER RES, V56, P4027; NILSSON B, 1977, J NEUROSURG, V47, P241, DOI 10.3171/jns.1977.47.2.0241; Nottet HSLM, 1999, J NEUROVIROL, V5, P659, DOI 10.3109/13550289909021294; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Raivich G, 1999, BRAIN RES REV, V30, P77, DOI 10.1016/S0165-0173(99)00007-7; RAIVICH G, 1994, NEUROPATH APPL NEURO, V20, P209; Schilling L, 1999, ADV EXP MED BIOL, V474, P123; SETHNA MP, 1991, J NEUROIMMUNOL, V34, P121, DOI 10.1016/0165-5728(91)90121-M; STEINIGER B, 1988, J NEUROIMMUNOL, V19, P111, DOI 10.1016/0165-5728(88)90040-9; STREIT WJ, 1989, EXP NEUROL, V105, P115, DOI 10.1016/0014-4886(89)90111-8; STREIT WJ, 1988, GLIA, V1, P301, DOI 10.1002/glia.440010502; WEINSTEIN DL, 1990, J NEUROSCI RES, V26, P55, DOI 10.1002/jnr.490260107; XU J, 1994, J ANAT, V184, P285; XU J, 1993, J ANAT, V182, P55; Yamanaka K, 1998, NEUROSCI RES, V31, P347, DOI 10.1016/S0168-0102(98)00052-2; Zhang ZG, 1997, BRAIN RES, V744, P189, DOI 10.1016/S0006-8993(96)01085-2	50	41	42	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2001	18	4					399	408		10.1089/089771501750170976			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	425TP	WOS:000168308000004	11336441				2021-06-18	
J	Balabanov, R; Goldman, H; Murphy, S; Pellizon, G; Owen, C; Rafols, J; Dore-Duffy, P				Balabanov, R; Goldman, H; Murphy, S; Pellizon, G; Owen, C; Rafols, J; Dore-Duffy, P			Endothelial cell activation following moderate traumatic brain injury	NEUROLOGICAL RESEARCH			English	Article						adhesion molecules; E-selectin; endothelial cell activation; glucose transporter; ICAM-1; transferrin receptor; traumatic brain injury	INTERCELLULAR-ADHESION MOLECULE-1; CENTRAL-NERVOUS-SYSTEM; TUMOR-NECROSIS-FACTOR; HYDROGEN-PEROXIDE; MULTIPLE-SCLEROSIS; ICAM-1 EXPRESSION; HYPOBARIC HYPOXIA; GENE-EXPRESSION; RAT-BRAIN; TRANSFERRIN	Traumatic brain injury (TBI) initiates a cascade of acute and chronic injury responses which include disturbances in the cerebrovasculature that may result in the activation of the microvascular endothelial development of a dysfunction endothelium. The present study examines endothelial cell (EC) activation in a percussion model of moderate TBI. The criteria for endothelial activation used in these studies was surface expression of a number of markers collectively termed endothelial activation antigens. Temporal induction of the major histocompatibility (MHC) class II molecules, E-selectin (CD62E), vascular cell adhesion molecule (VACM-1) (CD106) as well as altered expression of constitutively expressed intercellular adhesion molecule-1 (ICAM-1) (CD54), the glucose transporter protein (glut-1), the transferrin receptor (tfR) (CD71), and MHC class I molecules was examined at various times following impact Induction of E-selectin and increased expression of ICAM-1 was seen by 2 h post-impact (PI) and was sustained through 24 h PI. Decreased expression of immunologically reactive glut-1 and tfR was observed by 2-4 h PI and remained low up to 24 h PI. No induction of VCAM-1, MHC class II molecules or altered constitutive expression or MHC class I molecules was seen. Changes in EC activation were observed predominantly at the site of impact and were diminished temporarily. These results indicate that mild concussive injury to the brain results in activation of the endothelium.	Wayne State Univ, Sch Med, Dept Neurol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Anat, Detroit, MI 48201 USA	Dore-Duffy, P (corresponding author), Wayne State Univ, Sch Med, Dept Neurol, 421 E Canfield Ave 3206 Elliman Bldg, Detroit, MI 48201 USA.						Betz A. Lorris, 1993, P303; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BRADLEY JR, 1993, AM J PATHOL, V142, P1598; BRIELAND JK, 1992, ARCH BIOCHEM BIOPHYS, V294, P205; CABRE F, 1993, AGENTS ACTIONS, V38, P212, DOI 10.1007/BF01976213; CHIHARA J, 1992, J LIPID MEDIATOR, V5, P159; CLARK WM, 1991, J NEUROSURG, V75, P623, DOI 10.3171/jns.1991.75.4.0623; Cornford EM, 1996, J NEUROTRAUM, V13, P523, DOI 10.1089/neu.1996.13.523; CORTRAN R, 1988, ENDOTHELIAL CELL BIO, P335; DeWitt D S, 1988, Brain Inj, V2, P291, DOI 10.3109/02699058809150899; Dore-Duffy P, 1999, MICROVASC RES, V57, P75, DOI 10.1006/mvre.1998.2112; DOREDUFFY P, 1994, J CEREBR BLOOD F MET, V14, P837, DOI 10.1038/jcbfm.1994.105; FEUERSTEIN GZ, 1994, CEREBROVAS BRAIN MET, V6, P341; GASIC AC, 1991, CIRCULATION, V84, P2154, DOI 10.1161/01.CIR.84.5.2154; GERRITSEN ME, 1993, FASEB J, V7, P523; Goldman H, 1991, J NEUROTRAUM, V8, P129, DOI 10.1089/neu.1991.8.129; GUILIAN D, 1985, SCIENCE, V228, P497; HARIK SI, 1994, J APPL PHYSIOL, V77, P896; HARKER LA, 1988, ENDOTHELIAL CELLS, V1, P167; HARTUNG HP, 1994, NEUROLOGY, V44, P1153, DOI 10.1212/WNL.44.6.1153; HURWITZ AA, 1994, ADV NEUROIMMUNOL, V4, P249, DOI 10.1016/S0960-5428(06)80263-9; ISHIZUKA T, 1994, EUR J PHARMACOL, V262, P113, DOI 10.1016/0014-2999(94)90034-5; JANDER S, 1995, J CEREBR BLOOD F MET, V15, P42, DOI 10.1038/jcbfm.1995.5; KIM JS, 1995, J NEUROL SCI, V128, P45, DOI 10.1016/0022-510X(94)00203-Z; KOCHANEK PM, 1992, STROKE, V23, P1367, DOI 10.1161/01.STR.23.9.1367; KONTOS HA, 1992, J NEUROTRAUM, V9, P349, DOI 10.1089/neu.1992.9.349; LACASSE C, 1991, J LEUKOCYTE BIOL, V49, P245; LAFRENIE RM, 1993, CELL BIOPHYS, V23, P83; LAMANNA JC, 1992, J APPL PHYSIOL, V72, P2238; LEWIS MS, 1988, J CLIN INVEST, V82, P2045, DOI 10.1172/JCI113825; MATSUO Y, 1994, BRAIN RES, V656, P344, DOI 10.1016/0006-8993(94)91478-8; MILHOAN KA, 1992, AM J PHYSIOL, pH965; MORGANTIKOSSMAN MC, 1991, TRENDS PHARMACOL SCI, V13, P286; MORRIS CM, 1992, J NEUROCHEM, V59, P300, DOI 10.1111/j.1471-4159.1992.tb08904.x; MUNRO JM, 1989, AM J PATHOL, V135, P121; NOBLE E, 1991, AM J CARDIOL, V68, pC6; Noble KE, 1996, EUR J IMMUNOL, V26, P2944, DOI 10.1002/eji.1830261221; ORFEO T, 1994, J TRAUMA, V37, P347, DOI 10.1097/00005373-199409000-00003; ORUNDI PD, 1994, J NEUROTRAUM, V11, P105; PANEGYRES PK, 1992, J NEUROL NEUROSUR PS, V55, P4, DOI 10.1136/jnnp.55.1.4; POBER JS, 1988, AM J PATHOL, V133, P426; POBER JS, 1988, ENDOTHELIAL CELLS, V2, P259; Povlishock J T, 1992, Hum Cell, V5, P345; REHNCRONA S, 1989, J CEREBR BLOOD F MET, V9, P65, DOI 10.1038/jcbfm.1989.9; SASSEVILLE VG, 1992, AM J PATHOL, V141, P1021; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; SUZUKI Y, 1992, BIOCHEM BIOPH RES CO, V184, P1339, DOI 10.1016/S0006-291X(05)80029-4; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TAYLOR EM, 1991, J NEUROCHEM, V57, P1584, DOI 10.1111/j.1471-4159.1991.tb06355.x; THEIL EC, 1990, J BIOL CHEM, V265, P4771; WAKEFIELD AJ, 1994, J CLIN PATHOL, V47, P129, DOI 10.1136/jcp.47.2.129; WARD PA, 1991, MOL ASPECTS MED, V12, P169, DOI 10.1016/0098-2997(91)90012-B; WASHINGTON R, 1994, ANN NEUROL, V35, P89, DOI 10.1002/ana.410350114; WILSON J, 1990, BLOOD, V76, P2578; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S	55	41	44	0	6	FOREFRONT PUBL GROUP	WILTON	C/O MARY J RAWLINS, 5 RIVER RD, STE 113, WILTON, CT 06897 USA	0161-6412			NEUROL RES	Neurol. Res.	MAR-APR	2001	23	2-3					175	182		10.1179/016164101101198514			8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	422DX	WOS:000168104200009	11320596				2021-06-18	
J	Leclercq, PD; McKenzie, JE; Graham, DI; Gentleman, SM				Leclercq, PD; McKenzie, JE; Graham, DI; Gentleman, SM			Axonal injury is accentuated in the caudal corpus callosum of head-injured patients	JOURNAL OF NEUROTRAUMA			English	Article						amyloid precursor protein; corpus callosum; diffuse axonal injury; head injury; image analysis; immunohistochemistry	AMYLOID PRECURSOR PROTEIN; TRAUMATIC BRAIN INJURY; INTRACRANIAL-PRESSURE; WHITE-MATTER; BETA-APP; DAMAGE; ACCUMULATION; RAT; DIAGNOSIS; MARKER	Amyloid precursor protein (APP) accumulation is a sensitive marker for the axonal damage that is commonly seen in the brain as the result of head injury. This form of damage is particularly associated with midline structures such as the corpus callosum, although it is not clear whether some areas are more susceptible than others. The aim of this study was to determine if there was a differential distribution of axonal injury throughout the corpus callosum after head injury in an unselected group of cases. Coronal tissue sections from eight cases were taken at different levels through the corpus callosum, including the genu, body, and splenium, The sections were immunostained with an antibody to APP, and the amount of axonal damage at the different levels was quantified using computer image analysis to build up a rostro-caudal profile for each case. The profiles revealed a significantly higher APP load in caudal parts of the corpus callosum, This supports previous non-quantitative reports in the literature and has important implications in terms of choosing where tissue should be sampled to maximize the chance of detecting axonal injury post mortem.	Univ London Imperial Coll Sci Technol & Med, Sch Med, Div Neurosci & Psychol Med, Dept Neuroinflammat, London W6 8RP, England; Univ Glasgow, So Gen Hosp, Inst Neurol Sci, Dept Neuropathol, Glasgow, Lanark, Scotland	Gentleman, SM (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Div Neurosci & Psychol Med, Dept Neuroinflammat, Charing Cross Campus,St Dunstans Rd, London W6 8RP, England.						AbouHamden A, 1997, J NEUROTRAUM, V14, P699, DOI 10.1089/neu.1997.14.699; ADAMS JH, 1976, NEUROPATH APPL NEURO, V2, P323, DOI 10.1111/j.1365-2990.1976.tb00506.x; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ADAMS JH, 1985, NEUROPATH APPL NEURO, V11, P299, DOI 10.1111/j.1365-2990.1985.tb00027.x; Adams JH, 1992, GREENFIELDS NEUROPAT, P106; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; CAJAL SRY, 1959, DEGENERATION REGENER, V2; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; ESIRI MM, 1996, OPPENHEIMERS DIAGNOS, P15; Geddes JF, 2000, NEUROPATH APPL NEURO, V26, P105, DOI 10.1046/j.1365-2990.2000.026002105.x; Geddes JF, 1997, NEUROPATH APPL NEURO, V23, P339, DOI 10.1046/j.1365-2990.1997.4498044.x; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENNARELLI TA, 1987, 31ST P STAPP CAR CRA, P49; Gentleman SM, 1999, NEUROPATH APPL NEURO, V25, P41; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; GENTRY LR, 1988, AM J NEURORADIOL, V9, P1129; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; GRAHAM DI, 1987, NEUROPATH APPL NEURO, V13, P209, DOI 10.1111/j.1365-2990.1987.tb00184.x; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Graham DI, 2000, ACTA NEUROPATHOL, V99, P117, DOI 10.1007/PL00007414; GRAHAM DI, 1997, GREENFIELDS NEUROPAT, P197; KALARIA RN, 1993, NEUROREPORT, V4, P211, DOI 10.1097/00001756-199302000-00025; Kaur B, 1999, J CLIN PATHOL, V52, P203, DOI 10.1136/jcp.52.3.203; LEWEN A, 1995, NEUROREPORT, V6, P357, DOI 10.1097/00001756-199501000-00032; Lewis SB, 1996, J NEUROTRAUM, V13, P505, DOI 10.1089/neu.1996.13.505; Maxwell WL, 1997, J NEUROTRAUM, V14, P755; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; Nishimoto T, 1998, J BIOMECH ENG-T ASME, V120, P140, DOI 10.1115/1.2834294; NUKINA N, 1992, GERONTOLOGY, V38, P10; Pierce JES, 1996, J NEUROSCI, V16, P1083; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; SUENAGA T, 1994, ACTA NEUROPATHOL, V87, P450; Yam PS, 1997, BRAIN RES, V760, P150, DOI 10.1016/S0006-8993(97)00290-4	39	41	41	0	1	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JAN	2001	18	1					1	9		10.1089/089771501750055721			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	390EU	WOS:000166283400001	11200244				2021-06-18	
J	Possl, O; Jurgensmeyer, S; Karlbauer, F; Wenz, C; Goldenberg, G				Possl, O; Jurgensmeyer, S; Karlbauer, F; Wenz, C; Goldenberg, G			Stability of employment after brain injury: a 7-year follow-up study	BRAIN INJURY			English	Article							HEAD-INJURY; WORK; RETURN; REHABILITATION	Forty-three patients with severe traumatic brain injury (n = 24), cerebrovascular diseases (n = 15), or other acquired brain damage (n = 4) were followed-up 7-8 years after neuropsychological rehabilitation including a vocational re-entry programme. Current vocational status and work history since rehabilitation were investigated by means of a structured interview. Before interview, the patients were classified on the basis of medical records into four groups: (A) patients with minor residual neuropsychological impairments, (B) patients with minor impairments but psychopathological symptoms, (C) patients with persistent neuropsychological impairments showing no psychopathological symptoms, and (D) patients with persistent impairments and psychopathological symptoms. For patients in group A, a good, and for those in group D, a poor long-term employment outcome was predicted, while no predictions were made for the intermediate groups. Of the 43 interviewed subjects, 16 (37%) reported a stable return to work at pre-morbid level and seven (16%) at a lower level. In eight patients (19%), persisting difficulties in maintaining work were documented. Twelve subjects (28%) had retired within a period of 2 years after work trial. The relationship between patient classification and longterm employment outcome was only weak. Four out of 11 patients with a good prognosis (group A) experienced vocational adjustment problems or had retired. Three out of 10 patients with a poor prognosis (group D) were able to continue successfully with their previous jobs. These cases are described in detail. The employment outcome of the intermediate groups was very heterogeneous. The results suggest that particular attention should be paid to the long-term consequences of a reduced capacity for work, even if minor in degree. The success of patients despite a poor prognosis illustrate unsolved problems in relation to the ecological validity of neuropsychological measures of executive dysfunctions.	Stadt Krankenhaus Munchen Bogenhausen, Abt Neuropsychol, D-81925 Munich, Germany	Possl, O (corresponding author), Stadt Krankenhaus Munchen Bogenhausen, Abt Neuropsychol, Englschalkinger Str 77, D-81925 Munich, Germany.						ASHELY MJ, 1997, BRAIN INJURY, V11, P677; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; CREPEAU F, 1993, NEUROPSYCHOL REHABIL, V3, P5; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; Greenspan AI, 1996, BRAIN INJURY, V10, P207, DOI 10.1080/026990596124520; HAFFEY WJ, 1989, REHABIL PSYCHOL, V34, P147, DOI 10.1037//0090-5550.34.2.147; HARRICK L, 1994, BRAIN INJURY, V8, P439, DOI 10.3109/02699059409150995; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; Johnson R, 1998, NEUROPSYCHOL REHABIL, V8, P61, DOI 10.1080/713755552; JOHNSTONE B, 1995, NEUROREHABILITATION, V5, P75, DOI 10.3233/NRE-1995-5107; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; PONSFORD J, 1995, TRAUMATIC BRAIN INJU, P195; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Sale P., 1991, J HEAD TRAUMA REHAB, V6, P1, DOI [DOI 10.1097/00001199-199109000-00004, 10.1097/00001199-199109000-00004.]; Teasdale TW, 1997, NEUROPSYCHOL REHABIL, V7, P23, DOI 10.1080/713755521; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; WEHMAN P, 1990, VOCATIONAL REHABILIT; Wehman Paul, 1993, Brain Injury, V7, P31, DOI 10.3109/02699059309008154; WEHMAN PH, 1995, J HEAD TRAUMA REHAB, V10, P27; WEHMAN PH, 1990, ARCH PHYS MED REHAB, V71, P1047	23	41	41	1	6	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JAN	2001	15	1					15	27					13	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	384UF	WOS:000165963600002	11201311				2021-06-18	
J	Prins, ML; Hovda, DA				Prins, ML; Hovda, DA			Mapping cerebral glucose metabolism during spatial learning: Interactions of development and traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						autoradiography; brain injury; 2-deoxy-glucose; development; fluid percussion; Morris water maze	FLUID-PERCUSSION MODEL; MORRIS WATER-MAZE; RAT-BRAIN; POSTNATAL-DEVELOPMENT; PARIETAL CORTEX; MEMORY; MOTOR; HIPPOCAMPUS; TASK; IMMATURE	Previous studies have demonstrated that, compared to adults, postnatal clay 17 (P17) and P28 rats show remarkable cognitive recovery in the Morris water maze (MWM) following fluid percussion injury (FPI). This observed age-at-trauma effect could result from either younger animals solving the MWM task using noninjured neural circuitry or an inability of adult and P28 brains to activate appropriate neural networks due to trauma-induced neurological dysfunction. To address these possibilities, we compared "activated" brain regions during normal MWM acquisition and following FP injury. To generate "activated" images of the brain while animals were performing the MWM task, qualitative [C-14]2-deoxy-D-glucose was conducted on days 2, 5, and 14 during training in sham and injured adult, P28, and P17 rats. When maturational changes in cerebral glucose metabolism are taken into account, the results suggests similar activity changes in the cerebral cortex and lacunosum moleculare of CA1 during acquisition in all age groups, suggesting that the developmental rates of MWM learning do not correspond to different patterns of activated cerebral metabolism. Injured P17s, showing no latency deficits, revealed activated cerebral metabolic patterns similar to noninjured P17 animals. In P28 and adult cases, animals exhibited cognitive deficits and their metabolic studies indicated that the cortical-hippocampal pattern of activation was disrupted by marked injury-induced metabolic depression, which primarily affected the ipsilateral hemisphere and lasted for as long as 14 days in adult animals.	Dept Neurobiol, Los Angeles, CA USA; Dept Surg, Los Angeles, CA USA; Dept Mol & Med Pharmacol, Los Angeles, CA USA	Prins, ML (corresponding author), Virginia Commonwealth Univ Med Coll Virginia, Dept Anat, Sanger Hall,1101 E Marshall St,Box 980709, Richmond, VA 23298 USA.	mlprins@hsc.vcu.edu	Prins, Mayumi/J-9571-2015	Prins, Mayumi/0000-0001-7694-9739	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027544, P50NS030308] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS27544, NS30308] Funding Source: Medline		Adelson PD, 1997, J NEUROTRAUM, V14, P99, DOI 10.1089/neu.1997.14.99; BATES TE, 1994, DEV NEUROSCI-BASEL, V16, P321, DOI 10.1159/000112126; Biagas KV, 1996, J NEUROTRAUM, V13, P189, DOI 10.1089/neu.1996.13.189; Bontempi B, 1996, EUR J NEUROSCI, V8, P2348, DOI 10.1111/j.1460-9568.1996.tb01198.x; Dalezios Y, 1996, NEUROSCIENCE, V72, P325, DOI 10.1016/0306-4522(95)00516-1; DAUTH GW, 1985, ANN NEUROL, V17, P431, DOI 10.1002/ana.410170503; DESTRADE C, 1992, NATO ADV SCI I D-BEH, V68, P389; DIETRICH WD, 1994, J NEUROTRAUM, V11, P629, DOI 10.1089/neu.1994.11.629; DIMATTIA BD, 1988, BEHAV NEUROSCI, V102, P471, DOI 10.1037/0735-7044.102.4.471; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; EBRAHIMIGAILLARD A, 1994, SOMATOSENS MOT RES, V11, P229, DOI 10.3109/08990229409051391; FEENEY DM, 1985, PHYSIOL PSYCHOL, V13, P197; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; FRIEDMAN HR, 1994, J NEUROSCI, V14, P2775; GALEA LAM, 1994, BEHAV BRAIN RES, V60, P43, DOI 10.1016/0166-4328(94)90061-2; GINSBERG MD, 1977, NEUROLOGY, V27, P1042, DOI 10.1212/WNL.27.11.1042; GONZALEZLIMA F, 1993, PHYSIOL BEHAV, V54, P605, DOI 10.1016/0031-9384(93)90256-F; GRUNDL PD, 1994, J NEUROTRAUM, V11, P135, DOI 10.1089/neu.1994.11.135; HAIER RJ, 1992, BRAIN RES, V570, P134, DOI 10.1016/0006-8993(92)90573-R; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HOVDA DA, 1996, NEUROTRAUMA, P1459; INAO S, 1990, J NEUROTRAUM, V7, P100; JARRARD LE, 1993, BEHAV NEURAL BIOL, V60, P9, DOI 10.1016/0163-1047(93)90664-4; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; KOLB B, 1983, BEHAV NEUROSCI, V97, P13, DOI 10.1037/0735-7044.97.1.13; LEE SM, 1993, SOC NEUR ABSTR, V3, P1882; LISBERGER SG, 1988, SCIENCE, V242, P728, DOI 10.1126/science.3055293; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MARTINEZ JL, 1982, J COMP PHYSIOL PSYCH, V96, P721, DOI 10.1037/h0077922; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MEIBACH RC, 1980, BRAIN RES, V195, P167, DOI 10.1016/0006-8993(80)90874-4; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; NEHLIG A, 1993, PROG NEUROBIOL, V40, P163, DOI 10.1016/0301-0082(93)90022-K; NEHLIG A, 1988, J NEUROSCI, V8, P2321; OKEEFE J, 1987, EXP BRAIN RES, V68, P1; OKEEFE J, 1976, EXP NEUROL, V51, P78, DOI 10.1016/0014-4886(76)90055-8; OLTON DS, 1979, BEHAV BRAIN SCI, V2, P313, DOI 10.1017/S0140525X00062713; Pappius HM, 1995, NEUROCHEM RES, V20, P1311, DOI 10.1007/BF00992506; PAPPIUS HM, 1981, ANN NEUROL, V9, P484, DOI 10.1002/ana.410090511; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/0165-3806(96)00098-3; SARTER M, 1989, BEHAV NEUROSCI, V103, P1217; SCHENK F, 1985, EXP BRAIN RES, V58, P11; SOKOLOFF L, 1977, J NEUROCHEM, V29, P13, DOI 10.1111/j.1471-4159.1977.tb03919.x; SUTHERLAND RJ, 1988, J NEUROSCI, V8, P1863; Thomas S, 2000, J NEUROTRAUM, V17, P649, DOI 10.1089/089771500415409; WHISHAW IQ, 1984, BEHAV BRAIN RES, V11, P123, DOI 10.1016/0166-4328(84)90135-9; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289	50	41	41	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2001	18	1					31	46		10.1089/089771501750055758			16	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	390EU	WOS:000166283400004	11200248				2021-06-18	
J	Zhang, J; Lautar, S; Huang, S; Ramsey, C; Cheung, A; Li, JH				Zhang, J; Lautar, S; Huang, S; Ramsey, C; Cheung, A; Li, JH			GPI 6150 prevents H2O2 cytotoxicity by inhibiting poly(ADP-ribose) polymerase	BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS			English	Article						reactive oxygen species damage; NAD(+) depletion; small molecule PARP inhibitor; specificity of GPI 6150	ADP-RIBOSE SYNTHETASE; ISCHEMIA-REPERFUSION INJURY; FOCAL CEREBRAL-ISCHEMIA; NITRIC-OXIDE; DNA DAMAGE; CELLS; 3-AMINOBENZAMIDE; PROTECTION; MICE; DYSFUNCTION	GPI 6150 (1,11b-dihydro-[2H]benzopyrano[4,3,2-de]isoquinolin-3-one) is a novel inhibitor of poly(ADP-ribose) polymerase (PARP). It has demonstrated efficacy in rodent models of focal cerebral ischemia, traumatic brain injury, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine damage to dopaminergic neurons, regional myocardial ischemia, streptozotocin-induced diabetes, septic shock, and arthritis. Here we report the structure of GPI 6150, its enzymatic characteristics, and biochemical property in cytoprotection. As a competitive PARP inhibitor (K-i = 60 nM), GPI 6150 protected the P388D1 cells against hydrogen peroxide cytotoxicity, by preventing PARP activation and the depletion of NAD(+), the substrate for PARP. To address the concerns of potential side effects of PARP inhibition, we tested GPI 6150 and found it had no effect on the repair and expression of a plasmid DNA damaged by N-methyl-N'-nitro-N-nitrosoguanidine. Neither did it affect dehydrogenases with NAD co-enzyme. GPI 6150 was much less potent to inhibit mono-ADP-ribosyltransferase. There was no selectivity for GPI 6150 between PARP isozymes. These attributes render GPI 6150 a useful tool to probe the functions of PARP. (C) 2000 Academic Press.	Guilford Pharmaceut Inc, Baltimore, MD 21224 USA	Zhang, J (corresponding author), Guilford Pharmaceut Inc, 6611 Tributary St, Baltimore, MD 21224 USA.	zhang_j@guilfordpharm.com					Ame JC, 1999, J BIOL CHEM, V274, P17860, DOI 10.1074/jbc.274.25.17860; Ayoub I. A., 1998, Society for Neuroscience Abstracts, V24, P214; Babiychuk E, 1998, PLANT J, V15, P635, DOI 10.1046/j.1365-313x.1998.00240.x; BANASIK M, 1992, J BIOL CHEM, V267, P1569; BERGER NA, 1985, RADIAT RES, V101, P4, DOI 10.2307/3576299; Berghammer H, 1999, FEBS LETT, V449, P259, DOI 10.1016/S0014-5793(99)00448-2; Butler AJ, 1999, MOL CELL BIOL, V19, P296; Chatterjee PK, 2000, FASEB J, V14, P641; Cuzzocrea S, 1997, BRIT J PHARMACOL, V121, P1065, DOI 10.1038/sj.bjp.0701234; Dantzer F, 2000, BIOCHEMISTRY-US, V39, P7559, DOI 10.1021/bi0003442; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; Domenighini M, 1996, MOL MICROBIOL, V21, P667, DOI 10.1046/j.1365-2958.1996.321396.x; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Endres M, 1998, EUR J PHARMACOL, V351, P377, DOI 10.1016/S0014-2999(98)00381-1; Endres M, 1997, J CEREBR BLOOD F MET, V17, P1143, DOI 10.1097/00004647-199711000-00002; Grupp IL, 1999, J MOL CELL CARDIOL, V31, P297, DOI 10.1006/jmcc.1998.0864; Johansson M, 1999, GENOMICS, V57, P442, DOI 10.1006/geno.1999.5799; KALLMANN B, 1992, LIFE SCI, V51, P671, DOI 10.1016/0024-3205(92)90240-P; Kickhoefer VA, 1999, J CELL BIOL, V146, P917, DOI 10.1083/jcb.146.5.917; Koyama Y, 1999, GENE, V226, P339, DOI 10.1016/S0378-1119(98)00529-0; Lam TT, 1997, RES COMMUN MOL PATH, V95, P241; Lee HC, 2000, CHEM IMMUNOL, V75, P39; Liaudet L, 2000, P NATL ACAD SCI USA, V97, P10203, DOI 10.1073/pnas.170226797; Liaudet L, 2000, SHOCK, V14, P134, DOI 10.1097/00024382-200014020-00010; Lo EH, 1998, STROKE, V29, P830, DOI 10.1161/01.STR.29.4.830; LU XCM, 2000, SOC NEUR ABSTR, V26, P1026; McDonald MC, 2000, BRIT J PHARMACOL, V130, P843, DOI 10.1038/sj.bjp.0703391; MILAM KM, 1984, SCIENCE, V223, P589, DOI 10.1126/science.6420886; Miyamoto T, 1999, MOL CELL BIOL, V19, P2644; NISSELBA.JS, 1969, ANAL BIOCHEM, V27, P212, DOI 10.1016/0003-2697(69)90025-6; OIKAWA A, 1980, BIOCHEM BIOPH RES CO, V97, P1311, DOI 10.1016/S0006-291X(80)80009-X; Pieper AA, 1999, TRENDS PHARMACOL SCI, V20, P171, DOI 10.1016/S0165-6147(99)01292-4; Plaza S, 1999, ONCOGENE, V18, P1041, DOI 10.1038/sj.onc.1202406; Ruf A, 1996, P NATL ACAD SCI USA, V93, P7481, DOI 10.1073/pnas.93.15.7481; SCHRAUFSTATTER IU, 1986, P NATL ACAD SCI USA, V83, P4908, DOI 10.1073/pnas.83.13.4908; SHAH GM, 1995, ANAL BIOCHEM, V227, P1, DOI 10.1006/abio.1995.1245; Simbulan-Rosenthal CM, 1999, P NATL ACAD SCI USA, V96, P13191, DOI 10.1073/pnas.96.23.13191; SIMBULANROSENTH.CM, 2000, IN PRESS NUCL ACIDS; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Sun AY, 1998, ACTA PHARMACOL SIN, V19, P104; Szabo C, 1998, TRENDS PHARMACOL SCI, V19, P287, DOI 10.1016/S0165-6147(98)01193-6; Takahashi K, 1997, J CEREBR BLOOD F MET, V17, P1137, DOI 10.1097/00004647-199711000-00001; Thiemermann C, 1997, P NATL ACAD SCI USA, V94, P679, DOI 10.1073/pnas.94.2.679; Tokime T, 1998, J CEREBR BLOOD F MET, V18, P991; UEDA K, 1985, ANNU REV BIOCHEM, V54, P73, DOI 10.1146/annurev.bi.54.070185.000445; Walles T, 1998, CIRCULATION, V98, P260; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; Zhang J, 2000, PHARM TOXIC, P279; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500; Zhang J., 1998, Society for Neuroscience Abstracts, V24, P1226; Zhang J., 1999, Acta Physiologica Scandinavica, V167, P90; ZHANG J, 1999, EMERGING DRUGS PROSP, V4, P209; Zingarelli B, 1997, CARDIOVASC RES, V36, P205, DOI 10.1016/S0008-6363(97)00137-5; Zingarelli B, 1998, CIRC RES, V83, P85, DOI 10.1161/01.RES.83.1.85	54	41	43	0	9	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0006-291X	1090-2104		BIOCHEM BIOPH RES CO	Biochem. Biophys. Res. Commun.	NOV 30	2000	278	3					590	598		10.1006/bbrc.2000.3816			9	Biochemistry & Molecular Biology; Biophysics	Biochemistry & Molecular Biology; Biophysics	380KW	WOS:000165701900015	11095954				2021-06-18	
J	Proctor, MR; Cantu, RC				Proctor, MR; Cantu, RC			Head and neck injuries in young athletes	CLINICS IN SPORTS MEDICINE			English	Article							CERVICAL-SPINE; NERVOUS-SYSTEM; 2ND IMPACT; CHILDREN; SPORTS; CORD; CONCUSSION; PREVENTION; PLAYERS; SAFETY	Although injuries to the head and cervical spine are considered relatively uncommon in sports medicine, they can have a major impact on the individual athlete and the sport. These injuries account for some of the most catastrophic injuries seen in all levels of athletic participation. Concussion in sports is have a major impact on professional and college levels and is reaching epidemic proportions. The effects of paralyzing neck injuries in sports are devastating and are followed closely by our national media. In this article, the epidemiology, pathophysiology, and types of injury are reviewed, with in-depth discussion of cranial and spinal injuries.	Childrens Hosp, Dept Neurosurg, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Emerson Hosp, Dept Neurosurg, Concord, MA USA	Proctor, MR (corresponding author), Childrens Hosp, Dept Neurosurg, 300 Longwood Ave, Boston, MA 02115 USA.	proctor_m@al.tch.harvard.edu					ALEXANDER E, 1958, ARCH NEURO PSYCHIATR, V79, P146, DOI 10.1001/archneurpsyc.1958.02340020026006; BLAHD W H JR, 1985, Journal of Emergency Medicine, V2, P243, DOI 10.1016/0736-4679(85)90102-7; Cantu RC, 1999, PHYSICIAN SPORTSMED, V27, P35, DOI 10.3810/psm.1999.08.945; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; CANTU RC, 1992, PHYSICIAN SPORTSMED, V20, P55, DOI 10.1080/00913847.1992.11947483; CANTU RC, 1981, HLTH MAINTENANCE PHY; CANTU RC, 1987, EXERCISING ADULT, P129; Chorley Joseph N., 1998, Current Opinion in Pediatrics, V10, P350, DOI 10.1097/00008480-199808000-00004; Committee on Head Injury Nomenclature of Congress of Neurological Surgeons, 1966, CLIN NEUROSURG, V12, P386; COPE R, 1987, SOUTHERN MED J, V80, P33, DOI 10.1097/00007611-198701000-00008; EISMONT FJ, 1984, SPINE, V9, P663, DOI 10.1097/00007632-198410000-00001; FEKETE JF, 1968, CAN MED ASSOC J, V99, P1234; FELDICK HG, 1976, PHYSICIAN SPORTSMED, V4, P77; GRUBER R, 1985, Z KINDERCHIR, V40, P199; Gundry C R, 1999, Magn Reson Imaging Clin N Am, V7, P85; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; GUTHKELCH AN, 1980, EUR NEUROL, V19, P91, DOI 10.1159/000115133; HAMILTON MG, 1993, J TRAUMA, V34, P227, DOI 10.1097/00005373-199302000-00008; HERZOG RJ, 1991, SPINE, V16, pS178, DOI 10.1097/00007632-199106001-00001; HUGENHOLTZ H, 1982, CAN MED ASSOC J, V127, P827; JENNET B, 1971, SCI FDN NEUROLOGY, P441; Katoh S, 1996, SPINAL CORD, V34, P416, DOI 10.1038/sc.1996.74; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; KIM PCW, 1995, J PEDIATR SURG, V30, P1135, DOI 10.1016/0022-3468(95)90005-5; KRAUS JF, 1991, NEUROEPIDEMIOLOGY TR, P333; LINDSAY KW, 1980, BRIT MED J, V281, P789, DOI 10.1136/bmj.281.6243.789; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Maroon J C, 1980, Clin Neurosurg, V27, P414; Maroon JC, 1996, SPINE, V21, P2294, DOI 10.1097/00007632-199610010-00025; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; MATSUURA P, 1989, J BONE JOINT SURG AM, V71A, P183, DOI 10.2106/00004623-198971020-00003; MAYFIELD FH, 1955, CLIN NEUROSURGERY, V2; McAbee GN, 1996, PEDIATR NEUROL, V15, P235, DOI 10.1016/S0887-8994(96)00162-2; McGuffie AC, 1998, SCOT MED J, V43, P139, DOI 10.1177/003693309804300504; MEEUSEN R, 1992, SPORTS MED, V13, P337, DOI 10.2165/00007256-199213050-00004; Meggyesy Dave, 1970, OUT THEIR LEAGUE, P125; MUELLER F, 1996, CATASTROPHIC INJURIE, P41; MURPHEY F, 1959, AM J SURG, V98, P379, DOI 10.1016/0002-9610(59)90530-6; MYLES ST, 1992, CAN J SURG, V35, P643; NELSON DE, 1992, AM J DIS CHILD, V146, P611, DOI 10.1001/archpedi.1992.02160170091022; NOAKES TD, 1995, SPORTS MED, V20, P348, DOI 10.2165/00007256-199520050-00006; NUGENT GR, 1959, NEUROLOGY, V9, P273; OSENBACH RK, 1992, NEUROSURGERY, V30, P385, DOI 10.1227/00006123-199203000-00012; PENNING L, 1962, NEUROLOGY, V12, P513; PIZZUTILLO PD, 1993, AAOS INSTR COURSE LE, V42, P463; PRALL JA, 1995, INJURY, V26, P539, DOI 10.1016/0020-1383(95)00085-N; ROSENBAUM DM, 1986, AM J ROENTGENOL, V146, P1269, DOI 10.2214/ajr.146.6.1269; Rosenow JM, 1998, SURG NEUROL, V50, P608; Rotem TR, 1998, MED J AUSTRALIA, V168, P379, DOI 10.5694/j.1326-5377.1998.tb138989.x; ROWE BH, 1994, CAN FAM PHYSICIAN, V40, P68; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; SCHLER AT, 1998, CLIN SPORTS MED, V17, P195; Schneider R., 1973, HEAD NECK INJURIES F; Smith GA, 1998, PEDIATRICS, V101, P406, DOI 10.1542/peds.101.3.406; TATOR CH, 1984, CAN MED ASSOC J, V130, P875; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; TORG JS, 1985, MED SCI SPORT EXER, V17, P295; TORG JS, 1985, CLIN SPORT MED, V4, P45; Torg JS, 1996, J BONE JOINT SURG AM, V78A, P1308, DOI 10.2106/00004623-199609000-00003; Waltzman ML, 1999, PEDIATRICS, V103, DOI 10.1542/peds.103.5.e58; WOLF BERNARD S., 1956, JOUR MT SINAI HOSP, V23, P283; YARNELL PR, 1973, NEUROLOGY, V23, P196, DOI 10.1212/WNL.23.2.196	64	41	42	1	6	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0278-5919	1556-228X		CLIN SPORT MED	Clin. Sports Med.	OCT	2000	19	4					693	+		10.1016/S0278-5919(05)70233-7			24	Sport Sciences	Sport Sciences	358AX	WOS:000089536000008	11019736				2021-06-18	
J	Yeo, RA; Hill, D; Campbell, R; Vigil, J; Brooks, WM				Yeo, RA; Hill, D; Campbell, R; Vigil, J; Brooks, WM			Developmental instability and working memory ability in children: A magnetic resonance spectroscopy investigation	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article							FRONTAL-LOBE LESIONS; TRAUMATIC BRAIN INJURY; PROTON MR SPECTROSCOPY; FLUCTUATING ASYMMETRY; TEMPORAL-ORDER; CORTICAL ACTIVATION; PREFRONTAL CORTEX; AMNESIC PATIENTS; CHILDHOOD-ONSET; HAND PREFERENCE	This study of children (ages 7 through 12) wishes to determine (a) whether variation in frontal lobe brain chemistry, determined from proton magnetic resonance spectroscopy (H-1-MRS), is related to performance on a working memory task in children, and (b) whether developmental instability (DI; the imprecise expression of the genetic plan for development due to several known genetic and environmental effects) underlies phenotypic variation in brain chemistry. H-1-MRS assessed neurometabolites in a right frontal white matter voxel. The Visual Two-Back test assessed working memory. A composite measure of DI was created from measures of minor physical anomalies, fluctuating asymmetry of body characteristics, and fluctuating asymmetry of dermatoglyphic features. Greater DI strongly predicted lower concentrations of creatine-phosphocreatine (Cre) and choline-containing compounds, whereas Cre and N-acetyl-aspartate positively correlated with working memory skills. Working memory skills thus seem related to frontal lobe energy metabolism, which in turn is related to DI.	Univ New Mexico, Dept Psychol, Albuquerque, NM 87131 USA; Univ New Mexico, Dept Psychiat, Albuquerque, NM 87131 USA; Univ New Mexico, Coll Educ, Albuquerque, NM 87131 USA; Univ New Mexico, Dept Neurosci, Albuquerque, NM 87131 USA; Univ New Mexico, Clin & Magnet Resonance Imaging Ctr, Albuquerque, NM 87131 USA	Yeo, RA (corresponding author), Univ New Mexico, Dept Psychol, Albuquerque, NM 87131 USA.	ryeo@unm.edu		brooks, william/0000-0001-6227-7636			Baddeley A, 1998, PSYCHOL REV, V105, P158, DOI 10.1037/0033-295X.105.1.158; BARKER PB, 1993, NMR BIOMED, V6, P89, DOI 10.1002/nbm.1940060114; Bertolino A, 1998, AM J PSYCHIAT, V155, P1376, DOI 10.1176/ajp.155.10.1376; Brooks WM, 1999, MAGNET RESON MED, V41, P193, DOI 10.1002/(SICI)1522-2594(199901)41:1<193::AID-MRM27>3.0.CO;2-P; Brooks WM, 1998, BIOL PSYCHIAT, V43, P263, DOI 10.1016/S0006-3223(97)00462-9; Brooks WM, 1999, J RHEUMATOL, V26, P81; Carlson S, 1998, CEREB CORTEX, V8, P743, DOI 10.1093/cercor/8.8.743; CARPENTER PA, 1990, PSYCHOL REV, V97, P404, DOI 10.1037/0033-295X.97.3.404; CASEY BJ, 1995, NEUROIMAGE, V2, P221, DOI 10.1006/nimg.1995.1029; Chugani Harry T., 1994, P153; CLARKE GM, 1992, EVOLUTION, V46, P753, DOI [10.2307/2409643, 10.1111/j.1558-5646.1992.tb02081.x]; Cohen J D, 1994, Hum Brain Mapp, V1, P293, DOI 10.1002/hbm.460010407; Conners C. K., 1990, CONNERS RATING SCALE; Coull JT, 1996, NEUROPSYCHOLOGIA, V34, P1085, DOI 10.1016/0028-3932(96)00029-2; DAVIE CA, 1994, BRAIN, V117, P49, DOI 10.1093/brain/117.1.49; Denckla MB, 1996, J DEV BEHAV PEDIATR, V17, P114; FORD CC, 1992, NEUROLOGY, V42, P1408, DOI 10.1212/WNL.42.7.1408; Friedman SD, 1998, AM J NEURORADIOL, V19, P1879; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; Fry AF, 1996, PSYCHOL SCI, V7, P237, DOI 10.1111/j.1467-9280.1996.tb00366.x; Furlow FB, 1997, P ROY SOC B-BIOL SCI, V264, P823, DOI 10.1098/rspb.1997.0115; FUSTER JM, 1990, ANN NY ACAD SCI, V608, P318, DOI 10.1111/j.1749-6632.1990.tb48901.x; FUSTER JM, 1991, FRONTAL LOBE FUNCTIO, P83; GADOW KD, 1994, CHILD S INVENTORY MA; GOLDMANRAKIC PS, 1995, NEURON, V14, P477, DOI 10.1016/0896-6273(95)90304-6; GOLDMANRAKIC PS, 1991, FRONTAL LOBE FUNCTIO, P117; GORENSTEIN EE, 1989, J CLIN PSYCHOL, V45, P619, DOI 10.1002/1097-4679(198907)45:4<619::AID-JCLP2270450419>3.0.CO;2-M; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; Huttenlocher Peter R., 1994, P137; JANOWSKY JS, 1989, PSYCHOBIOLOGY, V17, P3; Jung RE, 1999, P ROY SOC B-BIOL SCI, V266, P1375, DOI 10.1098/rspb.1999.0790; KREIS R, 1993, MAGNET RESON MED, V30, P424, DOI 10.1002/mrm.1910300405; LEARY RF, 1983, NATURE, V301, P71, DOI 10.1038/301071a0; LopezVillegas D, 1997, P NATL ACAD SCI USA, V94, P9854, DOI 10.1073/pnas.94.18.9854; Mangels JA, 1997, NEUROPSYCHOLOGY, V11, P207, DOI 10.1037/0894-4105.11.2.207; Manning JT, 1997, EVOL HUM BEHAV, V18, P15, DOI 10.1016/S1090-5138(96)00072-4; MCANDREWS MP, 1991, NEUROPSYCHOLOGIA, V29, P849, DOI 10.1016/0028-3932(91)90051-9; MILNER B, 1991, NEUROPSYCHOLOGIA, V29, P601, DOI 10.1016/0028-3932(91)90013-X; MITTON JB, 1984, ANNU REV ECOL SYST, V15, P479; Moller A. P., 1997, ASYMMETRY DEV STABIL; Moore GJ, 1998, PEDIATR RADIOL, V28, P805, DOI 10.1007/s002470050470; PALMER AR, 1986, ANNU REV ECOL SYST, V17, P391, DOI 10.1146/annurev.es.17.110186.002135; PETRIDES M, 1993, P NATL ACAD SCI USA, V90, P878, DOI 10.1073/pnas.90.3.878; Rae C, 1996, P ROY SOC B-BIOL SCI, V263, P1061, DOI 10.1098/rspb.1996.0156; Rajanayagam V, 1997, AM J NEURORADIOL, V18, P1909; Richards TL, 1997, INT J NEURORADIOL, V3, P490; Sattler J. M., 1992, ASSESSMENT CHILDREN; SCHEIBEL A, 1990, BRAIN COGNITION, V12, P85, DOI 10.1016/0278-2626(90)90006-A; SHIMAMURA AP, 1990, NEUROPSYCHOLOGIA, V28, P803, DOI 10.1016/0028-3932(90)90004-8; Shimamura Arthur P., 1995, P803; Smith Edward E., 1995, P1009; Spindler KA, 1997, SCHIZOPHR RES, V27, P1, DOI 10.1016/S0920-9964(97)00074-1; Stevens AA, 1998, ARCH GEN PSYCHIAT, V55, P1097, DOI 10.1001/archpsyc.55.12.1097; SWARTZ BE, 1994, NEUROREPORT, V5, P925, DOI 10.1097/00001756-199404000-00018; THOMA R, IN PRESS LATERALITY; Thornhill R, 1997, BIOL REV, V72, P497, DOI 10.1017/S0006323197005082; VANVALEN L, 1962, EVOLUTION, V16, P125; Waldrop M, 1971, EXCEPTIONAL INFANT S, P343; WALDROP MF, 1989, UNPUB MANUAL ASSESSM; WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021; Wechsler D., 1991, WECHSLER INTELLIGENC; Yakovlev P.I., 1967, RETIONAL DEV BRAIN E, P3; YEO RA, 1993, GENETICA, V89, P281, DOI 10.1007/BF02424521; Yeo RA, 1997, NEUROPSYCHOLOGY, V11, P552, DOI 10.1037/0894-4105.11.4.552; Yeo RA, 1999, SCHIZOPHR RES, V39, P197, DOI 10.1016/S0920-9964(99)00074-2; YEO RA, 1993, PSYCHOBIOLOGY, V21, P161; Yeo RA, 1997, PSYCHIAT RES-NEUROIM, V76, P1, DOI 10.1016/S0925-4927(97)00056-5; YEO RA, 1998, DEV EXCEPTIONALITY P, P1; ZAMETKIN AJ, 1990, NEW ENGL J MED, V323, P1361, DOI 10.1056/NEJM199011153232001	69	41	41	0	0	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	8756-5641	1532-6942		DEV NEUROPSYCHOL	Dev. Neuropsychol.		2000	17	2					143	159		10.1207/S15326942DN1702_01			17	Psychology, Developmental; Psychology; Psychology, Experimental	Psychology	342TK	WOS:000088661100001	10955200				2021-06-18	
J	Hofman, PAM; Kemerink, GJ; Jolles, J; Wilmink, JT				Hofman, PAM; Kemerink, GJ; Jolles, J; Wilmink, JT			Quantitative analysis of magnetization transfer images of the brain: Effect of closed head injury, age and sex on white matter	MAGNETIC RESONANCE IN MEDICINE			English	Article						magnetization transfer; quantitative imaging; normal aging; MRI	MULTIPLE-SCLEROSIS LESIONS; HISTOPATHOLOGIC CORRELATION; MICROSCOPIC DISEASE; TRANSFER RATIO; ECHO IMAGES; MR; DECADES; BURDEN; LIFE; T1	Magnetization transfer (MT) imaging has an application in quantitative assessment of cerebral white matter. Previously published postprocessing methods have inherent problems, and therefore a new analysis technique is presented. This technique was found to be more sensitive for white matter changes in patients with a postconcussional syndrome, compared to other methods previously described. Because of the potential application of this technique in longitudinal and group studies, age and sex dependence of the MT ratio (MTR) of white matter were studied. In a group of 51 healthy subjects, a decrease in the mean MTR as well as an increasing distribution width of the MTR was found with increasing age. The mean MTR in males was higher than in females. These results stress the need to take age and sex into account when interpreting MTR data. Magn Reson Med 42:803-806, 1999. (C) 1999 Wiley-Liss, Inc.	Univ Hosp Maastricht, Dept Radiol, NL-6200 AZ Maastricht, Netherlands; Univ Hosp Maastricht, Dept Psychiat & Neuropsychiat, NL-6200 AZ Maastricht, Netherlands	Hofman, PAM (corresponding author), Univ Hosp Maastricht, Dept Radiol, POB 5800, NL-6200 AZ Maastricht, Netherlands.	pho@rdia.azm.nl					AGARTZ I, 1991, RADIOLOGY, V181, P537, DOI 10.1148/radiology.181.2.1924801; BLATTER DD, 1995, AM J NEURORADIOL, V16, P241; BOORSTEIN JM, 1994, RADIOLOGY, V191, P799, DOI 10.1148/radiology.191.3.8184068; BREGER RK, 1991, RADIOLOGY, V181, P545, DOI 10.1148/radiology.181.2.1924802; DOUSSET V, 1992, RADIOLOGY, V182, P483, DOI 10.1148/radiology.182.2.1732968; FRANCES CA, 1994, DIAGNOSTIC STAT MANU; HIEHLE JF, 1995, AM J NEURORADIOL, V16, P69; Kimura H, 1996, J COMPUT ASSIST TOMO, V20, P540, DOI 10.1097/00004728-199607000-00007; LEXA FJ, 1994, AM J NEURORADIOL, V15, P201; LOEVNER LA, 1995, RADIOLOGY, V196, P511, DOI 10.1148/radiology.196.2.7617869; MEHTA RC, 1995, AM J NEURORADIOL, V16, P2085; Murphy DGM, 1996, ARCH GEN PSYCHIAT, V53, P585; REISS AL, 1996, BRAINIMAGE; Silver NC, 1997, J NEUROL NEUROSUR PS, V62, P223, DOI 10.1136/jnnp.62.3.223; TEASDALE G, 1974, LANCET, V2, P81; TOMIAK MM, 1994, AM J NEURORADIOL, V15, P1569; vanBuchem MA, 1997, AM J NEURORADIOL, V18, P1287; vanBuchem MA, 1996, MAGN RESON MED, V36, P632, DOI 10.1002/mrm.1910360420; WOLFF SD, 1991, RADIOLOGY, V179, P133, DOI 10.1148/radiology.179.1.2006263; WOLFF SD, 1994, RADIOLOGY, V192, P593, DOI 10.1148/radiology.192.3.8058919; WONG KT, 1995, AM J NEURORADIOL, V16, P253	21	41	41	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0740-3194	1522-2594		MAGN RESON MED	Magn. Reson. Med.	OCT	1999	42	4					803	806		10.1002/(SICI)1522-2594(199910)42:4<803::AID-MRM24>3.3.CO;2-6			4	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	242MG	WOS:000082944400024	10502771	Bronze			2021-06-18	
J	Rao, VLR; Dogan, A; Bowen, KK; Dempsey, RJ				Rao, VLR; Dogan, A; Bowen, KK; Dempsey, RJ			Traumatic injury to rat brain upregulates neuronal nitric oxide synthase expression and L-[H-3]nitroarginine binding	JOURNAL OF NEUROTRAUMA			English	Article						mRNA; nitric oxide; neuronal nitric oxide synthase, L-nitroarginine; RT-PCR; traumatic brain injury; Western blotting	CORTICAL IMPACT INJURY; TRANSIENT FOCAL ISCHEMIA; NITROARGININE BINDING; NMDA RECEPTORS; MUTANT MICE; MITOCHONDRIAL; SYNAPTOSOMES; PHARMACOLOGY; MECHANISMS; INHIBITION	Overstimulation of N-methyl-D-aspartate (NMDA) receptors is felt to precipitate the neuronal damage following traumatic brain injury (TBI). NMDA receptor-mediated, glutamate-induced excitotoxicity is thought to be mediated via nitric oxide (NO) formed by neuronal nitric oxide synthase (nNOS), The present study examined the mRNA and protein levels of nNOS in the ipsilateral and contralateral cortex of rats as a function of time (5 minutes to 1 week) after controlled cortical impact (CCI) brain injury, Sham-operated rats served as controls. TBI resulted in a significant increase in the levels of nNOS mRNA (1.5- to 2.8-fold, p <.05) between 2 and 4 hours after the injury, There was also a significant increase in the levels of nNOS protein (by 55% to 90%,p <.05) and binding densities of the nNOS-specific ligand L-[H-3]nitroarginine (L-[H-3]NOARG) (by 35% to 59%,p <.05) between 2 and 12 hours after the injury, Increased nNOS expression and function may contribute to the concomitant excitotoxic neuronal death after TBI.	Univ Wisconsin, Dept Neurol Surg, Madison, WI 53792 USA; William S Middleton Mem Vet Adm Hosp, Madison, WI USA	Dempsey, RJ (corresponding author), Univ Wisconsin, Dept Neurol Surg, H4-336 CSC,600 Highland Ave, Madison, WI 53792 USA.		Dogan, Aclan/AAF-8305-2019				Alagarsamy S, 1998, J NEUROTRAUM, V15, P627, DOI 10.1089/neu.1998.15.627; Araki T, 1998, EUR J PHARMACOL, V354, P153, DOI 10.1016/S0014-2999(98)00457-9; Ayata C, 1997, J NEUROSCI, V17, P6908; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Beckman JS, 1996, ADV NEUROL, V71, P339; Bolanos JP, 1997, J NEUROCHEM, V68, P2227; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; Brorson JR, 1999, J NEUROSCI, V19, P147; Brown GC, 1997, MOL CELL BIOCHEM, V174, P189, DOI 10.1023/A:1006800322719; Caulfield JL, 1998, J BIOL CHEM, V273, P12689, DOI 10.1074/jbc.273.21.12689; CHOI DW, 1997, PRIMER CEREBROVASCUL, P187; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; Clementi E, 1998, P NATL ACAD SCI USA, V95, P7631, DOI 10.1073/pnas.95.13.7631; Cobbs CS, 1997, BRAIN RES, V751, P336, DOI 10.1016/S0006-8993(96)01429-1; Conti AC, 1998, J NEUROSCI, V18, P5663; Dawson VL, 1996, J NEUROSCI, V16, P2479; Dixon CE, 1998, J NEUROTRAUM, V15, P95, DOI 10.1089/neu.1998.15.95; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dogan A, 1999, J NEUROSURG, V90, P1078, DOI 10.3171/jns.1999.90.6.1078; Endres M, 1997, J CEREBR BLOOD F MET, V17, P1143, DOI 10.1097/00004647-199711000-00002; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Felley-Bosco E, 1998, CANCER METAST REV, V17, P25, DOI 10.1023/A:1005948420548; GALLY JA, 1990, P NATL ACAD SCI USA, V87, P3547, DOI 10.1073/pnas.87.9.3547; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; GORMAN LK, 1996, SOC NEUR ABST, V26; Gow AJ, 1996, FEBS LETT, V385, P63, DOI 10.1016/0014-5793(96)00347-X; Hara H, 1997, J CEREBR BLOOD F MET, V17, P515, DOI 10.1097/00004647-199705000-00005; Hara H, 1996, NEUROSCIENCE, V75, P881, DOI 10.1016/0306-4522(96)00313-2; Huang ZH, 1996, J CEREBR BLOOD F MET, V16, P981, DOI 10.1097/00004647-199609000-00023; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; Ikonomidou C, 1996, METAB BRAIN DIS, V11, P125, DOI 10.1007/BF02069500; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Lipton SA, 1996, NEUROCHEM INT, V29, P111, DOI 10.1016/0197-0186(95)00150-6; Lo EH, 1998, STROKE, V29, P830, DOI 10.1161/01.STR.29.4.830; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANZONI O, 1992, NEURON, V8, P653, DOI 10.1016/0896-6273(92)90087-T; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; McNaught KSP, 1998, J NEUROCHEM, V70, P1541; Mesenge C, 1996, J NEUROTRAUM, V13, P209, DOI 10.1089/neu.1996.13.209; Michel T, 1997, J CLIN INVEST, V100, P2146, DOI 10.1172/JCI119750; MONCADA S, 1991, PHARMACOL REV, V43, P109; MOUSSEAU DD, 1999, NEUROMETH, V34, P167; POGUN S, 1994, SYNAPSE, V18, P21, DOI 10.1002/syn.890180104; Rao AM, 1998, BRAIN RES, V793, P265, DOI 10.1016/S0006-8993(98)00183-8; Rao VLR, 1996, NEUROCHEM RES, V21, P355; Rao VLR, 1998, BRAIN RES, V783, P163, DOI 10.1016/S0006-8993(97)01301-2; Rao VLR, 1997, BRAIN RES, V765, P169, DOI 10.1016/S0006-8993(97)00652-5; Rao VLR, 1998, J NEUROCHEM, V70, P2020; Rao VLR, 1996, J NEUROCHEM, V66, P701; Rao VLR, 1998, METAB BRAIN DIS, V13, P175, DOI 10.1023/A:1023281307660; Rao VLR, 1996, J NEUROCHEM, V67, P1275; RINK A, 1995, AM J PATHOL, V147, P1575; Sakamoto KI, 1997, J NEUROTRAUM, V14, P349, DOI 10.1089/neu.1997.14.349; SCHMIDT K, 1995, J NEUROCHEM, V64, P1469; SempleRowland SL, 1995, J NEUROTRAUM, V12, P1003, DOI 10.1089/neu.1995.12.1003; Shimizu-Sasamata M, 1998, J NEUROSCI, V18, P9564; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; SIESJO BK, 1997, PRIMER CEREBROVASCUL, P172; Smith D H, 1995, New Horiz, V3, P562; Sriram K, 1998, J NEUROSCI, V18, P10287; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; SUN FY, 1995, BRAIN RES, V693, P163, DOI 10.1016/0006-8993(95)00731-5; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; TROTTI D, 1996, J BIOL CHEM, V271, P5967; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; Whalen MJ, 1997, J NEUROTRAUM, V14, P561, DOI 10.1089/neu.1997.14.561; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500; Zhao XR, 1998, J CEREBR BLOOD F MET, V18, P161, DOI 10.1097/00004647-199802000-00006	72	41	44	0	1	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	1999	16	10					865	877		10.1089/neu.1999.16.865			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	246JD	WOS:000083159900002	10547096				2021-06-18	
J	Morita-Fujimura, Y; Fujimura, M; Kawase, M; Chen, SF; Chan, PH				Morita-Fujimura, Y; Fujimura, M; Kawase, M; Chen, SF; Chan, PH			Release of mitochondrial cytochrome c and DNA fragmentation after cold injury-induced brain trauma in mice: possible role in neuronal apoptosis	NEUROSCIENCE LETTERS			English	Article						cold injury; cytochrome c; traumatic brain injury; apoptosis; mitochondrial injury; caspase	CUZN-SUPEROXIDE-DISMUTASE; FOCAL CEREBRAL-ISCHEMIA; CELL-DEATH; ACTIVATION; EDEMA; INHIBITION; INDUCTION; CASPASE-3; DAMAGE; ENZYME	Recent studies have shown that release of mitochondrial cytochrome c is a critical step in the apoptosis process. In this study, we examined the subcellular distribution of the cytochrome c protein after cold injury (Cl), in which apoptosis is assumed to participate. Western blotting and immunohistochemistry showed cytosolic cytochrome c as early as 1 h after Cl, and correspondingly, there was a reduction in mitochondrial cytochrome c after injury. Neuronal distribution of cytosolic cytochrome c was shown by double staining with a neuronal nuclear marker by immunohistochemistry. A significant amount of DNA laddering was detected 4 h after Cl, and increased in a time-dependent manner. These data suggest that early cytochrome c release from mitochondria may contribute to apoptosis induction after traumatic brain injury. (C) 1999 Elsevier Science Ireland Ltd. All rights reserved.	Stanford Univ, Sch Med, Dept Neurosurg, Palo Alto, CA 94304 USA; Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Palo Alto, CA 94304 USA; Stanford Univ, Sch Med, Program Neurosci, Palo Alto, CA 94304 USA; Stanford Univ, Sch Med, Dept Neurol Surg, Palo Alto, CA 94304 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA	Chan, PH (corresponding author), Stanford Univ, Sch Med, Dept Neurosurg, Palo Alto, CA 94304 USA.		Morita-fujimura, Yuiko/N-4804-2014; fujimura, yuiko/M-7393-2013		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS36147, NS14543, NS25372] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS014543, R01NS036147, R01NS025372, P50NS014543] Funding Source: NIH RePORTER		BOYER PD, 1977, ANNU REV BIOCHEM, V46, P955, DOI 10.1146/annurev.bi.46.070177.004515; CHAN PH, 1991, ANN NEUROL, V29, P482, DOI 10.1002/ana.410290506; Chan PH, 1996, STROKE, V27, P1124, DOI 10.1161/01.STR.27.6.1124; Fujimura M, 1998, J CEREBR BLOOD F MET, V18, P1239, DOI 10.1097/00004647-199811000-00010; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; KINOUCHI H, 1991, P NATL ACAD SCI USA, V88, P11158, DOI 10.1073/pnas.88.24.11158; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kondo T, 1997, J NEUROSCI, V17, P4180; Li F, 1997, J BIOL CHEM, V272, P30299, DOI 10.1074/jbc.272.48.30299; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MORITAFUJIMURA Y, 1999, IN PRESS J CEREB BLO; Murakami K, 1997, NEUROSCIENCE, V81, P231, DOI 10.1016/S0306-4522(97)00197-8; Namura S, 1998, J NEUROSCI, V18, P3659; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Piantadosi CA, 1996, STROKE, V27, P327, DOI 10.1161/01.STR.27.2.327; TOMINAGA T, 1992, NEUROSCI LETT, V139, P265, DOI 10.1016/0304-3940(92)90568-R; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	21	41	44	0	1	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	JUN 4	1999	267	3					201	205		10.1016/S0304-3940(99)00327-4			5	Neurosciences	Neurosciences & Neurology	202LK	WOS:000080653600014	10381011				2021-06-18	
J	Andersson, S; Gundersen, PM; Finset, A				Andersson, S; Gundersen, PM; Finset, A			Emotional activation during therapeutic interaction in traumatic brain injury: effect of apathy, self-awareness and implications for rehabilitation	BRAIN INJURY			English	Article							HEAD-INJURY; DISEASE; PERCEPTIONS; RELIABILITY; VALIDITY; LESIONS; SCALE	Apathy and reduced self-awareness are frequent occurring neurobehavioural sequelae following traumatic brain injury (TBI). Apathy, in terms of reduced goal directed activity and lowered motivation, and reduced self-awareness have a negative impact on the rehabilitation process. In this study, 30 patients suffering severe TBI were clinically rated for apathy and monitored for cardiovascular and electrodermal reactivity during baseline, neutral speech and therapeutic interaction. Applying a cut-off score criterion, two thirds of the TBI sample were classified as apathetic. The apathetic patients showed less psychophysiological reactivity from neutral speech to therapeutic interaction, compared to non-apathetic patients. They also reported less perceived emotional discomfort in the therapeutic situation measured with a visual analogue scale. Moreover, reduced self-awareness was associated with low autonomic reactivity. The results suggest that the reduced psychophysiological reactivity in apathetic patients may be a correlate to the lack of emotional responsivity, disengagement, lack of insight and concern about their own situation. Clinically, these results may have implications for psychotherapeutic intervention aimed at improving self-awareness. Recording psychophysiological responses during therapeutic interaction may serve as a method for monitoring emotional involvement during psychotherapy with TBI patients.	Sunnaas Rehabil Hosp, Neuropsychol Lab, Oslo, Norway; Univ Oslo, Dept Behav Sci Med, Oslo, Norway	Andersson, S (corresponding author), Sunnaas Rehabil Hosp, N-1450 Nesoddtangen, Norway.						Andersson S, 1999, PSYCHOL MED, V29, P447, DOI 10.1017/S0033291798008046; BENYISHAY Y, 1993, ARCH PHYS MED REHAB, V74, P204; BOGUSSLAVSKY J, 1991, ACTA NEUROL SCAND, V83, P309; BURNS A, 1990, J NERV MENT DIS, V178, P20, DOI 10.1097/00005053-199001000-00004; Cacioppo J. T., 1991, PSYCHOL ASSESSMENT, V3, P321, DOI [10.1037/1040-3590.3.3.321, DOI 10.1037/1040-3590.3.3.321]; CHRISTENSEN AL, 1992, ACTA NEUROL SCAND, V85, P32; CICERONE KD, 1989, REHABIL PSYCHOL, V34, P105, DOI 10.1037//0090-5550.34.2.105; CUMMINGS JL, 1993, ARCH NEUROL-CHICAGO, V50, P873, DOI 10.1001/archneur.1993.00540080076020; DEATON AV, 1986, REHABIL PSYCHOL, V31, P231, DOI 10.1037//0090-5550.31.4.231; DELIS D, 1987, CALIFORNIA VERBAL LE; DOODY RS, 1995, J NEUROPSYCH CLIN N, V7, P54; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; Galynker I, 1997, J NERV MENT DIS, V185, P616, DOI 10.1097/00005053-199710000-00004; Giacino JT, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199810000-00003; GRAY JM, 1994, CLIN REHABIL, V8, P188, DOI DOI 10.1080/09602010902949207; Herbert CM, 1989, CLIN REHABIL, V3, P125; Hillier SL, 1997, BRAIN INJURY, V11, P525, DOI 10.1080/713802189; HUGHES CF, 1994, J PERS, V62, P565, DOI 10.1111/j.1467-6494.1994.tb00309.x; Kant R, 1998, BRAIN INJURY, V12, P87, DOI 10.1080/026990598122908; LACEY JI, 1959, RES PSYCHOTHER, V1, P160; Lam C S, 1988, Brain Inj, V2, P235, DOI 10.3109/02699058809150947; Lang P.J., 1971, HDB PSYCHOTHERAPY BE, P75; LAPLANE D, 1989, BRAIN, V112, P699, DOI 10.1093/brain/112.3.699; Malec JF, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199706000-00002; MARIN RS, 1991, PSYCHIAT RES, V38, P143, DOI 10.1016/0165-1781(91)90040-V; MARIN RS, 1995, J NEUROPSYCH CLIN N, V7, P23; MARIN RS, 1991, J NEUROPSYCH CLIN N, V3, P243; MARIN RS, 1990, AM J PSYCHIAT, V147, P22; MARIN RS, 1997, REV PSYCHIAT, V15, P205; MATTHEW CG, 1964, INSTRUCTION MANUAL A; NOTARIUS CI, 1989, HDB SOCIAL PSYCHOPHY, P393; PENNEBAKER JW, 1987, J PERS SOC PSYCHOL, V52, P781, DOI 10.1037/0022-3514.52.4.781; Powell JH, 1996, J NEUROL NEUROSUR PS, V60, P416, DOI 10.1136/jnnp.60.4.416; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; Prigatano GP, 1998, CLIN NEUROPSYCHOL, V12, P56, DOI 10.1076/clin.12.1.56.1721; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; RANSEEN JD, 1990, INT J CLIN NEUROPSYC, V12, P29; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Sohlberg MM, 1998, J HEAD TRAUMA REHAB, V13, P62, DOI 10.1097/00001199-199810000-00008; STARKSTEIN SE, 1992, J NEUROPSYCH CLIN N, V4, P134; STARKSTEIN SE, 1993, STROKE, V24, P1625, DOI 10.1161/01.STR.24.11.1625; WATANABE MD, 1995, J NEUROPSYCH CLIN N, V7, P502; Wechsler D., 2008, WECHSLER ADULT INTEL; WECHSLER D, 1955, WECHSTER ADULT INTEL; WILLIAMS RB, 1972, PSYCHOSOM MED, V34, P194, DOI 10.1097/00006842-197205000-00002	46	41	42	0	9	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JUN	1999	13	6					393	404		10.1080/026990599121458			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	204DA	WOS:000080746600001	10401541				2021-06-18	
J	Hicks, RR; Li, CY; Zhang, LX; Dhillon, HS; Prasad, MR; Seroogy, KB				Hicks, RR; Li, CY; Zhang, LX; Dhillon, HS; Prasad, MR; Seroogy, KB			Alterations in BDNF and trkB mRNA levels in the cerebral cortex following experimental brain trauma in rats	JOURNAL OF NEUROTRAUMA			English	Article						head injury; neurotrophic factors; traumatic brain injury	NERVE GROWTH-FACTOR; NEUROTROPHIN-3 MESSENGER-RNAS; TRANSIENT FOREBRAIN ISCHEMIA; RETINAL GANGLION-CELLS; DOPAMINERGIC-NEURONS; INCREASED EXPRESSION; HIPPOCAMPAL-NEURONS; FULL-LENGTH; IN-VIVO; INJURY	Recent studies have suggested that brain-derived neurotrophic factor (BNDF) and its receptor, trkB, may provide neuroprotection following injury to the central nervous system. Conversely, other studies have implicated BDNF as a contributing factor to neurodegenerative events that occur following injury. In order to further investigate the role of BDNF in neuroprotection, we subjected adult rats to a lateral fluid percussion (FP) injury of moderate severity (2.0-2.1 atm) or sham injury. After survival periods of 1, 3, 6, 24, or 72 h, the brains were processed for the in situ hybridization localization of BDNF and trkB mRNAs using S-35-labeled cRNA probes. Hybridization levels were compared between injured and sham animals for regions of the cortex that were located within, adjacent to, and remote from the site of the cortical contusion. BDNF mRNA levels were significantly decreased in the injured cortex at 72 h, increased in adjacent cortical areas at 3 h, and increased bilaterally in the piriform cortex from 3 to 24 h post-FP injury. Expression of trkB mRNA was significantly decreased at all postinjury time-points in the injured cortex and at 24 h in the adjacent cortex. These results demonstrate that, following lateral FP injury, BDNF and trkB mRNA levels are decreased in cortical regions that contain degenerating neurons, generally unchanged in adjacent regions, and increased in remote areas. Thus, injury-induced decreases in the expression of BDNF and trkB may confer vulnerability to neurons within the cortical contusion.	Univ Kentucky, Div Phys Therapy, Lexington, KY 40536 USA; Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA; Univ Kentucky, Dept Surg, Lexington, KY 40536 USA	Hicks, RR (corresponding author), Univ Kentucky, Div Phys Therapy, Lexington, KY 40536 USA.	rrhick00@pop.uky.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS031816, R55NS031816, R01NS035164] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS31816, NS35164] Funding Source: Medline		ADAMS JH, 1992, GREENFIELDS NEUROPAT, P110; BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; BARNEOUD P, 1991, BEHAV BRAIN RES, V44, P87, DOI 10.1016/S0166-4328(05)80242-6; BECK T, 1994, J CEREBR BLOOD F MET, V14, P689, DOI 10.1038/jcbfm.1994.86; CASTROALAMANCOS MA, 1995, NEUROSCIENCE, V68, P793, DOI 10.1016/0306-4522(95)00178-L; CHENG B, 1994, BRAIN RES, V640, P56, DOI 10.1016/0006-8993(94)91857-0; Cheng Y, 1997, ANN NEUROL, V41, P521, DOI 10.1002/ana.410410416; COOPER PR, 1985, CENTRAL NERVOUS SYST, P217; Dietrich W. D., 1987, CEREBROVASC DIS, P285; Dietrich WD, 1996, J NEUROTRAUM, V13, P309, DOI 10.1089/neu.1996.13.309; DUNNMEYNELL AA, 1995, BRAIN RES, V675, P143, DOI 10.1016/0006-8993(95)00050-Z; ERNFORS P, 1991, NEURON, V7, P165, DOI 10.1016/0896-6273(91)90084-D; ERNFORS P, 1990, NEURON, V5, P511, DOI 10.1016/0896-6273(90)90090-3; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fryer RH, 1996, J COMP NEUROL, V374, P21, DOI 10.1002/(SICI)1096-9861(19961007)374:1<21::AID-CNE2>3.0.CO;2-P; GALL CM, 1992, MOL CELL NEUROSCI, V3, P56, DOI 10.1016/1044-7431(92)90009-Q; GALL CM, 1993, EXP NEUROL, V124, P150, DOI 10.1006/exnr.1993.1186; Goodness TP, 1997, EUR J NEUROSCI, V9, P1574, DOI 10.1111/j.1460-9568.1997.tb01515.x; Hagg T, 1998, EXP NEUROL, V149, P183, DOI 10.1006/exnr.1997.6684; HAYES RL, 1995, NEUROSCI LETT, V191, P121, DOI 10.1016/0304-3940(95)11561-X; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; Hicks RR, 1998, MOL BRAIN RES, V59, P264, DOI 10.1016/S0169-328X(98)00158-2; HUNTLEY CW, 1994, TRENDS NEUROSCI, V17, P536; ISACKSON PJ, 1991, NEURON, V6, P937, DOI 10.1016/0896-6273(91)90234-Q; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KINDY MS, 1993, J CEREBR BLOOD F MET, V13, P372, DOI 10.1038/jcbfm.1993.50; Klocker N, 1998, J NEUROSCI, V18, P1038; KOH JY, 1995, SCIENCE, V268, P573, DOI 10.1126/science.7725105; Kokaia Z, 1996, NEUROSCIENCE, V75, P197, DOI 10.1016/0306-4522(96)00257-6; Kokaia Z, 1996, MOL BRAIN RES, V38, P139, DOI 10.1016/0169-328X(96)00002-2; KOLB B, 1990, CEREBRAL CORTEX RAT, P25; KUBO T, 1995, DEV BRAIN RES, V85, P249, DOI 10.1016/0165-3806(94)00220-T; LINDHOLM D, 1994, J NEUROBIOL, V25, P1362, DOI 10.1002/neu.480251105; LINDSAY RM, 1994, TRENDS NEUROSCI, V17, P182, DOI 10.1016/0166-2236(94)90099-X; LINDVALL O, 1992, P NATL ACAD SCI USA, V89, P648, DOI 10.1073/pnas.89.2.648; Litaudon P, 1997, EUR J NEUROSCI, V9, P1593, DOI 10.1111/j.1460-9568.1997.tb01517.x; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MANSOURROBAEY S, 1994, P NATL ACAD SCI USA, V91, P1632, DOI 10.1073/pnas.91.5.1632; MATTSON MP, 1995, J NEUROCHEM, V65, P1740; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; MUDO G, 1993, NEUROSCIENCE, V57, P901, DOI 10.1016/0306-4522(93)90036-F; Mudo G, 1996, EPILEPSIA, V37, P198, DOI 10.1111/j.1528-1157.1996.tb00012.x; NAKAO N, 1995, EXP NEUROL, V131, P1, DOI 10.1016/0014-4886(95)90002-0; Numan S, 1997, EUR J NEUROSCI, V9, P489, DOI 10.1111/j.1460-9568.1997.tb01626.x; Padmaperuma B, 1996, BRAIN RES, V714, P19, DOI 10.1016/0006-8993(95)01579-5; PRASAD MR, 1994, J NEUROCHEM, V63, P773; Rudge JS, 1998, EXP NEUROL, V149, P398, DOI 10.1006/exnr.1997.6737; SATO K, 1995, NEUROSCIENCE, V64, P459, DOI 10.1016/0306-4522(94)00335-3; Schabitz WR, 1997, J CEREBR BLOOD F MET, V17, P500, DOI 10.1097/00004647-199705000-00003; Seroogy K., 1997, NEUROCHEMISTRY PRACT, P121; SEROOGY KB, 1994, J COMP NEUROL, V342, P321, DOI 10.1002/cne.903420302; SKAPER SD, 1993, J NEUROSCI RES, V34, P478, DOI 10.1002/jnr.490340413; SOSIN DM, 1989, JAMA-J AM MED ASSOC, V262, P2251, DOI 10.1001/jama.262.16.2251; Tanaka K, 1996, BRAIN RES, V737, P59, DOI 10.1016/0006-8993(96)00658-0; Tsukahara T, 1998, NEUROCHEM INT, V33, P201, DOI 10.1016/S0197-0186(97)00112-5; WETMORE C, 1994, J NEUROSCI, V14, P1688; Yang K, 1996, J NEUROSCI RES, V44, P157, DOI 10.1002/(SICI)1097-4547(19960415)44:2<157::AID-JNR8>3.0.CO;2-C; Yurek DM, 1996, EXP NEUROL, V137, P105, DOI 10.1006/exnr.1996.0011	60	41	42	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	1999	16	6					501	510		10.1089/neu.1999.16.501			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	206LD	WOS:000080879800006	10391366				2021-06-18	
J	Pieter, W; Zemper, ED				Pieter, W; Zemper, ED			Head and neck injuries in young taekwondo athletes	JOURNAL OF SPORTS MEDICINE AND PHYSICAL FITNESS			English	Article						taekwondo; head injuries; neck injuries; athletic injuries	TRAUMATIC BRAIN INJURY; SPINAL-INJURIES; CHAMPIONSHIPS; PLAYERS	Background. To investigate the location, type, situation and mechanism of head and neck injuries in young taekwondo athletes. Methods. Experimental design: Prospective. Setting: National and international taekwondo tournaments. Participants: 3,341 boys and 917 girls, aged 6 to 16 years. Measures: Injury rates per 1,000 athlete-exposures (A-E) for total number of head and neck injuries, location, type, situation, and mechanism of injury. Results. There was a significant difference between young male and female taekwondo athletes in total head and neck injury rate (p<0.001) with the boys (21.42/1,000 A-E) recording a higher rate than the girls (16.91/1,000 A-E). The head was the most often injured body part (6.10/1,000 A-E and 4.55/1,000 A-E for boys and girls, respectively). The contusion was the most often occurring injury type for both boys (8.41/1,000 A-E) and girls (7.80/1,000 A-E). The cerebral concussion ranked second in both boys (5.11/1,000 4-E) and girls (4.55/1,000 A-E). The unblocked attack was the major injury situation for both boys (19.78/1,000 A-E) and girls (14.96/1,000 A-E). As a consequence, the major injury mechanism was receiving a blow (20.93/1,000 A-E and 16.25/1,000 A-E for boys and girls, respectively). Only the buys (0.66/1,000 A-E) incurred the most serious head and neck injuries that resulted in greater than or equal to 21 days away from participation. Conclusions. The national and international taekwondo governing bodies should review their current injury prevention measures. Given the potentially debilitating nature of these injuries, inplications for any diagnostic capabilities on site should be carefully reviewed.	Univ N London, Sch Hlth & Sports Sci, London N7 8DB, England; ExRA, Eugene, OR USA	Pieter, W (corresponding author), Univ N London, Sch Hlth & Sports Sci, 166-220 Holloway Rd, London N7 8DB, England.						Andreasen I, 1992, SCAND J MED SCI SPOR, V3, P62; CAINE DJ, 1996, EPIDEMIOLOGY SPORTS; CITTAPIETROLUNGO TJ, 1993, ARCH PHYS MED REHAB, V74, P905; HUTCHINSON MR, 1995, MED SCI SPORT EXER, V27, P826; JORDAN BD, 1988, PHYSICIAN SPORTSMED, V16, P85, DOI 10.1080/00913847.1988.11709529; MANN DC, 1993, ORTHOPEDICS, V16, P159; Maroon J C, 1981, Phys Sportsmed, V9, P83, DOI 10.1080/00913847.1981.11711209; MATSUBAYASHI K, 1993, 1993 ADV BIOENGINEER, V26, P259; MCLATCHIE GR, 1994, ENCY SPORTS MED, V5, P609; MUELLER FO, 1986, PHYSICIAN SPORTSMED, V14, P139, DOI 10.1080/00913847.1986.11709202; NIEZGODA JA, 1990, ANN THORAC SURG, V50, P615, DOI 10.1016/0003-4975(90)90199-G; OLER M, 1991, J TRAUMA, V31, P251, DOI 10.1097/00005373-199131020-00017; Pieter W., 1994, Journal of Sports Traumatology and Related Research, V16, P49; PIETER W, 1997, 2 ANN C EUR COLL SPO; Pieter W, 1995, J HUM MOVEMENT STUD, V28, P1; PIETER W, 1996, EPIDEMIOLOGY SPORTS, P268; PIETER W, 1995, BOHN STAFLEU LOGHUM, V3205, P1; SCHMIDT RJ, 1975, MED SCI SPORT EXER, V7, P59; SCHMIDTOLSEN S, 1991, AM J SPORT MED, V19, P273, DOI 10.1177/036354659101900311; SIM FH, 1988, PHYSICIAN SPORTSMED, V16, P92, DOI 10.1080/00913847.1988.11709456; SMITH DJ, 1988, INT OPHTHALMOL CLIN, V28, P242, DOI 10.1097/00004397-198802830-00016; SOBUS KML, 1993, ARCH PHYS MED REHAB, V74, P902; STOREY MD, 1989, PHYSICIAN SPORTSMED, V17, P85; TATOR CH, 1984, CAN MED ASSOC J, V130, P875; TORG JS, 1990, AM J SPORT MED, V18, P50, DOI 10.1177/036354659001800109; Zandbergen A, THESIS TWENTSE AKAD; Zemper E D, 1989, Br J Sports Med, V23, P161; ZEMPER ED, 1989, PHYSICIAN SPORTSMED, V17, P100, DOI 10.1080/00913847.1989.11709915; ZEMPER ED, 1993, PRIMARY CARE SPORTS, P63	29	41	42	0	9	EDIZIONI MINERVA MEDICA	TURIN	CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY	0022-4707			J SPORT MED PHYS FIT	J. Sports Med. Phys. Fit.	JUN	1999	39	2					147	153					7	Sport Sciences	Sport Sciences	208FH	WOS:000080979800011	10399424				2021-06-18	
J	Schmitter-Edgecombe, M				Schmitter-Edgecombe, M			Effects of divided attention on perceptual and conceptual memory tests: An analysis using a process-dissociation approach	MEMORY & COGNITION			English	Article							CLOSED-HEAD-INJURY; WORD-STEM COMPLETION; IMPLICIT MEMORY; EXPLICIT MEMORY; UNCONSCIOUS INFLUENCES; DRIVEN PROCESSES; PERFORMANCE; AMNESIA; TASKS; INDEPENDENCE	In two experiments, the nature of the relation between attention available at learning and subsequent automatic and controlled influences of memory was explored. Participants studied word lists in full and divided encoding conditions. Memory for the word lists was then tested with a perceptually driven task (stem completion) in Experiment 1 and with a conceptually driven task (category association) in Experiment 2. For recall cued with word stems, automatic influences of memory derived using the process-dissociation procedure remained invariant across a manipulation of attention that substantially reduced conscious recollection for the learning episode. In contrast, for recall cued with category names, dividing attention at learning significantly reduced the parameter estimates representing both controlled and automatic memory processes. These findings were similar to those obtained using indirect test instructions. The results suggest that, in contrast to perceptual priming, conceptual priming may be enhanced by semantic processing, and this effect is not an artifact of contamination from conscious retrieval processes.	Washington State Univ, Dept Psychol, Pullman, WA 99164 USA	Schmitter-Edgecombe, M (corresponding author), Washington State Univ, Dept Psychol, Pullman, WA 99164 USA.	schmitter-e@wsu.edu					Baddeley A., 1974, PSYCHOL LEARN MOTIV, P47, DOI [10.1016/s0079-7421(08)60452-1, DOI 10.1016/S0079-7421(08)60452-1]; BADDELEY AD, 1969, BRIT J PSYCHOL, V60, P51, DOI 10.1111/j.2044-8295.1969.tb01175.x; BARTZ WH, 1970, J EXP PSYCHOL, V84, P380, DOI 10.1037/h0029100; BASSILI JN, 1989, Q J EXP PSYCHOL-A, V41, P439, DOI 10.1080/14640748908402375; BATTIG WF, 1969, J EXP PSYCHOL, V80, P1, DOI 10.1037/h0027577; BENNET B, 1965, BRIT J PSYCHOL, V56, P413; BENTIN S, 1992, J EXP PSYCHOL LEARN, V18, P1270, DOI 10.1037/0278-7393.18.6.1270; BLAXTON TA, 1989, J EXP PSYCHOL LEARN, V15, P657, DOI 10.1037/0278-7393.15.4.657; BUCHNER A, 1995, J EXP PSYCHOL GEN, V124, P137, DOI 10.1037/0096-3445.124.2.137; BUCKNER RL, 1995, J NEUROSCI, V15, P12; Cermak Laird S., 1993, P287; CERMAK LS, 1995, NEUROPSYCHOLOGY, V9, P281, DOI 10.1037/0894-4105.9.3.281; CERMAK LS, 1973, NEUROPSYCHOLOGIA, V11, P85, DOI 10.1016/0028-3932(73)90068-7; Cohen J., 1977, STAT ANAL BEHAV SCI; Cowan N, 1996, J EXP PSYCHOL GEN, V125, P195, DOI 10.1037/0096-3445.125.2.195; Craik FIM, 1982, AGING COGNITIVE PROC, P191, DOI DOI 10.1007/978-1-4684-4178-9_11; CRAIK FIM, 1983, PHILOS T R SOC B, V302, P155; CURRAN T, 1995, J EXP PSYCHOL LEARN, V21, P531, DOI 10.1037/0278-7393.21.3.531; Curran T, 1997, J EXP PSYCHOL LEARN, V23, P496, DOI 10.1037/0278-7393.23.2.496; Dodson CS, 1996, J EXP PSYCHOL GEN, V125, P181, DOI 10.1037/0096-3445.125.2.181; Erdfelder E, 1996, BEHAV RES METH INS C, V28, P1, DOI 10.3758/BF03203630; FAHY JF, 1995, J INT NEUROPSYCH SOC, V1, P183; GOLDSTEIN FC, 1990, J CLIN EXP NEUROPSYC, V12, P286, DOI 10.1080/01688639008400975; GRAF P, 1985, J EXP PSYCHOL LEARN, V11, P386, DOI 10.1037/0278-7393.11.2.386; GRAF P, 1985, J EXP PSYCHOL LEARN, V11, P501, DOI 10.1037/0278-7393.11.3.501; GRAF P, 1994, EUR J COGN PSYCHOL, V6, P113, DOI 10.1080/09541449408520139; GREENE RL, 1986, Q J EXP PSYCHOL-A, V38, P663, DOI 10.1080/14640748608401619; HAIST F, 1991, PSYCHOBIOLOGY, V19, P275; HAMANN SB, 1990, J EXP PSYCHOL LEARN, V16, P970, DOI 10.1037/0278-7393.16.6.970; Hamann SB, 1996, J EXP PSYCHOL LEARN, V22, P933; Hay JF, 1996, J EXP PSYCHOL LEARN, V22, P1323, DOI 10.1037/0278-7393.22.6.1323; Hintzman DL, 1997, J EXP PSYCHOL LEARN, V23, P511, DOI 10.1037/0278-7393.23.2.511; Hunt K. P., 1971, PSYCHONOMIC MONOGR S, V4, P97; ISINGRINI M, 1995, MEM COGNITION, V23, P462, DOI 10.3758/BF03197247; Jacoby LL, 1997, J EXP PSYCHOL LEARN, V23, P505, DOI 10.1037/0278-7393.23.2.505; JACOBY LL, 1991, J MEM LANG, V30, P513, DOI 10.1016/0749-596X(91)90025-F; JACOBY LL, 1989, J EXP PSYCHOL GEN, V118, P115, DOI 10.1037/0096-3445.118.2.115; Jacoby LL, 1998, J EXP PSYCHOL LEARN, V24, P3, DOI 10.1037/0278-7393.24.1.3; JACOBY LL, 1993, J EXP PSYCHOL GEN, V122, P139, DOI 10.1037/0096-3445.122.2.139; Jacoby LL, 1997, CARN S COGN, P13; Jacoby LL, 1997, J EXP PSYCHOL LEARN, V23, P484, DOI 10.1037/0278-7393.23.2.484; JOORDENS S, 1993, J EXP PSYCHOL GEN, V122, P462, DOI 10.1037/0096-3445.122.4.462; Keane MM, 1997, NEUROPSYCHOLOGY, V11, P59, DOI 10.1037/0894-4105.11.1.59; KOMATSU S, 1995, EUR J COGN PSYCHOL, V7, P19, DOI 10.1080/09541449508520155; KORIAT A, 1976, ACTA PSYCHOL, V40, P57, DOI 10.1016/0001-6918(76)90044-5; Kucera H, 1967, COMPUTATIONAL ANAL P; McKone E, 1997, MEM COGNITION, V25, P352, DOI 10.3758/BF03211291; Mecklenbrauker S, 1996, SWISS J PSYCHOL, V55, P34; Mulligan NW, 1997, J EXP PSYCHOL LEARN, V23, P280, DOI 10.1037/0278-7393.23.2.280; Mulligan NW, 1998, J EXP PSYCHOL LEARN, V24, P27, DOI 10.1037/0278-7393.24.1.27; Mulligan NW, 1996, MEM COGNITION, V24, P453, DOI 10.3758/BF03200934; Mulligan NW, 1997, MEM COGNITION, V25, P11, DOI 10.3758/BF03197281; MUTTER SA, 1990, COGNITIVE NEUROPSYCH, V7, P329, DOI 10.1080/02643299008253447; PARKIN AJ, 1990, MEM COGNITION, V18, P507, DOI 10.3758/BF03198483; PARKIN AJ, 1990, EUROPEAN J COGNITIVE, V2, P71, DOI DOI 10.1080/09541449008406198; PERRUCHET P, 1989, MEM COGNITION, V17, P77, DOI 10.3758/BF03199559; RAPPOLD VA, 1991, J EXP PSYCHOL LEARN, V17, P103, DOI 10.1037/0278-7393.17.1.103; Reingold EM, 1996, J EXP PSYCHOL LEARN, V22, P397; RICHARDSONKLAVEHN A, 1988, ANNU REV PSYCHOL, V39, P475, DOI 10.1146/annurev.ps.39.020188.002355; ROEDIGER HL, 1992, J EXP PSYCHOL LEARN, V18, P1251, DOI 10.1037/0278-7393.18.6.1251; ROEDIGER HL, 1990, AM PSYCHOL, V45, P1043, DOI 10.1037/0003-066X.45.9.1043; Roediger HL., 1989, VARIETIES MEMORY CON, P3; ROTHKEGEL R, 1998, APPLETREE STAT INFER; SCHACTER DL, 1992, J COGNITIVE NEUROSCI, V4, P244, DOI 10.1162/jocn.1992.4.3.244; SCHACTER DL, 1992, AM PSYCHOL, V47, P559, DOI 10.1037/0003-066X.47.4.559; SCHACTER DL, 1990, ANN NY ACAD SCI, V608, P543, DOI 10.1111/j.1749-6632.1990.tb48909.x; SCHACTER DL, 1987, J EXP PSYCHOL LEARN, V13, P501, DOI 10.1037/0278-7393.13.3.501; Schmidt S, 1996, AGRO FOOD IND HI TEC, V7, P2; SchmitterEdgecombe M, 1996, NEUROPSYCHOLOGY, V10, P155; SHIMAMURA AP, 1986, Q J EXP PSYCHOL-A, V38, P619, DOI 10.1080/14640748608401617; Shum D, 1996, J HEAD TRAUMA REHAB, V11, P43, DOI 10.1097/00001199-199604000-00005; SMITH ER, 1988, J EXP SOC PSYCHOL, V24, P490, DOI 10.1016/0022-1031(88)90048-0; SQUIRE LR, 1992, P NATL ACAD SCI USA, V89, P1837, DOI 10.1073/pnas.89.5.1837; SRINIVAS K, 1990, J MEM LANG, V29, P389, DOI 10.1016/0749-596X(90)90063-6; TOTH JP, 1994, J EXP PSYCHOL LEARN, V20, P290, DOI 10.1037/0278-7393.20.2.290; TOTH JP, 1995, EUR J COGN PSYCHOL, V7, P113, DOI 10.1080/09541449508403095; TULVING E, 1990, SCIENCE, V247, P301, DOI 10.1126/science.2296719; Vakil E, 1997, J Int Neuropsychol Soc, V3, P327; Wagner AD, 1997, J EXP PSYCHOL LEARN, V23, P305, DOI 10.1037/0278-7393.23.2.305; Wechsler D., 1981, WAIS R MANUAL WECHSL; Wolters G, 1997, MEM COGNITION, V25, P764, DOI 10.3758/BF03211319; Yonelinas AP, 1996, CONSCIOUS COGN, V5, P131, DOI 10.1006/ccog.1996.0008	82	41	45	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-502X	1532-5946		MEM COGNITION	Mem. Cogn.	MAY	1999	27	3					512	525		10.3758/BF03211545			14	Psychology, Experimental	Psychology	199KC	WOS:000080479200011	10355240	Bronze			2021-06-18	
J	Markowitsch, HJ; Calabrese, P; Neufeld, H; Gehlen, W; Durwen, HF				Markowitsch, HJ; Calabrese, P; Neufeld, H; Gehlen, W; Durwen, HF			Retrograde amnesia for world knowledge and preserved memory for autobiographic events. A case report	CORTEX			English	Article						traumatic brain injury; retrograde amnesia; general knowledge; episodic memory	EPISODIC MEMORY; FUNCTIONAL NEUROANATOMY; TEMPORAL POLE; BRAIN-REGIONS; RETRIEVAL; CORTEX; ORGANIZATION	A patient (PC) with severe and chronic retrograde amnesia for world knowledge (tested with famous events and famous faces), but unimpaired autobiographical memory is described. The 64-year-old man had traumatic brain injury four years prior to the present evaluation. Current brain imaging showed principally damage involving the infero-lateral prefrontal and the lateral temporal regions of the left-hemisphere. PC was of average intelligence, had no depression and only minor language problems, but manifested some additional anterograde memory deficits and performed subaverage in various frontal lobe-sensitive tests. Patient PC represents one of the very few cases with a preserved retrograde episodic and an impaired retrograde knowledge system, showing a dissociation between preserved retrieval of autobiographical events and amnesia for nonpersonal famous events. It is hypothesized that the sparing of autobiographical memories can be linked to the integrity of the right frontal and temporo-polar cortices.	Univ Bielefeld, D-33501 Bielefeld, Germany; Univ Clin Bochum, Dept Neurol, Bochum, Germany	Markowitsch, HJ (corresponding author), Univ Bielefeld, POB 100131, D-33501 Bielefeld, Germany.		Calabrese, Pasquale/AAL-5291-2020				ARNOLD SE, 1994, ARCH NEUROL-CHICAGO, V51, P145, DOI 10.1001/archneur.1994.00540140051014; Calabrese P, 1996, J NEUROL NEUROSUR PS, V61, P304, DOI 10.1136/jnnp.61.3.304; CRONINGOLOMB A, 1986, NEUROPSYCHOLOGIA, V24, P881, DOI 10.1016/0028-3932(86)90088-6; DAHL G, 1986, REDUZIERTER WECHSLER; DERENZI E, 1987, CORTEX, V23, P575, DOI 10.1016/S0010-9452(87)80050-3; DERENZI E, 1962, BRAIN, V85, P665, DOI 10.1093/brain/85.4.665; DONALD MW, 1977, INT ENCY PSYCHIAT PS, V2, P455; EBNER A, 1987, ZUGANG VERSTANDNIS H; Fink GR, 1996, J NEUROSCI, V16, P4275; Fletcher PC, 1997, TRENDS NEUROSCI, V20, P213, DOI 10.1016/S0166-2236(96)01013-2; FRANZEN EA, 1973, NEUROPSYCHOLOGIA, V11, P141, DOI 10.1016/0028-3932(73)90002-X; GROSSI D, 1988, CORTEX, V24, P457, DOI 10.1016/S0010-9452(88)80009-1; HAUTZINGER M, 1991, NERVENARZT, V62, P689; JETTER W, 1986, CORTEX, V22, P229, DOI 10.1016/S0010-9452(86)80047-8; KAPUR N, 1992, BRAIN, V115, P73, DOI 10.1093/brain/115.1.73; KAPUR S, 1994, P NATL ACAD SCI USA, V91, P2008, DOI 10.1073/pnas.91.6.2008; Kopelman M D, 1994, Memory, V2, P211, DOI 10.1080/09658219408258945; Kopelman M. D., 1990, AUTOBIOGRAPHICAL MEM; Kroll NEA, 1997, BRAIN, V120, P1377, DOI 10.1093/brain/120.8.1377; Leplow B, 1997, DIAGNOSTICA, V43, P193; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Markowitsch H J, 1997, Cogn Neuropsychiatry, V2, P135, DOI 10.1080/135468097396379; MARKOWITSCH HJ, 1993, J CLIN EXP NEUROPSYC, V15, P627, DOI 10.1080/01688639308402586; MARKOWITSCH HJ, 1985, J COMP NEUROL, V242, P425, DOI 10.1002/cne.902420310; MARKOWITSCH HJ, 1993, J NEUROL NEUROSUR PS, V56, P988, DOI 10.1136/jnnp.56.9.988; Markowitsch HJ, 1995, BRAIN RES REV, V21, P117, DOI 10.1016/0165-0173(95)00007-0; Markowitsch HJ, 1997, TRENDS NEUROSCI, V20, P557; MARKOWITSCH J, 1995, COGNITIVE NEUROSCIEN, P665; MILNER B, 1985, HUM NEUROBIOL, V4, P137; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; Orgass B., 1982, TOKEN TEST DTSCH BEA; RYAN C, 1979, ALCOHOL INTOXICATION, P109; SHALLICE T, 1994, NATURE, V368, P633, DOI 10.1038/368633a0; SPREEN E, 1991, COMPENDIUM NEUROPSYC; SQUIRE LR, 1993, ANNU REV PSYCHOL, V44, P453, DOI 10.1146/annurev.ps.44.020193.002321; Stuss D.T., 1994, NEUROPSYCHOLOGY, V8, P355, DOI [DOI 10.1037/0894-4105.8.3.355, 10.1037/0894-4105.8.3.355]; TULVING E, 1994, P NATL ACAD SCI USA, V91, P2016, DOI 10.1073/pnas.91.6.2016; TULVING E, 1994, P NATL ACAD SCI USA, V91, P2012, DOI 10.1073/pnas.91.6.2012; Tulving E, 1983, ELEMENTS EPISODIC ME; Tulving Endel, 1995, P839; Warrington EK., 1984, RECOGNITION MEMORY T; YOUNG AW, 1995, BRAIN, V118, P15, DOI 10.1093/brain/118.1.15; Zimmermann P, 1993, TESTBATTERIE AUFMERK	43	41	41	0	4	MASSON DIVISIONE PERIODICI	MILAN	VIA FRATELLI BRESSAN 2, 20126 MILAN, ITALY	0010-9452			CORTEX	Cortex	APR	1999	35	2					243	252		10.1016/S0010-9452(08)70797-4			10	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	198AC	WOS:000080398700007	10369096				2021-06-18	
J	Rivara, FP				Rivara, FP			Pediatric injury control in 1999: Where do we go from here?	PEDIATRICS			English	Article							TRAUMATIC BRAIN INJURY; FUNCTIONAL INDEPENDENCE MEASURE; UNITED-STATES; POSTTRAUMATIC SEIZURES; BURN PREVENTION; HEAD-INJURY; CHILDREN; REHABILITATION; PREDICTORS; DEATHS		Univ Washington, Dept Pediat, Harborview Injury Prevent & Res Ctr, Seattle, WA 98195 USA; Univ Washington, Dept Epidemiol, Harborview Injury Prevent & Res Ctr, Seattle, WA 98195 USA	Rivara, FP (corresponding author), Univ Washington, Harborview Med Ctr, 325 9Th Ave,Box 359960, Seattle, WA 98104 USA.						AITKEN M, IN PRESS ARCH PHYS M; Asher K N, 1995, Inj Prev, V1, P228, DOI 10.1136/ip.1.4.228; BERNARD AR, 1994, STUDY LOUISIANAS REC; Braver ER, 1997, JAMA-J AM MED ASSOC, V278, P1437, DOI 10.1001/jama.278.17.1437; Butcher JL, 1996, J TRAUMA, V41, P4, DOI 10.1097/00005373-199607000-00002; COOK L, 1994, ARCH PHYS MED REHAB, V75, P390, DOI 10.1016/0003-9993(94)90160-0; COPE DN, 1995, BRAIN INJURY, V9, P649, DOI 10.3109/02699059509008224; DAVIS RL, 1994, ANN EMERG MED, V24, P640, DOI 10.1016/S0196-0644(94)70273-X; DESAI M H, 1991, Journal of Burn Care and Rehabilitation, V12, P482, DOI 10.1097/00004630-199109000-00016; DIEKEMA DS, 1993, PEDIATRICS, V91, P612; DIGUISEPPI CG, 1989, JAMA-J AM MED ASSOC, V262, P2256, DOI 10.1001/jama.262.16.2256; Ellis AA, 1997, PUBLIC HEALTH REP, V112, P73; ERBAUGH SJ, 1986, PERCEPT MOTOR SKILL, V62, P439, DOI 10.2466/pms.1986.62.2.439; ERDMANN TC, 1991, PEDIATRICS, V88, P572; FAY GC, 1993, ARCH PHYS MED REHAB, V74, P895; FELDMAN KW, 1978, PEDIATRICS, V62, P1; Gean A D, 1995, New Horiz, V3, P549; Graham JD, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.1.e3; Guyer B, 1997, PEDIATRICS, V100, P905, DOI 10.1542/peds.100.6.905; HEIMBACH D, 1992, WORLD J SURG, V16, P10, DOI 10.1007/BF02067108; HERRSTEDT L, 1992, ACCIDENT ANAL PREV, V24, P3, DOI 10.1016/0001-4575(92)90067-S; *I MED, 1998, INJ CONTR; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; JOHNSTON C, 1994, PEDIATRICS, V93, P960; Jonsson C E, 1997, Acta Chir Plast, V39, P3; Kann L, 1995, MMWR CDC Surveill Summ, V44, P1; Kellermann AL, 1996, NEW ENGL J MED, V335, P1438, DOI 10.1056/NEJM199611073351906; KLEINBERGER M, 1997, 41 ANN M ASS ADV AUT; Landgraf JM, 1996, CHILD HLTH QUESTIONN, V1st; LEVIN HS, 1992, J NEUROTRAUM, V9, pS359; LEWIS RJ, 1993, ANN EMERG MED, V22, P1114, DOI 10.1016/S0196-0644(05)80974-6; MACKENZIE EJ, 1993, J ORTHOP TRAUMA, V7, P393, DOI 10.1097/00005131-199310000-00001; Malec JF, 1996, ARCH PHYS MED REHAB, V77, P198, DOI 10.1016/S0003-9993(96)90168-9; MCLOUGHLIN E, 1982, AM J PUBLIC HEALTH, V72, P241, DOI 10.2105/AJPH.72.3.241; Miller Erik C., 1997, Journal of Emergency Medicine, V15, P453, DOI 10.1016/S0736-4679(97)00071-1; Morrow SE, 1996, J PEDIATR SURG, V31, P329, DOI 10.1016/S0022-3468(96)90732-0; *NAT CTR STAT AN, 1986, 806 DOT HS NAT CTR S; *NAT CTR STAT AN, 1997, 808 DOT HS NAT CTR S; *NAT HIGHW TRAFF S, 1997, TRAFF SAF FACTS 1996; *NAT RES COUNC, 1985, INJ AM; *NAT TRANSP SAF BO, 1996, SAF STUD PERF US CHI, V1; National Center for Health Statistics, 1997, HLTH PEOPL 2000 REV; Ottenbacher KJ, 1997, ARCH PHYS MED REHAB, V78, P1309, DOI 10.1016/S0003-9993(97)90302-6; PARTYKA SC, 1984, RESTRAINT USE FATALI; QUAN L, 1992, PEDIATRICS, V90, P909; Quan L, 1998, Inj Prev, V4, P203; Rauchschwalbe R, 1997, PEDIATRICS, V100, part. no., DOI 10.1542/peds.100.4.e1; Rivara FP, 1997, NEW ENGL J MED, V337, P543, DOI 10.1056/NEJM199708213370807; Rivara FP, 1996, PEDIATRICS, V97, P791; RIVARA FP, 1990, AM J DIS CHILD, V144, P692, DOI 10.1001/archpedi.1990.02150300090023; RIVARA FP, REV PREVENTION STRAT; ROBERTS I, 1995, BRIT MED J, V310, P91, DOI 10.1136/bmj.310.6972.91; Roberts I, 1996, BRIT MED J, V312, P29, DOI 10.1136/bmj.312.7022.29; ROBERTS I, 1994, AUST J PUBLIC HEALTH, V18, P209; Ryan CM, 1998, NEW ENGL J MED, V338, P362, DOI 10.1056/NEJM199802053380604; SAFFLE JR, 1993, AM J SURG, V166, P581, DOI 10.1016/S0002-9610(05)80661-0; Schieber R A, 1996, Inj Prev, V2, P228, DOI 10.1136/ip.2.3.228; Schierhout G, 1998, BMJ-BRIT MED J, V316, P961, DOI 10.1136/bmj.316.7136.961; Scholer SJ, 1998, PEDIATRICS, V101, DOI 10.1542/peds.101.5.e12; Schunk JE, 1996, PEDIATR EMERG CARE, V12, P160, DOI 10.1097/00006565-199606000-00004; *SOC AUT ENG, 1997, CHILD OCC PROT 2 S P; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Spack L, 1997, PEDIATR EMERG CARE, V13, P98, DOI 10.1097/00006565-199704000-00004; Speech Thomas J., 1993, Brain Injury, V7, P333, DOI 10.3109/02699059309034959; STARFIELD B, 1995, MED CARE, V33, P553, DOI 10.1097/00005650-199505000-00008; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; THOMPSON DC, 1998, COCHRANE LIB; Treser CD, 1997, J PUBLIC HEALTH POL, V18, P346, DOI 10.2307/3343315; Whyte J, 1997, AM J PHYS MED REHAB, V76, P440, DOI 10.1097/00002060-199711000-00002; WILLIAMS AF, 1979, AM J PUBLIC HEALTH, V69, P455, DOI 10.2105/AJPH.69.5.455; WINTEMUTE GJ, 1990, AM J DIS CHILD, V144, P663, DOI 10.1001/archpedi.1990.02150300061018; Ytterstad B, 1998, Inj Prev, V4, P176; Zeitlin REK, 1998, BURNS, V24, P3, DOI 10.1016/S0305-4179(97)00052-1; Zuckerman GB, 1998, ARCH PEDIAT ADOL MED, V152, P134; 1993, MMWR, V42, P681	75	41	42	0	2	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	APR	1999	103	4		S			883	888					6	Pediatrics	Pediatrics	183YW	WOS:000079583400008	10103326				2021-06-18	
J	Catroppa, C; Anderson, V; Stargatt, R				Catroppa, C; Anderson, V; Stargatt, R			A prospective analysis of the recovery of attention following pediatric head injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						head injury; children; attention; recovery	CHILDREN; DEFICITS	Little is known about specific attentional sequelae following a closed head injury, their pattern of recovery or their interaction with ongoing development. The present study examined attentional abilities in a group of children who had sustained a mild, moderate, or severe head injury. Results showed that the severe head injury group exhibited greater deficits on a number of attentional measures at acute and 6 months postinjury phases, in comparison to children in the mild and moderate head injury groups. Specifically, deficits were most evident on timed tasks where speed of processing was an integral component. Difficulties persisted to at least 6 months postinjury and so may lead to cumulative deficits over time.	Royal Childrens Hosp, Dept Psychol, Parkville, Vic 3052, Australia; Univ Melbourne, Parkville, Vic 3052, Australia	Catroppa, C (corresponding author), Royal Childrens Hosp, Dept Psychol, Flemington Rd, Parkville, Vic 3052, Australia.						Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; ANDERSON V, IN PRESS NEUROPSYCHO; BROUWER WH, 1988, ROAD USER BEHAV THEO, P296; COOLEY EL, 1990, DEV NEUROPSYCHOL, V6, P239, DOI 10.1080/87565649009540465; Daniel A. E., 1983, POWER PRIVILEGE PRES; Dennis M., 1989, CLIN NEUROPSYCHOLOGY, P89; Dennis M., 1995, TRAUMATIC HEAD INJUR, P165; EIBEN CF, 1984, ARCH PHYS MED REHAB, V65, P168; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; FAY GC, 1993, ARCH PHYS MED REHAB, V74, P895; Goldstein FC, 1985, DEV NEUROPSYCHOL, V1, P195, DOI 10.1080/87565648509540310; Gronwall D, 1997, J Int Neuropsychol Soc, V3, P592; HALPERIN JM, 1991, INT J NEUROSCI, V58, P171, DOI 10.3109/00207459108985433; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; KRAUS JF, 1987, HEAD INJURY, P1; Lenneberg Eric H., 1967, BIOL FDN LANGUAGE; MCKAY KE, 1994, DEV NEUROPSYCHOL, V10, P121, DOI 10.1080/87565649409540572; MIRSKY A F, 1991, Neuropsychology Review, V2, P109, DOI 10.1007/BF01109051; MURRAY R, 1992, BRAIN COGNITION, V18, P99, DOI 10.1016/0278-2626(92)90072-T; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Reitan R, 1974, CLIN NEUROPSYCHOLOGY; Sparrow S., 1984, VINELAND ADAPTIVE BE; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Talland G.A., 1965, DERANGED MEMORY; TAYLOR HG, 1992, ADV CHILD NEUROPSYCH, V1, P50; TEASDALE G, 1974, LANCET, V2, P81; Timmermans SR, 1991, COGNITIVE REHABILITA, V9, P26; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; WALSH KW, 1978, NEUORPSYCHOLOGY CLIN; Wechsler D., 1991, MANUAL WECHSLER INTE; WOOD RL, 1988, J LEARN DISABIL, V21, P327, DOI 10.1177/002221948802100603	32	41	41	0	0	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH STREET, NEW YORK, NY 10011-4211 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JAN	1999	5	1					48	57		10.1017/S1355617799511077			10	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	162BR	WOS:000078325800007	9989024				2021-06-18	
J	Doornhein, K; de Haan, EHF				Doornhein, K; de Haan, EHF			Cognitive training for memory deficits in stroke patients	NEUROPSYCHOLOGICAL REHABILITATION			English	Article								This study was set up to evaluate the efficacy of a memory training programme in a group of stroke patients. Berg, Koning-Haanstra, and Deelman (1991) developed a training procedure which successfully improved the memory performance of a group of closed head injury patients. The training programme consists of six simple memory strategies, which are applied to daily memory problems that are selected with the patient. Two groups of stroke patients with demonstrable memory deficits were randomly assigned to the training programme or a non-specific training programme involving repetitive practice on memory tasks. After a four week training period retesting showed a significant improvement of the trained memory skills, but there was no improvement on control memory tasks. Subjective ratings of everyday memory functioning did not differ between the two groups.	Univ Utrecht, Psychol Lab, NL-3584 CS Utrecht, Netherlands				de Haan, Edward/0000-0003-0312-3674			Berg I. J., 1991, NEUROPSYCHOL REHABIL, V1, P97, DOI [DOI 10.1080/09602019108401384, 10.1080/09602019108401384]; BERG IJ, 1993, MEMORY REHABILITATIO; De Renzi E., 1982, DISORDERS SPACE EXPL; DEHAAN RJ, 1995, STROKE, V26, P402, DOI 10.1161/01.STR.26.3.402; GLISKEY EL, 1994, COGNITIVE NEUROPSYCH, P528; MEYBOOMDEJONG B, 1995, ZORG BEROERTE; NEWCOMBE F, 1987, NEUROPSYCHOLOGIA, V25, P149, DOI 10.1016/0028-3932(87)90127-8; NEWCOMBE F, 1985, J CLIN EXP NEUROPSYC, V7, P663, DOI 10.1080/01688638508401290; Reinink ER, 1987, 8727 U GRON DEP NEUR; SAAN RJ, 1986, VIJFTIEN WOORDEN TES; SCOGIN F, 1988, PSYCHOL AGING, V3, P334, DOI 10.1037/0882-7974.3.4.334; Stewart FM, 1996, BRIT J CLIN PSYCHOL, V35, P369, DOI 10.1111/j.2044-8260.1996.tb01191.x; TATEMICHI TK, 1994, J NEUROL NEUROSUR PS, V57, P202, DOI 10.1136/jnnp.57.2.202; van Crevel H, 1991, Ned Tijdschr Geneeskd, V135, P2280; VENEMA JW, 1989, 8938 U GRON DEP NEUR; Verhage F, 1964, INTELLIGENTIE LEEFTI; Wade D T, 1986, Int Rehabil Med, V8, P60; WILSON B, 1982, CORTEX, V18, P580; Wilson B.A., 1992, CLIN MANAGEMENT MEMO, V2nd	19	41	42	0	12	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	OCT	1998	8	4					393	400		10.1080/713755579			8	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	133JR	WOS:000076683900002					2021-06-18	
J	Suchanek, B; Struppeck, H; Fahrig, T				Suchanek, B; Struppeck, H; Fahrig, T			The 5-HT1A receptor agonist BAY x 3702 prevents staurosporine-induced apoptosis	EUROPEAN JOURNAL OF PHARMACOLOGY			English	Article						BAY x 3702; staurosporine; 5-HT1A receptor; apoptosis	PROGRAMMED CELL-DEATH; CEREBRAL-ISCHEMIA; RAT-BRAIN; ALZHEIMERS-DISEASE; DNA FRAGMENTATION; INDUCTION; NEURONS; ANTAGONIST; WAY-100635; INHIBITORS	The 5-HT1A receptor agonist (-)-(R)-2-[4-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]butyl]-1,2-benzisothiazol-3(2H)-one1,1-dioxide monohydrochloride (BAY x 3702) was recently shown to have pronounced neuroprotective effects in rat models of cerebral ischemia and traumatic brain injury. In the present study we investigated the neuroprotective effects of BAY x 3702 in primary cultures of hippocampal and cortical neurons. Cell death was induced by 25 nM of the apoptosis inducing agent staurosporine and analyzed 24 h later by release of lactate dehydrogenase, formation of apoptotic bodies and DNA fragmentation. A significant neuroprotection was seen after pretreatment of the affected neurons with 50 pM to 1 mu M BAY x 3702. The effects of BAY x 3702 were completely blocked by the selective 5-HT1A receptor antagonist N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl) cyclohexanecarboxamide trihydrochloride) (WAY-100635). These results indicate that low concentrations of BAY x 3702 protect cortical as well as hippocampal neurons from apoptotic cell death via a 5-HT1A receptor mediated pathway. (C) 1998 Elsevier Science B.V. All rights reserved.	Bayer, CNS Res, Pharma Forschungszentrum, D-42096 Wuppertal, Germany	Suchanek, B (corresponding author), Bayer, CNS Res, Pharma Forschungszentrum, Aprather Weg, D-42096 Wuppertal, Germany.						Ahlemeyer B, 1997, BRAIN RES, V777, P179; ANDRADE R, 1992, DRUG DEVELOP RES, V26, P275, DOI 10.1002/ddr.430260307; BANERJEE P, 1996, SOC NEUR ABSTR; BERTRAND R, 1994, EXP CELL RES, V211, P314, DOI 10.1006/excr.1994.1093; BIELENBERG GW, 1990, EUR J PHARMACOL, V183, P1953, DOI 10.1016/0014-2999(90)92302-Y; BODEGREUEL KM, 1990, STROKE, V21, P164; Boix J, 1997, NEUROPHARMACOLOGY, V36, P811, DOI 10.1016/S0028-3908(97)00030-0; CHALMERS DT, 1991, BRAIN RES, V561, P51, DOI 10.1016/0006-8993(91)90748-K; CHOI DW, 1987, J NEUROSCI, V7, P357; COLINO A, 1987, NATURE, V328, P73, DOI 10.1038/328073a0; CONTRERAS PC, 1992, LIFE SCI, V51, P1145, DOI 10.1016/0024-3205(92)90516-R; DAVIES MF, 1987, BRAIN RES, V423, P347, DOI 10.1016/0006-8993(87)90861-4; De Vry Jean, 1997, Drugs of the Future, V22, P341; DEVRY J, 1995, PSYCHOPHARMACOLOGY, V121, P1; DEVRY J, 1998, IN PRESS J PHARM EXP; DOWSON G, 1997, J NEUROCHEM, V68, P2363; FORSTER EA, 1995, EUR J PHARMACOL, V281, P81, DOI 10.1016/0014-2999(95)00234-C; FUJITAYAMAGUCHI Y, 1988, BIOCHEM BIOPH RES CO, V157, P955, DOI 10.1016/S0006-291X(88)80967-7; HORVATH E, 1997, J NEUROTRAUMA, V14; HORVATH E, 1997, SOC NEUR ABSTR; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; JARVIS WD, 1994, CANCER RES, V54, P1707; KHAWAJA X, 1995, J NEUROCHEM, V64, P2716; KRUMAN I, 1997, SOC NEUR ABSTR; LINNIK MD, 1993, STROKE, V24, P2002, DOI 10.1161/01.STR.24.12.2002; MACMANUS JP, 1993, NEUROSCI LETT, V164, P89, DOI 10.1016/0304-3940(93)90864-H; Nicotera P, 1997, CELL DEATH DIFFER, V4, P435, DOI 10.1038/sj.cdd.4400265; NIXON RA, 1994, ANN NY ACAD SCI, V747, P77; PorteraCailliau C, 1997, J COMP NEUROL, V378, P88, DOI 10.1002/(SICI)1096-9861(19970203)378:1<88::AID-CNE5>3.0.CO;2-G; Posmantur R, 1997, J NEUROCHEM, V68, P2328; PREHN JHM, 1993, BRAIN RES, V630, P10, DOI 10.1016/0006-8993(93)90636-2; PREHN JHM, 1991, EUR J PHARMACOL, V203, P213, DOI 10.1016/0014-2999(91)90717-5; RINK A, 1995, AM J PATHOL, V147, P1575; Singh JK, 1996, J NEUROCHEM, V66, P2361; TAMARAT K, 1991, J PHYS IV, V1, P347, DOI 10.1051/jp4:1991452; Vito P, 1996, SCIENCE, V271, P521, DOI 10.1126/science.271.5248.521; YANAGIHARA N, 1991, J NEUROCHEM, V56, P294, DOI 10.1111/j.1471-4159.1991.tb02595.x	37	41	41	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0014-2999			EUR J PHARMACOL	Eur. J. Pharmacol.	AUG 14	1998	355	1					95	101		10.1016/S0014-2999(98)00469-5			7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	113VT	WOS:000075575100012	9754943				2021-06-18	
J	Max, JE; Koele, SL; Lindgren, SD; Robin, DA; Smith, WL; Sato, Y; Arndt, S				Max, JE; Koele, SL; Lindgren, SD; Robin, DA; Smith, WL; Sato, Y; Arndt, S			Adaptive functioning following traumatic brain injury and orthopedic injury: A controlled study	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							CLOSED-HEAD-INJURY; CHILDREN; PREDICTORS; SEQUELAE; SEVERITY; SCALE; COMA	Objective: To study adaptive functioning after severe traumatic brain injury (TBI). Design: Case-control study. Setting: A university hospital and three regional and four community hospitals. Subjects: A consecutive series (n = 24) of children age 5 through 14 years who suffered severe TBI were individually matched to subjects who sustained a mild TBI and to a second group who sustained an orthopedic injury with no evidence of TBI. Main Outcome Measures: Standardized adaptive functioning, intellectual, psychiatric, and neuroimaging assessments were conducted on average 2 years after injury. Results: Severe TBI was associated with significantly (p <.05) lower Vineland Adaptive Behavior composite, communication, and socialization standard scores and lower Child Behavior Checklist parent-rated social competence scores compared with children with orthopedic injury. Severe TBI and mild TBI subjects were significantly (p <.05) more impaired than orthopedic subjects on teacher-rated adaptive function. Family functioning, psychiatric disorder in the child, and IQ were significant variables, explaining between 22% and 47% of the variance in adaptive functioning outcomes. Conclusions: Severe TBI is associated with significant deficits in child adaptive functioning. This association appears to be mediated by family dysfunction, child psychiatric disorder, and intellectual deficits. (C) 1998 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	Univ Iowa, Dept Psychiat, Iowa City, IA 52242 USA; Univ Iowa, Dept Radiol, Iowa City, IA 52242 USA; Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA; Univ Iowa, Dept Speech Pathol & Audiol, Iowa City, IA 52242 USA	Max, JE (corresponding author), Univ Iowa, Dept Psychiat, 1876 JPP, Iowa City, IA 52242 USA.		Arndt, Stephan/A-6976-2013; Robin, Donald/F-2109-2010	Arndt, Stephan/0000-0003-0783-8204; Sato, Yutaka/0000-0002-5245-232X	NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH31593, MHCRC43271, MH40856] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R37MH031593, P50MH043271, R01MH031593, R01MH040856, P30MH043271] Funding Source: NIH RePORTER		Achenbach T. M., 1991, MANUAL CHILD BEHAV C; Achenbach T.M., 1991, MANUAL TEACHERS REPO; American Psychiatric Association, 1987, DIAGN STAT MAN MENT; ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; ASARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; Barry CT, 1996, CHILD NEUROPSYCHOL, V2, P213, DOI 10.1080/09297049608402254; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; DISCALA C, 1991, ARCH PHYS MED REHAB, V72, P662; EPSTEIN NB, 1981, HDB FAMILY THERAPY, P444; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; Fletcher JM, 1996, J CHILD NEUROL, V11, P283, DOI 10.1177/088307389601100404; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; KNIGHTS R M, 1991, Brain Injury, V5, P339, DOI 10.3109/02699059109008107; LECKMAN JF, 1982, ARCH GEN PSYCHIAT, V39, P879; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; Max JE, 1998, J AM ACAD CHILD PSY, V37, P83, DOI 10.1097/00004583-199801000-00021; Max JE, 1998, J AM ACAD CHILD PSY, V37, P297, DOI 10.1097/00004583-199803000-00015; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; MAX JE, 1992, RULES BEST ESTIMATE; MAX JE, 1997, J AM ACAD CHILD ADOL, V36, P96; MILLER IW, 1994, FAM PROCESS, V33, P53, DOI 10.1111/j.1545-5300.1994.00053.x; ORVASCHEL H, 1982, J AM ACAD CHILD PSY, V21, P392, DOI 10.1016/S0002-7138(09)60944-4; PAPERO PH, 1993, NEUROPSYCHOL REHABIL, V3, P321, DOI 10.1080/09602019308401445; PERROTT SB, 1991, DEV NEUROPSYCHOL, V7, P69, DOI 10.1080/87565649109540477; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; SAMEROFF AJ, 1975, MERRILL PALMER QUART, V21, P267; Sparrow S., 1984, VINELAND ADAPTIVE BE; Taylor H.G., 1995, TRAUMATIC HEAD INJUR, P188; TEASDALE G, 1974, LANCET, V2, P81; Wechsler D., 1974, MANUAL WECHSLER INTE; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617	34	41	41	0	7	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	1998	79	8					893	899		10.1016/S0003-9993(98)90084-3			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	108MJ	WOS:000075269800003	9710159				2021-06-18	
J	Max, JE; Castillo, CS; Bokura, H; Robin, DA; Lindgren, SD; Smith, WL; Sato, Y; Mattheis, PJ				Max, JE; Castillo, CS; Bokura, H; Robin, DA; Lindgren, SD; Smith, WL; Sato, Y; Mattheis, PJ			Oppositional defiant disorder symptomatology after traumatic brain injury: A prospective study	JOURNAL OF NERVOUS AND MENTAL DISEASE			English	Article							CHILDREN; RELIABILITY; SCALE	Our goal was to prospectively study the course of oppositional defiant disorder (ODD) symptomatology in children and adolescents in the first 2 years after traumatic brain injury (TBI). Fifty children aged 6 to 14, hospitalized after TBI, were assessed soon after TBI regarding injury severity; preinjury psychiatric, socioeconomic, family functioning, and family psychiatric history status; and neuroimaging was analyzed. ODD symptomatology in the first year after TBI was related to preinjury family function, social class, and preinjury ODD symptomatology. Increased severity of TBI predicted ODD symptomatology 2 years after injury. Change (from before TBI) in ODD symptomatology at 6, 12, and 24 months after TBI was influenced by socioeconomic status. Only at 2 years after injury was severity of injury a predictor of change in ODD symptomatology. The influence of psychosocial factors appears greater than severity of injury in accounting for ODD symptomatology and change in such symptomatology in the first but not the second year after TBI in children and adolescents. This appears related to persistence of new ODD symptomatology after more serious TBL.	Univ Iowa, Dept Psychiat, Iowa City, IA 52242 USA; Cedar Ctr, Cedar Rapids, IA USA; Yasugi Daiichi Hosp, Shimane, Japan; Univ Iowa, Dept Speech Pathol & Audiol, Iowa City, IA 52242 USA; Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA; Univ Iowa, Dept Radiol, Iowa City, IA 52242 USA; Univ Montana, Missoula, MT 59812 USA	Max, JE (corresponding author), Univ Iowa Hosp & Clin, Dept Psychiat, 1876 JPP, Iowa City, IA 52242 USA.		Robin, Donald/F-2109-2010	Sato, Yutaka/0000-0002-5245-232X	NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH31593, MHCRC43271, MH40856] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [P50MH043271, R01MH031593, P30MH043271, R01MH040856, R37MH031593] Funding Source: NIH RePORTER		ANDREASEN NC, 1977, ARCH GEN PSYCHIAT, V34, P1229; BERRYHILL P, 1995, NEUROSURGERY, V37, P392, DOI 10.1227/00006123-199509000-00004; BLACK P, 1971, HEAD INJURIES, P131; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; CHAMBERS WJ, 1985, ARCH GEN PSYCHIAT, V42, P696; EARLS F, 1994, CHILD ADOLESCENT PSY, P308; GOODMAN R, 1994, CHILD ADOLESCENT PSY, P172; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; KRAUS JF, 1987, PEDIATRICS, V79, P501; LEMKUHL G, 1990, BRAIN BEHAV CHILD PS, P267; Lindgren S.D., 1987, ADV BEHAVIORAL ASSES, V3, P57; Max JE, 1997, BRAIN INJURY, V11, P699; Max JE, 1997, J AM ACAD CHILD PSY, V36, P404, DOI 10.1097/00004583-199703000-00020; Max JE, 1998, J AM ACAD CHILD PSY, V37, P297, DOI 10.1097/00004583-199803000-00015; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 1997, J AM ACAD CHILD PSY, V36, P94, DOI 10.1097/00004583-199701000-00022; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1595, DOI 10.1016/S0890-8567(09)66570-9; Max JE, 1998, BRAIN INJURY, V12, P41; MILLER IW, 1994, FAM PROCESS, V33, P53, DOI 10.1111/j.1545-5300.1994.00053.x; ORVASCHEL H, 1982, J AM ACAD CHILD PSY, V21, P392, DOI 10.1016/S0002-7138(09)60944-4; TEASDALE G, 1974, LANCET, V2, P81	21	41	41	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	0022-3018			J NERV MENT DIS	J. Nerv. Ment. Dis.	JUN	1998	186	6					325	332		10.1097/00005053-199806000-00001			8	Clinical Neurology; Psychiatry	Neurosciences & Neurology; Psychiatry	ZV640	WOS:000074326100001	9653415				2021-06-18	
J	Max, JE; Robin, DA; Lindgren, SD; Smith, WL; Sato, Y; Mattheis, PJ; Stierwalt, JAG; Castillo, CS				Max, JE; Robin, DA; Lindgren, SD; Smith, WL; Sato, Y; Mattheis, PJ; Stierwalt, JAG; Castillo, CS			Traumatic brain injury in children and adolescents: Psychiatric disorders at one year	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							HEAD-INJURY; RELIABILITY; DEPRESSION	Factors predictive of psychiatric outcome in the second 6 months following traumatic brain injury (TBI) in 43 children and adolescents were assessed prospectively. The outcome measure was the presence of a psychiatric disorder not present before the injury ("novel"). Out of six models tested, four were predictive of novel psychiatric disorder: preinjury family function, family psychiatric history, socioeconomic class/intellectual function, and behavior/adaptive function. Post hoc analyses suggested that preinjury family functioning measured by a structured interview was a significant predictive variable. Severity of injury, when reclassified as severe versus mild/moderate TBI, significantly predicted novel psychiatric disorders. These data suggest that some children, identifiable through clinical assessment, are at increased risk for psychiatric disorders following TBI.	Univ Iowa, Dept Psychiat, Iowa City, IA 52242 USA; Univ Iowa, Dept Speech Pathol & Audiol, Iowa City, IA 52242 USA; Univ Iowa, Dept Radiol, Iowa City, IA 52242 USA	Max, JE (corresponding author), Univ Iowa Hosp & Clin, Dept Psychiat, 1876 JPP, Iowa City, IA 52242 USA.		Robin, Donald/F-2109-2010	Sato, Yutaka/0000-0002-5245-232X			ANDREASEN NC, 1977, ARCH GEN PSYCHIAT, V34, P1229; Black P, 1981, BRAIN DYSFUNCTION CH, P171; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; CHAMBERS WJ, 1985, ARCH GEN PSYCHIAT, V42, P696; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; Garmezy N., 1994, CHILD ADOLESCENT PSY, P191; HIERONYMUS AN, 1991, TESTS BASIC SKILLS F; HOLLINGSHEAD AB, 1975, 4 FATOR INDEX SOCIAL; KRAUS JF, 1987, PEDIATRICS, V79, P501; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; Lindgren S.D., 1987, ADV BEHAVIORAL ASSES, V3, P57; MARSHALL LD, 1991, J NEUROSURG, V75, P514; Max JE, 1998, J AM ACAD CHILD PSY, V37, P297, DOI 10.1097/00004583-199803000-00015; Max JE, 1997, J NERV MENT DIS, V185, P394, DOI 10.1097/00005053-199706000-00006; MILLER IW, 1994, FAM PROCESS, V33, P53, DOI 10.1111/j.1545-5300.1994.00053.x; ORVASCHEL H, 1982, J AM ACAD CHILD PSY, V21, P392, DOI 10.1016/S0002-7138(09)60944-4; Sparrow S., 1984, VINELAND ADAPTIVE BE; *SPSS INC, 1993, SPSS WIND PROF STAT; TEASDALE G, 1974, LANCET, V2, P281	20	41	41	0	2	AMER PSYCHIATRIC ASSOCIATION	WASHINGTON	1400 K ST NW, WASHINGTON, DC 20005 USA	0895-0172			J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	SUM	1998	10	3					290	297		10.1176/jnp.10.3.290			8	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	106GJ	WOS:000075121300004	9706536				2021-06-18	
J	van der Sluis, CK; Eisma, WH; Groothoff, JW; ten Duis, HJ				van der Sluis, CK; Eisma, WH; Groothoff, JW; ten Duis, HJ			Long-term physical, psychological and social consequences of severe injuries	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article							TRAUMATIC BRAIN INJURY; HEAD-INJURY; FOLLOW-UP; RETURN; IMPAIRMENT; WORK; RECOVERY; SCALES; CARE	This 6 year follow-up study was designed to evaluate the long-term physical, psychological and social outcomes of severely injured patients (Injury Severity Score of greater than or equal to 16). Patients were treated at the University Hospital Groningen, the Netherlands, between January 1989 and December 1989. Outcomes were assessed using a postal questionnaire. After injury, the 55 respondents had predominantly complaints of the extremities, the spine and the head. Psychological complaints were present in 84 per cent of patients and mainly concerned Jr?fatigue, slowness and memory impairments. Despite these physical and psychological complaints, 74 per cent of patients were able to return to work and the majory succeeded in complying with job requirements. Injuries of the extremities and the spine were risk factors Jot failing to return to work. Social consequences were also reflected in broken marriages (6/22) and changes of leisure activities (45 per cent). Oil the basis of the impairments and disabilities revealed, we conclude that further improvement of the long-tern? outcomes of severely injured patients may be achieved by advancements in the treatment of injuries to the head, spine oi extremities, comprehensive psychological support and vocational rehabilitation. (C) 1998 Elsevier Science Ltd. All rights reserved.	Univ Groningen Hosp, Dept Rehabil, NL-9700 RB Groningen, Netherlands	van der Sluis, CK (corresponding author), Univ Groningen Hosp, Dept Rehabil, POB 30001, NL-9700 RB Groningen, Netherlands.						*AM ASS AUT MED, 1985, ABBR INJ SCAL 1985 R; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BULL JP, 1985, ACCIDENT ANAL PREV, V17, P387, DOI 10.1016/0001-4575(85)90093-4; CORNES P, 1992, INJURY, V23, P256, DOI 10.1016/S0020-1383(05)80011-7; DOWNIE WW, 1978, ANN RHEUM DIS, V37, P378, DOI 10.1136/ard.37.4.378; FRUTIGER A, 1991, J TRAUMA, V31, P1216, DOI 10.1097/00005373-199109000-00004; GORIS RJA, 1983, WORLD J SURG, V7, P12, DOI 10.1007/BF01655907; HOLBROOK TL, 1994, J TRAUMA, V36, P74, DOI 10.1097/00005373-199401000-00011; KIVIOJA AH, 1990, J TRAUMA, V30, P480, DOI 10.1097/00005373-199030040-00020; LARSSON TJ, 1995, SCAND J SOC MED, V23, P121, DOI 10.1177/140349489502300207; LAUWERS LF, 1986, INTENS CARE MED, V12, P296; LYLE DM, 1991, INT DISABILITY STUDI, V12, P113; MACKENZIE EJ, 1993, J TRAUMA, V34, P528, DOI 10.1097/00005373-199304000-00009; MACKENZIE EJ, 1987, AM J PUBLIC HEALTH, V77, P329, DOI 10.2105/AJPH.77.3.329; MORRIS JA, 1991, J TRAUMA, V31, P827, DOI 10.1097/00005373-199106000-00014; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; RHODES M, 1988, J TRAUMA, V28, P931, DOI 10.1097/00005373-198807000-00005; RIIPINEN M, 1994, SCAND J REHABIL MED, V26, P103; SCOTT J, 1979, ANN RHEUM DIS, V38, P560, DOI 10.1136/ard.38.6.560; SLUIS CK, 1995, J TRAUMA INJURY INFE, V38, P681; *STAT NETH, 1995, VAD HLTH STAT NETH 1; TATE DG, 1992, AM J PHYS MED REHAB, V71, P92, DOI 10.1097/00002060-199204000-00006; World Health Organization, 1980, INT CLASS IMP DIS HA	26	41	41	0	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383			INJURY	Injury-Int. J. Care Inj.	MAY	1998	29	4					281	285		10.1016/S0020-1383(97)00199-X			5	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	ZW532	WOS:000074420400007	9743748	Green Published			2021-06-18	
J	Drummond, JC; Patel, PM; Cole, DJ; Kelly, PJ				Drummond, JC; Patel, PM; Cole, DJ; Kelly, PJ			The Effect of the reduction of colloid oncotic pressure, with and without reduction of osmolality, on post-traumatic cerebral edema	ANESTHESIOLOGY			English	Article; Proceedings Paper	Annual Meeting of the American-Society-of-Anesthesiologists	OCT 17-25, 1996	NEW ORLEANS, LOUISIANA	Amer Soc Anesthesiologists		cerebral edema; fluid percussion injury; fluid resuscitation; head injury; osmolality; trauma	BRAIN-BARRIER PERMEABILITY; PLASMA OSMOLALITY; CRYOGENIC INJURY; PENTASTARCH; ISCHEMIA; RESUSCITATION; HEMODILUTION; REPERFUSION; SALINE; RATS	Background: It has been asserted that reduction of colloid oncotic pressure (COP) can aggravate traumatic brain edema. To explore this issue, the authors measured the effect of COP reduction, with and without a simultaneous decrease in osmolality, on the development of brain edema after fluid percussion injury (FPI). Methods: Isoflurane-anesthetized Wistar rats received a 2.7-atm right parasagittal FPI followed by isovolemic exchange with (1) normal saline (NS); (2) half-normal saline (0.5 NS); (3) whole blood (WB); or (4) hetastarch (Hespan, Dupont). Shed blood (16 mi) was replaced with donor erythrocytes suspended in the study fluid. The WB group received heparinized fresh donor WB. Central venous pressure was maintained with additional study fluid as required. The specific gravity (SG) of the cortex and subcortex near the impact site was determined 4.5 h after FPI. The water content of the hemispheres was also determined using the wet-dry method. To define the status of the blood-brain barrier in the non-FPI hemisphere, two additional groups (FPI, non-FPI) were studied. Both groups received 30 mg/kg Evans' blue and NS at 4 ml/kg(-1)/h(-1). Four hours after FPI, the concentration of Evans' blue in the hemispheres was determined. Results: After exchange, COP (mmHg +/- SD) decreased in the NS (9.6 +/- 2.1) and 0.5 NS (8.5 +/- 0.5) groups and was unchanged in the WB (16.7 +/- 3.3) and hetastarch (18.9 +/- 1.1) groups. Osmolality was unchanged in the WB group (295 +/- 5 mOsm/kg), increased in the NS (304 +/- 3 mOsm/kg) and hetastarch (306 +/- 2 mOsm/kg) groups, and was decreased in the 0.5 NS group (261 +/- 6 mOsm/kg). The Evans' blue data indicated that FPI resulted in blood-brain barrier damage in both hemispheres. In all four exchange groups, the SG of both cortical and subcortical tissue was less (indicating greater water content) in the impact hemisphere than in the nonimpact hemisphere. The SG was less in both hemispheres, although it was less in both hemispheres in the NS and 0.5 NS groups than in the WB and hetastarch groups. The lowest SG values were observed in the 0.5 NS group. The wet-dry water content determinations yielded a similar pattern of edema formation. Conclusions: These data, while confirming the important edematogenic effect of decreased osmolality, indicate that COP reduction per se can also aggravate brain edema after a mild to moderate mechanical head injury.	Univ Calif San Diego, Dept Anesthesia, San Diego, CA 92103 USA; Vet Affairs Med Ctr, San Diego, CA 92161 USA; Loma Linda Univ, Sch Med, Dept Anesthesiol, Loma Linda, CA USA	Drummond, JC (corresponding author), Univ Calif San Diego, Med Ctr, Dept Anesthesiol, 200 W Arbor Dr, San Diego, CA 92103 USA.				NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R29-GMS2098-01A1] Funding Source: Medline		COLE DJ, 1990, CAN J NEUROL SCI, V17, P372, DOI 10.1017/S0317167100030900; GO KG, 1972, J NEUROL SCI, V16, P209, DOI 10.1016/0022-510X(72)90090-1; GOULIN GD, 1994, ANESTH ANALG, V79, P1036; KAIEDA R, 1989, ANESTHESIOLOGY, V71, P554, DOI 10.1097/00000542-198910000-00013; KAIEDA R, 1989, NEUROSURGERY, V24, P671, DOI 10.1227/00006123-198905000-00003; KOROSUE K, 1990, J NEUROSURG, V73, P576, DOI 10.3171/jns.1990.73.4.0576; MARMAROU A, 1982, J NEUROSURG, V56, P246, DOI 10.3171/jns.1982.56.2.0246; NAGY KK, 1993, CIRC SHOCK, V40, P289; PROUGH DS, 1994, ANESTH ANALG, V79, P1034; RACKOW EC, 1977, CHEST, V72, P709, DOI 10.1378/chest.72.6.709; SCHELL RM, 1992, ANESTHESIOLOGY, V77, P86, DOI 10.1097/00000542-199207000-00013; SHAPIRA Y, 1995, J NEUROSURG ANESTH, V7, P17, DOI 10.1097/00008506-199501000-00004; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; TRANMER BI, 1989, NEUROSURGERY, V25, P173, DOI 10.1227/00006123-198908000-00004; VIRGILIO RW, 1979, SURGERY, V85, P129; Weed LH, 1919, AM J PHYSIOL, V48, P512; ZIKRIA BA, 1989, SURGERY, V105, P625; ZORNOW MH, 1988, ANESTHESIOLOGY, V69, P180, DOI 10.1097/00000542-198808000-00005; ZORNOW MH, 1987, ANESTHESIOLOGY, V67, P936, DOI 10.1097/00000542-198712000-00010	19	41	43	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	0003-3022			ANESTHESIOLOGY	Anesthesiology	APR	1998	88	4					993	1002		10.1097/00000542-199804000-00020			10	Anesthesiology	Anesthesiology	ZG645	WOS:000073024700020	9579509				2021-06-18	
J	Aloe, L; Fiore, M				Aloe, L; Fiore, M			TNF-alpha expressed in the brain of transgenic mice lowers central tyroxine hydroxylase immunoreactivity and alters grooming behavior	NEUROSCIENCE LETTERS			English	Article						tumor necrosis factor-alpha; transgenic mice; behavior; grooming; tyroxine hydroxylase; nerve growth factor; nerve growth factor-antibody	NERVE GROWTH-FACTOR; TUMOR-NECROSIS-FACTOR; RATS	Tumor necrosis factor-alpha (TNF-alpha) is a cytokine involved in a wide range of biological effects both in physiological and non-physiological conditions. It is also produced in the central nervous system (CNS) where it has been implicated in reparative processes after traumatic injuries and in CNS demyelination, neurodegeneration and inflammation. Using transgenic mice (Tg-m) expressing TNF-alpha specifically in the CNS, we showed that the overexpression of this cytokine reduced tyroxine hydroxilase immunoreactivity (TH-ir) in the caudate-putamen and in the dorsomedial hypothalamic areas and impaired grooming behavior. We also showed that this behavior is increased following anti-nerve growth factor injection. These findings support the hypothesis, proposed by others, that TNF-alpha is involved in the degenerative processes which occur in Parkinson's disease. (C) 1997 Elsevier Science Ireland Ltd.	CNR, Inst Neurobiol, I-00137 Rome, Italy	Aloe, L (corresponding author), CNR, Inst Neurobiol, Viale Marx 15, I-00137 Rome, Italy.		Fiore, Marco/B-6112-2015	Fiore, Marco/0000-0001-6806-9715			AGID Y, 1993, ADV NEUROL, V60, P148; Alleva E, 1993, Rev Neurosci, V4, P41; Aloe L, 1997, NEUROPSYCHOBIOLOGY, V36, P65, DOI 10.1159/000119364; ALOE L, 1994, AUTOIMMUNITY, V19, P141, DOI 10.3109/08916939409009542; BOCCHINI G, 1966, P NATL ACAD SCI USA, V64, P787; Date I, 1996, J NEUROSURG, V84, P1006, DOI 10.3171/jns.1996.84.6.1006; FLORE M, 1996, BRAIN BEHAV IMMUNOL, V10, P126; Franklin K. B. J., 1997, MOUSE BRAIN STEREOTA; Hattori A, 1996, FEBS LETT, V379, P157, DOI 10.1016/0014-5793(95)01502-7; Labandeira-Garcia JL, 1996, EXP BRAIN RES, V108, P69; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; MERRILL JE, 1992, DEV NEUROSCI-BASEL, V14, P1, DOI 10.1159/000111642; MOGI M, 1994, NEUROSCI LETT, V165, P208, DOI 10.1016/0304-3940(94)90746-3; OLSON L, 1997, TRENDS NEUROSCI, V20, P227; PROBERT L, 1995, P NATL ACAD SCI USA, V92, P11294, DOI 10.1073/pnas.92.24.11294; SPRUIJT BM, 1992, PHYSIOL REV, V72, P825; STOECKEL K, 1976, J NEUROCHEM, V26, P1207, DOI 10.1111/j.1471-4159.1976.tb07008.x; TORRE E, 1986, NEUROCHEM INT, V9, P85, DOI 10.1016/0197-0186(86)90035-5; TRACEY KJ, 1994, ANNU REV MED, V45, P491, DOI 10.1146/annurev.med.45.1.491; Tseng JL, 1997, J NEUROSCI, V17, P325; Wang CX, 1996, J NEUROIMMUNOL, V69, P151	21	41	43	0	1	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	NOV 28	1997	238	1-2					65	68		10.1016/S0304-3940(97)00850-1			4	Neurosciences	Neurosciences & Neurology	YP383	WOS:000071271400017	9464656				2021-06-18	
J	Hartl, R; Medary, MB; Ruge, M; Arfors, KE; Ghajar, J				Hartl, R; Medary, MB; Ruge, M; Arfors, KE; Ghajar, J			Early white blood cell dynamics after traumatic brain injury: Effects on the cerebral microcirculation	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						blood-brain barrier; cranial window inflammation; leukocytes; microcirculation; traumatic brain injury; videomicroscopy	ISCHEMIA-REPERFUSION INJURY; FLUID-PERCUSSION MODEL; TUMOR-NECROSIS-FACTOR; SEVERE HEAD-INJURY; RAT-BRAIN; NEUTROPHIL ACCUMULATION; INTRACRANIAL-PRESSURE; LEUKOCYTE ADHESION; ENDOTHELIAL DYSFUNCTION; TIME-COURSE	Increasing clinical and experimental evidence suggests that traumatic brain injury (TBI) elicits an acute inflammatory response. In the present study we investigated whether white blood cells (WBC) are activated in the cerebral microcirculation early after TBI and whether WBC accumulation affects the posttraumatic cerebrovascular response. Twenty-four anesthetized rabbits had chronic cranial windows implanted 3 weeks before experimentation. Animals were divided into four experimental groups and were studied for 7 hours (groups I, IIa, and III) or 2 hours (group IIb). Intravital fluorescence videomicroscopy was used to visualize WBC (rhodamine 6G, intravenously), pial vessel diameters, and blood-brain barrier (BBB) integrity (Na+-fluorescein) at 6 hours (groups I, IIa, and III) or 1 hour (group IIb) after TBI. Group I (n = 5) consisted of sham-operated animals. Groups IIa (n = 7) and IIb (n = 5) received fluid-percussion injury at 1 hour. Group III (n = 7) received fluid-percussion injury and 1 mg/kg anti-adhesion monoclonal antibody (MoAb) ''IB4'' 5 minutes before injury. Venular WBC sticking, intracranial pressure (ICP), and arterial vessel diameters increased significantly for 6 hours after trauma. IB4 reduced WBC margination and prevented vasodilation. Intracranial pressure was not reduced by treatment with IB4. Blood-brain barrier damage occurred at 1 hour but not at 6 hours after TBI and was independent of WBC activation. This first report using intravital videomicroscopy to study the inflammatory response after TBI reveals upregulated interaction between WBC and cerebral endothelium that can be manipulated pharmacologically. White blood cell activation is associated with pial arteriolar vasodilation. White blood cells do not induce BBB breakdown less than 6 hours after TBI and do not contribute to posttraumatic ICP elevation. The role of WBC more than 6 hours after TBI should be investigated further.	CORNELL UNIV,COLL MED,NEW YORK,NY	Hartl, R (corresponding author), AITKEN NEUROSCI CTR,523 E 72ND ST,8TH FLOOR,NEW YORK,NY 10021, USA.						AKOPOV SE, 1994, STROKE, V25, P2246, DOI 10.1161/01.STR.25.11.2246; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Bednar MM, 1996, NEUROL RES, V18, P171; BIAGAS KV, 1992, J NEUROTRAUM, V9, P363, DOI 10.1089/neu.1992.9.363; CARDEN DL, 1990, CIRC RES, V66, P1436, DOI 10.1161/01.RES.66.5.1436; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; Clark RSB, 1996, J NEUROTRAUM, V13, P333, DOI 10.1089/neu.1996.13.333; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; CORVIN S, 1990, ACT NEUR S, V51, P55; DeKosky ST, 1996, ANN NEUROL, V39, P123, DOI 10.1002/ana.410390118; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; DIRNAGL U, 1994, STROKE, V25, P1028, DOI 10.1161/01.STR.25.5.1028; DIXON C E, 1988, Journal of Neurotrauma, V5, P91, DOI 10.1089/neu.1988.5.91; ENTERS EK, 1992, BRAIN RES, V576, P271; Fan Lei, 1995, Molecular Brain Research, V30, P125, DOI 10.1016/0169-328X(94)00287-O; GIDDAY J, 1995, J CEREB BLOOD FLO S1, V15, pS135; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; Hartl R, 1996, J CEREBR BLOOD F MET, V16, P1108; HELMKE B, 1996, INT J MICROCIRC, V10, P164; HORNER HC, 1992, SOC NEUR ABSTR, V8, P173; HOUSE SD, 1987, MICROVASC RES, V34, P363, DOI 10.1016/0026-2862(87)90068-9; KACZOROWSKI SL, 1995, J CEREBR BLOOD F MET, V15, P860, DOI 10.1038/jcbfm.1995.107; KESKIL S, 1994, ACTA NEUROCHIR, V131, P211, DOI 10.1007/BF01808615; KOCHANEK PM, 1992, STROKE, V23, P1367, DOI 10.1161/01.STR.23.9.1367; KONTOS HA, 1985, ANN BIOMED ENG, V13, P329, DOI 10.1007/BF02584251; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; KUBES P, 1990, AM J PHYSIOL, V259, pG859; KUBES P, 1992, CELLULAR MOL MECH IN; Kunkel EJ, 1996, J EXP MED, V183, P57, DOI 10.1084/jem.183.1.57; KUROSE I, 1994, CIRC RES, V74, P336, DOI 10.1161/01.RES.74.2.336; LEVASSEUR JE, 1975, STROKE, V6, P308, DOI 10.1161/01.STR.6.3.308; Lindauer U, 1996, J CEREBR BLOOD F MET, V16, P1143, DOI 10.1097/00004647-199611000-00008; LUNDBERG C, 1990, BLOOD, V76, P1240; MATSUO Y, 1995, J CEREBR BLOOD F MET, V15, P941, DOI 10.1038/jcbfm.1995.119; MATSUO Y, 1994, STROKE, V25, P1469, DOI 10.1161/01.STR.25.7.1469; MCCLAIN C, 1991, J LAB CLIN MED, V118, P225; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MEDARY M, 1997, UNPUB J TRAUMA; MENGER MD, 1992, AM J PHYSIOL, V263, pH1892; MILLER JD, 1992, BRIT J SURG, V79, P60, DOI 10.1002/bjs.1800790122; NOLTE D, 1994, AM J PHYSIOL-HEART C, V267, pH1320; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; PFENNINGER EG, 1989, J NEUROSURG, V70, P774, DOI 10.3171/jns.1989.70.5.0774; RUBIN BB, 1992, SURGERY, V112, P263; Scalia R, 1996, SHOCK, V6, P177, DOI 10.1097/00024382-199609000-00004; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; SCHURER L, 1990, ACT NEUR S, V51, P49; SHIGA Y, 1991, NEUROSCI LETT, V125, P110, DOI 10.1016/0304-3940(91)90003-C; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; SIEMIONOW M, 1995, J RECONSTR MICROSURG, V11, P7, DOI 10.1055/s-2007-1006504; Soares HD, 1995, J NEUROSCI, V15, P8223; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; TANNO H, 1992, J NEUROTRAUM, V9, P335, DOI 10.1089/neu.1992.9.335; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; THIBAULT LE, 1992, J NEUROTRAUM, V9, P311, DOI 10.1089/neu.1992.9.311; UHL MW, 1994, J NEUROTRAUM, V11, P303, DOI 10.1089/neu.1994.11.303; UNTERBERG A, 1993, NEUROSURGERY, V32, P17, DOI 10.1227/00006123-199301000-00003; UNTERBERG A, 1988, ACTA NEUROPATHOL, P238; VANDENBRINK WA, 1994, ACT NEUR S, V60, P456; VILLRINGER A, 1994, CIRC RES, V75, P55, DOI 10.1161/01.RES.75.1.55; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; WEI EP, 1981, CIRC RES, V48, P95, DOI 10.1161/01.RES.48.1.95; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WELBOURN CRB, 1991, BRIT J SURG, V78, P651, DOI 10.1002/bjs.1800780607; WHALEN MJ, 1997, 10 INT S INTR PRESS; WILSON JT, 1995, J TRAUMA, V39, P473; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; YAN HQ, 1992, EUR J IMMUNOL, V22, P2963, DOI 10.1002/eji.1830221131; ZHUANG J, 1993, J TRAUMA, V35, P415, DOI 10.1097/00005373-199309000-00014	73	41	42	0	4	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	NOV	1997	17	11					1210	1220					11	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	YH666	WOS:A1997YH66600010	9390653				2021-06-18	
J	Tang, YP; Noda, Y; Hasegawa, T; Nabeshima, T				Tang, YP; Noda, Y; Hasegawa, T; Nabeshima, T			A concussive-like brain injury model in mice .2. Selective neuronal loss in the cortex and hippocampus	JOURNAL OF NEUROTRAUMA			English	Article						concussive brain injury (CBI); cortex; hippocampus; mouse; neuronal cell loss; traumatic brain injury (TBI); weight-drop impact	FLUID-PERCUSSION MODEL; MILD HEAD-INJURY; CORTICAL IMPACT; RATS; ACID; DEATH; GLUTAMATE; PATHOPHYSIOLOGY; VULNERABILITY; ANTAGONISTS	A novel concussive-like brain injury (CLBI) model characterized by transient neurobehavioral depression, short duration of brain edema, and long-lasting memory deficits has been reported in our companion paper. This was achieved by dropping a 21-g weight from a height of 25 cm onto the head of a mouse. In the present study, we examined the histopathological changes in this model. Male ddY mice were subjected to either the trauma or sham injury. Gross pathological examination of the brain 1 h posttrauma did not demonstrate subdural, subarachnoid, intraventricular, periventricular, and intraparenchymatous hemorrhage, focal lesions or contusions. Microscopic examination 24 h posttrauma with Nissl staining (cresyl violet), however, revealed a selective bilateral neuronal cell loss in the cerebral cortex and hippocampus but not in the regions of the thalamus, cerebellum, and brain stem. The characteristics of neuronal cell loss in the cortex suggested that this pathology was related in part, to the head impact dynamics, since the cell loss was noted in the central portion of the supraventricular cerebral cortex (p < 0.001), the site of the weight impact, gradually decreasing peripheral to this site, and disappearing in the areas remote from this locus. In contrast, neuronal cell loss seen in the hippocampus did not suggest that this pathology was directly associated with the impact site. Neuronal cell loss was concentrated in the pyramidal cell layer of CA2 (p < 0.01) and CA3 (p < 0.01), and a lesser degree was noted in the subfields of CA3c (p < 0.05) and the hilar region (p < 0.05) but not in the subfields of CA1 and the dentate gyrus layers. The present study characterized the histopathological change seen in the CLBI model, demonstrating the selective neuronal cell loss following weight-drop concussion in mice.	NAGOYA UNIV,SCH MED,DEPT NEUROPHARMACOL,SHOWA KU,NAGOYA,AICHI 466,JAPAN; NAGOYA UNIV,SCH MED,HOSP PHARM,SHOWA KU,NAGOYA,AICHI 466,JAPAN			Tang, Ya-Ping/A-1035-2011				AMARAL DG, 1989, NEUROSCIENCE, V31, P571, DOI 10.1016/0306-4522(89)90424-7; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Delahunty TM, 1995, J NEUROTRAUM, V12, P1045, DOI 10.1089/neu.1995.12.1045; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FADAN AI, 1989, SCIENCE, V244, P798; FAROOQUI AA, 1991, BRAIN RES REV, V16, P171, DOI 10.1016/0165-0173(91)90004-R; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Gennarelli T.A., 1985, CENTRAL NERVOUS SYST, P391; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; HALL ED, 1985, J NEUROSURG, V62, P882, DOI 10.3171/jns.1985.62.6.0882; Hayes R L, 1987, Brain Inj, V1, P93, DOI 10.3109/02699058709034449; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; KATAYAMA Y, 1995, BRAIN PATHOL, V5, P427, DOI 10.1111/j.1750-3639.1995.tb00621.x; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KIRINO T, 1982, BRAIN RES, V239, P57, DOI 10.1016/0006-8993(82)90833-2; KIRINO T, 1984, ACTA NEUROPATHOL, V62, P201, DOI 10.1007/BF00691853; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; LANGFITT TW, 1982, J NEUROSURG, V56, P19, DOI 10.3171/jns.1982.56.1.0019; LEVIN HS, 1990, J CLIN EXP NEUROPSYC, V12, P129, DOI 10.1080/01688639008400960; LIDVALL HF, 1975, LANCET, V1, P100; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MANAKA S, 1978, NEUROSCI LETT, V8, P255, DOI 10.1016/0304-3940(78)90131-3; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MELDRUM B, 1985, TRENDS NEUROSCI, V8, P47, DOI 10.1016/0166-2236(85)90024-4; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; MODY I, 1994, HIPPOCAMPUS, V4, P275, DOI 10.1002/hipo.450040309; MONAGHAN DT, 1986, P NATL ACAD SCI USA, V83, P7532, DOI 10.1073/pnas.83.19.7532; NABESHIMA T, 1991, J PHARMACOL EXP THER, V256, P378; Nelson S, 1966, HEAD INJURY, P444; NILSSON B, 1977, J NEUROSURG, V47, P241, DOI 10.3171/jns.1977.47.2.0241; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; NIQUET J, 1994, J NEUROCYTOL, V23, P641, DOI 10.1007/BF01191558; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; RIMEL RW, 1981, NEUROSURGERY, V9, P211; RINK A, 1995, AM J PATHOL, V147, P1575; ROTHMAN S, 1984, J NEUROSCI, V4, P1884; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; SHIMA K, 1991, J NEUROSURG, V74, P270, DOI 10.3171/jns.1991.74.2.0270; SLOVITER RS, 1987, SCIENCE, V235, P73, DOI 10.1126/science.2879352; SMITH DH, 1993, J NEUROSCI, V13, P5383; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; STORMMATHISEN J, 1984, NEUROSCIENCE, V111, P79; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; SYMONDS C, 1962, LANCET, V1, P1; TECOMA ES, 1989, NEURON, V2, P1541, DOI 10.1016/0896-6273(89)90042-1; WALKER AE, 1994, J NEUROSURG, V81, P493, DOI 10.3171/jns.1994.81.3.0493; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; WILLIAMSON A, 1994, HIPPOCAMPUS, V4, P226, DOI 10.1002/hipo.450040213	55	41	47	0	9	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	NOV	1997	14	11					863	873		10.1089/neu.1997.14.863			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	YK511	WOS:A1997YK51100005	9421457				2021-06-18	
J	Masson, F; Vecsey, J; Salmi, LR; Dartigues, JF; Erny, P; Maurette, P				Masson, F; Vecsey, J; Salmi, LR; Dartigues, JF; Erny, P; Maurette, P			Disability and handicap 5 years after a head injury: A population-based study	JOURNAL OF CLINICAL EPIDEMIOLOGY			English	Article						epidemiology; head injury; long-term outcome; incidence; disability; handicap	TRAUMATIC BRAIN INJURY; IMPAIRMENT; RECOVERY; COMA; MORTALITY; RELATIVES; SEVERITY; COUNTY	A population-based cohort of 407 head trauma patients has been studied since 1986 to estimate the prevalence of long-term disabilities and handicaps by means of a structured questionnaire. Five years later, 64 patients were deceased and 36 were lost to follow-up. Prevalence of subjective and behavioral complaints was high whatever the initial head trauma severity. Lethality in severe head injuries was 56%, and half of the survivors remained disabled. In minor and moderate head injured patients, most disabilities were related to extracranial injuries. Taking all disabilities into consideration, each Bear 24 per 100,000 patients of such a population are likely to suffer from at least one long-lasting disability, including 10 per 100,000 whose disabilities are due to extracranial injuries. Head injuries induce long lasting handicap in 9 per 100,000 habitants which is severe in 2 per 100,000. These figures point to the need of reinforcing preventive actions and long-term care of these patients. (C) 1997 Elsevier Science Inc.	HOP PELLEGRIN, DEPT ANESTHESIE REANIMAT 1, F-33076 BORDEAUX, FRANCE; HOP PELLEGRIN, SERV READAPTAT FONCT, F-33076 BORDEAUX, FRANCE; UNIV BORDEAUX 2, INSERM U330, DEPT EPIDEMIOL & INFORMAT MED, F-33076 BORDEAUX, FRANCE			DARTIGUES, Jean Francois/T-4513-2019; Salmi, Louis-Rachid/T-1982-2019				ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; Annoni J M, 1992, Disabil Rehabil, V14, P23; BOHNEN N, 1994, BRAIN INJURY, V8, P701, DOI 10.3109/02699059409151024; BROOKS DN, 1984, J CLIN NEUROPSYCHOL, V6, P71, DOI 10.1080/01688638408401198; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; BROWN SJ, 1994, J NEUROPSYCH CLIN N, V6, P15; COLLE MB, 1990, MORTALITE CAUSES DEC; *COMM INJ SCAL, 1980, ABBR INJ SCAL AIS 19; Commission for Racial Equality, 1985, INJ AM CONT PUBL HLT, P1; COPE DN, 1995, BRAIN INJURY, V9, P649, DOI 10.3109/02699059509008224; DACEY R, 1991, J TRAUMA, V31, P217, DOI 10.1097/00005373-199131020-00011; FIFE D, 1986, AM J PUBLIC HEALTH, V76, P773, DOI 10.2105/AJPH.76.7.773; GENNARELLI TA, 1989, J TRAUMA, V29, P1193, DOI 10.1097/00005373-198909000-00002; HOOK O, 1988, SCAND J REHABIL MED, P65; JENNETT B, 1975, LANCET, V1, P480; JOHANSSON E, 1991, SCAND J REHABIL MED, V23, P179; KLAUBER MR, 1985, J NEUROSURG, V62, P528, DOI 10.3171/jns.1985.62.4.0528; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; MACKENZIE EJ, 1987, AM J PUBLIC HEALTH, V77, P329, DOI 10.2105/AJPH.77.3.329; MACKENZIE EJ, 1988, J TRAUMA, V28, P281, DOI 10.1097/00005373-198803000-00003; MAURETTE P, 1992, J TRAUMA, V33, P728, DOI 10.1097/00005373-199211000-00023; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; RAO N, 1990, Brain Injury, V4, P49, DOI 10.3109/02699059009026148; ROSS BL, 1994, AM J PHYS MED REHAB, V73, P341, DOI 10.1097/00002060-199409000-00007; SBORDONE RJ, 1995, BRAIN INJURY, V9, P285, DOI 10.3109/02699059509008199; SHACKFORD SR, 1993, ARCH SURG-CHICAGO, V128, P571, DOI 10.1001/archsurg.1993.01420170107016; SLEET DA, 1987, J TRAUMA, V27, P695, DOI 10.1097/00005373-198707000-00001; TATE RL, 1989, ACTA NEUROL SCAND, V79, P97, DOI 10.1111/j.1600-0404.1989.tb03719.x; TEASDALE G, 1974, LANCET, V2, P81; TIRET L, 1989, AM J PUBLIC HEALTH, V79, P316, DOI 10.2105/AJPH.79.3.316; TIRET L, 1990, INT J EPIDEMIOL, V19, P133, DOI 10.1093/ije/19.1.133; TRUELLE JL, 1992, SCAND J REHABIL MED, P115; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; VAZQUEZBARQUERO A, 1992, EUR J EPIDEMIOL, V8, P832, DOI 10.1007/BF00145328; World Health Organization, 1980, INT CLASS IMP DIS HA	38	41	41	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0895-4356	1878-5921		J CLIN EPIDEMIOL	J. Clin. Epidemiol.	MAY	1997	50	5					595	601		10.1016/S0895-4356(97)00012-7			7	Health Care Sciences & Services; Public, Environmental & Occupational Health	Health Care Sciences & Services; Public, Environmental & Occupational Health	XD004	WOS:A1997XD00400011	9180652				2021-06-18	
J	Freed, S; Hellerstein, LF				Freed, S; Hellerstein, LF			Visual electrodiagnostic findings in mild traumatic brain injury	BRAIN INJURY			English	Article							PATTERN REVERSAL; HEAD TRAUMA; WHIPLASH	Patients with traumatic brain injury (TBI) frequently exhibit varied forms of visual system dysfunction including: binocular, oculomotor, accommodative, refractive error shift, visual field loss, and visual perceptual deficits. A 5-year collaborative study between optometry and ophthalmology was initiated to follow documented mild TBI patients utilizing diagnostic methods to assess the quantity and quality of visual system deficits and recovery. A group of patients with mild TBI receiving optometric rehabilitation were compared with a group of age-matched, gender-matched, and headsize-matched TBI patients not receiving such treatment. Eighteen patients diagnosed with mild TBI underwent a treatment regimen of optometric rehabilitation (group I); 32 patients diagnosed with mild TBI did not receive optometric rehabilitation (group II). Pattern visually evoked cortical potential (VECP) testing and electroretinography (ERG) evaluation were utilized initially, repeated 6-12 months later and then 12-18 months after baseline. All TBI patients' VECP and ERG results were compared to age-matched headsize-matched controls. Once the ERG had been used to exclude retinal involvement, identification of visual pathway dysfunction was possible with the VECP. Full-field ERG results in all groups were not remarkable and not sensitive for patients with mild TBI. Initial testing results revealed that 72% of those TBI patients in group I demonstrated VECP waveform abnormalities and 81% of those patients in group II showed waveform dysfunction. In the testing performed 12-18 months later, 38% of group I TBI patients, after receiving a treatment regimen of optometric rehabilitation, showed VECP waveform abnormalities; 78% of group II TBI patients demonstrated waveform abnormalities. VECP evaluation in patients with mild TBI can provide a useful and reliable tool for objective assessment of visual system deficit and recovery. Significant differences in visual system recovery were shown when comparing group I and group II.	COLORADO EYE CTR OPHTHALMOL,PHYSIOL LAB,DENVER,CO; HOMESTEAD PK VIS CLIN PC,ENGLEWOOD,CO							Aksionoff E B, 1992, J Am Optom Assoc, V63, P554; *AM OPT ASS, 1991, DEF OPT VIS THER; BAKER RS, 1991, SURV OPHTHALMOL, V35, P245, DOI 10.1016/0039-6257(91)90046-I; BECK RW, 1985, AM ORTHOPTICS J, V35, P103; BERNE SA, J OPTOMETRY VISUAL D, V21, P13; BLUMHARDT LD, 1977, BRIT J OPHTHALMOL, V61, P454, DOI 10.1136/bjo.61.7.454; BURKE JP, 1992, GRAEF ARCH CLIN EXP, V230, P335, DOI 10.1007/BF00165941; Cohen A H, 1992, J Am Optom Assoc, V63, P530; COPENHAVER RM, 1964, INVEST OPHTH VISUAL, V3, P665; CREWS SJ, 1978, DOC OPHTHALMOL, V15, P13; FOWLER MS, 1991, BR ORTHOPTIC J, V48, P2; FRACO RF, 1989, BRIT J OPTOMETRY, V46, P40; GIANUTSOS R, 1988, ARCH PHYS MED REHAB, V69, P573; GIANUTSOS R, 1988, J VISION REHABILITAT, V2, P37; Hall A. V., 1982, CLIN APPLICATIONS EV, P1; HALLIDAY AM, 1980, EVOKED POTENTIAL, P282; HARDING GFA, 1991, PRINCIPLES PRACTICE, P35; Harrison RJ, 1987, BINOC VIS, V2, P93; Hellerstein L F, 1995, J Am Optom Assoc, V66, P634; HELLERSTEIN LF, 1994, J BEHAV OPTOMETRY, V5, P143; JEFFREYS DA, 1972, EXP BRAIN RES, V16, P1; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; KAY T, 1986, MINOR HEAD INJURY IN, P1; MARMOR MF, 1991, PRINCIPLES PRACTICE, P283; MAZOW ML, 1982, AM ORTHOPT J, V32, P31; NEETENS A, 1983, NEURO-OPHTHALMOLOGY, V3, P43, DOI 10.3109/01658108309009717; *NEUR REH ASS, 1992, DEF NEUR REH; OOSTERVELD WJ, 1991, ACTA OTO-LARYNGOL, V111, P201, DOI 10.3109/00016489109137375; PADULA WV, 1992, J OPTOM VIS DEV, V23, P4; PRATTJOHNSON JA, 1973, BRIT J OPHTHALMOL, V57, P347, DOI 10.1136/bjo.57.5.347; ROBINSON K, 1984, J NEUROL SCI, V64, P225, DOI 10.1016/0022-510X(84)90172-2; ROSENTHAL M, 1990, REHABILITATION ADULT, P351; RUBENSTEIN MP, 1980, INVESTIGATIVE OPHTHL, V19, P318; RUBENSTEIN MP, 1986, EXCERPTA MED INT C S, P464; SABETES NR, 1991, J CLIN NEUROOPHTHLAM, V11, P273; STANWORTH A, 1974, BRIT J OPHTHALMOL, V58, P266, DOI 10.1136/bjo.58.3.266; Tierney D W, 1988, J Am Optom Assoc, V59, P614; TOYANAGA N, 1986, DOC OPHTHALMOL, V63, P23; TYLER CW, 1981, VISION RES, V21, P607, DOI 10.1016/0042-6989(81)90109-7; Vogel M S, 1992, J Am Optom Assoc, V63, P542; WIESINGER H, 1962, Va Med Mon (1918), V89, P165; Zasler N., 1993, J HEAD TRAUMA REHAB, V8, P13	42	41	41	0	5	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	JAN	1997	11	1					25	36		10.1080/026990597123782			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	WB723	WOS:A1997WB72300003	9012549				2021-06-18	
J	Sosin, DM; Sacks, JJ; Webb, KW				Sosin, DM; Sacks, JJ; Webb, KW			Pediatric head injuries and deaths from bicycling in the United States	PEDIATRICS			English	Article						children; traumatic brain injury; head injury; mortality; injury; bicycles; helmets	HELMET USE; SAFETY HELMETS; CHILDREN	Objective. To estimate the potential benefit of increasing bicycle helmet use among children and adolescents in the United States. Design. All bicycle-related deaths (Multiple Cause-of-Death Public Use Data Tapes, 1989 through 1992) and bicycle-related injuries treated in sampled emergency departments (National Electronic Injury Surveillance System, 1989 through 1993) were used to calculate traumatic brain injury-associated death and head injury rates per 1000000 US residents. Preventable injuries and deaths were estimated by calculating the population-attributable risk of head injury due to nonuse of bicycle helmets. Patients. US residents aged 0 through 19 years who were injured or who died as a result of a bicycle crash. Results. An average of 247 traumatic brain injury deaths and 140000 head injuries among children and adolescents younger than 20 years were related to bicycle crashes each year in the United States. As many as 184 deaths and 116000 head injuries might have been prevented annually if these riders had worn helmets. An additional 19000 mouth and chin injuries were treated each year. The youngest age groups had the highest proportions of both head and mouth injuries. Conclusion. There continues to be a need to advocate for greater use of bicycle helmets, particularly among young children. Helmet design changes should be considered to prevent mouth injuries.		Sosin, DM (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR INJURY PREVENT & CONTROL,ATLANTA,GA 30341, USA.						*AM AC PED, 1989, TIPP INJ PREV PROGR; BUCCINI RV, 1987, AM PUBL HLTH ASS 115; *BUR CENS, 1993, CURR POP REP SER P, V25; Centers for Disease Control and Prevention, 1995, MMWR-MORBID MORTAL W, V44, P1; *CONS PROD SAF COM, 1994, NAT EL INJ SURV SYST; *CTR DIS CONTR, 1992, MMWR-MORBID MORTAL W, V41, P1; *CTR DIS CONTR PRE, 1993, MMWR-MORBID MORTAL W, V42, P359; DANNENBERG AL, 1993, PUBLIC HEALTH REP, V108, P212; DIGUISEPPI CG, 1990, AM J DIS CHILD, V144, P83, DOI 10.1001/archpedi.1990.02150250093041; FIFE D, 1983, J TRAUMA, V23, P745, DOI 10.1097/00005373-198308000-00011; Grimard G, 1995, Inj Prev, V1, P21, DOI 10.1136/ip.1.1.21; HOWLAND J, 1989, AM J DIS CHILD, V143, P741, DOI 10.1001/archpedi.1989.02150180123033; KANN L, 1995, MMWR-MORBID MORTAL W, V44, pSS1; MAIMARIS C, 1994, BRIT MED J, V308, P1537, DOI 10.1136/bmj.308.6943.1537; MCDERMOTT FT, 1993, J TRAUMA, V34, P834, DOI 10.1097/00005373-199306000-00015; NAKAYAMA DK, 1990, J TRAUMA, V30, P1390, DOI 10.1097/00005373-199011000-00012; RIVARA FP, 1994, PEDIATRICS, V93, P567; RODGERS GB, 1994, BICYCLE USE HAZARD P; SACKS JJ, 1991, JAMA-J AM MED ASSOC, V266, P3016, DOI 10.1001/jama.266.21.3016; SPENCE LJ, 1993, J PEDIATR SURG, V28, P214, DOI 10.1016/S0022-3468(05)80278-7; THOMAS S, 1994, BRIT MED J, V308, P173, DOI 10.1136/bmj.308.6922.173; THOMPSON DC, 1990, AM J PUBLIC HEALTH, V80, P1471, DOI 10.2105/AJPH.80.12.1471; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; *WHO, 1977, MAN INT CLASS DIS	24	41	42	0	2	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD, ELK GROVE VILLAGE, IL 60007-1098	0031-4005			PEDIATRICS	Pediatrics	NOV	1996	98	5					868	870					3	Pediatrics	Pediatrics	VR466	WOS:A1996VR46600002	8909479				2021-06-18	
J	Eldadah, BA; Yakovlev, AG; Faden, AI				Eldadah, BA; Yakovlev, AG; Faden, AI			A new approach for the electrophoretic detection of apoptosis	NUCLEIC ACIDS RESEARCH			English	Article							TRAUMATIC BRAIN INJURY; CEREBELLAR GRANULE NEURONS; CELL-DEATH; DNA FRAGMENTATION; RAT; ACTIVATION	Apoptotic cell death is often characterized by internucleosomal cleavage of genomic DNA, which exhibits a distinctive ladder upon electrophoresis. However, techniques used for the isolation and detection of DNA to demonstrate laddering may not be sufficiently sensitive, particularly when cleaved DNA is present at modest levels. We propose a new approach for isolating total cellular DNP, using a silica-based resin that improves the resolution of DNA laddering. In addition, we introduce a rapid DNA labeling method that can increase the sensitivity of detecting DNA laddering, Each of these methods can be used for DNA from cell cultures or tissues.	GEORGETOWN UNIV,MED CTR,DEPT NEUROL,WASHINGTON,DC 20007; GEORGETOWN UNIV,MED CTR,GEORGETOWN INST COGNIT & COMPUTAT SCI,WASHINGTON,DC 20007							Atabay C, 1996, J NEUROSCI RES, V43, P465; Beilharz Erica J., 1995, Molecular Brain Research, V29, P1, DOI 10.1016/0169-328X(94)00217-3; CLARK JM, 1988, NUCLEIC ACIDS RES, V16, P9677, DOI 10.1093/nar/16.20.9677; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; FAVARON M, 1988, P NATL ACAD SCI USA, V85, P7351, DOI 10.1073/pnas.85.19.7351; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; RINK A, 1995, AM J PATHOL, V147, P1575; ROSL F, 1992, NUCLEIC ACIDS RES, V20, P5243, DOI 10.1093/nar/20.19.5243; Sambrook J, 1989, MOL CLONING LAB MANU, VII; SCHWARTZMAN RA, 1993, ENDOCR REV, V14, P133, DOI 10.1210/er.14.2.133; SUN FY, 1995, BRAIN RES, V673, P133, DOI 10.1016/0006-8993(94)01413-C; TILLY JL, 1993, J CELL PHYSIOL, V154, P519, DOI 10.1002/jcp.1041540310; WONG P, 1994, BIOCHEM CELL BIOL, V72, P649, DOI 10.1139/o94-085; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YAKOVLEV AG, 1996, J NEUROTRAUM, V12, P767; YAN GM, 1995, J NEUROCHEM, V65, P2425	17	41	41	0	1	OXFORD UNIV PRESS UNITED KINGDOM	OXFORD	WALTON ST JOURNALS DEPT, OXFORD, ENGLAND OX2 6DP	0305-1048			NUCLEIC ACIDS RES	Nucleic Acids Res.	OCT 15	1996	24	20					4092	4093		10.1093/nar/24.20.4092			2	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	VP702	WOS:A1996VP70200031	8918817	Bronze, Green Published			2021-06-18	
J	Mateer, CA; Mapou, RL				Mateer, CA; Mapou, RL			Understanding, evaluating, and managing attention disorders following traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						attention; evaluation; neuropsychology; treatment	CLOSED-HEAD-INJURY; DEFICITS; PERFORMANCE; MARKERS; PROGRAM; DAMAGE	Disorders of attention are among the most frequently reported problems following traumatic brain injury (TBI). However, considerable disagreement exists regarding the most appropriate definitions and conceptualizations of attention. This article addresses several issues related to attentional disorders following TBI. First, we summarize the types of attentional impairments observed in TBI. Next, we describe several multicomponent models of attention. We discuss the merits and applicability of each model and suggest psychometric approaches to the assessment of attention based on these models. Finally, we summarize controversies and relevant research findings with regard to the rehabilitation of individuals with attentional disorders.	CTR NEUROREHABIL,BETHESDA,MD; GEORGETOWN UNIV,SCH MED,DEPT NEUROL PSYCHOL,WASHINGTON,DC	Mateer, CA (corresponding author), UNIV VICTORIA,DEPT PSYCHOL,POB 3050,VICTORIA,BC V8W 3P5,CANADA.		Mapou, Robert/AAC-9897-2021				AUERBACH SH, 1986, J HEAD TRAUMA REHAB, V1, P1, DOI DOI 10.1097/00001199-198609000-00004; Baribeau J., 1989, J NEUROL REHABIL, V3, P71; Ben-Yishay Y., 1987, NEUROPSYCHOLOGICAL R; BOHNEN NI, 1991, MILD HEAD INJURY POS; Brooks N., 1984, CLOSED HEAD INJURY P; BUTTERS N, 1993, NEUROPSYCHOLOGY, V7, P3; COOLEY EL, 1990, DEV NEUROPSYCHOL, V6, P239, DOI 10.1080/87565649009540465; DELAND N, 1992, BAYCR C ATT THEOR CL; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; DILLER L, 1974, REHABILITATION MONOG, V50; Ethier M, 1989, CANADIAN J REHABILIT, V2, P223; ETHIER M, 1989, CANADIAN J REHABILIT, V3, P7; FINLEY G, 1987, P AM ASSOC CANC RES, V28, P180; FORD JM, 1994, ELECTROEN CLIN NEURO, V90, P214, DOI 10.1016/0013-4694(94)90093-0; Gray J M, 1989, Brain Inj, V3, P163, DOI 10.3109/02699058909004548; Gray J. M., 1992, NEUROPSYCHOL REHABIL, V2, P97; GRONWALL D, 1987, NEUROBEHAVIORAL RECO; GRONWALL D, 1991, NEUROPSYCHOLOGY, V5, P235; Gronwall D.M., 1974, PSYCHOL EFFECTS CONC; Harris J E, 1981, Int Rehabil Med, V3, P206; Heaton R.K., 1991, COMPREHENSIVE NORMS; Heilman K.M.V.E., 1993, CLIN NEUROPSYCHOLOGY; HEINZE HJ, 1992, NEUROPSYCHOLOGIA, V30, P495, DOI 10.1016/0028-3932(92)90054-P; HINKELDEY N S, 1990, Brain Injury, V4, P115, DOI 10.3109/02699059009026157; Kewman D G, 1988, Brain Inj, V2, P131, DOI 10.3109/02699058809150937; Levin H. S., 1989, J CLIN EXP NEUROPSYC, V12, P129; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LEZAK MD, 1994, NEUROPSYCHOLOGICAL A; MALEC J, 1984, COGNITIVE REHABILITA, V2, P18; Mapou R. L., 1995, CLIN NEUROPSYCHOLOGI; Mateer C.A., 1990, COGNITIVE REHABILITA; Mateer C.A., 1988, NEUROPSYCHOLOGICAL S; Mateer C.A., 1987, J HEAD TRAUMA REHAB, V2, P74, DOI [10.1097/00001199-198709000-00009, DOI 10.1097/00001199-198709000-00009]; MATEER CA, 1995, WORKSH W REED ARM ME; MATEER CA, 1992, REHABILITATION POST; MILLER E, 1981, BRIT J CLIN PSYCHOL, V20, P69, DOI 10.1111/j.2044-8260.1981.tb00498.x; MIRSKY A F, 1991, Neuropsychology Review, V2, P109, DOI 10.1007/BF01109051; MIRSKY AF, 1987, ENVIRON HEALTH PERSP, V74, P191, DOI 10.2307/3430449; MIRSKY AF, 1995, CLIN NEUROPSYCHOLOGI; NIEMANN H, 1990, J CONSULT CLIN PSYCH, V58, P811, DOI 10.1037/0022-006X.58.6.811; NISSEN M, 1986, J HEAD TRAUMA REHAB, V1, P13; PICANO JJ, 1992, ARCH CLIN NEUROPSYCH, V7, P271, DOI 10.1016/0887-6177(92)90168-M; POGGE DL, 1994, J CLIN EXP NEUROPSYC, V16, P344, DOI 10.1080/01688639408402645; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; PONSFORD JL, 1988, J CLIN EXP NEUROPSYC, V10, P693, DOI 10.1080/01688638808402808; POWELL GE, 1981, BRAIN FUNCTION THERA; RASKIN E, 1993, M AM COLL REH MED DE; Ruff R. M., 1989, J HEAD TRAUMA REHAB, V4, P20, DOI [10.1097/00001199-198909000-00006, DOI 10.1097/00001199-198909000-00006]; RUGG MD, 1993, NEUROPSYCHOLOGIA, V31, P373, DOI 10.1016/0028-3932(93)90161-R; RUSSELL EW, 1992, J CLIN PSYCHOL, V48, P530, DOI 10.1002/1097-4679(199207)48:4<530::AID-JCLP2270480415>3.0.CO;2-B; SCHMIDT M, 1994, ARCH CLIN NEUROPSYCH, V9, P383, DOI 10.1016/0887-6177(94)90002-7; Shum D. H. K., 1990, CLIN NEUROPSYCHOL, V4, P151, DOI DOI 10.1080/13854049008401508; SHUM DHK, 1994, J CLIN EXP NEUROPSYC, V16, P531, DOI 10.1080/01688639408402664; SIVAK M, 1984, INT J REHABIL RES, V7, P389, DOI 10.1097/00004356-198412000-00002; SIVAK M, 1984, ARCH PHYS MED REHAB, V65, P163; Sohlberg M. M., 1989, INTRO COGNITIVE REHA; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; SOHLBERG MM, 1993, ATTENTION PROCESS TR, V2; STABLUM F, 1994, CORTEX, V30, P603, DOI 10.1016/S0010-9452(13)80238-9; STURM W, 1983, ARCH PSYCHIAT NERVEN, V233, P9, DOI 10.1007/BF00540034; STURM W, 1993, DEV ASSESSMENT REHAB; Stuss D.T., 1987, CLIN NEUROPSYCHOL, V1, P139, DOI DOI 10.1080/13854048708520046; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; VANZOMEREN AH, 1984, CLOSED HEAD INJURY P; VANZOMEREN AH, 1987, NEUROBEHAVIORAL RECO; WHYTE J, 1992, ARCH PHYS MED REHAB, V73, P1094; Wood R L, 1987, Int Disabil Stud, V9, P149; ZUBIN J, 1975, EXPT APPROACHES PSYC	71	41	44	0	1	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21701	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	APR	1996	11	2					1	16					16	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	UD674	WOS:A1996UD67400002					2021-06-18	
J	Meythaler, JM; DeVivo, MJ; Hayne, JB				Meythaler, JM; DeVivo, MJ; Hayne, JB			Cost-effectiveness of routine screening for proximal deep venous thrombosis in acquired brain injury patients admitted to rehabilitation	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							TOTAL HIP-REPLACEMENT; VEIN-THROMBOSIS; COMPRESSION ULTRASONOGRAPHY; IMPEDANCE PLETHYSMOGRAPHY; PNEUMATIC COMPRESSION; COLORECTAL-CANCER; THROMBOEMBOLISM; PREVENTION; SURGERY; PROPHYLAXIS	Objective: Determine the prevalence of proximal deep venous thrombosis (DVT) among acquired brain injury patients on admission to rehabilitation and assess cost-effectiveness of routine ultrasound screening for proximal DVT in those patients. Design: Prospective study, sequential case series. Setting: University tertiary care rehabilitation center. Data Set: One hundred sixteen traumatic brain injury patients (TBI) and 48 nontraumatic brain injury patients were admitted to our brain injury (BI) unit over a 21-month period and screened for a DVT on admission to rehabilitation utilizing real time, spectral Doppler, and color Doppler ultrasound, Patients with a previous clinically recognized and treated DVT were excluded. No patients had been treated with prophylactic anticoagulation or intermittent anticoagulation since their BI and all patients were within 4 months of the original injury, Results: Fourteen patients in total (8.5%) were found to have a DVT in the thigh or popliteal area, 9 of the 116 patients in the TBI group (7.8%), and 5 of the 48 patients in the nontraumatic BI group (10.4%). Statistically, there was no significant difference in the total number of detected proximal lower extremity DVTs between the TBI and the nontraumatic BI groups (Fisher's exact test). In the TBI group 22 patients had associated lower extremity or pelvic fractures, but this factor appeared not to be significant, because only 1 of the 22 patients was discovered to have a DVT. The average admission Glascow Coma Score (GCS) of the TBI group was 8.6 but there was no correlation with the GCS and the prevalence of DVT. The additional cost of screening for and treating the additional DVTs utilizing color Doppler ultrasound is conservatively estimated to be $674.84 per patient admitted to the BI rehabilitation unit. It can be estimated the cost of saving one life is $129,527.83. Conclusion: DVT screening in this patient population appears to be more cost-effective than mass screening programs for either breast cancer or colorectal cancer. The cost per year of life saved, estimated at only $2,977.65 ($129,527.83/43.5 years) for DVT screening for brain injury patients on admission to rehabilitation, is lower than those costs proposed for comparable programs with significant social support. (C) 1996 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation		Meythaler, JM (corresponding author), UNIV ALABAMA,CTR SPAIN REHABIL,SCH MED,DEPT REHABIL MED,1717 6TH AVE S,,BIRMINGHAM,AL 35233, USA.						BRACH BB, 1977, J TRAUMA, V17, P289, DOI 10.1097/00005373-197704000-00005; BRANDSTATER ME, 1992, ARCH PHYS MED REHAB, V73, pS379; BURKE AM, 1979, SURG GYNECOL OBSTET, V148, P9; BYERS T, 1992, CANCER, V70, P1288, DOI 10.1002/1097-0142(19920901)70:3+<1288::AID-CNCR2820701515>3.0.CO;2-1; COON WW, 1984, CLIN CHEST MED, V5, P391; FERREE BA, 1993, SPINE, V18, P315, DOI 10.1097/00007632-199303000-00001; FOGELHOLM R, 1992, J NEUROL NEUROSUR PS, V55, P1121, DOI 10.1136/jnnp.55.12.1121; FRANCIS CW, 1992, JAMA-J AM MED ASSOC, V267, P2911, DOI 10.1001/jama.267.21.2911; GEERTS WH, 1994, NEW ENGL J MED, V331, P1601, DOI 10.1056/NEJM199412153312401; GELMERS HJ, 1980, ACTA NEUROL SCAND, V61, P517; GITEL SN, 1979, J BONE JOINT SURG AM, V61, P653, DOI 10.2106/00004623-197961050-00002; GREEN D, 1988, JAMA-J AM MED ASSOC, V260, P1255, DOI 10.1001/jama.260.9.1255; GREENFIELD LJ, 1988, SURGERY, V104, P706; GRUMBACH K, 1994, JAMA-J AM MED ASSOC, V272, P1458, DOI 10.1001/jama.272.18.1458; HEIJBOER H, 1993, NEW ENGL J MED, V329, P1365, DOI 10.1056/NEJM199311043291901; HULL RD, 1985, ANN INTERN MED, V102, P21, DOI 10.7326/0003-4819-102-1-21; KATTLOVE H, 1995, JAMA-J AM MED ASSOC, V273, P142, DOI 10.1001/jama.273.2.142; KONTOS HA, CECIL TXB MED, P355; LACHMANN EA, 1992, ARCH PHYS MED REHAB, V73, P482; Lamb G C, 1993, J Am Paraplegia Soc, V16, P153; LENSING AWA, 1989, NEW ENGL J MED, V320, P342, DOI 10.1056/NEJM198902093200602; OSTER G, 1987, JAMA-J AM MED ASSOC, V257, P203, DOI 10.1001/jama.257.2.203; OUDKERK M, 1993, ARCH INTERN MED, V153, P947, DOI 10.1001/archinte.153.8.947; PEDERSEN OM, 1991, ARCH INTERN MED, V151, P2217, DOI 10.1001/archinte.151.11.2217; ROSBERG B, 1981, ANN CLIN RES, V13, P84; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; SASAHARA AA, 1979, AM J CARDIOL, V43, P1214, DOI 10.1016/0002-9149(79)90156-5; SEVITT S, 1961, BRIT J SURG, V48, P475, DOI 10.1002/bjs.18004821103; SEVITT S, 1969, THROMBOSIS, P29; STAMATAKIS JD, 1977, BRIT MED J, V2, P223, DOI 10.1136/bmj.2.6081.223; STEINBERG DP, 1993, ARCH PHYS MED REHAB, V64, P1243; TEASDALE G, 1974, LANCET, V2, P81; VERSTRAETE M, 1993, NEW ENGL J MED, V329, P1418, DOI 10.1056/NEJM199311043291911; WAGNER JL, 1991, ANN INTERN MED, V115, P807, DOI 10.7326/0003-4819-115-10-807; WEINMANN EE, 1994, NEW ENGL J MED, V331, P1630, DOI 10.1056/NEJM199412153312407; WHEELER HB, 1994, ARCH INTERN MED, V154, P1921, DOI 10.1001/archinte.154.17.1921; 1994, VITAL STATISTICS U A, V2; 1986, JAMA-J AM MED ASSOC, V256, P744	38	41	41	0	2	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JAN	1996	77	1					1	5		10.1016/S0003-9993(96)90210-5			5	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	TN532	WOS:A1996TN53200001	8554463				2021-06-18	
J	SCHLAGETER, K; GRAY, B; HALL, K; SHAW, R; SAMMET, R				SCHLAGETER, K; GRAY, B; HALL, K; SHAW, R; SAMMET, R			INCIDENCE AND TREATMENT OF VISUAL DYSFUNCTION IN TRAUMATIC BRAIN INJURY	BRAIN INJURY			English	Article								The incidence of visual dysfunction and effectiveness of visual exercises in acute traumatically brain injured inpatients in a rehabilitation programme were studied. Vision evaluation norms were established on 23 hospital staff. The evaluation was then administered to 51 inpatients within days after admission. An additional 21 patients were unable to participate, usually due to decreased cognition or agitation. Thirty of 51 (59%) scored impaired in one or more of the following: pursuits, saccades, ocular posturing, stereopsis, extra-ocular movements, and near/far eso-exotropia. For patients having dysfunction in pursuits or saccades, a 2-week baseline was followed by vision exercises. During the baseline interval patients were evaluated by an optometrist to verify therapists' findings. Six patients who participated in several weeks of treatment were evaluated at 2-week intervals by an independent rater. Progress is graphically illustrated. Conclusions were that the suitability of an inpatient vision programme, from our experience, is questionable. However, an initial evaluation proved valuable for informing staff of patients' visual status and for referral to an optometrist/ophthalmologist for further treatment.	SANTA CLARA VALLEY MED CTR,751 S BASCOM AVE,SAN JOSE,CA 95128							BECKER J, 1987, ARCH PHYSICAL M 1001; BERNE SA, 1990, J OPTOM VIS DEV, V21, P13; BOUSKA MJ, 1988, OCCUPATIONAL THERAPY, V69, P573; Cohen A H, 1978, J Am Optom Assoc, V49, P831; Cohen M, 1989, Brain Inj, V3, P187, DOI 10.3109/02699058909004551; ELISEVICH KV, 1984, SURG NEUROL, V22, P565, DOI 10.1016/0090-3019(84)90433-6; ELSTON JS, 1984, BRIT J OPHTHALMOL, V68, P538, DOI 10.1136/bjo.68.8.538; HALL KM, 1992, NEUROREHABILITATION, V2, P97; Harrison RJ, 1987, BINOC VIS, V2, P93; KADET TS, 1987, 6TH NAT HEAD INJ F A; KROHEL GB, 1986, ANN OPHTHALMOL, V18, P101; MITCHELL R, 1983, AUST ORTHOP J, V20, P31; NEGER RE, 1989, J HEAD TRAUMA REHAB, V4, P27; PADULA WV, 1988, POSTTRAUMA VISION SY, P167; PADULA WV, 1988, N ENGL J OPTOM   DEC, P16; Roca P D, 1972, Ann Ophthalmol, V4, P63; Tierney D W, 1988, J Am Optom Assoc, V59, P614; UZZELL BP, 1988, ARCH NEUROL-CHICAGO, V45, P420, DOI 10.1001/archneur.1988.00520280066017	18	41	41	0	12	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	SEP-OCT	1993	7	5					439	448		10.3109/02699059309029687			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	MA172	WOS:A1993MA17200007	8401486				2021-06-18	
